{
  "nodes": [
    {
      "id": "naratriptan"
    },
    {
      "id": "human 5-HT1B"
    },
    {
      "id": "sumatriptan"
    },
    {
      "id": "5-HT1D"
    },
    {
      "id": "[3H]eletriptan"
    },
    {
      "id": "[3H]sumatriptan"
    },
    {
      "id": "eletriptan"
    },
    {
      "id": "drug"
    },
    {
      "id": "(R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole"
    },
    {
      "id": "rizatriptan"
    },
    {
      "id": "putative 5-ht1f receptor"
    },
    {
      "id": "radioligands"
    },
    {
      "id": "5-HT1D receptors"
    },
    {
      "id": "human recombinant 5-HT1B"
    },
    {
      "id": "HeLa cells"
    },
    {
      "id": "human 5-HT1B receptors"
    },
    {
      "id": "5-HT1D receptor"
    },
    {
      "id": "vasoconstrictor activity"
    },
    {
      "id": "5-HT1B receptor"
    },
    {
      "id": "acute treatment of migraine headache"
    },
    {
      "id": "5-HT1B/1D receptor agonists"
    },
    {
      "id": "migraine"
    },
    {
      "id": "zolmitriptan"
    },
    {
      "id": "5-HT receptors"
    },
    {
      "id": "5-HT receptor"
    },
    {
      "id": "DR"
    },
    {
      "id": "PCP-like hyperlocomotion"
    },
    {
      "id": "DM analogs"
    },
    {
      "id": "anticonvulsant activity"
    },
    {
      "id": "DM"
    },
    {
      "id": "DF"
    },
    {
      "id": "PCP sites"
    },
    {
      "id": "adverse effects"
    },
    {
      "id": "dextromethorphan"
    },
    {
      "id": "dextrorphan"
    },
    {
      "id": "sigma receptors"
    },
    {
      "id": "biphasic effects"
    },
    {
      "id": "sigma-1 receptors"
    },
    {
      "id": "dimemorfan"
    },
    {
      "id": "therapeutic use"
    },
    {
      "id": "antitussive"
    },
    {
      "id": "dose-dependent decrease"
    },
    {
      "id": "ligands"
    },
    {
      "id": "anticonvulsant effects"
    },
    {
      "id": "PCP"
    },
    {
      "id": "CNS effects"
    },
    {
      "id": "hyperlocomotion"
    },
    {
      "id": "locomotor effects"
    },
    {
      "id": "sigma-2 receptors"
    },
    {
      "id": "NMDA"
    },
    {
      "id": "locomotor activity"
    },
    {
      "id": "supramaximal electroshock test"
    },
    {
      "id": "(+)-3-methyl-N-methylmorphinan"
    },
    {
      "id": "NMDA-linked PCP sites"
    },
    {
      "id": "neuroprotective effects"
    },
    {
      "id": "sigma-1 receptor"
    },
    {
      "id": "(+)-3-methoxy-N-methylmorphinan"
    },
    {
      "id": "DM/sigma receptors"
    },
    {
      "id": "phencyclidine"
    },
    {
      "id": "pimozide"
    },
    {
      "id": "human dopamine transporter"
    },
    {
      "id": "ziprasidone"
    },
    {
      "id": "norepinephrine transporter"
    },
    {
      "id": "norepinephrine"
    },
    {
      "id": "potency"
    },
    {
      "id": "human serotonin, norepinephrine, and dopamine transporters"
    },
    {
      "id": "[3H]WIN35428"
    },
    {
      "id": "chlorpromazine"
    },
    {
      "id": "compounds"
    },
    {
      "id": "[3H]imipramine"
    },
    {
      "id": "zotepine"
    },
    {
      "id": "fluperlapine"
    },
    {
      "id": "K(D)"
    },
    {
      "id": "dopamine"
    },
    {
      "id": "chlorprothixene"
    },
    {
      "id": "Pharmacological profile"
    },
    {
      "id": "neuroleptics"
    },
    {
      "id": "human monoamine transporters"
    },
    {
      "id": "monoamine"
    },
    {
      "id": "[3H]nisoxetine"
    },
    {
      "id": "promazine"
    },
    {
      "id": "triflupromazine"
    },
    {
      "id": "drug interactions"
    },
    {
      "id": "human serotonin transporter"
    },
    {
      "id": "haloperidol metabolite"
    },
    {
      "id": "data"
    },
    {
      "id": "therapeutic and adverse effects"
    },
    {
      "id": "haloperidol"
    },
    {
      "id": "equilibrium dissociation constants"
    },
    {
      "id": "serotonin"
    },
    {
      "id": "metabolite"
    },
    {
      "id": "radioligand binding techniques"
    },
    {
      "id": "study"
    },
    {
      "id": "Ang II receptor blockade"
    },
    {
      "id": "double-blind, placebo-controlled, randomized, 4-way crossover study"
    },
    {
      "id": "Blockade of the renin-angiotensin system"
    },
    {
      "id": "30 hours"
    },
    {
      "id": "valsartan"
    },
    {
      "id": "irbesartan"
    },
    {
      "id": "Ang II-induced systolic blood pressure increase"
    },
    {
      "id": "effect"
    },
    {
      "id": "drugs"
    },
    {
      "id": "residual effect"
    },
    {
      "id": "24 hours"
    },
    {
      "id": "recommended starting dose"
    },
    {
      "id": "reactive changes in plasma Ang II levels"
    },
    {
      "id": "Ang II"
    },
    {
      "id": "reactive rise in plasma Ang II levels"
    },
    {
      "id": "losartan"
    },
    {
      "id": "50 mg"
    },
    {
      "id": "systolic blood pressure"
    },
    {
      "id": "normotensive subjects"
    },
    {
      "id": "4 hours"
    },
    {
      "id": "in vitro receptor assay"
    },
    {
      "id": "time"
    },
    {
      "id": "relative efficacy"
    },
    {
      "id": "antagonists"
    },
    {
      "id": "first administration"
    },
    {
      "id": "single dose"
    },
    {
      "id": "P<0.01"
    },
    {
      "id": "renin-angiotensin system"
    },
    {
      "id": "12 subjects"
    },
    {
      "id": "results"
    },
    {
      "id": "angiotensin"
    },
    {
      "id": "Angiotensin II receptor blockade"
    },
    {
      "id": "direct comparison"
    },
    {
      "id": "AT1 receptor antagonists"
    },
    {
      "id": "80 mg"
    },
    {
      "id": "150 mg"
    },
    {
      "id": "placebo"
    },
    {
      "id": "1-week intervals"
    },
    {
      "id": "plasma Ang II levels"
    },
    {
      "id": "in vitro Ang II receptor assay"
    },
    {
      "id": "Angiotensin II"
    },
    {
      "id": "AT1 receptor"
    },
    {
      "id": "angiotensin (Ang) II AT1 receptor antagonists"
    },
    {
      "id": "treatment of hypertension"
    },
    {
      "id": "marked, significant blockade"
    },
    {
      "id": "3 independent methods"
    },
    {
      "id": "inhibition of the blood pressure response to exogenous Ang II"
    },
    {
      "id": "3 drugs"
    },
    {
      "id": "hypertension"
    },
    {
      "id": "drug intake"
    },
    {
      "id": "direct comparisons"
    },
    {
      "id": "humans"
    },
    {
      "id": "renin"
    },
    {
      "id": "Disodium cromoglycate"
    },
    {
      "id": "small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia"
    },
    {
      "id": "terbutaline-induced desensitization"
    },
    {
      "id": "human volunteers"
    },
    {
      "id": "beta-adrenoceptor-mediated cardiovascular and noncardiovascular responses"
    },
    {
      "id": "healthy male volunteers"
    },
    {
      "id": "beta 1-adrenoceptor cardiovascular function"
    },
    {
      "id": "exercise-induced tachycardia"
    },
    {
      "id": "terbutaline"
    },
    {
      "id": "Tremulousness"
    },
    {
      "id": "beta 2-adrenoceptor-mediated noncardiovascular effect"
    },
    {
      "id": "increase in heart rate"
    },
    {
      "id": "isoprenaline"
    },
    {
      "id": "long-term beta 2-adrenoceptor agonist therapy"
    },
    {
      "id": "desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects"
    },
    {
      "id": "beta 2-Adrenoceptor cardiovascular function"
    },
    {
      "id": "reduction of diastolic blood pressure"
    },
    {
      "id": "beta 2-adrenoceptor-mediated cardiovascular in vivo functions"
    },
    {
      "id": "ketotifen"
    },
    {
      "id": "antianaphylactic drug"
    },
    {
      "id": "disodium cromoglycate"
    },
    {
      "id": "Exercise-induced tachycardia"
    },
    {
      "id": "rightward shift of beta 2-adrenoceptor-mediated responses"
    },
    {
      "id": "antiallergic drug"
    },
    {
      "id": "cromolyn sodium"
    },
    {
      "id": "isoprenaline-induced decrease in diastolic blood pressure"
    },
    {
      "id": "double-blind, placebo-controlled, randomized design"
    },
    {
      "id": "beta 2-adrenoceptor agonist"
    },
    {
      "id": "unselective beta-adrenoceptor agonist"
    },
    {
      "id": "isoprenaline-induced tachycardia"
    },
    {
      "id": "Caffeine"
    },
    {
      "id": "cell-cycle progression"
    },
    {
      "id": "checkpoint kinase ATM"
    },
    {
      "id": "repair of DNA"
    },
    {
      "id": "Inhibition of ATM"
    },
    {
      "id": "attenuation of DNA-damage checkpoint responses"
    },
    {
      "id": "molecular explanation"
    },
    {
      "id": "radiation-induced activation"
    },
    {
      "id": "ATM kinase activity"
    },
    {
      "id": "kinase Cds1"
    },
    {
      "id": "Chk2"
    },
    {
      "id": "model compound"
    },
    {
      "id": "increased radiosensitivity"
    },
    {
      "id": "replication"
    },
    {
      "id": "agents"
    },
    {
      "id": "cells"
    },
    {
      "id": "recovery curve"
    },
    {
      "id": "standard model of protein synthesis and degradation"
    },
    {
      "id": "half-life of the SERT recovery"
    },
    {
      "id": "striatum"
    },
    {
      "id": "RTI-76"
    },
    {
      "id": "wash and temperature resistant inhibition"
    },
    {
      "id": "[3H]-5-HT uptake"
    },
    {
      "id": "recovery of SERT binding"
    },
    {
      "id": "dose- and time-dependent reduction"
    },
    {
      "id": "SERT"
    },
    {
      "id": "turnover parameters"
    },
    {
      "id": "turnover"
    },
    {
      "id": "production rate"
    },
    {
      "id": "production rate constant"
    },
    {
      "id": "ligand binding"
    },
    {
      "id": "SERT binding densities"
    },
    {
      "id": "days"
    },
    {
      "id": "Serotonin transporter"
    },
    {
      "id": "in vivo intracerebroventricular injections"
    },
    {
      "id": "nmol"
    },
    {
      "id": "hippocampus"
    },
    {
      "id": "preliminary studies"
    },
    {
      "id": "in vitro incubation"
    },
    {
      "id": "regions"
    },
    {
      "id": "serotonergic innervation"
    },
    {
      "id": "irreversible inhibitor"
    },
    {
      "id": "Citalopram"
    },
    {
      "id": "RTI-76-induced inhibition"
    },
    {
      "id": "control levels"
    },
    {
      "id": "degradation rate constant"
    },
    {
      "id": "half-life of recovery"
    },
    {
      "id": "median midbrain raphe nuclei"
    },
    {
      "id": "Bmax"
    },
    {
      "id": "dorsal midbrain raphe nuclei"
    },
    {
      "id": "fmol mg protein (-1)h(-1)"
    },
    {
      "id": "rat cerebral cortex"
    },
    {
      "id": "h(-1)"
    },
    {
      "id": "chemotherapy"
    },
    {
      "id": "doxorubicin"
    },
    {
      "id": "Eastern Cooperative Oncology Group trial E3186"
    },
    {
      "id": "question"
    },
    {
      "id": "CAF"
    },
    {
      "id": "maintenance cyclophosphamide"
    },
    {
      "id": "secondary randomization"
    },
    {
      "id": "chemohormonal therapy"
    },
    {
      "id": "overall survival"
    },
    {
      "id": "231 patients"
    },
    {
      "id": "simultaneous hormonal therapy"
    },
    {
      "id": "additional benefit"
    },
    {
      "id": "Time to treatment failure (TTF)"
    },
    {
      "id": "17.4 months"
    },
    {
      "id": "response rates"
    },
    {
      "id": "68.9%"
    },
    {
      "id": "cyclophosphamide"
    },
    {
      "id": "CAFTH"
    },
    {
      "id": "Pharmacia-Upjohn"
    },
    {
      "id": "tamoxifen"
    },
    {
      "id": "fluorouracil"
    },
    {
      "id": "patients"
    },
    {
      "id": "prednisone"
    },
    {
      "id": "front-line therapy"
    },
    {
      "id": "complete response"
    },
    {
      "id": "initial chemotherapy"
    },
    {
      "id": "aggressiveness"
    },
    {
      "id": "methotrexate"
    },
    {
      "id": "disease"
    },
    {
      "id": "30.0 months"
    },
    {
      "id": "29.3 months"
    },
    {
      "id": "first-line therapy"
    },
    {
      "id": "metastatic, hormone-sensitive breast cancer"
    },
    {
      "id": "chemotherapy alone"
    },
    {
      "id": "TH"
    },
    {
      "id": "January 1988"
    },
    {
      "id": "Halotestin"
    },
    {
      "id": "fluoxymesterone"
    },
    {
      "id": "hormonal therapy"
    },
    {
      "id": "standard therapy"
    },
    {
      "id": "13.4 months"
    },
    {
      "id": "ER-unknown"
    },
    {
      "id": "partial response"
    },
    {
      "id": "10.3 months"
    },
    {
      "id": "ER-positive patients"
    },
    {
      "id": "metastatic breast cancer"
    },
    {
      "id": "metastatic hormone-sensitive disease"
    },
    {
      "id": "P =.048"
    },
    {
      "id": "P =.99"
    },
    {
      "id": "induction therapy"
    },
    {
      "id": "location"
    },
    {
      "id": "ER status"
    },
    {
      "id": "bulk"
    },
    {
      "id": "69.2%"
    },
    {
      "id": "Eastern Cooperative Oncology Group"
    },
    {
      "id": "December 1992"
    },
    {
      "id": "P =.087"
    },
    {
      "id": "estrogen receptor (ER)-positive"
    },
    {
      "id": "potentially hormone-sensitive metastatic breast cancer"
    },
    {
      "id": "cytotoxicity"
    },
    {
      "id": "cancer"
    },
    {
      "id": "precursors"
    },
    {
      "id": "oxidative stress"
    },
    {
      "id": "mNQO activity"
    },
    {
      "id": "dicoumarol"
    },
    {
      "id": "18-kDa bands"
    },
    {
      "id": "polyclonal antibodies"
    },
    {
      "id": "cytosolic NQO1"
    },
    {
      "id": "Quinone oxidoreductases"
    },
    {
      "id": "quinones"
    },
    {
      "id": "NRH:quinone oxidoreductase 2"
    },
    {
      "id": "cytosolic forms of quinone oxidoreductases"
    },
    {
      "id": "NADPH"
    },
    {
      "id": "toxicity"
    },
    {
      "id": "synthetic quinones"
    },
    {
      "id": "environmental quinones"
    },
    {
      "id": "ammonium sulfate fractionation"
    },
    {
      "id": "Western analysis"
    },
    {
      "id": "NQO2"
    },
    {
      "id": "NADH"
    },
    {
      "id": "NQO activity"
    },
    {
      "id": "rat liver microsomes"
    },
    {
      "id": "mutagenicity"
    },
    {
      "id": "2,6-dichlorophenolindophenol"
    },
    {
      "id": "microsomal mNQO proteins"
    },
    {
      "id": "quinone toxicity"
    },
    {
      "id": "29-kDa bands"
    },
    {
      "id": "microsomal NQO (mNQO)"
    },
    {
      "id": "menadione"
    },
    {
      "id": "DEAE-Sephacel column chromatography"
    },
    {
      "id": "NQO1"
    },
    {
      "id": "NAD(P)H:quinone oxidoreductase 1"
    },
    {
      "id": "microsomal proteins"
    },
    {
      "id": "cytosolic NQOs"
    },
    {
      "id": "detergent Chaps"
    },
    {
      "id": "flavoproteins"
    },
    {
      "id": "eNOS"
    },
    {
      "id": "Gi proteins"
    },
    {
      "id": "methiothepin"
    },
    {
      "id": "5-HT2 receptor"
    },
    {
      "id": "L-N omega-iminoethyl-L-ornithine"
    },
    {
      "id": "endothelial nitric oxide synthase"
    },
    {
      "id": "nitric oxide"
    },
    {
      "id": "5-NOT"
    },
    {
      "id": "[3H]L-citrulline"
    },
    {
      "id": "[3H]L-Cit"
    },
    {
      "id": "BAEC cultures"
    },
    {
      "id": "endothelial cells"
    },
    {
      "id": "5-HT1B receptor/eNOS pathway"
    },
    {
      "id": "NO"
    },
    {
      "id": "L-Nomega -monomethyl-L-arginine"
    },
    {
      "id": "PTX"
    },
    {
      "id": "5-nonyloxytryptamine"
    },
    {
      "id": "5-hydroxytryptamine"
    },
    {
      "id": "isamoltane"
    },
    {
      "id": "L-NMMA"
    },
    {
      "id": "bovine aortic endothelial cell cultures"
    },
    {
      "id": "[3H]L-arginine"
    },
    {
      "id": "5-HT"
    },
    {
      "id": "L-NIO"
    },
    {
      "id": "[3H]L-Arg"
    },
    {
      "id": "vascular 5-HT receptors"
    },
    {
      "id": "pertussis toxin"
    },
    {
      "id": "tasosartan"
    },
    {
      "id": "relative binding affinities"
    },
    {
      "id": "insurmountable antagonism"
    },
    {
      "id": "zolasartan"
    },
    {
      "id": "slow off-rate"
    },
    {
      "id": "occupancy of the AT1 receptor"
    },
    {
      "id": "chemical structure"
    },
    {
      "id": "angiotensin II type 1 (AT1) receptor antagonists"
    },
    {
      "id": "angiotensin I converting enzyme inhibitors"
    },
    {
      "id": "telmisartan"
    },
    {
      "id": "eprosartan"
    },
    {
      "id": "noncompetitive antagonism"
    },
    {
      "id": "candesartan"
    },
    {
      "id": "E3174"
    },
    {
      "id": "active metabolite"
    },
    {
      "id": "duration of the antihypertensive effect"
    },
    {
      "id": "'sartans'"
    },
    {
      "id": "clinical development"
    },
    {
      "id": "saprisartan"
    },
    {
      "id": "Losartan"
    },
    {
      "id": "surmountable antagonism"
    },
    {
      "id": "renin-angiotensin-aldosterone system"
    },
    {
      "id": "candesartan cilexetil"
    },
    {
      "id": "angiotensin II receptor antagonists"
    },
    {
      "id": "Pharmacological properties"
    },
    {
      "id": "AT1 receptor antagonism"
    },
    {
      "id": "angiotensin II"
    },
    {
      "id": "competitive antagonism"
    },
    {
      "id": "antihypertensive efficacy"
    },
    {
      "id": "slow dissociation kinetics"
    },
    {
      "id": "AT1 receptor antagonist"
    },
    {
      "id": "prodrug"
    },
    {
      "id": "UFT"
    },
    {
      "id": "adjuvant chemotherapy programs"
    },
    {
      "id": "colorectal tumors"
    },
    {
      "id": "1,2-dimethylhydrazine"
    },
    {
      "id": "thymidine kinase"
    },
    {
      "id": "enzymes"
    },
    {
      "id": "pre-operative adjuvant chemotherapy programs"
    },
    {
      "id": "1-(2-tetrahydrofuryl)-5-FU"
    },
    {
      "id": "inactive ternary complex"
    },
    {
      "id": "intracellular folate"
    },
    {
      "id": "leucovorin"
    },
    {
      "id": "thymidylate synthase inhibition"
    },
    {
      "id": "tumor cells"
    },
    {
      "id": "Thymidylate synthase"
    },
    {
      "id": "de novo pathway"
    },
    {
      "id": "uracil"
    },
    {
      "id": "pyrimidine nucleotide synthesis"
    },
    {
      "id": "post-operative adjuvant chemotherapy programs"
    },
    {
      "id": "rat colorectal carcinomas"
    },
    {
      "id": "tumor growth"
    },
    {
      "id": "5-fluorodeoxyuridine monophosphate"
    },
    {
      "id": "thymidine kinase activity"
    },
    {
      "id": "colorectal carcinogenesis"
    },
    {
      "id": "rats"
    },
    {
      "id": "salvage pathways"
    },
    {
      "id": "thrombin"
    },
    {
      "id": "thrombosis"
    },
    {
      "id": "death"
    },
    {
      "id": "high-dose argatroban patients"
    },
    {
      "id": "TIMI grade 3 flow"
    },
    {
      "id": "reperfusion"
    },
    {
      "id": "TPA"
    },
    {
      "id": "revascularization"
    },
    {
      "id": "heparin patients"
    },
    {
      "id": "Major bleeding"
    },
    {
      "id": "low-dose argatroban patients"
    },
    {
      "id": "heparin"
    },
    {
      "id": "argatroban"
    },
    {
      "id": "small-molecule, direct thrombin inhibitor"
    },
    {
      "id": "cardiogenic shock"
    },
    {
      "id": "adverse clinical outcome"
    },
    {
      "id": "recurrent myocardial infarction"
    },
    {
      "id": "tissue plasminogen activator"
    },
    {
      "id": "recurrent ischemia"
    },
    {
      "id": "thrombolysis"
    },
    {
      "id": "A multicenter, randomized study"
    },
    {
      "id": "acute myocardial infarction"
    },
    {
      "id": "high-dose argatroban"
    },
    {
      "id": "low-dose argatroban"
    },
    {
      "id": "clot-bound thrombin"
    },
    {
      "id": "congestive heart failure"
    },
    {
      "id": "myocardial infarction with novastan and TPA (MINT) study"
    },
    {
      "id": "primary end point"
    },
    {
      "id": "rate of thrombolysis in myocardial infarction (TIMI) grade 3 flow"
    },
    {
      "id": "AMI"
    },
    {
      "id": "novastan"
    },
    {
      "id": "adverse events"
    },
    {
      "id": "study discontinuation"
    },
    {
      "id": "Entacapone"
    },
    {
      "id": "motor function scores"
    },
    {
      "id": "Diarrhoea"
    },
    {
      "id": "nondopaminergic events"
    },
    {
      "id": "abdominal pain"
    },
    {
      "id": "Dopaminergic events"
    },
    {
      "id": "COMT"
    },
    {
      "id": "urine discolouration"
    },
    {
      "id": "efficacy"
    },
    {
      "id": "trials"
    },
    {
      "id": "treatment"
    },
    {
      "id": "clinical benefits"
    },
    {
      "id": "standard levodopa/AADC inhibitor"
    },
    {
      "id": "nausea"
    },
    {
      "id": "AADC"
    },
    {
      "id": "aromatic L-amino acid decarboxylase inhibitor"
    },
    {
      "id": "dose of levodopa/AADC inhibitor"
    },
    {
      "id": "end-of-dose deterioration"
    },
    {
      "id": "'wearing off' phenomenon"
    },
    {
      "id": "levodopa"
    },
    {
      "id": "daily 'on' time"
    },
    {
      "id": "response to levodopa"
    },
    {
      "id": "studies"
    },
    {
      "id": "activities of daily living scores"
    },
    {
      "id": "Unified Parkinson's Disease Rating Scale"
    },
    {
      "id": "UPDRS"
    },
    {
      "id": "strategies"
    },
    {
      "id": "'off' time"
    },
    {
      "id": "constipation"
    },
    {
      "id": "peripheral catechol-O-methyltransferase"
    },
    {
      "id": "selegiline"
    },
    {
      "id": "tolerability"
    },
    {
      "id": "scores"
    },
    {
      "id": "controlled release levodopa/ AADC inhibitor"
    },
    {
      "id": "effects of levodopa"
    },
    {
      "id": "inhibitor"
    },
    {
      "id": "Parkinson's disease"
    },
    {
      "id": "mentation scores"
    },
    {
      "id": "dyskinesia"
    },
    {
      "id": "rabbit aortic strips"
    },
    {
      "id": "functional inhibitory characteristics"
    },
    {
      "id": "other ARBs"
    },
    {
      "id": "angiotensin II type 1 receptor blockers"
    },
    {
      "id": "insurmountable and long-lasting antagonist"
    },
    {
      "id": "maximal contractile response"
    },
    {
      "id": "blood pressure responses"
    },
    {
      "id": "Ang II-induced blood pressure responses"
    },
    {
      "id": "lipophilicity"
    },
    {
      "id": "concentrations"
    },
    {
      "id": "ARBs"
    },
    {
      "id": "repeated washing"
    },
    {
      "id": "vessels"
    },
    {
      "id": "rat portal vein preparations"
    },
    {
      "id": "speed of recovery"
    },
    {
      "id": "incubation temperature"
    },
    {
      "id": "clinical use"
    },
    {
      "id": "EXP"
    },
    {
      "id": "active metabolite EXP 3174"
    },
    {
      "id": "inhibitory effect"
    },
    {
      "id": "nondetectable plasma concentrations"
    },
    {
      "id": "concentration-response curve"
    },
    {
      "id": "duration"
    },
    {
      "id": "vascular preparations"
    },
    {
      "id": "ARB"
    },
    {
      "id": "rightward parallel shift"
    },
    {
      "id": "plasma-protein binding"
    },
    {
      "id": "major effects"
    },
    {
      "id": "magnitude of inhibition"
    },
    {
      "id": "maximal response"
    },
    {
      "id": "Cooling"
    },
    {
      "id": "persistent inhibition"
    },
    {
      "id": "Ang II response"
    },
    {
      "id": "nonprotein bound concentrations"
    },
    {
      "id": "vascular contractile responses"
    },
    {
      "id": "washing"
    },
    {
      "id": "administration"
    },
    {
      "id": "AT1-receptor blockers"
    },
    {
      "id": "isolated vessels"
    },
    {
      "id": "conscious rats"
    },
    {
      "id": "inhibition"
    },
    {
      "id": "platelet COX-1"
    },
    {
      "id": "plasma prostaglandin E2 levels"
    },
    {
      "id": "11 healthy volunteers"
    },
    {
      "id": "15 mg/day meloxicam"
    },
    {
      "id": "COX-1"
    },
    {
      "id": "incubation"
    },
    {
      "id": "prostaglandin E2"
    },
    {
      "id": "monocyte COX-2 activity"
    },
    {
      "id": "serum thromboxane B2 levels"
    },
    {
      "id": "mean"
    },
    {
      "id": "effects"
    },
    {
      "id": "two isozymes"
    },
    {
      "id": "IC50 value"
    },
    {
      "id": "COX-2"
    },
    {
      "id": "in vitro"
    },
    {
      "id": "platelet COX-1 activity"
    },
    {
      "id": "25%"
    },
    {
      "id": "37 degrees C"
    },
    {
      "id": "S.D."
    },
    {
      "id": "51%"
    },
    {
      "id": "7 consecutive days"
    },
    {
      "id": "15 mg of meloxicam"
    },
    {
      "id": "meloxicam"
    },
    {
      "id": "dose-dependent reductions"
    },
    {
      "id": "interindividual variation"
    },
    {
      "id": "steady-state plasma levels"
    },
    {
      "id": "7.5 mg/day meloxicam"
    },
    {
      "id": "heparinized whole blood samples"
    },
    {
      "id": "lipopolysaccharide"
    },
    {
      "id": "monocyte COX-2"
    },
    {
      "id": "10 microgram/ml"
    },
    {
      "id": "production"
    },
    {
      "id": "therapeutic blood levels of meloxicam"
    },
    {
      "id": "selective inhibition"
    },
    {
      "id": "ex vivo"
    },
    {
      "id": "plasma"
    },
    {
      "id": "35%"
    },
    {
      "id": "daily dose"
    },
    {
      "id": "whole blood"
    },
    {
      "id": "60 min"
    },
    {
      "id": "dose-dependent inhibition"
    },
    {
      "id": "monocyte cyclooxygenase-2"
    },
    {
      "id": "24 h"
    },
    {
      "id": "Concentration-response curves"
    },
    {
      "id": "oral dosing"
    },
    {
      "id": "n"
    },
    {
      "id": "thromboxane B2"
    },
    {
      "id": "whole blood samples"
    },
    {
      "id": "biochemical selectivity"
    },
    {
      "id": "platelet cyclooxygenase-1"
    },
    {
      "id": "randomized, double-blind, crossover design"
    },
    {
      "id": "seventh dose"
    },
    {
      "id": "regimen"
    },
    {
      "id": "7.5 mg of meloxicam"
    },
    {
      "id": "monocyte cyclooxygenase (COX)-2"
    },
    {
      "id": "stereospecificity"
    },
    {
      "id": "nociceptin receptor"
    },
    {
      "id": "EC(50)"
    },
    {
      "id": "50 nM"
    },
    {
      "id": "opioids"
    },
    {
      "id": "activity"
    },
    {
      "id": "naloxone benzoylhydrazone"
    },
    {
      "id": "pure antagonist"
    },
    {
      "id": "lofentanil"
    },
    {
      "id": "mu-opioid receptor-selective agonist"
    },
    {
      "id": "full agonism"
    },
    {
      "id": "affinity"
    },
    {
      "id": "opioid recognition site"
    },
    {
      "id": "two receptor classes"
    },
    {
      "id": "Opioid activity profiles"
    },
    {
      "id": "similarities"
    },
    {
      "id": "functional profile"
    },
    {
      "id": "nociceptin-stimulated [35S]GTPgammaS binding"
    },
    {
      "id": "ORL1"
    },
    {
      "id": "high sequence homology"
    },
    {
      "id": "kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist"
    },
    {
      "id": "(-)-quadazocine"
    },
    {
      "id": "nonselective opioid receptor antagonist"
    },
    {
      "id": "[3H]nociceptin"
    },
    {
      "id": "enhancement"
    },
    {
      "id": "opioid receptor agonists"
    },
    {
      "id": "nociceptin/orphanin FQ"
    },
    {
      "id": "most opioids"
    },
    {
      "id": "design"
    },
    {
      "id": "(+)-quadazocine"
    },
    {
      "id": "both receptors"
    },
    {
      "id": "partial agonism"
    },
    {
      "id": "opioid receptors"
    },
    {
      "id": "[35S]GTPgammaS binding"
    },
    {
      "id": "nonpeptide nociceptin receptor agonists"
    },
    {
      "id": "partial agonists"
    },
    {
      "id": "human ORL1 receptors"
    },
    {
      "id": "orphanin FQ"
    },
    {
      "id": "peptide agonist"
    },
    {
      "id": "rat brain receptors"
    },
    {
      "id": "Nociceptin"
    },
    {
      "id": "sufentanil"
    },
    {
      "id": "potent nociceptin receptor agonists"
    },
    {
      "id": "ohmefentanyl"
    },
    {
      "id": "buprenorphine"
    },
    {
      "id": "nonselective opioid receptor partial agonist"
    },
    {
      "id": "rat brain"
    },
    {
      "id": "orphan receptor"
    },
    {
      "id": "opioid receptor-like 1 (ORL1)"
    },
    {
      "id": "Lofentanil"
    },
    {
      "id": "pure antagonism"
    },
    {
      "id": "etorphine"
    },
    {
      "id": "nonselective opioid receptor agonist"
    },
    {
      "id": "leads"
    },
    {
      "id": "structural and functional homology"
    },
    {
      "id": "findings"
    },
    {
      "id": "antagonism"
    },
    {
      "id": "IC(50)"
    },
    {
      "id": "62 nM"
    },
    {
      "id": "human recombinant ORL1 receptors"
    },
    {
      "id": "related piperidines"
    },
    {
      "id": "classical opioid receptors"
    },
    {
      "id": "diets"
    },
    {
      "id": "GLA"
    },
    {
      "id": "Delta-5-desaturase activity"
    },
    {
      "id": "enzymatic step"
    },
    {
      "id": "GLA and EPA combination"
    },
    {
      "id": "gamma-linolenic acid"
    },
    {
      "id": "clinical symptoms"
    },
    {
      "id": "lipid mediators"
    },
    {
      "id": "DGLA"
    },
    {
      "id": "neutrophil glycerolipids"
    },
    {
      "id": "in vivo effects"
    },
    {
      "id": "adult volunteers"
    },
    {
      "id": "controlled diets"
    },
    {
      "id": "in vitro studies"
    },
    {
      "id": "HEP-G2 liver cells"
    },
    {
      "id": "supplementation period"
    },
    {
      "id": "human diets"
    },
    {
      "id": "AA synthesis"
    },
    {
      "id": "EPA"
    },
    {
      "id": "serum AA levels"
    },
    {
      "id": "eicosapentaenoic acid"
    },
    {
      "id": "elongation product of GLA"
    },
    {
      "id": "dihomo-gamma-linolenic acid"
    },
    {
      "id": "supplementation strategy"
    },
    {
      "id": "serum levels of EPA"
    },
    {
      "id": "lipid mediators of inflammation"
    },
    {
      "id": "chronic inflammatory disorders"
    },
    {
      "id": "serum arachidonic acid accumulation"
    },
    {
      "id": "Neutrophils"
    },
    {
      "id": "leukotrienes"
    },
    {
      "id": "AA levels"
    },
    {
      "id": "serum arachidonate (AA) levels"
    },
    {
      "id": "side effect"
    },
    {
      "id": "fatty acid"
    },
    {
      "id": "AA"
    },
    {
      "id": "rheumatoid arthritis"
    },
    {
      "id": "proinflammatory AA metabolites"
    },
    {
      "id": "cytosensor microphysiometer"
    },
    {
      "id": "ligand-induced extracellular acidification rate changes"
    },
    {
      "id": "dexmedetomidine"
    },
    {
      "id": "agonist potency"
    },
    {
      "id": "A-54741"
    },
    {
      "id": "agonist-induced acidification rate responses"
    },
    {
      "id": "G(i/o) proteins"
    },
    {
      "id": "Human alpha(2A)-adrenoceptors"
    },
    {
      "id": "Chinese hamster lung (CHL) fibroblasts"
    },
    {
      "id": "human alpha(2A)-adrenoceptor"
    },
    {
      "id": "recombinant protein"
    },
    {
      "id": "UK-14304"
    },
    {
      "id": "maximum response"
    },
    {
      "id": "B-HT 920"
    },
    {
      "id": "noradrenaline"
    },
    {
      "id": "agonist"
    },
    {
      "id": "doxazosin"
    },
    {
      "id": "selective alpha(1)-adrenoceptor ligands"
    },
    {
      "id": "noradrenaline responses"
    },
    {
      "id": "untransfected CHL cells"
    },
    {
      "id": "rauwolscine"
    },
    {
      "id": "acidification rate changes"
    },
    {
      "id": "alpha(2A)-adrenoceptors"
    },
    {
      "id": "extracellular acidification rate changes"
    },
    {
      "id": "prazosin"
    },
    {
      "id": "selective alpha(2)-adrenoceptor ligand"
    },
    {
      "id": "Chinese hamster lung cells"
    },
    {
      "id": "TWIK-2"
    },
    {
      "id": "immune system"
    },
    {
      "id": "2P domain K(+) channel"
    },
    {
      "id": "inactivation"
    },
    {
      "id": "TWIK-2 channels"
    },
    {
      "id": "cysteine 53"
    },
    {
      "id": "subunit self-assembly"
    },
    {
      "id": "visualization"
    },
    {
      "id": "discrete single channel events"
    },
    {
      "id": "kinetic of inactivation"
    },
    {
      "id": "temperature-sensitive"
    },
    {
      "id": "M1P1 external loop"
    },
    {
      "id": "low conductance"
    },
    {
      "id": "mild inward rectification"
    },
    {
      "id": "symmetrical K(+) conditions"
    },
    {
      "id": "functional expression"
    },
    {
      "id": "Rat TWIK-2"
    },
    {
      "id": "human TWIK-2"
    },
    {
      "id": "delayed activities"
    },
    {
      "id": "base-line activity"
    },
    {
      "id": "outward rectification"
    },
    {
      "id": "Ba(2+)"
    },
    {
      "id": "quinine"
    },
    {
      "id": "COS cells"
    },
    {
      "id": "quinidine"
    },
    {
      "id": "2P domain K+ channel"
    },
    {
      "id": "transient activity"
    },
    {
      "id": "functional role"
    },
    {
      "id": "cell electrogenesis"
    },
    {
      "id": "TWIK-2 currents"
    },
    {
      "id": "depolarized potentials"
    },
    {
      "id": "rectification"
    },
    {
      "id": "gastrointestinal tract"
    },
    {
      "id": "physiological K(+) gradient"
    },
    {
      "id": "vasculature"
    },
    {
      "id": "Reduced expression"
    },
    {
      "id": "surface carbohydrate moieties"
    },
    {
      "id": "FcgammaRII"
    },
    {
      "id": "differential loss"
    },
    {
      "id": "CD15"
    },
    {
      "id": "neutrophil responsiveness"
    },
    {
      "id": "stimuli"
    },
    {
      "id": "panel"
    },
    {
      "id": "monoclonal antibodies"
    },
    {
      "id": "profile"
    },
    {
      "id": "surface molecule expression"
    },
    {
      "id": "complement receptor type 1"
    },
    {
      "id": "CD35"
    },
    {
      "id": "LFA-3"
    },
    {
      "id": "Neutrophil apoptosis"
    },
    {
      "id": "CD63"
    },
    {
      "id": "azurophilic granules"
    },
    {
      "id": "apoptotic neutrophils"
    },
    {
      "id": "nuclear degradation"
    },
    {
      "id": "BOB78 positive neutrophils"
    },
    {
      "id": "biotinylated thrombospondin"
    },
    {
      "id": "exposure"
    },
    {
      "id": "thrombospondin binding moieties"
    },
    {
      "id": "down-regulation"
    },
    {
      "id": "adhesive interactions"
    },
    {
      "id": "immunoglobulin superfamily members"
    },
    {
      "id": "ICAM-3"
    },
    {
      "id": "human neutrophils"
    },
    {
      "id": "integrin-associated proteins"
    },
    {
      "id": "apoptosis"
    },
    {
      "id": "specific changes"
    },
    {
      "id": "shedding"
    },
    {
      "id": "surface molecular changes"
    },
    {
      "id": "spontaneous apoptosis"
    },
    {
      "id": "90 kDa antigen"
    },
    {
      "id": "intracellular granules"
    },
    {
      "id": "aminopeptidase-N"
    },
    {
      "id": "CD13"
    },
    {
      "id": "Cellular interactions"
    },
    {
      "id": "BOB78"
    },
    {
      "id": "subpopulation"
    },
    {
      "id": "receptors"
    },
    {
      "id": "TNFalpha"
    },
    {
      "id": "CD120b"
    },
    {
      "id": "urokinase plasminogen activator receptor"
    },
    {
      "id": "CD87"
    },
    {
      "id": "intact plasma membranes"
    },
    {
      "id": "recognition"
    },
    {
      "id": "CR1"
    },
    {
      "id": "functional downregulation"
    },
    {
      "id": "mAb"
    },
    {
      "id": "PECAM-1"
    },
    {
      "id": "CD31"
    },
    {
      "id": "specific granules"
    },
    {
      "id": "granule mobilisation"
    },
    {
      "id": "CD32"
    },
    {
      "id": "degranulation responses"
    },
    {
      "id": "sialic acid"
    },
    {
      "id": "reduced levels"
    },
    {
      "id": "CD16"
    },
    {
      "id": "pro-inflammatory mediators"
    },
    {
      "id": "in vitro culture"
    },
    {
      "id": "CD58"
    },
    {
      "id": "lectins"
    },
    {
      "id": "CD50"
    },
    {
      "id": "monoclonal antibody"
    },
    {
      "id": "C5a"
    },
    {
      "id": "CD88"
    },
    {
      "id": "receptor mobilisation"
    },
    {
      "id": "CD66acde"
    },
    {
      "id": "CD66b"
    },
    {
      "id": "increased expression"
    },
    {
      "id": "activities"
    },
    {
      "id": "other receptors"
    },
    {
      "id": "minimal D2 occupancy"
    },
    {
      "id": "12 hours"
    },
    {
      "id": "doses"
    },
    {
      "id": "300 mg/d"
    },
    {
      "id": "5-HT2a occupancy"
    },
    {
      "id": "12 to 14 hours"
    },
    {
      "id": "positron emission tomography study"
    },
    {
      "id": "quetiapine"
    },
    {
      "id": "additional subjects"
    },
    {
      "id": "transiently high D2 occupancy"
    },
    {
      "id": "minimal levels"
    },
    {
      "id": "D2 occupancy"
    },
    {
      "id": "positron emission tomography (PET) imaging"
    },
    {
      "id": "antipsychotic effect"
    },
    {
      "id": "extrapyramidal symptoms"
    },
    {
      "id": "baseline"
    },
    {
      "id": "Future studies"
    },
    {
      "id": "information"
    },
    {
      "id": "clinical profile"
    },
    {
      "id": "transient D2 occupancy"
    },
    {
      "id": "2 to 3 hours"
    },
    {
      "id": "last dose"
    },
    {
      "id": "atypical antipsychotic medication"
    },
    {
      "id": "Clinical efficacy"
    },
    {
      "id": "freedom"
    },
    {
      "id": "serotonin type 2a (5-HT2a) receptor systems"
    },
    {
      "id": "dosing interval"
    },
    {
      "id": "adverse effect ratings"
    },
    {
      "id": "schizophrenia"
    },
    {
      "id": "time of PET scanning"
    },
    {
      "id": "nonpharmacological effects"
    },
    {
      "id": "dopamine type 2 (D2) receptor systems"
    },
    {
      "id": "3 weeks"
    },
    {
      "id": "clinical dose range"
    },
    {
      "id": "150 mg/d"
    },
    {
      "id": "600 mg/d"
    },
    {
      "id": "prolactin level elevation"
    },
    {
      "id": "0%-27% D2 occupancy"
    },
    {
      "id": "12 weeks"
    },
    {
      "id": "suggestion"
    },
    {
      "id": "450 mg/d"
    },
    {
      "id": "58%-64% D2 occupancy"
    },
    {
      "id": "Quetiapine's low D2 occupancy"
    },
    {
      "id": "CB1 receptors"
    },
    {
      "id": "peripheral neurones"
    },
    {
      "id": "cannabinoid CB1 receptor agonists"
    },
    {
      "id": "muscle spasm"
    },
    {
      "id": "endogenous cannabinoid system"
    },
    {
      "id": "clinical potential"
    },
    {
      "id": "CB2 receptors"
    },
    {
      "id": "immune cells"
    },
    {
      "id": "THC"
    },
    {
      "id": "therapeutic window"
    },
    {
      "id": "spasticity"
    },
    {
      "id": "spinal cord injury"
    },
    {
      "id": "endocannabinoid levels"
    },
    {
      "id": "additional drug treatments"
    },
    {
      "id": "disorders"
    },
    {
      "id": "CB1 receptor antagonists"
    },
    {
      "id": "disorders of cognition"
    },
    {
      "id": "cannabinoid formulations"
    },
    {
      "id": "therapeutic potential"
    },
    {
      "id": "benefits"
    },
    {
      "id": "risks"
    },
    {
      "id": "therapeutic advantages"
    },
    {
      "id": "individual cannabinoids"
    },
    {
      "id": "Cannabis"
    },
    {
      "id": "appetite suppressants"
    },
    {
      "id": "chronic pain"
    },
    {
      "id": "dose range"
    },
    {
      "id": "cannabinoids"
    },
    {
      "id": "pharmacology"
    },
    {
      "id": "selective CB1 and CB2 receptor ligands"
    },
    {
      "id": "central neurones"
    },
    {
      "id": "bronchial asthma"
    },
    {
      "id": "selected symptoms"
    },
    {
      "id": "glaucoma"
    },
    {
      "id": "cannabinoid receptors"
    },
    {
      "id": "memory"
    },
    {
      "id": "D 9 - tetrahydrocannabinol"
    },
    {
      "id": "Endogenous cannabinoid receptor agonists"
    },
    {
      "id": "endocannabinoids"
    },
    {
      "id": "psychotropic activity"
    },
    {
      "id": "nabilone"
    },
    {
      "id": "multiple sclerosis"
    },
    {
      "id": "antiemetics"
    },
    {
      "id": "oral dose"
    },
    {
      "id": "patient"
    },
    {
      "id": "CB2 receptor ligands"
    },
    {
      "id": "clinical applications"
    },
    {
      "id": "variable absorption"
    },
    {
      "id": "appetite stimulants"
    },
    {
      "id": "modes of administration"
    },
    {
      "id": "antizyme"
    },
    {
      "id": "23-kDa protein"
    },
    {
      "id": "protein"
    },
    {
      "id": "mouse ODC"
    },
    {
      "id": "Antizyme inhibitor"
    },
    {
      "id": "ornithine decarboxylase"
    },
    {
      "id": "Ornithine decarboxylase"
    },
    {
      "id": "spermidine"
    },
    {
      "id": "ODC molecules"
    },
    {
      "id": "degradation"
    },
    {
      "id": "ODC reactivation"
    },
    {
      "id": "mouse fibroblasts"
    },
    {
      "id": "Antizyme"
    },
    {
      "id": "AZI"
    },
    {
      "id": "polyamines"
    },
    {
      "id": "ribosomal frameshifting"
    },
    {
      "id": "ODC"
    },
    {
      "id": "mouse AZI cDNA"
    },
    {
      "id": "ODC activity"
    },
    {
      "id": "spermine"
    },
    {
      "id": "transient transfection"
    },
    {
      "id": "AZI-expressing plasmid construct"
    },
    {
      "id": "putrescine"
    },
    {
      "id": "feedback inhibition"
    },
    {
      "id": "cloning"
    },
    {
      "id": "polyamine production"
    },
    {
      "id": "proliferation"
    },
    {
      "id": "cell growth"
    },
    {
      "id": "26 S proteasome"
    },
    {
      "id": "AZI mRNA content"
    },
    {
      "id": "growth stimulation"
    },
    {
      "id": "antizyme inhibitor"
    },
    {
      "id": "AZI synthesis"
    },
    {
      "id": "antizyme suppression"
    },
    {
      "id": "ODC transcripts"
    },
    {
      "id": "density of binding sites (Bmax)"
    },
    {
      "id": "saturation isotherms"
    },
    {
      "id": "activation of transcription"
    },
    {
      "id": "dexamethasone stimulation"
    },
    {
      "id": "Northern blot analyses"
    },
    {
      "id": "glucocorticoid receptor mRNA"
    },
    {
      "id": "equilibrium dissociation constant (Kd)"
    },
    {
      "id": "[3H]dexamethasone"
    },
    {
      "id": "primary cultures of human bronchial epithelial cells"
    },
    {
      "id": "glucocorticoid receptors"
    },
    {
      "id": "RU-486"
    },
    {
      "id": "dexamethasone"
    },
    {
      "id": "Bronchial epithelial cells"
    },
    {
      "id": "airway inflammation"
    },
    {
      "id": "Transfection"
    },
    {
      "id": "airway epithelium"
    },
    {
      "id": "anti-inflammatory effects"
    },
    {
      "id": "primary human bronchial epithelial cells"
    },
    {
      "id": "Pharmacological characterization"
    },
    {
      "id": "glucocorticoid-responsive reporter plasmid"
    },
    {
      "id": "pTAT3-CAT"
    },
    {
      "id": "mifepristone"
    },
    {
      "id": "glucocorticoid receptor activation"
    },
    {
      "id": "radioligand binding assay"
    },
    {
      "id": "pharmacological specificity"
    },
    {
      "id": "SEM"
    },
    {
      "id": "glucocorticoid receptor antagonist"
    },
    {
      "id": "glucocorticoids"
    },
    {
      "id": "dexamethasone effect"
    },
    {
      "id": "ligand-activated transcriptional regulator"
    },
    {
      "id": "inhaled steroids"
    },
    {
      "id": "western blot analyses"
    },
    {
      "id": "High-affinity binding"
    },
    {
      "id": "Isoproterenol+chromanol 293B"
    },
    {
      "id": "spontaneous TdP"
    },
    {
      "id": "LQT3"
    },
    {
      "id": "ATX-II"
    },
    {
      "id": "late I(Na)"
    },
    {
      "id": "nicorandil"
    },
    {
      "id": "QT interval"
    },
    {
      "id": "LQT2"
    },
    {
      "id": "congenital long-QT syndrome"
    },
    {
      "id": "Transmembrane action potentials"
    },
    {
      "id": "endocardial cells"
    },
    {
      "id": "epicardial cells"
    },
    {
      "id": "canine left ventricle"
    },
    {
      "id": "torsade de pointes (TdP)"
    },
    {
      "id": "LQT1"
    },
    {
      "id": "long-QT syndrome (LQTS)"
    },
    {
      "id": "d-sotalol"
    },
    {
      "id": "I(Kr)"
    },
    {
      "id": "transmural dispersion of repolarization (TDR)"
    },
    {
      "id": "M cells"
    },
    {
      "id": "action potential duration at 90% repolarization (APD(90))"
    },
    {
      "id": "acquired LQTS"
    },
    {
      "id": "Isoproterenol"
    },
    {
      "id": "beta-adrenergic tone"
    },
    {
      "id": "I(Ks)"
    },
    {
      "id": "293B+/-isoproterenol"
    },
    {
      "id": "stimulation-induced TdP"
    },
    {
      "id": "K(+) channel opener"
    },
    {
      "id": "arterially perfused wedge"
    },
    {
      "id": "Chromanol 293B"
    },
    {
      "id": "(-)-pindolol"
    },
    {
      "id": "5-HT1B"
    },
    {
      "id": "antidepressant agents"
    },
    {
      "id": "ICI118,551"
    },
    {
      "id": "NAD"
    },
    {
      "id": "DA"
    },
    {
      "id": "beta 1/2-ARs"
    },
    {
      "id": "beta 1/2-adrenergic receptors"
    },
    {
      "id": "5-HT1A"
    },
    {
      "id": "WAY100,635"
    },
    {
      "id": "fluoxetine"
    },
    {
      "id": "5-HT reuptake inhibitors"
    },
    {
      "id": "betaxolol"
    },
    {
      "id": "beta 1-AR"
    },
    {
      "id": "SB224,289"
    },
    {
      "id": "5-HT1B receptors"
    },
    {
      "id": "frontal cortex"
    },
    {
      "id": "5-HT1A receptors"
    },
    {
      "id": "duloxetine"
    },
    {
      "id": "accumbens"
    },
    {
      "id": "beta 2-AR"
    },
    {
      "id": "freely-moving rats"
    },
    {
      "id": "hepatic nicotinamide cofactors"
    },
    {
      "id": "tammar wallaby"
    },
    {
      "id": "koala"
    },
    {
      "id": "Cytochrome P450 4A"
    },
    {
      "id": "koala liver"
    },
    {
      "id": "Reverse transcription"
    },
    {
      "id": "koala liver mRNA"
    },
    {
      "id": "peroxisomal enzymes"
    },
    {
      "id": "polymerase chain reaction"
    },
    {
      "id": "cDNA clone"
    },
    {
      "id": "Microsomal lauric acid hydroxylation"
    },
    {
      "id": "CYP"
    },
    {
      "id": "CYP4A15"
    },
    {
      "id": "NAD/nicotinamide-adenine dinucleotide phosphate"
    },
    {
      "id": "tammar wallaby liver"
    },
    {
      "id": "cyanide-insensitive palmitoyl-CoA oxidation"
    },
    {
      "id": "rat"
    },
    {
      "id": "Macropus eugenii"
    },
    {
      "id": "Phascolarctos cinereus"
    },
    {
      "id": "cyanide-insensitive palmitoyl coenzyme A oxidative activity"
    },
    {
      "id": "hepatic nicotinamide-adenine dinucleotide"
    },
    {
      "id": "primers"
    },
    {
      "id": "human CYP4A11"
    },
    {
      "id": "microsomal lauric acid hydroxylase activity"
    },
    {
      "id": "nicotinamide cofactors"
    },
    {
      "id": "rat liver"
    },
    {
      "id": "CYP4A family"
    },
    {
      "id": "Pemetrexed disodium"
    },
    {
      "id": "multitargeted antifolate"
    },
    {
      "id": "LY231514"
    },
    {
      "id": "dihydrofolate reductase"
    },
    {
      "id": "Gemcitabine"
    },
    {
      "id": "thymidylate synthase"
    },
    {
      "id": "breast cancer"
    },
    {
      "id": "solid tumors"
    },
    {
      "id": "glycinamide ribonucleotide formyl transferase"
    },
    {
      "id": "Alimta"
    },
    {
      "id": "Gemzar"
    },
    {
      "id": "women"
    },
    {
      "id": "endometriosis"
    },
    {
      "id": "GnRH agonist"
    },
    {
      "id": "hormonal agents"
    },
    {
      "id": "MCP-1 expression"
    },
    {
      "id": "endometrial epithelial cells"
    },
    {
      "id": "danazol"
    },
    {
      "id": "testosterone analog"
    },
    {
      "id": "direct regulatory action"
    },
    {
      "id": "epithelial cells"
    },
    {
      "id": "human endometrium"
    },
    {
      "id": "primary cultures"
    },
    {
      "id": "steroid hormone analogs"
    },
    {
      "id": "secretion"
    },
    {
      "id": "enzyme-linked immunosorbent assay"
    },
    {
      "id": "hormonal treatments"
    },
    {
      "id": "mRNA steady-state levels"
    },
    {
      "id": "Northern blot analysis"
    },
    {
      "id": "cytokines"
    },
    {
      "id": "messenger RNA"
    },
    {
      "id": "Endometrial tissue biopsy"
    },
    {
      "id": "laparoscopy"
    },
    {
      "id": "dose-dependent inhibitory effect"
    },
    {
      "id": "PATIENT(S)"
    },
    {
      "id": "Buserelin acetate"
    },
    {
      "id": "anti-inflammatory glucocorticoid hormone"
    },
    {
      "id": "infertility"
    },
    {
      "id": "medical treatment"
    },
    {
      "id": "MCP-1 protein"
    },
    {
      "id": "pelvic pain"
    },
    {
      "id": "clinical manifestations"
    },
    {
      "id": "mechanisms"
    },
    {
      "id": "menadione-induced hepatic oxidative damage"
    },
    {
      "id": "DTD activity"
    },
    {
      "id": "menadione elimination"
    },
    {
      "id": "Sch B pretreatment"
    },
    {
      "id": "plasma alanine aminotransferase activity"
    },
    {
      "id": "Schisandrin B"
    },
    {
      "id": "DT-diaphorase activity"
    },
    {
      "id": "hepatocyte culture"
    },
    {
      "id": "schisandrin B"
    },
    {
      "id": "hepatic malondialdehyde level"
    },
    {
      "id": "Sch B"
    },
    {
      "id": "hepatoprotection"
    },
    {
      "id": "mice"
    },
    {
      "id": "menadione hepatotoxicity"
    },
    {
      "id": "biochemical mechanism"
    },
    {
      "id": "DTD"
    },
    {
      "id": "dibenzocyclooctadiene derivative"
    },
    {
      "id": "fruit of Schisandra chinensis"
    },
    {
      "id": "hepatocytes"
    },
    {
      "id": "Sch B pretreated rats"
    },
    {
      "id": "hepatotoxicity"
    },
    {
      "id": "hepatocellular DTD activity"
    },
    {
      "id": "menadione-induced hepatotoxicity"
    },
    {
      "id": "DT-diaphorase"
    },
    {
      "id": "cyclo-oxygenase-2 (COX-2) expression"
    },
    {
      "id": "uninvolved mucosa"
    },
    {
      "id": "inhibition of intermediate biomarkers"
    },
    {
      "id": "distal bowel"
    },
    {
      "id": "effective protective agent"
    },
    {
      "id": "experimental models of colon carcinogenesis"
    },
    {
      "id": "chemopreventive efficacy"
    },
    {
      "id": "nabumetone"
    },
    {
      "id": "excess"
    },
    {
      "id": "AOM-treated rats"
    },
    {
      "id": "Nabumetone"
    },
    {
      "id": "2 models of experimental colon carcinogenesis"
    },
    {
      "id": "excess of PPAR-delta"
    },
    {
      "id": "pre-neoplastic mucosa"
    },
    {
      "id": "chemoprevention"
    },
    {
      "id": "colon cancer"
    },
    {
      "id": "distal colon"
    },
    {
      "id": "complex ACF"
    },
    {
      "id": "peroxisome proliferator-activated receptor-delta (PPAR-delta)"
    },
    {
      "id": "up-regulation"
    },
    {
      "id": "experimental colon carcinogenesis"
    },
    {
      "id": "Distal bowel selectivity"
    },
    {
      "id": "non-steroidal anti-inflammatory drugs (NSAIDs)"
    },
    {
      "id": "gastro-intestinal toxicity"
    },
    {
      "id": "reductions"
    },
    {
      "id": "MIN mice"
    },
    {
      "id": "putative NSAID target"
    },
    {
      "id": "non-steroidal anti-inflammatory drug nabumetone"
    },
    {
      "id": "striking distal predilection of nabumetone"
    },
    {
      "id": "distal bowel over-expression of COX-2 and PPAR-delta"
    },
    {
      "id": "intestinal tumors"
    },
    {
      "id": "AOM-induced colonic tumorigenesis"
    },
    {
      "id": "MIN mice studies"
    },
    {
      "id": "proximal bowel"
    },
    {
      "id": "regional selectivity"
    },
    {
      "id": "aberrant crypt foci (ACF)"
    },
    {
      "id": "azoxymethane (AOM)-treated Fisher 344 rats"
    },
    {
      "id": "conventional NSAIDs"
    },
    {
      "id": "electrochemical gradient"
    },
    {
      "id": "mitochondrial respiration"
    },
    {
      "id": "UCP-3 induction"
    },
    {
      "id": "PPARalpha mRNA"
    },
    {
      "id": "UCP-3"
    },
    {
      "id": "fatty acids"
    },
    {
      "id": "Uncoupling proteins"
    },
    {
      "id": "H(+) ions"
    },
    {
      "id": "Peroxisome proliferator-activated receptor alpha"
    },
    {
      "id": "PPARalpha activators"
    },
    {
      "id": "Wy-14,643"
    },
    {
      "id": "bezafibrate"
    },
    {
      "id": "fibrates"
    },
    {
      "id": "mitochondrial membrane potential"
    },
    {
      "id": "uncoupling protein-3 mRNA"
    },
    {
      "id": "Wy-14,643 treatment"
    },
    {
      "id": "preadipocytes"
    },
    {
      "id": "bezafibrate treatment"
    },
    {
      "id": "UCPs"
    },
    {
      "id": "fuel substrates"
    },
    {
      "id": "UCP-3 expression"
    },
    {
      "id": "adipocytes"
    },
    {
      "id": "Wy-14, 643"
    },
    {
      "id": "inner mitochondrial membrane transporters"
    },
    {
      "id": "ATP synthesis"
    },
    {
      "id": "PPARalpha"
    },
    {
      "id": "RXRalpha mRNA"
    },
    {
      "id": "UCP-2 mRNA"
    },
    {
      "id": "oxidation of fatty acids"
    },
    {
      "id": "triglycerides"
    },
    {
      "id": "UCP-3 mRNA"
    },
    {
      "id": "5-HT1A receptor agonists"
    },
    {
      "id": "antidepressant drugs"
    },
    {
      "id": "40-week-old control mice brains"
    },
    {
      "id": "buspirone"
    },
    {
      "id": "partial 5-HT1A agonist"
    },
    {
      "id": "4-week-old male mice"
    },
    {
      "id": "antidepressant-like effects"
    },
    {
      "id": "tricyclic"
    },
    {
      "id": "4-week-old mice"
    },
    {
      "id": "40-week-old male mice"
    },
    {
      "id": "40-week-old mice"
    },
    {
      "id": "mouse forced swimming test"
    },
    {
      "id": "selective serotonin reuptake inhibitors"
    },
    {
      "id": "maprotiline"
    },
    {
      "id": "noradrenline reuptake inhibitor"
    },
    {
      "id": "serotonin reuptake inhibitors"
    },
    {
      "id": "anti-immobility effect"
    },
    {
      "id": "antidepressant administration"
    },
    {
      "id": "Antidepressant activity"
    },
    {
      "id": "forced swimming test"
    },
    {
      "id": "noradrenaline reuptake inhibitors"
    },
    {
      "id": "5-HT1 receptors"
    },
    {
      "id": "venlafaxine"
    },
    {
      "id": "antidepressant drug"
    },
    {
      "id": "mixed serotonin and noradrenaline reuptake inhibitors"
    },
    {
      "id": "fluvoxamine"
    },
    {
      "id": "sertraline"
    },
    {
      "id": "5-HT1B receptor agonists"
    },
    {
      "id": "anpirtoline"
    },
    {
      "id": "imipramine"
    },
    {
      "id": "elderly mice"
    },
    {
      "id": "5-HT1B agonist"
    },
    {
      "id": "4-week-old control mice brains"
    },
    {
      "id": "old mice"
    },
    {
      "id": "terminal half-life"
    },
    {
      "id": "NDGA"
    },
    {
      "id": "peak plasma concentration"
    },
    {
      "id": "Nordihydroguaiaretic acid"
    },
    {
      "id": "mouse tumor model"
    },
    {
      "id": "intravenous nordihydroguaiaretic acid"
    },
    {
      "id": "mouse"
    },
    {
      "id": "5-lipoxygenase"
    },
    {
      "id": "Pharmacokinetic analysis"
    },
    {
      "id": "mouse plasma"
    },
    {
      "id": "clearance"
    },
    {
      "id": "cancer cell lines"
    },
    {
      "id": "limit of detection"
    },
    {
      "id": "reverse-phase high-performance liquid chromatography (HPLC) method"
    },
    {
      "id": "pharmacokinetics"
    },
    {
      "id": "high-performance liquid chromatography"
    },
    {
      "id": "pyridostigmine plus exercise training"
    },
    {
      "id": "plasma butyrylcholinesterase (BChE) activity"
    },
    {
      "id": "experimental groups"
    },
    {
      "id": "pyridostigmine"
    },
    {
      "id": "interactive effect"
    },
    {
      "id": "combination"
    },
    {
      "id": "Acetylcholinesterase (AChE) activity"
    },
    {
      "id": "red blood cells"
    },
    {
      "id": "control"
    },
    {
      "id": "Gulf War veterans"
    },
    {
      "id": "nerve agents"
    },
    {
      "id": "sciatic nerve"
    },
    {
      "id": "oxidative stress response"
    },
    {
      "id": "triceps muscle"
    },
    {
      "id": "histological changes"
    },
    {
      "id": "malondialdehyde"
    },
    {
      "id": "subchronic oral dose"
    },
    {
      "id": "biochemical changes"
    },
    {
      "id": "histological abnormalities"
    },
    {
      "id": "lipid peroxidation"
    },
    {
      "id": "peripheral tissues"
    },
    {
      "id": "sedentary control"
    },
    {
      "id": "perturbation"
    },
    {
      "id": "delayed effects"
    },
    {
      "id": "delayed toxic effects"
    },
    {
      "id": "histology"
    },
    {
      "id": "Male NIH Swiss mice"
    },
    {
      "id": "physical stress"
    },
    {
      "id": "Creatine phosphokinase activity"
    },
    {
      "id": "exercise training"
    },
    {
      "id": "integrity"
    },
    {
      "id": "skeletal muscle"
    },
    {
      "id": "platelets"
    },
    {
      "id": "treadmill exercise"
    },
    {
      "id": "blood"
    },
    {
      "id": "cholinesterase activity"
    },
    {
      "id": "animals"
    },
    {
      "id": "reactivation potentials of BuChE"
    },
    {
      "id": "oxime-reactivated enzyme activity"
    },
    {
      "id": "Neuroparalysis"
    },
    {
      "id": "organophosphate poisoning"
    },
    {
      "id": "BuChE"
    },
    {
      "id": "clinical severity of poisoning"
    },
    {
      "id": "intermediate syndrome"
    },
    {
      "id": "persistent inhibition of BuChE"
    },
    {
      "id": "time after organophosphate ingestion"
    },
    {
      "id": "oxime treatment"
    },
    {
      "id": "lack of oxime efficacy"
    },
    {
      "id": "timing of oxime treatment"
    },
    {
      "id": "earlier studies"
    },
    {
      "id": "patients who received oxime prior to hospitalization"
    },
    {
      "id": "rate of intermediate syndrome"
    },
    {
      "id": "unreactivated enzyme activity"
    },
    {
      "id": "oxime"
    },
    {
      "id": "hospitalization"
    },
    {
      "id": "in vitro pralidoxime-reactivated BuChE"
    },
    {
      "id": "cohort"
    },
    {
      "id": "Namba Scale"
    },
    {
      "id": "temporal profile"
    },
    {
      "id": "BuChE activity"
    },
    {
      "id": "muscle power"
    },
    {
      "id": "severity of poisoning"
    },
    {
      "id": "enzyme"
    },
    {
      "id": "butyrylcholinesterase"
    },
    {
      "id": "levels of BuChE at admission"
    },
    {
      "id": "reactivation potential of the enzyme at admission"
    },
    {
      "id": "patients who developed intermediate syndrome"
    },
    {
      "id": "NGF protein"
    },
    {
      "id": "8-12 h exposure"
    },
    {
      "id": "vitamin D(3) analogue"
    },
    {
      "id": "CB1093"
    },
    {
      "id": "nerve growth factor"
    },
    {
      "id": "PNS"
    },
    {
      "id": "Pharmacological modulation"
    },
    {
      "id": "vitamin D receptor"
    },
    {
      "id": "NGF protein levels"
    },
    {
      "id": "72 h"
    },
    {
      "id": "clenbuterol"
    },
    {
      "id": "nerve growth factor synthesis"
    },
    {
      "id": "calcaemic effects"
    },
    {
      "id": "propranolol"
    },
    {
      "id": "NGF mRNA levels"
    },
    {
      "id": "24 h exposure"
    },
    {
      "id": "VDR binding"
    },
    {
      "id": "beta(2)-adrenoceptor agonists"
    },
    {
      "id": "NGF mRNA"
    },
    {
      "id": "10 nM"
    },
    {
      "id": "Mobility shift assays"
    },
    {
      "id": "whole cell extracts"
    },
    {
      "id": "700% increase"
    },
    {
      "id": "80%"
    },
    {
      "id": "vitamin D nuclear receptor"
    },
    {
      "id": "transcription factor"
    },
    {
      "id": "AP1 binding"
    },
    {
      "id": "3T3 cells"
    },
    {
      "id": "NGF"
    },
    {
      "id": "rational strategy"
    },
    {
      "id": "long-acting beta(2)-adrenoceptor agonist"
    },
    {
      "id": "AP-1 binding"
    },
    {
      "id": "150% increase"
    },
    {
      "id": "NGF levels"
    },
    {
      "id": "neurodegenerative disorders"
    },
    {
      "id": "mechanism of NGF induction"
    },
    {
      "id": "VDR"
    },
    {
      "id": "L929 cells"
    },
    {
      "id": "30 min"
    },
    {
      "id": "non-small cell lung cancers"
    },
    {
      "id": "ALIMTA"
    },
    {
      "id": "pemetrexed disodium"
    },
    {
      "id": "folate-dependent enzymes"
    },
    {
      "id": "combinations"
    },
    {
      "id": "bladder"
    },
    {
      "id": "pyrimidine nucleoside antimetabolite"
    },
    {
      "id": "head and neck"
    },
    {
      "id": "preclinical studies"
    },
    {
      "id": "cytotoxic synergy"
    },
    {
      "id": "glycinamide ribonucleotide formyltransferase"
    },
    {
      "id": "solid tumours"
    },
    {
      "id": "Clinical activity"
    },
    {
      "id": "phase I study"
    },
    {
      "id": "pemetrexed"
    },
    {
      "id": "ovarian cancers"
    },
    {
      "id": "partial responses"
    },
    {
      "id": "antimetabolite"
    },
    {
      "id": "pancreatic"
    },
    {
      "id": "breast"
    },
    {
      "id": "non-small cell lung"
    },
    {
      "id": "in vivo"
    },
    {
      "id": "international phase II study"
    },
    {
      "id": "alpha-thrombin"
    },
    {
      "id": "nuclear diacylglycerol mass"
    },
    {
      "id": "phospholipase D"
    },
    {
      "id": "nuclear localization"
    },
    {
      "id": "DGK-delta"
    },
    {
      "id": "DGK"
    },
    {
      "id": "signaling cascades"
    },
    {
      "id": "translocation"
    },
    {
      "id": "nucleus"
    },
    {
      "id": "hydrolysis"
    },
    {
      "id": "phosphatidic acid"
    },
    {
      "id": "Nuclear diacylglycerol kinase-theta"
    },
    {
      "id": "immunofluorescence microscopy analyses"
    },
    {
      "id": "Diacylglycerol kinase"
    },
    {
      "id": "DGK-theta"
    },
    {
      "id": "Houssa, B."
    },
    {
      "id": "Kanoh, H."
    },
    {
      "id": "J. Biol. Chem."
    },
    {
      "id": "agonist-induced activity"
    },
    {
      "id": "nuclear DGK-theta activity"
    },
    {
      "id": "diacylglycerol"
    },
    {
      "id": "phosphatidylserine"
    },
    {
      "id": "Kranenburg, O."
    },
    {
      "id": "nuclei"
    },
    {
      "id": "constitutively active RhoA"
    },
    {
      "id": "Chem. Phys. Lipids"
    },
    {
      "id": "quiescent IIC9 cells"
    },
    {
      "id": "Wada, I."
    },
    {
      "id": "nuclear DGK activity"
    },
    {
      "id": "nuclear activity"
    },
    {
      "id": "Kai, M."
    },
    {
      "id": "van Blitterswijk, W. J."
    },
    {
      "id": "de Widt, J."
    },
    {
      "id": "Sakane, F."
    },
    {
      "id": "alpha-thrombin stimulation"
    },
    {
      "id": "monoclonal anti-DGK-theta antibody"
    },
    {
      "id": "alpha-thrombin-stimulated nuclear activity"
    },
    {
      "id": "quiescent fibroblasts"
    },
    {
      "id": "nuclear lipid metabolism"
    },
    {
      "id": "signal transduction cascades"
    },
    {
      "id": "Western blot"
    },
    {
      "id": "Moolenaar, W. H."
    },
    {
      "id": "phosphatidylcholine"
    },
    {
      "id": "lipid second messengers"
    },
    {
      "id": "quiescent IIC9 fibroblasts"
    },
    {
      "id": "Imai, S."
    },
    {
      "id": "Carbonic anhydrase"
    },
    {
      "id": "reversible hydration reaction"
    },
    {
      "id": "in vitro effects"
    },
    {
      "id": "clonidine"
    },
    {
      "id": "control group"
    },
    {
      "id": "CA"
    },
    {
      "id": "zinc enzyme"
    },
    {
      "id": "vasodilating agents"
    },
    {
      "id": "CA I activity"
    },
    {
      "id": "vascular smooth muscle CA I"
    },
    {
      "id": "vasodilating processes"
    },
    {
      "id": "blood pressure"
    },
    {
      "id": "verapamil"
    },
    {
      "id": "group 2"
    },
    {
      "id": "desmopressin"
    },
    {
      "id": "carbonic anhydrase I"
    },
    {
      "id": "vascular smooth muscle"
    },
    {
      "id": "CO2"
    },
    {
      "id": "indomethacin"
    },
    {
      "id": "thromboxane A2"
    },
    {
      "id": "vasodilating drugs"
    },
    {
      "id": "direct mechanism of action"
    },
    {
      "id": "amlodipine"
    },
    {
      "id": "reserpine"
    },
    {
      "id": "In vivo"
    },
    {
      "id": "six groups"
    },
    {
      "id": "vasoconstrictive therapeutic agents"
    },
    {
      "id": "substances"
    },
    {
      "id": "group 5"
    },
    {
      "id": "acetazolamide"
    },
    {
      "id": "group 1"
    },
    {
      "id": "orciprenaline"
    },
    {
      "id": "purified human red blood cell CA I"
    },
    {
      "id": "pHi changes"
    },
    {
      "id": "activation"
    },
    {
      "id": "hydralazine"
    },
    {
      "id": "vasopressin"
    },
    {
      "id": "acute experiments"
    },
    {
      "id": "vasoconstrictive agents"
    },
    {
      "id": "prostaglandin I2"
    },
    {
      "id": "vasodilating substances"
    },
    {
      "id": "indapamide"
    },
    {
      "id": "Vasoconstrictive drugs"
    },
    {
      "id": "group 4"
    },
    {
      "id": "furosemide"
    },
    {
      "id": "purified and human erythrocyte CA I activity"
    },
    {
      "id": "prostaglandin F2 alpha"
    },
    {
      "id": "isozyme"
    },
    {
      "id": "five rabbits"
    },
    {
      "id": "acid-base balance"
    },
    {
      "id": "group 3"
    },
    {
      "id": "vascular tonus"
    },
    {
      "id": "rabbits"
    },
    {
      "id": "In vitro results"
    },
    {
      "id": "vasoconstrictive processes"
    },
    {
      "id": "results of this study"
    },
    {
      "id": "leukotriene B4"
    },
    {
      "id": "Vascular smooth muscle CA I activity"
    },
    {
      "id": "cDNAs"
    },
    {
      "id": "isoforms"
    },
    {
      "id": "C1-tetrahydrofolate interconverting enzymes"
    },
    {
      "id": "plastids"
    },
    {
      "id": "mitochondria"
    },
    {
      "id": "Tetrahydrofolate coenzymes"
    },
    {
      "id": "polyglutamylated"
    },
    {
      "id": "cytosol"
    },
    {
      "id": "gene"
    },
    {
      "id": "DHFS"
    },
    {
      "id": "folylpolyglutamate synthetase"
    },
    {
      "id": "chloroplast"
    },
    {
      "id": "folate molecule"
    },
    {
      "id": "Arabidopsis thaliana"
    },
    {
      "id": "FPGS"
    },
    {
      "id": "compartmentation"
    },
    {
      "id": "glutamate residues"
    },
    {
      "id": "dihydrofolate synthetase"
    },
    {
      "id": "yeast mutants"
    },
    {
      "id": "DHFS activity"
    },
    {
      "id": "gamma-glutamyl-conjugated tetrahydrofolate derivatives"
    },
    {
      "id": "multicompartmentation"
    },
    {
      "id": "plant cell"
    },
    {
      "id": "dihydrofolate"
    },
    {
      "id": "organisms"
    },
    {
      "id": "Tetrahydrofolate"
    },
    {
      "id": "serine hydroxymethyltransferase"
    },
    {
      "id": "polyglutamylated folate coenzymes"
    },
    {
      "id": "one-carbon (C1) metabolism"
    },
    {
      "id": "biosynthesis"
    },
    {
      "id": "glutamate incorporation"
    },
    {
      "id": "FPGS activity"
    },
    {
      "id": "folate-mediated reactions"
    },
    {
      "id": "plants"
    },
    {
      "id": "tacrine"
    },
    {
      "id": "brain penetration"
    },
    {
      "id": "new type of acetylcholinesterase inhibitor"
    },
    {
      "id": "new class of AChE inhibitors"
    },
    {
      "id": "hepatotoxic liability"
    },
    {
      "id": "Donepezil hydrochloride"
    },
    {
      "id": "physostigmine"
    },
    {
      "id": "clinical trials"
    },
    {
      "id": "cognitive deficits"
    },
    {
      "id": "Alzheimer's disease (AD)"
    },
    {
      "id": "acetylcholinesterase (AChE) inhibitors"
    },
    {
      "id": "Alzheimer's disease"
    },
    {
      "id": "cholinergic system"
    },
    {
      "id": "oral activity"
    },
    {
      "id": "Leflunomide"
    },
    {
      "id": "tumour therapy"
    },
    {
      "id": "dermatological experience"
    },
    {
      "id": "psoriasis"
    },
    {
      "id": "bullous pemphigoid"
    },
    {
      "id": "therapy"
    },
    {
      "id": "pharmacological immunomodulation"
    },
    {
      "id": "anti-inflammatory action"
    },
    {
      "id": "role"
    },
    {
      "id": "years"
    },
    {
      "id": "dermatologist's therapeutic armamentarium"
    },
    {
      "id": "mechanism of action"
    },
    {
      "id": "inflammatory pathways"
    },
    {
      "id": "Drug-related adverse effects"
    },
    {
      "id": "A 77 1726"
    },
    {
      "id": "dihydroorotate dehydrogenase"
    },
    {
      "id": "key enzyme"
    },
    {
      "id": "therapeutic agent"
    },
    {
      "id": "isoxazole derivative"
    },
    {
      "id": "autoimmune diseases"
    },
    {
      "id": "immunosuppressants"
    },
    {
      "id": "graft rejection"
    },
    {
      "id": "immunosuppressant"
    },
    {
      "id": "M1"
    },
    {
      "id": "immunomodulatory agent"
    },
    {
      "id": "pyrimidine de novo synthesis"
    },
    {
      "id": "active metabolite A 77 1726 (M1)"
    },
    {
      "id": "mechanisms of action"
    },
    {
      "id": "patient responsiveness"
    },
    {
      "id": "cell surface expression"
    },
    {
      "id": "activation marker CD25"
    },
    {
      "id": "immunomodulatory recombinant fusion protein"
    },
    {
      "id": "first extracellular domain of LFA-3"
    },
    {
      "id": "CD2/CD16-dependent apoptosis"
    },
    {
      "id": "CD2(+) cells"
    },
    {
      "id": "biological activity of alefacept"
    },
    {
      "id": "intracellular signals"
    },
    {
      "id": "CD2"
    },
    {
      "id": "isoforms of alefacept"
    },
    {
      "id": "amino acid substitutions"
    },
    {
      "id": "Alefacept"
    },
    {
      "id": "phase II and III clinical trials"
    },
    {
      "id": "chronic plaque psoriasis"
    },
    {
      "id": "human IgG1 hinge, C(H)2, and C(H)3 domains"
    },
    {
      "id": "function"
    },
    {
      "id": "extracellular signal-regulated kinase phosphorylation"
    },
    {
      "id": "IgG1 C(H)2 domain"
    },
    {
      "id": "Fc gamma R(+) cells"
    },
    {
      "id": "human CD2-transgenic mice"
    },
    {
      "id": "Fc gamma R binding"
    },
    {
      "id": "systems"
    },
    {
      "id": "CD16 signaling"
    },
    {
      "id": "sensitive CD2(+) target cells"
    },
    {
      "id": "Fc gamma RIII (CD16)"
    },
    {
      "id": "CD2(+) human memory-effector T cells"
    },
    {
      "id": "disease expression"
    },
    {
      "id": "binding to CD16"
    },
    {
      "id": "cognate interactions"
    },
    {
      "id": "human CD2"
    },
    {
      "id": "binding to CD2"
    },
    {
      "id": "NK cells"
    },
    {
      "id": "release of granzyme B"
    },
    {
      "id": "effector molecule"
    },
    {
      "id": "pharmacological effects of alefacept"
    },
    {
      "id": "immunomodulatory recombinant LFA-3/IgG1 fusion protein"
    },
    {
      "id": "important therapeutic option"
    },
    {
      "id": "treatment of multiple myeloma"
    },
    {
      "id": "Thalidomide"
    },
    {
      "id": "newly diagnosed patients"
    },
    {
      "id": "anti-angiogenic effects"
    },
    {
      "id": "multiple myeloma"
    },
    {
      "id": "widespread clinical use"
    },
    {
      "id": "certain malignancies"
    },
    {
      "id": "extensive preclinical studies"
    },
    {
      "id": "mechanism of action of thalidomide"
    },
    {
      "id": "practice"
    },
    {
      "id": "management of various disease states"
    },
    {
      "id": "erythema nodosum leprosum"
    },
    {
      "id": "effective oral agent"
    },
    {
      "id": "severe teratogenicity"
    },
    {
      "id": "immunomodulatory effects"
    },
    {
      "id": "inhibition of TNF alpha"
    },
    {
      "id": "relapsed and refractory disease"
    },
    {
      "id": "TNF alpha"
    },
    {
      "id": "single agent"
    },
    {
      "id": "FDA"
    },
    {
      "id": "diazoxide-sensitive"
    },
    {
      "id": "diffuse forms"
    },
    {
      "id": "neonates"
    },
    {
      "id": "KIR6.2"
    },
    {
      "id": "mutations"
    },
    {
      "id": "glutamate dehydrogenase gene"
    },
    {
      "id": "sequence analysis of cDNA"
    },
    {
      "id": "Hyperammonaemia"
    },
    {
      "id": "Hyperinsulinism"
    },
    {
      "id": "clinical presentations"
    },
    {
      "id": "diazoxide"
    },
    {
      "id": "severe hypoglycaemia"
    },
    {
      "id": "oversecretion of insulin"
    },
    {
      "id": "Heterogeneity"
    },
    {
      "id": "persistent hyperinsulinaemic hypoglycaemia"
    },
    {
      "id": "neonatal-onset patients"
    },
    {
      "id": "transient forms"
    },
    {
      "id": "childhood-onset"
    },
    {
      "id": "histological examination"
    },
    {
      "id": "adenoma"
    },
    {
      "id": "focal adenomatous hyperplasia"
    },
    {
      "id": "diffuse form of hyperinsulinism"
    },
    {
      "id": "infants"
    },
    {
      "id": "molecular studies"
    },
    {
      "id": "heterogeneous disorder"
    },
    {
      "id": "surgical treatment"
    },
    {
      "id": "surgically-treated patients"
    },
    {
      "id": "therapeutic outcome"
    },
    {
      "id": "i.v. glucose"
    },
    {
      "id": "reverse transcriptase-polymerase chain reaction"
    },
    {
      "id": "permanent hyperinsulinism"
    },
    {
      "id": "polymerase chain reaction-single strand conformational polymorphism analysis"
    },
    {
      "id": "genes"
    },
    {
      "id": "SUR1"
    },
    {
      "id": "infancy-onset"
    },
    {
      "id": "age of onset of hypoglycaemia"
    },
    {
      "id": "hyperinsulinaemic hypoglycaemia"
    },
    {
      "id": "hyperinsulinism-hyperammonaemia syndrome"
    },
    {
      "id": "infancy-onset hyperinsulinism"
    },
    {
      "id": "tolerance to hypoglycaemia"
    },
    {
      "id": "clinical severity"
    },
    {
      "id": "plasma glucose levels"
    },
    {
      "id": "focal forms"
    },
    {
      "id": "glucokinase gene"
    },
    {
      "id": "genetic counselling"
    },
    {
      "id": "childhood onset hyperinsulinism"
    },
    {
      "id": "therapeutic management"
    },
    {
      "id": "Aliskiren"
    },
    {
      "id": "octanamide"
    },
    {
      "id": "Renin"
    },
    {
      "id": "angiotensin (Ang) II"
    },
    {
      "id": "urinary aldosterone levels"
    },
    {
      "id": "Plasma drug levels"
    },
    {
      "id": "plasma active renin"
    },
    {
      "id": "Ang II receptor antagonists"
    },
    {
      "id": "nonpeptidic renin inhibitor"
    },
    {
      "id": "SPP100"
    },
    {
      "id": "renin inhibitor"
    },
    {
      "id": "enalapril"
    },
    {
      "id": "Plasma aldosterone levels"
    },
    {
      "id": "oral administration"
    },
    {
      "id": "IC50"
    },
    {
      "id": "plasma renin activity"
    },
    {
      "id": "healthy volunteers"
    },
    {
      "id": "double-blind, 3-way crossover protocol"
    },
    {
      "id": "heart rate"
    },
    {
      "id": "natriuresis"
    },
    {
      "id": "cardiovascular diseases"
    },
    {
      "id": "sodium diet"
    },
    {
      "id": "maximal concentrations"
    },
    {
      "id": "renin inhibitors"
    },
    {
      "id": "steady state"
    },
    {
      "id": "nanomolar range"
    },
    {
      "id": "ACE-inhibitors"
    },
    {
      "id": "Ang I"
    },
    {
      "id": "urine"
    },
    {
      "id": "renal diseases"
    },
    {
      "id": "people"
    },
    {
      "id": "diabetes"
    },
    {
      "id": "safety implications"
    },
    {
      "id": "growth-stimulating potential"
    },
    {
      "id": "in vitro potency"
    },
    {
      "id": "insulin detemir"
    },
    {
      "id": "fatty acid chain"
    },
    {
      "id": "LysB29"
    },
    {
      "id": "NN304"
    },
    {
      "id": "aspart"
    },
    {
      "id": "rapid-acting insulin analogs"
    },
    {
      "id": "mitogenic potencies"
    },
    {
      "id": "IGF-I receptor affinity"
    },
    {
      "id": "metabolic potencies"
    },
    {
      "id": "lispro"
    },
    {
      "id": "analog"
    },
    {
      "id": "balance"
    },
    {
      "id": "molar basis"
    },
    {
      "id": "insulin analogs"
    },
    {
      "id": "toxico-pharmacological properties"
    },
    {
      "id": "insulin glargine"
    },
    {
      "id": "insulin receptor affinities"
    },
    {
      "id": "B31B32diArg"
    },
    {
      "id": "safety profile"
    },
    {
      "id": "molecular modifications"
    },
    {
      "id": "human insulin"
    },
    {
      "id": "insulin lispro"
    },
    {
      "id": "B28Lys,B29Pro human insulin"
    },
    {
      "id": "primary mouse adipocytes"
    },
    {
      "id": "detemir"
    },
    {
      "id": "B29Lys(epsilon-tetradecanoyl)"
    },
    {
      "id": "A21Gly substitutions"
    },
    {
      "id": "Chinese hamster ovary cells"
    },
    {
      "id": "human insulin receptor"
    },
    {
      "id": "glargine"
    },
    {
      "id": "long-acting insulin analogs"
    },
    {
      "id": "A21Gly,B31Arg,B32Arg human insulin"
    },
    {
      "id": "insulin aspart"
    },
    {
      "id": "B28Asp human insulin"
    },
    {
      "id": "receptor binding properties"
    },
    {
      "id": "receptor affinities"
    },
    {
      "id": "purified human receptors"
    },
    {
      "id": "analogs of human insulin"
    },
    {
      "id": "desB30 human insulin"
    },
    {
      "id": "insulin receptor dissociation rates"
    },
    {
      "id": "human hormone"
    },
    {
      "id": "human osteosarcoma cells"
    },
    {
      "id": "insulin receptor off-rates"
    },
    {
      "id": "Cilostazol"
    },
    {
      "id": "omeprazole"
    },
    {
      "id": "erythromycin"
    },
    {
      "id": "HDL"
    },
    {
      "id": "adenosine receptors"
    },
    {
      "id": "A2"
    },
    {
      "id": "cholesterol"
    },
    {
      "id": "A1"
    },
    {
      "id": "cAMP"
    },
    {
      "id": "phosphodiesterase (PDE) 3A"
    },
    {
      "id": "PDE 3"
    },
    {
      "id": "2-oxo-quinoline derivative"
    },
    {
      "id": "serum triglycerides"
    },
    {
      "id": "cytochrome P450 systems"
    },
    {
      "id": "6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone"
    },
    {
      "id": "adenosine"
    },
    {
      "id": "OPC-13013"
    },
    {
      "id": "Molecular models"
    },
    {
      "id": "PDE3 inhibitors"
    },
    {
      "id": "kinetic characteristics of inhibition"
    },
    {
      "id": "mutant enzymes"
    },
    {
      "id": "nonconserved T844"
    },
    {
      "id": "cilostazol selectivity"
    },
    {
      "id": "D950A"
    },
    {
      "id": "diminished sensitivity"
    },
    {
      "id": "interaction sites"
    },
    {
      "id": "milrinone"
    },
    {
      "id": "cilostazol"
    },
    {
      "id": "F1004A"
    },
    {
      "id": "model"
    },
    {
      "id": "PDE4B crystal structure"
    },
    {
      "id": "mutants"
    },
    {
      "id": "differential sensitivity"
    },
    {
      "id": "substrate-binding pocket"
    },
    {
      "id": "PDE3A"
    },
    {
      "id": "distinct residues"
    },
    {
      "id": "Mutants Y751A"
    },
    {
      "id": "reduced sensitivity"
    },
    {
      "id": "D950"
    },
    {
      "id": "PDE families"
    },
    {
      "id": "amino acid residues"
    },
    {
      "id": "site-directed mutagenesis technique"
    },
    {
      "id": "baculovirus/Sf9 cell system"
    },
    {
      "id": "key residues"
    },
    {
      "id": "substrate"
    },
    {
      "id": "highly conserved residuals Y751"
    },
    {
      "id": "F1004"
    },
    {
      "id": "development"
    },
    {
      "id": "potent and specific inhibitory drugs"
    },
    {
      "id": "molecular modeling"
    },
    {
      "id": "inhibitors"
    },
    {
      "id": "homology"
    },
    {
      "id": "increased K(i)"
    },
    {
      "id": "Q975A"
    },
    {
      "id": "common residues"
    },
    {
      "id": "selective inhibitors"
    },
    {
      "id": "flexible size"
    },
    {
      "id": "F972A"
    },
    {
      "id": "active site"
    },
    {
      "id": "structure"
    },
    {
      "id": "inhibitory sites"
    },
    {
      "id": "mutants T844A"
    },
    {
      "id": "alanine"
    },
    {
      "id": "PDE3"
    },
    {
      "id": "site-directed mutagenesis"
    },
    {
      "id": "interacting residues"
    },
    {
      "id": "PDE3 active site"
    },
    {
      "id": "PDE3-selective inhibitor binding"
    },
    {
      "id": "cyclic nucleotide phosphodiesterase type 3A"
    },
    {
      "id": "pharmacokinetic profile"
    },
    {
      "id": "Fondaparinux sodium"
    },
    {
      "id": "synthetic factor Xa inhibitors"
    },
    {
      "id": "dose"
    },
    {
      "id": "unchanged compound"
    },
    {
      "id": "elderly volunteers"
    },
    {
      "id": "young volunteers"
    },
    {
      "id": "factor Xa"
    },
    {
      "id": "antithrombin III"
    },
    {
      "id": "C(max)"
    },
    {
      "id": "Steady state"
    },
    {
      "id": "absorption"
    },
    {
      "id": "absolute bioavailability"
    },
    {
      "id": "subcutaneous dose"
    },
    {
      "id": "Distribution volume"
    },
    {
      "id": "blood volume"
    },
    {
      "id": "arterial and venous thrombotic disorders"
    },
    {
      "id": "young male volunteers"
    },
    {
      "id": "prevention"
    },
    {
      "id": "venous thromboembolism"
    },
    {
      "id": "major orthopaedic surgery"
    },
    {
      "id": "Within-subject variability"
    },
    {
      "id": "AUC"
    },
    {
      "id": "area under the concentration-time curve"
    },
    {
      "id": "Plasma clearance"
    },
    {
      "id": "total-subject variability"
    },
    {
      "id": "renal clearance"
    },
    {
      "id": "metabolism"
    },
    {
      "id": "End products"
    },
    {
      "id": "Apoptosis"
    },
    {
      "id": "Microarray"
    },
    {
      "id": "Activated transcription factor 4"
    },
    {
      "id": "Nonsterol mevalonate metabolites"
    },
    {
      "id": "GGPP"
    },
    {
      "id": "Apoptotic effects"
    },
    {
      "id": "CC cells"
    },
    {
      "id": "HMG-CoA reductase"
    },
    {
      "id": "Mevalonate pathway"
    },
    {
      "id": "Biosynthesis"
    },
    {
      "id": "rhoA"
    },
    {
      "id": "Products"
    },
    {
      "id": "Cellular functions"
    },
    {
      "id": "Treatment"
    },
    {
      "id": "HNSCC cell lines"
    },
    {
      "id": "Therapeutic target"
    },
    {
      "id": "Cervical carcinomas"
    },
    {
      "id": "Biochemical data"
    },
    {
      "id": "Depletion"
    },
    {
      "id": "Mediators"
    },
    {
      "id": "Membrane integrity"
    },
    {
      "id": "Lovastatin"
    },
    {
      "id": "Inhibitor"
    },
    {
      "id": "Anticancer properties"
    },
    {
      "id": "Differentially expressed genes"
    },
    {
      "id": "Acyl-CoA-binding protein"
    },
    {
      "id": "HNSCC cells"
    },
    {
      "id": "Biochemical analysis"
    },
    {
      "id": "Apoptotic response"
    },
    {
      "id": "Tumor types"
    },
    {
      "id": "Cholesterol"
    },
    {
      "id": "Head and neck squamous cell carcinomas"
    },
    {
      "id": "SCC9"
    },
    {
      "id": "CC"
    },
    {
      "id": "Mevalonate metabolites"
    },
    {
      "id": "Rate-limiting enzyme"
    },
    {
      "id": "SCC25"
    },
    {
      "id": "Geranylgeranyl pyrophosphate"
    },
    {
      "id": "HMG-CoA"
    },
    {
      "id": "3-hydroxy-3-methylglutaryl coenzyme A"
    },
    {
      "id": "HNSCC"
    },
    {
      "id": "Cell cycle progression"
    },
    {
      "id": "Squamous cell carcinomas"
    },
    {
      "id": "Sterols"
    },
    {
      "id": "Cell signaling"
    },
    {
      "id": "Protein synthesis"
    },
    {
      "id": "Diazepam-binding inhibitor"
    },
    {
      "id": "Transcription"
    },
    {
      "id": "Expression analysis"
    },
    {
      "id": "Nonsterol moiety"
    },
    {
      "id": "tyrosine hydroxylase"
    },
    {
      "id": "DMI"
    },
    {
      "id": "NET"
    },
    {
      "id": "desipramine"
    },
    {
      "id": "NET inhibitor"
    },
    {
      "id": "catecholamines"
    },
    {
      "id": "Th"
    },
    {
      "id": "synaptic norepinephrine"
    },
    {
      "id": "NE"
    },
    {
      "id": "dopamine beta-hydroxylase"
    },
    {
      "id": "adrenoreceptor"
    },
    {
      "id": "Dbh"
    },
    {
      "id": "catecholamine depletion"
    },
    {
      "id": "DMI treatment"
    },
    {
      "id": "endogenous NE"
    },
    {
      "id": "nAChR agonists"
    },
    {
      "id": "analgesia"
    },
    {
      "id": "Neuronal nicotinic acetylcholine receptor"
    },
    {
      "id": "nAChR"
    },
    {
      "id": "artificial cerebrospinal fluid"
    },
    {
      "id": "nicotine"
    },
    {
      "id": "central nervous system"
    },
    {
      "id": "L2-L4 dermatomes"
    },
    {
      "id": "spinal cord"
    },
    {
      "id": "nAChR antagonists"
    },
    {
      "id": "alpha(4)beta(2*) nAChRs"
    },
    {
      "id": "noradrenergic terminals"
    },
    {
      "id": "metanicotine"
    },
    {
      "id": "alpha(4)beta(2*)-preferring nAChR antagonists"
    },
    {
      "id": "glutamate release"
    },
    {
      "id": "neurotransmitter release"
    },
    {
      "id": "spinal norepinephrine release"
    },
    {
      "id": "nitric oxide synthase inhibitors"
    },
    {
      "id": "synaptosomes"
    },
    {
      "id": "microdialysates"
    },
    {
      "id": "antinociception"
    },
    {
      "id": "microdialysis probes"
    },
    {
      "id": "glutamate antagonists"
    },
    {
      "id": "presynaptic terminals"
    },
    {
      "id": "nicotinic agonists"
    },
    {
      "id": "alpha(4)beta(2*) nAChR agonist"
    },
    {
      "id": "Nicotinic acetylcholine receptor"
    },
    {
      "id": "nAChR subtypes"
    },
    {
      "id": "alpha(7*)-preferring nAChR antagonists"
    },
    {
      "id": "nitric oxide synthesis"
    },
    {
      "id": "nicotinic antagonists"
    },
    {
      "id": "volatile anesthetic halothane"
    },
    {
      "id": "light-induced photoreceptor degeneration"
    },
    {
      "id": "Albino mice"
    },
    {
      "id": "high levels of white or blue light"
    },
    {
      "id": "critical number of photons"
    },
    {
      "id": "retinal degeneration"
    },
    {
      "id": "rhodopsin-mediated uptake"
    },
    {
      "id": "halothane"
    },
    {
      "id": "photon absorption"
    },
    {
      "id": "light exposure"
    },
    {
      "id": "halothane anesthesia"
    },
    {
      "id": "metabolic rhodopsin regeneration"
    },
    {
      "id": "photoreceptors"
    },
    {
      "id": "degeneration"
    },
    {
      "id": "white light"
    },
    {
      "id": "rhodopsin"
    },
    {
      "id": "process"
    },
    {
      "id": "photoreversal of bleaching"
    },
    {
      "id": "Protective effect"
    },
    {
      "id": "retinas"
    },
    {
      "id": "rodent retina"
    },
    {
      "id": "retina"
    },
    {
      "id": "blue light"
    },
    {
      "id": "in situ staining"
    },
    {
      "id": "apoptotic nuclei"
    },
    {
      "id": "photoreceptor cells"
    },
    {
      "id": "Rhodopsin regeneration"
    },
    {
      "id": "bleaching"
    },
    {
      "id": "rhodopsin levels"
    },
    {
      "id": "darkness"
    },
    {
      "id": "blue-light-induced photoreceptor cell death"
    },
    {
      "id": "white light-induced retinal degeneration"
    },
    {
      "id": "functional rhodopsin"
    },
    {
      "id": "bleaching intermediates"
    },
    {
      "id": "TUNEL assay"
    },
    {
      "id": "Retinal morphology"
    },
    {
      "id": "light microscopy"
    },
    {
      "id": "rhodopsin molecules"
    },
    {
      "id": "fragmented genomic DNA"
    },
    {
      "id": "retinal light damage"
    },
    {
      "id": "Nonanesthetized animals"
    },
    {
      "id": "controls"
    },
    {
      "id": "high numbers of photons"
    },
    {
      "id": "visual cycle"
    },
    {
      "id": "pigment epithelium"
    },
    {
      "id": "five novel mutations"
    },
    {
      "id": "IVS12-8T-->A"
    },
    {
      "id": "31del10"
    },
    {
      "id": "PCCB gene"
    },
    {
      "id": "catabolism"
    },
    {
      "id": "odd-numbered chain length fatty acids"
    },
    {
      "id": "Korean patients"
    },
    {
      "id": "threonine"
    },
    {
      "id": "betaPCC-subunit"
    },
    {
      "id": "1527del3 homozygote patient"
    },
    {
      "id": "homozygotes"
    },
    {
      "id": "1527del3"
    },
    {
      "id": "deficiency"
    },
    {
      "id": "propionyl-CoA carboxylase (PCC, EC 6.4.1.3)"
    },
    {
      "id": "five patients"
    },
    {
      "id": "PCC enzyme assay"
    },
    {
      "id": "three cases"
    },
    {
      "id": "late manifestations"
    },
    {
      "id": "heterogeneity"
    },
    {
      "id": "PCCA gene"
    },
    {
      "id": "Two neonatal-onset patients"
    },
    {
      "id": "PCC activities"
    },
    {
      "id": "one known mutation"
    },
    {
      "id": "T428I"
    },
    {
      "id": "propionic acidemia"
    },
    {
      "id": "Y439C"
    },
    {
      "id": "T428I mutation"
    },
    {
      "id": "severe clinical courses"
    },
    {
      "id": "residual enzyme activities"
    },
    {
      "id": "biotin-dependent enzyme"
    },
    {
      "id": "carboxylation"
    },
    {
      "id": "eight Korean patients"
    },
    {
      "id": "organic acid analysis"
    },
    {
      "id": "null enzyme activities"
    },
    {
      "id": "D-methylmalonyl-CoA"
    },
    {
      "id": "heteropolymeric enzyme"
    },
    {
      "id": "beta-subunits"
    },
    {
      "id": "mRNA"
    },
    {
      "id": "molecular analysis"
    },
    {
      "id": "1527del3 homozygotes"
    },
    {
      "id": "1357insT"
    },
    {
      "id": "autosomal recessive inborn error"
    },
    {
      "id": "1527del3 mutation"
    },
    {
      "id": "lymphoblasts"
    },
    {
      "id": "T428I homozygotes"
    },
    {
      "id": "propionyl-CoA"
    },
    {
      "id": "Clinical symptoms"
    },
    {
      "id": "neonatal-onset"
    },
    {
      "id": "alleles"
    },
    {
      "id": "Caucasian populations"
    },
    {
      "id": "molecular pathology"
    },
    {
      "id": "PCC"
    },
    {
      "id": "Alleleic frequency"
    },
    {
      "id": "This finding"
    },
    {
      "id": "Propionic acidemia (PA)"
    },
    {
      "id": "alpha-subunits"
    },
    {
      "id": "valine"
    },
    {
      "id": "late-onset form"
    },
    {
      "id": "this study"
    },
    {
      "id": "Korean patients with PA"
    },
    {
      "id": "Western blot analysis"
    },
    {
      "id": "PA"
    },
    {
      "id": "isoleucine"
    },
    {
      "id": "Oriental populations"
    },
    {
      "id": "methionine"
    },
    {
      "id": "postmenopausal women"
    },
    {
      "id": "advanced breast cancer"
    },
    {
      "id": "Fulvestrant"
    },
    {
      "id": "megestrol acetate"
    },
    {
      "id": "adverse event"
    },
    {
      "id": "Endocrine therapy"
    },
    {
      "id": "therapies"
    },
    {
      "id": "therapeutic profile"
    },
    {
      "id": "estrogen receptor-positive"
    },
    {
      "id": "aromatase inhibitors"
    },
    {
      "id": "tamoxifen failure"
    },
    {
      "id": "partial agonist property"
    },
    {
      "id": "thromboembolic events"
    },
    {
      "id": "estrogen antagonist"
    },
    {
      "id": "anastrozole"
    },
    {
      "id": "weight gain"
    },
    {
      "id": "agonist activity"
    },
    {
      "id": "progesterone receptor-positive"
    },
    {
      "id": "fluid retention"
    },
    {
      "id": "second-line therapy"
    },
    {
      "id": "prior endocrine therapy"
    },
    {
      "id": "aromatase inhibitor"
    },
    {
      "id": "estrogen receptor"
    },
    {
      "id": "agent"
    },
    {
      "id": "new class of drug"
    },
    {
      "id": "estrogen receptor downregulators"
    },
    {
      "id": "endocrine therapies"
    },
    {
      "id": "Two phase III trials"
    },
    {
      "id": "residues"
    },
    {
      "id": "association"
    },
    {
      "id": "ornithine carbamoyltransferase"
    },
    {
      "id": "enzyme complex"
    },
    {
      "id": "lysine residues"
    },
    {
      "id": "sensitivity of OTCase"
    },
    {
      "id": "SMG loop"
    },
    {
      "id": "C terminus"
    },
    {
      "id": "signal"
    },
    {
      "id": "affinity for ornithine"
    },
    {
      "id": "Lys-260"
    },
    {
      "id": "Asn-185"
    },
    {
      "id": "ornithine binding residues"
    },
    {
      "id": "cysteines"
    },
    {
      "id": "trimeric structure"
    },
    {
      "id": "substrates"
    },
    {
      "id": "stable complex"
    },
    {
      "id": "catalysis"
    },
    {
      "id": "enzyme catalytic activities"
    },
    {
      "id": "arginase"
    },
    {
      "id": "OTCase"
    },
    {
      "id": "Asp-182"
    },
    {
      "id": "catalytic activity"
    },
    {
      "id": "Lys-268"
    },
    {
      "id": "interaction"
    },
    {
      "id": "nonallosteric enzymes"
    },
    {
      "id": "Yeast epiarginase"
    },
    {
      "id": "enzyme-enzyme activity control"
    },
    {
      "id": "ornithine"
    },
    {
      "id": "catalytic domain"
    },
    {
      "id": "Glu-256"
    },
    {
      "id": "epiarginase function"
    },
    {
      "id": "arginine"
    },
    {
      "id": "regulatory activities"
    },
    {
      "id": "cooperative association"
    },
    {
      "id": "Asn-184"
    },
    {
      "id": "Cys-289"
    },
    {
      "id": "Lys-263"
    },
    {
      "id": "activity of OTCase"
    },
    {
      "id": "Lys-265"
    },
    {
      "id": "melperone"
    },
    {
      "id": "ACh"
    },
    {
      "id": "clozapine"
    },
    {
      "id": "iloperidone"
    },
    {
      "id": "5-HT(2A)"
    },
    {
      "id": "acetylcholine"
    },
    {
      "id": "olanzapine"
    },
    {
      "id": "Quetiapine"
    },
    {
      "id": "WAY100635"
    },
    {
      "id": "risperidone"
    },
    {
      "id": "5-HT(1A)"
    },
    {
      "id": "D(2)"
    },
    {
      "id": "Iloperidone"
    },
    {
      "id": "cysteinyl leukotriene antagonist"
    },
    {
      "id": "adhesive interaction"
    },
    {
      "id": "blood eosinophils"
    },
    {
      "id": "pranlukast"
    },
    {
      "id": "FMLP-activated eosinophil adhesion"
    },
    {
      "id": "inhibitory action"
    },
    {
      "id": "CysLT antagonist"
    },
    {
      "id": "chemotactic response"
    },
    {
      "id": "LTD4"
    },
    {
      "id": "adhesion"
    },
    {
      "id": "eosinophils"
    },
    {
      "id": "pulmonary endothelial cells"
    },
    {
      "id": "endothelial activating cytokines"
    },
    {
      "id": "expression"
    },
    {
      "id": "adhesion molecules"
    },
    {
      "id": "Pranlukast hydrate"
    },
    {
      "id": "eosinophil accumulation"
    },
    {
      "id": "asthmatic airways"
    },
    {
      "id": "eosinophil spontaneous adhesion"
    },
    {
      "id": "TNF-alpha-stimulated pulmonary endothelial cells"
    },
    {
      "id": "accumulation"
    },
    {
      "id": "resting endothelial cells"
    },
    {
      "id": "asthmatic airway"
    },
    {
      "id": "cysteinyl leukotriene (CysLT) antagonists"
    },
    {
      "id": "mechanism"
    },
    {
      "id": "action"
    },
    {
      "id": "resting pulmonary endothelial cells"
    },
    {
      "id": "Study"
    },
    {
      "id": "IL-5"
    },
    {
      "id": "pranlukast hydrate"
    },
    {
      "id": "PET ligand"
    },
    {
      "id": "in vivo imaging"
    },
    {
      "id": "radioactivity"
    },
    {
      "id": "hypothalamus"
    },
    {
      "id": "(S,S)-[(11)C]-MeNER"
    },
    {
      "id": "in vivo brain distribution"
    },
    {
      "id": "[(11)C]-labeled enantiomers"
    },
    {
      "id": "MeNER"
    },
    {
      "id": "ligand"
    },
    {
      "id": "reboxetine"
    },
    {
      "id": "norepinephrine reuptake inhibitors"
    },
    {
      "id": "novel radiotracers"
    },
    {
      "id": "(R,R)-enantiomer"
    },
    {
      "id": "washout of radioactivity"
    },
    {
      "id": "regional distribution pattern"
    },
    {
      "id": "(S,S)-enantiomer"
    },
    {
      "id": "brain"
    },
    {
      "id": "Hypothalamus to striatum ratios"
    },
    {
      "id": "reuptake inhibitors of dopamine"
    },
    {
      "id": "In vitro autoradiography studies"
    },
    {
      "id": "brain region"
    },
    {
      "id": "rat brain slices"
    },
    {
      "id": "brain uptake"
    },
    {
      "id": "in vivo evaluation"
    },
    {
      "id": "tail-vein injection"
    },
    {
      "id": "carbon-11"
    },
    {
      "id": "positron emission tomography"
    },
    {
      "id": "NET rich region"
    },
    {
      "id": "(R,R) and (S,S) enantiomers of 2-[(2-methoxyphenoxy)phenylmethyl]morpholine"
    },
    {
      "id": "PET"
    },
    {
      "id": "binding"
    },
    {
      "id": "schizophrenic inpatients"
    },
    {
      "id": "Blood sampling"
    },
    {
      "id": "discontinuation"
    },
    {
      "id": "Css"
    },
    {
      "id": "coadministration"
    },
    {
      "id": "homochlorcyclizine"
    },
    {
      "id": "UKU score"
    },
    {
      "id": "CYP2D6-catalyzed metabolism"
    },
    {
      "id": "promethazine"
    },
    {
      "id": "steady-state plasma concentrations"
    },
    {
      "id": "reduced haloperidol"
    },
    {
      "id": "clinical assessments"
    },
    {
      "id": "Udvalg for kliniske undersogelser (UKU) side effect rating scale"
    },
    {
      "id": "Brief Psychiatric Rating Scale (BPRS)"
    },
    {
      "id": "inhibitory effects"
    },
    {
      "id": "BPRS score"
    },
    {
      "id": "Histamine H1-receptor antagonists"
    },
    {
      "id": "CYP2D6"
    },
    {
      "id": "clinical doses"
    },
    {
      "id": "quadruple eradication regimen"
    },
    {
      "id": "rabeprazole 20 to 40 mg/day"
    },
    {
      "id": "rabeprazole 10 mg/day"
    },
    {
      "id": "triple-therapy regimen"
    },
    {
      "id": "Rabeprazole"
    },
    {
      "id": "lansoprazole"
    },
    {
      "id": "rabeprazole 10 to 40 mg/day"
    },
    {
      "id": "ranitidine"
    },
    {
      "id": "proton pump inhibitors"
    },
    {
      "id": "Helicobacter pylori eradication therapy"
    },
    {
      "id": "dosage adjustment"
    },
    {
      "id": "renal impairment"
    },
    {
      "id": "prevention of relapse"
    },
    {
      "id": "H(2) antagonists"
    },
    {
      "id": "diarrhoea"
    },
    {
      "id": "amoxicillin"
    },
    {
      "id": "acid-related disorders"
    },
    {
      "id": "Symptom relief"
    },
    {
      "id": "rabeprazole 20 mg/day"
    },
    {
      "id": "H. pylori"
    },
    {
      "id": "pharyngitis"
    },
    {
      "id": "peptic ulcers"
    },
    {
      "id": "serum gastrin levels"
    },
    {
      "id": "healing of GORD"
    },
    {
      "id": "heartburn"
    },
    {
      "id": "headache"
    },
    {
      "id": "hepatic impairment"
    },
    {
      "id": "eradication rates"
    },
    {
      "id": "rabeprazole 10mg twice daily"
    },
    {
      "id": "gastrointestinal symptoms"
    },
    {
      "id": "rabeprazole 60 to 120 mg/day"
    },
    {
      "id": "endoscopic lesions"
    },
    {
      "id": "gastric proton pump"
    },
    {
      "id": "Histological changes"
    },
    {
      "id": "omeprazole 20 mg/day"
    },
    {
      "id": "clarithromycin"
    },
    {
      "id": "rhinitis"
    },
    {
      "id": "acid secretion"
    },
    {
      "id": "oesophagitis"
    },
    {
      "id": "recurrence of symptoms"
    },
    {
      "id": "maximum concentration"
    },
    {
      "id": "body weight"
    },
    {
      "id": "Retigabine"
    },
    {
      "id": "renal excretion"
    },
    {
      "id": "phase II metabolism"
    },
    {
      "id": "N-glucuronidation"
    },
    {
      "id": "single 200-mg oral dose"
    },
    {
      "id": "retigabine"
    },
    {
      "id": "56%"
    },
    {
      "id": "sex"
    },
    {
      "id": "white subjects"
    },
    {
      "id": "12 women"
    },
    {
      "id": "young women"
    },
    {
      "id": "retigabine elimination"
    },
    {
      "id": "elderly subjects"
    },
    {
      "id": "elderly patients"
    },
    {
      "id": "KCNQ3/5 channels"
    },
    {
      "id": "M-current potassium channel opener"
    },
    {
      "id": "ANOVA"
    },
    {
      "id": "age"
    },
    {
      "id": "disposition"
    },
    {
      "id": "M-current potassium channel"
    },
    {
      "id": "KCNQ2/3"
    },
    {
      "id": "72-hour period"
    },
    {
      "id": "12 men"
    },
    {
      "id": "2 hours"
    },
    {
      "id": "half-life"
    },
    {
      "id": "Subjects"
    },
    {
      "id": "AWD21-360"
    },
    {
      "id": "plasma concentrations"
    },
    {
      "id": "acetylated metabolite"
    },
    {
      "id": "apparent clearance"
    },
    {
      "id": "decline of renal function"
    },
    {
      "id": "42%"
    },
    {
      "id": "acetylation"
    },
    {
      "id": "apparent clearance normalized for weight"
    },
    {
      "id": "30%"
    },
    {
      "id": "0.68 L x h(-1) x kg(-1)"
    },
    {
      "id": "young men"
    },
    {
      "id": "antiepileptic drug"
    },
    {
      "id": "young subjects"
    },
    {
      "id": "18-40 years"
    },
    {
      "id": "0.67 L x h(-1) x kg(-1)"
    },
    {
      "id": "66-81 years"
    },
    {
      "id": "age group"
    },
    {
      "id": "20%"
    },
    {
      "id": "sex-related differences"
    },
    {
      "id": "8.5 hours"
    },
    {
      "id": "phases"
    },
    {
      "id": "drug discovery and development process"
    },
    {
      "id": "P-gp assays"
    },
    {
      "id": "28 reference compounds"
    },
    {
      "id": "recommendations"
    },
    {
      "id": "screening strategies"
    },
    {
      "id": "functional assays"
    },
    {
      "id": "transcellular transport assay"
    },
    {
      "id": "P-glycoprotein"
    },
    {
      "id": "P-gp"
    },
    {
      "id": "drug-drug interactions"
    },
    {
      "id": "transporter"
    },
    {
      "id": "species differences"
    },
    {
      "id": "test systems"
    },
    {
      "id": "ATPase activity assay"
    },
    {
      "id": "drug discovery process"
    },
    {
      "id": "in vitro P-glycoprotein screening assays"
    },
    {
      "id": "drug discovery"
    },
    {
      "id": "human P-gp"
    },
    {
      "id": "cellular uptake"
    },
    {
      "id": "calcein AM"
    },
    {
      "id": "ATP-dependent drug efflux pump"
    },
    {
      "id": "inhibition assays"
    },
    {
      "id": "cytochrome P450 3A4"
    },
    {
      "id": "in silico predictions"
    },
    {
      "id": "rhodamine-123"
    },
    {
      "id": "porcine P-gp"
    },
    {
      "id": "CYP3A4"
    },
    {
      "id": "indirect fluorescence indicator screening assay"
    },
    {
      "id": "subset of compounds"
    },
    {
      "id": "mouse P-gp"
    },
    {
      "id": "dexamethasone treatment"
    },
    {
      "id": "granulation tissue atrophy"
    },
    {
      "id": "selective COX-2 inhibition"
    },
    {
      "id": "keratinocyte proliferation"
    },
    {
      "id": "inducible cyclooxygenase-2 (COX-2) enzyme"
    },
    {
      "id": "inflammatory diseases"
    },
    {
      "id": "Selective cyclooxygenase-2 inhibition"
    },
    {
      "id": "healing"
    },
    {
      "id": "Infiltrating macrophages"
    },
    {
      "id": "wound site"
    },
    {
      "id": "cutaneous full-thickness, sutured, incisional wound model"
    },
    {
      "id": "hairless SKH-1 mice"
    },
    {
      "id": "nonselective COX inhibition"
    },
    {
      "id": "dermal angiogenesis"
    },
    {
      "id": "microscopic morphology of the wounds"
    },
    {
      "id": "epithelial cancers"
    },
    {
      "id": "dermal fibroblasts"
    },
    {
      "id": "SC-791"
    },
    {
      "id": "selective COX-2 inhibitor"
    },
    {
      "id": "cutaneous full-thickness incisional wounds"
    },
    {
      "id": "SKH-1 mice"
    },
    {
      "id": "COX-2 expression"
    },
    {
      "id": "nonselective COX inhibitors"
    },
    {
      "id": "inhibition of COX-2"
    },
    {
      "id": "incisional skin wound healing"
    },
    {
      "id": "wound tensile strength"
    },
    {
      "id": "diclofenac"
    },
    {
      "id": "nonselective COX inhibitor"
    },
    {
      "id": "macroscopic morphology of the wounds"
    },
    {
      "id": "keratinocytes"
    },
    {
      "id": "celecoxib"
    },
    {
      "id": "keratinocyte differentiation"
    },
    {
      "id": "wound healing process"
    },
    {
      "id": "tissue repair"
    },
    {
      "id": "surgical skin wounds"
    },
    {
      "id": "angiogenesis"
    },
    {
      "id": "epidermal atrophy"
    },
    {
      "id": "wounds"
    },
    {
      "id": "healing period"
    },
    {
      "id": "selective COX-2 inhibitors"
    },
    {
      "id": "wound strength"
    },
    {
      "id": "plasmin"
    },
    {
      "id": "alpha 2-antiplasmin"
    },
    {
      "id": "glomerular and tubular epithelial cell surface"
    },
    {
      "id": "plasminogen"
    },
    {
      "id": "lysine binding sites"
    },
    {
      "id": "chromogenic tripeptide"
    },
    {
      "id": "S-2251"
    },
    {
      "id": "gp330"
    },
    {
      "id": "benzamidine"
    },
    {
      "id": "urokinase"
    },
    {
      "id": "epsilon-amino caproic acid"
    },
    {
      "id": "natural inhibitors"
    },
    {
      "id": "plasminogen binding sites"
    },
    {
      "id": "Km"
    },
    {
      "id": "EACA"
    },
    {
      "id": "Vmax"
    },
    {
      "id": "Heymann nephritis autoantigen"
    },
    {
      "id": "ELISA"
    },
    {
      "id": "lysine analogue"
    },
    {
      "id": "5TFI"
    },
    {
      "id": "mIL-2"
    },
    {
      "id": "isoleucine auxotrophic Escherichia coli host strain"
    },
    {
      "id": "tryptic peptide analysis"
    },
    {
      "id": "protein product"
    },
    {
      "id": "fluorinated cytokines"
    },
    {
      "id": "stable and functional structures"
    },
    {
      "id": "specificity constant"
    },
    {
      "id": "k(cat)/K(m)"
    },
    {
      "id": "fluorinated protein"
    },
    {
      "id": "maximal proliferative response"
    },
    {
      "id": "IleRS"
    },
    {
      "id": "murine dihydrofolate reductase"
    },
    {
      "id": "cytokine"
    },
    {
      "id": "murine interleukin-2"
    },
    {
      "id": "matrix-assisted laser desorption ionization mass spectrometry"
    },
    {
      "id": "mDHFR"
    },
    {
      "id": "maximal responses"
    },
    {
      "id": "wild-type cytokines"
    },
    {
      "id": "concentration"
    },
    {
      "id": "wild-type mIL-2"
    },
    {
      "id": "5TFI-supplemented minimal medium"
    },
    {
      "id": "minimal medium"
    },
    {
      "id": "E. coli isoleucyl-tRNA synthetase"
    },
    {
      "id": "model target protein"
    },
    {
      "id": "d,l-2-amino-5,5,5-trifluoro-3-methyl pentanoic acid"
    },
    {
      "id": "fluorinated derivatives"
    },
    {
      "id": "rate of activation"
    },
    {
      "id": "trifluoroisoleucine"
    },
    {
      "id": "in vivo incorporation"
    },
    {
      "id": "3TFI"
    },
    {
      "id": "d,l-2-amino-3-trifluoromethyl pentanoic acid"
    },
    {
      "id": "recombinant proteins"
    },
    {
      "id": "Escherichia coli host strain"
    },
    {
      "id": "isoleucine residues"
    },
    {
      "id": "MALDI-MS"
    },
    {
      "id": "Amino acid analysis"
    },
    {
      "id": "isoleucine positions"
    },
    {
      "id": "Escherichia coli"
    },
    {
      "id": "proteins"
    },
    {
      "id": "host strain"
    },
    {
      "id": "HT-29/Inv2"
    },
    {
      "id": "COX-2 expression levels"
    },
    {
      "id": "LD(50)"
    },
    {
      "id": "HT-29/Inv1"
    },
    {
      "id": "dUTP"
    },
    {
      "id": "nick end labeling"
    },
    {
      "id": "biotin"
    },
    {
      "id": "COX-2 inhibitors"
    },
    {
      "id": "tumor invasion"
    },
    {
      "id": "in vitro Matrigel invasive potential"
    },
    {
      "id": "HT-29 variants"
    },
    {
      "id": "invasive potential"
    },
    {
      "id": "etodolac"
    },
    {
      "id": "growth medium"
    },
    {
      "id": "HT-29 colon cancer cell lines"
    },
    {
      "id": "In vivo experiments"
    },
    {
      "id": "SCID mice"
    },
    {
      "id": "subcutaneous tumors"
    },
    {
      "id": "HT-29/Inv3"
    },
    {
      "id": "invasiveness"
    },
    {
      "id": "terminal deoxynucleotidyl transferase"
    },
    {
      "id": "Cyclooxygenase-2"
    },
    {
      "id": "etolodac"
    },
    {
      "id": "growth"
    },
    {
      "id": "DNA fragmentation"
    },
    {
      "id": "Colon cancer cells"
    },
    {
      "id": "parental HT-29"
    },
    {
      "id": "in vitro growth inhibition assays"
    },
    {
      "id": "colon cancer patients"
    },
    {
      "id": "comparison"
    },
    {
      "id": "hNET point mutations"
    },
    {
      "id": "inhibitory potency"
    },
    {
      "id": "18 mutations"
    },
    {
      "id": "hNET amino acid residues"
    },
    {
      "id": "12 additional mutations"
    },
    {
      "id": "IL1"
    },
    {
      "id": "Ki"
    },
    {
      "id": "microM"
    },
    {
      "id": "three mutations"
    },
    {
      "id": "MrIA binding"
    },
    {
      "id": "site"
    },
    {
      "id": "previous data"
    },
    {
      "id": "TMDs 2"
    },
    {
      "id": "hNET"
    },
    {
      "id": "predicted extracellular loops 4"
    },
    {
      "id": "MrIA"
    },
    {
      "id": "uptake"
    },
    {
      "id": "[3H]norepinephrine"
    },
    {
      "id": "TMD2"
    },
    {
      "id": "[3H]dopamine"
    },
    {
      "id": "norepinephrine uptake"
    },
    {
      "id": "mutant hNETs"
    },
    {
      "id": "cocaine"
    },
    {
      "id": "binding sites"
    },
    {
      "id": "tricyclic antidepressants"
    },
    {
      "id": "predicted extracellular loops 3"
    },
    {
      "id": "chi-Conopeptide MrIA"
    },
    {
      "id": "TMDs 5"
    },
    {
      "id": "interactions"
    },
    {
      "id": "TMDs 11"
    },
    {
      "id": "human norepinephrine transporter"
    },
    {
      "id": "other mutations"
    },
    {
      "id": "MrIA potency"
    },
    {
      "id": "one mutation"
    },
    {
      "id": "TMD6"
    },
    {
      "id": "intracellular loop (IL) 3"
    },
    {
      "id": "COS-7 cells"
    },
    {
      "id": "TMDs 4"
    },
    {
      "id": "serotonin transporter"
    },
    {
      "id": "MrIA inhibitory potency"
    },
    {
      "id": "transmembrane domain (TMD) 8"
    },
    {
      "id": "prazosin-binding sites"
    },
    {
      "id": "alpha(1)-adrenoceptors"
    },
    {
      "id": "WB4101"
    },
    {
      "id": "alpha(1)-adrenoceptor antagonists"
    },
    {
      "id": "human alpha(1b)-adrenoceptors"
    },
    {
      "id": "293 cells"
    },
    {
      "id": "triamterene"
    },
    {
      "id": "[(3)H]prazosin"
    },
    {
      "id": "phentolamine-insensitive labeling"
    },
    {
      "id": "adrenoceptors"
    },
    {
      "id": "[(125)I]iodoarylazidoprazosin"
    },
    {
      "id": "phentolamine-insensitive sites"
    },
    {
      "id": "rat kidney"
    },
    {
      "id": "guanfacine"
    },
    {
      "id": "imidazoline recognition sites"
    },
    {
      "id": "human alpha(1a)-adrenoceptors"
    },
    {
      "id": "agmatine"
    },
    {
      "id": "phentolamine-sensitive alpha(1)-adrenoceptor"
    },
    {
      "id": "human liver"
    },
    {
      "id": "phentolamine"
    },
    {
      "id": "terazosin"
    },
    {
      "id": "quinazoline derivatives"
    },
    {
      "id": "guanabenz"
    },
    {
      "id": "tamsulosin"
    },
    {
      "id": "corynanthine"
    },
    {
      "id": "amiloride"
    },
    {
      "id": "renal Na(+)-transporter"
    },
    {
      "id": "rabbit kidney"
    },
    {
      "id": "human kidney"
    },
    {
      "id": "Patients"
    },
    {
      "id": "one-week washout period"
    },
    {
      "id": "rofecoxib"
    },
    {
      "id": "warfarin"
    },
    {
      "id": "increases"
    },
    {
      "id": "International Normalized Ratio (INR)"
    },
    {
      "id": "Changes"
    },
    {
      "id": "weeks 1, 2, and 3"
    },
    {
      "id": "cyclooxygenase-2 (COX-2) inhibitor comparator"
    },
    {
      "id": "traditional nonsteroidal antiinflammatory medications"
    },
    {
      "id": "COX-2 inhibitor"
    },
    {
      "id": "warfarin therapy"
    },
    {
      "id": "week 1"
    },
    {
      "id": "week 2"
    },
    {
      "id": "rate of edema"
    },
    {
      "id": "medical intervention"
    },
    {
      "id": "rofecoxib group"
    },
    {
      "id": "three weeks"
    },
    {
      "id": "blood samples"
    },
    {
      "id": "finger stick"
    },
    {
      "id": "acetaminophen"
    },
    {
      "id": "Adverse drug reactions"
    },
    {
      "id": "salsalate"
    },
    {
      "id": "Data"
    },
    {
      "id": "16 patients"
    },
    {
      "id": "specific receptor binding of FMLP"
    },
    {
      "id": "FMLP-(3H) binding assay"
    },
    {
      "id": "sodium cromoglycate"
    },
    {
      "id": "biologic meaning"
    },
    {
      "id": "nedocromil sodium"
    },
    {
      "id": "asthmatic patients"
    },
    {
      "id": "FMLP binding"
    },
    {
      "id": "haplotype pair"
    },
    {
      "id": "beta(1)-adrenergic receptor"
    },
    {
      "id": "antihypertensive response"
    },
    {
      "id": "metoprolol"
    },
    {
      "id": "codon 49 genotype"
    },
    {
      "id": "predictor"
    },
    {
      "id": "baseline daytime diastolic blood pressure"
    },
    {
      "id": "determinants"
    },
    {
      "id": "polymorphisms"
    },
    {
      "id": "389 genotypes"
    },
    {
      "id": "hypothesis"
    },
    {
      "id": "Ser49Arg389/Ser49Arg389 diplotype"
    },
    {
      "id": "decline"
    },
    {
      "id": "treatment phase 24-hour ambulatory blood pressure monitoring"
    },
    {
      "id": "4 weeks"
    },
    {
      "id": "hypertensive men and women"
    },
    {
      "id": "35 to 65 years"
    },
    {
      "id": "multiregression analysis"
    },
    {
      "id": "predictors"
    },
    {
      "id": "variant allele"
    },
    {
      "id": "future"
    },
    {
      "id": "interpatient variability"
    },
    {
      "id": "blood pressure response"
    },
    {
      "id": "response"
    },
    {
      "id": "200 mg"
    },
    {
      "id": "beta(1)-adrenergic receptor haplotypes"
    },
    {
      "id": "diastolic blood pressure response"
    },
    {
      "id": "impact"
    },
    {
      "id": "variables"
    },
    {
      "id": "Arg"
    },
    {
      "id": "50 mg metoprolol"
    },
    {
      "id": "weekly titration"
    },
    {
      "id": "stable dose"
    },
    {
      "id": "beta-blocker monotherapy"
    },
    {
      "id": "codon 389 genotype"
    },
    {
      "id": "restriction fragment length polymorphism"
    },
    {
      "id": "Our data"
    },
    {
      "id": "14.7 mm Hg"
    },
    {
      "id": "diplotype"
    },
    {
      "id": "reduction"
    },
    {
      "id": "Multilinear regression"
    },
    {
      "id": "Beta 1-adrenergic receptor polymorphisms"
    },
    {
      "id": "Baseline studies"
    },
    {
      "id": "24-hour ambulatory blood pressure monitoring"
    },
    {
      "id": "daytime diastolic blood pressure"
    },
    {
      "id": "Gly49Arg389/Ser49Gly389 diplotype"
    },
    {
      "id": "0.5 mm Hg"
    },
    {
      "id": "codon 389"
    },
    {
      "id": "uncomplicated hypertension"
    },
    {
      "id": "genotype"
    },
    {
      "id": "LTB4"
    },
    {
      "id": "neutrophil migration"
    },
    {
      "id": "naked filters"
    },
    {
      "id": "extravasation"
    },
    {
      "id": "neutrophils"
    },
    {
      "id": "Nedocromil sodium"
    },
    {
      "id": "Tilade"
    },
    {
      "id": "epithelial monolayers"
    },
    {
      "id": "filters"
    },
    {
      "id": "chemotaxis"
    },
    {
      "id": "peripheral circulation"
    },
    {
      "id": "nedocromil"
    },
    {
      "id": "sites of inflammation"
    },
    {
      "id": "neutrophil chemotaxis"
    },
    {
      "id": "WEB 2086"
    },
    {
      "id": "cellular barrier"
    },
    {
      "id": "PAF"
    },
    {
      "id": "Platelet-activating factor antagonists"
    },
    {
      "id": "receptor antagonist"
    },
    {
      "id": "cellular barriers"
    },
    {
      "id": "noncellular barriers"
    },
    {
      "id": "endothelial monolayers"
    },
    {
      "id": "chemoattractant"
    },
    {
      "id": "N-formyl-methionyl-leucyl-phenylalanine"
    },
    {
      "id": "FMLP"
    },
    {
      "id": "in vitro assay"
    },
    {
      "id": "antiinflammatory activity"
    },
    {
      "id": "asthma"
    },
    {
      "id": "platelet-activating factor"
    },
    {
      "id": "inflammatory conditions"
    },
    {
      "id": "mode of action"
    },
    {
      "id": "N-ethylmaleimide"
    },
    {
      "id": "reducing activity"
    },
    {
      "id": "alpha 2-adrenoceptor"
    },
    {
      "id": "neural substrate"
    },
    {
      "id": "alpha N-acetyl beta-endorphin-(1-31)"
    },
    {
      "id": "neuropeptide"
    },
    {
      "id": "[D-Ala2]-Deltorphin II"
    },
    {
      "id": "antinociceptive activity"
    },
    {
      "id": "DPDPE"
    },
    {
      "id": "delta agonists"
    },
    {
      "id": "modulatory activity"
    },
    {
      "id": "non-competitive regulator"
    },
    {
      "id": "DADLE"
    },
    {
      "id": "analgesic activity"
    },
    {
      "id": "Naloxone"
    },
    {
      "id": "Gi/Go transducer proteins"
    },
    {
      "id": "acetylated peptide"
    },
    {
      "id": "mu opioid"
    },
    {
      "id": "beta-endorphin-(1-31)"
    },
    {
      "id": "regulatory activity"
    },
    {
      "id": "mu receptor"
    },
    {
      "id": "enhancing activity"
    },
    {
      "id": "antagonist"
    },
    {
      "id": "DAGO"
    },
    {
      "id": "supraspinal antinociception"
    },
    {
      "id": "peptide"
    },
    {
      "id": "alpha 2-adrenoceptor agonist"
    },
    {
      "id": "morphine"
    },
    {
      "id": "Ang-II"
    },
    {
      "id": "BRG"
    },
    {
      "id": "arterial blood pressure variability"
    },
    {
      "id": "BBB"
    },
    {
      "id": "blood-brain barrier"
    },
    {
      "id": "RAS"
    },
    {
      "id": "APV"
    },
    {
      "id": "total mortality"
    },
    {
      "id": "AT1"
    },
    {
      "id": "fast Fourier transform"
    },
    {
      "id": "HRV"
    },
    {
      "id": "heart rate variability"
    },
    {
      "id": "ACE inhibitors"
    },
    {
      "id": "autonomic cardiovascular control"
    },
    {
      "id": "baroreflex gain"
    },
    {
      "id": "25 young males"
    },
    {
      "id": "circulating Ang-II levels"
    },
    {
      "id": "600 mg/day"
    },
    {
      "id": "angiotensin type 1 (AT1) blockers"
    },
    {
      "id": "total power of HRV"
    },
    {
      "id": "FFT"
    },
    {
      "id": "HR"
    },
    {
      "id": "AT1 antagonism"
    },
    {
      "id": "ECG"
    },
    {
      "id": "electrocardiogram"
    },
    {
      "id": "7 days"
    },
    {
      "id": "Ang-II levels"
    },
    {
      "id": "radioimmunoassay"
    },
    {
      "id": "angiotensin type 1 (AT1) receptor blocker"
    },
    {
      "id": "Power spectra of HRV"
    },
    {
      "id": "mean AP"
    },
    {
      "id": "arterial blood pressure"
    },
    {
      "id": "Finapres"
    },
    {
      "id": "circulating angiotensin II"
    },
    {
      "id": "low/high frequency (LF/HF) ratio of HRV"
    },
    {
      "id": "double-blind randomized cross-over design"
    },
    {
      "id": "AP"
    },
    {
      "id": "aggravation"
    },
    {
      "id": "elevation of blood glucose"
    },
    {
      "id": "t-plasminogen activator-plasminogen activator inhibitor 1-complex"
    },
    {
      "id": "morning"
    },
    {
      "id": "von Willebrand factor"
    },
    {
      "id": "next morning"
    },
    {
      "id": "endothelial injury"
    },
    {
      "id": "blood coagulation"
    },
    {
      "id": "night work"
    },
    {
      "id": "night duty"
    },
    {
      "id": "Previous studies"
    },
    {
      "id": "Japanese taxi drivers"
    },
    {
      "id": "duty day"
    },
    {
      "id": "preventive measures"
    },
    {
      "id": "rest"
    },
    {
      "id": "occupational groups"
    },
    {
      "id": "midnight"
    },
    {
      "id": "anticoagulant food"
    },
    {
      "id": "urine normetanephrine/creatinine"
    },
    {
      "id": "following morning"
    },
    {
      "id": "hematocrit"
    },
    {
      "id": "social support"
    },
    {
      "id": "mortality rate"
    },
    {
      "id": "cardiovascular disease"
    },
    {
      "id": "night taxi driving"
    },
    {
      "id": "acute events of cardiovascular disease"
    },
    {
      "id": "Twenty-nine taxi drivers"
    },
    {
      "id": "aged taxi drivers"
    },
    {
      "id": "water intake"
    },
    {
      "id": "walking"
    },
    {
      "id": "disturbed circadian rhythms"
    },
    {
      "id": "anti-thrombin III"
    },
    {
      "id": "blood glucose"
    },
    {
      "id": "daytime work"
    },
    {
      "id": "night sleep"
    },
    {
      "id": "nap"
    },
    {
      "id": "cardiovascular events"
    },
    {
      "id": "aged Japanese taxi drivers"
    },
    {
      "id": "acute vascular events"
    },
    {
      "id": "conditions"
    },
    {
      "id": "short exercise"
    },
    {
      "id": "46 taxi drivers"
    },
    {
      "id": "blood concentration"
    },
    {
      "id": "sympathetic nervous system functions"
    },
    {
      "id": "cardiovascular risk factors"
    },
    {
      "id": "night duty day"
    },
    {
      "id": "risk factors"
    },
    {
      "id": "daily rhythm"
    },
    {
      "id": "little sleep"
    },
    {
      "id": "enzyme 5-lipoxygenase"
    },
    {
      "id": "LTs"
    },
    {
      "id": "rectal dialysates"
    },
    {
      "id": "5-LO"
    },
    {
      "id": "existing new LT inhibitors"
    },
    {
      "id": "level of inhibition"
    },
    {
      "id": "proof"
    },
    {
      "id": "stage"
    },
    {
      "id": "randomized, double-blind, placebo-controlled trial"
    },
    {
      "id": "beneficial effects"
    },
    {
      "id": "endogenous LTs"
    },
    {
      "id": "amounts"
    },
    {
      "id": "biochemical manipulation"
    },
    {
      "id": "clinical efficacy"
    },
    {
      "id": "benzothiophene hydroxyurea"
    },
    {
      "id": "5-LO inhibition"
    },
    {
      "id": "animal models"
    },
    {
      "id": "selective 5-LO inhibitor"
    },
    {
      "id": "5-LO inhibitors"
    },
    {
      "id": "substrate-analogous"
    },
    {
      "id": "zileuton"
    },
    {
      "id": "symptom scores"
    },
    {
      "id": "800-mg oral dose"
    },
    {
      "id": "sulphasalazine"
    },
    {
      "id": "LT production"
    },
    {
      "id": "conventional drugs"
    },
    {
      "id": "chemokinetic metabolite"
    },
    {
      "id": "putative 5-LO inhibitor"
    },
    {
      "id": "IBD"
    },
    {
      "id": "mean inhibition"
    },
    {
      "id": "sigmoidoscopy score"
    },
    {
      "id": "concomitant sulphasalazine treatment"
    },
    {
      "id": "hydroxamic acids"
    },
    {
      "id": "inflammatory bowel disease"
    },
    {
      "id": "pretreatment conditions"
    },
    {
      "id": "corticosteroids"
    },
    {
      "id": "arachidonic acid"
    },
    {
      "id": "histology score"
    },
    {
      "id": "chemotactic metabolite"
    },
    {
      "id": "5-Lipoxygenase inhibitors"
    },
    {
      "id": "acute colitis"
    },
    {
      "id": "main disadvantage"
    },
    {
      "id": "high potency of LTs"
    },
    {
      "id": "inflamed mucosa"
    },
    {
      "id": "target tissue of inflammation"
    },
    {
      "id": "antioxidants"
    },
    {
      "id": "active ulcerative colitis"
    },
    {
      "id": "miscellaneous group of inhibitors"
    },
    {
      "id": "zileuton 800 mg b.i.d."
    },
    {
      "id": "5-aminosalicylic acid"
    },
    {
      "id": "aberrant protein synthesis ability"
    },
    {
      "id": "Str(r) mutant"
    },
    {
      "id": "Increased productivity"
    },
    {
      "id": "aberration"
    },
    {
      "id": "enhanced translation activity"
    },
    {
      "id": "point mutation"
    },
    {
      "id": "salinomycin"
    },
    {
      "id": "70S complex stability"
    },
    {
      "id": "mutation"
    },
    {
      "id": "rpoB gene"
    },
    {
      "id": "low Mg(2+) concentrations"
    },
    {
      "id": "Streptomyces albus"
    },
    {
      "id": "industrial strain"
    },
    {
      "id": "salinomycin productivity"
    },
    {
      "id": "spontaneous isolates"
    },
    {
      "id": "gentamicin"
    },
    {
      "id": "K88R mutation"
    },
    {
      "id": "Mutants"
    },
    {
      "id": "enhanced salinomycin production"
    },
    {
      "id": "aberrant protein synthesis mechanism"
    },
    {
      "id": "triple mutation"
    },
    {
      "id": "stationary-phase cells"
    },
    {
      "id": "drug resistance-producing mutations"
    },
    {
      "id": "strain improvement"
    },
    {
      "id": "RNA polymerase beta subunit"
    },
    {
      "id": "poly(U)-directed cell-free translation system"
    },
    {
      "id": "rpsL gene"
    },
    {
      "id": "ribosomal protein S12"
    },
    {
      "id": "salinomycin production enhancement"
    },
    {
      "id": "streptomycin (Str(r))"
    },
    {
      "id": "Rif(r) mutant"
    },
    {
      "id": "rifampin (Rif(r))"
    },
    {
      "id": "S12 protein"
    },
    {
      "id": "K88R mutant ribosome"
    },
    {
      "id": "antibiotic-overproducing industrial strain"
    },
    {
      "id": "hRRM2"
    },
    {
      "id": "UV-induced DNA repair"
    },
    {
      "id": "antisense hRRM2"
    },
    {
      "id": "sensitivity to UV irradiation"
    },
    {
      "id": "p53R2"
    },
    {
      "id": "KB cells"
    },
    {
      "id": "p53R2 binding"
    },
    {
      "id": "hRRM1"
    },
    {
      "id": "PC3 cells"
    },
    {
      "id": "hRRM2 binding"
    },
    {
      "id": "Confocal microscopy"
    },
    {
      "id": "UV treatment"
    },
    {
      "id": "colony-forming ability"
    },
    {
      "id": "deoxyribonucleoside diphosphates"
    },
    {
      "id": "DNA synthesis"
    },
    {
      "id": "p53R2 sense expression vectors"
    },
    {
      "id": "RR holoenzyme"
    },
    {
      "id": "cytoplasm"
    },
    {
      "id": "Coomassie Blue-stained band"
    },
    {
      "id": "RR activity"
    },
    {
      "id": "hRRM2 expression vectors"
    },
    {
      "id": "mutant p53"
    },
    {
      "id": "truncated COOH-terminal"
    },
    {
      "id": "Ribonucleotide reductase (RR)"
    },
    {
      "id": "hydroxyurea"
    },
    {
      "id": "ribonucleoside diphosphates"
    },
    {
      "id": "p53-mutant cell line PC3"
    },
    {
      "id": "DNA repair"
    },
    {
      "id": "Coimmunoprecipitation assays"
    },
    {
      "id": "agarose-conjugated goat antihuman RRM1 antibody"
    },
    {
      "id": "UV-induced activation"
    },
    {
      "id": "transcription of p53R2"
    },
    {
      "id": "human tumors"
    },
    {
      "id": "human prostate cancer PC3 cells"
    },
    {
      "id": "RR family member"
    },
    {
      "id": "hRRM2 expression"
    },
    {
      "id": "molecular mechanism"
    },
    {
      "id": "RRM2 inhibitors"
    },
    {
      "id": "p53R2 mRNA levels"
    },
    {
      "id": "Northern blot"
    },
    {
      "id": "hRRM2 mRNA levels"
    },
    {
      "id": "human oropharyngeal cancer KB cells"
    },
    {
      "id": "wild-type p53"
    },
    {
      "id": "UV irradiation"
    },
    {
      "id": "wild-type PC3 cells"
    },
    {
      "id": "p53R2 antisense expression vectors"
    },
    {
      "id": "terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)-positive cells"
    },
    {
      "id": "vehicle control"
    },
    {
      "id": "therapeutic intervention"
    },
    {
      "id": "cell death"
    },
    {
      "id": "traumatic spinal cord injury"
    },
    {
      "id": "Minocycline"
    },
    {
      "id": "hind limb motor function"
    },
    {
      "id": "functional recovery"
    },
    {
      "id": "lesion size"
    },
    {
      "id": "RT-PCR analyses"
    },
    {
      "id": "interleukin-10 mRNA"
    },
    {
      "id": "Rats"
    },
    {
      "id": "vehicle"
    },
    {
      "id": "DNA laddering"
    },
    {
      "id": "weight-drop contusion injury"
    },
    {
      "id": "caspase-3 activity"
    },
    {
      "id": "injured rat"
    },
    {
      "id": "DNA gel electrophoresis"
    },
    {
      "id": "anti-inflammatory drug"
    },
    {
      "id": "Basso-Beattie-Bresnahan (BBB) locomotor open field behavioral rating test"
    },
    {
      "id": "tumor necrosis factor-alpha expression"
    },
    {
      "id": "spinal cord injury (SCI)"
    },
    {
      "id": "Morphological analysis"
    },
    {
      "id": "BBB scores"
    },
    {
      "id": "vehicle-treated rats"
    },
    {
      "id": "minocycline-treated rats"
    },
    {
      "id": "minocycline-treated spinal cords"
    },
    {
      "id": "vehicle-treated spinal cords"
    },
    {
      "id": "fenfluramine"
    },
    {
      "id": "primary pulmonary hypertension (PPH)"
    },
    {
      "id": "mutated receptor"
    },
    {
      "id": "normal expression"
    },
    {
      "id": "5-HT(2B) mutation"
    },
    {
      "id": "PPH patients"
    },
    {
      "id": "molecular pathways"
    },
    {
      "id": "fenfluramine-associated primary pulmonary hypertension"
    },
    {
      "id": "transfected receptor"
    },
    {
      "id": "CHO cells"
    },
    {
      "id": "dominant negative effect"
    },
    {
      "id": "premature truncation"
    },
    {
      "id": "appetite-suppressants"
    },
    {
      "id": "constitutive activity"
    },
    {
      "id": "Serotonin 5-HT(2B) receptor"
    },
    {
      "id": "loss of function mutation"
    },
    {
      "id": "wild-type receptor"
    },
    {
      "id": "appetite-suppressant drug-associated PPH"
    },
    {
      "id": "receptor"
    },
    {
      "id": "pulmonary arterial relaxation"
    },
    {
      "id": "nitric oxide production"
    },
    {
      "id": "Functional analysis"
    },
    {
      "id": "Loss of serotonin 5-HT(2B) receptor function"
    },
    {
      "id": "Appetite-suppressant drug"
    },
    {
      "id": "mouse model"
    },
    {
      "id": "intracellular calcium release"
    },
    {
      "id": "man"
    },
    {
      "id": "cell membrane"
    },
    {
      "id": "inositol-phosphates cascade"
    },
    {
      "id": "second messenger"
    },
    {
      "id": "control subjects"
    },
    {
      "id": "human 5-HT(2B) gene"
    },
    {
      "id": "Carteolol"
    },
    {
      "id": "timolol"
    },
    {
      "id": "most serious side effects"
    },
    {
      "id": "beta-Blockers"
    },
    {
      "id": "cardioselective"
    },
    {
      "id": "beta 1-receptors"
    },
    {
      "id": "combined action"
    },
    {
      "id": "case"
    },
    {
      "id": "theoretical advantage"
    },
    {
      "id": "carteolol"
    },
    {
      "id": "nonselective beta-blockers"
    },
    {
      "id": "precipitation"
    },
    {
      "id": "Topical beta-blockers"
    },
    {
      "id": "intraocular pressure (IOP)"
    },
    {
      "id": "Metipranolol"
    },
    {
      "id": "partial beta-agonist activity"
    },
    {
      "id": "Ocular beta-blockers"
    },
    {
      "id": "glaucoma management"
    },
    {
      "id": "epinephrine"
    },
    {
      "id": "topical beta-blockers"
    },
    {
      "id": "metipranolol"
    },
    {
      "id": "types"
    },
    {
      "id": "nonselective"
    },
    {
      "id": "diminished side effects"
    },
    {
      "id": "beta-blocker"
    },
    {
      "id": "first choice"
    },
    {
      "id": "Local stinging"
    },
    {
      "id": "problem"
    },
    {
      "id": "levobunolol"
    },
    {
      "id": "Betaxolol"
    },
    {
      "id": "adverse respiratory effects"
    },
    {
      "id": "blockade"
    },
    {
      "id": "fall"
    },
    {
      "id": "sympathetic nerve endings"
    },
    {
      "id": "risk"
    },
    {
      "id": "caution"
    },
    {
      "id": "history"
    },
    {
      "id": "bronchospasm"
    },
    {
      "id": "antiglaucoma medications"
    },
    {
      "id": "exacerbation"
    },
    {
      "id": "respiratory disease"
    },
    {
      "id": "chronic obstructive airways disease"
    },
    {
      "id": "aqueous humour production"
    },
    {
      "id": "Clinical pharmacological aspects"
    },
    {
      "id": "individual basis"
    },
    {
      "id": "beta 1- and beta 2-adrenoceptors"
    },
    {
      "id": "adrenaline"
    },
    {
      "id": "ciliary epithelium"
    },
    {
      "id": "nonselective agents"
    },
    {
      "id": "Glc1P"
    },
    {
      "id": "minimal movement"
    },
    {
      "id": "Arg569"
    },
    {
      "id": "relative positions"
    },
    {
      "id": "structures"
    },
    {
      "id": "frames"
    },
    {
      "id": "specific recognition"
    },
    {
      "id": "oligosaccharide"
    },
    {
      "id": "2.0A crystal structure"
    },
    {
      "id": "MalP/Glc1P binary complex"
    },
    {
      "id": "6-hydroxyl group"
    },
    {
      "id": "Glc1P substrate"
    },
    {
      "id": "maltotetraose"
    },
    {
      "id": "G4"
    },
    {
      "id": "conformation"
    },
    {
      "id": "residue Arg569"
    },
    {
      "id": "negative-charged Glc1P"
    },
    {
      "id": "allosteric transition"
    },
    {
      "id": "mammalian enzyme"
    },
    {
      "id": "phosphate group"
    },
    {
      "id": "PLP"
    },
    {
      "id": "molecular movie"
    },
    {
      "id": "enzymatic reaction"
    },
    {
      "id": "crystal damage"
    },
    {
      "id": "substrate phosphate group"
    },
    {
      "id": "maltopentaose"
    },
    {
      "id": "G5"
    },
    {
      "id": "active MalP enzyme"
    },
    {
      "id": "alpha-1,4-glycosidic bond"
    },
    {
      "id": "maltodextrins"
    },
    {
      "id": "non-reducing glucosyl residues"
    },
    {
      "id": "linear oligosaccharides"
    },
    {
      "id": "loop 280s"
    },
    {
      "id": "bacterial enzyme"
    },
    {
      "id": "maltodextrin phosphorylase"
    },
    {
      "id": "His377"
    },
    {
      "id": "hydrogen bond"
    },
    {
      "id": "MalP"
    },
    {
      "id": "glucose-1-phosphate"
    },
    {
      "id": "muscle glycogen phosphorylase"
    },
    {
      "id": "GP"
    },
    {
      "id": "synergism"
    },
    {
      "id": "MalP ternary complex"
    },
    {
      "id": "crystals"
    },
    {
      "id": "phosphorolysis"
    },
    {
      "id": "model system"
    },
    {
      "id": "mobile region"
    },
    {
      "id": "5'-phosphate group"
    },
    {
      "id": "Enzymatic catalysis"
    },
    {
      "id": "Escherichia coli maltodextrin phosphorylase"
    },
    {
      "id": "catalytic site"
    },
    {
      "id": "diffusion"
    },
    {
      "id": "MalP/Glc1P crystals"
    },
    {
      "id": "elongation of the oligosaccharide chain"
    },
    {
      "id": "inactive forms of mammalian GP"
    },
    {
      "id": "formation of phosphate"
    },
    {
      "id": "maltodextrin synthesis"
    },
    {
      "id": "conformational change"
    },
    {
      "id": "380s loop"
    },
    {
      "id": "active forms of mammalian GP"
    },
    {
      "id": "pyridoxal phosphate"
    },
    {
      "id": "essential pyridoxal phosphate"
    },
    {
      "id": "inactive form of GP"
    },
    {
      "id": "PLP cofactor"
    },
    {
      "id": "catalytic channel"
    },
    {
      "id": "2.2A"
    },
    {
      "id": "1.8A"
    },
    {
      "id": "allosteric properties"
    },
    {
      "id": "oligosaccharide substrates"
    },
    {
      "id": "MalP structures"
    },
    {
      "id": "loperamide"
    },
    {
      "id": "human hypothalamo-pituitary-adrenal axis"
    },
    {
      "id": "basal ACTH levels"
    },
    {
      "id": "ACTH peak"
    },
    {
      "id": "combined pituitary stimulation test"
    },
    {
      "id": "GnRH"
    },
    {
      "id": "ACTH levels"
    },
    {
      "id": "TRH"
    },
    {
      "id": "cortisol levels"
    },
    {
      "id": "human CRH"
    },
    {
      "id": "opiate agonist"
    },
    {
      "id": "mu-receptors"
    },
    {
      "id": "GH-releasing hormone"
    },
    {
      "id": "stress-induced elevation of cortisol levels"
    },
    {
      "id": "suprapituitary site"
    },
    {
      "id": "pituitary site"
    },
    {
      "id": "area under the curve of ACTH"
    },
    {
      "id": "pituitary hormone secretion"
    },
    {
      "id": "CRH-induced ACTH secretion"
    },
    {
      "id": "insulin-hypoglycemia-induced ACTH levels"
    },
    {
      "id": "basal ACTH secretion"
    },
    {
      "id": "basal ACTH plasma levels"
    },
    {
      "id": "CRH-stimulated levels"
    },
    {
      "id": "alpha-receptor subunits (alpha-PDGFR)"
    },
    {
      "id": "differential regulation"
    },
    {
      "id": "PDGF B-chain (c-sis) homodimer (PDGF BB)"
    },
    {
      "id": "beta-receptor subunits (beta-PDGFR)"
    },
    {
      "id": "beta-PDGFR"
    },
    {
      "id": "mitogenic signals"
    },
    {
      "id": "PDGF/JNK-1"
    },
    {
      "id": "p21WAF1/CIP1 promoter activity"
    },
    {
      "id": "PDGF signaling"
    },
    {
      "id": "strength"
    },
    {
      "id": "PDGF BB activation"
    },
    {
      "id": "cell cycle transition"
    },
    {
      "id": "progression factors"
    },
    {
      "id": "PDGF AA"
    },
    {
      "id": "p21WAF1/CIP1"
    },
    {
      "id": "alpha-PDGFR-activated JNK-1"
    },
    {
      "id": "signaling component"
    },
    {
      "id": "serum"
    },
    {
      "id": "alpha-PDGFR"
    },
    {
      "id": "downstream mediator"
    },
    {
      "id": "tumor suppressor gene product p53"
    },
    {
      "id": "inhibitory signals"
    },
    {
      "id": "competent factor"
    },
    {
      "id": "cell cycle entry"
    },
    {
      "id": "growth stimulatory signals"
    },
    {
      "id": "cell cycle"
    },
    {
      "id": "G1/S checkpoint"
    },
    {
      "id": "phenotypic transformation"
    },
    {
      "id": "NIH 3T3 cells"
    },
    {
      "id": "c-Jun NH2-terminal kinase-1"
    },
    {
      "id": "Platelet-derived growth factor (PDGF)"
    },
    {
      "id": "mesenchymal cells"
    },
    {
      "id": "transformation"
    },
    {
      "id": "specificity"
    },
    {
      "id": "inhibitor of cell cycle-dependent kinases"
    },
    {
      "id": "p53"
    },
    {
      "id": "viral counterpart v-sis"
    },
    {
      "id": "S phase"
    },
    {
      "id": "PDGF induction"
    },
    {
      "id": "molecular basis"
    },
    {
      "id": "Platelet-derived growth factor (PDGF) receptor-alpha"
    },
    {
      "id": "beta-PDGFR activation"
    },
    {
      "id": "p21WAF1/CIP1 expression"
    },
    {
      "id": "growth-promoting signal"
    },
    {
      "id": "PDGF-induced p21WAF1/CIP1 promoter activity"
    },
    {
      "id": "stress-activated protein kinase-1"
    },
    {
      "id": "G1"
    },
    {
      "id": "therapeutic index"
    },
    {
      "id": "tranylcypromine"
    },
    {
      "id": "CYP2C19"
    },
    {
      "id": "CYP2C9"
    },
    {
      "id": "Inhibitory effects"
    },
    {
      "id": "therapeutic doses"
    },
    {
      "id": "cytochrome P450 enzymes"
    },
    {
      "id": "CYP2C19 substrates"
    },
    {
      "id": "substrate concentrations"
    },
    {
      "id": "product concentrations"
    },
    {
      "id": "HPLC"
    },
    {
      "id": "CYP enzymes"
    },
    {
      "id": "monoamine oxidase inhibitor"
    },
    {
      "id": "monoamine oxidase (MAO)"
    },
    {
      "id": "UV detection"
    },
    {
      "id": "additional TATA elements"
    },
    {
      "id": "CldATP incorporation"
    },
    {
      "id": "promoter TATA element"
    },
    {
      "id": "Double-stranded DNA templates"
    },
    {
      "id": "HeLa extract"
    },
    {
      "id": "2-chloro-2'-deoxyadenosine"
    },
    {
      "id": "chronic lymphocytic leukemia"
    },
    {
      "id": "in vitro pol II transcription"
    },
    {
      "id": "control substrates"
    },
    {
      "id": "transcription"
    },
    {
      "id": "CldAMP-substituted TATA sequences"
    },
    {
      "id": "gene regulatory sequences"
    },
    {
      "id": "plateau"
    },
    {
      "id": "2-chlorodeoxyadenosine triphosphate"
    },
    {
      "id": "CldATP"
    },
    {
      "id": "synthesis"
    },
    {
      "id": "radiolabeled 44-base transcripts"
    },
    {
      "id": "TATA box consensus sequences"
    },
    {
      "id": "2-chlorodeoxyadenosine monophosphate"
    },
    {
      "id": "CldAMP"
    },
    {
      "id": "binding interactions"
    },
    {
      "id": "human TATA box-binding protein"
    },
    {
      "id": "20 min"
    },
    {
      "id": "TBP"
    },
    {
      "id": "CldAMP substitution"
    },
    {
      "id": "TATA box"
    },
    {
      "id": "CldAdo"
    },
    {
      "id": "cladribine"
    },
    {
      "id": "nucleoside analog"
    },
    {
      "id": "coding sequences"
    },
    {
      "id": "cellular DNA"
    },
    {
      "id": "chain terminator"
    },
    {
      "id": "CldAMP-substituted promoter sequences"
    },
    {
      "id": "dissociation"
    },
    {
      "id": "hairy cell leukemia"
    },
    {
      "id": "site-specific CldAMP residues"
    },
    {
      "id": "adenovirus major late promoter"
    },
    {
      "id": "novel strategy"
    },
    {
      "id": "specific protein/DNA interactions"
    },
    {
      "id": "DNA"
    },
    {
      "id": "in vitro gel-shift assays"
    },
    {
      "id": "transcriptional antagonist"
    },
    {
      "id": "transcript production"
    },
    {
      "id": "Time-course studies"
    },
    {
      "id": "transcriptional processes"
    },
    {
      "id": "human RNA polymerase II"
    },
    {
      "id": "pol II"
    },
    {
      "id": "dAMP"
    },
    {
      "id": "antileukemia drug"
    },
    {
      "id": "SLC36A2"
    },
    {
      "id": "chromosomal location"
    },
    {
      "id": "human SLC36A1 gene"
    },
    {
      "id": "multiple alternative mRNAs"
    },
    {
      "id": "candidate locus"
    },
    {
      "id": "peripheral neuropathy"
    },
    {
      "id": "muscle"
    },
    {
      "id": "Mouse Slc36a2"
    },
    {
      "id": "bone"
    },
    {
      "id": "SLC36 cluster of amino acid transporter genes"
    },
    {
      "id": "SLC36A3"
    },
    {
      "id": "testis"
    },
    {
      "id": "lysosomal amino acid transporter LYAAT1/PAT1"
    },
    {
      "id": "Polymorphisms"
    },
    {
      "id": "5q32"
    },
    {
      "id": "truncated proteins"
    },
    {
      "id": "fat tissue"
    },
    {
      "id": "5q31-33"
    },
    {
      "id": "SLC36A1"
    },
    {
      "id": "numerous tissues"
    },
    {
      "id": "kidney"
    },
    {
      "id": "Chromosome (Chr) 11"
    },
    {
      "id": "candidate gene"
    },
    {
      "id": "5q-myelodysplastic syndrome"
    },
    {
      "id": "glycine transporter tramdorinl/PAT2"
    },
    {
      "id": "amino acid transport proteins"
    },
    {
      "id": "Studies"
    },
    {
      "id": "monkeys"
    },
    {
      "id": "compounds of this class"
    },
    {
      "id": "obesity"
    },
    {
      "id": "heart"
    },
    {
      "id": "atorvastatin"
    },
    {
      "id": "compound"
    },
    {
      "id": "GC-1"
    },
    {
      "id": "beta-isoform of the thyroid hormone receptor"
    },
    {
      "id": "selective thyroid hormone receptor modulator"
    },
    {
      "id": "plasma levels"
    },
    {
      "id": "lipoprotein (a)"
    },
    {
      "id": "current report"
    },
    {
      "id": "loss of muscle"
    },
    {
      "id": "triglyceride"
    },
    {
      "id": "loss of fat"
    },
    {
      "id": "lipid disorders"
    },
    {
      "id": "Selective activation of thyroid hormone signaling pathways"
    },
    {
      "id": "ATR"
    },
    {
      "id": "downstream effectors"
    },
    {
      "id": "Arabidopsis"
    },
    {
      "id": "atr mutants"
    },
    {
      "id": "UV-B light"
    },
    {
      "id": "atr-/- mutants"
    },
    {
      "id": "fertile"
    },
    {
      "id": "G2 arrest"
    },
    {
      "id": "gamma-irradiation"
    },
    {
      "id": "viable"
    },
    {
      "id": "aphidicolin"
    },
    {
      "id": "HU"
    },
    {
      "id": "novel checkpoint"
    },
    {
      "id": "DNA damage signals"
    },
    {
      "id": "plant cells"
    },
    {
      "id": "DNA replication"
    },
    {
      "id": "HU-treated wild-type plants"
    },
    {
      "id": "HU-treated atr plants"
    },
    {
      "id": "essential gene"
    },
    {
      "id": "mildly sensitive"
    },
    {
      "id": "atr plants"
    },
    {
      "id": "phenotypically wild-type"
    },
    {
      "id": "hypersensitive"
    },
    {
      "id": "wild-type plants"
    },
    {
      "id": "altered expression"
    },
    {
      "id": "AtRNR1"
    },
    {
      "id": "compaction of nuclei"
    },
    {
      "id": "G1 arrest"
    },
    {
      "id": "double-strand breaks"
    },
    {
      "id": "gamma-radiation"
    },
    {
      "id": "damage-induced cell-cycle checkpoints"
    },
    {
      "id": "cell-cycle regulation"
    },
    {
      "id": "low levels of deoxynucleotide triphosphates"
    },
    {
      "id": "Ataxia telangiectasia-mutated and Rad3-related"
    },
    {
      "id": "cell-cycle checkpoints"
    },
    {
      "id": "G2-phase cell-cycle checkpoint"
    },
    {
      "id": "ribonucleotide reductase large subunit"
    },
    {
      "id": "beta(1)- and beta(2)-adrenoceptors"
    },
    {
      "id": "catecholamine-induced myocardial remodeling"
    },
    {
      "id": "bisoprolol groups"
    },
    {
      "id": "control isoprenaline-treated group"
    },
    {
      "id": "Blockade of beta 1-adrenoceptors"
    },
    {
      "id": "isoprenaline-induced cardiac fibrosis"
    },
    {
      "id": "bisoprolol"
    },
    {
      "id": "selective beta(2)-adrenoceptor agonist"
    },
    {
      "id": "beta(2)-adrenoceptor desensitization"
    },
    {
      "id": "down-regulation of left ventricular beta(2)-adrenoceptors"
    },
    {
      "id": "salbutamol"
    },
    {
      "id": "isoprenaline-induced left ventricular fibrosis"
    },
    {
      "id": "interstitial fibrosis"
    },
    {
      "id": "beta(2)-adrenoceptors"
    },
    {
      "id": "beta-adrenoceptors"
    },
    {
      "id": "cardiac remodeling process"
    },
    {
      "id": "beta(1)-adrenoceptor blockade"
    },
    {
      "id": "apical region"
    },
    {
      "id": "salbutamol groups"
    },
    {
      "id": "selective beta(1)-adrenoceptor antagonist"
    },
    {
      "id": "beta(1)-adrenoceptors"
    },
    {
      "id": "pretreatment with salbutamol"
    },
    {
      "id": "beta(2)-adrenoceptors down-regulation"
    },
    {
      "id": "Wistar rats"
    },
    {
      "id": "2-week chronic isoprenaline administration"
    },
    {
      "id": "desensitization of beta 2-adrenoceptors"
    },
    {
      "id": "alpha(1A)-adrenoceptor"
    },
    {
      "id": "pupillary dilation"
    },
    {
      "id": "alpha(1D)-adrenoceptor"
    },
    {
      "id": "alpha-adrenoceptor subtypes"
    },
    {
      "id": "alpha-adrenoceptors"
    },
    {
      "id": "mydriatic responses"
    },
    {
      "id": "L-765314"
    },
    {
      "id": "adrenoceptor subtypes"
    },
    {
      "id": "8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione"
    },
    {
      "id": "agonist activation"
    },
    {
      "id": "nonselective alpha-adrenoceptor antagonists"
    },
    {
      "id": "phenoxybenzamine"
    },
    {
      "id": "2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane"
    },
    {
      "id": "alpha(1A)-Adrenoceptor selective antagonists"
    },
    {
      "id": "5-methylurapidil"
    },
    {
      "id": "Pupillary dilator response curves"
    },
    {
      "id": "intravenous injection"
    },
    {
      "id": "WB-4101"
    },
    {
      "id": "BMY-7378"
    },
    {
      "id": "alpha(1D)-adrenoceptor selective antagonist"
    },
    {
      "id": "alpha(1B)-adrenoceptor selective antagonist"
    },
    {
      "id": "4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline"
    },
    {
      "id": "systemic administration"
    },
    {
      "id": "sympathetic nerve stimulation"
    },
    {
      "id": "selective alpha(1)-adrenoceptor antagonist"
    },
    {
      "id": "pentobarbital-anesthetized rats"
    },
    {
      "id": "alpha(2)-adrenoceptor antagonist"
    },
    {
      "id": "alpha(1B)-adrenoceptors"
    },
    {
      "id": "sympathetic mydriasis"
    },
    {
      "id": "neural activation"
    },
    {
      "id": "mydriasis"
    },
    {
      "id": "species"
    },
    {
      "id": "exclusive subtype"
    },
    {
      "id": "antagonistic effects"
    },
    {
      "id": "cervical sympathetic nerve stimulation"
    },
    {
      "id": "Ketoconazole"
    },
    {
      "id": "androgen binding sites"
    },
    {
      "id": "Additional binding studies"
    },
    {
      "id": "men"
    },
    {
      "id": "chronic mycotic infections"
    },
    {
      "id": "androgen deficiency"
    },
    {
      "id": "oligospermia"
    },
    {
      "id": "Fifty percent displacement"
    },
    {
      "id": "6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole"
    },
    {
      "id": "dose of ketoconazole"
    },
    {
      "id": "androgen binding studies"
    },
    {
      "id": "imidazoles"
    },
    {
      "id": "receptor proteins"
    },
    {
      "id": "1,25(OH)2 vitamin D3"
    },
    {
      "id": "non-steroidal compound"
    },
    {
      "id": "multiple steroid hormone receptors"
    },
    {
      "id": "clotrimazole"
    },
    {
      "id": "[3H]R1881 binding"
    },
    {
      "id": "AR"
    },
    {
      "id": "imidazole anti-fungal agent"
    },
    {
      "id": "50% occupancy"
    },
    {
      "id": "human androgen receptor"
    },
    {
      "id": "class of compounds"
    },
    {
      "id": "human androgen receptors"
    },
    {
      "id": "Scatchard method"
    },
    {
      "id": "fluconozole"
    },
    {
      "id": "dispersed, intact cultured human skin fibroblasts"
    },
    {
      "id": "gynecomastia"
    },
    {
      "id": "sex steroid binding globulin"
    },
    {
      "id": "SSBG"
    },
    {
      "id": "impotence"
    },
    {
      "id": "[3H]methyltrienolone"
    },
    {
      "id": "R1881"
    },
    {
      "id": "miconazole"
    },
    {
      "id": "22 degrees C"
    },
    {
      "id": "decreased testosterone levels"
    },
    {
      "id": "gonadal function"
    },
    {
      "id": "ligand binding sites"
    },
    {
      "id": "decreased libido"
    },
    {
      "id": "smaller compounds"
    },
    {
      "id": "20-amino acid span"
    },
    {
      "id": "substrate access channel"
    },
    {
      "id": "aldehyde dehydrogenases"
    },
    {
      "id": "enzyme superfamily"
    },
    {
      "id": "Retinaldehyde dehydrogenase II"
    },
    {
      "id": "retinoic acid"
    },
    {
      "id": "disordered loop"
    },
    {
      "id": "means"
    },
    {
      "id": "experiments"
    },
    {
      "id": "retinaldehyde dehydrogenase type II"
    },
    {
      "id": "structural difference"
    },
    {
      "id": "catalytic machinery"
    },
    {
      "id": "RalDH2"
    },
    {
      "id": "developing embryo"
    },
    {
      "id": "x-ray structure"
    },
    {
      "id": "disorder to order transition"
    },
    {
      "id": "A disorder to order transition"
    },
    {
      "id": "kinetic techniques"
    },
    {
      "id": "retinal"
    },
    {
      "id": "crystallographic techniques"
    },
    {
      "id": "spectroscopic techniques"
    },
    {
      "id": "transcriptional regulator"
    },
    {
      "id": "mean integrated optical density"
    },
    {
      "id": "androgen receptor"
    },
    {
      "id": "NP group"
    },
    {
      "id": "ovary tissues"
    },
    {
      "id": "LSAB"
    },
    {
      "id": "normal saline"
    },
    {
      "id": "testis tissues"
    },
    {
      "id": "nandrolone phenylpropionate"
    },
    {
      "id": "burned rats"
    },
    {
      "id": "deep second-degree cutaneous burn"
    },
    {
      "id": "20% total body surface area"
    },
    {
      "id": "NP"
    },
    {
      "id": "sexual glands"
    },
    {
      "id": "dose level"
    },
    {
      "id": "liver tissue"
    },
    {
      "id": "liver"
    },
    {
      "id": "scalding"
    },
    {
      "id": "immunohistochemistry ENVISION"
    },
    {
      "id": "internal standards"
    },
    {
      "id": "enzymatic activities"
    },
    {
      "id": "interfering acid alpha-glucosidase"
    },
    {
      "id": "Niemann-Pick A/B disease"
    },
    {
      "id": "affected individuals"
    },
    {
      "id": "Krabbe disease"
    },
    {
      "id": "multiplex screening method"
    },
    {
      "id": "lysosomal enzymes"
    },
    {
      "id": "budget limits"
    },
    {
      "id": "newborn-screening centers"
    },
    {
      "id": "Fabry disease"
    },
    {
      "id": "Gaucher disease"
    },
    {
      "id": "dried blood spots"
    },
    {
      "id": "enzyme source"
    },
    {
      "id": "newborn-screening cards"
    },
    {
      "id": "solid-phase extraction"
    },
    {
      "id": "buffer components"
    },
    {
      "id": "Pompe disease"
    },
    {
      "id": "cassette of substrates"
    },
    {
      "id": "healthy individuals"
    },
    {
      "id": "minimum activities"
    },
    {
      "id": "healthy noncarrier individuals"
    },
    {
      "id": "Direct multiplex assay"
    },
    {
      "id": "data sets"
    },
    {
      "id": "heterozygous carriers"
    },
    {
      "id": "syndromes"
    },
    {
      "id": "silica gel"
    },
    {
      "id": "newborn screening"
    },
    {
      "id": "liquid-liquid extraction"
    },
    {
      "id": "supply costs"
    },
    {
      "id": "Acarbose"
    },
    {
      "id": "Rehydrated dried blood spots"
    },
    {
      "id": "enzyme substrates"
    },
    {
      "id": "reagent"
    },
    {
      "id": "tandem mass spectrometry"
    },
    {
      "id": "enzymatic product detection"
    },
    {
      "id": "condition"
    },
    {
      "id": "SV2A"
    },
    {
      "id": "synaptic vesicle exocytosis"
    },
    {
      "id": "synaptic vesicle protein"
    },
    {
      "id": "presynaptic neurotransmitter release"
    },
    {
      "id": "levetiracetam"
    },
    {
      "id": "synaptic vesicle protein modulator"
    },
    {
      "id": "class of anticonvulsants"
    },
    {
      "id": "Psychopharmacology"
    },
    {
      "id": "anticonvulsants"
    },
    {
      "id": "COX isozymes"
    },
    {
      "id": "nimesulide"
    },
    {
      "id": "Aspirin"
    },
    {
      "id": "ketoprofen"
    },
    {
      "id": "colon"
    },
    {
      "id": "canine tissues"
    },
    {
      "id": "NS398"
    },
    {
      "id": "Canine COX-2"
    },
    {
      "id": "dogs"
    },
    {
      "id": "ileum"
    },
    {
      "id": "proinflammatory inducible enzyme"
    },
    {
      "id": "carprofen"
    },
    {
      "id": "NSAIDs"
    },
    {
      "id": "jejunum"
    },
    {
      "id": "whole blood COX assays"
    },
    {
      "id": "enzyme activity"
    },
    {
      "id": "northern blot analyses"
    },
    {
      "id": "constitutive housekeeping enzyme"
    },
    {
      "id": "protein expression"
    },
    {
      "id": "cerebral cortex"
    },
    {
      "id": "lung"
    },
    {
      "id": "COX-2 mRNA"
    },
    {
      "id": "stomach"
    },
    {
      "id": "nonselective NSAIDs"
    },
    {
      "id": "tolfenamic acid"
    },
    {
      "id": "isozymes"
    },
    {
      "id": "canine cyclooxygenase (COX)-1 and -2"
    },
    {
      "id": "nonsteroidal anti-inflammatory drugs"
    },
    {
      "id": "cyclooxygenase-1 and -2"
    },
    {
      "id": "COX-2-selective inhibitors"
    },
    {
      "id": "COX-1 mRNA"
    },
    {
      "id": "cyclooxygenase"
    },
    {
      "id": "duodenum"
    },
    {
      "id": "meclofenamic acid"
    },
    {
      "id": "spleen"
    },
    {
      "id": "ovary"
    },
    {
      "id": "piroxicam"
    },
    {
      "id": "40 patients"
    },
    {
      "id": "conventional therapy"
    },
    {
      "id": "carvedilol"
    },
    {
      "id": "symptoms"
    },
    {
      "id": "neurohumoral activation"
    },
    {
      "id": "decrease in plasma BNP concentration"
    },
    {
      "id": "EF >/=45%"
    },
    {
      "id": "New York Heart Association functional class"
    },
    {
      "id": "mild or moderate heart failure"
    },
    {
      "id": "benefits of carvedilol"
    },
    {
      "id": "patients with heart failure and depressed ejection fraction"
    },
    {
      "id": "patients with preserved EF"
    },
    {
      "id": "left ventricular dilation"
    },
    {
      "id": "plasma B-type natriuretic peptide concentration"
    },
    {
      "id": "high plasma concentration of BNP"
    },
    {
      "id": "ischemic cause of heart failure"
    },
    {
      "id": "exercise capacity"
    },
    {
      "id": "plasma BNP concentration"
    },
    {
      "id": "end points"
    },
    {
      "id": "Terbinafine"
    },
    {
      "id": "squalene epoxidase inhibition"
    },
    {
      "id": "fungi"
    },
    {
      "id": "ergosterol"
    },
    {
      "id": "Candida albicans"
    },
    {
      "id": "ergosterol biosynthesis"
    },
    {
      "id": "pathogenic fungi"
    },
    {
      "id": "squalene epoxidase"
    },
    {
      "id": "squalene"
    },
    {
      "id": "cytochrome P-450 type"
    },
    {
      "id": "cell wall synthesis"
    },
    {
      "id": "fungal cell membranes"
    },
    {
      "id": "filamentous form"
    },
    {
      "id": "yeast form"
    },
    {
      "id": "rat liver squalene epoxidase"
    },
    {
      "id": "drug concentrations"
    },
    {
      "id": "fungal membrane function"
    },
    {
      "id": "Lamisil"
    },
    {
      "id": "cholesterol biosynthesis"
    },
    {
      "id": "radiolabelled precursors"
    },
    {
      "id": "peroxidase activities"
    },
    {
      "id": "treatment strategies"
    },
    {
      "id": "thalidomide"
    },
    {
      "id": "bifunctional enzyme"
    },
    {
      "id": "cyclooxygenase activities"
    },
    {
      "id": "irinotecan"
    },
    {
      "id": "pancreatic cancer"
    },
    {
      "id": "stability"
    },
    {
      "id": "change"
    },
    {
      "id": "gemcitabine"
    },
    {
      "id": "low-doses"
    },
    {
      "id": "metastatic pancreatic cancer"
    },
    {
      "id": "therapeutic strategy"
    },
    {
      "id": "PG biosynthesis"
    },
    {
      "id": "outcomes"
    },
    {
      "id": "peroxidase activity"
    },
    {
      "id": "proximate carcinogens"
    },
    {
      "id": "TNF-mRNA"
    },
    {
      "id": "Chemotherapy"
    },
    {
      "id": "survival benefit"
    },
    {
      "id": "recurrence"
    },
    {
      "id": "COX"
    },
    {
      "id": "metastases"
    },
    {
      "id": "cooling agent 10"
    },
    {
      "id": "potencies"
    },
    {
      "id": "Ca(2+) response"
    },
    {
      "id": "low pH"
    },
    {
      "id": "BCTC"
    },
    {
      "id": "TRPM8"
    },
    {
      "id": "fluorometric imaging plate reader (FLIPR) assay"
    },
    {
      "id": "mouse cold-menthol receptor"
    },
    {
      "id": "menthol"
    },
    {
      "id": "low temperatures"
    },
    {
      "id": "FrescolatML"
    },
    {
      "id": "PMD38"
    },
    {
      "id": "VR1"
    },
    {
      "id": "hydroxycitronellal"
    },
    {
      "id": "vanilloid receptor type-1"
    },
    {
      "id": "protons"
    },
    {
      "id": "linalool"
    },
    {
      "id": "N-arachidonoyl-dopamine"
    },
    {
      "id": "geraniol"
    },
    {
      "id": "frescolatMAG"
    },
    {
      "id": "CMR1"
    },
    {
      "id": "Ca(2+)-permeable channel"
    },
    {
      "id": "eucalyptol"
    },
    {
      "id": "EC(50) values"
    },
    {
      "id": "TRPV1"
    },
    {
      "id": "transient receptor potential (TRP) family"
    },
    {
      "id": "menthol-related substances"
    },
    {
      "id": "recombinant mouse TRPM8"
    },
    {
      "id": "(+)menthol"
    },
    {
      "id": "cooling sensation"
    },
    {
      "id": "(-)menthol"
    },
    {
      "id": "WS-3"
    },
    {
      "id": "capsazepine"
    },
    {
      "id": "icilin"
    },
    {
      "id": "CoolactP"
    },
    {
      "id": "odorants"
    },
    {
      "id": "Coolact P"
    },
    {
      "id": "HEK293 cells"
    },
    {
      "id": "WS-23"
    },
    {
      "id": "agonists"
    },
    {
      "id": "TRPM8 currents"
    },
    {
      "id": "Cooling Agent 10"
    },
    {
      "id": "mTRPM8"
    },
    {
      "id": "thio-BCTC"
    },
    {
      "id": "hVR1-transfected HEK293 cells"
    },
    {
      "id": "FrescolatMGA"
    },
    {
      "id": "unrecognised expression"
    },
    {
      "id": "P2X4 receptor"
    },
    {
      "id": "P2X receptors"
    },
    {
      "id": "P2Y1"
    },
    {
      "id": "specific antibodies"
    },
    {
      "id": "P2 receptors"
    },
    {
      "id": "progenitors"
    },
    {
      "id": "megakaryocytes"
    },
    {
      "id": "potential role"
    },
    {
      "id": "P2Y12"
    },
    {
      "id": "differentiation"
    },
    {
      "id": "specific receptor subtype"
    },
    {
      "id": "P2X1"
    },
    {
      "id": "P2Y2"
    },
    {
      "id": "CD34+ stem and progenitor cells"
    },
    {
      "id": "specific P2 receptor profiles"
    },
    {
      "id": "inflammatory cells"
    },
    {
      "id": "selective agonists"
    },
    {
      "id": "biological effects"
    },
    {
      "id": "G protein-coupled P2Y receptors"
    },
    {
      "id": "clopidogrel"
    },
    {
      "id": "P2 receptor mRNA expression profiles"
    },
    {
      "id": "human lymphocytes"
    },
    {
      "id": "Extracellular nucleotides"
    },
    {
      "id": "P2 receptor mRNA expression patterns"
    },
    {
      "id": "P2Y receptors"
    },
    {
      "id": "monocytes"
    },
    {
      "id": "progenitor/stem cell function"
    },
    {
      "id": "P2Y11"
    },
    {
      "id": "P2Y13"
    },
    {
      "id": "high mRNA expression"
    },
    {
      "id": "quantitative mRNA assay"
    },
    {
      "id": "hematopoietic lineage"
    },
    {
      "id": "multiple ionotropic P2X receptors"
    },
    {
      "id": "physiological functions"
    },
    {
      "id": "pharmacological experiments"
    },
    {
      "id": "P2 receptor subtypes"
    },
    {
      "id": "LPS injection"
    },
    {
      "id": "White blood cell (WBC) count"
    },
    {
      "id": "Groups of horses"
    },
    {
      "id": "PGE2 levels"
    },
    {
      "id": "Etodolac"
    },
    {
      "id": "Equine synovitis"
    },
    {
      "id": "Non-steroidal anti-inflammatory drugs (NSAIDs)"
    },
    {
      "id": "TXB2"
    },
    {
      "id": "Phenylbutazone"
    },
    {
      "id": "Anti-inflammatory effects"
    },
    {
      "id": "Anti-inflammatory agent"
    },
    {
      "id": "Non-selective cyclooxygenase inhibitors"
    },
    {
      "id": "Inflammation"
    },
    {
      "id": "Physiologic functions"
    },
    {
      "id": "Middle carpal joint"
    },
    {
      "id": "Gastrointestinal side effects"
    },
    {
      "id": "Lipopolysaccharide-induced synovitis"
    },
    {
      "id": "Sites of inflammation"
    },
    {
      "id": "Cyclooxygenase isoforms"
    },
    {
      "id": "Synovial fluid"
    },
    {
      "id": "PGE2"
    },
    {
      "id": "Synovitis"
    },
    {
      "id": "Horses"
    },
    {
      "id": "Lipopolysaccharide (LPS)"
    },
    {
      "id": "Preferential cyclooxygenase inhibitors"
    },
    {
      "id": "Gastric mucosal integrity"
    },
    {
      "id": "Untreated horses"
    },
    {
      "id": "Present study"
    },
    {
      "id": "Drugs"
    },
    {
      "id": "COX-1 prostanoid"
    },
    {
      "id": "Non-selective COX inhibitor"
    },
    {
      "id": "Preferential COX-2 inhibitor"
    },
    {
      "id": "C3T"
    },
    {
      "id": "apoA-I production"
    },
    {
      "id": "Rho kinase inhibitor"
    },
    {
      "id": "simvastatin"
    },
    {
      "id": "apoA-I"
    },
    {
      "id": "pitavastatin"
    },
    {
      "id": "HMG-CoA reductase inhibition"
    },
    {
      "id": "apoA-I expression"
    },
    {
      "id": "Y27632"
    },
    {
      "id": "ABCA1 induction"
    },
    {
      "id": "lipidation of apoA-I"
    },
    {
      "id": "Rho activity"
    },
    {
      "id": "statins"
    },
    {
      "id": "apoA-I synthesis"
    },
    {
      "id": "ABCA1 mRNA"
    },
    {
      "id": "apoA-I secretion"
    },
    {
      "id": "mevalonate"
    },
    {
      "id": "HMG-CoA reductase inhibitors"
    },
    {
      "id": "Rho"
    },
    {
      "id": "SU11248"
    },
    {
      "id": "metronomic chemotherapy"
    },
    {
      "id": "\"chemo-switch\" protocol"
    },
    {
      "id": "complete responses"
    },
    {
      "id": "imatinib"
    },
    {
      "id": "maximum-tolerated dose (MTD)"
    },
    {
      "id": "multitargeted, metronomic, and maximum-tolerated dose \"chemo-switch\" regimen"
    },
    {
      "id": "objective responses"
    },
    {
      "id": "VEGFR inhibition"
    },
    {
      "id": "late-stage disease"
    },
    {
      "id": "kinase inhibitors"
    },
    {
      "id": "platelet-derived growth factor receptors"
    },
    {
      "id": "pericyte coverage"
    },
    {
      "id": "VEGFR inhibitors"
    },
    {
      "id": "early-stage disease"
    },
    {
      "id": "endothelial cell apoptosis"
    },
    {
      "id": "tractable clinical strategy"
    },
    {
      "id": "standard-of-care chemotherapy"
    },
    {
      "id": "PDGFRs"
    },
    {
      "id": "antiangiogenic therapies"
    },
    {
      "id": "angiogenic switch"
    },
    {
      "id": "multistep tumorigenesis"
    },
    {
      "id": "ongoing angiogenesis"
    },
    {
      "id": "parameters"
    },
    {
      "id": "sensitized endothelial cells"
    },
    {
      "id": "multitargeted inhibition"
    },
    {
      "id": "MTD regimen"
    },
    {
      "id": "transitory regression"
    },
    {
      "id": "survival advantage"
    },
    {
      "id": "receptor tyrosine kinase inhibitors"
    },
    {
      "id": "PDGFR-mediated pericyte support"
    },
    {
      "id": "sequential MTD"
    },
    {
      "id": "VEGFR"
    },
    {
      "id": "stringent preclinical model"
    },
    {
      "id": "PDGFR"
    },
    {
      "id": "PDFGR"
    },
    {
      "id": "pericyte support"
    },
    {
      "id": "Pericytes"
    },
    {
      "id": "tumor neovasculature"
    },
    {
      "id": "tumor endothelial cells"
    },
    {
      "id": "novel maintenance regimen"
    },
    {
      "id": "pre-existing tumor vasculature"
    },
    {
      "id": "rapid regrowth"
    },
    {
      "id": "tumor vessels"
    },
    {
      "id": "stable disease"
    },
    {
      "id": "pancreatic islets"
    },
    {
      "id": "average helical displacement"
    },
    {
      "id": "halogen atom"
    },
    {
      "id": "ring system"
    },
    {
      "id": "atypical"
    },
    {
      "id": "typical antipsychotics"
    },
    {
      "id": "loxapine"
    },
    {
      "id": "larger displacements"
    },
    {
      "id": "receptor interactions"
    },
    {
      "id": "atypical antipsychotics"
    },
    {
      "id": "corresponding halogen atom"
    },
    {
      "id": "TMH5"
    },
    {
      "id": "typical"
    },
    {
      "id": "stronger non-bonded interactions"
    },
    {
      "id": "experimental observation"
    },
    {
      "id": "Molecular dynamics simulations"
    },
    {
      "id": "TMHs 3"
    },
    {
      "id": "TMHs 2"
    },
    {
      "id": "model of the dopamine D2 receptor"
    },
    {
      "id": "TMHs 7"
    },
    {
      "id": "atypical antipsychotic drugs"
    },
    {
      "id": "typical antipsychotic drugs"
    },
    {
      "id": "Atypical and typical antipsychotic drug interactions"
    },
    {
      "id": "dopamine D2 receptor"
    },
    {
      "id": "bupropion"
    },
    {
      "id": "antidepressant effect"
    },
    {
      "id": "99mTc-TRODAT-SPECT"
    },
    {
      "id": "baseline DAT activity"
    },
    {
      "id": "DAT"
    },
    {
      "id": "depressed patients"
    },
    {
      "id": "average occupancy of bupropion"
    },
    {
      "id": "international findings"
    },
    {
      "id": "depression"
    },
    {
      "id": "3 weeks' bupropion treatment"
    },
    {
      "id": "change in DAT activity"
    },
    {
      "id": "9 depressed patients"
    },
    {
      "id": "dopamine transporter"
    },
    {
      "id": "dopamine transporter activity"
    },
    {
      "id": "occupancy of bupropion"
    },
    {
      "id": "liver glycogen contents"
    },
    {
      "id": "normoglycemic stressed animals"
    },
    {
      "id": "bosentan"
    },
    {
      "id": "insulin levels"
    },
    {
      "id": "mild diabetic rats"
    },
    {
      "id": "serum glucose"
    },
    {
      "id": "intraperitoneal injection"
    },
    {
      "id": "streptozotocin"
    },
    {
      "id": "stress-induced hyperglycemia"
    },
    {
      "id": "ETB receptor"
    },
    {
      "id": "metabolic changes"
    },
    {
      "id": "stress"
    },
    {
      "id": "endothelin receptor antagonist"
    },
    {
      "id": "glycogen content"
    },
    {
      "id": "severely diabetic rats"
    },
    {
      "id": "insulin-induced hypoglycemia"
    },
    {
      "id": "Restraining water immersion stress"
    },
    {
      "id": "severe stress"
    },
    {
      "id": "plasma ET-1 levels"
    },
    {
      "id": "Mild diabetes"
    },
    {
      "id": "hypoglycemic action of insulin"
    },
    {
      "id": "ETA receptor"
    },
    {
      "id": "insulin secretion"
    },
    {
      "id": "ET-1"
    },
    {
      "id": "insulin resistance"
    },
    {
      "id": "liver glycogenolysis"
    },
    {
      "id": "RTKs"
    },
    {
      "id": "PDGFbeta-receptor"
    },
    {
      "id": "Transforming versions of Flt3"
    },
    {
      "id": "gene expression"
    },
    {
      "id": "SU5416"
    },
    {
      "id": "Flt3 kinase"
    },
    {
      "id": "hematopoietic class III receptor tyrosine kinase (RTK) Flt3"
    },
    {
      "id": "Flk2"
    },
    {
      "id": "Flt3"
    },
    {
      "id": "STI571"
    },
    {
      "id": "bis(1H-2-indolyl)-1-methanone"
    },
    {
      "id": "Compounds"
    },
    {
      "id": "indolinones"
    },
    {
      "id": "indolocarbazoles"
    },
    {
      "id": "wildtype Flt3"
    },
    {
      "id": "Flt3-ITD"
    },
    {
      "id": "Imatinib"
    },
    {
      "id": "STAT5"
    },
    {
      "id": "PKC412"
    },
    {
      "id": "Flt3 signaling"
    },
    {
      "id": "piperazonyl quinazoline"
    },
    {
      "id": "Flt3 receptor tyrosine kinase"
    },
    {
      "id": "leukemia"
    },
    {
      "id": "novel drugs"
    },
    {
      "id": "acute myeloid leukemia (AML)"
    },
    {
      "id": "Flt3 tyrosine kinase activity"
    },
    {
      "id": "class III RTKs"
    },
    {
      "id": "quinoxaline"
    },
    {
      "id": "activation mechanisms"
    },
    {
      "id": "class III RTK family"
    },
    {
      "id": "drug target"
    },
    {
      "id": "prognosis"
    },
    {
      "id": "D-65476"
    },
    {
      "id": "probes"
    },
    {
      "id": "Flt3 mutant"
    },
    {
      "id": "Gleevec"
    },
    {
      "id": "leukemic blasts"
    },
    {
      "id": "AG1296"
    },
    {
      "id": "ATP binding center"
    },
    {
      "id": "ATP"
    },
    {
      "id": "signaling"
    },
    {
      "id": "phosphoinositide-3-kinase/Akt signaling cascades"
    },
    {
      "id": "phosphoinositide-3-kinase"
    },
    {
      "id": "phenylalanine 691 side-chain"
    },
    {
      "id": "cell transformation"
    },
    {
      "id": "internal tandem duplication"
    },
    {
      "id": "Flt3 juxtamembrane domain"
    },
    {
      "id": "STK1"
    },
    {
      "id": "signaling pathways"
    },
    {
      "id": "CT53518"
    },
    {
      "id": "kinases"
    },
    {
      "id": "c-Kit"
    },
    {
      "id": "CEP-701"
    },
    {
      "id": "phenylaminopyrimidine"
    },
    {
      "id": "activated versions"
    },
    {
      "id": "Signal transduction"
    },
    {
      "id": "RAS/MAP-Kinase"
    },
    {
      "id": "Akt"
    },
    {
      "id": "perturbations"
    },
    {
      "id": "electron transport chain enzyme activity"
    },
    {
      "id": "TBARS"
    },
    {
      "id": "thiobarbituric acid"
    },
    {
      "id": "GSSG"
    },
    {
      "id": "GSH"
    },
    {
      "id": "complex II/III"
    },
    {
      "id": "PC"
    },
    {
      "id": "RP-1"
    },
    {
      "id": "O2-"
    },
    {
      "id": "radioprotection"
    },
    {
      "id": "mitochondrial system"
    },
    {
      "id": "complex I/III"
    },
    {
      "id": "radiation damage"
    },
    {
      "id": "treatment groups"
    },
    {
      "id": "Podophyllum hexandrum"
    },
    {
      "id": "Whole body y-irradiation"
    },
    {
      "id": "radiation"
    },
    {
      "id": "thiobarbituric acid reactive substance"
    },
    {
      "id": "complex-I"
    },
    {
      "id": "complex I/II"
    },
    {
      "id": "succinate-cytochrome c oxidoreductase"
    },
    {
      "id": "glutathione"
    },
    {
      "id": "complex I"
    },
    {
      "id": "NADH-ubiquinone oxidoreductase"
    },
    {
      "id": "superoxide anion"
    },
    {
      "id": "biochemical milieu"
    },
    {
      "id": "MMP"
    },
    {
      "id": "irradiation"
    },
    {
      "id": "NADH-cytochrome c oxidoreductase"
    },
    {
      "id": "protein carbonyl"
    },
    {
      "id": "serious adverse events"
    },
    {
      "id": "common adverse events"
    },
    {
      "id": "doses ranging from 0.02 to 0.2 microg/kg"
    },
    {
      "id": "study drug"
    },
    {
      "id": "meal and acetaminophen (part 2)"
    },
    {
      "id": "0.2-microg/kg exenatide"
    },
    {
      "id": "meal"
    },
    {
      "id": "study initiation"
    },
    {
      "id": "exenatide"
    },
    {
      "id": "eight subjects"
    },
    {
      "id": "0.3-microg/kg exenatide"
    },
    {
      "id": "0.1-microg/kg exenatide"
    },
    {
      "id": "days 1, 3, 5, 7, and 9"
    },
    {
      "id": "study B"
    },
    {
      "id": "0.05-microg/kg doses"
    },
    {
      "id": "part 2"
    },
    {
      "id": "Parts 1 and 2 of study B"
    },
    {
      "id": "six and eight patients"
    },
    {
      "id": "0.02-microg/kg doses"
    },
    {
      "id": "Administration"
    },
    {
      "id": "dose-proportional exenatide pharmacokinetics"
    },
    {
      "id": "meal (part 1)"
    },
    {
      "id": "postprandial plasma glucagon"
    },
    {
      "id": "postprandial plasma glucose excursion"
    },
    {
      "id": "Pharmacokinetics"
    },
    {
      "id": "preprandial exenatide"
    },
    {
      "id": "Exenatide doses of 0.02-0.2 microg/kg"
    },
    {
      "id": "postprandial glucose excursions"
    },
    {
      "id": "pharmacodynamics"
    },
    {
      "id": "second study"
    },
    {
      "id": "single s.c. dose"
    },
    {
      "id": "0.1-microg/kg doses"
    },
    {
      "id": "gastric emptying"
    },
    {
      "id": "patient withdrawals"
    },
    {
      "id": "0.4-microg/kg exenatide"
    },
    {
      "id": "study A"
    },
    {
      "id": "type 2 diabetes mellitus"
    },
    {
      "id": "plasma exenatide pharmacokinetic profiles"
    },
    {
      "id": "dose proportional"
    },
    {
      "id": "Nausea"
    },
    {
      "id": "antidiabetic pharmacodynamic activity"
    },
    {
      "id": "consecutive days"
    },
    {
      "id": "overnight fast"
    },
    {
      "id": "severity"
    },
    {
      "id": "first study"
    },
    {
      "id": "suppression of plasma glucagon"
    },
    {
      "id": "Part 1 of study B"
    },
    {
      "id": "exenatide doses of 0.01 and 0.1 microg/ kg"
    },
    {
      "id": "vomiting"
    },
    {
      "id": "safety"
    },
    {
      "id": "s.c. injection"
    },
    {
      "id": "oral antidiabetic agents"
    },
    {
      "id": "liquid acetaminophen"
    },
    {
      "id": "rate of gastric emptying"
    },
    {
      "id": "insulinotropism"
    },
    {
      "id": "crystal structure"
    },
    {
      "id": "PSMA ectodomain"
    },
    {
      "id": "PSMA structure"
    },
    {
      "id": "chemotherapeutics"
    },
    {
      "id": "PSMA"
    },
    {
      "id": "GCPII"
    },
    {
      "id": "docking studies"
    },
    {
      "id": "folate"
    },
    {
      "id": "small molecule substrates"
    },
    {
      "id": "protease domain"
    },
    {
      "id": "catalytic residues"
    },
    {
      "id": "transferrin"
    },
    {
      "id": "prostate-specific membrane antigen"
    },
    {
      "id": "tumor marker"
    },
    {
      "id": "substrate-binding arginine patch"
    },
    {
      "id": "natural substrate"
    },
    {
      "id": "prostate cancer cells"
    },
    {
      "id": "glutamate carboxypeptidase"
    },
    {
      "id": "catalytic mechanism"
    },
    {
      "id": "N-acetyl-l-aspartyl-l-glutamate"
    },
    {
      "id": "transferrin receptor"
    },
    {
      "id": "protease activity"
    },
    {
      "id": "anticancer drug"
    },
    {
      "id": "target"
    },
    {
      "id": "anticancer imaging"
    },
    {
      "id": "neurological disorders"
    },
    {
      "id": "peptidase"
    },
    {
      "id": "nonprostatic solid tumor neovasculature"
    },
    {
      "id": "homodimer"
    },
    {
      "id": "therapeutic agents"
    },
    {
      "id": "binuclear zinc site"
    },
    {
      "id": "iron"
    },
    {
      "id": "cancer-imaging agents"
    },
    {
      "id": "fulminant hepatitis"
    },
    {
      "id": "Jo2"
    },
    {
      "id": "Bid"
    },
    {
      "id": "caspase-9"
    },
    {
      "id": "caspase-3"
    },
    {
      "id": "liver tissues"
    },
    {
      "id": "cytochrome c release"
    },
    {
      "id": "histopathological alterations"
    },
    {
      "id": "minocycline pretreatment"
    },
    {
      "id": "pharmaceutical treatment"
    },
    {
      "id": "antiapoptotic effects"
    },
    {
      "id": "liver extracts"
    },
    {
      "id": "Jo2-challenged mice"
    },
    {
      "id": "neurons"
    },
    {
      "id": "activating anti-Fas antibody"
    },
    {
      "id": "caspase-8"
    },
    {
      "id": "mitochondrial apoptotic pathway"
    },
    {
      "id": "animal death"
    },
    {
      "id": "mouse livers"
    },
    {
      "id": "downstream caspase activation"
    },
    {
      "id": "lethal effect"
    },
    {
      "id": "Intraperitoneal injection"
    },
    {
      "id": "cartilage"
    },
    {
      "id": "caspase activation"
    },
    {
      "id": "periodontal tissues"
    },
    {
      "id": "liver diseases"
    },
    {
      "id": "Fas"
    },
    {
      "id": "serum alanine/aspartate transaminase activities"
    },
    {
      "id": "survival kinetics"
    },
    {
      "id": "liver sections"
    },
    {
      "id": "C57BL/6J mice"
    },
    {
      "id": "Peptidylarginine deiminases"
    },
    {
      "id": "PAD"
    },
    {
      "id": "deletion analyses"
    },
    {
      "id": "Sp1-binding sites"
    },
    {
      "id": "rodents"
    },
    {
      "id": "promoter region"
    },
    {
      "id": "PADI2"
    },
    {
      "id": "Sp1/Sp3 cooperation"
    },
    {
      "id": "human PAD2 gene"
    },
    {
      "id": "minimal promoter sequence"
    },
    {
      "id": "nucleotides -132 to -41"
    },
    {
      "id": "PAD2"
    },
    {
      "id": "Sp1"
    },
    {
      "id": "binding factors"
    },
    {
      "id": "reporter gene constructions"
    },
    {
      "id": "2 kb region"
    },
    {
      "id": "Sp3"
    },
    {
      "id": "transcription factors"
    },
    {
      "id": "citrulline residues"
    },
    {
      "id": "transfected human keratinocytes"
    },
    {
      "id": "cis-acting elements"
    },
    {
      "id": "PADI2 region"
    },
    {
      "id": "promoter activity"
    },
    {
      "id": "protein-bound arginine residues"
    },
    {
      "id": "human keratinocytes"
    },
    {
      "id": "Ca(2+) ion"
    },
    {
      "id": "TATA"
    },
    {
      "id": "electrophoretic mobility shift assays"
    },
    {
      "id": "PAD3"
    },
    {
      "id": "peptidylarginine deiminase type II gene"
    },
    {
      "id": "PAD1"
    },
    {
      "id": "PAD4"
    },
    {
      "id": "CAAT boxes"
    },
    {
      "id": "tissues"
    },
    {
      "id": "organs"
    },
    {
      "id": "transcription initiation site"
    },
    {
      "id": "PAD6"
    },
    {
      "id": "H2S"
    },
    {
      "id": "gas"
    },
    {
      "id": "CSE"
    },
    {
      "id": "mRNA signal"
    },
    {
      "id": "pancreas"
    },
    {
      "id": "histological evidence"
    },
    {
      "id": "neutrophil sequestration"
    },
    {
      "id": "pancreatic myeloperoxidase oxidase"
    },
    {
      "id": "possibility"
    },
    {
      "id": "forms of inflammation"
    },
    {
      "id": "cystathionine-beta-synthase"
    },
    {
      "id": "vasodilator activity"
    },
    {
      "id": "L-cysteine"
    },
    {
      "id": "CBS"
    },
    {
      "id": "therapeutic treatment"
    },
    {
      "id": "CSE inhibitor"
    },
    {
      "id": "lung MPO activity"
    },
    {
      "id": "Cystathionine-gamma-lyase"
    },
    {
      "id": "PAG"
    },
    {
      "id": "MPO activity"
    },
    {
      "id": "pancreatic acinar cell injury/necrosis"
    },
    {
      "id": "lung injury"
    },
    {
      "id": "hyperamylasemia"
    },
    {
      "id": "H2S synthesizing enzyme activity"
    },
    {
      "id": "hydrogen sulfide"
    },
    {
      "id": "prophylactic treatment"
    },
    {
      "id": "cardiovascular system"
    },
    {
      "id": "proinflammatory role"
    },
    {
      "id": "inflammatory condition"
    },
    {
      "id": "Hydrogen sulfide"
    },
    {
      "id": "plasma amylase"
    },
    {
      "id": "acute pancreatitis"
    },
    {
      "id": "rat arteries"
    },
    {
      "id": "DL-propargylglycine"
    },
    {
      "id": "CSE blockade"
    },
    {
      "id": "cystathionine-gamma-lyase"
    },
    {
      "id": "paper"
    },
    {
      "id": "pancreatitis"
    },
    {
      "id": "caerulein-induced pancreatitis"
    },
    {
      "id": "functional activity"
    },
    {
      "id": "1 microM dopamine induced-Ca2+ flux"
    },
    {
      "id": "intrinsic activity"
    },
    {
      "id": "D4.4 receptor"
    },
    {
      "id": "agonist-induced GTP-gamma-S binding assay"
    },
    {
      "id": "membrane"
    },
    {
      "id": "A-381393"
    },
    {
      "id": "ability"
    },
    {
      "id": "5-HT2A"
    },
    {
      "id": "dopamine D4 receptor"
    },
    {
      "id": "receptor selectivity"
    },
    {
      "id": "2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole"
    },
    {
      "id": "L-745870"
    },
    {
      "id": "D1, D2, D3 and D5 dopamine receptors"
    },
    {
      "id": "novel selective D4 antagonist"
    },
    {
      "id": "2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole"
    },
    {
      "id": "[3H]-spiperone competition binding assays"
    },
    {
      "id": "human dopamine D4.4 receptor expressing cells"
    },
    {
      "id": "human dopamine D2L or D3 receptor cells"
    },
    {
      "id": "penile erection"
    },
    {
      "id": "selective D4 agonist PD168077"
    },
    {
      "id": "recombinant human dopamine D4.4 receptor"
    },
    {
      "id": "panel of more than 70 receptors and channels"
    },
    {
      "id": "subcutaneous administration"
    },
    {
      "id": "Activator of G protein signaling 3"
    },
    {
      "id": "protein kinase A signaling"
    },
    {
      "id": "Galpha(i)"
    },
    {
      "id": "cAMP production"
    },
    {
      "id": "opiate activation"
    },
    {
      "id": "AGS3 antisense"
    },
    {
      "id": "reinstatement of heroin-seeking behavior"
    },
    {
      "id": "heroin-seeking behavior"
    },
    {
      "id": "AGS3"
    },
    {
      "id": "betagamma"
    },
    {
      "id": "Galpha(i3)-GDP"
    },
    {
      "id": "opiates"
    },
    {
      "id": "PKA signaling"
    },
    {
      "id": "Galpha(i3)/betagamma/AGS3"
    },
    {
      "id": "mu opiate receptor"
    },
    {
      "id": "AGS3 knockdown"
    },
    {
      "id": "NAc core"
    },
    {
      "id": "Galpha(i3) knockdown"
    },
    {
      "id": "Galpha(i3)"
    },
    {
      "id": "NAc"
    },
    {
      "id": "heroin addiction"
    },
    {
      "id": "NAc shell"
    },
    {
      "id": "opiate receptors"
    },
    {
      "id": "G(i/o)"
    },
    {
      "id": "betagamma dimers"
    },
    {
      "id": "human relapse"
    },
    {
      "id": "protein kinase A"
    },
    {
      "id": "alpha subunits"
    },
    {
      "id": "betagamma subunits"
    },
    {
      "id": "relapse"
    },
    {
      "id": "lipolysis"
    },
    {
      "id": "adipose tissue"
    },
    {
      "id": "HM74A"
    },
    {
      "id": "inhibition of lipolysis"
    },
    {
      "id": "G-protein coupled receptor"
    },
    {
      "id": "Niacin"
    },
    {
      "id": "anti-lipolytic effect"
    },
    {
      "id": "physiological/pharmacological role"
    },
    {
      "id": "G-protein coupled receptor HM74A"
    },
    {
      "id": "high affinities"
    },
    {
      "id": "Gi signaling events"
    },
    {
      "id": "human embryonic kidney HEK293 cells"
    },
    {
      "id": "direct evidence"
    },
    {
      "id": "nicotinic acid"
    },
    {
      "id": "3T3L1 adipocytes"
    },
    {
      "id": "differentiated 3T3L1 adipocytes"
    },
    {
      "id": "hypoxia-inducible factor-1alpha"
    },
    {
      "id": "O2-dependent prolyl hydroxylase domain enzymes"
    },
    {
      "id": "enzyme family"
    },
    {
      "id": "Collagen prolyl hydroxylase"
    },
    {
      "id": "PHD"
    },
    {
      "id": "PHD enzymes"
    },
    {
      "id": "stromal cell infiltration"
    },
    {
      "id": "HIF pathway"
    },
    {
      "id": "HIF"
    },
    {
      "id": "prolyl hydroxylases"
    },
    {
      "id": "hypoxia-inducible factor"
    },
    {
      "id": "haem oxygenase 1"
    },
    {
      "id": "nonhydroxylated HIF-1alpha"
    },
    {
      "id": "HIF stabilization"
    },
    {
      "id": "VEGF"
    },
    {
      "id": "ischemic disease"
    },
    {
      "id": "endothelin-1"
    },
    {
      "id": "intracellular free Ca2+"
    },
    {
      "id": "vascular endothelial growth factor"
    },
    {
      "id": "adrenomedullin"
    },
    {
      "id": "endothelial cell-specific proliferation"
    },
    {
      "id": "arterial smooth muscle"
    },
    {
      "id": "PHD activity"
    },
    {
      "id": "blood vessel density"
    },
    {
      "id": "cardiovascular therapy"
    },
    {
      "id": "pro-angiogenic phenotype"
    },
    {
      "id": "COX family"
    },
    {
      "id": "naproxen"
    },
    {
      "id": "ibuprofen"
    },
    {
      "id": "Conventional nonselective NSAIDs"
    },
    {
      "id": "gastrointestinal disorders"
    },
    {
      "id": "flurbiprofen"
    },
    {
      "id": "ketorolac"
    },
    {
      "id": "first degree relatives"
    },
    {
      "id": "diabetic patients"
    },
    {
      "id": "Islet cell antibodies"
    },
    {
      "id": "predictive value"
    },
    {
      "id": "HLA-DQB typing"
    },
    {
      "id": "Type 1 diabetic children"
    },
    {
      "id": "islet-cell antibody-negative children"
    },
    {
      "id": "susceptibility alleles"
    },
    {
      "id": "islet-cell antibody-positive children"
    },
    {
      "id": "fasting plasma glucose"
    },
    {
      "id": "feature"
    },
    {
      "id": "blood sample"
    },
    {
      "id": "mean interval"
    },
    {
      "id": "DQB1-Asp57-negative"
    },
    {
      "id": "indirect immunofluorescence technique"
    },
    {
      "id": "islet-cell antibodies titre"
    },
    {
      "id": "insulin autoantibodies"
    },
    {
      "id": "future development"
    },
    {
      "id": "family history of diabetes"
    },
    {
      "id": "Type 1 (insulin-dependent) diabetes"
    },
    {
      "id": "Juvenile Diabetes Foundation units"
    },
    {
      "id": "Sera"
    },
    {
      "id": "French schoolchildren"
    },
    {
      "id": "high-titre positive sera"
    },
    {
      "id": "subjects"
    },
    {
      "id": "restriction mapping techniques"
    },
    {
      "id": "background populations"
    },
    {
      "id": "prevalence rate"
    },
    {
      "id": "confidence interval"
    },
    {
      "id": "months"
    },
    {
      "id": "fluorescence"
    },
    {
      "id": "385 nm"
    },
    {
      "id": "active sites"
    },
    {
      "id": "dimeric 5-aminolevulinate synthase"
    },
    {
      "id": "absorption spectra"
    },
    {
      "id": "maxima"
    },
    {
      "id": "330 nm absorption band"
    },
    {
      "id": "coenzyme structure"
    },
    {
      "id": "2XALAS"
    },
    {
      "id": "pyridoxal 5'-phosphate"
    },
    {
      "id": "wild-type ALAS"
    },
    {
      "id": "A(410)/A(330) ratio"
    },
    {
      "id": "510 nm"
    },
    {
      "id": "subunit interface"
    },
    {
      "id": "amino acids"
    },
    {
      "id": "rates"
    },
    {
      "id": "ALAS"
    },
    {
      "id": "Transient kinetic analysis"
    },
    {
      "id": "decay"
    },
    {
      "id": "spectroscopic properties"
    },
    {
      "id": "formation"
    },
    {
      "id": "quinonoid intermediate EQ(2)"
    },
    {
      "id": "pH"
    },
    {
      "id": "330 nm absorption species"
    },
    {
      "id": "aldamine"
    },
    {
      "id": "385 nm emission intensity"
    },
    {
      "id": "2XALAS-catalyzed reaction"
    },
    {
      "id": "ketoenamine"
    },
    {
      "id": "active form"
    },
    {
      "id": "kinetic properties"
    },
    {
      "id": "polypeptide chain dimer"
    },
    {
      "id": "kinetic mechanism"
    },
    {
      "id": "410 nm absorption species"
    },
    {
      "id": "coenzyme"
    },
    {
      "id": "enolimine"
    },
    {
      "id": "Schiff base"
    },
    {
      "id": "subunits"
    },
    {
      "id": "5-aminolevulinate synthase"
    },
    {
      "id": "pK"
    },
    {
      "id": "turnover number"
    },
    {
      "id": "enteric nervous system"
    },
    {
      "id": "irritable bowel syndrome"
    },
    {
      "id": "Serotonin"
    },
    {
      "id": "substituted benzamide prokinetics"
    },
    {
      "id": "prokinetic action"
    },
    {
      "id": "gastrointestinal motility"
    },
    {
      "id": "pharmacological data"
    },
    {
      "id": "5-HT antagonists"
    },
    {
      "id": "experimental evidence"
    },
    {
      "id": "cisapride"
    },
    {
      "id": "functional dyspepsia"
    },
    {
      "id": "metoclopramide"
    },
    {
      "id": "granisetron"
    },
    {
      "id": "selective 5-HT3 antagonists"
    },
    {
      "id": "renzapride"
    },
    {
      "id": "5-HT4 agonist activity"
    },
    {
      "id": "non-cardiac chest pain"
    },
    {
      "id": "gastrointestinal motor function"
    },
    {
      "id": "ondansetron"
    },
    {
      "id": "gut"
    },
    {
      "id": "tropisetron"
    },
    {
      "id": "5-HT4 receptors"
    },
    {
      "id": "5-HT3 receptors"
    },
    {
      "id": "agonist effects"
    },
    {
      "id": "sensation"
    },
    {
      "id": "refractory nausea"
    },
    {
      "id": "5-HT4 antagonist"
    },
    {
      "id": "5-HT agonists"
    },
    {
      "id": "visceral pain"
    },
    {
      "id": "clinical implications"
    },
    {
      "id": "recognition sites"
    },
    {
      "id": "zacopride"
    },
    {
      "id": "gastrooesophageal reflux"
    },
    {
      "id": "colonic motility"
    },
    {
      "id": "C776G"
    },
    {
      "id": "CAD"
    },
    {
      "id": "French population"
    },
    {
      "id": "Methylenetetrahydrofolate reductase polymorphism"
    },
    {
      "id": "t-Hcys"
    },
    {
      "id": "MTRRAA genotype"
    },
    {
      "id": "moderate hyperhomocysteinemia"
    },
    {
      "id": "CAD group"
    },
    {
      "id": "248 matched healthy controls"
    },
    {
      "id": "MTHFR 677TT"
    },
    {
      "id": "TCN C776G"
    },
    {
      "id": "homocysteine"
    },
    {
      "id": "folates"
    },
    {
      "id": "MTRR A allele"
    },
    {
      "id": "CAD patients"
    },
    {
      "id": "MTHFR 677T frequency"
    },
    {
      "id": "A1298C"
    },
    {
      "id": "coronary artery disease"
    },
    {
      "id": "allele"
    },
    {
      "id": "MTRRA66G polymorphism"
    },
    {
      "id": "MTHFR C677T"
    },
    {
      "id": "homocysteine plasma level"
    },
    {
      "id": "substitutions A2756G"
    },
    {
      "id": "MTR"
    },
    {
      "id": "vitamin fortification"
    },
    {
      "id": "530 CAD patients"
    },
    {
      "id": "A66G"
    },
    {
      "id": "odds ratios"
    },
    {
      "id": "vitamin B12"
    },
    {
      "id": "MTRA2756G"
    },
    {
      "id": "MTRR"
    },
    {
      "id": "multivariate analysis"
    },
    {
      "id": "North Europe studies"
    },
    {
      "id": "methionine synthase"
    },
    {
      "id": "transcobalamin"
    },
    {
      "id": "TCN"
    },
    {
      "id": "carriers of MTRRAA"
    },
    {
      "id": "methionine synthase reductase"
    },
    {
      "id": "functional antagonist"
    },
    {
      "id": "human receptor"
    },
    {
      "id": "potential mechanism-related toxicology"
    },
    {
      "id": "novel CCR5 antagonists"
    },
    {
      "id": "Molecular cloning"
    },
    {
      "id": "chemokine receptor CCR5"
    },
    {
      "id": "[3H]-maraviroc"
    },
    {
      "id": "human recombinant CCR5"
    },
    {
      "id": "maraviroc"
    },
    {
      "id": "[125I]-MIP-1beta"
    },
    {
      "id": "macaque"
    },
    {
      "id": "rhesus macaque"
    },
    {
      "id": "macaque CCR5"
    },
    {
      "id": "pre-clinical evaluation"
    },
    {
      "id": "binding properties"
    },
    {
      "id": "MIP-1beta"
    },
    {
      "id": "competition binding studies"
    },
    {
      "id": "human chemokines"
    },
    {
      "id": "high affinity"
    },
    {
      "id": "K(d)"
    },
    {
      "id": "UK-427,857"
    },
    {
      "id": "CCR5"
    },
    {
      "id": "human"
    },
    {
      "id": "radioligand binding characterization"
    },
    {
      "id": "cyclooxygenase type 1"
    },
    {
      "id": "flushing"
    },
    {
      "id": "PUMA-G"
    },
    {
      "id": "macrophages"
    },
    {
      "id": "release"
    },
    {
      "id": "prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors"
    },
    {
      "id": "flushing response"
    },
    {
      "id": "antilipolytic effects"
    },
    {
      "id": "PGE(2)"
    },
    {
      "id": "prostaglandin E(2)"
    },
    {
      "id": "wild-type bone marrow"
    },
    {
      "id": "irradiated PUMA-G-deficient mice"
    },
    {
      "id": "pharmacological tools"
    },
    {
      "id": "GPR109A"
    },
    {
      "id": "prostaglandin D(2)"
    },
    {
      "id": "PGD(2)"
    },
    {
      "id": "niacin"
    },
    {
      "id": "antidyslipidemic drug"
    },
    {
      "id": "patient compliance"
    },
    {
      "id": "G-protein-coupled receptor"
    },
    {
      "id": "HDL-cholesterol levels"
    },
    {
      "id": "skin"
    },
    {
      "id": "pharmacotherapeutical use"
    },
    {
      "id": "transplantation"
    },
    {
      "id": "Niemann-Pick C1 Like 1 (NPC1L1) protein"
    },
    {
      "id": "ABCG5"
    },
    {
      "id": "Sterol transporters"
    },
    {
      "id": "new lipid lowering drugs"
    },
    {
      "id": "ezetimibe"
    },
    {
      "id": "natural sterols"
    },
    {
      "id": "sterol efflux pumps"
    },
    {
      "id": "intestinal sterol absorption"
    },
    {
      "id": "sitosterolemia"
    },
    {
      "id": "direct cholesterol absorption inhibitor"
    },
    {
      "id": "ABCG8"
    },
    {
      "id": "ATP-binding cassette (ABC) transporters"
    },
    {
      "id": "processes"
    },
    {
      "id": "rare disease"
    },
    {
      "id": "liver X receptors (LXRs)"
    },
    {
      "id": "derivatives of plant sterols"
    },
    {
      "id": "hepatic sterol output"
    },
    {
      "id": "sterol transporter"
    },
    {
      "id": "sterol transport processes"
    },
    {
      "id": "small intestine"
    },
    {
      "id": "oxysterols"
    },
    {
      "id": "defective structures"
    },
    {
      "id": "brain phospholipids"
    },
    {
      "id": "lithium"
    },
    {
      "id": "bipolar disorder"
    },
    {
      "id": "Valproic acid"
    },
    {
      "id": "Acsl"
    },
    {
      "id": "phospholipase A(2)"
    },
    {
      "id": "docosahexaenoic acid"
    },
    {
      "id": "brain microsomal long-chain fatty acyl-CoA synthetases"
    },
    {
      "id": "carbamazepine"
    },
    {
      "id": "valproyl-CoA"
    },
    {
      "id": "docosahexaenoyl-CoA"
    },
    {
      "id": "arachidonoyl-CoA"
    },
    {
      "id": "brain arachidonic acid cascade"
    },
    {
      "id": "palmitoyl-CoA"
    },
    {
      "id": "p75 neurotrophin receptor"
    },
    {
      "id": "p75NTR"
    },
    {
      "id": "cell adhesion"
    },
    {
      "id": "p75NTR protein expression"
    },
    {
      "id": "IGFBP5 protein levels"
    },
    {
      "id": "Immunoblot analysis"
    },
    {
      "id": "PLAUR"
    },
    {
      "id": "cellular retinoic acid-binding protein I"
    },
    {
      "id": "RAR-beta"
    },
    {
      "id": "neo control PC-3 cells"
    },
    {
      "id": "retinoic acid receptors"
    },
    {
      "id": "expression levels"
    },
    {
      "id": "RARs"
    },
    {
      "id": "p75NTR siRNA"
    },
    {
      "id": "tumor suppression"
    },
    {
      "id": "IGFBP5"
    },
    {
      "id": "RAR-gamma"
    },
    {
      "id": "protein levels"
    },
    {
      "id": "retinoids"
    },
    {
      "id": "nitroblue tetrazolium-associated functional cell differentiation"
    },
    {
      "id": "re-introduction"
    },
    {
      "id": "PC-3 prostate tumor cells"
    },
    {
      "id": "de-differentiation"
    },
    {
      "id": "prostate cancer"
    },
    {
      "id": "complementary deoxyribonucleic acid microarray"
    },
    {
      "id": "human cancer-related genes"
    },
    {
      "id": "tumor suppressor"
    },
    {
      "id": "PLAUR protein"
    },
    {
      "id": "signal transduction"
    },
    {
      "id": "cDNA microarray profiling"
    },
    {
      "id": "p75NTR-regulated gene expression"
    },
    {
      "id": "all-trans retinoic acid"
    },
    {
      "id": "CRABPI"
    },
    {
      "id": "prostate epithelial cells"
    },
    {
      "id": "retinoid X receptor"
    },
    {
      "id": "differentially expressed genes"
    },
    {
      "id": "regulation of differentiation"
    },
    {
      "id": "RAR-alpha"
    },
    {
      "id": "tumor suppressor gene"
    },
    {
      "id": "microarray"
    },
    {
      "id": "9-cis retinoic acid"
    },
    {
      "id": "p75NTR-transfected cells"
    },
    {
      "id": "transcripts"
    },
    {
      "id": "RXR-alpha"
    },
    {
      "id": "prostate growth"
    },
    {
      "id": "localized sequestration"
    },
    {
      "id": "RXR-beta"
    },
    {
      "id": "quantitative real-time polymerase chain reaction"
    },
    {
      "id": "tumor cell invasion"
    },
    {
      "id": "p75NTR protein"
    },
    {
      "id": "gene expression pattern"
    },
    {
      "id": "p75NTR PC-3 cells"
    },
    {
      "id": "metastasis"
    },
    {
      "id": "neo cells"
    },
    {
      "id": "research"
    },
    {
      "id": "urinary organic acids"
    },
    {
      "id": "voyage"
    },
    {
      "id": "inborn error patient"
    },
    {
      "id": "masses"
    },
    {
      "id": "Carboxylase activities"
    },
    {
      "id": "human genes"
    },
    {
      "id": "biotin deficiency"
    },
    {
      "id": "tissue level"
    },
    {
      "id": "aspects"
    },
    {
      "id": "vitamin biotin"
    },
    {
      "id": "regulatory meaning"
    },
    {
      "id": "gas chromatography-mass spectrometry"
    },
    {
      "id": "hexokinases"
    },
    {
      "id": "field"
    },
    {
      "id": "inherited metabolic disorders"
    },
    {
      "id": "Saccharomyces cerevisiae"
    },
    {
      "id": "HCS"
    },
    {
      "id": "biotin effects"
    },
    {
      "id": "HCS mRNA levels"
    },
    {
      "id": "deficient animals"
    },
    {
      "id": "mRNAs"
    },
    {
      "id": "biotin injection"
    },
    {
      "id": "metabolic abnormalities"
    },
    {
      "id": "protein feeding"
    },
    {
      "id": "biotin-deficient"
    },
    {
      "id": "phenomenon"
    },
    {
      "id": "malnourished individuals"
    },
    {
      "id": "intestine"
    },
    {
      "id": "specific genes"
    },
    {
      "id": "nutritional disorder"
    },
    {
      "id": "proteomes"
    },
    {
      "id": "multiple carboxylase deficiency (MCD)"
    },
    {
      "id": "MCD clinical manifestations"
    },
    {
      "id": "infant malnutrition"
    },
    {
      "id": "comparative studies"
    },
    {
      "id": "article"
    },
    {
      "id": "logic"
    },
    {
      "id": "enigma"
    },
    {
      "id": "hyperosmotic diuretic solution"
    },
    {
      "id": "glycerol"
    },
    {
      "id": "Glyceol"
    },
    {
      "id": "saline"
    },
    {
      "id": "CTLN2"
    },
    {
      "id": "fructose"
    },
    {
      "id": "high signal intensities"
    },
    {
      "id": "insular cortices"
    },
    {
      "id": "hepatic argininosuccinate synthetase activity"
    },
    {
      "id": "recurrent encephalopathy"
    },
    {
      "id": "hyperammonemia"
    },
    {
      "id": "differential diagnosis"
    },
    {
      "id": "Asian patients"
    },
    {
      "id": "serum pancreatic secretory trypsin inhibitor"
    },
    {
      "id": "hepatic citrin protein expression"
    },
    {
      "id": "brain edema"
    },
    {
      "id": "repeated unconsciousness"
    },
    {
      "id": "compound heterozygote"
    },
    {
      "id": "Ex1-1G>A"
    },
    {
      "id": "SLC25A13 gene"
    },
    {
      "id": "plasma citrulline level"
    },
    {
      "id": "clinical course"
    },
    {
      "id": "plasma ammonia level"
    },
    {
      "id": "autosomal recessive disorder"
    },
    {
      "id": "citrin"
    },
    {
      "id": "S225X"
    },
    {
      "id": "intractable seizures"
    },
    {
      "id": "plasma ammonia levels"
    },
    {
      "id": "hyperosmotic and high sugar solutions"
    },
    {
      "id": "coma"
    },
    {
      "id": "altered consciousness"
    },
    {
      "id": "D-mannitol"
    },
    {
      "id": "bilateral cingulate gyri"
    },
    {
      "id": "adult-onset type II citrullinemia"
    },
    {
      "id": "hepatic encephalopathy"
    },
    {
      "id": "Brain MRI"
    },
    {
      "id": "PSTI"
    },
    {
      "id": "Deltaxprt null mutants"
    },
    {
      "id": "virulent background"
    },
    {
      "id": "promastigotes"
    },
    {
      "id": "purine salvage"
    },
    {
      "id": "parasite life cycle stages"
    },
    {
      "id": "Deltaaprt null mutants"
    },
    {
      "id": "anabolic routes"
    },
    {
      "id": "Leishmania donovani"
    },
    {
      "id": "three phosphoribosyltransferase enzymes"
    },
    {
      "id": "hypoxanthine-guanine phosphoribosyltransferase"
    },
    {
      "id": "adenine aminohydrolase enzyme"
    },
    {
      "id": "L. donovani"
    },
    {
      "id": "Deltahgprt null mutants"
    },
    {
      "id": "Leishmania species"
    },
    {
      "id": "adenine phosphoribosyltransferase"
    },
    {
      "id": "three knockout strains"
    },
    {
      "id": "infection"
    },
    {
      "id": "bone marrow-derived murine macrophages"
    },
    {
      "id": "targeted gene replacement"
    },
    {
      "id": "phosphoribosyltransferases"
    },
    {
      "id": "axenic amastigotes"
    },
    {
      "id": "APRT"
    },
    {
      "id": "mammalian macrophages"
    },
    {
      "id": "this genus"
    },
    {
      "id": "purine nutrients"
    },
    {
      "id": "infectivity"
    },
    {
      "id": "null mutants"
    },
    {
      "id": "amastigotes"
    },
    {
      "id": "HGPRT"
    },
    {
      "id": "viability"
    },
    {
      "id": "XPRT"
    },
    {
      "id": "xanthine phosphoribosyltransferase"
    },
    {
      "id": "hosts"
    },
    {
      "id": "NISHTKEKKKGKAKKKRLTK"
    },
    {
      "id": "renal accumulation of gentamicin"
    },
    {
      "id": "N-WASP181-200"
    },
    {
      "id": "megalin"
    },
    {
      "id": "alpha-helix content"
    },
    {
      "id": "basic peptides"
    },
    {
      "id": "gentamicin binding"
    },
    {
      "id": "glycines"
    },
    {
      "id": "lysines"
    },
    {
      "id": "rat renal brush-border membrane"
    },
    {
      "id": "BBM"
    },
    {
      "id": "proximal tubule cells"
    },
    {
      "id": "20-residue basic peptide"
    },
    {
      "id": "trypsin"
    },
    {
      "id": "megalin ligands"
    },
    {
      "id": "N-WASP180-200"
    },
    {
      "id": "endocytic receptor"
    },
    {
      "id": "renal uptake of gentamicin"
    },
    {
      "id": "isolated rat renal brush-border membrane"
    },
    {
      "id": "cytochrome c"
    },
    {
      "id": "native BBM"
    },
    {
      "id": "alpha-helix conformation"
    },
    {
      "id": "mutant peptides"
    },
    {
      "id": "basic peptide fragments of cytochrome c"
    },
    {
      "id": "selection method"
    },
    {
      "id": "subsequent therapies"
    },
    {
      "id": "unfavourable variables"
    },
    {
      "id": "5-fluorouracil"
    },
    {
      "id": "populations"
    },
    {
      "id": "28-bp sequence"
    },
    {
      "id": "gene promoter"
    },
    {
      "id": "SNP"
    },
    {
      "id": "combined effect"
    },
    {
      "id": "TS"
    },
    {
      "id": "biological target"
    },
    {
      "id": "colorectal cancer"
    },
    {
      "id": "Paraffin-embedded sections"
    },
    {
      "id": "immuno-histochemistry"
    },
    {
      "id": "Mab TS106"
    },
    {
      "id": "PFS"
    },
    {
      "id": "C SNP"
    },
    {
      "id": "response to chemotherapy"
    },
    {
      "id": "CRC patients"
    },
    {
      "id": "expression pattern"
    },
    {
      "id": "consensus"
    },
    {
      "id": "value"
    },
    {
      "id": "prognostic factors"
    },
    {
      "id": "variable agreement"
    },
    {
      "id": "Cytoplasmic expression pattern"
    },
    {
      "id": "single nucleotide polymorphism"
    },
    {
      "id": "clinical outcome"
    },
    {
      "id": "level of protein expression"
    },
    {
      "id": "5FU"
    },
    {
      "id": "RFLP"
    },
    {
      "id": "progression-free survival"
    },
    {
      "id": "predictive factors"
    },
    {
      "id": "low risk"
    },
    {
      "id": "expression level"
    },
    {
      "id": "disease-free survival"
    },
    {
      "id": "number of variable tandem-repeats"
    },
    {
      "id": "restriction-length-fragment polymorphism"
    },
    {
      "id": "region"
    },
    {
      "id": "high risk"
    },
    {
      "id": "survival"
    },
    {
      "id": "VNTR"
    },
    {
      "id": "polymerase-chain reaction"
    },
    {
      "id": "PCR"
    },
    {
      "id": "Low TS expression levels"
    },
    {
      "id": "favourable variables"
    },
    {
      "id": "TS levels"
    },
    {
      "id": "pharmacological agents"
    },
    {
      "id": "AMPK"
    },
    {
      "id": "intracellular fatty acid partitioning"
    },
    {
      "id": "metabolic dysregulation"
    },
    {
      "id": "premature atherosclerosis"
    },
    {
      "id": "factors"
    },
    {
      "id": "malonyl CoA"
    },
    {
      "id": "Metabolic syndrome"
    },
    {
      "id": "lipid abnormalities"
    },
    {
      "id": "dysregulation"
    },
    {
      "id": "cellular dysfunction"
    },
    {
      "id": "central obesity"
    },
    {
      "id": "fuel-sensing and signaling mechanism"
    },
    {
      "id": "diseases"
    },
    {
      "id": "malonyl coenzyme A"
    },
    {
      "id": "type 2 diabetes"
    },
    {
      "id": "dyslipidemia"
    },
    {
      "id": "therapeutic targets"
    },
    {
      "id": "adenosine monophosphate-activated protein kinase"
    },
    {
      "id": "lipopolysaccharide (LPS)"
    },
    {
      "id": "mPGES-2"
    },
    {
      "id": "PGE2 production"
    },
    {
      "id": "PS liposomes"
    },
    {
      "id": "membrane-bound prostaglandin E synthase-1 (mPGES-1)"
    },
    {
      "id": "terminal PGESs"
    },
    {
      "id": "phosphatidylserine (PS)"
    },
    {
      "id": "PS-mediated recognition"
    },
    {
      "id": "Cyclooxygenase (COX)-2"
    },
    {
      "id": "PS-specific receptor"
    },
    {
      "id": "PS-recognizing receptors"
    },
    {
      "id": "high density lipoprotein"
    },
    {
      "id": "prostaglandin E synthases"
    },
    {
      "id": "apoptotic cells"
    },
    {
      "id": "phagocytosis"
    },
    {
      "id": "microglia"
    },
    {
      "id": "cytosolic PGES (cPGES)"
    },
    {
      "id": "p44/p42 extracellular signal-regulated kinase (ERK)"
    },
    {
      "id": "SR-BI"
    },
    {
      "id": "PS liposomes treatment"
    },
    {
      "id": "anti-inflammatory molecule"
    },
    {
      "id": "phosphatidylcholine liposomes treatment"
    },
    {
      "id": "phagocytic pathway"
    },
    {
      "id": "endosomes/lysosomes"
    },
    {
      "id": "p38 mitogen-activated protein kinase"
    },
    {
      "id": "class B scavenger receptor (SR-B)"
    },
    {
      "id": "NS-398"
    },
    {
      "id": "COX-1 inhibitor"
    },
    {
      "id": "primary cultured rat microglia"
    },
    {
      "id": "culture medium"
    },
    {
      "id": "phosphatidylserine liposome"
    },
    {
      "id": "probucol"
    },
    {
      "id": "low-density lipoprotein cholesterol"
    },
    {
      "id": "vitamin E group"
    },
    {
      "id": "Total fecal sterol content"
    },
    {
      "id": "aortic fatty streak"
    },
    {
      "id": "HC-control group"
    },
    {
      "id": "cholesterol metabolism"
    },
    {
      "id": "plasma paraoxonase activity"
    },
    {
      "id": "plasma high-density lipoprotein-cholesterol (HDL-C)"
    },
    {
      "id": "Vitamin E"
    },
    {
      "id": "high-cholesterol diet"
    },
    {
      "id": "Male rabbits"
    },
    {
      "id": "0.05% probucol"
    },
    {
      "id": "plasma total-cholesterol (total-C)"
    },
    {
      "id": "plasma HDL-C-related factors"
    },
    {
      "id": "risk factor"
    },
    {
      "id": "probucol group"
    },
    {
      "id": "HMG-CoA reductase activity"
    },
    {
      "id": "negative effect"
    },
    {
      "id": "plasma HDL-C concentration"
    },
    {
      "id": "atherogenic signs"
    },
    {
      "id": "other groups"
    },
    {
      "id": "probucol groups"
    },
    {
      "id": "Hepatic ACAT activity"
    },
    {
      "id": "0.5% high-cholesterol (HC) diet"
    },
    {
      "id": "atherosclerosis"
    },
    {
      "id": "HDL-cholesterol concentration"
    },
    {
      "id": "apo B-100"
    },
    {
      "id": "paraoxonase activity"
    },
    {
      "id": "apo C-III"
    },
    {
      "id": "0.03% vitamin E"
    },
    {
      "id": "HDL-C/total-C ratio levels"
    },
    {
      "id": "tRNAs"
    },
    {
      "id": "mitochondrial (mt) genome"
    },
    {
      "id": "Mt-tRNAs"
    },
    {
      "id": "biased sequences"
    },
    {
      "id": "position 73"
    },
    {
      "id": "universally conserved major aspartate identity element"
    },
    {
      "id": "Sequence alignments"
    },
    {
      "id": "various AspRSs"
    },
    {
      "id": "human mt-AspRS"
    },
    {
      "id": "G73"
    },
    {
      "id": "size variations"
    },
    {
      "id": "loops"
    },
    {
      "id": "classical tertiary interactions"
    },
    {
      "id": "Asp-220"
    },
    {
      "id": "E. coli AspRS-tRNA(Asp) complex"
    },
    {
      "id": "reverse evolution"
    },
    {
      "id": "mt-tRNA(Asp) identity elements"
    },
    {
      "id": "identity role"
    },
    {
      "id": "GUC anticodon"
    },
    {
      "id": "aminoacyl-tRNA synthetases"
    },
    {
      "id": "nuclear genome"
    },
    {
      "id": "bacterial ancestor"
    },
    {
      "id": "aspartylation systems"
    },
    {
      "id": "human mt-tRNA(Asp) transcripts"
    },
    {
      "id": "mammalian mitochondria"
    },
    {
      "id": "translational machinery"
    },
    {
      "id": "Restriction"
    },
    {
      "id": "aspartylation identity set"
    },
    {
      "id": "rapid mutagenic rate"
    },
    {
      "id": "prokaryotic-type AspRS"
    },
    {
      "id": "Escherichia coli enzyme"
    },
    {
      "id": "identity elements"
    },
    {
      "id": "human mt-aspartate system"
    },
    {
      "id": "nucleotides"
    },
    {
      "id": "aspartylation"
    },
    {
      "id": "stems"
    },
    {
      "id": "crystallographic structure"
    },
    {
      "id": "mt-aaRSs"
    },
    {
      "id": "primordial identity signal"
    },
    {
      "id": "aminoacylation system"
    },
    {
      "id": "tRNA(Asp)"
    },
    {
      "id": "Gly-269"
    },
    {
      "id": "dobutamine"
    },
    {
      "id": "contractility"
    },
    {
      "id": "Gly389beta1AR subjects"
    },
    {
      "id": "dobutamine-induced hemodynamic effects"
    },
    {
      "id": "diastolic blood pressure"
    },
    {
      "id": "Arg389-beta1AR subjects"
    },
    {
      "id": "male homozygous Gly389beta1AR subjects"
    },
    {
      "id": "homozygous Ser49-beta1AR"
    },
    {
      "id": "dobutamine-induced heart rate and contractility increases"
    },
    {
      "id": "PRA"
    },
    {
      "id": "Codon 389 beta1AR polymorphism"
    },
    {
      "id": "Arg389Gly-beta1AR polymorphism"
    },
    {
      "id": "receptor signaling"
    },
    {
      "id": "dobutamine-induced PRA increase"
    },
    {
      "id": "therapeutic responses"
    },
    {
      "id": "betaAR-blocker treatment"
    },
    {
      "id": "Arg389Gly beta1-adrenoceptor polymorphism"
    },
    {
      "id": "plasma-renin activity"
    },
    {
      "id": "hemodynamic effects"
    },
    {
      "id": "male homozygous Arg389-beta1AR subjects"
    },
    {
      "id": "beta1AR polymorphisms"
    },
    {
      "id": "catecholamine"
    },
    {
      "id": "Succinate"
    },
    {
      "id": "sake (Japanese rice wine) fermentation"
    },
    {
      "id": "TCA cycle"
    },
    {
      "id": "oxidative direction"
    },
    {
      "id": "fumarate reduction"
    },
    {
      "id": "anaerobic conditions"
    },
    {
      "id": "expression of enzymes"
    },
    {
      "id": "SDH1"
    },
    {
      "id": "YPD medium"
    },
    {
      "id": "succinic acid"
    },
    {
      "id": "Saccharomyces cerevisiae strains"
    },
    {
      "id": "KGD1"
    },
    {
      "id": "alpha-ketoglutarate dehydrogenase"
    },
    {
      "id": "aerobic conditions"
    },
    {
      "id": "succinate dehydrogenase"
    },
    {
      "id": "gene disrupted mutant"
    },
    {
      "id": "pathway"
    },
    {
      "id": "fumarate"
    },
    {
      "id": "growth condition"
    },
    {
      "id": "fumarate reductase isozyme genes"
    },
    {
      "id": "OSM1"
    },
    {
      "id": "double mutant"
    },
    {
      "id": "succinate productivity"
    },
    {
      "id": "malate"
    },
    {
      "id": "liquid culture"
    },
    {
      "id": "glucose"
    },
    {
      "id": "taste component"
    },
    {
      "id": "yeasts"
    },
    {
      "id": "FUM1"
    },
    {
      "id": "KGD1 diruptant"
    },
    {
      "id": "FRDS"
    },
    {
      "id": "parent"
    },
    {
      "id": "gene disruptions"
    },
    {
      "id": "two pathways"
    },
    {
      "id": "alpha-ketoglutarate oxidation"
    },
    {
      "id": "wild-type strain"
    },
    {
      "id": "fumarase"
    },
    {
      "id": "SDH1 disruptants"
    },
    {
      "id": "glucose-buffered solution"
    },
    {
      "id": "bexarotene"
    },
    {
      "id": "p55 subunits"
    },
    {
      "id": "p75 subunits"
    },
    {
      "id": "CD25 expression"
    },
    {
      "id": "IL-2R expression"
    },
    {
      "id": "reliable conclusions"
    },
    {
      "id": "precise distribution"
    },
    {
      "id": "acquisition of response"
    },
    {
      "id": "tadpole tissues"
    },
    {
      "id": "Amphibian metamorphosis"
    },
    {
      "id": "thyroid hormones"
    },
    {
      "id": "hybridization signals"
    },
    {
      "id": "Cytosolic Thyroid Hormone-Binding Protein"
    },
    {
      "id": "Tissue samples"
    },
    {
      "id": "specimens"
    },
    {
      "id": "clear expression"
    },
    {
      "id": "several tissues"
    },
    {
      "id": "M2-pyruvate kinase"
    },
    {
      "id": "Thyroid hormone receptor"
    },
    {
      "id": "obligatory paedomorphic salamander"
    },
    {
      "id": "Necturus maculosus"
    },
    {
      "id": "urinary organs"
    },
    {
      "id": "other tissues"
    },
    {
      "id": "hormones"
    },
    {
      "id": "thyroid hormone receptors"
    },
    {
      "id": "pharmacological means"
    },
    {
      "id": "non-cross-hybridizing RNA probes"
    },
    {
      "id": "Necturus TRalpha genes"
    },
    {
      "id": "Necturus tissues"
    },
    {
      "id": "TRs"
    },
    {
      "id": "obligatory paedomorphic Amphibian"
    },
    {
      "id": "two TH-related genes"
    },
    {
      "id": "CTHBP"
    },
    {
      "id": "stromelysin 3"
    },
    {
      "id": "direct TH target gene"
    },
    {
      "id": "Xenopus laevis"
    },
    {
      "id": "thyroid hormone"
    },
    {
      "id": "TRbeta"
    },
    {
      "id": "TR gene expression patterns"
    },
    {
      "id": "Necturus TRalpha gene"
    },
    {
      "id": "in situ hybridization"
    },
    {
      "id": "ST3"
    },
    {
      "id": "TRalpha"
    },
    {
      "id": "TRbeta genes"
    },
    {
      "id": "myocardium"
    },
    {
      "id": "cytosolic TH binding protein"
    },
    {
      "id": "digestive organs"
    },
    {
      "id": "previously held hypotheses"
    },
    {
      "id": "amoxapine"
    },
    {
      "id": "central 5-HT receptors"
    },
    {
      "id": "amitriptyline"
    },
    {
      "id": "opioid peptides"
    },
    {
      "id": "serotoninergic neurotransmission"
    },
    {
      "id": "5-HT2 receptors"
    },
    {
      "id": "central effect"
    },
    {
      "id": "mu and delta classes of opioid receptors"
    },
    {
      "id": "regions of the brain"
    },
    {
      "id": "opioidergic neurotransmission"
    },
    {
      "id": "Bezold-Jarisch reflex"
    },
    {
      "id": "opiodergic systems"
    },
    {
      "id": "[3H]ketanserin"
    },
    {
      "id": "cortical membranes"
    },
    {
      "id": "5-HT3 antagonist"
    },
    {
      "id": "serotoninergic systems"
    },
    {
      "id": "[3H]zacopride"
    },
    {
      "id": "reeler heterozygous mouse (+/rl)"
    },
    {
      "id": "animal model"
    },
    {
      "id": "spine density"
    },
    {
      "id": "GABAergic neurons"
    },
    {
      "id": "psychotic brain"
    },
    {
      "id": "GAD67 promoters"
    },
    {
      "id": "synaptic function"
    },
    {
      "id": "long-term potentiation (LTP)"
    },
    {
      "id": "RELN"
    },
    {
      "id": "Brain abnormalities"
    },
    {
      "id": "dendritic arbors"
    },
    {
      "id": "DNA methyltransferase 1"
    },
    {
      "id": "DNMT1"
    },
    {
      "id": "Reelin"
    },
    {
      "id": "synaptic plasticity"
    },
    {
      "id": "LTP"
    },
    {
      "id": "reelin"
    },
    {
      "id": "postmortem psychotic brain"
    },
    {
      "id": "epigenesis"
    },
    {
      "id": "brain and behavioral abnormalities"
    },
    {
      "id": "Hypermethlyation of RELN and GAD67 promoters"
    },
    {
      "id": "Reelin down-regulation"
    },
    {
      "id": "psychosis endophenotypes"
    },
    {
      "id": "neuronal guidance"
    },
    {
      "id": "+/rl"
    },
    {
      "id": "glycoprotein"
    },
    {
      "id": "behavioral abnormalities"
    },
    {
      "id": "genetic heterozygocity"
    },
    {
      "id": "reelin (RELN) and GAD67 promoters"
    },
    {
      "id": "glutamic acid de carboxylase 67"
    },
    {
      "id": "cortex"
    },
    {
      "id": "telencephalic GABAergic neurons"
    },
    {
      "id": "psychosis"
    },
    {
      "id": "GAD67"
    },
    {
      "id": "cholesterol metabolites"
    },
    {
      "id": "SREBP-1c"
    },
    {
      "id": "retinal dehydrogenases"
    },
    {
      "id": "RALDH genes"
    },
    {
      "id": "LXRalpha/beta"
    },
    {
      "id": "RALDHs"
    },
    {
      "id": "RA biosynthesis"
    },
    {
      "id": "vitamin A"
    },
    {
      "id": "LXR"
    },
    {
      "id": "sterol regulatory element binding protein-1c"
    },
    {
      "id": "RA"
    },
    {
      "id": "pravastatin sodium"
    },
    {
      "id": "RALDH1 and 2"
    },
    {
      "id": "liver X receptor"
    },
    {
      "id": "fluorouracil exposure"
    },
    {
      "id": "genotyping"
    },
    {
      "id": "limitations"
    },
    {
      "id": "adaptation"
    },
    {
      "id": "fluorouracil exposure ranges"
    },
    {
      "id": "serious toxicity"
    },
    {
      "id": "methods"
    },
    {
      "id": "DPD activity"
    },
    {
      "id": "Pharmacokinetic target values"
    },
    {
      "id": "regimens"
    },
    {
      "id": "fluorouracil toxicity"
    },
    {
      "id": "individuals"
    },
    {
      "id": "DPD activity tests"
    },
    {
      "id": "AUC threshold"
    },
    {
      "id": "mg.h/L"
    },
    {
      "id": "approach"
    },
    {
      "id": "randomised clinical studies"
    },
    {
      "id": "stomatitis"
    },
    {
      "id": "complete or partial loss"
    },
    {
      "id": "targets"
    },
    {
      "id": "fluorouracil starting dose"
    },
    {
      "id": "phenotyping methods"
    },
    {
      "id": "chronomodulated regimens"
    },
    {
      "id": "fluorouracil test dose approach"
    },
    {
      "id": "assessment"
    },
    {
      "id": "individual dihydropyrimidine dehydrogenase (DPD) activity"
    },
    {
      "id": "definition"
    },
    {
      "id": "hand-foot syndrome"
    },
    {
      "id": "therapeutic activity"
    },
    {
      "id": "continuous 5-day infusions"
    },
    {
      "id": "monitoring"
    },
    {
      "id": "dose adjustment"
    },
    {
      "id": "area under the plasma concentration-time curve (AUC)"
    },
    {
      "id": "dose adaptation"
    },
    {
      "id": "routine clinical safety monitoring"
    },
    {
      "id": "fluorouracil elimination"
    },
    {
      "id": "fluorouracil administration"
    },
    {
      "id": "tumour response"
    },
    {
      "id": "anticancer chemotherapy"
    },
    {
      "id": "fluorouracil exposures"
    },
    {
      "id": "administration rates"
    },
    {
      "id": "Caucasians"
    },
    {
      "id": "fluorouracil plasma concentrations"
    },
    {
      "id": "nonlinear pharmacokinetics"
    },
    {
      "id": "combination of genotyping and phenotyping"
    },
    {
      "id": "prediction of toxicity"
    },
    {
      "id": "leukopenia"
    },
    {
      "id": "chemical entity"
    },
    {
      "id": "Desvenlafaxine succinate"
    },
    {
      "id": "[3H]NE"
    },
    {
      "id": "DVS"
    },
    {
      "id": "IC50 values"
    },
    {
      "id": "binding affinity"
    },
    {
      "id": "human dopamine (DA) transporter"
    },
    {
      "id": "K(i) values"
    },
    {
      "id": "human serotonin (5-HT) transporter"
    },
    {
      "id": "male rat brain"
    },
    {
      "id": "norepinephrine (NE) transporter"
    },
    {
      "id": "hSERT"
    },
    {
      "id": "reuptake inhibitor"
    },
    {
      "id": "Competitive radioligand binding assays"
    },
    {
      "id": "nontransporter targets"
    },
    {
      "id": "[3H]5-HT"
    },
    {
      "id": "salt form"
    },
    {
      "id": "angiotensin II type 1 receptor (AT1) blocker"
    },
    {
      "id": "AT1 blocker"
    },
    {
      "id": "untreated group"
    },
    {
      "id": "mean aortic pressure"
    },
    {
      "id": "treated group"
    },
    {
      "id": "mitochondrial F0F1-ATPase subunits"
    },
    {
      "id": "Animals with heart failure"
    },
    {
      "id": "myocardial high-energy phosphate levels"
    },
    {
      "id": "subendocardial phosphocreatine-to-ATP ratios"
    },
    {
      "id": "phosphocreatine"
    },
    {
      "id": "postinfarction LV remodeling"
    },
    {
      "id": "mitochondrial F0F1-ATPase expression"
    },
    {
      "id": "F0F1-ATPase expression"
    },
    {
      "id": "myocardial bioenergetics"
    },
    {
      "id": "infarction"
    },
    {
      "id": "myocardial bioenergetic consequences"
    },
    {
      "id": "high-energy phosphate levels"
    },
    {
      "id": "olmesartan medoxomil"
    },
    {
      "id": "hearts"
    },
    {
      "id": "Functional consequences"
    },
    {
      "id": "LV-to-body weight ratio"
    },
    {
      "id": "severe LV dysfunction"
    },
    {
      "id": "untreated pigs"
    },
    {
      "id": "normal pigs"
    },
    {
      "id": "porcine model"
    },
    {
      "id": "hemodynamics"
    },
    {
      "id": "Congestive heart failure"
    },
    {
      "id": "ascites"
    },
    {
      "id": "contractile dysfunction"
    },
    {
      "id": "myocardial perfusion"
    },
    {
      "id": "abnormal myocardial bioenergetic phenotype"
    },
    {
      "id": "bioenergetic consequences"
    },
    {
      "id": "untreated animals"
    },
    {
      "id": "phosphate levels"
    },
    {
      "id": "pigs"
    },
    {
      "id": "structural left ventricular (LV) remodeling"
    },
    {
      "id": "ligation"
    },
    {
      "id": "left circumflex coronary artery"
    },
    {
      "id": "F0F1-ATPase subunits"
    },
    {
      "id": "RARalpha"
    },
    {
      "id": "Am80"
    },
    {
      "id": "RARbeta-specific"
    },
    {
      "id": "skin diseases"
    },
    {
      "id": "synthetic retinoid"
    },
    {
      "id": "application"
    },
    {
      "id": "beta"
    },
    {
      "id": "tamibarotene"
    },
    {
      "id": "RARgamma-"
    },
    {
      "id": "Th1 dominant autoimmune diseases"
    },
    {
      "id": "APL"
    },
    {
      "id": "all-trans-retinoic acid"
    },
    {
      "id": "endogeneous retinoid"
    },
    {
      "id": "Retinoid therapy"
    },
    {
      "id": "ATRA"
    },
    {
      "id": "mimics"
    },
    {
      "id": "RARalpha-"
    },
    {
      "id": "gamma"
    },
    {
      "id": "Retinoid"
    },
    {
      "id": "nuclear hormone receptor superfamily"
    },
    {
      "id": "RXRs-nonbinding"
    },
    {
      "id": "RXRalpha"
    },
    {
      "id": "synthetic retinoids"
    },
    {
      "id": "medicinal properties"
    },
    {
      "id": "acute promyelocytic leukemia"
    },
    {
      "id": "experimental autoimmune encephalomyelitis"
    },
    {
      "id": "relapsed APL"
    },
    {
      "id": "acidic fibroblast growth factor"
    },
    {
      "id": "broad-spectrum chemoresistance"
    },
    {
      "id": "bFGF"
    },
    {
      "id": "antiproliferation"
    },
    {
      "id": "responding tumors"
    },
    {
      "id": "tumors"
    },
    {
      "id": "proapoptotic effects"
    },
    {
      "id": "bcl-2"
    },
    {
      "id": "Antiproliferative effects"
    },
    {
      "id": "bFGF staining"
    },
    {
      "id": "paclitaxel"
    },
    {
      "id": "basic FGF"
    },
    {
      "id": "aFGF"
    },
    {
      "id": "FGF expression"
    },
    {
      "id": "paclitaxel activity"
    },
    {
      "id": "Bladder tumors"
    },
    {
      "id": "basic fibroblast growth factor"
    },
    {
      "id": "human patient tumors"
    },
    {
      "id": "tumor sensitivity"
    },
    {
      "id": "Pgp"
    },
    {
      "id": "Pgp expression"
    },
    {
      "id": "apoptotic index"
    },
    {
      "id": "prostate cancer patients"
    },
    {
      "id": "paclitaxel resistance"
    },
    {
      "id": "aFGF staining"
    },
    {
      "id": "tumor grade"
    },
    {
      "id": "Bcl-2"
    },
    {
      "id": "tumor stage"
    },
    {
      "id": "histocultures"
    },
    {
      "id": "ovarian"
    },
    {
      "id": "tumor-stromal interaction"
    },
    {
      "id": "neuroglial interactions"
    },
    {
      "id": "peripheral nerve injury"
    },
    {
      "id": "sciatic nerve injury"
    },
    {
      "id": "retinoic acid receptors beta"
    },
    {
      "id": "retinoid X receptor alpha-staining"
    },
    {
      "id": "regenerating axons"
    },
    {
      "id": "Protein levels"
    },
    {
      "id": "retinoid X receptor alpha"
    },
    {
      "id": "Experiments"
    },
    {
      "id": "Schwann cell primary cultures"
    },
    {
      "id": "retinoic acid receptor alpha"
    },
    {
      "id": "complete transection"
    },
    {
      "id": "lesion-induced inflammatory reaction"
    },
    {
      "id": "degenerating nerves"
    },
    {
      "id": "transcript concentrations"
    },
    {
      "id": "retinoic acid signaling system"
    },
    {
      "id": "axonal regeneration"
    },
    {
      "id": "retinoid receptors"
    },
    {
      "id": "ErbB3"
    },
    {
      "id": "retinoic acid receptor beta"
    },
    {
      "id": "cell nuclei"
    },
    {
      "id": "Immunohistochemical staining"
    },
    {
      "id": "Cell culture experiments"
    },
    {
      "id": "injury-induced degeneration"
    },
    {
      "id": "Schwann cells"
    },
    {
      "id": "crush injury"
    },
    {
      "id": "retinoic acid receptors alpha"
    },
    {
      "id": "non-lesioned nerves"
    },
    {
      "id": "retinoid X receptors"
    },
    {
      "id": "neuregulin receptor"
    },
    {
      "id": "regeneration"
    },
    {
      "id": "injury"
    },
    {
      "id": "autotrophic organisms"
    },
    {
      "id": "nitrate reductase"
    },
    {
      "id": "Mo-enzymes"
    },
    {
      "id": "aldehyde oxidase"
    },
    {
      "id": "bacterial nitrogenase"
    },
    {
      "id": "FeMo-cofactor"
    },
    {
      "id": "abscisic acid"
    },
    {
      "id": "cysteine desulfurases"
    },
    {
      "id": "molybdenum cofactor (Moco)"
    },
    {
      "id": "apoproteins"
    },
    {
      "id": "molybdenum"
    },
    {
      "id": "sulfite oxidase"
    },
    {
      "id": "xanthine dehydrogenase"
    },
    {
      "id": "Mo-site"
    },
    {
      "id": "plant sulfite oxidase"
    },
    {
      "id": "redox active center"
    },
    {
      "id": "Moco-sulfurase enzyme"
    },
    {
      "id": "reactive oxygen"
    },
    {
      "id": "sulfur"
    },
    {
      "id": "Mo"
    },
    {
      "id": "inorganic nitrogen"
    },
    {
      "id": "l-cysteine"
    },
    {
      "id": "transition element"
    },
    {
      "id": "biological systems"
    },
    {
      "id": "metal"
    },
    {
      "id": "cofactor"
    },
    {
      "id": "sulfur-containing amino acids"
    },
    {
      "id": "copper"
    },
    {
      "id": "pterin"
    },
    {
      "id": "nitrogen"
    },
    {
      "id": "aldehydes"
    },
    {
      "id": "Moco-carrier proteins"
    },
    {
      "id": "active compound"
    },
    {
      "id": "eukaryotes"
    },
    {
      "id": "carbon"
    },
    {
      "id": "purine"
    },
    {
      "id": "phytohormone"
    },
    {
      "id": "sulfite"
    },
    {
      "id": "sensory compounds"
    },
    {
      "id": "promiscuous relationships"
    },
    {
      "id": "heat-activated TRPV3"
    },
    {
      "id": "molecular receptors"
    },
    {
      "id": "natural compounds"
    },
    {
      "id": "camphor"
    },
    {
      "id": "TRPV3"
    },
    {
      "id": "\"sensory compounds\""
    },
    {
      "id": "thermoTRPs"
    },
    {
      "id": "analgesic"
    },
    {
      "id": "TRPA1"
    },
    {
      "id": "other thermoTRPs"
    },
    {
      "id": "paradoxical role"
    },
    {
      "id": "thermal sensations"
    },
    {
      "id": "cold-activated thermoTRP ion channel"
    },
    {
      "id": "human physiological studies"
    },
    {
      "id": "warm sensation"
    },
    {
      "id": "cinnamaldehyde"
    },
    {
      "id": "pain sensations"
    },
    {
      "id": "temperature-activated transient receptor potential (thermoTRP) ion channels"
    },
    {
      "id": "cooling effect"
    },
    {
      "id": "RET expression"
    },
    {
      "id": "Y1062 phosphorylation"
    },
    {
      "id": "quantitative polymerase chain reaction"
    },
    {
      "id": "fluorescence-activated cell sorter analysis"
    },
    {
      "id": "annexin V/propidium iodide staining"
    },
    {
      "id": "imatinib monotherapy"
    },
    {
      "id": "systemic treatment"
    },
    {
      "id": "Dose-dependent decreases"
    },
    {
      "id": "RET Y1062 phosphorylation"
    },
    {
      "id": "gastrointestinal stromal tumors"
    },
    {
      "id": "RET-mediated MTC cell growth"
    },
    {
      "id": "nonapoptotic cell death"
    },
    {
      "id": "tyrosine kinase inhibitor"
    },
    {
      "id": "chronic myelogenous leukemia"
    },
    {
      "id": "medullary thyroid cancer cells"
    },
    {
      "id": "RET mutations"
    },
    {
      "id": "multiple endocrine neoplasia Type 2A"
    },
    {
      "id": "cell proliferation"
    },
    {
      "id": "3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay"
    },
    {
      "id": "RET gene"
    },
    {
      "id": "tyrosine kinase receptor"
    },
    {
      "id": "protein expression levels"
    },
    {
      "id": "apoptotic cell death"
    },
    {
      "id": "imatinib-induced cell-cycle arrest"
    },
    {
      "id": "multiple endocrine neoplasia Type 2B"
    },
    {
      "id": "MTC-derived cell lines"
    },
    {
      "id": "multiple endocrine neoplasia-associated mutant RET receptors"
    },
    {
      "id": "inhibitory concentration of 50% levels"
    },
    {
      "id": "25 +/- 4 micromol/L"
    },
    {
      "id": "concentration of imatinib"
    },
    {
      "id": "RET"
    },
    {
      "id": "Activating mutations"
    },
    {
      "id": "RET protein levels"
    },
    {
      "id": "Surgical resection"
    },
    {
      "id": "curative treatment"
    },
    {
      "id": "23 +/- 2 micromol/L"
    },
    {
      "id": "medullary thyroid carcinoma (MTC)"
    },
    {
      "id": "anti-CD11a monoclonal antibody"
    },
    {
      "id": "M5 muscarinic ACh receptor mRNA"
    },
    {
      "id": "Simvastatin"
    },
    {
      "id": "immunosuppressive effects"
    },
    {
      "id": "antithymocyte globulin"
    },
    {
      "id": "LFA-1-mediated pathways"
    },
    {
      "id": "CD11a"
    },
    {
      "id": "LFA-1 alpha chain"
    },
    {
      "id": "Lymphocyte function associated antigen-1"
    },
    {
      "id": "LFA-1"
    },
    {
      "id": "lymphocytic cholinergic activity"
    },
    {
      "id": "ACh release"
    },
    {
      "id": "non-neuronal cholinergic system"
    },
    {
      "id": "ACh synthesis"
    },
    {
      "id": "expression of ChAT"
    },
    {
      "id": "CD11a-mediated pathways"
    },
    {
      "id": "cholesterol-lowering drug"
    },
    {
      "id": "CD18"
    },
    {
      "id": "LFA-1 signaling"
    },
    {
      "id": "choline acetyltransferase"
    },
    {
      "id": "ChAT"
    },
    {
      "id": "leukocyte migration"
    },
    {
      "id": "cholesterol-lowering activity"
    },
    {
      "id": "allosteric site"
    },
    {
      "id": "MOLT-3 cells"
    },
    {
      "id": "human leukemic T cell line"
    },
    {
      "id": "ChAT mRNA expression"
    },
    {
      "id": "non-neuronal cholinergic activity"
    },
    {
      "id": "modification of lymphocytic cholinergic activity"
    },
    {
      "id": "immunomodulation"
    },
    {
      "id": "T cell activation"
    },
    {
      "id": "ChAT activity"
    },
    {
      "id": "overexpression"
    },
    {
      "id": "POX"
    },
    {
      "id": "oxidation"
    },
    {
      "id": "proline"
    },
    {
      "id": "MnSOD"
    },
    {
      "id": "ROS generation"
    },
    {
      "id": "proline oxidase"
    },
    {
      "id": "apoptotic response"
    },
    {
      "id": "cell shrinkage"
    },
    {
      "id": "POX activity"
    },
    {
      "id": "mitochondrial MnSOD"
    },
    {
      "id": "mitochondrial inner-membrane protein"
    },
    {
      "id": "pyrroline- 5-carboxylate"
    },
    {
      "id": "DLD-1.POX cells"
    },
    {
      "id": "L-proline"
    },
    {
      "id": "apoptotic effect"
    },
    {
      "id": "P5C"
    },
    {
      "id": "POX-inducible colorectal cancer cells"
    },
    {
      "id": "DLD-1.POX"
    },
    {
      "id": "chromatin condensation"
    },
    {
      "id": "D,L-threo-beta-benzyloxyaspartate"
    },
    {
      "id": "transporter antagonist"
    },
    {
      "id": "transporters"
    },
    {
      "id": "glutamate removal"
    },
    {
      "id": "GLAST"
    },
    {
      "id": "glutamate uptake"
    },
    {
      "id": "glutamate-aspartate transporters"
    },
    {
      "id": "whole-cell recordings"
    },
    {
      "id": "whole-mount preparations"
    },
    {
      "id": "D-aspartate-induced currents"
    },
    {
      "id": "outside-out patches"
    },
    {
      "id": "rates of release"
    },
    {
      "id": "glutamate clearance mechanisms"
    },
    {
      "id": "steady-state currents"
    },
    {
      "id": "prominent feature of GLAST"
    },
    {
      "id": "Saturation of transporters"
    },
    {
      "id": "transporter currents"
    },
    {
      "id": "inward currents"
    },
    {
      "id": "photolysis of caged D-aspartate"
    },
    {
      "id": "anions"
    },
    {
      "id": "transporter-associated anion channel"
    },
    {
      "id": "dihydrokainate"
    },
    {
      "id": "Ribbon synapses"
    },
    {
      "id": "afferent dendrites"
    },
    {
      "id": "transmitter uptake"
    },
    {
      "id": "IHC afferent synapses"
    },
    {
      "id": "IPCs"
    },
    {
      "id": "inner hair cell afferent synapses"
    },
    {
      "id": "responses"
    },
    {
      "id": "glutamate transporter-1"
    },
    {
      "id": "DsRed expression"
    },
    {
      "id": "rat organ of Corti"
    },
    {
      "id": "inner hair cells (IHCs)"
    },
    {
      "id": "mammalian cochlea"
    },
    {
      "id": "examination of cochlea"
    },
    {
      "id": "GLAST-Discosoma red (DsRed) promoter reporter mice"
    },
    {
      "id": "supporting cells"
    },
    {
      "id": "GLAST-/- cochleas"
    },
    {
      "id": "D-aspartate"
    },
    {
      "id": "transporter substrate"
    },
    {
      "id": "afferent terminals"
    },
    {
      "id": "L-glutamate"
    },
    {
      "id": "glutamate-aspartate transporter"
    },
    {
      "id": "glial cells"
    },
    {
      "id": "inner phalangeal cells (IPCs)"
    },
    {
      "id": "excitatory amino acid transporter 1"
    },
    {
      "id": "presynaptic membranes"
    },
    {
      "id": "major sites for glutamate removal"
    },
    {
      "id": "postsynaptic membranes"
    },
    {
      "id": "excitatory amino acid transporter 2"
    },
    {
      "id": "spontaneous locomotor activity"
    },
    {
      "id": "familiar environments"
    },
    {
      "id": "control mice"
    },
    {
      "id": "Chronic treatment"
    },
    {
      "id": "novel environment"
    },
    {
      "id": "norepinephrine transporter knockout mice"
    },
    {
      "id": "Coadministration"
    },
    {
      "id": "osmotic minipump"
    },
    {
      "id": "norepinephrine transporter blockade"
    },
    {
      "id": "antidepressants"
    },
    {
      "id": "dopamine transporter blockade"
    },
    {
      "id": "Acute inactivation"
    },
    {
      "id": "Chronic inactivation"
    },
    {
      "id": "Acute treatment"
    },
    {
      "id": "GBR 12909"
    },
    {
      "id": "dopamine transporter blocker"
    },
    {
      "id": "basal spontaneous locomotor activity"
    },
    {
      "id": "norepinephrine transporter-blocking antidepressants"
    },
    {
      "id": "Chronic antidepressant treatment"
    },
    {
      "id": "Acute administration"
    },
    {
      "id": "vesicular glutamate transporter 1"
    },
    {
      "id": "vesicular storage"
    },
    {
      "id": "transcytosis"
    },
    {
      "id": "autoregulation"
    },
    {
      "id": "KCl"
    },
    {
      "id": "VGLUT1"
    },
    {
      "id": "Glutamate signaling"
    },
    {
      "id": "bone homeostasis"
    },
    {
      "id": "osteoclasts"
    },
    {
      "id": "glutamate"
    },
    {
      "id": "suppression"
    },
    {
      "id": "bone resorption"
    },
    {
      "id": "mGluR8"
    },
    {
      "id": "class III metabotropic glutamate receptor"
    },
    {
      "id": "transcytotic vesicles"
    },
    {
      "id": "exocytosis"
    },
    {
      "id": "bone-resorbing osteoclasts"
    },
    {
      "id": "degradation products"
    },
    {
      "id": "VGLUT1-/- knockout mice"
    },
    {
      "id": "regulation"
    },
    {
      "id": "Ca2+"
    },
    {
      "id": "osteoporosis"
    },
    {
      "id": "stimulation"
    },
    {
      "id": "bone matrix"
    },
    {
      "id": "Abarelix"
    },
    {
      "id": "testosterone surge"
    },
    {
      "id": "phase III clinical trials"
    },
    {
      "id": "phase II clinical trials"
    },
    {
      "id": "LHRH agonists"
    },
    {
      "id": "serum testosterone"
    },
    {
      "id": "medical castration"
    },
    {
      "id": "Gonadotropin-releasing hormone (GnRH) receptor antagonism"
    },
    {
      "id": "advanced and metastatic prostate cancer"
    },
    {
      "id": "Gonadotropin-releasing hormone antagonist"
    },
    {
      "id": "Luteinizing hormone-releasing hormone (LHRH) agonist therapy"
    },
    {
      "id": "bone metastatic disease"
    },
    {
      "id": "LHRH agonist activity"
    },
    {
      "id": "flare phenomenon"
    },
    {
      "id": "worsening of disease"
    },
    {
      "id": "nonsteroidal antagonist"
    },
    {
      "id": "LH"
    },
    {
      "id": "GnRH receptor antagonist"
    },
    {
      "id": "disease flare"
    },
    {
      "id": "KGF"
    },
    {
      "id": "cell viability"
    },
    {
      "id": "paracrine growth factor"
    },
    {
      "id": "PCSCs"
    },
    {
      "id": "cancerous stroma"
    },
    {
      "id": "KGFR"
    },
    {
      "id": "keratinocyte growth factor"
    },
    {
      "id": "phospho-Akt expression"
    },
    {
      "id": "estrogen receptors"
    },
    {
      "id": "RT-PCR"
    },
    {
      "id": "stromal cells"
    },
    {
      "id": "KGF antiserum"
    },
    {
      "id": "anti-apoptotic protein expression"
    },
    {
      "id": "primary cultured human prostate cancer stromal cells"
    },
    {
      "id": "fibroblast growth factor-7"
    },
    {
      "id": "anti-apoptotic actions"
    },
    {
      "id": "ICI 182,780"
    },
    {
      "id": "anti-apoptotic effects"
    },
    {
      "id": "dynamic protein expression"
    },
    {
      "id": "human cancer epithelial cells"
    },
    {
      "id": "mitogenic effects"
    },
    {
      "id": "cyclin-D1"
    },
    {
      "id": "phosphorylation of Akt"
    },
    {
      "id": "survival factor"
    },
    {
      "id": "Bcl-xL"
    },
    {
      "id": "cell cycle machinery"
    },
    {
      "id": "benign prostatic hyperplasia"
    },
    {
      "id": "autocrine factor"
    },
    {
      "id": "FGF-7"
    },
    {
      "id": "BPH"
    },
    {
      "id": "anti-apoptotic machinery"
    },
    {
      "id": "clear-cell renal cell carcinoma"
    },
    {
      "id": "sunitinib"
    },
    {
      "id": "PDGFR-beta"
    },
    {
      "id": "advances"
    },
    {
      "id": "PDGF-beta"
    },
    {
      "id": "VEGF receptor"
    },
    {
      "id": "tumor cell growth"
    },
    {
      "id": "transforming growth factor-alpha"
    },
    {
      "id": "von Hippel-Lindau disease protein"
    },
    {
      "id": "epidermal growth factor receptor"
    },
    {
      "id": "single-agent therapy"
    },
    {
      "id": "TGF-alpha"
    },
    {
      "id": "Sorafenib"
    },
    {
      "id": "Raf isoforms"
    },
    {
      "id": "EGFR"
    },
    {
      "id": "lymphangiogenesis"
    },
    {
      "id": "AG013736"
    },
    {
      "id": "multiple VEGFRs"
    },
    {
      "id": "combination therapy"
    },
    {
      "id": "platelet-derived growth factor-beta"
    },
    {
      "id": "tumor cell survival"
    },
    {
      "id": "active MKIs"
    },
    {
      "id": "early clinical results"
    },
    {
      "id": "pathways dysregulated in clear-cell RCC"
    },
    {
      "id": "PDGF receptor-beta"
    },
    {
      "id": "Raf pathways"
    },
    {
      "id": "multiple-kinase inhibitors"
    },
    {
      "id": "review"
    },
    {
      "id": "biology of clear-cell RCC"
    },
    {
      "id": "ongoing and future sorafenib-based combination therapy trials"
    },
    {
      "id": "RCC"
    },
    {
      "id": "scientific rationales"
    },
    {
      "id": "TGF-alpha/EGFR signaling"
    },
    {
      "id": "new targets of opportunity"
    },
    {
      "id": "chronotropic effect"
    },
    {
      "id": "RR stereoisomer"
    },
    {
      "id": "non-specific side effects"
    },
    {
      "id": "comparison studies"
    },
    {
      "id": "phenylephrine"
    },
    {
      "id": "mean arterial pressure"
    },
    {
      "id": "labetalol"
    },
    {
      "id": "alpha 1-adrenoceptors"
    },
    {
      "id": "alpha 2-adrenoceptor blocking potencies"
    },
    {
      "id": "alpha 1-adrenoceptor blocking potencies"
    },
    {
      "id": "Prazosin"
    },
    {
      "id": "RR-SR (50:50) stereoisomers"
    },
    {
      "id": "pressor effect"
    },
    {
      "id": "liver toxicity"
    },
    {
      "id": "beta 1-adrenoceptor blocking potencies"
    },
    {
      "id": "pithed rats"
    },
    {
      "id": "beta-adrenoceptor blocking activities"
    },
    {
      "id": "reports"
    },
    {
      "id": "postmarketing surveillance"
    },
    {
      "id": "clinical importance"
    },
    {
      "id": "RS enantiomer"
    },
    {
      "id": "alpha receptor actions"
    },
    {
      "id": "SR stereoisomer"
    },
    {
      "id": "beta 1-adrenoceptors"
    },
    {
      "id": "beta receptor actions"
    },
    {
      "id": "SS enantiomer"
    },
    {
      "id": "intravenous dosing"
    },
    {
      "id": "alpha 2-adrenoceptors"
    },
    {
      "id": "dilevalol"
    },
    {
      "id": "alpha-adrenoceptor blocking activities"
    },
    {
      "id": "rat heart"
    },
    {
      "id": "i.v. administration"
    },
    {
      "id": "systemic hypertension"
    },
    {
      "id": "homogenized rat cerebral cortex"
    },
    {
      "id": "cGMP"
    },
    {
      "id": "GAF-B"
    },
    {
      "id": "dimerization of PDE5"
    },
    {
      "id": "PDE5Delta1-534"
    },
    {
      "id": "C domain"
    },
    {
      "id": "PDE5Delta1-321"
    },
    {
      "id": "GAF-B domain"
    },
    {
      "id": "PDE5Delta1-465"
    },
    {
      "id": "C-terminal portion of GAF-B"
    },
    {
      "id": "GAF-A"
    },
    {
      "id": "regulatory domain (R domain)"
    },
    {
      "id": "GAFs"
    },
    {
      "id": "phosphorylation site"
    },
    {
      "id": "PDE5 constructs"
    },
    {
      "id": "3-isobutyl-1-methylxanthine"
    },
    {
      "id": "vardenafil-based compounds"
    },
    {
      "id": "N-terminal 46 amino acids"
    },
    {
      "id": "Phosphodiesterase-5 dimerization"
    },
    {
      "id": "K(m) values"
    },
    {
      "id": "full-length PDE5"
    },
    {
      "id": "mammalian cGMP-binding phosphodiesterase"
    },
    {
      "id": "GAF-B-mediated PDE5 dimerization"
    },
    {
      "id": "vardenafil potency"
    },
    {
      "id": "Truncated proteins"
    },
    {
      "id": "monomers"
    },
    {
      "id": "selectivity"
    },
    {
      "id": "N-terminal truncation mutants"
    },
    {
      "id": "Phosphodiesterase-5 (PDE5)"
    },
    {
      "id": "sequence between GAF-A and -B"
    },
    {
      "id": "sildenafil"
    },
    {
      "id": "tadalafil"
    },
    {
      "id": "complete GAF-B"
    },
    {
      "id": "Anabaena adenylyl cyclases"
    },
    {
      "id": "PDE5Delta1-419"
    },
    {
      "id": "classes of inhibitors"
    },
    {
      "id": "cyclic nucleotide-dependent protein kinases (cNPKs)"
    },
    {
      "id": "Escherichia coli FhlAs"
    },
    {
      "id": "dimers"
    },
    {
      "id": "PDE5 R domain"
    },
    {
      "id": "UK-122764"
    },
    {
      "id": "ligands for PR"
    },
    {
      "id": "Progesterone"
    },
    {
      "id": "nuclear receptor hormones"
    },
    {
      "id": "non-steroidal PR ligands"
    },
    {
      "id": "modulator properties"
    },
    {
      "id": "menstruation"
    },
    {
      "id": "gestation"
    },
    {
      "id": "evolution"
    },
    {
      "id": "The evolution of progesterone receptor ligands"
    },
    {
      "id": "gestational properties"
    },
    {
      "id": "PR"
    },
    {
      "id": "drug-like steroids"
    },
    {
      "id": "therapeutic applications"
    },
    {
      "id": "progesterone receptor"
    },
    {
      "id": "Ay mice"
    },
    {
      "id": "Restricted feeding"
    },
    {
      "id": "food intake"
    },
    {
      "id": "hyperglycemia"
    },
    {
      "id": "chronic hyperphagia"
    },
    {
      "id": "plasma des-acyl ghrelin levels"
    },
    {
      "id": "hypothalamic 5-HT1B receptor gene expression"
    },
    {
      "id": "8-wk-old obese Ay mice"
    },
    {
      "id": "hyperinsulinemia"
    },
    {
      "id": "5-HT2C receptor mutant mice"
    },
    {
      "id": "food"
    },
    {
      "id": "m-chlorophenylpiperazine"
    },
    {
      "id": "anorexic effects"
    },
    {
      "id": "5-HT2C receptors"
    },
    {
      "id": "food-restricted Ay mice"
    },
    {
      "id": "plasma total ghrelin"
    },
    {
      "id": "agouti peptide"
    },
    {
      "id": "hypothalamic 5-HT2C receptor gene expression"
    },
    {
      "id": "5-wk-old Ay mice"
    },
    {
      "id": "central melanocortin (MC) pathway"
    },
    {
      "id": "Hyperphagia"
    },
    {
      "id": "late-onset obesity"
    },
    {
      "id": "serotonin (5-HT)2C receptors"
    },
    {
      "id": "satiety signaling"
    },
    {
      "id": "impaired glucose tolerance"
    },
    {
      "id": "Selective Estrogen Receptor Modulators"
    },
    {
      "id": "Postmenopausal Breast Cancer"
    },
    {
      "id": "adjuvant tamoxifen therapy"
    },
    {
      "id": "ER-agonist properties"
    },
    {
      "id": "SERMs"
    },
    {
      "id": "keoxifene"
    },
    {
      "id": "cross-resistance"
    },
    {
      "id": "review article"
    },
    {
      "id": "resistant disease"
    },
    {
      "id": "droloxifene"
    },
    {
      "id": "endometrial cancer"
    },
    {
      "id": "toremifene"
    },
    {
      "id": "thromboembolic complications"
    },
    {
      "id": "ER-positive breast cancer"
    },
    {
      "id": "AIs"
    },
    {
      "id": "ER"
    },
    {
      "id": "tamoxifen-like agonist effects"
    },
    {
      "id": "signaling pathway"
    },
    {
      "id": "idoxifene"
    },
    {
      "id": "estrogen"
    },
    {
      "id": "antagonist properties"
    },
    {
      "id": "ER antagonist"
    },
    {
      "id": "ER-positive disease"
    },
    {
      "id": "mu- and delta-receptors"
    },
    {
      "id": "tolerance"
    },
    {
      "id": "DPDPE treatment"
    },
    {
      "id": "mu-opioid receptor"
    },
    {
      "id": "receptor type"
    },
    {
      "id": "[D-Pen2,D-Pen5]enkephalin"
    },
    {
      "id": "rat brain opioid receptors"
    },
    {
      "id": "midbrain"
    },
    {
      "id": "AD50"
    },
    {
      "id": "delta-opioid receptor-selective agonist"
    },
    {
      "id": "[3H]Tyr-D-Ala-Gly-MePhe-Gly-ol"
    },
    {
      "id": "mu-receptor binding"
    },
    {
      "id": "[D-Ala2,D-Leu5]enkephalin"
    },
    {
      "id": "[3H]DPDPE saturation binding data"
    },
    {
      "id": "Kd values"
    },
    {
      "id": "[3H]DPDPE"
    },
    {
      "id": "delta-receptor binding"
    },
    {
      "id": "opioid ligands"
    },
    {
      "id": "mu- and delta-opioid receptor binding activities"
    },
    {
      "id": "DAMGO"
    },
    {
      "id": "delta-opioid receptor binding activity"
    },
    {
      "id": "delta cx binding sites"
    },
    {
      "id": "mu cx binding sites"
    },
    {
      "id": "micrograms/kg"
    },
    {
      "id": "i.c.v."
    },
    {
      "id": "Sprague-Dawley rats"
    },
    {
      "id": "Scatchard analysis"
    },
    {
      "id": "Bmax values"
    },
    {
      "id": "antinociceptive response"
    },
    {
      "id": "complications"
    },
    {
      "id": "PLOD1 gene"
    },
    {
      "id": "exon 13"
    },
    {
      "id": "A 4 year old girl"
    },
    {
      "id": "molecular diagnosis"
    },
    {
      "id": "c.1362delC"
    },
    {
      "id": "truncation"
    },
    {
      "id": "clinical presentation"
    },
    {
      "id": "autosomal recessive connective tissue disease"
    },
    {
      "id": "Ehlers Danlos type VI"
    },
    {
      "id": "eye globe"
    },
    {
      "id": "ruptures of arteries"
    },
    {
      "id": "collagen biosynthesis"
    },
    {
      "id": "frameshift"
    },
    {
      "id": "lysyl hydroxylase"
    },
    {
      "id": "neonatal hypotonia"
    },
    {
      "id": "joints"
    },
    {
      "id": "EDS VI"
    },
    {
      "id": "Early diagnosis"
    },
    {
      "id": "genetic counseling"
    },
    {
      "id": "prenatal diagnosis"
    },
    {
      "id": "unaffected embryo"
    },
    {
      "id": "high doses of ascorbic acid"
    },
    {
      "id": "family"
    },
    {
      "id": "median growth inhibitory concentrations"
    },
    {
      "id": "GI(50)"
    },
    {
      "id": "Compounds 41"
    },
    {
      "id": "antitumor agents"
    },
    {
      "id": "Compounds 19"
    },
    {
      "id": "20.1microM"
    },
    {
      "id": "Compounds 31"
    },
    {
      "id": "23.5microM"
    },
    {
      "id": "quinazoline analogs"
    },
    {
      "id": "functional groups"
    },
    {
      "id": "synthesized compounds"
    },
    {
      "id": "mammalian DHFR"
    },
    {
      "id": "DHFR"
    },
    {
      "id": "Compounds 30"
    },
    {
      "id": "0.4microM"
    },
    {
      "id": "DHFR IC(50) values"
    },
    {
      "id": "15microM"
    },
    {
      "id": "DHFR inhibitors"
    },
    {
      "id": "Compounds 47"
    },
    {
      "id": "antitumor activity"
    },
    {
      "id": "mammalian cells"
    },
    {
      "id": "mammalian DHFR activity"
    },
    {
      "id": "potent new leads"
    },
    {
      "id": "anticancer drugs"
    },
    {
      "id": "9.1microM"
    },
    {
      "id": "4(3H)-quinazolinone analogs"
    },
    {
      "id": "molecular modeling study"
    },
    {
      "id": "26.7microM"
    },
    {
      "id": "structure features"
    },
    {
      "id": "human DHFR"
    },
    {
      "id": "antitumor potency"
    },
    {
      "id": "Molecular modeling studies"
    },
    {
      "id": "potent DHFR inhibition"
    },
    {
      "id": "dihydrofolate reductase inhibition"
    },
    {
      "id": "series of compounds"
    },
    {
      "id": "Synthesis"
    },
    {
      "id": "standard in vitro tissue culture assay panel"
    },
    {
      "id": "MTX"
    },
    {
      "id": "Compounds 28"
    },
    {
      "id": "0.5microM"
    },
    {
      "id": "antitumor testing"
    },
    {
      "id": "IC(50) values"
    },
    {
      "id": "Telmisartan"
    },
    {
      "id": "peroxisome proliferator-activated receptor gamma"
    },
    {
      "id": "AT1R expression"
    },
    {
      "id": "AT1R"
    },
    {
      "id": "thoracic aorta"
    },
    {
      "id": "Wistar-Kyoto rat"
    },
    {
      "id": "Northern blotting analysis"
    },
    {
      "id": "AT1R mRNA"
    },
    {
      "id": "Western blotting analysis"
    },
    {
      "id": "GC box"
    },
    {
      "id": "AT1R gene expression"
    },
    {
      "id": "GW9662"
    },
    {
      "id": "PPARgamma"
    },
    {
      "id": "promoter activity of AT1R"
    },
    {
      "id": "luciferase assay"
    },
    {
      "id": "vascular smooth muscle cells"
    },
    {
      "id": "angiotensin II function"
    },
    {
      "id": "olmesartan"
    },
    {
      "id": "PPARgamma activators"
    },
    {
      "id": "angiotensin II type 1 receptor"
    },
    {
      "id": "AT1R blockade"
    },
    {
      "id": "AT1R promoter activity"
    },
    {
      "id": "11-cis retinal"
    },
    {
      "id": "visual pigments"
    },
    {
      "id": "nuclear hormone receptor ligand"
    },
    {
      "id": "all-trans retinol"
    },
    {
      "id": "Raldh2"
    },
    {
      "id": "yolk vitamin A"
    },
    {
      "id": "retinal dehydrogenase 2"
    },
    {
      "id": "knock down"
    },
    {
      "id": "Lratb"
    },
    {
      "id": "homeostatic mechanism"
    },
    {
      "id": "leci-thin:retinol acyltransferase"
    },
    {
      "id": "chromophore"
    },
    {
      "id": "retinoid signaling"
    },
    {
      "id": "zebrafish embryo"
    },
    {
      "id": "embryonic patterning defects"
    },
    {
      "id": "vertebrate development"
    },
    {
      "id": "retinyl esters"
    },
    {
      "id": "larval vision"
    },
    {
      "id": "lratb"
    },
    {
      "id": "embryonic compartments"
    },
    {
      "id": "retinyl ester formation"
    },
    {
      "id": "embryonic retinoid homeostasis"
    },
    {
      "id": "gene regulation"
    },
    {
      "id": "zebrafish"
    },
    {
      "id": "retinoic acid synthesis"
    },
    {
      "id": "embryogenesis"
    },
    {
      "id": "surface receptors"
    },
    {
      "id": "bioinformatics"
    },
    {
      "id": "ticlopidine"
    },
    {
      "id": "head area"
    },
    {
      "id": "LGTGPLRTFV"
    },
    {
      "id": "purine nucleotides"
    },
    {
      "id": "Molecular modeling"
    },
    {
      "id": "primary structures"
    },
    {
      "id": "PDB code: 1VZ1"
    },
    {
      "id": "probable sites"
    },
    {
      "id": "bottom area"
    },
    {
      "id": "simple scoring matrix"
    },
    {
      "id": "analysis"
    },
    {
      "id": "structural model"
    },
    {
      "id": "ADP"
    },
    {
      "id": "new drugs"
    },
    {
      "id": "energy minimization"
    },
    {
      "id": "middle area"
    },
    {
      "id": "extracellular nucleotides"
    },
    {
      "id": "pyrimidine nucleotides"
    },
    {
      "id": "3D structure"
    },
    {
      "id": "bovine rhodopsin"
    },
    {
      "id": "VGLITNGLAM"
    },
    {
      "id": "RTRGVGKVPR"
    },
    {
      "id": "ADP/ATP analogs"
    },
    {
      "id": "LGAKILSVVI"
    },
    {
      "id": "PDB code: 1HZX"
    },
    {
      "id": "InsightII/Homology module"
    },
    {
      "id": "platelet aggregation"
    },
    {
      "id": "Purinergic receptors"
    },
    {
      "id": "template"
    },
    {
      "id": "thienopyridine drugs"
    },
    {
      "id": "purines"
    },
    {
      "id": "PDB code 1ddd"
    },
    {
      "id": "intermolecular energy"
    },
    {
      "id": "cell surface receptors"
    },
    {
      "id": "ATP-binding proteins"
    },
    {
      "id": "Protein Data Bank"
    },
    {
      "id": "G protein-coupled receptors"
    },
    {
      "id": "Cd"
    },
    {
      "id": "PDGFRalpha kinases"
    },
    {
      "id": "c-fos"
    },
    {
      "id": "Cadmium"
    },
    {
      "id": "toxic pollutant"
    },
    {
      "id": "Akt activity"
    },
    {
      "id": "PDGFRalpha phosphorylation"
    },
    {
      "id": "ICI"
    },
    {
      "id": "Akt phosphorylation"
    },
    {
      "id": "ERK1/2"
    },
    {
      "id": "c-jun expression"
    },
    {
      "id": "PDGFRalpha kinases activity"
    },
    {
      "id": "mitogenic signaling"
    },
    {
      "id": "PDGFA"
    },
    {
      "id": "ERK1/2 phosphorylation"
    },
    {
      "id": "ERalpha-dependent mechanism"
    },
    {
      "id": "Breast cancer (BC)"
    },
    {
      "id": "estrogen exposure"
    },
    {
      "id": "Hormone-related cancers"
    },
    {
      "id": "estrogenic environmental contaminants"
    },
    {
      "id": "ER-antagonist ICI 182,780"
    },
    {
      "id": "Cd-stimulated proliferation"
    },
    {
      "id": "ERK1/2 activity"
    },
    {
      "id": "ERbeta"
    },
    {
      "id": "BC cells proliferation"
    },
    {
      "id": "ERalpha expression"
    },
    {
      "id": "PDGFA expression"
    },
    {
      "id": "c-jun"
    },
    {
      "id": "proto-oncogenes"
    },
    {
      "id": "specific kinases inhibitors"
    },
    {
      "id": "MCF-7 cell proliferation"
    },
    {
      "id": "Estradiol (E2)"
    },
    {
      "id": "c-fos expression"
    },
    {
      "id": "estrogen receptor (ER)"
    },
    {
      "id": "cationic amino acid transporters"
    },
    {
      "id": "l-arginine"
    },
    {
      "id": "system y(+)"
    },
    {
      "id": "peritubular cells"
    },
    {
      "id": "Sertoli cells"
    },
    {
      "id": "system B(0+)"
    },
    {
      "id": "contribution"
    },
    {
      "id": "Arginine"
    },
    {
      "id": "biological processes"
    },
    {
      "id": "trans stimulation"
    },
    {
      "id": "delivery"
    },
    {
      "id": "extracellular cationic amino acids"
    },
    {
      "id": "neutral amino acids"
    },
    {
      "id": "properties"
    },
    {
      "id": "y(+)L system"
    },
    {
      "id": "upregulation"
    },
    {
      "id": "arginine transport"
    },
    {
      "id": "somatic tubular cells"
    },
    {
      "id": "system y(+)L"
    },
    {
      "id": "SLC3A2"
    },
    {
      "id": "SLC7A1"
    },
    {
      "id": "sensitivity"
    },
    {
      "id": "NO synthesis"
    },
    {
      "id": "profiles"
    },
    {
      "id": "cis inhibition"
    },
    {
      "id": "pachytene spermatocytes"
    },
    {
      "id": "germ cells"
    },
    {
      "id": "cationic amino acids"
    },
    {
      "id": "efficiency"
    },
    {
      "id": "early spermatids"
    },
    {
      "id": "seminiferous tubule cells"
    },
    {
      "id": "Na(+) dependence"
    },
    {
      "id": "transport"
    },
    {
      "id": "SLC7A7"
    },
    {
      "id": "l-arginine transport"
    },
    {
      "id": "cationic amino acid transport"
    },
    {
      "id": "rat seminiferous tubule cells"
    },
    {
      "id": "SLC7A2"
    },
    {
      "id": "key role"
    },
    {
      "id": "SLC7A6"
    },
    {
      "id": "Multiple pathways"
    },
    {
      "id": "[1'-(14)C]"
    },
    {
      "id": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs"
    },
    {
      "id": "MTA"
    },
    {
      "id": "[2'-(3)H]"
    },
    {
      "id": "[9-(15)N]"
    },
    {
      "id": "cationic center"
    },
    {
      "id": "[5'-(3)H(2)]"
    },
    {
      "id": "sigma (C-H) antibonding orbitals"
    },
    {
      "id": "MTAP"
    },
    {
      "id": "leaving group"
    },
    {
      "id": "3'-OH"
    },
    {
      "id": "zwitterion"
    },
    {
      "id": "ribosyl zwitterion"
    },
    {
      "id": "H1'-C1'-C2'-H2'"
    },
    {
      "id": "human 5'-methylthioadenosine phosphorylase"
    },
    {
      "id": "[4'-(3)H]"
    },
    {
      "id": "[Me-(3)H(3)]"
    },
    {
      "id": "lone pairs of sulfur"
    },
    {
      "id": "Human MTAP"
    },
    {
      "id": "phosphate nucleophile"
    },
    {
      "id": "5'-methylthioadenosine"
    },
    {
      "id": "adenine leaving group"
    },
    {
      "id": "anionic leaving group"
    },
    {
      "id": "[1'-(3)H]"
    },
    {
      "id": "oxygen nucleophile"
    },
    {
      "id": "36 months"
    },
    {
      "id": "worsening"
    },
    {
      "id": "arthralgia"
    },
    {
      "id": "CD11a subunit"
    },
    {
      "id": "surface molecule"
    },
    {
      "id": "reversible changes"
    },
    {
      "id": "laboratory values"
    },
    {
      "id": "improvement"
    },
    {
      "id": "PASI score"
    },
    {
      "id": "elevated alkaline phosphatases"
    },
    {
      "id": "rare cases"
    },
    {
      "id": "thrombocytopenia"
    },
    {
      "id": "moderate-to-severe cutaneous plaque psoriasis"
    },
    {
      "id": "adults"
    },
    {
      "id": "marketing authorisation"
    },
    {
      "id": "France"
    },
    {
      "id": "randomised studies"
    },
    {
      "id": "systemic treatments"
    },
    {
      "id": "intolerance"
    },
    {
      "id": "3 months"
    },
    {
      "id": "MA"
    },
    {
      "id": "side-effects"
    },
    {
      "id": "naive T lymphocytes"
    },
    {
      "id": "Efalizumab"
    },
    {
      "id": "Serono"
    },
    {
      "id": "clinical trial data"
    },
    {
      "id": "ICAM-1 molecule"
    },
    {
      "id": "antigen-presenting cells"
    },
    {
      "id": "contraindication"
    },
    {
      "id": "indications"
    },
    {
      "id": "biotherapies"
    },
    {
      "id": "position"
    },
    {
      "id": "therapeutic arsenal"
    },
    {
      "id": "humanised monoclonal antibody"
    },
    {
      "id": "Intercellular Adhesion Molecule-1"
    },
    {
      "id": "PASI-75"
    },
    {
      "id": "Food and Drug Administration"
    },
    {
      "id": "United States"
    },
    {
      "id": "extrapolation"
    },
    {
      "id": "single weekly subcutaneous injection"
    },
    {
      "id": "long-term benefit/risk ratio"
    },
    {
      "id": "influenza-like syndrome"
    },
    {
      "id": "psoriatic plaque"
    },
    {
      "id": "reactivation"
    },
    {
      "id": "steps"
    },
    {
      "id": "immunological process"
    },
    {
      "id": "cyclosporine"
    },
    {
      "id": "indication"
    },
    {
      "id": "cutaneous psoriasis"
    },
    {
      "id": "molecule"
    },
    {
      "id": "T lymphocytes"
    },
    {
      "id": "transaminases"
    },
    {
      "id": "T lymphocyte"
    },
    {
      "id": "good responders"
    },
    {
      "id": "memory T lymphocytes"
    },
    {
      "id": "1 mg/kg"
    },
    {
      "id": "lymphocyte migration"
    },
    {
      "id": "moderate-to-severe psoriasis"
    },
    {
      "id": "failure"
    },
    {
      "id": "joint involvement"
    },
    {
      "id": "outbreak"
    },
    {
      "id": "prescription"
    },
    {
      "id": "monthly monitoring"
    },
    {
      "id": "systemic therapy"
    },
    {
      "id": "September 2005"
    },
    {
      "id": "antibody"
    },
    {
      "id": "anti-TNF alpha agents"
    },
    {
      "id": "plaque psoriasis"
    },
    {
      "id": "treatment option"
    },
    {
      "id": "hyperlymphocytosis"
    },
    {
      "id": "Raptiva"
    },
    {
      "id": "IgG1"
    },
    {
      "id": "phototherapy"
    },
    {
      "id": "platelet counts"
    },
    {
      "id": "minor hypersensitivity reactions"
    },
    {
      "id": "biotechnology"
    },
    {
      "id": "Leucocyte Function-associated Antigen-1"
    },
    {
      "id": "ICAM-1"
    },
    {
      "id": "recombinant strains"
    },
    {
      "id": "flavinogenic yeast Candida famata"
    },
    {
      "id": "flavinogenic yeast Candida famata strains"
    },
    {
      "id": "riboflavin kinase activity"
    },
    {
      "id": "riboflavin"
    },
    {
      "id": "construction"
    },
    {
      "id": "flavinmononucleotide overproducers"
    },
    {
      "id": "increase"
    },
    {
      "id": "strong promoters"
    },
    {
      "id": "regulated RIB1"
    },
    {
      "id": "DNA fragment"
    },
    {
      "id": "flavinmononucleotide"
    },
    {
      "id": "constitutive TEF1 promoter"
    },
    {
      "id": "riboflavin kinase"
    },
    {
      "id": "Debaryomyces hansenii FMN1 gene"
    },
    {
      "id": "FMN1 gene"
    },
    {
      "id": "Riboflavin kinase activity"
    },
    {
      "id": "isolated transformants"
    },
    {
      "id": "strong constitutive TEF1 promoter"
    },
    {
      "id": "gene engineering"
    },
    {
      "id": "c-Src"
    },
    {
      "id": "GnRH receptor"
    },
    {
      "id": "Calcium-dependent tyrosine kinase Pyk2"
    },
    {
      "id": "Prostate tumor growth"
    },
    {
      "id": "Hic-5"
    },
    {
      "id": "Cultured rat ventral prostate cells"
    },
    {
      "id": "Testosterone"
    },
    {
      "id": "Androgen receptor"
    },
    {
      "id": "GnRH analogs"
    },
    {
      "id": "Prostate cancer cells"
    },
    {
      "id": "Pyk2"
    },
    {
      "id": "Androgen"
    },
    {
      "id": "Rat ventral prostate organ cultures"
    },
    {
      "id": "Prostatic cancer"
    },
    {
      "id": "BPH-1 cells"
    },
    {
      "id": "Focal adhesion protein"
    },
    {
      "id": "LNCaP cells"
    },
    {
      "id": "Gonadotropin-releasing hormone"
    },
    {
      "id": "Dominant negative Pyk2"
    },
    {
      "id": "Green fluorescent protein-tagged human androgen receptor"
    },
    {
      "id": "Sex steroid hormone receptor"
    },
    {
      "id": "Non-receptor tyrosine kinase c-Src"
    },
    {
      "id": "Antiproliferative cell cycle arrest"
    },
    {
      "id": "Human androgen receptor"
    },
    {
      "id": "Prostate cells"
    },
    {
      "id": "Focal adhesion complexes"
    },
    {
      "id": "Human prostate PC3 cells"
    },
    {
      "id": "Normal tissue"
    },
    {
      "id": "Gonadotropins"
    },
    {
      "id": "Steroid receptor co-factor"
    },
    {
      "id": "Expression"
    },
    {
      "id": "E17.5"
    },
    {
      "id": "Genes"
    },
    {
      "id": "Glypicans 1, 2, 3 and 5"
    },
    {
      "id": "Mature cells"
    },
    {
      "id": "Proprotein convertase subtilisin/kexin type 2"
    },
    {
      "id": "Proprotein convertase subtilisin/kexin type 1"
    },
    {
      "id": "Pcsk1"
    },
    {
      "id": "Chlorate"
    },
    {
      "id": "Endocrine cell development"
    },
    {
      "id": "Neurogenin 3"
    },
    {
      "id": "Neurog3"
    },
    {
      "id": "Heparan sulphate 2-sulfotransferase"
    },
    {
      "id": "Pancreatic and duodenal homeobox gene 1"
    },
    {
      "id": "E13.5"
    },
    {
      "id": "Solute carrier family 2 (facilitated glucose transporter), member 2"
    },
    {
      "id": "Slc2a1"
    },
    {
      "id": "Pro-hormone convertase 2"
    },
    {
      "id": "Pcsk2"
    },
    {
      "id": "Syndecans"
    },
    {
      "id": "Chlorate-treated pancreases"
    },
    {
      "id": "Beta cell number"
    },
    {
      "id": "Sulphated proteoglycans"
    },
    {
      "id": "Beta cell development"
    },
    {
      "id": "Endogenous sulphated proteoglycans"
    },
    {
      "id": "Insulin-positive cells"
    },
    {
      "id": "Proteoglycan action"
    },
    {
      "id": "Embryonic pancreatic mesenchyme"
    },
    {
      "id": "Endocrine cell differentiation"
    },
    {
      "id": "Glucose transporter 2"
    },
    {
      "id": "In vitro model of pancreas development"
    },
    {
      "id": "Pancreas development"
    },
    {
      "id": "Beta cells"
    },
    {
      "id": "Embryonic stem cells"
    },
    {
      "id": "Embryonic development"
    },
    {
      "id": "Progenitor cell proliferation"
    },
    {
      "id": "Epithelium-mesenchyme interactions"
    },
    {
      "id": "Pancreatic endocrine cell differentiation"
    },
    {
      "id": "Inhibitory effect"
    },
    {
      "id": "Glycosaminoglycan chain-modifying enzymes"
    },
    {
      "id": "Mesenchyme"
    },
    {
      "id": "Alpha cell development"
    },
    {
      "id": "Pdx1"
    },
    {
      "id": "Pro-hormone convertase 1/3"
    },
    {
      "id": "Embryonic pancreases"
    },
    {
      "id": "40 mmol/l chlorate"
    },
    {
      "id": "Glypicans"
    },
    {
      "id": "Immature embryonic day (E) 13.5 rat pancreases"
    },
    {
      "id": "Early endocrine progenitor cells"
    },
    {
      "id": "30 mmol/l chlorate"
    },
    {
      "id": "Proteoglycan sulphation"
    },
    {
      "id": "Mechanism"
    },
    {
      "id": "superoxide dismutase activities"
    },
    {
      "id": "hyperthyroidism conditions"
    },
    {
      "id": "significant effect"
    },
    {
      "id": "thyroid activity variations"
    },
    {
      "id": "state of oxidizing stress"
    },
    {
      "id": "thyroid activity"
    },
    {
      "id": "antioxidant enzyme activities"
    },
    {
      "id": "tissular contents"
    },
    {
      "id": "non-enzymatic antioxidants"
    },
    {
      "id": "reduced glutathione"
    },
    {
      "id": "homogenate"
    },
    {
      "id": "marked increase"
    },
    {
      "id": "glutathione reductase activity"
    },
    {
      "id": "L-thyroxine sodium salt"
    },
    {
      "id": "0.0012%"
    },
    {
      "id": "vitamin E"
    },
    {
      "id": "cardiac tissues"
    },
    {
      "id": "drinking water"
    },
    {
      "id": "hepatic tissues"
    },
    {
      "id": "hypothyroidism rats"
    },
    {
      "id": "glutathione peroxidase activity"
    },
    {
      "id": "0.05% benzythiouracile"
    },
    {
      "id": "BTU"
    },
    {
      "id": "oxidizing-stress parameters"
    },
    {
      "id": "Hypothyroidism conditions"
    },
    {
      "id": "five weeks"
    },
    {
      "id": "enzymatic antioxidants"
    },
    {
      "id": "pronounced increase"
    },
    {
      "id": "catalase activities"
    },
    {
      "id": "total MUFAs"
    },
    {
      "id": "PBMC D6D genes"
    },
    {
      "id": "D5D"
    },
    {
      "id": "European countries"
    },
    {
      "id": "MUFA diets"
    },
    {
      "id": "high EFAs intake"
    },
    {
      "id": "PBMC D5D genes"
    },
    {
      "id": "high SFAs"
    },
    {
      "id": "high MUFAs"
    },
    {
      "id": "Diet"
    },
    {
      "id": "delta-5 and delta-6 desaturases"
    },
    {
      "id": "high SFA diets"
    },
    {
      "id": "dietary intake"
    },
    {
      "id": "saturated fatty acids"
    },
    {
      "id": "D6D"
    },
    {
      "id": "LA"
    },
    {
      "id": "delta-5 desaturase"
    },
    {
      "id": "composition of fatty acids"
    },
    {
      "id": "delta-6 desaturase"
    },
    {
      "id": "Three-day dietary records"
    },
    {
      "id": "follow-up study"
    },
    {
      "id": "Levels of expression"
    },
    {
      "id": "peripheral blood mononuclear cells"
    },
    {
      "id": "Chinese"
    },
    {
      "id": "LNA"
    },
    {
      "id": "monounsaturated fatty acids"
    },
    {
      "id": "essential fatty acids"
    },
    {
      "id": "Europeans"
    },
    {
      "id": "linoleic acid"
    },
    {
      "id": "healthy Chinese subjects"
    },
    {
      "id": "total SFAs"
    },
    {
      "id": "SFAs"
    },
    {
      "id": "alpha-linolenic acid"
    },
    {
      "id": "MUFAs"
    },
    {
      "id": "EFAs"
    },
    {
      "id": "European subjects"
    },
    {
      "id": "clinical activity"
    },
    {
      "id": "Decitabine"
    },
    {
      "id": "Correlative laboratory studies"
    },
    {
      "id": "recent clinical trials"
    },
    {
      "id": "Review Purpose"
    },
    {
      "id": "Epigenetic changes"
    },
    {
      "id": "malignant transformation"
    },
    {
      "id": "critical genes"
    },
    {
      "id": "connection"
    },
    {
      "id": "promoter hypermethylation"
    },
    {
      "id": "p15(INK4B)"
    },
    {
      "id": "hypomethylation of gene-specific promoters"
    },
    {
      "id": "therapeutic effects"
    },
    {
      "id": "hematologic malignancies"
    },
    {
      "id": "global hypomethylation"
    },
    {
      "id": "threshold"
    },
    {
      "id": "DNA methyltransferase"
    },
    {
      "id": "myelodysplastic syndromes"
    },
    {
      "id": "Low-dose decitabine"
    },
    {
      "id": "demethylating activity"
    },
    {
      "id": "bench"
    },
    {
      "id": "DNA methylation"
    },
    {
      "id": "bedside"
    },
    {
      "id": "multiple clinical trials"
    },
    {
      "id": "hypermethylation"
    },
    {
      "id": "translational research"
    },
    {
      "id": "TGF-beta expression"
    },
    {
      "id": "malignant glioma cells"
    },
    {
      "id": "PFD-related agents"
    },
    {
      "id": "human cancers"
    },
    {
      "id": "transforming growth factor (TGF)-beta"
    },
    {
      "id": "experimental treatment"
    },
    {
      "id": "PFD"
    },
    {
      "id": "PFD treatment"
    },
    {
      "id": "growth inhibition"
    },
    {
      "id": "downregulation of TGF-beta"
    },
    {
      "id": "pirfenidone"
    },
    {
      "id": "growth-inhibitory effects"
    },
    {
      "id": "antifibrotic drug"
    },
    {
      "id": "immunosuppressive properties"
    },
    {
      "id": "TGF-beta2"
    },
    {
      "id": "TGF-beta2 protein levels"
    },
    {
      "id": "human glioma cell lines"
    },
    {
      "id": "TGF-beta-sensitive CCL-64 cells"
    },
    {
      "id": "mature TGF-beta2 protein"
    },
    {
      "id": "matrix metalloproteinase (MMP)-11"
    },
    {
      "id": "5-methyl-1-phenyl-2-(1H)-pyridone"
    },
    {
      "id": "Pirfenidone"
    },
    {
      "id": "conditioned media"
    },
    {
      "id": "TGF-beta pro-protein convertase"
    },
    {
      "id": "glioma cells"
    },
    {
      "id": "enhanced TGF-beta activity"
    },
    {
      "id": "TGF-beta2 mRNA levels"
    },
    {
      "id": "TGF-beta target gene"
    },
    {
      "id": "human malignant gliomas"
    },
    {
      "id": "furin"
    },
    {
      "id": "furin substrate"
    },
    {
      "id": "direct inhibition"
    },
    {
      "id": "carcinogenesis"
    },
    {
      "id": "Reticulated platelets"
    },
    {
      "id": "flow cytometry"
    },
    {
      "id": "Postaspirin serum TxB2 levels"
    },
    {
      "id": "ex vivo additional COX-1"
    },
    {
      "id": "tertiles"
    },
    {
      "id": "platelet studies"
    },
    {
      "id": "Light transmission aggregometry"
    },
    {
      "id": "antiplatelet effects of aspirin"
    },
    {
      "id": "Baseline platelet aggregation"
    },
    {
      "id": "upper tertile"
    },
    {
      "id": "uninhibited COX-1"
    },
    {
      "id": "postaspirin aggregations"
    },
    {
      "id": "Stimulated P-selectin"
    },
    {
      "id": "integrin alpha(IIb)beta(3) expression"
    },
    {
      "id": "Immature (reticulated) platelets"
    },
    {
      "id": "variability"
    },
    {
      "id": "5 microm ADP"
    },
    {
      "id": "aspirin"
    },
    {
      "id": "platelet COX-2 expression"
    },
    {
      "id": "percentage of reticulated platelets"
    },
    {
      "id": "20 microm ADP"
    },
    {
      "id": "COX-2 inhibition"
    },
    {
      "id": "diminished antiplatelet effects of aspirin"
    },
    {
      "id": "Platelet COX-2 expression"
    },
    {
      "id": "lower two tertiles"
    },
    {
      "id": "serum thromboxane B(2) (TxB2) levels"
    },
    {
      "id": "P-selectin"
    },
    {
      "id": "incidence of aspirin resistance"
    },
    {
      "id": "lower tertile"
    },
    {
      "id": "role of reticulated platelets"
    },
    {
      "id": "increased aspirin resistance"
    },
    {
      "id": "uninhibited cyclooxygenase (COX)-1"
    },
    {
      "id": "1 microg mL(-1) collagen"
    },
    {
      "id": "lower tertile of reticulated platelets"
    },
    {
      "id": "increased reactivity"
    },
    {
      "id": "COX-2 activity"
    },
    {
      "id": "single 325-mg dose of aspirin"
    },
    {
      "id": "collagen"
    },
    {
      "id": "BAAT"
    },
    {
      "id": "conjugation"
    },
    {
      "id": "endogenous BAAT"
    },
    {
      "id": "primary human hepatocytes"
    },
    {
      "id": "GFP-tagged hBAAT"
    },
    {
      "id": "primary bile acids"
    },
    {
      "id": "digitonin permeabilization assays"
    },
    {
      "id": "subcellular location"
    },
    {
      "id": "rBaat"
    },
    {
      "id": "peroxisomes"
    },
    {
      "id": "hBAAT"
    },
    {
      "id": "immunofluorescence microscopy"
    },
    {
      "id": "endogenous hBAAT"
    },
    {
      "id": "glycine"
    },
    {
      "id": "N"
    },
    {
      "id": "Bile acid-coenzyme A:amino acid N-acyltransferase"
    },
    {
      "id": "Coenzyme A"
    },
    {
      "id": "GFP-tagged rat Baat"
    },
    {
      "id": "human fibroblasts"
    },
    {
      "id": "human BAAT"
    },
    {
      "id": "primary rat hepatocytes"
    },
    {
      "id": "green fluorescent protein"
    },
    {
      "id": "rat Baat"
    },
    {
      "id": "taurine"
    },
    {
      "id": "secondary bile acids"
    },
    {
      "id": "GFP-tagged rBaat"
    },
    {
      "id": "GFP-SKL"
    },
    {
      "id": "peroxisomal markers"
    },
    {
      "id": "recombinant GFP-SKL"
    },
    {
      "id": "cytosolic pool"
    },
    {
      "id": "DsRed-SKL"
    },
    {
      "id": "fibroblasts"
    },
    {
      "id": "observations"
    },
    {
      "id": "intracellular transport"
    },
    {
      "id": "bile acid-CoA:amino acid N-acyltransferase"
    },
    {
      "id": "Liver"
    },
    {
      "id": "Unconjugated or deconjugated bile salts"
    },
    {
      "id": "Human"
    },
    {
      "id": "intracellular bile salt transport"
    },
    {
      "id": "bile acids"
    },
    {
      "id": "Catalase"
    },
    {
      "id": "GFP"
    },
    {
      "id": "peroxisomal location"
    },
    {
      "id": "cytosolic fractions"
    },
    {
      "id": "enterohepatic circulation"
    },
    {
      "id": "unconjugated/deconjugated bile salts"
    },
    {
      "id": "peroxisomal import machinery"
    },
    {
      "id": "Rat"
    },
    {
      "id": "amino acid"
    },
    {
      "id": "hBAAT/rBaat"
    },
    {
      "id": "massive intra-abdominal hemorrhage"
    },
    {
      "id": "gamma-carboxylase"
    },
    {
      "id": "gamma-carboxylation"
    },
    {
      "id": "postnatal hemorrhage"
    },
    {
      "id": "F5-deficient mice"
    },
    {
      "id": "functionally critical substrates"
    },
    {
      "id": "components"
    },
    {
      "id": "blood coagulation cascade"
    },
    {
      "id": "partial midembryonic loss"
    },
    {
      "id": "posttranslational modification"
    },
    {
      "id": "vitamin K-dependent gamma-glutamyl carboxylase"
    },
    {
      "id": "null mutation"
    },
    {
      "id": "Ggcx gene"
    },
    {
      "id": "gamma-glutamyl carboxylase"
    },
    {
      "id": "Heterozygous mice"
    },
    {
      "id": "Ggcx(+/-) intercross"
    },
    {
      "id": "partial developmental block"
    },
    {
      "id": "gamma-carboxyglutamic acid"
    },
    {
      "id": "glutamic acid residues"
    },
    {
      "id": "phenotype"
    },
    {
      "id": "redundant carboxylase pathway"
    },
    {
      "id": "prothrombin-deficient mice"
    },
    {
      "id": "Fatal hemorrhage"
    },
    {
      "id": "factor V-deficient mice"
    },
    {
      "id": "Gla"
    },
    {
      "id": "biological activity"
    },
    {
      "id": "prothrombin"
    },
    {
      "id": "neonate"
    },
    {
      "id": "vitamin K-dependent clotting factors X"
    },
    {
      "id": "vitamin K-dependent clotting factors IX"
    },
    {
      "id": "hemorrhage"
    },
    {
      "id": "Ggcx(-/-) offspring"
    },
    {
      "id": "Neuroprotection"
    },
    {
      "id": "ERalpha"
    },
    {
      "id": "primary mesencephalic neurons"
    },
    {
      "id": "estrogen receptor alpha"
    },
    {
      "id": "mitotic inhibitor"
    },
    {
      "id": "estrogen-mediated neuroprotection"
    },
    {
      "id": "dopamine neurons"
    },
    {
      "id": "HPTE"
    },
    {
      "id": "protection"
    },
    {
      "id": "dopamine neuron death"
    },
    {
      "id": "ERbeta agonist"
    },
    {
      "id": "DPN"
    },
    {
      "id": "estrogenic effects"
    },
    {
      "id": "mixed population of cells"
    },
    {
      "id": "molecular and cellular mechanisms"
    },
    {
      "id": "estrogen action"
    },
    {
      "id": "MPP(+) toxicity"
    },
    {
      "id": "primary cultures of mouse mesencephalon"
    },
    {
      "id": "17beta-estradiol"
    },
    {
      "id": "indirect mechanism"
    },
    {
      "id": "glial cell interaction"
    },
    {
      "id": "estrogen receptor beta"
    },
    {
      "id": "dopamine cell loss"
    },
    {
      "id": "ERalpha agonist"
    },
    {
      "id": "MPP+"
    },
    {
      "id": "astrocytes"
    },
    {
      "id": "complex I inhibitor"
    },
    {
      "id": "1-methyl-4-phenyl pyridinium"
    },
    {
      "id": "5-fluoro-2'-deoxyuridine"
    },
    {
      "id": "two cell types"
    },
    {
      "id": "MPP(+)"
    },
    {
      "id": "estrogen pre-treatment"
    },
    {
      "id": "single nucleotide polymorphisms"
    },
    {
      "id": "GSTA1-52"
    },
    {
      "id": "Urine"
    },
    {
      "id": "work shift"
    },
    {
      "id": "carbon disulfide (CS(2))"
    },
    {
      "id": "toxic compounds"
    },
    {
      "id": "Genotyping"
    },
    {
      "id": "ordinary PCR"
    },
    {
      "id": "TTCA levels"
    },
    {
      "id": "injection and compression molding"
    },
    {
      "id": "GSTM1"
    },
    {
      "id": "statistically significant differences"
    },
    {
      "id": "survey"
    },
    {
      "id": "rubber industry"
    },
    {
      "id": "hazardous substances"
    },
    {
      "id": "modifying effects"
    },
    {
      "id": "microwaves"
    },
    {
      "id": "vulcanization workers"
    },
    {
      "id": "southern Sweden rubber industries"
    },
    {
      "id": "biomarker"
    },
    {
      "id": "agarose electrophoresis"
    },
    {
      "id": "glutathione-related genes"
    },
    {
      "id": "TTCA"
    },
    {
      "id": "hot air"
    },
    {
      "id": "Swedish rubber industry"
    },
    {
      "id": "exposed workers"
    },
    {
      "id": "GSTP1-114"
    },
    {
      "id": "deletions"
    },
    {
      "id": "GSTP1-105"
    },
    {
      "id": "fluid-bed"
    },
    {
      "id": "GSTT1"
    },
    {
      "id": "GCLM-588"
    },
    {
      "id": "2-thiothiazolidine-4-carboxylic acid"
    },
    {
      "id": "real-time PCR"
    },
    {
      "id": "liquid chromatograpy tandem mass spectrometry"
    },
    {
      "id": "GCLC-129"
    },
    {
      "id": "inter- and intraindividual variability"
    },
    {
      "id": "genetic variation"
    },
    {
      "id": "salt bath"
    },
    {
      "id": "genotypes"
    },
    {
      "id": "developing retinal ganglion cell layer"
    },
    {
      "id": "AC5"
    },
    {
      "id": "genetic approach"
    },
    {
      "id": "calcium modulated cyclases"
    },
    {
      "id": "AC"
    },
    {
      "id": "extracellular signals"
    },
    {
      "id": "AC1"
    },
    {
      "id": "retinal axon terminals"
    },
    {
      "id": "cyclases"
    },
    {
      "id": "neurotransmitters"
    },
    {
      "id": "central brain targets"
    },
    {
      "id": "dorsal lateral geniculate nucleus"
    },
    {
      "id": "segregation retinal fibres"
    },
    {
      "id": "barrelless mouse strain"
    },
    {
      "id": "retinal projections"
    },
    {
      "id": "eyes"
    },
    {
      "id": "visual thalamus"
    },
    {
      "id": "Transmembrane isoforms of adenylate cyclases"
    },
    {
      "id": "AC subtypes"
    },
    {
      "id": "superior colliculus"
    },
    {
      "id": "morphogens"
    },
    {
      "id": "AC3"
    },
    {
      "id": "AC2"
    },
    {
      "id": "Ipsilateral retinal axons"
    },
    {
      "id": "AC1(-/-) mice"
    },
    {
      "id": "AC8"
    },
    {
      "id": "AC1/AC8 double-knockout mice"
    },
    {
      "id": "ventral lateral geniculate nucleus"
    },
    {
      "id": "Adcy1 gene"
    },
    {
      "id": "AC9"
    },
    {
      "id": "RGC"
    },
    {
      "id": "Adcy genes"
    },
    {
      "id": "visual centres"
    },
    {
      "id": "barrelless mouse mutants"
    },
    {
      "id": "calcium entry"
    },
    {
      "id": "functional differences"
    },
    {
      "id": "NAc shell subregions"
    },
    {
      "id": "localized activation of CREB"
    },
    {
      "id": "changes in CREB phosphorylation"
    },
    {
      "id": "subsequent challenge injection"
    },
    {
      "id": "cocaine-induced CREB activity"
    },
    {
      "id": "authors"
    },
    {
      "id": "immunohistochemistry"
    },
    {
      "id": "nucleus accumbens (NAc)"
    },
    {
      "id": "CREB-dependent gene transcription"
    },
    {
      "id": "withdrawal"
    },
    {
      "id": "present study"
    },
    {
      "id": "cAMP response element binding protein"
    },
    {
      "id": "nucleus accumbens subregions"
    },
    {
      "id": "long-lasting drug-induced changes"
    },
    {
      "id": "5 zones of analysis"
    },
    {
      "id": "temporal determinants"
    },
    {
      "id": "CREB phosphorylation"
    },
    {
      "id": "analyzed subregions of the NAc"
    },
    {
      "id": "cyclic adenosine monophosphate (cAMP) response element binding protein (CREB)"
    },
    {
      "id": "short drug-free period"
    },
    {
      "id": "CREB"
    },
    {
      "id": "late cocaine effects"
    },
    {
      "id": "cocaine sensitization"
    },
    {
      "id": "late cocaine sensitization"
    },
    {
      "id": "subregions of the NAc"
    },
    {
      "id": "stage of drug exposure"
    },
    {
      "id": "challenge injection"
    },
    {
      "id": "2 drug-free days"
    },
    {
      "id": "5 days of cocaine"
    },
    {
      "id": "early cocaine sensitization"
    },
    {
      "id": "cyclic adenosine monophosphate"
    },
    {
      "id": "3 most dorsomedial zones of the shell"
    },
    {
      "id": "neurochemistry"
    },
    {
      "id": "behavior"
    },
    {
      "id": "discrete zones of analysis"
    },
    {
      "id": "cocaine-induced activation"
    },
    {
      "id": "Repeated cocaine"
    },
    {
      "id": "cessation of repeated cocaine"
    },
    {
      "id": "drug-free period"
    },
    {
      "id": "early cocaine effects"
    },
    {
      "id": "cocaine effects"
    },
    {
      "id": "subjective effects of cocaine"
    },
    {
      "id": "anatomical determinants"
    },
    {
      "id": "most ventrolateral region of the shell"
    },
    {
      "id": "cell population"
    },
    {
      "id": "dorsomedial zones of the shell"
    },
    {
      "id": "long drug-free period"
    },
    {
      "id": "connectivity"
    },
    {
      "id": "CREB activity"
    },
    {
      "id": "zones of analysis"
    },
    {
      "id": "shell"
    },
    {
      "id": "Cr supplementation"
    },
    {
      "id": "GAMT deficiency"
    },
    {
      "id": "Cr"
    },
    {
      "id": "MR spectra"
    },
    {
      "id": "35 days"
    },
    {
      "id": "N-acetylasparate"
    },
    {
      "id": "thalamus/hippocampus"
    },
    {
      "id": "repeated MRS measurements"
    },
    {
      "id": "longitudinal Cr supplementation study"
    },
    {
      "id": "Creatine"
    },
    {
      "id": "Cr deficiency"
    },
    {
      "id": "guanidinoacetate methyltransferase"
    },
    {
      "id": "Cr levels"
    },
    {
      "id": "MRS"
    },
    {
      "id": "hind leg muscle"
    },
    {
      "id": "brain Cr"
    },
    {
      "id": "Localized 1H magnetic resonance spectroscopy"
    },
    {
      "id": "muscular Cr uptake"
    },
    {
      "id": "Cr transporter expression"
    },
    {
      "id": "GAMT-/-"
    },
    {
      "id": "Cr administration"
    },
    {
      "id": "first day of supplementation"
    },
    {
      "id": "cerebellum"
    },
    {
      "id": "Con mice"
    },
    {
      "id": "0.8 mM/day"
    },
    {
      "id": "locations"
    },
    {
      "id": "uptake of Cr"
    },
    {
      "id": "2 g.kg body wt-1.day-1 Cr"
    },
    {
      "id": "NAA"
    },
    {
      "id": "Cr-free diet"
    },
    {
      "id": "magnetic resonance spectroscopy"
    },
    {
      "id": "FAD"
    },
    {
      "id": "Thermus thermophilus PRODH"
    },
    {
      "id": "3,4-Dehydro-l-proline"
    },
    {
      "id": "FAD conformation"
    },
    {
      "id": "communication"
    },
    {
      "id": "Structure-based sequence analysis"
    },
    {
      "id": "conserved motifs"
    },
    {
      "id": "bifunctional enzymes"
    },
    {
      "id": "PutA"
    },
    {
      "id": "catalytic core"
    },
    {
      "id": "PutA PRODH domain"
    },
    {
      "id": "PRODH"
    },
    {
      "id": "l-tetrahydro-2-furoic acid"
    },
    {
      "id": "competitive inhibitor"
    },
    {
      "id": "Proline dehydrogenase"
    },
    {
      "id": "monofunctional enzymes"
    },
    {
      "id": "P5CDH"
    },
    {
      "id": "O(2)"
    },
    {
      "id": "substrate recognition"
    },
    {
      "id": "strands"
    },
    {
      "id": "barrel"
    },
    {
      "id": "PutA/PRODH family"
    },
    {
      "id": "distorted (betaalpha)(8) barrel catalytic core domain"
    },
    {
      "id": "Delta(1)-pyrroline-5-carboxylate dehydrogenase"
    },
    {
      "id": "midpoint potential"
    },
    {
      "id": "kinetic parameters"
    },
    {
      "id": "k(cat)"
    },
    {
      "id": "bacteria"
    },
    {
      "id": "monofunctional proline dehydrogenase"
    },
    {
      "id": "biochemical data"
    },
    {
      "id": "Thermus thermophilus"
    },
    {
      "id": "hydrophobic alpha-helical domain"
    },
    {
      "id": "superoxide production"
    },
    {
      "id": "human PRODH"
    },
    {
      "id": "proline utilization A"
    },
    {
      "id": "carboxyl-terminal ends"
    },
    {
      "id": "helix 8"
    },
    {
      "id": "p53-mediated apoptosis"
    },
    {
      "id": "K(m)"
    },
    {
      "id": "K(I)"
    },
    {
      "id": "Biochemical studies"
    },
    {
      "id": "membrane association"
    },
    {
      "id": "superoxide"
    },
    {
      "id": "2.0-A resolution structure"
    },
    {
      "id": "eukaryotic and bacterial monofunctional PRODHs"
    },
    {
      "id": "AS expression"
    },
    {
      "id": "arginine-dependent processes"
    },
    {
      "id": "TNF-alpha mRNA"
    },
    {
      "id": "normal corresponding tissues"
    },
    {
      "id": "pyrimidines"
    },
    {
      "id": "TNF-alpha"
    },
    {
      "id": "AS mRNA"
    },
    {
      "id": "malignant OSE cells"
    },
    {
      "id": "argininosuccinate synthetase"
    },
    {
      "id": "arginine synthesis"
    },
    {
      "id": "normal ovarian surface epithelium (OSE)"
    },
    {
      "id": "IGROV-1 ovarian cancer cells"
    },
    {
      "id": "arginine-dependent metabolic pathways"
    },
    {
      "id": "tumour progression"
    },
    {
      "id": "inflammation"
    },
    {
      "id": "ovarian tumorigenesis"
    },
    {
      "id": "stomach cancer"
    },
    {
      "id": "AS protein"
    },
    {
      "id": "ovarian cancer cells"
    },
    {
      "id": "normal OSE cells"
    },
    {
      "id": "rate-limiting enzyme"
    },
    {
      "id": "molecular pathway"
    },
    {
      "id": "epidemiological studies"
    },
    {
      "id": "ovarian tumour samples"
    },
    {
      "id": "epithelial tumours"
    },
    {
      "id": "cDNA cancer profiling array"
    },
    {
      "id": "normal ovarian tissue"
    },
    {
      "id": "accelerated carcinogenesis"
    },
    {
      "id": "matched normal ovarian"
    },
    {
      "id": "pro-inflammatory cytokine"
    },
    {
      "id": "invasion"
    },
    {
      "id": "tumour necrosis factor-alpha"
    },
    {
      "id": "DLDH"
    },
    {
      "id": "EC 1.8.1.4"
    },
    {
      "id": "levels of DLDH diaphorase activity"
    },
    {
      "id": "rat tissues"
    },
    {
      "id": "electron donor"
    },
    {
      "id": "Mammalian mitochondrial dihydrolipoamide dehydrogenase"
    },
    {
      "id": "nitroblue tetrazolium"
    },
    {
      "id": "NBT"
    },
    {
      "id": "mass spectral techniques"
    },
    {
      "id": "DLDH post-translational modifications"
    },
    {
      "id": "mitochondrial DLDH"
    },
    {
      "id": "gel-based method"
    },
    {
      "id": "dihydrolipoamide dehydrogenase diaphorase activity"
    },
    {
      "id": "in-gel activity-staining method"
    },
    {
      "id": "conventional spectrophotometric method"
    },
    {
      "id": "quantification"
    },
    {
      "id": "diaphorase"
    },
    {
      "id": "dihydrolipoamide"
    },
    {
      "id": "Rat brain mitochondrial extracts"
    },
    {
      "id": "source of DLDH"
    },
    {
      "id": "activity staining of DLDH diaphorase"
    },
    {
      "id": "protein amount"
    },
    {
      "id": "electron-accepting molecules"
    },
    {
      "id": "nicotinamide adenine dinucleotide (reduced form)"
    },
    {
      "id": "DLDH dehydrogenase activity"
    },
    {
      "id": "Histochemical staining"
    },
    {
      "id": "effects of thiol-reactive reagents"
    },
    {
      "id": "diaphorase activity staining"
    },
    {
      "id": "nongradient BN-PAGE (9%)"
    },
    {
      "id": "NAD(+)"
    },
    {
      "id": "blue native PAGE"
    },
    {
      "id": "NEM"
    },
    {
      "id": "electron acceptor"
    },
    {
      "id": "ubiquinone"
    },
    {
      "id": "cPLA2alpha C2 domain"
    },
    {
      "id": "physiological Ca2+ levels"
    },
    {
      "id": "C2 domains"
    },
    {
      "id": "Ca2+ binding"
    },
    {
      "id": "PKCalpha"
    },
    {
      "id": "regions of the cell"
    },
    {
      "id": "cell"
    },
    {
      "id": "cPLA2alpha"
    },
    {
      "id": "lipid mixture"
    },
    {
      "id": "plasma membrane inner leaflet"
    },
    {
      "id": "membrane targeting"
    },
    {
      "id": "cellular membrane"
    },
    {
      "id": "phosphatidylinositol-4,5-bisphosphate"
    },
    {
      "id": "target lipids"
    },
    {
      "id": "C2 domain-directed intracellular targeting"
    },
    {
      "id": "coincidence detection"
    },
    {
      "id": "effective Ca2+ affinity"
    },
    {
      "id": "coupled binding equilibrium"
    },
    {
      "id": "functional diversity"
    },
    {
      "id": "MATA"
    },
    {
      "id": "isolated PKCalpha C2 domain"
    },
    {
      "id": "physiological ligand concentrations"
    },
    {
      "id": "targeting studies"
    },
    {
      "id": "Ca2+ activation"
    },
    {
      "id": "PKCalpha C2 domain"
    },
    {
      "id": "localized pools"
    },
    {
      "id": "Ca2+ affinity"
    },
    {
      "id": "PS"
    },
    {
      "id": "target membrane"
    },
    {
      "id": "local concentration"
    },
    {
      "id": "protein kinase Calpha"
    },
    {
      "id": "target docking"
    },
    {
      "id": "membrane surfaces"
    },
    {
      "id": "PIP2"
    },
    {
      "id": "super-physiological concentrations"
    },
    {
      "id": "docking interactions"
    },
    {
      "id": "TAMA mechanism"
    },
    {
      "id": "targeting specificity"
    },
    {
      "id": "physiological bulk Ca2+ concentrations"
    },
    {
      "id": "C2 domain"
    },
    {
      "id": "protein signaling motif"
    },
    {
      "id": "eukaryotic signaling proteins"
    },
    {
      "id": "Stopped-flow kinetic studies"
    },
    {
      "id": "molecular events"
    },
    {
      "id": "TAMA"
    },
    {
      "id": "target-activated messenger affinity"
    },
    {
      "id": "Ca2+-activated membrane docking"
    },
    {
      "id": "physiological Ca2+ signals"
    },
    {
      "id": "messenger-activated target affinity"
    },
    {
      "id": "plasma membrane"
    },
    {
      "id": "internal membranes"
    },
    {
      "id": "internal membrane mimic"
    },
    {
      "id": "multiple signals"
    },
    {
      "id": "cytosolic phospholipase A2alpha"
    },
    {
      "id": "signaling event"
    },
    {
      "id": "membrane docking"
    },
    {
      "id": "C2 domain Ca2+ affinity"
    },
    {
      "id": "Total BAT activity"
    },
    {
      "id": "Liver subcellular organelles"
    },
    {
      "id": "Clofibrate treatment"
    },
    {
      "id": "Subcellular localization"
    },
    {
      "id": "Subcellular distribution"
    },
    {
      "id": "Bile acid coenzyme A:amino acid N-acyltransferase activity"
    },
    {
      "id": "Livers"
    },
    {
      "id": "Subcellular compartments"
    },
    {
      "id": "BAT"
    },
    {
      "id": "Effect"
    },
    {
      "id": "BAT activity"
    },
    {
      "id": "BAT specific activity"
    },
    {
      "id": "Whole liver homogenate"
    },
    {
      "id": "Male rats"
    },
    {
      "id": "Cytosol"
    },
    {
      "id": "Young adult female Sprague-Dawley rats"
    },
    {
      "id": "Quantification"
    },
    {
      "id": "Peroxisomal BAT specific activity"
    },
    {
      "id": "Rosiglitazone"
    },
    {
      "id": "Overall change"
    },
    {
      "id": "Cytosolic BAT specific activity"
    },
    {
      "id": "Female rats"
    },
    {
      "id": "Response"
    },
    {
      "id": "Amidation"
    },
    {
      "id": "Amino acids"
    },
    {
      "id": "Glycine"
    },
    {
      "id": "Regulation"
    },
    {
      "id": "Bile acid coenzyme A:amino acid N-acyltransferase"
    },
    {
      "id": "Peroxisomes"
    },
    {
      "id": "Young adult male Sprague-Dawley rats"
    },
    {
      "id": "Novel finding"
    },
    {
      "id": "Bile acids"
    },
    {
      "id": "Rat liver"
    },
    {
      "id": "Cholestyramine"
    },
    {
      "id": "Peroxisomal matrix"
    },
    {
      "id": "Heavy mitochondrial fraction"
    },
    {
      "id": "Taurine"
    },
    {
      "id": "MK-801"
    },
    {
      "id": "NMDA receptor"
    },
    {
      "id": "energy impairment"
    },
    {
      "id": "Abeta(1-40) toxicity"
    },
    {
      "id": "plasma membrane integrity"
    },
    {
      "id": "NMDA receptors"
    },
    {
      "id": "NR1"
    },
    {
      "id": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate"
    },
    {
      "id": "NR1/NR2A receptors"
    },
    {
      "id": "NR1/NR2A expression"
    },
    {
      "id": "Abeta(1-40)"
    },
    {
      "id": "Abeta"
    },
    {
      "id": "Neurotoxicity"
    },
    {
      "id": "NMDA receptor subtypes"
    },
    {
      "id": "beta-amyloid peptide"
    },
    {
      "id": "glutamate toxicity"
    },
    {
      "id": "intracellular calcium"
    },
    {
      "id": "NR1/NR2A-composed NMDA receptors"
    },
    {
      "id": "calcium homeostasis"
    },
    {
      "id": "NR1/NR2B subunits"
    },
    {
      "id": "single-cell calcium imaging"
    },
    {
      "id": "NR1/NR2B receptor subtypes"
    },
    {
      "id": "beta-amyloid"
    },
    {
      "id": "NR1/NR2A receptor subtypes"
    },
    {
      "id": "intracellular ATP"
    },
    {
      "id": "N-methyl-D-aspartate receptors"
    },
    {
      "id": "NR1/NR2B receptors"
    },
    {
      "id": "NR1/NR2A subunits"
    },
    {
      "id": "necrotic cell death"
    },
    {
      "id": "calpains"
    },
    {
      "id": "NR2A-D subunits"
    },
    {
      "id": "caspases 2, 3, 8 and 9"
    },
    {
      "id": "NR1/NR2A"
    },
    {
      "id": "CYP2C9 variants"
    },
    {
      "id": "CYP2C9*3"
    },
    {
      "id": "explanation"
    },
    {
      "id": "significant difference"
    },
    {
      "id": "low-dose VKORC1*2 haplotype"
    },
    {
      "id": "difficulties"
    },
    {
      "id": "warfarin S/R ratios"
    },
    {
      "id": "patients previously haplotyped for VKORC1"
    },
    {
      "id": "plasma warfarin concentration"
    },
    {
      "id": "VKORC1*4"
    },
    {
      "id": "Dose-dependent variations"
    },
    {
      "id": "(R)-warfarin clearance"
    },
    {
      "id": "VKORC1 haplotype"
    },
    {
      "id": "unidentified factors"
    },
    {
      "id": "stable therapeutic prothrombin time--International Normalized Ratio"
    },
    {
      "id": "Samples"
    },
    {
      "id": "warfarin S/R ratio"
    },
    {
      "id": "result"
    },
    {
      "id": "VKORC1*2"
    },
    {
      "id": "metabolic clearance"
    },
    {
      "id": "CYP2C9*2"
    },
    {
      "id": "(S)-warfarin clearance"
    },
    {
      "id": "warfarin enantiomers"
    },
    {
      "id": "genetic determinant"
    },
    {
      "id": "Nonparametric statistical analysis"
    },
    {
      "id": "warfarin dose requirement"
    },
    {
      "id": "Plasma S/R ratio"
    },
    {
      "id": "two patient groups"
    },
    {
      "id": "high-dose haplotypes VKORC1*3"
    },
    {
      "id": "other factors"
    },
    {
      "id": "VKORC1*3 or VKORC1*4 patients"
    },
    {
      "id": "anticoagulation therapy"
    },
    {
      "id": "acute lymphoblastic leukemia cells"
    },
    {
      "id": "asparagine depletion"
    },
    {
      "id": "increased concentrations of asparagine"
    },
    {
      "id": "asparagine biosynthesis"
    },
    {
      "id": "asparaginase resistance"
    },
    {
      "id": "ALL"
    },
    {
      "id": "children"
    },
    {
      "id": "MSCs"
    },
    {
      "id": "ASNS expression levels"
    },
    {
      "id": "Mesenchymal cells"
    },
    {
      "id": "leukemic cell microenvironment"
    },
    {
      "id": "Asparagine secretion"
    },
    {
      "id": "enforced ASNS expression"
    },
    {
      "id": "enhanced protection"
    },
    {
      "id": "protective effect"
    },
    {
      "id": "asparagine synthetase"
    },
    {
      "id": "bone marrow-derived mesenchymal cells"
    },
    {
      "id": "ASNS"
    },
    {
      "id": "B-lineage ALL"
    },
    {
      "id": "hyperdiploidy"
    },
    {
      "id": "susceptibility"
    },
    {
      "id": "cellular ASNS expression"
    },
    {
      "id": "T-lineage ALL"
    },
    {
      "id": "leukemic cells"
    },
    {
      "id": "microenvironment"
    },
    {
      "id": "asparaginase cytotoxicity"
    },
    {
      "id": "asparaginase"
    },
    {
      "id": "ALL therapy"
    },
    {
      "id": "MSC niches"
    },
    {
      "id": "bone marrow"
    },
    {
      "id": "safe haven"
    },
    {
      "id": "RNA interference"
    },
    {
      "id": "TEL-AML1"
    },
    {
      "id": "protective effects"
    },
    {
      "id": "cysteine 360"
    },
    {
      "id": "covalent adducts"
    },
    {
      "id": "radioactive peptide mapping"
    },
    {
      "id": "reversed-phase high pressure liquid chromatography"
    },
    {
      "id": "lysine 69"
    },
    {
      "id": "sequence PFYAVKC"
    },
    {
      "id": "cyclic imine S-(2-(1-pyrroline)methyl)cysteine"
    },
    {
      "id": "S-((2-pyrrolidine)methyl)cysteine"
    },
    {
      "id": "mouse ornithine decarboxylase"
    },
    {
      "id": "NaBH4"
    },
    {
      "id": "ODCs"
    },
    {
      "id": "DFMO"
    },
    {
      "id": "stable adduct"
    },
    {
      "id": "recombinant enzyme"
    },
    {
      "id": "consensus sequence of SXHK"
    },
    {
      "id": "lysine"
    },
    {
      "id": "mouse sequence"
    },
    {
      "id": "major adduct"
    },
    {
      "id": "[5-14C]DFMO"
    },
    {
      "id": "alpha-difluoromethylornithine"
    },
    {
      "id": "enzyme-activated irreversible inhibitor"
    },
    {
      "id": "peptides"
    },
    {
      "id": "sequence -WGPTCDGL(I)D-"
    },
    {
      "id": "gas-phase peptide sequencing"
    },
    {
      "id": "eukaryote ODCs"
    },
    {
      "id": "S-((2-pyrrole)methyl)cysteine"
    },
    {
      "id": "DFMO-cysteine adduct"
    },
    {
      "id": "total labeling"
    },
    {
      "id": "E. coli"
    },
    {
      "id": "decarboxylases"
    },
    {
      "id": "spectral evidence"
    },
    {
      "id": "carboxymethylated protein"
    },
    {
      "id": "endoproteinase Lys-C"
    },
    {
      "id": "holoenzyme form"
    },
    {
      "id": "NaB[3H]4"
    },
    {
      "id": "tryptic peptides"
    },
    {
      "id": "Delta 6 desaturase"
    },
    {
      "id": "post-D6D products"
    },
    {
      "id": "24:6n-3"
    },
    {
      "id": "competition"
    },
    {
      "id": "docosapentaenoic acid"
    },
    {
      "id": "22:5n-3"
    },
    {
      "id": "ALA"
    },
    {
      "id": "DHA"
    },
    {
      "id": "HepG2 cell membranes"
    },
    {
      "id": "parallel pattern"
    },
    {
      "id": "22:6n-3"
    },
    {
      "id": "HepG2 cell phospholipids"
    },
    {
      "id": ">18 microM ALA"
    },
    {
      "id": "cell membranes"
    },
    {
      "id": "supplemented ALA"
    },
    {
      "id": "18:3n-3"
    },
    {
      "id": "cell phospholipids"
    },
    {
      "id": "1.8-72 microM"
    },
    {
      "id": "fatty acid metabolism"
    },
    {
      "id": "long-chain metabolites"
    },
    {
      "id": "level of DHA"
    },
    {
      "id": "Supplementation"
    },
    {
      "id": "HepG2 cells"
    },
    {
      "id": "24:5n-3"
    },
    {
      "id": "20:5n-3"
    },
    {
      "id": "saturation"
    },
    {
      "id": "preformed DHA"
    },
    {
      "id": "incorporation"
    },
    {
      "id": "Trace amine-associated receptor 1"
    },
    {
      "id": "isomers of methamphetamine"
    },
    {
      "id": "mTAAR1"
    },
    {
      "id": "species-dependent stereoselectivity"
    },
    {
      "id": "METH"
    },
    {
      "id": "POHA"
    },
    {
      "id": "endogenous biogenic amines"
    },
    {
      "id": "AMPH"
    },
    {
      "id": "accumulation of cAMP"
    },
    {
      "id": "HEK-293 cells"
    },
    {
      "id": "trace amines (TAs)"
    },
    {
      "id": "S-(+)-METH"
    },
    {
      "id": "rTAAR1"
    },
    {
      "id": "human embryonic kidney (HEK)-293 cells"
    },
    {
      "id": "rat trace amine-associated receptor 1"
    },
    {
      "id": "beta-phenylethylamine"
    },
    {
      "id": "PEA"
    },
    {
      "id": "species of TAAR1"
    },
    {
      "id": "TYR"
    },
    {
      "id": "rodent TAAR1s"
    },
    {
      "id": "TAAR1"
    },
    {
      "id": "S-(+)-isomers"
    },
    {
      "id": "R-(-)"
    },
    {
      "id": "synthetic amines"
    },
    {
      "id": "catecholamine neurotransmitters"
    },
    {
      "id": "hrChTAAR1"
    },
    {
      "id": "human-rat chimera"
    },
    {
      "id": "h-rChTAAR1"
    },
    {
      "id": "methamphetamine"
    },
    {
      "id": "para-tyramine"
    },
    {
      "id": "isomer"
    },
    {
      "id": "mouse TAAR1"
    },
    {
      "id": "isomers of amphetamine"
    },
    {
      "id": "amphetamine"
    },
    {
      "id": "para-hydroxyamphetamine"
    },
    {
      "id": "in vitro results"
    },
    {
      "id": "enantiomeric selectivity"
    },
    {
      "id": "PDE4 inhibitors"
    },
    {
      "id": "allergic contact dermatitis"
    },
    {
      "id": "anti-inflammatory activity"
    },
    {
      "id": "skin homogenates"
    },
    {
      "id": "chronic obstructive pulmonary disease"
    },
    {
      "id": "skin disorders"
    },
    {
      "id": "arachidonic acid induced skin inflammation"
    },
    {
      "id": "Highly selective phosphodiesterase 4 inhibitors"
    },
    {
      "id": "Th2 dominated acute phase"
    },
    {
      "id": "atopic dermatitis"
    },
    {
      "id": "systemically active PDE4 inhibitors"
    },
    {
      "id": "CC-10004"
    },
    {
      "id": "cipamfylline"
    },
    {
      "id": "topically active PDE4 inhibitors"
    },
    {
      "id": "early clinical trials"
    },
    {
      "id": "ovalbumin sensitised guinea pigs"
    },
    {
      "id": "guinea pigs"
    },
    {
      "id": "Th1 dominated chronic phase"
    },
    {
      "id": "cilomilast"
    },
    {
      "id": "AWD 12-281"
    },
    {
      "id": "clinical evaluation"
    },
    {
      "id": "Results"
    },
    {
      "id": "potent and selective PDE4 inhibitor"
    },
    {
      "id": "GW 842470"
    },
    {
      "id": "phosphodiesterase (PDE) 4"
    },
    {
      "id": "degrading enzyme"
    },
    {
      "id": "topical treatment"
    },
    {
      "id": "non-immune cells"
    },
    {
      "id": "CP80,633"
    },
    {
      "id": "Th1 cytokines"
    },
    {
      "id": "T cells"
    },
    {
      "id": "allergic skin diseases"
    },
    {
      "id": "Th2 cytokines"
    },
    {
      "id": "cyclic AMP"
    },
    {
      "id": "broad anti-inflammatory/immuno-modulatory action"
    },
    {
      "id": "models of allergic and irritant skin inflammation"
    },
    {
      "id": "GLP-1 receptor expression"
    },
    {
      "id": "other tumors"
    },
    {
      "id": "GLP-1 receptors"
    },
    {
      "id": "brain tumors"
    },
    {
      "id": "GLP-1 receptor targeting"
    },
    {
      "id": "nuclear medicine"
    },
    {
      "id": "GLP-1 receptor protein expression"
    },
    {
      "id": "receptor autoradiography"
    },
    {
      "id": "novel molecular target"
    },
    {
      "id": "targeted radiotherapy"
    },
    {
      "id": "nonneoplastic tissues"
    },
    {
      "id": "GLP-1 receptor"
    },
    {
      "id": "insulinomas"
    },
    {
      "id": "lung neuroendocrine tumors"
    },
    {
      "id": "in vivo scintigraphy"
    },
    {
      "id": "GLP-1 receptor-expressing tumors"
    },
    {
      "id": "nonneoplastic human tissues"
    },
    {
      "id": "lymph nodes"
    },
    {
      "id": "in vivo targeting"
    },
    {
      "id": "therapeutic purposes"
    },
    {
      "id": "GLP-1 receptor scintigraphy"
    },
    {
      "id": "low-background signal"
    },
    {
      "id": "lymphomas"
    },
    {
      "id": "receptor binding"
    },
    {
      "id": "glucagon(1-29)"
    },
    {
      "id": "pheochromocytomas"
    },
    {
      "id": "endocrine tumors"
    },
    {
      "id": "gut neuroendocrine tumors"
    },
    {
      "id": "diagnostic purposes"
    },
    {
      "id": "low receptor expression"
    },
    {
      "id": "adrenal gland"
    },
    {
      "id": "human normal tissues"
    },
    {
      "id": "specific tissue compartments"
    },
    {
      "id": "Peptide hormone receptors"
    },
    {
      "id": "(125)I-GLP-1(7-36)amide"
    },
    {
      "id": "GLP-1 receptor identification"
    },
    {
      "id": "carcinomas"
    },
    {
      "id": "embryonic tumors"
    },
    {
      "id": "exendin-4"
    },
    {
      "id": "normal tissues surrounding tumors"
    },
    {
      "id": "Pharmacologic competition experiments"
    },
    {
      "id": "specificity of the procedure"
    },
    {
      "id": "GLP-1(7-36)amide"
    },
    {
      "id": "GLP-2"
    },
    {
      "id": "somatostatin receptors"
    },
    {
      "id": "cation modulation"
    },
    {
      "id": "extracellular acidification"
    },
    {
      "id": "dipole"
    },
    {
      "id": "neurotransmitter binding"
    },
    {
      "id": "Na+/Cl- dipole"
    },
    {
      "id": "kainate receptor activation"
    },
    {
      "id": "Kainate-selective ionotropic glutamate receptors"
    },
    {
      "id": "Cl-"
    },
    {
      "id": "GluR6 kinetics"
    },
    {
      "id": "physiological pH"
    },
    {
      "id": "external anions"
    },
    {
      "id": "KARs"
    },
    {
      "id": "cation species"
    },
    {
      "id": "Na+"
    },
    {
      "id": "cations"
    },
    {
      "id": "external Na+"
    },
    {
      "id": "divalent ions"
    },
    {
      "id": "external ions"
    },
    {
      "id": "GluR6 KARs"
    },
    {
      "id": "Na+ and Cl- ions"
    },
    {
      "id": "docking order"
    },
    {
      "id": "common effect on KARs"
    },
    {
      "id": "ions of opposite charge"
    },
    {
      "id": "divalent and alkali metal ions"
    },
    {
      "id": "time course of KAR channel activity"
    },
    {
      "id": "time KARs remain in the open state"
    },
    {
      "id": "GluRs"
    },
    {
      "id": "neurotransmitter L-glutamate"
    },
    {
      "id": "GluR6 receptors"
    },
    {
      "id": "KAR activation"
    },
    {
      "id": "charged amino acids"
    },
    {
      "id": "tethered ions"
    },
    {
      "id": "novel gating feature"
    },
    {
      "id": "kainate receptors"
    },
    {
      "id": "agonist binding"
    },
    {
      "id": "kinetic assay"
    },
    {
      "id": "inosine 5'-monophosphate dehydrogenase activity"
    },
    {
      "id": "DNA samples"
    },
    {
      "id": "PCR amplification"
    },
    {
      "id": "mycophenolic acid inhibition"
    },
    {
      "id": "L263F variant"
    },
    {
      "id": "inter-individual difference"
    },
    {
      "id": "baseline inosine 5'-monophosphate dehydrogenase activity"
    },
    {
      "id": "Genetic variant"
    },
    {
      "id": "transplant recipients"
    },
    {
      "id": "mycophenolic acid"
    },
    {
      "id": "Variants"
    },
    {
      "id": "inter-individual variability"
    },
    {
      "id": "baseline enzyme activity"
    },
    {
      "id": "transplant patients"
    },
    {
      "id": "Inosine 5'-monophosphate dehydrogenase 2"
    },
    {
      "id": "purine synthesis"
    },
    {
      "id": "nonsynonymous variant L263F"
    },
    {
      "id": "Nine genetic variants"
    },
    {
      "id": "rarer alleles"
    },
    {
      "id": "bidirectional direct DNA sequencing"
    },
    {
      "id": "exon/intron junctions"
    },
    {
      "id": "IMPDH2 genes"
    },
    {
      "id": "IMPDH2"
    },
    {
      "id": "genetic diversity"
    },
    {
      "id": "L263F"
    },
    {
      "id": "immunosuppressive efficacy"
    },
    {
      "id": "wild-type"
    },
    {
      "id": "side effects"
    },
    {
      "id": "variant Km"
    },
    {
      "id": "inosine 5'-monophosphate"
    },
    {
      "id": "solid organ transplant patients"
    },
    {
      "id": "exons"
    },
    {
      "id": "inosine 5'-monophosphate dehydrogenase-deficient strain"
    },
    {
      "id": "drug efficacy"
    },
    {
      "id": "human inosine 5'-monophosphate dehydrogenase 2"
    },
    {
      "id": "Escherichia coli h712"
    },
    {
      "id": "activated lymphocytes"
    },
    {
      "id": "enzymatic activity"
    },
    {
      "id": "reduced nicotinamide adenine dinucleotide production"
    },
    {
      "id": "nicotinamide adenine dinucleotide"
    },
    {
      "id": "novel functional variant"
    },
    {
      "id": "IMPDH2 variants"
    },
    {
      "id": "IMPDH2 gene"
    },
    {
      "id": "mRNA expressions"
    },
    {
      "id": "Panax notoginseng saponins"
    },
    {
      "id": "cerebral ischemia-reperfusion"
    },
    {
      "id": "caspase-1"
    },
    {
      "id": "brain tissue"
    },
    {
      "id": "mRNA expression levels"
    },
    {
      "id": "IL-1RI"
    },
    {
      "id": "cysteinyl-aspartate specific protease-1"
    },
    {
      "id": "sham-operation group"
    },
    {
      "id": "cerebral injury"
    },
    {
      "id": "IL-1 beta"
    },
    {
      "id": "cerebral ischemia"
    },
    {
      "id": "cysteinyl-aspartate specific protease"
    },
    {
      "id": "reverse transcription polymerase chain reaction assay"
    },
    {
      "id": "mRNA expression level"
    },
    {
      "id": "Focal cerebral ischemia reperfusion"
    },
    {
      "id": "correlative factors"
    },
    {
      "id": "interleukin-1 beta"
    },
    {
      "id": "IL-1ra"
    },
    {
      "id": "intercellular adhesion molecule-1"
    },
    {
      "id": "method of nylon monofilament"
    },
    {
      "id": "statistical differences"
    },
    {
      "id": "correlative inflammatory factors"
    },
    {
      "id": "interleukin-1 receptor type I"
    },
    {
      "id": "internal carotid artery"
    },
    {
      "id": "PNS group"
    },
    {
      "id": "interleukin-1 receptor antagonist"
    },
    {
      "id": "visual P1 component"
    },
    {
      "id": "polymorphic modulation"
    },
    {
      "id": "common genetic polymorphism"
    },
    {
      "id": "auditory N1 component amplitude"
    },
    {
      "id": "T allele homozygotes"
    },
    {
      "id": "Ser543Ser"
    },
    {
      "id": "early components"
    },
    {
      "id": "Parallel modulation"
    },
    {
      "id": "early latency modality-specific event-related potential (ERP) components"
    },
    {
      "id": "task factors"
    },
    {
      "id": "cognitive event-related potentials"
    },
    {
      "id": "both modalities"
    },
    {
      "id": "top-down modulation"
    },
    {
      "id": "sense thymine-to-cytosine polymorphism"
    },
    {
      "id": "audition"
    },
    {
      "id": "early event-related potentials"
    },
    {
      "id": "auditory and visual oddball target detection tasks"
    },
    {
      "id": "sensory processing"
    },
    {
      "id": "modalities"
    },
    {
      "id": "c.1629T-C"
    },
    {
      "id": "CHRNA4 polymorphism"
    },
    {
      "id": "auditory and visual modalities"
    },
    {
      "id": "human nicotinic alpha4beta2 receptor"
    },
    {
      "id": "C allele carriers"
    },
    {
      "id": "Nicotine receptor gene CHRNA4"
    },
    {
      "id": "vision"
    },
    {
      "id": "reliable indication"
    },
    {
      "id": "TCR-induced calcium release"
    },
    {
      "id": "Jurkat T lymphocytes"
    },
    {
      "id": "calponin homology domain"
    },
    {
      "id": "calcium mobilization"
    },
    {
      "id": "TCR"
    },
    {
      "id": "calmodulin"
    },
    {
      "id": "calcium"
    },
    {
      "id": "calponin homology (CH) domain"
    },
    {
      "id": "Vav1"
    },
    {
      "id": "calcium flux"
    },
    {
      "id": "CH domain"
    },
    {
      "id": "binding site"
    },
    {
      "id": "Vav1 CH domain"
    },
    {
      "id": "calcium signaling"
    },
    {
      "id": "T cell development"
    },
    {
      "id": "Jurkat cells"
    },
    {
      "id": "calmodulin inhibitor"
    },
    {
      "id": "multiple structural domains"
    },
    {
      "id": "T cell antigen receptor"
    },
    {
      "id": "guanine nucleotide exchange activity"
    },
    {
      "id": "J.Vav1"
    },
    {
      "id": "calcium release"
    },
    {
      "id": "vav1-null Jurkat T cells"
    },
    {
      "id": "scaffold function"
    },
    {
      "id": "CH-deleted Vav1"
    },
    {
      "id": "nuclear factor of activated T cells"
    },
    {
      "id": "TCR activation"
    },
    {
      "id": "guanine nucleotide exchange factor"
    },
    {
      "id": "hematopoietic cells"
    },
    {
      "id": "VIAAT"
    },
    {
      "id": "Neuroendocrine cell line"
    },
    {
      "id": "Vesicles"
    },
    {
      "id": "GlyT2"
    },
    {
      "id": "Neuronal transporter"
    },
    {
      "id": "Mechanisms"
    },
    {
      "id": "Vesicular inhibitory phenotype"
    },
    {
      "id": "Point mutation"
    },
    {
      "id": "GABA transmission"
    },
    {
      "id": "Glycine specificity"
    },
    {
      "id": "Cytosolic availability"
    },
    {
      "id": "VIAAT-containing terminals"
    },
    {
      "id": "Uptake"
    },
    {
      "id": "High cytosolic glycine concentration"
    },
    {
      "id": "Vesicular loading"
    },
    {
      "id": "Vesicular glycinergic phenotype"
    },
    {
      "id": "Mixed events"
    },
    {
      "id": "GABA"
    },
    {
      "id": "Inhibitory transmitters"
    },
    {
      "id": "UNC-47"
    },
    {
      "id": "Plasmalemmal transporters"
    },
    {
      "id": "Caenorhabditis elegans"
    },
    {
      "id": "Species"
    },
    {
      "id": "Glycine exocytosis"
    },
    {
      "id": "Inhibitory interneurons"
    },
    {
      "id": "Vertebrates"
    },
    {
      "id": "Glycine transmission"
    },
    {
      "id": "Worm"
    },
    {
      "id": "GlyT1"
    },
    {
      "id": "Quantal release"
    },
    {
      "id": "Transporters"
    },
    {
      "id": "Neurons"
    },
    {
      "id": "VIAAT ortholog"
    },
    {
      "id": "Reverse mode"
    },
    {
      "id": "Secretory cell"
    },
    {
      "id": "Glial transporter"
    },
    {
      "id": "Double-sniffer patch-clamp technique"
    },
    {
      "id": "Postnatal development"
    },
    {
      "id": "Vesicular inhibitory amino acid transporter"
    },
    {
      "id": "AODs"
    },
    {
      "id": "Biochemical assessments"
    },
    {
      "id": "Female adults with intellectual disability"
    },
    {
      "id": "Physically active subjects"
    },
    {
      "id": "Relationship"
    },
    {
      "id": "Long-term physical activity"
    },
    {
      "id": "Antioxidant defense (AOD)"
    },
    {
      "id": "GPX"
    },
    {
      "id": "Superoxide dismutase"
    },
    {
      "id": "Inactivity"
    },
    {
      "id": "Persons with ID"
    },
    {
      "id": "Plasma vitamin levels"
    },
    {
      "id": "Sedentary control subjects"
    },
    {
      "id": "Control subjects"
    },
    {
      "id": "Vitamin A"
    },
    {
      "id": "Adults with ID"
    },
    {
      "id": "SOD"
    },
    {
      "id": "Active female adults"
    },
    {
      "id": "Glutathione peroxidase"
    },
    {
      "id": "Nonactive female adults"
    },
    {
      "id": "Nonrandomized study"
    },
    {
      "id": "Physically active lifestyle"
    },
    {
      "id": "Lifestyle"
    },
    {
      "id": "Regular physical activity"
    },
    {
      "id": "Inactive persons with ID"
    },
    {
      "id": "CAT"
    },
    {
      "id": "Sedentary lifestyle"
    },
    {
      "id": "Physical activity"
    },
    {
      "id": "Plasma antioxidant status"
    },
    {
      "id": "Inactive lifestyle"
    },
    {
      "id": "Total antioxidant status"
    },
    {
      "id": "Prospective study"
    },
    {
      "id": "Antioxidant defense (AOD) system"
    },
    {
      "id": "Oxidative stress (OS)"
    },
    {
      "id": "Low levels of antioxidants"
    },
    {
      "id": "Contractile tension"
    },
    {
      "id": "contraction"
    },
    {
      "id": "alpha(1)-AR triple-KO mice"
    },
    {
      "id": "alpha(1A)-adrenoceptors"
    },
    {
      "id": "vas deferens"
    },
    {
      "id": "ejaculation"
    },
    {
      "id": "attenuation of contractility"
    },
    {
      "id": "electrically stimulated vas deferens"
    },
    {
      "id": "lower urinary tract symptoms"
    },
    {
      "id": "physiological contribution"
    },
    {
      "id": "alpha(1)-adrenoceptor subtype-selective knockout (KO) mice"
    },
    {
      "id": "fertility"
    },
    {
      "id": "Alpha(1)-adrenoceptor antagonists"
    },
    {
      "id": "Alpha1-adrenoceptors"
    },
    {
      "id": "male sexual function"
    },
    {
      "id": "molecular level"
    },
    {
      "id": "alpha(1)-adrenoceptor subtypes"
    },
    {
      "id": "pregnancy rate"
    },
    {
      "id": "sperm ejaculation"
    },
    {
      "id": "alpha(1A)-adrenoceptor KO mice"
    },
    {
      "id": "alpha(1A)-, alpha(1B)- and alpha(1D)-AR KO mice"
    },
    {
      "id": "vascular response"
    },
    {
      "id": "ejaculatory dysfunction"
    },
    {
      "id": "mutagenesis"
    },
    {
      "id": "proposed dual action mechanism of SPD"
    },
    {
      "id": "dynamics simulations"
    },
    {
      "id": "conformational \"open-closed\" process"
    },
    {
      "id": "mechanism of the dual action of SPD"
    },
    {
      "id": "dual action mechanism"
    },
    {
      "id": "signal transduction model"
    },
    {
      "id": "(-)-Stepholidine (SPD)"
    },
    {
      "id": "dopamine receptor D1 agonist"
    },
    {
      "id": "computational approach"
    },
    {
      "id": "binding entrances"
    },
    {
      "id": "dopamine receptors"
    },
    {
      "id": "biophysical experiments"
    },
    {
      "id": "SPD"
    },
    {
      "id": "D1 receptors"
    },
    {
      "id": "active ingredient"
    },
    {
      "id": "Chinese herb Stephania"
    },
    {
      "id": "protein structure prediction"
    },
    {
      "id": "D2 receptors"
    },
    {
      "id": "molecular dynamics simulations"
    },
    {
      "id": "surface features"
    },
    {
      "id": "Potential binding conformations"
    },
    {
      "id": "natural product (-)-stepholidine"
    },
    {
      "id": "D2 receptor"
    },
    {
      "id": "D1 and D2 receptors"
    },
    {
      "id": "D1-SPD structure"
    },
    {
      "id": "K-167_EL-2-E-302_EL-3 salt bridge"
    },
    {
      "id": "electrostatic potentials"
    },
    {
      "id": "Insights"
    },
    {
      "id": "dynamical behaviors"
    },
    {
      "id": "modeling"
    },
    {
      "id": "subsequent signal transduction model"
    },
    {
      "id": "interaction modes"
    },
    {
      "id": "structural and functional characteristics"
    },
    {
      "id": "simulations"
    },
    {
      "id": "binding of SPD"
    },
    {
      "id": "extracellular domain"
    },
    {
      "id": "D2 antagonist"
    },
    {
      "id": "Dopamine D1 receptor"
    },
    {
      "id": "D2-SPD complexes"
    },
    {
      "id": "experimental data"
    },
    {
      "id": "D1-SPD complexes"
    },
    {
      "id": "automated molecular docking"
    },
    {
      "id": "dual function"
    },
    {
      "id": "Isothiocyanates"
    },
    {
      "id": "urinary excretion"
    },
    {
      "id": "chemopreventive properties"
    },
    {
      "id": "odds ratio (OR)"
    },
    {
      "id": "confidence interval (CI)"
    },
    {
      "id": "GSTT1 null"
    },
    {
      "id": "multicentric case-control study"
    },
    {
      "id": "Czech Republic"
    },
    {
      "id": "cancer prevention"
    },
    {
      "id": "P-interaction"
    },
    {
      "id": "Central and Eastern European Kidney Cancer Study"
    },
    {
      "id": "cruciferous vegetable intake"
    },
    {
      "id": "Glutathione S-transferase polymorphisms"
    },
    {
      "id": "functional or non-synonymous polymorphisms"
    },
    {
      "id": "GSTT1 deletion"
    },
    {
      "id": "gene-diet interactions"
    },
    {
      "id": "GSTM3 3 bp deletion"
    },
    {
      "id": "low intake of cruciferous vegetables"
    },
    {
      "id": "relationship"
    },
    {
      "id": "host genetic factors"
    },
    {
      "id": "GSTM1 deletion"
    },
    {
      "id": "cruciferous vegetables"
    },
    {
      "id": "cases"
    },
    {
      "id": "genotyped cases"
    },
    {
      "id": "P-trend"
    },
    {
      "id": "kidney cancer risks"
    },
    {
      "id": "GSTM1/T1 null genotypes"
    },
    {
      "id": "cancer risk"
    },
    {
      "id": "evidence"
    },
    {
      "id": "high intake of cruciferous vegetables"
    },
    {
      "id": "food group"
    },
    {
      "id": "IVS6 + 22-AGG"
    },
    {
      "id": "GST genotype"
    },
    {
      "id": "V224I G>A substitution"
    },
    {
      "id": "Romania"
    },
    {
      "id": "glutathione S-transferases"
    },
    {
      "id": "Poland"
    },
    {
      "id": "kidney cancer risk"
    },
    {
      "id": "GSTs"
    },
    {
      "id": "Russia"
    },
    {
      "id": "GSTP1 I105V A>G substitution"
    },
    {
      "id": "common, functional genetic polymorphisms"
    },
    {
      "id": "PHD oxygen sensors"
    },
    {
      "id": "effectors"
    },
    {
      "id": "cellular signalling pathways"
    },
    {
      "id": "HIFalpha stability"
    },
    {
      "id": "hydroxylated HIFalpha"
    },
    {
      "id": "proteasomal degradation"
    },
    {
      "id": "oxygen availability"
    },
    {
      "id": "prolyl-4-hydroxylase domain (PHD) proteins"
    },
    {
      "id": "Cellular oxygen"
    },
    {
      "id": "vitamin C"
    },
    {
      "id": "gallic acid"
    },
    {
      "id": "functions of these antioxidants"
    },
    {
      "id": "cobalt"
    },
    {
      "id": "vitamin C oxidation"
    },
    {
      "id": "Krebs cycle intermediates"
    },
    {
      "id": "physiological relevance"
    },
    {
      "id": "PHD abundance"
    },
    {
      "id": "normoxic conditions"
    },
    {
      "id": "hypoxic conditions"
    },
    {
      "id": "HIFalpha stabilization"
    },
    {
      "id": "Copper"
    },
    {
      "id": "n-propyl gallate"
    },
    {
      "id": "all three PHDs"
    },
    {
      "id": "N-acetyl-L-cysteine"
    },
    {
      "id": "von Hippel-Lindau (pVHL) tumor suppressor"
    },
    {
      "id": "prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins"
    },
    {
      "id": "cellular concentrations"
    },
    {
      "id": "ubiquitinylation"
    },
    {
      "id": "drug targets"
    },
    {
      "id": "purified PHD1 to 3"
    },
    {
      "id": "cell-free in vitro microtiter plate-based peptide hydroxylation assay"
    },
    {
      "id": "influence"
    },
    {
      "id": "hypoxia-inducible factor (HIF) alpha subunits"
    },
    {
      "id": "ferrous iron"
    },
    {
      "id": "hydroxylation"
    },
    {
      "id": "nickel salts"
    },
    {
      "id": "transition metals"
    },
    {
      "id": "prostaglandin synthesis"
    },
    {
      "id": "prostaglandin"
    },
    {
      "id": "convulsions"
    },
    {
      "id": "hippocampal neurons"
    },
    {
      "id": "PTZ"
    },
    {
      "id": "whole brain homogenate"
    },
    {
      "id": "kindling score"
    },
    {
      "id": "kindling epilepsy"
    },
    {
      "id": "Brain"
    },
    {
      "id": "cyclooxygenases"
    },
    {
      "id": "biochemical alterations"
    },
    {
      "id": "cortical neurons"
    },
    {
      "id": "PTZ-kindled mice"
    },
    {
      "id": "biochemical parameters"
    },
    {
      "id": "whole brain"
    },
    {
      "id": "PTZ-induced kindling"
    },
    {
      "id": "myeloperoxidase"
    },
    {
      "id": "nitrite"
    },
    {
      "id": "neuroprotection"
    },
    {
      "id": "chemical kindling"
    },
    {
      "id": "normal control group"
    },
    {
      "id": "kindling"
    },
    {
      "id": "subconvulsive dose"
    },
    {
      "id": "scoring scale"
    },
    {
      "id": "18-kDa integral nuclear membrane protein"
    },
    {
      "id": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism"
    },
    {
      "id": "proton"
    },
    {
      "id": "hydroxyl group"
    },
    {
      "id": "LTC4S"
    },
    {
      "id": "xenobiotics"
    },
    {
      "id": "three cysteinyl leukotriene ligands"
    },
    {
      "id": "5-lipoxygenase pathway"
    },
    {
      "id": "threefold symmetric trimer"
    },
    {
      "id": "unit"
    },
    {
      "id": "microsomal prostaglandin E synthase 1"
    },
    {
      "id": "thiolate anion"
    },
    {
      "id": "MGST3"
    },
    {
      "id": "metabolites"
    },
    {
      "id": "LTE4"
    },
    {
      "id": "C6"
    },
    {
      "id": "C5"
    },
    {
      "id": "glutathione metabolism"
    },
    {
      "id": "structural basis"
    },
    {
      "id": "cysteinyl leukotrienes"
    },
    {
      "id": "leukotriene (LT)C4"
    },
    {
      "id": "Crystal structure"
    },
    {
      "id": "human membrane protein"
    },
    {
      "id": "high substrate specificity"
    },
    {
      "id": "MGSTs"
    },
    {
      "id": "atomic structure"
    },
    {
      "id": "human LTC4S"
    },
    {
      "id": "interface"
    },
    {
      "id": "adjacent monomers"
    },
    {
      "id": "LTC4 synthase"
    },
    {
      "id": "LTA4"
    },
    {
      "id": "5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid"
    },
    {
      "id": "LTC4"
    },
    {
      "id": "smooth muscle constriction"
    },
    {
      "id": "proinflammatory pathway"
    },
    {
      "id": "endogenous substrate"
    },
    {
      "id": "X-ray crystallography"
    },
    {
      "id": "insights"
    },
    {
      "id": "functional domains"
    },
    {
      "id": "Arg 31"
    },
    {
      "id": "neighbouring monomer"
    },
    {
      "id": "multiple cysteinyl leukotriene receptors"
    },
    {
      "id": "membrane-associated proteins"
    },
    {
      "id": "Arg 104"
    },
    {
      "id": "monomer"
    },
    {
      "id": "loop structure"
    },
    {
      "id": "U-shaped conformation"
    },
    {
      "id": "LTC4S inhibitors"
    },
    {
      "id": "microsomal glutathione S-transferases"
    },
    {
      "id": "eicosanoid metabolism"
    },
    {
      "id": "complex with glutathione"
    },
    {
      "id": "LTC4S monomer"
    },
    {
      "id": "four transmembrane alpha-helices"
    },
    {
      "id": "biosynthesis of LTC4"
    },
    {
      "id": "3.3 A resolution"
    },
    {
      "id": "thioether bond"
    },
    {
      "id": "5-lipoxygenase-activating protein"
    },
    {
      "id": "functions"
    },
    {
      "id": "slow-reacting substance of anaphylaxis"
    },
    {
      "id": "MGST2"
    },
    {
      "id": "cysteinyl leukotriene biosynthesis"
    },
    {
      "id": "excitotoxicity"
    },
    {
      "id": "beta-N-oxalyl amino-L-alanine"
    },
    {
      "id": "motor neuron disease"
    },
    {
      "id": "pyramidal system"
    },
    {
      "id": "glutaredoxin"
    },
    {
      "id": "L-BOAA"
    },
    {
      "id": "male mice"
    },
    {
      "id": "Therapeutic interventions"
    },
    {
      "id": "female mice"
    },
    {
      "id": "mitochondrial function"
    },
    {
      "id": "L-propargyl glycine"
    },
    {
      "id": "complex I activity"
    },
    {
      "id": "non-protein thiol"
    },
    {
      "id": "antisense oligonucleotides"
    },
    {
      "id": "Estrogen"
    },
    {
      "id": "mitochondrial dysfunction"
    },
    {
      "id": "CNS"
    },
    {
      "id": "glutathione loss"
    },
    {
      "id": "diethyl maleate"
    },
    {
      "id": "neurolathyrism"
    },
    {
      "id": "Oxidative stress"
    },
    {
      "id": "neurodegeneration"
    },
    {
      "id": "thiol groups"
    },
    {
      "id": "thiol homeostasis"
    },
    {
      "id": "L-BOAA toxicity"
    },
    {
      "id": "mitochondrial complex I loss"
    },
    {
      "id": "redox status"
    },
    {
      "id": "AP1"
    },
    {
      "id": "cellular redox status"
    },
    {
      "id": "thiol disulfide oxidoreductase"
    },
    {
      "id": "antioxidant"
    },
    {
      "id": "protein thiol homeostasis"
    },
    {
      "id": "Ovariectomy"
    },
    {
      "id": "mitochondrial complex I"
    },
    {
      "id": "motor neurons"
    },
    {
      "id": "alpha-methyl-DL-aspartate"
    },
    {
      "id": "AS"
    },
    {
      "id": "NO formation"
    },
    {
      "id": "L-citrulline formation"
    },
    {
      "id": "L-citrulline recycling"
    },
    {
      "id": "citrulline-NO cycle"
    },
    {
      "id": "NO production"
    },
    {
      "id": "L-citrulline"
    },
    {
      "id": "Endothelial nitric oxide production"
    },
    {
      "id": "L-arginine"
    },
    {
      "id": "[14C]-L-arginine"
    },
    {
      "id": "argininosuccinate synthase"
    },
    {
      "id": "DISPERSE"
    },
    {
      "id": "Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST-segment Elevation myocardial infarction"
    },
    {
      "id": "4-week intervals"
    },
    {
      "id": "standard regimen"
    },
    {
      "id": "loading dose"
    },
    {
      "id": "AZD6140"
    },
    {
      "id": "antiplatelet effects"
    },
    {
      "id": "reversible oral P2Y(12) receptor antagonist"
    },
    {
      "id": "day 1"
    },
    {
      "id": "Adenosine diphosphate"
    },
    {
      "id": "4-h postdose"
    },
    {
      "id": "P2Y12 receptor antagonist"
    },
    {
      "id": "acute coronary syndromes"
    },
    {
      "id": "clopidogrel-pretreated patients"
    },
    {
      "id": "DISPERSE-2"
    },
    {
      "id": "poor inhibition of platelet aggregation"
    },
    {
      "id": "optical aggregometry"
    },
    {
      "id": "monoamine oxidase inhibition"
    },
    {
      "id": "elevation in brain ORN"
    },
    {
      "id": "Phenelzine"
    },
    {
      "id": "brain ornithine"
    },
    {
      "id": "therapeutic properties"
    },
    {
      "id": "PLZ"
    },
    {
      "id": "dose- and time-response studies"
    },
    {
      "id": "GABA-T"
    },
    {
      "id": "GABA-transaminase"
    },
    {
      "id": "ORN"
    },
    {
      "id": "TCP"
    },
    {
      "id": "MAO inhibitor"
    },
    {
      "id": "brain GABA levels"
    },
    {
      "id": "PLZ doses"
    },
    {
      "id": "PLZ-induced increase in brain ORN"
    },
    {
      "id": "increased ORN"
    },
    {
      "id": "neuroprotective properties"
    },
    {
      "id": "Pretreatment"
    },
    {
      "id": "MAO"
    },
    {
      "id": "nonselective irreversible inhibitor"
    },
    {
      "id": "monoamine oxidase"
    },
    {
      "id": "ORN levels"
    },
    {
      "id": "PLZ-treated animals"
    },
    {
      "id": "escitalopram"
    },
    {
      "id": "citalopram"
    },
    {
      "id": "discontinuation symptoms"
    },
    {
      "id": "panic disorder"
    },
    {
      "id": "social phobia"
    },
    {
      "id": "pharmacological aspects"
    },
    {
      "id": "selective serotonin re-uptake inhibitors"
    },
    {
      "id": "muscarinic receptors"
    },
    {
      "id": "transporter proteins"
    },
    {
      "id": "multiple-dose pharmacokinetics"
    },
    {
      "id": "drugs metabolised by CYP2D6"
    },
    {
      "id": "impulse control disorders"
    },
    {
      "id": "anxiety disorders"
    },
    {
      "id": "CYP isozymes"
    },
    {
      "id": "histamine H1"
    },
    {
      "id": "(S)-enantiomer of citalopram"
    },
    {
      "id": "bioavailability"
    },
    {
      "id": "first-line agent"
    },
    {
      "id": "major depression"
    },
    {
      "id": "protein binding"
    },
    {
      "id": "serotonin re-uptake"
    },
    {
      "id": "obsessive-compulsive disorder"
    },
    {
      "id": "elderly"
    },
    {
      "id": "generalised anxiety disorder"
    },
    {
      "id": "Phenserine"
    },
    {
      "id": "cognition"
    },
    {
      "id": "translational efficiency"
    },
    {
      "id": "iron-responsive element"
    },
    {
      "id": "(+)-Posiphen"
    },
    {
      "id": "(-)-phenserine"
    },
    {
      "id": "AChE"
    },
    {
      "id": "active enantiomer"
    },
    {
      "id": "beta-amyloid precursor protein"
    },
    {
      "id": "5'-untranslated region"
    },
    {
      "id": "APP gene"
    },
    {
      "id": "Phase II studies"
    },
    {
      "id": "progression of Alzheimer's disease"
    },
    {
      "id": "APP expression"
    },
    {
      "id": "(+)-phenserine"
    },
    {
      "id": "AChE inhibitor"
    },
    {
      "id": "enantiomers"
    },
    {
      "id": "APP mRNA"
    },
    {
      "id": "regulatory element"
    },
    {
      "id": "posiphen"
    },
    {
      "id": "APP translation"
    },
    {
      "id": "acetylcholinesterase"
    },
    {
      "id": "APP"
    },
    {
      "id": "graft"
    },
    {
      "id": "extension"
    },
    {
      "id": "patient survival"
    },
    {
      "id": "three year"
    },
    {
      "id": "Mean serum creatinine"
    },
    {
      "id": "mg/dL"
    },
    {
      "id": "first 36 months"
    },
    {
      "id": "Graft survival"
    },
    {
      "id": "one yr"
    },
    {
      "id": "mean total cholesterol"
    },
    {
      "id": "mTOR inhibitors"
    },
    {
      "id": "proliferation signal inhibitors"
    },
    {
      "id": "first long-term prospective study"
    },
    {
      "id": "regimen of everolimus, cyclosporine, and corticosteroids"
    },
    {
      "id": "four patients"
    },
    {
      "id": "statin therapy"
    },
    {
      "id": "prospective clinical trials"
    },
    {
      "id": "CNI inhibitors"
    },
    {
      "id": "extension study"
    },
    {
      "id": "two yr"
    },
    {
      "id": "Mean daily dose of everolimus"
    },
    {
      "id": "mg/m(2) BSA"
    },
    {
      "id": "Biopsy-proven acute rejection"
    },
    {
      "id": "one patient"
    },
    {
      "id": "three patients"
    },
    {
      "id": "Group 2"
    },
    {
      "id": "Multicenter trial"
    },
    {
      "id": "multicenter, open-label study"
    },
    {
      "id": "de novo pediatric renal transplant patients"
    },
    {
      "id": "mm/L"
    },
    {
      "id": "microm/L"
    },
    {
      "id": "three cases of viral infection"
    },
    {
      "id": "one case of cytomegalovirus infection"
    },
    {
      "id": "pediatric renal transplant recipients"
    },
    {
      "id": "Biopsy-proven chronic allograft rejection"
    },
    {
      "id": "de novo pediatric renal transplantation"
    },
    {
      "id": "Group 1"
    },
    {
      "id": "study medication"
    },
    {
      "id": "remaining 16 patients"
    },
    {
      "id": "everolimus"
    },
    {
      "id": "each age group"
    },
    {
      "id": "H3R mRNA"
    },
    {
      "id": "BDL cholangiocytes"
    },
    {
      "id": "RAMH"
    },
    {
      "id": "cholangiocyte proliferation"
    },
    {
      "id": "BDL rats"
    },
    {
      "id": "Galpha(i/o) proteins"
    },
    {
      "id": "cholangiocyte hyperplasia/damage"
    },
    {
      "id": "thioperamide maleate"
    },
    {
      "id": "H3R"
    },
    {
      "id": "PKA"
    },
    {
      "id": "immunofluorescence"
    },
    {
      "id": "Histamine"
    },
    {
      "id": "H2R"
    },
    {
      "id": "biliary growth"
    },
    {
      "id": "ELK-1 pathway"
    },
    {
      "id": "extracellular signal-regulated kinase 1/2"
    },
    {
      "id": "cholangiocyte growth"
    },
    {
      "id": "H1R"
    },
    {
      "id": "Elk-1"
    },
    {
      "id": "cholangiocyte hyperplasia"
    },
    {
      "id": "ets-like gene-1"
    },
    {
      "id": "cholangiocytes"
    },
    {
      "id": "cAMP-dependent PKA"
    },
    {
      "id": "H4R"
    },
    {
      "id": "(R)-(alpha)-(-)-methylhistamine dihydrobromide"
    },
    {
      "id": "histamine G-coupled receptor proteins"
    },
    {
      "id": "cholangiocyte RNA"
    },
    {
      "id": "adenosine 3', 5'-monophosphate"
    },
    {
      "id": "AQP5 protein level"
    },
    {
      "id": "SMG"
    },
    {
      "id": "parasympathetic denervation"
    },
    {
      "id": "chorda tympani"
    },
    {
      "id": "extract"
    },
    {
      "id": "AQP5 protein"
    },
    {
      "id": "aquaporin 5"
    },
    {
      "id": "AQP5"
    },
    {
      "id": "denervation of the cervical sympathetic trunk"
    },
    {
      "id": "sympathectomy"
    },
    {
      "id": "cevimeline"
    },
    {
      "id": "M3 muscarinic receptor agonist"
    },
    {
      "id": "Degradation"
    },
    {
      "id": "rat submandibular gland"
    },
    {
      "id": "submandibular lysosomal fraction"
    },
    {
      "id": "recovery"
    },
    {
      "id": "CTD"
    },
    {
      "id": "mRNA level"
    },
    {
      "id": "AQP1 protein level"
    },
    {
      "id": "parasympathectomy"
    },
    {
      "id": "chloroquine"
    },
    {
      "id": "denaturant"
    },
    {
      "id": "cevimeline hydrochloride"
    },
    {
      "id": "transcriptional mechanism"
    },
    {
      "id": "lysosomes"
    },
    {
      "id": "chorda tympani denervation"
    },
    {
      "id": "pilocarpine"
    },
    {
      "id": "total membrane fraction"
    },
    {
      "id": "submandibular gland"
    },
    {
      "id": "parasympathetic nerves"
    },
    {
      "id": "contralateral gland"
    },
    {
      "id": "spread of malignant gliomas"
    },
    {
      "id": "stathmin"
    },
    {
      "id": "migration"
    },
    {
      "id": "Nitrosoureas"
    },
    {
      "id": "therapeutic benefits"
    },
    {
      "id": "cell movement-related processes"
    },
    {
      "id": "[1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]"
    },
    {
      "id": "CCNU"
    },
    {
      "id": "neoplastic cells"
    },
    {
      "id": "surrounding brain"
    },
    {
      "id": "antiproliferative effects"
    },
    {
      "id": "down-regulation of cellular stathmin levels"
    },
    {
      "id": "cellular stathmin levels"
    },
    {
      "id": "Malignant gliomas"
    },
    {
      "id": "primary intrinsic brain tumors"
    },
    {
      "id": "stathmin expression"
    },
    {
      "id": "lesions"
    },
    {
      "id": "microtubule-destabilizing protein"
    },
    {
      "id": "malignant glioma cell motility"
    },
    {
      "id": "cell movement"
    },
    {
      "id": "cell cycle progression"
    },
    {
      "id": "inhibition of stathmin"
    },
    {
      "id": "sublethal nitrosourea concentrations"
    },
    {
      "id": "initial site of tumor formation"
    },
    {
      "id": "DNA alkylating agents"
    },
    {
      "id": "N-desethyloxybutynin"
    },
    {
      "id": "cholinergic side effects"
    },
    {
      "id": "(3)H-NMS"
    },
    {
      "id": "m2"
    },
    {
      "id": "R enantiomers"
    },
    {
      "id": "S enantiomers"
    },
    {
      "id": "human cloned muscarinic m1-5 receptors"
    },
    {
      "id": "Oxybutynin"
    },
    {
      "id": "binding assay"
    },
    {
      "id": "human muscarinic receptor"
    },
    {
      "id": "parent drug"
    },
    {
      "id": "m1, m3 and m4 receptors"
    },
    {
      "id": "parent compound"
    },
    {
      "id": "muscarinic receptor"
    },
    {
      "id": "major metabolite"
    },
    {
      "id": "urinary incontinence"
    },
    {
      "id": "m1 and m3 receptors"
    },
    {
      "id": "m5"
    },
    {
      "id": "R-enantiomer"
    },
    {
      "id": "non-selective muscarinic receptor antagonist"
    },
    {
      "id": "FCGR2A"
    },
    {
      "id": "rituximab"
    },
    {
      "id": "FCGR2A, any histidine allele"
    },
    {
      "id": "FCGR2A arginine/arginine"
    },
    {
      "id": "Combined analysis"
    },
    {
      "id": "unfavorable genotypes"
    },
    {
      "id": "metastatic colorectal cancer patients"
    },
    {
      "id": "Cetuximab"
    },
    {
      "id": "antibody-dependent cell-mediated cytotoxicity (ADCC)"
    },
    {
      "id": "role of ADCC of cetuximab"
    },
    {
      "id": "gene polymorphisms"
    },
    {
      "id": "allele-specific polymerase chain reaction (PCR) -based method"
    },
    {
      "id": "favorable genotypes"
    },
    {
      "id": "FCGR3A-V158F"
    },
    {
      "id": "progression-free survival (PFS)"
    },
    {
      "id": "FCGA3A-V158F"
    },
    {
      "id": "IgG FcgammaR polymorphisms"
    },
    {
      "id": "FCGR2A-H131R"
    },
    {
      "id": "FCGR3A, any phenylalanine allele"
    },
    {
      "id": "FCGA2A-H131R"
    },
    {
      "id": "genomic DNA"
    },
    {
      "id": "valine/valine"
    },
    {
      "id": "single-agent cetuximab"
    },
    {
      "id": "ImClone0144 trial"
    },
    {
      "id": "Fragment c"
    },
    {
      "id": "follicular lymphoma"
    },
    {
      "id": "peripheral blood samples"
    },
    {
      "id": "FCGR3A polymorphisms"
    },
    {
      "id": "IgG1 mAb"
    },
    {
      "id": "median PFS"
    },
    {
      "id": "Fragment c (Fc) portion"
    },
    {
      "id": "metastatic colorectal cancer (CRC)"
    },
    {
      "id": "molecular markers"
    },
    {
      "id": "Fragment c gamma receptors (FcgammaR)"
    },
    {
      "id": "chimeric immunoglobulin G 1 (IgG1) anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb)"
    },
    {
      "id": "preliminary data"
    },
    {
      "id": "trastuzumab"
    },
    {
      "id": "FcgammaR"
    },
    {
      "id": "HepG2"
    },
    {
      "id": "hepatocyte cell line"
    },
    {
      "id": "amiodarone"
    },
    {
      "id": "B2-O-CH(2)CH(2)-N-diethyl"
    },
    {
      "id": "basic nitrogen"
    },
    {
      "id": "group"
    },
    {
      "id": "B2-O-CH(2)-CH(2)-N-pyrrolidine"
    },
    {
      "id": "organ toxicity"
    },
    {
      "id": "amiodarone analogues"
    },
    {
      "id": "2-n-butyl-3-[3,5 diiodo-4-diethylaminoethoxybenzoyl]-benzofuran"
    },
    {
      "id": "human ether-a-go-go-related protein (hERG) channel inhibition"
    },
    {
      "id": "B2-O-CH(2)-CH(2)-N-piperidine"
    },
    {
      "id": "hERG channel"
    },
    {
      "id": "acid"
    },
    {
      "id": "mitochondrial involvement"
    },
    {
      "id": "hERG channel interaction"
    },
    {
      "id": "phenolic side chain"
    },
    {
      "id": "B2-O-CH(2)-CH(2)-N-diisopropyl"
    },
    {
      "id": "structural analogues"
    },
    {
      "id": "B2-O-CH(2)-CH(2)-OH"
    },
    {
      "id": "alcohol"
    },
    {
      "id": "A549 cells"
    },
    {
      "id": "pneumocyte line"
    },
    {
      "id": "B2-O-CH(2)-COOH"
    },
    {
      "id": "mono- and bis-desethylated metabolites"
    },
    {
      "id": "Interactions"
    },
    {
      "id": "pharmacological methods"
    },
    {
      "id": "in silico methods"
    },
    {
      "id": "class III antiarrhythmic drug"
    },
    {
      "id": "gas chromatography"
    },
    {
      "id": "holo-alpha-lactalbumin"
    },
    {
      "id": "alpha-lactalbumin"
    },
    {
      "id": "Apo-alpha-lactalbumin"
    },
    {
      "id": "association constants"
    },
    {
      "id": "apo-forms of human alpha-lactalbumin"
    },
    {
      "id": "EDTA"
    },
    {
      "id": "nondenaturing conditions"
    },
    {
      "id": "partition equilibrium method"
    },
    {
      "id": "holo-forms of human alpha-lactalbumin"
    },
    {
      "id": "oleic and palmitic acids"
    },
    {
      "id": "human alpha-lactalbumin"
    },
    {
      "id": "binding parameters"
    },
    {
      "id": "neomycin"
    },
    {
      "id": "cholesteryl esters"
    },
    {
      "id": "lower-density lipoproteins"
    },
    {
      "id": "acipimox"
    },
    {
      "id": "LDL"
    },
    {
      "id": "absorbable agents"
    },
    {
      "id": "lipid-lowering agents"
    },
    {
      "id": "arterial disease"
    },
    {
      "id": "reverse transport"
    },
    {
      "id": "nonabsorbable compounds"
    },
    {
      "id": "anion-exchange resins"
    },
    {
      "id": "VLDL"
    },
    {
      "id": "plasma very-low-density lipoproteins"
    },
    {
      "id": "gastrointestinal lumen"
    },
    {
      "id": "LDL receptor expression"
    },
    {
      "id": "low-density lipoproteins"
    },
    {
      "id": "liver high-affinity lipoprotein receptors"
    },
    {
      "id": "beta-sitosterol"
    },
    {
      "id": "recirculation"
    },
    {
      "id": "patient's phenotype"
    },
    {
      "id": "pharmacological treatment"
    },
    {
      "id": "fibric acids"
    },
    {
      "id": "LDL delipidation"
    },
    {
      "id": "receptor uptake"
    },
    {
      "id": "hypercholesterolemia"
    },
    {
      "id": "high-density lipoproteins"
    },
    {
      "id": "hyperlipoproteinemias"
    },
    {
      "id": "transaminase enzymes"
    },
    {
      "id": "N2-acetylphenelzine"
    },
    {
      "id": "phenelzine"
    },
    {
      "id": "neurochemical properties"
    },
    {
      "id": "whole-brain levels"
    },
    {
      "id": "gamma-aminobutyric acid"
    },
    {
      "id": "amino acid neurotransmitters"
    },
    {
      "id": "rat model"
    },
    {
      "id": "3,4-dihydroxyphenylacetic acetic"
    },
    {
      "id": "monoamine oxidase-A"
    },
    {
      "id": "5-hydroxyindole-3-acetic acid"
    },
    {
      "id": "monoamine oxidase-B"
    },
    {
      "id": "N2 position"
    },
    {
      "id": "biogenic amines"
    },
    {
      "id": "homovanillic acid"
    },
    {
      "id": "Lapatinib"
    },
    {
      "id": "capecitabine"
    },
    {
      "id": "HER2-positive, locally advanced breast cancer"
    },
    {
      "id": "anthracycline"
    },
    {
      "id": "response rate"
    },
    {
      "id": "GW572016"
    },
    {
      "id": "time to progression"
    },
    {
      "id": "hazard ratio"
    },
    {
      "id": "high-fat meal"
    },
    {
      "id": "T(max)"
    },
    {
      "id": "clinical toxicities"
    },
    {
      "id": "pivotal clinical trial"
    },
    {
      "id": "malignancies"
    },
    {
      "id": "MBC"
    },
    {
      "id": "inflammatory breast cancer"
    },
    {
      "id": "English-language publications"
    },
    {
      "id": "MEDLINE"
    },
    {
      "id": "Phase III trial"
    },
    {
      "id": "rash"
    },
    {
      "id": "21-day cycle"
    },
    {
      "id": "diarrhea"
    },
    {
      "id": "taxane"
    },
    {
      "id": "Cardiac toxicity"
    },
    {
      "id": "dosing"
    },
    {
      "id": "human epidermal growth factor receptor"
    },
    {
      "id": "San Antonio Breast Cancer Symposium"
    },
    {
      "id": "PO QD"
    },
    {
      "id": "tyrosine kinases"
    },
    {
      "id": "drug accumulation"
    },
    {
      "id": "t(1/2)"
    },
    {
      "id": "standard treatment"
    },
    {
      "id": "HER2"
    },
    {
      "id": "CI"
    },
    {
      "id": "continuous dosing"
    },
    {
      "id": "ErbB2"
    },
    {
      "id": "human epidermal growth factor receptor 2"
    },
    {
      "id": "cytochrome P450 3A4 isozyme"
    },
    {
      "id": "Phase II trials"
    },
    {
      "id": "FDA Web site"
    },
    {
      "id": "fatigue"
    },
    {
      "id": "central nervous system metastases"
    },
    {
      "id": "grades"
    },
    {
      "id": "solid tumor types"
    },
    {
      "id": "American Society of Clinical Oncology abstracts database"
    },
    {
      "id": "US Food and Drug Administration"
    },
    {
      "id": "Captopril"
    },
    {
      "id": "MMP-9"
    },
    {
      "id": "monocrotaline"
    },
    {
      "id": "matrix metalloproteinase-9"
    },
    {
      "id": "echocardiography"
    },
    {
      "id": "right ventricular dysfunction"
    },
    {
      "id": "matrix metalloproteinase-2"
    },
    {
      "id": "MMP-2"
    },
    {
      "id": "cardiomyocyte hypertrophy"
    },
    {
      "id": "right ventricular sections"
    },
    {
      "id": "right ventricular weight/tail length ratio"
    },
    {
      "id": "right ventricular hypertrophy"
    },
    {
      "id": "ACE"
    },
    {
      "id": "fibrosis"
    },
    {
      "id": "angiotensin converting enzyme (ACE) inhibitors"
    },
    {
      "id": "Western blotting"
    },
    {
      "id": "matrix metalloproteinase (MMP)"
    },
    {
      "id": "right ventricular remodeling"
    },
    {
      "id": "pulmonary artery pressure"
    },
    {
      "id": "gelatin zymography"
    },
    {
      "id": "angiotensin converting enzyme"
    },
    {
      "id": "5alpha-reductase inhibitors (5alphaRIs)"
    },
    {
      "id": "lower urinary tract symptoms (LUTS)"
    },
    {
      "id": "benign prostatic hyperplasia (BPH)"
    },
    {
      "id": "Cochrane databases"
    },
    {
      "id": "reviews"
    },
    {
      "id": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)"
    },
    {
      "id": "terms"
    },
    {
      "id": "oxybutynin"
    },
    {
      "id": "increased risk"
    },
    {
      "id": "urinary retention"
    },
    {
      "id": "dutasteride"
    },
    {
      "id": "finasteride"
    },
    {
      "id": "statistically significant benefits"
    },
    {
      "id": "IPSS scores"
    },
    {
      "id": "Combination of Avodart and Tamsulosin study"
    },
    {
      "id": "key trials"
    },
    {
      "id": "addition of an anti-muscarinic agent"
    },
    {
      "id": "highly select cohort of men"
    },
    {
      "id": "propiverine"
    },
    {
      "id": "anti-muscarinic agents"
    },
    {
      "id": "relevant trials"
    },
    {
      "id": "rate of clinical progression"
    },
    {
      "id": "combination medical therapy"
    },
    {
      "id": "Avodart"
    },
    {
      "id": "monotherapy"
    },
    {
      "id": "detrusor overactivity"
    },
    {
      "id": "adequate alleviation of symptoms"
    },
    {
      "id": "first-line alpha(1)-ARAs"
    },
    {
      "id": "Medical Therapy of Prostatic Symptoms (MTOPS) study"
    },
    {
      "id": "long-term use"
    },
    {
      "id": "available data"
    },
    {
      "id": "severe symptoms"
    },
    {
      "id": "disease progression"
    },
    {
      "id": "finasteride monotherapy"
    },
    {
      "id": "risk of acute urinary retention"
    },
    {
      "id": "tolterodine"
    },
    {
      "id": "patient satisfaction"
    },
    {
      "id": "recent trials"
    },
    {
      "id": "2-year preliminary results"
    },
    {
      "id": "vardenafil"
    },
    {
      "id": "anticholinergics"
    },
    {
      "id": "doxazosin monotherapy"
    },
    {
      "id": "urinary frequency"
    },
    {
      "id": "component"
    },
    {
      "id": "overactive bladder"
    },
    {
      "id": "International Prostate Symptom Score (IPSS)"
    },
    {
      "id": "quality of life scores"
    },
    {
      "id": "storage symptoms"
    },
    {
      "id": "erectile dysfunction"
    },
    {
      "id": "larger prostate size"
    },
    {
      "id": "symptoms of bladder outlet obstruction"
    },
    {
      "id": "flavoxate"
    },
    {
      "id": "Theoretic concerns"
    },
    {
      "id": "alfuzosin"
    },
    {
      "id": "niflumic acid"
    },
    {
      "id": "Panx1 currents"
    },
    {
      "id": "flufenamic acid"
    },
    {
      "id": "frequency of functional expression"
    },
    {
      "id": "mouse Panx1"
    },
    {
      "id": "indanyloxyacetic acid 94"
    },
    {
      "id": "Pannexin (Panx) 1"
    },
    {
      "id": "gap junction proteins"
    },
    {
      "id": "variants"
    },
    {
      "id": "functional properties"
    },
    {
      "id": "Panx1"
    },
    {
      "id": "gap junctions"
    },
    {
      "id": "DIDS"
    },
    {
      "id": "P2X(7)R antagonist"
    },
    {
      "id": "hemichannel"
    },
    {
      "id": "passage"
    },
    {
      "id": "pharmacological characterization"
    },
    {
      "id": "pannexin-1 currents"
    },
    {
      "id": "probenecid"
    },
    {
      "id": "connexins"
    },
    {
      "id": "purine receptors"
    },
    {
      "id": "human Panx1 variants"
    },
    {
      "id": "disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate"
    },
    {
      "id": "P2X(7)R"
    },
    {
      "id": "5-nitro-2-(3-phenylpropylamino)benzoic acid"
    },
    {
      "id": "UTP"
    },
    {
      "id": "pharmacological properties"
    },
    {
      "id": "panx1 expression"
    },
    {
      "id": "P2X(7)R activation"
    },
    {
      "id": "carbenoxolone"
    },
    {
      "id": "ATP-evoked currents"
    },
    {
      "id": "human PANX1 gene"
    },
    {
      "id": "GTP"
    },
    {
      "id": "localization patterns"
    },
    {
      "id": "large molecules"
    },
    {
      "id": "disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate"
    },
    {
      "id": "phospholipase C transduction"
    },
    {
      "id": "P2X(7)R currents"
    },
    {
      "id": "purinergic P2X(7) receptor"
    },
    {
      "id": "Triphosphate nucleotides"
    },
    {
      "id": "Panx1-mediated currents"
    },
    {
      "id": "extracellular calcium"
    },
    {
      "id": "plasma membrane hemichannel"
    },
    {
      "id": "PNH"
    },
    {
      "id": "BCS"
    },
    {
      "id": "terminal complement"
    },
    {
      "id": "key complement regulatory protein"
    },
    {
      "id": "CD59"
    },
    {
      "id": "hepatic artery thrombosis"
    },
    {
      "id": "retransplantation"
    },
    {
      "id": "Budd-Chiari syndrome"
    },
    {
      "id": "intravascular complement-mediated lysis"
    },
    {
      "id": "hemoglobinuria"
    },
    {
      "id": "anti-complement antibody"
    },
    {
      "id": "eculizumab"
    },
    {
      "id": "case reports"
    },
    {
      "id": "paroxysmal nocturnal hemoglobinuria"
    },
    {
      "id": "Affected red blood cells"
    },
    {
      "id": "PNH patients"
    },
    {
      "id": "early thrombotic portal vein occlusion"
    },
    {
      "id": "liver transplantation"
    },
    {
      "id": "venous thromboses"
    },
    {
      "id": "somatic mutations"
    },
    {
      "id": "phosphatidylinositol glycan-complementation class A gene"
    },
    {
      "id": "humanized monoclonal antibody"
    },
    {
      "id": "recurrent BCS"
    },
    {
      "id": "rare, acquired hemolytic anemia"
    },
    {
      "id": "anemia"
    },
    {
      "id": "Hepatic venous outflow thrombosis"
    },
    {
      "id": "D1-like receptors"
    },
    {
      "id": "D3 dopamine receptor"
    },
    {
      "id": "D2-like receptor family"
    },
    {
      "id": "Vascular smooth muscle cell (VSMC) proliferation"
    },
    {
      "id": "vascular diseases"
    },
    {
      "id": "VSMC proliferation"
    },
    {
      "id": "immortalized aortic A10 cells"
    },
    {
      "id": "insulin-induced VSMC proliferation"
    },
    {
      "id": "insulin-mediated VSMC proliferation"
    },
    {
      "id": "fenoldopam"
    },
    {
      "id": "D1-like receptor agonist"
    },
    {
      "id": "stimulatory effect"
    },
    {
      "id": "MAP kinase"
    },
    {
      "id": "humoral factors"
    },
    {
      "id": "important role"
    },
    {
      "id": "regulation of blood pressure"
    },
    {
      "id": "pathogenesis"
    },
    {
      "id": "essential hypertension"
    },
    {
      "id": "insulin"
    },
    {
      "id": "insulin-induced vascular smooth muscle cell proliferation"
    },
    {
      "id": "Insulin"
    },
    {
      "id": "proliferative hormone"
    },
    {
      "id": "insulin receptor expression"
    },
    {
      "id": "insulin receptor mRNA"
    },
    {
      "id": "Dl-like receptors"
    },
    {
      "id": "SCH23390"
    },
    {
      "id": "D1-like receptor antagonist"
    },
    {
      "id": "Fenoldopam"
    },
    {
      "id": "D1-like receptor"
    },
    {
      "id": "MAP kinase inhibitor"
    },
    {
      "id": "aberrant insulin"
    },
    {
      "id": "Dl-like receptor functions"
    },
    {
      "id": "[H]-thymidine incorporation"
    },
    {
      "id": "PKC"
    },
    {
      "id": "RAMP3 residues"
    },
    {
      "id": "wild-type RAMPs"
    },
    {
      "id": "insert-negative form of the calcitonin receptor"
    },
    {
      "id": "Targeted substitution"
    },
    {
      "id": "Position 74"
    },
    {
      "id": "Calcitonin-family receptors"
    },
    {
      "id": "calcitonin receptor-like receptor (CL)"
    },
    {
      "id": "CL-based receptors"
    },
    {
      "id": "RAMPs"
    },
    {
      "id": "G protein-coupled receptor pharmacology"
    },
    {
      "id": "AM affinity"
    },
    {
      "id": "Mutant RAMP/CT(a) receptor complexes"
    },
    {
      "id": "phenotypes"
    },
    {
      "id": "CL/RAMP3"
    },
    {
      "id": "AM2 receptor"
    },
    {
      "id": "RAMP2"
    },
    {
      "id": "CL/RAMP2"
    },
    {
      "id": "N-terminal receptor activity-modifying protein residues"
    },
    {
      "id": "amylin receptor"
    },
    {
      "id": "Amylin (Amy) receptors"
    },
    {
      "id": "RAMP hetero-oligomers"
    },
    {
      "id": "CT(a)"
    },
    {
      "id": "RAMP1"
    },
    {
      "id": "receptor pharmacology"
    },
    {
      "id": "calcitonin receptor"
    },
    {
      "id": "AMY3"
    },
    {
      "id": "RAMP3"
    },
    {
      "id": "adrenomedullin (AM) receptors"
    },
    {
      "id": "Cos7 cells"
    },
    {
      "id": "AM1 receptor"
    },
    {
      "id": "alphaCGRP potency"
    },
    {
      "id": "CGRP receptors"
    },
    {
      "id": "Mutant RAMPs"
    },
    {
      "id": "calcitonin gene-related peptide"
    },
    {
      "id": "AMY1"
    },
    {
      "id": "AM receptors"
    },
    {
      "id": "RAMP1 residues"
    },
    {
      "id": "AM pharmacology"
    },
    {
      "id": "AM potency"
    },
    {
      "id": "RAMP1 S103N"
    },
    {
      "id": "rAmy potency"
    },
    {
      "id": "Calcitonin gene-related peptide (CGRP) receptors"
    },
    {
      "id": "CL/RAMP1"
    },
    {
      "id": "Phe93"
    },
    {
      "id": "AMY2"
    },
    {
      "id": "receptor activity-modifying protein (RAMP)"
    },
    {
      "id": "Agonist-stimulated cAMP production"
    },
    {
      "id": "W74E mutations"
    },
    {
      "id": "cell-surface expression"
    },
    {
      "id": "complexes"
    },
    {
      "id": "RAMP1/RAMP3"
    },
    {
      "id": "goal"
    },
    {
      "id": "calcium antagonist"
    },
    {
      "id": "class"
    },
    {
      "id": "clinically approved antihypertensive drugs"
    },
    {
      "id": "isradipine"
    },
    {
      "id": "available antihypertensive drugs"
    },
    {
      "id": "therapeutically relevant concentrations"
    },
    {
      "id": "Antihypertensive drugs"
    },
    {
      "id": "progress"
    },
    {
      "id": "pharmacology T-type Ca(2+) channels"
    },
    {
      "id": "mixed T- and L-type blockers"
    },
    {
      "id": "T-type channels"
    },
    {
      "id": "cardiac pacemaking"
    },
    {
      "id": "cell line"
    },
    {
      "id": "recombinant Ca(v)3.2 channels"
    },
    {
      "id": "nifedipine"
    },
    {
      "id": "potent T-channel blockers"
    },
    {
      "id": "physiological role"
    },
    {
      "id": "L-type Ca(2+) channels"
    },
    {
      "id": "human Cav3.2 T-type Ca2+ channels"
    },
    {
      "id": "analogs"
    },
    {
      "id": "calcium channel blocker"
    },
    {
      "id": "classes of compounds"
    },
    {
      "id": "dihydropyridines"
    },
    {
      "id": "renal hemodynamics"
    },
    {
      "id": "efonidipine"
    },
    {
      "id": "phenylalkylamines"
    },
    {
      "id": "nitrendipine"
    },
    {
      "id": "research studies"
    },
    {
      "id": "L-type currents"
    },
    {
      "id": "selective L-type blockers"
    },
    {
      "id": "Ca(v)3.2 T-type channel"
    },
    {
      "id": "Molecular pharmacology"
    },
    {
      "id": "present results"
    },
    {
      "id": "notion"
    },
    {
      "id": "felodipine"
    },
    {
      "id": "Ca(2+) influx assay"
    },
    {
      "id": "mibefradil"
    },
    {
      "id": "antiarrhythmics"
    },
    {
      "id": "substantial fraction"
    },
    {
      "id": "T-current"
    },
    {
      "id": "antihypertensives"
    },
    {
      "id": "aldosterone secretion"
    },
    {
      "id": "widely prescribed dihydropyridines"
    },
    {
      "id": "Sergliflozin etabonate"
    },
    {
      "id": "antihyperglycemic effects"
    },
    {
      "id": "diabetic condition"
    },
    {
      "id": "normal rats"
    },
    {
      "id": "SGLT2"
    },
    {
      "id": "glucose reabsorption"
    },
    {
      "id": "urinary glucose excretion"
    },
    {
      "id": "dose-dependent manner"
    },
    {
      "id": "glycemic response"
    },
    {
      "id": "postprandial hyperglycemia"
    },
    {
      "id": "glycated hemoglobin"
    },
    {
      "id": "selective SGLT2 inhibitor"
    },
    {
      "id": "plasma glucose"
    },
    {
      "id": "low-affinity sodium glucose cotransporter"
    },
    {
      "id": "hypoglycemia"
    },
    {
      "id": "unique approach"
    },
    {
      "id": "diabetic rats"
    },
    {
      "id": "plasma glucose level"
    },
    {
      "id": "gliclazide"
    },
    {
      "id": "sulfonylurea"
    },
    {
      "id": "streptozotocin-induced diabetic rats"
    },
    {
      "id": "Zucker fatty rats"
    },
    {
      "id": "mild streptozotocin-induced diabetes"
    },
    {
      "id": "novel therapeutic target"
    },
    {
      "id": "glucose loading"
    },
    {
      "id": "glycemic control"
    },
    {
      "id": "body weight gain"
    },
    {
      "id": "sucrose loading"
    },
    {
      "id": "selective inhibition of SGLT2"
    },
    {
      "id": "voglibose"
    },
    {
      "id": "alpha-glucosidase inhibitor"
    },
    {
      "id": "treatment of diabetes"
    },
    {
      "id": "report"
    },
    {
      "id": "moderate streptozotocin-induced diabetes"
    },
    {
      "id": "neonatal streptozotocin-induced diabetic rats"
    },
    {
      "id": "inhibition constants K(i)"
    },
    {
      "id": "capillary"
    },
    {
      "id": "30 mM borate-phosphate buffer"
    },
    {
      "id": "procedure"
    },
    {
      "id": "screening"
    },
    {
      "id": "plugs"
    },
    {
      "id": "AChE solution"
    },
    {
      "id": "waiting period"
    },
    {
      "id": "2 min"
    },
    {
      "id": "applicability"
    },
    {
      "id": "proposed methodology"
    },
    {
      "id": "reaction product"
    },
    {
      "id": "thiocholine"
    },
    {
      "id": "method"
    },
    {
      "id": "AChE Inhibitor screening"
    },
    {
      "id": "acetylthiocholine"
    },
    {
      "id": "capillary electrophoresis"
    },
    {
      "id": "acetylcholinesterase inhibitors"
    },
    {
      "id": "peak area"
    },
    {
      "id": "neostigmine"
    },
    {
      "id": "bibliographic values"
    },
    {
      "id": "TCh"
    },
    {
      "id": "inhibitory action mechanism"
    },
    {
      "id": "CE"
    },
    {
      "id": "in vitro evaluation"
    },
    {
      "id": "pH 8.0"
    },
    {
      "id": "capillary inlet methodology"
    },
    {
      "id": "capillary inlet"
    },
    {
      "id": "edrophonium"
    },
    {
      "id": "effectiveness"
    },
    {
      "id": "methodology"
    },
    {
      "id": "substrate solution"
    },
    {
      "id": "water"
    },
    {
      "id": "230 nm"
    },
    {
      "id": "threo-methylphenidate"
    },
    {
      "id": "d-MPH"
    },
    {
      "id": "monoamines"
    },
    {
      "id": "Haloperidol"
    },
    {
      "id": "Occupancy"
    },
    {
      "id": "Dopamine D(2/3) binding"
    },
    {
      "id": "Drug-naive patients"
    },
    {
      "id": "Midbrain"
    },
    {
      "id": "Dopamine D(2/3) receptor apparent binding potential (BPapp)"
    },
    {
      "id": "Ligand [(123)I]epidepride"
    },
    {
      "id": "Statistically significant differences"
    },
    {
      "id": "Clozapine group"
    },
    {
      "id": "Single-photon emission computed tomography (SPECT)"
    },
    {
      "id": "Medication"
    },
    {
      "id": "Clozapine"
    },
    {
      "id": "Temporal poles"
    },
    {
      "id": "Comparison group"
    },
    {
      "id": "Healthy controls"
    },
    {
      "id": "Olanzapine"
    },
    {
      "id": "Schizophrenia"
    },
    {
      "id": "Temporal cortex"
    },
    {
      "id": "Overestimation"
    },
    {
      "id": "Antipsychotics"
    },
    {
      "id": "Midbrain dopamine D(2/3) receptor BP(app)"
    },
    {
      "id": "Typical antipsychotics"
    },
    {
      "id": "Dopamine D(2) receptor modulation"
    },
    {
      "id": "Olanzapine group"
    },
    {
      "id": "Second-generation antipsychotics"
    },
    {
      "id": "Brain areas"
    },
    {
      "id": "Dopamine D2/3 receptor"
    },
    {
      "id": "Therapeutic efficacy"
    },
    {
      "id": "Midbrain dopamine D(2/3) occupancy"
    },
    {
      "id": "Altered nigrostriatal dopamine neurotransmission"
    },
    {
      "id": "Dopamine transmission"
    },
    {
      "id": "Extrastriatal brain regions"
    },
    {
      "id": "Classical antipsychotics"
    },
    {
      "id": "Haloperidol group"
    },
    {
      "id": "Acute phase of schizophrenia"
    },
    {
      "id": "Clinical relevance"
    },
    {
      "id": "Cortical dopamine D(2/3) receptors"
    },
    {
      "id": "percent content"
    },
    {
      "id": "low-molecular-weight heparins (LMWHs)"
    },
    {
      "id": "Enoxaparin"
    },
    {
      "id": "shorter oligosaccharides"
    },
    {
      "id": "high affinity (HA) pools"
    },
    {
      "id": "HSQC"
    },
    {
      "id": "correlations"
    },
    {
      "id": "chain distribution"
    },
    {
      "id": "AT-bs"
    },
    {
      "id": "differences"
    },
    {
      "id": "Structural features"
    },
    {
      "id": "biological activities"
    },
    {
      "id": "content"
    },
    {
      "id": "pentasaccharide"
    },
    {
      "id": "length"
    },
    {
      "id": "antithrombin (AT)"
    },
    {
      "id": "molecular weight parameters"
    },
    {
      "id": "parent LMWHs"
    },
    {
      "id": "distribution"
    },
    {
      "id": "chain length oligosaccharides"
    },
    {
      "id": "Dalteparin"
    },
    {
      "id": "SE chromatographic system"
    },
    {
      "id": "HSQC-NMR spectra"
    },
    {
      "id": "Tinzaparin"
    },
    {
      "id": "absolute molecular weights"
    },
    {
      "id": "signals"
    },
    {
      "id": "disaccharide sequence G-A*"
    },
    {
      "id": "triple detector (TDA)"
    },
    {
      "id": "no affinity (NA) pools"
    },
    {
      "id": "terminal groups"
    },
    {
      "id": "size-exclusion (SE) chromatography"
    },
    {
      "id": "uronic acid residues"
    },
    {
      "id": "2D-NMR spectra"
    },
    {
      "id": "structure-activity relationships"
    },
    {
      "id": "longest chains"
    },
    {
      "id": "SE chromatograms"
    },
    {
      "id": "investigation"
    },
    {
      "id": "glucosamine"
    },
    {
      "id": "AT-binding sequence A-G-A*-I-A (AT-bs)"
    },
    {
      "id": "AT-mediated anticoagulant activity"
    },
    {
      "id": "HA species"
    },
    {
      "id": "selected fractions"
    },
    {
      "id": "sulfate substituents"
    },
    {
      "id": "Alterations"
    },
    {
      "id": "number"
    },
    {
      "id": "capacity"
    },
    {
      "id": "peripheral alpha-2B adrenergic receptors"
    },
    {
      "id": "biologic effects"
    },
    {
      "id": "etomidate"
    },
    {
      "id": "hemodynamic profile"
    },
    {
      "id": "other anesthetics"
    },
    {
      "id": "hypotension"
    },
    {
      "id": "abnormal responses"
    },
    {
      "id": "etomidate induction"
    },
    {
      "id": "Alpha-2B adrenergic receptor"
    },
    {
      "id": "anesthesia"
    },
    {
      "id": "vasoconstriction"
    },
    {
      "id": "hemodynamic parameters"
    },
    {
      "id": "cardiovascular stability"
    },
    {
      "id": "cardiopulmonary compromise"
    },
    {
      "id": "N-carbamylglutamate"
    },
    {
      "id": "branched-chain organic acidemias"
    },
    {
      "id": "methylmalonic acidemias"
    },
    {
      "id": "competitive inhibition"
    },
    {
      "id": "N-acetylglutamate synthetase"
    },
    {
      "id": "propionic acidemias"
    },
    {
      "id": "Hyperammonemia"
    },
    {
      "id": "Oral carglumic acid"
    },
    {
      "id": "isovaleric acidemia"
    },
    {
      "id": "autosomal recessive disease"
    },
    {
      "id": "pathophysiological process"
    },
    {
      "id": "dialysis therapy"
    },
    {
      "id": "isovaleryl-CoA dehydrogenase"
    },
    {
      "id": "N-carbamylglutamate treatment"
    },
    {
      "id": "acute neonatal hyperammonemia"
    },
    {
      "id": "leucine metabolism"
    },
    {
      "id": "oral load"
    },
    {
      "id": "carglumic acid"
    },
    {
      "id": "plasma ammonia concentration"
    },
    {
      "id": "Na+ transport processes"
    },
    {
      "id": "human lung epithelial cells"
    },
    {
      "id": "I(ouabain)"
    },
    {
      "id": "I(amiloride)"
    },
    {
      "id": "alpha1-AMPK"
    },
    {
      "id": "ENaC"
    },
    {
      "id": "phenformin"
    },
    {
      "id": "AMPK (alpha1) activity"
    },
    {
      "id": "AICAR"
    },
    {
      "id": "apical amiloride-sensitive Na(+) channels"
    },
    {
      "id": "monolayer resistance"
    },
    {
      "id": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside"
    },
    {
      "id": "adenine nucleotide concentration"
    },
    {
      "id": "H441 lung epithelial cells"
    },
    {
      "id": "metformin"
    },
    {
      "id": "apical Na+ conductance"
    },
    {
      "id": "AMPK activation"
    },
    {
      "id": "H441 cells"
    },
    {
      "id": "air interface"
    },
    {
      "id": "NAD(P)H autofluorescence"
    },
    {
      "id": "confocal microscopy"
    },
    {
      "id": "Compound C"
    },
    {
      "id": "transepithelial resistance"
    },
    {
      "id": "Ussing chambers"
    },
    {
      "id": "cellular ATP"
    },
    {
      "id": "AMP"
    },
    {
      "id": "cellular AMP:ATP ratio"
    },
    {
      "id": "AMP-activated protein kinase"
    },
    {
      "id": "ENaC activity"
    },
    {
      "id": "Pharmacological activators"
    },
    {
      "id": "transepithelial amiloride-sensitive short circuit current"
    },
    {
      "id": "Adenine nucleotide"
    },
    {
      "id": "reverse phase HPLC"
    },
    {
      "id": "AMPK activity"
    },
    {
      "id": "SAMS peptide"
    },
    {
      "id": "radiolabelled phosphate"
    },
    {
      "id": "H441 monolayers"
    },
    {
      "id": "ouabain-sensitive basolateral short circuit current"
    },
    {
      "id": "permeable filters"
    },
    {
      "id": "Na+K+ATPase"
    },
    {
      "id": "cell systems"
    },
    {
      "id": "estramustine phosphate"
    },
    {
      "id": "chick brain MAP2:tubulin microtubules"
    },
    {
      "id": "MAP2"
    },
    {
      "id": "molecules of estramustine phosphate"
    },
    {
      "id": "MAP2:tubulin interaction"
    },
    {
      "id": "tubulin-binding sites"
    },
    {
      "id": "moles"
    },
    {
      "id": "Kd"
    },
    {
      "id": "microM estramustine phosphate"
    },
    {
      "id": "basic residues"
    },
    {
      "id": "MAP2 sites"
    },
    {
      "id": "tubulin"
    },
    {
      "id": "role of fulvestrant"
    },
    {
      "id": "current treatment guidelines"
    },
    {
      "id": "FDA approval"
    },
    {
      "id": "effective and well-tolerated drug"
    },
    {
      "id": "treatment of metastatic estrogen-sensitive breast cancer"
    },
    {
      "id": "progression"
    },
    {
      "id": "loss of disease control"
    },
    {
      "id": "Published scientific literature"
    },
    {
      "id": "fulvestrant"
    },
    {
      "id": "selected publications"
    },
    {
      "id": "expected disease course"
    },
    {
      "id": "current issues"
    },
    {
      "id": "therapies for estrogen-sensitive breast cancer"
    },
    {
      "id": "combination with other therapies"
    },
    {
      "id": "hormone-refractory state"
    },
    {
      "id": "ongoing investigations"
    },
    {
      "id": "presented abstracts"
    },
    {
      "id": "present"
    },
    {
      "id": "potential advantages"
    },
    {
      "id": "estrogen targeted therapies"
    },
    {
      "id": "unique mechanism of action"
    },
    {
      "id": "estrogen deprivation"
    },
    {
      "id": "treatment of breast cancer"
    },
    {
      "id": "antiendocrine agent"
    },
    {
      "id": "clinical benefit"
    },
    {
      "id": "antiestrogen therapeutic armamentarium"
    },
    {
      "id": "Work"
    },
    {
      "id": "Pharmacologic advances"
    },
    {
      "id": "1800s"
    },
    {
      "id": "estrogen-sensitive breast cancer"
    },
    {
      "id": "2002"
    },
    {
      "id": "relapses"
    },
    {
      "id": "past decades"
    },
    {
      "id": "pure estrogen receptor downregulator"
    },
    {
      "id": "mortality of estrogen-sensitive breast cancer"
    },
    {
      "id": "1985"
    },
    {
      "id": "CINV"
    },
    {
      "id": "acute phase"
    },
    {
      "id": "Intravenous palonosetron"
    },
    {
      "id": "dolasetron"
    },
    {
      "id": "acute-phase CINV"
    },
    {
      "id": "adult patients"
    },
    {
      "id": "Palonosetron"
    },
    {
      "id": "oral palonosetron"
    },
    {
      "id": "US"
    },
    {
      "id": "option"
    },
    {
      "id": "MEC"
    },
    {
      "id": "pharmacological profile"
    },
    {
      "id": "first-generation 5-HT3 receptor antagonists"
    },
    {
      "id": "postoperative nausea and vomiting (PONV)"
    },
    {
      "id": "surgery"
    },
    {
      "id": "HEC"
    },
    {
      "id": "chemotherapy-induced nausea and vomiting (CINV)"
    },
    {
      "id": "formulation"
    },
    {
      "id": "oral formulations"
    },
    {
      "id": "PONV"
    },
    {
      "id": "delayed-phase CINV"
    },
    {
      "id": "PONV prevention"
    },
    {
      "id": "delayed phase"
    },
    {
      "id": "5-HT3 receptor"
    },
    {
      "id": "second-generation serotonin 5-HT3 receptor antagonist"
    },
    {
      "id": "highly emetogenic chemotherapy (HEC)"
    },
    {
      "id": "intravenous ondansetron"
    },
    {
      "id": "intravenous granisetron"
    },
    {
      "id": "moderately emetogenic chemotherapy (MEC)"
    },
    {
      "id": "acute poisoning"
    },
    {
      "id": "organophosphorus pesticides"
    },
    {
      "id": "obidoxime"
    },
    {
      "id": "OP poisoning"
    },
    {
      "id": "OPs"
    },
    {
      "id": "warfare nerve agents"
    },
    {
      "id": "pralidoxime"
    },
    {
      "id": "AChE reactivator"
    },
    {
      "id": "neurotransmission"
    },
    {
      "id": "atropine"
    },
    {
      "id": "pyridinium oximes"
    },
    {
      "id": "antidotes"
    },
    {
      "id": "trimedoxime"
    },
    {
      "id": "carbamate pesticides"
    },
    {
      "id": "antimuscarinic agent"
    },
    {
      "id": "AChE inhibition"
    },
    {
      "id": "respiratory failure"
    },
    {
      "id": "HI-6"
    },
    {
      "id": "OP"
    },
    {
      "id": "Medical treatment"
    },
    {
      "id": "Organophosphorus compounds"
    },
    {
      "id": "pesticides"
    },
    {
      "id": "soman"
    },
    {
      "id": "cholinergic fibers"
    },
    {
      "id": "nervous systems"
    },
    {
      "id": "cholinergic receptor sites"
    },
    {
      "id": "sarin"
    },
    {
      "id": "diazepam"
    },
    {
      "id": "tabun"
    },
    {
      "id": "human medicine"
    },
    {
      "id": "VX"
    },
    {
      "id": "18F-AV-45"
    },
    {
      "id": "autoradiography"
    },
    {
      "id": "plaque labeling"
    },
    {
      "id": "pathogenesis processes"
    },
    {
      "id": "AD"
    },
    {
      "id": "ex vivo autoradiography"
    },
    {
      "id": "transgenic AD model mice"
    },
    {
      "id": "Abeta plaques"
    },
    {
      "id": "monkey"
    },
    {
      "id": "Alzheimer disease (AD)"
    },
    {
      "id": "high brain uptake"
    },
    {
      "id": "healthy mice"
    },
    {
      "id": "in vitro binding"
    },
    {
      "id": "Metabolites"
    },
    {
      "id": "control brains"
    },
    {
      "id": "biomarkers"
    },
    {
      "id": "fibrillary Abeta peptide aggregates"
    },
    {
      "id": "AD brains"
    },
    {
      "id": "beta-amyloid plaques"
    },
    {
      "id": "AD transgenic mice (APPswe/PSEN1)"
    },
    {
      "id": "Abeta aggregates"
    },
    {
      "id": "postmortem AD brain tissue"
    },
    {
      "id": "phase III clinical studies"
    },
    {
      "id": "Imaging agents"
    },
    {
      "id": "Small-animal PET"
    },
    {
      "id": "monkey brain"
    },
    {
      "id": "in vivo biodistribution"
    },
    {
      "id": "in vitro binding assay"
    },
    {
      "id": "PET agent"
    },
    {
      "id": "postmortem human brain sections"
    },
    {
      "id": "rapid washout"
    },
    {
      "id": "living human brain"
    },
    {
      "id": "(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine"
    },
    {
      "id": "triptorelin"
    },
    {
      "id": "Luteinizing hormone-releasing hormone (LHRH) agonists"
    },
    {
      "id": "Clinical data"
    },
    {
      "id": "degarelix"
    },
    {
      "id": "pure GnRH antagonists"
    },
    {
      "id": "decreases"
    },
    {
      "id": "testosterone levels"
    },
    {
      "id": "co-administration"
    },
    {
      "id": "hormonal castration"
    },
    {
      "id": "advanced or metastasizing hormone-dependent prostate carcinoma"
    },
    {
      "id": "antiandrogen"
    },
    {
      "id": "potential effects"
    },
    {
      "id": "Hormonal therapy"
    },
    {
      "id": "locally advanced and metastatic prostate cancer"
    },
    {
      "id": "de-sensitization"
    },
    {
      "id": "complication rate"
    },
    {
      "id": "gonadotrophin-releasing hormone antagonists"
    },
    {
      "id": "agonist effect"
    },
    {
      "id": "leuprorelin"
    },
    {
      "id": "testosterone flare"
    },
    {
      "id": "transient acceleration"
    },
    {
      "id": "cancer activity"
    },
    {
      "id": "goserelin"
    },
    {
      "id": "buserelin"
    },
    {
      "id": "rapid androgen suppression"
    },
    {
      "id": "short term"
    },
    {
      "id": "increase or 'surge'"
    },
    {
      "id": "USA Food and Drug Administration"
    },
    {
      "id": "castrate levels"
    },
    {
      "id": "gonadotrophin-releasing hormone (GnRH) receptor"
    },
    {
      "id": "Chromium levels"
    },
    {
      "id": "workers"
    },
    {
      "id": "BCr"
    },
    {
      "id": "male"
    },
    {
      "id": "average age"
    },
    {
      "id": "adverse health effects"
    },
    {
      "id": "skin rashes"
    },
    {
      "id": "chromium"
    },
    {
      "id": "tannery workers"
    },
    {
      "id": "threat"
    },
    {
      "id": "urinary chromium excretion"
    },
    {
      "id": "routine procedures"
    },
    {
      "id": "hematological, hepatic and renal function impairment"
    },
    {
      "id": "biological fluids"
    },
    {
      "id": "gastritis"
    },
    {
      "id": "nmol/L"
    },
    {
      "id": "chronic bronchitis"
    },
    {
      "id": "excessive exposure"
    },
    {
      "id": "33 years"
    },
    {
      "id": "high-sensitive C-reactive protein"
    },
    {
      "id": "upper limit"
    },
    {
      "id": "Agency for Toxic Substance and Drug Registry"
    },
    {
      "id": "tanneries"
    },
    {
      "id": "objective"
    },
    {
      "id": "Toxic effects"
    },
    {
      "id": "inflammatory changes"
    },
    {
      "id": "median (interquartile range)"
    },
    {
      "id": "Sialkot"
    },
    {
      "id": "routine biochemical tests"
    },
    {
      "id": "conjunctivitis"
    },
    {
      "id": "240 males"
    },
    {
      "id": "Pakistan"
    },
    {
      "id": "Blood complete counts"
    },
    {
      "id": "enhanced oxidative stress"
    },
    {
      "id": "graphite furnace atomic absorption spectrophotometer Perkin Elmer analyst-200"
    },
    {
      "id": "Chromium"
    },
    {
      "id": "leather industry"
    },
    {
      "id": "body systems"
    },
    {
      "id": "blood (BCr)"
    },
    {
      "id": "testicular genes"
    },
    {
      "id": "CD1 mice"
    },
    {
      "id": "spermatogenesis"
    },
    {
      "id": "testes"
    },
    {
      "id": "TBBPA"
    },
    {
      "id": "environment"
    },
    {
      "id": "Experimental animals"
    },
    {
      "id": "reproductive parameters"
    },
    {
      "id": "tetrabrombisphenol A"
    },
    {
      "id": "flame retardant"
    },
    {
      "id": "morphometry"
    },
    {
      "id": "seminiferous tubules"
    },
    {
      "id": "reproduction"
    },
    {
      "id": "cell lines"
    },
    {
      "id": "hormonal systems"
    },
    {
      "id": "Tetrabromobisphenol A"
    },
    {
      "id": "sperm quality"
    },
    {
      "id": "F1 generation"
    },
    {
      "id": "control animals"
    },
    {
      "id": "trans-generational effect"
    },
    {
      "id": "industry"
    },
    {
      "id": "generations"
    },
    {
      "id": "outbred mice"
    },
    {
      "id": "human body"
    },
    {
      "id": "epicatechin"
    },
    {
      "id": "chemopreventive activity"
    },
    {
      "id": "combined treatment"
    },
    {
      "id": "malondialdhyde (MDA)"
    },
    {
      "id": "constituents"
    },
    {
      "id": "antimutagenic activities"
    },
    {
      "id": "cellular membranes"
    },
    {
      "id": "superoxide dismutase"
    },
    {
      "id": "tea extracts"
    },
    {
      "id": "antioxidant defense"
    },
    {
      "id": "nicotine-induced carcinogenesis"
    },
    {
      "id": "catalase"
    },
    {
      "id": "free radical scavenger"
    },
    {
      "id": "human diet"
    },
    {
      "id": "antitumor activities"
    },
    {
      "id": "nicotine injected rats"
    },
    {
      "id": "pulmonary diseases"
    },
    {
      "id": "apples"
    },
    {
      "id": "antibacterial activities"
    },
    {
      "id": "MDA"
    },
    {
      "id": "glutathione peroxidase"
    },
    {
      "id": "untreated rats"
    },
    {
      "id": "diet"
    },
    {
      "id": "tea"
    },
    {
      "id": "biological functions"
    },
    {
      "id": "antiviral activities"
    },
    {
      "id": "tobacco smoke"
    },
    {
      "id": "antioxidative activities"
    },
    {
      "id": "lipid-soluble antioxidant vitamin"
    },
    {
      "id": "chocolate"
    },
    {
      "id": "HFD-induced increases"
    },
    {
      "id": "serum lipids"
    },
    {
      "id": "Quercetin"
    },
    {
      "id": "fat accumulation"
    },
    {
      "id": "lipogenesis"
    },
    {
      "id": "HFD-induced obesity"
    },
    {
      "id": "thiobarbituric acid-reactive substance (TBARS)"
    },
    {
      "id": "HFD-induced gains"
    },
    {
      "id": "liver weight"
    },
    {
      "id": "Quercetin supplementation"
    },
    {
      "id": "Pparg"
    },
    {
      "id": "white adipose tissue weight"
    },
    {
      "id": "lipid metabolism-related genes"
    },
    {
      "id": "expression profiles"
    },
    {
      "id": "high-fat diet"
    },
    {
      "id": "lipid droplets"
    },
    {
      "id": "hepatic gene expression"
    },
    {
      "id": "lipid metabolism"
    },
    {
      "id": "anti-obesity effects"
    },
    {
      "id": "Fdft1"
    },
    {
      "id": "expression patterns"
    },
    {
      "id": "Fasn"
    },
    {
      "id": "hepatic lipid accumulation"
    },
    {
      "id": "immunoblot assays"
    },
    {
      "id": "physiological effects"
    },
    {
      "id": "hyperlipidemia"
    },
    {
      "id": "Apoa4"
    },
    {
      "id": "Cd36"
    },
    {
      "id": "Aldh1b1"
    },
    {
      "id": "epididymal fat pads"
    },
    {
      "id": "Fnta"
    },
    {
      "id": "Gpam"
    },
    {
      "id": "C57B1/6 mice"
    },
    {
      "id": "Acaca"
    },
    {
      "id": "Pon1"
    },
    {
      "id": "lipid metabolism genes"
    },
    {
      "id": "Abcg5"
    },
    {
      "id": "quantitative reverse transcriptase-polymerase chain reaction"
    },
    {
      "id": "osteolytic events"
    },
    {
      "id": "tumor cell-driven events"
    },
    {
      "id": "BMM-supplied CTSK"
    },
    {
      "id": "CCL2-driven pathways"
    },
    {
      "id": "inflammatory events"
    },
    {
      "id": "CTSK"
    },
    {
      "id": "tumor progression"
    },
    {
      "id": "BMMs"
    },
    {
      "id": "bone-tumor microenvironment"
    },
    {
      "id": "COX-2-driven pathways"
    },
    {
      "id": "prostate tumor progression"
    },
    {
      "id": "proteases"
    },
    {
      "id": "Macrophage cathepsin K"
    },
    {
      "id": "prostate tumor growth"
    },
    {
      "id": "inflammatory factors"
    },
    {
      "id": "Bone marrow macrophages"
    },
    {
      "id": "macrophage-regulated processes"
    },
    {
      "id": "skeleton"
    },
    {
      "id": "cysteine protease cathepsin K"
    },
    {
      "id": "potent collagenase"
    },
    {
      "id": "multiple pathways"
    },
    {
      "id": "MET"
    },
    {
      "id": "XL184"
    },
    {
      "id": "oral tyrosine kinase inhibitor"
    },
    {
      "id": "Primary end points"
    },
    {
      "id": "Cabozantinib"
    },
    {
      "id": "Response Evaluation Criteria in Solid Tumors"
    },
    {
      "id": "RECIST"
    },
    {
      "id": "MTC"
    },
    {
      "id": "Additional end points"
    },
    {
      "id": "global phase III pivotal study"
    },
    {
      "id": "17 (49%) of 35 patients"
    },
    {
      "id": "Dose-limiting toxicities"
    },
    {
      "id": "grade 3 palmar plantar erythrodysesthesia"
    },
    {
      "id": "anti-invasive effects"
    },
    {
      "id": "preclinical models"
    },
    {
      "id": "grade 2 mucositis"
    },
    {
      "id": "dose interruption"
    },
    {
      "id": "18 patients"
    },
    {
      "id": "tumor shrinkage"
    },
    {
      "id": "30% or more"
    },
    {
      "id": "cabozantinib"
    },
    {
      "id": "vascular endothelial growth factor receptor 2"
    },
    {
      "id": "PPE"
    },
    {
      "id": "SD"
    },
    {
      "id": "lipase elevations"
    },
    {
      "id": "AST"
    },
    {
      "id": "antitumor effects"
    },
    {
      "id": "antiangiogenic effects"
    },
    {
      "id": "VEGFR2"
    },
    {
      "id": "Eighty-five patients"
    },
    {
      "id": "37"
    },
    {
      "id": "68% of patients"
    },
    {
      "id": "RET mutational status"
    },
    {
      "id": "measurable disease"
    },
    {
      "id": "MTC-enriched cohort"
    },
    {
      "id": "Ten (29%) of 35 patients"
    },
    {
      "id": "confirmed partial response"
    },
    {
      "id": "phase I dose-escalation study"
    },
    {
      "id": "medullary thyroid cancer"
    },
    {
      "id": "15 (41%) of 37 patients"
    },
    {
      "id": "6 months or longer"
    },
    {
      "id": "ClinicalTrials.gov number NCT00215605"
    },
    {
      "id": "advanced solid tumors"
    },
    {
      "id": "maximum-tolerated dose"
    },
    {
      "id": "oral cabozantinib"
    },
    {
      "id": "6 months"
    },
    {
      "id": "MTD"
    },
    {
      "id": "175 mg daily"
    },
    {
      "id": "biomarker analyses"
    },
    {
      "id": "mucositis"
    },
    {
      "id": "ALT"
    },
    {
      "id": "MTD determination"
    },
    {
      "id": "levels"
    },
    {
      "id": "control intestine"
    },
    {
      "id": "tissue morphology"
    },
    {
      "id": "therapeutic targeting"
    },
    {
      "id": "Tet-O\u0394N89\u03b2-catenin system"
    },
    {
      "id": "oncogenic \u03b2-catenin expression"
    },
    {
      "id": "3D 'crypt culture'"
    },
    {
      "id": "target genes"
    },
    {
      "id": "Ascl2"
    },
    {
      "id": "reversal"
    },
    {
      "id": "Wnt signaling"
    },
    {
      "id": "Wnt pathway inhibitor"
    },
    {
      "id": "oncogenic Wnt signaling"
    },
    {
      "id": "tetracycline-inducible transgenic mouse model"
    },
    {
      "id": "removal"
    },
    {
      "id": "rapid advance"
    },
    {
      "id": "early stage compounds"
    },
    {
      "id": "efficacy models"
    },
    {
      "id": "drug discovery pipeline"
    },
    {
      "id": "Axin2"
    },
    {
      "id": "reversible system"
    },
    {
      "id": "rapid in vivo responses"
    },
    {
      "id": "in vivo models"
    },
    {
      "id": "doxycycline removal"
    },
    {
      "id": "\u0394N89\u03b2-catenin"
    },
    {
      "id": "CCT036477"
    },
    {
      "id": "intestinal hyperplasia"
    },
    {
      "id": "in vitro models"
    },
    {
      "id": "4 h"
    },
    {
      "id": "hours"
    },
    {
      "id": "medium throughput in vitro approaches"
    },
    {
      "id": "small molecule Wnt inhibitor"
    },
    {
      "id": "truncated \u03b2-catenin"
    },
    {
      "id": "C-myc"
    },
    {
      "id": "doxycycline withdrawal"
    },
    {
      "id": "Wnt target gene expression"
    },
    {
      "id": "(3)H-inositolmonophosphate formation"
    },
    {
      "id": "mGlu5-receptor dependent long-term depression"
    },
    {
      "id": "Schaffer collateral-CA1 synapse"
    },
    {
      "id": "mGlu5 receptors"
    },
    {
      "id": "animal model for treatment-resistant depression"
    },
    {
      "id": "cLH rats"
    },
    {
      "id": "changes in the expression and function of mGlu5 receptors"
    },
    {
      "id": "enhanced mGlu5 receptor function"
    },
    {
      "id": "behavioral phenotype"
    },
    {
      "id": "expression of mGlu5 receptors"
    },
    {
      "id": "basal dendritic spine density"
    },
    {
      "id": "depressive-like phenotype"
    },
    {
      "id": "DHPG-induced long-term depression (LTD)"
    },
    {
      "id": "control cNLH rats"
    },
    {
      "id": "mGlu1/5 receptor signaling"
    },
    {
      "id": "in vivo measurement"
    },
    {
      "id": "CA1 pyramidal cell"
    },
    {
      "id": "congenitally learned helpless rats"
    },
    {
      "id": "i.c.v. injection of DHPG"
    },
    {
      "id": "chronic treatment of cLH rats with MPEP"
    },
    {
      "id": "learned helplessness"
    },
    {
      "id": "glutamatergic system"
    },
    {
      "id": "treatment of major depression"
    },
    {
      "id": "rats bred for congenital learned helplessness (cLH)"
    },
    {
      "id": "control strain"
    },
    {
      "id": "LTD induced by low frequency stimulation"
    },
    {
      "id": "Schaffer collaterals"
    },
    {
      "id": "Schaffer collateral/CA1 pyramidal cell synapses"
    },
    {
      "id": "congenitally not learned helpless rats (cNLH)"
    },
    {
      "id": "resistance against inescapable stress"
    },
    {
      "id": "DHPG-stimulated polyphosphoinositides hydrolysis"
    },
    {
      "id": "hippocampal slices"
    },
    {
      "id": "genetic model of depression"
    },
    {
      "id": "Special Issue"
    },
    {
      "id": "Metabotropic Glutamate Receptors"
    },
    {
      "id": "pathophysiology"
    },
    {
      "id": "CYP17"
    },
    {
      "id": "thecal cells"
    },
    {
      "id": "P450scc"
    },
    {
      "id": "PCOS rat model"
    },
    {
      "id": "polycystic ovaries"
    },
    {
      "id": "multiple large cysts"
    },
    {
      "id": "stromal-interstitial tissue"
    },
    {
      "id": "endogenous hyperandrogenism"
    },
    {
      "id": "steroidogenic enzymes"
    },
    {
      "id": "hCG"
    },
    {
      "id": "ovarian tissue"
    },
    {
      "id": "PCOS"
    },
    {
      "id": "western-blot"
    },
    {
      "id": "estrous cycle"
    },
    {
      "id": "granulosa layers"
    },
    {
      "id": "thecal layers"
    },
    {
      "id": "control rats"
    },
    {
      "id": "androgen biosynthesis"
    },
    {
      "id": "ultimate carcinogen"
    },
    {
      "id": "solvation"
    },
    {
      "id": "solvent reaction field methods"
    },
    {
      "id": "Hartree-Fock"
    },
    {
      "id": "flexible basis sets"
    },
    {
      "id": "reactivities"
    },
    {
      "id": "carcinogenicity"
    },
    {
      "id": "Langevin dipoles"
    },
    {
      "id": "chemical reactivity"
    },
    {
      "id": "MP2 methods"
    },
    {
      "id": "guanine"
    },
    {
      "id": "N7 position"
    },
    {
      "id": "reactions"
    },
    {
      "id": "ultimate carcinogen scavengers"
    },
    {
      "id": "chemical reaction"
    },
    {
      "id": "high reactivity value"
    },
    {
      "id": "experimental value"
    },
    {
      "id": "25.36 kcal/mol"
    },
    {
      "id": "activation free energy"
    },
    {
      "id": "window of reactivity"
    },
    {
      "id": "propylene oxide"
    },
    {
      "id": "epoxy type"
    },
    {
      "id": "PI3K inhibitor"
    },
    {
      "id": "Pik3ca(H1047R)"
    },
    {
      "id": "mammary tumorigenesis"
    },
    {
      "id": "PIK3CA"
    },
    {
      "id": "catalytic subunit p110\u03b1"
    },
    {
      "id": "breast tumors"
    },
    {
      "id": "histological types"
    },
    {
      "id": "tissue-specific conditional expression"
    },
    {
      "id": "Pik3ca(e20H1047R) mutant allele"
    },
    {
      "id": "Pik3ca(H1047R)-driven mammary tumors"
    },
    {
      "id": "Whole-exome analysis"
    },
    {
      "id": "latent Pik3ca(H1047R) allele"
    },
    {
      "id": "PI3K"
    },
    {
      "id": "Trp53 mutations"
    },
    {
      "id": "adenocarinoma"
    },
    {
      "id": "Conditional activation"
    },
    {
      "id": "PI3K inhibition"
    },
    {
      "id": "Oncogenic mutations"
    },
    {
      "id": "human breast cancers"
    },
    {
      "id": "GDC-0941"
    },
    {
      "id": "endogenous Pik3ca allele"
    },
    {
      "id": "knock-in mouse model"
    },
    {
      "id": "spindle cell tumors"
    },
    {
      "id": "C-Y-W-E-L-E-W-L-P-C-A"
    },
    {
      "id": "Ca(2+)uptake assays"
    },
    {
      "id": "preparations from cardiac sarcoplasmic reticulum"
    },
    {
      "id": "pharmacophore"
    },
    {
      "id": "small molecules"
    },
    {
      "id": "heart failure"
    },
    {
      "id": "aberrations"
    },
    {
      "id": "portion of phospholamban"
    },
    {
      "id": "NMR"
    },
    {
      "id": "cyclic peptide"
    },
    {
      "id": "structure-activity analysis"
    },
    {
      "id": "model of phospholamban -cyclic peptide complex"
    },
    {
      "id": "cardiac sarcoplasmic Ca(2+)ATPase"
    },
    {
      "id": "phospholamban"
    },
    {
      "id": "molecules"
    },
    {
      "id": "inhibitory activity of phospholamban"
    },
    {
      "id": "modulation"
    },
    {
      "id": "therapeutic approach"
    },
    {
      "id": "phospholamban (1-36)"
    },
    {
      "id": "experimental heart failure models"
    },
    {
      "id": "examples of such molecules"
    },
    {
      "id": "inhibitors of phospholamban"
    },
    {
      "id": "phage-display peptide library screening"
    },
    {
      "id": "sarcoplasmic Ca(2+)ATPase"
    },
    {
      "id": "active and inactive alanine-mutated cyclic peptides"
    },
    {
      "id": "inhibition of the phospholamban function"
    },
    {
      "id": "series of alanine point-mutated cyclic peptides"
    },
    {
      "id": "deficits in fear extinction"
    },
    {
      "id": "AMN082"
    },
    {
      "id": "impaired extinction acquisition"
    },
    {
      "id": "Anxiety disorders"
    },
    {
      "id": "fear"
    },
    {
      "id": "drug treatments"
    },
    {
      "id": "adjuncts"
    },
    {
      "id": "valproic acid"
    },
    {
      "id": "MS-275"
    },
    {
      "id": "impaired extinction consolidation/retrieval"
    },
    {
      "id": "Deep brain stimulation"
    },
    {
      "id": "resistance to fear extinction"
    },
    {
      "id": "129S1/SvImJ (S1) mice"
    },
    {
      "id": "extinction learning"
    },
    {
      "id": "high frequency stimulation"
    },
    {
      "id": "weak fear conditioning"
    },
    {
      "id": "fear reduction"
    },
    {
      "id": "histone deacetylase (HDAC) inhibitor"
    },
    {
      "id": "nucleus accumbens"
    },
    {
      "id": "ventral striatum"
    },
    {
      "id": "GABAergic enhancer"
    },
    {
      "id": "treatment resistance"
    },
    {
      "id": "Cognitive Enhancers"
    },
    {
      "id": "PEPA"
    },
    {
      "id": "extinction acquisition"
    },
    {
      "id": "d-cycloserine"
    },
    {
      "id": "extinction training"
    },
    {
      "id": "exposure-based therapies"
    },
    {
      "id": "HDAC inhibiting properties"
    },
    {
      "id": "histone deacetylase inhibitors"
    },
    {
      "id": "mGlu7 agonism properties"
    },
    {
      "id": "DBS"
    },
    {
      "id": "extreme fear extinction deficit"
    },
    {
      "id": "metabotropic glutamate receptor 7 (mGlu7) agonist"
    },
    {
      "id": "AMPA receptor potentiator"
    },
    {
      "id": "N-methly-d-aspartate partial agonist"
    },
    {
      "id": "glutamatergic drugs"
    },
    {
      "id": "deficient extinction consolidation/retrieval"
    },
    {
      "id": "massed extinction training"
    },
    {
      "id": "non-pharmacological manipulations"
    },
    {
      "id": "deficiency in extinction memory consolidation/retrieval"
    },
    {
      "id": "extinction retrieval"
    },
    {
      "id": "no exposure to dental amalgams"
    },
    {
      "id": "completed clinical trial"
    },
    {
      "id": "parent study"
    },
    {
      "id": "Amalgams"
    },
    {
      "id": "mercury (Hg)"
    },
    {
      "id": "statistical model"
    },
    {
      "id": "nonsignificant relationship"
    },
    {
      "id": "urinary levels of GST-\u03c0"
    },
    {
      "id": "glutathione-S-transferases (GST)-\u03b1"
    },
    {
      "id": "PT"
    },
    {
      "id": "GST-\u03c0"
    },
    {
      "id": "distal tubules"
    },
    {
      "id": "average exposure to amalgams"
    },
    {
      "id": "dental amalgam fillings"
    },
    {
      "id": "dental amalgams"
    },
    {
      "id": "ongoing kidney damage"
    },
    {
      "id": "Urinary biomarkers of kidney integrity"
    },
    {
      "id": "Casa Pia children's dental amalgam trial"
    },
    {
      "id": "increasing Hg exposure"
    },
    {
      "id": "GST-\u03b1"
    },
    {
      "id": "biomarkers of kidney integrity"
    },
    {
      "id": "mercury exposure"
    },
    {
      "id": "kidney integrity biomarkers"
    },
    {
      "id": "Our study"
    },
    {
      "id": "dose-dependent correlation"
    },
    {
      "id": "Hg"
    },
    {
      "id": "kidney damage"
    },
    {
      "id": "cumulative exposure to Hg"
    },
    {
      "id": "urinary levels of GST-\u03b1"
    },
    {
      "id": "proximal tubules (PTs)"
    },
    {
      "id": "study subjects"
    },
    {
      "id": "covariate adjustment"
    },
    {
      "id": "urinary GST-\u03b1 levels"
    },
    {
      "id": "8-year course of the study"
    },
    {
      "id": "dental restorative material"
    },
    {
      "id": "amalgam group"
    },
    {
      "id": "PJ34 treatment"
    },
    {
      "id": "PARP-1 binding"
    },
    {
      "id": "PJ34"
    },
    {
      "id": "NIS mRNA levels"
    },
    {
      "id": "H3K27me3"
    },
    {
      "id": "repressive mark"
    },
    {
      "id": "multimeric repressor"
    },
    {
      "id": "NIS expression"
    },
    {
      "id": "radio-iodine uptake"
    },
    {
      "id": "PARP inhibitor PJ34"
    },
    {
      "id": "epigenetic marks"
    },
    {
      "id": "H3K9K14ac"
    },
    {
      "id": "PARP inhibition"
    },
    {
      "id": "transcriptional regulatory mechanisms"
    },
    {
      "id": "thyroid cancer"
    },
    {
      "id": "PARP inhibitors"
    },
    {
      "id": "NIS gene expression"
    },
    {
      "id": "PARP-1"
    },
    {
      "id": "H3K4me3"
    },
    {
      "id": "histone modification activation marks"
    },
    {
      "id": "NIS promoter activity"
    },
    {
      "id": "Cyproterone acetate"
    },
    {
      "id": "hirsutism"
    },
    {
      "id": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase"
    },
    {
      "id": "3-keto-4-ene-steroids"
    },
    {
      "id": "cyanoketone"
    },
    {
      "id": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase"
    },
    {
      "id": "androst-5-ene-3 beta, 17 beta-diol"
    },
    {
      "id": "norgestrel"
    },
    {
      "id": "Ki values"
    },
    {
      "id": "4-MA"
    },
    {
      "id": "Ki value"
    },
    {
      "id": "progestin"
    },
    {
      "id": "3 beta-HSD activity"
    },
    {
      "id": "epostane"
    },
    {
      "id": "3 beta-HSD"
    },
    {
      "id": "Trilostane"
    },
    {
      "id": "17 alpha-hydroxy pregnenolone"
    },
    {
      "id": "5 alpha-reductase"
    },
    {
      "id": "RU2323"
    },
    {
      "id": "norethindrone"
    },
    {
      "id": "pregnenolone"
    },
    {
      "id": "promegestone"
    },
    {
      "id": "Synthetic progestin compounds"
    },
    {
      "id": "dehydroepiandrosterone"
    },
    {
      "id": "human placenta"
    },
    {
      "id": "oral contraceptives"
    },
    {
      "id": "hormonal steroids"
    },
    {
      "id": "5 alpha-reductase inhibitor"
    },
    {
      "id": "acne"
    },
    {
      "id": "synthetic progestins"
    },
    {
      "id": "direct effect"
    },
    {
      "id": "D2/D3 receptors"
    },
    {
      "id": "quinpirole"
    },
    {
      "id": "dopaminergic neurons"
    },
    {
      "id": "7-OH-DPAT"
    },
    {
      "id": "maximal dendrite length"
    },
    {
      "id": "dopamine agonists"
    },
    {
      "id": "extracellular signal-regulated kinase"
    },
    {
      "id": "ERK"
    },
    {
      "id": "GF109203"
    },
    {
      "id": "D2/D3 receptor signalling pathway"
    },
    {
      "id": "SB-277011-A"
    },
    {
      "id": "phosphorylation"
    },
    {
      "id": "neurotrophic effects"
    },
    {
      "id": "tyrosine hydroxylase immunoreactivity"
    },
    {
      "id": "TH-IR"
    },
    {
      "id": "D3 receptor-dependent neurotransmission"
    },
    {
      "id": "number of primary dendrites"
    },
    {
      "id": "[3H]dopamine uptake"
    },
    {
      "id": "sulpiride"
    },
    {
      "id": "Dopamine D3 receptor-preferring agonists"
    },
    {
      "id": "TH-IR-positive mesencephalic neurons"
    },
    {
      "id": "neuroprotective actions"
    },
    {
      "id": "Clinical improvements"
    },
    {
      "id": "neuronal-enriched primary cultures"
    },
    {
      "id": "mesencephalic dopaminergic neurons"
    },
    {
      "id": "dendrite arborization"
    },
    {
      "id": "D2/D3 receptor antagonist"
    },
    {
      "id": "7-hydroxy-N,N-di-propyl-2-aminotetralin"
    },
    {
      "id": "LY294002"
    },
    {
      "id": "neuroregenerative properties"
    },
    {
      "id": "mouse embryo mesencephalon"
    },
    {
      "id": "PD98059"
    },
    {
      "id": "D3 receptor antagonist"
    },
    {
      "id": "net hepatic glycogen synthesis"
    },
    {
      "id": "vivo"
    },
    {
      "id": "hepatic portal vein glucose infusion"
    },
    {
      "id": "glycogen synthesis"
    },
    {
      "id": "intraportal glucose infusion"
    },
    {
      "id": "fructose infusion"
    },
    {
      "id": "control period"
    },
    {
      "id": "percent of glucose"
    },
    {
      "id": "portal vein glucose infusion"
    },
    {
      "id": "Liver glycogen levels"
    },
    {
      "id": "hyperglycemic-normoinsulinemia"
    },
    {
      "id": "Gly+INS"
    },
    {
      "id": "SCGly+INS"
    },
    {
      "id": "purpose"
    },
    {
      "id": "decrease"
    },
    {
      "id": "insulin signaling"
    },
    {
      "id": "SCGly"
    },
    {
      "id": "Gly"
    },
    {
      "id": "groups"
    },
    {
      "id": "Liver glycogen loading"
    },
    {
      "id": "SCGly+PoG"
    },
    {
      "id": "hepatic glycogen"
    },
    {
      "id": "intraportal fructose infusion"
    },
    {
      "id": "Gly+PoG"
    },
    {
      "id": "experimental period"
    },
    {
      "id": "PoG"
    },
    {
      "id": "INS"
    },
    {
      "id": "glycogen"
    },
    {
      "id": "basal insulin"
    },
    {
      "id": "Carbonic anhydrase inhibitors"
    },
    {
      "id": "CA XIV"
    },
    {
      "id": "X-ray crystal structures"
    },
    {
      "id": "CA II adducts"
    },
    {
      "id": "CA XII"
    },
    {
      "id": "isozyme CA II"
    },
    {
      "id": "active site water molecules"
    },
    {
      "id": "Thiazide diuretics"
    },
    {
      "id": "mammalian isoforms of carbonic anhydrase"
    },
    {
      "id": "trichloromethiazide"
    },
    {
      "id": "hCA VB"
    },
    {
      "id": "hCA IX"
    },
    {
      "id": "chlorthalidone"
    },
    {
      "id": "carbonic anhydrase (CA)"
    },
    {
      "id": "ethoxzolamide"
    },
    {
      "id": "classical inhibitors"
    },
    {
      "id": "CA VII"
    },
    {
      "id": "CA II inhibitors"
    },
    {
      "id": "medicinal chemistry applications"
    },
    {
      "id": "CA XIII"
    },
    {
      "id": "CA IX"
    },
    {
      "id": "water molecules"
    },
    {
      "id": "difference of activity"
    },
    {
      "id": "K(I)s"
    },
    {
      "id": "hCA XIII"
    },
    {
      "id": "enolic OH"
    },
    {
      "id": "hydrogen bonds"
    },
    {
      "id": "adducts"
    },
    {
      "id": "isozyme II"
    },
    {
      "id": "methazolamide"
    },
    {
      "id": "binding modes"
    },
    {
      "id": "chlorthalidone scaffolds"
    },
    {
      "id": "CA I"
    },
    {
      "id": "high ceiling diuretics"
    },
    {
      "id": "hCA VII"
    },
    {
      "id": "nanomolar inhibitors"
    },
    {
      "id": "furosemide scaffolds"
    },
    {
      "id": "trichloromethiazide scaffolds"
    },
    {
      "id": "enolic (lactimic) tautomeric form"
    },
    {
      "id": "Asn67"
    },
    {
      "id": "EC 4.2.1.1"
    },
    {
      "id": "Cocaine"
    },
    {
      "id": "drugs of abuse"
    },
    {
      "id": "initial biochemical analysis"
    },
    {
      "id": "cocaine-hydrolyzing mutants of BChE"
    },
    {
      "id": "butyrylcholinesterase variants"
    },
    {
      "id": "cocaine hydrolase activity"
    },
    {
      "id": "Recent studies"
    },
    {
      "id": "promising potential treatment option"
    },
    {
      "id": "reward centers of the brain"
    },
    {
      "id": "Plants"
    },
    {
      "id": "serum enzyme butyrylcholinesterase"
    },
    {
      "id": "cocaine hydrolase variants of BChE"
    },
    {
      "id": "those"
    },
    {
      "id": "long periods of abstinence"
    },
    {
      "id": "BChE"
    },
    {
      "id": "engineered BChE proteins"
    },
    {
      "id": "large amounts"
    },
    {
      "id": "Cocaine addiction"
    },
    {
      "id": "personal and social consequences"
    },
    {
      "id": "FDA-approved treatment"
    },
    {
      "id": "likelihood of relapse"
    },
    {
      "id": "design of variants of BChE"
    },
    {
      "id": "(-)-cocaine"
    },
    {
      "id": "promising means"
    },
    {
      "id": "proof-of-principle"
    },
    {
      "id": "MagnICON virus-assisted transient expression system"
    },
    {
      "id": "desired properties"
    },
    {
      "id": "millions of people"
    },
    {
      "id": "other areas of the body"
    },
    {
      "id": "other sources"
    },
    {
      "id": "80% chance of relapse"
    },
    {
      "id": "rehabilitation"
    },
    {
      "id": "Nicotiana benthamiana"
    },
    {
      "id": "human pathogens"
    },
    {
      "id": "Tub expression"
    },
    {
      "id": "fasting blood glucose"
    },
    {
      "id": "leptin"
    },
    {
      "id": "melanin-concentrating hormone"
    },
    {
      "id": "thyroid-releasing hormone"
    },
    {
      "id": "Food intake"
    },
    {
      "id": "orexin"
    },
    {
      "id": "DIO mice"
    },
    {
      "id": "Tub"
    },
    {
      "id": "proopiomelanocortin"
    },
    {
      "id": "fasting"
    },
    {
      "id": "hypothalamic nuclei"
    },
    {
      "id": "Tub antisense oligonucleotide"
    },
    {
      "id": "ASO"
    },
    {
      "id": "tub gene"
    },
    {
      "id": "energy balance"
    },
    {
      "id": "signaling proteins"
    },
    {
      "id": "intracerebroventricular insulin"
    },
    {
      "id": "IRTK"
    },
    {
      "id": "refeeding"
    },
    {
      "id": "metabolic characteristics"
    },
    {
      "id": "Tub tyrosine phosphorylation"
    },
    {
      "id": "nutritional status"
    },
    {
      "id": "Tub-p-tyr"
    },
    {
      "id": "neuropeptide expression"
    },
    {
      "id": "insulin receptor tyrosine kinase"
    },
    {
      "id": "hepatic glucose output"
    },
    {
      "id": "protein tyrosine phosphatase 1B"
    },
    {
      "id": "insulin-induced Tub-p-tyr"
    },
    {
      "id": "hepatic glucose metabolism"
    },
    {
      "id": "leptin resistance"
    },
    {
      "id": "O(2) consumption"
    },
    {
      "id": "leptin receptor"
    },
    {
      "id": "LEPR"
    },
    {
      "id": "Janus kinase 2"
    },
    {
      "id": "JAK2"
    },
    {
      "id": "elastic rubber"
    },
    {
      "id": "second molar"
    },
    {
      "id": "ETM"
    },
    {
      "id": "mechano-adaptive response"
    },
    {
      "id": "osteoclast activation"
    },
    {
      "id": "bone remodeling"
    },
    {
      "id": "sympathetic neuromarkers"
    },
    {
      "id": "PRO treatment"
    },
    {
      "id": "amount of tooth movement"
    },
    {
      "id": "osteoclast increase"
    },
    {
      "id": "ISO"
    },
    {
      "id": "isoproterenol"
    },
    {
      "id": "Nerve fibers"
    },
    {
      "id": "Oc.N/BS"
    },
    {
      "id": "osteoclast number"
    },
    {
      "id": "sympathetic signaling"
    },
    {
      "id": "sympathetic nervous system"
    },
    {
      "id": "bone architecture"
    },
    {
      "id": "\u03b2-agonist"
    },
    {
      "id": "osteoclast parameters"
    },
    {
      "id": "tooth movement"
    },
    {
      "id": "sensory nerve fibers"
    },
    {
      "id": "sensory neuromarkers"
    },
    {
      "id": "Chemical sympathectomy"
    },
    {
      "id": "CGRP"
    },
    {
      "id": "ISO treatment"
    },
    {
      "id": "6-OHDA"
    },
    {
      "id": "bone surface"
    },
    {
      "id": "alveolar socket"
    },
    {
      "id": "PRO"
    },
    {
      "id": "3-day ETM"
    },
    {
      "id": "periodontal ligament"
    },
    {
      "id": "NPY"
    },
    {
      "id": "neuropeptide Y"
    },
    {
      "id": "M2"
    },
    {
      "id": "\u03b2-antagonist"
    },
    {
      "id": "vehicle treatment"
    },
    {
      "id": "upper left first molar"
    },
    {
      "id": "5-day ETM"
    },
    {
      "id": "sympathetic signal"
    },
    {
      "id": "Experimental tooth movement"
    },
    {
      "id": "6-hydroxydopamine"
    },
    {
      "id": "apo-10'-lycopenoic acid"
    },
    {
      "id": "lycopene eccentric cleavage products"
    },
    {
      "id": "apo-14'-lycopenoic acid"
    },
    {
      "id": "hsp-70 expressions"
    },
    {
      "id": "tomato lycopene"
    },
    {
      "id": "antioxidant properties"
    },
    {
      "id": "apo-lycopenoic acids"
    },
    {
      "id": "COX-2 expressions"
    },
    {
      "id": "oxidative effects"
    },
    {
      "id": "H2O2"
    },
    {
      "id": "ROS production"
    },
    {
      "id": "oxidation products"
    },
    {
      "id": "lycopene derivatives"
    },
    {
      "id": "MAPK phosphorylation"
    },
    {
      "id": "lycopene"
    },
    {
      "id": "cigarette smoke extract"
    },
    {
      "id": "NOX-4 expressions"
    },
    {
      "id": "human macrophages"
    },
    {
      "id": "chronic diseases"
    },
    {
      "id": "THP-1 macrophages"
    },
    {
      "id": "8-OHdG formation"
    },
    {
      "id": "hsp-90 expressions"
    },
    {
      "id": "NF-\u03baB inactivation"
    },
    {
      "id": "LPL activity"
    },
    {
      "id": "liver kinase B1"
    },
    {
      "id": "protein kinase B"
    },
    {
      "id": "SAPK/JNK/c-Jun"
    },
    {
      "id": "phosphorylated levels"
    },
    {
      "id": "GIP receptor protein"
    },
    {
      "id": "Retn(-/-) mice"
    },
    {
      "id": "Retn(+/-) mice"
    },
    {
      "id": "tumor necrosis factor"
    },
    {
      "id": "TNF receptor 2"
    },
    {
      "id": "GIP responsiveness"
    },
    {
      "id": "Jun NH(2)-terminal kinase"
    },
    {
      "id": "SAPK"
    },
    {
      "id": "resistin"
    },
    {
      "id": "GIP"
    },
    {
      "id": "Resistin knockout mice"
    },
    {
      "id": "glucose-dependent insulinotropic polypeptide receptor"
    },
    {
      "id": "resistin treatment"
    },
    {
      "id": "LPL responsiveness"
    },
    {
      "id": "stress-activated protein kinase"
    },
    {
      "id": "Retn(+/+) mice"
    },
    {
      "id": "primary adipocytes"
    },
    {
      "id": "TNFR2"
    },
    {
      "id": "GIP-regulated adipocyte functions"
    },
    {
      "id": "PKB/LKB1/AMPK/LPL pathway"
    },
    {
      "id": "adipocyte"
    },
    {
      "id": "TNF"
    },
    {
      "id": "Glucose-dependent insulinotropic polypeptide"
    },
    {
      "id": "incretin hormone"
    },
    {
      "id": "GIP signaling"
    },
    {
      "id": "c-Jun-mediated transcriptional activation"
    },
    {
      "id": "Gipr"
    },
    {
      "id": "JNK"
    },
    {
      "id": "3T3-L1 cells"
    },
    {
      "id": "current study"
    },
    {
      "id": "GIPR expression"
    },
    {
      "id": "fat metabolism"
    },
    {
      "id": "fatty acid uptake"
    },
    {
      "id": "GIPR"
    },
    {
      "id": "PKB"
    },
    {
      "id": "TPA-response element"
    },
    {
      "id": "TRE-III"
    },
    {
      "id": "LKB1"
    },
    {
      "id": "Chromatin immunoprecipitation assays"
    },
    {
      "id": "exposures"
    },
    {
      "id": "Toxicity profile"
    },
    {
      "id": "iv dose administration"
    },
    {
      "id": "Findings"
    },
    {
      "id": "cellular responses"
    },
    {
      "id": "Laboratory findings"
    },
    {
      "id": "histopathological findings"
    },
    {
      "id": "Small-molecule IAP antagonists"
    },
    {
      "id": "cancer therapeutics"
    },
    {
      "id": "GDC-0152"
    },
    {
      "id": "small-molecule drug"
    },
    {
      "id": "systemic inflammatory response"
    },
    {
      "id": "tumor necrosis factor alpha (TNF-\u03b1)"
    },
    {
      "id": "Inhibitor-of-apoptosis (IAP) proteins"
    },
    {
      "id": "hepatic injury"
    },
    {
      "id": "small-molecule IAP antagonist"
    },
    {
      "id": "blood neutrophil count"
    },
    {
      "id": "safety biomarkers"
    },
    {
      "id": "GDC-0152 exposure"
    },
    {
      "id": "cancers"
    },
    {
      "id": "tumor cell apoptosis"
    },
    {
      "id": "apoptosis/necrosis"
    },
    {
      "id": "malignant cells"
    },
    {
      "id": "inflammatory infiltrates"
    },
    {
      "id": "liver transaminases"
    },
    {
      "id": "plasma cytokines"
    },
    {
      "id": "normal cells"
    },
    {
      "id": "cellular context"
    },
    {
      "id": "IAP antagonism"
    },
    {
      "id": "chemokines"
    },
    {
      "id": "NF-\u03baB transcriptional activity"
    },
    {
      "id": "toxicology profile"
    },
    {
      "id": "TNF-\u03b1-mediated toxicity"
    },
    {
      "id": "single-agent tumor activity"
    },
    {
      "id": "IAPs"
    },
    {
      "id": "markers of inflammation"
    },
    {
      "id": "inflammatory leukogram"
    },
    {
      "id": "TNF-\u03b1 pharmacology"
    },
    {
      "id": "serum monocyte chemoattractant protein-1"
    },
    {
      "id": "pleiotropic cytokine"
    },
    {
      "id": "cell survival"
    },
    {
      "id": "DIR"
    },
    {
      "id": "protein kinase C"
    },
    {
      "id": "cPKC antagonist"
    },
    {
      "id": "5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile"
    },
    {
      "id": "brain pathways"
    },
    {
      "id": "addiction"
    },
    {
      "id": "DA concentration"
    },
    {
      "id": "dopamine D2 agonist"
    },
    {
      "id": "phospholipase C"
    },
    {
      "id": "dynasore"
    },
    {
      "id": "extracellular recordings"
    },
    {
      "id": "brain slices"
    },
    {
      "id": "conventional subtype of protein kinase C"
    },
    {
      "id": "desensitization"
    },
    {
      "id": "\u03b2-ARK1 inhibitor"
    },
    {
      "id": "GRK2"
    },
    {
      "id": "neurotensin receptors"
    },
    {
      "id": "G protein-coupled receptor kinase-2"
    },
    {
      "id": "G\u00f66976"
    },
    {
      "id": "Dopaminergic neurons"
    },
    {
      "id": "dynamin"
    },
    {
      "id": "cPKC"
    },
    {
      "id": "G protein-coupled receptor kinase"
    },
    {
      "id": "Gq-linked neurotransmitters"
    },
    {
      "id": "ventral tegmental area"
    },
    {
      "id": "D2 agonist"
    },
    {
      "id": "D2 receptor sensitivity"
    },
    {
      "id": "DA-inhibition reversal"
    },
    {
      "id": "neurotensin"
    },
    {
      "id": "5-HT(2) receptors"
    },
    {
      "id": "D1-like DA receptors"
    },
    {
      "id": "5A apolipoprotein mimetic peptide"
    },
    {
      "id": "plasma-free cholesterol"
    },
    {
      "id": "simulated annealing analysis"
    },
    {
      "id": "F-18"
    },
    {
      "id": "A"
    },
    {
      "id": "cholesterol efflux"
    },
    {
      "id": "radiolabeled macrophages"
    },
    {
      "id": "molecular dynamics modeling"
    },
    {
      "id": "hinge region"
    },
    {
      "id": "two helices"
    },
    {
      "id": "ABCA1 transporter"
    },
    {
      "id": "aqueous solvent"
    },
    {
      "id": "EE peptide"
    },
    {
      "id": "Hydrophobic amino acids"
    },
    {
      "id": "W-21"
    },
    {
      "id": "lipid microdomain"
    },
    {
      "id": "E"
    },
    {
      "id": "F"
    },
    {
      "id": "Intravenous injection"
    },
    {
      "id": "C57BL/6 mice"
    },
    {
      "id": "W"
    },
    {
      "id": "apolipoproteins"
    },
    {
      "id": "phospholipid vesicles"
    },
    {
      "id": "phospholipids"
    },
    {
      "id": "adrenocortical aldosterone and cortisol release"
    },
    {
      "id": "Incubation"
    },
    {
      "id": "Cells"
    },
    {
      "id": "causative relationship"
    },
    {
      "id": "in vivo lipoprotein modifications"
    },
    {
      "id": "Jak-2"
    },
    {
      "id": "oral glucose tolerance test"
    },
    {
      "id": "NGT-VLDL"
    },
    {
      "id": "hormone release"
    },
    {
      "id": "PRAEDIAS prevention study"
    },
    {
      "id": "department"
    },
    {
      "id": "increased cardiovascular morbidity and mortality"
    },
    {
      "id": "prediabetic individuals"
    },
    {
      "id": "glycoxidative modifications"
    },
    {
      "id": "lipoproteins"
    },
    {
      "id": "aldosterone"
    },
    {
      "id": "type 2 diabetes mellitus (T2DM)"
    },
    {
      "id": "aldosterone and cortisol release"
    },
    {
      "id": "human adrenocortical H295R cells"
    },
    {
      "id": "IGT-VLDL"
    },
    {
      "id": "NGT individuals"
    },
    {
      "id": "etiological factor"
    },
    {
      "id": "steroidogenesis"
    },
    {
      "id": "cortisol"
    },
    {
      "id": "in vivo modified VLDL"
    },
    {
      "id": "adrenocortical steroidogenesis"
    },
    {
      "id": "in vivo modified lipoproteins"
    },
    {
      "id": "normal glucose tolerance (NGT)"
    },
    {
      "id": "Circulating very-low-density lipoprotein"
    },
    {
      "id": "adrenocortical cortisol and aldosterone synthesis"
    },
    {
      "id": "stimulating effect"
    },
    {
      "id": "Jak-2-ERK dependent pathway"
    },
    {
      "id": "prediabetic hormonal dysregulation"
    },
    {
      "id": "IGT subjects"
    },
    {
      "id": "cardiovascular homeostasis"
    },
    {
      "id": "in vitro modified lipoproteins"
    },
    {
      "id": "supernatants"
    },
    {
      "id": "specific pharmacological inhibitors"
    },
    {
      "id": "mineralization"
    },
    {
      "id": "Col1a1-Cnn1 mice"
    },
    {
      "id": "Tartrate-resistant acid phosphatase"
    },
    {
      "id": "TRAP"
    },
    {
      "id": "Morphology analyses"
    },
    {
      "id": "thickness"
    },
    {
      "id": "ratio of RANKL to OPG"
    },
    {
      "id": "Col1a1-Cnn1 osteoblasts"
    },
    {
      "id": "CNN1"
    },
    {
      "id": "H1 calponin"
    },
    {
      "id": "osteoclast formation"
    },
    {
      "id": "early osteoblast differentiation"
    },
    {
      "id": "osteoblasts"
    },
    {
      "id": "bone formation"
    },
    {
      "id": "late stage differentiation"
    },
    {
      "id": "RANKL"
    },
    {
      "id": "cytoskeleton"
    },
    {
      "id": "embryonic stage"
    },
    {
      "id": "Col1a1-Cnn1 transgenic mice"
    },
    {
      "id": "osteoblast function"
    },
    {
      "id": "smooth muscle-specific, actin-binding protein"
    },
    {
      "id": "Cnn1"
    },
    {
      "id": "osteoblast-specific 3.6-kb Col1a1 promoter"
    },
    {
      "id": "Col1a1 promoter"
    },
    {
      "id": "TRAP staining"
    },
    {
      "id": "osteoclast numbers"
    },
    {
      "id": "bone mass"
    },
    {
      "id": "transgenic mice"
    },
    {
      "id": "adult stage"
    },
    {
      "id": "OPG"
    },
    {
      "id": "tibias"
    },
    {
      "id": "actin-binding protein"
    },
    {
      "id": "actin"
    },
    {
      "id": "osteoblast lineage cells"
    },
    {
      "id": "smooth muscle contractive activity"
    },
    {
      "id": "trabecular number"
    },
    {
      "id": "osteoclastogenesis"
    },
    {
      "id": "LY293558"
    },
    {
      "id": "survival rate"
    },
    {
      "id": "pretreatment"
    },
    {
      "id": "real-case scenario"
    },
    {
      "id": "medication"
    },
    {
      "id": "(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid"
    },
    {
      "id": "\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid"
    },
    {
      "id": "GluK1"
    },
    {
      "id": "rapid death"
    },
    {
      "id": "intramuscular administration"
    },
    {
      "id": "neuronal loss"
    },
    {
      "id": "seizures"
    },
    {
      "id": "anticonvulsant efficacy"
    },
    {
      "id": "peripheral toxic effects"
    },
    {
      "id": "GluR5"
    },
    {
      "id": "neuropathology"
    },
    {
      "id": "unexpected attack"
    },
    {
      "id": "anticonvulsant compounds"
    },
    {
      "id": "seizure suppression"
    },
    {
      "id": "time course"
    },
    {
      "id": "brain levels"
    },
    {
      "id": "Analysis"
    },
    {
      "id": "LY293558 pharmacokinetics"
    },
    {
      "id": "medical assistance"
    },
    {
      "id": "immediate pharmacologic intervention"
    },
    {
      "id": "Animal models"
    },
    {
      "id": "AMPA receptor"
    },
    {
      "id": "brain damage"
    },
    {
      "id": "brain regions"
    },
    {
      "id": "amygdala"
    },
    {
      "id": "route of administration"
    },
    {
      "id": "liquid chromatography/mass spectrometry/mass spectrometry"
    },
    {
      "id": "identification"
    },
    {
      "id": "stable isotope-labels"
    },
    {
      "id": "LC-MS/MS"
    },
    {
      "id": "peptide sequence"
    },
    {
      "id": "human peptide"
    },
    {
      "id": "mass"
    },
    {
      "id": "1753"
    },
    {
      "id": "positive correlation"
    },
    {
      "id": "enzyme activity levels"
    },
    {
      "id": "drug-metabolizing enzymes"
    },
    {
      "id": "UDP-glucuronosyltransferases"
    },
    {
      "id": "UGTs"
    },
    {
      "id": "commercial recombinant preparations"
    },
    {
      "id": "BD Biosciences"
    },
    {
      "id": "hydrophilic glucuronides"
    },
    {
      "id": "(13)C6(15)N4"
    },
    {
      "id": "quantitation"
    },
    {
      "id": "LC-MS"
    },
    {
      "id": "SIL peptide"
    },
    {
      "id": "1763"
    },
    {
      "id": "labelled peptide"
    },
    {
      "id": "UGT1A1"
    },
    {
      "id": "individual human liver microsomal samples"
    },
    {
      "id": "liver microsomes"
    },
    {
      "id": "individual human donors"
    },
    {
      "id": "residues 54-69"
    },
    {
      "id": "exon 1"
    },
    {
      "id": "protein digests"
    },
    {
      "id": "endogeonous compounds"
    },
    {
      "id": "human UGT1A1 protein"
    },
    {
      "id": "sequence RIYLSADPALVVIEHG"
    },
    {
      "id": "UGT1A1 content"
    },
    {
      "id": "human UGT1A1"
    },
    {
      "id": "stable isotope-labelled (SIL) peptide"
    },
    {
      "id": "unique peptide"
    },
    {
      "id": "excretion"
    },
    {
      "id": "Glucuronidation activity studies"
    },
    {
      "id": "supersomes"
    },
    {
      "id": "pooled human liver microsomes"
    },
    {
      "id": "10 amu"
    },
    {
      "id": "precursor ion monitoring"
    },
    {
      "id": "standard curve"
    },
    {
      "id": "complex biological matrices"
    },
    {
      "id": "selective COX-1 inhibitors"
    },
    {
      "id": "ulcerogenic effects"
    },
    {
      "id": "Cyclooxygenase (COX)-1"
    },
    {
      "id": "arterioles"
    },
    {
      "id": "goblet cells"
    },
    {
      "id": "feeding"
    },
    {
      "id": "cimetidine"
    },
    {
      "id": "level"
    },
    {
      "id": "localization"
    },
    {
      "id": "ulcers"
    },
    {
      "id": "cyclooxygenase (COX) isoforms"
    },
    {
      "id": "duodenal ulcers"
    },
    {
      "id": "COX inhibitors"
    },
    {
      "id": "Brunner's gland cells"
    },
    {
      "id": "Gastrointestinal lesions"
    },
    {
      "id": "enzyme immunoassay"
    },
    {
      "id": "SC-560"
    },
    {
      "id": "smooth muscle cells"
    },
    {
      "id": "venules"
    },
    {
      "id": "duodenal mucosa"
    },
    {
      "id": "Auerbach's plexus"
    },
    {
      "id": "capillaries"
    },
    {
      "id": "morning meal"
    },
    {
      "id": "day 4"
    },
    {
      "id": "Meissner's plexus"
    },
    {
      "id": "basal granulated cells"
    },
    {
      "id": "gastrointestinal mucosa"
    },
    {
      "id": "nicotine group"
    },
    {
      "id": "chewing tobacco"
    },
    {
      "id": "declarative memory consolidation"
    },
    {
      "id": "learning"
    },
    {
      "id": "early visual cortex"
    },
    {
      "id": "control substance"
    },
    {
      "id": "memory consolidation"
    },
    {
      "id": "learning effects"
    },
    {
      "id": "Electroencephalographic recordings"
    },
    {
      "id": "alpha activity"
    },
    {
      "id": "improvements"
    },
    {
      "id": "texture elements"
    },
    {
      "id": "non-smoking men"
    },
    {
      "id": "visual texture discrimination task (TDT)"
    },
    {
      "id": "group comparison"
    },
    {
      "id": "P300 latencies"
    },
    {
      "id": "declarative learning"
    },
    {
      "id": "retinal location"
    },
    {
      "id": "Nicotine"
    },
    {
      "id": "training"
    },
    {
      "id": "TDT training"
    },
    {
      "id": "substance consumption"
    },
    {
      "id": "perceptual learning"
    },
    {
      "id": "non-declarative learning"
    },
    {
      "id": "experience-dependent plasticity"
    },
    {
      "id": "dose-dependent cholinergic modulation"
    },
    {
      "id": "orientation"
    },
    {
      "id": "consolidation processes"
    },
    {
      "id": "sensory cortices"
    },
    {
      "id": "low L-BMAA concentrations"
    },
    {
      "id": "protein ubiquitination"
    },
    {
      "id": "high-concentration effects"
    },
    {
      "id": "20S proteasomal"
    },
    {
      "id": "onset and slow progression of ALS/PDC"
    },
    {
      "id": "Guam"
    },
    {
      "id": "L-BMAA"
    },
    {
      "id": "caspase 12 cleavage"
    },
    {
      "id": "low-potency excitotoxin"
    },
    {
      "id": "Parkinsonism-dementia complex (PDC)"
    },
    {
      "id": "nonexcitotoxic conditions"
    },
    {
      "id": "protein incorporation"
    },
    {
      "id": "(14)C-L-BMAA exposures"
    },
    {
      "id": "L-BMAA-mediated cytotoxicity"
    },
    {
      "id": "L-BMAA treatment"
    },
    {
      "id": "low nonexcitotoxic concentrations"
    },
    {
      "id": "high L-BMAA concentrations"
    },
    {
      "id": "reactive oxygen species"
    },
    {
      "id": "caspase 12 activity"
    },
    {
      "id": "L-BMAA-transport"
    },
    {
      "id": "human SH-SY5Y neuroblastoma cells"
    },
    {
      "id": "impairment of cellular protein homeostasis"
    },
    {
      "id": "phosphorylation of elf2\u03b1"
    },
    {
      "id": "Binding of L-BMAA to intracellular proteins"
    },
    {
      "id": "ER stress"
    },
    {
      "id": "human neuroblastoma SH-SY5Y cells"
    },
    {
      "id": "expression of the endoplasmic reticulum (ER) stress marker CHOP"
    },
    {
      "id": "cyanobacterial \u03b2-N-methylamino-L-alanine"
    },
    {
      "id": "SH-SY5Y cells"
    },
    {
      "id": "L-BMAA concentrations"
    },
    {
      "id": "toxic effects"
    },
    {
      "id": "incorporation into proteins"
    },
    {
      "id": "protein oxidization"
    },
    {
      "id": "amyotrophic lateral sclerosis (ALS)"
    },
    {
      "id": "shedding process"
    },
    {
      "id": "thiol isomerase"
    },
    {
      "id": "neuronal cells"
    },
    {
      "id": "subunit oligomerisation"
    },
    {
      "id": "mAChR"
    },
    {
      "id": "Cellular release"
    },
    {
      "id": "carbachol"
    },
    {
      "id": "metalloprotease"
    },
    {
      "id": "batimastat"
    },
    {
      "id": "transmembrane domain"
    },
    {
      "id": "SH-SY5Y"
    },
    {
      "id": "muscarinic acetylcholine receptor"
    },
    {
      "id": "amyloid fibrils"
    },
    {
      "id": "muscarine"
    },
    {
      "id": "membrane anchor"
    },
    {
      "id": "physiological function"
    },
    {
      "id": "cholinergic synapses"
    },
    {
      "id": "physiology"
    },
    {
      "id": "anchorage"
    },
    {
      "id": "hydrolytic enzyme"
    },
    {
      "id": "neurotransmitter"
    },
    {
      "id": "amyloid precursor protein"
    },
    {
      "id": "membrane proteins"
    },
    {
      "id": "pathology"
    },
    {
      "id": "Proline Rich Membrane Anchor"
    },
    {
      "id": "mAChR antagonist"
    },
    {
      "id": "non-catalytic functions"
    },
    {
      "id": "neuronal cell surface"
    },
    {
      "id": "neuroblastoma cell lines SH-SY5Y"
    },
    {
      "id": "neuronal cell lines"
    },
    {
      "id": "NB7"
    },
    {
      "id": "transmembrane protein"
    },
    {
      "id": "related enzyme"
    },
    {
      "id": "mouse basal forebrain cell line SN56"
    },
    {
      "id": "AD research"
    },
    {
      "id": "membrane fractions"
    },
    {
      "id": "GM6001"
    },
    {
      "id": "PRiMA"
    },
    {
      "id": "PPA"
    },
    {
      "id": "reciprocal regulation"
    },
    {
      "id": "antisense"
    },
    {
      "id": "Y1R"
    },
    {
      "id": "Neuropeptide Y Y1 receptor"
    },
    {
      "id": "antioxidative enzymes"
    },
    {
      "id": "appetite suppression"
    },
    {
      "id": "anorectic response"
    },
    {
      "id": "c-AMP response element-binding protein"
    },
    {
      "id": "antiobesity drugs"
    },
    {
      "id": "3G-RSV"
    },
    {
      "id": "oxidative stress-induced cell death"
    },
    {
      "id": "piceid"
    },
    {
      "id": "histone H3 deacetylation"
    },
    {
      "id": "RSV"
    },
    {
      "id": "extracellular fractions"
    },
    {
      "id": "4'G-RSV"
    },
    {
      "id": "C2C12 cells"
    },
    {
      "id": "SIRT1 knockdown"
    },
    {
      "id": "polydatin"
    },
    {
      "id": "C2C12 cell proliferation"
    },
    {
      "id": "SIRT1"
    },
    {
      "id": "intracellular antioxidative mechanism"
    },
    {
      "id": "resveratrol-4'-O-\u03b2-d-glucoside"
    },
    {
      "id": "SOD2 expression"
    },
    {
      "id": "cell-protective function"
    },
    {
      "id": "water solubility"
    },
    {
      "id": "NAD(+)-dependent protein deacetylase SIRT1"
    },
    {
      "id": "resveratrol"
    },
    {
      "id": "resveratrol glucosides"
    },
    {
      "id": "health"
    },
    {
      "id": "resveratrol-3-O-\u03b2-d-glucoside"
    },
    {
      "id": "intracellular fractions"
    },
    {
      "id": "trans-3,5,4'-trihydroxystilbene"
    },
    {
      "id": "SOD2"
    },
    {
      "id": "in vitro antioxidative activity"
    },
    {
      "id": "oxidative stress-induced apoptosis"
    },
    {
      "id": "natural polyphenol"
    },
    {
      "id": "glycosylated forms"
    },
    {
      "id": "glycosyl RSVs"
    },
    {
      "id": "RSV prodrug"
    },
    {
      "id": "mitochondrial superoxide dismutase"
    },
    {
      "id": "SIRT1-dependent histone H3 deacetylation"
    },
    {
      "id": "accuracy"
    },
    {
      "id": "phenolic compounds"
    },
    {
      "id": "diode array and accurate mass spectrometry detection"
    },
    {
      "id": "electrospray ionisation (DAD/ESI-am-MS)"
    },
    {
      "id": "mass accuracy"
    },
    {
      "id": "each selected phenolic compound"
    },
    {
      "id": "range"
    },
    {
      "id": "Instrumental parameters"
    },
    {
      "id": "resolution"
    },
    {
      "id": "UHPLC-DAD/ESI-am-MS method"
    },
    {
      "id": "mass spectrometric method"
    },
    {
      "id": "accurate mass measurements"
    },
    {
      "id": "Thirty-nine phenolic compounds"
    },
    {
      "id": "ultra high performance liquid chromatography (UHPLC)"
    },
    {
      "id": "apple fruits"
    },
    {
      "id": "model deviation"
    },
    {
      "id": "scan speed"
    },
    {
      "id": "apple extracts"
    },
    {
      "id": "intra/inter-day precision"
    },
    {
      "id": "[(14)C]anagliptin"
    },
    {
      "id": "fraction"
    },
    {
      "id": "Renal clearance"
    },
    {
      "id": "glomerular filtration rate"
    },
    {
      "id": "BCRP"
    },
    {
      "id": "anagliptin"
    },
    {
      "id": "unchanged drug"
    },
    {
      "id": "total plasma radioactivity area under the curve"
    },
    {
      "id": "MDR1"
    },
    {
      "id": "dipeptidyl peptidase-4"
    },
    {
      "id": "MRP2"
    },
    {
      "id": "dipeptidyl peptidase-4 inhibitor"
    },
    {
      "id": "unbound M1"
    },
    {
      "id": "active renal elimination"
    },
    {
      "id": "unbound anagliptin"
    },
    {
      "id": "OAT1"
    },
    {
      "id": "postdose"
    },
    {
      "id": "faeces"
    },
    {
      "id": "carboxylate metabolite"
    },
    {
      "id": "MRP4"
    },
    {
      "id": "OAT3"
    },
    {
      "id": "healthy men"
    },
    {
      "id": "neuronal death"
    },
    {
      "id": "FTY720"
    },
    {
      "id": "relapsing-remitting multiple sclerosis"
    },
    {
      "id": "FTY720-P"
    },
    {
      "id": "rat cortical neurons"
    },
    {
      "id": "in vitro model"
    },
    {
      "id": "Mixed cultures of mouse cortical cells"
    },
    {
      "id": "N-methyl-d-aspartate"
    },
    {
      "id": "Fingolimod"
    },
    {
      "id": "cultured cortical neurons"
    },
    {
      "id": "neuronal viability"
    },
    {
      "id": "excitotoxic death"
    },
    {
      "id": "neuroinflammation"
    },
    {
      "id": "S1P"
    },
    {
      "id": "S1PRs"
    },
    {
      "id": "sphingosine-1-phosphate receptor"
    },
    {
      "id": "pathways"
    },
    {
      "id": "S1PR"
    },
    {
      "id": "PtdIns-3-K"
    },
    {
      "id": "NMDA pulse"
    },
    {
      "id": "pure cultures of mouse cortical neurons"
    },
    {
      "id": "W146"
    },
    {
      "id": "type-1 S1PR"
    },
    {
      "id": "mitogen associated protein kinase"
    },
    {
      "id": "S1P1R"
    },
    {
      "id": "autoimmunity"
    },
    {
      "id": "MAPK"
    },
    {
      "id": "secondary lymphoid organs"
    },
    {
      "id": "cells resident in the CNS"
    },
    {
      "id": "sphingosine-1-phosphate"
    },
    {
      "id": "phosphatidylinositol-3-kinase"
    },
    {
      "id": "nine male healthy volunteers"
    },
    {
      "id": "short therapeutic hexapeptide"
    },
    {
      "id": "Lower Limit of Quantification"
    },
    {
      "id": "single intravenous bolus administration"
    },
    {
      "id": "100, 200 and 400 \u03bcg/kg of body weight"
    },
    {
      "id": "His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,)"
    },
    {
      "id": "Disposition"
    },
    {
      "id": "GHRP-6"
    },
    {
      "id": "(13)C(3)Ala-GHRP-6"
    },
    {
      "id": "internal standard"
    },
    {
      "id": "12h"
    },
    {
      "id": "tissue viability"
    },
    {
      "id": "elimination half-life"
    },
    {
      "id": "distribution half-life"
    },
    {
      "id": "7.6 \u00b1 1.9 min"
    },
    {
      "id": "Pharmacokinetic study"
    },
    {
      "id": "values"
    },
    {
      "id": "specific LC-MS method"
    },
    {
      "id": "Akaike index (AIC)"
    },
    {
      "id": "one-compartment model"
    },
    {
      "id": "bi-exponential function"
    },
    {
      "id": "R(2)"
    },
    {
      "id": "Atypical GHRP-6 concentration spikes"
    },
    {
      "id": "four out of the nine subjects"
    },
    {
      "id": "FDA guidelines"
    },
    {
      "id": "Dose dependence analysis"
    },
    {
      "id": "Area under the Curve (AUC)"
    },
    {
      "id": "5 ng/mL"
    },
    {
      "id": "Growth Hormone-Releasing Peptide 6"
    },
    {
      "id": "human plasma"
    },
    {
      "id": "MW=872.44 Da"
    },
    {
      "id": "Gil et al., 2012, J. Pharm. Biomed. Anal. 60, 19-25"
    },
    {
      "id": "85%"
    },
    {
      "id": "growth hormone secretagogue"
    },
    {
      "id": "growth hormone"
    },
    {
      "id": "elimination phase"
    },
    {
      "id": "mathematic modeling"
    },
    {
      "id": "2.5 \u00b1 1.1h"
    },
    {
      "id": "0.99"
    },
    {
      "id": "(pGlu-Gln)-CCK-8"
    },
    {
      "id": "oral glucose tolerance"
    },
    {
      "id": "(pGlu-Gln)-CCK-8 mice"
    },
    {
      "id": "islet number"
    },
    {
      "id": "insulin sensitivity"
    },
    {
      "id": "glucose tolerance"
    },
    {
      "id": "circulating glucose"
    },
    {
      "id": "alpha-cells"
    },
    {
      "id": "GLP-1"
    },
    {
      "id": "lean controls"
    },
    {
      "id": "triacylglycerol accumulation"
    },
    {
      "id": "circulating insulin"
    },
    {
      "id": "glucagon"
    },
    {
      "id": "high fat mice"
    },
    {
      "id": "energy intake"
    },
    {
      "id": "obesity-diabetes"
    },
    {
      "id": "beta-cells"
    },
    {
      "id": "metabolic effects"
    },
    {
      "id": "intraperitoneal glucose tolerance"
    },
    {
      "id": "cholecystokinin receptor"
    },
    {
      "id": "genetic ob/ob mice"
    },
    {
      "id": "LDL-cholesterol"
    },
    {
      "id": "islet size"
    },
    {
      "id": "diet-induced obesity-diabetes"
    },
    {
      "id": "pancreatic glucagon content"
    },
    {
      "id": "ob/ob mice"
    },
    {
      "id": "calcium chelator"
    },
    {
      "id": "potentiation"
    },
    {
      "id": "group I metabotropic glutamate receptors"
    },
    {
      "id": "Ser836"
    },
    {
      "id": "GluK5 C-terminal domain"
    },
    {
      "id": "serines"
    },
    {
      "id": "Ser840"
    },
    {
      "id": "agonist responses"
    },
    {
      "id": "Protein kinase C"
    },
    {
      "id": "calcium signal"
    },
    {
      "id": "mGlu1"
    },
    {
      "id": "C-terminal domain"
    },
    {
      "id": "inhibitor of phospholipase C"
    },
    {
      "id": "phorbol 12-myristate,13-acetate"
    },
    {
      "id": "GluK5"
    },
    {
      "id": "1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid"
    },
    {
      "id": "high-affinity KAR subunits"
    },
    {
      "id": "native KARs"
    },
    {
      "id": "heteromeric KAR-mediated currents"
    },
    {
      "id": "membrane proximal region"
    },
    {
      "id": "Ser833"
    },
    {
      "id": "homomeric KAR-mediated currents"
    },
    {
      "id": "BAPTA"
    },
    {
      "id": "GluK2"
    },
    {
      "id": "okadaic acid"
    },
    {
      "id": "phosphatase inhibitor"
    },
    {
      "id": "overall charge"
    },
    {
      "id": "Confocal immunohistochemistry"
    },
    {
      "id": "cultured rat cortex"
    },
    {
      "id": "mGlu modulation"
    },
    {
      "id": "lavendustin A"
    },
    {
      "id": "mGlu signaling"
    },
    {
      "id": "rat hippocampus"
    },
    {
      "id": "heteromeric kainate receptors"
    },
    {
      "id": "Kainate receptors"
    },
    {
      "id": "ionotropic glutamate receptors"
    },
    {
      "id": "GDP\u03b2S"
    },
    {
      "id": "synaptic transmission"
    },
    {
      "id": "CAG repeat length"
    },
    {
      "id": "receptor activity"
    },
    {
      "id": "TCDD"
    },
    {
      "id": "PC-3"
    },
    {
      "id": "2,3,7,8-tetrachlorodibenzo-p-dioxin"
    },
    {
      "id": "AR activity"
    },
    {
      "id": "PNT1A"
    },
    {
      "id": "CAG repeats"
    },
    {
      "id": "normal length range"
    },
    {
      "id": "polymorphic CAG repeat"
    },
    {
      "id": "transcriptional activity"
    },
    {
      "id": "AhR"
    },
    {
      "id": "androgen receptor (AR)"
    },
    {
      "id": "cell-specific effect"
    },
    {
      "id": "human prostate cells"
    },
    {
      "id": "aryl hydrocarbon receptor"
    },
    {
      "id": "5\u03b1-dihydrotestosterone"
    },
    {
      "id": "ARs"
    },
    {
      "id": "shortest AR variant"
    },
    {
      "id": "CYP1A1 mRNA expression"
    },
    {
      "id": "non-tumor prostate cells"
    },
    {
      "id": "AhR target gene"
    },
    {
      "id": "AR CAG length"
    },
    {
      "id": "AR gene"
    },
    {
      "id": "epigenetic mechanism"
    },
    {
      "id": "anti-neoplastic activity"
    },
    {
      "id": "RAS-GTPase"
    },
    {
      "id": "gene family"
    },
    {
      "id": "Ibandronate"
    },
    {
      "id": "posttranslational isoprenylation"
    },
    {
      "id": "inhibiting their activity"
    },
    {
      "id": "aminobisphosphonates"
    },
    {
      "id": "small GTPases"
    },
    {
      "id": "bisphosphonates"
    },
    {
      "id": "epigenetic mechanisms"
    },
    {
      "id": "down-regulation of DNMT1"
    },
    {
      "id": "epigenetic DNA demethylation"
    },
    {
      "id": "epigenetic DNA-methylation"
    },
    {
      "id": "up-regulation of caspases"
    },
    {
      "id": "FAS-expression"
    },
    {
      "id": "anticancer activity"
    },
    {
      "id": "DNA-CpG-demethylation"
    },
    {
      "id": "immortalized non-neoplastic MC3T3-E1 osteoblastic cells"
    },
    {
      "id": "re-isoprenylation"
    },
    {
      "id": "farnesyl-transferase-inhibition"
    },
    {
      "id": "clinical success"
    },
    {
      "id": "geranylgeranyl-pyrophosphate"
    },
    {
      "id": "modulation of the activity of small-GTPases"
    },
    {
      "id": "stimulation of FAS-expression"
    },
    {
      "id": "MC3T3-E1 non-neoplastic cells"
    },
    {
      "id": "mouse CCL-51 breast cancer cells"
    },
    {
      "id": "farnesylpyrophosphate"
    },
    {
      "id": "siRNA vector"
    },
    {
      "id": "cationic liposome"
    },
    {
      "id": "siRNA lipoplexes-induced toxicity"
    },
    {
      "id": "long-lasting effect"
    },
    {
      "id": "anionic polymer"
    },
    {
      "id": "particles"
    },
    {
      "id": "plasmid-containing lipoplexes"
    },
    {
      "id": "polyglutamate"
    },
    {
      "id": "polyglutamate-containing ones"
    },
    {
      "id": "plasmid DNA-containing siRNA lipoplexes"
    },
    {
      "id": "siRNA-lipoplexes"
    },
    {
      "id": "in vivo toxicity"
    },
    {
      "id": "lipoplexes"
    },
    {
      "id": "polypeptide"
    },
    {
      "id": "nucleic acid"
    },
    {
      "id": "plasmid DNA"
    },
    {
      "id": "cell survival capacity"
    },
    {
      "id": "Systemic injection"
    },
    {
      "id": "siRNA molecule"
    },
    {
      "id": "elevation"
    },
    {
      "id": "assayed cytokines"
    },
    {
      "id": "cationic liposomes"
    },
    {
      "id": "tumoral cell lines"
    },
    {
      "id": "siRNA lipoplexes efficiency"
    },
    {
      "id": "polysaccharide"
    },
    {
      "id": "apoptosis pathway"
    },
    {
      "id": "treated cells"
    },
    {
      "id": "siRNA delivery system"
    },
    {
      "id": "in vitro toxicity"
    },
    {
      "id": "hemoglobin"
    },
    {
      "id": "glucose-6-phosphatase"
    },
    {
      "id": "key enzymes"
    },
    {
      "id": "alkaline phosphatase"
    },
    {
      "id": "hexokinase"
    },
    {
      "id": "glibenclamide"
    },
    {
      "id": "asiatic acid"
    },
    {
      "id": "fructose-1,6-bisphosphatase"
    },
    {
      "id": "pyruvate kinase"
    },
    {
      "id": "hepatic enzymes"
    },
    {
      "id": "carbohydrate metabolism"
    },
    {
      "id": "anti-inflammatory activities"
    },
    {
      "id": "glucose-6-phosphate dehydrogenase"
    },
    {
      "id": "glycosylated hemoglobin"
    },
    {
      "id": "body weight loss"
    },
    {
      "id": "pentacyclic triterpene"
    },
    {
      "id": "key regulatory enzymes"
    },
    {
      "id": "antihyperglycemic effect"
    },
    {
      "id": "aspartate transaminase"
    },
    {
      "id": "ALP"
    },
    {
      "id": "bioactive compound"
    },
    {
      "id": "antioxidant activities"
    },
    {
      "id": "triterpenoid derivative"
    },
    {
      "id": "Centella asiatica"
    },
    {
      "id": "alanine transaminase"
    },
    {
      "id": "diabetes mellitus"
    },
    {
      "id": "STZ"
    },
    {
      "id": "ER\u03b1 cistromes"
    },
    {
      "id": "MCF-7 breast cancer cells"
    },
    {
      "id": "proto-oncogene PIM-1"
    },
    {
      "id": "ER\u03b1 targets"
    },
    {
      "id": "estrogens"
    },
    {
      "id": "breast cancer cell proliferation"
    },
    {
      "id": "ER\u03b1-regulated enhancers"
    },
    {
      "id": "PIM-1"
    },
    {
      "id": "PIM-1 expression"
    },
    {
      "id": "invasive breast tumors"
    },
    {
      "id": "estradiol"
    },
    {
      "id": "growth-promoting role"
    },
    {
      "id": "Proto-oncogene PIM-1"
    },
    {
      "id": "ER\u03b1 target gene"
    },
    {
      "id": "MCF-7 cells"
    },
    {
      "id": "CDKN2B expression"
    },
    {
      "id": "target gene"
    },
    {
      "id": "malignancy"
    },
    {
      "id": "cyclin-dependent protein kinase inhibitor CDKN1A"
    },
    {
      "id": "higher tumor grade"
    },
    {
      "id": "series of substituted N-[3-(3-methoxyphenyl)propyl] amides"
    },
    {
      "id": "FLIPR high-throughput screening assay"
    },
    {
      "id": "extremely potent MT(2)-selective ligands"
    },
    {
      "id": "invaluable tools"
    },
    {
      "id": "two subtypes of mammalian G protein-coupled melatonin receptors"
    },
    {
      "id": "melatonin"
    },
    {
      "id": "pharmacological potencies"
    },
    {
      "id": "human melatonin MT(2) receptors"
    },
    {
      "id": "therapeutic potentials"
    },
    {
      "id": "insomnia"
    },
    {
      "id": "functional roles"
    },
    {
      "id": "distinct melatonin receptor subtypes"
    },
    {
      "id": "synthetic melatonin agonists"
    },
    {
      "id": "17 other GPCRs"
    },
    {
      "id": "GPCRs"
    },
    {
      "id": "substituted phenylpropylamides"
    },
    {
      "id": "melatonin MT2 receptor"
    },
    {
      "id": "2q"
    },
    {
      "id": "most potent subtype-selective ligand"
    },
    {
      "id": "cross-reactivity"
    },
    {
      "id": "Melatonin"
    },
    {
      "id": "major physiological processes"
    },
    {
      "id": "seasonal adaptation"
    },
    {
      "id": "ERK phosphorylation"
    },
    {
      "id": "circadian rhythm"
    },
    {
      "id": "structural moieties"
    },
    {
      "id": "benzyloxyl substituent"
    },
    {
      "id": "C6 position"
    },
    {
      "id": "MT(1) potency"
    },
    {
      "id": "3-methoxyphenyl ring"
    },
    {
      "id": "highly potent subtype-selective ligands"
    },
    {
      "id": "MT(2) EC(50)"
    },
    {
      "id": "MT(2) receptor"
    },
    {
      "id": "MT(2) potency"
    },
    {
      "id": "subtype-selective melatoninergic compounds"
    },
    {
      "id": "drug development"
    },
    {
      "id": "subtype-selectivity"
    },
    {
      "id": "cAMP assays"
    },
    {
      "id": "mammalian G protein-coupled melatonin receptors"
    },
    {
      "id": "inhibition of forskolin-elevated cAMP"
    },
    {
      "id": "recombinant cell lines"
    },
    {
      "id": "native cell lines"
    },
    {
      "id": "human melatonin MT(1) receptors"
    },
    {
      "id": "Structure-activity relationship analysis"
    },
    {
      "id": "elevation of [Ca(2+)]i"
    },
    {
      "id": "melatonin receptors"
    },
    {
      "id": "circadian-related sleep disorders"
    },
    {
      "id": "hormone"
    },
    {
      "id": "Airway epithelial cells"
    },
    {
      "id": "pathogens"
    },
    {
      "id": "bronchial epithelial cells (HBECs)"
    },
    {
      "id": "cell accumulation"
    },
    {
      "id": "G(0)/G(1) phase"
    },
    {
      "id": "p21 nuclear accumulation"
    },
    {
      "id": "trypan blue-exclusion assay"
    },
    {
      "id": "cell number"
    },
    {
      "id": "Rb protein"
    },
    {
      "id": "human pulmonary epithelial cells"
    },
    {
      "id": "Rb phosphorylation"
    },
    {
      "id": "human alveolar epithelial cells (A549)"
    },
    {
      "id": "late apoptosis"
    },
    {
      "id": "heme oxygenase-1 (HO-1)"
    },
    {
      "id": "HO-1 expression"
    },
    {
      "id": "flow cytometric analysis"
    },
    {
      "id": "p21 protein stability"
    },
    {
      "id": "Cell cycle regulation"
    },
    {
      "id": "p21"
    },
    {
      "id": "supplemental compound"
    },
    {
      "id": "HO-1"
    },
    {
      "id": "retinoblastoma (Rb) protein"
    },
    {
      "id": "proteasomal proteolytic pathway"
    },
    {
      "id": "cellular proliferation"
    },
    {
      "id": "nuclear p21 accumulation"
    },
    {
      "id": "p21 protein"
    },
    {
      "id": "experimental study"
    },
    {
      "id": "oxytocin administration"
    },
    {
      "id": "processing"
    },
    {
      "id": "emotional faces"
    },
    {
      "id": "oxytocin"
    },
    {
      "id": "attention"
    },
    {
      "id": "pictures"
    },
    {
      "id": "emotional facial expressions"
    },
    {
      "id": "allocation of attention"
    },
    {
      "id": "disgusted face"
    },
    {
      "id": "neural processing"
    },
    {
      "id": "facial stimuli"
    },
    {
      "id": "happy and disgusted faces"
    },
    {
      "id": "amplitudes"
    },
    {
      "id": "negative feedback"
    },
    {
      "id": "double-blind, placebo-controlled within-subjects design"
    },
    {
      "id": "16 IU of intranasal oxytocin"
    },
    {
      "id": "event-related potential (ERP) responses"
    },
    {
      "id": "48 female undergraduate students"
    },
    {
      "id": "maternal love withdrawal"
    },
    {
      "id": "placebo administration"
    },
    {
      "id": "Significant associations"
    },
    {
      "id": "LPP amplitude"
    },
    {
      "id": "event-related potentials (ERPs)"
    },
    {
      "id": "ERPs"
    },
    {
      "id": "performance feedback"
    },
    {
      "id": "feedback stimuli"
    },
    {
      "id": "Participants"
    },
    {
      "id": "love withdrawal"
    },
    {
      "id": "mothers"
    },
    {
      "id": "female participants"
    },
    {
      "id": "ganglion cells"
    },
    {
      "id": "mouse retina preparation"
    },
    {
      "id": "(S)-3,4-dicarboxyphenylglycine"
    },
    {
      "id": "DCPG"
    },
    {
      "id": "glutamate release sites"
    },
    {
      "id": "inhibitory currents"
    },
    {
      "id": "allosteric compounds"
    },
    {
      "id": "light responses"
    },
    {
      "id": "peak excitatory currents"
    },
    {
      "id": "ON-ganglion cells"
    },
    {
      "id": "AZ"
    },
    {
      "id": "synaptic responses"
    },
    {
      "id": "orthosteric compounds"
    },
    {
      "id": "metabotropic glutamate receptor 8"
    },
    {
      "id": "excitatory currents"
    },
    {
      "id": "OFF-ganglion cell"
    },
    {
      "id": "allosteric modulator"
    },
    {
      "id": "bright stimuli"
    },
    {
      "id": "retinal ganglion cell"
    },
    {
      "id": "dim stimuli"
    },
    {
      "id": "receptor stimulation"
    },
    {
      "id": "bright light stimulation"
    },
    {
      "id": "whole-cell voltage-clamped ganglion cells"
    },
    {
      "id": "isolated, superfused mouse retina preparation"
    },
    {
      "id": "endogenous glutamate"
    },
    {
      "id": "ON-OFF-ganglion cells"
    },
    {
      "id": "orthosteric agonist"
    },
    {
      "id": "positive allosteric modulator"
    },
    {
      "id": "AZ12216052"
    },
    {
      "id": "Helenalin"
    },
    {
      "id": "sesquiterpene lactone"
    },
    {
      "id": "carcinoma cells"
    },
    {
      "id": "HCT116 cells"
    },
    {
      "id": "regulated in development and DNA damage responses (REDD) 1"
    },
    {
      "id": "REDD) 1"
    },
    {
      "id": "ROS scavengers"
    },
    {
      "id": "glutathione ethyl ester"
    },
    {
      "id": "human renal carcinoma ACHN cells"
    },
    {
      "id": "N-acetylcystine"
    },
    {
      "id": "Caki cells"
    },
    {
      "id": "renal cell carcinoma"
    },
    {
      "id": "endoplasmic reticulum (ER) stress-related genes"
    },
    {
      "id": "CHOP"
    },
    {
      "id": "siRNA"
    },
    {
      "id": "anti-tumor activities"
    },
    {
      "id": "NAC"
    },
    {
      "id": "intracellular reactive oxygen species"
    },
    {
      "id": "helenalin"
    },
    {
      "id": "CCAAT enhancer-binding protein-homologous protein"
    },
    {
      "id": "activating transcription factor-4"
    },
    {
      "id": "GEE"
    },
    {
      "id": "ACHN cells"
    },
    {
      "id": "HT29"
    },
    {
      "id": "human renal carcinoma Caki cells"
    },
    {
      "id": "ATF4"
    },
    {
      "id": "endoplasmic reticulum stress"
    },
    {
      "id": "ROS"
    },
    {
      "id": "human colon carcinoma HT29"
    },
    {
      "id": "CREB activation"
    },
    {
      "id": "ERK activation"
    },
    {
      "id": "reconsolidation"
    },
    {
      "id": "ERK and CREB signaling pathway"
    },
    {
      "id": "prefrontal cortex"
    },
    {
      "id": "retrieval"
    },
    {
      "id": "METH-induced spatial memory changes"
    },
    {
      "id": "memory retrieval"
    },
    {
      "id": "spatial memory retrieval"
    },
    {
      "id": "memory reconsolidation"
    },
    {
      "id": "neuroplastic changes"
    },
    {
      "id": "1.0 mg/kg dose of METH"
    },
    {
      "id": "spatial memory reconsolidation"
    },
    {
      "id": "spatial memory consolidation"
    },
    {
      "id": "METH-treated mouse groups"
    },
    {
      "id": "cAMP response element-binding protein"
    },
    {
      "id": "Morris water maze"
    },
    {
      "id": "PFC"
    },
    {
      "id": "Drugs of abuse"
    },
    {
      "id": "processes of spatial memory"
    },
    {
      "id": "internal rotation patterns"
    },
    {
      "id": "theoretical predictions"
    },
    {
      "id": "enantiomeric pairs"
    },
    {
      "id": "conformers"
    },
    {
      "id": "diisopropyl ketone"
    },
    {
      "id": "(CH(3))(2)HC-CO-CH(CH(3))(2)"
    },
    {
      "id": "symmetry"
    },
    {
      "id": "Conformational landscape"
    },
    {
      "id": "conformer"
    },
    {
      "id": "C(2) symmetry"
    },
    {
      "id": "two-dimensional potential energy surface"
    },
    {
      "id": "enantiomeric pair"
    },
    {
      "id": "barriers to internal rotation"
    },
    {
      "id": "B3LYP/6-311++G(d,p) level"
    },
    {
      "id": "MP2/6-311++G(d,p) level of theory"
    },
    {
      "id": "gas-phase structures"
    },
    {
      "id": "ab initio calculations"
    },
    {
      "id": "transitions"
    },
    {
      "id": "theoretical constants"
    },
    {
      "id": "C(2) conformer"
    },
    {
      "id": "stationary points"
    },
    {
      "id": "harmonic frequency calculations"
    },
    {
      "id": "gas-phase structure"
    },
    {
      "id": "MP2 method"
    },
    {
      "id": "rotational constants"
    },
    {
      "id": "microwave spectroscopy"
    },
    {
      "id": "sextic centrifugal distortion constants"
    },
    {
      "id": "isopropyl groups"
    },
    {
      "id": "supersonic jet"
    },
    {
      "id": "methyl groups"
    },
    {
      "id": "quantum chemical calculations"
    },
    {
      "id": "centrifugal distortion constants"
    },
    {
      "id": "experimental constants"
    },
    {
      "id": "levels of theory"
    },
    {
      "id": "HF method"
    },
    {
      "id": "molecular beam Fourier transform microwave spectroscopy"
    },
    {
      "id": "B3LYP method"
    },
    {
      "id": "cm(-1)"
    },
    {
      "id": "energy decomposition analysis"
    },
    {
      "id": "two complexes"
    },
    {
      "id": "bidentate ligands"
    },
    {
      "id": "hydrogen bonding stability"
    },
    {
      "id": "non-covalent metal-ligand bonds"
    },
    {
      "id": "inter-atomic interactions"
    },
    {
      "id": "charge transfer term"
    },
    {
      "id": "reported experimental behaviors"
    },
    {
      "id": "higher stability"
    },
    {
      "id": "complex 3"
    },
    {
      "id": "observed properties"
    },
    {
      "id": "structural stability"
    },
    {
      "id": "quantum properties"
    },
    {
      "id": "QTAIM"
    },
    {
      "id": "three forms of rapta-C complexes"
    },
    {
      "id": "NEDA"
    },
    {
      "id": "three models of rapta-C complexes"
    },
    {
      "id": "bidentate coordination"
    },
    {
      "id": "molecular properties"
    },
    {
      "id": "DFT"
    },
    {
      "id": "hybrid functional"
    },
    {
      "id": "intramolecular forces"
    },
    {
      "id": "polarization contributions"
    },
    {
      "id": "complex 2"
    },
    {
      "id": "rapta-C based complex"
    },
    {
      "id": "insight"
    },
    {
      "id": "nature of intramolecular forces"
    },
    {
      "id": "polarization"
    },
    {
      "id": "theoretical approach"
    },
    {
      "id": "complex 1"
    },
    {
      "id": "basis set"
    },
    {
      "id": "electrostatic terms"
    },
    {
      "id": "work"
    },
    {
      "id": "ECP"
    },
    {
      "id": "exchange repulsion"
    },
    {
      "id": "Caffeic acid"
    },
    {
      "id": "Individual phenolics"
    },
    {
      "id": "Bound flavonoid contents"
    },
    {
      "id": "Catechin equivalents"
    },
    {
      "id": "Free flavonoid contents"
    },
    {
      "id": "Free phenolics"
    },
    {
      "id": "Litchi pulp"
    },
    {
      "id": "Compound"
    },
    {
      "id": "Free fractions"
    },
    {
      "id": "13 varieties"
    },
    {
      "id": "Antioxidant activity"
    },
    {
      "id": "Flavonoid contents"
    },
    {
      "id": "Flavonoids"
    },
    {
      "id": "Total flavonoid contents"
    },
    {
      "id": "DPPH scavenging capacity methods"
    },
    {
      "id": "Free phenolic contents"
    },
    {
      "id": "Gallic acid equivalents"
    },
    {
      "id": "Varietal differences"
    },
    {
      "id": "Phytochemical contents"
    },
    {
      "id": "Cultivars"
    },
    {
      "id": "Southern China"
    },
    {
      "id": "Free form"
    },
    {
      "id": "Phenolic contents"
    },
    {
      "id": "(+)-catechin"
    },
    {
      "id": "Bound phenolic contents"
    },
    {
      "id": "Chlorogenic acid"
    },
    {
      "id": "Rutin"
    },
    {
      "id": "Total phenolic contents"
    },
    {
      "id": "Varietal discrepancy"
    },
    {
      "id": "Bound fractions"
    },
    {
      "id": "Gallic acid"
    },
    {
      "id": "Phenolic profiles"
    },
    {
      "id": "FRAP"
    },
    {
      "id": "(-)-epicatechin"
    },
    {
      "id": "molar percentages"
    },
    {
      "id": "CPP"
    },
    {
      "id": "total sugar"
    },
    {
      "id": "Cyclocarya paliurus leaves"
    },
    {
      "id": "hot water extraction"
    },
    {
      "id": "physicochemical properties"
    },
    {
      "id": "TGA"
    },
    {
      "id": "uronic acid"
    },
    {
      "id": "galactose"
    },
    {
      "id": "anion-exchange chromatography"
    },
    {
      "id": "anticancer effect"
    },
    {
      "id": "3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide"
    },
    {
      "id": "ethanol precipitation"
    },
    {
      "id": "Fourier transform infrared spectrometry"
    },
    {
      "id": "monosaccharides"
    },
    {
      "id": "rhamnose"
    },
    {
      "id": "GPC"
    },
    {
      "id": "physicochemical characterisation"
    },
    {
      "id": "gel permeation chromatography"
    },
    {
      "id": "molecular weight"
    },
    {
      "id": "DLS"
    },
    {
      "id": "deproteinisation"
    },
    {
      "id": "Purification"
    },
    {
      "id": "inhibition effect"
    },
    {
      "id": "dynamic light scattering"
    },
    {
      "id": "thermal gravimetric analysis"
    },
    {
      "id": "mannose"
    },
    {
      "id": "GC-MS"
    },
    {
      "id": "human gastric cancer HeLa cells"
    },
    {
      "id": "viscometry analysis"
    },
    {
      "id": "MTT"
    },
    {
      "id": "arabinose"
    },
    {
      "id": "FTIR"
    },
    {
      "id": "UV-visible spectrophotometry"
    },
    {
      "id": "MTT assay"
    },
    {
      "id": "xylose"
    },
    {
      "id": "Cyclocarya paliurus (Batal.) Iljinskaja polysaccharide"
    },
    {
      "id": "intracellular GTP depletion"
    },
    {
      "id": "transcription elongation"
    },
    {
      "id": "ELL"
    },
    {
      "id": "eleven-nineteen lysine-rich leukaemia"
    },
    {
      "id": "super elongation complex"
    },
    {
      "id": "ELL3"
    },
    {
      "id": "CDK9"
    },
    {
      "id": "cyclin-dependent kinase 9"
    },
    {
      "id": "ELL3 mRNA expression"
    },
    {
      "id": "F7 up-regulation"
    },
    {
      "id": "P-TEFb"
    },
    {
      "id": "6-mercaptopurine"
    },
    {
      "id": "Ribavirin"
    },
    {
      "id": "AFF4"
    },
    {
      "id": "F7"
    },
    {
      "id": "human hepatoma cell line"
    },
    {
      "id": "ribavirin treatment"
    },
    {
      "id": "FVII gene"
    },
    {
      "id": "basal mechanism"
    },
    {
      "id": "ribavirin-induced FVII mRNA up-regulation"
    },
    {
      "id": "P-TEFb complex"
    },
    {
      "id": "pleiotropic functions"
    },
    {
      "id": "positive-transcription elongation factor b"
    },
    {
      "id": "FVII mRNA transcription elongation"
    },
    {
      "id": "coagulation factor VII gene expression"
    },
    {
      "id": "Factor VII"
    },
    {
      "id": "hepatitis C virus-infected haemophilia patients"
    },
    {
      "id": "hepatitis C virus"
    },
    {
      "id": "knockdown of ELL3"
    },
    {
      "id": "vitamin K"
    },
    {
      "id": "FVII mRNA transcription"
    },
    {
      "id": "haemophilia patients"
    },
    {
      "id": "Coagulation FVII"
    },
    {
      "id": "ELL3 recruitment"
    },
    {
      "id": "IMPDH"
    },
    {
      "id": "inosine-5'-monophosphate dehydrogenase"
    },
    {
      "id": "ribavirin-induced up-regulation"
    },
    {
      "id": "transport process"
    },
    {
      "id": "rCtr1"
    },
    {
      "id": "DRG neurons"
    },
    {
      "id": "platinum-induced neurotoxicity"
    },
    {
      "id": "cold temperature"
    },
    {
      "id": "HEK/rCtr1 cells"
    },
    {
      "id": "neurodegenerative processes"
    },
    {
      "id": "silver"
    },
    {
      "id": "copper transporter 1"
    },
    {
      "id": "rat Ctr1"
    },
    {
      "id": "cultured rat DRG neurons"
    },
    {
      "id": "platinum"
    },
    {
      "id": "membrane transporter"
    },
    {
      "id": "Ctr1"
    },
    {
      "id": "rCtr1 protein"
    },
    {
      "id": "Heterologous expression"
    },
    {
      "id": "platinum anticancer drugs"
    },
    {
      "id": "copper toxicity"
    },
    {
      "id": "cisplatin"
    },
    {
      "id": "platinum drugs"
    },
    {
      "id": "carboplatin"
    },
    {
      "id": "cytotoxicities"
    },
    {
      "id": "oxaliplatin"
    },
    {
      "id": "temperature"
    },
    {
      "id": "copper homeostasis"
    },
    {
      "id": "oxaliplatin cytotoxicity"
    },
    {
      "id": "oxaliplatin exposure"
    },
    {
      "id": "alternative mechanisms"
    },
    {
      "id": "zinc"
    },
    {
      "id": "neuronal cell body plasma membranes"
    },
    {
      "id": "Energy-restricted diet"
    },
    {
      "id": "24 weeks"
    },
    {
      "id": "Free Androgen Index"
    },
    {
      "id": "Week 12"
    },
    {
      "id": "Glucose"
    },
    {
      "id": "Baseline"
    },
    {
      "id": "Sex hormone-binding globulin"
    },
    {
      "id": "Week 24"
    },
    {
      "id": "Physical exercise"
    },
    {
      "id": "Orlistat administration"
    },
    {
      "id": "Weight loss"
    },
    {
      "id": "AMH"
    },
    {
      "id": "Overweight and obese women with polycystic ovary syndrome"
    },
    {
      "id": "Insulin sensitivity"
    },
    {
      "id": "Overweight and obese controls"
    },
    {
      "id": "IR indices"
    },
    {
      "id": "Insulin Resistance"
    },
    {
      "id": "FAI"
    },
    {
      "id": "Serum Anti-M\u00fcllerian Hormone"
    },
    {
      "id": "FSH"
    },
    {
      "id": "Women with polycystic ovary syndrome"
    },
    {
      "id": "Hyperandrogenism"
    },
    {
      "id": "PRL"
    },
    {
      "id": "Androgens"
    },
    {
      "id": "SHBG"
    },
    {
      "id": "3 times per day"
    },
    {
      "id": "120 mg"
    },
    {
      "id": "Montmorillonite"
    },
    {
      "id": "xyloglucan"
    },
    {
      "id": "XG adsorption"
    },
    {
      "id": "quartz crystal microbalance analysis"
    },
    {
      "id": "clay bionanocomposites"
    },
    {
      "id": "processing routes"
    },
    {
      "id": "nanocomposites"
    },
    {
      "id": "FE-SEM"
    },
    {
      "id": "moisture durability"
    },
    {
      "id": "water-soluble biopolymers"
    },
    {
      "id": "strong XG-MTM interactions"
    },
    {
      "id": "MTM"
    },
    {
      "id": "reinforcement efficiency"
    },
    {
      "id": "strong in-plane orientation"
    },
    {
      "id": "clay platelets"
    },
    {
      "id": "oriented bionanocomposite coatings"
    },
    {
      "id": "barrier properties"
    },
    {
      "id": "nanostructural control"
    },
    {
      "id": "XG dimensions"
    },
    {
      "id": "composites"
    },
    {
      "id": "unmodified biological polymer"
    },
    {
      "id": "Mechanical and gas barrier properties"
    },
    {
      "id": "high relative humidity"
    },
    {
      "id": "XG"
    },
    {
      "id": "continuous water-based processing"
    },
    {
      "id": "Bioinspired and highly oriented clay nanocomposites"
    },
    {
      "id": "xyloglucan biopolymer matrix"
    },
    {
      "id": "nanostructure"
    },
    {
      "id": "highly oriented and intercalated clay platelets"
    },
    {
      "id": "atomistic simulations"
    },
    {
      "id": "highly oriented and well-dispersed MTM"
    },
    {
      "id": "mechanical and barrier properties"
    },
    {
      "id": "TEM"
    },
    {
      "id": "Properties"
    },
    {
      "id": "humid conditions"
    },
    {
      "id": "XRD"
    },
    {
      "id": "UCCB01-125"
    },
    {
      "id": "inflammatory pain"
    },
    {
      "id": "PSD-95"
    },
    {
      "id": "NMDAR antagonist"
    },
    {
      "id": "PSD-95 inhibition"
    },
    {
      "id": "NMDAR antagonism-related side-effects"
    },
    {
      "id": "long-term memory"
    },
    {
      "id": "NMDAR-related activity"
    },
    {
      "id": "chronic inflammatory pain"
    },
    {
      "id": "motor performance"
    },
    {
      "id": "NMDAR antagonism"
    },
    {
      "id": "motor functions"
    },
    {
      "id": "dimeric PSD-95 inhibitor"
    },
    {
      "id": "CFA-induced mechanical hypersensitivity"
    },
    {
      "id": "CFA-induced hypersensitivity"
    },
    {
      "id": "cognitive performance"
    },
    {
      "id": "CFA model"
    },
    {
      "id": "mechanical hypersensitivity"
    },
    {
      "id": "cognitive functions"
    },
    {
      "id": "NMDAR activation"
    },
    {
      "id": "anti-nociceptive action"
    },
    {
      "id": "NMDAR"
    },
    {
      "id": "chronic pain states"
    },
    {
      "id": "neuronal NO synthase"
    },
    {
      "id": "side-effect profiles"
    },
    {
      "id": "NMDAR ion channel function"
    },
    {
      "id": "NMDAR/PSD-95/nNOS complex"
    },
    {
      "id": "CRAC treatment"
    },
    {
      "id": "atheroma deposits"
    },
    {
      "id": "hypocholesterolemic agent"
    },
    {
      "id": "high cholesterol diet"
    },
    {
      "id": "LDL cholesterol"
    },
    {
      "id": "cholesterol recognition/interaction amino acid sequence"
    },
    {
      "id": "markers"
    },
    {
      "id": "muscular damage"
    },
    {
      "id": "carboxy-terminus"
    },
    {
      "id": "TSPO"
    },
    {
      "id": "serum creatine kinase"
    },
    {
      "id": "translocator protein (18-kDa) TSPO"
    },
    {
      "id": "cholesterol-binding protein"
    },
    {
      "id": "aorta"
    },
    {
      "id": "circulating cholesterol levels"
    },
    {
      "id": "ApoE knock-out B6.129P2-Apoetm1Unc/J mice"
    },
    {
      "id": "lipid homeostasis"
    },
    {
      "id": "CRAC"
    },
    {
      "id": "atherosclerotic plaques"
    },
    {
      "id": "domain"
    },
    {
      "id": "cholesterol recognition/interaction amino acid consensus"
    },
    {
      "id": "VLNYYVWR human CRAC sequence"
    },
    {
      "id": "free cholesterol"
    },
    {
      "id": "anti-atherogenic properties"
    },
    {
      "id": "blood vessels"
    },
    {
      "id": "cardiac damage"
    },
    {
      "id": "2% high cholesterol diet"
    },
    {
      "id": "neurological damage"
    },
    {
      "id": "CRAC domain"
    },
    {
      "id": "total cholesterol"
    },
    {
      "id": "translocator protein TSPO"
    },
    {
      "id": "circulating HDL"
    },
    {
      "id": "high fat diet (HFD)"
    },
    {
      "id": "GIP hypersecretion"
    },
    {
      "id": "nutrient ingestion"
    },
    {
      "id": "knockdown of Rfx6"
    },
    {
      "id": "cellular content"
    },
    {
      "id": "energy accumulation"
    },
    {
      "id": "secretion of GIP"
    },
    {
      "id": "Rfx6"
    },
    {
      "id": "GIP content"
    },
    {
      "id": "gastric inhibitory polypeptide"
    },
    {
      "id": "incretin"
    },
    {
      "id": "Transcriptional regulatory factor X6"
    },
    {
      "id": "GIP mRNA expression"
    },
    {
      "id": "expression levels of Rfx6 mRNA"
    },
    {
      "id": "HFD-fed mice"
    },
    {
      "id": "glucose-stimulated insulin secretion"
    },
    {
      "id": "isolated K-cells"
    },
    {
      "id": "Microarray analysis"
    },
    {
      "id": "enteroendocrine K-cells"
    },
    {
      "id": "HFD"
    },
    {
      "id": "GIP mRNA expression in K-cells"
    },
    {
      "id": "high fat diet-induced obesity"
    },
    {
      "id": "GIP-GFP knock-in mice"
    },
    {
      "id": "overexpression of Rfx6"
    },
    {
      "id": "Plasma GIP levels"
    },
    {
      "id": "obese state"
    },
    {
      "id": "region in the gip promoter"
    },
    {
      "id": "gip promoter activity"
    },
    {
      "id": "total measured endogenous bile acids"
    },
    {
      "id": "glycocholic acid"
    },
    {
      "id": "TCA"
    },
    {
      "id": "cellular viability"
    },
    {
      "id": "suspended rat hepatocytes"
    },
    {
      "id": "RTV"
    },
    {
      "id": "hepatocyte viability"
    },
    {
      "id": "lopinavir"
    },
    {
      "id": "bile acid disposition"
    },
    {
      "id": "[(3)H]TCA accumulation"
    },
    {
      "id": "LPV"
    },
    {
      "id": "Antiretroviral protease inhibitors"
    },
    {
      "id": "ritonavir"
    },
    {
      "id": "endogenous bile acid"
    },
    {
      "id": "sandwich-cultured rat hepatocytes"
    },
    {
      "id": "BSEP inhibitors"
    },
    {
      "id": "[(3)H]TCA biliary clearance"
    },
    {
      "id": "LPV/r"
    },
    {
      "id": "bile acid transport"
    },
    {
      "id": "concentration-dependent effect"
    },
    {
      "id": "SCRH"
    },
    {
      "id": "adaptive responses"
    },
    {
      "id": "drug-induced liver injury"
    },
    {
      "id": "ATP assays"
    },
    {
      "id": "\u03b1/\u03b2-tauromuricholic acid"
    },
    {
      "id": "initial uptake rates"
    },
    {
      "id": "glycochenodeoxycholic acid"
    },
    {
      "id": "Inhibition"
    },
    {
      "id": "intracellular accumulation"
    },
    {
      "id": "bile"
    },
    {
      "id": "exogenous bile acid"
    },
    {
      "id": "rat hepatocytes"
    },
    {
      "id": "CDCA"
    },
    {
      "id": "bile salt export pump"
    },
    {
      "id": "Lactate dehydrogenase"
    },
    {
      "id": "[(3)H]taurocholic acid"
    },
    {
      "id": "taurochenodeoxycholic acid"
    },
    {
      "id": "BSEP"
    },
    {
      "id": "[(14)C]chenodeoxycholic acid"
    },
    {
      "id": "nTiO2 products"
    },
    {
      "id": "P25"
    },
    {
      "id": "titanium dioxide nanoparticles (nTiO2)"
    },
    {
      "id": "Nanoparticle toxicity"
    },
    {
      "id": "A-100"
    },
    {
      "id": "daphnia"
    },
    {
      "id": "A-100 (\u223c140 nm)"
    },
    {
      "id": "ecotoxicity"
    },
    {
      "id": "product composition"
    },
    {
      "id": "chronic ecotoxicity"
    },
    {
      "id": "D. magna"
    },
    {
      "id": "crystalline structure"
    },
    {
      "id": "test design"
    },
    {
      "id": "reproduction studies"
    },
    {
      "id": "environmentally relevant concentrations"
    },
    {
      "id": "dissolved organic carbon"
    },
    {
      "id": "accumulation of nTiO2"
    },
    {
      "id": "A-100 (\u223c330 nm)"
    },
    {
      "id": "P25 (\u223c130 nm)"
    },
    {
      "id": "environmental risk assessment"
    },
    {
      "id": "nanoparticles"
    },
    {
      "id": "wildlife"
    },
    {
      "id": "semi-static test design"
    },
    {
      "id": "Daphnia magna"
    },
    {
      "id": "semi-static exposure scenario"
    },
    {
      "id": "flow-through exposure scenario"
    },
    {
      "id": "particle size"
    },
    {
      "id": "bottom of the test vessel"
    },
    {
      "id": "number of released offspring"
    },
    {
      "id": "flow-through experiment"
    },
    {
      "id": "environmental risk"
    },
    {
      "id": "nanoparticle characteristics"
    },
    {
      "id": "standard test protocols"
    },
    {
      "id": "targeting functionality"
    },
    {
      "id": "stable metal-oxide nanoparticles"
    },
    {
      "id": "imaging functionality"
    },
    {
      "id": "route"
    },
    {
      "id": "Magnetic nanoclusters"
    },
    {
      "id": "MNCs"
    },
    {
      "id": "poly(acrylic acid-co-propargyl acrylate)"
    },
    {
      "id": "extended coverage"
    },
    {
      "id": "serum proteins"
    },
    {
      "id": "NIR emission"
    },
    {
      "id": "challenge"
    },
    {
      "id": "therapeutic functionality"
    },
    {
      "id": "Composite nanoclusters"
    },
    {
      "id": "targeted cellular imaging"
    },
    {
      "id": "magnetic functionality"
    },
    {
      "id": "magnetic Fe(3)O(4) nanoparticles"
    },
    {
      "id": "bovine serum albumin"
    },
    {
      "id": "near-infrared (NIR) emitting fluorophore"
    },
    {
      "id": "photodynamic therapy"
    },
    {
      "id": "azide-modified indocyanine green"
    },
    {
      "id": "co-precipitation"
    },
    {
      "id": "iron salts"
    },
    {
      "id": "biofunctionality"
    },
    {
      "id": "aqueous environment"
    },
    {
      "id": "fluorophore"
    },
    {
      "id": "copolymer stabilizers"
    },
    {
      "id": "alkyne surface functionality"
    },
    {
      "id": "multimodal imaging probes"
    },
    {
      "id": "chemical functionality"
    },
    {
      "id": "near-infrared fluorescence"
    },
    {
      "id": "indocyanine green fluorophores"
    },
    {
      "id": "nontoxic core-shell macromolecule"
    },
    {
      "id": "A549 human epithelial cells"
    },
    {
      "id": "binding pockets"
    },
    {
      "id": "human serum albumin (HSA) core"
    },
    {
      "id": "Dendronized G2-DHSA-doxorubicin"
    },
    {
      "id": "cationized shell region"
    },
    {
      "id": "ethynyl-G2.0-PAMAM dendrons"
    },
    {
      "id": "core-shell biohybrid"
    },
    {
      "id": "attachment"
    },
    {
      "id": "loading"
    },
    {
      "id": "reservoir"
    },
    {
      "id": "lipophilic molecules"
    },
    {
      "id": "binding capacity"
    },
    {
      "id": "electron paramagnetic resonance (EPR) spectroscopy"
    },
    {
      "id": "drug molecules"
    },
    {
      "id": "native protein"
    },
    {
      "id": "HSA"
    },
    {
      "id": "dendritic PAMAM shell"
    },
    {
      "id": "drug loading"
    },
    {
      "id": "pockets"
    },
    {
      "id": "Dendronized albumin core-shell transporters"
    },
    {
      "id": "drug loading capacity"
    },
    {
      "id": "lipophilic guests"
    },
    {
      "id": "dendronized G2-DHSA"
    },
    {
      "id": "ethynyl-G3.0-PAMAM dendrons"
    },
    {
      "id": "imaging agent"
    },
    {
      "id": "carbonic anhydrase II"
    },
    {
      "id": "(18) F surrogates"
    },
    {
      "id": "(18) F"
    },
    {
      "id": "in situ click-chemistry"
    },
    {
      "id": "(19) F-bearing fragments"
    },
    {
      "id": "(19) F"
    },
    {
      "id": "PET probes"
    },
    {
      "id": "chemical characteristics"
    },
    {
      "id": "lead hits"
    },
    {
      "id": "biological characteristics"
    },
    {
      "id": "CA II"
    },
    {
      "id": "PET probe discovery"
    },
    {
      "id": "in situ"
    },
    {
      "id": "target affinities"
    },
    {
      "id": "Ras-dva"
    },
    {
      "id": "Pit-1"
    },
    {
      "id": "reporter construct"
    },
    {
      "id": "chicken ras-dva 5'-flanking region"
    },
    {
      "id": "glucocorticoid-regulated gene"
    },
    {
      "id": "embryonic anterior pituitary gland"
    },
    {
      "id": "ras-dva mRNA"
    },
    {
      "id": "direct transcriptional target"
    },
    {
      "id": "functional differentiation"
    },
    {
      "id": "lactotrophs"
    },
    {
      "id": "pituitary somatotrophs"
    },
    {
      "id": "anterior neural fold protein-1/homeobox expressed in embryonic stem cells-1"
    },
    {
      "id": "DNA elements"
    },
    {
      "id": "5'-flanking region"
    },
    {
      "id": "pituitary cells"
    },
    {
      "id": "expression profile"
    },
    {
      "id": "chicken embryonic pituitary gland"
    },
    {
      "id": "corticosterone"
    },
    {
      "id": "glucocorticoid receptor (GR) binding sites"
    },
    {
      "id": "Mutagenesis"
    },
    {
      "id": "Glucocorticoids"
    },
    {
      "id": "Pituitary ras-dva mRNA levels"
    },
    {
      "id": "embryonic day (e) 18"
    },
    {
      "id": "Pit-1 site"
    },
    {
      "id": "ras-dva promoter activity"
    },
    {
      "id": "chicken e11 pituitary cells"
    },
    {
      "id": "Pit-1 lineage"
    },
    {
      "id": "glucocorticoid regulation"
    },
    {
      "id": "Glucocorticoid treatment"
    },
    {
      "id": "developing chicken anterior pituitary"
    },
    {
      "id": "pituitary development"
    },
    {
      "id": "pituitary-specific transcription factor-1 (Pit-1) binding sites"
    },
    {
      "id": "glucocorticoid"
    },
    {
      "id": "hatch"
    },
    {
      "id": "Ras-dva expression"
    },
    {
      "id": "pituitary gland"
    },
    {
      "id": "in vivo regulation"
    },
    {
      "id": "probe"
    },
    {
      "id": "high expression"
    },
    {
      "id": "populations of activated macrophages"
    },
    {
      "id": "legumain activity"
    },
    {
      "id": "ideal marker"
    },
    {
      "id": "primary tumor inflammation"
    },
    {
      "id": "activity-based probe"
    },
    {
      "id": "mouse models of cancer"
    },
    {
      "id": "active legumain"
    },
    {
      "id": "previously reported probes"
    },
    {
      "id": "primary macrophages"
    },
    {
      "id": "macrophage activation"
    },
    {
      "id": "tumor microenvironment"
    },
    {
      "id": "tumorigenesis"
    },
    {
      "id": "cancer progression"
    },
    {
      "id": "quenched activity-based probe"
    },
    {
      "id": "legumain"
    },
    {
      "id": "lysosomal cysteine protease"
    },
    {
      "id": "whole cells"
    },
    {
      "id": "early stage metastatic lesions"
    },
    {
      "id": "biological function"
    },
    {
      "id": "title compounds"
    },
    {
      "id": "JMC08-4"
    },
    {
      "id": "dual function inhibitors"
    },
    {
      "id": "AA metabolic network"
    },
    {
      "id": "multi-target drugs"
    },
    {
      "id": "5-hydroxytryptamines"
    },
    {
      "id": "leukotriene A(4) hydrolase"
    },
    {
      "id": "LTA(4)H-h"
    },
    {
      "id": "hnps-PLA(2)"
    },
    {
      "id": "9.2 \u00b1 0.5 \u03bcM"
    },
    {
      "id": "human nonpancreatic secretory phospholipase A(2)"
    },
    {
      "id": "inhibitory activity"
    },
    {
      "id": "human leukotriene A(4) hydrolase"
    },
    {
      "id": "5-hydroxytryptamine compounds"
    },
    {
      "id": "new dual-target inhibitors"
    },
    {
      "id": "molecular docking"
    },
    {
      "id": "structure of compound JMC08-4"
    },
    {
      "id": "phospholipase A2"
    },
    {
      "id": "dual-target inhibitor"
    },
    {
      "id": "in vitro bioassay"
    },
    {
      "id": "LTA(4)H"
    },
    {
      "id": "2.4 \u00b1 1.4 \u03bcM"
    },
    {
      "id": "anti-inflammatory drugs"
    },
    {
      "id": "leukotriene A4 hydrolase"
    },
    {
      "id": "PLA(2)"
    },
    {
      "id": "previous study"
    },
    {
      "id": "1\u03b1,25-dihydroxyvitamin D(3)"
    },
    {
      "id": "Oat3"
    },
    {
      "id": "1,25(OH)(2)D(3)"
    },
    {
      "id": "JBP485"
    },
    {
      "id": "AUCs"
    },
    {
      "id": "immunohistochemical analysis"
    },
    {
      "id": "1\u03b1,25-dihydroxyvitamin D\u2083"
    },
    {
      "id": "organic anion transporters"
    },
    {
      "id": "intravenous administration"
    },
    {
      "id": "corn oil"
    },
    {
      "id": "western blotting"
    },
    {
      "id": "kidney slices"
    },
    {
      "id": "urine concentrations"
    },
    {
      "id": "liquid chromatography/tandem mass spectrometry"
    },
    {
      "id": "Oat1"
    },
    {
      "id": "(Oat)1"
    },
    {
      "id": "organic anion transporter"
    },
    {
      "id": "Quantitative polymerase chain reaction"
    },
    {
      "id": "Oats"
    },
    {
      "id": "pharmacokinetic mechanism"
    },
    {
      "id": "ndk strains"
    },
    {
      "id": "nucleoside diphosphate kinase"
    },
    {
      "id": "mutator phenotype"
    },
    {
      "id": "Mutational consequences"
    },
    {
      "id": "mutator effect"
    },
    {
      "id": "lacZ reversion markers"
    },
    {
      "id": "mutational properties"
    },
    {
      "id": "dcd strains"
    },
    {
      "id": "dCTP"
    },
    {
      "id": "error rates"
    },
    {
      "id": "dNTPs"
    },
    {
      "id": "dNTP pools"
    },
    {
      "id": "mismatch-repair"
    },
    {
      "id": "G\u00b7C\u2192T\u00b7A transversions"
    },
    {
      "id": "mutability"
    },
    {
      "id": "replication error rates"
    },
    {
      "id": "dNTP pool alterations"
    },
    {
      "id": "mutL"
    },
    {
      "id": "A\u00b7T\u2192T\u00b7A transversions"
    },
    {
      "id": "polymerase"
    },
    {
      "id": "dATP"
    },
    {
      "id": "rifampicin-resistant mutants"
    },
    {
      "id": "5'-deoxynucleoside-triphosphate DNA precursors"
    },
    {
      "id": "rifampicin"
    },
    {
      "id": "dCTP deaminase"
    },
    {
      "id": "ndk mutator"
    },
    {
      "id": "dNTP pool imbalances"
    },
    {
      "id": "dGTP"
    },
    {
      "id": "hyperoside"
    },
    {
      "id": "human umbilical vein endothelial cells"
    },
    {
      "id": "FXa"
    },
    {
      "id": "Antithrombotic activities"
    },
    {
      "id": "profibrinolytic activities"
    },
    {
      "id": "Oenanthe javanica"
    },
    {
      "id": "activated factor X"
    },
    {
      "id": "anticoagulant activities"
    },
    {
      "id": "tumor necrosis factor-(TNF)-\u03b1"
    },
    {
      "id": "PAI-1"
    },
    {
      "id": "HUVECs"
    },
    {
      "id": "IMG"
    },
    {
      "id": "activated partial thromboplastin time"
    },
    {
      "id": "aPTT"
    },
    {
      "id": "prothrombin time"
    },
    {
      "id": "TNF-\u03b1"
    },
    {
      "id": "methoxy group"
    },
    {
      "id": "tissue-type plasminogen activator"
    },
    {
      "id": "t-PA"
    },
    {
      "id": "novel anticoagulant"
    },
    {
      "id": "plasminogen activator inhibitor type 1"
    },
    {
      "id": "anticoagulant function"
    },
    {
      "id": "isorhamnetin-3-O-galactoside"
    },
    {
      "id": "PAI-1 to t-PA ratio"
    },
    {
      "id": "6\u03b2-hydroxylation"
    },
    {
      "id": "budesonide"
    },
    {
      "id": "\u0394(6)-dehydrogenation"
    },
    {
      "id": "inhaled glucocorticoids"
    },
    {
      "id": "Asthma"
    },
    {
      "id": "interenzyme variability"
    },
    {
      "id": "rates of metabolism"
    },
    {
      "id": "flunisolide"
    },
    {
      "id": "rates of clearance"
    },
    {
      "id": "GCs"
    },
    {
      "id": "CYP3A family of enzymes"
    },
    {
      "id": "CYP3A5"
    },
    {
      "id": "CYP3A7"
    },
    {
      "id": "21-nortriamcinolone acetonide"
    },
    {
      "id": "NMR analysis"
    },
    {
      "id": "triamcinolone acetonide"
    },
    {
      "id": "liquid chromatography-mass spectrometry"
    },
    {
      "id": "\u0394(6)-flunisolide"
    },
    {
      "id": "fluticasone propionate"
    },
    {
      "id": "interdrug variability"
    },
    {
      "id": "metabolic fate"
    },
    {
      "id": "GC metabolism"
    },
    {
      "id": "asthma sufferers"
    },
    {
      "id": "steroid insensitivity"
    },
    {
      "id": "21-carboxy metabolites"
    },
    {
      "id": "metabolic catalyst"
    },
    {
      "id": "lungs"
    },
    {
      "id": "D-ring substituents"
    },
    {
      "id": "high glucose-induced apoptosis"
    },
    {
      "id": "cardiomyopathy"
    },
    {
      "id": "AMPK-induced autophagy"
    },
    {
      "id": "cardiomyocyte apoptosis"
    },
    {
      "id": "high glucose"
    },
    {
      "id": "JNK1-Bcl-2 signaling"
    },
    {
      "id": "Beclin1 binding to Bcl-2"
    },
    {
      "id": "autophagy"
    },
    {
      "id": "cardiac apoptosis"
    },
    {
      "id": "dissociation of Bcl-2 from Beclin1"
    },
    {
      "id": "Beclin1-Bcl-2 complex"
    },
    {
      "id": "H9c2 cells"
    },
    {
      "id": "cardiac autophagy"
    },
    {
      "id": "cardiac structure"
    },
    {
      "id": "Diabetic cardiomyopathy"
    },
    {
      "id": "suppression of cardiac autophagy"
    },
    {
      "id": "interaction between Beclin1 and Bcl-2"
    },
    {
      "id": "inhibition of autophagy"
    },
    {
      "id": "dissociating Beclin1 and Bcl-2"
    },
    {
      "id": "JNK1-Bcl-2 pathways"
    },
    {
      "id": "cardiac function"
    },
    {
      "id": "Metformin"
    },
    {
      "id": "human lung cancer cells"
    },
    {
      "id": "specific small interfering RNA"
    },
    {
      "id": "p38 knockdown"
    },
    {
      "id": "paclitaxel therapy"
    },
    {
      "id": "cytotoxic effect"
    },
    {
      "id": "constitutive activate MKK6"
    },
    {
      "id": "HA-p38 MAPK vectors"
    },
    {
      "id": "human NSCLC cells"
    },
    {
      "id": "p38 activity"
    },
    {
      "id": "ERCC1"
    },
    {
      "id": "NSCLC patients"
    },
    {
      "id": "platinum-containing chemotherapy"
    },
    {
      "id": "antineoplastic drug"
    },
    {
      "id": "Taxol"
    },
    {
      "id": "excision repair cross-complementing 1"
    },
    {
      "id": "DNA repair capacity"
    },
    {
      "id": "p38 MAPK inhibitor SB202190"
    },
    {
      "id": "mRNA levels"
    },
    {
      "id": "non-small cell lung cancer"
    },
    {
      "id": "p38 MAPK"
    },
    {
      "id": "p38 MAPK signaling"
    },
    {
      "id": "MKK3/6"
    },
    {
      "id": "p38 MAPK-mediated ERCC1 expression"
    },
    {
      "id": "inputs"
    },
    {
      "id": "adenylyl cyclase VII"
    },
    {
      "id": "G13 pathway"
    },
    {
      "id": "AC7"
    },
    {
      "id": "AC isoforms"
    },
    {
      "id": "intracellular cAMP responses"
    },
    {
      "id": "N-terminus"
    },
    {
      "id": "C1b domain"
    },
    {
      "id": "G(13) pathway"
    },
    {
      "id": "cellular function"
    },
    {
      "id": "bone marrow-derived macrophages"
    },
    {
      "id": "G\u03b2\u03b3"
    },
    {
      "id": "domains"
    },
    {
      "id": "ACs"
    },
    {
      "id": "Exchange"
    },
    {
      "id": "adenylyl cyclases"
    },
    {
      "id": "G(s)"
    },
    {
      "id": "mutagenesis screen"
    },
    {
      "id": "C1a domain"
    },
    {
      "id": "point mutations"
    },
    {
      "id": "H1 hypervariable loop"
    },
    {
      "id": "three hypervariable loops"
    },
    {
      "id": "H3"
    },
    {
      "id": "candidates"
    },
    {
      "id": "antibody engineering"
    },
    {
      "id": "Nanobodies"
    },
    {
      "id": "binding domains"
    },
    {
      "id": "conformational isomers"
    },
    {
      "id": "canonical conformation"
    },
    {
      "id": "Markovian model"
    },
    {
      "id": "kinetics"
    },
    {
      "id": "characteristics"
    },
    {
      "id": "amino acid sequence"
    },
    {
      "id": "H1"
    },
    {
      "id": "propensity"
    },
    {
      "id": "canonical structure"
    },
    {
      "id": "selected mutations"
    },
    {
      "id": "thermodynamic propensity"
    },
    {
      "id": "H1 type 1 canonical structure"
    },
    {
      "id": "H1 loop structure"
    },
    {
      "id": "noncanonical conformation"
    },
    {
      "id": "H2"
    },
    {
      "id": "Free energy landscapes"
    },
    {
      "id": "existence"
    },
    {
      "id": "antigenic surfaces"
    },
    {
      "id": "canonical conformations"
    },
    {
      "id": "functionality"
    },
    {
      "id": "high solubility"
    },
    {
      "id": "single-domain antibodies"
    },
    {
      "id": "binding surface"
    },
    {
      "id": "stable type 1 canonical conformation"
    },
    {
      "id": "H1 loop"
    },
    {
      "id": "three-point mutant"
    },
    {
      "id": "llama VHH"
    },
    {
      "id": "all-atomistic, explicit-solvent, biased molecular dynamic simulations"
    },
    {
      "id": "mutant loops"
    },
    {
      "id": "rigid three-point mutant"
    },
    {
      "id": "noncanonical conformations"
    },
    {
      "id": "wild-type loops"
    },
    {
      "id": "prefolded framework"
    },
    {
      "id": "proximal residues"
    },
    {
      "id": "anti-hCG llama nanobody"
    },
    {
      "id": "small size"
    },
    {
      "id": "(humanized) type 1 canonical conformation"
    },
    {
      "id": "camelids"
    },
    {
      "id": "hypervariable loops"
    },
    {
      "id": "PI3K/Akt signaling pathway"
    },
    {
      "id": "isoorientin"
    },
    {
      "id": "mitochondrial-mediated apoptosis"
    },
    {
      "id": "flavonoid compound"
    },
    {
      "id": "plant species"
    },
    {
      "id": "Phyllostachys pubescens"
    },
    {
      "id": "Bax/Bcl-2 ratio"
    },
    {
      "id": "p-p38"
    },
    {
      "id": "SP600125"
    },
    {
      "id": "p38 kinases"
    },
    {
      "id": "Patrinia"
    },
    {
      "id": "Isoorientin"
    },
    {
      "id": "human hepatoblastoma cancer cells"
    },
    {
      "id": "ERK1/2 kinase"
    },
    {
      "id": "SB203580"
    },
    {
      "id": "p38 inhibitor"
    },
    {
      "id": "p-JNK"
    },
    {
      "id": "MAPK kinases"
    },
    {
      "id": "Drosophyllum lusitanicum"
    },
    {
      "id": "MAPK signaling pathways"
    },
    {
      "id": "cleaved caspase-3"
    },
    {
      "id": "U0126"
    },
    {
      "id": "ERK1/2 inhibitor"
    },
    {
      "id": "JNK inhibitor"
    },
    {
      "id": "upstream signaling molecules"
    },
    {
      "id": "MAPK singaling pathway"
    },
    {
      "id": "ROS inhibitor"
    },
    {
      "id": "MAPK signals"
    },
    {
      "id": "4261-42-1"
    },
    {
      "id": "dendrimers"
    },
    {
      "id": "PrP(Sc)"
    },
    {
      "id": "host protein"
    },
    {
      "id": "PrP(C)"
    },
    {
      "id": "new working model"
    },
    {
      "id": "dendrimer/prion interactions"
    },
    {
      "id": "modified poly(propylene-imine) dendrimers"
    },
    {
      "id": "charge"
    },
    {
      "id": "aberrantly folded isoform"
    },
    {
      "id": "surface groups"
    },
    {
      "id": "antiprion activity"
    },
    {
      "id": "high density"
    },
    {
      "id": "reactive surface groups"
    },
    {
      "id": "in vitro antiprion ability"
    },
    {
      "id": "poly(propylene imine) dendrimers"
    },
    {
      "id": "Prion diseases"
    },
    {
      "id": "issue"
    },
    {
      "id": "synthetic molecules"
    },
    {
      "id": "modified dendrimers"
    },
    {
      "id": "forms"
    },
    {
      "id": "protease-resistant PrP(Sc)"
    },
    {
      "id": "in vitro setting"
    },
    {
      "id": "prion strain-dependent manner"
    },
    {
      "id": "surface group composition"
    },
    {
      "id": "proteolysis"
    },
    {
      "id": "size"
    },
    {
      "id": "anionic glycodendrimer"
    },
    {
      "id": "intracellular setting"
    },
    {
      "id": "oxadiazine series"
    },
    {
      "id": "GSMs"
    },
    {
      "id": "SAR explorations"
    },
    {
      "id": "hERG activity"
    },
    {
      "id": "fused oxadiazepines"
    },
    {
      "id": "gamma secretase modulators"
    },
    {
      "id": "7i"
    },
    {
      "id": "core structure"
    },
    {
      "id": "hERG inhibition profile"
    },
    {
      "id": "Diazinon"
    },
    {
      "id": "indoor pest control"
    },
    {
      "id": "neonatal exposure"
    },
    {
      "id": "hippocampi"
    },
    {
      "id": "PND 85 mice"
    },
    {
      "id": "novel object recognition test"
    },
    {
      "id": "PND 81"
    },
    {
      "id": "NMDA subunits"
    },
    {
      "id": "0.5 mg/kg diazinon"
    },
    {
      "id": "PND 8"
    },
    {
      "id": "Japan"
    },
    {
      "id": "4 consecutive days"
    },
    {
      "id": "PND 46"
    },
    {
      "id": "real-time RT-PCR"
    },
    {
      "id": "diazinon"
    },
    {
      "id": "NMDA receptor subunits NR1"
    },
    {
      "id": "PND 50 mice"
    },
    {
      "id": "CaMK-IV"
    },
    {
      "id": "signal transduction molecules"
    },
    {
      "id": "adult mice"
    },
    {
      "id": "hippocampus-dependent novel object recognition ability"
    },
    {
      "id": "calcium/calmodulin-dependent protein kinase (CaMK)-IV"
    },
    {
      "id": "protein kinase"
    },
    {
      "id": "young adult mice"
    },
    {
      "id": "Male offspring"
    },
    {
      "id": "0 mg/kg diazinon"
    },
    {
      "id": "NMDA receptor subunits NR2B"
    },
    {
      "id": "home gardening"
    },
    {
      "id": "novel object recognition"
    },
    {
      "id": "cyclic AMP responsive element binding protein (CREB)-1"
    },
    {
      "id": "adulthood"
    },
    {
      "id": "5 mg/kg diazinon"
    },
    {
      "id": "agriculture"
    },
    {
      "id": "nerve growth factor mRNA"
    },
    {
      "id": "PND 85"
    },
    {
      "id": "poor ability to discriminate between novel and familiar objects"
    },
    {
      "id": "PND 49 tests"
    },
    {
      "id": "CREB-1"
    },
    {
      "id": "Diazinon-injected mice"
    },
    {
      "id": "organophosphate pesticide"
    },
    {
      "id": "PND 84 tests"
    },
    {
      "id": "neurotrophin"
    },
    {
      "id": "C3H/HeN mice"
    },
    {
      "id": "PND 50"
    },
    {
      "id": "hippocampus-dependent novel object recognition test performance"
    },
    {
      "id": "neurotrophins"
    },
    {
      "id": "signal transduction pathway-related genes"
    },
    {
      "id": "rapid membrane initiated steroid signals"
    },
    {
      "id": "MISS"
    },
    {
      "id": "Pharmacological activation"
    },
    {
      "id": "therapeutic interventions"
    },
    {
      "id": "selective estrogen receptors modulators"
    },
    {
      "id": "neurodegenerative diseases"
    },
    {
      "id": "physiological processes"
    },
    {
      "id": "ER\u03b1"
    },
    {
      "id": "human physiology"
    },
    {
      "id": "ER\u03b2"
    },
    {
      "id": " undesired effects"
    },
    {
      "id": "Estrogens"
    },
    {
      "id": "prostate"
    },
    {
      "id": "recurrence of breast cancer"
    },
    {
      "id": "in vivo molecular \"dissection\""
    },
    {
      "id": "activation functions"
    },
    {
      "id": "AF-2"
    },
    {
      "id": "subfunctions"
    },
    {
      "id": "reproductive tract"
    },
    {
      "id": "endometrial"
    },
    {
      "id": "metabolic diseases"
    },
    {
      "id": "deleterious ones"
    },
    {
      "id": "bone integrity"
    },
    {
      "id": "integrated approach"
    },
    {
      "id": "target gene transcription"
    },
    {
      "id": "genomic action"
    },
    {
      "id": "Targeted ER gene inactivation"
    },
    {
      "id": "ER modulation"
    },
    {
      "id": "hormone replacement"
    },
    {
      "id": "menopause"
    },
    {
      "id": "vascular system"
    },
    {
      "id": "colorectal"
    },
    {
      "id": "inflammatory-immune diseases"
    },
    {
      "id": "AF-1"
    },
    {
      "id": "molecular approach"
    },
    {
      "id": "steroid signals"
    },
    {
      "id": "beneficial actions"
    },
    {
      "id": "mammals"
    },
    {
      "id": "actions"
    },
    {
      "id": "silver nanoparticles"
    },
    {
      "id": "surface properties"
    },
    {
      "id": "absorption properties"
    },
    {
      "id": "photothermal activity"
    },
    {
      "id": "SERS"
    },
    {
      "id": "1064 nm excitation wavelength"
    },
    {
      "id": "weaker signal"
    },
    {
      "id": "HGNs"
    },
    {
      "id": "absorption efficiency"
    },
    {
      "id": "5 times"
    },
    {
      "id": "Optical analysis"
    },
    {
      "id": "biological importance"
    },
    {
      "id": "0.81%"
    },
    {
      "id": "improved synthesis"
    },
    {
      "id": "citrate reduced gold"
    },
    {
      "id": "physical sizes"
    },
    {
      "id": "LSPR"
    },
    {
      "id": "775 nm"
    },
    {
      "id": "hollow gold"
    },
    {
      "id": "1320 nm"
    },
    {
      "id": "strong signal"
    },
    {
      "id": "salts"
    },
    {
      "id": "obvious signals"
    },
    {
      "id": "standard citrate reduced gold"
    },
    {
      "id": "tunable localized surface plasmon resonance"
    },
    {
      "id": "continuous laser"
    },
    {
      "id": "785 nm excitation wavelength"
    },
    {
      "id": "nanoparticle suspensions"
    },
    {
      "id": "hollow gold nanospheres"
    },
    {
      "id": "tissue penetration"
    },
    {
      "id": "autofluorescence"
    },
    {
      "id": "650 nm"
    },
    {
      "id": "NIR optical properties"
    },
    {
      "id": "scattering properties"
    },
    {
      "id": "citrate reduced gold nanoparticles"
    },
    {
      "id": "surface enhanced Raman scattering"
    },
    {
      "id": "near infrared region"
    },
    {
      "id": "similar conditions"
    },
    {
      "id": "610 nm"
    },
    {
      "id": "1080 nm"
    },
    {
      "id": "one micrometer"
    },
    {
      "id": "clinic"
    },
    {
      "id": "nanocomplexes"
    },
    {
      "id": "PKAA"
    },
    {
      "id": "APAP-intoxicated mice"
    },
    {
      "id": "APAP"
    },
    {
      "id": "Acid-degradable cationic poly(ketal amidoamine)"
    },
    {
      "id": "siRNA carrier"
    },
    {
      "id": "positive charges"
    },
    {
      "id": "acid-cleavable ketal linkages"
    },
    {
      "id": "backbone"
    },
    {
      "id": "PKAA/anti-TNF-\u03b1 siRNA nanocomplexes"
    },
    {
      "id": "in vivo siRNA delivery efficacy"
    },
    {
      "id": "rapid degradation"
    },
    {
      "id": "acid-degradable poly(ketal amidoamine)"
    },
    {
      "id": "siRNA carriers"
    },
    {
      "id": "delivery efficiency"
    },
    {
      "id": "buffering capability"
    },
    {
      "id": "secondary amine groups"
    },
    {
      "id": "endosomolytic activity"
    },
    {
      "id": "poly(amidoamine)"
    },
    {
      "id": "anti-TNF (tumor necrosis factor)-\u03b1 siRNA"
    },
    {
      "id": "acidic pH"
    },
    {
      "id": "physiological conditions"
    },
    {
      "id": "acute liver failure"
    },
    {
      "id": "biocompatibility"
    },
    {
      "id": "pH sensitivity"
    },
    {
      "id": "Cell culture studies"
    },
    {
      "id": "LPS"
    },
    {
      "id": "hepatic cellular damages"
    },
    {
      "id": "diameter"
    },
    {
      "id": "acidic endosomes"
    },
    {
      "id": "PQ poisoning"
    },
    {
      "id": "Asia"
    },
    {
      "id": "ultrastructural evidences"
    },
    {
      "id": "electron microscopy"
    },
    {
      "id": "neurons apoptosis"
    },
    {
      "id": "acute paraquat poisoning"
    },
    {
      "id": "substantia nigra"
    },
    {
      "id": "SN"
    },
    {
      "id": "Iba-1"
    },
    {
      "id": "Paraquat"
    },
    {
      "id": "common herbicide"
    },
    {
      "id": "major medical problem"
    },
    {
      "id": "PQ"
    },
    {
      "id": "astrocyte edema"
    },
    {
      "id": "acute neurotoxicological findings"
    },
    {
      "id": "laser cofocal microscopy"
    },
    {
      "id": "NeuN/8-OHdG immunofluorescence double labeling"
    },
    {
      "id": "direct CNS toxicity"
    },
    {
      "id": "acute neurotoxic changes"
    },
    {
      "id": "non-lethal dose of PQ"
    },
    {
      "id": "Central nervous system"
    },
    {
      "id": "one week"
    },
    {
      "id": "lethal dose of PQ"
    },
    {
      "id": "normal adrenals"
    },
    {
      "id": "HSD3B2"
    },
    {
      "id": "CYP11B2"
    },
    {
      "id": "resected adrenal glands"
    },
    {
      "id": "SCPA"
    },
    {
      "id": "steroidogenic characteristics"
    },
    {
      "id": "APA"
    },
    {
      "id": "CYP11B2 mRNA level"
    },
    {
      "id": "CYP11B1"
    },
    {
      "id": "CPA"
    },
    {
      "id": "CYP17/HSD3B2 ratio"
    },
    {
      "id": "real-time quantitative PCR"
    },
    {
      "id": "subclinical Cushing's syndrome"
    },
    {
      "id": "NFA"
    },
    {
      "id": "Steroidogenic enzyme expression"
    },
    {
      "id": "Aldosterone-producing adenoma"
    },
    {
      "id": "human adrenal tumors"
    },
    {
      "id": "Low ratio of CYP17/HSD3B2"
    },
    {
      "id": "high expression of CYP11B2"
    },
    {
      "id": "Cushing's syndrome"
    },
    {
      "id": "cellular processes"
    },
    {
      "id": "cell cycle arrest"
    },
    {
      "id": "BiFC signal"
    },
    {
      "id": "nutlin-3"
    },
    {
      "id": "Dysfunction"
    },
    {
      "id": "Puma transactivation"
    },
    {
      "id": "p53 interaction"
    },
    {
      "id": "Mdm2"
    },
    {
      "id": "bimolecular fluorescence complementation (BiFC) analysis"
    },
    {
      "id": "protein interactions"
    },
    {
      "id": "synergistic drug efficacy"
    },
    {
      "id": "anti-tumor therapies"
    },
    {
      "id": "Venus-based BiFC system"
    },
    {
      "id": "modulators of p53-p53 and p53-Mdm2 interactions"
    },
    {
      "id": "pathologies"
    },
    {
      "id": "live mammalian cells"
    },
    {
      "id": "disruptor of p53-Mdm2 interaction"
    },
    {
      "id": "living cells"
    },
    {
      "id": "Live-cell imaging"
    },
    {
      "id": "Venus-based bimolecular fluorescence complementation system"
    },
    {
      "id": "commercially available chemical library"
    },
    {
      "id": "protein phosphatase inhibitors"
    },
    {
      "id": "modulators of protein interactions"
    },
    {
      "id": "specificity of the assay"
    },
    {
      "id": "modulators of p53-Mdm2 complex formation"
    },
    {
      "id": "therapeutic target"
    },
    {
      "id": "target-based drug discovery strategies"
    },
    {
      "id": "PARP cleavage"
    },
    {
      "id": "new modulators of p53-p53 and p53-Mdm2 interactions"
    },
    {
      "id": "BiFC approach"
    },
    {
      "id": "cav-1"
    },
    {
      "id": "Wogonin"
    },
    {
      "id": "caveolin-1"
    },
    {
      "id": "oxidant"
    },
    {
      "id": "vascular permeability"
    },
    {
      "id": "transendothelial cell migration"
    },
    {
      "id": "p38"
    },
    {
      "id": "actin remodeling"
    },
    {
      "id": "VE-cadherin"
    },
    {
      "id": "albumin uptake"
    },
    {
      "id": "root of Scutellaria baicalensis Georgi"
    },
    {
      "id": "anisomycin"
    },
    {
      "id": "human breast carcinoma cell MDA-MB-231"
    },
    {
      "id": "monoflavonoid"
    },
    {
      "id": "\u03b2-catenin"
    },
    {
      "id": "anti-oxidant activity"
    },
    {
      "id": "Apomorphine"
    },
    {
      "id": "non-narcotic derivative"
    },
    {
      "id": "off-states"
    },
    {
      "id": "Adverse effects"
    },
    {
      "id": "severe emesis"
    },
    {
      "id": "rTRPV3"
    },
    {
      "id": "dorsal root ganglion neurons"
    },
    {
      "id": "TRPA1 channels"
    },
    {
      "id": "rTRPV1"
    },
    {
      "id": "apomorphine treatment"
    },
    {
      "id": "reversible voltage-dependent inhibition"
    },
    {
      "id": "heterologously expressed TRPA1 channels"
    },
    {
      "id": "endogenous TRPA1"
    },
    {
      "id": "cultured dorsal root ganglion neurons"
    },
    {
      "id": "rTRPV2"
    },
    {
      "id": "pain"
    },
    {
      "id": "human TRPA1"
    },
    {
      "id": "molecular target"
    },
    {
      "id": "hTRPM2"
    },
    {
      "id": "cellular redox sensor"
    },
    {
      "id": "activation of TRPA1"
    },
    {
      "id": "ulceration"
    },
    {
      "id": "injection site"
    },
    {
      "id": "mTRPV4"
    },
    {
      "id": "adverse side effects"
    },
    {
      "id": "painful injections"
    },
    {
      "id": "dopamine agonist"
    },
    {
      "id": "rTRPM3"
    },
    {
      "id": "hTRPM8"
    },
    {
      "id": "enterochromaffin model cell line QGP-1"
    },
    {
      "id": "irreversible activation"
    },
    {
      "id": "sensory transient receptor potential (TRP) channels"
    },
    {
      "id": "reduction of single-channel open times"
    },
    {
      "id": "bimodal modulator"
    },
    {
      "id": "modified TRAP assay"
    },
    {
      "id": "titled compounds"
    },
    {
      "id": "compounds 4a and 4b"
    },
    {
      "id": "expression of Cyclin D1"
    },
    {
      "id": "Eight novel 4,5-tetrahydropyrazolo[1,5-d][1,4]oxazepine derivatives"
    },
    {
      "id": "novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives"
    },
    {
      "id": "IC(50) value"
    },
    {
      "id": "TERT"
    },
    {
      "id": "telomerase"
    },
    {
      "id": "telomerase inhibitors"
    },
    {
      "id": "phospho-AKT"
    },
    {
      "id": "PI3K/AKT pathway"
    },
    {
      "id": "compound 4a"
    },
    {
      "id": "Design and synthesis"
    },
    {
      "id": "estradiol (E2)"
    },
    {
      "id": "WNT1 inducible signaling pathway protein 2"
    },
    {
      "id": "conjugated estrogens (CEs)"
    },
    {
      "id": "amphiregulin"
    },
    {
      "id": "menopausal hormone therapy"
    },
    {
      "id": "CE/BZA"
    },
    {
      "id": "human breast cancer cells"
    },
    {
      "id": "bazedoxifene (BZA)"
    },
    {
      "id": "X-linked inhibitor of apoptosis protein"
    },
    {
      "id": "p70S6K"
    },
    {
      "id": "breast cancer incidence"
    },
    {
      "id": "cMyc"
    },
    {
      "id": "stimulatory effects"
    },
    {
      "id": "pS2"
    },
    {
      "id": "tissue-selective estrogen complex (TSEC)"
    },
    {
      "id": "progestogen"
    },
    {
      "id": "estrogen agonistic effects"
    },
    {
      "id": "survivin"
    },
    {
      "id": "occult breast neoplasms"
    },
    {
      "id": "tumor incidence"
    },
    {
      "id": "antiestrogenic effects"
    },
    {
      "id": "(-) Epicatechin"
    },
    {
      "id": "adenosine triphosphate"
    },
    {
      "id": "myocardial infarction"
    },
    {
      "id": "mitochondrial multi-marker enzymes"
    },
    {
      "id": "multi-enzymes"
    },
    {
      "id": "myocardial infarcted rats"
    },
    {
      "id": "glutathione reductase"
    },
    {
      "id": "isocitrate"
    },
    {
      "id": "cardiac diagnostic markers"
    },
    {
      "id": "tricarboxylic acid cycle"
    },
    {
      "id": "heart mitochondrial lipid peroxidation"
    },
    {
      "id": "heart mitochondrial glutathione peroxidase"
    },
    {
      "id": "respiratory chain enzymes"
    },
    {
      "id": "Cardiac mitochondrial damage"
    },
    {
      "id": "hydroxyl radical"
    },
    {
      "id": "\u03b1-ketoglutarate"
    },
    {
      "id": "NADH-dehydrogenases"
    },
    {
      "id": "scavenging activity"
    },
    {
      "id": "in vitro study"
    },
    {
      "id": "cytochrome-C-oxidase"
    },
    {
      "id": "succinate"
    },
    {
      "id": "mitochondrial damage"
    },
    {
      "id": "antioxidant enzymes"
    },
    {
      "id": "free radicals"
    },
    {
      "id": "cardiac mitochondria"
    },
    {
      "id": "decisive role"
    },
    {
      "id": "dietary carbohydrate intake"
    },
    {
      "id": "negative regulation"
    },
    {
      "id": "human SCD-1 gene expression"
    },
    {
      "id": "TR-\u03b2"
    },
    {
      "id": "site A"
    },
    {
      "id": "human SCD-1 gene promoter"
    },
    {
      "id": "TH receptor-\u03b2"
    },
    {
      "id": "SCD-1 gene expression"
    },
    {
      "id": "thyroid hormone receptor"
    },
    {
      "id": "Luciferase assays"
    },
    {
      "id": "mouse SCD-1 gene promoter"
    },
    {
      "id": "SREBP-1c -independent pathways"
    },
    {
      "id": "SREBP-1c-dependent pathways"
    },
    {
      "id": "the region"
    },
    {
      "id": "Stearoyl-CoA desaturase-1"
    },
    {
      "id": "SREBP-1c effect"
    },
    {
      "id": "-124 and -92 bp"
    },
    {
      "id": "Dietary carbohydrates"
    },
    {
      "id": "responsible region"
    },
    {
      "id": "chemical content"
    },
    {
      "id": "water:ethanol (50:50)"
    },
    {
      "id": "ethanol"
    },
    {
      "id": "flavonoids"
    },
    {
      "id": "extracts"
    },
    {
      "id": "Obtained results"
    },
    {
      "id": "Cretan barberry"
    },
    {
      "id": "extraction procedures"
    },
    {
      "id": "phenolic content"
    },
    {
      "id": "optimization"
    },
    {
      "id": "UHPLC-HRMS/MS"
    },
    {
      "id": "ESI probe"
    },
    {
      "id": "solvents"
    },
    {
      "id": "antioxidant assessment"
    },
    {
      "id": "total phenolic content"
    },
    {
      "id": "Cretan barberry herb"
    },
    {
      "id": "antioxidant capacity"
    },
    {
      "id": "DPPH"
    },
    {
      "id": "Folin-Ciocalteu"
    },
    {
      "id": "SFE"
    },
    {
      "id": "ASE"
    },
    {
      "id": "different extraction protocols"
    },
    {
      "id": "Berberis cretica"
    },
    {
      "id": "spectral data"
    },
    {
      "id": "extraction method"
    },
    {
      "id": "caffeic and benzoic acids"
    },
    {
      "id": "Major constituents"
    },
    {
      "id": "HPLC-DAD"
    },
    {
      "id": "antioxidant agent"
    },
    {
      "id": "assays"
    },
    {
      "id": "applied methods"
    },
    {
      "id": "maceration"
    },
    {
      "id": "ASE methodologies"
    },
    {
      "id": "SFE methodologies"
    },
    {
      "id": "chromatographic data"
    },
    {
      "id": "simple phenolic acids"
    },
    {
      "id": "antioxidant activity"
    },
    {
      "id": "hybrid IT-Orbital trap spectrometer"
    },
    {
      "id": "beneficial conditions"
    },
    {
      "id": "methanol"
    },
    {
      "id": "green technologies"
    },
    {
      "id": "peroxide value"
    },
    {
      "id": "different roasting methods"
    },
    {
      "id": "off-odours"
    },
    {
      "id": "storage"
    },
    {
      "id": "concentration of aliphatic aldehydes"
    },
    {
      "id": "three different approaches"
    },
    {
      "id": "infrared (IR)"
    },
    {
      "id": "water activity"
    },
    {
      "id": "Nine medium roasted almond samples"
    },
    {
      "id": "37 \u00b0C"
    },
    {
      "id": "six months"
    },
    {
      "id": "Shelf-life"
    },
    {
      "id": "main volatile components"
    },
    {
      "id": "almonds"
    },
    {
      "id": "almond samples"
    },
    {
      "id": "Aliphatic aldehydes"
    },
    {
      "id": "hexanal"
    },
    {
      "id": "volatile components"
    },
    {
      "id": "GC/MS analysis"
    },
    {
      "id": "overall quality"
    },
    {
      "id": "first three months"
    },
    {
      "id": "sensory quality"
    },
    {
      "id": "moisture content"
    },
    {
      "id": "infrared dry-roasted almonds"
    },
    {
      "id": "roasted almonds"
    },
    {
      "id": "HA heating"
    },
    {
      "id": "Infrared heating"
    },
    {
      "id": "roasting technology"
    },
    {
      "id": "three different temperatures"
    },
    {
      "id": "140 \u00b0C"
    },
    {
      "id": "colour"
    },
    {
      "id": "eight months"
    },
    {
      "id": "(E)-2-octenal"
    },
    {
      "id": "SIRHA heating"
    },
    {
      "id": "three months"
    },
    {
      "id": "150 \u00b0C"
    },
    {
      "id": "alcohols"
    },
    {
      "id": "sequential infrared and hot air (SIRHA)"
    },
    {
      "id": "nonanal"
    },
    {
      "id": "roasted samples"
    },
    {
      "id": "traditional hot air roasting"
    },
    {
      "id": "130 \u00b0C"
    },
    {
      "id": "paper bags"
    },
    {
      "id": "pyrazines"
    },
    {
      "id": "heating methods"
    },
    {
      "id": "regular hot air (HA)"
    },
    {
      "id": "Se-EPS"
    },
    {
      "id": "superoxide dismutase (SOD)"
    },
    {
      "id": "Exopolysaccharide (EPS)"
    },
    {
      "id": "Lactococcus lactis subsp. Lactis culture broth"
    },
    {
      "id": "thymus indices"
    },
    {
      "id": "EPS"
    },
    {
      "id": "haemolytic complement activity (HC(50))"
    },
    {
      "id": "immunomodulatory activity"
    },
    {
      "id": "in vivo antioxidant activity"
    },
    {
      "id": "malondialdehyde (MDA)"
    },
    {
      "id": "livers"
    },
    {
      "id": "in vivo immunoenhancement activity"
    },
    {
      "id": "cyclophosphamide (CY)"
    },
    {
      "id": "SeCl(2)O"
    },
    {
      "id": "selenium exopolysaccharide"
    },
    {
      "id": "Lactococcus lactis subsp. lactis"
    },
    {
      "id": "CY"
    },
    {
      "id": "immunosuppressed mice"
    },
    {
      "id": "Selenium chloride oxide (SeCl(2)O)"
    },
    {
      "id": "superoxide anions"
    },
    {
      "id": "glutathione peroxidase (GSH-Px)"
    },
    {
      "id": "spleen indices"
    },
    {
      "id": "HC(50)"
    },
    {
      "id": "GSH-Px"
    },
    {
      "id": "hydroxyl radicals"
    },
    {
      "id": "in vitro antioxidant activity"
    },
    {
      "id": "in vivo immunomodulatory activity"
    },
    {
      "id": "macrophage phagocytosis"
    },
    {
      "id": "catalase (CAT)"
    },
    {
      "id": "selenium-exopolysaccharide"
    },
    {
      "id": "DPEP"
    },
    {
      "id": "iNOS"
    },
    {
      "id": "inducible nitric oxide synthase"
    },
    {
      "id": "inflammatory cytokines"
    },
    {
      "id": "tumor necrosis factor-\u03b1"
    },
    {
      "id": "inhibitor \u03baB (I\u03baB)-\u03b1"
    },
    {
      "id": "IL-6"
    },
    {
      "id": "NF-\u03baB"
    },
    {
      "id": "trans-1,3-diphenyl-2,3-epoxypropane-1-one"
    },
    {
      "id": "inflammatory mediators"
    },
    {
      "id": "interleukin (IL)-1\u03b2"
    },
    {
      "id": "cyclooxygenase-2"
    },
    {
      "id": "NF-\u03baB p50"
    },
    {
      "id": "down regulation"
    },
    {
      "id": "glutamate decarboxylase mRNA"
    },
    {
      "id": "Radioreceptor binding assays"
    },
    {
      "id": "curcumin"
    },
    {
      "id": "BCL2-associated X protein"
    },
    {
      "id": "excitotoxic neuronal death"
    },
    {
      "id": "density"
    },
    {
      "id": "\u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate"
    },
    {
      "id": "insulin treatment"
    },
    {
      "id": "diabetic rat"
    },
    {
      "id": "caspase 3"
    },
    {
      "id": "Gene expression studies"
    },
    {
      "id": "glutamate transport"
    },
    {
      "id": "caspase 8"
    },
    {
      "id": "neurochemical parameters"
    },
    {
      "id": "events"
    },
    {
      "id": "neuroprotective effect"
    },
    {
      "id": "immunohistochemical studies"
    },
    {
      "id": "therapeutic role"
    },
    {
      "id": "glutathione peroxidases gene expression"
    },
    {
      "id": "neurotransmitter receptor"
    },
    {
      "id": "Functional activity"
    },
    {
      "id": "glutamate aspartate transporter"
    },
    {
      "id": "metabolic shift"
    },
    {
      "id": "aerobic glycolysis"
    },
    {
      "id": "silencing"
    },
    {
      "id": "biosynthetic and proliferative advantages"
    },
    {
      "id": "glucose carbon"
    },
    {
      "id": "lipids"
    },
    {
      "id": "normoxic stabilization"
    },
    {
      "id": "hypoxia-inducible factor-1\u03b1"
    },
    {
      "id": "HIF-1\u03b1"
    },
    {
      "id": "metabolic sensor"
    },
    {
      "id": "cellular energy homeostasis"
    },
    {
      "id": "Myc"
    },
    {
      "id": "lymphomagenesis"
    },
    {
      "id": "tumor development"
    },
    {
      "id": "Warburg effect"
    },
    {
      "id": "tumor metabolism"
    },
    {
      "id": "Inactivation"
    },
    {
      "id": "nontransformed cells"
    },
    {
      "id": "cellular metabolic pathways"
    },
    {
      "id": "\u03b11 catalytic subunit of AMPK"
    },
    {
      "id": "transformed cells"
    },
    {
      "id": "tumor suppressor functions"
    },
    {
      "id": "AMPK\u03b1"
    },
    {
      "id": "AMPK\u03b1 signaling"
    },
    {
      "id": "Genetic ablation"
    },
    {
      "id": "cancer cells"
    },
    {
      "id": "biomass accumulation"
    },
    {
      "id": "NSCs"
    },
    {
      "id": "SAL"
    },
    {
      "id": "food materials"
    },
    {
      "id": "pAkt level"
    },
    {
      "id": "pGSK-3\u03b2"
    },
    {
      "id": "OEC CM"
    },
    {
      "id": "PI3K/Akt pathway"
    },
    {
      "id": "neural stem cells"
    },
    {
      "id": "Sal toxicity"
    },
    {
      "id": "BDNF"
    },
    {
      "id": "endogenous threats"
    },
    {
      "id": "transplanted NSCs"
    },
    {
      "id": "GDNF"
    },
    {
      "id": "TH(+ve) colonies"
    },
    {
      "id": "Olfactory Ensheathing Cell's Conditioned Media"
    },
    {
      "id": "catechol isoquinoline"
    },
    {
      "id": "Salsolinol"
    },
    {
      "id": "MPTP"
    },
    {
      "id": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine"
    },
    {
      "id": "PI3K survival signaling"
    },
    {
      "id": "repressed PI3K/Akt signaling"
    },
    {
      "id": "pCREB"
    },
    {
      "id": "Multiple neurotrophic factor support"
    },
    {
      "id": "dopaminergic neurotoxin"
    },
    {
      "id": "10\u03bcM SAL"
    },
    {
      "id": "mechanism of toxicity"
    },
    {
      "id": "apoptotic changes"
    },
    {
      "id": "adult neurogenesis"
    },
    {
      "id": "immature BBB"
    },
    {
      "id": "PD brain"
    },
    {
      "id": "embryonic day 11 rat fetal brain"
    },
    {
      "id": "suppressive cues"
    },
    {
      "id": "diseased brain"
    },
    {
      "id": "Morphological impairment"
    },
    {
      "id": "neurotrophin support"
    },
    {
      "id": "impaired BBB"
    },
    {
      "id": "alcohol beverages"
    },
    {
      "id": "Parkinsonian brain"
    },
    {
      "id": "mitochondrial impairment"
    },
    {
      "id": "TUNEL positivity"
    },
    {
      "id": "disease process"
    },
    {
      "id": "loss of mitochondrial viability"
    },
    {
      "id": "syn-8-oxoG/dAMP base pair"
    },
    {
      "id": "G-C to T-A transversion"
    },
    {
      "id": "DNA polymerase (pol) \u03b2"
    },
    {
      "id": "gap filling"
    },
    {
      "id": "templating anti-8-oxoG"
    },
    {
      "id": "incoming cytosine"
    },
    {
      "id": "Ternary complexes"
    },
    {
      "id": "incoming dATP-analogue"
    },
    {
      "id": "wild-type enzyme"
    },
    {
      "id": "8-oxoG"
    },
    {
      "id": "anti-conformation"
    },
    {
      "id": "cytosine"
    },
    {
      "id": "substitution"
    },
    {
      "id": "fidelity"
    },
    {
      "id": "R283K mutant"
    },
    {
      "id": "base lesion"
    },
    {
      "id": "8-oxo-7,8-dihydro-2'-deoxyguanosine"
    },
    {
      "id": "incoming dCTP"
    },
    {
      "id": "templating 8-oxoG"
    },
    {
      "id": "adenine"
    },
    {
      "id": "binary DNA complex"
    },
    {
      "id": "8-oxoG in equilibrium between anti- and syn-forms"
    },
    {
      "id": "DNA polymerase minor groove interactions"
    },
    {
      "id": "mutagenic bypass"
    },
    {
      "id": "templating 8-oxoguanine lesion"
    },
    {
      "id": "G-A mismatched structure"
    },
    {
      "id": "R283K pol \u03b2"
    },
    {
      "id": "pol \u03b2"
    },
    {
      "id": "anti- and syn-8-oxoG"
    },
    {
      "id": "R283K"
    },
    {
      "id": "Error-free DNA synthesis"
    },
    {
      "id": "Structural studies"
    },
    {
      "id": "Kinetic studies"
    },
    {
      "id": "base excision repair"
    },
    {
      "id": "mispair"
    },
    {
      "id": "syn-conformation"
    },
    {
      "id": "coding potential"
    },
    {
      "id": "templating (anti-/syn-equilibrium)"
    },
    {
      "id": "incoming nucleotide"
    },
    {
      "id": "syn-8-oxoG"
    },
    {
      "id": "insertion specificity"
    },
    {
      "id": "aldosterone synthase"
    },
    {
      "id": "potent and selective dual inhibitors"
    },
    {
      "id": "32 nM"
    },
    {
      "id": "CYP19"
    },
    {
      "id": "compounds 3k"
    },
    {
      "id": "decisive structural features"
    },
    {
      "id": "CYP19 inhibitors"
    },
    {
      "id": "substituents"
    },
    {
      "id": "pyridinylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones"
    },
    {
      "id": "common template"
    },
    {
      "id": "candidate"
    },
    {
      "id": "evaluation in vivo"
    },
    {
      "id": "41 nM"
    },
    {
      "id": "compounds 3n"
    },
    {
      "id": "methylene bridge"
    },
    {
      "id": "aromatase"
    },
    {
      "id": "compounds 3p"
    },
    {
      "id": "inhibitory activities"
    },
    {
      "id": "Tetrahydropyrroloquinolinone type dual inhibitors"
    },
    {
      "id": "postmenopausal breast cancer patients"
    },
    {
      "id": "CVD"
    },
    {
      "id": "compound 3p"
    },
    {
      "id": "breast cancer patients"
    },
    {
      "id": "cardiovascular risks"
    },
    {
      "id": "Dual inhibitors"
    },
    {
      "id": "estrogen deficiency"
    },
    {
      "id": "CVD risk"
    },
    {
      "id": "opposite effects"
    },
    {
      "id": "compounds 3j"
    },
    {
      "id": "adjuvant therapy"
    },
    {
      "id": "stressful conditions"
    },
    {
      "id": "hypoxia"
    },
    {
      "id": "growth inhibitory effects"
    },
    {
      "id": "E235"
    },
    {
      "id": "knockdown"
    },
    {
      "id": "N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide"
    },
    {
      "id": "senescence"
    },
    {
      "id": "ISR"
    },
    {
      "id": "DNA damage response signaling"
    },
    {
      "id": "Ser15-phosphorylated p53"
    },
    {
      "id": "G2/M phase"
    },
    {
      "id": "chemical libraries"
    },
    {
      "id": "modulators"
    },
    {
      "id": "human tumor cell lines"
    },
    {
      "id": "S-phase cells"
    },
    {
      "id": "phosphorylated checkpoint kinase 2"
    },
    {
      "id": "physical DNA damage"
    },
    {
      "id": "\u03bcM doses"
    },
    {
      "id": "redox homeostasis"
    },
    {
      "id": "\u03b3-H2AX"
    },
    {
      "id": "overactivation"
    },
    {
      "id": "tumor cell death"
    },
    {
      "id": "cell types"
    },
    {
      "id": "HT1080 human fibrosarcoma"
    },
    {
      "id": "cellular adaptation"
    },
    {
      "id": "Integrated Stress Response"
    },
    {
      "id": "signaling program"
    },
    {
      "id": "nutrient deprivation"
    },
    {
      "id": "ATF4 knockdown cells"
    },
    {
      "id": "activating transcription factor 4"
    },
    {
      "id": "small molecule"
    },
    {
      "id": "modifiers"
    },
    {
      "id": "amino acid metabolism"
    },
    {
      "id": "small-molecule screen"
    },
    {
      "id": "ATF4 expression"
    },
    {
      "id": "mouse tumor cell lines"
    },
    {
      "id": "B16F10 mouse melanoma cells"
    },
    {
      "id": "intestinal first-pass metabolism"
    },
    {
      "id": "new drug candidates"
    },
    {
      "id": "GFJ"
    },
    {
      "id": "liquid chromatography/MS/MS"
    },
    {
      "id": "blood levels"
    },
    {
      "id": "In vitro experiments"
    },
    {
      "id": "rat hepatic microsomal fractions"
    },
    {
      "id": "MDZ"
    },
    {
      "id": "mechanism-based inactivation"
    },
    {
      "id": "4-hydroxylation"
    },
    {
      "id": "hepatic microsomal fractions"
    },
    {
      "id": "triazolam"
    },
    {
      "id": "kinetic profiles"
    },
    {
      "id": "MDZ oxidation"
    },
    {
      "id": "human hepatic microsomal fractions"
    },
    {
      "id": "rat intestinal microsomal fractions"
    },
    {
      "id": "TRZ 1'-hydroxylation"
    },
    {
      "id": "TRZ"
    },
    {
      "id": "drug candidates"
    },
    {
      "id": "CYP3A enzymes"
    },
    {
      "id": "cytochrome P450 3A"
    },
    {
      "id": "in vitro oxidation"
    },
    {
      "id": "midazolam"
    },
    {
      "id": "parent compounds"
    },
    {
      "id": "intestinal microsomal oxidation"
    },
    {
      "id": "intestinal microsomal fractions"
    },
    {
      "id": "grapefruit juice"
    },
    {
      "id": "in vivo oxidation"
    },
    {
      "id": "first-pass effects"
    },
    {
      "id": "1'-hydroxylation"
    },
    {
      "id": "rat microsomes"
    },
    {
      "id": "Substrate inhibition"
    },
    {
      "id": "human microsomes"
    },
    {
      "id": "mouse hepatic microsomal fractions"
    },
    {
      "id": "human intestinal microsomal fractions"
    },
    {
      "id": "evaluation methodology"
    },
    {
      "id": "mouse intestinal microsomal fractions"
    },
    {
      "id": "tap water"
    },
    {
      "id": "linear accelerator"
    },
    {
      "id": "quinic acid"
    },
    {
      "id": "radioprotective compounds"
    },
    {
      "id": "protective ability"
    },
    {
      "id": "phenolic acids"
    },
    {
      "id": "alkaline comet assay"
    },
    {
      "id": "radioprotective effect"
    },
    {
      "id": "phytochemicals"
    },
    {
      "id": "Siemens Mevatron MD2"
    },
    {
      "id": "Siemens AG"
    },
    {
      "id": "DNA damage"
    },
    {
      "id": "chlorogenic acid"
    },
    {
      "id": "Radioprotection"
    },
    {
      "id": "X-ray irradiation-induced genomic instability"
    },
    {
      "id": "non-tumorigenic human blood lymphocytes"
    },
    {
      "id": "X-ray induced DNA damage"
    },
    {
      "id": "radiation-induced DNA damage"
    },
    {
      "id": "human blood lymphocytes"
    },
    {
      "id": "healthy human donors"
    },
    {
      "id": "USA"
    },
    {
      "id": "ganglioside clusters"
    },
    {
      "id": "A\u03b2 assembly"
    },
    {
      "id": "ASIGN"
    },
    {
      "id": "synaptosomal membranes"
    },
    {
      "id": "Density"
    },
    {
      "id": "factor"
    },
    {
      "id": "ganglioside-enriched microdomains"
    },
    {
      "id": "A\u03b2 assembly process"
    },
    {
      "id": "distinctive GM1 domain"
    },
    {
      "id": "A\u03b2"
    },
    {
      "id": "presynaptic neuronal membranes"
    },
    {
      "id": "reconstituted lipid bilayer"
    },
    {
      "id": "critical density of GM1"
    },
    {
      "id": "A\u03b2 binding"
    },
    {
      "id": "atomic force microscopic study"
    },
    {
      "id": "morphology"
    },
    {
      "id": "A\u03b2-sensitive ganglioside nanocluster (ASIGN)"
    },
    {
      "id": "detergent-resistant membrane microdomain (DRM) fraction"
    },
    {
      "id": "aged mouse brain"
    },
    {
      "id": "spherical assembly of amyloid \u03b2-protein"
    },
    {
      "id": "synaptic plasma membranes"
    },
    {
      "id": "high density of GM1"
    },
    {
      "id": "ganglioside-bound A\u03b2 (GA\u03b2)"
    },
    {
      "id": "endogenous seed"
    },
    {
      "id": "DRM fraction"
    },
    {
      "id": "nanoclusters"
    },
    {
      "id": "deposition of amyloid \u03b2-protein (A\u03b2)"
    },
    {
      "id": "hallmark"
    },
    {
      "id": "initiation of the A\u03b2 assembly process"
    },
    {
      "id": "GA\u03b2"
    },
    {
      "id": "A\u03b2 fibril formation"
    },
    {
      "id": "artificial GM1 cluster-binding peptide"
    },
    {
      "id": "spherical A\u03b2"
    },
    {
      "id": "assembly"
    },
    {
      "id": "ganglioside"
    },
    {
      "id": "longevity"
    },
    {
      "id": "cellular energy sensor"
    },
    {
      "id": "life span"
    },
    {
      "id": "energy sensing"
    },
    {
      "id": "life span modulator"
    },
    {
      "id": "Stenesen and colleagues"
    },
    {
      "id": "AMP biosynthesis"
    },
    {
      "id": "Drosophila"
    },
    {
      "id": "dietary restriction"
    },
    {
      "id": "aging"
    },
    {
      "id": "C. elegans"
    },
    {
      "id": "promiscuity"
    },
    {
      "id": "CAR"
    },
    {
      "id": "constitutive androstane receptor"
    },
    {
      "id": "3D structures"
    },
    {
      "id": "ligand-binding specificity"
    },
    {
      "id": "nuclear xenobiotic receptors"
    },
    {
      "id": "ligand specificities"
    },
    {
      "id": "PXR"
    },
    {
      "id": "pregnane X receptor"
    },
    {
      "id": "metabolic enzymes"
    },
    {
      "id": "ligand-binding site"
    },
    {
      "id": "nuclear receptors"
    },
    {
      "id": "ligand-binding domain"
    },
    {
      "id": "ligand profiles"
    },
    {
      "id": "LBD structures"
    },
    {
      "id": "LBD"
    },
    {
      "id": "crystal structures"
    },
    {
      "id": "Mn"
    },
    {
      "id": "trace element"
    },
    {
      "id": "Mn(2+)"
    },
    {
      "id": "oxidative cellular damage"
    },
    {
      "id": "oxidative DNA damage"
    },
    {
      "id": "SH-SY5Y cellular viability"
    },
    {
      "id": "neuronal SH-SY5Y cells"
    },
    {
      "id": "DNA single strand breaks"
    },
    {
      "id": "welding fumes"
    },
    {
      "id": "body burdens of Mn"
    },
    {
      "id": "exogenous chemical antioxidants"
    },
    {
      "id": "TUNEL"
    },
    {
      "id": "smelters"
    },
    {
      "id": "Manganese"
    },
    {
      "id": "neurological symptoms"
    },
    {
      "id": "idiopathic Parkinson's disease (IPD)"
    },
    {
      "id": "normal function"
    },
    {
      "id": "thymine base lesions"
    },
    {
      "id": "1mM N-acetylcysteine (NAC)"
    },
    {
      "id": "Mn(2+)-induction"
    },
    {
      "id": "thymine lesions"
    },
    {
      "id": "SH-SY5Y cell line"
    },
    {
      "id": "apoptotic pathway"
    },
    {
      "id": "oxidatively modified thymine bases"
    },
    {
      "id": "alkaline comet assay analysis"
    },
    {
      "id": "mines"
    },
    {
      "id": "neurological health concerns"
    },
    {
      "id": "annexin V/propidium iodide (PI) apoptosis assays"
    },
    {
      "id": "DNA strand breaks"
    },
    {
      "id": "parental nutrition"
    },
    {
      "id": "1mM glutathione (GSH)"
    },
    {
      "id": "N-acetylcysteine"
    },
    {
      "id": "manganism"
    },
    {
      "id": "vapors"
    },
    {
      "id": "gas chromatography/mass spectrometry analysis"
    },
    {
      "id": "progressive neurodegenerative disorder"
    },
    {
      "id": "antioxidant protection"
    },
    {
      "id": "Lipases"
    },
    {
      "id": "CESs"
    },
    {
      "id": "orlistat"
    },
    {
      "id": "CES2"
    },
    {
      "id": "organ toxicities"
    },
    {
      "id": "alternative target"
    },
    {
      "id": "carboxylesterase"
    },
    {
      "id": "human CES1"
    },
    {
      "id": "common drugs"
    },
    {
      "id": "anticancer prodrugs"
    },
    {
      "id": "CES2 activity"
    },
    {
      "id": "mouse CESs"
    },
    {
      "id": "CES1"
    },
    {
      "id": "altered therapeutic activity"
    },
    {
      "id": "medicines"
    },
    {
      "id": "anti-obesity drug"
    },
    {
      "id": "recombinant CESs"
    },
    {
      "id": "PPD"
    },
    {
      "id": "\u03b1/\u03b2 hydrolase fold superfamily"
    },
    {
      "id": "standard substrates"
    },
    {
      "id": "CES2 polymorphic variants"
    },
    {
      "id": "source"
    },
    {
      "id": "Liver microsomes"
    },
    {
      "id": "pentyl carbamate"
    },
    {
      "id": "cell killing activity"
    },
    {
      "id": "antiobesity agent"
    },
    {
      "id": "doxazolidine"
    },
    {
      "id": "lipase activity"
    },
    {
      "id": "lipid absorption"
    },
    {
      "id": "carboxylesterases"
    },
    {
      "id": "gastrointestinal lipases"
    },
    {
      "id": "gastrointestinal track"
    },
    {
      "id": "Carboxylesterase-2"
    },
    {
      "id": "rat CESs"
    },
    {
      "id": "p-aminobenzyl carbamate"
    },
    {
      "id": "toxicological responses"
    },
    {
      "id": "p300"
    },
    {
      "id": "dystrophic heart"
    },
    {
      "id": "Duchenne muscular dystrophy"
    },
    {
      "id": "Resveratrol"
    },
    {
      "id": "p300 mRNA"
    },
    {
      "id": "mdx heart"
    },
    {
      "id": "ubiquitin-proteasome pathway"
    },
    {
      "id": "proteasome"
    },
    {
      "id": "p300 protein"
    },
    {
      "id": "\u03b1(1)-agonist phenylephrine"
    },
    {
      "id": "atrial natriuretic peptide promoter"
    },
    {
      "id": "cardiac diastolic function"
    },
    {
      "id": "SIRT1 protein"
    },
    {
      "id": "ubiquitin"
    },
    {
      "id": "dystrophic cardiomyopathy"
    },
    {
      "id": "cardiac hypertrophy"
    },
    {
      "id": "pro-hypertrophic co-activator p300 protein"
    },
    {
      "id": "immunohistochemical staining"
    },
    {
      "id": "active caspase-3"
    },
    {
      "id": "3-nitrotyrosine"
    },
    {
      "id": "ex vivo exposure"
    },
    {
      "id": "Lead"
    },
    {
      "id": "Pb treatments"
    },
    {
      "id": "BaP treatments"
    },
    {
      "id": "Pb"
    },
    {
      "id": "Pathological conditions"
    },
    {
      "id": "chronic Pb and BaP exposure"
    },
    {
      "id": "Ingestion"
    },
    {
      "id": "Benzo[a]pyrene"
    },
    {
      "id": "Inhalation"
    },
    {
      "id": "single, short-term exposure"
    },
    {
      "id": "markers of apoptosis"
    },
    {
      "id": "BaP"
    },
    {
      "id": "Ex vivo samples"
    },
    {
      "id": "Oral mucosa cells"
    },
    {
      "id": "markers of oxidative and nitrosative stress"
    },
    {
      "id": "Human oral mucosa"
    },
    {
      "id": "Nitrosative stress"
    },
    {
      "id": "Smokers' samples"
    },
    {
      "id": "8-epi-PGF2a"
    },
    {
      "id": "Nonsmokers' samples"
    },
    {
      "id": "3-NT"
    },
    {
      "id": "8-epi-prostaglandin F2 alpha"
    },
    {
      "id": "Fourth generation PPI dendrimers"
    },
    {
      "id": "(1)H NMR spectroscopies"
    },
    {
      "id": "pH dependent in vitro release"
    },
    {
      "id": "SMPPI"
    },
    {
      "id": "dual targeted system"
    },
    {
      "id": "carbohydrate receptors"
    },
    {
      "id": "hemolytic toxicity"
    },
    {
      "id": "SPPI"
    },
    {
      "id": "ZDV loaded MPPI"
    },
    {
      "id": "ZDV loaded SPPI"
    },
    {
      "id": "in vitro drug release"
    },
    {
      "id": "ZDV loaded SMPPI"
    },
    {
      "id": "sialic acid conjugated PPI dendrimers"
    },
    {
      "id": "ZDV"
    },
    {
      "id": "antiretroviral drug"
    },
    {
      "id": "size exclusion chromatography"
    },
    {
      "id": "PPI"
    },
    {
      "id": "dual ligand dendritic system"
    },
    {
      "id": "sialic acid conjugated-mannosylated PPI dendrimers"
    },
    {
      "id": "MPPI"
    },
    {
      "id": "site specific delivery"
    },
    {
      "id": "macrophage uptake"
    },
    {
      "id": "anti-HIV drug"
    },
    {
      "id": "FT-IR"
    },
    {
      "id": "drug concentration"
    },
    {
      "id": "6th hr"
    },
    {
      "id": "sialoadhesin"
    },
    {
      "id": "zidovudine"
    },
    {
      "id": "mannose conjugated PPI dendrimers"
    },
    {
      "id": "in vivo blood level"
    },
    {
      "id": "albino rats"
    },
    {
      "id": "poly(propyleneimine) (PPI)"
    },
    {
      "id": "tissue distribution studies"
    },
    {
      "id": "macrophage cells"
    },
    {
      "id": "differential scanning calorimetry"
    },
    {
      "id": "sialic acid conjugated-mannosylated poly(propyleneimine) (PPI) dendritic nano-constructs"
    },
    {
      "id": "dendritic nano-constructs"
    },
    {
      "id": "dual ligand system"
    },
    {
      "id": "CA-Xaa-NHOH"
    },
    {
      "id": "tyrosinase"
    },
    {
      "id": "caffeoyl-amino acidyl-hydroxamic acid"
    },
    {
      "id": "aromatic ring"
    },
    {
      "id": "caffeic acid"
    },
    {
      "id": "prolyl hydroxamic acid"
    },
    {
      "id": "HCA-Phe-NHOH"
    },
    {
      "id": "ferulic acid"
    },
    {
      "id": "sinapic acid"
    },
    {
      "id": "hydroxycinnamic acid derivatives"
    },
    {
      "id": "phenylalanyl hydroxamic acid"
    },
    {
      "id": "melanin content"
    },
    {
      "id": "hydroxycinnamoyl phenylalanyl"
    },
    {
      "id": "HCA-Pro-NHOH"
    },
    {
      "id": "Trolox"
    },
    {
      "id": "melanocytes Mel-Ab cell"
    },
    {
      "id": "phenylalanine"
    },
    {
      "id": "HCA"
    },
    {
      "id": "Methylation"
    },
    {
      "id": "lysine 4"
    },
    {
      "id": "SET1"
    },
    {
      "id": "histone H3"
    },
    {
      "id": "SET1 protein"
    },
    {
      "id": "lysine methyltransferase"
    },
    {
      "id": "frq expression"
    },
    {
      "id": "strains"
    },
    {
      "id": "H3K4 methylation"
    },
    {
      "id": "light-mediated frq regulation"
    },
    {
      "id": "chromatin"
    },
    {
      "id": "circadian oscillator"
    },
    {
      "id": "light"
    },
    {
      "id": "feedback loops"
    },
    {
      "id": "light-regulated gene expression"
    },
    {
      "id": "H3K4me"
    },
    {
      "id": "circadian-regulated gene expression"
    },
    {
      "id": "clock gene expression"
    },
    {
      "id": "set1"
    },
    {
      "id": "Neurospora CHD1"
    },
    {
      "id": "frq gene"
    },
    {
      "id": "White Collar 2"
    },
    {
      "id": "frq promoter"
    },
    {
      "id": "frq"
    },
    {
      "id": "clock-mediated frq regulation"
    },
    {
      "id": "chromatin regulation"
    },
    {
      "id": "histone-modifying enzymes"
    },
    {
      "id": "strain"
    },
    {
      "id": "frequency gene"
    },
    {
      "id": "clock function"
    },
    {
      "id": "WC-2"
    },
    {
      "id": "chromatin-remodeling enzymes"
    },
    {
      "id": "time-of-day gene expression"
    },
    {
      "id": "\u0394set1"
    },
    {
      "id": "chromatin state"
    },
    {
      "id": "CHD1"
    },
    {
      "id": "frq regulation"
    },
    {
      "id": "eukaryotic transcription"
    },
    {
      "id": "low-dose gentamicin"
    },
    {
      "id": "mild renal damage"
    },
    {
      "id": "specific risk"
    },
    {
      "id": "uranyl nitrate (UN)"
    },
    {
      "id": "hemopexin"
    },
    {
      "id": "chronic predisposition"
    },
    {
      "id": "life conditions"
    },
    {
      "id": "VDBP"
    },
    {
      "id": "subnephrotoxic treatments"
    },
    {
      "id": "potentially nephrotoxic drugs"
    },
    {
      "id": "vitamin D binding protein"
    },
    {
      "id": "Drug nephrotoxicity"
    },
    {
      "id": "health problem"
    },
    {
      "id": "AKI severity"
    },
    {
      "id": "gentamicin nephrotoxicity"
    },
    {
      "id": "renal damage"
    },
    {
      "id": "hidden, chronic predisposition to gentamicin nephrotoxicity"
    },
    {
      "id": "acquired sensitization"
    },
    {
      "id": "sensitization"
    },
    {
      "id": "Acquired sensitization"
    },
    {
      "id": "silent risk"
    },
    {
      "id": "AKI incidence"
    },
    {
      "id": "acute kidney injury (AKI)"
    },
    {
      "id": "treatments"
    },
    {
      "id": "albumin"
    },
    {
      "id": "technology"
    },
    {
      "id": "clinical level"
    },
    {
      "id": "chronically acquired sensitization"
    },
    {
      "id": "plain water"
    },
    {
      "id": "histological level"
    },
    {
      "id": "economic problem"
    },
    {
      "id": "associated costs"
    },
    {
      "id": "chronic, subnephrotoxic insult"
    },
    {
      "id": "kidneys"
    },
    {
      "id": "nitrate"
    },
    {
      "id": "experimental nephrotoxin"
    },
    {
      "id": "specific urinary markers"
    },
    {
      "id": "additional clinical procedures"
    },
    {
      "id": "functional level"
    },
    {
      "id": "ICA-105574"
    },
    {
      "id": "ICA"
    },
    {
      "id": "inverse functional response"
    },
    {
      "id": "EAG channels"
    },
    {
      "id": "S5/pore helix/S6"
    },
    {
      "id": "one subunit"
    },
    {
      "id": "mixed agonist"
    },
    {
      "id": "mutant EAG"
    },
    {
      "id": "functional response"
    },
    {
      "id": "ICA binding site"
    },
    {
      "id": "S6"
    },
    {
      "id": "adjacent subunit"
    },
    {
      "id": "specific amino acids"
    },
    {
      "id": "putative binding pocket"
    },
    {
      "id": "three residues"
    },
    {
      "id": "intrinsic mechanisms of inactivation"
    },
    {
      "id": "rate"
    },
    {
      "id": "3-nitro-N-[4-phenoxyphenyl]-benzamide"
    },
    {
      "id": "same site"
    },
    {
      "id": "ERG channels"
    },
    {
      "id": "opposite functional effects"
    },
    {
      "id": "ERG inactivation"
    },
    {
      "id": "hydrophobic pocket"
    },
    {
      "id": "common binding site"
    },
    {
      "id": "EAG"
    },
    {
      "id": "EAG K(+) channels"
    },
    {
      "id": "K(+) channels"
    },
    {
      "id": "voltage dependence"
    },
    {
      "id": "EAG potassium channels"
    },
    {
      "id": "potassium channels"
    },
    {
      "id": "Rapid and voltage-dependent inactivation"
    },
    {
      "id": "ERG K(+) channels"
    },
    {
      "id": "ERG"
    },
    {
      "id": "slow and fast mechanisms"
    },
    {
      "id": "channel types"
    },
    {
      "id": "inactivation gating"
    },
    {
      "id": "resultant agonist or antagonist activity"
    },
    {
      "id": "channel-specific differences"
    },
    {
      "id": "ERG potassium channels"
    },
    {
      "id": "extent"
    },
    {
      "id": "Mutations"
    },
    {
      "id": "EAG/ERG chimera channels"
    },
    {
      "id": "positive potentials"
    },
    {
      "id": "channel-specific orientation"
    },
    {
      "id": "mechanisms of inactivation gating"
    },
    {
      "id": "ether-a-go-go-related gene"
    },
    {
      "id": "ether-a-go-go"
    },
    {
      "id": "outward currents"
    },
    {
      "id": "EAG inactivation"
    },
    {
      "id": "LT4"
    },
    {
      "id": "Brazil"
    },
    {
      "id": "University Hospitals"
    },
    {
      "id": "Universidade Federal do Cear\u00e1-UFC"
    },
    {
      "id": "2292 consecutive patients"
    },
    {
      "id": "inclusion criteria"
    },
    {
      "id": "referral centers"
    },
    {
      "id": "levothyroxine (LT4) replacement treatment"
    },
    {
      "id": "LEVOTHYROXINE REPLACEMENT"
    },
    {
      "id": "breakfast"
    },
    {
      "id": "Unicamp"
    },
    {
      "id": "questionnaire"
    },
    {
      "id": "Clinicians"
    },
    {
      "id": "thyroid hormone replacement"
    },
    {
      "id": "Serum TSH"
    },
    {
      "id": "interview"
    },
    {
      "id": "social-economic status"
    },
    {
      "id": "clinicians' orientations"
    },
    {
      "id": "thyroid medication"
    },
    {
      "id": "Universidade Federal do Rio de Janeiro -UFRJ"
    },
    {
      "id": "PRIMARY HYPOTHYROIDISM PATIENTS"
    },
    {
      "id": "correct use of LT4"
    },
    {
      "id": "primary hypothyroidism"
    },
    {
      "id": "MULTICENTRE STUDY"
    },
    {
      "id": "TSH values"
    },
    {
      "id": "reference range"
    },
    {
      "id": "therapeutic range"
    },
    {
      "id": "abnormal serum TSH"
    },
    {
      "id": "undertreated patients"
    },
    {
      "id": "clinical and biochemical conditions"
    },
    {
      "id": "over treated patients"
    },
    {
      "id": "TSH"
    },
    {
      "id": "normal range"
    },
    {
      "id": "other medication"
    },
    {
      "id": "life quality"
    },
    {
      "id": "thyroid replacement"
    },
    {
      "id": "Universidade Federal do Paran\u00e1 - UFPR"
    },
    {
      "id": "continent"
    },
    {
      "id": "EMT"
    },
    {
      "id": "TAM"
    },
    {
      "id": "Tamoxifen"
    },
    {
      "id": "epithelial-to-mesenchymal transition"
    },
    {
      "id": "c-Myc"
    },
    {
      "id": "TAM-treated cells"
    },
    {
      "id": "Snail"
    },
    {
      "id": "TAM-induced EMT"
    },
    {
      "id": "microRNAs"
    },
    {
      "id": "miR-200 family"
    },
    {
      "id": "tumor suppressive functions"
    },
    {
      "id": "N-cadherin"
    },
    {
      "id": "hormone-responsive breast cancer"
    },
    {
      "id": "selective estrogen receptor modulator"
    },
    {
      "id": "TAM treatment"
    },
    {
      "id": "motility"
    },
    {
      "id": "miR-200"
    },
    {
      "id": "miRNA family"
    },
    {
      "id": "estrogen-like effect"
    },
    {
      "id": "key factors of EMT"
    },
    {
      "id": "miR-200 microRNAs"
    },
    {
      "id": "mechanism of TAM-induced EMT"
    },
    {
      "id": "promoter of miR-200 miRNAs"
    },
    {
      "id": "ECC-1 cells"
    },
    {
      "id": "down-regulation of miR-200"
    },
    {
      "id": "miRNAs"
    },
    {
      "id": "E-cadherin"
    },
    {
      "id": "miR-200b"
    },
    {
      "id": "zinc finger E-box binding homeobox 2"
    },
    {
      "id": "Ishikawa cells"
    },
    {
      "id": "TAA"
    },
    {
      "id": "ED2(+) liver cells"
    },
    {
      "id": "CD3(+) lymphocytes"
    },
    {
      "id": "EMIQ"
    },
    {
      "id": "heme oxygenase-1(+) liver cells"
    },
    {
      "id": "N-diethylnitrosamine"
    },
    {
      "id": "thiobarbituric acid-reactive substance"
    },
    {
      "id": "hepatic macrophages"
    },
    {
      "id": "proinflammatory factors"
    },
    {
      "id": "preneoplastic cells"
    },
    {
      "id": "liver tissue environment"
    },
    {
      "id": "lymphocytes"
    },
    {
      "id": "GST-P(+) liver cell foci"
    },
    {
      "id": "TAA-induced tumor promotion"
    },
    {
      "id": "DR5(+) cells"
    },
    {
      "id": "preneoplastic cell apoptosis"
    },
    {
      "id": "hepatocarcinogenic process"
    },
    {
      "id": "DR5"
    },
    {
      "id": "proliferating cells"
    },
    {
      "id": "cyclooxygenase-2(+) liver cells"
    },
    {
      "id": "tumor promotion"
    },
    {
      "id": "non-transformed liver cells"
    },
    {
      "id": "thioacetamide"
    },
    {
      "id": "preneoplastic liver cell lesions"
    },
    {
      "id": "8-hydroxydeoxyguanosine"
    },
    {
      "id": "TUNEL(+) apoptotic cells"
    },
    {
      "id": "two-stage hepatocarcinogenesis model"
    },
    {
      "id": "hepatocellular tumor promotion"
    },
    {
      "id": "4-hydroxy-2-nonenal(+) cells"
    },
    {
      "id": "anxiogenic effects"
    },
    {
      "id": "PNU-120596"
    },
    {
      "id": "memory impairment"
    },
    {
      "id": "anxiety-like behavior"
    },
    {
      "id": "serotonin 5-HT1a receptor antagonist"
    },
    {
      "id": "methyllycaconitine"
    },
    {
      "id": "\u03b17 receptor antagonist"
    },
    {
      "id": "PNU-282987"
    },
    {
      "id": "spatial-learning"
    },
    {
      "id": "anxiety"
    },
    {
      "id": "episodic memory"
    },
    {
      "id": "positive allosteric modulators (PAMs)"
    },
    {
      "id": "therapeutic drugs"
    },
    {
      "id": "cognitive impairment"
    },
    {
      "id": "Agonists"
    },
    {
      "id": "\u03b17 nicotinic acetylcholine receptor"
    },
    {
      "id": "\u03b17 subtype of nAChRs"
    },
    {
      "id": "Sprague Dawley rats"
    },
    {
      "id": "WAY-100135"
    },
    {
      "id": "5-HT1a receptor antagonist"
    },
    {
      "id": "behavioral tests"
    },
    {
      "id": "cognitive function"
    },
    {
      "id": "\u03b17 receptors"
    },
    {
      "id": "\u03b17-selective agonist"
    },
    {
      "id": "\u03b17 and non-\u03b17 subtypes of nAChRs"
    },
    {
      "id": "\u03b17 nicotinic ACh receptor"
    },
    {
      "id": "scopolamine"
    },
    {
      "id": "microcosamine A (4)"
    },
    {
      "id": "Alkaloids"
    },
    {
      "id": "Microcos paniculata"
    },
    {
      "id": "cytotoxic fractions"
    },
    {
      "id": "chloroform-soluble extracts"
    },
    {
      "id": "selective cytotoxic agent"
    },
    {
      "id": "colon cancer cells"
    },
    {
      "id": "human \u03b13\u03b24 or \u03b14\u03b22 nicotinic acetylcholine receptors"
    },
    {
      "id": "normal colon cells"
    },
    {
      "id": "leaves"
    },
    {
      "id": "liriodenine (6)"
    },
    {
      "id": "small tree"
    },
    {
      "id": "stem bark"
    },
    {
      "id": "M. paniculata"
    },
    {
      "id": "South Asia"
    },
    {
      "id": "Southeast Asia"
    },
    {
      "id": "piperidine alkaloids"
    },
    {
      "id": "microgrewiapines A-C (1-3)"
    },
    {
      "id": "nAChRs"
    },
    {
      "id": "large shrub"
    },
    {
      "id": "branches"
    },
    {
      "id": "7'-(3',4'-dihydroxyphenyl)-N-[4-methoxyphenyl)ethyl]propenamide (5)"
    },
    {
      "id": "microgrewiapine A (1)"
    },
    {
      "id": "h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes"
    },
    {
      "id": "Compounds 1-6"
    },
    {
      "id": "HT-29 human colon cancer cell line"
    },
    {
      "id": "1a (microgrewiapine A 3-acetate)"
    },
    {
      "id": "Enzymes"
    },
    {
      "id": "Human fibroblasts"
    },
    {
      "id": "CPT2"
    },
    {
      "id": "CACT"
    },
    {
      "id": "Export"
    },
    {
      "id": "Mitochondrial acylcarnitine formation"
    },
    {
      "id": "Carnitine/acylcarnitine translocase"
    },
    {
      "id": "OCTN2"
    },
    {
      "id": "Cell lines"
    },
    {
      "id": "Carnitine"
    },
    {
      "id": "Carnitine palmitoyltransferase 2"
    },
    {
      "id": "Acylcarnitines"
    },
    {
      "id": "Mock-transduced controls"
    },
    {
      "id": "Plasma"
    },
    {
      "id": "Accumulation"
    },
    {
      "id": "Acylcarnitine"
    },
    {
      "id": "Extracellular medium"
    },
    {
      "id": "mFAODs"
    },
    {
      "id": "Plasmalemmal carnitine transporter"
    },
    {
      "id": "Mitochondrial fatty acid \u03b2-oxidation disorders"
    },
    {
      "id": "Pharmacological inhibition"
    },
    {
      "id": "Extracellular fluids"
    },
    {
      "id": "Octanoylcarnitine"
    },
    {
      "id": "Lentiviral shRNA"
    },
    {
      "id": "Medium-chain acyl-CoA dehydrogenase"
    },
    {
      "id": "MCAD-deficient individuals"
    },
    {
      "id": "Decanoic acid"
    },
    {
      "id": "Acyl-CoAs"
    },
    {
      "id": "MCAD"
    },
    {
      "id": "MCAD knockdown"
    },
    {
      "id": "ventral SN"
    },
    {
      "id": "dopaminergic neurotoxins"
    },
    {
      "id": "resistance to injury"
    },
    {
      "id": "PD"
    },
    {
      "id": "surviving mDA neurons"
    },
    {
      "id": "substantia nigra (SN)"
    },
    {
      "id": "calbindin-D28k"
    },
    {
      "id": "calcium-binding protein"
    },
    {
      "id": "distinct subpopulations"
    },
    {
      "id": "calbindin-negative Pitx-3-dependent cells"
    },
    {
      "id": "Pitx3"
    },
    {
      "id": "Cell-mapping studies"
    },
    {
      "id": "mDA neurons"
    },
    {
      "id": "The transcription factor Pitx3"
    },
    {
      "id": "midbrain dopaminergic neurons"
    },
    {
      "id": "selective pattern"
    },
    {
      "id": "vulnerability"
    },
    {
      "id": "SN mDA neurons"
    },
    {
      "id": "Pitx3 function"
    },
    {
      "id": "Pitx3-deficient mice"
    },
    {
      "id": "developmental loss"
    },
    {
      "id": "ImpaiRment"
    },
    {
      "id": "locomotor deficits"
    },
    {
      "id": "Pitx3-expressing SN cells"
    },
    {
      "id": "MPTP treatment"
    },
    {
      "id": "neurodegenerative stress"
    },
    {
      "id": "mDA cell loss"
    },
    {
      "id": "The homeodomain transcription factor Pitx3"
    },
    {
      "id": "midbrain dopaminergic (mDA) neurons"
    },
    {
      "id": "toxic injury"
    },
    {
      "id": "mDA cell subpopulations"
    },
    {
      "id": "adult Pitx3-hypomorphic (aphakia) mice"
    },
    {
      "id": "Pitx3 hemizygous mice"
    },
    {
      "id": "ventral tegmental area (VTA)"
    },
    {
      "id": "Pitx3-dependent pathways"
    },
    {
      "id": "MPTP-resistant Pitx3-autonomous, calbindin-positive neurons"
    },
    {
      "id": "Parkinson's disease (PD) models"
    },
    {
      "id": "curative therapy"
    },
    {
      "id": "myelofibrosis"
    },
    {
      "id": "novel approaches"
    },
    {
      "id": "JAK-signal transducer and activator of transcription pathway"
    },
    {
      "id": "hematopoiesis"
    },
    {
      "id": "life-threatening complications"
    },
    {
      "id": "thrombotic events"
    },
    {
      "id": "current treatment strategies"
    },
    {
      "id": "specific symptomology"
    },
    {
      "id": "splenomegaly"
    },
    {
      "id": "orphan disease state"
    },
    {
      "id": "unmet medical need"
    },
    {
      "id": "Ruxolitinib"
    },
    {
      "id": "combination with other treatments"
    },
    {
      "id": "prevalent mutation"
    },
    {
      "id": "gain-of-function mutation"
    },
    {
      "id": "myelofibrosis-related symptoms"
    },
    {
      "id": "small-molecule inhibitor"
    },
    {
      "id": "Adverse events"
    },
    {
      "id": "hematologic"
    },
    {
      "id": "JAK2 V617F"
    },
    {
      "id": "medical therapies"
    },
    {
      "id": "first drug"
    },
    {
      "id": "United States Food and Drug Administration"
    },
    {
      "id": "dysregulated cellular proliferation"
    },
    {
      "id": "symptomatic intermediate- or high-risk myelofibrosis"
    },
    {
      "id": "older population"
    },
    {
      "id": "toxicologic events"
    },
    {
      "id": "molecular mutations"
    },
    {
      "id": "aggressive therapy"
    },
    {
      "id": "hemorrhagic episodes"
    },
    {
      "id": "JAK1"
    },
    {
      "id": "allogeneic hematopoietic stem cell transplantation"
    },
    {
      "id": "transformation to leukemia"
    },
    {
      "id": "molecularly targeted therapy"
    },
    {
      "id": "myeloproliferative neoplasm"
    },
    {
      "id": "bone marrow fibrosis"
    },
    {
      "id": "treatment options"
    },
    {
      "id": "Emerging research"
    },
    {
      "id": "Janus kinase (JAK) family"
    },
    {
      "id": "extramedullary hematopoiesis"
    },
    {
      "id": "induced behaviors"
    },
    {
      "id": "prosocial effects"
    },
    {
      "id": "modulatory role"
    },
    {
      "id": "milk let-down reflex"
    },
    {
      "id": "neuronal processes"
    },
    {
      "id": "psychological phenomena"
    },
    {
      "id": "reward processes"
    },
    {
      "id": "psychostimulant effects"
    },
    {
      "id": "MDMA"
    },
    {
      "id": "psychiatric disorders"
    },
    {
      "id": "autism"
    },
    {
      "id": "medicine"
    },
    {
      "id": "novel intervention"
    },
    {
      "id": "Clinical trials"
    },
    {
      "id": "Ecstasy"
    },
    {
      "id": "field of research"
    },
    {
      "id": "pharmacological limitations"
    },
    {
      "id": "psychostimulant addiction"
    },
    {
      "id": "3,4-methylenedioxymethamphetamine"
    },
    {
      "id": "parturition"
    },
    {
      "id": "behavioral processes"
    },
    {
      "id": "physiological activity"
    },
    {
      "id": "memory processes"
    },
    {
      "id": "H-bonds"
    },
    {
      "id": "Hyp\u00b7Hyp base pair"
    },
    {
      "id": "six key points"
    },
    {
      "id": "Hyp\u00b7Hyp\u2194Hyp*\u00b7Hyp* tautomerization"
    },
    {
      "id": "synchronous tautomerization process"
    },
    {
      "id": "Hyp\u00b7Hyp"
    },
    {
      "id": "energetic parameters"
    },
    {
      "id": "course of the tautomerization"
    },
    {
      "id": "C2H\u2026O2 H-bond"
    },
    {
      "id": "Hyp\u00b7Cyt base pair"
    },
    {
      "id": "sweeps"
    },
    {
      "id": "electron-topological \"fingerprints\""
    },
    {
      "id": "concerted asynchronous tautomerization process"
    },
    {
      "id": "tautomerization"
    },
    {
      "id": "theoretical investigations"
    },
    {
      "id": "Hyp\u00b7Thy* base pair"
    },
    {
      "id": "intrinsic reaction coordinate (IRC)"
    },
    {
      "id": "electron-topological parameters"
    },
    {
      "id": "polar parameters"
    },
    {
      "id": "continuum"
    },
    {
      "id": "double proton transfer (DPT)"
    },
    {
      "id": "concerted and asynchronous process"
    },
    {
      "id": "Hyp*\u00b7Thy base pair"
    },
    {
      "id": "Hyp*\u00b7Hyp* base pair"
    },
    {
      "id": "QTAIM topological analysis"
    },
    {
      "id": "Hyp*\u00b7Cyt* base pair"
    },
    {
      "id": "hydrophobic interfaces"
    },
    {
      "id": "protein-nucleic acid interactions"
    },
    {
      "id": "DNA bases"
    },
    {
      "id": "low dielectric constant (\u03b5\u2009=\u20094)"
    },
    {
      "id": "O6H\u2026O4 H-bond"
    },
    {
      "id": "Hyp*\u00b7Thy"
    },
    {
      "id": "in vacuo"
    },
    {
      "id": "concerted and synchronous process"
    },
    {
      "id": "Hyp\u00b7Hyp homodimer"
    },
    {
      "id": "nine key points"
    },
    {
      "id": "hypoxanthine"
    },
    {
      "id": "Hyp\u00b7Cyt"
    },
    {
      "id": "physico-chemical \"anatomy\""
    },
    {
      "id": "topological analysis"
    },
    {
      "id": "key points"
    },
    {
      "id": "B3LYP/6-311++G(d,p) level of QM theory"
    },
    {
      "id": "QM theory"
    },
    {
      "id": "Hyp*\u00b7Thy\u2194Hyp\u00b7Thy* tautomerization"
    },
    {
      "id": "Hyp\u00b7Cyt\u2194Hyp*\u00b7Cyt* tautomerization"
    },
    {
      "id": "QM"
    },
    {
      "id": "geometric parameters"
    },
    {
      "id": "Ser26 phosphorylation"
    },
    {
      "id": "BAD proapoptotic activity"
    },
    {
      "id": "mortality"
    },
    {
      "id": "I\u03baB kinase complex"
    },
    {
      "id": "IKK"
    },
    {
      "id": "target gene products"
    },
    {
      "id": "caspases"
    },
    {
      "id": "BAD"
    },
    {
      "id": "BH3-only protein"
    },
    {
      "id": "NF-\u03baB activation"
    },
    {
      "id": "cultured cells"
    },
    {
      "id": "immune responses"
    },
    {
      "id": "JNK activation"
    },
    {
      "id": "serine-26"
    },
    {
      "id": "MEFs"
    },
    {
      "id": "RelA"
    },
    {
      "id": "Ser26"
    },
    {
      "id": "proapoptotic BH3-only BAD protein"
    },
    {
      "id": "TNF\u03b1"
    },
    {
      "id": "Ikk\u03b2(-/-) mouse embryonic fibroblasts"
    },
    {
      "id": "cRel"
    },
    {
      "id": "functional \u03b2-cell mass"
    },
    {
      "id": "Lineage-tracing studies"
    },
    {
      "id": "rat insulin 2 promoter-driven cre-lox"
    },
    {
      "id": "pancreatic duct ligation (PDL)"
    },
    {
      "id": "\u03b2-Cells"
    },
    {
      "id": "injured adult mouse pancreas"
    },
    {
      "id": "accurate measurement"
    },
    {
      "id": "traditional morphometry methodologies"
    },
    {
      "id": "sequential administration"
    },
    {
      "id": "thymidine analogs"
    },
    {
      "id": "\u03b2-cell mass"
    },
    {
      "id": "PDL-induced injury"
    },
    {
      "id": "\u03b2-cell progenitors"
    },
    {
      "id": "ductal ligation-induced injury"
    },
    {
      "id": "massive pancreatic injury"
    },
    {
      "id": "week"
    },
    {
      "id": "\u03b2-cell lineage"
    },
    {
      "id": "Pancreatic Duct Ligation-Induced Injury"
    },
    {
      "id": "Adult Mice"
    },
    {
      "id": "\u03b2-cell content"
    },
    {
      "id": "entire pancreas"
    },
    {
      "id": "potential bias"
    },
    {
      "id": "cell-autonomous manner"
    },
    {
      "id": "\u03b2-cell mass expansion"
    },
    {
      "id": "pancreatic composition"
    },
    {
      "id": "developmental biology topic"
    },
    {
      "id": "diabetes research"
    },
    {
      "id": "adult \u03b2-cell progenitors"
    },
    {
      "id": "insulin content"
    },
    {
      "id": "low-frequency ubiquitous cre-lox"
    },
    {
      "id": "adult mouse pancreas"
    },
    {
      "id": "11"
    },
    {
      "id": "aerial parts of Isodon tenuifolius"
    },
    {
      "id": "12"
    },
    {
      "id": "absolute configurations"
    },
    {
      "id": "15"
    },
    {
      "id": "ent-kauranoids"
    },
    {
      "id": "four known compounds"
    },
    {
      "id": "17"
    },
    {
      "id": "Selected compounds"
    },
    {
      "id": "1"
    },
    {
      "id": "3"
    },
    {
      "id": "isolates"
    },
    {
      "id": "18"
    },
    {
      "id": "abietane diterpenoids"
    },
    {
      "id": "tenuifolins A-M"
    },
    {
      "id": "14"
    },
    {
      "id": "diterpenoids"
    },
    {
      "id": "isoabietenins A-C"
    },
    {
      "id": "20"
    },
    {
      "id": "known compounds"
    },
    {
      "id": "9"
    },
    {
      "id": "new metabolites"
    },
    {
      "id": "6"
    },
    {
      "id": "LPS-activated RAW264.7 macrophages"
    },
    {
      "id": "RAW264.7 macrophages"
    },
    {
      "id": "10"
    },
    {
      "id": "5"
    },
    {
      "id": "2"
    },
    {
      "id": "7"
    },
    {
      "id": "8"
    },
    {
      "id": "small panel of human tumor cell lines"
    },
    {
      "id": "16"
    },
    {
      "id": "13"
    },
    {
      "id": "19"
    },
    {
      "id": "Bioactive abietane and ent-kaurane diterpenoids"
    },
    {
      "id": "Isodon tenuifolius"
    },
    {
      "id": "4"
    },
    {
      "id": "Three new abietane diterpenoids"
    },
    {
      "id": "13 new ent-kauranoids"
    },
    {
      "id": "single-crystal X-ray diffraction"
    },
    {
      "id": "detailed spectroscopic analysis"
    },
    {
      "id": "fibrotic processes"
    },
    {
      "id": "BMP-2 processing"
    },
    {
      "id": "endogenous FSAP"
    },
    {
      "id": "Factor VII-activating protease"
    },
    {
      "id": "local growth factors"
    },
    {
      "id": "truncated mature BMP-2 peptide"
    },
    {
      "id": "Arg(289)"
    },
    {
      "id": "pro-BMP-2"
    },
    {
      "id": "FSAP"
    },
    {
      "id": "N-terminal heparin binding region"
    },
    {
      "id": "mature BMP-2"
    },
    {
      "id": "Gln(283)"
    },
    {
      "id": "circulating protease"
    },
    {
      "id": "cell differentiation"
    },
    {
      "id": "truncated peptide"
    },
    {
      "id": "Lys(290)"
    },
    {
      "id": "BMPs"
    },
    {
      "id": "observation"
    },
    {
      "id": "BMP-2"
    },
    {
      "id": "mature heparin-binding growth factor"
    },
    {
      "id": "calcification"
    },
    {
      "id": "heparin binding region"
    },
    {
      "id": "pro-form"
    },
    {
      "id": "Factor VIIa"
    },
    {
      "id": "activated protein C"
    },
    {
      "id": "Factor Xa"
    },
    {
      "id": "bone morphogenetic proteins"
    },
    {
      "id": "Arg(282)"
    },
    {
      "id": "N-terminal sequencing"
    },
    {
      "id": "intracellular processing"
    },
    {
      "id": "osteogenic differentiation"
    },
    {
      "id": "canonical PC cleavage site"
    },
    {
      "id": "C2C12 myoblasts"
    },
    {
      "id": "pro-protein convertases"
    },
    {
      "id": "Plasmin"
    },
    {
      "id": "Thrombin"
    },
    {
      "id": "PCs"
    },
    {
      "id": "The factor VII-activating protease"
    },
    {
      "id": "bone morphogenetic protein-2"
    },
    {
      "id": "N-terminal region"
    },
    {
      "id": "R or S configuration"
    },
    {
      "id": "C-3"
    },
    {
      "id": "beta-hydroxy fatty acid subunit"
    },
    {
      "id": "cyclic scaffold of 1"
    },
    {
      "id": "multiple minimizations"
    },
    {
      "id": "generated conformers"
    },
    {
      "id": "lowest energy conformers"
    },
    {
      "id": "B3LYP geometry optimizations"
    },
    {
      "id": "absolute configuration"
    },
    {
      "id": "challenges"
    },
    {
      "id": "structure of 1"
    },
    {
      "id": "Maestro"
    },
    {
      "id": "amino or hydroxy acids"
    },
    {
      "id": "excellent agreement"
    },
    {
      "id": "NOE-derived distance constraints"
    },
    {
      "id": "solvent effects"
    },
    {
      "id": "conformational search"
    },
    {
      "id": "S stereoisomer"
    },
    {
      "id": "hydrogen-bonding stability studies"
    },
    {
      "id": "stereogenic centers"
    },
    {
      "id": "Marfey's"
    },
    {
      "id": "combination of molecular modeling and NOE distance constraint calculations"
    },
    {
      "id": "absolute configuration of the final stereogenic center of 1"
    },
    {
      "id": "small quantities of sample"
    },
    {
      "id": "conformation of 1"
    },
    {
      "id": "Schr\u00f6dinger suite"
    },
    {
      "id": "OPLS2005 force field"
    },
    {
      "id": "Macromodel"
    },
    {
      "id": "R and S stereoisomers"
    },
    {
      "id": "Computationally assisted assignment"
    },
    {
      "id": "NMR-constrained conformational search"
    },
    {
      "id": "kahalalide Y configuration"
    },
    {
      "id": "cyclic peptides"
    },
    {
      "id": "kahalalide Y (1)"
    },
    {
      "id": "Bryopsis pennata"
    },
    {
      "id": "AUC(0-\u221e)"
    },
    {
      "id": "Time-separated administration"
    },
    {
      "id": "o-hydroxy atorvastatin"
    },
    {
      "id": "Almorexant"
    },
    {
      "id": "steady-state"
    },
    {
      "id": "atorvastatin exposure"
    },
    {
      "id": "almorexant dose"
    },
    {
      "id": "hydroxyacid simvastatin"
    },
    {
      "id": "relative time of administration"
    },
    {
      "id": "single doses"
    },
    {
      "id": "simvastatin exposure"
    },
    {
      "id": "intestinal CYP3A4 inhibition"
    },
    {
      "id": "hepatic CYP3A4 inhibition"
    },
    {
      "id": "Pharmacokinetic interactions"
    },
    {
      "id": "dual orexin receptor antagonist"
    },
    {
      "id": "healthy male subjects"
    },
    {
      "id": "CYP3A4 activity"
    },
    {
      "id": "Acsl4 promoter"
    },
    {
      "id": "putative binding sites"
    },
    {
      "id": "Sp1 binding site"
    },
    {
      "id": "specificity protein"
    },
    {
      "id": "Acsl4 mRNA"
    },
    {
      "id": "cAMP response element-binding site"
    },
    {
      "id": "cAMP stimulation"
    },
    {
      "id": "alternative splice variants"
    },
    {
      "id": "MA-10 cells"
    },
    {
      "id": "Kr\u00fcppel-like factor"
    },
    {
      "id": "mouse promoter region"
    },
    {
      "id": "Functional characterization"
    },
    {
      "id": "basal activity"
    },
    {
      "id": "mouse steroidogenic MA-10 Leydig cells"
    },
    {
      "id": "Sequence analysis"
    },
    {
      "id": "1.5-kb fragment"
    },
    {
      "id": "Acsl4"
    },
    {
      "id": "synaptic development"
    },
    {
      "id": "Acyl-CoA synthetase 4"
    },
    {
      "id": "expression of Acsl4"
    },
    {
      "id": "pituitary hormones"
    },
    {
      "id": "tissue- and cell-specific factors"
    },
    {
      "id": "Acsl4 transcription"
    },
    {
      "id": "proximal promoter"
    },
    {
      "id": "cellular functions"
    },
    {
      "id": "growth factors"
    },
    {
      "id": "cancer metastasis"
    },
    {
      "id": "promoter of the Acsl4 mouse gene"
    },
    {
      "id": "Acsl4 mouse gene"
    },
    {
      "id": "acyl-CoA synthetase 4 gene"
    },
    {
      "id": "KIEs"
    },
    {
      "id": "temperature dependence of kinetic isotope effects"
    },
    {
      "id": "direct link"
    },
    {
      "id": "promoting vibrations"
    },
    {
      "id": "Fast protein motions"
    },
    {
      "id": "enzyme H-transfer reactions"
    },
    {
      "id": "vibrational motions"
    },
    {
      "id": "isotopic substitution"
    },
    {
      "id": "gold standard descriptor"
    },
    {
      "id": "KIE temperature dependence"
    },
    {
      "id": "H-transfer"
    },
    {
      "id": "quantum tunneling"
    },
    {
      "id": "(15)N"
    },
    {
      "id": "heavy isotope"
    },
    {
      "id": "(13)C"
    },
    {
      "id": "heavy isotope labeling"
    },
    {
      "id": "fast motions"
    },
    {
      "id": "pentaerythritol tetranitrate reductase"
    },
    {
      "id": "PETNR"
    },
    {
      "id": "considerable debate"
    },
    {
      "id": "enzyme-catalyzed H-transfer"
    },
    {
      "id": "observed KIE"
    },
    {
      "id": "past 15 years"
    },
    {
      "id": "fast dynamics"
    },
    {
      "id": "reaction chemistry"
    },
    {
      "id": "(2)H"
    },
    {
      "id": "causality"
    },
    {
      "id": "experimental KIEs"
    },
    {
      "id": "enzyme reactions"
    },
    {
      "id": "anomalous temperature dependence of KIEs"
    },
    {
      "id": "Coupling of fast protein dynamics"
    },
    {
      "id": "fast motions hypothesis"
    },
    {
      "id": "inference"
    },
    {
      "id": "enzyme chemistry"
    },
    {
      "id": "temperature-independent KIEs"
    },
    {
      "id": "non-exchangeable atoms"
    },
    {
      "id": "3,4-dihydropyrimidinones"
    },
    {
      "id": "formylphenylboronic acids"
    },
    {
      "id": "common analytic procedures"
    },
    {
      "id": "1H NMR"
    },
    {
      "id": "modes of activation"
    },
    {
      "id": "microwave irradiation"
    },
    {
      "id": "convenient analysis"
    },
    {
      "id": "12 green chemistry principles"
    },
    {
      "id": "11 novel hybrid-boron-containing molecules"
    },
    {
      "id": "Green approach"
    },
    {
      "id": "1,4-dihydropyridines"
    },
    {
      "id": "characterizations"
    },
    {
      "id": "accurate mass data"
    },
    {
      "id": "target molecules"
    },
    {
      "id": "11B NMR"
    },
    {
      "id": "meta"
    },
    {
      "id": "multicomponent production"
    },
    {
      "id": "ortho"
    },
    {
      "id": "B-3CR practices"
    },
    {
      "id": "Multicomponent reactions"
    },
    {
      "id": "green chemistry"
    },
    {
      "id": "unexpected ions"
    },
    {
      "id": "thioglycerol"
    },
    {
      "id": "FAB+-mode"
    },
    {
      "id": "number of steps"
    },
    {
      "id": "purification requirements"
    },
    {
      "id": "mantle heating"
    },
    {
      "id": "H-4CR practices"
    },
    {
      "id": "biginelli esters"
    },
    {
      "id": "13C NMR"
    },
    {
      "id": "hantzsch esters"
    },
    {
      "id": "boron"
    },
    {
      "id": "products"
    },
    {
      "id": "expected products"
    },
    {
      "id": "para"
    },
    {
      "id": "green solvent"
    },
    {
      "id": "Infrared Radiation (IR) irradiation"
    },
    {
      "id": "HRMS"
    },
    {
      "id": "FAB+MS"
    },
    {
      "id": "IR"
    },
    {
      "id": "catalytic active site"
    },
    {
      "id": "1,3,4-thiadiazole analogues"
    },
    {
      "id": "oral admission"
    },
    {
      "id": "biological evaluation"
    },
    {
      "id": "analogues 8"
    },
    {
      "id": "non-competitive AChE inhibitor"
    },
    {
      "id": "\u03bcM"
    },
    {
      "id": "nM range"
    },
    {
      "id": "1,3,4-thiadiazole derivatives"
    },
    {
      "id": "acetyl- and butyrylcholinesterase inhibitors"
    },
    {
      "id": "Docking simulations"
    },
    {
      "id": "key binding interactions"
    },
    {
      "id": "drug-likeness"
    },
    {
      "id": "scoring function"
    },
    {
      "id": "reference inhibitor"
    },
    {
      "id": "selectivity index"
    },
    {
      "id": "kinetic studies"
    },
    {
      "id": "derivative (1)"
    },
    {
      "id": "mixed-type of AChE inhibition"
    },
    {
      "id": "analogues"
    },
    {
      "id": "Lipinski"
    },
    {
      "id": "Zif268"
    },
    {
      "id": "zinc-finger protein 268"
    },
    {
      "id": "Dopamine D2 receptor"
    },
    {
      "id": "D2R"
    },
    {
      "id": "DNA-binding transcription factor"
    },
    {
      "id": "raclopride"
    },
    {
      "id": "growth factor"
    },
    {
      "id": "Erk1/2"
    },
    {
      "id": "immediate-early gene"
    },
    {
      "id": "shRNA"
    },
    {
      "id": "D2R inhibitor"
    },
    {
      "id": "adenoviral delivery"
    },
    {
      "id": "small hairpin RNA"
    },
    {
      "id": "glial cell line-derived neurotrophic factor"
    },
    {
      "id": "GDNF promoter"
    },
    {
      "id": "potassium"
    },
    {
      "id": "Compounds 1-9"
    },
    {
      "id": "C31-C33 polyacetylenes (1-9)"
    },
    {
      "id": "known congeners"
    },
    {
      "id": "Petrosia sp. marine sponge"
    },
    {
      "id": "Structures"
    },
    {
      "id": "mass spectrometry"
    },
    {
      "id": "A2058 (melanoma)"
    },
    {
      "id": "pellynols C (6)"
    },
    {
      "id": "pellynols I (9)"
    },
    {
      "id": "human lung cancer cells (H460)"
    },
    {
      "id": "H460"
    },
    {
      "id": "cytotoxic evaluation"
    },
    {
      "id": "new and known acyclic Ene-Ynes"
    },
    {
      "id": "IMR-90 quiescent human fibroblast cells"
    },
    {
      "id": "pellynols F (8)"
    },
    {
      "id": "1D- and 2D-NMR analysis"
    },
    {
      "id": "H460 (lung)"
    },
    {
      "id": "H522-T1 (lung)"
    },
    {
      "id": "human cancer cell lines"
    },
    {
      "id": "pellynols A (5)"
    },
    {
      "id": "Isolation work"
    },
    {
      "id": "American Samoa"
    },
    {
      "id": "American Samoa Petrosia sp. Sponge"
    },
    {
      "id": "specific rotation values"
    },
    {
      "id": "(-)-petrosynoic acids A-D (1-4)"
    },
    {
      "id": "new compounds"
    },
    {
      "id": "pellynols D (7)"
    },
    {
      "id": "PAT-type 5-HT2C agonists"
    },
    {
      "id": "DOI-elicited-HTR"
    },
    {
      "id": "affinities"
    },
    {
      "id": "literature"
    },
    {
      "id": "PAT"
    },
    {
      "id": "SB-206553"
    },
    {
      "id": "5-HT2B/2C"
    },
    {
      "id": "PLC"
    },
    {
      "id": "M100907"
    },
    {
      "id": "differential effects"
    },
    {
      "id": "DOI"
    },
    {
      "id": "mouse head-twitch response"
    },
    {
      "id": "dose-dependent biphasic effects"
    },
    {
      "id": "hallucinogenic 5-HT2A/2B/2C receptor agonist"
    },
    {
      "id": "C57Bl/6J mice"
    },
    {
      "id": "C57Bl/6J"
    },
    {
      "id": "strain of mice"
    },
    {
      "id": "5-HT2C receptor-mediated Gq-phospholipase C (PLC) signaling"
    },
    {
      "id": "Gq-phospholipase C"
    },
    {
      "id": "WAY 161503"
    },
    {
      "id": "5-HT2C receptor agonists"
    },
    {
      "id": "human 5-HT2A"
    },
    {
      "id": "functional selectivity"
    },
    {
      "id": "5-HT2C receptor ligands"
    },
    {
      "id": "head-twitch response model"
    },
    {
      "id": "locomotion"
    },
    {
      "id": "mouse 5-HT2C receptor-mediated PLC signaling"
    },
    {
      "id": "HEK cells"
    },
    {
      "id": "Ro 60-0175"
    },
    {
      "id": "SB-242084"
    },
    {
      "id": "5-HT2C receptor"
    },
    {
      "id": "2,5-dimethoxy-4-iodoamphetamine"
    },
    {
      "id": "HTR response"
    },
    {
      "id": "HTR"
    },
    {
      "id": "CP 809101"
    },
    {
      "id": "PATs"
    },
    {
      "id": "structurally diverse 5-HT2C ligands"
    },
    {
      "id": "receptor species"
    },
    {
      "id": "mCPP"
    },
    {
      "id": "classes of 5-HT2C receptor compounds"
    },
    {
      "id": "1-methylpsilocin"
    },
    {
      "id": "in vitro molecular pharmacology studies"
    },
    {
      "id": "5-HT2C receptor signaling outcomes"
    },
    {
      "id": "5-HT2A/2B antagonist activity"
    },
    {
      "id": "4-phenyl-2-N,N-dimethyl-aminotetralin"
    },
    {
      "id": "ligand functional selectivity"
    },
    {
      "id": "causal genes"
    },
    {
      "id": "susceptibility loci"
    },
    {
      "id": "gain- and loss-of-function of \u03b1-synuclein"
    },
    {
      "id": "\u03b2-cells"
    },
    {
      "id": "Ide knock-out (KO) mice"
    },
    {
      "id": "\u03b1-synuclein levels"
    },
    {
      "id": "T2D patients"
    },
    {
      "id": "Ide gene"
    },
    {
      "id": "haploinsufficient"
    },
    {
      "id": "IDE levels"
    },
    {
      "id": "\u03b2-cell degeneration"
    },
    {
      "id": "Ide deficiency"
    },
    {
      "id": "\u03b2-cell function"
    },
    {
      "id": "oral glucose stimulation"
    },
    {
      "id": "IDE"
    },
    {
      "id": "neutralization of amyloidogenic proteins"
    },
    {
      "id": "Ide"
    },
    {
      "id": "suppression of \u03b1-synuclein levels"
    },
    {
      "id": "autophagic flux"
    },
    {
      "id": "type 2 diabetes (T2D) risk loci"
    },
    {
      "id": "impaired \u03b2-cell function"
    },
    {
      "id": "glucose stimulated insulin secretion (GSIS)"
    },
    {
      "id": "impaired replenishment of the releasable pool of granules"
    },
    {
      "id": "microtubule content"
    },
    {
      "id": "Genome wide association studies"
    },
    {
      "id": "HHEX/IDE T2D locus"
    },
    {
      "id": "amyloidogenic proteins"
    },
    {
      "id": "autophagic signaling"
    },
    {
      "id": "cobalt chloride"
    },
    {
      "id": "hypoxia mimetic CoCl(2)"
    },
    {
      "id": "Solid tumors"
    },
    {
      "id": "neuroblastoma"
    },
    {
      "id": "autophagic inhibitors"
    },
    {
      "id": "apoptotic signaling"
    },
    {
      "id": "Autophagy"
    },
    {
      "id": "mutated p53 neuroblastoma cells"
    },
    {
      "id": "LC3-II expression"
    },
    {
      "id": "p53 location"
    },
    {
      "id": "Hypoxia"
    },
    {
      "id": "p53 stabilization"
    },
    {
      "id": "CoCl2"
    },
    {
      "id": "hypoxic areas"
    },
    {
      "id": "autophagic process"
    },
    {
      "id": "transcriptional activity inhibition"
    },
    {
      "id": "p53(WT)SHSY5Y cells"
    },
    {
      "id": "aggressiveness increase"
    },
    {
      "id": "proteasomal HIF-1 degradation"
    },
    {
      "id": "p53(wt)"
    },
    {
      "id": "Beclin-1"
    },
    {
      "id": "pro-autophagic genes"
    },
    {
      "id": "p53(mut)"
    },
    {
      "id": "inactivated p53"
    },
    {
      "id": "ATG 5-12"
    },
    {
      "id": "shRNA-p53 down-regulation"
    },
    {
      "id": "SKNBE(2c)"
    },
    {
      "id": "DNA-binding mutated p53 neuroblastoma cell line"
    },
    {
      "id": "HIF-1"
    },
    {
      "id": "CoCl2 time exposure"
    },
    {
      "id": "cell fate regulation"
    },
    {
      "id": "pifithrin alpha"
    },
    {
      "id": "hypoxic mimetic stress"
    },
    {
      "id": "large range of concentrations"
    },
    {
      "id": "4 organic chemicals (NCM1)"
    },
    {
      "id": "Northerners' blood"
    },
    {
      "id": "human coronary artery endothelial cells"
    },
    {
      "id": "very-low-density lipoprotein"
    },
    {
      "id": "NCM2"
    },
    {
      "id": "dietary habits"
    },
    {
      "id": "culture conditions"
    },
    {
      "id": "ethanol exposure"
    },
    {
      "id": "endothelial nitric oxide synthase (eNOS) protein expression"
    },
    {
      "id": "LVG"
    },
    {
      "id": "endpoint"
    },
    {
      "id": "lifestyle"
    },
    {
      "id": "endothelial dysfunction"
    },
    {
      "id": "Northern contaminant mixtures"
    },
    {
      "id": "morphological and functional changes"
    },
    {
      "id": "Northern populations"
    },
    {
      "id": "mixtures of various environmental contaminants"
    },
    {
      "id": "22 organic and inorganic chemicals (NCM2)"
    },
    {
      "id": "mixture"
    },
    {
      "id": "uptake of small peptides"
    },
    {
      "id": "two mixtures"
    },
    {
      "id": "NCM1 treatment"
    },
    {
      "id": "nitric oxide (NO) release"
    },
    {
      "id": "total protein yield"
    },
    {
      "id": "one or one group of contaminants"
    },
    {
      "id": "contaminants"
    },
    {
      "id": "high fat/sugar diet"
    },
    {
      "id": "cell morphology"
    },
    {
      "id": "24h of exposure"
    },
    {
      "id": "effects of NCMs"
    },
    {
      "id": "PAI"
    },
    {
      "id": "membrane damage"
    },
    {
      "id": "prostacyclin"
    },
    {
      "id": "NCMs"
    },
    {
      "id": "markers of cytotoxicity"
    },
    {
      "id": "cardiovascular health risk"
    },
    {
      "id": "plasminogen activator inhibitor (PAI)"
    },
    {
      "id": "endothelial function"
    },
    {
      "id": "low-density lipoprotein"
    },
    {
      "id": "cell density"
    },
    {
      "id": "geological location"
    },
    {
      "id": "2004-2005"
    },
    {
      "id": "interaction of high fat and sugar diet"
    },
    {
      "id": "cell size"
    },
    {
      "id": "cell membrane integrity"
    },
    {
      "id": "release of endothelin-1 (ET-1)"
    },
    {
      "id": "secretion of ET-1"
    },
    {
      "id": "Arctic"
    },
    {
      "id": "0.1% ethanol"
    },
    {
      "id": "metabolic activities"
    },
    {
      "id": "cytochrome P450 (CYP) isozymes"
    },
    {
      "id": "influence of IR and IPC"
    },
    {
      "id": "activities of CYP1A2"
    },
    {
      "id": "K(10)"
    },
    {
      "id": "IPC group"
    },
    {
      "id": "MRT"
    },
    {
      "id": "IR group"
    },
    {
      "id": "pharmacokinetic parameters"
    },
    {
      "id": "IPC"
    },
    {
      "id": "five specific probe drugs"
    },
    {
      "id": "t(1/2\u03b2)"
    },
    {
      "id": "software of DAS 2.0"
    },
    {
      "id": "CLs"
    },
    {
      "id": "activities of cytochrome P450 isozymes"
    },
    {
      "id": "tolbutamide"
    },
    {
      "id": "cocktail approach"
    },
    {
      "id": "chlorzoxazone"
    },
    {
      "id": "five probe drugs"
    },
    {
      "id": "concentrations of probe drugs"
    },
    {
      "id": "CYP2E1"
    },
    {
      "id": "Blood samples"
    },
    {
      "id": "time-points"
    },
    {
      "id": "sham groups"
    },
    {
      "id": "mixture of five probe drugs"
    },
    {
      "id": "caffeine"
    },
    {
      "id": "five-drug cocktail approach"
    },
    {
      "id": "HPLC method"
    },
    {
      "id": "oleoyl-D-valinolamide"
    },
    {
      "id": "acylethanolamide derivatives"
    },
    {
      "id": "palmitoyl-L-valinolamide"
    },
    {
      "id": "1 mg/kg i.p."
    },
    {
      "id": "stearoyl-L-valinolamide"
    },
    {
      "id": "POMC"
    },
    {
      "id": "oleoyl-L-valinolamide"
    },
    {
      "id": "injections"
    },
    {
      "id": "Receptor binding"
    },
    {
      "id": "TRPV1 receptors"
    },
    {
      "id": "orally"
    },
    {
      "id": "orexigenic genes"
    },
    {
      "id": "elaidoyl-L-valinolamide"
    },
    {
      "id": "antiobesity compounds"
    },
    {
      "id": "39 days"
    },
    {
      "id": "CART"
    },
    {
      "id": "FAAH mRNA expression"
    },
    {
      "id": "elaidoyl-D-valinolamide"
    },
    {
      "id": "Hypothalamic RT-PCR"
    },
    {
      "id": "mRNA expression"
    },
    {
      "id": "glucose levels"
    },
    {
      "id": "anorexigenic genes"
    },
    {
      "id": "PPAR\u03b1 receptors"
    },
    {
      "id": "anorectic pathways"
    },
    {
      "id": "CaMKK2"
    },
    {
      "id": "hypothalamic pro-opiomelanocortin"
    },
    {
      "id": "CYP3A4/5 substrate probe"
    },
    {
      "id": "alfentanil"
    },
    {
      "id": "CYP2B6 inhibition"
    },
    {
      "id": "methadone concentrations"
    },
    {
      "id": "intestinal CYP3A4/5"
    },
    {
      "id": "dose-adjusted plasma area under the curve"
    },
    {
      "id": "R- and S-methadone"
    },
    {
      "id": "metabolite formation clearances"
    },
    {
      "id": "deuterium-labeled racemic methadone"
    },
    {
      "id": "CYP2B6"
    },
    {
      "id": "Methadone N-demethylation"
    },
    {
      "id": "clinical disposition"
    },
    {
      "id": "CYP isoform"
    },
    {
      "id": "deuterium"
    },
    {
      "id": "racemic methadone"
    },
    {
      "id": "preliminary clinical investigation"
    },
    {
      "id": "cytochrome P4502B6"
    },
    {
      "id": "methadone metabolism"
    },
    {
      "id": "hepatic cytochrome P4502B6"
    },
    {
      "id": "mechanism-based CYP2B6 inhibitor"
    },
    {
      "id": "plasma metabolite/methadone area under the curve ratios"
    },
    {
      "id": "hepatic CYP3A4/5"
    },
    {
      "id": "Integrin-based adhesions"
    },
    {
      "id": "cell motility"
    },
    {
      "id": "isoforms 1 and 4"
    },
    {
      "id": "RNAi"
    },
    {
      "id": "p53 knockdown"
    },
    {
      "id": "cell metabolic activity"
    },
    {
      "id": "interaction partners"
    },
    {
      "id": "cell-substrate adhesion"
    },
    {
      "id": "HAUSP"
    },
    {
      "id": "p53 deubiquitinating enzyme"
    },
    {
      "id": "etoposide"
    },
    {
      "id": "endogenous supervillin"
    },
    {
      "id": "supervillin overexpression"
    },
    {
      "id": "USP7-mediated p53 deubiquitination"
    },
    {
      "id": "Supervillin"
    },
    {
      "id": "USP7"
    },
    {
      "id": "supervillin phenotype"
    },
    {
      "id": "p53 protein"
    },
    {
      "id": "locus"
    },
    {
      "id": "cross-talk"
    },
    {
      "id": "splice form of supervillin (isoform 4)"
    },
    {
      "id": "downstream target genes"
    },
    {
      "id": "supervillin N terminus"
    },
    {
      "id": "adhesion regulatory protein"
    },
    {
      "id": "USP7 and p53 association"
    },
    {
      "id": "p53 inhibition"
    },
    {
      "id": "cell motility pathways"
    },
    {
      "id": "SUMO1"
    },
    {
      "id": "ubiquitin-like protein"
    },
    {
      "id": "survival signaling"
    },
    {
      "id": "tumor suppressor protein"
    },
    {
      "id": "supervillin knockdown cells"
    },
    {
      "id": "advanced colorectal cancer patients"
    },
    {
      "id": "camptosar"
    },
    {
      "id": "5-fluorouracil/irinotecan-based regimens"
    },
    {
      "id": "novel genetic markers"
    },
    {
      "id": "250 Italian FOLFIRI-treated patients"
    },
    {
      "id": "severe hematologic toxicity"
    },
    {
      "id": "5-marker risk haplotype"
    },
    {
      "id": "P value"
    },
    {
      "id": "HIa"
    },
    {
      "id": "Haplotype analyses"
    },
    {
      "id": "5-FU"
    },
    {
      "id": "HIII"
    },
    {
      "id": "unfavorable alleles"
    },
    {
      "id": "absence of severe neutropenia"
    },
    {
      "id": "3'UTR single-nucleotide polymorphism (SNP)"
    },
    {
      "id": "functional UGT1A variants"
    },
    {
      "id": "UDP-glucuronosyltransferase (UGT) 1A1*28"
    },
    {
      "id": "3'untranscribed region (3'UTR)"
    },
    {
      "id": "UGT1A locus"
    },
    {
      "id": "UGT1A variations"
    },
    {
      "id": "multivariate analyses"
    },
    {
      "id": "folic acid"
    },
    {
      "id": "specific SNPs"
    },
    {
      "id": "UGT1A"
    },
    {
      "id": "SNPs"
    },
    {
      "id": "neutropenia grade 3-4"
    },
    {
      "id": "dosage effect"
    },
    {
      "id": "irinotecan (camptosar)-based regimens"
    },
    {
      "id": "irinotecan toxicity"
    },
    {
      "id": "risk haplotypes"
    },
    {
      "id": "haplotype II (HII)"
    },
    {
      "id": "irinotecan pharmacogenetics"
    },
    {
      "id": "combined cohorts"
    },
    {
      "id": "UGT1A haplotype"
    },
    {
      "id": "irinotecan-induced hematological toxicity"
    },
    {
      "id": "drug-induced severe toxicity"
    },
    {
      "id": "pharmacogenetic testing"
    },
    {
      "id": "protective HI"
    },
    {
      "id": "severe neutropenia"
    },
    {
      "id": "FOLFIRI"
    },
    {
      "id": "Italian cohort"
    },
    {
      "id": "our cohort"
    },
    {
      "id": "HI"
    },
    {
      "id": "UGTs 1A9/1A7/1A1"
    },
    {
      "id": "UGT1A candidate markers"
    },
    {
      "id": "central region of UGT1A"
    },
    {
      "id": "167 patients"
    },
    {
      "id": "FTIR experiments"
    },
    {
      "id": "DC gate"
    },
    {
      "id": "D115"
    },
    {
      "id": "dark-adapted state"
    },
    {
      "id": "Vibrational spectroscopic experiments"
    },
    {
      "id": "structural changes"
    },
    {
      "id": "photocycle"
    },
    {
      "id": "interpretation"
    },
    {
      "id": "homology models"
    },
    {
      "id": "approximate DFT method"
    },
    {
      "id": "DFTB"
    },
    {
      "id": "K states"
    },
    {
      "id": "bacteriorhodopsin"
    },
    {
      "id": "protonated D156"
    },
    {
      "id": "water molecule"
    },
    {
      "id": "channelrhodopsin-2"
    },
    {
      "id": "light-gated ion channel"
    },
    {
      "id": "full DFT results"
    },
    {
      "id": "hydrogen-bonded network"
    },
    {
      "id": "C[double bond, length as m-dash]O stretch vibration"
    },
    {
      "id": "carboxylic acids"
    },
    {
      "id": "vibrational spectra"
    },
    {
      "id": "QM/MM framework"
    },
    {
      "id": "FTIR spectral difference"
    },
    {
      "id": "indirect model"
    },
    {
      "id": "C128"
    },
    {
      "id": "vibrational analysis"
    },
    {
      "id": "recent reparametrization"
    },
    {
      "id": "effects of hydrogen bonding"
    },
    {
      "id": "buried aspartic acids"
    },
    {
      "id": "QM/MM simulations"
    },
    {
      "id": "activated mRNA expression"
    },
    {
      "id": "NR4A3"
    },
    {
      "id": "NR4A2"
    },
    {
      "id": "hyaluronic acid (HA)"
    },
    {
      "id": "human cell lines"
    },
    {
      "id": "THP-1 monocytes"
    },
    {
      "id": "nanocomplexes (NPs)"
    },
    {
      "id": "chitosan"
    },
    {
      "id": "intra-articular (I.A.) route"
    },
    {
      "id": "mouse knee"
    },
    {
      "id": "matrix metalloproteinases (MMPs) 1, 3 and 13"
    },
    {
      "id": "NR4A1"
    },
    {
      "id": "SW1353 chondrocytes"
    },
    {
      "id": "specific concentrations"
    },
    {
      "id": "NR4A2 mRNA expression"
    },
    {
      "id": "U937"
    },
    {
      "id": "on-going inflammatory arthritis"
    },
    {
      "id": "key regulator"
    },
    {
      "id": "rheumatoid arthritis (RA)"
    },
    {
      "id": "salmon calcitonin (sCT)"
    },
    {
      "id": "rationale"
    },
    {
      "id": "intra-articular salmon calcitonin-based nanocomplex"
    },
    {
      "id": "experimental inflammatory arthritis"
    },
    {
      "id": "osteoarthritis (OA)"
    },
    {
      "id": "K/BxN serum transfer model"
    },
    {
      "id": "potential biomarker"
    },
    {
      "id": "anti-arthritic effects"
    },
    {
      "id": "I.A. delivery"
    },
    {
      "id": "Prolonged inappropriate inflammatory responses"
    },
    {
      "id": "human T47D breast cancer cells"
    },
    {
      "id": "remarkable anti-inflammatory effects"
    },
    {
      "id": "expression of NR4A2"
    },
    {
      "id": "joint inflammation"
    },
    {
      "id": "sCT receptors"
    },
    {
      "id": "Ad-mixtures of sCT and HA"
    },
    {
      "id": "potentially valuable therapeutic target"
    },
    {
      "id": "orphan nuclear receptor"
    },
    {
      "id": "local bone architecture"
    },
    {
      "id": "effector"
    },
    {
      "id": "Cl(-) uptake"
    },
    {
      "id": "PRL signaling"
    },
    {
      "id": "ionocytes"
    },
    {
      "id": "gill"
    },
    {
      "id": "pituitary hormone"
    },
    {
      "id": "oPRL"
    },
    {
      "id": "ncc transcripts"
    },
    {
      "id": "ovine PRL"
    },
    {
      "id": "\u03941-9-G129R-hPRL"
    },
    {
      "id": "Prolactin"
    },
    {
      "id": "ncc gene"
    },
    {
      "id": "trpv6"
    },
    {
      "id": "pure human PRL receptor antagonist"
    },
    {
      "id": "regulator"
    },
    {
      "id": "ion"
    },
    {
      "id": "PRL receptor"
    },
    {
      "id": "PRL receptors"
    },
    {
      "id": "cultured gill filaments"
    },
    {
      "id": "epithelial Ca(2+) channel"
    },
    {
      "id": "ecac"
    },
    {
      "id": "ion uptake"
    },
    {
      "id": "ncc"
    },
    {
      "id": "concentration-dependent manner"
    },
    {
      "id": "Na(+)/Cl(-) cotransporter"
    },
    {
      "id": "Cl(-)"
    },
    {
      "id": "Na(+)/H(+) exchanger"
    },
    {
      "id": "Na(+)"
    },
    {
      "id": "water transport"
    },
    {
      "id": "nhe3b"
    },
    {
      "id": "ion uptake Na+/Cl- cotransporter"
    },
    {
      "id": "zebrafish gill"
    },
    {
      "id": "osmoregulatory tissues"
    },
    {
      "id": "prlra"
    },
    {
      "id": "vertebrate species"
    },
    {
      "id": "Ion-poor conditions"
    },
    {
      "id": "slc12a10.2"
    },
    {
      "id": "Ca(2+)"
    },
    {
      "id": "slc9a3.2"
    },
    {
      "id": "PRL action"
    },
    {
      "id": "target tissues"
    },
    {
      "id": "prlra transcripts"
    },
    {
      "id": "systemic PRL"
    },
    {
      "id": "H(+)"
    },
    {
      "id": "Parathyroid hormone (1-34)"
    },
    {
      "id": "osteoblast differentiation"
    },
    {
      "id": "interleukin-11"
    },
    {
      "id": "IL-11 small interfering RNA"
    },
    {
      "id": "effect of dexamethasone on apoptosis of mPOBs"
    },
    {
      "id": "Glucocorticoid (GC) excess"
    },
    {
      "id": "PTH(1-34) and dexamethasone"
    },
    {
      "id": "osteoblast differentiation and apoptosis"
    },
    {
      "id": "PTH(1-34) and GCs"
    },
    {
      "id": "IL-11 expression"
    },
    {
      "id": "PTH(1-34) treatment"
    },
    {
      "id": "Dexamethasone"
    },
    {
      "id": "\u0394FosB expression"
    },
    {
      "id": "IL-11"
    },
    {
      "id": "JunD"
    },
    {
      "id": "heterodimers"
    },
    {
      "id": "Smad1 phosphorylation"
    },
    {
      "id": "dexamethasone-GC receptor complex"
    },
    {
      "id": "expression of dickkopf-1 and -2"
    },
    {
      "id": "High doses of PTH(1-34)"
    },
    {
      "id": "\u0394FosB"
    },
    {
      "id": "Intermittent PTH (1-34) administration"
    },
    {
      "id": "inhibition of bone formation"
    },
    {
      "id": "IL-11 gene transcription enhanced by PTH(1-34)"
    },
    {
      "id": "mechanical strain"
    },
    {
      "id": "PTH(1-34)"
    },
    {
      "id": "PTH(1-34)-induced Smad1 phosphorylation"
    },
    {
      "id": "PKC\u03b4"
    },
    {
      "id": "neutralizing anti-IL-11 antibody"
    },
    {
      "id": "interleukin (IL)-11 gene transcription"
    },
    {
      "id": "protein kinase C (PKC)-\u03b4-mediated phosphorylation"
    },
    {
      "id": "IL-11 gene transcription"
    },
    {
      "id": "effect of mechanical strain"
    },
    {
      "id": "glucocorticoid excess"
    },
    {
      "id": "mPOBs from PKC\u03b4 knockout mice"
    },
    {
      "id": "tumor specimens"
    },
    {
      "id": "DNA Damage"
    },
    {
      "id": "Human Gastric Carcinoma"
    },
    {
      "id": "oxidative stress (OS) status"
    },
    {
      "id": "8-Oxo-7'8-dihydro-2'-deoxyguanosine"
    },
    {
      "id": "peripheral mononuclear cells (PMNC)"
    },
    {
      "id": "healthy control subjects"
    },
    {
      "id": "8-oxo-dG"
    },
    {
      "id": "DNA repair enzyme mRNA expression"
    },
    {
      "id": "hOGG1"
    },
    {
      "id": "MTH1"
    },
    {
      "id": "PMNC"
    },
    {
      "id": "tumor tissues"
    },
    {
      "id": "tumor resection"
    },
    {
      "id": "damaged base"
    },
    {
      "id": "gastrectomy"
    },
    {
      "id": "reduced/oxidized glutathione"
    },
    {
      "id": "affected patients"
    },
    {
      "id": "healthy population"
    },
    {
      "id": "DNA repair activity"
    },
    {
      "id": "gastric cancer patients"
    },
    {
      "id": "human gastric carcinoma (HGC) samples"
    },
    {
      "id": "normal tissue"
    },
    {
      "id": "healthy controls"
    },
    {
      "id": "Tumor Marker"
    },
    {
      "id": "normal mucosa"
    },
    {
      "id": "mutagenic base"
    },
    {
      "id": "MUYTH"
    },
    {
      "id": "normal gastric tissue"
    },
    {
      "id": "RAD51"
    },
    {
      "id": "Oxidative Stress"
    },
    {
      "id": "N-terminal PDZ domain"
    },
    {
      "id": "PDZ domain"
    },
    {
      "id": "essential light chains"
    },
    {
      "id": "light chains"
    },
    {
      "id": "lever"
    },
    {
      "id": "long axis"
    },
    {
      "id": "Mus musculus myosin-18A gene"
    },
    {
      "id": "\u03b2"
    },
    {
      "id": "GOLPH3"
    },
    {
      "id": "ATP hydrolysis"
    },
    {
      "id": "Myosin-18A\u03b2-S1 molecules"
    },
    {
      "id": "motor domain"
    },
    {
      "id": "\u03b1"
    },
    {
      "id": "myosin-18A binding partner"
    },
    {
      "id": "myosin-18A"
    },
    {
      "id": "constructs"
    },
    {
      "id": "regulatory light chains"
    },
    {
      "id": "rate of ATP hydrolysis"
    },
    {
      "id": "Mammalian myosin-18A"
    },
    {
      "id": "myosin"
    },
    {
      "id": "subfragment-1 (S1)-like constructs"
    },
    {
      "id": "baculovirus/Sf9 cell expression system"
    },
    {
      "id": "Myosin-18A\u03b1-S1 molecules"
    },
    {
      "id": "Myosin-18A\u03b2-S1"
    },
    {
      "id": "pre-power stroke conformation"
    },
    {
      "id": "immunological surfactant proteins"
    },
    {
      "id": "myosin-18\u03b2 species"
    },
    {
      "id": "noncanonical light chain binding site"
    },
    {
      "id": "neck"
    },
    {
      "id": "myosin-18A isoforms"
    },
    {
      "id": "coiled-coil"
    },
    {
      "id": "myosin-18A\u03b1 isoform"
    },
    {
      "id": "Sf9 cell expression system"
    },
    {
      "id": "Sf9 cell"
    },
    {
      "id": "equilibrium"
    },
    {
      "id": "myosin conformations"
    },
    {
      "id": "incompetent form"
    },
    {
      "id": "Myosin-18A\u03b1-S1"
    },
    {
      "id": "myosin motor domain"
    },
    {
      "id": "Phosphorylation"
    },
    {
      "id": "competent form"
    },
    {
      "id": "Electron microscopy"
    },
    {
      "id": "myosin-18A-S1"
    },
    {
      "id": "Recombinant heavy meromyosin-like constructs"
    },
    {
      "id": "N-methylanthraniloyl-nucleotides"
    },
    {
      "id": "myosin-18A\u03b1"
    },
    {
      "id": "IQ motif"
    },
    {
      "id": "Actin binding"
    },
    {
      "id": "nucleotide"
    },
    {
      "id": "actin binding data"
    },
    {
      "id": "baculovirus"
    },
    {
      "id": "Golgi localization"
    },
    {
      "id": "traditional molecular motor"
    },
    {
      "id": "tropomyosin"
    },
    {
      "id": "myosin-2"
    },
    {
      "id": "AML"
    },
    {
      "id": "crossover design"
    },
    {
      "id": "14-day washout"
    },
    {
      "id": "Twenty-four healthy men"
    },
    {
      "id": "CXM 500 mg alone"
    },
    {
      "id": "participants"
    },
    {
      "id": "significant differences"
    },
    {
      "id": "enhancement effect"
    },
    {
      "id": "\u03b2-lactam antibiotic bioavailability"
    },
    {
      "id": "LEX"
    },
    {
      "id": "peptidomimetic \u03b2-lactam antibiotics"
    },
    {
      "id": "geometric mean ratios"
    },
    {
      "id": "90% confidence interval"
    },
    {
      "id": "CXM"
    },
    {
      "id": "CXM 500 mg 2 hours after oral administration of AML 5 mg"
    },
    {
      "id": "oral bioavailability"
    },
    {
      "id": "cephalexin"
    },
    {
      "id": "LEX 500 mg 2 hours after oral administration of AML 5 mg"
    },
    {
      "id": "Pharmacokinetic data"
    },
    {
      "id": "noncompartmental modeling"
    },
    {
      "id": "maximum concentration of drug in serum"
    },
    {
      "id": "WinNonlin software"
    },
    {
      "id": "cefuroxime axetil"
    },
    {
      "id": "LEX 500 mg alone"
    },
    {
      "id": "basis sets"
    },
    {
      "id": "insufficient basis set"
    },
    {
      "id": "MP2 data"
    },
    {
      "id": "High-level quantum chemical calculations"
    },
    {
      "id": "biologically-relevant conformers"
    },
    {
      "id": "tetrapeptides"
    },
    {
      "id": "Accurate quantum chemical energies"
    },
    {
      "id": "tetrapeptide conformations"
    },
    {
      "id": "MP2 approach"
    },
    {
      "id": "PI3K/AKT inhibition"
    },
    {
      "id": "pro-survival signalling system"
    },
    {
      "id": "LY294002-induced apoptosis"
    },
    {
      "id": "pharmacological inhibitors"
    },
    {
      "id": "primary cultures of rat CGCs"
    },
    {
      "id": "p38 MAPK kinase pathway"
    },
    {
      "id": "Parkinson's disease (PD)"
    },
    {
      "id": "neuronal apoptosis"
    },
    {
      "id": "pro-apoptotic gene dp5"
    },
    {
      "id": "c-Jun"
    },
    {
      "id": "participation"
    },
    {
      "id": "p38 MAPK/c-Jun/dp5"
    },
    {
      "id": "c-Jun phosphorylation"
    },
    {
      "id": "phosphorylation of c-Jun"
    },
    {
      "id": "target of c-Jun"
    },
    {
      "id": "PI3K/AKT inhibitor"
    },
    {
      "id": "mitogen-activated protein kinase (MAPK) pathway"
    },
    {
      "id": "cultured cerebellar granule cells (CGCs)"
    },
    {
      "id": "glutathione S-transferase placental form"
    },
    {
      "id": "GST-P"
    },
    {
      "id": "heptachlor"
    },
    {
      "id": "promotion stage"
    },
    {
      "id": "HCB"
    },
    {
      "id": "cytochrome P450 (CYP) 3A1"
    },
    {
      "id": "GST-P-positive foci"
    },
    {
      "id": "combination of residual organochlorine pesticides"
    },
    {
      "id": "foods"
    },
    {
      "id": "mixtures"
    },
    {
      "id": "medium-term rat liver bioassay"
    },
    {
      "id": "cytochrome P450 (CYP) 2B1"
    },
    {
      "id": "metabolic activation"
    },
    {
      "id": "preneoplastic foci"
    },
    {
      "id": "hepatocarcinogenesis"
    },
    {
      "id": "cell proliferation induction"
    },
    {
      "id": "HEP"
    },
    {
      "id": "hexachlorobenzene"
    },
    {
      "id": "organochlorine pesticides"
    },
    {
      "id": "Male F344 rats"
    },
    {
      "id": "diethylnitrosamine"
    },
    {
      "id": "partial hepatectomy"
    },
    {
      "id": "DEN"
    },
    {
      "id": "individual residual organochlorine pesticides"
    },
    {
      "id": "phytosteryl phenolates"
    },
    {
      "id": "three different in vitro model systems"
    },
    {
      "id": "bulk oil model system"
    },
    {
      "id": "lab"
    },
    {
      "id": "\u03b2-carotene-linoleate model system"
    },
    {
      "id": "\u03b2-carotene-linoleate assay"
    },
    {
      "id": "emulsion model system"
    },
    {
      "id": "phytosteryl ferulates"
    },
    {
      "id": "multidimensional antioxidant activity determinations"
    },
    {
      "id": "reaction mechanisms"
    },
    {
      "id": "overall understanding"
    },
    {
      "id": "LDL-C oxidation"
    },
    {
      "id": "mechanisms of antioxidant action"
    },
    {
      "id": "low-density lipoprotein cholesterol (LDL-C) oxidation assay"
    },
    {
      "id": "bulk oil system"
    },
    {
      "id": "physiochemical and biological properties"
    },
    {
      "id": "model systems"
    },
    {
      "id": "ionic strength"
    },
    {
      "id": "selective immobilization"
    },
    {
      "id": "BLG"
    },
    {
      "id": "SPBs"
    },
    {
      "id": "isothermal titration calorimetry"
    },
    {
      "id": "ITC"
    },
    {
      "id": "BSA"
    },
    {
      "id": "photoemulsion polymerization"
    },
    {
      "id": "stoichiometry"
    },
    {
      "id": "cationic spherical polyelectrolyte brushes"
    },
    {
      "id": "poly(2-aminoethylmethacrylate hydrochloride)"
    },
    {
      "id": "Binding energetics"
    },
    {
      "id": "pH regions"
    },
    {
      "id": "papain"
    },
    {
      "id": "aggregation"
    },
    {
      "id": "polystyrene core"
    },
    {
      "id": "\u03b2-lactoglobulin"
    },
    {
      "id": "amount"
    },
    {
      "id": "releasing"
    },
    {
      "id": "zeta potential"
    },
    {
      "id": "PAEMH shell"
    },
    {
      "id": "core surface"
    },
    {
      "id": "SPB applications"
    },
    {
      "id": "antibodies"
    },
    {
      "id": "protein purification"
    },
    {
      "id": "turbidimetric titration"
    },
    {
      "id": "Jaffe, E."
    },
    {
      "id": "Arch. Bioch. Biophys"
    },
    {
      "id": "case study"
    },
    {
      "id": "disease mechanisms"
    },
    {
      "id": "multimer"
    },
    {
      "id": "dynamic equilibrium"
    },
    {
      "id": "quaternary structure dynamics"
    },
    {
      "id": "porphobilinogen synthase"
    },
    {
      "id": "multimer-specific ligand binding site"
    },
    {
      "id": "morpheein model"
    },
    {
      "id": "allostery"
    },
    {
      "id": "Selwood, T."
    },
    {
      "id": "HIV integrase"
    },
    {
      "id": "PBGS"
    },
    {
      "id": "allosteric regulation"
    },
    {
      "id": "successful drug discovery efforts"
    },
    {
      "id": "disease-associated proteins"
    },
    {
      "id": "tumor necrosis factor \u03b1"
    },
    {
      "id": "functionally distinct assemblies"
    },
    {
      "id": "drug side effects"
    },
    {
      "id": "subunit conformation"
    },
    {
      "id": "quaternary structure equilibrium"
    },
    {
      "id": "transthyretin"
    },
    {
      "id": "allosteric drug discovery"
    },
    {
      "id": "drug discovery efforts"
    },
    {
      "id": "phenylalanine hydroxylase"
    },
    {
      "id": "Four highly accepted assays"
    },
    {
      "id": "ORAC"
    },
    {
      "id": "\u03b2-CLAMS"
    },
    {
      "id": "RAA 129%"
    },
    {
      "id": "Further studies"
    },
    {
      "id": "health beneficial effects"
    },
    {
      "id": "staghorn sumac fruit"
    },
    {
      "id": "PCL"
    },
    {
      "id": "anthocyanidins"
    },
    {
      "id": "419 Da"
    },
    {
      "id": "ethanolic extract"
    },
    {
      "id": "81.6 mg GAE/ g DW"
    },
    {
      "id": "79.95 \u03bcmol AAE/g DW"
    },
    {
      "id": "total polyphenols content"
    },
    {
      "id": "fruit"
    },
    {
      "id": "aboriginal peoples"
    },
    {
      "id": "various illnesses"
    },
    {
      "id": "water extract"
    },
    {
      "id": "46.3mg GAE/g DW"
    },
    {
      "id": "449 Da"
    },
    {
      "id": "Rhus hirta L."
    },
    {
      "id": "Staghorn sumac"
    },
    {
      "id": "native tree"
    },
    {
      "id": "chemical characterisation"
    },
    {
      "id": "aglycones"
    },
    {
      "id": "433 Da"
    },
    {
      "id": "phytochemical composition"
    },
    {
      "id": "anthocyanins"
    },
    {
      "id": "Eastern Canada"
    },
    {
      "id": "1544 \u03bcmol TE/g DW"
    },
    {
      "id": "qualitative studies"
    },
    {
      "id": "HPLC-DAD-MS"
    },
    {
      "id": "novel group of unique anthocyanins"
    },
    {
      "id": "polyphenols"
    },
    {
      "id": "4513 \u03bcmol TE/g DW"
    },
    {
      "id": "Quantitative data"
    },
    {
      "id": "UHPLC"
    },
    {
      "id": "Paeoniflorin"
    },
    {
      "id": "radiation-induced oxidative injury"
    },
    {
      "id": "radiation-induced endothelial cellular damage"
    },
    {
      "id": "radiation-induced injury"
    },
    {
      "id": "ZNPP"
    },
    {
      "id": "oxidative injury"
    },
    {
      "id": "zinc protoporphyrin IX"
    },
    {
      "id": "heme oxygenase-1 pathway"
    },
    {
      "id": "NF-E2-related factor 2"
    },
    {
      "id": "EA.hy926 cells"
    },
    {
      "id": "human EA.hy926 endothelial cells"
    },
    {
      "id": "Nrf2 siRNA"
    },
    {
      "id": "nuclear translocation"
    },
    {
      "id": "radiation-induced damage"
    },
    {
      "id": "LDH leakage"
    },
    {
      "id": "Nrf2/HO-1 pathway"
    },
    {
      "id": "nuclear factor erythroid 2 related factor-2"
    },
    {
      "id": "Pulmonary endothelial cells"
    },
    {
      "id": "radiation-induced lung injury"
    },
    {
      "id": "Nrf-2"
    },
    {
      "id": "Vicia faba L."
    },
    {
      "id": "subspecies minor"
    },
    {
      "id": "whole seeds"
    },
    {
      "id": "aqueous (70%) acetone"
    },
    {
      "id": "subspecies major"
    },
    {
      "id": "faba bean"
    },
    {
      "id": "cotyledons"
    },
    {
      "id": "hulls"
    },
    {
      "id": "(80%) ethanol"
    },
    {
      "id": "antiradical activity (DPPH)"
    },
    {
      "id": "15-LOX"
    },
    {
      "id": "tannins"
    },
    {
      "id": "Aqueous ethanol (80%) extract"
    },
    {
      "id": "lentil seeds"
    },
    {
      "id": "legume fractions"
    },
    {
      "id": "Acetone"
    },
    {
      "id": "reducing power (RP)"
    },
    {
      "id": "phenolic contents"
    },
    {
      "id": "lentil hulls"
    },
    {
      "id": "oxygen radical absorbance capacity (ORAC)"
    },
    {
      "id": "COX pathway"
    },
    {
      "id": "faba bean hull extracts"
    },
    {
      "id": "LOX inhibitory activity"
    },
    {
      "id": "Algeria"
    },
    {
      "id": "Phenolics content"
    },
    {
      "id": "deoxynivalenol"
    },
    {
      "id": "mitogen activated protein kinases"
    },
    {
      "id": "ex vivo models"
    },
    {
      "id": "in vivo experiments"
    },
    {
      "id": "DON-contaminated diet"
    },
    {
      "id": "2.3 mg DON/kg feed"
    },
    {
      "id": "Trichothecenes"
    },
    {
      "id": "cell junction proteins"
    },
    {
      "id": "Twelve weaning piglets"
    },
    {
      "id": "Explants"
    },
    {
      "id": "10 \u03bcM DON"
    },
    {
      "id": "in vivo exposure"
    },
    {
      "id": "intestinal tissue"
    },
    {
      "id": "DON"
    },
    {
      "id": "intestinal lesions"
    },
    {
      "id": "similarity"
    },
    {
      "id": "low doses of DON"
    },
    {
      "id": "ERK 1/2"
    },
    {
      "id": "The food contaminant"
    },
    {
      "id": "homeostasis"
    },
    {
      "id": "models"
    },
    {
      "id": "in vivo results"
    },
    {
      "id": "toxin"
    },
    {
      "id": "ex vivo results"
    },
    {
      "id": "control diet"
    },
    {
      "id": "jejunal explants"
    },
    {
      "id": "Pigs"
    },
    {
      "id": "DON-diet"
    },
    {
      "id": "jejunal score"
    },
    {
      "id": "cell turnover"
    },
    {
      "id": "intestinal barrier function"
    },
    {
      "id": "5 \u03bcM DON"
    },
    {
      "id": "enterocytes"
    },
    {
      "id": "ex vivo model"
    },
    {
      "id": "barrier function"
    },
    {
      "id": "immune protection"
    },
    {
      "id": "jejunal explant model"
    },
    {
      "id": "toxicological studies"
    },
    {
      "id": "Intestinal changes"
    },
    {
      "id": "histological score"
    },
    {
      "id": "Six weaning piglets"
    },
    {
      "id": "normal 46,XY genital virilization"
    },
    {
      "id": "androgen receptor gene expression"
    },
    {
      "id": "androgen receptor gene"
    },
    {
      "id": "urethral mucosa"
    },
    {
      "id": "amount of androgen receptor mRNA"
    },
    {
      "id": "quantitative real time PCR"
    },
    {
      "id": "negative correlation"
    },
    {
      "id": "penile size"
    },
    {
      "id": "control phimosis subjects"
    },
    {
      "id": "eutopic urethral opening"
    },
    {
      "id": "Androgen Receptor mRNA"
    },
    {
      "id": "Quantitative Real Time PCR"
    },
    {
      "id": "patients with hypospadias"
    },
    {
      "id": "aim of this study"
    },
    {
      "id": "Urethral Mucosa"
    },
    {
      "id": "patients with middle idiopathic hypospadias"
    },
    {
      "id": "urethral mucosa of patients with hypospadias"
    },
    {
      "id": "Prepubertal individuals"
    },
    {
      "id": "hypospadias patients"
    },
    {
      "id": "correlation"
    },
    {
      "id": "reduced androgen sensitivity"
    },
    {
      "id": "genital tissues"
    },
    {
      "id": "number of CAG repeats"
    },
    {
      "id": "critical lower level of androgen receptor mRNA expression"
    },
    {
      "id": "determining factor"
    },
    {
      "id": "Hypospadias"
    },
    {
      "id": "Middle Idiopathic Hypospadias"
    },
    {
      "id": "mean (SD) ages"
    },
    {
      "id": "androgen receptor mRNA levels"
    },
    {
      "id": "GeneScan analysis"
    },
    {
      "id": "normal androgen receptor mRNA levels"
    },
    {
      "id": "frequent male genital abnormality"
    },
    {
      "id": "androgen sensitive tissues"
    },
    {
      "id": "Androgen action"
    },
    {
      "id": "level of androgen receptor mRNA expression"
    },
    {
      "id": "4-fluoroquinuclidine"
    },
    {
      "id": "pKa"
    },
    {
      "id": "HTS hit (1)"
    },
    {
      "id": "4-phenyl-1-(quinuclidin-3-ylmethyl)quinolin-2(1H)-one"
    },
    {
      "id": "quinolone"
    },
    {
      "id": "High throughput screening"
    },
    {
      "id": "brain penetrance"
    },
    {
      "id": "transporter-mediated efflux"
    },
    {
      "id": "quinuclidine moiety"
    },
    {
      "id": "efflux"
    },
    {
      "id": "Caco-2 assay"
    },
    {
      "id": "recombinant human histidine decarboxylase"
    },
    {
      "id": "histidine methyl ester"
    },
    {
      "id": "rugosin A"
    },
    {
      "id": "main components"
    },
    {
      "id": "Agents"
    },
    {
      "id": "HDC activity"
    },
    {
      "id": "Rugosin D"
    },
    {
      "id": "non-competitive type of inhibition"
    },
    {
      "id": "tellimagrandin II"
    },
    {
      "id": "rugosin A methyl ester"
    },
    {
      "id": "HDC"
    },
    {
      "id": "histamine-mediated symptoms"
    },
    {
      "id": "stomach ulceration"
    },
    {
      "id": "active food constituents"
    },
    {
      "id": "clinically available HDC inhibitors"
    },
    {
      "id": "Filipendula ulmaria"
    },
    {
      "id": "ellagitannins"
    },
    {
      "id": "meadowsweet"
    },
    {
      "id": "allergies"
    },
    {
      "id": "Histidine decarboxylase"
    },
    {
      "id": "histamine"
    },
    {
      "id": "novel compound"
    },
    {
      "id": "food products"
    },
    {
      "id": "potent HDC inhibitors"
    },
    {
      "id": "bioactive amine"
    },
    {
      "id": "ethyl acetate extract"
    },
    {
      "id": "substrate analogue inhibitor"
    },
    {
      "id": "petal"
    },
    {
      "id": "Breakthrough emesis"
    },
    {
      "id": "Chemotherapy cycles"
    },
    {
      "id": "Management"
    },
    {
      "id": "Newer agents"
    },
    {
      "id": "Rolapitant"
    },
    {
      "id": "NK1 receptor"
    },
    {
      "id": "Older agents"
    },
    {
      "id": "Second-generation 5-HT3 receptor antagonist"
    },
    {
      "id": "Combination"
    },
    {
      "id": "Current agents"
    },
    {
      "id": "Control"
    },
    {
      "id": "Emesis"
    },
    {
      "id": "Binding capacity"
    },
    {
      "id": "Aprepitant"
    },
    {
      "id": "NK1 receptor antagonist drug class"
    },
    {
      "id": "Ginger"
    },
    {
      "id": "Efficacy"
    },
    {
      "id": "Acute emesis"
    },
    {
      "id": "Single-day chemotherapy"
    },
    {
      "id": "Mechanism of action"
    },
    {
      "id": "Emetogenicity"
    },
    {
      "id": "Chemotherapeutic agents"
    },
    {
      "id": "Delayed emesis"
    },
    {
      "id": "Netupitant"
    },
    {
      "id": "Gabapentin"
    },
    {
      "id": "First-generation 5-HT3 receptor antagonists"
    },
    {
      "id": "Serotonin 5-HT3 receptor antagonist"
    },
    {
      "id": "Phase III clinical trials"
    },
    {
      "id": "Clinical settings"
    },
    {
      "id": "Bone marrow transplantation"
    },
    {
      "id": "Multiple-day chemotherapy"
    },
    {
      "id": "US-FDA approved antipsychotic"
    },
    {
      "id": "Patient risk factors"
    },
    {
      "id": "Prevention"
    },
    {
      "id": "Antipsychotic"
    },
    {
      "id": "Cannabinoids"
    },
    {
      "id": "Neurokinin 1 (NK1) receptor antagonist"
    },
    {
      "id": "Chemotherapy-induced nausea and vomiting"
    },
    {
      "id": "Quality of life"
    },
    {
      "id": "Half-life"
    },
    {
      "id": "Preventative agent"
    },
    {
      "id": "dissolved oxygen"
    },
    {
      "id": "DO"
    },
    {
      "id": "in vivo chicken embryo model"
    },
    {
      "id": "CEM"
    },
    {
      "id": "in vitro polyphenolics erythrocyte model"
    },
    {
      "id": "prooxidant activity"
    },
    {
      "id": "hypoxia-related inflammation"
    },
    {
      "id": "HPO"
    },
    {
      "id": "two-phase kinetic pattern"
    },
    {
      "id": "GA"
    },
    {
      "id": "phase II HPO production"
    },
    {
      "id": "cervical muscles"
    },
    {
      "id": "liposis"
    },
    {
      "id": "Fe (II) ions"
    },
    {
      "id": "semiquinone"
    },
    {
      "id": "hydrogen peroxide"
    },
    {
      "id": "chicken cervical muscles"
    },
    {
      "id": "kinetic coefficients"
    },
    {
      "id": "Zenker's necrosis"
    },
    {
      "id": "PEM"
    },
    {
      "id": "gene hif-1\u03b1"
    },
    {
      "id": "phase I HPO production"
    },
    {
      "id": "physicochemical action mechanisms"
    },
    {
      "id": "Fe (III) ion"
    },
    {
      "id": "hemolysis"
    },
    {
      "id": "hemorrhage inducer"
    },
    {
      "id": "atypical pathways"
    },
    {
      "id": "dose-responsive manner"
    },
    {
      "id": "quinone"
    },
    {
      "id": "cervical muscle inflammation"
    },
    {
      "id": "TNF-\u03b1-canonical pathway"
    },
    {
      "id": "dysvascularization"
    },
    {
      "id": "in vitro polyphenolics-erythrocyte model"
    },
    {
      "id": "Inflammatory edema"
    },
    {
      "id": "RBC disruption"
    },
    {
      "id": "Fe(2+) ion"
    },
    {
      "id": "NF\u03baB"
    },
    {
      "id": "SAR"
    },
    {
      "id": "Rock inhibitors"
    },
    {
      "id": "amino acid derived quinazolinones"
    },
    {
      "id": "Rock"
    },
    {
      "id": "Amino acid derived quinazolines"
    },
    {
      "id": "pan-Rock (I & II) inhibitors"
    },
    {
      "id": "sub-nanomolar inhibition"
    },
    {
      "id": "non-amino acid derived quinazolinones"
    },
    {
      "id": "amino acid-derived quinazolines"
    },
    {
      "id": "nanomolar potency"
    },
    {
      "id": "ppMLC cell based assays"
    },
    {
      "id": "cytochrome P-450 inhibition"
    },
    {
      "id": "human microsomal stability"
    },
    {
      "id": "lead optimization studies"
    },
    {
      "id": "ED50"
    },
    {
      "id": "prodrugs"
    },
    {
      "id": "antibacterial activity"
    },
    {
      "id": "linezolid-resistant strains"
    },
    {
      "id": "Solubility"
    },
    {
      "id": "structural modification"
    },
    {
      "id": "compound 85"
    },
    {
      "id": "Oxazolidinone ring substitution"
    },
    {
      "id": "polar groups"
    },
    {
      "id": "(pyridin-3-yl) benzoxazinyl-oxazolidinones"
    },
    {
      "id": "Gram-positive pathogens"
    },
    {
      "id": "various substituents"
    },
    {
      "id": "pyridyl ring"
    },
    {
      "id": "new series of benzoxazinyl-oxazolidinone analogues"
    },
    {
      "id": "small and nonbasic substituents"
    },
    {
      "id": "sterically demanding or basic substituents"
    },
    {
      "id": "MRSA systemic infection model"
    },
    {
      "id": "hERG inhibition"
    },
    {
      "id": "imidazolidinone ring"
    },
    {
      "id": "structure-activity relationship (SAR) trends"
    },
    {
      "id": "antibacterial agent"
    },
    {
      "id": "linezolid"
    },
    {
      "id": "Plasma NBUP concentrations"
    },
    {
      "id": "Genders"
    },
    {
      "id": "NBUP"
    },
    {
      "id": "Expiratory time"
    },
    {
      "id": "Asphyxia"
    },
    {
      "id": "BUP"
    },
    {
      "id": "Deaths"
    },
    {
      "id": "P-gp expression"
    },
    {
      "id": "Swiss mice"
    },
    {
      "id": "Female Fvb mice"
    },
    {
      "id": "BUP-related respiratory toxicity"
    },
    {
      "id": "Mice"
    },
    {
      "id": "NBUP transport"
    },
    {
      "id": "Gender"
    },
    {
      "id": "Variability"
    },
    {
      "id": "NBUP-related reduction"
    },
    {
      "id": "Fvb mice"
    },
    {
      "id": "Inspiratory time"
    },
    {
      "id": "Male Fvb mice"
    },
    {
      "id": "Blood-brain barrier"
    },
    {
      "id": "P-gp-mediated transport"
    },
    {
      "id": "Females"
    },
    {
      "id": "Ventilation"
    },
    {
      "id": "Plethysmography"
    },
    {
      "id": "Transport"
    },
    {
      "id": "In situ cerebral perfusion"
    },
    {
      "id": "Plasma BUP concentrations"
    },
    {
      "id": "Norbuprenorphine"
    },
    {
      "id": "Toxic metabolite"
    },
    {
      "id": "Ceiling respiratory effects"
    },
    {
      "id": "Strains"
    },
    {
      "id": "Respiratory effects"
    },
    {
      "id": "Metabolite"
    },
    {
      "id": "NBUP administration"
    },
    {
      "id": "Strain-related differences"
    },
    {
      "id": "Males"
    },
    {
      "id": "Strain-related variability"
    },
    {
      "id": "Minute volume"
    },
    {
      "id": "BUP administration"
    },
    {
      "id": "Gender-related differences"
    },
    {
      "id": "Strain"
    },
    {
      "id": "diflunisal"
    },
    {
      "id": "acetyldiflunisal"
    },
    {
      "id": "target enzyme"
    },
    {
      "id": "Human serum albumin"
    },
    {
      "id": "lysine 199"
    },
    {
      "id": "circulation"
    },
    {
      "id": "acetylated albumin"
    },
    {
      "id": "IIA subdomain"
    },
    {
      "id": "Lys199"
    },
    {
      "id": "fluorescence quenching"
    },
    {
      "id": "Mass spectrometry"
    },
    {
      "id": "preliminary structure-activity relationship"
    },
    {
      "id": "3-aryl acrylic amide derivatives"
    },
    {
      "id": "l-dopa"
    },
    {
      "id": "eight human tumor cell lines"
    },
    {
      "id": "MCF-7"
    },
    {
      "id": "simplified saframycin-ecteinascidin skeleton"
    },
    {
      "id": "Compound 28"
    },
    {
      "id": "3-thiophenyl acrylic amide side chain"
    },
    {
      "id": "BGC-803"
    },
    {
      "id": "A2780"
    },
    {
      "id": "Twenty four compounds"
    },
    {
      "id": "3-aryl acrylic amide side chains"
    },
    {
      "id": "selective cytotoxicity"
    },
    {
      "id": "MDA-MB-231"
    },
    {
      "id": "HCT-8"
    },
    {
      "id": "simplified saframycin-ecteinascidin pentacyclic skeleton"
    },
    {
      "id": "BEL-7402"
    },
    {
      "id": "14-step stereospecific route"
    },
    {
      "id": "A549"
    },
    {
      "id": "MX-1"
    },
    {
      "id": "potent antitumor activity"
    },
    {
      "id": "\u03b1-methyltyrosine"
    },
    {
      "id": "tyrosine hydroxylase inhibitor"
    },
    {
      "id": "DA release"
    },
    {
      "id": "de novo catecholamine synthesis"
    },
    {
      "id": "vesicular dopamine release"
    },
    {
      "id": "MeHg"
    },
    {
      "id": "intracellular DA"
    },
    {
      "id": "undifferentiated pheochromocytoma (PC12) cells"
    },
    {
      "id": "vesicular content depleting drug reserpine"
    },
    {
      "id": "rat pheochromocytoma (PC12) cells"
    },
    {
      "id": "methylmercury"
    },
    {
      "id": "vesicular exocytosis"
    },
    {
      "id": "tyrosine hydroxylase activity"
    },
    {
      "id": "DA synthesis"
    },
    {
      "id": "DA storage utilization"
    },
    {
      "id": "DA precursor accumulation"
    },
    {
      "id": "gonad phenotype"
    },
    {
      "id": "EDCs"
    },
    {
      "id": "phenotypic status of the gonad"
    },
    {
      "id": "Sox9b"
    },
    {
      "id": "gonad development"
    },
    {
      "id": "key endpoint"
    },
    {
      "id": "hazard assessment"
    },
    {
      "id": "aquatic bioassays"
    },
    {
      "id": "US Environmental Protection Agency"
    },
    {
      "id": "relative expression levels"
    },
    {
      "id": "17\u03b2-estradiol"
    },
    {
      "id": "Environ Toxicol Chem"
    },
    {
      "id": "SETAC"
    },
    {
      "id": "permutational multivariate analysis of variance"
    },
    {
      "id": "protamine"
    },
    {
      "id": "gonad maintenance"
    },
    {
      "id": "sexual genotype"
    },
    {
      "id": "reverse-transcription quantitative polymerase chain reaction"
    },
    {
      "id": "japanese medaka"
    },
    {
      "id": "Oryzias latipes"
    },
    {
      "id": "fish species"
    },
    {
      "id": "Fig1\u03b1"
    },
    {
      "id": "ZPC1"
    },
    {
      "id": "Office of Economic Cooperation and Development"
    },
    {
      "id": "endocrine-disrupting chemicals"
    },
    {
      "id": "trenbolone"
    },
    {
      "id": "gene expression data"
    },
    {
      "id": "histological techniques"
    },
    {
      "id": "17\u03b2-trenbolone"
    },
    {
      "id": "risk assessment"
    },
    {
      "id": "BPA"
    },
    {
      "id": "pancreatic insulin content"
    },
    {
      "id": "systemic glucose metabolism"
    },
    {
      "id": "(14)C-glucose oxidation"
    },
    {
      "id": "IR protein levels"
    },
    {
      "id": "gastrocnemius muscle"
    },
    {
      "id": "GLUT4 protein levels"
    },
    {
      "id": "Adult male Wistar albino rats"
    },
    {
      "id": "three groups"
    },
    {
      "id": "GLUT4 translocation"
    },
    {
      "id": "mice endocrine pancreas"
    },
    {
      "id": "serum insulin"
    },
    {
      "id": "cytosolic fraction"
    },
    {
      "id": "male rat"
    },
    {
      "id": "plastic food and beverage containers"
    },
    {
      "id": "human exposure"
    },
    {
      "id": "Akt protein levels"
    },
    {
      "id": "epoxy resins"
    },
    {
      "id": "serum testosterone levels"
    },
    {
      "id": "bisphenol-A"
    },
    {
      "id": "estrogenic monomer"
    },
    {
      "id": "groups II and III"
    },
    {
      "id": "endocrine-disrupting chemical"
    },
    {
      "id": "200 mg/kg bw/day"
    },
    {
      "id": "insulin signal transduction"
    },
    {
      "id": "Group I"
    },
    {
      "id": "postprandial hyperinsulinemia"
    },
    {
      "id": "insulin-signaling molecules"
    },
    {
      "id": "fasting blood glucose level"
    },
    {
      "id": "glucose oxidation"
    },
    {
      "id": "20 mg/kg bw/day"
    },
    {
      "id": "adult male albino rat"
    },
    {
      "id": "one-pot domino reactions"
    },
    {
      "id": "Tautomerization"
    },
    {
      "id": "Elimination sequence of reactions"
    },
    {
      "id": "one-pot domino synthesis"
    },
    {
      "id": "highly functionalized dihydrobenzo[b]thiophenes"
    },
    {
      "id": "5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile"
    },
    {
      "id": "5-amino-2,7-diaryl-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitriles"
    },
    {
      "id": "intramolecular Thorpe-Ziegler cyclization"
    },
    {
      "id": "AChE inhibitory activity"
    },
    {
      "id": "Michael addition"
    },
    {
      "id": "5-aryldihydro-3(2H)-thiophenones"
    },
    {
      "id": "malononitrile"
    },
    {
      "id": "AChE inhibitors"
    },
    {
      "id": "aromatic aldehydes"
    },
    {
      "id": "Knoevenagel condensation"
    },
    {
      "id": "morpholine"
    },
    {
      "id": "TKI-resistant FLT3-ITD+ AML patients"
    },
    {
      "id": "Secondary point mutations"
    },
    {
      "id": "Fms-like tyrosine kinase 3"
    },
    {
      "id": "substitutions"
    },
    {
      "id": "high degree of resistance"
    },
    {
      "id": "Saturation mutagenesis"
    },
    {
      "id": "FLT3 AL mutations"
    },
    {
      "id": "ponatinib"
    },
    {
      "id": "early clinical efficacy"
    },
    {
      "id": "ITD mutations"
    },
    {
      "id": "FLT3"
    },
    {
      "id": "Substitution"
    },
    {
      "id": "FLT3 \"gatekeeper\" phenylalanine"
    },
    {
      "id": "KD"
    },
    {
      "id": "in vitro activity"
    },
    {
      "id": "AP24534"
    },
    {
      "id": "TKI-naive patients"
    },
    {
      "id": "leucine"
    },
    {
      "id": "chronic myeloid leukemia"
    },
    {
      "id": "F691L"
    },
    {
      "id": "mild resistance"
    },
    {
      "id": "FLT3 TKI-resistant F691 substitutions"
    },
    {
      "id": "FLT3 activation loop"
    },
    {
      "id": "quizartinib"
    },
    {
      "id": "FLT3 inhibitors"
    },
    {
      "id": "Alternative strategies"
    },
    {
      "id": "kinase domain mutants"
    },
    {
      "id": "TKI"
    },
    {
      "id": "residue D835"
    },
    {
      "id": "resistance"
    },
    {
      "id": "sorafenib"
    },
    {
      "id": "TKI-resistant FLT3-ITD D835 mutations"
    },
    {
      "id": "AC220"
    },
    {
      "id": "BCR-ABL KD mutation"
    },
    {
      "id": "FLT3-ITD mutant isoforms"
    },
    {
      "id": "acquired clinical resistance"
    },
    {
      "id": "FLT3-ITD"
    },
    {
      "id": "AL"
    },
    {
      "id": "DCC-2036"
    },
    {
      "id": "tyrosine kinase domain"
    },
    {
      "id": "multikinase inhibitor"
    },
    {
      "id": "switch control inhibitor"
    },
    {
      "id": "D835"
    },
    {
      "id": "D839"
    },
    {
      "id": "chemotherapy-resistant acute myeloid leukemia"
    },
    {
      "id": "Y842"
    },
    {
      "id": "central nervous system effects"
    },
    {
      "id": "\u03b3-aminobutyric acid inhibition"
    },
    {
      "id": "RDX"
    },
    {
      "id": "toxicant action"
    },
    {
      "id": "Absorption"
    },
    {
      "id": "490 ng/g"
    },
    {
      "id": "highest-exposure group"
    },
    {
      "id": "DNX"
    },
    {
      "id": "Average RDX concentrations"
    },
    {
      "id": "123 ng/g"
    },
    {
      "id": "reductive transformation products"
    },
    {
      "id": "hexahydro-1,3,5-trinitroso-1,3,5-triazine"
    },
    {
      "id": "hexahydro-1,3,5-trinitro-1,3,5-triazine"
    },
    {
      "id": "B6C3F1 mice"
    },
    {
      "id": "11.1 ng/mL"
    },
    {
      "id": "hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine"
    },
    {
      "id": "exposed mice"
    },
    {
      "id": "32"
    },
    {
      "id": "TNX"
    },
    {
      "id": "MNX"
    },
    {
      "id": "233 ng/g"
    },
    {
      "id": "amount of RDX"
    },
    {
      "id": "3319 ng/g"
    },
    {
      "id": "2013"
    },
    {
      "id": "Average MNX concentrations"
    },
    {
      "id": "stomachs"
    },
    {
      "id": "144 ng/g"
    },
    {
      "id": "Mus musculus"
    },
    {
      "id": "higher exposures"
    },
    {
      "id": "5 mg/kg"
    },
    {
      "id": "0 mg/kg"
    },
    {
      "id": "contaminated feed"
    },
    {
      "id": "potential formation"
    },
    {
      "id": "50 mg/kg"
    },
    {
      "id": "maximum average concentration"
    },
    {
      "id": "500 mg/kg"
    },
    {
      "id": "165.1 ng/g"
    },
    {
      "id": "RDX exposure"
    },
    {
      "id": "0.5 mg/kg"
    },
    {
      "id": "28 d"
    },
    {
      "id": "N-nitroso metabolites"
    },
    {
      "id": "dose-dependent pattern"
    },
    {
      "id": "matrices"
    },
    {
      "id": "hexahydro-1,3-dinitroso-5-nitro-1,3,5-triazine"
    },
    {
      "id": "25.6 ng/g"
    },
    {
      "id": "RDX metabolites"
    },
    {
      "id": "2697 ng/g"
    },
    {
      "id": "biotransformation"
    },
    {
      "id": "182 ng/mL"
    },
    {
      "id": "35900 ng/g"
    },
    {
      "id": "51.1 ng/g"
    },
    {
      "id": "1295-1303"
    },
    {
      "id": "tested tissues"
    },
    {
      "id": "Pim-1"
    },
    {
      "id": "2-aminothiazole derivatives"
    },
    {
      "id": "chemotherapeutic resistance"
    },
    {
      "id": "potential"
    },
    {
      "id": "synergistic inhibitory effect"
    },
    {
      "id": "enzymatic assays"
    },
    {
      "id": "adjuvant agents"
    },
    {
      "id": "treatment of cancer diseases"
    },
    {
      "id": "noncompetitive inhibitors"
    },
    {
      "id": "synergistic effect"
    },
    {
      "id": "prostate cancer cell lines"
    },
    {
      "id": "PC3"
    },
    {
      "id": "ATP-competitive indolyl-pyrrolone scaffold"
    },
    {
      "id": "structure-activity relationship data"
    },
    {
      "id": "serine/threonine kinase"
    },
    {
      "id": "virtual screening campaign"
    },
    {
      "id": "ATP-competitive inhibitors"
    },
    {
      "id": "cancer therapy"
    },
    {
      "id": "2-aminothiazoles"
    },
    {
      "id": "initiation"
    },
    {
      "id": "allosteric inhibition"
    },
    {
      "id": "ATP-competitive compounds"
    },
    {
      "id": "inhibition of cell proliferation"
    },
    {
      "id": "Pim-1 inhibitors"
    },
    {
      "id": "peptide substrate"
    },
    {
      "id": "ATP-noncompetitive compounds"
    },
    {
      "id": "anticancer agent"
    },
    {
      "id": "combination strategy"
    },
    {
      "id": "z-VAD-fmk"
    },
    {
      "id": "caspase"
    },
    {
      "id": "BSC 3g"
    },
    {
      "id": "G2/M Arrest"
    },
    {
      "id": "Human Breast Cancer MCF-7 Cells"
    },
    {
      "id": "BSC treatment"
    },
    {
      "id": "cytotoxic activity"
    },
    {
      "id": "tumour cells"
    },
    {
      "id": "BSC 3n"
    },
    {
      "id": "CDK1"
    },
    {
      "id": "Bisacylimidoselenocarbamate derivatives"
    },
    {
      "id": "cyclin A an B1"
    },
    {
      "id": "cell-cycle arrest"
    },
    {
      "id": "late G2/M"
    },
    {
      "id": "leukaemia CCRF-CEM cells"
    },
    {
      "id": "caspase-2"
    },
    {
      "id": "CDK2"
    },
    {
      "id": "pancaspase inhibitor"
    },
    {
      "id": "Bisacylimidoselenocarbamates"
    },
    {
      "id": "MCF-7 Cells"
    },
    {
      "id": "caspase-dependent pathway"
    },
    {
      "id": "BSC treated cells"
    },
    {
      "id": "lethal mitosis"
    },
    {
      "id": "breast adenocarcinoma MCF-7 cells"
    },
    {
      "id": "BSC"
    },
    {
      "id": "p21CIP1"
    },
    {
      "id": "anticancer agents"
    },
    {
      "id": "rapamycin"
    },
    {
      "id": "P-gp substrates"
    },
    {
      "id": "DUN"
    },
    {
      "id": "actinomycin-D"
    },
    {
      "id": "OPN"
    },
    {
      "id": "extracellular matrix protein"
    },
    {
      "id": "drug resistance"
    },
    {
      "id": "sensitive tumors"
    },
    {
      "id": "osteopontin"
    },
    {
      "id": "Daunomycin"
    },
    {
      "id": "chemotherapeutic agent"
    },
    {
      "id": "p-glycoprotein"
    },
    {
      "id": "ATP-binding cassette transporter"
    },
    {
      "id": "hypoxic condition"
    },
    {
      "id": "arginine-glycine-aspartic acid (RGD) domain"
    },
    {
      "id": "integrin"
    },
    {
      "id": "\u03b1v\u03b23 integrin"
    },
    {
      "id": "P-gp transporter"
    },
    {
      "id": "\u03b1v\u03b23"
    },
    {
      "id": "Multidrug resistance"
    },
    {
      "id": "Osteopontin"
    },
    {
      "id": "cytotoxic action"
    },
    {
      "id": "OPN knockdown"
    },
    {
      "id": "cell adhesion factors"
    },
    {
      "id": "soluble factors"
    },
    {
      "id": "PC-3 cells"
    },
    {
      "id": "pump activity"
    },
    {
      "id": "drug transporter"
    },
    {
      "id": "drug pumping-out activity"
    },
    {
      "id": "aspartic acid"
    },
    {
      "id": "RGD domain"
    },
    {
      "id": "\u03b1v\u03b23 monoclonal antibody"
    },
    {
      "id": "diesel exhaust particles (DEP)"
    },
    {
      "id": "air pollutants"
    },
    {
      "id": "chronic airway diseases"
    },
    {
      "id": "COPD"
    },
    {
      "id": "airway epithelial cells"
    },
    {
      "id": "deleterious effects"
    },
    {
      "id": "A549 cell"
    },
    {
      "id": "foetal calf serum (FCS)"
    },
    {
      "id": "DEP-induced changes"
    },
    {
      "id": "3.3%FCS"
    },
    {
      "id": "apoptosis regulating proteins"
    },
    {
      "id": "Extravasation"
    },
    {
      "id": "p27"
    },
    {
      "id": "N-acetylcysteine (NAC)"
    },
    {
      "id": "interleukin (IL)-8"
    },
    {
      "id": "JNK2 mRNA expression"
    },
    {
      "id": "inflamed airways"
    },
    {
      "id": "p21(CIP1/WAF1)"
    },
    {
      "id": "cyclin E mRNA expression"
    },
    {
      "id": "oxidant stress pathways"
    },
    {
      "id": "c-jun N-terminal kinase (JNK)"
    },
    {
      "id": "airway epithelial cell apoptosis"
    },
    {
      "id": "patent review"
    },
    {
      "id": "patent applications"
    },
    {
      "id": "PAMs"
    },
    {
      "id": "mGlu2 receptors"
    },
    {
      "id": "brain areas"
    },
    {
      "id": "mGluR2 positive allosteric modulators"
    },
    {
      "id": "mGlu2 receptor"
    },
    {
      "id": "medicinal chemistry"
    },
    {
      "id": "positive allosteric modulators"
    },
    {
      "id": "alternative site"
    },
    {
      "id": "2009"
    },
    {
      "id": "earlier review"
    },
    {
      "id": "journal"
    },
    {
      "id": "group II subfamily of metabotropic glutamate receptors"
    },
    {
      "id": "mGlu3 receptor"
    },
    {
      "id": "glutamate hyperfunction"
    },
    {
      "id": "mGlu"
    },
    {
      "id": "mGlu2 receptor PAMs"
    },
    {
      "id": "December 2012"
    },
    {
      "id": "neuropharmacology"
    },
    {
      "id": "allosteric approach"
    },
    {
      "id": "mGlu2"
    },
    {
      "id": "April 2009"
    },
    {
      "id": "presynaptic nerve terminals"
    },
    {
      "id": "GABA release"
    },
    {
      "id": "maximum drug dose"
    },
    {
      "id": "2 consecutive months"
    },
    {
      "id": "recent years"
    },
    {
      "id": "2010"
    },
    {
      "id": "prescription information"
    },
    {
      "id": "1.6 million people"
    },
    {
      "id": "Cholinesterase inhibitors"
    },
    {
      "id": "pharmacological intervention"
    },
    {
      "id": "donepezil"
    },
    {
      "id": "drug type"
    },
    {
      "id": "hazards ratio (HR)"
    },
    {
      "id": "cognitive symptoms"
    },
    {
      "id": "Non-persistence"
    },
    {
      "id": "AD drug"
    },
    {
      "id": "study period"
    },
    {
      "id": "population-based study"
    },
    {
      "id": "risk of non-persistence"
    },
    {
      "id": "Older age"
    },
    {
      "id": "95 % confidence interval (CI)"
    },
    {
      "id": "gap in prescribing"
    },
    {
      "id": "63 consecutive days"
    },
    {
      "id": "failure to maintain dose-maximisation"
    },
    {
      "id": "AD medications"
    },
    {
      "id": "Health Service Executive-Primary Care Reimbursement Services prescription claims database"
    },
    {
      "id": "Republic of Ireland"
    },
    {
      "id": "January 2006"
    },
    {
      "id": "prescriptions"
    },
    {
      "id": "multiple anti-dementia medications"
    },
    {
      "id": "reasons"
    },
    {
      "id": "dose-maximisation"
    },
    {
      "id": "dose titrations"
    },
    {
      "id": "rivastigmine"
    },
    {
      "id": "persistence"
    },
    {
      "id": "memantine"
    },
    {
      "id": "two-thirds of patients"
    },
    {
      "id": "'real world'"
    },
    {
      "id": "initiation dose"
    },
    {
      "id": "community"
    },
    {
      "id": "75+ years"
    },
    {
      "id": "anti-dementia medications"
    },
    {
      "id": "2007"
    },
    {
      "id": "20,729 patients"
    },
    {
      "id": "December 2010"
    },
    {
      "id": "galantamine"
    },
    {
      "id": "12 months"
    },
    {
      "id": "<75 years"
    },
    {
      "id": "clinical trial setting"
    },
    {
      "id": "flexibility"
    },
    {
      "id": "S16 phosphorylation"
    },
    {
      "id": "(1)H,(15)N amide resonances"
    },
    {
      "id": "spectrum"
    },
    {
      "id": "folded protein"
    },
    {
      "id": "reduced conformational heterogeneity"
    },
    {
      "id": "serine/threonine residues"
    },
    {
      "id": "phospho-binding loop"
    },
    {
      "id": "NMR spectroscopy"
    },
    {
      "id": "level of phosphorylation"
    },
    {
      "id": "phosphate moiety"
    },
    {
      "id": "phospho-substrate"
    },
    {
      "id": "Nuclear Magnetic Resonance (NMR) spectroscopy"
    },
    {
      "id": "PKA phosphorylation site"
    },
    {
      "id": "S16"
    },
    {
      "id": "phospho-S16"
    },
    {
      "id": "functional consequences"
    },
    {
      "id": "unphosphorylated state"
    },
    {
      "id": "phosphorylated Tau peptide"
    },
    {
      "id": "WW phosphorylation"
    },
    {
      "id": "functional regulation"
    },
    {
      "id": "hyperphosphorylated neuronal Tau protein"
    },
    {
      "id": "resonances"
    },
    {
      "id": "WW domain"
    },
    {
      "id": "molecular dynamics simulation"
    },
    {
      "id": "phosphorylation event"
    },
    {
      "id": "solvent-exposed flexible loops"
    },
    {
      "id": "analytical characterization"
    },
    {
      "id": "Pin1 protein"
    },
    {
      "id": "decreased affinity"
    },
    {
      "id": "Pin1 WW domain"
    },
    {
      "id": "phosphorylated partner"
    },
    {
      "id": "globular protein"
    },
    {
      "id": "obstacles"
    },
    {
      "id": "Detection"
    },
    {
      "id": "phospho-WW"
    },
    {
      "id": "chemical shift changes"
    },
    {
      "id": "OATP1B1"
    },
    {
      "id": "OATP isoforms"
    },
    {
      "id": "substrate specificity"
    },
    {
      "id": "human hepatocytes"
    },
    {
      "id": "anionic drugs"
    },
    {
      "id": "rosuvastatin"
    },
    {
      "id": "siRNA technology"
    },
    {
      "id": "hepatic drug transporters"
    },
    {
      "id": "hepatic uptake"
    },
    {
      "id": "AtuFECT01"
    },
    {
      "id": "Off-target effects"
    },
    {
      "id": "novel lipid"
    },
    {
      "id": "Organic anion transporting polypeptide 1B1"
    },
    {
      "id": "new chemical entities"
    },
    {
      "id": "drug metabolizing enzymes"
    },
    {
      "id": "estrone-3-sulfate"
    },
    {
      "id": "co-regulators"
    },
    {
      "id": "protein malnutrition"
    },
    {
      "id": "gastrotoxicity"
    },
    {
      "id": "histopathological deterioration"
    },
    {
      "id": "Weanling male Wistar rats"
    },
    {
      "id": "2.5% protein diet"
    },
    {
      "id": "normally-fed control"
    },
    {
      "id": "protein-malnourished drug-treated groups"
    },
    {
      "id": "mucus levels"
    },
    {
      "id": "two-electron reduction"
    },
    {
      "id": "normal (24%) protein diet"
    },
    {
      "id": "rat stomach"
    },
    {
      "id": "PM-MMC rats"
    },
    {
      "id": "quinone reductase"
    },
    {
      "id": "PM-CP rats"
    },
    {
      "id": "gamma-glutamyltransferase"
    },
    {
      "id": "5-fluorouracil (FU)"
    },
    {
      "id": "glutathione S-transferase"
    },
    {
      "id": "normally-fed drug-treated groups"
    },
    {
      "id": "CCBL pathway"
    },
    {
      "id": "CP activation"
    },
    {
      "id": "cysteine S-conjugate beta-lyase (CCBL)"
    },
    {
      "id": "cisplatin (CP)"
    },
    {
      "id": "mitomycin C (MMC)"
    },
    {
      "id": "xanthine oxidase"
    },
    {
      "id": "PM-FU rats"
    },
    {
      "id": "cytochrome P450 1A1/2"
    },
    {
      "id": "PM-FU"
    },
    {
      "id": "prostaglandin E2 production"
    },
    {
      "id": "PM-CP"
    },
    {
      "id": "permeability"
    },
    {
      "id": "protein-malnourished control (PM)"
    },
    {
      "id": "dihydropyrimidine dehydrogenase"
    },
    {
      "id": "FU elimination"
    },
    {
      "id": "aminopeptidase N"
    },
    {
      "id": "PM-MMC"
    },
    {
      "id": "magnesium oxide"
    },
    {
      "id": "spironolactone"
    },
    {
      "id": "free fatty acids"
    },
    {
      "id": "Serum free fatty acid"
    },
    {
      "id": "PCOS patients"
    },
    {
      "id": "FFA levels"
    },
    {
      "id": "FFAs"
    },
    {
      "id": "repeated measure ANOVA"
    },
    {
      "id": "PCOS women"
    },
    {
      "id": "Group 3"
    },
    {
      "id": "glucophage"
    },
    {
      "id": "spironolactone-treated patients"
    },
    {
      "id": "glucose tolerance test"
    },
    {
      "id": "glucose load"
    },
    {
      "id": "area under the curve"
    },
    {
      "id": "ABT-288"
    },
    {
      "id": "abuse liability"
    },
    {
      "id": "histamine H3 receptor antagonist"
    },
    {
      "id": "d-amphetamine"
    },
    {
      "id": "motor activity"
    },
    {
      "id": "H3 antagonists"
    },
    {
      "id": "potential for abuse"
    },
    {
      "id": "Histamine H3 receptor antagonists"
    },
    {
      "id": "wakefulness-promoting effects"
    },
    {
      "id": "human population"
    },
    {
      "id": "stimulant-like properties"
    },
    {
      "id": "stimulant effects"
    },
    {
      "id": "psychomotor stimulant-like effects"
    },
    {
      "id": "Drug discrimination"
    },
    {
      "id": "amphetamine-like stimulus properties"
    },
    {
      "id": "physical dependence"
    },
    {
      "id": "reinforcing effects"
    },
    {
      "id": "amphetamine-like discriminative stimulus effects"
    },
    {
      "id": "locomotor-stimulant effects"
    },
    {
      "id": "preclinical data"
    },
    {
      "id": "cross-sensitization"
    },
    {
      "id": "drug self-administration"
    },
    {
      "id": "cognitive-enhancing effects"
    },
    {
      "id": "binding model 12b"
    },
    {
      "id": "c-Met"
    },
    {
      "id": "compound 12b"
    },
    {
      "id": "EBC-1 cell"
    },
    {
      "id": "5-(benzyloxy)pyridin-2(1H)-one derivatives"
    },
    {
      "id": "c-Met inhibitors"
    },
    {
      "id": "5-(benzyloxy)pyridin-2(1H)-ones"
    },
    {
      "id": "c-Met inhibition"
    },
    {
      "id": "c-Met constitutive activation"
    },
    {
      "id": "amides"
    },
    {
      "id": "C-3 position"
    },
    {
      "id": "11 kinases"
    },
    {
      "id": "c-Met IC50"
    },
    {
      "id": "docking analysis"
    },
    {
      "id": "12nM"
    },
    {
      "id": "benzoimidazoles"
    },
    {
      "id": "SIRT1 gene"
    },
    {
      "id": "Direct sequencing"
    },
    {
      "id": "T-to-C exchange"
    },
    {
      "id": "SIRT1-L107P"
    },
    {
      "id": "autoimmune-mediated \u03b2 cell destruction"
    },
    {
      "id": "insulin deficiency"
    },
    {
      "id": "SIRT1 mutation"
    },
    {
      "id": "leucine-to-proline mutation at residue 107"
    },
    {
      "id": "type 1 diabetes"
    },
    {
      "id": "lean body mass"
    },
    {
      "id": "exome sequencing"
    },
    {
      "id": "monogenic form of type 1 diabetes"
    },
    {
      "id": "26-year-old man"
    },
    {
      "id": "human autoimmunity"
    },
    {
      "id": "residue 107"
    },
    {
      "id": "affected members"
    },
    {
      "id": "autoimmune disorder"
    },
    {
      "id": "histone deacetylase"
    },
    {
      "id": "T cell reactivity"
    },
    {
      "id": "\u03b2 cell antigens"
    },
    {
      "id": "age-related diseases"
    },
    {
      "id": "autoantibodies"
    },
    {
      "id": "ulcerative colitis"
    },
    {
      "id": "insulin-producing cells"
    },
    {
      "id": "oxytocin receptor gene"
    },
    {
      "id": "polymorphism"
    },
    {
      "id": "Web-based assessments"
    },
    {
      "id": "functioning of males"
    },
    {
      "id": "negative social environments"
    },
    {
      "id": "combined impact"
    },
    {
      "id": "ongoing stress"
    },
    {
      "id": "different domains"
    },
    {
      "id": "functioning of females"
    },
    {
      "id": "impaired daily functioning"
    },
    {
      "id": "associations"
    },
    {
      "id": "quality of social environments"
    },
    {
      "id": "9/11"
    },
    {
      "id": "acute stress"
    },
    {
      "id": "constraint"
    },
    {
      "id": "mental health"
    },
    {
      "id": "collective stress"
    },
    {
      "id": "PTS symptoms"
    },
    {
      "id": "economic stress"
    },
    {
      "id": "post-traumatic stress symptoms"
    },
    {
      "id": "OXTR"
    },
    {
      "id": "interpersonal conflict"
    },
    {
      "id": "A allele"
    },
    {
      "id": "Saliva"
    },
    {
      "id": "mail"
    },
    {
      "id": "impaired functioning"
    },
    {
      "id": "genetic vulnerability"
    },
    {
      "id": "September 11th terrorist attacks"
    },
    {
      "id": "elevated PTS symptoms"
    },
    {
      "id": "high economic stress"
    },
    {
      "id": "rs53576 genotype"
    },
    {
      "id": "704 respondents"
    },
    {
      "id": "pre-9/11 mental health"
    },
    {
      "id": "GG genotype"
    },
    {
      "id": "level of economic stress"
    },
    {
      "id": "moderators"
    },
    {
      "id": "Environmental stress"
    },
    {
      "id": "time-domains"
    },
    {
      "id": "delay"
    },
    {
      "id": "CORT"
    },
    {
      "id": "180 min"
    },
    {
      "id": "number of visits"
    },
    {
      "id": "s.c."
    },
    {
      "id": "transcriptional regulation"
    },
    {
      "id": "reward-based decision-making"
    },
    {
      "id": "neuronal activity"
    },
    {
      "id": "disadvantageous arm"
    },
    {
      "id": "rodent model"
    },
    {
      "id": "c-Fos expression"
    },
    {
      "id": "c-Fos labelling"
    },
    {
      "id": "Corticosteroid hormones"
    },
    {
      "id": "rapid and delayed time domain"
    },
    {
      "id": "saline treated rats"
    },
    {
      "id": "h"
    },
    {
      "id": "modes of corticosteroid action"
    },
    {
      "id": "behavioural testing"
    },
    {
      "id": "rapid corticosteroid effect"
    },
    {
      "id": "Iowa Gambling Task"
    },
    {
      "id": "rapid versus delayed actions"
    },
    {
      "id": "behavioural paradigm"
    },
    {
      "id": "cognitive tasks"
    },
    {
      "id": "insular cortex"
    },
    {
      "id": "minutes"
    },
    {
      "id": "trial blocks"
    },
    {
      "id": "rIGT"
    },
    {
      "id": "non-genomic pathways"
    },
    {
      "id": "infralimbic cortex"
    },
    {
      "id": "lateral orbitofrontal cortex"
    },
    {
      "id": "rapid corticosteroid actions"
    },
    {
      "id": "B16/F1 melanoma"
    },
    {
      "id": "Melanoma"
    },
    {
      "id": "Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide"
    },
    {
      "id": "lactam bridge-cyclized alpha-MSH peptide"
    },
    {
      "id": "alpha-MSH peptide"
    },
    {
      "id": "B16/F1 melanoma-bearing C57 mice"
    },
    {
      "id": "(177)Lu-DOTA-GGNle-CycMSHhex"
    },
    {
      "id": "urinary clearance"
    },
    {
      "id": "normal organ"
    },
    {
      "id": "imaging probe"
    },
    {
      "id": "C57 mice"
    },
    {
      "id": "SPECT/CT"
    },
    {
      "id": "tumor"
    },
    {
      "id": "melanoma lesions"
    },
    {
      "id": "Lu-177"
    },
    {
      "id": "melanoma treatment"
    },
    {
      "id": "injected dose"
    },
    {
      "id": "urinary system"
    },
    {
      "id": "body"
    },
    {
      "id": "three novel missense mutations"
    },
    {
      "id": "p.Tyr1055Cys"
    },
    {
      "id": "Mowat-Wilson syndrome (MWS)"
    },
    {
      "id": "de novo heterozygous mutations"
    },
    {
      "id": "ZEB2 gene"
    },
    {
      "id": "zebrafish morphant technology"
    },
    {
      "id": "rescue experiments"
    },
    {
      "id": "partial loss of function of ZEB2"
    },
    {
      "id": "repression of E-cadherin"
    },
    {
      "id": "E-cadherin promoter"
    },
    {
      "id": "ZEB2 target gene"
    },
    {
      "id": "ZEB2 zinc-finger missense mutations"
    },
    {
      "id": "hypomorphic alleles"
    },
    {
      "id": "p.Ser1071Pro"
    },
    {
      "id": "highly conserved C-zinc-finger (C-ZF) domain"
    },
    {
      "id": "Patients' phenotype"
    },
    {
      "id": "facial gestalt of MWS"
    },
    {
      "id": "Hirschsprung disease (HSCR)"
    },
    {
      "id": "three missense mutations"
    },
    {
      "id": "known functional domain of ZEB2"
    },
    {
      "id": "ZEB2"
    },
    {
      "id": "C-ZF"
    },
    {
      "id": "epilepsy"
    },
    {
      "id": "haplo-insufficiency"
    },
    {
      "id": "heart defects"
    },
    {
      "id": "multiple congenital anomaly syndrome"
    },
    {
      "id": "large gene deletions"
    },
    {
      "id": "mutant human ZEB2 mRNAs"
    },
    {
      "id": "distinctive facial gestalt"
    },
    {
      "id": "p.His1045Arg"
    },
    {
      "id": "severe intellectual disability (ID)"
    },
    {
      "id": "moderate ID"
    },
    {
      "id": "Functional domains"
    },
    {
      "id": "corpus callosum agenesis"
    },
    {
      "id": "zinc-finger"
    },
    {
      "id": "clinical spectrum of ZEB2 mutations"
    },
    {
      "id": "microcephaly"
    },
    {
      "id": "premature stop codons"
    },
    {
      "id": "conotruncal heart defects"
    },
    {
      "id": "urogenital malformations"
    },
    {
      "id": "suggestive facial gestalt"
    },
    {
      "id": "congenital malformation"
    },
    {
      "id": "wild-type (WT) human ZEB2 mRNAs"
    },
    {
      "id": "early embryonic development"
    },
    {
      "id": "embryo rescue"
    },
    {
      "id": "severity of patients' phenotype"
    },
    {
      "id": "lesser degrees of ID"
    },
    {
      "id": "SNP-containing cDNA"
    },
    {
      "id": "frequent-to-rare codon conversion"
    },
    {
      "id": "HtrA1's conformation"
    },
    {
      "id": "mRNA translation rate"
    },
    {
      "id": "synonymous SNPs"
    },
    {
      "id": "common variants"
    },
    {
      "id": "high-temperature requirement A1 (HTRA1)"
    },
    {
      "id": "Synonymous single nucleotide polymorphisms (SNPs)"
    },
    {
      "id": "HtrA1's abilities"
    },
    {
      "id": "IGF-1"
    },
    {
      "id": "inherited risk"
    },
    {
      "id": "neovascular age-related macular degeneration (NvAMD)"
    },
    {
      "id": "less frequently used codons"
    },
    {
      "id": "common codons"
    },
    {
      "id": "Ala34"
    },
    {
      "id": "homeostatic protein quality control mechanisms"
    },
    {
      "id": "NvAMD"
    },
    {
      "id": "HTRA1"
    },
    {
      "id": "anti-HtrA1 antibody"
    },
    {
      "id": "synonymous codon usage"
    },
    {
      "id": "protein function"
    },
    {
      "id": "NvAMD-associated synonymous polymorphisms"
    },
    {
      "id": "HtrA1's putative insulin-like growth factor 1 (IGF-1) binding domain"
    },
    {
      "id": "transcript's coding region"
    },
    {
      "id": "Gly36"
    },
    {
      "id": "HtrA1's function"
    },
    {
      "id": "Silent Polymorphisms"
    },
    {
      "id": "HtrA1"
    },
    {
      "id": "Insulin-Like Growth Factor 1"
    },
    {
      "id": "IGF-1-stimulated signaling events"
    },
    {
      "id": "Age-Related Macular Degeneration"
    },
    {
      "id": "release of pro-inflammatory factors"
    },
    {
      "id": "monocyte chemotactic protein-1"
    },
    {
      "id": "anti-inflammatory effect"
    },
    {
      "id": "diabetic conditions"
    },
    {
      "id": "potential beneficial action"
    },
    {
      "id": "late stages of diabetes"
    },
    {
      "id": "membrane fluidity"
    },
    {
      "id": "Membranar effects"
    },
    {
      "id": "experimental conditions"
    },
    {
      "id": "quercetin"
    },
    {
      "id": "epigallocatechin gallate"
    },
    {
      "id": "transmembrane potential"
    },
    {
      "id": "beneficial action"
    },
    {
      "id": "Jurkat T lymphoblasts"
    },
    {
      "id": "increased concentration of advanced glycation end products"
    },
    {
      "id": "decrease of membrane fluidity"
    },
    {
      "id": "various pathologies"
    },
    {
      "id": "advanced glycation end products"
    },
    {
      "id": "HUVEC"
    },
    {
      "id": "high glucose conditions"
    },
    {
      "id": "investigated polyphenols"
    },
    {
      "id": "l-glutamine"
    },
    {
      "id": "stretpozotocin-nicotinamide induced diabetic rats"
    },
    {
      "id": "plasma active (GLP-1) (7-36) amide"
    },
    {
      "id": "blood sugar"
    },
    {
      "id": "plasma insulin"
    },
    {
      "id": "sitagliptin"
    },
    {
      "id": "pancreatic insulin"
    },
    {
      "id": "overnight fasted Sprague Dawley rats"
    },
    {
      "id": "Type 2 diabetes"
    },
    {
      "id": "GLP-1 receptor agonistic activity"
    },
    {
      "id": "active GLP-1 (7-36) amide"
    },
    {
      "id": "Plasma glucose"
    },
    {
      "id": "type 2 diabetic patients"
    },
    {
      "id": "non-essential amino acid"
    },
    {
      "id": "colonic active (GLP-1) (7-36) amide"
    },
    {
      "id": "nicotinamide"
    },
    {
      "id": "diabetic control"
    },
    {
      "id": "Molecular docking study"
    },
    {
      "id": "nondiabetic"
    },
    {
      "id": "Pharmacological Characterization"
    },
    {
      "id": "Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4)"
    },
    {
      "id": "Dmt(1)"
    },
    {
      "id": "iv administration"
    },
    {
      "id": "EM-1 analogues"
    },
    {
      "id": "(2-furyl)Map(4)"
    },
    {
      "id": "Endomorphin-1"
    },
    {
      "id": "\u03bc-Opioid Agonists"
    },
    {
      "id": "analogue 12"
    },
    {
      "id": "agonistic potency"
    },
    {
      "id": "(R)-\u03b2Pro(2)"
    },
    {
      "id": "cAMP accumulation assays"
    },
    {
      "id": "tail-flick test"
    },
    {
      "id": "picomolar range"
    },
    {
      "id": "mouse brain homogenates"
    },
    {
      "id": "3.72 pM"
    },
    {
      "id": "Ki(\u03bc)"
    },
    {
      "id": "99.5%"
    },
    {
      "id": "Emax"
    },
    {
      "id": "(R/S)-\u03b2Pro(2)"
    },
    {
      "id": "\u03b1-methylene-\u03b2-aminopropanoic acids"
    },
    {
      "id": "Map"
    },
    {
      "id": "Design"
    },
    {
      "id": "MOR"
    },
    {
      "id": "subpicomolar range"
    },
    {
      "id": "(ph)Map(4)"
    },
    {
      "id": "\u03bc-opioid receptor"
    },
    {
      "id": "Trp(3)"
    },
    {
      "id": "Forskolin-induced cAMP accumulation assays"
    },
    {
      "id": "EC50"
    },
    {
      "id": "0.0421 pM"
    },
    {
      "id": "Forskolin"
    },
    {
      "id": "EM-1"
    },
    {
      "id": "structure-activity study"
    },
    {
      "id": "Hinokitiol"
    },
    {
      "id": "platelet activation"
    },
    {
      "id": "cosmetics"
    },
    {
      "id": "protein kinase C (PKC)"
    },
    {
      "id": "thromboembolic disorders"
    },
    {
      "id": "mitogen-activated protein kinases (MAPKs)"
    },
    {
      "id": "activation of MAPKs"
    },
    {
      "id": "tropolone-related bioactive compound"
    },
    {
      "id": "antimicrobial agent"
    },
    {
      "id": "atherothrombotic processes"
    },
    {
      "id": "PKC activation"
    },
    {
      "id": "fluorescent triflavin probe"
    },
    {
      "id": "PLC\u03b32-PKC cascade"
    },
    {
      "id": "thrombus formation"
    },
    {
      "id": "collagen-induced aggregation"
    },
    {
      "id": "anticancer activities"
    },
    {
      "id": "\u03b1IIb\u03b23 integrin"
    },
    {
      "id": "intracellular calcium mobilization"
    },
    {
      "id": "phospholipase C (PLC)\u03b32"
    },
    {
      "id": "platelet membrane"
    },
    {
      "id": "hair tonics"
    },
    {
      "id": "hydroxyl radical (OH) formation"
    },
    {
      "id": "thrombogenesis"
    },
    {
      "id": "blockade of CRFRs"
    },
    {
      "id": "glutamatergic transmission"
    },
    {
      "id": "dopamine (DA)"
    },
    {
      "id": "presynaptic glutamate release"
    },
    {
      "id": "excitatory transmission"
    },
    {
      "id": "other subregions of the extended amygdala"
    },
    {
      "id": "glutamatergic neurotransmission"
    },
    {
      "id": "behaviors"
    },
    {
      "id": "CRFRs"
    },
    {
      "id": "CeAL neurons"
    },
    {
      "id": "extended amygdala"
    },
    {
      "id": "lateral subdivision of the central amygdala"
    },
    {
      "id": "CeA"
    },
    {
      "id": "catecholamine signaling"
    },
    {
      "id": "dissociable effects of CRF"
    },
    {
      "id": "different types of glutamatergic neurotransmission"
    },
    {
      "id": "spontaneous glutamate release"
    },
    {
      "id": "CeAL"
    },
    {
      "id": "cardiovascular responses"
    },
    {
      "id": "CRF"
    },
    {
      "id": "frequency"
    },
    {
      "id": "optogenetically evoked glutamate release"
    },
    {
      "id": "lateral subdivision of the CeA (CeAL)"
    },
    {
      "id": "isoproterenol (ISO)"
    },
    {
      "id": "CRF enhancement"
    },
    {
      "id": "distinct mechanisms"
    },
    {
      "id": "sEPSC kinetics"
    },
    {
      "id": "effect of CRF"
    },
    {
      "id": "CRFR1"
    },
    {
      "id": "central nucleus of the amygdala (CeA)"
    },
    {
      "id": "Corticotropin releasing factor"
    },
    {
      "id": "CRFR2 receptors"
    },
    {
      "id": "spontaneous excitatory transmission"
    },
    {
      "id": "whole-cell patch-clamp electrophysiology recordings"
    },
    {
      "id": "hyper-active autonomic nerves"
    },
    {
      "id": "BoNT/A"
    },
    {
      "id": "SV2"
    },
    {
      "id": "therapeutic utility"
    },
    {
      "id": "BoNT/E"
    },
    {
      "id": "SNAP-25"
    },
    {
      "id": "protease"
    },
    {
      "id": "rat sympathetic neurons"
    },
    {
      "id": "non-neuronal cells"
    },
    {
      "id": "Chimeras"
    },
    {
      "id": "non-cleavable SNAP-25"
    },
    {
      "id": "detergent-solubilised neurons"
    },
    {
      "id": "acceptor-binding HC domain"
    },
    {
      "id": "BoNT/A protease"
    },
    {
      "id": "HC"
    },
    {
      "id": "peri-somatic boutons"
    },
    {
      "id": "botulinum neurotoxin type A"
    },
    {
      "id": "endoprotease"
    },
    {
      "id": "botulinum neurotoxin A"
    },
    {
      "id": "intact cells"
    },
    {
      "id": "autonomic transmission"
    },
    {
      "id": "Tetrodotoxin-sensitive spontaneous cholinergic neurotransmission"
    },
    {
      "id": "toxin's acceptor"
    },
    {
      "id": "counterparts"
    },
    {
      "id": "BoNT/B"
    },
    {
      "id": "GR"
    },
    {
      "id": "effector mechanisms"
    },
    {
      "id": "dimerization-mediated transactivation"
    },
    {
      "id": "Chronic elevation of GCs"
    },
    {
      "id": "lethality"
    },
    {
      "id": "potent GC dexamethasone"
    },
    {
      "id": "GR(dim/dim) mice"
    },
    {
      "id": "Absolute triglyceride synthesis"
    },
    {
      "id": "epididymal fat depots"
    },
    {
      "id": "disease-relevant GC target pathways"
    },
    {
      "id": "exaggerated response"
    },
    {
      "id": "DNA binding"
    },
    {
      "id": "transcriptional repression"
    },
    {
      "id": "protein-protein interactions"
    },
    {
      "id": "adipose triacylglycerol metabolism"
    },
    {
      "id": "functional GR dimerization domain"
    },
    {
      "id": "wild-type mice"
    },
    {
      "id": "muscle protein synthesis"
    },
    {
      "id": "severe runting"
    },
    {
      "id": "DEX"
    },
    {
      "id": "skin collagen synthesis rates"
    },
    {
      "id": "heavy water labeling"
    },
    {
      "id": "metabolic fluxes"
    },
    {
      "id": "inguinal fat depots"
    },
    {
      "id": "selective GR modulators"
    },
    {
      "id": "GR transactivation"
    },
    {
      "id": "dimerization domain of GR"
    },
    {
      "id": "GR(dim/dim) mouse"
    },
    {
      "id": "attenuated transactivation"
    },
    {
      "id": "De novo lipogenesis"
    },
    {
      "id": "therapeutic anti-inflammatory effects"
    },
    {
      "id": "intact repression"
    },
    {
      "id": "GC treatment"
    },
    {
      "id": "repression"
    },
    {
      "id": "glucocorticoid (GC) receptor"
    },
    {
      "id": "Goishi tea"
    },
    {
      "id": "obesity-related disorder"
    },
    {
      "id": "normal group"
    },
    {
      "id": "adiponectin levels"
    },
    {
      "id": "induced obese mice"
    },
    {
      "id": "adipose cell"
    },
    {
      "id": "obesity group"
    },
    {
      "id": "adipocytokines"
    },
    {
      "id": "visceral fat weight"
    },
    {
      "id": "obesity three sub-groups"
    },
    {
      "id": "fractions"
    },
    {
      "id": "tumor necrosis factor-alpha"
    },
    {
      "id": "cholesterol level"
    },
    {
      "id": "water layer"
    },
    {
      "id": "ethyl-acetate layer"
    },
    {
      "id": "metabolic syndrome"
    },
    {
      "id": "normal sub-groups"
    },
    {
      "id": "interleukin-6"
    },
    {
      "id": "exogenous nonsteroidal agents"
    },
    {
      "id": "BK \u03b21 site"
    },
    {
      "id": "carotid artery-infusion"
    },
    {
      "id": "HENA"
    },
    {
      "id": "pressurized cerebral arteries"
    },
    {
      "id": "channels made of cbv1 + \u03b24"
    },
    {
      "id": "Novel Nonsteroidal Agent"
    },
    {
      "id": "steroid-sensing site"
    },
    {
      "id": "BK \u03b21 steroid-sensing site"
    },
    {
      "id": "channels made of \u03b21T169A"
    },
    {
      "id": "sodium 3-hydroxyolean-12-en-30-oate (HENA)"
    },
    {
      "id": "Cholane Steroid-Recognition Site"
    },
    {
      "id": "BK Channel \u03b21-Subunit"
    },
    {
      "id": "BK (cbv1 + \u03b21) channels"
    },
    {
      "id": "rat cerebral artery myocytes"
    },
    {
      "id": "chemical structure database similarity search"
    },
    {
      "id": "lithocholic acid (LCA)"
    },
    {
      "id": "Cerebrovascular Dilation"
    },
    {
      "id": "channels made of cbv1 + \u03b22"
    },
    {
      "id": "two-step reaction"
    },
    {
      "id": "\u03b21-containing BK channels"
    },
    {
      "id": "BK channels"
    },
    {
      "id": "myogenic tone"
    },
    {
      "id": "electrophysiologic results"
    },
    {
      "id": "cerebral arteries"
    },
    {
      "id": "selective BK-channel targeting"
    },
    {
      "id": "endogenous steroid"
    },
    {
      "id": "arteries"
    },
    {
      "id": "KCNMB1 knockout mouse"
    },
    {
      "id": "BK \u03b21"
    },
    {
      "id": "vasodilation"
    },
    {
      "id": "native channels"
    },
    {
      "id": "Ca(2+)/voltage-gated K(+) large conductance (BK) channel \u03b21 subunit"
    },
    {
      "id": "C57BL/6 mouse"
    },
    {
      "id": "Thr169"
    },
    {
      "id": "HENA action"
    },
    {
      "id": "channels made of cbv1 + \u03b23"
    },
    {
      "id": "BK channel activation"
    },
    {
      "id": "pial cerebral arterioles"
    },
    {
      "id": "oral curcuminoids supplementation"
    },
    {
      "id": "study populations"
    },
    {
      "id": "carry-over effect"
    },
    {
      "id": "Curcuminoids"
    },
    {
      "id": "Obese Individuals"
    },
    {
      "id": "serum concentrations"
    },
    {
      "id": "anti-Hsp27"
    },
    {
      "id": "Curcuminoid supplementation"
    },
    {
      "id": "serum pro-oxidant-antioxidant balance"
    },
    {
      "id": "PAB"
    },
    {
      "id": "period of 30 days"
    },
    {
      "id": "Immune Response"
    },
    {
      "id": "Oxidized LDL"
    },
    {
      "id": "antibody titres"
    },
    {
      "id": "Heat Shock Protein 27"
    },
    {
      "id": "obese individuals"
    },
    {
      "id": "randomized double-blind placebo-controlled cross-over trial"
    },
    {
      "id": "functional qualities"
    },
    {
      "id": "anti-oxLDL"
    },
    {
      "id": "Pro-Oxidant-Antioxidant Balance"
    },
    {
      "id": "wash-out period"
    },
    {
      "id": "2 weeks"
    },
    {
      "id": "anti-inflammatory properties"
    },
    {
      "id": "oxidative stress burden"
    },
    {
      "id": "anti-Hsp27 titres"
    },
    {
      "id": "oxLDL"
    },
    {
      "id": "Hsp27"
    },
    {
      "id": "anti-oxLDL titres"
    },
    {
      "id": "alternate regimen"
    },
    {
      "id": "Serum PAB"
    },
    {
      "id": "curcuminoid supplement"
    },
    {
      "id": "Steroidal glycosides"
    },
    {
      "id": "Morphological observation"
    },
    {
      "id": "two-dimensional (2D) NMR analysis"
    },
    {
      "id": "(22R)-spirosolanol glycoside (11)"
    },
    {
      "id": "caspase-3 activity level"
    },
    {
      "id": "cytotoxic activities"
    },
    {
      "id": "flow cytometry analysis"
    },
    {
      "id": "A549 human lung adenocarcinoma cells"
    },
    {
      "id": "Fritillaria meleagris"
    },
    {
      "id": "Liliaceae"
    },
    {
      "id": "hydrolytic cleavage"
    },
    {
      "id": "HL-60 human promyelocytic leukemia cells"
    },
    {
      "id": "5\u03b2-spirostanol glycoside (2)"
    },
    {
      "id": "bulbs"
    },
    {
      "id": "spectroscopic analysis"
    },
    {
      "id": "isolated compounds"
    },
    {
      "id": "cholestane derivative (17a)"
    },
    {
      "id": "chromatographic analysis"
    },
    {
      "id": "IRE1"
    },
    {
      "id": "X-box binding protein 1"
    },
    {
      "id": "XBP1 deficiency"
    },
    {
      "id": "XBP1"
    },
    {
      "id": "\u03b1-cells"
    },
    {
      "id": "endoplasmic reticulum (ER) stress"
    },
    {
      "id": "\u03b1-cell biology"
    },
    {
      "id": "\u03b2-cell dysfunction"
    },
    {
      "id": "T2D"
    },
    {
      "id": "stable XBP1 knock down \u03b1-cell line, \u03b1XBPKD"
    },
    {
      "id": "\u03b1-cell function"
    },
    {
      "id": "glucose intolerance"
    },
    {
      "id": "\u03b1XBPKO mice"
    },
    {
      "id": "blunted suppression"
    },
    {
      "id": "pancreatic alpha cell function"
    },
    {
      "id": "upstream activator"
    },
    {
      "id": "tyrosine phosphorylation"
    },
    {
      "id": "glucagon secretion"
    },
    {
      "id": "glucose stimulation"
    },
    {
      "id": "\u03b1XBPKD cells"
    },
    {
      "id": "Type 2 diabetes mellitus (T2D) patients"
    },
    {
      "id": "\u03b1-cell specific XBP1 knockout (\u03b1XBPKO) mice"
    },
    {
      "id": "hyperglucagonemia"
    },
    {
      "id": "unfolded protein response (UPR)"
    },
    {
      "id": "dysfunctional glucagon secretion"
    },
    {
      "id": "altered insulin signaling"
    },
    {
      "id": "mild insulin resistance"
    },
    {
      "id": "IRS-1 (pY(896))"
    },
    {
      "id": "pancreatic \u03b1-cells"
    },
    {
      "id": "serine phosphorylation (pS(307))"
    },
    {
      "id": "IRS-1"
    },
    {
      "id": "GTLE"
    },
    {
      "id": "Aluminium Chloride"
    },
    {
      "id": "BFb"
    },
    {
      "id": "basal forebrain"
    },
    {
      "id": "AlCl3"
    },
    {
      "id": "active avoidance tasks"
    },
    {
      "id": "FbC"
    },
    {
      "id": "forebrain cortex"
    },
    {
      "id": "total glutathione content"
    },
    {
      "id": "green tea"
    },
    {
      "id": "cytochrome c oxidase"
    },
    {
      "id": "Green Tea Leaf Extract"
    },
    {
      "id": "Camellia sinensis L."
    },
    {
      "id": "Aluminium"
    },
    {
      "id": "TGC"
    },
    {
      "id": "(-)-epigallocatechin gallate"
    },
    {
      "id": "rutin"
    },
    {
      "id": "depletion"
    },
    {
      "id": "antioxidant defence system"
    },
    {
      "id": "testicular steroidogenic enzymes"
    },
    {
      "id": "RUT"
    },
    {
      "id": "17\u03b2-HSD"
    },
    {
      "id": "abnormal sperm count"
    },
    {
      "id": "Se"
    },
    {
      "id": "synergistic role"
    },
    {
      "id": "3\u03b2-hydroxysteroid dehydrogenase"
    },
    {
      "id": "Cd-induced testes damage"
    },
    {
      "id": "Cd-induced testicular injury"
    },
    {
      "id": "testicular toxicity"
    },
    {
      "id": "lactate dehydrogenase"
    },
    {
      "id": "HSD"
    },
    {
      "id": "glutathione-S-transferase"
    },
    {
      "id": "acid phosphatase"
    },
    {
      "id": "testicular pathophysiology"
    },
    {
      "id": "oxidative damage"
    },
    {
      "id": "Cd-induced alterations"
    },
    {
      "id": "selenium"
    },
    {
      "id": "epididymal sperm counts"
    },
    {
      "id": "testicular Se levels"
    },
    {
      "id": "plasma testosterone"
    },
    {
      "id": "GST"
    },
    {
      "id": "plasma Se levels"
    },
    {
      "id": "cadmium"
    },
    {
      "id": "Selenium"
    },
    {
      "id": "nuclear actions"
    },
    {
      "id": "normal neuronal functions"
    },
    {
      "id": "neuronal calcium homeostasis"
    },
    {
      "id": "amyloid precursor protein (APP)"
    },
    {
      "id": "amyloid \u03b2-peptide (A\u03b2)"
    },
    {
      "id": "synaptic actions"
    },
    {
      "id": "amyloid-degrading enzyme"
    },
    {
      "id": "neprilysin"
    },
    {
      "id": "physiological actions"
    },
    {
      "id": "opportunities"
    },
    {
      "id": "neurogeneration"
    },
    {
      "id": "learning and memory deficits"
    },
    {
      "id": "fuller understanding"
    },
    {
      "id": "endogenous APP"
    },
    {
      "id": "calcium oscillations"
    },
    {
      "id": "secretase-mediated processing"
    },
    {
      "id": "amplitude"
    },
    {
      "id": "pathological actions"
    },
    {
      "id": "spine structure"
    },
    {
      "id": "diverse range of genes"
    },
    {
      "id": "APP itself"
    },
    {
      "id": "intensive studies"
    },
    {
      "id": "Synaptic spine loss"
    },
    {
      "id": "APP function"
    },
    {
      "id": "emerging evidence"
    },
    {
      "id": "metabolic network"
    },
    {
      "id": "key epigenetic regulator"
    },
    {
      "id": "aquaporin-1"
    },
    {
      "id": "emerging areas"
    },
    {
      "id": "intracellular domain of APP (AICD)"
    },
    {
      "id": "spine functions"
    },
    {
      "id": "primary cortical neurons"
    },
    {
      "id": "PTH therapy"
    },
    {
      "id": "osteoblastogenesis"
    },
    {
      "id": "PTHrP"
    },
    {
      "id": "local factor"
    },
    {
      "id": "Osteoporosis"
    },
    {
      "id": "poor bone microarchitecture"
    },
    {
      "id": "PTH-related protein"
    },
    {
      "id": "osteogenic actions"
    },
    {
      "id": "PTH-unrelated C-terminal region"
    },
    {
      "id": "PTH type 1 receptor"
    },
    {
      "id": "osteoblast survival"
    },
    {
      "id": "N-terminal PTHrP peptides"
    },
    {
      "id": "bone anabolic therapies"
    },
    {
      "id": "osteoporosis rodent models"
    },
    {
      "id": "intermittent administration"
    },
    {
      "id": "parathyroid hormone"
    },
    {
      "id": "low bone mineral density"
    },
    {
      "id": "fractures"
    },
    {
      "id": "Bone anabolism"
    },
    {
      "id": "PTH"
    },
    {
      "id": "cellular and molecular mechanisms"
    },
    {
      "id": "anabolic actions"
    },
    {
      "id": "bone regeneration"
    },
    {
      "id": "skeletal alterations"
    },
    {
      "id": "N-terminal domain"
    },
    {
      "id": "Osteoporosis therapies"
    },
    {
      "id": "antiresorptive drugs"
    },
    {
      "id": "extant literature"
    },
    {
      "id": "Pharmacotherapy"
    },
    {
      "id": "core symptoms"
    },
    {
      "id": "restricted and repetitive behaviors"
    },
    {
      "id": "impairments"
    },
    {
      "id": "social interaction"
    },
    {
      "id": "treatment of core symptoms"
    },
    {
      "id": "Newer lines of research"
    },
    {
      "id": "cholinergic and glutamatergic agents"
    },
    {
      "id": "issues"
    },
    {
      "id": "heterogeneity of the disorder"
    },
    {
      "id": "mood stabilizers"
    },
    {
      "id": "study of treatments"
    },
    {
      "id": "efficacious treatments"
    },
    {
      "id": "core social symptoms"
    },
    {
      "id": "current review"
    },
    {
      "id": "statistical power"
    },
    {
      "id": "mixed results"
    },
    {
      "id": "secretin"
    },
    {
      "id": "study design"
    },
    {
      "id": "autistic disorder"
    },
    {
      "id": "repetitive behaviors"
    },
    {
      "id": "cytokine release"
    },
    {
      "id": "IL-10"
    },
    {
      "id": "damage"
    },
    {
      "id": "toxicological properties"
    },
    {
      "id": "JWH-073"
    },
    {
      "id": "DNA migration"
    },
    {
      "id": "Toxicological profiles"
    },
    {
      "id": "synthetic cannabinoids"
    },
    {
      "id": "immunomodulatory activities"
    },
    {
      "id": "cytotoxic responses"
    },
    {
      "id": "genotoxic effects"
    },
    {
      "id": "concentration range"
    },
    {
      "id": "primary cells"
    },
    {
      "id": "genotoxic activities"
    },
    {
      "id": "naphthoylindole compounds"
    },
    {
      "id": "JWH-122"
    },
    {
      "id": "binding affinities"
    },
    {
      "id": "cannabinoid receptor subtype CB1"
    },
    {
      "id": "benzoylindole"
    },
    {
      "id": "AM-694"
    },
    {
      "id": "breast derived cells"
    },
    {
      "id": "liver cells"
    },
    {
      "id": "estrogenic activities"
    },
    {
      "id": "bone marrow cells"
    },
    {
      "id": "drug tests"
    },
    {
      "id": "exposure levels"
    },
    {
      "id": "JWH-210"
    },
    {
      "id": "hormonal activities"
    },
    {
      "id": "single cell gel electrophoresis assays"
    },
    {
      "id": "body fluids"
    },
    {
      "id": "cannabimimetic effects"
    },
    {
      "id": "anti-estrogenic effects"
    },
    {
      "id": "buccal cells"
    },
    {
      "id": "IL-12/23p40"
    },
    {
      "id": "JWH-018"
    },
    {
      "id": "marihuana"
    },
    {
      "id": "experimental work"
    },
    {
      "id": "drug users"
    },
    {
      "id": "TNF\u03b1 levels"
    },
    {
      "id": "users"
    },
    {
      "id": "lysosomal activities"
    },
    {
      "id": "tetrahydrocannabinol"
    },
    {
      "id": "cannabinoid receptor ligand"
    },
    {
      "id": "protein synthesis"
    },
    {
      "id": "U2-OS"
    },
    {
      "id": "TR146"
    },
    {
      "id": "fed and fasted simulated colonic fluids"
    },
    {
      "id": "colonic mRNA expression"
    },
    {
      "id": "biorelevant media"
    },
    {
      "id": "colonic fluids"
    },
    {
      "id": "TNF-\u03b1 responses"
    },
    {
      "id": "CD.TNF-\u03b1 siRNA-treated mice"
    },
    {
      "id": "total colon weight"
    },
    {
      "id": "DSS-control mice"
    },
    {
      "id": "clinical signs of colitis"
    },
    {
      "id": "RAW264.7 cells"
    },
    {
      "id": "CD.siRNA TNF-\u03b1"
    },
    {
      "id": "CD.siRNA"
    },
    {
      "id": "gel electrophoresis"
    },
    {
      "id": "CD nanocomplexes"
    },
    {
      "id": "induced acute-colitis"
    },
    {
      "id": "Gene silencing"
    },
    {
      "id": "murine model"
    },
    {
      "id": "TNF-alpha (TNF-\u03b1)"
    },
    {
      "id": "inflammatory response"
    },
    {
      "id": "Inflammatory bowel disease (IBD)"
    },
    {
      "id": "TNF-\u03b1 siRNA delivery"
    },
    {
      "id": "local CD-based TNF-\u03b1 siRNA delivery system"
    },
    {
      "id": "Female C57BL/6 mice"
    },
    {
      "id": "dextran sodium sulphate (DSS)"
    },
    {
      "id": "gene levels"
    },
    {
      "id": "intrarectal administration"
    },
    {
      "id": "aberrantly expressed genes"
    },
    {
      "id": "RNA interference (RNAi)"
    },
    {
      "id": "amphiphilic cationic cyclodextrin (CD) vector"
    },
    {
      "id": "control solution"
    },
    {
      "id": "chronic relapsing inflammation"
    },
    {
      "id": "modified cyclodextrin delivery system"
    },
    {
      "id": "putative microtubule-binding site"
    },
    {
      "id": "KIF4"
    },
    {
      "id": "hydrolyzed phosphate"
    },
    {
      "id": "phosphate tube"
    },
    {
      "id": "backdoor"
    },
    {
      "id": "Kinesin"
    },
    {
      "id": "ATP-Induced Isomerization"
    },
    {
      "id": "mobile regions"
    },
    {
      "id": "switch I"
    },
    {
      "id": "specific binding"
    },
    {
      "id": "sole element"
    },
    {
      "id": "partner heads"
    },
    {
      "id": "dimeric KIFs"
    },
    {
      "id": "tight structural coordination"
    },
    {
      "id": "catalytic center"
    },
    {
      "id": "inter-domain regulation"
    },
    {
      "id": "ATPase activity"
    },
    {
      "id": "local conformational change"
    },
    {
      "id": "switch II"
    },
    {
      "id": "processive movement"
    },
    {
      "id": "AMPPNP"
    },
    {
      "id": "adenylyl imidodiphosphate"
    },
    {
      "id": "neck linker"
    },
    {
      "id": "power stroke"
    },
    {
      "id": "ATP binding step"
    },
    {
      "id": "molecular snapshots"
    },
    {
      "id": "energy"
    },
    {
      "id": "microtubule-based molecular motors"
    },
    {
      "id": "nucleotide-binding pocket"
    },
    {
      "id": "non-hydrolyzable ATP analog"
    },
    {
      "id": "KIF1A structures"
    },
    {
      "id": "ATP analogs"
    },
    {
      "id": "stabilization"
    },
    {
      "id": "inter-domain communication"
    },
    {
      "id": "Kinesin superfamily proteins"
    },
    {
      "id": "KIFs"
    },
    {
      "id": "neck-linker element"
    },
    {
      "id": "structural insights"
    },
    {
      "id": "artemisinin"
    },
    {
      "id": "Inducer Activity"
    },
    {
      "id": "antioxidant functions"
    },
    {
      "id": "active extracts"
    },
    {
      "id": "NAD(P)H : quinone oxidoreductase"
    },
    {
      "id": "murine hepatoma cells"
    },
    {
      "id": "xenobiotic metabolism"
    },
    {
      "id": "anti-inflammatory functions"
    },
    {
      "id": "endoperoxide moiety"
    },
    {
      "id": "Asteraceae family"
    },
    {
      "id": "Asteraceae families"
    },
    {
      "id": "deoxyartemisinin"
    },
    {
      "id": "assay"
    },
    {
      "id": "NAD(P)H : quinone oxidoreductase inducer activity"
    },
    {
      "id": "chronic degenerative diseases"
    },
    {
      "id": "multifunctional cytoprotective enzyme"
    },
    {
      "id": "Apocynaceae"
    },
    {
      "id": "Artemisia monosperma"
    },
    {
      "id": "Saudi Arabian Medicinal Plants"
    },
    {
      "id": "Medicinal plants"
    },
    {
      "id": "traditional medicine"
    },
    {
      "id": "NAD(P)H : Quinone Oxidoreductase 1"
    },
    {
      "id": "Brassicaceae"
    },
    {
      "id": "biologically-active phytochemicals"
    },
    {
      "id": "27 Saudi Arabian medicinal plants"
    },
    {
      "id": "microtiter plate wells"
    },
    {
      "id": "plant sources"
    },
    {
      "id": "Apiaceae"
    },
    {
      "id": "malaria"
    },
    {
      "id": "18 different plant families"
    },
    {
      "id": "viscus lumen"
    },
    {
      "id": "contrast agent"
    },
    {
      "id": "DOTA linkage"
    },
    {
      "id": "pantoprazole molecule"
    },
    {
      "id": "proton pumps"
    },
    {
      "id": "conjugate"
    },
    {
      "id": "pantoprazole"
    },
    {
      "id": "Magnetic resonance imaging (MRI)"
    },
    {
      "id": "gastrointestinal (GI) structure"
    },
    {
      "id": "proton pump inhibitor"
    },
    {
      "id": "DOTA (Gd(3+))-conjugate"
    },
    {
      "id": "Gd-based MRI contrast agent"
    },
    {
      "id": "Gd"
    },
    {
      "id": "chelating agent"
    },
    {
      "id": "mechanism-based strategic location"
    },
    {
      "id": "DOTA"
    },
    {
      "id": "wall"
    },
    {
      "id": "limitation"
    },
    {
      "id": "imaging studies"
    },
    {
      "id": "proton-pump inhibitor"
    },
    {
      "id": "GI tract"
    },
    {
      "id": "gastric wall"
    },
    {
      "id": "viscus wall"
    },
    {
      "id": "histological assessment"
    },
    {
      "id": "HE staining"
    },
    {
      "id": "OVA"
    },
    {
      "id": "eosinophil count"
    },
    {
      "id": "IL-17A level"
    },
    {
      "id": "eosinophilia"
    },
    {
      "id": "lung tissue"
    },
    {
      "id": "Treg cells"
    },
    {
      "id": "Asthma mice model"
    },
    {
      "id": "ovalbumin"
    },
    {
      "id": "BALF levels"
    },
    {
      "id": "Treg/Th17 cytokines"
    },
    {
      "id": "allergic asthma"
    },
    {
      "id": "Curcumin"
    },
    {
      "id": "allergic airway inflammation"
    },
    {
      "id": "differential cell count"
    },
    {
      "id": "Wright-Giemsa staining"
    },
    {
      "id": "BAL fluid"
    },
    {
      "id": "CD4(+)CD25(+) regulatory T cells"
    },
    {
      "id": "Flow cytometry (FCM) studies"
    },
    {
      "id": "results in vivo"
    },
    {
      "id": "therapeutic drug"
    },
    {
      "id": "Th17 cells"
    },
    {
      "id": "allergic inflammation"
    },
    {
      "id": "ovalbumin-sensitized mice"
    },
    {
      "id": "hematoxylin and eosin staining"
    },
    {
      "id": "Th17 balance"
    },
    {
      "id": "bronchoalveolar lavage fluid"
    },
    {
      "id": "FCM"
    },
    {
      "id": "curcumin treatments"
    },
    {
      "id": "model group"
    },
    {
      "id": "Airway resistance"
    },
    {
      "id": "forced oscillation technique"
    },
    {
      "id": "Histological studies"
    },
    {
      "id": "IL-10 level"
    },
    {
      "id": "underlying mechanisms"
    },
    {
      "id": "BALF"
    },
    {
      "id": "Tregs"
    },
    {
      "id": "inflammatory"
    },
    {
      "id": "Raw"
    },
    {
      "id": "interleukin (IL)-17A"
    },
    {
      "id": "6-acylaminoalkyl"
    },
    {
      "id": "tetracyclic quino[3,2-b]benzo[1,4]thiazines"
    },
    {
      "id": "2,2'-dichloro-3,3'-diquinolinyl disulfide"
    },
    {
      "id": "tumor necrosis factor alpha"
    },
    {
      "id": "CH3"
    },
    {
      "id": "Br"
    },
    {
      "id": "diquinodithiin"
    },
    {
      "id": "human peripheral blood mononuclear cells"
    },
    {
      "id": "PBMC"
    },
    {
      "id": "colon cancer SV-948 cells"
    },
    {
      "id": "epidermal carcinoma A-341 cells"
    },
    {
      "id": "azaphenothiazines"
    },
    {
      "id": "sulfonylaminoalkyl"
    },
    {
      "id": "several-step syntheses"
    },
    {
      "id": "Cl"
    },
    {
      "id": "structure-activity relationship"
    },
    {
      "id": "6H"
    },
    {
      "id": "6-dialkylaminoalkyl"
    },
    {
      "id": "CF3"
    },
    {
      "id": "proliferative response"
    },
    {
      "id": "phytohemagglutin A"
    },
    {
      "id": "tests"
    },
    {
      "id": "SCH3"
    },
    {
      "id": "aminoalkyl"
    },
    {
      "id": "quino[3,2-b]benzo[1,4]thiazines"
    },
    {
      "id": "immunological properties"
    },
    {
      "id": "PHA"
    },
    {
      "id": "leukemia L-1210 cells"
    },
    {
      "id": "H"
    },
    {
      "id": "Cases"
    },
    {
      "id": "Pathogenetic Implications"
    },
    {
      "id": "C cells"
    },
    {
      "id": "cromogranin"
    },
    {
      "id": "thyroid transcription factor-1"
    },
    {
      "id": "TTF-1"
    },
    {
      "id": "Titf-1"
    },
    {
      "id": "ectopic thyroid tissue in the adrenal gland (ETTAG)"
    },
    {
      "id": "cystic adrenal mass"
    },
    {
      "id": "Ectopic Thyroid Tissue"
    },
    {
      "id": "embryonic descent pathway"
    },
    {
      "id": "normal orthotopic thyroid tissue"
    },
    {
      "id": "KRAS mutations"
    },
    {
      "id": "real-time polymerase chain reaction analysis"
    },
    {
      "id": "immunohistochemical positivity"
    },
    {
      "id": "CK 7"
    },
    {
      "id": "human sodium iodide symporter"
    },
    {
      "id": "fifth decade"
    },
    {
      "id": "congenital hernia of Morgagni"
    },
    {
      "id": "W\u00f6lfler area"
    },
    {
      "id": "in situ hybridization analysis"
    },
    {
      "id": "FOXE1"
    },
    {
      "id": "tongue"
    },
    {
      "id": "medial thyroid anlage"
    },
    {
      "id": "synaptophysin"
    },
    {
      "id": "incidental cystic adrenal masses"
    },
    {
      "id": "cytokeratin"
    },
    {
      "id": "TTF-2"
    },
    {
      "id": "abdominal ultrasonography"
    },
    {
      "id": "congenital defect of the anterior diaphragm"
    },
    {
      "id": "follicular nature"
    },
    {
      "id": "pendrin"
    },
    {
      "id": "thyroperoxidase"
    },
    {
      "id": "thyroid embryology"
    },
    {
      "id": "over-descent"
    },
    {
      "id": "medial thyroid anlagen derived cells"
    },
    {
      "id": "PAX8"
    },
    {
      "id": "thyroglobulin gene"
    },
    {
      "id": "BRAF mutations"
    },
    {
      "id": "medial thyroid anlage derived cells"
    },
    {
      "id": "Nkx2.1"
    },
    {
      "id": "paired box gene 8"
    },
    {
      "id": "thyroglobulin"
    },
    {
      "id": "heterotopia"
    },
    {
      "id": "work-up"
    },
    {
      "id": "thyroid malignancy"
    },
    {
      "id": "normal follicular cells"
    },
    {
      "id": "CK AE1/AE3"
    },
    {
      "id": "ETTAG pathogenesis"
    },
    {
      "id": "adult females"
    },
    {
      "id": "hNIS"
    },
    {
      "id": "calcitonin"
    },
    {
      "id": "Adrenal Gland"
    },
    {
      "id": "computed tomography images"
    },
    {
      "id": "trachea"
    },
    {
      "id": "nano- and microgram doses"
    },
    {
      "id": "midazolam pharmacokinetics"
    },
    {
      "id": "Area under the plasma concentration-time curve"
    },
    {
      "id": "CYP3A"
    },
    {
      "id": "in vivo method"
    },
    {
      "id": "regular doses"
    },
    {
      "id": "nanogram doses"
    },
    {
      "id": "Midazolam"
    },
    {
      "id": "ketoconazole"
    },
    {
      "id": "midazolam oral clearance"
    },
    {
      "id": "Clinical Pharmacology & Therapeutics"
    },
    {
      "id": "entire range of doses"
    },
    {
      "id": "1,540%"
    },
    {
      "id": "92.8%"
    },
    {
      "id": "advance online publication"
    },
    {
      "id": "20 March 2013"
    },
    {
      "id": "CYP3A inhibitor"
    },
    {
      "id": "four escalating single doses"
    },
    {
      "id": "oral midazolam"
    },
    {
      "id": "healthy participants"
    },
    {
      "id": "CYP3A5 carrier status"
    },
    {
      "id": "CYP3A Probe Substrate"
    },
    {
      "id": "Drug Interactions"
    },
    {
      "id": "Cmax"
    },
    {
      "id": "pharmacokinetics linearity"
    },
    {
      "id": "30,000-fold concentration range"
    },
    {
      "id": "400 mg q.d."
    },
    {
      "id": "doi:10.1038/clpt.2013.27"
    },
    {
      "id": "363%"
    },
    {
      "id": "strong CYP3A inhibitors"
    },
    {
      "id": "0.0001-3 mg"
    },
    {
      "id": "epithelial phenotype"
    },
    {
      "id": "elisidepsin"
    },
    {
      "id": "marine compound"
    },
    {
      "id": "Predictive factors"
    },
    {
      "id": "ErbB1"
    },
    {
      "id": "potent and broad cytotoxic effects"
    },
    {
      "id": "vimentin expression"
    },
    {
      "id": "combination settings"
    },
    {
      "id": "23 cancer cell lines"
    },
    {
      "id": "origin"
    },
    {
      "id": "rapid oncosis"
    },
    {
      "id": "DU-PM cells"
    },
    {
      "id": "acquired resistance"
    },
    {
      "id": "vimentin"
    },
    {
      "id": "Bcl2"
    },
    {
      "id": "Combinations"
    },
    {
      "id": "clinical settings"
    },
    {
      "id": "phase II clinical development"
    },
    {
      "id": "ErbB1-inhibitors"
    },
    {
      "id": "kahalalide f"
    },
    {
      "id": "synergistic effects"
    },
    {
      "id": "elisidepsin cytotoxicity"
    },
    {
      "id": "selected genes"
    },
    {
      "id": "PM02734"
    },
    {
      "id": "ErbB3 signaling pathways"
    },
    {
      "id": "ErbB3-expressing cells"
    },
    {
      "id": "KRAS activating mutations"
    },
    {
      "id": "Kahalalide F family"
    },
    {
      "id": "chemotherapies"
    },
    {
      "id": "KRAS"
    },
    {
      "id": "synthetic marine-derived cyclic peptide"
    },
    {
      "id": "Irvalec"
    },
    {
      "id": "mutational state"
    },
    {
      "id": "Muc1 expression"
    },
    {
      "id": "lapatinib"
    },
    {
      "id": "catheterized rat model"
    },
    {
      "id": "intestinal components of oral bioavailability"
    },
    {
      "id": "in vivo metabolite characterization"
    },
    {
      "id": "administration of [(14)C] AMG 221"
    },
    {
      "id": "hepatic bioavailability (FH)"
    },
    {
      "id": "hepatic first-pass extraction"
    },
    {
      "id": "AMG 221"
    },
    {
      "id": "gut lumen"
    },
    {
      "id": "hepatic components of oral bioavailability"
    },
    {
      "id": "chronic vascular catheters"
    },
    {
      "id": "absorption phase"
    },
    {
      "id": "intestinal extraction"
    },
    {
      "id": "first-pass component of oral bioavailability"
    },
    {
      "id": "hepatic distribution"
    },
    {
      "id": "standard in vivo metabolism studies"
    },
    {
      "id": "components contributing to the oral disposition"
    },
    {
      "id": "intestinal extraction ratios"
    },
    {
      "id": "time points"
    },
    {
      "id": "estimates of hepatic and intestinal contribution to oral bioavailability"
    },
    {
      "id": "preclinical ADME characteristics"
    },
    {
      "id": "hepatic extraction ratios"
    },
    {
      "id": "intestinal first-pass extraction"
    },
    {
      "id": "gut extraction"
    },
    {
      "id": "systemically administered drug"
    },
    {
      "id": "Mass balance data"
    },
    {
      "id": "hepatic extraction"
    },
    {
      "id": "11\u03b2-HSD1 inhibitor"
    },
    {
      "id": "oral dose administration"
    },
    {
      "id": "drug candidate"
    },
    {
      "id": "novel drug candidate"
    },
    {
      "id": "chemical warfare agent"
    },
    {
      "id": "brain nAChR-mediated functions"
    },
    {
      "id": "acetylcholinesterase (AChE) inhibitor"
    },
    {
      "id": "Acetylcholinesterase"
    },
    {
      "id": "large-amplitude EPSCs"
    },
    {
      "id": "EPSCs"
    },
    {
      "id": "rat hippocampal slices"
    },
    {
      "id": "mecamylamine"
    },
    {
      "id": "nAChR-dependent glutamate transmission"
    },
    {
      "id": "neurotoxicological effects"
    },
    {
      "id": "spontaneous glutamate excitatory postsynaptic currents"
    },
    {
      "id": "CA1 stratum radiatum interneurons"
    },
    {
      "id": "nicotinic modulation"
    },
    {
      "id": "acetylcholine (ACh)"
    },
    {
      "id": "inter-event intervals"
    },
    {
      "id": "glutamate inputs"
    },
    {
      "id": "irreversible AChE inhibitor"
    },
    {
      "id": "whole-cell patch-clamp technique"
    },
    {
      "id": "brain nicotinic acetylcholine receptors"
    },
    {
      "id": "reversible AChE inhibitor"
    },
    {
      "id": "burst-like EPSCs"
    },
    {
      "id": "control guinea pigs"
    },
    {
      "id": "infecting virus"
    },
    {
      "id": "mouse vagina"
    },
    {
      "id": "antiherpetic action"
    },
    {
      "id": "plaque reduction assay"
    },
    {
      "id": "CDM"
    },
    {
      "id": "cytokine production"
    },
    {
      "id": "leaf extracts"
    },
    {
      "id": "Melia azedarach L"
    },
    {
      "id": "1-cinnamoyl-3,11-dihydroxymeliacarpin"
    },
    {
      "id": "antiherpetic effect"
    },
    {
      "id": "microbicide"
    },
    {
      "id": "Murine Macrophages"
    },
    {
      "id": "HSV-2"
    },
    {
      "id": "IFN-\u03b3"
    },
    {
      "id": "Meliacine"
    },
    {
      "id": "partially purified extract source"
    },
    {
      "id": "acridine orange staining"
    },
    {
      "id": "therapeutic effect"
    },
    {
      "id": "murine genital herpes"
    },
    {
      "id": "1-Cinnamoyl-3,11-Dihydroxymeliacarpin"
    },
    {
      "id": "Cytokine Production"
    },
    {
      "id": "herpetic infections"
    },
    {
      "id": "HSV infection"
    },
    {
      "id": "bioassay"
    },
    {
      "id": "Herpes Simplex Virus type 2"
    },
    {
      "id": "Vero cells"
    },
    {
      "id": "Copyright"
    },
    {
      "id": "John Wiley & Sons, Ltd."
    },
    {
      "id": "ELISA method"
    },
    {
      "id": "immunomodulatory effect"
    },
    {
      "id": "limonoid"
    },
    {
      "id": "lung cells"
    },
    {
      "id": "CYP3A4 hydroxylation"
    },
    {
      "id": "[M6]"
    },
    {
      "id": "cytochrome P450 3A enzyme-mediated metabolism"
    },
    {
      "id": "BDP"
    },
    {
      "id": "contributions"
    },
    {
      "id": "[M4]"
    },
    {
      "id": "recombinant enzymes"
    },
    {
      "id": "changes"
    },
    {
      "id": "individual differences"
    },
    {
      "id": "glucocorticoid receptor-mediated processes"
    },
    {
      "id": "[M5]"
    },
    {
      "id": "Inhaled glucocorticoids"
    },
    {
      "id": "esterases"
    },
    {
      "id": "microsomes"
    },
    {
      "id": "BDP disposition"
    },
    {
      "id": "Cytochrome P450 3A Enzymes"
    },
    {
      "id": "Beclomethasone Dipropionate"
    },
    {
      "id": "esterase-dependent metabolites"
    },
    {
      "id": "dehydrogenation"
    },
    {
      "id": "[M1]"
    },
    {
      "id": "CYP3A5 mRNA induction"
    },
    {
      "id": "variations"
    },
    {
      "id": "glucocorticoid resistance"
    },
    {
      "id": "[M1-M3]"
    },
    {
      "id": "insensitivity"
    },
    {
      "id": "inactive metabolites"
    },
    {
      "id": "glucocorticoid receptor"
    },
    {
      "id": "A549 lung cells"
    },
    {
      "id": "DPX2 liver cells"
    },
    {
      "id": "fumarate ion"
    },
    {
      "id": "small-amplitude motion"
    },
    {
      "id": "spin-lattice relaxation times"
    },
    {
      "id": "desolvate"
    },
    {
      "id": "relaxation times"
    },
    {
      "id": "MAS"
    },
    {
      "id": "ethanol solvate"
    },
    {
      "id": "pharmaceutical material"
    },
    {
      "id": "activation barriers"
    },
    {
      "id": "(13)C spin-lattice relaxation times"
    },
    {
      "id": "activation parameter"
    },
    {
      "id": "32 kJ mol(-1)"
    },
    {
      "id": "relaxation rate maxima"
    },
    {
      "id": "Jump rates"
    },
    {
      "id": "1D-EXSY"
    },
    {
      "id": "dynamics"
    },
    {
      "id": "desolvates"
    },
    {
      "id": "Exact calculations"
    },
    {
      "id": "motional models"
    },
    {
      "id": "frequency scale"
    },
    {
      "id": "dynamic processes"
    },
    {
      "id": "phenyl ring rotation"
    },
    {
      "id": "Solid-state NMR"
    },
    {
      "id": "methyl group rotational diffusion"
    },
    {
      "id": "solvates"
    },
    {
      "id": "formoterol fumarate"
    },
    {
      "id": "material"
    },
    {
      "id": "magic-angle spinning conditions"
    },
    {
      "id": "100s of MHz"
    },
    {
      "id": "ambient temperature"
    },
    {
      "id": "murine frontal cortex networks"
    },
    {
      "id": "neuroactive substances"
    },
    {
      "id": "\u03c9-agatoxin"
    },
    {
      "id": "spontaneous action potential firing"
    },
    {
      "id": "spontaneous activity"
    },
    {
      "id": "neuronal networks"
    },
    {
      "id": "unit specific responses"
    },
    {
      "id": "spinal cord networks"
    },
    {
      "id": "\u03c9-Agatoxin-IVA"
    },
    {
      "id": "P/Q-type Ca(2+) channel blocker"
    },
    {
      "id": "two clusters"
    },
    {
      "id": "\u03c9-agatoxin exposure"
    },
    {
      "id": "P/Q-type voltage gated Ca(2+) channels"
    },
    {
      "id": "differential responses"
    },
    {
      "id": "\u03c9-agatoxin IVA"
    },
    {
      "id": "bicuculline"
    },
    {
      "id": "single response"
    },
    {
      "id": "action potential firing rate"
    },
    {
      "id": "murine frontal cortex"
    },
    {
      "id": "statistically significant effects"
    },
    {
      "id": "microelectrode arrays (MEAs)"
    },
    {
      "id": "neurotoxin"
    },
    {
      "id": "presynaptic Ca(2+) currents"
    },
    {
      "id": "extracellular action potentials"
    },
    {
      "id": "postsynaptic potentials"
    },
    {
      "id": "inhibitory neuronal populations"
    },
    {
      "id": "network activity"
    },
    {
      "id": "GABAA inhibitor"
    },
    {
      "id": "unique clusters"
    },
    {
      "id": "excitatory neuronal populations"
    },
    {
      "id": "action potential generation"
    },
    {
      "id": "LB-4b"
    },
    {
      "id": "anti-angiogenesis effects"
    },
    {
      "id": "block effects"
    },
    {
      "id": "APN inhibitors"
    },
    {
      "id": "synthetic methods"
    },
    {
      "id": "bestatin"
    },
    {
      "id": "synthetic APN inhibitor"
    },
    {
      "id": "anti-invasion effects"
    },
    {
      "id": "potent synthetic APN inhibitor"
    },
    {
      "id": "high total yield"
    },
    {
      "id": "cancer cell invasion"
    },
    {
      "id": "modification of dopamine levels"
    },
    {
      "id": "Microglia"
    },
    {
      "id": "PQ-treated mice"
    },
    {
      "id": "dopamine turnover"
    },
    {
      "id": "fluorescent-tagged antibodies"
    },
    {
      "id": "degenerating neuronal processes"
    },
    {
      "id": "substantia nigra pars compacta"
    },
    {
      "id": "HVA"
    },
    {
      "id": "paraquat dichloride"
    },
    {
      "id": "25mg/kg/week"
    },
    {
      "id": "concentration of dopamine"
    },
    {
      "id": "neurotoxicity"
    },
    {
      "id": "DOPAC"
    },
    {
      "id": "GFAP immunoreactivity"
    },
    {
      "id": "DOPAC concentrations"
    },
    {
      "id": "chromogenic antibodies"
    },
    {
      "id": "neuronal degeneration"
    },
    {
      "id": "astrocytic response"
    },
    {
      "id": "paraquat"
    },
    {
      "id": "DA concentrations"
    },
    {
      "id": "apparent phenotypic change"
    },
    {
      "id": "male C57BL/6J mice"
    },
    {
      "id": "previous published stereological studies"
    },
    {
      "id": "uptake of silver stain"
    },
    {
      "id": "4 doses"
    },
    {
      "id": "inconsistent stereological evidence"
    },
    {
      "id": "loss of DA neurons"
    },
    {
      "id": "number of TH(+) neurons"
    },
    {
      "id": "reduced immunolabeling"
    },
    {
      "id": "tyrosine-hydroxylase-positive neurons"
    },
    {
      "id": "3,4-dihydroxyphenylacetic acid"
    },
    {
      "id": "microglial response"
    },
    {
      "id": "MPTP-mediated cell death"
    },
    {
      "id": "10mg/kg/week"
    },
    {
      "id": "IBA-1 immunoreactivity"
    },
    {
      "id": "administered dose"
    },
    {
      "id": "loss of TH(+) neurons"
    },
    {
      "id": "neuronal cell death"
    },
    {
      "id": "TH(+) neurons"
    },
    {
      "id": "degenerating neurons"
    },
    {
      "id": "stereological studies"
    },
    {
      "id": "positive control substance"
    },
    {
      "id": "Pharmacokinetic studies"
    },
    {
      "id": "caspase 3 assays"
    },
    {
      "id": "15mg/kg/week"
    },
    {
      "id": "reduction in TH(+) neurons"
    },
    {
      "id": "neurochemical studies"
    },
    {
      "id": "weeks"
    },
    {
      "id": "10mg/kg/dose"
    },
    {
      "id": "neuropathological studies"
    },
    {
      "id": "doses of PQ"
    },
    {
      "id": "suppression function"
    },
    {
      "id": "suppressive function"
    },
    {
      "id": "innovative in vitro HTS assay"
    },
    {
      "id": "640 FDA drugs"
    },
    {
      "id": "novel chemical entities"
    },
    {
      "id": "Treg-based immune therapies"
    },
    {
      "id": "regulatory T cells (Treg)"
    },
    {
      "id": "75 drugs"
    },
    {
      "id": "Treg numbers"
    },
    {
      "id": "GFP signal"
    },
    {
      "id": "Foxp3(+) Treg cells"
    },
    {
      "id": "32 drugs"
    },
    {
      "id": "TGF\u03b2"
    },
    {
      "id": "Treg-promoting drugs"
    },
    {
      "id": "FACS analysis"
    },
    {
      "id": "70 drugs"
    },
    {
      "id": "high throughput screening (HTS) strategies"
    },
    {
      "id": "novel drug candidates"
    },
    {
      "id": "surface and intracellular markers"
    },
    {
      "id": "natural Treg cells"
    },
    {
      "id": "CD4(+) T cells"
    },
    {
      "id": "Foxp3-GFP transgenic mice"
    },
    {
      "id": "clinical application"
    },
    {
      "id": "CD4(+)Foxp3(+) regulatory T cells"
    },
    {
      "id": "immune homeostasis"
    },
    {
      "id": "existing drugs"
    },
    {
      "id": "Treg HTS assay"
    },
    {
      "id": "compound libraries"
    },
    {
      "id": "novel series"
    },
    {
      "id": "ATP-competitive Janus kinase 3 (JAK3) inhibitors"
    },
    {
      "id": "5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers"
    },
    {
      "id": "JAK3 kinase inhibitors"
    },
    {
      "id": "Janus kinase 3"
    },
    {
      "id": "phenyl ether moiety"
    },
    {
      "id": "vector"
    },
    {
      "id": "5H-pyrrolo[2,3-b]pyrazine scaffold"
    },
    {
      "id": "12b"
    },
    {
      "id": "potent JAK3 inhibitors"
    },
    {
      "id": "JAK family"
    },
    {
      "id": "initial leads"
    },
    {
      "id": "compounds 1a"
    },
    {
      "id": "kinase selectivity"
    },
    {
      "id": "JAK3"
    },
    {
      "id": "JAK family selectivity"
    },
    {
      "id": "compounds 1h"
    },
    {
      "id": "12d"
    },
    {
      "id": "Computational and crystallographic analysis"
    },
    {
      "id": "Exploration"
    },
    {
      "id": "series"
    },
    {
      "id": "Discovery"
    },
    {
      "id": "unmodified antibody"
    },
    {
      "id": "gold nanoparticle"
    },
    {
      "id": "interparticle spacing"
    },
    {
      "id": "Particle Size"
    },
    {
      "id": "flexible IgG"
    },
    {
      "id": "small-angle X-ray scattering measurements"
    },
    {
      "id": "equilibrium configuration"
    },
    {
      "id": "IgG"
    },
    {
      "id": "peptide-capped particles"
    },
    {
      "id": "expanded hybrid material"
    },
    {
      "id": "Controlled Assembly"
    },
    {
      "id": "Antibody Recognition"
    },
    {
      "id": "Gold Nanoparticles"
    },
    {
      "id": "assemblies"
    },
    {
      "id": "antibody linker"
    },
    {
      "id": "Fab-Fab angle"
    },
    {
      "id": "sizes"
    },
    {
      "id": "Fab arms"
    },
    {
      "id": "wnk8 mutant"
    },
    {
      "id": "severe salinity"
    },
    {
      "id": "WNKs"
    },
    {
      "id": "plant growth"
    },
    {
      "id": "AtWNK8"
    },
    {
      "id": "hypocotyl"
    },
    {
      "id": "Catalase activity"
    },
    {
      "id": "sorbitol treatment"
    },
    {
      "id": "Peroxidase activity"
    },
    {
      "id": "osmotic stress tolerance"
    },
    {
      "id": "pistil"
    },
    {
      "id": "With no lysine kinases"
    },
    {
      "id": "salt stress tolerance"
    },
    {
      "id": "stamen"
    },
    {
      "id": "Proline content"
    },
    {
      "id": "Proline"
    },
    {
      "id": "Osmotic stresses"
    },
    {
      "id": "NaCl treatment"
    },
    {
      "id": "primary root"
    },
    {
      "id": "2'-aminoanilides"
    },
    {
      "id": "tert-butylcarbamate group"
    },
    {
      "id": "tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors"
    },
    {
      "id": "Apoptosis Induction"
    },
    {
      "id": "colony-forming potential"
    },
    {
      "id": "Cancer Cells"
    },
    {
      "id": "HDAC"
    },
    {
      "id": "pyrrole-based hydroxamates"
    },
    {
      "id": "histone H3 acetylation"
    },
    {
      "id": "HT29 cancer cells"
    },
    {
      "id": "Compound 10c"
    },
    {
      "id": "HDAC6"
    },
    {
      "id": "neuroblastoma LAN-5 cells"
    },
    {
      "id": "Cytodifferentiation"
    },
    {
      "id": "Antiproliferative Activities"
    },
    {
      "id": "benzene-based hydroxamates"
    },
    {
      "id": "acetyl-\u03b1-tubulin levels"
    },
    {
      "id": "human acute myeloid leukemia U937 cells"
    },
    {
      "id": "Compound 8b"
    },
    {
      "id": "hydroxamates"
    },
    {
      "id": "colon HCT116"
    },
    {
      "id": "SAHA"
    },
    {
      "id": "chronic myeloid leukemia K562 cells"
    },
    {
      "id": "pyrrole anilide 9c"
    },
    {
      "id": "cytodifferentiating effect"
    },
    {
      "id": "lung H1299"
    },
    {
      "id": "steatohepatitis"
    },
    {
      "id": "6 weeks"
    },
    {
      "id": "Blood"
    },
    {
      "id": "ferritins"
    },
    {
      "id": "non-alcoholic fatty liver disease"
    },
    {
      "id": "transferrin receptor 1 and 2"
    },
    {
      "id": "Experiment 1"
    },
    {
      "id": "Experiment 2"
    },
    {
      "id": "CIE"
    },
    {
      "id": "HE"
    },
    {
      "id": "hepcidin"
    },
    {
      "id": "carbonyl iron"
    },
    {
      "id": "22.4mg/day"
    },
    {
      "id": "Phlebotomy"
    },
    {
      "id": "serum transaminase"
    },
    {
      "id": "EZETIMIBE"
    },
    {
      "id": "HEPATIC IRON LEVELS"
    },
    {
      "id": "C"
    },
    {
      "id": "ferritinH"
    },
    {
      "id": "hepatic iron uptake transporter expression"
    },
    {
      "id": "HIE"
    },
    {
      "id": "hepatic iron concentrations"
    },
    {
      "id": "ferritinL"
    },
    {
      "id": "dietary iron restriction"
    },
    {
      "id": "MICE"
    },
    {
      "id": "HIGH-FAT DIET"
    },
    {
      "id": "0.3mg/day"
    },
    {
      "id": "hephaestin"
    },
    {
      "id": "DMT1"
    },
    {
      "id": "iron metabolism"
    },
    {
      "id": "ATO"
    },
    {
      "id": "Notch signaling blockade"
    },
    {
      "id": "repopulation"
    },
    {
      "id": "neurosphere"
    },
    {
      "id": "downregulation"
    },
    {
      "id": "Notch pathway"
    },
    {
      "id": "CSLCs"
    },
    {
      "id": "glioblastoma proliferation"
    },
    {
      "id": "neurosphere recovery"
    },
    {
      "id": "neurosphere recovery assay"
    },
    {
      "id": "neurosphere formation"
    },
    {
      "id": "Arsenic trioxide"
    },
    {
      "id": "Notch signaling"
    },
    {
      "id": "cancer stem-like cells"
    },
    {
      "id": "AKT"
    },
    {
      "id": "ATO treatment"
    },
    {
      "id": "glioblastoma cell lines"
    },
    {
      "id": "STAT3"
    },
    {
      "id": "GBM"
    },
    {
      "id": "secondary neurosphere formation"
    },
    {
      "id": "glioblastoma multiforme"
    },
    {
      "id": "glioblastoma"
    },
    {
      "id": "rat bone marrow mesenchymal stem cells"
    },
    {
      "id": "tPNS"
    },
    {
      "id": "Kdr"
    },
    {
      "id": "rBMSCs"
    },
    {
      "id": "endothelial-like cells"
    },
    {
      "id": "Flt-1"
    },
    {
      "id": "implantation"
    },
    {
      "id": "Total saponins of Panax notoginseng"
    },
    {
      "id": "angiogenesis ability"
    },
    {
      "id": "Matrigel model"
    },
    {
      "id": "capillary network forming"
    },
    {
      "id": "relative receptors signals"
    },
    {
      "id": "VEGF-A"
    },
    {
      "id": "vitro"
    },
    {
      "id": "main constituents"
    },
    {
      "id": "Panax Notoginseng"
    },
    {
      "id": "traditional Chinese medicine"
    },
    {
      "id": "AIMS OF THE STUDY"
    },
    {
      "id": "MAP3K5 expression"
    },
    {
      "id": "high fetal hemoglobin (HbF)"
    },
    {
      "id": "disease severity"
    },
    {
      "id": "\u03b2-hemoglobinopathy patients"
    },
    {
      "id": "PDE7B variant"
    },
    {
      "id": "severe disease phenotype"
    },
    {
      "id": "genetic variations"
    },
    {
      "id": "\u03b2-thalassemia disease severity"
    },
    {
      "id": "intronic MAP3K5 gene variants"
    },
    {
      "id": "low HbF levels"
    },
    {
      "id": "MAP3K5 mRNA expression levels"
    },
    {
      "id": "compound heterozygous sickle cell disease/\u03b2-thalassemia patients"
    },
    {
      "id": "erythroid progenitor cells"
    },
    {
      "id": "KLF1 haploinsufficient individuals"
    },
    {
      "id": "response to HU treatment"
    },
    {
      "id": "MAP3K5"
    },
    {
      "id": "chromosome 6q23"
    },
    {
      "id": "hydroxyurea treatment efficacy"
    },
    {
      "id": "short tandem repeat"
    },
    {
      "id": "MAP3K5 promoter"
    },
    {
      "id": "HU treatment efficacy"
    },
    {
      "id": "HU treatment"
    },
    {
      "id": "MAP3K5 gene"
    },
    {
      "id": "PDE7B genes"
    },
    {
      "id": "HbF augmentation treatment"
    },
    {
      "id": "HTS campaign"
    },
    {
      "id": "M5 PAMs"
    },
    {
      "id": "VU0467903"
    },
    {
      "id": "ML326"
    },
    {
      "id": "phenethyl ether linkage"
    },
    {
      "id": "ML129/ML172 cores"
    },
    {
      "id": "M1-M4 EC50s"
    },
    {
      "id": "ML129"
    },
    {
      "id": "MLPCN probes"
    },
    {
      "id": "human M5 EC50s"
    },
    {
      "id": "M5 PAM"
    },
    {
      "id": "isatin core"
    },
    {
      "id": "southern phenethyl ether linkage"
    },
    {
      "id": "rat M5 EC50s"
    },
    {
      "id": "M5 EC50"
    },
    {
      "id": "ACh CRC"
    },
    {
      "id": "ML172"
    },
    {
      "id": "RXFP2 mRNA"
    },
    {
      "id": "TIC"
    },
    {
      "id": "INSL3 mRNA"
    },
    {
      "id": "luteinization"
    },
    {
      "id": "preovulatory LH surge"
    },
    {
      "id": "INSL3"
    },
    {
      "id": "LH surge"
    },
    {
      "id": "developing bovine antral follicles"
    },
    {
      "id": "In situ hybridization"
    },
    {
      "id": "CYP11A1"
    },
    {
      "id": "theca-derived INSL3"
    },
    {
      "id": "dominant preovulatory follicle"
    },
    {
      "id": "RXFP2"
    },
    {
      "id": "Insulin-Like Peptide 3"
    },
    {
      "id": "testicular Leydig cells"
    },
    {
      "id": "peripheral blood"
    },
    {
      "id": "granulosa cell"
    },
    {
      "id": "9- to 10-mm follicles"
    },
    {
      "id": "luteolysis"
    },
    {
      "id": "STAR"
    },
    {
      "id": "follicle maturation"
    },
    {
      "id": "Circulating INSL3 Levels"
    },
    {
      "id": "Synchronized Estrous Cycles"
    },
    {
      "id": "progesterone secretion"
    },
    {
      "id": "CL function"
    },
    {
      "id": "INSL3 protein"
    },
    {
      "id": "plasma INSL3"
    },
    {
      "id": "Ovary"
    },
    {
      "id": "CL"
    },
    {
      "id": "theca interna cell"
    },
    {
      "id": "estradiol-17\u03b2"
    },
    {
      "id": "TIC function"
    },
    {
      "id": "Corpora Lutea"
    },
    {
      "id": "Development"
    },
    {
      "id": "Bovine Antral Follicles"
    },
    {
      "id": "cattle"
    },
    {
      "id": "follicular TIC"
    },
    {
      "id": "INSL3 action"
    },
    {
      "id": "large (11-18 mm) estrogen-active follicles"
    },
    {
      "id": "INSL3 production"
    },
    {
      "id": "Z-stereoisomer 1"
    },
    {
      "id": "2,3,5,7-tetramethoxyphenanthrene (5)"
    },
    {
      "id": "PMA-induced HL-60 cells"
    },
    {
      "id": "HL-60 cells"
    },
    {
      "id": "(Z)- and (E)-3,4,3',5'-Tetramethoxystilbene"
    },
    {
      "id": "Cancer-Related Signaling"
    },
    {
      "id": "(Z)-3,4,3',5'-tetramethoxystilbene (1)"
    },
    {
      "id": "solid tumor cells"
    },
    {
      "id": "(E)-3,4,3',5'-tetramethoxystilbene (2)"
    },
    {
      "id": "NF-\u03baB signaling"
    },
    {
      "id": "Ap-1"
    },
    {
      "id": "time-dependent photoisomerization"
    },
    {
      "id": "E-isomer (2)"
    },
    {
      "id": "Bioassay-guided fractionation"
    },
    {
      "id": "stilbenes"
    },
    {
      "id": "cervical carcinomas"
    },
    {
      "id": "Modulation"
    },
    {
      "id": "PMA"
    },
    {
      "id": "(E)-3,5,4'-trimethoxystilbene (3)"
    },
    {
      "id": "skin melanoma"
    },
    {
      "id": "breast carcinomas"
    },
    {
      "id": "1D- and 2D-NMR spectroscopy"
    },
    {
      "id": "myc"
    },
    {
      "id": "Cytotoxicity"
    },
    {
      "id": "luciferase reporter gene assays"
    },
    {
      "id": "leaves of Eugenia rigida"
    },
    {
      "id": "Stat3"
    },
    {
      "id": "Eugenia rigida"
    },
    {
      "id": "Ets"
    },
    {
      "id": "cervical carcinoma"
    },
    {
      "id": "HRESIMS"
    },
    {
      "id": "Notch"
    },
    {
      "id": "skin melanoma cells"
    },
    {
      "id": "UHPLC/APCI-MS"
    },
    {
      "id": "epidermal carcinomas"
    },
    {
      "id": "Smad3/4"
    },
    {
      "id": "human leukemia cells"
    },
    {
      "id": "reproductive competence"
    },
    {
      "id": "male rats"
    },
    {
      "id": "impairment"
    },
    {
      "id": "Androgen deprivation"
    },
    {
      "id": "pre-puberty"
    },
    {
      "id": "premature antiandrogen exposure"
    },
    {
      "id": "proteins expression"
    },
    {
      "id": "pubertal rat epididymis"
    },
    {
      "id": "epididymis histology"
    },
    {
      "id": "fertility capacity"
    },
    {
      "id": "histological organization"
    },
    {
      "id": "adult rat epididymis"
    },
    {
      "id": "PND75"
    },
    {
      "id": "puberty"
    },
    {
      "id": "specific proteins"
    },
    {
      "id": "Rab11A"
    },
    {
      "id": "molecular mechanisms"
    },
    {
      "id": "PND21"
    },
    {
      "id": "PND50"
    },
    {
      "id": "epididymis"
    },
    {
      "id": "sexually immature rats"
    },
    {
      "id": "precocious hormonal injury"
    },
    {
      "id": "experimental testosterone deprivation"
    },
    {
      "id": "immature animals"
    },
    {
      "id": "impaired epididymal function"
    },
    {
      "id": "epididymal tissue"
    },
    {
      "id": "PND44"
    },
    {
      "id": "peripuberty"
    },
    {
      "id": "testosterone"
    },
    {
      "id": "hepatic mRNA expressions"
    },
    {
      "id": "SREBP1C"
    },
    {
      "id": "fisetin supplementation"
    },
    {
      "id": "hepatic lipogenesis"
    },
    {
      "id": "SCD-1 genes"
    },
    {
      "id": "triglyceride (TG)"
    },
    {
      "id": "high fat diet group"
    },
    {
      "id": "hepatic TG content"
    },
    {
      "id": "high fat diet"
    },
    {
      "id": "Fisetin supplementation"
    },
    {
      "id": "hepatic steatosis"
    },
    {
      "id": "circulating glucose concentrations"
    },
    {
      "id": "gluconeogenesis"
    },
    {
      "id": "HF diet"
    },
    {
      "id": "epididymal mRNA abundance"
    },
    {
      "id": "GLUT4"
    },
    {
      "id": "hepatic mRNA abundance"
    },
    {
      "id": "ATPCL"
    },
    {
      "id": "glucose concentrations"
    },
    {
      "id": "PPAR\u03b3"
    },
    {
      "id": "fisetin"
    },
    {
      "id": "G6Pase"
    },
    {
      "id": "GLUT4 expression"
    },
    {
      "id": "FAS"
    },
    {
      "id": "glucose metabolism"
    },
    {
      "id": "differentiated 3T3-L1 adipocytes"
    },
    {
      "id": "loss of function approach"
    },
    {
      "id": "IECs"
    },
    {
      "id": "Loss of AnxA2"
    },
    {
      "id": "IEC migration"
    },
    {
      "id": "dynamics of \u03b21 integrin"
    },
    {
      "id": "wound closure"
    },
    {
      "id": "Annexin A2"
    },
    {
      "id": "membrane associated, Actin binding protein"
    },
    {
      "id": "\u03b21 integrin internalization"
    },
    {
      "id": "intestinal epithelial cells"
    },
    {
      "id": "barrier"
    },
    {
      "id": "underlying tissue compartment"
    },
    {
      "id": "gastrointestinal epithelium"
    },
    {
      "id": "cell-matrix adhesion"
    },
    {
      "id": "AnxA2"
    },
    {
      "id": "internalization of cell surface \u03b21 integrin"
    },
    {
      "id": "cell migration"
    },
    {
      "id": "\u03b21 integrin protein"
    },
    {
      "id": "cell-matrix adhesive properties"
    },
    {
      "id": "cell surface \u03b21 integrin"
    },
    {
      "id": "luminal contents"
    },
    {
      "id": "intestinal epithelial cell migration"
    },
    {
      "id": "pulse-chase biotinylation experiments"
    },
    {
      "id": "functional effects"
    },
    {
      "id": "Mucosal wounds"
    },
    {
      "id": "epithelial barrier"
    },
    {
      "id": "AnxA2 specific shRNA"
    },
    {
      "id": "down-regulation of AnxA2"
    },
    {
      "id": "migrating IECs"
    },
    {
      "id": "mucosal homeostasis"
    },
    {
      "id": "IEC movement"
    },
    {
      "id": "active turnover of cell-matrix associations"
    },
    {
      "id": "forward cell movement"
    },
    {
      "id": "dynamic turnover of integrin based adhesions"
    },
    {
      "id": "host age"
    },
    {
      "id": "Low-grade inflammation"
    },
    {
      "id": "Visceral Adiposity"
    },
    {
      "id": "metabolic phenotype"
    },
    {
      "id": "T-bet-deficient hosts"
    },
    {
      "id": "adoptive transfer"
    },
    {
      "id": "T-bet-deficient CD4(+) T cells"
    },
    {
      "id": "wild-type CD4(+) T cells"
    },
    {
      "id": "visceral fat"
    },
    {
      "id": "T-bet"
    },
    {
      "id": "Insulin Sensitivity"
    },
    {
      "id": "T-bet(-/-)xRag2(-/-) mice"
    },
    {
      "id": "adaptive immunity"
    },
    {
      "id": "metabolic physiology"
    },
    {
      "id": "immune cell numbers"
    },
    {
      "id": "young T-bet(-/-) mice"
    },
    {
      "id": "Rag2(-/-) mice"
    },
    {
      "id": "Immune Cell Transcription Factor"
    },
    {
      "id": "T-bet expression"
    },
    {
      "id": "adaptive immune system"
    },
    {
      "id": "cytokine secretion"
    },
    {
      "id": "fat"
    },
    {
      "id": "visceral adipose tissue"
    },
    {
      "id": "host glucose homeostasis"
    },
    {
      "id": "energy expenditure"
    },
    {
      "id": "obesity-associated insulin resistance"
    },
    {
      "id": "Chinese patients"
    },
    {
      "id": "rs351855G/A"
    },
    {
      "id": "chemotherapy response"
    },
    {
      "id": "NSCLC"
    },
    {
      "id": "AA genotype"
    },
    {
      "id": "21.1 months"
    },
    {
      "id": "chemotherapy effect"
    },
    {
      "id": "SPSS software"
    },
    {
      "id": "responders"
    },
    {
      "id": "Three polymorphisms"
    },
    {
      "id": "non-responders"
    },
    {
      "id": "version 16.0"
    },
    {
      "id": "AA carrier"
    },
    {
      "id": "rs145302848C/G"
    },
    {
      "id": "genotype frequencies"
    },
    {
      "id": "G genotype"
    },
    {
      "id": "platinum-based chemotherapy"
    },
    {
      "id": "629 patients"
    },
    {
      "id": "Stage IV NSCLC"
    },
    {
      "id": "Stage III (A+B) NSCLC"
    },
    {
      "id": "occurrence"
    },
    {
      "id": "729 age- and gender-matched healthy controls"
    },
    {
      "id": "smoking habits"
    },
    {
      "id": "FGFR4 genetic polymorphisms"
    },
    {
      "id": "FGFR4 gene"
    },
    {
      "id": "A-allele"
    },
    {
      "id": "GG+GA genotype"
    },
    {
      "id": "16.5 months"
    },
    {
      "id": "rs147603016G/A"
    },
    {
      "id": "GA genotype carriers"
    },
    {
      "id": "GG genotype carriers"
    },
    {
      "id": "Con A-sandwiched microstructures"
    },
    {
      "id": "tag particles"
    },
    {
      "id": "functionalized magnetic particles"
    },
    {
      "id": "Tandem assays"
    },
    {
      "id": "Ag@SiO2 tag particles"
    },
    {
      "id": "Tandem Assays"
    },
    {
      "id": "mannose-functionalized Fe3 O4 @SiO2"
    },
    {
      "id": "SiO2"
    },
    {
      "id": "biomaterials"
    },
    {
      "id": "Functionalized Core/Shell Particles"
    },
    {
      "id": "Magnetic Separation"
    },
    {
      "id": "Fe3 O4"
    },
    {
      "id": "tandem assay"
    },
    {
      "id": "Protein"
    },
    {
      "id": "Surface-Enhanced Raman Scattering"
    },
    {
      "id": "Ag"
    },
    {
      "id": "Sandcastle Worm"
    },
    {
      "id": "Multipart Copolyelectrolyte Adhesive"
    },
    {
      "id": "Tube-building sabellariid polychaetes"
    },
    {
      "id": "geology"
    },
    {
      "id": "Co-secretion"
    },
    {
      "id": "Catechol Oxidase"
    },
    {
      "id": "ecology"
    },
    {
      "id": "shorelines"
    },
    {
      "id": "active cue"
    },
    {
      "id": "fully cured glue"
    },
    {
      "id": "polyphosphoproteins"
    },
    {
      "id": "divalent cations"
    },
    {
      "id": "Distinct sets"
    },
    {
      "id": "oppositely charged components"
    },
    {
      "id": "polycationic Pc2 proteins"
    },
    {
      "id": "major components"
    },
    {
      "id": "granules"
    },
    {
      "id": "Phragmatopoma californica"
    },
    {
      "id": "Pc3A/B"
    },
    {
      "id": "conspecific larval settlement"
    },
    {
      "id": "oxidative cross-linking"
    },
    {
      "id": "sabellariid worms"
    },
    {
      "id": "multipart polyelectrolytic adhesive"
    },
    {
      "id": "tubular shells"
    },
    {
      "id": "Curing"
    },
    {
      "id": "Peptidyl-DOPA"
    },
    {
      "id": "mineral particles"
    },
    {
      "id": "counter-polyanion"
    },
    {
      "id": "Pc1"
    },
    {
      "id": "polycationic Pc1 proteins"
    },
    {
      "id": "Heterogeneous granules"
    },
    {
      "id": "western coast of North America"
    },
    {
      "id": "Fewkes"
    },
    {
      "id": "Pc2"
    },
    {
      "id": "concentrated granules"
    },
    {
      "id": "Homogeneous granules"
    },
    {
      "id": "sulfated macromolecules"
    },
    {
      "id": "L-DOPA"
    },
    {
      "id": "rapid and spatially homogeneous curing"
    },
    {
      "id": "preassembled adhesive packets"
    },
    {
      "id": "separate cell types"
    },
    {
      "id": "DICO"
    },
    {
      "id": "human hepatoma cells"
    },
    {
      "id": "G2/M cell cycle arrest"
    },
    {
      "id": "p-cdc25c"
    },
    {
      "id": "cyclin A"
    },
    {
      "id": "Western blot assay"
    },
    {
      "id": "Bax"
    },
    {
      "id": "nonaromatic B-ring flavonoid"
    },
    {
      "id": "ROS-mediated mitochondrial pathway"
    },
    {
      "id": "p-CDK1"
    },
    {
      "id": "cyclin B1"
    },
    {
      "id": "Macrothelypteris torresiana"
    },
    {
      "id": "antineoplastic mechanism"
    },
    {
      "id": "alkaline phosphatase activity"
    },
    {
      "id": "bone development"
    },
    {
      "id": "RunX2"
    },
    {
      "id": "osteoprotegerin"
    },
    {
      "id": "prominent markers for differentiation of osteoblast"
    },
    {
      "id": "mouse bone marrow mesenchymal stem cells (BMMSCs)"
    },
    {
      "id": "osteocalcin"
    },
    {
      "id": "osterix"
    },
    {
      "id": "vegetables"
    },
    {
      "id": "osteoblast specific differentiation activities"
    },
    {
      "id": "osteodegenerative disorders"
    },
    {
      "id": "afferent arteriole (Ra)"
    },
    {
      "id": "serum thyrotropin levels"
    },
    {
      "id": "intrarenal hemodynamic parameters"
    },
    {
      "id": "glomerular filtration rate (GFR)"
    },
    {
      "id": "creatinine metabolism"
    },
    {
      "id": "sodium-replete state"
    },
    {
      "id": "Serum thyroid stimulating hormone (TSH)"
    },
    {
      "id": "multiple regression analysis"
    },
    {
      "id": "renal plasma flow (RPF)"
    },
    {
      "id": "Thyroid hormone"
    },
    {
      "id": "serum creatinine"
    },
    {
      "id": "thyroid disease"
    },
    {
      "id": "Renal hemodynamics"
    },
    {
      "id": "Gomez`s formulae"
    },
    {
      "id": "Low thyroid function"
    },
    {
      "id": "mean blood pressure"
    },
    {
      "id": "vascular resistance"
    },
    {
      "id": "glomerular hemodynamics"
    },
    {
      "id": "efferent arteriole (Re)"
    },
    {
      "id": "plasma clearance"
    },
    {
      "id": "para-aminohippurate (CPAH)"
    },
    {
      "id": "normal range (0.69-4.30 \u03bcIU/ml)"
    },
    {
      "id": "renal blood flow (RBF)"
    },
    {
      "id": "inulin (Cin)"
    },
    {
      "id": "antihypertensive treatment"
    },
    {
      "id": "Sardinian wine extracts"
    },
    {
      "id": "intestinal inflammation"
    },
    {
      "id": "Cannonau red wine extract"
    },
    {
      "id": "phenolic fraction"
    },
    {
      "id": "dietary oxysterols"
    },
    {
      "id": "interleukin synthesis"
    },
    {
      "id": "phenolics"
    },
    {
      "id": "oxysterol-dependent ROS production"
    },
    {
      "id": "Cholesterol auto-oxidation products"
    },
    {
      "id": "pro-inflammatory effect"
    },
    {
      "id": "red-ox equilibrium"
    },
    {
      "id": "typical grape varieties"
    },
    {
      "id": "Sardinia"
    },
    {
      "id": "Phenolic compounds"
    },
    {
      "id": "red wine"
    },
    {
      "id": "Oxysterol-dependent NOX1 activation"
    },
    {
      "id": "Vermentino white wine extract"
    },
    {
      "id": "mixture of oxysterols"
    },
    {
      "id": "phenolic extracts"
    },
    {
      "id": "NOX1"
    },
    {
      "id": "colonic NADPH-oxidase NOX1"
    },
    {
      "id": "inflammatory interleukins"
    },
    {
      "id": "oxysterol-related NOX1 induction"
    },
    {
      "id": "CaCo-2 cell pre-incubation"
    },
    {
      "id": "wines"
    },
    {
      "id": "differentiated CaCo-2 colonic epithelial cells"
    },
    {
      "id": "pro-inflammatory events"
    },
    {
      "id": "cholesterol-rich foods"
    },
    {
      "id": "pro-oxidant events"
    },
    {
      "id": "intestinal mucosal damage"
    },
    {
      "id": "NOX1 down-regulation"
    },
    {
      "id": "IL-8"
    },
    {
      "id": "cytokine-modulating therapeutic proteins"
    },
    {
      "id": "BMT patients"
    },
    {
      "id": "500 pg/ml"
    },
    {
      "id": "Physiologically-Based Pharmacokinetic Modelling Approach"
    },
    {
      "id": "Disease-Drug Interactions"
    },
    {
      "id": "100 pg/mL"
    },
    {
      "id": "cyclosporine AUC"
    },
    {
      "id": "observed data"
    },
    {
      "id": "physiologically-based pharmacokinetic model"
    },
    {
      "id": "accepted article preview"
    },
    {
      "id": "10 April 2013"
    },
    {
      "id": "Suppression"
    },
    {
      "id": "TP-DDI"
    },
    {
      "id": "simvastatin AUC"
    },
    {
      "id": "virtual rheumatoid arthritis patients"
    },
    {
      "id": "TP"
    },
    {
      "id": "CYP3A4 substrates"
    },
    {
      "id": "magnitude of interaction"
    },
    {
      "id": "~3-fold"
    },
    {
      "id": "cytokine levels"
    },
    {
      "id": "doi:10.1038/clpt.2013.79"
    },
    {
      "id": "TP-DDI risk"
    },
    {
      "id": "CYPs"
    },
    {
      "id": "pathophysiological factors"
    },
    {
      "id": "clinical data"
    },
    {
      "id": "therapeutic protein-drug drug interactions"
    },
    {
      "id": "triggered release"
    },
    {
      "id": "hydrophilic model compound"
    },
    {
      "id": "stimuli-responsive nanoparticles"
    },
    {
      "id": "PW-HIFU exposure"
    },
    {
      "id": "temperatures"
    },
    {
      "id": "polydispersity index (PDI)"
    },
    {
      "id": "liposomes"
    },
    {
      "id": "shear forces"
    },
    {
      "id": "reversible liposome destabilization"
    },
    {
      "id": "formulations"
    },
    {
      "id": "local drug delivery"
    },
    {
      "id": "high-intensity focused ultrasound (HIFU)"
    },
    {
      "id": "inertial cavitation"
    },
    {
      "id": "new mechanism"
    },
    {
      "id": "HIFU-triggered release"
    },
    {
      "id": "fluorescein"
    },
    {
      "id": "thermosensitive liposomes (TSL)"
    },
    {
      "id": "phospholipid bilayer"
    },
    {
      "id": "fluorescein release"
    },
    {
      "id": "Nile red"
    },
    {
      "id": "lipophilic model compound"
    },
    {
      "id": "non-thermosensitive liposomes (NTSL)"
    },
    {
      "id": "release mechanism"
    },
    {
      "id": "lipophilic compounds"
    },
    {
      "id": "radiation force-induced acoustic streaming"
    },
    {
      "id": "main mechanism"
    },
    {
      "id": "mean liposome size"
    },
    {
      "id": "CW-HIFU exposure"
    },
    {
      "id": "temperature elevation"
    },
    {
      "id": "NR release"
    },
    {
      "id": "pulsed wave (PW)-HIFU"
    },
    {
      "id": "continuous wave- (CW)-HIFU"
    },
    {
      "id": "Tm"
    },
    {
      "id": "microbubbles"
    },
    {
      "id": "Dynamic light scattering analysis"
    },
    {
      "id": "walls"
    },
    {
      "id": "exposure chamber"
    },
    {
      "id": "cavitation"
    },
    {
      "id": "loaded amount"
    },
    {
      "id": "hydrophilic compounds"
    },
    {
      "id": "Nrf2-Keap1 axis"
    },
    {
      "id": "Nrf2"
    },
    {
      "id": "Arsenic"
    },
    {
      "id": "arsenic toxicity"
    },
    {
      "id": "p62"
    },
    {
      "id": "LC3"
    },
    {
      "id": "tert-butylhydroquinone"
    },
    {
      "id": "sulforaphane"
    },
    {
      "id": "autophagy dysfunction"
    },
    {
      "id": "Keap1-C151"
    },
    {
      "id": "cancer-promoting function"
    },
    {
      "id": "Nrf2-Keap1 pathway"
    },
    {
      "id": "Keap1"
    },
    {
      "id": "autophagosomes"
    },
    {
      "id": "autophagic pathway"
    },
    {
      "id": "C101"
    },
    {
      "id": "single step"
    },
    {
      "id": "C101-NO"
    },
    {
      "id": "C47-NO"
    },
    {
      "id": "post-translational control"
    },
    {
      "id": "GSTP1-1"
    },
    {
      "id": "human glutathione transferase (GST) P1-1"
    },
    {
      "id": "steric hindrance"
    },
    {
      "id": "dimer interface"
    },
    {
      "id": "Kinetics experiments"
    },
    {
      "id": "long term nitric oxide storage"
    },
    {
      "id": "S-nitrosation"
    },
    {
      "id": "cellular oxidative stress"
    },
    {
      "id": "first report"
    },
    {
      "id": "detoxification enzyme"
    },
    {
      "id": "nitrosation experiments"
    },
    {
      "id": "GSNO binding"
    },
    {
      "id": "denitrosation"
    },
    {
      "id": "helix \u03b12"
    },
    {
      "id": "process of protein transnitrosation"
    },
    {
      "id": "dynamic active-site helix"
    },
    {
      "id": "chemical step"
    },
    {
      "id": "pre-equilibrium"
    },
    {
      "id": "cellular reductant"
    },
    {
      "id": "minimal mechanism"
    },
    {
      "id": "spontaneous GSNO-mediated transnitrosation"
    },
    {
      "id": "open and closed conformations"
    },
    {
      "id": "transfer"
    },
    {
      "id": "negative cooperativity"
    },
    {
      "id": "transient kinetic methods"
    },
    {
      "id": "C47"
    },
    {
      "id": "CysNO"
    },
    {
      "id": "spontaneous protein transnitrosation"
    },
    {
      "id": "GSNO binding site"
    },
    {
      "id": "post-translational modification"
    },
    {
      "id": "protein cysteine residues"
    },
    {
      "id": "physiologically important processes"
    },
    {
      "id": "protein regulation"
    },
    {
      "id": "glutathione transferase P1-1"
    },
    {
      "id": "systemic cilostazol treatment"
    },
    {
      "id": "retinal ischemia"
    },
    {
      "id": "management"
    },
    {
      "id": "diabetic retinal vascular dysfunction"
    },
    {
      "id": "RGCs"
    },
    {
      "id": "Retinal Ganglion Cell damage"
    },
    {
      "id": "Diabetic Rats"
    },
    {
      "id": "diabetic complications"
    },
    {
      "id": "Otsuka Long-Evans Tokushima Fatty (OLETF) rats"
    },
    {
      "id": "0.9 % saline solution"
    },
    {
      "id": "GFAP"
    },
    {
      "id": "Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNLEL) staining"
    },
    {
      "id": "RGC layer"
    },
    {
      "id": "OLETF rats"
    },
    {
      "id": "immunofluorescence staining"
    },
    {
      "id": "vertical sections"
    },
    {
      "id": "retinal ganglion cell death"
    },
    {
      "id": "diabetic retina"
    },
    {
      "id": "ramified pattern"
    },
    {
      "id": "cilostazol treatment"
    },
    {
      "id": "Neuroprotective Effects"
    },
    {
      "id": "Neurodegeneration"
    },
    {
      "id": "diabetic retinopathy"
    },
    {
      "id": "whole-mount retinas"
    },
    {
      "id": "TUNEL-positive cells"
    },
    {
      "id": "outer plexiform layer"
    },
    {
      "id": "LETO rats"
    },
    {
      "id": "Long-Evans Tokushima Otsuka (LETO) rats"
    },
    {
      "id": "30mg/kg"
    },
    {
      "id": "ganglion cell layer"
    },
    {
      "id": "retinal ganglion cell (RGC) death"
    },
    {
      "id": "nondiabetic controls"
    },
    {
      "id": "doi:10.1038/clpt.2013.69"
    },
    {
      "id": "homozygous carriers of C29R"
    },
    {
      "id": "609\u2009\u00b1\u2009152 pmol 5-FU min(-1) mg(-1)"
    },
    {
      "id": "aggressive cancers"
    },
    {
      "id": "noncarriers"
    },
    {
      "id": "activity levels"
    },
    {
      "id": "DPD"
    },
    {
      "id": "genetic associations"
    },
    {
      "id": "European-American volunteers"
    },
    {
      "id": "P = 0.00029"
    },
    {
      "id": "circulating mononuclear-cell DPD enzyme activity"
    },
    {
      "id": "DPYD-Y186C variant"
    },
    {
      "id": "Individuals of African Ancestry"
    },
    {
      "id": "African Americans"
    },
    {
      "id": "Y186C"
    },
    {
      "id": "carriers"
    },
    {
      "id": "279\u2009\u00b1\u200935 pmol 5-FU min(-1) mg(-1)"
    },
    {
      "id": "responses to 5-FU"
    },
    {
      "id": "reduced DPD activity"
    },
    {
      "id": "P = 0.013"
    },
    {
      "id": "racial groups"
    },
    {
      "id": "enzyme dihydropyrimidine dehydrogenase"
    },
    {
      "id": "DPYD gene"
    },
    {
      "id": "1 May 2013"
    },
    {
      "id": "African-American cohort"
    },
    {
      "id": "Y186C carriers"
    },
    {
      "id": "480\u2009\u00b1\u2009152 pmol 5-FU min(-1) mg(-1)"
    },
    {
      "id": "African-American volunteers"
    },
    {
      "id": "514\u2009\u00b1\u2009168 pmol 5-FU min(-1) mg(-1)"
    },
    {
      "id": "DPYD variations"
    },
    {
      "id": "5-Fluorouracil"
    },
    {
      "id": "antinociceptive action"
    },
    {
      "id": "acute pain"
    },
    {
      "id": "capsaicin-activated currents"
    },
    {
      "id": "patch-clamp recordings"
    },
    {
      "id": "Ph\u03b11\u03b2"
    },
    {
      "id": "capsaicin-induced Ca(2+) transients"
    },
    {
      "id": "nociceptive behavior"
    },
    {
      "id": "MVIIA"
    },
    {
      "id": "SB366791"
    },
    {
      "id": "rat model of spontaneous pain"
    },
    {
      "id": "capsaicin"
    },
    {
      "id": "Ca(2+) transients"
    },
    {
      "id": "venom"
    },
    {
      "id": "Ph\u03b11\u03b2 toxin"
    },
    {
      "id": "ziconotide"
    },
    {
      "id": "nocifensive behavior"
    },
    {
      "id": "\u03c9-conotoxin MVIIA"
    },
    {
      "id": "N-type Ca(2+) channel blocker"
    },
    {
      "id": "persistent pain"
    },
    {
      "id": "analgesic action"
    },
    {
      "id": "high voltage activated calcium channels"
    },
    {
      "id": "armed spider Phoneutria nigriventer"
    },
    {
      "id": "dorsal root ganglia (DRG) neurons"
    },
    {
      "id": "TRPV1 receptor"
    },
    {
      "id": "N-type"
    },
    {
      "id": "TRPV1 channels"
    },
    {
      "id": "TRPV1 antagonist"
    },
    {
      "id": "glucocorticoid stress-response (GSR)"
    },
    {
      "id": "0.5MAhR group"
    },
    {
      "id": "lactational exposure"
    },
    {
      "id": "M group"
    },
    {
      "id": "1.0 mg/kg/day"
    },
    {
      "id": "dams"
    },
    {
      "id": "mixture of aryl hydrocarbon receptor (AhR) agonists"
    },
    {
      "id": "Perinatal events"
    },
    {
      "id": "0.5 mg/kg/day"
    },
    {
      "id": "chemical mixture (M)"
    },
    {
      "id": "experiment"
    },
    {
      "id": "mixtures of environmental contaminants"
    },
    {
      "id": "polychlorinated biphenyls (PCBs)"
    },
    {
      "id": "cookie"
    },
    {
      "id": "hypothalamo-pituitary-adrenal axis"
    },
    {
      "id": "C/C group"
    },
    {
      "id": "in utero/postnatal exposure"
    },
    {
      "id": "1.8 ng/kg/day"
    },
    {
      "id": "PC-dibenzodioxins"
    },
    {
      "id": "PC-dibenzofurans"
    },
    {
      "id": "MM groups"
    },
    {
      "id": "predisposition"
    },
    {
      "id": "stress-induced diseases"
    },
    {
      "id": "glucocorticoid receptor (GR) gene promoter"
    },
    {
      "id": "abundance of GR"
    },
    {
      "id": "treated groups"
    },
    {
      "id": "non-ortho PCBs"
    },
    {
      "id": "metabolic impairments"
    },
    {
      "id": "C/M group"
    },
    {
      "id": "in utero exposure"
    },
    {
      "id": "postnatal day (PND) 20"
    },
    {
      "id": "CM group"
    },
    {
      "id": "environmental contaminants"
    },
    {
      "id": "four groups"
    },
    {
      "id": "M/C group"
    },
    {
      "id": "0.5M group"
    },
    {
      "id": "developmental exposure"
    },
    {
      "id": "glucocorticoid receptor promoter"
    },
    {
      "id": "control (C) litters"
    },
    {
      "id": "birth"
    },
    {
      "id": "mental health impairments"
    },
    {
      "id": "M/M group"
    },
    {
      "id": "M litters"
    },
    {
      "id": "gestation day (GD) 0"
    },
    {
      "id": "adult male offspring"
    },
    {
      "id": "phosphorylation of Extracellular-Signal-Regulated Kinase"
    },
    {
      "id": "cotinine"
    },
    {
      "id": "LPO"
    },
    {
      "id": "neuroactive effects"
    },
    {
      "id": "DH\u03b2E"
    },
    {
      "id": "dihydro-beta-eritroidine"
    },
    {
      "id": "memory extinction"
    },
    {
      "id": "behavioral parameters"
    },
    {
      "id": "Extracellular-Signal-Regulated Kinase"
    },
    {
      "id": "COT"
    },
    {
      "id": "Young male rats"
    },
    {
      "id": "cannulae"
    },
    {
      "id": "memory extinction tests sessions"
    },
    {
      "id": "nicotine-attributed effects"
    },
    {
      "id": "alkaloid"
    },
    {
      "id": "cotinine-nicotine interactions"
    },
    {
      "id": "fear memory"
    },
    {
      "id": "biochemical assays"
    },
    {
      "id": "MLA"
    },
    {
      "id": "NIC"
    },
    {
      "id": "reproductive processes"
    },
    {
      "id": "sex steroid receptors"
    },
    {
      "id": "uteri"
    },
    {
      "id": "ethanol intake"
    },
    {
      "id": "oviducts"
    },
    {
      "id": "adult rats"
    },
    {
      "id": "ovaries"
    },
    {
      "id": "tissue samples"
    },
    {
      "id": "E2"
    },
    {
      "id": "sex hormones"
    },
    {
      "id": "progesterone"
    },
    {
      "id": "6-sulfatoxymelatonin"
    },
    {
      "id": "steroid receptors"
    },
    {
      "id": "ethanol-preferring rats"
    },
    {
      "id": "melatonin receptor subunits"
    },
    {
      "id": "6-STM"
    },
    {
      "id": "melatonin treatment"
    },
    {
      "id": "ER-\u03b1"
    },
    {
      "id": "PRB"
    },
    {
      "id": "Ovarian AR"
    },
    {
      "id": "MT1R"
    },
    {
      "id": "P4"
    },
    {
      "id": "ethanol-melatonin combination"
    },
    {
      "id": "150 days"
    },
    {
      "id": "androgen"
    },
    {
      "id": "Chronic ethanol intake"
    },
    {
      "id": "sex hormone disturbances"
    },
    {
      "id": "ER-\u03b2"
    },
    {
      "id": "SP6001325"
    },
    {
      "id": "JNK signaling pathway"
    },
    {
      "id": "AT1R upregulation"
    },
    {
      "id": "sodium arsenite"
    },
    {
      "id": "AT1AR"
    },
    {
      "id": "arsenic-induced aberrant AT1R signaling"
    },
    {
      "id": "pathogenesis of hypertension"
    },
    {
      "id": "phosphorylations"
    },
    {
      "id": "SA"
    },
    {
      "id": "AP-1"
    },
    {
      "id": "angiotensin II Type I receptor"
    },
    {
      "id": "ROS-mediated activation"
    },
    {
      "id": "chronic arsenic exposure"
    },
    {
      "id": "arsenic exposure-induced hypertension"
    },
    {
      "id": "molecular pathogenesis"
    },
    {
      "id": "AT1BR"
    },
    {
      "id": "1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors"
    },
    {
      "id": "HIV capsid (CA) assembly"
    },
    {
      "id": "favorable substitutions"
    },
    {
      "id": "labile stereocenter"
    },
    {
      "id": "analog 27"
    },
    {
      "id": "immature Gag assembly"
    },
    {
      "id": "Gag"
    },
    {
      "id": "benzotriazepine scaffolds"
    },
    {
      "id": "C3-phenyl moiety"
    },
    {
      "id": "antiviral potency"
    },
    {
      "id": "spirobenzodiazepine scaffolds"
    },
    {
      "id": "1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series"
    },
    {
      "id": "HIV capsid assembly inhibitors"
    },
    {
      "id": "high-resolution structural information"
    },
    {
      "id": "Structure-activity relationships (SAR)"
    },
    {
      "id": "mature CA assembly"
    },
    {
      "id": "C3 position"
    },
    {
      "id": "Xanthium strumarium"
    },
    {
      "id": "galactitol"
    },
    {
      "id": "methyl-3,5-di-O-caffeoylquinate"
    },
    {
      "id": "rhAR"
    },
    {
      "id": "rat lens"
    },
    {
      "id": "recombinant human AR"
    },
    {
      "id": "Lineweaver-Burk plots"
    },
    {
      "id": "phenolic"
    },
    {
      "id": "erythrocytes"
    },
    {
      "id": "rat lenses"
    },
    {
      "id": "rAR"
    },
    {
      "id": "Aldose Reductase"
    },
    {
      "id": "rat lens AR"
    },
    {
      "id": "aldose reductase"
    },
    {
      "id": "caffeoylquinic acids"
    },
    {
      "id": "In Situ Conversion"
    },
    {
      "id": "Hydrothermally Etching"
    },
    {
      "id": "Growth Mechanism"
    },
    {
      "id": "TiO2 Nanorod Arrays"
    },
    {
      "id": "Quantum Dot-Sensitized Solar Cells"
    },
    {
      "id": "CdSe QDs"
    },
    {
      "id": "Nanotube Arrays"
    },
    {
      "id": "TiO2"
    },
    {
      "id": "FTO Substrate"
    },
    {
      "id": "Transparent Conductive Substrates"
    },
    {
      "id": "TiO2 arrays"
    },
    {
      "id": "Hydrothermal Selective Etching"
    },
    {
      "id": "Electrode"
    },
    {
      "id": "Solar Cells"
    },
    {
      "id": "Hydrothermal Growth"
    },
    {
      "id": "Polycrystalline"
    },
    {
      "id": "Bundle of 2-5 nm single crystalline nanocolumns"
    },
    {
      "id": "[001]"
    },
    {
      "id": "(001) core"
    },
    {
      "id": "QDs"
    },
    {
      "id": "Inert Sidewall"
    },
    {
      "id": "(110) face"
    },
    {
      "id": "CdSe"
    },
    {
      "id": "Energy Conversion Efficiency"
    },
    {
      "id": "Single Crystalline"
    },
    {
      "id": "Mor32u"
    },
    {
      "id": "descriptors"
    },
    {
      "id": "inactive p-methoxy analog (4d)"
    },
    {
      "id": "Gu value"
    },
    {
      "id": "cytotoxic compound (4k)"
    },
    {
      "id": "tetrahydroisoquinolines 4k"
    },
    {
      "id": "lead pharmacophores"
    },
    {
      "id": "tetrahydroisoquinolines"
    },
    {
      "id": "QSAR studies"
    },
    {
      "id": "1-Substituted-N-tosyl-1,2,3,4-tetrahydroisoquinoline analogs"
    },
    {
      "id": "modified Pictet-Spengler reaction"
    },
    {
      "id": "N-tosyl-1,2,3,4-tetrahydroisoquinoline derivatives"
    },
    {
      "id": "QSAR study"
    },
    {
      "id": "molecular mass compound (4f)"
    },
    {
      "id": "Trimethoxy analog 4f"
    },
    {
      "id": "4a-4l"
    },
    {
      "id": "QSAR models"
    },
    {
      "id": "o-hydroxy derivative 4k"
    },
    {
      "id": "MOLT-3 cell lines"
    },
    {
      "id": "3D Petitjean index (PJI3)"
    },
    {
      "id": "total symmetry index (Gu)"
    },
    {
      "id": "Mor31v"
    },
    {
      "id": "A-549"
    },
    {
      "id": "3D-MoRSE"
    },
    {
      "id": "investigated compounds"
    },
    {
      "id": "p-methoxy analog 4d"
    },
    {
      "id": "HuCCA-1"
    },
    {
      "id": "tetrahydroisoquinolines 4f"
    },
    {
      "id": "Cd-resistant cells"
    },
    {
      "id": "RBL-2H3 cells"
    },
    {
      "id": "metal transporters"
    },
    {
      "id": "roles"
    },
    {
      "id": "Cd(2+)"
    },
    {
      "id": "ZIP8 expression"
    },
    {
      "id": "ZIP8"
    },
    {
      "id": "hyperaccumulation"
    },
    {
      "id": "Zrt-, Irt-related protein 8"
    },
    {
      "id": "RBL-Mnr cells"
    },
    {
      "id": "high sensitivity"
    },
    {
      "id": "metals"
    },
    {
      "id": "Slc39a8"
    },
    {
      "id": "LC50 values"
    },
    {
      "id": "CdCl2"
    },
    {
      "id": "MnCl2"
    },
    {
      "id": "RBL-Cdr cells"
    },
    {
      "id": "HgCl2"
    },
    {
      "id": "cadmium-resistant RBL-2H3 cells"
    },
    {
      "id": "manganese-resistant RBL-2H3 cells"
    },
    {
      "id": "Mn-resistant cells"
    },
    {
      "id": "manganese"
    },
    {
      "id": "metallothionein"
    },
    {
      "id": "pivotal role"
    },
    {
      "id": "AgNO3"
    },
    {
      "id": "continuous exposure"
    },
    {
      "id": "Rat basophilic leukemia RBL-2H3 cells"
    },
    {
      "id": "slow oxidative skeletal muscle myofiber gene program"
    },
    {
      "id": "PPAR\u03b3 coactivator 1\u03b1"
    },
    {
      "id": "MAPKAPK2/3"
    },
    {
      "id": "MAPK-activated protein kinases 2 and 3"
    },
    {
      "id": "MK2/3"
    },
    {
      "id": "cross-striated muscle"
    },
    {
      "id": "PGC-1\u03b1"
    },
    {
      "id": "SERCA2a gene expression"
    },
    {
      "id": "Sp1 ratio"
    },
    {
      "id": "enhanced force"
    },
    {
      "id": "MK2/3(-/-) mice"
    },
    {
      "id": "SERCA2a Expression"
    },
    {
      "id": "transcriptome analyses"
    },
    {
      "id": "MK2/3(-/-) cardiomyocytes"
    },
    {
      "id": "enzymatic activity of MK2/3"
    },
    {
      "id": "critical factor"
    },
    {
      "id": "unique muscle phenotype"
    },
    {
      "id": "reduced fatigability"
    },
    {
      "id": "Cardiomyocyte Function"
    },
    {
      "id": "protein kinases"
    },
    {
      "id": "relaxation"
    },
    {
      "id": "promoters"
    },
    {
      "id": "slow fiber-specific sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) 2 gene"
    },
    {
      "id": "MK2/3 double knockout mice"
    },
    {
      "id": "MK2/3(-/-)"
    },
    {
      "id": "force parameters"
    },
    {
      "id": "MK2/3(-/-) soleus muscle"
    },
    {
      "id": "fast fiber-specific myosin heavy chain IId/x"
    },
    {
      "id": "novel target"
    },
    {
      "id": "therapeutic strategies"
    },
    {
      "id": "SERCA2"
    },
    {
      "id": "calcium dynamics"
    },
    {
      "id": "MK2 catalytic activity"
    },
    {
      "id": "impaired SERCA2 function"
    },
    {
      "id": "Skeletal Muscle"
    },
    {
      "id": "p38-MK2/3 axis"
    },
    {
      "id": "Fiber Type Composition"
    },
    {
      "id": "fiber type changes"
    },
    {
      "id": "proteome analyses"
    },
    {
      "id": "CAPE"
    },
    {
      "id": "phospho-Akt Thr 308"
    },
    {
      "id": "cell cycle inhibitor p27Kip"
    },
    {
      "id": "Akt2"
    },
    {
      "id": "Caffeic acid phenethyl ester (CAPE)"
    },
    {
      "id": "honeybee hive propolis"
    },
    {
      "id": "Akt1"
    },
    {
      "id": "G2/M phase cell population"
    },
    {
      "id": "phospho-FOXO1 Thr24"
    },
    {
      "id": "phospho-Akt Ser473"
    },
    {
      "id": "cyclin D1"
    },
    {
      "id": "GSK3\u03b2"
    },
    {
      "id": "FOXO1"
    },
    {
      "id": "patients with OSCC oral cancer"
    },
    {
      "id": "colony formation"
    },
    {
      "id": "Caffeic Acid Phenethyl Ester"
    },
    {
      "id": "Akt3"
    },
    {
      "id": "Skp2"
    },
    {
      "id": "phospho-NF-\u03baB Ser536"
    },
    {
      "id": "chemotherapeutic drug"
    },
    {
      "id": "oral cancers"
    },
    {
      "id": "phospho-FoxO3a Thr32"
    },
    {
      "id": "Rb"
    },
    {
      "id": "G1 phase cell population"
    },
    {
      "id": "phospho-Rb Ser807/811"
    },
    {
      "id": "FOXO3a"
    },
    {
      "id": "Akt Signaling"
    },
    {
      "id": "multidrug resistance"
    },
    {
      "id": "cell cycle-targeting activity"
    },
    {
      "id": "SB"
    },
    {
      "id": "IL-8 receptor B"
    },
    {
      "id": "microtubules targeting"
    },
    {
      "id": "microtubules"
    },
    {
      "id": "SB225002"
    },
    {
      "id": "dual mechanisms"
    },
    {
      "id": "IL-8-drivin cancer progression"
    },
    {
      "id": "Molecular Mechanisms"
    },
    {
      "id": "caspase-independent cell death"
    },
    {
      "id": "colorectal adenocarcinoma cells SW480"
    },
    {
      "id": "SW480"
    },
    {
      "id": "SB265610"
    },
    {
      "id": "BAK-dependent mitochondrial apoptosis"
    },
    {
      "id": "BAK"
    },
    {
      "id": "vinblastine"
    },
    {
      "id": "vinblastine-binding site"
    },
    {
      "id": "BubR1-dependent mitotic arrest"
    },
    {
      "id": "anti-nociceptive effects"
    },
    {
      "id": "mitotic arrest"
    },
    {
      "id": "microtubule destabilizing activity"
    },
    {
      "id": "prometaphase arrest"
    },
    {
      "id": "microtubule polymerization"
    },
    {
      "id": "SB-induced caspase-independent cell death"
    },
    {
      "id": "hyperphosphorylation"
    },
    {
      "id": "antitumor agent"
    },
    {
      "id": "antimitotic activity"
    },
    {
      "id": "pharmacologic inhibition"
    },
    {
      "id": "p38 MAPK activity"
    },
    {
      "id": "IL-8RB"
    },
    {
      "id": "BclxL"
    },
    {
      "id": "IL-8RB antagonistic activity"
    },
    {
      "id": "\u03b2-tubulin subunit"
    },
    {
      "id": "microtubule inhibitor"
    },
    {
      "id": "BubR1"
    },
    {
      "id": "invasive hepatocellular carcinoma HLE cells"
    },
    {
      "id": "HLE cells"
    },
    {
      "id": "mitochondrial apoptosis"
    },
    {
      "id": "in vivo anti-inflammatory effects"
    },
    {
      "id": "multivalent GAG"
    },
    {
      "id": "syndecan-1 proteoglycan"
    },
    {
      "id": "library"
    },
    {
      "id": "GAG valency"
    },
    {
      "id": "chain type"
    },
    {
      "id": "bis- and tris-xylosides"
    },
    {
      "id": "PGs"
    },
    {
      "id": "elongated embryos"
    },
    {
      "id": "GAG multivalency"
    },
    {
      "id": "sprouty4"
    },
    {
      "id": "FGFR"
    },
    {
      "id": "FGF Signaling"
    },
    {
      "id": "Zebrafish Development"
    },
    {
      "id": "GAG chains"
    },
    {
      "id": "elongation"
    },
    {
      "id": "reporters"
    },
    {
      "id": "mkp3"
    },
    {
      "id": "SU5402"
    },
    {
      "id": "tyrosine kinase"
    },
    {
      "id": "FGF/FGFR interactions"
    },
    {
      "id": "mono-xylosides"
    },
    {
      "id": "elongation phenotype"
    },
    {
      "id": "Endogenous GAGs"
    },
    {
      "id": "xyloside treatment"
    },
    {
      "id": "biological significance"
    },
    {
      "id": "injection"
    },
    {
      "id": "embryos"
    },
    {
      "id": "FGF8"
    },
    {
      "id": "FGF target gene mkp3"
    },
    {
      "id": "FGF8 morpholino"
    },
    {
      "id": "scaffold"
    },
    {
      "id": "monovalent GAG"
    },
    {
      "id": "dimerized GAG chains"
    },
    {
      "id": "FGF-mediated signal transduction pathways"
    },
    {
      "id": "signaling molecules"
    },
    {
      "id": "fibroblast growth factors"
    },
    {
      "id": "bivalent xylosides"
    },
    {
      "id": "Proteoglycans"
    },
    {
      "id": "FGFs"
    },
    {
      "id": "gain-of-function phenotype"
    },
    {
      "id": "Dimerized Glycosaminoglycan Chains"
    },
    {
      "id": "GAG/FGF/FGFR interactions"
    },
    {
      "id": "glycosaminoglycan (GAG) side chains"
    },
    {
      "id": "FGF/FGFR signaling"
    },
    {
      "id": "in vivo findings"
    },
    {
      "id": "protein kinase activity"
    },
    {
      "id": "Fisetin"
    },
    {
      "id": "GSH levels"
    },
    {
      "id": "GSH metabolism"
    },
    {
      "id": "Transcription Factors"
    },
    {
      "id": "toxic stress"
    },
    {
      "id": "GSH-associated metabolism"
    },
    {
      "id": "intracellular redox environment"
    },
    {
      "id": "Nrf2-dependent gene transcription"
    },
    {
      "id": "ATF4-dependent gene transcription"
    },
    {
      "id": "gene transcription"
    },
    {
      "id": "Glutathione"
    },
    {
      "id": "nuclear accumulation"
    },
    {
      "id": "oocytes"
    },
    {
      "id": "TAp73"
    },
    {
      "id": "cisplatin-induced oocyte death"
    },
    {
      "id": "cisplatin-induced apoptosis"
    },
    {
      "id": "oocyte cell death"
    },
    {
      "id": "sterility"
    },
    {
      "id": "early follicles"
    },
    {
      "id": "imatinib mesylate"
    },
    {
      "id": "fertoprotective drug"
    },
    {
      "id": "Early menopause"
    },
    {
      "id": "cisplatin-induced DNA damage"
    },
    {
      "id": "conditional deletion"
    },
    {
      "id": "master regulator"
    },
    {
      "id": "c-Abl kinase"
    },
    {
      "id": "damage response"
    },
    {
      "id": "TAp63"
    },
    {
      "id": "Trp63"
    },
    {
      "id": "c-Abl kinase inhibitor"
    },
    {
      "id": "c-Abl"
    },
    {
      "id": "BAX"
    },
    {
      "id": "TAp73-BAX-mediated apoptosis"
    },
    {
      "id": "primordial follicles"
    },
    {
      "id": "p53 family signaling network"
    },
    {
      "id": "programmed cell death"
    },
    {
      "id": "avascular regions"
    },
    {
      "id": "endocrine function"
    },
    {
      "id": "c-Abl/TAp73"
    },
    {
      "id": "c-Abl kinase inhibitors"
    },
    {
      "id": "c-Abl-induced BAX expression"
    },
    {
      "id": "MDRD and CKD-EPI equations"
    },
    {
      "id": "mClcr"
    },
    {
      "id": "dose calculation errors"
    },
    {
      "id": "many drugs"
    },
    {
      "id": "elderly individuals"
    },
    {
      "id": "low Scr values"
    },
    {
      "id": "arbitrary value of 1.0 mg/dl"
    },
    {
      "id": "performance"
    },
    {
      "id": "bias"
    },
    {
      "id": "Kidney function"
    },
    {
      "id": "Modification of Diet in Renal Disease (MDRD)"
    },
    {
      "id": "mean \u00b1 SD age"
    },
    {
      "id": "CG values"
    },
    {
      "id": "common practice of rounding or replacing low Scr values"
    },
    {
      "id": "kidney function estimation equations"
    },
    {
      "id": "Glomerular Filtration Rate Equations"
    },
    {
      "id": "Creatinine Clearance"
    },
    {
      "id": "precision"
    },
    {
      "id": "alternative eGFR equations"
    },
    {
      "id": "pharmacokinetic outcomes measures"
    },
    {
      "id": "pharmacodynamic outcomes measures"
    },
    {
      "id": "Cockcroft-Gault (CG)"
    },
    {
      "id": "dosages"
    },
    {
      "id": "Older Individuals"
    },
    {
      "id": "Baltimore Longitudinal Study on Aging"
    },
    {
      "id": "community-dwelling volunteers"
    },
    {
      "id": "Baltimore Longitudinal Study of Aging"
    },
    {
      "id": "mean serum creatinine concentration (Scr)"
    },
    {
      "id": "equations estimating glomerular filtration rate"
    },
    {
      "id": "older adults"
    },
    {
      "id": "mean 24-hour measured creatinine clearance (mClcr)"
    },
    {
      "id": "CG equation"
    },
    {
      "id": "Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)"
    },
    {
      "id": "Dose calculation errors (discordance)"
    },
    {
      "id": "renal dosage adjustments"
    },
    {
      "id": "older populations"
    },
    {
      "id": "Renal Drug Dosing"
    },
    {
      "id": "median dose discordance rates"
    },
    {
      "id": "drug dose discordance"
    },
    {
      "id": "individuals with severe renal impairment"
    },
    {
      "id": "ethyl acetate fraction"
    },
    {
      "id": "stomach tissues"
    },
    {
      "id": "AFE"
    },
    {
      "id": "Acacia ferruginea stem bark"
    },
    {
      "id": "leucoderma"
    },
    {
      "id": "diseases of the blood"
    },
    {
      "id": "ethanol mediated ulcer"
    },
    {
      "id": "ethanol control group"
    },
    {
      "id": "in vitro systems"
    },
    {
      "id": "ABTS(\u2022+) scavenging"
    },
    {
      "id": "anti-ulcerogenic activities"
    },
    {
      "id": "itching"
    },
    {
      "id": "Enzyme activities"
    },
    {
      "id": "DPPH(\u2022)"
    },
    {
      "id": "anti-ulcer agent"
    },
    {
      "id": "gastric ulcer"
    },
    {
      "id": "crude acetone extract"
    },
    {
      "id": "sub-fractions"
    },
    {
      "id": "antioxidant potential"
    },
    {
      "id": "gastric damage"
    },
    {
      "id": "free radical scavenging activities"
    },
    {
      "id": "phosphomolybdenum reduction activities"
    },
    {
      "id": "ABTS"
    },
    {
      "id": "Acetone extract"
    },
    {
      "id": "ethanol ingestion"
    },
    {
      "id": "traditional systems of medicine"
    },
    {
      "id": "RBV tripalmitate"
    },
    {
      "id": "RBV tripalmitate-loaded PHEA-EDA-PLA-GAL micelles"
    },
    {
      "id": "PHEA-EDA-PLA-GAL"
    },
    {
      "id": "PHEA-EDA-PLA-GAL copolymer"
    },
    {
      "id": "ribavirin"
    },
    {
      "id": "hepatitis C treatment"
    },
    {
      "id": "hepatitis C"
    },
    {
      "id": "nanostructures"
    },
    {
      "id": "competitive inhibition assay"
    },
    {
      "id": "free GAL"
    },
    {
      "id": "Polymeric micelles"
    },
    {
      "id": "alpha,beta-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-DL-aspartamide"
    },
    {
      "id": "PHEA-EDA"
    },
    {
      "id": "copolymer"
    },
    {
      "id": "Liver-targeted RBV tripalmitate-loaded micelles"
    },
    {
      "id": "aqueous media"
    },
    {
      "id": "HEPATOCYTES"
    },
    {
      "id": "galactosylated polylactide-polyaminoacid conjugate"
    },
    {
      "id": "micelles-based liver-targeted drug delivery strategy"
    },
    {
      "id": "polylactic acid"
    },
    {
      "id": "RBV"
    },
    {
      "id": "PLA"
    },
    {
      "id": "in vitro experiments"
    },
    {
      "id": "ASGPR"
    },
    {
      "id": "GAL"
    },
    {
      "id": "lactose"
    },
    {
      "id": "RIBAVIRIN PRODRUG"
    },
    {
      "id": "hydrophobic RBV prodrug"
    },
    {
      "id": "micelles"
    },
    {
      "id": "GALACTOSYLATED MICELLES"
    },
    {
      "id": "drug delivery strategy"
    },
    {
      "id": "Reconstitution"
    },
    {
      "id": "Complexes"
    },
    {
      "id": "macromolecules"
    },
    {
      "id": "reduction sensitive heteromer"
    },
    {
      "id": "proMatrix Metalloproteinase-9"
    },
    {
      "id": "SDS-stable heteromers"
    },
    {
      "id": "CSPGs"
    },
    {
      "id": "disulphide bonds"
    },
    {
      "id": "gelatin"
    },
    {
      "id": "Versican"
    },
    {
      "id": "Serglycin"
    },
    {
      "id": "hemopexin-like (PEX) domain"
    },
    {
      "id": "heteromer formation"
    },
    {
      "id": "SDS-soluble proMMP-9\u00b7CSPG heteromer"
    },
    {
      "id": "proMMP-9"
    },
    {
      "id": "fibronectin-like (FnII) module"
    },
    {
      "id": "CSPG"
    },
    {
      "id": "core protein"
    },
    {
      "id": "TIMP-1"
    },
    {
      "id": "proMMP-9\u00b7CSPG complexes"
    },
    {
      "id": "complex formation"
    },
    {
      "id": "proMMP-9\u00b7CSPG heteromer"
    },
    {
      "id": "monocytic cell lines"
    },
    {
      "id": "chondroitin sulphate proteoglycan"
    },
    {
      "id": "proMMP-9 monomer"
    },
    {
      "id": "macrophage cell line THP-1"
    },
    {
      "id": "chronic exposure"
    },
    {
      "id": "combined Na2SeO3+NaAsO2 treatment group"
    },
    {
      "id": "SOD1"
    },
    {
      "id": "MDA content"
    },
    {
      "id": "Na2SeO3 intervention group"
    },
    {
      "id": "NaAsO2 group"
    },
    {
      "id": "arsenic"
    },
    {
      "id": "Na2SeO3"
    },
    {
      "id": "metalloid"
    },
    {
      "id": "control groups"
    },
    {
      "id": "Txnrd1"
    },
    {
      "id": "combined treatment group"
    },
    {
      "id": "HSP70"
    },
    {
      "id": "Oxidative stress related genes"
    },
    {
      "id": "liver stress state"
    },
    {
      "id": "chronic poisoning"
    },
    {
      "id": "As"
    },
    {
      "id": "NaAsO2"
    },
    {
      "id": "Na2SeO3 groups"
    },
    {
      "id": "GPx"
    },
    {
      "id": "chronic arsenic poisoning"
    },
    {
      "id": "public health"
    },
    {
      "id": "AMPK\u03b11"
    },
    {
      "id": "SOCE"
    },
    {
      "id": "TRPC channels"
    },
    {
      "id": "STIM1 Phosphorylation"
    },
    {
      "id": "AMP-activated Protein Kinase"
    },
    {
      "id": "Ca2+ entry"
    },
    {
      "id": "p38\u03b2"
    },
    {
      "id": "PAR-1"
    },
    {
      "id": "p38\u03b2 phosphorylation"
    },
    {
      "id": "CaMKK\u03b2"
    },
    {
      "id": "Protease-activated Receptor-1"
    },
    {
      "id": "Store-operated Ca2+ Entry"
    },
    {
      "id": "isoform \u03b11"
    },
    {
      "id": "isoform \u03b12"
    },
    {
      "id": "AMPK catalytic subunit"
    },
    {
      "id": "STIM1-puncta formation"
    },
    {
      "id": "p38\u03b2 MAPK"
    },
    {
      "id": "Endothelial Cells"
    },
    {
      "id": "Orai channels"
    },
    {
      "id": "permeability responses"
    },
    {
      "id": "AICAR pretreatment"
    },
    {
      "id": "PAR-1-induced increase in permeability"
    },
    {
      "id": "endothelial SOCE"
    },
    {
      "id": "p38beta Mitogen-activated Protein Kinase"
    },
    {
      "id": "STIM1"
    },
    {
      "id": "serine residues"
    },
    {
      "id": "Ca2+ sensor STIM1"
    },
    {
      "id": "p38 MAPK isoforms"
    },
    {
      "id": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors"
    },
    {
      "id": "MMPs"
    },
    {
      "id": "pyrrolidine mercaptosulfide"
    },
    {
      "id": "kinetic and biological characteristics"
    },
    {
      "id": "trans- form"
    },
    {
      "id": "biological compatibility"
    },
    {
      "id": "2-mercaptocyclopentane arylsulfonamide"
    },
    {
      "id": "intermediate- and deep-pocket MMPs"
    },
    {
      "id": "cis-(3S,4R)- stereochemistry"
    },
    {
      "id": "MMPIs"
    },
    {
      "id": "shallow-pocketed MMPs"
    },
    {
      "id": "MMP-7"
    },
    {
      "id": "MMP-1"
    },
    {
      "id": "MMP-14"
    },
    {
      "id": "Matrix Metalloproteinase Inhibitors"
    },
    {
      "id": "3-Mercaptopyrrolidine Core"
    },
    {
      "id": "mercaptosulfide functionality"
    },
    {
      "id": "cyclopentane"
    },
    {
      "id": "oxidative stability"
    },
    {
      "id": "MMP-13"
    },
    {
      "id": "mercaptosulfonamides"
    },
    {
      "id": "pyrrolidine frameworks"
    },
    {
      "id": "PON1 gene polymorphism"
    },
    {
      "id": "AChE enzyme activities"
    },
    {
      "id": "54 individuals"
    },
    {
      "id": "OP compounds"
    },
    {
      "id": "acetylcholinesterase (AChE)"
    },
    {
      "id": "192 Q/R polymorphism"
    },
    {
      "id": "enzyme activities"
    },
    {
      "id": "Turkish population"
    },
    {
      "id": "organophosphate"
    },
    {
      "id": "Organophosphate (OP) compounds"
    },
    {
      "id": "market"
    },
    {
      "id": "54 healthy unrelated controls"
    },
    {
      "id": "QQ genotype"
    },
    {
      "id": "192 R(-) genotype carriers"
    },
    {
      "id": "192 R(+)"
    },
    {
      "id": "192 R(-)"
    },
    {
      "id": "paraoxonase"
    },
    {
      "id": "mean AChE concentration"
    },
    {
      "id": "OP-exposed group"
    },
    {
      "id": "probability of susceptibility"
    },
    {
      "id": "standard polymerase chain reaction-restriction fragment length polymorphism technique"
    },
    {
      "id": "PON1 enzyme activities"
    },
    {
      "id": "local purposes"
    },
    {
      "id": "PON1 activities"
    },
    {
      "id": "QR + RR genotypes"
    },
    {
      "id": "PON1 192 R(+) genotype carriers"
    },
    {
      "id": "haemoglobin (Hb)"
    },
    {
      "id": "PON"
    },
    {
      "id": "pesticide groups"
    },
    {
      "id": "Paraoxonase 1 (PON1) enzyme"
    },
    {
      "id": "chronic level"
    },
    {
      "id": "industrial purposes"
    },
    {
      "id": "organophosphorus insecticides"
    },
    {
      "id": "OP-exposed groups"
    },
    {
      "id": "organophosphorus compounds"
    },
    {
      "id": "occupational reasons"
    },
    {
      "id": "pizotifen"
    },
    {
      "id": "tertiary aliphatic amines"
    },
    {
      "id": "nortriptyline"
    },
    {
      "id": "secondary or primary amines"
    },
    {
      "id": "cyclic amines"
    },
    {
      "id": "UGT1A3"
    },
    {
      "id": "UGT2B10"
    },
    {
      "id": "diphenhydramine"
    },
    {
      "id": "UGT1A4"
    },
    {
      "id": "imidazole group"
    },
    {
      "id": "recombinant UGT2B10"
    },
    {
      "id": "trifluoperazine"
    },
    {
      "id": "human UDP-glucuronosyltransferase (UGT) 2B10"
    },
    {
      "id": "tertiary cyclic amine"
    },
    {
      "id": "clinical significance"
    },
    {
      "id": "Human UGT2B10"
    },
    {
      "id": "afloqualone"
    },
    {
      "id": "inhibition studies"
    },
    {
      "id": "hecogenin"
    },
    {
      "id": "Drug N-glucuronidations"
    },
    {
      "id": "amine-containing compounds"
    },
    {
      "id": "drug clearance"
    },
    {
      "id": "tertiary amines"
    },
    {
      "id": "Vmax values"
    },
    {
      "id": "therapeutic concentrations"
    },
    {
      "id": "western blot analysis"
    },
    {
      "id": "C/EBP\u03b1"
    },
    {
      "id": "Tecomella undulata"
    },
    {
      "id": "bark"
    },
    {
      "id": "ethyl acetate extract of Tecomella undulata bark"
    },
    {
      "id": "anti obesity efficiency"
    },
    {
      "id": "LPL"
    },
    {
      "id": "active fractions"
    },
    {
      "id": "In-vivo studies"
    },
    {
      "id": "F1"
    },
    {
      "id": "E2F1"
    },
    {
      "id": "adipogenesis"
    },
    {
      "id": "sqRT-PCR"
    },
    {
      "id": "disease ailments"
    },
    {
      "id": "modulation of SIRT1"
    },
    {
      "id": "adipogenesis mediators"
    },
    {
      "id": "adiponectin"
    },
    {
      "id": "semi quantitative RT-PCR"
    },
    {
      "id": "EATUB"
    },
    {
      "id": "EATUB fractions"
    },
    {
      "id": "3T3-L1 fibroblasts"
    },
    {
      "id": "scientific evidence"
    },
    {
      "id": "pharmacologic interventions"
    },
    {
      "id": "antiobesity activity"
    },
    {
      "id": "traditional claim"
    },
    {
      "id": "High Fat Diet"
    },
    {
      "id": "obese mice"
    },
    {
      "id": "HFD induced obese mice"
    },
    {
      "id": "lipid profile"
    },
    {
      "id": "bioactive fraction"
    },
    {
      "id": "metabolic disorders"
    },
    {
      "id": "F1-F7"
    },
    {
      "id": "overall conformational similarity"
    },
    {
      "id": "multiple closed structures"
    },
    {
      "id": "2B4-paroxetine structure"
    },
    {
      "id": "previously solved closed structure"
    },
    {
      "id": "active site cavity volume"
    },
    {
      "id": "paroxetine complex"
    },
    {
      "id": "complex with amlodipine"
    },
    {
      "id": "new sub-chamber"
    },
    {
      "id": "active site side chains"
    },
    {
      "id": "Cytochrome P450 2B4"
    },
    {
      "id": "drug paroxetine"
    },
    {
      "id": "cluster of protein conformations"
    },
    {
      "id": "various ligands"
    },
    {
      "id": "new structure"
    },
    {
      "id": "active site size"
    },
    {
      "id": "compact complex with 4-(4-chlorophenyl)imidazole"
    },
    {
      "id": "4-(4-chlorophenyl)imidazole"
    },
    {
      "id": "Paroxetine"
    },
    {
      "id": "X-ray crystal structure"
    },
    {
      "id": "15 previously solved structures of P450 2B4"
    },
    {
      "id": "accessible space"
    },
    {
      "id": "heme"
    },
    {
      "id": "F-G cassette"
    },
    {
      "id": "active site shape"
    },
    {
      "id": "ligand free state"
    },
    {
      "id": "binding pocket"
    },
    {
      "id": "16 structures of P450 2B4"
    },
    {
      "id": "P450 2B4"
    },
    {
      "id": "secondary structural elements"
    },
    {
      "id": "HP"
    },
    {
      "id": "Alanine aminotransferase"
    },
    {
      "id": "oxidative burden"
    },
    {
      "id": "co-treatment"
    },
    {
      "id": "Self reversal group"
    },
    {
      "id": "toxicant treatments"
    },
    {
      "id": "CCl4"
    },
    {
      "id": "colorimetric methods"
    },
    {
      "id": "N-acetyl cysteine"
    },
    {
      "id": "Biochemical determinations"
    },
    {
      "id": "general findings"
    },
    {
      "id": "human etiology"
    },
    {
      "id": "micronodular cirrhosis"
    },
    {
      "id": "toxicants"
    },
    {
      "id": "liver samples"
    },
    {
      "id": "experimental chronic hepatotoxicity models"
    },
    {
      "id": "administration of CCl4"
    },
    {
      "id": "protective activity"
    },
    {
      "id": "Bilirubin"
    },
    {
      "id": "liver fibrosis"
    },
    {
      "id": "liver markers"
    },
    {
      "id": "aniline"
    },
    {
      "id": "Cytochrome P450 2E1"
    },
    {
      "id": "hepatotoxic agents"
    },
    {
      "id": "Serum markers of liver damage"
    },
    {
      "id": "organosulfur compound"
    },
    {
      "id": "CYP 450 2E1"
    },
    {
      "id": "carbon tetrachloride"
    },
    {
      "id": "Aspartate aminotransferase"
    },
    {
      "id": "NAC treatment"
    },
    {
      "id": "toxicant groups"
    },
    {
      "id": "CCl4 toxicity"
    },
    {
      "id": "histological findings"
    },
    {
      "id": "Hydroxyproline"
    },
    {
      "id": "co-administration of NAC"
    },
    {
      "id": "normal levels"
    },
    {
      "id": "chronic liver pathology"
    },
    {
      "id": "hepatic prefibrogenic events"
    },
    {
      "id": "wistar rat"
    },
    {
      "id": "Allium plants"
    },
    {
      "id": "coconut oil"
    },
    {
      "id": "Alkaline phosphatase"
    },
    {
      "id": "TAA toxicity"
    },
    {
      "id": "Mitochondria"
    },
    {
      "id": "Human deficiency diseases"
    },
    {
      "id": "mitochondrial steroidogenic enzymes"
    },
    {
      "id": "11\u03b2-hydroxylase"
    },
    {
      "id": "StAR"
    },
    {
      "id": "acute regulator"
    },
    {
      "id": "Components"
    },
    {
      "id": "PKAR1A"
    },
    {
      "id": "TSPO-associated protein 7"
    },
    {
      "id": "PAP7"
    },
    {
      "id": "cholesterol side-chain cleavage enzyme"
    },
    {
      "id": "18kDa translocator protein"
    },
    {
      "id": "OMM"
    },
    {
      "id": "access of cholesterol"
    },
    {
      "id": "steroidogenic acute regulatory protein"
    },
    {
      "id": "electron transfer proteins"
    },
    {
      "id": "ACBD3"
    },
    {
      "id": "electron-transfer partners"
    },
    {
      "id": "ferredoxin"
    },
    {
      "id": "VDAC-1"
    },
    {
      "id": "chronic regulator"
    },
    {
      "id": "protein kinase A regulatory subunit 1\u03b1"
    },
    {
      "id": "steroidogenic cells"
    },
    {
      "id": "outer mitochondrial membrane"
    },
    {
      "id": "placenta"
    },
    {
      "id": "voltage-dependent anion chanel"
    },
    {
      "id": "enzyme system"
    },
    {
      "id": "cholesterol import machine"
    },
    {
      "id": "adrenal"
    },
    {
      "id": "renal tubular cells"
    },
    {
      "id": "vitamin D"
    },
    {
      "id": "Steroid hormone biosynthesis"
    },
    {
      "id": "net steroidogenic capacity"
    },
    {
      "id": "complex multi-component molecular machine"
    },
    {
      "id": "Steroid hormone synthesis"
    },
    {
      "id": "gonad"
    },
    {
      "id": "StAR action"
    },
    {
      "id": "ferredoxin reductase"
    },
    {
      "id": "bioactive RS -GRA"
    },
    {
      "id": "EAE"
    },
    {
      "id": "interleukin-1\u03b2"
    },
    {
      "id": "IL-1\u03b2"
    },
    {
      "id": "therapeutic perspective"
    },
    {
      "id": "caspase 3 expression"
    },
    {
      "id": "RS -GRA"
    },
    {
      "id": "model of multiple sclerosis"
    },
    {
      "id": "immunization"
    },
    {
      "id": "Tuscan black kale"
    },
    {
      "id": "Brassica oleracea L. var. acephala sabellica"
    },
    {
      "id": "Brassica vegetables"
    },
    {
      "id": "(RS )-glucoraphanin"
    },
    {
      "id": "Myrosinase"
    },
    {
      "id": "myrosinase"
    },
    {
      "id": "glucosinolates"
    },
    {
      "id": "pro-inflammatory cytokine production"
    },
    {
      "id": "myelin oligodendroglial glycoprotein peptide"
    },
    {
      "id": "NF-kB translocation"
    },
    {
      "id": "Cruciferae"
    },
    {
      "id": "Experimental Model of Multiple Sclerosis"
    },
    {
      "id": "MOG35-55"
    },
    {
      "id": "Clinical score"
    },
    {
      "id": "standardized scoring system"
    },
    {
      "id": "isothiocyanates"
    },
    {
      "id": "weight loss"
    },
    {
      "id": "spinal cord tissues"
    },
    {
      "id": "signs of EAE"
    },
    {
      "id": "Pathway analysis"
    },
    {
      "id": "Hepatotoxicity"
    },
    {
      "id": "Functions"
    },
    {
      "id": "Glucose metabolism"
    },
    {
      "id": "Differential expression of genes"
    },
    {
      "id": "Cell stress pathway"
    },
    {
      "id": "TP-induced hepatotoxicity"
    },
    {
      "id": "Cell cycle"
    },
    {
      "id": "Phosphoenolpyruvate carboxykinase activities"
    },
    {
      "id": "Insulin signaling pathway"
    },
    {
      "id": "3329 differentially expressed genes"
    },
    {
      "id": "Caspase-3 activity"
    },
    {
      "id": "Systemic lupus erythematosus"
    },
    {
      "id": "14days"
    },
    {
      "id": "TP treatment"
    },
    {
      "id": "Leprosy"
    },
    {
      "id": "GSH/GSSG ratio"
    },
    {
      "id": "Glucose metabolism pathway"
    },
    {
      "id": "IGF1"
    },
    {
      "id": "Glucose-6-phosphatase activities"
    },
    {
      "id": "Overall TP-induced hepatotoxicity"
    },
    {
      "id": "TWHF"
    },
    {
      "id": "Hepatic gene expression profiles"
    },
    {
      "id": "Serum glucose"
    },
    {
      "id": "Nephritis"
    },
    {
      "id": "Triptolide"
    },
    {
      "id": "Genome-wide microarray analyses"
    },
    {
      "id": "Liver glycogen"
    },
    {
      "id": "Current study"
    },
    {
      "id": "Rheumatoid arthritis"
    },
    {
      "id": "Gene expression profiling"
    },
    {
      "id": "Clinical use"
    },
    {
      "id": "1000\u03bcg/kg"
    },
    {
      "id": "300\u03bcg/kg"
    },
    {
      "id": "Hepatotoxic effects"
    },
    {
      "id": "Hepatocyte apoptosis"
    },
    {
      "id": "Hepatic redox status"
    },
    {
      "id": "esterase D"
    },
    {
      "id": "detoxication enzymes"
    },
    {
      "id": "radiosensitivity"
    },
    {
      "id": "gamma-ray radiation"
    },
    {
      "id": "S and G2 phases"
    },
    {
      "id": "microdeletion of chromosome 11p"
    },
    {
      "id": "retinoblastoma (Rb)"
    },
    {
      "id": "microdeletions of 11p"
    },
    {
      "id": "Lymphocyte cultures"
    },
    {
      "id": "S-formyl glutathione hydrolase"
    },
    {
      "id": "microdeletion of chromosome 13"
    },
    {
      "id": "Chromatid and chromosome lesions"
    },
    {
      "id": "microdeletions of 13q"
    },
    {
      "id": "Wilms tumor (WT)"
    },
    {
      "id": "Rates"
    },
    {
      "id": "FMO3 protein expression"
    },
    {
      "id": "FMO2"
    },
    {
      "id": "benzydamine"
    },
    {
      "id": "drug metabolism"
    },
    {
      "id": "cynomolgus macaque"
    },
    {
      "id": "cynomolgus livers"
    },
    {
      "id": "FMO3 expression"
    },
    {
      "id": "inter-animal variations"
    },
    {
      "id": "cynomolgus FMO6"
    },
    {
      "id": "FMO5"
    },
    {
      "id": "Amino acid sequences"
    },
    {
      "id": "human FMO1-5"
    },
    {
      "id": "FMO3"
    },
    {
      "id": "trimethylamine"
    },
    {
      "id": "FMO6"
    },
    {
      "id": "tissue types"
    },
    {
      "id": "human FMO6P"
    },
    {
      "id": "benzydamine N-oxygenation"
    },
    {
      "id": "cynomolgus FMO1-5"
    },
    {
      "id": "alternative splicing"
    },
    {
      "id": "FMOs"
    },
    {
      "id": "flavin-containing monooxygenases"
    },
    {
      "id": "cynomolgus FMO genes"
    },
    {
      "id": "foreign compounds"
    },
    {
      "id": "phylogenetic tree"
    },
    {
      "id": "FMO1"
    },
    {
      "id": "methimazole"
    },
    {
      "id": "FMO4"
    },
    {
      "id": "Cynomolgus FMO1"
    },
    {
      "id": "sequence identities"
    },
    {
      "id": "cynomolgus FMO3"
    },
    {
      "id": "endogenous biochemicals"
    },
    {
      "id": "monosaccharide"
    },
    {
      "id": "isomalyngamide A backbone"
    },
    {
      "id": "mechanism for inhibition of metastatic activities"
    },
    {
      "id": "integrin-mediated antimetastatic pathway"
    },
    {
      "id": "disaccharide appendages"
    },
    {
      "id": "two glycosylated derivatives 4 and 5"
    },
    {
      "id": "nontoxic concentration levels"
    },
    {
      "id": "invasive ability"
    },
    {
      "id": "metastatic events"
    },
    {
      "id": "galactose appendages"
    },
    {
      "id": "Three, new, fully synthetic glycosylated isomalyngamide A analogs 4-6"
    },
    {
      "id": "anti-migratory activities"
    },
    {
      "id": "Glycosylation"
    },
    {
      "id": "inactivation of the expression"
    },
    {
      "id": "paxillin"
    },
    {
      "id": "MDA-MB-231 cells"
    },
    {
      "id": "Evidence"
    },
    {
      "id": "derivative 6"
    },
    {
      "id": "potent activity"
    },
    {
      "id": "isomalyngamide A analogs"
    },
    {
      "id": "p-FAK"
    },
    {
      "id": "human breast adenocarcinoma MDA-MB-231 cells"
    },
    {
      "id": "lactose moiety"
    },
    {
      "id": "ACTH increase"
    },
    {
      "id": "early phase"
    },
    {
      "id": "nadir"
    },
    {
      "id": "CRH"
    },
    {
      "id": "ACTH curves"
    },
    {
      "id": "pattern of ACTH response"
    },
    {
      "id": "Loperamide"
    },
    {
      "id": "plasma ACTH response"
    },
    {
      "id": "loperamide administration"
    },
    {
      "id": "inhibitory role"
    },
    {
      "id": "ACTH secretion"
    },
    {
      "id": "peripheral opiate agonist"
    },
    {
      "id": "Addison's disease"
    },
    {
      "id": "Corticotropin-releasing Hormone"
    },
    {
      "id": "supra-pituitary level"
    },
    {
      "id": "corticotropin-releasing hormone"
    },
    {
      "id": "ACTH response"
    },
    {
      "id": "lactate dehydrogenase-X activity"
    },
    {
      "id": "180 days of age"
    },
    {
      "id": "Testosterone level"
    },
    {
      "id": "jaundiced (jj) male Gunn rats"
    },
    {
      "id": "testicular maturation"
    },
    {
      "id": "reduced nicotinamide adenine dinucleotide"
    },
    {
      "id": "delay of testicular maturation"
    },
    {
      "id": "RIA"
    },
    {
      "id": "LDH-X"
    },
    {
      "id": "lactate dehydrogenase-X"
    },
    {
      "id": "Testicular cytosolic LDH-X activity"
    },
    {
      "id": "nonjaundiced (Jj) male Gunn rats"
    },
    {
      "id": "jaundiced males"
    },
    {
      "id": "young jaundiced male rats"
    },
    {
      "id": "testis and sperm-specific enzyme"
    },
    {
      "id": "Developmental changes"
    },
    {
      "id": "50 and 60 days of age"
    },
    {
      "id": "50 days of age"
    },
    {
      "id": "30 and 50 days of age"
    },
    {
      "id": "5L rat hepatoma cells"
    },
    {
      "id": "TCDD toxicity"
    },
    {
      "id": "eukaryotic translation initiation factor 4E-binding protein 1"
    },
    {
      "id": "mammalian target of rapamycin"
    },
    {
      "id": "insulin-like growth factor binding protein 4"
    },
    {
      "id": "IGFBP-4"
    },
    {
      "id": "Fao"
    },
    {
      "id": "TCDD-induced secreted factor"
    },
    {
      "id": "quantitative proteomic studies"
    },
    {
      "id": "rat hepatoma cell lines"
    },
    {
      "id": "Igfbp-4 gene"
    },
    {
      "id": "promoter"
    },
    {
      "id": "mTOR"
    },
    {
      "id": "dioxin exposure"
    },
    {
      "id": "protein synthesis initiation"
    },
    {
      "id": "IGFBP-4 protein"
    },
    {
      "id": "dioxin toxicity"
    },
    {
      "id": "translation initiation"
    },
    {
      "id": "dioxin responsive element(s)"
    },
    {
      "id": "chromosomal translocations"
    },
    {
      "id": "multicolour spectral karyotyping"
    },
    {
      "id": "SKY"
    },
    {
      "id": "insulin receptor substrate 1"
    },
    {
      "id": "fact"
    },
    {
      "id": "taenia caeci"
    },
    {
      "id": "ambenonium"
    },
    {
      "id": "guinea-pig ileal longitudinal smooth muscle"
    },
    {
      "id": "drug receptors"
    },
    {
      "id": "bethanechol"
    },
    {
      "id": "property"
    },
    {
      "id": "Schild analyses"
    },
    {
      "id": "pKB values"
    },
    {
      "id": "tissue responses"
    },
    {
      "id": "Schild regressions"
    },
    {
      "id": "linear regression"
    },
    {
      "id": "mean pKB"
    },
    {
      "id": "underestimation"
    },
    {
      "id": "criteria"
    },
    {
      "id": "antimuscarinic effects"
    },
    {
      "id": "organ selectivity"
    },
    {
      "id": "tissue"
    },
    {
      "id": "ambenonium antagonism"
    },
    {
      "id": "acetylcholine responses"
    },
    {
      "id": "pKB estimates"
    },
    {
      "id": "population of receptors"
    },
    {
      "id": "dual effect"
    },
    {
      "id": "regressions"
    },
    {
      "id": "slope"
    },
    {
      "id": "rat anococcygeus muscle"
    },
    {
      "id": "acetylcholinesterase inhibitor"
    },
    {
      "id": "Statistical analysis"
    },
    {
      "id": "unity"
    },
    {
      "id": "clorgyline"
    },
    {
      "id": "monoamine oxidase type A"
    },
    {
      "id": "debrisoquin"
    },
    {
      "id": "striatium"
    },
    {
      "id": "catechols"
    },
    {
      "id": "nialamide"
    },
    {
      "id": "MAO-A"
    },
    {
      "id": "deamination"
    },
    {
      "id": "peripheral neuronal MAO"
    },
    {
      "id": "DHPG"
    },
    {
      "id": "(-)deprenyl"
    },
    {
      "id": "dihydroxyphenylglycol"
    },
    {
      "id": "central dopaminergic activity"
    },
    {
      "id": "monoamine oxidase inhibitors"
    },
    {
      "id": "MAO-B"
    },
    {
      "id": "peripheral neurons"
    },
    {
      "id": "deaminated metabolites"
    },
    {
      "id": "MAO inhibitors"
    },
    {
      "id": "residual levels"
    },
    {
      "id": "dihydroxyphenylacetic acid"
    },
    {
      "id": "Indoxyl 3-sulfate"
    },
    {
      "id": "AhR activation"
    },
    {
      "id": "experimental autoimmune encephalomyelitis (EAE)"
    },
    {
      "id": "IL-6 signaling pathways"
    },
    {
      "id": "I3S"
    },
    {
      "id": "Th17 differentiation"
    },
    {
      "id": "STAT3 activation"
    },
    {
      "id": "uremic toxin"
    },
    {
      "id": "IL-17-producing cells"
    },
    {
      "id": "AhR ligands"
    },
    {
      "id": "ROR\u03b3t"
    },
    {
      "id": "master transcription factor"
    },
    {
      "id": "PP2"
    },
    {
      "id": "c-Src activity"
    },
    {
      "id": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine"
    },
    {
      "id": "CD4T cell differentiation"
    },
    {
      "id": "prototypical AhR ligand"
    },
    {
      "id": "N-terminal portion"
    },
    {
      "id": "cartilage link protein family"
    },
    {
      "id": "synovial fluid"
    },
    {
      "id": "TSG-6/I alpha I complex"
    },
    {
      "id": "chondroitin sulfate ABC lyase"
    },
    {
      "id": "C-terminal half"
    },
    {
      "id": "CUB domain"
    },
    {
      "id": "cross-linking"
    },
    {
      "id": "I alpha I"
    },
    {
      "id": "human serum"
    },
    {
      "id": "hyaluronan binding proteins"
    },
    {
      "id": "TSG-6"
    },
    {
      "id": "complex"
    },
    {
      "id": "reducing conditions"
    },
    {
      "id": "TSG-6 protein"
    },
    {
      "id": "polypeptide chains"
    },
    {
      "id": "recombinant TSG-6"
    },
    {
      "id": "sequence homology"
    },
    {
      "id": "N-terminal microsequencing"
    },
    {
      "id": "rabbit serum"
    },
    {
      "id": "mouse serum"
    },
    {
      "id": "arthritic diseases"
    },
    {
      "id": "developmentally regulated proteins"
    },
    {
      "id": "35-kDa glycoprotein"
    },
    {
      "id": "arthritis"
    },
    {
      "id": "bovine serum"
    },
    {
      "id": "8 M urea"
    },
    {
      "id": "HC2"
    },
    {
      "id": "IL-1"
    },
    {
      "id": "bikunin"
    },
    {
      "id": "chondroitin sulfate"
    },
    {
      "id": "4 degrees C"
    },
    {
      "id": "serum protein inter-alpha-inhibitor"
    },
    {
      "id": "hyaluronan binding protein"
    },
    {
      "id": "Microsequencing"
    },
    {
      "id": "SDS-PAGE"
    },
    {
      "id": "inter-alpha-inhibitor"
    },
    {
      "id": "calycopterin"
    },
    {
      "id": "H2O2-induced oxidative stress"
    },
    {
      "id": "colorimetric assay"
    },
    {
      "id": "SOD activity"
    },
    {
      "id": "Nrf2 pathway"
    },
    {
      "id": "stress-sensing transcription factors"
    },
    {
      "id": "flavonoid calycopterin"
    },
    {
      "id": "Dracocephalum kotschyi"
    },
    {
      "id": "PC12 cells"
    },
    {
      "id": "dithionitrobenzoic acid method"
    },
    {
      "id": "phase II detoxifying enzyme system"
    },
    {
      "id": "whole cell lysate"
    },
    {
      "id": "western blot method"
    },
    {
      "id": "\u03b3-GCS"
    },
    {
      "id": "comet assay"
    },
    {
      "id": "DNA in tail"
    },
    {
      "id": "nuclear factor erythroid 2-related factor 2"
    },
    {
      "id": "H2O2-induced disruption"
    },
    {
      "id": "cytochrome C release"
    },
    {
      "id": "mitochondrial homeostasis"
    },
    {
      "id": "calycopterin pretreated cells"
    },
    {
      "id": "cell function"
    },
    {
      "id": "phosphorylated CREB"
    },
    {
      "id": "natural flavone"
    },
    {
      "id": "natural neuroprotective flavonoid"
    },
    {
      "id": "p-CREB"
    },
    {
      "id": "differentiated PC12 cells"
    },
    {
      "id": "glutamylcysteine synthetase"
    },
    {
      "id": "survived cells"
    },
    {
      "id": "heme oxygenase 1"
    },
    {
      "id": "ophthalmic solutions"
    },
    {
      "id": "reactive airway disease"
    },
    {
      "id": "Double-blind comparative trials"
    },
    {
      "id": "primary open-angle glaucoma (POAG)"
    },
    {
      "id": "dosage and administration"
    },
    {
      "id": "ocular hypertension (OHT)"
    },
    {
      "id": "chemistry"
    },
    {
      "id": "ophthalmic beta-blocking agents"
    },
    {
      "id": "prolonged use"
    },
    {
      "id": "beta-adrenergic blocking agents"
    },
    {
      "id": "nonselective beta-adrenergic blocking agent"
    },
    {
      "id": "disadvantages"
    },
    {
      "id": "local ocular adverse reactions"
    },
    {
      "id": "systemic beta blockade"
    },
    {
      "id": "advantages"
    },
    {
      "id": "once-daily dosing"
    },
    {
      "id": "ophthalmic beta blocker"
    },
    {
      "id": "cardioselective beta-adrenergic blocker"
    },
    {
      "id": "hereditary angioedema plasma"
    },
    {
      "id": "C-1-inhibitor"
    },
    {
      "id": "Factor XIIf"
    },
    {
      "id": "normal plasma"
    },
    {
      "id": "factor XII active fragment"
    },
    {
      "id": "alpha 2-macroglobulin"
    },
    {
      "id": "125I-Factor XIIf -inhibitor complexes"
    },
    {
      "id": "active 125I-Factor XIIf"
    },
    {
      "id": "125I-Factor XII"
    },
    {
      "id": "sodium dodecyl sulfate polyacrylamide gel electrophoresis"
    },
    {
      "id": "prekallikrein-deficient plasma"
    },
    {
      "id": "Factor XII"
    },
    {
      "id": "alpha 1-antitrypsin"
    },
    {
      "id": "Autoradiography"
    },
    {
      "id": "three protein bands"
    },
    {
      "id": "40 000-Da molecule"
    },
    {
      "id": "total binding species"
    },
    {
      "id": "three proteins"
    },
    {
      "id": "principal components"
    },
    {
      "id": "calcitonin receptors"
    },
    {
      "id": "molecular sieving"
    },
    {
      "id": "Sephacryl S-200"
    },
    {
      "id": "apparent molecular masses"
    },
    {
      "id": "100 000 Da"
    },
    {
      "id": "molecular masses"
    },
    {
      "id": "40 000 Da"
    },
    {
      "id": "protein bands"
    },
    {
      "id": "reducing agent"
    },
    {
      "id": "2-mercaptoethanol"
    },
    {
      "id": "Cross-linked receptor"
    },
    {
      "id": "volume"
    },
    {
      "id": "solubilization"
    },
    {
      "id": "Synthetic salmon calcitonin"
    },
    {
      "id": "renal membranes"
    },
    {
      "id": "renal calcitonin receptor"
    },
    {
      "id": "major band"
    },
    {
      "id": "solubilized membranes"
    },
    {
      "id": "Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis"
    },
    {
      "id": "purified fractions"
    },
    {
      "id": "bifunctional reagent"
    },
    {
      "id": "disuccinimidyl suberate"
    },
    {
      "id": "33 000 Da"
    },
    {
      "id": "polyacrylamide gels"
    },
    {
      "id": "cross-linked calcitonin receptor"
    },
    {
      "id": "site II"
    },
    {
      "id": "number of binding sites"
    },
    {
      "id": "salmon calcitonin"
    },
    {
      "id": "Ka2"
    },
    {
      "id": "site I"
    },
    {
      "id": "Ka1"
    },
    {
      "id": "18 000 Da"
    },
    {
      "id": "purification factor"
    },
    {
      "id": "rat kidney membranes"
    },
    {
      "id": "photo-affinity cross-linking"
    },
    {
      "id": "hydroxysuccinimidyl azidobenzonate reagent"
    },
    {
      "id": "receptor subunits"
    },
    {
      "id": "characterization"
    },
    {
      "id": "renal receptors"
    },
    {
      "id": "affinity chromatography"
    },
    {
      "id": "S-S bonds"
    },
    {
      "id": "high-affinity sites"
    },
    {
      "id": "total loss"
    },
    {
      "id": "high-affinity site"
    },
    {
      "id": "70 000 Da"
    },
    {
      "id": "covalent cross-linking techniques"
    },
    {
      "id": "Estramustine binding protein"
    },
    {
      "id": "EMBP"
    },
    {
      "id": "percentage"
    },
    {
      "id": "positive melanoma cells"
    },
    {
      "id": "interval"
    },
    {
      "id": "diagnosis"
    },
    {
      "id": "pilot study"
    },
    {
      "id": "Radioimmunoassay"
    },
    {
      "id": "metastatic tissue"
    },
    {
      "id": "malignant melanoma"
    },
    {
      "id": "primary tumours"
    },
    {
      "id": "prognostic significance"
    },
    {
      "id": "primary malignant melanomas"
    },
    {
      "id": "positive stain"
    },
    {
      "id": "54 kD cytosolic glycoprotein"
    },
    {
      "id": "hormone-linked cytostatic drugs"
    },
    {
      "id": "occurrence of metastases"
    },
    {
      "id": "craniofacial structures"
    },
    {
      "id": "first branchial arch"
    },
    {
      "id": "teratogen"
    },
    {
      "id": "serious congenital malformations"
    },
    {
      "id": "candidate genes"
    },
    {
      "id": "mammalian craniofacial development"
    },
    {
      "id": "teratogen-treated embryos"
    },
    {
      "id": "nicotinic acetylcholine receptor subunit alpha"
    },
    {
      "id": "NAChR"
    },
    {
      "id": "isotretinoin"
    },
    {
      "id": "Accutane"
    },
    {
      "id": "in situ transcription/aRNA techniques"
    },
    {
      "id": "Altered gene expression"
    },
    {
      "id": "retinoic acid receptor gamma"
    },
    {
      "id": "type 1 cellular retinoid binding protein"
    },
    {
      "id": "transforming growth factor beta 2"
    },
    {
      "id": "aRNA techniques"
    },
    {
      "id": "RA-induced defects"
    },
    {
      "id": "control embryos"
    },
    {
      "id": "panel of 40 candidate genes"
    },
    {
      "id": "tretinoin"
    },
    {
      "id": "morphogenetic processes"
    },
    {
      "id": "pregnant LM/Bc mice"
    },
    {
      "id": "LM/Bc mice"
    },
    {
      "id": "congenital malformations"
    },
    {
      "id": "Retin-A"
    },
    {
      "id": "in situ transcription"
    },
    {
      "id": "gestational day"
    },
    {
      "id": "GD"
    },
    {
      "id": "second branchial arch"
    },
    {
      "id": "murine branchial arches"
    },
    {
      "id": "dermatologic disorders"
    },
    {
      "id": "RAR gamma"
    },
    {
      "id": "CRBP-1"
    },
    {
      "id": "malformations"
    },
    {
      "id": "TGF beta 2"
    },
    {
      "id": "hypomethioninemia"
    },
    {
      "id": "male infant"
    },
    {
      "id": "lethargy"
    },
    {
      "id": "methyl-B12 deficiency"
    },
    {
      "id": "cblE"
    },
    {
      "id": "megaloblastic anemia"
    },
    {
      "id": "age 6 weeks"
    },
    {
      "id": "staring spells"
    },
    {
      "id": "Methionine synthase activity"
    },
    {
      "id": "vitamin B12 concentrations"
    },
    {
      "id": "optimal reducing conditions"
    },
    {
      "id": "cblE disease"
    },
    {
      "id": "suboptimal reducing conditions"
    },
    {
      "id": "Vitamin B12"
    },
    {
      "id": "hydroxocobalamin treatment"
    },
    {
      "id": "intubation"
    },
    {
      "id": "Methyl-B12 content"
    },
    {
      "id": "Fibroblasts"
    },
    {
      "id": "homocystinuria"
    },
    {
      "id": "serum folate"
    },
    {
      "id": "Psychometric testing"
    },
    {
      "id": "developmental age"
    },
    {
      "id": "[14C]-methyl-tetrahydrofolate"
    },
    {
      "id": "adenosyl-B12 content"
    },
    {
      "id": "9 months"
    },
    {
      "id": "[14C]-propionate"
    },
    {
      "id": "age 15 months"
    },
    {
      "id": "ventilation"
    },
    {
      "id": "methylcobalamin deficiency"
    },
    {
      "id": "medium"
    },
    {
      "id": "Sodium-dependent norepinephrine-induced currents"
    },
    {
      "id": "catecholamine transport"
    },
    {
      "id": "ion permeation"
    },
    {
      "id": "inhibitor sensitivities"
    },
    {
      "id": "native membranes"
    },
    {
      "id": "antidepressant-sensitive transporters"
    },
    {
      "id": "cotransport"
    },
    {
      "id": "transporter copies"
    },
    {
      "id": "radioligand binding"
    },
    {
      "id": "Whole-cell voltage-clamp"
    },
    {
      "id": "hNET-293 cells"
    },
    {
      "id": "norepinephrine-transporter"
    },
    {
      "id": "transport cycle"
    },
    {
      "id": "hNET cDNA"
    },
    {
      "id": "biochemical analysis"
    },
    {
      "id": "hNET-specific antibodies"
    },
    {
      "id": "transfected cells"
    },
    {
      "id": "Na(+)-dependent transport of NE"
    },
    {
      "id": "patch-clamp recording"
    },
    {
      "id": "NE+"
    },
    {
      "id": "NE transporter"
    },
    {
      "id": "complete DNA sequence"
    },
    {
      "id": "dideoxy chain termination"
    },
    {
      "id": "Alu repetitive sequences"
    },
    {
      "id": "intron A"
    },
    {
      "id": "5' flanking regions"
    },
    {
      "id": "gene for factor IX"
    },
    {
      "id": "gene for human prothrombin"
    },
    {
      "id": "3' flanking regions"
    },
    {
      "id": "human genomic DNA libraries"
    },
    {
      "id": "gene for blood coagulation factor IX"
    },
    {
      "id": "50 base pair insert"
    },
    {
      "id": "Z-DNA structures"
    },
    {
      "id": "mature protein"
    },
    {
      "id": "KpnI repetitive sequences"
    },
    {
      "id": "region flanking the 5' end of the gene"
    },
    {
      "id": "eight exons"
    },
    {
      "id": "3' noncoding regions"
    },
    {
      "id": "cDNA"
    },
    {
      "id": "hybridization probe"
    },
    {
      "id": "Nucleotide sequence"
    },
    {
      "id": "overlapping lambda phages"
    },
    {
      "id": "intervening sequences"
    },
    {
      "id": "left-handed helical DNA"
    },
    {
      "id": "gene for human protein C"
    },
    {
      "id": "415 amino acids"
    },
    {
      "id": "3' end of the gene"
    },
    {
      "id": "alternating purine-pyrimidine sequences"
    },
    {
      "id": "human factor IX"
    },
    {
      "id": "antihemophilic factor B"
    },
    {
      "id": "clone"
    },
    {
      "id": "intron D"
    },
    {
      "id": "5' flanking region"
    },
    {
      "id": "1.9-kb HindIII subfamily repeat"
    },
    {
      "id": "33.5 kilobases"
    },
    {
      "id": "clones"
    },
    {
      "id": "human protein"
    },
    {
      "id": "seven introns"
    },
    {
      "id": "38 kilobases"
    },
    {
      "id": "coding regions"
    },
    {
      "id": "chemical degradation methods"
    },
    {
      "id": "intron F"
    },
    {
      "id": "prepro leader sequence"
    },
    {
      "id": "genomic libraries"
    },
    {
      "id": "Phenylpropanolamine"
    },
    {
      "id": "Anorexia"
    },
    {
      "id": "Feeding control"
    },
    {
      "id": "Diethylpropion"
    },
    {
      "id": "Reuptake"
    },
    {
      "id": "Dopamine"
    },
    {
      "id": "Nerve terminals"
    },
    {
      "id": "Fluoxetine"
    },
    {
      "id": "Phentermine"
    },
    {
      "id": "Beta- and alpha 1-adrenoceptors"
    },
    {
      "id": "Noradrenaline"
    },
    {
      "id": "Anorectic action"
    },
    {
      "id": "Humans"
    },
    {
      "id": "Satiating effect"
    },
    {
      "id": "Dexfenfluramine"
    },
    {
      "id": "Sertraline"
    },
    {
      "id": "5-HT uptake inhibitors"
    },
    {
      "id": "Neurochemical mechanism"
    },
    {
      "id": "Anorectic drugs"
    },
    {
      "id": "(+)-amphetamine"
    },
    {
      "id": "Anorectic agent"
    },
    {
      "id": "Subtypes"
    },
    {
      "id": "Neurotransmitters"
    },
    {
      "id": "Receptor types"
    },
    {
      "id": "Food craving"
    },
    {
      "id": "Eating disorders"
    },
    {
      "id": "Alpha 1-adrenoceptors"
    },
    {
      "id": "D1 dopamine receptors"
    },
    {
      "id": "Binge-eating"
    },
    {
      "id": "emedastine"
    },
    {
      "id": "chlorpheniramine"
    },
    {
      "id": "allergic conjunctivitis"
    },
    {
      "id": "histamine induced vascular permeability changes"
    },
    {
      "id": "conjunctiva"
    },
    {
      "id": "vascular permeability changes"
    },
    {
      "id": "clemastine"
    },
    {
      "id": "antazoline"
    },
    {
      "id": "topical ocular administration"
    },
    {
      "id": "pheniramine"
    },
    {
      "id": "platelet-activating-factor"
    },
    {
      "id": "topical ocular anti-histaminic activity"
    },
    {
      "id": "brompheniramine"
    },
    {
      "id": "allergic response"
    },
    {
      "id": "anti-histamines"
    },
    {
      "id": "conjunctivitis models"
    },
    {
      "id": "antigen"
    },
    {
      "id": "histamine H1 antagonist"
    },
    {
      "id": "pyrilamine"
    },
    {
      "id": "passive conjunctival anaphylaxis model"
    },
    {
      "id": "levocabastine"
    },
    {
      "id": "1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)- benzimidazole difumarate"
    },
    {
      "id": "histamine H1 receptor"
    },
    {
      "id": "topical ocular use"
    },
    {
      "id": "product"
    },
    {
      "id": "ultraviolet spectral studies"
    },
    {
      "id": "potassium cyanide"
    },
    {
      "id": "reaction"
    },
    {
      "id": "4-Hydroxymandelic acid"
    },
    {
      "id": "Mimosine"
    },
    {
      "id": "3,4-dihydroxymandelic acid"
    },
    {
      "id": "mushroom tyrosinase"
    },
    {
      "id": "active site copper"
    },
    {
      "id": "sodium azide"
    },
    {
      "id": "3-methoxy-4-hydroxymandelic acid"
    },
    {
      "id": "monophenols"
    },
    {
      "id": "Tyrosinase"
    },
    {
      "id": "Sugumaran, M."
    },
    {
      "id": "FEBS Lett."
    },
    {
      "id": "3,4-dihydroxybenzyl alcohol"
    },
    {
      "id": "intermediates"
    },
    {
      "id": "quinone methide production"
    },
    {
      "id": "high-performance liquid chromatography (HPLC)"
    },
    {
      "id": "Phenol oxidase inhibitors"
    },
    {
      "id": "galactose oxidase"
    },
    {
      "id": "oxidative decarboxylation"
    },
    {
      "id": "phenylthiourea"
    },
    {
      "id": "quinone methide derivative"
    },
    {
      "id": "oxidative decarboxylation reaction"
    },
    {
      "id": "Phenol oxidase"
    },
    {
      "id": "(3,4-dihydroxybenzoyl)formic acid"
    },
    {
      "id": "diphenols"
    },
    {
      "id": "ceruloplasmin"
    },
    {
      "id": "o-diphenols"
    },
    {
      "id": "3,4-dihydroxybenzaldehyde"
    },
    {
      "id": "cuticular phenol oxidase"
    },
    {
      "id": "4-alkylcatechols"
    },
    {
      "id": "3,4-dihydroxymandelate"
    },
    {
      "id": "ascorbate oxidase"
    },
    {
      "id": "peroxidase"
    },
    {
      "id": "quinone methides"
    },
    {
      "id": "Lipke, H."
    },
    {
      "id": "infrared spectral studies"
    },
    {
      "id": "bradykinin"
    },
    {
      "id": "alpha-AR mRNA level"
    },
    {
      "id": "Actinomycin D"
    },
    {
      "id": "H-7"
    },
    {
      "id": "alpha-AR gene transcription"
    },
    {
      "id": "alpha 1B-adrenergic receptor mRNA"
    },
    {
      "id": "(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride"
    },
    {
      "id": "ryanodine"
    },
    {
      "id": "down-regulation of alpha-AR mRNA"
    },
    {
      "id": "Phorbol esters"
    },
    {
      "id": "protein kinase C inhibitor"
    },
    {
      "id": "rate of alpha-AR mRNA degradation"
    },
    {
      "id": "EGTA"
    },
    {
      "id": "sustained phosphorylation"
    },
    {
      "id": "protein kinase C substrate"
    },
    {
      "id": "protein phosphatase inhibitor"
    },
    {
      "id": "stability of the mRNA"
    },
    {
      "id": "alpha-AR mRNA"
    },
    {
      "id": "basal mRNA levels"
    },
    {
      "id": "outer cell membrane"
    },
    {
      "id": "Gram-negative bacteria"
    },
    {
      "id": "Cefepime"
    },
    {
      "id": "PBPs 2 and 3"
    },
    {
      "id": "N-methyl-pyrrolidine moiety"
    },
    {
      "id": "zwitterionic properties"
    },
    {
      "id": "methicillin-susceptible Staphylococcus aureus"
    },
    {
      "id": "cefotaxime-resistant Enterobacteriaceae"
    },
    {
      "id": "MIC90"
    },
    {
      "id": "latamoxef"
    },
    {
      "id": "coagulase-negative staphylococci"
    },
    {
      "id": "beta-lactamase producers"
    },
    {
      "id": "methoxyimino-aminothiazolyl cephalosporin"
    },
    {
      "id": "broad-spectrum of activity"
    },
    {
      "id": "Haemophilus influenzae"
    },
    {
      "id": "chromosomally-mediated beta-lactamases"
    },
    {
      "id": "Gram-negative organisms"
    },
    {
      "id": "meningitis"
    },
    {
      "id": "bacterial species"
    },
    {
      "id": "Gram-negative pathogens"
    },
    {
      "id": "Enterobacteriaceae"
    },
    {
      "id": "beta-lactamases"
    },
    {
      "id": "ceftazidime-resistant Enterobacteriaceae"
    },
    {
      "id": "experimental infections"
    },
    {
      "id": "chronic staphylococcal osteomyelitis"
    },
    {
      "id": "cefpirome"
    },
    {
      "id": "Pseudomonas aeruginosa"
    },
    {
      "id": "Neiserria gonorrhoeae"
    },
    {
      "id": "strains of P. aeruginosa"
    },
    {
      "id": "ceftazidime"
    },
    {
      "id": "plasmid"
    },
    {
      "id": "PBP 3"
    },
    {
      "id": "Neiserria meningitidis"
    },
    {
      "id": "Streptococcus pyogenes"
    },
    {
      "id": "cefoperazone"
    },
    {
      "id": "neonatal rats"
    },
    {
      "id": "Streptococcus pneumoniae"
    },
    {
      "id": "Moraxella catarrhalis"
    },
    {
      "id": "beta-lactamase"
    },
    {
      "id": "cefotaxime"
    },
    {
      "id": "Degenerate oligonucleotides"
    },
    {
      "id": "conserved amino acids"
    },
    {
      "id": "unique sequence"
    },
    {
      "id": "rat hypothalamic cDNA"
    },
    {
      "id": "MR77"
    },
    {
      "id": "full-length clone"
    },
    {
      "id": "transmembrane domains V"
    },
    {
      "id": "5-HT1E-like rat and human 5-hydroxytryptamine receptor genes"
    },
    {
      "id": "human homolog"
    },
    {
      "id": "encoded protein"
    },
    {
      "id": "amino acid identity"
    },
    {
      "id": "rat 5-HT1B receptors"
    },
    {
      "id": "adenylate cyclase"
    },
    {
      "id": "125I-labeled LSD binding"
    },
    {
      "id": "ergot alkaloids"
    },
    {
      "id": "transmembrane domains III"
    },
    {
      "id": "known receptors"
    },
    {
      "id": "5-carboxyamidotryptamine"
    },
    {
      "id": "mixed 5-HT1A/1D agonist"
    },
    {
      "id": "additional 5-HT1E-like receptor"
    },
    {
      "id": "expressed receptor"
    },
    {
      "id": "ergotamine"
    },
    {
      "id": "broken cell preparations"
    },
    {
      "id": "sequences"
    },
    {
      "id": "rat genomic library"
    },
    {
      "id": "5-HT1C"
    },
    {
      "id": "methysergide"
    },
    {
      "id": "resulting product"
    },
    {
      "id": "Sequential polymerase chain reaction experiments"
    },
    {
      "id": "guanine nucleotide-binding protein (G-protein)-coupled receptor"
    },
    {
      "id": "transmembrane domains VI"
    },
    {
      "id": "selective 5-HT1D agonist"
    },
    {
      "id": "5-HT2"
    },
    {
      "id": "5-HT1 class"
    },
    {
      "id": "125I-labeled d-lysergic acid diethylamide"
    },
    {
      "id": "LSD"
    },
    {
      "id": "intronless open reading frame"
    },
    {
      "id": "366-amino acid seven-transmembrane domain protein"
    },
    {
      "id": "MR77 gene"
    },
    {
      "id": "rat 5-HT1A receptors"
    },
    {
      "id": "human 5-HT1E receptors"
    },
    {
      "id": "sequential reactions"
    },
    {
      "id": "eukaryotic expression vector system"
    },
    {
      "id": "rat sequence"
    },
    {
      "id": "conserved transmembrane domains"
    },
    {
      "id": "CosM6 cells"
    },
    {
      "id": "rat 5-HT1D receptors"
    },
    {
      "id": "fibrin(ogen)"
    },
    {
      "id": "( Glu1]Pg)"
    },
    {
      "id": "Fibrinogen"
    },
    {
      "id": "two-chain rec-t-PA"
    },
    {
      "id": "systemic fibrinogenolysis"
    },
    {
      "id": "Cl-(-)"
    },
    {
      "id": "[Glu1]Pg"
    },
    {
      "id": "human [Glu1]plasminogen"
    },
    {
      "id": "Chloride"
    },
    {
      "id": "epsilon-aminocaproic acid"
    },
    {
      "id": "human tissue plasminogen activator"
    },
    {
      "id": "rat striatum"
    },
    {
      "id": "amantadine induction of Fos"
    },
    {
      "id": "Amantadine"
    },
    {
      "id": "Fos expression"
    },
    {
      "id": "dopamine D2 receptor antagonist"
    },
    {
      "id": "distribution pattern of Fos"
    },
    {
      "id": "dopaminomimetics"
    },
    {
      "id": "ventral-medial part of the striatum"
    },
    {
      "id": "1-aminoadamantane"
    },
    {
      "id": "dorsal-medial part of the striatum"
    },
    {
      "id": "dopamine D1"
    },
    {
      "id": "NMDA receptor antagonists"
    },
    {
      "id": "central part of the striatum"
    },
    {
      "id": "dopamine D1 receptors"
    },
    {
      "id": "N-methyl-D-aspartate"
    },
    {
      "id": "ion channels"
    },
    {
      "id": "ions"
    },
    {
      "id": "channel-like events"
    },
    {
      "id": "transmitter"
    },
    {
      "id": "net charge"
    },
    {
      "id": "fixed stoichiometry"
    },
    {
      "id": "T-mode"
    },
    {
      "id": "C-mode"
    },
    {
      "id": "transmitter-induced current"
    },
    {
      "id": "Norepinephrine transporters"
    },
    {
      "id": "channel modes of conduction"
    },
    {
      "id": "guanethidine"
    },
    {
      "id": "hNET substrate"
    },
    {
      "id": "reuptake"
    },
    {
      "id": "coupled cotransport"
    },
    {
      "id": "cotransported ions"
    },
    {
      "id": "aqueous pore"
    },
    {
      "id": "transporter protein"
    },
    {
      "id": "hNETs"
    },
    {
      "id": "transmitter molecule"
    },
    {
      "id": "Neurotransmitter transporters"
    },
    {
      "id": "low probability"
    },
    {
      "id": "C-mode opening"
    },
    {
      "id": "charges"
    },
    {
      "id": "blockers"
    },
    {
      "id": "antidepressant desipramine"
    },
    {
      "id": "transporter regulation"
    },
    {
      "id": "fixed-stoichiometry transporter"
    },
    {
      "id": "ion gradients"
    },
    {
      "id": "NE uptake data"
    },
    {
      "id": "functional modes of conduction"
    },
    {
      "id": "Voltage-clamp data"
    },
    {
      "id": "classical transporter mode (T-mode)"
    },
    {
      "id": "channel open time"
    },
    {
      "id": "novel channel mode (C-mode)"
    },
    {
      "id": "gamma-aminobutyric acid transporter gene family"
    },
    {
      "id": "topoisomerase II inhibitor"
    },
    {
      "id": "topoisomerase II inhibitors"
    },
    {
      "id": "secondary leukemia"
    },
    {
      "id": "myelodysplasia"
    },
    {
      "id": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements"
    },
    {
      "id": "ALL-1 gene"
    },
    {
      "id": "Htrxl"
    },
    {
      "id": "HRX"
    },
    {
      "id": "morphologic features"
    },
    {
      "id": "primary cancers"
    },
    {
      "id": "clinical features"
    },
    {
      "id": "breakpoint cluster region"
    },
    {
      "id": "DNA topoisomerase II inhibitor"
    },
    {
      "id": "topoisomerase II inhibitor-associated leukemia"
    },
    {
      "id": "sporadic cases"
    },
    {
      "id": "MLL"
    },
    {
      "id": "molecular rearrangement"
    },
    {
      "id": "11q23 involvement"
    },
    {
      "id": "Exposure histories"
    },
    {
      "id": "secondary 11q23 leukemia"
    },
    {
      "id": "Southern blot"
    },
    {
      "id": "pediatric cases"
    },
    {
      "id": "dactinomycin"
    },
    {
      "id": "acute lymphoblastic leukemia (ALL)"
    },
    {
      "id": "cytogenetic features"
    },
    {
      "id": "chromosomal band 11q23"
    },
    {
      "id": "mixed lineage"
    },
    {
      "id": "topoisomerase II"
    },
    {
      "id": "DNA topoisomerase II"
    },
    {
      "id": "collagen formation"
    },
    {
      "id": "cardiac fibroblasts"
    },
    {
      "id": "cardiac fibrosis"
    },
    {
      "id": "non-epithelial MR"
    },
    {
      "id": "normotensive animals"
    },
    {
      "id": "tissue renin-angiotensin systems"
    },
    {
      "id": "salt"
    },
    {
      "id": "MR occupancy"
    },
    {
      "id": "locus of aldosterone action"
    },
    {
      "id": "left ventricles"
    },
    {
      "id": "high salt intake"
    },
    {
      "id": "model of mineralocorticoid excess"
    },
    {
      "id": "low salt intake"
    },
    {
      "id": "collagen deposition"
    },
    {
      "id": "uninephrectomized rats"
    },
    {
      "id": "1% NaCl solution"
    },
    {
      "id": "mineralocorticoid-induced hypokalemia"
    },
    {
      "id": "potassium canrenoate"
    },
    {
      "id": "perivascular cardiac fibrosis"
    },
    {
      "id": "plasma renin-angiotensin systems"
    },
    {
      "id": "9 alpha-fluorocortisol"
    },
    {
      "id": "cardiac effect"
    },
    {
      "id": "elevated blood pressure"
    },
    {
      "id": "interstitial cardiac fibrosis"
    },
    {
      "id": "Perindopril"
    },
    {
      "id": "classical MR"
    },
    {
      "id": "Mineralocorticoids"
    },
    {
      "id": "right ventricles"
    },
    {
      "id": "RU28318"
    },
    {
      "id": "seizure frequency"
    },
    {
      "id": "hypogonadism"
    },
    {
      "id": "testolactone"
    },
    {
      "id": "Antiepileptic drug"
    },
    {
      "id": "serum estradiol"
    },
    {
      "id": "reproductive and sexual dysfunction"
    },
    {
      "id": "sexual dysfunction"
    },
    {
      "id": "serum levels"
    },
    {
      "id": "sexual function"
    },
    {
      "id": "biologically active testosterone"
    },
    {
      "id": "thioridazine"
    },
    {
      "id": "calmodulin antagonists"
    },
    {
      "id": "progesterone receptors"
    },
    {
      "id": "ER-positive T47D human breast cancer cell lines"
    },
    {
      "id": "ER-positive human breast tumors"
    },
    {
      "id": "neuroleptic agents"
    },
    {
      "id": "W-13"
    },
    {
      "id": "MCF-7 human breast cancer cell growth"
    },
    {
      "id": "W-12"
    },
    {
      "id": "calmodulin antagonism"
    },
    {
      "id": "growth-inhibitory properties"
    },
    {
      "id": "human breast cancer cell proliferation"
    },
    {
      "id": "ZR75-1B human breast cancer cell lines"
    },
    {
      "id": "ER-negative human breast tumors"
    },
    {
      "id": "[3H]thymidine incorporation"
    },
    {
      "id": "serum-free medium"
    },
    {
      "id": "polypeptide hormones"
    },
    {
      "id": "estradiol binding properties"
    },
    {
      "id": "epidermal growth factor"
    },
    {
      "id": "Permanent cell culture lines"
    },
    {
      "id": "experimental models"
    },
    {
      "id": "MCF-7 ER"
    },
    {
      "id": "breast cancer cell growth"
    },
    {
      "id": "human breast cancer tissue"
    },
    {
      "id": "tissue culture"
    },
    {
      "id": "MCF-7 cell line"
    },
    {
      "id": "insulin-like growth factor I"
    },
    {
      "id": "50% inhibition concentration values"
    },
    {
      "id": "proliferation assays"
    },
    {
      "id": "stripped calf serum"
    },
    {
      "id": "administration of ketotifen"
    },
    {
      "id": "airway response"
    },
    {
      "id": "administration of HOE 140"
    },
    {
      "id": "gaseous formaldehyde"
    },
    {
      "id": "airway microvascular leakage"
    },
    {
      "id": "Leakage of dye"
    },
    {
      "id": "Activation of bradykinin receptors"
    },
    {
      "id": "tachykinin and bradykinin receptors"
    },
    {
      "id": "Extravasation of Evans blue dye"
    },
    {
      "id": "15 ppm formaldehyde"
    },
    {
      "id": "mast cells"
    },
    {
      "id": "administration of CP-99,994"
    },
    {
      "id": "microvascular leakage"
    },
    {
      "id": "(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)"
    },
    {
      "id": "mast cell-stabilizing properties"
    },
    {
      "id": "increase in vascular permeability"
    },
    {
      "id": "rat airway"
    },
    {
      "id": "CP-99,994"
    },
    {
      "id": "tachykinin NK1 receptor"
    },
    {
      "id": "main bronchi"
    },
    {
      "id": "NK1 receptor stimulation"
    },
    {
      "id": "formaldehyde"
    },
    {
      "id": "10 min inhalation"
    },
    {
      "id": "HOE 140"
    },
    {
      "id": "bradykinin B2 receptor"
    },
    {
      "id": "airway tissues"
    },
    {
      "id": "[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]"
    },
    {
      "id": "(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)"
    },
    {
      "id": "dose-dependent reduction"
    },
    {
      "id": "11-dehydro-thromboxane B2"
    },
    {
      "id": "PGHS"
    },
    {
      "id": "cyclooxygenase activity"
    },
    {
      "id": "PGHS-1"
    },
    {
      "id": "prostaglandin IF2 alpha"
    },
    {
      "id": "renal"
    },
    {
      "id": "arachidonate metabolism"
    },
    {
      "id": "inducible prostaglandin H synthase"
    },
    {
      "id": "eicosanoid biosynthesis"
    },
    {
      "id": "production of TXB2"
    },
    {
      "id": "whole blood clotting"
    },
    {
      "id": "500 mg daily"
    },
    {
      "id": "timecourse"
    },
    {
      "id": "serum TXB2 levels"
    },
    {
      "id": "prostanoid biosynthesis"
    },
    {
      "id": "discontinuation of nabumetone"
    },
    {
      "id": "predrug levels"
    },
    {
      "id": "urinary 11-dehydro-TXB2 excretion"
    },
    {
      "id": "selective inhibitor"
    },
    {
      "id": "low-dose aspirin"
    },
    {
      "id": "platelet"
    },
    {
      "id": "cumulative inhibition"
    },
    {
      "id": "whole blood TXB2 production"
    },
    {
      "id": "platelet turnover"
    },
    {
      "id": "in vivo indexes"
    },
    {
      "id": "PGF2 alpha"
    },
    {
      "id": "healthy subjects"
    },
    {
      "id": "constitutive PGHS-1 pathway"
    },
    {
      "id": "daily administration"
    },
    {
      "id": "40 mg"
    },
    {
      "id": "1000 mg daily"
    },
    {
      "id": "fluorescence in situ hybridization (FISH) analysis"
    },
    {
      "id": "Southern blot analysis"
    },
    {
      "id": "rearrangement"
    },
    {
      "id": "complete remission"
    },
    {
      "id": "translocational splitting"
    },
    {
      "id": "DNA-topoisomerase II inhibitors"
    },
    {
      "id": "t(8;21)"
    },
    {
      "id": "1500 mg"
    },
    {
      "id": "intravenously"
    },
    {
      "id": "chromosome 21"
    },
    {
      "id": "breakpoint"
    },
    {
      "id": "alkylating agent"
    },
    {
      "id": "therapy-related acute myeloblastic leukemia"
    },
    {
      "id": "AML1 gene"
    },
    {
      "id": "4000 mg"
    },
    {
      "id": "Cytogenetic analysis"
    },
    {
      "id": "cumulative dose"
    },
    {
      "id": "etoposide administration"
    },
    {
      "id": "interphase"
    },
    {
      "id": "AML of FAB M2"
    },
    {
      "id": "chromosome 16"
    },
    {
      "id": "59-year-old female"
    },
    {
      "id": "deletion of 7q"
    },
    {
      "id": "5500 mg"
    },
    {
      "id": "mitoxantrone"
    },
    {
      "id": "malignant lymphoma"
    },
    {
      "id": "t(16;21)(q24;q22)"
    },
    {
      "id": "t-AML"
    },
    {
      "id": "rare translocation"
    },
    {
      "id": "metaphase"
    },
    {
      "id": "Cyclic flow variations"
    },
    {
      "id": "recurrent thrombus formation"
    },
    {
      "id": "Infusion of FVIIa"
    },
    {
      "id": "CFVs"
    },
    {
      "id": "TF"
    },
    {
      "id": "factor VII"
    },
    {
      "id": "AP-1 treated animals"
    },
    {
      "id": "AP-1 and FVIIai bindings to TF"
    },
    {
      "id": "FVIIa"
    },
    {
      "id": "arterial thrombosis"
    },
    {
      "id": "aurintrycarboxilic acid"
    },
    {
      "id": "interaction between extrinsic coagulation pathway activation and platelet aggregation"
    },
    {
      "id": "intravascular thrombus formation"
    },
    {
      "id": "ATA"
    },
    {
      "id": "platelet glycoprotein Ib"
    },
    {
      "id": "extrinsic coagulation pathway"
    },
    {
      "id": "tissue factor"
    },
    {
      "id": "activation of extrinsic coagulation by FVIIa"
    },
    {
      "id": "inhibition of platelet function"
    },
    {
      "id": "ex vivo platelet aggregation"
    },
    {
      "id": "antithrombotic activity"
    },
    {
      "id": "experimental model"
    },
    {
      "id": "external constrictor"
    },
    {
      "id": "endothelially-injured rabbit carotid arteries"
    },
    {
      "id": "ridogrel e ATA treated rabbits"
    },
    {
      "id": "FX"
    },
    {
      "id": "human recombinant FVIIa"
    },
    {
      "id": "Activated partial thromboplastin time"
    },
    {
      "id": "FVIIai infusion"
    },
    {
      "id": "dual thromboxane A2 synthetase inhibitor"
    },
    {
      "id": "thromboxane A2 synthetase"
    },
    {
      "id": "inhibition of FVII binding to TF"
    },
    {
      "id": "antithrombotic effects"
    },
    {
      "id": "recurrent arterial thrombosis"
    },
    {
      "id": "activation of the extrinsic coagulation pathway"
    },
    {
      "id": "ridogrel"
    },
    {
      "id": "inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction"
    },
    {
      "id": "Folt's model"
    },
    {
      "id": "recombinant human FVIIa"
    },
    {
      "id": "antiplatelet-treated rabbits"
    },
    {
      "id": "intra-arterial infusion"
    },
    {
      "id": "thromboxane A2 receptor antagonist"
    },
    {
      "id": "Carotid blood flow"
    },
    {
      "id": "Doppler flow probe"
    },
    {
      "id": "FVIIai treated animals"
    },
    {
      "id": "activated FVII"
    },
    {
      "id": "Inactivated factor VII"
    },
    {
      "id": "thromboxane A2 receptor"
    },
    {
      "id": "New Zealand White rabbits"
    },
    {
      "id": "human recombinant FVIIai"
    },
    {
      "id": "FVIIai"
    },
    {
      "id": "arterial damage"
    },
    {
      "id": "constrictor"
    },
    {
      "id": "active site-blocked FVIIa"
    },
    {
      "id": "rabbit model of intravascular thrombus formation"
    },
    {
      "id": "FVII"
    },
    {
      "id": "small catheter (26G)"
    },
    {
      "id": "stenosis"
    },
    {
      "id": "rabbit TF"
    },
    {
      "id": "FIX"
    },
    {
      "id": "Administration of FVIIai"
    },
    {
      "id": "systemic coagulation"
    },
    {
      "id": "thrombin formation"
    },
    {
      "id": "FVIIai treated rabbits"
    },
    {
      "id": "FVII-VIIa"
    },
    {
      "id": "chlorothiazide-inhibitable 22Na uptake"
    },
    {
      "id": "Peripheral blood mononuclear cells (PBMC)"
    },
    {
      "id": "Gitelman's syndrome (GS)"
    },
    {
      "id": "thiazide-sensitive NaCl cotransport"
    },
    {
      "id": "PBMC NaCl cotransport"
    },
    {
      "id": "underlying cause"
    },
    {
      "id": "defective NCCT NaCl cotransport"
    },
    {
      "id": "chlorothiazide"
    },
    {
      "id": "NCCT mRNA"
    },
    {
      "id": "patient's paternal allele"
    },
    {
      "id": "GGT --> GTT"
    },
    {
      "id": "maternal allele"
    },
    {
      "id": "patient's genomic DNA"
    },
    {
      "id": "3' splice site mutation"
    },
    {
      "id": "22Na uptake"
    },
    {
      "id": "patients' NCCT cDNA"
    },
    {
      "id": "control PBMC"
    },
    {
      "id": "bumetanide"
    },
    {
      "id": "119-bp insertion"
    },
    {
      "id": "exons 3"
    },
    {
      "id": "5' splice site mutation"
    },
    {
      "id": "NaCl"
    },
    {
      "id": "full-length NCCT cDNA"
    },
    {
      "id": "normal PBMC"
    },
    {
      "id": "functional significance"
    },
    {
      "id": "exons 4"
    },
    {
      "id": "Northern analysis"
    },
    {
      "id": "brothers"
    },
    {
      "id": "human thiazide-sensitive sodium chloride cotransporter gene"
    },
    {
      "id": "premature stop codon"
    },
    {
      "id": "amino acid 187"
    },
    {
      "id": "CAG --> CAA"
    },
    {
      "id": "paternal allele"
    },
    {
      "id": "NCCT"
    },
    {
      "id": "genomic NCCT mutations"
    },
    {
      "id": "amino acid 920"
    },
    {
      "id": "intron 24"
    },
    {
      "id": "intron 3"
    },
    {
      "id": "22Na"
    },
    {
      "id": "patient's maternal allele"
    },
    {
      "id": "sodium chloride"
    },
    {
      "id": "mutational analysis"
    },
    {
      "id": "exon 24"
    },
    {
      "id": "normal chromosomes"
    },
    {
      "id": "functional evidence"
    },
    {
      "id": "sequence"
    },
    {
      "id": "thiazide"
    },
    {
      "id": "Genetic analysis"
    },
    {
      "id": "human renal NCCT cDNA"
    },
    {
      "id": "parents"
    },
    {
      "id": "cryptic splice site"
    },
    {
      "id": "TSC"
    },
    {
      "id": "nonreentrant catecholamine-mediated ventricular tachycardia"
    },
    {
      "id": "endogenous adenosine"
    },
    {
      "id": "VT cycle length"
    },
    {
      "id": "newly recognized form of clinical VT"
    },
    {
      "id": "antiarrhythmic effects"
    },
    {
      "id": "noncardiac receptor-mediated effects"
    },
    {
      "id": "muscarinic cholinergic receptor"
    },
    {
      "id": "Dipyridamole"
    },
    {
      "id": "sustained nonreentrant, nonautomatic, catecholamine-mediated VT"
    },
    {
      "id": "tachycardia"
    },
    {
      "id": "exogenous adenosine"
    },
    {
      "id": "autonomic tone"
    },
    {
      "id": "Valsalva"
    },
    {
      "id": "myocardial stretch"
    },
    {
      "id": "myocardial receptor-mediated effects"
    },
    {
      "id": "dipyridamole"
    },
    {
      "id": "reentrant VT"
    },
    {
      "id": "Adenosine"
    },
    {
      "id": "catecholamine-mediated VT"
    },
    {
      "id": "cardiac dimensions"
    },
    {
      "id": "Edrophonium"
    },
    {
      "id": "arterial chemoreceptors"
    },
    {
      "id": "receptor-mediated effects"
    },
    {
      "id": "nonreentrant catecholamine-mediated VT"
    },
    {
      "id": "nucleoside transport blocker"
    },
    {
      "id": "form of nonreentrant, catecholamine-mediated VT"
    },
    {
      "id": "rapid pacing"
    },
    {
      "id": "adenosine A1"
    },
    {
      "id": "aminophylline"
    },
    {
      "id": "competitive adenosine A1-receptor antagonist"
    },
    {
      "id": "receptor-mediated inhibition"
    },
    {
      "id": "Reentrant ventricular tachycardia (VT)"
    },
    {
      "id": "nucleoside"
    },
    {
      "id": "VT"
    },
    {
      "id": "delayed afterdepolarizations"
    },
    {
      "id": "vagal maneuvers"
    },
    {
      "id": "venous return"
    },
    {
      "id": "automaticity"
    },
    {
      "id": "cycle length dependence"
    },
    {
      "id": "cholinesterase inhibitor"
    },
    {
      "id": "Valsalva maneuver"
    },
    {
      "id": "triggered activity"
    },
    {
      "id": "nonselective MAO inhibitors"
    },
    {
      "id": "adverse effect profiles"
    },
    {
      "id": "hallucinations"
    },
    {
      "id": "SSRIs"
    },
    {
      "id": "true serotonin syndrome"
    },
    {
      "id": "meperidine"
    },
    {
      "id": "selegiline therapy"
    },
    {
      "id": "tyramine-induced hypertension"
    },
    {
      "id": "low tyramine diet"
    },
    {
      "id": "deprenyl"
    },
    {
      "id": "dizziness"
    },
    {
      "id": "MAO-B inhibitor"
    },
    {
      "id": "benign cardiac arrhythmias"
    },
    {
      "id": "pethidine"
    },
    {
      "id": "moclobemide"
    },
    {
      "id": "monoamine oxidase type B"
    },
    {
      "id": "peak dose dyskinesias"
    },
    {
      "id": "Mortality"
    },
    {
      "id": "'cheese effect'"
    },
    {
      "id": "psychiatric complications"
    },
    {
      "id": "fluctuations in disability"
    },
    {
      "id": "tricyclic antidepressant"
    },
    {
      "id": "selective, reversible MAO-A inhibitor"
    },
    {
      "id": "orthostatic hypotension"
    },
    {
      "id": "murine PGHS-1"
    },
    {
      "id": "murine PGHS-2"
    },
    {
      "id": "prostaglandin endoperoxide (PGH) synthase"
    },
    {
      "id": "PGH synthase-1 and -2"
    },
    {
      "id": "tumor promoters"
    },
    {
      "id": "PGH synthase-2"
    },
    {
      "id": "PGG2"
    },
    {
      "id": "COX II"
    },
    {
      "id": "6-Methoxy-2-naphthylacetic acid"
    },
    {
      "id": "Relafen"
    },
    {
      "id": "PGH synthase-1"
    },
    {
      "id": "ovarian follicles"
    },
    {
      "id": "mitogens"
    },
    {
      "id": "COX I"
    },
    {
      "id": "sulindac sulfide"
    },
    {
      "id": "Indomethacin"
    },
    {
      "id": "PGH2"
    },
    {
      "id": "cos-1 cells"
    },
    {
      "id": "antiinflammatory agent"
    },
    {
      "id": "Ibuprofen"
    },
    {
      "id": "PGHS isozyme"
    },
    {
      "id": "meclofenamate"
    },
    {
      "id": "dofetilide"
    },
    {
      "id": "HERG/IKr channels"
    },
    {
      "id": "affinity of BEAG K+ channels"
    },
    {
      "id": "loss of high-affinity drug binding"
    },
    {
      "id": "loss of C-type inactivation"
    },
    {
      "id": "chimeric approach"
    },
    {
      "id": "HERG S620T"
    },
    {
      "id": "high-affinity block"
    },
    {
      "id": "BEAG T432S"
    },
    {
      "id": "S5-S6 linker"
    },
    {
      "id": "HERG"
    },
    {
      "id": "bovine ether-a-go-go channel"
    },
    {
      "id": "drug binding"
    },
    {
      "id": "biophysical properties"
    },
    {
      "id": "IKr"
    },
    {
      "id": "BEAG"
    },
    {
      "id": "single amino acid residues"
    },
    {
      "id": "direct interaction"
    },
    {
      "id": "respective mutated site chains"
    },
    {
      "id": "serine"
    },
    {
      "id": "position HERG 620"
    },
    {
      "id": "Molecular determinants"
    },
    {
      "id": "dofetilide block"
    },
    {
      "id": "MK-499"
    },
    {
      "id": "E4031"
    },
    {
      "id": "molecular determinants for dofetilide block"
    },
    {
      "id": "human ether-a-go-go-related gene"
    },
    {
      "id": "K+ channel"
    },
    {
      "id": "submicromolar concentrations"
    },
    {
      "id": "Xenopus oocytes"
    },
    {
      "id": "dofetilide binding"
    },
    {
      "id": "HERG K+ channels"
    },
    {
      "id": "chimeras"
    },
    {
      "id": "C-type inactivation"
    },
    {
      "id": "class III antiarrhythmic methanesulfonanilide drugs"
    },
    {
      "id": "indirect allosteric modifications"
    },
    {
      "id": "structure of the channel protein"
    },
    {
      "id": "pharmacological management"
    },
    {
      "id": "rapid component of the cardiac delayed rectifier K+ current"
    },
    {
      "id": "S5-S6 linker region"
    },
    {
      "id": "intact C-type inactivation process"
    },
    {
      "id": "high-affinity drug binding"
    },
    {
      "id": "arrhythmias"
    },
    {
      "id": "pore region of HERG"
    },
    {
      "id": "i.v. injection"
    },
    {
      "id": "ritanserin"
    },
    {
      "id": "lowest active doses"
    },
    {
      "id": "neuroendocrine experiments"
    },
    {
      "id": "parallel group"
    },
    {
      "id": "mixed 5-HT and catecholamine antagonists"
    },
    {
      "id": "open field test"
    },
    {
      "id": "potent antagonists"
    },
    {
      "id": "mirtazapine"
    },
    {
      "id": "mixed 5-HT1/5-HT2 receptor antagonists"
    },
    {
      "id": "exploratory activity"
    },
    {
      "id": "s.c. treatment"
    },
    {
      "id": "attentuation"
    },
    {
      "id": "mCPP-induced behavioural inhibition"
    },
    {
      "id": "meta-chlorophenylpiperazine"
    },
    {
      "id": "5-HT1"
    },
    {
      "id": "exploration"
    },
    {
      "id": "open field area"
    },
    {
      "id": "exploratory behaviour"
    },
    {
      "id": "testing"
    },
    {
      "id": "emergence procedure"
    },
    {
      "id": "mCPP-treated animals"
    },
    {
      "id": "general state of arousal"
    },
    {
      "id": "mianserin"
    },
    {
      "id": "selective 5-HT2A/5-HT2C antagonist"
    },
    {
      "id": "behavioural inhibition"
    },
    {
      "id": "dose-related manner"
    },
    {
      "id": "i.v. treatment"
    },
    {
      "id": "5-HT2C"
    },
    {
      "id": "plasma prolactin"
    },
    {
      "id": "intraperitoneal administration"
    },
    {
      "id": "forskolin-stimulated Isc"
    },
    {
      "id": "primary cultures of mouse trachea epithelia"
    },
    {
      "id": "IK"
    },
    {
      "id": "CFTR Cl- channels"
    },
    {
      "id": "L-cells"
    },
    {
      "id": "salicylic acid"
    },
    {
      "id": "forskolin"
    },
    {
      "id": "forskolin-dependent Isc"
    },
    {
      "id": "CFTR"
    },
    {
      "id": "ICl"
    },
    {
      "id": "Isc"
    },
    {
      "id": "cAMP-mediated Cl- secretion"
    },
    {
      "id": "basolateral K+ currents"
    },
    {
      "id": "basolateral membrane K+ channels"
    },
    {
      "id": "CFTR function"
    },
    {
      "id": "secretory epithelia"
    },
    {
      "id": "forskolin-induced Isc"
    },
    {
      "id": "MTEs"
    },
    {
      "id": "Cl- secretion"
    },
    {
      "id": "short-lived block"
    },
    {
      "id": "CFTR Cl- current"
    },
    {
      "id": "single channel amplitude"
    },
    {
      "id": "apical Cl- currents"
    },
    {
      "id": "Nystatin"
    },
    {
      "id": "apical membrane"
    },
    {
      "id": "cystic fibrosis transmembrane conductance regulator"
    },
    {
      "id": "human bronchial epithelia"
    },
    {
      "id": "airway epithelia"
    },
    {
      "id": "T84 cells"
    },
    {
      "id": "CFTR expression"
    },
    {
      "id": "K+"
    },
    {
      "id": "basolateral membrane"
    },
    {
      "id": "human colonic epithelia"
    },
    {
      "id": "HBEs"
    },
    {
      "id": "colonic epithelia"
    },
    {
      "id": "Ca2+-sensitizing binding site"
    },
    {
      "id": "Met-80"
    },
    {
      "id": "hydrophobic surfaces"
    },
    {
      "id": "N-terminal regulatory domain"
    },
    {
      "id": "drug binding sites"
    },
    {
      "id": "Putkey, J. A."
    },
    {
      "id": "helices C"
    },
    {
      "id": "NMR heteronuclear single-quantum coherence spectra"
    },
    {
      "id": "[methyl-13C]Met-labeled cTnC"
    },
    {
      "id": "cTnC"
    },
    {
      "id": "Ca2+-sensitizing compounds"
    },
    {
      "id": "Liu, W."
    },
    {
      "id": "bepridil"
    },
    {
      "id": "Met-45"
    },
    {
      "id": "Met-60"
    },
    {
      "id": "cardiac troponin C"
    },
    {
      "id": "shallow hydrophobic cup"
    },
    {
      "id": "C-terminal domains"
    },
    {
      "id": "isotope-filtered nuclear Overhauser effects"
    },
    {
      "id": "helix B"
    },
    {
      "id": "Spyracopoulos, L."
    },
    {
      "id": "spin-labeled phenothiazine"
    },
    {
      "id": "Sykes, B. D."
    },
    {
      "id": "Sia, S."
    },
    {
      "id": "Li, M. X."
    },
    {
      "id": "regulatory site II"
    },
    {
      "id": "Met methyl groups"
    },
    {
      "id": "Gagne, S. M."
    },
    {
      "id": "state-dependent cocaine block"
    },
    {
      "id": "steady-state inactivation"
    },
    {
      "id": "shifts"
    },
    {
      "id": "sodium channel isoforms"
    },
    {
      "id": "linear shifts"
    },
    {
      "id": "steady-state cocaine block"
    },
    {
      "id": "hH1 channels"
    },
    {
      "id": "Low affinity block"
    },
    {
      "id": "Cocaine block"
    },
    {
      "id": "block"
    },
    {
      "id": "mu1 channels"
    },
    {
      "id": "coexpression"
    },
    {
      "id": "large positive shifts"
    },
    {
      "id": "whole-cell voltage clamp"
    },
    {
      "id": "HEK293t cells"
    },
    {
      "id": "mu1/hH1 channel chimeras"
    },
    {
      "id": "human cardiac (hH1) muscle sodium channels"
    },
    {
      "id": "cocaine affinity"
    },
    {
      "id": "resting channels"
    },
    {
      "id": "resting mu1 channels"
    },
    {
      "id": "rat skeletal (mu1) muscle sodium channels"
    },
    {
      "id": "channel activation"
    },
    {
      "id": "channels"
    },
    {
      "id": "inactivated channels"
    },
    {
      "id": "wild-type channels"
    },
    {
      "id": "rat brain beta1 subunit"
    },
    {
      "id": "high affinity block"
    },
    {
      "id": "manipulations"
    },
    {
      "id": "central muscarinic M2 receptors"
    },
    {
      "id": "vasopressin release"
    },
    {
      "id": "sympathetic outflow"
    },
    {
      "id": "Pressor and bradycardic effects"
    },
    {
      "id": "cardiovascular effects"
    },
    {
      "id": "Atropine"
    },
    {
      "id": "tacrine-induced bradycardia"
    },
    {
      "id": "i.v. cholinesterase inhibitors"
    },
    {
      "id": "non-selective muscarinic receptor antagonist atropine"
    },
    {
      "id": "tacrine pressor response"
    },
    {
      "id": "Central injection"
    },
    {
      "id": "muscarinic receptor antagonists"
    },
    {
      "id": "methylatropine"
    },
    {
      "id": "intravenous (i.v.) route"
    },
    {
      "id": "[beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin"
    },
    {
      "id": "vasopressin V1 receptor antagonist"
    },
    {
      "id": "muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol"
    },
    {
      "id": "muscarinic M1 receptor antagonist pirenzepine"
    },
    {
      "id": "systolic and diastolic blood pressure"
    },
    {
      "id": "i.c.v. administration"
    },
    {
      "id": "muscarinic M2 receptor antagonist methoctramine"
    },
    {
      "id": "tacrine pressor effects"
    },
    {
      "id": "acetylcholinesterase inhibitor-induced bradycardia"
    },
    {
      "id": "peripheral muscarinic mechanisms"
    },
    {
      "id": "debrisoquine"
    },
    {
      "id": "fractional rate of loss"
    },
    {
      "id": "Amezinium"
    },
    {
      "id": "uptake1"
    },
    {
      "id": "noradrenaline deamination"
    },
    {
      "id": "3H-noradrenaline"
    },
    {
      "id": "rat lungs"
    },
    {
      "id": "myocardial cells"
    },
    {
      "id": "non-neuronal uptake1"
    },
    {
      "id": "amine"
    },
    {
      "id": "uptake2"
    },
    {
      "id": "catecholamine transporter"
    },
    {
      "id": "uptake2 transporter"
    }
  ],
  "links": [
    {
      "source": "naratriptan",
      "target": "human 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "naratriptan",
      "target": "5-HT1D",
      "label": "Regulates"
    },
    {
      "source": "naratriptan",
      "target": "putative 5-ht1f receptor",
      "label": "Regulates"
    },
    {
      "source": "sumatriptan",
      "target": "5-HT1D",
      "label": "Regulates"
    },
    {
      "source": "sumatriptan",
      "target": "putative 5-ht1f receptor",
      "label": "Regulates"
    },
    {
      "source": "sumatriptan",
      "target": "human 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "sumatriptan",
      "target": "selective 5-HT1D agonist",
      "label": "is a"
    },
    {
      "source": "[3H]eletriptan",
      "target": "[3H]sumatriptan",
      "label": "has_faster_association_rate_than"
    },
    {
      "source": "[3H]eletriptan",
      "target": "5-HT1D receptors",
      "label": "Regulates"
    },
    {
      "source": "[3H]eletriptan",
      "target": "human 5-HT1B receptors",
      "label": "Regulates"
    },
    {
      "source": "[3H]eletriptan",
      "target": "5-HT1B receptor",
      "label": "has_higher_affinity_at"
    },
    {
      "source": "[3H]eletriptan",
      "target": "5-HT1D receptor",
      "label": "has_higher_affinity_at"
    },
    {
      "source": "[3H]eletriptan",
      "target": "human recombinant 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "[3H]eletriptan",
      "target": "radioligands",
      "label": "is_a"
    },
    {
      "source": "[3H]sumatriptan",
      "target": "radioligands",
      "label": "is_a"
    },
    {
      "source": "[3H]sumatriptan",
      "target": "5-HT1D receptor",
      "label": "Regulates"
    },
    {
      "source": "[3H]sumatriptan",
      "target": "human recombinant 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "eletriptan",
      "target": "5-HT1D",
      "label": "Regulates"
    },
    {
      "source": "eletriptan",
      "target": "drug",
      "label": "is_a"
    },
    {
      "source": "eletriptan",
      "target": "vasoconstrictor activity",
      "label": "has"
    },
    {
      "source": "eletriptan",
      "target": "acute treatment of migraine headache",
      "label": "used_for"
    },
    {
      "source": "eletriptan",
      "target": "putative 5-ht1f receptor",
      "label": "Regulates"
    },
    {
      "source": "eletriptan",
      "target": "5-HT receptors",
      "label": "Regulates"
    },
    {
      "source": "eletriptan",
      "target": "5-HT receptor",
      "label": "Regulates"
    },
    {
      "source": "eletriptan",
      "target": "human 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "drug",
      "target": "effects of levodopa",
      "label": "potentiates"
    },
    {
      "source": "drug",
      "target": "treatment",
      "label": "represents advance in"
    },
    {
      "source": "drug",
      "target": "prevention",
      "label": "represents advance in"
    },
    {
      "source": "drug",
      "target": "systemic treatment",
      "label": "for"
    },
    {
      "source": "drug",
      "target": "treatment option",
      "label": "constitutes"
    },
    {
      "source": "drug",
      "target": "anesthesia",
      "label": "provides"
    },
    {
      "source": "drug",
      "target": "hemodynamic parameters",
      "label": "causes no gross changes in"
    },
    {
      "source": "drug",
      "target": "reward centers of the brain",
      "label": "can influence"
    },
    {
      "source": "drug",
      "target": "other areas of the body",
      "label": "can affect"
    },
    {
      "source": "drug",
      "target": "molecule",
      "label": "is in a"
    },
    {
      "source": "drug",
      "target": "urinary excretion",
      "label": "does not affect"
    },
    {
      "source": "drug",
      "target": "PGF2 alpha",
      "label": "does not affect"
    },
    {
      "source": "(R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole",
      "target": "eletriptan",
      "label": "is_chemical_formula_of"
    },
    {
      "source": "rizatriptan",
      "target": "putative 5-ht1f receptor",
      "label": "Regulates"
    },
    {
      "source": "rizatriptan",
      "target": "human 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "rizatriptan",
      "target": "5-HT1D",
      "label": "Regulates"
    },
    {
      "source": "radioligands",
      "target": "5-HT1D receptor",
      "label": "has_rates_determined_at"
    },
    {
      "source": "human recombinant 5-HT1B",
      "target": "HeLa cells",
      "label": "expressed_in"
    },
    {
      "source": "HeLa cells",
      "target": "inhibition",
      "label": "exhibited"
    },
    {
      "source": "HeLa cells",
      "target": "MR77 gene",
      "label": "transfected with"
    },
    {
      "source": "5-HT1D receptor",
      "target": "HeLa cells",
      "label": "expressed_in"
    },
    {
      "source": "5-HT1B/1D receptor agonists",
      "target": "migraine",
      "label": "treats"
    },
    {
      "source": "zolmitriptan",
      "target": "putative 5-ht1f receptor",
      "label": "Regulates"
    },
    {
      "source": "zolmitriptan",
      "target": "human 5-HT1B",
      "label": "Regulates"
    },
    {
      "source": "zolmitriptan",
      "target": "5-HT1D",
      "label": "Regulates"
    },
    {
      "source": "5-HT receptors",
      "target": "eNOS",
      "label": "mediates"
    },
    {
      "source": "5-HT receptor",
      "target": "5-HT1 class",
      "label": "is of the"
    },
    {
      "source": "DR",
      "target": "PCP-like hyperlocomotion",
      "label": "causes"
    },
    {
      "source": "DR",
      "target": "adverse effects",
      "label": "produces"
    },
    {
      "source": "DR",
      "target": "biphasic effects",
      "label": "exhibits"
    },
    {
      "source": "DR",
      "target": "sigma-1 receptors",
      "label": "binds to"
    },
    {
      "source": "DR",
      "target": "ligands",
      "label": "is a"
    },
    {
      "source": "DR",
      "target": "anticonvulsant effects",
      "label": "produces"
    },
    {
      "source": "DR",
      "target": "sigma-2 receptors",
      "label": "binds to"
    },
    {
      "source": "DR",
      "target": "therapeutic use",
      "label": "limits"
    },
    {
      "source": "DR",
      "target": "PCP sites",
      "label": "binds to"
    },
    {
      "source": "PCP-like hyperlocomotion",
      "target": "adverse effects",
      "label": "is a type of"
    },
    {
      "source": "DM analogs",
      "target": "anticonvulsant activity",
      "label": "have"
    },
    {
      "source": "DM",
      "target": "PCP-like hyperlocomotion",
      "label": "causes"
    },
    {
      "source": "DM",
      "target": "PCP sites",
      "label": "binds to"
    },
    {
      "source": "DM",
      "target": "dextrorphan",
      "label": "metabolized into"
    },
    {
      "source": "DM",
      "target": "ligands",
      "label": "is a"
    },
    {
      "source": "DM",
      "target": "biphasic effects",
      "label": "exhibits"
    },
    {
      "source": "DM",
      "target": "sigma-1 receptors",
      "label": "binds to"
    },
    {
      "source": "DM",
      "target": "anticonvulsant effects",
      "label": "produces"
    },
    {
      "source": "DM",
      "target": "NMDA",
      "label": "is an antagonist of"
    },
    {
      "source": "DM",
      "target": "sigma-2 receptors",
      "label": "binds to"
    },
    {
      "source": "DM",
      "target": "neuroprotective effects",
      "label": "has"
    },
    {
      "source": "DF",
      "target": "DM",
      "label": "is an analog of"
    },
    {
      "source": "DF",
      "target": "PCP-like hyperlocomotion",
      "label": "does not cause"
    },
    {
      "source": "DF",
      "target": "sigma receptors",
      "label": "binds to"
    },
    {
      "source": "DF",
      "target": "PCP sites",
      "label": "binds to"
    },
    {
      "source": "DF",
      "target": "dose-dependent decrease",
      "label": "produces"
    },
    {
      "source": "DF",
      "target": "DR",
      "label": "does not form"
    },
    {
      "source": "DF",
      "target": "CNS effects",
      "label": "has"
    },
    {
      "source": "DF",
      "target": "ligands",
      "label": "is a"
    },
    {
      "source": "DF",
      "target": "sigma-1 receptors",
      "label": "binds to"
    },
    {
      "source": "DF",
      "target": "adverse effects",
      "label": "has"
    },
    {
      "source": "DF",
      "target": "antitussive",
      "label": "has"
    },
    {
      "source": "DF",
      "target": "anticonvulsant effects",
      "label": "produces"
    },
    {
      "source": "DF",
      "target": "NMDA-linked PCP sites",
      "label": "binds to"
    },
    {
      "source": "DF",
      "target": "sigma-2 receptors",
      "label": "binds to"
    },
    {
      "source": "PCP sites",
      "target": "anticonvulsant activity",
      "label": "does not mediate"
    },
    {
      "source": "adverse effects",
      "target": "hyperlocomotion",
      "label": "include"
    },
    {
      "source": "adverse effects",
      "target": "nonselective NSAIDs",
      "label": "associated with"
    },
    {
      "source": "adverse effects",
      "target": "wildlife",
      "label": "observed in"
    },
    {
      "source": "adverse effects",
      "target": "gonad phenotype",
      "label": "similar to"
    },
    {
      "source": "adverse effects",
      "target": "exposure",
      "label": "of"
    },
    {
      "source": "adverse effects",
      "target": "air pollutants",
      "label": "are caused by"
    },
    {
      "source": "adverse effects",
      "target": "levobunolol",
      "label": "is reviewed for"
    },
    {
      "source": "adverse effects",
      "target": "betaxolol",
      "label": "is reviewed for"
    },
    {
      "source": "dextromethorphan",
      "target": "DM",
      "label": "is also known as"
    },
    {
      "source": "dextromethorphan",
      "target": "(+)-3-methoxy-N-methylmorphinan",
      "label": "is also known as"
    },
    {
      "source": "dextrorphan",
      "target": "PCP",
      "label": "is a type of"
    },
    {
      "source": "dextrorphan",
      "target": "DR",
      "label": "is also known as"
    },
    {
      "source": "dextrorphan",
      "target": "phencyclidine",
      "label": "is a type of"
    },
    {
      "source": "biphasic effects",
      "target": "locomotor activity",
      "label": "on"
    },
    {
      "source": "dimemorfan",
      "target": "therapeutic use",
      "label": "has"
    },
    {
      "source": "dimemorfan",
      "target": "antitussive",
      "label": "used as"
    },
    {
      "source": "dimemorfan",
      "target": "anticonvulsant effects",
      "label": "produces"
    },
    {
      "source": "dimemorfan",
      "target": "locomotor effects",
      "label": "produces"
    },
    {
      "source": "dimemorfan",
      "target": "DF",
      "label": "is also known as"
    },
    {
      "source": "dimemorfan",
      "target": "(+)-3-methyl-N-methylmorphinan",
      "label": "is also known as"
    },
    {
      "source": "dimemorfan",
      "target": "sigma-1 receptor",
      "label": "binds to"
    },
    {
      "source": "dose-dependent decrease",
      "target": "locomotor activity",
      "label": "on"
    },
    {
      "source": "ligands",
      "target": "multimer-specific ligand binding site",
      "label": "bind to"
    },
    {
      "source": "ligands",
      "target": "Gold Nanoparticles",
      "label": "stabilize"
    },
    {
      "source": "anticonvulsant effects",
      "target": "supramaximal electroshock test",
      "label": "measured by"
    },
    {
      "source": "CNS effects",
      "target": "NMDA",
      "label": "associated with"
    },
    {
      "source": "CNS effects",
      "target": "DM/sigma receptors",
      "label": "associated with"
    },
    {
      "source": "NMDA",
      "target": "NR1/NR2A receptors",
      "label": "stimulates"
    },
    {
      "source": "NMDA",
      "target": "neuronal death",
      "label": "causes"
    },
    {
      "source": "locomotor activity",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "neuroprotective effects",
      "target": "estrogen",
      "label": "are of"
    },
    {
      "source": "pimozide",
      "target": "human dopamine transporter",
      "label": "has notable potency at"
    },
    {
      "source": "pimozide",
      "target": "potency",
      "label": "has"
    },
    {
      "source": "pimozide",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "pimozide",
      "target": "estradiol",
      "label": "blocked growth induced by"
    },
    {
      "source": "pimozide",
      "target": "ER-positive T47D human breast cancer cell lines",
      "label": "blocked cell growth in"
    },
    {
      "source": "pimozide",
      "target": "MDA-MB-231",
      "label": "blocked [3H]thymidine incorporation in"
    },
    {
      "source": "pimozide",
      "target": "ER-positive human breast tumors",
      "label": "controls growth of"
    },
    {
      "source": "pimozide",
      "target": "human breast cancer cell proliferation",
      "label": "inhibits"
    },
    {
      "source": "pimozide",
      "target": "ZR75-1B human breast cancer cell lines",
      "label": "blocked cell growth in"
    },
    {
      "source": "pimozide",
      "target": "insulin",
      "label": "has Ki in presence of"
    },
    {
      "source": "pimozide",
      "target": "epidermal growth factor",
      "label": "has Ki in presence of"
    },
    {
      "source": "pimozide",
      "target": "MCF-7 human breast cancer cell growth",
      "label": "inhibits"
    },
    {
      "source": "pimozide",
      "target": "calmodulin antagonists",
      "label": "is a type of"
    },
    {
      "source": "pimozide",
      "target": "cell growth",
      "label": "blocked"
    },
    {
      "source": "pimozide",
      "target": "MCF-7 cells",
      "label": "blocked"
    },
    {
      "source": "pimozide",
      "target": "breast cancer cell growth",
      "label": "affects"
    },
    {
      "source": "pimozide",
      "target": "neuroleptic agents",
      "label": "is a type of"
    },
    {
      "source": "pimozide",
      "target": "ER-negative human breast tumors",
      "label": "controls growth of"
    },
    {
      "source": "pimozide",
      "target": "polypeptide hormones",
      "label": "controls growth induced by"
    },
    {
      "source": "pimozide",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "pimozide",
      "target": "estradiol binding properties",
      "label": "has no effect on"
    },
    {
      "source": "pimozide",
      "target": "growth-inhibitory properties",
      "label": "has"
    },
    {
      "source": "pimozide",
      "target": "[3H]thymidine incorporation",
      "label": "blocked"
    },
    {
      "source": "pimozide",
      "target": "MCF-7 ER",
      "label": "has no effect on"
    },
    {
      "source": "pimozide",
      "target": "MCF-7 cell line",
      "label": "affects"
    },
    {
      "source": "pimozide",
      "target": "mechanisms of action",
      "label": "has"
    },
    {
      "source": "pimozide",
      "target": "insulin-like growth factor I",
      "label": "has Ki in presence of"
    },
    {
      "source": "pimozide",
      "target": "progesterone receptors",
      "label": "does not interfere with"
    },
    {
      "source": "pimozide",
      "target": "growth inhibition",
      "label": "causes"
    },
    {
      "source": "pimozide",
      "target": "serum-free medium",
      "label": "has Ki in"
    },
    {
      "source": "pimozide",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "human dopamine transporter",
      "target": "dopamine",
      "label": "transports"
    },
    {
      "source": "ziprasidone",
      "target": "human dopamine transporter",
      "label": "has notable potency at"
    },
    {
      "source": "ziprasidone",
      "target": "potency",
      "label": "has"
    },
    {
      "source": "ziprasidone",
      "target": "compounds",
      "label": "is a type of"
    },
    {
      "source": "ziprasidone",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "ziprasidone",
      "target": "human serotonin transporter",
      "label": "regulates"
    },
    {
      "source": "ziprasidone",
      "target": "5-HT(2A)",
      "label": "Downregulator"
    },
    {
      "source": "ziprasidone",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "ziprasidone",
      "target": "D(2)",
      "label": "Downregulator"
    },
    {
      "source": "ziprasidone",
      "target": "5-HT(1A)",
      "label": "Agonist"
    },
    {
      "source": "ziprasidone",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "norepinephrine transporter",
      "target": "norepinephrine",
      "label": "transports"
    },
    {
      "source": "norepinephrine transporter",
      "target": "antidepressant drugs",
      "label": "is target for"
    },
    {
      "source": "norepinephrine transporter",
      "target": "synaptic norepinephrine",
      "label": "controls availability of"
    },
    {
      "source": "norepinephrine transporter",
      "target": "adrenoreceptor",
      "label": "regulates"
    },
    {
      "source": "norepinephrine transporter",
      "target": "NET",
      "label": "is_a"
    },
    {
      "source": "norepinephrine transporter",
      "target": "locomotor activity",
      "label": "inactivation affects"
    },
    {
      "source": "norepinephrine transporter",
      "target": "Acute inactivation",
      "label": "is target of"
    },
    {
      "source": "norepinephrine transporter",
      "target": "Chronic inactivation",
      "label": "is target of"
    },
    {
      "source": "norepinephrine",
      "target": "microdialysates",
      "label": "measured in"
    },
    {
      "source": "norepinephrine",
      "target": "spontaneous locomotor activity",
      "label": "regulates"
    },
    {
      "source": "norepinephrine",
      "target": "stimulatory effect",
      "label": "has"
    },
    {
      "source": "norepinephrine",
      "target": "sympathetic nerve endings",
      "label": "located in"
    },
    {
      "source": "norepinephrine",
      "target": "alpha 1B-adrenergic receptor mRNA",
      "label": "destabilizes"
    },
    {
      "source": "potency",
      "target": "uptake",
      "label": "is for inhibition of"
    },
    {
      "source": "potency",
      "target": "three mutations",
      "label": "is for"
    },
    {
      "source": "potency",
      "target": "MrIA",
      "label": "is of"
    },
    {
      "source": "potency",
      "target": "norepinephrine uptake",
      "label": "is for inhibition of"
    },
    {
      "source": "potency",
      "target": "one mutation",
      "label": "is for"
    },
    {
      "source": "potency",
      "target": "IC50",
      "label": "measured_by"
    },
    {
      "source": "potency",
      "target": "linezolid",
      "label": "is better than that of"
    },
    {
      "source": "potency",
      "target": "EC50",
      "label": "is"
    },
    {
      "source": "human serotonin, norepinephrine, and dopamine transporters",
      "target": "[3H]WIN35428",
      "label": "studied with"
    },
    {
      "source": "human serotonin, norepinephrine, and dopamine transporters",
      "target": "[3H]imipramine",
      "label": "studied with"
    },
    {
      "source": "human serotonin, norepinephrine, and dopamine transporters",
      "target": "norepinephrine",
      "label": "transports"
    },
    {
      "source": "human serotonin, norepinephrine, and dopamine transporters",
      "target": "[3H]nisoxetine",
      "label": "studied with"
    },
    {
      "source": "human serotonin, norepinephrine, and dopamine transporters",
      "target": "dopamine",
      "label": "transports"
    },
    {
      "source": "human serotonin, norepinephrine, and dopamine transporters",
      "target": "serotonin",
      "label": "transports"
    },
    {
      "source": "chlorpromazine",
      "target": "compounds",
      "label": "is a type of"
    },
    {
      "source": "chlorpromazine",
      "target": "norepinephrine transporter",
      "label": "regulates"
    },
    {
      "source": "chlorpromazine",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "chlorpromazine",
      "target": "human serotonin transporter",
      "label": "regulates"
    },
    {
      "source": "compounds",
      "target": "transporter",
      "label": "interact with"
    },
    {
      "source": "compounds",
      "target": "substrates",
      "label": "classified as"
    },
    {
      "source": "compounds",
      "target": "inhibitors",
      "label": "classified as"
    },
    {
      "source": "compounds",
      "target": "5-LO inhibitors",
      "label": "are"
    },
    {
      "source": "compounds",
      "target": "experimental evidence",
      "label": "supported by"
    },
    {
      "source": "compounds",
      "target": "retinoic acid receptors",
      "label": "activate"
    },
    {
      "source": "compounds",
      "target": "uptake",
      "label": "differ in"
    },
    {
      "source": "compounds",
      "target": "active site",
      "label": "fit within"
    },
    {
      "source": "compounds",
      "target": "concentration",
      "label": "differ in"
    },
    {
      "source": "compounds",
      "target": "basic nitrogen",
      "label": "carry"
    },
    {
      "source": "compounds",
      "target": "hERG channel",
      "label": "interact with"
    },
    {
      "source": "compounds",
      "target": "cytotoxicity",
      "label": "tested for"
    },
    {
      "source": "compounds",
      "target": "affinity",
      "label": "HAS_PROPERTY"
    },
    {
      "source": "compounds",
      "target": "P2X(7)R currents",
      "label": "did not inhibit"
    },
    {
      "source": "compounds",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "compounds",
      "target": "Ca(v)3.2 T-type channel",
      "label": "block"
    },
    {
      "source": "compounds",
      "target": "classes of compounds",
      "label": "include"
    },
    {
      "source": "compounds",
      "target": "Ca(2+) influx assay",
      "label": "tested using"
    },
    {
      "source": "compounds",
      "target": "tacrine",
      "label": "are"
    },
    {
      "source": "compounds",
      "target": "neostigmine",
      "label": "are"
    },
    {
      "source": "compounds",
      "target": "edrophonium",
      "label": "are"
    },
    {
      "source": "compounds",
      "target": "activity",
      "label": "have"
    },
    {
      "source": "compounds",
      "target": "selectivity",
      "label": "retained"
    },
    {
      "source": "compounds",
      "target": "medicinal chemistry applications",
      "label": "HAS_APPLICATION"
    },
    {
      "source": "compounds",
      "target": "microcosamine A (4)",
      "label": "include"
    },
    {
      "source": "compounds",
      "target": "human \u03b13\u03b24 or \u03b14\u03b22 nicotinic acetylcholine receptors",
      "label": "have effects on"
    },
    {
      "source": "compounds",
      "target": "liriodenine (6)",
      "label": "include"
    },
    {
      "source": "compounds",
      "target": "nAChR antagonists",
      "label": "are"
    },
    {
      "source": "compounds",
      "target": "7'-(3',4'-dihydroxyphenyl)-N-[4-methoxyphenyl)ethyl]propenamide (5)",
      "label": "include"
    },
    {
      "source": "compounds",
      "target": "inhibitory effects",
      "label": "showed"
    },
    {
      "source": "compounds",
      "target": "BuChE",
      "label": "inhibited"
    },
    {
      "source": "compounds",
      "target": "catalytic active site",
      "label": "occupied"
    },
    {
      "source": "compounds",
      "target": "properties",
      "label": "possess"
    },
    {
      "source": "compounds",
      "target": "AChE",
      "label": "inhibited"
    },
    {
      "source": "compounds",
      "target": "differences",
      "label": "had"
    },
    {
      "source": "compounds",
      "target": "phosphorylation of c-Jun",
      "label": "decreased"
    },
    {
      "source": "compounds",
      "target": "mRNA levels",
      "label": "lowered"
    },
    {
      "source": "compounds",
      "target": "PKA",
      "label": "inhibit"
    },
    {
      "source": "compounds",
      "target": "kinases",
      "label": "inhibit"
    },
    {
      "source": "compounds",
      "target": "prodrugs",
      "label": "converted to"
    },
    {
      "source": "compounds",
      "target": "potent antitumor activity",
      "label": "exhibited"
    },
    {
      "source": "compounds",
      "target": "damage",
      "label": "induced"
    },
    {
      "source": "compounds",
      "target": "anti-estrogenic effects",
      "label": "caused"
    },
    {
      "source": "compounds",
      "target": "6-acylaminoalkyl",
      "label": "grouped as"
    },
    {
      "source": "compounds",
      "target": "inhibitory activities",
      "label": "exhibited"
    },
    {
      "source": "compounds",
      "target": "sulfonylaminoalkyl",
      "label": "grouped as"
    },
    {
      "source": "compounds",
      "target": "production",
      "label": "tested for effects on"
    },
    {
      "source": "compounds",
      "target": "6H",
      "label": "grouped as"
    },
    {
      "source": "compounds",
      "target": "6-dialkylaminoalkyl",
      "label": "grouped as"
    },
    {
      "source": "compounds",
      "target": "proliferative response",
      "label": "tested for effects on"
    },
    {
      "source": "compounds",
      "target": "growth inhibition",
      "label": "tested for"
    },
    {
      "source": "compounds",
      "target": "anticancer activity",
      "label": "exhibited"
    },
    {
      "source": "compounds",
      "target": "GSH metabolism",
      "label": "have effects on"
    },
    {
      "source": "compounds",
      "target": "treatment options",
      "label": "are useful as"
    },
    {
      "source": "compounds",
      "target": "GSH levels",
      "label": "increase"
    },
    {
      "source": "compounds",
      "target": "Transcription Factors",
      "label": "can upregulate"
    },
    {
      "source": "zotepine",
      "target": "norepinephrine transporter",
      "label": "regulates"
    },
    {
      "source": "zotepine",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "fluperlapine",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "fluperlapine",
      "target": "human serotonin transporter",
      "label": "regulates"
    },
    {
      "source": "fluperlapine",
      "target": "compounds",
      "label": "is a type of"
    },
    {
      "source": "K(D)",
      "target": "human serotonin, norepinephrine, and dopamine transporters",
      "label": "is determined for"
    },
    {
      "source": "K(D)",
      "target": "neuroleptics",
      "label": "is determined for"
    },
    {
      "source": "K(D)",
      "target": "haloperidol metabolite",
      "label": "is determined for"
    },
    {
      "source": "dopamine",
      "target": "4-week-old control mice brains",
      "label": "concentration lower in"
    },
    {
      "source": "dopamine",
      "target": "40-week-old control mice brains",
      "label": "concentration higher in"
    },
    {
      "source": "dopamine",
      "target": "D2 receptor sensitivity",
      "label": "decreases"
    },
    {
      "source": "chlorprothixene",
      "target": "norepinephrine transporter",
      "label": "regulates"
    },
    {
      "source": "chlorprothixene",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "Pharmacological profile",
      "target": "neuroleptics",
      "label": "is profile of"
    },
    {
      "source": "Pharmacological profile",
      "target": "human monoamine transporters",
      "label": "is studied at"
    },
    {
      "source": "human monoamine transporters",
      "target": "monoamine",
      "label": "transports"
    },
    {
      "source": "promazine",
      "target": "norepinephrine transporter",
      "label": "regulates"
    },
    {
      "source": "promazine",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "triflupromazine",
      "target": "compounds",
      "label": "is a type of"
    },
    {
      "source": "triflupromazine",
      "target": "K(D)",
      "label": "has"
    },
    {
      "source": "triflupromazine",
      "target": "human serotonin transporter",
      "label": "regulates"
    },
    {
      "source": "drug interactions",
      "target": "neuroleptics",
      "label": "are interactions of"
    },
    {
      "source": "human serotonin transporter",
      "target": "serotonin",
      "label": "transports"
    },
    {
      "source": "haloperidol metabolite",
      "target": "haloperidol",
      "label": "is metabolite of"
    },
    {
      "source": "haloperidol metabolite",
      "target": "metabolite",
      "label": "is a type of"
    },
    {
      "source": "data",
      "target": "therapeutic and adverse effects",
      "label": "predicts"
    },
    {
      "source": "data",
      "target": "drug interactions",
      "label": "predicts"
    },
    {
      "source": "data",
      "target": "transient D2 occupancy",
      "label": "suggest"
    },
    {
      "source": "data",
      "target": "hypothesis",
      "label": "support"
    },
    {
      "source": "data",
      "target": "redundant carboxylase pathway",
      "label": "exclude"
    },
    {
      "source": "data",
      "target": "functionally critical substrates",
      "label": "suggest"
    },
    {
      "source": "data",
      "target": "evidence",
      "label": "provide"
    },
    {
      "source": "data",
      "target": "beneficial effects",
      "label": "identify"
    },
    {
      "source": "data",
      "target": "direct effect",
      "label": "suggest"
    },
    {
      "source": "data",
      "target": "Liver glycogen loading",
      "label": "indicates"
    },
    {
      "source": "data",
      "target": "blockade",
      "label": "showed"
    },
    {
      "source": "data",
      "target": "mechano-adaptive response",
      "label": "suggest"
    },
    {
      "source": "data",
      "target": "drugs",
      "label": "is for"
    },
    {
      "source": "data",
      "target": "phosphorylation",
      "label": "suggests"
    },
    {
      "source": "data",
      "target": "mice",
      "label": "obtained in"
    },
    {
      "source": "data",
      "target": "rats",
      "label": "obtained in"
    },
    {
      "source": "data",
      "target": "Brazil",
      "label": "about"
    },
    {
      "source": "data",
      "target": "MULTICENTRE STUDY",
      "label": "is of"
    },
    {
      "source": "data",
      "target": "selective pattern",
      "label": "suggest a link between"
    },
    {
      "source": "data",
      "target": "Pitx3 function",
      "label": "suggest a link between"
    },
    {
      "source": "data",
      "target": "literature",
      "label": "found in"
    },
    {
      "source": "data",
      "target": "remarkable anti-inflammatory effects",
      "label": "highlight"
    },
    {
      "source": "data",
      "target": "myosin-18A",
      "label": "indicates"
    },
    {
      "source": "data",
      "target": "adverse effects",
      "label": "used to determine"
    },
    {
      "source": "data",
      "target": "permutational multivariate analysis of variance",
      "label": "inputted into"
    },
    {
      "source": "data",
      "target": "sexual genotype",
      "label": "used in conjunction with"
    },
    {
      "source": "data",
      "target": "partial loss of function of ZEB2",
      "label": "provides evidence for"
    },
    {
      "source": "data",
      "target": "XBP1 deficiency",
      "label": "indicate"
    },
    {
      "source": "data",
      "target": "postmenopausal women",
      "label": "COLLECTED_FROM"
    },
    {
      "source": "data",
      "target": "toxicological properties",
      "label": "concerns"
    },
    {
      "source": "data",
      "target": "notion",
      "label": "support"
    },
    {
      "source": "data",
      "target": "inhibitory role",
      "label": "suggest"
    },
    {
      "source": "data",
      "target": "ambenonium",
      "label": "suggested"
    },
    {
      "source": "data",
      "target": "mixed 5-HT and catecholamine antagonists",
      "label": "indicates"
    },
    {
      "source": "data",
      "target": "mixed 5-HT1/5-HT2 receptor antagonists",
      "label": "indicates"
    },
    {
      "source": "data",
      "target": "state-dependent cocaine block",
      "label": "indicate"
    },
    {
      "source": "therapeutic and adverse effects",
      "target": "neuroleptics",
      "label": "are effects of"
    },
    {
      "source": "equilibrium dissociation constants",
      "target": "K(D)",
      "label": "is also known as"
    },
    {
      "source": "serotonin",
      "target": "40-week-old control mice brains",
      "label": "concentration higher in"
    },
    {
      "source": "serotonin",
      "target": "4-week-old control mice brains",
      "label": "concentration lower in"
    },
    {
      "source": "serotonin",
      "target": "inhibition",
      "label": "causes"
    },
    {
      "source": "serotonin",
      "target": "activation of TRPA1",
      "label": "released upon"
    },
    {
      "source": "serotonin",
      "target": "5-HT",
      "label": "is also known as"
    },
    {
      "source": "serotonin",
      "target": "vascular permeability changes",
      "label": "induces"
    },
    {
      "source": "serotonin",
      "target": "5-hydroxytryptamine",
      "label": "is"
    },
    {
      "source": "metabolite",
      "target": "enzyme",
      "label": "formed by action of"
    },
    {
      "source": "metabolite",
      "target": "PLZ",
      "label": "of"
    },
    {
      "source": "metabolite",
      "target": "MAO",
      "label": "formed by action of"
    },
    {
      "source": "metabolite",
      "target": "brain GABA levels",
      "label": "responsible for"
    },
    {
      "source": "metabolite",
      "target": "elevation in brain ORN",
      "label": "responsible for"
    },
    {
      "source": "metabolite",
      "target": "HER2",
      "label": "not active against"
    },
    {
      "source": "metabolite",
      "target": "EGFR",
      "label": "active against"
    },
    {
      "source": "metabolite",
      "target": "fear memory",
      "label": "improved"
    },
    {
      "source": "radioligand binding techniques",
      "target": "equilibrium dissociation constants",
      "label": "determine"
    },
    {
      "source": "study",
      "target": "Ang II receptor blockade",
      "label": "evaluated"
    },
    {
      "source": "study",
      "target": "double-blind, placebo-controlled, randomized, 4-way crossover study",
      "label": "is a"
    },
    {
      "source": "study",
      "target": "effects",
      "label": "explores"
    },
    {
      "source": "study",
      "target": "transiently high D2 occupancy",
      "label": "revealed"
    },
    {
      "source": "study",
      "target": "information",
      "label": "relates"
    },
    {
      "source": "study",
      "target": "delayed effects",
      "label": "investigates"
    },
    {
      "source": "study",
      "target": "F1004",
      "label": "implies"
    },
    {
      "source": "study",
      "target": "highly conserved residuals Y751",
      "label": "implies"
    },
    {
      "source": "study",
      "target": "D950",
      "label": "implies"
    },
    {
      "source": "study",
      "target": "coadministration",
      "label": "suggests"
    },
    {
      "source": "study",
      "target": "tractable clinical strategy",
      "label": "demonstrates"
    },
    {
      "source": "study",
      "target": "chemical entity",
      "label": "characterizes"
    },
    {
      "source": "study",
      "target": "efficacy",
      "label": "confirms"
    },
    {
      "source": "study",
      "target": "good responders",
      "label": "in"
    },
    {
      "source": "study",
      "target": "modifying effects",
      "label": "aimed to determine"
    },
    {
      "source": "study",
      "target": "TTCA levels",
      "label": "aimed to determine"
    },
    {
      "source": "study",
      "target": "IMPDH2 variants",
      "label": "aimed to characterize"
    },
    {
      "source": "study",
      "target": "clinically approved antihypertensive drugs",
      "label": "identified"
    },
    {
      "source": "study",
      "target": "procedure",
      "label": "presents"
    },
    {
      "source": "study",
      "target": "correlations",
      "label": "critical for establishing"
    },
    {
      "source": "study",
      "target": "responses",
      "label": "aimed to analyze"
    },
    {
      "source": "study",
      "target": "knock-in mouse model",
      "label": "reports development of"
    },
    {
      "source": "study",
      "target": "quinpirole",
      "label": "investigated effects of"
    },
    {
      "source": "study",
      "target": "amphetamine",
      "label": "investigated effects of"
    },
    {
      "source": "study",
      "target": "7-OH-DPAT",
      "label": "investigated effects of"
    },
    {
      "source": "study",
      "target": "7-hydroxy-N,N-di-propyl-2-aminotetralin",
      "label": "investigated effects of"
    },
    {
      "source": "study",
      "target": "stability",
      "label": "shows"
    },
    {
      "source": "study",
      "target": "ras-dva mRNA",
      "label": "characterizes regulation of"
    },
    {
      "source": "study",
      "target": "effect",
      "label": "reveals"
    },
    {
      "source": "study",
      "target": "H1 loop",
      "label": "focuses on"
    },
    {
      "source": "study",
      "target": "Shelf-life",
      "label": "evaluated"
    },
    {
      "source": "study",
      "target": "alternative target",
      "label": "provides"
    },
    {
      "source": "study",
      "target": "hypothesis",
      "label": "tests"
    },
    {
      "source": "study",
      "target": "patients",
      "label": "found"
    },
    {
      "source": "study",
      "target": "Four highly accepted assays",
      "label": "used"
    },
    {
      "source": "study",
      "target": "B6C3F1 mice",
      "label": "involved"
    },
    {
      "source": "study",
      "target": "dosing",
      "label": "assessed"
    },
    {
      "source": "study",
      "target": "predictors",
      "label": "assessed"
    },
    {
      "source": "study",
      "target": "persistence",
      "label": "assessed"
    },
    {
      "source": "study",
      "target": "reasons",
      "label": "should explore"
    },
    {
      "source": "study",
      "target": "protein malnutrition",
      "label": "investigated"
    },
    {
      "source": "study",
      "target": "5-fluorouracil (FU)",
      "label": "investigated"
    },
    {
      "source": "study",
      "target": "cisplatin (CP)",
      "label": "investigated"
    },
    {
      "source": "study",
      "target": "mitomycin C (MMC)",
      "label": "investigated"
    },
    {
      "source": "study",
      "target": "toxicity",
      "label": "investigated"
    },
    {
      "source": "study",
      "target": "metabolism",
      "label": "investigated"
    },
    {
      "source": "study",
      "target": "functional consequences",
      "label": "analyzes"
    },
    {
      "source": "study",
      "target": "reduction in TH(+) neurons",
      "label": "suggests"
    },
    {
      "source": "study",
      "target": "release mechanism",
      "label": "aimed to investigate"
    },
    {
      "source": "study",
      "target": "54 individuals",
      "label": "includes"
    },
    {
      "source": "study",
      "target": "AChE enzyme activities",
      "label": "measured"
    },
    {
      "source": "study",
      "target": "54 healthy unrelated controls",
      "label": "includes"
    },
    {
      "source": "study",
      "target": "probability of susceptibility",
      "label": "aims to profile"
    },
    {
      "source": "study",
      "target": "PON1 gene polymorphism",
      "label": "aims to determine effects of"
    },
    {
      "source": "study",
      "target": "PON1 enzyme activities",
      "label": "measured"
    },
    {
      "source": "study",
      "target": "immunomodulatory effects",
      "label": "examines"
    },
    {
      "source": "study",
      "target": "neuroprotective effects",
      "label": "examines"
    },
    {
      "source": "study",
      "target": "testicular maturation",
      "label": "designed to examine"
    },
    {
      "source": "study",
      "target": "eicosanoid biosynthesis",
      "label": "investigates"
    },
    {
      "source": "study",
      "target": "functional significance",
      "label": "determined"
    },
    {
      "source": "study",
      "target": "PBMC NaCl cotransport",
      "label": "aimed to determine if"
    },
    {
      "source": "study",
      "target": "Peripheral blood mononuclear cells (PBMC)",
      "label": "aimed to determine if"
    },
    {
      "source": "Ang II receptor blockade",
      "target": "valsartan",
      "label": "greater than"
    },
    {
      "source": "Ang II receptor blockade",
      "target": "reactive rise in plasma Ang II levels",
      "label": "assessed by"
    },
    {
      "source": "Ang II receptor blockade",
      "target": "normotensive subjects",
      "label": "occurs in"
    },
    {
      "source": "Ang II receptor blockade",
      "target": "in vitro receptor assay",
      "label": "assessed with"
    },
    {
      "source": "Ang II receptor blockade",
      "target": "recommended starting dose",
      "label": "induced by"
    },
    {
      "source": "Ang II receptor blockade",
      "target": "losartan",
      "label": "greater than"
    },
    {
      "source": "Blockade of the renin-angiotensin system",
      "target": "30 hours",
      "label": "assessed at"
    },
    {
      "source": "Blockade of the renin-angiotensin system",
      "target": "4 hours",
      "label": "assessed at"
    },
    {
      "source": "Blockade of the renin-angiotensin system",
      "target": "24 hours",
      "label": "assessed at"
    },
    {
      "source": "Blockade of the renin-angiotensin system",
      "target": "drug intake",
      "label": "assessed after"
    },
    {
      "source": "Blockade of the renin-angiotensin system",
      "target": "3 independent methods",
      "label": "assessed by"
    },
    {
      "source": "valsartan",
      "target": "Ang II-induced systolic blood pressure increase",
      "label": "blocked"
    },
    {
      "source": "valsartan",
      "target": "80 mg",
      "label": "is"
    },
    {
      "source": "valsartan",
      "target": "4 hours",
      "label": "effect at"
    },
    {
      "source": "valsartan",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "valsartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "valsartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "irbesartan",
      "target": "30 hours",
      "label": "induced at"
    },
    {
      "source": "irbesartan",
      "target": "Ang II-induced systolic blood pressure increase",
      "label": "blocked"
    },
    {
      "source": "irbesartan",
      "target": "Ang II receptor blockade",
      "label": "induces"
    },
    {
      "source": "irbesartan",
      "target": "150 mg",
      "label": "is"
    },
    {
      "source": "irbesartan",
      "target": "4 hours",
      "label": "effect at"
    },
    {
      "source": "irbesartan",
      "target": "marked, significant blockade",
      "label": "induced"
    },
    {
      "source": "irbesartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "irbesartan",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "irbesartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "irbesartan",
      "target": "major effects",
      "label": "had no"
    },
    {
      "source": "irbesartan",
      "target": "rightward parallel shift",
      "label": "caused"
    },
    {
      "source": "irbesartan",
      "target": "rabbit aortic strips",
      "label": "studied in"
    },
    {
      "source": "irbesartan",
      "target": "angiotensin II type 1 receptor blockers",
      "label": "is a type of"
    },
    {
      "source": "irbesartan",
      "target": "rat portal vein preparations",
      "label": "studied in"
    },
    {
      "source": "Ang II-induced systolic blood pressure increase",
      "target": "Ang II",
      "label": "induced by"
    },
    {
      "source": "Ang II-induced systolic blood pressure increase",
      "target": "systolic blood pressure",
      "label": "is a type of"
    },
    {
      "source": "effect",
      "target": "drugs",
      "label": "of"
    },
    {
      "source": "effect",
      "target": "time",
      "label": "declined with"
    },
    {
      "source": "effect",
      "target": "cysteinyl leukotriene antagonist",
      "label": "is of"
    },
    {
      "source": "effect",
      "target": "adhesive interaction",
      "label": "is on"
    },
    {
      "source": "effect",
      "target": "pranlukast hydrate",
      "label": "is of"
    },
    {
      "source": "effect",
      "target": "asthmatic patients",
      "label": "is relevant for"
    },
    {
      "source": "effect",
      "target": "patients",
      "label": "should be assessed in"
    },
    {
      "source": "effect",
      "target": "timolol",
      "label": "is comparable to"
    },
    {
      "source": "effect",
      "target": "net hepatic glycogen synthesis",
      "label": "on"
    },
    {
      "source": "effect",
      "target": "Liver glycogen loading",
      "label": "of"
    },
    {
      "source": "effect",
      "target": "atropine",
      "label": "blocked by"
    },
    {
      "source": "effect",
      "target": "carbachol",
      "label": "of"
    },
    {
      "source": "effect",
      "target": "selected mutations",
      "label": "of"
    },
    {
      "source": "effect",
      "target": "electrophysiologic results",
      "label": "consistent with"
    },
    {
      "source": "effect",
      "target": "lithocholic acid (LCA)",
      "label": "larger than"
    },
    {
      "source": "drugs",
      "target": "endocannabinoid levels",
      "label": "AUGMENT"
    },
    {
      "source": "drugs",
      "target": "effects",
      "label": "PRODUCE"
    },
    {
      "source": "drugs",
      "target": "cannabinoid receptors",
      "label": "ACTIVATE"
    },
    {
      "source": "drugs",
      "target": "psychotropic activity",
      "label": "HAVE"
    },
    {
      "source": "drugs",
      "target": "CB1 receptors",
      "label": "ACT_THROUGH"
    },
    {
      "source": "drugs",
      "target": "clinical applications",
      "label": "HAS"
    },
    {
      "source": "drugs",
      "target": "therapeutic index",
      "label": "have a"
    },
    {
      "source": "drugs",
      "target": "alpha(1A)-adrenoceptors",
      "label": "are selective for"
    },
    {
      "source": "drugs",
      "target": "I(ouabain)",
      "label": "have pharmacological effects on"
    },
    {
      "source": "drugs",
      "target": "I(amiloride)",
      "label": "have pharmacological effects on"
    },
    {
      "source": "drugs",
      "target": "AMPK activation",
      "label": "have pharmacological effects on"
    },
    {
      "source": "drugs",
      "target": "adenine nucleotide concentration",
      "label": "have pharmacological effects on"
    },
    {
      "source": "drugs",
      "target": "transepithelial amiloride-sensitive short circuit current",
      "label": "have pharmacological effects on"
    },
    {
      "source": "drugs",
      "target": "ouabain-sensitive basolateral short circuit current",
      "label": "have pharmacological effects on"
    },
    {
      "source": "drugs",
      "target": "extreme fear extinction deficit",
      "label": "rescue"
    },
    {
      "source": "drugs",
      "target": "pathway",
      "label": "target"
    },
    {
      "source": "drugs",
      "target": "Alzheimer's disease",
      "label": "treat"
    },
    {
      "source": "drugs",
      "target": "cell death",
      "label": "caused"
    },
    {
      "source": "drugs",
      "target": "renal dosage adjustments",
      "label": "require"
    },
    {
      "source": "drugs",
      "target": "systolic and diastolic blood pressure",
      "label": "increased"
    },
    {
      "source": "drugs",
      "target": "heart rate",
      "label": "decreased"
    },
    {
      "source": "residual effect",
      "target": "24 hours",
      "label": "at"
    },
    {
      "source": "residual effect",
      "target": "3 drugs",
      "label": "found with"
    },
    {
      "source": "recommended starting dose",
      "target": "irbesartan",
      "label": "of"
    },
    {
      "source": "recommended starting dose",
      "target": "antagonists",
      "label": "of"
    },
    {
      "source": "reactive changes in plasma Ang II levels",
      "target": "Ang II",
      "label": "involve"
    },
    {
      "source": "reactive changes in plasma Ang II levels",
      "target": "plasma Ang II levels",
      "label": "affect"
    },
    {
      "source": "Ang II",
      "target": "circulating angiotensin II",
      "label": "is an abbreviation for"
    },
    {
      "source": "reactive rise in plasma Ang II levels",
      "target": "Ang II",
      "label": "involves"
    },
    {
      "source": "reactive rise in plasma Ang II levels",
      "target": "plasma Ang II levels",
      "label": "is a change in"
    },
    {
      "source": "losartan",
      "target": "50 mg",
      "label": "is"
    },
    {
      "source": "losartan",
      "target": "Ang II-induced systolic blood pressure increase",
      "label": "blocked"
    },
    {
      "source": "losartan",
      "target": "4 hours",
      "label": "effect at"
    },
    {
      "source": "losartan",
      "target": "rabbit aortic strips",
      "label": "studied in"
    },
    {
      "source": "losartan",
      "target": "angiotensin II type 1 receptor blockers",
      "label": "is a type of"
    },
    {
      "source": "losartan",
      "target": "rat portal vein preparations",
      "label": "studied in"
    },
    {
      "source": "losartan",
      "target": "rightward parallel shift",
      "label": "caused"
    },
    {
      "source": "losartan",
      "target": "major effects",
      "label": "had no"
    },
    {
      "source": "systolic blood pressure",
      "target": "control group",
      "label": "compared with"
    },
    {
      "source": "time",
      "target": "postdose",
      "label": "is"
    },
    {
      "source": "relative efficacy",
      "target": "antagonists",
      "label": "of"
    },
    {
      "source": "antagonists",
      "target": "renin-angiotensin system",
      "label": "block"
    },
    {
      "source": "antagonists",
      "target": "affinity",
      "label": "lack"
    },
    {
      "source": "antagonists",
      "target": "nociceptin receptor",
      "label": "at"
    },
    {
      "source": "antagonists",
      "target": "TRPM8",
      "label": "of"
    },
    {
      "source": "antagonists",
      "target": "gastrointestinal motility",
      "label": "modulates"
    },
    {
      "source": "antagonists",
      "target": "sensation",
      "label": "modulates"
    },
    {
      "source": "antagonists",
      "target": "clinical implications",
      "label": "has"
    },
    {
      "source": "antagonists",
      "target": "probable sites",
      "label": "docked to"
    },
    {
      "source": "antagonists",
      "target": "dynamin",
      "label": "inhibit"
    },
    {
      "source": "antagonists",
      "target": "G protein-coupled receptor kinase-2",
      "label": "inhibit"
    },
    {
      "source": "antagonists",
      "target": "HTR response",
      "label": "attenuate"
    },
    {
      "source": "antagonists",
      "target": "s.c. treatment",
      "label": "administered_via"
    },
    {
      "source": "antagonists",
      "target": "oral administration",
      "label": "administered_via"
    },
    {
      "source": "antagonists",
      "target": "i.v. treatment",
      "label": "administered_via"
    },
    {
      "source": "first administration",
      "target": "recommended starting dose",
      "label": "of"
    },
    {
      "source": "single dose",
      "target": "irbesartan",
      "label": "of"
    },
    {
      "source": "single dose",
      "target": "losartan",
      "label": "of"
    },
    {
      "source": "single dose",
      "target": "placebo",
      "label": "of"
    },
    {
      "source": "single dose",
      "target": "valsartan",
      "label": "of"
    },
    {
      "source": "P<0.01",
      "target": "drugs",
      "label": "is between"
    },
    {
      "source": "renin-angiotensin system",
      "target": "angiotensin",
      "label": "includes"
    },
    {
      "source": "renin-angiotensin system",
      "target": "humans",
      "label": "is in"
    },
    {
      "source": "renin-angiotensin system",
      "target": "renin",
      "label": "includes"
    },
    {
      "source": "12 subjects",
      "target": "single dose",
      "label": "received"
    },
    {
      "source": "12 subjects",
      "target": "1-week intervals",
      "label": "received at"
    },
    {
      "source": "12 subjects",
      "target": "International Normalized Ratio (INR)",
      "label": "had change in"
    },
    {
      "source": "12 subjects",
      "target": "COX-2 inhibitor",
      "label": "received"
    },
    {
      "source": "results",
      "target": "in vitro receptor assay",
      "label": "obtained with"
    },
    {
      "source": "results",
      "target": "reactive rise in plasma Ang II levels",
      "label": "obtained by"
    },
    {
      "source": "results",
      "target": "minimal D2 occupancy",
      "label": "with"
    },
    {
      "source": "results",
      "target": "delayed toxic effects",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "aggravation",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "Sp1/Sp3 cooperation",
      "label": "suggest"
    },
    {
      "source": "results",
      "target": "direct evidence",
      "label": "provided"
    },
    {
      "source": "results",
      "target": "ketoenamine",
      "label": "suggest"
    },
    {
      "source": "results",
      "target": "Necturus tissues",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "previously held hypotheses",
      "label": "are in contrast to"
    },
    {
      "source": "results",
      "target": "DPD activity tests",
      "label": "of"
    },
    {
      "source": "results",
      "target": "efficacy",
      "label": "concern"
    },
    {
      "source": "results",
      "target": "state of oxidizing stress",
      "label": "show"
    },
    {
      "source": "results",
      "target": "thyroid activity variations",
      "label": "explain"
    },
    {
      "source": "results",
      "target": "recent clinical trials",
      "label": "from"
    },
    {
      "source": "results",
      "target": "levels of DLDH diaphorase activity",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "alpha(1)-adrenoceptors",
      "label": "demonstrate"
    },
    {
      "source": "results",
      "target": "three year",
      "label": "at"
    },
    {
      "source": "results",
      "target": "multicenter, open-label study",
      "label": "from"
    },
    {
      "source": "results",
      "target": "bibliographic values",
      "label": "compared with"
    },
    {
      "source": "results",
      "target": "effectiveness",
      "label": "confirms"
    },
    {
      "source": "results",
      "target": "Quercetin",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "reversal",
      "label": "demonstrate"
    },
    {
      "source": "results",
      "target": "Our study",
      "label": "of"
    },
    {
      "source": "results",
      "target": "osteoclast parameters",
      "label": "pertain to"
    },
    {
      "source": "results",
      "target": "PRO treatment",
      "label": "similar to"
    },
    {
      "source": "results",
      "target": "amount of tooth movement",
      "label": "pertain to"
    },
    {
      "source": "results",
      "target": "insight",
      "label": "provide"
    },
    {
      "source": "results",
      "target": "information",
      "label": "are"
    },
    {
      "source": "results",
      "target": "alkaline comet assay",
      "label": "of"
    },
    {
      "source": "results",
      "target": "observation",
      "label": "supported by"
    },
    {
      "source": "results",
      "target": "hydroxyacid simvastatin",
      "label": "obtained for"
    },
    {
      "source": "results",
      "target": "5-HT2C receptor agonists",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "antagonists",
      "label": "indicate"
    },
    {
      "source": "results",
      "target": "ligand functional selectivity",
      "label": "in accordance with"
    },
    {
      "source": "results",
      "target": "specific SNPs",
      "label": "suggest"
    },
    {
      "source": "results",
      "target": "PRL signaling",
      "label": "suggest"
    },
    {
      "source": "results",
      "target": "template",
      "label": "provide"
    },
    {
      "source": "results",
      "target": "potential",
      "label": "highlight"
    },
    {
      "source": "results",
      "target": "Pim-1",
      "label": "establish"
    },
    {
      "source": "results",
      "target": "recombinant enzymes",
      "label": "observed using"
    },
    {
      "source": "results",
      "target": "microsomes",
      "label": "observed using"
    },
    {
      "source": "results",
      "target": "previous published stereological studies",
      "label": "question"
    },
    {
      "source": "results",
      "target": "experimental data",
      "label": "provide"
    },
    {
      "source": "results",
      "target": "T-bet",
      "label": "reveal a role for"
    },
    {
      "source": "results",
      "target": "post-translational control",
      "label": "provides insight into"
    },
    {
      "source": "results",
      "target": "first report",
      "label": "constitute"
    },
    {
      "source": "results",
      "target": "process of protein transnitrosation",
      "label": "provides insight into"
    },
    {
      "source": "results",
      "target": "investigation",
      "label": "support"
    },
    {
      "source": "results",
      "target": "pivotal role",
      "label": "suggest"
    },
    {
      "source": "results",
      "target": "AChE enzyme activities",
      "label": "analyzed for"
    },
    {
      "source": "results",
      "target": "therapeutic perspective",
      "label": "demonstrate"
    },
    {
      "source": "results",
      "target": "breakpoint",
      "label": "suggest"
    },
    {
      "source": "results",
      "target": "Peripheral blood mononuclear cells (PBMC)",
      "label": "demonstrate use of"
    },
    {
      "source": "results",
      "target": "mechanism",
      "label": "delineate"
    },
    {
      "source": "results",
      "target": "study",
      "label": "are from"
    },
    {
      "source": "Angiotensin II receptor blockade",
      "target": "normotensive subjects",
      "label": "occurs in"
    },
    {
      "source": "Angiotensin II receptor blockade",
      "target": "Angiotensin II",
      "label": "involves"
    },
    {
      "source": "Angiotensin II receptor blockade",
      "target": "AT1 receptor",
      "label": "targets"
    },
    {
      "source": "Angiotensin II receptor blockade",
      "target": "direct comparison",
      "label": "is a"
    },
    {
      "source": "direct comparison",
      "target": "AT1 receptor antagonists",
      "label": "of"
    },
    {
      "source": "placebo",
      "target": "7 days",
      "label": "duration"
    },
    {
      "source": "placebo",
      "target": "meal",
      "label": "administered before"
    },
    {
      "source": "placebo",
      "target": "days 1, 3, 5, 7, and 9",
      "label": "administered on"
    },
    {
      "source": "placebo",
      "target": "period of 30 days",
      "label": "received for"
    },
    {
      "source": "in vitro Ang II receptor assay",
      "target": "Ang II",
      "label": "measures"
    },
    {
      "source": "in vitro Ang II receptor assay",
      "target": "AT1 receptor",
      "label": "measures"
    },
    {
      "source": "AT1 receptor",
      "target": "angiotensin II",
      "label": "mediates actions of"
    },
    {
      "source": "angiotensin (Ang) II AT1 receptor antagonists",
      "target": "treatment of hypertension",
      "label": "used for"
    },
    {
      "source": "treatment of hypertension",
      "target": "hypertension",
      "label": "addresses"
    },
    {
      "source": "marked, significant blockade",
      "target": "placebo",
      "label": "versus"
    },
    {
      "source": "3 independent methods",
      "target": "inhibition of the blood pressure response to exogenous Ang II",
      "label": "include"
    },
    {
      "source": "3 independent methods",
      "target": "in vitro Ang II receptor assay",
      "label": "include"
    },
    {
      "source": "3 independent methods",
      "target": "reactive changes in plasma Ang II levels",
      "label": "include"
    },
    {
      "source": "inhibition of the blood pressure response to exogenous Ang II",
      "target": "systolic blood pressure",
      "label": "affects"
    },
    {
      "source": "inhibition of the blood pressure response to exogenous Ang II",
      "target": "Ang II",
      "label": "involves"
    },
    {
      "source": "hypertension",
      "target": "heart",
      "label": "affects"
    },
    {
      "source": "direct comparisons",
      "target": "relative efficacy",
      "label": "of"
    },
    {
      "source": "humans",
      "target": "exposures",
      "label": "had"
    },
    {
      "source": "humans",
      "target": "Findings",
      "label": "did not exhibit"
    },
    {
      "source": "humans",
      "target": "modes of corticosteroid action",
      "label": "provide evidence for"
    },
    {
      "source": "Disodium cromoglycate",
      "target": "small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia",
      "label": "did not affect"
    },
    {
      "source": "Disodium cromoglycate",
      "target": "terbutaline-induced desensitization",
      "label": "does not prevent"
    },
    {
      "source": "Disodium cromoglycate",
      "target": "rightward shift of beta 2-adrenoceptor-mediated responses",
      "label": "did not affect"
    },
    {
      "source": "terbutaline-induced desensitization",
      "target": "human volunteers",
      "label": "occurs in"
    },
    {
      "source": "terbutaline-induced desensitization",
      "target": "beta-adrenoceptor-mediated cardiovascular and noncardiovascular responses",
      "label": "affects"
    },
    {
      "source": "terbutaline-induced desensitization",
      "target": "beta 2-adrenoceptor-mediated cardiovascular in vivo functions",
      "label": "affects"
    },
    {
      "source": "healthy male volunteers",
      "target": "placebo",
      "label": "received"
    },
    {
      "source": "healthy male volunteers",
      "target": "terbutaline",
      "label": "received"
    },
    {
      "source": "healthy male volunteers",
      "target": "disodium cromoglycate",
      "label": "received"
    },
    {
      "source": "healthy male volunteers",
      "target": "double-blind, placebo-controlled, randomized design",
      "label": "participated in"
    },
    {
      "source": "beta 1-adrenoceptor cardiovascular function",
      "target": "exercise-induced tachycardia",
      "label": "assessed by"
    },
    {
      "source": "terbutaline",
      "target": "Tremulousness",
      "label": "caused"
    },
    {
      "source": "terbutaline",
      "target": "Exercise-induced tachycardia",
      "label": "blunted"
    },
    {
      "source": "terbutaline",
      "target": "small rightward shift in beta 1-adrenoceptor-mediated exercise tachycardia",
      "label": "caused"
    },
    {
      "source": "terbutaline",
      "target": "isoprenaline-induced decrease in diastolic blood pressure",
      "label": "caused attenuation of"
    },
    {
      "source": "terbutaline",
      "target": "beta 2-adrenoceptor agonist",
      "label": "is a"
    },
    {
      "source": "terbutaline",
      "target": "rightward shift of beta 2-adrenoceptor-mediated responses",
      "label": "caused"
    },
    {
      "source": "terbutaline",
      "target": "isoprenaline-induced tachycardia",
      "label": "caused attenuation of"
    },
    {
      "source": "Tremulousness",
      "target": "beta 2-adrenoceptor-mediated noncardiovascular effect",
      "label": "is a"
    },
    {
      "source": "increase in heart rate",
      "target": "isoprenaline",
      "label": "induced by"
    },
    {
      "source": "isoprenaline",
      "target": "unselective beta-adrenoceptor agonist",
      "label": "is an"
    },
    {
      "source": "isoprenaline",
      "target": "chronotropic effect",
      "label": "causes"
    },
    {
      "source": "isoprenaline",
      "target": "heart rate",
      "label": "increases"
    },
    {
      "source": "isoprenaline",
      "target": "i.v. administration",
      "label": "administered via"
    },
    {
      "source": "isoprenaline",
      "target": "doses",
      "label": "administered at"
    },
    {
      "source": "long-term beta 2-adrenoceptor agonist therapy",
      "target": "desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects",
      "label": "leads to"
    },
    {
      "source": "desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "beta 2-Adrenoceptor cardiovascular function",
      "target": "reduction of diastolic blood pressure",
      "label": "assessed by"
    },
    {
      "source": "beta 2-Adrenoceptor cardiovascular function",
      "target": "increase in heart rate",
      "label": "assessed by"
    },
    {
      "source": "reduction of diastolic blood pressure",
      "target": "isoprenaline",
      "label": "induced by"
    },
    {
      "source": "ketotifen",
      "target": "antianaphylactic drug",
      "label": "is an"
    },
    {
      "source": "ketotifen",
      "target": "desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects",
      "label": "attenuates"
    },
    {
      "source": "ketotifen",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "ketotifen",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "ketotifen",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "ketotifen",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "ketotifen",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "ketotifen",
      "target": "histamine H1 receptor",
      "label": "is antagonist of"
    },
    {
      "source": "ketotifen",
      "target": "mast cell-stabilizing properties",
      "label": "has"
    },
    {
      "source": "disodium cromoglycate",
      "target": "antiallergic drug",
      "label": "is an"
    },
    {
      "source": "disodium cromoglycate",
      "target": "terbutaline-induced desensitization",
      "label": "effect investigated on"
    },
    {
      "source": "cromolyn sodium",
      "target": "desensitization of beta 2-adrenoceptor-mediated cardiovascular and noncardiovascular effects",
      "label": "does not attenuate"
    },
    {
      "source": "Caffeine",
      "target": "cell-cycle progression",
      "label": "uncouples"
    },
    {
      "source": "Caffeine",
      "target": "checkpoint kinase ATM",
      "label": "inhibits"
    },
    {
      "source": "Caffeine",
      "target": "repair of DNA",
      "label": "uncouples"
    },
    {
      "source": "Caffeine",
      "target": "radiation-induced activation",
      "label": "inhibits"
    },
    {
      "source": "Caffeine",
      "target": "ATM kinase activity",
      "label": "inhibits"
    },
    {
      "source": "Caffeine",
      "target": "model compound",
      "label": "serves as"
    },
    {
      "source": "Caffeine",
      "target": "replication",
      "label": "uncouples"
    },
    {
      "source": "Inhibition of ATM",
      "target": "attenuation of DNA-damage checkpoint responses",
      "label": "provides"
    },
    {
      "source": "Inhibition of ATM",
      "target": "molecular explanation",
      "label": "provides"
    },
    {
      "source": "Inhibition of ATM",
      "target": "increased radiosensitivity",
      "label": "provides"
    },
    {
      "source": "kinase Cds1",
      "target": "Chk2",
      "label": "also known as"
    },
    {
      "source": "replication",
      "target": "macrophages",
      "label": "in"
    },
    {
      "source": "agents",
      "target": "cells",
      "label": "sensitize"
    },
    {
      "source": "agents",
      "target": "efficacy",
      "label": "HAVE"
    },
    {
      "source": "agents",
      "target": "treatment",
      "label": "for"
    },
    {
      "source": "agents",
      "target": "vascular endothelial growth factor",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "transforming growth factor-alpha",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "VEGFR",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "PDGF-beta",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "VEGF receptor",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "epidermal growth factor receptor",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "pathways dysregulated in clear-cell RCC",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "PDGFR-beta",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "VEGF",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "PDGF receptor-beta",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "platelet-derived growth factor-beta",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "Raf pathways",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "TGF-alpha",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "EGFR",
      "label": "target"
    },
    {
      "source": "agents",
      "target": "adjuvant agents",
      "label": "for use as"
    },
    {
      "source": "agents",
      "target": "disadvantages",
      "label": "have"
    },
    {
      "source": "agents",
      "target": "advantages",
      "label": "have"
    },
    {
      "source": "agents",
      "target": "PGHS isozyme",
      "label": "are_selective_for"
    },
    {
      "source": "cells",
      "target": "cytotoxicity",
      "label": "protected from"
    },
    {
      "source": "cells",
      "target": "oxidative stress",
      "label": "protected from"
    },
    {
      "source": "cells",
      "target": "cancer",
      "label": "protected against"
    },
    {
      "source": "cells",
      "target": "toxicity",
      "label": "protected against"
    },
    {
      "source": "cells",
      "target": "mutagenicity",
      "label": "protected against"
    },
    {
      "source": "cells",
      "target": "p53R2 sense expression vectors",
      "label": "transfected with"
    },
    {
      "source": "cells",
      "target": "hRRM2 expression vectors",
      "label": "transfected with"
    },
    {
      "source": "cells",
      "target": "mutant p53",
      "label": "possess"
    },
    {
      "source": "cells",
      "target": "UV treatment",
      "label": "exposed to"
    },
    {
      "source": "cells",
      "target": "p53R2 antisense expression vectors",
      "label": "transfected with"
    },
    {
      "source": "cells",
      "target": "recombinant human dopamine D4.4 receptor",
      "label": "express"
    },
    {
      "source": "cells",
      "target": "glucose-buffered solution",
      "label": "incubated in"
    },
    {
      "source": "cells",
      "target": "hNET",
      "label": "express"
    },
    {
      "source": "cells",
      "target": "human serotonin (5-HT) transporter",
      "label": "express"
    },
    {
      "source": "cells",
      "target": "norepinephrine (NE) transporter",
      "label": "express"
    },
    {
      "source": "cells",
      "target": "hSERT",
      "label": "express"
    },
    {
      "source": "cells",
      "target": "apoptotic response",
      "label": "exhibit"
    },
    {
      "source": "cells",
      "target": "POX",
      "label": "overproduce"
    },
    {
      "source": "cells",
      "target": "Abeta(1-40)",
      "label": "pre-exposed to"
    },
    {
      "source": "cells",
      "target": "NR1/NR2A",
      "label": "express"
    },
    {
      "source": "cells",
      "target": "cytotoxicities",
      "label": "to"
    },
    {
      "source": "cells",
      "target": "Pit-1 lineage",
      "label": "are of the"
    },
    {
      "source": "cells",
      "target": "urethral mucosa",
      "label": "obtained from"
    },
    {
      "source": "cells",
      "target": "advanced glycation end products",
      "label": "exposed to"
    },
    {
      "source": "cells",
      "target": "epithelial phenotype",
      "label": "harbor"
    },
    {
      "source": "cells",
      "target": "toxic stress",
      "label": "are protected from"
    },
    {
      "source": "cells",
      "target": "central nervous system",
      "label": "located outside"
    },
    {
      "source": "cells",
      "target": "positive stain",
      "label": "had"
    },
    {
      "source": "recovery curve",
      "target": "standard model of protein synthesis and degradation",
      "label": "fit"
    },
    {
      "source": "half-life of the SERT recovery",
      "target": "striatum",
      "label": "measured in"
    },
    {
      "source": "half-life of the SERT recovery",
      "target": "hippocampus",
      "label": "measured in"
    },
    {
      "source": "half-life of the SERT recovery",
      "target": "days",
      "label": "has unit"
    },
    {
      "source": "striatum",
      "target": "regions",
      "label": "is a type of"
    },
    {
      "source": "striatum",
      "target": "NET",
      "label": "devoid_of"
    },
    {
      "source": "striatum",
      "target": "brain region",
      "label": "is_a"
    },
    {
      "source": "RTI-76",
      "target": "wash and temperature resistant inhibition",
      "label": "produced"
    },
    {
      "source": "RTI-76",
      "target": "dose- and time-dependent reduction",
      "label": "caused"
    },
    {
      "source": "RTI-76",
      "target": "ligand binding",
      "label": "inhibits"
    },
    {
      "source": "RTI-76",
      "target": "irreversible inhibitor",
      "label": "is a type of"
    },
    {
      "source": "wash and temperature resistant inhibition",
      "target": "SERT binding densities",
      "label": "affects"
    },
    {
      "source": "[3H]-5-HT uptake",
      "target": "recovery of SERT binding",
      "label": "correlated with"
    },
    {
      "source": "dose- and time-dependent reduction",
      "target": "striatum",
      "label": "occurred in"
    },
    {
      "source": "dose- and time-dependent reduction",
      "target": "SERT binding densities",
      "label": "of"
    },
    {
      "source": "dose- and time-dependent reduction",
      "target": "hippocampus",
      "label": "occurred in"
    },
    {
      "source": "SERT",
      "target": "turnover parameters",
      "label": "has"
    },
    {
      "source": "SERT",
      "target": "turnover",
      "label": "has property"
    },
    {
      "source": "turnover parameters",
      "target": "striatum",
      "label": "determined in"
    },
    {
      "source": "turnover parameters",
      "target": "hippocampus",
      "label": "determined in"
    },
    {
      "source": "turnover",
      "target": "production rate",
      "label": "determined by"
    },
    {
      "source": "turnover",
      "target": "recovery of SERT binding",
      "label": "determined from"
    },
    {
      "source": "turnover",
      "target": "degradation rate constant",
      "label": "determined by"
    },
    {
      "source": "turnover",
      "target": "half-life of recovery",
      "label": "determined by"
    },
    {
      "source": "production rate constant",
      "target": "striatum",
      "label": "measured in"
    },
    {
      "source": "production rate constant",
      "target": "hippocampus",
      "label": "measured in"
    },
    {
      "source": "production rate constant",
      "target": "fmol mg protein (-1)h(-1)",
      "label": "has unit"
    },
    {
      "source": "SERT binding densities",
      "target": "days",
      "label": "recovered over"
    },
    {
      "source": "SERT binding densities",
      "target": "control levels",
      "label": "reached"
    },
    {
      "source": "SERT binding densities",
      "target": "Bmax",
      "label": "is also known as"
    },
    {
      "source": "Serotonin transporter",
      "target": "RTI-76",
      "label": "studied using"
    },
    {
      "source": "in vivo intracerebroventricular injections",
      "target": "nmol",
      "label": "involved quantity"
    },
    {
      "source": "in vivo intracerebroventricular injections",
      "target": "RTI-76",
      "label": "involved"
    },
    {
      "source": "hippocampus",
      "target": "regions",
      "label": "is a type of"
    },
    {
      "source": "hippocampus",
      "target": "biochemical assays",
      "label": "was dissected for"
    },
    {
      "source": "preliminary studies",
      "target": "in vitro incubation",
      "label": "involved"
    },
    {
      "source": "in vitro incubation",
      "target": "RTI-76",
      "label": "with"
    },
    {
      "source": "in vitro incubation",
      "target": "rat cerebral cortex",
      "label": "of"
    },
    {
      "source": "regions",
      "target": "serotonergic innervation",
      "label": "receive"
    },
    {
      "source": "regions",
      "target": "regulation",
      "label": "mediate"
    },
    {
      "source": "regions",
      "target": "AC7",
      "label": "of"
    },
    {
      "source": "regions",
      "target": "heteromer formation",
      "label": "involved in"
    },
    {
      "source": "regions",
      "target": "hemopexin-like (PEX) domain",
      "label": "are in"
    },
    {
      "source": "serotonergic innervation",
      "target": "median midbrain raphe nuclei",
      "label": "from"
    },
    {
      "source": "serotonergic innervation",
      "target": "dorsal midbrain raphe nuclei",
      "label": "from"
    },
    {
      "source": "irreversible inhibitor",
      "target": "ligand binding",
      "label": "inhibits"
    },
    {
      "source": "Citalopram",
      "target": "RTI-76-induced inhibition",
      "label": "protected against"
    },
    {
      "source": "degradation rate constant",
      "target": "striatum",
      "label": "measured in"
    },
    {
      "source": "degradation rate constant",
      "target": "h(-1)",
      "label": "has unit"
    },
    {
      "source": "degradation rate constant",
      "target": "hippocampus",
      "label": "measured in"
    },
    {
      "source": "chemotherapy",
      "target": "doxorubicin",
      "label": "consists of"
    },
    {
      "source": "chemotherapy",
      "target": "CAF",
      "label": "is also known as"
    },
    {
      "source": "chemotherapy",
      "target": "cyclophosphamide",
      "label": "consists of"
    },
    {
      "source": "chemotherapy",
      "target": "fluorouracil",
      "label": "consists of"
    },
    {
      "source": "chemotherapy",
      "target": "front-line therapy",
      "label": "is a type of"
    },
    {
      "source": "chemotherapy",
      "target": "first-line therapy",
      "label": "is a type of"
    },
    {
      "source": "chemotherapy",
      "target": "sterility",
      "label": "causes"
    },
    {
      "source": "chemotherapy",
      "target": "Early menopause",
      "label": "causes"
    },
    {
      "source": "chemotherapy",
      "target": "alkylating agent",
      "label": "involved"
    },
    {
      "source": "chemotherapy",
      "target": "treatment",
      "label": "consisted of"
    },
    {
      "source": "chemotherapy",
      "target": "DNA-topoisomerase II inhibitors",
      "label": "involved"
    },
    {
      "source": "doxorubicin",
      "target": "DNA damage",
      "label": "induces"
    },
    {
      "source": "doxorubicin",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "doxorubicin",
      "target": "P-gp substrates",
      "label": "is a"
    },
    {
      "source": "Eastern Cooperative Oncology Group trial E3186",
      "target": "question",
      "label": "explores"
    },
    {
      "source": "maintenance cyclophosphamide",
      "target": "secondary randomization",
      "label": "was part of"
    },
    {
      "source": "chemohormonal therapy",
      "target": "overall survival",
      "label": "does not improve"
    },
    {
      "source": "chemohormonal therapy",
      "target": "Time to treatment failure (TTF)",
      "label": "prolongs"
    },
    {
      "source": "chemohormonal therapy",
      "target": "front-line therapy",
      "label": "is a type of"
    },
    {
      "source": "chemohormonal therapy",
      "target": "CAFTH",
      "label": "is also known as"
    },
    {
      "source": "chemohormonal therapy",
      "target": "first-line therapy",
      "label": "is a type of"
    },
    {
      "source": "overall survival",
      "target": "30.0 months",
      "label": "had value"
    },
    {
      "source": "overall survival",
      "target": "29.3 months",
      "label": "had value"
    },
    {
      "source": "overall survival",
      "target": "AA genotype",
      "label": "is of patients with"
    },
    {
      "source": "overall survival",
      "target": "GG+GA genotype",
      "label": "longer than"
    },
    {
      "source": "231 patients",
      "target": "chemotherapy",
      "label": "received"
    },
    {
      "source": "231 patients",
      "target": "January 1988",
      "label": "randomized between"
    },
    {
      "source": "231 patients",
      "target": "ER-unknown",
      "label": "had"
    },
    {
      "source": "231 patients",
      "target": "metastatic breast cancer",
      "label": "had"
    },
    {
      "source": "231 patients",
      "target": "December 1992",
      "label": "randomized between"
    },
    {
      "source": "231 patients",
      "target": "estrogen receptor (ER)-positive",
      "label": "had"
    },
    {
      "source": "231 patients",
      "target": "chemohormonal therapy",
      "label": "received"
    },
    {
      "source": "simultaneous hormonal therapy",
      "target": "additional benefit",
      "label": "provides"
    },
    {
      "source": "additional benefit",
      "target": "chemotherapy alone",
      "label": "compared with"
    },
    {
      "source": "Time to treatment failure (TTF)",
      "target": "17.4 months",
      "label": "had value"
    },
    {
      "source": "Time to treatment failure (TTF)",
      "target": "13.4 months",
      "label": "had value"
    },
    {
      "source": "Time to treatment failure (TTF)",
      "target": "10.3 months",
      "label": "had value"
    },
    {
      "source": "Time to treatment failure (TTF)",
      "target": "ER-positive patients",
      "label": "is for"
    },
    {
      "source": "Time to treatment failure (TTF)",
      "target": "P =.048",
      "label": "had P value of"
    },
    {
      "source": "Time to treatment failure (TTF)",
      "target": "P =.087",
      "label": "had P value of"
    },
    {
      "source": "response rates",
      "target": "68.9%",
      "label": "had value"
    },
    {
      "source": "response rates",
      "target": "complete response",
      "label": "include"
    },
    {
      "source": "response rates",
      "target": "partial response",
      "label": "include"
    },
    {
      "source": "response rates",
      "target": "P =.99",
      "label": "had P value of"
    },
    {
      "source": "response rates",
      "target": "69.2%",
      "label": "had value"
    },
    {
      "source": "cyclophosphamide",
      "target": "MTD regimen",
      "label": "used in"
    },
    {
      "source": "cyclophosphamide",
      "target": "metronomic chemotherapy",
      "label": "used in"
    },
    {
      "source": "CAFTH",
      "target": "Pharmacia-Upjohn",
      "label": "manufactured by"
    },
    {
      "source": "CAFTH",
      "target": "tamoxifen",
      "label": "includes"
    },
    {
      "source": "CAFTH",
      "target": "CAF",
      "label": "includes"
    },
    {
      "source": "CAFTH",
      "target": "Halotestin",
      "label": "includes"
    },
    {
      "source": "tamoxifen",
      "target": "therapeutic profile",
      "label": "has"
    },
    {
      "source": "tamoxifen",
      "target": "partial agonist property",
      "label": "has"
    },
    {
      "source": "tamoxifen",
      "target": "risks",
      "label": "has"
    },
    {
      "source": "tamoxifen",
      "target": "cell viability",
      "label": "reduced"
    },
    {
      "source": "tamoxifen",
      "target": "ER-agonist properties",
      "label": "possesses"
    },
    {
      "source": "tamoxifen",
      "target": "advanced breast cancer",
      "label": "has been in use for treatment of"
    },
    {
      "source": "tamoxifen",
      "target": "endometrial cancer",
      "label": "is associated with increased risk of"
    },
    {
      "source": "tamoxifen",
      "target": "thromboembolic complications",
      "label": "is associated with"
    },
    {
      "source": "tamoxifen",
      "target": "SERMs",
      "label": "is a type of"
    },
    {
      "source": "tamoxifen",
      "target": "estrogen",
      "label": "blocks action of"
    },
    {
      "source": "tamoxifen",
      "target": "antagonist properties",
      "label": "possesses"
    },
    {
      "source": "tamoxifen",
      "target": "ER-positive disease",
      "label": "is a treatment option for"
    },
    {
      "source": "tamoxifen",
      "target": "ER",
      "label": "binds to"
    },
    {
      "source": "tamoxifen",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "tamoxifen",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "tamoxifen",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "tamoxifen",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "tamoxifen",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "fluorouracil",
      "target": "solid tumours",
      "label": "used against"
    },
    {
      "source": "fluorouracil",
      "target": "therapeutic window",
      "label": "has"
    },
    {
      "source": "patients",
      "target": "prednisone",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "methotrexate",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "maintenance cyclophosphamide",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "TH",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "initial chemotherapy",
      "label": "receive"
    },
    {
      "source": "patients",
      "target": "complete response",
      "label": "experienced"
    },
    {
      "source": "patients",
      "target": "potentially hormone-sensitive metastatic breast cancer",
      "label": "had"
    },
    {
      "source": "patients",
      "target": "heparin",
      "label": "were randomized to receive"
    },
    {
      "source": "patients",
      "target": "high-dose argatroban",
      "label": "were randomized to receive"
    },
    {
      "source": "patients",
      "target": "AMI",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "acute myocardial infarction",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "low-dose argatroban",
      "label": "were randomized to receive"
    },
    {
      "source": "patients",
      "target": "end-of-dose deterioration",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Parkinson's disease",
      "label": "suffering from"
    },
    {
      "source": "patients",
      "target": "doses",
      "label": "assigned to"
    },
    {
      "source": "patients",
      "target": "schizophrenia",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "non-small cell lung cancers",
      "label": "treated for"
    },
    {
      "source": "patients",
      "target": "chronic plaque psoriasis",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "KIR6.2",
      "label": "with mutations in"
    },
    {
      "source": "patients",
      "target": "diazoxide",
      "label": "are resistant to"
    },
    {
      "source": "patients",
      "target": "childhood-onset",
      "label": "include"
    },
    {
      "source": "patients",
      "target": "surgical treatment",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "SUR1",
      "label": "with mutations in"
    },
    {
      "source": "patients",
      "target": "infancy-onset",
      "label": "include"
    },
    {
      "source": "patients",
      "target": "hyperinsulinaemic hypoglycaemia",
      "label": "investigated for"
    },
    {
      "source": "patients",
      "target": "childhood onset hyperinsulinism",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "hyperinsulinism-hyperammonaemia syndrome",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "therapies",
      "label": "respond to"
    },
    {
      "source": "patients",
      "target": "estrogen receptor-positive",
      "label": "are"
    },
    {
      "source": "patients",
      "target": "progesterone receptor-positive",
      "label": "are"
    },
    {
      "source": "patients",
      "target": "variant allele",
      "label": "compared with"
    },
    {
      "source": "patients",
      "target": "Arg",
      "label": "homozygous for"
    },
    {
      "source": "patients",
      "target": "50 mg metoprolol",
      "label": "took"
    },
    {
      "source": "patients",
      "target": "reduction",
      "label": "had"
    },
    {
      "source": "patients",
      "target": "hypertension",
      "label": "with"
    },
    {
      "source": "patients",
      "target": "uncomplicated hypertension",
      "label": "with"
    },
    {
      "source": "patients",
      "target": "IBD",
      "label": "has"
    },
    {
      "source": "patients",
      "target": "concomitant sulphasalazine treatment",
      "label": "not receiving"
    },
    {
      "source": "patients",
      "target": "active ulcerative colitis",
      "label": "has"
    },
    {
      "source": "patients",
      "target": "appetite-suppressant drug-associated PPH",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "betaxolol",
      "label": "do not respond to"
    },
    {
      "source": "patients",
      "target": "respiratory disease",
      "label": "are free of"
    },
    {
      "source": "patients",
      "target": "individual basis",
      "label": "are assessed on an"
    },
    {
      "source": "patients",
      "target": "Niemann-Pick A/B disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Fabry disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Krabbe disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Gaucher disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Pompe disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "pancreatic cancer",
      "label": "of"
    },
    {
      "source": "patients",
      "target": "single s.c. dose",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "type 2 diabetes mellitus",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "sitosterolemia",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "unfavourable variables",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "5-fluorouracil",
      "label": "treated with"
    },
    {
      "source": "patients",
      "target": "colorectal cancer",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "5FU",
      "label": "treated with"
    },
    {
      "source": "patients",
      "target": "high risk",
      "label": "classified as"
    },
    {
      "source": "patients",
      "target": "favourable variables",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "low risk",
      "label": "classified as"
    },
    {
      "source": "patients",
      "target": "bone metastatic disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "resistant disease",
      "label": "relapse with"
    },
    {
      "source": "patients",
      "target": "tamoxifen",
      "label": "respond to"
    },
    {
      "source": "patients",
      "target": "single weekly subcutaneous injection",
      "label": "treated with"
    },
    {
      "source": "patients",
      "target": "Efalizumab",
      "label": "treated with"
    },
    {
      "source": "patients",
      "target": "plaque psoriasis",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "placebo",
      "label": "on"
    },
    {
      "source": "patients",
      "target": "hematologic malignancies",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "response",
      "label": "have lower chance of achieving"
    },
    {
      "source": "patients",
      "target": "promoter hypermethylation",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "VKORC1*4",
      "label": "carry"
    },
    {
      "source": "patients",
      "target": "VKORC1*2",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "high-dose haplotypes VKORC1*3",
      "label": "carry"
    },
    {
      "source": "patients",
      "target": "anticoagulation therapy",
      "label": "undergo"
    },
    {
      "source": "patients",
      "target": "warfarin S/R ratios",
      "label": "had"
    },
    {
      "source": "patients",
      "target": "acute coronary syndromes",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "renal impairment",
      "label": "has"
    },
    {
      "source": "patients",
      "target": "hepatic impairment",
      "label": "has"
    },
    {
      "source": "patients",
      "target": "one yr",
      "label": "received for"
    },
    {
      "source": "patients",
      "target": "corticosteroids",
      "label": "received with"
    },
    {
      "source": "patients",
      "target": "cyclosporine",
      "label": "received with"
    },
    {
      "source": "patients",
      "target": "extension study",
      "label": "entered"
    },
    {
      "source": "patients",
      "target": "everolimus",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "metastatic colorectal cancer (CRC)",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "inflammatory breast cancer",
      "label": "diagnosed with"
    },
    {
      "source": "patients",
      "target": "MBC",
      "label": "diagnosed with"
    },
    {
      "source": "patients",
      "target": "central nervous system metastases",
      "label": "diagnosed with"
    },
    {
      "source": "patients",
      "target": "recent clinical trials",
      "label": "in"
    },
    {
      "source": "patients",
      "target": "severe symptoms",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "highly select cohort of men",
      "label": "were"
    },
    {
      "source": "patients",
      "target": "larger prostate size",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "cardiopulmonary compromise",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "branched-chain organic acidemias",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "MEC",
      "label": "receiving"
    },
    {
      "source": "patients",
      "target": "HEC",
      "label": "receiving"
    },
    {
      "source": "patients",
      "target": "medullary thyroid cancer",
      "label": "had"
    },
    {
      "source": "patients",
      "target": "advanced solid tumors",
      "label": "had"
    },
    {
      "source": "patients",
      "target": "LT4",
      "label": "took"
    },
    {
      "source": "patients",
      "target": "referral centers",
      "label": "followed in"
    },
    {
      "source": "patients",
      "target": "thyroid hormone replacement",
      "label": "subjected to"
    },
    {
      "source": "patients",
      "target": "thyroid medication",
      "label": "taking"
    },
    {
      "source": "patients",
      "target": "thyroid hormones",
      "label": "taking"
    },
    {
      "source": "patients",
      "target": "primary hypothyroidism",
      "label": "with"
    },
    {
      "source": "patients",
      "target": "questionnaire",
      "label": "answered a"
    },
    {
      "source": "patients",
      "target": "abnormal serum TSH",
      "label": "had an"
    },
    {
      "source": "patients",
      "target": "thyroid replacement",
      "label": "on"
    },
    {
      "source": "patients",
      "target": "medication",
      "label": "instructed to take"
    },
    {
      "source": "patients",
      "target": "TSH",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "aggressive therapy",
      "label": "not considered fit for"
    },
    {
      "source": "patients",
      "target": "myelofibrosis",
      "label": "diagnosed with"
    },
    {
      "source": "patients",
      "target": "controls",
      "label": "show no significant differences compared to"
    },
    {
      "source": "patients",
      "target": "ITD mutations",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "AML",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "TKI-resistant FLT3-ITD D835 mutations",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "chemotherapy-resistant acute myeloid leukemia",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "internal tandem duplication",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "suggestive facial gestalt",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "congenital malformation",
      "label": "are in the absence of"
    },
    {
      "source": "patients",
      "target": "lesser degrees of ID",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "allergic asthma",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "GG genotype",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "platinum-based chemotherapy",
      "label": "received"
    },
    {
      "source": "patients",
      "target": "sodium-replete state",
      "label": "kept in"
    },
    {
      "source": "patients",
      "target": "thyroid disease",
      "label": "without"
    },
    {
      "source": "patients",
      "target": "antihypertensive treatment",
      "label": "with"
    },
    {
      "source": "patients",
      "target": "microdeletion of chromosome 11p",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "retinoblastoma (Rb)",
      "label": "affected by"
    },
    {
      "source": "patients",
      "target": "microdeletions of 11p",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "microdeletion of chromosome 13",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "microdeletions of 13q",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Wilms tumor (WT)",
      "label": "affected by"
    },
    {
      "source": "patients",
      "target": "Addison's disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "arthritic diseases",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "rheumatoid arthritis",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "reactive airway disease",
      "label": "have"
    },
    {
      "source": "patients",
      "target": "Gitelman's syndrome (GS)",
      "label": "have"
    },
    {
      "source": "prednisone",
      "target": "secondary randomization",
      "label": "was part of"
    },
    {
      "source": "front-line therapy",
      "target": "metastatic breast cancer",
      "label": "is for"
    },
    {
      "source": "complete response",
      "target": "induction therapy",
      "label": "is a result of"
    },
    {
      "source": "initial chemotherapy",
      "target": "aggressiveness",
      "label": "is due to"
    },
    {
      "source": "initial chemotherapy",
      "target": "disease",
      "label": "is due to"
    },
    {
      "source": "initial chemotherapy",
      "target": "location",
      "label": "is due to"
    },
    {
      "source": "initial chemotherapy",
      "target": "bulk",
      "label": "is due to"
    },
    {
      "source": "methotrexate",
      "target": "secondary randomization",
      "label": "was part of"
    },
    {
      "source": "methotrexate",
      "target": "small molecule substrates",
      "label": "is a type of"
    },
    {
      "source": "methotrexate",
      "target": "anticancer drug",
      "label": "is an"
    },
    {
      "source": "first-line therapy",
      "target": "metastatic, hormone-sensitive breast cancer",
      "label": "is for"
    },
    {
      "source": "first-line therapy",
      "target": "patients",
      "label": "for"
    },
    {
      "source": "first-line therapy",
      "target": "United States",
      "label": "used in"
    },
    {
      "source": "first-line therapy",
      "target": "indication",
      "label": "used for"
    },
    {
      "source": "first-line therapy",
      "target": "MBC",
      "label": "for"
    },
    {
      "source": "TH",
      "target": "secondary randomization",
      "label": "was part of"
    },
    {
      "source": "TH",
      "target": "negative regulation",
      "label": "exerted"
    },
    {
      "source": "TH",
      "target": "human SCD-1 gene expression",
      "label": "negatively regulates"
    },
    {
      "source": "TH",
      "target": "mouse SCD-1 gene promoter",
      "label": "negatively regulates"
    },
    {
      "source": "TH",
      "target": "SREBP-1c",
      "label": "negatively regulates"
    },
    {
      "source": "Halotestin",
      "target": "fluoxymesterone",
      "label": "is a form of"
    },
    {
      "source": "hormonal therapy",
      "target": "standard therapy",
      "label": "represents"
    },
    {
      "source": "hormonal therapy",
      "target": "advanced and metastatic prostate cancer",
      "label": "is for"
    },
    {
      "source": "standard therapy",
      "target": "metastatic hormone-sensitive disease",
      "label": "is for"
    },
    {
      "source": "metastatic breast cancer",
      "target": "taxane",
      "label": "received previous treatment including"
    },
    {
      "source": "metastatic breast cancer",
      "target": "anthracycline",
      "label": "received previous treatment including"
    },
    {
      "source": "metastatic breast cancer",
      "target": "trastuzumab",
      "label": "received previous treatment including"
    },
    {
      "source": "ER status",
      "target": "overall survival",
      "label": "had no effect on"
    },
    {
      "source": "Eastern Cooperative Oncology Group",
      "target": "study",
      "label": "conducted"
    },
    {
      "source": "cytotoxicity",
      "target": "properties",
      "label": "is a"
    },
    {
      "source": "cytotoxicity",
      "target": "mitochondrial involvement",
      "label": "suggests"
    },
    {
      "source": "cytotoxicity",
      "target": "hERG channel interaction",
      "label": "is distinct from"
    },
    {
      "source": "cytotoxicity",
      "target": "mitochondrial membrane potential",
      "label": "is associated with"
    },
    {
      "source": "cytotoxicity",
      "target": "cisplatin",
      "label": "of"
    },
    {
      "source": "cytotoxicity",
      "target": "carboplatin",
      "label": "of"
    },
    {
      "source": "cytotoxicity",
      "target": "oxaliplatin",
      "label": "of"
    },
    {
      "source": "cytotoxicity",
      "target": "copper",
      "label": "of"
    },
    {
      "source": "cytotoxicity",
      "target": "drug loading",
      "label": "resulting from"
    },
    {
      "source": "cytotoxicity",
      "target": "stability",
      "label": "resulting from"
    },
    {
      "source": "cytotoxicity",
      "target": "SMPPI",
      "label": "evaluated for"
    },
    {
      "source": "cytotoxicity",
      "target": "PPI",
      "label": "evaluated for"
    },
    {
      "source": "cytotoxicity",
      "target": "SPPI",
      "label": "evaluated for"
    },
    {
      "source": "cytotoxicity",
      "target": "MPPI",
      "label": "evaluated for"
    },
    {
      "source": "cytotoxicity",
      "target": "human lung cancer cells (H460)",
      "label": "against"
    },
    {
      "source": "cytotoxicity",
      "target": "3-aryl acrylic amide derivatives",
      "label": "is of"
    },
    {
      "source": "cancer",
      "target": "precursors",
      "label": "caused by"
    },
    {
      "source": "cancer",
      "target": "synthetic quinones",
      "label": "caused by"
    },
    {
      "source": "cancer",
      "target": "environmental quinones",
      "label": "caused by"
    },
    {
      "source": "cancer",
      "target": "prostate",
      "label": "affects"
    },
    {
      "source": "cancer",
      "target": "reproductive tract",
      "label": "affects"
    },
    {
      "source": "cancer",
      "target": "colorectal",
      "label": "affects"
    },
    {
      "source": "oxidative stress",
      "target": "risk factor",
      "label": "is a"
    },
    {
      "source": "oxidative stress",
      "target": "body systems",
      "label": "on"
    },
    {
      "source": "oxidative stress",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "oxidative stress",
      "target": "nicotine",
      "label": "is induced by"
    },
    {
      "source": "oxidative stress",
      "target": "onset and slow progression of ALS/PDC",
      "label": "contributing factor in"
    },
    {
      "source": "oxidative stress",
      "target": "hippocampus",
      "label": "occurs in"
    },
    {
      "source": "oxidative stress",
      "target": "neurons",
      "label": "is detected in"
    },
    {
      "source": "oxidative stress",
      "target": "laser cofocal microscopy",
      "label": "detection uses"
    },
    {
      "source": "oxidative stress",
      "target": "NeuN/8-OHdG immunofluorescence double labeling",
      "label": "detection uses"
    },
    {
      "source": "oxidative stress",
      "target": "SN",
      "label": "is detected in"
    },
    {
      "source": "oxidative stress",
      "target": "expression",
      "label": "leads to"
    },
    {
      "source": "oxidative stress",
      "target": "diabetic rats",
      "label": "in"
    },
    {
      "source": "oxidative stress",
      "target": "CREB",
      "label": "caused decrease in"
    },
    {
      "source": "oxidative stress",
      "target": "neurodegenerative diseases",
      "label": "has central role in"
    },
    {
      "source": "oxidative stress",
      "target": "neuropathology",
      "label": "has central role in"
    },
    {
      "source": "oxidative stress",
      "target": "Nrf2",
      "label": "caused decrease in"
    },
    {
      "source": "mNQO activity",
      "target": "dicoumarol",
      "label": "is insensitive to"
    },
    {
      "source": "mNQO activity",
      "target": "NADPH",
      "label": "has lower affinity for"
    },
    {
      "source": "mNQO activity",
      "target": "ammonium sulfate fractionation",
      "label": "partially purified by"
    },
    {
      "source": "mNQO activity",
      "target": "NADH",
      "label": "has higher affinity for"
    },
    {
      "source": "mNQO activity",
      "target": "2,6-dichlorophenolindophenol",
      "label": "catalyzes reduction of"
    },
    {
      "source": "mNQO activity",
      "target": "menadione",
      "label": "catalyzes reduction of"
    },
    {
      "source": "mNQO activity",
      "target": "DEAE-Sephacel column chromatography",
      "label": "partially purified by"
    },
    {
      "source": "mNQO activity",
      "target": "detergent Chaps",
      "label": "partially purified by"
    },
    {
      "source": "dicoumarol",
      "target": "cytosolic NQO1",
      "label": "is an inhibitor of"
    },
    {
      "source": "18-kDa bands",
      "target": "polyclonal antibodies",
      "label": "cross-reacted with"
    },
    {
      "source": "polyclonal antibodies",
      "target": "cytosolic NQO1",
      "label": "raised against"
    },
    {
      "source": "cytosolic NQO1",
      "target": "cells",
      "label": "protects"
    },
    {
      "source": "Quinone oxidoreductases",
      "target": "quinones",
      "label": "detoxifies"
    },
    {
      "source": "Quinone oxidoreductases",
      "target": "cells",
      "label": "protects"
    },
    {
      "source": "Quinone oxidoreductases",
      "target": "flavoproteins",
      "label": "is a"
    },
    {
      "source": "quinones",
      "target": "Tyrosinase",
      "label": "is a product of"
    },
    {
      "source": "NRH:quinone oxidoreductase 2",
      "target": "cytosolic forms of quinone oxidoreductases",
      "label": "is a type of"
    },
    {
      "source": "toxicity",
      "target": "synthetic quinones",
      "label": "caused by"
    },
    {
      "source": "toxicity",
      "target": "environmental quinones",
      "label": "caused by"
    },
    {
      "source": "toxicity",
      "target": "precursors",
      "label": "caused by"
    },
    {
      "source": "toxicity",
      "target": "amyloid fibrils",
      "label": "of"
    },
    {
      "source": "toxicity",
      "target": "long-lasting effect",
      "label": "is a"
    },
    {
      "source": "toxicity",
      "target": "cell survival capacity",
      "label": "decreased"
    },
    {
      "source": "toxicity",
      "target": "copper",
      "label": "of"
    },
    {
      "source": "toxicity",
      "target": "platinum anticancer drugs",
      "label": "of"
    },
    {
      "source": "toxicity",
      "target": "PI3K survival signaling",
      "label": "focuses on"
    },
    {
      "source": "toxicity",
      "target": "SAL",
      "label": "of"
    },
    {
      "source": "toxicity",
      "target": "NSCs",
      "label": "toward"
    },
    {
      "source": "toxicity",
      "target": "apoptosis",
      "label": "focuses on"
    },
    {
      "source": "toxicity",
      "target": "rat stomach",
      "label": "occurs in"
    },
    {
      "source": "toxicity",
      "target": "Cd(2+)",
      "label": "of"
    },
    {
      "source": "toxicity",
      "target": "Mn(2+)",
      "label": "of"
    },
    {
      "source": "Western analysis",
      "target": "18-kDa bands",
      "label": "revealed"
    },
    {
      "source": "Western analysis",
      "target": "29-kDa bands",
      "label": "revealed"
    },
    {
      "source": "Western analysis",
      "target": "microsomal proteins",
      "label": "performed on"
    },
    {
      "source": "NQO2",
      "target": "NRH:quinone oxidoreductase 2",
      "label": "is an abbreviation for"
    },
    {
      "source": "NADH",
      "target": "electron donor",
      "label": "is"
    },
    {
      "source": "NADH",
      "target": "reduced nicotinamide adenine dinucleotide",
      "label": "is an abbreviation for"
    },
    {
      "source": "NQO activity",
      "target": "rat liver microsomes",
      "label": "purified from"
    },
    {
      "source": "NQO activity",
      "target": "microsomal NQO (mNQO)",
      "label": "designated as"
    },
    {
      "source": "mutagenicity",
      "target": "environmental quinones",
      "label": "caused by"
    },
    {
      "source": "mutagenicity",
      "target": "synthetic quinones",
      "label": "caused by"
    },
    {
      "source": "mutagenicity",
      "target": "precursors",
      "label": "caused by"
    },
    {
      "source": "mutagenicity",
      "target": "quinones",
      "label": "caused by"
    },
    {
      "source": "microsomal mNQO proteins",
      "target": "mutagenicity",
      "label": "provides protection against"
    },
    {
      "source": "microsomal mNQO proteins",
      "target": "quinone toxicity",
      "label": "provides protection against"
    },
    {
      "source": "microsomal mNQO proteins",
      "target": "cytosolic NQOs",
      "label": "provides additional protection after"
    },
    {
      "source": "29-kDa bands",
      "target": "polyclonal antibodies",
      "label": "cross-reacted with"
    },
    {
      "source": "menadione",
      "target": "menadione-induced hepatic oxidative damage",
      "label": "causes"
    },
    {
      "source": "menadione",
      "target": "hepatotoxicity",
      "label": "causes"
    },
    {
      "source": "NQO1",
      "target": "NAD(P)H:quinone oxidoreductase 1",
      "label": "is an abbreviation for"
    },
    {
      "source": "NAD(P)H:quinone oxidoreductase 1",
      "target": "cytosolic forms of quinone oxidoreductases",
      "label": "is a type of"
    },
    {
      "source": "eNOS",
      "target": "[3H]L-citrulline",
      "label": "produces"
    },
    {
      "source": "eNOS",
      "target": "[3H]L-Cit",
      "label": "produces"
    },
    {
      "source": "eNOS",
      "target": "BAEC cultures",
      "label": "located in"
    },
    {
      "source": "eNOS",
      "target": "nitric oxide",
      "label": "catalyzes production of"
    },
    {
      "source": "eNOS",
      "target": "NO",
      "label": "catalyzes production of"
    },
    {
      "source": "eNOS",
      "target": "L-citrulline",
      "label": "catalyzes production of"
    },
    {
      "source": "Gi proteins",
      "target": "eNOS",
      "label": "involved in"
    },
    {
      "source": "methiothepin",
      "target": "5-HT2 receptor",
      "label": "Antagonist"
    },
    {
      "source": "methiothepin",
      "target": "5-HT1B receptor",
      "label": "Antagonist"
    },
    {
      "source": "L-N omega-iminoethyl-L-ornithine",
      "target": "eNOS",
      "label": "Antagonist"
    },
    {
      "source": "endothelial nitric oxide synthase",
      "target": "nitric oxide",
      "label": "catalyzes production of"
    },
    {
      "source": "endothelial nitric oxide synthase",
      "target": "NO",
      "label": "catalyzes production of"
    },
    {
      "source": "endothelial nitric oxide synthase",
      "target": "bovine aortic endothelial cell cultures",
      "label": "located in"
    },
    {
      "source": "endothelial nitric oxide synthase",
      "target": "L-citrulline",
      "label": "catalyzes production of"
    },
    {
      "source": "nitric oxide",
      "target": "endothelial cells",
      "label": "mediates"
    },
    {
      "source": "nitric oxide",
      "target": "production",
      "label": "induce"
    },
    {
      "source": "nitric oxide",
      "target": "NO",
      "label": "is"
    },
    {
      "source": "nitric oxide",
      "target": "L-arginine",
      "label": "is produced from"
    },
    {
      "source": "5-NOT",
      "target": "eNOS",
      "label": "Upregulator"
    },
    {
      "source": "5-NOT",
      "target": "5-HT1B receptor",
      "label": "Agonist"
    },
    {
      "source": "endothelial cells",
      "target": "endothelial activating cytokines",
      "label": "are stimulated with"
    },
    {
      "source": "endothelial cells",
      "target": "NO",
      "label": "produce"
    },
    {
      "source": "endothelial cells",
      "target": "[14C]-L-arginine",
      "label": "were incubated with"
    },
    {
      "source": "endothelial cells",
      "target": "blood vessels",
      "label": "are part of"
    },
    {
      "source": "5-HT1B receptor/eNOS pathway",
      "target": "eNOS",
      "label": "involves"
    },
    {
      "source": "5-HT1B receptor/eNOS pathway",
      "target": "5-HT1B receptor",
      "label": "involves"
    },
    {
      "source": "NO",
      "target": "endothelial cells",
      "label": "mediates"
    },
    {
      "source": "NO",
      "target": "L-arginine",
      "label": "is produced from"
    },
    {
      "source": "L-Nomega -monomethyl-L-arginine",
      "target": "eNOS",
      "label": "Antagonist"
    },
    {
      "source": "PTX",
      "target": "eNOS",
      "label": "inhibits"
    },
    {
      "source": "5-nonyloxytryptamine",
      "target": "5-HT1B receptor",
      "label": "Agonist"
    },
    {
      "source": "5-nonyloxytryptamine",
      "target": "eNOS",
      "label": "Upregulator"
    },
    {
      "source": "5-hydroxytryptamine",
      "target": "eNOS",
      "label": "Upregulator"
    },
    {
      "source": "5-hydroxytryptamine",
      "target": "endothelial nitric oxide synthase",
      "label": "Upregulator"
    },
    {
      "source": "5-hydroxytryptamine",
      "target": "5-HT",
      "label": "is also known as"
    },
    {
      "source": "5-hydroxytryptamine",
      "target": "Nerve terminals",
      "label": "is released from"
    },
    {
      "source": "isamoltane",
      "target": "5-HT1B receptor",
      "label": "Antagonist"
    },
    {
      "source": "L-NMMA",
      "target": "eNOS",
      "label": "Antagonist"
    },
    {
      "source": "[3H]L-arginine",
      "target": "eNOS",
      "label": "Substrate"
    },
    {
      "source": "5-HT",
      "target": "eNOS",
      "label": "Upregulator"
    },
    {
      "source": "5-HT",
      "target": "enteric nervous system",
      "label": "found in"
    },
    {
      "source": "5-HT",
      "target": "gastrointestinal motor function",
      "label": "controls"
    },
    {
      "source": "5-HT",
      "target": "serotonin",
      "label": "is"
    },
    {
      "source": "5-HT",
      "target": "Feeding control",
      "label": "has role in"
    },
    {
      "source": "5-HT",
      "target": "Nerve terminals",
      "label": "is released from"
    },
    {
      "source": "L-NIO",
      "target": "eNOS",
      "label": "Antagonist"
    },
    {
      "source": "[3H]L-Arg",
      "target": "eNOS",
      "label": "Substrate"
    },
    {
      "source": "vascular 5-HT receptors",
      "target": "eNOS",
      "label": "Upregulator"
    },
    {
      "source": "pertussis toxin",
      "target": "eNOS",
      "label": "inhibits"
    },
    {
      "source": "pertussis toxin",
      "target": "cells",
      "label": "treated"
    },
    {
      "source": "pertussis toxin",
      "target": "acidification rate changes",
      "label": "abolished"
    },
    {
      "source": "pertussis toxin",
      "target": "Gi/Go transducer proteins",
      "label": "impairs"
    },
    {
      "source": "pertussis toxin",
      "target": "reducing activity",
      "label": "blocks"
    },
    {
      "source": "pertussis toxin",
      "target": "Neuroprotection",
      "label": "attenuates"
    },
    {
      "source": "tasosartan",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "tasosartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "tasosartan",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "tasosartan",
      "target": "surmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "tasosartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "zolasartan",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "zolasartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "zolasartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "slow off-rate",
      "target": "occupancy of the AT1 receptor",
      "label": "may extend"
    },
    {
      "source": "slow off-rate",
      "target": "duration of the antihypertensive effect",
      "label": "may lengthen"
    },
    {
      "source": "angiotensin II type 1 (AT1) receptor antagonists",
      "target": "angiotensin I converting enzyme inhibitors",
      "label": "avoid nonspecificity of"
    },
    {
      "source": "angiotensin II type 1 (AT1) receptor antagonists",
      "target": "renin-angiotensin-aldosterone system",
      "label": "block"
    },
    {
      "source": "telmisartan",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "telmisartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "telmisartan",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "telmisartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "telmisartan",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "eprosartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "eprosartan",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "eprosartan",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "eprosartan",
      "target": "surmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "eprosartan",
      "target": "APV",
      "label": "did not alter"
    },
    {
      "source": "eprosartan",
      "target": "AT1",
      "label": "Antagonist"
    },
    {
      "source": "eprosartan",
      "target": "heart rate variability",
      "label": "Downregulator"
    },
    {
      "source": "eprosartan",
      "target": "baroreflex gain",
      "label": "Downregulator"
    },
    {
      "source": "eprosartan",
      "target": "circulating Ang-II levels",
      "label": "Upregulator"
    },
    {
      "source": "eprosartan",
      "target": "600 mg/day",
      "label": "has dosage"
    },
    {
      "source": "eprosartan",
      "target": "BRG",
      "label": "diminished"
    },
    {
      "source": "eprosartan",
      "target": "total power of HRV",
      "label": "diminished"
    },
    {
      "source": "eprosartan",
      "target": "7 days",
      "label": "duration"
    },
    {
      "source": "eprosartan",
      "target": "angiotensin type 1 (AT1) receptor blocker",
      "label": "is a type of"
    },
    {
      "source": "eprosartan",
      "target": "mean AP",
      "label": "Downregulator"
    },
    {
      "source": "eprosartan",
      "target": "heart rate",
      "label": "Upregulator"
    },
    {
      "source": "eprosartan",
      "target": "AT1 antagonism",
      "label": "causes"
    },
    {
      "source": "eprosartan",
      "target": "low/high frequency (LF/HF) ratio of HRV",
      "label": "did not alter"
    },
    {
      "source": "noncompetitive antagonism",
      "target": "antihypertensive efficacy",
      "label": "does not determine"
    },
    {
      "source": "candesartan",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "candesartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "candesartan",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "candesartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "candesartan",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "candesartan",
      "target": "insurmountable and long-lasting antagonist",
      "label": "is an"
    },
    {
      "source": "candesartan",
      "target": "angiotensin II type 1 receptor blockers",
      "label": "is a type of"
    },
    {
      "source": "candesartan",
      "target": "rat portal vein preparations",
      "label": "studied in"
    },
    {
      "source": "candesartan",
      "target": "concentrations",
      "label": "at"
    },
    {
      "source": "candesartan",
      "target": "maximal contractile response",
      "label": "caused decrease in"
    },
    {
      "source": "candesartan",
      "target": "conscious rats",
      "label": "given to"
    },
    {
      "source": "candesartan",
      "target": "rabbit aortic strips",
      "label": "studied in"
    },
    {
      "source": "candesartan",
      "target": "AT1R expression",
      "label": "did not suppress"
    },
    {
      "source": "E3174",
      "target": "active metabolite",
      "label": "is an"
    },
    {
      "source": "E3174",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "E3174",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "E3174",
      "target": "Losartan",
      "label": "is active metabolite of"
    },
    {
      "source": "E3174",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "E3174",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "active metabolite",
      "target": "venlafaxine",
      "label": "of"
    },
    {
      "source": "active metabolite",
      "target": "excitotoxic death",
      "label": "protects against"
    },
    {
      "source": "active metabolite",
      "target": "neurons",
      "label": "protects"
    },
    {
      "source": "active metabolite",
      "target": "PGHS",
      "label": "inhibits"
    },
    {
      "source": "active metabolite",
      "target": "inducible prostaglandin H synthase",
      "label": "inhibits"
    },
    {
      "source": "active metabolite",
      "target": "selective inhibitor",
      "label": "is a"
    },
    {
      "source": "active metabolite",
      "target": "nabumetone",
      "label": "is metabolite of"
    },
    {
      "source": "'sartans'",
      "target": "clinical development",
      "label": "completed"
    },
    {
      "source": "saprisartan",
      "target": "insurmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "saprisartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "saprisartan",
      "target": "chemical structure",
      "label": "is based on"
    },
    {
      "source": "Losartan",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "Losartan",
      "target": "surmountable antagonism",
      "label": "exhibits"
    },
    {
      "source": "Losartan",
      "target": "AT1 receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "Losartan",
      "target": "noncompetitive antagonism",
      "label": "exhibits"
    },
    {
      "source": "Losartan",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "Losartan",
      "target": "cardiac fibrosis",
      "label": "does not affect"
    },
    {
      "source": "candesartan cilexetil",
      "target": "relative binding affinities",
      "label": "has"
    },
    {
      "source": "candesartan cilexetil",
      "target": "prodrug",
      "label": "is a"
    },
    {
      "source": "candesartan cilexetil",
      "target": "AT1 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "angiotensin II receptor antagonists",
      "target": "Pharmacological properties",
      "label": "have"
    },
    {
      "source": "AT1 receptor antagonism",
      "target": "surmountable antagonism",
      "label": "is characterized as"
    },
    {
      "source": "AT1 receptor antagonism",
      "target": "insurmountable antagonism",
      "label": "is characterized as"
    },
    {
      "source": "AT1 receptor antagonism",
      "target": "noncompetitive antagonism",
      "label": "is characterized as"
    },
    {
      "source": "angiotensin II",
      "target": "Ang II",
      "label": "is an abbreviation for"
    },
    {
      "source": "competitive antagonism",
      "target": "antihypertensive efficacy",
      "label": "does not determine"
    },
    {
      "source": "slow dissociation kinetics",
      "target": "insurmountable antagonism",
      "label": "underlie"
    },
    {
      "source": "prodrug",
      "target": "diflunisal",
      "label": "is of"
    },
    {
      "source": "UFT",
      "target": "adjuvant chemotherapy programs",
      "label": "useful for"
    },
    {
      "source": "UFT",
      "target": "colorectal tumors",
      "label": "affects"
    },
    {
      "source": "UFT",
      "target": "pre-operative adjuvant chemotherapy programs",
      "label": "useful for"
    },
    {
      "source": "UFT",
      "target": "post-operative adjuvant chemotherapy programs",
      "label": "useful for"
    },
    {
      "source": "UFT",
      "target": "rat colorectal carcinomas",
      "label": "affects"
    },
    {
      "source": "UFT",
      "target": "tumor growth",
      "label": "suppressed"
    },
    {
      "source": "UFT",
      "target": "thymidylate synthase inhibition",
      "label": "increased"
    },
    {
      "source": "UFT",
      "target": "thymidine kinase activity",
      "label": "decreased"
    },
    {
      "source": "UFT",
      "target": "colorectal carcinogenesis",
      "label": "suppressed"
    },
    {
      "source": "colorectal tumors",
      "target": "rats",
      "label": "occur in"
    },
    {
      "source": "1,2-dimethylhydrazine",
      "target": "colorectal tumors",
      "label": "induces"
    },
    {
      "source": "1,2-dimethylhydrazine",
      "target": "rat colorectal carcinomas",
      "label": "induces"
    },
    {
      "source": "thymidine kinase",
      "target": "enzymes",
      "label": "is a type of"
    },
    {
      "source": "thymidine kinase",
      "target": "pyrimidine nucleotide synthesis",
      "label": "involved in"
    },
    {
      "source": "thymidine kinase",
      "target": "salvage pathways",
      "label": "involved in"
    },
    {
      "source": "enzymes",
      "target": "proliferation",
      "label": "is essential for"
    },
    {
      "source": "enzymes",
      "target": "mammalian macrophages",
      "label": "is essential for proliferation within"
    },
    {
      "source": "enzymes",
      "target": "infectivity",
      "label": "is essential for"
    },
    {
      "source": "enzymes",
      "target": "amastigotes",
      "label": "is essential for transformation into"
    },
    {
      "source": "enzymes",
      "target": "viability",
      "label": "is essential for"
    },
    {
      "source": "enzymes",
      "target": "molybdenum",
      "label": "require"
    },
    {
      "source": "enzymes",
      "target": "sulfur",
      "label": "catalyze metabolism of"
    },
    {
      "source": "enzymes",
      "target": "Mo",
      "label": "require"
    },
    {
      "source": "enzymes",
      "target": "nitrogen",
      "label": "catalyze metabolism of"
    },
    {
      "source": "enzymes",
      "target": "carbon",
      "label": "catalyze metabolism of"
    },
    {
      "source": "enzymes",
      "target": "other sources",
      "label": "derived from"
    },
    {
      "source": "enzymes",
      "target": "regulation",
      "label": "restore"
    },
    {
      "source": "enzymes",
      "target": "\u03b1/\u03b2 hydrolase fold superfamily",
      "label": "belongs to"
    },
    {
      "source": "enzymes",
      "target": "antioxidant functions",
      "label": "have"
    },
    {
      "source": "enzymes",
      "target": "xenobiotic metabolism",
      "label": "involved in"
    },
    {
      "source": "enzymes",
      "target": "anti-inflammatory functions",
      "label": "have"
    },
    {
      "source": "1-(2-tetrahydrofuryl)-5-FU",
      "target": "UFT",
      "label": "is part of"
    },
    {
      "source": "inactive ternary complex",
      "target": "intracellular folate",
      "label": "formed with"
    },
    {
      "source": "leucovorin",
      "target": "adjuvant chemotherapy programs",
      "label": "useful for"
    },
    {
      "source": "leucovorin",
      "target": "colorectal tumors",
      "label": "affects"
    },
    {
      "source": "leucovorin",
      "target": "pre-operative adjuvant chemotherapy programs",
      "label": "useful for"
    },
    {
      "source": "leucovorin",
      "target": "tumor growth",
      "label": "suppressed"
    },
    {
      "source": "leucovorin",
      "target": "thymidine kinase activity",
      "label": "decreased"
    },
    {
      "source": "leucovorin",
      "target": "post-operative adjuvant chemotherapy programs",
      "label": "useful for"
    },
    {
      "source": "leucovorin",
      "target": "rat colorectal carcinomas",
      "label": "affects"
    },
    {
      "source": "leucovorin",
      "target": "thymidylate synthase inhibition",
      "label": "increased"
    },
    {
      "source": "leucovorin",
      "target": "colorectal carcinogenesis",
      "label": "suppressed"
    },
    {
      "source": "thymidylate synthase inhibition",
      "target": "tumor cells",
      "label": "occurs in"
    },
    {
      "source": "Thymidylate synthase",
      "target": "de novo pathway",
      "label": "involved in"
    },
    {
      "source": "Thymidylate synthase",
      "target": "pyrimidine nucleotide synthesis",
      "label": "involved in"
    },
    {
      "source": "Thymidylate synthase",
      "target": "enzymes",
      "label": "is a type of"
    },
    {
      "source": "Thymidylate synthase",
      "target": "biological target",
      "label": "is a"
    },
    {
      "source": "uracil",
      "target": "UFT",
      "label": "is part of"
    },
    {
      "source": "tumor growth",
      "target": "CTSK",
      "label": "is impaired by absence of"
    },
    {
      "source": "tumor growth",
      "target": "bone",
      "label": "occurs in"
    },
    {
      "source": "tumor growth",
      "target": "vivo",
      "label": "occurs in"
    },
    {
      "source": "5-fluorodeoxyuridine monophosphate",
      "target": "inactive ternary complex",
      "label": "forms"
    },
    {
      "source": "5-fluorodeoxyuridine monophosphate",
      "target": "Thymidylate synthase",
      "label": "inhibits"
    },
    {
      "source": "thymidine kinase activity",
      "target": "tumor cells",
      "label": "occurs in"
    },
    {
      "source": "rats",
      "target": "halothane",
      "label": "anesthetized with"
    },
    {
      "source": "rats",
      "target": "high levels of white or blue light",
      "label": "exposed to"
    },
    {
      "source": "rats",
      "target": "bisoprolol",
      "label": "received treatment with"
    },
    {
      "source": "rats",
      "target": "salbutamol",
      "label": "pretreated with"
    },
    {
      "source": "rats",
      "target": "hyperthyroidism conditions",
      "label": "suffering from"
    },
    {
      "source": "rats",
      "target": "localized activation of CREB",
      "label": "yielded"
    },
    {
      "source": "rats",
      "target": "vehicle",
      "label": "pretreated by"
    },
    {
      "source": "rats",
      "target": "Captopril",
      "label": "administrated"
    },
    {
      "source": "rats",
      "target": "mild streptozotocin-induced diabetes",
      "label": "had"
    },
    {
      "source": "rats",
      "target": "moderate streptozotocin-induced diabetes",
      "label": "had"
    },
    {
      "source": "rats",
      "target": "insulin",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "estrous cycle",
      "label": "displayed abnormal"
    },
    {
      "source": "rats",
      "target": "hCG",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "androgen biosynthesis",
      "label": "displayed increasing"
    },
    {
      "source": "rats",
      "target": "exposures",
      "label": "had"
    },
    {
      "source": "rats",
      "target": "Findings",
      "label": "exhibited"
    },
    {
      "source": "rats",
      "target": "soman",
      "label": "exposed to"
    },
    {
      "source": "rats",
      "target": "PPA",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "streptozotocin",
      "label": "injected with"
    },
    {
      "source": "rats",
      "target": "1,25(OH)(2)D(3)",
      "label": "were injected with"
    },
    {
      "source": "rats",
      "target": "lethal dose of PQ",
      "label": "are treated with"
    },
    {
      "source": "rats",
      "target": "(-) Epicatechin",
      "label": "pretreated with"
    },
    {
      "source": "rats",
      "target": "triazolam",
      "label": "orally administered"
    },
    {
      "source": "rats",
      "target": "GFJ",
      "label": "pretreated by"
    },
    {
      "source": "rats",
      "target": "MDZ",
      "label": "orally administered"
    },
    {
      "source": "rats",
      "target": "grapefruit juice",
      "label": "pretreated by"
    },
    {
      "source": "rats",
      "target": "tap water",
      "label": "pretreated by"
    },
    {
      "source": "rats",
      "target": "midazolam",
      "label": "orally administered"
    },
    {
      "source": "rats",
      "target": "TRZ",
      "label": "orally administered"
    },
    {
      "source": "rats",
      "target": "uranyl nitrate (UN)",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "plain water",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "low-dose gentamicin",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "acute kidney injury (AKI)",
      "label": "can be sensitized to"
    },
    {
      "source": "rats",
      "target": "IR group",
      "label": "divided into"
    },
    {
      "source": "rats",
      "target": "IPC group",
      "label": "divided into"
    },
    {
      "source": "rats",
      "target": "sham groups",
      "label": "divided into"
    },
    {
      "source": "rats",
      "target": "mixture of five probe drugs",
      "label": "injected with"
    },
    {
      "source": "rats",
      "target": "diets",
      "label": "given"
    },
    {
      "source": "rats",
      "target": "partial hepatectomy",
      "label": "subjected_to"
    },
    {
      "source": "rats",
      "target": "cocaine",
      "label": "trained to self-administer"
    },
    {
      "source": "rats",
      "target": "sitagliptin",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "diabetic control",
      "label": "divided into group"
    },
    {
      "source": "rats",
      "target": "l-glutamine",
      "label": "treated with"
    },
    {
      "source": "rats",
      "target": "nondiabetic",
      "label": "divided into group"
    },
    {
      "source": "rats",
      "target": "chronic vascular catheters",
      "label": "have"
    },
    {
      "source": "rats",
      "target": "HF diet",
      "label": "fed"
    },
    {
      "source": "rats",
      "target": "9 alpha-fluorocortisol",
      "label": "rendered hypertensive by"
    },
    {
      "source": "rats",
      "target": "cardiac hypertrophy",
      "label": "rendered hypertensive without"
    },
    {
      "source": "thrombin",
      "target": "thrombosis",
      "label": "plays a crucial role in"
    },
    {
      "source": "thrombin",
      "target": "thrombolysis",
      "label": "plays a crucial role in"
    },
    {
      "source": "thrombin",
      "target": "human umbilical vein endothelial cells",
      "label": "produced in"
    },
    {
      "source": "thrombin",
      "target": "HUVECs",
      "label": "produced in"
    },
    {
      "source": "thrombin",
      "target": "SOCE",
      "label": "activates"
    },
    {
      "source": "death",
      "target": "high-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "death",
      "target": "heparin patients",
      "label": "occurred in"
    },
    {
      "source": "death",
      "target": "low-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "death",
      "target": "apoptosis pathway",
      "label": "follows"
    },
    {
      "source": "TIMI grade 3 flow",
      "target": "high-dose argatroban patients",
      "label": "was significantly more frequent in"
    },
    {
      "source": "TIMI grade 3 flow",
      "target": "heparin patients",
      "label": "was achieved in"
    },
    {
      "source": "TIMI grade 3 flow",
      "target": "low-dose argatroban patients",
      "label": "was achieved in"
    },
    {
      "source": "reperfusion",
      "target": "TPA",
      "label": "is with"
    },
    {
      "source": "reperfusion",
      "target": "tissue plasminogen activator",
      "label": "is induced by"
    },
    {
      "source": "reperfusion",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "revascularization",
      "target": "heparin patients",
      "label": "occurred in"
    },
    {
      "source": "revascularization",
      "target": "low-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "revascularization",
      "target": "high-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "Major bleeding",
      "target": "low-dose argatroban patients",
      "label": "was observed in"
    },
    {
      "source": "Major bleeding",
      "target": "high-dose argatroban patients",
      "label": "was observed in"
    },
    {
      "source": "Major bleeding",
      "target": "heparin patients",
      "label": "was observed in"
    },
    {
      "source": "heparin",
      "target": "TPA",
      "label": "is adjunct to"
    },
    {
      "source": "heparin",
      "target": "tissue plasminogen activator",
      "label": "is adjunct to"
    },
    {
      "source": "argatroban",
      "target": "reperfusion",
      "label": "affects"
    },
    {
      "source": "argatroban",
      "target": "small-molecule, direct thrombin inhibitor",
      "label": "is a"
    },
    {
      "source": "argatroban",
      "target": "thrombolysis",
      "label": "enhances"
    },
    {
      "source": "argatroban",
      "target": "clot-bound thrombin",
      "label": "inhibits"
    },
    {
      "source": "argatroban",
      "target": "heparin",
      "label": "has advantages over"
    },
    {
      "source": "argatroban",
      "target": "TPA",
      "label": "is adjunct to"
    },
    {
      "source": "argatroban",
      "target": "tissue plasminogen activator",
      "label": "is adjunct to"
    },
    {
      "source": "small-molecule, direct thrombin inhibitor",
      "target": "thrombin",
      "label": "inhibits"
    },
    {
      "source": "cardiogenic shock",
      "target": "heparin patients",
      "label": "occurred in"
    },
    {
      "source": "cardiogenic shock",
      "target": "low-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "cardiogenic shock",
      "target": "high-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "adverse clinical outcome",
      "target": "recurrent myocardial infarction",
      "label": "is a composite of"
    },
    {
      "source": "adverse clinical outcome",
      "target": "recurrent ischemia",
      "label": "is a composite of"
    },
    {
      "source": "adverse clinical outcome",
      "target": "congestive heart failure",
      "label": "is a composite of"
    },
    {
      "source": "adverse clinical outcome",
      "target": "low-dose argatroban patients",
      "label": "incidence was lower in"
    },
    {
      "source": "adverse clinical outcome",
      "target": "death",
      "label": "is a composite of"
    },
    {
      "source": "adverse clinical outcome",
      "target": "high-dose argatroban patients",
      "label": "incidence was lower in"
    },
    {
      "source": "adverse clinical outcome",
      "target": "revascularization",
      "label": "is a composite of"
    },
    {
      "source": "adverse clinical outcome",
      "target": "cardiogenic shock",
      "label": "is a composite of"
    },
    {
      "source": "recurrent myocardial infarction",
      "target": "heparin patients",
      "label": "occurred in"
    },
    {
      "source": "recurrent myocardial infarction",
      "target": "low-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "recurrent myocardial infarction",
      "target": "high-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "tissue plasminogen activator",
      "target": "systemic fibrinogenolysis",
      "label": "accompanies"
    },
    {
      "source": "recurrent ischemia",
      "target": "low-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "recurrent ischemia",
      "target": "high-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "recurrent ischemia",
      "target": "heparin patients",
      "label": "occurred in"
    },
    {
      "source": "thrombolysis",
      "target": "TPA",
      "label": "is enhanced with"
    },
    {
      "source": "A multicenter, randomized study",
      "target": "acute myocardial infarction",
      "label": "is conducted for"
    },
    {
      "source": "A multicenter, randomized study",
      "target": "heparin",
      "label": "compares"
    },
    {
      "source": "A multicenter, randomized study",
      "target": "argatroban",
      "label": "compares"
    },
    {
      "source": "high-dose argatroban",
      "target": "TPA",
      "label": "was administered in addition to"
    },
    {
      "source": "low-dose argatroban",
      "target": "TPA",
      "label": "was administered in addition to"
    },
    {
      "source": "congestive heart failure",
      "target": "heparin patients",
      "label": "occurred in"
    },
    {
      "source": "congestive heart failure",
      "target": "low-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "congestive heart failure",
      "target": "high-dose argatroban patients",
      "label": "occurred in"
    },
    {
      "source": "myocardial infarction with novastan and TPA (MINT) study",
      "target": "TPA",
      "label": "involves"
    },
    {
      "source": "myocardial infarction with novastan and TPA (MINT) study",
      "target": "A multicenter, randomized study",
      "label": "is a type of"
    },
    {
      "source": "myocardial infarction with novastan and TPA (MINT) study",
      "target": "novastan",
      "label": "involves"
    },
    {
      "source": "primary end point",
      "target": "rate of thrombolysis in myocardial infarction (TIMI) grade 3 flow",
      "label": "was"
    },
    {
      "source": "adverse events",
      "target": "study discontinuation",
      "label": "leads to"
    },
    {
      "source": "adverse events",
      "target": "transplant patients",
      "label": "occur in"
    },
    {
      "source": "Entacapone",
      "target": "motor function scores",
      "label": "improves"
    },
    {
      "source": "Entacapone",
      "target": "COMT",
      "label": "inhibits"
    },
    {
      "source": "Entacapone",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "Entacapone",
      "target": "clinical benefits",
      "label": "provides"
    },
    {
      "source": "Entacapone",
      "target": "standard levodopa/AADC inhibitor",
      "label": "administered with"
    },
    {
      "source": "Entacapone",
      "target": "dose of levodopa/AADC inhibitor",
      "label": "administered with"
    },
    {
      "source": "Entacapone",
      "target": "drug",
      "label": "is a"
    },
    {
      "source": "Entacapone",
      "target": "activities of daily living scores",
      "label": "improves"
    },
    {
      "source": "Entacapone",
      "target": "levodopa",
      "label": "is an adjunct to"
    },
    {
      "source": "Entacapone",
      "target": "peripheral catechol-O-methyltransferase",
      "label": "inhibits"
    },
    {
      "source": "Entacapone",
      "target": "selegiline",
      "label": "administered with"
    },
    {
      "source": "Entacapone",
      "target": "patients",
      "label": "administered to"
    },
    {
      "source": "Entacapone",
      "target": "scores",
      "label": "improves"
    },
    {
      "source": "Entacapone",
      "target": "controlled release levodopa/ AADC inhibitor",
      "label": "administered with"
    },
    {
      "source": "Entacapone",
      "target": "tolerability",
      "label": "has"
    },
    {
      "source": "Entacapone",
      "target": "inhibitor",
      "label": "is a"
    },
    {
      "source": "Entacapone",
      "target": "mentation scores",
      "label": "has no effect on"
    },
    {
      "source": "Diarrhoea",
      "target": "nondopaminergic events",
      "label": "is a"
    },
    {
      "source": "abdominal pain",
      "target": "nondopaminergic events",
      "label": "is a"
    },
    {
      "source": "Dopaminergic events",
      "target": "Entacapone",
      "label": "are common with"
    },
    {
      "source": "Dopaminergic events",
      "target": "nausea",
      "label": "includes"
    },
    {
      "source": "Dopaminergic events",
      "target": "drug",
      "label": "are related to"
    },
    {
      "source": "Dopaminergic events",
      "target": "dyskinesia",
      "label": "includes"
    },
    {
      "source": "urine discolouration",
      "target": "placebo",
      "label": "occurs more frequently than"
    },
    {
      "source": "urine discolouration",
      "target": "Entacapone",
      "label": "occurs more frequently with"
    },
    {
      "source": "urine discolouration",
      "target": "nondopaminergic events",
      "label": "is a"
    },
    {
      "source": "efficacy",
      "target": "patients",
      "label": "in"
    },
    {
      "source": "efficacy",
      "target": "strategies",
      "label": "not compared with"
    },
    {
      "source": "efficacy",
      "target": "selected symptoms",
      "label": "AGAINST"
    },
    {
      "source": "efficacy",
      "target": "antiangiogenic therapies",
      "label": "is of"
    },
    {
      "source": "efficacy",
      "target": "36 months",
      "label": "up to"
    },
    {
      "source": "efficacy",
      "target": "prescription",
      "label": "of"
    },
    {
      "source": "efficacy",
      "target": "PASI-75",
      "label": "measured by"
    },
    {
      "source": "efficacy",
      "target": "atopic dermatitis",
      "label": "in"
    },
    {
      "source": "efficacy",
      "target": "malignancies",
      "label": "in"
    },
    {
      "source": "efficacy",
      "target": "combination therapy",
      "label": "of"
    },
    {
      "source": "efficacy",
      "target": "cholinergic system",
      "label": "of"
    },
    {
      "source": "efficacy",
      "target": "splenomegaly",
      "label": "in reducing"
    },
    {
      "source": "efficacy",
      "target": "myelofibrosis-related symptoms",
      "label": "in reducing"
    },
    {
      "source": "efficacy",
      "target": "DOI",
      "label": "of"
    },
    {
      "source": "efficacy",
      "target": "potentiation",
      "label": "is"
    },
    {
      "source": "efficacy",
      "target": "intraocular pressure (IOP)",
      "label": "reduces"
    },
    {
      "source": "efficacy",
      "target": "experimental infections",
      "label": "is shown in"
    },
    {
      "source": "trials",
      "target": "treatment",
      "label": "are for"
    },
    {
      "source": "trials",
      "target": "patients",
      "label": "involve"
    },
    {
      "source": "treatment",
      "target": "daily 'on' time",
      "label": "increases"
    },
    {
      "source": "treatment",
      "target": "Entacapone",
      "label": "is with"
    },
    {
      "source": "treatment",
      "target": "'off' time",
      "label": "decreases"
    },
    {
      "source": "treatment",
      "target": "7 consecutive days",
      "label": "duration"
    },
    {
      "source": "treatment",
      "target": "randomized, double-blind, crossover design",
      "label": "design"
    },
    {
      "source": "treatment",
      "target": "arterial and venous thrombotic disorders",
      "label": "of"
    },
    {
      "source": "treatment",
      "target": "COX-2 inhibitor",
      "label": "involved"
    },
    {
      "source": "treatment",
      "target": "patients",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "syndromes",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "neurological disorders",
      "label": "of"
    },
    {
      "source": "treatment",
      "target": "skin diseases",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "APL",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "autoimmune diseases",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "acute promyelocytic leukemia",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "relapsed APL",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "systemic hypertension",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "complications",
      "label": "prevented"
    },
    {
      "source": "treatment",
      "target": "high doses of ascorbic acid",
      "label": "involved"
    },
    {
      "source": "treatment",
      "target": "moderate-to-severe psoriasis",
      "label": "of"
    },
    {
      "source": "treatment",
      "target": "myelodysplastic syndromes",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "lower urinary tract symptoms (LUTS)",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "benign prostatic hyperplasia (BPH)",
      "label": "of"
    },
    {
      "source": "treatment",
      "target": "obesity-diabetes",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "serum creatine kinase",
      "label": "prevented increase in"
    },
    {
      "source": "treatment",
      "target": "psychiatric disorders",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "thromboembolic disorders",
      "label": "of"
    },
    {
      "source": "treatment",
      "target": "asthma",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "proteins expression",
      "label": "impaired"
    },
    {
      "source": "treatment",
      "target": "150 days",
      "label": "lasted"
    },
    {
      "source": "treatment",
      "target": "obesity",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "disease ailments",
      "label": "is for"
    },
    {
      "source": "treatment",
      "target": "bioactive RS -GRA",
      "label": "involved"
    },
    {
      "source": "treatment",
      "target": "tissues",
      "label": "of"
    },
    {
      "source": "treatment",
      "target": "acetylcholinesterase inhibitor",
      "label": "involved"
    },
    {
      "source": "treatment",
      "target": "debrisoquin",
      "label": "with"
    },
    {
      "source": "treatment",
      "target": "disease",
      "label": "for"
    },
    {
      "source": "treatment",
      "target": "DNA-topoisomerase II inhibitors",
      "label": "with"
    },
    {
      "source": "treatment",
      "target": "alkylating agent",
      "label": "with"
    },
    {
      "source": "clinical benefits",
      "target": "AADC",
      "label": "are of"
    },
    {
      "source": "clinical benefits",
      "target": "aromatic L-amino acid decarboxylase inhibitor",
      "label": "are of"
    },
    {
      "source": "clinical benefits",
      "target": "levodopa",
      "label": "are of"
    },
    {
      "source": "nausea",
      "target": "clinical toxicities",
      "label": "is a type of"
    },
    {
      "source": "nausea",
      "target": "apomorphine treatment",
      "label": "occur during"
    },
    {
      "source": "end-of-dose deterioration",
      "target": "'wearing off' phenomenon",
      "label": "also known as"
    },
    {
      "source": "end-of-dose deterioration",
      "target": "response to levodopa",
      "label": "is in"
    },
    {
      "source": "levodopa",
      "target": "Mortality",
      "label": "increases"
    },
    {
      "source": "studies",
      "target": "Entacapone",
      "label": "supports the use of"
    },
    {
      "source": "studies",
      "target": "treatment",
      "label": "are for"
    },
    {
      "source": "studies",
      "target": "adenine aminohydrolase enzyme",
      "label": "revealed presence of"
    },
    {
      "source": "studies",
      "target": "populations",
      "label": "conducted in"
    },
    {
      "source": "studies",
      "target": "results",
      "label": "validate"
    },
    {
      "source": "studies",
      "target": "patients",
      "label": "suggest"
    },
    {
      "source": "studies",
      "target": "cruciferous vegetables",
      "label": "investigate"
    },
    {
      "source": "studies",
      "target": "kidney cancer risk",
      "label": "investigate"
    },
    {
      "source": "studies",
      "target": "impulse control disorders",
      "label": "needed for"
    },
    {
      "source": "studies",
      "target": "(pGlu-Gln)-CCK-8",
      "label": "emphasize potential of"
    },
    {
      "source": "studies",
      "target": "non-lethal dose of PQ",
      "label": "will use"
    },
    {
      "source": "studies",
      "target": "direct CNS toxicity",
      "label": "will demonstrate"
    },
    {
      "source": "studies",
      "target": "acute neurotoxic changes",
      "label": "focus on"
    },
    {
      "source": "studies",
      "target": "effect",
      "label": "find no"
    },
    {
      "source": "studies",
      "target": "fenfluramine",
      "label": "of"
    },
    {
      "source": "studies",
      "target": "mood stabilizers",
      "label": "of"
    },
    {
      "source": "studies",
      "target": "secretin",
      "label": "of"
    },
    {
      "source": "studies",
      "target": "opiates",
      "label": "of"
    },
    {
      "source": "studies",
      "target": "CYP3A4",
      "label": "show"
    },
    {
      "source": "studies",
      "target": "CYP3A5",
      "label": "show"
    },
    {
      "source": "studies",
      "target": "A549 lung cells",
      "label": "conducted using"
    },
    {
      "source": "studies",
      "target": "DPX2 liver cells",
      "label": "conducted using"
    },
    {
      "source": "studies",
      "target": "molecular mechanisms",
      "label": "investigate"
    },
    {
      "source": "studies",
      "target": "experimental testosterone deprivation",
      "label": "focused on"
    },
    {
      "source": "studies",
      "target": "biological significance",
      "label": "examined"
    },
    {
      "source": "Unified Parkinson's Disease Rating Scale",
      "target": "UPDRS",
      "label": "also known as"
    },
    {
      "source": "UPDRS",
      "target": "scores",
      "label": "has"
    },
    {
      "source": "strategies",
      "target": "Parkinson's disease",
      "label": "are for the treatment of"
    },
    {
      "source": "strategies",
      "target": "routine clinical safety monitoring",
      "label": "compared to"
    },
    {
      "source": "constipation",
      "target": "nondopaminergic events",
      "label": "is a"
    },
    {
      "source": "selegiline",
      "target": "Parkinson's disease",
      "label": "used in treatment of"
    },
    {
      "source": "selegiline",
      "target": "hallucinations",
      "label": "potentiates"
    },
    {
      "source": "selegiline",
      "target": "SSRIs",
      "label": "concomitant use well tolerated with"
    },
    {
      "source": "selegiline",
      "target": "MAO-B",
      "label": "is an inhibitor of"
    },
    {
      "source": "selegiline",
      "target": "insomnia",
      "label": "causes"
    },
    {
      "source": "selegiline",
      "target": "citalopram",
      "label": "concomitant use well tolerated with"
    },
    {
      "source": "selegiline",
      "target": "tyramine-induced hypertension",
      "label": "does not potentiate"
    },
    {
      "source": "selegiline",
      "target": "true serotonin syndrome",
      "label": "causes"
    },
    {
      "source": "selegiline",
      "target": "dizziness",
      "label": "causes"
    },
    {
      "source": "selegiline",
      "target": "nausea",
      "label": "causes"
    },
    {
      "source": "selegiline",
      "target": "MAO-B inhibitor",
      "label": "is a"
    },
    {
      "source": "selegiline",
      "target": "monoamine oxidase type B",
      "label": "is an inhibitor of"
    },
    {
      "source": "selegiline",
      "target": "adverse effects",
      "label": "potentiates"
    },
    {
      "source": "selegiline",
      "target": "peak dose dyskinesias",
      "label": "potentiates"
    },
    {
      "source": "selegiline",
      "target": "'cheese effect'",
      "label": "does not potentiate"
    },
    {
      "source": "selegiline",
      "target": "constipation",
      "label": "causes"
    },
    {
      "source": "selegiline",
      "target": "levodopa",
      "label": "combined with"
    },
    {
      "source": "selegiline",
      "target": "psychiatric complications",
      "label": "potentiates"
    },
    {
      "source": "selegiline",
      "target": "fluctuations in disability",
      "label": "potentiates"
    },
    {
      "source": "selegiline",
      "target": "fatigue",
      "label": "causes"
    },
    {
      "source": "selegiline",
      "target": "selective serotonin reuptake inhibitors",
      "label": "concomitant use well tolerated with"
    },
    {
      "source": "selegiline",
      "target": "Mortality",
      "label": "increases"
    },
    {
      "source": "selegiline",
      "target": "tricyclic antidepressant",
      "label": "caution advised when combining with"
    },
    {
      "source": "selegiline",
      "target": "monotherapy",
      "label": "well tolerated as"
    },
    {
      "source": "selegiline",
      "target": "orthostatic hypotension",
      "label": "potentiates"
    },
    {
      "source": "tolerability",
      "target": "strategies",
      "label": "not compared with"
    },
    {
      "source": "tolerability",
      "target": "omeprazole",
      "label": "is similar to"
    },
    {
      "source": "tolerability",
      "target": "ranitidine",
      "label": "is similar to"
    },
    {
      "source": "tolerability",
      "target": "placebo",
      "label": "is similar to"
    },
    {
      "source": "tolerability",
      "target": "exenatide",
      "label": "studied for"
    },
    {
      "source": "inhibitor",
      "target": "interfering acid alpha-glucosidase",
      "label": "inhibits"
    },
    {
      "source": "inhibitor",
      "target": "squalene epoxidase",
      "label": "inhibits"
    },
    {
      "source": "inhibitor",
      "target": "acetylcholinesterase",
      "label": "inhibits"
    },
    {
      "source": "rabbit aortic strips",
      "target": "vascular preparations",
      "label": "is a type of"
    },
    {
      "source": "functional inhibitory characteristics",
      "target": "other ARBs",
      "label": "differ from"
    },
    {
      "source": "functional inhibitory characteristics",
      "target": "candesartan",
      "label": "of"
    },
    {
      "source": "functional inhibitory characteristics",
      "target": "angiotensin II type 1 receptor blockers",
      "label": "of"
    },
    {
      "source": "angiotensin II type 1 receptor blockers",
      "target": "ARB",
      "label": "is a type of"
    },
    {
      "source": "insurmountable and long-lasting antagonist",
      "target": "vascular contractile responses",
      "label": "of"
    },
    {
      "source": "maximal contractile response",
      "target": "angiotensin II",
      "label": "of"
    },
    {
      "source": "maximal contractile response",
      "target": "concentration-response curve",
      "label": "part of"
    },
    {
      "source": "maximal contractile response",
      "target": "Ang II",
      "label": "of"
    },
    {
      "source": "blood pressure responses",
      "target": "Ang II-induced blood pressure responses",
      "label": "part of"
    },
    {
      "source": "lipophilicity",
      "target": "compounds",
      "label": "of"
    },
    {
      "source": "concentrations",
      "target": "ARBs",
      "label": "of"
    },
    {
      "source": "concentrations",
      "target": "clinical use",
      "label": "relevant to"
    },
    {
      "source": "concentrations",
      "target": "rectal dialysates",
      "label": "found in"
    },
    {
      "source": "concentrations",
      "target": "prostaglandin E2",
      "label": "are of"
    },
    {
      "source": "concentrations",
      "target": "LTB4",
      "label": "are of"
    },
    {
      "source": "concentrations",
      "target": "peptide",
      "label": "are of"
    },
    {
      "source": "concentrations",
      "target": "5 mg/kg",
      "label": "include"
    },
    {
      "source": "concentrations",
      "target": "0 mg/kg",
      "label": "include"
    },
    {
      "source": "concentrations",
      "target": "50 mg/kg",
      "label": "include"
    },
    {
      "source": "concentrations",
      "target": "500 mg/kg",
      "label": "include"
    },
    {
      "source": "concentrations",
      "target": "0.5 mg/kg",
      "label": "include"
    },
    {
      "source": "concentrations",
      "target": "body fluids",
      "label": "are in"
    },
    {
      "source": "concentrations",
      "target": "clinical settings",
      "label": "relevant for"
    },
    {
      "source": "concentrations",
      "target": "DOPAC",
      "label": "of"
    },
    {
      "source": "concentrations",
      "target": "DHPG",
      "label": "of"
    },
    {
      "source": "repeated washing",
      "target": "vessels",
      "label": "of"
    },
    {
      "source": "rat portal vein preparations",
      "target": "vascular preparations",
      "label": "is a type of"
    },
    {
      "source": "speed of recovery",
      "target": "incubation temperature",
      "label": "independent of"
    },
    {
      "source": "speed of recovery",
      "target": "Ang II response",
      "label": "of"
    },
    {
      "source": "clinical use",
      "target": "treatment",
      "label": "is for"
    },
    {
      "source": "clinical use",
      "target": "combination settings",
      "label": "is in"
    },
    {
      "source": "clinical use",
      "target": "elisidepsin",
      "label": "is of"
    },
    {
      "source": "EXP",
      "target": "active metabolite EXP 3174",
      "label": "is an abbreviation for"
    },
    {
      "source": "EXP",
      "target": "rightward parallel shift",
      "label": "caused"
    },
    {
      "source": "EXP",
      "target": "major effects",
      "label": "had no"
    },
    {
      "source": "active metabolite EXP 3174",
      "target": "rabbit aortic strips",
      "label": "studied in"
    },
    {
      "source": "active metabolite EXP 3174",
      "target": "rat portal vein preparations",
      "label": "studied in"
    },
    {
      "source": "active metabolite EXP 3174",
      "target": "angiotensin II type 1 receptor blockers",
      "label": "is a type of"
    },
    {
      "source": "inhibitory effect",
      "target": "nondetectable plasma concentrations",
      "label": "persisted despite"
    },
    {
      "source": "inhibitory effect",
      "target": "ARBs",
      "label": "of"
    },
    {
      "source": "inhibitory effect",
      "target": "EXP",
      "label": "of"
    },
    {
      "source": "inhibitory effect",
      "target": "repeated washing",
      "label": "persisted despite"
    },
    {
      "source": "inhibitory effect",
      "target": "candesartan",
      "label": "of"
    },
    {
      "source": "inhibitory effect",
      "target": "washing",
      "label": "disappeared after"
    },
    {
      "source": "inhibitory effect",
      "target": "irbesartan",
      "label": "of"
    },
    {
      "source": "inhibitory effect",
      "target": "losartan",
      "label": "of"
    },
    {
      "source": "inhibitory effect",
      "target": "Ang II-induced blood pressure responses",
      "label": "on"
    },
    {
      "source": "inhibitory effect",
      "target": "alpha-helix content",
      "label": "related to"
    },
    {
      "source": "inhibitory effect",
      "target": "gentamicin binding",
      "label": "on"
    },
    {
      "source": "inhibitory effect",
      "target": "D1-like receptors",
      "label": "is of"
    },
    {
      "source": "inhibitory effect",
      "target": "insulin-induced VSMC proliferation",
      "label": "is on"
    },
    {
      "source": "inhibitory effect",
      "target": "insulin-mediated VSMC proliferation",
      "label": "is on"
    },
    {
      "source": "inhibitory effect",
      "target": "important role",
      "label": "plays"
    },
    {
      "source": "inhibitory effect",
      "target": "insulin receptor expression",
      "label": "is on"
    },
    {
      "source": "inhibitory effect",
      "target": "organic anion transporters",
      "label": "is mediated by"
    },
    {
      "source": "inhibitory effect",
      "target": "JBP485",
      "label": "targets"
    },
    {
      "source": "inhibitory effect",
      "target": "expression",
      "label": "targets"
    },
    {
      "source": "inhibitory effect",
      "target": "1,25(OH)(2)D(3)",
      "label": "is caused by"
    },
    {
      "source": "inhibitory effect",
      "target": "GR(dim/dim) mice",
      "label": "compared with"
    },
    {
      "source": "inhibitory effect",
      "target": "skin collagen synthesis rates",
      "label": "on"
    },
    {
      "source": "inhibitory effect",
      "target": "wild-type mice",
      "label": "greater in"
    },
    {
      "source": "inhibitory effect",
      "target": "bone",
      "label": "on"
    },
    {
      "source": "nondetectable plasma concentrations",
      "target": "candesartan",
      "label": "of"
    },
    {
      "source": "duration",
      "target": "lipophilicity",
      "label": "not related to"
    },
    {
      "source": "duration",
      "target": "inhibitory effect",
      "label": "of"
    },
    {
      "source": "plasma-protein binding",
      "target": "ARBs",
      "label": "determined for"
    },
    {
      "source": "major effects",
      "target": "maximal response",
      "label": "on"
    },
    {
      "source": "magnitude of inhibition",
      "target": "other ARBs",
      "label": "of"
    },
    {
      "source": "magnitude of inhibition",
      "target": "incubation temperature",
      "label": "independent of"
    },
    {
      "source": "maximal response",
      "target": "Ang II",
      "label": "to"
    },
    {
      "source": "Cooling",
      "target": "persistent inhibition",
      "label": "prevented"
    },
    {
      "source": "Cooling",
      "target": "rat portal vein preparations",
      "label": "of"
    },
    {
      "source": "persistent inhibition",
      "target": "Ang II response",
      "label": "of"
    },
    {
      "source": "nonprotein bound concentrations",
      "target": "clinical use",
      "label": "in"
    },
    {
      "source": "vascular contractile responses",
      "target": "Ang II",
      "label": "to"
    },
    {
      "source": "administration",
      "target": "candesartan",
      "label": "of"
    },
    {
      "source": "administration",
      "target": "plasma prostaglandin E2 levels",
      "label": "did not affect"
    },
    {
      "source": "administration",
      "target": "serum thromboxane B2 levels",
      "label": "did not affect"
    },
    {
      "source": "administration",
      "target": "placebo",
      "label": "of"
    },
    {
      "source": "administration",
      "target": "15 mg of meloxicam",
      "label": "of"
    },
    {
      "source": "administration",
      "target": "dose-dependent reductions",
      "label": "caused"
    },
    {
      "source": "administration",
      "target": "7.5 mg of meloxicam",
      "label": "of"
    },
    {
      "source": "administration",
      "target": "drinking water",
      "label": "via"
    },
    {
      "source": "administration",
      "target": "0.05% benzythiouracile",
      "label": "involved"
    },
    {
      "source": "administration",
      "target": "L-thyroxine sodium salt",
      "label": "involved"
    },
    {
      "source": "administration",
      "target": "N-carbamylglutamate",
      "label": "is of"
    },
    {
      "source": "administration",
      "target": "Oral carglumic acid",
      "label": "is of"
    },
    {
      "source": "administration",
      "target": "intraperitoneal injection",
      "label": "by"
    },
    {
      "source": "administration",
      "target": "doses",
      "label": "at"
    },
    {
      "source": "administration",
      "target": "weeks",
      "label": "for"
    },
    {
      "source": "administration",
      "target": "male C57BL/6J mice",
      "label": "to"
    },
    {
      "source": "administration",
      "target": "debrisoquin",
      "label": "of"
    },
    {
      "source": "administration",
      "target": "clorgyline",
      "label": "of"
    },
    {
      "source": "administration",
      "target": "nialamide",
      "label": "of"
    },
    {
      "source": "AT1-receptor blockers",
      "target": "isolated vessels",
      "label": "located in"
    },
    {
      "source": "conscious rats",
      "target": "rats",
      "label": "is a type of"
    },
    {
      "source": "inhibition",
      "target": "platelet COX-1",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "COX-1",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "incubation",
      "label": "after"
    },
    {
      "source": "inhibition",
      "target": "monocyte COX-2",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "in vitro",
      "label": "occurred"
    },
    {
      "source": "inhibition",
      "target": "blood pressure",
      "label": "reduced"
    },
    {
      "source": "inhibition",
      "target": "metabolic rhodopsin regeneration",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "neutrophil chemotaxis",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "IC50 values",
      "label": "produced"
    },
    {
      "source": "inhibition",
      "target": "human dopamine (DA) transporter",
      "label": "at"
    },
    {
      "source": "inhibition",
      "target": "mammalian DHFR activity",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "transaminase enzymes",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "doxycycline removal",
      "label": "occurred after"
    },
    {
      "source": "inhibition",
      "target": "24 h",
      "label": "occurred within"
    },
    {
      "source": "inhibition",
      "target": "Wnt target gene expression",
      "label": "is of"
    },
    {
      "source": "inhibition",
      "target": "sarcoplasmic Ca(2+)ATPase",
      "label": "affects"
    },
    {
      "source": "inhibition",
      "target": "blockade",
      "label": "resulted in"
    },
    {
      "source": "inhibition",
      "target": "dynasore",
      "label": "reversal was blocked by"
    },
    {
      "source": "inhibition",
      "target": "cPKC antagonist",
      "label": "reversal was blocked by"
    },
    {
      "source": "inhibition",
      "target": "\u03b2-ARK1 inhibitor",
      "label": "reversal was blocked by"
    },
    {
      "source": "inhibition",
      "target": "COX-2",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "ulcers",
      "label": "causes"
    },
    {
      "source": "inhibition",
      "target": "Cyclooxygenase (COX)-1",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "ER\u03b2",
      "label": "targets"
    },
    {
      "source": "inhibition",
      "target": "therapeutic interventions",
      "label": "provides basis for"
    },
    {
      "source": "inhibition",
      "target": "ER\u03b1",
      "label": "targets"
    },
    {
      "source": "inhibition",
      "target": "ISR",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "tumor cell death",
      "label": "induces"
    },
    {
      "source": "inhibition",
      "target": "hydrolysis",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "carboxylesterase",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "CES2 polymorphic variants",
      "label": "varied among"
    },
    {
      "source": "inhibition",
      "target": "source",
      "label": "is a major"
    },
    {
      "source": "inhibition",
      "target": "nM range",
      "label": "occurred in"
    },
    {
      "source": "inhibition",
      "target": "enzymes",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "ketoconazole",
      "label": "is by"
    },
    {
      "source": "inhibition",
      "target": "MAO-A",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "peripheral neuronal MAO",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "monoamine oxidase type A",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "MAO-B",
      "label": "of"
    },
    {
      "source": "inhibition",
      "target": "adenylate cyclase",
      "label": "is of"
    },
    {
      "source": "inhibition",
      "target": "open field test",
      "label": "observed_in"
    },
    {
      "source": "inhibition",
      "target": "exploratory activity",
      "label": "affects"
    },
    {
      "source": "inhibition",
      "target": "rats",
      "label": "observed_in"
    },
    {
      "source": "inhibition",
      "target": "emergence procedure",
      "label": "observed_in"
    },
    {
      "source": "inhibition",
      "target": "parameters",
      "label": "manifest_in"
    },
    {
      "source": "plasma prostaglandin E2 levels",
      "target": "mean",
      "label": "has"
    },
    {
      "source": "plasma prostaglandin E2 levels",
      "target": "S.D.",
      "label": "has"
    },
    {
      "source": "11 healthy volunteers",
      "target": "15 mg/day meloxicam",
      "label": "received"
    },
    {
      "source": "11 healthy volunteers",
      "target": "7.5 mg/day meloxicam",
      "label": "received"
    },
    {
      "source": "11 healthy volunteers",
      "target": "placebo",
      "label": "received"
    },
    {
      "source": "COX-1",
      "target": "constitutive housekeeping enzyme",
      "label": "is a"
    },
    {
      "source": "COX-1",
      "target": "protein expression",
      "label": "has"
    },
    {
      "source": "COX-1",
      "target": "humans",
      "label": "role determined in"
    },
    {
      "source": "COX-1",
      "target": "dogs",
      "label": "role applies to"
    },
    {
      "source": "COX-1",
      "target": "Physiologic functions",
      "label": "involved in"
    },
    {
      "source": "COX-1",
      "target": "enzymes",
      "label": "is an"
    },
    {
      "source": "COX-1",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "COX-1",
      "target": "COX family",
      "label": "is part of"
    },
    {
      "source": "COX-1",
      "target": "PGE2 production",
      "label": "involved in"
    },
    {
      "source": "COX-1",
      "target": "IC(50)",
      "label": "has"
    },
    {
      "source": "incubation",
      "target": "37 degrees C",
      "label": "temperature"
    },
    {
      "source": "incubation",
      "target": "24 h",
      "label": "duration"
    },
    {
      "source": "incubation",
      "target": "whole blood samples",
      "label": "with"
    },
    {
      "source": "incubation",
      "target": "meloxicam",
      "label": "of"
    },
    {
      "source": "prostaglandin E2",
      "target": "monocyte COX-2 activity",
      "label": "is an index of"
    },
    {
      "source": "prostaglandin E2",
      "target": "plasma",
      "label": "measured in"
    },
    {
      "source": "prostaglandin E2",
      "target": "anti-inflammatory molecule",
      "label": "is a type of"
    },
    {
      "source": "monocyte COX-2 activity",
      "target": "51%",
      "label": "reduced by"
    },
    {
      "source": "effects",
      "target": "two isozymes",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "meloxicam",
      "label": "of"
    },
    {
      "source": "effects",
      "target": "daily dose",
      "label": "function of"
    },
    {
      "source": "effects",
      "target": "interindividual variation",
      "label": "function of"
    },
    {
      "source": "effects",
      "target": "oral dosing",
      "label": "occurred after"
    },
    {
      "source": "effects",
      "target": "2 to 3 hours",
      "label": "occurred after"
    },
    {
      "source": "effects",
      "target": "last dose",
      "label": "occurred after"
    },
    {
      "source": "effects",
      "target": "drug",
      "label": "of"
    },
    {
      "source": "effects",
      "target": "clinical dose range",
      "label": "across"
    },
    {
      "source": "effects",
      "target": "steady-state plasma concentrations",
      "label": "are on"
    },
    {
      "source": "effects",
      "target": "heart rate",
      "label": "have minimal effect on"
    },
    {
      "source": "effects",
      "target": "loss of muscle",
      "label": "do not cause"
    },
    {
      "source": "effects",
      "target": "possibility",
      "label": "raise"
    },
    {
      "source": "effects",
      "target": "proinflammatory role",
      "label": "suggest"
    },
    {
      "source": "effects",
      "target": "drugs",
      "label": "are of"
    },
    {
      "source": "effects",
      "target": "common genetic polymorphism",
      "label": "are of"
    },
    {
      "source": "effects",
      "target": "components",
      "label": "are on"
    },
    {
      "source": "effects",
      "target": "pretreatment",
      "label": "inhibited by"
    },
    {
      "source": "effects",
      "target": "strong XG-MTM interactions",
      "label": "due to"
    },
    {
      "source": "effects",
      "target": "barrier properties",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "highly oriented and well-dispersed MTM",
      "label": "due to"
    },
    {
      "source": "effects",
      "target": "AML",
      "label": "are of"
    },
    {
      "source": "effects",
      "target": "healthy volunteers",
      "label": "observed in"
    },
    {
      "source": "effects",
      "target": "homeostasis",
      "label": "impair"
    },
    {
      "source": "effects",
      "target": "membrane fluidity",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "cell membranes",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "quercetin",
      "label": "exerted by"
    },
    {
      "source": "effects",
      "target": "epigallocatechin gallate",
      "label": "exerted by"
    },
    {
      "source": "effects",
      "target": "transmembrane potential",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "experimental conditions",
      "label": "in"
    },
    {
      "source": "effects",
      "target": "cells",
      "label": "for"
    },
    {
      "source": "effects",
      "target": "curcumin",
      "label": "exerted by"
    },
    {
      "source": "effects",
      "target": "serum pro-oxidant-antioxidant balance",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "curcuminoid supplement",
      "label": "are of"
    },
    {
      "source": "effects",
      "target": "antibody titres",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "data",
      "label": "indicated with"
    },
    {
      "source": "effects",
      "target": "repetitive behaviors",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "\u03c9-agatoxin",
      "label": "are of"
    },
    {
      "source": "effects",
      "target": "toxin",
      "label": "are of"
    },
    {
      "source": "effects",
      "target": "murine frontal cortex networks",
      "label": "are on"
    },
    {
      "source": "effects",
      "target": "angiogenesis",
      "label": "on"
    },
    {
      "source": "effects",
      "target": "tPNS",
      "label": "of"
    },
    {
      "source": "effects",
      "target": "angiogenesis ability",
      "label": "on"
    },
    {
      "source": "IC50 value",
      "target": "COX-2",
      "label": "is 10-fold lower for"
    },
    {
      "source": "IC50 value",
      "target": "in vitro",
      "label": "measured"
    },
    {
      "source": "IC50 value",
      "target": "inhibition",
      "label": "for"
    },
    {
      "source": "IC50 value",
      "target": "meloxicam",
      "label": "of"
    },
    {
      "source": "IC50 value",
      "target": "COX-1",
      "label": "is 10-fold higher for"
    },
    {
      "source": "IC50 value",
      "target": "50 nM",
      "label": "is"
    },
    {
      "source": "IC50 value",
      "target": "etoposide",
      "label": "is lower than"
    },
    {
      "source": "IC50 value",
      "target": "MOLT-3 cell lines",
      "label": "observed for"
    },
    {
      "source": "COX-2",
      "target": "wound healing process",
      "label": "has role in"
    },
    {
      "source": "COX-2",
      "target": "dogs",
      "label": "role applies to"
    },
    {
      "source": "COX-2",
      "target": "proinflammatory inducible enzyme",
      "label": "is a"
    },
    {
      "source": "COX-2",
      "target": "humans",
      "label": "role determined in"
    },
    {
      "source": "COX-2",
      "target": "peroxidase activities",
      "label": "possesses"
    },
    {
      "source": "COX-2",
      "target": "cyclooxygenase activities",
      "label": "possesses"
    },
    {
      "source": "COX-2",
      "target": "bifunctional enzyme",
      "label": "is a"
    },
    {
      "source": "COX-2",
      "target": "Sites of inflammation",
      "label": "up-regulated at"
    },
    {
      "source": "COX-2",
      "target": "COX family",
      "label": "is part of"
    },
    {
      "source": "COX-2",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "COX-2",
      "target": "enzymes",
      "label": "is an"
    },
    {
      "source": "COX-2",
      "target": "antiplatelet effects of aspirin",
      "label": "decrease"
    },
    {
      "source": "COX-2",
      "target": "venules",
      "label": "localized in"
    },
    {
      "source": "COX-2",
      "target": "duodenal mucosa",
      "label": "plays role in protection of"
    },
    {
      "source": "COX-2",
      "target": "capillaries",
      "label": "localized in"
    },
    {
      "source": "COX-2",
      "target": "protection",
      "label": "plays role in"
    },
    {
      "source": "COX-2",
      "target": "basal granulated cells",
      "label": "localized in"
    },
    {
      "source": "COX-2",
      "target": "IC(50)",
      "label": "has"
    },
    {
      "source": "platelet COX-1 activity",
      "target": "25%",
      "label": "reduced by"
    },
    {
      "source": "platelet COX-1 activity",
      "target": "35%",
      "label": "reduced by"
    },
    {
      "source": "meloxicam",
      "target": "dose-dependent inhibition",
      "label": "causes"
    },
    {
      "source": "meloxicam",
      "target": "selective COX-2 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "dose-dependent reductions",
      "target": "monocyte COX-2 activity",
      "label": "in"
    },
    {
      "source": "dose-dependent reductions",
      "target": "platelet COX-1 activity",
      "label": "in"
    },
    {
      "source": "interindividual variation",
      "target": "steady-state plasma levels",
      "label": "in"
    },
    {
      "source": "heparinized whole blood samples",
      "target": "lipopolysaccharide",
      "label": "incubated with"
    },
    {
      "source": "lipopolysaccharide",
      "target": "10 microgram/ml",
      "label": "concentration"
    },
    {
      "source": "lipopolysaccharide",
      "target": "LPS",
      "label": "abbreviated as"
    },
    {
      "source": "production",
      "target": "platelet COX-1 activity",
      "label": "is an index of"
    },
    {
      "source": "production",
      "target": "thromboxane B2",
      "label": "of"
    },
    {
      "source": "production",
      "target": "peritubular cells",
      "label": "occurs in"
    },
    {
      "source": "production",
      "target": "Sertoli cells",
      "label": "occurs in"
    },
    {
      "source": "production",
      "target": "cytokines",
      "label": "of"
    },
    {
      "source": "production",
      "target": "human peripheral blood mononuclear cells",
      "label": "by"
    },
    {
      "source": "production",
      "target": "tumor necrosis factor alpha",
      "label": "of"
    },
    {
      "source": "production",
      "target": "lipopolysaccharide",
      "label": "induced by"
    },
    {
      "source": "therapeutic blood levels of meloxicam",
      "target": "selective inhibition",
      "label": "associated with"
    },
    {
      "source": "selective inhibition",
      "target": "ex vivo",
      "label": "occurs in"
    },
    {
      "source": "selective inhibition",
      "target": "in vitro",
      "label": "occurs in"
    },
    {
      "source": "selective inhibition",
      "target": "monocyte cyclooxygenase (COX)-2",
      "label": "of"
    },
    {
      "source": "plasma",
      "target": "mice",
      "label": "is part of"
    },
    {
      "source": "plasma",
      "target": "Factor XIIf",
      "label": "inactivates"
    },
    {
      "source": "whole blood",
      "target": "60 min",
      "label": "clotted for"
    },
    {
      "source": "dose-dependent inhibition",
      "target": "monocyte cyclooxygenase-2",
      "label": "of"
    },
    {
      "source": "dose-dependent inhibition",
      "target": "platelet cyclooxygenase-1",
      "label": "of"
    },
    {
      "source": "dose-dependent inhibition",
      "target": "aberrant crypt foci (ACF)",
      "label": "is of"
    },
    {
      "source": "Concentration-response curves",
      "target": "inhibition",
      "label": "for"
    },
    {
      "source": "oral dosing",
      "target": "nabumetone",
      "label": "involves"
    },
    {
      "source": "n",
      "target": "11 healthy volunteers",
      "label": "refers to"
    },
    {
      "source": "thromboxane B2",
      "target": "whole blood",
      "label": "in"
    },
    {
      "source": "biochemical selectivity",
      "target": "effects",
      "label": "was inadequate to separate"
    },
    {
      "source": "seventh dose",
      "target": "regimen",
      "label": "is part of"
    },
    {
      "source": "stereospecificity",
      "target": "nociceptin receptor",
      "label": "retained at"
    },
    {
      "source": "stereospecificity",
      "target": "opioid receptors",
      "label": "required at"
    },
    {
      "source": "EC(50)",
      "target": "50 nM",
      "label": "is"
    },
    {
      "source": "opioids",
      "target": "activity",
      "label": "possess"
    },
    {
      "source": "opioids",
      "target": "full agonism",
      "label": "display"
    },
    {
      "source": "opioids",
      "target": "opioid receptor agonists",
      "label": "are"
    },
    {
      "source": "opioids",
      "target": "partial agonists",
      "label": "are"
    },
    {
      "source": "opioids",
      "target": "antagonists",
      "label": "are"
    },
    {
      "source": "opioids",
      "target": "leads",
      "label": "provide"
    },
    {
      "source": "activity",
      "target": "nociceptin receptor",
      "label": "at"
    },
    {
      "source": "activity",
      "target": "nedocromil",
      "label": "is of"
    },
    {
      "source": "activity",
      "target": "inhibition",
      "label": "is not mediated by"
    },
    {
      "source": "activity",
      "target": "forms of inflammation",
      "label": "is in"
    },
    {
      "source": "activity",
      "target": "promastigotes",
      "label": "thought to be restricted to"
    },
    {
      "source": "activity",
      "target": "nontransporter targets",
      "label": "at"
    },
    {
      "source": "activity",
      "target": "cationic amino acid transporters",
      "label": "of"
    },
    {
      "source": "activity",
      "target": "solid tumor types",
      "label": "in"
    },
    {
      "source": "activity",
      "target": "results",
      "label": "is of"
    },
    {
      "source": "activity",
      "target": "FSAP",
      "label": "weaker compared with"
    },
    {
      "source": "activity",
      "target": "CYP3A",
      "label": "is of"
    },
    {
      "source": "activity",
      "target": "spinal cord networks",
      "label": "is from"
    },
    {
      "source": "activity",
      "target": "murine frontal cortex networks",
      "label": "is in"
    },
    {
      "source": "activity",
      "target": "hydroxylation",
      "label": "DETERMINED_AS"
    },
    {
      "source": "activity",
      "target": "liver microsomes",
      "label": "DETERMINED_IN"
    },
    {
      "source": "naloxone benzoylhydrazone",
      "target": "pure antagonist",
      "label": "was a"
    },
    {
      "source": "naloxone benzoylhydrazone",
      "target": "kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist",
      "label": "is a"
    },
    {
      "source": "pure antagonist",
      "target": "rat brain",
      "label": "at"
    },
    {
      "source": "pure antagonist",
      "target": "human ORL1 receptors",
      "label": "at"
    },
    {
      "source": "lofentanil",
      "target": "mu-opioid receptor-selective agonist",
      "label": "is a"
    },
    {
      "source": "lofentanil",
      "target": "[3H]nociceptin",
      "label": "displaced"
    },
    {
      "source": "full agonism",
      "target": "nociceptin receptor",
      "label": "at"
    },
    {
      "source": "full agonism",
      "target": "enhancement",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "nociceptin-stimulated [35S]GTPgammaS binding",
      "label": "determined using"
    },
    {
      "source": "affinity",
      "target": "[3H]nociceptin",
      "label": "determined using"
    },
    {
      "source": "affinity",
      "target": "nociceptin receptor",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "classical opioid receptors",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "hERG channel",
      "label": "is towards"
    },
    {
      "source": "affinity",
      "target": "antithrombin (AT)",
      "label": "to"
    },
    {
      "source": "affinity",
      "target": "isoforms",
      "label": "IS_FOR"
    },
    {
      "source": "affinity",
      "target": "target",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "proteins",
      "label": "of"
    },
    {
      "source": "affinity",
      "target": "ITC",
      "label": "determined by"
    },
    {
      "source": "affinity",
      "target": "SPBs",
      "label": "onto"
    },
    {
      "source": "affinity",
      "target": "picomolar range",
      "label": "is in"
    },
    {
      "source": "affinity",
      "target": "MOR",
      "label": "toward"
    },
    {
      "source": "affinity",
      "target": "\u03bc-opioid receptor",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "imipramine",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "UGT2B10",
      "label": "of"
    },
    {
      "source": "affinity",
      "target": "diphenhydramine",
      "label": "for"
    },
    {
      "source": "affinity",
      "target": "amitriptyline",
      "label": "for"
    },
    {
      "source": "opioid recognition site",
      "target": "two receptor classes",
      "label": "on"
    },
    {
      "source": "Opioid activity profiles",
      "target": "similarities",
      "label": "indicate"
    },
    {
      "source": "similarities",
      "target": "nociceptin/orphanin FQ",
      "label": "between"
    },
    {
      "source": "similarities",
      "target": "opioid receptors",
      "label": "between"
    },
    {
      "source": "functional profile",
      "target": "nociceptin-stimulated [35S]GTPgammaS binding",
      "label": "determined using"
    },
    {
      "source": "functional profile",
      "target": "[3H]nociceptin",
      "label": "determined using"
    },
    {
      "source": "ORL1",
      "target": "high sequence homology",
      "label": "has"
    },
    {
      "source": "high sequence homology",
      "target": "opioid receptors",
      "label": "between"
    },
    {
      "source": "high sequence homology",
      "target": "ORL1",
      "label": "between"
    },
    {
      "source": "(-)-quadazocine",
      "target": "nonselective opioid receptor antagonist",
      "label": "is a"
    },
    {
      "source": "(-)-quadazocine",
      "target": "partial agonism",
      "label": "displayed"
    },
    {
      "source": "(-)-quadazocine",
      "target": "pure antagonism",
      "label": "exhibited"
    },
    {
      "source": "[3H]nociceptin",
      "target": "rat brain receptors",
      "label": "at"
    },
    {
      "source": "enhancement",
      "target": "[35S]GTPgammaS binding",
      "label": "of"
    },
    {
      "source": "most opioids",
      "target": "affinity",
      "label": "lack"
    },
    {
      "source": "design",
      "target": "antagonists",
      "label": "of"
    },
    {
      "source": "design",
      "target": "nonpeptide nociceptin receptor agonists",
      "label": "of"
    },
    {
      "source": "design",
      "target": "loops",
      "label": "of"
    },
    {
      "source": "design",
      "target": "goal",
      "label": "is a step toward"
    },
    {
      "source": "(+)-quadazocine",
      "target": "both receptors",
      "label": "is inactive at"
    },
    {
      "source": "partial agonism",
      "target": "opioid receptors",
      "label": "at"
    },
    {
      "source": "partial agonism",
      "target": "human ORL1 receptors",
      "label": "at"
    },
    {
      "source": "[35S]GTPgammaS binding",
      "target": "human recombinant ORL1 receptors",
      "label": "to"
    },
    {
      "source": "nonpeptide nociceptin receptor agonists",
      "target": "affinity",
      "label": "lack"
    },
    {
      "source": "partial agonists",
      "target": "nociceptin receptor",
      "label": "at"
    },
    {
      "source": "orphanin FQ",
      "target": "peptide agonist",
      "label": "is a"
    },
    {
      "source": "peptide agonist",
      "target": "orphan receptor",
      "label": "for"
    },
    {
      "source": "Nociceptin",
      "target": "peptide agonist",
      "label": "is a"
    },
    {
      "source": "sufentanil",
      "target": "potent nociceptin receptor agonists",
      "label": "is a"
    },
    {
      "source": "sufentanil",
      "target": "related piperidines",
      "label": "is a"
    },
    {
      "source": "ohmefentanyl",
      "target": "potent nociceptin receptor agonists",
      "label": "is a"
    },
    {
      "source": "ohmefentanyl",
      "target": "related piperidines",
      "label": "is a"
    },
    {
      "source": "buprenorphine",
      "target": "nonselective opioid receptor partial agonist",
      "label": "is a"
    },
    {
      "source": "buprenorphine",
      "target": "partial agonism",
      "label": "displayed"
    },
    {
      "source": "buprenorphine",
      "target": "pure antagonism",
      "label": "exhibited"
    },
    {
      "source": "orphan receptor",
      "target": "opioid receptor-like 1 (ORL1)",
      "label": "is"
    },
    {
      "source": "Lofentanil",
      "target": "full agonism",
      "label": "exhibited"
    },
    {
      "source": "pure antagonism",
      "target": "rat brain receptors",
      "label": "at"
    },
    {
      "source": "etorphine",
      "target": "nonselective opioid receptor agonist",
      "label": "is a"
    },
    {
      "source": "etorphine",
      "target": "potent nociceptin receptor agonists",
      "label": "is a"
    },
    {
      "source": "etorphine",
      "target": "analgesic activity",
      "label": "has"
    },
    {
      "source": "etorphine",
      "target": "mu- and delta-receptors",
      "label": "InteractsWith"
    },
    {
      "source": "etorphine",
      "target": "tolerance",
      "label": "Induces"
    },
    {
      "source": "etorphine",
      "target": "opioid ligands",
      "label": "IsA"
    },
    {
      "source": "etorphine",
      "target": "mu- and delta-opioid receptor binding activities",
      "label": "Downregulator"
    },
    {
      "source": "leads",
      "target": "design",
      "label": "for"
    },
    {
      "source": "structural and functional homology",
      "target": "opioid recognition site",
      "label": "of"
    },
    {
      "source": "findings",
      "target": "structural and functional homology",
      "label": "illustrate"
    },
    {
      "source": "findings",
      "target": "high mRNA expression",
      "label": "include"
    },
    {
      "source": "findings",
      "target": "research",
      "label": "are from"
    },
    {
      "source": "findings",
      "target": "physiological ligand concentrations",
      "label": "emphasize the importance of"
    },
    {
      "source": "findings",
      "target": "structural basis",
      "label": "provide"
    },
    {
      "source": "findings",
      "target": "2-year preliminary results",
      "label": "confirmed by"
    },
    {
      "source": "findings",
      "target": "AMPK activity",
      "label": "suggest"
    },
    {
      "source": "findings",
      "target": "same site",
      "label": "suggest"
    },
    {
      "source": "findings",
      "target": "oxytocin",
      "label": "about"
    },
    {
      "source": "findings",
      "target": "knockdown",
      "label": "complemented by"
    },
    {
      "source": "findings",
      "target": "SPB applications",
      "label": "lay foundation for"
    },
    {
      "source": "findings",
      "target": "combined impact",
      "label": "suggest"
    },
    {
      "source": "findings",
      "target": "clinical spectrum of ZEB2 mutations",
      "label": "broaden"
    },
    {
      "source": "findings",
      "target": "oral curcuminoids supplementation",
      "label": "suggest"
    },
    {
      "source": "findings",
      "target": "curcumin",
      "label": "support use of"
    },
    {
      "source": "antagonism",
      "target": "opioid receptors",
      "label": "at"
    },
    {
      "source": "antagonism",
      "target": "population of receptors",
      "label": "of"
    },
    {
      "source": "antagonism",
      "target": "blockade",
      "label": "by"
    },
    {
      "source": "IC(50)",
      "target": "62 nM",
      "label": "is"
    },
    {
      "source": "IC(50)",
      "target": "microM",
      "label": "measured in"
    },
    {
      "source": "diets",
      "target": "GLA",
      "label": "supplemented with"
    },
    {
      "source": "diets",
      "target": "EPA",
      "label": "supplemented with"
    },
    {
      "source": "diets",
      "target": "mixtures",
      "label": "contain"
    },
    {
      "source": "diets",
      "target": "HEP",
      "label": "contain"
    },
    {
      "source": "diets",
      "target": "HCB",
      "label": "contain"
    },
    {
      "source": "GLA",
      "target": "clinical symptoms",
      "label": "attenuates"
    },
    {
      "source": "GLA",
      "target": "lipid mediators",
      "label": "reduces"
    },
    {
      "source": "GLA",
      "target": "lipid mediators of inflammation",
      "label": "reduces generation of"
    },
    {
      "source": "GLA",
      "target": "chronic inflammatory disorders",
      "label": "attenuates"
    },
    {
      "source": "Delta-5-desaturase activity",
      "target": "enzymatic step",
      "label": "is a"
    },
    {
      "source": "enzymatic step",
      "target": "AA synthesis",
      "label": "involved in"
    },
    {
      "source": "GLA and EPA combination",
      "target": "humans",
      "label": "tested in"
    },
    {
      "source": "GLA and EPA combination",
      "target": "in vivo effects",
      "label": "has"
    },
    {
      "source": "GLA and EPA combination",
      "target": "serum AA levels",
      "label": "not induce increases in"
    },
    {
      "source": "GLA and EPA combination",
      "target": "proinflammatory AA metabolites",
      "label": "reduces synthesis of"
    },
    {
      "source": "gamma-linolenic acid",
      "target": "diets",
      "label": "supplemented"
    },
    {
      "source": "lipid mediators",
      "target": "inflammation",
      "label": "mediate"
    },
    {
      "source": "lipid mediators",
      "target": "smooth muscle constriction",
      "label": "mediate"
    },
    {
      "source": "DGLA",
      "target": "neutrophil glycerolipids",
      "label": "levels increased in"
    },
    {
      "source": "DGLA",
      "target": "supplementation period",
      "label": "increased during"
    },
    {
      "source": "in vivo effects",
      "target": "serotonin type 2a (5-HT2a) receptor systems",
      "label": "at"
    },
    {
      "source": "in vivo effects",
      "target": "dopamine type 2 (D2) receptor systems",
      "label": "at"
    },
    {
      "source": "in vivo effects",
      "target": "collagen formation",
      "label": "on"
    },
    {
      "source": "adult volunteers",
      "target": "controlled diets",
      "label": "consumed"
    },
    {
      "source": "controlled diets",
      "target": "EPA",
      "label": "supplemented with"
    },
    {
      "source": "controlled diets",
      "target": "GLA",
      "label": "supplemented with"
    },
    {
      "source": "in vitro studies",
      "target": "HEP-G2 liver cells",
      "label": "utilized"
    },
    {
      "source": "human diets",
      "target": "GLA",
      "label": "supplemented with"
    },
    {
      "source": "EPA",
      "target": "neutrophil glycerolipids",
      "label": "levels increased in"
    },
    {
      "source": "EPA",
      "target": "supplementation period",
      "label": "increased during"
    },
    {
      "source": "EPA",
      "target": "Delta-5-desaturase activity",
      "label": "blocked"
    },
    {
      "source": "eicosapentaenoic acid",
      "target": "diets",
      "label": "supplemented"
    },
    {
      "source": "eicosapentaenoic acid",
      "target": "humans",
      "label": "prevents accumulation in"
    },
    {
      "source": "eicosapentaenoic acid",
      "target": "serum arachidonic acid accumulation",
      "label": "prevents"
    },
    {
      "source": "eicosapentaenoic acid",
      "target": "Delta-5-desaturase activity",
      "label": "blocked"
    },
    {
      "source": "eicosapentaenoic acid",
      "target": "20:5n-3",
      "label": "is also known as"
    },
    {
      "source": "elongation product of GLA",
      "target": "dihomo-gamma-linolenic acid",
      "label": "is"
    },
    {
      "source": "dihomo-gamma-linolenic acid",
      "target": "DGLA",
      "label": "is also known as"
    },
    {
      "source": "supplementation strategy",
      "target": "serum levels of EPA",
      "label": "increased"
    },
    {
      "source": "supplementation strategy",
      "target": "serum AA levels",
      "label": "prevented elevations in"
    },
    {
      "source": "supplementation strategy",
      "target": "AA levels",
      "label": "did not increase"
    },
    {
      "source": "supplementation strategy",
      "target": "GLA",
      "label": "maintained capacity of"
    },
    {
      "source": "Neutrophils",
      "target": "leukotrienes",
      "label": "synthesized lower quantities of"
    },
    {
      "source": "Neutrophils",
      "target": "AA",
      "label": "released"
    },
    {
      "source": "serum arachidonate (AA) levels",
      "target": "side effect",
      "label": "is a"
    },
    {
      "source": "side effect",
      "target": "patient compliance",
      "label": "affects"
    },
    {
      "source": "fatty acid",
      "target": "serum arachidonate (AA) levels",
      "label": "causes increase in"
    },
    {
      "source": "AA",
      "target": "diabetic rats",
      "label": "administered to"
    },
    {
      "source": "AA",
      "target": "anti-inflammatory activities",
      "label": "has"
    },
    {
      "source": "AA",
      "target": "key regulatory enzymes",
      "label": "modulates"
    },
    {
      "source": "AA",
      "target": "antihyperglycemic effect",
      "label": "has"
    },
    {
      "source": "AA",
      "target": "body weight loss",
      "label": "protected against"
    },
    {
      "source": "AA",
      "target": "bioactive compound",
      "label": "is a"
    },
    {
      "source": "AA",
      "target": "antioxidant activities",
      "label": "has"
    },
    {
      "source": "AA",
      "target": "streptozotocin-induced diabetic rats",
      "label": "acts on"
    },
    {
      "source": "AA",
      "target": "triterpenoid derivative",
      "label": "is a"
    },
    {
      "source": "AA",
      "target": "hepatic enzymes",
      "label": "affects activity of"
    },
    {
      "source": "AA",
      "target": "carbohydrate metabolism",
      "label": "regulates"
    },
    {
      "source": "AA",
      "target": "active avoidance tasks",
      "label": "is an abbreviation for"
    },
    {
      "source": "rheumatoid arthritis",
      "target": "chronic inflammatory disorders",
      "label": "is a type of"
    },
    {
      "source": "cytosensor microphysiometer",
      "target": "ligand-induced extracellular acidification rate changes",
      "label": "measures"
    },
    {
      "source": "dexmedetomidine",
      "target": "agonist potency",
      "label": "has"
    },
    {
      "source": "dexmedetomidine",
      "target": "partial agonists",
      "label": "behaved as"
    },
    {
      "source": "dexmedetomidine",
      "target": "agonist",
      "label": "is an"
    },
    {
      "source": "A-54741",
      "target": "agonist potency",
      "label": "has"
    },
    {
      "source": "A-54741",
      "target": "maximum response",
      "label": "had"
    },
    {
      "source": "A-54741",
      "target": "agonist",
      "label": "is an"
    },
    {
      "source": "agonist-induced acidification rate responses",
      "target": "G(i/o) proteins",
      "label": "mediated via"
    },
    {
      "source": "agonist-induced acidification rate responses",
      "target": "recombinant protein",
      "label": "mediated by"
    },
    {
      "source": "G(i/o) proteins",
      "target": "pertussis toxin",
      "label": "are sensitive to"
    },
    {
      "source": "Human alpha(2A)-adrenoceptors",
      "target": "Chinese hamster lung (CHL) fibroblasts",
      "label": "expressed in"
    },
    {
      "source": "Human alpha(2A)-adrenoceptors",
      "target": "cytosensor microphysiometer",
      "label": "characterized using"
    },
    {
      "source": "human alpha(2A)-adrenoceptor",
      "target": "recombinant protein",
      "label": "is a"
    },
    {
      "source": "UK-14304",
      "target": "maximum response",
      "label": "had"
    },
    {
      "source": "UK-14304",
      "target": "agonist",
      "label": "is an"
    },
    {
      "source": "UK-14304",
      "target": "agonist potency",
      "label": "has"
    },
    {
      "source": "B-HT 920",
      "target": "partial agonists",
      "label": "behaved as"
    },
    {
      "source": "B-HT 920",
      "target": "agonist",
      "label": "is an"
    },
    {
      "source": "B-HT 920",
      "target": "agonist potency",
      "label": "has"
    },
    {
      "source": "noradrenaline",
      "target": "agonist",
      "label": "is an"
    },
    {
      "source": "noradrenaline",
      "target": "untransfected CHL cells",
      "label": "had no effect on"
    },
    {
      "source": "noradrenaline",
      "target": "agonist potency",
      "label": "has"
    },
    {
      "source": "noradrenaline",
      "target": "maximum response",
      "label": "had"
    },
    {
      "source": "noradrenaline",
      "target": "4-week-old mice",
      "label": "concentration higher in"
    },
    {
      "source": "noradrenaline",
      "target": "[(3)H]prazosin",
      "label": "was without effect on binding of"
    },
    {
      "source": "doxazosin",
      "target": "selective alpha(1)-adrenoceptor ligands",
      "label": "is a"
    },
    {
      "source": "doxazosin",
      "target": "noradrenaline responses",
      "label": "had no effect on"
    },
    {
      "source": "doxazosin",
      "target": "quinazoline derivatives",
      "label": "is a type of"
    },
    {
      "source": "doxazosin",
      "target": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "label": "is a"
    },
    {
      "source": "rauwolscine",
      "target": "affinity",
      "label": "has"
    },
    {
      "source": "rauwolscine",
      "target": "selective alpha(2)-adrenoceptor ligand",
      "label": "is a"
    },
    {
      "source": "rauwolscine",
      "target": "acidification rate changes",
      "label": "antagonized"
    },
    {
      "source": "rauwolscine",
      "target": "[(3)H]prazosin",
      "label": "was without effect on binding of"
    },
    {
      "source": "rauwolscine",
      "target": "alpha(2)-adrenoceptor antagonist",
      "label": "is"
    },
    {
      "source": "rauwolscine",
      "target": "antagonistic effects",
      "label": "has no"
    },
    {
      "source": "alpha(2A)-adrenoceptors",
      "target": "extracellular acidification rate changes",
      "label": "characterized using"
    },
    {
      "source": "alpha(2A)-adrenoceptors",
      "target": "Chinese hamster lung cells",
      "label": "expressed in"
    },
    {
      "source": "prazosin",
      "target": "selective alpha(1)-adrenoceptor ligands",
      "label": "is a"
    },
    {
      "source": "prazosin",
      "target": "noradrenaline responses",
      "label": "had no effect on"
    },
    {
      "source": "prazosin",
      "target": "selective alpha(1)-adrenoceptor antagonist",
      "label": "is"
    },
    {
      "source": "TWIK-2",
      "target": "immune system",
      "label": "expressed in"
    },
    {
      "source": "TWIK-2",
      "target": "2P domain K(+) channel",
      "label": "is a type of"
    },
    {
      "source": "TWIK-2",
      "target": "COS cells",
      "label": "expressed in"
    },
    {
      "source": "TWIK-2",
      "target": "2P domain K+ channel",
      "label": "is a type of"
    },
    {
      "source": "TWIK-2",
      "target": "gastrointestinal tract",
      "label": "expressed in"
    },
    {
      "source": "TWIK-2",
      "target": "low conductance",
      "label": "shows"
    },
    {
      "source": "TWIK-2",
      "target": "vasculature",
      "label": "expressed in"
    },
    {
      "source": "2P domain K(+) channel",
      "target": "inactivation",
      "label": "exhibits"
    },
    {
      "source": "2P domain K(+) channel",
      "target": "functional role",
      "label": "plays a"
    },
    {
      "source": "2P domain K(+) channel",
      "target": "COS cells",
      "label": "expressed in"
    },
    {
      "source": "inactivation",
      "target": "TWIK-2 channels",
      "label": "is an intrinsic property of"
    },
    {
      "source": "inactivation",
      "target": "channel types",
      "label": "of"
    },
    {
      "source": "cysteine 53",
      "target": "subunit self-assembly",
      "label": "not critical for"
    },
    {
      "source": "cysteine 53",
      "target": "M1P1 external loop",
      "label": "located in"
    },
    {
      "source": "cysteine 53",
      "target": "functional expression",
      "label": "required for"
    },
    {
      "source": "visualization",
      "target": "discrete single channel events",
      "label": "of"
    },
    {
      "source": "kinetic of inactivation",
      "target": "temperature-sensitive",
      "label": "is"
    },
    {
      "source": "low conductance",
      "target": "visualization",
      "label": "prevents"
    },
    {
      "source": "mild inward rectification",
      "target": "symmetrical K(+) conditions",
      "label": "occurs in"
    },
    {
      "source": "functional expression",
      "target": "TWIK-2",
      "label": "of"
    },
    {
      "source": "functional expression",
      "target": "5-HT1E-like rat and human 5-hydroxytryptamine receptor genes",
      "label": "pertains to"
    },
    {
      "source": "Rat TWIK-2",
      "target": "human TWIK-2",
      "label": "has larger currents than"
    },
    {
      "source": "Rat TWIK-2",
      "target": "outward rectification",
      "label": "exhibits"
    },
    {
      "source": "Rat TWIK-2",
      "target": "mild inward rectification",
      "label": "exhibits"
    },
    {
      "source": "human TWIK-2",
      "target": "outward rectification",
      "label": "exhibits"
    },
    {
      "source": "human TWIK-2",
      "target": "mild inward rectification",
      "label": "exhibits"
    },
    {
      "source": "delayed activities",
      "target": "TWIK-2",
      "label": "of"
    },
    {
      "source": "base-line activity",
      "target": "TWIK-2",
      "label": "of"
    },
    {
      "source": "outward rectification",
      "target": "physiological K(+) gradient",
      "label": "occurs in"
    },
    {
      "source": "Ba(2+)",
      "target": "TWIK-2",
      "label": "inhibits"
    },
    {
      "source": "quinine",
      "target": "TWIK-2",
      "label": "inhibits"
    },
    {
      "source": "quinidine",
      "target": "TWIK-2",
      "label": "inhibits"
    },
    {
      "source": "transient activity",
      "target": "TWIK-2",
      "label": "of"
    },
    {
      "source": "functional role",
      "target": "cell electrogenesis",
      "label": "in"
    },
    {
      "source": "TWIK-2 currents",
      "target": "depolarized potentials",
      "label": "inactivates at"
    },
    {
      "source": "rectification",
      "target": "TWIK-2 channels",
      "label": "is an intrinsic property of"
    },
    {
      "source": "gastrointestinal tract",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "Reduced expression",
      "target": "surface carbohydrate moieties",
      "label": "affects"
    },
    {
      "source": "Reduced expression",
      "target": "FcgammaRII",
      "label": "affects"
    },
    {
      "source": "Reduced expression",
      "target": "complement receptor type 1",
      "label": "affects"
    },
    {
      "source": "Reduced expression",
      "target": "apoptosis",
      "label": "associated with"
    },
    {
      "source": "Reduced expression",
      "target": "neutrophil responsiveness",
      "label": "limits"
    },
    {
      "source": "Reduced expression",
      "target": "CD63",
      "label": "affects"
    },
    {
      "source": "Reduced expression",
      "target": "receptors",
      "label": "affects"
    },
    {
      "source": "Reduced expression",
      "target": "CR1",
      "label": "affects"
    },
    {
      "source": "surface carbohydrate moieties",
      "target": "sialic acid",
      "label": "include"
    },
    {
      "source": "FcgammaRII",
      "target": "CD32",
      "label": "is also known as"
    },
    {
      "source": "differential loss",
      "target": "CD15",
      "label": "affects"
    },
    {
      "source": "differential loss",
      "target": "CD120b",
      "label": "affects"
    },
    {
      "source": "differential loss",
      "target": "CD16",
      "label": "affects"
    },
    {
      "source": "neutrophil responsiveness",
      "target": "stimuli",
      "label": "to"
    },
    {
      "source": "stimuli",
      "target": "degranulation responses",
      "label": "trigger"
    },
    {
      "source": "panel",
      "target": "monoclonal antibodies",
      "label": "consists of"
    },
    {
      "source": "panel",
      "target": "lectins",
      "label": "consists of"
    },
    {
      "source": "profile",
      "target": "surface molecule expression",
      "label": "describes"
    },
    {
      "source": "complement receptor type 1",
      "target": "CD35",
      "label": "is also known as"
    },
    {
      "source": "LFA-3",
      "target": "Neutrophil apoptosis",
      "label": "is not altered by"
    },
    {
      "source": "LFA-3",
      "target": "CD58",
      "label": "is also known as"
    },
    {
      "source": "Neutrophil apoptosis",
      "target": "down-regulation",
      "label": "accompanied by"
    },
    {
      "source": "CD63",
      "target": "azurophilic granules",
      "label": "is found in"
    },
    {
      "source": "apoptotic neutrophils",
      "target": "nuclear degradation",
      "label": "exhibit"
    },
    {
      "source": "apoptotic neutrophils",
      "target": "intact plasma membranes",
      "label": "retain"
    },
    {
      "source": "apoptotic neutrophils",
      "target": "recognition",
      "label": "imply"
    },
    {
      "source": "apoptotic neutrophils",
      "target": "functional downregulation",
      "label": "imply"
    },
    {
      "source": "BOB78 positive neutrophils",
      "target": "biotinylated thrombospondin",
      "label": "bind"
    },
    {
      "source": "exposure",
      "target": "thrombospondin binding moieties",
      "label": "of"
    },
    {
      "source": "exposure",
      "target": "elderly patients",
      "label": "occurs in"
    },
    {
      "source": "exposure",
      "target": "body weight",
      "label": "related to"
    },
    {
      "source": "exposure",
      "target": "42%",
      "label": "increased by"
    },
    {
      "source": "exposure",
      "target": "decline of renal function",
      "label": "related to"
    },
    {
      "source": "exposure",
      "target": "20%",
      "label": "increased by"
    },
    {
      "source": "exposure",
      "target": "Swedish rubber industry",
      "label": "in"
    },
    {
      "source": "exposure",
      "target": "death",
      "label": "causes"
    },
    {
      "source": "exposure",
      "target": "brain damage",
      "label": "causes"
    },
    {
      "source": "exposure",
      "target": "oxaliplatin",
      "label": "to"
    },
    {
      "source": "exposure",
      "target": "BSEP inhibitors",
      "label": "to"
    },
    {
      "source": "exposure",
      "target": "EDCs",
      "label": "to"
    },
    {
      "source": "down-regulation",
      "target": "adhesive interactions",
      "label": "alters"
    },
    {
      "source": "down-regulation",
      "target": "integrin-associated proteins",
      "label": "affects"
    },
    {
      "source": "down-regulation",
      "target": "immunoglobulin superfamily members",
      "label": "affects"
    },
    {
      "source": "down-regulation",
      "target": "receptor type",
      "label": "Affects"
    },
    {
      "source": "immunoglobulin superfamily members",
      "target": "ICAM-3",
      "label": "include"
    },
    {
      "source": "immunoglobulin superfamily members",
      "target": "PECAM-1",
      "label": "include"
    },
    {
      "source": "immunoglobulin superfamily members",
      "target": "CD66acde",
      "label": "include"
    },
    {
      "source": "immunoglobulin superfamily members",
      "target": "CD66b",
      "label": "include"
    },
    {
      "source": "ICAM-3",
      "target": "CD50",
      "label": "is also known as"
    },
    {
      "source": "human neutrophils",
      "target": "surface molecule expression",
      "label": "has"
    },
    {
      "source": "human neutrophils",
      "target": "spontaneous apoptosis",
      "label": "undergo"
    },
    {
      "source": "integrin-associated proteins",
      "target": "urokinase plasminogen activator receptor",
      "label": "include"
    },
    {
      "source": "integrin-associated proteins",
      "target": "CD63",
      "label": "include"
    },
    {
      "source": "apoptosis",
      "target": "in situ staining",
      "label": "verified by"
    },
    {
      "source": "apoptosis",
      "target": "photoreceptor cells",
      "label": "affects"
    },
    {
      "source": "apoptosis",
      "target": "fragmented genomic DNA",
      "label": "verified by detection of"
    },
    {
      "source": "apoptosis",
      "target": "TUNEL assay",
      "label": "detected by"
    },
    {
      "source": "apoptosis",
      "target": "DNA fragmentation",
      "label": "detected by"
    },
    {
      "source": "apoptosis",
      "target": "tumor cells",
      "label": "is of"
    },
    {
      "source": "apoptosis",
      "target": "tumors",
      "label": "in"
    },
    {
      "source": "apoptosis",
      "target": "fluorescence-activated cell sorter analysis",
      "label": "studied_by"
    },
    {
      "source": "apoptosis",
      "target": "proline",
      "label": "is dependent on"
    },
    {
      "source": "apoptosis",
      "target": "mitochondria",
      "label": "is mediated by"
    },
    {
      "source": "apoptosis",
      "target": "testes",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "ROS generation",
      "label": "via"
    },
    {
      "source": "apoptosis",
      "target": "Caki cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "renal cell carcinoma",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "carcinoma cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "HCT116 cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "human renal carcinoma Caki cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "reactive oxygen species",
      "label": "is dependent on"
    },
    {
      "source": "apoptosis",
      "target": "endoplasmic reticulum stress",
      "label": "is independent of"
    },
    {
      "source": "apoptosis",
      "target": "cytotoxicity",
      "label": "is cause for"
    },
    {
      "source": "apoptosis",
      "target": "cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "preneoplastic cells",
      "label": "is of"
    },
    {
      "source": "apoptosis",
      "target": "regeneration",
      "label": "leads to"
    },
    {
      "source": "apoptosis",
      "target": "cultured cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "neurons",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "cultured cerebellar granule cells (CGCs)",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "enterocytes",
      "label": "of"
    },
    {
      "source": "apoptosis",
      "target": "PC-3 cells",
      "label": "occurs in"
    },
    {
      "source": "apoptosis",
      "target": "airway epithelial cells",
      "label": "affects"
    },
    {
      "source": "apoptosis",
      "target": "A549 human lung adenocarcinoma cells",
      "label": "occurred in"
    },
    {
      "source": "apoptosis",
      "target": "upregulation",
      "label": "causes"
    },
    {
      "source": "apoptosis",
      "target": "downregulation",
      "label": "causes"
    },
    {
      "source": "apoptosis",
      "target": "caspase 3 expression",
      "label": "includes"
    },
    {
      "source": "apoptosis",
      "target": "Bax",
      "label": "includes"
    },
    {
      "source": "specific changes",
      "target": "shedding",
      "label": "involves"
    },
    {
      "source": "specific changes",
      "target": "apoptosis",
      "label": "associated with"
    },
    {
      "source": "specific changes",
      "target": "receptor mobilisation",
      "label": "involves"
    },
    {
      "source": "surface molecular changes",
      "target": "exposure",
      "label": "associated with"
    },
    {
      "source": "spontaneous apoptosis",
      "target": "in vitro culture",
      "label": "occurs during"
    },
    {
      "source": "90 kDa antigen",
      "target": "intracellular granules",
      "label": "localised in"
    },
    {
      "source": "aminopeptidase-N",
      "target": "CD13",
      "label": "is also known as"
    },
    {
      "source": "Cellular interactions",
      "target": "Reduced expression",
      "label": "influenced by"
    },
    {
      "source": "BOB78",
      "target": "90 kDa antigen",
      "label": "recognises"
    },
    {
      "source": "BOB78",
      "target": "subpopulation",
      "label": "defines"
    },
    {
      "source": "subpopulation",
      "target": "apoptotic neutrophils",
      "label": "of"
    },
    {
      "source": "subpopulation",
      "target": "PD",
      "label": "degenerates in"
    },
    {
      "source": "receptors",
      "target": "apoptotic neutrophils",
      "label": "on"
    },
    {
      "source": "receptors",
      "target": "reduced levels",
      "label": "expressed at"
    },
    {
      "source": "receptors",
      "target": "pro-inflammatory mediators",
      "label": "for"
    },
    {
      "source": "receptors",
      "target": "astrocytes",
      "label": "expressed by"
    },
    {
      "source": "receptors",
      "target": "mesencephalic dopaminergic neurons",
      "label": "expressed by"
    },
    {
      "source": "receptors",
      "target": "ligand profiles",
      "label": "have"
    },
    {
      "source": "receptors",
      "target": "ligand-binding domain",
      "label": "have"
    },
    {
      "source": "receptors",
      "target": "immunological surfactant proteins",
      "label": "are for"
    },
    {
      "source": "TNFalpha",
      "target": "CD120b",
      "label": "is also known as"
    },
    {
      "source": "urokinase plasminogen activator receptor",
      "target": "CD87",
      "label": "is also known as"
    },
    {
      "source": "CR1",
      "target": "specific granules",
      "label": "is found in"
    },
    {
      "source": "mAb",
      "target": "surface molecular changes",
      "label": "defines"
    },
    {
      "source": "PECAM-1",
      "target": "CD31",
      "label": "is also known as"
    },
    {
      "source": "granule mobilisation",
      "target": "apoptosis",
      "label": "does not accompany"
    },
    {
      "source": "pro-inflammatory mediators",
      "target": "TNFalpha",
      "label": "include"
    },
    {
      "source": "pro-inflammatory mediators",
      "target": "C5a",
      "label": "include"
    },
    {
      "source": "monoclonal antibody",
      "target": "BOB78",
      "label": "is also known as"
    },
    {
      "source": "monoclonal antibody",
      "target": "rabbit TF",
      "label": "targets"
    },
    {
      "source": "C5a",
      "target": "CD88",
      "label": "is also known as"
    },
    {
      "source": "increased expression",
      "target": "aminopeptidase-N",
      "label": "affects"
    },
    {
      "source": "activities",
      "target": "other receptors",
      "label": "on"
    },
    {
      "source": "activities",
      "target": "culture medium",
      "label": "located in"
    },
    {
      "source": "activities",
      "target": "BChE",
      "label": "of"
    },
    {
      "source": "activities",
      "target": "membrane fractions",
      "label": "located in"
    },
    {
      "source": "activities",
      "target": "AChE",
      "label": "of"
    },
    {
      "source": "activities",
      "target": "pathways",
      "label": "modulated by"
    },
    {
      "source": "activities",
      "target": "ACs",
      "label": "of"
    },
    {
      "source": "activities",
      "target": "control",
      "label": "ensure"
    },
    {
      "source": "minimal D2 occupancy",
      "target": "12 hours",
      "label": "occurred after"
    },
    {
      "source": "minimal D2 occupancy",
      "target": "0%-27% D2 occupancy",
      "label": "is"
    },
    {
      "source": "minimal D2 occupancy",
      "target": "last dose",
      "label": "occurred after"
    },
    {
      "source": "doses",
      "target": "300 mg/d",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "150 mg/d",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "600 mg/d",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "quetiapine",
      "label": "of"
    },
    {
      "source": "doses",
      "target": "450 mg/d",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "fluorouracil exposure",
      "label": "adapted to"
    },
    {
      "source": "doses",
      "target": "therapeutic index",
      "label": "not individualised due to"
    },
    {
      "source": "doses",
      "target": "metabolism",
      "label": "not individualised due to variabilities in"
    },
    {
      "source": "doses",
      "target": "targets",
      "label": "not individualised due to variabilities in"
    },
    {
      "source": "doses",
      "target": "administration rates",
      "label": "not individualised due to variabilities in"
    },
    {
      "source": "doses",
      "target": "nonlinear pharmacokinetics",
      "label": "not individualised due to"
    },
    {
      "source": "doses",
      "target": "21-day cycle",
      "label": "part of"
    },
    {
      "source": "doses",
      "target": "diflunisal",
      "label": "are of"
    },
    {
      "source": "doses",
      "target": "acetyldiflunisal",
      "label": "are of"
    },
    {
      "source": "doses",
      "target": "recent years",
      "label": "maximised in"
    },
    {
      "source": "doses",
      "target": "25mg/kg/week",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "10mg/kg/week",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "15mg/kg/week",
      "label": "include"
    },
    {
      "source": "doses",
      "target": "body weight",
      "label": "BASED_ON"
    },
    {
      "source": "doses",
      "target": "nialamide",
      "label": "of"
    },
    {
      "source": "doses",
      "target": "debrisoquin",
      "label": "of"
    },
    {
      "source": "doses",
      "target": "clorgyline",
      "label": "of"
    },
    {
      "source": "5-HT2a occupancy",
      "target": "12 to 14 hours",
      "label": "measured after"
    },
    {
      "source": "5-HT2a occupancy",
      "target": "positron emission tomography (PET) imaging",
      "label": "measured using"
    },
    {
      "source": "5-HT2a occupancy",
      "target": "last dose",
      "label": "measured after"
    },
    {
      "source": "5-HT2a occupancy",
      "target": "3 weeks",
      "label": "measured after"
    },
    {
      "source": "5-HT2a occupancy",
      "target": "treatment",
      "label": "measured after"
    },
    {
      "source": "positron emission tomography study",
      "target": "quetiapine",
      "label": "investigates"
    },
    {
      "source": "positron emission tomography study",
      "target": "antipsychotic effect",
      "label": "finds"
    },
    {
      "source": "positron emission tomography study",
      "target": "schizophrenia",
      "label": "investigates"
    },
    {
      "source": "quetiapine",
      "target": "antipsychotic effect",
      "label": "has"
    },
    {
      "source": "quetiapine",
      "target": "transiently high D2 occupancy",
      "label": "shows"
    },
    {
      "source": "quetiapine",
      "target": "atypical antipsychotic medication",
      "label": "is a type of"
    },
    {
      "source": "quetiapine",
      "target": "results",
      "label": "achieved"
    },
    {
      "source": "quetiapine",
      "target": "extrapyramidal symptoms",
      "label": "improved"
    },
    {
      "source": "quetiapine",
      "target": "prolactin level elevation",
      "label": "improved"
    },
    {
      "source": "quetiapine",
      "target": "in vivo effects",
      "label": "has"
    },
    {
      "source": "quetiapine",
      "target": "5-HT(2A)",
      "label": "Downregulator"
    },
    {
      "source": "quetiapine",
      "target": "acetylcholine",
      "label": "Regulator"
    },
    {
      "source": "quetiapine",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "quetiapine",
      "target": "dopamine",
      "label": "Regulator"
    },
    {
      "source": "quetiapine",
      "target": "5-HT(1A)",
      "label": "Agonist"
    },
    {
      "source": "quetiapine",
      "target": "D(2)",
      "label": "Downregulator"
    },
    {
      "source": "quetiapine",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "additional subjects",
      "target": "effects",
      "label": "examine"
    },
    {
      "source": "transiently high D2 occupancy",
      "target": "minimal levels",
      "label": "decreases to"
    },
    {
      "source": "transiently high D2 occupancy",
      "target": "single dose",
      "label": "occurs after"
    },
    {
      "source": "transiently high D2 occupancy",
      "target": "dosing interval",
      "label": "decreases by"
    },
    {
      "source": "transiently high D2 occupancy",
      "target": "2 to 3 hours",
      "label": "occurs after"
    },
    {
      "source": "transiently high D2 occupancy",
      "target": "58%-64% D2 occupancy",
      "label": "is"
    },
    {
      "source": "minimal levels",
      "target": "12 hours",
      "label": "reached in"
    },
    {
      "source": "D2 occupancy",
      "target": "positron emission tomography (PET) imaging",
      "label": "measured using"
    },
    {
      "source": "D2 occupancy",
      "target": "last dose",
      "label": "measured after"
    },
    {
      "source": "D2 occupancy",
      "target": "3 weeks",
      "label": "measured after"
    },
    {
      "source": "D2 occupancy",
      "target": "treatment",
      "label": "measured after"
    },
    {
      "source": "D2 occupancy",
      "target": "12 to 14 hours",
      "label": "measured after"
    },
    {
      "source": "antipsychotic effect",
      "target": "transiently high D2 occupancy",
      "label": "associated with"
    },
    {
      "source": "extrapyramidal symptoms",
      "target": "baseline",
      "label": "noted at"
    },
    {
      "source": "Future studies",
      "target": "activities",
      "label": "control for"
    },
    {
      "source": "Future studies",
      "target": "nonpharmacological effects",
      "label": "control for"
    },
    {
      "source": "Future studies",
      "target": "suggestion",
      "label": "confirm"
    },
    {
      "source": "Future studies",
      "target": "mechanism",
      "label": "should focus on determining"
    },
    {
      "source": "information",
      "target": "clinical profile",
      "label": "to"
    },
    {
      "source": "information",
      "target": "structure-activity relationships",
      "label": "useful in establishing"
    },
    {
      "source": "information",
      "target": "analysis",
      "label": "useful in"
    },
    {
      "source": "information",
      "target": "drug receptors",
      "label": "about"
    },
    {
      "source": "transient D2 occupancy",
      "target": "antipsychotic effect",
      "label": "sufficient for"
    },
    {
      "source": "Clinical efficacy",
      "target": "baseline",
      "label": "obtained at"
    },
    {
      "source": "Clinical efficacy",
      "target": "time of PET scanning",
      "label": "obtained at"
    },
    {
      "source": "Clinical efficacy",
      "target": "12 weeks",
      "label": "obtained at"
    },
    {
      "source": "freedom",
      "target": "extrapyramidal symptoms",
      "label": "from"
    },
    {
      "source": "freedom",
      "target": "prolactin level elevation",
      "label": "from"
    },
    {
      "source": "adverse effect ratings",
      "target": "baseline",
      "label": "obtained at"
    },
    {
      "source": "adverse effect ratings",
      "target": "time of PET scanning",
      "label": "obtained at"
    },
    {
      "source": "adverse effect ratings",
      "target": "12 weeks",
      "label": "obtained at"
    },
    {
      "source": "schizophrenia",
      "target": "diseases",
      "label": "is a type of"
    },
    {
      "source": "prolactin level elevation",
      "target": "baseline",
      "label": "noted at"
    },
    {
      "source": "12 weeks",
      "target": "treatment",
      "label": "of"
    },
    {
      "source": "Quetiapine's low D2 occupancy",
      "target": "freedom",
      "label": "explains"
    },
    {
      "source": "CB1 receptors",
      "target": "peripheral neurones",
      "label": "LOCATED_ON"
    },
    {
      "source": "CB1 receptors",
      "target": "central neurones",
      "label": "LOCATED_ON"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "muscle spasm",
      "label": "USED_FOR"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "chronic pain",
      "label": "USED_FOR"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "bronchial asthma",
      "label": "USED_FOR"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "glaucoma",
      "label": "USED_FOR"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "antiemetics",
      "label": "USED_AS"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "spasticity",
      "label": "USED_FOR"
    },
    {
      "source": "cannabinoid CB1 receptor agonists",
      "target": "appetite stimulants",
      "label": "USED_AS"
    },
    {
      "source": "muscle spasm",
      "target": "spinal cord injury",
      "label": "ASSOCIATED_WITH"
    },
    {
      "source": "muscle spasm",
      "target": "multiple sclerosis",
      "label": "ASSOCIATED_WITH"
    },
    {
      "source": "endogenous cannabinoid system",
      "target": "clinical potential",
      "label": "FUELED_INTEREST_IN"
    },
    {
      "source": "endogenous cannabinoid system",
      "target": "selective CB1 and CB2 receptor ligands",
      "label": "LED_TO_DEVELOPMENT_OF"
    },
    {
      "source": "clinical potential",
      "target": "cannabinoids",
      "label": "IS_OF"
    },
    {
      "source": "CB2 receptors",
      "target": "immune cells",
      "label": "LOCATED_ON"
    },
    {
      "source": "immune cells",
      "target": "skin",
      "label": "located in"
    },
    {
      "source": "THC",
      "target": "therapeutic window",
      "label": "HAS"
    },
    {
      "source": "THC",
      "target": "cannabinoid CB1 receptor agonists",
      "label": "IS_A"
    },
    {
      "source": "THC",
      "target": "variable absorption",
      "label": "UNDERGOES"
    },
    {
      "source": "therapeutic window",
      "target": "dose range",
      "label": "IS_A"
    },
    {
      "source": "spasticity",
      "target": "spinal cord injury",
      "label": "ASSOCIATED_WITH"
    },
    {
      "source": "spasticity",
      "target": "multiple sclerosis",
      "label": "ASSOCIATED_WITH"
    },
    {
      "source": "additional drug treatments",
      "target": "disorders",
      "label": "NEEDED_TO_MANAGE"
    },
    {
      "source": "disorders",
      "target": "schizophrenia",
      "label": "includes"
    },
    {
      "source": "disorders",
      "target": "anxiety",
      "label": "includes"
    },
    {
      "source": "CB1 receptor antagonists",
      "target": "disorders of cognition",
      "label": "USED_FOR"
    },
    {
      "source": "CB1 receptor antagonists",
      "target": "schizophrenia",
      "label": "USED_FOR"
    },
    {
      "source": "CB1 receptor antagonists",
      "target": "appetite suppressants",
      "label": "USED_AS"
    },
    {
      "source": "CB1 receptor antagonists",
      "target": "memory",
      "label": "USED_FOR"
    },
    {
      "source": "CB1 receptor antagonists",
      "target": "clinical applications",
      "label": "HAS"
    },
    {
      "source": "cannabinoid formulations",
      "target": "therapeutic potential",
      "label": "REQUIRED_FOR"
    },
    {
      "source": "therapeutic potential",
      "target": "Cannabis",
      "label": "IS_OF"
    },
    {
      "source": "therapeutic potential",
      "target": "cannabinoid CB1 receptor agonists",
      "label": "IS_OF"
    },
    {
      "source": "therapeutic potential",
      "target": "diseases",
      "label": "for"
    },
    {
      "source": "therapeutic potential",
      "target": "allosteric approach",
      "label": "is of"
    },
    {
      "source": "therapeutic potential",
      "target": "transplantation",
      "label": "for"
    },
    {
      "source": "therapeutic potential",
      "target": "autoimmune diseases",
      "label": "for"
    },
    {
      "source": "benefits",
      "target": "risks",
      "label": "OUTWEIGH"
    },
    {
      "source": "therapeutic advantages",
      "target": "individual cannabinoids",
      "label": "OVER"
    },
    {
      "source": "therapeutic advantages",
      "target": "selective L-type blockers",
      "label": "over"
    },
    {
      "source": "Cannabis",
      "target": "pharmacology",
      "label": "HAS_FIELD"
    },
    {
      "source": "Cannabis",
      "target": "clinical use",
      "label": "HAS_RATIONALE_FOR"
    },
    {
      "source": "Cannabis",
      "target": "therapeutic advantages",
      "label": "HAS"
    },
    {
      "source": "cannabinoids",
      "target": "pharmacology",
      "label": "HAS_FIELD"
    },
    {
      "source": "cannabinoids",
      "target": "clinical use",
      "label": "HAS_RATIONALE_FOR"
    },
    {
      "source": "cannabinoids",
      "target": "disorders",
      "label": "ARE_EFFECTIVE_AGAINST"
    },
    {
      "source": "pharmacology",
      "target": "exenatide",
      "label": "studied for"
    },
    {
      "source": "pharmacology",
      "target": "novel CCR5 antagonists",
      "label": "of"
    },
    {
      "source": "pharmacology",
      "target": "betaxolol",
      "label": "is reviewed for"
    },
    {
      "source": "pharmacology",
      "target": "levobunolol",
      "label": "is reviewed for"
    },
    {
      "source": "cannabinoid receptors",
      "target": "CB1 receptors",
      "label": "HAS_TYPE"
    },
    {
      "source": "cannabinoid receptors",
      "target": "CB2 receptors",
      "label": "HAS_TYPE"
    },
    {
      "source": "D 9 - tetrahydrocannabinol",
      "target": "cannabinoid CB1 receptor agonists",
      "label": "IS_A"
    },
    {
      "source": "D 9 - tetrahydrocannabinol",
      "target": "THC",
      "label": "ALSO_KNOWN_AS"
    },
    {
      "source": "Endogenous cannabinoid receptor agonists",
      "target": "endocannabinoids",
      "label": "ALSO_KNOWN_AS"
    },
    {
      "source": "nabilone",
      "target": "cannabinoid CB1 receptor agonists",
      "label": "IS_A"
    },
    {
      "source": "oral dose",
      "target": "patient",
      "label": "DIFFICULT_TO_PREDICT_FOR"
    },
    {
      "source": "patient",
      "target": "fenfluramine-associated primary pulmonary hypertension",
      "label": "has"
    },
    {
      "source": "patient",
      "target": "multiple carboxylase deficiency (MCD)",
      "label": "has"
    },
    {
      "source": "patient",
      "target": "BCS",
      "label": "has"
    },
    {
      "source": "patient",
      "target": "paroxysmal nocturnal hemoglobinuria",
      "label": "has"
    },
    {
      "source": "patient",
      "target": "eculizumab",
      "label": "receiving"
    },
    {
      "source": "patient",
      "target": "liver transplantation",
      "label": "undergoing"
    },
    {
      "source": "patient",
      "target": "PNH",
      "label": "has"
    },
    {
      "source": "patient",
      "target": "anti-complement antibody",
      "label": "treated with"
    },
    {
      "source": "patient",
      "target": "congenital hernia of Morgagni",
      "label": "had"
    },
    {
      "source": "patient",
      "target": "hypomethioninemia",
      "label": "had"
    },
    {
      "source": "patient",
      "target": "megaloblastic anemia",
      "label": "had"
    },
    {
      "source": "patient",
      "target": "stimuli",
      "label": "unresponsive to"
    },
    {
      "source": "patient",
      "target": "vitamin B12 concentrations",
      "label": "had normal"
    },
    {
      "source": "patient",
      "target": "hydroxocobalamin treatment",
      "label": "responded to"
    },
    {
      "source": "patient",
      "target": "intubation",
      "label": "required"
    },
    {
      "source": "patient",
      "target": "homocystinuria",
      "label": "had"
    },
    {
      "source": "patient",
      "target": "serum folate",
      "label": "had normal"
    },
    {
      "source": "patient",
      "target": "ventilation",
      "label": "required"
    },
    {
      "source": "patient",
      "target": "complete remission",
      "label": "entered"
    },
    {
      "source": "patient",
      "target": "chemotherapy",
      "label": "treated with"
    },
    {
      "source": "patient",
      "target": "AML of FAB M2",
      "label": "developed"
    },
    {
      "source": "CB2 receptor ligands",
      "target": "clinical applications",
      "label": "HAS"
    },
    {
      "source": "modes of administration",
      "target": "therapeutic potential",
      "label": "REQUIRED_FOR"
    },
    {
      "source": "antizyme",
      "target": "23-kDa protein",
      "label": "is a"
    },
    {
      "source": "antizyme",
      "target": "degradation",
      "label": "promotes"
    },
    {
      "source": "antizyme",
      "target": "ODC activity",
      "label": "inhibits"
    },
    {
      "source": "antizyme",
      "target": "ODC",
      "label": "binds to"
    },
    {
      "source": "protein",
      "target": "mouse ODC",
      "label": "has homology to"
    },
    {
      "source": "protein",
      "target": "primary human bronchial epithelial cells",
      "label": "expressed in"
    },
    {
      "source": "protein",
      "target": "enzyme superfamily",
      "label": "is part of"
    },
    {
      "source": "protein",
      "target": "malignant OSE cells",
      "label": "is differentially regulated in"
    },
    {
      "source": "protein",
      "target": "normal OSE cells",
      "label": "is differentially regulated compared with"
    },
    {
      "source": "protein",
      "target": "fatty acids",
      "label": "interacts with"
    },
    {
      "source": "protein",
      "target": "rabbit serum",
      "label": "is present in"
    },
    {
      "source": "protein",
      "target": "mouse serum",
      "label": "is present in"
    },
    {
      "source": "protein",
      "target": "bovine serum",
      "label": "is present in"
    },
    {
      "source": "protein",
      "target": "I alpha I",
      "label": "was identified as"
    },
    {
      "source": "protein",
      "target": "human serum",
      "label": "was purified from"
    },
    {
      "source": "protein",
      "target": "inter-alpha-inhibitor",
      "label": "was identified as"
    },
    {
      "source": "protein",
      "target": "TSG-6",
      "label": "binds"
    },
    {
      "source": "mouse ODC",
      "target": "lysine",
      "label": "contains"
    },
    {
      "source": "Antizyme inhibitor",
      "target": "ornithine decarboxylase",
      "label": "releases"
    },
    {
      "source": "Antizyme inhibitor",
      "target": "mouse fibroblasts",
      "label": "is induced in"
    },
    {
      "source": "ornithine decarboxylase",
      "target": "antizyme suppression",
      "label": "released from"
    },
    {
      "source": "Ornithine decarboxylase",
      "target": "spermidine",
      "label": "catalyses synthesis of"
    },
    {
      "source": "Ornithine decarboxylase",
      "target": "spermine",
      "label": "catalyses synthesis of"
    },
    {
      "source": "Ornithine decarboxylase",
      "target": "putrescine",
      "label": "catalyses synthesis of"
    },
    {
      "source": "Ornithine decarboxylase",
      "target": "polyamines",
      "label": "catalyses synthesis of"
    },
    {
      "source": "ODC molecules",
      "target": "degradation",
      "label": "tagged for"
    },
    {
      "source": "ODC molecules",
      "target": "antizyme",
      "label": "inactivated by"
    },
    {
      "source": "degradation",
      "target": "26 S proteasome",
      "label": "by"
    },
    {
      "source": "degradation",
      "target": "estrogen receptor",
      "label": "of"
    },
    {
      "source": "degradation",
      "target": "vitamin D",
      "label": "of"
    },
    {
      "source": "ODC reactivation",
      "target": "mouse fibroblasts",
      "label": "takes place in"
    },
    {
      "source": "ODC reactivation",
      "target": "transient transfection",
      "label": "upon"
    },
    {
      "source": "Antizyme",
      "target": "AZI",
      "label": "is inhibited by"
    },
    {
      "source": "Antizyme",
      "target": "antizyme inhibitor",
      "label": "is inhibited by"
    },
    {
      "source": "AZI",
      "target": "ODC",
      "label": "releases"
    },
    {
      "source": "AZI",
      "target": "ODC activity",
      "label": "has no"
    },
    {
      "source": "polyamines",
      "target": "ribosomal frameshifting",
      "label": "cause"
    },
    {
      "source": "polyamines",
      "target": "apoptosis",
      "label": "induce"
    },
    {
      "source": "polyamines",
      "target": "cell growth",
      "label": "essential for"
    },
    {
      "source": "polyamines",
      "target": "antizyme",
      "label": "induce synthesis of"
    },
    {
      "source": "ODC",
      "target": "spermidine",
      "label": "catalyses synthesis of"
    },
    {
      "source": "ODC",
      "target": "spermine",
      "label": "catalyses synthesis of"
    },
    {
      "source": "ODC",
      "target": "putrescine",
      "label": "catalyses synthesis of"
    },
    {
      "source": "ODC",
      "target": "antizyme suppression",
      "label": "released from"
    },
    {
      "source": "ODC",
      "target": "polyamines",
      "label": "catalyses synthesis of"
    },
    {
      "source": "mouse AZI cDNA",
      "target": "protein",
      "label": "encodes"
    },
    {
      "source": "ODC activity",
      "target": "cells",
      "label": "induced by stimulation of"
    },
    {
      "source": "ODC activity",
      "target": "feedback inhibition",
      "label": "subjected to"
    },
    {
      "source": "transient transfection",
      "target": "AZI-expressing plasmid construct",
      "label": "with"
    },
    {
      "source": "feedback inhibition",
      "target": "polyamines",
      "label": "by"
    },
    {
      "source": "cloning",
      "target": "mouse AZI cDNA",
      "label": "of"
    },
    {
      "source": "polyamine production",
      "target": "proliferation",
      "label": "needed for"
    },
    {
      "source": "polyamine production",
      "target": "cell growth",
      "label": "needed for"
    },
    {
      "source": "proliferation",
      "target": "Col1a1-Cnn1 mice",
      "label": "was decreased in"
    },
    {
      "source": "proliferation",
      "target": "cytoskeleton",
      "label": "decreased due to alterations in"
    },
    {
      "source": "proliferation",
      "target": "osteoblasts",
      "label": "of"
    },
    {
      "source": "AZI mRNA content",
      "target": "growth stimulation",
      "label": "increases upon"
    },
    {
      "source": "AZI mRNA content",
      "target": "ODC transcripts",
      "label": "earlier than"
    },
    {
      "source": "AZI synthesis",
      "target": "ODC molecules",
      "label": "rescuing"
    },
    {
      "source": "density of binding sites (Bmax)",
      "target": "saturation isotherms",
      "label": "determined from"
    },
    {
      "source": "density of binding sites (Bmax)",
      "target": "SEM",
      "label": "associated with"
    },
    {
      "source": "density of binding sites (Bmax)",
      "target": "[3H]dexamethasone",
      "label": "for"
    },
    {
      "source": "activation of transcription",
      "target": "dexamethasone stimulation",
      "label": "following"
    },
    {
      "source": "Northern blot analyses",
      "target": "glucocorticoid receptor mRNA",
      "label": "demonstrated expression of"
    },
    {
      "source": "glucocorticoid receptor mRNA",
      "target": "primary human bronchial epithelial cells",
      "label": "expressed in"
    },
    {
      "source": "equilibrium dissociation constant (Kd)",
      "target": "[3H]dexamethasone",
      "label": "for"
    },
    {
      "source": "equilibrium dissociation constant (Kd)",
      "target": "saturation isotherms",
      "label": "determined from"
    },
    {
      "source": "equilibrium dissociation constant (Kd)",
      "target": "SEM",
      "label": "associated with"
    },
    {
      "source": "primary cultures of human bronchial epithelial cells",
      "target": "glucocorticoid receptors",
      "label": "possess"
    },
    {
      "source": "glucocorticoid receptors",
      "target": "dexamethasone",
      "label": "activated by"
    },
    {
      "source": "glucocorticoid receptors",
      "target": "radioligand binding assay",
      "label": "activity shown using"
    },
    {
      "source": "glucocorticoid receptors",
      "target": "primary human bronchial epithelial cells",
      "label": "characterized in"
    },
    {
      "source": "glucocorticoid receptors",
      "target": "glucocorticoid-responsive reporter plasmid",
      "label": "assessed using"
    },
    {
      "source": "glucocorticoid receptors",
      "target": "glucocorticoids",
      "label": "confers responsiveness to"
    },
    {
      "source": "glucocorticoid receptors",
      "target": "ligand-activated transcriptional regulator",
      "label": "function as"
    },
    {
      "source": "RU-486",
      "target": "dexamethasone",
      "label": "counteracted effect of"
    },
    {
      "source": "RU-486",
      "target": "glucocorticoid receptor activation",
      "label": "counteracted"
    },
    {
      "source": "RU-486",
      "target": "glucocorticoid receptor antagonist",
      "label": "is a"
    },
    {
      "source": "dexamethasone",
      "target": "MCP-1 expression",
      "label": "Downregulator"
    },
    {
      "source": "dexamethasone",
      "target": "anti-inflammatory glucocorticoid hormone",
      "label": "is an"
    },
    {
      "source": "dexamethasone",
      "target": "wound tensile strength",
      "label": "reduced"
    },
    {
      "source": "dexamethasone",
      "target": "wounds",
      "label": "reduced tensile strength of"
    },
    {
      "source": "Bronchial epithelial cells",
      "target": "airway inflammation",
      "label": "play role in"
    },
    {
      "source": "Bronchial epithelial cells",
      "target": "inhaled steroids",
      "label": "target for"
    },
    {
      "source": "Transfection",
      "target": "activation of transcription",
      "label": "resulted in"
    },
    {
      "source": "Transfection",
      "target": "primary human bronchial epithelial cells",
      "label": "of"
    },
    {
      "source": "Transfection",
      "target": "pTAT3-CAT",
      "label": "with"
    },
    {
      "source": "airway epithelium",
      "target": "anti-inflammatory effects",
      "label": "target for"
    },
    {
      "source": "anti-inflammatory effects",
      "target": "inhaled steroids",
      "label": "of"
    },
    {
      "source": "anti-inflammatory effects",
      "target": "clopidogrel",
      "label": "are of"
    },
    {
      "source": "anti-inflammatory effects",
      "target": "pharmaceutical treatment",
      "label": "is central to"
    },
    {
      "source": "anti-inflammatory effects",
      "target": "neurons",
      "label": "affect"
    },
    {
      "source": "anti-inflammatory effects",
      "target": "cartilage",
      "label": "affect"
    },
    {
      "source": "anti-inflammatory effects",
      "target": "periodontal tissues",
      "label": "affect"
    },
    {
      "source": "Pharmacological characterization",
      "target": "primary human bronchial epithelial cells",
      "label": "in"
    },
    {
      "source": "Pharmacological characterization",
      "target": "glucocorticoid receptors",
      "label": "of"
    },
    {
      "source": "glucocorticoid-responsive reporter plasmid",
      "target": "pTAT3-CAT",
      "label": "is"
    },
    {
      "source": "mifepristone",
      "target": "glucocorticoid receptor activation",
      "label": "counteracted"
    },
    {
      "source": "mifepristone",
      "target": "glucocorticoid receptor antagonist",
      "label": "is a"
    },
    {
      "source": "mifepristone",
      "target": "dexamethasone",
      "label": "counteracted effect of"
    },
    {
      "source": "pharmacological specificity",
      "target": "[3H]dexamethasone",
      "label": "demonstrated for"
    },
    {
      "source": "dexamethasone effect",
      "target": "glucocorticoid receptors",
      "label": "mediated through"
    },
    {
      "source": "western blot analyses",
      "target": "protein",
      "label": "demonstrated expression of"
    },
    {
      "source": "western blot analyses",
      "target": "COX isozymes",
      "label": "determines expression of"
    },
    {
      "source": "western blot analyses",
      "target": "canine tissues",
      "label": "used for"
    },
    {
      "source": "High-affinity binding",
      "target": "[3H]dexamethasone",
      "label": "demonstrated for"
    },
    {
      "source": "Isoproterenol+chromanol 293B",
      "target": "spontaneous TdP",
      "label": "induces"
    },
    {
      "source": "Isoproterenol+chromanol 293B",
      "target": "transmural dispersion of repolarization (TDR)",
      "label": "increases"
    },
    {
      "source": "Isoproterenol+chromanol 293B",
      "target": "action potential duration at 90% repolarization (APD(90))",
      "label": "prolongs"
    },
    {
      "source": "Isoproterenol+chromanol 293B",
      "target": "stimulation-induced TdP",
      "label": "induces"
    },
    {
      "source": "LQT3",
      "target": "spontaneous TdP",
      "label": "associated with"
    },
    {
      "source": "LQT3",
      "target": "congenital long-QT syndrome",
      "label": "is a form of"
    },
    {
      "source": "LQT3",
      "target": "stimulation-induced TdP",
      "label": "associated with"
    },
    {
      "source": "LQT3",
      "target": "long-QT syndrome (LQTS)",
      "label": "is a model of"
    },
    {
      "source": "ATX-II",
      "target": "late I(Na)",
      "label": "augments"
    },
    {
      "source": "ATX-II",
      "target": "transmural dispersion of repolarization (TDR)",
      "label": "increases"
    },
    {
      "source": "ATX-II",
      "target": "stimulation-induced TdP",
      "label": "induces"
    },
    {
      "source": "ATX-II",
      "target": "action potential duration at 90% repolarization (APD(90))",
      "label": "prolongs"
    },
    {
      "source": "ATX-II",
      "target": "spontaneous TdP",
      "label": "induces"
    },
    {
      "source": "late I(Na)",
      "target": "LQT3",
      "label": "models"
    },
    {
      "source": "nicorandil",
      "target": "QT interval",
      "label": "abbreviates"
    },
    {
      "source": "nicorandil",
      "target": "torsade de pointes (TdP)",
      "label": "reverses induction of"
    },
    {
      "source": "nicorandil",
      "target": "action potential duration at 90% repolarization (APD(90))",
      "label": "reverses increase of"
    },
    {
      "source": "nicorandil",
      "target": "293B+/-isoproterenol",
      "label": "reverses effects of"
    },
    {
      "source": "nicorandil",
      "target": "K(+) channel opener",
      "label": "is a"
    },
    {
      "source": "nicorandil",
      "target": "transmural dispersion of repolarization (TDR)",
      "label": "reverses increase of"
    },
    {
      "source": "nicorandil",
      "target": "d-sotalol",
      "label": "reverses effects of"
    },
    {
      "source": "nicorandil",
      "target": "ATX-II",
      "label": "partially reverses effect of"
    },
    {
      "source": "LQT2",
      "target": "spontaneous TdP",
      "label": "associated with"
    },
    {
      "source": "LQT2",
      "target": "congenital long-QT syndrome",
      "label": "is a form of"
    },
    {
      "source": "LQT2",
      "target": "stimulation-induced TdP",
      "label": "associated with"
    },
    {
      "source": "LQT2",
      "target": "long-QT syndrome (LQTS)",
      "label": "is a model of"
    },
    {
      "source": "congenital long-QT syndrome",
      "target": "late I(Na)",
      "label": "caused by augmented"
    },
    {
      "source": "congenital long-QT syndrome",
      "target": "I(Ks)",
      "label": "caused by reduced"
    },
    {
      "source": "congenital long-QT syndrome",
      "target": "long-QT syndrome (LQTS)",
      "label": "is a type of"
    },
    {
      "source": "congenital long-QT syndrome",
      "target": "I(Kr)",
      "label": "caused by reduced"
    },
    {
      "source": "Transmembrane action potentials",
      "target": "endocardial cells",
      "label": "recorded from"
    },
    {
      "source": "Transmembrane action potentials",
      "target": "epicardial cells",
      "label": "recorded from"
    },
    {
      "source": "Transmembrane action potentials",
      "target": "M cells",
      "label": "recorded from"
    },
    {
      "source": "endocardial cells",
      "target": "canine left ventricle",
      "label": "part of"
    },
    {
      "source": "epicardial cells",
      "target": "canine left ventricle",
      "label": "part of"
    },
    {
      "source": "LQT1",
      "target": "long-QT syndrome (LQTS)",
      "label": "is a model of"
    },
    {
      "source": "LQT1",
      "target": "spontaneous TdP",
      "label": "associated with"
    },
    {
      "source": "LQT1",
      "target": "stimulation-induced TdP",
      "label": "associated with"
    },
    {
      "source": "LQT1",
      "target": "congenital long-QT syndrome",
      "label": "is a form of"
    },
    {
      "source": "d-sotalol",
      "target": "I(Kr)",
      "label": "blocks"
    },
    {
      "source": "d-sotalol",
      "target": "action potential duration at 90% repolarization (APD(90))",
      "label": "prolongs"
    },
    {
      "source": "d-sotalol",
      "target": "stimulation-induced TdP",
      "label": "induces"
    },
    {
      "source": "d-sotalol",
      "target": "spontaneous TdP",
      "label": "induces"
    },
    {
      "source": "d-sotalol",
      "target": "transmural dispersion of repolarization (TDR)",
      "label": "increases"
    },
    {
      "source": "I(Kr)",
      "target": "LQT2",
      "label": "models"
    },
    {
      "source": "M cells",
      "target": "canine left ventricle",
      "label": "part of"
    },
    {
      "source": "acquired LQTS",
      "target": "I(Kr)",
      "label": "caused by reduced"
    },
    {
      "source": "acquired LQTS",
      "target": "late I(Na)",
      "label": "caused by augmented"
    },
    {
      "source": "acquired LQTS",
      "target": "I(Ks)",
      "label": "caused by reduced"
    },
    {
      "source": "Isoproterenol",
      "target": "beta-adrenergic tone",
      "label": "mimics"
    },
    {
      "source": "I(Ks)",
      "target": "LQT1",
      "label": "models"
    },
    {
      "source": "K(+) channel opener",
      "target": "stimulation-induced TdP",
      "label": "prevents"
    },
    {
      "source": "K(+) channel opener",
      "target": "torsade de pointes (TdP)",
      "label": "prevents"
    },
    {
      "source": "K(+) channel opener",
      "target": "QT interval",
      "label": "abbreviates"
    },
    {
      "source": "K(+) channel opener",
      "target": "spontaneous TdP",
      "label": "prevents"
    },
    {
      "source": "K(+) channel opener",
      "target": "transmural dispersion of repolarization (TDR)",
      "label": "reduces"
    },
    {
      "source": "arterially perfused wedge",
      "target": "canine left ventricle",
      "label": "from"
    },
    {
      "source": "Chromanol 293B",
      "target": "I(Ks)",
      "label": "blocks"
    },
    {
      "source": "(-)-pindolol",
      "target": "5-HT1B",
      "label": "modulates transmission via actions at"
    },
    {
      "source": "(-)-pindolol",
      "target": "antidepressant agents",
      "label": "influences actions of"
    },
    {
      "source": "(-)-pindolol",
      "target": "NAD",
      "label": "did not enhance ability of duloxetine to elevate"
    },
    {
      "source": "(-)-pindolol",
      "target": "DA",
      "label": "enhanced ability of fluoxetine to elevate"
    },
    {
      "source": "(-)-pindolol",
      "target": "beta 1/2-ARs",
      "label": "modulates transmission via actions at"
    },
    {
      "source": "(-)-pindolol",
      "target": "beta 1/2-adrenergic receptors",
      "label": "possesses affinity for"
    },
    {
      "source": "(-)-pindolol",
      "target": "5-HT1A",
      "label": "modulates transmission via actions at"
    },
    {
      "source": "(-)-pindolol",
      "target": "dopamine",
      "label": "increased extracellular levels of"
    },
    {
      "source": "(-)-pindolol",
      "target": "5-HT reuptake inhibitors",
      "label": "potentiated increase in 5-HT elicited by"
    },
    {
      "source": "(-)-pindolol",
      "target": "frontal cortex",
      "label": "increased levels in"
    },
    {
      "source": "(-)-pindolol",
      "target": "noradrenaline",
      "label": "increased extracellular levels of"
    },
    {
      "source": "(-)-pindolol",
      "target": "5-HT1A receptors",
      "label": "facilitates transmission by stimulation of"
    },
    {
      "source": "(-)-pindolol",
      "target": "5-HT",
      "label": "modulates levels of"
    },
    {
      "source": "(-)-pindolol",
      "target": "serotonin",
      "label": "modulates levels of"
    },
    {
      "source": "(-)-pindolol",
      "target": "fluoxetine",
      "label": "potentiated increase in 5-HT elicited by"
    },
    {
      "source": "(-)-pindolol",
      "target": "duloxetine",
      "label": "potentiated increase in 5-HT elicited by"
    },
    {
      "source": "(-)-pindolol",
      "target": "accumbens",
      "label": "did not increase levels in"
    },
    {
      "source": "(-)-pindolol",
      "target": "striatum",
      "label": "did not increase levels in"
    },
    {
      "source": "(-)-pindolol",
      "target": "freely-moving rats",
      "label": "studied in"
    },
    {
      "source": "ICI118,551",
      "target": "NAD",
      "label": "did not increase basal levels of"
    },
    {
      "source": "ICI118,551",
      "target": "DA",
      "label": "did not increase basal levels of"
    },
    {
      "source": "ICI118,551",
      "target": "fluoxetine",
      "label": "did not affect actions of"
    },
    {
      "source": "ICI118,551",
      "target": "5-HT",
      "label": "did not increase basal levels of"
    },
    {
      "source": "ICI118,551",
      "target": "(-)-pindolol",
      "label": "blunted influence of"
    },
    {
      "source": "ICI118,551",
      "target": "beta 2-AR",
      "label": "is antagonist of"
    },
    {
      "source": "NAD",
      "target": "tammar wallaby liver",
      "label": "lower in"
    },
    {
      "source": "NAD",
      "target": "koala",
      "label": "higher in"
    },
    {
      "source": "NAD",
      "target": "rat liver",
      "label": "lower in"
    },
    {
      "source": "DA",
      "target": "D2 receptor sensitivity",
      "label": "decreases"
    },
    {
      "source": "DA",
      "target": "glutamatergic transmission",
      "label": "has effects on"
    },
    {
      "source": "WAY100,635",
      "target": "fluoxetine",
      "label": "did not potentiate increase in NAD elicited by"
    },
    {
      "source": "WAY100,635",
      "target": "5-HT1A receptors",
      "label": "is antagonist of"
    },
    {
      "source": "WAY100,635",
      "target": "NAD",
      "label": "attenuated (-)-pindolol-induced increase in"
    },
    {
      "source": "WAY100,635",
      "target": "DA",
      "label": "attenuated (-)-pindolol-induced increase in"
    },
    {
      "source": "fluoxetine",
      "target": "true serotonin syndrome",
      "label": "causes"
    },
    {
      "source": "fluoxetine",
      "target": "adverse effects",
      "label": "causes"
    },
    {
      "source": "fluoxetine",
      "target": "selegiline",
      "label": "combined with"
    },
    {
      "source": "betaxolol",
      "target": "fluoxetine",
      "label": "did not affect actions of"
    },
    {
      "source": "betaxolol",
      "target": "beta 1-AR",
      "label": "is antagonist of"
    },
    {
      "source": "betaxolol",
      "target": "5-HT",
      "label": "did not increase basal levels of"
    },
    {
      "source": "betaxolol",
      "target": "(-)-pindolol",
      "label": "blunted influence of"
    },
    {
      "source": "betaxolol",
      "target": "DA",
      "label": "did not increase basal levels of"
    },
    {
      "source": "betaxolol",
      "target": "NAD",
      "label": "did not increase basal levels of"
    },
    {
      "source": "betaxolol",
      "target": "cardioselective",
      "label": "is"
    },
    {
      "source": "betaxolol",
      "target": "beta-Blockers",
      "label": "is a type of"
    },
    {
      "source": "betaxolol",
      "target": "risk",
      "label": "has lower"
    },
    {
      "source": "betaxolol",
      "target": "glaucoma",
      "label": "is used for"
    },
    {
      "source": "betaxolol",
      "target": "beta-blocker",
      "label": "is a"
    },
    {
      "source": "betaxolol",
      "target": "timolol",
      "label": "is similar to"
    },
    {
      "source": "betaxolol",
      "target": "levobunolol",
      "label": "produces less beta 1-adrenergic receptor blockade than"
    },
    {
      "source": "betaxolol",
      "target": "primary open-angle glaucoma (POAG)",
      "label": "controls intraocular pressure (IOP) for"
    },
    {
      "source": "betaxolol",
      "target": "ocular hypertension (OHT)",
      "label": "controls intraocular pressure (IOP) for"
    },
    {
      "source": "betaxolol",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "betaxolol",
      "target": "beta-adrenergic blocking agents",
      "label": "is a type of"
    },
    {
      "source": "betaxolol",
      "target": "patients",
      "label": "is safer for"
    },
    {
      "source": "betaxolol",
      "target": "ophthalmic solutions",
      "label": "is marketed as"
    },
    {
      "source": "betaxolol",
      "target": "ophthalmic beta-blocking agents",
      "label": "is a type of"
    },
    {
      "source": "betaxolol",
      "target": "cardioselective beta-adrenergic blocker",
      "label": "is a"
    },
    {
      "source": "betaxolol",
      "target": "local ocular adverse reactions",
      "label": "causes"
    },
    {
      "source": "betaxolol",
      "target": "intraocular pressure (IOP)",
      "label": "reduces"
    },
    {
      "source": "SB224,289",
      "target": "5-HT1B receptors",
      "label": "is antagonist of"
    },
    {
      "source": "SB224,289",
      "target": "fluoxetine",
      "label": "did not potentiate increase in NAD elicited by"
    },
    {
      "source": "SB224,289",
      "target": "NAD",
      "label": "was ineffective on (-)-pindolol-induced increase in"
    },
    {
      "source": "SB224,289",
      "target": "DA",
      "label": "was ineffective on (-)-pindolol-induced increase in"
    },
    {
      "source": "5-HT1B receptors",
      "target": "(-)-pindolol",
      "label": "are not involved in (-)-pindolol's facilitation"
    },
    {
      "source": "5-HT1B receptors",
      "target": "antidepressant drugs",
      "label": "mediate effects of"
    },
    {
      "source": "5-HT1B receptors",
      "target": "5-HT1A receptors",
      "label": "more altered than"
    },
    {
      "source": "5-HT1B receptors",
      "target": "old mice",
      "label": "involved in"
    },
    {
      "source": "5-HT1B receptors",
      "target": "40-week-old mice",
      "label": "altered in"
    },
    {
      "source": "5-HT1B receptors",
      "target": "Antidepressant activity",
      "label": "involved in"
    },
    {
      "source": "5-HT1B receptors",
      "target": "brain region",
      "label": "located in"
    },
    {
      "source": "5-HT1B receptors",
      "target": "Satiating effect",
      "label": "mediate"
    },
    {
      "source": "5-HT1A receptors",
      "target": "40-week-old mice",
      "label": "altered in"
    },
    {
      "source": "5-HT1A receptors",
      "target": "Antidepressant activity",
      "label": "involved in"
    },
    {
      "source": "5-HT1A receptors",
      "target": "antidepressant drugs",
      "label": "mediate effects of"
    },
    {
      "source": "5-HT1A receptors",
      "target": "old mice",
      "label": "involved in"
    },
    {
      "source": "5-HT1A receptors",
      "target": "brain region",
      "label": "located in"
    },
    {
      "source": "hepatic nicotinamide cofactors",
      "target": "tammar wallaby",
      "label": "determined in"
    },
    {
      "source": "hepatic nicotinamide cofactors",
      "target": "koala",
      "label": "determined in"
    },
    {
      "source": "hepatic nicotinamide cofactors",
      "target": "rat",
      "label": "determined in"
    },
    {
      "source": "tammar wallaby",
      "target": "Macropus eugenii",
      "label": "is a species of"
    },
    {
      "source": "koala",
      "target": "Phascolarctos cinereus",
      "label": "is a species of"
    },
    {
      "source": "Cytochrome P450 4A",
      "target": "koala liver",
      "label": "present in"
    },
    {
      "source": "Reverse transcription",
      "target": "koala liver mRNA",
      "label": "performed on"
    },
    {
      "source": "Reverse transcription",
      "target": "polymerase chain reaction",
      "label": "followed by"
    },
    {
      "source": "Reverse transcription",
      "target": "cDNA clone",
      "label": "resulted in"
    },
    {
      "source": "peroxisomal enzymes",
      "target": "koala liver",
      "label": "present in"
    },
    {
      "source": "polymerase chain reaction",
      "target": "cDNA clone",
      "label": "resulted in"
    },
    {
      "source": "polymerase chain reaction",
      "target": "primers",
      "label": "used with"
    },
    {
      "source": "polymerase chain reaction",
      "target": "restriction fragment length polymorphism",
      "label": "with"
    },
    {
      "source": "cDNA clone",
      "target": "human CYP4A11",
      "label": "has deduced amino acid sequence identity to"
    },
    {
      "source": "Microsomal lauric acid hydroxylation",
      "target": "tammar wallaby",
      "label": "lower in"
    },
    {
      "source": "Microsomal lauric acid hydroxylation",
      "target": "rat",
      "label": "lower in"
    },
    {
      "source": "Microsomal lauric acid hydroxylation",
      "target": "koala",
      "label": "higher in"
    },
    {
      "source": "CYP",
      "target": "CYP4A15",
      "label": "named"
    },
    {
      "source": "NAD/nicotinamide-adenine dinucleotide phosphate",
      "target": "tammar wallaby liver",
      "label": "lower in"
    },
    {
      "source": "NAD/nicotinamide-adenine dinucleotide phosphate",
      "target": "koala",
      "label": "higher in"
    },
    {
      "source": "NAD/nicotinamide-adenine dinucleotide phosphate",
      "target": "rat liver",
      "label": "lower in"
    },
    {
      "source": "cyanide-insensitive palmitoyl-CoA oxidation",
      "target": "koala",
      "label": "absent in"
    },
    {
      "source": "cyanide-insensitive palmitoyl coenzyme A oxidative activity",
      "target": "tammar wallaby",
      "label": "examined in"
    },
    {
      "source": "cyanide-insensitive palmitoyl coenzyme A oxidative activity",
      "target": "koala",
      "label": "examined in"
    },
    {
      "source": "cyanide-insensitive palmitoyl coenzyme A oxidative activity",
      "target": "rat",
      "label": "compared to"
    },
    {
      "source": "hepatic nicotinamide-adenine dinucleotide",
      "target": "NAD",
      "label": "is also known as"
    },
    {
      "source": "primers",
      "target": "CYP4A family",
      "label": "based on"
    },
    {
      "source": "primers",
      "target": "sequential reactions",
      "label": "for"
    },
    {
      "source": "microsomal lauric acid hydroxylase activity",
      "target": "tammar wallaby",
      "label": "examined in"
    },
    {
      "source": "microsomal lauric acid hydroxylase activity",
      "target": "koala",
      "label": "examined in"
    },
    {
      "source": "microsomal lauric acid hydroxylase activity",
      "target": "rat",
      "label": "compared to"
    },
    {
      "source": "nicotinamide cofactors",
      "target": "koala liver",
      "label": "present in"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "multitargeted antifolate",
      "label": "is a type of"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "Gemcitabine",
      "label": "is used in combination with"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "metastatic breast cancer",
      "label": "is evaluated in combination for treatment of"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "thymidylate synthase",
      "label": "inhibits"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "solid tumors",
      "label": "is active in"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "glycinamide ribonucleotide formyl transferase",
      "label": "inhibits"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "dihydrofolate reductase",
      "label": "inhibits"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "breast cancer",
      "label": "treats"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "Alimta",
      "label": "has alias"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "Gemzar",
      "label": "is used in combination with"
    },
    {
      "source": "Pemetrexed disodium",
      "target": "LY231514",
      "label": "has alias"
    },
    {
      "source": "LY231514",
      "target": "dihydrofolate reductase",
      "label": "inhibits"
    },
    {
      "source": "LY231514",
      "target": "breast cancer",
      "label": "is active in"
    },
    {
      "source": "LY231514",
      "target": "thymidylate synthase",
      "label": "inhibits"
    },
    {
      "source": "LY231514",
      "target": "solid tumors",
      "label": "is active in"
    },
    {
      "source": "LY231514",
      "target": "multitargeted antifolate",
      "label": "is a type of"
    },
    {
      "source": "LY231514",
      "target": "glycinamide ribonucleotide formyl transferase",
      "label": "inhibits"
    },
    {
      "source": "Gemcitabine",
      "target": "breast cancer",
      "label": "treats"
    },
    {
      "source": "Gemcitabine",
      "target": "metastatic breast cancer",
      "label": "is evaluated in combination for treatment of"
    },
    {
      "source": "Gemcitabine",
      "target": "Gemzar",
      "label": "has alias"
    },
    {
      "source": "Gemcitabine",
      "target": "non-small cell lung cancers",
      "label": "approved for treatment of"
    },
    {
      "source": "Gemcitabine",
      "target": "pyrimidine nucleoside antimetabolite",
      "label": "is a type of"
    },
    {
      "source": "Gemcitabine",
      "target": "pancreatic",
      "label": "approved for treatment of"
    },
    {
      "source": "solid tumors",
      "target": "prostate",
      "label": "include"
    },
    {
      "source": "solid tumors",
      "target": "colon",
      "label": "include"
    },
    {
      "source": "solid tumors",
      "target": "pancreas",
      "label": "include"
    },
    {
      "source": "Alimta",
      "target": "solid tumors",
      "label": "is active in"
    },
    {
      "source": "Alimta",
      "target": "thymidylate synthase",
      "label": "inhibits"
    },
    {
      "source": "Alimta",
      "target": "multitargeted antifolate",
      "label": "is a type of"
    },
    {
      "source": "Alimta",
      "target": "glycinamide ribonucleotide formyl transferase",
      "label": "inhibits"
    },
    {
      "source": "Alimta",
      "target": "dihydrofolate reductase",
      "label": "inhibits"
    },
    {
      "source": "Alimta",
      "target": "breast cancer",
      "label": "is active in"
    },
    {
      "source": "women",
      "target": "endometriosis",
      "label": "have"
    },
    {
      "source": "women",
      "target": "infertility",
      "label": "present with"
    },
    {
      "source": "women",
      "target": "pelvic pain",
      "label": "present with"
    },
    {
      "source": "women",
      "target": "HER2-positive, locally advanced breast cancer",
      "label": "diagnosed with"
    },
    {
      "source": "women",
      "target": "MBC",
      "label": "diagnosed with"
    },
    {
      "source": "women",
      "target": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "label": "are affected by"
    },
    {
      "source": "women",
      "target": "men",
      "label": "are more frequently affected than"
    },
    {
      "source": "women",
      "target": "mean serum creatinine concentration (Scr)",
      "label": "have"
    },
    {
      "source": "women",
      "target": "mean 24-hour measured creatinine clearance (mClcr)",
      "label": "have"
    },
    {
      "source": "women",
      "target": "mean \u00b1 SD age",
      "label": "have"
    },
    {
      "source": "endometriosis",
      "target": "laparoscopy",
      "label": "diagnosed by"
    },
    {
      "source": "GnRH agonist",
      "target": "hormonal agents",
      "label": "is a type of"
    },
    {
      "source": "hormonal agents",
      "target": "direct regulatory action",
      "label": "exert"
    },
    {
      "source": "hormonal agents",
      "target": "medical treatment",
      "label": "used in"
    },
    {
      "source": "hormonal agents",
      "target": "MCP-1 expression",
      "label": "affect"
    },
    {
      "source": "MCP-1 expression",
      "target": "protein",
      "label": "analyzed at level of"
    },
    {
      "source": "MCP-1 expression",
      "target": "messenger RNA",
      "label": "analyzed at level of"
    },
    {
      "source": "MCP-1 expression",
      "target": "endometrial epithelial cells",
      "label": "occurs in"
    },
    {
      "source": "endometrial epithelial cells",
      "target": "women",
      "label": "from"
    },
    {
      "source": "danazol",
      "target": "testosterone analog",
      "label": "is a"
    },
    {
      "source": "danazol",
      "target": "MCP-1 expression",
      "label": "Downregulator"
    },
    {
      "source": "danazol",
      "target": "hormonal agents",
      "label": "is a type of"
    },
    {
      "source": "direct regulatory action",
      "target": "MCP-1 expression",
      "label": "on"
    },
    {
      "source": "epithelial cells",
      "target": "human endometrium",
      "label": "isolated from"
    },
    {
      "source": "epithelial cells",
      "target": "urinary organs",
      "label": "are of"
    },
    {
      "source": "epithelial cells",
      "target": "digestive organs",
      "label": "are of"
    },
    {
      "source": "primary cultures",
      "target": "steroid hormone analogs",
      "label": "exposed to"
    },
    {
      "source": "primary cultures",
      "target": "cytokines",
      "label": "exposed to"
    },
    {
      "source": "primary cultures",
      "target": "epithelial cells",
      "label": "consist of"
    },
    {
      "source": "secretion",
      "target": "enzyme-linked immunosorbent assay",
      "label": "measured by"
    },
    {
      "source": "secretion",
      "target": "MCP-1 protein",
      "label": "of"
    },
    {
      "source": "secretion",
      "target": "KCl",
      "label": "stimulated by"
    },
    {
      "source": "secretion",
      "target": "VGLUT1-/- knockout mice",
      "label": "absent in"
    },
    {
      "source": "secretion",
      "target": "Ca2+",
      "label": "dependent on"
    },
    {
      "source": "secretion",
      "target": "ATP",
      "label": "stimulated by"
    },
    {
      "source": "secretion",
      "target": "vascular endothelial growth factor",
      "label": "of"
    },
    {
      "source": "hormonal treatments",
      "target": "endometriosis",
      "label": "act on"
    },
    {
      "source": "hormonal treatments",
      "target": "clinical manifestations",
      "label": "influence"
    },
    {
      "source": "hormonal treatments",
      "target": "mechanisms",
      "label": "act by"
    },
    {
      "source": "mRNA steady-state levels",
      "target": "Northern blot analysis",
      "label": "measured by"
    },
    {
      "source": "cytokines",
      "target": "nitric oxide",
      "label": "induce"
    },
    {
      "source": "cytokines",
      "target": "skin homogenates",
      "label": "are determined in"
    },
    {
      "source": "cytokines",
      "target": "soluble factors",
      "label": "is a type of"
    },
    {
      "source": "cytokines",
      "target": "PGH synthase-2",
      "label": "induces"
    },
    {
      "source": "messenger RNA",
      "target": "thyroglobulin gene",
      "label": "is of"
    },
    {
      "source": "Endometrial tissue biopsy",
      "target": "laparoscopy",
      "label": "performed at"
    },
    {
      "source": "dose-dependent inhibitory effect",
      "target": "protein",
      "label": "occurred at level of"
    },
    {
      "source": "dose-dependent inhibitory effect",
      "target": "messenger RNA",
      "label": "occurred at level of"
    },
    {
      "source": "PATIENT(S)",
      "target": "women",
      "label": "are"
    },
    {
      "source": "Buserelin acetate",
      "target": "MCP-1 expression",
      "label": "had no significant effect on"
    },
    {
      "source": "Buserelin acetate",
      "target": "GnRH agonist",
      "label": "Agonist"
    },
    {
      "source": "medical treatment",
      "target": "endometriosis",
      "label": "for"
    },
    {
      "source": "medical treatment",
      "target": "thyroid cancer",
      "label": "of"
    },
    {
      "source": "mechanisms",
      "target": "adhesive interaction",
      "label": "are other than"
    },
    {
      "source": "mechanisms",
      "target": "expression",
      "label": "regulate"
    },
    {
      "source": "mechanisms",
      "target": "antitumor activity",
      "label": "important for"
    },
    {
      "source": "mechanisms",
      "target": "variability",
      "label": "for"
    },
    {
      "source": "mechanisms",
      "target": "susceptibility",
      "label": "regulate"
    },
    {
      "source": "mechanisms",
      "target": "biologic effects",
      "label": "account for"
    },
    {
      "source": "mechanisms",
      "target": "calcium",
      "label": "involve"
    },
    {
      "source": "mechanisms",
      "target": "multi-enzymes",
      "label": "involve"
    },
    {
      "source": "mechanisms",
      "target": "reduced glutathione",
      "label": "involve"
    },
    {
      "source": "mechanisms",
      "target": "adenosine triphosphate",
      "label": "involve"
    },
    {
      "source": "mechanisms",
      "target": "scavenging activity",
      "label": "involve"
    },
    {
      "source": "mechanisms",
      "target": "ion uptake",
      "label": "of"
    },
    {
      "source": "mechanisms",
      "target": "high salt intake",
      "label": "underlie"
    },
    {
      "source": "mechanisms",
      "target": "cardiovascular effects",
      "label": "underlie"
    },
    {
      "source": "menadione-induced hepatic oxidative damage",
      "target": "mice",
      "label": "occurred in"
    },
    {
      "source": "DTD activity",
      "target": "menadione elimination",
      "label": "associated with"
    },
    {
      "source": "DTD activity",
      "target": "hepatocytes",
      "label": "is found in"
    },
    {
      "source": "menadione elimination",
      "target": "hepatocyte culture",
      "label": "occurred in"
    },
    {
      "source": "Sch B pretreatment",
      "target": "plasma alanine aminotransferase activity",
      "label": "decreased"
    },
    {
      "source": "Sch B pretreatment",
      "target": "hepatic malondialdehyde level",
      "label": "decreased"
    },
    {
      "source": "Sch B pretreatment",
      "target": "hepatoprotection",
      "label": "afforded"
    },
    {
      "source": "Sch B pretreatment",
      "target": "menadione hepatotoxicity",
      "label": "provides protection against"
    },
    {
      "source": "Sch B pretreatment",
      "target": "hepatocellular DTD activity",
      "label": "enhanced"
    },
    {
      "source": "Sch B pretreatment",
      "target": "menadione-induced hepatic oxidative damage",
      "label": "protected against"
    },
    {
      "source": "Schisandrin B",
      "target": "DT-diaphorase activity",
      "label": "enhances"
    },
    {
      "source": "Schisandrin B",
      "target": "menadione-induced hepatotoxicity",
      "label": "protects against"
    },
    {
      "source": "DT-diaphorase activity",
      "target": "hepatocytes",
      "label": "is found in"
    },
    {
      "source": "schisandrin B",
      "target": "Sch B pretreatment",
      "label": "is used in"
    },
    {
      "source": "schisandrin B",
      "target": "dibenzocyclooctadiene derivative",
      "label": "is a"
    },
    {
      "source": "Sch B",
      "target": "Sch B pretreatment",
      "label": "is used in"
    },
    {
      "source": "Sch B",
      "target": "dibenzocyclooctadiene derivative",
      "label": "is a"
    },
    {
      "source": "mice",
      "target": "exercise training",
      "label": "sacrificed after"
    },
    {
      "source": "mice",
      "target": "treatment groups",
      "label": "belong to"
    },
    {
      "source": "mice",
      "target": "brain and behavioral abnormalities",
      "label": "display"
    },
    {
      "source": "mice",
      "target": "gamma-glutamyl carboxylase",
      "label": "lack"
    },
    {
      "source": "mice",
      "target": "guanidinoacetate methyltransferase",
      "label": "lacking"
    },
    {
      "source": "mice",
      "target": "CTSK",
      "label": "are deficient in"
    },
    {
      "source": "mice",
      "target": "isoproterenol",
      "label": "injected with"
    },
    {
      "source": "mice",
      "target": "propranolol",
      "label": "injected with"
    },
    {
      "source": "mice",
      "target": "GFJ",
      "label": "pretreated by"
    },
    {
      "source": "mice",
      "target": "MDZ",
      "label": "orally administered"
    },
    {
      "source": "mice",
      "target": "vehicle",
      "label": "pretreated by"
    },
    {
      "source": "mice",
      "target": "grapefruit juice",
      "label": "pretreated by"
    },
    {
      "source": "mice",
      "target": "tap water",
      "label": "pretreated by"
    },
    {
      "source": "mice",
      "target": "midazolam",
      "label": "orally administered"
    },
    {
      "source": "mice",
      "target": "TRZ",
      "label": "orally administered"
    },
    {
      "source": "mice",
      "target": "triazolam",
      "label": "orally administered"
    },
    {
      "source": "mice",
      "target": "RDX",
      "label": "exposed to"
    },
    {
      "source": "mice",
      "target": "normal group",
      "label": "divided into"
    },
    {
      "source": "mice",
      "target": "obesity group",
      "label": "divided into"
    },
    {
      "source": "mice",
      "target": "high-fat diet",
      "label": "fed with"
    },
    {
      "source": "mice",
      "target": "induced acute-colitis",
      "label": "have"
    },
    {
      "source": "mice",
      "target": "experimental groups",
      "label": "assigned to"
    },
    {
      "source": "mice",
      "target": "weight loss",
      "label": "observed for"
    },
    {
      "source": "mice",
      "target": "signs of EAE",
      "label": "observed for"
    },
    {
      "source": "biochemical mechanism",
      "target": "hepatoprotection",
      "label": "involved in"
    },
    {
      "source": "DTD",
      "target": "DTD activity",
      "label": "has"
    },
    {
      "source": "dibenzocyclooctadiene derivative",
      "target": "fruit of Schisandra chinensis",
      "label": "isolated from"
    },
    {
      "source": "hepatocytes",
      "target": "Sch B pretreated rats",
      "label": "isolated from"
    },
    {
      "source": "Sch B pretreated rats",
      "target": "DTD activity",
      "label": "increased"
    },
    {
      "source": "DT-diaphorase",
      "target": "DT-diaphorase activity",
      "label": "has"
    },
    {
      "source": "cyclo-oxygenase-2 (COX-2) expression",
      "target": "uninvolved mucosa",
      "label": "is found in"
    },
    {
      "source": "cyclo-oxygenase-2 (COX-2) expression",
      "target": "excess",
      "label": "showed"
    },
    {
      "source": "inhibition of intermediate biomarkers",
      "target": "distal bowel",
      "label": "is greater in"
    },
    {
      "source": "effective protective agent",
      "target": "experimental models of colon carcinogenesis",
      "label": "is effective in"
    },
    {
      "source": "chemopreventive efficacy",
      "target": "nabumetone",
      "label": "is of"
    },
    {
      "source": "nabumetone",
      "target": "complex ACF",
      "label": "reduced"
    },
    {
      "source": "nabumetone",
      "target": "dose-dependent inhibition",
      "label": "caused"
    },
    {
      "source": "nabumetone",
      "target": "reductions",
      "label": "resulted in"
    },
    {
      "source": "nabumetone",
      "target": "effective protective agent",
      "label": "is an"
    },
    {
      "source": "nabumetone",
      "target": "intestinal tumors",
      "label": "suppressed"
    },
    {
      "source": "nabumetone",
      "target": "azoxymethane (AOM)-treated Fisher 344 rats",
      "label": "was tested in"
    },
    {
      "source": "nabumetone",
      "target": "500 mg daily",
      "label": "administered at"
    },
    {
      "source": "nabumetone",
      "target": "cyclooxygenase activity",
      "label": "inhibits"
    },
    {
      "source": "nabumetone",
      "target": "prostanoid biosynthesis",
      "label": "affects"
    },
    {
      "source": "nabumetone",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "nabumetone",
      "target": "healthy subjects",
      "label": "inhibits in"
    },
    {
      "source": "nabumetone",
      "target": "steady state",
      "label": "reaches"
    },
    {
      "source": "nabumetone",
      "target": "dose-dependent reduction",
      "label": "causes"
    },
    {
      "source": "nabumetone",
      "target": "anti-inflammatory drug",
      "label": "is a type of"
    },
    {
      "source": "nabumetone",
      "target": "ex vivo",
      "label": "inhibits"
    },
    {
      "source": "nabumetone",
      "target": "1000 mg daily",
      "label": "administered at"
    },
    {
      "source": "excess",
      "target": "AOM-treated rats",
      "label": "was observed in"
    },
    {
      "source": "excess",
      "target": "MIN mice",
      "label": "was observed in"
    },
    {
      "source": "excess",
      "target": "proximal bowel",
      "label": "is relative to"
    },
    {
      "source": "excess",
      "target": "distal bowel",
      "label": "is in"
    },
    {
      "source": "Nabumetone",
      "target": "2 models of experimental colon carcinogenesis",
      "label": "was evaluated in"
    },
    {
      "source": "Nabumetone",
      "target": "conventional NSAIDs",
      "label": "is safer than"
    },
    {
      "source": "excess of PPAR-delta",
      "target": "pre-neoplastic mucosa",
      "label": "is in"
    },
    {
      "source": "excess of PPAR-delta",
      "target": "distal colon",
      "label": "is in"
    },
    {
      "source": "chemoprevention",
      "target": "colon cancer",
      "label": "is of"
    },
    {
      "source": "chemoprevention",
      "target": "experimental colon carcinogenesis",
      "label": "is of"
    },
    {
      "source": "chemoprevention",
      "target": "non-steroidal anti-inflammatory drug nabumetone",
      "label": "is achieved by"
    },
    {
      "source": "peroxisome proliferator-activated receptor-delta (PPAR-delta)",
      "target": "up-regulation",
      "label": "demonstrated"
    },
    {
      "source": "peroxisome proliferator-activated receptor-delta (PPAR-delta)",
      "target": "putative NSAID target",
      "label": "is a"
    },
    {
      "source": "up-regulation",
      "target": "AOM-induced colonic tumorigenesis",
      "label": "occurred during"
    },
    {
      "source": "up-regulation",
      "target": "EMT",
      "label": "leads to"
    },
    {
      "source": "up-regulation",
      "target": "TAM-induced EMT",
      "label": "mediates"
    },
    {
      "source": "up-regulation",
      "target": "down-regulation of miR-200",
      "label": "leads to"
    },
    {
      "source": "Distal bowel selectivity",
      "target": "chemoprevention",
      "label": "is involved in"
    },
    {
      "source": "non-steroidal anti-inflammatory drugs (NSAIDs)",
      "target": "gastro-intestinal toxicity",
      "label": "have potential"
    },
    {
      "source": "non-steroidal anti-inflammatory drugs (NSAIDs)",
      "target": "chemoprevention",
      "label": "are used for"
    },
    {
      "source": "gastro-intestinal toxicity",
      "target": "chemoprevention",
      "label": "hinders"
    },
    {
      "source": "reductions",
      "target": "interaction",
      "label": "of"
    },
    {
      "source": "reductions",
      "target": "C(max)",
      "label": "observed in"
    },
    {
      "source": "reductions",
      "target": "AUC(0-\u221e)",
      "label": "observed in"
    },
    {
      "source": "striking distal predilection of nabumetone",
      "target": "distal bowel over-expression of COX-2 and PPAR-delta",
      "label": "is explained by"
    },
    {
      "source": "MIN mice studies",
      "target": "chemopreventive efficacy",
      "label": "confirmed"
    },
    {
      "source": "regional selectivity",
      "target": "cyclo-oxygenase-2 (COX-2) expression",
      "label": "was evaluated by assessing"
    },
    {
      "source": "electrochemical gradient",
      "target": "mitochondrial respiration",
      "label": "develops_during"
    },
    {
      "source": "electrochemical gradient",
      "target": "ATP synthesis",
      "label": "develops_at_expense_of"
    },
    {
      "source": "UCP-3 induction",
      "target": "PPARalpha mRNA",
      "label": "correlated_with"
    },
    {
      "source": "UCP-3 induction",
      "target": "oxidation of fatty acids",
      "label": "indicates"
    },
    {
      "source": "UCP-3 induction",
      "target": "RXRalpha mRNA",
      "label": "correlated_with"
    },
    {
      "source": "UCP-3",
      "target": "fatty acids",
      "label": "involved_in_regulation_of"
    },
    {
      "source": "fatty acids",
      "target": "fuel substrates",
      "label": "is_a"
    },
    {
      "source": "fatty acids",
      "target": "gas chromatography",
      "label": "not detected by"
    },
    {
      "source": "fatty acids",
      "target": "holo-alpha-lactalbumin",
      "label": "not bound to"
    },
    {
      "source": "Uncoupling proteins",
      "target": "H(+) ions",
      "label": "acts_as_pores_for"
    },
    {
      "source": "Uncoupling proteins",
      "target": "electrochemical gradient",
      "label": "dissipates"
    },
    {
      "source": "Uncoupling proteins",
      "target": "inner mitochondrial membrane transporters",
      "label": "is_a"
    },
    {
      "source": "Peroxisome proliferator-activated receptor alpha",
      "target": "PPARalpha activators",
      "label": "is_a"
    },
    {
      "source": "PPARalpha activators",
      "target": "UCP-3 mRNA",
      "label": "up-regulated"
    },
    {
      "source": "Wy-14,643",
      "target": "PPARalpha activators",
      "label": "is_a"
    },
    {
      "source": "Wy-14,643",
      "target": "uncoupling protein-3 mRNA",
      "label": "increases"
    },
    {
      "source": "Wy-14,643",
      "target": "fibrates",
      "label": "is_a"
    },
    {
      "source": "Wy-14,643",
      "target": "UCP-3 expression",
      "label": "caused"
    },
    {
      "source": "Wy-14,643",
      "target": "mitochondrial membrane potential",
      "label": "No_Effect_On"
    },
    {
      "source": "bezafibrate",
      "target": "fibrates",
      "label": "is_a"
    },
    {
      "source": "bezafibrate",
      "target": "mitochondrial membrane potential",
      "label": "No_Effect_On"
    },
    {
      "source": "bezafibrate",
      "target": "UCP-3 induction",
      "label": "leads_to"
    },
    {
      "source": "bezafibrate",
      "target": "UCP-2 mRNA",
      "label": "modified"
    },
    {
      "source": "bezafibrate",
      "target": "uncoupling protein-3 mRNA",
      "label": "increases"
    },
    {
      "source": "bezafibrate",
      "target": "PPARalpha activators",
      "label": "is_a"
    },
    {
      "source": "mitochondrial membrane potential",
      "target": "MMP",
      "label": "is"
    },
    {
      "source": "Wy-14,643 treatment",
      "target": "mitochondrial membrane potential",
      "label": "No_Effect_On"
    },
    {
      "source": "preadipocytes",
      "target": "UCP-3 induction",
      "label": "showed_induction_of"
    },
    {
      "source": "preadipocytes",
      "target": "adipocytes",
      "label": "converts_to"
    },
    {
      "source": "preadipocytes",
      "target": "RXRalpha mRNA",
      "label": "has_higher_expression_of"
    },
    {
      "source": "preadipocytes",
      "target": "PPARalpha mRNA",
      "label": "has_higher_expression_of"
    },
    {
      "source": "preadipocytes",
      "target": "LPL",
      "label": "exhibited decreased"
    },
    {
      "source": "preadipocytes",
      "target": "controls",
      "label": "compared to"
    },
    {
      "source": "preadipocytes",
      "target": "PPAR\u03b3",
      "label": "exhibited decreased"
    },
    {
      "source": "preadipocytes",
      "target": "C/EBP\u03b1",
      "label": "exhibited decreased"
    },
    {
      "source": "preadipocytes",
      "target": "E2F1",
      "label": "exhibited decreased"
    },
    {
      "source": "preadipocytes",
      "target": "leptin",
      "label": "exhibited decreased"
    },
    {
      "source": "preadipocytes",
      "target": "adiponectin",
      "label": "exhibited increased"
    },
    {
      "source": "preadipocytes",
      "target": "SIRT1",
      "label": "exhibited increased"
    },
    {
      "source": "bezafibrate treatment",
      "target": "UCP-3 induction",
      "label": "resulted_in"
    },
    {
      "source": "bezafibrate treatment",
      "target": "mitochondrial membrane potential",
      "label": "No_Effect_On"
    },
    {
      "source": "UCPs",
      "target": "H(+) ions",
      "label": "acts_as_pores_for"
    },
    {
      "source": "UCPs",
      "target": "electrochemical gradient",
      "label": "dissipates"
    },
    {
      "source": "UCPs",
      "target": "inner mitochondrial membrane transporters",
      "label": "is_a"
    },
    {
      "source": "UCP-3 expression",
      "target": "mitochondrial membrane potential",
      "label": "No_Effect_On"
    },
    {
      "source": "adipocytes",
      "target": "UCP-3 induction",
      "label": "showed_induction_of"
    },
    {
      "source": "adipocytes",
      "target": "adiponectin",
      "label": "exhibited increased"
    },
    {
      "source": "adipocytes",
      "target": "SIRT1",
      "label": "exhibited increased"
    },
    {
      "source": "adipocytes",
      "target": "C/EBP\u03b1",
      "label": "exhibited decreased"
    },
    {
      "source": "adipocytes",
      "target": "PPAR\u03b3",
      "label": "exhibited decreased"
    },
    {
      "source": "adipocytes",
      "target": "controls",
      "label": "compared to"
    },
    {
      "source": "adipocytes",
      "target": "E2F1",
      "label": "exhibited decreased"
    },
    {
      "source": "adipocytes",
      "target": "leptin",
      "label": "exhibited decreased"
    },
    {
      "source": "adipocytes",
      "target": "LPL",
      "label": "exhibited decreased"
    },
    {
      "source": "Wy-14, 643",
      "target": "UCP-3 induction",
      "label": "leads_to"
    },
    {
      "source": "PPARalpha",
      "target": "PPARalpha activators",
      "label": "is_a"
    },
    {
      "source": "oxidation of fatty acids",
      "target": "triglycerides",
      "label": "limits_storage_as"
    },
    {
      "source": "5-HT1A receptor agonists",
      "target": "antidepressant drugs",
      "label": "tested with"
    },
    {
      "source": "antidepressant drugs",
      "target": "4-week-old male mice",
      "label": "action investigated in"
    },
    {
      "source": "antidepressant drugs",
      "target": "40-week-old male mice",
      "label": "action investigated in"
    },
    {
      "source": "antidepressant drugs",
      "target": "4-week-old mice",
      "label": "active in"
    },
    {
      "source": "antidepressant drugs",
      "target": "40-week-old mice",
      "label": "active in"
    },
    {
      "source": "antidepressant drugs",
      "target": "mouse forced swimming test",
      "label": "action investigated using"
    },
    {
      "source": "antidepressant drugs",
      "target": "NET",
      "label": "Regulator"
    },
    {
      "source": "buspirone",
      "target": "partial 5-HT1A agonist",
      "label": "is a"
    },
    {
      "source": "buspirone",
      "target": "antidepressant-like effects",
      "label": "enhanced"
    },
    {
      "source": "buspirone",
      "target": "fluvoxamine",
      "label": "enhanced effects of"
    },
    {
      "source": "buspirone",
      "target": "elderly mice",
      "label": "enhanced effects in"
    },
    {
      "source": "buspirone",
      "target": "sertraline",
      "label": "did not enhance effects of"
    },
    {
      "source": "buspirone",
      "target": "4-week-old mice",
      "label": "enhanced effects in"
    },
    {
      "source": "tricyclic",
      "target": "4-week-old mice",
      "label": "more active in"
    },
    {
      "source": "tricyclic",
      "target": "40-week-old mice",
      "label": "less active in"
    },
    {
      "source": "selective serotonin reuptake inhibitors",
      "target": "mouse forced swimming test",
      "label": "inactive in"
    },
    {
      "source": "selective serotonin reuptake inhibitors",
      "target": "40-week-old male mice",
      "label": "inactive in"
    },
    {
      "source": "selective serotonin reuptake inhibitors",
      "target": "SSRIs",
      "label": "is also known as"
    },
    {
      "source": "maprotiline",
      "target": "noradrenline reuptake inhibitor",
      "label": "is a"
    },
    {
      "source": "serotonin reuptake inhibitors",
      "target": "40-week-old mice",
      "label": "less active in"
    },
    {
      "source": "serotonin reuptake inhibitors",
      "target": "4-week-old mice",
      "label": "more active in"
    },
    {
      "source": "anti-immobility effect",
      "target": "antidepressant administration",
      "label": "occurs after"
    },
    {
      "source": "anti-immobility effect",
      "target": "40-week-old male mice",
      "label": "lower in"
    },
    {
      "source": "anti-immobility effect",
      "target": "4-week-old male mice",
      "label": "higher in"
    },
    {
      "source": "Antidepressant activity",
      "target": "forced swimming test",
      "label": "studied using"
    },
    {
      "source": "Antidepressant activity",
      "target": "4-week-old male mice",
      "label": "studied in"
    },
    {
      "source": "Antidepressant activity",
      "target": "40-week-old male mice",
      "label": "studied in"
    },
    {
      "source": "noradrenaline reuptake inhibitors",
      "target": "40-week-old mice",
      "label": "less active in"
    },
    {
      "source": "noradrenaline reuptake inhibitors",
      "target": "4-week-old mice",
      "label": "more active in"
    },
    {
      "source": "5-HT1 receptors",
      "target": "selective serotonin reuptake inhibitors",
      "label": "alteration affects"
    },
    {
      "source": "venlafaxine",
      "target": "antidepressant drug",
      "label": "is a"
    },
    {
      "source": "venlafaxine",
      "target": "mixed serotonin and noradrenaline reuptake inhibitors",
      "label": "is a"
    },
    {
      "source": "venlafaxine",
      "target": "40-week-old mice",
      "label": "most active in"
    },
    {
      "source": "venlafaxine",
      "target": "control mice",
      "label": "administered to"
    },
    {
      "source": "venlafaxine",
      "target": "osmotic minipump",
      "label": "administered via"
    },
    {
      "source": "venlafaxine",
      "target": "norepinephrine transporter knockout mice",
      "label": "administered to"
    },
    {
      "source": "fluvoxamine",
      "target": "40-week-old mice",
      "label": "inactive in"
    },
    {
      "source": "fluvoxamine",
      "target": "selective serotonin reuptake inhibitors",
      "label": "is a"
    },
    {
      "source": "sertraline",
      "target": "selective serotonin reuptake inhibitors",
      "label": "is a"
    },
    {
      "source": "5-HT1B receptor agonists",
      "target": "antidepressant drugs",
      "label": "tested with"
    },
    {
      "source": "anpirtoline",
      "target": "sertraline",
      "label": "did not enhance effects of"
    },
    {
      "source": "anpirtoline",
      "target": "5-HT1B agonist",
      "label": "is a"
    },
    {
      "source": "anpirtoline",
      "target": "4-week-old mice",
      "label": "enhanced effects in"
    },
    {
      "source": "anpirtoline",
      "target": "antidepressant-like effects",
      "label": "enhanced"
    },
    {
      "source": "imipramine",
      "target": "tricyclic",
      "label": "is a"
    },
    {
      "source": "imipramine",
      "target": "norepinephrine transporter knockout mice",
      "label": "administered to"
    },
    {
      "source": "imipramine",
      "target": "control mice",
      "label": "administered to"
    },
    {
      "source": "imipramine",
      "target": "osmotic minipump",
      "label": "administered via"
    },
    {
      "source": "imipramine",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "imipramine",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "imipramine",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "imipramine",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "imipramine",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "terminal half-life",
      "target": "NDGA",
      "label": "of"
    },
    {
      "source": "terminal half-life",
      "target": "young volunteers",
      "label": "observed in"
    },
    {
      "source": "terminal half-life",
      "target": "elderly volunteers",
      "label": "observed in"
    },
    {
      "source": "NDGA",
      "target": "peak plasma concentration",
      "label": "results in"
    },
    {
      "source": "NDGA",
      "target": "5-lipoxygenase",
      "label": "inhibits"
    },
    {
      "source": "NDGA",
      "target": "mouse plasma",
      "label": "detected in"
    },
    {
      "source": "NDGA",
      "target": "clearance",
      "label": "has"
    },
    {
      "source": "NDGA",
      "target": "cancer cell lines",
      "label": "active against"
    },
    {
      "source": "NDGA",
      "target": "ornithine decarboxylase",
      "label": "inhibits"
    },
    {
      "source": "NDGA",
      "target": "mouse",
      "label": "administered to"
    },
    {
      "source": "NDGA",
      "target": "mouse tumor model",
      "label": "active against"
    },
    {
      "source": "peak plasma concentration",
      "target": "C(max)",
      "label": "is also known as"
    },
    {
      "source": "peak plasma concentration",
      "target": "Cmax",
      "label": "is also known as"
    },
    {
      "source": "Nordihydroguaiaretic acid",
      "target": "mouse tumor model",
      "label": "active against"
    },
    {
      "source": "Nordihydroguaiaretic acid",
      "target": "5-lipoxygenase",
      "label": "inhibits"
    },
    {
      "source": "Nordihydroguaiaretic acid",
      "target": "cancer cell lines",
      "label": "active against"
    },
    {
      "source": "Nordihydroguaiaretic acid",
      "target": "ornithine decarboxylase",
      "label": "inhibits"
    },
    {
      "source": "intravenous nordihydroguaiaretic acid",
      "target": "mouse",
      "label": "administered to"
    },
    {
      "source": "Pharmacokinetic analysis",
      "target": "intravenous nordihydroguaiaretic acid",
      "label": "of"
    },
    {
      "source": "Pharmacokinetic analysis",
      "target": "high-performance liquid chromatography",
      "label": "performed by"
    },
    {
      "source": "clearance",
      "target": "GCs",
      "label": "of"
    },
    {
      "source": "clearance",
      "target": "infecting virus",
      "label": "of"
    },
    {
      "source": "clearance",
      "target": "UGT2B10",
      "label": "of"
    },
    {
      "source": "clearance",
      "target": "amitriptyline",
      "label": "for"
    },
    {
      "source": "clearance",
      "target": "imipramine",
      "label": "for"
    },
    {
      "source": "clearance",
      "target": "diphenhydramine",
      "label": "for"
    },
    {
      "source": "limit of detection",
      "target": "reverse-phase high-performance liquid chromatography (HPLC) method",
      "label": "of"
    },
    {
      "source": "reverse-phase high-performance liquid chromatography (HPLC) method",
      "target": "NDGA",
      "label": "detects"
    },
    {
      "source": "pharmacokinetics",
      "target": "NDGA",
      "label": "of"
    },
    {
      "source": "pharmacokinetics",
      "target": "elderly volunteers",
      "label": "determined in"
    },
    {
      "source": "pharmacokinetics",
      "target": "young volunteers",
      "label": "determined in"
    },
    {
      "source": "pharmacokinetics",
      "target": "Fondaparinux sodium",
      "label": "of"
    },
    {
      "source": "pharmacokinetics",
      "target": "studies",
      "label": "determined in"
    },
    {
      "source": "pharmacokinetics",
      "target": "young male volunteers",
      "label": "consistent with findings in"
    },
    {
      "source": "pharmacokinetics",
      "target": "healthy volunteers",
      "label": "studied in"
    },
    {
      "source": "pharmacokinetics",
      "target": "sex",
      "label": "compared by"
    },
    {
      "source": "pharmacokinetics",
      "target": "ANOVA",
      "label": "compared using"
    },
    {
      "source": "pharmacokinetics",
      "target": "retigabine",
      "label": "pertains to"
    },
    {
      "source": "pharmacokinetics",
      "target": "age group",
      "label": "compared by"
    },
    {
      "source": "pharmacokinetics",
      "target": "individuals",
      "label": "varies in"
    },
    {
      "source": "pharmacokinetics",
      "target": "nine male healthy volunteers",
      "label": "studied in"
    },
    {
      "source": "pharmacokinetics",
      "target": "short therapeutic hexapeptide",
      "label": "of"
    },
    {
      "source": "pharmacokinetics",
      "target": "single intravenous bolus administration",
      "label": "studied after"
    },
    {
      "source": "pharmacokinetics",
      "target": "oral admission",
      "label": "occurs after"
    },
    {
      "source": "pharmacokinetics",
      "target": "human body",
      "label": "occurs in"
    },
    {
      "source": "pharmacokinetics",
      "target": "administration",
      "label": "were assessed following"
    },
    {
      "source": "pharmacokinetics",
      "target": "paraquat dichloride",
      "label": "of"
    },
    {
      "source": "pharmacokinetics",
      "target": "betaxolol",
      "label": "is reviewed for"
    },
    {
      "source": "pharmacokinetics",
      "target": "levobunolol",
      "label": "is reviewed for"
    },
    {
      "source": "pyridostigmine plus exercise training",
      "target": "plasma butyrylcholinesterase (BChE) activity",
      "label": "Downregulator"
    },
    {
      "source": "pyridostigmine plus exercise training",
      "target": "Acetylcholinesterase (AChE) activity",
      "label": "Downregulator"
    },
    {
      "source": "pyridostigmine plus exercise training",
      "target": "interactive effect",
      "label": "caused"
    },
    {
      "source": "pyridostigmine plus exercise training",
      "target": "Creatine phosphokinase activity",
      "label": "Upregulator"
    },
    {
      "source": "pyridostigmine plus exercise training",
      "target": "perturbation",
      "label": "caused"
    },
    {
      "source": "plasma butyrylcholinesterase (BChE) activity",
      "target": "control",
      "label": "compared to"
    },
    {
      "source": "experimental groups",
      "target": "pyridostigmine",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "sedentary control",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "pyridostigmine plus exercise training",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "animals",
      "label": "composed of"
    },
    {
      "source": "experimental groups",
      "target": "exercise training",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "control group",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "dexamethasone",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "model group",
      "label": "includes"
    },
    {
      "source": "experimental groups",
      "target": "curcumin",
      "label": "includes"
    },
    {
      "source": "pyridostigmine",
      "target": "histological changes",
      "label": "causes delayed effects on"
    },
    {
      "source": "pyridostigmine",
      "target": "biochemical changes",
      "label": "causes delayed effects on"
    },
    {
      "source": "pyridostigmine",
      "target": "exercise training",
      "label": "interacts with"
    },
    {
      "source": "pyridostigmine",
      "target": "plasma butyrylcholinesterase (BChE) activity",
      "label": "Downregulator"
    },
    {
      "source": "interactive effect",
      "target": "combination",
      "label": "caused by"
    },
    {
      "source": "interactive effect",
      "target": "malondialdehyde",
      "label": "Upregulator"
    },
    {
      "source": "combination",
      "target": "oxidative stress response",
      "label": "caused"
    },
    {
      "source": "combination",
      "target": "pyridostigmine plus exercise training",
      "label": "is"
    },
    {
      "source": "combination",
      "target": "kinetic techniques",
      "label": "of"
    },
    {
      "source": "combination",
      "target": "crystallographic techniques",
      "label": "of"
    },
    {
      "source": "combination",
      "target": "spectroscopic techniques",
      "label": "of"
    },
    {
      "source": "combination",
      "target": "celecoxib",
      "label": "includes"
    },
    {
      "source": "combination",
      "target": "thalidomide",
      "label": "includes"
    },
    {
      "source": "combination",
      "target": "irinotecan",
      "label": "includes"
    },
    {
      "source": "combination",
      "target": "treatment",
      "label": "represents"
    },
    {
      "source": "combination",
      "target": "response rate",
      "label": "associated with improvement in"
    },
    {
      "source": "combination",
      "target": "time to progression",
      "label": "associated with increase in"
    },
    {
      "source": "combination",
      "target": "clinical trials",
      "label": "observed in"
    },
    {
      "source": "combination",
      "target": "human NSCLC cells",
      "label": "is useful for"
    },
    {
      "source": "Acetylcholinesterase (AChE) activity",
      "target": "red blood cells",
      "label": "not altered in"
    },
    {
      "source": "Acetylcholinesterase (AChE) activity",
      "target": "sciatic nerve",
      "label": "not altered in"
    },
    {
      "source": "Acetylcholinesterase (AChE) activity",
      "target": "control",
      "label": "compared to"
    },
    {
      "source": "Acetylcholinesterase (AChE) activity",
      "target": "triceps muscle",
      "label": "located in"
    },
    {
      "source": "Acetylcholinesterase (AChE) activity",
      "target": "platelets",
      "label": "not altered in"
    },
    {
      "source": "control",
      "target": "intracellular cAMP responses",
      "label": "of"
    },
    {
      "source": "Gulf War veterans",
      "target": "nerve agents",
      "label": "exposed to"
    },
    {
      "source": "Gulf War veterans",
      "target": "pyridostigmine",
      "label": "took"
    },
    {
      "source": "Gulf War veterans",
      "target": "physical stress",
      "label": "experienced"
    },
    {
      "source": "sciatic nerve",
      "target": "mice",
      "label": "isolated from"
    },
    {
      "source": "triceps muscle",
      "target": "mice",
      "label": "isolated from"
    },
    {
      "source": "triceps muscle",
      "target": "control",
      "label": "compared between"
    },
    {
      "source": "triceps muscle",
      "target": "experimental groups",
      "label": "compared between"
    },
    {
      "source": "histological changes",
      "target": "peripheral tissues",
      "label": "observed in"
    },
    {
      "source": "histological changes",
      "target": "intestine",
      "label": "occur in"
    },
    {
      "source": "malondialdehyde",
      "target": "control",
      "label": "compared to"
    },
    {
      "source": "malondialdehyde",
      "target": "lipid peroxidation",
      "label": "is product of"
    },
    {
      "source": "malondialdehyde",
      "target": "triceps muscle",
      "label": "located in"
    },
    {
      "source": "malondialdehyde",
      "target": "whole brain homogenate",
      "label": "found in"
    },
    {
      "source": "malondialdehyde",
      "target": "routine procedures",
      "label": "carried out by"
    },
    {
      "source": "malondialdehyde",
      "target": "MDA",
      "label": "is also known as"
    },
    {
      "source": "subchronic oral dose",
      "target": "pyridostigmine",
      "label": "of"
    },
    {
      "source": "biochemical changes",
      "target": "peripheral tissues",
      "label": "observed in"
    },
    {
      "source": "histological abnormalities",
      "target": "triceps muscle",
      "label": "not detected in"
    },
    {
      "source": "lipid peroxidation",
      "target": "peripheral tissues",
      "label": "measured in"
    },
    {
      "source": "lipid peroxidation",
      "target": "cardiac tissues",
      "label": "in"
    },
    {
      "source": "lipid peroxidation",
      "target": "Wistar rats",
      "label": "investigated in"
    },
    {
      "source": "lipid peroxidation",
      "target": "hepatic tissues",
      "label": "in"
    },
    {
      "source": "lipid peroxidation",
      "target": "hippocampus",
      "label": "is a parameter of"
    },
    {
      "source": "lipid peroxidation",
      "target": "biochemical parameters",
      "label": "is a"
    },
    {
      "source": "lipid peroxidation",
      "target": "stomach tissues",
      "label": "DETERMINED_IN"
    },
    {
      "source": "lipid peroxidation",
      "target": "LPO",
      "label": "IS_A"
    },
    {
      "source": "peripheral tissues",
      "target": "mice",
      "label": "from"
    },
    {
      "source": "perturbation",
      "target": "combination",
      "label": "caused by"
    },
    {
      "source": "perturbation",
      "target": "integrity",
      "label": "affects"
    },
    {
      "source": "delayed effects",
      "target": "lipid peroxidation",
      "label": "affects"
    },
    {
      "source": "delayed effects",
      "target": "histology",
      "label": "affects"
    },
    {
      "source": "delayed effects",
      "target": "treadmill exercise",
      "label": "caused by"
    },
    {
      "source": "delayed effects",
      "target": "cholinesterase activity",
      "label": "affects"
    },
    {
      "source": "delayed effects",
      "target": "pyridostigmine",
      "label": "caused by"
    },
    {
      "source": "delayed toxic effects",
      "target": "skeletal muscle",
      "label": "occurred in"
    },
    {
      "source": "delayed toxic effects",
      "target": "subchronic oral dose",
      "label": "caused by"
    },
    {
      "source": "histology",
      "target": "peripheral tissues",
      "label": "measured in"
    },
    {
      "source": "Male NIH Swiss mice",
      "target": "experimental groups",
      "label": "divided into"
    },
    {
      "source": "physical stress",
      "target": "delayed toxic effects",
      "label": "enhanced"
    },
    {
      "source": "physical stress",
      "target": "histological changes",
      "label": "causes delayed effects on"
    },
    {
      "source": "physical stress",
      "target": "biochemical changes",
      "label": "causes delayed effects on"
    },
    {
      "source": "Creatine phosphokinase activity",
      "target": "exercise training",
      "label": "compared to"
    },
    {
      "source": "Creatine phosphokinase activity",
      "target": "pyridostigmine",
      "label": "compared to"
    },
    {
      "source": "Creatine phosphokinase activity",
      "target": "control",
      "label": "compared to"
    },
    {
      "source": "Creatine phosphokinase activity",
      "target": "plasma",
      "label": "located in"
    },
    {
      "source": "integrity",
      "target": "skeletal muscle",
      "label": "of"
    },
    {
      "source": "skeletal muscle",
      "target": "mice",
      "label": "of"
    },
    {
      "source": "skeletal muscle",
      "target": "systemic glucose metabolism",
      "label": "PlaysRoleIn"
    },
    {
      "source": "skeletal muscle",
      "target": "male rat",
      "label": "PartOf"
    },
    {
      "source": "skeletal muscle",
      "target": "adult male albino rat",
      "label": "PartOf"
    },
    {
      "source": "platelets",
      "target": "arterial thrombosis",
      "label": "play a role in"
    },
    {
      "source": "blood",
      "target": "mice",
      "label": "isolated from"
    },
    {
      "source": "blood",
      "target": "72-hour period",
      "label": "collected over"
    },
    {
      "source": "blood",
      "target": "dogs",
      "label": "obtained from"
    },
    {
      "source": "blood",
      "target": "healthy mice",
      "label": "of"
    },
    {
      "source": "blood",
      "target": "insulin",
      "label": "collected for"
    },
    {
      "source": "blood",
      "target": "glucose",
      "label": "collected for"
    },
    {
      "source": "blood",
      "target": "aldosterone",
      "label": "collected for"
    },
    {
      "source": "blood",
      "target": "FFAs",
      "label": "collected for"
    },
    {
      "source": "cholinesterase activity",
      "target": "peripheral tissues",
      "label": "measured in"
    },
    {
      "source": "animals",
      "target": "massive intra-abdominal hemorrhage",
      "label": "die of"
    },
    {
      "source": "animals",
      "target": "vehicle",
      "label": "pretreated with"
    },
    {
      "source": "animals",
      "target": "PLZ",
      "label": "treated with"
    },
    {
      "source": "animals",
      "target": "tranylcypromine",
      "label": "pretreated with"
    },
    {
      "source": "animals",
      "target": "TCP",
      "label": "pretreated with"
    },
    {
      "source": "animals",
      "target": "treatment",
      "label": "received"
    },
    {
      "source": "animals",
      "target": "low salt intake",
      "label": "on"
    },
    {
      "source": "animals",
      "target": "four groups",
      "label": "divided into"
    },
    {
      "source": "animals",
      "target": "intra-arterial infusion",
      "label": "received"
    },
    {
      "source": "animals",
      "target": "ATA",
      "label": "received"
    },
    {
      "source": "animals",
      "target": "ridogrel",
      "label": "received"
    },
    {
      "source": "animals",
      "target": "AP-1",
      "label": "received"
    },
    {
      "source": "animals",
      "target": "aurintrycarboxilic acid",
      "label": "received"
    },
    {
      "source": "reactivation potentials of BuChE",
      "target": "oxime-reactivated enzyme activity",
      "label": "is difference between"
    },
    {
      "source": "reactivation potentials of BuChE",
      "target": "time after organophosphate ingestion",
      "label": "declined with"
    },
    {
      "source": "reactivation potentials of BuChE",
      "target": "unreactivated enzyme activity",
      "label": "is difference between"
    },
    {
      "source": "Neuroparalysis",
      "target": "organophosphate poisoning",
      "label": "in"
    },
    {
      "source": "BuChE",
      "target": "clinical severity of poisoning",
      "label": "reflects"
    },
    {
      "source": "BuChE",
      "target": "earlier studies",
      "label": "confirms"
    },
    {
      "source": "clinical severity of poisoning",
      "target": "Namba Scale",
      "label": "assessed by"
    },
    {
      "source": "clinical severity of poisoning",
      "target": "intermediate syndrome",
      "label": "correlated with"
    },
    {
      "source": "intermediate syndrome",
      "target": "persistent inhibition of BuChE",
      "label": "associated with"
    },
    {
      "source": "oxime treatment",
      "target": "lack of oxime efficacy",
      "label": "exhibits"
    },
    {
      "source": "lack of oxime efficacy",
      "target": "timing of oxime treatment",
      "label": "due to"
    },
    {
      "source": "lack of oxime efficacy",
      "target": "severity of poisoning",
      "label": "due to"
    },
    {
      "source": "patients who received oxime prior to hospitalization",
      "target": "rate of intermediate syndrome",
      "label": "had higher"
    },
    {
      "source": "patients who received oxime prior to hospitalization",
      "target": "levels of BuChE at admission",
      "label": "had lower"
    },
    {
      "source": "oxime",
      "target": "hospitalization",
      "label": "received prior to"
    },
    {
      "source": "oxime",
      "target": "organophosphate poisoning",
      "label": "efficacy in"
    },
    {
      "source": "oxime",
      "target": "OP",
      "label": "protects_against"
    },
    {
      "source": "in vitro pralidoxime-reactivated BuChE",
      "target": "cohort",
      "label": "studied in"
    },
    {
      "source": "in vitro pralidoxime-reactivated BuChE",
      "target": "lack of oxime efficacy",
      "label": "has relationship to"
    },
    {
      "source": "in vitro pralidoxime-reactivated BuChE",
      "target": "intermediate syndrome",
      "label": "has relationship to"
    },
    {
      "source": "cohort",
      "target": "compound heterozygous sickle cell disease/\u03b2-thalassemia patients",
      "label": "consists of"
    },
    {
      "source": "temporal profile",
      "target": "clinical severity of poisoning",
      "label": "correlated to"
    },
    {
      "source": "temporal profile",
      "target": "enzyme",
      "label": "of"
    },
    {
      "source": "temporal profile",
      "target": "cohort",
      "label": "studied in"
    },
    {
      "source": "temporal profile",
      "target": "lack of oxime efficacy",
      "label": "has relationship to"
    },
    {
      "source": "temporal profile",
      "target": "butyrylcholinesterase",
      "label": "of"
    },
    {
      "source": "temporal profile",
      "target": "BuChE",
      "label": "of"
    },
    {
      "source": "temporal profile",
      "target": "intermediate syndrome",
      "label": "has relationship to"
    },
    {
      "source": "BuChE activity",
      "target": "muscle power",
      "label": "showed relationship to"
    },
    {
      "source": "enzyme",
      "target": "substrate access channel",
      "label": "requires"
    },
    {
      "source": "enzyme",
      "target": "PLP",
      "label": "is dependent on"
    },
    {
      "source": "enzyme",
      "target": "pyridoxal 5'-phosphate",
      "label": "is dependent on"
    },
    {
      "source": "enzyme",
      "target": "spectroscopic properties",
      "label": "has"
    },
    {
      "source": "enzyme",
      "target": "kinetic properties",
      "label": "has"
    },
    {
      "source": "enzyme",
      "target": "turnover number",
      "label": "has"
    },
    {
      "source": "enzyme",
      "target": "fluorouracil elimination",
      "label": "controls"
    },
    {
      "source": "enzyme",
      "target": "collagen biosynthesis",
      "label": "is necessary for"
    },
    {
      "source": "enzyme",
      "target": "riboflavin",
      "label": "converts"
    },
    {
      "source": "enzyme",
      "target": "flavinmononucleotide",
      "label": "converts to"
    },
    {
      "source": "enzyme",
      "target": "accumulation",
      "label": "plays a regulatory role in"
    },
    {
      "source": "enzyme",
      "target": "synthesis",
      "label": "plays a regulatory role in"
    },
    {
      "source": "enzyme",
      "target": "non-immune cells",
      "label": "is expressed in"
    },
    {
      "source": "enzyme",
      "target": "biosynthesis of LTC4",
      "label": "is pivotal for"
    },
    {
      "source": "enzyme",
      "target": "C-1-inhibitor",
      "label": "was complexed with"
    },
    {
      "source": "enzyme",
      "target": "alpha 2-antiplasmin",
      "label": "formed complexes with"
    },
    {
      "source": "enzyme",
      "target": "antithrombin III",
      "label": "formed complexes with"
    },
    {
      "source": "butyrylcholinesterase",
      "target": "related enzyme",
      "label": "is a type of"
    },
    {
      "source": "reactivation potential of the enzyme at admission",
      "target": "severity of poisoning",
      "label": "decreased with"
    },
    {
      "source": "reactivation potential of the enzyme at admission",
      "target": "patients who developed intermediate syndrome",
      "label": "was lower in"
    },
    {
      "source": "NGF protein",
      "target": "8-12 h exposure",
      "label": "has maxima at"
    },
    {
      "source": "NGF protein",
      "target": "3T3 cells",
      "label": "is in"
    },
    {
      "source": "NGF protein",
      "target": "10 nM",
      "label": "has maxima at"
    },
    {
      "source": "vitamin D(3) analogue",
      "target": "CB1093",
      "label": "is"
    },
    {
      "source": "CB1093",
      "target": "NGF protein levels",
      "label": "increases"
    },
    {
      "source": "CB1093",
      "target": "calcaemic effects",
      "label": "has"
    },
    {
      "source": "CB1093",
      "target": "nerve growth factor synthesis",
      "label": "induces"
    },
    {
      "source": "CB1093",
      "target": "NGF levels",
      "label": "stimulates"
    },
    {
      "source": "CB1093",
      "target": "NGF mRNA levels",
      "label": "increases"
    },
    {
      "source": "CB1093",
      "target": "VDR binding",
      "label": "causes"
    },
    {
      "source": "nerve growth factor",
      "target": "PNS",
      "label": "is increased in"
    },
    {
      "source": "PNS",
      "target": "mRNA expressions",
      "label": "investigated for effects on"
    },
    {
      "source": "PNS",
      "target": "cerebral ischemia-reperfusion",
      "label": "investigated after"
    },
    {
      "source": "PNS",
      "target": "cerebral ischemia",
      "label": "administered before"
    },
    {
      "source": "PNS",
      "target": "mRNA expression levels",
      "label": "had no effect on"
    },
    {
      "source": "PNS",
      "target": "mRNA expression level",
      "label": "inhibits"
    },
    {
      "source": "Pharmacological modulation",
      "target": "vitamin D receptor",
      "label": "compares"
    },
    {
      "source": "Pharmacological modulation",
      "target": "beta(2)-adrenoceptor agonists",
      "label": "compares"
    },
    {
      "source": "Pharmacological modulation",
      "target": "nerve growth factor synthesis",
      "label": "modulates"
    },
    {
      "source": "vitamin D receptor",
      "target": "nuclear receptors",
      "label": "is a type of"
    },
    {
      "source": "NGF protein levels",
      "target": "72 h",
      "label": "sustained for"
    },
    {
      "source": "NGF protein levels",
      "target": "24 h exposure",
      "label": "is maximal at"
    },
    {
      "source": "NGF protein levels",
      "target": "3T3 cells",
      "label": "is in"
    },
    {
      "source": "NGF protein levels",
      "target": "L929 cells",
      "label": "is in"
    },
    {
      "source": "clenbuterol",
      "target": "nerve growth factor synthesis",
      "label": "induces"
    },
    {
      "source": "clenbuterol",
      "target": "NGF protein",
      "label": "increases"
    },
    {
      "source": "clenbuterol",
      "target": "long-acting beta(2)-adrenoceptor agonist",
      "label": "is a"
    },
    {
      "source": "clenbuterol",
      "target": "AP1 binding",
      "label": "increases"
    },
    {
      "source": "clenbuterol",
      "target": "NGF mRNA levels",
      "label": "has no effect on"
    },
    {
      "source": "clenbuterol",
      "target": "NGF levels",
      "label": "stimulates"
    },
    {
      "source": "clenbuterol",
      "target": "NGF mRNA",
      "label": "increases"
    },
    {
      "source": "propranolol",
      "target": "clenbuterol",
      "label": "antagonizes"
    },
    {
      "source": "propranolol",
      "target": "[(3)H]prazosin",
      "label": "was without effect on binding of"
    },
    {
      "source": "propranolol",
      "target": "comparison studies",
      "label": "used for"
    },
    {
      "source": "propranolol",
      "target": "beta 1-adrenoceptors",
      "label": "acts on"
    },
    {
      "source": "propranolol",
      "target": "intravenous dosing",
      "label": "administered via"
    },
    {
      "source": "propranolol",
      "target": "potency",
      "label": "evaluated for"
    },
    {
      "source": "propranolol",
      "target": "\u03b2-antagonist",
      "label": "is a type of"
    },
    {
      "source": "NGF mRNA levels",
      "target": "24 h exposure",
      "label": "is maximal at"
    },
    {
      "source": "NGF mRNA levels",
      "target": "3T3 cells",
      "label": "is in"
    },
    {
      "source": "NGF mRNA levels",
      "target": "L929 cells",
      "label": "is in"
    },
    {
      "source": "NGF mRNA levels",
      "target": "72 h",
      "label": "sustained for"
    },
    {
      "source": "VDR binding",
      "target": "24 h exposure",
      "label": "maintained up to"
    },
    {
      "source": "VDR binding",
      "target": "NGF mRNA",
      "label": "preceded"
    },
    {
      "source": "VDR binding",
      "target": "exposure",
      "label": "increased after"
    },
    {
      "source": "VDR binding",
      "target": "30 min",
      "label": "increased at"
    },
    {
      "source": "NGF mRNA",
      "target": "10 nM",
      "label": "has maxima at"
    },
    {
      "source": "NGF mRNA",
      "target": "8-12 h exposure",
      "label": "has maxima at"
    },
    {
      "source": "NGF mRNA",
      "target": "3T3 cells",
      "label": "is in"
    },
    {
      "source": "Mobility shift assays",
      "target": "whole cell extracts",
      "label": "performed on"
    },
    {
      "source": "700% increase",
      "target": "80%",
      "label": "is greater than"
    },
    {
      "source": "700% increase",
      "target": "L929 cells",
      "label": "occurs in"
    },
    {
      "source": "80%",
      "target": "3T3 cells",
      "label": "occurs in"
    },
    {
      "source": "vitamin D nuclear receptor",
      "target": "transcription factor",
      "label": "acts as a"
    },
    {
      "source": "transcription factor",
      "target": "pituitary development",
      "label": "critical in"
    },
    {
      "source": "AP1 binding",
      "target": "3T3 cells",
      "label": "is in"
    },
    {
      "source": "NGF",
      "target": "rational strategy",
      "label": "is a"
    },
    {
      "source": "rational strategy",
      "target": "neurodegenerative disorders",
      "label": "for treating"
    },
    {
      "source": "AP-1 binding",
      "target": "150% increase",
      "label": "shows"
    },
    {
      "source": "AP-1 binding",
      "target": "mechanism of NGF induction",
      "label": "is a commonality in"
    },
    {
      "source": "NGF levels",
      "target": "700% increase",
      "label": "shows"
    },
    {
      "source": "NGF levels",
      "target": "in vitro",
      "label": "occurs"
    },
    {
      "source": "NGF levels",
      "target": "80%",
      "label": "shows"
    },
    {
      "source": "VDR",
      "target": "transcription factor",
      "label": "acts as a"
    },
    {
      "source": "VDR",
      "target": "promiscuity",
      "label": "has"
    },
    {
      "source": "VDR",
      "target": "specificity",
      "label": "has"
    },
    {
      "source": "VDR",
      "target": "nuclear xenobiotic receptors",
      "label": "is a type of"
    },
    {
      "source": "VDR",
      "target": "ligand-binding site",
      "label": "has"
    },
    {
      "source": "VDR",
      "target": "ligand specificities",
      "label": "has"
    },
    {
      "source": "VDR",
      "target": "vitamin D receptor",
      "label": "is also known as"
    },
    {
      "source": "VDR",
      "target": "3D structures",
      "label": "has"
    },
    {
      "source": "VDR",
      "target": "genes",
      "label": "control"
    },
    {
      "source": "30 min",
      "target": "behavioural testing",
      "label": "is prior to"
    },
    {
      "source": "30 min",
      "target": "rapid and delayed time domain",
      "label": "is a time point for"
    },
    {
      "source": "ALIMTA",
      "target": "dihydrofolate reductase",
      "label": "inhibits"
    },
    {
      "source": "ALIMTA",
      "target": "folate-dependent enzymes",
      "label": "inhibits"
    },
    {
      "source": "ALIMTA",
      "target": "glycinamide ribonucleotide formyltransferase",
      "label": "inhibits"
    },
    {
      "source": "ALIMTA",
      "target": "thymidylate synthase",
      "label": "inhibits"
    },
    {
      "source": "ALIMTA",
      "target": "antimetabolite",
      "label": "is a type of"
    },
    {
      "source": "pemetrexed disodium",
      "target": "folate-dependent enzymes",
      "label": "inhibits"
    },
    {
      "source": "pemetrexed disodium",
      "target": "bladder",
      "label": "is active in"
    },
    {
      "source": "pemetrexed disodium",
      "target": "head and neck",
      "label": "is active in"
    },
    {
      "source": "pemetrexed disodium",
      "target": "glycinamide ribonucleotide formyltransferase",
      "label": "inhibits"
    },
    {
      "source": "pemetrexed disodium",
      "target": "ALIMTA",
      "label": "is also known as"
    },
    {
      "source": "pemetrexed disodium",
      "target": "solid tumours",
      "label": "is active in"
    },
    {
      "source": "pemetrexed disodium",
      "target": "ovarian cancers",
      "label": "is active in"
    },
    {
      "source": "pemetrexed disodium",
      "target": "antimetabolite",
      "label": "is a type of"
    },
    {
      "source": "pemetrexed disodium",
      "target": "thymidylate synthase",
      "label": "inhibits"
    },
    {
      "source": "pemetrexed disodium",
      "target": "breast",
      "label": "is active in"
    },
    {
      "source": "pemetrexed disodium",
      "target": "non-small cell lung",
      "label": "is active in"
    },
    {
      "source": "pemetrexed disodium",
      "target": "dihydrofolate reductase",
      "label": "inhibits"
    },
    {
      "source": "combinations",
      "target": "in vitro",
      "label": "studied in"
    },
    {
      "source": "combinations",
      "target": "in vivo",
      "label": "studied in"
    },
    {
      "source": "preclinical studies",
      "target": "cytotoxic synergy",
      "label": "show"
    },
    {
      "source": "cytotoxic synergy",
      "target": "pemetrexed",
      "label": "between"
    },
    {
      "source": "cytotoxic synergy",
      "target": "Gemcitabine",
      "label": "between"
    },
    {
      "source": "Clinical activity",
      "target": "phase I study",
      "label": "observed in"
    },
    {
      "source": "phase I study",
      "target": "partial responses",
      "label": "resulted in"
    },
    {
      "source": "phase I study",
      "target": "patients",
      "label": "included"
    },
    {
      "source": "phase I study",
      "target": "cabozantinib",
      "label": "involved"
    },
    {
      "source": "partial responses",
      "target": "patients",
      "label": "observed in"
    },
    {
      "source": "international phase II study",
      "target": "non-small cell lung cancers",
      "label": "is ongoing for"
    },
    {
      "source": "alpha-thrombin",
      "target": "nuclear diacylglycerol mass",
      "label": "increases"
    },
    {
      "source": "alpha-thrombin",
      "target": "phospholipase D",
      "label": "activates"
    },
    {
      "source": "alpha-thrombin",
      "target": "translocation",
      "label": "induced"
    },
    {
      "source": "alpha-thrombin",
      "target": "nuclear DGK activity",
      "label": "increases"
    },
    {
      "source": "alpha-thrombin",
      "target": "quiescent fibroblasts",
      "label": "stimulates"
    },
    {
      "source": "alpha-thrombin",
      "target": "quiescent IIC9 fibroblasts",
      "label": "added to"
    },
    {
      "source": "alpha-thrombin",
      "target": "lipid second messengers",
      "label": "leads to production of"
    },
    {
      "source": "phospholipase D",
      "target": "hydrolysis",
      "label": "catalyzes"
    },
    {
      "source": "nuclear localization",
      "target": "DGK-delta",
      "label": "is of"
    },
    {
      "source": "DGK-delta",
      "target": "nuclei",
      "label": "present in"
    },
    {
      "source": "DGK-delta",
      "target": "Sakane, F.",
      "label": "inhibition reviewed by"
    },
    {
      "source": "DGK",
      "target": "signaling cascades",
      "label": "regulated in"
    },
    {
      "source": "DGK",
      "target": "phosphatidic acid",
      "label": "converts to"
    },
    {
      "source": "DGK",
      "target": "diacylglycerol",
      "label": "catalyzes conversion of"
    },
    {
      "source": "signaling cascades",
      "target": "Houssa, B.",
      "label": "reviewed by"
    },
    {
      "source": "signaling cascades",
      "target": "van Blitterswijk, W. J.",
      "label": "reviewed by"
    },
    {
      "source": "translocation",
      "target": "nucleus",
      "label": "to"
    },
    {
      "source": "translocation",
      "target": "DGK-theta",
      "label": "of"
    },
    {
      "source": "translocation",
      "target": "nuclear activity",
      "label": "responsible for"
    },
    {
      "source": "translocation",
      "target": "p53R2",
      "label": "of"
    },
    {
      "source": "translocation",
      "target": "cytoplasm",
      "label": "from"
    },
    {
      "source": "translocation",
      "target": "hRRM2",
      "label": "of"
    },
    {
      "source": "hydrolysis",
      "target": "phosphatidic acid",
      "label": "generates"
    },
    {
      "source": "hydrolysis",
      "target": "phosphatidylcholine",
      "label": "of"
    },
    {
      "source": "hydrolysis",
      "target": "inhibitor",
      "label": "involves"
    },
    {
      "source": "hydrolysis",
      "target": "pH 8.0",
      "label": "occurs at"
    },
    {
      "source": "hydrolysis",
      "target": "acetylthiocholine",
      "label": "acts on"
    },
    {
      "source": "hydrolysis",
      "target": "AChE",
      "label": "involves"
    },
    {
      "source": "hydrolysis",
      "target": "common drugs",
      "label": "of"
    },
    {
      "source": "hydrolysis",
      "target": "standard substrates",
      "label": "of"
    },
    {
      "source": "hydrolysis",
      "target": "anticancer prodrugs",
      "label": "of"
    },
    {
      "source": "hydrolysis",
      "target": "ATP",
      "label": "of"
    },
    {
      "source": "hydrolysis",
      "target": "glucosinolates",
      "label": "acts on"
    },
    {
      "source": "Nuclear diacylglycerol kinase-theta",
      "target": "alpha-thrombin",
      "label": "activated by"
    },
    {
      "source": "immunofluorescence microscopy analyses",
      "target": "translocation",
      "label": "showed"
    },
    {
      "source": "Diacylglycerol kinase",
      "target": "phosphatidic acid",
      "label": "converts to"
    },
    {
      "source": "Diacylglycerol kinase",
      "target": "diacylglycerol",
      "label": "catalyzes conversion of"
    },
    {
      "source": "DGK-theta",
      "target": "Houssa, B.",
      "label": "inhibition reviewed by"
    },
    {
      "source": "DGK-theta",
      "target": "nuclei",
      "label": "present in"
    },
    {
      "source": "DGK-theta",
      "target": "alpha-thrombin stimulation",
      "label": "responsive to"
    },
    {
      "source": "Houssa, B.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "Houssa, B.",
      "target": "Chem. Phys. Lipids",
      "label": "published in"
    },
    {
      "source": "Kanoh, H.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "J. Biol. Chem.",
      "target": "cardiac troponin C",
      "label": "describes structure of"
    },
    {
      "source": "J. Biol. Chem.",
      "target": "cTnC",
      "label": "describes structure of"
    },
    {
      "source": "agonist-induced activity",
      "target": "nuclear DGK-theta activity",
      "label": "is of"
    },
    {
      "source": "phosphatidylserine",
      "target": "DGK-delta",
      "label": "inhibits"
    },
    {
      "source": "phosphatidylserine",
      "target": "alpha-thrombin-stimulated nuclear activity",
      "label": "did not inhibit"
    },
    {
      "source": "phosphatidylserine",
      "target": "target lipids",
      "label": "is a type of"
    },
    {
      "source": "phosphatidylserine",
      "target": "cell membranes",
      "label": "is exposed on"
    },
    {
      "source": "Kranenburg, O.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "nuclei",
      "target": "quiescent IIC9 cells",
      "label": "isolated from"
    },
    {
      "source": "constitutively active RhoA",
      "target": "DGK-theta",
      "label": "inhibits"
    },
    {
      "source": "constitutively active RhoA",
      "target": "alpha-thrombin-stimulated nuclear activity",
      "label": "inhibited"
    },
    {
      "source": "Wada, I.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "Kai, M.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "van Blitterswijk, W. J.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "van Blitterswijk, W. J.",
      "target": "Chem. Phys. Lipids",
      "label": "published in"
    },
    {
      "source": "de Widt, J.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "Sakane, F.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "monoclonal anti-DGK-theta antibody",
      "target": "alpha-thrombin-stimulated nuclear activity",
      "label": "inhibited"
    },
    {
      "source": "nuclear lipid metabolism",
      "target": "signal transduction cascades",
      "label": "plays role in"
    },
    {
      "source": "Western blot",
      "target": "translocation",
      "label": "showed"
    },
    {
      "source": "Moolenaar, W. H.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "phosphatidylcholine",
      "target": "target lipids",
      "label": "is a type of"
    },
    {
      "source": "phosphatidylcholine",
      "target": "membrane targeting",
      "label": "drives"
    },
    {
      "source": "lipid second messengers",
      "target": "nucleus",
      "label": "produced in"
    },
    {
      "source": "Imai, S.",
      "target": "J. Biol. Chem.",
      "label": "published in"
    },
    {
      "source": "Carbonic anhydrase",
      "target": "reversible hydration reaction",
      "label": "catalyses"
    },
    {
      "source": "Carbonic anhydrase",
      "target": "zinc enzyme",
      "label": "is a"
    },
    {
      "source": "Carbonic anhydrase",
      "target": "acid-base balance",
      "label": "plays a role in"
    },
    {
      "source": "reversible hydration reaction",
      "target": "CO2",
      "label": "of"
    },
    {
      "source": "in vitro effects",
      "target": "clonidine",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "vascular smooth muscle CA I",
      "label": "are on"
    },
    {
      "source": "in vitro effects",
      "target": "verapamil",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "noradrenaline",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "indomethacin",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "prazosin",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "thromboxane A2",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "amlodipine",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "reserpine",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "angiotensin II",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "irbesartan",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "purified human red blood cell CA I",
      "label": "are on"
    },
    {
      "source": "in vitro effects",
      "target": "hydralazine",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "vasopressin",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "prostaglandin I2",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "indapamide",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "furosemide",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "prostaglandin F2 alpha",
      "label": "are of"
    },
    {
      "source": "in vitro effects",
      "target": "leukotriene B4",
      "label": "are of"
    },
    {
      "source": "clonidine",
      "target": "antinociceptive activity",
      "label": "has"
    },
    {
      "source": "clonidine",
      "target": "alpha 2-adrenoceptor agonist",
      "label": "is an"
    },
    {
      "source": "control group",
      "target": "placebo",
      "label": "administered"
    },
    {
      "source": "control group",
      "target": "normal saline",
      "label": "received"
    },
    {
      "source": "control group",
      "target": "mean aortic pressure",
      "label": "has_lower"
    },
    {
      "source": "control group",
      "target": "LV-to-body weight ratio",
      "label": "has"
    },
    {
      "source": "control group",
      "target": "control substance",
      "label": "received"
    },
    {
      "source": "control group",
      "target": "training",
      "label": "showed improvements after"
    },
    {
      "source": "CA",
      "target": "zinc enzyme",
      "label": "is a"
    },
    {
      "source": "CA",
      "target": "reversible hydration reaction",
      "label": "catalyses"
    },
    {
      "source": "CA",
      "target": "acid-base balance",
      "label": "plays a role in"
    },
    {
      "source": "vasodilating agents",
      "target": "CA I activity",
      "label": "affect"
    },
    {
      "source": "vascular smooth muscle CA I",
      "target": "vasodilating processes",
      "label": "involved in"
    },
    {
      "source": "vascular smooth muscle CA I",
      "target": "rabbits",
      "label": "isolated from"
    },
    {
      "source": "vascular smooth muscle CA I",
      "target": "vasoconstrictive processes",
      "label": "involved in"
    },
    {
      "source": "blood pressure",
      "target": "normotensive subjects",
      "label": "remained unchanged in"
    },
    {
      "source": "blood pressure",
      "target": "treatment",
      "label": "after"
    },
    {
      "source": "blood pressure",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "blood pressure",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "blood pressure",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "blood pressure",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "blood pressure",
      "target": "46 taxi drivers",
      "label": "of"
    },
    {
      "source": "group 2",
      "target": "desmopressin",
      "label": "administered"
    },
    {
      "source": "carbonic anhydrase I",
      "target": "vascular smooth muscle",
      "label": "located in"
    },
    {
      "source": "indomethacin",
      "target": "COX isozymes",
      "label": "regulates"
    },
    {
      "source": "indomethacin",
      "target": "COX-1",
      "label": "has increased selectivity towards"
    },
    {
      "source": "indomethacin",
      "target": "PGE2 production",
      "label": "suppresses"
    },
    {
      "source": "indomethacin",
      "target": "COX-1 inhibitor",
      "label": "is a type of"
    },
    {
      "source": "vasodilating drugs",
      "target": "direct mechanism of action",
      "label": "act by"
    },
    {
      "source": "vasodilating drugs",
      "target": "isozyme",
      "label": "reduce activity of"
    },
    {
      "source": "amlodipine",
      "target": "research studies",
      "label": "is appropriate for"
    },
    {
      "source": "amlodipine",
      "target": "potent T-channel blockers",
      "label": "is less potent than"
    },
    {
      "source": "amlodipine",
      "target": "oral bioavailability",
      "label": "has effects on"
    },
    {
      "source": "reserpine",
      "target": "vesicular content depleting drug reserpine",
      "label": "is"
    },
    {
      "source": "reserpine",
      "target": "DA release",
      "label": "abolishes"
    },
    {
      "source": "In vivo",
      "target": "six groups",
      "label": "involved"
    },
    {
      "source": "six groups",
      "target": "substances",
      "label": "administered"
    },
    {
      "source": "six groups",
      "target": "five rabbits",
      "label": "consisted of"
    },
    {
      "source": "vasoconstrictive therapeutic agents",
      "target": "CA I activity",
      "label": "increase"
    },
    {
      "source": "substances",
      "target": "acute experiments",
      "label": "used in"
    },
    {
      "source": "substances",
      "target": "TRPM8",
      "label": "activate"
    },
    {
      "source": "substances",
      "target": "cooling sensation",
      "label": "produce"
    },
    {
      "source": "group 5",
      "target": "acetazolamide",
      "label": "administered"
    },
    {
      "source": "acetazolamide",
      "target": "classical inhibitors",
      "label": "IS_A"
    },
    {
      "source": "group 1",
      "target": "orciprenaline",
      "label": "administered"
    },
    {
      "source": "pHi changes",
      "target": "activation",
      "label": "induced by"
    },
    {
      "source": "pHi changes",
      "target": "inhibition",
      "label": "induced by"
    },
    {
      "source": "pHi changes",
      "target": "vascular tonus",
      "label": "responsible for"
    },
    {
      "source": "activation",
      "target": "blood pressure",
      "label": "increased"
    },
    {
      "source": "activation",
      "target": "IleRS",
      "label": "is by"
    },
    {
      "source": "activation",
      "target": "in vitro",
      "label": "occurs"
    },
    {
      "source": "activation",
      "target": "caspase-9",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "naive T lymphocytes",
      "label": "involves"
    },
    {
      "source": "activation",
      "target": "memory T lymphocytes",
      "label": "involves"
    },
    {
      "source": "activation",
      "target": "terminal complement",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "G(13) pathway",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "AC7",
      "label": "synergized with"
    },
    {
      "source": "activation",
      "target": "hepatic macrophages",
      "label": "is of"
    },
    {
      "source": "activation",
      "target": "pro-BMP-2",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "cell differentiation",
      "label": "can regulate"
    },
    {
      "source": "activation",
      "target": "FSAP",
      "label": "by"
    },
    {
      "source": "activation",
      "target": "calcification",
      "label": "can regulate"
    },
    {
      "source": "activation",
      "target": "mature BMP-2",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "similarity",
      "label": "exhibits"
    },
    {
      "source": "activation",
      "target": "MAPK",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "IRE1",
      "label": "is of"
    },
    {
      "source": "activation",
      "target": "phosphorylation",
      "label": "leads to"
    },
    {
      "source": "activation",
      "target": "AKT",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "STAT3",
      "label": "of"
    },
    {
      "source": "activation",
      "target": "vitamin D",
      "label": "of"
    },
    {
      "source": "hydralazine",
      "target": "hypoxia-inducible factor-1alpha",
      "label": "induced protein of"
    },
    {
      "source": "hydralazine",
      "target": "stromal cell infiltration",
      "label": "increased"
    },
    {
      "source": "hydralazine",
      "target": "HIF pathway",
      "label": "activates"
    },
    {
      "source": "hydralazine",
      "target": "prolyl hydroxylases",
      "label": "inhibits"
    },
    {
      "source": "hydralazine",
      "target": "angiogenesis",
      "label": "induces"
    },
    {
      "source": "hydralazine",
      "target": "intracellular free Ca2+",
      "label": "inhibits accumulation of"
    },
    {
      "source": "hydralazine",
      "target": "nonhydroxylated HIF-1alpha",
      "label": "induced"
    },
    {
      "source": "hydralazine",
      "target": "vascular endothelial growth factor",
      "label": "induces"
    },
    {
      "source": "hydralazine",
      "target": "endothelial cell-specific proliferation",
      "label": "induced"
    },
    {
      "source": "hydralazine",
      "target": "arterial smooth muscle",
      "label": "relaxes"
    },
    {
      "source": "hydralazine",
      "target": "VEGF",
      "label": "elevated plasma levels of"
    },
    {
      "source": "hydralazine",
      "target": "blood vessel density",
      "label": "increased"
    },
    {
      "source": "hydralazine",
      "target": "cardiovascular therapy",
      "label": "is used in"
    },
    {
      "source": "hydralazine",
      "target": "PHD activity",
      "label": "inhibited"
    },
    {
      "source": "hydralazine",
      "target": "pro-angiogenic phenotype",
      "label": "initiates"
    },
    {
      "source": "vasoconstrictive agents",
      "target": "vascular smooth muscle CA I",
      "label": "increased"
    },
    {
      "source": "vasoconstrictive agents",
      "target": "purified and human erythrocyte CA I activity",
      "label": "increased"
    },
    {
      "source": "vasoconstrictive agents",
      "target": "CA I activity",
      "label": "affect"
    },
    {
      "source": "vasodilating substances",
      "target": "direct mechanism of action",
      "label": "reduced activity by"
    },
    {
      "source": "vasodilating substances",
      "target": "isozyme",
      "label": "reduced activity of"
    },
    {
      "source": "indapamide",
      "target": "Carbonic anhydrase inhibitors",
      "label": "IS_A"
    },
    {
      "source": "indapamide",
      "target": "CA XII",
      "label": "INHIBITS"
    },
    {
      "source": "indapamide",
      "target": "active site water molecules",
      "label": "LACKS_INTERACTION_WITH"
    },
    {
      "source": "indapamide",
      "target": "CA VII",
      "label": "INHIBITS"
    },
    {
      "source": "indapamide",
      "target": "isozyme CA II",
      "label": "INHIBITS"
    },
    {
      "source": "indapamide",
      "target": "CA IX",
      "label": "INHIBITS"
    },
    {
      "source": "indapamide",
      "target": "CA XIII",
      "label": "INHIBITS"
    },
    {
      "source": "indapamide",
      "target": "K(I)s",
      "label": "HAS"
    },
    {
      "source": "indapamide",
      "target": "nanomolar inhibitors",
      "label": "IS_A"
    },
    {
      "source": "Vasoconstrictive drugs",
      "target": "carbonic anhydrase I",
      "label": "increase"
    },
    {
      "source": "group 4",
      "target": "irbesartan",
      "label": "administered"
    },
    {
      "source": "furosemide",
      "target": "CA XIV",
      "label": "INHIBITS"
    },
    {
      "source": "furosemide",
      "target": "isozyme CA II",
      "label": "INHIBITS"
    },
    {
      "source": "furosemide",
      "target": "CA I",
      "label": "INHIBITS"
    },
    {
      "source": "furosemide",
      "target": "nanomolar inhibitors",
      "label": "IS_A"
    },
    {
      "source": "furosemide",
      "target": "Carbonic anhydrase inhibitors",
      "label": "IS_A"
    },
    {
      "source": "furosemide",
      "target": "K(I)s",
      "label": "HAS"
    },
    {
      "source": "group 3",
      "target": "verapamil",
      "label": "administered"
    },
    {
      "source": "rabbits",
      "target": "high-cholesterol diet",
      "label": "fed"
    },
    {
      "source": "In vitro results",
      "target": "vasoconstrictive agents",
      "label": "showed that"
    },
    {
      "source": "results of this study",
      "target": "pHi changes",
      "label": "suggest"
    },
    {
      "source": "leukotriene B4",
      "target": "LTB4",
      "label": "is also known as"
    },
    {
      "source": "Vascular smooth muscle CA I activity",
      "target": "control group",
      "label": "compared with"
    },
    {
      "source": "cDNAs",
      "target": "isoforms",
      "label": "code for"
    },
    {
      "source": "cDNAs",
      "target": "DHFS",
      "label": "code for"
    },
    {
      "source": "cDNAs",
      "target": "Activated transcription factor 4",
      "label": "include"
    },
    {
      "source": "cDNAs",
      "target": "Acyl-CoA-binding protein",
      "label": "include"
    },
    {
      "source": "cDNAs",
      "target": "rhoA",
      "label": "include"
    },
    {
      "source": "cDNAs",
      "target": "Diazepam-binding inhibitor",
      "label": "include"
    },
    {
      "source": "cDNAs",
      "target": "cynomolgus FMO6",
      "label": "of"
    },
    {
      "source": "cDNAs",
      "target": "cynomolgus FMO1-5",
      "label": "of"
    },
    {
      "source": "cDNAs",
      "target": "murine PGHS-2",
      "label": "are_for"
    },
    {
      "source": "cDNAs",
      "target": "murine PGHS-1",
      "label": "are_for"
    },
    {
      "source": "isoforms",
      "target": "mitochondria",
      "label": "present in"
    },
    {
      "source": "isoforms",
      "target": "gene",
      "label": "encoded by"
    },
    {
      "source": "isoforms",
      "target": "chloroplast",
      "label": "present in"
    },
    {
      "source": "isoforms",
      "target": "cytosol",
      "label": "present in"
    },
    {
      "source": "isoforms",
      "target": "compartmentation",
      "label": "has"
    },
    {
      "source": "isoforms",
      "target": "Arabidopsis thaliana",
      "label": "isolated from"
    },
    {
      "source": "isoforms",
      "target": "rodents",
      "label": "exist in"
    },
    {
      "source": "isoforms",
      "target": "humans",
      "label": "exist in"
    },
    {
      "source": "isoforms",
      "target": "enzymes",
      "label": "are a type of"
    },
    {
      "source": "isoforms",
      "target": "\u03b1",
      "label": "include"
    },
    {
      "source": "isoforms",
      "target": "\u03b2",
      "label": "include"
    },
    {
      "source": "isoforms",
      "target": "JAK family",
      "label": "are in"
    },
    {
      "source": "C1-tetrahydrofolate interconverting enzymes",
      "target": "plastids",
      "label": "present in"
    },
    {
      "source": "C1-tetrahydrofolate interconverting enzymes",
      "target": "cytosol",
      "label": "present in"
    },
    {
      "source": "C1-tetrahydrofolate interconverting enzymes",
      "target": "mitochondria",
      "label": "present in"
    },
    {
      "source": "mitochondria",
      "target": "dihydrofolate",
      "label": "site of synthesis of"
    },
    {
      "source": "mitochondria",
      "target": "liver",
      "label": "isolated from"
    },
    {
      "source": "mitochondria",
      "target": "liver tissues",
      "label": "are of"
    },
    {
      "source": "Tetrahydrofolate coenzymes",
      "target": "polyglutamylated",
      "label": "is"
    },
    {
      "source": "Tetrahydrofolate coenzymes",
      "target": "one-carbon (C1) metabolism",
      "label": "involved in"
    },
    {
      "source": "gene",
      "target": "beta(1)-adrenergic receptor",
      "label": "for"
    },
    {
      "source": "gene",
      "target": "cytosolic TH binding protein",
      "label": "encodes"
    },
    {
      "source": "gene",
      "target": "FSAP",
      "label": "encodes for"
    },
    {
      "source": "gene",
      "target": "eight exons",
      "label": "contained"
    },
    {
      "source": "gene",
      "target": "33.5 kilobases",
      "label": "contained"
    },
    {
      "source": "gene",
      "target": "human factor IX",
      "label": "is for"
    },
    {
      "source": "gene",
      "target": "seven introns",
      "label": "contained"
    },
    {
      "source": "DHFS",
      "target": "folate molecule",
      "label": "catalyzes attachment to"
    },
    {
      "source": "DHFS",
      "target": "mitochondria",
      "label": "present in"
    },
    {
      "source": "DHFS",
      "target": "glutamate residues",
      "label": "catalyzes attachment of"
    },
    {
      "source": "DHFS",
      "target": "Arabidopsis thaliana",
      "label": "isolated from"
    },
    {
      "source": "folylpolyglutamate synthetase",
      "target": "isoforms",
      "label": "has"
    },
    {
      "source": "folylpolyglutamate synthetase",
      "target": "folate molecule",
      "label": "catalyzes attachment to"
    },
    {
      "source": "folylpolyglutamate synthetase",
      "target": "Arabidopsis thaliana",
      "label": "characterized in"
    },
    {
      "source": "folylpolyglutamate synthetase",
      "target": "glutamate residues",
      "label": "catalyzes attachment of"
    },
    {
      "source": "FPGS",
      "target": "mitochondria",
      "label": "present in"
    },
    {
      "source": "FPGS",
      "target": "chloroplast",
      "label": "present in"
    },
    {
      "source": "FPGS",
      "target": "cytosol",
      "label": "present in"
    },
    {
      "source": "FPGS",
      "target": "isoforms",
      "label": "has"
    },
    {
      "source": "FPGS",
      "target": "multicompartmentation",
      "label": "has"
    },
    {
      "source": "FPGS",
      "target": "glutamate residues",
      "label": "catalyzes attachment of"
    },
    {
      "source": "FPGS",
      "target": "polyglutamylated folate coenzymes",
      "label": "supplies"
    },
    {
      "source": "FPGS",
      "target": "compartmentation",
      "label": "has"
    },
    {
      "source": "FPGS",
      "target": "folate molecule",
      "label": "catalyzes attachment to"
    },
    {
      "source": "FPGS",
      "target": "folate-mediated reactions",
      "label": "combined with"
    },
    {
      "source": "glutamate residues",
      "target": "folate molecule",
      "label": "attached to"
    },
    {
      "source": "dihydrofolate synthetase",
      "target": "glutamate residues",
      "label": "catalyzes attachment of"
    },
    {
      "source": "dihydrofolate synthetase",
      "target": "folate molecule",
      "label": "catalyzes attachment to"
    },
    {
      "source": "dihydrofolate synthetase",
      "target": "Arabidopsis thaliana",
      "label": "characterized in"
    },
    {
      "source": "yeast mutants",
      "target": "DHFS activity",
      "label": "deficient in"
    },
    {
      "source": "yeast mutants",
      "target": "FPGS activity",
      "label": "deficient in"
    },
    {
      "source": "gamma-glutamyl-conjugated tetrahydrofolate derivatives",
      "target": "mitochondria",
      "label": "present in"
    },
    {
      "source": "gamma-glutamyl-conjugated tetrahydrofolate derivatives",
      "target": "plastids",
      "label": "present in"
    },
    {
      "source": "gamma-glutamyl-conjugated tetrahydrofolate derivatives",
      "target": "cytosol",
      "label": "present in"
    },
    {
      "source": "multicompartmentation",
      "target": "plant cell",
      "label": "occurs in"
    },
    {
      "source": "dihydrofolate",
      "target": "plant cell",
      "label": "synthesized in"
    },
    {
      "source": "organisms",
      "target": "Tetrahydrofolate",
      "label": "synthesize"
    },
    {
      "source": "organisms",
      "target": "Saccharomyces cerevisiae",
      "label": "include"
    },
    {
      "source": "organisms",
      "target": "mouse",
      "label": "include"
    },
    {
      "source": "serine hydroxymethyltransferase",
      "target": "mitochondria",
      "label": "present in"
    },
    {
      "source": "serine hydroxymethyltransferase",
      "target": "plastids",
      "label": "present in"
    },
    {
      "source": "serine hydroxymethyltransferase",
      "target": "cytosol",
      "label": "present in"
    },
    {
      "source": "polyglutamylated folate coenzymes",
      "target": "one-carbon (C1) metabolism",
      "label": "required for"
    },
    {
      "source": "biosynthesis",
      "target": "Tetrahydrofolate",
      "label": "of"
    },
    {
      "source": "biosynthesis",
      "target": "plants",
      "label": "occurs in"
    },
    {
      "source": "biosynthesis",
      "target": "hormonal steroids",
      "label": "of"
    },
    {
      "source": "glutamate incorporation",
      "target": "dihydrofolate",
      "label": "into"
    },
    {
      "source": "glutamate incorporation",
      "target": "Tetrahydrofolate",
      "label": "into"
    },
    {
      "source": "folate-mediated reactions",
      "target": "polyglutamylated folate coenzymes",
      "label": "supplies"
    },
    {
      "source": "plants",
      "target": "Asteraceae family",
      "label": "belong to"
    },
    {
      "source": "tacrine",
      "target": "brain penetration",
      "label": "has poor"
    },
    {
      "source": "tacrine",
      "target": "hepatotoxic liability",
      "label": "has"
    },
    {
      "source": "tacrine",
      "target": "clinical trials",
      "label": "performed poorly in"
    },
    {
      "source": "tacrine",
      "target": "acetylcholinesterase (AChE) inhibitors",
      "label": "is an"
    },
    {
      "source": "tacrine",
      "target": "oral activity",
      "label": "has poor"
    },
    {
      "source": "tacrine",
      "target": "intravenous (i.v.) route",
      "label": "administered by"
    },
    {
      "source": "tacrine",
      "target": "acetylcholinesterase inhibitors",
      "label": "is a type of"
    },
    {
      "source": "tacrine",
      "target": "pressor effect",
      "label": "induced"
    },
    {
      "source": "tacrine",
      "target": "mechanisms",
      "label": "chosen as model to study"
    },
    {
      "source": "brain penetration",
      "target": "subcutaneous administration",
      "label": "occurs after"
    },
    {
      "source": "new type of acetylcholinesterase inhibitor",
      "target": "compounds",
      "label": "overcomes disadvantages of"
    },
    {
      "source": "new class of AChE inhibitors",
      "target": "adverse effects",
      "label": "has"
    },
    {
      "source": "Donepezil hydrochloride",
      "target": "new class of AChE inhibitors",
      "label": "inaugurates"
    },
    {
      "source": "Donepezil hydrochloride",
      "target": "drug",
      "label": "is a"
    },
    {
      "source": "Donepezil hydrochloride",
      "target": "Alzheimer's disease",
      "label": "treats"
    },
    {
      "source": "physostigmine",
      "target": "clinical trials",
      "label": "performed poorly in"
    },
    {
      "source": "physostigmine",
      "target": "acetylcholinesterase (AChE) inhibitors",
      "label": "is an"
    },
    {
      "source": "physostigmine",
      "target": "hepatotoxic liability",
      "label": "has"
    },
    {
      "source": "physostigmine",
      "target": "oral activity",
      "label": "has poor"
    },
    {
      "source": "physostigmine",
      "target": "brain penetration",
      "label": "has poor"
    },
    {
      "source": "physostigmine",
      "target": "intravenous (i.v.) route",
      "label": "administered by"
    },
    {
      "source": "physostigmine",
      "target": "acetylcholinesterase inhibitors",
      "label": "is a type of"
    },
    {
      "source": "clinical trials",
      "target": "relapsed and refractory disease",
      "label": "confirmed benefit in"
    },
    {
      "source": "clinical trials",
      "target": "combination",
      "label": "were conducted in"
    },
    {
      "source": "clinical trials",
      "target": "single agent",
      "label": "were conducted as"
    },
    {
      "source": "cognitive deficits",
      "target": "Alzheimer's disease (AD)",
      "label": "are characteristic of"
    },
    {
      "source": "acetylcholinesterase (AChE) inhibitors",
      "target": "drug",
      "label": "are developed as"
    },
    {
      "source": "acetylcholinesterase (AChE) inhibitors",
      "target": "Alzheimer's disease",
      "label": "treats"
    },
    {
      "source": "cholinergic system",
      "target": "cognitive deficits",
      "label": "is related to"
    },
    {
      "source": "cholinergic system",
      "target": "memory consolidation",
      "label": "has a role in"
    },
    {
      "source": "cholinergic system",
      "target": "declarative learning",
      "label": "modulates"
    },
    {
      "source": "Leflunomide",
      "target": "tumour therapy",
      "label": "is used for"
    },
    {
      "source": "Leflunomide",
      "target": "pharmacological immunomodulation",
      "label": "is a drug for"
    },
    {
      "source": "Leflunomide",
      "target": "anti-inflammatory action",
      "label": "exhibits"
    },
    {
      "source": "Leflunomide",
      "target": "prodrug",
      "label": "is a"
    },
    {
      "source": "Leflunomide",
      "target": "drug",
      "label": "is a"
    },
    {
      "source": "Leflunomide",
      "target": "Drug-related adverse effects",
      "label": "has"
    },
    {
      "source": "Leflunomide",
      "target": "mechanism of action",
      "label": "has a"
    },
    {
      "source": "Leflunomide",
      "target": "therapy",
      "label": "is approved for"
    },
    {
      "source": "Leflunomide",
      "target": "therapeutic agent",
      "label": "is a"
    },
    {
      "source": "Leflunomide",
      "target": "isoxazole derivative",
      "label": "is an"
    },
    {
      "source": "Leflunomide",
      "target": "autoimmune diseases",
      "label": "is used for"
    },
    {
      "source": "Leflunomide",
      "target": "immunosuppressants",
      "label": "is unrelated to"
    },
    {
      "source": "Leflunomide",
      "target": "graft rejection",
      "label": "is used for"
    },
    {
      "source": "Leflunomide",
      "target": "immunosuppressant",
      "label": "is a"
    },
    {
      "source": "Leflunomide",
      "target": "immunomodulatory agent",
      "label": "is an"
    },
    {
      "source": "Leflunomide",
      "target": "active metabolite A 77 1726 (M1)",
      "label": "is converted to"
    },
    {
      "source": "dermatological experience",
      "target": "psoriasis",
      "label": "gained in"
    },
    {
      "source": "dermatological experience",
      "target": "bullous pemphigoid",
      "label": "gained in"
    },
    {
      "source": "therapy",
      "target": "rheumatoid arthritis",
      "label": "is for"
    },
    {
      "source": "therapy",
      "target": "people",
      "label": "for"
    },
    {
      "source": "therapy",
      "target": "COX-2 inhibitor",
      "label": "involved"
    },
    {
      "source": "therapy",
      "target": "rofecoxib",
      "label": "involved"
    },
    {
      "source": "therapy",
      "target": "celecoxib",
      "label": "involved"
    },
    {
      "source": "role",
      "target": "years",
      "label": "will evolve during the next"
    },
    {
      "source": "role",
      "target": "dermatologist's therapeutic armamentarium",
      "label": "is in"
    },
    {
      "source": "role",
      "target": "Leflunomide",
      "label": "of"
    },
    {
      "source": "role",
      "target": "antigenic surfaces",
      "label": "in binding"
    },
    {
      "source": "role",
      "target": "metabolites",
      "label": "is_mediated_by"
    },
    {
      "source": "role",
      "target": "spine structure",
      "label": "is_in"
    },
    {
      "source": "role",
      "target": "APP",
      "label": "is_for"
    },
    {
      "source": "role",
      "target": "spine functions",
      "label": "is_in"
    },
    {
      "source": "mechanism of action",
      "target": "inflammatory pathways",
      "label": "affects"
    },
    {
      "source": "mechanism of action",
      "target": "ezetimibe",
      "label": "of"
    },
    {
      "source": "mechanism of action",
      "target": "Pim-1",
      "label": "not characterized for"
    },
    {
      "source": "mechanism of action",
      "target": "allosteric inhibition",
      "label": "resembles"
    },
    {
      "source": "A 77 1726",
      "target": "dihydroorotate dehydrogenase",
      "label": "blocks"
    },
    {
      "source": "dihydroorotate dehydrogenase",
      "target": "key enzyme",
      "label": "is a"
    },
    {
      "source": "dihydroorotate dehydrogenase",
      "target": "pyrimidine de novo synthesis",
      "label": "is an enzyme of"
    },
    {
      "source": "therapeutic agent",
      "target": "asthma",
      "label": "is effective against"
    },
    {
      "source": "therapeutic agent",
      "target": "inflammatory conditions",
      "label": "for"
    },
    {
      "source": "therapeutic agent",
      "target": "treatment",
      "label": "for"
    },
    {
      "source": "therapeutic agent",
      "target": "prevention",
      "label": "for"
    },
    {
      "source": "M1",
      "target": "dihydroorotate dehydrogenase",
      "label": "blocks"
    },
    {
      "source": "M1",
      "target": "BCRP",
      "label": "is a substrate of"
    },
    {
      "source": "M1",
      "target": "MRP2",
      "label": "is a substrate of"
    },
    {
      "source": "M1",
      "target": "components",
      "label": "is a"
    },
    {
      "source": "M1",
      "target": "total plasma radioactivity area under the curve",
      "label": "accounts for"
    },
    {
      "source": "M1",
      "target": "dose",
      "label": "accounts for"
    },
    {
      "source": "M1",
      "target": "carboxylate metabolite",
      "label": "is a"
    },
    {
      "source": "M1",
      "target": "MRP4",
      "label": "is a substrate of"
    },
    {
      "source": "M1",
      "target": "OAT3",
      "label": "is a substrate of"
    },
    {
      "source": "M1",
      "target": "plasma",
      "label": "found in"
    },
    {
      "source": "mechanisms of action",
      "target": "patient responsiveness",
      "label": "contribute to"
    },
    {
      "source": "mechanisms of action",
      "target": "biological activity of alefacept",
      "label": "influence"
    },
    {
      "source": "mechanisms of action",
      "target": "efficacy",
      "label": "contribute to"
    },
    {
      "source": "cell surface expression",
      "target": "activation marker CD25",
      "label": "of"
    },
    {
      "source": "immunomodulatory recombinant fusion protein",
      "target": "first extracellular domain of LFA-3",
      "label": "composed of"
    },
    {
      "source": "immunomodulatory recombinant fusion protein",
      "target": "human IgG1 hinge, C(H)2, and C(H)3 domains",
      "label": "composed of"
    },
    {
      "source": "CD2/CD16-dependent apoptosis",
      "target": "CD2(+) cells",
      "label": "affects"
    },
    {
      "source": "intracellular signals",
      "target": "CD2",
      "label": "mediated via"
    },
    {
      "source": "intracellular signals",
      "target": "Fc gamma RIII (CD16)",
      "label": "mediated via"
    },
    {
      "source": "intracellular signals",
      "target": "p44/p42 extracellular signal-regulated kinase (ERK)",
      "label": "includes"
    },
    {
      "source": "isoforms of alefacept",
      "target": "amino acid substitutions",
      "label": "have"
    },
    {
      "source": "isoforms of alefacept",
      "target": "Fc gamma R binding",
      "label": "confirmed requirement for"
    },
    {
      "source": "amino acid substitutions",
      "target": "IgG1 C(H)2 domain",
      "label": "located in"
    },
    {
      "source": "amino acid substitutions",
      "target": "Fc gamma R binding",
      "label": "impact"
    },
    {
      "source": "Alefacept",
      "target": "phase II and III clinical trials",
      "label": "evaluated in"
    },
    {
      "source": "Alefacept",
      "target": "function",
      "label": "modulates"
    },
    {
      "source": "Alefacept",
      "target": "extracellular signal-regulated kinase phosphorylation",
      "label": "increases"
    },
    {
      "source": "Alefacept",
      "target": "Fc gamma R(+) cells",
      "label": "activates"
    },
    {
      "source": "Alefacept",
      "target": "CD2/CD16-dependent apoptosis",
      "label": "induces"
    },
    {
      "source": "Alefacept",
      "target": "CD2(+) human memory-effector T cells",
      "label": "induces apoptosis of"
    },
    {
      "source": "Alefacept",
      "target": "disease expression",
      "label": "reduces"
    },
    {
      "source": "Alefacept",
      "target": "cognate interactions",
      "label": "mediates"
    },
    {
      "source": "Alefacept",
      "target": "release of granzyme B",
      "label": "induces"
    },
    {
      "source": "Alefacept",
      "target": "cell surface expression",
      "label": "up-regulates"
    },
    {
      "source": "Alefacept",
      "target": "CD16 signaling",
      "label": "induces"
    },
    {
      "source": "Alefacept",
      "target": "immunomodulatory recombinant fusion protein",
      "label": "is a type of"
    },
    {
      "source": "Alefacept",
      "target": "intracellular signals",
      "label": "activates"
    },
    {
      "source": "Alefacept",
      "target": "cells",
      "label": "activates"
    },
    {
      "source": "Alefacept",
      "target": "immunomodulatory recombinant LFA-3/IgG1 fusion protein",
      "label": "is a type of"
    },
    {
      "source": "Alefacept",
      "target": "effector molecule",
      "label": "acts as an"
    },
    {
      "source": "function",
      "target": "CD2(+) human memory-effector T cells",
      "label": "of"
    },
    {
      "source": "function",
      "target": "hRRM2",
      "label": "of"
    },
    {
      "source": "function",
      "target": "p53R2",
      "label": "of"
    },
    {
      "source": "function",
      "target": "fertility",
      "label": "in"
    },
    {
      "source": "function",
      "target": "receptors",
      "label": "of"
    },
    {
      "source": "function",
      "target": "liver",
      "label": "in"
    },
    {
      "source": "function",
      "target": "enzymes",
      "label": "of"
    },
    {
      "source": "function",
      "target": "lung",
      "label": "in"
    },
    {
      "source": "Fc gamma R(+) cells",
      "target": "sensitive CD2(+) target cells",
      "label": "induces apoptosis of"
    },
    {
      "source": "Fc gamma R(+) cells",
      "target": "NK cells",
      "label": "example"
    },
    {
      "source": "human CD2-transgenic mice",
      "target": "Fc gamma R binding",
      "label": "confirmed requirement for"
    },
    {
      "source": "Fc gamma R binding",
      "target": "pharmacological effects of alefacept",
      "label": "required for detection of"
    },
    {
      "source": "systems",
      "target": "CD16 signaling",
      "label": "show"
    },
    {
      "source": "CD16 signaling",
      "target": "binding to CD16",
      "label": "requires"
    },
    {
      "source": "CD16 signaling",
      "target": "binding to CD2",
      "label": "requires"
    },
    {
      "source": "CD16 signaling",
      "target": "CD16",
      "label": "mediated through"
    },
    {
      "source": "CD16 signaling",
      "target": "CD2",
      "label": "not mediated through"
    },
    {
      "source": "disease expression",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "cognate interactions",
      "target": "human CD2",
      "label": "involve"
    },
    {
      "source": "cognate interactions",
      "target": "CD16",
      "label": "involve"
    },
    {
      "source": "effector molecule",
      "target": "cognate interactions",
      "label": "mediates"
    },
    {
      "source": "important therapeutic option",
      "target": "treatment of multiple myeloma",
      "label": "is for the"
    },
    {
      "source": "Thalidomide",
      "target": "newly diagnosed patients",
      "label": "is under study for"
    },
    {
      "source": "Thalidomide",
      "target": "important therapeutic option",
      "label": "is established as an"
    },
    {
      "source": "Thalidomide",
      "target": "anti-angiogenic effects",
      "label": "has"
    },
    {
      "source": "Thalidomide",
      "target": "multiple myeloma",
      "label": "is used for"
    },
    {
      "source": "Thalidomide",
      "target": "widespread clinical use",
      "label": "removed from"
    },
    {
      "source": "Thalidomide",
      "target": "practice",
      "label": "returned to"
    },
    {
      "source": "Thalidomide",
      "target": "effective oral agent",
      "label": "is an"
    },
    {
      "source": "Thalidomide",
      "target": "severe teratogenicity",
      "label": "has"
    },
    {
      "source": "Thalidomide",
      "target": "certain malignancies",
      "label": "is used for"
    },
    {
      "source": "Thalidomide",
      "target": "treatment of multiple myeloma",
      "label": "is used in the"
    },
    {
      "source": "Thalidomide",
      "target": "TNF alpha",
      "label": "inhibits"
    },
    {
      "source": "Thalidomide",
      "target": "immunomodulatory effects",
      "label": "has"
    },
    {
      "source": "Thalidomide",
      "target": "FDA",
      "label": "was approved by"
    },
    {
      "source": "certain malignancies",
      "target": "multiple myeloma",
      "label": "include"
    },
    {
      "source": "extensive preclinical studies",
      "target": "mechanism of action of thalidomide",
      "label": "generated insight into"
    },
    {
      "source": "extensive preclinical studies",
      "target": "multiple myeloma",
      "label": "were conducted in"
    },
    {
      "source": "management of various disease states",
      "target": "erythema nodosum leprosum",
      "label": "includes"
    },
    {
      "source": "management of various disease states",
      "target": "certain malignancies",
      "label": "includes"
    },
    {
      "source": "effective oral agent",
      "target": "management of various disease states",
      "label": "is used in the"
    },
    {
      "source": "immunomodulatory effects",
      "target": "inhibition of TNF alpha",
      "label": "include"
    },
    {
      "source": "FDA",
      "target": "Food and Drug Administration",
      "label": "also known as"
    },
    {
      "source": "diazoxide-sensitive",
      "target": "diffuse forms",
      "label": "is not different in"
    },
    {
      "source": "diazoxide-sensitive",
      "target": "age of onset of hypoglycaemia",
      "label": "depends on"
    },
    {
      "source": "diazoxide-sensitive",
      "target": "focal forms",
      "label": "is not different in"
    },
    {
      "source": "neonates",
      "target": "diazoxide-sensitive",
      "label": "with Hyperammonaemia are"
    },
    {
      "source": "neonates",
      "target": "i.v. glucose",
      "label": "required more"
    },
    {
      "source": "neonates",
      "target": "surgical treatment",
      "label": "received"
    },
    {
      "source": "neonates",
      "target": "propionic acidemias",
      "label": "have"
    },
    {
      "source": "neonates",
      "target": "isovaleric acidemia",
      "label": "have"
    },
    {
      "source": "neonates",
      "target": "methylmalonic acidemias",
      "label": "have"
    },
    {
      "source": "KIR6.2",
      "target": "neonates",
      "label": "found in"
    },
    {
      "source": "KIR6.2",
      "target": "infants",
      "label": "found in"
    },
    {
      "source": "mutations",
      "target": "glutamate dehydrogenase gene",
      "label": "found in"
    },
    {
      "source": "mutations",
      "target": "KIR6.2",
      "label": "include"
    },
    {
      "source": "mutations",
      "target": "SUR1",
      "label": "include"
    },
    {
      "source": "mutations",
      "target": "glucokinase gene",
      "label": "not found in"
    },
    {
      "source": "mutations",
      "target": "alleles",
      "label": "responsible for"
    },
    {
      "source": "mutations",
      "target": "affinity for ornithine",
      "label": "reduced"
    },
    {
      "source": "mutations",
      "target": "interaction",
      "label": "impaired"
    },
    {
      "source": "mutations",
      "target": "residues",
      "label": "identify"
    },
    {
      "source": "mutations",
      "target": "Flt3",
      "label": "activate"
    },
    {
      "source": "mutations",
      "target": "SLC25A13 gene",
      "label": "affect"
    },
    {
      "source": "mutations",
      "target": "compound heterozygote",
      "label": "are a type of"
    },
    {
      "source": "mutations",
      "target": "Trp53 mutations",
      "label": "include"
    },
    {
      "source": "mutations",
      "target": "haplo-insufficiency",
      "label": "lead to"
    },
    {
      "source": "mutations",
      "target": "patients' NCCT cDNA",
      "label": "detected in"
    },
    {
      "source": "glutamate dehydrogenase gene",
      "target": "infants",
      "label": "mutations found in"
    },
    {
      "source": "glutamate dehydrogenase gene",
      "target": "neonates",
      "label": "mutations found in"
    },
    {
      "source": "sequence analysis of cDNA",
      "target": "mutations",
      "label": "used to find"
    },
    {
      "source": "Hyperammonaemia",
      "target": "patients",
      "label": "found in"
    },
    {
      "source": "Hyperammonaemia",
      "target": "neonates",
      "label": "found in"
    },
    {
      "source": "Hyperammonaemia",
      "target": "infants",
      "label": "found in"
    },
    {
      "source": "Hyperinsulinism",
      "target": "clinical presentations",
      "label": "has"
    },
    {
      "source": "Hyperinsulinism",
      "target": "severe hypoglycaemia",
      "label": "is characterized by"
    },
    {
      "source": "Hyperinsulinism",
      "target": "molecular studies",
      "label": "has"
    },
    {
      "source": "Hyperinsulinism",
      "target": "heterogeneous disorder",
      "label": "is a"
    },
    {
      "source": "Hyperinsulinism",
      "target": "therapeutic management",
      "label": "has"
    },
    {
      "source": "severe hypoglycaemia",
      "target": "oversecretion of insulin",
      "label": "is caused by"
    },
    {
      "source": "Heterogeneity",
      "target": "persistent hyperinsulinaemic hypoglycaemia",
      "label": "is a characteristic of"
    },
    {
      "source": "Heterogeneity",
      "target": "therapeutic outcome",
      "label": "impacts"
    },
    {
      "source": "Heterogeneity",
      "target": "Hyperinsulinism",
      "label": "of"
    },
    {
      "source": "Heterogeneity",
      "target": "genetic counselling",
      "label": "impacts"
    },
    {
      "source": "neonatal-onset patients",
      "target": "transient forms",
      "label": "include"
    },
    {
      "source": "neonatal-onset patients",
      "target": "permanent hyperinsulinism",
      "label": "include"
    },
    {
      "source": "histological examination",
      "target": "adenoma",
      "label": "confirmed"
    },
    {
      "source": "focal adenomatous hyperplasia",
      "target": "neonates",
      "label": "found in"
    },
    {
      "source": "focal adenomatous hyperplasia",
      "target": "infants",
      "label": "found in"
    },
    {
      "source": "diffuse form of hyperinsulinism",
      "target": "infants",
      "label": "found in"
    },
    {
      "source": "diffuse form of hyperinsulinism",
      "target": "neonates",
      "label": "found in"
    },
    {
      "source": "infants",
      "target": "diazoxide-sensitive",
      "label": "are more often"
    },
    {
      "source": "infants",
      "target": "i.v. glucose",
      "label": "required less"
    },
    {
      "source": "infants",
      "target": "medical treatment",
      "label": "received"
    },
    {
      "source": "infants",
      "target": "biotin-deficient",
      "label": "were"
    },
    {
      "source": "infants",
      "target": "nutritional disorder",
      "label": "have"
    },
    {
      "source": "surgically-treated patients",
      "target": "diffuse form of hyperinsulinism",
      "label": "had"
    },
    {
      "source": "surgically-treated patients",
      "target": "focal adenomatous hyperplasia",
      "label": "had"
    },
    {
      "source": "i.v. glucose",
      "target": "plasma glucose levels",
      "label": "maintains"
    },
    {
      "source": "reverse transcriptase-polymerase chain reaction",
      "target": "sequence analysis of cDNA",
      "label": "used for"
    },
    {
      "source": "polymerase chain reaction-single strand conformational polymorphism analysis",
      "target": "genes",
      "label": "used for analysis of"
    },
    {
      "source": "polymerase chain reaction-single strand conformational polymorphism analysis",
      "target": "glucokinase gene",
      "label": "did not find mutations in"
    },
    {
      "source": "genes",
      "target": "expression of enzymes",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "Saccharomyces cerevisiae strains",
      "label": "disrupted in"
    },
    {
      "source": "genes",
      "target": "cationic amino acid transporters",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "Decitabine",
      "label": "activated by"
    },
    {
      "source": "genes",
      "target": "proteins",
      "label": "code for"
    },
    {
      "source": "genes",
      "target": "tumor necrosis factor",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "TNF receptor 2",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "Jun NH(2)-terminal kinase",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "SAPK",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "stress-activated protein kinase",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "TNFR2",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "TNF",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "Retn(-/-) mice",
      "label": "were downregulated in"
    },
    {
      "source": "genes",
      "target": "JNK",
      "label": "encode"
    },
    {
      "source": "genes",
      "target": "redox homeostasis",
      "label": "are involved in"
    },
    {
      "source": "genes",
      "target": "amino acid metabolism",
      "label": "are involved in"
    },
    {
      "source": "genes",
      "target": "transport",
      "label": "are involved in"
    },
    {
      "source": "genes",
      "target": "gluconeogenesis",
      "label": "involved in"
    },
    {
      "source": "genes",
      "target": "hepatic lipogenesis",
      "label": "involved in"
    },
    {
      "source": "genes",
      "target": "esterase D",
      "label": "are for"
    },
    {
      "source": "genes",
      "target": "microdeletions of 11p",
      "label": "are deleted in"
    },
    {
      "source": "genes",
      "target": "catalase",
      "label": "are for"
    },
    {
      "source": "genes",
      "target": "microdeletions of 13q",
      "label": "are deleted in"
    },
    {
      "source": "SUR1",
      "target": "neonates",
      "label": "found in"
    },
    {
      "source": "SUR1",
      "target": "infants",
      "label": "found in"
    },
    {
      "source": "hyperinsulinism-hyperammonaemia syndrome",
      "target": "glutamate dehydrogenase gene",
      "label": "is associated with mutation in"
    },
    {
      "source": "infancy-onset hyperinsulinism",
      "target": "tolerance to hypoglycaemia",
      "label": "is associated with"
    },
    {
      "source": "clinical severity",
      "target": "age of onset of hypoglycaemia",
      "label": "varies with"
    },
    {
      "source": "clinical severity",
      "target": "Hyperinsulinism",
      "label": "of"
    },
    {
      "source": "clinical severity",
      "target": "infants",
      "label": "is lower in"
    },
    {
      "source": "clinical severity",
      "target": "neonates",
      "label": "is higher in"
    },
    {
      "source": "Aliskiren",
      "target": "octanamide",
      "label": "is an"
    },
    {
      "source": "Aliskiren",
      "target": "hypertension",
      "label": "treats"
    },
    {
      "source": "Aliskiren",
      "target": "urinary aldosterone levels",
      "label": "decreases"
    },
    {
      "source": "Aliskiren",
      "target": "Plasma drug levels",
      "label": "has property"
    },
    {
      "source": "Aliskiren",
      "target": "plasma active renin",
      "label": "increases"
    },
    {
      "source": "Aliskiren",
      "target": "Ang II receptor antagonists",
      "label": "is an alternative to"
    },
    {
      "source": "Aliskiren",
      "target": "nonpeptidic renin inhibitor",
      "label": "is a"
    },
    {
      "source": "Aliskiren",
      "target": "oral administration",
      "label": "is administered via"
    },
    {
      "source": "Aliskiren",
      "target": "IC50",
      "label": "has property"
    },
    {
      "source": "Aliskiren",
      "target": "Angiotensin II",
      "label": "decreases"
    },
    {
      "source": "Aliskiren",
      "target": "plasma renin activity",
      "label": "decreases"
    },
    {
      "source": "Aliskiren",
      "target": "double-blind, 3-way crossover protocol",
      "label": "tested using"
    },
    {
      "source": "Aliskiren",
      "target": "natriuresis",
      "label": "enhances"
    },
    {
      "source": "Aliskiren",
      "target": "cardiovascular diseases",
      "label": "treats"
    },
    {
      "source": "Aliskiren",
      "target": "renin inhibitor",
      "label": "is a"
    },
    {
      "source": "Aliskiren",
      "target": "steady state",
      "label": "reached"
    },
    {
      "source": "Aliskiren",
      "target": "humans",
      "label": "affects"
    },
    {
      "source": "Aliskiren",
      "target": "enalapril",
      "label": "has equivalent effect to"
    },
    {
      "source": "Aliskiren",
      "target": "Plasma aldosterone levels",
      "label": "decreases"
    },
    {
      "source": "Aliskiren",
      "target": "ACE-inhibitors",
      "label": "is an alternative to"
    },
    {
      "source": "Aliskiren",
      "target": "Ang I",
      "label": "decreases"
    },
    {
      "source": "Aliskiren",
      "target": "urine",
      "label": "excreted in"
    },
    {
      "source": "Aliskiren",
      "target": "Ang II",
      "label": "decreases"
    },
    {
      "source": "Aliskiren",
      "target": "renal diseases",
      "label": "treats"
    },
    {
      "source": "Aliskiren",
      "target": "healthy volunteers",
      "label": "tested in"
    },
    {
      "source": "Renin",
      "target": "angiotensin (Ang) II",
      "label": "determines"
    },
    {
      "source": "Plasma drug levels",
      "target": "maximal concentrations",
      "label": "reached"
    },
    {
      "source": "SPP100",
      "target": "renin inhibitor",
      "label": "is a"
    },
    {
      "source": "SPP100",
      "target": "octanamide",
      "label": "is an"
    },
    {
      "source": "SPP100",
      "target": "healthy volunteers",
      "label": "tested in"
    },
    {
      "source": "SPP100",
      "target": "IC50",
      "label": "has property"
    },
    {
      "source": "SPP100",
      "target": "Angiotensin II",
      "label": "decreases"
    },
    {
      "source": "SPP100",
      "target": "nonpeptidic renin inhibitor",
      "label": "is a"
    },
    {
      "source": "SPP100",
      "target": "double-blind, 3-way crossover protocol",
      "label": "tested using"
    },
    {
      "source": "renin inhibitor",
      "target": "Ang II",
      "label": "decreases"
    },
    {
      "source": "enalapril",
      "target": "Plasma aldosterone levels",
      "label": "decreases"
    },
    {
      "source": "enalapril",
      "target": "urinary aldosterone levels",
      "label": "decreases"
    },
    {
      "source": "oral administration",
      "target": "AML",
      "label": "is of"
    },
    {
      "source": "IC50",
      "target": "nanomolar range",
      "label": "is in"
    },
    {
      "source": "IC50",
      "target": "enzyme activity",
      "label": "inhibits"
    },
    {
      "source": "IC50",
      "target": "\u03bcM",
      "label": "measured in"
    },
    {
      "source": "healthy volunteers",
      "target": "enalapril",
      "label": "received"
    },
    {
      "source": "healthy volunteers",
      "target": "sodium diet",
      "label": "on diet"
    },
    {
      "source": "healthy volunteers",
      "target": "placebo",
      "label": "received"
    },
    {
      "source": "healthy volunteers",
      "target": "Aliskiren",
      "label": "received"
    },
    {
      "source": "healthy volunteers",
      "target": "platelet studies",
      "label": "had"
    },
    {
      "source": "heart rate",
      "target": "normotensive subjects",
      "label": "remained unchanged in"
    },
    {
      "source": "cardiovascular diseases",
      "target": "CVD",
      "label": "also known as"
    },
    {
      "source": "renin inhibitors",
      "target": "oral administration",
      "label": "lacked"
    },
    {
      "source": "urine",
      "target": "blood",
      "label": "studied instead of"
    },
    {
      "source": "urine",
      "target": "affected patients",
      "label": "from"
    },
    {
      "source": "urine",
      "target": "healthy population",
      "label": "levels decreased to values of"
    },
    {
      "source": "urine",
      "target": "gastric cancer patients",
      "label": "from"
    },
    {
      "source": "urine",
      "target": "healthy control subjects",
      "label": "from"
    },
    {
      "source": "people",
      "target": "diabetes",
      "label": "has"
    },
    {
      "source": "diabetes",
      "target": "intraperitoneal injection",
      "label": "induced by"
    },
    {
      "source": "diabetes",
      "target": "rats",
      "label": "induced in"
    },
    {
      "source": "diabetes",
      "target": "plasma total ghrelin",
      "label": "associated with low levels of"
    },
    {
      "source": "safety implications",
      "target": "growth-stimulating potential",
      "label": "of"
    },
    {
      "source": "growth-stimulating potential",
      "target": "insulin glargine",
      "label": "of"
    },
    {
      "source": "in vitro potency",
      "target": "insulin detemir",
      "label": "of"
    },
    {
      "source": "insulin detemir",
      "target": "NN304",
      "label": "is a type of"
    },
    {
      "source": "insulin detemir",
      "target": "metabolic potencies",
      "label": "has"
    },
    {
      "source": "insulin detemir",
      "target": "analog",
      "label": "is an"
    },
    {
      "source": "insulin detemir",
      "target": "molar basis",
      "label": "effective on"
    },
    {
      "source": "insulin detemir",
      "target": "humans",
      "label": "effective in"
    },
    {
      "source": "insulin detemir",
      "target": "LysB29",
      "label": "has"
    },
    {
      "source": "insulin detemir",
      "target": "receptor affinities",
      "label": "has"
    },
    {
      "source": "insulin detemir",
      "target": "mitogenic potencies",
      "label": "has"
    },
    {
      "source": "insulin detemir",
      "target": "fatty acid chain",
      "label": "has"
    },
    {
      "source": "insulin detemir",
      "target": "human insulin",
      "label": "effective as"
    },
    {
      "source": "fatty acid chain",
      "target": "LysB29",
      "label": "attached to"
    },
    {
      "source": "NN304",
      "target": "B29Lys(epsilon-tetradecanoyl)",
      "label": "is a type of"
    },
    {
      "source": "NN304",
      "target": "desB30 human insulin",
      "label": "is a type of"
    },
    {
      "source": "aspart",
      "target": "rapid-acting insulin analogs",
      "label": "is a type of"
    },
    {
      "source": "aspart",
      "target": "human insulin",
      "label": "resembles"
    },
    {
      "source": "mitogenic potencies",
      "target": "IGF-I receptor affinity",
      "label": "correlated with"
    },
    {
      "source": "mitogenic potencies",
      "target": "human osteosarcoma cells",
      "label": "determined in"
    },
    {
      "source": "mitogenic potencies",
      "target": "insulin receptor off-rates",
      "label": "correlated with"
    },
    {
      "source": "metabolic potencies",
      "target": "insulin receptor affinities",
      "label": "correlated with"
    },
    {
      "source": "metabolic potencies",
      "target": "primary mouse adipocytes",
      "label": "evaluated using"
    },
    {
      "source": "lispro",
      "target": "rapid-acting insulin analogs",
      "label": "is a type of"
    },
    {
      "source": "lispro",
      "target": "IGF-I receptor affinity",
      "label": "has"
    },
    {
      "source": "lispro",
      "target": "human insulin",
      "label": "resembles"
    },
    {
      "source": "balance",
      "target": "mitogenic potencies",
      "label": "between"
    },
    {
      "source": "balance",
      "target": "metabolic potencies",
      "label": "between"
    },
    {
      "source": "balance",
      "target": "local growth factors",
      "label": "of"
    },
    {
      "source": "insulin analogs",
      "target": "toxico-pharmacological properties",
      "label": "has"
    },
    {
      "source": "insulin analogs",
      "target": "mitogenic potencies",
      "label": "has"
    },
    {
      "source": "insulin analogs",
      "target": "clinical use",
      "label": "designed for"
    },
    {
      "source": "insulin analogs",
      "target": "metabolic potencies",
      "label": "has"
    },
    {
      "source": "insulin analogs",
      "target": "receptor binding properties",
      "label": "has"
    },
    {
      "source": "insulin glargine",
      "target": "IGF-I receptor affinity",
      "label": "has"
    },
    {
      "source": "insulin glargine",
      "target": "B31B32diArg",
      "label": "has"
    },
    {
      "source": "insulin glargine",
      "target": "mitogenic potencies",
      "label": "has"
    },
    {
      "source": "insulin glargine",
      "target": "A21Gly substitutions",
      "label": "has"
    },
    {
      "source": "insulin glargine",
      "target": "A21Gly,B31Arg,B32Arg human insulin",
      "label": "is a type of"
    },
    {
      "source": "safety profile",
      "target": "molecular modifications",
      "label": "compromised by"
    },
    {
      "source": "safety profile",
      "target": "adverse events",
      "label": "is in terms of"
    },
    {
      "source": "safety profile",
      "target": "treatment",
      "label": "is comparable between"
    },
    {
      "source": "safety profile",
      "target": "patients",
      "label": "is in"
    },
    {
      "source": "insulin lispro",
      "target": "B28Lys,B29Pro human insulin",
      "label": "is a type of"
    },
    {
      "source": "detemir",
      "target": "human insulin",
      "label": "differs from"
    },
    {
      "source": "detemir",
      "target": "long-acting insulin analogs",
      "label": "is a type of"
    },
    {
      "source": "Chinese hamster ovary cells",
      "target": "human insulin receptor",
      "label": "overexpresses"
    },
    {
      "source": "glargine",
      "target": "human insulin",
      "label": "differs from"
    },
    {
      "source": "glargine",
      "target": "long-acting insulin analogs",
      "label": "is a type of"
    },
    {
      "source": "insulin aspart",
      "target": "B28Asp human insulin",
      "label": "is a type of"
    },
    {
      "source": "receptor affinities",
      "target": "purified human receptors",
      "label": "measured using"
    },
    {
      "source": "analogs of human insulin",
      "target": "therapy",
      "label": "improves"
    },
    {
      "source": "insulin receptor dissociation rates",
      "target": "Chinese hamster ovary cells",
      "label": "determined using"
    },
    {
      "source": "human hormone",
      "target": "safety profile",
      "label": "has"
    },
    {
      "source": "Cilostazol",
      "target": "omeprazole",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "Cilostazol",
      "target": "erythromycin",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "Cilostazol",
      "target": "HDL",
      "label": "INCREASES"
    },
    {
      "source": "Cilostazol",
      "target": "cholesterol",
      "label": "INCREASES"
    },
    {
      "source": "Cilostazol",
      "target": "phosphodiesterase (PDE) 3A",
      "label": "INHIBITS"
    },
    {
      "source": "Cilostazol",
      "target": "2-oxo-quinoline derivative",
      "label": "IS_A"
    },
    {
      "source": "Cilostazol",
      "target": "serum triglycerides",
      "label": "DECREASES"
    },
    {
      "source": "Cilostazol",
      "target": "cytochrome P450 systems",
      "label": "IS_SUBSTRATE_OF"
    },
    {
      "source": "Cilostazol",
      "target": "cAMP",
      "label": "AFFECTS_LEVELS_OF"
    },
    {
      "source": "Cilostazol",
      "target": "6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone",
      "label": "IS_A"
    },
    {
      "source": "Cilostazol",
      "target": "adenosine",
      "label": "INHIBITS_UPTAKE_OF"
    },
    {
      "source": "Cilostazol",
      "target": "OPC-13013",
      "label": "IS_A"
    },
    {
      "source": "Cilostazol",
      "target": "diabetic complications",
      "label": "manages"
    },
    {
      "source": "Cilostazol",
      "target": "Neuroprotective Effects",
      "label": "has"
    },
    {
      "source": "Cilostazol",
      "target": "retinal ganglion cell death",
      "label": "affects"
    },
    {
      "source": "HDL",
      "target": "adrenocortical aldosterone and cortisol release",
      "label": "has stimulating effect on"
    },
    {
      "source": "adenosine receptors",
      "target": "A2",
      "label": "INCLUDES"
    },
    {
      "source": "adenosine receptors",
      "target": "A1",
      "label": "INCLUDES"
    },
    {
      "source": "cholesterol",
      "target": "RA biosynthesis",
      "label": "has crosstalk with"
    },
    {
      "source": "cholesterol",
      "target": "RA",
      "label": "enhanced cellular content of"
    },
    {
      "source": "cholesterol",
      "target": "RALDH1 and 2",
      "label": "enhanced expression of"
    },
    {
      "source": "cholesterol",
      "target": "ABCA1 transporter",
      "label": "Substrate"
    },
    {
      "source": "cholesterol",
      "target": "5A apolipoprotein mimetic peptide",
      "label": "Substrate"
    },
    {
      "source": "cholesterol",
      "target": "OMM",
      "label": "moves from"
    },
    {
      "source": "cholesterol",
      "target": "P450scc",
      "label": "moves to"
    },
    {
      "source": "cAMP",
      "target": "adenosine receptors",
      "label": "LEVELS_DEPEND_ON"
    },
    {
      "source": "cAMP",
      "target": "cholangiocyte hyperplasia/damage",
      "label": "modulates"
    },
    {
      "source": "cAMP",
      "target": "second messenger",
      "label": "is a"
    },
    {
      "source": "cAMP",
      "target": "Acsl4 mRNA",
      "label": "regulates"
    },
    {
      "source": "cAMP",
      "target": "Cl- secretion",
      "label": "mediates"
    },
    {
      "source": "phosphodiesterase (PDE) 3A",
      "target": "PDE 3",
      "label": "IS_ISOFORM_OF"
    },
    {
      "source": "adenosine",
      "target": "VT",
      "label": "suppressed"
    },
    {
      "source": "Molecular models",
      "target": "PDE3 inhibitors",
      "label": "show"
    },
    {
      "source": "kinetic characteristics of inhibition",
      "target": "mutant enzymes",
      "label": "of"
    },
    {
      "source": "kinetic characteristics of inhibition",
      "target": "cilostazol",
      "label": "analyzed_by"
    },
    {
      "source": "kinetic characteristics of inhibition",
      "target": "milrinone",
      "label": "analyzed_by"
    },
    {
      "source": "nonconserved T844",
      "target": "cilostazol selectivity",
      "label": "responsible_for"
    },
    {
      "source": "cilostazol selectivity",
      "target": "PDE3A",
      "label": "of"
    },
    {
      "source": "D950A",
      "target": "diminished sensitivity",
      "label": "exhibited"
    },
    {
      "source": "D950A",
      "target": "reduced sensitivity",
      "label": "exhibited"
    },
    {
      "source": "diminished sensitivity",
      "target": "cilostazol",
      "label": "to"
    },
    {
      "source": "interaction sites",
      "target": "milrinone",
      "label": "interacts_with"
    },
    {
      "source": "interaction sites",
      "target": "cilostazol",
      "label": "interacts_with"
    },
    {
      "source": "interaction sites",
      "target": "cyclic nucleotide phosphodiesterase type 3A",
      "label": "of"
    },
    {
      "source": "milrinone",
      "target": "distinct residues",
      "label": "interacts_with"
    },
    {
      "source": "milrinone",
      "target": "PDE3 inhibitors",
      "label": "is_a"
    },
    {
      "source": "milrinone",
      "target": "common residues",
      "label": "shares"
    },
    {
      "source": "milrinone",
      "target": "PDE3",
      "label": "inhibits"
    },
    {
      "source": "cilostazol",
      "target": "PDE3 inhibitors",
      "label": "is_a"
    },
    {
      "source": "cilostazol",
      "target": "distinct residues",
      "label": "interacts_with"
    },
    {
      "source": "cilostazol",
      "target": "common residues",
      "label": "shares"
    },
    {
      "source": "cilostazol",
      "target": "PDE3",
      "label": "inhibits"
    },
    {
      "source": "F1004A",
      "target": "diminished sensitivity",
      "label": "exhibited"
    },
    {
      "source": "F1004A",
      "target": "reduced sensitivity",
      "label": "exhibited"
    },
    {
      "source": "model",
      "target": "PDE4B crystal structure",
      "label": "based_on"
    },
    {
      "source": "model",
      "target": "homology",
      "label": "based_on"
    },
    {
      "source": "model",
      "target": "target-based drug discovery strategies",
      "label": "is an alternative to"
    },
    {
      "source": "model",
      "target": "GAG/FGF/FGFR interactions",
      "label": "is for"
    },
    {
      "source": "model",
      "target": "oxidative burden",
      "label": "AGAINST"
    },
    {
      "source": "mutants",
      "target": "differential sensitivity",
      "label": "exhibited"
    },
    {
      "source": "mutants",
      "target": "baculovirus/Sf9 cell system",
      "label": "expressed_in"
    },
    {
      "source": "mutants",
      "target": "site-directed mutagenesis",
      "label": "produced by"
    },
    {
      "source": "mutants",
      "target": "COS-7 cells",
      "label": "expressed in"
    },
    {
      "source": "mutants",
      "target": "vardenafil-based compounds",
      "label": "has higher affinity for"
    },
    {
      "source": "mutants",
      "target": "propensity",
      "label": "have"
    },
    {
      "source": "differential sensitivity",
      "target": "inhibitors",
      "label": "to"
    },
    {
      "source": "differential sensitivity",
      "target": "light responses",
      "label": "is of"
    },
    {
      "source": "substrate-binding pocket",
      "target": "PDE3A",
      "label": "part_of"
    },
    {
      "source": "distinct residues",
      "target": "active site",
      "label": "located_at"
    },
    {
      "source": "Mutants Y751A",
      "target": "reduced sensitivity",
      "label": "exhibited"
    },
    {
      "source": "Mutants Y751A",
      "target": "diminished sensitivity",
      "label": "exhibited"
    },
    {
      "source": "reduced sensitivity",
      "target": "milrinone",
      "label": "to"
    },
    {
      "source": "D950",
      "target": "PDE families",
      "label": "located_in"
    },
    {
      "source": "D950",
      "target": "key residues",
      "label": "are"
    },
    {
      "source": "amino acid residues",
      "target": "site-directed mutagenesis technique",
      "label": "modified_by"
    },
    {
      "source": "amino acid residues",
      "target": "alanine",
      "label": "mutated_to"
    },
    {
      "source": "amino acid residues",
      "target": "PDE3-selective inhibitor binding",
      "label": "involved_in"
    },
    {
      "source": "key residues",
      "target": "substrate",
      "label": "involved_in_binding_of"
    },
    {
      "source": "key residues",
      "target": "inhibitors",
      "label": "involved_in_binding_of"
    },
    {
      "source": "key residues",
      "target": "C-terminal domain",
      "label": "located in"
    },
    {
      "source": "substrate",
      "target": "MAO",
      "label": "for"
    },
    {
      "source": "highly conserved residuals Y751",
      "target": "key residues",
      "label": "are"
    },
    {
      "source": "highly conserved residuals Y751",
      "target": "PDE families",
      "label": "located_in"
    },
    {
      "source": "F1004",
      "target": "key residues",
      "label": "are"
    },
    {
      "source": "F1004",
      "target": "PDE families",
      "label": "located_in"
    },
    {
      "source": "development",
      "target": "potent and specific inhibitory drugs",
      "label": "leads_to_development_of"
    },
    {
      "source": "development",
      "target": "selective thyroid hormone receptor modulator",
      "label": "of"
    },
    {
      "source": "development",
      "target": "LTC4S inhibitors",
      "label": "is of"
    },
    {
      "source": "development",
      "target": "medial thyroid anlage",
      "label": "is of"
    },
    {
      "source": "molecular modeling",
      "target": "interaction sites",
      "label": "used_for"
    },
    {
      "source": "inhibitors",
      "target": "CYP2D6",
      "label": "are of"
    },
    {
      "source": "inhibitors",
      "target": "drug discovery process",
      "label": "should be found early in"
    },
    {
      "source": "inhibitors",
      "target": "P-gp",
      "label": "of"
    },
    {
      "source": "inhibitors",
      "target": "cytochrome P450 3A4",
      "label": "of"
    },
    {
      "source": "inhibitors",
      "target": "Flt3 signaling",
      "label": "suppress"
    },
    {
      "source": "inhibitors",
      "target": "Flt3 tyrosine kinase activity",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "pathways",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "PtdIns-3-K",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "mitogen associated protein kinase",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "Neuroprotection",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "MAPK",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "phosphatidylinositol-3-kinase",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "HDC",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "sub-nanomolar inhibition",
      "label": "possessed"
    },
    {
      "source": "inhibitors",
      "target": "Rock",
      "label": "inhibit"
    },
    {
      "source": "inhibitors",
      "target": "cytochrome P-450 inhibition",
      "label": "possessed"
    },
    {
      "source": "inhibitors",
      "target": "nanomolar potency",
      "label": "possessed"
    },
    {
      "source": "inhibitors",
      "target": "human microsomal stability",
      "label": "possessed"
    },
    {
      "source": "increased K(i)",
      "target": "cilostazol",
      "label": "for"
    },
    {
      "source": "Q975A",
      "target": "increased K(i)",
      "label": "exhibited"
    },
    {
      "source": "selective inhibitors",
      "target": "flexible size",
      "label": "can_be_designed_with"
    },
    {
      "source": "flexible size",
      "target": "PDE3 active site",
      "label": "targets"
    },
    {
      "source": "F972A",
      "target": "increased K(i)",
      "label": "exhibited"
    },
    {
      "source": "active site",
      "target": "human DHFR",
      "label": "of"
    },
    {
      "source": "active site",
      "target": "GSTP1-1",
      "label": "of"
    },
    {
      "source": "structure",
      "target": "inhibitory sites",
      "label": "of"
    },
    {
      "source": "structure",
      "target": "development",
      "label": "contributes_to"
    },
    {
      "source": "structure",
      "target": "HSQC",
      "label": "defined by"
    },
    {
      "source": "structure",
      "target": "2D-NMR spectra",
      "label": "defined by"
    },
    {
      "source": "structure",
      "target": "MP2 method",
      "label": "optimized using"
    },
    {
      "source": "structure",
      "target": "levels of theory",
      "label": "optimized at"
    },
    {
      "source": "structure",
      "target": "conformer",
      "label": "is of"
    },
    {
      "source": "structure",
      "target": "HF method",
      "label": "optimized using"
    },
    {
      "source": "structure",
      "target": "B3LYP method",
      "label": "optimized using"
    },
    {
      "source": "structure",
      "target": "flexible IgG",
      "label": "is of"
    },
    {
      "source": "structure",
      "target": "antibody linker",
      "label": "is of"
    },
    {
      "source": "mutants T844A",
      "target": "increased K(i)",
      "label": "exhibited"
    },
    {
      "source": "alanine",
      "target": "amino acid neurotransmitters",
      "label": "is a type of"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "interaction sites",
      "label": "used_for"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "RAMP3 residues",
      "label": "was used to introduce"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "RAMP1 residues",
      "label": "was used to introduce"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "serines",
      "label": "used to identify"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "ICA binding site",
      "label": "suggests"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "single amino acid residues",
      "label": "localizes"
    },
    {
      "source": "site-directed mutagenesis",
      "target": "molecular determinants for dofetilide block",
      "label": "identifies"
    },
    {
      "source": "interacting residues",
      "target": "substrate-binding pocket",
      "label": "located_in"
    },
    {
      "source": "pharmacokinetic profile",
      "target": "Fondaparinux sodium",
      "label": "of"
    },
    {
      "source": "pharmacokinetic profile",
      "target": "drug",
      "label": "is a characteristic of"
    },
    {
      "source": "pharmacokinetic profile",
      "target": "85%",
      "label": "includes"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "synthetic factor Xa inhibitors",
      "label": "is a class of"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "dose",
      "label": "approved for use at"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "treatment",
      "label": "investigated for"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "terminal half-life",
      "label": "has"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "prevention",
      "label": "approved for"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "urine",
      "label": "excreted in"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "unchanged compound",
      "label": "excreted as"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "Plasma clearance",
      "label": "has"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "renal clearance",
      "label": "has"
    },
    {
      "source": "Fondaparinux sodium",
      "target": "metabolism",
      "label": "has no evidence of"
    },
    {
      "source": "synthetic factor Xa inhibitors",
      "target": "factor Xa",
      "label": "inhibits"
    },
    {
      "source": "synthetic factor Xa inhibitors",
      "target": "antithrombin III",
      "label": "binds to"
    },
    {
      "source": "dose",
      "target": "high-fat meal",
      "label": "administered with"
    },
    {
      "source": "dose",
      "target": "food",
      "label": "administered with"
    },
    {
      "source": "dose",
      "target": "[(14)C]anagliptin",
      "label": "of"
    },
    {
      "source": "dose",
      "target": "urine",
      "label": "recovered in"
    },
    {
      "source": "dose",
      "target": "unchanged drug",
      "label": "eliminated as"
    },
    {
      "source": "dose",
      "target": "faeces",
      "label": "recovered in"
    },
    {
      "source": "unchanged compound",
      "target": "dose",
      "label": "is a percentage of"
    },
    {
      "source": "elderly volunteers",
      "target": "healthy volunteers",
      "label": "are a type of"
    },
    {
      "source": "young volunteers",
      "target": "healthy volunteers",
      "label": "are a type of"
    },
    {
      "source": "C(max)",
      "target": "Steady state",
      "label": "increased at"
    },
    {
      "source": "C(max)",
      "target": "subcutaneous dose",
      "label": "occurred after"
    },
    {
      "source": "C(max)",
      "target": "young volunteers",
      "label": "observed in"
    },
    {
      "source": "C(max)",
      "target": "atorvastatin",
      "label": "is of"
    },
    {
      "source": "C(max)",
      "target": "o-hydroxy atorvastatin",
      "label": "is of"
    },
    {
      "source": "Steady state",
      "target": "dose",
      "label": "obtained after"
    },
    {
      "source": "absorption",
      "target": "young volunteers",
      "label": "observed in"
    },
    {
      "source": "absorption",
      "target": "subcutaneous dose",
      "label": "resulted from"
    },
    {
      "source": "absorption",
      "target": "gut",
      "label": "occurs in"
    },
    {
      "source": "absolute bioavailability",
      "target": "subcutaneous dose",
      "label": "resulted from"
    },
    {
      "source": "absolute bioavailability",
      "target": "young volunteers",
      "label": "observed in"
    },
    {
      "source": "Distribution volume",
      "target": "blood volume",
      "label": "limited to"
    },
    {
      "source": "prevention",
      "target": "arterial and venous thrombotic disorders",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "venous thromboembolism",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "nausea",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "chemotherapy-induced nausea and vomiting (CINV)",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "postoperative nausea and vomiting (PONV)",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "delayed-phase CINV",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "CINV",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "acute-phase CINV",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "vomiting",
      "label": "of"
    },
    {
      "source": "prevention",
      "target": "thromboembolic disorders",
      "label": "of"
    },
    {
      "source": "venous thromboembolism",
      "target": "major orthopaedic surgery",
      "label": "in"
    },
    {
      "source": "Within-subject variability",
      "target": "C(max)",
      "label": "for"
    },
    {
      "source": "Within-subject variability",
      "target": "area under the concentration-time curve",
      "label": "for"
    },
    {
      "source": "AUC",
      "target": "Steady state",
      "label": "increased at"
    },
    {
      "source": "AUC",
      "target": "IR group",
      "label": "increased in"
    },
    {
      "source": "AUC",
      "target": "IPC group",
      "label": "increased in"
    },
    {
      "source": "AUC",
      "target": "five probe drugs",
      "label": "are of"
    },
    {
      "source": "AUC",
      "target": "entire range of doses",
      "label": "was linear over"
    },
    {
      "source": "AUC",
      "target": "1,540%",
      "label": "increased by"
    },
    {
      "source": "area under the concentration-time curve",
      "target": "AUC",
      "label": "is also known as"
    },
    {
      "source": "area under the concentration-time curve",
      "target": "LEX",
      "label": "is for"
    },
    {
      "source": "total-subject variability",
      "target": "C(max)",
      "label": "for"
    },
    {
      "source": "total-subject variability",
      "target": "area under the concentration-time curve",
      "label": "for"
    },
    {
      "source": "renal clearance",
      "target": "JBP485",
      "label": "is of"
    },
    {
      "source": "renal clearance",
      "target": "1,25(OH)(2)D(3)",
      "label": "decreased after"
    },
    {
      "source": "metabolism",
      "target": "M1",
      "label": "produces"
    },
    {
      "source": "metabolism",
      "target": "humans",
      "label": "in"
    },
    {
      "source": "metabolism",
      "target": "[(14)C]anagliptin",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "budesonide",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "flunisolide",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "triamcinolone acetonide",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "fluticasone propionate",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "CYP3A family of enzymes",
      "label": "by"
    },
    {
      "source": "metabolism",
      "target": "GCs",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "D-ring substituents",
      "label": "occurs on"
    },
    {
      "source": "metabolism",
      "target": "rat stomach",
      "label": "occurs in"
    },
    {
      "source": "metabolism",
      "target": "in vitro",
      "label": "occurs in"
    },
    {
      "source": "metabolism",
      "target": "BDP",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "changes",
      "label": "related to"
    },
    {
      "source": "metabolism",
      "target": "foreign compounds",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "endogenous biochemicals",
      "label": "of"
    },
    {
      "source": "metabolism",
      "target": "norepinephrine",
      "label": "of"
    },
    {
      "source": "End products",
      "target": "Apoptosis",
      "label": "have role in"
    },
    {
      "source": "Apoptosis",
      "target": "CC cells",
      "label": "affects"
    },
    {
      "source": "Apoptosis",
      "target": "HNSCC cells",
      "label": "affects"
    },
    {
      "source": "Apoptosis",
      "target": "Squamous cell carcinomas",
      "label": "affects"
    },
    {
      "source": "Apoptosis",
      "target": "Oral mucosa cells",
      "label": "occurs in"
    },
    {
      "source": "Microarray",
      "target": "Apoptosis",
      "label": "studies"
    },
    {
      "source": "Microarray",
      "target": "Biochemical data",
      "label": "linked to"
    },
    {
      "source": "Microarray",
      "target": "cDNAs",
      "label": "involves"
    },
    {
      "source": "Nonsterol mevalonate metabolites",
      "target": "GGPP",
      "label": "include"
    },
    {
      "source": "GGPP",
      "target": "Apoptotic effects",
      "label": "inhibited"
    },
    {
      "source": "GGPP",
      "target": "rhoA",
      "label": "regulates"
    },
    {
      "source": "Apoptotic effects",
      "target": "CC cells",
      "label": "occur in"
    },
    {
      "source": "Apoptotic effects",
      "target": "HNSCC cells",
      "label": "occur in"
    },
    {
      "source": "Apoptotic effects",
      "target": "Lovastatin",
      "label": "are effects of"
    },
    {
      "source": "HMG-CoA reductase",
      "target": "Mevalonate pathway",
      "label": "is enzyme of"
    },
    {
      "source": "HMG-CoA reductase",
      "target": "Therapeutic target",
      "label": "is a"
    },
    {
      "source": "HMG-CoA reductase",
      "target": "Rate-limiting enzyme",
      "label": "is a"
    },
    {
      "source": "HMG-CoA reductase",
      "target": "3-hydroxy-3-methylglutaryl coenzyme A",
      "label": "acts on"
    },
    {
      "source": "Biosynthesis",
      "target": "Mevalonate pathway",
      "label": "is of"
    },
    {
      "source": "Biosynthesis",
      "target": "End products",
      "label": "leads to"
    },
    {
      "source": "Products",
      "target": "Cellular functions",
      "label": "are vital for"
    },
    {
      "source": "Products",
      "target": "Mevalonate pathway",
      "label": "are products of"
    },
    {
      "source": "Products",
      "target": "drug tests",
      "label": "are non-detectable with"
    },
    {
      "source": "Products",
      "target": "cannabimimetic effects",
      "label": "have"
    },
    {
      "source": "Products",
      "target": "marihuana",
      "label": "are surrogate for"
    },
    {
      "source": "Products",
      "target": "synthetic cannabinoids",
      "label": "contain"
    },
    {
      "source": "Cellular functions",
      "target": "Membrane integrity",
      "label": "include"
    },
    {
      "source": "Cellular functions",
      "target": "Cell cycle progression",
      "label": "include"
    },
    {
      "source": "Cellular functions",
      "target": "Cell signaling",
      "label": "include"
    },
    {
      "source": "Cellular functions",
      "target": "Protein synthesis",
      "label": "include"
    },
    {
      "source": "Treatment",
      "target": "HNSCC cell lines",
      "label": "applied to"
    },
    {
      "source": "Treatment",
      "target": "Lovastatin",
      "label": "involves"
    },
    {
      "source": "Treatment",
      "target": "study initiation",
      "label": "stopped before"
    },
    {
      "source": "Treatment",
      "target": "oral antidiabetic agents",
      "label": "involved"
    },
    {
      "source": "HNSCC cell lines",
      "target": "SCC9",
      "label": "include"
    },
    {
      "source": "HNSCC cell lines",
      "target": "SCC25",
      "label": "include"
    },
    {
      "source": "Therapeutic target",
      "target": "Cervical carcinomas",
      "label": "for"
    },
    {
      "source": "Therapeutic target",
      "target": "Head and neck squamous cell carcinomas",
      "label": "for"
    },
    {
      "source": "Therapeutic target",
      "target": "CC",
      "label": "for"
    },
    {
      "source": "Therapeutic target",
      "target": "HNSCC",
      "label": "for"
    },
    {
      "source": "Depletion",
      "target": "Mediators",
      "label": "is a"
    },
    {
      "source": "Mediators",
      "target": "Anticancer properties",
      "label": "mediate"
    },
    {
      "source": "Mediators",
      "target": "Apoptotic response",
      "label": "mediate"
    },
    {
      "source": "Mediators",
      "target": "Apoptosis",
      "label": "mediate"
    },
    {
      "source": "Lovastatin",
      "target": "Inhibitor",
      "label": "is an"
    },
    {
      "source": "Lovastatin",
      "target": "Apoptosis",
      "label": "induces"
    },
    {
      "source": "Lovastatin",
      "target": "Mevalonate metabolites",
      "label": "perturbs levels of"
    },
    {
      "source": "Lovastatin",
      "target": "rhoA",
      "label": "regulates"
    },
    {
      "source": "Lovastatin",
      "target": "Sterols",
      "label": "perturbs levels of"
    },
    {
      "source": "Lovastatin",
      "target": "Transcription",
      "label": "modulates"
    },
    {
      "source": "Lovastatin",
      "target": "Apoptotic response",
      "label": "induces"
    },
    {
      "source": "Lovastatin",
      "target": "HMG-CoA reductase",
      "label": "downregulates"
    },
    {
      "source": "Anticancer properties",
      "target": "Lovastatin",
      "label": "are properties of"
    },
    {
      "source": "Differentially expressed genes",
      "target": "Mediators",
      "label": "are"
    },
    {
      "source": "Biochemical analysis",
      "target": "Apoptosis",
      "label": "studies"
    },
    {
      "source": "Apoptotic response",
      "target": "Tumor types",
      "label": "occurs in"
    },
    {
      "source": "Tumor types",
      "target": "CC",
      "label": "include"
    },
    {
      "source": "Tumor types",
      "target": "HNSCC",
      "label": "include"
    },
    {
      "source": "Cholesterol",
      "target": "Products",
      "label": "is a type of"
    },
    {
      "source": "Geranylgeranyl pyrophosphate",
      "target": "GGPP",
      "label": "is an abbreviation for"
    },
    {
      "source": "HMG-CoA",
      "target": "3-hydroxy-3-methylglutaryl coenzyme A",
      "label": "is an abbreviation for"
    },
    {
      "source": "Expression analysis",
      "target": "Treatment",
      "label": "follows"
    },
    {
      "source": "Nonsterol moiety",
      "target": "Geranylgeranyl pyrophosphate",
      "label": "is a type of"
    },
    {
      "source": "tyrosine hydroxylase",
      "target": "DA",
      "label": "lacks"
    },
    {
      "source": "tyrosine hydroxylase",
      "target": "dopamine",
      "label": "lacks"
    },
    {
      "source": "tyrosine hydroxylase",
      "target": "NE",
      "label": "lacks"
    },
    {
      "source": "DMI",
      "target": "NET",
      "label": "Downregulator"
    },
    {
      "source": "DMI",
      "target": "NET inhibitor",
      "label": "is a type of"
    },
    {
      "source": "NET",
      "target": "antidepressant drugs",
      "label": "is target for"
    },
    {
      "source": "NET",
      "target": "synaptic norepinephrine",
      "label": "controls availability of"
    },
    {
      "source": "NET",
      "target": "adrenoreceptor",
      "label": "regulates"
    },
    {
      "source": "NET",
      "target": "endogenous NE",
      "label": "does not require"
    },
    {
      "source": "NET",
      "target": "positron emission tomography",
      "label": "imaged_by"
    },
    {
      "source": "desipramine",
      "target": "NET inhibitor",
      "label": "is a type of"
    },
    {
      "source": "desipramine",
      "target": "norepinephrine transporter",
      "label": "Regulator"
    },
    {
      "source": "desipramine",
      "target": "NET",
      "label": "Downregulator"
    },
    {
      "source": "desipramine",
      "target": "norepinephrine reuptake inhibitors",
      "label": "is_a"
    },
    {
      "source": "desipramine",
      "target": "norepinephrine uptake",
      "label": "inhibits"
    },
    {
      "source": "desipramine",
      "target": "norepinephrine transporter knockout mice",
      "label": "administered to"
    },
    {
      "source": "desipramine",
      "target": "control mice",
      "label": "administered to"
    },
    {
      "source": "desipramine",
      "target": "osmotic minipump",
      "label": "administered via"
    },
    {
      "source": "desipramine",
      "target": "secondary or primary amines",
      "label": "contains"
    },
    {
      "source": "desipramine",
      "target": "fractional rate of loss",
      "label": "reduced"
    },
    {
      "source": "catecholamines",
      "target": "norepinephrine transporter",
      "label": "Regulator"
    },
    {
      "source": "catecholamines",
      "target": "glutamatergic neurotransmission",
      "label": "enhance"
    },
    {
      "source": "Th",
      "target": "DA",
      "label": "lacks"
    },
    {
      "source": "Th",
      "target": "dopamine",
      "label": "lacks"
    },
    {
      "source": "Th",
      "target": "NE",
      "label": "lacks"
    },
    {
      "source": "NE",
      "target": "alpha 1B-adrenergic receptor mRNA",
      "label": "down-regulates"
    },
    {
      "source": "NE",
      "target": "alpha-AR mRNA level",
      "label": "decreased"
    },
    {
      "source": "NE",
      "target": "alpha-AR mRNA",
      "label": "down-regulates"
    },
    {
      "source": "NE",
      "target": "rate of alpha-AR mRNA degradation",
      "label": "increased"
    },
    {
      "source": "dopamine beta-hydroxylase",
      "target": "NE",
      "label": "lacks"
    },
    {
      "source": "dopamine beta-hydroxylase",
      "target": "reaction",
      "label": "did not catalyze"
    },
    {
      "source": "Dbh",
      "target": "NE",
      "label": "lacks"
    },
    {
      "source": "catecholamine depletion",
      "target": "NET",
      "label": "Downregulator"
    },
    {
      "source": "DMI treatment",
      "target": "NET",
      "label": "Downregulator"
    },
    {
      "source": "nAChR agonists",
      "target": "analgesia",
      "label": "act for"
    },
    {
      "source": "nAChR agonists",
      "target": "alpha(4)beta(2*) nAChRs",
      "label": "act on"
    },
    {
      "source": "nAChR agonists",
      "target": "noradrenergic terminals",
      "label": "act on"
    },
    {
      "source": "nAChR agonists",
      "target": "glutamate release",
      "label": "do not stimulate indirectly through"
    },
    {
      "source": "nAChR agonists",
      "target": "spinal norepinephrine release",
      "label": "stimulate"
    },
    {
      "source": "nAChR agonists",
      "target": "antinociception",
      "label": "produce"
    },
    {
      "source": "nAChR agonists",
      "target": "neurotransmitter release",
      "label": "stimulate"
    },
    {
      "source": "nAChR agonists",
      "target": "nAChR subtypes",
      "label": "act on"
    },
    {
      "source": "nAChR agonists",
      "target": "nitric oxide synthesis",
      "label": "do not stimulate indirectly through"
    },
    {
      "source": "Neuronal nicotinic acetylcholine receptor",
      "target": "nAChR",
      "label": "is a type of"
    },
    {
      "source": "nAChR",
      "target": "central nervous system",
      "label": "located in"
    },
    {
      "source": "nAChR",
      "target": "neurotransmitter release",
      "label": "stimulate"
    },
    {
      "source": "nAChR",
      "target": "presynaptic terminals",
      "label": "located on"
    },
    {
      "source": "nAChR",
      "target": "anxiety",
      "label": "is associated with"
    },
    {
      "source": "nAChR",
      "target": "brain",
      "label": "is expressed in"
    },
    {
      "source": "nAChR",
      "target": "cognitive function",
      "label": "is associated with"
    },
    {
      "source": "artificial cerebrospinal fluid",
      "target": "nicotine",
      "label": "contains"
    },
    {
      "source": "artificial cerebrospinal fluid",
      "target": "nAChR antagonists",
      "label": "contains"
    },
    {
      "source": "artificial cerebrospinal fluid",
      "target": "metanicotine",
      "label": "contains"
    },
    {
      "source": "nicotine",
      "target": "nAChR",
      "label": "is an agonist for"
    },
    {
      "source": "nicotine",
      "target": "spinal norepinephrine release",
      "label": "induced"
    },
    {
      "source": "nicotine",
      "target": "risk factor",
      "label": "is a"
    },
    {
      "source": "nicotine",
      "target": "tobacco smoke",
      "label": "is a component of"
    },
    {
      "source": "nicotine",
      "target": "anxiogenic effects",
      "label": "has"
    },
    {
      "source": "nicotine",
      "target": "\u03b17 and non-\u03b17 subtypes of nAChRs",
      "label": "activates"
    },
    {
      "source": "nicotine",
      "target": "phosphorylation of Extracellular-Signal-Regulated Kinase",
      "label": "increased"
    },
    {
      "source": "nicotine",
      "target": "LPO",
      "label": "decreased"
    },
    {
      "source": "nicotine",
      "target": "alkaloid",
      "label": "is an"
    },
    {
      "source": "nicotine",
      "target": "fear memory",
      "label": "improved"
    },
    {
      "source": "nicotine",
      "target": "biochemical parameters",
      "label": "affects"
    },
    {
      "source": "nicotine",
      "target": "memory extinction",
      "label": "affects"
    },
    {
      "source": "L2-L4 dermatomes",
      "target": "spinal cord",
      "label": "part of"
    },
    {
      "source": "alpha(4)beta(2*) nAChRs",
      "target": "noradrenergic terminals",
      "label": "located on"
    },
    {
      "source": "metanicotine",
      "target": "alpha(4)beta(2*)-preferring nAChR antagonists",
      "label": "effect blocked by"
    },
    {
      "source": "metanicotine",
      "target": "alpha(4)beta(2*) nAChR agonist",
      "label": "is a"
    },
    {
      "source": "metanicotine",
      "target": "spinal norepinephrine release",
      "label": "induced"
    },
    {
      "source": "metanicotine",
      "target": "alpha(7*)-preferring nAChR antagonists",
      "label": "effect less blocked by"
    },
    {
      "source": "metanicotine",
      "target": "alpha(4)beta(2*) nAChRs",
      "label": "is an agonist for"
    },
    {
      "source": "neurotransmitter release",
      "target": "spinal norepinephrine release",
      "label": "induces"
    },
    {
      "source": "spinal norepinephrine release",
      "target": "nitric oxide synthase inhibitors",
      "label": "not reduced by"
    },
    {
      "source": "spinal norepinephrine release",
      "target": "glutamate antagonists",
      "label": "not reduced by"
    },
    {
      "source": "spinal norepinephrine release",
      "target": "nicotinic antagonists",
      "label": "reduced by"
    },
    {
      "source": "synaptosomes",
      "target": "spinal cord",
      "label": "prepared from"
    },
    {
      "source": "synaptosomes",
      "target": "nAChR antagonists",
      "label": "incubated with"
    },
    {
      "source": "synaptosomes",
      "target": "nAChR agonists",
      "label": "incubated with"
    },
    {
      "source": "synaptosomes",
      "target": "aged mouse brain",
      "label": "prepared from"
    },
    {
      "source": "synaptosomes",
      "target": "brain",
      "label": "prepared from"
    },
    {
      "source": "antinociception",
      "target": "animals",
      "label": "occurs in"
    },
    {
      "source": "microdialysis probes",
      "target": "artificial cerebrospinal fluid",
      "label": "perfused with"
    },
    {
      "source": "microdialysis probes",
      "target": "L2-L4 dermatomes",
      "label": "inserted in"
    },
    {
      "source": "nicotinic agonists",
      "target": "norepinephrine",
      "label": "stimulated release of"
    },
    {
      "source": "Nicotinic acetylcholine receptor",
      "target": "spinal norepinephrine release",
      "label": "regulates"
    },
    {
      "source": "nAChR subtypes",
      "target": "noradrenergic terminals",
      "label": "located on"
    },
    {
      "source": "volatile anesthetic halothane",
      "target": "light-induced photoreceptor degeneration",
      "label": "protects against"
    },
    {
      "source": "light-induced photoreceptor degeneration",
      "target": "rodent retina",
      "label": "occurs in"
    },
    {
      "source": "Albino mice",
      "target": "high levels of white or blue light",
      "label": "exposed to"
    },
    {
      "source": "Albino mice",
      "target": "halothane",
      "label": "anesthetized with"
    },
    {
      "source": "critical number of photons",
      "target": "retinal degeneration",
      "label": "induce"
    },
    {
      "source": "critical number of photons",
      "target": "white light-induced retinal degeneration",
      "label": "initiate"
    },
    {
      "source": "rhodopsin-mediated uptake",
      "target": "critical number of photons",
      "label": "is of"
    },
    {
      "source": "halothane",
      "target": "metabolic rhodopsin regeneration",
      "label": "inhibited"
    },
    {
      "source": "halothane",
      "target": "retina",
      "label": "did not protect"
    },
    {
      "source": "halothane",
      "target": "rhodopsin-mediated uptake",
      "label": "prevented"
    },
    {
      "source": "halothane",
      "target": "photon absorption",
      "label": "impeded"
    },
    {
      "source": "photon absorption",
      "target": "light exposure",
      "label": "occurs during"
    },
    {
      "source": "photon absorption",
      "target": "rhodopsin",
      "label": "performed by"
    },
    {
      "source": "photon absorption",
      "target": "high numbers of photons",
      "label": "is of"
    },
    {
      "source": "halothane anesthesia",
      "target": "metabolic rhodopsin regeneration",
      "label": "inhibited"
    },
    {
      "source": "halothane anesthesia",
      "target": "blue-light-induced photoreceptor cell death",
      "label": "did not protect against"
    },
    {
      "source": "halothane anesthesia",
      "target": "photon absorption",
      "label": "prevented"
    },
    {
      "source": "photoreceptors",
      "target": "rats",
      "label": "belong to"
    },
    {
      "source": "photoreceptors",
      "target": "halothane",
      "label": "anesthetized with"
    },
    {
      "source": "photoreceptors",
      "target": "degeneration",
      "label": "protected against"
    },
    {
      "source": "photoreceptors",
      "target": "mice",
      "label": "belong to"
    },
    {
      "source": "degeneration",
      "target": "white light",
      "label": "induced by"
    },
    {
      "source": "degeneration",
      "target": "Alzheimer's disease (AD)",
      "label": "associated with"
    },
    {
      "source": "degeneration",
      "target": "neurons",
      "label": "affects"
    },
    {
      "source": "degeneration",
      "target": "Parkinson's disease (PD)",
      "label": "associated with"
    },
    {
      "source": "degeneration",
      "target": "neurological disorders",
      "label": "associated with"
    },
    {
      "source": "process",
      "target": "photoreversal of bleaching",
      "label": "is termed"
    },
    {
      "source": "process",
      "target": "Purification",
      "label": "results in"
    },
    {
      "source": "photoreversal of bleaching",
      "target": "rhodopsin molecules",
      "label": "enables"
    },
    {
      "source": "photoreversal of bleaching",
      "target": "visual cycle",
      "label": "does not depend on"
    },
    {
      "source": "Protective effect",
      "target": "inhibition",
      "label": "is"
    },
    {
      "source": "Protective effect",
      "target": "retinal light damage",
      "label": "reduces"
    },
    {
      "source": "Protective effect",
      "target": "halothane anesthesia",
      "label": "is caused by"
    },
    {
      "source": "retinas",
      "target": "mice",
      "label": "belong to"
    },
    {
      "source": "retinas",
      "target": "rats",
      "label": "belong to"
    },
    {
      "source": "retinas",
      "target": "OLETF rats",
      "label": "from"
    },
    {
      "source": "retina",
      "target": "blue light",
      "label": "against"
    },
    {
      "source": "in situ staining",
      "target": "apoptotic nuclei",
      "label": "targets"
    },
    {
      "source": "Rhodopsin regeneration",
      "target": "bleaching",
      "label": "occurs after"
    },
    {
      "source": "Rhodopsin regeneration",
      "target": "darkness",
      "label": "occurs in"
    },
    {
      "source": "Rhodopsin regeneration",
      "target": "rhodopsin levels",
      "label": "determined by measuring"
    },
    {
      "source": "rhodopsin levels",
      "target": "retinas",
      "label": "measured in"
    },
    {
      "source": "functional rhodopsin",
      "target": "bleaching intermediates",
      "label": "is restored from"
    },
    {
      "source": "TUNEL assay",
      "target": "in situ staining",
      "label": "is a type of"
    },
    {
      "source": "TUNEL assay",
      "target": "dUTP",
      "label": "involves"
    },
    {
      "source": "TUNEL assay",
      "target": "nick end labeling",
      "label": "involves"
    },
    {
      "source": "TUNEL assay",
      "target": "biotin",
      "label": "involves"
    },
    {
      "source": "TUNEL assay",
      "target": "terminal deoxynucleotidyl transferase",
      "label": "is based on"
    },
    {
      "source": "Retinal morphology",
      "target": "light microscopy",
      "label": "assessed by"
    },
    {
      "source": "rhodopsin molecules",
      "target": "critical number of photons",
      "label": "absorb"
    },
    {
      "source": "Nonanesthetized animals",
      "target": "controls",
      "label": "served as"
    },
    {
      "source": "controls",
      "target": "functional or non-synonymous polymorphisms",
      "label": "genotyped for"
    },
    {
      "source": "controls",
      "target": "nmol/L",
      "label": "had"
    },
    {
      "source": "controls",
      "target": "mean (SD) ages",
      "label": "had"
    },
    {
      "source": "visual cycle",
      "target": "pigment epithelium",
      "label": "occurs via"
    },
    {
      "source": "five novel mutations",
      "target": "IVS12-8T-->A",
      "label": "include"
    },
    {
      "source": "five novel mutations",
      "target": "31del10",
      "label": "include"
    },
    {
      "source": "five novel mutations",
      "target": "1357insT",
      "label": "include"
    },
    {
      "source": "five novel mutations",
      "target": "Y439C",
      "label": "include"
    },
    {
      "source": "five novel mutations",
      "target": "1527del3",
      "label": "include"
    },
    {
      "source": "IVS12-8T-->A",
      "target": "PCCB gene",
      "label": "found in"
    },
    {
      "source": "31del10",
      "target": "PCCB gene",
      "label": "found in"
    },
    {
      "source": "PCCB gene",
      "target": "Korean patients",
      "label": "analyzed in"
    },
    {
      "source": "PCCB gene",
      "target": "mutations",
      "label": "has"
    },
    {
      "source": "catabolism",
      "target": "odd-numbered chain length fatty acids",
      "label": "of"
    },
    {
      "source": "catabolism",
      "target": "threonine",
      "label": "of"
    },
    {
      "source": "catabolism",
      "target": "valine",
      "label": "of"
    },
    {
      "source": "catabolism",
      "target": "cholesterol",
      "label": "of"
    },
    {
      "source": "catabolism",
      "target": "isoleucine",
      "label": "of"
    },
    {
      "source": "catabolism",
      "target": "methionine",
      "label": "of"
    },
    {
      "source": "catabolism",
      "target": "bone matrix",
      "label": "of"
    },
    {
      "source": "Korean patients",
      "target": "propionic acidemia",
      "label": "have"
    },
    {
      "source": "threonine",
      "target": "Flt3 mutant",
      "label": "renders sensitive"
    },
    {
      "source": "betaPCC-subunit",
      "target": "1527del3 homozygote patient",
      "label": "absent in"
    },
    {
      "source": "1527del3 homozygote patient",
      "target": "molecular pathology",
      "label": "suggests"
    },
    {
      "source": "homozygotes",
      "target": "1527del3",
      "label": "with"
    },
    {
      "source": "homozygotes",
      "target": "T428I",
      "label": "with"
    },
    {
      "source": "1527del3",
      "target": "PCCB gene",
      "label": "found in"
    },
    {
      "source": "deficiency",
      "target": "propionyl-CoA carboxylase (PCC, EC 6.4.1.3)",
      "label": "of"
    },
    {
      "source": "deficiency",
      "target": "lysosomal enzymes",
      "label": "is in"
    },
    {
      "source": "deficiency",
      "target": "urinary organic acids",
      "label": "is metabolically significant by studying"
    },
    {
      "source": "deficiency",
      "target": "urine",
      "label": "is metabolically significant by studying"
    },
    {
      "source": "deficiency",
      "target": "isovaleryl-CoA dehydrogenase",
      "label": "is of"
    },
    {
      "source": "propionyl-CoA carboxylase (PCC, EC 6.4.1.3)",
      "target": "biotin-dependent enzyme",
      "label": "is a type of"
    },
    {
      "source": "five patients",
      "target": "PCC enzyme assay",
      "label": "confirmed by"
    },
    {
      "source": "PCC enzyme assay",
      "target": "lymphoblasts",
      "label": "performed in"
    },
    {
      "source": "three cases",
      "target": "late manifestations",
      "label": "had"
    },
    {
      "source": "three cases",
      "target": "residual enzyme activities",
      "label": "had"
    },
    {
      "source": "heterogeneity",
      "target": "PCCA gene",
      "label": "observed in"
    },
    {
      "source": "heterogeneity",
      "target": "cblE disease",
      "label": "in"
    },
    {
      "source": "Two neonatal-onset patients",
      "target": "PCC activities",
      "label": "showed undetectable"
    },
    {
      "source": "Two neonatal-onset patients",
      "target": "homozygotes",
      "label": "were"
    },
    {
      "source": "Two neonatal-onset patients",
      "target": "null enzyme activities",
      "label": "had"
    },
    {
      "source": "one known mutation",
      "target": "T428I",
      "label": "is"
    },
    {
      "source": "T428I",
      "target": "PCCB gene",
      "label": "found in"
    },
    {
      "source": "Y439C",
      "target": "PCCB gene",
      "label": "found in"
    },
    {
      "source": "T428I mutation",
      "target": "severe clinical courses",
      "label": "responsible for"
    },
    {
      "source": "T428I mutation",
      "target": "null enzyme activities",
      "label": "responsible for"
    },
    {
      "source": "biotin-dependent enzyme",
      "target": "carboxylation",
      "label": "catalyzes"
    },
    {
      "source": "carboxylation",
      "target": "D-methylmalonyl-CoA",
      "label": "produces"
    },
    {
      "source": "carboxylation",
      "target": "propionyl-CoA",
      "label": "of"
    },
    {
      "source": "carboxylation",
      "target": "gamma-carboxylase",
      "label": "is catalyzed by"
    },
    {
      "source": "carboxylation",
      "target": "posttranslational modification",
      "label": "is a type of"
    },
    {
      "source": "carboxylation",
      "target": "vitamin K-dependent gamma-glutamyl carboxylase",
      "label": "is catalyzed by"
    },
    {
      "source": "carboxylation",
      "target": "gamma-carboxyglutamic acid",
      "label": "produces"
    },
    {
      "source": "carboxylation",
      "target": "glutamic acid residues",
      "label": "modifies"
    },
    {
      "source": "carboxylation",
      "target": "Gla",
      "label": "produces"
    },
    {
      "source": "eight Korean patients",
      "target": "organic acid analysis",
      "label": "identified by"
    },
    {
      "source": "eight Korean patients",
      "target": "PA",
      "label": "have"
    },
    {
      "source": "heteropolymeric enzyme",
      "target": "beta-subunits",
      "label": "composed of"
    },
    {
      "source": "heteropolymeric enzyme",
      "target": "alpha-subunits",
      "label": "composed of"
    },
    {
      "source": "mRNA",
      "target": "PCCB gene",
      "label": "of"
    },
    {
      "source": "mRNA",
      "target": "1527del3 homozygotes",
      "label": "found in"
    },
    {
      "source": "mRNA",
      "target": "T428I homozygotes",
      "label": "found in"
    },
    {
      "source": "mRNA",
      "target": "injury-induced degeneration",
      "label": "investigated during"
    },
    {
      "source": "mRNA",
      "target": "regeneration",
      "label": "investigated during"
    },
    {
      "source": "mRNA",
      "target": "Retn(+/-) mice",
      "label": "was decreased in"
    },
    {
      "source": "mRNA",
      "target": "Retn(-/-) mice",
      "label": "was decreased in"
    },
    {
      "source": "molecular analysis",
      "target": "one known mutation",
      "label": "identified"
    },
    {
      "source": "molecular analysis",
      "target": "five novel mutations",
      "label": "identified"
    },
    {
      "source": "1357insT",
      "target": "PCCB gene",
      "label": "found in"
    },
    {
      "source": "autosomal recessive inborn error",
      "target": "catabolism",
      "label": "involves"
    },
    {
      "source": "1527del3 mutation",
      "target": "severe clinical courses",
      "label": "responsible for"
    },
    {
      "source": "1527del3 mutation",
      "target": "null enzyme activities",
      "label": "responsible for"
    },
    {
      "source": "Clinical symptoms",
      "target": "neonatal-onset",
      "label": "present as"
    },
    {
      "source": "Clinical symptoms",
      "target": "late-onset form",
      "label": "present as"
    },
    {
      "source": "alleles",
      "target": "Caucasian populations",
      "label": "characterized in"
    },
    {
      "source": "alleles",
      "target": "Oriental populations",
      "label": "characterized in"
    },
    {
      "source": "PCC",
      "target": "heteropolymeric enzyme",
      "label": "is a type of"
    },
    {
      "source": "Alleleic frequency",
      "target": "T428I",
      "label": "of"
    },
    {
      "source": "Alleleic frequency",
      "target": "this study",
      "label": "measured in"
    },
    {
      "source": "Alleleic frequency",
      "target": "Korean patients with PA",
      "label": "measured in"
    },
    {
      "source": "This finding",
      "target": "T428I mutation",
      "label": "implies"
    },
    {
      "source": "This finding",
      "target": "1527del3 mutation",
      "label": "implies"
    },
    {
      "source": "Propionic acidemia (PA)",
      "target": "deficiency",
      "label": "caused by"
    },
    {
      "source": "Propionic acidemia (PA)",
      "target": "autosomal recessive inborn error",
      "label": "is an"
    },
    {
      "source": "this study",
      "target": "testes",
      "label": "evaluated"
    },
    {
      "source": "this study",
      "target": "epididymis histology",
      "label": "evaluated"
    },
    {
      "source": "this study",
      "target": "PND75",
      "label": "evaluated on"
    },
    {
      "source": "this study",
      "target": "PND50",
      "label": "evaluated on"
    },
    {
      "source": "this study",
      "target": "sexually immature rats",
      "label": "used"
    },
    {
      "source": "this study",
      "target": "premature antiandrogen exposure",
      "label": "evaluated after"
    },
    {
      "source": "this study",
      "target": "proteins expression",
      "label": "evaluated"
    },
    {
      "source": "Western blot analysis",
      "target": "betaPCC-subunit",
      "label": "used for"
    },
    {
      "source": "Western blot analysis",
      "target": "expression of mGlu5 receptors",
      "label": "showed"
    },
    {
      "source": "Western blot analysis",
      "target": "spinal cord tissues",
      "label": "performed on"
    },
    {
      "source": "methionine",
      "target": "3 weeks",
      "label": "normalized after"
    },
    {
      "source": "postmenopausal women",
      "target": "advanced breast cancer",
      "label": "have"
    },
    {
      "source": "postmenopausal women",
      "target": "prior endocrine therapy",
      "label": "failed"
    },
    {
      "source": "postmenopausal women",
      "target": "adjuvant tamoxifen therapy",
      "label": "have progressed on"
    },
    {
      "source": "advanced breast cancer",
      "target": "taxane",
      "label": "received previous treatment including"
    },
    {
      "source": "advanced breast cancer",
      "target": "anthracycline",
      "label": "received previous treatment including"
    },
    {
      "source": "advanced breast cancer",
      "target": "trastuzumab",
      "label": "received previous treatment including"
    },
    {
      "source": "Fulvestrant",
      "target": "degradation",
      "label": "induces"
    },
    {
      "source": "Fulvestrant",
      "target": "estrogen antagonist",
      "label": "is"
    },
    {
      "source": "Fulvestrant",
      "target": "safety profile",
      "label": "provides"
    },
    {
      "source": "Fulvestrant",
      "target": "anastrozole",
      "label": "is equally as effective as"
    },
    {
      "source": "Fulvestrant",
      "target": "agonist activity",
      "label": "lacks"
    },
    {
      "source": "Fulvestrant",
      "target": "agent",
      "label": "is"
    },
    {
      "source": "Fulvestrant",
      "target": "postmenopausal women",
      "label": "is effective in treatment of"
    },
    {
      "source": "Fulvestrant",
      "target": "advanced breast cancer",
      "label": "is effective in treatment of"
    },
    {
      "source": "Fulvestrant",
      "target": "ER",
      "label": "destroys"
    },
    {
      "source": "Fulvestrant",
      "target": "tamoxifen-like agonist effects",
      "label": "is not associated with"
    },
    {
      "source": "Fulvestrant",
      "target": "signaling pathway",
      "label": "destroys"
    },
    {
      "source": "Fulvestrant",
      "target": "SERMs",
      "label": "produces high response rates compared with"
    },
    {
      "source": "Fulvestrant",
      "target": "aromatase inhibitors",
      "label": "is not cross-resistant to"
    },
    {
      "source": "Fulvestrant",
      "target": "ER antagonist",
      "label": "is a type of"
    },
    {
      "source": "Fulvestrant",
      "target": "tamoxifen",
      "label": "is not cross-resistant to"
    },
    {
      "source": "Fulvestrant",
      "target": "FDA approval",
      "label": "received"
    },
    {
      "source": "Fulvestrant",
      "target": "combination with other therapies",
      "label": "is used in"
    },
    {
      "source": "Fulvestrant",
      "target": "single agent",
      "label": "is used as"
    },
    {
      "source": "Fulvestrant",
      "target": "antiendocrine agent",
      "label": "is a"
    },
    {
      "source": "Fulvestrant",
      "target": "antiestrogen therapeutic armamentarium",
      "label": "is an addition to"
    },
    {
      "source": "Fulvestrant",
      "target": "effective and well-tolerated drug",
      "label": "is an"
    },
    {
      "source": "Fulvestrant",
      "target": "estrogen-sensitive breast cancer",
      "label": "is for"
    },
    {
      "source": "Fulvestrant",
      "target": "pure estrogen receptor downregulator",
      "label": "is a"
    },
    {
      "source": "Fulvestrant",
      "target": "unique mechanism of action",
      "label": "has"
    },
    {
      "source": "megestrol acetate",
      "target": "adverse event",
      "label": "causes"
    },
    {
      "source": "megestrol acetate",
      "target": "therapeutic profile",
      "label": "has"
    },
    {
      "source": "megestrol acetate",
      "target": "fluid retention",
      "label": "causes"
    },
    {
      "source": "megestrol acetate",
      "target": "risks",
      "label": "has"
    },
    {
      "source": "megestrol acetate",
      "target": "weight gain",
      "label": "causes"
    },
    {
      "source": "adverse event",
      "target": "weight gain",
      "label": "is"
    },
    {
      "source": "adverse event",
      "target": "fluid retention",
      "label": "is"
    },
    {
      "source": "Endocrine therapy",
      "target": "first-line therapy",
      "label": "is"
    },
    {
      "source": "Endocrine therapy",
      "target": "postmenopausal women",
      "label": "is standard of care for treatment of"
    },
    {
      "source": "Endocrine therapy",
      "target": "estrogen receptor",
      "label": "targets"
    },
    {
      "source": "Endocrine therapy",
      "target": "ER-positive breast cancer",
      "label": "is standard of care for treatment of"
    },
    {
      "source": "Endocrine therapy",
      "target": "ER",
      "label": "targets"
    },
    {
      "source": "aromatase inhibitors",
      "target": "tamoxifen failure",
      "label": "used after"
    },
    {
      "source": "aromatase inhibitors",
      "target": "second-line therapy",
      "label": "are used as"
    },
    {
      "source": "aromatase inhibitors",
      "target": "AIs",
      "label": "are also known as"
    },
    {
      "source": "aromatase inhibitors",
      "target": "estrogen",
      "label": "create a 'no' environment for"
    },
    {
      "source": "aromatase inhibitors",
      "target": "cardiovascular diseases",
      "label": "increase risk of"
    },
    {
      "source": "aromatase inhibitors",
      "target": "postmenopausal breast cancer patients",
      "label": "applied to"
    },
    {
      "source": "partial agonist property",
      "target": "thromboembolic events",
      "label": "leads to"
    },
    {
      "source": "anastrozole",
      "target": "tamoxifen",
      "label": "is as effective as"
    },
    {
      "source": "anastrozole",
      "target": "aromatase inhibitor",
      "label": "is a type of"
    },
    {
      "source": "anastrozole",
      "target": "first-line therapy",
      "label": "used as"
    },
    {
      "source": "anastrozole",
      "target": "AIs",
      "label": "is a type of"
    },
    {
      "source": "aromatase inhibitor",
      "target": "aromatase",
      "label": "inhibits"
    },
    {
      "source": "agent",
      "target": "new class of drug",
      "label": "is in"
    },
    {
      "source": "agent",
      "target": "estrogen receptor downregulators",
      "label": "is in"
    },
    {
      "source": "agent",
      "target": "specific concentrations",
      "label": "at"
    },
    {
      "source": "new class of drug",
      "target": "estrogen receptor downregulators",
      "label": "is"
    },
    {
      "source": "endocrine therapies",
      "target": "aromatase inhibitors",
      "label": "include"
    },
    {
      "source": "endocrine therapies",
      "target": "tamoxifen",
      "label": "include"
    },
    {
      "source": "endocrine therapies",
      "target": "breast cancer",
      "label": "treat"
    },
    {
      "source": "endocrine therapies",
      "target": "megestrol acetate",
      "label": "include"
    },
    {
      "source": "Two phase III trials",
      "target": "Fulvestrant",
      "label": "proven effectiveness of"
    },
    {
      "source": "residues",
      "target": "association",
      "label": "are required for"
    },
    {
      "source": "residues",
      "target": "catalysis",
      "label": "are important for"
    },
    {
      "source": "residues",
      "target": "enzyme catalytic activities",
      "label": "are responsible for"
    },
    {
      "source": "residues",
      "target": "arginase",
      "label": "are part of"
    },
    {
      "source": "residues",
      "target": "regulatory activities",
      "label": "are responsible for"
    },
    {
      "source": "residues",
      "target": "ornithine carbamoyltransferase",
      "label": "are part of"
    },
    {
      "source": "residues",
      "target": "classical tertiary interactions",
      "label": "form"
    },
    {
      "source": "association",
      "target": "control groups",
      "label": "found in"
    },
    {
      "source": "association",
      "target": "OP-exposed groups",
      "label": "found in"
    },
    {
      "source": "ornithine carbamoyltransferase",
      "target": "enzyme complex",
      "label": "forms"
    },
    {
      "source": "enzyme complex",
      "target": "activity of OTCase",
      "label": "inhibits"
    },
    {
      "source": "lysine residues",
      "target": "sensitivity of OTCase",
      "label": "mediate"
    },
    {
      "source": "lysine residues",
      "target": "SMG loop",
      "label": "are located in"
    },
    {
      "source": "lysine residues",
      "target": "signal",
      "label": "are involved in enhancing"
    },
    {
      "source": "sensitivity of OTCase",
      "target": "ornithine",
      "label": "is to"
    },
    {
      "source": "sensitivity of OTCase",
      "target": "arginase",
      "label": "is to"
    },
    {
      "source": "C terminus",
      "target": "protein",
      "label": "is part of"
    },
    {
      "source": "signal",
      "target": "ornithine",
      "label": "is given by"
    },
    {
      "source": "signal",
      "target": "catalytic domain",
      "label": "is for closure of"
    },
    {
      "source": "signal",
      "target": "glycogen synthesis",
      "label": "stimulates"
    },
    {
      "source": "Lys-260",
      "target": "lysine residues",
      "label": "is a type of"
    },
    {
      "source": "Asn-185",
      "target": "ornithine binding residues",
      "label": "is a type of"
    },
    {
      "source": "ornithine binding residues",
      "target": "OTCase",
      "label": "are part of"
    },
    {
      "source": "cysteines",
      "target": "trimeric structure",
      "label": "are not crucial for"
    },
    {
      "source": "cysteines",
      "target": "arginase",
      "label": "are part of"
    },
    {
      "source": "cysteines",
      "target": "epiarginase function",
      "label": "are crucial for"
    },
    {
      "source": "cysteines",
      "target": "catalytic activity",
      "label": "are not crucial for"
    },
    {
      "source": "substrates",
      "target": "stable complex",
      "label": "trigger formation of"
    },
    {
      "source": "substrates",
      "target": "drug discovery process",
      "label": "should be found early in"
    },
    {
      "source": "substrates",
      "target": "P-gp",
      "label": "of"
    },
    {
      "source": "substrates",
      "target": "membrane",
      "label": "cross"
    },
    {
      "source": "substrates",
      "target": "fixed stoichiometry",
      "label": "cross with"
    },
    {
      "source": "catalysis",
      "target": "crystals",
      "label": "occurs in"
    },
    {
      "source": "catalysis",
      "target": "maltodextrin synthesis",
      "label": "is for"
    },
    {
      "source": "catalysis",
      "target": "retinaldehyde dehydrogenase type II",
      "label": "occurs in"
    },
    {
      "source": "arginase",
      "target": "catalytic activity",
      "label": "has"
    },
    {
      "source": "arginase",
      "target": "enzyme complex",
      "label": "forms"
    },
    {
      "source": "OTCase",
      "target": "enzyme complex",
      "label": "forms"
    },
    {
      "source": "Asp-182",
      "target": "ornithine binding residues",
      "label": "is a type of"
    },
    {
      "source": "catalytic activity",
      "target": "(-)-cocaine",
      "label": "is against"
    },
    {
      "source": "Lys-268",
      "target": "lysine residues",
      "label": "is a type of"
    },
    {
      "source": "interaction",
      "target": "arginase",
      "label": "is with"
    },
    {
      "source": "interaction",
      "target": "AR",
      "label": "is between"
    },
    {
      "source": "interaction",
      "target": "Scatchard method",
      "label": "analyzed by"
    },
    {
      "source": "interaction",
      "target": "Ketoconazole",
      "label": "is between"
    },
    {
      "source": "interaction",
      "target": "D1-like receptors",
      "label": "is between"
    },
    {
      "source": "interaction",
      "target": "insulin",
      "label": "is between"
    },
    {
      "source": "interaction",
      "target": "proteins",
      "label": "involves"
    },
    {
      "source": "interaction",
      "target": "dendritic PAMAM shell",
      "label": "with"
    },
    {
      "source": "interaction",
      "target": "1\u03b1,25-dihydroxyvitamin D(3)",
      "label": "involves"
    },
    {
      "source": "interaction",
      "target": "1,25(OH)(2)D(3)",
      "label": "involves"
    },
    {
      "source": "interaction",
      "target": "inhibitory effect",
      "label": "is explained by"
    },
    {
      "source": "interaction",
      "target": "JBP485",
      "label": "involves"
    },
    {
      "source": "interaction",
      "target": "intestinal CYP3A4 inhibition",
      "label": "caused by"
    },
    {
      "source": "interaction",
      "target": "hepatic CYP3A4 inhibition",
      "label": "caused by"
    },
    {
      "source": "interaction",
      "target": "peptidomimetic \u03b2-lactam antibiotics",
      "label": "may be specific to"
    },
    {
      "source": "nonallosteric enzymes",
      "target": "stable complex",
      "label": "form"
    },
    {
      "source": "Yeast epiarginase",
      "target": "enzyme-enzyme activity control",
      "label": "is a type of"
    },
    {
      "source": "ornithine",
      "target": "enzyme complex",
      "label": "triggers formation of"
    },
    {
      "source": "ornithine",
      "target": "biological processes",
      "label": "important for"
    },
    {
      "source": "ornithine",
      "target": "amino acid",
      "label": "is an"
    },
    {
      "source": "catalytic domain",
      "target": "cGMP",
      "label": "hydrolyzes"
    },
    {
      "source": "Glu-256",
      "target": "ornithine binding residues",
      "label": "is a type of"
    },
    {
      "source": "arginine",
      "target": "enzyme complex",
      "label": "triggers formation of"
    },
    {
      "source": "arginine",
      "target": "(13)C6(15)N4",
      "label": "is labelled with"
    },
    {
      "source": "cooperative association",
      "target": "stable complex",
      "label": "induces"
    },
    {
      "source": "Asn-184",
      "target": "ornithine binding residues",
      "label": "is a type of"
    },
    {
      "source": "Cys-289",
      "target": "ornithine binding residues",
      "label": "is a type of"
    },
    {
      "source": "Lys-263",
      "target": "lysine residues",
      "label": "is a type of"
    },
    {
      "source": "Lys-265",
      "target": "lysine residues",
      "label": "is a type of"
    },
    {
      "source": "melperone",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "melperone",
      "target": "5-HT(2A)",
      "label": "Downregulator"
    },
    {
      "source": "melperone",
      "target": "acetylcholine",
      "label": "Regulator"
    },
    {
      "source": "melperone",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "melperone",
      "target": "dopamine",
      "label": "Regulator"
    },
    {
      "source": "melperone",
      "target": "D(2)",
      "label": "Downregulator"
    },
    {
      "source": "clozapine",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "clozapine",
      "target": "5-HT(2A)",
      "label": "Downregulator"
    },
    {
      "source": "clozapine",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "clozapine",
      "target": "5-HT(1A)",
      "label": "Agonist"
    },
    {
      "source": "clozapine",
      "target": "D(2)",
      "label": "Downregulator"
    },
    {
      "source": "clozapine",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "iloperidone",
      "target": "5-HT(2A)",
      "label": "Downregulator"
    },
    {
      "source": "iloperidone",
      "target": "acetylcholine",
      "label": "Regulator"
    },
    {
      "source": "iloperidone",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "iloperidone",
      "target": "dopamine",
      "label": "Regulator"
    },
    {
      "source": "iloperidone",
      "target": "D(2)",
      "label": "Downregulator"
    },
    {
      "source": "iloperidone",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "acetylcholine",
      "target": "ACh",
      "label": "is also known as"
    },
    {
      "source": "acetylcholine",
      "target": "cholinergic receptor sites",
      "label": "accumulates_at"
    },
    {
      "source": "acetylcholine",
      "target": "declarative memory consolidation",
      "label": "reduced efficacy facilitate"
    },
    {
      "source": "acetylcholine",
      "target": "consolidation processes",
      "label": "affects"
    },
    {
      "source": "acetylcholine",
      "target": "cholinergic synapses",
      "label": "located in"
    },
    {
      "source": "acetylcholine",
      "target": "acetylcholinesterase",
      "label": "Substrate"
    },
    {
      "source": "acetylcholine",
      "target": "AChE",
      "label": "Substrate"
    },
    {
      "source": "olanzapine",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "olanzapine",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "olanzapine",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "olanzapine",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "olanzapine",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "olanzapine",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "olanzapine",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "Quetiapine",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "Quetiapine",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "WAY100635",
      "target": "DA",
      "label": "Downregulator"
    },
    {
      "source": "WAY100635",
      "target": "5-HT(1A)",
      "label": "Antagonist"
    },
    {
      "source": "WAY100635",
      "target": "ACh",
      "label": "Downregulator"
    },
    {
      "source": "risperidone",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "risperidone",
      "target": "ACh",
      "label": "Regulator"
    },
    {
      "source": "Iloperidone",
      "target": "DA",
      "label": "Regulator"
    },
    {
      "source": "adhesive interaction",
      "target": "blood eosinophils",
      "label": "is between"
    },
    {
      "source": "adhesive interaction",
      "target": "pulmonary endothelial cells",
      "label": "is between"
    },
    {
      "source": "adhesive interaction",
      "target": "eosinophils",
      "label": "is between"
    },
    {
      "source": "adhesive interaction",
      "target": "endothelial cells",
      "label": "is between"
    },
    {
      "source": "pranlukast",
      "target": "FMLP-activated eosinophil adhesion",
      "label": "did not modulate"
    },
    {
      "source": "pranlukast",
      "target": "expression",
      "label": "did not modify"
    },
    {
      "source": "pranlukast",
      "target": "eosinophil spontaneous adhesion",
      "label": "did not modify"
    },
    {
      "source": "FMLP-activated eosinophil adhesion",
      "target": "resting endothelial cells",
      "label": "is to"
    },
    {
      "source": "inhibitory action",
      "target": "mechanisms",
      "label": "involves"
    },
    {
      "source": "inhibitory action",
      "target": "CysLT antagonist",
      "label": "is of"
    },
    {
      "source": "inhibitory action",
      "target": "eosinophil accumulation",
      "label": "is on"
    },
    {
      "source": "inhibitory action",
      "target": "lipid peroxidation",
      "label": "on"
    },
    {
      "source": "inhibitory action",
      "target": "polyphenols",
      "label": "of"
    },
    {
      "source": "inhibitory action",
      "target": "decrease of membrane fluidity",
      "label": "associated with"
    },
    {
      "source": "CysLT antagonist",
      "target": "adhesive interaction",
      "label": "modifies"
    },
    {
      "source": "chemotactic response",
      "target": "LTD4",
      "label": "is induced by"
    },
    {
      "source": "chemotactic response",
      "target": "eosinophils",
      "label": "is of"
    },
    {
      "source": "adhesion",
      "target": "eosinophils",
      "label": "is of"
    },
    {
      "source": "adhesion",
      "target": "LTD4",
      "label": "is induced by"
    },
    {
      "source": "adhesion",
      "target": "IL-5",
      "label": "is activated by"
    },
    {
      "source": "pulmonary endothelial cells",
      "target": "non-neuronal uptake1",
      "label": "are a site for"
    },
    {
      "source": "expression",
      "target": "adhesion molecules",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "endothelial cells",
      "label": "is on"
    },
    {
      "source": "expression",
      "target": "hRRM2",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "p53R2",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "P2X receptors",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "P2Y receptors",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "Sp3",
      "label": "involves"
    },
    {
      "source": "expression",
      "target": "Sp1",
      "label": "involves"
    },
    {
      "source": "expression",
      "target": "human keratinocytes",
      "label": "occurs in"
    },
    {
      "source": "expression",
      "target": "PADI2",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "peptidylarginine deiminase type II gene",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "human PAD2 gene",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "MnSOD",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "mitochondrial MnSOD",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "cationic amino acid transporters",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "RT-PCR",
      "label": "studied by"
    },
    {
      "source": "expression",
      "target": "genes",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "cytokines",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "chemokines",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "tumor necrosis factor alpha (TNF-\u03b1)",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "Western blot",
      "label": "examined by"
    },
    {
      "source": "expression",
      "target": "duodenum",
      "label": "in"
    },
    {
      "source": "expression",
      "target": "immunohistochemistry",
      "label": "examined by"
    },
    {
      "source": "expression",
      "target": "cyclooxygenase (COX) isoforms",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "Oat3",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "1,25(OH)(2)D(3)",
      "label": "changes in response to"
    },
    {
      "source": "expression",
      "target": "Oat1",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "(Oat)1",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "organic anion transporter",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "Oats",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "rat kidney",
      "label": "is located in"
    },
    {
      "source": "expression",
      "target": "NMDA subunits",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "PND 85 mice",
      "label": "not changed in"
    },
    {
      "source": "expression",
      "target": "signal transduction molecules",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "hippocampi",
      "label": "occurs in"
    },
    {
      "source": "expression",
      "target": "TNF-\u03b1",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "BCL2-associated X protein",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "caspase 3",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "glutamate transport",
      "label": "reduces"
    },
    {
      "source": "expression",
      "target": "caspase 8",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "glutamate aspartate transporter",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "trpv6",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "PRL receptor",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "ncc",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "prlra",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "Na(+)/H(+) exchanger",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "nhe3b",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "ecac",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "transcripts",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "slc9a3.2",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "epithelial Ca(2+) channel",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "slc12a10.2",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "Na(+)/Cl(-) cotransporter",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "lung cells",
      "label": "in"
    },
    {
      "source": "expression",
      "target": "liver cells",
      "label": "in"
    },
    {
      "source": "expression",
      "target": "lung",
      "label": "in"
    },
    {
      "source": "expression",
      "target": "CYP3A",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "enzymes",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "liver",
      "label": "in"
    },
    {
      "source": "expression",
      "target": "glucocorticoid receptor",
      "label": "via"
    },
    {
      "source": "expression",
      "target": "Flt-1",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "Kdr",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "VEGF-A",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "ZIP8",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "metallothionein",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "syndecan-1 proteoglycan",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "mkp3",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "multivalent GAG",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "FGF target gene mkp3",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "reporters",
      "label": "is of"
    },
    {
      "source": "expression",
      "target": "TAp63",
      "label": "is dependent on"
    },
    {
      "source": "expression",
      "target": "TAp73",
      "label": "of"
    },
    {
      "source": "expression",
      "target": "c-Abl",
      "label": "of"
    },
    {
      "source": "Pranlukast hydrate",
      "target": "CysLT antagonist",
      "label": "is a"
    },
    {
      "source": "Pranlukast hydrate",
      "target": "adhesion",
      "label": "blocked"
    },
    {
      "source": "Pranlukast hydrate",
      "target": "chemotactic response",
      "label": "blocked"
    },
    {
      "source": "eosinophil accumulation",
      "target": "asthmatic airways",
      "label": "is in"
    },
    {
      "source": "eosinophil spontaneous adhesion",
      "target": "TNF-alpha-stimulated pulmonary endothelial cells",
      "label": "is to"
    },
    {
      "source": "eosinophil spontaneous adhesion",
      "target": "resting pulmonary endothelial cells",
      "label": "is to"
    },
    {
      "source": "accumulation",
      "target": "eosinophils",
      "label": "is of"
    },
    {
      "source": "accumulation",
      "target": "asthmatic airway",
      "label": "is in"
    },
    {
      "source": "accumulation",
      "target": "2XALAS-catalyzed reaction",
      "label": "is greater in"
    },
    {
      "source": "accumulation",
      "target": "quinonoid intermediate EQ(2)",
      "label": "is of"
    },
    {
      "source": "accumulation",
      "target": "concentration",
      "label": "is related to"
    },
    {
      "source": "accumulation",
      "target": "ALA",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "HepG2 cell membranes",
      "label": "in"
    },
    {
      "source": "accumulation",
      "target": "HepG2 cell phospholipids",
      "label": "in"
    },
    {
      "source": "accumulation",
      "target": "cell membranes",
      "label": "in"
    },
    {
      "source": "accumulation",
      "target": "docosapentaenoic acid",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "cell phospholipids",
      "label": "in"
    },
    {
      "source": "accumulation",
      "target": "DHA",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "eicosapentaenoic acid",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "24:6n-3",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "long-chain metabolites",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "saturation",
      "label": "approached"
    },
    {
      "source": "accumulation",
      "target": "24:5n-3",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "incorporation",
      "label": "not limited by"
    },
    {
      "source": "accumulation",
      "target": "post-D6D products",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "HEK/rCtr1 cells",
      "label": "by"
    },
    {
      "source": "accumulation",
      "target": "cultured rat DRG neurons",
      "label": "by"
    },
    {
      "source": "accumulation",
      "target": "temperature",
      "label": "dependent on"
    },
    {
      "source": "accumulation",
      "target": "oxaliplatin exposure",
      "label": "during"
    },
    {
      "source": "accumulation",
      "target": "copper",
      "label": "inhibited by"
    },
    {
      "source": "accumulation",
      "target": "exposure",
      "label": "during"
    },
    {
      "source": "accumulation",
      "target": "total measured endogenous bile acids",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "SCRH",
      "label": "occurs in"
    },
    {
      "source": "accumulation",
      "target": "PrP(Sc)",
      "label": "is of"
    },
    {
      "source": "accumulation",
      "target": "glutamate",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "oxidative DNA damage",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "DNA single strand breaks",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "cadmium",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "manganese",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "TAp73",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "c-Abl",
      "label": "of"
    },
    {
      "source": "accumulation",
      "target": "potencies",
      "label": "is a reason for"
    },
    {
      "source": "cysteinyl leukotriene (CysLT) antagonists",
      "target": "accumulation",
      "label": "reduce"
    },
    {
      "source": "mechanism",
      "target": "action",
      "label": "is of"
    },
    {
      "source": "mechanism",
      "target": "clinical activity",
      "label": "of"
    },
    {
      "source": "mechanism",
      "target": "capacity",
      "label": "is"
    },
    {
      "source": "mechanism",
      "target": "cardiovascular stability",
      "label": "provides basis for"
    },
    {
      "source": "mechanism",
      "target": "transitions",
      "label": "of"
    },
    {
      "source": "mechanism",
      "target": "glomerular filtration rate (GFR)",
      "label": "underlies"
    },
    {
      "source": "mechanism",
      "target": "newly recognized form of clinical VT",
      "label": "is of"
    },
    {
      "source": "action",
      "target": "lipid absorption",
      "label": "reduces"
    },
    {
      "source": "action",
      "target": "gastrointestinal lipases",
      "label": "inhibits"
    },
    {
      "source": "action",
      "target": "CYP3A4 hydroxylation",
      "label": "of"
    },
    {
      "source": "action",
      "target": "esterases",
      "label": "of"
    },
    {
      "source": "Study",
      "target": "effect",
      "label": "is on"
    },
    {
      "source": "PET ligand",
      "target": "NET",
      "label": "used_for_imaging"
    },
    {
      "source": "in vivo imaging",
      "target": "norepinephrine transporter",
      "label": "of"
    },
    {
      "source": "radioactivity",
      "target": "hypothalamus",
      "label": "uptake_in"
    },
    {
      "source": "radioactivity",
      "target": "brain",
      "label": "distributed_in"
    },
    {
      "source": "radioactivity",
      "target": "striatum",
      "label": "uptake_in"
    },
    {
      "source": "hypothalamus",
      "target": "NET rich region",
      "label": "is_a"
    },
    {
      "source": "(S,S)-[(11)C]-MeNER",
      "target": "PET ligand",
      "label": "is_a"
    },
    {
      "source": "(S,S)-[(11)C]-MeNER",
      "target": "regional distribution pattern",
      "label": "produced"
    },
    {
      "source": "(S,S)-[(11)C]-MeNER",
      "target": "Hypothalamus to striatum ratios",
      "label": "achieved"
    },
    {
      "source": "in vivo brain distribution",
      "target": "[(11)C]-labeled enantiomers",
      "label": "of"
    },
    {
      "source": "[(11)C]-labeled enantiomers",
      "target": "rats",
      "label": "evaluated_in"
    },
    {
      "source": "MeNER",
      "target": "ligand",
      "label": "is_a"
    },
    {
      "source": "MeNER",
      "target": "reboxetine",
      "label": "is_analogue_of"
    },
    {
      "source": "MeNER",
      "target": "carbon-11",
      "label": "radiolabelled_with"
    },
    {
      "source": "ligand",
      "target": "NET",
      "label": "used_for_imaging"
    },
    {
      "source": "ligand",
      "target": "norepinephrine transporter",
      "label": "binds_to"
    },
    {
      "source": "reboxetine",
      "target": "norepinephrine reuptake inhibitors",
      "label": "is_a"
    },
    {
      "source": "reboxetine",
      "target": "ligand",
      "label": "is_a"
    },
    {
      "source": "reboxetine",
      "target": "control mice",
      "label": "administered to"
    },
    {
      "source": "reboxetine",
      "target": "norepinephrine transporter knockout mice",
      "label": "administered to"
    },
    {
      "source": "reboxetine",
      "target": "osmotic minipump",
      "label": "administered via"
    },
    {
      "source": "reboxetine",
      "target": "GBR 12909",
      "label": "coadministered with"
    },
    {
      "source": "norepinephrine reuptake inhibitors",
      "target": "Hypothalamus to striatum ratios",
      "label": "reduced"
    },
    {
      "source": "norepinephrine reuptake inhibitors",
      "target": "norepinephrine",
      "label": "inhibits_reuptake_of"
    },
    {
      "source": "novel radiotracers",
      "target": "in vivo imaging",
      "label": "used_for"
    },
    {
      "source": "(R,R)-enantiomer",
      "target": "washout of radioactivity",
      "label": "produced"
    },
    {
      "source": "(R,R)-enantiomer",
      "target": "brain uptake",
      "label": "produced"
    },
    {
      "source": "regional distribution pattern",
      "target": "NET",
      "label": "consistent_with"
    },
    {
      "source": "(S,S)-enantiomer",
      "target": "radioactivity",
      "label": "produced_distribution_of"
    },
    {
      "source": "brain",
      "target": "Carboxylase activities",
      "label": "spared from reduction of"
    },
    {
      "source": "brain",
      "target": "mice",
      "label": "is part of"
    },
    {
      "source": "brain",
      "target": "monkey",
      "label": "of"
    },
    {
      "source": "brain",
      "target": "healthy mice",
      "label": "of"
    },
    {
      "source": "reuptake inhibitors of dopamine",
      "target": "dopamine",
      "label": "contains"
    },
    {
      "source": "reuptake inhibitors of dopamine",
      "target": "binding",
      "label": "no_effect_on"
    },
    {
      "source": "In vitro autoradiography studies",
      "target": "(S,S)-[(11)C]-MeNER",
      "label": "performed_with"
    },
    {
      "source": "In vitro autoradiography studies",
      "target": "rat brain slices",
      "label": "performed_on"
    },
    {
      "source": "in vivo evaluation",
      "target": "novel radiotracers",
      "label": "of"
    },
    {
      "source": "tail-vein injection",
      "target": "(R,R)-enantiomer",
      "label": "of"
    },
    {
      "source": "positron emission tomography",
      "target": "PET",
      "label": "is_a"
    },
    {
      "source": "positron emission tomography",
      "target": "in vivo",
      "label": "is"
    },
    {
      "source": "(R,R) and (S,S) enantiomers of 2-[(2-methoxyphenoxy)phenylmethyl]morpholine",
      "target": "MeNER",
      "label": "is_a"
    },
    {
      "source": "PET",
      "target": "Abeta plaques",
      "label": "is of"
    },
    {
      "source": "binding",
      "target": "additional TATA elements",
      "label": "is to"
    },
    {
      "source": "binding",
      "target": "midbrain",
      "label": "OccursIn"
    },
    {
      "source": "binding",
      "target": "cortex",
      "label": "OccursIn"
    },
    {
      "source": "binding",
      "target": "striatum",
      "label": "OccursIn"
    },
    {
      "source": "binding",
      "target": "loop structure",
      "label": "is stabilized by a"
    },
    {
      "source": "binding",
      "target": "human cloned muscarinic m1-5 receptors",
      "label": "occurs on"
    },
    {
      "source": "binding",
      "target": "(3)H-NMS",
      "label": "is of"
    },
    {
      "source": "binding",
      "target": "ionic strength",
      "label": "is affected by"
    },
    {
      "source": "binding",
      "target": "BLG",
      "label": "for"
    },
    {
      "source": "binding",
      "target": "SPBs",
      "label": "onto"
    },
    {
      "source": "binding",
      "target": "pH",
      "label": "is affected by"
    },
    {
      "source": "binding",
      "target": "BSA",
      "label": "for"
    },
    {
      "source": "binding",
      "target": "proteins",
      "label": "between"
    },
    {
      "source": "binding",
      "target": "papain",
      "label": "for"
    },
    {
      "source": "binding",
      "target": "ITC",
      "label": "observed by"
    },
    {
      "source": "binding",
      "target": "stoichiometry",
      "label": "is affected by"
    },
    {
      "source": "binding",
      "target": "\u03b2-lactoglobulin",
      "label": "for"
    },
    {
      "source": "binding",
      "target": "DLS",
      "label": "observed by"
    },
    {
      "source": "binding",
      "target": "bovine serum albumin",
      "label": "for"
    },
    {
      "source": "binding",
      "target": "zeta potential",
      "label": "observed by"
    },
    {
      "source": "binding",
      "target": "dynamic light scattering",
      "label": "observed by"
    },
    {
      "source": "binding",
      "target": "cationic spherical polyelectrolyte brushes",
      "label": "between"
    },
    {
      "source": "binding",
      "target": "isothermal titration calorimetry",
      "label": "observed by"
    },
    {
      "source": "binding",
      "target": "turbidimetric titration",
      "label": "observed by"
    },
    {
      "source": "binding",
      "target": "E-cadherin promoter",
      "label": "targets"
    },
    {
      "source": "binding",
      "target": "fluorescent triflavin probe",
      "label": "of"
    },
    {
      "source": "binding",
      "target": "\u03b1IIb\u03b23 integrin",
      "label": "to"
    },
    {
      "source": "binding",
      "target": "serotonin",
      "label": "displaced by"
    },
    {
      "source": "binding",
      "target": "biogenic amines",
      "label": "not displaced by"
    },
    {
      "source": "schizophrenic inpatients",
      "target": "haloperidol",
      "label": "receiving"
    },
    {
      "source": "Blood sampling",
      "target": "discontinuation",
      "label": "performed after"
    },
    {
      "source": "Blood sampling",
      "target": "coadministration",
      "label": "performed during"
    },
    {
      "source": "discontinuation",
      "target": "treatment",
      "label": "of"
    },
    {
      "source": "Css",
      "target": "coadministration",
      "label": "is higher during"
    },
    {
      "source": "Css",
      "target": "haloperidol",
      "label": "are of"
    },
    {
      "source": "Css",
      "target": "reduced haloperidol",
      "label": "are of"
    },
    {
      "source": "Css",
      "target": "discontinuation",
      "label": "is higher than after"
    },
    {
      "source": "coadministration",
      "target": "Css",
      "label": "increases"
    },
    {
      "source": "coadministration",
      "target": "promethazine",
      "label": "involves"
    },
    {
      "source": "coadministration",
      "target": "clinical doses",
      "label": "involves"
    },
    {
      "source": "coadministration",
      "target": "homochlorcyclizine",
      "label": "involves"
    },
    {
      "source": "homochlorcyclizine",
      "target": "inhibitors",
      "label": "are"
    },
    {
      "source": "homochlorcyclizine",
      "target": "inhibitory effects",
      "label": "causes"
    },
    {
      "source": "homochlorcyclizine",
      "target": "patients",
      "label": "coadministered to"
    },
    {
      "source": "homochlorcyclizine",
      "target": "steady-state plasma concentrations",
      "label": "increase"
    },
    {
      "source": "UKU score",
      "target": "study",
      "label": "found in"
    },
    {
      "source": "CYP2D6-catalyzed metabolism",
      "target": "haloperidol",
      "label": "is of"
    },
    {
      "source": "CYP2D6-catalyzed metabolism",
      "target": "reduced haloperidol",
      "label": "is of"
    },
    {
      "source": "CYP2D6-catalyzed metabolism",
      "target": "metabolism",
      "label": "is a type of"
    },
    {
      "source": "promethazine",
      "target": "inhibitors",
      "label": "are"
    },
    {
      "source": "promethazine",
      "target": "inhibitory effects",
      "label": "causes"
    },
    {
      "source": "promethazine",
      "target": "patients",
      "label": "coadministered to"
    },
    {
      "source": "promethazine",
      "target": "steady-state plasma concentrations",
      "label": "increase"
    },
    {
      "source": "steady-state plasma concentrations",
      "target": "reduced haloperidol",
      "label": "are of"
    },
    {
      "source": "steady-state plasma concentrations",
      "target": "Css",
      "label": "is also known as"
    },
    {
      "source": "steady-state plasma concentrations",
      "target": "haloperidol",
      "label": "are of"
    },
    {
      "source": "clinical assessments",
      "target": "Udvalg for kliniske undersogelser (UKU) side effect rating scale",
      "label": "performed by"
    },
    {
      "source": "clinical assessments",
      "target": "Brief Psychiatric Rating Scale (BPRS)",
      "label": "performed by"
    },
    {
      "source": "inhibitory effects",
      "target": "CYP2D6-catalyzed metabolism",
      "label": "are on"
    },
    {
      "source": "inhibitory effects",
      "target": "neutrophil chemotaxis",
      "label": "on"
    },
    {
      "source": "inhibitory effects",
      "target": "neutrophils",
      "label": "on"
    },
    {
      "source": "inhibitory effects",
      "target": "COX pathway",
      "label": "on"
    },
    {
      "source": "BPRS score",
      "target": "study",
      "label": "found in"
    },
    {
      "source": "Histamine H1-receptor antagonists",
      "target": "steady-state plasma concentrations",
      "label": "increase"
    },
    {
      "source": "CYP2D6",
      "target": "pharmacokinetic parameters",
      "label": "activities reflected by"
    },
    {
      "source": "quadruple eradication regimen",
      "target": "rabeprazole 20 to 40 mg/day",
      "label": "includes"
    },
    {
      "source": "quadruple eradication regimen",
      "target": "eradication rates",
      "label": "achieved"
    },
    {
      "source": "rabeprazole 10 mg/day",
      "target": "placebo",
      "label": "is superior to for maintenance of healing"
    },
    {
      "source": "rabeprazole 10 mg/day",
      "target": "omeprazole 20 mg/day",
      "label": "is similar to for maintenance of healing"
    },
    {
      "source": "triple-therapy regimen",
      "target": "Rabeprazole",
      "label": "includes"
    },
    {
      "source": "triple-therapy regimen",
      "target": "lansoprazole",
      "label": "includes"
    },
    {
      "source": "triple-therapy regimen",
      "target": "H. pylori",
      "label": "used for"
    },
    {
      "source": "triple-therapy regimen",
      "target": "omeprazole",
      "label": "includes"
    },
    {
      "source": "Rabeprazole",
      "target": "proton pump inhibitors",
      "label": "is a"
    },
    {
      "source": "Rabeprazole",
      "target": "Helicobacter pylori eradication therapy",
      "label": "forms part of"
    },
    {
      "source": "Rabeprazole",
      "target": "prevention of relapse",
      "label": "has efficacy in"
    },
    {
      "source": "Rabeprazole",
      "target": "H(2) antagonists",
      "label": "is an alternative to"
    },
    {
      "source": "Rabeprazole",
      "target": "diarrhoea",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "acid-related disorders",
      "label": "used in management of"
    },
    {
      "source": "Rabeprazole",
      "target": "pharyngitis",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "peptic ulcers",
      "label": "has efficacy in"
    },
    {
      "source": "Rabeprazole",
      "target": "lansoprazole",
      "label": "is as effective as for eradication of H. pylori"
    },
    {
      "source": "Rabeprazole",
      "target": "healing of GORD",
      "label": "has efficacy in"
    },
    {
      "source": "Rabeprazole",
      "target": "heartburn",
      "label": "is more effective than for relieving"
    },
    {
      "source": "Rabeprazole",
      "target": "headache",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "nausea",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "adverse events",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "abdominal pain",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "Symptom relief",
      "label": "has efficacy in"
    },
    {
      "source": "Rabeprazole",
      "target": "gastrointestinal symptoms",
      "label": "is more effective than for relieving"
    },
    {
      "source": "Rabeprazole",
      "target": "gastric proton pump",
      "label": "is an inhibitor of"
    },
    {
      "source": "Rabeprazole",
      "target": "rhinitis",
      "label": "causes"
    },
    {
      "source": "Rabeprazole",
      "target": "acid secretion",
      "label": "causes inhibition of"
    },
    {
      "source": "Rabeprazole",
      "target": "omeprazole",
      "label": "is as effective as for eradication of H. pylori"
    },
    {
      "source": "Rabeprazole",
      "target": "tolerability",
      "label": "has"
    },
    {
      "source": "rabeprazole 10 to 40 mg/day",
      "target": "ranitidine",
      "label": "is superior to for Symptom relief"
    },
    {
      "source": "rabeprazole 10 to 40 mg/day",
      "target": "placebo",
      "label": "is superior to for Symptom relief"
    },
    {
      "source": "rabeprazole 10 to 40 mg/day",
      "target": "omeprazole",
      "label": "has similar efficacy to for peptic ulcer healing"
    },
    {
      "source": "Helicobacter pylori eradication therapy",
      "target": "Rabeprazole",
      "label": "includes"
    },
    {
      "source": "Helicobacter pylori eradication therapy",
      "target": "amoxicillin",
      "label": "includes"
    },
    {
      "source": "Helicobacter pylori eradication therapy",
      "target": "clarithromycin",
      "label": "includes"
    },
    {
      "source": "Helicobacter pylori eradication therapy",
      "target": "eradication rates",
      "label": "achieved"
    },
    {
      "source": "dosage adjustment",
      "target": "renal impairment",
      "label": "not necessary in"
    },
    {
      "source": "dosage adjustment",
      "target": "hepatic impairment",
      "label": "not necessary in"
    },
    {
      "source": "Symptom relief",
      "target": "ranitidine",
      "label": "is superior to"
    },
    {
      "source": "Symptom relief",
      "target": "placebo",
      "label": "is superior to"
    },
    {
      "source": "Symptom relief",
      "target": "omeprazole",
      "label": "is similar to"
    },
    {
      "source": "rabeprazole 20 mg/day",
      "target": "omeprazole",
      "label": "is as effective as for healing of GORD"
    },
    {
      "source": "rabeprazole 20 mg/day",
      "target": "ranitidine",
      "label": "is superior to for healing of GORD"
    },
    {
      "source": "rabeprazole 20 mg/day",
      "target": "oesophagitis",
      "label": "is more effective than for maintaining healing of"
    },
    {
      "source": "serum gastrin levels",
      "target": "proton pump inhibitors",
      "label": "are typical of"
    },
    {
      "source": "rabeprazole 10mg twice daily",
      "target": "omeprazole",
      "label": "is as effective as for healing of GORD"
    },
    {
      "source": "rabeprazole 10mg twice daily",
      "target": "ranitidine",
      "label": "is superior to for healing of GORD"
    },
    {
      "source": "rabeprazole 60 to 120 mg/day",
      "target": "endoscopic lesions",
      "label": "can prevent"
    },
    {
      "source": "rabeprazole 60 to 120 mg/day",
      "target": "recurrence of symptoms",
      "label": "can prevent"
    },
    {
      "source": "Histological changes",
      "target": "proton pump inhibitors",
      "label": "are typical of"
    },
    {
      "source": "maximum concentration",
      "target": "body weight",
      "label": "related to"
    },
    {
      "source": "maximum concentration",
      "target": "56%",
      "label": "increased by"
    },
    {
      "source": "maximum concentration",
      "target": "elderly subjects",
      "label": "similar in"
    },
    {
      "source": "maximum concentration",
      "target": "2 hours",
      "label": "occurred within"
    },
    {
      "source": "body weight",
      "target": "lean controls",
      "label": "similar to"
    },
    {
      "source": "Retigabine",
      "target": "renal excretion",
      "label": "undergoes"
    },
    {
      "source": "Retigabine",
      "target": "phase II metabolism",
      "label": "undergoes"
    },
    {
      "source": "renal excretion",
      "target": "JBP485",
      "label": "is of"
    },
    {
      "source": "phase II metabolism",
      "target": "N-glucuronidation",
      "label": "includes"
    },
    {
      "source": "phase II metabolism",
      "target": "age",
      "label": "scarcely affected by"
    },
    {
      "source": "phase II metabolism",
      "target": "acetylation",
      "label": "includes"
    },
    {
      "source": "N-glucuronidation",
      "target": "imipramine",
      "label": "of"
    },
    {
      "source": "N-glucuronidation",
      "target": "diphenhydramine",
      "label": "of"
    },
    {
      "source": "N-glucuronidation",
      "target": "amine-containing compounds",
      "label": "of"
    },
    {
      "source": "N-glucuronidation",
      "target": "amitriptyline",
      "label": "of"
    },
    {
      "source": "N-glucuronidation",
      "target": "therapeutic concentrations",
      "label": "occurs at"
    },
    {
      "source": "single 200-mg oral dose",
      "target": "retigabine",
      "label": "is of"
    },
    {
      "source": "retigabine",
      "target": "KCNQ3/5 channels",
      "label": "is selective for"
    },
    {
      "source": "retigabine",
      "target": "M-current potassium channel opener",
      "label": "is a"
    },
    {
      "source": "retigabine",
      "target": "M-current potassium channel",
      "label": "Upregulator"
    },
    {
      "source": "retigabine",
      "target": "KCNQ2/3",
      "label": "Upregulator"
    },
    {
      "source": "retigabine",
      "target": "young men",
      "label": "observed in"
    },
    {
      "source": "retigabine",
      "target": "antiepileptic drug",
      "label": "is a type of"
    },
    {
      "source": "retigabine",
      "target": "0.67 L x h(-1) x kg(-1)",
      "label": "has apparent clearance of"
    },
    {
      "source": "retigabine",
      "target": "maximum concentration",
      "label": "has maximum concentration"
    },
    {
      "source": "retigabine",
      "target": "8.5 hours",
      "label": "has mean terminal half-life of"
    },
    {
      "source": "sex",
      "target": "pharmacokinetics",
      "label": "affects"
    },
    {
      "source": "sex",
      "target": "disposition",
      "label": "affects"
    },
    {
      "source": "white subjects",
      "target": "12 women",
      "label": "includes"
    },
    {
      "source": "white subjects",
      "target": "12 men",
      "label": "includes"
    },
    {
      "source": "young women",
      "target": "maximum concentration",
      "label": "had higher"
    },
    {
      "source": "young women",
      "target": "exposure",
      "label": "had higher"
    },
    {
      "source": "young women",
      "target": "0.68 L x h(-1) x kg(-1)",
      "label": "had similar clearance"
    },
    {
      "source": "retigabine elimination",
      "target": "elderly subjects",
      "label": "slower in"
    },
    {
      "source": "retigabine elimination",
      "target": "half-life",
      "label": "resulted in"
    },
    {
      "source": "retigabine elimination",
      "target": "exposure",
      "label": "resulted in"
    },
    {
      "source": "retigabine elimination",
      "target": "decline of renal function",
      "label": "related to"
    },
    {
      "source": "elderly subjects",
      "target": "single 200-mg oral dose",
      "label": "received"
    },
    {
      "source": "elderly subjects",
      "target": "66-81 years",
      "label": "has age range"
    },
    {
      "source": "M-current potassium channel opener",
      "target": "KCNQ2/3",
      "label": "acts on"
    },
    {
      "source": "M-current potassium channel opener",
      "target": "KCNQ3/5 channels",
      "label": "acts on"
    },
    {
      "source": "age",
      "target": "disposition",
      "label": "affects"
    },
    {
      "source": "age",
      "target": "pharmacokinetics",
      "label": "affects"
    },
    {
      "source": "age",
      "target": "feature",
      "label": "is a"
    },
    {
      "source": "disposition",
      "target": "retigabine",
      "label": "pertains to"
    },
    {
      "source": "disposition",
      "target": "anagliptin",
      "label": "of"
    },
    {
      "source": "disposition",
      "target": "sandwich-cultured rat hepatocytes",
      "label": "determined in"
    },
    {
      "source": "disposition",
      "target": "CDCA",
      "label": "of"
    },
    {
      "source": "disposition",
      "target": "[(3)H]taurocholic acid",
      "label": "of"
    },
    {
      "source": "disposition",
      "target": "suspended rat hepatocytes",
      "label": "determined in"
    },
    {
      "source": "disposition",
      "target": "TCA",
      "label": "of"
    },
    {
      "source": "disposition",
      "target": "SCRH",
      "label": "determined in"
    },
    {
      "source": "disposition",
      "target": "[(14)C]chenodeoxycholic acid",
      "label": "of"
    },
    {
      "source": "disposition",
      "target": "anionic drugs",
      "label": "of"
    },
    {
      "source": "half-life",
      "target": "30%",
      "label": "increased by"
    },
    {
      "source": "half-life",
      "target": "decline of renal function",
      "label": "related to"
    },
    {
      "source": "half-life",
      "target": "anagliptin",
      "label": "of"
    },
    {
      "source": "half-life",
      "target": "M1",
      "label": "of"
    },
    {
      "source": "Subjects",
      "target": "AWD21-360",
      "label": "exposed to"
    },
    {
      "source": "Subjects",
      "target": "dobutamine",
      "label": "infused with"
    },
    {
      "source": "Subjects",
      "target": "bisoprolol",
      "label": "pretreated with"
    },
    {
      "source": "Subjects",
      "target": "tertiles",
      "label": "divided into"
    },
    {
      "source": "Subjects",
      "target": "deuterium-labeled racemic methadone",
      "label": "received"
    },
    {
      "source": "plasma concentrations",
      "target": "acetylated metabolite",
      "label": "is of"
    },
    {
      "source": "plasma concentrations",
      "target": "retigabine",
      "label": "is of"
    },
    {
      "source": "plasma concentrations",
      "target": "unchanged drug",
      "label": "of"
    },
    {
      "source": "plasma concentrations",
      "target": "time",
      "label": "attained at"
    },
    {
      "source": "plasma concentrations",
      "target": "1,25(OH)(2)D(3)",
      "label": "increased after"
    },
    {
      "source": "plasma concentrations",
      "target": "JBP485",
      "label": "are of"
    },
    {
      "source": "plasma concentrations",
      "target": "liquid chromatography/tandem mass spectrometry",
      "label": "were determined by"
    },
    {
      "source": "acetylated metabolite",
      "target": "AWD21-360",
      "label": "is"
    },
    {
      "source": "apparent clearance",
      "target": "exposure",
      "label": "decrease results in"
    },
    {
      "source": "apparent clearance",
      "target": "elderly patients",
      "label": "decreases in"
    },
    {
      "source": "decline of renal function",
      "target": "age",
      "label": "occurs with"
    },
    {
      "source": "acetylation",
      "target": "inhibition",
      "label": "interferes with"
    },
    {
      "source": "acetylation",
      "target": "phenelzine",
      "label": "of"
    },
    {
      "source": "acetylation",
      "target": "N2 position",
      "label": "occurs at"
    },
    {
      "source": "apparent clearance normalized for weight",
      "target": "30%",
      "label": "decreased by"
    },
    {
      "source": "young subjects",
      "target": "18-40 years",
      "label": "has age range"
    },
    {
      "source": "young subjects",
      "target": "single 200-mg oral dose",
      "label": "received"
    },
    {
      "source": "sex-related differences",
      "target": "disposition",
      "label": "in"
    },
    {
      "source": "phases",
      "target": "drug discovery and development process",
      "label": "of"
    },
    {
      "source": "P-gp assays",
      "target": "28 reference compounds",
      "label": "validated and compared by testing"
    },
    {
      "source": "P-gp assays",
      "target": "functional assays",
      "label": "include"
    },
    {
      "source": "P-gp assays",
      "target": "compounds",
      "label": "used to classify"
    },
    {
      "source": "P-gp assays",
      "target": "in silico predictions",
      "label": "include"
    },
    {
      "source": "P-gp assays",
      "target": "inhibition assays",
      "label": "include"
    },
    {
      "source": "28 reference compounds",
      "target": "inhibitors",
      "label": "include"
    },
    {
      "source": "recommendations",
      "target": "screening strategies",
      "label": "given on"
    },
    {
      "source": "recommendations",
      "target": "correct use of LT4",
      "label": "about"
    },
    {
      "source": "screening strategies",
      "target": "phases",
      "label": "applied to"
    },
    {
      "source": "functional assays",
      "target": "transcellular transport assay",
      "label": "include"
    },
    {
      "source": "functional assays",
      "target": "ATPase activity assay",
      "label": "include"
    },
    {
      "source": "transcellular transport assay",
      "target": "subset of compounds",
      "label": "is for"
    },
    {
      "source": "P-glycoprotein",
      "target": "absorption",
      "label": "affects"
    },
    {
      "source": "P-glycoprotein",
      "target": "compounds",
      "label": "affects the absorption and disposition of"
    },
    {
      "source": "P-glycoprotein",
      "target": "P-gp",
      "label": "is also known as"
    },
    {
      "source": "P-glycoprotein",
      "target": "disposition",
      "label": "affects"
    },
    {
      "source": "P-glycoprotein",
      "target": "transporter",
      "label": "is a"
    },
    {
      "source": "P-glycoprotein",
      "target": "ATP-dependent drug efflux pump",
      "label": "is a type of"
    },
    {
      "source": "P-glycoprotein",
      "target": "multidrug resistance",
      "label": "is associated with"
    },
    {
      "source": "P-gp",
      "target": "drug-drug interactions",
      "label": "plays role in"
    },
    {
      "source": "P-gp",
      "target": "transporter",
      "label": "is a"
    },
    {
      "source": "P-gp",
      "target": "ATP-dependent drug efflux pump",
      "label": "is a type of"
    },
    {
      "source": "P-gp",
      "target": "ATP-binding cassette transporter",
      "label": "is a type of"
    },
    {
      "source": "drug-drug interactions",
      "target": "hepatic drug transporters",
      "label": "involve"
    },
    {
      "source": "transporter",
      "target": "intestinal sterol absorption",
      "label": "is essential for"
    },
    {
      "source": "transporter",
      "target": "drug molecules",
      "label": "for"
    },
    {
      "source": "species differences",
      "target": "test systems",
      "label": "studied in"
    },
    {
      "source": "species differences",
      "target": "indirect fluorescence indicator screening assay",
      "label": "studied in"
    },
    {
      "source": "test systems",
      "target": "human P-gp",
      "label": "express"
    },
    {
      "source": "test systems",
      "target": "porcine P-gp",
      "label": "express"
    },
    {
      "source": "test systems",
      "target": "mouse P-gp",
      "label": "express"
    },
    {
      "source": "in vitro P-glycoprotein screening assays",
      "target": "drug discovery",
      "label": "has recommendations for use in"
    },
    {
      "source": "cellular uptake",
      "target": "calcein AM",
      "label": "of"
    },
    {
      "source": "cellular uptake",
      "target": "rhodamine-123",
      "label": "of"
    },
    {
      "source": "cellular uptake",
      "target": "macrophage cells",
      "label": "occurs in"
    },
    {
      "source": "cellular uptake",
      "target": "ZDV",
      "label": "is of"
    },
    {
      "source": "inhibition assays",
      "target": "cellular uptake",
      "label": "based on"
    },
    {
      "source": "cytochrome P450 3A4",
      "target": "CYP3A4",
      "label": "is also known as"
    },
    {
      "source": "CYP3A4",
      "target": "metabolic catalyst",
      "label": "is"
    },
    {
      "source": "CYP3A4",
      "target": "pharmacokinetic parameters",
      "label": "activities reflected by"
    },
    {
      "source": "CYP3A4",
      "target": "Methadone N-demethylation",
      "label": "catalyzes"
    },
    {
      "source": "CYP3A4",
      "target": "BDP",
      "label": "metabolizes"
    },
    {
      "source": "CYP3A4",
      "target": "rates",
      "label": "metabolized at similar"
    },
    {
      "source": "dexamethasone treatment",
      "target": "granulation tissue atrophy",
      "label": "resulted in"
    },
    {
      "source": "dexamethasone treatment",
      "target": "epidermal atrophy",
      "label": "resulted in"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "keratinocyte proliferation",
      "label": "did not alter"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "microscopic morphology of the wounds",
      "label": "had no significant effect on"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "healing",
      "label": "does not affect"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "macroscopic morphology of the wounds",
      "label": "had no significant effect on"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "keratinocyte differentiation",
      "label": "did not alter"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "surgical skin wounds",
      "label": "does not affect healing of"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "dermal angiogenesis",
      "label": "did not alter"
    },
    {
      "source": "selective COX-2 inhibition",
      "target": "wound tensile strength",
      "label": "did not alter"
    },
    {
      "source": "inducible cyclooxygenase-2 (COX-2) enzyme",
      "target": "inflammatory diseases",
      "label": "is upregulated in"
    },
    {
      "source": "inducible cyclooxygenase-2 (COX-2) enzyme",
      "target": "epithelial cancers",
      "label": "is upregulated in"
    },
    {
      "source": "inducible cyclooxygenase-2 (COX-2) enzyme",
      "target": "tissue repair",
      "label": "has role in"
    },
    {
      "source": "inducible cyclooxygenase-2 (COX-2) enzyme",
      "target": "angiogenesis",
      "label": "has role in"
    },
    {
      "source": "Selective cyclooxygenase-2 inhibition",
      "target": "healing",
      "label": "does not affect"
    },
    {
      "source": "Selective cyclooxygenase-2 inhibition",
      "target": "cutaneous full-thickness incisional wounds",
      "label": "does not affect healing of"
    },
    {
      "source": "healing",
      "target": "wound strength",
      "label": "monitored for recovery of"
    },
    {
      "source": "Infiltrating macrophages",
      "target": "wound site",
      "label": "located at"
    },
    {
      "source": "Infiltrating macrophages",
      "target": "COX-2",
      "label": "expressed"
    },
    {
      "source": "cutaneous full-thickness, sutured, incisional wound model",
      "target": "hairless SKH-1 mice",
      "label": "used in"
    },
    {
      "source": "nonselective COX inhibition",
      "target": "dermal angiogenesis",
      "label": "did not alter"
    },
    {
      "source": "nonselective COX inhibition",
      "target": "wound tensile strength",
      "label": "did not alter"
    },
    {
      "source": "nonselective COX inhibition",
      "target": "keratinocyte proliferation",
      "label": "did not alter"
    },
    {
      "source": "nonselective COX inhibition",
      "target": "microscopic morphology of the wounds",
      "label": "had no significant effect on"
    },
    {
      "source": "nonselective COX inhibition",
      "target": "macroscopic morphology of the wounds",
      "label": "had no significant effect on"
    },
    {
      "source": "nonselective COX inhibition",
      "target": "keratinocyte differentiation",
      "label": "did not alter"
    },
    {
      "source": "dermal fibroblasts",
      "target": "wound site",
      "label": "located at"
    },
    {
      "source": "dermal fibroblasts",
      "target": "COX-2",
      "label": "expressed"
    },
    {
      "source": "SC-791",
      "target": "selective COX-2 inhibitor",
      "label": "is a"
    },
    {
      "source": "selective COX-2 inhibitor",
      "target": "celecoxib",
      "label": "is"
    },
    {
      "source": "selective COX-2 inhibitor",
      "target": "SC-791",
      "label": "is"
    },
    {
      "source": "selective COX-2 inhibitor",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "selective COX-2 inhibitor",
      "target": "etodolac",
      "label": "is"
    },
    {
      "source": "cutaneous full-thickness incisional wounds",
      "target": "SKH-1 mice",
      "label": "occur in"
    },
    {
      "source": "COX-2 expression",
      "target": "nonselective COX inhibitors",
      "label": "not affected by"
    },
    {
      "source": "COX-2 expression",
      "target": "selective COX-2 inhibitors",
      "label": "not affected by"
    },
    {
      "source": "COX-2 expression",
      "target": "invasiveness",
      "label": "correlates with"
    },
    {
      "source": "inhibition of COX-2",
      "target": "incisional skin wound healing",
      "label": "would affect"
    },
    {
      "source": "wound tensile strength",
      "target": "healing period",
      "label": "reduced throughout"
    },
    {
      "source": "diclofenac",
      "target": "nonselective COX inhibitor",
      "label": "is a"
    },
    {
      "source": "diclofenac",
      "target": "COX isozymes",
      "label": "regulates"
    },
    {
      "source": "nonselective COX inhibitor",
      "target": "diclofenac",
      "label": "is"
    },
    {
      "source": "keratinocytes",
      "target": "wound site",
      "label": "located at"
    },
    {
      "source": "keratinocytes",
      "target": "COX-2",
      "label": "expressed"
    },
    {
      "source": "celecoxib",
      "target": "selective COX-2 inhibitor",
      "label": "is a"
    },
    {
      "source": "celecoxib",
      "target": "warfarin",
      "label": "interacts with"
    },
    {
      "source": "celecoxib",
      "target": "three weeks",
      "label": "administered for"
    },
    {
      "source": "celecoxib",
      "target": "activity",
      "label": "has"
    },
    {
      "source": "celecoxib",
      "target": "mechanisms of action",
      "label": "has"
    },
    {
      "source": "celecoxib",
      "target": "PG biosynthesis",
      "label": "inhibits"
    },
    {
      "source": "celecoxib",
      "target": "low-doses",
      "label": "is used in"
    },
    {
      "source": "celecoxib",
      "target": "solid tumors",
      "label": "demonstrates activity against"
    },
    {
      "source": "celecoxib",
      "target": "selective COX-2 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "angiogenesis",
      "target": "rat bone marrow mesenchymal stem cells",
      "label": "in"
    },
    {
      "source": "angiogenesis",
      "target": "vivo",
      "label": "in"
    },
    {
      "source": "angiogenesis",
      "target": "implantation",
      "label": "induced by"
    },
    {
      "source": "selective COX-2 inhibitors",
      "target": "ulcers",
      "label": "produced"
    },
    {
      "source": "selective COX-2 inhibitors",
      "target": "duodenum",
      "label": "produced ulcers in"
    },
    {
      "source": "selective COX-2 inhibitors",
      "target": "Gastrointestinal lesions",
      "label": "did not cause"
    },
    {
      "source": "selective COX-2 inhibitors",
      "target": "ulcerogenic effects",
      "label": "have"
    },
    {
      "source": "plasmin",
      "target": "alpha 2-antiplasmin",
      "label": "is protected from inactivation by"
    },
    {
      "source": "plasmin",
      "target": "glomerular and tubular epithelial cell surface",
      "label": "is produced on"
    },
    {
      "source": "plasmin",
      "target": "S-2251",
      "label": "cleaves"
    },
    {
      "source": "plasmin",
      "target": "gp330",
      "label": "remains bound to"
    },
    {
      "source": "plasmin",
      "target": "chromogenic tripeptide",
      "label": "cleaves"
    },
    {
      "source": "alpha 2-antiplasmin",
      "target": "plasmin",
      "label": "is natural inhibitor of"
    },
    {
      "source": "plasminogen",
      "target": "lysine binding sites",
      "label": "binding is not through"
    },
    {
      "source": "plasminogen",
      "target": "gp330",
      "label": "binds to"
    },
    {
      "source": "plasminogen",
      "target": "natural inhibitors",
      "label": "binding to gp330 protects plasmin from"
    },
    {
      "source": "plasminogen",
      "target": "plasminogen binding sites",
      "label": "binding is not through"
    },
    {
      "source": "plasminogen",
      "target": "plasmin",
      "label": "binding to gp330 increases production of"
    },
    {
      "source": "chromogenic tripeptide",
      "target": "S-2251",
      "label": "is"
    },
    {
      "source": "gp330",
      "target": "plasmin",
      "label": "does not change enzymatic activity of"
    },
    {
      "source": "gp330",
      "target": "plasminogen",
      "label": "serves as receptor site for"
    },
    {
      "source": "gp330",
      "target": "urokinase",
      "label": "enhances conversion of plasminogen to plasmin by"
    },
    {
      "source": "gp330",
      "target": "Km",
      "label": "does not change"
    },
    {
      "source": "gp330",
      "target": "Vmax",
      "label": "increases"
    },
    {
      "source": "benzamidine",
      "target": "gp330",
      "label": "inhibits binding of plasminogen to"
    },
    {
      "source": "urokinase",
      "target": "plasmin",
      "label": "converts plasminogen to"
    },
    {
      "source": "urokinase",
      "target": "plasminogen",
      "label": "activates"
    },
    {
      "source": "epsilon-amino caproic acid",
      "target": "gp330",
      "label": "does not inhibit binding of plasminogen to"
    },
    {
      "source": "natural inhibitors",
      "target": "plasmin",
      "label": "inactivate"
    },
    {
      "source": "EACA",
      "target": "gp330",
      "label": "inhibits binding of plasminogen to"
    },
    {
      "source": "EACA",
      "target": "human [Glu1]plasminogen",
      "label": "Upregulator"
    },
    {
      "source": "EACA",
      "target": "tissue plasminogen activator",
      "label": "Upregulator"
    },
    {
      "source": "EACA",
      "target": "t-PA",
      "label": "Upregulator"
    },
    {
      "source": "EACA",
      "target": "( Glu1]Pg)",
      "label": "Upregulator"
    },
    {
      "source": "Heymann nephritis autoantigen",
      "target": "gp330",
      "label": "is"
    },
    {
      "source": "ELISA",
      "target": "gp330",
      "label": "analyzes binding of plasmin to"
    },
    {
      "source": "lysine analogue",
      "target": "gp330",
      "label": "does not inhibit binding of plasminogen to"
    },
    {
      "source": "5TFI",
      "target": "mIL-2",
      "label": "was introduced into"
    },
    {
      "source": "5TFI",
      "target": "isoleucine auxotrophic Escherichia coli host strain",
      "label": "was incorporated in"
    },
    {
      "source": "5TFI",
      "target": "murine dihydrofolate reductase",
      "label": "was incorporated into"
    },
    {
      "source": "5TFI",
      "target": "matrix-assisted laser desorption ionization mass spectrometry",
      "label": "incorporation was confirmed by"
    },
    {
      "source": "5TFI",
      "target": "tryptic peptide analysis",
      "label": "incorporation was confirmed by"
    },
    {
      "source": "5TFI",
      "target": "mDHFR",
      "label": "was incorporated into"
    },
    {
      "source": "5TFI",
      "target": "murine interleukin-2",
      "label": "was introduced into"
    },
    {
      "source": "5TFI",
      "target": "model target protein",
      "label": "was incorporated into"
    },
    {
      "source": "5TFI",
      "target": "5TFI-supplemented minimal medium",
      "label": "was incorporated using"
    },
    {
      "source": "5TFI",
      "target": "d,l-2-amino-5,5,5-trifluoro-3-methyl pentanoic acid",
      "label": "is abbreviated as"
    },
    {
      "source": "5TFI",
      "target": "isoleucine positions",
      "label": "was introduced at"
    },
    {
      "source": "5TFI",
      "target": "cytokine",
      "label": "was introduced into"
    },
    {
      "source": "isoleucine auxotrophic Escherichia coli host strain",
      "target": "Escherichia coli host strain",
      "label": "is a type of"
    },
    {
      "source": "isoleucine auxotrophic Escherichia coli host strain",
      "target": "Escherichia coli",
      "label": "is a type of"
    },
    {
      "source": "isoleucine auxotrophic Escherichia coli host strain",
      "target": "host strain",
      "label": "is a type of"
    },
    {
      "source": "tryptic peptide analysis",
      "target": "protein product",
      "label": "analyzes"
    },
    {
      "source": "protein product",
      "target": "SNP-containing cDNA",
      "label": "generated from"
    },
    {
      "source": "protein product",
      "target": "proteolysis",
      "label": "displayed enhanced susceptibility to"
    },
    {
      "source": "protein product",
      "target": "anti-HtrA1 antibody",
      "label": "displayed reduced affinity for"
    },
    {
      "source": "fluorinated cytokines",
      "target": "stable and functional structures",
      "label": "can fold into"
    },
    {
      "source": "specificity constant",
      "target": "k(cat)/K(m)",
      "label": "is"
    },
    {
      "source": "k(cat)/K(m)",
      "target": "isoleucine",
      "label": "is compared to"
    },
    {
      "source": "k(cat)/K(m)",
      "target": "5TFI",
      "label": "is lower for"
    },
    {
      "source": "fluorinated protein",
      "target": "maximal proliferative response",
      "label": "elicits"
    },
    {
      "source": "IleRS",
      "target": "specificity constant",
      "label": "yielded"
    },
    {
      "source": "murine dihydrofolate reductase",
      "target": "mDHFR",
      "label": "is abbreviated as"
    },
    {
      "source": "cytokine",
      "target": "murine interleukin-2",
      "label": "is"
    },
    {
      "source": "murine interleukin-2",
      "target": "mIL-2",
      "label": "is abbreviated as"
    },
    {
      "source": "matrix-assisted laser desorption ionization mass spectrometry",
      "target": "MALDI-MS",
      "label": "is abbreviated as"
    },
    {
      "source": "maximal responses",
      "target": "wild-type cytokines",
      "label": "are equivalent for"
    },
    {
      "source": "maximal responses",
      "target": "fluorinated cytokines",
      "label": "are equivalent for"
    },
    {
      "source": "concentration",
      "target": "wild-type mIL-2",
      "label": "is higher than"
    },
    {
      "source": "concentration",
      "target": "fluorinated protein",
      "label": "is of"
    },
    {
      "source": "concentration",
      "target": "mammalian cells",
      "label": "within"
    },
    {
      "source": "concentration",
      "target": ">18 microM ALA",
      "label": "is"
    },
    {
      "source": "concentration",
      "target": "supplemented ALA",
      "label": "of"
    },
    {
      "source": "concentration",
      "target": "1.8-72 microM",
      "label": "has range"
    },
    {
      "source": "concentration",
      "target": "ALA",
      "label": "of"
    },
    {
      "source": "concentration",
      "target": "A-100 (\u223c330 nm)",
      "label": "of"
    },
    {
      "source": "concentration",
      "target": "statistically significant effects",
      "label": "produced"
    },
    {
      "source": "concentration",
      "target": "activity",
      "label": "is required to alter"
    },
    {
      "source": "wild-type mIL-2",
      "target": "EC(50)",
      "label": "has"
    },
    {
      "source": "5TFI-supplemented minimal medium",
      "target": "minimal medium",
      "label": "is a type of"
    },
    {
      "source": "5TFI-supplemented minimal medium",
      "target": "isoleucine",
      "label": "was depleted of"
    },
    {
      "source": "E. coli isoleucyl-tRNA synthetase",
      "target": "IleRS",
      "label": "is abbreviated as"
    },
    {
      "source": "E. coli isoleucyl-tRNA synthetase",
      "target": "specificity constant",
      "label": "yielded"
    },
    {
      "source": "model target protein",
      "target": "murine dihydrofolate reductase",
      "label": "is"
    },
    {
      "source": "d,l-2-amino-5,5,5-trifluoro-3-methyl pentanoic acid",
      "target": "fluorinated derivatives",
      "label": "is a type of"
    },
    {
      "source": "fluorinated derivatives",
      "target": "isoleucine",
      "label": "are derivatives of"
    },
    {
      "source": "rate of activation",
      "target": "E. coli isoleucyl-tRNA synthetase",
      "label": "is by"
    },
    {
      "source": "rate of activation",
      "target": "5TFI",
      "label": "is of"
    },
    {
      "source": "trifluoroisoleucine",
      "target": "in vivo incorporation",
      "label": "undergoes"
    },
    {
      "source": "in vivo incorporation",
      "target": "recombinant proteins",
      "label": "is into"
    },
    {
      "source": "in vivo incorporation",
      "target": "proteins",
      "label": "is into"
    },
    {
      "source": "3TFI",
      "target": "d,l-2-amino-3-trifluoromethyl pentanoic acid",
      "label": "is abbreviated as"
    },
    {
      "source": "3TFI",
      "target": "activation",
      "label": "yielded no evidence for"
    },
    {
      "source": "3TFI",
      "target": "in vivo incorporation",
      "label": "yielded no evidence for"
    },
    {
      "source": "d,l-2-amino-3-trifluoromethyl pentanoic acid",
      "target": "fluorinated derivatives",
      "label": "is a type of"
    },
    {
      "source": "isoleucine residues",
      "target": "5TFI",
      "label": "were replaced by"
    },
    {
      "source": "MALDI-MS",
      "target": "protein product",
      "label": "analyzes"
    },
    {
      "source": "Amino acid analysis",
      "target": "isoleucine residues",
      "label": "showed replacement of"
    },
    {
      "source": "Escherichia coli",
      "target": "mutational properties",
      "label": "has"
    },
    {
      "source": "proteins",
      "target": "hexokinases",
      "label": "include"
    },
    {
      "source": "proteins",
      "target": "HCS",
      "label": "include"
    },
    {
      "source": "proteins",
      "target": "regulation",
      "label": "are involved in"
    },
    {
      "source": "proteins",
      "target": "blood coagulation",
      "label": "are involved in"
    },
    {
      "source": "proteins",
      "target": "spermatogenesis",
      "label": "play role in"
    },
    {
      "source": "proteins",
      "target": "transporters",
      "label": "include"
    },
    {
      "source": "proteins",
      "target": "metabolic enzymes",
      "label": "include"
    },
    {
      "source": "proteins",
      "target": "markers",
      "label": "used as"
    },
    {
      "source": "proteins",
      "target": "equilibrium",
      "label": "exist as"
    },
    {
      "source": "proteins",
      "target": "cholesterol",
      "label": "move"
    },
    {
      "source": "proteins",
      "target": "protein synthesis initiation",
      "label": "regulated at"
    },
    {
      "source": "HT-29/Inv2",
      "target": "COX-2 expression levels",
      "label": "has"
    },
    {
      "source": "HT-29/Inv2",
      "target": "in vitro Matrigel invasive potential",
      "label": "has"
    },
    {
      "source": "LD(50)",
      "target": "HT-29/Inv1",
      "label": "is 0.6 mM for"
    },
    {
      "source": "LD(50)",
      "target": "HT-29/Inv2",
      "label": "is 0.5 mM for"
    },
    {
      "source": "LD(50)",
      "target": "HT-29/Inv3",
      "label": "is 0.5 mM for"
    },
    {
      "source": "LD(50)",
      "target": "parental HT-29",
      "label": "is 1.8 mM for"
    },
    {
      "source": "HT-29/Inv1",
      "target": "COX-2 expression levels",
      "label": "has"
    },
    {
      "source": "HT-29/Inv1",
      "target": "in vitro Matrigel invasive potential",
      "label": "has"
    },
    {
      "source": "biotin",
      "target": "voyage",
      "label": "conducted"
    },
    {
      "source": "COX-2 inhibitors",
      "target": "tumor invasion",
      "label": "prevent"
    },
    {
      "source": "COX-2 inhibitors",
      "target": "Gastrointestinal side effects",
      "label": "cause reduced"
    },
    {
      "source": "COX-2 inhibitors",
      "target": "Inflammation",
      "label": "reduce"
    },
    {
      "source": "tumor invasion",
      "target": "colon cancer patients",
      "label": "occurs in"
    },
    {
      "source": "in vitro Matrigel invasive potential",
      "target": "COX-2 expression levels",
      "label": "shows graded increases with"
    },
    {
      "source": "HT-29 variants",
      "target": "invasive potential",
      "label": "have higher"
    },
    {
      "source": "HT-29 variants",
      "target": "etodolac",
      "label": "are sensitive to"
    },
    {
      "source": "etodolac",
      "target": "growth medium",
      "label": "was used in"
    },
    {
      "source": "etodolac",
      "target": "apoptosis",
      "label": "produced"
    },
    {
      "source": "etodolac",
      "target": "in vitro growth inhibition assays",
      "label": "sensitivity measured by"
    },
    {
      "source": "etodolac",
      "target": "HT-29 colon cancer cell lines",
      "label": "was tested on"
    },
    {
      "source": "etodolac",
      "target": "COX-2",
      "label": "downregulates"
    },
    {
      "source": "etodolac",
      "target": "Canine COX-2",
      "label": "selectively inhibits"
    },
    {
      "source": "etodolac",
      "target": "COX-1",
      "label": "downregulates"
    },
    {
      "source": "HT-29 colon cancer cell lines",
      "target": "HT-29/Inv1",
      "label": "include"
    },
    {
      "source": "HT-29 colon cancer cell lines",
      "target": "HT-29/Inv2",
      "label": "include"
    },
    {
      "source": "HT-29 colon cancer cell lines",
      "target": "HT-29/Inv3",
      "label": "include"
    },
    {
      "source": "In vivo experiments",
      "target": "SCID mice",
      "label": "conducted in"
    },
    {
      "source": "subcutaneous tumors",
      "target": "HT-29/Inv3",
      "label": "induced by"
    },
    {
      "source": "HT-29/Inv3",
      "target": "COX-2 expression levels",
      "label": "has"
    },
    {
      "source": "HT-29/Inv3",
      "target": "in vitro Matrigel invasive potential",
      "label": "has"
    },
    {
      "source": "invasiveness",
      "target": "Colon cancer cells",
      "label": "is a characteristic of"
    },
    {
      "source": "Cyclooxygenase-2",
      "target": "COX-2",
      "label": "is also known as"
    },
    {
      "source": "etolodac",
      "target": "growth",
      "label": "inhibited"
    },
    {
      "source": "etolodac",
      "target": "parental HT-29",
      "label": "inhibited growth more than"
    },
    {
      "source": "growth",
      "target": "subcutaneous tumors",
      "label": "of"
    },
    {
      "source": "growth",
      "target": "human gastric cancer HeLa cells",
      "label": "of"
    },
    {
      "source": "DNA fragmentation",
      "target": "apoptosis",
      "label": "does not account for"
    },
    {
      "source": "Colon cancer cells",
      "target": "apoptosis",
      "label": "are susceptible to induction of"
    },
    {
      "source": "in vitro growth inhibition assays",
      "target": "LD(50)",
      "label": "determine"
    },
    {
      "source": "comparison",
      "target": "results",
      "label": "is of"
    },
    {
      "source": "comparison",
      "target": "previous data",
      "label": "is with"
    },
    {
      "source": "hNET point mutations",
      "target": "inhibitory potency",
      "label": "affect"
    },
    {
      "source": "inhibitory potency",
      "target": "MrIA",
      "label": "is of"
    },
    {
      "source": "inhibitory potency",
      "target": "AChE",
      "label": "was stronger against"
    },
    {
      "source": "inhibitory potency",
      "target": "BuChE",
      "label": "was stronger than against"
    },
    {
      "source": "inhibitory potency",
      "target": "compounds",
      "label": "of"
    },
    {
      "source": "18 mutations",
      "target": "hNET amino acid residues",
      "label": "involve"
    },
    {
      "source": "hNET amino acid residues",
      "target": "human dopamine transporter",
      "label": "exchanged with"
    },
    {
      "source": "12 additional mutations",
      "target": "IL1",
      "label": "located in"
    },
    {
      "source": "12 additional mutations",
      "target": "TMDs 2",
      "label": "located in"
    },
    {
      "source": "12 additional mutations",
      "target": "TMDs 5",
      "label": "located in"
    },
    {
      "source": "12 additional mutations",
      "target": "TMDs 11",
      "label": "located in"
    },
    {
      "source": "12 additional mutations",
      "target": "TMDs 4",
      "label": "located in"
    },
    {
      "source": "Ki",
      "target": "microM",
      "label": "measured in"
    },
    {
      "source": "Ki",
      "target": "[3H]norepinephrine",
      "label": "is for"
    },
    {
      "source": "Ki",
      "target": "[3H]dopamine",
      "label": "is for"
    },
    {
      "source": "Ki",
      "target": "mycophenolic acid inhibition",
      "label": "is for"
    },
    {
      "source": "three mutations",
      "target": "IL1",
      "label": "located in"
    },
    {
      "source": "three mutations",
      "target": "predicted extracellular loops 4",
      "label": "located in"
    },
    {
      "source": "three mutations",
      "target": "TMD2",
      "label": "located in"
    },
    {
      "source": "three mutations",
      "target": "predicted extracellular loops 3",
      "label": "located in"
    },
    {
      "source": "three mutations",
      "target": "MrIA inhibitory potency",
      "label": "reduced"
    },
    {
      "source": "three mutations",
      "target": "transmembrane domain (TMD) 8",
      "label": "located in"
    },
    {
      "source": "MrIA binding",
      "target": "site",
      "label": "occurs at"
    },
    {
      "source": "MrIA binding",
      "target": "hNET",
      "label": "to"
    },
    {
      "source": "site",
      "target": "binding sites",
      "label": "overlaps with"
    },
    {
      "source": "previous data",
      "target": "cocaine",
      "label": "is for"
    },
    {
      "source": "previous data",
      "target": "desipramine",
      "label": "is for"
    },
    {
      "source": "hNET",
      "target": "cell line",
      "label": "used to establish"
    },
    {
      "source": "hNET",
      "target": "channel-like events",
      "label": "exhibits"
    },
    {
      "source": "hNET",
      "target": "gamma-aminobutyric acid transporter gene family",
      "label": "is a member of"
    },
    {
      "source": "hNET",
      "target": "fixed stoichiometry",
      "label": "has"
    },
    {
      "source": "MrIA",
      "target": "potency",
      "label": "decreased"
    },
    {
      "source": "MrIA",
      "target": "human dopamine transporter",
      "label": "does not inhibit"
    },
    {
      "source": "MrIA",
      "target": "serotonin transporter",
      "label": "does not inhibit"
    },
    {
      "source": "uptake",
      "target": "[3H]norepinephrine",
      "label": "is of"
    },
    {
      "source": "uptake",
      "target": "[3H]dopamine",
      "label": "is of"
    },
    {
      "source": "uptake",
      "target": "hNET",
      "label": "is by"
    },
    {
      "source": "uptake",
      "target": "heart",
      "label": "into"
    },
    {
      "source": "uptake",
      "target": "[3H]NE",
      "label": "is of"
    },
    {
      "source": "uptake",
      "target": "hSERT",
      "label": "is by"
    },
    {
      "source": "uptake",
      "target": "[3H]5-HT",
      "label": "is of"
    },
    {
      "source": "uptake",
      "target": "mammalian cells",
      "label": "within"
    },
    {
      "source": "uptake",
      "target": "neutral amino acids",
      "label": "by"
    },
    {
      "source": "uptake",
      "target": "cationic amino acids",
      "label": "by"
    },
    {
      "source": "uptake",
      "target": "cold temperature",
      "label": "inhibited by"
    },
    {
      "source": "uptake",
      "target": "silver",
      "label": "inhibited by"
    },
    {
      "source": "uptake",
      "target": "copper",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "platinum anticancer drugs",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "HEK/rCtr1 cells",
      "label": "by"
    },
    {
      "source": "uptake",
      "target": "cisplatin",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "carboplatin",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "oxaliplatin",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "rCtr1",
      "label": "mediated by"
    },
    {
      "source": "uptake",
      "target": "cultured rat DRG neurons",
      "label": "by"
    },
    {
      "source": "uptake",
      "target": "zinc",
      "label": "inhibited by"
    },
    {
      "source": "uptake",
      "target": "kidney slices",
      "label": "occurs in"
    },
    {
      "source": "uptake",
      "target": "1,25(OH)(2)D(3)",
      "label": "decreased after"
    },
    {
      "source": "uptake",
      "target": "liquid chromatography/tandem mass spectrometry",
      "label": "was determined by"
    },
    {
      "source": "uptake",
      "target": "JBP485",
      "label": "is of"
    },
    {
      "source": "uptake",
      "target": "Cd(2+)",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "metals",
      "label": "of"
    },
    {
      "source": "uptake",
      "target": "Mn(2+)",
      "label": "of"
    },
    {
      "source": "norepinephrine uptake",
      "target": "mutant hNETs",
      "label": "is by"
    },
    {
      "source": "cocaine",
      "target": "norepinephrine uptake",
      "label": "inhibits"
    },
    {
      "source": "cocaine",
      "target": "cocaine-induced CREB activity",
      "label": "induces"
    },
    {
      "source": "cocaine",
      "target": "localized activation of CREB",
      "label": "causes"
    },
    {
      "source": "cocaine",
      "target": "cocaine-induced activation",
      "label": "induces"
    },
    {
      "source": "cocaine",
      "target": "cAMP response element binding protein",
      "label": "activates"
    },
    {
      "source": "cocaine",
      "target": "cocaine sensitization",
      "label": "causes"
    },
    {
      "source": "binding sites",
      "target": "tricyclic antidepressants",
      "label": "are for"
    },
    {
      "source": "binding sites",
      "target": "human norepinephrine transporter",
      "label": "located on"
    },
    {
      "source": "binding sites",
      "target": "cocaine",
      "label": "are for"
    },
    {
      "source": "binding sites",
      "target": "desipramine",
      "label": "are for"
    },
    {
      "source": "binding sites",
      "target": "site II",
      "label": "include"
    },
    {
      "source": "binding sites",
      "target": "site I",
      "label": "include"
    },
    {
      "source": "chi-Conopeptide MrIA",
      "target": "binding sites",
      "label": "overlaps"
    },
    {
      "source": "interactions",
      "target": "hNET",
      "label": "involve"
    },
    {
      "source": "interactions",
      "target": "chi-Conopeptide MrIA",
      "label": "involve"
    },
    {
      "source": "interactions",
      "target": "human norepinephrine transporter",
      "label": "involve"
    },
    {
      "source": "interactions",
      "target": "genotype",
      "label": "are between"
    },
    {
      "source": "interactions",
      "target": "task factors",
      "label": "are between"
    },
    {
      "source": "interactions",
      "target": "regular doses",
      "label": "evaluated after"
    },
    {
      "source": "interactions",
      "target": "nanogram doses",
      "label": "evaluated after"
    },
    {
      "source": "interactions",
      "target": "CYP3A inhibitor",
      "label": "with"
    },
    {
      "source": "human norepinephrine transporter",
      "target": "hNET",
      "label": "is also known as"
    },
    {
      "source": "other mutations",
      "target": "MrIA potency",
      "label": "no influence on"
    },
    {
      "source": "one mutation",
      "target": "TMD6",
      "label": "located in"
    },
    {
      "source": "one mutation",
      "target": "intracellular loop (IL) 3",
      "label": "located in"
    },
    {
      "source": "prazosin-binding sites",
      "target": "alpha(1)-adrenoceptors",
      "label": "are unlikely to be"
    },
    {
      "source": "prazosin-binding sites",
      "target": "adrenoceptors",
      "label": "are distinct from"
    },
    {
      "source": "prazosin-binding sites",
      "target": "rat kidney",
      "label": "are minor in"
    },
    {
      "source": "prazosin-binding sites",
      "target": "phentolamine",
      "label": "are insensitive to"
    },
    {
      "source": "prazosin-binding sites",
      "target": "rabbit kidney",
      "label": "detected in"
    },
    {
      "source": "prazosin-binding sites",
      "target": "human kidney",
      "label": "located in"
    },
    {
      "source": "alpha(1)-adrenoceptors",
      "target": "mydriatic responses",
      "label": "involved in"
    },
    {
      "source": "alpha(1)-adrenoceptors",
      "target": "blood pressure",
      "label": "role in"
    },
    {
      "source": "alpha(1)-adrenoceptors",
      "target": "contractility",
      "label": "are required for"
    },
    {
      "source": "alpha(1)-adrenoceptors",
      "target": "ejaculation",
      "label": "role in"
    },
    {
      "source": "alpha(1)-adrenoceptors",
      "target": "function",
      "label": "have"
    },
    {
      "source": "alpha(1)-adrenoceptors",
      "target": "vascular response",
      "label": "role in"
    },
    {
      "source": "WB4101",
      "target": "alpha(1)-adrenoceptor antagonists",
      "label": "is an"
    },
    {
      "source": "WB4101",
      "target": "[(3)H]prazosin",
      "label": "did not inhibit binding of"
    },
    {
      "source": "human alpha(1b)-adrenoceptors",
      "target": "293 cells",
      "label": "expressed in"
    },
    {
      "source": "triamterene",
      "target": "[(3)H]prazosin",
      "label": "displaced binding of"
    },
    {
      "source": "triamterene",
      "target": "renal Na(+)-transporter",
      "label": "is a ligand for"
    },
    {
      "source": "[(3)H]prazosin",
      "target": "phentolamine-insensitive sites",
      "label": "bound to"
    },
    {
      "source": "phentolamine-insensitive labeling",
      "target": "human alpha(1b)-adrenoceptors",
      "label": "is larger than"
    },
    {
      "source": "phentolamine-insensitive labeling",
      "target": "human alpha(1a)-adrenoceptors",
      "label": "is larger than"
    },
    {
      "source": "[(125)I]iodoarylazidoprazosin",
      "target": "phentolamine-insensitive labeling",
      "label": "showed"
    },
    {
      "source": "phentolamine-insensitive sites",
      "target": "terazosin",
      "label": "are sensitive to"
    },
    {
      "source": "phentolamine-insensitive sites",
      "target": "quinazoline derivatives",
      "label": "are sensitive to"
    },
    {
      "source": "phentolamine-insensitive sites",
      "target": "human liver",
      "label": "not detected in"
    },
    {
      "source": "phentolamine-insensitive sites",
      "target": "doxazosin",
      "label": "are sensitive to"
    },
    {
      "source": "guanfacine",
      "target": "imidazoline recognition sites",
      "label": "is a ligand for"
    },
    {
      "source": "guanfacine",
      "target": "[(3)H]prazosin",
      "label": "displaced binding of"
    },
    {
      "source": "human alpha(1a)-adrenoceptors",
      "target": "293 cells",
      "label": "expressed in"
    },
    {
      "source": "agmatine",
      "target": "[(3)H]prazosin",
      "label": "displaced binding of"
    },
    {
      "source": "agmatine",
      "target": "imidazoline recognition sites",
      "label": "is a ligand for"
    },
    {
      "source": "phentolamine-sensitive alpha(1)-adrenoceptor",
      "target": "human liver",
      "label": "detected in"
    },
    {
      "source": "terazosin",
      "target": "quinazoline derivatives",
      "label": "is a type of"
    },
    {
      "source": "guanabenz",
      "target": "[(3)H]prazosin",
      "label": "prevented binding of"
    },
    {
      "source": "guanabenz",
      "target": "imidazoline recognition sites",
      "label": "is a ligand for"
    },
    {
      "source": "tamsulosin",
      "target": "alpha(1)-adrenoceptor antagonists",
      "label": "is an"
    },
    {
      "source": "tamsulosin",
      "target": "[(3)H]prazosin",
      "label": "did not inhibit binding of"
    },
    {
      "source": "tamsulosin",
      "target": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "label": "is a"
    },
    {
      "source": "corynanthine",
      "target": "[(3)H]prazosin",
      "label": "did not inhibit binding of"
    },
    {
      "source": "corynanthine",
      "target": "alpha(1)-adrenoceptor antagonists",
      "label": "is an"
    },
    {
      "source": "amiloride",
      "target": "renal Na(+)-transporter",
      "label": "is a ligand for"
    },
    {
      "source": "amiloride",
      "target": "[(3)H]prazosin",
      "label": "displaced binding of"
    },
    {
      "source": "Patients",
      "target": "one-week washout period",
      "label": "underwent"
    },
    {
      "source": "Patients",
      "target": "treatment",
      "label": "crossed over to"
    },
    {
      "source": "Patients",
      "target": "cyclooxygenase-2 (COX-2) inhibitor comparator",
      "label": "taking"
    },
    {
      "source": "Patients",
      "target": "warfarin therapy",
      "label": "stable on"
    },
    {
      "source": "Patients",
      "target": "celecoxib",
      "label": "received"
    },
    {
      "source": "Patients",
      "target": "rofecoxib",
      "label": "received"
    },
    {
      "source": "Patients",
      "target": "Medication",
      "label": "treated with"
    },
    {
      "source": "Patients",
      "target": "Schizophrenia",
      "label": "have"
    },
    {
      "source": "Patients",
      "target": "adverse effects",
      "label": "are susceptible to"
    },
    {
      "source": "Patients",
      "target": "chronic airway diseases",
      "label": "have"
    },
    {
      "source": "Patients",
      "target": "donepezil",
      "label": "had doses maximised"
    },
    {
      "source": "Patients",
      "target": "January 2006",
      "label": "received prescriptions during"
    },
    {
      "source": "Patients",
      "target": "memantine",
      "label": "had doses maximised"
    },
    {
      "source": "Patients",
      "target": "maximum drug dose",
      "label": "received"
    },
    {
      "source": "Patients",
      "target": "prescriptions",
      "label": "received"
    },
    {
      "source": "Patients",
      "target": "December 2010",
      "label": "received prescriptions during"
    },
    {
      "source": "Patients",
      "target": "study",
      "label": "were included in"
    },
    {
      "source": "rofecoxib",
      "target": "warfarin",
      "label": "interacts with"
    },
    {
      "source": "rofecoxib",
      "target": "three weeks",
      "label": "administered for"
    },
    {
      "source": "rofecoxib",
      "target": "chemical kindling",
      "label": "has protective effect against"
    },
    {
      "source": "rofecoxib",
      "target": "COX-2",
      "label": "is a selective inhibitor of"
    },
    {
      "source": "rofecoxib",
      "target": "mice",
      "label": "has effect in"
    },
    {
      "source": "increases",
      "target": "International Normalized Ratio (INR)",
      "label": "in"
    },
    {
      "source": "increases",
      "target": "therapy",
      "label": "observed after addition of"
    },
    {
      "source": "increases",
      "target": "warfarin therapy",
      "label": "observed in patients on"
    },
    {
      "source": "International Normalized Ratio (INR)",
      "target": "weeks 1, 2, and 3",
      "label": "increased at"
    },
    {
      "source": "International Normalized Ratio (INR)",
      "target": "celecoxib",
      "label": "increased with"
    },
    {
      "source": "International Normalized Ratio (INR)",
      "target": "rofecoxib",
      "label": "increased with"
    },
    {
      "source": "International Normalized Ratio (INR)",
      "target": "therapy",
      "label": "measured during"
    },
    {
      "source": "International Normalized Ratio (INR)",
      "target": "baseline",
      "label": "measured at"
    },
    {
      "source": "International Normalized Ratio (INR)",
      "target": "blood samples",
      "label": "measured using"
    },
    {
      "source": "Changes",
      "target": "International Normalized Ratio (INR)",
      "label": "in"
    },
    {
      "source": "Changes",
      "target": "week 1",
      "label": "significant at"
    },
    {
      "source": "Changes",
      "target": "week 2",
      "label": "significant at"
    },
    {
      "source": "cyclooxygenase-2 (COX-2) inhibitor comparator",
      "target": "traditional nonsteroidal antiinflammatory medications",
      "label": "includes"
    },
    {
      "source": "cyclooxygenase-2 (COX-2) inhibitor comparator",
      "target": "acetaminophen",
      "label": "includes"
    },
    {
      "source": "cyclooxygenase-2 (COX-2) inhibitor comparator",
      "target": "salsalate",
      "label": "includes"
    },
    {
      "source": "COX-2 inhibitor",
      "target": "three weeks",
      "label": "administered for"
    },
    {
      "source": "rate of edema",
      "target": "medical intervention",
      "label": "required"
    },
    {
      "source": "rate of edema",
      "target": "rofecoxib group",
      "label": "higher in"
    },
    {
      "source": "blood samples",
      "target": "finger stick",
      "label": "obtained by"
    },
    {
      "source": "acetaminophen",
      "target": "APAP",
      "label": "is also known as"
    },
    {
      "source": "Adverse drug reactions",
      "target": "COX-2 inhibitor",
      "label": "similar for"
    },
    {
      "source": "Data",
      "target": "16 patients",
      "label": "collected for"
    },
    {
      "source": "Data",
      "target": "Novel finding",
      "label": "support"
    },
    {
      "source": "Data",
      "target": "Medical Therapy of Prostatic Symptoms (MTOPS) study",
      "label": "from"
    },
    {
      "source": "Data",
      "target": "TP treatment",
      "label": "suggest"
    },
    {
      "source": "specific receptor binding of FMLP",
      "target": "FMLP-(3H) binding assay",
      "label": "evaluated using"
    },
    {
      "source": "specific receptor binding of FMLP",
      "target": "human neutrophils",
      "label": "evaluated in"
    },
    {
      "source": "sodium cromoglycate",
      "target": "cells",
      "label": "treated"
    },
    {
      "source": "biologic meaning",
      "target": "effect",
      "label": "pertains to"
    },
    {
      "source": "nedocromil sodium",
      "target": "cells",
      "label": "treated"
    },
    {
      "source": "nedocromil sodium",
      "target": "specific receptor binding of FMLP",
      "label": "inhibits"
    },
    {
      "source": "nedocromil sodium",
      "target": "FMLP binding",
      "label": "influenced"
    },
    {
      "source": "nedocromil sodium",
      "target": "neutrophil migration",
      "label": "affects"
    },
    {
      "source": "haplotype pair",
      "target": "beta(1)-adrenergic receptor",
      "label": "for"
    },
    {
      "source": "haplotype pair",
      "target": "predictor",
      "label": "was a significant"
    },
    {
      "source": "haplotype pair",
      "target": "diplotype",
      "label": "is a type of"
    },
    {
      "source": "antihypertensive response",
      "target": "metoprolol",
      "label": "to"
    },
    {
      "source": "metoprolol",
      "target": "CYP2D6",
      "label": "is probe drug for"
    },
    {
      "source": "codon 49 genotype",
      "target": "beta(1)-adrenergic receptor",
      "label": "for"
    },
    {
      "source": "codon 49 genotype",
      "target": "polymerase chain reaction",
      "label": "determined by"
    },
    {
      "source": "codon 49 genotype",
      "target": "diastolic blood pressure response",
      "label": "can predict"
    },
    {
      "source": "codon 49 genotype",
      "target": "predictor",
      "label": "is a"
    },
    {
      "source": "predictor",
      "target": "response",
      "label": "of"
    },
    {
      "source": "baseline daytime diastolic blood pressure",
      "target": "predictor",
      "label": "is a"
    },
    {
      "source": "determinants",
      "target": "antihypertensive response",
      "label": "of"
    },
    {
      "source": "polymorphisms",
      "target": "antihypertensive response",
      "label": "associated with"
    },
    {
      "source": "polymorphisms",
      "target": "gene",
      "label": "in"
    },
    {
      "source": "polymorphisms",
      "target": "French population",
      "label": "evaluated in"
    },
    {
      "source": "polymorphisms",
      "target": "248 matched healthy controls",
      "label": "investigated in"
    },
    {
      "source": "polymorphisms",
      "target": "530 CAD patients",
      "label": "investigated in"
    },
    {
      "source": "polymorphisms",
      "target": "t-Hcys",
      "label": "effects investigated with"
    },
    {
      "source": "polymorphisms",
      "target": "CAD",
      "label": "association evaluated with"
    },
    {
      "source": "polymorphisms",
      "target": "TTCA levels",
      "label": "modify effects of"
    },
    {
      "source": "polymorphisms",
      "target": "GSTT1",
      "label": "in"
    },
    {
      "source": "polymorphisms",
      "target": "GSTM1",
      "label": "in"
    },
    {
      "source": "polymorphisms",
      "target": "glutathione-related genes",
      "label": "of"
    },
    {
      "source": "polymorphisms",
      "target": "role of ADCC of cetuximab",
      "label": "indicate"
    },
    {
      "source": "polymorphisms",
      "target": "molecular markers",
      "label": "are"
    },
    {
      "source": "polymorphisms",
      "target": "vascular diseases",
      "label": "related to"
    },
    {
      "source": "389 genotypes",
      "target": "beta(1)-adrenergic receptor",
      "label": "for"
    },
    {
      "source": "389 genotypes",
      "target": "polymerase chain reaction",
      "label": "determined by"
    },
    {
      "source": "389 genotypes",
      "target": "diastolic blood pressure response",
      "label": "can predict"
    },
    {
      "source": "hypothesis",
      "target": "antihypertensive response",
      "label": "concerns"
    },
    {
      "source": "hypothesis",
      "target": "polymorphisms",
      "label": "concerns"
    },
    {
      "source": "hypothesis",
      "target": "dysregulation",
      "label": "proposes"
    },
    {
      "source": "hypothesis",
      "target": "Panx1",
      "label": "concerns"
    },
    {
      "source": "hypothesis",
      "target": "hemichannel",
      "label": "concerns"
    },
    {
      "source": "hypothesis",
      "target": "contributions",
      "label": "explored by evaluating"
    },
    {
      "source": "Ser49Arg389/Ser49Arg389 diplotype",
      "target": "decline",
      "label": "demonstrated"
    },
    {
      "source": "decline",
      "target": "blood pressure",
      "label": "in"
    },
    {
      "source": "decline",
      "target": "14.7 mm Hg",
      "label": "of"
    },
    {
      "source": "treatment phase 24-hour ambulatory blood pressure monitoring",
      "target": "4 weeks",
      "label": "repeated after"
    },
    {
      "source": "4 weeks",
      "target": "stable dose",
      "label": "at"
    },
    {
      "source": "hypertensive men and women",
      "target": "35 to 65 years",
      "label": "aged"
    },
    {
      "source": "multiregression analysis",
      "target": "predictors",
      "label": "identified"
    },
    {
      "source": "predictors",
      "target": "blood pressure",
      "label": "of"
    },
    {
      "source": "predictors",
      "target": "dose-maximisation",
      "label": "of"
    },
    {
      "source": "predictors",
      "target": "Non-persistence",
      "label": "of"
    },
    {
      "source": "predictors",
      "target": "variables",
      "label": "are of"
    },
    {
      "source": "future",
      "target": "codon 49 genotype",
      "label": "might use"
    },
    {
      "source": "future",
      "target": "389 genotypes",
      "label": "might use"
    },
    {
      "source": "future",
      "target": "beta(1)-adrenergic receptor haplotypes",
      "label": "might use"
    },
    {
      "source": "future",
      "target": "drug target",
      "label": "for"
    },
    {
      "source": "interpatient variability",
      "target": "blood pressure response",
      "label": "exists in"
    },
    {
      "source": "interpatient variability",
      "target": "clearance",
      "label": "affects"
    },
    {
      "source": "blood pressure response",
      "target": "beta-blocker monotherapy",
      "label": "to"
    },
    {
      "source": "blood pressure response",
      "target": "metoprolol",
      "label": "to"
    },
    {
      "source": "response",
      "target": "200 mg",
      "label": "or"
    },
    {
      "source": "response",
      "target": "hypermethylation",
      "label": "compared to absence of"
    },
    {
      "source": "response",
      "target": "rituximab",
      "label": "to"
    },
    {
      "source": "response",
      "target": "follicular lymphoma",
      "label": "in"
    },
    {
      "source": "response",
      "target": "treatment",
      "label": "is of"
    },
    {
      "source": "response",
      "target": "4 h",
      "label": "occurred within"
    },
    {
      "source": "response",
      "target": "portal vein glucose infusion",
      "label": "to"
    },
    {
      "source": "response",
      "target": "hyperglycemia",
      "label": "to"
    },
    {
      "source": "response",
      "target": "experimental period",
      "label": "measured in"
    },
    {
      "source": "response",
      "target": "PoG",
      "label": "to"
    },
    {
      "source": "response",
      "target": "INS",
      "label": "to"
    },
    {
      "source": "response",
      "target": "basal insulin",
      "label": "to"
    },
    {
      "source": "response",
      "target": "advanced colorectal cancer patients",
      "label": "occurs in"
    },
    {
      "source": "response",
      "target": "Chinese patients",
      "label": "is of"
    },
    {
      "source": "response",
      "target": "chemotherapy",
      "label": "is to"
    },
    {
      "source": "beta(1)-adrenergic receptor haplotypes",
      "target": "diastolic blood pressure response",
      "label": "can predict"
    },
    {
      "source": "diastolic blood pressure response",
      "target": "metoprolol",
      "label": "to"
    },
    {
      "source": "impact",
      "target": "variables",
      "label": "of"
    },
    {
      "source": "impact",
      "target": "blood pressure response",
      "label": "on"
    },
    {
      "source": "impact",
      "target": "genotype",
      "label": "of"
    },
    {
      "source": "impact",
      "target": "cytokine release",
      "label": "on"
    },
    {
      "source": "variables",
      "target": "TS",
      "label": "associated with"
    },
    {
      "source": "variables",
      "target": "Thymidylate synthase",
      "label": "associated with"
    },
    {
      "source": "variables",
      "target": "progression-free survival",
      "label": "associated with"
    },
    {
      "source": "variables",
      "target": "PFS",
      "label": "associated with"
    },
    {
      "source": "variables",
      "target": "clinical outcome",
      "label": "predicts"
    },
    {
      "source": "variables",
      "target": "response to chemotherapy",
      "label": "predicts"
    },
    {
      "source": "variables",
      "target": "'real world'",
      "label": "are found in"
    },
    {
      "source": "Arg",
      "target": "codon 389",
      "label": "at"
    },
    {
      "source": "50 mg metoprolol",
      "target": "weekly titration",
      "label": "with"
    },
    {
      "source": "weekly titration",
      "target": "response",
      "label": "to"
    },
    {
      "source": "codon 389 genotype",
      "target": "predictor",
      "label": "is a"
    },
    {
      "source": "Our data",
      "target": "determinants",
      "label": "suggest"
    },
    {
      "source": "Our data",
      "target": "critical lower level of androgen receptor mRNA expression",
      "label": "suggests"
    },
    {
      "source": "reduction",
      "target": "daytime diastolic blood pressure",
      "label": "in"
    },
    {
      "source": "reduction",
      "target": "electron-accepting molecules",
      "label": "of"
    },
    {
      "source": "reduction",
      "target": "nicotinamide adenine dinucleotide (reduced form)",
      "label": "is dependent on"
    },
    {
      "source": "reduction",
      "target": "testosterone levels",
      "label": "Downregulator"
    },
    {
      "source": "reduction",
      "target": "increase or 'surge'",
      "label": "accompanied_by"
    },
    {
      "source": "reduction",
      "target": "LH",
      "label": "Downregulator"
    },
    {
      "source": "reduction",
      "target": "glycogen synthesis",
      "label": "in"
    },
    {
      "source": "reduction",
      "target": "SCGly+INS",
      "label": "observed in"
    },
    {
      "source": "reduction",
      "target": "decrease",
      "label": "accompanied by"
    },
    {
      "source": "reduction",
      "target": "increase",
      "label": "accompanied by"
    },
    {
      "source": "reduction",
      "target": "network activity",
      "label": "is in"
    },
    {
      "source": "Multilinear regression",
      "target": "impact",
      "label": "performed to determine"
    },
    {
      "source": "Beta 1-adrenergic receptor polymorphisms",
      "target": "antihypertensive response",
      "label": "associated with"
    },
    {
      "source": "Beta 1-adrenergic receptor polymorphisms",
      "target": "determinants",
      "label": "are important"
    },
    {
      "source": "Baseline studies",
      "target": "24-hour ambulatory blood pressure monitoring",
      "label": "included"
    },
    {
      "source": "Gly49Arg389/Ser49Gly389 diplotype",
      "target": "0.5 mm Hg",
      "label": "demonstrated decline of"
    },
    {
      "source": "LTB4",
      "target": "chemokinetic metabolite",
      "label": "is a"
    },
    {
      "source": "LTB4",
      "target": "arachidonic acid",
      "label": "is a metabolite of"
    },
    {
      "source": "LTB4",
      "target": "chemotactic metabolite",
      "label": "is a"
    },
    {
      "source": "neutrophil migration",
      "target": "naked filters",
      "label": "occurs through"
    },
    {
      "source": "neutrophil migration",
      "target": "endothelial monolayers",
      "label": "occurs through"
    },
    {
      "source": "neutrophil migration",
      "target": "cellular barriers",
      "label": "occurs through"
    },
    {
      "source": "neutrophil migration",
      "target": "noncellular barriers",
      "label": "occurs through"
    },
    {
      "source": "neutrophil migration",
      "target": "epithelial monolayers",
      "label": "occurs through"
    },
    {
      "source": "extravasation",
      "target": "neutrophils",
      "label": "of"
    },
    {
      "source": "extravasation",
      "target": "peripheral circulation",
      "label": "from"
    },
    {
      "source": "extravasation",
      "target": "sites of inflammation",
      "label": "to"
    },
    {
      "source": "extravasation",
      "target": "cellular barriers",
      "label": "through"
    },
    {
      "source": "neutrophils",
      "target": "nedocromil",
      "label": "pretreated with"
    },
    {
      "source": "neutrophils",
      "target": "WEB 2086",
      "label": "pretreated with"
    },
    {
      "source": "Nedocromil sodium",
      "target": "Tilade",
      "label": "is also known as"
    },
    {
      "source": "Nedocromil sodium",
      "target": "therapeutic agent",
      "label": "is a"
    },
    {
      "source": "Nedocromil sodium",
      "target": "antiinflammatory activity",
      "label": "exhibits"
    },
    {
      "source": "epithelial monolayers",
      "target": "filters",
      "label": "cultured on"
    },
    {
      "source": "chemotaxis",
      "target": "leukotriene B4",
      "label": "responds to"
    },
    {
      "source": "chemotaxis",
      "target": "PAF",
      "label": "responds to"
    },
    {
      "source": "chemotaxis",
      "target": "cellular barriers",
      "label": "occurs through"
    },
    {
      "source": "chemotaxis",
      "target": "noncellular barriers",
      "label": "occurs through"
    },
    {
      "source": "chemotaxis",
      "target": "N-formyl-methionyl-leucyl-phenylalanine",
      "label": "responds to"
    },
    {
      "source": "nedocromil",
      "target": "inhibitory effects",
      "label": "has"
    },
    {
      "source": "nedocromil",
      "target": "chemotaxis",
      "label": "does not affect"
    },
    {
      "source": "nedocromil",
      "target": "therapeutic agent",
      "label": "is a"
    },
    {
      "source": "WEB 2086",
      "target": "neutrophil migration",
      "label": "affects"
    },
    {
      "source": "WEB 2086",
      "target": "receptor antagonist",
      "label": "is a"
    },
    {
      "source": "cellular barrier",
      "target": "WEB 2086",
      "label": "pretreated with"
    },
    {
      "source": "cellular barrier",
      "target": "nedocromil",
      "label": "pretreated with"
    },
    {
      "source": "PAF",
      "target": "neutrophil migration",
      "label": "induces"
    },
    {
      "source": "Platelet-activating factor antagonists",
      "target": "inhibitory effects",
      "label": "have"
    },
    {
      "source": "Platelet-activating factor antagonists",
      "target": "asthma",
      "label": "may be effective in"
    },
    {
      "source": "receptor antagonist",
      "target": "PAF",
      "label": "of"
    },
    {
      "source": "receptor antagonist",
      "target": "platelet-activating factor",
      "label": "of"
    },
    {
      "source": "endothelial monolayers",
      "target": "filters",
      "label": "cultured on"
    },
    {
      "source": "chemoattractant",
      "target": "neutrophil migration",
      "label": "stimulates"
    },
    {
      "source": "N-formyl-methionyl-leucyl-phenylalanine",
      "target": "FMLP",
      "label": "is also known as"
    },
    {
      "source": "in vitro assay",
      "target": "extravasation",
      "label": "mimics"
    },
    {
      "source": "antiinflammatory activity",
      "target": "in vitro",
      "label": "occurs"
    },
    {
      "source": "mode of action",
      "target": "Nedocromil sodium",
      "label": "is of"
    },
    {
      "source": "N-ethylmaleimide",
      "target": "reducing activity",
      "label": "blocks"
    },
    {
      "source": "N-ethylmaleimide",
      "target": "Gi/Go transducer proteins",
      "label": "impairs"
    },
    {
      "source": "N-ethylmaleimide",
      "target": "NEM",
      "label": "is also known as"
    },
    {
      "source": "alpha 2-adrenoceptor",
      "target": "neural substrate",
      "label": "acts on"
    },
    {
      "source": "neural substrate",
      "target": "alpha N-acetyl beta-endorphin-(1-31)",
      "label": "is involved in"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "neuropeptide",
      "label": "is a"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "[D-Ala2]-Deltorphin II",
      "label": "does not alter"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "antinociceptive activity",
      "label": "increases"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "modulatory activity",
      "label": "has"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "non-competitive regulator",
      "label": "is a"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "alpha 2-adrenoceptor",
      "label": "regulates"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "reducing activity",
      "label": "has"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "acetylated peptide",
      "label": "is an"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "mu opioid",
      "label": "regulates"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "opioids",
      "label": "regulates"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "regulatory activity",
      "label": "has"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "enhancing activity",
      "label": "has"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "analgesia",
      "label": "enhances"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "analgesic activity",
      "label": "reduces"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "DPDPE",
      "label": "does not alter"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "supraspinal antinociception",
      "label": "affects"
    },
    {
      "source": "alpha N-acetyl beta-endorphin-(1-31)",
      "target": "peptide",
      "label": "is a"
    },
    {
      "source": "[D-Ala2]-Deltorphin II",
      "target": "delta agonists",
      "label": "is a"
    },
    {
      "source": "antinociceptive activity",
      "target": "iv administration",
      "label": "occurred after"
    },
    {
      "source": "DPDPE",
      "target": "delta agonists",
      "label": "is a"
    },
    {
      "source": "DPDPE",
      "target": "AD50",
      "label": "Upregulator"
    },
    {
      "source": "DPDPE",
      "target": "tolerance",
      "label": "Induces"
    },
    {
      "source": "DPDPE",
      "target": "delta-opioid receptor-selective agonist",
      "label": "IsA"
    },
    {
      "source": "DPDPE",
      "target": "doses",
      "label": "HasProperty"
    },
    {
      "source": "DPDPE",
      "target": "i.c.v.",
      "label": "AdministeredVia"
    },
    {
      "source": "DPDPE",
      "target": "Sprague-Dawley rats",
      "label": "AdministeredTo"
    },
    {
      "source": "DPDPE",
      "target": "antinociceptive response",
      "label": "Induces"
    },
    {
      "source": "DADLE",
      "target": "analgesia",
      "label": "produces"
    },
    {
      "source": "DADLE",
      "target": "antinociceptive activity",
      "label": "evokes"
    },
    {
      "source": "DADLE",
      "target": "mu- and delta-receptors",
      "label": "InteractsWith"
    },
    {
      "source": "DADLE",
      "target": "tolerance",
      "label": "Induces"
    },
    {
      "source": "DADLE",
      "target": "opioid ligands",
      "label": "IsA"
    },
    {
      "source": "DADLE",
      "target": "mu- and delta-opioid receptor binding activities",
      "label": "Downregulator"
    },
    {
      "source": "Naloxone",
      "target": "modulatory activity",
      "label": "does not prevent"
    },
    {
      "source": "Naloxone",
      "target": "mu receptor",
      "label": "acts at"
    },
    {
      "source": "Naloxone",
      "target": "antagonist",
      "label": "is an"
    },
    {
      "source": "Gi/Go transducer proteins",
      "target": "neural substrate",
      "label": "is a"
    },
    {
      "source": "mu opioid",
      "target": "neural substrate",
      "label": "acts on"
    },
    {
      "source": "beta-endorphin-(1-31)",
      "target": "analgesic activity",
      "label": "has"
    },
    {
      "source": "antagonist",
      "target": "glutamate transporter-1",
      "label": "of"
    },
    {
      "source": "antagonist",
      "target": "Y1R",
      "label": "inhibits"
    },
    {
      "source": "antagonist",
      "target": "tissue responses",
      "label": "of"
    },
    {
      "source": "antagonist",
      "target": "responses",
      "label": "of"
    },
    {
      "source": "DAGO",
      "target": "analgesia",
      "label": "has"
    },
    {
      "source": "DAGO",
      "target": "antinociceptive activity",
      "label": "evokes"
    },
    {
      "source": "supraspinal antinociception",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "peptide",
      "target": "hypocholesterolemic agent",
      "label": "could be used as"
    },
    {
      "source": "peptide",
      "target": "venom",
      "label": "purified from"
    },
    {
      "source": "morphine",
      "target": "analgesia",
      "label": "antagonized"
    },
    {
      "source": "morphine",
      "target": "analgesic activity",
      "label": "has"
    },
    {
      "source": "morphine",
      "target": "tail-flick test",
      "label": "tested in"
    },
    {
      "source": "Ang-II",
      "target": "angiotensin II",
      "label": "is an abbreviation for"
    },
    {
      "source": "BRG",
      "target": "arterial blood pressure variability",
      "label": "calculated from"
    },
    {
      "source": "BRG",
      "target": "baroreflex gain",
      "label": "is an abbreviation for"
    },
    {
      "source": "BRG",
      "target": "Power spectra of HRV",
      "label": "calculated from"
    },
    {
      "source": "arterial blood pressure variability",
      "target": "fast Fourier transform",
      "label": "calculated by"
    },
    {
      "source": "BBB",
      "target": "blood-brain barrier",
      "label": "is an abbreviation for"
    },
    {
      "source": "RAS",
      "target": "renin-angiotensin system",
      "label": "is an abbreviation for"
    },
    {
      "source": "APV",
      "target": "arterial blood pressure variability",
      "label": "is an abbreviation for"
    },
    {
      "source": "total mortality",
      "target": "cardiovascular diseases",
      "label": "occurs in"
    },
    {
      "source": "HRV",
      "target": "heart rate variability",
      "label": "is an abbreviation for"
    },
    {
      "source": "ACE inhibitors",
      "target": "total mortality",
      "label": "Downregulator"
    },
    {
      "source": "ACE inhibitors",
      "target": "autonomic cardiovascular control",
      "label": "affects"
    },
    {
      "source": "ACE inhibitors",
      "target": "heart rate variability",
      "label": "Upregulator"
    },
    {
      "source": "ACE inhibitors",
      "target": "baroreflex gain",
      "label": "Upregulator"
    },
    {
      "source": "ACE inhibitors",
      "target": "renin-angiotensin system",
      "label": "Antagonist"
    },
    {
      "source": "autonomic cardiovascular control",
      "target": "heart rate variability",
      "label": "includes"
    },
    {
      "source": "autonomic cardiovascular control",
      "target": "baroreflex gain",
      "label": "includes"
    },
    {
      "source": "25 young males",
      "target": "eprosartan",
      "label": "took"
    },
    {
      "source": "25 young males",
      "target": "placebo",
      "label": "took"
    },
    {
      "source": "25 young males",
      "target": "double-blind randomized cross-over design",
      "label": "participated in"
    },
    {
      "source": "angiotensin type 1 (AT1) blockers",
      "target": "heart rate variability",
      "label": "affect"
    },
    {
      "source": "angiotensin type 1 (AT1) blockers",
      "target": "baroreflex gain",
      "label": "affect"
    },
    {
      "source": "angiotensin type 1 (AT1) blockers",
      "target": "blood-brain barrier",
      "label": "act on"
    },
    {
      "source": "FFT",
      "target": "fast Fourier transform",
      "label": "is an abbreviation for"
    },
    {
      "source": "HR",
      "target": "heart rate",
      "label": "is an abbreviation for"
    },
    {
      "source": "AT1 antagonism",
      "target": "heart rate variability",
      "label": "Downregulator"
    },
    {
      "source": "AT1 antagonism",
      "target": "baroreflex gain",
      "label": "Downregulator"
    },
    {
      "source": "ECG",
      "target": "electrocardiogram",
      "label": "is an abbreviation for"
    },
    {
      "source": "7 days",
      "target": "doxycycline withdrawal",
      "label": "followed"
    },
    {
      "source": "Ang-II levels",
      "target": "radioimmunoassay",
      "label": "measured by"
    },
    {
      "source": "Power spectra of HRV",
      "target": "fast Fourier transform",
      "label": "calculated by"
    },
    {
      "source": "arterial blood pressure",
      "target": "Finapres",
      "label": "measured by"
    },
    {
      "source": "circulating angiotensin II",
      "target": "heart rate variability",
      "label": "Downregulator"
    },
    {
      "source": "circulating angiotensin II",
      "target": "baroreflex gain",
      "label": "Downregulator"
    },
    {
      "source": "double-blind randomized cross-over design",
      "target": "4 weeks",
      "label": "includes"
    },
    {
      "source": "AP",
      "target": "arterial blood pressure",
      "label": "is an abbreviation for"
    },
    {
      "source": "aggravation",
      "target": "elevation of blood glucose",
      "label": "associated with"
    },
    {
      "source": "aggravation",
      "target": "endothelial injury",
      "label": "associated with"
    },
    {
      "source": "aggravation",
      "target": "disturbed circadian rhythms",
      "label": "associated with"
    },
    {
      "source": "aggravation",
      "target": "night work",
      "label": "induced by"
    },
    {
      "source": "aggravation",
      "target": "sympathetic nervous system functions",
      "label": "is of"
    },
    {
      "source": "aggravation",
      "target": "blood coagulation",
      "label": "associated with increased"
    },
    {
      "source": "aggravation",
      "target": "blood concentration",
      "label": "associated with increased"
    },
    {
      "source": "elevation of blood glucose",
      "target": "next morning",
      "label": "occurs in"
    },
    {
      "source": "elevation of blood glucose",
      "target": "night work",
      "label": "induced by"
    },
    {
      "source": "elevation of blood glucose",
      "target": "midnight",
      "label": "occurs at"
    },
    {
      "source": "t-plasminogen activator-plasminogen activator inhibitor 1-complex",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "t-plasminogen activator-plasminogen activator inhibitor 1-complex",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "t-plasminogen activator-plasminogen activator inhibitor 1-complex",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "t-plasminogen activator-plasminogen activator inhibitor 1-complex",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "morning",
      "target": "night duty",
      "label": "after"
    },
    {
      "source": "morning",
      "target": "daytime work",
      "label": "after"
    },
    {
      "source": "von Willebrand factor",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "von Willebrand factor",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "von Willebrand factor",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "von Willebrand factor",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "endothelial injury",
      "target": "night work",
      "label": "induced by"
    },
    {
      "source": "blood coagulation",
      "target": "night work",
      "label": "induced by"
    },
    {
      "source": "night duty",
      "target": "little sleep",
      "label": "with"
    },
    {
      "source": "Previous studies",
      "target": "Japanese taxi drivers",
      "label": "showed"
    },
    {
      "source": "Previous studies",
      "target": "peroxisomal location",
      "label": "INDICATE"
    },
    {
      "source": "Japanese taxi drivers",
      "target": "occupational groups",
      "label": "compared to"
    },
    {
      "source": "Japanese taxi drivers",
      "target": "risk factors",
      "label": "are exposed to"
    },
    {
      "source": "Japanese taxi drivers",
      "target": "mortality rate",
      "label": "have"
    },
    {
      "source": "preventive measures",
      "target": "rest",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "anticoagulant food",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "social support",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "water intake",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "walking",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "nap",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "short exercise",
      "label": "include"
    },
    {
      "source": "preventive measures",
      "target": "cardiovascular events",
      "label": "are for"
    },
    {
      "source": "rest",
      "target": "night work",
      "label": "during"
    },
    {
      "source": "urine normetanephrine/creatinine",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "urine normetanephrine/creatinine",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "urine normetanephrine/creatinine",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "urine normetanephrine/creatinine",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "hematocrit",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "hematocrit",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "hematocrit",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "hematocrit",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "mortality rate",
      "target": "cardiovascular disease",
      "label": "is due to"
    },
    {
      "source": "night taxi driving",
      "target": "acute events of cardiovascular disease",
      "label": "prevents"
    },
    {
      "source": "acute events of cardiovascular disease",
      "target": "aged taxi drivers",
      "label": "occur among"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "hematocrit",
      "label": "were examined for"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "anti-thrombin III",
      "label": "were examined for"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "t-plasminogen activator-plasminogen activator inhibitor 1-complex",
      "label": "were examined for"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "blood glucose",
      "label": "were examined for"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "von Willebrand factor",
      "label": "were examined for"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "blood pressure",
      "label": "were examined for"
    },
    {
      "source": "Twenty-nine taxi drivers",
      "target": "urine normetanephrine/creatinine",
      "label": "were examined for"
    },
    {
      "source": "disturbed circadian rhythms",
      "target": "night work",
      "label": "induced by"
    },
    {
      "source": "anti-thrombin III",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "anti-thrombin III",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "anti-thrombin III",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "anti-thrombin III",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "blood glucose",
      "target": "duty day",
      "label": "measured during"
    },
    {
      "source": "blood glucose",
      "target": "midnight",
      "label": "measured at"
    },
    {
      "source": "blood glucose",
      "target": "46 taxi drivers",
      "label": "of"
    },
    {
      "source": "blood glucose",
      "target": "morning",
      "label": "measured in"
    },
    {
      "source": "blood glucose",
      "target": "following morning",
      "label": "measured in"
    },
    {
      "source": "daytime work",
      "target": "night sleep",
      "label": "followed by"
    },
    {
      "source": "nap",
      "target": "night work",
      "label": "during"
    },
    {
      "source": "cardiovascular events",
      "target": "aged Japanese taxi drivers",
      "label": "occur in"
    },
    {
      "source": "cardiovascular events",
      "target": "patients",
      "label": "occur in"
    },
    {
      "source": "acute vascular events",
      "target": "aged taxi drivers",
      "label": "occur in"
    },
    {
      "source": "conditions",
      "target": "acute vascular events",
      "label": "favour"
    },
    {
      "source": "conditions",
      "target": "trans-generational effect",
      "label": "enable evaluation of"
    },
    {
      "source": "blood concentration",
      "target": "night work",
      "label": "induced by"
    },
    {
      "source": "cardiovascular risk factors",
      "target": "night duty day",
      "label": "occur during"
    },
    {
      "source": "daily rhythm",
      "target": "cardiovascular risk factors",
      "label": "is of"
    },
    {
      "source": "enzyme 5-lipoxygenase",
      "target": "leukotrienes",
      "label": "produces"
    },
    {
      "source": "enzyme 5-lipoxygenase",
      "target": "LTs",
      "label": "produces"
    },
    {
      "source": "enzyme 5-lipoxygenase",
      "target": "biochemical manipulation",
      "label": "is a target for"
    },
    {
      "source": "LTs",
      "target": "inflamed mucosa",
      "label": "generated in"
    },
    {
      "source": "rectal dialysates",
      "target": "patients",
      "label": "from"
    },
    {
      "source": "5-LO",
      "target": "LTs",
      "label": "produces"
    },
    {
      "source": "5-LO",
      "target": "leukotrienes",
      "label": "produces"
    },
    {
      "source": "existing new LT inhibitors",
      "target": "level of inhibition",
      "label": "achieves"
    },
    {
      "source": "proof",
      "target": "stage",
      "label": "is a"
    },
    {
      "source": "stage",
      "target": "drug",
      "label": "is for assessing"
    },
    {
      "source": "randomized, double-blind, placebo-controlled trial",
      "target": "patients",
      "label": "conducted in"
    },
    {
      "source": "beneficial effects",
      "target": "patients",
      "label": "observed in"
    },
    {
      "source": "beneficial effects",
      "target": "drug treatments",
      "label": "of"
    },
    {
      "source": "beneficial effects",
      "target": "DBS",
      "label": "of"
    },
    {
      "source": "beneficial effects",
      "target": "treatment",
      "label": "persisted after cessation of"
    },
    {
      "source": "endogenous LTs",
      "target": "amounts",
      "label": "present in"
    },
    {
      "source": "endogenous LTs",
      "target": "effects",
      "label": "produces"
    },
    {
      "source": "clinical efficacy",
      "target": "randomized, double-blind, placebo-controlled trial",
      "label": "tested in"
    },
    {
      "source": "clinical efficacy",
      "target": "zileuton 800 mg b.i.d.",
      "label": "is of"
    },
    {
      "source": "clinical efficacy",
      "target": "betaxolol",
      "label": "is reviewed for"
    },
    {
      "source": "clinical efficacy",
      "target": "levobunolol",
      "label": "is reviewed for"
    },
    {
      "source": "benzothiophene hydroxyurea",
      "target": "5-LO",
      "label": "inhibits"
    },
    {
      "source": "benzothiophene hydroxyurea",
      "target": "selective 5-LO inhibitor",
      "label": "is a"
    },
    {
      "source": "5-LO inhibition",
      "target": "animal models",
      "label": "occurs in"
    },
    {
      "source": "5-LO inhibition",
      "target": "healing",
      "label": "accelerates"
    },
    {
      "source": "animal models",
      "target": "acute colitis",
      "label": "are models of"
    },
    {
      "source": "animal models",
      "target": "rheumatoid arthritis",
      "label": "are models of"
    },
    {
      "source": "animal models",
      "target": "experimental autoimmune encephalomyelitis",
      "label": "are models of"
    },
    {
      "source": "animal models",
      "target": "intestinal first-pass metabolism",
      "label": "for"
    },
    {
      "source": "selective 5-LO inhibitor",
      "target": "treatment",
      "label": "evaluated for"
    },
    {
      "source": "5-LO inhibitors",
      "target": "substrate-analogous",
      "label": "includes"
    },
    {
      "source": "5-LO inhibitors",
      "target": "inflammatory bowel disease",
      "label": "treats"
    },
    {
      "source": "5-LO inhibitors",
      "target": "antioxidants",
      "label": "includes"
    },
    {
      "source": "5-LO inhibitors",
      "target": "miscellaneous group of inhibitors",
      "label": "includes"
    },
    {
      "source": "zileuton",
      "target": "symptom scores",
      "label": "improved"
    },
    {
      "source": "zileuton",
      "target": "5-LO",
      "label": "inhibits"
    },
    {
      "source": "zileuton",
      "target": "sigmoidoscopy score",
      "label": "did not improve"
    },
    {
      "source": "zileuton",
      "target": "pretreatment conditions",
      "label": "compared to"
    },
    {
      "source": "zileuton",
      "target": "histology score",
      "label": "improved"
    },
    {
      "source": "zileuton",
      "target": "selective 5-LO inhibitor",
      "label": "is a"
    },
    {
      "source": "zileuton",
      "target": "placebo",
      "label": "compared to"
    },
    {
      "source": "800-mg oral dose",
      "target": "prostaglandin E2",
      "label": "does not reduce"
    },
    {
      "source": "800-mg oral dose",
      "target": "LTB4",
      "label": "reduces"
    },
    {
      "source": "800-mg oral dose",
      "target": "concentrations",
      "label": "does not reduce"
    },
    {
      "source": "800-mg oral dose",
      "target": "zileuton",
      "label": "is a dose of"
    },
    {
      "source": "sulphasalazine",
      "target": "LT production",
      "label": "inhibits"
    },
    {
      "source": "conventional drugs",
      "target": "LT production",
      "label": "inhibits"
    },
    {
      "source": "putative 5-LO inhibitor",
      "target": "LT production",
      "label": "blocks"
    },
    {
      "source": "mean inhibition",
      "target": "LTB4",
      "label": "is of"
    },
    {
      "source": "mean inhibition",
      "target": "target tissue of inflammation",
      "label": "occurs in"
    },
    {
      "source": "hydroxamic acids",
      "target": "selective inhibitors",
      "label": "are"
    },
    {
      "source": "hydroxamic acids",
      "target": "5-LO",
      "label": "inhibits"
    },
    {
      "source": "corticosteroids",
      "target": "LT production",
      "label": "inhibits"
    },
    {
      "source": "arachidonic acid",
      "target": "brain phospholipids",
      "label": "turnover occurs in"
    },
    {
      "source": "arachidonic acid",
      "target": "5-lipoxygenase pathway",
      "label": "is processed through"
    },
    {
      "source": "5-Lipoxygenase inhibitors",
      "target": "inflammatory bowel disease",
      "label": "treats"
    },
    {
      "source": "main disadvantage",
      "target": "high potency of LTs",
      "label": "relates to"
    },
    {
      "source": "main disadvantage",
      "target": "existing new LT inhibitors",
      "label": "is of"
    },
    {
      "source": "high potency of LTs",
      "target": "LTs",
      "label": "is a property of"
    },
    {
      "source": "antioxidants",
      "target": "PHD activity",
      "label": "influences"
    },
    {
      "source": "antioxidants",
      "target": "oxidative cellular damage",
      "label": "provide protection against"
    },
    {
      "source": "antioxidants",
      "target": "therapeutic strategy",
      "label": "are"
    },
    {
      "source": "antioxidants",
      "target": "antioxidant protection",
      "label": "provide"
    },
    {
      "source": "5-aminosalicylic acid",
      "target": "LT production",
      "label": "inhibits"
    },
    {
      "source": "aberrant protein synthesis ability",
      "target": "Str(r) mutant",
      "label": "occurs in"
    },
    {
      "source": "aberrant protein synthesis ability",
      "target": "70S complex stability",
      "label": "is a result of"
    },
    {
      "source": "aberrant protein synthesis ability",
      "target": "salinomycin production enhancement",
      "label": "is responsible for"
    },
    {
      "source": "Str(r) mutant",
      "target": "point mutation",
      "label": "has"
    },
    {
      "source": "Str(r) mutant",
      "target": "K88R mutation",
      "label": "contains"
    },
    {
      "source": "Increased productivity",
      "target": "Str(r) mutant",
      "label": "occurs in"
    },
    {
      "source": "Increased productivity",
      "target": "salinomycin",
      "label": "is of"
    },
    {
      "source": "Increased productivity",
      "target": "aberrant protein synthesis mechanism",
      "label": "is a result of"
    },
    {
      "source": "aberration",
      "target": "enhanced translation activity",
      "label": "manifests as"
    },
    {
      "source": "enhanced translation activity",
      "target": "stationary-phase cells",
      "label": "occurs in"
    },
    {
      "source": "point mutation",
      "target": "rpsL gene",
      "label": "is located in"
    },
    {
      "source": "point mutation",
      "target": "R283K",
      "label": "is"
    },
    {
      "source": "point mutation",
      "target": "S5-S6 linker region",
      "label": "is in"
    },
    {
      "source": "70S complex stability",
      "target": "low Mg(2+) concentrations",
      "label": "occurs in"
    },
    {
      "source": "mutation",
      "target": "rpoB gene",
      "label": "is located in"
    },
    {
      "source": "mutation",
      "target": "premature truncation",
      "label": "causes"
    },
    {
      "source": "mutation",
      "target": "patient",
      "label": "found in"
    },
    {
      "source": "mutation",
      "target": "control subjects",
      "label": "not found in"
    },
    {
      "source": "mutation",
      "target": "processing",
      "label": "did not inhibit"
    },
    {
      "source": "mutation",
      "target": "heparin binding region",
      "label": "of"
    },
    {
      "source": "mutation",
      "target": "SIRT1 gene",
      "label": "located in"
    },
    {
      "source": "mutation",
      "target": "dimerization domain of GR",
      "label": "is in"
    },
    {
      "source": "rpoB gene",
      "target": "RNA polymerase beta subunit",
      "label": "encodes"
    },
    {
      "source": "Streptomyces albus",
      "target": "salinomycin",
      "label": "produces"
    },
    {
      "source": "industrial strain",
      "target": "salinomycin productivity",
      "label": "has"
    },
    {
      "source": "spontaneous isolates",
      "target": "gentamicin",
      "label": "are resistant to"
    },
    {
      "source": "spontaneous isolates",
      "target": "streptomycin (Str(r))",
      "label": "are resistant to"
    },
    {
      "source": "spontaneous isolates",
      "target": "rifampin (Rif(r))",
      "label": "are resistant to"
    },
    {
      "source": "K88R mutation",
      "target": "S12 protein",
      "label": "is located in"
    },
    {
      "source": "Mutants",
      "target": "enhanced salinomycin production",
      "label": "exhibit"
    },
    {
      "source": "Mutants",
      "target": "spontaneous isolates",
      "label": "are a type of"
    },
    {
      "source": "triple mutation",
      "target": "salinomycin productivity",
      "label": "improves"
    },
    {
      "source": "drug resistance-producing mutations",
      "target": "strain improvement",
      "label": "leads to"
    },
    {
      "source": "poly(U)-directed cell-free translation system",
      "target": "enhanced translation activity",
      "label": "observes"
    },
    {
      "source": "rpsL gene",
      "target": "ribosomal protein S12",
      "label": "encodes"
    },
    {
      "source": "Rif(r) mutant",
      "target": "mutation",
      "label": "has"
    },
    {
      "source": "K88R mutant ribosome",
      "target": "70S complex stability",
      "label": "exhibits"
    },
    {
      "source": "antibiotic-overproducing industrial strain",
      "target": "Streptomyces albus",
      "label": "is a strain of"
    },
    {
      "source": "hRRM2",
      "target": "UV-induced DNA repair",
      "label": "complements"
    },
    {
      "source": "hRRM2",
      "target": "PC3 cells",
      "label": "up-regulated in"
    },
    {
      "source": "hRRM2",
      "target": "RR activity",
      "label": "maintains"
    },
    {
      "source": "hRRM2",
      "target": "UV treatment",
      "label": "up-regulated by"
    },
    {
      "source": "hRRM2",
      "target": "RR holoenzyme",
      "label": "forms"
    },
    {
      "source": "hRRM2",
      "target": "p53R2",
      "label": "complements"
    },
    {
      "source": "hRRM2",
      "target": "KB cells",
      "label": "up-regulated in"
    },
    {
      "source": "antisense hRRM2",
      "target": "sensitivity to UV irradiation",
      "label": "resulted in greater"
    },
    {
      "source": "antisense hRRM2",
      "target": "hRRM2 expression",
      "label": "led to decreased"
    },
    {
      "source": "p53R2",
      "target": "KB cells",
      "label": "up-regulated in"
    },
    {
      "source": "p53R2",
      "target": "PC3 cells",
      "label": "down-regulated in"
    },
    {
      "source": "p53R2",
      "target": "Coomassie Blue-stained band",
      "label": "standardized relative to"
    },
    {
      "source": "p53R2",
      "target": "Western blot",
      "label": "analyzed by"
    },
    {
      "source": "p53R2",
      "target": "RR family member",
      "label": "is a"
    },
    {
      "source": "p53R2 binding",
      "target": "hRRM1",
      "label": "to"
    },
    {
      "source": "p53R2 binding",
      "target": "RR holoenzyme",
      "label": "forms"
    },
    {
      "source": "p53R2 binding",
      "target": "p53-mutant cell line PC3",
      "label": "impaired in"
    },
    {
      "source": "p53R2 binding",
      "target": "KB cells",
      "label": "increased in"
    },
    {
      "source": "p53R2 binding",
      "target": "UV irradiation",
      "label": "in response to"
    },
    {
      "source": "p53R2 binding",
      "target": "PC3 cells",
      "label": "decreased in"
    },
    {
      "source": "PC3 cells",
      "target": "p53R2 binding",
      "label": "deficient in"
    },
    {
      "source": "PC3 cells",
      "target": "transcription of p53R2",
      "label": "deficient in"
    },
    {
      "source": "PC3 cells",
      "target": "wild-type PC3 cells",
      "label": "compared to"
    },
    {
      "source": "hRRM2 binding",
      "target": "hRRM1",
      "label": "to"
    },
    {
      "source": "hRRM2 binding",
      "target": "KB cells",
      "label": "increased in"
    },
    {
      "source": "hRRM2 binding",
      "target": "PC3 cells",
      "label": "increased in"
    },
    {
      "source": "Confocal microscopy",
      "target": "translocation",
      "label": "confirmed"
    },
    {
      "source": "UV treatment",
      "target": "colony-forming ability",
      "label": "affects"
    },
    {
      "source": "deoxyribonucleoside diphosphates",
      "target": "DNA synthesis",
      "label": "essential for"
    },
    {
      "source": "deoxyribonucleoside diphosphates",
      "target": "DNA repair",
      "label": "essential for"
    },
    {
      "source": "DNA synthesis",
      "target": "polymerase",
      "label": "accuracy depends on"
    },
    {
      "source": "DNA synthesis",
      "target": "5'-deoxynucleoside-triphosphate DNA precursors",
      "label": "accuracy depends on"
    },
    {
      "source": "RR activity",
      "target": "KB cells",
      "label": "unchanged in"
    },
    {
      "source": "RR activity",
      "target": "UV treatment",
      "label": "measured following"
    },
    {
      "source": "RR activity",
      "target": "PC3 cells",
      "label": "increased in"
    },
    {
      "source": "RR activity",
      "target": "hRRM2 expression",
      "label": "consistent with"
    },
    {
      "source": "mutant p53",
      "target": "truncated COOH-terminal",
      "label": "has"
    },
    {
      "source": "mutant p53",
      "target": "Ribonucleotide reductase (RR)",
      "label": "regulates"
    },
    {
      "source": "Ribonucleotide reductase (RR)",
      "target": "deoxyribonucleoside diphosphates",
      "label": "produces"
    },
    {
      "source": "Ribonucleotide reductase (RR)",
      "target": "ribonucleoside diphosphates",
      "label": "converts"
    },
    {
      "source": "Ribonucleotide reductase (RR)",
      "target": "hRRM2",
      "label": "consists of"
    },
    {
      "source": "Ribonucleotide reductase (RR)",
      "target": "hRRM1",
      "label": "consists of"
    },
    {
      "source": "hydroxyurea",
      "target": "sensitivity to UV irradiation",
      "label": "resulted in increased"
    },
    {
      "source": "hydroxyurea",
      "target": "hRRM2",
      "label": "inhibited"
    },
    {
      "source": "Coimmunoprecipitation assays",
      "target": "agarose-conjugated goat antihuman RRM1 antibody",
      "label": "used"
    },
    {
      "source": "UV-induced activation",
      "target": "transcription of p53R2",
      "label": "of"
    },
    {
      "source": "UV-induced activation",
      "target": "p53-mutant cell line PC3",
      "label": "impaired in"
    },
    {
      "source": "transcription of p53R2",
      "target": "UV irradiation",
      "label": "in response to"
    },
    {
      "source": "human tumors",
      "target": "mutant p53",
      "label": "possess"
    },
    {
      "source": "human prostate cancer PC3 cells",
      "target": "mutant p53",
      "label": "possess"
    },
    {
      "source": "hRRM2 expression",
      "target": "Western blot",
      "label": "seen in"
    },
    {
      "source": "molecular mechanism",
      "target": "mutant p53",
      "label": "describes regulation by"
    },
    {
      "source": "molecular mechanism",
      "target": "transcytosis",
      "label": "of"
    },
    {
      "source": "molecular mechanism",
      "target": "ribavirin-induced up-regulation",
      "label": "of"
    },
    {
      "source": "molecular mechanism",
      "target": "regulation",
      "label": "of"
    },
    {
      "source": "molecular mechanism",
      "target": "\u03b2-cell degeneration",
      "label": "is for"
    },
    {
      "source": "RRM2 inhibitors",
      "target": "cells",
      "label": "affect"
    },
    {
      "source": "p53R2 mRNA levels",
      "target": "Northern blot",
      "label": "assessed by"
    },
    {
      "source": "p53R2 mRNA levels",
      "target": "Western blot",
      "label": "paralleled"
    },
    {
      "source": "hRRM2 mRNA levels",
      "target": "Western blot",
      "label": "paralleled"
    },
    {
      "source": "hRRM2 mRNA levels",
      "target": "Northern blot",
      "label": "assessed by"
    },
    {
      "source": "human oropharyngeal cancer KB cells",
      "target": "wild-type p53",
      "label": "possess"
    },
    {
      "source": "terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)-positive cells",
      "target": "vehicle control",
      "label": "compared to"
    },
    {
      "source": "therapeutic intervention",
      "target": "cell death",
      "label": "reduces"
    },
    {
      "source": "therapeutic intervention",
      "target": "functional recovery",
      "label": "improves"
    },
    {
      "source": "therapeutic intervention",
      "target": "AD",
      "label": "is_in"
    },
    {
      "source": "cell death",
      "target": "fluorescence-activated cell sorter analysis",
      "label": "studied_by"
    },
    {
      "source": "cell death",
      "target": "Autophagy",
      "label": "caused by"
    },
    {
      "source": "cell death",
      "target": "leukaemia CCRF-CEM cells",
      "label": "occurs in"
    },
    {
      "source": "cell death",
      "target": "breast adenocarcinoma MCF-7 cells",
      "label": "occurs in"
    },
    {
      "source": "traumatic spinal cord injury",
      "target": "rat",
      "label": "occurs in"
    },
    {
      "source": "Minocycline",
      "target": "cytokines",
      "label": "modulated expression of"
    },
    {
      "source": "Minocycline",
      "target": "hind limb motor function",
      "label": "improved"
    },
    {
      "source": "Minocycline",
      "target": "cell death",
      "label": "reduces"
    },
    {
      "source": "Minocycline",
      "target": "DNA laddering",
      "label": "decreased"
    },
    {
      "source": "Minocycline",
      "target": "lesion size",
      "label": "reduced"
    },
    {
      "source": "Minocycline",
      "target": "caspase-3 activity",
      "label": "reduced"
    },
    {
      "source": "Minocycline",
      "target": "traumatic spinal cord injury",
      "label": "is a treatment for"
    },
    {
      "source": "Minocycline",
      "target": "interleukin-10 mRNA",
      "label": "increased"
    },
    {
      "source": "Minocycline",
      "target": "anti-inflammatory drug",
      "label": "is a type of"
    },
    {
      "source": "Minocycline",
      "target": "functional recovery",
      "label": "improves"
    },
    {
      "source": "Minocycline",
      "target": "tumor necrosis factor-alpha expression",
      "label": "decreased"
    },
    {
      "source": "Minocycline",
      "target": "spinal cord injury (SCI)",
      "label": "administered after"
    },
    {
      "source": "Minocycline",
      "target": "terminal deoxynucleotidyl transferase (TdT)-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL)-positive cells",
      "label": "reduced"
    },
    {
      "source": "Minocycline",
      "target": "fulminant hepatitis",
      "label": "eases"
    },
    {
      "source": "Minocycline",
      "target": "cytochrome c release",
      "label": "Downregulator"
    },
    {
      "source": "Minocycline",
      "target": "antiapoptotic effects",
      "label": "has"
    },
    {
      "source": "Minocycline",
      "target": "anti-inflammatory effects",
      "label": "has"
    },
    {
      "source": "Minocycline",
      "target": "mitochondrial apoptotic pathway",
      "label": "involves"
    },
    {
      "source": "Minocycline",
      "target": "caspase activation",
      "label": "Not"
    },
    {
      "source": "Minocycline",
      "target": "survival kinetics",
      "label": "improved"
    },
    {
      "source": "hind limb motor function",
      "target": "Basso-Beattie-Bresnahan (BBB) locomotor open field behavioral rating test",
      "label": "measured by"
    },
    {
      "source": "functional recovery",
      "target": "injured rat",
      "label": "occurs in"
    },
    {
      "source": "functional recovery",
      "target": "spinal cord injury (SCI)",
      "label": "follows"
    },
    {
      "source": "lesion size",
      "target": "vehicle control",
      "label": "compared to"
    },
    {
      "source": "lesion size",
      "target": "minocycline-treated spinal cords",
      "label": "increased in"
    },
    {
      "source": "lesion size",
      "target": "vehicle-treated spinal cords",
      "label": "increased in"
    },
    {
      "source": "RT-PCR analyses",
      "target": "interleukin-10 mRNA",
      "label": "revealed"
    },
    {
      "source": "RT-PCR analyses",
      "target": "tumor necrosis factor-alpha expression",
      "label": "revealed"
    },
    {
      "source": "Rats",
      "target": "vehicle",
      "label": "treated with"
    },
    {
      "source": "Rats",
      "target": "weight-drop contusion injury",
      "label": "received"
    },
    {
      "source": "Rats",
      "target": "Minocycline",
      "label": "treated with"
    },
    {
      "source": "Rats",
      "target": "PLZ doses",
      "label": "treated with"
    },
    {
      "source": "weight-drop contusion injury",
      "target": "spinal cord",
      "label": "affects"
    },
    {
      "source": "caspase-3 activity",
      "target": "vehicle control",
      "label": "compared to"
    },
    {
      "source": "DNA gel electrophoresis",
      "target": "DNA laddering",
      "label": "revealed decrease in"
    },
    {
      "source": "Morphological analysis",
      "target": "lesion size",
      "label": "showed increase in"
    },
    {
      "source": "BBB scores",
      "target": "vehicle-treated rats",
      "label": "compared to"
    },
    {
      "source": "BBB scores",
      "target": "minocycline-treated rats",
      "label": "higher in"
    },
    {
      "source": "fenfluramine",
      "target": "primary pulmonary hypertension (PPH)",
      "label": "implicated in"
    },
    {
      "source": "fenfluramine",
      "target": "Appetite-suppressant drug",
      "label": "is a type of"
    },
    {
      "source": "fenfluramine",
      "target": "food intake",
      "label": "suppressed"
    },
    {
      "source": "fenfluramine",
      "target": "anorexic effects",
      "label": "induces"
    },
    {
      "source": "mutated receptor",
      "target": "normal expression",
      "label": "has"
    },
    {
      "source": "mutated receptor",
      "target": "dominant negative effect",
      "label": "produced no"
    },
    {
      "source": "mutated receptor",
      "target": "constitutive activity",
      "label": "has no"
    },
    {
      "source": "mutated receptor",
      "target": "intracellular calcium release",
      "label": "fails to activate"
    },
    {
      "source": "mutated receptor",
      "target": "inositol-phosphates cascade",
      "label": "fails to activate"
    },
    {
      "source": "mutated receptor",
      "target": "second messenger",
      "label": "fails to activate"
    },
    {
      "source": "normal expression",
      "target": "cell membrane",
      "label": "at"
    },
    {
      "source": "5-HT(2B) mutation",
      "target": "PPH patients",
      "label": "not found in"
    },
    {
      "source": "PPH patients",
      "target": "appetite-suppressants",
      "label": "not associated with"
    },
    {
      "source": "molecular pathways",
      "target": "primary pulmonary hypertension (PPH)",
      "label": "mediate"
    },
    {
      "source": "fenfluramine-associated primary pulmonary hypertension",
      "target": "man",
      "label": "occurs in"
    },
    {
      "source": "transfected receptor",
      "target": "CHO cells",
      "label": "expressed in"
    },
    {
      "source": "transfected receptor",
      "target": "COS cells",
      "label": "expressed in"
    },
    {
      "source": "dominant negative effect",
      "target": "wild-type receptor",
      "label": "on"
    },
    {
      "source": "premature truncation",
      "target": "protein product",
      "label": "of"
    },
    {
      "source": "Serotonin 5-HT(2B) receptor",
      "target": "loss of function mutation",
      "label": "has"
    },
    {
      "source": "Serotonin 5-HT(2B) receptor",
      "target": "fenfluramine-associated primary pulmonary hypertension",
      "label": "associated with"
    },
    {
      "source": "loss of function mutation",
      "target": "patient",
      "label": "found in"
    },
    {
      "source": "receptor",
      "target": "pulmonary arterial relaxation",
      "label": "mediates"
    },
    {
      "source": "receptor",
      "target": "transferrin",
      "label": "for"
    },
    {
      "source": "receptor",
      "target": "iron",
      "label": "for"
    },
    {
      "source": "receptor",
      "target": "gut",
      "label": "identified in"
    },
    {
      "source": "pulmonary arterial relaxation",
      "target": "nitric oxide production",
      "label": "via"
    },
    {
      "source": "nitric oxide production",
      "target": "LPS-activated RAW264.7 macrophages",
      "label": "in"
    },
    {
      "source": "Functional analysis",
      "target": "transfected receptor",
      "label": "of"
    },
    {
      "source": "Loss of serotonin 5-HT(2B) receptor function",
      "target": "fenfluramine-associated primary pulmonary hypertension",
      "label": "may predispose to"
    },
    {
      "source": "mouse model",
      "target": "Serotonin 5-HT(2B) receptor",
      "label": "incriminates"
    },
    {
      "source": "mouse model",
      "target": "cancer",
      "label": "is a model of"
    },
    {
      "source": "mouse model",
      "target": "parameters",
      "label": "revealed"
    },
    {
      "source": "mouse model",
      "target": "efficacy",
      "label": "demonstrated"
    },
    {
      "source": "mouse model",
      "target": "Cr deficiency",
      "label": "of"
    },
    {
      "source": "mouse model",
      "target": "in vivo siRNA delivery efficacy",
      "label": "used to evaluate"
    },
    {
      "source": "mouse model",
      "target": "acute liver failure",
      "label": "has"
    },
    {
      "source": "mouse model",
      "target": "allergic asthma",
      "label": "is a model of"
    },
    {
      "source": "intracellular calcium release",
      "target": "macaque CCR5",
      "label": "mediated_through"
    },
    {
      "source": "intracellular calcium release",
      "target": "MIP-1beta",
      "label": "induced_by"
    },
    {
      "source": "intracellular calcium release",
      "target": "human recombinant CCR5",
      "label": "mediated_through"
    },
    {
      "source": "second messenger",
      "target": "cellular function",
      "label": "controls"
    },
    {
      "source": "human 5-HT(2B) gene",
      "target": "patients",
      "label": "analyzed in"
    },
    {
      "source": "Carteolol",
      "target": "timolol",
      "label": "is compared with"
    },
    {
      "source": "Carteolol",
      "target": "theoretical advantage",
      "label": "has"
    },
    {
      "source": "Carteolol",
      "target": "partial beta-agonist activity",
      "label": "has"
    },
    {
      "source": "timolol",
      "target": "intraocular pressure (IOP)",
      "label": "is effective in lowering"
    },
    {
      "source": "timolol",
      "target": "agent",
      "label": "is an"
    },
    {
      "source": "timolol",
      "target": "beta-Blockers",
      "label": "is a type of"
    },
    {
      "source": "timolol",
      "target": "patients",
      "label": "is reserved for"
    },
    {
      "source": "timolol",
      "target": "nonselective",
      "label": "is"
    },
    {
      "source": "timolol",
      "target": "ophthalmic beta blocker",
      "label": "is an"
    },
    {
      "source": "most serious side effects",
      "target": "beta-Blockers",
      "label": "of"
    },
    {
      "source": "most serious side effects",
      "target": "precipitation",
      "label": "include"
    },
    {
      "source": "most serious side effects",
      "target": "exacerbation",
      "label": "include"
    },
    {
      "source": "beta-Blockers",
      "target": "antiglaucoma medications",
      "label": "can be used with"
    },
    {
      "source": "cardioselective",
      "target": "beta 1-receptors",
      "label": "block"
    },
    {
      "source": "combined action",
      "target": "case",
      "label": "is suspect in"
    },
    {
      "source": "combined action",
      "target": "epinephrine",
      "label": "with"
    },
    {
      "source": "combined action",
      "target": "adrenaline",
      "label": "with"
    },
    {
      "source": "case",
      "target": "nonselective beta-blockers",
      "label": "involves"
    },
    {
      "source": "theoretical advantage",
      "target": "diminished side effects",
      "label": "is in"
    },
    {
      "source": "carteolol",
      "target": "beta-Blockers",
      "label": "is a type of"
    },
    {
      "source": "carteolol",
      "target": "nonselective",
      "label": "is"
    },
    {
      "source": "precipitation",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "precipitation",
      "target": "bronchospasm",
      "label": "of"
    },
    {
      "source": "Topical beta-blockers",
      "target": "intraocular pressure (IOP)",
      "label": "reduce"
    },
    {
      "source": "Topical beta-blockers",
      "target": "blockade",
      "label": "act by"
    },
    {
      "source": "intraocular pressure (IOP)",
      "target": "prolonged use",
      "label": "reduction is maintained by"
    },
    {
      "source": "Metipranolol",
      "target": "partial beta-agonist activity",
      "label": "does not have"
    },
    {
      "source": "Metipranolol",
      "target": "effect",
      "label": "has"
    },
    {
      "source": "Ocular beta-blockers",
      "target": "glaucoma management",
      "label": "are used in"
    },
    {
      "source": "Ocular beta-blockers",
      "target": "Clinical pharmacological aspects",
      "label": "have"
    },
    {
      "source": "topical beta-blockers",
      "target": "glaucoma",
      "label": "are used in"
    },
    {
      "source": "metipranolol",
      "target": "beta-Blockers",
      "label": "is a type of"
    },
    {
      "source": "metipranolol",
      "target": "nonselective",
      "label": "is"
    },
    {
      "source": "types",
      "target": "nonselective",
      "label": "include"
    },
    {
      "source": "types",
      "target": "topical beta-blockers",
      "label": "of"
    },
    {
      "source": "types",
      "target": "cardioselective",
      "label": "include"
    },
    {
      "source": "nonselective",
      "target": "beta 1- and beta 2-adrenoceptors",
      "label": "block"
    },
    {
      "source": "diminished side effects",
      "target": "partial beta-agonist activity",
      "label": "are conferred by"
    },
    {
      "source": "beta-blocker",
      "target": "first choice",
      "label": "is"
    },
    {
      "source": "Local stinging",
      "target": "problem",
      "label": "can be a"
    },
    {
      "source": "problem",
      "target": "betaxolol",
      "label": "for patients using"
    },
    {
      "source": "levobunolol",
      "target": "nonselective",
      "label": "is"
    },
    {
      "source": "levobunolol",
      "target": "timolol",
      "label": "is similar to"
    },
    {
      "source": "levobunolol",
      "target": "patients",
      "label": "is reserved for"
    },
    {
      "source": "levobunolol",
      "target": "effect",
      "label": "has"
    },
    {
      "source": "levobunolol",
      "target": "beta-Blockers",
      "label": "is a type of"
    },
    {
      "source": "levobunolol",
      "target": "ophthalmic solutions",
      "label": "is marketed as"
    },
    {
      "source": "levobunolol",
      "target": "ophthalmic beta-blocking agents",
      "label": "is a type of"
    },
    {
      "source": "levobunolol",
      "target": "nonselective beta-adrenergic blocking agent",
      "label": "is a"
    },
    {
      "source": "levobunolol",
      "target": "local ocular adverse reactions",
      "label": "causes"
    },
    {
      "source": "levobunolol",
      "target": "intraocular pressure (IOP)",
      "label": "reduces"
    },
    {
      "source": "levobunolol",
      "target": "systemic beta blockade",
      "label": "causes"
    },
    {
      "source": "levobunolol",
      "target": "primary open-angle glaucoma (POAG)",
      "label": "controls intraocular pressure (IOP) for"
    },
    {
      "source": "levobunolol",
      "target": "ocular hypertension (OHT)",
      "label": "controls intraocular pressure (IOP) for"
    },
    {
      "source": "levobunolol",
      "target": "once-daily dosing",
      "label": "allows"
    },
    {
      "source": "levobunolol",
      "target": "beta-adrenergic blocking agents",
      "label": "is a type of"
    },
    {
      "source": "levobunolol",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "Betaxolol",
      "target": "adverse respiratory effects",
      "label": "is free of"
    },
    {
      "source": "Betaxolol",
      "target": "patients",
      "label": "is less effective in"
    },
    {
      "source": "Betaxolol",
      "target": "effect",
      "label": "has an"
    },
    {
      "source": "Betaxolol",
      "target": "intraocular pressure (IOP)",
      "label": "lowers"
    },
    {
      "source": "adverse respiratory effects",
      "target": "dose",
      "label": "may be related to"
    },
    {
      "source": "blockade",
      "target": "fall",
      "label": "causes"
    },
    {
      "source": "blockade",
      "target": "sympathetic nerve endings",
      "label": "affects"
    },
    {
      "source": "blockade",
      "target": "neurotrophic effects",
      "label": "of"
    },
    {
      "source": "blockade",
      "target": "tooth movement",
      "label": "inhibited"
    },
    {
      "source": "blockade",
      "target": "osteoclast increase",
      "label": "inhibited"
    },
    {
      "source": "blockade",
      "target": "sympathetic signaling",
      "label": "of"
    },
    {
      "source": "blockade",
      "target": "responses",
      "label": "of"
    },
    {
      "source": "blockade",
      "target": "acetylcholinesterase",
      "label": "of"
    },
    {
      "source": "blockade",
      "target": "muscarinic receptors",
      "label": "of"
    },
    {
      "source": "fall",
      "target": "aqueous humour production",
      "label": "in"
    },
    {
      "source": "sympathetic nerve endings",
      "target": "ciliary epithelium",
      "label": "are located in"
    },
    {
      "source": "risk",
      "target": "most serious side effects",
      "label": "of precipitating"
    },
    {
      "source": "risk",
      "target": "islet-cell antibodies titre",
      "label": "increases with"
    },
    {
      "source": "risk",
      "target": "subjects",
      "label": "increases in"
    },
    {
      "source": "risk",
      "target": "stomatitis",
      "label": "of"
    },
    {
      "source": "risk",
      "target": "hand-foot syndrome",
      "label": "of"
    },
    {
      "source": "risk",
      "target": "continuous 5-day infusions",
      "label": "during"
    },
    {
      "source": "risk",
      "target": "fluorouracil exposures",
      "label": "related to"
    },
    {
      "source": "risk",
      "target": "diarrhoea",
      "label": "of"
    },
    {
      "source": "risk",
      "target": "leukopenia",
      "label": "of"
    },
    {
      "source": "risk",
      "target": "outbreak",
      "label": "of"
    },
    {
      "source": "risk",
      "target": "severe hematologic toxicity",
      "label": "of"
    },
    {
      "source": "risk",
      "target": "sex",
      "label": "normalized to"
    },
    {
      "source": "risk",
      "target": "smoking habits",
      "label": "normalized to"
    },
    {
      "source": "risk",
      "target": "NSCLC",
      "label": "is for development of"
    },
    {
      "source": "risk",
      "target": "age",
      "label": "normalized to"
    },
    {
      "source": "caution",
      "target": "history",
      "label": "should be exercised in patients with"
    },
    {
      "source": "history",
      "target": "respiratory disease",
      "label": "of"
    },
    {
      "source": "exacerbation",
      "target": "chronic obstructive airways disease",
      "label": "of"
    },
    {
      "source": "exacerbation",
      "target": "nonselective agents",
      "label": "is caused by"
    },
    {
      "source": "Glc1P",
      "target": "catalysis",
      "label": "promotes"
    },
    {
      "source": "Glc1P",
      "target": "phosphate group",
      "label": "bends"
    },
    {
      "source": "minimal movement",
      "target": "Arg569",
      "label": "involves"
    },
    {
      "source": "minimal movement",
      "target": "protein",
      "label": "is of"
    },
    {
      "source": "Arg569",
      "target": "substrate phosphate group",
      "label": "tracks"
    },
    {
      "source": "Arg569",
      "target": "loop 280s",
      "label": "held away by"
    },
    {
      "source": "Arg569",
      "target": "catalytic site",
      "label": "held away from"
    },
    {
      "source": "relative positions",
      "target": "substrates",
      "label": "are of"
    },
    {
      "source": "relative positions",
      "target": "catalytic channel",
      "label": "are in"
    },
    {
      "source": "structures",
      "target": "frames",
      "label": "used as"
    },
    {
      "source": "structures",
      "target": "elongation of the oligosaccharide chain",
      "label": "show"
    },
    {
      "source": "structures",
      "target": "formation of phosphate",
      "label": "show"
    },
    {
      "source": "structures",
      "target": "diffusion",
      "label": "solved after"
    },
    {
      "source": "structures",
      "target": "2.2A",
      "label": "refined at"
    },
    {
      "source": "structures",
      "target": "1.8A",
      "label": "refined at"
    },
    {
      "source": "structures",
      "target": "NMR",
      "label": "determined by"
    },
    {
      "source": "structures",
      "target": "phospholamban (1-36)",
      "label": "are of"
    },
    {
      "source": "structures",
      "target": "active and inactive alanine-mutated cyclic peptides",
      "label": "are of"
    },
    {
      "source": "structures",
      "target": "R or S configuration",
      "label": "have"
    },
    {
      "source": "structures",
      "target": "two-dimensional (2D) NMR analysis",
      "label": "were determined by"
    },
    {
      "source": "structures",
      "target": "hydrolytic cleavage",
      "label": "were determined by"
    },
    {
      "source": "structures",
      "target": "new compounds",
      "label": "are of"
    },
    {
      "source": "frames",
      "target": "molecular movie",
      "label": "are part of"
    },
    {
      "source": "specific recognition",
      "target": "oligosaccharide",
      "label": "is of"
    },
    {
      "source": "oligosaccharide",
      "target": "catalytic site",
      "label": "bound to"
    },
    {
      "source": "2.0A crystal structure",
      "target": "MalP/Glc1P binary complex",
      "label": "is of"
    },
    {
      "source": "6-hydroxyl group",
      "target": "Glc1P substrate",
      "label": "is part of"
    },
    {
      "source": "Glc1P substrate",
      "target": "conformation",
      "label": "adopts"
    },
    {
      "source": "maltotetraose",
      "target": "G4",
      "label": "is also known as"
    },
    {
      "source": "conformation",
      "target": "inactive forms of mammalian GP",
      "label": "seen with"
    },
    {
      "source": "conformation",
      "target": "active forms of mammalian GP",
      "label": "seen with"
    },
    {
      "source": "conformation",
      "target": "dynamic active-site helix",
      "label": "of"
    },
    {
      "source": "residue Arg569",
      "target": "negative-charged Glc1P",
      "label": "stabilizes"
    },
    {
      "source": "allosteric transition",
      "target": "mammalian enzyme",
      "label": "is of"
    },
    {
      "source": "allosteric transition",
      "target": "activation",
      "label": "required for"
    },
    {
      "source": "phosphate group",
      "target": "PLP",
      "label": "contacts"
    },
    {
      "source": "phosphate group",
      "target": "5'-phosphate group",
      "label": "not in close contact with"
    },
    {
      "source": "molecular movie",
      "target": "minimal movement",
      "label": "shows"
    },
    {
      "source": "molecular movie",
      "target": "relative positions",
      "label": "reveals"
    },
    {
      "source": "enzymatic reaction",
      "target": "crystal damage",
      "label": "occurs without"
    },
    {
      "source": "enzymatic reaction",
      "target": "hydrolysis",
      "label": "is a type of"
    },
    {
      "source": "enzymatic reaction",
      "target": "capillary inlet methodology",
      "label": "occurs at"
    },
    {
      "source": "enzymatic reaction",
      "target": "capillary inlet",
      "label": "occurs at"
    },
    {
      "source": "maltopentaose",
      "target": "G5",
      "label": "is also known as"
    },
    {
      "source": "active MalP enzyme",
      "target": "residue Arg569",
      "label": "contains"
    },
    {
      "source": "alpha-1,4-glycosidic bond",
      "target": "maltodextrins",
      "label": "is found in"
    },
    {
      "source": "non-reducing glucosyl residues",
      "target": "linear oligosaccharides",
      "label": "are part of"
    },
    {
      "source": "bacterial enzyme",
      "target": "maltodextrin phosphorylase",
      "label": "is a type of"
    },
    {
      "source": "maltodextrin phosphorylase",
      "target": "MalP",
      "label": "is also known as"
    },
    {
      "source": "His377",
      "target": "hydrogen bond",
      "label": "forms"
    },
    {
      "source": "His377",
      "target": "conformational change",
      "label": "triggers"
    },
    {
      "source": "hydrogen bond",
      "target": "6-hydroxyl group",
      "label": "with"
    },
    {
      "source": "MalP",
      "target": "glucose-1-phosphate",
      "label": "produces"
    },
    {
      "source": "MalP",
      "target": "model system",
      "label": "used as"
    },
    {
      "source": "MalP",
      "target": "phosphorolysis",
      "label": "catalyses"
    },
    {
      "source": "MalP",
      "target": "linear oligosaccharides",
      "label": "has higher affinity for"
    },
    {
      "source": "MalP",
      "target": "GP",
      "label": "has higher affinity than"
    },
    {
      "source": "MalP",
      "target": "allosteric properties",
      "label": "exhibits no"
    },
    {
      "source": "MalP",
      "target": "non-reducing glucosyl residues",
      "label": "removes"
    },
    {
      "source": "glucose-1-phosphate",
      "target": "Glc1P",
      "label": "is also known as"
    },
    {
      "source": "muscle glycogen phosphorylase",
      "target": "GP",
      "label": "is also known as"
    },
    {
      "source": "synergism",
      "target": "MalP ternary complex",
      "label": "promotes"
    },
    {
      "source": "synergism",
      "target": "substrates",
      "label": "between"
    },
    {
      "source": "synergism",
      "target": "noncompetitive inhibitors",
      "label": "between"
    },
    {
      "source": "synergism",
      "target": "ATP-competitive inhibitors",
      "label": "between"
    },
    {
      "source": "phosphorolysis",
      "target": "alpha-1,4-glycosidic bond",
      "label": "acts on"
    },
    {
      "source": "model system",
      "target": "catalysis",
      "label": "used to study"
    },
    {
      "source": "mobile region",
      "target": "specific recognition",
      "label": "contributes to"
    },
    {
      "source": "mobile region",
      "target": "catalytic site",
      "label": "folds over"
    },
    {
      "source": "mobile region",
      "target": "synergism",
      "label": "contributes to"
    },
    {
      "source": "5'-phosphate group",
      "target": "essential pyridoxal phosphate",
      "label": "is part of"
    },
    {
      "source": "Enzymatic catalysis",
      "target": "crystals",
      "label": "occurs in"
    },
    {
      "source": "Enzymatic catalysis",
      "target": "Escherichia coli maltodextrin phosphorylase",
      "label": "is associated with"
    },
    {
      "source": "catalytic site",
      "target": "inhibitors",
      "label": "has affinity for"
    },
    {
      "source": "catalytic site",
      "target": "classes of inhibitors",
      "label": "has affinity for"
    },
    {
      "source": "catalytic site",
      "target": "cGMP",
      "label": "has affinity for"
    },
    {
      "source": "catalytic site",
      "target": "mouse ornithine decarboxylase",
      "label": "is part of"
    },
    {
      "source": "diffusion",
      "target": "MalP/Glc1P crystals",
      "label": "occurs into"
    },
    {
      "source": "conformational change",
      "target": "380s loop",
      "label": "is of"
    },
    {
      "source": "conformational change",
      "target": "extracellular domain",
      "label": "of"
    },
    {
      "source": "conformational change",
      "target": "alpha-lactalbumin",
      "label": "induced in"
    },
    {
      "source": "conformational change",
      "target": "protein",
      "label": "enables"
    },
    {
      "source": "380s loop",
      "target": "mobile region",
      "label": "is a"
    },
    {
      "source": "pyridoxal phosphate",
      "target": "PLP",
      "label": "is also known as"
    },
    {
      "source": "essential pyridoxal phosphate",
      "target": "PLP cofactor",
      "label": "is a"
    },
    {
      "source": "inactive form of GP",
      "target": "allosteric transition",
      "label": "requires"
    },
    {
      "source": "PLP cofactor",
      "target": "PLP",
      "label": "is also known as"
    },
    {
      "source": "oligosaccharide substrates",
      "target": "MalP/Glc1P crystals",
      "label": "diffuse into"
    },
    {
      "source": "MalP structures",
      "target": "His377",
      "label": "reveal"
    },
    {
      "source": "loperamide",
      "target": "human hypothalamo-pituitary-adrenal axis",
      "label": "affects"
    },
    {
      "source": "loperamide",
      "target": "basal ACTH levels",
      "label": "reduces"
    },
    {
      "source": "loperamide",
      "target": "ACTH peak",
      "label": "did not affect"
    },
    {
      "source": "loperamide",
      "target": "ACTH levels",
      "label": "suppresses"
    },
    {
      "source": "loperamide",
      "target": "cortisol levels",
      "label": "reduces"
    },
    {
      "source": "loperamide",
      "target": "opiate agonist",
      "label": "is a"
    },
    {
      "source": "loperamide",
      "target": "stress-induced elevation of cortisol levels",
      "label": "has no effect on"
    },
    {
      "source": "loperamide",
      "target": "suprapituitary site",
      "label": "might act at"
    },
    {
      "source": "loperamide",
      "target": "pituitary site",
      "label": "might act at"
    },
    {
      "source": "loperamide",
      "target": "area under the curve of ACTH",
      "label": "reduced"
    },
    {
      "source": "loperamide",
      "target": "pituitary hormone secretion",
      "label": "affects"
    },
    {
      "source": "loperamide",
      "target": "CRH-induced ACTH secretion",
      "label": "does not reduce"
    },
    {
      "source": "loperamide",
      "target": "insulin-hypoglycemia-induced ACTH levels",
      "label": "has no effect on"
    },
    {
      "source": "loperamide",
      "target": "basal ACTH secretion",
      "label": "did not reduce"
    },
    {
      "source": "loperamide",
      "target": "basal ACTH plasma levels",
      "label": "suppressed"
    },
    {
      "source": "loperamide",
      "target": "CRH-stimulated levels",
      "label": "did not influence"
    },
    {
      "source": "combined pituitary stimulation test",
      "target": "GnRH",
      "label": "involves"
    },
    {
      "source": "combined pituitary stimulation test",
      "target": "TRH",
      "label": "involves"
    },
    {
      "source": "combined pituitary stimulation test",
      "target": "human CRH",
      "label": "involves"
    },
    {
      "source": "combined pituitary stimulation test",
      "target": "GH-releasing hormone",
      "label": "involves"
    },
    {
      "source": "GnRH",
      "target": "c-Src",
      "label": "induces activation of"
    },
    {
      "source": "GnRH",
      "target": "Cultured rat ventral prostate cells",
      "label": "stimulates androgen receptor mobilization in"
    },
    {
      "source": "GnRH",
      "target": "Hic-5",
      "label": "induces association and nuclear translocation of"
    },
    {
      "source": "GnRH",
      "target": "Androgen receptor",
      "label": "stimulates mobilization of"
    },
    {
      "source": "GnRH",
      "target": "Androgen",
      "label": "antagonizes effects of"
    },
    {
      "source": "GnRH",
      "target": "Rat ventral prostate organ cultures",
      "label": "affects"
    },
    {
      "source": "GnRH",
      "target": "BPH-1 cells",
      "label": "stimulates androgen receptor mobilization in"
    },
    {
      "source": "GnRH",
      "target": "LNCaP cells",
      "label": "stimulates androgen receptor mobilization in"
    },
    {
      "source": "GnRH",
      "target": "Pyk2",
      "label": "induces activation of"
    },
    {
      "source": "GnRH",
      "target": "Testosterone",
      "label": "functionally antagonizes actions of"
    },
    {
      "source": "GnRH",
      "target": "Human prostate PC3 cells",
      "label": "stimulates androgen receptor mobilization in"
    },
    {
      "source": "ACTH levels",
      "target": "nadir",
      "label": "fell to"
    },
    {
      "source": "ACTH levels",
      "target": "loperamide administration",
      "label": "fell after"
    },
    {
      "source": "ACTH levels",
      "target": "dose-related manner",
      "label": "increase_is"
    },
    {
      "source": "opiate agonist",
      "target": "mu-receptors",
      "label": "has specificity for"
    },
    {
      "source": "alpha-receptor subunits (alpha-PDGFR)",
      "target": "differential regulation",
      "label": "is involved in"
    },
    {
      "source": "differential regulation",
      "target": "cell cycle",
      "label": "is of"
    },
    {
      "source": "differential regulation",
      "target": "transformation",
      "label": "is of"
    },
    {
      "source": "PDGF B-chain (c-sis) homodimer (PDGF BB)",
      "target": "beta-receptor subunits (beta-PDGFR)",
      "label": "activates"
    },
    {
      "source": "PDGF B-chain (c-sis) homodimer (PDGF BB)",
      "target": "alpha-receptor subunits (alpha-PDGFR)",
      "label": "activates"
    },
    {
      "source": "PDGF B-chain (c-sis) homodimer (PDGF BB)",
      "target": "progression factors",
      "label": "can serve as"
    },
    {
      "source": "PDGF B-chain (c-sis) homodimer (PDGF BB)",
      "target": "competent factor",
      "label": "can serve as"
    },
    {
      "source": "PDGF B-chain (c-sis) homodimer (PDGF BB)",
      "target": "phenotypic transformation",
      "label": "induces"
    },
    {
      "source": "beta-receptor subunits (beta-PDGFR)",
      "target": "differential regulation",
      "label": "is involved in"
    },
    {
      "source": "beta-PDGFR",
      "target": "mitogenic signals",
      "label": "induces"
    },
    {
      "source": "beta-PDGFR",
      "target": "growth-promoting signal",
      "label": "induces"
    },
    {
      "source": "PDGF/JNK-1",
      "target": "p21WAF1/CIP1 promoter activity",
      "label": "induces"
    },
    {
      "source": "p21WAF1/CIP1 promoter activity",
      "target": "p53",
      "label": "is reduced in absence of"
    },
    {
      "source": "PDGF signaling",
      "target": "strength",
      "label": "has feature"
    },
    {
      "source": "PDGF signaling",
      "target": "specificity",
      "label": "has feature"
    },
    {
      "source": "PDGF BB activation",
      "target": "cell cycle transition",
      "label": "results in"
    },
    {
      "source": "PDGF BB activation",
      "target": "alpha-PDGFR",
      "label": "involves"
    },
    {
      "source": "PDGF BB activation",
      "target": "p21WAF1/CIP1",
      "label": "up-regulates expression of"
    },
    {
      "source": "PDGF BB activation",
      "target": "beta-PDGFR",
      "label": "involves"
    },
    {
      "source": "cell cycle transition",
      "target": "S phase",
      "label": "is to"
    },
    {
      "source": "cell cycle transition",
      "target": "G1",
      "label": "is from"
    },
    {
      "source": "progression factors",
      "target": "serum",
      "label": "are found in"
    },
    {
      "source": "progression factors",
      "target": "cell cycle",
      "label": "enable transit of"
    },
    {
      "source": "PDGF AA",
      "target": "p21WAF1/CIP1",
      "label": "up-regulates expression of"
    },
    {
      "source": "PDGF AA",
      "target": "competent factor",
      "label": "functions as"
    },
    {
      "source": "PDGF AA",
      "target": "alpha-PDGFR",
      "label": "activates"
    },
    {
      "source": "PDGF AA",
      "target": "transformation",
      "label": "fails to induce"
    },
    {
      "source": "p21WAF1/CIP1",
      "target": "inhibitor of cell cycle-dependent kinases",
      "label": "is an"
    },
    {
      "source": "p21WAF1/CIP1",
      "target": "downstream mediator",
      "label": "is a"
    },
    {
      "source": "alpha-PDGFR-activated JNK-1",
      "target": "signaling component",
      "label": "is a"
    },
    {
      "source": "alpha-PDGFR-activated JNK-1",
      "target": "PDGF induction",
      "label": "is critical for"
    },
    {
      "source": "serum",
      "target": "apoptosis",
      "label": "modulates"
    },
    {
      "source": "alpha-PDGFR",
      "target": "inhibitory signals",
      "label": "mediates activation of"
    },
    {
      "source": "alpha-PDGFR",
      "target": "strength",
      "label": "modulates"
    },
    {
      "source": "alpha-PDGFR",
      "target": "growth stimulatory signals",
      "label": "mediates activation of"
    },
    {
      "source": "alpha-PDGFR",
      "target": "c-Jun NH2-terminal kinase-1",
      "label": "activates"
    },
    {
      "source": "alpha-PDGFR",
      "target": "transformation",
      "label": "antagonizes"
    },
    {
      "source": "alpha-PDGFR",
      "target": "specificity",
      "label": "modulates"
    },
    {
      "source": "alpha-PDGFR",
      "target": "mitogenic signals",
      "label": "induces"
    },
    {
      "source": "alpha-PDGFR",
      "target": "stress-activated protein kinase-1",
      "label": "activates"
    },
    {
      "source": "downstream mediator",
      "target": "tumor suppressor gene product p53",
      "label": "is of"
    },
    {
      "source": "competent factor",
      "target": "cell cycle entry",
      "label": "stimulates"
    },
    {
      "source": "competent factor",
      "target": "progression factors",
      "label": "requires"
    },
    {
      "source": "cell cycle",
      "target": "G1/S checkpoint",
      "label": "transits beyond"
    },
    {
      "source": "phenotypic transformation",
      "target": "NIH 3T3 cells",
      "label": "occurs in"
    },
    {
      "source": "c-Jun NH2-terminal kinase-1",
      "target": "PDGF-induced p21WAF1/CIP1 promoter activity",
      "label": "is critical for"
    },
    {
      "source": "Platelet-derived growth factor (PDGF)",
      "target": "mesenchymal cells",
      "label": "is a mitogen for"
    },
    {
      "source": "specificity",
      "target": "Abeta plaques",
      "label": "to"
    },
    {
      "source": "p53",
      "target": "cellular processes",
      "label": "regulates"
    },
    {
      "source": "p53",
      "target": "Autophagy",
      "label": "involved in"
    },
    {
      "source": "p53",
      "target": "autophagic process",
      "label": "inhibits"
    },
    {
      "source": "p53",
      "target": "transcription",
      "label": "enhances"
    },
    {
      "source": "p53",
      "target": "cell fate regulation",
      "label": "involved in"
    },
    {
      "source": "p53",
      "target": "tumor suppressor protein",
      "label": "is a type of"
    },
    {
      "source": "viral counterpart v-sis",
      "target": "competent factor",
      "label": "can serve as"
    },
    {
      "source": "viral counterpart v-sis",
      "target": "progression factors",
      "label": "can serve as"
    },
    {
      "source": "PDGF induction",
      "target": "p21WAF1/CIP1 promoter activity",
      "label": "is of"
    },
    {
      "source": "molecular basis",
      "target": "differential regulation",
      "label": "is for"
    },
    {
      "source": "molecular basis",
      "target": "apoptosis",
      "label": "of"
    },
    {
      "source": "molecular basis",
      "target": "GLP-1 receptor agonistic activity",
      "label": "is for"
    },
    {
      "source": "molecular basis",
      "target": "protein regulation",
      "label": "for"
    },
    {
      "source": "molecular basis",
      "target": "high-resolution structural information",
      "label": "is rationalized using"
    },
    {
      "source": "Platelet-derived growth factor (PDGF) receptor-alpha",
      "target": "c-Jun NH2-terminal kinase-1",
      "label": "activates"
    },
    {
      "source": "beta-PDGFR activation",
      "target": "p21WAF1/CIP1 expression",
      "label": "fails to induce"
    },
    {
      "source": "PDGF-induced p21WAF1/CIP1 promoter activity",
      "target": "p53",
      "label": "is independent of"
    },
    {
      "source": "tranylcypromine",
      "target": "CYP2C19",
      "label": "inhibits"
    },
    {
      "source": "tranylcypromine",
      "target": "CYP2D6",
      "label": "is a competitive inhibitor of"
    },
    {
      "source": "tranylcypromine",
      "target": "drugs",
      "label": "is coadministered with"
    },
    {
      "source": "tranylcypromine",
      "target": "CYP2C9",
      "label": "is a noncompetitive inhibitor of"
    },
    {
      "source": "tranylcypromine",
      "target": "cytochrome P450 enzymes",
      "label": "inhibits"
    },
    {
      "source": "tranylcypromine",
      "target": "CYP2C19 substrates",
      "label": "interacts with"
    },
    {
      "source": "tranylcypromine",
      "target": "Inhibitory effects",
      "label": "causes"
    },
    {
      "source": "tranylcypromine",
      "target": "CYP enzymes",
      "label": "inhibits"
    },
    {
      "source": "tranylcypromine",
      "target": "monoamine oxidase inhibitor",
      "label": "is a"
    },
    {
      "source": "tranylcypromine",
      "target": "monoamine oxidase (MAO)",
      "label": "is an inhibitor of"
    },
    {
      "source": "tranylcypromine",
      "target": "MAO inhibitor",
      "label": "is an"
    },
    {
      "source": "CYP2C9",
      "target": "pharmacokinetic parameters",
      "label": "activities reflected by"
    },
    {
      "source": "Inhibitory effects",
      "target": "CYP2D6",
      "label": "affect"
    },
    {
      "source": "Inhibitory effects",
      "target": "therapeutic doses",
      "label": "are not clinically significant at"
    },
    {
      "source": "Inhibitory effects",
      "target": "CYP2C9",
      "label": "affect"
    },
    {
      "source": "Inhibitory effects",
      "target": "CYP2C19",
      "label": "affect"
    },
    {
      "source": "Inhibitory effects",
      "target": "cytochrome P450 enzymes",
      "label": "affect"
    },
    {
      "source": "substrate concentrations",
      "target": "tranylcypromine",
      "label": "coincubated with"
    },
    {
      "source": "substrate concentrations",
      "target": "CYP enzymes",
      "label": "coincubated in presence of"
    },
    {
      "source": "product concentrations",
      "target": "HPLC",
      "label": "quantified by"
    },
    {
      "source": "HPLC",
      "target": "UV detection",
      "label": "uses"
    },
    {
      "source": "CldATP incorporation",
      "target": "promoter TATA element",
      "label": "occurs into"
    },
    {
      "source": "CldATP incorporation",
      "target": "gene regulatory sequences",
      "label": "occurs into"
    },
    {
      "source": "CldATP incorporation",
      "target": "novel strategy",
      "label": "may provide"
    },
    {
      "source": "Double-stranded DNA templates",
      "target": "HeLa extract",
      "label": "were incubated with"
    },
    {
      "source": "Double-stranded DNA templates",
      "target": "coding sequences",
      "label": "contain"
    },
    {
      "source": "Double-stranded DNA templates",
      "target": "site-specific CldAMP residues",
      "label": "were synthesized with"
    },
    {
      "source": "Double-stranded DNA templates",
      "target": "adenovirus major late promoter",
      "label": "contain"
    },
    {
      "source": "Double-stranded DNA templates",
      "target": "control",
      "label": "were synthesized as"
    },
    {
      "source": "2-chloro-2'-deoxyadenosine",
      "target": "chronic lymphocytic leukemia",
      "label": "is effective in treating"
    },
    {
      "source": "2-chloro-2'-deoxyadenosine",
      "target": "CldAdo",
      "label": "is also known as"
    },
    {
      "source": "2-chloro-2'-deoxyadenosine",
      "target": "nucleoside analog",
      "label": "is a type of"
    },
    {
      "source": "2-chloro-2'-deoxyadenosine",
      "target": "hairy cell leukemia",
      "label": "is effective in treating"
    },
    {
      "source": "2-chloro-2'-deoxyadenosine",
      "target": "transcriptional antagonist",
      "label": "is an"
    },
    {
      "source": "2-chloro-2'-deoxyadenosine",
      "target": "antileukemia drug",
      "label": "is a type of"
    },
    {
      "source": "in vitro pol II transcription",
      "target": "control substrates",
      "label": "was compared with"
    },
    {
      "source": "transcription",
      "target": "CldAMP-substituted TATA sequences",
      "label": "occurred on"
    },
    {
      "source": "transcription",
      "target": "plateau",
      "label": "reached a"
    },
    {
      "source": "transcription",
      "target": "PADI2",
      "label": "of"
    },
    {
      "source": "transcription",
      "target": "pro-autophagic genes",
      "label": "of"
    },
    {
      "source": "plateau",
      "target": "20 min",
      "label": "was reached after"
    },
    {
      "source": "2-chlorodeoxyadenosine triphosphate",
      "target": "CldATP",
      "label": "is also known as"
    },
    {
      "source": "synthesis",
      "target": "radiolabeled 44-base transcripts",
      "label": "produces"
    },
    {
      "source": "synthesis",
      "target": "DHA",
      "label": "of"
    },
    {
      "source": "synthesis",
      "target": "core-shell biohybrid",
      "label": "of"
    },
    {
      "source": "synthesis",
      "target": "probe",
      "label": "of"
    },
    {
      "source": "synthesis",
      "target": "cAMP",
      "label": "of"
    },
    {
      "source": "TATA box consensus sequences",
      "target": "2-chlorodeoxyadenosine monophosphate",
      "label": "can be substituted with"
    },
    {
      "source": "TATA box consensus sequences",
      "target": "CldAMP",
      "label": "can be substituted with"
    },
    {
      "source": "binding interactions",
      "target": "human TATA box-binding protein",
      "label": "involve"
    },
    {
      "source": "binding interactions",
      "target": "TBP",
      "label": "involve"
    },
    {
      "source": "binding interactions",
      "target": "CldAMP-substituted TATA sequences",
      "label": "were disrupted on"
    },
    {
      "source": "human TATA box-binding protein",
      "target": "TBP",
      "label": "is also known as"
    },
    {
      "source": "CldAMP substitution",
      "target": "TATA box",
      "label": "occurs within"
    },
    {
      "source": "CldAMP substitution",
      "target": "in vitro pol II transcription",
      "label": "decreased"
    },
    {
      "source": "CldAMP substitution",
      "target": "dAMP",
      "label": "is for"
    },
    {
      "source": "CldAdo",
      "target": "cladribine",
      "label": "is also known as"
    },
    {
      "source": "CldAdo",
      "target": "cellular DNA",
      "label": "is incorporated into"
    },
    {
      "source": "CldAdo",
      "target": "chain terminator",
      "label": "is not a"
    },
    {
      "source": "CldAdo",
      "target": "nucleoside analog",
      "label": "is a type of"
    },
    {
      "source": "CldAdo",
      "target": "hairy cell leukemia",
      "label": "is effective in treating"
    },
    {
      "source": "CldAdo",
      "target": "chronic lymphocytic leukemia",
      "label": "is effective in treating"
    },
    {
      "source": "cladribine",
      "target": "nucleoside analog",
      "label": "is a type of"
    },
    {
      "source": "cladribine",
      "target": "hairy cell leukemia",
      "label": "is effective in treating"
    },
    {
      "source": "cladribine",
      "target": "chronic lymphocytic leukemia",
      "label": "is effective in treating"
    },
    {
      "source": "nucleoside analog",
      "target": "transcriptional antagonist",
      "label": "acts as a"
    },
    {
      "source": "CldAMP-substituted promoter sequences",
      "target": "dissociation",
      "label": "prevented"
    },
    {
      "source": "CldAMP-substituted promoter sequences",
      "target": "TBP",
      "label": "sequestered"
    },
    {
      "source": "CldAMP-substituted promoter sequences",
      "target": "binding",
      "label": "prevented"
    },
    {
      "source": "dissociation",
      "target": "DNA",
      "label": "is from"
    },
    {
      "source": "novel strategy",
      "target": "specific protein/DNA interactions",
      "label": "is to modulate"
    },
    {
      "source": "novel strategy",
      "target": "patients",
      "label": "for"
    },
    {
      "source": "novel strategy",
      "target": "CVD risk",
      "label": "reduces"
    },
    {
      "source": "novel strategy",
      "target": "adjuvant therapy",
      "label": "for"
    },
    {
      "source": "novel strategy",
      "target": "breast cancer patients",
      "label": "for"
    },
    {
      "source": "in vitro gel-shift assays",
      "target": "binding interactions",
      "label": "demonstrated"
    },
    {
      "source": "transcript production",
      "target": "control substrates",
      "label": "increased on"
    },
    {
      "source": "Time-course studies",
      "target": "transcript production",
      "label": "showed"
    },
    {
      "source": "transcriptional processes",
      "target": "CldATP incorporation",
      "label": "are affected by"
    },
    {
      "source": "human RNA polymerase II",
      "target": "pol II",
      "label": "is also known as"
    },
    {
      "source": "SLC36A2",
      "target": "chromosomal location",
      "label": "is a candidate gene based on"
    },
    {
      "source": "SLC36A2",
      "target": "muscle",
      "label": "is most abundant in"
    },
    {
      "source": "SLC36A2",
      "target": "kidney",
      "label": "is most abundant in"
    },
    {
      "source": "SLC36A2",
      "target": "candidate locus",
      "label": "is excluded as"
    },
    {
      "source": "SLC36A2",
      "target": "candidate gene",
      "label": "is a"
    },
    {
      "source": "SLC36A2",
      "target": "glycine transporter tramdorinl/PAT2",
      "label": "encodes"
    },
    {
      "source": "SLC36A2",
      "target": "bone",
      "label": "is a candidate gene based on its expression in"
    },
    {
      "source": "human SLC36A1 gene",
      "target": "multiple alternative mRNAs",
      "label": "generates"
    },
    {
      "source": "human SLC36A1 gene",
      "target": "lysosomal amino acid transporter LYAAT1/PAT1",
      "label": "encodes"
    },
    {
      "source": "multiple alternative mRNAs",
      "target": "truncated proteins",
      "label": "encode"
    },
    {
      "source": "candidate locus",
      "target": "peripheral neuropathy",
      "label": "for"
    },
    {
      "source": "peripheral neuropathy",
      "target": "5q31-33",
      "label": "has been mapped to"
    },
    {
      "source": "Mouse Slc36a2",
      "target": "bone",
      "label": "is expressed in"
    },
    {
      "source": "Mouse Slc36a2",
      "target": "fat tissue",
      "label": "is expressed in"
    },
    {
      "source": "SLC36 cluster of amino acid transporter genes",
      "target": "mice",
      "label": "are clustered in"
    },
    {
      "source": "SLC36 cluster of amino acid transporter genes",
      "target": "humans",
      "label": "are clustered in"
    },
    {
      "source": "SLC36 cluster of amino acid transporter genes",
      "target": "5q32",
      "label": "are clustered on"
    },
    {
      "source": "SLC36 cluster of amino acid transporter genes",
      "target": "Chromosome (Chr) 11",
      "label": "are clustered on"
    },
    {
      "source": "SLC36 cluster of amino acid transporter genes",
      "target": "amino acid transport proteins",
      "label": "encode"
    },
    {
      "source": "SLC36A3",
      "target": "testis",
      "label": "is restricted to"
    },
    {
      "source": "Polymorphisms",
      "target": "SLC36A2",
      "label": "exclude"
    },
    {
      "source": "SLC36A1",
      "target": "numerous tissues",
      "label": "is expressed in"
    },
    {
      "source": "kidney",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "candidate gene",
      "target": "5q-myelodysplastic syndrome",
      "label": "for"
    },
    {
      "source": "Studies",
      "target": "monkeys",
      "label": "conducted in"
    },
    {
      "source": "Studies",
      "target": "rats",
      "label": "conducted in"
    },
    {
      "source": "Studies",
      "target": "mice",
      "label": "conducted in"
    },
    {
      "source": "Studies",
      "target": "continent",
      "label": "done in"
    },
    {
      "source": "Studies",
      "target": "Control",
      "label": "are necessary for"
    },
    {
      "source": "Studies",
      "target": "osteoporosis rodent models",
      "label": "CONDUCTED_IN"
    },
    {
      "source": "compounds of this class",
      "target": "obesity",
      "label": "treat"
    },
    {
      "source": "compounds of this class",
      "target": "lipid disorders",
      "label": "treat"
    },
    {
      "source": "obesity",
      "target": "plasma total ghrelin",
      "label": "associated with low levels of"
    },
    {
      "source": "obesity",
      "target": "Tub",
      "label": "modulates"
    },
    {
      "source": "heart",
      "target": "Carboxylase activities",
      "label": "spared from reduction of"
    },
    {
      "source": "atorvastatin",
      "target": "compound",
      "label": "is a"
    },
    {
      "source": "atorvastatin",
      "target": "HMG-CoA reductase",
      "label": "blocks"
    },
    {
      "source": "atorvastatin",
      "target": "apoA-I",
      "label": "induced"
    },
    {
      "source": "atorvastatin",
      "target": "apoA-I expression",
      "label": "induced"
    },
    {
      "source": "atorvastatin",
      "target": "administration",
      "label": "was concomitantly"
    },
    {
      "source": "atorvastatin",
      "target": "single doses",
      "label": "administered as"
    },
    {
      "source": "compound",
      "target": "animal models",
      "label": "is active in"
    },
    {
      "source": "compound",
      "target": "wall",
      "label": "defines"
    },
    {
      "source": "compound",
      "target": "Magnetic resonance imaging (MRI)",
      "label": "will facilitate"
    },
    {
      "source": "compound",
      "target": "dermatologic disorders",
      "label": "treats"
    },
    {
      "source": "GC-1",
      "target": "beta-isoform of the thyroid hormone receptor",
      "label": "binds to"
    },
    {
      "source": "GC-1",
      "target": "cholesterol",
      "label": "lowers"
    },
    {
      "source": "GC-1",
      "target": "lipoprotein (a)",
      "label": "decreases"
    },
    {
      "source": "GC-1",
      "target": "triglyceride",
      "label": "decreases"
    },
    {
      "source": "GC-1",
      "target": "atorvastatin",
      "label": "has more efficacy than"
    },
    {
      "source": "GC-1",
      "target": "uptake",
      "label": "has"
    },
    {
      "source": "GC-1",
      "target": "compound",
      "label": "is a"
    },
    {
      "source": "GC-1",
      "target": "loss of fat",
      "label": "induces"
    },
    {
      "source": "GC-1",
      "target": "plasma levels",
      "label": "decreases"
    },
    {
      "source": "GC-1",
      "target": "Selective activation of thyroid hormone signaling pathways",
      "label": "causes"
    },
    {
      "source": "GC-1",
      "target": "body weight",
      "label": "controls"
    },
    {
      "source": "selective thyroid hormone receptor modulator",
      "target": "GC-1",
      "label": "is"
    },
    {
      "source": "plasma levels",
      "target": "lipoprotein (a)",
      "label": "of"
    },
    {
      "source": "plasma levels",
      "target": "triglyceride",
      "label": "of"
    },
    {
      "source": "current report",
      "target": "development",
      "label": "describes"
    },
    {
      "source": "ATR",
      "target": "Arabidopsis thaliana",
      "label": "acts in"
    },
    {
      "source": "ATR",
      "target": "essential gene",
      "label": "is an"
    },
    {
      "source": "ATR",
      "target": "double-strand breaks",
      "label": "plays a secondary role in response to"
    },
    {
      "source": "ATR",
      "target": "cell-cycle regulation",
      "label": "plays a central role in"
    },
    {
      "source": "ATR",
      "target": "DNA damage signals",
      "label": "transmits"
    },
    {
      "source": "ATR",
      "target": "G2-phase cell-cycle checkpoint",
      "label": "regulates"
    },
    {
      "source": "ATR",
      "target": "animals",
      "label": "is found in"
    },
    {
      "source": "downstream effectors",
      "target": "cell-cycle progression",
      "label": "affect"
    },
    {
      "source": "downstream effectors",
      "target": "Jak-2",
      "label": "of"
    },
    {
      "source": "Arabidopsis",
      "target": "Arabidopsis thaliana",
      "label": "is"
    },
    {
      "source": "atr mutants",
      "target": "UV-B light",
      "label": "are hypersensitive to"
    },
    {
      "source": "atr mutants",
      "target": "aphidicolin",
      "label": "are hypersensitive to"
    },
    {
      "source": "atr mutants",
      "target": "mildly sensitive",
      "label": "are"
    },
    {
      "source": "atr mutants",
      "target": "hypersensitive",
      "label": "are"
    },
    {
      "source": "atr mutants",
      "target": "gamma-radiation",
      "label": "are mildly sensitive to"
    },
    {
      "source": "atr mutants",
      "target": "HU",
      "label": "are hypersensitive to"
    },
    {
      "source": "atr mutants",
      "target": "G2 arrest",
      "label": "show defective"
    },
    {
      "source": "atr mutants",
      "target": "hydroxyurea",
      "label": "are hypersensitive to"
    },
    {
      "source": "atr-/- mutants",
      "target": "fertile",
      "label": "are"
    },
    {
      "source": "atr-/- mutants",
      "target": "viable",
      "label": "are"
    },
    {
      "source": "atr-/- mutants",
      "target": "phenotypically wild-type",
      "label": "are"
    },
    {
      "source": "atr-/- mutants",
      "target": "damage-induced cell-cycle checkpoints",
      "label": "exhibit alteration of"
    },
    {
      "source": "atr-/- mutants",
      "target": "altered expression",
      "label": "exhibit"
    },
    {
      "source": "G2 arrest",
      "target": "gamma-irradiation",
      "label": "occurs in response to"
    },
    {
      "source": "G2 arrest",
      "target": "atr mutants",
      "label": "is defective in"
    },
    {
      "source": "G2 arrest",
      "target": "atr plants",
      "label": "occurs in"
    },
    {
      "source": "G2 arrest",
      "target": "wild-type plants",
      "label": "occurs in"
    },
    {
      "source": "G2 arrest",
      "target": "compaction of nuclei",
      "label": "results in"
    },
    {
      "source": "G2 arrest",
      "target": "cell death",
      "label": "results in"
    },
    {
      "source": "G2 arrest",
      "target": "aphidicolin",
      "label": "occurs in response to"
    },
    {
      "source": "HU",
      "target": "novel checkpoint",
      "label": "invokes"
    },
    {
      "source": "HU",
      "target": "plants",
      "label": "acts in"
    },
    {
      "source": "HU",
      "target": "HbF augmentation treatment",
      "label": "is used as"
    },
    {
      "source": "novel checkpoint",
      "target": "low levels of deoxynucleotide triphosphates",
      "label": "is responsive to"
    },
    {
      "source": "DNA damage signals",
      "target": "downstream effectors",
      "label": "are transmitted to"
    },
    {
      "source": "plant cells",
      "target": "DNA replication",
      "label": "cope with problems related to"
    },
    {
      "source": "HU-treated wild-type plants",
      "target": "cell death",
      "label": "do not show signs of"
    },
    {
      "source": "HU-treated wild-type plants",
      "target": "G1 arrest",
      "label": "arrest in"
    },
    {
      "source": "HU-treated atr plants",
      "target": "cell death",
      "label": "do not show signs of"
    },
    {
      "source": "HU-treated atr plants",
      "target": "G1 arrest",
      "label": "arrest in"
    },
    {
      "source": "altered expression",
      "target": "AtRNR1",
      "label": "is of"
    },
    {
      "source": "AtRNR1",
      "target": "ribonucleotide reductase large subunit",
      "label": "is a"
    },
    {
      "source": "gamma-radiation",
      "target": "radiation-induced endothelial cellular damage",
      "label": "induces"
    },
    {
      "source": "gamma-radiation",
      "target": "radiation-induced injury",
      "label": "induces"
    },
    {
      "source": "gamma-radiation",
      "target": "oxidative injury",
      "label": "induces"
    },
    {
      "source": "gamma-radiation",
      "target": "radiation-induced oxidative injury",
      "label": "induces"
    },
    {
      "source": "gamma-radiation",
      "target": "radiation-induced damage",
      "label": "induces"
    },
    {
      "source": "gamma-radiation",
      "target": "radiation-induced lung injury",
      "label": "induces"
    },
    {
      "source": "Ataxia telangiectasia-mutated and Rad3-related",
      "target": "ATR",
      "label": "is"
    },
    {
      "source": "cell-cycle checkpoints",
      "target": "plant cells",
      "label": "are important for"
    },
    {
      "source": "beta(1)- and beta(2)-adrenoceptors",
      "target": "catecholamine-induced myocardial remodeling",
      "label": "involved in"
    },
    {
      "source": "beta(1)- and beta(2)-adrenoceptors",
      "target": "interstitial fibrosis",
      "label": "involved in"
    },
    {
      "source": "bisoprolol groups",
      "target": "control isoprenaline-treated group",
      "label": "compared with"
    },
    {
      "source": "bisoprolol groups",
      "target": "isoprenaline-induced left ventricular fibrosis",
      "label": "reduced"
    },
    {
      "source": "Blockade of beta 1-adrenoceptors",
      "target": "isoprenaline-induced cardiac fibrosis",
      "label": "reduces"
    },
    {
      "source": "bisoprolol",
      "target": "selective beta(1)-adrenoceptor antagonist",
      "label": "is a"
    },
    {
      "source": "bisoprolol",
      "target": "beta(1)-adrenoceptors",
      "label": "antagonizes"
    },
    {
      "source": "bisoprolol",
      "target": "dobutamine-induced heart rate and contractility increases",
      "label": "reduced"
    },
    {
      "source": "bisoprolol",
      "target": "Arg389-beta1AR subjects",
      "label": "suppressed dobutamine-induced PRA increase in"
    },
    {
      "source": "bisoprolol",
      "target": "Gly389beta1AR subjects",
      "label": "suppressed dobutamine-induced PRA increase in"
    },
    {
      "source": "bisoprolol",
      "target": "dobutamine-induced PRA increase",
      "label": "suppressed"
    },
    {
      "source": "selective beta(2)-adrenoceptor agonist",
      "target": "beta(2)-adrenoceptor desensitization",
      "label": "induces"
    },
    {
      "source": "down-regulation of left ventricular beta(2)-adrenoceptors",
      "target": "control",
      "label": "compared to"
    },
    {
      "source": "salbutamol",
      "target": "beta(2)-adrenoceptor desensitization",
      "label": "induces"
    },
    {
      "source": "salbutamol",
      "target": "beta(2)-adrenoceptors",
      "label": "agonizes"
    },
    {
      "source": "salbutamol",
      "target": "selective beta(2)-adrenoceptor agonist",
      "label": "is a"
    },
    {
      "source": "isoprenaline-induced left ventricular fibrosis",
      "target": "apical region",
      "label": "reduced in"
    },
    {
      "source": "beta-adrenoceptors",
      "target": "cardiac remodeling process",
      "label": "involved in"
    },
    {
      "source": "beta(1)-adrenoceptor blockade",
      "target": "isoprenaline-induced cardiac fibrosis",
      "label": "provided protection against"
    },
    {
      "source": "salbutamol groups",
      "target": "control isoprenaline-treated group",
      "label": "compared with"
    },
    {
      "source": "salbutamol groups",
      "target": "isoprenaline-induced left ventricular fibrosis",
      "label": "reduced"
    },
    {
      "source": "selective beta(1)-adrenoceptor antagonist",
      "target": "beta(1)-adrenoceptors",
      "label": "antagonizes"
    },
    {
      "source": "pretreatment with salbutamol",
      "target": "down-regulation of left ventricular beta(2)-adrenoceptors",
      "label": "induced"
    },
    {
      "source": "beta(2)-adrenoceptors down-regulation",
      "target": "isoprenaline-induced cardiac fibrosis",
      "label": "provided protection against"
    },
    {
      "source": "Wistar rats",
      "target": "2-week chronic isoprenaline administration",
      "label": "subjected to"
    },
    {
      "source": "Wistar rats",
      "target": "deep second-degree cutaneous burn",
      "label": "had"
    },
    {
      "source": "Wistar rats",
      "target": "monocrotaline",
      "label": "injected with"
    },
    {
      "source": "Wistar rats",
      "target": "saline",
      "label": "injected with"
    },
    {
      "source": "desensitization of beta 2-adrenoceptors",
      "target": "isoprenaline-induced cardiac fibrosis",
      "label": "reduces"
    },
    {
      "source": "alpha(1A)-adrenoceptor",
      "target": "pupillary dilation",
      "label": "mediates"
    },
    {
      "source": "alpha(1A)-adrenoceptor",
      "target": "mydriatic responses",
      "label": "mediates"
    },
    {
      "source": "alpha(1A)-adrenoceptor",
      "target": "exclusive subtype",
      "label": "is"
    },
    {
      "source": "pupillary dilation",
      "target": "agonist activation",
      "label": "in response to"
    },
    {
      "source": "pupillary dilation",
      "target": "sympathetic nerve stimulation",
      "label": "elicited by"
    },
    {
      "source": "pupillary dilation",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "pupillary dilation",
      "target": "neural activation",
      "label": "in response to"
    },
    {
      "source": "alpha(1D)-adrenoceptor",
      "target": "pupillary dilation",
      "label": "does not mediate"
    },
    {
      "source": "alpha-adrenoceptor subtypes",
      "target": "pupillary dilation",
      "label": "mediates"
    },
    {
      "source": "alpha-adrenoceptors",
      "target": "pupillary dilation",
      "label": "mediates"
    },
    {
      "source": "mydriatic responses",
      "target": "L-765314",
      "label": "not antagonized by"
    },
    {
      "source": "mydriatic responses",
      "target": "norepinephrine",
      "label": "to"
    },
    {
      "source": "mydriatic responses",
      "target": "selective alpha(1)-adrenoceptor antagonist",
      "label": "inhibited by"
    },
    {
      "source": "mydriatic responses",
      "target": "WB-4101",
      "label": "antagonized by"
    },
    {
      "source": "mydriatic responses",
      "target": "species",
      "label": "occurs in"
    },
    {
      "source": "mydriatic responses",
      "target": "BMY-7378",
      "label": "not antagonized by"
    },
    {
      "source": "mydriatic responses",
      "target": "systemic administration",
      "label": "inhibited by"
    },
    {
      "source": "mydriatic responses",
      "target": "5-methylurapidil",
      "label": "antagonized by"
    },
    {
      "source": "L-765314",
      "target": "alpha(1B)-adrenoceptor selective antagonist",
      "label": "is"
    },
    {
      "source": "L-765314",
      "target": "mydriasis",
      "label": "ineffective in inhibiting"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione",
      "label": "delineated by"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "L-765314",
      "label": "delineated by"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "WB-4101",
      "label": "delineated by"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline",
      "label": "delineated by"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "5-methylurapidil",
      "label": "delineated by"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane",
      "label": "delineated by"
    },
    {
      "source": "adrenoceptor subtypes",
      "target": "BMY-7378",
      "label": "delineated by"
    },
    {
      "source": "8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione",
      "target": "alpha(1D)-adrenoceptor selective antagonist",
      "label": "is"
    },
    {
      "source": "nonselective alpha-adrenoceptor antagonists",
      "target": "phenoxybenzamine",
      "label": "includes"
    },
    {
      "source": "nonselective alpha-adrenoceptor antagonists",
      "target": "phentolamine",
      "label": "includes"
    },
    {
      "source": "2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane",
      "target": "alpha(1A)-Adrenoceptor selective antagonists",
      "label": "is"
    },
    {
      "source": "5-methylurapidil",
      "target": "alpha(1A)-Adrenoceptor selective antagonists",
      "label": "is"
    },
    {
      "source": "Pupillary dilator response curves",
      "target": "intravenous injection",
      "label": "generated by"
    },
    {
      "source": "intravenous injection",
      "target": "pentobarbital-anesthetized rats",
      "label": "in"
    },
    {
      "source": "intravenous injection",
      "target": "norepinephrine",
      "label": "of"
    },
    {
      "source": "intravenous injection",
      "target": "18F-AV-45",
      "label": "of"
    },
    {
      "source": "WB-4101",
      "target": "alpha(1A)-Adrenoceptor selective antagonists",
      "label": "is"
    },
    {
      "source": "BMY-7378",
      "target": "alpha(1D)-adrenoceptor selective antagonist",
      "label": "is"
    },
    {
      "source": "4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline",
      "target": "alpha(1B)-adrenoceptor selective antagonist",
      "label": "is"
    },
    {
      "source": "systemic administration",
      "target": "nonselective alpha-adrenoceptor antagonists",
      "label": "of"
    },
    {
      "source": "alpha(1B)-adrenoceptors",
      "target": "sympathetic mydriasis",
      "label": "do not mediate"
    },
    {
      "source": "sympathetic mydriasis",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "mydriasis",
      "target": "cervical sympathetic nerve stimulation",
      "label": "evoked by"
    },
    {
      "source": "Ketoconazole",
      "target": "androgen binding sites",
      "label": "competes for"
    },
    {
      "source": "Ketoconazole",
      "target": "non-steroidal compound",
      "label": "is a"
    },
    {
      "source": "Ketoconazole",
      "target": "imidazole anti-fungal agent",
      "label": "is a"
    },
    {
      "source": "Ketoconazole",
      "target": "human androgen receptors",
      "label": "binds to"
    },
    {
      "source": "Ketoconazole",
      "target": "androgen deficiency",
      "label": "produced"
    },
    {
      "source": "Ketoconazole",
      "target": "human androgen receptor",
      "label": "interacts with"
    },
    {
      "source": "Ketoconazole",
      "target": "sex steroid binding globulin",
      "label": "has affinity for"
    },
    {
      "source": "Ketoconazole",
      "target": "men",
      "label": "produced features in"
    },
    {
      "source": "Ketoconazole",
      "target": "gonadal function",
      "label": "affects"
    },
    {
      "source": "Ketoconazole",
      "target": "[3H]methyltrienolone",
      "label": "competes with"
    },
    {
      "source": "Ketoconazole",
      "target": "receptor proteins",
      "label": "has affinity for"
    },
    {
      "source": "androgen binding sites",
      "target": "dispersed, intact cultured human skin fibroblasts",
      "label": "located in"
    },
    {
      "source": "androgen binding sites",
      "target": "22 degrees C",
      "label": "tested at"
    },
    {
      "source": "Additional binding studies",
      "target": "Ketoconazole",
      "label": "performed with"
    },
    {
      "source": "men",
      "target": "chronic mycotic infections",
      "label": "treated for"
    },
    {
      "source": "men",
      "target": "benign prostatic hyperplasia (BPH)",
      "label": "with"
    },
    {
      "source": "men",
      "target": "addition of an anti-muscarinic agent",
      "label": "benefit from"
    },
    {
      "source": "men",
      "target": "adequate alleviation of symptoms",
      "label": "not receiving"
    },
    {
      "source": "men",
      "target": "overactive bladder",
      "label": "with"
    },
    {
      "source": "men",
      "target": "TCDD",
      "label": "exposed to"
    },
    {
      "source": "men",
      "target": "2,3,7,8-tetrachlorodibenzo-p-dioxin",
      "label": "exposed to"
    },
    {
      "source": "men",
      "target": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "label": "are affected by"
    },
    {
      "source": "men",
      "target": "mean \u00b1 SD age",
      "label": "have"
    },
    {
      "source": "men",
      "target": "mean serum creatinine concentration (Scr)",
      "label": "have"
    },
    {
      "source": "men",
      "target": "mean 24-hour measured creatinine clearance (mClcr)",
      "label": "have"
    },
    {
      "source": "androgen deficiency",
      "target": "oligospermia",
      "label": "includes"
    },
    {
      "source": "androgen deficiency",
      "target": "gynecomastia",
      "label": "includes"
    },
    {
      "source": "androgen deficiency",
      "target": "impotence",
      "label": "includes"
    },
    {
      "source": "androgen deficiency",
      "target": "decreased testosterone levels",
      "label": "includes"
    },
    {
      "source": "androgen deficiency",
      "target": "decreased libido",
      "label": "includes"
    },
    {
      "source": "Fifty percent displacement",
      "target": "6.4 +/- 1.8 (SE) x 10(-5) M ketoconazole",
      "label": "achieved by"
    },
    {
      "source": "Fifty percent displacement",
      "target": "[3H]R1881 binding",
      "label": "is of"
    },
    {
      "source": "dose of ketoconazole",
      "target": "plasma",
      "label": "not achieved in"
    },
    {
      "source": "dose of ketoconazole",
      "target": "50% occupancy",
      "label": "causes"
    },
    {
      "source": "androgen binding studies",
      "target": "imidazoles",
      "label": "performed with"
    },
    {
      "source": "imidazoles",
      "target": "clotrimazole",
      "label": "includes"
    },
    {
      "source": "imidazoles",
      "target": "class of compounds",
      "label": "are a"
    },
    {
      "source": "imidazoles",
      "target": "fluconozole",
      "label": "includes"
    },
    {
      "source": "imidazoles",
      "target": "miconazole",
      "label": "includes"
    },
    {
      "source": "receptor proteins",
      "target": "1,25(OH)2 vitamin D3",
      "label": "are for"
    },
    {
      "source": "receptor proteins",
      "target": "glucocorticoids",
      "label": "are for"
    },
    {
      "source": "non-steroidal compound",
      "target": "multiple steroid hormone receptors",
      "label": "binds to"
    },
    {
      "source": "non-steroidal compound",
      "target": "SSBG",
      "label": "binds to"
    },
    {
      "source": "[3H]R1881 binding",
      "target": "AR",
      "label": "is to"
    },
    {
      "source": "AR",
      "target": "testis",
      "label": "is located in"
    },
    {
      "source": "AR",
      "target": "ovary tissues",
      "label": "is located in"
    },
    {
      "source": "AR",
      "target": "liver tissue",
      "label": "is located in"
    },
    {
      "source": "AR",
      "target": "testis tissues",
      "label": "is located in"
    },
    {
      "source": "AR",
      "target": "liver",
      "label": "is located in"
    },
    {
      "source": "AR",
      "target": "androgen",
      "label": "is a"
    },
    {
      "source": "50% occupancy",
      "target": "human androgen receptor",
      "label": "is of"
    },
    {
      "source": "human androgen receptors",
      "target": "AR",
      "label": "is also known as"
    },
    {
      "source": "sex steroid binding globulin",
      "target": "SSBG",
      "label": "is also known as"
    },
    {
      "source": "[3H]methyltrienolone",
      "target": "R1881",
      "label": "is also known as"
    },
    {
      "source": "ligand binding sites",
      "target": "proteins",
      "label": "are of"
    },
    {
      "source": "smaller compounds",
      "target": "active site",
      "label": "enter"
    },
    {
      "source": "20-amino acid span",
      "target": "substrate access channel",
      "label": "is in"
    },
    {
      "source": "20-amino acid span",
      "target": "aldehyde dehydrogenases",
      "label": "is in"
    },
    {
      "source": "20-amino acid span",
      "target": "retinaldehyde dehydrogenase type II",
      "label": "is in"
    },
    {
      "source": "20-amino acid span",
      "target": "disordered loop",
      "label": "is a"
    },
    {
      "source": "aldehyde dehydrogenases",
      "target": "enzyme superfamily",
      "label": "are part of"
    },
    {
      "source": "Retinaldehyde dehydrogenase II",
      "target": "retinoic acid",
      "label": "converts to"
    },
    {
      "source": "Retinaldehyde dehydrogenase II",
      "target": "developing embryo",
      "label": "acts in"
    },
    {
      "source": "Retinaldehyde dehydrogenase II",
      "target": "retinal",
      "label": "converts"
    },
    {
      "source": "retinoic acid",
      "target": "transcriptional regulator",
      "label": "is a"
    },
    {
      "source": "retinoic acid",
      "target": "vitamin A",
      "label": "constitutes"
    },
    {
      "source": "retinoic acid",
      "target": "expression",
      "label": "has effect on"
    },
    {
      "source": "retinoic acid",
      "target": "ErbB3",
      "label": "has effect on"
    },
    {
      "source": "retinoic acid",
      "target": "retinoic acid receptors",
      "label": "effect mediated via"
    },
    {
      "source": "retinoic acid",
      "target": "neuroglial interactions",
      "label": "regulates"
    },
    {
      "source": "retinoic acid",
      "target": "retinoid X receptors",
      "label": "effect mediated via"
    },
    {
      "source": "retinoic acid",
      "target": "neuregulin receptor",
      "label": "has effect on"
    },
    {
      "source": "retinoic acid",
      "target": "nuclear hormone receptor ligand",
      "label": "is a"
    },
    {
      "source": "retinoic acid",
      "target": "embryonic patterning defects",
      "label": "leads to"
    },
    {
      "source": "retinoic acid",
      "target": "RA",
      "label": "is also known as"
    },
    {
      "source": "retinoic acid",
      "target": "teratogen",
      "label": "is a"
    },
    {
      "source": "retinoic acid",
      "target": "compound",
      "label": "is a"
    },
    {
      "source": "disordered loop",
      "target": "means",
      "label": "provides"
    },
    {
      "source": "disordered loop",
      "target": "catalysis",
      "label": "orders during"
    },
    {
      "source": "means",
      "target": "enzyme",
      "label": "is for"
    },
    {
      "source": "means",
      "target": "catalytic machinery",
      "label": "restricts access to"
    },
    {
      "source": "means",
      "target": "OMM",
      "label": "loads into"
    },
    {
      "source": "means",
      "target": "cholesterol",
      "label": "loads"
    },
    {
      "source": "experiments",
      "target": "combination",
      "label": "are a"
    },
    {
      "source": "experiments",
      "target": "disorder to order transition",
      "label": "suggests"
    },
    {
      "source": "experiments",
      "target": "Cr supplementation",
      "label": "to optimize"
    },
    {
      "source": "experiments",
      "target": "neuronal-enriched primary cultures",
      "label": "performed on"
    },
    {
      "source": "experiments",
      "target": "hypothesis",
      "label": "tested"
    },
    {
      "source": "structural difference",
      "target": "protein",
      "label": "is between"
    },
    {
      "source": "structural difference",
      "target": "aldehyde dehydrogenases",
      "label": "is between"
    },
    {
      "source": "catalytic machinery",
      "target": "smaller compounds",
      "label": "is accessed by"
    },
    {
      "source": "RalDH2",
      "target": "developing embryo",
      "label": "acts in"
    },
    {
      "source": "RalDH2",
      "target": "retinal",
      "label": "converts"
    },
    {
      "source": "RalDH2",
      "target": "retinoic acid",
      "label": "converts to"
    },
    {
      "source": "x-ray structure",
      "target": "structural difference",
      "label": "revealed"
    },
    {
      "source": "x-ray structure",
      "target": "enzyme",
      "label": "of"
    },
    {
      "source": "disorder to order transition",
      "target": "catalytic activity",
      "label": "is linked to"
    },
    {
      "source": "A disorder to order transition",
      "target": "catalysis",
      "label": "accompanies"
    },
    {
      "source": "mean integrated optical density",
      "target": "androgen receptor",
      "label": "measures"
    },
    {
      "source": "mean integrated optical density",
      "target": "LSAB",
      "label": "measured by"
    },
    {
      "source": "mean integrated optical density",
      "target": "scalding",
      "label": "measured after"
    },
    {
      "source": "mean integrated optical density",
      "target": "immunohistochemistry ENVISION",
      "label": "measured by"
    },
    {
      "source": "androgen receptor",
      "target": "liver",
      "label": "is located in"
    },
    {
      "source": "androgen receptor",
      "target": "sexual glands",
      "label": "is located in"
    },
    {
      "source": "androgen receptor",
      "target": "Western blot",
      "label": "determined by"
    },
    {
      "source": "NP group",
      "target": "ovary tissues",
      "label": "showed no significant difference in density of AR in"
    },
    {
      "source": "NP group",
      "target": "testis tissues",
      "label": "showed no significant difference in density of AR in"
    },
    {
      "source": "NP group",
      "target": "NP",
      "label": "received"
    },
    {
      "source": "NP group",
      "target": "liver tissue",
      "label": "resulted in higher density of AR in"
    },
    {
      "source": "normal saline",
      "target": "placebo",
      "label": "served as"
    },
    {
      "source": "nandrolone phenylpropionate",
      "target": "androgen receptor",
      "label": "has effects on"
    },
    {
      "source": "nandrolone phenylpropionate",
      "target": "burned rats",
      "label": "was studied in"
    },
    {
      "source": "deep second-degree cutaneous burn",
      "target": "20% total body surface area",
      "label": "covered"
    },
    {
      "source": "NP",
      "target": "burned rats",
      "label": "was used with safety in"
    },
    {
      "source": "NP",
      "target": "sexual glands",
      "label": "has side-effect on"
    },
    {
      "source": "NP",
      "target": "dose level",
      "label": "was used at"
    },
    {
      "source": "NP",
      "target": "on-going inflammatory arthritis",
      "label": "during"
    },
    {
      "source": "NP",
      "target": "intra-articular (I.A.) route",
      "label": "injected by"
    },
    {
      "source": "NP",
      "target": "anti-arthritic effects",
      "label": "elicits"
    },
    {
      "source": "NP",
      "target": "joint inflammation",
      "label": "reduced"
    },
    {
      "source": "NP",
      "target": "expression of NR4A2",
      "label": "reduced"
    },
    {
      "source": "NP",
      "target": "local bone architecture",
      "label": "preserved"
    },
    {
      "source": "liver",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "liver",
      "target": "mice",
      "label": "is part of"
    },
    {
      "source": "internal standards",
      "target": "enzymatic activities",
      "label": "quantify"
    },
    {
      "source": "enzymatic activities",
      "target": "healthy individuals",
      "label": "measured in"
    },
    {
      "source": "enzymatic activities",
      "target": "minimum activities",
      "label": "are below"
    },
    {
      "source": "enzymatic activities",
      "target": "heterozygous carriers",
      "label": "measured in"
    },
    {
      "source": "interfering acid alpha-glucosidase",
      "target": "neutrophils",
      "label": "is present in"
    },
    {
      "source": "affected individuals",
      "target": "Krabbe disease",
      "label": "were detected for"
    },
    {
      "source": "affected individuals",
      "target": "Gaucher disease",
      "label": "were detected for"
    },
    {
      "source": "affected individuals",
      "target": "Pompe disease",
      "label": "were detected for"
    },
    {
      "source": "affected individuals",
      "target": "Niemann-Pick A/B disease",
      "label": "were detected for"
    },
    {
      "source": "affected individuals",
      "target": "Fabry disease",
      "label": "were detected for"
    },
    {
      "source": "multiplex screening method",
      "target": "lysosomal enzymes",
      "label": "is for"
    },
    {
      "source": "multiplex screening method",
      "target": "newborn-screening cards",
      "label": "uses"
    },
    {
      "source": "lysosomal enzymes",
      "target": "Niemann-Pick A/B disease",
      "label": "cause"
    },
    {
      "source": "lysosomal enzymes",
      "target": "Fabry disease",
      "label": "cause"
    },
    {
      "source": "lysosomal enzymes",
      "target": "Krabbe disease",
      "label": "cause"
    },
    {
      "source": "lysosomal enzymes",
      "target": "Gaucher disease",
      "label": "cause"
    },
    {
      "source": "lysosomal enzymes",
      "target": "Pompe disease",
      "label": "cause"
    },
    {
      "source": "lysosomal enzymes",
      "target": "dried blood spots",
      "label": "are found in"
    },
    {
      "source": "lysosomal enzymes",
      "target": "regulation",
      "label": "involved in"
    },
    {
      "source": "budget limits",
      "target": "newborn-screening centers",
      "label": "are of"
    },
    {
      "source": "dried blood spots",
      "target": "enzyme source",
      "label": "are"
    },
    {
      "source": "dried blood spots",
      "target": "patients",
      "label": "are from"
    },
    {
      "source": "newborn-screening cards",
      "target": "dried blood spots",
      "label": "contain"
    },
    {
      "source": "solid-phase extraction",
      "target": "buffer components",
      "label": "removes"
    },
    {
      "source": "solid-phase extraction",
      "target": "silica gel",
      "label": "uses"
    },
    {
      "source": "cassette of substrates",
      "target": "enzymatic activities",
      "label": "quantifies"
    },
    {
      "source": "minimum activities",
      "target": "healthy noncarrier individuals",
      "label": "measured in"
    },
    {
      "source": "minimum activities",
      "target": "heterozygous carriers",
      "label": "measured in"
    },
    {
      "source": "Direct multiplex assay",
      "target": "lysosomal enzymes",
      "label": "measures"
    },
    {
      "source": "Direct multiplex assay",
      "target": "newborn screening",
      "label": "is for"
    },
    {
      "source": "Direct multiplex assay",
      "target": "dried blood spots",
      "label": "uses"
    },
    {
      "source": "data sets",
      "target": "heterozygous carriers",
      "label": "are for"
    },
    {
      "source": "data sets",
      "target": "healthy individuals",
      "label": "are for"
    },
    {
      "source": "newborn screening",
      "target": "deficiency",
      "label": "detects"
    },
    {
      "source": "liquid-liquid extraction",
      "target": "solid-phase extraction",
      "label": "followed by"
    },
    {
      "source": "liquid-liquid extraction",
      "target": "buffer components",
      "label": "removes"
    },
    {
      "source": "supply costs",
      "target": "budget limits",
      "label": "are within"
    },
    {
      "source": "Acarbose",
      "target": "lysosomal enzymes",
      "label": "enables analysis of"
    },
    {
      "source": "Acarbose",
      "target": "inhibitor",
      "label": "is an"
    },
    {
      "source": "Rehydrated dried blood spots",
      "target": "enzyme substrates",
      "label": "incubated with"
    },
    {
      "source": "reagent",
      "target": "supply costs",
      "label": "contributes to"
    },
    {
      "source": "tandem mass spectrometry",
      "target": "enzymatic product detection",
      "label": "is used for"
    },
    {
      "source": "condition",
      "target": "data sets",
      "label": "overlaps with"
    },
    {
      "source": "SV2A",
      "target": "synaptic vesicle exocytosis",
      "label": "is involved with"
    },
    {
      "source": "SV2A",
      "target": "presynaptic neurotransmitter release",
      "label": "is involved with"
    },
    {
      "source": "synaptic vesicle protein",
      "target": "SV2A",
      "label": "is known as"
    },
    {
      "source": "levetiracetam",
      "target": "mechanism of action",
      "label": "has"
    },
    {
      "source": "levetiracetam",
      "target": "synaptic vesicle protein",
      "label": "binds to"
    },
    {
      "source": "levetiracetam",
      "target": "synaptic vesicle protein modulator",
      "label": "is a type of"
    },
    {
      "source": "levetiracetam",
      "target": "class of anticonvulsants",
      "label": "is a member of"
    },
    {
      "source": "Psychopharmacology",
      "target": "anticonvulsants",
      "label": "concerns"
    },
    {
      "source": "COX isozymes",
      "target": "dogs",
      "label": "distributed in"
    },
    {
      "source": "COX isozymes",
      "target": "isozymes",
      "label": "are"
    },
    {
      "source": "nimesulide",
      "target": "COX-1",
      "label": "downregulates"
    },
    {
      "source": "nimesulide",
      "target": "COX-2",
      "label": "is a preferential inhibitor of"
    },
    {
      "source": "nimesulide",
      "target": "Canine COX-2",
      "label": "selectively inhibits"
    },
    {
      "source": "nimesulide",
      "target": "PTZ",
      "label": "administered before"
    },
    {
      "source": "nimesulide",
      "target": "kindling score",
      "label": "decreased"
    },
    {
      "source": "nimesulide",
      "target": "biochemical alterations",
      "label": "controlled"
    },
    {
      "source": "nimesulide",
      "target": "mice",
      "label": "offered neuroprotection in"
    },
    {
      "source": "nimesulide",
      "target": "PTZ-induced kindling",
      "label": "has neuroprotective effect against"
    },
    {
      "source": "nimesulide",
      "target": "vehicle",
      "label": "administered before"
    },
    {
      "source": "nimesulide",
      "target": "biochemical parameters",
      "label": "affects"
    },
    {
      "source": "nimesulide",
      "target": "neuroprotection",
      "label": "provides"
    },
    {
      "source": "nimesulide",
      "target": "kindling epilepsy",
      "label": "has effect against"
    },
    {
      "source": "Aspirin",
      "target": "COX isozymes",
      "label": "regulates"
    },
    {
      "source": "Aspirin",
      "target": "PGH2",
      "label": "prevents_formation_of"
    },
    {
      "source": "Aspirin",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "ketoprofen",
      "target": "COX isozymes",
      "label": "regulates"
    },
    {
      "source": "ketoprofen",
      "target": "COX-1",
      "label": "has increased selectivity towards"
    },
    {
      "source": "colon",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "canine tissues",
      "target": "COX-2 mRNA",
      "label": "express"
    },
    {
      "source": "canine tissues",
      "target": "COX-1 mRNA",
      "label": "express"
    },
    {
      "source": "canine tissues",
      "target": "dogs",
      "label": "obtained from"
    },
    {
      "source": "NS398",
      "target": "Canine COX-2",
      "label": "selectively inhibits"
    },
    {
      "source": "NS398",
      "target": "COX-1",
      "label": "downregulates"
    },
    {
      "source": "NS398",
      "target": "COX-2",
      "label": "downregulates"
    },
    {
      "source": "dogs",
      "target": "exposures",
      "label": "had"
    },
    {
      "source": "dogs",
      "target": "Findings",
      "label": "exhibited"
    },
    {
      "source": "ileum",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "carprofen",
      "target": "COX-2 inhibitors",
      "label": "is a"
    },
    {
      "source": "carprofen",
      "target": "COX-1",
      "label": "downregulates"
    },
    {
      "source": "carprofen",
      "target": "COX-2",
      "label": "downregulates"
    },
    {
      "source": "NSAIDs",
      "target": "COX-2",
      "label": "evaluated for selectivity for"
    },
    {
      "source": "NSAIDs",
      "target": "cAMP-mediated Cl- secretion",
      "label": "inhibit"
    },
    {
      "source": "jejunum",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "whole blood COX assays",
      "target": "blood",
      "label": "used"
    },
    {
      "source": "whole blood COX assays",
      "target": "COX-2",
      "label": "determine selectivity for"
    },
    {
      "source": "northern blot analyses",
      "target": "COX isozymes",
      "label": "determines tissue distribution of"
    },
    {
      "source": "northern blot analyses",
      "target": "canine tissues",
      "label": "used for"
    },
    {
      "source": "protein expression",
      "target": "injury-induced degeneration",
      "label": "investigated during"
    },
    {
      "source": "protein expression",
      "target": "regeneration",
      "label": "investigated during"
    },
    {
      "source": "protein expression",
      "target": "time",
      "label": "is dependent on"
    },
    {
      "source": "protein expression",
      "target": "concentration",
      "label": "is dependent on"
    },
    {
      "source": "protein expression",
      "target": "selected genes",
      "label": "is of"
    },
    {
      "source": "cerebral cortex",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "cerebral cortex",
      "target": "diabetes",
      "label": "of"
    },
    {
      "source": "lung",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "stomach",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "stomach",
      "target": "mice",
      "label": "is part of"
    },
    {
      "source": "tolfenamic acid",
      "target": "COX-1",
      "label": "downregulates"
    },
    {
      "source": "tolfenamic acid",
      "target": "COX-2",
      "label": "downregulates"
    },
    {
      "source": "tolfenamic acid",
      "target": "COX-2 inhibitors",
      "label": "is a"
    },
    {
      "source": "canine cyclooxygenase (COX)-1 and -2",
      "target": "nonsteroidal anti-inflammatory drugs",
      "label": "sensitive to"
    },
    {
      "source": "canine cyclooxygenase (COX)-1 and -2",
      "target": "isozymes",
      "label": "are"
    },
    {
      "source": "nonsteroidal anti-inflammatory drugs",
      "target": "NSAIDs",
      "label": "are"
    },
    {
      "source": "nonsteroidal anti-inflammatory drugs",
      "target": "ulcers",
      "label": "cause"
    },
    {
      "source": "nonsteroidal anti-inflammatory drugs",
      "target": "duodenum",
      "label": "cause ulcers in"
    },
    {
      "source": "cyclooxygenase-1 and -2",
      "target": "nonsteroidal anti-inflammatory drugs",
      "label": "sensitive to"
    },
    {
      "source": "cyclooxygenase-1 and -2",
      "target": "canine tissues",
      "label": "expressed in"
    },
    {
      "source": "cyclooxygenase-1 and -2",
      "target": "isozymes",
      "label": "are"
    },
    {
      "source": "COX-2-selective inhibitors",
      "target": "adverse effects",
      "label": "reduces"
    },
    {
      "source": "cyclooxygenase",
      "target": "isozymes",
      "label": "has"
    },
    {
      "source": "cyclooxygenase",
      "target": "prostaglandin endoperoxide (PGH) synthase",
      "label": "is_a"
    },
    {
      "source": "duodenum",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "duodenum",
      "target": "12 weeks",
      "label": "removed after"
    },
    {
      "source": "meclofenamic acid",
      "target": "COX isozymes",
      "label": "regulates"
    },
    {
      "source": "spleen",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "ovary",
      "target": "canine tissues",
      "label": "is a"
    },
    {
      "source": "piroxicam",
      "target": "COX isozymes",
      "label": "regulates"
    },
    {
      "source": "piroxicam",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "40 patients",
      "target": "conventional therapy",
      "label": "assigned to"
    },
    {
      "source": "40 patients",
      "target": "EF >/=45%",
      "label": "have"
    },
    {
      "source": "40 patients",
      "target": "mild or moderate heart failure",
      "label": "have"
    },
    {
      "source": "40 patients",
      "target": "carvedilol",
      "label": "assigned to"
    },
    {
      "source": "conventional therapy",
      "target": "New York Heart Association functional class",
      "label": "did not improve"
    },
    {
      "source": "conventional therapy",
      "target": "plasma BNP concentration",
      "label": "did not improve"
    },
    {
      "source": "conventional therapy",
      "target": "exercise capacity",
      "label": "did not improve"
    },
    {
      "source": "carvedilol",
      "target": "symptoms",
      "label": "decreased"
    },
    {
      "source": "carvedilol",
      "target": "neurohumoral activation",
      "label": "decreased"
    },
    {
      "source": "carvedilol",
      "target": "decrease in plasma BNP concentration",
      "label": "correlated with"
    },
    {
      "source": "carvedilol",
      "target": "New York Heart Association functional class",
      "label": "improved"
    },
    {
      "source": "carvedilol",
      "target": "plasma B-type natriuretic peptide concentration",
      "label": "has effects on"
    },
    {
      "source": "carvedilol",
      "target": "exercise capacity",
      "label": "increased"
    },
    {
      "source": "carvedilol",
      "target": "end points",
      "label": "improved"
    },
    {
      "source": "benefits of carvedilol",
      "target": "patients with heart failure and depressed ejection fraction",
      "label": "elucidated in"
    },
    {
      "source": "benefits of carvedilol",
      "target": "patients with preserved EF",
      "label": "not understood in"
    },
    {
      "source": "left ventricular dilation",
      "target": "decrease in plasma BNP concentration",
      "label": "predictive of"
    },
    {
      "source": "high plasma concentration of BNP",
      "target": "decrease in plasma BNP concentration",
      "label": "predictive of"
    },
    {
      "source": "ischemic cause of heart failure",
      "target": "decrease in plasma BNP concentration",
      "label": "predictive of"
    },
    {
      "source": "Terbinafine",
      "target": "squalene epoxidase inhibition",
      "label": "has mechanism"
    },
    {
      "source": "Terbinafine",
      "target": "fungi",
      "label": "has fungicidal action against"
    },
    {
      "source": "Terbinafine",
      "target": "Candida albicans",
      "label": "causes growth inhibition in"
    },
    {
      "source": "Terbinafine",
      "target": "inhibitor",
      "label": "is a potent non-competitive"
    },
    {
      "source": "Terbinafine",
      "target": "squalene epoxidase",
      "label": "inhibits"
    },
    {
      "source": "Terbinafine",
      "target": "cholesterol biosynthesis",
      "label": "has no effect on"
    },
    {
      "source": "fungi",
      "target": "ergosterol",
      "label": "become deficient in"
    },
    {
      "source": "fungi",
      "target": "squalene",
      "label": "accumulate"
    },
    {
      "source": "ergosterol",
      "target": "fungal cell membranes",
      "label": "is essential component of"
    },
    {
      "source": "ergosterol",
      "target": "Candida albicans",
      "label": "deficiency results in growth inhibition of"
    },
    {
      "source": "ergosterol biosynthesis",
      "target": "pathogenic fungi",
      "label": "occurs in"
    },
    {
      "source": "squalene epoxidase",
      "target": "cytochrome P-450 type",
      "label": "is not a"
    },
    {
      "source": "squalene",
      "target": "cell wall synthesis",
      "label": "interferes with"
    },
    {
      "source": "squalene",
      "target": "rat liver squalene epoxidase",
      "label": "is competitive with inhibition of"
    },
    {
      "source": "squalene",
      "target": "fungal membrane function",
      "label": "interferes with"
    },
    {
      "source": "cytochrome P-450 type",
      "target": "enzymes",
      "label": "is a class of"
    },
    {
      "source": "filamentous form",
      "target": "yeast form",
      "label": "is more susceptible than"
    },
    {
      "source": "drug concentrations",
      "target": "rat liver squalene epoxidase",
      "label": "affect inhibition of"
    },
    {
      "source": "drug concentrations",
      "target": "breast cancer cell growth",
      "label": "inhibit"
    },
    {
      "source": "Lamisil",
      "target": "squalene epoxidase",
      "label": "inhibits"
    },
    {
      "source": "Lamisil",
      "target": "Terbinafine",
      "label": "is also known as"
    },
    {
      "source": "radiolabelled precursors",
      "target": "ergosterol biosynthesis",
      "label": "are used for"
    },
    {
      "source": "treatment strategies",
      "target": "thalidomide",
      "label": "use"
    },
    {
      "source": "treatment strategies",
      "target": "irinotecan",
      "label": "use"
    },
    {
      "source": "treatment strategies",
      "target": "celecoxib",
      "label": "use"
    },
    {
      "source": "thalidomide",
      "target": "stability",
      "label": "decreased"
    },
    {
      "source": "thalidomide",
      "target": "low-doses",
      "label": "is used in"
    },
    {
      "source": "thalidomide",
      "target": "solid tumors",
      "label": "demonstrates activity against"
    },
    {
      "source": "thalidomide",
      "target": "PG biosynthesis",
      "label": "does not completely inhibit"
    },
    {
      "source": "thalidomide",
      "target": "COX-2 expression",
      "label": "does not completely inhibit"
    },
    {
      "source": "thalidomide",
      "target": "activity",
      "label": "has"
    },
    {
      "source": "thalidomide",
      "target": "mechanisms of action",
      "label": "has"
    },
    {
      "source": "bifunctional enzyme",
      "target": "cyclooxygenase activities",
      "label": "possesses"
    },
    {
      "source": "bifunctional enzyme",
      "target": "peroxidase activities",
      "label": "possesses"
    },
    {
      "source": "irinotecan",
      "target": "mechanisms of action",
      "label": "has"
    },
    {
      "source": "irinotecan",
      "target": "low-doses",
      "label": "is used in"
    },
    {
      "source": "pancreatic cancer",
      "target": "recurrence",
      "label": "has"
    },
    {
      "source": "pancreatic cancer",
      "target": "metastases",
      "label": "has"
    },
    {
      "source": "stability",
      "target": "COX-2 mRNA",
      "label": "of"
    },
    {
      "source": "stability",
      "target": "TNF-mRNA",
      "label": "of"
    },
    {
      "source": "stability",
      "target": "hydrogen bonding stability",
      "label": "associated with"
    },
    {
      "source": "stability",
      "target": "two complexes",
      "label": "is of"
    },
    {
      "source": "stability",
      "target": "non-covalent metal-ligand bonds",
      "label": "associated with"
    },
    {
      "source": "stability",
      "target": "three forms of rapta-C complexes",
      "label": "is of"
    },
    {
      "source": "stability",
      "target": "charge transfer term",
      "label": "governed by"
    },
    {
      "source": "stability",
      "target": "conditions",
      "label": "under"
    },
    {
      "source": "stability",
      "target": "noncanonical conformation",
      "label": "from"
    },
    {
      "source": "stability",
      "target": "(humanized) type 1 canonical conformation",
      "label": "to"
    },
    {
      "source": "stability",
      "target": "mouse brain homogenates",
      "label": "measured in"
    },
    {
      "source": "stability",
      "target": "protein kinase activity",
      "label": "is dependent on"
    },
    {
      "source": "stability",
      "target": "complex",
      "label": "is of"
    },
    {
      "source": "change",
      "target": "gemcitabine",
      "label": "of"
    },
    {
      "source": "change",
      "target": "outcomes",
      "label": "could provide"
    },
    {
      "source": "change",
      "target": "irinotecan",
      "label": "to"
    },
    {
      "source": "change",
      "target": "serum concentrations",
      "label": "not observed in"
    },
    {
      "source": "gemcitabine",
      "target": "pancreatic cancer",
      "label": "is standard chemotherapy for"
    },
    {
      "source": "gemcitabine",
      "target": "mechanisms of action",
      "label": "has"
    },
    {
      "source": "metastatic pancreatic cancer",
      "target": "celecoxib",
      "label": "responded to"
    },
    {
      "source": "metastatic pancreatic cancer",
      "target": "combination",
      "label": "responded to"
    },
    {
      "source": "metastatic pancreatic cancer",
      "target": "thalidomide",
      "label": "responded to"
    },
    {
      "source": "metastatic pancreatic cancer",
      "target": "irinotecan",
      "label": "responded to"
    },
    {
      "source": "therapeutic strategy",
      "target": "celecoxib",
      "label": "combines"
    },
    {
      "source": "therapeutic strategy",
      "target": "thalidomide",
      "label": "combines"
    },
    {
      "source": "therapeutic strategy",
      "target": "agent",
      "label": "is more effective than"
    },
    {
      "source": "therapeutic strategy",
      "target": "information",
      "label": "contributes"
    },
    {
      "source": "therapeutic strategy",
      "target": "oxidative DNA damage",
      "label": "provides protection against"
    },
    {
      "source": "therapeutic strategy",
      "target": "Mn(2+)-induction",
      "label": "provides protection against"
    },
    {
      "source": "therapeutic strategy",
      "target": "pain",
      "label": "for"
    },
    {
      "source": "outcomes",
      "target": "myelofibrosis",
      "label": "in"
    },
    {
      "source": "peroxidase activity",
      "target": "proximate carcinogens",
      "label": "can generate"
    },
    {
      "source": "Chemotherapy",
      "target": "survival benefit",
      "label": "has not resulted in"
    },
    {
      "source": "COX",
      "target": "peroxidase activity",
      "label": "has"
    },
    {
      "source": "COX",
      "target": "prostaglandin synthesis",
      "label": "is an enzyme in"
    },
    {
      "source": "COX",
      "target": "cytochrome c oxidase",
      "label": "is an abbreviation for"
    },
    {
      "source": "metastases",
      "target": "malignant melanoma",
      "label": "associated with"
    },
    {
      "source": "cooling agent 10",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "cooling agent 10",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "Ca(2+) response",
      "target": "low pH",
      "label": "potentiated by"
    },
    {
      "source": "Ca(2+) response",
      "target": "hVR1-transfected HEK293 cells",
      "label": "of"
    },
    {
      "source": "BCTC",
      "target": "TRPM8",
      "label": "blocks response of"
    },
    {
      "source": "BCTC",
      "target": "IC(50)",
      "label": "has"
    },
    {
      "source": "BCTC",
      "target": "VR1",
      "label": "is an antagonist of"
    },
    {
      "source": "TRPM8",
      "target": "menthol",
      "label": "activated by"
    },
    {
      "source": "TRPM8",
      "target": "low temperatures",
      "label": "activated by"
    },
    {
      "source": "TRPM8",
      "target": "VR1",
      "label": "related to"
    },
    {
      "source": "TRPM8",
      "target": "protons",
      "label": "inhibited by"
    },
    {
      "source": "TRPM8",
      "target": "TRPV1",
      "label": "related to"
    },
    {
      "source": "TRPM8",
      "target": "transient receptor potential (TRP) family",
      "label": "belongs to"
    },
    {
      "source": "TRPM8",
      "target": "vanilloid receptor type-1",
      "label": "related to"
    },
    {
      "source": "TRPM8",
      "target": "Ca(2+)-permeable channel",
      "label": "is a"
    },
    {
      "source": "TRPM8",
      "target": "eucalyptol",
      "label": "activated by"
    },
    {
      "source": "TRPM8",
      "target": "CMR1",
      "label": "is a"
    },
    {
      "source": "TRPM8",
      "target": "ligands",
      "label": "responds to"
    },
    {
      "source": "TRPM8",
      "target": "icilin",
      "label": "activated by"
    },
    {
      "source": "TRPM8",
      "target": "cold-activated thermoTRP ion channel",
      "label": "is a type of"
    },
    {
      "source": "fluorometric imaging plate reader (FLIPR) assay",
      "target": "mouse cold-menthol receptor",
      "label": "used for characterization of"
    },
    {
      "source": "fluorometric imaging plate reader (FLIPR) assay",
      "target": "VR1",
      "label": "used for characterization of"
    },
    {
      "source": "fluorometric imaging plate reader (FLIPR) assay",
      "target": "TRPM8",
      "label": "used for characterization of"
    },
    {
      "source": "fluorometric imaging plate reader (FLIPR) assay",
      "target": "vanilloid receptor type-1",
      "label": "used for characterization of"
    },
    {
      "source": "mouse cold-menthol receptor",
      "target": "TRPM8",
      "label": "is"
    },
    {
      "source": "menthol",
      "target": "heat-activated TRPV3",
      "label": "activates"
    },
    {
      "source": "menthol",
      "target": "TRPM8",
      "label": "activates"
    },
    {
      "source": "menthol",
      "target": "analgesic",
      "label": "is used as"
    },
    {
      "source": "menthol",
      "target": "TRPA1",
      "label": "inhibits"
    },
    {
      "source": "menthol",
      "target": "paradoxical role",
      "label": "has"
    },
    {
      "source": "menthol",
      "target": "warm sensation",
      "label": "modulates"
    },
    {
      "source": "menthol",
      "target": "promiscuous relationships",
      "label": "has"
    },
    {
      "source": "menthol",
      "target": "cooling effect",
      "label": "is known for"
    },
    {
      "source": "FrescolatML",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "FrescolatML",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "FrescolatML",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "PMD38",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "PMD38",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "PMD38",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "VR1",
      "target": "ligands",
      "label": "responds to"
    },
    {
      "source": "VR1",
      "target": "protons",
      "label": "potentiated by"
    },
    {
      "source": "hydroxycitronellal",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "hydroxycitronellal",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "hydroxycitronellal",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "vanilloid receptor type-1",
      "target": "VR1",
      "label": "is"
    },
    {
      "source": "linalool",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "linalool",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "linalool",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "N-arachidonoyl-dopamine",
      "target": "VR1",
      "label": "is an endogenous agonist of"
    },
    {
      "source": "geraniol",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "geraniol",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "geraniol",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "frescolatMAG",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "frescolatMAG",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "CMR1",
      "target": "Ca(2+)-permeable channel",
      "label": "is a"
    },
    {
      "source": "eucalyptol",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "eucalyptol",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "menthol-related substances",
      "target": "recombinant mouse TRPM8",
      "label": "affect"
    },
    {
      "source": "menthol-related substances",
      "target": "TRPM8",
      "label": "activate"
    },
    {
      "source": "recombinant mouse TRPM8",
      "target": "HEK293 cells",
      "label": "expressed in"
    },
    {
      "source": "(+)menthol",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "(+)menthol",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "(-)menthol",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "(-)menthol",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "WS-3",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "WS-3",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "WS-3",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "capsazepine",
      "target": "VR1",
      "label": "is an antagonist of"
    },
    {
      "source": "capsazepine",
      "target": "IC(50)",
      "label": "has"
    },
    {
      "source": "capsazepine",
      "target": "TRPM8",
      "label": "blocks response of"
    },
    {
      "source": "icilin",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "icilin",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "CoolactP",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "odorants",
      "target": "recombinant mouse TRPM8",
      "label": "affect"
    },
    {
      "source": "Coolact P",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "Coolact P",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "HEK293 cells",
      "target": "Abeta(1-40)",
      "label": "exposed to"
    },
    {
      "source": "HEK293 cells",
      "target": "NR1/NR2B subunits",
      "label": "express"
    },
    {
      "source": "HEK293 cells",
      "target": "NR1/NR2A subunits",
      "label": "express"
    },
    {
      "source": "HEK293 cells",
      "target": "TRPV1 receptor",
      "label": "express"
    },
    {
      "source": "WS-23",
      "target": "EC(50) values",
      "label": "has"
    },
    {
      "source": "WS-23",
      "target": "potencies",
      "label": "has"
    },
    {
      "source": "WS-23",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "agonists",
      "target": "TRPM8",
      "label": "of"
    },
    {
      "source": "agonists",
      "target": "sensation",
      "label": "modulates"
    },
    {
      "source": "agonists",
      "target": "clinical implications",
      "label": "has"
    },
    {
      "source": "agonists",
      "target": "gastrointestinal motility",
      "label": "modulates"
    },
    {
      "source": "agonists",
      "target": "muscarinic acetylcholine receptor",
      "label": "of"
    },
    {
      "source": "agonists",
      "target": "mAChR",
      "label": "of"
    },
    {
      "source": "agonists",
      "target": "\u03b17 nicotinic acetylcholine receptor",
      "label": "target"
    },
    {
      "source": "agonists",
      "target": "nAChR",
      "label": "target"
    },
    {
      "source": "TRPM8 currents",
      "target": "low pH",
      "label": "suppressed by"
    },
    {
      "source": "Cooling Agent 10",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "mTRPM8",
      "target": "HEK293 cells",
      "label": "expressed in"
    },
    {
      "source": "thio-BCTC",
      "target": "TRPM8",
      "label": "blocks response of"
    },
    {
      "source": "thio-BCTC",
      "target": "IC(50)",
      "label": "has"
    },
    {
      "source": "thio-BCTC",
      "target": "VR1",
      "label": "is an antagonist of"
    },
    {
      "source": "FrescolatMGA",
      "target": "TRPM8",
      "label": "is an agonist of"
    },
    {
      "source": "unrecognised expression",
      "target": "P2X4 receptor",
      "label": "of"
    },
    {
      "source": "P2X4 receptor",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2X4 receptor",
      "target": "human lymphocytes",
      "label": "has highest expression in"
    },
    {
      "source": "P2X4 receptor",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2X4 receptor",
      "target": "monocytes",
      "label": "has highest expression in"
    },
    {
      "source": "P2X4 receptor",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "P2X receptors",
      "target": "human lymphocytes",
      "label": "are present in"
    },
    {
      "source": "P2X receptors",
      "target": "monocytes",
      "label": "are present in"
    },
    {
      "source": "P2Y1",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2Y1",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "P2Y1",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2Y1",
      "target": "PDB code 1ddd",
      "label": "has PDB code"
    },
    {
      "source": "specific antibodies",
      "target": "P2 receptors",
      "label": "are to"
    },
    {
      "source": "specific antibodies",
      "target": "progenitors",
      "label": "can identify"
    },
    {
      "source": "P2 receptors",
      "target": "progenitor/stem cell function",
      "label": "are involved in"
    },
    {
      "source": "P2 receptors",
      "target": "potential role",
      "label": "have"
    },
    {
      "source": "P2 receptors",
      "target": "hematopoietic lineage",
      "label": "are involved in"
    },
    {
      "source": "P2 receptors",
      "target": "CD34+ stem and progenitor cells",
      "label": "are present in"
    },
    {
      "source": "P2 receptors",
      "target": "purine nucleotides",
      "label": "activated by"
    },
    {
      "source": "P2 receptors",
      "target": "pyrimidine nucleotides",
      "label": "activated by"
    },
    {
      "source": "progenitors",
      "target": "megakaryocytes",
      "label": "are for"
    },
    {
      "source": "progenitors",
      "target": "human lymphocytes",
      "label": "are for"
    },
    {
      "source": "progenitors",
      "target": "monocytes",
      "label": "are for"
    },
    {
      "source": "progenitors",
      "target": "\u03b2-cell lineage",
      "label": "are not converted to"
    },
    {
      "source": "progenitors",
      "target": "\u03b2-cell mass expansion",
      "label": "do not contribute to"
    },
    {
      "source": "potential role",
      "target": "P2 receptors",
      "label": "of"
    },
    {
      "source": "P2Y12",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "P2Y12",
      "target": "anti-inflammatory effects",
      "label": "explains"
    },
    {
      "source": "P2Y12",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2Y12",
      "target": "human lymphocytes",
      "label": "is present in"
    },
    {
      "source": "P2Y12",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2Y12",
      "target": "antagonists",
      "label": "has"
    },
    {
      "source": "P2Y12",
      "target": "new drugs",
      "label": "is target of"
    },
    {
      "source": "P2Y12",
      "target": "ticlopidine",
      "label": "is target of"
    },
    {
      "source": "P2Y12",
      "target": "ADP/ATP analogs",
      "label": "inhibited by"
    },
    {
      "source": "P2Y12",
      "target": "thienopyridine drugs",
      "label": "is target of"
    },
    {
      "source": "P2Y12",
      "target": "clopidogrel",
      "label": "is target of"
    },
    {
      "source": "specific receptor subtype",
      "target": "antagonists",
      "label": "lacks"
    },
    {
      "source": "specific receptor subtype",
      "target": "selective agonists",
      "label": "lacks"
    },
    {
      "source": "P2X1",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "P2X1",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2X1",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2Y2",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2Y2",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2Y2",
      "target": "human lymphocytes",
      "label": "has highest expression in"
    },
    {
      "source": "P2Y2",
      "target": "monocytes",
      "label": "has highest expression in"
    },
    {
      "source": "P2Y2",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "specific P2 receptor profiles",
      "target": "inflammatory cells",
      "label": "are present in"
    },
    {
      "source": "inflammatory cells",
      "target": "neutrophils",
      "label": "include"
    },
    {
      "source": "inflammatory cells",
      "target": "eosinophils",
      "label": "include"
    },
    {
      "source": "inflammatory cells",
      "target": "T cells",
      "label": "include"
    },
    {
      "source": "inflammatory cells",
      "target": "macrophages",
      "label": "include"
    },
    {
      "source": "inflammatory cells",
      "target": "monocytes",
      "label": "include"
    },
    {
      "source": "biological effects",
      "target": "G protein-coupled P2Y receptors",
      "label": "mediated by"
    },
    {
      "source": "biological effects",
      "target": "multiple ionotropic P2X receptors",
      "label": "mediated by"
    },
    {
      "source": "clopidogrel",
      "target": "antagonists",
      "label": "is a type of"
    },
    {
      "source": "clopidogrel",
      "target": "standard regimen",
      "label": "is a"
    },
    {
      "source": "clopidogrel",
      "target": "loading dose",
      "label": "was administered with"
    },
    {
      "source": "clopidogrel",
      "target": "cardiovascular events",
      "label": "reduces"
    },
    {
      "source": "clopidogrel",
      "target": "antiplatelet effects",
      "label": "has"
    },
    {
      "source": "clopidogrel",
      "target": "platelet aggregation",
      "label": "inhibits"
    },
    {
      "source": "clopidogrel",
      "target": "aspirin",
      "label": "is combined with"
    },
    {
      "source": "clopidogrel",
      "target": "poor inhibition of platelet aggregation",
      "label": "can lead to"
    },
    {
      "source": "P2 receptor mRNA expression profiles",
      "target": "human lymphocytes",
      "label": "are present in"
    },
    {
      "source": "P2 receptor mRNA expression profiles",
      "target": "monocytes",
      "label": "are present in"
    },
    {
      "source": "P2 receptor mRNA expression profiles",
      "target": "CD34+ stem and progenitor cells",
      "label": "are present in"
    },
    {
      "source": "Extracellular nucleotides",
      "target": "biological effects",
      "label": "exert"
    },
    {
      "source": "P2 receptor mRNA expression patterns",
      "target": "CD34+ stem and progenitor cells",
      "label": "studied in"
    },
    {
      "source": "P2Y receptors",
      "target": "human lymphocytes",
      "label": "are present in"
    },
    {
      "source": "P2Y receptors",
      "target": "monocytes",
      "label": "are present in"
    },
    {
      "source": "P2Y11",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "P2Y11",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2Y11",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2Y13",
      "target": "proliferation",
      "label": "is involved in"
    },
    {
      "source": "P2Y13",
      "target": "CD34+ stem and progenitor cells",
      "label": "expressed in"
    },
    {
      "source": "P2Y13",
      "target": "monocytes",
      "label": "has highest expression in"
    },
    {
      "source": "P2Y13",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "high mRNA expression",
      "target": "P2Y12",
      "label": "of"
    },
    {
      "source": "high mRNA expression",
      "target": "P2Y13",
      "label": "of"
    },
    {
      "source": "quantitative mRNA assay",
      "target": "hypothesis",
      "label": "assessed"
    },
    {
      "source": "quantitative mRNA assay",
      "target": "P2 receptors",
      "label": "for"
    },
    {
      "source": "physiological functions",
      "target": "specific receptor subtype",
      "label": "established to"
    },
    {
      "source": "pharmacological experiments",
      "target": "P2 receptor subtypes",
      "label": "suggested presence of"
    },
    {
      "source": "LPS injection",
      "target": "White blood cell (WBC) count",
      "label": "increases"
    },
    {
      "source": "LPS injection",
      "target": "PGE2 levels",
      "label": "increases"
    },
    {
      "source": "LPS injection",
      "target": "Middle carpal joint",
      "label": "into"
    },
    {
      "source": "Groups of horses",
      "target": "Treatment",
      "label": "received"
    },
    {
      "source": "Groups of horses",
      "target": "Phenylbutazone",
      "label": "received"
    },
    {
      "source": "Groups of horses",
      "target": "Etodolac",
      "label": "received"
    },
    {
      "source": "Groups of horses",
      "target": "Horses",
      "label": "is a type of"
    },
    {
      "source": "Etodolac",
      "target": "Equine synovitis",
      "label": "treats"
    },
    {
      "source": "Etodolac",
      "target": "TXB2",
      "label": "did not reduce"
    },
    {
      "source": "Etodolac",
      "target": "Anti-inflammatory agent",
      "label": "is a"
    },
    {
      "source": "Etodolac",
      "target": "PGE2 levels",
      "label": "reduced"
    },
    {
      "source": "Etodolac",
      "target": "White blood cell (WBC) count",
      "label": "reduced"
    },
    {
      "source": "Etodolac",
      "target": "Anti-inflammatory effects",
      "label": "has"
    },
    {
      "source": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
      "target": "COX-2",
      "label": "inhibit"
    },
    {
      "source": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
      "target": "Cyclooxygenase isoforms",
      "label": "inhibit"
    },
    {
      "source": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
      "target": "COX-1",
      "label": "inhibit"
    },
    {
      "source": "TXB2",
      "target": "COX-1 prostanoid",
      "label": "is a"
    },
    {
      "source": "TXB2",
      "target": "platelet",
      "label": "is a product of"
    },
    {
      "source": "TXB2",
      "target": "arachidonate metabolism",
      "label": "is a product of"
    },
    {
      "source": "Phenylbutazone",
      "target": "Anti-inflammatory effects",
      "label": "has"
    },
    {
      "source": "Phenylbutazone",
      "target": "Equine synovitis",
      "label": "treats"
    },
    {
      "source": "Phenylbutazone",
      "target": "White blood cell (WBC) count",
      "label": "reduced"
    },
    {
      "source": "Phenylbutazone",
      "target": "PGE2 levels",
      "label": "reduced"
    },
    {
      "source": "Phenylbutazone",
      "target": "Anti-inflammatory agent",
      "label": "is an"
    },
    {
      "source": "Phenylbutazone",
      "target": "TXB2",
      "label": "reduced"
    },
    {
      "source": "Non-selective cyclooxygenase inhibitors",
      "target": "Inflammation",
      "label": "reduce"
    },
    {
      "source": "Non-selective cyclooxygenase inhibitors",
      "target": "Lipopolysaccharide-induced synovitis",
      "label": "reduce"
    },
    {
      "source": "Non-selective cyclooxygenase inhibitors",
      "target": "Gastrointestinal side effects",
      "label": "cause"
    },
    {
      "source": "Physiologic functions",
      "target": "Gastric mucosal integrity",
      "label": "include"
    },
    {
      "source": "Lipopolysaccharide-induced synovitis",
      "target": "Horses",
      "label": "affects"
    },
    {
      "source": "Synovial fluid",
      "target": "PGE2",
      "label": "analyzed for"
    },
    {
      "source": "Synovial fluid",
      "target": "White blood cell (WBC) count",
      "label": "analyzed for"
    },
    {
      "source": "Synovial fluid",
      "target": "TXB2",
      "label": "analyzed for"
    },
    {
      "source": "Synovitis",
      "target": "Horses",
      "label": "affects"
    },
    {
      "source": "Synovitis",
      "target": "Non-steroidal anti-inflammatory drugs (NSAIDs)",
      "label": "treated by"
    },
    {
      "source": "Lipopolysaccharide (LPS)",
      "target": "Lipopolysaccharide-induced synovitis",
      "label": "induces"
    },
    {
      "source": "Preferential cyclooxygenase inhibitors",
      "target": "Inflammation",
      "label": "reduce"
    },
    {
      "source": "Preferential cyclooxygenase inhibitors",
      "target": "Lipopolysaccharide-induced synovitis",
      "label": "reduce"
    },
    {
      "source": "Untreated horses",
      "target": "Horses",
      "label": "is a type of"
    },
    {
      "source": "Present study",
      "target": "Anti-inflammatory effects",
      "label": "objective is to compare"
    },
    {
      "source": "Present study",
      "target": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "label": "investigated"
    },
    {
      "source": "Present study",
      "target": "Occupancy",
      "label": "investigated"
    },
    {
      "source": "Drugs",
      "target": "PGE2 levels",
      "label": "reduced"
    },
    {
      "source": "Non-selective COX inhibitor",
      "target": "Phenylbutazone",
      "label": "is"
    },
    {
      "source": "Preferential COX-2 inhibitor",
      "target": "Etodolac",
      "label": "is"
    },
    {
      "source": "C3T",
      "target": "apoA-I production",
      "label": "increased"
    },
    {
      "source": "Rho kinase inhibitor",
      "target": "apoA-I production",
      "label": "increased"
    },
    {
      "source": "simvastatin",
      "target": "apoA-I",
      "label": "induced"
    },
    {
      "source": "simvastatin",
      "target": "apoA-I expression",
      "label": "induced"
    },
    {
      "source": "simvastatin",
      "target": "single doses",
      "label": "administered as"
    },
    {
      "source": "pitavastatin",
      "target": "apoA-I production",
      "label": "promotes"
    },
    {
      "source": "pitavastatin",
      "target": "ABCA1 induction",
      "label": "causes"
    },
    {
      "source": "pitavastatin",
      "target": "lipidation of apoA-I",
      "label": "causes"
    },
    {
      "source": "pitavastatin",
      "target": "Rho activity",
      "label": "suppresses"
    },
    {
      "source": "pitavastatin",
      "target": "apoA-I",
      "label": "induced"
    },
    {
      "source": "pitavastatin",
      "target": "ABCA1 mRNA",
      "label": "increased"
    },
    {
      "source": "pitavastatin",
      "target": "HMG-CoA reductase",
      "label": "inhibits"
    },
    {
      "source": "pitavastatin",
      "target": "apoA-I expression",
      "label": "induced"
    },
    {
      "source": "pitavastatin",
      "target": "catabolism",
      "label": "protects from"
    },
    {
      "source": "HMG-CoA reductase inhibition",
      "target": "apoA-I expression",
      "label": "causes"
    },
    {
      "source": "HMG-CoA reductase inhibition",
      "target": "ABCA1 mRNA",
      "label": "causes"
    },
    {
      "source": "Y27632",
      "target": "apoA-I production",
      "label": "increased"
    },
    {
      "source": "statins",
      "target": "HDL",
      "label": "elevates"
    },
    {
      "source": "statins",
      "target": "apoA-I synthesis",
      "label": "affects"
    },
    {
      "source": "statins",
      "target": "apoA-I expression",
      "label": "induced"
    },
    {
      "source": "statins",
      "target": "apoA-I secretion",
      "label": "affects"
    },
    {
      "source": "mevalonate",
      "target": "apoA-I expression",
      "label": "inhibited"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "HDL",
      "label": "elevates"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "expression",
      "label": "induce"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "VLDL",
      "label": "reduce"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "LDL",
      "label": "reduce"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "liver high-affinity lipoprotein receptors",
      "label": "induce expression of"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "biosynthesis",
      "label": "interfere with"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "cholesterol",
      "label": "interfere with biosynthesis of"
    },
    {
      "source": "HMG-CoA reductase inhibitors",
      "target": "plasma very-low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "Rho",
      "target": "apoA-I production",
      "label": "increased"
    },
    {
      "source": "SU11248",
      "target": "metronomic chemotherapy",
      "label": "used in concert with"
    },
    {
      "source": "SU11248",
      "target": "maximum-tolerated dose (MTD)",
      "label": "used in concert with"
    },
    {
      "source": "SU11248",
      "target": "VEGFR inhibition",
      "label": "used in concert with"
    },
    {
      "source": "SU11248",
      "target": "PDGFR-mediated pericyte support",
      "label": "disrupts"
    },
    {
      "source": "SU11248",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "SU11248",
      "target": "indolinones",
      "label": "is a type of"
    },
    {
      "source": "metronomic chemotherapy",
      "target": "late-stage disease",
      "label": "does not show benefit against"
    },
    {
      "source": "metronomic chemotherapy",
      "target": "sensitized endothelial cells",
      "label": "targets"
    },
    {
      "source": "metronomic chemotherapy",
      "target": "early-stage disease",
      "label": "shows benefit against"
    },
    {
      "source": "metronomic chemotherapy",
      "target": "ongoing angiogenesis",
      "label": "inhibits"
    },
    {
      "source": "metronomic chemotherapy",
      "target": "pre-existing tumor vasculature",
      "label": "destabilizes"
    },
    {
      "source": "metronomic chemotherapy",
      "target": "stable disease",
      "label": "produced"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "complete responses",
      "label": "gave"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "endothelial cell apoptosis",
      "label": "increased"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "multitargeted inhibition",
      "label": "involves"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "survival advantage",
      "label": "gave"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "sequential MTD",
      "label": "involves"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "metronomic chemotherapy",
      "label": "involves"
    },
    {
      "source": "\"chemo-switch\" protocol",
      "target": "model",
      "label": "used in"
    },
    {
      "source": "imatinib",
      "target": "maximum-tolerated dose (MTD)",
      "label": "used in concert with"
    },
    {
      "source": "imatinib",
      "target": "VEGFR inhibition",
      "label": "enhanced efficacy in combination with"
    },
    {
      "source": "imatinib",
      "target": "pericyte coverage",
      "label": "reduced"
    },
    {
      "source": "imatinib",
      "target": "metronomic chemotherapy",
      "label": "used in concert with"
    },
    {
      "source": "imatinib",
      "target": "PDGFR-mediated pericyte support",
      "label": "disrupts"
    },
    {
      "source": "imatinib",
      "target": "efficacy",
      "label": "enhanced"
    },
    {
      "source": "imatinib",
      "target": "Dose-dependent decreases",
      "label": "caused"
    },
    {
      "source": "imatinib",
      "target": "RET Y1062 phosphorylation",
      "label": "inhibited"
    },
    {
      "source": "imatinib",
      "target": "gastrointestinal stromal tumors",
      "label": "treats"
    },
    {
      "source": "imatinib",
      "target": "RET-mediated MTC cell growth",
      "label": "inhibits"
    },
    {
      "source": "imatinib",
      "target": "nonapoptotic cell death",
      "label": "induced"
    },
    {
      "source": "imatinib",
      "target": "tyrosine kinase inhibitor",
      "label": "is_a"
    },
    {
      "source": "imatinib",
      "target": "chronic myelogenous leukemia",
      "label": "treats"
    },
    {
      "source": "imatinib",
      "target": "drug",
      "label": "is_a_potential"
    },
    {
      "source": "imatinib",
      "target": "protein expression levels",
      "label": "affected"
    },
    {
      "source": "imatinib",
      "target": "apoptotic cell death",
      "label": "induced"
    },
    {
      "source": "imatinib",
      "target": "medullary thyroid cancer cells",
      "label": "has_cellular_effects_on"
    },
    {
      "source": "imatinib",
      "target": "imatinib-induced cell-cycle arrest",
      "label": "induced"
    },
    {
      "source": "imatinib",
      "target": "RET protein levels",
      "label": "affects"
    },
    {
      "source": "imatinib",
      "target": "oocytes",
      "label": "protects"
    },
    {
      "source": "imatinib",
      "target": "cisplatin-induced oocyte death",
      "label": "protects from"
    },
    {
      "source": "imatinib",
      "target": "cisplatin-induced apoptosis",
      "label": "inhibits"
    },
    {
      "source": "imatinib",
      "target": "cisplatin-induced DNA damage",
      "label": "does not block"
    },
    {
      "source": "imatinib",
      "target": "c-Abl kinase",
      "label": "inhibits"
    },
    {
      "source": "imatinib",
      "target": "damage response",
      "label": "does not block"
    },
    {
      "source": "imatinib",
      "target": "oocyte cell death",
      "label": "abrogates"
    },
    {
      "source": "imatinib",
      "target": "fertoprotective drug",
      "label": "is a"
    },
    {
      "source": "imatinib",
      "target": "nuclear accumulation",
      "label": "inhibited"
    },
    {
      "source": "imatinib",
      "target": "endocrine function",
      "label": "conserves"
    },
    {
      "source": "imatinib",
      "target": "c-Abl kinase inhibitor",
      "label": "is a type of"
    },
    {
      "source": "imatinib",
      "target": "upregulation",
      "label": "inhibited"
    },
    {
      "source": "imatinib",
      "target": "downregulation",
      "label": "inhibited"
    },
    {
      "source": "multitargeted, metronomic, and maximum-tolerated dose \"chemo-switch\" regimen",
      "target": "objective responses",
      "label": "produces"
    },
    {
      "source": "multitargeted, metronomic, and maximum-tolerated dose \"chemo-switch\" regimen",
      "target": "survival benefit",
      "label": "produces"
    },
    {
      "source": "kinase inhibitors",
      "target": "platelet-derived growth factor receptors",
      "label": "target"
    },
    {
      "source": "kinase inhibitors",
      "target": "PDGFRs",
      "label": "target"
    },
    {
      "source": "pericyte coverage",
      "target": "tumor vessels",
      "label": "is of"
    },
    {
      "source": "VEGFR inhibitors",
      "target": "early-stage disease",
      "label": "show benefit against"
    },
    {
      "source": "VEGFR inhibitors",
      "target": "ongoing angiogenesis",
      "label": "inhibit"
    },
    {
      "source": "VEGFR inhibitors",
      "target": "sensitized endothelial cells",
      "label": "target"
    },
    {
      "source": "VEGFR inhibitors",
      "target": "late-stage disease",
      "label": "do not show benefit against"
    },
    {
      "source": "VEGFR inhibitors",
      "target": "pre-existing tumor vasculature",
      "label": "destabilize"
    },
    {
      "source": "endothelial cell apoptosis",
      "target": "efficacy",
      "label": "is concordant with"
    },
    {
      "source": "tractable clinical strategy",
      "target": "standard-of-care chemotherapy",
      "label": "involves"
    },
    {
      "source": "tractable clinical strategy",
      "target": "stringent preclinical model",
      "label": "demonstrated in"
    },
    {
      "source": "standard-of-care chemotherapy",
      "target": "novel maintenance regimen",
      "label": "is followed by"
    },
    {
      "source": "angiogenic switch",
      "target": "multistep tumorigenesis",
      "label": "occurs during"
    },
    {
      "source": "multistep tumorigenesis",
      "target": "pancreatic islets",
      "label": "is of"
    },
    {
      "source": "parameters",
      "target": "angiogenic switch",
      "label": "are of"
    },
    {
      "source": "parameters",
      "target": "control",
      "label": "to"
    },
    {
      "source": "parameters",
      "target": "K(10)",
      "label": "include"
    },
    {
      "source": "parameters",
      "target": "IPC group",
      "label": "exhibited tendency for"
    },
    {
      "source": "parameters",
      "target": "MRT",
      "label": "include"
    },
    {
      "source": "parameters",
      "target": "AUC",
      "label": "include"
    },
    {
      "source": "parameters",
      "target": "t(1/2\u03b2)",
      "label": "include"
    },
    {
      "source": "parameters",
      "target": "CLs",
      "label": "include"
    },
    {
      "source": "parameters",
      "target": "IR group",
      "label": "exhibited tendency for"
    },
    {
      "source": "parameters",
      "target": "exploration",
      "label": "quantify"
    },
    {
      "source": "multitargeted inhibition",
      "target": "VEGFR",
      "label": "inhibits"
    },
    {
      "source": "multitargeted inhibition",
      "target": "PDGFR",
      "label": "inhibits"
    },
    {
      "source": "MTD regimen",
      "target": "transitory regression",
      "label": "caused"
    },
    {
      "source": "MTD regimen",
      "target": "apoptosis",
      "label": "elicited"
    },
    {
      "source": "MTD regimen",
      "target": "endothelial cells",
      "label": "did not elicit apoptosis in"
    },
    {
      "source": "MTD regimen",
      "target": "rapid regrowth",
      "label": "caused"
    },
    {
      "source": "receptor tyrosine kinase inhibitors",
      "target": "PDGFR-mediated pericyte support",
      "label": "disrupt"
    },
    {
      "source": "PDGFR-mediated pericyte support",
      "target": "tumor endothelial cells",
      "label": "supports"
    },
    {
      "source": "VEGFR",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "VEGFR",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "VEGFR",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "VEGFR",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "PDFGR",
      "target": "pericyte support",
      "label": "is targeted to disrupt"
    },
    {
      "source": "Pericytes",
      "target": "tumor neovasculature",
      "label": "are important for"
    },
    {
      "source": "stable disease",
      "target": "SD",
      "label": "is"
    },
    {
      "source": "stable disease",
      "target": "6 months",
      "label": "lasted for"
    },
    {
      "source": "average helical displacement",
      "target": "dopamine",
      "label": "is less for atypical than for"
    },
    {
      "source": "average helical displacement",
      "target": "atypical",
      "label": "is less for typical than for"
    },
    {
      "source": "average helical displacement",
      "target": "typical",
      "label": "increased for"
    },
    {
      "source": "halogen atom",
      "target": "ring system",
      "label": "part of"
    },
    {
      "source": "atypical",
      "target": "larger displacements",
      "label": "induced"
    },
    {
      "source": "atypical",
      "target": "typical",
      "label": "induced larger displacements into TMH5 than"
    },
    {
      "source": "typical antipsychotics",
      "target": "loxapine",
      "label": "include"
    },
    {
      "source": "typical antipsychotics",
      "target": "haloperidol",
      "label": "include"
    },
    {
      "source": "larger displacements",
      "target": "TMH5",
      "label": "into"
    },
    {
      "source": "receptor interactions",
      "target": "atypical antipsychotics",
      "label": "involve"
    },
    {
      "source": "receptor interactions",
      "target": "typical antipsychotics",
      "label": "involve"
    },
    {
      "source": "receptor interactions",
      "target": "dopamine",
      "label": "involve"
    },
    {
      "source": "atypical antipsychotics",
      "target": "clozapine",
      "label": "include"
    },
    {
      "source": "atypical antipsychotics",
      "target": "melperone",
      "label": "include"
    },
    {
      "source": "atypical antipsychotics",
      "target": "TMHs 3",
      "label": "interacted in direction of"
    },
    {
      "source": "atypical antipsychotics",
      "target": "TMHs 2",
      "label": "interacted in direction of"
    },
    {
      "source": "atypical antipsychotics",
      "target": "TMHs 7",
      "label": "interacted in direction of"
    },
    {
      "source": "atypical antipsychotics",
      "target": "halogen atom",
      "label": "interacted with"
    },
    {
      "source": "corresponding halogen atom",
      "target": "TMH5",
      "label": "in direction of"
    },
    {
      "source": "typical",
      "target": "corresponding halogen atom",
      "label": "had"
    },
    {
      "source": "typical",
      "target": "stronger non-bonded interactions",
      "label": "had"
    },
    {
      "source": "typical",
      "target": "atypical",
      "label": "had stronger non-bonded interactions with receptor than"
    },
    {
      "source": "stronger non-bonded interactions",
      "target": "experimental observation",
      "label": "in agreement with"
    },
    {
      "source": "stronger non-bonded interactions",
      "target": "receptor",
      "label": "with"
    },
    {
      "source": "Molecular dynamics simulations",
      "target": "average helical displacement",
      "label": "indicated"
    },
    {
      "source": "model of the dopamine D2 receptor",
      "target": "receptor interactions",
      "label": "used to study"
    },
    {
      "source": "atypical antipsychotic drugs",
      "target": "receptor",
      "label": "dissociate faster from"
    },
    {
      "source": "atypical antipsychotic drugs",
      "target": "typical antipsychotic drugs",
      "label": "dissociate faster from receptor than"
    },
    {
      "source": "Atypical and typical antipsychotic drug interactions",
      "target": "dopamine D2 receptor",
      "label": "interact with"
    },
    {
      "source": "bupropion",
      "target": "antidepressant effect",
      "label": "has"
    },
    {
      "source": "bupropion",
      "target": "DAT",
      "label": "affects"
    },
    {
      "source": "bupropion",
      "target": "depression",
      "label": "is used in"
    },
    {
      "source": "bupropion",
      "target": "dopamine transporter",
      "label": "is a blocker of"
    },
    {
      "source": "bupropion",
      "target": "dopamine transporter activity",
      "label": "affects"
    },
    {
      "source": "bupropion",
      "target": "osmotic minipump",
      "label": "administered via"
    },
    {
      "source": "bupropion",
      "target": "spontaneous locomotor activity",
      "label": "increased"
    },
    {
      "source": "bupropion",
      "target": "basal spontaneous locomotor activity",
      "label": "increased"
    },
    {
      "source": "bupropion",
      "target": "norepinephrine transporter knockout mice",
      "label": "administered to"
    },
    {
      "source": "bupropion",
      "target": "norepinephrine transporter",
      "label": "is a blocker of"
    },
    {
      "source": "bupropion",
      "target": "control mice",
      "label": "administered to"
    },
    {
      "source": "99mTc-TRODAT-SPECT",
      "target": "baseline DAT activity",
      "label": "measured"
    },
    {
      "source": "baseline DAT activity",
      "target": "depressed patients",
      "label": "is of"
    },
    {
      "source": "average occupancy of bupropion",
      "target": "international findings",
      "label": "is similar to"
    },
    {
      "source": "average occupancy of bupropion",
      "target": "DAT",
      "label": "is on"
    },
    {
      "source": "average occupancy of bupropion",
      "target": "9 depressed patients",
      "label": "measured in"
    },
    {
      "source": "depression",
      "target": "levels",
      "label": "of"
    },
    {
      "source": "3 weeks' bupropion treatment",
      "target": "change in DAT activity",
      "label": "resulted in"
    },
    {
      "source": "change in DAT activity",
      "target": "occupancy of bupropion",
      "label": "corresponds to"
    },
    {
      "source": "liver glycogen contents",
      "target": "normoglycemic stressed animals",
      "label": "measured in"
    },
    {
      "source": "bosentan",
      "target": "insulin levels",
      "label": "studied for effect on"
    },
    {
      "source": "bosentan",
      "target": "mild diabetic rats",
      "label": "studied for effect on serum glucose in"
    },
    {
      "source": "bosentan",
      "target": "serum glucose",
      "label": "studied for effect on"
    },
    {
      "source": "bosentan",
      "target": "ETB receptor",
      "label": "is antagonist of"
    },
    {
      "source": "bosentan",
      "target": "endothelin receptor antagonist",
      "label": "is"
    },
    {
      "source": "bosentan",
      "target": "severely diabetic rats",
      "label": "studied for effect on serum glucose in"
    },
    {
      "source": "bosentan",
      "target": "insulin-induced hypoglycemia",
      "label": "studied for effect on"
    },
    {
      "source": "bosentan",
      "target": "stress-induced hyperglycemia",
      "label": "partially prevented"
    },
    {
      "source": "bosentan",
      "target": "liver glycogen contents",
      "label": "studied for effect on"
    },
    {
      "source": "bosentan",
      "target": "hypoglycemic action of insulin",
      "label": "potentiated"
    },
    {
      "source": "bosentan",
      "target": "glycogen content",
      "label": "partially prevented decrease of"
    },
    {
      "source": "bosentan",
      "target": "ETA receptor",
      "label": "is antagonist of"
    },
    {
      "source": "bosentan",
      "target": "insulin secretion",
      "label": "has no effect on"
    },
    {
      "source": "bosentan",
      "target": "metabolic changes",
      "label": "has effect on"
    },
    {
      "source": "insulin levels",
      "target": "normoglycemic stressed animals",
      "label": "measured in"
    },
    {
      "source": "serum glucose",
      "target": "mild diabetic rats",
      "label": "measured in"
    },
    {
      "source": "serum glucose",
      "target": "normoglycemic stressed animals",
      "label": "measured in"
    },
    {
      "source": "intraperitoneal injection",
      "target": "streptozotocin",
      "label": "uses"
    },
    {
      "source": "streptozotocin",
      "target": "diabetes mellitus",
      "label": "induces"
    },
    {
      "source": "streptozotocin",
      "target": "STZ",
      "label": "is"
    },
    {
      "source": "streptozotocin",
      "target": "diabetic rat",
      "label": "induces"
    },
    {
      "source": "streptozotocin",
      "target": "diabetic rats",
      "label": "induces"
    },
    {
      "source": "streptozotocin",
      "target": "Type 2 diabetes",
      "label": "induced"
    },
    {
      "source": "stress-induced hyperglycemia",
      "target": "normoglycemic stressed animals",
      "label": "occurs in"
    },
    {
      "source": "metabolic changes",
      "target": "stress",
      "label": "occur during"
    },
    {
      "source": "metabolic changes",
      "target": "diabetes",
      "label": "occur during"
    },
    {
      "source": "stress",
      "target": "glycogen content",
      "label": "causes decrease of"
    },
    {
      "source": "stress",
      "target": "insulin levels",
      "label": "causes decrease of"
    },
    {
      "source": "stress",
      "target": "stress-induced hyperglycemia",
      "label": "causes"
    },
    {
      "source": "glycogen content",
      "target": "normoglycemic stressed animals",
      "label": "decreased in"
    },
    {
      "source": "glycogen content",
      "target": "liver",
      "label": "decreased in"
    },
    {
      "source": "glycogen content",
      "target": "diabetic rats",
      "label": "decreased in"
    },
    {
      "source": "Restraining water immersion stress",
      "target": "severe stress",
      "label": "is a model for"
    },
    {
      "source": "severe stress",
      "target": "plasma ET-1 levels",
      "label": "elevates"
    },
    {
      "source": "plasma ET-1 levels",
      "target": "diabetes",
      "label": "are elevated in"
    },
    {
      "source": "plasma ET-1 levels",
      "target": "stress",
      "label": "are elevated in"
    },
    {
      "source": "Mild diabetes",
      "target": "intraperitoneal injection",
      "label": "induced by"
    },
    {
      "source": "Mild diabetes",
      "target": "rats",
      "label": "induced in"
    },
    {
      "source": "insulin secretion",
      "target": "mild diabetic rats",
      "label": "measured in"
    },
    {
      "source": "insulin secretion",
      "target": "oral glucose stimulation",
      "label": "is in response to"
    },
    {
      "source": "insulin secretion",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "insulin secretion",
      "target": "glucose intolerance",
      "label": "leads to"
    },
    {
      "source": "ET-1",
      "target": "insulin resistance",
      "label": "causes"
    },
    {
      "source": "ET-1",
      "target": "liver glycogenolysis",
      "label": "stimulates"
    },
    {
      "source": "insulin resistance",
      "target": "DIO mice",
      "label": "occurs in"
    },
    {
      "source": "insulin resistance",
      "target": "male mice",
      "label": "LocatedIn"
    },
    {
      "source": "RTKs",
      "target": "PDGFbeta-receptor",
      "label": "include"
    },
    {
      "source": "RTKs",
      "target": "c-Kit",
      "label": "include"
    },
    {
      "source": "Transforming versions of Flt3",
      "target": "gene expression",
      "label": "results in"
    },
    {
      "source": "Transforming versions of Flt3",
      "target": "STAT5",
      "label": "activates"
    },
    {
      "source": "Transforming versions of Flt3",
      "target": "signaling",
      "label": "exhibit altered"
    },
    {
      "source": "Transforming versions of Flt3",
      "target": "cell transformation",
      "label": "results in"
    },
    {
      "source": "gene expression",
      "target": "D5D",
      "label": "of"
    },
    {
      "source": "gene expression",
      "target": "delta-5 and delta-6 desaturases",
      "label": "of"
    },
    {
      "source": "gene expression",
      "target": "D6D",
      "label": "of"
    },
    {
      "source": "gene expression",
      "target": "delta-5 desaturase",
      "label": "of"
    },
    {
      "source": "gene expression",
      "target": "delta-6 desaturase",
      "label": "of"
    },
    {
      "source": "gene expression",
      "target": "7 days",
      "label": "normalized by"
    },
    {
      "source": "gene expression",
      "target": "control animals",
      "label": "was undistinguishable from"
    },
    {
      "source": "gene expression",
      "target": "diverse range of genes",
      "label": "controls"
    },
    {
      "source": "gene expression",
      "target": "rat liver",
      "label": "occurs in"
    },
    {
      "source": "gene expression",
      "target": "chronic poisoning",
      "label": "occurs under"
    },
    {
      "source": "SU5416",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "SU5416",
      "target": "indolinones",
      "label": "is a type of"
    },
    {
      "source": "hematopoietic class III receptor tyrosine kinase (RTK) Flt3",
      "target": "Flk2",
      "label": "is also known as"
    },
    {
      "source": "hematopoietic class III receptor tyrosine kinase (RTK) Flt3",
      "target": "drug target",
      "label": "is a potential"
    },
    {
      "source": "hematopoietic class III receptor tyrosine kinase (RTK) Flt3",
      "target": "STK1",
      "label": "is also known as"
    },
    {
      "source": "Flt3",
      "target": "STI571",
      "label": "is resistant to"
    },
    {
      "source": "Flt3",
      "target": "Imatinib",
      "label": "is resistant to"
    },
    {
      "source": "Flt3",
      "target": "apoptosis",
      "label": "plays a role in resistance to"
    },
    {
      "source": "Flt3",
      "target": "class III RTKs",
      "label": "is homologous to"
    },
    {
      "source": "Flt3",
      "target": "acute myeloid leukemia (AML)",
      "label": "is involved in"
    },
    {
      "source": "Flt3",
      "target": "leukemic blasts",
      "label": "affects"
    },
    {
      "source": "Flt3",
      "target": "differentiation",
      "label": "plays a role in prevention of"
    },
    {
      "source": "Flt3",
      "target": "proliferation",
      "label": "plays a role in"
    },
    {
      "source": "Flt3",
      "target": "Gleevec",
      "label": "is resistant to"
    },
    {
      "source": "Flt3",
      "target": "phenylaminopyrimidine",
      "label": "is resistant to"
    },
    {
      "source": "Flt3",
      "target": "RAS/MAP-Kinase",
      "label": "activates"
    },
    {
      "source": "Flt3",
      "target": "phosphoinositide-3-kinase/Akt signaling cascades",
      "label": "activates"
    },
    {
      "source": "STI571",
      "target": "RTKs",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "bis(1H-2-indolyl)-1-methanone",
      "target": "Compounds",
      "label": "is a type of"
    },
    {
      "source": "bis(1H-2-indolyl)-1-methanone",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "Compounds",
      "target": "wildtype Flt3",
      "label": "exhibit selectivity for"
    },
    {
      "source": "Compounds",
      "target": "novel drugs",
      "label": "are potential"
    },
    {
      "source": "Compounds",
      "target": "probes",
      "label": "are potential"
    },
    {
      "source": "Compounds",
      "target": "kinases",
      "label": "exhibit selectivity for"
    },
    {
      "source": "Compounds",
      "target": "Flt3 kinase",
      "label": "are potent inhibitors of"
    },
    {
      "source": "Compounds",
      "target": "activated versions",
      "label": "exhibit selectivity for"
    },
    {
      "source": "Compounds",
      "target": "therapeutic potential",
      "label": "establish"
    },
    {
      "source": "Compounds",
      "target": "clinical trials",
      "label": "advancing in"
    },
    {
      "source": "indolinones",
      "target": "Compounds",
      "label": "are a type of"
    },
    {
      "source": "indolinones",
      "target": "Flt3 kinase",
      "label": "are potent inhibitors of"
    },
    {
      "source": "indolocarbazoles",
      "target": "Flt3 kinase",
      "label": "are potent inhibitors of"
    },
    {
      "source": "indolocarbazoles",
      "target": "Compounds",
      "label": "are a type of"
    },
    {
      "source": "Flt3-ITD",
      "target": "mutations",
      "label": "is a type of"
    },
    {
      "source": "Flt3-ITD",
      "target": "prognosis",
      "label": "is associated with unfavorable"
    },
    {
      "source": "Imatinib",
      "target": "RTKs",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "PKC412",
      "target": "indolocarbazoles",
      "label": "is a type of"
    },
    {
      "source": "PKC412",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "piperazonyl quinazoline",
      "target": "Compounds",
      "label": "is a type of"
    },
    {
      "source": "piperazonyl quinazoline",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "Flt3 receptor tyrosine kinase",
      "target": "leukemia",
      "label": "is a drug target in"
    },
    {
      "source": "Flt3 receptor tyrosine kinase",
      "target": "drug target",
      "label": "is a"
    },
    {
      "source": "leukemia",
      "target": "children",
      "label": "occurs in"
    },
    {
      "source": "novel drugs",
      "target": "acute myeloid leukemia (AML)",
      "label": "are against"
    },
    {
      "source": "quinoxaline",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "quinoxaline",
      "target": "Compounds",
      "label": "is a type of"
    },
    {
      "source": "activation mechanisms",
      "target": "class III RTK family",
      "label": "are in"
    },
    {
      "source": "drug target",
      "target": "malignancies",
      "label": "against"
    },
    {
      "source": "prognosis",
      "target": "NSCLC",
      "label": "is of"
    },
    {
      "source": "D-65476",
      "target": "bis(1H-2-indolyl)-1-methanone",
      "label": "is a type of"
    },
    {
      "source": "D-65476",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "probes",
      "target": "signaling pathways",
      "label": "are for understanding"
    },
    {
      "source": "probes",
      "target": "activation mechanisms",
      "label": "are for understanding"
    },
    {
      "source": "Flt3 mutant",
      "target": "STI571",
      "label": "is sensitive to"
    },
    {
      "source": "Gleevec",
      "target": "RTKs",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "AG1296",
      "target": "quinoxaline",
      "label": "is a type of"
    },
    {
      "source": "AG1296",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "ATP binding center",
      "target": "ATP",
      "label": "binds"
    },
    {
      "source": "ATP",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "ATP",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "ATP",
      "target": "cellular AMP:ATP ratio",
      "label": "is part of"
    },
    {
      "source": "ATP",
      "target": "ATP-Induced Isomerization",
      "label": "induces"
    },
    {
      "source": "phosphoinositide-3-kinase/Akt signaling cascades",
      "target": "phosphoinositide-3-kinase",
      "label": "includes"
    },
    {
      "source": "phosphoinositide-3-kinase/Akt signaling cascades",
      "target": "Akt",
      "label": "includes"
    },
    {
      "source": "phenylalanine 691 side-chain",
      "target": "Flt3",
      "label": "prevents binding of STI571 to"
    },
    {
      "source": "phenylalanine 691 side-chain",
      "target": "ATP binding center",
      "label": "is in"
    },
    {
      "source": "internal tandem duplication",
      "target": "Flt3 juxtamembrane domain",
      "label": "occurs in"
    },
    {
      "source": "internal tandem duplication",
      "target": "mutations",
      "label": "is a type of"
    },
    {
      "source": "signaling pathways",
      "target": "class III RTK family",
      "label": "are in"
    },
    {
      "source": "signaling pathways",
      "target": "cell turnover",
      "label": "regulate"
    },
    {
      "source": "signaling pathways",
      "target": "differentiation",
      "label": "regulate"
    },
    {
      "source": "CT53518",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "CT53518",
      "target": "piperazonyl quinazoline",
      "label": "is a type of"
    },
    {
      "source": "CEP-701",
      "target": "indolocarbazoles",
      "label": "is a type of"
    },
    {
      "source": "CEP-701",
      "target": "Flt3 kinase",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "phenylaminopyrimidine",
      "target": "RTKs",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "Signal transduction",
      "target": "Flt3",
      "label": "is of"
    },
    {
      "source": "perturbations",
      "target": "electron transport chain enzyme activity",
      "label": "include"
    },
    {
      "source": "perturbations",
      "target": "PC",
      "label": "include"
    },
    {
      "source": "perturbations",
      "target": "O2-",
      "label": "include"
    },
    {
      "source": "perturbations",
      "target": "TBARS",
      "label": "include"
    },
    {
      "source": "TBARS",
      "target": "thiobarbituric acid",
      "label": "reacts with"
    },
    {
      "source": "TBARS",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "GSSG",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "GSH",
      "target": "complex II/III",
      "label": "Upregulator"
    },
    {
      "source": "GSH",
      "target": "complex I/III",
      "label": "Upregulator"
    },
    {
      "source": "GSH",
      "target": "complex I",
      "label": "Upregulator"
    },
    {
      "source": "GSH",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "GSH",
      "target": "complex I activity",
      "label": "is not critical for maintaining"
    },
    {
      "source": "GSH",
      "target": "cells",
      "label": "provides defense for"
    },
    {
      "source": "GSH",
      "target": "intracellular redox environment",
      "label": "regulates"
    },
    {
      "source": "GSH",
      "target": "stomach tissues",
      "label": "OBSERVED_IN"
    },
    {
      "source": "GSH",
      "target": "Enzyme activities",
      "label": "IS_A_TYPE_OF"
    },
    {
      "source": "GSH",
      "target": "colorimetric methods",
      "label": "DETERMINED_BY"
    },
    {
      "source": "GSH",
      "target": "liver samples",
      "label": "DETERMINED_IN"
    },
    {
      "source": "GSH",
      "target": "liver markers",
      "label": "IS_A"
    },
    {
      "source": "complex II/III",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "PC",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "PC",
      "target": "target lipids",
      "label": "is a type of"
    },
    {
      "source": "PC",
      "target": "membrane targeting",
      "label": "drives"
    },
    {
      "source": "RP-1",
      "target": "O2-",
      "label": "reduced"
    },
    {
      "source": "RP-1",
      "target": "radioprotection",
      "label": "provides"
    },
    {
      "source": "RP-1",
      "target": "radiation damage",
      "label": "protects against"
    },
    {
      "source": "RP-1",
      "target": "TBARS",
      "label": "reduced"
    },
    {
      "source": "RP-1",
      "target": "mitochondrial system",
      "label": "protects"
    },
    {
      "source": "RP-1",
      "target": "GSH",
      "label": "enhanced"
    },
    {
      "source": "RP-1",
      "target": "perturbations",
      "label": "modulates"
    },
    {
      "source": "RP-1",
      "target": "biochemical milieu",
      "label": "modulates"
    },
    {
      "source": "RP-1",
      "target": "PC",
      "label": "reduced"
    },
    {
      "source": "RP-1",
      "target": "mechanism",
      "label": "has"
    },
    {
      "source": "RP-1",
      "target": "glutathione",
      "label": "increased"
    },
    {
      "source": "RP-1",
      "target": "mechanism of action",
      "label": "has"
    },
    {
      "source": "RP-1",
      "target": "MMP",
      "label": "inhibited decrease of"
    },
    {
      "source": "O2-",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "radioprotection",
      "target": "mitochondrial system",
      "label": "targets"
    },
    {
      "source": "radiation damage",
      "target": "mitochondrial system",
      "label": "affects"
    },
    {
      "source": "Podophyllum hexandrum",
      "target": "radiation damage",
      "label": "modifies"
    },
    {
      "source": "Podophyllum hexandrum",
      "target": "radioprotection",
      "label": "provides"
    },
    {
      "source": "Whole body y-irradiation",
      "target": "O2-",
      "label": "increased"
    },
    {
      "source": "Whole body y-irradiation",
      "target": "TBARS",
      "label": "increased"
    },
    {
      "source": "Whole body y-irradiation",
      "target": "PC",
      "label": "increased"
    },
    {
      "source": "radiation",
      "target": "O2-",
      "label": "induced"
    },
    {
      "source": "radiation",
      "target": "TBARS",
      "label": "induced"
    },
    {
      "source": "radiation",
      "target": "MMP",
      "label": "decreased"
    },
    {
      "source": "radiation",
      "target": "PC",
      "label": "induced"
    },
    {
      "source": "radiation",
      "target": "perturbations",
      "label": "induced"
    },
    {
      "source": "thiobarbituric acid reactive substance",
      "target": "TBARS",
      "label": "is"
    },
    {
      "source": "complex-I",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "complex I/II",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "succinate-cytochrome c oxidoreductase",
      "target": "complex II/III",
      "label": "is"
    },
    {
      "source": "glutathione",
      "target": "GSH",
      "label": "is"
    },
    {
      "source": "glutathione",
      "target": "GSSG",
      "label": "is"
    },
    {
      "source": "glutathione",
      "target": "whole brain homogenate",
      "label": "found in"
    },
    {
      "source": "glutathione",
      "target": "thiolate anion",
      "label": "provides"
    },
    {
      "source": "glutathione",
      "target": "U-shaped conformation",
      "label": "resides in a"
    },
    {
      "source": "glutathione",
      "target": "mitochondrial function",
      "label": "maintains"
    },
    {
      "source": "glutathione",
      "target": "non-protein thiol",
      "label": "is a"
    },
    {
      "source": "glutathione",
      "target": "antioxidant",
      "label": "is an"
    },
    {
      "source": "glutathione",
      "target": "thymine base lesions",
      "label": "attenuates"
    },
    {
      "source": "glutathione",
      "target": "stomach tissues",
      "label": "DETERMINED_IN"
    },
    {
      "source": "NADH-ubiquinone oxidoreductase",
      "target": "complex-I",
      "label": "is"
    },
    {
      "source": "superoxide anion",
      "target": "O2-",
      "label": "is"
    },
    {
      "source": "MMP",
      "target": "mitochondria",
      "label": "measured in"
    },
    {
      "source": "irradiation",
      "target": "glutathione",
      "label": "increased"
    },
    {
      "source": "NADH-cytochrome c oxidoreductase",
      "target": "complex I/II",
      "label": "is"
    },
    {
      "source": "protein carbonyl",
      "target": "PC",
      "label": "is"
    },
    {
      "source": "serious adverse events",
      "target": "treatment",
      "label": "related to"
    },
    {
      "source": "common adverse events",
      "target": "doses ranging from 0.02 to 0.2 microg/kg",
      "label": "occurred at"
    },
    {
      "source": "common adverse events",
      "target": "severity",
      "label": "had"
    },
    {
      "source": "study drug",
      "target": "meal and acetaminophen (part 2)",
      "label": "injected before"
    },
    {
      "source": "study drug",
      "target": "meal (part 1)",
      "label": "injected before"
    },
    {
      "source": "study drug",
      "target": "overnight fast",
      "label": "injected after"
    },
    {
      "source": "0.2-microg/kg exenatide",
      "target": "meal",
      "label": "administered before"
    },
    {
      "source": "0.2-microg/kg exenatide",
      "target": "days 1, 3, 5, 7, and 9",
      "label": "administered on"
    },
    {
      "source": "meal",
      "target": "liquid acetaminophen",
      "label": "combined with"
    },
    {
      "source": "exenatide",
      "target": "postprandial plasma glucagon",
      "label": "suppressed"
    },
    {
      "source": "exenatide",
      "target": "postprandial plasma glucose excursion",
      "label": "reduced"
    },
    {
      "source": "exenatide",
      "target": "patients",
      "label": "studied in"
    },
    {
      "source": "exenatide",
      "target": "doses ranging from 0.02 to 0.2 microg/kg",
      "label": "reduced at"
    },
    {
      "source": "exenatide",
      "target": "gastric emptying",
      "label": "reduced by slowing of"
    },
    {
      "source": "exenatide",
      "target": "suppression of plasma glucagon",
      "label": "reduced by"
    },
    {
      "source": "exenatide",
      "target": "insulinotropism",
      "label": "reduced by"
    },
    {
      "source": "eight subjects",
      "target": "0.3-microg/kg exenatide",
      "label": "received"
    },
    {
      "source": "eight subjects",
      "target": "0.2-microg/kg exenatide",
      "label": "received"
    },
    {
      "source": "eight subjects",
      "target": "0.4-microg/kg exenatide",
      "label": "received"
    },
    {
      "source": "eight subjects",
      "target": "0.1-microg/kg exenatide",
      "label": "received"
    },
    {
      "source": "eight subjects",
      "target": "placebo",
      "label": "received"
    },
    {
      "source": "0.3-microg/kg exenatide",
      "target": "meal",
      "label": "administered before"
    },
    {
      "source": "0.3-microg/kg exenatide",
      "target": "days 1, 3, 5, 7, and 9",
      "label": "administered on"
    },
    {
      "source": "0.1-microg/kg exenatide",
      "target": "days 1, 3, 5, 7, and 9",
      "label": "administered on"
    },
    {
      "source": "0.1-microg/kg exenatide",
      "target": "meal",
      "label": "administered before"
    },
    {
      "source": "study B",
      "target": "patients",
      "label": "involved"
    },
    {
      "source": "0.05-microg/kg doses",
      "target": "part 2",
      "label": "given in"
    },
    {
      "source": "Parts 1 and 2 of study B",
      "target": "six and eight patients",
      "label": "enrolled"
    },
    {
      "source": "0.02-microg/kg doses",
      "target": "part 2",
      "label": "given in"
    },
    {
      "source": "Administration",
      "target": "dose-proportional exenatide pharmacokinetics",
      "label": "resulted in"
    },
    {
      "source": "Administration",
      "target": "preprandial exenatide",
      "label": "of"
    },
    {
      "source": "Administration",
      "target": "antidiabetic pharmacodynamic activity",
      "label": "resulted in"
    },
    {
      "source": "Administration",
      "target": "s.c. injection",
      "label": "by"
    },
    {
      "source": "Pharmacokinetics",
      "target": "exenatide",
      "label": "studied for"
    },
    {
      "source": "Pharmacokinetics",
      "target": "[(14)C]anagliptin",
      "label": "of"
    },
    {
      "source": "Pharmacokinetics",
      "target": "humans",
      "label": "in"
    },
    {
      "source": "Exenatide doses of 0.02-0.2 microg/kg",
      "target": "postprandial glucose excursions",
      "label": "lowered"
    },
    {
      "source": "pharmacodynamics",
      "target": "exenatide",
      "label": "studied for"
    },
    {
      "source": "second study",
      "target": "study B",
      "label": "is also known as"
    },
    {
      "source": "single s.c. dose",
      "target": "exenatide",
      "label": "contained"
    },
    {
      "source": "single s.c. dose",
      "target": "consecutive days",
      "label": "administered on"
    },
    {
      "source": "single s.c. dose",
      "target": "placebo",
      "label": "contained"
    },
    {
      "source": "0.1-microg/kg doses",
      "target": "part 2",
      "label": "given in"
    },
    {
      "source": "patient withdrawals",
      "target": "treatment",
      "label": "related to"
    },
    {
      "source": "0.4-microg/kg exenatide",
      "target": "meal",
      "label": "administered before"
    },
    {
      "source": "0.4-microg/kg exenatide",
      "target": "days 1, 3, 5, 7, and 9",
      "label": "administered on"
    },
    {
      "source": "study A",
      "target": "eight subjects",
      "label": "involved"
    },
    {
      "source": "plasma exenatide pharmacokinetic profiles",
      "target": "dose proportional",
      "label": "appeared"
    },
    {
      "source": "Nausea",
      "target": "common adverse events",
      "label": "is a type of"
    },
    {
      "source": "Nausea",
      "target": "Current agents",
      "label": "is not well controlled by"
    },
    {
      "source": "severity",
      "target": "histological evidence",
      "label": "determined by"
    },
    {
      "source": "severity",
      "target": "lung MPO activity",
      "label": "determined by"
    },
    {
      "source": "severity",
      "target": "pancreatic acinar cell injury/necrosis",
      "label": "determined by"
    },
    {
      "source": "severity",
      "target": "neutrophil sequestration",
      "label": "determined by"
    },
    {
      "source": "severity",
      "target": "lung injury",
      "label": "is of"
    },
    {
      "source": "severity",
      "target": "hyperamylasemia",
      "label": "determined by"
    },
    {
      "source": "severity",
      "target": "pancreatitis",
      "label": "is of"
    },
    {
      "source": "severity",
      "target": "caerulein-induced pancreatitis",
      "label": "is of"
    },
    {
      "source": "severity",
      "target": "diabetic condition",
      "label": "of the"
    },
    {
      "source": "first study",
      "target": "study A",
      "label": "is also known as"
    },
    {
      "source": "first study",
      "target": "study",
      "label": "is a"
    },
    {
      "source": "first study",
      "target": "midazolam pharmacokinetics",
      "label": "shows"
    },
    {
      "source": "Part 1 of study B",
      "target": "exenatide doses of 0.01 and 0.1 microg/ kg",
      "label": "used"
    },
    {
      "source": "vomiting",
      "target": "common adverse events",
      "label": "is a type of"
    },
    {
      "source": "safety",
      "target": "exenatide",
      "label": "studied for"
    },
    {
      "source": "safety",
      "target": "novel CCR5 antagonists",
      "label": "of"
    },
    {
      "source": "safety",
      "target": "combination therapy",
      "label": "of"
    },
    {
      "source": "liquid acetaminophen",
      "target": "rate of gastric emptying",
      "label": "used to assess"
    },
    {
      "source": "crystal structure",
      "target": "PSMA ectodomain",
      "label": "is of"
    },
    {
      "source": "crystal structure",
      "target": "prostate-specific membrane antigen",
      "label": "is of"
    },
    {
      "source": "crystal structure",
      "target": "HSA",
      "label": "is of"
    },
    {
      "source": "crystal structure",
      "target": "resolution",
      "label": "has"
    },
    {
      "source": "crystal structure",
      "target": "KIF4",
      "label": "of"
    },
    {
      "source": "crystal structure",
      "target": "systems",
      "label": "is unknown for"
    },
    {
      "source": "crystal structure",
      "target": "material",
      "label": "is of"
    },
    {
      "source": "PSMA ectodomain",
      "target": "homodimer",
      "label": "reveals a"
    },
    {
      "source": "PSMA structure",
      "target": "chemotherapeutics",
      "label": "facilitates development of"
    },
    {
      "source": "PSMA structure",
      "target": "docking studies",
      "label": "combined with"
    },
    {
      "source": "PSMA structure",
      "target": "agents",
      "label": "facilitates development of"
    },
    {
      "source": "PSMA structure",
      "target": "inhibitors",
      "label": "provides insight into"
    },
    {
      "source": "PSMA structure",
      "target": "natural substrate",
      "label": "provides insight into"
    },
    {
      "source": "PSMA structure",
      "target": "cancer-imaging agents",
      "label": "facilitates development of"
    },
    {
      "source": "PSMA structure",
      "target": "catalytic mechanism",
      "label": "combined with"
    },
    {
      "source": "PSMA",
      "target": "GCPII",
      "label": "acts as"
    },
    {
      "source": "PSMA",
      "target": "prostate cancer cells",
      "label": "is expressed in"
    },
    {
      "source": "PSMA",
      "target": "small molecule substrates",
      "label": "acts on"
    },
    {
      "source": "PSMA",
      "target": "glutamate carboxypeptidase",
      "label": "acts as"
    },
    {
      "source": "PSMA",
      "target": "nonprostatic solid tumor neovasculature",
      "label": "is expressed in"
    },
    {
      "source": "PSMA",
      "target": "target",
      "label": "is a"
    },
    {
      "source": "GCPII",
      "target": "small molecule substrates",
      "label": "acts on"
    },
    {
      "source": "docking studies",
      "target": "natural substrate",
      "label": "provides insight into"
    },
    {
      "source": "docking studies",
      "target": "inhibitors",
      "label": "provides insight into"
    },
    {
      "source": "folate",
      "target": "small molecule substrates",
      "label": "is a type of"
    },
    {
      "source": "protease domain",
      "target": "catalytic residues",
      "label": "contains"
    },
    {
      "source": "protease domain",
      "target": "substrate-binding arginine patch",
      "label": "contains"
    },
    {
      "source": "protease domain",
      "target": "PSMA",
      "label": "is part of"
    },
    {
      "source": "protease domain",
      "target": "binuclear zinc site",
      "label": "contains"
    },
    {
      "source": "transferrin",
      "target": "chronic predisposition",
      "label": "associated with"
    },
    {
      "source": "transferrin",
      "target": "proteins",
      "label": "is a"
    },
    {
      "source": "transferrin",
      "target": "urine",
      "label": "increased in"
    },
    {
      "source": "prostate-specific membrane antigen",
      "target": "tumor marker",
      "label": "is a"
    },
    {
      "source": "prostate-specific membrane antigen",
      "target": "PSMA",
      "label": "is also known as"
    },
    {
      "source": "prostate-specific membrane antigen",
      "target": "peptidase",
      "label": "is a"
    },
    {
      "source": "glutamate carboxypeptidase",
      "target": "small molecule substrates",
      "label": "acts on"
    },
    {
      "source": "glutamate carboxypeptidase",
      "target": "GCPII",
      "label": "is also known as"
    },
    {
      "source": "catalytic mechanism",
      "target": "inhibitors",
      "label": "provides insight into"
    },
    {
      "source": "catalytic mechanism",
      "target": "natural substrate",
      "label": "provides insight into"
    },
    {
      "source": "N-acetyl-l-aspartyl-l-glutamate",
      "target": "natural substrate",
      "label": "is a"
    },
    {
      "source": "N-acetyl-l-aspartyl-l-glutamate",
      "target": "neuropeptide",
      "label": "is a"
    },
    {
      "source": "N-acetyl-l-aspartyl-l-glutamate",
      "target": "small molecule substrates",
      "label": "is a type of"
    },
    {
      "source": "transferrin receptor",
      "target": "protease activity",
      "label": "lacks"
    },
    {
      "source": "transferrin receptor",
      "target": "receptor",
      "label": "is a"
    },
    {
      "source": "target",
      "target": "anticancer imaging",
      "label": "for"
    },
    {
      "source": "target",
      "target": "therapeutic agents",
      "label": "for"
    },
    {
      "source": "target",
      "target": "phage-display peptide library screening",
      "label": "for"
    },
    {
      "source": "target",
      "target": "cancer therapy",
      "label": "in"
    },
    {
      "source": "target",
      "target": "rat sympathetic neurons",
      "label": "studied in"
    },
    {
      "source": "target",
      "target": "therapeutic utility",
      "label": "contributes to"
    },
    {
      "source": "target",
      "target": "peri-somatic boutons",
      "label": "localised on"
    },
    {
      "source": "homodimer",
      "target": "transferrin receptor",
      "label": "has structural similarity to"
    },
    {
      "source": "iron",
      "target": "vitamin C oxidation",
      "label": "does not catalyze"
    },
    {
      "source": "iron",
      "target": "PHD activity",
      "label": "regulates"
    },
    {
      "source": "iron",
      "target": "physiological relevance",
      "label": "has"
    },
    {
      "source": "fulminant hepatitis",
      "target": "histopathological alterations",
      "label": "caused"
    },
    {
      "source": "fulminant hepatitis",
      "target": "animal death",
      "label": "resulted in"
    },
    {
      "source": "fulminant hepatitis",
      "target": "serum alanine/aspartate transaminase activities",
      "label": "increased"
    },
    {
      "source": "fulminant hepatitis",
      "target": "C57BL/6J mice",
      "label": "occurs in"
    },
    {
      "source": "Jo2",
      "target": "Bid",
      "label": "triggered"
    },
    {
      "source": "Jo2",
      "target": "caspase-9",
      "label": "induced"
    },
    {
      "source": "Jo2",
      "target": "fulminant hepatitis",
      "label": "induces"
    },
    {
      "source": "Jo2",
      "target": "activating anti-Fas antibody",
      "label": "is a type of"
    },
    {
      "source": "Jo2",
      "target": "caspase-8",
      "label": "triggered"
    },
    {
      "source": "Jo2",
      "target": "caspase-3",
      "label": "induced"
    },
    {
      "source": "Bid",
      "target": "mouse livers",
      "label": "is in"
    },
    {
      "source": "caspase-9",
      "target": "liver tissues",
      "label": "is in"
    },
    {
      "source": "caspase-3",
      "target": "liver tissues",
      "label": "is in"
    },
    {
      "source": "liver tissues",
      "target": "Jo2-challenged mice",
      "label": "are from"
    },
    {
      "source": "cytochrome c release",
      "target": "mitochondria",
      "label": "is from"
    },
    {
      "source": "histopathological alterations",
      "target": "liver sections",
      "label": "are in"
    },
    {
      "source": "minocycline pretreatment",
      "target": "caspase-9",
      "label": "Downregulator"
    },
    {
      "source": "minocycline pretreatment",
      "target": "caspase-3",
      "label": "Downregulator"
    },
    {
      "source": "minocycline pretreatment",
      "target": "lethal effect",
      "label": "resisted"
    },
    {
      "source": "minocycline pretreatment",
      "target": "Bid",
      "label": "Not"
    },
    {
      "source": "minocycline pretreatment",
      "target": "caspase-8",
      "label": "Not"
    },
    {
      "source": "pharmaceutical treatment",
      "target": "liver diseases",
      "label": "is for"
    },
    {
      "source": "antiapoptotic effects",
      "target": "pharmaceutical treatment",
      "label": "is central to"
    },
    {
      "source": "antiapoptotic effects",
      "target": "neurons",
      "label": "affect"
    },
    {
      "source": "antiapoptotic effects",
      "target": "cartilage",
      "label": "affect"
    },
    {
      "source": "antiapoptotic effects",
      "target": "periodontal tissues",
      "label": "affect"
    },
    {
      "source": "liver extracts",
      "target": "Jo2-challenged mice",
      "label": "are from"
    },
    {
      "source": "neurons",
      "target": "calbindin-D28k",
      "label": "express"
    },
    {
      "source": "neurons",
      "target": "ventral tegmental area (VTA)",
      "label": "are located in"
    },
    {
      "source": "neurons",
      "target": "lateral subdivision of the CeA (CeAL)",
      "label": "located in"
    },
    {
      "source": "caspase-8",
      "target": "mouse livers",
      "label": "is in"
    },
    {
      "source": "mitochondrial apoptotic pathway",
      "target": "downstream caspase activation",
      "label": "blocks"
    },
    {
      "source": "mitochondrial apoptotic pathway",
      "target": "cytochrome c release",
      "label": "prevents"
    },
    {
      "source": "Intraperitoneal injection",
      "target": "fulminant hepatitis",
      "label": "resulted in"
    },
    {
      "source": "Intraperitoneal injection",
      "target": "oPRL",
      "label": "involved"
    },
    {
      "source": "Intraperitoneal injection",
      "target": "ovine PRL",
      "label": "involved"
    },
    {
      "source": "Fas",
      "target": "fulminant hepatitis",
      "label": "triggers"
    },
    {
      "source": "Peptidylarginine deiminases",
      "target": "PAD",
      "label": "also known as"
    },
    {
      "source": "Peptidylarginine deiminases",
      "target": "citrulline residues",
      "label": "convert into"
    },
    {
      "source": "Peptidylarginine deiminases",
      "target": "protein-bound arginine residues",
      "label": "convert"
    },
    {
      "source": "Peptidylarginine deiminases",
      "target": "Ca(2+) ion",
      "label": "activity is dependent on"
    },
    {
      "source": "deletion analyses",
      "target": "Sp1-binding sites",
      "label": "revealed"
    },
    {
      "source": "deletion analyses",
      "target": "Sp3",
      "label": "identified"
    },
    {
      "source": "deletion analyses",
      "target": "Sp1",
      "label": "identified"
    },
    {
      "source": "rodents",
      "target": "modes of corticosteroid action",
      "label": "provide evidence for"
    },
    {
      "source": "promoter region",
      "target": "PADI2",
      "label": "of"
    },
    {
      "source": "promoter region",
      "target": "transfected human keratinocytes",
      "label": "characterized using"
    },
    {
      "source": "promoter region",
      "target": "human PAD2 gene",
      "label": "of"
    },
    {
      "source": "Sp1/Sp3 cooperation",
      "target": "transcription",
      "label": "controls"
    },
    {
      "source": "human PAD2 gene",
      "target": "PADI2",
      "label": "also known as"
    },
    {
      "source": "minimal promoter sequence",
      "target": "nucleotides -132 to -41",
      "label": "is located at"
    },
    {
      "source": "PAD2",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "PAD2",
      "target": "species",
      "label": "is expressed in"
    },
    {
      "source": "PAD2",
      "target": "humans",
      "label": "is expressed in"
    },
    {
      "source": "PAD2",
      "target": "tissues",
      "label": "is expressed in"
    },
    {
      "source": "PAD2",
      "target": "organs",
      "label": "is expressed in"
    },
    {
      "source": "PAD2",
      "target": "rodents",
      "label": "is expressed in"
    },
    {
      "source": "Sp1",
      "target": "binding factors",
      "label": "is a type of"
    },
    {
      "source": "Sp1",
      "target": "promoter activity",
      "label": "is important for"
    },
    {
      "source": "Sp1",
      "target": "transcription factors",
      "label": "is a type of"
    },
    {
      "source": "Sp1",
      "target": "mouse promoter region",
      "label": "has_role_in"
    },
    {
      "source": "reporter gene constructions",
      "target": "2 kb region",
      "label": "derived from"
    },
    {
      "source": "reporter gene constructions",
      "target": "minimal promoter sequence",
      "label": "defined"
    },
    {
      "source": "2 kb region",
      "target": "transcription initiation site",
      "label": "is upstream of"
    },
    {
      "source": "Sp3",
      "target": "transcription factors",
      "label": "is a type of"
    },
    {
      "source": "Sp3",
      "target": "promoter activity",
      "label": "is important for"
    },
    {
      "source": "Sp3",
      "target": "binding factors",
      "label": "is a type of"
    },
    {
      "source": "transcription factors",
      "target": "CREB",
      "label": "includes"
    },
    {
      "source": "transcription factors",
      "target": "Sp1",
      "label": "includes"
    },
    {
      "source": "transcription factors",
      "target": "development",
      "label": "are involved in"
    },
    {
      "source": "transcription factors",
      "target": "migration",
      "label": "are involved in"
    },
    {
      "source": "transcription factors",
      "target": "FOXE1",
      "label": "include"
    },
    {
      "source": "transcription factors",
      "target": "TTF-1",
      "label": "include"
    },
    {
      "source": "transcription factors",
      "target": "PAX8",
      "label": "include"
    },
    {
      "source": "cis-acting elements",
      "target": "PADI2 region",
      "label": "are in"
    },
    {
      "source": "PADI2 region",
      "target": "TATA",
      "label": "lacks"
    },
    {
      "source": "PADI2 region",
      "target": "CAAT boxes",
      "label": "lacks"
    },
    {
      "source": "promoter activity",
      "target": "chicken e11 pituitary cells",
      "label": "in"
    },
    {
      "source": "electrophoretic mobility shift assays",
      "target": "specific antibodies",
      "label": "used"
    },
    {
      "source": "electrophoretic mobility shift assays",
      "target": "Sp1-binding sites",
      "label": "revealed"
    },
    {
      "source": "electrophoretic mobility shift assays",
      "target": "Sp3",
      "label": "identified"
    },
    {
      "source": "electrophoretic mobility shift assays",
      "target": "Sp1",
      "label": "identified"
    },
    {
      "source": "PAD3",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "peptidylarginine deiminase type II gene",
      "target": "PADI2",
      "label": "also known as"
    },
    {
      "source": "PAD1",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "PAD4",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "tissues",
      "target": "exposed mice",
      "label": "belong to"
    },
    {
      "source": "tissues",
      "target": "pKB values",
      "label": "have"
    },
    {
      "source": "transcription initiation site",
      "target": "Acsl4 mouse gene",
      "label": "is_part_of"
    },
    {
      "source": "PAD6",
      "target": "isoforms",
      "label": "is an"
    },
    {
      "source": "H2S",
      "target": "blood pressure",
      "label": "lowers"
    },
    {
      "source": "H2S",
      "target": "gas",
      "label": "is a"
    },
    {
      "source": "H2S",
      "target": "vasodilator activity",
      "label": "has"
    },
    {
      "source": "H2S",
      "target": "activity",
      "label": "may exert"
    },
    {
      "source": "H2S",
      "target": "severity",
      "label": "regulates"
    },
    {
      "source": "H2S",
      "target": "cardiovascular system",
      "label": "is formed in"
    },
    {
      "source": "H2S",
      "target": "inflammatory condition",
      "label": "has effect in"
    },
    {
      "source": "H2S",
      "target": "rat arteries",
      "label": "relaxes"
    },
    {
      "source": "CSE",
      "target": "mRNA signal",
      "label": "is determined by"
    },
    {
      "source": "CSE",
      "target": "pancreas",
      "label": "is in"
    },
    {
      "source": "CSE",
      "target": "H2S",
      "label": "forms"
    },
    {
      "source": "CSE",
      "target": "L-cysteine",
      "label": "utilizes"
    },
    {
      "source": "CSE",
      "target": "key enzyme",
      "label": "is a"
    },
    {
      "source": "histological evidence",
      "target": "lung injury",
      "label": "is of"
    },
    {
      "source": "neutrophil sequestration",
      "target": "pancreatic myeloperoxidase oxidase",
      "label": "measured by"
    },
    {
      "source": "neutrophil sequestration",
      "target": "pancreas",
      "label": "occurs in"
    },
    {
      "source": "neutrophil sequestration",
      "target": "MPO activity",
      "label": "measured by"
    },
    {
      "source": "possibility",
      "target": "selection method",
      "label": "enables"
    },
    {
      "source": "possibility",
      "target": "combined effect",
      "label": "based on"
    },
    {
      "source": "cystathionine-beta-synthase",
      "target": "H2S",
      "label": "forms"
    },
    {
      "source": "cystathionine-beta-synthase",
      "target": "L-cysteine",
      "label": "utilizes"
    },
    {
      "source": "L-cysteine",
      "target": "substrate",
      "label": "is a"
    },
    {
      "source": "CBS",
      "target": "L-cysteine",
      "label": "utilizes"
    },
    {
      "source": "CBS",
      "target": "H2S",
      "label": "forms"
    },
    {
      "source": "therapeutic treatment",
      "target": "CSE inhibitor",
      "label": "used"
    },
    {
      "source": "therapeutic treatment",
      "target": "PAG",
      "label": "used"
    },
    {
      "source": "therapeutic treatment",
      "target": "DL-propargylglycine",
      "label": "used"
    },
    {
      "source": "CSE inhibitor",
      "target": "severity",
      "label": "reduced"
    },
    {
      "source": "Cystathionine-gamma-lyase",
      "target": "H2S",
      "label": "forms"
    },
    {
      "source": "Cystathionine-gamma-lyase",
      "target": "L-cysteine",
      "label": "utilizes"
    },
    {
      "source": "PAG",
      "target": "MPO activity",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "hyperamylasemia",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "severity",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "pancreatic myeloperoxidase oxidase",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "plasma amylase",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "lung MPO activity",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "neutrophil sequestration",
      "label": "reduced"
    },
    {
      "source": "PAG",
      "target": "pancreatic acinar cell injury/necrosis",
      "label": "reduced"
    },
    {
      "source": "hyperamylasemia",
      "target": "plasma amylase",
      "label": "is"
    },
    {
      "source": "H2S synthesizing enzyme activity",
      "target": "pancreas",
      "label": "is in"
    },
    {
      "source": "hydrogen sulfide",
      "target": "lung injury",
      "label": "has role in"
    },
    {
      "source": "hydrogen sulfide",
      "target": "acute pancreatitis",
      "label": "has role in"
    },
    {
      "source": "prophylactic treatment",
      "target": "CSE inhibitor",
      "label": "used"
    },
    {
      "source": "prophylactic treatment",
      "target": "PAG",
      "label": "used"
    },
    {
      "source": "prophylactic treatment",
      "target": "DL-propargylglycine",
      "label": "used"
    },
    {
      "source": "proinflammatory role",
      "target": "H2S",
      "label": "is of"
    },
    {
      "source": "inflammatory condition",
      "target": "acute pancreatitis",
      "label": "includes"
    },
    {
      "source": "Hydrogen sulfide",
      "target": "gas",
      "label": "is a"
    },
    {
      "source": "Hydrogen sulfide",
      "target": "vasodilator activity",
      "label": "has"
    },
    {
      "source": "DL-propargylglycine",
      "target": "severity",
      "label": "reduced"
    },
    {
      "source": "CSE blockade",
      "target": "effects",
      "label": "has"
    },
    {
      "source": "cystathionine-gamma-lyase",
      "target": "key enzyme",
      "label": "is a"
    },
    {
      "source": "paper",
      "target": "CSE",
      "label": "reports presence of"
    },
    {
      "source": "paper",
      "target": "H2S synthesizing enzyme activity",
      "label": "reports presence of"
    },
    {
      "source": "paper",
      "target": "1,3,4-thiadiazole derivatives",
      "label": "describes"
    },
    {
      "source": "functional activity",
      "target": "1 microM dopamine induced-Ca2+ flux",
      "label": "is measured by"
    },
    {
      "source": "functional activity",
      "target": "agonist-induced GTP-gamma-S binding assay",
      "label": "is measured by"
    },
    {
      "source": "functional activity",
      "target": "prothrombin",
      "label": "is of"
    },
    {
      "source": "functional activity",
      "target": "vitamin K-dependent clotting factors X",
      "label": "is of"
    },
    {
      "source": "functional activity",
      "target": "vitamin K-dependent clotting factors IX",
      "label": "is of"
    },
    {
      "source": "functional activity",
      "target": "Ca(2+)uptake assays",
      "label": "tested in"
    },
    {
      "source": "1 microM dopamine induced-Ca2+ flux",
      "target": "dopamine",
      "label": "is induced by"
    },
    {
      "source": "intrinsic activity",
      "target": "D4.4 receptor",
      "label": "in"
    },
    {
      "source": "membrane",
      "target": "cells",
      "label": "from"
    },
    {
      "source": "A-381393",
      "target": "ability",
      "label": "enhances"
    },
    {
      "source": "A-381393",
      "target": "5-HT2A",
      "label": "has moderate affinity for"
    },
    {
      "source": "A-381393",
      "target": "intrinsic activity",
      "label": "did not exhibit"
    },
    {
      "source": "A-381393",
      "target": "functional activity",
      "label": "inhibited"
    },
    {
      "source": "A-381393",
      "target": "receptor selectivity",
      "label": "exhibits better"
    },
    {
      "source": "A-381393",
      "target": "in vivo",
      "label": "has good brain penetration"
    },
    {
      "source": "A-381393",
      "target": "L-745870",
      "label": "is in contrast to"
    },
    {
      "source": "A-381393",
      "target": "brain penetration",
      "label": "has good"
    },
    {
      "source": "A-381393",
      "target": "dopamine D4 receptor",
      "label": "is a potent antagonist of"
    },
    {
      "source": "A-381393",
      "target": "D1, D2, D3 and D5 dopamine receptors",
      "label": "has selectivity over"
    },
    {
      "source": "A-381393",
      "target": "novel selective D4 antagonist",
      "label": "is a"
    },
    {
      "source": "A-381393",
      "target": "human dopamine D4.4 receptor expressing cells",
      "label": "inhibited activity in"
    },
    {
      "source": "A-381393",
      "target": "clozapine",
      "label": "compared to"
    },
    {
      "source": "A-381393",
      "target": "conscious rats",
      "label": "inhibited penile erection in"
    },
    {
      "source": "A-381393",
      "target": "membrane",
      "label": "bound to"
    },
    {
      "source": "A-381393",
      "target": "human dopamine D2L or D3 receptor cells",
      "label": "did not inhibit activity in"
    },
    {
      "source": "A-381393",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "A-381393",
      "target": "panel of more than 70 receptors and channels",
      "label": "shows no affinity for"
    },
    {
      "source": "A-381393",
      "target": "penile erection",
      "label": "inhibited"
    },
    {
      "source": "ability",
      "target": "dopamine D4 receptor",
      "label": "to study"
    },
    {
      "source": "ability",
      "target": "antithrombin (AT)",
      "label": "to bind"
    },
    {
      "source": "ability",
      "target": "charge",
      "label": "is not dependent on"
    },
    {
      "source": "ability",
      "target": "high density",
      "label": "requires"
    },
    {
      "source": "dopamine D4 receptor",
      "target": "in vivo",
      "label": "can be studied"
    },
    {
      "source": "dopamine D4 receptor",
      "target": "in vitro",
      "label": "can be studied"
    },
    {
      "source": "2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole",
      "target": "A-381393",
      "label": "is also known as"
    },
    {
      "source": "2-[4-(3,4-Dimethylphenlyl)piperazin-1-ylmethyl]-1H benzoimidazole",
      "target": "A-381393",
      "label": "is also known as"
    },
    {
      "source": "[3H]-spiperone competition binding assays",
      "target": "A-381393",
      "label": "showed binding of"
    },
    {
      "source": "penile erection",
      "target": "selective D4 agonist PD168077",
      "label": "induced by"
    },
    {
      "source": "Activator of G protein signaling 3",
      "target": "protein kinase A signaling",
      "label": "regulates"
    },
    {
      "source": "Activator of G protein signaling 3",
      "target": "heroin-seeking behavior",
      "label": "regulates"
    },
    {
      "source": "Activator of G protein signaling 3",
      "target": "opiate activation",
      "label": "regulates"
    },
    {
      "source": "Activator of G protein signaling 3",
      "target": "relapse",
      "label": "regulates"
    },
    {
      "source": "Galpha(i)",
      "target": "cAMP production",
      "label": "inhibits"
    },
    {
      "source": "cAMP production",
      "target": "calcium entry",
      "label": "in response to"
    },
    {
      "source": "cAMP production",
      "target": "human embryonic kidney (HEK)-293 cells",
      "label": "occurs in"
    },
    {
      "source": "cAMP production",
      "target": "human T47D breast cancer cells",
      "label": "in"
    },
    {
      "source": "opiate activation",
      "target": "Activator of G protein signaling 3",
      "label": "requires"
    },
    {
      "source": "opiate activation",
      "target": "AGS3",
      "label": "requires"
    },
    {
      "source": "opiate activation",
      "target": "Galpha(i3)",
      "label": "requires"
    },
    {
      "source": "AGS3 antisense",
      "target": "reinstatement of heroin-seeking behavior",
      "label": "eliminates"
    },
    {
      "source": "AGS3 antisense",
      "target": "NAc core",
      "label": "acts in"
    },
    {
      "source": "AGS3 antisense",
      "target": "NAc shell",
      "label": "does not act in"
    },
    {
      "source": "reinstatement of heroin-seeking behavior",
      "target": "human relapse",
      "label": "is a model of"
    },
    {
      "source": "AGS3",
      "target": "betagamma",
      "label": "enhances action of"
    },
    {
      "source": "AGS3",
      "target": "Galpha(i3)-GDP",
      "label": "competes for binding to"
    },
    {
      "source": "betagamma",
      "target": "Galpha(i3)-GDP",
      "label": "competes for binding to"
    },
    {
      "source": "betagamma",
      "target": "molecular pathways",
      "label": "regulates"
    },
    {
      "source": "betagamma",
      "target": "protein kinase A",
      "label": "regulates"
    },
    {
      "source": "opiates",
      "target": "PKA signaling",
      "label": "activate"
    },
    {
      "source": "Galpha(i3)/betagamma/AGS3",
      "target": "mu opiate receptor",
      "label": "mediates"
    },
    {
      "source": "Galpha(i3)/betagamma/AGS3",
      "target": "heroin-seeking behavior",
      "label": "mediates"
    },
    {
      "source": "Galpha(i3)/betagamma/AGS3",
      "target": "PKA signaling",
      "label": "mediates"
    },
    {
      "source": "AGS3 knockdown",
      "target": "PKA signaling",
      "label": "prevents"
    },
    {
      "source": "AGS3 knockdown",
      "target": "opiate activation",
      "label": "prevents"
    },
    {
      "source": "Galpha(i3) knockdown",
      "target": "opiate activation",
      "label": "prevents"
    },
    {
      "source": "Galpha(i3) knockdown",
      "target": "PKA signaling",
      "label": "prevents"
    },
    {
      "source": "NAc",
      "target": "heroin addiction",
      "label": "is central to"
    },
    {
      "source": "NAc shell",
      "target": "5 zones of analysis",
      "label": "separated_into"
    },
    {
      "source": "opiate receptors",
      "target": "G(i/o)",
      "label": "dissociates"
    },
    {
      "source": "G(i/o)",
      "target": "alpha subunits",
      "label": "dissociates into"
    },
    {
      "source": "G(i/o)",
      "target": "betagamma subunits",
      "label": "dissociates into"
    },
    {
      "source": "betagamma dimers",
      "target": "PKA signaling",
      "label": "mediate activation of"
    },
    {
      "source": "lipolysis",
      "target": "adipose tissue",
      "label": "occurs in"
    },
    {
      "source": "HM74A",
      "target": "inhibition of lipolysis",
      "label": "mediated"
    },
    {
      "source": "HM74A",
      "target": "Niacin",
      "label": "binds"
    },
    {
      "source": "HM74A",
      "target": "high affinities",
      "label": "binds at"
    },
    {
      "source": "HM74A",
      "target": "anti-lipolytic effect",
      "label": "is sufficient to mediate"
    },
    {
      "source": "HM74A",
      "target": "Gi signaling events",
      "label": "mediates"
    },
    {
      "source": "HM74A",
      "target": "differentiated 3T3L1 adipocytes",
      "label": "is expressed in"
    },
    {
      "source": "HM74A",
      "target": "humans",
      "label": "found in"
    },
    {
      "source": "HM74A",
      "target": "flushing",
      "label": "mediates"
    },
    {
      "source": "inhibition of lipolysis",
      "target": "Niacin",
      "label": "is mediated by"
    },
    {
      "source": "G-protein coupled receptor",
      "target": "Niacin",
      "label": "identified to"
    },
    {
      "source": "G-protein coupled receptor",
      "target": "nicotinic acid",
      "label": "identified to"
    },
    {
      "source": "Niacin",
      "target": "lipolysis",
      "label": "mediates"
    },
    {
      "source": "Niacin",
      "target": "G-protein coupled receptor HM74A",
      "label": "mediates through"
    },
    {
      "source": "anti-lipolytic effect",
      "target": "Niacin",
      "label": "is of"
    },
    {
      "source": "anti-lipolytic effect",
      "target": "adipose tissue",
      "label": "occurs in"
    },
    {
      "source": "physiological/pharmacological role",
      "target": "receptor",
      "label": "is of"
    },
    {
      "source": "G-protein coupled receptor HM74A",
      "target": "lipolysis",
      "label": "mediates"
    },
    {
      "source": "Gi signaling events",
      "target": "human embryonic kidney HEK293 cells",
      "label": "occur in"
    },
    {
      "source": "Gi signaling events",
      "target": "3T3L1 adipocytes",
      "label": "occur in"
    },
    {
      "source": "nicotinic acid",
      "target": "antilipolytic effects",
      "label": "induces"
    },
    {
      "source": "nicotinic acid",
      "target": "niacin",
      "label": "is also known as"
    },
    {
      "source": "nicotinic acid",
      "target": "antidyslipidemic drug",
      "label": "is a type of"
    },
    {
      "source": "nicotinic acid",
      "target": "HDL-cholesterol levels",
      "label": "induces"
    },
    {
      "source": "nicotinic acid",
      "target": "flushing",
      "label": "induces"
    },
    {
      "source": "nicotinic acid",
      "target": "pharmacotherapeutical use",
      "label": "has"
    },
    {
      "source": "nicotinic acid",
      "target": "plasma very-low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "nicotinic acid",
      "target": "clearance",
      "label": "improve"
    },
    {
      "source": "nicotinic acid",
      "target": "VLDL",
      "label": "improve clearance of"
    },
    {
      "source": "nicotinic acid",
      "target": "LDL",
      "label": "interfere with biosynthesis of"
    },
    {
      "source": "nicotinic acid",
      "target": "low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "nicotinic acid",
      "target": "biosynthesis",
      "label": "interfere with"
    },
    {
      "source": "3T3L1 adipocytes",
      "target": "HM74A",
      "label": "express"
    },
    {
      "source": "O2-dependent prolyl hydroxylase domain enzymes",
      "target": "enzyme family",
      "label": "are members of"
    },
    {
      "source": "O2-dependent prolyl hydroxylase domain enzymes",
      "target": "hypoxia-inducible factor",
      "label": "regulate"
    },
    {
      "source": "Collagen prolyl hydroxylase",
      "target": "hydralazine",
      "label": "is a target of"
    },
    {
      "source": "Collagen prolyl hydroxylase",
      "target": "enzyme family",
      "label": "is a member of"
    },
    {
      "source": "PHD",
      "target": "PHD enzymes",
      "label": "is a type of"
    },
    {
      "source": "PHD",
      "target": "HIF",
      "label": "regulates"
    },
    {
      "source": "PHD enzymes",
      "target": "HIF",
      "label": "regulate"
    },
    {
      "source": "PHD enzymes",
      "target": "O2-dependent prolyl hydroxylase domain enzymes",
      "label": "are a type of"
    },
    {
      "source": "HIF",
      "target": "haem oxygenase 1",
      "label": "has downstream target"
    },
    {
      "source": "HIF",
      "target": "VEGF",
      "label": "has downstream target"
    },
    {
      "source": "HIF",
      "target": "ischemic disease",
      "label": "is a potential target for treatment of"
    },
    {
      "source": "HIF",
      "target": "endothelin-1",
      "label": "has downstream target"
    },
    {
      "source": "HIF",
      "target": "adrenomedullin",
      "label": "has downstream target"
    },
    {
      "source": "HIF",
      "target": "vascular endothelial growth factor",
      "label": "has downstream target"
    },
    {
      "source": "nonhydroxylated HIF-1alpha",
      "target": "HIF stabilization",
      "label": "is evidence for"
    },
    {
      "source": "VEGF",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "VEGF",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "VEGF",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "VEGF",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "VEGF",
      "target": "dose-responsive manner",
      "label": "was downregulated in a"
    },
    {
      "source": "VEGF",
      "target": "OLETF rats",
      "label": "expression in"
    },
    {
      "source": "VEGF",
      "target": "outer plexiform layer",
      "label": "expression extended into"
    },
    {
      "source": "VEGF",
      "target": "retinas",
      "label": "expression in"
    },
    {
      "source": "VEGF",
      "target": "LETO rats",
      "label": "expression in"
    },
    {
      "source": "VEGF",
      "target": "ganglion cell layer",
      "label": "expression limited to"
    },
    {
      "source": "vascular endothelial growth factor",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "vascular endothelial growth factor",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "vascular endothelial growth factor",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "vascular endothelial growth factor",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "vascular endothelial growth factor",
      "target": "VEGF",
      "label": "is"
    },
    {
      "source": "PHD activity",
      "target": "HIF pathway",
      "label": "inhibition leads to activation of"
    },
    {
      "source": "PHD activity",
      "target": "HIF stabilization",
      "label": "inhibition leads to"
    },
    {
      "source": "PHD activity",
      "target": "HIFalpha stability",
      "label": "regulates"
    },
    {
      "source": "PHD activity",
      "target": "oxygen availability",
      "label": "depends on"
    },
    {
      "source": "PHD activity",
      "target": "normoxic conditions",
      "label": "regulates under"
    },
    {
      "source": "PHD activity",
      "target": "hypoxic conditions",
      "label": "regulates under"
    },
    {
      "source": "PHD activity",
      "target": "purified PHD1 to 3",
      "label": "is of"
    },
    {
      "source": "COX family",
      "target": "isoforms",
      "label": "contains"
    },
    {
      "source": "COX family",
      "target": "enzymes",
      "label": "contains"
    },
    {
      "source": "naproxen",
      "target": "COX-1",
      "label": "has less selectivity towards"
    },
    {
      "source": "naproxen",
      "target": "COX",
      "label": "is a non-selective inhibitor of"
    },
    {
      "source": "naproxen",
      "target": "mice",
      "label": "has effect in"
    },
    {
      "source": "naproxen",
      "target": "chemical kindling",
      "label": "has protective effect against"
    },
    {
      "source": "ibuprofen",
      "target": "COX-1",
      "label": "has less selectivity towards"
    },
    {
      "source": "Conventional nonselective NSAIDs",
      "target": "gastrointestinal disorders",
      "label": "associated with a risk of"
    },
    {
      "source": "Conventional nonselective NSAIDs",
      "target": "COX family",
      "label": "have selectivity towards"
    },
    {
      "source": "flurbiprofen",
      "target": "COX-1",
      "label": "has increased selectivity towards"
    },
    {
      "source": "ketorolac",
      "target": "COX-1",
      "label": "has increased selectivity towards"
    },
    {
      "source": "ketorolac",
      "target": "selective COX-1 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "first degree relatives",
      "target": "diabetic patients",
      "label": "are of"
    },
    {
      "source": "Islet cell antibodies",
      "target": "predictive value",
      "label": "have"
    },
    {
      "source": "Islet cell antibodies",
      "target": "indirect immunofluorescence technique",
      "label": "screened by"
    },
    {
      "source": "Islet cell antibodies",
      "target": "Juvenile Diabetes Foundation units",
      "label": "measured in"
    },
    {
      "source": "Islet cell antibodies",
      "target": "French schoolchildren",
      "label": "found in"
    },
    {
      "source": "Islet cell antibodies",
      "target": "Sera",
      "label": "found in"
    },
    {
      "source": "Islet cell antibodies",
      "target": "background populations",
      "label": "found in"
    },
    {
      "source": "predictive value",
      "target": "future development",
      "label": "for"
    },
    {
      "source": "predictive value",
      "target": "first degree relatives",
      "label": "present in"
    },
    {
      "source": "HLA-DQB typing",
      "target": "Type 1 diabetic children",
      "label": "performed in"
    },
    {
      "source": "HLA-DQB typing",
      "target": "islet-cell antibody-negative children",
      "label": "performed in"
    },
    {
      "source": "HLA-DQB typing",
      "target": "islet-cell antibody-positive children",
      "label": "performed in"
    },
    {
      "source": "HLA-DQB typing",
      "target": "restriction mapping techniques",
      "label": "performed by"
    },
    {
      "source": "susceptibility alleles",
      "target": "islet-cell antibody-positive children",
      "label": "distribution not significantly different between"
    },
    {
      "source": "susceptibility alleles",
      "target": "DQB1-Asp57-negative",
      "label": "are"
    },
    {
      "source": "susceptibility alleles",
      "target": "islet-cell antibody-negative children",
      "label": "distribution not significantly different between"
    },
    {
      "source": "fasting plasma glucose",
      "target": "feature",
      "label": "is a"
    },
    {
      "source": "feature",
      "target": "islet-cell antibody-negative children",
      "label": "not significantly different between"
    },
    {
      "source": "feature",
      "target": "islet-cell antibody-positive children",
      "label": "not significantly different between"
    },
    {
      "source": "blood sample",
      "target": "mean interval",
      "label": "obtained after"
    },
    {
      "source": "blood sample",
      "target": "islet-cell antibody-positive children",
      "label": "obtained from"
    },
    {
      "source": "mean interval",
      "target": "months",
      "label": "measured in"
    },
    {
      "source": "islet-cell antibodies titre",
      "target": "Sera",
      "label": "stable in"
    },
    {
      "source": "insulin autoantibodies",
      "target": "feature",
      "label": "is a"
    },
    {
      "source": "future development",
      "target": "Type 1 (insulin-dependent) diabetes",
      "label": "is of"
    },
    {
      "source": "family history of diabetes",
      "target": "feature",
      "label": "is a"
    },
    {
      "source": "Sera",
      "target": "islet-cell antibodies titre",
      "label": "demonstrated"
    },
    {
      "source": "Sera",
      "target": "Islet cell antibodies",
      "label": "screened for"
    },
    {
      "source": "high-titre positive sera",
      "target": "Sera",
      "label": "is a type of"
    },
    {
      "source": "subjects",
      "target": "impaired glucose tolerance",
      "label": "have"
    },
    {
      "source": "subjects",
      "target": "alternate regimen",
      "label": "crossed over to"
    },
    {
      "source": "prevalence rate",
      "target": "confidence interval",
      "label": "has"
    },
    {
      "source": "fluorescence",
      "target": "385 nm",
      "label": "is at"
    },
    {
      "source": "fluorescence",
      "target": "510 nm",
      "label": "is not at"
    },
    {
      "source": "active sites",
      "target": "dimeric 5-aminolevulinate synthase",
      "label": "are of"
    },
    {
      "source": "active sites",
      "target": "subunit interface",
      "label": "are located on"
    },
    {
      "source": "active sites",
      "target": "bioinformatics",
      "label": "predicted by"
    },
    {
      "source": "active sites",
      "target": "Molecular modeling",
      "label": "predicted by"
    },
    {
      "source": "active sites",
      "target": "ADP",
      "label": "binds"
    },
    {
      "source": "active sites",
      "target": "ATP",
      "label": "binds"
    },
    {
      "source": "dimeric 5-aminolevulinate synthase",
      "target": "ALAS",
      "label": "is also known as"
    },
    {
      "source": "absorption spectra",
      "target": "maxima",
      "label": "had"
    },
    {
      "source": "absorption spectra",
      "target": "ALAS",
      "label": "are of"
    },
    {
      "source": "absorption spectra",
      "target": "2XALAS",
      "label": "are of"
    },
    {
      "source": "330 nm absorption band",
      "target": "fluorescence",
      "label": "showed"
    },
    {
      "source": "coenzyme structure",
      "target": "2XALAS",
      "label": "is more prominent in"
    },
    {
      "source": "coenzyme structure",
      "target": "ALAS",
      "label": "is in"
    },
    {
      "source": "coenzyme structure",
      "target": "pH",
      "label": "is affected by"
    },
    {
      "source": "coenzyme structure",
      "target": "enzyme",
      "label": "confers"
    },
    {
      "source": "coenzyme structure",
      "target": "wild-type ALAS",
      "label": "is relative to"
    },
    {
      "source": "2XALAS",
      "target": "wild-type ALAS",
      "label": "has greater turnover number than"
    },
    {
      "source": "2XALAS",
      "target": "enzyme",
      "label": "yielded"
    },
    {
      "source": "2XALAS",
      "target": "A(410)/A(330) ratio",
      "label": "has"
    },
    {
      "source": "A(410)/A(330) ratio",
      "target": "pH",
      "label": "is affected by"
    },
    {
      "source": "subunit interface",
      "target": "amino acids",
      "label": "has contribution from"
    },
    {
      "source": "amino acids",
      "target": "subunits",
      "label": "are from"
    },
    {
      "source": "amino acids",
      "target": "aromatic ring",
      "label": "have"
    },
    {
      "source": "rates",
      "target": "ALAS",
      "label": "are similar in"
    },
    {
      "source": "rates",
      "target": "2XALAS",
      "label": "are similar in"
    },
    {
      "source": "rates",
      "target": "l-arginine transport",
      "label": "of"
    },
    {
      "source": "rates",
      "target": "lipid peroxidation",
      "label": "of"
    },
    {
      "source": "rates",
      "target": "vitamin E",
      "label": "of"
    },
    {
      "source": "ALAS",
      "target": "enzyme",
      "label": "is a"
    },
    {
      "source": "Transient kinetic analysis",
      "target": "decay",
      "label": "is of"
    },
    {
      "source": "Transient kinetic analysis",
      "target": "formation",
      "label": "is of"
    },
    {
      "source": "decay",
      "target": "quinonoid intermediate EQ(2)",
      "label": "is of"
    },
    {
      "source": "spectroscopic properties",
      "target": "2XALAS",
      "label": "are of"
    },
    {
      "source": "formation",
      "target": "quinonoid intermediate EQ(2)",
      "label": "is of"
    },
    {
      "source": "formation",
      "target": "amyloid fibrils",
      "label": "of"
    },
    {
      "source": "formation",
      "target": "DNA single strand breaks",
      "label": "of"
    },
    {
      "source": "formation",
      "target": "thymine base lesions",
      "label": "of"
    },
    {
      "source": "formation",
      "target": "oxidative DNA damage",
      "label": "of"
    },
    {
      "source": "330 nm absorption species",
      "target": "aldamine",
      "label": "attributed to"
    },
    {
      "source": "330 nm absorption species",
      "target": "enolimine",
      "label": "is not"
    },
    {
      "source": "385 nm emission intensity",
      "target": "pH",
      "label": "increased with"
    },
    {
      "source": "385 nm emission intensity",
      "target": "pK",
      "label": "has"
    },
    {
      "source": "ketoenamine",
      "target": "active form",
      "label": "is"
    },
    {
      "source": "ketoenamine",
      "target": "coenzyme structure",
      "label": "forms"
    },
    {
      "source": "active form",
      "target": "coenzyme",
      "label": "is of"
    },
    {
      "source": "kinetic properties",
      "target": "2XALAS",
      "label": "are of"
    },
    {
      "source": "polypeptide chain dimer",
      "target": "2XALAS",
      "label": "is also known as"
    },
    {
      "source": "kinetic mechanism",
      "target": "enzyme",
      "label": "confers"
    },
    {
      "source": "kinetic mechanism",
      "target": "wild-type ALAS",
      "label": "is relative to"
    },
    {
      "source": "410 nm absorption species",
      "target": "ketoenamine",
      "label": "attributed to"
    },
    {
      "source": "enolimine",
      "target": "Schiff base",
      "label": "is a form of"
    },
    {
      "source": "subunits",
      "target": "polypeptide chain dimer",
      "label": "are linked into"
    },
    {
      "source": "5-aminolevulinate synthase",
      "target": "enzyme",
      "label": "is converted into"
    },
    {
      "source": "5-aminolevulinate synthase",
      "target": "subunits",
      "label": "has"
    },
    {
      "source": "pK",
      "target": "enzymes",
      "label": "is for"
    },
    {
      "source": "irritable bowel syndrome",
      "target": "gastrointestinal disorders",
      "label": "is a type of"
    },
    {
      "source": "Serotonin",
      "target": "5-hydroxytryptamine",
      "label": "also known as"
    },
    {
      "source": "Serotonin",
      "target": "gastrointestinal motor function",
      "label": "controls"
    },
    {
      "source": "Serotonin",
      "target": "enteric nervous system",
      "label": "found in"
    },
    {
      "source": "Serotonin",
      "target": "5-HT",
      "label": "also known as"
    },
    {
      "source": "substituted benzamide prokinetics",
      "target": "prokinetic action",
      "label": "has"
    },
    {
      "source": "substituted benzamide prokinetics",
      "target": "agonist effects",
      "label": "has"
    },
    {
      "source": "substituted benzamide prokinetics",
      "target": "5-HT3 receptors",
      "label": "blocks"
    },
    {
      "source": "prokinetic action",
      "target": "agonist effects",
      "label": "based on"
    },
    {
      "source": "pharmacological data",
      "target": "5-HT antagonists",
      "label": "supports use of"
    },
    {
      "source": "pharmacological data",
      "target": "5-HT agonists",
      "label": "supports use of"
    },
    {
      "source": "5-HT antagonists",
      "target": "gastrointestinal disorders",
      "label": "beneficial for"
    },
    {
      "source": "5-HT antagonists",
      "target": "behavioural inhibition",
      "label": "reverse"
    },
    {
      "source": "cisapride",
      "target": "prokinetic action",
      "label": "has"
    },
    {
      "source": "cisapride",
      "target": "substituted benzamide prokinetics",
      "label": "is a type of"
    },
    {
      "source": "cisapride",
      "target": "5-HT3 receptors",
      "label": "blocks"
    },
    {
      "source": "cisapride",
      "target": "agonist effects",
      "label": "has"
    },
    {
      "source": "functional dyspepsia",
      "target": "gastrointestinal disorders",
      "label": "is a type of"
    },
    {
      "source": "metoclopramide",
      "target": "substituted benzamide prokinetics",
      "label": "is a type of"
    },
    {
      "source": "metoclopramide",
      "target": "5-HT3 receptors",
      "label": "blocks"
    },
    {
      "source": "metoclopramide",
      "target": "agonist effects",
      "label": "has"
    },
    {
      "source": "metoclopramide",
      "target": "prokinetic action",
      "label": "has"
    },
    {
      "source": "granisetron",
      "target": "selective 5-HT3 antagonists",
      "label": "is a type of"
    },
    {
      "source": "granisetron",
      "target": "5-HT4 agonist activity",
      "label": "lacks"
    },
    {
      "source": "renzapride",
      "target": "5-HT4 agonist activity",
      "label": "has"
    },
    {
      "source": "renzapride",
      "target": "selective 5-HT3 antagonists",
      "label": "is a type of"
    },
    {
      "source": "non-cardiac chest pain",
      "target": "gastrointestinal disorders",
      "label": "is a type of"
    },
    {
      "source": "ondansetron",
      "target": "selective 5-HT3 antagonists",
      "label": "is a type of"
    },
    {
      "source": "ondansetron",
      "target": "5-HT4 agonist activity",
      "label": "lacks"
    },
    {
      "source": "tropisetron",
      "target": "selective 5-HT3 antagonists",
      "label": "is a type of"
    },
    {
      "source": "tropisetron",
      "target": "5-HT4 antagonist",
      "label": "is a"
    },
    {
      "source": "5-HT4 receptors",
      "target": "receptor",
      "label": "is a type of"
    },
    {
      "source": "5-HT3 receptors",
      "target": "visceral pain",
      "label": "modulates"
    },
    {
      "source": "5-HT3 receptors",
      "target": "colonic motility",
      "label": "modulates"
    },
    {
      "source": "5-HT3 receptors",
      "target": "receptor",
      "label": "is a type of"
    },
    {
      "source": "5-HT3 receptors",
      "target": "cortical membranes",
      "label": "located in"
    },
    {
      "source": "agonist effects",
      "target": "5-HT4 receptors",
      "label": "acts on"
    },
    {
      "source": "refractory nausea",
      "target": "gastrointestinal disorders",
      "label": "is a type of"
    },
    {
      "source": "5-HT agonists",
      "target": "gastrointestinal disorders",
      "label": "beneficial for"
    },
    {
      "source": "recognition sites",
      "target": "gut",
      "label": "identified in"
    },
    {
      "source": "zacopride",
      "target": "5-HT4 agonist activity",
      "label": "has"
    },
    {
      "source": "zacopride",
      "target": "selective 5-HT3 antagonists",
      "label": "is a type of"
    },
    {
      "source": "gastrooesophageal reflux",
      "target": "gastrointestinal disorders",
      "label": "is a type of"
    },
    {
      "source": "C776G",
      "target": "CAD",
      "label": "association needs further evaluation with"
    },
    {
      "source": "C776G",
      "target": "t-Hcys",
      "label": "association needs further evaluation with"
    },
    {
      "source": "C776G",
      "target": "transcobalamin",
      "label": "is a polymorphism of"
    },
    {
      "source": "C776G",
      "target": "TCN",
      "label": "is a polymorphism of"
    },
    {
      "source": "French population",
      "target": "vitamin fortification",
      "label": "without"
    },
    {
      "source": "Methylenetetrahydrofolate reductase polymorphism",
      "target": "t-Hcys",
      "label": "is a determinant of"
    },
    {
      "source": "Methylenetetrahydrofolate reductase polymorphism",
      "target": "homocysteine plasma level",
      "label": "is a determinant of"
    },
    {
      "source": "t-Hcys",
      "target": "CAD group",
      "label": "higher in"
    },
    {
      "source": "t-Hcys",
      "target": "MTHFR 677TT",
      "label": "higher in"
    },
    {
      "source": "t-Hcys",
      "target": "allele",
      "label": "higher than in"
    },
    {
      "source": "t-Hcys",
      "target": "odds ratios",
      "label": "has"
    },
    {
      "source": "t-Hcys",
      "target": "controls",
      "label": "higher than in"
    },
    {
      "source": "t-Hcys",
      "target": "CAD",
      "label": "is a predictor of"
    },
    {
      "source": "t-Hcys",
      "target": "multivariate analysis",
      "label": "identified in"
    },
    {
      "source": "t-Hcys",
      "target": "carriers of MTRRAA",
      "label": "higher in"
    },
    {
      "source": "MTRRAA genotype",
      "target": "moderate hyperhomocysteinemia",
      "label": "is a genetic determinant of"
    },
    {
      "source": "MTRRAA genotype",
      "target": "odds ratios",
      "label": "has"
    },
    {
      "source": "MTRRAA genotype",
      "target": "CAD",
      "label": "is a predictor of"
    },
    {
      "source": "MTRRAA genotype",
      "target": "North Europe studies",
      "label": "contrasts with findings in"
    },
    {
      "source": "MTRRAA genotype",
      "target": "French population",
      "label": "found in"
    },
    {
      "source": "MTRRAA genotype",
      "target": "multivariate analysis",
      "label": "identified in"
    },
    {
      "source": "TCN C776G",
      "target": "homocysteine",
      "label": "not associated with"
    },
    {
      "source": "TCN C776G",
      "target": "French population",
      "label": "studied in"
    },
    {
      "source": "TCN C776G",
      "target": "coronary artery disease",
      "label": "not associated with"
    },
    {
      "source": "homocysteine",
      "target": "methionine",
      "label": "replaced"
    },
    {
      "source": "folates",
      "target": "248 matched healthy controls",
      "label": "investigated in"
    },
    {
      "source": "folates",
      "target": "530 CAD patients",
      "label": "investigated in"
    },
    {
      "source": "folates",
      "target": "t-Hcys",
      "label": "effects investigated with"
    },
    {
      "source": "MTRR A allele",
      "target": "CAD patients",
      "label": "frequency higher in"
    },
    {
      "source": "MTRR A allele",
      "target": "controls",
      "label": "frequency higher than in"
    },
    {
      "source": "MTHFR 677T frequency",
      "target": "CAD patients",
      "label": "no difference observed in"
    },
    {
      "source": "MTHFR 677T frequency",
      "target": "controls",
      "label": "no difference observed in"
    },
    {
      "source": "A1298C",
      "target": "homocysteine",
      "label": "not associated with"
    },
    {
      "source": "A1298C",
      "target": "French population",
      "label": "studied in"
    },
    {
      "source": "A1298C",
      "target": "coronary artery disease",
      "label": "not associated with"
    },
    {
      "source": "MTRRA66G polymorphism",
      "target": "homocysteine",
      "label": "associated with"
    },
    {
      "source": "MTRRA66G polymorphism",
      "target": "coronary artery disease",
      "label": "associated with"
    },
    {
      "source": "MTRRA66G polymorphism",
      "target": "French population",
      "label": "studied in"
    },
    {
      "source": "MTHFR C677T",
      "target": "homocysteine plasma level",
      "label": "is a determinant of"
    },
    {
      "source": "MTHFR C677T",
      "target": "coronary artery disease",
      "label": "not associated with"
    },
    {
      "source": "MTHFR C677T",
      "target": "French population",
      "label": "studied in"
    },
    {
      "source": "MTHFR C677T",
      "target": "homocysteine",
      "label": "not associated with"
    },
    {
      "source": "MTHFR C677T",
      "target": "CAD",
      "label": "has limited association with"
    },
    {
      "source": "MTHFR C677T",
      "target": "t-Hcys",
      "label": "is a determinant of"
    },
    {
      "source": "substitutions A2756G",
      "target": "MTR",
      "label": "is a polymorphism of"
    },
    {
      "source": "substitutions A2756G",
      "target": "t-Hcys",
      "label": "association needs further evaluation with"
    },
    {
      "source": "substitutions A2756G",
      "target": "CAD",
      "label": "association needs further evaluation with"
    },
    {
      "source": "substitutions A2756G",
      "target": "methionine synthase",
      "label": "is a polymorphism of"
    },
    {
      "source": "A66G",
      "target": "t-Hcys",
      "label": "association needs further evaluation with"
    },
    {
      "source": "A66G",
      "target": "MTRR",
      "label": "is a polymorphism of"
    },
    {
      "source": "A66G",
      "target": "CAD",
      "label": "association needs further evaluation with"
    },
    {
      "source": "A66G",
      "target": "methionine synthase reductase",
      "label": "is a polymorphism of"
    },
    {
      "source": "vitamin B12",
      "target": "248 matched healthy controls",
      "label": "investigated in"
    },
    {
      "source": "vitamin B12",
      "target": "530 CAD patients",
      "label": "investigated in"
    },
    {
      "source": "vitamin B12",
      "target": "t-Hcys",
      "label": "effects investigated with"
    },
    {
      "source": "MTRA2756G",
      "target": "homocysteine",
      "label": "not associated with"
    },
    {
      "source": "MTRA2756G",
      "target": "French population",
      "label": "studied in"
    },
    {
      "source": "MTRA2756G",
      "target": "coronary artery disease",
      "label": "not associated with"
    },
    {
      "source": "functional antagonist",
      "target": "human receptor",
      "label": "of"
    },
    {
      "source": "functional antagonist",
      "target": "macaque CCR5",
      "label": "of"
    },
    {
      "source": "potential mechanism-related toxicology",
      "target": "novel CCR5 antagonists",
      "label": "of"
    },
    {
      "source": "Molecular cloning",
      "target": "chemokine receptor CCR5",
      "label": "targets"
    },
    {
      "source": "Molecular cloning",
      "target": "5-HT1E-like rat and human 5-hydroxytryptamine receptor genes",
      "label": "pertains to"
    },
    {
      "source": "chemokine receptor CCR5",
      "target": "rhesus macaque",
      "label": "originates_from"
    },
    {
      "source": "chemokine receptor CCR5",
      "target": "human",
      "label": "originates_from"
    },
    {
      "source": "[3H]-maraviroc",
      "target": "human recombinant CCR5",
      "label": "binds_to"
    },
    {
      "source": "[3H]-maraviroc",
      "target": "macaque CCR5",
      "label": "binds_to"
    },
    {
      "source": "[3H]-maraviroc",
      "target": "high affinity",
      "label": "has_property"
    },
    {
      "source": "human recombinant CCR5",
      "target": "binding properties",
      "label": "has_property"
    },
    {
      "source": "maraviroc",
      "target": "functional antagonist",
      "label": "is_a"
    },
    {
      "source": "maraviroc",
      "target": "novel CCR5 antagonists",
      "label": "is_a"
    },
    {
      "source": "maraviroc",
      "target": "macaque CCR5",
      "label": "inhibits_binding_to"
    },
    {
      "source": "maraviroc",
      "target": "intracellular calcium release",
      "label": "antagonizes"
    },
    {
      "source": "maraviroc",
      "target": "human recombinant CCR5",
      "label": "inhibits_binding_to"
    },
    {
      "source": "maraviroc",
      "target": "potency",
      "label": "has_property"
    },
    {
      "source": "maraviroc",
      "target": "high affinity",
      "label": "has_property"
    },
    {
      "source": "maraviroc",
      "target": "[125I]-MIP-1beta",
      "label": "inhibits_binding_of"
    },
    {
      "source": "maraviroc",
      "target": "UK-427,857",
      "label": "also_known_as"
    },
    {
      "source": "[125I]-MIP-1beta",
      "target": "human recombinant CCR5",
      "label": "binds_to"
    },
    {
      "source": "[125I]-MIP-1beta",
      "target": "kinetic properties",
      "label": "has_property"
    },
    {
      "source": "[125I]-MIP-1beta",
      "target": "macaque CCR5",
      "label": "binds_to"
    },
    {
      "source": "[125I]-MIP-1beta",
      "target": "high affinity",
      "label": "has_property"
    },
    {
      "source": "macaque",
      "target": "safety",
      "label": "suitable_to_evaluate"
    },
    {
      "source": "macaque",
      "target": "species",
      "label": "is_a"
    },
    {
      "source": "macaque",
      "target": "potential mechanism-related toxicology",
      "label": "suitable_to_evaluate"
    },
    {
      "source": "macaque",
      "target": "pre-clinical evaluation",
      "label": "suitable_for"
    },
    {
      "source": "macaque",
      "target": "pharmacology",
      "label": "suitable_to_evaluate"
    },
    {
      "source": "pre-clinical evaluation",
      "target": "novel CCR5 antagonists",
      "label": "targets"
    },
    {
      "source": "binding properties",
      "target": "[125I]-MIP-1beta",
      "label": "characterizes"
    },
    {
      "source": "binding properties",
      "target": "[3H]-maraviroc",
      "label": "characterizes"
    },
    {
      "source": "competition binding studies",
      "target": "affinity",
      "label": "determine"
    },
    {
      "source": "human chemokines",
      "target": "macaque CCR5",
      "label": "has_affinity_for"
    },
    {
      "source": "human chemokines",
      "target": "human recombinant CCR5",
      "label": "has_affinity_for"
    },
    {
      "source": "high affinity",
      "target": "K(d)",
      "label": "measured_by"
    },
    {
      "source": "UK-427,857",
      "target": "novel CCR5 antagonists",
      "label": "is_a"
    },
    {
      "source": "CCR5",
      "target": "rhesus macaque",
      "label": "originates_from"
    },
    {
      "source": "human",
      "target": "human FMO1-5",
      "label": "includes"
    },
    {
      "source": "human",
      "target": "human FMO6P",
      "label": "includes"
    },
    {
      "source": "radioligand binding characterization",
      "target": "chemokine receptor CCR5",
      "label": "targets"
    },
    {
      "source": "cyclooxygenase type 1",
      "target": "flushing",
      "label": "is required for"
    },
    {
      "source": "flushing",
      "target": "release",
      "label": "involves"
    },
    {
      "source": "PUMA-G",
      "target": "macrophages",
      "label": "expressed in"
    },
    {
      "source": "PUMA-G",
      "target": "immune cells",
      "label": "expressed in"
    },
    {
      "source": "PUMA-G",
      "target": "flushing",
      "label": "mediates"
    },
    {
      "source": "PUMA-G",
      "target": "mice",
      "label": "found in"
    },
    {
      "source": "PUMA-G",
      "target": "GPR109A",
      "label": "is orthologue of"
    },
    {
      "source": "macrophages",
      "target": "atherosclerotic plaques",
      "label": "are found in"
    },
    {
      "source": "macrophages",
      "target": "lipopolysaccharide",
      "label": "stimulated by"
    },
    {
      "source": "macrophages",
      "target": "HSV infection",
      "label": "are not permissive to"
    },
    {
      "source": "release",
      "target": "PGD(2)",
      "label": "of"
    },
    {
      "source": "release",
      "target": "PGE(2)",
      "label": "of"
    },
    {
      "source": "release",
      "target": "interleukin (IL)-8",
      "label": "is of"
    },
    {
      "source": "release",
      "target": "stimuli-responsive nanoparticles",
      "label": "is from"
    },
    {
      "source": "release",
      "target": "PW-HIFU exposure",
      "label": "occurred after"
    },
    {
      "source": "release",
      "target": "lipophilic compounds",
      "label": "is of"
    },
    {
      "source": "release",
      "target": "radiation force-induced acoustic streaming",
      "label": "originates from"
    },
    {
      "source": "release",
      "target": "drugs",
      "label": "is of"
    },
    {
      "source": "release",
      "target": "liposomes",
      "label": "is from"
    },
    {
      "source": "release",
      "target": "hydrophilic compounds",
      "label": "is of"
    },
    {
      "source": "release",
      "target": "non-thermosensitive liposomes (NTSL)",
      "label": "occurred from"
    },
    {
      "source": "prostaglandin D(2) (PGD(2)) and prostaglandin E(2) (PGE(2)) receptors",
      "target": "flushing response",
      "label": "is required for"
    },
    {
      "source": "flushing response",
      "target": "side effect",
      "label": "is a type of"
    },
    {
      "source": "antilipolytic effects",
      "target": "adipocytes",
      "label": "occur in"
    },
    {
      "source": "PGE(2)",
      "target": "immune cells",
      "label": "released from"
    },
    {
      "source": "prostaglandin E(2)",
      "target": "PGE(2)",
      "label": "is also known as"
    },
    {
      "source": "wild-type bone marrow",
      "target": "irradiated PUMA-G-deficient mice",
      "label": "transplanted into"
    },
    {
      "source": "pharmacological tools",
      "target": "lipid disorders",
      "label": "treat"
    },
    {
      "source": "GPR109A",
      "target": "flushing",
      "label": "mediates"
    },
    {
      "source": "GPR109A",
      "target": "G-protein-coupled receptor",
      "label": "is a type of"
    },
    {
      "source": "GPR109A",
      "target": "antilipolytic effects",
      "label": "mediates"
    },
    {
      "source": "GPR109A",
      "target": "PUMA-G",
      "label": "is also known as"
    },
    {
      "source": "GPR109A",
      "target": "HM74A",
      "label": "is also known as"
    },
    {
      "source": "prostaglandin D(2)",
      "target": "PGD(2)",
      "label": "is also known as"
    },
    {
      "source": "PGD(2)",
      "target": "immune cells",
      "label": "released from"
    },
    {
      "source": "niacin",
      "target": "antidyslipidemic drug",
      "label": "is a type of"
    },
    {
      "source": "pharmacotherapeutical use",
      "target": "flushing response",
      "label": "causes"
    },
    {
      "source": "transplantation",
      "target": "flushing response",
      "label": "restores"
    },
    {
      "source": "Niemann-Pick C1 Like 1 (NPC1L1) protein",
      "target": "gut",
      "label": "located in"
    },
    {
      "source": "Niemann-Pick C1 Like 1 (NPC1L1) protein",
      "target": "sterol transporter",
      "label": "is a"
    },
    {
      "source": "ABCG5",
      "target": "cholesterol",
      "label": "regulated by"
    },
    {
      "source": "ABCG5",
      "target": "sterol efflux pumps",
      "label": "is a type of"
    },
    {
      "source": "ABCG5",
      "target": "liver X receptors (LXRs)",
      "label": "regulated via"
    },
    {
      "source": "ABCG5",
      "target": "ATP-binding cassette (ABC) transporters",
      "label": "is a type of"
    },
    {
      "source": "Sterol transporters",
      "target": "new lipid lowering drugs",
      "label": "are targets of"
    },
    {
      "source": "Sterol transporters",
      "target": "natural sterols",
      "label": "are targets of"
    },
    {
      "source": "ezetimibe",
      "target": "direct cholesterol absorption inhibitor",
      "label": "is a"
    },
    {
      "source": "ezetimibe",
      "target": "steatohepatitis",
      "label": "treats"
    },
    {
      "source": "ezetimibe",
      "target": "non-alcoholic fatty liver disease",
      "label": "treats"
    },
    {
      "source": "ezetimibe",
      "target": "hepatic iron uptake transporter expression",
      "label": "induced"
    },
    {
      "source": "ezetimibe",
      "target": "0.3mg/day",
      "label": "has dosage"
    },
    {
      "source": "ezetimibe",
      "target": "iron metabolism",
      "label": "affects"
    },
    {
      "source": "sterol efflux pumps",
      "target": "intestinal sterol absorption",
      "label": "regulate"
    },
    {
      "source": "sterol efflux pumps",
      "target": "hepatic sterol output",
      "label": "regulate"
    },
    {
      "source": "sitosterolemia",
      "target": "rare disease",
      "label": "is a"
    },
    {
      "source": "ABCG8",
      "target": "ATP-binding cassette (ABC) transporters",
      "label": "is a type of"
    },
    {
      "source": "ABCG8",
      "target": "cholesterol",
      "label": "regulated by"
    },
    {
      "source": "ABCG8",
      "target": "liver X receptors (LXRs)",
      "label": "regulated via"
    },
    {
      "source": "ABCG8",
      "target": "sterol efflux pumps",
      "label": "is a type of"
    },
    {
      "source": "processes",
      "target": "mechanism of action",
      "label": "involved in"
    },
    {
      "source": "liver X receptors (LXRs)",
      "target": "derivatives of plant sterols",
      "label": "activated by"
    },
    {
      "source": "liver X receptors (LXRs)",
      "target": "oxysterols",
      "label": "activated by"
    },
    {
      "source": "sterol transport processes",
      "target": "small intestine",
      "label": "occur in"
    },
    {
      "source": "sterol transport processes",
      "target": "liver",
      "label": "occur in"
    },
    {
      "source": "oxysterols",
      "target": "LXR",
      "label": "are ligands for"
    },
    {
      "source": "oxysterols",
      "target": "sterol regulatory element binding protein-1c",
      "label": "upregulated"
    },
    {
      "source": "oxysterols",
      "target": "liver X receptor",
      "label": "are ligands for"
    },
    {
      "source": "oxysterols",
      "target": "RALDH genes",
      "label": "induced"
    },
    {
      "source": "oxysterols",
      "target": "SREBP-1c",
      "label": "upregulated"
    },
    {
      "source": "oxysterols",
      "target": "inflammatory cytokines",
      "label": "induce"
    },
    {
      "source": "oxysterols",
      "target": "cholesterol-rich foods",
      "label": "present in"
    },
    {
      "source": "oxysterols",
      "target": "intestinal mucosal damage",
      "label": "cause"
    },
    {
      "source": "oxysterols",
      "target": "homeostasis",
      "label": "interfere with"
    },
    {
      "source": "defective structures",
      "target": "patients",
      "label": "found in"
    },
    {
      "source": "defective structures",
      "target": "ABCG8",
      "label": "found in"
    },
    {
      "source": "defective structures",
      "target": "ABCG5",
      "label": "found in"
    },
    {
      "source": "lithium",
      "target": "bipolar disorder",
      "label": "treats"
    },
    {
      "source": "lithium",
      "target": "arachidonic acid",
      "label": "reduces turnover of"
    },
    {
      "source": "lithium",
      "target": "phospholipase A(2)",
      "label": "decreases activity of"
    },
    {
      "source": "Valproic acid",
      "target": "Acsl",
      "label": "inhibits"
    },
    {
      "source": "Valproic acid",
      "target": "docosahexaenoic acid",
      "label": "affects turnover of"
    },
    {
      "source": "Valproic acid",
      "target": "bipolar disorder",
      "label": "treats"
    },
    {
      "source": "Valproic acid",
      "target": "docosahexaenoyl-CoA",
      "label": "inhibits synthesis of"
    },
    {
      "source": "Valproic acid",
      "target": "brain arachidonic acid cascade",
      "label": "reduces"
    },
    {
      "source": "Valproic acid",
      "target": "arachidonic acid",
      "label": "affects turnover of"
    },
    {
      "source": "Valproic acid",
      "target": "arachidonoyl-CoA",
      "label": "inhibits formation of"
    },
    {
      "source": "Valproic acid",
      "target": "brain microsomal long-chain fatty acyl-CoA synthetases",
      "label": "inhibits"
    },
    {
      "source": "Valproic acid",
      "target": "palmitoyl-CoA",
      "label": "inhibits synthesis of"
    },
    {
      "source": "Valproic acid",
      "target": "phospholipase A(2)",
      "label": "does not alter activity of"
    },
    {
      "source": "Acsl",
      "target": "brain microsomal long-chain fatty acyl-CoA synthetases",
      "label": "is a type of"
    },
    {
      "source": "Acsl",
      "target": "valproyl-CoA",
      "label": "does not produce"
    },
    {
      "source": "phospholipase A(2)",
      "target": "arachidonic acid",
      "label": "is selective for"
    },
    {
      "source": "docosahexaenoic acid",
      "target": "brain phospholipids",
      "label": "turnover occurs in"
    },
    {
      "source": "docosahexaenoic acid",
      "target": "22:6n-3",
      "label": "is also known as"
    },
    {
      "source": "docosahexaenoic acid",
      "target": "DHA",
      "label": "is also known as"
    },
    {
      "source": "brain microsomal long-chain fatty acyl-CoA synthetases",
      "target": "arachidonic acid",
      "label": "converts"
    },
    {
      "source": "brain microsomal long-chain fatty acyl-CoA synthetases",
      "target": "arachidonoyl-CoA",
      "label": "produces"
    },
    {
      "source": "carbamazepine",
      "target": "phospholipase A(2)",
      "label": "decreases activity of"
    },
    {
      "source": "carbamazepine",
      "target": "arachidonic acid",
      "label": "reduces turnover of"
    },
    {
      "source": "carbamazepine",
      "target": "bipolar disorder",
      "label": "treats"
    },
    {
      "source": "carbamazepine",
      "target": "secondary or primary amines",
      "label": "contains"
    },
    {
      "source": "p75 neurotrophin receptor",
      "target": "in vivo",
      "label": "is diminished"
    },
    {
      "source": "p75 neurotrophin receptor",
      "target": "epithelial cells",
      "label": "is diminished in"
    },
    {
      "source": "p75 neurotrophin receptor",
      "target": "in vitro",
      "label": "is diminished"
    },
    {
      "source": "p75 neurotrophin receptor",
      "target": "prostate cancer",
      "label": "is diminished during progression of"
    },
    {
      "source": "p75NTR",
      "target": "cell adhesion",
      "label": "modulated"
    },
    {
      "source": "p75NTR",
      "target": "apoptosis",
      "label": "modulated"
    },
    {
      "source": "p75NTR",
      "target": "molecular mechanism",
      "label": "has a"
    },
    {
      "source": "p75NTR",
      "target": "tumor suppression",
      "label": "affects"
    },
    {
      "source": "p75NTR",
      "target": "tumor suppressor",
      "label": "acts as"
    },
    {
      "source": "p75NTR",
      "target": "signal transduction",
      "label": "modulated"
    },
    {
      "source": "p75NTR",
      "target": "differentially expressed genes",
      "label": "resulted in"
    },
    {
      "source": "p75NTR",
      "target": "regulation of differentiation",
      "label": "modulated"
    },
    {
      "source": "p75NTR",
      "target": "in vivo",
      "label": "is diminished"
    },
    {
      "source": "p75NTR",
      "target": "epithelial cells",
      "label": "is diminished in"
    },
    {
      "source": "p75NTR",
      "target": "prostate growth",
      "label": "has a role in"
    },
    {
      "source": "p75NTR",
      "target": "gene expression",
      "label": "modulated"
    },
    {
      "source": "p75NTR",
      "target": "tumor cell invasion",
      "label": "modulated"
    },
    {
      "source": "p75NTR",
      "target": "in vitro",
      "label": "is diminished"
    },
    {
      "source": "p75NTR",
      "target": "de-differentiation",
      "label": "reverses"
    },
    {
      "source": "p75NTR",
      "target": "prostate cancer",
      "label": "is diminished during progression of"
    },
    {
      "source": "p75NTR",
      "target": "CRABPI",
      "label": "up-regulates"
    },
    {
      "source": "p75NTR",
      "target": "gene expression pattern",
      "label": "altered"
    },
    {
      "source": "p75NTR",
      "target": "differentiation",
      "label": "is involved in"
    },
    {
      "source": "p75NTR",
      "target": "metastasis",
      "label": "modulated"
    },
    {
      "source": "p75NTR protein expression",
      "target": "IGFBP5 protein levels",
      "label": "increased"
    },
    {
      "source": "p75NTR protein expression",
      "target": "cellular retinoic acid-binding protein I",
      "label": "increased"
    },
    {
      "source": "p75NTR protein expression",
      "target": "PLAUR protein",
      "label": "decreased"
    },
    {
      "source": "p75NTR protein expression",
      "target": "CRABPI",
      "label": "increased"
    },
    {
      "source": "p75NTR protein expression",
      "target": "PLAUR",
      "label": "decreased"
    },
    {
      "source": "p75NTR protein expression",
      "target": "IGFBP5",
      "label": "increased"
    },
    {
      "source": "Immunoblot analysis",
      "target": "PLAUR",
      "label": "confirmed decreased"
    },
    {
      "source": "Immunoblot analysis",
      "target": "IGFBP5",
      "label": "confirmed increased"
    },
    {
      "source": "Immunoblot analysis",
      "target": "IGFBP5 protein levels",
      "label": "confirmed increased"
    },
    {
      "source": "Immunoblot analysis",
      "target": "cellular retinoic acid-binding protein I",
      "label": "confirmed increased"
    },
    {
      "source": "Immunoblot analysis",
      "target": "CRABPI",
      "label": "confirmed increased"
    },
    {
      "source": "Immunoblot analysis",
      "target": "PLAUR protein",
      "label": "confirmed decreased"
    },
    {
      "source": "RAR-beta",
      "target": "neo control PC-3 cells",
      "label": "is absent in"
    },
    {
      "source": "RAR-beta",
      "target": "tumor suppressor gene",
      "label": "acts as"
    },
    {
      "source": "RAR-beta",
      "target": "p75NTR PC-3 cells",
      "label": "is re-expressed in"
    },
    {
      "source": "retinoic acid receptors",
      "target": "expression levels",
      "label": "have"
    },
    {
      "source": "retinoic acid receptors",
      "target": "RARalpha",
      "label": "include"
    },
    {
      "source": "retinoic acid receptors",
      "target": "beta",
      "label": "include"
    },
    {
      "source": "retinoic acid receptors",
      "target": "nuclear hormone receptor superfamily",
      "label": "are members of"
    },
    {
      "source": "retinoic acid receptors",
      "target": "RXRalpha",
      "label": "include"
    },
    {
      "source": "retinoic acid receptors",
      "target": "gamma",
      "label": "include"
    },
    {
      "source": "expression levels",
      "target": "real-time RT-PCR",
      "label": "examined using"
    },
    {
      "source": "expression levels",
      "target": "NMDA receptor",
      "label": "of"
    },
    {
      "source": "expression levels",
      "target": "neurotrophins",
      "label": "of"
    },
    {
      "source": "expression levels",
      "target": "frequency",
      "label": "modifies"
    },
    {
      "source": "expression levels",
      "target": "endogenous APP",
      "label": "are_of"
    },
    {
      "source": "expression levels",
      "target": "amplitude",
      "label": "modifies"
    },
    {
      "source": "RARs",
      "target": "expression levels",
      "label": "have"
    },
    {
      "source": "p75NTR siRNA",
      "target": "RAR-beta",
      "label": "knockdown levels of"
    },
    {
      "source": "p75NTR siRNA",
      "target": "RXR-alpha",
      "label": "knockdown levels of"
    },
    {
      "source": "p75NTR siRNA",
      "target": "RXR-beta",
      "label": "knockdown levels of"
    },
    {
      "source": "RAR-gamma",
      "target": "protein levels",
      "label": "has"
    },
    {
      "source": "protein levels",
      "target": "immunohistochemistry",
      "label": "determined by"
    },
    {
      "source": "protein levels",
      "target": "western-blot",
      "label": "determined by"
    },
    {
      "source": "protein levels",
      "target": "TNF-\u03b1",
      "label": "of"
    },
    {
      "source": "protein levels",
      "target": "IL-6",
      "label": "of"
    },
    {
      "source": "protein levels",
      "target": "western blot analysis",
      "label": "determined using"
    },
    {
      "source": "retinoids",
      "target": "nitroblue tetrazolium-associated functional cell differentiation",
      "label": "promoted"
    },
    {
      "source": "retinoids",
      "target": "RXR-alpha",
      "label": "are available to"
    },
    {
      "source": "retinoids",
      "target": "RXR-beta",
      "label": "are available to"
    },
    {
      "source": "retinoids",
      "target": "CRABPI",
      "label": "bind"
    },
    {
      "source": "retinoids",
      "target": "RAR-beta",
      "label": "are available to"
    },
    {
      "source": "retinoids",
      "target": "Th1 dominant autoimmune diseases",
      "label": "target"
    },
    {
      "source": "nitroblue tetrazolium-associated functional cell differentiation",
      "target": "neo control PC-3 cells",
      "label": "did not occur in"
    },
    {
      "source": "nitroblue tetrazolium-associated functional cell differentiation",
      "target": "p75NTR PC-3 cells",
      "label": "occurred in"
    },
    {
      "source": "re-introduction",
      "target": "PC-3 prostate tumor cells",
      "label": "into"
    },
    {
      "source": "re-introduction",
      "target": "p75NTR",
      "label": "of"
    },
    {
      "source": "de-differentiation",
      "target": "prostate cancer",
      "label": "of"
    },
    {
      "source": "de-differentiation",
      "target": "prostate epithelial cells",
      "label": "occurs in"
    },
    {
      "source": "prostate cancer",
      "target": "men",
      "label": "increased incidence in"
    },
    {
      "source": "complementary deoxyribonucleic acid microarray",
      "target": "human cancer-related genes",
      "label": "composed of"
    },
    {
      "source": "cDNA microarray profiling",
      "target": "p75NTR-regulated gene expression",
      "label": "revealed"
    },
    {
      "source": "cDNA microarray profiling",
      "target": "differentiation",
      "label": "revealed"
    },
    {
      "source": "all-trans retinoic acid",
      "target": "CRABPI",
      "label": "bind"
    },
    {
      "source": "all-trans retinoic acid",
      "target": "nitroblue tetrazolium-associated functional cell differentiation",
      "label": "promoted"
    },
    {
      "source": "CRABPI",
      "target": "localized sequestration",
      "label": "causes"
    },
    {
      "source": "retinoid X receptor",
      "target": "protein levels",
      "label": "exhibited increasing"
    },
    {
      "source": "RAR-alpha",
      "target": "protein levels",
      "label": "has"
    },
    {
      "source": "tumor suppressor gene",
      "target": "de-differentiation",
      "label": "is lost during"
    },
    {
      "source": "microarray",
      "target": "differentially expressed genes",
      "label": "identified"
    },
    {
      "source": "9-cis retinoic acid",
      "target": "nitroblue tetrazolium-associated functional cell differentiation",
      "label": "promoted"
    },
    {
      "source": "9-cis retinoic acid",
      "target": "CRABPI",
      "label": "bind"
    },
    {
      "source": "p75NTR-transfected cells",
      "target": "transcripts",
      "label": "contain"
    },
    {
      "source": "transcripts",
      "target": "gill",
      "label": "located within"
    },
    {
      "source": "transcripts",
      "target": "alternative splicing",
      "label": "due to"
    },
    {
      "source": "transcripts",
      "target": "cynomolgus FMO6",
      "label": "isolated for"
    },
    {
      "source": "RXR-alpha",
      "target": "protein levels",
      "label": "exhibited increasing"
    },
    {
      "source": "localized sequestration",
      "target": "retinoids",
      "label": "of"
    },
    {
      "source": "RXR-beta",
      "target": "protein levels",
      "label": "exhibited increasing"
    },
    {
      "source": "quantitative real-time polymerase chain reaction",
      "target": "differentially expressed genes",
      "label": "used for confirmation of"
    },
    {
      "source": "p75NTR protein",
      "target": "RXR-alpha",
      "label": "re-expression increased"
    },
    {
      "source": "p75NTR protein",
      "target": "RXR-beta",
      "label": "re-expression increased"
    },
    {
      "source": "metastasis",
      "target": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "label": "should be considered for"
    },
    {
      "source": "neo cells",
      "target": "transcripts",
      "label": "contain"
    },
    {
      "source": "research",
      "target": "patient",
      "label": "started with"
    },
    {
      "source": "research",
      "target": "aspects",
      "label": "deals with"
    },
    {
      "source": "research",
      "target": "field",
      "label": "rooted in"
    },
    {
      "source": "research",
      "target": "atypical antipsychotics",
      "label": "needed on"
    },
    {
      "source": "research",
      "target": "treatment of core symptoms",
      "label": "on"
    },
    {
      "source": "research",
      "target": "antidepressants",
      "label": "needed on"
    },
    {
      "source": "urinary organic acids",
      "target": "gas chromatography-mass spectrometry",
      "label": "analyzed by"
    },
    {
      "source": "voyage",
      "target": "inborn error patient",
      "label": "originated from"
    },
    {
      "source": "voyage",
      "target": "regulatory meaning",
      "label": "aimed at finding"
    },
    {
      "source": "masses",
      "target": "muscle",
      "label": "reduced in"
    },
    {
      "source": "masses",
      "target": "adipose tissue",
      "label": "reduced in"
    },
    {
      "source": "masses",
      "target": "liver",
      "label": "reduced in"
    },
    {
      "source": "masses",
      "target": "spleen",
      "label": "reduced in"
    },
    {
      "source": "masses",
      "target": "kidney",
      "label": "reduced in"
    },
    {
      "source": "masses",
      "target": "intestine",
      "label": "reduced in"
    },
    {
      "source": "Carboxylase activities",
      "target": "muscle",
      "label": "reduced in"
    },
    {
      "source": "Carboxylase activities",
      "target": "adipose tissue",
      "label": "reduced in"
    },
    {
      "source": "Carboxylase activities",
      "target": "liver",
      "label": "reduced in"
    },
    {
      "source": "Carboxylase activities",
      "target": "spleen",
      "label": "reduced in"
    },
    {
      "source": "Carboxylase activities",
      "target": "intestine",
      "label": "reduced in"
    },
    {
      "source": "Carboxylase activities",
      "target": "kidney",
      "label": "reduced in"
    },
    {
      "source": "human genes",
      "target": "biotin",
      "label": "depend on"
    },
    {
      "source": "human genes",
      "target": "expression",
      "label": "depend on biotin for"
    },
    {
      "source": "biotin deficiency",
      "target": "tissue level",
      "label": "studied at"
    },
    {
      "source": "aspects",
      "target": "vitamin biotin",
      "label": "are of"
    },
    {
      "source": "field",
      "target": "inherited metabolic disorders",
      "label": "is of"
    },
    {
      "source": "field",
      "target": "medicinal chemistry",
      "label": "includes"
    },
    {
      "source": "field",
      "target": "mGlu2 receptor PAMs",
      "label": "is of"
    },
    {
      "source": "field",
      "target": "pharmacology",
      "label": "includes"
    },
    {
      "source": "biotin effects",
      "target": "proteins",
      "label": "on"
    },
    {
      "source": "biotin effects",
      "target": "specific genes",
      "label": "on"
    },
    {
      "source": "biotin effects",
      "target": "proteomes",
      "label": "on"
    },
    {
      "source": "HCS mRNA levels",
      "target": "deficient animals",
      "label": "were low in"
    },
    {
      "source": "HCS mRNA levels",
      "target": "biotin injection",
      "label": "increased upon"
    },
    {
      "source": "mRNAs",
      "target": "brain",
      "label": "remained unchanged in"
    },
    {
      "source": "mRNAs",
      "target": "heart",
      "label": "remained unchanged in"
    },
    {
      "source": "metabolic abnormalities",
      "target": "protein feeding",
      "label": "became apparent after"
    },
    {
      "source": "phenomenon",
      "target": "malnourished individuals",
      "label": "may contribute to worsening of"
    },
    {
      "source": "intestine",
      "target": "mice",
      "label": "is part of"
    },
    {
      "source": "MCD clinical manifestations",
      "target": "infant malnutrition",
      "label": "resemble"
    },
    {
      "source": "comparative studies",
      "target": "organisms",
      "label": "among"
    },
    {
      "source": "article",
      "target": "findings",
      "label": "summarizes"
    },
    {
      "source": "article",
      "target": "Special Issue",
      "label": "is part of"
    },
    {
      "source": "logic",
      "target": "enigma",
      "label": "is of"
    },
    {
      "source": "hyperosmotic diuretic solution",
      "target": "glycerol",
      "label": "contains"
    },
    {
      "source": "hyperosmotic diuretic solution",
      "target": "saline",
      "label": "contains"
    },
    {
      "source": "hyperosmotic diuretic solution",
      "target": "fructose",
      "label": "contains"
    },
    {
      "source": "glycerol",
      "target": "brain edema",
      "label": "does not treat"
    },
    {
      "source": "glycerol",
      "target": "CTLN2",
      "label": "not recommended for"
    },
    {
      "source": "Glyceol",
      "target": "hyperosmotic diuretic solution",
      "label": "is a type of"
    },
    {
      "source": "Glyceol",
      "target": "saline",
      "label": "contains"
    },
    {
      "source": "Glyceol",
      "target": "glycerol",
      "label": "contains"
    },
    {
      "source": "Glyceol",
      "target": "fructose",
      "label": "contains"
    },
    {
      "source": "Glyceol",
      "target": "brain edema",
      "label": "alleviates"
    },
    {
      "source": "CTLN2",
      "target": "mutations",
      "label": "diagnosed by"
    },
    {
      "source": "CTLN2",
      "target": "hepatic argininosuccinate synthetase activity",
      "label": "diagnosed by"
    },
    {
      "source": "CTLN2",
      "target": "differential diagnosis",
      "label": "is a"
    },
    {
      "source": "CTLN2",
      "target": "serum pancreatic secretory trypsin inhibitor",
      "label": "diagnosed by"
    },
    {
      "source": "CTLN2",
      "target": "hepatic citrin protein expression",
      "label": "diagnosed by"
    },
    {
      "source": "CTLN2",
      "target": "plasma citrulline level",
      "label": "diagnosed by"
    },
    {
      "source": "CTLN2",
      "target": "autosomal recessive disorder",
      "label": "is a type of"
    },
    {
      "source": "CTLN2",
      "target": "recurrent encephalopathy",
      "label": "characterized by"
    },
    {
      "source": "high signal intensities",
      "target": "insular cortices",
      "label": "located at"
    },
    {
      "source": "high signal intensities",
      "target": "bilateral cingulate gyri",
      "label": "located at"
    },
    {
      "source": "high signal intensities",
      "target": "hepatic encephalopathy",
      "label": "suggests"
    },
    {
      "source": "recurrent encephalopathy",
      "target": "hyperammonemia",
      "label": "associated with"
    },
    {
      "source": "differential diagnosis",
      "target": "Asian patients",
      "label": "relevant for"
    },
    {
      "source": "Asian patients",
      "target": "repeated unconsciousness",
      "label": "present with"
    },
    {
      "source": "serum pancreatic secretory trypsin inhibitor",
      "target": "PSTI",
      "label": "also known as"
    },
    {
      "source": "repeated unconsciousness",
      "target": "hyperammonemia",
      "label": "associated with"
    },
    {
      "source": "compound heterozygote",
      "target": "Ex1-1G>A",
      "label": "includes"
    },
    {
      "source": "compound heterozygote",
      "target": "S225X",
      "label": "includes"
    },
    {
      "source": "Ex1-1G>A",
      "target": "mutations",
      "label": "is a type of"
    },
    {
      "source": "SLC25A13 gene",
      "target": "citrin",
      "label": "encodes"
    },
    {
      "source": "clinical course",
      "target": "Glyceol",
      "label": "worsened by"
    },
    {
      "source": "clinical course",
      "target": "hyperosmotic and high sugar solutions",
      "label": "deteriorated by"
    },
    {
      "source": "plasma ammonia level",
      "target": "liver diseases",
      "label": "elevated without evidence of"
    },
    {
      "source": "autosomal recessive disorder",
      "target": "mutations",
      "label": "caused by"
    },
    {
      "source": "S225X",
      "target": "mutations",
      "label": "is a type of"
    },
    {
      "source": "intractable seizures",
      "target": "plasma ammonia levels",
      "label": "associated with"
    },
    {
      "source": "coma",
      "target": "altered consciousness",
      "label": "occurred after"
    },
    {
      "source": "D-mannitol",
      "target": "CTLN2",
      "label": "recommended for"
    },
    {
      "source": "D-mannitol",
      "target": "brain edema",
      "label": "treats"
    },
    {
      "source": "adult-onset type II citrullinemia",
      "target": "CTLN2",
      "label": "also known as"
    },
    {
      "source": "Brain MRI",
      "target": "high signal intensities",
      "label": "revealed"
    },
    {
      "source": "Deltaxprt null mutants",
      "target": "virulent background",
      "label": "created within"
    },
    {
      "source": "Deltaxprt null mutants",
      "target": "targeted gene replacement",
      "label": "created by"
    },
    {
      "source": "virulent background",
      "target": "Leishmania donovani",
      "label": "is of"
    },
    {
      "source": "purine salvage",
      "target": "parasite life cycle stages",
      "label": "occurs in"
    },
    {
      "source": "purine salvage",
      "target": "anabolic routes",
      "label": "occurs through"
    },
    {
      "source": "Deltaaprt null mutants",
      "target": "virulent background",
      "label": "created within"
    },
    {
      "source": "Deltaaprt null mutants",
      "target": "targeted gene replacement",
      "label": "created by"
    },
    {
      "source": "Leishmania donovani",
      "target": "in vitro",
      "label": "are viable"
    },
    {
      "source": "Leishmania donovani",
      "target": "APRT",
      "label": "is deficient in"
    },
    {
      "source": "Leishmania donovani",
      "target": "mammalian macrophages",
      "label": "are viable within"
    },
    {
      "source": "Leishmania donovani",
      "target": "XPRT",
      "label": "is deficient in"
    },
    {
      "source": "Leishmania donovani",
      "target": "HGPRT",
      "label": "is deficient in"
    },
    {
      "source": "three phosphoribosyltransferase enzymes",
      "target": "hypoxanthine-guanine phosphoribosyltransferase",
      "label": "include"
    },
    {
      "source": "three phosphoribosyltransferase enzymes",
      "target": "adenine phosphoribosyltransferase",
      "label": "include"
    },
    {
      "source": "three phosphoribosyltransferase enzymes",
      "target": "xanthine phosphoribosyltransferase",
      "label": "include"
    },
    {
      "source": "hypoxanthine-guanine phosphoribosyltransferase",
      "target": "HGPRT",
      "label": "is also known as"
    },
    {
      "source": "adenine aminohydrolase enzyme",
      "target": "L. donovani",
      "label": "is in"
    },
    {
      "source": "adenine aminohydrolase enzyme",
      "target": "axenic amastigotes",
      "label": "is in"
    },
    {
      "source": "Deltahgprt null mutants",
      "target": "virulent background",
      "label": "created within"
    },
    {
      "source": "Deltahgprt null mutants",
      "target": "targeted gene replacement",
      "label": "created by"
    },
    {
      "source": "Leishmania species",
      "target": "three phosphoribosyltransferase enzymes",
      "label": "express"
    },
    {
      "source": "adenine phosphoribosyltransferase",
      "target": "APRT",
      "label": "is also known as"
    },
    {
      "source": "three knockout strains",
      "target": "promastigotes",
      "label": "was viable as"
    },
    {
      "source": "three knockout strains",
      "target": "axenic amastigotes",
      "label": "was viable as"
    },
    {
      "source": "three knockout strains",
      "target": "infection",
      "label": "is capable of maintaining"
    },
    {
      "source": "infection",
      "target": "bone marrow-derived murine macrophages",
      "label": "is in"
    },
    {
      "source": "phosphoribosyltransferases",
      "target": "purine salvage",
      "label": "is not essential for"
    },
    {
      "source": "phosphoribosyltransferases",
      "target": "viability",
      "label": "is not essential for"
    },
    {
      "source": "this genus",
      "target": "purine nutrients",
      "label": "acquires"
    },
    {
      "source": "this genus",
      "target": "hosts",
      "label": "acquires from"
    },
    {
      "source": "null mutants",
      "target": "virulent background",
      "label": "created within"
    },
    {
      "source": "viability",
      "target": "human tumor cell lines",
      "label": "decreased in"
    },
    {
      "source": "viability",
      "target": "mouse tumor cell lines",
      "label": "decreased in"
    },
    {
      "source": "xanthine phosphoribosyltransferase",
      "target": "XPRT",
      "label": "is also known as"
    },
    {
      "source": "NISHTKEKKKGKAKKKRLTK",
      "target": "renal accumulation of gentamicin",
      "label": "inhibits"
    },
    {
      "source": "N-WASP181-200",
      "target": "megalin",
      "label": "interact with"
    },
    {
      "source": "N-WASP181-200",
      "target": "20-residue basic peptide",
      "label": "is a"
    },
    {
      "source": "N-WASP181-200",
      "target": "inhibitory effect",
      "label": "has"
    },
    {
      "source": "N-WASP181-200",
      "target": "renal accumulation of gentamicin",
      "label": "inhibits"
    },
    {
      "source": "N-WASP181-200",
      "target": "NISHTKEKKKGKAKKKRLTK",
      "label": "is also known as"
    },
    {
      "source": "N-WASP181-200",
      "target": "gentamicin binding",
      "label": "inhibited"
    },
    {
      "source": "megalin",
      "target": "endocytic receptor",
      "label": "is an"
    },
    {
      "source": "megalin",
      "target": "renal uptake of gentamicin",
      "label": "involved in"
    },
    {
      "source": "basic peptides",
      "target": "gentamicin binding",
      "label": "inhibits"
    },
    {
      "source": "basic peptides",
      "target": "megalin",
      "label": "interact with"
    },
    {
      "source": "basic peptides",
      "target": "renal accumulation of gentamicin",
      "label": "decrease"
    },
    {
      "source": "gentamicin binding",
      "target": "rat renal brush-border membrane",
      "label": "occurs at"
    },
    {
      "source": "gentamicin binding",
      "target": "BBM",
      "label": "occurs at"
    },
    {
      "source": "gentamicin binding",
      "target": "native BBM",
      "label": "compared with"
    },
    {
      "source": "gentamicin binding",
      "target": "isolated rat renal brush-border membrane",
      "label": "occurs at"
    },
    {
      "source": "glycines",
      "target": "lysines",
      "label": "substituted for"
    },
    {
      "source": "BBM",
      "target": "proximal tubule cells",
      "label": "is part of"
    },
    {
      "source": "20-residue basic peptide",
      "target": "renal accumulation of gentamicin",
      "label": "inhibits"
    },
    {
      "source": "trypsin",
      "target": "megalin",
      "label": "caused disappearance of"
    },
    {
      "source": "trypsin",
      "target": "gentamicin binding",
      "label": "decreased"
    },
    {
      "source": "trypsin",
      "target": "inhibitory effect",
      "label": "decreased"
    },
    {
      "source": "megalin ligands",
      "target": "renal accumulation of gentamicin",
      "label": "decrease"
    },
    {
      "source": "megalin ligands",
      "target": "gentamicin binding",
      "label": "inhibits"
    },
    {
      "source": "megalin ligands",
      "target": "megalin",
      "label": "interact with"
    },
    {
      "source": "N-WASP180-200",
      "target": "basic peptides",
      "label": "is a type of"
    },
    {
      "source": "endocytic receptor",
      "target": "renal uptake of gentamicin",
      "label": "involved in"
    },
    {
      "source": "isolated rat renal brush-border membrane",
      "target": "BBM",
      "label": "is also known as"
    },
    {
      "source": "cytochrome c",
      "target": "renal accumulation of gentamicin",
      "label": "inhibits"
    },
    {
      "source": "alpha-helix conformation",
      "target": "inhibitory effect",
      "label": "plays a role in"
    },
    {
      "source": "mutant peptides",
      "target": "basic peptides",
      "label": "is a type of"
    },
    {
      "source": "basic peptide fragments of cytochrome c",
      "target": "gentamicin binding",
      "label": "inhibited"
    },
    {
      "source": "selection method",
      "target": "subsequent therapies",
      "label": "for"
    },
    {
      "source": "5-fluorouracil",
      "target": "chemotherapeutic drug",
      "label": "is a type of"
    },
    {
      "source": "5-fluorouracil",
      "target": "cell proliferation",
      "label": "inhibited"
    },
    {
      "source": "28-bp sequence",
      "target": "gene promoter",
      "label": "located within"
    },
    {
      "source": "SNP",
      "target": "patients",
      "label": "determined in"
    },
    {
      "source": "SNP",
      "target": "RFLP",
      "label": "determined by"
    },
    {
      "source": "SNP",
      "target": "restriction-length-fragment polymorphism",
      "label": "determined by"
    },
    {
      "source": "SNP",
      "target": "region",
      "label": "located within"
    },
    {
      "source": "SNP",
      "target": "rs53576 genotype",
      "label": "is a type of"
    },
    {
      "source": "combined effect",
      "target": "parameters",
      "label": "of"
    },
    {
      "source": "TS",
      "target": "biological target",
      "label": "is a"
    },
    {
      "source": "biological target",
      "target": "5-fluorouracil",
      "label": "of"
    },
    {
      "source": "biological target",
      "target": "5FU",
      "label": "of"
    },
    {
      "source": "Paraffin-embedded sections",
      "target": "immuno-histochemistry",
      "label": "analyzed by"
    },
    {
      "source": "Paraffin-embedded sections",
      "target": "CRC patients",
      "label": "from"
    },
    {
      "source": "immuno-histochemistry",
      "target": "Mab TS106",
      "label": "uses"
    },
    {
      "source": "immuno-histochemistry",
      "target": "expression pattern",
      "label": "analyzes"
    },
    {
      "source": "immuno-histochemistry",
      "target": "TS levels",
      "label": "analyzes"
    },
    {
      "source": "PFS",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "C SNP",
      "target": "variables",
      "label": "is a type of"
    },
    {
      "source": "response to chemotherapy",
      "target": "CRC patients",
      "label": "occurs in"
    },
    {
      "source": "expression pattern",
      "target": "TS",
      "label": "of"
    },
    {
      "source": "expression pattern",
      "target": "disease-free survival",
      "label": "predicts"
    },
    {
      "source": "expression pattern",
      "target": "survival",
      "label": "associated with"
    },
    {
      "source": "expression pattern",
      "target": "Thymidylate synthase",
      "label": "of"
    },
    {
      "source": "expression pattern",
      "target": "genes",
      "label": "is of"
    },
    {
      "source": "consensus",
      "target": "value",
      "label": "concerns"
    },
    {
      "source": "value",
      "target": "SNP",
      "label": "of"
    },
    {
      "source": "value",
      "target": "single nucleotide polymorphism",
      "label": "of"
    },
    {
      "source": "prognostic factors",
      "target": "variable agreement",
      "label": "has"
    },
    {
      "source": "Cytoplasmic expression pattern",
      "target": "variables",
      "label": "is a type of"
    },
    {
      "source": "Cytoplasmic expression pattern",
      "target": "C SNP",
      "label": "associated with"
    },
    {
      "source": "single nucleotide polymorphism",
      "target": "disease-free survival",
      "label": "predicts"
    },
    {
      "source": "single nucleotide polymorphism",
      "target": "region",
      "label": "located within"
    },
    {
      "source": "single nucleotide polymorphism",
      "target": "Thymidylate synthase",
      "label": "of"
    },
    {
      "source": "single nucleotide polymorphism",
      "target": "SNP",
      "label": "is a type of"
    },
    {
      "source": "clinical outcome",
      "target": "CRC patients",
      "label": "occurs in"
    },
    {
      "source": "clinical outcome",
      "target": "metastatic colorectal cancer patients",
      "label": "of"
    },
    {
      "source": "level of protein expression",
      "target": "prognostic factors",
      "label": "proposed as"
    },
    {
      "source": "level of protein expression",
      "target": "predictive factors",
      "label": "proposed as"
    },
    {
      "source": "progression-free survival",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "predictive factors",
      "target": "variable agreement",
      "label": "has"
    },
    {
      "source": "low risk",
      "target": "PFS",
      "label": "shows"
    },
    {
      "source": "expression level",
      "target": "disease-free survival",
      "label": "predicts"
    },
    {
      "source": "expression level",
      "target": "Thymidylate synthase",
      "label": "of"
    },
    {
      "source": "expression level",
      "target": "nerve growth factor mRNA",
      "label": "of"
    },
    {
      "source": "disease-free survival",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "number of variable tandem-repeats",
      "target": "28-bp sequence",
      "label": "is a repeat of"
    },
    {
      "source": "number of variable tandem-repeats",
      "target": "predictive factors",
      "label": "proposed as"
    },
    {
      "source": "number of variable tandem-repeats",
      "target": "prognostic factors",
      "label": "proposed as"
    },
    {
      "source": "survival",
      "target": "immediate pharmacologic intervention",
      "label": "possible without"
    },
    {
      "source": "survival",
      "target": "pretreatment",
      "label": "possible without"
    },
    {
      "source": "VNTR",
      "target": "polymerase-chain reaction",
      "label": "determined by"
    },
    {
      "source": "VNTR",
      "target": "PCR",
      "label": "determined by"
    },
    {
      "source": "VNTR",
      "target": "patients",
      "label": "determined in"
    },
    {
      "source": "Low TS expression levels",
      "target": "variables",
      "label": "is a type of"
    },
    {
      "source": "pharmacological agents",
      "target": "AMPK",
      "label": "activate"
    },
    {
      "source": "pharmacological agents",
      "target": "therapeutic targets",
      "label": "could be"
    },
    {
      "source": "pharmacological agents",
      "target": "malonyl CoA",
      "label": "decrease"
    },
    {
      "source": "AMPK",
      "target": "intracellular fatty acid partitioning",
      "label": "alters"
    },
    {
      "source": "AMPK",
      "target": "interaction between Beclin1 and Bcl-2",
      "label": "affects"
    },
    {
      "source": "AMPK",
      "target": "tumor growth",
      "label": "suppresses"
    },
    {
      "source": "AMPK",
      "target": "Warburg effect",
      "label": "negatively regulates"
    },
    {
      "source": "AMPK",
      "target": "aerobic glycolysis",
      "label": "negatively regulates"
    },
    {
      "source": "AMPK",
      "target": "tumor metabolism",
      "label": "has a role in"
    },
    {
      "source": "AMPK",
      "target": "metabolic sensor",
      "label": "is a"
    },
    {
      "source": "AMPK",
      "target": "tumor suppressor functions",
      "label": "is linked with"
    },
    {
      "source": "AMPK",
      "target": "tumorigenesis",
      "label": "has a role in"
    },
    {
      "source": "AMPK",
      "target": "longevity",
      "label": "links to"
    },
    {
      "source": "AMPK",
      "target": "cellular energy sensor",
      "label": "is a"
    },
    {
      "source": "AMPK",
      "target": "life span",
      "label": "prolongs"
    },
    {
      "source": "AMPK",
      "target": "energy sensing",
      "label": "links"
    },
    {
      "source": "AMPK",
      "target": "life span modulator",
      "label": "is a"
    },
    {
      "source": "AMPK",
      "target": "Drosophila",
      "label": "acts in"
    },
    {
      "source": "AMPK",
      "target": "dietary restriction",
      "label": "mimics"
    },
    {
      "source": "AMPK",
      "target": "aging",
      "label": "slows"
    },
    {
      "source": "AMPK",
      "target": "C. elegans",
      "label": "acts in"
    },
    {
      "source": "AMPK",
      "target": "STIM1 Phosphorylation",
      "label": "causes"
    },
    {
      "source": "AMPK",
      "target": "p38\u03b2 MAPK",
      "label": "has effector"
    },
    {
      "source": "metabolic dysregulation",
      "target": "premature atherosclerosis",
      "label": "characterized by"
    },
    {
      "source": "metabolic dysregulation",
      "target": "central obesity",
      "label": "characterized by"
    },
    {
      "source": "metabolic dysregulation",
      "target": "diseases",
      "label": "characterized by"
    },
    {
      "source": "metabolic dysregulation",
      "target": "type 2 diabetes",
      "label": "characterized by"
    },
    {
      "source": "metabolic dysregulation",
      "target": "dyslipidemia",
      "label": "characterized by"
    },
    {
      "source": "metabolic dysregulation",
      "target": "insulin resistance",
      "label": "characterized by"
    },
    {
      "source": "factors",
      "target": "malonyl CoA",
      "label": "decrease"
    },
    {
      "source": "factors",
      "target": "AMPK",
      "label": "activate"
    },
    {
      "source": "factors",
      "target": "therapeutic targets",
      "label": "could be"
    },
    {
      "source": "factors",
      "target": "inter-individual difference",
      "label": "contribute to"
    },
    {
      "source": "factors",
      "target": "top-down modulation",
      "label": "are common to"
    },
    {
      "source": "factors",
      "target": "Nanoparticle toxicity",
      "label": "trigger"
    },
    {
      "source": "factors",
      "target": "environmental risk assessment",
      "label": "considered for"
    },
    {
      "source": "malonyl CoA",
      "target": "intracellular fatty acid partitioning",
      "label": "alters"
    },
    {
      "source": "Metabolic syndrome",
      "target": "lipid abnormalities",
      "label": "linked to"
    },
    {
      "source": "Metabolic syndrome",
      "target": "metabolic dysregulation",
      "label": "is defined as"
    },
    {
      "source": "lipid abnormalities",
      "target": "cellular dysfunction",
      "label": "leads to"
    },
    {
      "source": "dysregulation",
      "target": "lipid abnormalities",
      "label": "is cause of"
    },
    {
      "source": "dysregulation",
      "target": "AMPK",
      "label": "reflected by change in"
    },
    {
      "source": "dysregulation",
      "target": "fuel-sensing and signaling mechanism",
      "label": "is of"
    },
    {
      "source": "dysregulation",
      "target": "malonyl CoA",
      "label": "reflected by change in"
    },
    {
      "source": "fuel-sensing and signaling mechanism",
      "target": "malonyl coenzyme A",
      "label": "includes"
    },
    {
      "source": "fuel-sensing and signaling mechanism",
      "target": "adenosine monophosphate-activated protein kinase",
      "label": "includes"
    },
    {
      "source": "diseases",
      "target": "central nervous system",
      "label": "affect"
    },
    {
      "source": "diseases",
      "target": "neurodegenerative diseases",
      "label": "include"
    },
    {
      "source": "diseases",
      "target": "cancer",
      "label": "include"
    },
    {
      "source": "diseases",
      "target": "metabolic diseases",
      "label": "include"
    },
    {
      "source": "diseases",
      "target": "osteoporosis",
      "label": "include"
    },
    {
      "source": "diseases",
      "target": "cardiovascular diseases",
      "label": "include"
    },
    {
      "source": "diseases",
      "target": "inflammatory-immune diseases",
      "label": "include"
    },
    {
      "source": "diseases",
      "target": "oxidant",
      "label": "associated with"
    },
    {
      "source": "diseases",
      "target": "vascular permeability",
      "label": "associated with"
    },
    {
      "source": "diseases",
      "target": "schizophrenia",
      "label": "includes"
    },
    {
      "source": "diseases",
      "target": "anxiety",
      "label": "includes"
    },
    {
      "source": "diseases",
      "target": "hyper-active autonomic nerves",
      "label": "due to"
    },
    {
      "source": "diseases",
      "target": "impaired SERCA2 function",
      "label": "related to"
    },
    {
      "source": "diseases",
      "target": "fiber type changes",
      "label": "related to"
    },
    {
      "source": "lipopolysaccharide (LPS)",
      "target": "mPGES-2",
      "label": "upregulates"
    },
    {
      "source": "lipopolysaccharide (LPS)",
      "target": "membrane-bound prostaglandin E synthase-1 (mPGES-1)",
      "label": "induces"
    },
    {
      "source": "lipopolysaccharide (LPS)",
      "target": "Cyclooxygenase (COX)-2",
      "label": "induces"
    },
    {
      "source": "lipopolysaccharide (LPS)",
      "target": "cytosolic PGES (cPGES)",
      "label": "upregulates"
    },
    {
      "source": "mPGES-2",
      "target": "PGE2 production",
      "label": "plays role in"
    },
    {
      "source": "mPGES-2",
      "target": "COX-1",
      "label": "coupled with"
    },
    {
      "source": "mPGES-2",
      "target": "terminal PGESs",
      "label": "is a type of"
    },
    {
      "source": "PS liposomes",
      "target": "PGE2 production",
      "label": "induces"
    },
    {
      "source": "PS liposomes",
      "target": "membrane-bound prostaglandin E synthase-1 (mPGES-1)",
      "label": "does not induce"
    },
    {
      "source": "PS liposomes",
      "target": "apoptotic cells",
      "label": "mimics"
    },
    {
      "source": "PS liposomes",
      "target": "microglia",
      "label": "mimics effects on"
    },
    {
      "source": "PS liposomes",
      "target": "Cyclooxygenase (COX)-2",
      "label": "does not induce"
    },
    {
      "source": "PS liposomes",
      "target": "macrophages",
      "label": "mimics effects on"
    },
    {
      "source": "PS liposomes",
      "target": "cytosolic PGES (cPGES)",
      "label": "upregulates"
    },
    {
      "source": "PS liposomes",
      "target": "endosomes/lysosomes",
      "label": "sorted to"
    },
    {
      "source": "PS liposomes",
      "target": "p38 mitogen-activated protein kinase",
      "label": "does not induce activation of"
    },
    {
      "source": "PS liposomes",
      "target": "phagocytic pathway",
      "label": "used to elucidate"
    },
    {
      "source": "PS liposomes",
      "target": "p44/p42 extracellular signal-regulated kinase (ERK)",
      "label": "induces activation of"
    },
    {
      "source": "PS liposomes",
      "target": "mPGES-2",
      "label": "upregulates"
    },
    {
      "source": "terminal PGESs",
      "target": "PGE2 production",
      "label": "plays role in"
    },
    {
      "source": "terminal PGESs",
      "target": "COX-1",
      "label": "coupled with"
    },
    {
      "source": "phosphatidylserine (PS)",
      "target": "PS-mediated recognition",
      "label": "mediates"
    },
    {
      "source": "PS-specific receptor",
      "target": "PS-recognizing receptors",
      "label": "is a type of"
    },
    {
      "source": "PS-recognizing receptors",
      "target": "intracellular signals",
      "label": "transduces"
    },
    {
      "source": "PS-recognizing receptors",
      "target": "PGE2 production",
      "label": "promotes"
    },
    {
      "source": "high density lipoprotein",
      "target": "PGE2 production",
      "label": "suppresses"
    },
    {
      "source": "high density lipoprotein",
      "target": "class B scavenger receptor (SR-B)",
      "label": "is a ligand for"
    },
    {
      "source": "prostaglandin E synthases",
      "target": "PGE2 production",
      "label": "involved in"
    },
    {
      "source": "apoptotic cells",
      "target": "phagocytosis",
      "label": "undergoes"
    },
    {
      "source": "apoptotic cells",
      "target": "phosphatidylserine (PS)",
      "label": "recognized via"
    },
    {
      "source": "phagocytosis",
      "target": "PGE2 production",
      "label": "leads to"
    },
    {
      "source": "microglia",
      "target": "PS liposomes",
      "label": "phagocytoses"
    },
    {
      "source": "microglia",
      "target": "apoptotic cells",
      "label": "engulfs"
    },
    {
      "source": "microglia",
      "target": "prostaglandin E2",
      "label": "secretes"
    },
    {
      "source": "microglia",
      "target": "PGE2 production",
      "label": "produces"
    },
    {
      "source": "microglia",
      "target": "Iba-1",
      "label": "is labeled by"
    },
    {
      "source": "microglia",
      "target": "striatum",
      "label": "activates in"
    },
    {
      "source": "microglia",
      "target": "one week",
      "label": "activates within"
    },
    {
      "source": "microglia",
      "target": "substantia nigra",
      "label": "activates in"
    },
    {
      "source": "cytosolic PGES (cPGES)",
      "target": "COX-1",
      "label": "coupled with"
    },
    {
      "source": "p44/p42 extracellular signal-regulated kinase (ERK)",
      "target": "SR-BI",
      "label": "activation is independent of"
    },
    {
      "source": "SR-BI",
      "target": "PGE2 production",
      "label": "plays role in"
    },
    {
      "source": "PS liposomes treatment",
      "target": "PGE2 production",
      "label": "leads to"
    },
    {
      "source": "PS liposomes treatment",
      "target": "intracellular signals",
      "label": "leads to"
    },
    {
      "source": "anti-inflammatory molecule",
      "target": "central nervous system",
      "label": "acts in"
    },
    {
      "source": "phosphatidylcholine liposomes treatment",
      "target": "PGE2 production",
      "label": "does not increase"
    },
    {
      "source": "phagocytic pathway",
      "target": "PGE2 production",
      "label": "leads to"
    },
    {
      "source": "p38 mitogen-activated protein kinase",
      "target": "MAPK",
      "label": "is an alias for"
    },
    {
      "source": "NS-398",
      "target": "COX-2 inhibitor",
      "label": "is a type of"
    },
    {
      "source": "NS-398",
      "target": "PGE2 production",
      "label": "does not suppress"
    },
    {
      "source": "primary cultured rat microglia",
      "target": "culture medium",
      "label": "has"
    },
    {
      "source": "phosphatidylserine liposome",
      "target": "PGE2 production",
      "label": "induces"
    },
    {
      "source": "probucol",
      "target": "low-density lipoprotein cholesterol",
      "label": "Downregulator"
    },
    {
      "source": "probucol",
      "target": "cholesterol metabolism",
      "label": "Upregulator"
    },
    {
      "source": "probucol",
      "target": "oxidative stress",
      "label": "Downregulator"
    },
    {
      "source": "probucol",
      "target": "antioxidants",
      "label": "is a"
    },
    {
      "source": "probucol",
      "target": "plasma total-cholesterol (total-C)",
      "label": "Downregulator"
    },
    {
      "source": "probucol",
      "target": "reverse transport",
      "label": "accelerate"
    },
    {
      "source": "probucol",
      "target": "plasma very-low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "probucol",
      "target": "cholesteryl esters",
      "label": "accelerate reverse transport of"
    },
    {
      "source": "probucol",
      "target": "VLDL",
      "label": "reduce"
    },
    {
      "source": "probucol",
      "target": "LDL",
      "label": "reduce"
    },
    {
      "source": "probucol",
      "target": "low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "probucol",
      "target": "mechanisms",
      "label": "act by"
    },
    {
      "source": "vitamin E group",
      "target": "Total fecal sterol content",
      "label": "Upregulator"
    },
    {
      "source": "vitamin E group",
      "target": "plasma paraoxonase activity",
      "label": "Upregulator"
    },
    {
      "source": "vitamin E group",
      "target": "plasma high-density lipoprotein-cholesterol (HDL-C)",
      "label": "Upregulator"
    },
    {
      "source": "vitamin E group",
      "target": "Hepatic ACAT activity",
      "label": "Downregulator"
    },
    {
      "source": "vitamin E group",
      "target": "HDL-C/total-C ratio levels",
      "label": "Upregulator"
    },
    {
      "source": "aortic fatty streak",
      "target": "HC-control group",
      "label": "of"
    },
    {
      "source": "Vitamin E",
      "target": "antioxidants",
      "label": "is a"
    },
    {
      "source": "Vitamin E",
      "target": "plasma total-cholesterol (total-C)",
      "label": "Downregulator"
    },
    {
      "source": "Vitamin E",
      "target": "plasma HDL-C-related factors",
      "label": "Regulator"
    },
    {
      "source": "Vitamin E",
      "target": "oxidative stress",
      "label": "Downregulator"
    },
    {
      "source": "Vitamin E",
      "target": "low-density lipoprotein cholesterol",
      "label": "Downregulator"
    },
    {
      "source": "Vitamin E",
      "target": "HDL-cholesterol concentration",
      "label": "Regulator"
    },
    {
      "source": "Vitamin E",
      "target": "paraoxonase activity",
      "label": "Regulator"
    },
    {
      "source": "Male rabbits",
      "target": "0.05% probucol",
      "label": "fed"
    },
    {
      "source": "Male rabbits",
      "target": "0.5% high-cholesterol (HC) diet",
      "label": "fed"
    },
    {
      "source": "Male rabbits",
      "target": "0.03% vitamin E",
      "label": "fed"
    },
    {
      "source": "risk factor",
      "target": "atherosclerosis",
      "label": "of"
    },
    {
      "source": "risk factor",
      "target": "pulmonary diseases",
      "label": "contributes to development of"
    },
    {
      "source": "risk factor",
      "target": "cardiovascular diseases",
      "label": "contributes to development of"
    },
    {
      "source": "risk factor",
      "target": "drug-induced liver injury",
      "label": "for"
    },
    {
      "source": "probucol group",
      "target": "HMG-CoA reductase activity",
      "label": "Upregulator"
    },
    {
      "source": "probucol group",
      "target": "apo B-100",
      "label": "Downregulator"
    },
    {
      "source": "probucol group",
      "target": "apo C-III",
      "label": "Downregulator"
    },
    {
      "source": "negative effect",
      "target": "plasma HDL-C concentration",
      "label": "Downregulator"
    },
    {
      "source": "negative effect",
      "target": "structural modification",
      "label": "is of"
    },
    {
      "source": "atherogenic signs",
      "target": "other groups",
      "label": "not discovered in"
    },
    {
      "source": "atherogenic signs",
      "target": "aortic fatty streak",
      "label": "discovered in"
    },
    {
      "source": "probucol groups",
      "target": "Hepatic ACAT activity",
      "label": "Downregulator"
    },
    {
      "source": "probucol groups",
      "target": "Total fecal sterol content",
      "label": "Upregulator"
    },
    {
      "source": "tRNAs",
      "target": "mitochondrial (mt) genome",
      "label": "encoded by"
    },
    {
      "source": "Mt-tRNAs",
      "target": "biased sequences",
      "label": "are atypical with"
    },
    {
      "source": "Mt-tRNAs",
      "target": "residues",
      "label": "lack"
    },
    {
      "source": "Mt-tRNAs",
      "target": "size variations",
      "label": "exhibit"
    },
    {
      "source": "position 73",
      "target": "universally conserved major aspartate identity element",
      "label": "is site of"
    },
    {
      "source": "position 73",
      "target": "human mt-tRNA(Asp) transcripts",
      "label": "is not involved in"
    },
    {
      "source": "position 73",
      "target": "nucleotides",
      "label": "can be occupied by"
    },
    {
      "source": "universally conserved major aspartate identity element",
      "target": "G73",
      "label": "is"
    },
    {
      "source": "Sequence alignments",
      "target": "various AspRSs",
      "label": "are of"
    },
    {
      "source": "human mt-AspRS",
      "target": "G73",
      "label": "becomes more discriminative to"
    },
    {
      "source": "G73",
      "target": "primordial identity signal",
      "label": "is also known as"
    },
    {
      "source": "G73",
      "target": "E. coli AspRS-tRNA(Asp) complex",
      "label": "is in"
    },
    {
      "source": "size variations",
      "target": "loops",
      "label": "occur in"
    },
    {
      "source": "size variations",
      "target": "stems",
      "label": "occur in"
    },
    {
      "source": "loops",
      "target": "conformation",
      "label": "have"
    },
    {
      "source": "Asp-220",
      "target": "E. coli AspRS-tRNA(Asp) complex",
      "label": "is a residue in"
    },
    {
      "source": "Asp-220",
      "target": "G73",
      "label": "contacts"
    },
    {
      "source": "reverse evolution",
      "target": "mt-tRNA(Asp) identity elements",
      "label": "is of"
    },
    {
      "source": "mt-tRNA(Asp) identity elements",
      "target": "bacterial ancestor",
      "label": "are in regard to"
    },
    {
      "source": "identity role",
      "target": "GUC anticodon",
      "label": "is of"
    },
    {
      "source": "GUC anticodon",
      "target": "aspartylation systems",
      "label": "is involved in"
    },
    {
      "source": "aminoacyl-tRNA synthetases",
      "target": "nuclear genome",
      "label": "coded by"
    },
    {
      "source": "human mt-tRNA(Asp) transcripts",
      "target": "identity role",
      "label": "confirm"
    },
    {
      "source": "mammalian mitochondria",
      "target": "translational machinery",
      "label": "contains"
    },
    {
      "source": "mammalian mitochondria",
      "target": "aminoacylation system",
      "label": "contains"
    },
    {
      "source": "Restriction",
      "target": "aspartylation identity set",
      "label": "occurs in"
    },
    {
      "source": "Restriction",
      "target": "rapid mutagenic rate",
      "label": "is driven by"
    },
    {
      "source": "rapid mutagenic rate",
      "target": "mitochondrial (mt) genome",
      "label": "is of"
    },
    {
      "source": "prokaryotic-type AspRS",
      "target": "Escherichia coli enzyme",
      "label": "is similar to"
    },
    {
      "source": "prokaryotic-type AspRS",
      "target": "tRNA(Asp)",
      "label": "recognizes"
    },
    {
      "source": "identity elements",
      "target": "Mt-tRNAs",
      "label": "are in"
    },
    {
      "source": "human mt-aspartate system",
      "target": "prokaryotic-type AspRS",
      "label": "involves"
    },
    {
      "source": "nucleotides",
      "target": "aspartylation",
      "label": "do not affect"
    },
    {
      "source": "crystallographic structure",
      "target": "E. coli AspRS-tRNA(Asp) complex",
      "label": "is of"
    },
    {
      "source": "mt-aaRSs",
      "target": "Mt-tRNAs",
      "label": "are cognate to"
    },
    {
      "source": "Gly-269",
      "target": "Asp-220",
      "label": "is at position of"
    },
    {
      "source": "dobutamine",
      "target": "contractility",
      "label": "increased"
    },
    {
      "source": "dobutamine",
      "target": "Gly389beta1AR subjects",
      "label": "decreased diastolic blood pressure in"
    },
    {
      "source": "dobutamine",
      "target": "heart rate",
      "label": "increased"
    },
    {
      "source": "dobutamine",
      "target": "diastolic blood pressure",
      "label": "decreased"
    },
    {
      "source": "dobutamine",
      "target": "Arg389-beta1AR subjects",
      "label": "increased PRA in"
    },
    {
      "source": "dobutamine",
      "target": "PRA",
      "label": "increased"
    },
    {
      "source": "contractility",
      "target": "vas deferens",
      "label": "of"
    },
    {
      "source": "contractility",
      "target": "sperm ejaculation",
      "label": "leads to"
    },
    {
      "source": "contractility",
      "target": "MK2/3(-/-) cardiomyocytes",
      "label": "occurs in"
    },
    {
      "source": "dobutamine-induced hemodynamic effects",
      "target": "genotype",
      "label": "depends on"
    },
    {
      "source": "dobutamine-induced hemodynamic effects",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "male homozygous Gly389beta1AR subjects",
      "target": "homozygous Ser49-beta1AR",
      "label": "is a type of"
    },
    {
      "source": "PRA",
      "target": "progesterone",
      "label": "is a"
    },
    {
      "source": "Codon 389 beta1AR polymorphism",
      "target": "PRA",
      "label": "determines"
    },
    {
      "source": "Codon 389 beta1AR polymorphism",
      "target": "hemodynamic effects",
      "label": "determines"
    },
    {
      "source": "Arg389Gly-beta1AR polymorphism",
      "target": "receptor signaling",
      "label": "decreases"
    },
    {
      "source": "dobutamine-induced PRA increase",
      "target": "genotype",
      "label": "depends on"
    },
    {
      "source": "dobutamine-induced PRA increase",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "therapeutic responses",
      "target": "betaAR-blocker treatment",
      "label": "are to"
    },
    {
      "source": "Arg389Gly beta1-adrenoceptor polymorphism",
      "target": "plasma-renin activity",
      "label": "affects"
    },
    {
      "source": "male homozygous Arg389-beta1AR subjects",
      "target": "homozygous Ser49-beta1AR",
      "label": "is a type of"
    },
    {
      "source": "beta1AR polymorphisms",
      "target": "therapeutic responses",
      "label": "predicts"
    },
    {
      "source": "catecholamine",
      "target": "plasma-renin activity",
      "label": "affects"
    },
    {
      "source": "catecholamine",
      "target": "glutamatergic transmission",
      "label": "enhances"
    },
    {
      "source": "Succinate",
      "target": "sake (Japanese rice wine) fermentation",
      "label": "produced during"
    },
    {
      "source": "Succinate",
      "target": "taste component",
      "label": "is a"
    },
    {
      "source": "Succinate",
      "target": "yeasts",
      "label": "produced by"
    },
    {
      "source": "TCA cycle",
      "target": "oxidative direction",
      "label": "is a"
    },
    {
      "source": "TCA cycle",
      "target": "succinic acid",
      "label": "is involved in production of"
    },
    {
      "source": "fumarate reduction",
      "target": "anaerobic conditions",
      "label": "occurs under"
    },
    {
      "source": "expression of enzymes",
      "target": "TCA cycle",
      "label": "required in"
    },
    {
      "source": "SDH1",
      "target": "YPD medium",
      "label": "cultured in"
    },
    {
      "source": "SDH1",
      "target": "aerobic conditions",
      "label": "produced increased level of succinate under"
    },
    {
      "source": "SDH1",
      "target": "gene disrupted mutant",
      "label": "is a"
    },
    {
      "source": "SDH1",
      "target": "succinate dehydrogenase",
      "label": "is a"
    },
    {
      "source": "YPD medium",
      "target": "glucose",
      "label": "contains"
    },
    {
      "source": "succinic acid",
      "target": "Saccharomyces cerevisiae",
      "label": "produced in"
    },
    {
      "source": "KGD1",
      "target": "alpha-ketoglutarate dehydrogenase",
      "label": "is a"
    },
    {
      "source": "KGD1",
      "target": "aerobic conditions",
      "label": "produced lower level of succinate under"
    },
    {
      "source": "KGD1",
      "target": "gene disrupted mutant",
      "label": "is a"
    },
    {
      "source": "KGD1",
      "target": "YPD medium",
      "label": "cultured in"
    },
    {
      "source": "alpha-ketoglutarate dehydrogenase",
      "target": "gene disrupted mutant",
      "label": "is a"
    },
    {
      "source": "succinate dehydrogenase",
      "target": "gene disrupted mutant",
      "label": "is a"
    },
    {
      "source": "gene disrupted mutant",
      "target": "wild-type strain",
      "label": "compared to"
    },
    {
      "source": "gene disrupted mutant",
      "target": "malate",
      "label": "did not form"
    },
    {
      "source": "gene disrupted mutant",
      "target": "fumarate",
      "label": "produced higher levels of"
    },
    {
      "source": "pathway",
      "target": "anaerobic conditions",
      "label": "examined under"
    },
    {
      "source": "pathway",
      "target": "liquid culture",
      "label": "examined in"
    },
    {
      "source": "pathway",
      "target": "glucose",
      "label": "examined with"
    },
    {
      "source": "pathway",
      "target": "Saccharomyces cerevisiae strains",
      "label": "examined using"
    },
    {
      "source": "pathway",
      "target": "aerobic conditions",
      "label": "examined under"
    },
    {
      "source": "pathway",
      "target": "Succinate",
      "label": "leads to accumulation of"
    },
    {
      "source": "fumarate",
      "target": "TCA cycle",
      "label": "synthesized through"
    },
    {
      "source": "fumarate",
      "target": "glucose",
      "label": "synthesis occurs in presence of"
    },
    {
      "source": "growth condition",
      "target": "anaerobic conditions",
      "label": "shifted to"
    },
    {
      "source": "growth condition",
      "target": "aerobic conditions",
      "label": "shifted from"
    },
    {
      "source": "fumarate reductase isozyme genes",
      "target": "OSM1",
      "label": "include"
    },
    {
      "source": "fumarate reductase isozyme genes",
      "target": "FRDS",
      "label": "include"
    },
    {
      "source": "double mutant",
      "target": "succinate productivity",
      "label": "showed"
    },
    {
      "source": "double mutant",
      "target": "fumarate reductase isozyme genes",
      "label": "is a mutant of"
    },
    {
      "source": "succinate productivity",
      "target": "parent",
      "label": "compared to"
    },
    {
      "source": "malate",
      "target": "TCA cycle",
      "label": "synthesized through"
    },
    {
      "source": "malate",
      "target": "glucose",
      "label": "synthesis occurs in presence of"
    },
    {
      "source": "glucose",
      "target": "molar percentages",
      "label": "has"
    },
    {
      "source": "glucose",
      "target": "LVG",
      "label": "is part of"
    },
    {
      "source": "taste component",
      "target": "yeasts",
      "label": "produced by"
    },
    {
      "source": "FUM1",
      "target": "gene disrupted mutant",
      "label": "is a"
    },
    {
      "source": "FUM1",
      "target": "fumarase",
      "label": "is a"
    },
    {
      "source": "KGD1 diruptant",
      "target": "anaerobic conditions",
      "label": "cultured under"
    },
    {
      "source": "gene disruptions",
      "target": "succinic acid",
      "label": "affect"
    },
    {
      "source": "gene disruptions",
      "target": "Saccharomyces cerevisiae",
      "label": "occur in"
    },
    {
      "source": "gene disruptions",
      "target": "TCA cycle",
      "label": "affect"
    },
    {
      "source": "two pathways",
      "target": "alpha-ketoglutarate oxidation",
      "label": "include"
    },
    {
      "source": "two pathways",
      "target": "fumarate reduction",
      "label": "include"
    },
    {
      "source": "alpha-ketoglutarate oxidation",
      "target": "TCA cycle",
      "label": "via"
    },
    {
      "source": "fumarase",
      "target": "gene disrupted mutant",
      "label": "is a"
    },
    {
      "source": "SDH1 disruptants",
      "target": "anaerobic conditions",
      "label": "cultured under"
    },
    {
      "source": "bexarotene",
      "target": "p55 subunits",
      "label": "Upregulator"
    },
    {
      "source": "bexarotene",
      "target": "p75 subunits",
      "label": "Upregulator"
    },
    {
      "source": "bexarotene",
      "target": "CD25 expression",
      "label": "Upregulator"
    },
    {
      "source": "bexarotene",
      "target": "IL-2R expression",
      "label": "Regulator"
    },
    {
      "source": "reliable conclusions",
      "target": "precise distribution",
      "label": "are about"
    },
    {
      "source": "acquisition of response",
      "target": "tadpole tissues",
      "label": "is of"
    },
    {
      "source": "tadpole tissues",
      "target": "thyroid hormone",
      "label": "respond to"
    },
    {
      "source": "Amphibian metamorphosis",
      "target": "thyroid hormones",
      "label": "is controlled by"
    },
    {
      "source": "Amphibian metamorphosis",
      "target": "acquisition of response",
      "label": "depends on"
    },
    {
      "source": "Amphibian metamorphosis",
      "target": "pharmacological means",
      "label": "cannot be induced by"
    },
    {
      "source": "Amphibian metamorphosis",
      "target": "TH",
      "label": "is controlled by"
    },
    {
      "source": "thyroid hormones",
      "target": "therapeutic range",
      "label": "not in"
    },
    {
      "source": "hybridization signals",
      "target": "reliable conclusions",
      "label": "are too low to draw"
    },
    {
      "source": "hybridization signals",
      "target": "other tissues",
      "label": "are in"
    },
    {
      "source": "Cytosolic Thyroid Hormone-Binding Protein",
      "target": "gene",
      "label": "is a"
    },
    {
      "source": "Tissue samples",
      "target": "specimens",
      "label": "obtained from"
    },
    {
      "source": "specimens",
      "target": "Necturus maculosus",
      "label": "are of"
    },
    {
      "source": "clear expression",
      "target": "several tissues",
      "label": "is in"
    },
    {
      "source": "clear expression",
      "target": "Necturus TRalpha gene",
      "label": "is of"
    },
    {
      "source": "clear expression",
      "target": "TRbeta",
      "label": "is of"
    },
    {
      "source": "clear expression",
      "target": "TRalpha",
      "label": "is of"
    },
    {
      "source": "several tissues",
      "target": "skeletal muscle",
      "label": "include"
    },
    {
      "source": "several tissues",
      "target": "central nervous system",
      "label": "include"
    },
    {
      "source": "several tissues",
      "target": "epithelial cells",
      "label": "include"
    },
    {
      "source": "several tissues",
      "target": "myocardium",
      "label": "include"
    },
    {
      "source": "M2-pyruvate kinase",
      "target": "gene",
      "label": "is a"
    },
    {
      "source": "Thyroid hormone receptor",
      "target": "obligatory paedomorphic salamander",
      "label": "is expressed in"
    },
    {
      "source": "Thyroid hormone receptor",
      "target": "Necturus maculosus",
      "label": "is expressed in"
    },
    {
      "source": "Necturus maculosus",
      "target": "obligatory paedomorphic Amphibian",
      "label": "is"
    },
    {
      "source": "hormones",
      "target": "thyroid hormone receptors",
      "label": "bind to"
    },
    {
      "source": "hormones",
      "target": "gene expression",
      "label": "control"
    },
    {
      "source": "hormones",
      "target": "TRs",
      "label": "bind to"
    },
    {
      "source": "hormones",
      "target": "Amphibian metamorphosis",
      "label": "induce"
    },
    {
      "source": "non-cross-hybridizing RNA probes",
      "target": "Necturus TRalpha genes",
      "label": "obtained from"
    },
    {
      "source": "non-cross-hybridizing RNA probes",
      "target": "TRbeta genes",
      "label": "obtained from"
    },
    {
      "source": "Necturus tissues",
      "target": "TRs",
      "label": "express"
    },
    {
      "source": "Necturus tissues",
      "target": "TH",
      "label": "are responsive to"
    },
    {
      "source": "two TH-related genes",
      "target": "CTHBP",
      "label": "include"
    },
    {
      "source": "two TH-related genes",
      "target": "Cytosolic Thyroid Hormone-Binding Protein",
      "label": "include"
    },
    {
      "source": "two TH-related genes",
      "target": "M2-pyruvate kinase",
      "label": "include"
    },
    {
      "source": "two TH-related genes",
      "target": "stromelysin 3",
      "label": "include"
    },
    {
      "source": "CTHBP",
      "target": "TRs",
      "label": "expression is distinct from"
    },
    {
      "source": "stromelysin 3",
      "target": "direct TH target gene",
      "label": "is a"
    },
    {
      "source": "direct TH target gene",
      "target": "Xenopus laevis",
      "label": "is in"
    },
    {
      "source": "thyroid hormone",
      "target": "SCD-1 gene expression",
      "label": "negatively regulates"
    },
    {
      "source": "TRbeta",
      "target": "brain",
      "label": "is expressed in"
    },
    {
      "source": "TR gene expression patterns",
      "target": "Necturus maculosus",
      "label": "are in"
    },
    {
      "source": "in situ hybridization",
      "target": "non-cross-hybridizing RNA probes",
      "label": "used"
    },
    {
      "source": "ST3",
      "target": "TRs",
      "label": "expression is distinct from"
    },
    {
      "source": "amoxapine",
      "target": "central 5-HT receptors",
      "label": "affects"
    },
    {
      "source": "amoxapine",
      "target": "5-HT1A receptors",
      "label": "is not a ligand of"
    },
    {
      "source": "amoxapine",
      "target": "5-HT1B receptors",
      "label": "does not affect"
    },
    {
      "source": "amoxapine",
      "target": "central effect",
      "label": "has"
    },
    {
      "source": "amoxapine",
      "target": "mu and delta classes of opioid receptors",
      "label": "affects"
    },
    {
      "source": "amoxapine",
      "target": "5-HT2 receptors",
      "label": "interacts with"
    },
    {
      "source": "amoxapine",
      "target": "5-HT3 receptors",
      "label": "binds to"
    },
    {
      "source": "amoxapine",
      "target": "5-HT3 antagonist",
      "label": "acts as"
    },
    {
      "source": "amoxapine",
      "target": "opioid peptides",
      "label": "affects"
    },
    {
      "source": "amoxapine",
      "target": "antidepressant drugs",
      "label": "is a type of"
    },
    {
      "source": "amitriptyline",
      "target": "opioid peptides",
      "label": "affects"
    },
    {
      "source": "amitriptyline",
      "target": "5-HT3 receptors",
      "label": "is inactive on"
    },
    {
      "source": "amitriptyline",
      "target": "5-HT1A receptors",
      "label": "does not affect"
    },
    {
      "source": "amitriptyline",
      "target": "central 5-HT receptors",
      "label": "affects"
    },
    {
      "source": "amitriptyline",
      "target": "central effect",
      "label": "has"
    },
    {
      "source": "amitriptyline",
      "target": "antidepressant drugs",
      "label": "is a type of"
    },
    {
      "source": "amitriptyline",
      "target": "5-HT1B receptors",
      "label": "does not affect"
    },
    {
      "source": "amitriptyline",
      "target": "mu and delta classes of opioid receptors",
      "label": "affects"
    },
    {
      "source": "amitriptyline",
      "target": "5-HT2 receptors",
      "label": "interacts with"
    },
    {
      "source": "amitriptyline",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "amitriptyline",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "amitriptyline",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "amitriptyline",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "amitriptyline",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "opioid peptides",
      "target": "spinal cord",
      "label": "located in"
    },
    {
      "source": "opioid peptides",
      "target": "regions of the brain",
      "label": "located in"
    },
    {
      "source": "serotoninergic neurotransmission",
      "target": "rat brain",
      "label": "located in"
    },
    {
      "source": "serotoninergic neurotransmission",
      "target": "spinal cord",
      "label": "located in"
    },
    {
      "source": "5-HT2 receptors",
      "target": "cerebral cortex",
      "label": "located in"
    },
    {
      "source": "5-HT2 receptors",
      "target": "cortical membranes",
      "label": "located in"
    },
    {
      "source": "mu and delta classes of opioid receptors",
      "target": "spinal cord",
      "label": "located in"
    },
    {
      "source": "mu and delta classes of opioid receptors",
      "target": "regions of the brain",
      "label": "located in"
    },
    {
      "source": "opioidergic neurotransmission",
      "target": "spinal cord",
      "label": "located in"
    },
    {
      "source": "opioidergic neurotransmission",
      "target": "rat brain",
      "label": "located in"
    },
    {
      "source": "Bezold-Jarisch reflex",
      "target": "5-HT3 receptors",
      "label": "is dependent on"
    },
    {
      "source": "opiodergic systems",
      "target": "central effect",
      "label": "are implicated in"
    },
    {
      "source": "[3H]ketanserin",
      "target": "5-HT2 receptors",
      "label": "labels"
    },
    {
      "source": "serotoninergic systems",
      "target": "central effect",
      "label": "are implicated in"
    },
    {
      "source": "[3H]zacopride",
      "target": "5-HT3 receptors",
      "label": "labels"
    },
    {
      "source": "reeler heterozygous mouse (+/rl)",
      "target": "animal model",
      "label": "is an"
    },
    {
      "source": "animal model",
      "target": "epigenesis",
      "label": "combines"
    },
    {
      "source": "animal model",
      "target": "genetic heterozygocity",
      "label": "combines"
    },
    {
      "source": "animal model",
      "target": "psychosis",
      "label": "for"
    },
    {
      "source": "spine density",
      "target": "hippocampus",
      "label": "is in"
    },
    {
      "source": "spine density",
      "target": "cortex",
      "label": "is in"
    },
    {
      "source": "GABAergic neurons",
      "target": "psychotic brain",
      "label": "are in"
    },
    {
      "source": "GAD67 promoters",
      "target": "GABAergic neurons",
      "label": "are hypermethylated in"
    },
    {
      "source": "synaptic function",
      "target": "long-term potentiation (LTP)",
      "label": "includes"
    },
    {
      "source": "synaptic function",
      "target": "LTP",
      "label": "includes"
    },
    {
      "source": "RELN",
      "target": "GABAergic neurons",
      "label": "is hypermethylated in"
    },
    {
      "source": "Brain abnormalities",
      "target": "dendritic arbors",
      "label": "include reduction in"
    },
    {
      "source": "Brain abnormalities",
      "target": "glutamic acid de carboxylase 67",
      "label": "include reduction in"
    },
    {
      "source": "Brain abnormalities",
      "target": "spine density",
      "label": "include reduction in"
    },
    {
      "source": "Brain abnormalities",
      "target": "psychotic brain",
      "label": "are similar to"
    },
    {
      "source": "Brain abnormalities",
      "target": "GAD67",
      "label": "include reduction in"
    },
    {
      "source": "Brain abnormalities",
      "target": "synaptic function",
      "label": "include abnormalities in"
    },
    {
      "source": "dendritic arbors",
      "target": "hippocampus",
      "label": "are in"
    },
    {
      "source": "dendritic arbors",
      "target": "cortex",
      "label": "are in"
    },
    {
      "source": "DNA methyltransferase 1",
      "target": "DNMT1",
      "label": "is"
    },
    {
      "source": "DNMT1",
      "target": "epigenetic DNA-methylation",
      "label": "causes"
    },
    {
      "source": "Reelin",
      "target": "synaptic plasticity",
      "label": "plays an important role in"
    },
    {
      "source": "Reelin",
      "target": "neuronal guidance",
      "label": "plays an important role in"
    },
    {
      "source": "Reelin",
      "target": "glycoprotein",
      "label": "is a"
    },
    {
      "source": "synaptic plasticity",
      "target": "depressive-like phenotype",
      "label": "associated with"
    },
    {
      "source": "reelin",
      "target": "postmortem psychotic brain",
      "label": "is down-regulated in"
    },
    {
      "source": "brain and behavioral abnormalities",
      "target": "+/rl",
      "label": "are similar to"
    },
    {
      "source": "Hypermethlyation of RELN and GAD67 promoters",
      "target": "methionine",
      "label": "can be induced by"
    },
    {
      "source": "Reelin down-regulation",
      "target": "psychosis endophenotypes",
      "label": "is associated with"
    },
    {
      "source": "Reelin down-regulation",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "Reelin down-regulation",
      "target": "psychosis",
      "label": "plays a role in"
    },
    {
      "source": "glycoprotein",
      "target": "telencephalic GABAergic neurons",
      "label": "secreted by"
    },
    {
      "source": "behavioral abnormalities",
      "target": "+/rl",
      "label": "are in"
    },
    {
      "source": "reelin (RELN) and GAD67 promoters",
      "target": "GABAergic neurons",
      "label": "are hypermethylated in"
    },
    {
      "source": "cholesterol metabolites",
      "target": "SREBP-1c",
      "label": "upregulated"
    },
    {
      "source": "cholesterol metabolites",
      "target": "retinal dehydrogenases",
      "label": "regulates"
    },
    {
      "source": "cholesterol metabolites",
      "target": "RA biosynthesis",
      "label": "regulates"
    },
    {
      "source": "cholesterol metabolites",
      "target": "sterol regulatory element binding protein-1c",
      "label": "upregulated"
    },
    {
      "source": "cholesterol metabolites",
      "target": "RALDH genes",
      "label": "induced"
    },
    {
      "source": "SREBP-1c",
      "target": "RALDH genes",
      "label": "bound to regulatory regions of"
    },
    {
      "source": "SREBP-1c",
      "target": "decisive role",
      "label": "does not play"
    },
    {
      "source": "retinal dehydrogenases",
      "target": "RA biosynthesis",
      "label": "catalyzes"
    },
    {
      "source": "retinal dehydrogenases",
      "target": "retinal",
      "label": "catalyzes biosynthesis from"
    },
    {
      "source": "LXRalpha/beta",
      "target": "RALDH genes",
      "label": "downregulated expression of"
    },
    {
      "source": "RALDHs",
      "target": "RA biosynthesis",
      "label": "catalyzes"
    },
    {
      "source": "RALDHs",
      "target": "retinal",
      "label": "catalyzes biosynthesis from"
    },
    {
      "source": "vitamin A",
      "target": "vertebrate development",
      "label": "is required for"
    },
    {
      "source": "vitamin A",
      "target": "11-cis retinal",
      "label": "is required for production of"
    },
    {
      "source": "vitamin A",
      "target": "retinoic acid",
      "label": "is required for production of"
    },
    {
      "source": "sterol regulatory element binding protein-1c",
      "target": "RALDH genes",
      "label": "bound to regulatory regions of"
    },
    {
      "source": "RA",
      "target": "vitamin A",
      "label": "constitutes"
    },
    {
      "source": "RA",
      "target": "tretinoin",
      "label": "is a form of"
    },
    {
      "source": "RA",
      "target": "isotretinoin",
      "label": "is a form of"
    },
    {
      "source": "RA",
      "target": "gestational day",
      "label": "administered on"
    },
    {
      "source": "pravastatin sodium",
      "target": "RALDH1 and 2",
      "label": "downregulated expression of"
    },
    {
      "source": "genotyping",
      "target": "limitations",
      "label": "has"
    },
    {
      "source": "limitations",
      "target": "issues",
      "label": "include"
    },
    {
      "source": "limitations",
      "target": "statistical power",
      "label": "in"
    },
    {
      "source": "limitations",
      "target": "study design",
      "label": "in"
    },
    {
      "source": "limitations",
      "target": "efficacious treatments",
      "label": "prevent"
    },
    {
      "source": "adaptation",
      "target": "doses",
      "label": "of"
    },
    {
      "source": "adaptation",
      "target": "fluorouracil starting dose",
      "label": "of"
    },
    {
      "source": "fluorouracil exposure ranges",
      "target": "serious toxicity",
      "label": "without"
    },
    {
      "source": "fluorouracil exposure ranges",
      "target": "therapeutic activity",
      "label": "have"
    },
    {
      "source": "methods",
      "target": "DPD activity",
      "label": "assess"
    },
    {
      "source": "methods",
      "target": "phenotyping methods",
      "label": "include"
    },
    {
      "source": "methods",
      "target": "genotyping",
      "label": "include"
    },
    {
      "source": "methods",
      "target": "patients",
      "label": "used for"
    },
    {
      "source": "methods",
      "target": "amino or hydroxy acids",
      "label": "for assigning"
    },
    {
      "source": "DPD activity",
      "target": "P = 0.00029",
      "label": "difference had p-value of"
    },
    {
      "source": "DPD activity",
      "target": "noncarriers",
      "label": "was compared with"
    },
    {
      "source": "DPD activity",
      "target": "P = 0.013",
      "label": "difference had p-value of"
    },
    {
      "source": "DPD activity",
      "target": "carriers",
      "label": "was lower in"
    },
    {
      "source": "Pharmacokinetic target values",
      "target": "regimens",
      "label": "for"
    },
    {
      "source": "regimens",
      "target": "chronomodulated regimens",
      "label": "include"
    },
    {
      "source": "fluorouracil toxicity",
      "target": "individuals",
      "label": "varies in"
    },
    {
      "source": "individuals",
      "target": "GSTT1 null",
      "label": "have"
    },
    {
      "source": "individuals",
      "target": "GSTM1/T1 null genotypes",
      "label": "have"
    },
    {
      "source": "individuals",
      "target": "common, functional genetic polymorphisms",
      "label": "have"
    },
    {
      "source": "individuals",
      "target": "average exposure to amalgams",
      "label": "had"
    },
    {
      "source": "individuals",
      "target": "oral glucose tolerance test",
      "label": "underwent"
    },
    {
      "source": "individuals",
      "target": "normal glucose tolerance (NGT)",
      "label": "have"
    },
    {
      "source": "individuals",
      "target": "specific risk",
      "label": "have"
    },
    {
      "source": "individuals",
      "target": "A allele",
      "label": "have"
    },
    {
      "source": "individuals",
      "target": "OPs",
      "label": "exposed to"
    },
    {
      "source": "individuals",
      "target": "chronic level",
      "label": "exposed at"
    },
    {
      "source": "individuals",
      "target": "organophosphorus insecticides",
      "label": "exposed to"
    },
    {
      "source": "individuals",
      "target": "occupational reasons",
      "label": "exposed due to"
    },
    {
      "source": "DPD activity tests",
      "target": "fluorouracil administration",
      "label": "before"
    },
    {
      "source": "AUC threshold",
      "target": "mg.h/L",
      "label": "is"
    },
    {
      "source": "approach",
      "target": "randomised clinical studies",
      "label": "evaluated in"
    },
    {
      "source": "approach",
      "target": "efficacy",
      "label": "increases"
    },
    {
      "source": "approach",
      "target": "toxicity",
      "label": "prevents"
    },
    {
      "source": "approach",
      "target": "liquid chromatography/mass spectrometry/mass spectrometry",
      "label": "uses"
    },
    {
      "source": "approach",
      "target": "identification",
      "label": "is for"
    },
    {
      "source": "approach",
      "target": "LC-MS/MS",
      "label": "uses"
    },
    {
      "source": "approach",
      "target": "quantitation",
      "label": "is for"
    },
    {
      "source": "approach",
      "target": "local drug delivery",
      "label": "is for"
    },
    {
      "source": "randomised clinical studies",
      "target": "strategies",
      "label": "compare"
    },
    {
      "source": "complete or partial loss",
      "target": "DPD activity",
      "label": "of"
    },
    {
      "source": "complete or partial loss",
      "target": "fluorouracil exposure",
      "label": "leads to increased"
    },
    {
      "source": "complete or partial loss",
      "target": "toxicity",
      "label": "leads to increased"
    },
    {
      "source": "complete or partial loss",
      "target": "Caucasians",
      "label": "occurs in"
    },
    {
      "source": "targets",
      "target": "thymidylate synthase",
      "label": "include"
    },
    {
      "source": "targets",
      "target": "retinoids",
      "label": "are of"
    },
    {
      "source": "targets",
      "target": "treatment",
      "label": "is for"
    },
    {
      "source": "fluorouracil starting dose",
      "target": "results",
      "label": "adapted to"
    },
    {
      "source": "phenotyping methods",
      "target": "limitations",
      "label": "has"
    },
    {
      "source": "chronomodulated regimens",
      "target": "trials",
      "label": "evaluated in"
    },
    {
      "source": "chronomodulated regimens",
      "target": "efficacy",
      "label": "yielded"
    },
    {
      "source": "chronomodulated regimens",
      "target": "tolerability",
      "label": "yielded"
    },
    {
      "source": "fluorouracil test dose approach",
      "target": "limitations",
      "label": "has"
    },
    {
      "source": "assessment",
      "target": "individual dihydropyrimidine dehydrogenase (DPD) activity",
      "label": "of"
    },
    {
      "source": "individual dihydropyrimidine dehydrogenase (DPD) activity",
      "target": "enzyme",
      "label": "is an"
    },
    {
      "source": "definition",
      "target": "fluorouracil exposure ranges",
      "label": "of"
    },
    {
      "source": "definition",
      "target": "dose adaptation",
      "label": "is a prerequisite for"
    },
    {
      "source": "hand-foot syndrome",
      "target": "clinical toxicities",
      "label": "is a type of"
    },
    {
      "source": "monitoring",
      "target": "dose adjustment",
      "label": "useful for"
    },
    {
      "source": "monitoring",
      "target": "fluorouracil plasma concentrations",
      "label": "of"
    },
    {
      "source": "area under the plasma concentration-time curve (AUC)",
      "target": "mg.h/L",
      "label": "is"
    },
    {
      "source": "fluorouracil administration",
      "target": "assessment",
      "label": "individualised by"
    },
    {
      "source": "tumour response",
      "target": "area under the plasma concentration-time curve (AUC)",
      "label": "related to"
    },
    {
      "source": "anticancer chemotherapy",
      "target": "fluorouracil",
      "label": "uses"
    },
    {
      "source": "fluorouracil exposures",
      "target": "AUC threshold",
      "label": "above"
    },
    {
      "source": "combination of genotyping and phenotyping",
      "target": "prediction of toxicity",
      "label": "improves"
    },
    {
      "source": "chemical entity",
      "target": "Desvenlafaxine succinate",
      "label": "is"
    },
    {
      "source": "Desvenlafaxine succinate",
      "target": "serotonin",
      "label": "inhibits reuptake of"
    },
    {
      "source": "Desvenlafaxine succinate",
      "target": "reuptake inhibitor",
      "label": "is a"
    },
    {
      "source": "Desvenlafaxine succinate",
      "target": "norepinephrine",
      "label": "inhibits reuptake of"
    },
    {
      "source": "Desvenlafaxine succinate",
      "target": "DVS",
      "label": "is also known as"
    },
    {
      "source": "DVS",
      "target": "uptake",
      "label": "inhibits"
    },
    {
      "source": "DVS",
      "target": "male rat brain",
      "label": "penetrated"
    },
    {
      "source": "DVS",
      "target": "activity",
      "label": "showed no significant"
    },
    {
      "source": "DVS",
      "target": "hypothalamus",
      "label": "penetrated"
    },
    {
      "source": "DVS",
      "target": "inhibition",
      "label": "causes"
    },
    {
      "source": "DVS",
      "target": "binding affinity",
      "label": "showed"
    },
    {
      "source": "DVS",
      "target": "active metabolite",
      "label": "is an"
    },
    {
      "source": "DVS",
      "target": "salt form",
      "label": "is a"
    },
    {
      "source": "IC50 values",
      "target": "hNET",
      "label": "are for"
    },
    {
      "source": "IC50 values",
      "target": "hSERT",
      "label": "are for"
    },
    {
      "source": "IC50 values",
      "target": "DPPH",
      "label": "FOR"
    },
    {
      "source": "IC50 values",
      "target": "ABTS",
      "label": "FOR"
    },
    {
      "source": "binding affinity",
      "target": "human dopamine (DA) transporter",
      "label": "at"
    },
    {
      "source": "binding affinity",
      "target": "Abeta plaques",
      "label": "to"
    },
    {
      "source": "binding affinity",
      "target": "K(d)",
      "label": "has value"
    },
    {
      "source": "binding affinity",
      "target": "ex vivo autoradiography",
      "label": "evaluated by"
    },
    {
      "source": "binding affinity",
      "target": "albumin",
      "label": "is to"
    },
    {
      "source": "binding affinity",
      "target": "diflunisal",
      "label": "is for"
    },
    {
      "source": "K(i) values",
      "target": "human serotonin (5-HT) transporter",
      "label": "are related to"
    },
    {
      "source": "K(i) values",
      "target": "norepinephrine (NE) transporter",
      "label": "are related to"
    },
    {
      "source": "K(i) values",
      "target": "DVS",
      "label": "are for"
    },
    {
      "source": "K(i) values",
      "target": "histidine methyl ester",
      "label": "are comparable to"
    },
    {
      "source": "Competitive radioligand binding assays",
      "target": "cells",
      "label": "used"
    },
    {
      "source": "angiotensin II type 1 receptor (AT1) blocker",
      "target": "AT1 blocker",
      "label": "is_a_type_of"
    },
    {
      "source": "angiotensin II type 1 receptor (AT1) blocker",
      "target": "postinfarction LV remodeling",
      "label": "benefits"
    },
    {
      "source": "angiotensin II type 1 receptor (AT1) blocker",
      "target": "hearts",
      "label": "benefits"
    },
    {
      "source": "angiotensin II type 1 receptor (AT1) blocker",
      "target": "contractile dysfunction",
      "label": "benefits"
    },
    {
      "source": "angiotensin II type 1 receptor (AT1) blocker",
      "target": "structural left ventricular (LV) remodeling",
      "label": "benefits"
    },
    {
      "source": "AT1 blocker",
      "target": "myocardial bioenergetic consequences",
      "label": "has"
    },
    {
      "source": "AT1 blocker",
      "target": "hearts",
      "label": "acts_in"
    },
    {
      "source": "untreated group",
      "target": "mean aortic pressure",
      "label": "has_higher"
    },
    {
      "source": "untreated group",
      "target": "mitochondrial F0F1-ATPase subunits",
      "label": "reduced"
    },
    {
      "source": "untreated group",
      "target": "controls",
      "label": "compared_with"
    },
    {
      "source": "untreated group",
      "target": "LV-to-body weight ratio",
      "label": "has_higher"
    },
    {
      "source": "untreated group",
      "target": "subendocardial phosphocreatine-to-ATP ratios",
      "label": "has_lower"
    },
    {
      "source": "treated group",
      "target": "mitochondrial F0F1-ATPase subunits",
      "label": "did_not_reduce"
    },
    {
      "source": "treated group",
      "target": "controls",
      "label": "compared_with"
    },
    {
      "source": "treated group",
      "target": "LV-to-body weight ratio",
      "label": "has_lower"
    },
    {
      "source": "treated group",
      "target": "subendocardial phosphocreatine-to-ATP ratios",
      "label": "has"
    },
    {
      "source": "mitochondrial F0F1-ATPase subunits",
      "target": "F0F1-ATPase subunits",
      "label": "is_a_type_of"
    },
    {
      "source": "Animals with heart failure",
      "target": "myocardial high-energy phosphate levels",
      "label": "reduced"
    },
    {
      "source": "Animals with heart failure",
      "target": "mitochondrial F0F1-ATPase expression",
      "label": "reduced"
    },
    {
      "source": "myocardial high-energy phosphate levels",
      "target": "high-energy phosphate levels",
      "label": "is_a_type_of"
    },
    {
      "source": "subendocardial phosphocreatine-to-ATP ratios",
      "target": "phosphocreatine",
      "label": "involves"
    },
    {
      "source": "subendocardial phosphocreatine-to-ATP ratios",
      "target": "ATP",
      "label": "involves"
    },
    {
      "source": "postinfarction LV remodeling",
      "target": "ligation",
      "label": "is_produced_by"
    },
    {
      "source": "mitochondrial F0F1-ATPase expression",
      "target": "F0F1-ATPase expression",
      "label": "is_a_type_of"
    },
    {
      "source": "myocardial bioenergetics",
      "target": "infarction",
      "label": "measured_after"
    },
    {
      "source": "high-energy phosphate levels",
      "target": "phosphate levels",
      "label": "is_a_type_of"
    },
    {
      "source": "olmesartan medoxomil",
      "target": "hearts",
      "label": "affects"
    },
    {
      "source": "olmesartan medoxomil",
      "target": "Functional consequences",
      "label": "has_consequence"
    },
    {
      "source": "olmesartan medoxomil",
      "target": "severe LV dysfunction",
      "label": "prevented"
    },
    {
      "source": "olmesartan medoxomil",
      "target": "abnormal myocardial bioenergetic phenotype",
      "label": "prevented"
    },
    {
      "source": "olmesartan medoxomil",
      "target": "bioenergetic consequences",
      "label": "has_consequence"
    },
    {
      "source": "olmesartan medoxomil",
      "target": "postinfarction LV remodeling",
      "label": "affects"
    },
    {
      "source": "untreated pigs",
      "target": "normal pigs",
      "label": "compared_against"
    },
    {
      "source": "porcine model",
      "target": "postinfarction LV remodeling",
      "label": "is_a_model_of"
    },
    {
      "source": "hemodynamics",
      "target": "infarction",
      "label": "measured_after"
    },
    {
      "source": "Congestive heart failure",
      "target": "ascites",
      "label": "evidenced_by"
    },
    {
      "source": "Congestive heart failure",
      "target": "untreated animals",
      "label": "developed_in"
    },
    {
      "source": "Congestive heart failure",
      "target": "treated group",
      "label": "absent_in"
    },
    {
      "source": "myocardial perfusion",
      "target": "infarction",
      "label": "measured_after"
    },
    {
      "source": "pigs",
      "target": "olmesartan medoxomil",
      "label": "received"
    },
    {
      "source": "ligation",
      "target": "left circumflex coronary artery",
      "label": "targets"
    },
    {
      "source": "Am80",
      "target": "RARbeta-specific",
      "label": "is specific for"
    },
    {
      "source": "Am80",
      "target": "RARgamma-",
      "label": "is nonbinding to"
    },
    {
      "source": "Am80",
      "target": "synthetic retinoid",
      "label": "is a type of"
    },
    {
      "source": "Am80",
      "target": "RARalpha-",
      "label": "is specific for"
    },
    {
      "source": "Am80",
      "target": "RXRs-nonbinding",
      "label": "is nonbinding to"
    },
    {
      "source": "synthetic retinoid",
      "target": "treatment",
      "label": "is effective in"
    },
    {
      "source": "application",
      "target": "retinoids",
      "label": "is of"
    },
    {
      "source": "application",
      "target": "treatment",
      "label": "is for"
    },
    {
      "source": "application",
      "target": "probe",
      "label": "of"
    },
    {
      "source": "application",
      "target": "combination of molecular modeling and NOE distance constraint calculations",
      "label": "is of"
    },
    {
      "source": "tamibarotene",
      "target": "RARgamma-",
      "label": "is nonbinding to"
    },
    {
      "source": "tamibarotene",
      "target": "synthetic retinoid",
      "label": "is a type of"
    },
    {
      "source": "tamibarotene",
      "target": "RARalpha-",
      "label": "is specific for"
    },
    {
      "source": "tamibarotene",
      "target": "RXRs-nonbinding",
      "label": "is nonbinding to"
    },
    {
      "source": "tamibarotene",
      "target": "RARbeta-specific",
      "label": "is specific for"
    },
    {
      "source": "Th1 dominant autoimmune diseases",
      "target": "targets",
      "label": "are"
    },
    {
      "source": "all-trans-retinoic acid",
      "target": "endogeneous retinoid",
      "label": "is an"
    },
    {
      "source": "Retinoid therapy",
      "target": "autoimmune diseases",
      "label": "is used for treating"
    },
    {
      "source": "ATRA",
      "target": "endogeneous retinoid",
      "label": "is an"
    },
    {
      "source": "ATRA",
      "target": "gamma",
      "label": "is a ligand for"
    },
    {
      "source": "ATRA",
      "target": "RARalpha",
      "label": "is a ligand for"
    },
    {
      "source": "ATRA",
      "target": "clinical use",
      "label": "is in"
    },
    {
      "source": "ATRA",
      "target": "beta",
      "label": "is a ligand for"
    },
    {
      "source": "mimics",
      "target": "clinical use",
      "label": "are in"
    },
    {
      "source": "Retinoid",
      "target": "compounds",
      "label": "is a collective term for"
    },
    {
      "source": "synthetic retinoids",
      "target": "medicinal properties",
      "label": "have"
    },
    {
      "source": "experimental autoimmune encephalomyelitis",
      "target": "EAE",
      "label": "is also known as"
    },
    {
      "source": "acidic fibroblast growth factor",
      "target": "solid tumors",
      "label": "present in"
    },
    {
      "source": "acidic fibroblast growth factor",
      "target": "broad-spectrum chemoresistance",
      "label": "causes"
    },
    {
      "source": "bFGF",
      "target": "p53",
      "label": "stronger predictor than"
    },
    {
      "source": "bFGF",
      "target": "solid tumors",
      "label": "present in"
    },
    {
      "source": "bFGF",
      "target": "Pgp expression",
      "label": "correlated with"
    },
    {
      "source": "bFGF",
      "target": "broad-spectrum chemoresistance",
      "label": "causes"
    },
    {
      "source": "bFGF",
      "target": "tumor sensitivity",
      "label": "showed inverse correlation with"
    },
    {
      "source": "bFGF",
      "target": "tumor grade",
      "label": "correlated with"
    },
    {
      "source": "bFGF",
      "target": "Bcl-2",
      "label": "stronger predictor than"
    },
    {
      "source": "bFGF",
      "target": "paclitaxel resistance",
      "label": "predictor of"
    },
    {
      "source": "bFGF",
      "target": "Pgp",
      "label": "stronger predictor than"
    },
    {
      "source": "antiproliferation",
      "target": "responding tumors",
      "label": "in"
    },
    {
      "source": "antiproliferation",
      "target": "tumors",
      "label": "in"
    },
    {
      "source": "tumors",
      "target": "bladder",
      "label": "from"
    },
    {
      "source": "tumors",
      "target": "bFGF staining",
      "label": "showed"
    },
    {
      "source": "tumors",
      "target": "paclitaxel",
      "label": "treated with"
    },
    {
      "source": "tumors",
      "target": "head and neck",
      "label": "from"
    },
    {
      "source": "tumors",
      "target": "prostate cancer patients",
      "label": "from"
    },
    {
      "source": "tumors",
      "target": "aFGF staining",
      "label": "showed"
    },
    {
      "source": "tumors",
      "target": "breast",
      "label": "from"
    },
    {
      "source": "tumors",
      "target": "histocultures",
      "label": "maintained in"
    },
    {
      "source": "tumors",
      "target": "ovarian",
      "label": "from"
    },
    {
      "source": "tumors",
      "target": "ErbB2",
      "label": "overexpress"
    },
    {
      "source": "tumors",
      "target": "HER2",
      "label": "overexpress"
    },
    {
      "source": "proapoptotic effects",
      "target": "bcl-2",
      "label": "correlated with"
    },
    {
      "source": "proapoptotic effects",
      "target": "p53",
      "label": "correlated with"
    },
    {
      "source": "proapoptotic effects",
      "target": "bFGF",
      "label": "correlated with"
    },
    {
      "source": "proapoptotic effects",
      "target": "paclitaxel",
      "label": "of"
    },
    {
      "source": "proapoptotic effects",
      "target": "P-glycoprotein",
      "label": "correlated with"
    },
    {
      "source": "proapoptotic effects",
      "target": "aFGF",
      "label": "correlated with"
    },
    {
      "source": "proapoptotic effects",
      "target": "Pgp",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "P-glycoprotein",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "aFGF",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "Pgp",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "bcl-2",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "p53",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "bFGF",
      "label": "correlated with"
    },
    {
      "source": "Antiproliferative effects",
      "target": "paclitaxel",
      "label": "of"
    },
    {
      "source": "paclitaxel",
      "target": "apoptosis",
      "label": "induced"
    },
    {
      "source": "paclitaxel",
      "target": "antiproliferation",
      "label": "inhibited"
    },
    {
      "source": "paclitaxel",
      "target": "protein",
      "label": "increases"
    },
    {
      "source": "paclitaxel",
      "target": "phosphorylation",
      "label": "increases"
    },
    {
      "source": "paclitaxel",
      "target": "antineoplastic drug",
      "label": "is a type of"
    },
    {
      "source": "paclitaxel",
      "target": "mRNA levels",
      "label": "increases"
    },
    {
      "source": "paclitaxel",
      "target": "non-small cell lung cancer",
      "label": "treats"
    },
    {
      "source": "paclitaxel",
      "target": "p38 MAPK",
      "label": "increases"
    },
    {
      "source": "paclitaxel",
      "target": "ERCC1",
      "label": "increases"
    },
    {
      "source": "paclitaxel",
      "target": "MKK3/6",
      "label": "increases"
    },
    {
      "source": "paclitaxel",
      "target": "anticancer agent",
      "label": "is an"
    },
    {
      "source": "paclitaxel",
      "target": "P-gp substrates",
      "label": "is a"
    },
    {
      "source": "paclitaxel",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "basic FGF",
      "target": "solid tumors",
      "label": "present in"
    },
    {
      "source": "basic FGF",
      "target": "broad-spectrum chemoresistance",
      "label": "causes"
    },
    {
      "source": "aFGF",
      "target": "solid tumors",
      "label": "present in"
    },
    {
      "source": "aFGF",
      "target": "broad-spectrum chemoresistance",
      "label": "causes"
    },
    {
      "source": "aFGF",
      "target": "tumor sensitivity",
      "label": "did not correlate with"
    },
    {
      "source": "aFGF",
      "target": "tumor stage",
      "label": "positively correlated with"
    },
    {
      "source": "FGF expression",
      "target": "paclitaxel activity",
      "label": "related to"
    },
    {
      "source": "FGF expression",
      "target": "tumors",
      "label": "in"
    },
    {
      "source": "paclitaxel activity",
      "target": "tumors",
      "label": "in"
    },
    {
      "source": "Bladder tumors",
      "target": "paclitaxel",
      "label": "treated with"
    },
    {
      "source": "basic fibroblast growth factor",
      "target": "human patient tumors",
      "label": "expressed in"
    },
    {
      "source": "basic fibroblast growth factor",
      "target": "paclitaxel resistance",
      "label": "correlates with"
    },
    {
      "source": "tumor sensitivity",
      "target": "paclitaxel",
      "label": "to"
    },
    {
      "source": "apoptotic index",
      "target": "responding tumors",
      "label": "in"
    },
    {
      "source": "paclitaxel resistance",
      "target": "human patient tumors",
      "label": "in"
    },
    {
      "source": "histocultures",
      "target": "tumor-stromal interaction",
      "label": "retain"
    },
    {
      "source": "neuroglial interactions",
      "target": "peripheral nerve injury",
      "label": "occur after"
    },
    {
      "source": "sciatic nerve injury",
      "target": "retinoic acid receptors beta",
      "label": "regulates"
    },
    {
      "source": "sciatic nerve injury",
      "target": "retinoid X receptor alpha",
      "label": "regulates"
    },
    {
      "source": "sciatic nerve injury",
      "target": "rat",
      "label": "tested in"
    },
    {
      "source": "sciatic nerve injury",
      "target": "retinoic acid receptors alpha",
      "label": "regulates"
    },
    {
      "source": "retinoid X receptor alpha-staining",
      "target": "regenerating axons",
      "label": "co-localized with"
    },
    {
      "source": "Protein levels",
      "target": "retinoid X receptor alpha",
      "label": "are of"
    },
    {
      "source": "Protein levels",
      "target": "retinoic acid receptor alpha",
      "label": "are of"
    },
    {
      "source": "Protein levels",
      "target": "retinoic acid receptor beta",
      "label": "are of"
    },
    {
      "source": "Protein levels",
      "target": "injury",
      "label": "upregulated after"
    },
    {
      "source": "retinoid X receptor alpha",
      "target": "cell nuclei",
      "label": "appeared in"
    },
    {
      "source": "retinoid X receptor alpha",
      "target": "macrophages",
      "label": "appeared in cell nuclei of"
    },
    {
      "source": "retinoid X receptor alpha",
      "target": "lesion-induced inflammatory reaction",
      "label": "appeared during"
    },
    {
      "source": "Experiments",
      "target": "Schwann cell primary cultures",
      "label": "conducted with"
    },
    {
      "source": "Experiments",
      "target": "retinoic acid",
      "label": "revealed effect of"
    },
    {
      "source": "Experiments",
      "target": "BAT activity",
      "label": "indicate"
    },
    {
      "source": "retinoic acid receptor alpha",
      "target": "complete transection",
      "label": "increased after"
    },
    {
      "source": "retinoic acid receptor alpha",
      "target": "lesion-induced inflammatory reaction",
      "label": "appeared during"
    },
    {
      "source": "retinoic acid receptor alpha",
      "target": "degenerating nerves",
      "label": "increased in"
    },
    {
      "source": "retinoic acid receptor alpha",
      "target": "cell nuclei",
      "label": "appeared in"
    },
    {
      "source": "retinoic acid receptor alpha",
      "target": "macrophages",
      "label": "appeared in cell nuclei of"
    },
    {
      "source": "transcript concentrations",
      "target": "retinoid X receptor alpha",
      "label": "are of"
    },
    {
      "source": "transcript concentrations",
      "target": "retinoic acid receptors",
      "label": "are of"
    },
    {
      "source": "transcript concentrations",
      "target": "non-lesioned nerves",
      "label": "higher than in"
    },
    {
      "source": "retinoic acid signaling system",
      "target": "axonal regeneration",
      "label": "is involved in"
    },
    {
      "source": "retinoid receptors",
      "target": "macrophages",
      "label": "expressed in"
    },
    {
      "source": "retinoid receptors",
      "target": "Schwann cells",
      "label": "expressed in"
    },
    {
      "source": "ErbB3",
      "target": "sensitivity",
      "label": "expression correlated with"
    },
    {
      "source": "ErbB3",
      "target": "DU-PM cells",
      "label": "was decreased in"
    },
    {
      "source": "retinoic acid receptor beta",
      "target": "complete transection",
      "label": "increased after"
    },
    {
      "source": "retinoic acid receptor beta",
      "target": "degenerating nerves",
      "label": "increased in"
    },
    {
      "source": "Immunohistochemical staining",
      "target": "macrophages",
      "label": "revealed expression in"
    },
    {
      "source": "Immunohistochemical staining",
      "target": "retinoid receptors",
      "label": "is of"
    },
    {
      "source": "Immunohistochemical staining",
      "target": "Schwann cells",
      "label": "revealed expression in"
    },
    {
      "source": "Cell culture experiments",
      "target": "retinoic acid signaling system",
      "label": "indicated involvement of"
    },
    {
      "source": "crush injury",
      "target": "transcript concentrations",
      "label": "causes increase in"
    },
    {
      "source": "regeneration",
      "target": "non-transformed liver cells",
      "label": "is of"
    },
    {
      "source": "injury",
      "target": "complex I inhibitor",
      "label": "induced by"
    },
    {
      "source": "autotrophic organisms",
      "target": "nitrate reductase",
      "label": "have"
    },
    {
      "source": "nitrate reductase",
      "target": "inorganic nitrogen",
      "label": "catalyzes assimilation of"
    },
    {
      "source": "nitrate reductase",
      "target": "Mo-site",
      "label": "does not require sulfuration of"
    },
    {
      "source": "Mo-enzymes",
      "target": "aldehyde oxidase",
      "label": "include"
    },
    {
      "source": "Mo-enzymes",
      "target": "sulfite oxidase",
      "label": "include"
    },
    {
      "source": "Mo-enzymes",
      "target": "catalytic site",
      "label": "have"
    },
    {
      "source": "Mo-enzymes",
      "target": "redox active center",
      "label": "need"
    },
    {
      "source": "Mo-enzymes",
      "target": "xanthine dehydrogenase",
      "label": "include"
    },
    {
      "source": "Mo-enzymes",
      "target": "molybdenum cofactor (Moco)",
      "label": "contain"
    },
    {
      "source": "aldehyde oxidase",
      "target": "abscisic acid",
      "label": "essential for biosynthesis of"
    },
    {
      "source": "aldehyde oxidase",
      "target": "Mo-site",
      "label": "requires sulfuration of"
    },
    {
      "source": "aldehyde oxidase",
      "target": "aldehydes",
      "label": "oxidizes"
    },
    {
      "source": "bacterial nitrogenase",
      "target": "FeMo-cofactor",
      "label": "contains"
    },
    {
      "source": "bacterial nitrogenase",
      "target": "Mo",
      "label": "contains"
    },
    {
      "source": "abscisic acid",
      "target": "phytohormone",
      "label": "is a"
    },
    {
      "source": "cysteine desulfurases",
      "target": "pyridoxal phosphate",
      "label": "are dependent on"
    },
    {
      "source": "cysteine desulfurases",
      "target": "l-cysteine",
      "label": "mobilize sulfur from"
    },
    {
      "source": "molybdenum cofactor (Moco)",
      "target": "apoproteins",
      "label": "is distributed to"
    },
    {
      "source": "molybdenum cofactor (Moco)",
      "target": "proteins",
      "label": "biosynthesis involves"
    },
    {
      "source": "molybdenum cofactor (Moco)",
      "target": "catalytic site",
      "label": "is at"
    },
    {
      "source": "molybdenum cofactor (Moco)",
      "target": "copper",
      "label": "biosynthesis includes"
    },
    {
      "source": "molybdenum cofactor (Moco)",
      "target": "iron",
      "label": "biosynthesis includes"
    },
    {
      "source": "molybdenum cofactor (Moco)",
      "target": "active compound",
      "label": "is an"
    },
    {
      "source": "apoproteins",
      "target": "Mo-enzymes",
      "label": "are part of"
    },
    {
      "source": "molybdenum",
      "target": "biological systems",
      "label": "is important for"
    },
    {
      "source": "molybdenum",
      "target": "transition element",
      "label": "is a"
    },
    {
      "source": "sulfite oxidase",
      "target": "sulfur-containing amino acids",
      "label": "catalyzes degradation of"
    },
    {
      "source": "sulfite oxidase",
      "target": "Mo-site",
      "label": "does not require sulfuration of"
    },
    {
      "source": "sulfite oxidase",
      "target": "sulfite",
      "label": "detoxifies"
    },
    {
      "source": "xanthine dehydrogenase",
      "target": "Mo-site",
      "label": "requires sulfuration of"
    },
    {
      "source": "xanthine dehydrogenase",
      "target": "reactive oxygen",
      "label": "involved in production of"
    },
    {
      "source": "xanthine dehydrogenase",
      "target": "purine",
      "label": "involved in catabolism of"
    },
    {
      "source": "plant sulfite oxidase",
      "target": "redox active center",
      "label": "does not need"
    },
    {
      "source": "redox active center",
      "target": "iron",
      "label": "involves"
    },
    {
      "source": "Moco-sulfurase enzyme",
      "target": "Mo-site",
      "label": "catalyzes sulfuration of"
    },
    {
      "source": "Moco-sulfurase enzyme",
      "target": "sulfur",
      "label": "mobilizes"
    },
    {
      "source": "Moco-sulfurase enzyme",
      "target": "l-cysteine",
      "label": "mobilizes sulfur from"
    },
    {
      "source": "Moco-sulfurase enzyme",
      "target": "pyridoxal phosphate",
      "label": "is dependent on"
    },
    {
      "source": "Moco-sulfurase enzyme",
      "target": "cysteine desulfurases",
      "label": "is a type of"
    },
    {
      "source": "Mo",
      "target": "transition element",
      "label": "is a"
    },
    {
      "source": "Mo",
      "target": "biological systems",
      "label": "is important for"
    },
    {
      "source": "Mo",
      "target": "FeMo-cofactor",
      "label": "is a constituent of"
    },
    {
      "source": "Mo",
      "target": "molybdenum cofactor (Moco)",
      "label": "forms"
    },
    {
      "source": "Mo",
      "target": "pterin",
      "label": "is bound to"
    },
    {
      "source": "metal",
      "target": "cofactor",
      "label": "requires"
    },
    {
      "source": "pterin",
      "target": "molybdenum cofactor (Moco)",
      "label": "forms"
    },
    {
      "source": "aldehydes",
      "target": "main volatile components",
      "label": "are"
    },
    {
      "source": "Moco-carrier proteins",
      "target": "molybdenum cofactor (Moco)",
      "label": "distribute"
    },
    {
      "source": "eukaryotes",
      "target": "Mo-enzymes",
      "label": "have"
    },
    {
      "source": "carbon",
      "target": "cationic center",
      "label": "is a"
    },
    {
      "source": "sensory compounds",
      "target": "promiscuous relationships",
      "label": "have"
    },
    {
      "source": "molecular receptors",
      "target": "natural compounds",
      "label": "are receptors of"
    },
    {
      "source": "natural compounds",
      "target": "thermal sensations",
      "label": "evoke"
    },
    {
      "source": "natural compounds",
      "target": "pain sensations",
      "label": "evoke"
    },
    {
      "source": "natural compounds",
      "target": "Nrf2",
      "label": "activate"
    },
    {
      "source": "natural compounds",
      "target": "pharmacological properties",
      "label": "have"
    },
    {
      "source": "camphor",
      "target": "TRPV3",
      "label": "was reported to activate"
    },
    {
      "source": "camphor",
      "target": "other thermoTRPs",
      "label": "modulates"
    },
    {
      "source": "\"sensory compounds\"",
      "target": "thermoTRPs",
      "label": "have promiscuous relationships with"
    },
    {
      "source": "human physiological studies",
      "target": "paradoxical role",
      "label": "demonstrate"
    },
    {
      "source": "cinnamaldehyde",
      "target": "TRPA1",
      "label": "was reported to activate"
    },
    {
      "source": "cinnamaldehyde",
      "target": "other thermoTRPs",
      "label": "modulates"
    },
    {
      "source": "temperature-activated transient receptor potential (thermoTRP) ion channels",
      "target": "molecular receptors",
      "label": "are"
    },
    {
      "source": "RET expression",
      "target": "Western blot analysis",
      "label": "determined_by"
    },
    {
      "source": "RET expression",
      "target": "quantitative polymerase chain reaction",
      "label": "determined_by"
    },
    {
      "source": "Y1062 phosphorylation",
      "target": "quantitative polymerase chain reaction",
      "label": "determined_by"
    },
    {
      "source": "Y1062 phosphorylation",
      "target": "Western blot analysis",
      "label": "determined_by"
    },
    {
      "source": "fluorescence-activated cell sorter analysis",
      "target": "annexin V/propidium iodide staining",
      "label": "uses"
    },
    {
      "source": "imatinib monotherapy",
      "target": "systemic treatment",
      "label": "is_not_a_good_option_for"
    },
    {
      "source": "Dose-dependent decreases",
      "target": "cell proliferation",
      "label": "in"
    },
    {
      "source": "tyrosine kinase inhibitor",
      "target": "potentiation",
      "label": "does not affect"
    },
    {
      "source": "medullary thyroid cancer cells",
      "target": "RET mutations",
      "label": "harbor"
    },
    {
      "source": "medullary thyroid cancer cells",
      "target": "multiple endocrine neoplasia Type 2A",
      "label": "harbor"
    },
    {
      "source": "medullary thyroid cancer cells",
      "target": "multiple endocrine neoplasia Type 2B",
      "label": "harbor"
    },
    {
      "source": "cell proliferation",
      "target": "3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide assay",
      "label": "determined_by"
    },
    {
      "source": "cell proliferation",
      "target": "7 days",
      "label": "normalized by"
    },
    {
      "source": "cell proliferation",
      "target": "control animals",
      "label": "was undistinguishable from"
    },
    {
      "source": "RET gene",
      "target": "tyrosine kinase receptor",
      "label": "encodes"
    },
    {
      "source": "apoptotic cell death",
      "target": "HL-60 human promyelocytic leukemia cells",
      "label": "occurred in"
    },
    {
      "source": "apoptotic cell death",
      "target": "mechanisms of action",
      "label": "occurred through"
    },
    {
      "source": "apoptotic cell death",
      "target": "TUNEL",
      "label": "evaluated using"
    },
    {
      "source": "apoptotic cell death",
      "target": "caspase 3 assays",
      "label": "evaluated using"
    },
    {
      "source": "imatinib-induced cell-cycle arrest",
      "target": "fluorescence-activated cell sorter analysis",
      "label": "studied_by"
    },
    {
      "source": "MTC-derived cell lines",
      "target": "multiple endocrine neoplasia-associated mutant RET receptors",
      "label": "express"
    },
    {
      "source": "inhibitory concentration of 50% levels",
      "target": "25 +/- 4 micromol/L",
      "label": "is"
    },
    {
      "source": "inhibitory concentration of 50% levels",
      "target": "23 +/- 2 micromol/L",
      "label": "is"
    },
    {
      "source": "concentration of imatinib",
      "target": "RET",
      "label": "inhibits"
    },
    {
      "source": "Activating mutations",
      "target": "RET gene",
      "label": "located_in"
    },
    {
      "source": "Activating mutations",
      "target": "medullary thyroid carcinoma (MTC)",
      "label": "cause"
    },
    {
      "source": "Surgical resection",
      "target": "curative treatment",
      "label": "is_a"
    },
    {
      "source": "anti-CD11a monoclonal antibody",
      "target": "M5 muscarinic ACh receptor mRNA",
      "label": "increases"
    },
    {
      "source": "anti-CD11a monoclonal antibody",
      "target": "ACh release",
      "label": "increases"
    },
    {
      "source": "anti-CD11a monoclonal antibody",
      "target": "expression of ChAT",
      "label": "increases"
    },
    {
      "source": "anti-CD11a monoclonal antibody",
      "target": "ACh synthesis",
      "label": "increases"
    },
    {
      "source": "anti-CD11a monoclonal antibody",
      "target": "mAb",
      "label": "is also known as"
    },
    {
      "source": "anti-CD11a monoclonal antibody",
      "target": "ChAT activity",
      "label": "increases"
    },
    {
      "source": "Simvastatin",
      "target": "immunosuppressive effects",
      "label": "exerts"
    },
    {
      "source": "Simvastatin",
      "target": "lymphocytic cholinergic activity",
      "label": "modulates"
    },
    {
      "source": "Simvastatin",
      "target": "cholesterol-lowering drug",
      "label": "is a type of"
    },
    {
      "source": "Simvastatin",
      "target": "CD11a-mediated pathways",
      "label": "acts via"
    },
    {
      "source": "Simvastatin",
      "target": "LFA-1 signaling",
      "label": "inhibits"
    },
    {
      "source": "Simvastatin",
      "target": "cholesterol-lowering activity",
      "label": "has"
    },
    {
      "source": "Simvastatin",
      "target": "allosteric site",
      "label": "binds to"
    },
    {
      "source": "Simvastatin",
      "target": "non-neuronal cholinergic activity",
      "label": "regulates"
    },
    {
      "source": "Simvastatin",
      "target": "modification of lymphocytic cholinergic activity",
      "label": "acts via"
    },
    {
      "source": "Simvastatin",
      "target": "immunomodulation",
      "label": "leads to"
    },
    {
      "source": "Simvastatin",
      "target": "anti-CD11a monoclonal antibody",
      "label": "counteracts"
    },
    {
      "source": "antithymocyte globulin",
      "target": "LFA-1-mediated pathways",
      "label": "acts via"
    },
    {
      "source": "antithymocyte globulin",
      "target": "non-neuronal cholinergic system",
      "label": "stimulates"
    },
    {
      "source": "CD11a",
      "target": "LFA-1 alpha chain",
      "label": "is a type of"
    },
    {
      "source": "Lymphocyte function associated antigen-1",
      "target": "LFA-1",
      "label": "is also known as"
    },
    {
      "source": "LFA-1",
      "target": "CD11a-mediated pathways",
      "label": "acts via"
    },
    {
      "source": "LFA-1",
      "target": "lymphocytic cholinergic activity",
      "label": "regulates"
    },
    {
      "source": "LFA-1",
      "target": "CD18",
      "label": "consists of"
    },
    {
      "source": "LFA-1",
      "target": "leukocyte migration",
      "label": "mediates"
    },
    {
      "source": "LFA-1",
      "target": "CD11a",
      "label": "consists of"
    },
    {
      "source": "LFA-1",
      "target": "T cell activation",
      "label": "mediates"
    },
    {
      "source": "LFA-1",
      "target": "Leucocyte Function-associated Antigen-1",
      "label": "also known as"
    },
    {
      "source": "LFA-1",
      "target": "ICAM-1",
      "label": "binds to"
    },
    {
      "source": "non-neuronal cholinergic system",
      "target": "ACh synthesis",
      "label": "affects"
    },
    {
      "source": "non-neuronal cholinergic system",
      "target": "ChAT mRNA expression",
      "label": "affects"
    },
    {
      "source": "choline acetyltransferase",
      "target": "ChAT",
      "label": "is also known as"
    },
    {
      "source": "allosteric site",
      "target": "CD11a",
      "label": "located on"
    },
    {
      "source": "MOLT-3 cells",
      "target": "human leukemic T cell line",
      "label": "is a type of"
    },
    {
      "source": "overexpression",
      "target": "POX",
      "label": "of"
    },
    {
      "source": "overexpression",
      "target": "proline oxidase",
      "label": "of"
    },
    {
      "source": "overexpression",
      "target": "ROS generation",
      "label": "is associated with"
    },
    {
      "source": "overexpression",
      "target": "apoptosis",
      "label": "is associated with"
    },
    {
      "source": "POX",
      "target": "oxidation",
      "label": "catalyzes"
    },
    {
      "source": "POX",
      "target": "cells",
      "label": "is induced in"
    },
    {
      "source": "POX",
      "target": "ROS generation",
      "label": "induces"
    },
    {
      "source": "POX",
      "target": "mitochondrial inner-membrane protein",
      "label": "is a"
    },
    {
      "source": "POX",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "oxidation",
      "target": "proline",
      "label": "of"
    },
    {
      "source": "oxidation",
      "target": "pyrroline- 5-carboxylate",
      "label": "produces"
    },
    {
      "source": "oxidation",
      "target": "P5C",
      "label": "produces"
    },
    {
      "source": "oxidation",
      "target": "NAD(+)",
      "label": "is dependent on"
    },
    {
      "source": "oxidation",
      "target": "dihydrolipoamide",
      "label": "of"
    },
    {
      "source": "oxidation",
      "target": "reduced nicotinamide adenine dinucleotide",
      "label": "of"
    },
    {
      "source": "oxidation",
      "target": "quinone methide derivative",
      "label": "produces"
    },
    {
      "source": "MnSOD",
      "target": "ROS generation",
      "label": "blunts"
    },
    {
      "source": "MnSOD",
      "target": "apoptosis",
      "label": "blunts"
    },
    {
      "source": "ROS generation",
      "target": "PMA-induced HL-60 cells",
      "label": "occurs in"
    },
    {
      "source": "proline oxidase",
      "target": "mitochondrial inner-membrane protein",
      "label": "is a"
    },
    {
      "source": "proline oxidase",
      "target": "oxidation",
      "label": "catalyzes"
    },
    {
      "source": "apoptotic response",
      "target": "cell shrinkage",
      "label": "involves"
    },
    {
      "source": "apoptotic response",
      "target": "mitochondria",
      "label": "is mediated by"
    },
    {
      "source": "apoptotic response",
      "target": "DNA fragmentation",
      "label": "involves"
    },
    {
      "source": "apoptotic response",
      "target": "L-proline",
      "label": "is dependent on"
    },
    {
      "source": "apoptotic response",
      "target": "cytochrome c",
      "label": "involves"
    },
    {
      "source": "apoptotic response",
      "target": "chromatin condensation",
      "label": "involves"
    },
    {
      "source": "apoptotic response",
      "target": "activation",
      "label": "involves"
    },
    {
      "source": "POX activity",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "POX activity",
      "target": "proline",
      "label": "requires"
    },
    {
      "source": "mitochondrial MnSOD",
      "target": "apoptosis",
      "label": "blunts"
    },
    {
      "source": "mitochondrial MnSOD",
      "target": "ROS generation",
      "label": "blunts"
    },
    {
      "source": "DLD-1.POX cells",
      "target": "cells",
      "label": "are a type of"
    },
    {
      "source": "apoptotic effect",
      "target": "L-proline",
      "label": "is specific for"
    },
    {
      "source": "POX-inducible colorectal cancer cells",
      "target": "DLD-1.POX",
      "label": "are"
    },
    {
      "source": "D,L-threo-beta-benzyloxyaspartate",
      "target": "transporter antagonist",
      "label": "is a"
    },
    {
      "source": "transporters",
      "target": "glutamate removal",
      "label": "involved in"
    },
    {
      "source": "transporters",
      "target": "humans",
      "label": "are found in"
    },
    {
      "source": "transporters",
      "target": "uptake",
      "label": "involved in"
    },
    {
      "source": "GLAST",
      "target": "glutamate uptake",
      "label": "mediates"
    },
    {
      "source": "GLAST",
      "target": "transmitter uptake",
      "label": "responsible for"
    },
    {
      "source": "GLAST",
      "target": "supporting cells",
      "label": "located in"
    },
    {
      "source": "glutamate uptake",
      "target": "inner hair cell afferent synapses",
      "label": "occurs at"
    },
    {
      "source": "glutamate-aspartate transporters",
      "target": "GLAST",
      "label": "is also known as"
    },
    {
      "source": "glutamate-aspartate transporters",
      "target": "excitatory amino acid transporter 1",
      "label": "is also known as"
    },
    {
      "source": "whole-cell recordings",
      "target": "whole-mount preparations",
      "label": "performed in"
    },
    {
      "source": "whole-cell recordings",
      "target": "afferent dendrites",
      "label": "made from"
    },
    {
      "source": "whole-cell recordings",
      "target": "inner hair cells (IHCs)",
      "label": "made from"
    },
    {
      "source": "whole-cell recordings",
      "target": "glial cells",
      "label": "made from"
    },
    {
      "source": "whole-mount preparations",
      "target": "rat organ of Corti",
      "label": "of"
    },
    {
      "source": "D-aspartate-induced currents",
      "target": "outside-out patches",
      "label": "occurred in"
    },
    {
      "source": "D-aspartate-induced currents",
      "target": "steady-state currents",
      "label": "exhibited"
    },
    {
      "source": "outside-out patches",
      "target": "IPCs",
      "label": "from"
    },
    {
      "source": "rates of release",
      "target": "glutamate clearance mechanisms",
      "label": "demands"
    },
    {
      "source": "steady-state currents",
      "target": "prominent feature of GLAST",
      "label": "is a"
    },
    {
      "source": "Saturation of transporters",
      "target": "transporter currents",
      "label": "failed to elicit"
    },
    {
      "source": "Saturation of transporters",
      "target": "photolysis of caged D-aspartate",
      "label": "by"
    },
    {
      "source": "transporter currents",
      "target": "inner hair cells (IHCs)",
      "label": "in"
    },
    {
      "source": "inward currents",
      "target": "glutamate-aspartate transporters",
      "label": "produced by"
    },
    {
      "source": "inward currents",
      "target": "D,L-threo-beta-benzyloxyaspartate",
      "label": "blocked by"
    },
    {
      "source": "inward currents",
      "target": "IPCs",
      "label": "occurred in"
    },
    {
      "source": "inward currents",
      "target": "anions",
      "label": "increased by"
    },
    {
      "source": "inward currents",
      "target": "dihydrokainate",
      "label": "inhibited by"
    },
    {
      "source": "inward currents",
      "target": "GLAST-/- cochleas",
      "label": "absent from"
    },
    {
      "source": "anions",
      "target": "transporter-associated anion channel",
      "label": "permeate"
    },
    {
      "source": "dihydrokainate",
      "target": "antagonist",
      "label": "is an"
    },
    {
      "source": "Ribbon synapses",
      "target": "afferent dendrites",
      "label": "formed between"
    },
    {
      "source": "Ribbon synapses",
      "target": "inner hair cells (IHCs)",
      "label": "formed between"
    },
    {
      "source": "Ribbon synapses",
      "target": "rates of release",
      "label": "sustain"
    },
    {
      "source": "Ribbon synapses",
      "target": "mammalian cochlea",
      "label": "located in"
    },
    {
      "source": "transmitter uptake",
      "target": "IHC afferent synapses",
      "label": "occurs at"
    },
    {
      "source": "inner hair cell afferent synapses",
      "target": "mammalian cochlea",
      "label": "located in"
    },
    {
      "source": "responses",
      "target": "prominent feature of GLAST",
      "label": "is a"
    },
    {
      "source": "responses",
      "target": "L-glutamate",
      "label": "elicited by"
    },
    {
      "source": "responses",
      "target": "Wnt pathway inhibitor",
      "label": "are to"
    },
    {
      "source": "responses",
      "target": "reversal",
      "label": "accompany"
    },
    {
      "source": "responses",
      "target": "taenia caeci",
      "label": "occur in"
    },
    {
      "source": "responses",
      "target": "guinea-pig ileal longitudinal smooth muscle",
      "label": "occur in"
    },
    {
      "source": "responses",
      "target": "bethanechol",
      "label": "to"
    },
    {
      "source": "responses",
      "target": "trachea",
      "label": "occur in"
    },
    {
      "source": "responses",
      "target": "tissues",
      "label": "occur in"
    },
    {
      "source": "responses",
      "target": "rat anococcygeus muscle",
      "label": "occur in"
    },
    {
      "source": "responses",
      "target": "acetylcholine",
      "label": "to"
    },
    {
      "source": "glutamate transporter-1",
      "target": "excitatory amino acid transporter 2",
      "label": "is also known as"
    },
    {
      "source": "DsRed expression",
      "target": "IPCs",
      "label": "restricted to"
    },
    {
      "source": "DsRed expression",
      "target": "supporting cells",
      "label": "restricted to"
    },
    {
      "source": "examination of cochlea",
      "target": "GLAST-Discosoma red (DsRed) promoter reporter mice",
      "label": "from"
    },
    {
      "source": "D-aspartate",
      "target": "transporter substrate",
      "label": "is a"
    },
    {
      "source": "D-aspartate",
      "target": "afferent terminals",
      "label": "applied to"
    },
    {
      "source": "D-aspartate",
      "target": "inward currents",
      "label": "elicited"
    },
    {
      "source": "L-glutamate",
      "target": "transcytosis",
      "label": "secreted through"
    },
    {
      "source": "L-glutamate",
      "target": "autoregulation",
      "label": "involved in"
    },
    {
      "source": "glutamate-aspartate transporter",
      "target": "glutamate uptake",
      "label": "mediates"
    },
    {
      "source": "glial cells",
      "target": "inner phalangeal cells (IPCs)",
      "label": "are"
    },
    {
      "source": "glial cells",
      "target": "mitotic inhibitor",
      "label": "removed by"
    },
    {
      "source": "glial cells",
      "target": "ERalpha",
      "label": "express"
    },
    {
      "source": "presynaptic membranes",
      "target": "major sites for glutamate removal",
      "label": "are not"
    },
    {
      "source": "postsynaptic membranes",
      "target": "major sites for glutamate removal",
      "label": "are not"
    },
    {
      "source": "spontaneous locomotor activity",
      "target": "familiar environments",
      "label": "occurred in"
    },
    {
      "source": "spontaneous locomotor activity",
      "target": "novel environment",
      "label": "occurred in"
    },
    {
      "source": "Chronic treatment",
      "target": "spontaneous locomotor activity",
      "label": "decreased"
    },
    {
      "source": "Chronic treatment",
      "target": "fasting plasma glucose",
      "label": "reduced"
    },
    {
      "source": "Chronic treatment",
      "target": "glycemic response",
      "label": "improved"
    },
    {
      "source": "Chronic treatment",
      "target": "glycated hemoglobin",
      "label": "reduced"
    },
    {
      "source": "Chronic treatment",
      "target": "Sergliflozin etabonate",
      "label": "with"
    },
    {
      "source": "Chronic treatment",
      "target": "Zucker fatty rats",
      "label": "acted on"
    },
    {
      "source": "norepinephrine transporter knockout mice",
      "target": "basal spontaneous locomotor activity",
      "label": "had"
    },
    {
      "source": "Coadministration",
      "target": "spontaneous locomotor activity",
      "label": "increased"
    },
    {
      "source": "Coadministration",
      "target": "celecoxib",
      "label": "of"
    },
    {
      "source": "Coadministration",
      "target": "SC-560",
      "label": "of"
    },
    {
      "source": "Coadministration",
      "target": "Gastrointestinal lesions",
      "label": "produced"
    },
    {
      "source": "norepinephrine transporter blockade",
      "target": "antidepressants",
      "label": "contributes to effects of"
    },
    {
      "source": "norepinephrine transporter blockade",
      "target": "spontaneous locomotor activity",
      "label": "contributes to effects on"
    },
    {
      "source": "antidepressants",
      "target": "spontaneous locomotor activity",
      "label": "affects"
    },
    {
      "source": "dopamine transporter blockade",
      "target": "Acute inactivation",
      "label": "coupled with"
    },
    {
      "source": "dopamine transporter blockade",
      "target": "Chronic inactivation",
      "label": "coupled with"
    },
    {
      "source": "Acute inactivation",
      "target": "spontaneous locomotor activity",
      "label": "decreases"
    },
    {
      "source": "Chronic inactivation",
      "target": "spontaneous locomotor activity",
      "label": "decreases"
    },
    {
      "source": "Acute treatment",
      "target": "spontaneous locomotor activity",
      "label": "decreased"
    },
    {
      "source": "GBR 12909",
      "target": "dopamine transporter blocker",
      "label": "is a"
    },
    {
      "source": "norepinephrine transporter-blocking antidepressants",
      "target": "spontaneous locomotor activity",
      "label": "decreased"
    },
    {
      "source": "Chronic antidepressant treatment",
      "target": "spontaneous locomotor activity",
      "label": "affects"
    },
    {
      "source": "Acute administration",
      "target": "spontaneous locomotor activity",
      "label": "affects"
    },
    {
      "source": "vesicular glutamate transporter 1",
      "target": "vesicular storage",
      "label": "essential for"
    },
    {
      "source": "vesicular glutamate transporter 1",
      "target": "exocytosis",
      "label": "essential for"
    },
    {
      "source": "vesicular glutamate transporter 1",
      "target": "glutamate",
      "label": "transports"
    },
    {
      "source": "vesicular storage",
      "target": "glutamate",
      "label": "stores"
    },
    {
      "source": "autoregulation",
      "target": "transcytosis",
      "label": "of"
    },
    {
      "source": "VGLUT1",
      "target": "vesicular storage",
      "label": "essential for"
    },
    {
      "source": "VGLUT1",
      "target": "transcytotic vesicles",
      "label": "localized in"
    },
    {
      "source": "VGLUT1",
      "target": "L-glutamate",
      "label": "accumulates"
    },
    {
      "source": "VGLUT1",
      "target": "exocytosis",
      "label": "essential for"
    },
    {
      "source": "VGLUT1",
      "target": "glutamate",
      "label": "transports"
    },
    {
      "source": "Glutamate signaling",
      "target": "bone homeostasis",
      "label": "plays role in"
    },
    {
      "source": "osteoclasts",
      "target": "L-glutamate",
      "label": "secrete"
    },
    {
      "source": "osteoclasts",
      "target": "vesicular glutamate transporter 1",
      "label": "express"
    },
    {
      "source": "osteoclasts",
      "target": "transcytosis",
      "label": "eliminate through"
    },
    {
      "source": "osteoclasts",
      "target": "mGluR8",
      "label": "express"
    },
    {
      "source": "osteoclasts",
      "target": "catabolism",
      "label": "involved in"
    },
    {
      "source": "osteoclasts",
      "target": "VGLUT1",
      "label": "express"
    },
    {
      "source": "osteoclasts",
      "target": "degradation products",
      "label": "eliminate"
    },
    {
      "source": "osteoclasts",
      "target": "Col1a1-Cnn1 osteoblasts",
      "label": "were increased when co-cultured with"
    },
    {
      "source": "glutamate",
      "target": "excitotoxicity",
      "label": "mediates"
    },
    {
      "source": "suppression",
      "target": "bone resorption",
      "label": "stimulates"
    },
    {
      "source": "suppression",
      "target": "antagonist",
      "label": "by"
    },
    {
      "source": "suppression",
      "target": "psoriasis",
      "label": "leads to expected activity in"
    },
    {
      "source": "suppression",
      "target": "RBL-Mnr cells",
      "label": "in"
    },
    {
      "source": "suppression",
      "target": "ZIP8 expression",
      "label": "of"
    },
    {
      "source": "suppression",
      "target": "cadmium-resistant RBL-2H3 cells",
      "label": "is a common feature of"
    },
    {
      "source": "suppression",
      "target": "manganese-resistant RBL-2H3 cells",
      "label": "is a common feature of"
    },
    {
      "source": "suppression",
      "target": "RBL-Cdr cells",
      "label": "in"
    },
    {
      "source": "mGluR8",
      "target": "class III metabotropic glutamate receptor",
      "label": "is a"
    },
    {
      "source": "mGluR8",
      "target": "glutamate release sites",
      "label": "is localized away from"
    },
    {
      "source": "mGluR8",
      "target": "synaptic responses",
      "label": "modulates"
    },
    {
      "source": "mGluR8",
      "target": "light responses",
      "label": "modulates"
    },
    {
      "source": "exocytosis",
      "target": "glutamate",
      "label": "of"
    },
    {
      "source": "bone-resorbing osteoclasts",
      "target": "degradation products",
      "label": "secrete"
    },
    {
      "source": "bone-resorbing osteoclasts",
      "target": "L-glutamate",
      "label": "secrete"
    },
    {
      "source": "degradation products",
      "target": "transcytosis",
      "label": "eliminated through"
    },
    {
      "source": "VGLUT1-/- knockout mice",
      "target": "osteoporosis",
      "label": "develop"
    },
    {
      "source": "regulation",
      "target": "transcytosis",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "AQP5 protein level",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "lipogenesis",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "inputs",
      "label": "provides"
    },
    {
      "source": "regulation",
      "target": "AC7",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "G(13) pathway",
      "label": "by"
    },
    {
      "source": "regulation",
      "target": "G\u03b2\u03b3",
      "label": "by"
    },
    {
      "source": "regulation",
      "target": "pathways",
      "label": "by"
    },
    {
      "source": "regulation",
      "target": "adenylyl cyclases",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "AC",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "AC2",
      "label": "compared with"
    },
    {
      "source": "regulation",
      "target": "G13 pathway",
      "label": "by"
    },
    {
      "source": "regulation",
      "target": "cAMP",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "BMPs",
      "label": "of"
    },
    {
      "source": "regulation",
      "target": "bone morphogenetic proteins",
      "label": "of"
    },
    {
      "source": "stimulation",
      "target": "secretion",
      "label": "inhibits"
    },
    {
      "source": "stimulation",
      "target": "agonist",
      "label": "by"
    },
    {
      "source": "stimulation",
      "target": "arginine transport",
      "label": "of"
    },
    {
      "source": "stimulation",
      "target": "bone remodeling",
      "label": "of"
    },
    {
      "source": "stimulation",
      "target": "osteoclast increase",
      "label": "accelerated"
    },
    {
      "source": "stimulation",
      "target": "responses",
      "label": "accelerated"
    },
    {
      "source": "stimulation",
      "target": "sympathetic signaling",
      "label": "of"
    },
    {
      "source": "stimulation",
      "target": "tooth movement",
      "label": "accelerated"
    },
    {
      "source": "stimulation",
      "target": "G(s)",
      "label": "by"
    },
    {
      "source": "Abarelix",
      "target": "testosterone surge",
      "label": "does not cause"
    },
    {
      "source": "Abarelix",
      "target": "medical castration",
      "label": "produces"
    },
    {
      "source": "Abarelix",
      "target": "LHRH agonist activity",
      "label": "is devoid of"
    },
    {
      "source": "Abarelix",
      "target": "LHRH agonists",
      "label": "compared with"
    },
    {
      "source": "Abarelix",
      "target": "GnRH receptor antagonist",
      "label": "is a"
    },
    {
      "source": "Abarelix",
      "target": "disease flare",
      "label": "abolishes risk of"
    },
    {
      "source": "Abarelix",
      "target": "co-administration",
      "label": "does_not_require"
    },
    {
      "source": "Abarelix",
      "target": "agonist effect",
      "label": "lacks"
    },
    {
      "source": "Abarelix",
      "target": "GnRH receptor",
      "label": "Antagonist"
    },
    {
      "source": "Abarelix",
      "target": "complication rate",
      "label": "has"
    },
    {
      "source": "Abarelix",
      "target": "pure GnRH antagonists",
      "label": "is_a"
    },
    {
      "source": "Abarelix",
      "target": "USA Food and Drug Administration",
      "label": "approved_by"
    },
    {
      "source": "Abarelix",
      "target": "decreases",
      "label": "causes"
    },
    {
      "source": "Abarelix",
      "target": "testosterone flare",
      "label": "prevents"
    },
    {
      "source": "Abarelix",
      "target": "prostate cancer",
      "label": "treats"
    },
    {
      "source": "Abarelix",
      "target": "hormonal castration",
      "label": "approved_for"
    },
    {
      "source": "testosterone surge",
      "target": "worsening of disease",
      "label": "can precipitate"
    },
    {
      "source": "testosterone surge",
      "target": "flare phenomenon",
      "label": "can precipitate"
    },
    {
      "source": "phase III clinical trials",
      "target": "Abarelix",
      "label": "demonstrate effects of"
    },
    {
      "source": "phase II clinical trials",
      "target": "Abarelix",
      "label": "demonstrate effects of"
    },
    {
      "source": "LHRH agonists",
      "target": "serum testosterone",
      "label": "cause a surge in"
    },
    {
      "source": "LHRH agonists",
      "target": "nonsteroidal antagonist",
      "label": "can be used with"
    },
    {
      "source": "LHRH agonists",
      "target": "LH",
      "label": "stimulate release of"
    },
    {
      "source": "Gonadotropin-releasing hormone (GnRH) receptor antagonism",
      "target": "medical castration",
      "label": "is an approach to"
    },
    {
      "source": "Gonadotropin-releasing hormone antagonist",
      "target": "prostate cancer",
      "label": "manages"
    },
    {
      "source": "Luteinizing hormone-releasing hormone (LHRH) agonist therapy",
      "target": "hormonal therapy",
      "label": "is a form of"
    },
    {
      "source": "Luteinizing hormone-releasing hormone (LHRH) agonist therapy",
      "target": "medical castration",
      "label": "induces"
    },
    {
      "source": "flare phenomenon",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "worsening of disease",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "LH",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "LH",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "LH",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "LH",
      "target": "CYP11A1",
      "label": "increased expression of"
    },
    {
      "source": "LH",
      "target": "STAR",
      "label": "increased expression of"
    },
    {
      "source": "LH",
      "target": "progesterone secretion",
      "label": "increased"
    },
    {
      "source": "LH",
      "target": "RXFP2",
      "label": "attenuated expression of"
    },
    {
      "source": "LH",
      "target": "INSL3",
      "label": "attenuated expression of"
    },
    {
      "source": "KGF",
      "target": "Bcl-2",
      "label": "resulted in up-regulation of"
    },
    {
      "source": "KGF",
      "target": "receptor",
      "label": "acts through"
    },
    {
      "source": "KGF",
      "target": "paracrine growth factor",
      "label": "serves as"
    },
    {
      "source": "KGF",
      "target": "prostate cancer",
      "label": "acts as autocrine factor in"
    },
    {
      "source": "KGF",
      "target": "cancerous stroma",
      "label": "has roles in"
    },
    {
      "source": "KGF",
      "target": "phospho-Akt expression",
      "label": "activates"
    },
    {
      "source": "KGF",
      "target": "inhibition",
      "label": "prevented"
    },
    {
      "source": "KGF",
      "target": "epithelial cells",
      "label": "acts on"
    },
    {
      "source": "KGF",
      "target": "fibroblast growth factor-7",
      "label": "is also known as"
    },
    {
      "source": "KGF",
      "target": "anti-apoptotic actions",
      "label": "activated"
    },
    {
      "source": "KGF",
      "target": "dynamic protein expression",
      "label": "modulated"
    },
    {
      "source": "KGF",
      "target": "mitogenic effects",
      "label": "exhibited"
    },
    {
      "source": "KGF",
      "target": "phosphorylation of Akt",
      "label": "resulted in"
    },
    {
      "source": "KGF",
      "target": "survival factor",
      "label": "serves as"
    },
    {
      "source": "KGF",
      "target": "primary cultured human prostate cancer stromal cells",
      "label": "serves as survival factor in"
    },
    {
      "source": "KGF",
      "target": "cell cycle machinery",
      "label": "triggered"
    },
    {
      "source": "KGF",
      "target": "benign prostatic hyperplasia",
      "label": "expressed in"
    },
    {
      "source": "KGF",
      "target": "autocrine factor",
      "label": "has"
    },
    {
      "source": "KGF",
      "target": "anti-apoptotic effects",
      "label": "exhibited"
    },
    {
      "source": "KGF",
      "target": "stromal cells",
      "label": "found in"
    },
    {
      "source": "KGF",
      "target": "BPH",
      "label": "acts as autocrine factor in"
    },
    {
      "source": "KGF",
      "target": "anti-apoptotic machinery",
      "label": "triggered"
    },
    {
      "source": "KGF",
      "target": "human cancer epithelial cells",
      "label": "found in"
    },
    {
      "source": "KGF",
      "target": "KGFR",
      "label": "acts through"
    },
    {
      "source": "paracrine growth factor",
      "target": "stromal cells",
      "label": "synthesized in"
    },
    {
      "source": "paracrine growth factor",
      "target": "epithelial cells",
      "label": "acts on"
    },
    {
      "source": "PCSCs",
      "target": "androgen receptor",
      "label": "did not possess"
    },
    {
      "source": "PCSCs",
      "target": "KGFR",
      "label": "possessed"
    },
    {
      "source": "PCSCs",
      "target": "primary cultured human prostate cancer stromal cells",
      "label": "are"
    },
    {
      "source": "PCSCs",
      "target": "estrogen receptors",
      "label": "possessed"
    },
    {
      "source": "KGFR",
      "target": "RT-PCR",
      "label": "determined by"
    },
    {
      "source": "KGFR",
      "target": "receptor",
      "label": "is a"
    },
    {
      "source": "KGFR",
      "target": "stromal cells",
      "label": "found in"
    },
    {
      "source": "KGFR",
      "target": "human cancer epithelial cells",
      "label": "found in"
    },
    {
      "source": "keratinocyte growth factor",
      "target": "cell viability",
      "label": "has effect on"
    },
    {
      "source": "keratinocyte growth factor",
      "target": "fibroblast growth factor-7",
      "label": "is also known as"
    },
    {
      "source": "keratinocyte growth factor",
      "target": "primary cultured human prostate cancer stromal cells",
      "label": "acts on"
    },
    {
      "source": "estrogen receptors",
      "target": "RT-PCR",
      "label": "determined by"
    },
    {
      "source": "estrogen receptors",
      "target": "ER\u03b1",
      "label": "include"
    },
    {
      "source": "estrogen receptors",
      "target": "ER\u03b2",
      "label": "include"
    },
    {
      "source": "KGF antiserum",
      "target": "anti-apoptotic protein expression",
      "label": "abolished"
    },
    {
      "source": "KGF antiserum",
      "target": "cell proliferation",
      "label": "abolished"
    },
    {
      "source": "fibroblast growth factor-7",
      "target": "FGF-7",
      "label": "is also known as"
    },
    {
      "source": "ICI 182,780",
      "target": "cell viability",
      "label": "reduced"
    },
    {
      "source": "ICI 182,780",
      "target": "ER",
      "label": "is an antagonist of"
    },
    {
      "source": "anti-apoptotic effects",
      "target": "Bcl-2",
      "label": "correlated with"
    },
    {
      "source": "anti-apoptotic effects",
      "target": "Bcl-xL",
      "label": "correlated with"
    },
    {
      "source": "anti-apoptotic effects",
      "target": "phospho-Akt expression",
      "label": "correlated with"
    },
    {
      "source": "mitogenic effects",
      "target": "cyclin-D1",
      "label": "correlated with"
    },
    {
      "source": "phosphorylation of Akt",
      "target": "Bcl-2",
      "label": "resulted in up-regulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "VEGFR",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "PDGF-beta",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "VEGF receptor",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "von Hippel-Lindau disease protein",
      "label": "characterized by loss of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "epidermal growth factor receptor",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "vascular endothelial growth factor",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "PDGFR-beta",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "VEGF",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "PDGF receptor-beta",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "platelet-derived growth factor-beta",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "Raf pathways",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "TGF-alpha",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "transforming growth factor-alpha",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "clear-cell renal cell carcinoma",
      "target": "EGFR",
      "label": "characterized by dysregulation of"
    },
    {
      "source": "sunitinib",
      "target": "PDGFR-beta",
      "label": "targets"
    },
    {
      "source": "sunitinib",
      "target": "multiple VEGFRs",
      "label": "targets"
    },
    {
      "source": "PDGFR-beta",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "PDGFR-beta",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "PDGFR-beta",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "PDGFR-beta",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "advances",
      "target": "clear-cell renal cell carcinoma",
      "label": "in treatment of"
    },
    {
      "source": "advances",
      "target": "biology of clear-cell RCC",
      "label": "in understanding of"
    },
    {
      "source": "advances",
      "target": "new targets of opportunity",
      "label": "delineate"
    },
    {
      "source": "PDGF-beta",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "PDGF-beta",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "PDGF-beta",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "PDGF-beta",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "VEGF receptor",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "VEGF receptor",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "VEGF receptor",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "VEGF receptor",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "transforming growth factor-alpha",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "transforming growth factor-alpha",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "transforming growth factor-alpha",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "transforming growth factor-alpha",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "epidermal growth factor receptor",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "epidermal growth factor receptor",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "epidermal growth factor receptor",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "epidermal growth factor receptor",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "single-agent therapy",
      "target": "clear-cell renal cell carcinoma",
      "label": "for"
    },
    {
      "source": "TGF-alpha",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "TGF-alpha",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "TGF-alpha",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "TGF-alpha",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "Sorafenib",
      "target": "Raf isoforms",
      "label": "inhibits"
    },
    {
      "source": "Sorafenib",
      "target": "VEGFR",
      "label": "enhances inhibition of"
    },
    {
      "source": "Sorafenib",
      "target": "single-agent therapy",
      "label": "has scientific rationales for"
    },
    {
      "source": "Sorafenib",
      "target": "combination therapy",
      "label": "has scientific rationales for"
    },
    {
      "source": "Sorafenib",
      "target": "active MKIs",
      "label": "is an example of"
    },
    {
      "source": "Sorafenib",
      "target": "multiple VEGFRs",
      "label": "targets"
    },
    {
      "source": "Sorafenib",
      "target": "PDGFR-beta",
      "label": "enhances inhibition of"
    },
    {
      "source": "Sorafenib",
      "target": "TGF-alpha/EGFR signaling",
      "label": "targets"
    },
    {
      "source": "EGFR",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "EGFR",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "EGFR",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "EGFR",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "AG013736",
      "target": "multiple VEGFRs",
      "label": "targets"
    },
    {
      "source": "AG013736",
      "target": "PDGFR-beta",
      "label": "targets"
    },
    {
      "source": "combination therapy",
      "target": "clear-cell renal cell carcinoma",
      "label": "for"
    },
    {
      "source": "combination therapy",
      "target": "dutasteride",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "patients",
      "label": "for"
    },
    {
      "source": "combination therapy",
      "target": "doxazosin",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "rate of clinical progression",
      "label": "lowers"
    },
    {
      "source": "combination therapy",
      "target": "finasteride",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "detrusor overactivity",
      "label": "relieves"
    },
    {
      "source": "combination therapy",
      "target": "disease progression",
      "label": "prevents"
    },
    {
      "source": "combination therapy",
      "target": "finasteride monotherapy",
      "label": "more effective than"
    },
    {
      "source": "combination therapy",
      "target": "anti-muscarinic agents",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "statistically significant benefits",
      "label": "results in"
    },
    {
      "source": "combination therapy",
      "target": "symptoms",
      "label": "reduces"
    },
    {
      "source": "combination therapy",
      "target": "treatment",
      "label": "in"
    },
    {
      "source": "combination therapy",
      "target": "doxazosin monotherapy",
      "label": "more effective than"
    },
    {
      "source": "combination therapy",
      "target": "International Prostate Symptom Score (IPSS)",
      "label": "decreases"
    },
    {
      "source": "combination therapy",
      "target": "5alpha-reductase inhibitors (5alphaRIs)",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "tamsulosin",
      "label": "involves"
    },
    {
      "source": "combination therapy",
      "target": "symptoms of bladder outlet obstruction",
      "label": "relieves"
    },
    {
      "source": "combination therapy",
      "target": "lower urinary tract symptoms (LUTS)",
      "label": "for"
    },
    {
      "source": "platelet-derived growth factor-beta",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "platelet-derived growth factor-beta",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "platelet-derived growth factor-beta",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "platelet-derived growth factor-beta",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "early clinical results",
      "target": "agents",
      "label": "of"
    },
    {
      "source": "PDGF receptor-beta",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "PDGF receptor-beta",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "PDGF receptor-beta",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "PDGF receptor-beta",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "Raf pathways",
      "target": "tumor cell survival",
      "label": "contributes to"
    },
    {
      "source": "Raf pathways",
      "target": "angiogenesis",
      "label": "contributes to"
    },
    {
      "source": "Raf pathways",
      "target": "tumor cell growth",
      "label": "contributes to"
    },
    {
      "source": "Raf pathways",
      "target": "lymphangiogenesis",
      "label": "contributes to"
    },
    {
      "source": "multiple-kinase inhibitors",
      "target": "Sorafenib",
      "label": "include"
    },
    {
      "source": "multiple-kinase inhibitors",
      "target": "sunitinib",
      "label": "include"
    },
    {
      "source": "multiple-kinase inhibitors",
      "target": "AG013736",
      "label": "include"
    },
    {
      "source": "review",
      "target": "early clinical results",
      "label": "presents"
    },
    {
      "source": "review",
      "target": "scientific rationales",
      "label": "describes"
    },
    {
      "source": "review",
      "target": "advances",
      "label": "examines"
    },
    {
      "source": "review",
      "target": "selected publications",
      "label": "includes"
    },
    {
      "source": "review",
      "target": "current issues",
      "label": "addresses"
    },
    {
      "source": "review",
      "target": "therapies for estrogen-sensitive breast cancer",
      "label": "addresses"
    },
    {
      "source": "review",
      "target": "ongoing investigations",
      "label": "outlines"
    },
    {
      "source": "review",
      "target": "Published scientific literature",
      "label": "covers"
    },
    {
      "source": "review",
      "target": "role of fulvestrant",
      "label": "highlights"
    },
    {
      "source": "review",
      "target": "evidence",
      "label": "presents"
    },
    {
      "source": "review",
      "target": "oxytocin",
      "label": "about"
    },
    {
      "source": "review",
      "target": "cellular and molecular mechanisms",
      "label": "DISCUSSES"
    },
    {
      "source": "ongoing and future sorafenib-based combination therapy trials",
      "target": "RCC",
      "label": "in"
    },
    {
      "source": "scientific rationales",
      "target": "ongoing and future sorafenib-based combination therapy trials",
      "label": "for"
    },
    {
      "source": "new targets of opportunity",
      "target": "treatment",
      "label": "for"
    },
    {
      "source": "RR stereoisomer",
      "target": "non-specific side effects",
      "label": "has"
    },
    {
      "source": "RR stereoisomer",
      "target": "alpha 1-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "RR stereoisomer",
      "target": "alpha 2-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "RR stereoisomer",
      "target": "liver toxicity",
      "label": "induces"
    },
    {
      "source": "RR stereoisomer",
      "target": "beta 1-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "RR stereoisomer",
      "target": "alpha receptor actions",
      "label": "exhibits"
    },
    {
      "source": "RR stereoisomer",
      "target": "beta receptor actions",
      "label": "exhibits"
    },
    {
      "source": "RR stereoisomer",
      "target": "alpha 2-adrenoceptors",
      "label": "lacks affinity at"
    },
    {
      "source": "comparison studies",
      "target": "rat heart",
      "label": "conducted in"
    },
    {
      "source": "comparison studies",
      "target": "homogenized rat cerebral cortex",
      "label": "conducted in"
    },
    {
      "source": "comparison studies",
      "target": "pithed rats",
      "label": "conducted in"
    },
    {
      "source": "phenylephrine",
      "target": "mean arterial pressure",
      "label": "increases"
    },
    {
      "source": "phenylephrine",
      "target": "pressor effect",
      "label": "causes"
    },
    {
      "source": "phenylephrine",
      "target": "doses",
      "label": "administered at"
    },
    {
      "source": "phenylephrine",
      "target": "i.v. administration",
      "label": "administered via"
    },
    {
      "source": "labetalol",
      "target": "alpha 1-adrenoceptors",
      "label": "acts on"
    },
    {
      "source": "labetalol",
      "target": "alpha 2-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "labetalol",
      "target": "beta 1-adrenoceptor blocking potencies",
      "label": "exhibits"
    },
    {
      "source": "labetalol",
      "target": "chronotropic effect",
      "label": "antagonizes"
    },
    {
      "source": "labetalol",
      "target": "alpha 1-adrenoceptor blocking potencies",
      "label": "exhibits"
    },
    {
      "source": "labetalol",
      "target": "oral dosing",
      "label": "administered via"
    },
    {
      "source": "labetalol",
      "target": "beta-adrenoceptor blocking activities",
      "label": "exhibits"
    },
    {
      "source": "labetalol",
      "target": "potency",
      "label": "has"
    },
    {
      "source": "labetalol",
      "target": "SR stereoisomer",
      "label": "is a mixture of"
    },
    {
      "source": "labetalol",
      "target": "beta 1-adrenoceptors",
      "label": "acts on"
    },
    {
      "source": "labetalol",
      "target": "pithed rats",
      "label": "administered to"
    },
    {
      "source": "labetalol",
      "target": "intravenous dosing",
      "label": "administered via"
    },
    {
      "source": "labetalol",
      "target": "liver toxicity",
      "label": "devoid of"
    },
    {
      "source": "labetalol",
      "target": "RR stereoisomer",
      "label": "is a mixture of"
    },
    {
      "source": "labetalol",
      "target": "doses",
      "label": "administered at"
    },
    {
      "source": "labetalol",
      "target": "pressor effect",
      "label": "antagonizes"
    },
    {
      "source": "labetalol",
      "target": "SS enantiomer",
      "label": "is a mixture of"
    },
    {
      "source": "labetalol",
      "target": "alpha-adrenoceptor blocking activities",
      "label": "exhibits"
    },
    {
      "source": "labetalol",
      "target": "alpha 2-adrenoceptors",
      "label": "lacks affinity at"
    },
    {
      "source": "labetalol",
      "target": "affinity",
      "label": "has"
    },
    {
      "source": "Prazosin",
      "target": "potency",
      "label": "evaluated for"
    },
    {
      "source": "Prazosin",
      "target": "comparison studies",
      "label": "used for"
    },
    {
      "source": "Prazosin",
      "target": "alpha 1-adrenoceptors",
      "label": "acts on"
    },
    {
      "source": "Prazosin",
      "target": "intravenous dosing",
      "label": "administered via"
    },
    {
      "source": "Prazosin",
      "target": "RR-SR (50:50) stereoisomers",
      "label": "has higher potency than"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "alpha 1-adrenoceptors",
      "label": "acts on"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "affinity",
      "label": "has"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "treatment",
      "label": "used for"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "chronotropic effect",
      "label": "antagonizes"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "pithed rats",
      "label": "administered to"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "oral dosing",
      "label": "administered via"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "beta-adrenoceptor blocking activities",
      "label": "exhibits"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "labetalol",
      "label": "has higher potency than"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "clinical importance",
      "label": "has potential"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "beta 1-adrenoceptors",
      "label": "acts on"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "beta 1-adrenoceptor blocking potencies",
      "label": "exhibits"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "intravenous dosing",
      "label": "administered via"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "alpha-adrenoceptor blocking activities",
      "label": "exhibits"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "alpha 1-adrenoceptor blocking potencies",
      "label": "exhibits"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "potency",
      "label": "has"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "pressor effect",
      "label": "antagonizes"
    },
    {
      "source": "RR-SR (50:50) stereoisomers",
      "target": "doses",
      "label": "administered at"
    },
    {
      "source": "liver toxicity",
      "target": "reports",
      "label": "indicated by"
    },
    {
      "source": "reports",
      "target": "postmarketing surveillance",
      "label": "from"
    },
    {
      "source": "reports",
      "target": "efficacy",
      "label": "concern"
    },
    {
      "source": "RS enantiomer",
      "target": "non-specific side effects",
      "label": "has"
    },
    {
      "source": "SR stereoisomer",
      "target": "alpha receptor actions",
      "label": "exhibits"
    },
    {
      "source": "SR stereoisomer",
      "target": "beta receptor actions",
      "label": "exhibits"
    },
    {
      "source": "SR stereoisomer",
      "target": "alpha 2-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "SR stereoisomer",
      "target": "alpha 2-adrenoceptors",
      "label": "lacks affinity at"
    },
    {
      "source": "SR stereoisomer",
      "target": "non-specific side effects",
      "label": "has"
    },
    {
      "source": "SR stereoisomer",
      "target": "beta 1-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "SR stereoisomer",
      "target": "alpha 1-adrenoceptor blocking potencies",
      "label": "has"
    },
    {
      "source": "SS enantiomer",
      "target": "alpha receptor actions",
      "label": "lacks"
    },
    {
      "source": "SS enantiomer",
      "target": "beta receptor actions",
      "label": "lacks"
    },
    {
      "source": "SS enantiomer",
      "target": "alpha 2-adrenoceptors",
      "label": "lacks affinity at"
    },
    {
      "source": "SS enantiomer",
      "target": "non-specific side effects",
      "label": "has"
    },
    {
      "source": "dilevalol",
      "target": "liver toxicity",
      "label": "induces"
    },
    {
      "source": "cGMP",
      "target": "GAF-A",
      "label": "binds to"
    },
    {
      "source": "cGMP",
      "target": "catalytic site",
      "label": "improves affinity of"
    },
    {
      "source": "cGMP",
      "target": "Phosphodiesterase-5 (PDE5)",
      "label": "increases phosphorylation of"
    },
    {
      "source": "GAF-B",
      "target": "dimerization of PDE5",
      "label": "contributes to"
    },
    {
      "source": "GAF-B",
      "target": "phosphorylation site",
      "label": "sequesters"
    },
    {
      "source": "GAF-B",
      "target": "GAF-A",
      "label": "inhibits binding to"
    },
    {
      "source": "GAF-B",
      "target": "selectivity",
      "label": "influences"
    },
    {
      "source": "GAF-B",
      "target": "affinity",
      "label": "influences"
    },
    {
      "source": "GAF-B",
      "target": "cGMP",
      "label": "inhibits binding of"
    },
    {
      "source": "PDE5Delta1-534",
      "target": "C domain",
      "label": "contains"
    },
    {
      "source": "C domain",
      "target": "cGMP",
      "label": "hydrolyzes"
    },
    {
      "source": "PDE5Delta1-321",
      "target": "GAF-B domain",
      "label": "contains"
    },
    {
      "source": "PDE5Delta1-321",
      "target": "sequence between GAF-A and -B",
      "label": "contains"
    },
    {
      "source": "PDE5Delta1-321",
      "target": "C domain",
      "label": "contains"
    },
    {
      "source": "PDE5Delta1-465",
      "target": "C-terminal portion of GAF-B",
      "label": "contains"
    },
    {
      "source": "PDE5Delta1-465",
      "target": "C domain",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "GAFs",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "GAF-B",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "mammalian cGMP-binding phosphodiesterase",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "Anabaena adenylyl cyclases",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "phosphorylation site",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "Escherichia coli FhlAs",
      "label": "contains"
    },
    {
      "source": "regulatory domain (R domain)",
      "target": "GAF-A",
      "label": "contains"
    },
    {
      "source": "phosphorylation site",
      "target": "cyclic nucleotide-dependent protein kinases (cNPKs)",
      "label": "is target for"
    },
    {
      "source": "PDE5 constructs",
      "target": "3-isobutyl-1-methylxanthine",
      "label": "has affinity for"
    },
    {
      "source": "PDE5 constructs",
      "target": "sildenafil",
      "label": "has affinity for"
    },
    {
      "source": "PDE5 constructs",
      "target": "tadalafil",
      "label": "has affinity for"
    },
    {
      "source": "PDE5 constructs",
      "target": "UK-122764",
      "label": "has affinity for"
    },
    {
      "source": "N-terminal 46 amino acids",
      "target": "Phosphodiesterase-5 dimerization",
      "label": "is involved in"
    },
    {
      "source": "N-terminal 46 amino acids",
      "target": "GAF-B-mediated PDE5 dimerization",
      "label": "are vital for"
    },
    {
      "source": "N-terminal 46 amino acids",
      "target": "vardenafil potency",
      "label": "provides for"
    },
    {
      "source": "N-terminal 46 amino acids",
      "target": "GAF-B domain",
      "label": "is part of"
    },
    {
      "source": "K(m) values",
      "target": "full-length PDE5",
      "label": "are similar to"
    },
    {
      "source": "K(m) values",
      "target": "cGMP",
      "label": "are for"
    },
    {
      "source": "K(m) values",
      "target": "mutants",
      "label": "are of"
    },
    {
      "source": "Truncated proteins",
      "target": "monomers",
      "label": "are"
    },
    {
      "source": "Truncated proteins",
      "target": "dimers",
      "label": "are"
    },
    {
      "source": "selectivity",
      "target": "isoforms",
      "label": "is against"
    },
    {
      "source": "selectivity",
      "target": "CYP11B1",
      "label": "toward"
    },
    {
      "source": "selectivity",
      "target": "CYP17",
      "label": "toward"
    },
    {
      "source": "selectivity",
      "target": "receptor species",
      "label": "regardless of"
    },
    {
      "source": "selectivity",
      "target": "c-Met",
      "label": "for"
    },
    {
      "source": "selectivity",
      "target": "11 kinases",
      "label": "compared to"
    },
    {
      "source": "N-terminal truncation mutants",
      "target": "PDE5Delta1-534",
      "label": "are"
    },
    {
      "source": "N-terminal truncation mutants",
      "target": "PDE5Delta1-465",
      "label": "are"
    },
    {
      "source": "N-terminal truncation mutants",
      "target": "PDE5Delta1-321",
      "label": "are"
    },
    {
      "source": "N-terminal truncation mutants",
      "target": "PDE5Delta1-419",
      "label": "are"
    },
    {
      "source": "Phosphodiesterase-5 (PDE5)",
      "target": "catalytic domain",
      "label": "contains"
    },
    {
      "source": "Phosphodiesterase-5 (PDE5)",
      "target": "C domain",
      "label": "contains"
    },
    {
      "source": "Phosphodiesterase-5 (PDE5)",
      "target": "regulatory domain (R domain)",
      "label": "contains"
    },
    {
      "source": "complete GAF-B",
      "target": "vardenafil-based compounds",
      "label": "confers higher affinity for"
    },
    {
      "source": "PDE5Delta1-419",
      "target": "GAF-B",
      "label": "contains"
    },
    {
      "source": "PDE5Delta1-419",
      "target": "C domain",
      "label": "contains"
    },
    {
      "source": "dimers",
      "target": "conditions",
      "label": "formed by controlling"
    },
    {
      "source": "PDE5 R domain",
      "target": "selectivity",
      "label": "influences"
    },
    {
      "source": "PDE5 R domain",
      "target": "affinity",
      "label": "influences"
    },
    {
      "source": "ligands for PR",
      "target": "drugs",
      "label": "developed into"
    },
    {
      "source": "ligands for PR",
      "target": "evolution",
      "label": "has"
    },
    {
      "source": "Progesterone",
      "target": "drug target",
      "label": "is"
    },
    {
      "source": "Progesterone",
      "target": "nuclear receptor hormones",
      "label": "is a type of"
    },
    {
      "source": "Progesterone",
      "target": "activity",
      "label": "has"
    },
    {
      "source": "Progesterone",
      "target": "menstruation",
      "label": "affects"
    },
    {
      "source": "Progesterone",
      "target": "gestation",
      "label": "affects"
    },
    {
      "source": "Progesterone",
      "target": "PR",
      "label": "regulates"
    },
    {
      "source": "Progesterone",
      "target": "progesterone receptor",
      "label": "regulates"
    },
    {
      "source": "non-steroidal PR ligands",
      "target": "modulator properties",
      "label": "have"
    },
    {
      "source": "non-steroidal PR ligands",
      "target": "research",
      "label": "developed based on"
    },
    {
      "source": "non-steroidal PR ligands",
      "target": "clinical applications",
      "label": "lack"
    },
    {
      "source": "non-steroidal PR ligands",
      "target": "future",
      "label": "represent"
    },
    {
      "source": "non-steroidal PR ligands",
      "target": "selectivity",
      "label": "have"
    },
    {
      "source": "non-steroidal PR ligands",
      "target": "therapeutic applications",
      "label": "have"
    },
    {
      "source": "The evolution of progesterone receptor ligands",
      "target": "ligands for PR",
      "label": "is the evolution of"
    },
    {
      "source": "gestational properties",
      "target": "Progesterone",
      "label": "are properties of"
    },
    {
      "source": "drug-like steroids",
      "target": "gestational properties",
      "label": "mimic"
    },
    {
      "source": "drug-like steroids",
      "target": "therapeutic applications",
      "label": "have"
    },
    {
      "source": "Ay mice",
      "target": "diabetes",
      "label": "develop"
    },
    {
      "source": "Ay mice",
      "target": "obesity",
      "label": "develop"
    },
    {
      "source": "Restricted feeding",
      "target": "body weight",
      "label": "reduced"
    },
    {
      "source": "Restricted feeding",
      "target": "hyperglycemia",
      "label": "reduced"
    },
    {
      "source": "Restricted feeding",
      "target": "hyperinsulinemia",
      "label": "reduced"
    },
    {
      "source": "Restricted feeding",
      "target": "plasma des-acyl ghrelin levels",
      "label": "reversed decreases in"
    },
    {
      "source": "Restricted feeding",
      "target": "hypothalamic 5-HT2C receptor gene expression",
      "label": "decreased"
    },
    {
      "source": "Restricted feeding",
      "target": "hypothalamic 5-HT1B receptor gene expression",
      "label": "decreased"
    },
    {
      "source": "hyperglycemia",
      "target": "\u03b1-cell function",
      "label": "suggests"
    },
    {
      "source": "chronic hyperphagia",
      "target": "plasma des-acyl ghrelin levels",
      "label": "decreases"
    },
    {
      "source": "chronic hyperphagia",
      "target": "hypothalamic 5-HT2C receptor gene expression",
      "label": "increases"
    },
    {
      "source": "chronic hyperphagia",
      "target": "hypothalamic 5-HT1B receptor gene expression",
      "label": "increases"
    },
    {
      "source": "plasma des-acyl ghrelin levels",
      "target": "8-wk-old obese Ay mice",
      "label": "decreased in"
    },
    {
      "source": "hypothalamic 5-HT1B receptor gene expression",
      "target": "8-wk-old obese Ay mice",
      "label": "increased in"
    },
    {
      "source": "5-HT2C receptor mutant mice",
      "target": "food",
      "label": "consume more"
    },
    {
      "source": "5-HT2C receptor mutant mice",
      "target": "late-onset obesity",
      "label": "leads to"
    },
    {
      "source": "5-HT2C receptor mutant mice",
      "target": "impaired glucose tolerance",
      "label": "leads to"
    },
    {
      "source": "food",
      "target": "AUC",
      "label": "increases"
    },
    {
      "source": "m-chlorophenylpiperazine",
      "target": "food intake",
      "label": "suppressed"
    },
    {
      "source": "m-chlorophenylpiperazine",
      "target": "anorexic effects",
      "label": "induces"
    },
    {
      "source": "anorexic effects",
      "target": "5-HT2C receptors",
      "label": "mediated by"
    },
    {
      "source": "anorexic effects",
      "target": "food-restricted Ay mice",
      "label": "attenuated in"
    },
    {
      "source": "anorexic effects",
      "target": "5-HT1B receptors",
      "label": "mediated by"
    },
    {
      "source": "5-HT2C receptors",
      "target": "mouse head-twitch response",
      "label": "has role in"
    },
    {
      "source": "agouti peptide",
      "target": "hypothalamic 5-HT2C receptor gene expression",
      "label": "down-regulates"
    },
    {
      "source": "agouti peptide",
      "target": "central melanocortin (MC) pathway",
      "label": "leads to perturbation of"
    },
    {
      "source": "agouti peptide",
      "target": "hypothalamic 5-HT1B receptor gene expression",
      "label": "down-regulates"
    },
    {
      "source": "hypothalamic 5-HT2C receptor gene expression",
      "target": "8-wk-old obese Ay mice",
      "label": "increased in"
    },
    {
      "source": "5-wk-old Ay mice",
      "target": "hypothalamic 5-HT2C receptor gene expression",
      "label": "associated with increases in"
    },
    {
      "source": "5-wk-old Ay mice",
      "target": "hypothalamic 5-HT1B receptor gene expression",
      "label": "associated with increases in"
    },
    {
      "source": "5-wk-old Ay mice",
      "target": "food",
      "label": "consumed more"
    },
    {
      "source": "5-wk-old Ay mice",
      "target": "plasma des-acyl ghrelin levels",
      "label": "associated with decreases in"
    },
    {
      "source": "central melanocortin (MC) pathway",
      "target": "satiety signaling",
      "label": "mediates"
    },
    {
      "source": "Hyperphagia",
      "target": "plasma des-acyl ghrelin levels",
      "label": "alters"
    },
    {
      "source": "Hyperphagia",
      "target": "hypothalamic 5-HT2C receptor gene expression",
      "label": "alters expression of"
    },
    {
      "source": "Hyperphagia",
      "target": "hypothalamic 5-HT1B receptor gene expression",
      "label": "alters expression of"
    },
    {
      "source": "serotonin (5-HT)2C receptors",
      "target": "central melanocortin (MC) pathway",
      "label": "is upstream of"
    },
    {
      "source": "Selective Estrogen Receptor Modulators",
      "target": "Postmenopausal Breast Cancer",
      "label": "are used for treatment of"
    },
    {
      "source": "SERMs",
      "target": "keoxifene",
      "label": "include"
    },
    {
      "source": "SERMs",
      "target": "cross-resistance",
      "label": "have shown"
    },
    {
      "source": "SERMs",
      "target": "tamoxifen",
      "label": "have been tested as substitutes for"
    },
    {
      "source": "SERMs",
      "target": "droloxifene",
      "label": "include"
    },
    {
      "source": "SERMs",
      "target": "toremifene",
      "label": "include"
    },
    {
      "source": "SERMs",
      "target": "ER-positive breast cancer",
      "label": "are for treatment of"
    },
    {
      "source": "SERMs",
      "target": "idoxifene",
      "label": "include"
    },
    {
      "source": "SERMs",
      "target": "Postmenopausal Breast Cancer",
      "label": "are used for treatment of"
    },
    {
      "source": "cross-resistance",
      "target": "tamoxifen",
      "label": "with"
    },
    {
      "source": "cross-resistance",
      "target": "expression",
      "label": "due to"
    },
    {
      "source": "cross-resistance",
      "target": "HgCl2",
      "label": "to"
    },
    {
      "source": "cross-resistance",
      "target": "AgNO3",
      "label": "to"
    },
    {
      "source": "cross-resistance",
      "target": "metal",
      "label": "to"
    },
    {
      "source": "review article",
      "target": "SERMs",
      "label": "discusses value of"
    },
    {
      "source": "ER",
      "target": "estrogen receptors",
      "label": "is an abbreviation for"
    },
    {
      "source": "ER",
      "target": "Targeted ER gene inactivation",
      "label": "is part of"
    },
    {
      "source": "ER",
      "target": "ER modulation",
      "label": "is part of"
    },
    {
      "source": "signaling pathway",
      "target": "GDNF",
      "label": "governs"
    },
    {
      "source": "estrogen",
      "target": "ERalpha",
      "label": "regulates"
    },
    {
      "source": "estrogen",
      "target": "dopamine neuron death",
      "label": "protects against"
    },
    {
      "source": "estrogen",
      "target": "Neuroprotection",
      "label": "is involved in"
    },
    {
      "source": "estrogen",
      "target": "human physiology",
      "label": "has role in"
    },
    {
      "source": "estrogen",
      "target": "pathophysiology",
      "label": "influence"
    },
    {
      "source": "estrogen",
      "target": "menopausal hormone therapy",
      "label": "is a component of"
    },
    {
      "source": "estrogen",
      "target": "breast cancer incidence",
      "label": "does not increase"
    },
    {
      "source": "ER antagonist",
      "target": "ICI 182,780",
      "label": "is"
    },
    {
      "source": "DPDPE treatment",
      "target": "mu-opioid receptor",
      "label": "Regulator"
    },
    {
      "source": "DPDPE treatment",
      "target": "binding",
      "label": "Downregulator"
    },
    {
      "source": "DPDPE treatment",
      "target": "delta-opioid receptor binding activity",
      "label": "Downregulator"
    },
    {
      "source": "[D-Pen2,D-Pen5]enkephalin",
      "target": "rat brain opioid receptors",
      "label": "Regulator"
    },
    {
      "source": "[D-Pen2,D-Pen5]enkephalin",
      "target": "delta-opioid receptor-selective agonist",
      "label": "IsA"
    },
    {
      "source": "[3H]Tyr-D-Ala-Gly-MePhe-Gly-ol",
      "target": "mu-receptor binding",
      "label": "UsedToMeasure"
    },
    {
      "source": "[D-Ala2,D-Leu5]enkephalin",
      "target": "tolerance",
      "label": "Induces"
    },
    {
      "source": "[D-Ala2,D-Leu5]enkephalin",
      "target": "mu- and delta-opioid receptor binding activities",
      "label": "Downregulator"
    },
    {
      "source": "[3H]DPDPE saturation binding data",
      "target": "Kd values",
      "label": "NoEffectOn"
    },
    {
      "source": "[3H]DPDPE saturation binding data",
      "target": "Bmax values",
      "label": "Decreases"
    },
    {
      "source": "[3H]DPDPE",
      "target": "delta-receptor binding",
      "label": "UsedToMeasure"
    },
    {
      "source": "DAMGO",
      "target": "mu-receptor binding",
      "label": "UsedToMeasure"
    },
    {
      "source": "delta cx binding sites",
      "target": "mu cx binding sites",
      "label": "InteractsWith"
    },
    {
      "source": "micrograms/kg",
      "target": "doses",
      "label": "HasUnit"
    },
    {
      "source": "Sprague-Dawley rats",
      "target": "high fat diet",
      "label": "fed on"
    },
    {
      "source": "Scatchard analysis",
      "target": "[3H]DPDPE saturation binding data",
      "label": "Analyzes"
    },
    {
      "source": "Scatchard analysis",
      "target": "binding sites",
      "label": "revealed"
    },
    {
      "source": "complications",
      "target": "level of phosphorylation",
      "label": "hinder characterization of"
    },
    {
      "source": "PLOD1 gene",
      "target": "exon 13",
      "label": "contains"
    },
    {
      "source": "exon 13",
      "target": "c.1362delC",
      "label": "contains"
    },
    {
      "source": "A 4 year old girl",
      "target": "molecular diagnosis",
      "label": "has"
    },
    {
      "source": "A 4 year old girl",
      "target": "clinical presentation",
      "label": "has"
    },
    {
      "source": "molecular diagnosis",
      "target": "EDS VI",
      "label": "is of"
    },
    {
      "source": "c.1362delC",
      "target": "truncation",
      "label": "leads to"
    },
    {
      "source": "c.1362delC",
      "target": "frameshift",
      "label": "leads to"
    },
    {
      "source": "truncation",
      "target": "lysyl hydroxylase",
      "label": "is of"
    },
    {
      "source": "autosomal recessive connective tissue disease",
      "target": "skin",
      "label": "involves"
    },
    {
      "source": "autosomal recessive connective tissue disease",
      "target": "joints",
      "label": "involves"
    },
    {
      "source": "Ehlers Danlos type VI",
      "target": "eye globe",
      "label": "has complication"
    },
    {
      "source": "Ehlers Danlos type VI",
      "target": "autosomal recessive connective tissue disease",
      "label": "is a type of"
    },
    {
      "source": "Ehlers Danlos type VI",
      "target": "ruptures of arteries",
      "label": "has complication"
    },
    {
      "source": "Ehlers Danlos type VI",
      "target": "neonatal hypotonia",
      "label": "has main feature"
    },
    {
      "source": "lysyl hydroxylase",
      "target": "enzyme",
      "label": "is a type of"
    },
    {
      "source": "Early diagnosis",
      "target": "treatment",
      "label": "allowed"
    },
    {
      "source": "Early diagnosis",
      "target": "genetic counseling",
      "label": "allowed"
    },
    {
      "source": "Early diagnosis",
      "target": "prenatal diagnosis",
      "label": "allowed"
    },
    {
      "source": "genetic counseling",
      "target": "family",
      "label": "is for"
    },
    {
      "source": "prenatal diagnosis",
      "target": "unaffected embryo",
      "label": "is of"
    },
    {
      "source": "family",
      "target": "mutation",
      "label": "carries"
    },
    {
      "source": "family",
      "target": "type 1 diabetes",
      "label": "has condition"
    },
    {
      "source": "median growth inhibitory concentrations",
      "target": "GI(50)",
      "label": "are"
    },
    {
      "source": "Compounds 41",
      "target": "antitumor agents",
      "label": "are"
    },
    {
      "source": "Compounds 41",
      "target": "26.7microM",
      "label": "has GI(50) of"
    },
    {
      "source": "Compounds 41",
      "target": "series of compounds",
      "label": "is part of"
    },
    {
      "source": "Compounds 41",
      "target": "median growth inhibitory concentrations",
      "label": "has"
    },
    {
      "source": "Compounds 41",
      "target": "DHFR IC(50) values",
      "label": "had"
    },
    {
      "source": "Compounds 41",
      "target": "antitumor potency",
      "label": "exert"
    },
    {
      "source": "antitumor agents",
      "target": "study",
      "label": "in"
    },
    {
      "source": "Compounds 19",
      "target": "20.1microM",
      "label": "has GI(50) of"
    },
    {
      "source": "Compounds 19",
      "target": "antitumor agents",
      "label": "are"
    },
    {
      "source": "Compounds 19",
      "target": "series of compounds",
      "label": "is part of"
    },
    {
      "source": "Compounds 19",
      "target": "median growth inhibitory concentrations",
      "label": "has"
    },
    {
      "source": "Compounds 19",
      "target": "DHFR IC(50) values",
      "label": "had"
    },
    {
      "source": "Compounds 19",
      "target": "antitumor potency",
      "label": "exert"
    },
    {
      "source": "Compounds 31",
      "target": "23.5microM",
      "label": "has GI(50) of"
    },
    {
      "source": "Compounds 31",
      "target": "0.4microM",
      "label": "has IC(50) value of"
    },
    {
      "source": "Compounds 31",
      "target": "median growth inhibitory concentrations",
      "label": "has"
    },
    {
      "source": "Compounds 31",
      "target": "DHFR inhibitors",
      "label": "are"
    },
    {
      "source": "Compounds 31",
      "target": "potent DHFR inhibition",
      "label": "combined"
    },
    {
      "source": "Compounds 31",
      "target": "series of compounds",
      "label": "is part of"
    },
    {
      "source": "Compounds 31",
      "target": "antitumor potency",
      "label": "combined"
    },
    {
      "source": "Compounds 31",
      "target": "antitumor agents",
      "label": "are"
    },
    {
      "source": "quinazoline analogs",
      "target": "functional groups",
      "label": "fitted with"
    },
    {
      "source": "quinazoline analogs",
      "target": "methotrexate",
      "label": "designed to resemble"
    },
    {
      "source": "quinazoline analogs",
      "target": "structure features",
      "label": "resemble"
    },
    {
      "source": "quinazoline analogs",
      "target": "MTX",
      "label": "designed to resemble"
    },
    {
      "source": "functional groups",
      "target": "inhibition",
      "label": "enhance"
    },
    {
      "source": "synthesized compounds",
      "target": "mammalian DHFR",
      "label": "inhibit"
    },
    {
      "source": "synthesized compounds",
      "target": "antitumor activity",
      "label": "evaluated for"
    },
    {
      "source": "synthesized compounds",
      "target": "in vitro",
      "label": "evaluated for"
    },
    {
      "source": "mammalian DHFR",
      "target": "DHFR",
      "label": "is a type of"
    },
    {
      "source": "Compounds 30",
      "target": "0.4microM",
      "label": "has IC(50) value of"
    },
    {
      "source": "Compounds 30",
      "target": "DHFR inhibitors",
      "label": "are"
    },
    {
      "source": "DHFR IC(50) values",
      "target": "15microM",
      "label": "are above"
    },
    {
      "source": "DHFR inhibitors",
      "target": "IC(50) values",
      "label": "have"
    },
    {
      "source": "Compounds 47",
      "target": "antitumor agents",
      "label": "are"
    },
    {
      "source": "Compounds 47",
      "target": "DHFR IC(50) values",
      "label": "had"
    },
    {
      "source": "Compounds 47",
      "target": "9.1microM",
      "label": "has GI(50) of"
    },
    {
      "source": "Compounds 47",
      "target": "antitumor potency",
      "label": "exert"
    },
    {
      "source": "Compounds 47",
      "target": "series of compounds",
      "label": "is part of"
    },
    {
      "source": "Compounds 47",
      "target": "median growth inhibitory concentrations",
      "label": "has"
    },
    {
      "source": "antitumor activity",
      "target": "standard in vitro tissue culture assay panel",
      "label": "in"
    },
    {
      "source": "antitumor activity",
      "target": "Decitabine",
      "label": "of"
    },
    {
      "source": "antitumor activity",
      "target": "Phase II trials",
      "label": "observed in"
    },
    {
      "source": "antitumor activity",
      "target": "SB225002",
      "label": "is of"
    },
    {
      "source": "antitumor activity",
      "target": "SB",
      "label": "of"
    },
    {
      "source": "antitumor activity",
      "target": "multidrug resistance",
      "label": "was unaffected by"
    },
    {
      "source": "potent new leads",
      "target": "anticancer drugs",
      "label": "for"
    },
    {
      "source": "4(3H)-quinazolinone analogs",
      "target": "molecular modeling study",
      "label": "are subject of"
    },
    {
      "source": "4(3H)-quinazolinone analogs",
      "target": "Synthesis",
      "label": "are subject of"
    },
    {
      "source": "4(3H)-quinazolinone analogs",
      "target": "antitumor testing",
      "label": "are subject of"
    },
    {
      "source": "4(3H)-quinazolinone analogs",
      "target": "dihydrofolate reductase inhibition",
      "label": "are subject of"
    },
    {
      "source": "structure features",
      "target": "methotrexate",
      "label": "of"
    },
    {
      "source": "structure features",
      "target": "MTX",
      "label": "of"
    },
    {
      "source": "human DHFR",
      "target": "DHFR",
      "label": "is a type of"
    },
    {
      "source": "antitumor potency",
      "target": "mode of action",
      "label": "through"
    },
    {
      "source": "Molecular modeling studies",
      "target": "compounds",
      "label": "assess fit of"
    },
    {
      "source": "dihydrofolate reductase inhibition",
      "target": "dihydrofolate reductase",
      "label": "is inhibition of"
    },
    {
      "source": "Synthesis",
      "target": "hollow gold nanospheres",
      "label": "is of"
    },
    {
      "source": "Synthesis",
      "target": "1,3,4-thiadiazole analogues",
      "label": "of"
    },
    {
      "source": "Synthesis",
      "target": "3-aryl acrylic amide derivatives",
      "label": "is of"
    },
    {
      "source": "Synthesis",
      "target": "present study",
      "label": "is part of"
    },
    {
      "source": "Compounds 28",
      "target": "0.5microM",
      "label": "has IC(50) value of"
    },
    {
      "source": "Compounds 28",
      "target": "DHFR inhibitors",
      "label": "are"
    },
    {
      "source": "IC(50) values",
      "target": "41 nM",
      "label": "include"
    },
    {
      "source": "IC(50) values",
      "target": "32 nM",
      "label": "include"
    },
    {
      "source": "Telmisartan",
      "target": "peroxisome proliferator-activated receptor gamma",
      "label": "is partial agonist of"
    },
    {
      "source": "Telmisartan",
      "target": "AT1R",
      "label": "is antagonist of"
    },
    {
      "source": "Telmisartan",
      "target": "PPARgamma",
      "label": "is partial agonist of"
    },
    {
      "source": "Telmisartan",
      "target": "angiotensin II function",
      "label": "inhibits"
    },
    {
      "source": "Telmisartan",
      "target": "AT1R mRNA",
      "label": "decreased"
    },
    {
      "source": "Telmisartan",
      "target": "AT1R gene expression",
      "label": "suppressed"
    },
    {
      "source": "Telmisartan",
      "target": "angiotensin II type 1 receptor",
      "label": "downregulates"
    },
    {
      "source": "Telmisartan",
      "target": "protein expression",
      "label": "decreased"
    },
    {
      "source": "Telmisartan",
      "target": "AT1R blockade",
      "label": "causes"
    },
    {
      "source": "Telmisartan",
      "target": "AT1R promoter activity",
      "label": "decreased"
    },
    {
      "source": "Telmisartan",
      "target": "AT1R expression",
      "label": "causes downregulation of"
    },
    {
      "source": "AT1R expression",
      "target": "renin-angiotensin system",
      "label": "contributes to inhibition of"
    },
    {
      "source": "thoracic aorta",
      "target": "Wistar-Kyoto rat",
      "label": "derived from"
    },
    {
      "source": "Northern blotting analysis",
      "target": "AT1R mRNA",
      "label": "used to examine"
    },
    {
      "source": "Western blotting analysis",
      "target": "protein expression",
      "label": "used to examine"
    },
    {
      "source": "GC box",
      "target": "AT1R gene expression",
      "label": "responsible for downregulation of"
    },
    {
      "source": "GW9662",
      "target": "PPARgamma",
      "label": "is antagonist of"
    },
    {
      "source": "GW9662",
      "target": "AT1R expression",
      "label": "prevented suppression of"
    },
    {
      "source": "promoter activity of AT1R",
      "target": "luciferase assay",
      "label": "examined by"
    },
    {
      "source": "vascular smooth muscle cells",
      "target": "thoracic aorta",
      "label": "derived from"
    },
    {
      "source": "olmesartan",
      "target": "AT1R expression",
      "label": "did not suppress"
    },
    {
      "source": "PPARgamma activators",
      "target": "AT1R expression",
      "label": "suppressed"
    },
    {
      "source": "AT1R blockade",
      "target": "renin-angiotensin system",
      "label": "contributes to inhibition of"
    },
    {
      "source": "11-cis retinal",
      "target": "visual pigments",
      "label": "is chromophore of"
    },
    {
      "source": "11-cis retinal",
      "target": "chromophore",
      "label": "is the"
    },
    {
      "source": "all-trans retinol",
      "target": "retinoic acid",
      "label": "is required for production of"
    },
    {
      "source": "all-trans retinol",
      "target": "vertebrate development",
      "label": "is required for"
    },
    {
      "source": "all-trans retinol",
      "target": "11-cis retinal",
      "label": "is required for production of"
    },
    {
      "source": "Raldh2",
      "target": "yolk vitamin A",
      "label": "competes for"
    },
    {
      "source": "Raldh2",
      "target": "embryonic compartments",
      "label": "defines"
    },
    {
      "source": "Raldh2",
      "target": "retinoic acid synthesis",
      "label": "is key enzyme for"
    },
    {
      "source": "retinal dehydrogenase 2",
      "target": "Raldh2",
      "label": "is also known as"
    },
    {
      "source": "retinal dehydrogenase 2",
      "target": "retinoic acid synthesis",
      "label": "is key enzyme for"
    },
    {
      "source": "knock down",
      "target": "Lratb",
      "label": "of"
    },
    {
      "source": "knock down",
      "target": "retinoic acid",
      "label": "results in increased"
    },
    {
      "source": "knock down",
      "target": "retinyl ester formation",
      "label": "blocks"
    },
    {
      "source": "Lratb",
      "target": "yolk vitamin A",
      "label": "competes for"
    },
    {
      "source": "Lratb",
      "target": "embryonic compartments",
      "label": "defines"
    },
    {
      "source": "Lratb",
      "target": "Raldh2",
      "label": "competes with"
    },
    {
      "source": "homeostatic mechanism",
      "target": "development",
      "label": "sequesters for"
    },
    {
      "source": "homeostatic mechanism",
      "target": "retinyl esters",
      "label": "sequesters in form of"
    },
    {
      "source": "homeostatic mechanism",
      "target": "larval vision",
      "label": "sequesters for"
    },
    {
      "source": "homeostatic mechanism",
      "target": "yolk vitamin A",
      "label": "sequesters"
    },
    {
      "source": "homeostatic mechanism",
      "target": "gene regulation",
      "label": "adjusts for"
    },
    {
      "source": "homeostatic mechanism",
      "target": "retinoic acid",
      "label": "adjusts"
    },
    {
      "source": "homeostatic mechanism",
      "target": "AD",
      "label": "predisposes_to"
    },
    {
      "source": "homeostatic mechanism",
      "target": "aging",
      "label": "predisposes_to"
    },
    {
      "source": "leci-thin:retinol acyltransferase",
      "target": "Lratb",
      "label": "is also known as"
    },
    {
      "source": "retinoid signaling",
      "target": "zebrafish embryo",
      "label": "occurs in"
    },
    {
      "source": "retinyl esters",
      "target": "retinoid signaling",
      "label": "is essential for"
    },
    {
      "source": "lratb",
      "target": "Raldh2",
      "label": "is expressed opposite to"
    },
    {
      "source": "lratb",
      "target": "embryogenesis",
      "label": "is expressed during"
    },
    {
      "source": "lratb",
      "target": "retinal dehydrogenase 2",
      "label": "is expressed opposite to"
    },
    {
      "source": "embryonic compartments",
      "target": "retinyl ester formation",
      "label": "are for"
    },
    {
      "source": "embryonic compartments",
      "target": "retinoic acid synthesis",
      "label": "are for"
    },
    {
      "source": "embryonic retinoid homeostasis",
      "target": "Lratb",
      "label": "depends on activity of"
    },
    {
      "source": "embryonic retinoid homeostasis",
      "target": "zebrafish",
      "label": "occurs in"
    },
    {
      "source": "embryonic retinoid homeostasis",
      "target": "leci-thin:retinol acyltransferase",
      "label": "depends on activity of"
    },
    {
      "source": "zebrafish",
      "target": "model",
      "label": "is a"
    },
    {
      "source": "surface receptors",
      "target": "P2 receptors",
      "label": "are called"
    },
    {
      "source": "surface receptors",
      "target": "extracellular nucleotides",
      "label": "are for"
    },
    {
      "source": "ticlopidine",
      "target": "antagonists",
      "label": "is a type of"
    },
    {
      "source": "ticlopidine",
      "target": "intestinal CYP3A4/5",
      "label": "did not inhibit"
    },
    {
      "source": "ticlopidine",
      "target": "dose-adjusted plasma area under the curve",
      "label": "increased"
    },
    {
      "source": "ticlopidine",
      "target": "metabolite formation clearances",
      "label": "decreased"
    },
    {
      "source": "ticlopidine",
      "target": "CYP2B6",
      "label": "inhibits"
    },
    {
      "source": "ticlopidine",
      "target": "mechanism-based CYP2B6 inhibitor",
      "label": "is a"
    },
    {
      "source": "ticlopidine",
      "target": "Methadone N-demethylation",
      "label": "inhibited"
    },
    {
      "source": "ticlopidine",
      "target": "plasma metabolite/methadone area under the curve ratios",
      "label": "decreased"
    },
    {
      "source": "ticlopidine",
      "target": "hepatic CYP3A4/5",
      "label": "did not inhibit"
    },
    {
      "source": "head area",
      "target": "LGTGPLRTFV",
      "label": "contains"
    },
    {
      "source": "Molecular modeling",
      "target": "ICA binding site",
      "label": "suggests"
    },
    {
      "source": "primary structures",
      "target": "PDB code: 1VZ1",
      "label": "has PDB code"
    },
    {
      "source": "primary structures",
      "target": "energy minimization",
      "label": "optimized by"
    },
    {
      "source": "primary structures",
      "target": "Protein Data Bank",
      "label": "accepted by"
    },
    {
      "source": "probable sites",
      "target": "bottom area",
      "label": "includes"
    },
    {
      "source": "probable sites",
      "target": "middle area",
      "label": "includes"
    },
    {
      "source": "probable sites",
      "target": "head area",
      "label": "includes"
    },
    {
      "source": "probable sites",
      "target": "simple scoring matrix",
      "label": "predicted using"
    },
    {
      "source": "bottom area",
      "target": "RTRGVGKVPR",
      "label": "contains"
    },
    {
      "source": "simple scoring matrix",
      "target": "analysis",
      "label": "built based on"
    },
    {
      "source": "analysis",
      "target": "ATP-binding proteins",
      "label": "is of"
    },
    {
      "source": "analysis",
      "target": "protein digests",
      "label": "is of"
    },
    {
      "source": "analysis",
      "target": "legumain activity",
      "label": "of"
    },
    {
      "source": "analysis",
      "target": "data",
      "label": "of"
    },
    {
      "source": "structural model",
      "target": "ADP",
      "label": "docked with"
    },
    {
      "source": "structural model",
      "target": "ATP",
      "label": "docked with"
    },
    {
      "source": "structural model",
      "target": "energy minimization",
      "label": "obtained by"
    },
    {
      "source": "structural model",
      "target": "molecular dynamics simulation",
      "label": "obtained by"
    },
    {
      "source": "structural model",
      "target": "phospho-WW",
      "label": "of"
    },
    {
      "source": "ADP",
      "target": "P2Y1",
      "label": "activates"
    },
    {
      "source": "ADP",
      "target": "P2Y12",
      "label": "activates"
    },
    {
      "source": "ADP",
      "target": "platelet aggregation",
      "label": "initiates"
    },
    {
      "source": "ADP",
      "target": "G protein-coupled receptors",
      "label": "activates"
    },
    {
      "source": "new drugs",
      "target": "platelet aggregation",
      "label": "inhibit"
    },
    {
      "source": "new drugs",
      "target": "diseases",
      "label": "treat"
    },
    {
      "source": "middle area",
      "target": "VGLITNGLAM",
      "label": "contains"
    },
    {
      "source": "middle area",
      "target": "LGAKILSVVI",
      "label": "contains"
    },
    {
      "source": "3D structure",
      "target": "bovine rhodopsin",
      "label": "constructed using"
    },
    {
      "source": "3D structure",
      "target": "InsightII/Homology module",
      "label": "constructed by"
    },
    {
      "source": "bovine rhodopsin",
      "target": "PDB code: 1HZX",
      "label": "has PDB code"
    },
    {
      "source": "bovine rhodopsin",
      "target": "template",
      "label": "is a"
    },
    {
      "source": "platelet aggregation",
      "target": "5 microm ADP",
      "label": "to"
    },
    {
      "source": "platelet aggregation",
      "target": "4-week intervals",
      "label": "was assessed at"
    },
    {
      "source": "platelet aggregation",
      "target": "day 1",
      "label": "was assessed on"
    },
    {
      "source": "platelet aggregation",
      "target": "4-h postdose",
      "label": "was assessed at"
    },
    {
      "source": "Purinergic receptors",
      "target": "ADP",
      "label": "prefers"
    },
    {
      "source": "Purinergic receptors",
      "target": "ATP",
      "label": "prefers"
    },
    {
      "source": "Purinergic receptors",
      "target": "purines",
      "label": "are receptors for"
    },
    {
      "source": "Purinergic receptors",
      "target": "cell surface receptors",
      "label": "is a type of"
    },
    {
      "source": "template",
      "target": "prodrugs",
      "label": "is for design of"
    },
    {
      "source": "intermolecular energy",
      "target": "antagonists",
      "label": "calculated for"
    },
    {
      "source": "Cd",
      "target": "PDGFRalpha kinases",
      "label": "activates"
    },
    {
      "source": "Cd",
      "target": "c-fos",
      "label": "activates"
    },
    {
      "source": "Cd",
      "target": "Akt",
      "label": "activates"
    },
    {
      "source": "Cd",
      "target": "Akt activity",
      "label": "stimulates"
    },
    {
      "source": "Cd",
      "target": "PDGFRalpha phosphorylation",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "Akt phosphorylation",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "ERK1/2",
      "label": "activates"
    },
    {
      "source": "Cd",
      "target": "c-jun expression",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "PDGFRalpha kinases activity",
      "label": "stimulates"
    },
    {
      "source": "Cd",
      "target": "PDGFA",
      "label": "activates"
    },
    {
      "source": "Cd",
      "target": "ERK1/2 phosphorylation",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "ERK1/2 activity",
      "label": "stimulates"
    },
    {
      "source": "Cd",
      "target": "ERbeta",
      "label": "had no effect on"
    },
    {
      "source": "Cd",
      "target": "BC cells proliferation",
      "label": "increases"
    },
    {
      "source": "Cd",
      "target": "ERalpha expression",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "PDGFA expression",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "c-jun",
      "label": "activates"
    },
    {
      "source": "Cd",
      "target": "ERalpha-dependent mechanism",
      "label": "acts by"
    },
    {
      "source": "Cd",
      "target": "MCF-7 cell proliferation",
      "label": "regulates"
    },
    {
      "source": "Cd",
      "target": "c-fos expression",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "toxic pollutant",
      "label": "is a"
    },
    {
      "source": "Cd",
      "target": "cell proliferation",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "depletion",
      "label": "caused"
    },
    {
      "source": "Cd",
      "target": "antioxidant defence system",
      "label": "induced"
    },
    {
      "source": "Cd",
      "target": "testicular steroidogenic enzymes",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "SOD",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "lipid peroxidation",
      "label": "induced"
    },
    {
      "source": "Cd",
      "target": "Cd-induced testes damage",
      "label": "induced"
    },
    {
      "source": "Cd",
      "target": "glutathione reductase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "GSH",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "GR",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "glutathione peroxidase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "testicular toxicity",
      "label": "induced"
    },
    {
      "source": "Cd",
      "target": "superoxide dismutase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "steroidogenesis",
      "label": "induced"
    },
    {
      "source": "Cd",
      "target": "glutathione-S-transferase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "oxidative damage",
      "label": "caused"
    },
    {
      "source": "Cd",
      "target": "Cd-induced alterations",
      "label": "induced"
    },
    {
      "source": "Cd",
      "target": "lactate dehydrogenase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "HSD",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "acid phosphatase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "CAT",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "3\u03b2-hydroxysteroid dehydrogenase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "GSH-Px",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "abnormal sperm count",
      "label": "increased"
    },
    {
      "source": "Cd",
      "target": "motility",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "glutathione",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "17\u03b2-HSD",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "GST",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "plasma testosterone",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "alkaline phosphatase",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "epididymal sperm counts",
      "label": "decreased"
    },
    {
      "source": "Cd",
      "target": "catalase",
      "label": "decreased"
    },
    {
      "source": "c-fos",
      "target": "proto-oncogenes",
      "label": "is a type of"
    },
    {
      "source": "c-fos",
      "target": "rat striatum",
      "label": "occurs_in"
    },
    {
      "source": "Cadmium",
      "target": "toxic pollutant",
      "label": "is a"
    },
    {
      "source": "Cadmium",
      "target": "mitogenic signaling",
      "label": "induces"
    },
    {
      "source": "Cadmium",
      "target": "ERalpha-dependent mechanism",
      "label": "acts by"
    },
    {
      "source": "Cadmium",
      "target": "oxidative damage",
      "label": "caused"
    },
    {
      "source": "ICI",
      "target": "PDGFRalpha phosphorylation",
      "label": "blocked"
    },
    {
      "source": "ICI",
      "target": "Akt phosphorylation",
      "label": "blocked"
    },
    {
      "source": "ICI",
      "target": "ERK1/2 phosphorylation",
      "label": "blocked"
    },
    {
      "source": "ERK1/2",
      "target": "cholangiocyte growth",
      "label": "downregulation of phosphorylation inhibits"
    },
    {
      "source": "ERK1/2",
      "target": "downstream effectors",
      "label": "is"
    },
    {
      "source": "Breast cancer (BC)",
      "target": "estrogen exposure",
      "label": "linked to"
    },
    {
      "source": "Hormone-related cancers",
      "target": "estrogenic environmental contaminants",
      "label": "linked to"
    },
    {
      "source": "ER-antagonist ICI 182,780",
      "target": "Cd-stimulated proliferation",
      "label": "blunted"
    },
    {
      "source": "c-jun",
      "target": "proto-oncogenes",
      "label": "is a type of"
    },
    {
      "source": "specific kinases inhibitors",
      "target": "Cd-stimulated proliferation",
      "label": "blocked"
    },
    {
      "source": "Estradiol (E2)",
      "target": "BC cells proliferation",
      "label": "stimulates"
    },
    {
      "source": "Estradiol (E2)",
      "target": "estrogen receptor (ER)",
      "label": "binds"
    },
    {
      "source": "estrogen receptor (ER)",
      "target": "growth inhibition",
      "label": "not involved in"
    },
    {
      "source": "cationic amino acid transporters",
      "target": "Sertoli cells",
      "label": "located in"
    },
    {
      "source": "cationic amino acid transporters",
      "target": "pachytene spermatocytes",
      "label": "located in"
    },
    {
      "source": "cationic amino acid transporters",
      "target": "early spermatids",
      "label": "located in"
    },
    {
      "source": "cationic amino acid transporters",
      "target": "peritubular cells",
      "label": "located in"
    },
    {
      "source": "l-arginine",
      "target": "system y(+)",
      "label": "taken up via"
    },
    {
      "source": "l-arginine",
      "target": "peritubular cells",
      "label": "taken up by"
    },
    {
      "source": "l-arginine",
      "target": "system y(+)L",
      "label": "taken up via"
    },
    {
      "source": "l-arginine",
      "target": "Sertoli cells",
      "label": "taken up by"
    },
    {
      "source": "system y(+)",
      "target": "SLC7A1",
      "label": "is"
    },
    {
      "source": "system y(+)",
      "target": "SLC7A2",
      "label": "is"
    },
    {
      "source": "Sertoli cells",
      "target": "rates",
      "label": "had"
    },
    {
      "source": "Sertoli cells",
      "target": "key role",
      "label": "play"
    },
    {
      "source": "system B(0+)",
      "target": "contribution",
      "label": "made"
    },
    {
      "source": "system B(0+)",
      "target": "system y(+)L",
      "label": "associated with"
    },
    {
      "source": "contribution",
      "target": "transport",
      "label": "to"
    },
    {
      "source": "Arginine",
      "target": "biological processes",
      "label": "important for"
    },
    {
      "source": "biological processes",
      "target": "testis",
      "label": "occurs in"
    },
    {
      "source": "trans stimulation",
      "target": "cationic amino acid transporters",
      "label": "of"
    },
    {
      "source": "delivery",
      "target": "extracellular cationic amino acids",
      "label": "of"
    },
    {
      "source": "delivery",
      "target": "seminiferous tubule cells",
      "label": "to"
    },
    {
      "source": "properties",
      "target": "y(+)L system",
      "label": "of"
    },
    {
      "source": "properties",
      "target": "dendrimers",
      "label": "are of"
    },
    {
      "source": "properties",
      "target": "ability",
      "label": "govern"
    },
    {
      "source": "properties",
      "target": "pharmacokinetics",
      "label": "suggest"
    },
    {
      "source": "properties",
      "target": "drug",
      "label": "of a"
    },
    {
      "source": "properties",
      "target": "information",
      "label": "provide"
    },
    {
      "source": "y(+)L system",
      "target": "Sertoli cells",
      "label": "predominates in"
    },
    {
      "source": "upregulation",
      "target": "arginine transport",
      "label": "of"
    },
    {
      "source": "upregulation",
      "target": "cytokines",
      "label": "caused by"
    },
    {
      "source": "upregulation",
      "target": "DR5",
      "label": "is of"
    },
    {
      "source": "upregulation",
      "target": "apoptosis",
      "label": "mediates"
    },
    {
      "source": "upregulation",
      "target": "p53",
      "label": "of"
    },
    {
      "source": "upregulation",
      "target": "oocyte cell death",
      "label": "contributes to"
    },
    {
      "source": "upregulation",
      "target": "Bax",
      "label": "of"
    },
    {
      "source": "arginine transport",
      "target": "somatic tubular cells",
      "label": "occurs in"
    },
    {
      "source": "arginine transport",
      "target": "Sertoli cells",
      "label": "occurs in"
    },
    {
      "source": "system y(+)L",
      "target": "SLC3A2",
      "label": "is"
    },
    {
      "source": "system y(+)L",
      "target": "SLC7A7",
      "label": "is"
    },
    {
      "source": "system y(+)L",
      "target": "SLC7A6",
      "label": "is"
    },
    {
      "source": "sensitivity",
      "target": "trans stimulation",
      "label": "to"
    },
    {
      "source": "sensitivity",
      "target": "regulation",
      "label": "to"
    },
    {
      "source": "sensitivity",
      "target": "DM",
      "label": "altered in"
    },
    {
      "source": "sensitivity",
      "target": "ErbB1-inhibitors",
      "label": "is to"
    },
    {
      "source": "sensitivity",
      "target": "elisidepsin",
      "label": "is to"
    },
    {
      "source": "NO synthesis",
      "target": "stimulation",
      "label": "does not depend on"
    },
    {
      "source": "profiles",
      "target": "cis inhibition",
      "label": "of"
    },
    {
      "source": "cis inhibition",
      "target": "uptake",
      "label": "of"
    },
    {
      "source": "germ cells",
      "target": "cationic amino acids",
      "label": "supplied with"
    },
    {
      "source": "germ cells",
      "target": "l-arginine",
      "label": "supplied with"
    },
    {
      "source": "efficiency",
      "target": "arginine transport",
      "label": "of"
    },
    {
      "source": "Na(+) dependence",
      "target": "transport",
      "label": "of"
    },
    {
      "source": "transport",
      "target": "cationic amino acids",
      "label": "of"
    },
    {
      "source": "transport",
      "target": "pachytene spermatocytes",
      "label": "occurs in"
    },
    {
      "source": "transport",
      "target": "early spermatids",
      "label": "occurs in"
    },
    {
      "source": "transport",
      "target": "amino acid",
      "label": "of"
    },
    {
      "source": "transport",
      "target": "Cd(2+)",
      "label": "of"
    },
    {
      "source": "transport",
      "target": "Mn(2+)",
      "label": "of"
    },
    {
      "source": "transport",
      "target": "potencies",
      "label": "is a reason for"
    },
    {
      "source": "cationic amino acid transport",
      "target": "rat seminiferous tubule cells",
      "label": "occurs in"
    },
    {
      "source": "key role",
      "target": "germ cells",
      "label": "in supplying"
    },
    {
      "source": "key role",
      "target": "neuronal calcium homeostasis",
      "label": "is_in"
    },
    {
      "source": "Multiple pathways",
      "target": "cationic amino acid transport",
      "label": "for"
    },
    {
      "source": "[1'-(14)C]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[1'-(14)C]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "MTA",
      "target": "MTAP",
      "label": "is a substrate of"
    },
    {
      "source": "[2'-(3)H]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[2'-(3)H]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "[9-(15)N]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[9-(15)N]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "cationic center",
      "target": "carbon",
      "label": "located at"
    },
    {
      "source": "[5'-(3)H(2)]",
      "target": "sigma (C-H) antibonding orbitals",
      "label": "arises from"
    },
    {
      "source": "[5'-(3)H(2)]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[5'-(3)H(2)]",
      "target": "lone pairs of sulfur",
      "label": "arises from"
    },
    {
      "source": "[5'-(3)H(2)]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "MTAP",
      "target": "cationic center",
      "label": "has"
    },
    {
      "source": "MTAP",
      "target": "leaving group",
      "label": "has insignificant bond order to"
    },
    {
      "source": "MTAP",
      "target": "5'-methylthioadenosine",
      "label": "catalyzes"
    },
    {
      "source": "MTAP",
      "target": "MTA",
      "label": "catalyzes"
    },
    {
      "source": "MTAP",
      "target": "Human MTAP",
      "label": "also known as"
    },
    {
      "source": "3'-OH",
      "target": "zwitterion",
      "label": "ionization indicates formation of"
    },
    {
      "source": "ribosyl zwitterion",
      "target": "H1'-C1'-C2'-H2'",
      "label": "corresponds to"
    },
    {
      "source": "human 5'-methylthioadenosine phosphorylase",
      "target": "MTAP",
      "label": "also known as"
    },
    {
      "source": "human 5'-methylthioadenosine phosphorylase",
      "target": "Human MTAP",
      "label": "also known as"
    },
    {
      "source": "[4'-(3)H]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[4'-(3)H]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "[4'-(3)H]",
      "target": "3'-OH",
      "label": "is sensitive to polarization of"
    },
    {
      "source": "[Me-(3)H(3)]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[Me-(3)H(3)]",
      "target": "lone pairs of sulfur",
      "label": "arises from"
    },
    {
      "source": "[Me-(3)H(3)]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "[Me-(3)H(3)]",
      "target": "sigma (C-H) antibonding orbitals",
      "label": "arises from"
    },
    {
      "source": "lone pairs of sulfur",
      "target": "sigma (C-H) antibonding orbitals",
      "label": "undergoes negative hyperconjugation with"
    },
    {
      "source": "Human MTAP",
      "target": "phosphate nucleophile",
      "label": "is characterized by"
    },
    {
      "source": "5'-methylthioadenosine",
      "target": "MTA",
      "label": "also known as"
    },
    {
      "source": "5'-methylthioadenosine",
      "target": "MTAP",
      "label": "is a substrate of"
    },
    {
      "source": "adenine leaving group",
      "target": "anionic leaving group",
      "label": "is a type of"
    },
    {
      "source": "[1'-(3)H]",
      "target": "[1'-(3)H], [1'-(14)C], [2'-(3)H], [4'-(3)H], [5'-(3)H(2)], [9-(15)N], and [Me-(3)H(3)] MTAs",
      "label": "is a component of"
    },
    {
      "source": "[1'-(3)H]",
      "target": "MTA",
      "label": "is a type of"
    },
    {
      "source": "oxygen nucleophile",
      "target": "carbon",
      "label": "is located near"
    },
    {
      "source": "worsening",
      "target": "arthralgia",
      "label": "of"
    },
    {
      "source": "CD11a subunit",
      "target": "surface molecule",
      "label": "is subunit of"
    },
    {
      "source": "surface molecule",
      "target": "T lymphocyte",
      "label": "is molecule of"
    },
    {
      "source": "reversible changes",
      "target": "laboratory values",
      "label": "in"
    },
    {
      "source": "laboratory values",
      "target": "elevated alkaline phosphatases",
      "label": "include"
    },
    {
      "source": "laboratory values",
      "target": "transaminases",
      "label": "include"
    },
    {
      "source": "laboratory values",
      "target": "hyperlymphocytosis",
      "label": "include"
    },
    {
      "source": "improvement",
      "target": "PASI score",
      "label": "in"
    },
    {
      "source": "improvement",
      "target": "patients",
      "label": "seen in"
    },
    {
      "source": "rare cases",
      "target": "thrombocytopenia",
      "label": "of"
    },
    {
      "source": "thrombocytopenia",
      "target": "discontinuation",
      "label": "reversible on"
    },
    {
      "source": "thrombocytopenia",
      "target": "toxicologic events",
      "label": "being a common"
    },
    {
      "source": "moderate-to-severe cutaneous plaque psoriasis",
      "target": "adults",
      "label": "affects"
    },
    {
      "source": "moderate-to-severe cutaneous plaque psoriasis",
      "target": "contraindication",
      "label": "in cases of"
    },
    {
      "source": "moderate-to-severe cutaneous plaque psoriasis",
      "target": "failure",
      "label": "in cases of"
    },
    {
      "source": "moderate-to-severe cutaneous plaque psoriasis",
      "target": "intolerance",
      "label": "in cases of"
    },
    {
      "source": "marketing authorisation",
      "target": "France",
      "label": "granted in"
    },
    {
      "source": "marketing authorisation",
      "target": "MA",
      "label": "also known as"
    },
    {
      "source": "marketing authorisation",
      "target": "September 2005",
      "label": "granted in"
    },
    {
      "source": "randomised studies",
      "target": "systemic treatments",
      "label": "compare"
    },
    {
      "source": "systemic treatments",
      "target": "cyclosporine",
      "label": "include"
    },
    {
      "source": "systemic treatments",
      "target": "standard therapy",
      "label": "include"
    },
    {
      "source": "systemic treatments",
      "target": "biotherapies",
      "label": "include"
    },
    {
      "source": "systemic treatments",
      "target": "methotrexate",
      "label": "include"
    },
    {
      "source": "systemic treatments",
      "target": "phototherapy",
      "label": "include"
    },
    {
      "source": "systemic treatments",
      "target": "psoriasis",
      "label": "for"
    },
    {
      "source": "intolerance",
      "target": "systemic treatments",
      "label": "of"
    },
    {
      "source": "3 months",
      "target": "therapy",
      "label": "of"
    },
    {
      "source": "side-effects",
      "target": "risk",
      "label": "include"
    },
    {
      "source": "side-effects",
      "target": "reversible changes",
      "label": "include"
    },
    {
      "source": "side-effects",
      "target": "influenza-like syndrome",
      "label": "include"
    },
    {
      "source": "side-effects",
      "target": "worsening",
      "label": "include"
    },
    {
      "source": "side-effects",
      "target": "minor hypersensitivity reactions",
      "label": "include"
    },
    {
      "source": "Efalizumab",
      "target": "Serono",
      "label": "also known as"
    },
    {
      "source": "Efalizumab",
      "target": "first-line therapy",
      "label": "used as"
    },
    {
      "source": "Efalizumab",
      "target": "humanised monoclonal antibody",
      "label": "is a"
    },
    {
      "source": "Efalizumab",
      "target": "CD11a",
      "label": "binds to"
    },
    {
      "source": "Efalizumab",
      "target": "FDA",
      "label": "approved by"
    },
    {
      "source": "Efalizumab",
      "target": "CD11a subunit",
      "label": "binds to"
    },
    {
      "source": "Efalizumab",
      "target": "LFA-1",
      "label": "prevents binding of"
    },
    {
      "source": "Efalizumab",
      "target": "anti-TNF alpha agents",
      "label": "less efficacious than"
    },
    {
      "source": "Efalizumab",
      "target": "treatment",
      "label": "approved for"
    },
    {
      "source": "Efalizumab",
      "target": "Raptiva",
      "label": "also known as"
    },
    {
      "source": "Efalizumab",
      "target": "steps",
      "label": "inhibits"
    },
    {
      "source": "Efalizumab",
      "target": "joint involvement",
      "label": "not effective against"
    },
    {
      "source": "Efalizumab",
      "target": "United States",
      "label": "approved in"
    },
    {
      "source": "clinical trial data",
      "target": "patients",
      "label": "available for"
    },
    {
      "source": "ICAM-1 molecule",
      "target": "keratinocytes",
      "label": "found on"
    },
    {
      "source": "ICAM-1 molecule",
      "target": "antigen-presenting cells",
      "label": "found on"
    },
    {
      "source": "ICAM-1 molecule",
      "target": "Intercellular Adhesion Molecule-1",
      "label": "also known as"
    },
    {
      "source": "ICAM-1 molecule",
      "target": "endothelial cells",
      "label": "found on"
    },
    {
      "source": "contraindication",
      "target": "systemic treatments",
      "label": "of"
    },
    {
      "source": "contraindication",
      "target": "liver transplantation",
      "label": "to"
    },
    {
      "source": "indications",
      "target": "moderate-to-severe cutaneous plaque psoriasis",
      "label": "are for"
    },
    {
      "source": "indications",
      "target": "adult patients",
      "label": "limited to"
    },
    {
      "source": "biotherapies",
      "target": "psoriasis",
      "label": "for"
    },
    {
      "source": "position",
      "target": "therapeutic arsenal",
      "label": "in"
    },
    {
      "source": "position",
      "target": "long-term benefit/risk ratio",
      "label": "depends upon"
    },
    {
      "source": "humanised monoclonal antibody",
      "target": "IgG1",
      "label": "is a type of"
    },
    {
      "source": "humanised monoclonal antibody",
      "target": "biotechnology",
      "label": "produced by"
    },
    {
      "source": "PASI-75",
      "target": "12 weeks",
      "label": "after"
    },
    {
      "source": "extrapolation",
      "target": "results",
      "label": "of"
    },
    {
      "source": "single weekly subcutaneous injection",
      "target": "1 mg/kg",
      "label": "dosage"
    },
    {
      "source": "long-term benefit/risk ratio",
      "target": "biotherapies",
      "label": "in relation to"
    },
    {
      "source": "psoriatic plaque",
      "target": "reactivation",
      "label": "involves"
    },
    {
      "source": "psoriatic plaque",
      "target": "lymphocyte migration",
      "label": "involves"
    },
    {
      "source": "psoriatic plaque",
      "target": "activation",
      "label": "involves"
    },
    {
      "source": "reactivation",
      "target": "skin",
      "label": "occurs in"
    },
    {
      "source": "steps",
      "target": "immunological process",
      "label": "are part of"
    },
    {
      "source": "immunological process",
      "target": "psoriatic plaque",
      "label": "responsible for formation of"
    },
    {
      "source": "indication",
      "target": "central dopaminergic activity",
      "label": "of"
    },
    {
      "source": "cutaneous psoriasis",
      "target": "discontinuation",
      "label": "occurs during or after"
    },
    {
      "source": "molecule",
      "target": "T lymphocytes",
      "label": "is essential for binding of"
    },
    {
      "source": "T lymphocytes",
      "target": "ICAM-1 molecule",
      "label": "bind to"
    },
    {
      "source": "T lymphocyte",
      "target": "LFA-1",
      "label": "has"
    },
    {
      "source": "moderate-to-severe psoriasis",
      "target": "systemic therapy",
      "label": "requires"
    },
    {
      "source": "failure",
      "target": "systemic treatments",
      "label": "of"
    },
    {
      "source": "joint involvement",
      "target": "psoriasis",
      "label": "in"
    },
    {
      "source": "outbreak",
      "target": "cutaneous psoriasis",
      "label": "of"
    },
    {
      "source": "prescription",
      "target": "drug",
      "label": "of"
    },
    {
      "source": "monthly monitoring",
      "target": "3 months",
      "label": "required over"
    },
    {
      "source": "monthly monitoring",
      "target": "platelet counts",
      "label": "of"
    },
    {
      "source": "antibody",
      "target": "biotherapies",
      "label": "has place among"
    },
    {
      "source": "recombinant strains",
      "target": "flavinogenic yeast Candida famata",
      "label": "are strains of"
    },
    {
      "source": "recombinant strains",
      "target": "construction",
      "label": "can be used for"
    },
    {
      "source": "recombinant strains",
      "target": "Debaryomyces hansenii FMN1 gene",
      "label": "contain"
    },
    {
      "source": "recombinant strains",
      "target": "DNA fragment",
      "label": "contain"
    },
    {
      "source": "flavinogenic yeast Candida famata strains",
      "target": "riboflavin kinase activity",
      "label": "has high"
    },
    {
      "source": "flavinogenic yeast Candida famata strains",
      "target": "gene engineering",
      "label": "constructed using"
    },
    {
      "source": "construction",
      "target": "flavinmononucleotide overproducers",
      "label": "of"
    },
    {
      "source": "increase",
      "target": "riboflavin kinase activity",
      "label": "of"
    },
    {
      "source": "increase",
      "target": "recombinant strains",
      "label": "observed in"
    },
    {
      "source": "increase",
      "target": "AMPK activation",
      "label": "in"
    },
    {
      "source": "increase",
      "target": "immunohistochemical studies",
      "label": "confirmed by"
    },
    {
      "source": "increase",
      "target": "density",
      "label": "in"
    },
    {
      "source": "strong promoters",
      "target": "regulated RIB1",
      "label": "include"
    },
    {
      "source": "strong promoters",
      "target": "constitutive TEF1 promoter",
      "label": "include"
    },
    {
      "source": "DNA fragment",
      "target": "strong promoters",
      "label": "driven by"
    },
    {
      "source": "DNA fragment",
      "target": "FMN1 gene",
      "label": "consists of"
    },
    {
      "source": "riboflavin kinase",
      "target": "enzyme",
      "label": "is a type of"
    },
    {
      "source": "Debaryomyces hansenii FMN1 gene",
      "target": "strong constitutive TEF1 promoter",
      "label": "under control of"
    },
    {
      "source": "FMN1 gene",
      "target": "riboflavin kinase",
      "label": "encodes"
    },
    {
      "source": "Riboflavin kinase activity",
      "target": "isolated transformants",
      "label": "found in"
    },
    {
      "source": "c-Src",
      "target": "Hic-5",
      "label": "promotes association between"
    },
    {
      "source": "c-Src",
      "target": "Human androgen receptor",
      "label": "promotes association between"
    },
    {
      "source": "GnRH receptor",
      "target": "Calcium-dependent tyrosine kinase Pyk2",
      "label": "involves"
    },
    {
      "source": "GnRH receptor",
      "target": "Prostate tumor growth",
      "label": "inhibits"
    },
    {
      "source": "GnRH receptor",
      "target": "Focal adhesion protein",
      "label": "involves"
    },
    {
      "source": "GnRH receptor",
      "target": "Hic-5",
      "label": "involves"
    },
    {
      "source": "GnRH receptor",
      "target": "Sex steroid hormone receptor",
      "label": "affects function of"
    },
    {
      "source": "GnRH receptor",
      "target": "Non-receptor tyrosine kinase c-Src",
      "label": "involves"
    },
    {
      "source": "GnRH receptor",
      "target": "Androgen receptor",
      "label": "induces nuclear translocation of"
    },
    {
      "source": "GnRH receptor",
      "target": "Steroid receptor co-factor",
      "label": "involves"
    },
    {
      "source": "Hic-5",
      "target": "Human androgen receptor",
      "label": "associates with"
    },
    {
      "source": "Testosterone",
      "target": "Androgen receptor",
      "label": "transcriptionally activates"
    },
    {
      "source": "Testosterone",
      "target": "Human androgen receptor",
      "label": "activates"
    },
    {
      "source": "Testosterone",
      "target": "Prostate cells",
      "label": "affects proliferation of"
    },
    {
      "source": "Testosterone",
      "target": "Normal tissue",
      "label": "affects growth of"
    },
    {
      "source": "Testosterone",
      "target": "Week 12",
      "label": "decreased at"
    },
    {
      "source": "Testosterone",
      "target": "reproductive and sexual dysfunction",
      "label": "treats"
    },
    {
      "source": "Testosterone",
      "target": "hypogonadism",
      "label": "treats"
    },
    {
      "source": "Testosterone",
      "target": "epilepsy",
      "label": "treats"
    },
    {
      "source": "Testosterone",
      "target": "men",
      "label": "treats"
    },
    {
      "source": "Androgen receptor",
      "target": "Hic-5",
      "label": "associates with"
    },
    {
      "source": "GnRH analogs",
      "target": "Prostate cancer cells",
      "label": "inhibits"
    },
    {
      "source": "GnRH analogs",
      "target": "Prostatic cancer",
      "label": "treats"
    },
    {
      "source": "GnRH analogs",
      "target": "Androgen",
      "label": "decreases"
    },
    {
      "source": "GnRH analogs",
      "target": "Antiproliferative cell cycle arrest",
      "label": "induces"
    },
    {
      "source": "GnRH analogs",
      "target": "Apoptosis",
      "label": "stimulates"
    },
    {
      "source": "GnRH analogs",
      "target": "Gonadotropins",
      "label": "inhibits"
    },
    {
      "source": "GnRH analogs",
      "target": "Human androgen receptor",
      "label": "modulates"
    },
    {
      "source": "Pyk2",
      "target": "Hic-5",
      "label": "opposes association between"
    },
    {
      "source": "Pyk2",
      "target": "Androgen receptor",
      "label": "opposes association between"
    },
    {
      "source": "Gonadotropin-releasing hormone",
      "target": "Testosterone",
      "label": "antagonizes"
    },
    {
      "source": "Dominant negative Pyk2",
      "target": "Green fluorescent protein-tagged human androgen receptor",
      "label": "enhances GnRH-induced nuclear translocation of"
    },
    {
      "source": "Focal adhesion complexes",
      "target": "Hic-5",
      "label": "involve"
    },
    {
      "source": "Expression",
      "target": "E17.5",
      "label": "decreased between"
    },
    {
      "source": "Expression",
      "target": "E13.5",
      "label": "decreased between"
    },
    {
      "source": "Expression",
      "target": "Early endocrine progenitor cells",
      "label": "occurred in"
    },
    {
      "source": "Genes",
      "target": "Glypicans 1, 2, 3 and 5",
      "label": "encode"
    },
    {
      "source": "Genes",
      "target": "Heparan sulphate 2-sulfotransferase",
      "label": "encode"
    },
    {
      "source": "Genes",
      "target": "Syndecans",
      "label": "encode"
    },
    {
      "source": "Genes",
      "target": "Glycosaminoglycan chain-modifying enzymes",
      "label": "encode"
    },
    {
      "source": "Genes",
      "target": "Glypicans",
      "label": "encode"
    },
    {
      "source": "Genes",
      "target": "E17.5",
      "label": "are expressed in"
    },
    {
      "source": "Genes",
      "target": "Immature embryonic day (E) 13.5 rat pancreases",
      "label": "are expressed in"
    },
    {
      "source": "Genes",
      "target": "Apoptosis",
      "label": "associated with"
    },
    {
      "source": "Genes",
      "target": "Insulin signaling pathway",
      "label": "associated with"
    },
    {
      "source": "Genes",
      "target": "Glucose metabolism",
      "label": "associated with"
    },
    {
      "source": "Genes",
      "target": "Cell cycle",
      "label": "associated with"
    },
    {
      "source": "Genes",
      "target": "Oxidative stress",
      "label": "associated with"
    },
    {
      "source": "Mature cells",
      "target": "Proprotein convertase subtilisin/kexin type 2",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Pancreatic and duodenal homeobox gene 1",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Pcsk1",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Pcsk2",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Proprotein convertase subtilisin/kexin type 1",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Solute carrier family 2 (facilitated glucose transporter), member 2",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Slc2a1",
      "label": "expressed"
    },
    {
      "source": "Mature cells",
      "target": "Pdx1",
      "label": "expressed"
    },
    {
      "source": "Proprotein convertase subtilisin/kexin type 2",
      "target": "Pro-hormone convertase 2",
      "label": "was previously known as"
    },
    {
      "source": "Proprotein convertase subtilisin/kexin type 2",
      "target": "Pcsk2",
      "label": "is also known as"
    },
    {
      "source": "Proprotein convertase subtilisin/kexin type 1",
      "target": "Pcsk1",
      "label": "is also known as"
    },
    {
      "source": "Proprotein convertase subtilisin/kexin type 1",
      "target": "Pro-hormone convertase 1/3",
      "label": "was previously known as"
    },
    {
      "source": "Chlorate",
      "target": "Endocrine cell development",
      "label": "activated"
    },
    {
      "source": "Chlorate",
      "target": "Neurog3",
      "label": "induced expression of"
    },
    {
      "source": "Chlorate",
      "target": "Endogenous sulphated proteoglycans",
      "label": "blocked the action of"
    },
    {
      "source": "Chlorate",
      "target": "Proteoglycan action",
      "label": "altered"
    },
    {
      "source": "Chlorate",
      "target": "Embryonic pancreases",
      "label": "treated"
    },
    {
      "source": "Chlorate",
      "target": "Neurogenin 3",
      "label": "induced expression of"
    },
    {
      "source": "Chlorate",
      "target": "Proteoglycan sulphation",
      "label": "is an inhibitor of"
    },
    {
      "source": "Chlorate",
      "target": "Inhibitory effect",
      "label": "blocked"
    },
    {
      "source": "Neurogenin 3",
      "target": "Neurog3",
      "label": "is also known as"
    },
    {
      "source": "Pancreatic and duodenal homeobox gene 1",
      "target": "Pdx1",
      "label": "is also known as"
    },
    {
      "source": "Solute carrier family 2 (facilitated glucose transporter), member 2",
      "target": "Slc2a1",
      "label": "is also known as"
    },
    {
      "source": "Solute carrier family 2 (facilitated glucose transporter), member 2",
      "target": "Glucose transporter 2",
      "label": "was previously known as"
    },
    {
      "source": "Chlorate-treated pancreases",
      "target": "Beta cell number",
      "label": "increased"
    },
    {
      "source": "Chlorate-treated pancreases",
      "target": "Alpha cell development",
      "label": "increased"
    },
    {
      "source": "Sulphated proteoglycans",
      "target": "Beta cell development",
      "label": "affect"
    },
    {
      "source": "Sulphated proteoglycans",
      "target": "Embryonic development",
      "label": "are essential to"
    },
    {
      "source": "Sulphated proteoglycans",
      "target": "Pancreatic endocrine cell differentiation",
      "label": "regulate"
    },
    {
      "source": "Sulphated proteoglycans",
      "target": "Inhibitory effect",
      "label": "play a role in"
    },
    {
      "source": "Insulin-positive cells",
      "target": "Mature cells",
      "label": "exhibited a phenotype of"
    },
    {
      "source": "Insulin-positive cells",
      "target": "Chlorate",
      "label": "developed in the presence of"
    },
    {
      "source": "Proteoglycan action",
      "target": "Pancreatic endocrine cell differentiation",
      "label": "affects"
    },
    {
      "source": "Embryonic pancreatic mesenchyme",
      "target": "Endocrine cell differentiation",
      "label": "inhibited"
    },
    {
      "source": "Embryonic pancreatic mesenchyme",
      "target": "Progenitor cell proliferation",
      "label": "enhanced"
    },
    {
      "source": "In vitro model of pancreas development",
      "target": "Pancreas development",
      "label": "is a model of"
    },
    {
      "source": "Beta cells",
      "target": "Embryonic stem cells",
      "label": "can be generated from"
    },
    {
      "source": "Epithelium-mesenchyme interactions",
      "target": "Pancreas development",
      "label": "play a major role in"
    },
    {
      "source": "Mesenchyme",
      "target": "Endocrine cell differentiation",
      "label": "has an inhibitory effect on"
    },
    {
      "source": "40 mmol/l chlorate",
      "target": "Beta cell number",
      "label": "increased"
    },
    {
      "source": "30 mmol/l chlorate",
      "target": "Beta cell number",
      "label": "increased"
    },
    {
      "source": "Mechanism",
      "target": "Beta cells",
      "label": "is useful for generating"
    },
    {
      "source": "Mechanism",
      "target": "Hepatotoxic effects",
      "label": "of"
    },
    {
      "source": "superoxide dismutase activities",
      "target": "hyperthyroidism conditions",
      "label": "increased in"
    },
    {
      "source": "hyperthyroidism conditions",
      "target": "administration",
      "label": "induced by"
    },
    {
      "source": "hyperthyroidism conditions",
      "target": "pronounced increase",
      "label": "expressed"
    },
    {
      "source": "hyperthyroidism conditions",
      "target": "five weeks",
      "label": "induced for"
    },
    {
      "source": "significant effect",
      "target": "rates",
      "label": "not observed on"
    },
    {
      "source": "thyroid activity variations",
      "target": "lipid peroxidation",
      "label": "related to"
    },
    {
      "source": "thyroid activity variations",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "thyroid activity variations",
      "target": "oxidizing-stress parameters",
      "label": "impacts"
    },
    {
      "source": "thyroid activity variations",
      "target": "tissular contents",
      "label": "related to"
    },
    {
      "source": "state of oxidizing stress",
      "target": "hyperthyroidism conditions",
      "label": "related to"
    },
    {
      "source": "thyroid activity",
      "target": "antioxidant enzyme activities",
      "label": "affects"
    },
    {
      "source": "thyroid activity",
      "target": "lipid peroxidation",
      "label": "affects"
    },
    {
      "source": "antioxidant enzyme activities",
      "target": "heart",
      "label": "located in"
    },
    {
      "source": "antioxidant enzyme activities",
      "target": "liver",
      "label": "located in"
    },
    {
      "source": "antioxidant enzyme activities",
      "target": "Wistar rats",
      "label": "investigated in"
    },
    {
      "source": "tissular contents",
      "target": "non-enzymatic antioxidants",
      "label": "contain"
    },
    {
      "source": "tissular contents",
      "target": "enzymatic antioxidants",
      "label": "contain"
    },
    {
      "source": "reduced glutathione",
      "target": "homogenate",
      "label": "located in"
    },
    {
      "source": "reduced glutathione",
      "target": "MDA",
      "label": "has negative correlation with"
    },
    {
      "source": "marked increase",
      "target": "glutathione reductase activity",
      "label": "in"
    },
    {
      "source": "L-thyroxine sodium salt",
      "target": "0.0012%",
      "label": "has concentration"
    },
    {
      "source": "vitamin E",
      "target": "cardiac tissues",
      "label": "in"
    },
    {
      "source": "vitamin E",
      "target": "hepatic tissues",
      "label": "in"
    },
    {
      "source": "vitamin E",
      "target": "cellular membranes",
      "label": "is an integral component of"
    },
    {
      "source": "vitamin E",
      "target": "free radical scavenger",
      "label": "is a"
    },
    {
      "source": "vitamin E",
      "target": "oxidative stress",
      "label": "has protective effect against"
    },
    {
      "source": "vitamin E",
      "target": "antioxidant defense",
      "label": "provides"
    },
    {
      "source": "vitamin E",
      "target": "antioxidants",
      "label": "acts as"
    },
    {
      "source": "vitamin E",
      "target": "cancer",
      "label": "is proposed to prevent"
    },
    {
      "source": "vitamin E",
      "target": "biological functions",
      "label": "has important"
    },
    {
      "source": "vitamin E",
      "target": "lipid-soluble antioxidant vitamin",
      "label": "is a"
    },
    {
      "source": "vitamin E",
      "target": "chemopreventive activity",
      "label": "provides"
    },
    {
      "source": "vitamin E",
      "target": "reactive oxygen species",
      "label": "ameliorated"
    },
    {
      "source": "vitamin E",
      "target": "protein oxidization",
      "label": "ameliorated"
    },
    {
      "source": "cardiac tissues",
      "target": "hypothyroidism rats",
      "label": "of"
    },
    {
      "source": "hepatic tissues",
      "target": "hypothyroidism rats",
      "label": "of"
    },
    {
      "source": "hypothyroidism rats",
      "target": "controls",
      "label": "compared to"
    },
    {
      "source": "glutathione peroxidase activity",
      "target": "reduced glutathione",
      "label": "associated with"
    },
    {
      "source": "glutathione peroxidase activity",
      "target": "rats",
      "label": "increased in"
    },
    {
      "source": "glutathione peroxidase activity",
      "target": "marked increase",
      "label": "associated with"
    },
    {
      "source": "0.05% benzythiouracile",
      "target": "BTU",
      "label": "is also known as"
    },
    {
      "source": "Hypothyroidism conditions",
      "target": "five weeks",
      "label": "induced for"
    },
    {
      "source": "Hypothyroidism conditions",
      "target": "administration",
      "label": "induced by"
    },
    {
      "source": "catalase activities",
      "target": "hyperthyroidism conditions",
      "label": "increased in"
    },
    {
      "source": "total MUFAs",
      "target": "PBMC D6D genes",
      "label": "has positive correlation with"
    },
    {
      "source": "total MUFAs",
      "target": "PBMC D5D genes",
      "label": "has positive correlation with"
    },
    {
      "source": "D5D",
      "target": "Chinese",
      "label": "in"
    },
    {
      "source": "D5D",
      "target": "peripheral blood mononuclear cells",
      "label": "found in"
    },
    {
      "source": "European countries",
      "target": "MUFA diets",
      "label": "have"
    },
    {
      "source": "European countries",
      "target": "high SFA diets",
      "label": "have"
    },
    {
      "source": "high EFAs intake",
      "target": "PBMC D5D genes",
      "label": "decreases expression of"
    },
    {
      "source": "high EFAs intake",
      "target": "PBMC D6D genes",
      "label": "decreases expression of"
    },
    {
      "source": "high SFAs",
      "target": "PBMC D6D genes",
      "label": "increases expression of"
    },
    {
      "source": "high SFAs",
      "target": "PBMC D5D genes",
      "label": "increases expression of"
    },
    {
      "source": "high MUFAs",
      "target": "PBMC D6D genes",
      "label": "increases expression of"
    },
    {
      "source": "high MUFAs",
      "target": "PBMC D5D genes",
      "label": "increases expression of"
    },
    {
      "source": "Diet",
      "target": "delta-5 and delta-6 desaturases",
      "label": "influences"
    },
    {
      "source": "Diet",
      "target": "gene expression",
      "label": "influences"
    },
    {
      "source": "Diet",
      "target": "Physical exercise",
      "label": "combined with"
    },
    {
      "source": "Diet",
      "target": "Serum Anti-M\u00fcllerian Hormone",
      "label": "increases"
    },
    {
      "source": "Diet",
      "target": "AMH",
      "label": "increases"
    },
    {
      "source": "delta-5 and delta-6 desaturases",
      "target": "healthy Chinese subjects",
      "label": "found in"
    },
    {
      "source": "delta-5 and delta-6 desaturases",
      "target": "European subjects",
      "label": "found in"
    },
    {
      "source": "dietary intake",
      "target": "saturated fatty acids",
      "label": "contained less"
    },
    {
      "source": "dietary intake",
      "target": "monounsaturated fatty acids",
      "label": "contained less"
    },
    {
      "source": "dietary intake",
      "target": "Chinese",
      "label": "of"
    },
    {
      "source": "dietary intake",
      "target": "essential fatty acids",
      "label": "contained more"
    },
    {
      "source": "dietary intake",
      "target": "SFAs",
      "label": "contained less"
    },
    {
      "source": "dietary intake",
      "target": "MUFAs",
      "label": "contained less"
    },
    {
      "source": "dietary intake",
      "target": "EFAs",
      "label": "contained more"
    },
    {
      "source": "D6D",
      "target": "Chinese",
      "label": "in"
    },
    {
      "source": "D6D",
      "target": "peripheral blood mononuclear cells",
      "label": "found in"
    },
    {
      "source": "D6D",
      "target": "enzyme",
      "label": "is an"
    },
    {
      "source": "LA",
      "target": "PBMC D5D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "LA",
      "target": "PBMC D6D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "delta-5 desaturase",
      "target": "peripheral blood mononuclear cells",
      "label": "found in"
    },
    {
      "source": "composition of fatty acids",
      "target": "Diet",
      "label": "in"
    },
    {
      "source": "delta-6 desaturase",
      "target": "peripheral blood mononuclear cells",
      "label": "found in"
    },
    {
      "source": "Three-day dietary records",
      "target": "subjects",
      "label": "from"
    },
    {
      "source": "follow-up study",
      "target": "gene expression",
      "label": "of"
    },
    {
      "source": "Levels of expression",
      "target": "RT-PCR",
      "label": "determined using"
    },
    {
      "source": "Levels of expression",
      "target": "PBMC D5D genes",
      "label": "of"
    },
    {
      "source": "Levels of expression",
      "target": "Europeans",
      "label": "has higher levels in"
    },
    {
      "source": "Levels of expression",
      "target": "PBMC D6D genes",
      "label": "of"
    },
    {
      "source": "Levels of expression",
      "target": "Chinese",
      "label": "has lower levels in"
    },
    {
      "source": "Chinese",
      "target": "European countries",
      "label": "live in"
    },
    {
      "source": "LNA",
      "target": "PBMC D5D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "LNA",
      "target": "PBMC D6D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "linoleic acid",
      "target": "PBMC D5D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "linoleic acid",
      "target": "PBMC D6D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "total SFAs",
      "target": "PBMC D5D genes",
      "label": "has positive correlation with"
    },
    {
      "source": "total SFAs",
      "target": "PBMC D6D genes",
      "label": "has positive correlation with"
    },
    {
      "source": "alpha-linolenic acid",
      "target": "PBMC D5D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "alpha-linolenic acid",
      "target": "PBMC D6D genes",
      "label": "has negative correlation with"
    },
    {
      "source": "alpha-linolenic acid",
      "target": "18:3n-3",
      "label": "is also known as"
    },
    {
      "source": "alpha-linolenic acid",
      "target": "ALA",
      "label": "is also known as"
    },
    {
      "source": "clinical activity",
      "target": "Decitabine",
      "label": "of"
    },
    {
      "source": "clinical activity",
      "target": "chronic myeloid leukemia",
      "label": "is_in"
    },
    {
      "source": "Decitabine",
      "target": "therapeutic effects",
      "label": "shows"
    },
    {
      "source": "Decitabine",
      "target": "DNA methyltransferase",
      "label": "inhibits"
    },
    {
      "source": "Decitabine",
      "target": "bench",
      "label": "connects to"
    },
    {
      "source": "Decitabine",
      "target": "critical genes",
      "label": "reactivates"
    },
    {
      "source": "Decitabine",
      "target": "bedside",
      "label": "connects to"
    },
    {
      "source": "Correlative laboratory studies",
      "target": "gene expression",
      "label": "show activation of"
    },
    {
      "source": "Correlative laboratory studies",
      "target": "hypomethylation of gene-specific promoters",
      "label": "show induction of"
    },
    {
      "source": "Correlative laboratory studies",
      "target": "global hypomethylation",
      "label": "show induction of"
    },
    {
      "source": "Correlative laboratory studies",
      "target": "multiple clinical trials",
      "label": "from"
    },
    {
      "source": "recent clinical trials",
      "target": "Decitabine",
      "label": "involve"
    },
    {
      "source": "recent clinical trials",
      "target": "hematologic malignancies",
      "label": "conducted in"
    },
    {
      "source": "Review Purpose",
      "target": "Epigenetic changes",
      "label": "is about"
    },
    {
      "source": "Epigenetic changes",
      "target": "malignant transformation",
      "label": "contributes to"
    },
    {
      "source": "Epigenetic changes",
      "target": "DNA methylation",
      "label": "marked by"
    },
    {
      "source": "malignant transformation",
      "target": "critical genes",
      "label": "silences"
    },
    {
      "source": "malignant transformation",
      "target": "cells",
      "label": "affects"
    },
    {
      "source": "connection",
      "target": "clinical activity",
      "label": "between"
    },
    {
      "source": "connection",
      "target": "demethylating activity",
      "label": "between"
    },
    {
      "source": "promoter hypermethylation",
      "target": "p15(INK4B)",
      "label": "of"
    },
    {
      "source": "promoter hypermethylation",
      "target": "baseline",
      "label": "at"
    },
    {
      "source": "therapeutic effects",
      "target": "patients",
      "label": "observed in"
    },
    {
      "source": "therapeutic effects",
      "target": "glucosinolates",
      "label": "attributed to"
    },
    {
      "source": "threshold",
      "target": "clinical outcome",
      "label": "influences"
    },
    {
      "source": "Low-dose decitabine",
      "target": "treatment",
      "label": "effective for"
    },
    {
      "source": "Low-dose decitabine",
      "target": "multiple clinical trials",
      "label": "studied in"
    },
    {
      "source": "DNA methylation",
      "target": "H3K4me",
      "label": "depends on"
    },
    {
      "source": "DNA methylation",
      "target": "frq promoter",
      "label": "occurs in"
    },
    {
      "source": "DNA methylation",
      "target": "glucocorticoid receptor (GR) gene promoter",
      "label": "targets"
    },
    {
      "source": "DNA methylation",
      "target": "glucocorticoid receptor promoter",
      "label": "targets"
    },
    {
      "source": "DNA methylation",
      "target": "male rats",
      "label": "occurs_in"
    },
    {
      "source": "translational research",
      "target": "mechanism",
      "label": "investigates"
    },
    {
      "source": "TGF-beta expression",
      "target": "malignant glioma cells",
      "label": "occurs in"
    },
    {
      "source": "PFD-related agents",
      "target": "human cancers",
      "label": "are promising agents for"
    },
    {
      "source": "human cancers",
      "target": "enhanced TGF-beta activity",
      "label": "are associated with"
    },
    {
      "source": "transforming growth factor (TGF)-beta",
      "target": "experimental treatment",
      "label": "is a target in"
    },
    {
      "source": "transforming growth factor (TGF)-beta",
      "target": "immunosuppressive properties",
      "label": "has"
    },
    {
      "source": "transforming growth factor (TGF)-beta",
      "target": "cytokine",
      "label": "is a"
    },
    {
      "source": "experimental treatment",
      "target": "human malignant gliomas",
      "label": "is for"
    },
    {
      "source": "PFD",
      "target": "human cancers",
      "label": "is a promising agent for"
    },
    {
      "source": "PFD",
      "target": "downregulation of TGF-beta",
      "label": "causes"
    },
    {
      "source": "PFD",
      "target": "TGF-beta2",
      "label": "Downregulator"
    },
    {
      "source": "PFD",
      "target": "mature TGF-beta2 protein",
      "label": "Downregulator"
    },
    {
      "source": "PFD",
      "target": "antifibrotic drug",
      "label": "is an"
    },
    {
      "source": "PFD",
      "target": "matrix metalloproteinase (MMP)-11",
      "label": "Downregulator"
    },
    {
      "source": "PFD",
      "target": "growth-inhibitory effects",
      "label": "elicits"
    },
    {
      "source": "PFD",
      "target": "TGF-beta pro-protein convertase",
      "label": "Downregulator"
    },
    {
      "source": "PFD",
      "target": "expression",
      "label": "causes decreased"
    },
    {
      "source": "PFD",
      "target": "TGF-beta2 mRNA levels",
      "label": "Downregulator"
    },
    {
      "source": "PFD",
      "target": "furin",
      "label": "Downregulator"
    },
    {
      "source": "PFD",
      "target": "direct inhibition",
      "label": "causes"
    },
    {
      "source": "PFD treatment",
      "target": "growth inhibition",
      "label": "Downregulator"
    },
    {
      "source": "growth inhibition",
      "target": "TGF-beta-sensitive CCL-64 cells",
      "label": "affects"
    },
    {
      "source": "growth inhibition",
      "target": "conditioned media",
      "label": "is mediated by"
    },
    {
      "source": "growth inhibition",
      "target": "colon cancer SV-948 cells",
      "label": "of"
    },
    {
      "source": "growth inhibition",
      "target": "epidermal carcinoma A-341 cells",
      "label": "of"
    },
    {
      "source": "growth inhibition",
      "target": "leukemia L-1210 cells",
      "label": "of"
    },
    {
      "source": "growth inhibition",
      "target": "neuroblastoma LAN-5 cells",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "SH-SY5Y cells",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "HT29 cancer cells",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "colon HCT116",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "chronic myeloid leukemia K562 cells",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "lung H1299",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "A549",
      "label": "occurred in"
    },
    {
      "source": "growth inhibition",
      "target": "stripped calf serum",
      "label": "occurs in presence of"
    },
    {
      "source": "pirfenidone",
      "target": "growth-inhibitory effects",
      "label": "elicits"
    },
    {
      "source": "pirfenidone",
      "target": "antifibrotic drug",
      "label": "is an"
    },
    {
      "source": "pirfenidone",
      "target": "TGF-beta2",
      "label": "Downregulator"
    },
    {
      "source": "TGF-beta2 protein levels",
      "target": "human glioma cell lines",
      "label": "found in"
    },
    {
      "source": "matrix metalloproteinase (MMP)-11",
      "target": "TGF-beta target gene",
      "label": "is a"
    },
    {
      "source": "matrix metalloproteinase (MMP)-11",
      "target": "furin substrate",
      "label": "is a"
    },
    {
      "source": "matrix metalloproteinase (MMP)-11",
      "target": "carcinogenesis",
      "label": "is involved in"
    },
    {
      "source": "5-methyl-1-phenyl-2-(1H)-pyridone",
      "target": "TGF-beta2",
      "label": "Downregulator"
    },
    {
      "source": "5-methyl-1-phenyl-2-(1H)-pyridone",
      "target": "growth-inhibitory effects",
      "label": "elicits"
    },
    {
      "source": "5-methyl-1-phenyl-2-(1H)-pyridone",
      "target": "antifibrotic drug",
      "label": "is an"
    },
    {
      "source": "Pirfenidone",
      "target": "TGF-beta expression",
      "label": "Downregulator"
    },
    {
      "source": "conditioned media",
      "target": "glioma cells",
      "label": "is from"
    },
    {
      "source": "furin",
      "target": "TGF-beta pro-protein convertase",
      "label": "is a"
    },
    {
      "source": "Reticulated platelets",
      "target": "flow cytometry",
      "label": "measured using"
    },
    {
      "source": "Reticulated platelets",
      "target": "antiplatelet effects of aspirin",
      "label": "decrease"
    },
    {
      "source": "Reticulated platelets",
      "target": "diminished antiplatelet effects of aspirin",
      "label": "associated with"
    },
    {
      "source": "Reticulated platelets",
      "target": "uninhibited COX-1",
      "label": "associated with because of"
    },
    {
      "source": "Reticulated platelets",
      "target": "increased aspirin resistance",
      "label": "associated with"
    },
    {
      "source": "Reticulated platelets",
      "target": "increased reactivity",
      "label": "associated with because of"
    },
    {
      "source": "Reticulated platelets",
      "target": "COX-2 activity",
      "label": "associated with because of"
    },
    {
      "source": "Postaspirin serum TxB2 levels",
      "target": "ex vivo additional COX-1",
      "label": "decreased with"
    },
    {
      "source": "Postaspirin serum TxB2 levels",
      "target": "COX-2 inhibition",
      "label": "decreased with"
    },
    {
      "source": "Postaspirin serum TxB2 levels",
      "target": "lower tertile",
      "label": "higher than in"
    },
    {
      "source": "Postaspirin serum TxB2 levels",
      "target": "upper tertile",
      "label": "higher in"
    },
    {
      "source": "tertiles",
      "target": "percentage of reticulated platelets",
      "label": "based on"
    },
    {
      "source": "platelet studies",
      "target": "Light transmission aggregometry",
      "label": "included"
    },
    {
      "source": "platelet studies",
      "target": "integrin alpha(IIb)beta(3) expression",
      "label": "included"
    },
    {
      "source": "platelet studies",
      "target": "serum thromboxane B(2) (TxB2) levels",
      "label": "included"
    },
    {
      "source": "platelet studies",
      "target": "P-selectin",
      "label": "included"
    },
    {
      "source": "platelet studies",
      "target": "single 325-mg dose of aspirin",
      "label": "performed after"
    },
    {
      "source": "Baseline platelet aggregation",
      "target": "upper tertile",
      "label": "greater in"
    },
    {
      "source": "Baseline platelet aggregation",
      "target": "1 microg mL(-1) collagen",
      "label": "to"
    },
    {
      "source": "Baseline platelet aggregation",
      "target": "lower tertile of reticulated platelets",
      "label": "greater than in"
    },
    {
      "source": "uninhibited COX-1",
      "target": "antiplatelet effects of aspirin",
      "label": "decrease"
    },
    {
      "source": "postaspirin aggregations",
      "target": "upper tertile",
      "label": "greater in"
    },
    {
      "source": "postaspirin aggregations",
      "target": "20 microm ADP",
      "label": "to"
    },
    {
      "source": "postaspirin aggregations",
      "target": "lower tertile of reticulated platelets",
      "label": "greater than in"
    },
    {
      "source": "postaspirin aggregations",
      "target": "5 microm ADP",
      "label": "to"
    },
    {
      "source": "postaspirin aggregations",
      "target": "collagen",
      "label": "to"
    },
    {
      "source": "Stimulated P-selectin",
      "target": "upper tertile",
      "label": "higher in"
    },
    {
      "source": "Stimulated P-selectin",
      "target": "aspirin",
      "label": "higher after"
    },
    {
      "source": "integrin alpha(IIb)beta(3) expression",
      "target": "aspirin",
      "label": "higher after"
    },
    {
      "source": "integrin alpha(IIb)beta(3) expression",
      "target": "upper tertile",
      "label": "higher in"
    },
    {
      "source": "Immature (reticulated) platelets",
      "target": "antiplatelet effects of aspirin",
      "label": "modulate"
    },
    {
      "source": "Immature (reticulated) platelets",
      "target": "COX-2",
      "label": "modulate through"
    },
    {
      "source": "Immature (reticulated) platelets",
      "target": "uninhibited cyclooxygenase (COX)-1",
      "label": "modulate through"
    },
    {
      "source": "variability",
      "target": "antiplatelet effects of aspirin",
      "label": "in"
    },
    {
      "source": "variability",
      "target": "pKB estimates",
      "label": "in"
    },
    {
      "source": "aspirin",
      "target": "40 mg",
      "label": "administered at"
    },
    {
      "source": "platelet COX-2 expression",
      "target": "flow cytometry",
      "label": "measured using"
    },
    {
      "source": "percentage of reticulated platelets",
      "target": "whole blood",
      "label": "in"
    },
    {
      "source": "Platelet COX-2 expression",
      "target": "lower two tertiles",
      "label": "detected in"
    },
    {
      "source": "Platelet COX-2 expression",
      "target": "upper tertile",
      "label": "detected in"
    },
    {
      "source": "incidence of aspirin resistance",
      "target": "lower tertile",
      "label": "higher than in"
    },
    {
      "source": "incidence of aspirin resistance",
      "target": "upper tertile",
      "label": "higher in"
    },
    {
      "source": "role of reticulated platelets",
      "target": "antiplatelet effects of aspirin",
      "label": "in"
    },
    {
      "source": "BAAT",
      "target": "conjugation",
      "label": "RESPONSIBLE_FOR"
    },
    {
      "source": "BAAT",
      "target": "primary bile acids",
      "label": "CONJUGATES"
    },
    {
      "source": "BAAT",
      "target": "enzyme",
      "label": "IS_A"
    },
    {
      "source": "BAAT",
      "target": "bile acids",
      "label": "CONJUGATES"
    },
    {
      "source": "BAAT",
      "target": "peroxisomes",
      "label": "HAS_LOCATION"
    },
    {
      "source": "BAAT",
      "target": "cytosolic fractions",
      "label": "DETECTED_IN"
    },
    {
      "source": "BAAT",
      "target": "secondary bile acids",
      "label": "CONJUGATES"
    },
    {
      "source": "conjugation",
      "target": "secondary bile acids",
      "label": "OF"
    },
    {
      "source": "conjugation",
      "target": "primary bile acids",
      "label": "OF"
    },
    {
      "source": "conjugation",
      "target": "hydrophilic glucuronides",
      "label": "produces"
    },
    {
      "source": "conjugation",
      "target": "xenobiotics",
      "label": "involves"
    },
    {
      "source": "conjugation",
      "target": "endogeonous compounds",
      "label": "involves"
    },
    {
      "source": "endogenous BAAT",
      "target": "primary human hepatocytes",
      "label": "LOCATED_IN"
    },
    {
      "source": "endogenous BAAT",
      "target": "primary rat hepatocytes",
      "label": "LOCATED_IN"
    },
    {
      "source": "GFP-tagged hBAAT",
      "target": "cytosol",
      "label": "LOCALIZED_TO"
    },
    {
      "source": "GFP-tagged hBAAT",
      "target": "fibroblasts",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "GFP-tagged hBAAT",
      "target": "observations",
      "label": "CONFIRMS"
    },
    {
      "source": "GFP-tagged hBAAT",
      "target": "primary rat hepatocytes",
      "label": "LOCATED_IN"
    },
    {
      "source": "GFP-tagged hBAAT",
      "target": "peroxisomes",
      "label": "SORTED_TO"
    },
    {
      "source": "primary bile acids",
      "target": "glycine",
      "label": "CONJUGATED_TO"
    },
    {
      "source": "primary bile acids",
      "target": "taurine",
      "label": "CONJUGATED_TO"
    },
    {
      "source": "digitonin permeabilization assays",
      "target": "subcellular location",
      "label": "USED_TO_DETERMINE"
    },
    {
      "source": "subcellular location",
      "target": "endogenous BAAT",
      "label": "OF"
    },
    {
      "source": "rBaat",
      "target": "peroxisomes",
      "label": "LOCALIZES_TO"
    },
    {
      "source": "rBaat",
      "target": "cytosol",
      "label": "PRESENT_IN"
    },
    {
      "source": "rBaat",
      "target": "peroxisomal enzymes",
      "label": "IS_A"
    },
    {
      "source": "rBaat",
      "target": "cytosolic fractions",
      "label": "HAS_NO"
    },
    {
      "source": "rBaat",
      "target": "primary rat hepatocytes",
      "label": "LOCATED_IN"
    },
    {
      "source": "hBAAT",
      "target": "cytosol",
      "label": "PRESENT_IN"
    },
    {
      "source": "hBAAT",
      "target": "peroxisomal enzymes",
      "label": "IS_A"
    },
    {
      "source": "hBAAT",
      "target": "primary rat hepatocytes",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "hBAAT",
      "target": "human fibroblasts",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "immunofluorescence microscopy",
      "target": "subcellular location",
      "label": "USED_TO_DETERMINE"
    },
    {
      "source": "endogenous hBAAT",
      "target": "peroxisomes",
      "label": "LOCALIZES_TO"
    },
    {
      "source": "endogenous hBAAT",
      "target": "primary human hepatocytes",
      "label": "LOCATED_IN"
    },
    {
      "source": "endogenous hBAAT",
      "target": "cytosolic fractions",
      "label": "HAS_NO"
    },
    {
      "source": "glycine",
      "target": "NR1/NR2A receptors",
      "label": "stimulates"
    },
    {
      "source": "N",
      "target": "Bile acid-coenzyme A:amino acid N-acyltransferase",
      "label": "IS_PART_OF"
    },
    {
      "source": "Bile acid-coenzyme A:amino acid N-acyltransferase",
      "target": "enzyme",
      "label": "IS_A"
    },
    {
      "source": "Bile acid-coenzyme A:amino acid N-acyltransferase",
      "target": "BAAT",
      "label": "IS_ALSO_KNOWN_AS"
    },
    {
      "source": "Coenzyme A",
      "target": "Bile acid-coenzyme A:amino acid N-acyltransferase",
      "label": "IS_PART_OF"
    },
    {
      "source": "GFP-tagged rat Baat",
      "target": "human fibroblasts",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "GFP-tagged rat Baat",
      "target": "primary rat hepatocytes",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "human BAAT",
      "target": "primary rat hepatocytes",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "human BAAT",
      "target": "human fibroblasts",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "green fluorescent protein",
      "target": "rat Baat",
      "label": "TAGS"
    },
    {
      "source": "green fluorescent protein",
      "target": "human BAAT",
      "label": "TAGS"
    },
    {
      "source": "secondary bile acids",
      "target": "glycine",
      "label": "CONJUGATED_TO"
    },
    {
      "source": "secondary bile acids",
      "target": "taurine",
      "label": "CONJUGATED_TO"
    },
    {
      "source": "GFP-tagged rBaat",
      "target": "human fibroblasts",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "GFP-tagged rBaat",
      "target": "primary rat hepatocytes",
      "label": "EXPRESSED_IN"
    },
    {
      "source": "GFP-tagged rBaat",
      "target": "peroxisomes",
      "label": "SORTED_TO"
    },
    {
      "source": "GFP-tagged rBaat",
      "target": "cytosol",
      "label": "DETECTED_IN"
    },
    {
      "source": "GFP-SKL",
      "target": "peroxisomal markers",
      "label": "IS_A"
    },
    {
      "source": "recombinant GFP-SKL",
      "target": "peroxisomal markers",
      "label": "IS_A"
    },
    {
      "source": "cytosolic pool",
      "target": "BAAT",
      "label": "OF"
    },
    {
      "source": "cytosolic pool",
      "target": "intracellular transport",
      "label": "HAS_IMPLICATIONS_FOR"
    },
    {
      "source": "DsRed-SKL",
      "target": "peroxisomal markers",
      "label": "IS_A"
    },
    {
      "source": "DsRed-SKL",
      "target": "peroxisomal import machinery",
      "label": "COMPETES_FOR"
    },
    {
      "source": "observations",
      "target": "homeostatic protein quality control mechanisms",
      "label": "implicate"
    },
    {
      "source": "observations",
      "target": "synonymous codon usage",
      "label": "highlight relevance of"
    },
    {
      "source": "intracellular transport",
      "target": "unconjugated/deconjugated bile salts",
      "label": "OF"
    },
    {
      "source": "bile acid-CoA:amino acid N-acyltransferase",
      "target": "Liver",
      "label": "HAS_LOCATION"
    },
    {
      "source": "bile acid-CoA:amino acid N-acyltransferase",
      "target": "peroxisomal enzymes",
      "label": "IS_A"
    },
    {
      "source": "bile acid-CoA:amino acid N-acyltransferase",
      "target": "intracellular bile salt transport",
      "label": "HAS_IMPLICATIONS_FOR"
    },
    {
      "source": "Unconjugated or deconjugated bile salts",
      "target": "Liver",
      "label": "RETURN_TO"
    },
    {
      "source": "Unconjugated or deconjugated bile salts",
      "target": "enterohepatic circulation",
      "label": "REENTER"
    },
    {
      "source": "Unconjugated or deconjugated bile salts",
      "target": "peroxisomes",
      "label": "SHUTTLE_THROUGH"
    },
    {
      "source": "Human",
      "target": "bile acid-CoA:amino acid N-acyltransferase",
      "label": "HAS_ENZYME"
    },
    {
      "source": "Catalase",
      "target": "peroxisomal markers",
      "label": "IS_A"
    },
    {
      "source": "GFP",
      "target": "rat Baat",
      "label": "TAGS"
    },
    {
      "source": "GFP",
      "target": "human BAAT",
      "label": "TAGS"
    },
    {
      "source": "peroxisomal location",
      "target": "BAAT",
      "label": "OF"
    },
    {
      "source": "Rat",
      "target": "bile acid-CoA:amino acid N-acyltransferase",
      "label": "HAS_ENZYME"
    },
    {
      "source": "amino acid",
      "target": "Bile acid-coenzyme A:amino acid N-acyltransferase",
      "label": "IS_PART_OF"
    },
    {
      "source": "amino acid",
      "target": "glutamate",
      "label": "precursor to"
    },
    {
      "source": "amino acid",
      "target": "polyamines",
      "label": "precursor to"
    },
    {
      "source": "amino acid",
      "target": "GABA",
      "label": "precursor to"
    },
    {
      "source": "amino acid",
      "target": "inhibition of the phospholamban function",
      "label": "important for"
    },
    {
      "source": "amino acid",
      "target": "arginine",
      "label": "is"
    },
    {
      "source": "hBAAT/rBaat",
      "target": "peroxisomal import machinery",
      "label": "COMPETES_FOR"
    },
    {
      "source": "gamma-carboxylation",
      "target": "developing embryo",
      "label": "occurs in"
    },
    {
      "source": "gamma-carboxylation",
      "target": "neonate",
      "label": "occurs in"
    },
    {
      "source": "postnatal hemorrhage",
      "target": "F5-deficient mice",
      "label": "is reported for"
    },
    {
      "source": "postnatal hemorrhage",
      "target": "prothrombin-deficient mice",
      "label": "is reported for"
    },
    {
      "source": "postnatal hemorrhage",
      "target": "factor V-deficient mice",
      "label": "is reported for"
    },
    {
      "source": "functionally critical substrates",
      "target": "components",
      "label": "are restricted to"
    },
    {
      "source": "functionally critical substrates",
      "target": "gamma-carboxylation",
      "label": "are for"
    },
    {
      "source": "components",
      "target": "blood coagulation cascade",
      "label": "are part of"
    },
    {
      "source": "components",
      "target": "cognitive event-related potentials",
      "label": "are of"
    },
    {
      "source": "partial midembryonic loss",
      "target": "F5-deficient mice",
      "label": "is reported for"
    },
    {
      "source": "partial midembryonic loss",
      "target": "prothrombin-deficient mice",
      "label": "is reported for"
    },
    {
      "source": "partial midembryonic loss",
      "target": "factor V-deficient mice",
      "label": "is reported for"
    },
    {
      "source": "posttranslational modification",
      "target": "biological activity",
      "label": "is required for"
    },
    {
      "source": "null mutation",
      "target": "Ggcx gene",
      "label": "is at"
    },
    {
      "source": "Heterozygous mice",
      "target": "development",
      "label": "exhibit"
    },
    {
      "source": "Heterozygous mice",
      "target": "functional activity",
      "label": "exhibit"
    },
    {
      "source": "Heterozygous mice",
      "target": "null mutation",
      "label": "carry"
    },
    {
      "source": "Heterozygous mice",
      "target": "survival",
      "label": "exhibit"
    },
    {
      "source": "Heterozygous mice",
      "target": "hemorrhage",
      "label": "do not exhibit"
    },
    {
      "source": "Ggcx(+/-) intercross",
      "target": "partial developmental block",
      "label": "revealed"
    },
    {
      "source": "phenotype",
      "target": "partial midembryonic loss",
      "label": "resembles"
    },
    {
      "source": "phenotype",
      "target": "postnatal hemorrhage",
      "label": "resembles"
    },
    {
      "source": "phenotype",
      "target": "host age",
      "label": "persisted with"
    },
    {
      "source": "phenotype",
      "target": "immune cell numbers",
      "label": "was associated with"
    },
    {
      "source": "phenotype",
      "target": "young T-bet(-/-) mice",
      "label": "is present in"
    },
    {
      "source": "phenotype",
      "target": "high-fat diet",
      "label": "persisted with"
    },
    {
      "source": "phenotype",
      "target": "cytokine secretion",
      "label": "was associated with"
    },
    {
      "source": "Fatal hemorrhage",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "biological activity",
      "target": "proteins",
      "label": "is of"
    },
    {
      "source": "biological activity",
      "target": "acetylcholinesterase inhibitors",
      "label": "is of"
    },
    {
      "source": "biological activity",
      "target": "osteogenic differentiation",
      "label": "shown by"
    },
    {
      "source": "biological activity",
      "target": "mature BMP-2",
      "label": "of"
    },
    {
      "source": "Ggcx(-/-) offspring",
      "target": "animals",
      "label": "are a type of"
    },
    {
      "source": "Neuroprotection",
      "target": "ERalpha",
      "label": "mediated by"
    },
    {
      "source": "Neuroprotection",
      "target": "MPP(+) toxicity",
      "label": "is against"
    },
    {
      "source": "Neuroprotection",
      "target": "primary cultures of mouse mesencephalon",
      "label": "occurs in"
    },
    {
      "source": "Neuroprotection",
      "target": "estrogen",
      "label": "provided by"
    },
    {
      "source": "Neuroprotection",
      "target": "two cell types",
      "label": "involves"
    },
    {
      "source": "ERalpha",
      "target": "dopamine neurons",
      "label": "is predominant on"
    },
    {
      "source": "ERalpha",
      "target": "protection",
      "label": "mediated"
    },
    {
      "source": "ERalpha",
      "target": "astrocytes",
      "label": "is predominant on"
    },
    {
      "source": "primary mesencephalic neurons",
      "target": "estrogen receptor alpha",
      "label": "express"
    },
    {
      "source": "primary mesencephalic neurons",
      "target": "estrogen receptor beta",
      "label": "express"
    },
    {
      "source": "primary mesencephalic neurons",
      "target": "ERbeta",
      "label": "express"
    },
    {
      "source": "primary mesencephalic neurons",
      "target": "ERalpha",
      "label": "express"
    },
    {
      "source": "estrogen receptor alpha",
      "target": "in vivo",
      "label": "is studied in"
    },
    {
      "source": "mitotic inhibitor",
      "target": "5-fluoro-2'-deoxyuridine",
      "label": "is"
    },
    {
      "source": "estrogen-mediated neuroprotection",
      "target": "cells",
      "label": "results from"
    },
    {
      "source": "estrogen-mediated neuroprotection",
      "target": "indirect mechanism",
      "label": "occurs through"
    },
    {
      "source": "HPTE",
      "target": "ERalpha",
      "label": "is an agonist of"
    },
    {
      "source": "HPTE",
      "target": "dopamine cell loss",
      "label": "protected against"
    },
    {
      "source": "protection",
      "target": "estrogen",
      "label": "afforded by"
    },
    {
      "source": "protection",
      "target": "ER",
      "label": "depends on"
    },
    {
      "source": "protection",
      "target": "ER antagonist",
      "label": "blocked by"
    },
    {
      "source": "protection",
      "target": "duodenal mucosa",
      "label": "of"
    },
    {
      "source": "protection",
      "target": "growth inhibitory effects",
      "label": "against"
    },
    {
      "source": "ERbeta agonist",
      "target": "DPN",
      "label": "is"
    },
    {
      "source": "DPN",
      "target": "dopamine cell loss",
      "label": "did not protect against"
    },
    {
      "source": "DPN",
      "target": "ERbeta",
      "label": "is an agonist of"
    },
    {
      "source": "estrogenic effects",
      "target": "mixed population of cells",
      "label": "examined in"
    },
    {
      "source": "molecular and cellular mechanisms",
      "target": "estrogen action",
      "label": "are of"
    },
    {
      "source": "estrogen action",
      "target": "Neuroprotection",
      "label": "is involved in"
    },
    {
      "source": "estrogen action",
      "target": "molecular and cellular mechanisms",
      "label": "has"
    },
    {
      "source": "17beta-estradiol",
      "target": "injury",
      "label": "protects from"
    },
    {
      "source": "17beta-estradiol",
      "target": "dopamine neurons",
      "label": "protects"
    },
    {
      "source": "17beta-estradiol",
      "target": "ER",
      "label": "regulates"
    },
    {
      "source": "indirect mechanism",
      "target": "glial cell interaction",
      "label": "involves"
    },
    {
      "source": "ERalpha agonist",
      "target": "HPTE",
      "label": "is"
    },
    {
      "source": "MPP+",
      "target": "dopamine neuron death",
      "label": "induces"
    },
    {
      "source": "astrocytes",
      "target": "GFAP immunoreactivity",
      "label": "identified by"
    },
    {
      "source": "astrocytes",
      "target": "hours",
      "label": "activated within"
    },
    {
      "source": "astrocytes",
      "target": "PQ-treated mice",
      "label": "were not activated in"
    },
    {
      "source": "complex I inhibitor",
      "target": "1-methyl-4-phenyl pyridinium",
      "label": "is"
    },
    {
      "source": "1-methyl-4-phenyl pyridinium",
      "target": "MPP(+)",
      "label": "is"
    },
    {
      "source": "5-fluoro-2'-deoxyuridine",
      "target": "neuroprotective effects",
      "label": "reduces"
    },
    {
      "source": "estrogen pre-treatment",
      "target": "protection",
      "label": "elicits"
    },
    {
      "source": "single nucleotide polymorphisms",
      "target": "GSTA1-52",
      "label": "include"
    },
    {
      "source": "single nucleotide polymorphisms",
      "target": "GSTP1-114",
      "label": "include"
    },
    {
      "source": "single nucleotide polymorphisms",
      "target": "GSTP1-105",
      "label": "include"
    },
    {
      "source": "single nucleotide polymorphisms",
      "target": "GCLM-588",
      "label": "include"
    },
    {
      "source": "single nucleotide polymorphisms",
      "target": "GCLC-129",
      "label": "include"
    },
    {
      "source": "GSTA1-52",
      "target": "TTCA levels",
      "label": "no impact on"
    },
    {
      "source": "Urine",
      "target": "work shift",
      "label": "collected during"
    },
    {
      "source": "Urine",
      "target": "exposed workers",
      "label": "collected from"
    },
    {
      "source": "Urine",
      "target": "controls",
      "label": "collected from"
    },
    {
      "source": "carbon disulfide (CS(2))",
      "target": "toxic compounds",
      "label": "is a type of"
    },
    {
      "source": "carbon disulfide (CS(2))",
      "target": "TTCA",
      "label": "biotransformed to"
    },
    {
      "source": "carbon disulfide (CS(2))",
      "target": "2-thiothiazolidine-4-carboxylic acid",
      "label": "biotransformed to"
    },
    {
      "source": "Genotyping",
      "target": "ordinary PCR",
      "label": "performed with"
    },
    {
      "source": "Genotyping",
      "target": "agarose electrophoresis",
      "label": "performed with"
    },
    {
      "source": "Genotyping",
      "target": "deletions",
      "label": "of"
    },
    {
      "source": "Genotyping",
      "target": "real-time PCR",
      "label": "performed with"
    },
    {
      "source": "Genotyping",
      "target": "single nucleotide polymorphisms",
      "label": "of"
    },
    {
      "source": "TTCA levels",
      "target": "injection and compression molding",
      "label": "lower with"
    },
    {
      "source": "TTCA levels",
      "target": "microwaves",
      "label": "highest with"
    },
    {
      "source": "TTCA levels",
      "target": "hot air",
      "label": "highest with"
    },
    {
      "source": "TTCA levels",
      "target": "fluid-bed",
      "label": "highest with"
    },
    {
      "source": "TTCA levels",
      "target": "Urine",
      "label": "found in"
    },
    {
      "source": "TTCA levels",
      "target": "liquid chromatograpy tandem mass spectrometry",
      "label": "analyzed by"
    },
    {
      "source": "TTCA levels",
      "target": "salt bath",
      "label": "highest with"
    },
    {
      "source": "GSTM1",
      "target": "statistically significant differences",
      "label": "associated with"
    },
    {
      "source": "statistically significant differences",
      "target": "exposed workers",
      "label": "found among"
    },
    {
      "source": "statistically significant differences",
      "target": "TTCA levels",
      "label": "in"
    },
    {
      "source": "statistically significant differences",
      "target": "controls",
      "label": "not found among"
    },
    {
      "source": "statistically significant differences",
      "target": "genotypes",
      "label": "between"
    },
    {
      "source": "survey",
      "target": "exposure",
      "label": "examines"
    },
    {
      "source": "rubber industry",
      "target": "hazardous substances",
      "label": "exposes to"
    },
    {
      "source": "rubber industry",
      "target": "diseases",
      "label": "associated with"
    },
    {
      "source": "modifying effects",
      "target": "glutathione-related genes",
      "label": "of"
    },
    {
      "source": "vulcanization workers",
      "target": "southern Sweden rubber industries",
      "label": "in"
    },
    {
      "source": "biomarker",
      "target": "carbon disulfide (CS(2))",
      "label": "for"
    },
    {
      "source": "biomarker",
      "target": "exposure",
      "label": "for"
    },
    {
      "source": "TTCA",
      "target": "biomarker",
      "label": "is a"
    },
    {
      "source": "GSTP1-114",
      "target": "TTCA levels",
      "label": "no impact on"
    },
    {
      "source": "deletions",
      "target": "GSTT1",
      "label": "of"
    },
    {
      "source": "deletions",
      "target": "GSTM1",
      "label": "of"
    },
    {
      "source": "GSTP1-105",
      "target": "TTCA levels",
      "label": "no impact on"
    },
    {
      "source": "GSTT1",
      "target": "statistically significant differences",
      "label": "associated with"
    },
    {
      "source": "GCLM-588",
      "target": "TTCA levels",
      "label": "no impact on"
    },
    {
      "source": "real-time PCR",
      "target": "H3R",
      "label": "evaluates"
    },
    {
      "source": "GCLC-129",
      "target": "TTCA levels",
      "label": "no impact on"
    },
    {
      "source": "inter- and intraindividual variability",
      "target": "genetic variation",
      "label": "due to"
    },
    {
      "source": "developing retinal ganglion cell layer",
      "target": "AC5",
      "label": "contains"
    },
    {
      "source": "developing retinal ganglion cell layer",
      "target": "AC3",
      "label": "contains"
    },
    {
      "source": "developing retinal ganglion cell layer",
      "target": "AC2",
      "label": "contains"
    },
    {
      "source": "developing retinal ganglion cell layer",
      "target": "AC1",
      "label": "contains"
    },
    {
      "source": "developing retinal ganglion cell layer",
      "target": "AC9",
      "label": "contains"
    },
    {
      "source": "developing retinal ganglion cell layer",
      "target": "AC8",
      "label": "contains"
    },
    {
      "source": "AC5",
      "target": "retinal axon terminals",
      "label": "not required for maturation of"
    },
    {
      "source": "AC5",
      "target": "segregation retinal fibres",
      "label": "role for"
    },
    {
      "source": "genetic approach",
      "target": "calcium modulated cyclases",
      "label": "tested role of"
    },
    {
      "source": "calcium modulated cyclases",
      "target": "AC1",
      "label": "include"
    },
    {
      "source": "calcium modulated cyclases",
      "target": "retinal projections",
      "label": "involved in development of"
    },
    {
      "source": "calcium modulated cyclases",
      "target": "AC8",
      "label": "include"
    },
    {
      "source": "calcium modulated cyclases",
      "target": "AC5",
      "label": "include"
    },
    {
      "source": "AC",
      "target": "extracellular signals",
      "label": "integrate"
    },
    {
      "source": "AC",
      "target": "cAMP production",
      "label": "regulate"
    },
    {
      "source": "AC",
      "target": "antioxidant capacity",
      "label": "is an abbreviation for"
    },
    {
      "source": "extracellular signals",
      "target": "neurotransmitters",
      "label": "include"
    },
    {
      "source": "extracellular signals",
      "target": "morphogens",
      "label": "include"
    },
    {
      "source": "AC1",
      "target": "retinal axon terminals",
      "label": "required for maturation of"
    },
    {
      "source": "AC1",
      "target": "cyclases",
      "label": "compared with"
    },
    {
      "source": "AC1",
      "target": "segregation retinal fibres",
      "label": "role for"
    },
    {
      "source": "AC1",
      "target": "barrelless mouse strain",
      "label": "observed in"
    },
    {
      "source": "AC1",
      "target": "RGC",
      "label": "localized in"
    },
    {
      "source": "central brain targets",
      "target": "dorsal lateral geniculate nucleus",
      "label": "include"
    },
    {
      "source": "central brain targets",
      "target": "superior colliculus",
      "label": "include"
    },
    {
      "source": "central brain targets",
      "target": "ventral lateral geniculate nucleus",
      "label": "include"
    },
    {
      "source": "dorsal lateral geniculate nucleus",
      "target": "AC1",
      "label": "expresses"
    },
    {
      "source": "dorsal lateral geniculate nucleus",
      "target": "AC8",
      "label": "expresses"
    },
    {
      "source": "retinal projections",
      "target": "eyes",
      "label": "from"
    },
    {
      "source": "retinal projections",
      "target": "visual thalamus",
      "label": "overlap in"
    },
    {
      "source": "retinal projections",
      "target": "superior colliculus",
      "label": "overlap in"
    },
    {
      "source": "Transmembrane isoforms of adenylate cyclases",
      "target": "cAMP production",
      "label": "regulate"
    },
    {
      "source": "Transmembrane isoforms of adenylate cyclases",
      "target": "extracellular signals",
      "label": "integrate"
    },
    {
      "source": "AC subtypes",
      "target": "developing retinal ganglion cell layer",
      "label": "found in"
    },
    {
      "source": "AC subtypes",
      "target": "central brain targets",
      "label": "expressed in"
    },
    {
      "source": "superior colliculus",
      "target": "AC1",
      "label": "expresses"
    },
    {
      "source": "superior colliculus",
      "target": "AC2",
      "label": "expresses"
    },
    {
      "source": "superior colliculus",
      "target": "AC8",
      "label": "expresses"
    },
    {
      "source": "Ipsilateral retinal axons",
      "target": "AC1(-/-) mice",
      "label": "remained exuberant in"
    },
    {
      "source": "AC1(-/-) mice",
      "target": "barrelless mouse mutants",
      "label": "exhibited abnormalities similar to"
    },
    {
      "source": "AC8",
      "target": "retinal axon terminals",
      "label": "not required for maturation of"
    },
    {
      "source": "AC8",
      "target": "segregation retinal fibres",
      "label": "role for"
    },
    {
      "source": "AC1/AC8 double-knockout mice",
      "target": "AC1(-/-) mice",
      "label": "exhibited similar abnormalities as"
    },
    {
      "source": "ventral lateral geniculate nucleus",
      "target": "AC2",
      "label": "expresses"
    },
    {
      "source": "ventral lateral geniculate nucleus",
      "target": "AC8",
      "label": "expresses"
    },
    {
      "source": "Adcy1 gene",
      "target": "segregation retinal fibres",
      "label": "involved in"
    },
    {
      "source": "Adcy1 gene",
      "target": "barrelless mouse strain",
      "label": "observed in"
    },
    {
      "source": "Adcy genes",
      "target": "visual centres",
      "label": "localized in"
    },
    {
      "source": "Adcy genes",
      "target": "in situ hybridization",
      "label": "localized using"
    },
    {
      "source": "functional differences",
      "target": "NAc shell subregions",
      "label": "are_among"
    },
    {
      "source": "localized activation of CREB",
      "target": "2 drug-free days",
      "label": "occurred_after"
    },
    {
      "source": "localized activation of CREB",
      "target": "3 most dorsomedial zones of the shell",
      "label": "occurred_in"
    },
    {
      "source": "changes in CREB phosphorylation",
      "target": "NAc",
      "label": "occurs_in"
    },
    {
      "source": "changes in CREB phosphorylation",
      "target": "subsequent challenge injection",
      "label": "occurs_after"
    },
    {
      "source": "changes in CREB phosphorylation",
      "target": "short drug-free period",
      "label": "occurs_after"
    },
    {
      "source": "changes in CREB phosphorylation",
      "target": "5 days of cocaine",
      "label": "occurs_after"
    },
    {
      "source": "changes in CREB phosphorylation",
      "target": "long drug-free period",
      "label": "occurs_after"
    },
    {
      "source": "subsequent challenge injection",
      "target": "challenge injection",
      "label": "is_a_type_of"
    },
    {
      "source": "cocaine-induced CREB activity",
      "target": "CREB activity",
      "label": "is_a_type_of"
    },
    {
      "source": "authors",
      "target": "immunohistochemistry",
      "label": "used"
    },
    {
      "source": "authors",
      "target": "changes in CREB phosphorylation",
      "label": "analyzed"
    },
    {
      "source": "authors",
      "target": "effects",
      "label": "compared"
    },
    {
      "source": "authors",
      "target": "study",
      "label": "conducted"
    },
    {
      "source": "authors",
      "target": "reductive transformation products",
      "label": "quantified"
    },
    {
      "source": "authors",
      "target": "RDX",
      "label": "quantified"
    },
    {
      "source": "immunohistochemistry",
      "target": "H3R",
      "label": "evaluates"
    },
    {
      "source": "immunohistochemistry",
      "target": "INSL3 protein",
      "label": "confirmed expression of"
    },
    {
      "source": "nucleus accumbens (NAc)",
      "target": "NAc",
      "label": "is_also_known_as"
    },
    {
      "source": "CREB-dependent gene transcription",
      "target": "withdrawal",
      "label": "varies_by"
    },
    {
      "source": "CREB-dependent gene transcription",
      "target": "long-lasting drug-induced changes",
      "label": "underlies"
    },
    {
      "source": "CREB-dependent gene transcription",
      "target": "stage of drug exposure",
      "label": "varies_by"
    },
    {
      "source": "CREB-dependent gene transcription",
      "target": "cell population",
      "label": "varies_by"
    },
    {
      "source": "present study",
      "target": "rats",
      "label": "conducted_in"
    },
    {
      "source": "present study",
      "target": "cocaine-induced activation",
      "label": "examined"
    },
    {
      "source": "present study",
      "target": "effects",
      "label": "assessed"
    },
    {
      "source": "present study",
      "target": "statistical model",
      "label": "used"
    },
    {
      "source": "present study",
      "target": "dose-dependent correlation",
      "label": "revealed"
    },
    {
      "source": "present study",
      "target": "optimization",
      "label": "goal is"
    },
    {
      "source": "present study",
      "target": "radioprotective effect",
      "label": "designed to determine"
    },
    {
      "source": "present study",
      "target": "EM-1 analogues",
      "label": "describes"
    },
    {
      "source": "present study",
      "target": "molecular mechanisms",
      "label": "investigated"
    },
    {
      "source": "present study",
      "target": "SB",
      "label": "introduced"
    },
    {
      "source": "present study",
      "target": "cell cycle-targeting activity",
      "label": "presented evidence for"
    },
    {
      "source": "cAMP response element binding protein",
      "target": "nucleus accumbens subregions",
      "label": "is activated in"
    },
    {
      "source": "cAMP response element binding protein",
      "target": "CREB",
      "label": "is also known as"
    },
    {
      "source": "long-lasting drug-induced changes",
      "target": "behavior",
      "label": "affect"
    },
    {
      "source": "long-lasting drug-induced changes",
      "target": "subjective effects of cocaine",
      "label": "affect"
    },
    {
      "source": "5 zones of analysis",
      "target": "neurochemistry",
      "label": "defined_by"
    },
    {
      "source": "5 zones of analysis",
      "target": "connectivity",
      "label": "defined_by"
    },
    {
      "source": "5 zones of analysis",
      "target": "zones of analysis",
      "label": "is_a_type_of"
    },
    {
      "source": "temporal determinants",
      "target": "functional differences",
      "label": "indicate"
    },
    {
      "source": "temporal determinants",
      "target": "cocaine-induced CREB activity",
      "label": "are_of"
    },
    {
      "source": "temporal determinants",
      "target": "CREB",
      "label": "suggest_involvement_of"
    },
    {
      "source": "CREB phosphorylation",
      "target": "analyzed subregions of the NAc",
      "label": "occurred_in"
    },
    {
      "source": "CREB phosphorylation",
      "target": "cessation of repeated cocaine",
      "label": "occurred_after"
    },
    {
      "source": "CREB phosphorylation",
      "target": "most ventrolateral region of the shell",
      "label": "excluded"
    },
    {
      "source": "analyzed subregions of the NAc",
      "target": "subregions of the NAc",
      "label": "is_a_type_of"
    },
    {
      "source": "cyclic adenosine monophosphate (cAMP) response element binding protein (CREB)",
      "target": "cAMP",
      "label": "contains"
    },
    {
      "source": "cyclic adenosine monophosphate (cAMP) response element binding protein (CREB)",
      "target": "cyclic adenosine monophosphate",
      "label": "contains"
    },
    {
      "source": "cyclic adenosine monophosphate (cAMP) response element binding protein (CREB)",
      "target": "CREB",
      "label": "is_also_known_as"
    },
    {
      "source": "short drug-free period",
      "target": "drug-free period",
      "label": "is_a_type_of"
    },
    {
      "source": "CREB",
      "target": "late cocaine effects",
      "label": "involved_in"
    },
    {
      "source": "CREB",
      "target": "early cocaine effects",
      "label": "involved_in"
    },
    {
      "source": "CREB",
      "target": "prefrontal cortex",
      "label": "located in"
    },
    {
      "source": "CREB",
      "target": "neuroplastic changes",
      "label": "involved in"
    },
    {
      "source": "CREB",
      "target": "transcription factor",
      "label": "is a type of"
    },
    {
      "source": "CREB",
      "target": "hippocampus",
      "label": "located in"
    },
    {
      "source": "CREB",
      "target": "mouse promoter region",
      "label": "has_role_in"
    },
    {
      "source": "CREB",
      "target": "stress-sensing transcription factors",
      "label": "is a type of"
    },
    {
      "source": "CREB",
      "target": "antioxidant capacity",
      "label": "plays important role in"
    },
    {
      "source": "late cocaine effects",
      "target": "cocaine effects",
      "label": "is_a_type_of"
    },
    {
      "source": "cocaine sensitization",
      "target": "late cocaine sensitization",
      "label": "has_stage"
    },
    {
      "source": "cocaine sensitization",
      "target": "early cocaine sensitization",
      "label": "has_stage"
    },
    {
      "source": "cocaine sensitization",
      "target": "cAMP response element binding protein",
      "label": "involves"
    },
    {
      "source": "2 drug-free days",
      "target": "drug-free period",
      "label": "is_a_type_of"
    },
    {
      "source": "cyclic adenosine monophosphate",
      "target": "cAMP",
      "label": "is_also_known_as"
    },
    {
      "source": "3 most dorsomedial zones of the shell",
      "target": "dorsomedial zones of the shell",
      "label": "is_a_type_of"
    },
    {
      "source": "3 most dorsomedial zones of the shell",
      "target": "shell",
      "label": "is_a_type_of"
    },
    {
      "source": "discrete zones of analysis",
      "target": "nucleus accumbens (NAc)",
      "label": "is_part_of"
    },
    {
      "source": "cocaine-induced activation",
      "target": "cyclic adenosine monophosphate (cAMP) response element binding protein (CREB)",
      "label": "is_of"
    },
    {
      "source": "cocaine-induced activation",
      "target": "discrete zones of analysis",
      "label": "occurs_in"
    },
    {
      "source": "Repeated cocaine",
      "target": "CREB phosphorylation",
      "label": "resulted_in"
    },
    {
      "source": "early cocaine effects",
      "target": "cocaine effects",
      "label": "is_a_type_of"
    },
    {
      "source": "anatomical determinants",
      "target": "cocaine-induced CREB activity",
      "label": "are_of"
    },
    {
      "source": "anatomical determinants",
      "target": "CREB",
      "label": "suggest_involvement_of"
    },
    {
      "source": "anatomical determinants",
      "target": "functional differences",
      "label": "indicate"
    },
    {
      "source": "most ventrolateral region of the shell",
      "target": "shell",
      "label": "is_a_type_of"
    },
    {
      "source": "long drug-free period",
      "target": "drug-free period",
      "label": "is_a_type_of"
    },
    {
      "source": "Cr supplementation",
      "target": "GAMT deficiency",
      "label": "in"
    },
    {
      "source": "Cr supplementation",
      "target": "35 days",
      "label": "for"
    },
    {
      "source": "Cr supplementation",
      "target": "2 g.kg body wt-1.day-1 Cr",
      "label": "with"
    },
    {
      "source": "Cr",
      "target": "MR spectra",
      "label": "detectable in"
    },
    {
      "source": "MR spectra",
      "target": "mice",
      "label": "of"
    },
    {
      "source": "N-acetylasparate",
      "target": "thalamus/hippocampus",
      "label": "observed in"
    },
    {
      "source": "thalamus/hippocampus",
      "target": "mice",
      "label": "of"
    },
    {
      "source": "repeated MRS measurements",
      "target": "longitudinal Cr supplementation study",
      "label": "performed in"
    },
    {
      "source": "longitudinal Cr supplementation study",
      "target": "mice",
      "label": "on"
    },
    {
      "source": "Creatine",
      "target": "brain",
      "label": "uptake in"
    },
    {
      "source": "Creatine",
      "target": "skeletal muscle",
      "label": "uptake in"
    },
    {
      "source": "Creatine",
      "target": "magnetic resonance spectroscopy",
      "label": "assessed by"
    },
    {
      "source": "Cr deficiency",
      "target": "guanidinoacetate methyltransferase",
      "label": "caused by"
    },
    {
      "source": "Cr deficiency",
      "target": "GAMT-/-",
      "label": "caused by"
    },
    {
      "source": "Cr levels",
      "target": "brain",
      "label": "in"
    },
    {
      "source": "Cr levels",
      "target": "Cr supplementation",
      "label": "studied after"
    },
    {
      "source": "Cr levels",
      "target": "35 days",
      "label": "higher after"
    },
    {
      "source": "Cr levels",
      "target": "Con mice",
      "label": "higher compared with"
    },
    {
      "source": "Cr levels",
      "target": "0.8 mM/day",
      "label": "increased by"
    },
    {
      "source": "Cr levels",
      "target": "locations",
      "label": "increased in"
    },
    {
      "source": "Cr levels",
      "target": "skeletal muscle",
      "label": "in"
    },
    {
      "source": "MRS",
      "target": "hind leg muscle",
      "label": "performed in"
    },
    {
      "source": "MRS",
      "target": "brain",
      "label": "performed in"
    },
    {
      "source": "MRS",
      "target": "cerebellum",
      "label": "performed in"
    },
    {
      "source": "MRS",
      "target": "thalamus/hippocampus",
      "label": "performed in"
    },
    {
      "source": "MRS",
      "target": "control mice",
      "label": "performed in"
    },
    {
      "source": "MRS",
      "target": "Con mice",
      "label": "performed in"
    },
    {
      "source": "hind leg muscle",
      "target": "mice",
      "label": "of"
    },
    {
      "source": "brain Cr",
      "target": "Cr supplementation",
      "label": "after"
    },
    {
      "source": "brain Cr",
      "target": "patients",
      "label": "are slow in"
    },
    {
      "source": "Localized 1H magnetic resonance spectroscopy",
      "target": "hind leg muscle",
      "label": "performed in"
    },
    {
      "source": "Localized 1H magnetic resonance spectroscopy",
      "target": "brain",
      "label": "performed in"
    },
    {
      "source": "Localized 1H magnetic resonance spectroscopy",
      "target": "cerebellum",
      "label": "performed in"
    },
    {
      "source": "Localized 1H magnetic resonance spectroscopy",
      "target": "thalamus/hippocampus",
      "label": "performed in"
    },
    {
      "source": "muscular Cr uptake",
      "target": "Cr transporter expression",
      "label": "independent of"
    },
    {
      "source": "GAMT-/-",
      "target": "Cr supplementation",
      "label": "before"
    },
    {
      "source": "Cr administration",
      "target": "first day of supplementation",
      "label": "during"
    },
    {
      "source": "Con mice",
      "target": "Cr-free diet",
      "label": "on"
    },
    {
      "source": "uptake of Cr",
      "target": "skeletal muscle",
      "label": "in"
    },
    {
      "source": "uptake of Cr",
      "target": "brain",
      "label": "compared with"
    },
    {
      "source": "NAA",
      "target": "thalamus/hippocampus",
      "label": "observed in"
    },
    {
      "source": "FAD",
      "target": "Thermus thermophilus PRODH",
      "label": "is of"
    },
    {
      "source": "FAD",
      "target": "helix 8",
      "label": "solvent-exposed due to shift of"
    },
    {
      "source": "FAD",
      "target": "PutA",
      "label": "compared with"
    },
    {
      "source": "Thermus thermophilus PRODH",
      "target": "O(2)",
      "label": "reacts with"
    },
    {
      "source": "Thermus thermophilus PRODH",
      "target": "distorted (betaalpha)(8) barrel catalytic core domain",
      "label": "has"
    },
    {
      "source": "Thermus thermophilus PRODH",
      "target": "hydrophobic alpha-helical domain",
      "label": "has"
    },
    {
      "source": "Thermus thermophilus PRODH",
      "target": "superoxide",
      "label": "produces"
    },
    {
      "source": "3,4-Dehydro-l-proline",
      "target": "substrate",
      "label": "is a type of"
    },
    {
      "source": "FAD conformation",
      "target": "communication",
      "label": "reflects requirements for"
    },
    {
      "source": "FAD conformation",
      "target": "Thermus thermophilus PRODH",
      "label": "is of"
    },
    {
      "source": "FAD conformation",
      "target": "membrane association",
      "label": "reflects requirements for"
    },
    {
      "source": "communication",
      "target": "P5CDH",
      "label": "with"
    },
    {
      "source": "Structure-based sequence analysis",
      "target": "conserved motifs",
      "label": "identified"
    },
    {
      "source": "Structure-based sequence analysis",
      "target": "PutA/PRODH family",
      "label": "is of"
    },
    {
      "source": "conserved motifs",
      "target": "substrate recognition",
      "label": "involved in"
    },
    {
      "source": "conserved motifs",
      "target": "cofactor",
      "label": "involved in"
    },
    {
      "source": "bifunctional enzymes",
      "target": "PutA",
      "label": "known as"
    },
    {
      "source": "bifunctional enzymes",
      "target": "proline utilization A",
      "label": "known as"
    },
    {
      "source": "catalytic core",
      "target": "PutA PRODH domain",
      "label": "is similar to"
    },
    {
      "source": "PRODH",
      "target": "bifunctional enzymes",
      "label": "can be fused into"
    },
    {
      "source": "PRODH",
      "target": "glutamate",
      "label": "produces"
    },
    {
      "source": "PRODH",
      "target": "proline",
      "label": "catalyzes oxidation of"
    },
    {
      "source": "PRODH",
      "target": "monofunctional enzymes",
      "label": "is a type of"
    },
    {
      "source": "l-tetrahydro-2-furoic acid",
      "target": "competitive inhibitor",
      "label": "is a type of"
    },
    {
      "source": "competitive inhibitor",
      "target": "K(I)",
      "label": "has"
    },
    {
      "source": "Proline dehydrogenase",
      "target": "monofunctional enzymes",
      "label": "is a type of"
    },
    {
      "source": "Proline dehydrogenase",
      "target": "bifunctional enzymes",
      "label": "can be fused into"
    },
    {
      "source": "Proline dehydrogenase",
      "target": "glutamate",
      "label": "produces"
    },
    {
      "source": "Proline dehydrogenase",
      "target": "proline",
      "label": "catalyzes oxidation of"
    },
    {
      "source": "monofunctional enzymes",
      "target": "eukaryotes",
      "label": "found in"
    },
    {
      "source": "monofunctional enzymes",
      "target": "bacteria",
      "label": "found in"
    },
    {
      "source": "P5CDH",
      "target": "bifunctional enzymes",
      "label": "can be fused into"
    },
    {
      "source": "P5CDH",
      "target": "monofunctional enzymes",
      "label": "is a type of"
    },
    {
      "source": "P5CDH",
      "target": "glutamate",
      "label": "produces"
    },
    {
      "source": "P5CDH",
      "target": "proline",
      "label": "catalyzes oxidation of"
    },
    {
      "source": "strands",
      "target": "barrel",
      "label": "are part of"
    },
    {
      "source": "Delta(1)-pyrroline-5-carboxylate dehydrogenase",
      "target": "monofunctional enzymes",
      "label": "is a type of"
    },
    {
      "source": "Delta(1)-pyrroline-5-carboxylate dehydrogenase",
      "target": "bifunctional enzymes",
      "label": "can be fused into"
    },
    {
      "source": "Delta(1)-pyrroline-5-carboxylate dehydrogenase",
      "target": "glutamate",
      "label": "produces"
    },
    {
      "source": "Delta(1)-pyrroline-5-carboxylate dehydrogenase",
      "target": "proline",
      "label": "catalyzes oxidation of"
    },
    {
      "source": "midpoint potential",
      "target": "FAD",
      "label": "is of"
    },
    {
      "source": "kinetic parameters",
      "target": "k(cat)",
      "label": "include"
    },
    {
      "source": "kinetic parameters",
      "target": "proline",
      "label": "are for"
    },
    {
      "source": "kinetic parameters",
      "target": "K(m)",
      "label": "include"
    },
    {
      "source": "kinetic parameters",
      "target": "inhibition constants K(i)",
      "label": "includes"
    },
    {
      "source": "kinetic parameters",
      "target": "inhibitory action mechanism",
      "label": "includes"
    },
    {
      "source": "kinetic parameters",
      "target": "IC(50)",
      "label": "includes"
    },
    {
      "source": "monofunctional proline dehydrogenase",
      "target": "structure",
      "label": "has"
    },
    {
      "source": "monofunctional proline dehydrogenase",
      "target": "biochemical data",
      "label": "has"
    },
    {
      "source": "monofunctional proline dehydrogenase",
      "target": "Thermus thermophilus",
      "label": "is from"
    },
    {
      "source": "hydrophobic alpha-helical domain",
      "target": "carboxyl-terminal ends",
      "label": "located above"
    },
    {
      "source": "superoxide production",
      "target": "human PRODH",
      "label": "underlies role of"
    },
    {
      "source": "human PRODH",
      "target": "p53-mediated apoptosis",
      "label": "involved in"
    },
    {
      "source": "carboxyl-terminal ends",
      "target": "strands",
      "label": "are part of"
    },
    {
      "source": "p53-mediated apoptosis",
      "target": "p53",
      "label": "mediated by"
    },
    {
      "source": "Biochemical studies",
      "target": "midpoint potential",
      "label": "show"
    },
    {
      "source": "2.0-A resolution structure",
      "target": "Thermus thermophilus PRODH",
      "label": "is of"
    },
    {
      "source": "eukaryotic and bacterial monofunctional PRODHs",
      "target": "human PRODH",
      "label": "has commonalities with"
    },
    {
      "source": "AS expression",
      "target": "arginine-dependent processes",
      "label": "is required for"
    },
    {
      "source": "AS expression",
      "target": "molecular pathway",
      "label": "provides"
    },
    {
      "source": "AS expression",
      "target": "TNF-alpha",
      "label": "is regulated by"
    },
    {
      "source": "arginine-dependent processes",
      "target": "pyrimidines",
      "label": "include"
    },
    {
      "source": "arginine-dependent processes",
      "target": "proline",
      "label": "include"
    },
    {
      "source": "arginine-dependent processes",
      "target": "polyamines",
      "label": "include"
    },
    {
      "source": "arginine-dependent processes",
      "target": "nitric oxide",
      "label": "include"
    },
    {
      "source": "arginine-dependent processes",
      "target": "cancer",
      "label": "occur in"
    },
    {
      "source": "TNF-alpha mRNA",
      "target": "normal corresponding tissues",
      "label": "has increased co-expression compared with"
    },
    {
      "source": "TNF-alpha mRNA",
      "target": "stomach cancer",
      "label": "has increased co-expression in"
    },
    {
      "source": "TNF-alpha mRNA",
      "target": "non-small cell lung",
      "label": "has increased co-expression in"
    },
    {
      "source": "TNF-alpha mRNA",
      "target": "epithelial tumours",
      "label": "has increased co-expression in"
    },
    {
      "source": "TNF-alpha",
      "target": "angiogenesis",
      "label": "modulates"
    },
    {
      "source": "TNF-alpha",
      "target": "metastasis",
      "label": "modulates"
    },
    {
      "source": "TNF-alpha",
      "target": "normal ovarian surface epithelium (OSE)",
      "label": "is dysregulated compared with"
    },
    {
      "source": "TNF-alpha",
      "target": "malignant OSE cells",
      "label": "is dysregulated in"
    },
    {
      "source": "TNF-alpha",
      "target": "argininosuccinate synthetase",
      "label": "induces expression of"
    },
    {
      "source": "TNF-alpha",
      "target": "AS mRNA",
      "label": "induces"
    },
    {
      "source": "TNF-alpha",
      "target": "pro-inflammatory cytokine",
      "label": "is a type of"
    },
    {
      "source": "TNF-alpha",
      "target": "invasion",
      "label": "modulates"
    },
    {
      "source": "AS mRNA",
      "target": "malignant OSE cells",
      "label": "is differentially regulated in"
    },
    {
      "source": "AS mRNA",
      "target": "IGROV-1 ovarian cancer cells",
      "label": "is induced in"
    },
    {
      "source": "AS mRNA",
      "target": "stomach cancer",
      "label": "has increased co-expression in"
    },
    {
      "source": "AS mRNA",
      "target": "normal OSE cells",
      "label": "is differentially regulated compared with"
    },
    {
      "source": "AS mRNA",
      "target": "non-small cell lung",
      "label": "has increased co-expression in"
    },
    {
      "source": "AS mRNA",
      "target": "ovarian tumour samples",
      "label": "has increased expression in"
    },
    {
      "source": "AS mRNA",
      "target": "epithelial tumours",
      "label": "has increased co-expression in"
    },
    {
      "source": "AS mRNA",
      "target": "TNF-alpha mRNA",
      "label": "co-expressed with"
    },
    {
      "source": "AS mRNA",
      "target": "matched normal ovarian",
      "label": "has increased expression compared with"
    },
    {
      "source": "AS mRNA",
      "target": "normal corresponding tissues",
      "label": "has increased co-expression compared with"
    },
    {
      "source": "argininosuccinate synthetase",
      "target": "arginine synthesis",
      "label": "is involved in"
    },
    {
      "source": "argininosuccinate synthetase",
      "target": "rate-limiting enzyme",
      "label": "is a type of"
    },
    {
      "source": "arginine-dependent metabolic pathways",
      "target": "tumour progression",
      "label": "are implicated in"
    },
    {
      "source": "arginine-dependent metabolic pathways",
      "target": "accelerated carcinogenesis",
      "label": "are implicated in"
    },
    {
      "source": "inflammation",
      "target": "ovarian tumorigenesis",
      "label": "associated with"
    },
    {
      "source": "inflammation",
      "target": "arginine-dependent metabolic pathways",
      "label": "is linked with"
    },
    {
      "source": "AS protein",
      "target": "ovarian cancer cells",
      "label": "co-localised in"
    },
    {
      "source": "AS protein",
      "target": "malignant OSE cells",
      "label": "has higher levels in"
    },
    {
      "source": "AS protein",
      "target": "normal ovarian tissue",
      "label": "has higher levels compared with"
    },
    {
      "source": "AS protein",
      "target": "TNF-alpha",
      "label": "co-localised with"
    },
    {
      "source": "molecular pathway",
      "target": "ovarian tumorigenesis",
      "label": "links to"
    },
    {
      "source": "molecular pathway",
      "target": "metabolism",
      "label": "links"
    },
    {
      "source": "molecular pathway",
      "target": "inflammation",
      "label": "links"
    },
    {
      "source": "epidemiological studies",
      "target": "inflammation",
      "label": "associated"
    },
    {
      "source": "cDNA cancer profiling array",
      "target": "AS mRNA",
      "label": "revealed increased expression of"
    },
    {
      "source": "tumour necrosis factor-alpha",
      "target": "TNF-alpha",
      "label": "is also known as"
    },
    {
      "source": "tumour necrosis factor-alpha",
      "target": "pro-inflammatory cytokine",
      "label": "is a type of"
    },
    {
      "source": "DLDH",
      "target": "EC 1.8.1.4",
      "label": "is also known as"
    },
    {
      "source": "DLDH",
      "target": "oxidation",
      "label": "catalyzes"
    },
    {
      "source": "DLDH",
      "target": "diaphorase",
      "label": "acts as"
    },
    {
      "source": "levels of DLDH diaphorase activity",
      "target": "rat tissues",
      "label": "found in"
    },
    {
      "source": "rat tissues",
      "target": "brain",
      "label": "include"
    },
    {
      "source": "Mammalian mitochondrial dihydrolipoamide dehydrogenase",
      "target": "oxidation",
      "label": "catalyzes"
    },
    {
      "source": "Mammalian mitochondrial dihydrolipoamide dehydrogenase",
      "target": "diaphorase",
      "label": "acts as"
    },
    {
      "source": "Mammalian mitochondrial dihydrolipoamide dehydrogenase",
      "target": "DLDH",
      "label": "is also known as"
    },
    {
      "source": "nitroblue tetrazolium",
      "target": "NBT",
      "label": "is also known as"
    },
    {
      "source": "NBT",
      "target": "electron acceptor",
      "label": "is"
    },
    {
      "source": "mass spectral techniques",
      "target": "DLDH post-translational modifications",
      "label": "used for studying"
    },
    {
      "source": "mitochondrial DLDH",
      "target": "mass spectral techniques",
      "label": "analyzed by"
    },
    {
      "source": "gel-based method",
      "target": "levels of DLDH diaphorase activity",
      "label": "determines"
    },
    {
      "source": "gel-based method",
      "target": "dihydrolipoamide dehydrogenase diaphorase activity",
      "label": "determines"
    },
    {
      "source": "gel-based method",
      "target": "mitochondrial DLDH",
      "label": "isolates"
    },
    {
      "source": "gel-based method",
      "target": "quantification",
      "label": "is for"
    },
    {
      "source": "gel-based method",
      "target": "Histochemical staining",
      "label": "is for"
    },
    {
      "source": "gel-based method",
      "target": "blue native PAGE",
      "label": "uses"
    },
    {
      "source": "in-gel activity-staining method",
      "target": "conventional spectrophotometric method",
      "label": "is in agreement with"
    },
    {
      "source": "conventional spectrophotometric method",
      "target": "dihydrolipoamide",
      "label": "uses"
    },
    {
      "source": "conventional spectrophotometric method",
      "target": "DLDH dehydrogenase activity",
      "label": "measures"
    },
    {
      "source": "quantification",
      "target": "dihydrolipoamide dehydrogenase diaphorase activity",
      "label": "measures"
    },
    {
      "source": "quantification",
      "target": "blue native PAGE",
      "label": "uses"
    },
    {
      "source": "quantification",
      "target": "signals",
      "label": "of"
    },
    {
      "source": "quantification",
      "target": "phenolic compounds",
      "label": "of"
    },
    {
      "source": "diaphorase",
      "target": "reduction",
      "label": "catalyzes"
    },
    {
      "source": "dihydrolipoamide",
      "target": "substrate",
      "label": "is"
    },
    {
      "source": "Rat brain mitochondrial extracts",
      "target": "source of DLDH",
      "label": "is"
    },
    {
      "source": "Rat brain mitochondrial extracts",
      "target": "nongradient BN-PAGE (9%)",
      "label": "resolved by"
    },
    {
      "source": "activity staining of DLDH diaphorase",
      "target": "protein amount",
      "label": "is dependent on"
    },
    {
      "source": "activity staining of DLDH diaphorase",
      "target": "time",
      "label": "is dependent on"
    },
    {
      "source": "electron-accepting molecules",
      "target": "ubiquinone",
      "label": "include"
    },
    {
      "source": "electron-accepting molecules",
      "target": "nitroblue tetrazolium",
      "label": "include"
    },
    {
      "source": "nicotinamide adenine dinucleotide (reduced form)",
      "target": "NADH",
      "label": "is also known as"
    },
    {
      "source": "DLDH dehydrogenase activity",
      "target": "substrate",
      "label": "has"
    },
    {
      "source": "Histochemical staining",
      "target": "blue native PAGE",
      "label": "uses"
    },
    {
      "source": "Histochemical staining",
      "target": "dihydrolipoamide dehydrogenase diaphorase activity",
      "label": "measures"
    },
    {
      "source": "effects of thiol-reactive reagents",
      "target": "dihydrolipoamide dehydrogenase diaphorase activity",
      "label": "on"
    },
    {
      "source": "diaphorase activity staining",
      "target": "NADH",
      "label": "uses"
    },
    {
      "source": "diaphorase activity staining",
      "target": "NBT",
      "label": "uses"
    },
    {
      "source": "nongradient BN-PAGE (9%)",
      "target": "diaphorase activity staining",
      "label": "followed by"
    },
    {
      "source": "cPLA2alpha C2 domain",
      "target": "physiological Ca2+ levels",
      "label": "is affected by"
    },
    {
      "source": "cPLA2alpha C2 domain",
      "target": "membrane targeting",
      "label": "is involved in"
    },
    {
      "source": "cPLA2alpha C2 domain",
      "target": "internal membranes",
      "label": "is targeted to"
    },
    {
      "source": "C2 domains",
      "target": "Ca2+ binding",
      "label": "are activated by"
    },
    {
      "source": "C2 domains",
      "target": "membrane targeting",
      "label": "are involved in"
    },
    {
      "source": "C2 domains",
      "target": "cellular membrane",
      "label": "dock to"
    },
    {
      "source": "C2 domains",
      "target": "functional diversity",
      "label": "exhibit"
    },
    {
      "source": "C2 domains",
      "target": "membrane surfaces",
      "label": "dock to"
    },
    {
      "source": "C2 domains",
      "target": "TAMA mechanism",
      "label": "utilize"
    },
    {
      "source": "PKCalpha",
      "target": "C2 domains",
      "label": "has"
    },
    {
      "source": "regions of the cell",
      "target": "cell",
      "label": "are part of"
    },
    {
      "source": "cPLA2alpha",
      "target": "C2 domains",
      "label": "has"
    },
    {
      "source": "lipid mixture",
      "target": "plasma membrane inner leaflet",
      "label": "mimics"
    },
    {
      "source": "membrane targeting",
      "target": "internal membrane mimic",
      "label": "occurs to"
    },
    {
      "source": "phosphatidylinositol-4,5-bisphosphate",
      "target": "target lipids",
      "label": "is a type of"
    },
    {
      "source": "target lipids",
      "target": "PKCalpha C2 domain",
      "label": "recruit"
    },
    {
      "source": "C2 domain-directed intracellular targeting",
      "target": "coincidence detection",
      "label": "requires"
    },
    {
      "source": "C2 domain-directed intracellular targeting",
      "target": "MATA",
      "label": "can exhibit"
    },
    {
      "source": "C2 domain-directed intracellular targeting",
      "target": "TAMA",
      "label": "can exhibit"
    },
    {
      "source": "coincidence detection",
      "target": "multiple signals",
      "label": "involves"
    },
    {
      "source": "effective Ca2+ affinity",
      "target": "coupled binding equilibrium",
      "label": "is increased by"
    },
    {
      "source": "coupled binding equilibrium",
      "target": "target docking",
      "label": "enables"
    },
    {
      "source": "coupled binding equilibrium",
      "target": "Ca2+ activation",
      "label": "enables"
    },
    {
      "source": "MATA",
      "target": "messenger-activated target affinity",
      "label": "is a type of"
    },
    {
      "source": "isolated PKCalpha C2 domain",
      "target": "physiological Ca2+ levels",
      "label": "is in the presence of"
    },
    {
      "source": "physiological ligand concentrations",
      "target": "targeting studies",
      "label": "are used in"
    },
    {
      "source": "Ca2+ activation",
      "target": "PKCalpha C2 domain",
      "label": "targets"
    },
    {
      "source": "Ca2+ activation",
      "target": "cPLA2alpha C2 domain",
      "label": "targets"
    },
    {
      "source": "PKCalpha C2 domain",
      "target": "lipid mixture",
      "label": "is recruited to"
    },
    {
      "source": "PKCalpha C2 domain",
      "target": "plasma membrane",
      "label": "is targeted to"
    },
    {
      "source": "localized pools",
      "target": "Ca2+ affinity",
      "label": "enhance"
    },
    {
      "source": "PS",
      "target": "target lipids",
      "label": "is a type of"
    },
    {
      "source": "target membrane",
      "target": "local concentration",
      "label": "provides"
    },
    {
      "source": "local concentration",
      "target": "target lipids",
      "label": "is of"
    },
    {
      "source": "protein kinase Calpha",
      "target": "C2 domains",
      "label": "has"
    },
    {
      "source": "PIP2",
      "target": "target lipids",
      "label": "is a type of"
    },
    {
      "source": "super-physiological concentrations",
      "target": "docking interactions",
      "label": "can drive"
    },
    {
      "source": "targeting specificity",
      "target": "physiological bulk Ca2+ concentrations",
      "label": "is achieved at"
    },
    {
      "source": "physiological bulk Ca2+ concentrations",
      "target": "signaling event",
      "label": "occur during"
    },
    {
      "source": "C2 domain",
      "target": "protein signaling motif",
      "label": "is a"
    },
    {
      "source": "C2 domain",
      "target": "target membrane",
      "label": "nears"
    },
    {
      "source": "protein signaling motif",
      "target": "eukaryotic signaling proteins",
      "label": "found in"
    },
    {
      "source": "Stopped-flow kinetic studies",
      "target": "molecular events",
      "label": "provide information about"
    },
    {
      "source": "molecular events",
      "target": "Ca2+-activated membrane docking",
      "label": "occur during"
    },
    {
      "source": "TAMA",
      "target": "target-activated messenger affinity",
      "label": "is a type of"
    },
    {
      "source": "Ca2+-activated membrane docking",
      "target": "membrane docking",
      "label": "is a type of"
    },
    {
      "source": "physiological Ca2+ signals",
      "target": "regions of the cell",
      "label": "occur in"
    },
    {
      "source": "plasma membrane",
      "target": "gastrocnemius muscle",
      "label": "PartOf"
    },
    {
      "source": "multiple signals",
      "target": "Ca2+",
      "label": "include"
    },
    {
      "source": "multiple signals",
      "target": "target lipids",
      "label": "include"
    },
    {
      "source": "cytosolic phospholipase A2alpha",
      "target": "C2 domains",
      "label": "has"
    },
    {
      "source": "C2 domain Ca2+ affinity",
      "target": "physiological Ca2+ signals",
      "label": "is too low to be activated by"
    },
    {
      "source": "Total BAT activity",
      "target": "Liver subcellular organelles",
      "label": "located in"
    },
    {
      "source": "Total BAT activity",
      "target": "Cytosol",
      "label": "found in"
    },
    {
      "source": "Total BAT activity",
      "target": "Peroxisomes",
      "label": "found in"
    },
    {
      "source": "Total BAT activity",
      "target": "Heavy mitochondrial fraction",
      "label": "found in"
    },
    {
      "source": "Clofibrate treatment",
      "target": "Subcellular localization",
      "label": "alters"
    },
    {
      "source": "Clofibrate treatment",
      "target": "Male rats",
      "label": "affected"
    },
    {
      "source": "Clofibrate treatment",
      "target": "BAT activity",
      "label": "does not regulate"
    },
    {
      "source": "Clofibrate treatment",
      "target": "Female rats",
      "label": "affected"
    },
    {
      "source": "Subcellular localization",
      "target": "BAT",
      "label": "of"
    },
    {
      "source": "Subcellular distribution",
      "target": "Bile acid coenzyme A:amino acid N-acyltransferase activity",
      "label": "of"
    },
    {
      "source": "Bile acid coenzyme A:amino acid N-acyltransferase activity",
      "target": "Rat liver",
      "label": "occurs in"
    },
    {
      "source": "Livers",
      "target": "Subcellular compartments",
      "label": "fractionated into"
    },
    {
      "source": "Livers",
      "target": "Young adult female Sprague-Dawley rats",
      "label": "from"
    },
    {
      "source": "Livers",
      "target": "Young adult male Sprague-Dawley rats",
      "label": "from"
    },
    {
      "source": "BAT",
      "target": "Amidation",
      "label": "catalyzes"
    },
    {
      "source": "Effect",
      "target": "BAT activity",
      "label": "on"
    },
    {
      "source": "BAT activity",
      "target": "Cytosol",
      "label": "resides in"
    },
    {
      "source": "BAT activity",
      "target": "Subcellular compartments",
      "label": "located in"
    },
    {
      "source": "BAT activity",
      "target": "Rat liver",
      "label": "in"
    },
    {
      "source": "BAT activity",
      "target": "Peroxisomal matrix",
      "label": "present in"
    },
    {
      "source": "BAT specific activity",
      "target": "Whole liver homogenate",
      "label": "in"
    },
    {
      "source": "Male rats",
      "target": "Peroxisomal BAT specific activity",
      "label": "increased"
    },
    {
      "source": "Male rats",
      "target": "Cytosolic BAT specific activity",
      "label": "decreased"
    },
    {
      "source": "Male rats",
      "target": "Response",
      "label": "showed"
    },
    {
      "source": "Quantification",
      "target": "Subcellular distribution",
      "label": "concerns"
    },
    {
      "source": "Quantification",
      "target": "Total BAT activity",
      "label": "of"
    },
    {
      "source": "Quantification",
      "target": "adaptive responses",
      "label": "may reveal"
    },
    {
      "source": "Rosiglitazone",
      "target": "Effect",
      "label": "had no"
    },
    {
      "source": "Overall change",
      "target": "BAT specific activity",
      "label": "not observed in"
    },
    {
      "source": "Female rats",
      "target": "Response",
      "label": "showed opposite"
    },
    {
      "source": "Female rats",
      "target": "Cytosolic BAT specific activity",
      "label": "increased"
    },
    {
      "source": "Female rats",
      "target": "Peroxisomal BAT specific activity",
      "label": "decreased"
    },
    {
      "source": "Female rats",
      "target": "TP-induced hepatotoxicity",
      "label": "were more sensitive to"
    },
    {
      "source": "Female rats",
      "target": "Males",
      "label": "were more sensitive than"
    },
    {
      "source": "Response",
      "target": "Clofibrate treatment",
      "label": "to"
    },
    {
      "source": "Amidation",
      "target": "Amino acids",
      "label": "uses"
    },
    {
      "source": "Amidation",
      "target": "Bile acids",
      "label": "of"
    },
    {
      "source": "Amino acids",
      "target": "Glycine",
      "label": "includes"
    },
    {
      "source": "Amino acids",
      "target": "Taurine",
      "label": "includes"
    },
    {
      "source": "Glycine",
      "target": "Vesicles",
      "label": "released from"
    },
    {
      "source": "Glycine",
      "target": "Inhibitory transmitters",
      "label": "is a type of"
    },
    {
      "source": "Glycine",
      "target": "VIAAT",
      "label": "is a substrate for"
    },
    {
      "source": "Glycine",
      "target": "Plasmalemmal transporters",
      "label": "is a substrate for"
    },
    {
      "source": "Glycine",
      "target": "GlyT1",
      "label": "is a substrate for"
    },
    {
      "source": "Glycine",
      "target": "Neurons",
      "label": "present in"
    },
    {
      "source": "Glycine",
      "target": "GlyT2",
      "label": "is a substrate for"
    },
    {
      "source": "Glycine",
      "target": "Vesicular inhibitory amino acid transporter",
      "label": "is a substrate for"
    },
    {
      "source": "Regulation",
      "target": "Subcellular distribution",
      "label": "concerns"
    },
    {
      "source": "Bile acid coenzyme A:amino acid N-acyltransferase",
      "target": "Amidation",
      "label": "catalyzes"
    },
    {
      "source": "Novel finding",
      "target": "Clofibrate treatment",
      "label": "states that"
    },
    {
      "source": "Cholestyramine",
      "target": "Effect",
      "label": "had no"
    },
    {
      "source": "MK-801",
      "target": "NMDA receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "MK-801",
      "target": "energy impairment",
      "label": "partially prevented"
    },
    {
      "source": "MK-801",
      "target": "cell viability",
      "label": "partially prevented decrease in"
    },
    {
      "source": "MK-801",
      "target": "NMDAR antagonist",
      "label": "is an"
    },
    {
      "source": "MK-801",
      "target": "long-term memory",
      "label": "disrupted"
    },
    {
      "source": "MK-801",
      "target": "motor performance",
      "label": "disrupted"
    },
    {
      "source": "MK-801",
      "target": "CFA-induced mechanical hypersensitivity",
      "label": "prevented development of"
    },
    {
      "source": "MK-801",
      "target": "side-effect profiles",
      "label": "causes"
    },
    {
      "source": "MK-801",
      "target": "attention",
      "label": "disrupted"
    },
    {
      "source": "MK-801",
      "target": "NMDA receptors",
      "label": "Antagonist"
    },
    {
      "source": "MK-801",
      "target": "amantadine induction of Fos",
      "label": "Downregulator"
    },
    {
      "source": "NMDA receptor",
      "target": "signal transduction pathway-related genes",
      "label": "has"
    },
    {
      "source": "NMDA receptor",
      "target": "excitotoxicity",
      "label": "mediates"
    },
    {
      "source": "Abeta(1-40) toxicity",
      "target": "plasma membrane integrity",
      "label": "causes loss of"
    },
    {
      "source": "NMDA receptors",
      "target": "NR1",
      "label": "composed of"
    },
    {
      "source": "NMDA receptors",
      "target": "NR2A-D subunits",
      "label": "composed of"
    },
    {
      "source": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate",
      "target": "NMDA receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate",
      "target": "energy impairment",
      "label": "partially prevented"
    },
    {
      "source": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate",
      "target": "cell viability",
      "label": "partially prevented decrease in"
    },
    {
      "source": "NR1/NR2A receptors",
      "target": "intracellular calcium",
      "label": "causes increase in"
    },
    {
      "source": "NR1/NR2A expression",
      "target": "Abeta(1-40) toxicity",
      "label": "increases"
    },
    {
      "source": "Abeta(1-40)",
      "target": "intracellular ATP",
      "label": "decreased"
    },
    {
      "source": "Abeta",
      "target": "Neurotoxicity",
      "label": "induces"
    },
    {
      "source": "Neurotoxicity",
      "target": "glutamate toxicity",
      "label": "involves"
    },
    {
      "source": "Neurotoxicity",
      "target": "Rats",
      "label": "occurs in"
    },
    {
      "source": "Neurotoxicity",
      "target": "Aluminium Chloride",
      "label": "is of"
    },
    {
      "source": "NMDA receptor subtypes",
      "target": "Abeta(1-40) toxicity",
      "label": "contributes to"
    },
    {
      "source": "beta-amyloid peptide",
      "target": "Neurotoxicity",
      "label": "induces"
    },
    {
      "source": "glutamate toxicity",
      "target": "NMDA receptors",
      "label": "results from overactivation of"
    },
    {
      "source": "glutamate toxicity",
      "target": "intracellular calcium",
      "label": "results from elevation of"
    },
    {
      "source": "glutamate toxicity",
      "target": "N-methyl-D-aspartate receptors",
      "label": "results from overactivation of"
    },
    {
      "source": "NR1/NR2A-composed NMDA receptors",
      "target": "HEK293 cells",
      "label": "mediate in"
    },
    {
      "source": "NR1/NR2A-composed NMDA receptors",
      "target": "calcium homeostasis",
      "label": "causes changes in"
    },
    {
      "source": "NR1/NR2A-composed NMDA receptors",
      "target": "necrotic cell death",
      "label": "mediate"
    },
    {
      "source": "single-cell calcium imaging",
      "target": "NR1/NR2B receptor subtypes",
      "label": "evidenced"
    },
    {
      "source": "single-cell calcium imaging",
      "target": "NR1/NR2A receptor subtypes",
      "label": "evidenced"
    },
    {
      "source": "beta-amyloid",
      "target": "HEK293 cells",
      "label": "causes toxicity in"
    },
    {
      "source": "NR1/NR2B receptors",
      "target": "intracellular calcium",
      "label": "causes opposite effects on"
    },
    {
      "source": "calpains",
      "target": "apoptosis",
      "label": "do not account for"
    },
    {
      "source": "caspases 2, 3, 8 and 9",
      "target": "apoptosis",
      "label": "do not account for"
    },
    {
      "source": "CYP2C9 variants",
      "target": "CYP2C9*3",
      "label": "include"
    },
    {
      "source": "CYP2C9 variants",
      "target": "CYP2C9*2",
      "label": "include"
    },
    {
      "source": "explanation",
      "target": "significant difference",
      "label": "is for"
    },
    {
      "source": "significant difference",
      "target": "warfarin S/R ratios",
      "label": "is in"
    },
    {
      "source": "significant difference",
      "target": "warfarin S/R ratio",
      "label": "is in"
    },
    {
      "source": "significant difference",
      "target": "CYP2C9 variants",
      "label": "did not originate from"
    },
    {
      "source": "significant difference",
      "target": "two patient groups",
      "label": "is between"
    },
    {
      "source": "significant difference",
      "target": "VKORC1*3 or VKORC1*4 patients",
      "label": "is between"
    },
    {
      "source": "significant difference",
      "target": "VKORC1*2",
      "label": "is between"
    },
    {
      "source": "significant difference",
      "target": "water activity",
      "label": "not observed in"
    },
    {
      "source": "significant difference",
      "target": "moisture content",
      "label": "not observed in"
    },
    {
      "source": "significant difference",
      "target": "CAG repeats",
      "label": "not observed in"
    },
    {
      "source": "significant difference",
      "target": "ACTH curves",
      "label": "between"
    },
    {
      "source": "significant difference",
      "target": "early phase",
      "label": "was in"
    },
    {
      "source": "low-dose VKORC1*2 haplotype",
      "target": "difficulties",
      "label": "is associated with"
    },
    {
      "source": "low-dose VKORC1*2 haplotype",
      "target": "genetic determinant",
      "label": "is"
    },
    {
      "source": "difficulties",
      "target": "stable therapeutic prothrombin time--International Normalized Ratio",
      "label": "to attain"
    },
    {
      "source": "warfarin S/R ratios",
      "target": "plasma",
      "label": "are in"
    },
    {
      "source": "warfarin S/R ratios",
      "target": "CYP2C9 variants",
      "label": "are related to"
    },
    {
      "source": "warfarin S/R ratios",
      "target": "other factors",
      "label": "are related to"
    },
    {
      "source": "patients previously haplotyped for VKORC1",
      "target": "plasma warfarin concentration",
      "label": "measured for"
    },
    {
      "source": "Dose-dependent variations",
      "target": "(R)-warfarin clearance",
      "label": "are in"
    },
    {
      "source": "Dose-dependent variations",
      "target": "(S)-warfarin clearance",
      "label": "are in"
    },
    {
      "source": "Dose-dependent variations",
      "target": "explanation",
      "label": "can be"
    },
    {
      "source": "VKORC1 haplotype",
      "target": "unidentified factors",
      "label": "are linked to"
    },
    {
      "source": "unidentified factors",
      "target": "metabolic clearance",
      "label": "are involved in"
    },
    {
      "source": "stable therapeutic prothrombin time--International Normalized Ratio",
      "target": "patients",
      "label": "is in"
    },
    {
      "source": "Samples",
      "target": "patients previously haplotyped for VKORC1",
      "label": "are from"
    },
    {
      "source": "Samples",
      "target": "CYP2C9 variants",
      "label": "were genotyped for"
    },
    {
      "source": "result",
      "target": "significant difference",
      "label": "shows"
    },
    {
      "source": "metabolic clearance",
      "target": "warfarin enantiomers",
      "label": "is of"
    },
    {
      "source": "genetic determinant",
      "target": "warfarin dose requirement",
      "label": "for"
    },
    {
      "source": "Nonparametric statistical analysis",
      "target": "significant difference",
      "label": "performed to elucidate"
    },
    {
      "source": "Plasma S/R ratio",
      "target": "VKORC1 haplotype",
      "label": "co-varies with"
    },
    {
      "source": "Plasma S/R ratio",
      "target": "warfarin",
      "label": "is of"
    },
    {
      "source": "acute lymphoblastic leukemia cells",
      "target": "asparagine depletion",
      "label": "are sensitive to"
    },
    {
      "source": "acute lymphoblastic leukemia cells",
      "target": "asparagine biosynthesis",
      "label": "have low"
    },
    {
      "source": "acute lymphoblastic leukemia cells",
      "target": "asparagine synthetase",
      "label": "have low expression of"
    },
    {
      "source": "acute lymphoblastic leukemia cells",
      "target": "ASNS",
      "label": "have low expression of"
    },
    {
      "source": "acute lymphoblastic leukemia cells",
      "target": "ASNS expression levels",
      "label": "have lower"
    },
    {
      "source": "acute lymphoblastic leukemia cells",
      "target": "asparaginase",
      "label": "are protected from"
    },
    {
      "source": "increased concentrations of asparagine",
      "target": "mechanism",
      "label": "is a"
    },
    {
      "source": "increased concentrations of asparagine",
      "target": "leukemic cell microenvironment",
      "label": "are in"
    },
    {
      "source": "increased concentrations of asparagine",
      "target": "protective effects",
      "label": "cause"
    },
    {
      "source": "asparaginase resistance",
      "target": "ALL",
      "label": "occurs in"
    },
    {
      "source": "children",
      "target": "ALL",
      "label": "have"
    },
    {
      "source": "children",
      "target": "no exposure to dental amalgams",
      "label": "had"
    },
    {
      "source": "children",
      "target": "dental amalgam fillings",
      "label": "had"
    },
    {
      "source": "children",
      "target": "secondary leukemia",
      "label": "developed"
    },
    {
      "source": "children",
      "target": "topoisomerase II inhibitors",
      "label": "received"
    },
    {
      "source": "MSCs",
      "target": "ASNS expression levels",
      "label": "have higher"
    },
    {
      "source": "MSCs",
      "target": "acute lymphoblastic leukemia cells",
      "label": "protected"
    },
    {
      "source": "MSCs",
      "target": "microenvironment",
      "label": "form"
    },
    {
      "source": "ASNS expression levels",
      "target": "bone marrow-derived mesenchymal cells",
      "label": "are found in"
    },
    {
      "source": "Mesenchymal cells",
      "target": "acute lymphoblastic leukemia cells",
      "label": "regulate response of"
    },
    {
      "source": "leukemic cell microenvironment",
      "target": "increased concentrations of asparagine",
      "label": "contains"
    },
    {
      "source": "Asparagine secretion",
      "target": "ASNS expression levels",
      "label": "is related to"
    },
    {
      "source": "Asparagine secretion",
      "target": "MSCs",
      "label": "is by"
    },
    {
      "source": "enforced ASNS expression",
      "target": "enhanced protection",
      "label": "conferred"
    },
    {
      "source": "protective effect",
      "target": "ASNS expression levels",
      "label": "correlated with"
    },
    {
      "source": "protective effect",
      "target": "radiation-induced endothelial cellular damage",
      "label": "against"
    },
    {
      "source": "protective effect",
      "target": "radiation-induced damage",
      "label": "against"
    },
    {
      "source": "protective effect",
      "target": "RGCs",
      "label": "on"
    },
    {
      "source": "protective effect",
      "target": "gastric damage",
      "label": "AGAINST"
    },
    {
      "source": "protective effect",
      "target": "gastric ulcer",
      "label": "AGAINST"
    },
    {
      "source": "B-lineage ALL",
      "target": "hyperdiploidy",
      "label": "is associated with"
    },
    {
      "source": "B-lineage ALL",
      "target": "TEL-AML1",
      "label": "is associated with"
    },
    {
      "source": "susceptibility",
      "target": "asparaginase",
      "label": "is to"
    },
    {
      "source": "susceptibility",
      "target": "leukemic cells",
      "label": "is of"
    },
    {
      "source": "cellular ASNS expression",
      "target": "B-lineage ALL",
      "label": "is low in"
    },
    {
      "source": "cellular ASNS expression",
      "target": "T-lineage ALL",
      "label": "is high in"
    },
    {
      "source": "leukemic cells",
      "target": "microenvironment",
      "label": "grow in"
    },
    {
      "source": "asparaginase cytotoxicity",
      "target": "MSCs",
      "label": "was mitigated by"
    },
    {
      "source": "asparaginase",
      "target": "ALL therapy",
      "label": "is a component of"
    },
    {
      "source": "MSC niches",
      "target": "bone marrow",
      "label": "are in"
    },
    {
      "source": "MSC niches",
      "target": "safe haven",
      "label": "form"
    },
    {
      "source": "safe haven",
      "target": "leukemic cells",
      "label": "is for"
    },
    {
      "source": "RNA interference",
      "target": "acute lymphoblastic leukemia cells",
      "label": "reduced protection of"
    },
    {
      "source": "RNA interference",
      "target": "MSCs",
      "label": "decreased capacity of"
    },
    {
      "source": "protective effects",
      "target": "cerebral injury",
      "label": "are on"
    },
    {
      "source": "protective effects",
      "target": "mRNA expressions",
      "label": "related to inhibiting"
    },
    {
      "source": "protective effects",
      "target": "PNS",
      "label": "are of"
    },
    {
      "source": "cysteine 360",
      "target": "covalent adducts",
      "label": "formed"
    },
    {
      "source": "cysteine 360",
      "target": "inhibitor",
      "label": "formed adducts with"
    },
    {
      "source": "cysteine 360",
      "target": "major adduct",
      "label": "is a type of"
    },
    {
      "source": "cysteine 360",
      "target": "sequence -WGPTCDGL(I)D-",
      "label": "is contained in"
    },
    {
      "source": "radioactive peptide mapping",
      "target": "reversed-phase high pressure liquid chromatography",
      "label": "uses"
    },
    {
      "source": "radioactive peptide mapping",
      "target": "gas-phase peptide sequencing",
      "label": "uses"
    },
    {
      "source": "lysine 69",
      "target": "mouse ODC",
      "label": "is part of"
    },
    {
      "source": "lysine 69",
      "target": "inhibitor",
      "label": "formed adducts with"
    },
    {
      "source": "lysine 69",
      "target": "mouse sequence",
      "label": "is part of"
    },
    {
      "source": "lysine 69",
      "target": "covalent adducts",
      "label": "formed"
    },
    {
      "source": "lysine 69",
      "target": "sequence PFYAVKC",
      "label": "is contained in"
    },
    {
      "source": "sequence PFYAVKC",
      "target": "eukaryotes",
      "label": "is found in"
    },
    {
      "source": "sequence PFYAVKC",
      "target": "ODCs",
      "label": "is found in"
    },
    {
      "source": "cyclic imine S-(2-(1-pyrroline)methyl)cysteine",
      "target": "S-((2-pyrrolidine)methyl)cysteine",
      "label": "converted to"
    },
    {
      "source": "cyclic imine S-(2-(1-pyrroline)methyl)cysteine",
      "target": "S-((2-pyrrole)methyl)cysteine",
      "label": "oxidized to"
    },
    {
      "source": "cyclic imine S-(2-(1-pyrroline)methyl)cysteine",
      "target": "spectral evidence",
      "label": "consistent with"
    },
    {
      "source": "S-((2-pyrrolidine)methyl)cysteine",
      "target": "NaBH4",
      "label": "formed by"
    },
    {
      "source": "mouse ornithine decarboxylase",
      "target": "Escherichia coli",
      "label": "expressed in"
    },
    {
      "source": "mouse ornithine decarboxylase",
      "target": "[5-14C]DFMO",
      "label": "labeled by"
    },
    {
      "source": "DFMO",
      "target": "enzyme",
      "label": "inactivates"
    },
    {
      "source": "DFMO",
      "target": "enzyme-activated irreversible inhibitor",
      "label": "is a type of"
    },
    {
      "source": "stable adduct",
      "target": "inhibitor",
      "label": "is between"
    },
    {
      "source": "stable adduct",
      "target": "pyridoxal 5'-phosphate",
      "label": "is between"
    },
    {
      "source": "stable adduct",
      "target": "enzyme",
      "label": "is between"
    },
    {
      "source": "recombinant enzyme",
      "target": "pyridoxal 5'-phosphate",
      "label": "has binding site for"
    },
    {
      "source": "consensus sequence of SXHK",
      "target": "lysine",
      "label": "contains"
    },
    {
      "source": "lysine",
      "target": "pyridoxal 5'-phosphate",
      "label": "binds"
    },
    {
      "source": "lysine",
      "target": "ODCs",
      "label": "is found in"
    },
    {
      "source": "lysine",
      "target": "E. coli",
      "label": "is found in"
    },
    {
      "source": "lysine",
      "target": "decarboxylases",
      "label": "is found in"
    },
    {
      "source": "major adduct",
      "target": "total labeling",
      "label": "accounts for"
    },
    {
      "source": "alpha-difluoromethylornithine",
      "target": "enzyme-activated irreversible inhibitor",
      "label": "is a type of"
    },
    {
      "source": "alpha-difluoromethylornithine",
      "target": "mouse ornithine decarboxylase",
      "label": "is an inhibitor of"
    },
    {
      "source": "alpha-difluoromethylornithine",
      "target": "enzyme",
      "label": "inactivates"
    },
    {
      "source": "peptides",
      "target": "catalytic site",
      "label": "form part of"
    },
    {
      "source": "sequence -WGPTCDGL(I)D-",
      "target": "eukaryote ODCs",
      "label": "is present in"
    },
    {
      "source": "DFMO-cysteine adduct",
      "target": "enzyme",
      "label": "formed in"
    },
    {
      "source": "DFMO-cysteine adduct",
      "target": "cyclic imine S-(2-(1-pyrroline)methyl)cysteine",
      "label": "is a type of"
    },
    {
      "source": "carboxymethylated protein",
      "target": "endoproteinase Lys-C",
      "label": "digested by"
    },
    {
      "source": "holoenzyme form",
      "target": "NaB[3H]4",
      "label": "reduced by"
    },
    {
      "source": "tryptic peptides",
      "target": "DFMO-cysteine adduct",
      "label": "contain"
    },
    {
      "source": "Delta 6 desaturase",
      "target": "enzyme",
      "label": "is an"
    },
    {
      "source": "Delta 6 desaturase",
      "target": "D6D",
      "label": "is also known as"
    },
    {
      "source": "Delta 6 desaturase",
      "target": "alpha-linolenic acid",
      "label": "converts"
    },
    {
      "source": "Delta 6 desaturase",
      "target": "docosahexaenoic acid",
      "label": "converts to"
    },
    {
      "source": "post-D6D products",
      "target": "24:6n-3",
      "label": "include"
    },
    {
      "source": "post-D6D products",
      "target": "22:5n-3",
      "label": "include"
    },
    {
      "source": "post-D6D products",
      "target": "DHA",
      "label": "include"
    },
    {
      "source": "competition",
      "target": "D6D",
      "label": "for"
    },
    {
      "source": "competition",
      "target": "ALA",
      "label": "between"
    },
    {
      "source": "competition",
      "target": "24:5n-3",
      "label": "between"
    },
    {
      "source": "competition",
      "target": "accumulation",
      "label": "contributes to"
    },
    {
      "source": "competition",
      "target": "Delta 6 desaturase",
      "label": "for"
    },
    {
      "source": "docosapentaenoic acid",
      "target": "22:5n-3",
      "label": "is also known as"
    },
    {
      "source": "DHA",
      "target": "ALA",
      "label": "is from"
    },
    {
      "source": "parallel pattern",
      "target": "accumulation",
      "label": "of"
    },
    {
      "source": "cell membranes",
      "target": "diabetic conditions",
      "label": "altered in"
    },
    {
      "source": "cell membranes",
      "target": "breast derived cells",
      "label": "of"
    },
    {
      "source": "cell membranes",
      "target": "buccal cells",
      "label": "of"
    },
    {
      "source": "fatty acid metabolism",
      "target": "accumulation",
      "label": "involves"
    },
    {
      "source": "long-chain metabolites",
      "target": "ALA",
      "label": "of"
    },
    {
      "source": "level of DHA",
      "target": "cell phospholipids",
      "label": "in"
    },
    {
      "source": "level of DHA",
      "target": "accumulation",
      "label": "is greater than"
    },
    {
      "source": "Supplementation",
      "target": "HepG2 cells",
      "label": "of"
    },
    {
      "source": "Supplementation",
      "target": "preformed DHA",
      "label": "with"
    },
    {
      "source": "Trace amine-associated receptor 1",
      "target": "isomers of methamphetamine",
      "label": "displays stereoselectivity for"
    },
    {
      "source": "Trace amine-associated receptor 1",
      "target": "species-dependent stereoselectivity",
      "label": "displays"
    },
    {
      "source": "Trace amine-associated receptor 1",
      "target": "isomers of amphetamine",
      "label": "displays stereoselectivity for"
    },
    {
      "source": "Trace amine-associated receptor 1",
      "target": "para-hydroxyamphetamine",
      "label": "displays stereoselectivity for"
    },
    {
      "source": "isomers of methamphetamine",
      "target": "mTAAR1",
      "label": "is a full agonist for"
    },
    {
      "source": "isomers of methamphetamine",
      "target": "h-rChTAAR1",
      "label": "is a full agonist for"
    },
    {
      "source": "isomers of methamphetamine",
      "target": "rTAAR1",
      "label": "is a partial agonist for"
    },
    {
      "source": "mTAAR1",
      "target": "species of TAAR1",
      "label": "is a type of"
    },
    {
      "source": "METH",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "METH",
      "target": "accumulation of cAMP",
      "label": "causes"
    },
    {
      "source": "METH",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "METH",
      "target": "spatial memory retrieval",
      "label": "did not facilitate"
    },
    {
      "source": "METH",
      "target": "spatial memory consolidation",
      "label": "facilitated"
    },
    {
      "source": "METH",
      "target": "spatial memory reconsolidation",
      "label": "did not facilitate"
    },
    {
      "source": "METH",
      "target": "processes of spatial memory",
      "label": "affects"
    },
    {
      "source": "POHA",
      "target": "endogenous biogenic amines",
      "label": "is related to"
    },
    {
      "source": "POHA",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "POHA",
      "target": "catecholamine neurotransmitters",
      "label": "is related to"
    },
    {
      "source": "POHA",
      "target": "methamphetamine",
      "label": "is a metabolite of"
    },
    {
      "source": "POHA",
      "target": "amphetamine",
      "label": "is a metabolite of"
    },
    {
      "source": "POHA",
      "target": "accumulation of cAMP",
      "label": "causes"
    },
    {
      "source": "endogenous biogenic amines",
      "target": "trace amines (TAs)",
      "label": "is a type of"
    },
    {
      "source": "AMPH",
      "target": "accumulation of cAMP",
      "label": "causes"
    },
    {
      "source": "AMPH",
      "target": "synthetic amines",
      "label": "is a type of"
    },
    {
      "source": "AMPH",
      "target": "endogenous biogenic amines",
      "label": "is related to"
    },
    {
      "source": "AMPH",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "AMPH",
      "target": "catecholamine neurotransmitters",
      "label": "is related to"
    },
    {
      "source": "AMPH",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "accumulation of cAMP",
      "target": "HEK-293 cells",
      "label": "occurs in"
    },
    {
      "source": "accumulation of cAMP",
      "target": "concentration",
      "label": "is dependent on"
    },
    {
      "source": "accumulation of cAMP",
      "target": "isomer",
      "label": "is dependent on"
    },
    {
      "source": "HEK-293 cells",
      "target": "species of TAAR1",
      "label": "expresses"
    },
    {
      "source": "S-(+)-METH",
      "target": "rTAAR1",
      "label": "has EC50 values for"
    },
    {
      "source": "S-(+)-METH",
      "target": "mTAAR1",
      "label": "has EC50 values for"
    },
    {
      "source": "S-(+)-METH",
      "target": "h-rChTAAR1",
      "label": "has EC50 values for"
    },
    {
      "source": "human embryonic kidney (HEK)-293 cells",
      "target": "rat trace amine-associated receptor 1",
      "label": "expresses"
    },
    {
      "source": "human embryonic kidney (HEK)-293 cells",
      "target": "rTAAR1",
      "label": "expresses"
    },
    {
      "source": "beta-phenylethylamine",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "PEA",
      "target": "species of TAAR1",
      "label": "is a full agonist for"
    },
    {
      "source": "PEA",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "TYR",
      "target": "rodent TAAR1s",
      "label": "is a full agonist for"
    },
    {
      "source": "TYR",
      "target": "h-rChTAAR1",
      "label": "is a partial agonist for"
    },
    {
      "source": "TYR",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "TAAR1",
      "target": "in vivo",
      "label": "is a novel mediator in"
    },
    {
      "source": "TAAR1",
      "target": "effects",
      "label": "is a novel mediator of"
    },
    {
      "source": "S-(+)-isomers",
      "target": "R-(-)",
      "label": "is more potent than"
    },
    {
      "source": "hrChTAAR1",
      "target": "human-rat chimera",
      "label": "is a type of"
    },
    {
      "source": "hrChTAAR1",
      "target": "species of TAAR1",
      "label": "is a type of"
    },
    {
      "source": "methamphetamine",
      "target": "synthetic amines",
      "label": "is a type of"
    },
    {
      "source": "methamphetamine",
      "target": "endogenous biogenic amines",
      "label": "is related to"
    },
    {
      "source": "methamphetamine",
      "target": "catecholamine neurotransmitters",
      "label": "is related to"
    },
    {
      "source": "methamphetamine",
      "target": "ERK activation",
      "label": "modulates"
    },
    {
      "source": "methamphetamine",
      "target": "spatial memory consolidation",
      "label": "modulates"
    },
    {
      "source": "methamphetamine",
      "target": "spatial memory retrieval",
      "label": "modulates"
    },
    {
      "source": "methamphetamine",
      "target": "processes of spatial memory",
      "label": "affects"
    },
    {
      "source": "methamphetamine",
      "target": "CREB activation",
      "label": "modulates"
    },
    {
      "source": "methamphetamine",
      "target": "spatial memory reconsolidation",
      "label": "modulates"
    },
    {
      "source": "para-tyramine",
      "target": "cAMP production",
      "label": "stimulates"
    },
    {
      "source": "mouse TAAR1",
      "target": "species of TAAR1",
      "label": "is a type of"
    },
    {
      "source": "amphetamine",
      "target": "maximal dendrite length",
      "label": "increased"
    },
    {
      "source": "amphetamine",
      "target": "dopaminergic neurons",
      "label": "effect on"
    },
    {
      "source": "amphetamine",
      "target": "number of primary dendrites",
      "label": "increased"
    },
    {
      "source": "amphetamine",
      "target": "[3H]dopamine uptake",
      "label": "increased"
    },
    {
      "source": "amphetamine",
      "target": "TH-IR-positive mesencephalic neurons",
      "label": "effect on"
    },
    {
      "source": "para-hydroxyamphetamine",
      "target": "synthetic amines",
      "label": "is a type of"
    },
    {
      "source": "in vitro results",
      "target": "TAAR1",
      "label": "suggests"
    },
    {
      "source": "enantiomeric selectivity",
      "target": "species of TAAR1",
      "label": "is determined for"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "allergic contact dermatitis",
      "label": "displayed anti-inflammatory action in"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "anti-inflammatory activity",
      "label": "indicate"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "chronic obstructive pulmonary disease",
      "label": "are under evaluation for treatment of"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "skin disorders",
      "label": "proposed to be efficacious for"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "arachidonic acid induced skin inflammation",
      "label": "displayed anti-inflammatory action in"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "efficacy",
      "label": "demonstrated"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "anti-inflammatory action",
      "label": "displayed"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "ovalbumin sensitised guinea pigs",
      "label": "displayed anti-inflammatory action in"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "cilomilast",
      "label": "include"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "asthma",
      "label": "are under evaluation for treatment of"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "Th1 cytokines",
      "label": "suppress"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "Th2 cytokines",
      "label": "suppress"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "AWD 12-281",
      "label": "include"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "broad anti-inflammatory/immuno-modulatory action",
      "label": "have"
    },
    {
      "source": "PDE4 inhibitors",
      "target": "models of allergic and irritant skin inflammation",
      "label": "have been tested in"
    },
    {
      "source": "allergic contact dermatitis",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "anti-inflammatory activity",
      "target": "Th2 dominated acute phase",
      "label": "is present in"
    },
    {
      "source": "anti-inflammatory activity",
      "target": "Th1 dominated chronic phase",
      "label": "is present in"
    },
    {
      "source": "skin disorders",
      "target": "atopic dermatitis",
      "label": "include"
    },
    {
      "source": "arachidonic acid induced skin inflammation",
      "target": "arachidonic acid",
      "label": "induced by"
    },
    {
      "source": "arachidonic acid induced skin inflammation",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "Highly selective phosphodiesterase 4 inhibitors",
      "target": "psoriasis",
      "label": "are for the treatment of"
    },
    {
      "source": "Highly selective phosphodiesterase 4 inhibitors",
      "target": "allergic skin diseases",
      "label": "are for the treatment of"
    },
    {
      "source": "Th2 dominated acute phase",
      "target": "atopic dermatitis",
      "label": "is a phase of"
    },
    {
      "source": "systemically active PDE4 inhibitors",
      "target": "CC-10004",
      "label": "include"
    },
    {
      "source": "CC-10004",
      "target": "systemically active PDE4 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "CC-10004",
      "target": "psoriasis",
      "label": "demonstrated efficacy in"
    },
    {
      "source": "cipamfylline",
      "target": "topically active PDE4 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "topically active PDE4 inhibitors",
      "target": "cipamfylline",
      "label": "include"
    },
    {
      "source": "topically active PDE4 inhibitors",
      "target": "CP80,633",
      "label": "include"
    },
    {
      "source": "early clinical trials",
      "target": "systemically active PDE4 inhibitors",
      "label": "involved"
    },
    {
      "source": "early clinical trials",
      "target": "topically active PDE4 inhibitors",
      "label": "involved"
    },
    {
      "source": "ovalbumin sensitised guinea pigs",
      "target": "guinea pigs",
      "label": "are a type of"
    },
    {
      "source": "guinea pigs",
      "target": "high cholesterol diet",
      "label": "were fed with"
    },
    {
      "source": "guinea pigs",
      "target": "2% high cholesterol diet",
      "label": "were fed with"
    },
    {
      "source": "Th1 dominated chronic phase",
      "target": "atopic dermatitis",
      "label": "is a phase of"
    },
    {
      "source": "cilomilast",
      "target": "PDE4 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "AWD 12-281",
      "target": "clinical evaluation",
      "label": "is under"
    },
    {
      "source": "AWD 12-281",
      "target": "GW 842470",
      "label": "is also known as"
    },
    {
      "source": "AWD 12-281",
      "target": "PDE4 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "AWD 12-281",
      "target": "potent and selective PDE4 inhibitor",
      "label": "is a type of"
    },
    {
      "source": "clinical evaluation",
      "target": "topical treatment",
      "label": "is for"
    },
    {
      "source": "clinical evaluation",
      "target": "TKI-resistant FLT3-ITD+ AML patients",
      "label": "is_in"
    },
    {
      "source": "clinical evaluation",
      "target": "TKI-naive patients",
      "label": "is_in"
    },
    {
      "source": "clinical evaluation",
      "target": "ponatinib",
      "label": "is_of"
    },
    {
      "source": "Results",
      "target": "potent and selective PDE4 inhibitor",
      "label": "are awaited for"
    },
    {
      "source": "Results",
      "target": "efficacy",
      "label": "demonstrated"
    },
    {
      "source": "Results",
      "target": "Cytosolic availability",
      "label": "suggest"
    },
    {
      "source": "Results",
      "target": "AODs",
      "label": "suggests"
    },
    {
      "source": "Results",
      "target": "Adults with ID",
      "label": "suggests"
    },
    {
      "source": "Results",
      "target": "Regular physical activity",
      "label": "suggests"
    },
    {
      "source": "Results",
      "target": "workers",
      "label": "revealed"
    },
    {
      "source": "potent and selective PDE4 inhibitor",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "phosphodiesterase (PDE) 4",
      "target": "degrading enzyme",
      "label": "is a"
    },
    {
      "source": "phosphodiesterase (PDE) 4",
      "target": "inflammatory cells",
      "label": "is predominant in"
    },
    {
      "source": "phosphodiesterase (PDE) 4",
      "target": "cyclic AMP",
      "label": "degrades"
    },
    {
      "source": "topical treatment",
      "target": "atopic dermatitis",
      "label": "is of"
    },
    {
      "source": "non-immune cells",
      "target": "fibroblasts",
      "label": "include"
    },
    {
      "source": "non-immune cells",
      "target": "keratinocytes",
      "label": "include"
    },
    {
      "source": "CP80,633",
      "target": "topically active PDE4 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "GLP-1 receptor expression",
      "target": "other tumors",
      "label": "evaluated in"
    },
    {
      "source": "GLP-1 receptor expression",
      "target": "nonneoplastic tissues",
      "label": "compared with"
    },
    {
      "source": "GLP-1 receptor expression",
      "target": "human tumors",
      "label": "occurs in"
    },
    {
      "source": "GLP-1 receptor expression",
      "target": "human normal tissues",
      "label": "occurs in"
    },
    {
      "source": "GLP-1 receptor expression",
      "target": "in vivo targeting",
      "label": "has potential for"
    },
    {
      "source": "GLP-1 receptors",
      "target": "brain tumors",
      "label": "expressed in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "liver",
      "label": "not identified in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "brain",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "lymph nodes",
      "label": "not identified in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "lung",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "spleen",
      "label": "not identified in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "lymphomas",
      "label": "not expressed in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "pheochromocytomas",
      "label": "expressed in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "endocrine tumors",
      "label": "expressed in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "nonneoplastic tissues",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "adrenal gland",
      "label": "not identified in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "novel molecular target",
      "label": "represent"
    },
    {
      "source": "GLP-1 receptors",
      "target": "carcinomas",
      "label": "not expressed in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "kidney",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "intestine",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "embryonic tumors",
      "label": "expressed in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "breast",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "pancreas",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptors",
      "target": "specific tissue compartments",
      "label": "present in"
    },
    {
      "source": "GLP-1 receptor targeting",
      "target": "nuclear medicine",
      "label": "development in"
    },
    {
      "source": "GLP-1 receptor protein expression",
      "target": "receptor autoradiography",
      "label": "investigated with"
    },
    {
      "source": "GLP-1 receptor protein expression",
      "target": "nonneoplastic human tissues",
      "label": "investigated in"
    },
    {
      "source": "GLP-1 receptor protein expression",
      "target": "human tumors",
      "label": "investigated in"
    },
    {
      "source": "receptor autoradiography",
      "target": "(125)I-GLP-1(7-36)amide",
      "label": "uses"
    },
    {
      "source": "novel molecular target",
      "target": "targeted radiotherapy",
      "label": "is for"
    },
    {
      "source": "novel molecular target",
      "target": "in vivo scintigraphy",
      "label": "is for"
    },
    {
      "source": "targeted radiotherapy",
      "target": "GLP-1 receptor-expressing tumors",
      "label": "is for"
    },
    {
      "source": "GLP-1 receptor",
      "target": "insulinomas",
      "label": "overexpressed in"
    },
    {
      "source": "GLP-1 receptor",
      "target": "lung neuroendocrine tumors",
      "label": "overexpressed in"
    },
    {
      "source": "GLP-1 receptor",
      "target": "gut neuroendocrine tumors",
      "label": "overexpressed in"
    },
    {
      "source": "in vivo scintigraphy",
      "target": "GLP-1 receptor-expressing tumors",
      "label": "is for"
    },
    {
      "source": "in vivo targeting",
      "target": "therapeutic purposes",
      "label": "is for"
    },
    {
      "source": "in vivo targeting",
      "target": "diagnostic purposes",
      "label": "is for"
    },
    {
      "source": "GLP-1 receptor scintigraphy",
      "target": "low-background signal",
      "label": "results in"
    },
    {
      "source": "low-background signal",
      "target": "low receptor expression",
      "label": "due to"
    },
    {
      "source": "receptor binding",
      "target": "glucagon(1-29)",
      "label": "has potency"
    },
    {
      "source": "receptor binding",
      "target": "GLP-1 receptor identification",
      "label": "provided proof of"
    },
    {
      "source": "receptor binding",
      "target": "exendin-4",
      "label": "has potency"
    },
    {
      "source": "receptor binding",
      "target": "GLP-1(7-36)amide",
      "label": "has potency"
    },
    {
      "source": "receptor binding",
      "target": "GLP-2",
      "label": "has potency"
    },
    {
      "source": "low receptor expression",
      "target": "normal tissues surrounding tumors",
      "label": "occurs in"
    },
    {
      "source": "specific tissue compartments",
      "target": "organs",
      "label": "are part of"
    },
    {
      "source": "Peptide hormone receptors",
      "target": "in vivo targeting",
      "label": "can be used for"
    },
    {
      "source": "Peptide hormone receptors",
      "target": "human tumors",
      "label": "overexpressed in"
    },
    {
      "source": "Pharmacologic competition experiments",
      "target": "specificity of the procedure",
      "label": "provide proof of"
    },
    {
      "source": "somatostatin receptors",
      "target": "in vivo targeting",
      "label": "can be used for"
    },
    {
      "source": "cation modulation",
      "target": "extracellular acidification",
      "label": "occurs via"
    },
    {
      "source": "cation modulation",
      "target": "divalent ions",
      "label": "occurs via"
    },
    {
      "source": "extracellular acidification",
      "target": "protons",
      "label": "involves"
    },
    {
      "source": "dipole",
      "target": "neurotransmitter binding",
      "label": "couples"
    },
    {
      "source": "dipole",
      "target": "common effect on KARs",
      "label": "accounts for"
    },
    {
      "source": "dipole",
      "target": "KAR activation",
      "label": "couples to"
    },
    {
      "source": "dipole",
      "target": "novel gating feature",
      "label": "is a"
    },
    {
      "source": "Na+/Cl- dipole",
      "target": "kainate receptor activation",
      "label": "couples to"
    },
    {
      "source": "Na+/Cl- dipole",
      "target": "agonist binding",
      "label": "couples"
    },
    {
      "source": "Kainate-selective ionotropic glutamate receptors",
      "target": "Cl-",
      "label": "require"
    },
    {
      "source": "Kainate-selective ionotropic glutamate receptors",
      "target": "external Na+",
      "label": "require"
    },
    {
      "source": "Kainate-selective ionotropic glutamate receptors",
      "target": "neurotransmitter L-glutamate",
      "label": "require"
    },
    {
      "source": "Cl-",
      "target": "activation",
      "label": "is required for"
    },
    {
      "source": "Cl-",
      "target": "t-PA",
      "label": "Downregulator"
    },
    {
      "source": "Cl-",
      "target": "( Glu1]Pg)",
      "label": "Downregulator"
    },
    {
      "source": "Cl-",
      "target": "human [Glu1]plasminogen",
      "label": "Downregulator"
    },
    {
      "source": "Cl-",
      "target": "tissue plasminogen activator",
      "label": "Downregulator"
    },
    {
      "source": "Cl-",
      "target": "two-chain rec-t-PA",
      "label": "Regulator"
    },
    {
      "source": "Cl-",
      "target": "[Glu1]Pg",
      "label": "Regulator"
    },
    {
      "source": "GluR6 kinetics",
      "target": "physiological pH",
      "label": "is unaffected by"
    },
    {
      "source": "external anions",
      "target": "KARs",
      "label": "coactivate"
    },
    {
      "source": "external anions",
      "target": "kainate receptors",
      "label": "coactivate"
    },
    {
      "source": "KARs",
      "target": "cation modulation",
      "label": "are subject to"
    },
    {
      "source": "KARs",
      "target": "central nervous system",
      "label": "expressed in"
    },
    {
      "source": "KARs",
      "target": "mGlu signaling",
      "label": "influenced by"
    },
    {
      "source": "KARs",
      "target": "synaptic transmission",
      "label": "involved in"
    },
    {
      "source": "cation species",
      "target": "Na+",
      "label": "compete with"
    },
    {
      "source": "cation species",
      "target": "time KARs remain in the open state",
      "label": "regulate"
    },
    {
      "source": "Na+",
      "target": "time KARs remain in the open state",
      "label": "regulates"
    },
    {
      "source": "cations",
      "target": "anions",
      "label": "bind before"
    },
    {
      "source": "cations",
      "target": "KARs",
      "label": "coactivate"
    },
    {
      "source": "cations",
      "target": "kainate receptors",
      "label": "coactivate"
    },
    {
      "source": "external Na+",
      "target": "activation",
      "label": "is required for"
    },
    {
      "source": "external ions",
      "target": "GluR6 KARs",
      "label": "regulate"
    },
    {
      "source": "Na+ and Cl- ions",
      "target": "dipole",
      "label": "establish"
    },
    {
      "source": "Na+ and Cl- ions",
      "target": "GluR6 receptors",
      "label": "coactivate"
    },
    {
      "source": "docking order",
      "target": "anions",
      "label": "involves"
    },
    {
      "source": "docking order",
      "target": "cations",
      "label": "involves"
    },
    {
      "source": "ions of opposite charge",
      "target": "cations",
      "label": "include"
    },
    {
      "source": "ions of opposite charge",
      "target": "external anions",
      "label": "include"
    },
    {
      "source": "divalent and alkali metal ions",
      "target": "time course of KAR channel activity",
      "label": "determine"
    },
    {
      "source": "GluRs",
      "target": "neurotransmitter L-glutamate",
      "label": "require"
    },
    {
      "source": "GluRs",
      "target": "external Na+",
      "label": "require"
    },
    {
      "source": "GluRs",
      "target": "activation",
      "label": "undergo"
    },
    {
      "source": "GluRs",
      "target": "Cl-",
      "label": "require"
    },
    {
      "source": "neurotransmitter L-glutamate",
      "target": "activation",
      "label": "is required for"
    },
    {
      "source": "charged amino acids",
      "target": "tethered ions",
      "label": "are used as"
    },
    {
      "source": "kinetic assay",
      "target": "inosine 5'-monophosphate dehydrogenase activity",
      "label": "demonstrated"
    },
    {
      "source": "inosine 5'-monophosphate dehydrogenase activity",
      "target": "L263F variant",
      "label": "is of"
    },
    {
      "source": "DNA samples",
      "target": "PCR amplification",
      "label": "were screened by"
    },
    {
      "source": "DNA samples",
      "target": "bidirectional direct DNA sequencing",
      "label": "were screened by"
    },
    {
      "source": "DNA samples",
      "target": "solid organ transplant patients",
      "label": "from"
    },
    {
      "source": "DNA samples",
      "target": "exons",
      "label": "were screened at"
    },
    {
      "source": "DNA samples",
      "target": "exon/intron junctions",
      "label": "were screened at"
    },
    {
      "source": "mycophenolic acid inhibition",
      "target": "L263F variant",
      "label": "is of"
    },
    {
      "source": "L263F variant",
      "target": "wild-type",
      "label": "has activity 10% of"
    },
    {
      "source": "inter-individual difference",
      "target": "baseline inosine 5'-monophosphate dehydrogenase activity",
      "label": "of"
    },
    {
      "source": "inter-individual difference",
      "target": "adverse events",
      "label": "of"
    },
    {
      "source": "inter-individual difference",
      "target": "drug efficacy",
      "label": "of"
    },
    {
      "source": "Genetic variant",
      "target": "site-directed mutagenesis",
      "label": "was constructed by"
    },
    {
      "source": "Genetic variant",
      "target": "inosine 5'-monophosphate dehydrogenase-deficient strain",
      "label": "was transformed to"
    },
    {
      "source": "transplant recipients",
      "target": "mycophenolic acid",
      "label": "receive"
    },
    {
      "source": "mycophenolic acid",
      "target": "F7",
      "label": "up-regulates"
    },
    {
      "source": "mycophenolic acid",
      "target": "inhibitors",
      "label": "is an"
    },
    {
      "source": "Variants",
      "target": "inter-individual variability",
      "label": "may account for"
    },
    {
      "source": "Variants",
      "target": "IMPDH2 gene",
      "label": "are in"
    },
    {
      "source": "inter-individual variability",
      "target": "baseline enzyme activity",
      "label": "in"
    },
    {
      "source": "inter-individual variability",
      "target": "immunosuppressive efficacy",
      "label": "in"
    },
    {
      "source": "inter-individual variability",
      "target": "side effects",
      "label": "in"
    },
    {
      "source": "Inosine 5'-monophosphate dehydrogenase 2",
      "target": "purine synthesis",
      "label": "is required for"
    },
    {
      "source": "purine synthesis",
      "target": "activated lymphocytes",
      "label": "occurs in"
    },
    {
      "source": "nonsynonymous variant L263F",
      "target": "inosine 5'-monophosphate dehydrogenase activity",
      "label": "has a significant impact on"
    },
    {
      "source": "Nine genetic variants",
      "target": "rarer alleles",
      "label": "include"
    },
    {
      "source": "Nine genetic variants",
      "target": "IMPDH2 gene",
      "label": "were identified in"
    },
    {
      "source": "exon/intron junctions",
      "target": "IMPDH2 genes",
      "label": "are part of"
    },
    {
      "source": "IMPDH2",
      "target": "genetic diversity",
      "label": "has low"
    },
    {
      "source": "L263F",
      "target": "enzyme activity",
      "label": "is associated with diminished"
    },
    {
      "source": "L263F",
      "target": "human inosine 5'-monophosphate dehydrogenase 2",
      "label": "is a variant in"
    },
    {
      "source": "side effects",
      "target": "participants",
      "label": "were not observed in"
    },
    {
      "source": "variant Km",
      "target": "inosine 5'-monophosphate",
      "label": "is for"
    },
    {
      "source": "variant Km",
      "target": "nicotinamide adenine dinucleotide",
      "label": "is for"
    },
    {
      "source": "exons",
      "target": "IMPDH2 genes",
      "label": "are part of"
    },
    {
      "source": "inosine 5'-monophosphate dehydrogenase-deficient strain",
      "target": "Escherichia coli h712",
      "label": "is a strain of"
    },
    {
      "source": "enzymatic activity",
      "target": "reduced nicotinamide adenine dinucleotide production",
      "label": "was measured by"
    },
    {
      "source": "novel functional variant",
      "target": "factors",
      "label": "is one of the"
    },
    {
      "source": "mRNA expressions",
      "target": "caspase-1",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "brain tissue",
      "label": "measured in"
    },
    {
      "source": "mRNA expressions",
      "target": "cysteinyl-aspartate specific protease-1",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "ICAM-1",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "cysteinyl-aspartate specific protease",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "reverse transcription polymerase chain reaction assay",
      "label": "determined by"
    },
    {
      "source": "mRNA expressions",
      "target": "caspase-8",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "caspase-3",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "correlative factors",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "interleukin-1 beta",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "IL-1ra",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "intercellular adhesion molecule-1",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "IL-1RI",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "correlative inflammatory factors",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "interleukin-1 receptor type I",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "interleukin-1 receptor antagonist",
      "label": "of"
    },
    {
      "source": "mRNA expressions",
      "target": "IL-1 beta",
      "label": "of"
    },
    {
      "source": "Panax notoginseng saponins",
      "target": "cerebral ischemia-reperfusion",
      "label": "effects occur after"
    },
    {
      "source": "Panax notoginseng saponins",
      "target": "mRNA expressions",
      "label": "has effect on"
    },
    {
      "source": "cerebral ischemia-reperfusion",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "mRNA expression levels",
      "target": "IL-1RI",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "untreated group",
      "label": "lower than"
    },
    {
      "source": "mRNA expression levels",
      "target": "sham-operation group",
      "label": "higher than"
    },
    {
      "source": "mRNA expression levels",
      "target": "IL-1 beta",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "brain tissue",
      "label": "in"
    },
    {
      "source": "mRNA expression levels",
      "target": "caspase-1",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "ICAM-1",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "PNS group",
      "label": "in"
    },
    {
      "source": "mRNA expression levels",
      "target": "caspase-3",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "statistical differences",
      "label": "had no"
    },
    {
      "source": "mRNA expression levels",
      "target": "caspase-8",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "IL-1ra",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "HSD3B2",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "CYP11B2",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "resected adrenal glands",
      "label": "in"
    },
    {
      "source": "mRNA expression levels",
      "target": "immunohistochemistry",
      "label": "studied using"
    },
    {
      "source": "mRNA expression levels",
      "target": "CYP11B1",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "CYP17",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "real-time quantitative PCR",
      "label": "studied using"
    },
    {
      "source": "mRNA expression levels",
      "target": "genes",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "Kdr",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "quantitative real time PCR",
      "label": "determined by"
    },
    {
      "source": "mRNA expression levels",
      "target": "VEGF-A",
      "label": "of"
    },
    {
      "source": "mRNA expression levels",
      "target": "Flt-1",
      "label": "of"
    },
    {
      "source": "cerebral injury",
      "target": "cerebral ischemia-reperfusion",
      "label": "induced by"
    },
    {
      "source": "cerebral ischemia",
      "target": "reperfusion",
      "label": "followed by"
    },
    {
      "source": "mRNA expression level",
      "target": "untreated group",
      "label": "lower than"
    },
    {
      "source": "mRNA expression level",
      "target": "brain tissue",
      "label": "in"
    },
    {
      "source": "mRNA expression level",
      "target": "PNS group",
      "label": "in"
    },
    {
      "source": "mRNA expression level",
      "target": "caspase-3",
      "label": "of"
    },
    {
      "source": "Focal cerebral ischemia reperfusion",
      "target": "rats",
      "label": "induced in"
    },
    {
      "source": "Focal cerebral ischemia reperfusion",
      "target": "method of nylon monofilament",
      "label": "induced by"
    },
    {
      "source": "method of nylon monofilament",
      "target": "internal carotid artery",
      "label": "via"
    },
    {
      "source": "statistical differences",
      "target": "untreated group",
      "label": "compared to"
    },
    {
      "source": "statistical differences",
      "target": "sham-operation group",
      "label": "compared to"
    },
    {
      "source": "visual P1 component",
      "target": "polymorphic modulation",
      "label": "revealed"
    },
    {
      "source": "common genetic polymorphism",
      "target": "human nicotinic alpha4beta2 receptor",
      "label": "is in"
    },
    {
      "source": "auditory N1 component amplitude",
      "target": "T allele homozygotes",
      "label": "was higher for"
    },
    {
      "source": "auditory N1 component amplitude",
      "target": "C allele carriers",
      "label": "was higher than for"
    },
    {
      "source": "Ser543Ser",
      "target": "early components",
      "label": "modulates"
    },
    {
      "source": "Ser543Ser",
      "target": "sense thymine-to-cytosine polymorphism",
      "label": "is"
    },
    {
      "source": "early components",
      "target": "both modalities",
      "label": "are in"
    },
    {
      "source": "Parallel modulation",
      "target": "early latency modality-specific event-related potential (ERP) components",
      "label": "is of"
    },
    {
      "source": "early latency modality-specific event-related potential (ERP) components",
      "target": "audition",
      "label": "are in"
    },
    {
      "source": "early latency modality-specific event-related potential (ERP) components",
      "target": "vision",
      "label": "are in"
    },
    {
      "source": "cognitive event-related potentials",
      "target": "auditory and visual modalities",
      "label": "are in"
    },
    {
      "source": "top-down modulation",
      "target": "sensory processing",
      "label": "is of"
    },
    {
      "source": "sense thymine-to-cytosine polymorphism",
      "target": "early components",
      "label": "modulates"
    },
    {
      "source": "early event-related potentials",
      "target": "auditory and visual oddball target detection tasks",
      "label": "are in"
    },
    {
      "source": "sensory processing",
      "target": "modalities",
      "label": "is across"
    },
    {
      "source": "c.1629T-C",
      "target": "early components",
      "label": "modulates"
    },
    {
      "source": "c.1629T-C",
      "target": "sense thymine-to-cytosine polymorphism",
      "label": "is"
    },
    {
      "source": "CHRNA4 polymorphism",
      "target": "factors",
      "label": "affects"
    },
    {
      "source": "Nicotine receptor gene CHRNA4",
      "target": "early event-related potentials",
      "label": "modulates"
    },
    {
      "source": "reliable indication",
      "target": "interactions",
      "label": "is of"
    },
    {
      "source": "TCR-induced calcium release",
      "target": "Jurkat T lymphocytes",
      "label": "occurs in"
    },
    {
      "source": "calponin homology domain",
      "target": "TCR-induced calcium release",
      "label": "is prerequisite to"
    },
    {
      "source": "calponin homology domain",
      "target": "Vav1",
      "label": "is part of"
    },
    {
      "source": "calponin homology domain",
      "target": "calmodulin",
      "label": "associates with"
    },
    {
      "source": "calcium mobilization",
      "target": "TCR",
      "label": "is stimulated by"
    },
    {
      "source": "calcium mobilization",
      "target": "nuclear factor of activated T cells",
      "label": "leads to activation of"
    },
    {
      "source": "calmodulin",
      "target": "calcium",
      "label": "binding is dependent on"
    },
    {
      "source": "calmodulin",
      "target": "TCR-induced calcium release",
      "label": "potentiates"
    },
    {
      "source": "calmodulin",
      "target": "TCR activation",
      "label": "binding is independent of"
    },
    {
      "source": "calmodulin",
      "target": "Vav1",
      "label": "binds to"
    },
    {
      "source": "calcium",
      "target": "conformational change",
      "label": "removal induces"
    },
    {
      "source": "calponin homology (CH) domain",
      "target": "Vav1",
      "label": "is part of"
    },
    {
      "source": "calponin homology (CH) domain",
      "target": "CH domain",
      "label": "is also known as"
    },
    {
      "source": "calponin homology (CH) domain",
      "target": "calcium mobilization",
      "label": "is required for"
    },
    {
      "source": "Vav1",
      "target": "calcium flux",
      "label": "regulates"
    },
    {
      "source": "Vav1",
      "target": "T cell activation",
      "label": "has role in"
    },
    {
      "source": "Vav1",
      "target": "T cell development",
      "label": "plays role in"
    },
    {
      "source": "Vav1",
      "target": "multiple structural domains",
      "label": "consists of"
    },
    {
      "source": "Vav1",
      "target": "TCR-induced calcium release",
      "label": "potentiates"
    },
    {
      "source": "Vav1",
      "target": "guanine nucleotide exchange factor",
      "label": "is a type of"
    },
    {
      "source": "Vav1",
      "target": "hematopoietic cells",
      "label": "is expressed in"
    },
    {
      "source": "Vav1",
      "target": "calmodulin",
      "label": "functions cooperatively with"
    },
    {
      "source": "CH domain",
      "target": "Vav1",
      "label": "is part of"
    },
    {
      "source": "binding site",
      "target": "CH domain",
      "label": "is located on"
    },
    {
      "source": "binding site",
      "target": "fatty acids",
      "label": "for"
    },
    {
      "source": "Vav1 CH domain",
      "target": "calcium signaling",
      "label": "is involved in"
    },
    {
      "source": "Jurkat cells",
      "target": "calmodulin inhibitor",
      "label": "treated with"
    },
    {
      "source": "calmodulin inhibitor",
      "target": "calcium release",
      "label": "causes deficiency in"
    },
    {
      "source": "multiple structural domains",
      "target": "scaffold function",
      "label": "facilitates"
    },
    {
      "source": "multiple structural domains",
      "target": "guanine nucleotide exchange activity",
      "label": "facilitates"
    },
    {
      "source": "T cell antigen receptor",
      "target": "TCR",
      "label": "is also known as"
    },
    {
      "source": "guanine nucleotide exchange activity",
      "target": "TCR",
      "label": "occurs following"
    },
    {
      "source": "J.Vav1",
      "target": "calcium release",
      "label": "causes deficiency in"
    },
    {
      "source": "vav1-null Jurkat T cells",
      "target": "J.Vav1",
      "label": "is also known as"
    },
    {
      "source": "scaffold function",
      "target": "TCR",
      "label": "occurs following"
    },
    {
      "source": "CH-deleted Vav1",
      "target": "calcium release",
      "label": "causes deficiency in"
    },
    {
      "source": "VIAAT",
      "target": "Neuroendocrine cell line",
      "label": "expressed in"
    },
    {
      "source": "VIAAT",
      "target": "Uptake",
      "label": "performs"
    },
    {
      "source": "VIAAT",
      "target": "Vesicular loading",
      "label": "performs"
    },
    {
      "source": "VIAAT",
      "target": "GlyT1",
      "label": "coexpressed with"
    },
    {
      "source": "VIAAT",
      "target": "Transporters",
      "label": "is a type of"
    },
    {
      "source": "VIAAT",
      "target": "GlyT2",
      "label": "coexpressed with"
    },
    {
      "source": "VIAAT",
      "target": "Vesicular glycinergic phenotype",
      "label": "determines"
    },
    {
      "source": "GlyT2",
      "target": "Neuronal transporter",
      "label": "is a"
    },
    {
      "source": "GlyT2",
      "target": "Vesicular glycinergic phenotype",
      "label": "determines"
    },
    {
      "source": "GlyT2",
      "target": "Glycine exocytosis",
      "label": "facilitates"
    },
    {
      "source": "GlyT2",
      "target": "GlyT1",
      "label": "more effective than"
    },
    {
      "source": "GlyT2",
      "target": "Reverse mode",
      "label": "unable to operate in"
    },
    {
      "source": "GlyT2",
      "target": "High cytosolic glycine concentration",
      "label": "maintains"
    },
    {
      "source": "GlyT2",
      "target": "Transporters",
      "label": "is a type of"
    },
    {
      "source": "Mechanisms",
      "target": "Vesicular inhibitory phenotype",
      "label": "specify"
    },
    {
      "source": "Vesicular inhibitory phenotype",
      "target": "Mixed events",
      "label": "altered through"
    },
    {
      "source": "Point mutation",
      "target": "GABA transmission",
      "label": "abolishes"
    },
    {
      "source": "Point mutation",
      "target": "Glycine specificity",
      "label": "confers"
    },
    {
      "source": "Point mutation",
      "target": "UNC-47",
      "label": "of"
    },
    {
      "source": "GABA transmission",
      "target": "Worm",
      "label": "in"
    },
    {
      "source": "Cytosolic availability",
      "target": "VIAAT-containing terminals",
      "label": "in"
    },
    {
      "source": "Cytosolic availability",
      "target": "Glycine transmission",
      "label": "crucial for"
    },
    {
      "source": "Cytosolic availability",
      "target": "Glycine",
      "label": "of"
    },
    {
      "source": "High cytosolic glycine concentration",
      "target": "Vesicular loading",
      "label": "required for"
    },
    {
      "source": "GABA",
      "target": "Inhibitory transmitters",
      "label": "is a type of"
    },
    {
      "source": "GABA",
      "target": "VIAAT",
      "label": "is a substrate for"
    },
    {
      "source": "GABA",
      "target": "Plasmalemmal transporters",
      "label": "is a substrate for"
    },
    {
      "source": "GABA",
      "target": "Neurons",
      "label": "present in"
    },
    {
      "source": "GABA",
      "target": "Uptake",
      "label": "competes for"
    },
    {
      "source": "GABA",
      "target": "Secretory cell",
      "label": "introduced into"
    },
    {
      "source": "GABA",
      "target": "Vesicular inhibitory amino acid transporter",
      "label": "is a substrate for"
    },
    {
      "source": "UNC-47",
      "target": "Glycine exocytosis",
      "label": "supports"
    },
    {
      "source": "UNC-47",
      "target": "VIAAT ortholog",
      "label": "is a"
    },
    {
      "source": "UNC-47",
      "target": "Caenorhabditis elegans",
      "label": "from"
    },
    {
      "source": "Plasmalemmal transporters",
      "target": "Neuroendocrine cell line",
      "label": "expressed in"
    },
    {
      "source": "Caenorhabditis elegans",
      "target": "Species",
      "label": "is a"
    },
    {
      "source": "Caenorhabditis elegans",
      "target": "Glycine transmission",
      "label": "lacks"
    },
    {
      "source": "Inhibitory interneurons",
      "target": "Vertebrates",
      "label": "located in"
    },
    {
      "source": "Glycine transmission",
      "target": "Vertebrates",
      "label": "in"
    },
    {
      "source": "Worm",
      "target": "Caenorhabditis elegans",
      "label": "refers to"
    },
    {
      "source": "GlyT1",
      "target": "Glial transporter",
      "label": "is a"
    },
    {
      "source": "Quantal release",
      "target": "GABA",
      "label": "is of"
    },
    {
      "source": "Quantal release",
      "target": "Glycine",
      "label": "is of"
    },
    {
      "source": "Transporters",
      "target": "Synthesis",
      "label": "involved in"
    },
    {
      "source": "Transporters",
      "target": "Export",
      "label": "involved in"
    },
    {
      "source": "Neurons",
      "target": "Postnatal development",
      "label": "present during"
    },
    {
      "source": "VIAAT ortholog",
      "target": "Caenorhabditis elegans",
      "label": "from"
    },
    {
      "source": "Double-sniffer patch-clamp technique",
      "target": "Quantal release",
      "label": "measures"
    },
    {
      "source": "AODs",
      "target": "Adults with ID",
      "label": "are found in"
    },
    {
      "source": "Biochemical assessments",
      "target": "Female adults with intellectual disability",
      "label": "conducted in"
    },
    {
      "source": "Biochemical assessments",
      "target": "Active female adults",
      "label": "conducted in"
    },
    {
      "source": "Biochemical assessments",
      "target": "Nonactive female adults",
      "label": "conducted in"
    },
    {
      "source": "Biochemical assessments",
      "target": "Total antioxidant status",
      "label": "assess"
    },
    {
      "source": "Female adults with intellectual disability",
      "target": "Persons with ID",
      "label": "is a type of"
    },
    {
      "source": "Physically active subjects",
      "target": "Subjects",
      "label": "is a type of"
    },
    {
      "source": "Physically active subjects",
      "target": "Vitamin A",
      "label": "had higher levels of"
    },
    {
      "source": "Physically active subjects",
      "target": "Vitamin E",
      "label": "had higher levels of"
    },
    {
      "source": "Relationship",
      "target": "Long-term physical activity",
      "label": "is between"
    },
    {
      "source": "Relationship",
      "target": "Inactivity",
      "label": "is between"
    },
    {
      "source": "Relationship",
      "target": "Plasma antioxidant status",
      "label": "is between"
    },
    {
      "source": "Relationship",
      "target": "Female adults with intellectual disability",
      "label": "is in"
    },
    {
      "source": "Long-term physical activity",
      "target": "Antioxidant defense (AOD) system",
      "label": "increases"
    },
    {
      "source": "Long-term physical activity",
      "target": "Physical activity",
      "label": "is a type of"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "GPX",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "Superoxide dismutase",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "SOD",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "Glutathione peroxidase",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "Vitamin A",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "Vitamin E",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "Catalase",
      "label": "includes"
    },
    {
      "source": "Antioxidant defense (AOD)",
      "target": "CAT",
      "label": "includes"
    },
    {
      "source": "Plasma vitamin levels",
      "target": "Physically active subjects",
      "label": "are higher in"
    },
    {
      "source": "Plasma vitamin levels",
      "target": "Sedentary control subjects",
      "label": "are lower in"
    },
    {
      "source": "Sedentary control subjects",
      "target": "Control subjects",
      "label": "is a type of"
    },
    {
      "source": "Sedentary control subjects",
      "target": "Vitamin A",
      "label": "had lower levels of"
    },
    {
      "source": "Sedentary control subjects",
      "target": "Vitamin E",
      "label": "had lower levels of"
    },
    {
      "source": "Sedentary control subjects",
      "target": "Subjects",
      "label": "is a type of"
    },
    {
      "source": "Adults with ID",
      "target": "Persons with ID",
      "label": "is a type of"
    },
    {
      "source": "SOD",
      "target": "Enzyme activities",
      "label": "IS_A_TYPE_OF"
    },
    {
      "source": "SOD",
      "target": "stomach tissues",
      "label": "OBSERVED_IN"
    },
    {
      "source": "Glutathione peroxidase",
      "target": "GPx",
      "label": "IS_A"
    },
    {
      "source": "Nonrandomized study",
      "target": "Relationship",
      "label": "evaluates"
    },
    {
      "source": "Physically active lifestyle",
      "target": "Lifestyle",
      "label": "is a type of"
    },
    {
      "source": "Physically active lifestyle",
      "target": "Inactive lifestyle",
      "label": "is opposed to"
    },
    {
      "source": "Regular physical activity",
      "target": "Physical activity",
      "label": "is a type of"
    },
    {
      "source": "Regular physical activity",
      "target": "AODs",
      "label": "is associated with"
    },
    {
      "source": "Inactive persons with ID",
      "target": "Persons with ID",
      "label": "is a type of"
    },
    {
      "source": "Inactive persons with ID",
      "target": "CAT",
      "label": "had lower levels of"
    },
    {
      "source": "Inactive persons with ID",
      "target": "GPX",
      "label": "had lower levels of"
    },
    {
      "source": "Inactive persons with ID",
      "target": "SOD",
      "label": "had lower levels of"
    },
    {
      "source": "CAT",
      "target": "stomach tissues",
      "label": "OBSERVED_IN"
    },
    {
      "source": "CAT",
      "target": "Enzyme activities",
      "label": "IS_A_TYPE_OF"
    },
    {
      "source": "CAT",
      "target": "colorimetric methods",
      "label": "DETERMINED_BY"
    },
    {
      "source": "CAT",
      "target": "liver samples",
      "label": "DETERMINED_IN"
    },
    {
      "source": "CAT",
      "target": "liver markers",
      "label": "IS_A"
    },
    {
      "source": "Sedentary lifestyle",
      "target": "Lifestyle",
      "label": "is a type of"
    },
    {
      "source": "Sedentary lifestyle",
      "target": "Oxidative stress (OS)",
      "label": "is associated with"
    },
    {
      "source": "Inactive lifestyle",
      "target": "Lifestyle",
      "label": "is a type of"
    },
    {
      "source": "Inactive lifestyle",
      "target": "Low levels of antioxidants",
      "label": "results in"
    },
    {
      "source": "Prospective study",
      "target": "Relationship",
      "label": "evaluates"
    },
    {
      "source": "Contractile tension",
      "target": "noradrenaline",
      "label": "in response to"
    },
    {
      "source": "Contractile tension",
      "target": "vas deferens",
      "label": "of"
    },
    {
      "source": "Contractile tension",
      "target": "alpha(1A)-adrenoceptor KO mice",
      "label": "was decreased in"
    },
    {
      "source": "contraction",
      "target": "alpha(1)-AR triple-KO mice",
      "label": "was abolished in"
    },
    {
      "source": "alpha(1A)-adrenoceptors",
      "target": "contractility",
      "label": "are required for"
    },
    {
      "source": "alpha(1A)-adrenoceptors",
      "target": "function",
      "label": "have"
    },
    {
      "source": "alpha(1A)-adrenoceptors",
      "target": "ejaculation",
      "label": "may contribute to"
    },
    {
      "source": "attenuation of contractility",
      "target": "electrically stimulated vas deferens",
      "label": "was observed in"
    },
    {
      "source": "lower urinary tract symptoms",
      "target": "benign prostatic hyperplasia",
      "label": "associated with"
    },
    {
      "source": "physiological contribution",
      "target": "alpha(1)-adrenoceptor subtype-selective knockout (KO) mice",
      "label": "was characterized using"
    },
    {
      "source": "physiological contribution",
      "target": "molecular level",
      "label": "has not been studied at"
    },
    {
      "source": "alpha(1)-adrenoceptor subtype-selective knockout (KO) mice",
      "target": "alpha(1A)-, alpha(1B)- and alpha(1D)-AR KO mice",
      "label": "include"
    },
    {
      "source": "Alpha(1)-adrenoceptor antagonists",
      "target": "hypertension",
      "label": "are used in treatment of"
    },
    {
      "source": "Alpha(1)-adrenoceptor antagonists",
      "target": "lower urinary tract symptoms",
      "label": "are used in treatment of"
    },
    {
      "source": "Alpha1-adrenoceptors",
      "target": "male sexual function",
      "label": "are required for"
    },
    {
      "source": "alpha(1)-adrenoceptor subtypes",
      "target": "alpha(1)-AR triple-KO mice",
      "label": "are deleted in"
    },
    {
      "source": "pregnancy rate",
      "target": "alpha(1)-AR triple-KO mice",
      "label": "reduction enhanced in"
    },
    {
      "source": "pregnancy rate",
      "target": "alpha(1A)-adrenoceptor KO mice",
      "label": "was reduced in"
    },
    {
      "source": "ejaculatory dysfunction",
      "target": "drugs",
      "label": "occurs with"
    },
    {
      "source": "ejaculatory dysfunction",
      "target": "side effects",
      "label": "is a type of"
    },
    {
      "source": "mutagenesis",
      "target": "proposed dual action mechanism of SPD",
      "label": "needed to improve"
    },
    {
      "source": "mutagenesis",
      "target": "signal transduction model",
      "label": "needed to test"
    },
    {
      "source": "dynamics simulations",
      "target": "conformational \"open-closed\" process",
      "label": "revealed"
    },
    {
      "source": "dynamics simulations",
      "target": "surface features",
      "label": "revealed"
    },
    {
      "source": "conformational \"open-closed\" process",
      "target": "binding entrances",
      "label": "of"
    },
    {
      "source": "mechanism of the dual action of SPD",
      "target": "dual action mechanism",
      "label": "is a type of"
    },
    {
      "source": "mechanism of the dual action of SPD",
      "target": "SPD",
      "label": "of"
    },
    {
      "source": "dual action mechanism",
      "target": "D1 and D2 receptors",
      "label": "on"
    },
    {
      "source": "dual action mechanism",
      "target": "SPD",
      "label": "of"
    },
    {
      "source": "(-)-Stepholidine (SPD)",
      "target": "dopamine receptor D1 agonist",
      "label": "functions as"
    },
    {
      "source": "(-)-Stepholidine (SPD)",
      "target": "active ingredient",
      "label": "is an"
    },
    {
      "source": "(-)-Stepholidine (SPD)",
      "target": "D2 antagonist",
      "label": "functions as"
    },
    {
      "source": "(-)-Stepholidine (SPD)",
      "target": "compound",
      "label": "is a"
    },
    {
      "source": "(-)-Stepholidine (SPD)",
      "target": "dual function",
      "label": "has"
    },
    {
      "source": "computational approach",
      "target": "dual action mechanism",
      "label": "investigates"
    },
    {
      "source": "computational approach",
      "target": "protein structure prediction",
      "label": "integrates"
    },
    {
      "source": "computational approach",
      "target": "molecular dynamics simulations",
      "label": "integrates"
    },
    {
      "source": "computational approach",
      "target": "new drugs",
      "label": "aims to develop"
    },
    {
      "source": "computational approach",
      "target": "automated molecular docking",
      "label": "integrates"
    },
    {
      "source": "binding entrances",
      "target": "dopamine receptors",
      "label": "of"
    },
    {
      "source": "biophysical experiments",
      "target": "proposed dual action mechanism of SPD",
      "label": "needed to improve"
    },
    {
      "source": "biophysical experiments",
      "target": "signal transduction model",
      "label": "needed to test"
    },
    {
      "source": "SPD",
      "target": "D1 receptors",
      "label": "Regulator"
    },
    {
      "source": "SPD",
      "target": "D2 receptors",
      "label": "Regulator"
    },
    {
      "source": "SPD",
      "target": "dopamine receptors",
      "label": "Regulator"
    },
    {
      "source": "active ingredient",
      "target": "Chinese herb Stephania",
      "label": "of"
    },
    {
      "source": "surface features",
      "target": "electrostatic potentials",
      "label": "of"
    },
    {
      "source": "Potential binding conformations",
      "target": "D1 receptors",
      "label": "of"
    },
    {
      "source": "Potential binding conformations",
      "target": "D2 receptors",
      "label": "of"
    },
    {
      "source": "natural product (-)-stepholidine",
      "target": "D2 receptor",
      "label": "Antagonist"
    },
    {
      "source": "natural product (-)-stepholidine",
      "target": "Dopamine D1 receptor",
      "label": "Agonist"
    },
    {
      "source": "D1-SPD structure",
      "target": "K-167_EL-2-E-302_EL-3 salt bridge",
      "label": "shows importance of"
    },
    {
      "source": "K-167_EL-2-E-302_EL-3 salt bridge",
      "target": "conformational change",
      "label": "plays role for"
    },
    {
      "source": "K-167_EL-2-E-302_EL-3 salt bridge",
      "target": "binding of SPD",
      "label": "plays role for"
    },
    {
      "source": "Insights",
      "target": "dynamical behaviors",
      "label": "concern"
    },
    {
      "source": "Insights",
      "target": "structural and functional characteristics",
      "label": "aid understanding of"
    },
    {
      "source": "Insights",
      "target": "interaction modes",
      "label": "concern"
    },
    {
      "source": "dynamical behaviors",
      "target": "D1 and D2 receptors",
      "label": "of"
    },
    {
      "source": "modeling",
      "target": "subsequent signal transduction model",
      "label": "is basis for"
    },
    {
      "source": "modeling",
      "target": "mechanism of the dual action of SPD",
      "label": "is basis for"
    },
    {
      "source": "interaction modes",
      "target": "SPD",
      "label": "with"
    },
    {
      "source": "structural and functional characteristics",
      "target": "dopamine receptors",
      "label": "of"
    },
    {
      "source": "simulations",
      "target": "subsequent signal transduction model",
      "label": "is basis for"
    },
    {
      "source": "simulations",
      "target": "mechanism of the dual action of SPD",
      "label": "is basis for"
    },
    {
      "source": "simulations",
      "target": "TP-DDI risk",
      "label": "provide steps towards predictions of"
    },
    {
      "source": "simulations",
      "target": "block",
      "label": "predict"
    },
    {
      "source": "simulations",
      "target": "state-dependent cocaine block",
      "label": "indicate"
    },
    {
      "source": "D2-SPD complexes",
      "target": "experimental data",
      "label": "agree with"
    },
    {
      "source": "experimental data",
      "target": "structure",
      "label": "is on the"
    },
    {
      "source": "D1-SPD complexes",
      "target": "experimental data",
      "label": "agree with"
    },
    {
      "source": "Isothiocyanates",
      "target": "urinary excretion",
      "label": "undergo"
    },
    {
      "source": "Isothiocyanates",
      "target": "chemopreventive properties",
      "label": "responsible for"
    },
    {
      "source": "Isothiocyanates",
      "target": "glutathione S-transferases",
      "label": "are conjugated by"
    },
    {
      "source": "Isothiocyanates",
      "target": "GSTs",
      "label": "are conjugated by"
    },
    {
      "source": "Isothiocyanates",
      "target": "glutathione",
      "label": "are conjugated to"
    },
    {
      "source": "urinary excretion",
      "target": "VDBP",
      "label": "involves"
    },
    {
      "source": "urinary excretion",
      "target": "hidden, chronic predisposition to gentamicin nephrotoxicity",
      "label": "correlates with"
    },
    {
      "source": "urinary excretion",
      "target": "hemopexin",
      "label": "involves"
    },
    {
      "source": "urinary excretion",
      "target": "transferrin",
      "label": "involves"
    },
    {
      "source": "urinary excretion",
      "target": "albumin",
      "label": "involves"
    },
    {
      "source": "urinary excretion",
      "target": "TXB2",
      "label": "measures"
    },
    {
      "source": "urinary excretion",
      "target": "in vivo indexes",
      "label": "is an index of"
    },
    {
      "source": "urinary excretion",
      "target": "PGF2 alpha",
      "label": "measures"
    },
    {
      "source": "urinary excretion",
      "target": "constitutive PGHS-1 pathway",
      "label": "is an index of"
    },
    {
      "source": "urinary excretion",
      "target": "prostaglandin IF2 alpha",
      "label": "measures"
    },
    {
      "source": "urinary excretion",
      "target": "11-dehydro-thromboxane B2",
      "label": "measures"
    },
    {
      "source": "chemopreventive properties",
      "target": "food group",
      "label": "of"
    },
    {
      "source": "odds ratio (OR)",
      "target": "confidence interval (CI)",
      "label": "has"
    },
    {
      "source": "odds ratio (OR)",
      "target": "low intake of cruciferous vegetables",
      "label": "for"
    },
    {
      "source": "odds ratio (OR)",
      "target": "P-trend",
      "label": "has"
    },
    {
      "source": "odds ratio (OR)",
      "target": "high intake of cruciferous vegetables",
      "label": "compared to"
    },
    {
      "source": "GSTT1 null",
      "target": "P-interaction",
      "label": "has"
    },
    {
      "source": "GSTT1 null",
      "target": "kidney cancer risks",
      "label": "associated with higher"
    },
    {
      "source": "multicentric case-control study",
      "target": "Czech Republic",
      "label": "conducted in"
    },
    {
      "source": "multicentric case-control study",
      "target": "cases",
      "label": "enrolled"
    },
    {
      "source": "multicentric case-control study",
      "target": "Romania",
      "label": "conducted in"
    },
    {
      "source": "multicentric case-control study",
      "target": "Poland",
      "label": "conducted in"
    },
    {
      "source": "multicentric case-control study",
      "target": "controls",
      "label": "enrolled"
    },
    {
      "source": "multicentric case-control study",
      "target": "Russia",
      "label": "conducted in"
    },
    {
      "source": "multicentric case-control study",
      "target": "cruciferous vegetable intake",
      "label": "investigated"
    },
    {
      "source": "cancer prevention",
      "target": "individuals",
      "label": "among"
    },
    {
      "source": "Central and Eastern European Kidney Cancer Study",
      "target": "cruciferous vegetable intake",
      "label": "investigates"
    },
    {
      "source": "Central and Eastern European Kidney Cancer Study",
      "target": "Glutathione S-transferase polymorphisms",
      "label": "investigates"
    },
    {
      "source": "Central and Eastern European Kidney Cancer Study",
      "target": "cancer risk",
      "label": "investigates"
    },
    {
      "source": "functional or non-synonymous polymorphisms",
      "target": "GSTT1 deletion",
      "label": "include"
    },
    {
      "source": "functional or non-synonymous polymorphisms",
      "target": "GSTM3 3 bp deletion",
      "label": "include"
    },
    {
      "source": "functional or non-synonymous polymorphisms",
      "target": "GSTM1 deletion",
      "label": "include"
    },
    {
      "source": "functional or non-synonymous polymorphisms",
      "target": "V224I G>A substitution",
      "label": "include"
    },
    {
      "source": "functional or non-synonymous polymorphisms",
      "target": "GSTP1 I105V A>G substitution",
      "label": "include"
    },
    {
      "source": "gene-diet interactions",
      "target": "controls",
      "label": "assessed using"
    },
    {
      "source": "gene-diet interactions",
      "target": "genotyped cases",
      "label": "assessed using"
    },
    {
      "source": "GSTM3 3 bp deletion",
      "target": "IVS6 + 22-AGG",
      "label": "also known as"
    },
    {
      "source": "low intake of cruciferous vegetables",
      "target": "GST genotype",
      "label": "stratified by"
    },
    {
      "source": "relationship",
      "target": "host genetic factors",
      "label": "modified by"
    },
    {
      "source": "relationship",
      "target": "structure",
      "label": "is related to"
    },
    {
      "source": "relationship",
      "target": "interparticle spacing",
      "label": "is between"
    },
    {
      "source": "relationship",
      "target": "Particle Size",
      "label": "is between"
    },
    {
      "source": "cruciferous vegetables",
      "target": "cancer prevention",
      "label": "involved in"
    },
    {
      "source": "cruciferous vegetables",
      "target": "kidney cancer risk",
      "label": "associated with reduced"
    },
    {
      "source": "genotyped cases",
      "target": "functional or non-synonymous polymorphisms",
      "label": "genotyped for"
    },
    {
      "source": "kidney cancer risks",
      "target": "individuals",
      "label": "observed among"
    },
    {
      "source": "GSTM1/T1 null genotypes",
      "target": "P-interaction",
      "label": "has"
    },
    {
      "source": "GSTM1/T1 null genotypes",
      "target": "kidney cancer risks",
      "label": "associated with higher"
    },
    {
      "source": "evidence",
      "target": "cruciferous vegetables",
      "label": "for role of"
    },
    {
      "source": "evidence",
      "target": "modulatory role",
      "label": "outlines"
    },
    {
      "source": "PHD oxygen sensors",
      "target": "effectors",
      "label": "are"
    },
    {
      "source": "PHD oxygen sensors",
      "target": "drug targets",
      "label": "are potential"
    },
    {
      "source": "effectors",
      "target": "cellular signalling pathways",
      "label": "are part of"
    },
    {
      "source": "hydroxylated HIFalpha",
      "target": "proteasomal degradation",
      "label": "undergoes"
    },
    {
      "source": "hydroxylated HIFalpha",
      "target": "ubiquitinylation",
      "label": "undergoes"
    },
    {
      "source": "prolyl-4-hydroxylase domain (PHD) proteins",
      "target": "Cellular oxygen",
      "label": "senses"
    },
    {
      "source": "prolyl-4-hydroxylase domain (PHD) proteins",
      "target": "hypoxia-inducible factor (HIF) alpha subunits",
      "label": "hydroxylates"
    },
    {
      "source": "vitamin C",
      "target": "PHD activity",
      "label": "regulates"
    },
    {
      "source": "vitamin C",
      "target": "physiological relevance",
      "label": "has"
    },
    {
      "source": "gallic acid",
      "target": "functions of these antioxidants",
      "label": "demonstrates"
    },
    {
      "source": "gallic acid",
      "target": "all three PHDs",
      "label": "inhibits"
    },
    {
      "source": "gallic acid",
      "target": "antioxidants",
      "label": "is a type of"
    },
    {
      "source": "gallic acid",
      "target": "hypoxia",
      "label": "induced"
    },
    {
      "source": "gallic acid",
      "target": "physicochemical action mechanisms",
      "label": "has"
    },
    {
      "source": "gallic acid",
      "target": "hemorrhage inducer",
      "label": "is a"
    },
    {
      "source": "gallic acid",
      "target": "dysvascularization",
      "label": "induced"
    },
    {
      "source": "cobalt",
      "target": "vitamin C oxidation",
      "label": "does not catalyze"
    },
    {
      "source": "Krebs cycle intermediates",
      "target": "PHD activity",
      "label": "regulates"
    },
    {
      "source": "Krebs cycle intermediates",
      "target": "physiological relevance",
      "label": "has"
    },
    {
      "source": "physiological relevance",
      "target": "cellular concentrations",
      "label": "is related to"
    },
    {
      "source": "PHD abundance",
      "target": "HIFalpha stability",
      "label": "regulates"
    },
    {
      "source": "PHD abundance",
      "target": "normoxic conditions",
      "label": "regulates under"
    },
    {
      "source": "PHD abundance",
      "target": "hypoxic conditions",
      "label": "regulates under"
    },
    {
      "source": "hypoxic conditions",
      "target": "HIFalpha stabilization",
      "label": "leads to"
    },
    {
      "source": "Copper",
      "target": "vitamin C oxidation",
      "label": "catalyzes"
    },
    {
      "source": "n-propyl gallate",
      "target": "antioxidants",
      "label": "is a type of"
    },
    {
      "source": "n-propyl gallate",
      "target": "functions of these antioxidants",
      "label": "demonstrates"
    },
    {
      "source": "n-propyl gallate",
      "target": "all three PHDs",
      "label": "inhibits"
    },
    {
      "source": "N-acetyl-L-cysteine",
      "target": "PHD activity",
      "label": "has no effect on"
    },
    {
      "source": "von Hippel-Lindau (pVHL) tumor suppressor",
      "target": "hydroxylated HIFalpha",
      "label": "binds"
    },
    {
      "source": "prolyl-4-hydroxylase domain (PHD) oxygen sensor proteins",
      "target": "function",
      "label": "has"
    },
    {
      "source": "cell-free in vitro microtiter plate-based peptide hydroxylation assay",
      "target": "influence",
      "label": "investigates"
    },
    {
      "source": "influence",
      "target": "developmental exposure",
      "label": "of"
    },
    {
      "source": "ferrous iron",
      "target": "PHD activity",
      "label": "influences"
    },
    {
      "source": "hydroxylation",
      "target": "hypoxic conditions",
      "label": "is reduced under"
    },
    {
      "source": "hydroxylation",
      "target": "[M6]",
      "label": "produces"
    },
    {
      "source": "hydroxylation",
      "target": "[M4]",
      "label": "produces"
    },
    {
      "source": "hydroxylation",
      "target": "aniline",
      "label": "OF"
    },
    {
      "source": "nickel salts",
      "target": "vitamin C oxidation",
      "label": "does not catalyze"
    },
    {
      "source": "transition metals",
      "target": "PHD activity",
      "label": "influences"
    },
    {
      "source": "prostaglandin synthesis",
      "target": "prostaglandin",
      "label": "produces"
    },
    {
      "source": "convulsions",
      "target": "hippocampal neurons",
      "label": "induce COX in"
    },
    {
      "source": "convulsions",
      "target": "cortical neurons",
      "label": "induce COX in"
    },
    {
      "source": "convulsions",
      "target": "COX",
      "label": "induce"
    },
    {
      "source": "PTZ",
      "target": "kindling epilepsy",
      "label": "induces"
    },
    {
      "source": "PTZ",
      "target": "malondialdehyde",
      "label": "upregulates"
    },
    {
      "source": "PTZ",
      "target": "glutathione",
      "label": "downregulates"
    },
    {
      "source": "PTZ",
      "target": "myeloperoxidase",
      "label": "upregulates"
    },
    {
      "source": "PTZ",
      "target": "nitrite",
      "label": "upregulates"
    },
    {
      "source": "PTZ",
      "target": "kindling",
      "label": "induces"
    },
    {
      "source": "PTZ",
      "target": "subconvulsive dose",
      "label": "was injected in a"
    },
    {
      "source": "kindling epilepsy",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "Brain",
      "target": "cyclooxygenases",
      "label": "contains"
    },
    {
      "source": "cyclooxygenases",
      "target": "COX",
      "label": "are also known as"
    },
    {
      "source": "biochemical alterations",
      "target": "PTZ",
      "label": "are due to"
    },
    {
      "source": "PTZ-kindled mice",
      "target": "malondialdehyde",
      "label": "had higher levels of"
    },
    {
      "source": "PTZ-kindled mice",
      "target": "myeloperoxidase",
      "label": "had higher levels of"
    },
    {
      "source": "PTZ-kindled mice",
      "target": "nitrite",
      "label": "had higher levels of"
    },
    {
      "source": "PTZ-kindled mice",
      "target": "glutathione",
      "label": "had lower levels of"
    },
    {
      "source": "PTZ-kindled mice",
      "target": "normal control group",
      "label": "compared with"
    },
    {
      "source": "biochemical parameters",
      "target": "whole brain",
      "label": "assessed in"
    },
    {
      "source": "biochemical parameters",
      "target": "lipid peroxidation",
      "label": "include"
    },
    {
      "source": "biochemical parameters",
      "target": "phosphorylation of Extracellular-Signal-Regulated Kinase",
      "label": "include"
    },
    {
      "source": "biochemical parameters",
      "target": "antioxidant capacity",
      "label": "include"
    },
    {
      "source": "myeloperoxidase",
      "target": "whole brain homogenate",
      "label": "found in"
    },
    {
      "source": "nitrite",
      "target": "whole brain homogenate",
      "label": "found in"
    },
    {
      "source": "neuroprotection",
      "target": "PTZ-induced kindling",
      "label": "is against"
    },
    {
      "source": "neuroprotection",
      "target": "excitotoxicity",
      "label": "is against"
    },
    {
      "source": "neuroprotection",
      "target": "motor neurons",
      "label": "occurs in"
    },
    {
      "source": "kindling",
      "target": "scoring scale",
      "label": "assessed by"
    },
    {
      "source": "18-kDa integral nuclear membrane protein",
      "target": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "label": "belongs to"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "microsomal prostaglandin E synthase 1",
      "label": "includes"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "glutathione metabolism",
      "label": "involved in"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "MGSTs",
      "label": "includes"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "membrane-associated proteins",
      "label": "is a type of"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "microsomal glutathione S-transferases",
      "label": "includes"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "eicosanoid metabolism",
      "label": "involved in"
    },
    {
      "source": "superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism",
      "target": "5-lipoxygenase-activating protein",
      "label": "includes"
    },
    {
      "source": "proton",
      "target": "hydroxyl group",
      "label": "forms"
    },
    {
      "source": "hydroxyl group",
      "target": "C5",
      "label": "is at"
    },
    {
      "source": "LTC4S",
      "target": "xenobiotics",
      "label": "does not conjugate to"
    },
    {
      "source": "LTC4S",
      "target": "MGST3",
      "label": "contrasts with"
    },
    {
      "source": "LTC4S",
      "target": "LTA4",
      "label": "conjugates to"
    },
    {
      "source": "LTC4S",
      "target": "enzyme",
      "label": "is a"
    },
    {
      "source": "LTC4S",
      "target": "glutathione",
      "label": "conjugates"
    },
    {
      "source": "LTC4S",
      "target": "MGST2",
      "label": "contrasts with"
    },
    {
      "source": "LTC4S",
      "target": "18-kDa integral nuclear membrane protein",
      "label": "is a"
    },
    {
      "source": "three cysteinyl leukotriene ligands",
      "target": "stability",
      "label": "have"
    },
    {
      "source": "three cysteinyl leukotriene ligands",
      "target": "potency",
      "label": "have"
    },
    {
      "source": "threefold symmetric trimer",
      "target": "unit",
      "label": "functions as a"
    },
    {
      "source": "unit",
      "target": "functional domains",
      "label": "has"
    },
    {
      "source": "thiolate anion",
      "target": "C6",
      "label": "attacks"
    },
    {
      "source": "thiolate anion",
      "target": "thioether bond",
      "label": "forms"
    },
    {
      "source": "metabolites",
      "target": "LTE4",
      "label": "include"
    },
    {
      "source": "metabolites",
      "target": "LTD4",
      "label": "include"
    },
    {
      "source": "metabolites",
      "target": "lycopene derivatives",
      "label": "is a type of"
    },
    {
      "source": "metabolites",
      "target": "GCs",
      "label": "of"
    },
    {
      "source": "C6",
      "target": "LTA4",
      "label": "is part of"
    },
    {
      "source": "structural basis",
      "target": "development",
      "label": "is for"
    },
    {
      "source": "cysteinyl leukotrienes",
      "target": "leukotriene (LT)C4",
      "label": "include"
    },
    {
      "source": "cysteinyl leukotrienes",
      "target": "lipid mediators",
      "label": "are a type of"
    },
    {
      "source": "cysteinyl leukotrienes",
      "target": "slow-reacting substance of anaphylaxis",
      "label": "are components of"
    },
    {
      "source": "cysteinyl leukotrienes",
      "target": "bronchial asthma",
      "label": "implicated in"
    },
    {
      "source": "leukotriene (LT)C4",
      "target": "metabolites",
      "label": "has metabolites"
    },
    {
      "source": "Crystal structure",
      "target": "human membrane protein",
      "label": "is of"
    },
    {
      "source": "human membrane protein",
      "target": "cysteinyl leukotriene biosynthesis",
      "label": "involved in"
    },
    {
      "source": "high substrate specificity",
      "target": "MGSTs",
      "label": "distinguishes from"
    },
    {
      "source": "high substrate specificity",
      "target": "LTA4",
      "label": "is for"
    },
    {
      "source": "high substrate specificity",
      "target": "LTC4S",
      "label": "distinguishes"
    },
    {
      "source": "high substrate specificity",
      "target": "glutathione",
      "label": "is for"
    },
    {
      "source": "atomic structure",
      "target": "human LTC4S",
      "label": "is of"
    },
    {
      "source": "atomic structure",
      "target": "X-ray crystallography",
      "label": "determined by"
    },
    {
      "source": "human LTC4S",
      "target": "complex with glutathione",
      "label": "is in a"
    },
    {
      "source": "interface",
      "target": "adjacent monomers",
      "label": "is between"
    },
    {
      "source": "LTC4 synthase",
      "target": "enzyme",
      "label": "is a"
    },
    {
      "source": "LTC4 synthase",
      "target": "LTC4S",
      "label": "is also known as"
    },
    {
      "source": "LTC4 synthase",
      "target": "18-kDa integral nuclear membrane protein",
      "label": "is a"
    },
    {
      "source": "LTA4",
      "target": "interface",
      "label": "fits into"
    },
    {
      "source": "LTA4",
      "target": "endogenous substrate",
      "label": "is a"
    },
    {
      "source": "5(S)-hydroxy-6(R)-S-glutathionyl-7,9-trans-11,14-cis-eicosatetraenoic acid",
      "target": "LTC4",
      "label": "is also known as"
    },
    {
      "source": "proinflammatory pathway",
      "target": "three cysteinyl leukotriene ligands",
      "label": "is mediated by"
    },
    {
      "source": "proinflammatory pathway",
      "target": "multiple cysteinyl leukotriene receptors",
      "label": "is mediated by"
    },
    {
      "source": "endogenous substrate",
      "target": "arachidonic acid",
      "label": "derived from"
    },
    {
      "source": "X-ray crystallography",
      "target": "insights",
      "label": "provides"
    },
    {
      "source": "insights",
      "target": "high substrate specificity",
      "label": "are into"
    },
    {
      "source": "insights",
      "target": "synaptic development",
      "label": "are_into"
    },
    {
      "source": "insights",
      "target": "cognition",
      "label": "are_into"
    },
    {
      "source": "insights",
      "target": "gene regulation",
      "label": "are_into"
    },
    {
      "source": "functional domains",
      "target": "interface",
      "label": "are across"
    },
    {
      "source": "Arg 31",
      "target": "neighbouring monomer",
      "label": "is in"
    },
    {
      "source": "Arg 31",
      "target": "proton",
      "label": "donates"
    },
    {
      "source": "multiple cysteinyl leukotriene receptors",
      "target": "functions",
      "label": "have"
    },
    {
      "source": "Arg 104",
      "target": "monomer",
      "label": "is part of"
    },
    {
      "source": "Arg 104",
      "target": "glutathione",
      "label": "activates"
    },
    {
      "source": "loop structure",
      "target": "interface",
      "label": "is at the top of"
    },
    {
      "source": "U-shaped conformation",
      "target": "interface",
      "label": "is within"
    },
    {
      "source": "LTC4S inhibitors",
      "target": "proinflammatory pathway",
      "label": "are for"
    },
    {
      "source": "complex with glutathione",
      "target": "3.3 A resolution",
      "label": "has"
    },
    {
      "source": "LTC4S monomer",
      "target": "four transmembrane alpha-helices",
      "label": "has"
    },
    {
      "source": "LTC4S monomer",
      "target": "threefold symmetric trimer",
      "label": "forms a"
    },
    {
      "source": "excitotoxicity",
      "target": "beta-N-oxalyl amino-L-alanine",
      "label": "caused by"
    },
    {
      "source": "excitotoxicity",
      "target": "neurodegeneration",
      "label": "plays synergistic role in"
    },
    {
      "source": "excitotoxicity",
      "target": "L-BOAA",
      "label": "caused by"
    },
    {
      "source": "excitotoxicity",
      "target": "onset and slow progression of ALS/PDC",
      "label": "contributing factor in"
    },
    {
      "source": "excitotoxicity",
      "target": "cerebral cortex",
      "label": "occurs in"
    },
    {
      "source": "beta-N-oxalyl amino-L-alanine",
      "target": "neurolathyrism",
      "label": "is causative factor of"
    },
    {
      "source": "motor neuron disease",
      "target": "pyramidal system",
      "label": "involves"
    },
    {
      "source": "glutaredoxin",
      "target": "neuroprotection",
      "label": "has important role in"
    },
    {
      "source": "glutaredoxin",
      "target": "enzyme",
      "label": "is an"
    },
    {
      "source": "glutaredoxin",
      "target": "proteins",
      "label": "maintains redox status of"
    },
    {
      "source": "glutaredoxin",
      "target": "mitochondrial function",
      "label": "maintains"
    },
    {
      "source": "glutaredoxin",
      "target": "mitochondrial complex I loss",
      "label": "downregulation leads to"
    },
    {
      "source": "glutaredoxin",
      "target": "CNS",
      "label": "is expressed in"
    },
    {
      "source": "glutaredoxin",
      "target": "redox status",
      "label": "maintains"
    },
    {
      "source": "glutaredoxin",
      "target": "thiol disulfide oxidoreductase",
      "label": "is a"
    },
    {
      "source": "glutaredoxin",
      "target": "mitochondrial dysfunction",
      "label": "downregulation leads to"
    },
    {
      "source": "glutaredoxin",
      "target": "L-BOAA toxicity",
      "label": "downregulation sensitizes to"
    },
    {
      "source": "L-BOAA",
      "target": "male mice",
      "label": "inhibits mitochondrial complex I in"
    },
    {
      "source": "L-BOAA",
      "target": "glutathione loss",
      "label": "causes"
    },
    {
      "source": "L-BOAA",
      "target": "thiol groups",
      "label": "inhibits mitochondrial complex I through oxidation of"
    },
    {
      "source": "L-BOAA",
      "target": "complex I",
      "label": "does not inhibit"
    },
    {
      "source": "L-BOAA",
      "target": "neurolathyrism",
      "label": "is causative factor of"
    },
    {
      "source": "L-BOAA",
      "target": "mitochondrial complex I",
      "label": "inhibits"
    },
    {
      "source": "Therapeutic interventions",
      "target": "glutaredoxin",
      "label": "upregulate"
    },
    {
      "source": "Therapeutic interventions",
      "target": "neuroprotection",
      "label": "offer"
    },
    {
      "source": "Therapeutic interventions",
      "target": "deficits in fear extinction",
      "label": "reverse"
    },
    {
      "source": "female mice",
      "target": "L-BOAA",
      "label": "are resistant to effects of"
    },
    {
      "source": "female mice",
      "target": "glutaredoxin",
      "label": "express higher levels of"
    },
    {
      "source": "L-propargyl glycine",
      "target": "complex I activity",
      "label": "does not inhibit"
    },
    {
      "source": "L-propargyl glycine",
      "target": "GSH",
      "label": "reduces"
    },
    {
      "source": "antisense oligonucleotides",
      "target": "glutaredoxin",
      "label": "cause downregulation of"
    },
    {
      "source": "Estrogen",
      "target": "mitochondrial dysfunction",
      "label": "protects against"
    },
    {
      "source": "Estrogen",
      "target": "cellular redox status",
      "label": "maintains"
    },
    {
      "source": "Estrogen",
      "target": "glutaredoxin",
      "label": "upregulates"
    },
    {
      "source": "mitochondrial dysfunction",
      "target": "CNS",
      "label": "occurs in"
    },
    {
      "source": "mitochondrial dysfunction",
      "target": "neurodegeneration",
      "label": "plays synergistic role in"
    },
    {
      "source": "mitochondrial dysfunction",
      "target": "excitotoxicity",
      "label": "has implications in"
    },
    {
      "source": "mitochondrial dysfunction",
      "target": "female mice",
      "label": "occurs in"
    },
    {
      "source": "glutathione loss",
      "target": "mitochondrial dysfunction",
      "label": "does not lead to"
    },
    {
      "source": "glutathione loss",
      "target": "complex I activity",
      "label": "does not inhibit"
    },
    {
      "source": "diethyl maleate",
      "target": "complex I activity",
      "label": "does not inhibit"
    },
    {
      "source": "diethyl maleate",
      "target": "GSH",
      "label": "reduces"
    },
    {
      "source": "neurolathyrism",
      "target": "motor neuron disease",
      "label": "is a type of"
    },
    {
      "source": "Oxidative stress",
      "target": "neurodegeneration",
      "label": "plays synergistic role in"
    },
    {
      "source": "Oxidative stress",
      "target": "Oral mucosa cells",
      "label": "occurs in"
    },
    {
      "source": "neurodegeneration",
      "target": "brain regions",
      "label": "occurred in"
    },
    {
      "source": "neurodegeneration",
      "target": "nonexcitotoxic conditions",
      "label": "occurs under"
    },
    {
      "source": "thiol homeostasis",
      "target": "mitochondrial function",
      "label": "is important for"
    },
    {
      "source": "L-BOAA toxicity",
      "target": "complex I activity",
      "label": "causes loss of"
    },
    {
      "source": "L-BOAA toxicity",
      "target": "mitochondrial complex I loss",
      "label": "is characterized by"
    },
    {
      "source": "L-BOAA toxicity",
      "target": "AP1",
      "label": "activates"
    },
    {
      "source": "L-BOAA toxicity",
      "target": "glutathione loss",
      "label": "causes"
    },
    {
      "source": "protein thiol homeostasis",
      "target": "neurodegeneration",
      "label": "dysregulation leads to"
    },
    {
      "source": "protein thiol homeostasis",
      "target": "Oxidative stress",
      "label": "dysregulation caused by"
    },
    {
      "source": "protein thiol homeostasis",
      "target": "mitochondrial dysfunction",
      "label": "dysregulation leads to"
    },
    {
      "source": "Ovariectomy",
      "target": "glutaredoxin",
      "label": "downregulates"
    },
    {
      "source": "Ovariectomy",
      "target": "L-BOAA toxicity",
      "label": "renders vulnerable to"
    },
    {
      "source": "alpha-methyl-DL-aspartate",
      "target": "AS",
      "label": "inhibits"
    },
    {
      "source": "alpha-methyl-DL-aspartate",
      "target": "NO production",
      "label": "inhibited"
    },
    {
      "source": "alpha-methyl-DL-aspartate",
      "target": "argininosuccinate synthase",
      "label": "inhibits"
    },
    {
      "source": "AS",
      "target": "citrulline-NO cycle",
      "label": "is a component of"
    },
    {
      "source": "NO formation",
      "target": "L-citrulline formation",
      "label": "is higher than"
    },
    {
      "source": "L-citrulline recycling",
      "target": "citrulline-NO cycle",
      "label": "occurs via"
    },
    {
      "source": "L-citrulline recycling",
      "target": "NO production",
      "label": "is essential for"
    },
    {
      "source": "L-citrulline recycling",
      "target": "Endothelial nitric oxide production",
      "label": "is coupled to"
    },
    {
      "source": "NO production",
      "target": "endothelial cells",
      "label": "occurs in"
    },
    {
      "source": "NO production",
      "target": "L-citrulline formation",
      "label": "exceeded"
    },
    {
      "source": "NO production",
      "target": "PSD-95",
      "label": "is mediated by"
    },
    {
      "source": "NO production",
      "target": "chronic pain states",
      "label": "is involved in"
    },
    {
      "source": "L-citrulline",
      "target": "L-arginine",
      "label": "is produced from"
    },
    {
      "source": "Endothelial nitric oxide production",
      "target": "citrulline-NO cycle",
      "label": "is coupled to"
    },
    {
      "source": "argininosuccinate synthase",
      "target": "citrulline-NO cycle",
      "label": "is a component of"
    },
    {
      "source": "DISPERSE",
      "target": "Dose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST-segment Elevation myocardial infarction",
      "label": "is also known as"
    },
    {
      "source": "AZD6140",
      "target": "antiplatelet effects",
      "label": "has"
    },
    {
      "source": "AZD6140",
      "target": "loading dose",
      "label": "was administered with"
    },
    {
      "source": "AZD6140",
      "target": "reversible oral P2Y(12) receptor antagonist",
      "label": "is a"
    },
    {
      "source": "AZD6140",
      "target": "clopidogrel",
      "label": "exhibits greater inhibition of platelet aggregation than"
    },
    {
      "source": "AZD6140",
      "target": "P2Y12 receptor antagonist",
      "label": "is a"
    },
    {
      "source": "AZD6140",
      "target": "platelet aggregation",
      "label": "inhibits"
    },
    {
      "source": "AZD6140",
      "target": "clopidogrel-pretreated patients",
      "label": "suppresses platelet aggregation in"
    },
    {
      "source": "Adenosine diphosphate",
      "target": "platelet aggregation",
      "label": "induces"
    },
    {
      "source": "DISPERSE-2",
      "target": "DISPERSE",
      "label": "is a substudy of"
    },
    {
      "source": "optical aggregometry",
      "target": "platelet aggregation",
      "label": "assesses"
    },
    {
      "source": "monoamine oxidase inhibition",
      "target": "elevation in brain ORN",
      "label": "prevents"
    },
    {
      "source": "Phenelzine",
      "target": "brain ornithine",
      "label": "causes an increase in"
    },
    {
      "source": "Phenelzine",
      "target": "GABA-T",
      "label": "inhibits"
    },
    {
      "source": "Phenelzine",
      "target": "GABA-transaminase",
      "label": "inhibits"
    },
    {
      "source": "Phenelzine",
      "target": "brain GABA levels",
      "label": "increases"
    },
    {
      "source": "Phenelzine",
      "target": "nonselective irreversible inhibitor",
      "label": "is a"
    },
    {
      "source": "therapeutic properties",
      "target": "PLZ",
      "label": "of"
    },
    {
      "source": "therapeutic properties",
      "target": "MDMA",
      "label": "of"
    },
    {
      "source": "PLZ",
      "target": "dose- and time-response studies",
      "label": "conducted"
    },
    {
      "source": "PLZ",
      "target": "GABA-T",
      "label": "inhibits"
    },
    {
      "source": "PLZ",
      "target": "GABA-transaminase",
      "label": "inhibits"
    },
    {
      "source": "PLZ",
      "target": "brain GABA levels",
      "label": "increases"
    },
    {
      "source": "PLZ",
      "target": "brain ornithine",
      "label": "elevates"
    },
    {
      "source": "PLZ",
      "target": "substrate",
      "label": "is a"
    },
    {
      "source": "PLZ",
      "target": "ORN",
      "label": "elevates"
    },
    {
      "source": "PLZ",
      "target": "nonselective irreversible inhibitor",
      "label": "is a"
    },
    {
      "source": "ORN",
      "target": "amino acid",
      "label": "is an"
    },
    {
      "source": "TCP",
      "target": "MAO inhibitor",
      "label": "is an"
    },
    {
      "source": "TCP",
      "target": "PLZ-induced increase in brain ORN",
      "label": "abolished"
    },
    {
      "source": "increased ORN",
      "target": "therapeutic properties",
      "label": "contributes to"
    },
    {
      "source": "increased ORN",
      "target": "neuroprotective properties",
      "label": "contributes to"
    },
    {
      "source": "neuroprotective properties",
      "target": "PLZ",
      "label": "of"
    },
    {
      "source": "Pretreatment",
      "target": "PLZ-induced increase in brain ORN",
      "label": "abolished"
    },
    {
      "source": "Pretreatment",
      "target": "orlistat",
      "label": "with"
    },
    {
      "source": "Pretreatment",
      "target": "cell killing activity",
      "label": "reduced"
    },
    {
      "source": "nonselective irreversible inhibitor",
      "target": "monoamine oxidase",
      "label": "inhibits"
    },
    {
      "source": "nonselective irreversible inhibitor",
      "target": "MAO",
      "label": "inhibits"
    },
    {
      "source": "ORN levels",
      "target": "PLZ-treated animals",
      "label": "increased in"
    },
    {
      "source": "escitalopram",
      "target": "citalopram",
      "label": "is less potent than"
    },
    {
      "source": "escitalopram",
      "target": "discontinuation symptoms",
      "label": "induces"
    },
    {
      "source": "escitalopram",
      "target": "panic disorder",
      "label": "used for pharmacotherapy of"
    },
    {
      "source": "escitalopram",
      "target": "tolerability",
      "label": "has"
    },
    {
      "source": "escitalopram",
      "target": "social phobia",
      "label": "used for pharmacotherapy of"
    },
    {
      "source": "escitalopram",
      "target": "pharmacological aspects",
      "label": "has"
    },
    {
      "source": "escitalopram",
      "target": "patients",
      "label": "administered to"
    },
    {
      "source": "escitalopram",
      "target": "selective serotonin re-uptake inhibitors",
      "label": "is less potent than"
    },
    {
      "source": "escitalopram",
      "target": "depression",
      "label": "approved for treatment of"
    },
    {
      "source": "escitalopram",
      "target": "muscarinic receptors",
      "label": "binds to"
    },
    {
      "source": "escitalopram",
      "target": "transporter proteins",
      "label": "has relation to"
    },
    {
      "source": "escitalopram",
      "target": "drugs metabolised by CYP2D6",
      "label": "coadministered with"
    },
    {
      "source": "escitalopram",
      "target": "anxiety disorders",
      "label": "is used for"
    },
    {
      "source": "escitalopram",
      "target": "histamine H1",
      "label": "binds to"
    },
    {
      "source": "escitalopram",
      "target": "CNS",
      "label": "inhibits serotonin re-uptake in"
    },
    {
      "source": "escitalopram",
      "target": "(S)-enantiomer of citalopram",
      "label": "is"
    },
    {
      "source": "escitalopram",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "escitalopram",
      "target": "food intake",
      "label": "is not affected by"
    },
    {
      "source": "escitalopram",
      "target": "bioavailability",
      "label": "has"
    },
    {
      "source": "escitalopram",
      "target": "first-line agent",
      "label": "is"
    },
    {
      "source": "escitalopram",
      "target": "major depression",
      "label": "is used for"
    },
    {
      "source": "escitalopram",
      "target": "pharmacokinetics",
      "label": "has"
    },
    {
      "source": "escitalopram",
      "target": "protein binding",
      "label": "has"
    },
    {
      "source": "escitalopram",
      "target": "serotonin re-uptake",
      "label": "inhibits"
    },
    {
      "source": "escitalopram",
      "target": "obsessive-compulsive disorder",
      "label": "used for pharmacotherapy of"
    },
    {
      "source": "escitalopram",
      "target": "elderly",
      "label": "administered to"
    },
    {
      "source": "escitalopram",
      "target": "generalised anxiety disorder",
      "label": "used for pharmacotherapy of"
    },
    {
      "source": "escitalopram",
      "target": "drug interactions",
      "label": "has potential for"
    },
    {
      "source": "escitalopram",
      "target": "CYP isozymes",
      "label": "is metabolised by"
    },
    {
      "source": "escitalopram",
      "target": "receptors",
      "label": "has relation to"
    },
    {
      "source": "citalopram",
      "target": "selective serotonin reuptake inhibitors",
      "label": "is a type of"
    },
    {
      "source": "citalopram",
      "target": "SSRIs",
      "label": "is a type of"
    },
    {
      "source": "multiple-dose pharmacokinetics",
      "target": "escitalopram",
      "label": "of"
    },
    {
      "source": "multiple-dose pharmacokinetics",
      "target": "doses",
      "label": "are proportional at"
    },
    {
      "source": "CYP isozymes",
      "target": "metabolic clearance",
      "label": "affect"
    },
    {
      "source": "CYP isozymes",
      "target": "rats",
      "label": "are in"
    },
    {
      "source": "Phenserine",
      "target": "cognition",
      "label": "improves"
    },
    {
      "source": "Phenserine",
      "target": "translational efficiency",
      "label": "reduces"
    },
    {
      "source": "Phenserine",
      "target": "AChE",
      "label": "is an inhibitor of"
    },
    {
      "source": "Phenserine",
      "target": "beta-amyloid precursor protein",
      "label": "modulates"
    },
    {
      "source": "Phenserine",
      "target": "Abeta",
      "label": "reduces formation of"
    },
    {
      "source": "Phenserine",
      "target": "Phase II studies",
      "label": "showed success in"
    },
    {
      "source": "Phenserine",
      "target": "beta-amyloid peptide",
      "label": "reduces formation of"
    },
    {
      "source": "Phenserine",
      "target": "Alzheimer's disease",
      "label": "was tested for"
    },
    {
      "source": "Phenserine",
      "target": "enantiomers",
      "label": "has"
    },
    {
      "source": "Phenserine",
      "target": "physostigmine",
      "label": "is a derivative of"
    },
    {
      "source": "Phenserine",
      "target": "regulatory element",
      "label": "interacts with"
    },
    {
      "source": "Phenserine",
      "target": "APP translation",
      "label": "reduces"
    },
    {
      "source": "Phenserine",
      "target": "acetylcholinesterase",
      "label": "is an inhibitor of"
    },
    {
      "source": "Phenserine",
      "target": "APP",
      "label": "modulates"
    },
    {
      "source": "translational efficiency",
      "target": "iron-responsive element",
      "label": "involves interaction with"
    },
    {
      "source": "translational efficiency",
      "target": "iron",
      "label": "involves interaction with"
    },
    {
      "source": "(+)-Posiphen",
      "target": "(-)-phenserine",
      "label": "can be combined with"
    },
    {
      "source": "(+)-Posiphen",
      "target": "progression of Alzheimer's disease",
      "label": "attenuates"
    },
    {
      "source": "(+)-Posiphen",
      "target": "drug",
      "label": "is a"
    },
    {
      "source": "(-)-phenserine",
      "target": "active enantiomer",
      "label": "is an"
    },
    {
      "source": "(-)-phenserine",
      "target": "APP expression",
      "label": "downregulates"
    },
    {
      "source": "(-)-phenserine",
      "target": "AChE",
      "label": "inhibits"
    },
    {
      "source": "AChE",
      "target": "OP",
      "label": "inhibited_by"
    },
    {
      "source": "AChE",
      "target": "neurotransmission",
      "label": "has_role_in"
    },
    {
      "source": "AChE",
      "target": "transmembrane domain",
      "label": "does not possess"
    },
    {
      "source": "AChE",
      "target": "pathogenesis",
      "label": "implicated in"
    },
    {
      "source": "AChE",
      "target": "hydrolytic enzyme",
      "label": "is a type of"
    },
    {
      "source": "AChE",
      "target": "neuronal cell surface",
      "label": "shed from"
    },
    {
      "source": "AChE",
      "target": "non-catalytic functions",
      "label": "has"
    },
    {
      "source": "AChE",
      "target": "toxicity",
      "label": "increases"
    },
    {
      "source": "AChE",
      "target": "formation",
      "label": "accelerates"
    },
    {
      "source": "AChE",
      "target": "IC50",
      "label": "has"
    },
    {
      "source": "AChE",
      "target": "acetylcholinesterase",
      "label": "is an abbreviation for"
    },
    {
      "source": "AChE",
      "target": "brain nAChR-mediated functions",
      "label": "has role in"
    },
    {
      "source": "AChE",
      "target": "nAChR-dependent glutamate transmission",
      "label": "inhibition facilitates"
    },
    {
      "source": "AChE",
      "target": "acetylcholine (ACh)",
      "label": "inhibition increases"
    },
    {
      "source": "5'-untranslated region",
      "target": "APP gene",
      "label": "is part of"
    },
    {
      "source": "(+)-phenserine",
      "target": "AChE inhibitor",
      "label": "is a weak"
    },
    {
      "source": "(+)-phenserine",
      "target": "posiphen",
      "label": "is also known as"
    },
    {
      "source": "(+)-phenserine",
      "target": "APP expression",
      "label": "downregulates"
    },
    {
      "source": "enantiomers",
      "target": "human muscarinic receptor",
      "label": "profiled on"
    },
    {
      "source": "enantiomers",
      "target": "binding",
      "label": "displace"
    },
    {
      "source": "enantiomers",
      "target": "human cloned muscarinic m1-5 receptors",
      "label": "evaluated on"
    },
    {
      "source": "APP mRNA",
      "target": "protein",
      "label": "is translated into"
    },
    {
      "source": "regulatory element",
      "target": "APP expression",
      "label": "controls"
    },
    {
      "source": "regulatory element",
      "target": "5'-untranslated region",
      "label": "is in"
    },
    {
      "source": "posiphen",
      "target": "AChE inhibitor",
      "label": "is a weak"
    },
    {
      "source": "acetylcholinesterase",
      "target": "AChE",
      "label": "is also known as"
    },
    {
      "source": "acetylcholinesterase",
      "target": "neurotransmission",
      "label": "has_role_in"
    },
    {
      "source": "acetylcholinesterase",
      "target": "neuronal cells",
      "label": "released from"
    },
    {
      "source": "acetylcholinesterase",
      "target": "hydrolytic enzyme",
      "label": "is a type of"
    },
    {
      "source": "APP",
      "target": "membrane proteins",
      "label": "is a type of"
    },
    {
      "source": "APP",
      "target": "key role",
      "label": "has"
    },
    {
      "source": "graft",
      "target": "extension",
      "label": "lost during"
    },
    {
      "source": "patient survival",
      "target": "three year",
      "label": "at"
    },
    {
      "source": "Mean serum creatinine",
      "target": "mg/dL",
      "label": "measured in"
    },
    {
      "source": "Mean serum creatinine",
      "target": "first 36 months",
      "label": "at"
    },
    {
      "source": "Mean serum creatinine",
      "target": "microm/L",
      "label": "measured in"
    },
    {
      "source": "Graft survival",
      "target": "one yr",
      "label": "at"
    },
    {
      "source": "mean total cholesterol",
      "target": "three year",
      "label": "at"
    },
    {
      "source": "mean total cholesterol",
      "target": "mm/L",
      "label": "measured in"
    },
    {
      "source": "mean total cholesterol",
      "target": "mg/dL",
      "label": "measured in"
    },
    {
      "source": "mTOR inhibitors",
      "target": "proliferation signal inhibitors",
      "label": "are also known as"
    },
    {
      "source": "first long-term prospective study",
      "target": "regimen of everolimus, cyclosporine, and corticosteroids",
      "label": "demonstrates"
    },
    {
      "source": "regimen of everolimus, cyclosporine, and corticosteroids",
      "target": "tolerability",
      "label": "provides"
    },
    {
      "source": "regimen of everolimus, cyclosporine, and corticosteroids",
      "target": "efficacy",
      "label": "provides"
    },
    {
      "source": "regimen of everolimus, cyclosporine, and corticosteroids",
      "target": "safety",
      "label": "provides"
    },
    {
      "source": "regimen of everolimus, cyclosporine, and corticosteroids",
      "target": "de novo pediatric renal transplant patients",
      "label": "provides in"
    },
    {
      "source": "four patients",
      "target": "statin therapy",
      "label": "received"
    },
    {
      "source": "four patients",
      "target": "each age group",
      "label": "distributed across"
    },
    {
      "source": "prospective clinical trials",
      "target": "CNI inhibitors",
      "label": "combined with"
    },
    {
      "source": "prospective clinical trials",
      "target": "mTOR inhibitors",
      "label": "involve"
    },
    {
      "source": "prospective clinical trials",
      "target": "de novo pediatric renal transplantation",
      "label": "conducted in"
    },
    {
      "source": "extension study",
      "target": "two yr",
      "label": "lasted for"
    },
    {
      "source": "Mean daily dose of everolimus",
      "target": "mg/m(2) BSA",
      "label": "expressed in"
    },
    {
      "source": "Mean daily dose of everolimus",
      "target": "first 36 months",
      "label": "measured during"
    },
    {
      "source": "Biopsy-proven acute rejection",
      "target": "one patient",
      "label": "occurred in"
    },
    {
      "source": "Biopsy-proven acute rejection",
      "target": "three patients",
      "label": "occurred in"
    },
    {
      "source": "one patient",
      "target": "Group 2",
      "label": "was in"
    },
    {
      "source": "one patient",
      "target": "graft",
      "label": "lost"
    },
    {
      "source": "one patient",
      "target": "Group 1",
      "label": "belonged to"
    },
    {
      "source": "three patients",
      "target": "Group 2",
      "label": "belonged to"
    },
    {
      "source": "three patients",
      "target": "study medication",
      "label": "discontinued"
    },
    {
      "source": "Group 2",
      "target": "magnesium oxide",
      "label": "treated with"
    },
    {
      "source": "Multicenter trial",
      "target": "results",
      "label": "reports"
    },
    {
      "source": "Multicenter trial",
      "target": "pediatric renal transplant recipients",
      "label": "conducted in"
    },
    {
      "source": "Multicenter trial",
      "target": "everolimus",
      "label": "investigates"
    },
    {
      "source": "multicenter, open-label study",
      "target": "de novo pediatric renal transplant patients",
      "label": "conducted in"
    },
    {
      "source": "three cases of viral infection",
      "target": "one case of cytomegalovirus infection",
      "label": "included"
    },
    {
      "source": "Biopsy-proven chronic allograft rejection",
      "target": "four patients",
      "label": "reported in"
    },
    {
      "source": "Group 1",
      "target": "glucophage",
      "label": "treated with"
    },
    {
      "source": "remaining 16 patients",
      "target": "Group 1",
      "label": "included"
    },
    {
      "source": "remaining 16 patients",
      "target": "extension study",
      "label": "entered"
    },
    {
      "source": "remaining 16 patients",
      "target": "Group 2",
      "label": "included"
    },
    {
      "source": "H3R mRNA",
      "target": "BDL cholangiocytes",
      "label": "increased in"
    },
    {
      "source": "RAMH",
      "target": "cholangiocyte proliferation",
      "label": "inhibits"
    },
    {
      "source": "RAMH",
      "target": "cAMP",
      "label": "decreased"
    },
    {
      "source": "RAMH",
      "target": "ELK-1 pathway",
      "label": "downregulates"
    },
    {
      "source": "RAMH",
      "target": "PKA",
      "label": "decreased phosphorylation of"
    },
    {
      "source": "RAMH",
      "target": "extracellular signal-regulated kinase 1/2",
      "label": "downregulates phosphorylation of"
    },
    {
      "source": "RAMH",
      "target": "ERK1/2",
      "label": "decreased phosphorylation of"
    },
    {
      "source": "RAMH",
      "target": "biliary growth",
      "label": "inhibits"
    },
    {
      "source": "RAMH",
      "target": "protein kinase A",
      "label": "downregulates phosphorylation of"
    },
    {
      "source": "RAMH",
      "target": "Elk-1",
      "label": "decreased phosphorylation of"
    },
    {
      "source": "RAMH",
      "target": "ets-like gene-1",
      "label": "downregulates phosphorylation of"
    },
    {
      "source": "RAMH",
      "target": "BDL cholangiocytes",
      "label": "stimulates"
    },
    {
      "source": "RAMH",
      "target": "cAMP-dependent PKA",
      "label": "downregulates"
    },
    {
      "source": "RAMH",
      "target": "H3R",
      "label": "is agonist of"
    },
    {
      "source": "BDL rats",
      "target": "RAMH",
      "label": "treated with"
    },
    {
      "source": "BDL rats",
      "target": "thioperamide maleate",
      "label": "treated with"
    },
    {
      "source": "Galpha(i/o) proteins",
      "target": "cAMP",
      "label": "reduces"
    },
    {
      "source": "Galpha(i/o) proteins",
      "target": "adenosine 3', 5'-monophosphate",
      "label": "reduces"
    },
    {
      "source": "thioperamide maleate",
      "target": "cholangiocyte proliferation",
      "label": "regulates"
    },
    {
      "source": "thioperamide maleate",
      "target": "H3R",
      "label": "is antagonist of"
    },
    {
      "source": "thioperamide maleate",
      "target": "cholangiocyte hyperplasia",
      "label": "increased"
    },
    {
      "source": "thioperamide maleate",
      "target": "Histamine",
      "label": "counteracts effect of"
    },
    {
      "source": "H3R",
      "target": "PKA",
      "label": "causes downregulation of phosphorylation of"
    },
    {
      "source": "H3R",
      "target": "biliary growth",
      "label": "regulates"
    },
    {
      "source": "H3R",
      "target": "ERK1/2",
      "label": "causes downregulation of phosphorylation of"
    },
    {
      "source": "H3R",
      "target": "liver sections",
      "label": "is expressed in"
    },
    {
      "source": "H3R",
      "target": "Elk-1",
      "label": "causes downregulation of phosphorylation of"
    },
    {
      "source": "H3R",
      "target": "Galpha(i/o) proteins",
      "label": "couples to"
    },
    {
      "source": "H3R",
      "target": "cholangiocyte RNA",
      "label": "is expressed in"
    },
    {
      "source": "PKA",
      "target": "cholangiocyte growth",
      "label": "downregulation of phosphorylation inhibits"
    },
    {
      "source": "immunofluorescence",
      "target": "H3R",
      "label": "evaluates"
    },
    {
      "source": "immunofluorescence",
      "target": "expression",
      "label": "was used to determine"
    },
    {
      "source": "Histamine",
      "target": "H2R",
      "label": "binds to"
    },
    {
      "source": "Histamine",
      "target": "H1R",
      "label": "binds to"
    },
    {
      "source": "Histamine",
      "target": "cholangiocyte growth",
      "label": "decreased"
    },
    {
      "source": "Histamine",
      "target": "H3R",
      "label": "binds to"
    },
    {
      "source": "Histamine",
      "target": "H4R",
      "label": "binds to"
    },
    {
      "source": "Histamine",
      "target": "histamine G-coupled receptor proteins",
      "label": "binds to"
    },
    {
      "source": "Elk-1",
      "target": "cholangiocyte growth",
      "label": "downregulation of phosphorylation inhibits"
    },
    {
      "source": "cholangiocytes",
      "target": "H3R",
      "label": "express"
    },
    {
      "source": "(R)-(alpha)-(-)-methylhistamine dihydrobromide",
      "target": "H3R",
      "label": "is agonist of"
    },
    {
      "source": "AQP5 protein level",
      "target": "SMG",
      "label": "located in"
    },
    {
      "source": "AQP5 protein level",
      "target": "rat submandibular gland",
      "label": "located in"
    },
    {
      "source": "AQP5 protein level",
      "target": "contralateral gland",
      "label": "decreased compared to"
    },
    {
      "source": "parasympathetic denervation",
      "target": "chorda tympani",
      "label": "of"
    },
    {
      "source": "parasympathetic denervation",
      "target": "Degradation",
      "label": "causes"
    },
    {
      "source": "extract",
      "target": "AQP5 protein",
      "label": "degraded"
    },
    {
      "source": "extract",
      "target": "submandibular lysosomal fraction",
      "label": "obtained from"
    },
    {
      "source": "AQP5 protein",
      "target": "total membrane fraction",
      "label": "located in"
    },
    {
      "source": "aquaporin 5",
      "target": "AQP5",
      "label": "is also known as"
    },
    {
      "source": "AQP5",
      "target": "submandibular gland",
      "label": "located in"
    },
    {
      "source": "denervation of the cervical sympathetic trunk",
      "target": "sympathectomy",
      "label": "is also known as"
    },
    {
      "source": "denervation of the cervical sympathetic trunk",
      "target": "AQP1 protein level",
      "label": "does not affect"
    },
    {
      "source": "denervation of the cervical sympathetic trunk",
      "target": "AQP5 protein level",
      "label": "does not affect"
    },
    {
      "source": "cevimeline",
      "target": "M3 muscarinic receptor agonist",
      "label": "is an"
    },
    {
      "source": "cevimeline",
      "target": "recovery",
      "label": "causes"
    },
    {
      "source": "M3 muscarinic receptor agonist",
      "target": "regulation",
      "label": "involved in"
    },
    {
      "source": "Degradation",
      "target": "AQP5",
      "label": "of"
    },
    {
      "source": "rat submandibular gland",
      "target": "SMG",
      "label": "is also known as"
    },
    {
      "source": "recovery",
      "target": "AQP5",
      "label": "of"
    },
    {
      "source": "recovery",
      "target": "testosterone levels",
      "label": "of"
    },
    {
      "source": "CTD",
      "target": "mRNA level",
      "label": "does not affect"
    },
    {
      "source": "CTD",
      "target": "parasympathectomy",
      "label": "is also known as"
    },
    {
      "source": "CTD",
      "target": "AQP5 protein level",
      "label": "reduces"
    },
    {
      "source": "mRNA level",
      "target": "AQP5",
      "label": "of"
    },
    {
      "source": "chloroquine",
      "target": "denaturant",
      "label": "is a type of"
    },
    {
      "source": "chloroquine",
      "target": "AQP5 protein level",
      "label": "increases"
    },
    {
      "source": "denaturant",
      "target": "lysosomes",
      "label": "of"
    },
    {
      "source": "cevimeline hydrochloride",
      "target": "mRNA level",
      "label": "does not affect"
    },
    {
      "source": "cevimeline hydrochloride",
      "target": "M3 muscarinic receptor agonist",
      "label": "is an"
    },
    {
      "source": "cevimeline hydrochloride",
      "target": "AQP5 protein level",
      "label": "recovers"
    },
    {
      "source": "cevimeline hydrochloride",
      "target": "AQP1 protein level",
      "label": "increases"
    },
    {
      "source": "transcriptional mechanism",
      "target": "regulation",
      "label": "not involved in"
    },
    {
      "source": "chorda tympani denervation",
      "target": "AQP5 protein level",
      "label": "decreases"
    },
    {
      "source": "chorda tympani denervation",
      "target": "AQP1 protein level",
      "label": "does not decrease"
    },
    {
      "source": "chorda tympani denervation",
      "target": "CTD",
      "label": "is also known as"
    },
    {
      "source": "pilocarpine",
      "target": "AQP5 protein level",
      "label": "does not recover"
    },
    {
      "source": "parasympathetic nerves",
      "target": "regulation",
      "label": "involved in"
    },
    {
      "source": "spread of malignant gliomas",
      "target": "brain",
      "label": "occurs within"
    },
    {
      "source": "stathmin",
      "target": "migration",
      "label": "mediates"
    },
    {
      "source": "stathmin",
      "target": "invasion",
      "label": "mediates"
    },
    {
      "source": "stathmin",
      "target": "microtubule-destabilizing protein",
      "label": "is a"
    },
    {
      "source": "stathmin",
      "target": "cell movement",
      "label": "regulates"
    },
    {
      "source": "stathmin",
      "target": "malignant glioma cell motility",
      "label": "has a role in"
    },
    {
      "source": "migration",
      "target": "osteoblasts",
      "label": "of"
    },
    {
      "source": "migration",
      "target": "Col1a1-Cnn1 mice",
      "label": "was decreased in"
    },
    {
      "source": "migration",
      "target": "cytoskeleton",
      "label": "decreased due to alterations in"
    },
    {
      "source": "migration",
      "target": "medial thyroid anlage",
      "label": "is of"
    },
    {
      "source": "Nitrosoureas",
      "target": "migration",
      "label": "inhibit"
    },
    {
      "source": "Nitrosoureas",
      "target": "therapeutic benefits",
      "label": "have"
    },
    {
      "source": "Nitrosoureas",
      "target": "cell movement-related processes",
      "label": "affect"
    },
    {
      "source": "Nitrosoureas",
      "target": "invasion",
      "label": "inhibit"
    },
    {
      "source": "Nitrosoureas",
      "target": "stathmin",
      "label": "modify"
    },
    {
      "source": "Nitrosoureas",
      "target": "proteins",
      "label": "modify"
    },
    {
      "source": "Nitrosoureas",
      "target": "antiproliferative effects",
      "label": "have"
    },
    {
      "source": "Nitrosoureas",
      "target": "DNA alkylating agents",
      "label": "are"
    },
    {
      "source": "therapeutic benefits",
      "target": "antiproliferative effects",
      "label": "are in addition to"
    },
    {
      "source": "[1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]",
      "target": "CCNU",
      "label": "is also known as"
    },
    {
      "source": "CCNU",
      "target": "invasion",
      "label": "causes decreases in"
    },
    {
      "source": "CCNU",
      "target": "stathmin",
      "label": "inhibits"
    },
    {
      "source": "CCNU",
      "target": "malignant glioma cell motility",
      "label": "causes decreases in"
    },
    {
      "source": "CCNU",
      "target": "migration",
      "label": "causes decreases in"
    },
    {
      "source": "CCNU",
      "target": "cell viability",
      "label": "has no effect on"
    },
    {
      "source": "neoplastic cells",
      "target": "surrounding brain",
      "label": "invade into"
    },
    {
      "source": "neoplastic cells",
      "target": "migration",
      "label": "perform"
    },
    {
      "source": "neoplastic cells",
      "target": "initial site of tumor formation",
      "label": "migrate from"
    },
    {
      "source": "neoplastic cells",
      "target": "invasion",
      "label": "perform"
    },
    {
      "source": "neoplastic cells",
      "target": "up-regulation of caspases",
      "label": "show"
    },
    {
      "source": "antiproliferative effects",
      "target": "E235",
      "label": "of"
    },
    {
      "source": "antiproliferative effects",
      "target": "cancer cell lines",
      "label": "occurred in"
    },
    {
      "source": "down-regulation of cellular stathmin levels",
      "target": "cellular stathmin levels",
      "label": "decreases"
    },
    {
      "source": "Malignant gliomas",
      "target": "primary intrinsic brain tumors",
      "label": "are a type of"
    },
    {
      "source": "stathmin expression",
      "target": "invasion",
      "label": "leads to decreases in"
    },
    {
      "source": "stathmin expression",
      "target": "malignant glioma cell motility",
      "label": "leads to decreases in"
    },
    {
      "source": "stathmin expression",
      "target": "migration",
      "label": "leads to decreases in"
    },
    {
      "source": "lesions",
      "target": "surgical treatment",
      "label": "are refractory to"
    },
    {
      "source": "microtubule-destabilizing protein",
      "target": "cell cycle progression",
      "label": "mediates"
    },
    {
      "source": "cell cycle progression",
      "target": "G(0)/G(1) phase",
      "label": "with a halt at"
    },
    {
      "source": "inhibition of stathmin",
      "target": "spread of malignant gliomas",
      "label": "limits"
    },
    {
      "source": "sublethal nitrosourea concentrations",
      "target": "[1-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea]",
      "label": "are concentrations of"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "cholinergic side effects",
      "label": "contributes to"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "binding assay",
      "label": "evaluated in"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "Oxybutynin",
      "label": "more potent than"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "parent drug",
      "label": "is more potent than"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "m1, m3 and m4 receptors",
      "label": "displaced binding at"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "major metabolite",
      "label": "is a"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "m1 and m3 receptors",
      "label": "has potency with"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "humans",
      "label": "is found in"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "m5",
      "label": "less potent at"
    },
    {
      "source": "N-desethyloxybutynin",
      "target": "m2",
      "label": "less potent at"
    },
    {
      "source": "cholinergic side effects",
      "target": "N-desethyloxybutynin",
      "label": "associated with"
    },
    {
      "source": "(3)H-NMS",
      "target": "m2",
      "label": "Regulator"
    },
    {
      "source": "(3)H-NMS",
      "target": "m5",
      "label": "Regulator"
    },
    {
      "source": "R enantiomers",
      "target": "S enantiomers",
      "label": "more potent than"
    },
    {
      "source": "Oxybutynin",
      "target": "binding assay",
      "label": "evaluated in"
    },
    {
      "source": "Oxybutynin",
      "target": "m1, m3 and m4 receptors",
      "label": "displaced binding at"
    },
    {
      "source": "Oxybutynin",
      "target": "parent compound",
      "label": "is a"
    },
    {
      "source": "Oxybutynin",
      "target": "muscarinic receptor",
      "label": "Antagonist"
    },
    {
      "source": "Oxybutynin",
      "target": "urinary incontinence",
      "label": "treats"
    },
    {
      "source": "Oxybutynin",
      "target": "parent drug",
      "label": "is a"
    },
    {
      "source": "Oxybutynin",
      "target": "m5",
      "label": "less potent at"
    },
    {
      "source": "Oxybutynin",
      "target": "m2",
      "label": "less potent at"
    },
    {
      "source": "Oxybutynin",
      "target": "non-selective muscarinic receptor antagonist",
      "label": "is a"
    },
    {
      "source": "parent compound",
      "target": "amiodarone",
      "label": "is"
    },
    {
      "source": "R-enantiomer",
      "target": "m1 and m3 receptors",
      "label": "has greater potency with"
    },
    {
      "source": "FCGR2A",
      "target": "clinical outcome",
      "label": "associated with"
    },
    {
      "source": "FCGR2A, any histidine allele",
      "target": "genotypes",
      "label": "is a type of"
    },
    {
      "source": "FCGR2A arginine/arginine",
      "target": "genotypes",
      "label": "is a type of"
    },
    {
      "source": "Combined analysis",
      "target": "unfavorable genotypes",
      "label": "showed"
    },
    {
      "source": "Combined analysis",
      "target": "favorable genotypes",
      "label": "showed"
    },
    {
      "source": "unfavorable genotypes",
      "target": "FCGR2A arginine/arginine",
      "label": "include"
    },
    {
      "source": "unfavorable genotypes",
      "target": "valine/valine",
      "label": "include"
    },
    {
      "source": "unfavorable genotypes",
      "target": "progression-free survival (PFS)",
      "label": "had"
    },
    {
      "source": "metastatic colorectal cancer patients",
      "target": "Cetuximab",
      "label": "treated with"
    },
    {
      "source": "metastatic colorectal cancer patients",
      "target": "single-agent cetuximab",
      "label": "treated with"
    },
    {
      "source": "metastatic colorectal cancer patients",
      "target": "ImClone0144 trial",
      "label": "enrolled onto"
    },
    {
      "source": "metastatic colorectal cancer patients",
      "target": "epidermal growth factor receptor",
      "label": "express"
    },
    {
      "source": "metastatic colorectal cancer patients",
      "target": "5-fluorouracil/irinotecan-based regimens",
      "label": "treated with"
    },
    {
      "source": "Cetuximab",
      "target": "monoclonal antibody",
      "label": "is a"
    },
    {
      "source": "Cetuximab",
      "target": "efficacy",
      "label": "has shown"
    },
    {
      "source": "Cetuximab",
      "target": "role of ADCC of cetuximab",
      "label": "is part of"
    },
    {
      "source": "Cetuximab",
      "target": "EGFR",
      "label": "is anti-"
    },
    {
      "source": "Cetuximab",
      "target": "epidermal growth factor receptor",
      "label": "is anti-"
    },
    {
      "source": "Cetuximab",
      "target": "chimeric immunoglobulin G 1 (IgG1) anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb)",
      "label": "is a"
    },
    {
      "source": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "target": "role of ADCC of cetuximab",
      "label": "is part of"
    },
    {
      "source": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "target": "rituximab",
      "label": "is a mode of action for"
    },
    {
      "source": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "target": "trastuzumab",
      "label": "is a mode of action for"
    },
    {
      "source": "gene polymorphisms",
      "target": "allele-specific polymerase chain reaction (PCR) -based method",
      "label": "assessed using"
    },
    {
      "source": "gene polymorphisms",
      "target": "FCGA3A-V158F",
      "label": "include"
    },
    {
      "source": "gene polymorphisms",
      "target": "FCGA2A-H131R",
      "label": "include"
    },
    {
      "source": "gene polymorphisms",
      "target": "PCR",
      "label": "assessed using"
    },
    {
      "source": "favorable genotypes",
      "target": "FCGR2A, any histidine allele",
      "label": "include"
    },
    {
      "source": "favorable genotypes",
      "target": "median PFS",
      "label": "showed"
    },
    {
      "source": "favorable genotypes",
      "target": "FCGR3A, any phenylalanine allele",
      "label": "include"
    },
    {
      "source": "FCGR3A-V158F",
      "target": "clinical outcome",
      "label": "associated with"
    },
    {
      "source": "FCGR3A-V158F",
      "target": "progression-free survival (PFS)",
      "label": "associated with"
    },
    {
      "source": "FCGR3A-V158F",
      "target": "response",
      "label": "predicts"
    },
    {
      "source": "FCGA3A-V158F",
      "target": "genomic DNA",
      "label": "assessed from"
    },
    {
      "source": "IgG FcgammaR polymorphisms",
      "target": "response",
      "label": "predict"
    },
    {
      "source": "FCGR2A-H131R",
      "target": "response",
      "label": "predicts"
    },
    {
      "source": "FCGR2A-H131R",
      "target": "clinical outcome",
      "label": "associated with"
    },
    {
      "source": "FCGR2A-H131R",
      "target": "progression-free survival (PFS)",
      "label": "associated with"
    },
    {
      "source": "FCGR3A, any phenylalanine allele",
      "target": "genotypes",
      "label": "is a type of"
    },
    {
      "source": "FCGA2A-H131R",
      "target": "genomic DNA",
      "label": "assessed from"
    },
    {
      "source": "genomic DNA",
      "target": "peripheral blood samples",
      "label": "extracted from"
    },
    {
      "source": "valine/valine",
      "target": "genotypes",
      "label": "is a type of"
    },
    {
      "source": "Fragment c",
      "target": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "label": "induces"
    },
    {
      "source": "Fragment c",
      "target": "IgG1 mAb",
      "label": "is part of"
    },
    {
      "source": "FCGR3A polymorphisms",
      "target": "clinical outcome",
      "label": "associated with"
    },
    {
      "source": "Fragment c (Fc) portion",
      "target": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "label": "induces"
    },
    {
      "source": "Fragment c (Fc) portion",
      "target": "IgG1 mAb",
      "label": "is part of"
    },
    {
      "source": "molecular markers",
      "target": "clinical outcome",
      "label": "predict"
    },
    {
      "source": "Fragment c gamma receptors (FcgammaR)",
      "target": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "label": "initiates"
    },
    {
      "source": "preliminary data",
      "target": "polymorphisms",
      "label": "suggest"
    },
    {
      "source": "FcgammaR",
      "target": "antibody-dependent cell-mediated cytotoxicity (ADCC)",
      "label": "initiates"
    },
    {
      "source": "HepG2",
      "target": "hepatocyte cell line",
      "label": "is a type of"
    },
    {
      "source": "HepG2",
      "target": "human hepatoma cell line",
      "label": "is a"
    },
    {
      "source": "HepG2",
      "target": "liver cells",
      "label": "is a type of"
    },
    {
      "source": "amiodarone",
      "target": "B2-O-CH(2)CH(2)-N-diethyl",
      "label": "is also known as"
    },
    {
      "source": "amiodarone",
      "target": "affinity",
      "label": "has"
    },
    {
      "source": "amiodarone",
      "target": "organ toxicity",
      "label": "demonstrates"
    },
    {
      "source": "amiodarone",
      "target": "2-n-butyl-3-[3,5 diiodo-4-diethylaminoethoxybenzoyl]-benzofuran",
      "label": "is also known as"
    },
    {
      "source": "amiodarone",
      "target": "cytotoxicity",
      "label": "has"
    },
    {
      "source": "amiodarone",
      "target": "hERG channel",
      "label": "interacts with"
    },
    {
      "source": "amiodarone",
      "target": "class III antiarrhythmic drug",
      "label": "is a"
    },
    {
      "source": "basic nitrogen",
      "target": "group",
      "label": "is a type of"
    },
    {
      "source": "basic nitrogen",
      "target": "phenolic side chain",
      "label": "is located in"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-pyrrolidine",
      "target": "amiodarone",
      "label": "is more toxic than"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-pyrrolidine",
      "target": "hERG channel",
      "label": "has higher affinity towards"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-pyrrolidine",
      "target": "affinity",
      "label": "revealed higher"
    },
    {
      "source": "amiodarone analogues",
      "target": "cytotoxicity",
      "label": "have better"
    },
    {
      "source": "amiodarone analogues",
      "target": "human ether-a-go-go-related protein (hERG) channel inhibition",
      "label": "retained"
    },
    {
      "source": "amiodarone analogues",
      "target": "hERG channel",
      "label": "interacts with"
    },
    {
      "source": "amiodarone analogues",
      "target": "basic nitrogen",
      "label": "contain"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-piperidine",
      "target": "amiodarone",
      "label": "is less toxic than"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-piperidine",
      "target": "hERG channel",
      "label": "has higher affinity towards"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-piperidine",
      "target": "affinity",
      "label": "revealed higher"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-piperidine",
      "target": "structural analogues",
      "label": "is a type of"
    },
    {
      "source": "acid",
      "target": "amiodarone",
      "label": "is more toxic than"
    },
    {
      "source": "acid",
      "target": "B2-O-CH(2)-COOH",
      "label": "is also known as"
    },
    {
      "source": "hERG channel interaction",
      "target": "properties",
      "label": "is a"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-diisopropyl",
      "target": "structural analogues",
      "label": "is a type of"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-N-diisopropyl",
      "target": "amiodarone",
      "label": "is less toxic than"
    },
    {
      "source": "B2-O-CH(2)-CH(2)-OH",
      "target": "amiodarone",
      "label": "is more toxic than"
    },
    {
      "source": "alcohol",
      "target": "amiodarone",
      "label": "is more toxic than"
    },
    {
      "source": "alcohol",
      "target": "B2-O-CH(2)-CH(2)-OH",
      "label": "is also known as"
    },
    {
      "source": "alcohol",
      "target": "endpoint",
      "label": "influence depended on"
    },
    {
      "source": "alcohol",
      "target": "mixture",
      "label": "influence depended on"
    },
    {
      "source": "alcohol",
      "target": "effects of NCMs",
      "label": "influenced"
    },
    {
      "source": "A549 cells",
      "target": "pneumocyte line",
      "label": "is a type of"
    },
    {
      "source": "B2-O-CH(2)-COOH",
      "target": "amiodarone",
      "label": "is more toxic than"
    },
    {
      "source": "mono- and bis-desethylated metabolites",
      "target": "amiodarone",
      "label": "are more toxic than"
    },
    {
      "source": "Interactions",
      "target": "pharmacological methods",
      "label": "measured using"
    },
    {
      "source": "Interactions",
      "target": "in silico methods",
      "label": "measured using"
    },
    {
      "source": "Interactions",
      "target": "negative social environments",
      "label": "occur between"
    },
    {
      "source": "Interactions",
      "target": "economic stress",
      "label": "occur between"
    },
    {
      "source": "Interactions",
      "target": "OXTR",
      "label": "based on"
    },
    {
      "source": "Interactions",
      "target": "rs53576 genotype",
      "label": "based on"
    },
    {
      "source": "holo-alpha-lactalbumin",
      "target": "fatty acids",
      "label": "unable to bind"
    },
    {
      "source": "holo-alpha-lactalbumin",
      "target": "nondenaturing conditions",
      "label": "isolated using"
    },
    {
      "source": "Apo-alpha-lactalbumin",
      "target": "association constants",
      "label": "has"
    },
    {
      "source": "Apo-alpha-lactalbumin",
      "target": "EDTA",
      "label": "obtained by treatment with"
    },
    {
      "source": "Apo-alpha-lactalbumin",
      "target": "fatty acids",
      "label": "binds"
    },
    {
      "source": "Apo-alpha-lactalbumin",
      "target": "binding site",
      "label": "displays"
    },
    {
      "source": "association constants",
      "target": "oleic and palmitic acids",
      "label": "for"
    },
    {
      "source": "apo-forms of human alpha-lactalbumin",
      "target": "fatty acids",
      "label": "interacts with"
    },
    {
      "source": "EDTA",
      "target": "AChE",
      "label": "Regulator"
    },
    {
      "source": "partition equilibrium method",
      "target": "holo-forms of human alpha-lactalbumin",
      "label": "used to study"
    },
    {
      "source": "partition equilibrium method",
      "target": "apo-forms of human alpha-lactalbumin",
      "label": "used to study"
    },
    {
      "source": "holo-forms of human alpha-lactalbumin",
      "target": "fatty acids",
      "label": "interacts with"
    },
    {
      "source": "human alpha-lactalbumin",
      "target": "fatty acids",
      "label": "interacts with"
    },
    {
      "source": "human alpha-lactalbumin",
      "target": "binding parameters",
      "label": "has"
    },
    {
      "source": "binding parameters",
      "target": "purified fractions",
      "label": "obtained for"
    },
    {
      "source": "neomycin",
      "target": "absorption",
      "label": "reduce"
    },
    {
      "source": "neomycin",
      "target": "bile acids",
      "label": "interrupt recirculation of"
    },
    {
      "source": "neomycin",
      "target": "recirculation",
      "label": "interrupt"
    },
    {
      "source": "neomycin",
      "target": "cholesterol",
      "label": "reduce absorption of"
    },
    {
      "source": "cholesteryl esters",
      "target": "lower-density lipoproteins",
      "label": "transported to"
    },
    {
      "source": "cholesteryl esters",
      "target": "high-density lipoproteins",
      "label": "transported from"
    },
    {
      "source": "acipimox",
      "target": "clearance",
      "label": "improve"
    },
    {
      "source": "acipimox",
      "target": "LDL",
      "label": "interfere with biosynthesis of"
    },
    {
      "source": "acipimox",
      "target": "biosynthesis",
      "label": "interfere with"
    },
    {
      "source": "acipimox",
      "target": "VLDL",
      "label": "improve clearance of"
    },
    {
      "source": "LDL",
      "target": "adrenocortical aldosterone and cortisol release",
      "label": "has stimulating effect on"
    },
    {
      "source": "absorbable agents",
      "target": "mechanisms",
      "label": "act by"
    },
    {
      "source": "absorbable agents",
      "target": "plasma very-low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "absorbable agents",
      "target": "VLDL",
      "label": "reduce"
    },
    {
      "source": "absorbable agents",
      "target": "LDL",
      "label": "reduce"
    },
    {
      "source": "absorbable agents",
      "target": "low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "lipid-lowering agents",
      "target": "arterial disease",
      "label": "prevent"
    },
    {
      "source": "lipid-lowering agents",
      "target": "nonabsorbable compounds",
      "label": "classified as"
    },
    {
      "source": "lipid-lowering agents",
      "target": "absorbable agents",
      "label": "classified as"
    },
    {
      "source": "lipid-lowering agents",
      "target": "patient's phenotype",
      "label": "choice depends on"
    },
    {
      "source": "lipid-lowering agents",
      "target": "hyperlipoproteinemias",
      "label": "ameliorate"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "cholesterol",
      "label": "reduce absorption of"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "gastrointestinal lumen",
      "label": "act within"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "LDL receptor expression",
      "label": "increase"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "bile acids",
      "label": "interrupt recirculation of"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "absorption",
      "label": "reduce"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "recirculation",
      "label": "interrupt"
    },
    {
      "source": "nonabsorbable compounds",
      "target": "hypercholesterolemia",
      "label": "treat"
    },
    {
      "source": "anion-exchange resins",
      "target": "cholesterol",
      "label": "reduce absorption of"
    },
    {
      "source": "anion-exchange resins",
      "target": "bile acids",
      "label": "interrupt recirculation of"
    },
    {
      "source": "anion-exchange resins",
      "target": "absorption",
      "label": "reduce"
    },
    {
      "source": "anion-exchange resins",
      "target": "recirculation",
      "label": "interrupt"
    },
    {
      "source": "VLDL",
      "target": "ERK1/2",
      "label": "recruits"
    },
    {
      "source": "VLDL",
      "target": "adrenocortical aldosterone and cortisol release",
      "label": "has greater stimulating effect on"
    },
    {
      "source": "VLDL",
      "target": "stimulating effect",
      "label": "induced"
    },
    {
      "source": "beta-sitosterol",
      "target": "recirculation",
      "label": "interrupt"
    },
    {
      "source": "beta-sitosterol",
      "target": "cholesterol",
      "label": "reduce absorption of"
    },
    {
      "source": "beta-sitosterol",
      "target": "bile acids",
      "label": "interrupt recirculation of"
    },
    {
      "source": "beta-sitosterol",
      "target": "absorption",
      "label": "reduce"
    },
    {
      "source": "patient's phenotype",
      "target": "pharmacological treatment",
      "label": "determines"
    },
    {
      "source": "fibric acids",
      "target": "plasma very-low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "fibric acids",
      "target": "LDL delipidation",
      "label": "improve"
    },
    {
      "source": "fibric acids",
      "target": "catabolism",
      "label": "stimulate"
    },
    {
      "source": "fibric acids",
      "target": "VLDL",
      "label": "reduce"
    },
    {
      "source": "fibric acids",
      "target": "receptor uptake",
      "label": "favor"
    },
    {
      "source": "fibric acids",
      "target": "LDL",
      "label": "reduce"
    },
    {
      "source": "fibric acids",
      "target": "low-density lipoproteins",
      "label": "reduce"
    },
    {
      "source": "transaminase enzymes",
      "target": "alanine",
      "label": "acts on"
    },
    {
      "source": "transaminase enzymes",
      "target": "gamma-aminobutyric acid",
      "label": "acts on"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "GABA",
      "label": "has effect on"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "whole-brain levels",
      "label": "causes increases in"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "neurochemical properties",
      "label": "has"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "monoamine oxidase inhibitor",
      "label": "is a"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "profile",
      "label": "has"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "phenelzine",
      "label": "compared with"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "inhibitor",
      "label": "is a"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "3,4-dihydroxyphenylacetic acetic",
      "label": "decreases"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "monoamine oxidase-A",
      "label": "inhibits"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "5-hydroxyindole-3-acetic acid",
      "label": "decreases"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "monoamine oxidase-B",
      "label": "inhibits"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "rat brain",
      "label": "has effect on"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "rat model",
      "label": "studied in"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "biogenic amines",
      "label": "has effect on"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "alanine",
      "label": "has effect on"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "drug",
      "label": "is a"
    },
    {
      "source": "N2-acetylphenelzine",
      "target": "homovanillic acid",
      "label": "decreases"
    },
    {
      "source": "phenelzine",
      "target": "neurochemical properties",
      "label": "has"
    },
    {
      "source": "phenelzine",
      "target": "monoamine oxidase inhibitor",
      "label": "is a"
    },
    {
      "source": "phenelzine",
      "target": "transaminase enzymes",
      "label": "inhibits"
    },
    {
      "source": "phenelzine",
      "target": "N2-acetylphenelzine",
      "label": "is more potent than"
    },
    {
      "source": "phenelzine",
      "target": "whole-brain levels",
      "label": "causes increases in"
    },
    {
      "source": "phenelzine",
      "target": "rat model",
      "label": "studied in"
    },
    {
      "source": "whole-brain levels",
      "target": "gamma-aminobutyric acid",
      "label": "are levels of"
    },
    {
      "source": "whole-brain levels",
      "target": "5-hydroxytryptamine",
      "label": "are levels of"
    },
    {
      "source": "whole-brain levels",
      "target": "alanine",
      "label": "are levels of"
    },
    {
      "source": "whole-brain levels",
      "target": "noradrenaline",
      "label": "are levels of"
    },
    {
      "source": "gamma-aminobutyric acid",
      "target": "amino acid neurotransmitters",
      "label": "is a type of"
    },
    {
      "source": "rat model",
      "target": "PCOS",
      "label": "is a model of"
    },
    {
      "source": "rat model",
      "target": "Iowa Gambling Task",
      "label": "is a model of"
    },
    {
      "source": "rat model",
      "target": "rIGT",
      "label": "is also known as"
    },
    {
      "source": "homovanillic acid",
      "target": "striatum",
      "label": "located in"
    },
    {
      "source": "homovanillic acid",
      "target": "HVA",
      "label": "is a"
    },
    {
      "source": "homovanillic acid",
      "target": "plasma",
      "label": "located in"
    },
    {
      "source": "Lapatinib",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "Lapatinib",
      "target": "antitumor activity",
      "label": "has"
    },
    {
      "source": "Lapatinib",
      "target": "pharmacokinetics",
      "label": "has"
    },
    {
      "source": "Lapatinib",
      "target": "GW572016",
      "label": "also known as"
    },
    {
      "source": "Lapatinib",
      "target": "malignancies",
      "label": "has role in treatment of"
    },
    {
      "source": "Lapatinib",
      "target": "safety profile",
      "label": "has"
    },
    {
      "source": "Lapatinib",
      "target": "human epidermal growth factor receptor",
      "label": "is dual inhibitor of"
    },
    {
      "source": "Lapatinib",
      "target": "tyrosine kinases",
      "label": "is dual inhibitor of"
    },
    {
      "source": "Lapatinib",
      "target": "human epidermal growth factor receptor 2",
      "label": "is dual inhibitor of"
    },
    {
      "source": "Lapatinib",
      "target": "cytochrome P450 3A4 isozyme",
      "label": "metabolized by"
    },
    {
      "source": "Lapatinib",
      "target": "clinical efficacy",
      "label": "has"
    },
    {
      "source": "Lapatinib",
      "target": "pharmacology",
      "label": "has"
    },
    {
      "source": "Lapatinib",
      "target": "capecitabine",
      "label": "indicated for use in combination with"
    },
    {
      "source": "Lapatinib",
      "target": "FDA",
      "label": "approved by"
    },
    {
      "source": "Lapatinib",
      "target": "breast cancer",
      "label": "has role in treatment of"
    },
    {
      "source": "Lapatinib",
      "target": "US Food and Drug Administration",
      "label": "approved by"
    },
    {
      "source": "Lapatinib",
      "target": "EGFR",
      "label": "is dual inhibitor of"
    },
    {
      "source": "Lapatinib",
      "target": "first-line therapy",
      "label": "used as"
    },
    {
      "source": "Lapatinib",
      "target": "epidermal growth factor receptor",
      "label": "is dual inhibitor of"
    },
    {
      "source": "Lapatinib",
      "target": "HER2",
      "label": "is dual inhibitor of"
    },
    {
      "source": "capecitabine",
      "target": "doses",
      "label": "administered in"
    },
    {
      "source": "HER2-positive, locally advanced breast cancer",
      "target": "anthracycline",
      "label": "progressed after treatment with"
    },
    {
      "source": "HER2-positive, locally advanced breast cancer",
      "target": "taxane",
      "label": "progressed after treatment with"
    },
    {
      "source": "HER2-positive, locally advanced breast cancer",
      "target": "trastuzumab",
      "label": "progressed after treatment with"
    },
    {
      "source": "time to progression",
      "target": "hazard ratio",
      "label": "has"
    },
    {
      "source": "time to progression",
      "target": "CI",
      "label": "has"
    },
    {
      "source": "high-fat meal",
      "target": "AUC",
      "label": "increases"
    },
    {
      "source": "T(max)",
      "target": "oral administration",
      "label": "occurs after"
    },
    {
      "source": "T(max)",
      "target": "Lapatinib",
      "label": "is property of"
    },
    {
      "source": "clinical toxicities",
      "target": "pivotal clinical trial",
      "label": "observed in"
    },
    {
      "source": "clinical toxicities",
      "target": "rash",
      "label": "include"
    },
    {
      "source": "clinical toxicities",
      "target": "capecitabine",
      "label": "associated with"
    },
    {
      "source": "clinical toxicities",
      "target": "nausea",
      "label": "include"
    },
    {
      "source": "clinical toxicities",
      "target": "fatigue",
      "label": "include"
    },
    {
      "source": "clinical toxicities",
      "target": "grades",
      "label": "has"
    },
    {
      "source": "clinical toxicities",
      "target": "Lapatinib",
      "label": "associated with"
    },
    {
      "source": "clinical toxicities",
      "target": "diarrhea",
      "label": "include"
    },
    {
      "source": "clinical toxicities",
      "target": "hand-foot syndrome",
      "label": "include"
    },
    {
      "source": "malignancies",
      "target": "HER2",
      "label": "overexpress"
    },
    {
      "source": "malignancies",
      "target": "EGFR",
      "label": "overexpress"
    },
    {
      "source": "MBC",
      "target": "trastuzumab",
      "label": "progressed after treatment with"
    },
    {
      "source": "MBC",
      "target": "standard treatment",
      "label": "progressed with"
    },
    {
      "source": "MBC",
      "target": "taxane",
      "label": "received previous treatment including"
    },
    {
      "source": "MBC",
      "target": "anthracycline",
      "label": "received previous treatment including"
    },
    {
      "source": "English-language publications",
      "target": "MEDLINE",
      "label": "identified through searches of"
    },
    {
      "source": "English-language publications",
      "target": "San Antonio Breast Cancer Symposium",
      "label": "identified through searches of"
    },
    {
      "source": "English-language publications",
      "target": "FDA Web site",
      "label": "identified through searches of"
    },
    {
      "source": "English-language publications",
      "target": "American Society of Clinical Oncology abstracts database",
      "label": "identified through searches of"
    },
    {
      "source": "MEDLINE",
      "target": "reviews",
      "label": "searched for"
    },
    {
      "source": "MEDLINE",
      "target": "relevant trials",
      "label": "searched for"
    },
    {
      "source": "Phase III trial",
      "target": "capecitabine",
      "label": "compared"
    },
    {
      "source": "Phase III trial",
      "target": "Lapatinib",
      "label": "compared"
    },
    {
      "source": "rash",
      "target": "clinical toxicities",
      "label": "is a type of"
    },
    {
      "source": "diarrhea",
      "target": "clinical toxicities",
      "label": "is a type of"
    },
    {
      "source": "Cardiac toxicity",
      "target": "trastuzumab",
      "label": "more frequent with"
    },
    {
      "source": "Cardiac toxicity",
      "target": "Lapatinib",
      "label": "less frequent with"
    },
    {
      "source": "dosing",
      "target": "capecitabine",
      "label": "given in combination with"
    },
    {
      "source": "dosing",
      "target": "PO QD",
      "label": "is"
    },
    {
      "source": "dosing",
      "target": "Lapatinib",
      "label": "is property of"
    },
    {
      "source": "dosing",
      "target": "community",
      "label": "can be improved in"
    },
    {
      "source": "dosing",
      "target": "anti-dementia medications",
      "label": "involves"
    },
    {
      "source": "dosing",
      "target": "AD medications",
      "label": "is of"
    },
    {
      "source": "drug accumulation",
      "target": "t(1/2)",
      "label": "causes"
    },
    {
      "source": "t(1/2)",
      "target": "continuous dosing",
      "label": "is associated with"
    },
    {
      "source": "t(1/2)",
      "target": "Lapatinib",
      "label": "is property of"
    },
    {
      "source": "CI",
      "target": "6 weeks",
      "label": "has duration"
    },
    {
      "source": "CI",
      "target": "carbonyl iron",
      "label": "contains"
    },
    {
      "source": "CI",
      "target": "C",
      "label": "includes"
    },
    {
      "source": "Phase II trials",
      "target": "activity",
      "label": "found"
    },
    {
      "source": "fatigue",
      "target": "clinical toxicities",
      "label": "is a type of"
    },
    {
      "source": "Captopril",
      "target": "MMP-9",
      "label": "inhibited"
    },
    {
      "source": "Captopril",
      "target": "matrix metalloproteinase-9",
      "label": "attenuates"
    },
    {
      "source": "Captopril",
      "target": "matrix metalloproteinase-2",
      "label": "attenuates"
    },
    {
      "source": "Captopril",
      "target": "MMP-2",
      "label": "inhibits"
    },
    {
      "source": "Captopril",
      "target": "ACE",
      "label": "inhibits"
    },
    {
      "source": "Captopril",
      "target": "right ventricular dysfunction",
      "label": "inhibited"
    },
    {
      "source": "Captopril",
      "target": "angiotensin converting enzyme (ACE) inhibitors",
      "label": "is a type of"
    },
    {
      "source": "Captopril",
      "target": "right ventricular hypertrophy",
      "label": "attenuates"
    },
    {
      "source": "Captopril",
      "target": "pulmonary artery pressure",
      "label": "did not attenuate"
    },
    {
      "source": "Captopril",
      "target": "angiotensin converting enzyme",
      "label": "inhibits"
    },
    {
      "source": "Captopril",
      "target": "fibrosis",
      "label": "inhibited"
    },
    {
      "source": "MMP-9",
      "target": "Western blotting",
      "label": "measured by"
    },
    {
      "source": "MMP-9",
      "target": "gelatin zymography",
      "label": "measured by"
    },
    {
      "source": "MMP-9",
      "target": "macrophage cell line THP-1",
      "label": "synthesized by"
    },
    {
      "source": "monocrotaline",
      "target": "MMP-2",
      "label": "increases"
    },
    {
      "source": "monocrotaline",
      "target": "right ventricular dysfunction",
      "label": "causes"
    },
    {
      "source": "monocrotaline",
      "target": "right ventricular weight/tail length ratio",
      "label": "increases"
    },
    {
      "source": "monocrotaline",
      "target": "cardiomyocyte hypertrophy",
      "label": "causes"
    },
    {
      "source": "monocrotaline",
      "target": "right ventricular hypertrophy",
      "label": "induces"
    },
    {
      "source": "monocrotaline",
      "target": "fibrosis",
      "label": "causes"
    },
    {
      "source": "monocrotaline",
      "target": "MMP-9",
      "label": "increases"
    },
    {
      "source": "matrix metalloproteinase-9",
      "target": "MMP-9",
      "label": "is also known as"
    },
    {
      "source": "echocardiography",
      "target": "right ventricular dysfunction",
      "label": "showed"
    },
    {
      "source": "MMP-2",
      "target": "Western blotting",
      "label": "measured by"
    },
    {
      "source": "MMP-2",
      "target": "gelatin zymography",
      "label": "measured by"
    },
    {
      "source": "cardiomyocyte hypertrophy",
      "target": "right ventricular sections",
      "label": "found in"
    },
    {
      "source": "fibrosis",
      "target": "right ventricular sections",
      "label": "found in"
    },
    {
      "source": "angiotensin converting enzyme (ACE) inhibitors",
      "target": "matrix metalloproteinase (MMP)",
      "label": "influence"
    },
    {
      "source": "matrix metalloproteinase (MMP)",
      "target": "right ventricular remodeling",
      "label": "involved in"
    },
    {
      "source": "5alpha-reductase inhibitors (5alphaRIs)",
      "target": "combination therapy",
      "label": "used in"
    },
    {
      "source": "5alpha-reductase inhibitors (5alphaRIs)",
      "target": "treatment",
      "label": "used in"
    },
    {
      "source": "lower urinary tract symptoms (LUTS)",
      "target": "benign prostatic hyperplasia (BPH)",
      "label": "associated with"
    },
    {
      "source": "Cochrane databases",
      "target": "reviews",
      "label": "searched for"
    },
    {
      "source": "Cochrane databases",
      "target": "relevant trials",
      "label": "searched for"
    },
    {
      "source": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "target": "combination therapy",
      "label": "used in"
    },
    {
      "source": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "target": "treatment",
      "label": "used in"
    },
    {
      "source": "terms",
      "target": "oxybutynin",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "finasteride",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "benign prostatic hyperplasia (BPH)",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "propiverine",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "anti-muscarinic agents",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "lower urinary tract symptoms (LUTS)",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "combination therapy",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "sildenafil",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "tolterodine",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "vardenafil",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "terazosin",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "anticholinergics",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "5alpha-reductase inhibitors (5alphaRIs)",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "tamsulosin",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "dutasteride",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "tadalafil",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "erectile dysfunction",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "doxazosin",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "flavoxate",
      "label": "include"
    },
    {
      "source": "terms",
      "target": "alfuzosin",
      "label": "include"
    },
    {
      "source": "increased risk",
      "target": "urinary retention",
      "label": "of"
    },
    {
      "source": "dutasteride",
      "target": "5alpha-reductase inhibitors (5alphaRIs)",
      "label": "is a"
    },
    {
      "source": "finasteride",
      "target": "5alpha-reductase inhibitors (5alphaRIs)",
      "label": "is a"
    },
    {
      "source": "statistically significant benefits",
      "target": "IPSS scores",
      "label": "in"
    },
    {
      "source": "statistically significant benefits",
      "target": "patient satisfaction",
      "label": "in"
    },
    {
      "source": "statistically significant benefits",
      "target": "urinary frequency",
      "label": "in"
    },
    {
      "source": "statistically significant benefits",
      "target": "quality of life scores",
      "label": "in"
    },
    {
      "source": "statistically significant benefits",
      "target": "storage symptoms",
      "label": "in"
    },
    {
      "source": "Combination of Avodart and Tamsulosin study",
      "target": "tamsulosin",
      "label": "involves"
    },
    {
      "source": "Combination of Avodart and Tamsulosin study",
      "target": "Avodart",
      "label": "involves"
    },
    {
      "source": "key trials",
      "target": "combination therapy",
      "label": "review"
    },
    {
      "source": "key trials",
      "target": "monotherapy",
      "label": "review"
    },
    {
      "source": "highly select cohort of men",
      "target": "benign prostatic hyperplasia (BPH)",
      "label": "with"
    },
    {
      "source": "highly select cohort of men",
      "target": "men",
      "label": "are"
    },
    {
      "source": "anti-muscarinic agents",
      "target": "increased risk",
      "label": "not associated with"
    },
    {
      "source": "anti-muscarinic agents",
      "target": "highly select cohort of men",
      "label": "used in"
    },
    {
      "source": "anti-muscarinic agents",
      "target": "treatment",
      "label": "used in"
    },
    {
      "source": "combination medical therapy",
      "target": "benign prostatic hyperplasia (BPH)",
      "label": "has role in"
    },
    {
      "source": "monotherapy",
      "target": "5alpha-reductase inhibitors (5alphaRIs)",
      "label": "involves"
    },
    {
      "source": "monotherapy",
      "target": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "label": "involves"
    },
    {
      "source": "monotherapy",
      "target": "anti-muscarinic agents",
      "label": "involves"
    },
    {
      "source": "monotherapy",
      "target": "adverse events",
      "label": "associated with"
    },
    {
      "source": "monotherapy",
      "target": "benign cardiac arrhythmias",
      "label": "causes"
    },
    {
      "source": "monotherapy",
      "target": "insomnia",
      "label": "causes"
    },
    {
      "source": "monotherapy",
      "target": "dizziness",
      "label": "causes"
    },
    {
      "source": "monotherapy",
      "target": "headache",
      "label": "causes"
    },
    {
      "source": "monotherapy",
      "target": "nausea",
      "label": "causes"
    },
    {
      "source": "adequate alleviation of symptoms",
      "target": "first-line alpha(1)-ARAs",
      "label": "from"
    },
    {
      "source": "Medical Therapy of Prostatic Symptoms (MTOPS) study",
      "target": "long-term use",
      "label": "indicated role for"
    },
    {
      "source": "long-term use",
      "target": "5alpha-reductase inhibitors (5alphaRIs)",
      "label": "of"
    },
    {
      "source": "long-term use",
      "target": "alpha(1)-adrenergic receptor antagonists (alpha(1)-ARAs)",
      "label": "of"
    },
    {
      "source": "available data",
      "target": "combination therapy",
      "label": "suggests"
    },
    {
      "source": "finasteride monotherapy",
      "target": "component",
      "label": "is a"
    },
    {
      "source": "risk of acute urinary retention",
      "target": "recent clinical trials",
      "label": "refuted in"
    },
    {
      "source": "recent trials",
      "target": "efficacy",
      "label": "studied"
    },
    {
      "source": "2-year preliminary results",
      "target": "Combination of Avodart and Tamsulosin study",
      "label": "from"
    },
    {
      "source": "doxazosin monotherapy",
      "target": "component",
      "label": "is a"
    },
    {
      "source": "Theoretic concerns",
      "target": "risk of acute urinary retention",
      "label": "regarding"
    },
    {
      "source": "niflumic acid",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "Panx1 currents",
      "target": "purine receptors",
      "label": "independent of"
    },
    {
      "source": "Panx1 currents",
      "target": "phospholipase C transduction",
      "label": "were independent of"
    },
    {
      "source": "Panx1 currents",
      "target": "intracellular calcium",
      "label": "were independent of"
    },
    {
      "source": "Panx1 currents",
      "target": "extracellular calcium",
      "label": "were independent of"
    },
    {
      "source": "flufenamic acid",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "frequency of functional expression",
      "target": "species",
      "label": "was dependent on"
    },
    {
      "source": "mouse Panx1",
      "target": "mammalian cells",
      "label": "expressed in"
    },
    {
      "source": "mouse Panx1",
      "target": "functional properties",
      "label": "showed identical"
    },
    {
      "source": "mouse Panx1",
      "target": "protein expression levels",
      "label": "showed identical"
    },
    {
      "source": "mouse Panx1",
      "target": "localization patterns",
      "label": "showed identical"
    },
    {
      "source": "indanyloxyacetic acid 94",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "Pannexin (Panx) 1",
      "target": "gap junction proteins",
      "label": "shares structural homology with"
    },
    {
      "source": "Pannexin (Panx) 1",
      "target": "protein",
      "label": "is a"
    },
    {
      "source": "gap junction proteins",
      "target": "connexins",
      "label": "are"
    },
    {
      "source": "variants",
      "target": "mammalian cells",
      "label": "expressed in"
    },
    {
      "source": "variants",
      "target": "human PANX1 gene",
      "label": "in"
    },
    {
      "source": "variants",
      "target": "3'untranscribed region (3'UTR)",
      "label": "located in"
    },
    {
      "source": "variants",
      "target": "response to HU treatment",
      "label": "are associated with"
    },
    {
      "source": "variants",
      "target": "\u03b2-thalassemia disease severity",
      "label": "are indicative of"
    },
    {
      "source": "variants",
      "target": "HU treatment efficacy",
      "label": "are associated with"
    },
    {
      "source": "Panx1",
      "target": "gap junctions",
      "label": "does not form"
    },
    {
      "source": "Panx1",
      "target": "P2X(7)R",
      "label": "coexpressed with"
    },
    {
      "source": "Panx1",
      "target": "hemichannel",
      "label": "acts as a"
    },
    {
      "source": "Panx1",
      "target": "mammalian cells",
      "label": "does not form gap junctions in"
    },
    {
      "source": "Panx1",
      "target": "purinergic P2X(7) receptor",
      "label": "coexpressed with"
    },
    {
      "source": "Panx1",
      "target": "plasma membrane hemichannel",
      "label": "may function as a"
    },
    {
      "source": "DIDS",
      "target": "P2X(7)R antagonist",
      "label": "acts as a"
    },
    {
      "source": "DIDS",
      "target": "ATP-evoked currents",
      "label": "inhibits"
    },
    {
      "source": "DIDS",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "hemichannel",
      "target": "passage",
      "label": "allows"
    },
    {
      "source": "passage",
      "target": "P2X(7)R activation",
      "label": "in response to"
    },
    {
      "source": "passage",
      "target": "large molecules",
      "label": "of"
    },
    {
      "source": "pharmacological characterization",
      "target": "pannexin-1 currents",
      "label": "of"
    },
    {
      "source": "pharmacological characterization",
      "target": "Panx1-mediated currents",
      "label": "of"
    },
    {
      "source": "pannexin-1 currents",
      "target": "mammalian cells",
      "label": "expressed in"
    },
    {
      "source": "probenecid",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "human Panx1 variants",
      "target": "protein expression levels",
      "label": "showed identical"
    },
    {
      "source": "human Panx1 variants",
      "target": "localization patterns",
      "label": "showed identical"
    },
    {
      "source": "human Panx1 variants",
      "target": "functional properties",
      "label": "showed identical"
    },
    {
      "source": "disodium 4,4'-diisothiocyanatostilbene-2,2'-disulfonate",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "5-nitro-2-(3-phenylpropylamino)benzoic acid",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "UTP",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "pharmacological properties",
      "target": "panx1 expression",
      "label": "of"
    },
    {
      "source": "panx1 expression",
      "target": "mammalian cells",
      "label": "in"
    },
    {
      "source": "carbenoxolone",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "GTP",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "disodium 4-acetamido-4'-isothiocyanato-stilben-2,2'-disulfonate",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "Triphosphate nucleotides",
      "target": "Panx1 currents",
      "label": "inhibited"
    },
    {
      "source": "Panx1-mediated currents",
      "target": "mammalian cells",
      "label": "in"
    },
    {
      "source": "extracellular calcium",
      "target": "DA release",
      "label": "modulates"
    },
    {
      "source": "PNH",
      "target": "contraindication",
      "label": "is considered"
    },
    {
      "source": "PNH",
      "target": "key complement regulatory protein",
      "label": "caused by absence of"
    },
    {
      "source": "PNH",
      "target": "rare, acquired hemolytic anemia",
      "label": "is a"
    },
    {
      "source": "PNH",
      "target": "somatic mutations",
      "label": "caused by"
    },
    {
      "source": "BCS",
      "target": "PNH",
      "label": "secondary to"
    },
    {
      "source": "BCS",
      "target": "PNH patients",
      "label": "is common in"
    },
    {
      "source": "terminal complement",
      "target": "C5",
      "label": "at"
    },
    {
      "source": "key complement regulatory protein",
      "target": "CD59",
      "label": "is"
    },
    {
      "source": "hepatic artery thrombosis",
      "target": "retransplantation",
      "label": "requires"
    },
    {
      "source": "Budd-Chiari syndrome",
      "target": "BCS",
      "label": "is"
    },
    {
      "source": "Budd-Chiari syndrome",
      "target": "patient",
      "label": "in"
    },
    {
      "source": "intravascular complement-mediated lysis",
      "target": "hemoglobinuria",
      "label": "results in"
    },
    {
      "source": "intravascular complement-mediated lysis",
      "target": "venous thromboses",
      "label": "results in"
    },
    {
      "source": "intravascular complement-mediated lysis",
      "target": "anemia",
      "label": "results in"
    },
    {
      "source": "anti-complement antibody",
      "target": "eculizumab",
      "label": "is"
    },
    {
      "source": "eculizumab",
      "target": "humanized monoclonal antibody",
      "label": "is a"
    },
    {
      "source": "case reports",
      "target": "outcomes",
      "label": "detail"
    },
    {
      "source": "case reports",
      "target": "hepatic artery thrombosis",
      "label": "detail"
    },
    {
      "source": "case reports",
      "target": "recurrent BCS",
      "label": "detail"
    },
    {
      "source": "case reports",
      "target": "early thrombotic portal vein occlusion",
      "label": "detail"
    },
    {
      "source": "paroxysmal nocturnal hemoglobinuria",
      "target": "PNH",
      "label": "is"
    },
    {
      "source": "Affected red blood cells",
      "target": "PNH patients",
      "label": "in"
    },
    {
      "source": "Affected red blood cells",
      "target": "intravascular complement-mediated lysis",
      "label": "undergo"
    },
    {
      "source": "early thrombotic portal vein occlusion",
      "target": "retransplantation",
      "label": "requires"
    },
    {
      "source": "liver transplantation",
      "target": "BCS",
      "label": "for"
    },
    {
      "source": "liver transplantation",
      "target": "Budd-Chiari syndrome",
      "label": "for"
    },
    {
      "source": "somatic mutations",
      "target": "phosphatidylinositol glycan-complementation class A gene",
      "label": "in"
    },
    {
      "source": "humanized monoclonal antibody",
      "target": "activation",
      "label": "blocks"
    },
    {
      "source": "anemia",
      "target": "toxicologic events",
      "label": "being a common"
    },
    {
      "source": "Hepatic venous outflow thrombosis",
      "target": "Budd-Chiari syndrome",
      "label": "is"
    },
    {
      "source": "D1-like receptors",
      "target": "insulin-induced vascular smooth muscle cell proliferation",
      "label": "inhibits"
    },
    {
      "source": "D1-like receptors",
      "target": "insulin receptor expression",
      "label": "down-regulates"
    },
    {
      "source": "D1-like receptors",
      "target": "stimulatory effect",
      "label": "inhibits"
    },
    {
      "source": "D3 dopamine receptor",
      "target": "D2-like receptor family",
      "label": "is a member of"
    },
    {
      "source": "D3 dopamine receptor",
      "target": "stimulatory effect",
      "label": "inhibits"
    },
    {
      "source": "Vascular smooth muscle cell (VSMC) proliferation",
      "target": "vascular diseases",
      "label": "is central to development of"
    },
    {
      "source": "Vascular smooth muscle cell (VSMC) proliferation",
      "target": "hormones",
      "label": "is regulated by"
    },
    {
      "source": "Vascular smooth muscle cell (VSMC) proliferation",
      "target": "humoral factors",
      "label": "is regulated by"
    },
    {
      "source": "vascular diseases",
      "target": "hypertension",
      "label": "includes"
    },
    {
      "source": "VSMC proliferation",
      "target": "immortalized aortic A10 cells",
      "label": "occurs in"
    },
    {
      "source": "VSMC proliferation",
      "target": "[H]-thymidine incorporation",
      "label": "determined by"
    },
    {
      "source": "fenoldopam",
      "target": "D1-like receptor agonist",
      "label": "is a type of"
    },
    {
      "source": "fenoldopam",
      "target": "stimulatory effect",
      "label": "inhibited"
    },
    {
      "source": "fenoldopam",
      "target": "inhibitory effect",
      "label": "has"
    },
    {
      "source": "stimulatory effect",
      "target": "VSMC proliferation",
      "label": "is on"
    },
    {
      "source": "MAP kinase",
      "target": "signaling pathway",
      "label": "is involved in"
    },
    {
      "source": "important role",
      "target": "regulation of blood pressure",
      "label": "is in"
    },
    {
      "source": "pathogenesis",
      "target": "essential hypertension",
      "label": "is of"
    },
    {
      "source": "pathogenesis",
      "target": "type 2 diabetes mellitus (T2DM)",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "insulin resistance",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "duodenal ulcers",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "AD",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "Alzheimer's disease",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "fibrotic processes",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "atherosclerosis",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "calcification",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "rheumatoid arthritis (RA)",
      "label": "of"
    },
    {
      "source": "pathogenesis",
      "target": "osteoarthritis (OA)",
      "label": "of"
    },
    {
      "source": "insulin",
      "target": "stimulatory effect",
      "label": "has"
    },
    {
      "source": "insulin",
      "target": "multiple large cysts",
      "label": "resulted in"
    },
    {
      "source": "insulin",
      "target": "endogenous hyperandrogenism",
      "label": "synergistically resulted in"
    },
    {
      "source": "insulin",
      "target": "steroidogenic enzymes",
      "label": "affects expression of"
    },
    {
      "source": "insulin",
      "target": "melanin-concentrating hormone",
      "label": "affects"
    },
    {
      "source": "insulin",
      "target": "thyroid-releasing hormone",
      "label": "affects"
    },
    {
      "source": "insulin",
      "target": "orexin",
      "label": "affects"
    },
    {
      "source": "insulin",
      "target": "proopiomelanocortin",
      "label": "affects"
    },
    {
      "source": "insulin",
      "target": "Tub",
      "label": "stimulates"
    },
    {
      "source": "insulin",
      "target": "Tub-p-tyr",
      "label": "induces"
    },
    {
      "source": "insulin",
      "target": "Food intake",
      "label": "affects"
    },
    {
      "source": "insulin",
      "target": "pancreatic alpha cell function",
      "label": "regulates"
    },
    {
      "source": "Insulin",
      "target": "proliferative hormone",
      "label": "is a type of"
    },
    {
      "source": "Insulin",
      "target": "VSMC proliferation",
      "label": "increased"
    },
    {
      "source": "Insulin",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "Insulin",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "Insulin",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "insulin receptor mRNA",
      "target": "time",
      "label": "is dependent on"
    },
    {
      "source": "insulin receptor mRNA",
      "target": "concentration",
      "label": "is dependent on"
    },
    {
      "source": "Dl-like receptors",
      "target": "inhibitory effect",
      "label": "has"
    },
    {
      "source": "SCH23390",
      "target": "D1-like receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "SCH23390",
      "target": "inhibitory effect",
      "label": "blocked"
    },
    {
      "source": "SCH23390",
      "target": "amantadine induction of Fos",
      "label": "Downregulator"
    },
    {
      "source": "SCH23390",
      "target": "dopamine D1",
      "label": "Antagonist"
    },
    {
      "source": "Fenoldopam",
      "target": "protein expression",
      "label": "inhibited"
    },
    {
      "source": "Fenoldopam",
      "target": "insulin receptor mRNA",
      "label": "inhibited"
    },
    {
      "source": "D1-like receptor",
      "target": "VSMC proliferation",
      "label": "had no effect on"
    },
    {
      "source": "MAP kinase inhibitor",
      "target": "inhibitory effect",
      "label": "blocked"
    },
    {
      "source": "aberrant insulin",
      "target": "pathogenesis",
      "label": "is involved in"
    },
    {
      "source": "Dl-like receptor functions",
      "target": "pathogenesis",
      "label": "is involved in"
    },
    {
      "source": "PKC",
      "target": "inhibitory effect",
      "label": "blocked"
    },
    {
      "source": "PKC",
      "target": "signaling pathway",
      "label": "is involved in"
    },
    {
      "source": "PKC",
      "target": "potentiation",
      "label": "inhibition reduced"
    },
    {
      "source": "RAMP3 residues",
      "target": "RAMP1",
      "label": "were introduced into"
    },
    {
      "source": "RAMP3 residues",
      "target": "receptor pharmacology",
      "label": "can alter"
    },
    {
      "source": "wild-type RAMPs",
      "target": "insert-negative form of the calcitonin receptor",
      "label": "were transfected with"
    },
    {
      "source": "wild-type RAMPs",
      "target": "Cos7 cells",
      "label": "were transfected into"
    },
    {
      "source": "wild-type RAMPs",
      "target": "CT(a)",
      "label": "were transfected with"
    },
    {
      "source": "insert-negative form of the calcitonin receptor",
      "target": "CT(a)",
      "label": "is also known as"
    },
    {
      "source": "Targeted substitution",
      "target": "Position 74",
      "label": "emphasized the importance of"
    },
    {
      "source": "Position 74",
      "target": "AM affinity",
      "label": "is critical for determining"
    },
    {
      "source": "Position 74",
      "target": "RAMP1",
      "label": "is located in"
    },
    {
      "source": "Position 74",
      "target": "AM pharmacology",
      "label": "is a key determinant of"
    },
    {
      "source": "Position 74",
      "target": "AM potency",
      "label": "is critical for determining"
    },
    {
      "source": "Position 74",
      "target": "RAMP3",
      "label": "is located in"
    },
    {
      "source": "Position 74",
      "target": "RAMP1/RAMP3",
      "label": "is located in"
    },
    {
      "source": "Calcitonin-family receptors",
      "target": "calcitonin receptor-like receptor (CL)",
      "label": "comprise"
    },
    {
      "source": "Calcitonin-family receptors",
      "target": "calcitonin receptor",
      "label": "comprise"
    },
    {
      "source": "Calcitonin-family receptors",
      "target": "receptor activity-modifying protein (RAMP)",
      "label": "comprise"
    },
    {
      "source": "CL-based receptors",
      "target": "expression",
      "label": "had unchanged"
    },
    {
      "source": "RAMPs",
      "target": "G protein-coupled receptor pharmacology",
      "label": "change"
    },
    {
      "source": "Mutant RAMP/CT(a) receptor complexes",
      "target": "phenotypes",
      "label": "displayed"
    },
    {
      "source": "CL/RAMP3",
      "target": "AM2 receptor",
      "label": "is"
    },
    {
      "source": "CL/RAMP3",
      "target": "AM receptors",
      "label": "is a type of"
    },
    {
      "source": "RAMP2",
      "target": "CL/RAMP2",
      "label": "is responsible for making"
    },
    {
      "source": "RAMP2",
      "target": "RAMP3",
      "label": "shares conserved residues with"
    },
    {
      "source": "CL/RAMP2",
      "target": "AM1 receptor",
      "label": "is"
    },
    {
      "source": "CL/RAMP2",
      "target": "AM receptors",
      "label": "is a type of"
    },
    {
      "source": "N-terminal receptor activity-modifying protein residues",
      "target": "amylin receptor",
      "label": "are important for"
    },
    {
      "source": "N-terminal receptor activity-modifying protein residues",
      "target": "adrenomedullin",
      "label": "are important for"
    },
    {
      "source": "N-terminal receptor activity-modifying protein residues",
      "target": "calcitonin gene-related peptide",
      "label": "are important for"
    },
    {
      "source": "Amylin (Amy) receptors",
      "target": "RAMP hetero-oligomers",
      "label": "are"
    },
    {
      "source": "Amylin (Amy) receptors",
      "target": "AMY3",
      "label": "include"
    },
    {
      "source": "Amylin (Amy) receptors",
      "target": "calcitonin receptor",
      "label": "are formed with"
    },
    {
      "source": "Amylin (Amy) receptors",
      "target": "AMY1",
      "label": "include"
    },
    {
      "source": "Amylin (Amy) receptors",
      "target": "AMY2",
      "label": "include"
    },
    {
      "source": "RAMP1",
      "target": "RAMP2",
      "label": "has different residues from"
    },
    {
      "source": "RAMP1",
      "target": "RAMP3",
      "label": "has different residues from"
    },
    {
      "source": "RAMP3",
      "target": "CL/RAMP3",
      "label": "is responsible for making"
    },
    {
      "source": "RAMP3",
      "target": "RAMP1",
      "label": "has sequence differences with"
    },
    {
      "source": "adrenomedullin (AM) receptors",
      "target": "CL/RAMP3",
      "label": "are"
    },
    {
      "source": "adrenomedullin (AM) receptors",
      "target": "CL/RAMP2",
      "label": "are"
    },
    {
      "source": "alphaCGRP potency",
      "target": "CGRP receptors",
      "label": "occurs at"
    },
    {
      "source": "Mutant RAMPs",
      "target": "CT(a)",
      "label": "were transfected with"
    },
    {
      "source": "Mutant RAMPs",
      "target": "insert-negative form of the calcitonin receptor",
      "label": "were transfected with"
    },
    {
      "source": "Mutant RAMPs",
      "target": "Cos7 cells",
      "label": "were transfected into"
    },
    {
      "source": "RAMP1 residues",
      "target": "RAMP3",
      "label": "were introduced into"
    },
    {
      "source": "RAMP1 residues",
      "target": "receptor pharmacology",
      "label": "can alter"
    },
    {
      "source": "RAMP1 S103N",
      "target": "rAmy potency",
      "label": "led to enhanced"
    },
    {
      "source": "rAmy potency",
      "target": "cell-surface expression",
      "label": "is related to increased"
    },
    {
      "source": "Calcitonin gene-related peptide (CGRP) receptors",
      "target": "CL/RAMP1",
      "label": "are"
    },
    {
      "source": "Phe93",
      "target": "RAMP1",
      "label": "is located in"
    },
    {
      "source": "Phe93",
      "target": "alphaCGRP potency",
      "label": "is an important contributor to"
    },
    {
      "source": "Agonist-stimulated cAMP production",
      "target": "cAMP production",
      "label": "is a type of"
    },
    {
      "source": "W74E mutations",
      "target": "rAmy potency",
      "label": "led to enhanced"
    },
    {
      "source": "cell-surface expression",
      "target": "complexes",
      "label": "is of"
    },
    {
      "source": "goal",
      "target": "study",
      "label": "of this"
    },
    {
      "source": "goal",
      "target": "compounds",
      "label": "was to identify"
    },
    {
      "source": "calcium antagonist",
      "target": "class",
      "label": "is a"
    },
    {
      "source": "clinically approved antihypertensive drugs",
      "target": "isradipine",
      "label": "include"
    },
    {
      "source": "clinically approved antihypertensive drugs",
      "target": "nitrendipine",
      "label": "include"
    },
    {
      "source": "clinically approved antihypertensive drugs",
      "target": "felodipine",
      "label": "include"
    },
    {
      "source": "clinically approved antihypertensive drugs",
      "target": "efonidipine",
      "label": "include"
    },
    {
      "source": "isradipine",
      "target": "potent T-channel blockers",
      "label": "is a"
    },
    {
      "source": "available antihypertensive drugs",
      "target": "therapeutically relevant concentrations",
      "label": "block T-current at"
    },
    {
      "source": "available antihypertensive drugs",
      "target": "mechanism of action",
      "label": "contribute to"
    },
    {
      "source": "available antihypertensive drugs",
      "target": "substantial fraction",
      "label": "block"
    },
    {
      "source": "Antihypertensive drugs",
      "target": "calcium antagonist",
      "label": "are a type of"
    },
    {
      "source": "Antihypertensive drugs",
      "target": "physiological role",
      "label": "establish"
    },
    {
      "source": "Antihypertensive drugs",
      "target": "calcium channel blocker",
      "label": "are a type of"
    },
    {
      "source": "progress",
      "target": "pharmacology T-type Ca(2+) channels",
      "label": "on the"
    },
    {
      "source": "progress",
      "target": "peak area",
      "label": "determined by"
    },
    {
      "source": "progress",
      "target": "enzymatic reaction",
      "label": "is of"
    },
    {
      "source": "progress",
      "target": "Wnt signaling",
      "label": "made in understanding importance of"
    },
    {
      "source": "mixed T- and L-type blockers",
      "target": "therapeutic advantages",
      "label": "have"
    },
    {
      "source": "T-type channels",
      "target": "cardiac pacemaking",
      "label": "play a role in"
    },
    {
      "source": "T-type channels",
      "target": "hypothesis",
      "label": "lead to"
    },
    {
      "source": "T-type channels",
      "target": "renal hemodynamics",
      "label": "play a role in"
    },
    {
      "source": "T-type channels",
      "target": "aldosterone secretion",
      "label": "play a role in"
    },
    {
      "source": "cell line",
      "target": "recombinant Ca(v)3.2 channels",
      "label": "expresses"
    },
    {
      "source": "cell line",
      "target": "biochemical analysis",
      "label": "suitable for"
    },
    {
      "source": "cell line",
      "target": "patch-clamp recording",
      "label": "suitable for"
    },
    {
      "source": "nifedipine",
      "target": "potent T-channel blockers",
      "label": "is less potent than"
    },
    {
      "source": "nifedipine",
      "target": "research studies",
      "label": "is appropriate for"
    },
    {
      "source": "nifedipine",
      "target": "nociceptive behavior",
      "label": "decreased"
    },
    {
      "source": "potent T-channel blockers",
      "target": "IC(50)",
      "label": "have"
    },
    {
      "source": "physiological role",
      "target": "L-type Ca(2+) channels",
      "label": "of"
    },
    {
      "source": "L-type Ca(2+) channels",
      "target": "vascular smooth muscle",
      "label": "located in"
    },
    {
      "source": "human Cav3.2 T-type Ca2+ channels",
      "target": "analogs",
      "label": "blocked by"
    },
    {
      "source": "human Cav3.2 T-type Ca2+ channels",
      "target": "antiarrhythmics",
      "label": "blocked by"
    },
    {
      "source": "human Cav3.2 T-type Ca2+ channels",
      "target": "antihypertensives",
      "label": "blocked by"
    },
    {
      "source": "calcium channel blocker",
      "target": "class",
      "label": "is a"
    },
    {
      "source": "classes of compounds",
      "target": "dihydropyridines",
      "label": "include"
    },
    {
      "source": "classes of compounds",
      "target": "phenylalkylamines",
      "label": "include"
    },
    {
      "source": "classes of compounds",
      "target": "differential effects",
      "label": "had"
    },
    {
      "source": "dihydropyridines",
      "target": "efonidipine",
      "label": "example"
    },
    {
      "source": "efonidipine",
      "target": "potent T-channel blockers",
      "label": "is a"
    },
    {
      "source": "phenylalkylamines",
      "target": "mibefradil",
      "label": "example"
    },
    {
      "source": "nitrendipine",
      "target": "potent T-channel blockers",
      "label": "is a"
    },
    {
      "source": "research studies",
      "target": "L-type currents",
      "label": "focus on"
    },
    {
      "source": "Ca(v)3.2 T-type channel",
      "target": "high affinity",
      "label": "is blocked with"
    },
    {
      "source": "Molecular pharmacology",
      "target": "human Cav3.2 T-type Ca2+ channels",
      "label": "of"
    },
    {
      "source": "present results",
      "target": "notion",
      "label": "support the"
    },
    {
      "source": "felodipine",
      "target": "potent T-channel blockers",
      "label": "is a"
    },
    {
      "source": "Ca(2+) influx assay",
      "target": "cell line",
      "label": "performed in"
    },
    {
      "source": "mibefradil",
      "target": "nociceptive behavior",
      "label": "decreased"
    },
    {
      "source": "substantial fraction",
      "target": "T-current",
      "label": "of"
    },
    {
      "source": "widely prescribed dihydropyridines",
      "target": "amlodipine",
      "label": "include"
    },
    {
      "source": "widely prescribed dihydropyridines",
      "target": "nifedipine",
      "label": "include"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "antihyperglycemic effects",
      "label": "has"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "normal rats",
      "label": "acted on"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "postprandial hyperglycemia",
      "label": "improved"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "selective SGLT2 inhibitor",
      "label": "is a"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "plasma glucose",
      "label": "inhibited increase in"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "hypoglycemia",
      "label": "does not result in"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "unique approach",
      "label": "may provide a"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "streptozotocin-induced diabetic rats",
      "label": "improves glycemic control in"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "Zucker fatty rats",
      "label": "improves glycemic control in"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "insulin secretion",
      "label": "inhibited plasma glucose increase independently of"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "body weight",
      "label": "did not affect"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "glycemic control",
      "label": "improves"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "body weight gain",
      "label": "does not result in"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "food intake",
      "label": "did not affect"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "neonatal streptozotocin-induced diabetic rats",
      "label": "improved postprandial hyperglycemia in"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "plasma glucose level",
      "label": "did not affect"
    },
    {
      "source": "Sergliflozin etabonate",
      "target": "urinary glucose excretion",
      "label": "increased"
    },
    {
      "source": "antihyperglycemic effects",
      "target": "normal rats",
      "label": "were examined in"
    },
    {
      "source": "antihyperglycemic effects",
      "target": "diabetic rats",
      "label": "were examined in"
    },
    {
      "source": "antihyperglycemic effects",
      "target": "severity",
      "label": "correlated with"
    },
    {
      "source": "antihyperglycemic effects",
      "target": "Sergliflozin etabonate",
      "label": "of"
    },
    {
      "source": "normal rats",
      "target": "AA",
      "label": "treated with"
    },
    {
      "source": "SGLT2",
      "target": "glucose reabsorption",
      "label": "is responsible for"
    },
    {
      "source": "SGLT2",
      "target": "novel therapeutic target",
      "label": "has been highlighted as a"
    },
    {
      "source": "glucose reabsorption",
      "target": "kidney",
      "label": "occurs in the"
    },
    {
      "source": "urinary glucose excretion",
      "target": "dose-dependent manner",
      "label": "occurred in a"
    },
    {
      "source": "glycemic response",
      "target": "glucose loading",
      "label": "occurred after"
    },
    {
      "source": "plasma glucose",
      "target": "sucrose loading",
      "label": "increased after"
    },
    {
      "source": "low-affinity sodium glucose cotransporter",
      "target": "SGLT2",
      "label": "is also known as"
    },
    {
      "source": "unique approach",
      "target": "treatment of diabetes",
      "label": "to the"
    },
    {
      "source": "diabetic rats",
      "target": "hemoglobin",
      "label": "showed decreased"
    },
    {
      "source": "diabetic rats",
      "target": "circulating insulin",
      "label": "showed decreased"
    },
    {
      "source": "diabetic rats",
      "target": "glycosylated hemoglobin",
      "label": "showed increased"
    },
    {
      "source": "diabetic rats",
      "target": "plasma glucose",
      "label": "showed increased"
    },
    {
      "source": "plasma glucose level",
      "target": "normal rats",
      "label": "of"
    },
    {
      "source": "gliclazide",
      "target": "plasma glucose level",
      "label": "did not affect"
    },
    {
      "source": "gliclazide",
      "target": "sulfonylurea",
      "label": "is a"
    },
    {
      "source": "gliclazide",
      "target": "postprandial hyperglycemia",
      "label": "did not improve"
    },
    {
      "source": "novel therapeutic target",
      "target": "treatment of diabetes",
      "label": "for the"
    },
    {
      "source": "selective inhibition of SGLT2",
      "target": "urinary glucose excretion",
      "label": "increased"
    },
    {
      "source": "selective inhibition of SGLT2",
      "target": "plasma glucose levels",
      "label": "decreased"
    },
    {
      "source": "voglibose",
      "target": "alpha-glucosidase inhibitor",
      "label": "is an"
    },
    {
      "source": "report",
      "target": "antihyperglycemic effects",
      "label": "examined the"
    },
    {
      "source": "report",
      "target": "approach",
      "label": "describes"
    },
    {
      "source": "report",
      "target": "5-hydroxytryptamine compounds",
      "label": "describes synthesis of"
    },
    {
      "source": "report",
      "target": "library",
      "label": "utilized"
    },
    {
      "source": "report",
      "target": "GAG valency",
      "label": "examined"
    },
    {
      "source": "report",
      "target": "chain type",
      "label": "examined"
    },
    {
      "source": "capillary",
      "target": "30 mM borate-phosphate buffer",
      "label": "filled with"
    },
    {
      "source": "30 mM borate-phosphate buffer",
      "target": "pH 8.0",
      "label": "has"
    },
    {
      "source": "procedure",
      "target": "screening",
      "label": "is for"
    },
    {
      "source": "procedure",
      "target": "capillary electrophoresis",
      "label": "based on"
    },
    {
      "source": "procedure",
      "target": "in vitro evaluation",
      "label": "is for"
    },
    {
      "source": "screening",
      "target": "acetylcholinesterase inhibitors",
      "label": "is for"
    },
    {
      "source": "plugs",
      "target": "AChE solution",
      "label": "contain"
    },
    {
      "source": "plugs",
      "target": "capillary",
      "label": "injected into"
    },
    {
      "source": "plugs",
      "target": "waiting period",
      "label": "stand during"
    },
    {
      "source": "plugs",
      "target": "substrate solution",
      "label": "contain"
    },
    {
      "source": "plugs",
      "target": "water",
      "label": "contain"
    },
    {
      "source": "waiting period",
      "target": "2 min",
      "label": "is"
    },
    {
      "source": "applicability",
      "target": "proposed methodology",
      "label": "is of"
    },
    {
      "source": "applicability",
      "target": "compounds",
      "label": "evaluated using"
    },
    {
      "source": "proposed methodology",
      "target": "kinetic parameters",
      "label": "estimates"
    },
    {
      "source": "reaction product",
      "target": "thiocholine",
      "label": "is a type of"
    },
    {
      "source": "thiocholine",
      "target": "TCh",
      "label": "is also known as"
    },
    {
      "source": "method",
      "target": "AChE Inhibitor screening",
      "label": "is for"
    },
    {
      "source": "method",
      "target": "capillary",
      "label": "uses"
    },
    {
      "source": "method",
      "target": "accuracy",
      "label": "validated for"
    },
    {
      "source": "method",
      "target": "range",
      "label": "validated for"
    },
    {
      "source": "method",
      "target": "model deviation",
      "label": "validated for"
    },
    {
      "source": "method",
      "target": "intra/inter-day precision",
      "label": "validated for"
    },
    {
      "source": "acetylthiocholine",
      "target": "AChE",
      "label": "is substrate for"
    },
    {
      "source": "capillary electrophoresis",
      "target": "enzymatic reaction",
      "label": "occurs after"
    },
    {
      "source": "acetylcholinesterase inhibitors",
      "target": "CE",
      "label": "screened by"
    },
    {
      "source": "acetylcholinesterase inhibitors",
      "target": "cardiovascular effects",
      "label": "induce"
    },
    {
      "source": "peak area",
      "target": "reaction product",
      "label": "is of"
    },
    {
      "source": "peak area",
      "target": "230 nm",
      "label": "measured at"
    },
    {
      "source": "neostigmine",
      "target": "acetylcholinesterase inhibitor",
      "label": "is an"
    },
    {
      "source": "CE",
      "target": "enzymatic reaction",
      "label": "occurs after"
    },
    {
      "source": "CE",
      "target": "ferritins",
      "label": "increases mRNA of"
    },
    {
      "source": "CE",
      "target": "transferrin receptor 1 and 2",
      "label": "increases mRNA of"
    },
    {
      "source": "CE",
      "target": "ferritinH",
      "label": "increases mRNA of"
    },
    {
      "source": "CE",
      "target": "hepcidin",
      "label": "increases mRNA of"
    },
    {
      "source": "CE",
      "target": "ezetimibe",
      "label": "includes"
    },
    {
      "source": "CE",
      "target": "C",
      "label": "includes"
    },
    {
      "source": "CE",
      "target": "hephaestin",
      "label": "increases mRNA of"
    },
    {
      "source": "CE",
      "target": "DMT1",
      "label": "increases mRNA of"
    },
    {
      "source": "CE",
      "target": "4 weeks",
      "label": "has duration"
    },
    {
      "source": "in vitro evaluation",
      "target": "biological activity",
      "label": "evaluates"
    },
    {
      "source": "edrophonium",
      "target": "VT cycle length",
      "label": "had no effect on"
    },
    {
      "source": "edrophonium",
      "target": "duration",
      "label": "had no effect on"
    },
    {
      "source": "edrophonium",
      "target": "reentrant VT",
      "label": "had no effect on"
    },
    {
      "source": "effectiveness",
      "target": "methodology",
      "label": "is of"
    },
    {
      "source": "effectiveness",
      "target": "oxytocin",
      "label": "of"
    },
    {
      "source": "substrate solution",
      "target": "inhibitor",
      "label": "contains"
    },
    {
      "source": "threo-methylphenidate",
      "target": "norepinephrine transporter",
      "label": "Downregulator"
    },
    {
      "source": "threo-methylphenidate",
      "target": "dopamine transporter",
      "label": "Downregulator"
    },
    {
      "source": "d-MPH",
      "target": "dopamine transporter",
      "label": "Regulator"
    },
    {
      "source": "monoamines",
      "target": "norepinephrine transporter",
      "label": "Substrate"
    },
    {
      "source": "monoamines",
      "target": "dopamine transporter",
      "label": "Substrate"
    },
    {
      "source": "Haloperidol",
      "target": "Occupancy",
      "label": "affects"
    },
    {
      "source": "Haloperidol",
      "target": "Patients",
      "label": "treated"
    },
    {
      "source": "Haloperidol",
      "target": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "label": "affects"
    },
    {
      "source": "Occupancy",
      "target": "Midbrain",
      "label": "occurs in"
    },
    {
      "source": "Occupancy",
      "target": "Temporal cortex",
      "label": "occurs in"
    },
    {
      "source": "Occupancy",
      "target": "Olanzapine group",
      "label": "higher in"
    },
    {
      "source": "Occupancy",
      "target": "Haloperidol group",
      "label": "highest in"
    },
    {
      "source": "Occupancy",
      "target": "Clozapine group",
      "label": "lowest in"
    },
    {
      "source": "Occupancy",
      "target": "Comparison group",
      "label": "changed based on"
    },
    {
      "source": "Occupancy",
      "target": "Brain areas",
      "label": "occurred in"
    },
    {
      "source": "Dopamine D(2/3) binding",
      "target": "Drug-naive patients",
      "label": "studied in"
    },
    {
      "source": "Dopamine D(2/3) binding",
      "target": "Ligand [(123)I]epidepride",
      "label": "studied using"
    },
    {
      "source": "Dopamine D(2/3) binding",
      "target": "Single-photon emission computed tomography (SPECT)",
      "label": "studied using"
    },
    {
      "source": "Dopamine D(2/3) binding",
      "target": "Patients",
      "label": "studied in"
    },
    {
      "source": "Dopamine D(2/3) binding",
      "target": "Healthy controls",
      "label": "studied in"
    },
    {
      "source": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "target": "Midbrain",
      "label": "investigated in"
    },
    {
      "source": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "target": "Temporal cortex",
      "label": "occurs in"
    },
    {
      "source": "Statistically significant differences",
      "target": "Clozapine group",
      "label": "between"
    },
    {
      "source": "Statistically significant differences",
      "target": "Temporal poles",
      "label": "not observed in"
    },
    {
      "source": "Statistically significant differences",
      "target": "Midbrain dopamine D(2/3) receptor BP(app)",
      "label": "observed in"
    },
    {
      "source": "Statistically significant differences",
      "target": "Olanzapine group",
      "label": "between"
    },
    {
      "source": "Statistically significant differences",
      "target": "Occupancy",
      "label": "observed in"
    },
    {
      "source": "Statistically significant differences",
      "target": "Haloperidol group",
      "label": "between"
    },
    {
      "source": "Medication",
      "target": "Clozapine",
      "label": "includes"
    },
    {
      "source": "Medication",
      "target": "Olanzapine",
      "label": "includes"
    },
    {
      "source": "Medication",
      "target": "Haloperidol",
      "label": "includes"
    },
    {
      "source": "Clozapine",
      "target": "Patients",
      "label": "treated"
    },
    {
      "source": "Clozapine",
      "target": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "label": "affects"
    },
    {
      "source": "Clozapine",
      "target": "Occupancy",
      "label": "affects"
    },
    {
      "source": "Comparison group",
      "target": "Healthy controls",
      "label": "includes"
    },
    {
      "source": "Comparison group",
      "target": "Drug-naive patients",
      "label": "includes"
    },
    {
      "source": "Olanzapine",
      "target": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "label": "affects"
    },
    {
      "source": "Olanzapine",
      "target": "Occupancy",
      "label": "affects"
    },
    {
      "source": "Olanzapine",
      "target": "Patients",
      "label": "treated"
    },
    {
      "source": "Olanzapine",
      "target": "Nausea",
      "label": "treats"
    },
    {
      "source": "Olanzapine",
      "target": "Breakthrough emesis",
      "label": "treats"
    },
    {
      "source": "Olanzapine",
      "target": "CINV",
      "label": "prevents"
    },
    {
      "source": "Olanzapine",
      "target": "Treatment",
      "label": "is an effective agent for"
    },
    {
      "source": "Olanzapine",
      "target": "US-FDA approved antipsychotic",
      "label": "is a type of"
    },
    {
      "source": "Olanzapine",
      "target": "Antipsychotic",
      "label": "is a type of"
    },
    {
      "source": "Olanzapine",
      "target": "Preventative agent",
      "label": "is an effective"
    },
    {
      "source": "Overestimation",
      "target": "Antipsychotics",
      "label": "occurred with"
    },
    {
      "source": "Overestimation",
      "target": "Healthy controls",
      "label": "occurred when using"
    },
    {
      "source": "Typical antipsychotics",
      "target": "Dopamine D(2) receptor modulation",
      "label": "affect"
    },
    {
      "source": "Typical antipsychotics",
      "target": "Therapeutic efficacy",
      "label": "mediate"
    },
    {
      "source": "Typical antipsychotics",
      "target": "Cortical dopamine D(2/3) receptors",
      "label": "occupy"
    },
    {
      "source": "Dopamine D(2) receptor modulation",
      "target": "Brain areas",
      "label": "occurs within"
    },
    {
      "source": "Second-generation antipsychotics",
      "target": "Dopamine D(2) receptor modulation",
      "label": "affect"
    },
    {
      "source": "Second-generation antipsychotics",
      "target": "Therapeutic efficacy",
      "label": "mediate"
    },
    {
      "source": "Second-generation antipsychotics",
      "target": "Cortical dopamine D(2/3) receptors",
      "label": "occupy"
    },
    {
      "source": "Dopamine D2/3 receptor",
      "target": "Dopamine D(2/3) receptor apparent binding potential (BPapp)",
      "label": "has"
    },
    {
      "source": "Dopamine D2/3 receptor",
      "target": "Occupancy",
      "label": "has"
    },
    {
      "source": "Midbrain dopamine D(2/3) occupancy",
      "target": "Altered nigrostriatal dopamine neurotransmission",
      "label": "modulates"
    },
    {
      "source": "Midbrain dopamine D(2/3) occupancy",
      "target": "Classical antipsychotics",
      "label": "differs between"
    },
    {
      "source": "Midbrain dopamine D(2/3) occupancy",
      "target": "Second-generation antipsychotics",
      "label": "differs between"
    },
    {
      "source": "Midbrain dopamine D(2/3) occupancy",
      "target": "Clinical relevance",
      "label": "has"
    },
    {
      "source": "Altered nigrostriatal dopamine neurotransmission",
      "target": "Acute phase of schizophrenia",
      "label": "occurs during"
    },
    {
      "source": "Dopamine transmission",
      "target": "Extrastriatal brain regions",
      "label": "occurs in"
    },
    {
      "source": "Dopamine transmission",
      "target": "Patients",
      "label": "illustrated among"
    },
    {
      "source": "percent content",
      "target": "low-molecular-weight heparins (LMWHs)",
      "label": "same for"
    },
    {
      "source": "percent content",
      "target": "HA species",
      "label": "of"
    },
    {
      "source": "low-molecular-weight heparins (LMWHs)",
      "target": "high affinity (HA) pools",
      "label": "fractionated into"
    },
    {
      "source": "low-molecular-weight heparins (LMWHs)",
      "target": "no affinity (NA) pools",
      "label": "fractionated into"
    },
    {
      "source": "Enoxaparin",
      "target": "structure",
      "label": "characterised by"
    },
    {
      "source": "Enoxaparin",
      "target": "shorter oligosaccharides",
      "label": "richer in"
    },
    {
      "source": "Enoxaparin",
      "target": "distribution",
      "label": "characterised by"
    },
    {
      "source": "high affinity (HA) pools",
      "target": "antithrombin (AT)",
      "label": "bind"
    },
    {
      "source": "correlations",
      "target": "Structural features",
      "label": "between"
    },
    {
      "source": "correlations",
      "target": "AT-mediated anticoagulant activity",
      "label": "between"
    },
    {
      "source": "correlations",
      "target": "observed properties",
      "label": "exist within"
    },
    {
      "source": "correlations",
      "target": "reported experimental behaviors",
      "label": "exist with"
    },
    {
      "source": "chain distribution",
      "target": "AT-bs",
      "label": "of"
    },
    {
      "source": "chain distribution",
      "target": "length",
      "label": "function of"
    },
    {
      "source": "AT-bs",
      "target": "longest chains",
      "label": "contained in"
    },
    {
      "source": "differences",
      "target": "chain distribution",
      "label": "observed for"
    },
    {
      "source": "differences",
      "target": "affinities",
      "label": "in"
    },
    {
      "source": "differences",
      "target": "expression",
      "label": "in"
    },
    {
      "source": "differences",
      "target": "BDP disposition",
      "label": "influences"
    },
    {
      "source": "differences",
      "target": "function",
      "label": "in"
    },
    {
      "source": "differences",
      "target": "OP-exposed group",
      "label": "found in"
    },
    {
      "source": "Structural features",
      "target": "biological activities",
      "label": "affect"
    },
    {
      "source": "Structural features",
      "target": "low-molecular-weight heparins (LMWHs)",
      "label": "of"
    },
    {
      "source": "Structural features",
      "target": "affinity",
      "label": "affect"
    },
    {
      "source": "content",
      "target": "pentasaccharide",
      "label": "of"
    },
    {
      "source": "content",
      "target": "terminal groups",
      "label": "of"
    },
    {
      "source": "content",
      "target": "uronic acid residues",
      "label": "of"
    },
    {
      "source": "content",
      "target": "glucosamine",
      "label": "of"
    },
    {
      "source": "content",
      "target": "AT-binding sequence A-G-A*-I-A (AT-bs)",
      "label": "of"
    },
    {
      "source": "content",
      "target": "sulfate substituents",
      "label": "of"
    },
    {
      "source": "content",
      "target": "quantification",
      "label": "through"
    },
    {
      "source": "molecular weight parameters",
      "target": "parent LMWHs",
      "label": "measured for"
    },
    {
      "source": "molecular weight parameters",
      "target": "SE chromatographic system",
      "label": "measured using"
    },
    {
      "source": "molecular weight parameters",
      "target": "selected fractions",
      "label": "measured for"
    },
    {
      "source": "distribution",
      "target": "chain length oligosaccharides",
      "label": "of"
    },
    {
      "source": "distribution",
      "target": "size-exclusion (SE) chromatography",
      "label": "determined by"
    },
    {
      "source": "distribution",
      "target": "sensory nerve fibers",
      "label": "of"
    },
    {
      "source": "distribution",
      "target": "toxicant action",
      "label": "affects"
    },
    {
      "source": "distribution",
      "target": "hexahydro-1,3,5-trinitro-1,3,5-triazine",
      "label": "is aspect of"
    },
    {
      "source": "Dalteparin",
      "target": "distribution",
      "label": "characterised by"
    },
    {
      "source": "Dalteparin",
      "target": "structure",
      "label": "characterised by"
    },
    {
      "source": "SE chromatographic system",
      "target": "absolute molecular weights",
      "label": "obtains"
    },
    {
      "source": "SE chromatographic system",
      "target": "triple detector (TDA)",
      "label": "has"
    },
    {
      "source": "HSQC-NMR spectra",
      "target": "content",
      "label": "evaluates"
    },
    {
      "source": "Tinzaparin",
      "target": "distribution",
      "label": "characterised by"
    },
    {
      "source": "Tinzaparin",
      "target": "structure",
      "label": "characterised by"
    },
    {
      "source": "signals",
      "target": "disaccharide sequence G-A*",
      "label": "of"
    },
    {
      "source": "triple detector (TDA)",
      "target": "absolute molecular weights",
      "label": "obtains"
    },
    {
      "source": "no affinity (NA) pools",
      "target": "antithrombin (AT)",
      "label": "bind"
    },
    {
      "source": "structure-activity relationships",
      "target": "C3-phenyl moiety",
      "label": "concerns"
    },
    {
      "source": "SE chromatograms",
      "target": "Enoxaparin",
      "label": "indicate"
    },
    {
      "source": "investigation",
      "target": "Structural features",
      "label": "on"
    },
    {
      "source": "investigation",
      "target": "hypothesis",
      "label": "tested"
    },
    {
      "source": "investigation",
      "target": "influence",
      "label": "focuses_on"
    },
    {
      "source": "glucosamine",
      "target": "cell proliferation",
      "label": "may inhibit"
    },
    {
      "source": "glucosamine",
      "target": "phosphorylation",
      "label": "found inhibitory effect on"
    },
    {
      "source": "glucosamine",
      "target": "bronchial epithelial cells (HBECs)",
      "label": "impacts on"
    },
    {
      "source": "glucosamine",
      "target": "p21 nuclear accumulation",
      "label": "induced"
    },
    {
      "source": "glucosamine",
      "target": "Rb protein",
      "label": "found inhibitory effect on"
    },
    {
      "source": "glucosamine",
      "target": "human pulmonary epithelial cells",
      "label": "acts on"
    },
    {
      "source": "glucosamine",
      "target": "p53",
      "label": "elevated"
    },
    {
      "source": "glucosamine",
      "target": "Rb phosphorylation",
      "label": "causes reduction in"
    },
    {
      "source": "glucosamine",
      "target": "human alveolar epithelial cells (A549)",
      "label": "impacts on"
    },
    {
      "source": "glucosamine",
      "target": "late apoptosis",
      "label": "induced"
    },
    {
      "source": "glucosamine",
      "target": "heme oxygenase-1 (HO-1)",
      "label": "elevated"
    },
    {
      "source": "glucosamine",
      "target": "HO-1 expression",
      "label": "modulates"
    },
    {
      "source": "glucosamine",
      "target": "anti-inflammatory molecule",
      "label": "is a potential"
    },
    {
      "source": "glucosamine",
      "target": "p21 protein stability",
      "label": "attenuated"
    },
    {
      "source": "glucosamine",
      "target": "Cell cycle regulation",
      "label": "regulates"
    },
    {
      "source": "glucosamine",
      "target": "p21",
      "label": "modulates"
    },
    {
      "source": "glucosamine",
      "target": "supplemental compound",
      "label": "is a"
    },
    {
      "source": "glucosamine",
      "target": "HO-1",
      "label": "elevated"
    },
    {
      "source": "glucosamine",
      "target": "retinoblastoma (Rb) protein",
      "label": "found inhibitory effect on"
    },
    {
      "source": "glucosamine",
      "target": "cell accumulation",
      "label": "enhanced"
    },
    {
      "source": "glucosamine",
      "target": "cell cycle progression",
      "label": "may disturb"
    },
    {
      "source": "glucosamine",
      "target": "apoptosis",
      "label": "inhibits through"
    },
    {
      "source": "glucosamine",
      "target": "cell number",
      "label": "caused a decrease in"
    },
    {
      "source": "glucosamine",
      "target": "mRNA",
      "label": "elevated"
    },
    {
      "source": "glucosamine",
      "target": "cellular proliferation",
      "label": "impacts on"
    },
    {
      "source": "glucosamine",
      "target": "nuclear p21 accumulation",
      "label": "modulates"
    },
    {
      "source": "glucosamine",
      "target": "protein expression",
      "label": "elevated"
    },
    {
      "source": "glucosamine",
      "target": "p21 protein",
      "label": "caused a reduction in"
    },
    {
      "source": "AT-binding sequence A-G-A*-I-A (AT-bs)",
      "target": "AT-bs",
      "label": "is"
    },
    {
      "source": "Alterations",
      "target": "number",
      "label": "in"
    },
    {
      "source": "Alterations",
      "target": "function",
      "label": "in"
    },
    {
      "source": "Alterations",
      "target": "abnormal responses",
      "label": "may account for"
    },
    {
      "source": "number",
      "target": "receptors",
      "label": "of"
    },
    {
      "source": "capacity",
      "target": "peripheral alpha-2B adrenergic receptors",
      "label": "is to bind and stimulate"
    },
    {
      "source": "capacity",
      "target": "transport process",
      "label": "via"
    },
    {
      "source": "capacity",
      "target": "copper",
      "label": "for accumulating"
    },
    {
      "source": "peripheral alpha-2B adrenergic receptors",
      "target": "vasoconstriction",
      "label": "stimulation leads to"
    },
    {
      "source": "biologic effects",
      "target": "etomidate",
      "label": "are of"
    },
    {
      "source": "etomidate",
      "target": "anesthesia",
      "label": "used in maintaining"
    },
    {
      "source": "etomidate",
      "target": "patients",
      "label": "used in"
    },
    {
      "source": "hemodynamic profile",
      "target": "etomidate",
      "label": "is of"
    },
    {
      "source": "hemodynamic profile",
      "target": "Alpha-2B adrenergic receptor",
      "label": "mediated by"
    },
    {
      "source": "other anesthetics",
      "target": "hypotension",
      "label": "produce"
    },
    {
      "source": "abnormal responses",
      "target": "etomidate induction",
      "label": "occur during"
    },
    {
      "source": "branched-chain organic acidemias",
      "target": "methylmalonic acidemias",
      "label": "includes"
    },
    {
      "source": "branched-chain organic acidemias",
      "target": "propionic acidemias",
      "label": "includes"
    },
    {
      "source": "branched-chain organic acidemias",
      "target": "isovaleric acidemia",
      "label": "includes"
    },
    {
      "source": "competitive inhibition",
      "target": "N-acetylglutamate synthetase",
      "label": "is of"
    },
    {
      "source": "Hyperammonemia",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "Hyperammonemia",
      "target": "neonates",
      "label": "occurs in"
    },
    {
      "source": "Hyperammonemia",
      "target": "pathophysiological process",
      "label": "has"
    },
    {
      "source": "Oral carglumic acid",
      "target": "Hyperammonemia",
      "label": "can correct"
    },
    {
      "source": "Oral carglumic acid",
      "target": "dialysis therapy",
      "label": "avoids"
    },
    {
      "source": "Oral carglumic acid",
      "target": "N-carbamylglutamate",
      "label": "is also known as"
    },
    {
      "source": "isovaleric acidemia",
      "target": "autosomal recessive disease",
      "label": "is a type of"
    },
    {
      "source": "isovaleric acidemia",
      "target": "deficiency",
      "label": "is caused by"
    },
    {
      "source": "autosomal recessive disease",
      "target": "leucine metabolism",
      "label": "affects"
    },
    {
      "source": "pathophysiological process",
      "target": "competitive inhibition",
      "label": "is via"
    },
    {
      "source": "N-carbamylglutamate treatment",
      "target": "acute neonatal hyperammonemia",
      "label": "is for"
    },
    {
      "source": "acute neonatal hyperammonemia",
      "target": "isovaleric acidemia",
      "label": "results from"
    },
    {
      "source": "oral load",
      "target": "carglumic acid",
      "label": "is of"
    },
    {
      "source": "carglumic acid",
      "target": "acute neonatal hyperammonemia",
      "label": "is considered for"
    },
    {
      "source": "plasma ammonia concentration",
      "target": "oral load",
      "label": "dropped after"
    },
    {
      "source": "Na+ transport processes",
      "target": "human lung epithelial cells",
      "label": "occurs across"
    },
    {
      "source": "I(ouabain)",
      "target": "Ussing chambers",
      "label": "measured in"
    },
    {
      "source": "I(ouabain)",
      "target": "H441 lung epithelial cells",
      "label": "occurs in"
    },
    {
      "source": "I(ouabain)",
      "target": "H441 monolayers",
      "label": "occurs across"
    },
    {
      "source": "I(amiloride)",
      "target": "I(ouabain)",
      "label": "is not related to"
    },
    {
      "source": "I(amiloride)",
      "target": "Ussing chambers",
      "label": "measured in"
    },
    {
      "source": "I(amiloride)",
      "target": "H441 lung epithelial cells",
      "label": "occurs in"
    },
    {
      "source": "alpha1-AMPK",
      "target": "ENaC",
      "label": "inhibits"
    },
    {
      "source": "alpha1-AMPK",
      "target": "apical amiloride-sensitive Na(+) channels",
      "label": "inhibits"
    },
    {
      "source": "alpha1-AMPK",
      "target": "clinical use",
      "label": "has implications for"
    },
    {
      "source": "phenformin",
      "target": "AMPK (alpha1) activity",
      "label": "increased"
    },
    {
      "source": "phenformin",
      "target": "apical Na+ conductance",
      "label": "affects"
    },
    {
      "source": "phenformin",
      "target": "cellular ATP",
      "label": "decreased"
    },
    {
      "source": "phenformin",
      "target": "monolayer resistance",
      "label": "decreased"
    },
    {
      "source": "phenformin",
      "target": "AMPK",
      "label": "activates"
    },
    {
      "source": "phenformin",
      "target": "AMP-activated protein kinase",
      "label": "activates"
    },
    {
      "source": "phenformin",
      "target": "I(ouabain)",
      "label": "decreased"
    },
    {
      "source": "phenformin",
      "target": "I(amiloride)",
      "label": "decreased"
    },
    {
      "source": "phenformin",
      "target": "ENaC activity",
      "label": "affects"
    },
    {
      "source": "phenformin",
      "target": "cellular AMP:ATP ratio",
      "label": "increased"
    },
    {
      "source": "AICAR",
      "target": "AMPK",
      "label": "activates"
    },
    {
      "source": "AICAR",
      "target": "monolayer resistance",
      "label": "decreased"
    },
    {
      "source": "AICAR",
      "target": "I(ouabain)",
      "label": "decreased"
    },
    {
      "source": "AICAR",
      "target": "AMP-activated protein kinase",
      "label": "activates"
    },
    {
      "source": "AICAR",
      "target": "I(amiloride)",
      "label": "decreased"
    },
    {
      "source": "AICAR",
      "target": "ENaC activity",
      "label": "affects"
    },
    {
      "source": "AICAR",
      "target": "AMPK (alpha1) activity",
      "label": "increased"
    },
    {
      "source": "AICAR",
      "target": "cellular ATP",
      "label": "decreased"
    },
    {
      "source": "AICAR",
      "target": "apical Na+ conductance",
      "label": "affects"
    },
    {
      "source": "AICAR",
      "target": "Ca2+ entry",
      "label": "prevents"
    },
    {
      "source": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside",
      "target": "AMPK",
      "label": "activates"
    },
    {
      "source": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside",
      "target": "AMP-activated protein kinase",
      "label": "activates"
    },
    {
      "source": "adenine nucleotide concentration",
      "target": "H441 lung epithelial cells",
      "label": "measured in"
    },
    {
      "source": "metformin",
      "target": "clinical use",
      "label": "has"
    },
    {
      "source": "metformin",
      "target": "I(amiloride)",
      "label": "decreased"
    },
    {
      "source": "metformin",
      "target": "AMP-activated protein kinase",
      "label": "activates"
    },
    {
      "source": "metformin",
      "target": "cellular AMP:ATP ratio",
      "label": "increased"
    },
    {
      "source": "metformin",
      "target": "AMPK (alpha1) activity",
      "label": "increased"
    },
    {
      "source": "metformin",
      "target": "AMPK",
      "label": "activated"
    },
    {
      "source": "metformin",
      "target": "cardiac autophagy",
      "label": "restored"
    },
    {
      "source": "metformin",
      "target": "dissociating Beclin1 and Bcl-2",
      "label": "caused"
    },
    {
      "source": "metformin",
      "target": "JNK1-Bcl-2 pathways",
      "label": "activated"
    },
    {
      "source": "AMPK activation",
      "target": "H441 lung epithelial cells",
      "label": "occurs in"
    },
    {
      "source": "AMPK activation",
      "target": "SCGly+PoG",
      "label": "observed in"
    },
    {
      "source": "AMPK activation",
      "target": "high glucose-induced apoptosis",
      "label": "attenuated"
    },
    {
      "source": "AMPK activation",
      "target": "cardiomyopathy",
      "label": "prevents"
    },
    {
      "source": "AMPK activation",
      "target": "JNK1-Bcl-2 signaling",
      "label": "stimulated"
    },
    {
      "source": "AMPK activation",
      "target": "dissociation of Bcl-2 from Beclin1",
      "label": "causes"
    },
    {
      "source": "AMPK activation",
      "target": "Beclin1-Bcl-2 complex",
      "label": "disrupted"
    },
    {
      "source": "AMPK activation",
      "target": "cardiac autophagy",
      "label": "restores"
    },
    {
      "source": "AMPK activation",
      "target": "Diabetic cardiomyopathy",
      "label": "prevents"
    },
    {
      "source": "AMPK activation",
      "target": "cardiomyocyte apoptosis",
      "label": "protects against"
    },
    {
      "source": "H441 cells",
      "target": "air interface",
      "label": "grown at"
    },
    {
      "source": "H441 cells",
      "target": "permeable filters",
      "label": "grown on"
    },
    {
      "source": "NAD(P)H autofluorescence",
      "target": "confocal microscopy",
      "label": "measured using"
    },
    {
      "source": "Compound C",
      "target": "phenformin",
      "label": "did not prevent action of"
    },
    {
      "source": "Compound C",
      "target": "AICAR",
      "label": "prevented action of"
    },
    {
      "source": "Compound C",
      "target": "AMPK",
      "label": "is an inhibitor of"
    },
    {
      "source": "Compound C",
      "target": "metformin",
      "label": "prevented action of"
    },
    {
      "source": "transepithelial resistance",
      "target": "Ussing chambers",
      "label": "measured in"
    },
    {
      "source": "AMP",
      "target": "cellular AMP:ATP ratio",
      "label": "is part of"
    },
    {
      "source": "Pharmacological activators",
      "target": "AMP-activated protein kinase",
      "label": "activates"
    },
    {
      "source": "Pharmacological activators",
      "target": "Na+ transport processes",
      "label": "affects"
    },
    {
      "source": "Adenine nucleotide",
      "target": "reverse phase HPLC",
      "label": "analysed by"
    },
    {
      "source": "AMPK activity",
      "target": "SAMS peptide",
      "label": "measured using"
    },
    {
      "source": "AMPK activity",
      "target": "radiolabelled phosphate",
      "label": "measured using"
    },
    {
      "source": "AMPK activity",
      "target": "tumor progression",
      "label": "loss fosters"
    },
    {
      "source": "AMPK activity",
      "target": "tumor development",
      "label": "opposes"
    },
    {
      "source": "Na+K+ATPase",
      "target": "cell systems",
      "label": "is a component of"
    },
    {
      "source": "estramustine phosphate",
      "target": "chick brain MAP2:tubulin microtubules",
      "label": "induces disassembly of"
    },
    {
      "source": "estramustine phosphate",
      "target": "MAP2",
      "label": "binds to"
    },
    {
      "source": "estramustine phosphate",
      "target": "MAP2 sites",
      "label": "competes for"
    },
    {
      "source": "MAP2",
      "target": "estramustine phosphate",
      "label": "binds"
    },
    {
      "source": "MAP2",
      "target": "moles",
      "label": "binds"
    },
    {
      "source": "molecules of estramustine phosphate",
      "target": "MAP2:tubulin interaction",
      "label": "inhibit"
    },
    {
      "source": "molecules of estramustine phosphate",
      "target": "tubulin-binding sites",
      "label": "interact with"
    },
    {
      "source": "molecules of estramustine phosphate",
      "target": "basic residues",
      "label": "neutralise"
    },
    {
      "source": "Kd",
      "target": "microM estramustine phosphate",
      "label": "is congruent to"
    },
    {
      "source": "tubulin",
      "target": "MAP2 sites",
      "label": "competes for"
    },
    {
      "source": "role of fulvestrant",
      "target": "current treatment guidelines",
      "label": "is in"
    },
    {
      "source": "FDA approval",
      "target": "2002",
      "label": "occurred in"
    },
    {
      "source": "effective and well-tolerated drug",
      "target": "treatment of metastatic estrogen-sensitive breast cancer",
      "label": "is for"
    },
    {
      "source": "progression",
      "target": "loss of disease control",
      "label": "leads to"
    },
    {
      "source": "progression",
      "target": "expected disease course",
      "label": "is an"
    },
    {
      "source": "progression",
      "target": "hormone-refractory state",
      "label": "leads to"
    },
    {
      "source": "loss of disease control",
      "target": "expected disease course",
      "label": "is an"
    },
    {
      "source": "Published scientific literature",
      "target": "fulvestrant",
      "label": "is on"
    },
    {
      "source": "Published scientific literature",
      "target": "presented abstracts",
      "label": "includes"
    },
    {
      "source": "Published scientific literature",
      "target": "present",
      "label": "covers period to"
    },
    {
      "source": "Published scientific literature",
      "target": "1985",
      "label": "covers period from"
    },
    {
      "source": "ongoing investigations",
      "target": "fulvestrant",
      "label": "are of"
    },
    {
      "source": "potential advantages",
      "target": "estrogen targeted therapies",
      "label": "are over"
    },
    {
      "source": "unique mechanism of action",
      "target": "potential advantages",
      "label": "offers"
    },
    {
      "source": "estrogen deprivation",
      "target": "treatment of breast cancer",
      "label": "is for"
    },
    {
      "source": "estrogen deprivation",
      "target": "1800s",
      "label": "understood since"
    },
    {
      "source": "clinical benefit",
      "target": "patients",
      "label": "is for"
    },
    {
      "source": "clinical benefit",
      "target": "phase I study",
      "label": "observed in"
    },
    {
      "source": "Work",
      "target": "clinical benefit",
      "label": "enhances"
    },
    {
      "source": "Pharmacologic advances",
      "target": "aromatase inhibitors",
      "label": "includes"
    },
    {
      "source": "Pharmacologic advances",
      "target": "tamoxifen",
      "label": "includes"
    },
    {
      "source": "Pharmacologic advances",
      "target": "past decades",
      "label": "occurred in"
    },
    {
      "source": "Pharmacologic advances",
      "target": "mortality of estrogen-sensitive breast cancer",
      "label": "contributed to reduced"
    },
    {
      "source": "Pharmacologic advances",
      "target": "field",
      "label": "occurred in"
    },
    {
      "source": "estrogen-sensitive breast cancer",
      "target": "relapses",
      "label": "presents with"
    },
    {
      "source": "estrogen-sensitive breast cancer",
      "target": "progression",
      "label": "shows"
    },
    {
      "source": "CINV",
      "target": "acute phase",
      "label": "occurs in"
    },
    {
      "source": "CINV",
      "target": "HEC",
      "label": "follows"
    },
    {
      "source": "CINV",
      "target": "highly emetogenic chemotherapy (HEC)",
      "label": "follows"
    },
    {
      "source": "CINV",
      "target": "delayed phase",
      "label": "occurs in"
    },
    {
      "source": "CINV",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "CINV",
      "target": "MEC",
      "label": "follows"
    },
    {
      "source": "CINV",
      "target": "Quality of life",
      "label": "is associated with deterioration in"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "dolasetron",
      "label": "noninferior to"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "ondansetron",
      "label": "has greater efficacy than"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "prevention",
      "label": "indicated for"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "CINV",
      "label": "prevents"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "placebo",
      "label": "superior to"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "PONV prevention",
      "label": "used for"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "option",
      "label": "is a"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "US",
      "label": "indicated in"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "intravenous ondansetron",
      "label": "noninferior to"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "intravenous granisetron",
      "label": "noninferior to"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "PONV",
      "label": "prevents"
    },
    {
      "source": "Intravenous palonosetron",
      "target": "agents",
      "label": "is an alternative to"
    },
    {
      "source": "acute-phase CINV",
      "target": "adult patients",
      "label": "occurs in"
    },
    {
      "source": "acute-phase CINV",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "adult patients",
      "target": "MEC",
      "label": "receiving"
    },
    {
      "source": "Palonosetron",
      "target": "prevention",
      "label": "used for"
    },
    {
      "source": "Palonosetron",
      "target": "clinical trials",
      "label": "tolerated in"
    },
    {
      "source": "Palonosetron",
      "target": "serotonin",
      "label": "is an antagonist of"
    },
    {
      "source": "Palonosetron",
      "target": "antagonist",
      "label": "is an"
    },
    {
      "source": "Palonosetron",
      "target": "pharmacological profile",
      "label": "has"
    },
    {
      "source": "Palonosetron",
      "target": "5-HT3 receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "Palonosetron",
      "target": "second-generation serotonin 5-HT3 receptor antagonist",
      "label": "is a"
    },
    {
      "source": "Palonosetron",
      "target": "Second-generation 5-HT3 receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "Palonosetron",
      "target": "Binding capacity",
      "label": "has a different"
    },
    {
      "source": "Palonosetron",
      "target": "Mechanism of action",
      "label": "has a different"
    },
    {
      "source": "Palonosetron",
      "target": "First-generation 5-HT3 receptor antagonists",
      "label": "differs from"
    },
    {
      "source": "Palonosetron",
      "target": "Half-life",
      "label": "has a different"
    },
    {
      "source": "oral palonosetron",
      "target": "US",
      "label": "approved in"
    },
    {
      "source": "oral palonosetron",
      "target": "prevention",
      "label": "approved for"
    },
    {
      "source": "oral palonosetron",
      "target": "Intravenous palonosetron",
      "label": "noninferior to"
    },
    {
      "source": "oral palonosetron",
      "target": "formulation",
      "label": "is a"
    },
    {
      "source": "oral palonosetron",
      "target": "oral formulations",
      "label": "is an addition to"
    },
    {
      "source": "oral palonosetron",
      "target": "CINV",
      "label": "prevents"
    },
    {
      "source": "option",
      "target": "prevention",
      "label": "for"
    },
    {
      "source": "MEC",
      "target": "mecamylamine",
      "label": "is an abbreviation for"
    },
    {
      "source": "pharmacological profile",
      "target": "first-generation 5-HT3 receptor antagonists",
      "label": "differs from"
    },
    {
      "source": "postoperative nausea and vomiting (PONV)",
      "target": "surgery",
      "label": "follows"
    },
    {
      "source": "postoperative nausea and vomiting (PONV)",
      "target": "24 hours",
      "label": "occurs within"
    },
    {
      "source": "chemotherapy-induced nausea and vomiting (CINV)",
      "target": "delayed phase",
      "label": "occurs in"
    },
    {
      "source": "chemotherapy-induced nausea and vomiting (CINV)",
      "target": "acute phase",
      "label": "occurs in"
    },
    {
      "source": "chemotherapy-induced nausea and vomiting (CINV)",
      "target": "moderately emetogenic chemotherapy (MEC)",
      "label": "follows"
    },
    {
      "source": "formulation",
      "target": "new working model",
      "label": "is of a"
    },
    {
      "source": "PONV",
      "target": "surgery",
      "label": "follows"
    },
    {
      "source": "PONV",
      "target": "24 hours",
      "label": "occurs within"
    },
    {
      "source": "acute poisoning",
      "target": "organophosphorus pesticides",
      "label": "caused_by"
    },
    {
      "source": "acute poisoning",
      "target": "carbamate pesticides",
      "label": "caused_by"
    },
    {
      "source": "obidoxime",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "obidoxime",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "obidoxime",
      "target": "AChE reactivator",
      "label": "is_an"
    },
    {
      "source": "OP poisoning",
      "target": "respiratory failure",
      "label": "causes"
    },
    {
      "source": "OP poisoning",
      "target": "AChE inhibition",
      "label": "involves"
    },
    {
      "source": "OP poisoning",
      "target": "humans",
      "label": "occurs_in"
    },
    {
      "source": "OPs",
      "target": "warfare nerve agents",
      "label": "are_a_type_of"
    },
    {
      "source": "OPs",
      "target": "pesticides",
      "label": "are_a_type_of"
    },
    {
      "source": "warfare nerve agents",
      "target": "soman",
      "label": "include"
    },
    {
      "source": "warfare nerve agents",
      "target": "sarin",
      "label": "include"
    },
    {
      "source": "warfare nerve agents",
      "target": "tabun",
      "label": "include"
    },
    {
      "source": "warfare nerve agents",
      "target": "VX",
      "label": "include"
    },
    {
      "source": "pralidoxime",
      "target": "AChE reactivator",
      "label": "is_an"
    },
    {
      "source": "pralidoxime",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "pralidoxime",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "neurotransmission",
      "target": "rat sympathetic neurons",
      "label": "studied in"
    },
    {
      "source": "atropine",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "atropine",
      "target": "antimuscarinic agent",
      "label": "is_an"
    },
    {
      "source": "atropine",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "atropine",
      "target": "LY293558",
      "label": "co-administered with"
    },
    {
      "source": "atropine",
      "target": "AChE",
      "label": "Downregulator"
    },
    {
      "source": "atropine",
      "target": "mAChR",
      "label": "Antagonist"
    },
    {
      "source": "atropine",
      "target": "mAChR antagonist",
      "label": "is an"
    },
    {
      "source": "atropine",
      "target": "effects",
      "label": "reversed"
    },
    {
      "source": "pyridinium oximes",
      "target": "antidotes",
      "label": "are_a_type_of"
    },
    {
      "source": "pyridinium oximes",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "pyridinium oximes",
      "target": "therapeutic agents",
      "label": "are_a_type_of"
    },
    {
      "source": "pyridinium oximes",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "pyridinium oximes",
      "target": "human medicine",
      "label": "has_application_in"
    },
    {
      "source": "pyridinium oximes",
      "target": "AChE reactivator",
      "label": "are_a_type_of"
    },
    {
      "source": "pyridinium oximes",
      "target": "Medical treatment",
      "label": "used_in"
    },
    {
      "source": "pyridinium oximes",
      "target": "AChE",
      "label": "reactivates"
    },
    {
      "source": "antidotes",
      "target": "endogenous threats",
      "label": "are for"
    },
    {
      "source": "trimedoxime",
      "target": "AChE reactivator",
      "label": "is_an"
    },
    {
      "source": "trimedoxime",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "trimedoxime",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "AChE inhibition",
      "target": "acetylcholine",
      "label": "results_in_accumulation_of"
    },
    {
      "source": "AChE inhibition",
      "target": "AChE",
      "label": "leads_to_inactivation_of"
    },
    {
      "source": "AChE inhibition",
      "target": "cholinergic fibers",
      "label": "produces_stimulation_of"
    },
    {
      "source": "AChE inhibition",
      "target": "acetylcholinesterase",
      "label": "leads_to_inactivation_of"
    },
    {
      "source": "HI-6",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "HI-6",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "HI-6",
      "target": "AChE reactivator",
      "label": "is_an"
    },
    {
      "source": "HI-6",
      "target": "LY293558",
      "label": "co-administered with"
    },
    {
      "source": "HI-6",
      "target": "oxime",
      "label": "is a type of"
    },
    {
      "source": "OP",
      "target": "AChE",
      "label": "inhibits"
    },
    {
      "source": "OP",
      "target": "acetylcholinesterase",
      "label": "inhibits"
    },
    {
      "source": "Medical treatment",
      "target": "acute poisoning",
      "label": "treats"
    },
    {
      "source": "Medical treatment",
      "target": "OP poisoning",
      "label": "treats"
    },
    {
      "source": "Organophosphorus compounds",
      "target": "pesticides",
      "label": "are_a_type_of"
    },
    {
      "source": "Organophosphorus compounds",
      "target": "warfare nerve agents",
      "label": "are_a_type_of"
    },
    {
      "source": "soman",
      "target": "nerve agents",
      "label": "is a type of"
    },
    {
      "source": "soman",
      "target": "chemical warfare agent",
      "label": "is a type of"
    },
    {
      "source": "soman",
      "target": "acetylcholinesterase (AChE) inhibitor",
      "label": "is a type of"
    },
    {
      "source": "soman",
      "target": "irreversible AChE inhibitor",
      "label": "is an"
    },
    {
      "source": "cholinergic fibers",
      "target": "nervous systems",
      "label": "are_located_in"
    },
    {
      "source": "diazepam",
      "target": "OP poisoning",
      "label": "used_for"
    },
    {
      "source": "diazepam",
      "target": "humans",
      "label": "used_in"
    },
    {
      "source": "18F-AV-45",
      "target": "specificity",
      "label": "has"
    },
    {
      "source": "18F-AV-45",
      "target": "binding affinity",
      "label": "has"
    },
    {
      "source": "18F-AV-45",
      "target": "Abeta plaques",
      "label": "binds to"
    },
    {
      "source": "18F-AV-45",
      "target": "PET agent",
      "label": "is a"
    },
    {
      "source": "18F-AV-45",
      "target": "phase III clinical studies",
      "label": "is in"
    },
    {
      "source": "autoradiography",
      "target": "plaque labeling",
      "label": "showed"
    },
    {
      "source": "autoradiography",
      "target": "postmortem human brain sections",
      "label": "of"
    },
    {
      "source": "plaque labeling",
      "target": "control brains",
      "label": "not in"
    },
    {
      "source": "plaque labeling",
      "target": "AD brains",
      "label": "in"
    },
    {
      "source": "pathogenesis processes",
      "target": "AD",
      "label": "is in"
    },
    {
      "source": "ex vivo autoradiography",
      "target": "transgenic AD model mice",
      "label": "in"
    },
    {
      "source": "ex vivo autoradiography",
      "target": "AD transgenic mice (APPswe/PSEN1)",
      "label": "of"
    },
    {
      "source": "Abeta plaques",
      "target": "Alzheimer disease (AD)",
      "label": "is a feature of"
    },
    {
      "source": "Abeta plaques",
      "target": "fibrillary Abeta peptide aggregates",
      "label": "contains"
    },
    {
      "source": "Abeta plaques",
      "target": "postmortem AD brain tissue",
      "label": "is in"
    },
    {
      "source": "Abeta plaques",
      "target": "AD brains",
      "label": "is in"
    },
    {
      "source": "Abeta plaques",
      "target": "brain",
      "label": "is in"
    },
    {
      "source": "Abeta plaques",
      "target": "living human brain",
      "label": "is in"
    },
    {
      "source": "high brain uptake",
      "target": "healthy mice",
      "label": "of"
    },
    {
      "source": "high brain uptake",
      "target": "monkey",
      "label": "of"
    },
    {
      "source": "in vitro binding",
      "target": "autoradiography",
      "label": "evaluated by"
    },
    {
      "source": "in vitro binding",
      "target": "in vitro binding assay",
      "label": "evaluated by"
    },
    {
      "source": "Metabolites",
      "target": "intravenous injection",
      "label": "produced after"
    },
    {
      "source": "Metabolites",
      "target": "blood",
      "label": "produced in"
    },
    {
      "source": "biomarkers",
      "target": "pathogenesis processes",
      "label": "is of"
    },
    {
      "source": "beta-amyloid plaques",
      "target": "Abeta plaques",
      "label": "is a"
    },
    {
      "source": "AD transgenic mice (APPswe/PSEN1)",
      "target": "Abeta aggregates",
      "label": "has"
    },
    {
      "source": "Abeta aggregates",
      "target": "brain",
      "label": "is in"
    },
    {
      "source": "phase III clinical studies",
      "target": "PET",
      "label": "is for"
    },
    {
      "source": "Imaging agents",
      "target": "Abeta plaques",
      "label": "targets"
    },
    {
      "source": "Imaging agents",
      "target": "biomarkers",
      "label": "is a"
    },
    {
      "source": "Small-animal PET",
      "target": "monkey brain",
      "label": "of"
    },
    {
      "source": "in vivo biodistribution",
      "target": "18F-AV-45",
      "label": "of"
    },
    {
      "source": "in vivo biodistribution",
      "target": "mice",
      "label": "in"
    },
    {
      "source": "PET agent",
      "target": "Abeta plaques",
      "label": "is for"
    },
    {
      "source": "rapid washout",
      "target": "brain",
      "label": "from"
    },
    {
      "source": "(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine",
      "target": "18F-AV-45",
      "label": "is a"
    },
    {
      "source": "triptorelin",
      "target": "Luteinizing hormone-releasing hormone (LHRH) agonists",
      "label": "is_a"
    },
    {
      "source": "Luteinizing hormone-releasing hormone (LHRH) agonists",
      "target": "gonadotrophin-releasing hormone (GnRH) receptor",
      "label": "Upregulator"
    },
    {
      "source": "Clinical data",
      "target": "degarelix",
      "label": "about"
    },
    {
      "source": "Clinical data",
      "target": "Abarelix",
      "label": "about"
    },
    {
      "source": "Clinical data",
      "target": "subjects",
      "label": "collected for"
    },
    {
      "source": "degarelix",
      "target": "pure GnRH antagonists",
      "label": "is_a"
    },
    {
      "source": "degarelix",
      "target": "complication rate",
      "label": "has"
    },
    {
      "source": "degarelix",
      "target": "decreases",
      "label": "causes"
    },
    {
      "source": "degarelix",
      "target": "testosterone flare",
      "label": "prevents"
    },
    {
      "source": "degarelix",
      "target": "co-administration",
      "label": "does_not_require"
    },
    {
      "source": "degarelix",
      "target": "agonist effect",
      "label": "lacks"
    },
    {
      "source": "degarelix",
      "target": "GnRH receptor",
      "label": "Antagonist"
    },
    {
      "source": "decreases",
      "target": "testosterone levels",
      "label": "Downregulator"
    },
    {
      "source": "decreases",
      "target": "castrate levels",
      "label": "reaches"
    },
    {
      "source": "hormonal castration",
      "target": "advanced or metastasizing hormone-dependent prostate carcinoma",
      "label": "treats"
    },
    {
      "source": "hormonal castration",
      "target": "rapid androgen suppression",
      "label": "requires"
    },
    {
      "source": "antiandrogen",
      "target": "potential effects",
      "label": "combats"
    },
    {
      "source": "potential effects",
      "target": "transient acceleration",
      "label": "are_of"
    },
    {
      "source": "potential effects",
      "target": "paraquat",
      "label": "of"
    },
    {
      "source": "potential effects",
      "target": "male C57BL/6J mice",
      "label": "in"
    },
    {
      "source": "potential effects",
      "target": "substantia nigra pars compacta",
      "label": "in"
    },
    {
      "source": "potential effects",
      "target": "striatum",
      "label": "in"
    },
    {
      "source": "Hormonal therapy",
      "target": "locally advanced and metastatic prostate cancer",
      "label": "treats"
    },
    {
      "source": "Hormonal therapy",
      "target": "treatment",
      "label": "is_a"
    },
    {
      "source": "de-sensitization",
      "target": "reduction",
      "label": "causes"
    },
    {
      "source": "complication rate",
      "target": "short term",
      "label": "occurs_in"
    },
    {
      "source": "gonadotrophin-releasing hormone antagonists",
      "target": "prostate cancer",
      "label": "treats"
    },
    {
      "source": "agonist effect",
      "target": "GnRH receptor",
      "label": "targets"
    },
    {
      "source": "leuprorelin",
      "target": "Luteinizing hormone-releasing hormone (LHRH) agonists",
      "label": "is_a"
    },
    {
      "source": "transient acceleration",
      "target": "cancer activity",
      "label": "affects"
    },
    {
      "source": "goserelin",
      "target": "Luteinizing hormone-releasing hormone (LHRH) agonists",
      "label": "is_a"
    },
    {
      "source": "buserelin",
      "target": "Luteinizing hormone-releasing hormone (LHRH) agonists",
      "label": "is_a"
    },
    {
      "source": "increase or 'surge'",
      "target": "LH",
      "label": "Upregulator"
    },
    {
      "source": "increase or 'surge'",
      "target": "antiandrogen",
      "label": "necessitates"
    },
    {
      "source": "increase or 'surge'",
      "target": "testosterone levels",
      "label": "Upregulator"
    },
    {
      "source": "gonadotrophin-releasing hormone (GnRH) receptor",
      "target": "de-sensitization",
      "label": "causes"
    },
    {
      "source": "Chromium levels",
      "target": "urine",
      "label": "measured in"
    },
    {
      "source": "Chromium levels",
      "target": "graphite furnace atomic absorption spectrophotometer Perkin Elmer analyst-200",
      "label": "analyzed using"
    },
    {
      "source": "Chromium levels",
      "target": "blood (BCr)",
      "label": "measured in"
    },
    {
      "source": "workers",
      "target": "BCr",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "adverse health effects",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "skin rashes",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "chromium",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "gastritis",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "chronic bronchitis",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "tanneries",
      "label": "located in"
    },
    {
      "source": "workers",
      "target": "hematological, hepatic and renal function impairment",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "conjunctivitis",
      "label": "had"
    },
    {
      "source": "workers",
      "target": "male",
      "label": "were"
    },
    {
      "source": "workers",
      "target": "excessive exposure",
      "label": "had"
    },
    {
      "source": "BCr",
      "target": "nmol/L",
      "label": "measured in"
    },
    {
      "source": "BCr",
      "target": "upper limit",
      "label": "above"
    },
    {
      "source": "male",
      "target": "average age",
      "label": "had"
    },
    {
      "source": "average age",
      "target": "33 years",
      "label": "was"
    },
    {
      "source": "adverse health effects",
      "target": "inflammatory changes",
      "label": "due to"
    },
    {
      "source": "adverse health effects",
      "target": "excessive exposure",
      "label": "due to"
    },
    {
      "source": "adverse health effects",
      "target": "enhanced oxidative stress",
      "label": "due to"
    },
    {
      "source": "chromium",
      "target": "biological fluids",
      "label": "found in"
    },
    {
      "source": "tannery workers",
      "target": "threat",
      "label": "under"
    },
    {
      "source": "tannery workers",
      "target": "median (interquartile range)",
      "label": "had"
    },
    {
      "source": "tannery workers",
      "target": "Sialkot",
      "label": "located at"
    },
    {
      "source": "threat",
      "target": "adverse health effects",
      "label": "of"
    },
    {
      "source": "urinary chromium excretion",
      "target": "controls",
      "label": "compared to"
    },
    {
      "source": "urinary chromium excretion",
      "target": "workers",
      "label": "high in"
    },
    {
      "source": "urinary chromium excretion",
      "target": "nmol/L",
      "label": "measured in"
    },
    {
      "source": "hematological, hepatic and renal function impairment",
      "target": "oxidative stress",
      "label": "caused by"
    },
    {
      "source": "excessive exposure",
      "target": "chromium",
      "label": "to"
    },
    {
      "source": "high-sensitive C-reactive protein",
      "target": "routine procedures",
      "label": "carried out by"
    },
    {
      "source": "upper limit",
      "target": "Agency for Toxic Substance and Drug Registry",
      "label": "set by"
    },
    {
      "source": "tanneries",
      "target": "Sialkot",
      "label": "located at"
    },
    {
      "source": "objective",
      "target": "Toxic effects",
      "label": "was to find out"
    },
    {
      "source": "objective",
      "target": "study",
      "label": "of the"
    },
    {
      "source": "objective",
      "target": "in vivo method",
      "label": "was to establish"
    },
    {
      "source": "Toxic effects",
      "target": "tannery workers",
      "label": "affect"
    },
    {
      "source": "Toxic effects",
      "target": "chromium",
      "label": "related to"
    },
    {
      "source": "median (interquartile range)",
      "target": "BCr",
      "label": "of"
    },
    {
      "source": "Sialkot",
      "target": "Pakistan",
      "label": "located in"
    },
    {
      "source": "routine biochemical tests",
      "target": "routine procedures",
      "label": "carried out by"
    },
    {
      "source": "240 males",
      "target": "workers",
      "label": "consisted of"
    },
    {
      "source": "240 males",
      "target": "controls",
      "label": "consisted of"
    },
    {
      "source": "Blood complete counts",
      "target": "routine procedures",
      "label": "carried out by"
    },
    {
      "source": "Chromium",
      "target": "leather industry",
      "label": "used in"
    },
    {
      "source": "testicular genes",
      "target": "CD1 mice",
      "label": "are found in"
    },
    {
      "source": "TBBPA",
      "target": "environment",
      "label": "found in"
    },
    {
      "source": "TBBPA",
      "target": "reproductive parameters",
      "label": "affects"
    },
    {
      "source": "TBBPA",
      "target": "flame retardant",
      "label": "is a type of"
    },
    {
      "source": "TBBPA",
      "target": "reproduction",
      "label": "did not affect"
    },
    {
      "source": "TBBPA",
      "target": "cell lines",
      "label": "affects"
    },
    {
      "source": "TBBPA",
      "target": "hormonal systems",
      "label": "may affect"
    },
    {
      "source": "TBBPA",
      "target": "sperm quality",
      "label": "did not affect"
    },
    {
      "source": "TBBPA",
      "target": "industry",
      "label": "is used in"
    },
    {
      "source": "TBBPA",
      "target": "human body",
      "label": "detected in"
    },
    {
      "source": "Experimental animals",
      "target": "apoptosis",
      "label": "showed increased incidence of"
    },
    {
      "source": "Experimental animals",
      "target": "F1 generation",
      "label": "are part of"
    },
    {
      "source": "Experimental animals",
      "target": "morphometry",
      "label": "showed changes in"
    },
    {
      "source": "reproductive parameters",
      "target": "generations",
      "label": "are of"
    },
    {
      "source": "tetrabrombisphenol A",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "tetrabrombisphenol A",
      "target": "expression",
      "label": "causes changes in"
    },
    {
      "source": "tetrabrombisphenol A",
      "target": "testicular genes",
      "label": "affects"
    },
    {
      "source": "morphometry",
      "target": "seminiferous tubules",
      "label": "is of"
    },
    {
      "source": "reproduction",
      "target": "daphnia",
      "label": "of"
    },
    {
      "source": "cell lines",
      "target": "immortalized non-neoplastic MC3T3-E1 osteoblastic cells",
      "label": "include"
    },
    {
      "source": "cell lines",
      "target": "mouse CCL-51 breast cancer cells",
      "label": "include"
    },
    {
      "source": "Tetrabromobisphenol A",
      "target": "flame retardant",
      "label": "is a type of"
    },
    {
      "source": "Tetrabromobisphenol A",
      "target": "TBBPA",
      "label": "is also known as"
    },
    {
      "source": "Tetrabromobisphenol A",
      "target": "industry",
      "label": "is used in"
    },
    {
      "source": "sperm quality",
      "target": "previous study",
      "label": "observed in"
    },
    {
      "source": "F1 generation",
      "target": "conditions",
      "label": "bred under"
    },
    {
      "source": "control animals",
      "target": "F1 generation",
      "label": "are part of"
    },
    {
      "source": "generations",
      "target": "outbred mice",
      "label": "are"
    },
    {
      "source": "epicatechin",
      "target": "chemopreventive activity",
      "label": "provides"
    },
    {
      "source": "epicatechin",
      "target": "antioxidants",
      "label": "is an"
    },
    {
      "source": "epicatechin",
      "target": "human diet",
      "label": "is present in"
    },
    {
      "source": "epicatechin",
      "target": "apples",
      "label": "is found in"
    },
    {
      "source": "epicatechin",
      "target": "oxidative stress",
      "label": "has protective effect against"
    },
    {
      "source": "epicatechin",
      "target": "antioxidant defense",
      "label": "provides"
    },
    {
      "source": "epicatechin",
      "target": "tea",
      "label": "is found in"
    },
    {
      "source": "epicatechin",
      "target": "chocolate",
      "label": "is found in"
    },
    {
      "source": "chemopreventive activity",
      "target": "nicotine-induced carcinogenesis",
      "label": "acts against"
    },
    {
      "source": "combined treatment",
      "target": "malondialdhyde (MDA)",
      "label": "reduces"
    },
    {
      "source": "combined treatment",
      "target": "MDA",
      "label": "reduces"
    },
    {
      "source": "combined treatment",
      "target": "oxidative stress",
      "label": "inhibits"
    },
    {
      "source": "malondialdhyde (MDA)",
      "target": "nicotine injected rats",
      "label": "is elevated in"
    },
    {
      "source": "constituents",
      "target": "antimutagenic activities",
      "label": "have"
    },
    {
      "source": "constituents",
      "target": "antitumor activities",
      "label": "have"
    },
    {
      "source": "constituents",
      "target": "antibacterial activities",
      "label": "have"
    },
    {
      "source": "constituents",
      "target": "antiviral activities",
      "label": "have"
    },
    {
      "source": "constituents",
      "target": "antioxidative activities",
      "label": "have"
    },
    {
      "source": "constituents",
      "target": "recombinant human histidine decarboxylase",
      "label": "inhibit"
    },
    {
      "source": "superoxide dismutase",
      "target": "combined treatment",
      "label": "activity is higher in"
    },
    {
      "source": "superoxide dismutase",
      "target": "untreated rats",
      "label": "activity is lower in"
    },
    {
      "source": "superoxide dismutase",
      "target": "stomach tissues",
      "label": "DETERMINED_IN"
    },
    {
      "source": "superoxide dismutase",
      "target": "reaction",
      "label": "did not catalyze"
    },
    {
      "source": "tea extracts",
      "target": "antimutagenic activities",
      "label": "have"
    },
    {
      "source": "tea extracts",
      "target": "antitumor activities",
      "label": "have"
    },
    {
      "source": "tea extracts",
      "target": "antibacterial activities",
      "label": "have"
    },
    {
      "source": "tea extracts",
      "target": "antiviral activities",
      "label": "have"
    },
    {
      "source": "tea extracts",
      "target": "antioxidative activities",
      "label": "have"
    },
    {
      "source": "antioxidant defense",
      "target": "nicotine-induced carcinogenesis",
      "label": "acts against"
    },
    {
      "source": "catalase",
      "target": "combined treatment",
      "label": "activity is higher in"
    },
    {
      "source": "catalase",
      "target": "untreated rats",
      "label": "activity is lower in"
    },
    {
      "source": "catalase",
      "target": "stomach tissues",
      "label": "DETERMINED_IN"
    },
    {
      "source": "catalase",
      "target": "CAT",
      "label": "IS_A"
    },
    {
      "source": "catalase",
      "target": "radiosensitivity",
      "label": "does not increase"
    },
    {
      "source": "catalase",
      "target": "detoxication enzymes",
      "label": "is a type of"
    },
    {
      "source": "MDA",
      "target": "nicotine injected rats",
      "label": "is elevated in"
    },
    {
      "source": "MDA",
      "target": "livers",
      "label": "levels in"
    },
    {
      "source": "MDA",
      "target": "serum",
      "label": "levels in"
    },
    {
      "source": "glutathione peroxidase",
      "target": "combined treatment",
      "label": "activity is higher in"
    },
    {
      "source": "glutathione peroxidase",
      "target": "untreated rats",
      "label": "activity is lower in"
    },
    {
      "source": "diet",
      "target": "vitamin E",
      "label": "is supplemented with"
    },
    {
      "source": "diet",
      "target": "epicatechin",
      "label": "is supplemented with"
    },
    {
      "source": "HFD-induced increases",
      "target": "serum lipids",
      "label": "includes"
    },
    {
      "source": "serum lipids",
      "target": "thiobarbituric acid-reactive substance (TBARS)",
      "label": "includes"
    },
    {
      "source": "serum lipids",
      "target": "triglyceride",
      "label": "includes"
    },
    {
      "source": "serum lipids",
      "target": "cholesterol",
      "label": "includes"
    },
    {
      "source": "Quercetin",
      "target": "fat accumulation",
      "label": "reduces"
    },
    {
      "source": "Quercetin",
      "target": "HFD-induced obesity",
      "label": "prevents"
    },
    {
      "source": "Quercetin",
      "target": "obesity",
      "label": "reduces"
    },
    {
      "source": "Quercetin",
      "target": "anti-obesity effects",
      "label": "has"
    },
    {
      "source": "Quercetin",
      "target": "hepatic gene expression",
      "label": "regulates"
    },
    {
      "source": "Quercetin",
      "target": "lipid metabolism genes",
      "label": "regulates"
    },
    {
      "source": "Quercetin",
      "target": "physiological effects",
      "label": "influences"
    },
    {
      "source": "Quercetin",
      "target": "alkaline phosphatase activity",
      "label": "Upregulator"
    },
    {
      "source": "Quercetin",
      "target": "fruit",
      "label": "is found in"
    },
    {
      "source": "Quercetin",
      "target": "bone development",
      "label": "affects"
    },
    {
      "source": "Quercetin",
      "target": "osteoblast differentiation",
      "label": "Upregulator"
    },
    {
      "source": "Quercetin",
      "target": "flavonoids",
      "label": "is a type of"
    },
    {
      "source": "Quercetin",
      "target": "vegetables",
      "label": "is found in"
    },
    {
      "source": "Quercetin",
      "target": "mineralization",
      "label": "demonstrated"
    },
    {
      "source": "Quercetin",
      "target": "osteodegenerative disorders",
      "label": "can be used for"
    },
    {
      "source": "Quercetin",
      "target": "osteoblast specific differentiation activities",
      "label": "has"
    },
    {
      "source": "fat accumulation",
      "target": "liver",
      "label": "occurs in"
    },
    {
      "source": "lipogenesis",
      "target": "transcription",
      "label": "at level of"
    },
    {
      "source": "lipogenesis",
      "target": "adipocytes",
      "label": "occurs in"
    },
    {
      "source": "lipogenesis",
      "target": "preadipocytes",
      "label": "occurs in"
    },
    {
      "source": "HFD-induced obesity",
      "target": "C57B1/6 mice",
      "label": "occurs in"
    },
    {
      "source": "HFD-induced gains",
      "target": "liver weight",
      "label": "includes"
    },
    {
      "source": "HFD-induced gains",
      "target": "white adipose tissue weight",
      "label": "includes"
    },
    {
      "source": "HFD-induced gains",
      "target": "body weight",
      "label": "includes"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Pparg",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "expression profiles",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "lipid droplets",
      "label": "reduced"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Fdft1",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "mice",
      "label": "administered to"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Fasn",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "hepatic lipid accumulation",
      "label": "reduced"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Apoa4",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Cd36",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Aldh1b1",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "HFD-induced gains",
      "label": "reduced"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Fnta",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Gpam",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Acaca",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "HFD-induced increases",
      "label": "reduced"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Pon1",
      "label": "altered"
    },
    {
      "source": "Quercetin supplementation",
      "target": "Abcg5",
      "label": "altered"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Pparg",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Fdft1",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Fasn",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Apoa4",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Cd36",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Aldh1b1",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Fnta",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Gpam",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Acaca",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Pon1",
      "label": "includes"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "liver",
      "label": "located in"
    },
    {
      "source": "lipid metabolism-related genes",
      "target": "Abcg5",
      "label": "includes"
    },
    {
      "source": "expression profiles",
      "target": "lipid metabolism-related genes",
      "label": "of"
    },
    {
      "source": "expression profiles",
      "target": "normal adrenals",
      "label": "analyzed in"
    },
    {
      "source": "expression profiles",
      "target": "steroidogenic enzymes",
      "label": "of"
    },
    {
      "source": "expression profiles",
      "target": "SCPA",
      "label": "analyzed in"
    },
    {
      "source": "expression profiles",
      "target": "NFA",
      "label": "analyzed in"
    },
    {
      "source": "expression profiles",
      "target": "CPA",
      "label": "analyzed in"
    },
    {
      "source": "expression profiles",
      "target": "APA",
      "label": "analyzed in"
    },
    {
      "source": "high-fat diet",
      "target": "fat accumulation",
      "label": "induces"
    },
    {
      "source": "high-fat diet",
      "target": "obesity",
      "label": "induces"
    },
    {
      "source": "high-fat diet",
      "target": "mice",
      "label": "administered to"
    },
    {
      "source": "high-fat diet",
      "target": "insulin-induced Tub-p-tyr",
      "label": "causes reduction in"
    },
    {
      "source": "high-fat diet",
      "target": "leptin",
      "label": "causes reduction in"
    },
    {
      "source": "lipid droplets",
      "target": "epididymal fat pads",
      "label": "located in"
    },
    {
      "source": "hepatic gene expression",
      "target": "lipid metabolism",
      "label": "related to"
    },
    {
      "source": "lipid metabolism",
      "target": "iron metabolism",
      "label": "interacts with"
    },
    {
      "source": "anti-obesity effects",
      "target": "regulation",
      "label": "related to"
    },
    {
      "source": "expression patterns",
      "target": "genes",
      "label": "of"
    },
    {
      "source": "expression patterns",
      "target": "immunoblot assays",
      "label": "confirmed by"
    },
    {
      "source": "expression patterns",
      "target": "quantitative reverse transcriptase-polymerase chain reaction",
      "label": "observed by"
    },
    {
      "source": "physiological effects",
      "target": "hyperlipidemia",
      "label": "of"
    },
    {
      "source": "osteolytic events",
      "target": "tumor cell-driven events",
      "label": "have interplay with"
    },
    {
      "source": "osteolytic events",
      "target": "bone-tumor microenvironment",
      "label": "occur in"
    },
    {
      "source": "tumor cell-driven events",
      "target": "bone-tumor microenvironment",
      "label": "occur in"
    },
    {
      "source": "BMM-supplied CTSK",
      "target": "CCL2-driven pathways",
      "label": "is involved in"
    },
    {
      "source": "BMM-supplied CTSK",
      "target": "COX-2-driven pathways",
      "label": "is involved in"
    },
    {
      "source": "CCL2-driven pathways",
      "target": "tumor progression",
      "label": "contribute to"
    },
    {
      "source": "inflammatory events",
      "target": "osteolytic events",
      "label": "have interplay with"
    },
    {
      "source": "inflammatory events",
      "target": "bone-tumor microenvironment",
      "label": "occur in"
    },
    {
      "source": "inflammatory events",
      "target": "tumor cell-driven events",
      "label": "have interplay with"
    },
    {
      "source": "CTSK",
      "target": "tumor progression",
      "label": "is involved in"
    },
    {
      "source": "CTSK",
      "target": "macrophage-regulated processes",
      "label": "has roles in"
    },
    {
      "source": "CTSK",
      "target": "potent collagenase",
      "label": "is a"
    },
    {
      "source": "tumor progression",
      "target": "CTSK",
      "label": "is impaired by absence of"
    },
    {
      "source": "tumor progression",
      "target": "bone",
      "label": "occurs in"
    },
    {
      "source": "BMMs",
      "target": "bone-tumor microenvironment",
      "label": "are critical components of"
    },
    {
      "source": "BMMs",
      "target": "osteoclasts",
      "label": "share common progenitors with"
    },
    {
      "source": "BMMs",
      "target": "prostate tumor growth",
      "label": "function in"
    },
    {
      "source": "BMMs",
      "target": "inflammatory factors",
      "label": "are source of"
    },
    {
      "source": "BMMs",
      "target": "proteases",
      "label": "are source of"
    },
    {
      "source": "COX-2-driven pathways",
      "target": "tumor progression",
      "label": "contribute to"
    },
    {
      "source": "prostate tumor progression",
      "target": "bone",
      "label": "occurs in"
    },
    {
      "source": "proteases",
      "target": "CTSK",
      "label": "include"
    },
    {
      "source": "proteases",
      "target": "cysteine protease cathepsin K",
      "label": "include"
    },
    {
      "source": "Macrophage cathepsin K",
      "target": "prostate tumor progression",
      "label": "promotes"
    },
    {
      "source": "prostate tumor growth",
      "target": "skeleton",
      "label": "occurs in"
    },
    {
      "source": "Bone marrow macrophages",
      "target": "osteoclasts",
      "label": "share common progenitors with"
    },
    {
      "source": "multiple pathways",
      "target": "MET",
      "label": "include"
    },
    {
      "source": "multiple pathways",
      "target": "VEGFR2",
      "label": "include"
    },
    {
      "source": "multiple pathways",
      "target": "RET",
      "label": "include"
    },
    {
      "source": "multiple pathways",
      "target": "MTC",
      "label": "are important in"
    },
    {
      "source": "XL184",
      "target": "oral tyrosine kinase inhibitor",
      "label": "is an"
    },
    {
      "source": "XL184",
      "target": "antiangiogenic effects",
      "label": "has"
    },
    {
      "source": "XL184",
      "target": "Cabozantinib",
      "label": "is"
    },
    {
      "source": "XL184",
      "target": "vascular endothelial growth factor receptor 2",
      "label": "inhibits"
    },
    {
      "source": "XL184",
      "target": "medullary thyroid cancer",
      "label": "has activity in"
    },
    {
      "source": "XL184",
      "target": "patients",
      "label": "has activity in"
    },
    {
      "source": "XL184",
      "target": "inhibitor",
      "label": "is a potent"
    },
    {
      "source": "XL184",
      "target": "antitumor effects",
      "label": "has"
    },
    {
      "source": "XL184",
      "target": "VEGFR2",
      "label": "inhibits"
    },
    {
      "source": "XL184",
      "target": "MET",
      "label": "inhibits"
    },
    {
      "source": "XL184",
      "target": "anti-invasive effects",
      "label": "has"
    },
    {
      "source": "XL184",
      "target": "RET",
      "label": "inhibits"
    },
    {
      "source": "Primary end points",
      "target": "safety",
      "label": "included"
    },
    {
      "source": "Primary end points",
      "target": "pharmacokinetics",
      "label": "included"
    },
    {
      "source": "Primary end points",
      "target": "maximum-tolerated dose",
      "label": "included"
    },
    {
      "source": "Primary end points",
      "target": "MTD determination",
      "label": "included"
    },
    {
      "source": "Cabozantinib",
      "target": "oral tyrosine kinase inhibitor",
      "label": "is an"
    },
    {
      "source": "Cabozantinib",
      "target": "MTC",
      "label": "is active in"
    },
    {
      "source": "Cabozantinib",
      "target": "patients",
      "label": "has activity in"
    },
    {
      "source": "Cabozantinib",
      "target": "multiple pathways",
      "label": "targets"
    },
    {
      "source": "Cabozantinib",
      "target": "XL184",
      "label": "is"
    },
    {
      "source": "Cabozantinib",
      "target": "clinical benefit",
      "label": "provides"
    },
    {
      "source": "Cabozantinib",
      "target": "safety profile",
      "label": "has a"
    },
    {
      "source": "Cabozantinib",
      "target": "medullary thyroid cancer",
      "label": "has activity in"
    },
    {
      "source": "Response Evaluation Criteria in Solid Tumors",
      "target": "RECIST",
      "label": "is"
    },
    {
      "source": "RECIST",
      "target": "Response Evaluation Criteria in Solid Tumors",
      "label": "is"
    },
    {
      "source": "MTC",
      "target": "medullary thyroid cancer",
      "label": "is"
    },
    {
      "source": "Additional end points",
      "target": "RECIST",
      "label": "included"
    },
    {
      "source": "Additional end points",
      "target": "response",
      "label": "included"
    },
    {
      "source": "Additional end points",
      "target": "RET mutational status",
      "label": "included"
    },
    {
      "source": "Additional end points",
      "target": "pharmacodynamics",
      "label": "included"
    },
    {
      "source": "Additional end points",
      "target": "biomarker analyses",
      "label": "included"
    },
    {
      "source": "global phase III pivotal study",
      "target": "MTC",
      "label": "is in"
    },
    {
      "source": "global phase III pivotal study",
      "target": "ClinicalTrials.gov number NCT00215605",
      "label": "has ClinicalTrials.gov number"
    },
    {
      "source": "17 (49%) of 35 patients",
      "target": "MTC",
      "label": "had"
    },
    {
      "source": "17 (49%) of 35 patients",
      "target": "measurable disease",
      "label": "had"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "grade 3 palmar plantar erythrodysesthesia",
      "label": "included"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "grade 2 mucositis",
      "label": "included"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "lipase elevations",
      "label": "included"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "AST",
      "label": "included"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "PPE",
      "label": "included"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "mucositis",
      "label": "included"
    },
    {
      "source": "Dose-limiting toxicities",
      "target": "ALT",
      "label": "included"
    },
    {
      "source": "grade 3 palmar plantar erythrodysesthesia",
      "target": "PPE",
      "label": "is"
    },
    {
      "source": "anti-invasive effects",
      "target": "preclinical models",
      "label": "observed in"
    },
    {
      "source": "grade 2 mucositis",
      "target": "dose interruption",
      "label": "resulted in"
    },
    {
      "source": "grade 2 mucositis",
      "target": "reduction",
      "label": "resulted in"
    },
    {
      "source": "18 patients",
      "target": "17 (49%) of 35 patients",
      "label": "included"
    },
    {
      "source": "18 patients",
      "target": "tumor shrinkage",
      "label": "experienced"
    },
    {
      "source": "tumor shrinkage",
      "target": "30% or more",
      "label": "was"
    },
    {
      "source": "cabozantinib",
      "target": "vascular endothelial growth factor receptor 2",
      "label": "inhibits"
    },
    {
      "source": "cabozantinib",
      "target": "MET",
      "label": "inhibits"
    },
    {
      "source": "cabozantinib",
      "target": "clinical benefit",
      "label": "showed"
    },
    {
      "source": "cabozantinib",
      "target": "antitumor effects",
      "label": "has"
    },
    {
      "source": "cabozantinib",
      "target": "VEGFR2",
      "label": "inhibits"
    },
    {
      "source": "cabozantinib",
      "target": "anti-invasive effects",
      "label": "has"
    },
    {
      "source": "cabozantinib",
      "target": "RET",
      "label": "inhibits"
    },
    {
      "source": "cabozantinib",
      "target": "antiangiogenic effects",
      "label": "has"
    },
    {
      "source": "cabozantinib",
      "target": "inhibitor",
      "label": "is a potent"
    },
    {
      "source": "PPE",
      "target": "grade 3 palmar plantar erythrodysesthesia",
      "label": "is"
    },
    {
      "source": "SD",
      "target": "stable disease",
      "label": "is"
    },
    {
      "source": "SD",
      "target": "6 months or longer",
      "label": "lasted for"
    },
    {
      "source": "AST",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "AST",
      "target": "serum",
      "label": "MEASURED_IN"
    },
    {
      "source": "AST",
      "target": "Serum markers of liver damage",
      "label": "IS_A"
    },
    {
      "source": "antitumor effects",
      "target": "preclinical models",
      "label": "observed in"
    },
    {
      "source": "antiangiogenic effects",
      "target": "preclinical models",
      "label": "observed in"
    },
    {
      "source": "Eighty-five patients",
      "target": "37",
      "label": "included"
    },
    {
      "source": "37",
      "target": "MTC",
      "label": "had"
    },
    {
      "source": "68% of patients",
      "target": "SD",
      "label": "had"
    },
    {
      "source": "68% of patients",
      "target": "confirmed partial response",
      "label": "had"
    },
    {
      "source": "68% of patients",
      "target": "MTC",
      "label": "had"
    },
    {
      "source": "MTC-enriched cohort",
      "target": "article",
      "label": "is the focus of"
    },
    {
      "source": "Ten (29%) of 35 patients",
      "target": "MTC",
      "label": "had"
    },
    {
      "source": "Ten (29%) of 35 patients",
      "target": "measurable disease",
      "label": "had"
    },
    {
      "source": "Ten (29%) of 35 patients",
      "target": "confirmed partial response",
      "label": "had a"
    },
    {
      "source": "phase I dose-escalation study",
      "target": "patients",
      "label": "conducted in"
    },
    {
      "source": "phase I dose-escalation study",
      "target": "oral cabozantinib",
      "label": "used"
    },
    {
      "source": "medullary thyroid cancer",
      "target": "MTC",
      "label": "is"
    },
    {
      "source": "15 (41%) of 37 patients",
      "target": "MTC",
      "label": "had"
    },
    {
      "source": "15 (41%) of 37 patients",
      "target": "stable disease",
      "label": "had"
    },
    {
      "source": "MTD",
      "target": "175 mg daily",
      "label": "was"
    },
    {
      "source": "ALT",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "ALT",
      "target": "alanine transaminase",
      "label": "is also known as"
    },
    {
      "source": "ALT",
      "target": "serum",
      "label": "MEASURED_IN"
    },
    {
      "source": "ALT",
      "target": "Serum markers of liver damage",
      "label": "IS_A"
    },
    {
      "source": "levels",
      "target": "control intestine",
      "label": "are below those in"
    },
    {
      "source": "levels",
      "target": "catechols",
      "label": "of"
    },
    {
      "source": "levels",
      "target": "DHPG",
      "label": "of"
    },
    {
      "source": "levels",
      "target": "homovanillic acid",
      "label": "of"
    },
    {
      "source": "levels",
      "target": "HVA",
      "label": "of"
    },
    {
      "source": "levels",
      "target": "deaminated metabolites",
      "label": "of"
    },
    {
      "source": "levels",
      "target": "DOPAC",
      "label": "of"
    },
    {
      "source": "tissue morphology",
      "target": "7 days",
      "label": "normalized by"
    },
    {
      "source": "tissue morphology",
      "target": "control animals",
      "label": "was undistinguishable from"
    },
    {
      "source": "therapeutic targeting",
      "target": "Tet-O\u0394N89\u03b2-catenin system",
      "label": "uses"
    },
    {
      "source": "therapeutic targeting",
      "target": "pathway",
      "label": "is of"
    },
    {
      "source": "therapeutic targeting",
      "target": "Wnt signaling",
      "label": "is of"
    },
    {
      "source": "oncogenic \u03b2-catenin expression",
      "target": "3D 'crypt culture'",
      "label": "was analyzed in"
    },
    {
      "source": "oncogenic \u03b2-catenin expression",
      "target": "in vivo models",
      "label": "was analyzed in"
    },
    {
      "source": "target genes",
      "target": "Ascl2",
      "label": "include"
    },
    {
      "source": "target genes",
      "target": "Axin2",
      "label": "include"
    },
    {
      "source": "target genes",
      "target": "levels",
      "label": "were downregulated to"
    },
    {
      "source": "target genes",
      "target": "C-myc",
      "label": "include"
    },
    {
      "source": "reversal",
      "target": "Wnt signaling",
      "label": "is of"
    },
    {
      "source": "reversal",
      "target": "inhibitors",
      "label": "is caused by"
    },
    {
      "source": "reversal",
      "target": "oncogenic Wnt signaling",
      "label": "is of"
    },
    {
      "source": "reversal",
      "target": "hours",
      "label": "should be studied within"
    },
    {
      "source": "Wnt signaling",
      "target": "colorectal cancer",
      "label": "is involved in initiation of"
    },
    {
      "source": "Wnt pathway inhibitor",
      "target": "therapeutic targeting",
      "label": "is a model for"
    },
    {
      "source": "oncogenic Wnt signaling",
      "target": "reversal",
      "label": "was"
    },
    {
      "source": "tetracycline-inducible transgenic mouse model",
      "target": "removal",
      "label": "was analyzed during"
    },
    {
      "source": "tetracycline-inducible transgenic mouse model",
      "target": "\u0394N89\u03b2-catenin",
      "label": "expresses"
    },
    {
      "source": "tetracycline-inducible transgenic mouse model",
      "target": "intestinal hyperplasia",
      "label": "exhibited"
    },
    {
      "source": "tetracycline-inducible transgenic mouse model",
      "target": "truncated \u03b2-catenin",
      "label": "expresses"
    },
    {
      "source": "removal",
      "target": "oncogenic \u03b2-catenin expression",
      "label": "is of"
    },
    {
      "source": "rapid advance",
      "target": "early stage compounds",
      "label": "is of"
    },
    {
      "source": "early stage compounds",
      "target": "efficacy models",
      "label": "advance into"
    },
    {
      "source": "efficacy models",
      "target": "drug discovery pipeline",
      "label": "are considered later in"
    },
    {
      "source": "reversible system",
      "target": "rapid in vivo responses",
      "label": "involves"
    },
    {
      "source": "reversible system",
      "target": "rapid advance",
      "label": "allows"
    },
    {
      "source": "reversible system",
      "target": "medium throughput in vitro approaches",
      "label": "involves"
    },
    {
      "source": "in vivo models",
      "target": "therapeutic targeting",
      "label": "are for"
    },
    {
      "source": "CCT036477",
      "target": "response",
      "label": "induced"
    },
    {
      "source": "in vitro models",
      "target": "therapeutic targeting",
      "label": "are for"
    },
    {
      "source": "hours",
      "target": "treatment",
      "label": "are of"
    },
    {
      "source": "small molecule Wnt inhibitor",
      "target": "CCT036477",
      "label": "is"
    },
    {
      "source": "(3)H-inositolmonophosphate formation",
      "target": "hippocampus",
      "label": "enhanced in"
    },
    {
      "source": "(3)H-inositolmonophosphate formation",
      "target": "cLH rats",
      "label": "enhanced in"
    },
    {
      "source": "(3)H-inositolmonophosphate formation",
      "target": "i.c.v. injection of DHPG",
      "label": "induced by"
    },
    {
      "source": "mGlu5-receptor dependent long-term depression",
      "target": "Schaffer collateral-CA1 synapse",
      "label": "occurs at"
    },
    {
      "source": "mGlu5-receptor dependent long-term depression",
      "target": "congenitally learned helpless rats",
      "label": "occurs in"
    },
    {
      "source": "mGlu5 receptors",
      "target": "animal model for treatment-resistant depression",
      "label": "investigated in"
    },
    {
      "source": "changes in the expression and function of mGlu5 receptors",
      "target": "hippocampus",
      "label": "occur in"
    },
    {
      "source": "changes in the expression and function of mGlu5 receptors",
      "target": "synaptic plasticity",
      "label": "underlie"
    },
    {
      "source": "enhanced mGlu5 receptor function",
      "target": "behavioral phenotype",
      "label": "contributes to"
    },
    {
      "source": "behavioral phenotype",
      "target": "genetic model of depression",
      "label": "is part of"
    },
    {
      "source": "expression of mGlu5 receptors",
      "target": "hippocampus",
      "label": "increased in"
    },
    {
      "source": "expression of mGlu5 receptors",
      "target": "cLH rats",
      "label": "increased in"
    },
    {
      "source": "expression of mGlu5 receptors",
      "target": "control cNLH rats",
      "label": "compared with"
    },
    {
      "source": "basal dendritic spine density",
      "target": "cLH rats",
      "label": "decreased in"
    },
    {
      "source": "basal dendritic spine density",
      "target": "CA1 pyramidal cell",
      "label": "decreased in"
    },
    {
      "source": "depressive-like phenotype",
      "target": "cLH rats",
      "label": "of"
    },
    {
      "source": "DHPG-induced long-term depression (LTD)",
      "target": "cLH rats",
      "label": "amplified in"
    },
    {
      "source": "DHPG-induced long-term depression (LTD)",
      "target": "Schaffer collateral/CA1 pyramidal cell synapses",
      "label": "amplified at"
    },
    {
      "source": "DHPG-induced long-term depression (LTD)",
      "target": "hippocampal slices",
      "label": "amplified in"
    },
    {
      "source": "mGlu1/5 receptor signaling",
      "target": "in vivo measurement",
      "label": "examined by"
    },
    {
      "source": "in vivo measurement",
      "target": "DHPG-stimulated polyphosphoinositides hydrolysis",
      "label": "measures"
    },
    {
      "source": "chronic treatment of cLH rats with MPEP",
      "target": "learned helplessness",
      "label": "did not reverse"
    },
    {
      "source": "glutamatergic system",
      "target": "treatment of major depression",
      "label": "implicated in"
    },
    {
      "source": "glutamatergic system",
      "target": "pathophysiology",
      "label": "implicated in"
    },
    {
      "source": "rats bred for congenital learned helplessness (cLH)",
      "target": "control strain",
      "label": "compared with"
    },
    {
      "source": "rats bred for congenital learned helplessness (cLH)",
      "target": "animal model for treatment-resistant depression",
      "label": "is an"
    },
    {
      "source": "control strain",
      "target": "resistance against inescapable stress",
      "label": "bred for"
    },
    {
      "source": "LTD induced by low frequency stimulation",
      "target": "Schaffer collaterals",
      "label": "of"
    },
    {
      "source": "congenitally not learned helpless rats (cNLH)",
      "target": "control strain",
      "label": "is a"
    },
    {
      "source": "Special Issue",
      "target": "Metabotropic Glutamate Receptors",
      "label": "entitled"
    },
    {
      "source": "Special Issue",
      "target": "Cognitive Enhancers",
      "label": "entitled"
    },
    {
      "source": "pathophysiology",
      "target": "diseases",
      "label": "is of"
    },
    {
      "source": "CYP17",
      "target": "thecal cells",
      "label": "increased expression in"
    },
    {
      "source": "CYP17",
      "target": "PCOS rat model",
      "label": "increased expression in"
    },
    {
      "source": "CYP17",
      "target": "stromal cells",
      "label": "increased expression in"
    },
    {
      "source": "CYP17",
      "target": "polycystic ovaries",
      "label": "expressed in"
    },
    {
      "source": "CYP17",
      "target": "endogenous hyperandrogenism",
      "label": "increased expression in"
    },
    {
      "source": "P450scc",
      "target": "stromal cells",
      "label": "increased expression in"
    },
    {
      "source": "P450scc",
      "target": "polycystic ovaries",
      "label": "expressed in"
    },
    {
      "source": "P450scc",
      "target": "endogenous hyperandrogenism",
      "label": "increased expression in"
    },
    {
      "source": "P450scc",
      "target": "thecal cells",
      "label": "increased expression in"
    },
    {
      "source": "P450scc",
      "target": "PCOS rat model",
      "label": "increased expression in"
    },
    {
      "source": "P450scc",
      "target": "electron-transfer partners",
      "label": "has"
    },
    {
      "source": "PCOS rat model",
      "target": "control rats",
      "label": "compared with"
    },
    {
      "source": "polycystic ovaries",
      "target": "rats",
      "label": "found in"
    },
    {
      "source": "multiple large cysts",
      "target": "stromal-interstitial tissue",
      "label": "had increased"
    },
    {
      "source": "multiple large cysts",
      "target": "granulosa layers",
      "label": "had diminished"
    },
    {
      "source": "multiple large cysts",
      "target": "thecal layers",
      "label": "had increased"
    },
    {
      "source": "endogenous hyperandrogenism",
      "target": "steroidogenic enzymes",
      "label": "upregulates expression of"
    },
    {
      "source": "endogenous hyperandrogenism",
      "target": "rat model",
      "label": "developed in"
    },
    {
      "source": "steroidogenic enzymes",
      "target": "CYP17",
      "label": "include"
    },
    {
      "source": "steroidogenic enzymes",
      "target": "ovarian tissue",
      "label": "expressed in"
    },
    {
      "source": "steroidogenic enzymes",
      "target": "P450scc",
      "label": "include"
    },
    {
      "source": "steroidogenic enzymes",
      "target": "11\u03b2-hydroxylase",
      "label": "include"
    },
    {
      "source": "steroidogenic enzymes",
      "target": "aldosterone synthase",
      "label": "include"
    },
    {
      "source": "steroidogenic enzymes",
      "target": "3\u03b2-hydroxysteroid dehydrogenase",
      "label": "include"
    },
    {
      "source": "hCG",
      "target": "steroidogenic enzymes",
      "label": "affects expression of"
    },
    {
      "source": "hCG",
      "target": "endogenous hyperandrogenism",
      "label": "synergistically resulted in"
    },
    {
      "source": "hCG",
      "target": "multiple large cysts",
      "label": "resulted in"
    },
    {
      "source": "hCG",
      "target": "Acsl4 mRNA",
      "label": "regulates"
    },
    {
      "source": "ultimate carcinogen",
      "target": "water",
      "label": "interacts with"
    },
    {
      "source": "ultimate carcinogen",
      "target": "proteins",
      "label": "interacts with"
    },
    {
      "source": "ultimate carcinogen",
      "target": "epoxy type",
      "label": "is of type"
    },
    {
      "source": "solvation",
      "target": "solvent reaction field methods",
      "label": "considered using"
    },
    {
      "source": "solvation",
      "target": "Langevin dipoles",
      "label": "considered using"
    },
    {
      "source": "Hartree-Fock",
      "target": "flexible basis sets",
      "label": "used with"
    },
    {
      "source": "reactivities",
      "target": "carcinogenicity",
      "label": "are related to"
    },
    {
      "source": "reactivities",
      "target": "ultimate carcinogen",
      "label": "are of"
    },
    {
      "source": "reactivities",
      "target": "DNA",
      "label": "are toward"
    },
    {
      "source": "chemical reactivity",
      "target": "ultimate carcinogen",
      "label": "is property of"
    },
    {
      "source": "chemical reactivity",
      "target": "carcinogenicity",
      "label": "is related to"
    },
    {
      "source": "MP2 methods",
      "target": "flexible basis sets",
      "label": "used with"
    },
    {
      "source": "guanine",
      "target": "N7 position",
      "label": "is at"
    },
    {
      "source": "reactions",
      "target": "ultimate carcinogen scavengers",
      "label": "are with"
    },
    {
      "source": "chemical reaction",
      "target": "guanine",
      "label": "involves"
    },
    {
      "source": "chemical reaction",
      "target": "DNA",
      "label": "involves"
    },
    {
      "source": "chemical reaction",
      "target": "propylene oxide",
      "label": "involves"
    },
    {
      "source": "high reactivity value",
      "target": "carcinogenicity",
      "label": "is associated with"
    },
    {
      "source": "experimental value",
      "target": "25.36 kcal/mol",
      "label": "is"
    },
    {
      "source": "activation free energy",
      "target": "experimental value",
      "label": "agrees with"
    },
    {
      "source": "activation free energy",
      "target": "chemical reaction",
      "label": "is for"
    },
    {
      "source": "window of reactivity",
      "target": "carcinogenicity",
      "label": "is relevant measure of"
    },
    {
      "source": "PI3K inhibitor",
      "target": "clinical development",
      "label": "is in"
    },
    {
      "source": "PI3K inhibitor",
      "target": "SAL",
      "label": "abolished protection against"
    },
    {
      "source": "PI3K inhibitor",
      "target": "Multiple neurotrophic factor support",
      "label": "abolished protection by"
    },
    {
      "source": "PI3K inhibitor",
      "target": "Olfactory Ensheathing Cell's Conditioned Media",
      "label": "abolished protection by"
    },
    {
      "source": "PI3K inhibitor",
      "target": "OEC CM",
      "label": "abolished protection by"
    },
    {
      "source": "PI3K inhibitor",
      "target": "NSCs",
      "label": "abolished protection of"
    },
    {
      "source": "Pik3ca(H1047R)",
      "target": "mammary tumorigenesis",
      "label": "promotes"
    },
    {
      "source": "Pik3ca(H1047R)",
      "target": "mutations",
      "label": "promotes emergence of"
    },
    {
      "source": "Pik3ca(H1047R)",
      "target": "Pik3ca(e20H1047R) mutant allele",
      "label": "is a type of"
    },
    {
      "source": "Pik3ca(H1047R)",
      "target": "knock-in mouse model",
      "label": "is in"
    },
    {
      "source": "PIK3CA",
      "target": "catalytic subunit p110\u03b1",
      "label": "encodes"
    },
    {
      "source": "PIK3CA",
      "target": "PI3K",
      "label": "encodes"
    },
    {
      "source": "PIK3CA",
      "target": "phosphoinositide-3-kinase",
      "label": "encodes"
    },
    {
      "source": "breast tumors",
      "target": "histological types",
      "label": "have"
    },
    {
      "source": "breast tumors",
      "target": "PI3K inhibition",
      "label": "respond to"
    },
    {
      "source": "tissue-specific conditional expression",
      "target": "Pik3ca(e20H1047R) mutant allele",
      "label": "involves"
    },
    {
      "source": "tissue-specific conditional expression",
      "target": "Pik3ca(H1047R)",
      "label": "involves"
    },
    {
      "source": "Pik3ca(e20H1047R) mutant allele",
      "target": "Pik3ca(H1047R)",
      "label": "contains"
    },
    {
      "source": "Pik3ca(H1047R)-driven mammary tumors",
      "target": "breast tumors",
      "label": "are a type of"
    },
    {
      "source": "Pik3ca(H1047R)-driven mammary tumors",
      "target": "Pik3ca(H1047R)",
      "label": "are driven by"
    },
    {
      "source": "Whole-exome analysis",
      "target": "mutations",
      "label": "identified"
    },
    {
      "source": "Whole-exome analysis",
      "target": "Pik3ca(H1047R)-driven mammary tumors",
      "label": "of"
    },
    {
      "source": "latent Pik3ca(H1047R) allele",
      "target": "breast tumors",
      "label": "resulted in"
    },
    {
      "source": "latent Pik3ca(H1047R) allele",
      "target": "Pik3ca(H1047R)",
      "label": "contains"
    },
    {
      "source": "Trp53 mutations",
      "target": "adenocarinoma",
      "label": "appeared during development of"
    },
    {
      "source": "Trp53 mutations",
      "target": "spindle cell tumors",
      "label": "appeared during development of"
    },
    {
      "source": "Conditional activation",
      "target": "latent Pik3ca(H1047R) allele",
      "label": "of"
    },
    {
      "source": "Conditional activation",
      "target": "Pik3ca(H1047R)",
      "label": "involves"
    },
    {
      "source": "Conditional activation",
      "target": "mammary tumorigenesis",
      "label": "promotes"
    },
    {
      "source": "Conditional activation",
      "target": "breast tumors",
      "label": "resulted in"
    },
    {
      "source": "Conditional activation",
      "target": "mutations",
      "label": "promotes emergence of"
    },
    {
      "source": "Oncogenic mutations",
      "target": "human breast cancers",
      "label": "occur in"
    },
    {
      "source": "Oncogenic mutations",
      "target": "PIK3CA",
      "label": "are in"
    },
    {
      "source": "GDC-0941",
      "target": "PI3K inhibitor",
      "label": "is a type of"
    },
    {
      "source": "GDC-0941",
      "target": "clinical development",
      "label": "is in"
    },
    {
      "source": "endogenous Pik3ca allele",
      "target": "tissue-specific conditional expression",
      "label": "was modified to allow"
    },
    {
      "source": "knock-in mouse model",
      "target": "GDC-0941",
      "label": "used to test efficacy of"
    },
    {
      "source": "knock-in mouse model",
      "target": "breast cancer",
      "label": "is for"
    },
    {
      "source": "C-Y-W-E-L-E-W-L-P-C-A",
      "target": "functional activity",
      "label": "has"
    },
    {
      "source": "C-Y-W-E-L-E-W-L-P-C-A",
      "target": "cyclic peptide",
      "label": "is a"
    },
    {
      "source": "C-Y-W-E-L-E-W-L-P-C-A",
      "target": "specificity",
      "label": "binds with"
    },
    {
      "source": "C-Y-W-E-L-E-W-L-P-C-A",
      "target": "phospholamban (1-36)",
      "label": "binds to"
    },
    {
      "source": "Ca(2+)uptake assays",
      "target": "preparations from cardiac sarcoplasmic reticulum",
      "label": "utilize"
    },
    {
      "source": "pharmacophore",
      "target": "small molecules",
      "label": "used for design of"
    },
    {
      "source": "small molecules",
      "target": "receptor",
      "label": "activate"
    },
    {
      "source": "heart failure",
      "target": "aberrations",
      "label": "involves"
    },
    {
      "source": "aberrations",
      "target": "inhibition",
      "label": "are in"
    },
    {
      "source": "portion of phospholamban",
      "target": "target",
      "label": "used as"
    },
    {
      "source": "NMR",
      "target": "dynamics",
      "label": "characterises"
    },
    {
      "source": "cyclic peptide",
      "target": "phospholamban",
      "label": "binds to"
    },
    {
      "source": "structure-activity analysis",
      "target": "model of phospholamban -cyclic peptide complex",
      "label": "allowed building"
    },
    {
      "source": "cardiac sarcoplasmic Ca(2+)ATPase",
      "target": "phospholamban",
      "label": "interacts with"
    },
    {
      "source": "phospholamban",
      "target": "inhibition",
      "label": "causes"
    },
    {
      "source": "molecules",
      "target": "inhibitory activity of phospholamban",
      "label": "interfere with"
    },
    {
      "source": "inhibitory activity of phospholamban",
      "target": "sarcoplasmic Ca(2+)ATPase",
      "label": "affects"
    },
    {
      "source": "modulation",
      "target": "therapeutic approach",
      "label": "is a"
    },
    {
      "source": "modulation",
      "target": "interaction",
      "label": "affects"
    },
    {
      "source": "modulation",
      "target": "adult mice",
      "label": "observed in"
    },
    {
      "source": "modulation",
      "target": "young adult mice",
      "label": "observed in"
    },
    {
      "source": "modulation",
      "target": "NMDA receptor",
      "label": "affects expression of"
    },
    {
      "source": "modulation",
      "target": "neurotrophin",
      "label": "affects expression of"
    },
    {
      "source": "therapeutic approach",
      "target": "Osteoporosis",
      "label": "FOR"
    },
    {
      "source": "therapeutic approach",
      "target": "intermittent administration",
      "label": "BASED_ON"
    },
    {
      "source": "therapeutic approach",
      "target": "ethanol mediated ulcer",
      "label": "FOR"
    },
    {
      "source": "experimental heart failure models",
      "target": "modulation",
      "label": "show"
    },
    {
      "source": "examples of such molecules",
      "target": "inhibitors of phospholamban",
      "label": "characterized as"
    },
    {
      "source": "examples of such molecules",
      "target": "small molecules",
      "label": "are"
    },
    {
      "source": "series of alanine point-mutated cyclic peptides",
      "target": "amino acid",
      "label": "identified"
    },
    {
      "source": "AMN082",
      "target": "impaired extinction acquisition",
      "label": "rescues"
    },
    {
      "source": "AMN082",
      "target": "metabotropic glutamate receptor 7 (mGlu7) agonist",
      "label": "is a"
    },
    {
      "source": "AMN082",
      "target": "deficient extinction consolidation/retrieval",
      "label": "rescues"
    },
    {
      "source": "Anxiety disorders",
      "target": "fear",
      "label": "characterized by"
    },
    {
      "source": "fear",
      "target": "extinction retrieval",
      "label": "during"
    },
    {
      "source": "drug treatments",
      "target": "adjuncts",
      "label": "are"
    },
    {
      "source": "drug treatments",
      "target": "HDAC inhibiting properties",
      "label": "have"
    },
    {
      "source": "drug treatments",
      "target": "mGlu7 agonism properties",
      "label": "have"
    },
    {
      "source": "adjuncts",
      "target": "treatment resistance",
      "label": "overcome"
    },
    {
      "source": "valproic acid",
      "target": "impaired extinction acquisition",
      "label": "rescues"
    },
    {
      "source": "valproic acid",
      "target": "histone deacetylase (HDAC) inhibitor",
      "label": "is a"
    },
    {
      "source": "valproic acid",
      "target": "GABAergic enhancer",
      "label": "is a"
    },
    {
      "source": "valproic acid",
      "target": "deficient extinction consolidation/retrieval",
      "label": "rescues"
    },
    {
      "source": "MS-275",
      "target": "impaired extinction consolidation/retrieval",
      "label": "rescues"
    },
    {
      "source": "MS-275",
      "target": "extinction acquisition",
      "label": "failed to affect"
    },
    {
      "source": "MS-275",
      "target": "extinction training",
      "label": "applied after"
    },
    {
      "source": "MS-275",
      "target": "histone deacetylase (HDAC) inhibitor",
      "label": "is a"
    },
    {
      "source": "Deep brain stimulation",
      "target": "resistance to fear extinction",
      "label": "rescues"
    },
    {
      "source": "Deep brain stimulation",
      "target": "high frequency stimulation",
      "label": "involves"
    },
    {
      "source": "Deep brain stimulation",
      "target": "extinction training",
      "label": "applied during"
    },
    {
      "source": "Deep brain stimulation",
      "target": "fear",
      "label": "reduced"
    },
    {
      "source": "129S1/SvImJ (S1) mice",
      "target": "extinction learning",
      "label": "lack"
    },
    {
      "source": "high frequency stimulation",
      "target": "ventral striatum",
      "label": "applied to"
    },
    {
      "source": "high frequency stimulation",
      "target": "nucleus accumbens",
      "label": "applied to"
    },
    {
      "source": "weak fear conditioning",
      "target": "fear reduction",
      "label": "permits"
    },
    {
      "source": "weak fear conditioning",
      "target": "deficiency in extinction memory consolidation/retrieval",
      "label": "reveals"
    },
    {
      "source": "fear reduction",
      "target": "massed extinction training",
      "label": "during"
    },
    {
      "source": "nucleus accumbens",
      "target": "ventral striatum",
      "label": "is a"
    },
    {
      "source": "treatment resistance",
      "target": "exposure-based therapies",
      "label": "in"
    },
    {
      "source": "PEPA",
      "target": "extinction acquisition",
      "label": "failed to affect"
    },
    {
      "source": "PEPA",
      "target": "AMPA receptor potentiator",
      "label": "is an"
    },
    {
      "source": "d-cycloserine",
      "target": "extinction training",
      "label": "applied after"
    },
    {
      "source": "d-cycloserine",
      "target": "N-methly-d-aspartate partial agonist",
      "label": "is a"
    },
    {
      "source": "d-cycloserine",
      "target": "impaired extinction consolidation/retrieval",
      "label": "rescues"
    },
    {
      "source": "histone deacetylase inhibitors",
      "target": "resistance to fear extinction",
      "label": "rescues"
    },
    {
      "source": "histone deacetylase inhibitors",
      "target": "HDAC",
      "label": "inhibit"
    },
    {
      "source": "histone deacetylase inhibitors",
      "target": "histone deacetylase",
      "label": "inhibit"
    },
    {
      "source": "DBS",
      "target": "extinction training",
      "label": "applied during"
    },
    {
      "source": "DBS",
      "target": "adjuncts",
      "label": "are"
    },
    {
      "source": "DBS",
      "target": "fear",
      "label": "reduced"
    },
    {
      "source": "glutamatergic drugs",
      "target": "resistance to fear extinction",
      "label": "rescues"
    },
    {
      "source": "non-pharmacological manipulations",
      "target": "extreme fear extinction deficit",
      "label": "rescue"
    },
    {
      "source": "completed clinical trial",
      "target": "parent study",
      "label": "is a"
    },
    {
      "source": "Amalgams",
      "target": "mercury (Hg)",
      "label": "contain"
    },
    {
      "source": "statistical model",
      "target": "parent study",
      "label": "is different from"
    },
    {
      "source": "nonsignificant relationship",
      "target": "urinary levels of GST-\u03c0",
      "label": "observed with"
    },
    {
      "source": "glutathione-S-transferases (GST)-\u03b1",
      "target": "PT",
      "label": "indicates damage at"
    },
    {
      "source": "glutathione-S-transferases (GST)-\u03b1",
      "target": "kidney damage",
      "label": "suggests"
    },
    {
      "source": "glutathione-S-transferases (GST)-\u03b1",
      "target": "mercury exposure",
      "label": "is related to"
    },
    {
      "source": "GST-\u03c0",
      "target": "distal tubules",
      "label": "indicates damage at"
    },
    {
      "source": "GST-\u03c0",
      "target": "biomarkers of kidney integrity",
      "label": "is a"
    },
    {
      "source": "GST-\u03c0",
      "target": "kidney damage",
      "label": "suggests"
    },
    {
      "source": "GST-\u03c0",
      "target": "mercury exposure",
      "label": "is related to"
    },
    {
      "source": "dental amalgams",
      "target": "ongoing kidney damage",
      "label": "contribute to"
    },
    {
      "source": "dental amalgams",
      "target": "dental restorative material",
      "label": "is a"
    },
    {
      "source": "ongoing kidney damage",
      "target": "PT",
      "label": "at the level of"
    },
    {
      "source": "Urinary biomarkers of kidney integrity",
      "target": "children",
      "label": "examined in"
    },
    {
      "source": "Urinary biomarkers of kidney integrity",
      "target": "completed clinical trial",
      "label": "from"
    },
    {
      "source": "Casa Pia children's dental amalgam trial",
      "target": "dental amalgams",
      "label": "assesses"
    },
    {
      "source": "Casa Pia children's dental amalgam trial",
      "target": "kidney integrity biomarkers",
      "label": "assesses"
    },
    {
      "source": "Casa Pia children's dental amalgam trial",
      "target": "mercury exposure",
      "label": "assesses"
    },
    {
      "source": "increasing Hg exposure",
      "target": "GST-\u03b1",
      "label": "has dose-dependent correlation with"
    },
    {
      "source": "increasing Hg exposure",
      "target": "GST-\u03c0",
      "label": "has dose-dependent correlation with"
    },
    {
      "source": "increasing Hg exposure",
      "target": "dental amalgams",
      "label": "originates from"
    },
    {
      "source": "GST-\u03b1",
      "target": "biomarkers of kidney integrity",
      "label": "is a"
    },
    {
      "source": "mercury exposure",
      "target": "kidney integrity biomarkers",
      "label": "has dose-dependent relationship with"
    },
    {
      "source": "mercury exposure",
      "target": "dental amalgams",
      "label": "originates from"
    },
    {
      "source": "Our study",
      "target": "dose-dependent correlation",
      "label": "determined"
    },
    {
      "source": "Hg",
      "target": "kidney",
      "label": "accumulates in"
    },
    {
      "source": "Hg",
      "target": "proximal tubules (PTs)",
      "label": "accumulates in"
    },
    {
      "source": "cumulative exposure to Hg",
      "target": "urinary levels of GST-\u03b1",
      "label": "has statistically significant dose-dependent correlation with"
    },
    {
      "source": "cumulative exposure to Hg",
      "target": "dental amalgams",
      "label": "originates from"
    },
    {
      "source": "urinary levels of GST-\u03b1",
      "target": "covariate adjustment",
      "label": "was adjusted by"
    },
    {
      "source": "study subjects",
      "target": "no exposure to dental amalgams",
      "label": "had"
    },
    {
      "source": "study subjects",
      "target": "amalgam group",
      "label": "from"
    },
    {
      "source": "urinary GST-\u03b1 levels",
      "target": "8-year course of the study",
      "label": "increased over"
    },
    {
      "source": "PJ34 treatment",
      "target": "PARP-1 binding",
      "label": "did not affect"
    },
    {
      "source": "PJ34 treatment",
      "target": "H3K9K14ac",
      "label": "increased"
    },
    {
      "source": "PJ34 treatment",
      "target": "H3K27me3",
      "label": "increased"
    },
    {
      "source": "PJ34 treatment",
      "target": "H3K4me3",
      "label": "increased"
    },
    {
      "source": "PJ34 treatment",
      "target": "histone modification activation marks",
      "label": "increased"
    },
    {
      "source": "PJ34 treatment",
      "target": "NIS promoter activity",
      "label": "increased"
    },
    {
      "source": "PJ34",
      "target": "NIS mRNA levels",
      "label": "induced increase in"
    },
    {
      "source": "PJ34",
      "target": "radio-iodine uptake",
      "label": "induced increase of"
    },
    {
      "source": "H3K27me3",
      "target": "repressive mark",
      "label": "is a"
    },
    {
      "source": "multimeric repressor",
      "target": "NIS expression",
      "label": "represses"
    },
    {
      "source": "PARP inhibitor PJ34",
      "target": "epigenetic marks",
      "label": "modifies"
    },
    {
      "source": "PARP inhibitor PJ34",
      "target": "NIS expression",
      "label": "modifies"
    },
    {
      "source": "PARP inhibitor PJ34",
      "target": "proliferation",
      "label": "modifies"
    },
    {
      "source": "PARP inhibition",
      "target": "transcriptional regulatory mechanisms",
      "label": "modulates"
    },
    {
      "source": "PARP inhibition",
      "target": "NIS gene expression",
      "label": "increases"
    },
    {
      "source": "PARP inhibitors",
      "target": "medical treatment",
      "label": "are tools for"
    },
    {
      "source": "PARP-1",
      "target": "multimeric repressor",
      "label": "is part of"
    },
    {
      "source": "H3K4me3",
      "target": "frq expression",
      "label": "has delayed phasing relative to"
    },
    {
      "source": "Cyproterone acetate",
      "target": "hirsutism",
      "label": "used to treat"
    },
    {
      "source": "Cyproterone acetate",
      "target": "prostate cancer",
      "label": "used to treat"
    },
    {
      "source": "Cyproterone acetate",
      "target": "progestin",
      "label": "is a"
    },
    {
      "source": "Cyproterone acetate",
      "target": "3 beta-HSD activity",
      "label": "Downregulator"
    },
    {
      "source": "Cyproterone acetate",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "Cyproterone acetate",
      "target": "acne",
      "label": "used to treat"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "3-keto-4-ene-steroids",
      "label": "produces"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "androst-5-ene-3 beta, 17 beta-diol",
      "label": "Substrate"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "17 alpha-hydroxy pregnenolone",
      "label": "Substrate"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "human placenta",
      "label": "purified from"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "pregnenolone",
      "label": "Substrate"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "biosynthesis",
      "label": "involved in"
    },
    {
      "source": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase",
      "target": "dehydroepiandrosterone",
      "label": "Substrate"
    },
    {
      "source": "cyanoketone",
      "target": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase",
      "label": "Downregulator"
    },
    {
      "source": "cyanoketone",
      "target": "3 beta-HSD",
      "label": "Downregulator"
    },
    {
      "source": "cyanoketone",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "norgestrel",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "norgestrel",
      "target": "3 beta-HSD activity",
      "label": "Downregulator"
    },
    {
      "source": "norgestrel",
      "target": "oral contraceptives",
      "label": "used as"
    },
    {
      "source": "4-MA",
      "target": "Ki value",
      "label": "has"
    },
    {
      "source": "4-MA",
      "target": "3 beta-HSD",
      "label": "Downregulator"
    },
    {
      "source": "4-MA",
      "target": "5 alpha-reductase",
      "label": "Downregulator"
    },
    {
      "source": "4-MA",
      "target": "5 alpha-reductase inhibitor",
      "label": "is a"
    },
    {
      "source": "4-MA",
      "target": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase",
      "label": "Downregulator"
    },
    {
      "source": "progestin",
      "target": "3 beta-HSD activity",
      "label": "Downregulator"
    },
    {
      "source": "progestin",
      "target": "menopausal hormone therapy",
      "label": "is a component of"
    },
    {
      "source": "epostane",
      "target": "3 beta-HSD",
      "label": "Downregulator"
    },
    {
      "source": "epostane",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "3 beta-HSD",
      "target": "17 alpha-hydroxy pregnenolone",
      "label": "Substrate"
    },
    {
      "source": "3 beta-HSD",
      "target": "pregnenolone",
      "label": "Substrate"
    },
    {
      "source": "3 beta-HSD",
      "target": "biosynthesis",
      "label": "involved in"
    },
    {
      "source": "3 beta-HSD",
      "target": "dehydroepiandrosterone",
      "label": "Substrate"
    },
    {
      "source": "3 beta-HSD",
      "target": "3-keto-4-ene-steroids",
      "label": "produces"
    },
    {
      "source": "3 beta-HSD",
      "target": "androst-5-ene-3 beta, 17 beta-diol",
      "label": "Substrate"
    },
    {
      "source": "Trilostane",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "Trilostane",
      "target": "3 beta-HSD",
      "label": "Downregulator"
    },
    {
      "source": "RU2323",
      "target": "3 beta-HSD activity",
      "label": "Downregulator"
    },
    {
      "source": "RU2323",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "RU2323",
      "target": "inhibitory effects",
      "label": "has"
    },
    {
      "source": "norethindrone",
      "target": "3 beta-HSD activity",
      "label": "Downregulator"
    },
    {
      "source": "norethindrone",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "norethindrone",
      "target": "oral contraceptives",
      "label": "used as"
    },
    {
      "source": "promegestone",
      "target": "Ki values",
      "label": "has"
    },
    {
      "source": "promegestone",
      "target": "3 beta-HSD activity",
      "label": "Downregulator"
    },
    {
      "source": "promegestone",
      "target": "inhibitory effects",
      "label": "has"
    },
    {
      "source": "Synthetic progestin compounds",
      "target": "promegestone",
      "label": "includes"
    },
    {
      "source": "Synthetic progestin compounds",
      "target": "RU2323",
      "label": "includes"
    },
    {
      "source": "synthetic progestins",
      "target": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase",
      "label": "Downregulator"
    },
    {
      "source": "direct effect",
      "target": "D2/D3 receptors",
      "label": "on"
    },
    {
      "source": "direct effect",
      "target": "D3 receptor-dependent neurotransmission",
      "label": "involves"
    },
    {
      "source": "quinpirole",
      "target": "dopaminergic neurons",
      "label": "effect on"
    },
    {
      "source": "quinpirole",
      "target": "extracellular signal-regulated kinase phosphorylation",
      "label": "increased"
    },
    {
      "source": "quinpirole",
      "target": "number of primary dendrites",
      "label": "increased"
    },
    {
      "source": "quinpirole",
      "target": "[3H]dopamine uptake",
      "label": "increased"
    },
    {
      "source": "quinpirole",
      "target": "TH-IR-positive mesencephalic neurons",
      "label": "effect on"
    },
    {
      "source": "quinpirole",
      "target": "phosphorylation",
      "label": "increased"
    },
    {
      "source": "quinpirole",
      "target": "maximal dendrite length",
      "label": "increased"
    },
    {
      "source": "quinpirole",
      "target": "D2 agonist",
      "label": "is a"
    },
    {
      "source": "quinpirole",
      "target": "zinc-finger protein 268",
      "label": "up-regulates"
    },
    {
      "source": "quinpirole",
      "target": "GDNF",
      "label": "up-regulates"
    },
    {
      "source": "quinpirole",
      "target": "D2R",
      "label": "is an agonist of"
    },
    {
      "source": "quinpirole",
      "target": "Dopamine D2 receptor",
      "label": "is an agonist of"
    },
    {
      "source": "quinpirole",
      "target": "agonist",
      "label": "is an"
    },
    {
      "source": "quinpirole",
      "target": "Zif268",
      "label": "up-regulates"
    },
    {
      "source": "dopaminergic neurons",
      "target": "tyrosine hydroxylase immunoreactivity",
      "label": "identified by"
    },
    {
      "source": "7-OH-DPAT",
      "target": "maximal dendrite length",
      "label": "increased"
    },
    {
      "source": "7-OH-DPAT",
      "target": "dopaminergic neurons",
      "label": "effect on"
    },
    {
      "source": "7-OH-DPAT",
      "target": "extracellular signal-regulated kinase phosphorylation",
      "label": "increased"
    },
    {
      "source": "7-OH-DPAT",
      "target": "number of primary dendrites",
      "label": "increased"
    },
    {
      "source": "7-OH-DPAT",
      "target": "TH-IR-positive mesencephalic neurons",
      "label": "effect on"
    },
    {
      "source": "7-OH-DPAT",
      "target": "[3H]dopamine uptake",
      "label": "increased"
    },
    {
      "source": "7-OH-DPAT",
      "target": "phosphorylation",
      "label": "increased"
    },
    {
      "source": "dopamine agonists",
      "target": "direct effect",
      "label": "act via"
    },
    {
      "source": "dopamine agonists",
      "target": "neurotrophic effects",
      "label": "produce"
    },
    {
      "source": "dopamine agonists",
      "target": "dendrite arborization",
      "label": "increase"
    },
    {
      "source": "extracellular signal-regulated kinase",
      "target": "ERK",
      "label": "is a type of"
    },
    {
      "source": "ERK",
      "target": "prefrontal cortex",
      "label": "located in"
    },
    {
      "source": "ERK",
      "target": "neuroplastic changes",
      "label": "involved in"
    },
    {
      "source": "ERK",
      "target": "hippocampus",
      "label": "located in"
    },
    {
      "source": "GF109203",
      "target": "D2/D3 receptor signalling pathway",
      "label": "inhibited"
    },
    {
      "source": "D2/D3 receptor signalling pathway",
      "target": "ERK",
      "label": "leads to"
    },
    {
      "source": "SB-277011-A",
      "target": "phosphorylation",
      "label": "blocked"
    },
    {
      "source": "SB-277011-A",
      "target": "neurotrophic effects",
      "label": "blocked"
    },
    {
      "source": "SB-277011-A",
      "target": "extracellular signal-regulated kinase phosphorylation",
      "label": "blocked"
    },
    {
      "source": "SB-277011-A",
      "target": "D3 receptor antagonist",
      "label": "is a"
    },
    {
      "source": "phosphorylation",
      "target": "extracellular signal-regulated kinase",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "key residues",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "agonist responses",
      "label": "results in"
    },
    {
      "source": "phosphorylation",
      "target": "overall charge",
      "label": "changes"
    },
    {
      "source": "phosphorylation",
      "target": "ERK 1/2",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "p38",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "serine/threonine residues",
      "label": "occurs on"
    },
    {
      "source": "phosphorylation",
      "target": "S16",
      "label": "occurs on"
    },
    {
      "source": "phosphorylation",
      "target": "PKA",
      "label": "catalyzed by"
    },
    {
      "source": "phosphorylation",
      "target": "resonances",
      "label": "does not shift"
    },
    {
      "source": "phosphorylation",
      "target": "solvent-exposed flexible loops",
      "label": "occurs in"
    },
    {
      "source": "phosphorylation",
      "target": "globular protein",
      "label": "occurs in"
    },
    {
      "source": "phosphorylation",
      "target": "Pin1 WW domain",
      "label": "occurs in"
    },
    {
      "source": "phosphorylation",
      "target": "folded protein",
      "label": "occurs in"
    },
    {
      "source": "phosphorylation",
      "target": "chemical shift changes",
      "label": "does not cause"
    },
    {
      "source": "phosphorylation",
      "target": "protein kinase C (PKC)",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "mitogen-activated protein kinases (MAPKs)",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "Akt",
      "label": "is of"
    },
    {
      "source": "phosphorylation",
      "target": "phospholipase C (PLC)\u03b32",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "JNK",
      "label": "is of"
    },
    {
      "source": "phosphorylation",
      "target": "AKT",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "STAT3",
      "label": "of"
    },
    {
      "source": "phosphorylation",
      "target": "STAT3 activation",
      "label": "stimulates"
    },
    {
      "source": "tyrosine hydroxylase immunoreactivity",
      "target": "TH-IR",
      "label": "is"
    },
    {
      "source": "sulpiride",
      "target": "neurotrophic effects",
      "label": "blocked"
    },
    {
      "source": "sulpiride",
      "target": "D2/D3 receptor antagonist",
      "label": "is a"
    },
    {
      "source": "sulpiride",
      "target": "dopamine D2 receptor antagonist",
      "label": "is_a"
    },
    {
      "source": "sulpiride",
      "target": "amantadine induction of Fos",
      "label": "Not"
    },
    {
      "source": "Dopamine D3 receptor-preferring agonists",
      "target": "extracellular signal-regulated kinase phosphorylation",
      "label": "increase"
    },
    {
      "source": "Dopamine D3 receptor-preferring agonists",
      "target": "neuroprotective actions",
      "label": "related to"
    },
    {
      "source": "Dopamine D3 receptor-preferring agonists",
      "target": "Clinical improvements",
      "label": "produce"
    },
    {
      "source": "Dopamine D3 receptor-preferring agonists",
      "target": "dendrite arborization",
      "label": "increase"
    },
    {
      "source": "Dopamine D3 receptor-preferring agonists",
      "target": "neuroregenerative properties",
      "label": "related to"
    },
    {
      "source": "Clinical improvements",
      "target": "Parkinson's disease",
      "label": "in"
    },
    {
      "source": "neuronal-enriched primary cultures",
      "target": "astrocytes",
      "label": "contain"
    },
    {
      "source": "neuronal-enriched primary cultures",
      "target": "mouse embryo mesencephalon",
      "label": "prepared from"
    },
    {
      "source": "dendrite arborization",
      "target": "mesencephalic dopaminergic neurons",
      "label": "of"
    },
    {
      "source": "7-hydroxy-N,N-di-propyl-2-aminotetralin",
      "target": "dopaminergic neurons",
      "label": "effect on"
    },
    {
      "source": "LY294002",
      "target": "D2/D3 receptor signalling pathway",
      "label": "inhibited"
    },
    {
      "source": "LY294002",
      "target": "Olfactory Ensheathing Cell's Conditioned Media",
      "label": "abolished protection by"
    },
    {
      "source": "LY294002",
      "target": "PI3K inhibitor",
      "label": "is a"
    },
    {
      "source": "LY294002",
      "target": "SAL",
      "label": "abolished protection against"
    },
    {
      "source": "LY294002",
      "target": "OEC CM",
      "label": "abolished protection by"
    },
    {
      "source": "LY294002",
      "target": "Multiple neurotrophic factor support",
      "label": "abolished protection by"
    },
    {
      "source": "LY294002",
      "target": "NSCs",
      "label": "abolished protection of"
    },
    {
      "source": "LY294002",
      "target": "p38 MAPK kinase pathway",
      "label": "activated"
    },
    {
      "source": "LY294002",
      "target": "JNK",
      "label": "did not activate"
    },
    {
      "source": "LY294002",
      "target": "c-Jun phosphorylation",
      "label": "enhanced"
    },
    {
      "source": "LY294002",
      "target": "PI3K/AKT inhibitor",
      "label": "is a"
    },
    {
      "source": "LY294002",
      "target": "PI3K/AKT pathway",
      "label": "inhibits"
    },
    {
      "source": "PD98059",
      "target": "D2/D3 receptor signalling pathway",
      "label": "inhibited"
    },
    {
      "source": "net hepatic glycogen synthesis",
      "target": "vivo",
      "label": "occurs in"
    },
    {
      "source": "net hepatic glycogen synthesis",
      "target": "hepatic portal vein glucose infusion",
      "label": "occurs during"
    },
    {
      "source": "net hepatic glycogen synthesis",
      "target": "hyperinsulinemia",
      "label": "occurs during"
    },
    {
      "source": "glycogen synthesis",
      "target": "intraportal glucose infusion",
      "label": "responds to"
    },
    {
      "source": "glycogen synthesis",
      "target": "hyperinsulinemia",
      "label": "responds to"
    },
    {
      "source": "fructose infusion",
      "target": "control period",
      "label": "stopped during"
    },
    {
      "source": "percent of glucose",
      "target": "liver",
      "label": "taken up by"
    },
    {
      "source": "percent of glucose",
      "target": "Gly+INS",
      "label": "observed in"
    },
    {
      "source": "percent of glucose",
      "target": "SCGly+INS",
      "label": "observed in"
    },
    {
      "source": "percent of glucose",
      "target": "SCGly+PoG",
      "label": "observed in"
    },
    {
      "source": "percent of glucose",
      "target": "Gly+PoG",
      "label": "observed in"
    },
    {
      "source": "percent of glucose",
      "target": "glycogen",
      "label": "deposited in"
    },
    {
      "source": "Liver glycogen levels",
      "target": "hyperglycemic-normoinsulinemia",
      "label": "measured during"
    },
    {
      "source": "Liver glycogen levels",
      "target": "SCGly",
      "label": "were"
    },
    {
      "source": "purpose",
      "target": "effect",
      "label": "determines"
    },
    {
      "source": "purpose",
      "target": "study",
      "label": "of"
    },
    {
      "source": "decrease",
      "target": "insulin signaling",
      "label": "in"
    },
    {
      "source": "decrease",
      "target": "PAB",
      "label": "in"
    },
    {
      "source": "decrease",
      "target": "uptake",
      "label": "in"
    },
    {
      "source": "SCGly",
      "target": "groups",
      "label": "applies to"
    },
    {
      "source": "SCGly",
      "target": "intraportal fructose infusion",
      "label": "resulted from"
    },
    {
      "source": "Gly",
      "target": "groups",
      "label": "applies to"
    },
    {
      "source": "Liver glycogen loading",
      "target": "glycogen synthesis",
      "label": "impairs"
    },
    {
      "source": "hepatic glycogen",
      "target": "percent of glucose",
      "label": "reduced"
    },
    {
      "source": "CA XIV",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "X-ray crystal structures",
      "target": "CA II adducts",
      "label": "ARE_OF"
    },
    {
      "source": "X-ray crystal structures",
      "target": "adducts",
      "label": "ARE_IN"
    },
    {
      "source": "CA XII",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "active site water molecules",
      "target": "chlorthalidone scaffolds",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "active site water molecules",
      "target": "difference of activity",
      "label": "RESPONSIBLE_FOR"
    },
    {
      "source": "active site water molecules",
      "target": "furosemide scaffolds",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "active site water molecules",
      "target": "trichloromethiazide scaffolds",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "Thiazide diuretics",
      "target": "mammalian isoforms of carbonic anhydrase",
      "label": "INHIBIT"
    },
    {
      "source": "mammalian isoforms of carbonic anhydrase",
      "target": "carbonic anhydrase (CA)",
      "label": "IS_A"
    },
    {
      "source": "mammalian isoforms of carbonic anhydrase",
      "target": "EC 4.2.1.1",
      "label": "IS_A"
    },
    {
      "source": "trichloromethiazide",
      "target": "Carbonic anhydrase inhibitors",
      "label": "IS_A"
    },
    {
      "source": "trichloromethiazide",
      "target": "CA VII",
      "label": "INHIBITS"
    },
    {
      "source": "trichloromethiazide",
      "target": "isozyme CA II",
      "label": "INHIBITS"
    },
    {
      "source": "trichloromethiazide",
      "target": "CA IX",
      "label": "INHIBITS"
    },
    {
      "source": "trichloromethiazide",
      "target": "K(I)s",
      "label": "HAS"
    },
    {
      "source": "trichloromethiazide",
      "target": "nanomolar inhibitors",
      "label": "IS_A"
    },
    {
      "source": "hCA VB",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "hCA IX",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "chlorthalidone",
      "target": "Carbonic anhydrase inhibitors",
      "label": "IS_A"
    },
    {
      "source": "chlorthalidone",
      "target": "isozyme CA II",
      "label": "INHIBITS"
    },
    {
      "source": "chlorthalidone",
      "target": "K(I)s",
      "label": "HAS"
    },
    {
      "source": "chlorthalidone",
      "target": "hCA IX",
      "label": "INHIBITS"
    },
    {
      "source": "chlorthalidone",
      "target": "hCA XIII",
      "label": "INHIBITS"
    },
    {
      "source": "chlorthalidone",
      "target": "hCA VII",
      "label": "INHIBITS"
    },
    {
      "source": "chlorthalidone",
      "target": "enolic (lactimic) tautomeric form",
      "label": "IS_IN"
    },
    {
      "source": "chlorthalidone",
      "target": "hCA VB",
      "label": "INHIBITS"
    },
    {
      "source": "chlorthalidone",
      "target": "nanomolar inhibitors",
      "label": "IS_A"
    },
    {
      "source": "ethoxzolamide",
      "target": "classical inhibitors",
      "label": "IS_A"
    },
    {
      "source": "CA VII",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "CA II inhibitors",
      "target": "medicinal chemistry applications",
      "label": "HAS_APPLICATION"
    },
    {
      "source": "CA XIII",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "CA IX",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "water molecules",
      "target": "difference of activity",
      "label": "CAUSES"
    },
    {
      "source": "hCA XIII",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "enolic OH",
      "target": "hydrogen bonds",
      "label": "PARTICIPATES_IN"
    },
    {
      "source": "hydrogen bonds",
      "target": "water molecules",
      "label": "ARE_WITH"
    },
    {
      "source": "hydrogen bonds",
      "target": "Asn67",
      "label": "ARE_WITH"
    },
    {
      "source": "adducts",
      "target": "isozyme II",
      "label": "ARE_WITH"
    },
    {
      "source": "methazolamide",
      "target": "classical inhibitors",
      "label": "IS_A"
    },
    {
      "source": "binding modes",
      "target": "compounds",
      "label": "EXPLOITED_FOR_DESIGNING"
    },
    {
      "source": "binding modes",
      "target": "CA II inhibitors",
      "label": "EXPLOITED_FOR_DESIGNING"
    },
    {
      "source": "CA I",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "high ceiling diuretics",
      "target": "mammalian isoforms of carbonic anhydrase",
      "label": "INHIBIT"
    },
    {
      "source": "hCA VII",
      "target": "isoforms",
      "label": "IS_A"
    },
    {
      "source": "Cocaine",
      "target": "drugs of abuse",
      "label": "is a type of"
    },
    {
      "source": "drugs of abuse",
      "target": "DA concentration",
      "label": "increase"
    },
    {
      "source": "drugs of abuse",
      "target": "D2 receptor sensitivity",
      "label": "cause reduction of"
    },
    {
      "source": "initial biochemical analysis",
      "target": "cocaine-hydrolyzing mutants of BChE",
      "label": "performed on"
    },
    {
      "source": "cocaine-hydrolyzing mutants of BChE",
      "target": "MagnICON virus-assisted transient expression system",
      "label": "expressed using"
    },
    {
      "source": "cocaine-hydrolyzing mutants of BChE",
      "target": "Nicotiana benthamiana",
      "label": "expressed in"
    },
    {
      "source": "butyrylcholinesterase variants",
      "target": "cocaine hydrolase activity",
      "label": "designed for"
    },
    {
      "source": "butyrylcholinesterase variants",
      "target": "catalytic activity",
      "label": "exhibit"
    },
    {
      "source": "Recent studies",
      "target": "promising potential treatment option",
      "label": "demonstrated"
    },
    {
      "source": "promising potential treatment option",
      "target": "serum enzyme butyrylcholinesterase",
      "label": "involves"
    },
    {
      "source": "Plants",
      "target": "butyrylcholinesterase variants",
      "label": "are a source of"
    },
    {
      "source": "Plants",
      "target": "engineered BChE proteins",
      "label": "can express"
    },
    {
      "source": "Plants",
      "target": "promising means",
      "label": "are"
    },
    {
      "source": "serum enzyme butyrylcholinesterase",
      "target": "BChE",
      "label": "is also known as"
    },
    {
      "source": "cocaine hydrolase variants of BChE",
      "target": "enzymes",
      "label": "are functionally equivalent to"
    },
    {
      "source": "cocaine hydrolase variants of BChE",
      "target": "human pathogens",
      "label": "are safe from"
    },
    {
      "source": "those",
      "target": "long periods of abstinence",
      "label": "experience"
    },
    {
      "source": "those",
      "target": "80% chance of relapse",
      "label": "have"
    },
    {
      "source": "those",
      "target": "rehabilitation",
      "label": "undergo"
    },
    {
      "source": "BChE",
      "target": "(-)-cocaine",
      "label": "is capable of breaking down"
    },
    {
      "source": "BChE",
      "target": "related enzyme",
      "label": "is a type of"
    },
    {
      "source": "engineered BChE proteins",
      "target": "desired properties",
      "label": "have"
    },
    {
      "source": "large amounts",
      "target": "cocaine hydrolase variants of BChE",
      "label": "of"
    },
    {
      "source": "Cocaine addiction",
      "target": "personal and social consequences",
      "label": "leads to"
    },
    {
      "source": "Cocaine addiction",
      "target": "millions of people",
      "label": "affects"
    },
    {
      "source": "FDA-approved treatment",
      "target": "likelihood of relapse",
      "label": "decreases"
    },
    {
      "source": "design of variants of BChE",
      "target": "catalytic activity",
      "label": "aims for"
    },
    {
      "source": "promising means",
      "target": "large amounts",
      "label": "to produce"
    },
    {
      "source": "proof-of-principle",
      "target": "Plants",
      "label": "shows that"
    },
    {
      "source": "Tub expression",
      "target": "fasting blood glucose",
      "label": "inhibition increases"
    },
    {
      "source": "Tub expression",
      "target": "Food intake",
      "label": "inhibition increases"
    },
    {
      "source": "Tub expression",
      "target": "leptin",
      "label": "inhibition blunts effect of"
    },
    {
      "source": "Tub expression",
      "target": "hypothalamus",
      "label": "occurs in"
    },
    {
      "source": "Tub expression",
      "target": "hepatic glucose output",
      "label": "inhibition increases"
    },
    {
      "source": "Tub expression",
      "target": "O(2) consumption",
      "label": "inhibition decreases"
    },
    {
      "source": "Tub expression",
      "target": "insulin",
      "label": "inhibition blunts effect of"
    },
    {
      "source": "leptin",
      "target": "melanin-concentrating hormone",
      "label": "affects"
    },
    {
      "source": "leptin",
      "target": "thyroid-releasing hormone",
      "label": "affects"
    },
    {
      "source": "leptin",
      "target": "orexin",
      "label": "affects"
    },
    {
      "source": "leptin",
      "target": "proopiomelanocortin",
      "label": "affects"
    },
    {
      "source": "leptin",
      "target": "Tub",
      "label": "stimulates"
    },
    {
      "source": "leptin",
      "target": "Tub-p-tyr",
      "label": "induces"
    },
    {
      "source": "leptin",
      "target": "Food intake",
      "label": "affects"
    },
    {
      "source": "Food intake",
      "target": "leptin",
      "label": "measured in response to"
    },
    {
      "source": "Food intake",
      "target": "fasting",
      "label": "measured in response to"
    },
    {
      "source": "Food intake",
      "target": "Tub antisense oligonucleotide",
      "label": "measured in response to"
    },
    {
      "source": "Food intake",
      "target": "intracerebroventricular insulin",
      "label": "measured in response to"
    },
    {
      "source": "Food intake",
      "target": "refeeding",
      "label": "measured in response to"
    },
    {
      "source": "Tub",
      "target": "nucleus",
      "label": "translocates to"
    },
    {
      "source": "Tub",
      "target": "hypothalamic nuclei",
      "label": "is modulated in"
    },
    {
      "source": "Tub",
      "target": "IRTK",
      "label": "is substrate of"
    },
    {
      "source": "Tub",
      "target": "neuropeptide expression",
      "label": "modulates"
    },
    {
      "source": "Tub",
      "target": "insulin",
      "label": "has role in"
    },
    {
      "source": "Tub",
      "target": "insulin receptor tyrosine kinase",
      "label": "is substrate of"
    },
    {
      "source": "Tub",
      "target": "leptin",
      "label": "controls effects of"
    },
    {
      "source": "Tub",
      "target": "insulin resistance",
      "label": "modulation contributes to"
    },
    {
      "source": "Tub",
      "target": "hepatic glucose metabolism",
      "label": "modulates"
    },
    {
      "source": "Tub",
      "target": "leptin resistance",
      "label": "modulation contributes to"
    },
    {
      "source": "Tub",
      "target": "leptin receptor",
      "label": "is substrate of"
    },
    {
      "source": "Tub",
      "target": "LEPR",
      "label": "is substrate of"
    },
    {
      "source": "Tub",
      "target": "Janus kinase 2",
      "label": "is substrate of"
    },
    {
      "source": "Tub",
      "target": "JAK2",
      "label": "is substrate of"
    },
    {
      "source": "Tub",
      "target": "energy balance",
      "label": "modulates"
    },
    {
      "source": "Tub antisense oligonucleotide",
      "target": "ASO",
      "label": "is a type of"
    },
    {
      "source": "ASO",
      "target": "Tub expression",
      "label": "inhibits"
    },
    {
      "source": "tub gene",
      "target": "energy balance",
      "label": "regulates"
    },
    {
      "source": "tub gene",
      "target": "obesity",
      "label": "mutation induces"
    },
    {
      "source": "energy balance",
      "target": "longevity",
      "label": "influences"
    },
    {
      "source": "signaling proteins",
      "target": "intracerebroventricular insulin",
      "label": "measured in response to"
    },
    {
      "source": "signaling proteins",
      "target": "refeeding",
      "label": "measured in response to"
    },
    {
      "source": "signaling proteins",
      "target": "leptin",
      "label": "measured in response to"
    },
    {
      "source": "signaling proteins",
      "target": "fasting",
      "label": "measured in response to"
    },
    {
      "source": "signaling proteins",
      "target": "Tub antisense oligonucleotide",
      "label": "measured in response to"
    },
    {
      "source": "metabolic characteristics",
      "target": "intracerebroventricular insulin",
      "label": "measured in response to"
    },
    {
      "source": "metabolic characteristics",
      "target": "refeeding",
      "label": "measured in response to"
    },
    {
      "source": "metabolic characteristics",
      "target": "leptin",
      "label": "measured in response to"
    },
    {
      "source": "metabolic characteristics",
      "target": "fasting",
      "label": "measured in response to"
    },
    {
      "source": "metabolic characteristics",
      "target": "Tub antisense oligonucleotide",
      "label": "measured in response to"
    },
    {
      "source": "Tub tyrosine phosphorylation",
      "target": "nutritional status",
      "label": "modulated by"
    },
    {
      "source": "Tub-p-tyr",
      "target": "nutritional status",
      "label": "modulated by"
    },
    {
      "source": "neuropeptide expression",
      "target": "leptin",
      "label": "measured in response to"
    },
    {
      "source": "neuropeptide expression",
      "target": "fasting",
      "label": "measured in response to"
    },
    {
      "source": "neuropeptide expression",
      "target": "Tub antisense oligonucleotide",
      "label": "measured in response to"
    },
    {
      "source": "neuropeptide expression",
      "target": "refeeding",
      "label": "measured in response to"
    },
    {
      "source": "neuropeptide expression",
      "target": "intracerebroventricular insulin",
      "label": "measured in response to"
    },
    {
      "source": "protein tyrosine phosphatase 1B",
      "target": "insulin-induced Tub-p-tyr",
      "label": "reverses reduction of"
    },
    {
      "source": "protein tyrosine phosphatase 1B",
      "target": "leptin",
      "label": "reverses reduction of"
    },
    {
      "source": "leptin resistance",
      "target": "DIO mice",
      "label": "occurs in"
    },
    {
      "source": "elastic rubber",
      "target": "second molar",
      "label": "inserted between"
    },
    {
      "source": "elastic rubber",
      "target": "M1",
      "label": "inserted between"
    },
    {
      "source": "elastic rubber",
      "target": "M2",
      "label": "inserted between"
    },
    {
      "source": "elastic rubber",
      "target": "upper left first molar",
      "label": "inserted between"
    },
    {
      "source": "ETM",
      "target": "stimulation",
      "label": "changes through"
    },
    {
      "source": "ETM",
      "target": "distribution",
      "label": "changes"
    },
    {
      "source": "ETM",
      "target": "sympathetic signaling",
      "label": "is controlled by"
    },
    {
      "source": "ETM",
      "target": "bone architecture",
      "label": "changes"
    },
    {
      "source": "ETM",
      "target": "osteoclast number",
      "label": "increased"
    },
    {
      "source": "ETM",
      "target": "tooth movement",
      "label": "induced"
    },
    {
      "source": "ETM",
      "target": "Oc.N/BS",
      "label": "increased"
    },
    {
      "source": "ETM",
      "target": "mechano-adaptive response",
      "label": "induced"
    },
    {
      "source": "ETM",
      "target": "sympathetic signal",
      "label": "mediates"
    },
    {
      "source": "ETM",
      "target": "drug treatments",
      "label": "increased in"
    },
    {
      "source": "ETM",
      "target": "osteoclast increase",
      "label": "induced"
    },
    {
      "source": "mechano-adaptive response",
      "target": "osteoclast activation",
      "label": "is controlled through"
    },
    {
      "source": "mechano-adaptive response",
      "target": "sympathetic signaling",
      "label": "is controlled by"
    },
    {
      "source": "osteoclast activation",
      "target": "sympathetic signaling",
      "label": "is regulated by"
    },
    {
      "source": "sympathetic neuromarkers",
      "target": "TH",
      "label": "include"
    },
    {
      "source": "sympathetic neuromarkers",
      "target": "NPY",
      "label": "include"
    },
    {
      "source": "sympathetic neuromarkers",
      "target": "neuropeptide Y",
      "label": "include"
    },
    {
      "source": "sympathetic neuromarkers",
      "target": "tyrosine hydroxylase",
      "label": "include"
    },
    {
      "source": "PRO treatment",
      "target": "amount of tooth movement",
      "label": "suppressed"
    },
    {
      "source": "PRO treatment",
      "target": "Oc.N/BS",
      "label": "suppressed"
    },
    {
      "source": "PRO treatment",
      "target": "3-day ETM",
      "label": "suppressed in"
    },
    {
      "source": "PRO treatment",
      "target": "vehicle treatment",
      "label": "compared with"
    },
    {
      "source": "PRO treatment",
      "target": "5-day ETM",
      "label": "suppressed in"
    },
    {
      "source": "ISO",
      "target": "isoproterenol",
      "label": "is an alias for"
    },
    {
      "source": "ISO",
      "target": "PI3K/Akt signaling pathway",
      "label": "inhibits"
    },
    {
      "source": "ISO",
      "target": "flavonoid compound",
      "label": "is a type of"
    },
    {
      "source": "ISO",
      "target": "Bax/Bcl-2 ratio",
      "label": "induced"
    },
    {
      "source": "ISO",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "ISO",
      "target": "HepG2 cells",
      "label": "acts in"
    },
    {
      "source": "ISO",
      "target": "JNK",
      "label": "increased expression of"
    },
    {
      "source": "ISO",
      "target": "p38 kinases",
      "label": "increased expression of"
    },
    {
      "source": "ISO",
      "target": "mitochondrial dysfunction",
      "label": "induces"
    },
    {
      "source": "ISO",
      "target": "ERK1/2 kinase",
      "label": "inhibited"
    },
    {
      "source": "ISO",
      "target": "cytochrome c",
      "label": "induced release of"
    },
    {
      "source": "ISO",
      "target": "cytotoxicity",
      "label": "induced"
    },
    {
      "source": "ISO",
      "target": "cell death",
      "label": "induced"
    },
    {
      "source": "ISO",
      "target": "ROS",
      "label": "stimulated"
    },
    {
      "source": "ISO",
      "target": "cleaved caspase-3",
      "label": "induced levels of"
    },
    {
      "source": "ISO",
      "target": "4261-42-1",
      "label": "has CAS RN"
    },
    {
      "source": "ISO",
      "target": "glutamatergic transmission",
      "label": "has effects on"
    },
    {
      "source": "isoproterenol",
      "target": "\u03b2-agonist",
      "label": "is a type of"
    },
    {
      "source": "isoproterenol",
      "target": "myocardial infarction",
      "label": "induces"
    },
    {
      "source": "isoproterenol",
      "target": "myocardial infarcted rats",
      "label": "induces"
    },
    {
      "source": "Nerve fibers",
      "target": "sympathetic neuromarkers",
      "label": "immunoreactive for"
    },
    {
      "source": "Nerve fibers",
      "target": "sensory neuromarkers",
      "label": "immunoreactive for"
    },
    {
      "source": "Nerve fibers",
      "target": "periodontal ligament",
      "label": "increased in"
    },
    {
      "source": "Nerve fibers",
      "target": "ETM",
      "label": "increased during"
    },
    {
      "source": "Oc.N/BS",
      "target": "osteoclast number",
      "label": "measures"
    },
    {
      "source": "Oc.N/BS",
      "target": "bone surface",
      "label": "measures on"
    },
    {
      "source": "osteoclast number",
      "target": "bone surface",
      "label": "on"
    },
    {
      "source": "sympathetic signaling",
      "target": "osteoclast activation",
      "label": "controls through"
    },
    {
      "source": "sympathetic nervous system",
      "target": "bone remodeling",
      "label": "is involved in"
    },
    {
      "source": "sensory nerve fibers",
      "target": "periodontal ligament",
      "label": "located in"
    },
    {
      "source": "sensory neuromarkers",
      "target": "calcitonin gene-related peptide",
      "label": "include"
    },
    {
      "source": "sensory neuromarkers",
      "target": "CGRP",
      "label": "include"
    },
    {
      "source": "Chemical sympathectomy",
      "target": "PRO treatment",
      "label": "showed similar results to"
    },
    {
      "source": "Chemical sympathectomy",
      "target": "6-OHDA",
      "label": "uses"
    },
    {
      "source": "Chemical sympathectomy",
      "target": "6-hydroxydopamine",
      "label": "uses"
    },
    {
      "source": "ISO treatment",
      "target": "Oc.N/BS",
      "label": "increased"
    },
    {
      "source": "ISO treatment",
      "target": "3-day ETM",
      "label": "increased in"
    },
    {
      "source": "ISO treatment",
      "target": "vehicle treatment",
      "label": "compared with"
    },
    {
      "source": "ISO treatment",
      "target": "amount of tooth movement",
      "label": "increased"
    },
    {
      "source": "bone surface",
      "target": "alveolar socket",
      "label": "is also known as"
    },
    {
      "source": "PRO",
      "target": "propranolol",
      "label": "is an alias for"
    },
    {
      "source": "NPY",
      "target": "GP",
      "label": "has reciprocal regulation with"
    },
    {
      "source": "NPY",
      "target": "CREB",
      "label": "has reciprocal regulation with"
    },
    {
      "source": "NPY",
      "target": "Y1R",
      "label": "has opposite expression pattern to"
    },
    {
      "source": "NPY",
      "target": "orexigenic genes",
      "label": "is_a"
    },
    {
      "source": "neuropeptide Y",
      "target": "appetite suppression",
      "label": "involved in regulating"
    },
    {
      "source": "Experimental tooth movement",
      "target": "osteoclast activation",
      "label": "induces"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "lycopene eccentric cleavage products",
      "label": "is a type of"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "antioxidant properties",
      "label": "has"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "ROS production",
      "label": "Downregulator"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "THP-1 macrophages",
      "label": "acts in"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "hsp-90 expressions",
      "label": "Downregulator"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "hsp-70 expressions",
      "label": "Downregulator"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "NF-\u03baB inactivation",
      "label": "causes"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "oxidative effects",
      "label": "counteracts"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "MAPK phosphorylation",
      "label": "Downregulator"
    },
    {
      "source": "apo-10'-lycopenoic acid",
      "target": "antioxidant",
      "label": "is a"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "hsp-70 expressions",
      "label": "Downregulator"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "antioxidant",
      "label": "is a"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "antioxidant properties",
      "label": "has"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "oxidative effects",
      "label": "counteracts"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "MAPK phosphorylation",
      "label": "Downregulator"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "lycopene eccentric cleavage products",
      "label": "is a type of"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "ROS production",
      "label": "Downregulator"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "cells",
      "label": "acts in"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "THP-1 macrophages",
      "label": "acts in"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "hsp-90 expressions",
      "label": "Downregulator"
    },
    {
      "source": "apo-14'-lycopenoic acid",
      "target": "NF-\u03baB inactivation",
      "label": "causes"
    },
    {
      "source": "tomato lycopene",
      "target": "antioxidant properties",
      "label": "has"
    },
    {
      "source": "tomato lycopene",
      "target": "chronic diseases",
      "label": "prevents"
    },
    {
      "source": "antioxidant properties",
      "target": "oxidation products",
      "label": "mediated by"
    },
    {
      "source": "antioxidant properties",
      "target": "metabolites",
      "label": "mediated by"
    },
    {
      "source": "apo-lycopenoic acids",
      "target": "COX-2 expressions",
      "label": "Downregulator"
    },
    {
      "source": "apo-lycopenoic acids",
      "target": "ROS production",
      "label": "Downregulator"
    },
    {
      "source": "apo-lycopenoic acids",
      "target": "cells",
      "label": "acts in"
    },
    {
      "source": "apo-lycopenoic acids",
      "target": "antioxidant properties",
      "label": "mediates"
    },
    {
      "source": "apo-lycopenoic acids",
      "target": "8-OHdG formation",
      "label": "Downregulator"
    },
    {
      "source": "apo-lycopenoic acids",
      "target": "NOX-4 expressions",
      "label": "Downregulator"
    },
    {
      "source": "oxidative effects",
      "target": "cigarette smoke extract",
      "label": "caused by"
    },
    {
      "source": "oxidative effects",
      "target": "H2O2",
      "label": "caused by"
    },
    {
      "source": "H2O2",
      "target": "ROS production",
      "label": "induces"
    },
    {
      "source": "H2O2",
      "target": "cav-1",
      "label": "Upregulator"
    },
    {
      "source": "H2O2",
      "target": "actin remodeling",
      "label": "Upregulator"
    },
    {
      "source": "H2O2",
      "target": "albumin uptake",
      "label": "Upregulator"
    },
    {
      "source": "H2O2",
      "target": "caveolin-1",
      "label": "Upregulator"
    },
    {
      "source": "H2O2",
      "target": "vascular permeability",
      "label": "Upregulator"
    },
    {
      "source": "H2O2",
      "target": "mitochondrial membrane potential",
      "label": "decreased"
    },
    {
      "source": "H2O2",
      "target": "MMP",
      "label": "decreased"
    },
    {
      "source": "oxidation products",
      "target": "lycopene derivatives",
      "label": "is a type of"
    },
    {
      "source": "lycopene",
      "target": "antioxidant properties",
      "label": "has"
    },
    {
      "source": "cigarette smoke extract",
      "target": "NOX-4 expressions",
      "label": "causes"
    },
    {
      "source": "cigarette smoke extract",
      "target": "ROS production",
      "label": "induces"
    },
    {
      "source": "cigarette smoke extract",
      "target": "COX-2 expressions",
      "label": "causes"
    },
    {
      "source": "human macrophages",
      "target": "H2O2",
      "label": "exposed to"
    },
    {
      "source": "human macrophages",
      "target": "cigarette smoke extract",
      "label": "exposed to"
    },
    {
      "source": "LPL activity",
      "target": "liver kinase B1",
      "label": "involves reduced phosphorylation of"
    },
    {
      "source": "LPL activity",
      "target": "phosphorylation",
      "label": "involves reduced"
    },
    {
      "source": "LPL activity",
      "target": "AMPK",
      "label": "involves reduced phosphorylation of"
    },
    {
      "source": "LPL activity",
      "target": "protein kinase B",
      "label": "involves activation of"
    },
    {
      "source": "LPL activity",
      "target": "AMP-activated protein kinase",
      "label": "involves reduced phosphorylation of"
    },
    {
      "source": "LPL activity",
      "target": "PKB",
      "label": "involves activation of"
    },
    {
      "source": "LPL activity",
      "target": "LKB1",
      "label": "involves reduced phosphorylation of"
    },
    {
      "source": "SAPK/JNK/c-Jun",
      "target": "phosphorylated levels",
      "label": "has"
    },
    {
      "source": "phosphorylated levels",
      "target": "Retn(-/-) mice",
      "label": "were decreased in"
    },
    {
      "source": "GIP receptor protein",
      "target": "Retn(-/-) mice",
      "label": "was decreased in"
    },
    {
      "source": "GIP receptor protein",
      "target": "Retn(+/-) mice",
      "label": "was decreased in"
    },
    {
      "source": "GIP responsiveness",
      "target": "Retn(+/-) mice",
      "label": "was blunted in"
    },
    {
      "source": "GIP responsiveness",
      "target": "Retn(-/-) mice",
      "label": "was compromised in"
    },
    {
      "source": "GIP responsiveness",
      "target": "GIPR expression",
      "label": "was due to reduced"
    },
    {
      "source": "resistin",
      "target": "GIP",
      "label": "mediates stimulation by"
    },
    {
      "source": "resistin",
      "target": "GIP-regulated adipocyte functions",
      "label": "has roles in"
    },
    {
      "source": "resistin",
      "target": "3T3-L1 cells",
      "label": "activity demonstrated in"
    },
    {
      "source": "resistin",
      "target": "LPL activity",
      "label": "mediates stimulation of"
    },
    {
      "source": "GIP",
      "target": "LPL activity",
      "label": "stimulates"
    },
    {
      "source": "GIP",
      "target": "Retn(+/+) mice",
      "label": "stimulated fatty acid uptake in"
    },
    {
      "source": "GIP",
      "target": "PKB/LKB1/AMPK/LPL pathway",
      "label": "stimulated"
    },
    {
      "source": "GIP",
      "target": "incretin hormone",
      "label": "is a type of"
    },
    {
      "source": "GIP",
      "target": "fatty acid uptake",
      "label": "stimulated"
    },
    {
      "source": "GIP",
      "target": "fat metabolism",
      "label": "plays a regulatory role in"
    },
    {
      "source": "GIP",
      "target": "nutrient ingestion",
      "label": "released in response to"
    },
    {
      "source": "GIP",
      "target": "energy accumulation",
      "label": "induces"
    },
    {
      "source": "GIP",
      "target": "glucose-stimulated insulin secretion",
      "label": "potentiates"
    },
    {
      "source": "GIP",
      "target": "incretin",
      "label": "is a type of"
    },
    {
      "source": "GIP",
      "target": "enteroendocrine K-cells",
      "label": "released from"
    },
    {
      "source": "Resistin knockout mice",
      "target": "glucose-dependent insulinotropic polypeptide receptor",
      "label": "exhibit impaired"
    },
    {
      "source": "Resistin knockout mice",
      "target": "adipocyte",
      "label": "exhibit impaired expression in"
    },
    {
      "source": "Resistin knockout mice",
      "target": "GIPR",
      "label": "exhibit impaired"
    },
    {
      "source": "Resistin knockout mice",
      "target": "GIPR expression",
      "label": "exhibit impaired"
    },
    {
      "source": "resistin treatment",
      "target": "LPL responsiveness",
      "label": "rescued"
    },
    {
      "source": "LPL responsiveness",
      "target": "GIP",
      "label": "is to"
    },
    {
      "source": "primary adipocytes",
      "target": "Retn(+/+) mice",
      "label": "isolated from"
    },
    {
      "source": "primary adipocytes",
      "target": "Retn(+/-) mice",
      "label": "isolated from"
    },
    {
      "source": "primary adipocytes",
      "target": "Retn(-/-) mice",
      "label": "isolated from"
    },
    {
      "source": "Glucose-dependent insulinotropic polypeptide",
      "target": "incretin hormone",
      "label": "is a type of"
    },
    {
      "source": "Glucose-dependent insulinotropic polypeptide",
      "target": "fat metabolism",
      "label": "plays a regulatory role in"
    },
    {
      "source": "GIP signaling",
      "target": "Retn(+/-) mice",
      "label": "was compromised in"
    },
    {
      "source": "GIP signaling",
      "target": "Retn(-/-) mice",
      "label": "was compromised in"
    },
    {
      "source": "c-Jun-mediated transcriptional activation",
      "target": "Gipr",
      "label": "is of"
    },
    {
      "source": "current study",
      "target": "resistin",
      "label": "investigates roles of"
    },
    {
      "source": "current study",
      "target": "human SCD-1 gene expression",
      "label": "examined regulation of"
    },
    {
      "source": "current study",
      "target": "SREBP-1c effect",
      "label": "evaluated"
    },
    {
      "source": "GIPR expression",
      "target": "c-Jun-mediated transcriptional activation",
      "label": "is associated with decreased"
    },
    {
      "source": "TPA-response element",
      "target": "TRE-III",
      "label": "is a type of"
    },
    {
      "source": "TPA-response element",
      "target": "c-Jun-mediated transcriptional activation",
      "label": "is responsible for"
    },
    {
      "source": "Chromatin immunoprecipitation assays",
      "target": "TPA-response element",
      "label": "identified"
    },
    {
      "source": "Chromatin immunoprecipitation assays",
      "target": "TH receptor-\u03b2",
      "label": "demonstrated recruitment of"
    },
    {
      "source": "Toxicity profile",
      "target": "dogs",
      "label": "characterized in"
    },
    {
      "source": "Toxicity profile",
      "target": "GDC-0152",
      "label": "of"
    },
    {
      "source": "Toxicity profile",
      "target": "rats",
      "label": "characterized in"
    },
    {
      "source": "Toxicity profile",
      "target": "TNF-\u03b1 pharmacology",
      "label": "is linked to"
    },
    {
      "source": "iv dose administration",
      "target": "doses",
      "label": "involved"
    },
    {
      "source": "Findings",
      "target": "species",
      "label": "in"
    },
    {
      "source": "Findings",
      "target": "systemic inflammatory response",
      "label": "consisted of"
    },
    {
      "source": "Findings",
      "target": "hepatic injury",
      "label": "consisted of"
    },
    {
      "source": "cellular responses",
      "target": "inflammation",
      "label": "comprise"
    },
    {
      "source": "cellular responses",
      "target": "death",
      "label": "comprise"
    },
    {
      "source": "cellular responses",
      "target": "proliferation",
      "label": "comprise"
    },
    {
      "source": "cellular responses",
      "target": "cellular context",
      "label": "depend on"
    },
    {
      "source": "cellular responses",
      "target": "cell survival",
      "label": "comprise"
    },
    {
      "source": "Laboratory findings",
      "target": "histopathological findings",
      "label": "associated with"
    },
    {
      "source": "Laboratory findings",
      "target": "liver transaminases",
      "label": "included"
    },
    {
      "source": "Laboratory findings",
      "target": "plasma cytokines",
      "label": "included"
    },
    {
      "source": "Laboratory findings",
      "target": "inflammatory leukogram",
      "label": "included"
    },
    {
      "source": "histopathological findings",
      "target": "inflammatory infiltrates",
      "label": "showed"
    },
    {
      "source": "histopathological findings",
      "target": "apoptosis/necrosis",
      "label": "showed"
    },
    {
      "source": "Small-molecule IAP antagonists",
      "target": "cancer therapeutics",
      "label": "are"
    },
    {
      "source": "Small-molecule IAP antagonists",
      "target": "clinical trials",
      "label": "tested in"
    },
    {
      "source": "GDC-0152",
      "target": "small-molecule drug",
      "label": "is a type of"
    },
    {
      "source": "GDC-0152",
      "target": "small-molecule IAP antagonist",
      "label": "is a type of"
    },
    {
      "source": "GDC-0152",
      "target": "tumor cell apoptosis",
      "label": "triggers"
    },
    {
      "source": "GDC-0152",
      "target": "iv dose administration",
      "label": "administered via"
    },
    {
      "source": "GDC-0152",
      "target": "IAPs",
      "label": "antagonizes"
    },
    {
      "source": "GDC-0152",
      "target": "NF-\u03baB transcriptional activity",
      "label": "induces"
    },
    {
      "source": "GDC-0152",
      "target": "Toxicity profile",
      "label": "has"
    },
    {
      "source": "tumor necrosis factor alpha (TNF-\u03b1)",
      "target": "cellular responses",
      "label": "drives"
    },
    {
      "source": "tumor necrosis factor alpha (TNF-\u03b1)",
      "target": "toxicity",
      "label": "drives"
    },
    {
      "source": "tumor necrosis factor alpha (TNF-\u03b1)",
      "target": "single-agent tumor activity",
      "label": "is important for"
    },
    {
      "source": "tumor necrosis factor alpha (TNF-\u03b1)",
      "target": "efficacy",
      "label": "drives"
    },
    {
      "source": "tumor necrosis factor alpha (TNF-\u03b1)",
      "target": "pleiotropic cytokine",
      "label": "is a type of"
    },
    {
      "source": "Inhibitor-of-apoptosis (IAP) proteins",
      "target": "apoptosis",
      "label": "suppress"
    },
    {
      "source": "Inhibitor-of-apoptosis (IAP) proteins",
      "target": "cancers",
      "label": "overexpressed in"
    },
    {
      "source": "blood neutrophil count",
      "target": "safety biomarkers",
      "label": "may have utility as"
    },
    {
      "source": "blood neutrophil count",
      "target": "GDC-0152 exposure",
      "label": "corresponded to"
    },
    {
      "source": "blood neutrophil count",
      "target": "toxicity",
      "label": "corresponded to"
    },
    {
      "source": "apoptosis/necrosis",
      "target": "tissues",
      "label": "found in"
    },
    {
      "source": "malignant cells",
      "target": "tumor necrosis factor alpha (TNF-\u03b1)",
      "label": "produce"
    },
    {
      "source": "inflammatory infiltrates",
      "target": "tissues",
      "label": "found in"
    },
    {
      "source": "normal cells",
      "target": "tumor necrosis factor alpha (TNF-\u03b1)",
      "label": "produce"
    },
    {
      "source": "IAP antagonism",
      "target": "tumor necrosis factor alpha (TNF-\u03b1)",
      "label": "leads to production of"
    },
    {
      "source": "chemokines",
      "target": "soluble factors",
      "label": "is a type of"
    },
    {
      "source": "NF-\u03baB transcriptional activity",
      "target": "expression",
      "label": "leads to"
    },
    {
      "source": "toxicology profile",
      "target": "TNF-\u03b1-mediated toxicity",
      "label": "consistent with"
    },
    {
      "source": "markers of inflammation",
      "target": "safety biomarkers",
      "label": "may have utility as"
    },
    {
      "source": "markers of inflammation",
      "target": "GDC-0152 exposure",
      "label": "corresponded to"
    },
    {
      "source": "markers of inflammation",
      "target": "toxicity",
      "label": "corresponded to"
    },
    {
      "source": "serum monocyte chemoattractant protein-1",
      "target": "GDC-0152 exposure",
      "label": "corresponded to"
    },
    {
      "source": "serum monocyte chemoattractant protein-1",
      "target": "safety biomarkers",
      "label": "may have utility as"
    },
    {
      "source": "serum monocyte chemoattractant protein-1",
      "target": "toxicity",
      "label": "corresponded to"
    },
    {
      "source": "DIR",
      "target": "protein kinase C",
      "label": "is dependent on"
    },
    {
      "source": "DIR",
      "target": "phospholipase C",
      "label": "is mediated by"
    },
    {
      "source": "DIR",
      "target": "conventional subtype of protein kinase C",
      "label": "is mediated by"
    },
    {
      "source": "DIR",
      "target": "\u03b2-ARK1 inhibitor",
      "label": "was blocked by"
    },
    {
      "source": "DIR",
      "target": "neurotensin receptors",
      "label": "is mediated by"
    },
    {
      "source": "DIR",
      "target": "D2 receptors",
      "label": "is mediated by"
    },
    {
      "source": "DIR",
      "target": "dynamin",
      "label": "is linked to"
    },
    {
      "source": "DIR",
      "target": "G protein-coupled receptor kinase",
      "label": "is dependent on"
    },
    {
      "source": "DIR",
      "target": "G protein-coupled receptor kinase-2",
      "label": "is linked to"
    },
    {
      "source": "DIR",
      "target": "5-HT(2) receptors",
      "label": "is mediated by"
    },
    {
      "source": "DIR",
      "target": "dynasore",
      "label": "was blocked by"
    },
    {
      "source": "DIR",
      "target": "D1-like DA receptors",
      "label": "is mediated by"
    },
    {
      "source": "protein kinase C",
      "target": "alpha-AR gene transcription",
      "label": "has permissive effect on"
    },
    {
      "source": "protein kinase C",
      "target": "stability of the mRNA",
      "label": "decreases"
    },
    {
      "source": "cPKC antagonist",
      "target": "5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile",
      "label": "is"
    },
    {
      "source": "5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile",
      "target": "G\u00f66976",
      "label": "is also known as"
    },
    {
      "source": "brain pathways",
      "target": "addiction",
      "label": "are related to"
    },
    {
      "source": "DA concentration",
      "target": "ventral tegmental area",
      "label": "is in"
    },
    {
      "source": "dopamine D2 agonist",
      "target": "inhibition",
      "label": "induces"
    },
    {
      "source": "phospholipase C",
      "target": "PLC",
      "label": "is also known as"
    },
    {
      "source": "dynasore",
      "target": "dynamin",
      "label": "blocks"
    },
    {
      "source": "extracellular recordings",
      "target": "brain slices",
      "label": "used in"
    },
    {
      "source": "conventional subtype of protein kinase C",
      "target": "cPKC",
      "label": "is also known as"
    },
    {
      "source": "desensitization",
      "target": "D2 receptors",
      "label": "affects"
    },
    {
      "source": "\u03b2-ARK1 inhibitor",
      "target": "GRK2",
      "label": "inhibits"
    },
    {
      "source": "GRK2",
      "target": "desensitization",
      "label": "plays a role in"
    },
    {
      "source": "G protein-coupled receptor kinase-2",
      "target": "GRK2",
      "label": "is also known as"
    },
    {
      "source": "Dopaminergic neurons",
      "target": "brain pathways",
      "label": "are components of"
    },
    {
      "source": "Dopaminergic neurons",
      "target": "ventral tegmental area",
      "label": "are located in"
    },
    {
      "source": "dynamin",
      "target": "desensitization",
      "label": "plays a role in"
    },
    {
      "source": "cPKC",
      "target": "desensitization",
      "label": "plays a role in"
    },
    {
      "source": "Gq-linked neurotransmitters",
      "target": "inhibition",
      "label": "causes reversal of"
    },
    {
      "source": "D2 receptor sensitivity",
      "target": "addiction",
      "label": "is a factor in"
    },
    {
      "source": "DA-inhibition reversal",
      "target": "DIR",
      "label": "is also known as"
    },
    {
      "source": "neurotensin",
      "target": "inhibition",
      "label": "produced reversal of"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "plasma-free cholesterol",
      "label": "increased"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "triglycerides",
      "label": "increased"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "cells",
      "label": "effluxes from"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "atherosclerosis",
      "label": "reduces"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "cholesterol",
      "label": "effluxes"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "animal models",
      "label": "reduces in"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "cholesterol efflux",
      "label": "increased"
    },
    {
      "source": "5A apolipoprotein mimetic peptide",
      "target": "inflammation",
      "label": "reduces"
    },
    {
      "source": "simulated annealing analysis",
      "target": "F-18",
      "label": "predicted"
    },
    {
      "source": "simulated annealing analysis",
      "target": "W-21",
      "label": "predicted"
    },
    {
      "source": "F-18",
      "target": "A",
      "label": "can be changed to"
    },
    {
      "source": "F-18",
      "target": "aqueous solvent",
      "label": "interacts with"
    },
    {
      "source": "F-18",
      "target": "F",
      "label": "can be changed to"
    },
    {
      "source": "F-18",
      "target": "E",
      "label": "can be changed to"
    },
    {
      "source": "F-18",
      "target": "W",
      "label": "can be changed to"
    },
    {
      "source": "F-18",
      "target": "hinge region",
      "label": "is in"
    },
    {
      "source": "cholesterol efflux",
      "target": "radiolabeled macrophages",
      "label": "is from"
    },
    {
      "source": "cholesterol efflux",
      "target": "ABCA1 transporter",
      "label": "is mediated by"
    },
    {
      "source": "molecular dynamics modeling",
      "target": "F-18",
      "label": "predicted"
    },
    {
      "source": "molecular dynamics modeling",
      "target": "W-21",
      "label": "predicted"
    },
    {
      "source": "hinge region",
      "target": "two helices",
      "label": "is between"
    },
    {
      "source": "hinge region",
      "target": "5A apolipoprotein mimetic peptide",
      "label": "is part of"
    },
    {
      "source": "EE peptide",
      "target": "plasma-free cholesterol",
      "label": "had no effect on"
    },
    {
      "source": "EE peptide",
      "target": "triglycerides",
      "label": "had no effect on"
    },
    {
      "source": "EE peptide",
      "target": "E",
      "label": "contains"
    },
    {
      "source": "EE peptide",
      "target": "cholesterol efflux",
      "label": "was inactive in promoting"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "5A apolipoprotein mimetic peptide",
      "label": "are important for function of"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "hinge region",
      "label": "are in"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "structure",
      "label": "are important in"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "cholesterol efflux",
      "label": "are essential for promoting"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "function",
      "label": "are important in"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "apolipoproteins",
      "label": "are on"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "phospholipid vesicles",
      "label": "bind"
    },
    {
      "source": "Hydrophobic amino acids",
      "target": "phospholipids",
      "label": "interact with"
    },
    {
      "source": "W-21",
      "target": "F",
      "label": "can be changed to"
    },
    {
      "source": "W-21",
      "target": "E",
      "label": "can be changed to"
    },
    {
      "source": "W-21",
      "target": "hinge region",
      "label": "is in"
    },
    {
      "source": "W-21",
      "target": "W",
      "label": "can be changed to"
    },
    {
      "source": "W-21",
      "target": "aqueous solvent",
      "label": "interacts with"
    },
    {
      "source": "W-21",
      "target": "A",
      "label": "can be changed to"
    },
    {
      "source": "lipid microdomain",
      "target": "cholesterol efflux",
      "label": "is during"
    },
    {
      "source": "lipid microdomain",
      "target": "ABCA1 transporter",
      "label": "is created by"
    },
    {
      "source": "E",
      "target": "cholesterol efflux",
      "label": "is less effective in promoting"
    },
    {
      "source": "Intravenous injection",
      "target": "C57BL/6 mice",
      "label": "in"
    },
    {
      "source": "Intravenous injection",
      "target": "5A apolipoprotein mimetic peptide",
      "label": "of"
    },
    {
      "source": "C57BL/6 mice",
      "target": "diets",
      "label": "fed"
    },
    {
      "source": "C57BL/6 mice",
      "target": "12 weeks",
      "label": "fed for"
    },
    {
      "source": "phospholipids",
      "target": "lipid microdomain",
      "label": "are in"
    },
    {
      "source": "Incubation",
      "target": "Cells",
      "label": "of"
    },
    {
      "source": "Incubation",
      "target": "in vitro modified lipoproteins",
      "label": "with"
    },
    {
      "source": "Incubation",
      "target": "specific pharmacological inhibitors",
      "label": "with"
    },
    {
      "source": "Cells",
      "target": "lipoproteins",
      "label": "incubated with"
    },
    {
      "source": "causative relationship",
      "target": "in vivo lipoprotein modifications",
      "label": "between"
    },
    {
      "source": "causative relationship",
      "target": "steroidogenesis",
      "label": "between"
    },
    {
      "source": "in vivo lipoprotein modifications",
      "target": "subjects",
      "label": "in"
    },
    {
      "source": "NGT-VLDL",
      "target": "hormone release",
      "label": "evoked"
    },
    {
      "source": "PRAEDIAS prevention study",
      "target": "department",
      "label": "located in"
    },
    {
      "source": "increased cardiovascular morbidity and mortality",
      "target": "prediabetic individuals",
      "label": "occurs in"
    },
    {
      "source": "glycoxidative modifications",
      "target": "lipoproteins",
      "label": "of"
    },
    {
      "source": "glycoxidative modifications",
      "target": "etiological factor",
      "label": "is"
    },
    {
      "source": "lipoproteins",
      "target": "NGT individuals",
      "label": "isolated from"
    },
    {
      "source": "lipoproteins",
      "target": "IGT subjects",
      "label": "isolated from"
    },
    {
      "source": "aldosterone",
      "target": "immunomodulation",
      "label": "has role in"
    },
    {
      "source": "aldosterone",
      "target": "pathogenesis",
      "label": "implicated in"
    },
    {
      "source": "aldosterone",
      "target": "cardiovascular homeostasis",
      "label": "has role in"
    },
    {
      "source": "aldosterone",
      "target": "estrogen deficiency",
      "label": "is a consequence of"
    },
    {
      "source": "aldosterone",
      "target": "cardiac fibrosis",
      "label": "causes"
    },
    {
      "source": "aldosterone",
      "target": "locus of aldosterone action",
      "label": "has"
    },
    {
      "source": "aldosterone",
      "target": "perivascular cardiac fibrosis",
      "label": "causes"
    },
    {
      "source": "aldosterone",
      "target": "interstitial cardiac fibrosis",
      "label": "causes"
    },
    {
      "source": "aldosterone",
      "target": "blood pressure",
      "label": "raises"
    },
    {
      "source": "aldosterone and cortisol release",
      "target": "human adrenocortical H295R cells",
      "label": "from"
    },
    {
      "source": "aldosterone and cortisol release",
      "target": "supernatants",
      "label": "measured in"
    },
    {
      "source": "IGT-VLDL",
      "target": "hormone release",
      "label": "evoked higher effect on"
    },
    {
      "source": "NGT individuals",
      "target": "PRAEDIAS prevention study",
      "label": "selected from"
    },
    {
      "source": "etiological factor",
      "target": "increased cardiovascular morbidity and mortality",
      "label": "for"
    },
    {
      "source": "steroidogenesis",
      "target": "APA",
      "label": "clarified in"
    },
    {
      "source": "cortisol",
      "target": "immunomodulation",
      "label": "has role in"
    },
    {
      "source": "cortisol",
      "target": "pathogenesis",
      "label": "implicated in"
    },
    {
      "source": "cortisol",
      "target": "cardiovascular homeostasis",
      "label": "has role in"
    },
    {
      "source": "in vivo modified VLDL",
      "target": "adrenocortical steroidogenesis",
      "label": "modulate"
    },
    {
      "source": "in vivo modified VLDL",
      "target": "prediabetic hormonal dysregulation",
      "label": "promote"
    },
    {
      "source": "adrenocortical steroidogenesis",
      "target": "Jak-2-ERK dependent pathway",
      "label": "via"
    },
    {
      "source": "in vivo modified lipoproteins",
      "target": "aldosterone and cortisol release",
      "label": "has impact on"
    },
    {
      "source": "Circulating very-low-density lipoprotein",
      "target": "adrenocortical cortisol and aldosterone synthesis",
      "label": "accelerates"
    },
    {
      "source": "Circulating very-low-density lipoprotein",
      "target": "subjects",
      "label": "from"
    },
    {
      "source": "stimulating effect",
      "target": "adrenocortical aldosterone and cortisol release",
      "label": "on"
    },
    {
      "source": "IGT subjects",
      "target": "PRAEDIAS prevention study",
      "label": "selected from"
    },
    {
      "source": "mineralization",
      "target": "Col1a1-Cnn1 mice",
      "label": "was significantly decreased in"
    },
    {
      "source": "mineralization",
      "target": "osteoblasts",
      "label": "of"
    },
    {
      "source": "Tartrate-resistant acid phosphatase",
      "target": "TRAP",
      "label": "is also known as"
    },
    {
      "source": "Morphology analyses",
      "target": "thickness",
      "label": "showed reduced"
    },
    {
      "source": "Morphology analyses",
      "target": "bone formation",
      "label": "showed defects in"
    },
    {
      "source": "Morphology analyses",
      "target": "trabecular number",
      "label": "showed reduced"
    },
    {
      "source": "ratio of RANKL to OPG",
      "target": "Col1a1-Cnn1 osteoblasts",
      "label": "was significantly increased in"
    },
    {
      "source": "CNN1",
      "target": "bone resorption",
      "label": "maintains bone homeostasis by coupling to"
    },
    {
      "source": "CNN1",
      "target": "bone",
      "label": "has effect on"
    },
    {
      "source": "CNN1",
      "target": "bone homeostasis",
      "label": "has novel function in maintaining"
    },
    {
      "source": "CNN1",
      "target": "smooth muscle-specific, actin-binding protein",
      "label": "is a"
    },
    {
      "source": "CNN1",
      "target": "bone formation",
      "label": "maintains bone homeostasis by coupling"
    },
    {
      "source": "H1 calponin",
      "target": "osteoclast formation",
      "label": "overexpression promotes"
    },
    {
      "source": "H1 calponin",
      "target": "osteoblast function",
      "label": "overexpression disrupts"
    },
    {
      "source": "H1 calponin",
      "target": "smooth muscle-specific, actin-binding protein",
      "label": "is a"
    },
    {
      "source": "H1 calponin",
      "target": "bone mass",
      "label": "overexpression leads to decrease in"
    },
    {
      "source": "H1 calponin",
      "target": "CNN1",
      "label": "is also known as"
    },
    {
      "source": "H1 calponin",
      "target": "osteoblast lineage cells",
      "label": "is overexpressed in"
    },
    {
      "source": "early osteoblast differentiation",
      "target": "Col1a1-Cnn1 mice",
      "label": "was increased in"
    },
    {
      "source": "bone formation",
      "target": "bone resorption",
      "label": "is coupled to"
    },
    {
      "source": "bone formation",
      "target": "embryonic stage",
      "label": "delayed at"
    },
    {
      "source": "late stage differentiation",
      "target": "osteoblasts",
      "label": "of"
    },
    {
      "source": "late stage differentiation",
      "target": "Col1a1-Cnn1 mice",
      "label": "derived from"
    },
    {
      "source": "RANKL",
      "target": "ratio of RANKL to OPG",
      "label": "is part of"
    },
    {
      "source": "Col1a1-Cnn1 transgenic mice",
      "target": "bone formation",
      "label": "showed delayed"
    },
    {
      "source": "Col1a1-Cnn1 transgenic mice",
      "target": "bone mass",
      "label": "showed decreased"
    },
    {
      "source": "smooth muscle-specific, actin-binding protein",
      "target": "smooth muscle contractive activity",
      "label": "regulates"
    },
    {
      "source": "smooth muscle-specific, actin-binding protein",
      "target": "actin-binding protein",
      "label": "is a type of"
    },
    {
      "source": "Cnn1",
      "target": "osteoblast-specific 3.6-kb Col1a1 promoter",
      "label": "is controlled by"
    },
    {
      "source": "osteoblast-specific 3.6-kb Col1a1 promoter",
      "target": "Col1a1 promoter",
      "label": "is a type of"
    },
    {
      "source": "TRAP staining",
      "target": "osteoclast numbers",
      "label": "revealed increased"
    },
    {
      "source": "TRAP staining",
      "target": "osteoclasts",
      "label": "revealed increased numbers of"
    },
    {
      "source": "osteoclast numbers",
      "target": "tibias",
      "label": "increased in"
    },
    {
      "source": "bone mass",
      "target": "adult stage",
      "label": "decreased at"
    },
    {
      "source": "bone mass",
      "target": "osteoclastogenesis",
      "label": "was associated with enhanced"
    },
    {
      "source": "transgenic mice",
      "target": "Cnn1",
      "label": "overexpress"
    },
    {
      "source": "OPG",
      "target": "ratio of RANKL to OPG",
      "label": "is part of"
    },
    {
      "source": "tibias",
      "target": "Col1a1-Cnn1 mice",
      "label": "are from"
    },
    {
      "source": "actin-binding protein",
      "target": "actin",
      "label": "binds"
    },
    {
      "source": "LY293558",
      "target": "survival rate",
      "label": "increased"
    },
    {
      "source": "LY293558",
      "target": "GluK1",
      "label": "is antagonist of"
    },
    {
      "source": "LY293558",
      "target": "intramuscular administration",
      "label": "administered via"
    },
    {
      "source": "LY293558",
      "target": "neurodegeneration",
      "label": "reduced"
    },
    {
      "source": "LY293558",
      "target": "anticonvulsant efficacy",
      "label": "has"
    },
    {
      "source": "LY293558",
      "target": "blood-brain barrier",
      "label": "crosses"
    },
    {
      "source": "LY293558",
      "target": "neuropathology",
      "label": "has efficacy against"
    },
    {
      "source": "LY293558",
      "target": "brain levels",
      "label": "has"
    },
    {
      "source": "LY293558",
      "target": "seizures",
      "label": "has efficacy against"
    },
    {
      "source": "LY293558",
      "target": "seizure suppression",
      "label": "causes"
    },
    {
      "source": "LY293558",
      "target": "AMPA receptor",
      "label": "is antagonist of"
    },
    {
      "source": "LY293558",
      "target": "compound",
      "label": "is a type of"
    },
    {
      "source": "LY293558",
      "target": "neuronal loss",
      "label": "prevented"
    },
    {
      "source": "pretreatment",
      "target": "real-case scenario",
      "label": "not possible in"
    },
    {
      "source": "pretreatment",
      "target": "rapid death",
      "label": "prevents"
    },
    {
      "source": "pretreatment",
      "target": "anticonvulsant compounds",
      "label": "enables testing of"
    },
    {
      "source": "pretreatment",
      "target": "cimetidine",
      "label": "with"
    },
    {
      "source": "real-case scenario",
      "target": "unexpected attack",
      "label": "involves"
    },
    {
      "source": "medication",
      "target": "pretreatment",
      "label": "is a type of"
    },
    {
      "source": "medication",
      "target": "breakfast",
      "label": "taken before"
    },
    {
      "source": "(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid",
      "target": "\u03b1-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid",
      "label": "is antagonist of"
    },
    {
      "source": "(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid",
      "target": "GluR5",
      "label": "is antagonist of"
    },
    {
      "source": "(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid",
      "target": "AMPA receptor",
      "label": "is antagonist of"
    },
    {
      "source": "(3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydroisoquinoline-3-carboxylic acid",
      "target": "GluK1",
      "label": "is antagonist of"
    },
    {
      "source": "rapid death",
      "target": "peripheral toxic effects",
      "label": "caused by"
    },
    {
      "source": "rapid death",
      "target": "respiratory failure",
      "label": "caused by"
    },
    {
      "source": "intramuscular administration",
      "target": "humans",
      "label": "is for"
    },
    {
      "source": "intramuscular administration",
      "target": "route of administration",
      "label": "is a type of"
    },
    {
      "source": "neuronal loss",
      "target": "hippocampus",
      "label": "occurred in"
    },
    {
      "source": "neuronal loss",
      "target": "amygdala",
      "label": "occurred in"
    },
    {
      "source": "seizures",
      "target": "pretreatment",
      "label": "control possible without"
    },
    {
      "source": "seizures",
      "target": "immediate pharmacologic intervention",
      "label": "control possible without"
    },
    {
      "source": "anticonvulsant efficacy",
      "target": "rats",
      "label": "studied in"
    },
    {
      "source": "unexpected attack",
      "target": "nerve agents",
      "label": "is with"
    },
    {
      "source": "seizure suppression",
      "target": "time course",
      "label": "has a"
    },
    {
      "source": "Analysis",
      "target": "LY293558 pharmacokinetics",
      "label": "performed on"
    },
    {
      "source": "LY293558 pharmacokinetics",
      "target": "intramuscular administration",
      "label": "studied after"
    },
    {
      "source": "medical assistance",
      "target": "real-case scenario",
      "label": "not immediately available in"
    },
    {
      "source": "Animal models",
      "target": "pretreatment",
      "label": "use"
    },
    {
      "source": "AMPA receptor",
      "target": "excitotoxicity",
      "label": "mediates"
    },
    {
      "source": "liquid chromatography/mass spectrometry/mass spectrometry",
      "target": "analysis",
      "label": "is a type of"
    },
    {
      "source": "identification",
      "target": "human UGT1A1",
      "label": "targets"
    },
    {
      "source": "identification",
      "target": "phenolic compounds",
      "label": "of"
    },
    {
      "source": "identification",
      "target": "phosphorylation",
      "label": "of"
    },
    {
      "source": "identification",
      "target": "12b",
      "label": "of"
    },
    {
      "source": "identification",
      "target": "12d",
      "label": "of"
    },
    {
      "source": "stable isotope-labels",
      "target": "amino acid",
      "label": "are in"
    },
    {
      "source": "LC-MS/MS",
      "target": "analysis",
      "label": "is a type of"
    },
    {
      "source": "peptide sequence",
      "target": "human peptide",
      "label": "is related to"
    },
    {
      "source": "mass",
      "target": "1753",
      "label": "increased from"
    },
    {
      "source": "mass",
      "target": "SIL peptide",
      "label": "is of"
    },
    {
      "source": "mass",
      "target": "1763",
      "label": "increased to"
    },
    {
      "source": "mass",
      "target": "10 amu",
      "label": "increased by"
    },
    {
      "source": "positive correlation",
      "target": "enzyme activity levels",
      "label": "is between"
    },
    {
      "source": "positive correlation",
      "target": "UGT1A1 content",
      "label": "is between"
    },
    {
      "source": "drug-metabolizing enzymes",
      "target": "conjugation",
      "label": "catalyse"
    },
    {
      "source": "drug-metabolizing enzymes",
      "target": "metabolism",
      "label": "essential for"
    },
    {
      "source": "UDP-glucuronosyltransferases",
      "target": "UGTs",
      "label": "are"
    },
    {
      "source": "UDP-glucuronosyltransferases",
      "target": "drug-metabolizing enzymes",
      "label": "are a type of"
    },
    {
      "source": "UGTs",
      "target": "drug-metabolizing enzymes",
      "label": "are a type of"
    },
    {
      "source": "commercial recombinant preparations",
      "target": "BD Biosciences",
      "label": "obtained from"
    },
    {
      "source": "commercial recombinant preparations",
      "target": "supersomes",
      "label": "are"
    },
    {
      "source": "hydrophilic glucuronides",
      "target": "excretion",
      "label": "undergo"
    },
    {
      "source": "(13)C6(15)N4",
      "target": "mass",
      "label": "causes increase in"
    },
    {
      "source": "quantitation",
      "target": "LC-MS",
      "label": "uses"
    },
    {
      "source": "quantitation",
      "target": "human UGT1A1",
      "label": "targets"
    },
    {
      "source": "quantitation",
      "target": "concentrations",
      "label": "uses"
    },
    {
      "source": "LC-MS",
      "target": "standard curve",
      "label": "produces"
    },
    {
      "source": "labelled peptide",
      "target": "UGT1A1",
      "label": "quantifies"
    },
    {
      "source": "UGT1A1",
      "target": "commercial recombinant preparations",
      "label": "is quantified in"
    },
    {
      "source": "UGT1A1",
      "target": "individual human liver microsomal samples",
      "label": "is quantified in"
    },
    {
      "source": "UGT1A1",
      "target": "pooled human liver microsomes",
      "label": "is quantified in"
    },
    {
      "source": "individual human liver microsomal samples",
      "target": "BD Biosciences",
      "label": "obtained from"
    },
    {
      "source": "liver microsomes",
      "target": "individual human donors",
      "label": "obtained from"
    },
    {
      "source": "residues 54-69",
      "target": "exon 1",
      "label": "are in"
    },
    {
      "source": "exon 1",
      "target": "human UGT1A1 protein",
      "label": "is part of"
    },
    {
      "source": "exon 1",
      "target": "androgen receptor gene",
      "label": "is part of"
    },
    {
      "source": "exon 1",
      "target": "HTRA1",
      "label": "part of"
    },
    {
      "source": "human UGT1A1 protein",
      "target": "sequence RIYLSADPALVVIEHG",
      "label": "has sequence"
    },
    {
      "source": "UGT1A1 content",
      "target": "liver microsomes",
      "label": "is in"
    },
    {
      "source": "human UGT1A1",
      "target": "complex biological matrices",
      "label": "is found in"
    },
    {
      "source": "stable isotope-labelled (SIL) peptide",
      "target": "unique peptide",
      "label": "is a type of"
    },
    {
      "source": "stable isotope-labelled (SIL) peptide",
      "target": "sequence RIYLSADPALVVIEHG",
      "label": "has sequence"
    },
    {
      "source": "unique peptide",
      "target": "residues 54-69",
      "label": "spans"
    },
    {
      "source": "Glucuronidation activity studies",
      "target": "positive correlation",
      "label": "demonstrated"
    },
    {
      "source": "supersomes",
      "target": "BD Biosciences",
      "label": "obtained from"
    },
    {
      "source": "pooled human liver microsomes",
      "target": "BD Biosciences",
      "label": "obtained from"
    },
    {
      "source": "precursor ion monitoring",
      "target": "UGT1A1",
      "label": "quantifies"
    },
    {
      "source": "selective COX-1 inhibitors",
      "target": "ulcerogenic effects",
      "label": "have"
    },
    {
      "source": "selective COX-1 inhibitors",
      "target": "ulcers",
      "label": "produced"
    },
    {
      "source": "selective COX-1 inhibitors",
      "target": "duodenum",
      "label": "produced ulcers in"
    },
    {
      "source": "selective COX-1 inhibitors",
      "target": "Gastrointestinal lesions",
      "label": "did not cause"
    },
    {
      "source": "ulcerogenic effects",
      "target": "gastrointestinal mucosa",
      "label": "on"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "arterioles",
      "label": "localized in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "goblet cells",
      "label": "localized in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "Brunner's gland cells",
      "label": "localized in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "protection",
      "label": "plays role in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "smooth muscle cells",
      "label": "localized in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "Auerbach's plexus",
      "label": "localized in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "Meissner's plexus",
      "label": "localized in"
    },
    {
      "source": "Cyclooxygenase (COX)-1",
      "target": "duodenal mucosa",
      "label": "plays role in protection of"
    },
    {
      "source": "feeding",
      "target": "expression",
      "label": "has effect on"
    },
    {
      "source": "feeding",
      "target": "level",
      "label": "has effect on"
    },
    {
      "source": "cimetidine",
      "target": "level",
      "label": "has effect on"
    },
    {
      "source": "cimetidine",
      "target": "effects",
      "label": "inhibited"
    },
    {
      "source": "cimetidine",
      "target": "expression",
      "label": "has effect on"
    },
    {
      "source": "level",
      "target": "enzyme immunoassay",
      "label": "examined by"
    },
    {
      "source": "level",
      "target": "duodenum",
      "label": "in"
    },
    {
      "source": "level",
      "target": "PGE(2)",
      "label": "of"
    },
    {
      "source": "level",
      "target": "protease-resistant PrP(Sc)",
      "label": "is of"
    },
    {
      "source": "localization",
      "target": "duodenum",
      "label": "in"
    },
    {
      "source": "localization",
      "target": "Western blot",
      "label": "examined by"
    },
    {
      "source": "localization",
      "target": "immunohistochemistry",
      "label": "examined by"
    },
    {
      "source": "localization",
      "target": "cyclooxygenase (COX) isoforms",
      "label": "of"
    },
    {
      "source": "ulcers",
      "target": "duodenum",
      "label": "occur in"
    },
    {
      "source": "cyclooxygenase (COX) isoforms",
      "target": "pathogenesis",
      "label": "role in"
    },
    {
      "source": "cyclooxygenase (COX) isoforms",
      "target": "duodenal ulcers",
      "label": "role in pathogenesis of"
    },
    {
      "source": "COX inhibitors",
      "target": "days",
      "label": "administered for"
    },
    {
      "source": "COX inhibitors",
      "target": "morning meal",
      "label": "administered after"
    },
    {
      "source": "Gastrointestinal lesions",
      "target": "small intestine",
      "label": "located in"
    },
    {
      "source": "Gastrointestinal lesions",
      "target": "day 4",
      "label": "examined on"
    },
    {
      "source": "SC-560",
      "target": "selective COX-1 inhibitors",
      "label": "is a type of"
    },
    {
      "source": "smooth muscle cells",
      "target": "blood vessels",
      "label": "are part of"
    },
    {
      "source": "nicotine group",
      "target": "chewing tobacco",
      "label": "received"
    },
    {
      "source": "nicotine group",
      "target": "training",
      "label": "showed improvements after"
    },
    {
      "source": "nicotine group",
      "target": "control group",
      "label": "showed more pronounced learning effects than"
    },
    {
      "source": "chewing tobacco",
      "target": "TDT training",
      "label": "received following"
    },
    {
      "source": "learning",
      "target": "early visual cortex",
      "label": "involved"
    },
    {
      "source": "learning effects",
      "target": "nicotine group",
      "label": "more pronounced in"
    },
    {
      "source": "Electroencephalographic recordings",
      "target": "alpha activity",
      "label": "showed reduced"
    },
    {
      "source": "Electroencephalographic recordings",
      "target": "P300 latencies",
      "label": "showed reduced"
    },
    {
      "source": "Electroencephalographic recordings",
      "target": "substance consumption",
      "label": "conducted during"
    },
    {
      "source": "alpha activity",
      "target": "nicotine group",
      "label": "reduced in"
    },
    {
      "source": "improvements",
      "target": "texture elements",
      "label": "specific to"
    },
    {
      "source": "improvements",
      "target": "retinal location",
      "label": "specific to"
    },
    {
      "source": "improvements",
      "target": "orientation",
      "label": "specific to"
    },
    {
      "source": "non-smoking men",
      "target": "visual texture discrimination task (TDT)",
      "label": "learned"
    },
    {
      "source": "group comparison",
      "target": "learning effects",
      "label": "showed"
    },
    {
      "source": "P300 latencies",
      "target": "nicotine group",
      "label": "reduced in"
    },
    {
      "source": "Nicotine",
      "target": "memory consolidation",
      "label": "facilitates"
    },
    {
      "source": "perceptual learning",
      "target": "non-declarative learning",
      "label": "is a type of"
    },
    {
      "source": "non-declarative learning",
      "target": "experience-dependent plasticity",
      "label": "involves"
    },
    {
      "source": "experience-dependent plasticity",
      "target": "sensory cortices",
      "label": "occurs in"
    },
    {
      "source": "dose-dependent cholinergic modulation",
      "target": "memory consolidation",
      "label": "of"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "protein ubiquitination",
      "label": "increased"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "20S proteasomal",
      "label": "increased"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "caspase 12 activity",
      "label": "increased"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "phosphorylation of elf2\u03b1",
      "label": "enhanced"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "expression of the endoplasmic reticulum (ER) stress marker CHOP",
      "label": "increased"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "SH-SY5Y cells",
      "label": "acts in"
    },
    {
      "source": "low L-BMAA concentrations",
      "target": "impairment of cellular protein homeostasis",
      "label": "result in"
    },
    {
      "source": "high-concentration effects",
      "target": "excitotoxicity",
      "label": "includes"
    },
    {
      "source": "high-concentration effects",
      "target": "oxidative stress",
      "label": "includes"
    },
    {
      "source": "onset and slow progression of ALS/PDC",
      "target": "Guam",
      "label": "occurs in"
    },
    {
      "source": "L-BMAA",
      "target": "caspase 12 cleavage",
      "label": "enhanced"
    },
    {
      "source": "L-BMAA",
      "target": "low-potency excitotoxin",
      "label": "is described as"
    },
    {
      "source": "L-BMAA",
      "target": "Parkinsonism-dementia complex (PDC)",
      "label": "is a factor in"
    },
    {
      "source": "L-BMAA",
      "target": "low nonexcitotoxic concentrations",
      "label": "acts at"
    },
    {
      "source": "L-BMAA",
      "target": "human neuroblastoma SH-SY5Y cells",
      "label": "acts in"
    },
    {
      "source": "L-BMAA",
      "target": "ER stress",
      "label": "induced"
    },
    {
      "source": "L-BMAA",
      "target": "amyotrophic lateral sclerosis (ALS)",
      "label": "is a factor in"
    },
    {
      "source": "L-BMAA",
      "target": "neurodegeneration",
      "label": "leads to"
    },
    {
      "source": "protein incorporation",
      "target": "(14)C-L-BMAA exposures",
      "label": "not detected in response to"
    },
    {
      "source": "L-BMAA-mediated cytotoxicity",
      "target": "L-BMAA treatment",
      "label": "observable following"
    },
    {
      "source": "high L-BMAA concentrations",
      "target": "reactive oxygen species",
      "label": "increased"
    },
    {
      "source": "high L-BMAA concentrations",
      "target": "protein oxidization",
      "label": "increased"
    },
    {
      "source": "reactive oxygen species",
      "target": "ROS",
      "label": "is also known as"
    },
    {
      "source": "L-BMAA-transport",
      "target": "human SH-SY5Y neuroblastoma cells",
      "label": "investigated in"
    },
    {
      "source": "impairment of cellular protein homeostasis",
      "target": "human SH-SY5Y neuroblastoma cells",
      "label": "investigated in"
    },
    {
      "source": "impairment of cellular protein homeostasis",
      "target": "ER stress",
      "label": "results in"
    },
    {
      "source": "Binding of L-BMAA to intracellular proteins",
      "target": "(14)C-L-BMAA exposures",
      "label": "detected in response to"
    },
    {
      "source": "ER stress",
      "target": "high-concentration effects",
      "label": "is independent from"
    },
    {
      "source": "cyanobacterial \u03b2-N-methylamino-L-alanine",
      "target": "L-BMAA",
      "label": "is"
    },
    {
      "source": "SH-SY5Y cells",
      "target": "apoptotic pathway",
      "label": "die via"
    },
    {
      "source": "L-BMAA concentrations",
      "target": "toxic effects",
      "label": "required for"
    },
    {
      "source": "toxic effects",
      "target": "food",
      "label": "occur via"
    },
    {
      "source": "toxic effects",
      "target": "concentrations",
      "label": "observed with"
    },
    {
      "source": "incorporation into proteins",
      "target": "human SH-SY5Y neuroblastoma cells",
      "label": "investigated in"
    },
    {
      "source": "shedding process",
      "target": "thiol isomerase",
      "label": "involves"
    },
    {
      "source": "shedding process",
      "target": "metalloprotease",
      "label": "mediated by"
    },
    {
      "source": "shedding process",
      "target": "AChE",
      "label": "of"
    },
    {
      "source": "subunit oligomerisation",
      "target": "BChE",
      "label": "shared by"
    },
    {
      "source": "subunit oligomerisation",
      "target": "AChE",
      "label": "of"
    },
    {
      "source": "subunit oligomerisation",
      "target": "butyrylcholinesterase",
      "label": "shared by"
    },
    {
      "source": "Cellular release",
      "target": "carbachol",
      "label": "enhanced by"
    },
    {
      "source": "Cellular release",
      "target": "AChE",
      "label": "of"
    },
    {
      "source": "Cellular release",
      "target": "SH-SY5Y",
      "label": "by"
    },
    {
      "source": "Cellular release",
      "target": "muscarine",
      "label": "enhanced by"
    },
    {
      "source": "carbachol",
      "target": "muscarinic acetylcholine receptor",
      "label": "Agonist"
    },
    {
      "source": "carbachol",
      "target": "agonists",
      "label": "is an"
    },
    {
      "source": "carbachol",
      "target": "AChE",
      "label": "Upregulator"
    },
    {
      "source": "carbachol",
      "target": "mAChR",
      "label": "Agonist"
    },
    {
      "source": "metalloprotease",
      "target": "batimastat",
      "label": "sensitive to"
    },
    {
      "source": "metalloprotease",
      "target": "EDTA",
      "label": "sensitive to"
    },
    {
      "source": "metalloprotease",
      "target": "GM6001",
      "label": "insensitive to"
    },
    {
      "source": "batimastat",
      "target": "AChE",
      "label": "Regulator"
    },
    {
      "source": "batimastat",
      "target": "metalloprotease",
      "label": "Regulator"
    },
    {
      "source": "amyloid fibrils",
      "target": "pathology",
      "label": "linked to"
    },
    {
      "source": "muscarine",
      "target": "AChE",
      "label": "Upregulator"
    },
    {
      "source": "muscarine",
      "target": "agonists",
      "label": "is an"
    },
    {
      "source": "muscarine",
      "target": "mAChR",
      "label": "Agonist"
    },
    {
      "source": "muscarine",
      "target": "muscarinic acetylcholine receptor",
      "label": "Agonist"
    },
    {
      "source": "membrane anchor",
      "target": "butyrylcholinesterase",
      "label": "shared by"
    },
    {
      "source": "membrane anchor",
      "target": "AChE",
      "label": "of"
    },
    {
      "source": "membrane anchor",
      "target": "BChE",
      "label": "shared by"
    },
    {
      "source": "physiological function",
      "target": "brain",
      "label": "located in"
    },
    {
      "source": "physiological function",
      "target": "BChE",
      "label": "of"
    },
    {
      "source": "physiology",
      "target": "BChE",
      "label": "of"
    },
    {
      "source": "physiology",
      "target": "AD research",
      "label": "benefits"
    },
    {
      "source": "physiology",
      "target": "AChE",
      "label": "of"
    },
    {
      "source": "anchorage",
      "target": "membrane",
      "label": "in"
    },
    {
      "source": "anchorage",
      "target": "Proline Rich Membrane Anchor",
      "label": "established via"
    },
    {
      "source": "anchorage",
      "target": "PRiMA",
      "label": "established via"
    },
    {
      "source": "hydrolytic enzyme",
      "target": "neurotransmitter",
      "label": "metabolizes"
    },
    {
      "source": "hydrolytic enzyme",
      "target": "acetylcholine",
      "label": "metabolizes"
    },
    {
      "source": "amyloid precursor protein",
      "target": "membrane proteins",
      "label": "is a type of"
    },
    {
      "source": "amyloid precursor protein",
      "target": "nuclear actions",
      "label": "has"
    },
    {
      "source": "amyloid precursor protein",
      "target": "synaptic actions",
      "label": "has"
    },
    {
      "source": "pathology",
      "target": "AD",
      "label": "of"
    },
    {
      "source": "Proline Rich Membrane Anchor",
      "target": "transmembrane protein",
      "label": "is a type of"
    },
    {
      "source": "non-catalytic functions",
      "target": "brain",
      "label": "located in"
    },
    {
      "source": "neuroblastoma cell lines SH-SY5Y",
      "target": "neuronal cell lines",
      "label": "is a type of"
    },
    {
      "source": "NB7",
      "target": "neuronal cell lines",
      "label": "is a type of"
    },
    {
      "source": "mouse basal forebrain cell line SN56",
      "target": "neuronal cell lines",
      "label": "is a type of"
    },
    {
      "source": "GM6001",
      "target": "metalloprotease",
      "label": "Not"
    },
    {
      "source": "PRiMA",
      "target": "transmembrane protein",
      "label": "is a type of"
    },
    {
      "source": "PPA",
      "target": "reciprocal regulation",
      "label": "affects"
    },
    {
      "source": "PPA",
      "target": "GP",
      "label": "increases"
    },
    {
      "source": "PPA",
      "target": "appetite suppression",
      "label": "mediates"
    },
    {
      "source": "PPA",
      "target": "CREB",
      "label": "increases"
    },
    {
      "source": "PPA",
      "target": "NPY",
      "label": "decreases"
    },
    {
      "source": "PPA",
      "target": "anorectic response",
      "label": "causes"
    },
    {
      "source": "PPA",
      "target": "antiobesity drugs",
      "label": "related to"
    },
    {
      "source": "PPA",
      "target": "Y1R",
      "label": "increases"
    },
    {
      "source": "reciprocal regulation",
      "target": "NPY",
      "label": "involves"
    },
    {
      "source": "reciprocal regulation",
      "target": "GP",
      "label": "involves"
    },
    {
      "source": "reciprocal regulation",
      "target": "hypothalamus",
      "label": "occurs in"
    },
    {
      "source": "reciprocal regulation",
      "target": "CREB",
      "label": "involves"
    },
    {
      "source": "antisense",
      "target": "Y1R",
      "label": "causes knockdown of"
    },
    {
      "source": "Y1R",
      "target": "anorectic response",
      "label": "modulates"
    },
    {
      "source": "Y1R",
      "target": "NPY",
      "label": "regulates"
    },
    {
      "source": "Y1R",
      "target": "GP",
      "label": "regulates"
    },
    {
      "source": "Y1R",
      "target": "reciprocal regulation",
      "label": "participates in"
    },
    {
      "source": "Y1R",
      "target": "CREB",
      "label": "regulates"
    },
    {
      "source": "Neuropeptide Y Y1 receptor",
      "target": "glutathione peroxidase",
      "label": "modifies"
    },
    {
      "source": "Neuropeptide Y Y1 receptor",
      "target": "c-AMP response element-binding protein",
      "label": "modifies"
    },
    {
      "source": "antioxidative enzymes",
      "target": "appetite suppression",
      "label": "involved in regulating"
    },
    {
      "source": "c-AMP response element-binding protein",
      "target": "appetite suppression",
      "label": "involved in regulating"
    },
    {
      "source": "3G-RSV",
      "target": "oxidative stress-induced cell death",
      "label": "did not mitigate"
    },
    {
      "source": "3G-RSV",
      "target": "piceid",
      "label": "is a"
    },
    {
      "source": "3G-RSV",
      "target": "histone H3 deacetylation",
      "label": "did not induce"
    },
    {
      "source": "3G-RSV",
      "target": "polydatin",
      "label": "is a"
    },
    {
      "source": "3G-RSV",
      "target": "SOD2 expression",
      "label": "did not induce"
    },
    {
      "source": "3G-RSV",
      "target": "RSV",
      "label": "has comparable antioxidant activity to"
    },
    {
      "source": "3G-RSV",
      "target": "SIRT1-dependent histone H3 deacetylation",
      "label": "did not induce"
    },
    {
      "source": "3G-RSV",
      "target": "cell death",
      "label": "did not mitigate"
    },
    {
      "source": "3G-RSV",
      "target": "C2C12 cell proliferation",
      "label": "did not inhibit"
    },
    {
      "source": "RSV",
      "target": "extracellular fractions",
      "label": "was found in"
    },
    {
      "source": "RSV",
      "target": "C2C12 cell proliferation",
      "label": "inhibited"
    },
    {
      "source": "RSV",
      "target": "NAD(+)-dependent protein deacetylase SIRT1",
      "label": "activates"
    },
    {
      "source": "RSV",
      "target": "cells",
      "label": "was taken up by"
    },
    {
      "source": "RSV",
      "target": "health",
      "label": "exerts beneficial effect on"
    },
    {
      "source": "RSV",
      "target": "intracellular fractions",
      "label": "was found in"
    },
    {
      "source": "RSV",
      "target": "SIRT1",
      "label": "activates"
    },
    {
      "source": "RSV",
      "target": "trans-3,5,4'-trihydroxystilbene",
      "label": "is a"
    },
    {
      "source": "RSV",
      "target": "diseases",
      "label": "exerts beneficial effect on"
    },
    {
      "source": "RSV",
      "target": "oxidative stress-induced cell death",
      "label": "mitigated"
    },
    {
      "source": "RSV",
      "target": "cell death",
      "label": "mitigated"
    },
    {
      "source": "RSV",
      "target": "natural polyphenol",
      "label": "is a"
    },
    {
      "source": "RSV",
      "target": "plants",
      "label": "is found in"
    },
    {
      "source": "RSV",
      "target": "glycosylated forms",
      "label": "exists as"
    },
    {
      "source": "4'G-RSV",
      "target": "histone H3 deacetylation",
      "label": "induced"
    },
    {
      "source": "4'G-RSV",
      "target": "cell death",
      "label": "mitigated"
    },
    {
      "source": "4'G-RSV",
      "target": "oxidative stress-induced cell death",
      "label": "mitigated"
    },
    {
      "source": "4'G-RSV",
      "target": "SOD2 expression",
      "label": "induced"
    },
    {
      "source": "4'G-RSV",
      "target": "water solubility",
      "label": "has high"
    },
    {
      "source": "4'G-RSV",
      "target": "RSV",
      "label": "was deglycosylated to"
    },
    {
      "source": "4'G-RSV",
      "target": "C2C12 cell proliferation",
      "label": "inhibited"
    },
    {
      "source": "4'G-RSV",
      "target": "RSV prodrug",
      "label": "is a useful"
    },
    {
      "source": "4'G-RSV",
      "target": "prodrug",
      "label": "is a"
    },
    {
      "source": "4'G-RSV",
      "target": "SIRT1-dependent histone H3 deacetylation",
      "label": "induced"
    },
    {
      "source": "C2C12 cells",
      "target": "3G-RSV",
      "label": "did not deglycosylate"
    },
    {
      "source": "SIRT1 knockdown",
      "target": "RSV",
      "label": "blunted effects of"
    },
    {
      "source": "SIRT1 knockdown",
      "target": "4'G-RSV",
      "label": "blunted effects of"
    },
    {
      "source": "SIRT1",
      "target": "intracellular antioxidative mechanism",
      "label": "induces"
    },
    {
      "source": "SIRT1",
      "target": "SOD2",
      "label": "induces"
    },
    {
      "source": "SIRT1",
      "target": "mitochondrial superoxide dismutase",
      "label": "induces"
    },
    {
      "source": "SIRT1",
      "target": "lysine residues",
      "label": "deacetylates"
    },
    {
      "source": "SIRT1",
      "target": "cardiomyocyte hypertrophy",
      "label": "inhibits"
    },
    {
      "source": "SIRT1",
      "target": "ubiquitin-proteasome pathway",
      "label": "acts via"
    },
    {
      "source": "SIRT1",
      "target": "p300 mRNA",
      "label": "does not down-regulate"
    },
    {
      "source": "SIRT1",
      "target": "p300 protein",
      "label": "down-regulates"
    },
    {
      "source": "SIRT1",
      "target": "dystrophic cardiomyopathy",
      "label": "has therapeutic potential for"
    },
    {
      "source": "SIRT1",
      "target": "atrial natriuretic peptide promoter",
      "label": "inhibits activation of"
    },
    {
      "source": "SIRT1",
      "target": "p300",
      "label": "induces down-regulation of"
    },
    {
      "source": "SIRT1",
      "target": "human autoimmunity",
      "label": "has role in"
    },
    {
      "source": "SIRT1",
      "target": "histone deacetylase",
      "label": "is a type of"
    },
    {
      "source": "SIRT1",
      "target": "age-related diseases",
      "label": "modulates"
    },
    {
      "source": "SIRT1",
      "target": "mRNA levels",
      "label": "has"
    },
    {
      "source": "SIRT1",
      "target": "protein levels",
      "label": "has"
    },
    {
      "source": "SIRT1",
      "target": "targets",
      "label": "is a"
    },
    {
      "source": "resveratrol-4'-O-\u03b2-d-glucoside",
      "target": "4'G-RSV",
      "label": "is a"
    },
    {
      "source": "cell-protective function",
      "target": "oxidative stress",
      "label": "is against"
    },
    {
      "source": "resveratrol",
      "target": "RSV",
      "label": "is a"
    },
    {
      "source": "resveratrol",
      "target": "trans-3,5,4'-trihydroxystilbene",
      "label": "is a"
    },
    {
      "source": "resveratrol",
      "target": "health",
      "label": "exerts beneficial effect on"
    },
    {
      "source": "resveratrol",
      "target": "natural polyphenol",
      "label": "is a"
    },
    {
      "source": "resveratrol",
      "target": "diseases",
      "label": "exerts beneficial effect on"
    },
    {
      "source": "resveratrol glucosides",
      "target": "cell-protective function",
      "label": "has"
    },
    {
      "source": "resveratrol-3-O-\u03b2-d-glucoside",
      "target": "3G-RSV",
      "label": "is a"
    },
    {
      "source": "in vitro antioxidative activity",
      "target": "oxidative stress-induced apoptosis",
      "label": "did not correlate with protection from"
    },
    {
      "source": "in vitro antioxidative activity",
      "target": "apoptosis",
      "label": "did not correlate with protection from"
    },
    {
      "source": "glycosylated forms",
      "target": "glycosyl RSVs",
      "label": "are"
    },
    {
      "source": "phenolic compounds",
      "target": "apple fruits",
      "label": "in"
    },
    {
      "source": "phenolic compounds",
      "target": "apple extracts",
      "label": "in"
    },
    {
      "source": "diode array and accurate mass spectrometry detection",
      "target": "electrospray ionisation (DAD/ESI-am-MS)",
      "label": "uses"
    },
    {
      "source": "mass accuracy",
      "target": "each selected phenolic compound",
      "label": "of"
    },
    {
      "source": "Instrumental parameters",
      "target": "resolution",
      "label": "include"
    },
    {
      "source": "Instrumental parameters",
      "target": "mass accuracy",
      "label": "include"
    },
    {
      "source": "Instrumental parameters",
      "target": "accurate mass measurements",
      "label": "optimised to establish"
    },
    {
      "source": "Instrumental parameters",
      "target": "scan speed",
      "label": "include"
    },
    {
      "source": "UHPLC-DAD/ESI-am-MS method",
      "target": "phenolic compounds",
      "label": "for determination of"
    },
    {
      "source": "mass spectrometric method",
      "target": "quantification",
      "label": "for"
    },
    {
      "source": "mass spectrometric method",
      "target": "identification",
      "label": "for"
    },
    {
      "source": "Thirty-nine phenolic compounds",
      "target": "ultra high performance liquid chromatography (UHPLC)",
      "label": "analysed using"
    },
    {
      "source": "ultra high performance liquid chromatography (UHPLC)",
      "target": "diode array and accurate mass spectrometry detection",
      "label": "coupled with"
    },
    {
      "source": "[(14)C]anagliptin",
      "target": "dipeptidyl peptidase-4",
      "label": "inhibits"
    },
    {
      "source": "[(14)C]anagliptin",
      "target": "dipeptidyl peptidase-4 inhibitor",
      "label": "is a"
    },
    {
      "source": "[(14)C]anagliptin",
      "target": "healthy men",
      "label": "administered to"
    },
    {
      "source": "fraction",
      "target": "dose",
      "label": "of"
    },
    {
      "source": "fraction",
      "target": "core protein",
      "label": "bound to"
    },
    {
      "source": "fraction",
      "target": "matrix metalloproteinase-9",
      "label": "of"
    },
    {
      "source": "fraction",
      "target": "chondroitin sulphate proteoglycan",
      "label": "bound to"
    },
    {
      "source": "fraction",
      "target": "reduction sensitive heteromer",
      "label": "is a"
    },
    {
      "source": "Renal clearance",
      "target": "glomerular filtration rate",
      "label": "exceeded"
    },
    {
      "source": "Renal clearance",
      "target": "unbound M1",
      "label": "of"
    },
    {
      "source": "Renal clearance",
      "target": "active renal elimination",
      "label": "indicates"
    },
    {
      "source": "Renal clearance",
      "target": "unbound anagliptin",
      "label": "of"
    },
    {
      "source": "anagliptin",
      "target": "MDR1",
      "label": "is a substrate of"
    },
    {
      "source": "anagliptin",
      "target": "MRP2",
      "label": "is a substrate of"
    },
    {
      "source": "anagliptin",
      "target": "OAT1",
      "label": "is a substrate of"
    },
    {
      "source": "anagliptin",
      "target": "metabolism",
      "label": "undergoes"
    },
    {
      "source": "anagliptin",
      "target": "dipeptidyl peptidase-4 inhibitor",
      "label": "is a"
    },
    {
      "source": "anagliptin",
      "target": "OAT3",
      "label": "is a substrate of"
    },
    {
      "source": "anagliptin",
      "target": "dipeptidyl peptidase-4",
      "label": "inhibits"
    },
    {
      "source": "unchanged drug",
      "target": "total plasma radioactivity area under the curve",
      "label": "accounts for"
    },
    {
      "source": "unchanged drug",
      "target": "plasma",
      "label": "found in"
    },
    {
      "source": "unchanged drug",
      "target": "urine",
      "label": "found in"
    },
    {
      "source": "unchanged drug",
      "target": "faeces",
      "label": "found in"
    },
    {
      "source": "unchanged drug",
      "target": "components",
      "label": "is a"
    },
    {
      "source": "FTY720",
      "target": "relapsing-remitting multiple sclerosis",
      "label": "is approved for treatment of"
    },
    {
      "source": "FTY720",
      "target": "Neuroprotection",
      "label": "is"
    },
    {
      "source": "FTY720",
      "target": "neuroinflammation",
      "label": "restrains"
    },
    {
      "source": "FTY720",
      "target": "neurons",
      "label": "protects"
    },
    {
      "source": "FTY720",
      "target": "excitotoxic death",
      "label": "protects against"
    },
    {
      "source": "FTY720",
      "target": "S1PRs",
      "label": "involves"
    },
    {
      "source": "FTY720",
      "target": "T lymphocytes",
      "label": "reduces egress of"
    },
    {
      "source": "FTY720",
      "target": "sphingosine-1-phosphate receptor",
      "label": "Upregulator"
    },
    {
      "source": "FTY720",
      "target": "S1PR",
      "label": "Upregulator"
    },
    {
      "source": "FTY720",
      "target": "pure cultures of mouse cortical neurons",
      "label": "retains protective activity in"
    },
    {
      "source": "FTY720",
      "target": "NMDA pulse",
      "label": "applied prior to"
    },
    {
      "source": "FTY720",
      "target": "autoimmunity",
      "label": "restrains"
    },
    {
      "source": "FTY720",
      "target": "rat cortical neurons",
      "label": "retains protective activity in"
    },
    {
      "source": "FTY720",
      "target": "neuronal viability",
      "label": "has effect on"
    },
    {
      "source": "FTY720",
      "target": "secondary lymphoid organs",
      "label": "reduces egress from"
    },
    {
      "source": "FTY720-P",
      "target": "rat cortical neurons",
      "label": "retains protective activity in"
    },
    {
      "source": "FTY720-P",
      "target": "neuronal viability",
      "label": "has effect on"
    },
    {
      "source": "FTY720-P",
      "target": "active metabolite",
      "label": "is"
    },
    {
      "source": "FTY720-P",
      "target": "Neuroprotection",
      "label": "is"
    },
    {
      "source": "FTY720-P",
      "target": "pure cultures of mouse cortical neurons",
      "label": "retains protective activity in"
    },
    {
      "source": "FTY720-P",
      "target": "NMDA pulse",
      "label": "applied prior to"
    },
    {
      "source": "in vitro model",
      "target": "neuronal death",
      "label": "is model of"
    },
    {
      "source": "in vitro model",
      "target": "excitotoxic death",
      "label": "is model of"
    },
    {
      "source": "Mixed cultures of mouse cortical cells",
      "target": "N-methyl-d-aspartate",
      "label": "challenged with"
    },
    {
      "source": "Mixed cultures of mouse cortical cells",
      "target": "NMDA",
      "label": "challenged with"
    },
    {
      "source": "N-methyl-d-aspartate",
      "target": "neuronal death",
      "label": "causes"
    },
    {
      "source": "Fingolimod",
      "target": "cultured cortical neurons",
      "label": "protects"
    },
    {
      "source": "Fingolimod",
      "target": "relapsing-remitting multiple sclerosis",
      "label": "is approved for treatment of"
    },
    {
      "source": "Fingolimod",
      "target": "excitotoxic death",
      "label": "protects against"
    },
    {
      "source": "Fingolimod",
      "target": "sphingosine-1-phosphate receptor",
      "label": "Upregulator"
    },
    {
      "source": "Fingolimod",
      "target": "S1PR",
      "label": "Upregulator"
    },
    {
      "source": "S1P",
      "target": "Neuroprotection",
      "label": "is"
    },
    {
      "source": "S1P",
      "target": "NMDA pulse",
      "label": "applied prior to"
    },
    {
      "source": "S1P",
      "target": "neuronal viability",
      "label": "has effect on"
    },
    {
      "source": "S1PRs",
      "target": "neurons",
      "label": "expressed by"
    },
    {
      "source": "S1PRs",
      "target": "cells resident in the CNS",
      "label": "expressed by"
    },
    {
      "source": "pathways",
      "target": "activities",
      "label": "modulate"
    },
    {
      "source": "W146",
      "target": "type-1 S1PR",
      "label": "Antagonist"
    },
    {
      "source": "W146",
      "target": "S1P1R",
      "label": "Antagonist"
    },
    {
      "source": "W146",
      "target": "antagonist",
      "label": "is"
    },
    {
      "source": "W146",
      "target": "Neuroprotection",
      "label": "inhibits"
    },
    {
      "source": "MAPK",
      "target": "signaling pathways",
      "label": "play role in"
    },
    {
      "source": "sphingosine-1-phosphate",
      "target": "neuronal viability",
      "label": "has effect on"
    },
    {
      "source": "short therapeutic hexapeptide",
      "target": "His-(D-Trp)-Ala-Trp-(D-Phe)-Lys-NH(2,)",
      "label": "is"
    },
    {
      "source": "short therapeutic hexapeptide",
      "target": "MW=872.44 Da",
      "label": "has"
    },
    {
      "source": "Lower Limit of Quantification",
      "target": "pharmacokinetic profile",
      "label": "sufficient for modeling"
    },
    {
      "source": "Lower Limit of Quantification",
      "target": "subjects",
      "label": "reached in"
    },
    {
      "source": "Lower Limit of Quantification",
      "target": "12h",
      "label": "reached at"
    },
    {
      "source": "Lower Limit of Quantification",
      "target": "5 ng/mL",
      "label": "is"
    },
    {
      "source": "single intravenous bolus administration",
      "target": "100, 200 and 400 \u03bcg/kg of body weight",
      "label": "of"
    },
    {
      "source": "100, 200 and 400 \u03bcg/kg of body weight",
      "target": "body weight",
      "label": "is based on"
    },
    {
      "source": "Disposition",
      "target": "GHRP-6",
      "label": "of"
    },
    {
      "source": "Disposition",
      "target": "Akaike index (AIC)",
      "label": "confirmed by"
    },
    {
      "source": "Disposition",
      "target": "bi-exponential function",
      "label": "fitted"
    },
    {
      "source": "Disposition",
      "target": "model",
      "label": "fits"
    },
    {
      "source": "Disposition",
      "target": "mathematic modeling",
      "label": "determined by"
    },
    {
      "source": "GHRP-6",
      "target": "tissue viability",
      "label": "enhances"
    },
    {
      "source": "GHRP-6",
      "target": "specific LC-MS method",
      "label": "quantified by"
    },
    {
      "source": "GHRP-6",
      "target": "human plasma",
      "label": "quantified in"
    },
    {
      "source": "GHRP-6",
      "target": "growth hormone secretagogue",
      "label": "is a"
    },
    {
      "source": "(13)C(3)Ala-GHRP-6",
      "target": "internal standard",
      "label": "is an"
    },
    {
      "source": "tissue viability",
      "target": "organs",
      "label": "occurs in"
    },
    {
      "source": "elimination half-life",
      "target": "GHRP-6",
      "label": "of"
    },
    {
      "source": "elimination half-life",
      "target": "2.5 \u00b1 1.1h",
      "label": "was"
    },
    {
      "source": "elimination half-life",
      "target": "active metabolite",
      "label": "is of"
    },
    {
      "source": "distribution half-life",
      "target": "7.6 \u00b1 1.9 min",
      "label": "was"
    },
    {
      "source": "distribution half-life",
      "target": "GHRP-6",
      "label": "of"
    },
    {
      "source": "Pharmacokinetic study",
      "target": "nine male healthy volunteers",
      "label": "conducted in"
    },
    {
      "source": "Pharmacokinetic study",
      "target": "GHRP-6",
      "label": "is a study of"
    },
    {
      "source": "Pharmacokinetic study",
      "target": "Growth Hormone-Releasing Peptide 6",
      "label": "is a study of"
    },
    {
      "source": "values",
      "target": "data",
      "label": "are coherent with"
    },
    {
      "source": "values",
      "target": "RAA 129%",
      "label": "for \u03b2-CLAMS are"
    },
    {
      "source": "values",
      "target": "79.95 \u03bcmol AAE/g DW",
      "label": "for FRAP are"
    },
    {
      "source": "values",
      "target": "1544 \u03bcmol TE/g DW",
      "label": "for ORAC are"
    },
    {
      "source": "values",
      "target": "4513 \u03bcmol TE/g DW",
      "label": "for PCL are"
    },
    {
      "source": "specific LC-MS method",
      "target": "(13)C(3)Ala-GHRP-6",
      "label": "used"
    },
    {
      "source": "specific LC-MS method",
      "target": "FDA guidelines",
      "label": "validated following"
    },
    {
      "source": "specific LC-MS method",
      "target": "Gil et al., 2012, J. Pharm. Biomed. Anal. 60, 19-25",
      "label": "developed by"
    },
    {
      "source": "Akaike index (AIC)",
      "target": "one-compartment model",
      "label": "is lower than that of"
    },
    {
      "source": "one-compartment model",
      "target": "subjects",
      "label": "applies to"
    },
    {
      "source": "bi-exponential function",
      "target": "R(2)",
      "label": "has"
    },
    {
      "source": "R(2)",
      "target": "0.99",
      "label": "is higher than"
    },
    {
      "source": "Atypical GHRP-6 concentration spikes",
      "target": "four out of the nine subjects",
      "label": "observed in"
    },
    {
      "source": "Atypical GHRP-6 concentration spikes",
      "target": "elimination phase",
      "label": "observed during"
    },
    {
      "source": "Dose dependence analysis",
      "target": "Area under the Curve (AUC)",
      "label": "revealed trend for"
    },
    {
      "source": "85%",
      "target": "Area under the Curve (AUC)",
      "label": "is of"
    },
    {
      "source": "growth hormone secretagogue",
      "target": "growth hormone",
      "label": "secretes"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "oral glucose tolerance",
      "label": "improved"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "insulin sensitivity",
      "label": "improved"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "glucose tolerance",
      "label": "improved"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "circulating glucose",
      "label": "reduced"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "insulin",
      "label": "reduced"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "triacylglycerol accumulation",
      "label": "prevented effect of high fat feeding on"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "beneficial effects",
      "label": "resulted in"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "high fat mice",
      "label": "causes beneficial metabolic effects in"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "energy intake",
      "label": "reduced"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "circulating insulin",
      "label": "reduced"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "metabolic effects",
      "label": "causes beneficial"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "intraperitoneal glucose tolerance",
      "label": "improved"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "LDL-cholesterol",
      "label": "reduced"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "treatment",
      "label": "has potential for"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "diet-induced obesity-diabetes",
      "label": "counters development of"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "pancreatic glucagon content",
      "label": "elevated"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "body weight",
      "label": "reduced"
    },
    {
      "source": "(pGlu-Gln)-CCK-8",
      "target": "ob/ob mice",
      "label": "causes beneficial metabolic effects in"
    },
    {
      "source": "(pGlu-Gln)-CCK-8 mice",
      "target": "islet number",
      "label": "revealed no changes in"
    },
    {
      "source": "(pGlu-Gln)-CCK-8 mice",
      "target": "alpha-cells",
      "label": "showed increased numbers of"
    },
    {
      "source": "(pGlu-Gln)-CCK-8 mice",
      "target": "beta-cells",
      "label": "showed increased turnover of"
    },
    {
      "source": "(pGlu-Gln)-CCK-8 mice",
      "target": "islet size",
      "label": "revealed no changes in"
    },
    {
      "source": "glucose tolerance",
      "target": "lean controls",
      "label": "similar to"
    },
    {
      "source": "alpha-cells",
      "target": "GLP-1",
      "label": "co-express"
    },
    {
      "source": "alpha-cells",
      "target": "glucagon",
      "label": "co-express"
    },
    {
      "source": "triacylglycerol accumulation",
      "target": "muscle",
      "label": "occurs in"
    },
    {
      "source": "triacylglycerol accumulation",
      "target": "liver",
      "label": "occurs in"
    },
    {
      "source": "circulating insulin",
      "target": "lean controls",
      "label": "similar to"
    },
    {
      "source": "energy intake",
      "target": "lean controls",
      "label": "similar to"
    },
    {
      "source": "metabolic effects",
      "target": "normoxic stabilization",
      "label": "require"
    },
    {
      "source": "metabolic effects",
      "target": "GR(dim/dim) mice",
      "label": "are exaggerated in"
    },
    {
      "source": "metabolic effects",
      "target": "adipose tissue",
      "label": "are exaggerated in"
    },
    {
      "source": "metabolic effects",
      "target": "GC treatment",
      "label": "are of"
    },
    {
      "source": "cholecystokinin receptor",
      "target": "genetic ob/ob mice",
      "label": "has beneficial effects in"
    },
    {
      "source": "cholecystokinin receptor",
      "target": "obesity-diabetes",
      "label": "protects against"
    },
    {
      "source": "calcium chelator",
      "target": "potentiation",
      "label": "blocks"
    },
    {
      "source": "calcium chelator",
      "target": "1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid",
      "label": "is a type of"
    },
    {
      "source": "potentiation",
      "target": "KARs",
      "label": "affects"
    },
    {
      "source": "potentiation",
      "target": "blockade",
      "label": "by"
    },
    {
      "source": "group I metabotropic glutamate receptors",
      "target": "agonist potency",
      "label": "does not change"
    },
    {
      "source": "group I metabotropic glutamate receptors",
      "target": "calcium signal",
      "label": "potentiates"
    },
    {
      "source": "group I metabotropic glutamate receptors",
      "target": "heteromeric KAR-mediated currents",
      "label": "potentiates"
    },
    {
      "source": "group I metabotropic glutamate receptors",
      "target": "homomeric KAR-mediated currents",
      "label": "does not potentiate"
    },
    {
      "source": "group I metabotropic glutamate receptors",
      "target": "heteromeric kainate receptors",
      "label": "potentiates"
    },
    {
      "source": "Ser836",
      "target": "GluK5 C-terminal domain",
      "label": "Part_of"
    },
    {
      "source": "Ser836",
      "target": "serines",
      "label": "is a type of"
    },
    {
      "source": "Ser836",
      "target": "membrane proximal region",
      "label": "located within"
    },
    {
      "source": "serines",
      "target": "GluK5 C-terminal domain",
      "label": "Part_of"
    },
    {
      "source": "serines",
      "target": "potentiation",
      "label": "required for"
    },
    {
      "source": "Ser840",
      "target": "serines",
      "label": "Part_of"
    },
    {
      "source": "Ser840",
      "target": "membrane proximal region",
      "label": "located within"
    },
    {
      "source": "Ser840",
      "target": "GluK5 C-terminal domain",
      "label": "Part_of"
    },
    {
      "source": "Protein kinase C",
      "target": "PKC",
      "label": "also known as"
    },
    {
      "source": "mGlu1",
      "target": "potentiation",
      "label": "causes"
    },
    {
      "source": "mGlu1",
      "target": "GluK5",
      "label": "causes potentiation of"
    },
    {
      "source": "mGlu1",
      "target": "GluK2",
      "label": "causes potentiation of"
    },
    {
      "source": "inhibitor of phospholipase C",
      "target": "potentiation",
      "label": "blocks"
    },
    {
      "source": "inhibitor of phospholipase C",
      "target": "phospholipase C",
      "label": "inhibits"
    },
    {
      "source": "phorbol 12-myristate,13-acetate",
      "target": "GluK5",
      "label": "potentiates"
    },
    {
      "source": "phorbol 12-myristate,13-acetate",
      "target": "PKC",
      "label": "activates"
    },
    {
      "source": "phorbol 12-myristate,13-acetate",
      "target": "GluK2",
      "label": "potentiates"
    },
    {
      "source": "1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid",
      "target": "BAPTA",
      "label": "also known as"
    },
    {
      "source": "high-affinity KAR subunits",
      "target": "group I metabotropic glutamate receptors",
      "label": "colocalizes with"
    },
    {
      "source": "native KARs",
      "target": "calcium signal",
      "label": "causes"
    },
    {
      "source": "membrane proximal region",
      "target": "GluK5 C-terminal domain",
      "label": "part of"
    },
    {
      "source": "Ser833",
      "target": "serines",
      "label": "Part_of"
    },
    {
      "source": "Ser833",
      "target": "membrane proximal region",
      "label": "located within"
    },
    {
      "source": "Ser833",
      "target": "GluK5 C-terminal domain",
      "label": "Part_of"
    },
    {
      "source": "BAPTA",
      "target": "calcium chelator",
      "label": "is a type of"
    },
    {
      "source": "okadaic acid",
      "target": "phosphatase inhibitor",
      "label": "is a type of"
    },
    {
      "source": "okadaic acid",
      "target": "NE",
      "label": "prolonged effect of"
    },
    {
      "source": "phosphatase inhibitor",
      "target": "potentiation",
      "label": "prolongs"
    },
    {
      "source": "overall charge",
      "target": "C-terminal domain",
      "label": "of"
    },
    {
      "source": "Confocal immunohistochemistry",
      "target": "cultured rat cortex",
      "label": "used to study"
    },
    {
      "source": "Confocal immunohistochemistry",
      "target": "rat hippocampus",
      "label": "used to study"
    },
    {
      "source": "mGlu modulation",
      "target": "KARs",
      "label": "affects"
    },
    {
      "source": "lavendustin A",
      "target": "tyrosine kinase inhibitor",
      "label": "is a type of"
    },
    {
      "source": "Kainate receptors",
      "target": "ionotropic glutamate receptors",
      "label": "is a type of"
    },
    {
      "source": "GDP\u03b2S",
      "target": "potentiation",
      "label": "attenuates"
    },
    {
      "source": "CAG repeat length",
      "target": "receptor activity",
      "label": "modifies effect on"
    },
    {
      "source": "CAG repeat length",
      "target": "2,3,7,8-tetrachlorodibenzo-p-dioxin",
      "label": "modifies effect of"
    },
    {
      "source": "receptor activity",
      "target": "human prostate cells",
      "label": "occurs in"
    },
    {
      "source": "TCDD",
      "target": "PC-3",
      "label": "influences"
    },
    {
      "source": "TCDD",
      "target": "AR activity",
      "label": "has CAG length dependent effect on"
    },
    {
      "source": "TCDD",
      "target": "AhR",
      "label": "acts through"
    },
    {
      "source": "TCDD",
      "target": "prostate cancer cells",
      "label": "influences"
    },
    {
      "source": "TCDD",
      "target": "cell-specific effect",
      "label": "has a"
    },
    {
      "source": "TCDD",
      "target": "CYP1A1 mRNA expression",
      "label": "induces"
    },
    {
      "source": "TCDD",
      "target": "aryl hydrocarbon receptor",
      "label": "acts through"
    },
    {
      "source": "TCDD",
      "target": "shortest AR variant",
      "label": "induces"
    },
    {
      "source": "TCDD",
      "target": "non-tumor prostate cells",
      "label": "influences"
    },
    {
      "source": "TCDD",
      "target": "PNT1A",
      "label": "influences"
    },
    {
      "source": "TCDD",
      "target": "tyrosine phosphorylation",
      "label": "interfered with"
    },
    {
      "source": "TCDD",
      "target": "insulin-like growth factor binding protein 4",
      "label": "induces"
    },
    {
      "source": "TCDD",
      "target": "ERK",
      "label": "inhibited activation of"
    },
    {
      "source": "TCDD",
      "target": "eukaryotic translation initiation factor 4E-binding protein 1",
      "label": "prevented activation of"
    },
    {
      "source": "TCDD",
      "target": "AKT",
      "label": "inhibited activation of"
    },
    {
      "source": "TCDD",
      "target": "STAT3 activation",
      "label": "stimulates"
    },
    {
      "source": "TCDD",
      "target": "c-Src",
      "label": "increases phosphorylation of"
    },
    {
      "source": "TCDD",
      "target": "prototypical AhR ligand",
      "label": "is a"
    },
    {
      "source": "2,3,7,8-tetrachlorodibenzo-p-dioxin",
      "target": "receptor activity",
      "label": "affects"
    },
    {
      "source": "2,3,7,8-tetrachlorodibenzo-p-dioxin",
      "target": "TCDD",
      "label": "is"
    },
    {
      "source": "2,3,7,8-tetrachlorodibenzo-p-dioxin",
      "target": "prototypical AhR ligand",
      "label": "is a"
    },
    {
      "source": "AR activity",
      "target": "PNT1A",
      "label": "occurs in"
    },
    {
      "source": "AR activity",
      "target": "PC-3",
      "label": "occurs in"
    },
    {
      "source": "CAG repeats",
      "target": "normal length range",
      "label": "are within"
    },
    {
      "source": "polymorphic CAG repeat",
      "target": "transcriptional activity",
      "label": "influences"
    },
    {
      "source": "AhR",
      "target": "androgen receptor (AR)",
      "label": "interacts with"
    },
    {
      "source": "cell-specific effect",
      "target": "AR activity",
      "label": "is on"
    },
    {
      "source": "aryl hydrocarbon receptor",
      "target": "androgen receptor (AR)",
      "label": "interacts with"
    },
    {
      "source": "5\u03b1-dihydrotestosterone",
      "target": "ARs",
      "label": "activates"
    },
    {
      "source": "ARs",
      "target": "CAG repeats",
      "label": "contain"
    },
    {
      "source": "shortest AR variant",
      "target": "PNT1A",
      "label": "is in"
    },
    {
      "source": "CYP1A1 mRNA expression",
      "target": "AhR target gene",
      "label": "is a type of"
    },
    {
      "source": "AR CAG length",
      "target": "CYP1A1 mRNA expression",
      "label": "does not affect"
    },
    {
      "source": "AR gene",
      "target": "polymorphic CAG repeat",
      "label": "contains"
    },
    {
      "source": "epigenetic mechanism",
      "target": "anti-neoplastic activity",
      "label": "underlies"
    },
    {
      "source": "epigenetic mechanism",
      "target": "clinical success",
      "label": "explains"
    },
    {
      "source": "anti-neoplastic activity",
      "target": "farnesyl-transferase-inhibition",
      "label": "is caused by"
    },
    {
      "source": "RAS-GTPase",
      "target": "gene family",
      "label": "is a member of"
    },
    {
      "source": "RAS-GTPase",
      "target": "epigenetic DNA-methylation",
      "label": "acts via"
    },
    {
      "source": "RAS-GTPase",
      "target": "FAS-expression",
      "label": "down-regulates"
    },
    {
      "source": "Ibandronate",
      "target": "posttranslational isoprenylation",
      "label": "prevents"
    },
    {
      "source": "Ibandronate",
      "target": "inhibiting their activity",
      "label": "causes"
    },
    {
      "source": "Ibandronate",
      "target": "epigenetic mechanisms",
      "label": "acts via"
    },
    {
      "source": "Ibandronate",
      "target": "DNMT1",
      "label": "does not affect"
    },
    {
      "source": "Ibandronate",
      "target": "FAS-expression",
      "label": "does not affect"
    },
    {
      "source": "Ibandronate",
      "target": "small GTPases",
      "label": "inhibits"
    },
    {
      "source": "Ibandronate",
      "target": "cell proliferation",
      "label": "attenuates"
    },
    {
      "source": "Ibandronate",
      "target": "anticancer activity",
      "label": "show"
    },
    {
      "source": "Ibandronate",
      "target": "MC3T3-E1 non-neoplastic cells",
      "label": "does not affect"
    },
    {
      "source": "Ibandronate",
      "target": "tumor cells",
      "label": "acts on"
    },
    {
      "source": "aminobisphosphonates",
      "target": "small GTPases",
      "label": "inhibits"
    },
    {
      "source": "aminobisphosphonates",
      "target": "anticancer activity",
      "label": "show"
    },
    {
      "source": "aminobisphosphonates",
      "target": "posttranslational isoprenylation",
      "label": "prevents"
    },
    {
      "source": "aminobisphosphonates",
      "target": "inhibiting their activity",
      "label": "causes"
    },
    {
      "source": "bisphosphonates",
      "target": "neoplastic cells",
      "label": "acts on"
    },
    {
      "source": "bisphosphonates",
      "target": "DNA-CpG-demethylation",
      "label": "acts by"
    },
    {
      "source": "bisphosphonates",
      "target": "apoptosis",
      "label": "induce"
    },
    {
      "source": "bisphosphonates",
      "target": "modulation of the activity of small-GTPases",
      "label": "acts via"
    },
    {
      "source": "bisphosphonates",
      "target": "stimulation of FAS-expression",
      "label": "acts by"
    },
    {
      "source": "down-regulation of DNMT1",
      "target": "epigenetic DNA demethylation",
      "label": "causes"
    },
    {
      "source": "epigenetic DNA demethylation",
      "target": "stimulation of FAS-expression",
      "label": "causes"
    },
    {
      "source": "up-regulation of caspases",
      "target": "apoptosis",
      "label": "suggests"
    },
    {
      "source": "anticancer activity",
      "target": "polysaccharide",
      "label": "of"
    },
    {
      "source": "anticancer activity",
      "target": "cisplatin",
      "label": "comparable to"
    },
    {
      "source": "anticancer activity",
      "target": "cell lines",
      "label": "against"
    },
    {
      "source": "re-isoprenylation",
      "target": "down-regulation of DNMT1",
      "label": "rescues"
    },
    {
      "source": "geranylgeranyl-pyrophosphate",
      "target": "re-isoprenylation",
      "label": "causes"
    },
    {
      "source": "farnesylpyrophosphate",
      "target": "re-isoprenylation",
      "label": "causes"
    },
    {
      "source": "siRNA vector",
      "target": "cationic liposome",
      "label": "contains"
    },
    {
      "source": "siRNA vector",
      "target": "anionic polymer",
      "label": "contains"
    },
    {
      "source": "siRNA vector",
      "target": "genes",
      "label": "silences"
    },
    {
      "source": "siRNA vector",
      "target": "siRNA molecule",
      "label": "contains"
    },
    {
      "source": "cationic liposome",
      "target": "particles",
      "label": "forms"
    },
    {
      "source": "cationic liposome",
      "target": "siRNA molecule",
      "label": "auto-associates with"
    },
    {
      "source": "siRNA lipoplexes-induced toxicity",
      "target": "cell line",
      "label": "is dependent on"
    },
    {
      "source": "anionic polymer",
      "target": "toxic effects",
      "label": "impacts"
    },
    {
      "source": "anionic polymer",
      "target": "polypeptide",
      "label": "can be"
    },
    {
      "source": "anionic polymer",
      "target": "nucleic acid",
      "label": "can be"
    },
    {
      "source": "anionic polymer",
      "target": "siRNA lipoplexes efficiency",
      "label": "enhances"
    },
    {
      "source": "anionic polymer",
      "target": "polysaccharide",
      "label": "can be"
    },
    {
      "source": "anionic polymer",
      "target": "siRNA delivery system",
      "label": "is part of"
    },
    {
      "source": "particles",
      "target": "lipoplexes",
      "label": "are called"
    },
    {
      "source": "plasmid-containing lipoplexes",
      "target": "toxicity",
      "label": "induces"
    },
    {
      "source": "polyglutamate",
      "target": "polyglutamate-containing ones",
      "label": "is contained in"
    },
    {
      "source": "polyglutamate",
      "target": "in vivo toxicity",
      "label": "reduces"
    },
    {
      "source": "polyglutamate",
      "target": "elevation",
      "label": "reduced"
    },
    {
      "source": "polyglutamate",
      "target": "anionic polymer",
      "label": "is a"
    },
    {
      "source": "polyglutamate",
      "target": "siRNA lipoplexes efficiency",
      "label": "enhances"
    },
    {
      "source": "polyglutamate",
      "target": "in vitro toxicity",
      "label": "reduces"
    },
    {
      "source": "plasmid DNA-containing siRNA lipoplexes",
      "target": "polyglutamate-containing ones",
      "label": "are more toxic than"
    },
    {
      "source": "plasmid DNA-containing siRNA lipoplexes",
      "target": "cationic liposomes",
      "label": "are more toxic than"
    },
    {
      "source": "siRNA-lipoplexes",
      "target": "toxic effects",
      "label": "induces"
    },
    {
      "source": "plasmid DNA",
      "target": "plasmid DNA-containing siRNA lipoplexes",
      "label": "is contained in"
    },
    {
      "source": "plasmid DNA",
      "target": "elevation",
      "label": "causes"
    },
    {
      "source": "cell survival capacity",
      "target": "generations",
      "label": "lasts for"
    },
    {
      "source": "Systemic injection",
      "target": "siRNA-lipoplexes",
      "label": "of"
    },
    {
      "source": "Systemic injection",
      "target": "production",
      "label": "triggered"
    },
    {
      "source": "Systemic injection",
      "target": "mice",
      "label": "to"
    },
    {
      "source": "elevation",
      "target": "assayed cytokines",
      "label": "of"
    },
    {
      "source": "tumoral cell lines",
      "target": "siRNA lipoplexes-induced toxicity",
      "label": "are more sensitive to"
    },
    {
      "source": "polysaccharide",
      "target": "Cyclocarya paliurus leaves",
      "label": "from"
    },
    {
      "source": "treated cells",
      "target": "death",
      "label": "underwent"
    },
    {
      "source": "glucose-6-phosphatase",
      "target": "key enzymes",
      "label": "is a"
    },
    {
      "source": "glucose-6-phosphatase",
      "target": "liver",
      "label": "increased in"
    },
    {
      "source": "glucose-6-phosphatase",
      "target": "carbohydrate metabolism",
      "label": "involved in"
    },
    {
      "source": "glucose-6-phosphatase",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "key enzymes",
      "target": "carbohydrate metabolism",
      "label": "involved in"
    },
    {
      "source": "key enzymes",
      "target": "activation",
      "label": "participate in"
    },
    {
      "source": "key enzymes",
      "target": "degradation",
      "label": "participate in"
    },
    {
      "source": "alkaline phosphatase",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "alkaline phosphatase",
      "target": "hepatic enzymes",
      "label": "is a"
    },
    {
      "source": "alkaline phosphatase",
      "target": "ALP",
      "label": "is"
    },
    {
      "source": "hexokinase",
      "target": "diabetic rats",
      "label": "decreased in"
    },
    {
      "source": "hexokinase",
      "target": "key enzymes",
      "label": "is a"
    },
    {
      "source": "hexokinase",
      "target": "liver",
      "label": "decreased in"
    },
    {
      "source": "glibenclamide",
      "target": "diabetic rats",
      "label": "prevented alterations in"
    },
    {
      "source": "asiatic acid",
      "target": "key enzymes",
      "label": "attenuates activity of"
    },
    {
      "source": "asiatic acid",
      "target": "pentacyclic triterpene",
      "label": "is a"
    },
    {
      "source": "asiatic acid",
      "target": "AA",
      "label": "is"
    },
    {
      "source": "fructose-1,6-bisphosphatase",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "fructose-1,6-bisphosphatase",
      "target": "carbohydrate metabolism",
      "label": "involved in"
    },
    {
      "source": "fructose-1,6-bisphosphatase",
      "target": "liver",
      "label": "increased in"
    },
    {
      "source": "fructose-1,6-bisphosphatase",
      "target": "key enzymes",
      "label": "is a"
    },
    {
      "source": "pyruvate kinase",
      "target": "diabetic rats",
      "label": "decreased in"
    },
    {
      "source": "pyruvate kinase",
      "target": "liver",
      "label": "decreased in"
    },
    {
      "source": "pyruvate kinase",
      "target": "key enzymes",
      "label": "is a"
    },
    {
      "source": "hepatic enzymes",
      "target": "carbohydrate metabolism",
      "label": "involved in"
    },
    {
      "source": "anti-inflammatory activities",
      "target": "legume fractions",
      "label": "is a property of"
    },
    {
      "source": "glucose-6-phosphate dehydrogenase",
      "target": "key enzymes",
      "label": "is a"
    },
    {
      "source": "glucose-6-phosphate dehydrogenase",
      "target": "liver",
      "label": "decreased in"
    },
    {
      "source": "glucose-6-phosphate dehydrogenase",
      "target": "diabetic rats",
      "label": "decreased in"
    },
    {
      "source": "body weight loss",
      "target": "diabetic rats",
      "label": "observed in"
    },
    {
      "source": "key regulatory enzymes",
      "target": "diabetic rats",
      "label": "in"
    },
    {
      "source": "aspartate transaminase",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "aspartate transaminase",
      "target": "AST",
      "label": "is"
    },
    {
      "source": "aspartate transaminase",
      "target": "hepatic enzymes",
      "label": "is a"
    },
    {
      "source": "ALP",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "ALP",
      "target": "serum",
      "label": "MEASURED_IN"
    },
    {
      "source": "ALP",
      "target": "Serum markers of liver damage",
      "label": "IS_A"
    },
    {
      "source": "antioxidant activities",
      "target": "total polyphenols content",
      "label": "correlated positively to"
    },
    {
      "source": "antioxidant activities",
      "target": "reducing power (RP)",
      "label": "measured using"
    },
    {
      "source": "antioxidant activities",
      "target": "phenolic contents",
      "label": "is related to"
    },
    {
      "source": "antioxidant activities",
      "target": "legume fractions",
      "label": "is a property of"
    },
    {
      "source": "antioxidant activities",
      "target": "antiradical activity (DPPH)",
      "label": "measured using"
    },
    {
      "source": "antioxidant activities",
      "target": "oxygen radical absorbance capacity (ORAC)",
      "label": "measured using"
    },
    {
      "source": "triterpenoid derivative",
      "target": "Centella asiatica",
      "label": "derivative of"
    },
    {
      "source": "alanine transaminase",
      "target": "diabetic rats",
      "label": "increased in"
    },
    {
      "source": "alanine transaminase",
      "target": "ALT",
      "label": "is"
    },
    {
      "source": "alanine transaminase",
      "target": "hepatic enzymes",
      "label": "is a"
    },
    {
      "source": "ER\u03b1 cistromes",
      "target": "MCF-7 breast cancer cells",
      "label": "are from"
    },
    {
      "source": "proto-oncogene PIM-1",
      "target": "ER\u03b1 targets",
      "label": "is a"
    },
    {
      "source": "proto-oncogene PIM-1",
      "target": "target gene",
      "label": "is a"
    },
    {
      "source": "estrogens",
      "target": "breast cancer cell proliferation",
      "label": "contribute to"
    },
    {
      "source": "estrogens",
      "target": "carcinogenesis",
      "label": "contribute to"
    },
    {
      "source": "ER\u03b1-regulated enhancers",
      "target": "PIM-1",
      "label": "mediate induction of"
    },
    {
      "source": "ER\u03b1-regulated enhancers",
      "target": "gene",
      "label": "are located upstream from"
    },
    {
      "source": "PIM-1",
      "target": "growth-promoting role",
      "label": "has a"
    },
    {
      "source": "PIM-1",
      "target": "ER\u03b1 target gene",
      "label": "is an"
    },
    {
      "source": "PIM-1",
      "target": "MCF-7 cells",
      "label": "attenuated proliferation of"
    },
    {
      "source": "PIM-1",
      "target": "CDKN2B expression",
      "label": "up-regulated"
    },
    {
      "source": "PIM-1",
      "target": "cyclin-dependent protein kinase inhibitor CDKN1A",
      "label": "up-regulated"
    },
    {
      "source": "PIM-1",
      "target": "proliferation",
      "label": "attenuated"
    },
    {
      "source": "PIM-1 expression",
      "target": "invasive breast tumors",
      "label": "is elevated in"
    },
    {
      "source": "PIM-1 expression",
      "target": "malignancy",
      "label": "is associated with"
    },
    {
      "source": "PIM-1 expression",
      "target": "higher tumor grade",
      "label": "is associated with"
    },
    {
      "source": "estradiol",
      "target": "PIM-1",
      "label": "induces expression of"
    },
    {
      "source": "estradiol",
      "target": "MCF-7 cells",
      "label": "induces expression in"
    },
    {
      "source": "estradiol",
      "target": "progesterone receptors",
      "label": "induces"
    },
    {
      "source": "Proto-oncogene PIM-1",
      "target": "estrogen receptor",
      "label": "is a target of"
    },
    {
      "source": "Proto-oncogene PIM-1",
      "target": "breast tumors",
      "label": "associates with"
    },
    {
      "source": "MCF-7 cells",
      "target": "polypeptide hormones",
      "label": "stimulated by"
    },
    {
      "source": "series of substituted N-[3-(3-methoxyphenyl)propyl] amides",
      "target": "FLIPR high-throughput screening assay",
      "label": "evaluated by"
    },
    {
      "source": "series of substituted N-[3-(3-methoxyphenyl)propyl] amides",
      "target": "pharmacological potencies",
      "label": "have"
    },
    {
      "source": "extremely potent MT(2)-selective ligands",
      "target": "invaluable tools",
      "label": "represent"
    },
    {
      "source": "extremely potent MT(2)-selective ligands",
      "target": "ERK phosphorylation",
      "label": "induced"
    },
    {
      "source": "extremely potent MT(2)-selective ligands",
      "target": "cross-reactivity",
      "label": "showed no"
    },
    {
      "source": "extremely potent MT(2)-selective ligands",
      "target": "drug development",
      "label": "are candidates for"
    },
    {
      "source": "invaluable tools",
      "target": "functional roles",
      "label": "are for delineating"
    },
    {
      "source": "two subtypes of mammalian G protein-coupled melatonin receptors",
      "target": "melatonin",
      "label": "mediate actions of"
    },
    {
      "source": "melatonin",
      "target": "inhibition of forskolin-elevated cAMP",
      "label": "causes"
    },
    {
      "source": "melatonin",
      "target": "elevation of [Ca(2+)]i",
      "label": "causes"
    },
    {
      "source": "pharmacological potencies",
      "target": "human melatonin MT(2) receptors",
      "label": "are towards"
    },
    {
      "source": "pharmacological potencies",
      "target": "human melatonin MT(1) receptors",
      "label": "are towards"
    },
    {
      "source": "therapeutic potentials",
      "target": "insomnia",
      "label": "include"
    },
    {
      "source": "therapeutic potentials",
      "target": "circadian-related sleep disorders",
      "label": "include"
    },
    {
      "source": "functional roles",
      "target": "distinct melatonin receptor subtypes",
      "label": "are of"
    },
    {
      "source": "synthetic melatonin agonists",
      "target": "insomnia",
      "label": "modulate"
    },
    {
      "source": "synthetic melatonin agonists",
      "target": "therapeutic potentials",
      "label": "have"
    },
    {
      "source": "synthetic melatonin agonists",
      "target": "circadian-related sleep disorders",
      "label": "modulate"
    },
    {
      "source": "17 other GPCRs",
      "target": "GPCRs",
      "label": "are a type of"
    },
    {
      "source": "substituted phenylpropylamides",
      "target": "melatonin MT2 receptor",
      "label": "act as agonists at"
    },
    {
      "source": "2q",
      "target": "most potent subtype-selective ligand",
      "label": "is a"
    },
    {
      "source": "2q",
      "target": "MT(2) receptor",
      "label": "has higher potency for"
    },
    {
      "source": "2q",
      "target": "inhibition of forskolin-elevated cAMP",
      "label": "causes"
    },
    {
      "source": "2q",
      "target": "elevation of [Ca(2+)]i",
      "label": "causes"
    },
    {
      "source": "2q",
      "target": "melatonin",
      "label": "has higher potency than"
    },
    {
      "source": "cross-reactivity",
      "target": "17 other GPCRs",
      "label": "to"
    },
    {
      "source": "Melatonin",
      "target": "major physiological processes",
      "label": "regulates"
    },
    {
      "source": "Melatonin",
      "target": "seasonal adaptation",
      "label": "regulates"
    },
    {
      "source": "Melatonin",
      "target": "circadian rhythm",
      "label": "regulates"
    },
    {
      "source": "Melatonin",
      "target": "hormone",
      "label": "is a"
    },
    {
      "source": "Melatonin",
      "target": "reproductive processes",
      "label": "regulates"
    },
    {
      "source": "Melatonin",
      "target": "estradiol",
      "label": "has opposite effects on"
    },
    {
      "source": "Melatonin",
      "target": "key role",
      "label": "plays"
    },
    {
      "source": "Melatonin",
      "target": "E2",
      "label": "decreased"
    },
    {
      "source": "Melatonin",
      "target": "6-sulfatoxymelatonin",
      "label": "increased"
    },
    {
      "source": "Melatonin",
      "target": "progesterone",
      "label": "increased"
    },
    {
      "source": "Melatonin",
      "target": "6-STM",
      "label": "increased"
    },
    {
      "source": "Melatonin",
      "target": "P4",
      "label": "increased"
    },
    {
      "source": "Melatonin",
      "target": "sex steroid receptors",
      "label": "regulates"
    },
    {
      "source": "major physiological processes",
      "target": "seasonal adaptation",
      "label": "include"
    },
    {
      "source": "major physiological processes",
      "target": "circadian rhythm",
      "label": "include"
    },
    {
      "source": "ERK phosphorylation",
      "target": "recombinant cell lines",
      "label": "occurs in"
    },
    {
      "source": "ERK phosphorylation",
      "target": "native cell lines",
      "label": "occurs in"
    },
    {
      "source": "structural moieties",
      "target": "extremely potent MT(2)-selective ligands",
      "label": "produced"
    },
    {
      "source": "structural moieties",
      "target": "subtype-selectivity",
      "label": "confer"
    },
    {
      "source": "benzyloxyl substituent",
      "target": "C6 position",
      "label": "incorporated at"
    },
    {
      "source": "benzyloxyl substituent",
      "target": "MT(1) potency",
      "label": "decreased"
    },
    {
      "source": "benzyloxyl substituent",
      "target": "MT(2) potency",
      "label": "enhanced"
    },
    {
      "source": "C6 position",
      "target": "3-methoxyphenyl ring",
      "label": "is part of"
    },
    {
      "source": "highly potent subtype-selective ligands",
      "target": "MT(2) EC(50)",
      "label": "have"
    },
    {
      "source": "subtype-selective melatoninergic compounds",
      "target": "drug development",
      "label": "are desirable for"
    },
    {
      "source": "subtype-selectivity",
      "target": "cAMP assays",
      "label": "verified with"
    },
    {
      "source": "subtype-selectivity",
      "target": "ERK phosphorylation",
      "label": "verified with"
    },
    {
      "source": "mammalian G protein-coupled melatonin receptors",
      "target": "two subtypes of mammalian G protein-coupled melatonin receptors",
      "label": "consist of"
    },
    {
      "source": "mammalian G protein-coupled melatonin receptors",
      "target": "melatonin receptors",
      "label": "are a type of"
    },
    {
      "source": "Structure-activity relationship analysis",
      "target": "highly potent subtype-selective ligands",
      "label": "analyzed"
    },
    {
      "source": "Airway epithelial cells",
      "target": "pathogens",
      "label": "play role against"
    },
    {
      "source": "cell accumulation",
      "target": "G(0)/G(1) phase",
      "label": "within"
    },
    {
      "source": "trypan blue-exclusion assay",
      "target": "cell number",
      "label": "observed"
    },
    {
      "source": "cell number",
      "target": "proliferation assays",
      "label": "is a type of"
    },
    {
      "source": "flow cytometric analysis",
      "target": "cell accumulation",
      "label": "noted"
    },
    {
      "source": "flow cytometric analysis",
      "target": "late apoptosis",
      "label": "noted"
    },
    {
      "source": "flow cytometric analysis",
      "target": "G(0)/G(1) phase",
      "label": "noted"
    },
    {
      "source": "p21 protein stability",
      "target": "proteasomal proteolytic pathway",
      "label": "via"
    },
    {
      "source": "p21",
      "target": "protection",
      "label": "conferred"
    },
    {
      "source": "experimental study",
      "target": "oxytocin administration",
      "label": "is on effect of"
    },
    {
      "source": "experimental study",
      "target": "neural processing",
      "label": "is on effect of"
    },
    {
      "source": "experimental study",
      "target": "48 female undergraduate students",
      "label": "conducted with"
    },
    {
      "source": "experimental study",
      "target": "event-related potentials (ERPs)",
      "label": "uses"
    },
    {
      "source": "experimental study",
      "target": "female participants",
      "label": "conducted with"
    },
    {
      "source": "experimental study",
      "target": "acute paraquat poisoning",
      "label": "investigates"
    },
    {
      "source": "experimental study",
      "target": "rat model",
      "label": "uses"
    },
    {
      "source": "oxytocin administration",
      "target": "neural processing",
      "label": "affects"
    },
    {
      "source": "oxytocin administration",
      "target": "event-related potential (ERP) responses",
      "label": "has impact on"
    },
    {
      "source": "processing",
      "target": "emotional faces",
      "label": "is of"
    },
    {
      "source": "processing",
      "target": "happy and disgusted faces",
      "label": "is of"
    },
    {
      "source": "processing",
      "target": "PC",
      "label": "by"
    },
    {
      "source": "processing",
      "target": "FSAP",
      "label": "by"
    },
    {
      "source": "oxytocin",
      "target": "attention",
      "label": "increased"
    },
    {
      "source": "oxytocin",
      "target": "processing",
      "label": "heightened"
    },
    {
      "source": "oxytocin",
      "target": "milk let-down reflex",
      "label": "involved_in"
    },
    {
      "source": "oxytocin",
      "target": "neuronal processes",
      "label": "attenuates"
    },
    {
      "source": "oxytocin",
      "target": "psychostimulant effects",
      "label": "has_modulatory_role_in"
    },
    {
      "source": "oxytocin",
      "target": "medicine",
      "label": "has_role_in"
    },
    {
      "source": "oxytocin",
      "target": "novel intervention",
      "label": "is_a"
    },
    {
      "source": "oxytocin",
      "target": "treatment",
      "label": "investigated_as"
    },
    {
      "source": "oxytocin",
      "target": "parturition",
      "label": "involved_in"
    },
    {
      "source": "oxytocin",
      "target": "polypeptide",
      "label": "is_a"
    },
    {
      "source": "oxytocin",
      "target": "behavioral processes",
      "label": "has_role_in"
    },
    {
      "source": "oxytocin",
      "target": "induced behaviors",
      "label": "attenuates"
    },
    {
      "source": "oxytocin",
      "target": "physiological activity",
      "label": "has"
    },
    {
      "source": "oxytocin",
      "target": "psychological phenomena",
      "label": "implicated_in"
    },
    {
      "source": "attention",
      "target": "feedback stimuli",
      "label": "is to"
    },
    {
      "source": "pictures",
      "target": "emotional facial expressions",
      "label": "combine"
    },
    {
      "source": "pictures",
      "target": "performance feedback",
      "label": "combine"
    },
    {
      "source": "allocation of attention",
      "target": "disgusted face",
      "label": "is toward"
    },
    {
      "source": "allocation of attention",
      "target": "negative feedback",
      "label": "is toward"
    },
    {
      "source": "neural processing",
      "target": "facial stimuli",
      "label": "is of"
    },
    {
      "source": "amplitudes",
      "target": "oxytocin",
      "label": "were more positive after"
    },
    {
      "source": "amplitudes",
      "target": "placebo administration",
      "label": "were compared to"
    },
    {
      "source": "negative feedback",
      "target": "disgusted face",
      "label": "is combined with"
    },
    {
      "source": "double-blind, placebo-controlled within-subjects design",
      "target": "16 IU of intranasal oxytocin",
      "label": "was used to study effects of"
    },
    {
      "source": "16 IU of intranasal oxytocin",
      "target": "ERPs",
      "label": "has effects on"
    },
    {
      "source": "event-related potential (ERP) responses",
      "target": "performance feedback",
      "label": "are with"
    },
    {
      "source": "event-related potential (ERP) responses",
      "target": "emotional faces",
      "label": "are to"
    },
    {
      "source": "maternal love withdrawal",
      "target": "allocation of attention",
      "label": "relates to"
    },
    {
      "source": "maternal love withdrawal",
      "target": "event-related potential (ERP) responses",
      "label": "has impact on"
    },
    {
      "source": "Significant associations",
      "target": "LPP amplitude",
      "label": "are with"
    },
    {
      "source": "ERPs",
      "target": "pictures",
      "label": "are to"
    },
    {
      "source": "Participants",
      "target": "love withdrawal",
      "label": "reported on"
    },
    {
      "source": "Participants",
      "target": "Web-based assessments",
      "label": "completed"
    },
    {
      "source": "love withdrawal",
      "target": "mothers",
      "label": "experienced from"
    },
    {
      "source": "ganglion cells",
      "target": "mouse retina preparation",
      "label": "are from"
    },
    {
      "source": "(S)-3,4-dicarboxyphenylglycine",
      "target": "DCPG",
      "label": "is also known as"
    },
    {
      "source": "(S)-3,4-dicarboxyphenylglycine",
      "target": "orthosteric agonist",
      "label": "is an"
    },
    {
      "source": "DCPG",
      "target": "excitatory currents",
      "label": "reduced"
    },
    {
      "source": "DCPG",
      "target": "orthosteric agonist",
      "label": "is an"
    },
    {
      "source": "glutamate release sites",
      "target": "VGLUT1",
      "label": "are immuno-labeled with"
    },
    {
      "source": "inhibitory currents",
      "target": "ganglion cells",
      "label": "are of"
    },
    {
      "source": "allosteric compounds",
      "target": "light responses",
      "label": "modulates"
    },
    {
      "source": "allosteric compounds",
      "target": "metabotropic glutamate receptor 8",
      "label": "are compounds of"
    },
    {
      "source": "light responses",
      "target": "AZ",
      "label": "have sensitivity to"
    },
    {
      "source": "light responses",
      "target": "retinal ganglion cell",
      "label": "are of"
    },
    {
      "source": "light responses",
      "target": "ganglion cells",
      "label": "are of"
    },
    {
      "source": "light responses",
      "target": "DCPG",
      "label": "have sensitivity to"
    },
    {
      "source": "peak excitatory currents",
      "target": "ON-ganglion cells",
      "label": "are in"
    },
    {
      "source": "peak excitatory currents",
      "target": "ON-OFF-ganglion cells",
      "label": "are in"
    },
    {
      "source": "peak excitatory currents",
      "target": "OFF-ganglion cell",
      "label": "are in"
    },
    {
      "source": "AZ",
      "target": "peak excitatory currents",
      "label": "enhanced"
    },
    {
      "source": "AZ",
      "target": "positive allosteric modulator",
      "label": "is a"
    },
    {
      "source": "synaptic responses",
      "target": "retinal ganglion cell",
      "label": "are of"
    },
    {
      "source": "orthosteric compounds",
      "target": "metabotropic glutamate receptor 8",
      "label": "are compounds of"
    },
    {
      "source": "orthosteric compounds",
      "target": "light responses",
      "label": "modulates"
    },
    {
      "source": "excitatory currents",
      "target": "OFF-ganglion cell",
      "label": "are of"
    },
    {
      "source": "allosteric modulator",
      "target": "bright stimuli",
      "label": "has stronger effects for"
    },
    {
      "source": "allosteric modulator",
      "target": "dim stimuli",
      "label": "has weaker effects for"
    },
    {
      "source": "receptor stimulation",
      "target": "bright light stimulation",
      "label": "is stronger during"
    },
    {
      "source": "receptor stimulation",
      "target": "endogenous glutamate",
      "label": "is by"
    },
    {
      "source": "whole-cell voltage-clamped ganglion cells",
      "target": "isolated, superfused mouse retina preparation",
      "label": "are from"
    },
    {
      "source": "orthosteric agonist",
      "target": "mGluR8",
      "label": "is specific to"
    },
    {
      "source": "positive allosteric modulator",
      "target": "mGluR8",
      "label": "modulates"
    },
    {
      "source": "AZ12216052",
      "target": "positive allosteric modulator",
      "label": "is a"
    },
    {
      "source": "AZ12216052",
      "target": "AZ",
      "label": "is also known as"
    },
    {
      "source": "Helenalin",
      "target": "sesquiterpene lactone",
      "label": "is a type of"
    },
    {
      "source": "Helenalin",
      "target": "anti-inflammatory activities",
      "label": "exhibits"
    },
    {
      "source": "Helenalin",
      "target": "apoptosis",
      "label": "increased"
    },
    {
      "source": "Helenalin",
      "target": "anti-tumor activities",
      "label": "exhibits"
    },
    {
      "source": "Helenalin",
      "target": "intracellular reactive oxygen species",
      "label": "increased production of"
    },
    {
      "source": "carcinoma cells",
      "target": "HCT116 cells",
      "label": "includes"
    },
    {
      "source": "carcinoma cells",
      "target": "human renal carcinoma ACHN cells",
      "label": "includes"
    },
    {
      "source": "carcinoma cells",
      "target": "human colon carcinoma HT29",
      "label": "includes"
    },
    {
      "source": "HCT116 cells",
      "target": "carcinoma cells",
      "label": "is a type of"
    },
    {
      "source": "regulated in development and DNA damage responses (REDD) 1",
      "target": "REDD) 1",
      "label": "is also known as"
    },
    {
      "source": "ROS scavengers",
      "target": "glutathione ethyl ester",
      "label": "includes"
    },
    {
      "source": "ROS scavengers",
      "target": "GEE",
      "label": "includes"
    },
    {
      "source": "ROS scavengers",
      "target": "NAC",
      "label": "includes"
    },
    {
      "source": "ROS scavengers",
      "target": "N-acetylcystine",
      "label": "includes"
    },
    {
      "source": "glutathione ethyl ester",
      "target": "apoptosis",
      "label": "reduced"
    },
    {
      "source": "glutathione ethyl ester",
      "target": "GEE",
      "label": "is also known as"
    },
    {
      "source": "N-acetylcystine",
      "target": "apoptosis",
      "label": "reduced"
    },
    {
      "source": "N-acetylcystine",
      "target": "NAC",
      "label": "is also known as"
    },
    {
      "source": "Caki cells",
      "target": "renal cell carcinoma",
      "label": "is a type of"
    },
    {
      "source": "endoplasmic reticulum (ER) stress-related genes",
      "target": "CHOP",
      "label": "includes"
    },
    {
      "source": "endoplasmic reticulum (ER) stress-related genes",
      "target": "regulated in development and DNA damage responses (REDD) 1",
      "label": "includes"
    },
    {
      "source": "endoplasmic reticulum (ER) stress-related genes",
      "target": "activating transcription factor-4",
      "label": "includes"
    },
    {
      "source": "endoplasmic reticulum (ER) stress-related genes",
      "target": "ATF4",
      "label": "includes"
    },
    {
      "source": "endoplasmic reticulum (ER) stress-related genes",
      "target": "CCAAT enhancer-binding protein-homologous protein",
      "label": "includes"
    },
    {
      "source": "CHOP",
      "target": "apoptosis",
      "label": "had no effect on"
    },
    {
      "source": "siRNA",
      "target": "CHOP",
      "label": "down-regulates"
    },
    {
      "source": "siRNA",
      "target": "ATF4",
      "label": "down-regulates"
    },
    {
      "source": "siRNA",
      "target": "p38 knockdown",
      "label": "causes"
    },
    {
      "source": "siRNA",
      "target": "growth inhibition",
      "label": "enhances"
    },
    {
      "source": "siRNA",
      "target": "ERCC1",
      "label": "inhibits"
    },
    {
      "source": "siRNA",
      "target": "cytotoxic effect",
      "label": "enhances"
    },
    {
      "source": "siRNA",
      "target": "clinic",
      "label": "has application in"
    },
    {
      "source": "siRNA",
      "target": "cytoplasm",
      "label": "released to"
    },
    {
      "source": "siRNA",
      "target": "toxicity",
      "label": "causes no"
    },
    {
      "source": "siRNA",
      "target": "mRNA expression",
      "label": "reduces"
    },
    {
      "source": "siRNA",
      "target": "AtuFECT01",
      "label": "delivered by"
    },
    {
      "source": "siRNA",
      "target": "drug-drug interactions",
      "label": "facilitates characterization of"
    },
    {
      "source": "siRNA",
      "target": "novel lipid",
      "label": "delivered by"
    },
    {
      "source": "siRNA",
      "target": "OATP1B1",
      "label": "assesses contribution of"
    },
    {
      "source": "siRNA",
      "target": "fed and fasted simulated colonic fluids",
      "label": "remained stable in"
    },
    {
      "source": "siRNA",
      "target": "CD nanocomplexes",
      "label": "is in"
    },
    {
      "source": "NAC",
      "target": "apoptosis",
      "label": "reduced"
    },
    {
      "source": "NAC",
      "target": "p-p38",
      "label": "suppressed"
    },
    {
      "source": "NAC",
      "target": "p-JNK",
      "label": "suppressed"
    },
    {
      "source": "NAC",
      "target": "ERK1/2 kinase",
      "label": "promoted effect on"
    },
    {
      "source": "NAC",
      "target": "ISO",
      "label": "failed to reverse effects of"
    },
    {
      "source": "NAC",
      "target": "phosphorylations",
      "label": "inhibits"
    },
    {
      "source": "NAC",
      "target": "AT1R expression",
      "label": "prevents"
    },
    {
      "source": "NAC",
      "target": "protective activity",
      "label": "HAS"
    },
    {
      "source": "NAC",
      "target": "organosulfur compound",
      "label": "IS_A"
    },
    {
      "source": "NAC",
      "target": "LPO",
      "label": "Downregulator"
    },
    {
      "source": "NAC",
      "target": "Bilirubin",
      "label": "Downregulator"
    },
    {
      "source": "NAC",
      "target": "experimental chronic hepatotoxicity models",
      "label": "AFFECTS"
    },
    {
      "source": "NAC",
      "target": "GPx",
      "label": "Upregulator"
    },
    {
      "source": "NAC",
      "target": "ALP",
      "label": "Downregulator"
    },
    {
      "source": "NAC",
      "target": "AST",
      "label": "Downregulator"
    },
    {
      "source": "NAC",
      "target": "GSH",
      "label": "Upregulator"
    },
    {
      "source": "NAC",
      "target": "model",
      "label": "VALIDATED_AS"
    },
    {
      "source": "NAC",
      "target": "ALT",
      "label": "Downregulator"
    },
    {
      "source": "NAC",
      "target": "CAT",
      "label": "Upregulator"
    },
    {
      "source": "NAC",
      "target": "hepatic prefibrogenic events",
      "label": "AFFECTS"
    },
    {
      "source": "helenalin",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "helenalin",
      "target": "endoplasmic reticulum (ER) stress-related genes",
      "label": "induced"
    },
    {
      "source": "CCAAT enhancer-binding protein-homologous protein",
      "target": "CHOP",
      "label": "is also known as"
    },
    {
      "source": "activating transcription factor-4",
      "target": "ATF4",
      "label": "is also known as"
    },
    {
      "source": "GEE",
      "target": "apoptosis",
      "label": "reduced"
    },
    {
      "source": "ACHN cells",
      "target": "carcinoma cells",
      "label": "is a type of"
    },
    {
      "source": "HT29",
      "target": "carcinoma cells",
      "label": "is a type of"
    },
    {
      "source": "ATF4",
      "target": "apoptosis",
      "label": "had no effect on"
    },
    {
      "source": "ATF4",
      "target": "genes",
      "label": "regulates"
    },
    {
      "source": "ATF4",
      "target": "ISR",
      "label": "is an effector of"
    },
    {
      "source": "ATF4",
      "target": "transcription factor",
      "label": "is a type of"
    },
    {
      "source": "ATF4",
      "target": "Transcription Factors",
      "label": "is a"
    },
    {
      "source": "ATF4",
      "target": "GSH levels",
      "label": "cooperates to increase"
    },
    {
      "source": "ATF4",
      "target": "GSH metabolism",
      "label": "plays critical role in"
    },
    {
      "source": "ROS",
      "target": "intracellular reactive oxygen species",
      "label": "is also known as"
    },
    {
      "source": "ROS",
      "target": "upstream signaling molecules",
      "label": "is a type of"
    },
    {
      "source": "ROS",
      "target": "MAPK singaling pathway",
      "label": "activates"
    },
    {
      "source": "ROS",
      "target": "RBC disruption",
      "label": "induces"
    },
    {
      "source": "ROS",
      "target": "Fe(2+) ion",
      "label": "induces"
    },
    {
      "source": "CREB activation",
      "target": "memory consolidation",
      "label": "not found following"
    },
    {
      "source": "CREB activation",
      "target": "retrieval",
      "label": "not found after"
    },
    {
      "source": "CREB activation",
      "target": "memory retrieval",
      "label": "found following"
    },
    {
      "source": "CREB activation",
      "target": "memory reconsolidation",
      "label": "not found following"
    },
    {
      "source": "CREB activation",
      "target": "hippocampus",
      "label": "occurs in"
    },
    {
      "source": "CREB activation",
      "target": "prefrontal cortex",
      "label": "occurs in"
    },
    {
      "source": "CREB activation",
      "target": "reconsolidation",
      "label": "not found after"
    },
    {
      "source": "CREB activation",
      "target": "METH-treated mouse groups",
      "label": "observed in"
    },
    {
      "source": "ERK activation",
      "target": "reconsolidation",
      "label": "not found after"
    },
    {
      "source": "ERK activation",
      "target": "METH-treated mouse groups",
      "label": "observed in"
    },
    {
      "source": "ERK activation",
      "target": "retrieval",
      "label": "not found after"
    },
    {
      "source": "ERK activation",
      "target": "memory consolidation",
      "label": "not found following"
    },
    {
      "source": "ERK activation",
      "target": "memory retrieval",
      "label": "found following"
    },
    {
      "source": "ERK activation",
      "target": "memory reconsolidation",
      "label": "not found following"
    },
    {
      "source": "ERK activation",
      "target": "hippocampus",
      "label": "occurs in"
    },
    {
      "source": "ERK activation",
      "target": "prefrontal cortex",
      "label": "occurs in"
    },
    {
      "source": "ERK and CREB signaling pathway",
      "target": "hippocampus",
      "label": "located in"
    },
    {
      "source": "ERK and CREB signaling pathway",
      "target": "METH-induced spatial memory changes",
      "label": "involved in"
    },
    {
      "source": "neuroplastic changes",
      "target": "memory",
      "label": "associated with"
    },
    {
      "source": "neuroplastic changes",
      "target": "learning",
      "label": "associated with"
    },
    {
      "source": "1.0 mg/kg dose of METH",
      "target": "spatial memory reconsolidation",
      "label": "had no effect on"
    },
    {
      "source": "1.0 mg/kg dose of METH",
      "target": "spatial memory retrieval",
      "label": "had no effect on"
    },
    {
      "source": "1.0 mg/kg dose of METH",
      "target": "spatial memory consolidation",
      "label": "facilitated"
    },
    {
      "source": "cAMP response element-binding protein",
      "target": "CREB",
      "label": "is a type of"
    },
    {
      "source": "Morris water maze",
      "target": "methamphetamine",
      "label": "used to examine effect of"
    },
    {
      "source": "Morris water maze",
      "target": "METH",
      "label": "used to examine effect of"
    },
    {
      "source": "PFC",
      "target": "prefrontal cortex",
      "label": "is a type of"
    },
    {
      "source": "Drugs of abuse",
      "target": "humans",
      "label": "affect"
    },
    {
      "source": "Drugs of abuse",
      "target": "memory",
      "label": "modulate"
    },
    {
      "source": "Drugs of abuse",
      "target": "learning",
      "label": "modulate"
    },
    {
      "source": "processes of spatial memory",
      "target": "mice",
      "label": "occurs in"
    },
    {
      "source": "internal rotation patterns",
      "target": "theoretical predictions",
      "label": "is in agreement with"
    },
    {
      "source": "internal rotation patterns",
      "target": "microwave spectroscopy",
      "label": "observed in"
    },
    {
      "source": "enantiomeric pairs",
      "target": "conformers",
      "label": "is of"
    },
    {
      "source": "conformers",
      "target": "diisopropyl ketone",
      "label": "is of"
    },
    {
      "source": "diisopropyl ketone",
      "target": "(CH(3))(2)HC-CO-CH(CH(3))(2)",
      "label": "is also known as"
    },
    {
      "source": "symmetry",
      "target": "Conformational landscape",
      "label": "is of"
    },
    {
      "source": "Conformational landscape",
      "target": "diisopropyl ketone",
      "label": "is of"
    },
    {
      "source": "conformer",
      "target": "C(2) symmetry",
      "label": "possesses"
    },
    {
      "source": "conformer",
      "target": "enantiomeric pair",
      "label": "appears as"
    },
    {
      "source": "conformer",
      "target": "supersonic jet",
      "label": "observed in"
    },
    {
      "source": "conformer",
      "target": "diisopropyl ketone",
      "label": "is of"
    },
    {
      "source": "two-dimensional potential energy surface",
      "target": "enantiomeric pairs",
      "label": "indicates"
    },
    {
      "source": "two-dimensional potential energy surface",
      "target": "symmetry",
      "label": "shows"
    },
    {
      "source": "barriers to internal rotation",
      "target": "B3LYP/6-311++G(d,p) level",
      "label": "determined at"
    },
    {
      "source": "barriers to internal rotation",
      "target": "MP2/6-311++G(d,p) level of theory",
      "label": "determined at"
    },
    {
      "source": "barriers to internal rotation",
      "target": "methyl groups",
      "label": "is of"
    },
    {
      "source": "barriers to internal rotation",
      "target": "cm(-1)",
      "label": "measured in"
    },
    {
      "source": "gas-phase structures",
      "target": "conformers",
      "label": "is of"
    },
    {
      "source": "gas-phase structures",
      "target": "ab initio calculations",
      "label": "optimized using"
    },
    {
      "source": "ab initio calculations",
      "target": "MP2/6-311++G(d,p) level of theory",
      "label": "performed at"
    },
    {
      "source": "transitions",
      "target": "conformer",
      "label": "is of"
    },
    {
      "source": "transitions",
      "target": "conformational isomers",
      "label": "between"
    },
    {
      "source": "theoretical constants",
      "target": "C(2) conformer",
      "label": "is of"
    },
    {
      "source": "theoretical constants",
      "target": "experimental constants",
      "label": "validated using"
    },
    {
      "source": "stationary points",
      "target": "harmonic frequency calculations",
      "label": "verified using"
    },
    {
      "source": "gas-phase structure",
      "target": "conformer",
      "label": "is of"
    },
    {
      "source": "gas-phase structure",
      "target": "molecular beam Fourier transform microwave spectroscopy",
      "label": "observed by"
    },
    {
      "source": "rotational constants",
      "target": "microwave spectroscopy",
      "label": "determined from"
    },
    {
      "source": "sextic centrifugal distortion constants",
      "target": "microwave spectroscopy",
      "label": "determined from"
    },
    {
      "source": "isopropyl groups",
      "target": "transitions",
      "label": "rotated to understand"
    },
    {
      "source": "quantum chemical calculations",
      "target": "microwave spectroscopy",
      "label": "validated by"
    },
    {
      "source": "centrifugal distortion constants",
      "target": "microwave spectroscopy",
      "label": "determined from"
    },
    {
      "source": "energy decomposition analysis",
      "target": "stability",
      "label": "indicated"
    },
    {
      "source": "energy decomposition analysis",
      "target": "inter-atomic interactions",
      "label": "indicated"
    },
    {
      "source": "two complexes",
      "target": "bidentate ligands",
      "label": "have"
    },
    {
      "source": "inter-atomic interactions",
      "target": "charge transfer term",
      "label": "governed by"
    },
    {
      "source": "inter-atomic interactions",
      "target": "three forms of rapta-C complexes",
      "label": "are in"
    },
    {
      "source": "charge transfer term",
      "target": "polarization",
      "label": "receives contributions from"
    },
    {
      "source": "charge transfer term",
      "target": "electrostatic terms",
      "label": "receives contributions from"
    },
    {
      "source": "reported experimental behaviors",
      "target": "biological activities",
      "label": "include"
    },
    {
      "source": "reported experimental behaviors",
      "target": "complexes",
      "label": "are of"
    },
    {
      "source": "higher stability",
      "target": "complex 3",
      "label": "is over"
    },
    {
      "source": "higher stability",
      "target": "polarization contributions",
      "label": "results from"
    },
    {
      "source": "higher stability",
      "target": "complex 2",
      "label": "is of"
    },
    {
      "source": "higher stability",
      "target": "complex 1",
      "label": "is of"
    },
    {
      "source": "higher stability",
      "target": "experimental observation",
      "label": "agrees with"
    },
    {
      "source": "higher stability",
      "target": "exchange repulsion",
      "label": "results from"
    },
    {
      "source": "structural stability",
      "target": "complexes",
      "label": "is of"
    },
    {
      "source": "quantum properties",
      "target": "QTAIM",
      "label": "include"
    },
    {
      "source": "quantum properties",
      "target": "NEDA",
      "label": "include"
    },
    {
      "source": "QTAIM",
      "target": "three models of rapta-C complexes",
      "label": "computed on"
    },
    {
      "source": "QTAIM",
      "target": "physico-chemical \"anatomy\"",
      "label": "provides perspective on"
    },
    {
      "source": "NEDA",
      "target": "three models of rapta-C complexes",
      "label": "computed on"
    },
    {
      "source": "three models of rapta-C complexes",
      "target": "DFT",
      "label": "studied using"
    },
    {
      "source": "bidentate coordination",
      "target": "molecular properties",
      "label": "affects"
    },
    {
      "source": "molecular properties",
      "target": "rapta-C based complex",
      "label": "are of"
    },
    {
      "source": "DFT",
      "target": "hybrid functional",
      "label": "uses"
    },
    {
      "source": "DFT",
      "target": "basis set",
      "label": "uses"
    },
    {
      "source": "intramolecular forces",
      "target": "structural stability",
      "label": "influence"
    },
    {
      "source": "polarization contributions",
      "target": "stability",
      "label": "contribute to"
    },
    {
      "source": "rapta-C based complex",
      "target": "theoretical approach",
      "label": "studied using"
    },
    {
      "source": "insight",
      "target": "nature of intramolecular forces",
      "label": "is into"
    },
    {
      "source": "basis set",
      "target": "ECP",
      "label": "used with"
    },
    {
      "source": "work",
      "target": "quantum properties",
      "label": "computes"
    },
    {
      "source": "Caffeic acid",
      "target": "Individual phenolics",
      "label": "is a type of"
    },
    {
      "source": "Individual phenolics",
      "target": "HPLC",
      "label": "were detected by"
    },
    {
      "source": "Individual phenolics",
      "target": "Litchi pulp",
      "label": "were detected in"
    },
    {
      "source": "Bound flavonoid contents",
      "target": "Catechin equivalents",
      "label": "are expressed as"
    },
    {
      "source": "Free flavonoid contents",
      "target": "Catechin equivalents",
      "label": "are expressed as"
    },
    {
      "source": "Free phenolics",
      "target": "Litchi pulp",
      "label": "exist in"
    },
    {
      "source": "Free phenolics",
      "target": "Free form",
      "label": "exist in"
    },
    {
      "source": "Free phenolics",
      "target": "Total phenolic contents",
      "label": "contributed to"
    },
    {
      "source": "Litchi pulp",
      "target": "13 varieties",
      "label": "is from"
    },
    {
      "source": "Litchi pulp",
      "target": "Cultivars",
      "label": "is from"
    },
    {
      "source": "Compound",
      "target": "Free fractions",
      "label": "is found in"
    },
    {
      "source": "Compound",
      "target": "Bound fractions",
      "label": "is found in"
    },
    {
      "source": "Antioxidant activity",
      "target": "Flavonoid contents",
      "label": "is correlated with"
    },
    {
      "source": "Antioxidant activity",
      "target": "DPPH scavenging capacity methods",
      "label": "was found by"
    },
    {
      "source": "Antioxidant activity",
      "target": "Phenolic contents",
      "label": "is correlated with"
    },
    {
      "source": "Antioxidant activity",
      "target": "Litchi pulp",
      "label": "is found in"
    },
    {
      "source": "Antioxidant activity",
      "target": "FRAP",
      "label": "was found by"
    },
    {
      "source": "Antioxidant activity",
      "target": "phytosteryl phenolates",
      "label": "is property of"
    },
    {
      "source": "Antioxidant activity",
      "target": "three different in vitro model systems",
      "label": "evaluated using"
    },
    {
      "source": "Antioxidant activity",
      "target": "phenolic acids",
      "label": "compared with activity of"
    },
    {
      "source": "Antioxidant activity",
      "target": "model systems",
      "label": "evaluated in"
    },
    {
      "source": "Flavonoids",
      "target": "Total flavonoid contents",
      "label": "contributed to"
    },
    {
      "source": "Flavonoids",
      "target": "Litchi pulp",
      "label": "exist in"
    },
    {
      "source": "Flavonoids",
      "target": "Free form",
      "label": "exist in"
    },
    {
      "source": "Total flavonoid contents",
      "target": "Catechin equivalents",
      "label": "are expressed as"
    },
    {
      "source": "Free phenolic contents",
      "target": "Gallic acid equivalents",
      "label": "are expressed as"
    },
    {
      "source": "Varietal differences",
      "target": "Phytochemical contents",
      "label": "are in"
    },
    {
      "source": "Varietal differences",
      "target": "Antioxidant activity",
      "label": "are in"
    },
    {
      "source": "Phytochemical contents",
      "target": "Litchi pulp",
      "label": "are of"
    },
    {
      "source": "Cultivars",
      "target": "Southern China",
      "label": "are cultivated in"
    },
    {
      "source": "(+)-catechin",
      "target": "Individual phenolics",
      "label": "is a type of"
    },
    {
      "source": "Bound phenolic contents",
      "target": "Gallic acid equivalents",
      "label": "are expressed as"
    },
    {
      "source": "Chlorogenic acid",
      "target": "Individual phenolics",
      "label": "is a type of"
    },
    {
      "source": "Rutin",
      "target": "Individual phenolics",
      "label": "is a type of"
    },
    {
      "source": "Rutin",
      "target": "testicular pathophysiology",
      "label": "attenuated"
    },
    {
      "source": "Total phenolic contents",
      "target": "Gallic acid equivalents",
      "label": "are expressed as"
    },
    {
      "source": "Varietal discrepancy",
      "target": "Antioxidant activity",
      "label": "is in"
    },
    {
      "source": "Gallic acid",
      "target": "Individual phenolics",
      "label": "is a type of"
    },
    {
      "source": "Phenolic profiles",
      "target": "Litchi pulp",
      "label": "are found in"
    },
    {
      "source": "FRAP",
      "target": "values",
      "label": "has"
    },
    {
      "source": "(-)-epicatechin",
      "target": "Individual phenolics",
      "label": "is a type of"
    },
    {
      "source": "(-)-epicatechin",
      "target": "GTLE",
      "label": "is found in"
    },
    {
      "source": "CPP",
      "target": "total sugar",
      "label": "contained"
    },
    {
      "source": "CPP",
      "target": "hot water extraction",
      "label": "isolated by"
    },
    {
      "source": "CPP",
      "target": "uronic acid",
      "label": "contained"
    },
    {
      "source": "CPP",
      "target": "anion-exchange chromatography",
      "label": "purified by"
    },
    {
      "source": "CPP",
      "target": "ethanol precipitation",
      "label": "isolated by"
    },
    {
      "source": "CPP",
      "target": "deproteinisation",
      "label": "purified by"
    },
    {
      "source": "CPP",
      "target": "protein",
      "label": "contained"
    },
    {
      "source": "CPP",
      "target": "monosaccharides",
      "label": "contained"
    },
    {
      "source": "CPP",
      "target": "inhibition effect",
      "label": "exhibited"
    },
    {
      "source": "physicochemical properties",
      "target": "TGA",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "Fourier transform infrared spectrometry",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "GPC",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "gel permeation chromatography",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "gas chromatography-mass spectrometry",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "DLS",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "dynamic light scattering",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "thermal gravimetric analysis",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "GC-MS",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "viscometry analysis",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "FTIR",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "UV-visible spectrophotometry",
      "label": "characterised by"
    },
    {
      "source": "physicochemical properties",
      "target": "CPP",
      "label": "of"
    },
    {
      "source": "physicochemical properties",
      "target": "investigated compounds",
      "label": "are of"
    },
    {
      "source": "galactose",
      "target": "molar percentages",
      "label": "has"
    },
    {
      "source": "anticancer effect",
      "target": "3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide",
      "label": "evaluated by"
    },
    {
      "source": "anticancer effect",
      "target": "CPP",
      "label": "of"
    },
    {
      "source": "anticancer effect",
      "target": "MTT",
      "label": "evaluated by"
    },
    {
      "source": "anticancer effect",
      "target": "human gastric cancer HeLa cells",
      "label": "in"
    },
    {
      "source": "anticancer effect",
      "target": "MTT assay",
      "label": "evaluated by"
    },
    {
      "source": "monosaccharides",
      "target": "galactose",
      "label": "included"
    },
    {
      "source": "monosaccharides",
      "target": "glucose",
      "label": "included"
    },
    {
      "source": "monosaccharides",
      "target": "rhamnose",
      "label": "included"
    },
    {
      "source": "monosaccharides",
      "target": "arabinose",
      "label": "included"
    },
    {
      "source": "monosaccharides",
      "target": "xylose",
      "label": "included"
    },
    {
      "source": "monosaccharides",
      "target": "mannose",
      "label": "included"
    },
    {
      "source": "rhamnose",
      "target": "molar percentages",
      "label": "has"
    },
    {
      "source": "physicochemical characterisation",
      "target": "polysaccharide",
      "label": "of"
    },
    {
      "source": "molecular weight",
      "target": "CPP",
      "label": "of"
    },
    {
      "source": "Purification",
      "target": "polysaccharide",
      "label": "of"
    },
    {
      "source": "Purification",
      "target": "calcitonin receptors",
      "label": "of"
    },
    {
      "source": "Purification",
      "target": "renal calcitonin receptor",
      "label": "of"
    },
    {
      "source": "Purification",
      "target": "molecular sieving",
      "label": "performed by"
    },
    {
      "source": "Purification",
      "target": "high-affinity sites",
      "label": "of"
    },
    {
      "source": "Purification",
      "target": "total loss",
      "label": "accompanied by"
    },
    {
      "source": "inhibition effect",
      "target": "growth",
      "label": "on"
    },
    {
      "source": "dynamic light scattering",
      "target": "DLS",
      "label": "is also known as"
    },
    {
      "source": "mannose",
      "target": "molar percentages",
      "label": "has"
    },
    {
      "source": "human gastric cancer HeLa cells",
      "target": "HeLa cells",
      "label": "is also known as"
    },
    {
      "source": "arabinose",
      "target": "molar percentages",
      "label": "has"
    },
    {
      "source": "xylose",
      "target": "molar percentages",
      "label": "has"
    },
    {
      "source": "Cyclocarya paliurus (Batal.) Iljinskaja polysaccharide",
      "target": "CPP",
      "label": "is also known as"
    },
    {
      "source": "intracellular GTP depletion",
      "target": "transcription elongation",
      "label": "activates"
    },
    {
      "source": "intracellular GTP depletion",
      "target": "F7",
      "label": "up-regulates"
    },
    {
      "source": "intracellular GTP depletion",
      "target": "super elongation complex",
      "label": "recruits"
    },
    {
      "source": "intracellular GTP depletion",
      "target": "FVII mRNA transcription elongation",
      "label": "modulates"
    },
    {
      "source": "intracellular GTP depletion",
      "target": "coagulation factor VII gene expression",
      "label": "activates"
    },
    {
      "source": "transcription elongation",
      "target": "FVII mRNA transcription",
      "label": "enhances"
    },
    {
      "source": "ELL",
      "target": "eleven-nineteen lysine-rich leukaemia",
      "label": "is a"
    },
    {
      "source": "super elongation complex",
      "target": "ELL3",
      "label": "contains"
    },
    {
      "source": "super elongation complex",
      "target": "P-TEFb",
      "label": "contains"
    },
    {
      "source": "super elongation complex",
      "target": "F7",
      "label": "is recruited to"
    },
    {
      "source": "super elongation complex",
      "target": "AFF4",
      "label": "contains"
    },
    {
      "source": "CDK9",
      "target": "cyclin-dependent kinase 9",
      "label": "is a"
    },
    {
      "source": "CDK9",
      "target": "F7",
      "label": "is recruited to"
    },
    {
      "source": "ELL3 mRNA expression",
      "target": "F7 up-regulation",
      "label": "precedes"
    },
    {
      "source": "P-TEFb",
      "target": "positive-transcription elongation factor b",
      "label": "is a"
    },
    {
      "source": "6-mercaptopurine",
      "target": "inhibitors",
      "label": "is an"
    },
    {
      "source": "6-mercaptopurine",
      "target": "F7",
      "label": "up-regulates"
    },
    {
      "source": "Ribavirin",
      "target": "AFF4",
      "label": "enhances recruitment of"
    },
    {
      "source": "Ribavirin",
      "target": "ELL3 mRNA expression",
      "label": "up-regulates"
    },
    {
      "source": "Ribavirin",
      "target": "CDK9",
      "label": "enhances recruitment of"
    },
    {
      "source": "AFF4",
      "target": "F7",
      "label": "is recruited to"
    },
    {
      "source": "ribavirin treatment",
      "target": "FVII gene",
      "label": "up-regulates"
    },
    {
      "source": "ribavirin treatment",
      "target": "hepatitis C virus-infected haemophilia patients",
      "label": "treats"
    },
    {
      "source": "ribavirin treatment",
      "target": "F7",
      "label": "up-regulates"
    },
    {
      "source": "basal mechanism",
      "target": "ribavirin-induced FVII mRNA up-regulation",
      "label": "for"
    },
    {
      "source": "ribavirin-induced FVII mRNA up-regulation",
      "target": "transcription elongation",
      "label": "is mediated by"
    },
    {
      "source": "ribavirin-induced FVII mRNA up-regulation",
      "target": "pleiotropic functions",
      "label": "has"
    },
    {
      "source": "P-TEFb complex",
      "target": "P-TEFb",
      "label": "contains"
    },
    {
      "source": "P-TEFb complex",
      "target": "transcription elongation",
      "label": "mediates"
    },
    {
      "source": "pleiotropic functions",
      "target": "in vivo",
      "label": "occur"
    },
    {
      "source": "Factor VII",
      "target": "hepatocytes",
      "label": "is synthesized in"
    },
    {
      "source": "Factor VII",
      "target": "glycoprotein",
      "label": "is a"
    },
    {
      "source": "Factor VII",
      "target": "vitamin K",
      "label": "is dependent on"
    },
    {
      "source": "hepatitis C virus-infected haemophilia patients",
      "target": "hepatitis C virus",
      "label": "are infected with"
    },
    {
      "source": "hepatitis C virus-infected haemophilia patients",
      "target": "haemophilia patients",
      "label": "are"
    },
    {
      "source": "knockdown of ELL3",
      "target": "ribavirin-induced FVII mRNA up-regulation",
      "label": "diminishes"
    },
    {
      "source": "Coagulation FVII",
      "target": "hepatocytes",
      "label": "is synthesized in"
    },
    {
      "source": "Coagulation FVII",
      "target": "glycoprotein",
      "label": "is a"
    },
    {
      "source": "Coagulation FVII",
      "target": "vitamin K",
      "label": "is dependent on"
    },
    {
      "source": "ELL3 recruitment",
      "target": "F7",
      "label": "targets"
    },
    {
      "source": "IMPDH",
      "target": "inosine-5'-monophosphate dehydrogenase",
      "label": "is a"
    },
    {
      "source": "ribavirin-induced up-regulation",
      "target": "F7",
      "label": "affects"
    },
    {
      "source": "transport process",
      "target": "rCtr1",
      "label": "mediated by"
    },
    {
      "source": "rCtr1",
      "target": "cells",
      "label": "sensitizes"
    },
    {
      "source": "rCtr1",
      "target": "membrane transporter",
      "label": "is a"
    },
    {
      "source": "rCtr1",
      "target": "copper",
      "label": "transports"
    },
    {
      "source": "rCtr1",
      "target": "platinum drugs",
      "label": "transports"
    },
    {
      "source": "DRG neurons",
      "target": "platinum-induced neurotoxicity",
      "label": "affected by"
    },
    {
      "source": "DRG neurons",
      "target": "neurodegenerative processes",
      "label": "affected by"
    },
    {
      "source": "DRG neurons",
      "target": "capacity",
      "label": "display"
    },
    {
      "source": "DRG neurons",
      "target": "copper toxicity",
      "label": "resist"
    },
    {
      "source": "DRG neurons",
      "target": "alternative mechanisms",
      "label": "use"
    },
    {
      "source": "HEK/rCtr1 cells",
      "target": "cytotoxicity",
      "label": "increased"
    },
    {
      "source": "HEK/rCtr1 cells",
      "target": "uptake",
      "label": "increased"
    },
    {
      "source": "neurodegenerative processes",
      "target": "transport",
      "label": "associated with"
    },
    {
      "source": "neurodegenerative processes",
      "target": "copper homeostasis",
      "label": "associated with"
    },
    {
      "source": "copper transporter 1",
      "target": "toxicity",
      "label": "has role in"
    },
    {
      "source": "copper transporter 1",
      "target": "uptake",
      "label": "has role in"
    },
    {
      "source": "rat Ctr1",
      "target": "toxicity",
      "label": "contributes to"
    },
    {
      "source": "rat Ctr1",
      "target": "uptake",
      "label": "contributes to"
    },
    {
      "source": "cultured rat DRG neurons",
      "target": "platinum",
      "label": "accumulated"
    },
    {
      "source": "cultured rat DRG neurons",
      "target": "rCtr1 protein",
      "label": "expressed"
    },
    {
      "source": "cultured rat DRG neurons",
      "target": "capacity",
      "label": "displayed"
    },
    {
      "source": "cultured rat DRG neurons",
      "target": "oxaliplatin cytotoxicity",
      "label": "sensitive to"
    },
    {
      "source": "cultured rat DRG neurons",
      "target": "copper toxicity",
      "label": "resistant to"
    },
    {
      "source": "platinum",
      "target": "oocytes",
      "label": "damages"
    },
    {
      "source": "membrane transporter",
      "target": "copper",
      "label": "transports"
    },
    {
      "source": "membrane transporter",
      "target": "platinum drugs",
      "label": "transports"
    },
    {
      "source": "Ctr1",
      "target": "toxicity",
      "label": "has role in"
    },
    {
      "source": "Ctr1",
      "target": "uptake",
      "label": "has role in"
    },
    {
      "source": "rCtr1 protein",
      "target": "cytoplasm",
      "label": "located in"
    },
    {
      "source": "rCtr1 protein",
      "target": "neuronal cell body plasma membranes",
      "label": "located on"
    },
    {
      "source": "Heterologous expression",
      "target": "HEK293 cells",
      "label": "in"
    },
    {
      "source": "cisplatin",
      "target": "expression",
      "label": "activates"
    },
    {
      "source": "cisplatin",
      "target": "nuclear accumulation",
      "label": "induces"
    },
    {
      "source": "cisplatin",
      "target": "accumulation",
      "label": "causes"
    },
    {
      "source": "cisplatin",
      "target": "TAp73",
      "label": "induces"
    },
    {
      "source": "cisplatin",
      "target": "c-Abl",
      "label": "induces"
    },
    {
      "source": "cytotoxicities",
      "target": "eight human tumor cell lines",
      "label": "tested against"
    },
    {
      "source": "cytotoxicities",
      "target": "compounds",
      "label": "are of"
    },
    {
      "source": "alternative mechanisms",
      "target": "oxaliplatin",
      "label": "take up"
    },
    {
      "source": "Energy-restricted diet",
      "target": "24 weeks",
      "label": "lasted"
    },
    {
      "source": "Free Androgen Index",
      "target": "Week 12",
      "label": "calculated at"
    },
    {
      "source": "Free Androgen Index",
      "target": "Baseline",
      "label": "calculated at"
    },
    {
      "source": "Free Androgen Index",
      "target": "Week 24",
      "label": "calculated at"
    },
    {
      "source": "Glucose",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "Glucose",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "Glucose",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "Sex hormone-binding globulin",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "Sex hormone-binding globulin",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "Sex hormone-binding globulin",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "Physical exercise",
      "target": "AMH",
      "label": "increases"
    },
    {
      "source": "Physical exercise",
      "target": "24 weeks",
      "label": "lasted"
    },
    {
      "source": "Physical exercise",
      "target": "Serum Anti-M\u00fcllerian Hormone",
      "label": "increases"
    },
    {
      "source": "Orlistat administration",
      "target": "Weight loss",
      "label": "resulted in"
    },
    {
      "source": "Orlistat administration",
      "target": "AMH",
      "label": "resulted in increased"
    },
    {
      "source": "Orlistat administration",
      "target": "Hyperandrogenism",
      "label": "resulted in improvement of"
    },
    {
      "source": "Orlistat administration",
      "target": "24 weeks",
      "label": "lasted"
    },
    {
      "source": "Orlistat administration",
      "target": "Diet",
      "label": "combined with"
    },
    {
      "source": "Orlistat administration",
      "target": "3 times per day",
      "label": "has frequency"
    },
    {
      "source": "Orlistat administration",
      "target": "Insulin sensitivity",
      "label": "resulted in improvement of"
    },
    {
      "source": "Orlistat administration",
      "target": "Physical exercise",
      "label": "combined with"
    },
    {
      "source": "Orlistat administration",
      "target": "Serum Anti-M\u00fcllerian Hormone",
      "label": "increases"
    },
    {
      "source": "Orlistat administration",
      "target": "120 mg",
      "label": "has dosage"
    },
    {
      "source": "AMH",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "AMH",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "AMH",
      "target": "Week 24",
      "label": "increased at"
    },
    {
      "source": "Overweight and obese women with polycystic ovary syndrome",
      "target": "Insulin sensitivity",
      "label": "experienced improvement of"
    },
    {
      "source": "Overweight and obese women with polycystic ovary syndrome",
      "target": "Weight loss",
      "label": "experienced"
    },
    {
      "source": "Overweight and obese women with polycystic ovary syndrome",
      "target": "AMH",
      "label": "experienced increased"
    },
    {
      "source": "Overweight and obese women with polycystic ovary syndrome",
      "target": "Hyperandrogenism",
      "label": "experienced improvement of"
    },
    {
      "source": "Overweight and obese controls",
      "target": "Energy-restricted diet",
      "label": "followed"
    },
    {
      "source": "Overweight and obese controls",
      "target": "Orlistat administration",
      "label": "followed"
    },
    {
      "source": "Overweight and obese controls",
      "target": "Physical exercise",
      "label": "followed"
    },
    {
      "source": "IR indices",
      "target": "Week 12",
      "label": "improved at"
    },
    {
      "source": "IR indices",
      "target": "Week 24",
      "label": "calculated at"
    },
    {
      "source": "IR indices",
      "target": "Baseline",
      "label": "calculated at"
    },
    {
      "source": "Insulin Resistance",
      "target": "Baseline",
      "label": "calculated at"
    },
    {
      "source": "Insulin Resistance",
      "target": "Week 24",
      "label": "calculated at"
    },
    {
      "source": "Insulin Resistance",
      "target": "Week 12",
      "label": "calculated at"
    },
    {
      "source": "FAI",
      "target": "Baseline",
      "label": "calculated at"
    },
    {
      "source": "FAI",
      "target": "Week 24",
      "label": "decreased at"
    },
    {
      "source": "FAI",
      "target": "Week 12",
      "label": "decreased at"
    },
    {
      "source": "FSH",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "FSH",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "FSH",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "Women with polycystic ovary syndrome",
      "target": "Physical exercise",
      "label": "followed"
    },
    {
      "source": "Women with polycystic ovary syndrome",
      "target": "Energy-restricted diet",
      "label": "followed"
    },
    {
      "source": "Women with polycystic ovary syndrome",
      "target": "Orlistat administration",
      "label": "followed"
    },
    {
      "source": "PRL",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "PRL",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "PRL",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "PRL",
      "target": "regulator",
      "label": "is a"
    },
    {
      "source": "PRL",
      "target": "target tissues",
      "label": "acts on"
    },
    {
      "source": "Androgens",
      "target": "Week 12",
      "label": "measured at"
    },
    {
      "source": "Androgens",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "Androgens",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "SHBG",
      "target": "Week 12",
      "label": "increased at"
    },
    {
      "source": "SHBG",
      "target": "Baseline",
      "label": "measured at"
    },
    {
      "source": "SHBG",
      "target": "Week 24",
      "label": "measured at"
    },
    {
      "source": "Montmorillonite",
      "target": "xyloglucan",
      "label": "combined with"
    },
    {
      "source": "Montmorillonite",
      "target": "unmodified biological polymer",
      "label": "combined with"
    },
    {
      "source": "Montmorillonite",
      "target": "XG",
      "label": "combined with"
    },
    {
      "source": "XG adsorption",
      "target": "quartz crystal microbalance analysis",
      "label": "measured by"
    },
    {
      "source": "XG adsorption",
      "target": "MTM",
      "label": "occurs on"
    },
    {
      "source": "clay bionanocomposites",
      "target": "processing routes",
      "label": "requires"
    },
    {
      "source": "processing routes",
      "target": "nanostructural control",
      "label": "have"
    },
    {
      "source": "nanocomposites",
      "target": "FE-SEM",
      "label": "characterized by"
    },
    {
      "source": "nanocomposites",
      "target": "TEM",
      "label": "characterized by"
    },
    {
      "source": "nanocomposites",
      "target": "XRD",
      "label": "characterized by"
    },
    {
      "source": "moisture durability",
      "target": "water-soluble biopolymers",
      "label": "is a concern with"
    },
    {
      "source": "MTM",
      "target": "unmodified biological polymer",
      "label": "combined with"
    },
    {
      "source": "MTM",
      "target": "XG",
      "label": "combined with"
    },
    {
      "source": "MTM",
      "target": "xyloglucan",
      "label": "combined with"
    },
    {
      "source": "reinforcement efficiency",
      "target": "strong XG-MTM interactions",
      "label": "due to"
    },
    {
      "source": "reinforcement efficiency",
      "target": "highly oriented and well-dispersed MTM",
      "label": "due to"
    },
    {
      "source": "strong in-plane orientation",
      "target": "clay platelets",
      "label": "of"
    },
    {
      "source": "oriented bionanocomposite coatings",
      "target": "strong in-plane orientation",
      "label": "have"
    },
    {
      "source": "oriented bionanocomposite coatings",
      "target": "continuous water-based processing",
      "label": "prepared by"
    },
    {
      "source": "XG dimensions",
      "target": "composites",
      "label": "in"
    },
    {
      "source": "XG dimensions",
      "target": "atomistic simulations",
      "label": "estimated using"
    },
    {
      "source": "Mechanical and gas barrier properties",
      "target": "high relative humidity",
      "label": "measured at"
    },
    {
      "source": "Bioinspired and highly oriented clay nanocomposites",
      "target": "xyloglucan biopolymer matrix",
      "label": "have"
    },
    {
      "source": "Bioinspired and highly oriented clay nanocomposites",
      "target": "mechanical and barrier properties",
      "label": "extend"
    },
    {
      "source": "nanostructure",
      "target": "highly oriented and intercalated clay platelets",
      "label": "shows"
    },
    {
      "source": "Properties",
      "target": "humid conditions",
      "label": "preserved in"
    },
    {
      "source": "UCCB01-125",
      "target": "inflammatory pain",
      "label": "reduces"
    },
    {
      "source": "UCCB01-125",
      "target": "dimeric PSD-95 inhibitor",
      "label": "is a"
    },
    {
      "source": "UCCB01-125",
      "target": "PSD-95",
      "label": "inhibits"
    },
    {
      "source": "UCCB01-125",
      "target": "CFA-induced hypersensitivity",
      "label": "reversed"
    },
    {
      "source": "UCCB01-125",
      "target": "cognitive performance",
      "label": "does not disrupt"
    },
    {
      "source": "UCCB01-125",
      "target": "CFA-induced mechanical hypersensitivity",
      "label": "prevented development of"
    },
    {
      "source": "UCCB01-125",
      "target": "motor performance",
      "label": "does not disrupt"
    },
    {
      "source": "UCCB01-125",
      "target": "side-effect profiles",
      "label": "is devoid of"
    },
    {
      "source": "PSD-95",
      "target": "NMDAR activation",
      "label": "mediates coupling between"
    },
    {
      "source": "PSD-95",
      "target": "NMDAR",
      "label": "binds to"
    },
    {
      "source": "PSD-95",
      "target": "NO production",
      "label": "mediates coupling between"
    },
    {
      "source": "PSD-95",
      "target": "neuronal NO synthase",
      "label": "binds to"
    },
    {
      "source": "PSD-95 inhibition",
      "target": "NMDAR antagonism-related side-effects",
      "label": "avoids"
    },
    {
      "source": "PSD-95 inhibition",
      "target": "NMDAR-related activity",
      "label": "modulates"
    },
    {
      "source": "PSD-95 inhibition",
      "target": "chronic inflammatory pain",
      "label": "prevents maintenance of"
    },
    {
      "source": "PSD-95 inhibition",
      "target": "NO production",
      "label": "decreases"
    },
    {
      "source": "PSD-95 inhibition",
      "target": "NMDAR ion channel function",
      "label": "does not interfere with"
    },
    {
      "source": "PSD-95 inhibition",
      "target": "NMDAR/PSD-95/nNOS complex",
      "label": "perturbs"
    },
    {
      "source": "NMDAR antagonism",
      "target": "motor functions",
      "label": "is associated with disturbances of"
    },
    {
      "source": "NMDAR antagonism",
      "target": "cognitive functions",
      "label": "is associated with disturbances of"
    },
    {
      "source": "NMDAR antagonism",
      "target": "anti-nociceptive action",
      "label": "shows"
    },
    {
      "source": "CFA model",
      "target": "mechanical hypersensitivity",
      "label": "involves"
    },
    {
      "source": "CFA model",
      "target": "inflammatory pain",
      "label": "is a model of"
    },
    {
      "source": "mechanical hypersensitivity",
      "target": "capsaicin",
      "label": "induced by"
    },
    {
      "source": "NMDAR activation",
      "target": "NO production",
      "label": "leads to"
    },
    {
      "source": "anti-nociceptive action",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "anti-nociceptive action",
      "target": "animal models",
      "label": "occurs in"
    },
    {
      "source": "CRAC treatment",
      "target": "atheroma deposits",
      "label": "removed"
    },
    {
      "source": "CRAC treatment",
      "target": "LDL cholesterol",
      "label": "decreased"
    },
    {
      "source": "CRAC treatment",
      "target": "toxicity",
      "label": "did not cause"
    },
    {
      "source": "CRAC treatment",
      "target": "circulating cholesterol levels",
      "label": "reduced"
    },
    {
      "source": "CRAC treatment",
      "target": "free cholesterol",
      "label": "decreased"
    },
    {
      "source": "CRAC treatment",
      "target": "total cholesterol",
      "label": "decreased"
    },
    {
      "source": "CRAC treatment",
      "target": "circulating HDL",
      "label": "induced an increase in"
    },
    {
      "source": "atheroma deposits",
      "target": "aorta",
      "label": "were removed from"
    },
    {
      "source": "hypocholesterolemic agent",
      "target": "anti-atherogenic properties",
      "label": "has"
    },
    {
      "source": "high cholesterol diet",
      "target": "serum creatine kinase",
      "label": "induced increase in"
    },
    {
      "source": "cholesterol recognition/interaction amino acid sequence",
      "target": "atherosclerosis",
      "label": "controls"
    },
    {
      "source": "cholesterol recognition/interaction amino acid sequence",
      "target": "hypercholesterolemia",
      "label": "controls"
    },
    {
      "source": "markers",
      "target": "muscular damage",
      "label": "of"
    },
    {
      "source": "markers",
      "target": "cardiac damage",
      "label": "of"
    },
    {
      "source": "markers",
      "target": "neurological damage",
      "label": "of"
    },
    {
      "source": "markers",
      "target": "life conditions",
      "label": "help optimize"
    },
    {
      "source": "markers",
      "target": "AKI severity",
      "label": "reduce"
    },
    {
      "source": "markers",
      "target": "AKI incidence",
      "label": "reduce"
    },
    {
      "source": "markers",
      "target": "hidden, chronic predisposition to gentamicin nephrotoxicity",
      "label": "for"
    },
    {
      "source": "markers",
      "target": "individuals",
      "label": "help stratify"
    },
    {
      "source": "markers",
      "target": "associated costs",
      "label": "reduce"
    },
    {
      "source": "markers",
      "target": "additional clinical procedures",
      "label": "help optimize"
    },
    {
      "source": "markers",
      "target": "treatments",
      "label": "help optimize"
    },
    {
      "source": "carboxy-terminus",
      "target": "TSPO",
      "label": "is part of"
    },
    {
      "source": "TSPO",
      "target": "lipid homeostasis",
      "label": "has a role in"
    },
    {
      "source": "TSPO",
      "target": "macrophages",
      "label": "expression increased in"
    },
    {
      "source": "TSPO",
      "target": "atherosclerosis",
      "label": "has a role in"
    },
    {
      "source": "serum creatine kinase",
      "target": "isoforms",
      "label": "has"
    },
    {
      "source": "serum creatine kinase",
      "target": "markers",
      "label": "are"
    },
    {
      "source": "translocator protein (18-kDa) TSPO",
      "target": "cholesterol-binding protein",
      "label": "is a"
    },
    {
      "source": "translocator protein (18-kDa) TSPO",
      "target": "endothelial cells",
      "label": "is present in"
    },
    {
      "source": "translocator protein (18-kDa) TSPO",
      "target": "smooth muscle cells",
      "label": "is present in"
    },
    {
      "source": "circulating cholesterol levels",
      "target": "ApoE knock-out B6.129P2-Apoetm1Unc/J mice",
      "label": "were reduced in"
    },
    {
      "source": "circulating cholesterol levels",
      "target": "guinea pigs",
      "label": "were reduced in"
    },
    {
      "source": "ApoE knock-out B6.129P2-Apoetm1Unc/J mice",
      "target": "high cholesterol diet",
      "label": "were fed with"
    },
    {
      "source": "CRAC",
      "target": "hypercholesterolemia",
      "label": "is a treatment of"
    },
    {
      "source": "CRAC",
      "target": "atherosclerosis",
      "label": "is a treatment of"
    },
    {
      "source": "CRAC",
      "target": "treatment",
      "label": "is a"
    },
    {
      "source": "domain",
      "target": "carboxy-terminus",
      "label": "is located in"
    },
    {
      "source": "domain",
      "target": "cholesterol recognition/interaction amino acid consensus",
      "label": "is characterized as"
    },
    {
      "source": "cholesterol recognition/interaction amino acid consensus",
      "target": "CRAC",
      "label": "is also known as"
    },
    {
      "source": "VLNYYVWR human CRAC sequence",
      "target": "ApoE knock-out B6.129P2-Apoetm1Unc/J mice",
      "label": "was administered to"
    },
    {
      "source": "VLNYYVWR human CRAC sequence",
      "target": "guinea pigs",
      "label": "was administered to"
    },
    {
      "source": "CRAC domain",
      "target": "cholesterol",
      "label": "binds to"
    },
    {
      "source": "translocator protein TSPO",
      "target": "cholesterol recognition/interaction amino acid sequence",
      "label": "contains"
    },
    {
      "source": "high fat diet (HFD)",
      "target": "GIP hypersecretion",
      "label": "induces"
    },
    {
      "source": "GIP hypersecretion",
      "target": "high fat diet-induced obesity",
      "label": "occurs in"
    },
    {
      "source": "knockdown of Rfx6",
      "target": "cellular content",
      "label": "decreased"
    },
    {
      "source": "knockdown of Rfx6",
      "target": "secretion of GIP",
      "label": "decreased"
    },
    {
      "source": "knockdown of Rfx6",
      "target": "GIP mRNA expression",
      "label": "decreased"
    },
    {
      "source": "energy accumulation",
      "target": "obesity",
      "label": "results in"
    },
    {
      "source": "energy accumulation",
      "target": "adipose tissue",
      "label": "occurs in"
    },
    {
      "source": "Rfx6",
      "target": "GIP content",
      "label": "increases"
    },
    {
      "source": "Rfx6",
      "target": "GIP hypersecretion",
      "label": "involved in"
    },
    {
      "source": "Rfx6",
      "target": "GIP mRNA expression",
      "label": "increases"
    },
    {
      "source": "Rfx6",
      "target": "isolated K-cells",
      "label": "expressed in"
    },
    {
      "source": "Rfx6",
      "target": "region in the gip promoter",
      "label": "bound to"
    },
    {
      "source": "GIP content",
      "target": "HFD-fed mice",
      "label": "increased in"
    },
    {
      "source": "gastric inhibitory polypeptide",
      "target": "incretin",
      "label": "is a type of"
    },
    {
      "source": "Transcriptional regulatory factor X6",
      "target": "GIP mRNA expression",
      "label": "increases"
    },
    {
      "source": "Transcriptional regulatory factor X6",
      "target": "isolated K-cells",
      "label": "expressed in"
    },
    {
      "source": "expression levels of Rfx6 mRNA",
      "target": "HFD-fed mice",
      "label": "increased in"
    },
    {
      "source": "Microarray analysis",
      "target": "Transcriptional regulatory factor X6",
      "label": "revealed expression of"
    },
    {
      "source": "Microarray analysis",
      "target": "Rfx6",
      "label": "revealed expression of"
    },
    {
      "source": "HFD",
      "target": "GIP hypersecretion",
      "label": "induced"
    },
    {
      "source": "HFD",
      "target": "obesity",
      "label": "induced"
    },
    {
      "source": "GIP mRNA expression in K-cells",
      "target": "HFD-fed mice",
      "label": "increased in"
    },
    {
      "source": "GIP-GFP knock-in mice",
      "target": "GFP",
      "label": "enable visualization of"
    },
    {
      "source": "overexpression of Rfx6",
      "target": "GIP mRNA expression",
      "label": "increased"
    },
    {
      "source": "Plasma GIP levels",
      "target": "obese state",
      "label": "increased in"
    },
    {
      "source": "region in the gip promoter",
      "target": "gip promoter activity",
      "label": "regulates"
    },
    {
      "source": "total measured endogenous bile acids",
      "target": "glycocholic acid",
      "label": "includes"
    },
    {
      "source": "total measured endogenous bile acids",
      "target": "TCA",
      "label": "includes"
    },
    {
      "source": "total measured endogenous bile acids",
      "target": "\u03b1/\u03b2-tauromuricholic acid",
      "label": "includes"
    },
    {
      "source": "total measured endogenous bile acids",
      "target": "glycochenodeoxycholic acid",
      "label": "includes"
    },
    {
      "source": "total measured endogenous bile acids",
      "target": "taurochenodeoxycholic acid",
      "label": "includes"
    },
    {
      "source": "cellular viability",
      "target": "suspended rat hepatocytes",
      "label": "determined in"
    },
    {
      "source": "cellular viability",
      "target": "SCRH",
      "label": "determined in"
    },
    {
      "source": "cellular viability",
      "target": "sandwich-cultured rat hepatocytes",
      "label": "determined in"
    },
    {
      "source": "RTV",
      "target": "hepatocyte viability",
      "label": "affects"
    },
    {
      "source": "RTV",
      "target": "BSEP inhibitors",
      "label": "is a"
    },
    {
      "source": "RTV",
      "target": "bile acid transport",
      "label": "affects"
    },
    {
      "source": "RTV",
      "target": "disposition",
      "label": "affects"
    },
    {
      "source": "RTV",
      "target": "accumulation",
      "label": "decreased"
    },
    {
      "source": "RTV",
      "target": "cellular viability",
      "label": "affects"
    },
    {
      "source": "RTV",
      "target": "initial uptake rates",
      "label": "did not affect"
    },
    {
      "source": "RTV",
      "target": "[(3)H]TCA biliary clearance",
      "label": "reduced"
    },
    {
      "source": "RTV",
      "target": "Antiretroviral protease inhibitors",
      "label": "is a type of"
    },
    {
      "source": "lopinavir",
      "target": "bile acid disposition",
      "label": "alters"
    },
    {
      "source": "lopinavir",
      "target": "BSEP inhibitors",
      "label": "is a"
    },
    {
      "source": "lopinavir",
      "target": "endogenous bile acid",
      "label": "alters"
    },
    {
      "source": "lopinavir",
      "target": "exogenous bile acid",
      "label": "alters"
    },
    {
      "source": "lopinavir",
      "target": "Antiretroviral protease inhibitors",
      "label": "is a type of"
    },
    {
      "source": "bile acid disposition",
      "target": "sandwich-cultured rat hepatocytes",
      "label": "occurs in"
    },
    {
      "source": "[(3)H]TCA accumulation",
      "target": "cells",
      "label": "occurs in"
    },
    {
      "source": "[(3)H]TCA accumulation",
      "target": "control",
      "label": "compared with"
    },
    {
      "source": "[(3)H]TCA accumulation",
      "target": "LPV",
      "label": "compared with"
    },
    {
      "source": "[(3)H]TCA accumulation",
      "target": "vehicle",
      "label": "compared with"
    },
    {
      "source": "[(3)H]TCA accumulation",
      "target": "SCRH",
      "label": "occurs in"
    },
    {
      "source": "[(3)H]TCA accumulation",
      "target": "bile",
      "label": "occurs in"
    },
    {
      "source": "LPV",
      "target": "Antiretroviral protease inhibitors",
      "label": "is a type of"
    },
    {
      "source": "LPV",
      "target": "[(3)H]TCA biliary clearance",
      "label": "reduced"
    },
    {
      "source": "LPV",
      "target": "accumulation",
      "label": "decreased"
    },
    {
      "source": "LPV",
      "target": "hepatocyte viability",
      "label": "affects"
    },
    {
      "source": "LPV",
      "target": "[(3)H]TCA accumulation",
      "label": "decreased"
    },
    {
      "source": "LPV",
      "target": "bile acid transport",
      "label": "affects"
    },
    {
      "source": "LPV",
      "target": "disposition",
      "label": "affects"
    },
    {
      "source": "LPV",
      "target": "cellular viability",
      "label": "affects"
    },
    {
      "source": "LPV",
      "target": "BSEP inhibitors",
      "label": "is a"
    },
    {
      "source": "LPV",
      "target": "initial uptake rates",
      "label": "did not affect"
    },
    {
      "source": "ritonavir",
      "target": "endogenous bile acid",
      "label": "alters"
    },
    {
      "source": "ritonavir",
      "target": "Antiretroviral protease inhibitors",
      "label": "is a type of"
    },
    {
      "source": "ritonavir",
      "target": "BSEP inhibitors",
      "label": "is a"
    },
    {
      "source": "ritonavir",
      "target": "exogenous bile acid",
      "label": "alters"
    },
    {
      "source": "ritonavir",
      "target": "bile acid disposition",
      "label": "alters"
    },
    {
      "source": "LPV/r",
      "target": "accumulation",
      "label": "decreased"
    },
    {
      "source": "LPV/r",
      "target": "hepatocyte viability",
      "label": "affects"
    },
    {
      "source": "LPV/r",
      "target": "bile acid transport",
      "label": "affects"
    },
    {
      "source": "LPV/r",
      "target": "disposition",
      "label": "affects"
    },
    {
      "source": "LPV/r",
      "target": "[(3)H]TCA accumulation",
      "label": "increased"
    },
    {
      "source": "LPV/r",
      "target": "cellular viability",
      "label": "affects"
    },
    {
      "source": "LPV/r",
      "target": "[(3)H]TCA biliary clearance",
      "label": "reduced"
    },
    {
      "source": "concentration-dependent effect",
      "target": "cellular viability",
      "label": "on"
    },
    {
      "source": "concentration-dependent effect",
      "target": "LPV",
      "label": "of"
    },
    {
      "source": "concentration-dependent effect",
      "target": "RTV",
      "label": "of"
    },
    {
      "source": "SCRH",
      "target": "rat hepatocytes",
      "label": "is a type of"
    },
    {
      "source": "adaptive responses",
      "target": "exposure",
      "label": "associated with"
    },
    {
      "source": "drug-induced liver injury",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "ATP assays",
      "target": "concentration-dependent effect",
      "label": "revealed"
    },
    {
      "source": "initial uptake rates",
      "target": "suspended rat hepatocytes",
      "label": "occurs in"
    },
    {
      "source": "Inhibition",
      "target": "intracellular accumulation",
      "label": "causes"
    },
    {
      "source": "Inhibition",
      "target": "bile salt export pump",
      "label": "of"
    },
    {
      "source": "Inhibition",
      "target": "BSEP",
      "label": "of"
    },
    {
      "source": "intracellular accumulation",
      "target": "bile acids",
      "label": "of"
    },
    {
      "source": "intracellular accumulation",
      "target": "risk factor",
      "label": "is a"
    },
    {
      "source": "Lactate dehydrogenase",
      "target": "concentration-dependent effect",
      "label": "revealed"
    },
    {
      "source": "nTiO2 products",
      "target": "P25",
      "label": "include"
    },
    {
      "source": "nTiO2 products",
      "target": "A-100",
      "label": "include"
    },
    {
      "source": "nTiO2 products",
      "target": "crystalline structure",
      "label": "have"
    },
    {
      "source": "titanium dioxide nanoparticles (nTiO2)",
      "target": "adverse effects",
      "label": "causes"
    },
    {
      "source": "titanium dioxide nanoparticles (nTiO2)",
      "target": "environment",
      "label": "released into"
    },
    {
      "source": "Nanoparticle toxicity",
      "target": "D. magna",
      "label": "to"
    },
    {
      "source": "Nanoparticle toxicity",
      "target": "reproduction studies",
      "label": "studied in"
    },
    {
      "source": "Nanoparticle toxicity",
      "target": "Daphnia magna",
      "label": "studied in"
    },
    {
      "source": "A-100 (\u223c140 nm)",
      "target": "A-100",
      "label": "is a type of"
    },
    {
      "source": "A-100 (\u223c140 nm)",
      "target": "number of released offspring",
      "label": "had no implication on"
    },
    {
      "source": "ecotoxicity",
      "target": "titanium dioxide nanoparticles (nTiO2)",
      "label": "of"
    },
    {
      "source": "ecotoxicity",
      "target": "Daphnia magna",
      "label": "to"
    },
    {
      "source": "product composition",
      "target": "factors",
      "label": "is a"
    },
    {
      "source": "product composition",
      "target": "crystalline structure",
      "label": "is"
    },
    {
      "source": "chronic ecotoxicity",
      "target": "nTiO2 products",
      "label": "of"
    },
    {
      "source": "chronic ecotoxicity",
      "target": "D. magna",
      "label": "to"
    },
    {
      "source": "test design",
      "target": "factors",
      "label": "is a"
    },
    {
      "source": "test design",
      "target": "Nanoparticle toxicity",
      "label": "is important for"
    },
    {
      "source": "environmentally relevant concentrations",
      "target": "dissolved organic carbon",
      "label": "of"
    },
    {
      "source": "accumulation of nTiO2",
      "target": "factors",
      "label": "is a"
    },
    {
      "source": "accumulation of nTiO2",
      "target": "semi-static test design",
      "label": "relevant for"
    },
    {
      "source": "accumulation of nTiO2",
      "target": "bottom of the test vessel",
      "label": "occurs at"
    },
    {
      "source": "A-100 (\u223c330 nm)",
      "target": "A-100",
      "label": "is a type of"
    },
    {
      "source": "A-100 (\u223c330 nm)",
      "target": "environmental risk",
      "label": "indicates"
    },
    {
      "source": "A-100 (\u223c330 nm)",
      "target": "reproduction",
      "label": "reduced"
    },
    {
      "source": "P25 (\u223c130 nm)",
      "target": "reproduction",
      "label": "did not adversely affect"
    },
    {
      "source": "P25 (\u223c130 nm)",
      "target": "P25",
      "label": "is a type of"
    },
    {
      "source": "environmental risk assessment",
      "target": "nanoparticles",
      "label": "of"
    },
    {
      "source": "semi-static test design",
      "target": "concentration",
      "label": "utilized for"
    },
    {
      "source": "semi-static exposure scenario",
      "target": "flow-through exposure scenario",
      "label": "compared with"
    },
    {
      "source": "semi-static exposure scenario",
      "target": "environmentally relevant concentrations",
      "label": "contains"
    },
    {
      "source": "flow-through exposure scenario",
      "target": "environmentally relevant concentrations",
      "label": "contains"
    },
    {
      "source": "particle size",
      "target": "factors",
      "label": "is a"
    },
    {
      "source": "flow-through experiment",
      "target": "A-100 (\u223c140 nm)",
      "label": "used"
    },
    {
      "source": "nanoparticle characteristics",
      "target": "factors",
      "label": "is a"
    },
    {
      "source": "standard test protocols",
      "target": "ecotoxicity",
      "label": "used to investigate"
    },
    {
      "source": "targeting functionality",
      "target": "stable metal-oxide nanoparticles",
      "label": "is loaded onto"
    },
    {
      "source": "imaging functionality",
      "target": "stable metal-oxide nanoparticles",
      "label": "is loaded onto"
    },
    {
      "source": "route",
      "target": "Magnetic nanoclusters",
      "label": "produces"
    },
    {
      "source": "Magnetic nanoclusters",
      "target": "near-infrared fluorescence",
      "label": "exhibiting"
    },
    {
      "source": "MNCs",
      "target": "poly(acrylic acid-co-propargyl acrylate)",
      "label": "composed of"
    },
    {
      "source": "MNCs",
      "target": "magnetic Fe(3)O(4) nanoparticles",
      "label": "composed of"
    },
    {
      "source": "MNCs",
      "target": "co-precipitation",
      "label": "formed by"
    },
    {
      "source": "MNCs",
      "target": "near-infrared (NIR) emitting fluorophore",
      "label": "were surface-modified with"
    },
    {
      "source": "MNCs",
      "target": "alkyne surface functionality",
      "label": "have"
    },
    {
      "source": "MNCs",
      "target": "multimodal imaging probes",
      "label": "can be utilized as"
    },
    {
      "source": "extended coverage",
      "target": "serum proteins",
      "label": "is of"
    },
    {
      "source": "extended coverage",
      "target": "MNCs",
      "label": "is on"
    },
    {
      "source": "serum proteins",
      "target": "NIR emission",
      "label": "induced"
    },
    {
      "source": "serum proteins",
      "target": "aqueous environment",
      "label": "isolated from"
    },
    {
      "source": "serum proteins",
      "target": "indocyanine green fluorophores",
      "label": "isolated"
    },
    {
      "source": "challenge",
      "target": "targeting functionality",
      "label": "is to load"
    },
    {
      "source": "challenge",
      "target": "therapeutic functionality",
      "label": "is to load"
    },
    {
      "source": "challenge",
      "target": "imaging functionality",
      "label": "is to load"
    },
    {
      "source": "challenge",
      "target": "deleterious ones",
      "label": "is to uncouple from"
    },
    {
      "source": "challenge",
      "target": "beneficial actions",
      "label": "is to uncouple"
    },
    {
      "source": "therapeutic functionality",
      "target": "stable metal-oxide nanoparticles",
      "label": "is loaded onto"
    },
    {
      "source": "Composite nanoclusters",
      "target": "targeted cellular imaging",
      "label": "offer opportunities for"
    },
    {
      "source": "Composite nanoclusters",
      "target": "magnetic functionality",
      "label": "have"
    },
    {
      "source": "Composite nanoclusters",
      "target": "biofunctionality",
      "label": "have"
    },
    {
      "source": "Composite nanoclusters",
      "target": "chemical functionality",
      "label": "have"
    },
    {
      "source": "bovine serum albumin",
      "target": "extended coverage",
      "label": "formed"
    },
    {
      "source": "bovine serum albumin",
      "target": "BSA",
      "label": "is also known as"
    },
    {
      "source": "near-infrared (NIR) emitting fluorophore",
      "target": "photodynamic therapy",
      "label": "is used in"
    },
    {
      "source": "near-infrared (NIR) emitting fluorophore",
      "target": "azide-modified indocyanine green",
      "label": "is"
    },
    {
      "source": "co-precipitation",
      "target": "iron salts",
      "label": "involves"
    },
    {
      "source": "co-precipitation",
      "target": "copolymer stabilizers",
      "label": "occurs in presence of"
    },
    {
      "source": "fluorophore",
      "target": "bovine serum albumin",
      "label": "complexed with"
    },
    {
      "source": "nontoxic core-shell macromolecule",
      "target": "A549 human epithelial cells",
      "label": "uptaken by"
    },
    {
      "source": "nontoxic core-shell macromolecule",
      "target": "dendritic PAMAM shell",
      "label": "uptake due to"
    },
    {
      "source": "binding pockets",
      "target": "human serum albumin (HSA) core",
      "label": "of"
    },
    {
      "source": "human serum albumin (HSA) core",
      "target": "reservoir",
      "label": "serves as"
    },
    {
      "source": "Dendronized G2-DHSA-doxorubicin",
      "target": "cytotoxicity",
      "label": "displayed"
    },
    {
      "source": "Dendronized G2-DHSA-doxorubicin",
      "target": "transporter",
      "label": "is a"
    },
    {
      "source": "cationized shell region",
      "target": "ethynyl-G2.0-PAMAM dendrons",
      "label": "consists of"
    },
    {
      "source": "cationized shell region",
      "target": "ethynyl-G3.0-PAMAM dendrons",
      "label": "consists of"
    },
    {
      "source": "core-shell biohybrid",
      "target": "human serum albumin (HSA) core",
      "label": "consists of"
    },
    {
      "source": "core-shell biohybrid",
      "target": "cationized shell region",
      "label": "consists of"
    },
    {
      "source": "attachment",
      "target": "nontoxic core-shell macromolecule",
      "label": "yielded"
    },
    {
      "source": "attachment",
      "target": "ethynyl-G2.0-PAMAM dendrons",
      "label": "of"
    },
    {
      "source": "attachment",
      "target": "HSA",
      "label": "to"
    },
    {
      "source": "loading",
      "target": "doxorubicin",
      "label": "of"
    },
    {
      "source": "loading",
      "target": "interaction",
      "label": "due to"
    },
    {
      "source": "loading",
      "target": "native protein",
      "label": "compared with"
    },
    {
      "source": "loading",
      "target": "binding pockets",
      "label": "due to"
    },
    {
      "source": "loading",
      "target": "dendronized G2-DHSA",
      "label": "observed for"
    },
    {
      "source": "reservoir",
      "target": "lipophilic molecules",
      "label": "for"
    },
    {
      "source": "binding capacity",
      "target": "electron paramagnetic resonance (EPR) spectroscopy",
      "label": "quantified by"
    },
    {
      "source": "binding capacity",
      "target": "lipophilic guests",
      "label": "of"
    },
    {
      "source": "binding capacity",
      "target": "phosphorylated Tau peptide",
      "label": "to"
    },
    {
      "source": "HSA",
      "target": "fatty acid",
      "label": "is complexed with"
    },
    {
      "source": "HSA",
      "target": "acetyldiflunisal",
      "label": "is complexed with"
    },
    {
      "source": "drug loading",
      "target": "SPPI",
      "label": "evaluated for"
    },
    {
      "source": "drug loading",
      "target": "MPPI",
      "label": "evaluated for"
    },
    {
      "source": "drug loading",
      "target": "SMPPI",
      "label": "evaluated for"
    },
    {
      "source": "drug loading",
      "target": "PPI",
      "label": "evaluated for"
    },
    {
      "source": "pockets",
      "target": "HSA",
      "label": "compared with"
    },
    {
      "source": "Dendronized albumin core-shell transporters",
      "target": "drug loading capacity",
      "label": "have"
    },
    {
      "source": "imaging agent",
      "target": "carbonic anhydrase II",
      "label": "for"
    },
    {
      "source": "imaging agent",
      "target": "in situ click-chemistry",
      "label": "derived from"
    },
    {
      "source": "imaging agent",
      "target": "positron emission tomography",
      "label": "for"
    },
    {
      "source": "(18) F surrogates",
      "target": "(18) F",
      "label": "are surrogates of"
    },
    {
      "source": "in situ click-chemistry",
      "target": "(19) F-bearing fragments",
      "label": "uses"
    },
    {
      "source": "(19) F-bearing fragments",
      "target": "(18) F surrogates",
      "label": "are"
    },
    {
      "source": "(19) F-bearing fragments",
      "target": "(19) F",
      "label": "contain"
    },
    {
      "source": "PET probes",
      "target": "chemical characteristics",
      "label": "have"
    },
    {
      "source": "PET probes",
      "target": "biological characteristics",
      "label": "have"
    },
    {
      "source": "PET probes",
      "target": "target affinities",
      "label": "have"
    },
    {
      "source": "lead hits",
      "target": "chemical characteristics",
      "label": "have"
    },
    {
      "source": "lead hits",
      "target": "biological characteristics",
      "label": "have"
    },
    {
      "source": "CA II",
      "target": "PET",
      "label": "is a good target for"
    },
    {
      "source": "PET probe discovery",
      "target": "in situ click-chemistry",
      "label": "uses"
    },
    {
      "source": "in situ",
      "target": "in vivo",
      "label": "leads to"
    },
    {
      "source": "Ras-dva",
      "target": "Pit-1",
      "label": "is regulated by"
    },
    {
      "source": "Ras-dva",
      "target": "embryonic anterior pituitary gland",
      "label": "located in"
    },
    {
      "source": "Ras-dva",
      "target": "anterior neural fold protein-1/homeobox expressed in embryonic stem cells-1",
      "label": "regulated by"
    },
    {
      "source": "Ras-dva",
      "target": "glucocorticoid",
      "label": "is regulated by"
    },
    {
      "source": "Ras-dva",
      "target": "gene",
      "label": "is a"
    },
    {
      "source": "Ras-dva",
      "target": "expression profile",
      "label": "has an"
    },
    {
      "source": "reporter construct",
      "target": "chicken ras-dva 5'-flanking region",
      "label": "driven by"
    },
    {
      "source": "reporter construct",
      "target": "pituitary cells",
      "label": "activated in"
    },
    {
      "source": "reporter construct",
      "target": "corticosterone",
      "label": "up-regulated by"
    },
    {
      "source": "chicken ras-dva 5'-flanking region",
      "target": "glucocorticoid receptor (GR) binding sites",
      "label": "contains"
    },
    {
      "source": "chicken ras-dva 5'-flanking region",
      "target": "pituitary-specific transcription factor-1 (Pit-1) binding sites",
      "label": "contains"
    },
    {
      "source": "glucocorticoid-regulated gene",
      "target": "cells",
      "label": "expressed in"
    },
    {
      "source": "ras-dva mRNA",
      "target": "direct transcriptional target",
      "label": "is a"
    },
    {
      "source": "ras-dva mRNA",
      "target": "developing chicken anterior pituitary",
      "label": "is found in"
    },
    {
      "source": "functional differentiation",
      "target": "lactotrophs",
      "label": "of"
    },
    {
      "source": "functional differentiation",
      "target": "pituitary somatotrophs",
      "label": "of"
    },
    {
      "source": "functional differentiation",
      "target": "embryogenesis",
      "label": "occurs during"
    },
    {
      "source": "anterior neural fold protein-1/homeobox expressed in embryonic stem cells-1",
      "target": "transcription factor",
      "label": "is a"
    },
    {
      "source": "DNA elements",
      "target": "5'-flanking region",
      "label": "within"
    },
    {
      "source": "DNA elements",
      "target": "glucocorticoid regulation",
      "label": "responsible for"
    },
    {
      "source": "expression profile",
      "target": "chicken embryonic pituitary gland",
      "label": "in"
    },
    {
      "source": "expression profile",
      "target": "in vivo regulation",
      "label": "consistent with"
    },
    {
      "source": "corticosterone",
      "target": "CORT",
      "label": "is also known as"
    },
    {
      "source": "corticosterone",
      "target": "reward-based decision-making",
      "label": "has effects on"
    },
    {
      "source": "corticosterone",
      "target": "rodent model",
      "label": "has effects in"
    },
    {
      "source": "Mutagenesis",
      "target": "promoter activity",
      "label": "decreased"
    },
    {
      "source": "Mutagenesis",
      "target": "Pit-1 site",
      "label": "of"
    },
    {
      "source": "Glucocorticoids",
      "target": "functional differentiation",
      "label": "play a role in"
    },
    {
      "source": "Glucocorticoids",
      "target": "TP-induced hepatotoxicity",
      "label": "might be involved in"
    },
    {
      "source": "Pituitary ras-dva mRNA levels",
      "target": "embryonic day (e) 18",
      "label": "peaked on"
    },
    {
      "source": "Pituitary ras-dva mRNA levels",
      "target": "hatch",
      "label": "decreased after"
    },
    {
      "source": "Pituitary ras-dva mRNA levels",
      "target": "embryogenesis",
      "label": "increased during"
    },
    {
      "source": "ras-dva promoter activity",
      "target": "corticosterone",
      "label": "induced by"
    },
    {
      "source": "Glucocorticoid treatment",
      "target": "ras-dva mRNA",
      "label": "increased"
    },
    {
      "source": "Glucocorticoid treatment",
      "target": "pituitary cells",
      "label": "applied to"
    },
    {
      "source": "Ras-dva expression",
      "target": "tissues",
      "label": "relative to"
    },
    {
      "source": "Ras-dva expression",
      "target": "pituitary gland",
      "label": "enriched in"
    },
    {
      "source": "Ras-dva expression",
      "target": "embryonic day (e) 18",
      "label": "enriched on"
    },
    {
      "source": "probe",
      "target": "previously reported probes",
      "label": "is more effective label than"
    },
    {
      "source": "probe",
      "target": "analysis",
      "label": "applied to"
    },
    {
      "source": "probe",
      "target": "legumain",
      "label": "is selective for"
    },
    {
      "source": "probe",
      "target": "whole cells",
      "label": "used in"
    },
    {
      "source": "probe",
      "target": "tissues",
      "label": "used in"
    },
    {
      "source": "high expression",
      "target": "populations of activated macrophages",
      "label": "occurs in"
    },
    {
      "source": "high expression",
      "target": "legumain activity",
      "label": "causes up-regulation of"
    },
    {
      "source": "legumain activity",
      "target": "inflammatory diseases",
      "label": "is up-regulated in"
    },
    {
      "source": "legumain activity",
      "target": "human cancers",
      "label": "is up-regulated in"
    },
    {
      "source": "legumain activity",
      "target": "mouse models of cancer",
      "label": "analyzed in"
    },
    {
      "source": "legumain activity",
      "target": "primary macrophages",
      "label": "analyzed in"
    },
    {
      "source": "legumain activity",
      "target": "macrophage activation",
      "label": "is correlated with"
    },
    {
      "source": "legumain activity",
      "target": "tumor microenvironment",
      "label": "occurs within"
    },
    {
      "source": "legumain activity",
      "target": "ideal marker",
      "label": "is"
    },
    {
      "source": "legumain activity",
      "target": "tumorigenesis",
      "label": "promotes"
    },
    {
      "source": "legumain activity",
      "target": "cancer progression",
      "label": "occurs during"
    },
    {
      "source": "legumain activity",
      "target": "inflammation",
      "label": "occurs during"
    },
    {
      "source": "ideal marker",
      "target": "primary tumor inflammation",
      "label": "for"
    },
    {
      "source": "ideal marker",
      "target": "early stage metastatic lesions",
      "label": "for"
    },
    {
      "source": "activity-based probe",
      "target": "legumain activity",
      "label": "developed to understand"
    },
    {
      "source": "activity-based probe",
      "target": "active legumain",
      "label": "binds"
    },
    {
      "source": "quenched activity-based probe",
      "target": "legumain",
      "label": "enables imaging of"
    },
    {
      "source": "quenched activity-based probe",
      "target": "cancer",
      "label": "enables imaging of"
    },
    {
      "source": "legumain",
      "target": "lysosomal cysteine protease",
      "label": "is a"
    },
    {
      "source": "legumain",
      "target": "biological function",
      "label": "has"
    },
    {
      "source": "title compounds",
      "target": "JMC08-4",
      "label": "has more potent inhibitory activity than"
    },
    {
      "source": "title compounds",
      "target": "inhibitory activity",
      "label": "showed"
    },
    {
      "source": "title compounds",
      "target": "LTA(4)H-h",
      "label": "inhibited"
    },
    {
      "source": "title compounds",
      "target": "hnps-PLA(2)",
      "label": "inhibited"
    },
    {
      "source": "JMC08-4",
      "target": "LTA(4)H-h",
      "label": "inhibits"
    },
    {
      "source": "JMC08-4",
      "target": "human nonpancreatic secretory phospholipase A(2)",
      "label": "inhibits"
    },
    {
      "source": "JMC08-4",
      "target": "human leukotriene A(4) hydrolase",
      "label": "inhibits"
    },
    {
      "source": "JMC08-4",
      "target": "hnps-PLA(2)",
      "label": "inhibits"
    },
    {
      "source": "JMC08-4",
      "target": "dual-target inhibitor",
      "label": "is a type of"
    },
    {
      "source": "dual function inhibitors",
      "target": "AA metabolic network",
      "label": "balance"
    },
    {
      "source": "dual function inhibitors",
      "target": "leukotriene A(4) hydrolase",
      "label": "target"
    },
    {
      "source": "dual function inhibitors",
      "target": "phospholipase A(2)",
      "label": "target"
    },
    {
      "source": "dual function inhibitors",
      "target": "phospholipase A2",
      "label": "target"
    },
    {
      "source": "dual function inhibitors",
      "target": "LTA(4)H",
      "label": "target"
    },
    {
      "source": "dual function inhibitors",
      "target": "anti-inflammatory drugs",
      "label": "are used as"
    },
    {
      "source": "dual function inhibitors",
      "target": "leukotriene A4 hydrolase",
      "label": "target"
    },
    {
      "source": "dual function inhibitors",
      "target": "PLA(2)",
      "label": "target"
    },
    {
      "source": "multi-target drugs",
      "target": "AA metabolic network",
      "label": "are towards"
    },
    {
      "source": "5-hydroxytryptamines",
      "target": "dual function inhibitors",
      "label": "are optimized as"
    },
    {
      "source": "LTA(4)H-h",
      "target": "2.4 \u00b1 1.4 \u03bcM",
      "label": "has IC(50) value of"
    },
    {
      "source": "hnps-PLA(2)",
      "target": "9.2 \u00b1 0.5 \u03bcM",
      "label": "has IC(50) value of"
    },
    {
      "source": "inhibitory activity",
      "target": "enzymes",
      "label": "against"
    },
    {
      "source": "inhibitory activity",
      "target": "in vitro bioassay",
      "label": "measured in"
    },
    {
      "source": "inhibitory activity",
      "target": "IC(50) value",
      "label": "has"
    },
    {
      "source": "inhibitory activity",
      "target": "nitric oxide production",
      "label": "against"
    },
    {
      "source": "new dual-target inhibitors",
      "target": "molecular docking",
      "label": "designed assisted by"
    },
    {
      "source": "new dual-target inhibitors",
      "target": "structure of compound JMC08-4",
      "label": "designed based on"
    },
    {
      "source": "previous study",
      "target": "multi-target drugs",
      "label": "discovered"
    },
    {
      "source": "1,25(OH)(2)D(3)",
      "target": "corn oil",
      "label": "was administered in"
    },
    {
      "source": "1,25(OH)(2)D(3)",
      "target": "expression",
      "label": "decreased"
    },
    {
      "source": "1,25(OH)(2)D(3)",
      "target": "renal excretion",
      "label": "inhibited"
    },
    {
      "source": "JBP485",
      "target": "intravenous administration",
      "label": "was measured after"
    },
    {
      "source": "AUCs",
      "target": "JBP485",
      "label": "are of"
    },
    {
      "source": "AUCs",
      "target": "1,25(OH)(2)D(3)",
      "label": "increased after"
    },
    {
      "source": "immunohistochemical analysis",
      "target": "expression",
      "label": "was used to determine"
    },
    {
      "source": "1\u03b1,25-dihydroxyvitamin D\u2083",
      "target": "inhibitory effect",
      "label": "causes"
    },
    {
      "source": "corn oil",
      "target": "control",
      "label": "is_a"
    },
    {
      "source": "western blotting",
      "target": "expression",
      "label": "was used to determine"
    },
    {
      "source": "western blotting",
      "target": "cilostazol treatment",
      "label": "demonstrated effect of"
    },
    {
      "source": "urine concentrations",
      "target": "liquid chromatography/tandem mass spectrometry",
      "label": "were determined by"
    },
    {
      "source": "urine concentrations",
      "target": "JBP485",
      "label": "are of"
    },
    {
      "source": "Quantitative polymerase chain reaction",
      "target": "expression",
      "label": "was used to determine"
    },
    {
      "source": "pharmacokinetic mechanism",
      "target": "interaction",
      "label": "describes"
    },
    {
      "source": "ndk strains",
      "target": "nucleoside diphosphate kinase",
      "label": "are defective in"
    },
    {
      "source": "ndk strains",
      "target": "mutator phenotype",
      "label": "have"
    },
    {
      "source": "ndk strains",
      "target": "mutability",
      "label": "display"
    },
    {
      "source": "ndk strains",
      "target": "dATP",
      "label": "have lowered levels of"
    },
    {
      "source": "ndk strains",
      "target": "dCTP",
      "label": "have enhanced levels of"
    },
    {
      "source": "ndk strains",
      "target": "mutator effect",
      "label": "have"
    },
    {
      "source": "ndk strains",
      "target": "dNTP pools",
      "label": "are characterized by"
    },
    {
      "source": "ndk strains",
      "target": "mutational properties",
      "label": "have"
    },
    {
      "source": "Mutational consequences",
      "target": "E. coli",
      "label": "occur in"
    },
    {
      "source": "mutator effect",
      "target": "lacZ reversion markers",
      "label": "is measured using"
    },
    {
      "source": "mutator effect",
      "target": "mismatch-repair",
      "label": "is associated with"
    },
    {
      "source": "mutator effect",
      "target": "G\u00b7C\u2192T\u00b7A transversions",
      "label": "is for"
    },
    {
      "source": "mutator effect",
      "target": "A\u00b7T\u2192T\u00b7A transversions",
      "label": "is specific for"
    },
    {
      "source": "dcd strains",
      "target": "dCTP",
      "label": "have increased levels of"
    },
    {
      "source": "dcd strains",
      "target": "dNTP pools",
      "label": "are characterized by"
    },
    {
      "source": "dcd strains",
      "target": "mutational properties",
      "label": "have"
    },
    {
      "source": "dcd strains",
      "target": "mutator effect",
      "label": "display"
    },
    {
      "source": "dcd strains",
      "target": "mutator phenotype",
      "label": "are characterized by"
    },
    {
      "source": "dcd strains",
      "target": "dCTP deaminase",
      "label": "are defective in"
    },
    {
      "source": "dcd strains",
      "target": "mutability",
      "label": "display"
    },
    {
      "source": "dcd strains",
      "target": "dGTP",
      "label": "have reduced levels of"
    },
    {
      "source": "error rates",
      "target": "dNTPs",
      "label": "are correlated with"
    },
    {
      "source": "dNTPs",
      "target": "error rates",
      "label": "are correlated with"
    },
    {
      "source": "mismatch-repair",
      "target": "mutL",
      "label": "is associated with"
    },
    {
      "source": "mutability",
      "target": "rifampicin-resistant mutants",
      "label": "is for"
    },
    {
      "source": "replication error rates",
      "target": "dNTP pool alterations",
      "label": "are correlated with"
    },
    {
      "source": "dNTP pool alterations",
      "target": "replication error rates",
      "label": "are correlated with"
    },
    {
      "source": "rifampicin-resistant mutants",
      "target": "rifampicin",
      "label": "are resistant to"
    },
    {
      "source": "5'-deoxynucleoside-triphosphate DNA precursors",
      "target": "dNTPs",
      "label": "are also known as"
    },
    {
      "source": "ndk mutator",
      "target": "dNTP pools",
      "label": "is explained by"
    },
    {
      "source": "dNTP pool imbalances",
      "target": "Mutational consequences",
      "label": "cause"
    },
    {
      "source": "hyperoside",
      "target": "thrombin",
      "label": "inhibited production of"
    },
    {
      "source": "hyperoside",
      "target": "FXa",
      "label": "inhibited production of"
    },
    {
      "source": "hyperoside",
      "target": "Antithrombotic activities",
      "label": "possesses"
    },
    {
      "source": "hyperoside",
      "target": "profibrinolytic activities",
      "label": "has"
    },
    {
      "source": "hyperoside",
      "target": "activated factor X",
      "label": "inhibited production of"
    },
    {
      "source": "hyperoside",
      "target": "anticoagulant activities",
      "label": "has"
    },
    {
      "source": "hyperoside",
      "target": "prothrombin time",
      "label": "prolonged"
    },
    {
      "source": "hyperoside",
      "target": "novel anticoagulant",
      "label": "is basis for development of"
    },
    {
      "source": "hyperoside",
      "target": "PT",
      "label": "prolonged"
    },
    {
      "source": "hyperoside",
      "target": "activated partial thromboplastin time",
      "label": "prolonged"
    },
    {
      "source": "hyperoside",
      "target": "aPTT",
      "label": "prolonged"
    },
    {
      "source": "hyperoside",
      "target": "PAI-1",
      "label": "inhibited production of"
    },
    {
      "source": "hyperoside",
      "target": "mouse",
      "label": "causes anticoagulant activities in"
    },
    {
      "source": "human umbilical vein endothelial cells",
      "target": "HUVECs",
      "label": "is"
    },
    {
      "source": "FXa",
      "target": "human umbilical vein endothelial cells",
      "label": "produced in"
    },
    {
      "source": "FXa",
      "target": "HUVECs",
      "label": "produced in"
    },
    {
      "source": "Oenanthe javanica",
      "target": "hyperoside",
      "label": "is source of"
    },
    {
      "source": "Oenanthe javanica",
      "target": "isorhamnetin-3-O-galactoside",
      "label": "is source of"
    },
    {
      "source": "activated factor X",
      "target": "HUVECs",
      "label": "produced in"
    },
    {
      "source": "activated factor X",
      "target": "FXa",
      "label": "is also known as"
    },
    {
      "source": "activated factor X",
      "target": "human umbilical vein endothelial cells",
      "label": "produced in"
    },
    {
      "source": "tumor necrosis factor-(TNF)-\u03b1",
      "target": "PAI-1",
      "label": "induces production of"
    },
    {
      "source": "tumor necrosis factor-(TNF)-\u03b1",
      "target": "TNF-\u03b1",
      "label": "is also known as"
    },
    {
      "source": "HUVECs",
      "target": "tumor necrosis factor-(TNF)-\u03b1",
      "label": "activated by"
    },
    {
      "source": "HUVECs",
      "target": "TNF-\u03b1",
      "label": "activated by"
    },
    {
      "source": "IMG",
      "target": "FXa",
      "label": "inhibited production of"
    },
    {
      "source": "IMG",
      "target": "activated factor X",
      "label": "inhibited production of"
    },
    {
      "source": "IMG",
      "target": "thrombin",
      "label": "inhibited production of"
    },
    {
      "source": "IMG",
      "target": "Antithrombotic activities",
      "label": "possesses"
    },
    {
      "source": "IMG",
      "target": "anticoagulant activities",
      "label": "has"
    },
    {
      "source": "IMG",
      "target": "prothrombin time",
      "label": "prolonged"
    },
    {
      "source": "IMG",
      "target": "novel anticoagulant",
      "label": "is basis for development of"
    },
    {
      "source": "IMG",
      "target": "PT",
      "label": "prolonged"
    },
    {
      "source": "IMG",
      "target": "aPTT",
      "label": "prolonged"
    },
    {
      "source": "IMG",
      "target": "activated partial thromboplastin time",
      "label": "prolonged"
    },
    {
      "source": "IMG",
      "target": "PAI-1",
      "label": "inhibited production of"
    },
    {
      "source": "IMG",
      "target": "mouse",
      "label": "causes anticoagulant activities in"
    },
    {
      "source": "IMG",
      "target": "PAI-1 to t-PA ratio",
      "label": "reduced"
    },
    {
      "source": "activated partial thromboplastin time",
      "target": "aPTT",
      "label": "is also known as"
    },
    {
      "source": "prothrombin time",
      "target": "PT",
      "label": "is also known as"
    },
    {
      "source": "prothrombin time",
      "target": "FVIIai infusion",
      "label": "prolonged by"
    },
    {
      "source": "TNF-\u03b1",
      "target": "PAI-1",
      "label": "induces production of"
    },
    {
      "source": "TNF-\u03b1",
      "target": "cervical muscles",
      "label": "is located in"
    },
    {
      "source": "TNF-\u03b1",
      "target": "Inflammatory bowel disease (IBD)",
      "label": "is associated with"
    },
    {
      "source": "TNF-\u03b1",
      "target": "IFN-\u03b3",
      "label": "combined with"
    },
    {
      "source": "methoxy group",
      "target": "IMG",
      "label": "is part of"
    },
    {
      "source": "methoxy group",
      "target": "anticoagulant function",
      "label": "positively regulates"
    },
    {
      "source": "tissue-type plasminogen activator",
      "target": "t-PA",
      "label": "is also known as"
    },
    {
      "source": "t-PA",
      "target": "human [Glu1]plasminogen",
      "label": "Upregulator"
    },
    {
      "source": "t-PA",
      "target": "( Glu1]Pg)",
      "label": "Upregulator"
    },
    {
      "source": "plasminogen activator inhibitor type 1",
      "target": "PAI-1",
      "label": "is also known as"
    },
    {
      "source": "isorhamnetin-3-O-galactoside",
      "target": "Antithrombotic activities",
      "label": "has"
    },
    {
      "source": "isorhamnetin-3-O-galactoside",
      "target": "profibrinolytic activities",
      "label": "has"
    },
    {
      "source": "isorhamnetin-3-O-galactoside",
      "target": "anticoagulant activities",
      "label": "has"
    },
    {
      "source": "6\u03b2-hydroxylation",
      "target": "budesonide",
      "label": "is metabolite of"
    },
    {
      "source": "6\u03b2-hydroxylation",
      "target": "flunisolide",
      "label": "is metabolite of"
    },
    {
      "source": "6\u03b2-hydroxylation",
      "target": "triamcinolone acetonide",
      "label": "is metabolite of"
    },
    {
      "source": "budesonide",
      "target": "CYP3A5",
      "label": "is substrate for"
    },
    {
      "source": "budesonide",
      "target": "CYP3A family of enzymes",
      "label": "is substrate for"
    },
    {
      "source": "\u0394(6)-dehydrogenation",
      "target": "budesonide",
      "label": "is metabolite of"
    },
    {
      "source": "\u0394(6)-dehydrogenation",
      "target": "flunisolide",
      "label": "is metabolite of"
    },
    {
      "source": "\u0394(6)-dehydrogenation",
      "target": "triamcinolone acetonide",
      "label": "is metabolite of"
    },
    {
      "source": "inhaled glucocorticoids",
      "target": "Asthma",
      "label": "is treatment for"
    },
    {
      "source": "interenzyme variability",
      "target": "rates of metabolism",
      "label": "affects"
    },
    {
      "source": "interenzyme variability",
      "target": "metabolic fate",
      "label": "affects"
    },
    {
      "source": "flunisolide",
      "target": "CYP3A family of enzymes",
      "label": "is substrate for"
    },
    {
      "source": "flunisolide",
      "target": "CYP3A7",
      "label": "not metabolized by"
    },
    {
      "source": "flunisolide",
      "target": "CYP3A5",
      "label": "not metabolized by"
    },
    {
      "source": "flunisolide",
      "target": "CYP3A4",
      "label": "is substrate for"
    },
    {
      "source": "rates of clearance",
      "target": "GCs",
      "label": "of"
    },
    {
      "source": "GCs",
      "target": "Asthma",
      "label": "is treatment for"
    },
    {
      "source": "CYP3A5",
      "target": "GC metabolism",
      "label": "is relevant to"
    },
    {
      "source": "CYP3A5",
      "target": "BDP",
      "label": "metabolized"
    },
    {
      "source": "CYP3A5",
      "target": "rates",
      "label": "metabolized at similar"
    },
    {
      "source": "CYP3A7",
      "target": "rates of metabolism",
      "label": "has"
    },
    {
      "source": "CYP3A7",
      "target": "BDP",
      "label": "does not metabolize"
    },
    {
      "source": "21-nortriamcinolone acetonide",
      "target": "NMR analysis",
      "label": "identified by"
    },
    {
      "source": "21-nortriamcinolone acetonide",
      "target": "liquid chromatography-mass spectrometry",
      "label": "identified by"
    },
    {
      "source": "21-nortriamcinolone acetonide",
      "target": "metabolites",
      "label": "is a type of"
    },
    {
      "source": "triamcinolone acetonide",
      "target": "CYP3A family of enzymes",
      "label": "is substrate for"
    },
    {
      "source": "triamcinolone acetonide",
      "target": "CYP3A5",
      "label": "is substrate for"
    },
    {
      "source": "\u0394(6)-flunisolide",
      "target": "NMR analysis",
      "label": "structure established by"
    },
    {
      "source": "fluticasone propionate",
      "target": "CYP3A5",
      "label": "is substrate for"
    },
    {
      "source": "fluticasone propionate",
      "target": "CYP3A family of enzymes",
      "label": "is substrate for"
    },
    {
      "source": "interdrug variability",
      "target": "metabolic fate",
      "label": "affects"
    },
    {
      "source": "interdrug variability",
      "target": "rates of metabolism",
      "label": "affects"
    },
    {
      "source": "GC metabolism",
      "target": "lungs",
      "label": "occurs in"
    },
    {
      "source": "asthma sufferers",
      "target": "steroid insensitivity",
      "label": "exhibit"
    },
    {
      "source": "asthma sufferers",
      "target": "inhaled glucocorticoids",
      "label": "are refractory to"
    },
    {
      "source": "21-carboxy metabolites",
      "target": "flunisolide",
      "label": "is metabolite of"
    },
    {
      "source": "21-carboxy metabolites",
      "target": "triamcinolone acetonide",
      "label": "is metabolite of"
    },
    {
      "source": "cardiomyopathy",
      "target": "Duchenne muscular dystrophy",
      "label": "is cause of death in"
    },
    {
      "source": "AMPK-induced autophagy",
      "target": "cardiomyocyte apoptosis",
      "label": "inhibits"
    },
    {
      "source": "AMPK-induced autophagy",
      "target": "Diabetic cardiomyopathy",
      "label": "ameliorates"
    },
    {
      "source": "cardiomyocyte apoptosis",
      "target": "diabetes",
      "label": "occurs in"
    },
    {
      "source": "high glucose",
      "target": "JNK1-Bcl-2 signaling",
      "label": "inhibited"
    },
    {
      "source": "high glucose",
      "target": "Beclin1 binding to Bcl-2",
      "label": "promoted"
    },
    {
      "source": "high glucose",
      "target": "H9c2 cells",
      "label": "treated"
    },
    {
      "source": "high glucose",
      "target": "AMPK activity",
      "label": "reduced"
    },
    {
      "source": "autophagy",
      "target": "cardiac apoptosis",
      "label": "protected against"
    },
    {
      "source": "autophagy",
      "target": "cardiac structure",
      "label": "improved"
    },
    {
      "source": "autophagy",
      "target": "cardiac function",
      "label": "improved"
    },
    {
      "source": "dissociation of Bcl-2 from Beclin1",
      "target": "cardiac autophagy",
      "label": "enhances"
    },
    {
      "source": "dissociation of Bcl-2 from Beclin1",
      "target": "Diabetic cardiomyopathy",
      "label": "prevents"
    },
    {
      "source": "dissociation of Bcl-2 from Beclin1",
      "target": "cardiomyocyte apoptosis",
      "label": "protects against"
    },
    {
      "source": "dissociation of Bcl-2 from Beclin1",
      "target": "AMPK activation",
      "label": "is mediated by"
    },
    {
      "source": "Diabetic cardiomyopathy",
      "target": "suppression of cardiac autophagy",
      "label": "associated with"
    },
    {
      "source": "interaction between Beclin1 and Bcl-2",
      "target": "apoptosis",
      "label": "regulates"
    },
    {
      "source": "interaction between Beclin1 and Bcl-2",
      "target": "autophagy",
      "label": "regulates"
    },
    {
      "source": "inhibition of autophagy",
      "target": "high glucose-induced apoptosis",
      "label": "promotes"
    },
    {
      "source": "Metformin",
      "target": "human lung cancer cells",
      "label": "sensitizes"
    },
    {
      "source": "Metformin",
      "target": "paclitaxel therapy",
      "label": "combined with"
    },
    {
      "source": "Metformin",
      "target": "type 2 diabetes",
      "label": "treats"
    },
    {
      "source": "Metformin",
      "target": "cytotoxic effect",
      "label": "augments"
    },
    {
      "source": "Metformin",
      "target": "anticancer drug",
      "label": "is a type of"
    },
    {
      "source": "Metformin",
      "target": "DNA repair capacity",
      "label": "decreases"
    },
    {
      "source": "Metformin",
      "target": "p38 mitogen-activated protein kinase",
      "label": "downregulates"
    },
    {
      "source": "Metformin",
      "target": "p38 MAPK signaling",
      "label": "inhibits"
    },
    {
      "source": "Metformin",
      "target": "p38 MAPK-mediated ERCC1 expression",
      "label": "decreases"
    },
    {
      "source": "specific small interfering RNA",
      "target": "p38 knockdown",
      "label": "causes"
    },
    {
      "source": "p38 knockdown",
      "target": "p38 activity",
      "label": "downregulates"
    },
    {
      "source": "p38 knockdown",
      "target": "ERCC1",
      "label": "decreases"
    },
    {
      "source": "cytotoxic effect",
      "target": "MTT assay",
      "label": "determined by"
    },
    {
      "source": "cytotoxic effect",
      "target": "acridine orange staining",
      "label": "determined by"
    },
    {
      "source": "constitutive activate MKK6",
      "target": "cell viability",
      "label": "abrogates"
    },
    {
      "source": "constitutive activate MKK6",
      "target": "DNA repair capacity",
      "label": "abrogates"
    },
    {
      "source": "constitutive activate MKK6",
      "target": "ERCC1",
      "label": "abrogates"
    },
    {
      "source": "HA-p38 MAPK vectors",
      "target": "cell viability",
      "label": "abrogates"
    },
    {
      "source": "HA-p38 MAPK vectors",
      "target": "DNA repair capacity",
      "label": "abrogates"
    },
    {
      "source": "HA-p38 MAPK vectors",
      "target": "ERCC1",
      "label": "abrogates"
    },
    {
      "source": "ERCC1",
      "target": "prognosis",
      "label": "associated with"
    },
    {
      "source": "ERCC1",
      "target": "DNA repair capacity",
      "label": "associated with"
    },
    {
      "source": "NSCLC patients",
      "target": "platinum-containing chemotherapy",
      "label": "treated with"
    },
    {
      "source": "Taxol",
      "target": "antineoplastic drug",
      "label": "is a type of"
    },
    {
      "source": "Taxol",
      "target": "non-small cell lung cancer",
      "label": "treats"
    },
    {
      "source": "excision repair cross-complementing 1",
      "target": "DNA repair capacity",
      "label": "associated with"
    },
    {
      "source": "excision repair cross-complementing 1",
      "target": "prognosis",
      "label": "associated with"
    },
    {
      "source": "p38 MAPK inhibitor SB202190",
      "target": "ERCC1",
      "label": "decreases"
    },
    {
      "source": "p38 MAPK inhibitor SB202190",
      "target": "p38 activity",
      "label": "downregulates"
    },
    {
      "source": "mRNA levels",
      "target": "pro-apoptotic gene dp5",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "AT1R",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "angiotensin II Type I receptor",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "AT1BR",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "AT1AR",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "Txnrd1",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "GPx",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "CAT",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "SOD1",
      "label": "are of"
    },
    {
      "source": "mRNA levels",
      "target": "semi quantitative RT-PCR",
      "label": "determined using"
    },
    {
      "source": "p38 MAPK signaling",
      "target": "MAPK",
      "label": "involves"
    },
    {
      "source": "p38 MAPK signaling",
      "target": "p38",
      "label": "involves"
    },
    {
      "source": "inputs",
      "target": "synthesis",
      "label": "mediate"
    },
    {
      "source": "adenylyl cyclase VII",
      "target": "G13 pathway",
      "label": "regulated by"
    },
    {
      "source": "adenylyl cyclase VII",
      "target": "regions",
      "label": "has"
    },
    {
      "source": "AC7",
      "target": "AC isoforms",
      "label": "is an"
    },
    {
      "source": "AC7",
      "target": "G(13) pathway",
      "label": "regulated by"
    },
    {
      "source": "intracellular cAMP responses",
      "target": "stimuli",
      "label": "responds to"
    },
    {
      "source": "N-terminus",
      "target": "regulation",
      "label": "important for"
    },
    {
      "source": "N-terminus",
      "target": "C1a domain",
      "label": "part of"
    },
    {
      "source": "N-terminus",
      "target": "BoNT/A",
      "label": "is of"
    },
    {
      "source": "C1b domain",
      "target": "regulation",
      "label": "important for"
    },
    {
      "source": "G(13) pathway",
      "target": "AC7",
      "label": "synergized with"
    },
    {
      "source": "bone marrow-derived macrophages",
      "target": "AC7",
      "label": "devoid of"
    },
    {
      "source": "domains",
      "target": "isoforms",
      "label": "between"
    },
    {
      "source": "domains",
      "target": "drug binding",
      "label": "involved in"
    },
    {
      "source": "Exchange",
      "target": "domains",
      "label": "of"
    },
    {
      "source": "mutagenesis screen",
      "target": "regions",
      "label": "identified"
    },
    {
      "source": "point mutations",
      "target": "H1 hypervariable loop",
      "label": "affects"
    },
    {
      "source": "point mutations",
      "target": "canonical conformations",
      "label": "affects"
    },
    {
      "source": "point mutations",
      "target": "noncanonical conformations",
      "label": "affects"
    },
    {
      "source": "H1 hypervariable loop",
      "target": "llama VHH",
      "label": "is part of"
    },
    {
      "source": "three hypervariable loops",
      "target": "H3",
      "label": "includes"
    },
    {
      "source": "three hypervariable loops",
      "target": "binding surface",
      "label": "form"
    },
    {
      "source": "three hypervariable loops",
      "target": "H1",
      "label": "includes"
    },
    {
      "source": "candidates",
      "target": "antibody engineering",
      "label": "for"
    },
    {
      "source": "antibody engineering",
      "target": "affinity",
      "label": "aims for"
    },
    {
      "source": "Nanobodies",
      "target": "binding domains",
      "label": "are"
    },
    {
      "source": "Nanobodies",
      "target": "functionality",
      "label": "derive"
    },
    {
      "source": "Nanobodies",
      "target": "single-domain antibodies",
      "label": "is a type of"
    },
    {
      "source": "Nanobodies",
      "target": "characteristics",
      "label": "have"
    },
    {
      "source": "Nanobodies",
      "target": "candidates",
      "label": "are"
    },
    {
      "source": "Nanobodies",
      "target": "camelids",
      "label": "found in"
    },
    {
      "source": "conformational isomers",
      "target": "canonical conformation",
      "label": "are of"
    },
    {
      "source": "conformational isomers",
      "target": "role",
      "label": "play"
    },
    {
      "source": "Markovian model",
      "target": "kinetics",
      "label": "elucidates"
    },
    {
      "source": "Markovian model",
      "target": "mechanism",
      "label": "elucidates"
    },
    {
      "source": "kinetics",
      "target": "transitions",
      "label": "of"
    },
    {
      "source": "characteristics",
      "target": "stability",
      "label": "include"
    },
    {
      "source": "characteristics",
      "target": "high solubility",
      "label": "include"
    },
    {
      "source": "characteristics",
      "target": "small size",
      "label": "include"
    },
    {
      "source": "amino acid sequence",
      "target": "H1",
      "label": "is of"
    },
    {
      "source": "amino acid sequence",
      "target": "H2",
      "label": "is of"
    },
    {
      "source": "amino acid sequence",
      "target": "proximal residues",
      "label": "is of"
    },
    {
      "source": "propensity",
      "target": "canonical structure",
      "label": "to be trapped in"
    },
    {
      "source": "propensity",
      "target": "stable type 1 canonical conformation",
      "label": "to form"
    },
    {
      "source": "selected mutations",
      "target": "amino acid sequence",
      "label": "are to"
    },
    {
      "source": "thermodynamic propensity",
      "target": "H1 type 1 canonical structure",
      "label": "to form"
    },
    {
      "source": "H1 loop structure",
      "target": "stability",
      "label": "has"
    },
    {
      "source": "Free energy landscapes",
      "target": "existence",
      "label": "reveal"
    },
    {
      "source": "existence",
      "target": "conformational isomers",
      "label": "of"
    },
    {
      "source": "functionality",
      "target": "three hypervariable loops",
      "label": "via"
    },
    {
      "source": "stable type 1 canonical conformation",
      "target": "H1 loop",
      "label": "is of"
    },
    {
      "source": "H1 loop",
      "target": "noncanonical conformation",
      "label": "exhibits"
    },
    {
      "source": "H1 loop",
      "target": "anti-hCG llama nanobody",
      "label": "is part of"
    },
    {
      "source": "three-point mutant",
      "target": "transitions",
      "label": "exhibits"
    },
    {
      "source": "three-point mutant",
      "target": "thermodynamic propensity",
      "label": "has"
    },
    {
      "source": "all-atomistic, explicit-solvent, biased molecular dynamic simulations",
      "target": "mutant loops",
      "label": "simulate"
    },
    {
      "source": "all-atomistic, explicit-solvent, biased molecular dynamic simulations",
      "target": "wild-type loops",
      "label": "simulate"
    },
    {
      "source": "mutant loops",
      "target": "prefolded framework",
      "label": "are in"
    },
    {
      "source": "rigid three-point mutant",
      "target": "propensity",
      "label": "has"
    },
    {
      "source": "wild-type loops",
      "target": "prefolded framework",
      "label": "are in"
    },
    {
      "source": "hypervariable loops",
      "target": "binding surface",
      "label": "can be tailored to obtain"
    },
    {
      "source": "isoorientin",
      "target": "mitochondrial-mediated apoptosis",
      "label": "induces"
    },
    {
      "source": "isoorientin",
      "target": "human hepatoblastoma cancer cells",
      "label": "acts on"
    },
    {
      "source": "flavonoid compound",
      "target": "plant species",
      "label": "can be extracted from"
    },
    {
      "source": "plant species",
      "target": "Phyllostachys pubescens",
      "label": "includes"
    },
    {
      "source": "plant species",
      "target": "Patrinia",
      "label": "includes"
    },
    {
      "source": "plant species",
      "target": "Drosophyllum lusitanicum",
      "label": "includes"
    },
    {
      "source": "SP600125",
      "target": "Bax/Bcl-2 ratio",
      "label": "prevented expression of"
    },
    {
      "source": "SP600125",
      "target": "cytochrome c",
      "label": "prevented expression of"
    },
    {
      "source": "SP600125",
      "target": "JNK inhibitor",
      "label": "is a"
    },
    {
      "source": "SP600125",
      "target": "cleaved caspase-3",
      "label": "prevented expression of"
    },
    {
      "source": "SP600125",
      "target": "JNK",
      "label": "inhibits"
    },
    {
      "source": "SP600125",
      "target": "LY294002-induced apoptosis",
      "label": "protected from"
    },
    {
      "source": "Isoorientin",
      "target": "ISO",
      "label": "is also known as"
    },
    {
      "source": "Isoorientin",
      "target": "flavonoid compound",
      "label": "is a type of"
    },
    {
      "source": "SB203580",
      "target": "p38 inhibitor",
      "label": "is a"
    },
    {
      "source": "SB203580",
      "target": "cleaved caspase-3",
      "label": "prevented expression of"
    },
    {
      "source": "SB203580",
      "target": "Bax/Bcl-2 ratio",
      "label": "prevented expression of"
    },
    {
      "source": "SB203580",
      "target": "cytochrome c",
      "label": "prevented expression of"
    },
    {
      "source": "SB203580",
      "target": "LY294002-induced apoptosis",
      "label": "protected from"
    },
    {
      "source": "SB203580",
      "target": "p38",
      "label": "inhibits"
    },
    {
      "source": "SB203580",
      "target": "STIM1-puncta formation",
      "label": "leads to"
    },
    {
      "source": "SB203580",
      "target": "p38 MAPK",
      "label": "is a selective inhibitor of"
    },
    {
      "source": "SB203580",
      "target": "STIM1 Phosphorylation",
      "label": "blocks"
    },
    {
      "source": "SB203580",
      "target": "Ca2+ entry",
      "label": "leads to"
    },
    {
      "source": "MAPK kinases",
      "target": "mitochondrial-mediated apoptosis",
      "label": "has roles on"
    },
    {
      "source": "MAPK kinases",
      "target": "HepG2 cells",
      "label": "acts in"
    },
    {
      "source": "MAPK signaling pathways",
      "target": "mitochondrial-mediated apoptosis",
      "label": "regulate"
    },
    {
      "source": "cleaved caspase-3",
      "target": "apoptosis",
      "label": "suggested"
    },
    {
      "source": "U0126",
      "target": "ERK1/2 inhibitor",
      "label": "is a type of"
    },
    {
      "source": "U0126",
      "target": "Bax/Bcl-2 ratio",
      "label": "enhanced"
    },
    {
      "source": "U0126",
      "target": "cytochrome c",
      "label": "enhanced release of"
    },
    {
      "source": "U0126",
      "target": "cleaved caspase-3",
      "label": "enhanced levels of"
    },
    {
      "source": "JNK inhibitor",
      "target": "cell viability",
      "label": "decreased"
    },
    {
      "source": "JNK inhibitor",
      "target": "AT1R expression",
      "label": "prevents"
    },
    {
      "source": "ROS inhibitor",
      "target": "NAC",
      "label": "is also known as"
    },
    {
      "source": "MAPK signals",
      "target": "mitochondrial-mediated apoptosis",
      "label": "is initiating event of"
    },
    {
      "source": "dendrimers",
      "target": "PrP(Sc)",
      "label": "eliminate"
    },
    {
      "source": "dendrimers",
      "target": "protease-resistant PrP(Sc)",
      "label": "are able to eliminate"
    },
    {
      "source": "dendrimers",
      "target": "in vitro setting",
      "label": "eliminate in"
    },
    {
      "source": "dendrimers",
      "target": "protein",
      "label": "destabilize"
    },
    {
      "source": "dendrimers",
      "target": "proteolysis",
      "label": "render susceptible to"
    },
    {
      "source": "dendrimers",
      "target": "intracellular setting",
      "label": "eliminate in"
    },
    {
      "source": "PrP(Sc)",
      "target": "aberrantly folded isoform",
      "label": "is an"
    },
    {
      "source": "host protein",
      "target": "PrP(C)",
      "label": "is"
    },
    {
      "source": "new working model",
      "target": "dendrimer/prion interactions",
      "label": "is for"
    },
    {
      "source": "modified poly(propylene-imine) dendrimers",
      "target": "charge",
      "label": "varied in"
    },
    {
      "source": "modified poly(propylene-imine) dendrimers",
      "target": "structure",
      "label": "varied in"
    },
    {
      "source": "modified poly(propylene-imine) dendrimers",
      "target": "surface group composition",
      "label": "varied in"
    },
    {
      "source": "modified poly(propylene-imine) dendrimers",
      "target": "size",
      "label": "varied in"
    },
    {
      "source": "charge",
      "target": "transport cycle",
      "label": "moves per"
    },
    {
      "source": "aberrantly folded isoform",
      "target": "host protein",
      "label": "is of"
    },
    {
      "source": "surface groups",
      "target": "antiprion activity",
      "label": "influence"
    },
    {
      "source": "high density",
      "target": "reactive surface groups",
      "label": "is of"
    },
    {
      "source": "in vitro antiprion ability",
      "target": "modified poly(propylene-imine) dendrimers",
      "label": "is of"
    },
    {
      "source": "poly(propylene imine) dendrimers",
      "target": "antiprion activity",
      "label": "have"
    },
    {
      "source": "Prion diseases",
      "target": "accumulation",
      "label": "characterized by"
    },
    {
      "source": "issue",
      "target": "in vitro antiprion ability",
      "label": "addressed by comparing"
    },
    {
      "source": "synthetic molecules",
      "target": "dendrimers",
      "label": "are known as"
    },
    {
      "source": "modified dendrimers",
      "target": "level",
      "label": "reduced"
    },
    {
      "source": "modified dendrimers",
      "target": "prion strain-dependent manner",
      "label": "reduced in a"
    },
    {
      "source": "modified dendrimers",
      "target": "anionic glycodendrimer",
      "label": "include"
    },
    {
      "source": "forms",
      "target": "synthetic molecules",
      "label": "are of"
    },
    {
      "source": "proteolysis",
      "target": "pro-BMP-2",
      "label": "of"
    },
    {
      "source": "proteolysis",
      "target": "FSAP",
      "label": "by"
    },
    {
      "source": "proteolysis",
      "target": "cell differentiation",
      "label": "can regulate"
    },
    {
      "source": "proteolysis",
      "target": "calcification",
      "label": "can regulate"
    },
    {
      "source": "proteolysis",
      "target": "mature BMP-2",
      "label": "of"
    },
    {
      "source": "oxadiazine series",
      "target": "GSMs",
      "label": "are a type of"
    },
    {
      "source": "oxadiazine series",
      "target": "hERG activity",
      "label": "has"
    },
    {
      "source": "SAR explorations",
      "target": "drugs",
      "label": "can lead to the identification of"
    },
    {
      "source": "fused oxadiazepines",
      "target": "gamma secretase modulators",
      "label": "are"
    },
    {
      "source": "gamma secretase modulators",
      "target": "Alzheimer's disease",
      "label": "treat"
    },
    {
      "source": "7i",
      "target": "fused oxadiazepines",
      "label": "is an example of"
    },
    {
      "source": "7i",
      "target": "GSMs",
      "label": "is a"
    },
    {
      "source": "7i",
      "target": "rats",
      "label": "is efficacious in"
    },
    {
      "source": "7i",
      "target": "hERG inhibition profile",
      "label": "has"
    },
    {
      "source": "core structure",
      "target": "fused oxadiazepines",
      "label": "was modified to yield"
    },
    {
      "source": "Diazinon",
      "target": "indoor pest control",
      "label": "used in"
    },
    {
      "source": "Diazinon",
      "target": "Japan",
      "label": "used in"
    },
    {
      "source": "Diazinon",
      "target": "home gardening",
      "label": "used in"
    },
    {
      "source": "Diazinon",
      "target": "agriculture",
      "label": "used in"
    },
    {
      "source": "Diazinon",
      "target": "organophosphate pesticide",
      "label": "is a type of"
    },
    {
      "source": "neonatal exposure",
      "target": "modulation",
      "label": "accompanied by"
    },
    {
      "source": "neonatal exposure",
      "target": "diazinon",
      "label": "is exposure to"
    },
    {
      "source": "neonatal exposure",
      "target": "hippocampus-dependent novel object recognition ability",
      "label": "impaired"
    },
    {
      "source": "neonatal exposure",
      "target": "novel object recognition",
      "label": "causes impairment of"
    },
    {
      "source": "neonatal exposure",
      "target": "hippocampus-dependent novel object recognition test performance",
      "label": "affects"
    },
    {
      "source": "neonatal exposure",
      "target": "expression",
      "label": "affects"
    },
    {
      "source": "hippocampi",
      "target": "PND 85 mice",
      "label": "are from"
    },
    {
      "source": "hippocampi",
      "target": "PND 85",
      "label": "collected on"
    },
    {
      "source": "hippocampi",
      "target": "adult mice",
      "label": "are from"
    },
    {
      "source": "hippocampi",
      "target": "PND 50",
      "label": "collected on"
    },
    {
      "source": "hippocampi",
      "target": "young adult mice",
      "label": "are from"
    },
    {
      "source": "novel object recognition test",
      "target": "PND 81",
      "label": "performed on"
    },
    {
      "source": "novel object recognition test",
      "target": "4 consecutive days",
      "label": "performed for"
    },
    {
      "source": "novel object recognition test",
      "target": "PND 46",
      "label": "performed on"
    },
    {
      "source": "0.5 mg/kg diazinon",
      "target": "PND 8",
      "label": "administration began on"
    },
    {
      "source": "0.5 mg/kg diazinon",
      "target": "4 consecutive days",
      "label": "administered for"
    },
    {
      "source": "NMDA receptor subunits NR1",
      "target": "PND 50 mice",
      "label": "mRNA levels reduced in"
    },
    {
      "source": "NMDA receptor subunits NR1",
      "target": "NMDA subunits",
      "label": "are"
    },
    {
      "source": "NMDA receptor subunits NR1",
      "target": "NMDA receptor",
      "label": "is a subunit of"
    },
    {
      "source": "CaMK-IV",
      "target": "PND 50 mice",
      "label": "mRNA levels reduced in"
    },
    {
      "source": "calcium/calmodulin-dependent protein kinase (CaMK)-IV",
      "target": "protein kinase",
      "label": "is a type of"
    },
    {
      "source": "calcium/calmodulin-dependent protein kinase (CaMK)-IV",
      "target": "NMDA receptor",
      "label": "is related to"
    },
    {
      "source": "calcium/calmodulin-dependent protein kinase (CaMK)-IV",
      "target": "PND 50 mice",
      "label": "mRNA levels reduced in"
    },
    {
      "source": "Male offspring",
      "target": "0 mg/kg diazinon",
      "label": "treated with"
    },
    {
      "source": "Male offspring",
      "target": "0.5 mg/kg diazinon",
      "label": "treated with"
    },
    {
      "source": "Male offspring",
      "target": "5 mg/kg diazinon",
      "label": "treated with"
    },
    {
      "source": "Male offspring",
      "target": "C3H/HeN mice",
      "label": "are offspring of"
    },
    {
      "source": "0 mg/kg diazinon",
      "target": "PND 8",
      "label": "administration began on"
    },
    {
      "source": "0 mg/kg diazinon",
      "target": "4 consecutive days",
      "label": "administered for"
    },
    {
      "source": "NMDA receptor subunits NR2B",
      "target": "NMDA receptor",
      "label": "is a subunit of"
    },
    {
      "source": "NMDA receptor subunits NR2B",
      "target": "PND 50 mice",
      "label": "mRNA levels reduced in"
    },
    {
      "source": "NMDA receptor subunits NR2B",
      "target": "NMDA subunits",
      "label": "are"
    },
    {
      "source": "novel object recognition",
      "target": "adulthood",
      "label": "impaired in"
    },
    {
      "source": "cyclic AMP responsive element binding protein (CREB)-1",
      "target": "transcription factor",
      "label": "is a type of"
    },
    {
      "source": "cyclic AMP responsive element binding protein (CREB)-1",
      "target": "PND 50 mice",
      "label": "mRNA levels reduced in"
    },
    {
      "source": "cyclic AMP responsive element binding protein (CREB)-1",
      "target": "NMDA receptor",
      "label": "is related to"
    },
    {
      "source": "5 mg/kg diazinon",
      "target": "PND 8",
      "label": "administration began on"
    },
    {
      "source": "5 mg/kg diazinon",
      "target": "4 consecutive days",
      "label": "administered for"
    },
    {
      "source": "nerve growth factor mRNA",
      "target": "PND 50 mice",
      "label": "reduced in"
    },
    {
      "source": "nerve growth factor mRNA",
      "target": "PND 85 mice",
      "label": "reduced in"
    },
    {
      "source": "poor ability to discriminate between novel and familiar objects",
      "target": "PND 49 tests",
      "label": "observed during"
    },
    {
      "source": "poor ability to discriminate between novel and familiar objects",
      "target": "PND 84 tests",
      "label": "observed during"
    },
    {
      "source": "CREB-1",
      "target": "PND 50 mice",
      "label": "mRNA levels reduced in"
    },
    {
      "source": "Diazinon-injected mice",
      "target": "poor ability to discriminate between novel and familiar objects",
      "label": "exhibited"
    },
    {
      "source": "rapid membrane initiated steroid signals",
      "target": "MISS",
      "label": "are also known as"
    },
    {
      "source": "rapid membrane initiated steroid signals",
      "target": "steroid signals",
      "label": "is a type of"
    },
    {
      "source": "Pharmacological activation",
      "target": "therapeutic interventions",
      "label": "provides basis for"
    },
    {
      "source": "Pharmacological activation",
      "target": "ER\u03b1",
      "label": "targets"
    },
    {
      "source": "Pharmacological activation",
      "target": "ER\u03b2",
      "label": "targets"
    },
    {
      "source": "therapeutic interventions",
      "target": "recurrence of breast cancer",
      "label": "prevents"
    },
    {
      "source": "therapeutic interventions",
      "target": "hormone replacement",
      "label": "include"
    },
    {
      "source": "selective estrogen receptors modulators",
      "target": "SERMs",
      "label": "are also known as"
    },
    {
      "source": "selective estrogen receptors modulators",
      "target": " undesired effects",
      "label": "induce"
    },
    {
      "source": "physiological processes",
      "target": "behavior",
      "label": "include"
    },
    {
      "source": "physiological processes",
      "target": "reproduction",
      "label": "include"
    },
    {
      "source": "physiological processes",
      "target": "bone integrity",
      "label": "include"
    },
    {
      "source": "physiological processes",
      "target": "cognition",
      "label": "include"
    },
    {
      "source": "physiological processes",
      "target": "vascular system",
      "label": "include"
    },
    {
      "source": "physiological processes",
      "target": "metabolism",
      "label": "include"
    },
    {
      "source": "physiological processes",
      "target": "mammals",
      "label": "occur in"
    },
    {
      "source": "ER\u03b1",
      "target": "rapid membrane initiated steroid signals",
      "label": "elicit"
    },
    {
      "source": "ER\u03b1",
      "target": "tissues",
      "label": "plays role in"
    },
    {
      "source": "ER\u03b1",
      "target": "activation functions",
      "label": "regulates through"
    },
    {
      "source": "ER\u03b1",
      "target": "target gene transcription",
      "label": "regulate"
    },
    {
      "source": "ER\u03b2",
      "target": "central nervous system",
      "label": "plays role in"
    },
    {
      "source": "ER\u03b2",
      "target": "activation functions",
      "label": "regulates through"
    },
    {
      "source": "ER\u03b2",
      "target": "heart",
      "label": "plays role in"
    },
    {
      "source": "ER\u03b2",
      "target": "rapid membrane initiated steroid signals",
      "label": "elicit"
    },
    {
      "source": "ER\u03b2",
      "target": "target gene transcription",
      "label": "regulate"
    },
    {
      "source": "Estrogens",
      "target": "physiological processes",
      "label": "influence"
    },
    {
      "source": "in vivo molecular \"dissection\"",
      "target": "mouse",
      "label": "performed in"
    },
    {
      "source": "in vivo molecular \"dissection\"",
      "target": "subfunctions",
      "label": "allowed delineation of"
    },
    {
      "source": "in vivo molecular \"dissection\"",
      "target": "ER\u03b1",
      "label": "is of"
    },
    {
      "source": "in vivo molecular \"dissection\"",
      "target": "integrated approach",
      "label": "is a type of"
    },
    {
      "source": "in vivo molecular \"dissection\"",
      "target": "ER modulation",
      "label": "optimizes"
    },
    {
      "source": "in vivo molecular \"dissection\"",
      "target": "molecular approach",
      "label": "is a type of"
    },
    {
      "source": "activation functions",
      "target": "AF-2",
      "label": "include"
    },
    {
      "source": "activation functions",
      "target": "estrogen receptor alpha",
      "label": "are functions of"
    },
    {
      "source": "activation functions",
      "target": "AF-1",
      "label": "include"
    },
    {
      "source": "subfunctions",
      "target": "receptor",
      "label": "are of"
    },
    {
      "source": "reproductive tract",
      "target": "endometrial",
      "label": "includes"
    },
    {
      "source": "reproductive tract",
      "target": "breast",
      "label": "includes"
    },
    {
      "source": "target gene transcription",
      "target": "genomic action",
      "label": "is a type of"
    },
    {
      "source": "Targeted ER gene inactivation",
      "target": "ER\u03b1",
      "label": "reveals role of"
    },
    {
      "source": "Targeted ER gene inactivation",
      "target": "ER\u03b2",
      "label": "reveals role of"
    },
    {
      "source": "hormone replacement",
      "target": "menopause",
      "label": "occurs at"
    },
    {
      "source": "actions",
      "target": "estrogen receptors",
      "label": "are mediated by"
    },
    {
      "source": "silver nanoparticles",
      "target": "surface properties",
      "label": "have"
    },
    {
      "source": "silver nanoparticles",
      "target": "physical sizes",
      "label": "have"
    },
    {
      "source": "absorption properties",
      "target": "photothermal activity",
      "label": "investigated by monitoring"
    },
    {
      "source": "absorption properties",
      "target": "HGNs",
      "label": "are of"
    },
    {
      "source": "SERS",
      "target": "1064 nm excitation wavelength",
      "label": "is at"
    },
    {
      "source": "SERS",
      "target": "biomaterials",
      "label": "assays of"
    },
    {
      "source": "weaker signal",
      "target": "HGNs",
      "label": "observed from"
    },
    {
      "source": "weaker signal",
      "target": "salts",
      "label": "observed after addition of"
    },
    {
      "source": "HGNs",
      "target": "LSPR",
      "label": "has"
    },
    {
      "source": "absorption efficiency",
      "target": "5 times",
      "label": "is higher by"
    },
    {
      "source": "absorption efficiency",
      "target": "HGNs",
      "label": "is of"
    },
    {
      "source": "absorption efficiency",
      "target": "0.81%",
      "label": "is"
    },
    {
      "source": "absorption efficiency",
      "target": "citrate reduced gold nanoparticles",
      "label": "is higher than"
    },
    {
      "source": "Optical analysis",
      "target": "biological importance",
      "label": "has"
    },
    {
      "source": "Optical analysis",
      "target": "near infrared region",
      "label": "is in"
    },
    {
      "source": "biological importance",
      "target": "tissue penetration",
      "label": "is due to"
    },
    {
      "source": "biological importance",
      "target": "autofluorescence",
      "label": "is due to reduced"
    },
    {
      "source": "improved synthesis",
      "target": "HGNs",
      "label": "is of"
    },
    {
      "source": "improved synthesis",
      "target": "tunable localized surface plasmon resonance",
      "label": "provides"
    },
    {
      "source": "improved synthesis",
      "target": "hollow gold nanospheres",
      "label": "is of"
    },
    {
      "source": "citrate reduced gold",
      "target": "physical sizes",
      "label": "has"
    },
    {
      "source": "citrate reduced gold",
      "target": "surface properties",
      "label": "has"
    },
    {
      "source": "LSPR",
      "target": "775 nm",
      "label": "is"
    },
    {
      "source": "LSPR",
      "target": "1320 nm",
      "label": "ranges up to"
    },
    {
      "source": "LSPR",
      "target": "650 nm",
      "label": "is"
    },
    {
      "source": "LSPR",
      "target": "610 nm",
      "label": "ranges from"
    },
    {
      "source": "LSPR",
      "target": "1080 nm",
      "label": "is"
    },
    {
      "source": "LSPR",
      "target": "one micrometer",
      "label": "is greater than"
    },
    {
      "source": "hollow gold",
      "target": "LSPR",
      "label": "has"
    },
    {
      "source": "strong signal",
      "target": "salts",
      "label": "observed after addition of"
    },
    {
      "source": "strong signal",
      "target": "hollow gold",
      "label": "observed from"
    },
    {
      "source": "obvious signals",
      "target": "standard citrate reduced gold",
      "label": "not observed in case of"
    },
    {
      "source": "obvious signals",
      "target": "silver",
      "label": "not observed in case of"
    },
    {
      "source": "obvious signals",
      "target": "HGNs",
      "label": "not observed in case of"
    },
    {
      "source": "tunable localized surface plasmon resonance",
      "target": "LSPR",
      "label": "is"
    },
    {
      "source": "continuous laser",
      "target": "785 nm excitation wavelength",
      "label": "is at"
    },
    {
      "source": "nanoparticle suspensions",
      "target": "continuous laser",
      "label": "illuminated by"
    },
    {
      "source": "nanoparticle suspensions",
      "target": "silver",
      "label": "include"
    },
    {
      "source": "nanoparticle suspensions",
      "target": "citrate reduced gold",
      "label": "include"
    },
    {
      "source": "nanoparticle suspensions",
      "target": "HGNs",
      "label": "include"
    },
    {
      "source": "hollow gold nanospheres",
      "target": "LSPR",
      "label": "have"
    },
    {
      "source": "NIR optical properties",
      "target": "hollow gold nanospheres",
      "label": "are of"
    },
    {
      "source": "scattering properties",
      "target": "citrate reduced gold",
      "label": "are compared to"
    },
    {
      "source": "scattering properties",
      "target": "nanoparticles",
      "label": "are of"
    },
    {
      "source": "scattering properties",
      "target": "surface enhanced Raman scattering",
      "label": "are shown using"
    },
    {
      "source": "scattering properties",
      "target": "silver nanoparticles",
      "label": "are compared to"
    },
    {
      "source": "citrate reduced gold nanoparticles",
      "target": "similar conditions",
      "label": "are under"
    },
    {
      "source": "surface enhanced Raman scattering",
      "target": "SERS",
      "label": "is"
    },
    {
      "source": "nanocomplexes",
      "target": "siRNA",
      "label": "release"
    },
    {
      "source": "nanocomplexes",
      "target": "positive charges",
      "label": "have"
    },
    {
      "source": "nanocomplexes",
      "target": "acidic pH",
      "label": "release siRNA at"
    },
    {
      "source": "nanocomplexes",
      "target": "physiological conditions",
      "label": "are stable under"
    },
    {
      "source": "nanocomplexes",
      "target": "diameter",
      "label": "have"
    },
    {
      "source": "PKAA",
      "target": "nanocomplexes",
      "label": "forms"
    },
    {
      "source": "PKAA",
      "target": "siRNA carrier",
      "label": "is a"
    },
    {
      "source": "PKAA",
      "target": "acid-cleavable ketal linkages",
      "label": "has"
    },
    {
      "source": "PKAA",
      "target": "delivery efficiency",
      "label": "has high"
    },
    {
      "source": "PKAA",
      "target": "buffering capability",
      "label": "exhibited"
    },
    {
      "source": "PKAA",
      "target": "anti-TNF (tumor necrosis factor)-\u03b1 siRNA",
      "label": "delivers"
    },
    {
      "source": "PKAA",
      "target": "siRNA",
      "label": "self-assembled with"
    },
    {
      "source": "PKAA",
      "target": "expression",
      "label": "inhibits"
    },
    {
      "source": "PKAA",
      "target": "cytotoxicity",
      "label": "has low"
    },
    {
      "source": "PKAA",
      "target": "endosomolytic activity",
      "label": "exhibited"
    },
    {
      "source": "APAP-intoxicated mice",
      "target": "APAP",
      "label": "intoxicated by"
    },
    {
      "source": "Acid-degradable cationic poly(ketal amidoamine)",
      "target": "RNA interference",
      "label": "enhances"
    },
    {
      "source": "Acid-degradable cationic poly(ketal amidoamine)",
      "target": "in vitro",
      "label": "enhances"
    },
    {
      "source": "Acid-degradable cationic poly(ketal amidoamine)",
      "target": "in vivo",
      "label": "enhances"
    },
    {
      "source": "acid-cleavable ketal linkages",
      "target": "backbone",
      "label": "are in"
    },
    {
      "source": "backbone",
      "target": "poly(amidoamine)",
      "label": "is part of"
    },
    {
      "source": "PKAA/anti-TNF-\u03b1 siRNA nanocomplexes",
      "target": "alanine transaminase",
      "label": "reduced"
    },
    {
      "source": "PKAA/anti-TNF-\u03b1 siRNA nanocomplexes",
      "target": "ALT",
      "label": "reduced"
    },
    {
      "source": "PKAA/anti-TNF-\u03b1 siRNA nanocomplexes",
      "target": "hepatic cellular damages",
      "label": "reduced"
    },
    {
      "source": "in vivo siRNA delivery efficacy",
      "target": "PKAA",
      "label": "is of"
    },
    {
      "source": "rapid degradation",
      "target": "siRNA",
      "label": "leads to release of"
    },
    {
      "source": "rapid degradation",
      "target": "acidic endosomes",
      "label": "occurs in"
    },
    {
      "source": "acid-degradable poly(ketal amidoamine)",
      "target": "siRNA carriers",
      "label": "has potential as"
    },
    {
      "source": "acid-degradable poly(ketal amidoamine)",
      "target": "endosomolytic activity",
      "label": "has potential"
    },
    {
      "source": "acid-degradable poly(ketal amidoamine)",
      "target": "biocompatibility",
      "label": "has"
    },
    {
      "source": "acid-degradable poly(ketal amidoamine)",
      "target": "pH sensitivity",
      "label": "has"
    },
    {
      "source": "acid-degradable poly(ketal amidoamine)",
      "target": "PKAA",
      "label": "is also known as"
    },
    {
      "source": "acid-degradable poly(ketal amidoamine)",
      "target": "delivery efficiency",
      "label": "has high"
    },
    {
      "source": "delivery efficiency",
      "target": "siRNA",
      "label": "is a challenge for"
    },
    {
      "source": "buffering capability",
      "target": "secondary amine groups",
      "label": "due to"
    },
    {
      "source": "secondary amine groups",
      "target": "backbone",
      "label": "are in"
    },
    {
      "source": "endosomolytic activity",
      "target": "secondary amine groups",
      "label": "due to"
    },
    {
      "source": "endosomolytic activity",
      "target": "rapid degradation",
      "label": "due to"
    },
    {
      "source": "anti-TNF (tumor necrosis factor)-\u03b1 siRNA",
      "target": "macrophages",
      "label": "delivered to"
    },
    {
      "source": "acute liver failure",
      "target": "acetaminophen",
      "label": "induced by"
    },
    {
      "source": "Cell culture studies",
      "target": "PKAA",
      "label": "demonstrated capability of"
    },
    {
      "source": "hepatic cellular damages",
      "target": "APAP-intoxicated mice",
      "label": "occurred in"
    },
    {
      "source": "PQ poisoning",
      "target": "Asia",
      "label": "is a problem in"
    },
    {
      "source": "PQ poisoning",
      "target": "major medical problem",
      "label": "is a type of"
    },
    {
      "source": "ultrastructural evidences",
      "target": "electron microscopy",
      "label": "are provided by"
    },
    {
      "source": "ultrastructural evidences",
      "target": "astrocyte edema",
      "label": "include"
    },
    {
      "source": "ultrastructural evidences",
      "target": "neurons apoptosis",
      "label": "include"
    },
    {
      "source": "neurons apoptosis",
      "target": "electron microscopy",
      "label": "is observed by"
    },
    {
      "source": "neurons apoptosis",
      "target": "rat brain",
      "label": "occurs in"
    },
    {
      "source": "acute paraquat poisoning",
      "target": "Central nervous system",
      "label": "causes damage to"
    },
    {
      "source": "substantia nigra",
      "target": "SN",
      "label": "is also known as"
    },
    {
      "source": "SN",
      "target": "substantia nigra",
      "label": "is also known as"
    },
    {
      "source": "Iba-1",
      "target": "microglia",
      "label": "labels"
    },
    {
      "source": "Paraquat",
      "target": "common herbicide",
      "label": "is a type of"
    },
    {
      "source": "Paraquat",
      "target": "PQ",
      "label": "is also known as"
    },
    {
      "source": "PQ",
      "target": "Paraquat",
      "label": "is also known as"
    },
    {
      "source": "PQ",
      "target": "direct CNS toxicity",
      "label": "causes"
    },
    {
      "source": "PQ",
      "target": "acute neurotoxic changes",
      "label": "causes"
    },
    {
      "source": "PQ",
      "target": "common herbicide",
      "label": "is a type of"
    },
    {
      "source": "PQ",
      "target": "HVA",
      "label": "did not alter"
    },
    {
      "source": "PQ",
      "target": "concentration of dopamine",
      "label": "did not alter"
    },
    {
      "source": "PQ",
      "target": "DOPAC",
      "label": "did not alter"
    },
    {
      "source": "PQ",
      "target": "neuronal degeneration",
      "label": "did not induce"
    },
    {
      "source": "PQ",
      "target": "degenerating neuronal processes",
      "label": "did not induce"
    },
    {
      "source": "PQ",
      "target": "DA",
      "label": "did not alter"
    },
    {
      "source": "PQ",
      "target": "3,4-dihydroxyphenylacetic acid",
      "label": "did not alter"
    },
    {
      "source": "PQ",
      "target": "homovanillic acid",
      "label": "did not alter"
    },
    {
      "source": "PQ",
      "target": "dopamine turnover",
      "label": "did not increase"
    },
    {
      "source": "astrocyte edema",
      "target": "electron microscopy",
      "label": "is observed by"
    },
    {
      "source": "astrocyte edema",
      "target": "rat brain",
      "label": "occurs in"
    },
    {
      "source": "acute neurotoxicological findings",
      "target": "rats",
      "label": "are found in"
    },
    {
      "source": "resected adrenal glands",
      "target": "CPA",
      "label": "include"
    },
    {
      "source": "resected adrenal glands",
      "target": "APA",
      "label": "include"
    },
    {
      "source": "resected adrenal glands",
      "target": "normal adrenals",
      "label": "include"
    },
    {
      "source": "resected adrenal glands",
      "target": "SCPA",
      "label": "include"
    },
    {
      "source": "resected adrenal glands",
      "target": "NFA",
      "label": "include"
    },
    {
      "source": "SCPA",
      "target": "subclinical Cushing's syndrome",
      "label": "combined with"
    },
    {
      "source": "steroidogenic characteristics",
      "target": "APA",
      "label": "of"
    },
    {
      "source": "CYP11B2 mRNA level",
      "target": "APA",
      "label": "in"
    },
    {
      "source": "CYP11B2 mRNA level",
      "target": "groups",
      "label": "higher than in"
    },
    {
      "source": "CPA",
      "target": "Cushing's syndrome",
      "label": "combined with"
    },
    {
      "source": "CYP17/HSD3B2 ratio",
      "target": "APA",
      "label": "in"
    },
    {
      "source": "CYP17/HSD3B2 ratio",
      "target": "groups",
      "label": "lower than in"
    },
    {
      "source": "CYP17/HSD3B2 ratio",
      "target": "mRNA",
      "label": "for"
    },
    {
      "source": "Steroidogenic enzyme expression",
      "target": "Aldosterone-producing adenoma",
      "label": "characterized in"
    },
    {
      "source": "Steroidogenic enzyme expression",
      "target": "human adrenal tumors",
      "label": "compared with"
    },
    {
      "source": "Low ratio of CYP17/HSD3B2",
      "target": "steroidogenic characteristics",
      "label": "explains"
    },
    {
      "source": "high expression of CYP11B2",
      "target": "steroidogenic characteristics",
      "label": "explains"
    },
    {
      "source": "cellular processes",
      "target": "cell cycle arrest",
      "label": "include"
    },
    {
      "source": "cellular processes",
      "target": "apoptosis",
      "label": "include"
    },
    {
      "source": "BiFC signal",
      "target": "nutlin-3",
      "label": "is mediated by"
    },
    {
      "source": "BiFC signal",
      "target": "Puma transactivation",
      "label": "correlated with"
    },
    {
      "source": "BiFC signal",
      "target": "cell death",
      "label": "correlated with"
    },
    {
      "source": "BiFC signal",
      "target": "PARP cleavage",
      "label": "correlated with"
    },
    {
      "source": "nutlin-3",
      "target": "disruptor of p53-Mdm2 interaction",
      "label": "is a"
    },
    {
      "source": "nutlin-3",
      "target": "specificity of the assay",
      "label": "validates"
    },
    {
      "source": "Dysfunction",
      "target": "p53",
      "label": "of"
    },
    {
      "source": "Dysfunction",
      "target": "pathologies",
      "label": "is associated with"
    },
    {
      "source": "p53 interaction",
      "target": "Mdm2",
      "label": "is with"
    },
    {
      "source": "p53 interaction",
      "target": "therapeutic target",
      "label": "is a promising"
    },
    {
      "source": "bimolecular fluorescence complementation (BiFC) analysis",
      "target": "protein interactions",
      "label": "visualizes"
    },
    {
      "source": "bimolecular fluorescence complementation (BiFC) analysis",
      "target": "method",
      "label": "is a"
    },
    {
      "source": "bimolecular fluorescence complementation (BiFC) analysis",
      "target": "modulators of protein interactions",
      "label": "identifies"
    },
    {
      "source": "protein interactions",
      "target": "living cells",
      "label": "occur in"
    },
    {
      "source": "synergistic drug efficacy",
      "target": "anti-tumor therapies",
      "label": "is achieved with"
    },
    {
      "source": "Venus-based BiFC system",
      "target": "modulators of p53-p53 and p53-Mdm2 interactions",
      "label": "screens for"
    },
    {
      "source": "modulators of p53-p53 and p53-Mdm2 interactions",
      "target": "live mammalian cells",
      "label": "are studied in"
    },
    {
      "source": "pathologies",
      "target": "neurodegenerative diseases",
      "label": "include"
    },
    {
      "source": "pathologies",
      "target": "cancer",
      "label": "include"
    },
    {
      "source": "Live-cell imaging",
      "target": "Venus-based bimolecular fluorescence complementation system",
      "label": "uses"
    },
    {
      "source": "Live-cell imaging",
      "target": "p53 interaction",
      "label": "is for"
    },
    {
      "source": "commercially available chemical library",
      "target": "protein phosphatase inhibitors",
      "label": "contains"
    },
    {
      "source": "modulators of p53-Mdm2 complex formation",
      "target": "commercially available chemical library",
      "label": "are found in"
    },
    {
      "source": "therapeutic target",
      "target": "cancer therapy",
      "label": "for"
    },
    {
      "source": "new modulators of p53-p53 and p53-Mdm2 interactions",
      "target": "synergistic drug efficacy",
      "label": "achieve"
    },
    {
      "source": "BiFC approach",
      "target": "modulators of p53-Mdm2 complex formation",
      "label": "identifies"
    },
    {
      "source": "Wogonin",
      "target": "caveolin-1",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "transendothelial cell migration",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "p38",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "VE-cadherin",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "vascular permeability",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "cav-1",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "root of Scutellaria baicalensis Georgi",
      "label": "extracted from"
    },
    {
      "source": "Wogonin",
      "target": "monoflavonoid",
      "label": "is a"
    },
    {
      "source": "Wogonin",
      "target": "actin remodeling",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "\u03b2-catenin",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "anti-oxidant activity",
      "label": "has"
    },
    {
      "source": "Wogonin",
      "target": "albumin uptake",
      "label": "Downregulator"
    },
    {
      "source": "Wogonin",
      "target": "therapeutic potential",
      "label": "has"
    },
    {
      "source": "oxidant",
      "target": "vascular permeability",
      "label": "Upregulator"
    },
    {
      "source": "vascular permeability",
      "target": "human umbilical vein endothelial cells",
      "label": "occurs in"
    },
    {
      "source": "transendothelial cell migration",
      "target": "human breast carcinoma cell MDA-MB-231",
      "label": "involves"
    },
    {
      "source": "actin remodeling",
      "target": "HUVECs",
      "label": "occurs in"
    },
    {
      "source": "albumin uptake",
      "target": "HUVECs",
      "label": "occurs in"
    },
    {
      "source": "anisomycin",
      "target": "p38",
      "label": "Upregulator"
    },
    {
      "source": "anisomycin",
      "target": "vascular permeability",
      "label": "Upregulator"
    },
    {
      "source": "anisomycin",
      "target": "cav-1",
      "label": "Upregulator"
    },
    {
      "source": "Apomorphine",
      "target": "non-narcotic derivative",
      "label": "is a"
    },
    {
      "source": "Apomorphine",
      "target": "TRPA1 channels",
      "label": "is a modulator of"
    },
    {
      "source": "Apomorphine",
      "target": "dopamine agonist",
      "label": "acts as a"
    },
    {
      "source": "Apomorphine",
      "target": "bimodal modulator",
      "label": "is a"
    },
    {
      "source": "Apomorphine",
      "target": "off-states",
      "label": "used to treat"
    },
    {
      "source": "non-narcotic derivative",
      "target": "morphine",
      "label": "of"
    },
    {
      "source": "off-states",
      "target": "patients",
      "label": "in"
    },
    {
      "source": "Adverse effects",
      "target": "severe emesis",
      "label": "include"
    },
    {
      "source": "Adverse effects",
      "target": "pain",
      "label": "include"
    },
    {
      "source": "Adverse effects",
      "target": "nausea",
      "label": "include"
    },
    {
      "source": "Adverse effects",
      "target": "apomorphine treatment",
      "label": "of"
    },
    {
      "source": "Adverse effects",
      "target": "ulceration",
      "label": "include"
    },
    {
      "source": "rTRPV3",
      "target": "dorsal root ganglion neurons",
      "label": "expressed in"
    },
    {
      "source": "rTRPV3",
      "target": "apomorphine treatment",
      "label": "are insensitive toward"
    },
    {
      "source": "rTRPV1",
      "target": "dorsal root ganglion neurons",
      "label": "expressed in"
    },
    {
      "source": "rTRPV1",
      "target": "apomorphine treatment",
      "label": "are insensitive toward"
    },
    {
      "source": "reversible voltage-dependent inhibition",
      "target": "heterologously expressed TRPA1 channels",
      "label": "of"
    },
    {
      "source": "reversible voltage-dependent inhibition",
      "target": "reduction of single-channel open times",
      "label": "resulting from"
    },
    {
      "source": "endogenous TRPA1",
      "target": "cultured dorsal root ganglion neurons",
      "label": "in"
    },
    {
      "source": "endogenous TRPA1",
      "target": "enterochromaffin model cell line QGP-1",
      "label": "in"
    },
    {
      "source": "cultured dorsal root ganglion neurons",
      "target": "rats",
      "label": "from"
    },
    {
      "source": "rTRPV2",
      "target": "apomorphine treatment",
      "label": "are insensitive toward"
    },
    {
      "source": "rTRPV2",
      "target": "dorsal root ganglion neurons",
      "label": "expressed in"
    },
    {
      "source": "pain",
      "target": "injection site",
      "label": "at"
    },
    {
      "source": "human TRPA1",
      "target": "molecular target",
      "label": "is a"
    },
    {
      "source": "hTRPM2",
      "target": "cellular redox sensor",
      "label": "is a"
    },
    {
      "source": "hTRPM2",
      "target": "apomorphine treatment",
      "label": "is insensitive toward"
    },
    {
      "source": "activation of TRPA1",
      "target": "adverse side effects",
      "label": "contribute to"
    },
    {
      "source": "ulceration",
      "target": "injection site",
      "label": "at"
    },
    {
      "source": "mTRPV4",
      "target": "dorsal root ganglion neurons",
      "label": "expressed in"
    },
    {
      "source": "mTRPV4",
      "target": "apomorphine treatment",
      "label": "are insensitive toward"
    },
    {
      "source": "adverse side effects",
      "target": "painful injections",
      "label": "include"
    },
    {
      "source": "adverse side effects",
      "target": "nausea",
      "label": "include"
    },
    {
      "source": "painful injections",
      "target": "apomorphine treatment",
      "label": "occur during"
    },
    {
      "source": "rTRPM3",
      "target": "dorsal root ganglion neurons",
      "label": "expressed in"
    },
    {
      "source": "rTRPM3",
      "target": "apomorphine treatment",
      "label": "are insensitive toward"
    },
    {
      "source": "hTRPM8",
      "target": "dorsal root ganglion neurons",
      "label": "expressed in"
    },
    {
      "source": "hTRPM8",
      "target": "apomorphine treatment",
      "label": "are insensitive toward"
    },
    {
      "source": "irreversible activation",
      "target": "TRPA1 channels",
      "label": "of"
    },
    {
      "source": "sensory transient receptor potential (TRP) channels",
      "target": "molecular target",
      "label": "are a"
    },
    {
      "source": "modified TRAP assay",
      "target": "titled compounds",
      "label": "used to test"
    },
    {
      "source": "titled compounds",
      "target": "telomerase",
      "label": "tested against"
    },
    {
      "source": "compounds 4a and 4b",
      "target": "expression of Cyclin D1",
      "label": "inhibit"
    },
    {
      "source": "compounds 4a and 4b",
      "target": "TERT",
      "label": "inhibit"
    },
    {
      "source": "compounds 4a and 4b",
      "target": "phospho-AKT",
      "label": "inhibit"
    },
    {
      "source": "compounds 4a and 4b",
      "target": "PI3K/AKT pathway",
      "label": "inhibit"
    },
    {
      "source": "compounds 4a and 4b",
      "target": "titled compounds",
      "label": "are"
    },
    {
      "source": "Eight novel 4,5-tetrahydropyrazolo[1,5-d][1,4]oxazepine derivatives",
      "target": "novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives",
      "label": "are a type of"
    },
    {
      "source": "Eight novel 4,5-tetrahydropyrazolo[1,5-d][1,4]oxazepine derivatives",
      "target": "anticancer activity",
      "label": "screened for"
    },
    {
      "source": "novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives",
      "target": "telomerase inhibitors",
      "label": "are"
    },
    {
      "source": "PI3K/AKT pathway",
      "target": "pro-survival signalling system",
      "label": "is a"
    },
    {
      "source": "compound 4a",
      "target": "inhibitory activity",
      "label": "showed"
    },
    {
      "source": "compound 4a",
      "target": "titled compounds",
      "label": "is a"
    },
    {
      "source": "Design and synthesis",
      "target": "novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives",
      "label": "produced"
    },
    {
      "source": "estradiol (E2)",
      "target": "WNT1 inducible signaling pathway protein 2",
      "label": "affects expression of"
    },
    {
      "source": "estradiol (E2)",
      "target": "apoptosis",
      "label": "reduces"
    },
    {
      "source": "estradiol (E2)",
      "target": "amphiregulin",
      "label": "stimulates expression of"
    },
    {
      "source": "estradiol (E2)",
      "target": "cMyc",
      "label": "affects expression of"
    },
    {
      "source": "estradiol (E2)",
      "target": "proliferation",
      "label": "is required for"
    },
    {
      "source": "estradiol (E2)",
      "target": "DNA synthesis",
      "label": "increases"
    },
    {
      "source": "estradiol (E2)",
      "target": "Akt",
      "label": "activates"
    },
    {
      "source": "estradiol (E2)",
      "target": "p70S6K",
      "label": "activates"
    },
    {
      "source": "estradiol (E2)",
      "target": "Bcl-2",
      "label": "up-regulates"
    },
    {
      "source": "estradiol (E2)",
      "target": "pS2",
      "label": "affects expression of"
    },
    {
      "source": "estradiol (E2)",
      "target": "MAPK",
      "label": "activates"
    },
    {
      "source": "estradiol (E2)",
      "target": "survivin",
      "label": "up-regulates"
    },
    {
      "source": "estradiol (E2)",
      "target": "progesterone receptor",
      "label": "stimulates expression of"
    },
    {
      "source": "estradiol (E2)",
      "target": "X-linked inhibitor of apoptosis protein",
      "label": "up-regulates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "DNA synthesis",
      "label": "increases"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "Akt",
      "label": "activates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "p70S6K",
      "label": "activates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "MAPK",
      "label": "activates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "pS2",
      "label": "affects expression of"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "Bcl-2",
      "label": "up-regulates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "progesterone receptor",
      "label": "stimulates expression of"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "survivin",
      "label": "up-regulates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "WNT1 inducible signaling pathway protein 2",
      "label": "affects expression of"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "amphiregulin",
      "label": "stimulates expression of"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "apoptosis",
      "label": "reduces"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "X-linked inhibitor of apoptosis protein",
      "label": "up-regulates"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "cMyc",
      "label": "affects expression of"
    },
    {
      "source": "conjugated estrogens (CEs)",
      "target": "proliferation",
      "label": "stimulates"
    },
    {
      "source": "menopausal hormone therapy",
      "target": "women",
      "label": "is administered to"
    },
    {
      "source": "menopausal hormone therapy",
      "target": "breast cancer incidence",
      "label": "increases"
    },
    {
      "source": "CE/BZA",
      "target": "human breast cancer cells",
      "label": "has inhibitory effects on"
    },
    {
      "source": "CE/BZA",
      "target": "tissue-selective estrogen complex (TSEC)",
      "label": "is a type of"
    },
    {
      "source": "CE/BZA",
      "target": "beneficial effects",
      "label": "has"
    },
    {
      "source": "CE/BZA",
      "target": "occult breast neoplasms",
      "label": "blocks growth of"
    },
    {
      "source": "CE/BZA",
      "target": "tumor incidence",
      "label": "reduces"
    },
    {
      "source": "CE/BZA",
      "target": "antiestrogenic effects",
      "label": "exerts"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "X-linked inhibitor of apoptosis protein",
      "label": "downregulates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "stimulatory effects",
      "label": "abrogates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "DNA synthesis",
      "label": "blocks"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "WNT1 inducible signaling pathway protein 2",
      "label": "blocks expression of"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "progesterone receptor",
      "label": "blocks expression of"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "cMyc",
      "label": "blocks expression of"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "Akt",
      "label": "downregulates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "p70S6K",
      "label": "downregulates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "amphiregulin",
      "label": "blocks expression of"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "estrogen agonistic effects",
      "label": "does not show"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "MAPK",
      "label": "downregulates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "apoptosis",
      "label": "blocks"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "Bcl-2",
      "label": "downregulates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "survivin",
      "label": "downregulates"
    },
    {
      "source": "bazedoxifene (BZA)",
      "target": "pS2",
      "label": "blocks expression of"
    },
    {
      "source": "tissue-selective estrogen complex (TSEC)",
      "target": "progestogen",
      "label": "eliminates requirement for"
    },
    {
      "source": "tissue-selective estrogen complex (TSEC)",
      "target": "menopausal hormone therapy",
      "label": "is a type of"
    },
    {
      "source": "(-) Epicatechin",
      "target": "adenosine triphosphate",
      "label": "enhances"
    },
    {
      "source": "(-) Epicatechin",
      "target": "mitochondrial multi-marker enzymes",
      "label": "enhances"
    },
    {
      "source": "(-) Epicatechin",
      "target": "tricarboxylic acid cycle",
      "label": "increases"
    },
    {
      "source": "(-) Epicatechin",
      "target": "calcium",
      "label": "decreases"
    },
    {
      "source": "(-) Epicatechin",
      "target": "respiratory chain enzymes",
      "label": "increases"
    },
    {
      "source": "(-) Epicatechin",
      "target": "multi-enzymes",
      "label": "increases"
    },
    {
      "source": "(-) Epicatechin",
      "target": "hydroxyl radical",
      "label": "scavenges"
    },
    {
      "source": "(-) Epicatechin",
      "target": "protective effects",
      "label": "has"
    },
    {
      "source": "(-) Epicatechin",
      "target": "scavenging activity",
      "label": "has"
    },
    {
      "source": "(-) Epicatechin",
      "target": "reduced glutathione",
      "label": "increases"
    },
    {
      "source": "(-) Epicatechin",
      "target": "mitochondrial damage",
      "label": "attenuates"
    },
    {
      "source": "(-) Epicatechin",
      "target": "antioxidant enzymes",
      "label": "increases"
    },
    {
      "source": "(-) Epicatechin",
      "target": "beneficial effects",
      "label": "has"
    },
    {
      "source": "(-) Epicatechin",
      "target": "superoxide",
      "label": "scavenges"
    },
    {
      "source": "(-) Epicatechin",
      "target": "free radicals",
      "label": "scavenges"
    },
    {
      "source": "(-) Epicatechin",
      "target": "cardiac mitochondria",
      "label": "has beneficial effects on"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "glutathione reductase",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "isocitrate",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "cardiac diagnostic markers",
      "label": "increased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "heart mitochondrial lipid peroxidation",
      "label": "increased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "heart mitochondrial glutathione peroxidase",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "adenosine triphosphate",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "\u03b1-ketoglutarate",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "NADH-dehydrogenases",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "malate",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "cytochrome-C-oxidase",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "succinate",
      "label": "decreased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "calcium",
      "label": "increased"
    },
    {
      "source": "myocardial infarcted rats",
      "target": "reduced glutathione",
      "label": "decreased"
    },
    {
      "source": "Cardiac mitochondrial damage",
      "target": "pathology",
      "label": "plays role in"
    },
    {
      "source": "Cardiac mitochondrial damage",
      "target": "myocardial infarction",
      "label": "plays role in"
    },
    {
      "source": "in vitro study",
      "target": "scavenging activity",
      "label": "revealed"
    },
    {
      "source": "in vitro study",
      "target": "potential beneficial action",
      "label": "highlighted"
    },
    {
      "source": "antioxidant enzymes",
      "target": "control groups",
      "label": "activities increased compared to"
    },
    {
      "source": "antioxidant enzymes",
      "target": "Na2SeO3 intervention group",
      "label": "activities increased in"
    },
    {
      "source": "antioxidant enzymes",
      "target": "Na2SeO3 groups",
      "label": "activities increased compared to"
    },
    {
      "source": "decisive role",
      "target": "negative regulation",
      "label": "is for"
    },
    {
      "source": "dietary carbohydrate intake",
      "target": "triglyceride",
      "label": "increases"
    },
    {
      "source": "negative regulation",
      "target": "TH",
      "label": "is caused by"
    },
    {
      "source": "TR-\u03b2",
      "target": "site A",
      "label": "does not directly bind to"
    },
    {
      "source": "site A",
      "target": "human SCD-1 gene promoter",
      "label": "is located in"
    },
    {
      "source": "TH receptor-\u03b2",
      "target": "the region",
      "label": "is recruited to"
    },
    {
      "source": "SCD-1 gene expression",
      "target": "SREBP-1c -independent pathways",
      "label": "is increased via"
    },
    {
      "source": "SCD-1 gene expression",
      "target": "SREBP-1c-dependent pathways",
      "label": "is increased via"
    },
    {
      "source": "SCD-1 gene expression",
      "target": "liver",
      "label": "occurs in"
    },
    {
      "source": "thyroid hormone receptor",
      "target": "gene promoter",
      "label": "does not directly bind to"
    },
    {
      "source": "Luciferase assays",
      "target": "TH",
      "label": "revealed suppression by"
    },
    {
      "source": "Stearoyl-CoA desaturase-1",
      "target": "triglyceride",
      "label": "increases"
    },
    {
      "source": "SREBP-1c effect",
      "target": "negative regulation",
      "label": "is on"
    },
    {
      "source": "-124 and -92 bp",
      "target": "site A",
      "label": "is referred to as"
    },
    {
      "source": "Dietary carbohydrates",
      "target": "SCD-1 gene expression",
      "label": "increase"
    },
    {
      "source": "responsible region",
      "target": "human SCD-1 gene promoter",
      "label": "is located in"
    },
    {
      "source": "responsible region",
      "target": "-124 and -92 bp",
      "label": "is"
    },
    {
      "source": "chemical content",
      "target": "results",
      "label": "is of"
    },
    {
      "source": "water:ethanol (50:50)",
      "target": "ethanol",
      "label": "contains"
    },
    {
      "source": "water:ethanol (50:50)",
      "target": "ASE methodologies",
      "label": "derived from"
    },
    {
      "source": "water:ethanol (50:50)",
      "target": "SFE methodologies",
      "label": "derived from"
    },
    {
      "source": "ethanol",
      "target": "green solvent",
      "label": "is a"
    },
    {
      "source": "flavonoids",
      "target": "extracts",
      "label": "present in"
    },
    {
      "source": "flavonoids",
      "target": "RunX2",
      "label": "Upregulator"
    },
    {
      "source": "flavonoids",
      "target": "osteoprotegerin",
      "label": "Upregulator"
    },
    {
      "source": "flavonoids",
      "target": "osteocalcin",
      "label": "Upregulator"
    },
    {
      "source": "flavonoids",
      "target": "osteoblast differentiation",
      "label": "induces"
    },
    {
      "source": "flavonoids",
      "target": "osteopontin",
      "label": "Upregulator"
    },
    {
      "source": "flavonoids",
      "target": "osterix",
      "label": "Upregulator"
    },
    {
      "source": "extracts",
      "target": "antioxidant capacity",
      "label": "have"
    },
    {
      "source": "extracts",
      "target": "NAD(P)H : quinone oxidoreductase",
      "label": "induce"
    },
    {
      "source": "extracts",
      "target": "Asteraceae families",
      "label": "from"
    },
    {
      "source": "extracts",
      "target": "Apocynaceae",
      "label": "from"
    },
    {
      "source": "extracts",
      "target": "chronic degenerative diseases",
      "label": "reduce risk for"
    },
    {
      "source": "extracts",
      "target": "27 Saudi Arabian medicinal plants",
      "label": "prepared from"
    },
    {
      "source": "extracts",
      "target": "Saudi Arabian Medicinal Plants",
      "label": "from"
    },
    {
      "source": "extracts",
      "target": "plant sources",
      "label": "from"
    },
    {
      "source": "extracts",
      "target": "Apiaceae",
      "label": "from"
    },
    {
      "source": "Obtained results",
      "target": "Cretan barberry",
      "label": "classify"
    },
    {
      "source": "Cretan barberry",
      "target": "antioxidant agent",
      "label": "is a"
    },
    {
      "source": "extraction procedures",
      "target": "phenolic content",
      "label": "influences"
    },
    {
      "source": "extraction procedures",
      "target": "antioxidant activity",
      "label": "influences"
    },
    {
      "source": "phenolic content",
      "target": "Cretan barberry herb",
      "label": "is of"
    },
    {
      "source": "optimization",
      "target": "different extraction protocols",
      "label": "of"
    },
    {
      "source": "UHPLC-HRMS/MS",
      "target": "ESI probe",
      "label": "equipped with"
    },
    {
      "source": "UHPLC-HRMS/MS",
      "target": "hybrid IT-Orbital trap spectrometer",
      "label": "is a"
    },
    {
      "source": "solvents",
      "target": "chemical content",
      "label": "affected"
    },
    {
      "source": "solvents",
      "target": "activity",
      "label": "affected"
    },
    {
      "source": "antioxidant assessment",
      "target": "total phenolic content",
      "label": "uses"
    },
    {
      "source": "antioxidant assessment",
      "target": "DPPH",
      "label": "uses"
    },
    {
      "source": "antioxidant assessment",
      "target": "assays",
      "label": "uses"
    },
    {
      "source": "total phenolic content",
      "target": "Folin-Ciocalteu",
      "label": "measured by"
    },
    {
      "source": "total phenolic content",
      "target": "assays",
      "label": "is an"
    },
    {
      "source": "antioxidant capacity",
      "target": "biochemical parameters",
      "label": "is a"
    },
    {
      "source": "antioxidant capacity",
      "target": "hippocampus",
      "label": "is a parameter of"
    },
    {
      "source": "DPPH",
      "target": "assays",
      "label": "is an"
    },
    {
      "source": "SFE",
      "target": "ASE",
      "label": "coupled with"
    },
    {
      "source": "different extraction protocols",
      "target": "Berberis cretica",
      "label": "applied to"
    },
    {
      "source": "different extraction protocols",
      "target": "extracts",
      "label": "yields"
    },
    {
      "source": "different extraction protocols",
      "target": "green technologies",
      "label": "employ"
    },
    {
      "source": "spectral data",
      "target": "flavonoids",
      "label": "revealed presence of"
    },
    {
      "source": "spectral data",
      "target": "caffeic and benzoic acids",
      "label": "revealed presence of"
    },
    {
      "source": "spectral data",
      "target": "simple phenolic acids",
      "label": "revealed presence of"
    },
    {
      "source": "extraction method",
      "target": "chemical content",
      "label": "affected"
    },
    {
      "source": "extraction method",
      "target": "activity",
      "label": "affected"
    },
    {
      "source": "caffeic and benzoic acids",
      "target": "extracts",
      "label": "present in"
    },
    {
      "source": "Major constituents",
      "target": "HPLC-DAD",
      "label": "elucidated using"
    },
    {
      "source": "Major constituents",
      "target": "UHPLC-HRMS/MS",
      "label": "elucidated using"
    },
    {
      "source": "assays",
      "target": "mitochondrial damage",
      "label": "reflect"
    },
    {
      "source": "assays",
      "target": "lysosomal activities",
      "label": "reflect"
    },
    {
      "source": "assays",
      "target": "protein synthesis",
      "label": "reflect"
    },
    {
      "source": "applied methods",
      "target": "maceration",
      "label": "include"
    },
    {
      "source": "applied methods",
      "target": "ASE",
      "label": "include"
    },
    {
      "source": "applied methods",
      "target": "SFE",
      "label": "include"
    },
    {
      "source": "SFE methodologies",
      "target": "ASE methodologies",
      "label": "combined with"
    },
    {
      "source": "chromatographic data",
      "target": "simple phenolic acids",
      "label": "revealed presence of"
    },
    {
      "source": "chromatographic data",
      "target": "flavonoids",
      "label": "revealed presence of"
    },
    {
      "source": "chromatographic data",
      "target": "caffeic and benzoic acids",
      "label": "revealed presence of"
    },
    {
      "source": "simple phenolic acids",
      "target": "caffeic and benzoic acids",
      "label": "are derivatives of"
    },
    {
      "source": "simple phenolic acids",
      "target": "extracts",
      "label": "present in"
    },
    {
      "source": "antioxidant activity",
      "target": "Cretan barberry herb",
      "label": "is of"
    },
    {
      "source": "beneficial conditions",
      "target": "methanol",
      "label": "calculated for"
    },
    {
      "source": "beneficial conditions",
      "target": "water:ethanol (50:50)",
      "label": "calculated for"
    },
    {
      "source": "methanol",
      "target": "SFE methodologies",
      "label": "derived from"
    },
    {
      "source": "methanol",
      "target": "ASE methodologies",
      "label": "derived from"
    },
    {
      "source": "peroxide value",
      "target": "different roasting methods",
      "label": "differed significantly for"
    },
    {
      "source": "peroxide value",
      "target": "roasted samples",
      "label": "increased significantly in"
    },
    {
      "source": "peroxide value",
      "target": "storage",
      "label": "increased during"
    },
    {
      "source": "off-odours",
      "target": "storage",
      "label": "produced during"
    },
    {
      "source": "concentration of aliphatic aldehydes",
      "target": "different roasting methods",
      "label": "differed significantly for"
    },
    {
      "source": "concentration of aliphatic aldehydes",
      "target": "storage",
      "label": "increased during"
    },
    {
      "source": "concentration of aliphatic aldehydes",
      "target": "roasted samples",
      "label": "increased significantly in"
    },
    {
      "source": "three different approaches",
      "target": "infrared (IR)",
      "label": "include"
    },
    {
      "source": "three different approaches",
      "target": "sequential infrared and hot air (SIRHA)",
      "label": "include"
    },
    {
      "source": "three different approaches",
      "target": "regular hot air (HA)",
      "label": "include"
    },
    {
      "source": "water activity",
      "target": "almond samples",
      "label": "among"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "37 \u00b0C",
      "label": "stored at"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "six months",
      "label": "stored for"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "eight months",
      "label": "stored for"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "three months",
      "label": "stored for"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "three different temperatures",
      "label": "processed at"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "paper bags",
      "label": "packed in"
    },
    {
      "source": "Nine medium roasted almond samples",
      "target": "heating methods",
      "label": "produced by"
    },
    {
      "source": "Shelf-life",
      "target": "peroxide value",
      "label": "determined by measuring changes in"
    },
    {
      "source": "Shelf-life",
      "target": "volatile components",
      "label": "determined by measuring changes in"
    },
    {
      "source": "Shelf-life",
      "target": "sensory quality",
      "label": "determined by measuring changes in"
    },
    {
      "source": "Shelf-life",
      "target": "moisture content",
      "label": "determined by measuring changes in"
    },
    {
      "source": "Shelf-life",
      "target": "infrared dry-roasted almonds",
      "label": "of"
    },
    {
      "source": "Shelf-life",
      "target": "colour",
      "label": "determined by measuring changes in"
    },
    {
      "source": "Shelf-life",
      "target": "almonds",
      "label": "of"
    },
    {
      "source": "Shelf-life",
      "target": "water activity",
      "label": "determined by measuring changes in"
    },
    {
      "source": "Shelf-life",
      "target": "roasted almonds",
      "label": "of"
    },
    {
      "source": "main volatile components",
      "target": "almonds",
      "label": "of"
    },
    {
      "source": "almonds",
      "target": "three different approaches",
      "label": "roasted with"
    },
    {
      "source": "almond samples",
      "target": "different roasting methods",
      "label": "processed with"
    },
    {
      "source": "Aliphatic aldehydes",
      "target": "hexanal",
      "label": "include"
    },
    {
      "source": "Aliphatic aldehydes",
      "target": "off-odours",
      "label": "produced as"
    },
    {
      "source": "Aliphatic aldehydes",
      "target": "(E)-2-octenal",
      "label": "include"
    },
    {
      "source": "Aliphatic aldehydes",
      "target": "nonanal",
      "label": "include"
    },
    {
      "source": "hexanal",
      "target": "peroxide value",
      "label": "better indicator than"
    },
    {
      "source": "hexanal",
      "target": "Shelf-life",
      "label": "better indicator of"
    },
    {
      "source": "GC/MS analysis",
      "target": "main volatile components",
      "label": "showed"
    },
    {
      "source": "overall quality",
      "target": "first three months",
      "label": "similar during"
    },
    {
      "source": "overall quality",
      "target": "roasted almonds",
      "label": "of"
    },
    {
      "source": "moisture content",
      "target": "almond samples",
      "label": "among"
    },
    {
      "source": "roasted almonds",
      "target": "HA heating",
      "label": "produced with"
    },
    {
      "source": "roasted almonds",
      "target": "SIRHA heating",
      "label": "produced with"
    },
    {
      "source": "Infrared heating",
      "target": "roasting technology",
      "label": "used to develop"
    },
    {
      "source": "roasting technology",
      "target": "traditional hot air roasting",
      "label": "more efficient than"
    },
    {
      "source": "three different temperatures",
      "target": "140 \u00b0C",
      "label": "include"
    },
    {
      "source": "three different temperatures",
      "target": "150 \u00b0C",
      "label": "include"
    },
    {
      "source": "three different temperatures",
      "target": "130 \u00b0C",
      "label": "include"
    },
    {
      "source": "alcohols",
      "target": "main volatile components",
      "label": "are"
    },
    {
      "source": "nonanal",
      "target": "peroxide value",
      "label": "better indicator than"
    },
    {
      "source": "nonanal",
      "target": "Shelf-life",
      "label": "better indicator of"
    },
    {
      "source": "pyrazines",
      "target": "main volatile components",
      "label": "are"
    },
    {
      "source": "Se-EPS",
      "target": "superoxide dismutase (SOD)",
      "label": "increased activity of"
    },
    {
      "source": "Se-EPS",
      "target": "thymus indices",
      "label": "increased"
    },
    {
      "source": "Se-EPS",
      "target": "haemolytic complement activity (HC(50))",
      "label": "increased"
    },
    {
      "source": "Se-EPS",
      "target": "immunomodulatory activity",
      "label": "showed stronger"
    },
    {
      "source": "Se-EPS",
      "target": "in vivo antioxidant activity",
      "label": "has"
    },
    {
      "source": "Se-EPS",
      "target": "malondialdehyde (MDA)",
      "label": "decreased levels of"
    },
    {
      "source": "Se-EPS",
      "target": "CAT",
      "label": "increased activity of"
    },
    {
      "source": "Se-EPS",
      "target": "in vivo immunoenhancement activity",
      "label": "has"
    },
    {
      "source": "Se-EPS",
      "target": "glutathione peroxidase (GSH-Px)",
      "label": "increased activity of"
    },
    {
      "source": "Se-EPS",
      "target": "GSH-Px",
      "label": "increased activity of"
    },
    {
      "source": "Se-EPS",
      "target": "hydroxyl radicals",
      "label": "scavenged"
    },
    {
      "source": "Se-EPS",
      "target": "macrophage phagocytosis",
      "label": "increased"
    },
    {
      "source": "Se-EPS",
      "target": "SOD",
      "label": "increased activity of"
    },
    {
      "source": "Se-EPS",
      "target": "spleen indices",
      "label": "increased"
    },
    {
      "source": "Se-EPS",
      "target": "HC(50)",
      "label": "increased"
    },
    {
      "source": "Se-EPS",
      "target": "in vitro antioxidant activity",
      "label": "showed stronger"
    },
    {
      "source": "Se-EPS",
      "target": "MDA",
      "label": "decreased levels of"
    },
    {
      "source": "Se-EPS",
      "target": "in vivo immunomodulatory activity",
      "label": "has"
    },
    {
      "source": "Se-EPS",
      "target": "superoxide anions",
      "label": "scavenged"
    },
    {
      "source": "Se-EPS",
      "target": "catalase (CAT)",
      "label": "increased activity of"
    },
    {
      "source": "Exopolysaccharide (EPS)",
      "target": "Lactococcus lactis subsp. Lactis culture broth",
      "label": "isolated from"
    },
    {
      "source": "EPS",
      "target": "SOD",
      "label": "increased activity of"
    },
    {
      "source": "EPS",
      "target": "Se-EPS",
      "label": "used to synthesize"
    },
    {
      "source": "EPS",
      "target": "superoxide anions",
      "label": "scavenged"
    },
    {
      "source": "EPS",
      "target": "MDA",
      "label": "decreased levels of"
    },
    {
      "source": "EPS",
      "target": "spleen indices",
      "label": "increased"
    },
    {
      "source": "EPS",
      "target": "HC(50)",
      "label": "increased"
    },
    {
      "source": "EPS",
      "target": "in vitro antioxidant activity",
      "label": "has"
    },
    {
      "source": "EPS",
      "target": "in vivo immunomodulatory activity",
      "label": "has"
    },
    {
      "source": "EPS",
      "target": "catalase (CAT)",
      "label": "increased activity of"
    },
    {
      "source": "EPS",
      "target": "superoxide dismutase (SOD)",
      "label": "increased activity of"
    },
    {
      "source": "EPS",
      "target": "thymus indices",
      "label": "increased"
    },
    {
      "source": "EPS",
      "target": "haemolytic complement activity (HC(50))",
      "label": "increased"
    },
    {
      "source": "EPS",
      "target": "selenium-exopolysaccharide",
      "label": "used to synthesize"
    },
    {
      "source": "EPS",
      "target": "Lactococcus lactis subsp. Lactis culture broth",
      "label": "isolated from"
    },
    {
      "source": "EPS",
      "target": "in vivo antioxidant activity",
      "label": "has"
    },
    {
      "source": "EPS",
      "target": "malondialdehyde (MDA)",
      "label": "decreased levels of"
    },
    {
      "source": "EPS",
      "target": "CAT",
      "label": "increased activity of"
    },
    {
      "source": "EPS",
      "target": "in vivo immunoenhancement activity",
      "label": "has"
    },
    {
      "source": "EPS",
      "target": "hydroxyl radicals",
      "label": "scavenged"
    },
    {
      "source": "EPS",
      "target": "GSH-Px",
      "label": "increased activity of"
    },
    {
      "source": "EPS",
      "target": "glutathione peroxidase (GSH-Px)",
      "label": "increased activity of"
    },
    {
      "source": "EPS",
      "target": "macrophage phagocytosis",
      "label": "increased"
    },
    {
      "source": "immunomodulatory activity",
      "target": "EPS",
      "label": "than did"
    },
    {
      "source": "in vivo antioxidant activity",
      "target": "EPS",
      "label": "shown by"
    },
    {
      "source": "malondialdehyde (MDA)",
      "target": "livers",
      "label": "levels in"
    },
    {
      "source": "malondialdehyde (MDA)",
      "target": "serum",
      "label": "levels in"
    },
    {
      "source": "livers",
      "target": "mice",
      "label": "located in"
    },
    {
      "source": "livers",
      "target": "12 weeks",
      "label": "removed after"
    },
    {
      "source": "in vivo immunoenhancement activity",
      "target": "cyclophosphamide (CY)",
      "label": "induced by"
    },
    {
      "source": "in vivo immunoenhancement activity",
      "target": "CY",
      "label": "induced by"
    },
    {
      "source": "cyclophosphamide (CY)",
      "target": "immunosuppressed mice",
      "label": "treatment in"
    },
    {
      "source": "SeCl(2)O",
      "target": "EPS",
      "label": "added to"
    },
    {
      "source": "selenium exopolysaccharide",
      "target": "Lactococcus lactis subsp. lactis",
      "label": "produced by"
    },
    {
      "source": "selenium exopolysaccharide",
      "target": "immunomodulatory activity",
      "label": "has"
    },
    {
      "source": "selenium exopolysaccharide",
      "target": "Antioxidant activity",
      "label": "has"
    },
    {
      "source": "CY",
      "target": "immunosuppressed mice",
      "label": "treatment in"
    },
    {
      "source": "Selenium chloride oxide (SeCl(2)O)",
      "target": "EPS",
      "label": "added to"
    },
    {
      "source": "in vitro antioxidant activity",
      "target": "EPS",
      "label": "shown by"
    },
    {
      "source": "DPEP",
      "target": "TNF-\u03b1",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "iNOS",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "inducible nitric oxide synthase",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "inflammatory cytokines",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "tumor necrosis factor-\u03b1",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "MAPK",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "inhibitor \u03baB (I\u03baB)-\u03b1",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "IL-6",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "NF-\u03baB",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "ERK",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "PGE(2)",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "JNK",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "interleukin (IL)-1\u03b2",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "cyclooxygenase-2",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "p38",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "NO",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "NF-\u03baB p50",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "prostaglandin E(2)",
      "label": "Downregulator"
    },
    {
      "source": "DPEP",
      "target": "COX-2",
      "label": "Downregulator"
    },
    {
      "source": "IL-6",
      "target": "cervical muscles",
      "label": "is located in"
    },
    {
      "source": "IL-6",
      "target": "ELISA",
      "label": "responses measured by"
    },
    {
      "source": "IL-6",
      "target": "PCR",
      "label": "responses measured by"
    },
    {
      "source": "IL-6",
      "target": "differentiated CaCo-2 colonic epithelial cells",
      "label": "up-regulated in"
    },
    {
      "source": "IL-6",
      "target": "CYP3A",
      "label": "suppresses"
    },
    {
      "source": "IL-6",
      "target": "CYP3A4 substrates",
      "label": "impacts"
    },
    {
      "source": "NF-\u03baB",
      "target": "transcription factor",
      "label": "is a type of"
    },
    {
      "source": "NF-\u03baB",
      "target": "target gene products",
      "label": "produces"
    },
    {
      "source": "NF-\u03baB",
      "target": "survival factor",
      "label": "is a type of"
    },
    {
      "source": "trans-1,3-diphenyl-2,3-epoxypropane-1-one",
      "target": "inflammatory mediators",
      "label": "Downregulator"
    },
    {
      "source": "down regulation",
      "target": "glutamate decarboxylase mRNA",
      "label": "of"
    },
    {
      "source": "down regulation",
      "target": "accumulation",
      "label": "leads to"
    },
    {
      "source": "Radioreceptor binding assays",
      "target": "increase",
      "label": "showed"
    },
    {
      "source": "curcumin",
      "target": "parameters",
      "label": "reversed"
    },
    {
      "source": "curcumin",
      "target": "neurochemical parameters",
      "label": "modulates"
    },
    {
      "source": "curcumin",
      "target": "therapeutic role",
      "label": "has"
    },
    {
      "source": "curcumin",
      "target": "neuroprotective effect",
      "label": "has"
    },
    {
      "source": "curcumin",
      "target": "excitotoxicity",
      "label": "ameliorates"
    },
    {
      "source": "curcumin",
      "target": "IL-17A level",
      "label": "reduces"
    },
    {
      "source": "curcumin",
      "target": "Th17 cells",
      "label": "inhibited"
    },
    {
      "source": "curcumin",
      "target": "Treg cells",
      "label": "increased"
    },
    {
      "source": "curcumin",
      "target": "eosinophil count",
      "label": "inhibited"
    },
    {
      "source": "curcumin",
      "target": "IL-10 level",
      "label": "increased"
    },
    {
      "source": "curcumin",
      "target": "underlying mechanisms",
      "label": "has"
    },
    {
      "source": "curcumin",
      "target": "eosinophilia",
      "label": "inhibited"
    },
    {
      "source": "curcumin",
      "target": "therapeutic drug",
      "label": "is a"
    },
    {
      "source": "curcumin",
      "target": "protective effects",
      "label": "has"
    },
    {
      "source": "curcumin",
      "target": "interleukin (IL)-17A",
      "label": "reduces"
    },
    {
      "source": "excitotoxic neuronal death",
      "target": "cerebral cortex",
      "label": "occurs in"
    },
    {
      "source": "excitotoxic neuronal death",
      "target": "expression",
      "label": "confirmed by"
    },
    {
      "source": "density",
      "target": "\u03b1-amino-3-hydroxy-5-methyl-4-isoxazole propionate",
      "label": "of"
    },
    {
      "source": "density",
      "target": "N-methyl-D-aspartate receptors",
      "label": "of"
    },
    {
      "source": "insulin treatment",
      "target": "parameters",
      "label": "reversed"
    },
    {
      "source": "insulin treatment",
      "target": "tyrosine phosphorylation",
      "label": "reduced"
    },
    {
      "source": "insulin treatment",
      "target": "phosphorylation",
      "label": "reduced"
    },
    {
      "source": "insulin treatment",
      "target": "serine phosphorylation (pS(307))",
      "label": "enhanced"
    },
    {
      "source": "Gene expression studies",
      "target": "down regulation",
      "label": "showed"
    },
    {
      "source": "Gene expression studies",
      "target": "diabetic rats",
      "label": "in"
    },
    {
      "source": "events",
      "target": "excitotoxic neuronal death",
      "label": "lead to"
    },
    {
      "source": "neuroprotective effect",
      "target": "excitotoxicity",
      "label": "on"
    },
    {
      "source": "therapeutic role",
      "target": "excitotoxicity",
      "label": "reduces"
    },
    {
      "source": "glutathione peroxidases gene expression",
      "target": "oxidative stress",
      "label": "indicates"
    },
    {
      "source": "neurotransmitter receptor",
      "target": "Functional activity",
      "label": "has"
    },
    {
      "source": "neurotransmitter receptor",
      "target": "sensitivity",
      "label": "has"
    },
    {
      "source": "Functional activity",
      "target": "DM",
      "label": "altered in"
    },
    {
      "source": "metabolic shift",
      "target": "aerobic glycolysis",
      "label": "is to"
    },
    {
      "source": "aerobic glycolysis",
      "target": "Warburg effect",
      "label": "is also known as"
    },
    {
      "source": "aerobic glycolysis",
      "target": "cancer cells",
      "label": "occurs in"
    },
    {
      "source": "silencing",
      "target": "biosynthetic and proliferative advantages",
      "label": "reverses"
    },
    {
      "source": "silencing",
      "target": "metabolic shift",
      "label": "reverses"
    },
    {
      "source": "silencing",
      "target": "HIF-1\u03b1",
      "label": "of"
    },
    {
      "source": "biosynthetic and proliferative advantages",
      "target": "AMPK\u03b1 signaling",
      "label": "are conferred by"
    },
    {
      "source": "glucose carbon",
      "target": "lipids",
      "label": "is allocated into"
    },
    {
      "source": "lipids",
      "target": "detergent-resistant membrane microdomain (DRM) fraction",
      "label": "extracted from"
    },
    {
      "source": "normoxic stabilization",
      "target": "hypoxia-inducible factor-1\u03b1",
      "label": "of"
    },
    {
      "source": "hypoxia-inducible factor-1\u03b1",
      "target": "HIF-1\u03b1",
      "label": "is also known as"
    },
    {
      "source": "HIF-1\u03b1",
      "target": "cervical muscles",
      "label": "is located in"
    },
    {
      "source": "metabolic sensor",
      "target": "cellular energy homeostasis",
      "label": "helps maintain"
    },
    {
      "source": "Myc",
      "target": "lymphomagenesis",
      "label": "induces"
    },
    {
      "source": "Inactivation",
      "target": "nontransformed cells",
      "label": "occurs in"
    },
    {
      "source": "Inactivation",
      "target": "transformed cells",
      "label": "occurs in"
    },
    {
      "source": "Inactivation",
      "target": "AMPK\u03b1",
      "label": "of"
    },
    {
      "source": "Inactivation",
      "target": "metabolic shift",
      "label": "promotes"
    },
    {
      "source": "Inactivation",
      "target": "biomass accumulation",
      "label": "promotes"
    },
    {
      "source": "Inactivation",
      "target": "glucose carbon",
      "label": "promotes allocation of"
    },
    {
      "source": "cellular metabolic pathways",
      "target": "proliferation",
      "label": "support"
    },
    {
      "source": "cellular metabolic pathways",
      "target": "cell growth",
      "label": "support"
    },
    {
      "source": "\u03b11 catalytic subunit of AMPK",
      "target": "AMPK",
      "label": "is a subunit of"
    },
    {
      "source": "Genetic ablation",
      "target": "\u03b11 catalytic subunit of AMPK",
      "label": "of"
    },
    {
      "source": "Genetic ablation",
      "target": "lymphomagenesis",
      "label": "accelerates"
    },
    {
      "source": "NSCs",
      "target": "transplantation",
      "label": "are candidates for"
    },
    {
      "source": "NSCs",
      "target": "TH(+ve) colonies",
      "label": "differentiated to"
    },
    {
      "source": "NSCs",
      "target": "function",
      "label": "need to overcome for"
    },
    {
      "source": "NSCs",
      "target": "survival",
      "label": "need to overcome for"
    },
    {
      "source": "NSCs",
      "target": "embryonic day 11 rat fetal brain",
      "label": "cultured from"
    },
    {
      "source": "NSCs",
      "target": "suppressive cues",
      "label": "overcome"
    },
    {
      "source": "NSCs",
      "target": "adult neurogenesis",
      "label": "are candidates for"
    },
    {
      "source": "NSCs",
      "target": "Parkinson's disease",
      "label": "are candidates for"
    },
    {
      "source": "NSCs",
      "target": "PD brain",
      "label": "are candidates for"
    },
    {
      "source": "SAL",
      "target": "food materials",
      "label": "present in"
    },
    {
      "source": "SAL",
      "target": "neural stem cells",
      "label": "has effect on"
    },
    {
      "source": "SAL",
      "target": "NSCs",
      "label": "has effect on"
    },
    {
      "source": "SAL",
      "target": "catechol isoquinoline",
      "label": "is a"
    },
    {
      "source": "SAL",
      "target": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",
      "label": "has structural similarity with"
    },
    {
      "source": "SAL",
      "target": "brain",
      "label": "can access"
    },
    {
      "source": "SAL",
      "target": "immature BBB",
      "label": "can access brain in conditions of"
    },
    {
      "source": "SAL",
      "target": "toxicity",
      "label": "exerts"
    },
    {
      "source": "SAL",
      "target": "impaired BBB",
      "label": "can access brain in conditions of"
    },
    {
      "source": "SAL",
      "target": "alcohol beverages",
      "label": "present in"
    },
    {
      "source": "SAL",
      "target": "cell death",
      "label": "elicited"
    },
    {
      "source": "SAL",
      "target": "dopaminergic neurotoxin",
      "label": "has structural similarity with"
    },
    {
      "source": "SAL",
      "target": "MPTP",
      "label": "has structural similarity with"
    },
    {
      "source": "SAL",
      "target": "loss of mitochondrial viability",
      "label": "elicited"
    },
    {
      "source": "pAkt level",
      "target": "pGSK-3\u03b2",
      "label": "affects"
    },
    {
      "source": "pAkt level",
      "target": "GDNF",
      "label": "affects"
    },
    {
      "source": "pAkt level",
      "target": "pCREB",
      "label": "affects"
    },
    {
      "source": "pAkt level",
      "target": "neurotrophins",
      "label": "affects"
    },
    {
      "source": "pAkt level",
      "target": "Bcl-2",
      "label": "affects"
    },
    {
      "source": "pAkt level",
      "target": "BDNF",
      "label": "affects"
    },
    {
      "source": "OEC CM",
      "target": "PI3K/Akt pathway",
      "label": "activated"
    },
    {
      "source": "OEC CM",
      "target": "NSCs",
      "label": "protected"
    },
    {
      "source": "OEC CM",
      "target": "SAL",
      "label": "protected against"
    },
    {
      "source": "neural stem cells",
      "target": "adult neurogenesis",
      "label": "are candidates for"
    },
    {
      "source": "neural stem cells",
      "target": "Parkinson's disease",
      "label": "are candidates for"
    },
    {
      "source": "neural stem cells",
      "target": "PD brain",
      "label": "are candidates for"
    },
    {
      "source": "neural stem cells",
      "target": "transplantation",
      "label": "are candidates for"
    },
    {
      "source": "Sal toxicity",
      "target": "BDNF",
      "label": "reduces"
    },
    {
      "source": "Sal toxicity",
      "target": "pGSK-3\u03b2",
      "label": "reduces"
    },
    {
      "source": "Sal toxicity",
      "target": "repressed PI3K/Akt signaling",
      "label": "suggests"
    },
    {
      "source": "Sal toxicity",
      "target": "GDNF",
      "label": "reduces"
    },
    {
      "source": "Sal toxicity",
      "target": "pAkt level",
      "label": "reduces"
    },
    {
      "source": "Sal toxicity",
      "target": "pCREB",
      "label": "reduces"
    },
    {
      "source": "Sal toxicity",
      "target": "neurotrophins",
      "label": "reduces"
    },
    {
      "source": "Sal toxicity",
      "target": "Bcl-2",
      "label": "reduces"
    },
    {
      "source": "endogenous threats",
      "target": "transplanted NSCs",
      "label": "affect"
    },
    {
      "source": "GDNF",
      "target": "dopaminergic neurons",
      "label": "is essential for"
    },
    {
      "source": "GDNF",
      "target": "growth factor",
      "label": "is a type of"
    },
    {
      "source": "GDNF",
      "target": "extracellular signal-regulated kinase 1/2",
      "label": "is dependent on"
    },
    {
      "source": "GDNF",
      "target": "G\u03b2\u03b3",
      "label": "is dependent on"
    },
    {
      "source": "Olfactory Ensheathing Cell's Conditioned Media",
      "target": "PI3K/Akt pathway",
      "label": "activated"
    },
    {
      "source": "Olfactory Ensheathing Cell's Conditioned Media",
      "target": "NSCs",
      "label": "protected"
    },
    {
      "source": "Olfactory Ensheathing Cell's Conditioned Media",
      "target": "SAL",
      "label": "protected against"
    },
    {
      "source": "Salsolinol",
      "target": "MPTP",
      "label": "has structural similarity with"
    },
    {
      "source": "Salsolinol",
      "target": "dopaminergic neurotoxin",
      "label": "has structural similarity with"
    },
    {
      "source": "Salsolinol",
      "target": "apoptotic changes",
      "label": "induced"
    },
    {
      "source": "Salsolinol",
      "target": "catechol isoquinoline",
      "label": "is a"
    },
    {
      "source": "Salsolinol",
      "target": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",
      "label": "has structural similarity with"
    },
    {
      "source": "Salsolinol",
      "target": "Parkinsonian brain",
      "label": "present in"
    },
    {
      "source": "Salsolinol",
      "target": "neural stem cells",
      "label": "induced apoptotic changes in"
    },
    {
      "source": "Salsolinol",
      "target": "disease process",
      "label": "associated with"
    },
    {
      "source": "MPTP",
      "target": "Microglia",
      "label": "activated"
    },
    {
      "source": "MPTP",
      "target": "DOPAC concentrations",
      "label": "reduced"
    },
    {
      "source": "MPTP",
      "target": "4 doses",
      "label": "administered as"
    },
    {
      "source": "MPTP",
      "target": "astrocytes",
      "label": "activated"
    },
    {
      "source": "MPTP",
      "target": "DA concentrations",
      "label": "reduced"
    },
    {
      "source": "MPTP",
      "target": "dopamine turnover",
      "label": "increased"
    },
    {
      "source": "MPTP",
      "target": "10mg/kg/dose",
      "label": "administered at"
    },
    {
      "source": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",
      "target": "positive control substance",
      "label": "is a"
    },
    {
      "source": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine",
      "target": "MPTP",
      "label": "is also known as"
    },
    {
      "source": "Multiple neurotrophic factor support",
      "target": "PI3K/Akt pathway",
      "label": "activated"
    },
    {
      "source": "Multiple neurotrophic factor support",
      "target": "NSCs",
      "label": "protected"
    },
    {
      "source": "Multiple neurotrophic factor support",
      "target": "SAL",
      "label": "protected against"
    },
    {
      "source": "10\u03bcM SAL",
      "target": "mechanism of toxicity",
      "label": "used to study"
    },
    {
      "source": "10\u03bcM SAL",
      "target": "mitochondrial impairment",
      "label": "initiated"
    },
    {
      "source": "suppressive cues",
      "target": "diseased brain",
      "label": "are from"
    },
    {
      "source": "Morphological impairment",
      "target": "apoptosis",
      "label": "suggested"
    },
    {
      "source": "neurotrophin support",
      "target": "apoptotic changes",
      "label": "ameliorates"
    },
    {
      "source": "TUNEL positivity",
      "target": "apoptosis",
      "label": "suggested"
    },
    {
      "source": "syn-8-oxoG/dAMP base pair",
      "target": "G-C to T-A transversion",
      "label": "results in"
    },
    {
      "source": "DNA polymerase (pol) \u03b2",
      "target": "gap filling",
      "label": "is confronted with"
    },
    {
      "source": "DNA polymerase (pol) \u03b2",
      "target": "8-oxoG",
      "label": "is confronted with"
    },
    {
      "source": "templating anti-8-oxoG",
      "target": "incoming cytosine",
      "label": "base pairs with"
    },
    {
      "source": "Ternary complexes",
      "target": "incoming dATP-analogue",
      "label": "are with"
    },
    {
      "source": "Ternary complexes",
      "target": "wild-type enzyme",
      "label": "resemble"
    },
    {
      "source": "Ternary complexes",
      "target": "incoming dCTP",
      "label": "are with"
    },
    {
      "source": "Ternary complexes",
      "target": "templating 8-oxoG",
      "label": "are with"
    },
    {
      "source": "Ternary complexes",
      "target": "G-A mismatched structure",
      "label": "resembles"
    },
    {
      "source": "8-oxoG",
      "target": "anti-conformation",
      "label": "adopts"
    },
    {
      "source": "8-oxoG",
      "target": "cytosine",
      "label": "base pairs with"
    },
    {
      "source": "8-oxoG",
      "target": "adenine",
      "label": "base pairs with"
    },
    {
      "source": "8-oxoG",
      "target": "syn-conformation",
      "label": "adopts"
    },
    {
      "source": "8-oxoG",
      "target": "coding potential",
      "label": "has"
    },
    {
      "source": "substitution",
      "target": "fidelity",
      "label": "results in increased"
    },
    {
      "source": "fidelity",
      "target": "8-oxoG",
      "label": "is opposite"
    },
    {
      "source": "R283K mutant",
      "target": "Ternary complexes",
      "label": "forms"
    },
    {
      "source": "base lesion",
      "target": "8-oxo-7,8-dihydro-2'-deoxyguanosine",
      "label": "is"
    },
    {
      "source": "base lesion",
      "target": "oxidative stress",
      "label": "results from"
    },
    {
      "source": "8-oxo-7,8-dihydro-2'-deoxyguanosine",
      "target": "8-oxoG",
      "label": "is also known as"
    },
    {
      "source": "binary DNA complex",
      "target": "8-oxoG in equilibrium between anti- and syn-forms",
      "label": "has"
    },
    {
      "source": "DNA polymerase minor groove interactions",
      "target": "mutagenic bypass",
      "label": "modulate"
    },
    {
      "source": "DNA polymerase minor groove interactions",
      "target": "templating 8-oxoguanine lesion",
      "label": "modulate"
    },
    {
      "source": "DNA polymerase minor groove interactions",
      "target": "fidelity",
      "label": "modulate"
    },
    {
      "source": "DNA polymerase minor groove interactions",
      "target": "8-oxoG",
      "label": "influence"
    },
    {
      "source": "DNA polymerase minor groove interactions",
      "target": "templating (anti-/syn-equilibrium)",
      "label": "influence"
    },
    {
      "source": "mutagenic bypass",
      "target": "8-oxoG",
      "label": "involves"
    },
    {
      "source": "R283K pol \u03b2",
      "target": "binary DNA complex",
      "label": "has"
    },
    {
      "source": "pol \u03b2",
      "target": "anti- and syn-8-oxoG",
      "label": "discriminates between"
    },
    {
      "source": "R283K",
      "target": "insertion specificity",
      "label": "alters"
    },
    {
      "source": "Error-free DNA synthesis",
      "target": "8-oxoG",
      "label": "involves"
    },
    {
      "source": "Structural studies",
      "target": "R283K pol \u03b2",
      "label": "are with"
    },
    {
      "source": "Kinetic studies",
      "target": "substitution",
      "label": "demonstrate"
    },
    {
      "source": "base excision repair",
      "target": "mispair",
      "label": "repairs"
    },
    {
      "source": "incoming nucleotide",
      "target": "syn-8-oxoG",
      "label": "is unable to induce"
    },
    {
      "source": "aldosterone synthase",
      "target": "CYP11B2",
      "label": "also known as"
    },
    {
      "source": "aldosterone synthase",
      "target": "Mitochondria",
      "label": "resides in"
    },
    {
      "source": "potent and selective dual inhibitors",
      "target": "CYP11B2",
      "label": "inhibit"
    },
    {
      "source": "potent and selective dual inhibitors",
      "target": "CYP19",
      "label": "inhibit"
    },
    {
      "source": "32 nM",
      "target": "CYP19",
      "label": "for"
    },
    {
      "source": "compounds 3k",
      "target": "potent and selective dual inhibitors",
      "label": "are"
    },
    {
      "source": "decisive structural features",
      "target": "CYP19 inhibitors",
      "label": "are of"
    },
    {
      "source": "decisive structural features",
      "target": "CYP11B2",
      "label": "are of"
    },
    {
      "source": "decisive structural features",
      "target": "common template",
      "label": "combined into"
    },
    {
      "source": "substituents",
      "target": "inhibition",
      "label": "cause increase in"
    },
    {
      "source": "substituents",
      "target": "methylene bridge",
      "label": "located on"
    },
    {
      "source": "substituents",
      "target": "inhibitory activities",
      "label": "influence"
    },
    {
      "source": "substituents",
      "target": "CH3",
      "label": "include"
    },
    {
      "source": "substituents",
      "target": "Br",
      "label": "include"
    },
    {
      "source": "substituents",
      "target": "Cl",
      "label": "include"
    },
    {
      "source": "substituents",
      "target": "CF3",
      "label": "include"
    },
    {
      "source": "substituents",
      "target": "SCH3",
      "label": "include"
    },
    {
      "source": "substituents",
      "target": "F",
      "label": "include"
    },
    {
      "source": "substituents",
      "target": "H",
      "label": "include"
    },
    {
      "source": "pyridinylmethyl substituted 1,2,5,6-tetrahydro-pyrrolo[3,2,1-ij]quinolin-4-ones",
      "target": "common template",
      "label": "designed using"
    },
    {
      "source": "candidate",
      "target": "evaluation in vivo",
      "label": "for"
    },
    {
      "source": "41 nM",
      "target": "CYP11B2",
      "label": "for"
    },
    {
      "source": "compounds 3n",
      "target": "potent and selective dual inhibitors",
      "label": "are"
    },
    {
      "source": "aromatase",
      "target": "CYP19",
      "label": "also known as"
    },
    {
      "source": "compounds 3p",
      "target": "potent and selective dual inhibitors",
      "label": "are"
    },
    {
      "source": "inhibitory activities",
      "target": "opposite effects",
      "label": "lead to"
    },
    {
      "source": "inhibitory activities",
      "target": "tests",
      "label": "observed in"
    },
    {
      "source": "Tetrahydropyrroloquinolinone type dual inhibitors",
      "target": "novel strategy",
      "label": "are a"
    },
    {
      "source": "Tetrahydropyrroloquinolinone type dual inhibitors",
      "target": "aldosterone synthase",
      "label": "are inhibitors of"
    },
    {
      "source": "Tetrahydropyrroloquinolinone type dual inhibitors",
      "target": "aromatase",
      "label": "are inhibitors of"
    },
    {
      "source": "CVD",
      "target": "aldosterone",
      "label": "caused by"
    },
    {
      "source": "compound 3p",
      "target": "selectivity",
      "label": "exhibited"
    },
    {
      "source": "compound 3p",
      "target": "candidate",
      "label": "is considered as"
    },
    {
      "source": "compound 3p",
      "target": "IC(50) values",
      "label": "exhibited"
    },
    {
      "source": "breast cancer patients",
      "target": "cardiovascular risks",
      "label": "have"
    },
    {
      "source": "Dual inhibitors",
      "target": "novel strategy",
      "label": "are proposed as"
    },
    {
      "source": "Dual inhibitors",
      "target": "aldosterone synthase",
      "label": "inhibit"
    },
    {
      "source": "Dual inhibitors",
      "target": "aromatase",
      "label": "inhibit"
    },
    {
      "source": "compounds 3j",
      "target": "potent and selective dual inhibitors",
      "label": "are"
    },
    {
      "source": "adjuvant therapy",
      "target": "patients with OSCC oral cancer",
      "label": "for"
    },
    {
      "source": "stressful conditions",
      "target": "hypoxia",
      "label": "include"
    },
    {
      "source": "stressful conditions",
      "target": "nutrient deprivation",
      "label": "include"
    },
    {
      "source": "hypoxia",
      "target": "tumor microenvironment",
      "label": "occurs in"
    },
    {
      "source": "growth inhibitory effects",
      "target": "E235",
      "label": "of"
    },
    {
      "source": "E235",
      "target": "compound",
      "label": "is a type of"
    },
    {
      "source": "E235",
      "target": "ISR",
      "label": "activated"
    },
    {
      "source": "E235",
      "target": "G2/M phase",
      "label": "increased"
    },
    {
      "source": "E235",
      "target": "S-phase cells",
      "label": "decreased"
    },
    {
      "source": "E235",
      "target": "physical DNA damage",
      "label": "does not cause"
    },
    {
      "source": "E235",
      "target": "viability",
      "label": "decreased"
    },
    {
      "source": "E235",
      "target": "DNA damage response signaling",
      "label": "activated"
    },
    {
      "source": "E235",
      "target": "small molecule",
      "label": "is a type of"
    },
    {
      "source": "E235",
      "target": "senescence",
      "label": "induced"
    },
    {
      "source": "E235",
      "target": "ATF4 expression",
      "label": "increased"
    },
    {
      "source": "knockdown",
      "target": "ATF4",
      "label": "of"
    },
    {
      "source": "knockdown",
      "target": "antiproliferative effects",
      "label": "increased"
    },
    {
      "source": "knockdown",
      "target": "BMP-2 processing",
      "label": "revealed"
    },
    {
      "source": "knockdown",
      "target": "FSAP",
      "label": "of"
    },
    {
      "source": "knockdown",
      "target": "hepatocytes",
      "label": "in"
    },
    {
      "source": "N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide",
      "target": "compound",
      "label": "is a type of"
    },
    {
      "source": "N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide",
      "target": "ISR",
      "label": "activated"
    },
    {
      "source": "N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide",
      "target": "ATF4 expression",
      "label": "increased"
    },
    {
      "source": "senescence",
      "target": "p21",
      "label": "is not dependent on"
    },
    {
      "source": "senescence",
      "target": "cell types",
      "label": "induced in"
    },
    {
      "source": "senescence",
      "target": "p53",
      "label": "is not dependent on"
    },
    {
      "source": "ISR",
      "target": "cellular adaptation",
      "label": "enables"
    },
    {
      "source": "DNA damage response signaling",
      "target": "Ser15-phosphorylated p53",
      "label": "increased"
    },
    {
      "source": "DNA damage response signaling",
      "target": "\u03b3-H2AX",
      "label": "increased"
    },
    {
      "source": "DNA damage response signaling",
      "target": "phosphorylated checkpoint kinase 2",
      "label": "increased"
    },
    {
      "source": "DNA damage response signaling",
      "target": "Chk2",
      "label": "increased"
    },
    {
      "source": "Ser15-phosphorylated p53",
      "target": "p53",
      "label": "is a type of"
    },
    {
      "source": "chemical libraries",
      "target": "modulators",
      "label": "screened for"
    },
    {
      "source": "modulators",
      "target": "ATF4 expression",
      "label": "of"
    },
    {
      "source": "phosphorylated checkpoint kinase 2",
      "target": "Chk2",
      "label": "is a type of"
    },
    {
      "source": "\u03bcM doses",
      "target": "E235",
      "label": "of"
    },
    {
      "source": "overactivation",
      "target": "tumor cell death",
      "label": "induces"
    },
    {
      "source": "overactivation",
      "target": "ISR",
      "label": "of"
    },
    {
      "source": "cell types",
      "target": "HT1080 human fibrosarcoma",
      "label": "include"
    },
    {
      "source": "cell types",
      "target": "B16F10 mouse melanoma cells",
      "label": "include"
    },
    {
      "source": "cellular adaptation",
      "target": "stressful conditions",
      "label": "to"
    },
    {
      "source": "Integrated Stress Response",
      "target": "signaling program",
      "label": "is a type of"
    },
    {
      "source": "nutrient deprivation",
      "target": "tumor microenvironment",
      "label": "occurs in"
    },
    {
      "source": "ATF4 knockdown cells",
      "target": "\u03b3-H2AX",
      "label": "abrogated"
    },
    {
      "source": "activating transcription factor 4",
      "target": "ISR",
      "label": "is an effector of"
    },
    {
      "source": "activating transcription factor 4",
      "target": "transcription factor",
      "label": "is a type of"
    },
    {
      "source": "activating transcription factor 4",
      "target": "Transcription Factors",
      "label": "is a"
    },
    {
      "source": "activating transcription factor 4",
      "target": "GSH metabolism",
      "label": "plays critical role in"
    },
    {
      "source": "modifiers",
      "target": "Integrated Stress Response",
      "label": "of"
    },
    {
      "source": "small-molecule screen",
      "target": "modifiers",
      "label": "is for"
    },
    {
      "source": "intestinal first-pass metabolism",
      "target": "new drug candidates",
      "label": "of"
    },
    {
      "source": "intestinal first-pass metabolism",
      "target": "drug candidates",
      "label": "of"
    },
    {
      "source": "GFJ",
      "target": "blood levels",
      "label": "elevated"
    },
    {
      "source": "GFJ",
      "target": "TRZ",
      "label": "had significant effect on"
    },
    {
      "source": "GFJ",
      "target": "intestinal microsomal oxidation",
      "label": "suppressed"
    },
    {
      "source": "liquid chromatography/MS/MS",
      "target": "blood levels",
      "label": "measured"
    },
    {
      "source": "liquid chromatography/MS/MS",
      "target": "parent compounds",
      "label": "measured"
    },
    {
      "source": "liquid chromatography/MS/MS",
      "target": "metabolites",
      "label": "measured"
    },
    {
      "source": "blood levels",
      "target": "metabolites",
      "label": "of"
    },
    {
      "source": "blood levels",
      "target": "parent compounds",
      "label": "of"
    },
    {
      "source": "In vitro experiments",
      "target": "rat hepatic microsomal fractions",
      "label": "used"
    },
    {
      "source": "In vitro experiments",
      "target": "human hepatic microsomal fractions",
      "label": "used"
    },
    {
      "source": "In vitro experiments",
      "target": "rat intestinal microsomal fractions",
      "label": "used"
    },
    {
      "source": "In vitro experiments",
      "target": "human intestinal microsomal fractions",
      "label": "used"
    },
    {
      "source": "In vitro experiments",
      "target": "mouse hepatic microsomal fractions",
      "label": "used"
    },
    {
      "source": "In vitro experiments",
      "target": "mouse intestinal microsomal fractions",
      "label": "used"
    },
    {
      "source": "MDZ",
      "target": "mechanism-based inactivation",
      "label": "caused"
    },
    {
      "source": "MDZ",
      "target": "cytochrome P450 3A",
      "label": "Downregulator"
    },
    {
      "source": "MDZ",
      "target": "Substrate inhibition",
      "label": "caused"
    },
    {
      "source": "mechanism-based inactivation",
      "target": "TRZ 1'-hydroxylation",
      "label": "of"
    },
    {
      "source": "mechanism-based inactivation",
      "target": "cytochrome P450 3A",
      "label": "of"
    },
    {
      "source": "mechanism-based inactivation",
      "target": "potencies",
      "label": "had similar"
    },
    {
      "source": "4-hydroxylation",
      "target": "hepatic microsomal fractions",
      "label": "in"
    },
    {
      "source": "4-hydroxylation",
      "target": "intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "kinetic profiles",
      "target": "MDZ oxidation",
      "label": "of"
    },
    {
      "source": "MDZ oxidation",
      "target": "rat microsomes",
      "label": "different from"
    },
    {
      "source": "MDZ oxidation",
      "target": "human microsomes",
      "label": "similar to"
    },
    {
      "source": "MDZ oxidation",
      "target": "mouse hepatic microsomal fractions",
      "label": "in"
    },
    {
      "source": "MDZ oxidation",
      "target": "mouse intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "TRZ 1'-hydroxylation",
      "target": "rat intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "TRZ 1'-hydroxylation",
      "target": "cytochrome P450 3A",
      "label": "dependent on"
    },
    {
      "source": "TRZ 1'-hydroxylation",
      "target": "mouse intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "TRZ 1'-hydroxylation",
      "target": "human intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "TRZ",
      "target": "cytochrome P450 3A",
      "label": "Substrate"
    },
    {
      "source": "drug candidates",
      "target": "CYP3A enzymes",
      "label": "metabolized by"
    },
    {
      "source": "cytochrome P450 3A",
      "target": "CYP3A",
      "label": "is also known as"
    },
    {
      "source": "in vitro oxidation",
      "target": "midazolam",
      "label": "of"
    },
    {
      "source": "in vitro oxidation",
      "target": "triazolam",
      "label": "of"
    },
    {
      "source": "midazolam",
      "target": "CYP3A4",
      "label": "is probe drug for"
    },
    {
      "source": "midazolam",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "midazolam",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "midazolam",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "midazolam",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "midazolam",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "intestinal microsomal oxidation",
      "target": "TRZ",
      "label": "of"
    },
    {
      "source": "intestinal microsomal oxidation",
      "target": "MDZ",
      "label": "of"
    },
    {
      "source": "in vivo oxidation",
      "target": "midazolam",
      "label": "of"
    },
    {
      "source": "in vivo oxidation",
      "target": "triazolam",
      "label": "of"
    },
    {
      "source": "first-pass effects",
      "target": "drug candidates",
      "label": "of"
    },
    {
      "source": "1'-hydroxylation",
      "target": "hepatic microsomal fractions",
      "label": "in"
    },
    {
      "source": "1'-hydroxylation",
      "target": "intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "Substrate inhibition",
      "target": "rat microsomes",
      "label": "different from"
    },
    {
      "source": "Substrate inhibition",
      "target": "1'-hydroxylation",
      "label": "caused reduction in"
    },
    {
      "source": "Substrate inhibition",
      "target": "human microsomes",
      "label": "similar to"
    },
    {
      "source": "Substrate inhibition",
      "target": "mouse hepatic microsomal fractions",
      "label": "in"
    },
    {
      "source": "Substrate inhibition",
      "target": "mouse intestinal microsomal fractions",
      "label": "in"
    },
    {
      "source": "Substrate inhibition",
      "target": "4-hydroxylation",
      "label": "did not cause reduction in"
    },
    {
      "source": "evaluation methodology",
      "target": "first-pass effects",
      "label": "for"
    },
    {
      "source": "evaluation methodology",
      "target": "intestinal first-pass metabolism",
      "label": "for"
    },
    {
      "source": "linear accelerator",
      "target": "irradiation",
      "label": "used for"
    },
    {
      "source": "quinic acid",
      "target": "radioprotective compounds",
      "label": "acts as"
    },
    {
      "source": "quinic acid",
      "target": "radioprotective effect",
      "label": "provided"
    },
    {
      "source": "quinic acid",
      "target": "DNA damage",
      "label": "decreased"
    },
    {
      "source": "protective ability",
      "target": "phenolic acids",
      "label": "of"
    },
    {
      "source": "protective ability",
      "target": "radiation-induced DNA damage",
      "label": "against"
    },
    {
      "source": "protective ability",
      "target": "human blood lymphocytes",
      "label": "in"
    },
    {
      "source": "protective ability",
      "target": "alkaline comet assay",
      "label": "assessed using"
    },
    {
      "source": "phenolic acids",
      "target": "Radioprotection",
      "label": "provide"
    },
    {
      "source": "radioprotective effect",
      "target": "phytochemicals",
      "label": "of"
    },
    {
      "source": "radioprotective effect",
      "target": "X-ray irradiation-induced genomic instability",
      "label": "against"
    },
    {
      "source": "phytochemicals",
      "target": "chronic degenerative diseases",
      "label": "protect against"
    },
    {
      "source": "Siemens Mevatron MD2",
      "target": "linear accelerator",
      "label": "is a type of"
    },
    {
      "source": "Siemens Mevatron MD2",
      "target": "Siemens AG",
      "label": "manufactured by"
    },
    {
      "source": "Siemens AG",
      "target": "USA",
      "label": "located in"
    },
    {
      "source": "DNA damage",
      "target": "irradiation",
      "label": "induced by"
    },
    {
      "source": "DNA damage",
      "target": "alkaline comet assay",
      "label": "determined by"
    },
    {
      "source": "DNA damage",
      "target": "p53",
      "label": "causes increase in"
    },
    {
      "source": "DNA damage",
      "target": "endogenous supervillin",
      "label": "causes down-regulation of"
    },
    {
      "source": "DNA damage",
      "target": "drug users",
      "label": "takes place in"
    },
    {
      "source": "chlorogenic acid",
      "target": "radioprotective compounds",
      "label": "acts as"
    },
    {
      "source": "chlorogenic acid",
      "target": "radioprotective effect",
      "label": "provided"
    },
    {
      "source": "chlorogenic acid",
      "target": "DNA damage",
      "label": "decreased"
    },
    {
      "source": "Radioprotection",
      "target": "in vitro",
      "label": "studied in"
    },
    {
      "source": "Radioprotection",
      "target": "X-ray induced DNA damage",
      "label": "on"
    },
    {
      "source": "Radioprotection",
      "target": "phenolic compounds",
      "label": "by"
    },
    {
      "source": "X-ray irradiation-induced genomic instability",
      "target": "non-tumorigenic human blood lymphocytes",
      "label": "in"
    },
    {
      "source": "X-ray induced DNA damage",
      "target": "human blood lymphocytes",
      "label": "in"
    },
    {
      "source": "human blood lymphocytes",
      "target": "healthy human donors",
      "label": "isolated from"
    },
    {
      "source": "ganglioside clusters",
      "target": "A\u03b2 assembly",
      "label": "do not accelerate"
    },
    {
      "source": "ganglioside clusters",
      "target": "A\u03b2 assembly process",
      "label": "play a key role in the"
    },
    {
      "source": "ganglioside clusters",
      "target": "presynaptic neuronal membranes",
      "label": "are in"
    },
    {
      "source": "ganglioside clusters",
      "target": "key role",
      "label": "play"
    },
    {
      "source": "ganglioside clusters",
      "target": "initiation of the A\u03b2 assembly process",
      "label": "play a key role in the"
    },
    {
      "source": "A\u03b2 assembly",
      "target": "distinctive GM1 domain",
      "label": "generated on"
    },
    {
      "source": "ASIGN",
      "target": "synaptosomal membranes",
      "label": "is on"
    },
    {
      "source": "ASIGN",
      "target": "high density of GM1",
      "label": "has"
    },
    {
      "source": "Density",
      "target": "factor",
      "label": "is a"
    },
    {
      "source": "Density",
      "target": "spherical assembly of amyloid \u03b2-protein",
      "label": "is a critical factor in the"
    },
    {
      "source": "Density",
      "target": "formation",
      "label": "is a critical factor in the"
    },
    {
      "source": "ganglioside-enriched microdomains",
      "target": "A\u03b2 assembly process",
      "label": "play a key role in the"
    },
    {
      "source": "ganglioside-enriched microdomains",
      "target": "presynaptic neuronal membranes",
      "label": "are in"
    },
    {
      "source": "ganglioside-enriched microdomains",
      "target": "key role",
      "label": "play"
    },
    {
      "source": "ganglioside-enriched microdomains",
      "target": "initiation of the A\u03b2 assembly process",
      "label": "play a key role in the"
    },
    {
      "source": "ganglioside-enriched microdomains",
      "target": "A\u03b2 assembly",
      "label": "play a key role in the"
    },
    {
      "source": "distinctive GM1 domain",
      "target": "A\u03b2-sensitive ganglioside nanocluster (ASIGN)",
      "label": "characterized as"
    },
    {
      "source": "distinctive GM1 domain",
      "target": "ASIGN",
      "label": "characterized as"
    },
    {
      "source": "A\u03b2",
      "target": "Alzheimer's disease (AD)",
      "label": "deposition is a hallmark of"
    },
    {
      "source": "A\u03b2",
      "target": "AD",
      "label": "deposition is a hallmark of"
    },
    {
      "source": "reconstituted lipid bilayer",
      "target": "lipids",
      "label": "composed of"
    },
    {
      "source": "critical density of GM1",
      "target": "A\u03b2 binding",
      "label": "induces"
    },
    {
      "source": "critical density of GM1",
      "target": "nanoclusters",
      "label": "is in"
    },
    {
      "source": "critical density of GM1",
      "target": "assembly",
      "label": "induces"
    },
    {
      "source": "atomic force microscopic study",
      "target": "morphology",
      "label": "is on the"
    },
    {
      "source": "atomic force microscopic study",
      "target": "spherical A\u03b2",
      "label": "observed"
    },
    {
      "source": "morphology",
      "target": "reconstituted lipid bilayer",
      "label": "is of a"
    },
    {
      "source": "spherical assembly of amyloid \u03b2-protein",
      "target": "synaptic plasma membranes",
      "label": "forms on"
    },
    {
      "source": "ganglioside-bound A\u03b2 (GA\u03b2)",
      "target": "endogenous seed",
      "label": "acts as"
    },
    {
      "source": "ganglioside-bound A\u03b2 (GA\u03b2)",
      "target": "ASIGN",
      "label": "generated on"
    },
    {
      "source": "endogenous seed",
      "target": "A\u03b2 fibril formation",
      "label": "for"
    },
    {
      "source": "DRM fraction",
      "target": "synaptosomes",
      "label": "is from"
    },
    {
      "source": "deposition of amyloid \u03b2-protein (A\u03b2)",
      "target": "hallmark",
      "label": "is a"
    },
    {
      "source": "deposition of amyloid \u03b2-protein (A\u03b2)",
      "target": "AD",
      "label": "is a hallmark of"
    },
    {
      "source": "deposition of amyloid \u03b2-protein (A\u03b2)",
      "target": "Alzheimer's disease (AD)",
      "label": "is a hallmark of"
    },
    {
      "source": "GA\u03b2",
      "target": "endogenous seed",
      "label": "acts as"
    },
    {
      "source": "GA\u03b2",
      "target": "ASIGN",
      "label": "generated on"
    },
    {
      "source": "A\u03b2 fibril formation",
      "target": "AD brains",
      "label": "occurs in"
    },
    {
      "source": "artificial GM1 cluster-binding peptide",
      "target": "high density of GM1",
      "label": "used to find"
    },
    {
      "source": "assembly",
      "target": "unmodified antibody",
      "label": "developed through recognition of"
    },
    {
      "source": "assembly",
      "target": "gold nanoparticle",
      "label": "is of"
    },
    {
      "source": "assembly",
      "target": "receptor subunits",
      "label": "of"
    },
    {
      "source": "ganglioside",
      "target": "A\u03b2",
      "label": "Regulator"
    },
    {
      "source": "cellular energy sensor",
      "target": "eukaryotes",
      "label": "conserved across"
    },
    {
      "source": "Stenesen and colleagues",
      "target": "AMP biosynthesis",
      "label": "alter"
    },
    {
      "source": "Stenesen and colleagues",
      "target": "AMPK",
      "label": "activate"
    },
    {
      "source": "AMP biosynthesis",
      "target": "AMPK",
      "label": "influences"
    },
    {
      "source": "CAR",
      "target": "constitutive androstane receptor",
      "label": "is also known as"
    },
    {
      "source": "CAR",
      "target": "ligand-binding site",
      "label": "has"
    },
    {
      "source": "CAR",
      "target": "ligand specificities",
      "label": "has"
    },
    {
      "source": "CAR",
      "target": "genes",
      "label": "control"
    },
    {
      "source": "CAR",
      "target": "nuclear xenobiotic receptors",
      "label": "is a type of"
    },
    {
      "source": "CAR",
      "target": "3D structures",
      "label": "has"
    },
    {
      "source": "CAR",
      "target": "promiscuity",
      "label": "has"
    },
    {
      "source": "CAR",
      "target": "specificity",
      "label": "has"
    },
    {
      "source": "constitutive androstane receptor",
      "target": "nuclear receptors",
      "label": "is a type of"
    },
    {
      "source": "3D structures",
      "target": "ligand-binding specificity",
      "label": "provide insights into"
    },
    {
      "source": "3D structures",
      "target": "activation mechanisms",
      "label": "provide insights into"
    },
    {
      "source": "nuclear xenobiotic receptors",
      "target": "ligand specificities",
      "label": "have"
    },
    {
      "source": "nuclear xenobiotic receptors",
      "target": "3D structures",
      "label": "have"
    },
    {
      "source": "PXR",
      "target": "pregnane X receptor",
      "label": "is also known as"
    },
    {
      "source": "PXR",
      "target": "ligand-binding site",
      "label": "has"
    },
    {
      "source": "PXR",
      "target": "ligand specificities",
      "label": "has"
    },
    {
      "source": "PXR",
      "target": "3D structures",
      "label": "has"
    },
    {
      "source": "PXR",
      "target": "genes",
      "label": "control"
    },
    {
      "source": "PXR",
      "target": "nuclear xenobiotic receptors",
      "label": "is a type of"
    },
    {
      "source": "PXR",
      "target": "promiscuity",
      "label": "has"
    },
    {
      "source": "PXR",
      "target": "specificity",
      "label": "has"
    },
    {
      "source": "pregnane X receptor",
      "target": "nuclear receptors",
      "label": "is a type of"
    },
    {
      "source": "metabolic enzymes",
      "target": "humans",
      "label": "are found in"
    },
    {
      "source": "ligand-binding domain",
      "target": "3D structures",
      "label": "has"
    },
    {
      "source": "ligand-binding domain",
      "target": "LBD",
      "label": "is also known as"
    },
    {
      "source": "ligand profiles",
      "target": "LBD structures",
      "label": "are in agreement with"
    },
    {
      "source": "LBD",
      "target": "3D structures",
      "label": "has"
    },
    {
      "source": "crystal structures",
      "target": "promiscuity",
      "label": "help understand"
    },
    {
      "source": "crystal structures",
      "target": "specificity",
      "label": "help understand"
    },
    {
      "source": "Mn",
      "target": "trace element",
      "label": "is a"
    },
    {
      "source": "Mn",
      "target": "oxidative DNA damage",
      "label": "promotes"
    },
    {
      "source": "Mn",
      "target": "accumulation",
      "label": "promotes"
    },
    {
      "source": "Mn",
      "target": "normal function",
      "label": "is required for"
    },
    {
      "source": "Mn",
      "target": "development",
      "label": "is required for"
    },
    {
      "source": "Mn",
      "target": "formation",
      "label": "promotes"
    },
    {
      "source": "trace element",
      "target": "normal function",
      "label": "is required for"
    },
    {
      "source": "trace element",
      "target": "development",
      "label": "is required for"
    },
    {
      "source": "Mn(2+)",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "Mn(2+)",
      "target": "formation",
      "label": "induces"
    },
    {
      "source": "Mn(2+)",
      "target": "SH-SY5Y cellular viability",
      "label": "decreases"
    },
    {
      "source": "Mn(2+)",
      "target": "oxidatively modified thymine bases",
      "label": "induces"
    },
    {
      "source": "Mn(2+)",
      "target": "accumulation",
      "label": "induces"
    },
    {
      "source": "oxidative DNA damage",
      "target": "neuronal SH-SY5Y cells",
      "label": "occurs in"
    },
    {
      "source": "oxidative DNA damage",
      "target": "apoptosis",
      "label": "leads to"
    },
    {
      "source": "oxidative DNA damage",
      "target": "SH-SY5Y cells",
      "label": "occurs in"
    },
    {
      "source": "SH-SY5Y cellular viability",
      "target": "controls",
      "label": "is compared to"
    },
    {
      "source": "DNA single strand breaks",
      "target": "alkaline comet assay analysis",
      "label": "is analyzed by"
    },
    {
      "source": "welding fumes",
      "target": "body burdens of Mn",
      "label": "causes"
    },
    {
      "source": "body burdens of Mn",
      "target": "neurological health concerns",
      "label": "are associated with"
    },
    {
      "source": "exogenous chemical antioxidants",
      "target": "oxidative DNA damage",
      "label": "abrogate"
    },
    {
      "source": "TUNEL",
      "target": "apoptosis",
      "label": "confirms"
    },
    {
      "source": "smelters",
      "target": "body burdens of Mn",
      "label": "causes"
    },
    {
      "source": "Manganese",
      "target": "trace element",
      "label": "is a"
    },
    {
      "source": "Manganese",
      "target": "thymine base lesions",
      "label": "induces"
    },
    {
      "source": "Manganese",
      "target": "oxidative DNA damage",
      "label": "induces"
    },
    {
      "source": "Manganese",
      "target": "manganism",
      "label": "causes"
    },
    {
      "source": "neurological symptoms",
      "target": "idiopathic Parkinson's disease (IPD)",
      "label": "are similar to"
    },
    {
      "source": "1mM N-acetylcysteine (NAC)",
      "target": "oxidative cellular damage",
      "label": "provides protection against"
    },
    {
      "source": "1mM N-acetylcysteine (NAC)",
      "target": "formation",
      "label": "reduces"
    },
    {
      "source": "1mM N-acetylcysteine (NAC)",
      "target": "DNA strand breaks",
      "label": "reduces"
    },
    {
      "source": "Mn(2+)-induction",
      "target": "thymine lesions",
      "label": "causes"
    },
    {
      "source": "thymine lesions",
      "target": "SH-SY5Y cell line",
      "label": "occur in"
    },
    {
      "source": "oxidatively modified thymine bases",
      "target": "gas chromatography/mass spectrometry analysis",
      "label": "is analyzed by"
    },
    {
      "source": "mines",
      "target": "body burdens of Mn",
      "label": "causes"
    },
    {
      "source": "annexin V/propidium iodide (PI) apoptosis assays",
      "target": "apoptosis",
      "label": "confirms"
    },
    {
      "source": "parental nutrition",
      "target": "body burdens of Mn",
      "label": "causes"
    },
    {
      "source": "1mM glutathione (GSH)",
      "target": "oxidative cellular damage",
      "label": "provides protection against"
    },
    {
      "source": "1mM glutathione (GSH)",
      "target": "formation",
      "label": "reduces"
    },
    {
      "source": "1mM glutathione (GSH)",
      "target": "DNA strand breaks",
      "label": "reduces"
    },
    {
      "source": "N-acetylcysteine",
      "target": "thymine base lesions",
      "label": "attenuates"
    },
    {
      "source": "N-acetylcysteine",
      "target": "phosphorylations",
      "label": "inhibits"
    },
    {
      "source": "manganism",
      "target": "neurological symptoms",
      "label": "has"
    },
    {
      "source": "manganism",
      "target": "progressive neurodegenerative disorder",
      "label": "is a"
    },
    {
      "source": "vapors",
      "target": "body burdens of Mn",
      "label": "causes"
    },
    {
      "source": "antioxidant protection",
      "target": "thymine lesions",
      "label": "affects"
    },
    {
      "source": "Lipases",
      "target": "CESs",
      "label": "are functionally related to"
    },
    {
      "source": "CESs",
      "target": "lipids",
      "label": "hydrolyzes"
    },
    {
      "source": "CESs",
      "target": "\u03b1/\u03b2 hydrolase fold superfamily",
      "label": "belongs to"
    },
    {
      "source": "orlistat",
      "target": "CESs",
      "label": "inhibits"
    },
    {
      "source": "orlistat",
      "target": "organ toxicities",
      "label": "linked to"
    },
    {
      "source": "orlistat",
      "target": "CES2 activity",
      "label": "inhibited"
    },
    {
      "source": "orlistat",
      "target": "CES1",
      "label": "did not inhibit"
    },
    {
      "source": "orlistat",
      "target": "anti-obesity drug",
      "label": "is"
    },
    {
      "source": "orlistat",
      "target": "antiobesity agent",
      "label": "is"
    },
    {
      "source": "orlistat",
      "target": "gastrointestinal lipases",
      "label": "inhibits"
    },
    {
      "source": "orlistat",
      "target": "CES2",
      "label": "has lower potency toward"
    },
    {
      "source": "orlistat",
      "target": "activation",
      "label": "has implications in"
    },
    {
      "source": "CES2",
      "target": "hydrolysis",
      "label": "is responsible for"
    },
    {
      "source": "CES2",
      "target": "liver",
      "label": "expressed in"
    },
    {
      "source": "CES2",
      "target": "orlistat",
      "label": "is sensitive target of"
    },
    {
      "source": "CES2",
      "target": "carboxylesterase",
      "label": "is a"
    },
    {
      "source": "CES2",
      "target": "gastrointestinal track",
      "label": "expressed in"
    },
    {
      "source": "alternative target",
      "target": "toxicological responses",
      "label": "involved in"
    },
    {
      "source": "carboxylesterase",
      "target": "lipase activity",
      "label": "has"
    },
    {
      "source": "human CES1",
      "target": "lipids",
      "label": "hydrolyzes"
    },
    {
      "source": "anticancer prodrugs",
      "target": "irinotecan",
      "label": "include"
    },
    {
      "source": "anticancer prodrugs",
      "target": "PPD",
      "label": "include"
    },
    {
      "source": "anticancer prodrugs",
      "target": "pentyl carbamate",
      "label": "include"
    },
    {
      "source": "anticancer prodrugs",
      "target": "doxazolidine",
      "label": "include"
    },
    {
      "source": "anticancer prodrugs",
      "target": "p-aminobenzyl carbamate",
      "label": "include"
    },
    {
      "source": "mouse CESs",
      "target": "orlistat",
      "label": "are sensitive to"
    },
    {
      "source": "altered therapeutic activity",
      "target": "medicines",
      "label": "of"
    },
    {
      "source": "medicines",
      "target": "orlistat",
      "label": "co-administered with"
    },
    {
      "source": "recombinant CESs",
      "target": "inhibition",
      "label": "tested for"
    },
    {
      "source": "source",
      "target": "altered therapeutic activity",
      "label": "for"
    },
    {
      "source": "Liver microsomes",
      "target": "inhibition",
      "label": "tested for"
    },
    {
      "source": "cell killing activity",
      "target": "PPD",
      "label": "of"
    },
    {
      "source": "carboxylesterases",
      "target": "\u03b1/\u03b2 hydrolase fold superfamily",
      "label": "belongs to"
    },
    {
      "source": "Carboxylesterase-2",
      "target": "orlistat",
      "label": "is target of"
    },
    {
      "source": "rat CESs",
      "target": "orlistat",
      "label": "are not sensitive to"
    },
    {
      "source": "p300",
      "target": "dystrophic heart",
      "label": "up-regulation is pathologically significant in"
    },
    {
      "source": "p300",
      "target": "atrial natriuretic peptide promoter",
      "label": "activates"
    },
    {
      "source": "Resveratrol",
      "target": "cardiomyocyte hypertrophy",
      "label": "inhibits"
    },
    {
      "source": "Resveratrol",
      "target": "p300 mRNA",
      "label": "does not down-regulate"
    },
    {
      "source": "Resveratrol",
      "target": "fibrosis",
      "label": "suppresses"
    },
    {
      "source": "Resveratrol",
      "target": "p300 protein",
      "label": "down-regulates"
    },
    {
      "source": "Resveratrol",
      "target": "cardiac diastolic function",
      "label": "restores"
    },
    {
      "source": "Resveratrol",
      "target": "SIRT1 protein",
      "label": "acts through"
    },
    {
      "source": "Resveratrol",
      "target": "NAD(+)-dependent protein deacetylase SIRT1",
      "label": "activates"
    },
    {
      "source": "Resveratrol",
      "target": "cardiomyopathy",
      "label": "improves"
    },
    {
      "source": "Resveratrol",
      "target": "cardiac hypertrophy",
      "label": "suppresses"
    },
    {
      "source": "p300 mRNA",
      "target": "mdx heart",
      "label": "is not up-regulated in"
    },
    {
      "source": "ubiquitin-proteasome pathway",
      "target": "proteasome",
      "label": "involves"
    },
    {
      "source": "ubiquitin-proteasome pathway",
      "target": "ubiquitin",
      "label": "involves"
    },
    {
      "source": "\u03b1(1)-agonist phenylephrine",
      "target": "cardiomyocyte hypertrophy",
      "label": "induces"
    },
    {
      "source": "SIRT1 protein",
      "target": "p300 protein",
      "label": "mediates modulation of"
    },
    {
      "source": "pro-hypertrophic co-activator p300 protein",
      "target": "mdx heart",
      "label": "is up-regulated in"
    },
    {
      "source": "immunohistochemical staining",
      "target": "active caspase-3",
      "label": "evaluates"
    },
    {
      "source": "immunohistochemical staining",
      "target": "3-nitrotyrosine",
      "label": "evaluates"
    },
    {
      "source": "immunohistochemical staining",
      "target": "8-epi-PGF2a",
      "label": "evaluates"
    },
    {
      "source": "immunohistochemical staining",
      "target": "3-NT",
      "label": "evaluates"
    },
    {
      "source": "immunohistochemical staining",
      "target": "8-epi-prostaglandin F2 alpha",
      "label": "evaluates"
    },
    {
      "source": "ex vivo exposure",
      "target": "Lead",
      "label": "involves"
    },
    {
      "source": "ex vivo exposure",
      "target": "Benzo[a]pyrene",
      "label": "involves"
    },
    {
      "source": "ex vivo exposure",
      "target": "DON",
      "label": "to"
    },
    {
      "source": "ex vivo exposure",
      "target": "activation",
      "label": "lead to"
    },
    {
      "source": "ex vivo exposure",
      "target": "intestinal tissue",
      "label": "of"
    },
    {
      "source": "ex vivo exposure",
      "target": "intestinal lesions",
      "label": "lead to"
    },
    {
      "source": "Lead",
      "target": "Pathological conditions",
      "label": "can lead to"
    },
    {
      "source": "Pb treatments",
      "target": "active caspase-3",
      "label": "Upregulates"
    },
    {
      "source": "Pb treatments",
      "target": "3-NT",
      "label": "Upregulates"
    },
    {
      "source": "BaP treatments",
      "target": "active caspase-3",
      "label": "Upregulates"
    },
    {
      "source": "BaP treatments",
      "target": "3-NT",
      "label": "Upregulates"
    },
    {
      "source": "Pb",
      "target": "Pathological conditions",
      "label": "can lead to"
    },
    {
      "source": "Pb",
      "target": "Oral mucosa cells",
      "label": "affects"
    },
    {
      "source": "Pb",
      "target": "8-epi-PGF2a",
      "label": "Upregulates"
    },
    {
      "source": "Pathological conditions",
      "target": "Nitrosative stress",
      "label": "mediated by"
    },
    {
      "source": "Pathological conditions",
      "target": "Oxidative stress",
      "label": "mediated by"
    },
    {
      "source": "Pathological conditions",
      "target": "Apoptosis",
      "label": "mediated by"
    },
    {
      "source": "chronic Pb and BaP exposure",
      "target": "Pb",
      "label": "involves"
    },
    {
      "source": "chronic Pb and BaP exposure",
      "target": "BaP",
      "label": "involves"
    },
    {
      "source": "Ingestion",
      "target": "Lead",
      "label": "is a route of exposure for"
    },
    {
      "source": "Ingestion",
      "target": "Benzo[a]pyrene",
      "label": "is a route of exposure for"
    },
    {
      "source": "Benzo[a]pyrene",
      "target": "Pathological conditions",
      "label": "can lead to"
    },
    {
      "source": "Inhalation",
      "target": "Lead",
      "label": "is a route of exposure for"
    },
    {
      "source": "Inhalation",
      "target": "Benzo[a]pyrene",
      "label": "is a route of exposure for"
    },
    {
      "source": "single, short-term exposure",
      "target": "markers of apoptosis",
      "label": "Upregulates"
    },
    {
      "source": "single, short-term exposure",
      "target": "Pb",
      "label": "involves"
    },
    {
      "source": "single, short-term exposure",
      "target": "BaP",
      "label": "involves"
    },
    {
      "source": "single, short-term exposure",
      "target": "markers of oxidative and nitrosative stress",
      "label": "Upregulates"
    },
    {
      "source": "markers of apoptosis",
      "target": "Oral mucosa cells",
      "label": "evaluated in"
    },
    {
      "source": "BaP",
      "target": "Pathological conditions",
      "label": "can lead to"
    },
    {
      "source": "BaP",
      "target": "8-epi-PGF2a",
      "label": "No effect on"
    },
    {
      "source": "BaP",
      "target": "Oral mucosa cells",
      "label": "affects"
    },
    {
      "source": "Ex vivo samples",
      "target": "Pb",
      "label": "exposed to"
    },
    {
      "source": "Ex vivo samples",
      "target": "BaP",
      "label": "exposed to"
    },
    {
      "source": "Ex vivo samples",
      "target": "Human oral mucosa",
      "label": "are from"
    },
    {
      "source": "Oral mucosa cells",
      "target": "Pb",
      "label": "incubated with"
    },
    {
      "source": "Oral mucosa cells",
      "target": "BaP",
      "label": "incubated with"
    },
    {
      "source": "Oral mucosa cells",
      "target": "ex vivo exposure",
      "label": "subjected to"
    },
    {
      "source": "markers of oxidative and nitrosative stress",
      "target": "Oral mucosa cells",
      "label": "evaluated in"
    },
    {
      "source": "Human oral mucosa",
      "target": "Lead",
      "label": "exposed to"
    },
    {
      "source": "Human oral mucosa",
      "target": "Benzo[a]pyrene",
      "label": "exposed to"
    },
    {
      "source": "Human oral mucosa",
      "target": "Pb",
      "label": "exposed to"
    },
    {
      "source": "Human oral mucosa",
      "target": "BaP",
      "label": "exposed to"
    },
    {
      "source": "Nitrosative stress",
      "target": "Oral mucosa cells",
      "label": "occurs in"
    },
    {
      "source": "Smokers' samples",
      "target": "markers of oxidative and nitrosative stress",
      "label": "Downregulates"
    },
    {
      "source": "Nonsmokers' samples",
      "target": "markers of oxidative and nitrosative stress",
      "label": "Associated with higher levels of"
    },
    {
      "source": "Fourth generation PPI dendrimers",
      "target": "(1)H NMR spectroscopies",
      "label": "characterized by"
    },
    {
      "source": "Fourth generation PPI dendrimers",
      "target": "size exclusion chromatography",
      "label": "confirmed by"
    },
    {
      "source": "Fourth generation PPI dendrimers",
      "target": "FT-IR",
      "label": "characterized by"
    },
    {
      "source": "Fourth generation PPI dendrimers",
      "target": "differential scanning calorimetry",
      "label": "confirmed by"
    },
    {
      "source": "Fourth generation PPI dendrimers",
      "target": "dendrimers",
      "label": "is a type of"
    },
    {
      "source": "pH dependent in vitro release",
      "target": "SMPPI",
      "label": "evaluated for"
    },
    {
      "source": "pH dependent in vitro release",
      "target": "PPI",
      "label": "evaluated for"
    },
    {
      "source": "pH dependent in vitro release",
      "target": "SPPI",
      "label": "evaluated for"
    },
    {
      "source": "pH dependent in vitro release",
      "target": "MPPI",
      "label": "evaluated for"
    },
    {
      "source": "SMPPI",
      "target": "dual targeted system",
      "label": "is a type of"
    },
    {
      "source": "SMPPI",
      "target": "(1)H NMR spectroscopies",
      "label": "characterized by"
    },
    {
      "source": "SMPPI",
      "target": "dual ligand dendritic system",
      "label": "is a type of"
    },
    {
      "source": "SMPPI",
      "target": "size exclusion chromatography",
      "label": "confirmed by"
    },
    {
      "source": "SMPPI",
      "target": "FT-IR",
      "label": "characterized by"
    },
    {
      "source": "SMPPI",
      "target": "sialic acid conjugated-mannosylated PPI dendrimers",
      "label": "is also known as"
    },
    {
      "source": "SMPPI",
      "target": "dendrimers",
      "label": "is a type of"
    },
    {
      "source": "SMPPI",
      "target": "drug concentration",
      "label": "increases"
    },
    {
      "source": "SMPPI",
      "target": "differential scanning calorimetry",
      "label": "confirmed by"
    },
    {
      "source": "SMPPI",
      "target": "cellular uptake",
      "label": "increases"
    },
    {
      "source": "SMPPI",
      "target": "dual ligand system",
      "label": "is a type of"
    },
    {
      "source": "dual targeted system",
      "target": "carbohydrate receptors",
      "label": "targets"
    },
    {
      "source": "dual targeted system",
      "target": "sialoadhesin",
      "label": "targets"
    },
    {
      "source": "carbohydrate receptors",
      "target": "ASGPR",
      "label": "include"
    },
    {
      "source": "hemolytic toxicity",
      "target": "SPPI",
      "label": "evaluated for"
    },
    {
      "source": "hemolytic toxicity",
      "target": "MPPI",
      "label": "evaluated for"
    },
    {
      "source": "hemolytic toxicity",
      "target": "SMPPI",
      "label": "evaluated for"
    },
    {
      "source": "hemolytic toxicity",
      "target": "PPI",
      "label": "evaluated for"
    },
    {
      "source": "SPPI",
      "target": "(1)H NMR spectroscopies",
      "label": "characterized by"
    },
    {
      "source": "SPPI",
      "target": "FT-IR",
      "label": "characterized by"
    },
    {
      "source": "SPPI",
      "target": "differential scanning calorimetry",
      "label": "confirmed by"
    },
    {
      "source": "SPPI",
      "target": "size exclusion chromatography",
      "label": "confirmed by"
    },
    {
      "source": "SPPI",
      "target": "dendrimers",
      "label": "is a type of"
    },
    {
      "source": "SPPI",
      "target": "sialic acid conjugated PPI dendrimers",
      "label": "is also known as"
    },
    {
      "source": "ZDV loaded MPPI",
      "target": "cytotoxicity",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded MPPI",
      "target": "in vitro drug release",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded MPPI",
      "target": "hemolytic toxicity",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded MPPI",
      "target": "ZDV",
      "label": "contains"
    },
    {
      "source": "ZDV loaded MPPI",
      "target": "MPPI",
      "label": "contains"
    },
    {
      "source": "ZDV loaded SPPI",
      "target": "in vitro drug release",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded SPPI",
      "target": "hemolytic toxicity",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded SPPI",
      "target": "SPPI",
      "label": "contains"
    },
    {
      "source": "ZDV loaded SPPI",
      "target": "ZDV",
      "label": "contains"
    },
    {
      "source": "ZDV loaded SPPI",
      "target": "cytotoxicity",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded SMPPI",
      "target": "cytotoxicity",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded SMPPI",
      "target": "in vitro drug release",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded SMPPI",
      "target": "ZDV",
      "label": "contains"
    },
    {
      "source": "ZDV loaded SMPPI",
      "target": "hemolytic toxicity",
      "label": "reduces"
    },
    {
      "source": "ZDV loaded SMPPI",
      "target": "SMPPI",
      "label": "contains"
    },
    {
      "source": "sialic acid conjugated PPI dendrimers",
      "target": "sialic acid",
      "label": "contains"
    },
    {
      "source": "ZDV",
      "target": "antiretroviral drug",
      "label": "is a type of"
    },
    {
      "source": "ZDV",
      "target": "anti-HIV drug",
      "label": "is a type of"
    },
    {
      "source": "PPI",
      "target": "dendrimers",
      "label": "is a type of"
    },
    {
      "source": "PPI",
      "target": "poly(propyleneimine) (PPI)",
      "label": "is also known as"
    },
    {
      "source": "dual ligand dendritic system",
      "target": "biocompatibility",
      "label": "enhances"
    },
    {
      "source": "dual ligand dendritic system",
      "target": "site specific delivery",
      "label": "enhances"
    },
    {
      "source": "sialic acid conjugated-mannosylated PPI dendrimers",
      "target": "sialic acid",
      "label": "contains"
    },
    {
      "source": "sialic acid conjugated-mannosylated PPI dendrimers",
      "target": "mannose",
      "label": "contains"
    },
    {
      "source": "MPPI",
      "target": "size exclusion chromatography",
      "label": "confirmed by"
    },
    {
      "source": "MPPI",
      "target": "dendrimers",
      "label": "is a type of"
    },
    {
      "source": "MPPI",
      "target": "mannose conjugated PPI dendrimers",
      "label": "is also known as"
    },
    {
      "source": "MPPI",
      "target": "(1)H NMR spectroscopies",
      "label": "characterized by"
    },
    {
      "source": "MPPI",
      "target": "differential scanning calorimetry",
      "label": "confirmed by"
    },
    {
      "source": "MPPI",
      "target": "FT-IR",
      "label": "characterized by"
    },
    {
      "source": "site specific delivery",
      "target": "antiretroviral drug",
      "label": "is of"
    },
    {
      "source": "macrophage uptake",
      "target": "PPI",
      "label": "evaluated for"
    },
    {
      "source": "macrophage uptake",
      "target": "SMPPI",
      "label": "evaluated for"
    },
    {
      "source": "macrophage uptake",
      "target": "SPPI",
      "label": "evaluated for"
    },
    {
      "source": "macrophage uptake",
      "target": "MPPI",
      "label": "evaluated for"
    },
    {
      "source": "drug concentration",
      "target": "6th hr",
      "label": "measured at"
    },
    {
      "source": "drug concentration",
      "target": "lymph nodes",
      "label": "is in"
    },
    {
      "source": "zidovudine",
      "target": "ZDV",
      "label": "is also known as"
    },
    {
      "source": "mannose conjugated PPI dendrimers",
      "target": "mannose",
      "label": "contains"
    },
    {
      "source": "in vivo blood level",
      "target": "albino rats",
      "label": "conducted in"
    },
    {
      "source": "tissue distribution studies",
      "target": "albino rats",
      "label": "conducted in"
    },
    {
      "source": "sialic acid conjugated-mannosylated poly(propyleneimine) (PPI) dendritic nano-constructs",
      "target": "dendritic nano-constructs",
      "label": "is a type of"
    },
    {
      "source": "CA-Xaa-NHOH",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "CA-Xaa-NHOH",
      "target": "antioxidant",
      "label": "acts as an"
    },
    {
      "source": "caffeoyl-amino acidyl-hydroxamic acid",
      "target": "antioxidant",
      "label": "acts as an"
    },
    {
      "source": "caffeoyl-amino acidyl-hydroxamic acid",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "caffeic acid",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "caffeic acid",
      "target": "proline",
      "label": "was conjugated with"
    },
    {
      "source": "caffeic acid",
      "target": "amino acids",
      "label": "was conjugated with"
    },
    {
      "source": "caffeic acid",
      "target": "melanin content",
      "label": "reduced"
    },
    {
      "source": "caffeic acid",
      "target": "lipid peroxidation",
      "label": "inhibited"
    },
    {
      "source": "prolyl hydroxamic acid",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "prolyl hydroxamic acid",
      "target": "antioxidant",
      "label": "is an"
    },
    {
      "source": "HCA-Phe-NHOH",
      "target": "antioxidant",
      "label": "is an"
    },
    {
      "source": "HCA-Phe-NHOH",
      "target": "antioxidant activity",
      "label": "exhibited enhanced"
    },
    {
      "source": "HCA-Phe-NHOH",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "ferulic acid",
      "target": "lipid peroxidation",
      "label": "inhibited"
    },
    {
      "source": "ferulic acid",
      "target": "bark",
      "label": "is from"
    },
    {
      "source": "sinapic acid",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "sinapic acid",
      "target": "melanin content",
      "label": "reduced"
    },
    {
      "source": "sinapic acid",
      "target": "lipid peroxidation",
      "label": "inhibited"
    },
    {
      "source": "hydroxycinnamic acid derivatives",
      "target": "phenylalanyl hydroxamic acid",
      "label": "were conjugated with"
    },
    {
      "source": "hydroxycinnamic acid derivatives",
      "target": "prolyl hydroxamic acid",
      "label": "were conjugated with"
    },
    {
      "source": "melanin content",
      "target": "melanocytes Mel-Ab cell",
      "label": "is found in"
    },
    {
      "source": "hydroxycinnamoyl phenylalanyl",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "hydroxycinnamoyl phenylalanyl",
      "target": "antioxidant",
      "label": "is an"
    },
    {
      "source": "HCA-Pro-NHOH",
      "target": "antioxidant activity",
      "label": "exhibited enhanced"
    },
    {
      "source": "HCA-Pro-NHOH",
      "target": "tyrosinase",
      "label": "Downregulator"
    },
    {
      "source": "HCA-Pro-NHOH",
      "target": "antioxidant",
      "label": "is an"
    },
    {
      "source": "Trolox",
      "target": "vitamin E",
      "label": "is an analogue of"
    },
    {
      "source": "phenylalanine",
      "target": "amino acids",
      "label": "is a"
    },
    {
      "source": "HCA",
      "target": "antioxidant activity",
      "label": "has"
    },
    {
      "source": "Methylation",
      "target": "lysine 4",
      "label": "occurs on"
    },
    {
      "source": "Methylation",
      "target": "histone H3",
      "label": "occurs on"
    },
    {
      "source": "Methylation",
      "target": "SET1 protein",
      "label": "catalyzed by"
    },
    {
      "source": "Methylation",
      "target": "clock gene expression",
      "label": "needed for"
    },
    {
      "source": "SET1",
      "target": "DNA methylation",
      "label": "required for"
    },
    {
      "source": "SET1",
      "target": "chromatin",
      "label": "modulates"
    },
    {
      "source": "SET1",
      "target": "frq regulation",
      "label": "needed for"
    },
    {
      "source": "SET1 protein",
      "target": "lysine methyltransferase",
      "label": "is a type of"
    },
    {
      "source": "frq expression",
      "target": "strains",
      "label": "altered in"
    },
    {
      "source": "frq expression",
      "target": "light-regulated gene expression",
      "label": "affected by"
    },
    {
      "source": "frq expression",
      "target": "circadian-regulated gene expression",
      "label": "affected by"
    },
    {
      "source": "strains",
      "target": "set1",
      "label": "lacks"
    },
    {
      "source": "H3K4 methylation",
      "target": "light-mediated frq regulation",
      "label": "has a role in"
    },
    {
      "source": "H3K4 methylation",
      "target": "clock-mediated frq regulation",
      "label": "has a role in"
    },
    {
      "source": "chromatin",
      "target": "frq",
      "label": "at"
    },
    {
      "source": "circadian oscillator",
      "target": "light",
      "label": "reset by"
    },
    {
      "source": "circadian oscillator",
      "target": "feedback loops",
      "label": "uses"
    },
    {
      "source": "circadian oscillator",
      "target": "time-of-day gene expression",
      "label": "controls"
    },
    {
      "source": "Neurospora CHD1",
      "target": "frq gene",
      "label": "required for regulation of"
    },
    {
      "source": "White Collar 2",
      "target": "frq promoter",
      "label": "associates with"
    },
    {
      "source": "White Collar 2",
      "target": "WC-2",
      "label": "is also known as"
    },
    {
      "source": "chromatin regulation",
      "target": "histone-modifying enzymes",
      "label": "necessitates regulation of"
    },
    {
      "source": "chromatin regulation",
      "target": "chromatin-remodeling enzymes",
      "label": "necessitates regulation of"
    },
    {
      "source": "chromatin regulation",
      "target": "eukaryotic transcription",
      "label": "is requisite for"
    },
    {
      "source": "histone-modifying enzymes",
      "target": "clock function",
      "label": "needed for"
    },
    {
      "source": "strain",
      "target": "SET1",
      "label": "lacks"
    },
    {
      "source": "frequency gene",
      "target": "frq",
      "label": "is also known as"
    },
    {
      "source": "WC-2",
      "target": "\u0394set1",
      "label": "shows prolonged association in"
    },
    {
      "source": "chromatin-remodeling enzymes",
      "target": "clock function",
      "label": "needed for"
    },
    {
      "source": "\u0394set1",
      "target": "chromatin state",
      "label": "suggests"
    },
    {
      "source": "CHD1",
      "target": "H3K4me3",
      "label": "binds"
    },
    {
      "source": "low-dose gentamicin",
      "target": "mild renal damage",
      "label": "causes"
    },
    {
      "source": "mild renal damage",
      "target": "renal damage",
      "label": "is a type of"
    },
    {
      "source": "mild renal damage",
      "target": "rats",
      "label": "magnified in"
    },
    {
      "source": "mild renal damage",
      "target": "histological level",
      "label": "evident at"
    },
    {
      "source": "mild renal damage",
      "target": "functional level",
      "label": "evident at"
    },
    {
      "source": "uranyl nitrate (UN)",
      "target": "drinking water",
      "label": "administered in"
    },
    {
      "source": "uranyl nitrate (UN)",
      "target": "mild renal damage",
      "label": "magnifies"
    },
    {
      "source": "uranyl nitrate (UN)",
      "target": "nitrate",
      "label": "contains"
    },
    {
      "source": "uranyl nitrate (UN)",
      "target": "experimental nephrotoxin",
      "label": "is an"
    },
    {
      "source": "uranyl nitrate (UN)",
      "target": "renal damage",
      "label": "causes"
    },
    {
      "source": "hemopexin",
      "target": "chronic predisposition",
      "label": "associated with"
    },
    {
      "source": "hemopexin",
      "target": "proteins",
      "label": "is a"
    },
    {
      "source": "hemopexin",
      "target": "urine",
      "label": "increased in"
    },
    {
      "source": "VDBP",
      "target": "vitamin D binding protein",
      "label": "is a synonym for"
    },
    {
      "source": "subnephrotoxic treatments",
      "target": "potentially nephrotoxic drugs",
      "label": "use"
    },
    {
      "source": "subnephrotoxic treatments",
      "target": "sensitization",
      "label": "cause"
    },
    {
      "source": "vitamin D binding protein",
      "target": "urine",
      "label": "increased in"
    },
    {
      "source": "vitamin D binding protein",
      "target": "chronic predisposition",
      "label": "associated with"
    },
    {
      "source": "vitamin D binding protein",
      "target": "proteins",
      "label": "is a"
    },
    {
      "source": "Drug nephrotoxicity",
      "target": "health problem",
      "label": "is a"
    },
    {
      "source": "Drug nephrotoxicity",
      "target": "economic problem",
      "label": "is an"
    },
    {
      "source": "gentamicin nephrotoxicity",
      "target": "VDBP",
      "label": "increases"
    },
    {
      "source": "gentamicin nephrotoxicity",
      "target": "Drug nephrotoxicity",
      "label": "is a type of"
    },
    {
      "source": "gentamicin nephrotoxicity",
      "target": "hemopexin",
      "label": "increases"
    },
    {
      "source": "gentamicin nephrotoxicity",
      "target": "transferrin",
      "label": "increases"
    },
    {
      "source": "gentamicin nephrotoxicity",
      "target": "albumin",
      "label": "increases"
    },
    {
      "source": "gentamicin nephrotoxicity",
      "target": "renal damage",
      "label": "is a type of"
    },
    {
      "source": "hidden, chronic predisposition to gentamicin nephrotoxicity",
      "target": "chronic predisposition",
      "label": "is a type of"
    },
    {
      "source": "hidden, chronic predisposition to gentamicin nephrotoxicity",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "acquired sensitization",
      "target": "sensitization",
      "label": "is a type of"
    },
    {
      "source": "sensitization",
      "target": "acute kidney injury (AKI)",
      "label": "is to"
    },
    {
      "source": "Acquired sensitization",
      "target": "silent risk",
      "label": "poses"
    },
    {
      "source": "treatments",
      "target": "disease",
      "label": "might trigger"
    },
    {
      "source": "treatments",
      "target": "crossover design",
      "label": "followed"
    },
    {
      "source": "treatments",
      "target": "antioxidant capacity",
      "label": "increased"
    },
    {
      "source": "albumin",
      "target": "chronic predisposition",
      "label": "associated with"
    },
    {
      "source": "albumin",
      "target": "proteins",
      "label": "is a"
    },
    {
      "source": "albumin",
      "target": "urine",
      "label": "increased in"
    },
    {
      "source": "technology",
      "target": "clinical level",
      "label": "available at"
    },
    {
      "source": "chronically acquired sensitization",
      "target": "acquired sensitization",
      "label": "is a type of"
    },
    {
      "source": "chronically acquired sensitization",
      "target": "specific urinary markers",
      "label": "detected through"
    },
    {
      "source": "chronically acquired sensitization",
      "target": "acute kidney injury (AKI)",
      "label": "is to"
    },
    {
      "source": "chronic, subnephrotoxic insult",
      "target": "kidneys",
      "label": "affects"
    },
    {
      "source": "chronic, subnephrotoxic insult",
      "target": "chronically acquired sensitization",
      "label": "results in"
    },
    {
      "source": "ICA-105574",
      "target": "ICA",
      "label": "is also known as"
    },
    {
      "source": "ICA-105574",
      "target": "opposite functional effects",
      "label": "elicits"
    },
    {
      "source": "ICA-105574",
      "target": "common binding site",
      "label": "interacts with"
    },
    {
      "source": "ICA",
      "target": "rate",
      "label": "enhances"
    },
    {
      "source": "ICA",
      "target": "3-nitro-N-[4-phenoxyphenyl]-benzamide",
      "label": "is also known as"
    },
    {
      "source": "ICA",
      "target": "ERG inactivation",
      "label": "attenuates"
    },
    {
      "source": "ICA",
      "target": "mixed agonist",
      "label": "is a"
    },
    {
      "source": "ICA",
      "target": "voltage dependence",
      "label": "does not alter"
    },
    {
      "source": "ICA",
      "target": "opposite functional effects",
      "label": "elicits"
    },
    {
      "source": "ICA",
      "target": "extent",
      "label": "enhances"
    },
    {
      "source": "ICA",
      "target": "channel-specific orientation",
      "label": "binds in"
    },
    {
      "source": "ICA",
      "target": "hydrophobic pocket",
      "label": "binds to"
    },
    {
      "source": "ICA",
      "target": "same site",
      "label": "binds to"
    },
    {
      "source": "inverse functional response",
      "target": "EAG channels",
      "label": "in"
    },
    {
      "source": "inverse functional response",
      "target": "intrinsic mechanisms of inactivation",
      "label": "related to"
    },
    {
      "source": "inverse functional response",
      "target": "ERG channels",
      "label": "in"
    },
    {
      "source": "inverse functional response",
      "target": "ICA binding site",
      "label": "related to"
    },
    {
      "source": "inverse functional response",
      "target": "ICA",
      "label": "to"
    },
    {
      "source": "S5/pore helix/S6",
      "target": "one subunit",
      "label": "is part of"
    },
    {
      "source": "mixed agonist",
      "target": "mutant EAG",
      "label": "of"
    },
    {
      "source": "mixed agonist",
      "target": "EAG/ERG chimera channels",
      "label": "of"
    },
    {
      "source": "mutant EAG",
      "target": "slow and fast mechanisms",
      "label": "inactivates by"
    },
    {
      "source": "functional response",
      "target": "ICA",
      "label": "to"
    },
    {
      "source": "ICA binding site",
      "target": "ERG",
      "label": "in"
    },
    {
      "source": "S6",
      "target": "adjacent subunit",
      "label": "is part of"
    },
    {
      "source": "specific amino acids",
      "target": "putative binding pocket",
      "label": "form"
    },
    {
      "source": "specific amino acids",
      "target": "three residues",
      "label": "except"
    },
    {
      "source": "specific amino acids",
      "target": "EAG",
      "label": "are conserved in"
    },
    {
      "source": "putative binding pocket",
      "target": "ICA",
      "label": "for"
    },
    {
      "source": "putative binding pocket",
      "target": "ERG",
      "label": "in"
    },
    {
      "source": "same site",
      "target": "ERG channels",
      "label": "in"
    },
    {
      "source": "same site",
      "target": "EAG channels",
      "label": "in"
    },
    {
      "source": "opposite functional effects",
      "target": "inactivation gating",
      "label": "on"
    },
    {
      "source": "opposite functional effects",
      "target": "inactivation",
      "label": "on"
    },
    {
      "source": "hydrophobic pocket",
      "target": "S5/pore helix/S6",
      "label": "bounded by"
    },
    {
      "source": "hydrophobic pocket",
      "target": "S6",
      "label": "bounded by"
    },
    {
      "source": "EAG K(+) channels",
      "target": "K(+) channels",
      "label": "is a type of"
    },
    {
      "source": "EAG K(+) channels",
      "target": "ether-a-go-go",
      "label": "is also known as"
    },
    {
      "source": "voltage dependence",
      "target": "positive potentials",
      "label": "to"
    },
    {
      "source": "voltage dependence",
      "target": "steady-state inactivation",
      "label": "is of"
    },
    {
      "source": "EAG potassium channels",
      "target": "potassium channels",
      "label": "is a type of"
    },
    {
      "source": "Rapid and voltage-dependent inactivation",
      "target": "ERG K(+) channels",
      "label": "occurs in"
    },
    {
      "source": "Rapid and voltage-dependent inactivation",
      "target": "outward currents",
      "label": "attenuates"
    },
    {
      "source": "ERG K(+) channels",
      "target": "K(+) channels",
      "label": "is a type of"
    },
    {
      "source": "ERG K(+) channels",
      "target": "ether-a-go-go-related gene",
      "label": "is also known as"
    },
    {
      "source": "inactivation gating",
      "target": "EAG potassium channels",
      "label": "of"
    },
    {
      "source": "inactivation gating",
      "target": "ERG potassium channels",
      "label": "of"
    },
    {
      "source": "resultant agonist or antagonist activity",
      "target": "channel-specific differences",
      "label": "determined by"
    },
    {
      "source": "channel-specific differences",
      "target": "mechanisms of inactivation gating",
      "label": "in"
    },
    {
      "source": "ERG potassium channels",
      "target": "potassium channels",
      "label": "is a type of"
    },
    {
      "source": "Mutations",
      "target": "functional response",
      "label": "did not alter"
    },
    {
      "source": "Mutations",
      "target": "EAG",
      "label": "introduced into"
    },
    {
      "source": "Mutations",
      "target": "ICA binding site",
      "label": "replicate"
    },
    {
      "source": "EAG/ERG chimera channels",
      "target": "slow and fast mechanisms",
      "label": "inactivates by"
    },
    {
      "source": "EAG inactivation",
      "target": "outward currents",
      "label": "reduces"
    },
    {
      "source": "LT4",
      "target": "breakfast",
      "label": "taken before"
    },
    {
      "source": "LT4",
      "target": "morning",
      "label": "taken in the"
    },
    {
      "source": "LT4",
      "target": "other medication",
      "label": "not taken with"
    },
    {
      "source": "University Hospitals",
      "target": "Universidade Federal do Cear\u00e1-UFC",
      "label": "include"
    },
    {
      "source": "University Hospitals",
      "target": "Unicamp",
      "label": "include"
    },
    {
      "source": "University Hospitals",
      "target": "Universidade Federal do Rio de Janeiro -UFRJ",
      "label": "include"
    },
    {
      "source": "University Hospitals",
      "target": "Universidade Federal do Paran\u00e1 - UFPR",
      "label": "include"
    },
    {
      "source": "2292 consecutive patients",
      "target": "inclusion criteria",
      "label": "met the"
    },
    {
      "source": "referral centers",
      "target": "University Hospitals",
      "label": "include"
    },
    {
      "source": "referral centers",
      "target": "Brazil",
      "label": "are in"
    },
    {
      "source": "levothyroxine (LT4) replacement treatment",
      "target": "patients",
      "label": "is for"
    },
    {
      "source": "LEVOTHYROXINE REPLACEMENT",
      "target": "Brazil",
      "label": "is in"
    },
    {
      "source": "LEVOTHYROXINE REPLACEMENT",
      "target": "PRIMARY HYPOTHYROIDISM PATIENTS",
      "label": "is for"
    },
    {
      "source": "questionnaire",
      "target": "information",
      "label": "inquired about"
    },
    {
      "source": "questionnaire",
      "target": "social-economic status",
      "label": "inquired about"
    },
    {
      "source": "questionnaire",
      "target": "clinicians' orientations",
      "label": "inquired about"
    },
    {
      "source": "questionnaire",
      "target": "clinical and biochemical conditions",
      "label": "inquired about"
    },
    {
      "source": "questionnaire",
      "target": "life quality",
      "label": "inquired about"
    },
    {
      "source": "Clinicians",
      "target": "patients",
      "label": "should monitor"
    },
    {
      "source": "Clinicians",
      "target": "recommendations",
      "label": "should give"
    },
    {
      "source": "Serum TSH",
      "target": "interview",
      "label": "checked close to"
    },
    {
      "source": "clinicians' orientations",
      "target": "patients",
      "label": "regarding"
    },
    {
      "source": "TSH values",
      "target": "reference range",
      "label": "were within"
    },
    {
      "source": "abnormal serum TSH",
      "target": "undertreated patients",
      "label": "includes"
    },
    {
      "source": "abnormal serum TSH",
      "target": "over treated patients",
      "label": "includes"
    },
    {
      "source": "TSH",
      "target": "normal range",
      "label": "is in"
    },
    {
      "source": "TAM",
      "target": "EMT",
      "label": "induces"
    },
    {
      "source": "TAM",
      "target": "hormone-responsive breast cancer",
      "label": "used for treatment of"
    },
    {
      "source": "TAM",
      "target": "miR-200 family",
      "label": "represses"
    },
    {
      "source": "TAM",
      "target": "endometrial cancer",
      "label": "induces"
    },
    {
      "source": "TAM",
      "target": "estrogen-like effect",
      "label": "has"
    },
    {
      "source": "TAM",
      "target": "selective estrogen receptor modulator",
      "label": "is a"
    },
    {
      "source": "Tamoxifen",
      "target": "epithelial-to-mesenchymal transition",
      "label": "promotes"
    },
    {
      "source": "Tamoxifen",
      "target": "c-Myc",
      "label": "up-regulates"
    },
    {
      "source": "Tamoxifen",
      "target": "selective estrogen receptor modulator",
      "label": "is a"
    },
    {
      "source": "Tamoxifen",
      "target": "miR-200 microRNAs",
      "label": "represses"
    },
    {
      "source": "Tamoxifen",
      "target": "hormone-responsive breast cancer",
      "label": "used for treatment of"
    },
    {
      "source": "Tamoxifen",
      "target": "estrogen-like effect",
      "label": "has"
    },
    {
      "source": "c-Myc",
      "target": "promoter of miR-200 miRNAs",
      "label": "represses"
    },
    {
      "source": "TAM-treated cells",
      "target": "Snail",
      "label": "show increased"
    },
    {
      "source": "TAM-treated cells",
      "target": "N-cadherin",
      "label": "show increased"
    },
    {
      "source": "TAM-treated cells",
      "target": "up-regulation",
      "label": "show"
    },
    {
      "source": "TAM-treated cells",
      "target": "E-cadherin",
      "label": "show decreased"
    },
    {
      "source": "Snail",
      "target": "key factors of EMT",
      "label": "is a"
    },
    {
      "source": "Snail",
      "target": "TAM-induced EMT",
      "label": "contributes to"
    },
    {
      "source": "microRNAs",
      "target": "TAM-induced EMT",
      "label": "involved in"
    },
    {
      "source": "miR-200 family",
      "target": "tumor suppressive functions",
      "label": "has"
    },
    {
      "source": "tumor suppressive functions",
      "target": "cancers",
      "label": "found in"
    },
    {
      "source": "N-cadherin",
      "target": "TAM-induced EMT",
      "label": "contributes to"
    },
    {
      "source": "N-cadherin",
      "target": "key factors of EMT",
      "label": "is a"
    },
    {
      "source": "TAM treatment",
      "target": "motility",
      "label": "leads to"
    },
    {
      "source": "TAM treatment",
      "target": "miR-200",
      "label": "reduces"
    },
    {
      "source": "TAM treatment",
      "target": "invasiveness",
      "label": "leads to"
    },
    {
      "source": "TAM treatment",
      "target": "EMT",
      "label": "leads to"
    },
    {
      "source": "miR-200",
      "target": "miRNA family",
      "label": "is a"
    },
    {
      "source": "miR-200",
      "target": "TAM-induced EMT",
      "label": "involved in"
    },
    {
      "source": "miR-200",
      "target": "c-Myc",
      "label": "regulates"
    },
    {
      "source": "estrogen-like effect",
      "target": "endometrial cancer",
      "label": "increases risk of"
    },
    {
      "source": "mechanism of TAM-induced EMT",
      "target": "therapeutic strategy",
      "label": "is a"
    },
    {
      "source": "ECC-1 cells",
      "target": "EMT",
      "label": "undergoes"
    },
    {
      "source": "down-regulation of miR-200",
      "target": "EMT",
      "label": "leads to"
    },
    {
      "source": "miRNAs",
      "target": "TAM-induced EMT",
      "label": "involved in"
    },
    {
      "source": "E-cadherin",
      "target": "TAM-induced EMT",
      "label": "contributes to"
    },
    {
      "source": "miR-200b",
      "target": "zinc finger E-box binding homeobox 2",
      "label": "targets"
    },
    {
      "source": "zinc finger E-box binding homeobox 2",
      "target": "miR-200b",
      "label": "is a target of"
    },
    {
      "source": "Ishikawa cells",
      "target": "EMT",
      "label": "undergoes"
    },
    {
      "source": "TAA",
      "target": "ED2(+) liver cells",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "CD3(+) lymphocytes",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "heme oxygenase-1(+) liver cells",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "GST-P(+) liver cell foci",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "apoptotic cells",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "proliferating cells",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "cyclooxygenase-2(+) liver cells",
      "label": "increases"
    },
    {
      "source": "TAA",
      "target": "rats",
      "label": "promotes"
    },
    {
      "source": "TAA",
      "target": "LPO",
      "label": "Upregulator"
    },
    {
      "source": "TAA",
      "target": "AST",
      "label": "Upregulator"
    },
    {
      "source": "TAA",
      "target": "toxicants",
      "label": "IS_A"
    },
    {
      "source": "TAA",
      "target": "GSH",
      "label": "Downregulator"
    },
    {
      "source": "TAA",
      "target": "hepatotoxic agents",
      "label": "IS_A"
    },
    {
      "source": "TAA",
      "target": "toxicant groups",
      "label": "IS_IN"
    },
    {
      "source": "TAA",
      "target": "GPx",
      "label": "Downregulator"
    },
    {
      "source": "TAA",
      "target": "CAT",
      "label": "Downregulator"
    },
    {
      "source": "TAA",
      "target": "Bilirubin",
      "label": "Upregulator"
    },
    {
      "source": "TAA",
      "target": "ALP",
      "label": "Upregulator"
    },
    {
      "source": "TAA",
      "target": "ALT",
      "label": "Upregulator"
    },
    {
      "source": "EMIQ",
      "target": "heme oxygenase-1(+) liver cells",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "thiobarbituric acid-reactive substance",
      "label": "increases liver levels of"
    },
    {
      "source": "EMIQ",
      "target": "activation",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "regeneration",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "GST-P(+) liver cell foci",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "TAA-induced tumor promotion",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "DR5(+) cells",
      "label": "decreases"
    },
    {
      "source": "EMIQ",
      "target": "preneoplastic cell apoptosis",
      "label": "modifies"
    },
    {
      "source": "EMIQ",
      "target": "hepatocarcinogenic process",
      "label": "protects against"
    },
    {
      "source": "EMIQ",
      "target": "apoptotic cells",
      "label": "decreases"
    },
    {
      "source": "EMIQ",
      "target": "proliferating cells",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "cyclooxygenase-2(+) liver cells",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "tumor promotion",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "8-hydroxydeoxyguanosine",
      "label": "increases liver levels of"
    },
    {
      "source": "EMIQ",
      "target": "TUNEL(+) apoptotic cells",
      "label": "increases"
    },
    {
      "source": "EMIQ",
      "target": "apoptosis",
      "label": "facilitates"
    },
    {
      "source": "EMIQ",
      "target": "4-hydroxy-2-nonenal(+) cells",
      "label": "increases"
    },
    {
      "source": "EMIQ",
      "target": "CD3(+) lymphocytes",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "ED2(+) liver cells",
      "label": "suppresses"
    },
    {
      "source": "EMIQ",
      "target": "DR5",
      "label": "causes upregulation of"
    },
    {
      "source": "EMIQ",
      "target": "liver tissue environment",
      "label": "modifies"
    },
    {
      "source": "N-diethylnitrosamine",
      "target": "rats",
      "label": "initiates"
    },
    {
      "source": "hepatic macrophages",
      "target": "proinflammatory factors",
      "label": "produces"
    },
    {
      "source": "liver tissue environment",
      "target": "lymphocytes",
      "label": "includes"
    },
    {
      "source": "liver tissue environment",
      "target": "hepatic macrophages",
      "label": "includes"
    },
    {
      "source": "TAA-induced tumor promotion",
      "target": "activation",
      "label": "involves"
    },
    {
      "source": "preneoplastic cell apoptosis",
      "target": "hepatocellular tumor promotion",
      "label": "is part of"
    },
    {
      "source": "thioacetamide",
      "target": "preneoplastic liver cell lesions",
      "label": "induces"
    },
    {
      "source": "thioacetamide",
      "target": "TAA",
      "label": "IS_A"
    },
    {
      "source": "two-stage hepatocarcinogenesis model",
      "target": "rats",
      "label": "uses"
    },
    {
      "source": "anxiogenic effects",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "anxiogenic effects",
      "target": "5-HT1a receptor antagonist",
      "label": "blocked by"
    },
    {
      "source": "anxiogenic effects",
      "target": "behavioral tests",
      "label": "observed in"
    },
    {
      "source": "PNU-120596",
      "target": "memory impairment",
      "label": "reversed"
    },
    {
      "source": "PNU-120596",
      "target": "Sprague Dawley rats",
      "label": "tested on"
    },
    {
      "source": "PNU-120596",
      "target": "cognitive impairment",
      "label": "reversed"
    },
    {
      "source": "PNU-120596",
      "target": "behavioral tests",
      "label": "tested in"
    },
    {
      "source": "PNU-120596",
      "target": "anxiety",
      "label": "effects on"
    },
    {
      "source": "PNU-120596",
      "target": "positive allosteric modulators (PAMs)",
      "label": "is a type of"
    },
    {
      "source": "PNU-120596",
      "target": "memory",
      "label": "effects on"
    },
    {
      "source": "PNU-120596",
      "target": "learning",
      "label": "effects on"
    },
    {
      "source": "PNU-120596",
      "target": "spatial-learning",
      "label": "did not improve"
    },
    {
      "source": "PNU-120596",
      "target": "episodic memory",
      "label": "did not improve"
    },
    {
      "source": "memory impairment",
      "target": "cognitive impairment",
      "label": "is a type of"
    },
    {
      "source": "anxiety-like behavior",
      "target": "serotonin 5-HT1a receptor antagonist",
      "label": "reduced by"
    },
    {
      "source": "anxiety-like behavior",
      "target": "PNU-282987",
      "label": "seen with"
    },
    {
      "source": "methyllycaconitine",
      "target": "anxiety-like behavior",
      "label": "unable to reverse"
    },
    {
      "source": "methyllycaconitine",
      "target": "\u03b17 receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "methyllycaconitine",
      "target": "donepezil",
      "label": "suppressed effects of"
    },
    {
      "source": "methyllycaconitine",
      "target": "biochemical parameters",
      "label": "affects"
    },
    {
      "source": "methyllycaconitine",
      "target": "memory extinction",
      "label": "affects"
    },
    {
      "source": "PNU-282987",
      "target": "learning",
      "label": "effects on"
    },
    {
      "source": "PNU-282987",
      "target": "spatial-learning",
      "label": "did not improve"
    },
    {
      "source": "PNU-282987",
      "target": "episodic memory",
      "label": "did not improve"
    },
    {
      "source": "PNU-282987",
      "target": "anxiety-like behavior",
      "label": "increased"
    },
    {
      "source": "PNU-282987",
      "target": "Sprague Dawley rats",
      "label": "tested on"
    },
    {
      "source": "PNU-282987",
      "target": "\u03b17-selective agonist",
      "label": "is a type of"
    },
    {
      "source": "PNU-282987",
      "target": "behavioral tests",
      "label": "tested in"
    },
    {
      "source": "PNU-282987",
      "target": "anxiety",
      "label": "effects on"
    },
    {
      "source": "PNU-282987",
      "target": "memory",
      "label": "effects on"
    },
    {
      "source": "PNU-282987",
      "target": "memory impairment",
      "label": "reversed"
    },
    {
      "source": "positive allosteric modulators (PAMs)",
      "target": "therapeutic drugs",
      "label": "considered for development as"
    },
    {
      "source": "positive allosteric modulators (PAMs)",
      "target": "\u03b17 subtype of nAChRs",
      "label": "are of"
    },
    {
      "source": "positive allosteric modulators (PAMs)",
      "target": "Agonists",
      "label": "are advantageous over"
    },
    {
      "source": "positive allosteric modulators (PAMs)",
      "target": "cognition",
      "label": "improve"
    },
    {
      "source": "therapeutic drugs",
      "target": "\u03b17 receptors",
      "label": "target"
    },
    {
      "source": "cognitive impairment",
      "target": "rats",
      "label": "induced in"
    },
    {
      "source": "Agonists",
      "target": "cognition",
      "label": "improve"
    },
    {
      "source": "Agonists",
      "target": "\u03b17 subtype of nAChRs",
      "label": "are of"
    },
    {
      "source": "\u03b17 nicotinic acetylcholine receptor",
      "target": "anxiety",
      "label": "is associated with"
    },
    {
      "source": "\u03b17 nicotinic acetylcholine receptor",
      "target": "brain",
      "label": "is expressed in"
    },
    {
      "source": "\u03b17 nicotinic acetylcholine receptor",
      "target": "cognitive function",
      "label": "is associated with"
    },
    {
      "source": "WAY-100135",
      "target": "serotonin 5-HT1a receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "\u03b17 nicotinic ACh receptor",
      "target": "anxiogenic effects",
      "label": "induces"
    },
    {
      "source": "scopolamine",
      "target": "cognitive impairment",
      "label": "induced"
    },
    {
      "source": "microcosamine A (4)",
      "target": "cytotoxic fractions",
      "label": "isolated from"
    },
    {
      "source": "Alkaloids",
      "target": "Microcos paniculata",
      "label": "from"
    },
    {
      "source": "Microcos paniculata",
      "target": "small tree",
      "label": "is a"
    },
    {
      "source": "Microcos paniculata",
      "target": "South Asia",
      "label": "grows in"
    },
    {
      "source": "Microcos paniculata",
      "target": "Southeast Asia",
      "label": "grows in"
    },
    {
      "source": "Microcos paniculata",
      "target": "large shrub",
      "label": "is a"
    },
    {
      "source": "cytotoxic fractions",
      "target": "chloroform-soluble extracts",
      "label": "are from"
    },
    {
      "source": "chloroform-soluble extracts",
      "target": "leaves",
      "label": "are from"
    },
    {
      "source": "chloroform-soluble extracts",
      "target": "stem bark",
      "label": "are from"
    },
    {
      "source": "chloroform-soluble extracts",
      "target": "branches",
      "label": "are from"
    },
    {
      "source": "selective cytotoxic agent",
      "target": "colon cancer cells",
      "label": "for"
    },
    {
      "source": "selective cytotoxic agent",
      "target": "normal colon cells",
      "label": "over"
    },
    {
      "source": "human \u03b13\u03b24 or \u03b14\u03b22 nicotinic acetylcholine receptors",
      "target": "nAChRs",
      "label": "are also known as"
    },
    {
      "source": "leaves",
      "target": "M. paniculata",
      "label": "of"
    },
    {
      "source": "liriodenine (6)",
      "target": "cytotoxic fractions",
      "label": "isolated from"
    },
    {
      "source": "stem bark",
      "target": "M. paniculata",
      "label": "of"
    },
    {
      "source": "piperidine alkaloids",
      "target": "microgrewiapines A-C (1-3)",
      "label": "include"
    },
    {
      "source": "microgrewiapines A-C (1-3)",
      "target": "cytotoxic fractions",
      "label": "isolated from"
    },
    {
      "source": "branches",
      "target": "M. paniculata",
      "label": "of"
    },
    {
      "source": "7'-(3',4'-dihydroxyphenyl)-N-[4-methoxyphenyl)ethyl]propenamide (5)",
      "target": "cytotoxic fractions",
      "label": "isolated from"
    },
    {
      "source": "microgrewiapine A (1)",
      "target": "h\u03b13\u03b24 and h\u03b14\u03b22 receptor subtypes",
      "label": "exhibits antagonistic activity for"
    },
    {
      "source": "microgrewiapine A (1)",
      "target": "selective cytotoxic agent",
      "label": "is a"
    },
    {
      "source": "Compounds 1-6",
      "target": "HT-29 human colon cancer cell line",
      "label": "showed cytotoxicity against"
    },
    {
      "source": "1a (microgrewiapine A 3-acetate)",
      "target": "HT-29 human colon cancer cell line",
      "label": "showed cytotoxicity against"
    },
    {
      "source": "Enzymes",
      "target": "Synthesis",
      "label": "involved in"
    },
    {
      "source": "Enzymes",
      "target": "Export",
      "label": "involved in"
    },
    {
      "source": "Human fibroblasts",
      "target": "CPT2",
      "label": "deficient in"
    },
    {
      "source": "Human fibroblasts",
      "target": "CACT",
      "label": "deficient in"
    },
    {
      "source": "Human fibroblasts",
      "target": "OCTN2",
      "label": "deficient in"
    },
    {
      "source": "Human fibroblasts",
      "target": "Plasmalemmal carnitine transporter",
      "label": "deficient in"
    },
    {
      "source": "Human fibroblasts",
      "target": "Carnitine palmitoyltransferase 2",
      "label": "deficient in"
    },
    {
      "source": "Human fibroblasts",
      "target": "Carnitine/acylcarnitine translocase",
      "label": "deficient in"
    },
    {
      "source": "CPT2",
      "target": "Mitochondrial acylcarnitine formation",
      "label": "crucial for"
    },
    {
      "source": "CPT2",
      "target": "Export",
      "label": "crucial for"
    },
    {
      "source": "CACT",
      "target": "Export",
      "label": "crucial for"
    },
    {
      "source": "CACT",
      "target": "Mitochondrial acylcarnitine formation",
      "label": "crucial for"
    },
    {
      "source": "Export",
      "target": "OCTN2",
      "label": "does not depend on"
    },
    {
      "source": "Export",
      "target": "Extracellular fluids",
      "label": "to"
    },
    {
      "source": "Carnitine/acylcarnitine translocase",
      "target": "Export",
      "label": "involved in"
    },
    {
      "source": "Carnitine/acylcarnitine translocase",
      "target": "Mitochondrial acylcarnitine formation",
      "label": "involved in"
    },
    {
      "source": "Carnitine/acylcarnitine translocase",
      "target": "Acylcarnitines",
      "label": "involved in synthesis of"
    },
    {
      "source": "Cell lines",
      "target": "Carnitine",
      "label": "loaded with"
    },
    {
      "source": "Cell lines",
      "target": "Accumulation",
      "label": "showed"
    },
    {
      "source": "Cell lines",
      "target": "Decanoic acid",
      "label": "loaded with"
    },
    {
      "source": "Carnitine palmitoyltransferase 2",
      "target": "Acylcarnitines",
      "label": "involved in export of"
    },
    {
      "source": "Carnitine palmitoyltransferase 2",
      "target": "Export",
      "label": "involved in"
    },
    {
      "source": "Carnitine palmitoyltransferase 2",
      "target": "Mitochondrial acylcarnitine formation",
      "label": "involved in"
    },
    {
      "source": "Acylcarnitines",
      "target": "OCTN2",
      "label": "export does not depend on"
    },
    {
      "source": "Acylcarnitines",
      "target": "mFAODs",
      "label": "used in diagnosis of"
    },
    {
      "source": "Acylcarnitines",
      "target": "Mitochondrial fatty acid \u03b2-oxidation disorders",
      "label": "used in diagnosis of"
    },
    {
      "source": "Mock-transduced controls",
      "target": "Carnitine",
      "label": "loaded with"
    },
    {
      "source": "Mock-transduced controls",
      "target": "Decanoic acid",
      "label": "loaded with"
    },
    {
      "source": "Plasma",
      "target": "Accumulation",
      "label": "reflects"
    },
    {
      "source": "Accumulation",
      "target": "Octanoylcarnitine",
      "label": "is of"
    },
    {
      "source": "Accumulation",
      "target": "Acyl-CoAs",
      "label": "is of"
    },
    {
      "source": "Acylcarnitine",
      "target": "Extracellular medium",
      "label": "measured in"
    },
    {
      "source": "Pharmacological inhibition",
      "target": "CPT2",
      "label": "of"
    },
    {
      "source": "Lentiviral shRNA",
      "target": "Medium-chain acyl-CoA dehydrogenase",
      "label": "used to knock down"
    },
    {
      "source": "Lentiviral shRNA",
      "target": "MCAD",
      "label": "used to knock down"
    },
    {
      "source": "MCAD-deficient individuals",
      "target": "Human fibroblasts",
      "label": "have"
    },
    {
      "source": "MCAD knockdown",
      "target": "Octanoylcarnitine",
      "label": "increased production of"
    },
    {
      "source": "ventral SN",
      "target": "dopaminergic neurotoxins",
      "label": "is susceptible to"
    },
    {
      "source": "ventral SN",
      "target": "region",
      "label": "is a type of"
    },
    {
      "source": "ventral SN",
      "target": "MPTP",
      "label": "is susceptible to"
    },
    {
      "source": "resistance to injury",
      "target": "PD",
      "label": "is observed in"
    },
    {
      "source": "resistance to injury",
      "target": "animal models",
      "label": "is observed in"
    },
    {
      "source": "surviving mDA neurons",
      "target": "substantia nigra (SN)",
      "label": "are located in"
    },
    {
      "source": "surviving mDA neurons",
      "target": "calbindin-D28k",
      "label": "express"
    },
    {
      "source": "calbindin-D28k",
      "target": "calcium-binding protein",
      "label": "is a type of"
    },
    {
      "source": "calcium-binding protein",
      "target": "resistance to injury",
      "label": "is associated with"
    },
    {
      "source": "distinct subpopulations",
      "target": "calbindin-negative Pitx-3-dependent cells",
      "label": "include"
    },
    {
      "source": "distinct subpopulations",
      "target": "MPTP-resistant Pitx3-autonomous, calbindin-positive neurons",
      "label": "include"
    },
    {
      "source": "calbindin-negative Pitx-3-dependent cells",
      "target": "vulnerability",
      "label": "display"
    },
    {
      "source": "calbindin-negative Pitx-3-dependent cells",
      "target": "subpopulation",
      "label": "correspond to"
    },
    {
      "source": "Pitx3",
      "target": "ventral SN",
      "label": "is primarily expressed in"
    },
    {
      "source": "Pitx3",
      "target": "mDA neurons",
      "label": "is not indiscriminately required by"
    },
    {
      "source": "Cell-mapping studies",
      "target": "Pitx3",
      "label": "revealed expression of"
    },
    {
      "source": "The transcription factor Pitx3",
      "target": "midbrain dopaminergic neurons",
      "label": "is expressed selectively in"
    },
    {
      "source": "midbrain dopaminergic neurons",
      "target": "neurodegenerative stress",
      "label": "are susceptible to"
    },
    {
      "source": "selective pattern",
      "target": "mDA cell loss",
      "label": "is of"
    },
    {
      "source": "vulnerability",
      "target": "mDA neurons",
      "label": "is of"
    },
    {
      "source": "vulnerability",
      "target": "toxic injury",
      "label": "is to"
    },
    {
      "source": "SN mDA neurons",
      "target": "MPTP",
      "label": "show increased sensitivity to"
    },
    {
      "source": "SN mDA neurons",
      "target": "distinct subpopulations",
      "label": "are represented by"
    },
    {
      "source": "SN mDA neurons",
      "target": "Pitx3 hemizygous mice",
      "label": "are found in"
    },
    {
      "source": "Pitx3-deficient mice",
      "target": "developmental loss",
      "label": "exhibit"
    },
    {
      "source": "Pitx3-deficient mice",
      "target": "locomotor deficits",
      "label": "exhibit"
    },
    {
      "source": "developmental loss",
      "target": "mDA neurons",
      "label": "is of"
    },
    {
      "source": "ImpaiRment",
      "target": "vulnerability",
      "label": "increases"
    },
    {
      "source": "ImpaiRment",
      "target": "Pitx3-dependent pathways",
      "label": "is of"
    },
    {
      "source": "locomotor deficits",
      "target": "Parkinson's disease (PD) models",
      "label": "resemble"
    },
    {
      "source": "Pitx3-expressing SN cells",
      "target": "MPTP treatment",
      "label": "are lost following"
    },
    {
      "source": "mDA cell loss",
      "target": "PD",
      "label": "is observed in"
    },
    {
      "source": "The homeodomain transcription factor Pitx3",
      "target": "midbrain dopaminergic (mDA) neurons",
      "label": "is critical for the survival of"
    },
    {
      "source": "mDA cell subpopulations",
      "target": "adult Pitx3-hypomorphic (aphakia) mice",
      "label": "are spared in"
    },
    {
      "source": "curative therapy",
      "target": "myelofibrosis",
      "label": "for"
    },
    {
      "source": "myelofibrosis",
      "target": "older population",
      "label": "manifests in"
    },
    {
      "source": "myelofibrosis",
      "target": "life-threatening complications",
      "label": "can lead to"
    },
    {
      "source": "myelofibrosis",
      "target": "molecularly targeted therapy",
      "label": "is a potential candidate for"
    },
    {
      "source": "myelofibrosis",
      "target": "orphan disease state",
      "label": "is an"
    },
    {
      "source": "myelofibrosis",
      "target": "myeloproliferative neoplasm",
      "label": "is a"
    },
    {
      "source": "myelofibrosis",
      "target": "unmet medical need",
      "label": "is an"
    },
    {
      "source": "novel approaches",
      "target": "outcomes",
      "label": "to improve"
    },
    {
      "source": "JAK-signal transducer and activator of transcription pathway",
      "target": "hematopoiesis",
      "label": "results in"
    },
    {
      "source": "JAK-signal transducer and activator of transcription pathway",
      "target": "dysregulated cellular proliferation",
      "label": "results in"
    },
    {
      "source": "life-threatening complications",
      "target": "thrombotic events",
      "label": "includes"
    },
    {
      "source": "life-threatening complications",
      "target": "hemorrhagic episodes",
      "label": "includes"
    },
    {
      "source": "life-threatening complications",
      "target": "transformation to leukemia",
      "label": "includes"
    },
    {
      "source": "current treatment strategies",
      "target": "specific symptomology",
      "label": "focused on targeting"
    },
    {
      "source": "current treatment strategies",
      "target": "efficacy",
      "label": "have limited"
    },
    {
      "source": "orphan disease state",
      "target": "unmet medical need",
      "label": "is an"
    },
    {
      "source": "Ruxolitinib",
      "target": "myelofibrosis",
      "label": "is a new treatment option for"
    },
    {
      "source": "Ruxolitinib",
      "target": "small-molecule inhibitor",
      "label": "is a"
    },
    {
      "source": "Ruxolitinib",
      "target": "JAK1",
      "label": "is a small-molecule inhibitor of"
    },
    {
      "source": "Ruxolitinib",
      "target": "first drug",
      "label": "became the"
    },
    {
      "source": "Ruxolitinib",
      "target": "JAK2",
      "label": "is a small-molecule inhibitor of"
    },
    {
      "source": "combination with other treatments",
      "target": "outcomes",
      "label": "will further enhance"
    },
    {
      "source": "prevalent mutation",
      "target": "gain-of-function mutation",
      "label": "is a type of"
    },
    {
      "source": "prevalent mutation",
      "target": "JAK2 V617F",
      "label": "is"
    },
    {
      "source": "gain-of-function mutation",
      "target": "Janus kinase (JAK) family",
      "label": "in the"
    },
    {
      "source": "Adverse events",
      "target": "hematologic",
      "label": "are primarily"
    },
    {
      "source": "JAK2 V617F",
      "target": "JAK-signal transducer and activator of transcription pathway",
      "label": "results in a constitutively active"
    },
    {
      "source": "JAK2 V617F",
      "target": "patients",
      "label": "identified in"
    },
    {
      "source": "medical therapies",
      "target": "disease progression",
      "label": "do not halt"
    },
    {
      "source": "first drug",
      "target": "United States Food and Drug Administration",
      "label": "approved by the"
    },
    {
      "source": "first drug",
      "target": "symptomatic intermediate- or high-risk myelofibrosis",
      "label": "for the treatment of"
    },
    {
      "source": "molecular mutations",
      "target": "patients",
      "label": "in"
    },
    {
      "source": "allogeneic hematopoietic stem cell transplantation",
      "target": "curative therapy",
      "label": "is a"
    },
    {
      "source": "myeloproliferative neoplasm",
      "target": "bone marrow fibrosis",
      "label": "characterized by"
    },
    {
      "source": "myeloproliferative neoplasm",
      "target": "extramedullary hematopoiesis",
      "label": "characterized by"
    },
    {
      "source": "treatment options",
      "target": "patients",
      "label": "for"
    },
    {
      "source": "Emerging research",
      "target": "molecular mutations",
      "label": "identified"
    },
    {
      "source": "induced behaviors",
      "target": "rodents",
      "label": "observed_in"
    },
    {
      "source": "induced behaviors",
      "target": "cocaine",
      "label": "caused_by"
    },
    {
      "source": "induced behaviors",
      "target": "methamphetamine",
      "label": "caused_by"
    },
    {
      "source": "prosocial effects",
      "target": "humans",
      "label": "observed_in"
    },
    {
      "source": "prosocial effects",
      "target": "MDMA",
      "label": "caused_by"
    },
    {
      "source": "prosocial effects",
      "target": "Ecstasy",
      "label": "caused_by"
    },
    {
      "source": "prosocial effects",
      "target": "3,4-methylenedioxymethamphetamine",
      "label": "caused_by"
    },
    {
      "source": "prosocial effects",
      "target": "rodents",
      "label": "observed_in"
    },
    {
      "source": "modulatory role",
      "target": "oxytocin",
      "label": "of"
    },
    {
      "source": "modulatory role",
      "target": "psychostimulant effects",
      "label": "concerns"
    },
    {
      "source": "modulatory role",
      "target": "prosocial effects",
      "label": "in"
    },
    {
      "source": "modulatory role",
      "target": "therapeutic properties",
      "label": "in"
    },
    {
      "source": "neuronal processes",
      "target": "rodents",
      "label": "observed_in"
    },
    {
      "source": "psychological phenomena",
      "target": "reward processes",
      "label": "includes"
    },
    {
      "source": "psychological phenomena",
      "target": "memory processes",
      "label": "includes"
    },
    {
      "source": "psychiatric disorders",
      "target": "autism",
      "label": "includes"
    },
    {
      "source": "psychiatric disorders",
      "target": "addiction",
      "label": "includes"
    },
    {
      "source": "psychiatric disorders",
      "target": "schizophrenia",
      "label": "includes"
    },
    {
      "source": "psychiatric disorders",
      "target": "anxiety",
      "label": "includes"
    },
    {
      "source": "novel intervention",
      "target": "psychostimulant addiction",
      "label": "for"
    },
    {
      "source": "Clinical trials",
      "target": "modulatory role",
      "label": "determine"
    },
    {
      "source": "Clinical trials",
      "target": "effectiveness",
      "label": "investigate"
    },
    {
      "source": "Clinical trials",
      "target": "Gabapentin",
      "label": "use"
    },
    {
      "source": "Clinical trials",
      "target": "Ginger",
      "label": "use"
    },
    {
      "source": "Clinical trials",
      "target": "Cannabinoids",
      "label": "use"
    },
    {
      "source": "field of research",
      "target": "pharmacological limitations",
      "label": "has"
    },
    {
      "source": "H-bonds",
      "target": "Hyp\u00b7Hyp base pair",
      "label": "are in"
    },
    {
      "source": "H-bonds",
      "target": "Hyp\u00b7Thy* base pair",
      "label": "are in"
    },
    {
      "source": "H-bonds",
      "target": "Hyp*\u00b7Cyt* base pair",
      "label": "are in"
    },
    {
      "source": "H-bonds",
      "target": "Hyp*\u00b7Hyp* base pair",
      "label": "are in"
    },
    {
      "source": "six key points",
      "target": "Hyp\u00b7Hyp\u2194Hyp*\u00b7Hyp* tautomerization",
      "label": "are of"
    },
    {
      "source": "synchronous tautomerization process",
      "target": "Hyp\u00b7Hyp",
      "label": "is for"
    },
    {
      "source": "synchronous tautomerization process",
      "target": "double proton transfer (DPT)",
      "label": "occurs via"
    },
    {
      "source": "energetic parameters",
      "target": "course of the tautomerization",
      "label": "describe"
    },
    {
      "source": "course of the tautomerization",
      "target": "intrinsic reaction coordinate (IRC)",
      "label": "is along"
    },
    {
      "source": "C2H\u2026O2 H-bond",
      "target": "Hyp\u00b7Cyt base pair",
      "label": "is in"
    },
    {
      "source": "sweeps",
      "target": "energetic parameters",
      "label": "are of"
    },
    {
      "source": "sweeps",
      "target": "polar parameters",
      "label": "are of"
    },
    {
      "source": "sweeps",
      "target": "electron-topological parameters",
      "label": "are of"
    },
    {
      "source": "sweeps",
      "target": "geometric parameters",
      "label": "are of"
    },
    {
      "source": "electron-topological \"fingerprints\"",
      "target": "concerted asynchronous tautomerization process",
      "label": "are of"
    },
    {
      "source": "electron-topological \"fingerprints\"",
      "target": "synchronous tautomerization process",
      "label": "are of"
    },
    {
      "source": "concerted asynchronous tautomerization process",
      "target": "Hyp*\u00b7Thy",
      "label": "is for"
    },
    {
      "source": "concerted asynchronous tautomerization process",
      "target": "Hyp\u00b7Cyt",
      "label": "is for"
    },
    {
      "source": "concerted asynchronous tautomerization process",
      "target": "double proton transfer (DPT)",
      "label": "occurs via"
    },
    {
      "source": "tautomerization",
      "target": "theoretical investigations",
      "label": "was studied by"
    },
    {
      "source": "tautomerization",
      "target": "Hyp\u00b7Thy* base pair",
      "label": "produces"
    },
    {
      "source": "tautomerization",
      "target": "continuum",
      "label": "was studied in"
    },
    {
      "source": "tautomerization",
      "target": "Hyp\u00b7Hyp base pair",
      "label": "converts"
    },
    {
      "source": "tautomerization",
      "target": "concerted and asynchronous process",
      "label": "is"
    },
    {
      "source": "tautomerization",
      "target": "double proton transfer (DPT)",
      "label": "occurs through"
    },
    {
      "source": "tautomerization",
      "target": "Hyp*\u00b7Thy base pair",
      "label": "converts"
    },
    {
      "source": "tautomerization",
      "target": "Hyp*\u00b7Hyp* base pair",
      "label": "produces"
    },
    {
      "source": "tautomerization",
      "target": "Hyp*\u00b7Cyt* base pair",
      "label": "produces"
    },
    {
      "source": "tautomerization",
      "target": "DNA bases",
      "label": "involves"
    },
    {
      "source": "tautomerization",
      "target": "in vacuo",
      "label": "was studied in"
    },
    {
      "source": "tautomerization",
      "target": "hypoxanthine",
      "label": "involves"
    },
    {
      "source": "tautomerization",
      "target": "concerted and synchronous process",
      "label": "is"
    },
    {
      "source": "tautomerization",
      "target": "Hyp\u00b7Cyt base pair",
      "label": "converts"
    },
    {
      "source": "theoretical investigations",
      "target": "QTAIM topological analysis",
      "label": "were combined with"
    },
    {
      "source": "theoretical investigations",
      "target": "B3LYP/6-311++G(d,p) level of QM theory",
      "label": "were performed at"
    },
    {
      "source": "electron-topological parameters",
      "target": "course of the tautomerization",
      "label": "describe"
    },
    {
      "source": "polar parameters",
      "target": "course of the tautomerization",
      "label": "describe"
    },
    {
      "source": "continuum",
      "target": "low dielectric constant (\u03b5\u2009=\u20094)",
      "label": "has"
    },
    {
      "source": "concerted and asynchronous process",
      "target": "Hyp\u00b7Cyt base pair",
      "label": "is for"
    },
    {
      "source": "concerted and asynchronous process",
      "target": "double proton transfer (DPT)",
      "label": "occurs through"
    },
    {
      "source": "concerted and asynchronous process",
      "target": "Hyp*\u00b7Thy base pair",
      "label": "is for"
    },
    {
      "source": "QTAIM topological analysis",
      "target": "topological analysis",
      "label": "is a type of"
    },
    {
      "source": "hydrophobic interfaces",
      "target": "protein-nucleic acid interactions",
      "label": "are part of"
    },
    {
      "source": "low dielectric constant (\u03b5\u2009=\u20094)",
      "target": "hydrophobic interfaces",
      "label": "corresponds to"
    },
    {
      "source": "O6H\u2026O4 H-bond",
      "target": "Hyp*\u00b7Thy base pair",
      "label": "is in"
    },
    {
      "source": "concerted and synchronous process",
      "target": "Hyp\u00b7Hyp homodimer",
      "label": "is for"
    },
    {
      "source": "concerted and synchronous process",
      "target": "double proton transfer (DPT)",
      "label": "occurs through"
    },
    {
      "source": "nine key points",
      "target": "intrinsic reaction coordinate (IRC)",
      "label": "are along"
    },
    {
      "source": "nine key points",
      "target": "Hyp*\u00b7Thy\u2194Hyp\u00b7Thy* tautomerization",
      "label": "are of"
    },
    {
      "source": "nine key points",
      "target": "Hyp\u00b7Cyt\u2194Hyp*\u00b7Cyt* tautomerization",
      "label": "are of"
    },
    {
      "source": "physico-chemical \"anatomy\"",
      "target": "tautomerization",
      "label": "describes"
    },
    {
      "source": "key points",
      "target": "electron-topological \"fingerprints\"",
      "label": "are"
    },
    {
      "source": "B3LYP/6-311++G(d,p) level of QM theory",
      "target": "QM theory",
      "label": "is a level of"
    },
    {
      "source": "QM",
      "target": "physico-chemical \"anatomy\"",
      "label": "provides perspective on"
    },
    {
      "source": "geometric parameters",
      "target": "course of the tautomerization",
      "label": "describe"
    },
    {
      "source": "Ser26 phosphorylation",
      "target": "BAD proapoptotic activity",
      "label": "inhibits"
    },
    {
      "source": "BAD proapoptotic activity",
      "target": "mortality",
      "label": "increases"
    },
    {
      "source": "BAD proapoptotic activity",
      "target": "apoptosis",
      "label": "accelerates"
    },
    {
      "source": "mortality",
      "target": "animals",
      "label": "occurs in"
    },
    {
      "source": "I\u03baB kinase complex",
      "target": "tumorigenesis",
      "label": "regulates"
    },
    {
      "source": "I\u03baB kinase complex",
      "target": "cell survival",
      "label": "regulates"
    },
    {
      "source": "I\u03baB kinase complex",
      "target": "inflammation",
      "label": "regulates"
    },
    {
      "source": "I\u03baB kinase complex",
      "target": "immune responses",
      "label": "regulates"
    },
    {
      "source": "IKK",
      "target": "NF-\u03baB",
      "label": "activates"
    },
    {
      "source": "IKK",
      "target": "apoptosis",
      "label": "inhibits"
    },
    {
      "source": "IKK",
      "target": "serine-26",
      "label": "phosphorylates"
    },
    {
      "source": "IKK",
      "target": "BAD",
      "label": "phosphorylates"
    },
    {
      "source": "target gene products",
      "target": "caspases",
      "label": "inhibit"
    },
    {
      "source": "target gene products",
      "target": "JNK activation",
      "label": "prevents"
    },
    {
      "source": "BAD",
      "target": "apoptosis",
      "label": "promotes"
    },
    {
      "source": "BAD",
      "target": "BH3-only protein",
      "label": "is a type of"
    },
    {
      "source": "BAD",
      "target": "proapoptotic BH3-only BAD protein",
      "label": "is a type of"
    },
    {
      "source": "NF-\u03baB activation",
      "target": "apoptosis",
      "label": "inhibits"
    },
    {
      "source": "NF-\u03baB activation",
      "target": "BAD",
      "label": "cooperates with"
    },
    {
      "source": "serine-26",
      "target": "Ser26",
      "label": "is also known as"
    },
    {
      "source": "MEFs",
      "target": "RelA",
      "label": "are deficient in"
    },
    {
      "source": "MEFs",
      "target": "cRel",
      "label": "are deficient in"
    },
    {
      "source": "TNF\u03b1",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "Ikk\u03b2(-/-) mouse embryonic fibroblasts",
      "target": "apoptosis",
      "label": "undergo"
    },
    {
      "source": "functional \u03b2-cell mass",
      "target": "proliferation",
      "label": "doubling occurs by"
    },
    {
      "source": "functional \u03b2-cell mass",
      "target": "week",
      "label": "doubles within"
    },
    {
      "source": "functional \u03b2-cell mass",
      "target": "differentiation",
      "label": "doubling occurs by"
    },
    {
      "source": "Lineage-tracing studies",
      "target": "rat insulin 2 promoter-driven cre-lox",
      "label": "use"
    },
    {
      "source": "Lineage-tracing studies",
      "target": "sequential administration",
      "label": "use"
    },
    {
      "source": "Lineage-tracing studies",
      "target": "low-frequency ubiquitous cre-lox",
      "label": "use"
    },
    {
      "source": "pancreatic duct ligation (PDL)",
      "target": "progenitors",
      "label": "does not activate"
    },
    {
      "source": "pancreatic duct ligation (PDL)",
      "target": "massive pancreatic injury",
      "label": "stimulates"
    },
    {
      "source": "\u03b2-Cells",
      "target": "injured adult mouse pancreas",
      "label": "are not generated in"
    },
    {
      "source": "\u03b2-Cells",
      "target": "Pancreatic Duct Ligation-Induced Injury",
      "label": "are not generated in"
    },
    {
      "source": "accurate measurement",
      "target": "traditional morphometry methodologies",
      "label": "is via"
    },
    {
      "source": "accurate measurement",
      "target": "\u03b2-cell content",
      "label": "is of"
    },
    {
      "source": "traditional morphometry methodologies",
      "target": "pancreas",
      "label": "sample"
    },
    {
      "source": "sequential administration",
      "target": "thymidine analogs",
      "label": "is of"
    },
    {
      "source": "\u03b2-cell mass",
      "target": "PDL-induced injury",
      "label": "is unchanged by"
    },
    {
      "source": "\u03b2-cell progenitors",
      "target": "ductal ligation-induced injury",
      "label": "can be activated by"
    },
    {
      "source": "\u03b2-cell progenitors",
      "target": "cell-autonomous manner",
      "label": "act in"
    },
    {
      "source": "\u03b2-cell progenitors",
      "target": "functional \u03b2-cell mass",
      "label": "double"
    },
    {
      "source": "ductal ligation-induced injury",
      "target": "adult mouse pancreas",
      "label": "is of"
    },
    {
      "source": "massive pancreatic injury",
      "target": "accurate measurement",
      "label": "complicates"
    },
    {
      "source": "massive pancreatic injury",
      "target": "pancreatic composition",
      "label": "alters"
    },
    {
      "source": "Pancreatic Duct Ligation-Induced Injury",
      "target": "Adult Mice",
      "label": "occurs in"
    },
    {
      "source": "entire pancreas",
      "target": "potential bias",
      "label": "is used to overcome"
    },
    {
      "source": "developmental biology topic",
      "target": "diabetes research",
      "label": "is in"
    },
    {
      "source": "adult \u03b2-cell progenitors",
      "target": "developmental biology topic",
      "label": "existence is"
    },
    {
      "source": "insulin content",
      "target": "PDL-induced injury",
      "label": "is unchanged by"
    },
    {
      "source": "11",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "11",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "11",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "11",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "12",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "12",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "12",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "12",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "absolute configurations",
      "target": "15",
      "label": "of"
    },
    {
      "source": "absolute configurations",
      "target": "single-crystal X-ray diffraction",
      "label": "confirmed by"
    },
    {
      "source": "absolute configurations",
      "target": "1",
      "label": "of"
    },
    {
      "source": "absolute configurations",
      "target": "16",
      "label": "of"
    },
    {
      "source": "15",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "15",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "15",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "15",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "ent-kauranoids",
      "target": "diterpenoids",
      "label": "is a type of"
    },
    {
      "source": "four known compounds",
      "target": "17",
      "label": "include"
    },
    {
      "source": "four known compounds",
      "target": "18",
      "label": "include"
    },
    {
      "source": "four known compounds",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "four known compounds",
      "target": "19",
      "label": "include"
    },
    {
      "source": "four known compounds",
      "target": "20",
      "label": "include"
    },
    {
      "source": "17",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "17",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "17",
      "target": "known compounds",
      "label": "is a"
    },
    {
      "source": "Selected compounds",
      "target": "compounds",
      "label": "is a type of"
    },
    {
      "source": "Selected compounds",
      "target": "cytotoxicity",
      "label": "evaluated for"
    },
    {
      "source": "Selected compounds",
      "target": "small panel of human tumor cell lines",
      "label": "evaluated against"
    },
    {
      "source": "Selected compounds",
      "target": "human tumor cell lines",
      "label": "evaluated against"
    },
    {
      "source": "1",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "1",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "1",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "1",
      "target": "abietane diterpenoids",
      "label": "is a"
    },
    {
      "source": "3",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "3",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "3",
      "target": "abietane diterpenoids",
      "label": "is a"
    },
    {
      "source": "3",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "isolates",
      "target": "inhibitory activity",
      "label": "exhibited"
    },
    {
      "source": "18",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "18",
      "target": "known compounds",
      "label": "is a"
    },
    {
      "source": "18",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "abietane diterpenoids",
      "target": "diterpenoids",
      "label": "is a type of"
    },
    {
      "source": "tenuifolins A-M",
      "target": "14",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "15",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "8",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "4",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "11",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "tenuifolins A-M",
      "target": "5",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "7",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "12",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "9",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "ent-kauranoids",
      "label": "is a type of"
    },
    {
      "source": "tenuifolins A-M",
      "target": "13",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "10",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "16",
      "label": "include"
    },
    {
      "source": "tenuifolins A-M",
      "target": "6",
      "label": "include"
    },
    {
      "source": "14",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "14",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "14",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "14",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "isoabietenins A-C",
      "target": "3",
      "label": "include"
    },
    {
      "source": "isoabietenins A-C",
      "target": "abietane diterpenoids",
      "label": "is a type of"
    },
    {
      "source": "isoabietenins A-C",
      "target": "1",
      "label": "include"
    },
    {
      "source": "isoabietenins A-C",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "isoabietenins A-C",
      "target": "2",
      "label": "include"
    },
    {
      "source": "20",
      "target": "known compounds",
      "label": "is a"
    },
    {
      "source": "20",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "20",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "9",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "9",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "9",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "9",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "new metabolites",
      "target": "detailed spectroscopic analysis",
      "label": "established on the basis of"
    },
    {
      "source": "6",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "6",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "6",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "6",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "LPS-activated RAW264.7 macrophages",
      "target": "RAW264.7 macrophages",
      "label": "is a type of"
    },
    {
      "source": "10",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "10",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "10",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "10",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "5",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "5",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "5",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "5",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "5",
      "target": "two glycosylated derivatives 4 and 5",
      "label": "is a part of"
    },
    {
      "source": "2",
      "target": "abietane diterpenoids",
      "label": "is a"
    },
    {
      "source": "2",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "2",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "2",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "7",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "7",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "7",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "7",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "8",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "8",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "8",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "8",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "16",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "16",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "16",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "16",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "13",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "13",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "13",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "13",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "19",
      "target": "known compounds",
      "label": "is a"
    },
    {
      "source": "19",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "19",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "Bioactive abietane and ent-kaurane diterpenoids",
      "target": "Isodon tenuifolius",
      "label": "from"
    },
    {
      "source": "4",
      "target": "new metabolites",
      "label": "is a"
    },
    {
      "source": "4",
      "target": "ent-kauranoids",
      "label": "is a"
    },
    {
      "source": "4",
      "target": "aerial parts of Isodon tenuifolius",
      "label": "isolated from"
    },
    {
      "source": "4",
      "target": "isolates",
      "label": "is an"
    },
    {
      "source": "4",
      "target": "two glycosylated derivatives 4 and 5",
      "label": "is a part of"
    },
    {
      "source": "Three new abietane diterpenoids",
      "target": "isoabietenins A-C",
      "label": "are"
    },
    {
      "source": "13 new ent-kauranoids",
      "target": "tenuifolins A-M",
      "label": "are"
    },
    {
      "source": "BMP-2 processing",
      "target": "endogenous FSAP",
      "label": "by"
    },
    {
      "source": "Factor VII-activating protease",
      "target": "pathogenesis",
      "label": "involved in"
    },
    {
      "source": "Factor VII-activating protease",
      "target": "circulating protease",
      "label": "is a"
    },
    {
      "source": "truncated mature BMP-2 peptide",
      "target": "Arg(289)",
      "label": "contains"
    },
    {
      "source": "truncated mature BMP-2 peptide",
      "target": "Lys(290)",
      "label": "contains"
    },
    {
      "source": "pro-BMP-2",
      "target": "N-terminal heparin binding region",
      "label": "cleaved in"
    },
    {
      "source": "pro-BMP-2",
      "target": "mature BMP-2",
      "label": "gives rise to"
    },
    {
      "source": "pro-BMP-2",
      "target": "truncated mature BMP-2 peptide",
      "label": "generates"
    },
    {
      "source": "pro-BMP-2",
      "target": "canonical PC cleavage site",
      "label": "cleaved at"
    },
    {
      "source": "pro-BMP-2",
      "target": "FSAP",
      "label": "cleaved by"
    },
    {
      "source": "FSAP",
      "target": "circulating protease",
      "label": "is a"
    },
    {
      "source": "FSAP",
      "target": "BMP-2",
      "label": "enhances activity of"
    },
    {
      "source": "FSAP",
      "target": "pro-form",
      "label": "enhances biological activity of"
    },
    {
      "source": "FSAP",
      "target": "regulation",
      "label": "has effect on"
    },
    {
      "source": "FSAP",
      "target": "pathogenesis",
      "label": "involved in"
    },
    {
      "source": "FSAP",
      "target": "balance",
      "label": "controls"
    },
    {
      "source": "FSAP",
      "target": "biological activity",
      "label": "enhances"
    },
    {
      "source": "N-terminal heparin binding region",
      "target": "mature BMP-2",
      "label": "of"
    },
    {
      "source": "mature BMP-2",
      "target": "Gln(283)",
      "label": "contains"
    },
    {
      "source": "mature BMP-2",
      "target": "Arg(282)",
      "label": "contains"
    },
    {
      "source": "mature BMP-2",
      "target": "truncated peptide",
      "label": "cleaved to"
    },
    {
      "source": "truncated peptide",
      "target": "Lys(290)",
      "label": "contains"
    },
    {
      "source": "truncated peptide",
      "target": "Arg(289)",
      "label": "contains"
    },
    {
      "source": "truncated peptide",
      "target": "N-terminal region",
      "label": "within"
    },
    {
      "source": "BMP-2",
      "target": "mature heparin-binding growth factor",
      "label": "secreted as"
    },
    {
      "source": "BMP-2",
      "target": "pro-form",
      "label": "produced as"
    },
    {
      "source": "mature heparin-binding growth factor",
      "target": "intracellular processing",
      "label": "formed after"
    },
    {
      "source": "calcification",
      "target": "vasculature",
      "label": "in"
    },
    {
      "source": "heparin binding region",
      "target": "BMP-2",
      "label": "of"
    },
    {
      "source": "Factor VIIa",
      "target": "activity",
      "label": "lacked"
    },
    {
      "source": "activated protein C",
      "target": "activity",
      "label": "lacked"
    },
    {
      "source": "Factor Xa",
      "target": "activity",
      "label": "lacked"
    },
    {
      "source": "N-terminal sequencing",
      "target": "pro-BMP-2",
      "label": "indicated"
    },
    {
      "source": "intracellular processing",
      "target": "pro-protein convertases",
      "label": "by"
    },
    {
      "source": "intracellular processing",
      "target": "PCs",
      "label": "by"
    },
    {
      "source": "osteogenic differentiation",
      "target": "C2C12 myoblasts",
      "label": "of"
    },
    {
      "source": "Plasmin",
      "target": "activity",
      "label": "exhibited"
    },
    {
      "source": "Thrombin",
      "target": "activity",
      "label": "lacked"
    },
    {
      "source": "The factor VII-activating protease",
      "target": "bone morphogenetic protein-2",
      "label": "enhances activity of"
    },
    {
      "source": "R or S configuration",
      "target": "C-3",
      "label": "at"
    },
    {
      "source": "C-3",
      "target": "beta-hydroxy fatty acid subunit",
      "label": "is part of"
    },
    {
      "source": "beta-hydroxy fatty acid subunit",
      "target": "cyclic scaffold of 1",
      "label": "completes"
    },
    {
      "source": "multiple minimizations",
      "target": "generated conformers",
      "label": "performed for"
    },
    {
      "source": "lowest energy conformers",
      "target": "B3LYP geometry optimizations",
      "label": "subjected to"
    },
    {
      "source": "lowest energy conformers",
      "target": "R and S stereoisomers",
      "label": "are of"
    },
    {
      "source": "B3LYP geometry optimizations",
      "target": "solvent effects",
      "label": "include"
    },
    {
      "source": "absolute configuration",
      "target": "challenges",
      "label": "yields"
    },
    {
      "source": "absolute configuration",
      "target": "cyclic peptides",
      "label": "of"
    },
    {
      "source": "challenges",
      "target": "stereogenic centers",
      "label": "result in unassigned"
    },
    {
      "source": "structure of 1",
      "target": "Maestro",
      "label": "sketched in"
    },
    {
      "source": "structure of 1",
      "target": "Schr\u00f6dinger suite",
      "label": "processed using"
    },
    {
      "source": "structure of 1",
      "target": "OPLS2005 force field",
      "label": "minimized using"
    },
    {
      "source": "structure of 1",
      "target": "Macromodel",
      "label": "minimized in"
    },
    {
      "source": "excellent agreement",
      "target": "NOE-derived distance constraints",
      "label": "with"
    },
    {
      "source": "excellent agreement",
      "target": "hydrogen-bonding stability studies",
      "label": "with"
    },
    {
      "source": "conformational search",
      "target": "structures",
      "label": "performed for"
    },
    {
      "source": "S stereoisomer",
      "target": "excellent agreement",
      "label": "shows"
    },
    {
      "source": "stereogenic centers",
      "target": "Marfey's",
      "label": "unassigned due to"
    },
    {
      "source": "stereogenic centers",
      "target": "small quantities of sample",
      "label": "unassigned due to"
    },
    {
      "source": "Marfey's",
      "target": "methods",
      "label": "is a type of"
    },
    {
      "source": "combination of molecular modeling and NOE distance constraint calculations",
      "target": "absolute configuration of the final stereogenic center of 1",
      "label": "determines"
    },
    {
      "source": "combination of molecular modeling and NOE distance constraint calculations",
      "target": "conformation of 1",
      "label": "determines"
    },
    {
      "source": "Computationally assisted assignment",
      "target": "NMR-constrained conformational search",
      "label": "uses"
    },
    {
      "source": "Computationally assisted assignment",
      "target": "kahalalide Y configuration",
      "label": "assigns"
    },
    {
      "source": "kahalalide Y (1)",
      "target": "Bryopsis pennata",
      "label": "isolated from"
    },
    {
      "source": "AUC(0-\u221e)",
      "target": "Time-separated administration",
      "label": "was unchanged following"
    },
    {
      "source": "AUC(0-\u221e)",
      "target": "atorvastatin",
      "label": "is of"
    },
    {
      "source": "AUC(0-\u221e)",
      "target": "o-hydroxy atorvastatin",
      "label": "is of"
    },
    {
      "source": "Time-separated administration",
      "target": "reductions",
      "label": "resulted in"
    },
    {
      "source": "o-hydroxy atorvastatin",
      "target": "doses",
      "label": "decrease independent of"
    },
    {
      "source": "o-hydroxy atorvastatin",
      "target": "C(max)",
      "label": "decreased"
    },
    {
      "source": "o-hydroxy atorvastatin",
      "target": "Time-separated administration",
      "label": "C(max) decreased following"
    },
    {
      "source": "o-hydroxy atorvastatin",
      "target": "AUC(0-\u221e)",
      "label": "decreased"
    },
    {
      "source": "Almorexant",
      "target": "CYP3A4",
      "label": "interacts with"
    },
    {
      "source": "Almorexant",
      "target": "steady-state",
      "label": "administered at"
    },
    {
      "source": "Almorexant",
      "target": "simvastatin",
      "label": "interacts with"
    },
    {
      "source": "Almorexant",
      "target": "atorvastatin",
      "label": "interacts with"
    },
    {
      "source": "Almorexant",
      "target": "C(max)",
      "label": "did not increase"
    },
    {
      "source": "Almorexant",
      "target": "cytochrome P450 3A4",
      "label": "interacts with"
    },
    {
      "source": "Almorexant",
      "target": "interaction",
      "label": "has"
    },
    {
      "source": "Almorexant",
      "target": "dual orexin receptor antagonist",
      "label": "is a"
    },
    {
      "source": "Almorexant",
      "target": "simvastatin exposure",
      "label": "increased"
    },
    {
      "source": "Almorexant",
      "target": "AUC(0-\u221e)",
      "label": "increased"
    },
    {
      "source": "Almorexant",
      "target": "CYP3A4 activity",
      "label": "affects"
    },
    {
      "source": "atorvastatin exposure",
      "target": "almorexant dose",
      "label": "increase independent of"
    },
    {
      "source": "atorvastatin exposure",
      "target": "relative time of administration",
      "label": "increase independent of"
    },
    {
      "source": "atorvastatin exposure",
      "target": "doses",
      "label": "increase irrespective of"
    },
    {
      "source": "atorvastatin exposure",
      "target": "atorvastatin exposure",
      "label": "increased"
    },
    {
      "source": "atorvastatin exposure",
      "target": "C(max)",
      "label": "increased"
    },
    {
      "source": "atorvastatin exposure",
      "target": "AUC(0-\u221e)",
      "label": "increased"
    },
    {
      "source": "atorvastatin exposure",
      "target": "time",
      "label": "increase irrespective of"
    },
    {
      "source": "simvastatin exposure",
      "target": "almorexant dose",
      "label": "is dependent on"
    },
    {
      "source": "simvastatin exposure",
      "target": "AUC(0-\u221e)",
      "label": "measured by"
    },
    {
      "source": "simvastatin exposure",
      "target": "relative time of administration",
      "label": "is dependent on"
    },
    {
      "source": "simvastatin exposure",
      "target": "C(max)",
      "label": "measured by"
    },
    {
      "source": "Pharmacokinetic interactions",
      "target": "Almorexant",
      "label": "occur between"
    },
    {
      "source": "Pharmacokinetic interactions",
      "target": "healthy male subjects",
      "label": "investigated in"
    },
    {
      "source": "Pharmacokinetic interactions",
      "target": "simvastatin",
      "label": "occur between"
    },
    {
      "source": "Pharmacokinetic interactions",
      "target": "atorvastatin",
      "label": "occur between"
    },
    {
      "source": "healthy male subjects",
      "target": "treatment groups",
      "label": "divided into"
    },
    {
      "source": "Acsl4 promoter",
      "target": "putative binding sites",
      "label": "has"
    },
    {
      "source": "Acsl4 promoter",
      "target": "TATA box",
      "label": "lacks"
    },
    {
      "source": "putative binding sites",
      "target": "transcription factors",
      "label": "are_for"
    },
    {
      "source": "Sp1 binding site",
      "target": "specificity protein",
      "label": "is_a_type_of"
    },
    {
      "source": "Sp1 binding site",
      "target": "Kr\u00fcppel-like factor",
      "label": "is_a_type_of"
    },
    {
      "source": "Sp1 binding site",
      "target": "basal activity",
      "label": "is_involved_in"
    },
    {
      "source": "Sp1 binding site",
      "target": "proximal promoter",
      "label": "is_located_in"
    },
    {
      "source": "Acsl4 mRNA",
      "target": "mouse steroidogenic MA-10 Leydig cells",
      "label": "is_found_in"
    },
    {
      "source": "cAMP response element-binding site",
      "target": "cAMP stimulation",
      "label": "is_involved_in"
    },
    {
      "source": "cAMP stimulation",
      "target": "Acsl4 transcription",
      "label": "affects"
    },
    {
      "source": "alternative splice variants",
      "target": "MA-10 cells",
      "label": "are_present_in"
    },
    {
      "source": "mouse promoter region",
      "target": "acyl-CoA synthetase 4 gene",
      "label": "is_part_of"
    },
    {
      "source": "Functional characterization",
      "target": "cAMP response element-binding site",
      "label": "revealed_involvement_of"
    },
    {
      "source": "Functional characterization",
      "target": "Sp1 binding site",
      "label": "revealed_involvement_of"
    },
    {
      "source": "Sequence analysis",
      "target": "1.5-kb fragment",
      "label": "performed_on"
    },
    {
      "source": "1.5-kb fragment",
      "target": "Acsl4 promoter",
      "label": "is_part_of"
    },
    {
      "source": "Acsl4",
      "target": "synaptic development",
      "label": "is_involved_in"
    },
    {
      "source": "Acsl4",
      "target": "cellular functions",
      "label": "is_involved_in"
    },
    {
      "source": "Acsl4",
      "target": "cancer metastasis",
      "label": "is_involved_in"
    },
    {
      "source": "Acsl4",
      "target": "steroidogenesis",
      "label": "is_involved_in"
    },
    {
      "source": "Acyl-CoA synthetase 4",
      "target": "synaptic development",
      "label": "is_involved_in"
    },
    {
      "source": "Acyl-CoA synthetase 4",
      "target": "Acsl4",
      "label": "is_also_known_as"
    },
    {
      "source": "Acyl-CoA synthetase 4",
      "target": "cellular functions",
      "label": "is_involved_in"
    },
    {
      "source": "Acyl-CoA synthetase 4",
      "target": "cancer metastasis",
      "label": "is_involved_in"
    },
    {
      "source": "Acyl-CoA synthetase 4",
      "target": "steroidogenesis",
      "label": "is_involved_in"
    },
    {
      "source": "expression of Acsl4",
      "target": "pituitary hormones",
      "label": "is_regulated_by"
    },
    {
      "source": "expression of Acsl4",
      "target": "tissue- and cell-specific factors",
      "label": "is_regulated_by"
    },
    {
      "source": "expression of Acsl4",
      "target": "growth factors",
      "label": "is_regulated_by"
    },
    {
      "source": "promoter of the Acsl4 mouse gene",
      "target": "Acsl4 mouse gene",
      "label": "is_part_of"
    },
    {
      "source": "KIEs",
      "target": "temperature dependence of kinetic isotope effects",
      "label": "refers to"
    },
    {
      "source": "temperature dependence of kinetic isotope effects",
      "target": "gold standard descriptor",
      "label": "has emerged as"
    },
    {
      "source": "direct link",
      "target": "promoting vibrations",
      "label": "is between"
    },
    {
      "source": "direct link",
      "target": "observed KIE",
      "label": "is between"
    },
    {
      "source": "promoting vibrations",
      "target": "protein",
      "label": "are in"
    },
    {
      "source": "Fast protein motions",
      "target": "enzyme H-transfer reactions",
      "label": "are coupled to"
    },
    {
      "source": "vibrational motions",
      "target": "isotopic substitution",
      "label": "were perturbed by"
    },
    {
      "source": "vibrational motions",
      "target": "pentaerythritol tetranitrate reductase",
      "label": "were perturbed in"
    },
    {
      "source": "gold standard descriptor",
      "target": "reactions",
      "label": "describes"
    },
    {
      "source": "KIE temperature dependence",
      "target": "temperature dependence of kinetic isotope effects",
      "label": "refers to"
    },
    {
      "source": "KIE temperature dependence",
      "target": "heavy isotope labeling",
      "label": "is perturbed by"
    },
    {
      "source": "H-transfer",
      "target": "quantum tunneling",
      "label": "can occur by"
    },
    {
      "source": "(15)N",
      "target": "heavy isotope",
      "label": "is a type of"
    },
    {
      "source": "(13)C",
      "target": "heavy isotope",
      "label": "is a type of"
    },
    {
      "source": "heavy isotope labeling",
      "target": "direct link",
      "label": "demonstrates"
    },
    {
      "source": "fast motions",
      "target": "H-transfer",
      "label": "facilitate"
    },
    {
      "source": "PETNR",
      "target": "pentaerythritol tetranitrate reductase",
      "label": "refers to"
    },
    {
      "source": "considerable debate",
      "target": "enzyme-catalyzed H-transfer",
      "label": "is in relation to"
    },
    {
      "source": "considerable debate",
      "target": "past 15 years",
      "label": "occurred over"
    },
    {
      "source": "fast dynamics",
      "target": "reaction chemistry",
      "label": "are coupled to"
    },
    {
      "source": "(2)H",
      "target": "heavy isotope",
      "label": "is a type of"
    },
    {
      "source": "causality",
      "target": "fast motions",
      "label": "is between"
    },
    {
      "source": "causality",
      "target": "experimental KIEs",
      "label": "impacts on"
    },
    {
      "source": "causality",
      "target": "enzyme chemistry",
      "label": "is between"
    },
    {
      "source": "experimental KIEs",
      "target": "enzyme reactions",
      "label": "are for"
    },
    {
      "source": "anomalous temperature dependence of KIEs",
      "target": "fast motions",
      "label": "is rationalized by"
    },
    {
      "source": "Coupling of fast protein dynamics",
      "target": "considerable debate",
      "label": "has ignited"
    },
    {
      "source": "Coupling of fast protein dynamics",
      "target": "enzyme chemistry",
      "label": "is coupled to"
    },
    {
      "source": "fast motions hypothesis",
      "target": "inference",
      "label": "is based on"
    },
    {
      "source": "fast motions hypothesis",
      "target": "temperature dependence of kinetic isotope effects",
      "label": "underpins"
    },
    {
      "source": "temperature-independent KIEs",
      "target": "fast dynamics",
      "label": "do not rule out a role for"
    },
    {
      "source": "non-exchangeable atoms",
      "target": "heavy isotope",
      "label": "were replaced with"
    },
    {
      "source": "3,4-dihydropyrimidinones",
      "target": "formylphenylboronic acids",
      "label": "derived from"
    },
    {
      "source": "formylphenylboronic acids",
      "target": "meta",
      "label": "include"
    },
    {
      "source": "formylphenylboronic acids",
      "target": "ortho",
      "label": "include"
    },
    {
      "source": "formylphenylboronic acids",
      "target": "para",
      "label": "include"
    },
    {
      "source": "common analytic procedures",
      "target": "1H NMR",
      "label": "include"
    },
    {
      "source": "common analytic procedures",
      "target": "11B NMR",
      "label": "include"
    },
    {
      "source": "common analytic procedures",
      "target": "13C NMR",
      "label": "include"
    },
    {
      "source": "common analytic procedures",
      "target": "HRMS",
      "label": "include"
    },
    {
      "source": "common analytic procedures",
      "target": "FAB+MS",
      "label": "include"
    },
    {
      "source": "common analytic procedures",
      "target": "IR",
      "label": "include"
    },
    {
      "source": "modes of activation",
      "target": "microwave irradiation",
      "label": "include"
    },
    {
      "source": "modes of activation",
      "target": "mantle heating",
      "label": "include"
    },
    {
      "source": "modes of activation",
      "target": "Infrared Radiation (IR) irradiation",
      "label": "include"
    },
    {
      "source": "convenient analysis",
      "target": "12 green chemistry principles",
      "label": "is of"
    },
    {
      "source": "11 novel hybrid-boron-containing molecules",
      "target": "Green approach",
      "label": "obtained using"
    },
    {
      "source": "11 novel hybrid-boron-containing molecules",
      "target": "3,4-dihydropyrimidinones",
      "label": "include"
    },
    {
      "source": "11 novel hybrid-boron-containing molecules",
      "target": "1,4-dihydropyridines",
      "label": "include"
    },
    {
      "source": "Green approach",
      "target": "B-3CR practices",
      "label": "involves"
    },
    {
      "source": "Green approach",
      "target": "H-4CR practices",
      "label": "involves"
    },
    {
      "source": "Green approach",
      "target": "modes of activation",
      "label": "uses"
    },
    {
      "source": "Green approach",
      "target": "convenient analysis",
      "label": "offers"
    },
    {
      "source": "1,4-dihydropyridines",
      "target": "formylphenylboronic acids",
      "label": "derived from"
    },
    {
      "source": "characterizations",
      "target": "common analytic procedures",
      "label": "used"
    },
    {
      "source": "accurate mass data",
      "target": "target molecules",
      "label": "enabled characterization of"
    },
    {
      "source": "accurate mass data",
      "target": "FAB+-mode",
      "label": "obtained in"
    },
    {
      "source": "accurate mass data",
      "target": "unexpected ions",
      "label": "is of"
    },
    {
      "source": "multicomponent production",
      "target": "Green approach",
      "label": "is a"
    },
    {
      "source": "multicomponent production",
      "target": "biginelli esters",
      "label": "produces"
    },
    {
      "source": "multicomponent production",
      "target": "hantzsch esters",
      "label": "produces"
    },
    {
      "source": "B-3CR practices",
      "target": "ethanol",
      "label": "use"
    },
    {
      "source": "Multicomponent reactions",
      "target": "green chemistry",
      "label": "meet requirements of"
    },
    {
      "source": "Multicomponent reactions",
      "target": "number of steps",
      "label": "reduce"
    },
    {
      "source": "Multicomponent reactions",
      "target": "purification requirements",
      "label": "reduce"
    },
    {
      "source": "unexpected ions",
      "target": "thioglycerol",
      "label": "interact with"
    },
    {
      "source": "unexpected ions",
      "target": "expected products",
      "label": "interact with"
    },
    {
      "source": "H-4CR practices",
      "target": "ethanol",
      "label": "use"
    },
    {
      "source": "biginelli esters",
      "target": "boron",
      "label": "contain"
    },
    {
      "source": "hantzsch esters",
      "target": "boron",
      "label": "contain"
    },
    {
      "source": "products",
      "target": "characterizations",
      "label": "underwent"
    },
    {
      "source": "expected products",
      "target": "target molecules",
      "label": "are"
    },
    {
      "source": "IR",
      "target": "metabolic activities",
      "label": "evaluates effects on"
    },
    {
      "source": "IR",
      "target": "activities of cytochrome P450 isozymes",
      "label": "affects"
    },
    {
      "source": "IR",
      "target": "CYP isozymes",
      "label": "decreases activities of"
    },
    {
      "source": "1,3,4-thiadiazole analogues",
      "target": "inhibitors",
      "label": "are"
    },
    {
      "source": "1,3,4-thiadiazole analogues",
      "target": "AChE",
      "label": "inhibit"
    },
    {
      "source": "1,3,4-thiadiazole analogues",
      "target": "BuChE",
      "label": "inhibit"
    },
    {
      "source": "biological evaluation",
      "target": "1,3,4-thiadiazole analogues",
      "label": "of"
    },
    {
      "source": "analogues 8",
      "target": "non-competitive AChE inhibitor",
      "label": "acted as"
    },
    {
      "source": "analogues 8",
      "target": "selectivity index",
      "label": "characterized by"
    },
    {
      "source": "1,3,4-thiadiazole derivatives",
      "target": "acetyl- and butyrylcholinesterase inhibitors",
      "label": "evaluated as"
    },
    {
      "source": "Docking simulations",
      "target": "key binding interactions",
      "label": "enabled detection of"
    },
    {
      "source": "key binding interactions",
      "target": "compounds",
      "label": "of"
    },
    {
      "source": "key binding interactions",
      "target": "AChE",
      "label": "with"
    },
    {
      "source": "drug-likeness",
      "target": "filters",
      "label": "assessed based on"
    },
    {
      "source": "drug-likeness",
      "target": "compounds",
      "label": "of"
    },
    {
      "source": "drug-likeness",
      "target": "Lipinski",
      "label": "assessed based on"
    },
    {
      "source": "scoring function",
      "target": "reference inhibitor",
      "label": "was higher than"
    },
    {
      "source": "scoring function",
      "target": "compounds",
      "label": "for"
    },
    {
      "source": "kinetic studies",
      "target": "analogues 8",
      "label": "showed"
    },
    {
      "source": "derivative (1)",
      "target": "mixed-type of AChE inhibition",
      "label": "exhibited"
    },
    {
      "source": "analogues",
      "target": "inhibition",
      "label": "showed"
    },
    {
      "source": "analogues",
      "target": "affinity",
      "label": "showed"
    },
    {
      "source": "analogues",
      "target": "stability",
      "label": "showed"
    },
    {
      "source": "Zif268",
      "target": "G\u03b2\u03b3",
      "label": "is dependent on"
    },
    {
      "source": "Zif268",
      "target": "DNA-binding transcription factor",
      "label": "is a type of"
    },
    {
      "source": "Zif268",
      "target": "Erk1/2",
      "label": "is dependent on"
    },
    {
      "source": "Zif268",
      "target": "immediate-early gene",
      "label": "is encoded by"
    },
    {
      "source": "Zif268",
      "target": "GDNF",
      "label": "up-regulates"
    },
    {
      "source": "Zif268",
      "target": "GDNF promoter",
      "label": "associates with"
    },
    {
      "source": "zinc-finger protein 268",
      "target": "DNA-binding transcription factor",
      "label": "is a type of"
    },
    {
      "source": "zinc-finger protein 268",
      "target": "immediate-early gene",
      "label": "is encoded by"
    },
    {
      "source": "Dopamine D2 receptor",
      "target": "Zif268",
      "label": "induces"
    },
    {
      "source": "Dopamine D2 receptor",
      "target": "glial cell line-derived neurotrophic factor",
      "label": "up-regulates"
    },
    {
      "source": "D2R",
      "target": "Zif268",
      "label": "induces"
    },
    {
      "source": "D2R",
      "target": "GDNF",
      "label": "induces"
    },
    {
      "source": "raclopride",
      "target": "GDNF",
      "label": "blocks increase of"
    },
    {
      "source": "raclopride",
      "target": "D2R inhibitor",
      "label": "is a type of"
    },
    {
      "source": "raclopride",
      "target": "D2R",
      "label": "inhibits"
    },
    {
      "source": "raclopride",
      "target": "Zif268",
      "label": "blocks increase of"
    },
    {
      "source": "shRNA",
      "target": "Zif268",
      "label": "targets"
    },
    {
      "source": "adenoviral delivery",
      "target": "small hairpin RNA",
      "label": "delivers"
    },
    {
      "source": "adenoviral delivery",
      "target": "shRNA",
      "label": "delivers"
    },
    {
      "source": "small hairpin RNA",
      "target": "shRNA",
      "label": "is a type of"
    },
    {
      "source": "glial cell line-derived neurotrophic factor",
      "target": "dopaminergic neurons",
      "label": "is essential for"
    },
    {
      "source": "glial cell line-derived neurotrophic factor",
      "target": "growth factor",
      "label": "is a type of"
    },
    {
      "source": "potassium",
      "target": "dopamine",
      "label": "evokes release of"
    },
    {
      "source": "Compounds 1-9",
      "target": "C31-C33 polyacetylenes (1-9)",
      "label": "are"
    },
    {
      "source": "Compounds 1-9",
      "target": "A2058 (melanoma)",
      "label": "active against"
    },
    {
      "source": "Compounds 1-9",
      "target": "cytotoxicity",
      "label": "exhibit"
    },
    {
      "source": "Compounds 1-9",
      "target": "IMR-90 quiescent human fibroblast cells",
      "label": "active against"
    },
    {
      "source": "Compounds 1-9",
      "target": "H460 (lung)",
      "label": "active against"
    },
    {
      "source": "Compounds 1-9",
      "target": "cancer cells",
      "label": "have limited selectivity for"
    },
    {
      "source": "Compounds 1-9",
      "target": "H522-T1 (lung)",
      "label": "active against"
    },
    {
      "source": "known congeners",
      "target": "Petrosia sp. marine sponge",
      "label": "isolated from"
    },
    {
      "source": "Petrosia sp. marine sponge",
      "target": "American Samoa",
      "label": "collected in"
    },
    {
      "source": "Structures",
      "target": "mass spectrometry",
      "label": "determined by"
    },
    {
      "source": "Structures",
      "target": "1D- and 2D-NMR analysis",
      "label": "determined by"
    },
    {
      "source": "Structures",
      "target": "C31-C33 polyacetylenes (1-9)",
      "label": "of"
    },
    {
      "source": "Structures",
      "target": "specific rotation values",
      "label": "determined by"
    },
    {
      "source": "Structures",
      "target": "American Samoa Petrosia sp. Sponge",
      "label": "from"
    },
    {
      "source": "mass spectrometry",
      "target": "disease-relevant GC target pathways",
      "label": "used to measure"
    },
    {
      "source": "mass spectrometry",
      "target": "metabolic fluxes",
      "label": "used to measure"
    },
    {
      "source": "A2058 (melanoma)",
      "target": "human cancer cell lines",
      "label": "is a type of"
    },
    {
      "source": "pellynols C (6)",
      "target": "known congeners",
      "label": "are"
    },
    {
      "source": "pellynols I (9)",
      "target": "known congeners",
      "label": "are"
    },
    {
      "source": "human lung cancer cells (H460)",
      "target": "H460",
      "label": "also known as"
    },
    {
      "source": "cytotoxic evaluation",
      "target": "new and known acyclic Ene-Ynes",
      "label": "of"
    },
    {
      "source": "new and known acyclic Ene-Ynes",
      "target": "American Samoa Petrosia sp. Sponge",
      "label": "from"
    },
    {
      "source": "pellynols F (8)",
      "target": "known congeners",
      "label": "are"
    },
    {
      "source": "H460 (lung)",
      "target": "human cancer cell lines",
      "label": "is a type of"
    },
    {
      "source": "H522-T1 (lung)",
      "target": "human cancer cell lines",
      "label": "is a type of"
    },
    {
      "source": "pellynols A (5)",
      "target": "known congeners",
      "label": "are"
    },
    {
      "source": "Isolation work",
      "target": "cytotoxicity",
      "label": "guided by"
    },
    {
      "source": "(-)-petrosynoic acids A-D (1-4)",
      "target": "new compounds",
      "label": "are"
    },
    {
      "source": "new compounds",
      "target": "Petrosia sp. marine sponge",
      "label": "isolated from"
    },
    {
      "source": "pellynols D (7)",
      "target": "known congeners",
      "label": "are"
    },
    {
      "source": "PAT-type 5-HT2C agonists",
      "target": "DOI-elicited-HTR",
      "label": "attenuated"
    },
    {
      "source": "PAT-type 5-HT2C agonists",
      "target": "5-HT2A/2B antagonist activity",
      "label": "has"
    },
    {
      "source": "DOI-elicited-HTR",
      "target": "C57Bl/6J mice",
      "label": "occurs in"
    },
    {
      "source": "DOI-elicited-HTR",
      "target": "C57Bl/6J",
      "label": "occurs in"
    },
    {
      "source": "affinities",
      "target": "mouse",
      "label": "at"
    },
    {
      "source": "affinities",
      "target": "human 5-HT2A",
      "label": "at"
    },
    {
      "source": "affinities",
      "target": "5-HT2C receptors",
      "label": "at"
    },
    {
      "source": "affinities",
      "target": "osteoblasts",
      "label": "OCCURS_IN"
    },
    {
      "source": "literature",
      "target": "glucocorticoid stress-response (GSR)",
      "label": "associates"
    },
    {
      "source": "PAT",
      "target": "PAT-type 5-HT2C agonists",
      "label": "is a type of"
    },
    {
      "source": "SB-206553",
      "target": "5-HT2B/2C",
      "label": "is an antagonist for"
    },
    {
      "source": "SB-206553",
      "target": "dose-dependent biphasic effects",
      "label": "resulted in"
    },
    {
      "source": "SB-206553",
      "target": "DOI-elicited-HTR",
      "label": "attenuated"
    },
    {
      "source": "PLC",
      "target": "phospholipase C",
      "label": "is also known as"
    },
    {
      "source": "PLC",
      "target": "Gq-phospholipase C",
      "label": "is also known as"
    },
    {
      "source": "M100907",
      "target": "5-HT2A",
      "label": "is an antagonist for"
    },
    {
      "source": "M100907",
      "target": "locomotion",
      "label": "decreased"
    },
    {
      "source": "M100907",
      "target": "DOI-elicited-HTR",
      "label": "attenuated"
    },
    {
      "source": "differential effects",
      "target": "locomotion",
      "label": "on"
    },
    {
      "source": "DOI",
      "target": "mouse head-twitch response",
      "label": "elicits"
    },
    {
      "source": "DOI",
      "target": "hallucinogenic 5-HT2A/2B/2C receptor agonist",
      "label": "is a type of"
    },
    {
      "source": "DOI",
      "target": "2,5-dimethoxy-4-iodoamphetamine",
      "label": "is also known as"
    },
    {
      "source": "DOI",
      "target": "HTR",
      "label": "elicits"
    },
    {
      "source": "DOI",
      "target": "mouse 5-HT2C receptor-mediated PLC signaling",
      "label": "activates"
    },
    {
      "source": "mouse head-twitch response",
      "target": "HTR",
      "label": "is also known as"
    },
    {
      "source": "dose-dependent biphasic effects",
      "target": "locomotion",
      "label": "on"
    },
    {
      "source": "hallucinogenic 5-HT2A/2B/2C receptor agonist",
      "target": "DOI",
      "label": "is"
    },
    {
      "source": "C57Bl/6J",
      "target": "strain of mice",
      "label": "is a type of"
    },
    {
      "source": "5-HT2C receptor-mediated Gq-phospholipase C (PLC) signaling",
      "target": "Gq-phospholipase C",
      "label": "involves"
    },
    {
      "source": "5-HT2C receptor-mediated Gq-phospholipase C (PLC) signaling",
      "target": "PLC",
      "label": "involves"
    },
    {
      "source": "5-HT2C receptor-mediated Gq-phospholipase C (PLC) signaling",
      "target": "phospholipase C",
      "label": "involves"
    },
    {
      "source": "Gq-phospholipase C",
      "target": "PLC",
      "label": "is also known as"
    },
    {
      "source": "WAY 161503",
      "target": "5-HT2C receptor agonists",
      "label": "is a type of"
    },
    {
      "source": "5-HT2C receptor agonists",
      "target": "locomotion",
      "label": "decreased"
    },
    {
      "source": "5-HT2C receptor agonists",
      "target": "DOI-elicited-HTR",
      "label": "attenuated"
    },
    {
      "source": "5-HT2C receptor agonists",
      "target": "HTR response",
      "label": "attenuate"
    },
    {
      "source": "5-HT2C receptor agonists",
      "target": "efficacy",
      "label": "reduced"
    },
    {
      "source": "functional selectivity",
      "target": "5-HT2C receptor ligands",
      "label": "utilizes"
    },
    {
      "source": "functional selectivity",
      "target": "head-twitch response model",
      "label": "utilizes"
    },
    {
      "source": "functional selectivity",
      "target": "in vivo",
      "label": "occurs in"
    },
    {
      "source": "functional selectivity",
      "target": "structurally diverse 5-HT2C ligands",
      "label": "utilizes"
    },
    {
      "source": "mouse 5-HT2C receptor-mediated PLC signaling",
      "target": "HEK cells",
      "label": "occurs in"
    },
    {
      "source": "Ro 60-0175",
      "target": "5-HT2C receptor agonists",
      "label": "is a type of"
    },
    {
      "source": "SB-242084",
      "target": "5-HT2C receptor",
      "label": "is an antagonist for"
    },
    {
      "source": "SB-242084",
      "target": "locomotion",
      "label": "increased"
    },
    {
      "source": "SB-242084",
      "target": "DOI-elicited-HTR",
      "label": "attenuated"
    },
    {
      "source": "5-HT2C receptor",
      "target": "functional selectivity",
      "label": "has"
    },
    {
      "source": "2,5-dimethoxy-4-iodoamphetamine",
      "target": "DOI",
      "label": "is also known as"
    },
    {
      "source": "2,5-dimethoxy-4-iodoamphetamine",
      "target": "head-twitch response model",
      "label": "elicits"
    },
    {
      "source": "HTR",
      "target": "mouse head-twitch response",
      "label": "is also known as"
    },
    {
      "source": "CP 809101",
      "target": "5-HT2C receptor agonists",
      "label": "is a type of"
    },
    {
      "source": "PATs",
      "target": "locomotion",
      "label": "did not alter"
    },
    {
      "source": "structurally diverse 5-HT2C ligands",
      "target": "5-HT2C receptor signaling outcomes",
      "label": "result in"
    },
    {
      "source": "mCPP",
      "target": "5-HT2C receptor agonists",
      "label": "is a type of"
    },
    {
      "source": "mCPP",
      "target": "i.v. injection",
      "label": "administered_via"
    },
    {
      "source": "mCPP",
      "target": "exploratory activity",
      "label": "reduces"
    },
    {
      "source": "mCPP",
      "target": "exploratory behaviour",
      "label": "reduces"
    },
    {
      "source": "mCPP",
      "target": "intravenous administration",
      "label": "administered_via"
    },
    {
      "source": "mCPP",
      "target": "ACTH levels",
      "label": "increases"
    },
    {
      "source": "mCPP",
      "target": "plasma prolactin",
      "label": "increases"
    },
    {
      "source": "mCPP",
      "target": "intraperitoneal administration",
      "label": "administered_via"
    },
    {
      "source": "mCPP",
      "target": "subcutaneous administration",
      "label": "administered_via"
    },
    {
      "source": "classes of 5-HT2C receptor compounds",
      "target": "DOI-elicited-HTR",
      "label": "attenuate"
    },
    {
      "source": "1-methylpsilocin",
      "target": "5-HT2C receptor agonists",
      "label": "is a type of"
    },
    {
      "source": "in vitro molecular pharmacology studies",
      "target": "efficacy",
      "label": "showed"
    },
    {
      "source": "5-HT2C receptor signaling outcomes",
      "target": "DOI",
      "label": "different compared to"
    },
    {
      "source": "4-phenyl-2-N,N-dimethyl-aminotetralin",
      "target": "PAT-type 5-HT2C agonists",
      "label": "is a type of"
    },
    {
      "source": "causal genes",
      "target": "susceptibility loci",
      "label": "are located in"
    },
    {
      "source": "gain- and loss-of-function of \u03b1-synuclein",
      "target": "\u03b2-cells",
      "label": "occurs in"
    },
    {
      "source": "gain- and loss-of-function of \u03b1-synuclein",
      "target": "autophagy",
      "label": "impair"
    },
    {
      "source": "gain- and loss-of-function of \u03b1-synuclein",
      "target": "glucose stimulated insulin secretion (GSIS)",
      "label": "impair"
    },
    {
      "source": "\u03b2-cells",
      "target": "Ide knock-out (KO) mice",
      "label": "are from"
    },
    {
      "source": "\u03b1-synuclein levels",
      "target": "T2D patients",
      "label": "are found in"
    },
    {
      "source": "\u03b1-synuclein levels",
      "target": "\u03b2-cells",
      "label": "are found in"
    },
    {
      "source": "\u03b1-synuclein levels",
      "target": "IDE levels",
      "label": "are inversely correlated with"
    },
    {
      "source": "Ide gene",
      "target": "haploinsufficient",
      "label": "is"
    },
    {
      "source": "Ide gene",
      "target": "glucose stimulated insulin secretion (GSIS)",
      "label": "is a regulator of"
    },
    {
      "source": "IDE levels",
      "target": "T2D patients",
      "label": "are found in"
    },
    {
      "source": "IDE levels",
      "target": "\u03b2-cells",
      "label": "are found in"
    },
    {
      "source": "\u03b2-cell degeneration",
      "target": "Ide deficiency",
      "label": "is a consequence of"
    },
    {
      "source": "\u03b2-cell function",
      "target": "Ide knock-out (KO) mice",
      "label": "assessed in"
    },
    {
      "source": "IDE",
      "target": "neutralization of amyloidogenic proteins",
      "label": "is involved in"
    },
    {
      "source": "neutralization of amyloidogenic proteins",
      "target": "amyloidogenic proteins",
      "label": "acts on"
    },
    {
      "source": "Ide",
      "target": "suppression of \u03b1-synuclein levels",
      "label": "is required for"
    },
    {
      "source": "Ide",
      "target": "insulin secretion",
      "label": "is required for"
    },
    {
      "source": "Ide",
      "target": "type 2 diabetes",
      "label": "is associated with"
    },
    {
      "source": "suppression of \u03b1-synuclein levels",
      "target": "\u03b2-cells",
      "label": "occurs in"
    },
    {
      "source": "autophagic flux",
      "target": "\u03b2-cells",
      "label": "is reduced in"
    },
    {
      "source": "autophagic flux",
      "target": "p62",
      "label": "blockage results in sequestration of"
    },
    {
      "source": "autophagic flux",
      "target": "LC3",
      "label": "blockage results in sequestration of"
    },
    {
      "source": "autophagic flux",
      "target": "Keap1",
      "label": "blockage results in sequestration of"
    },
    {
      "source": "autophagic flux",
      "target": "autophagosomes",
      "label": "blockage results in accumulation of"
    },
    {
      "source": "type 2 diabetes (T2D) risk loci",
      "target": "impaired \u03b2-cell function",
      "label": "linked to"
    },
    {
      "source": "glucose stimulated insulin secretion (GSIS)",
      "target": "impaired replenishment of the releasable pool of granules",
      "label": "is decreased due to"
    },
    {
      "source": "glucose stimulated insulin secretion (GSIS)",
      "target": "Ide knock-out (KO) mice",
      "label": "is decreased in"
    },
    {
      "source": "microtubule content",
      "target": "\u03b2-cells",
      "label": "is reduced in"
    },
    {
      "source": "Genome wide association studies",
      "target": "type 2 diabetes (T2D) risk loci",
      "label": "identified"
    },
    {
      "source": "HHEX/IDE T2D locus",
      "target": "insulin secretion",
      "label": "is associated with"
    },
    {
      "source": "autophagic signaling",
      "target": "ROS production",
      "label": "protects from"
    },
    {
      "source": "autophagic signaling",
      "target": "LC3-II expression",
      "label": "evidenced by increase of"
    },
    {
      "source": "autophagic signaling",
      "target": "cells",
      "label": "protects"
    },
    {
      "source": "autophagic signaling",
      "target": "cell death",
      "label": "protects from"
    },
    {
      "source": "autophagic signaling",
      "target": "Beclin-1",
      "label": "evidenced by increase of"
    },
    {
      "source": "autophagic signaling",
      "target": "ATG 5-12",
      "label": "evidenced by increase of"
    },
    {
      "source": "cobalt chloride",
      "target": "hypoxia mimetic CoCl(2)",
      "label": "is a"
    },
    {
      "source": "cobalt chloride",
      "target": "proteasomal HIF-1 degradation",
      "label": "inhibits"
    },
    {
      "source": "cobalt chloride",
      "target": "HIF-1",
      "label": "upregulates"
    },
    {
      "source": "cobalt chloride",
      "target": "reactive oxygen species",
      "label": "generates"
    },
    {
      "source": "hypoxia mimetic CoCl(2)",
      "target": "p53 stabilization",
      "label": "induces"
    },
    {
      "source": "Solid tumors",
      "target": "neuroblastoma",
      "label": "include"
    },
    {
      "source": "neuroblastoma",
      "target": "hypoxic areas",
      "label": "exhibits"
    },
    {
      "source": "autophagic inhibitors",
      "target": "apoptotic signaling",
      "label": "activates"
    },
    {
      "source": "autophagic inhibitors",
      "target": "cell death",
      "label": "enhances"
    },
    {
      "source": "Autophagy",
      "target": "mutated p53 neuroblastoma cells",
      "label": "occurs in"
    },
    {
      "source": "Autophagy",
      "target": "p53(wt)",
      "label": "not effective with"
    },
    {
      "source": "Autophagy",
      "target": "inactivated p53",
      "label": "effective with"
    },
    {
      "source": "Autophagy",
      "target": "hypoxia mimetic CoCl(2)",
      "label": "induced by"
    },
    {
      "source": "Autophagy",
      "target": "p53(mut)",
      "label": "effective with"
    },
    {
      "source": "p53 location",
      "target": "Autophagy",
      "label": "affects"
    },
    {
      "source": "Hypoxia",
      "target": "p53 stabilization",
      "label": "induces"
    },
    {
      "source": "Hypoxia",
      "target": "stress",
      "label": "is a"
    },
    {
      "source": "CoCl2",
      "target": "cell death",
      "label": "induces"
    },
    {
      "source": "CoCl2",
      "target": "p53(mut)",
      "label": "downregulates"
    },
    {
      "source": "hypoxic areas",
      "target": "cell death",
      "label": "leads to"
    },
    {
      "source": "hypoxic areas",
      "target": "aggressiveness increase",
      "label": "leads to"
    },
    {
      "source": "autophagic process",
      "target": "Hypoxia",
      "label": "responds to"
    },
    {
      "source": "transcriptional activity inhibition",
      "target": "p53(WT)SHSY5Y cells",
      "label": "affects"
    },
    {
      "source": "proteasomal HIF-1 degradation",
      "target": "HIF-1",
      "label": "involves"
    },
    {
      "source": "p53(mut)",
      "target": "apoptotic response",
      "label": "linked with"
    },
    {
      "source": "p53(mut)",
      "target": "neuroblastoma",
      "label": "located in"
    },
    {
      "source": "p53(mut)",
      "target": "cell death",
      "label": "linked with"
    },
    {
      "source": "p53(mut)",
      "target": "CoCl2 time exposure",
      "label": "decreases with"
    },
    {
      "source": "p53(mut)",
      "target": "autophagic process",
      "label": "implicated in"
    },
    {
      "source": "p53(mut)",
      "target": "hypoxic mimetic stress",
      "label": "responds to"
    },
    {
      "source": "shRNA-p53 down-regulation",
      "target": "p53(WT)SHSY5Y cells",
      "label": "affects"
    },
    {
      "source": "SKNBE(2c)",
      "target": "DNA-binding mutated p53 neuroblastoma cell line",
      "label": "is a"
    },
    {
      "source": "pifithrin alpha",
      "target": "transcriptional activity inhibition",
      "label": "causes"
    },
    {
      "source": "large range of concentrations",
      "target": "age",
      "label": "depends on"
    },
    {
      "source": "large range of concentrations",
      "target": "dietary habits",
      "label": "depends on"
    },
    {
      "source": "large range of concentrations",
      "target": "lifestyle",
      "label": "depends on"
    },
    {
      "source": "large range of concentrations",
      "target": "geological location",
      "label": "depends on"
    },
    {
      "source": "4 organic chemicals (NCM1)",
      "target": "Northerners' blood",
      "label": "were detected in"
    },
    {
      "source": "4 organic chemicals (NCM1)",
      "target": "2004-2005",
      "label": "detected during"
    },
    {
      "source": "human coronary artery endothelial cells",
      "target": "very-low-density lipoprotein",
      "label": "treated in presence/absence of"
    },
    {
      "source": "human coronary artery endothelial cells",
      "target": "glucose",
      "label": "treated in presence/absence of"
    },
    {
      "source": "human coronary artery endothelial cells",
      "target": "two mixtures",
      "label": "were treated with"
    },
    {
      "source": "human coronary artery endothelial cells",
      "target": "low-density lipoprotein",
      "label": "treated in presence/absence of"
    },
    {
      "source": "human coronary artery endothelial cells",
      "target": "0.1% ethanol",
      "label": "treated in presence/absence of"
    },
    {
      "source": "very-low-density lipoprotein",
      "target": "LVG",
      "label": "is part of"
    },
    {
      "source": "NCM2",
      "target": "cell viability",
      "label": "decreased"
    },
    {
      "source": "NCM2",
      "target": "endothelial nitric oxide synthase (eNOS) protein expression",
      "label": "decreased"
    },
    {
      "source": "NCM2",
      "target": "uptake of small peptides",
      "label": "decreased"
    },
    {
      "source": "NCM2",
      "target": "total protein yield",
      "label": "decreased"
    },
    {
      "source": "NCM2",
      "target": "PAI",
      "label": "caused no changes in"
    },
    {
      "source": "NCM2",
      "target": "membrane damage",
      "label": "caused"
    },
    {
      "source": "NCM2",
      "target": "prostacyclin",
      "label": "caused no changes in"
    },
    {
      "source": "NCM2",
      "target": "nitric oxide (NO) release",
      "label": "decreased"
    },
    {
      "source": "NCM2",
      "target": "secretion of ET-1",
      "label": "caused no changes in"
    },
    {
      "source": "culture conditions",
      "target": "ethanol exposure",
      "label": "typifying"
    },
    {
      "source": "culture conditions",
      "target": "high fat/sugar diet",
      "label": "typifying"
    },
    {
      "source": "ethanol exposure",
      "target": "endothelial dysfunction",
      "label": "influenced"
    },
    {
      "source": "LVG",
      "target": "endpoint",
      "label": "influence depended on"
    },
    {
      "source": "LVG",
      "target": "mixture",
      "label": "influence depended on"
    },
    {
      "source": "LVG",
      "target": "effects of NCMs",
      "label": "influenced"
    },
    {
      "source": "Northern contaminant mixtures",
      "target": "morphological and functional changes",
      "label": "induced"
    },
    {
      "source": "Northern contaminant mixtures",
      "target": "human coronary artery endothelial cells",
      "label": "induced changes in"
    },
    {
      "source": "Northern contaminant mixtures",
      "target": "large range of concentrations",
      "label": "are present at"
    },
    {
      "source": "morphological and functional changes",
      "target": "culture conditions",
      "label": "occurred under"
    },
    {
      "source": "Northern populations",
      "target": "mixtures of various environmental contaminants",
      "label": "are exposed to"
    },
    {
      "source": "mixtures of various environmental contaminants",
      "target": "Northern contaminant mixtures",
      "label": "are also known as"
    },
    {
      "source": "mixtures of various environmental contaminants",
      "target": "Arctic",
      "label": "are unique to"
    },
    {
      "source": "22 organic and inorganic chemicals (NCM2)",
      "target": "Northerners' blood",
      "label": "were detected in"
    },
    {
      "source": "22 organic and inorganic chemicals (NCM2)",
      "target": "2004-2005",
      "label": "detected during"
    },
    {
      "source": "two mixtures",
      "target": "4 organic chemicals (NCM1)",
      "label": "include"
    },
    {
      "source": "two mixtures",
      "target": "22 organic and inorganic chemicals (NCM2)",
      "label": "include"
    },
    {
      "source": "NCM1 treatment",
      "target": "nitric oxide (NO) release",
      "label": "caused no changes in"
    },
    {
      "source": "NCM1 treatment",
      "target": "uptake of small peptides",
      "label": "decreased"
    },
    {
      "source": "NCM1 treatment",
      "target": "plasminogen activator inhibitor (PAI)",
      "label": "decreased"
    },
    {
      "source": "NCM1 treatment",
      "target": "cell density",
      "label": "decreased"
    },
    {
      "source": "NCM1 treatment",
      "target": "endothelial nitric oxide synthase (eNOS) protein expression",
      "label": "caused no changes in"
    },
    {
      "source": "NCM1 treatment",
      "target": "cell size",
      "label": "increased"
    },
    {
      "source": "NCM1 treatment",
      "target": "cell viability",
      "label": "did not affect"
    },
    {
      "source": "NCM1 treatment",
      "target": "cell membrane integrity",
      "label": "disrupted"
    },
    {
      "source": "NCM1 treatment",
      "target": "release of endothelin-1 (ET-1)",
      "label": "decreased"
    },
    {
      "source": "one or one group of contaminants",
      "target": "contaminants",
      "label": "may be altered by"
    },
    {
      "source": "contaminants",
      "target": "high fat/sugar diet",
      "label": "combined with"
    },
    {
      "source": "contaminants",
      "target": "cardiovascular health risk",
      "label": "may contribute to"
    },
    {
      "source": "contaminants",
      "target": "ethanol exposure",
      "label": "combined with"
    },
    {
      "source": "cell morphology",
      "target": "24h of exposure",
      "label": "examined after"
    },
    {
      "source": "effects of NCMs",
      "target": "in vivo",
      "label": "occur"
    },
    {
      "source": "NCMs",
      "target": "endothelial dysfunction",
      "label": "caused"
    },
    {
      "source": "NCMs",
      "target": "concentrations",
      "label": "caused endothelial dysfunction at"
    },
    {
      "source": "NCMs",
      "target": "in vitro",
      "label": "caused endothelial dysfunction"
    },
    {
      "source": "markers of cytotoxicity",
      "target": "24h of exposure",
      "label": "examined after"
    },
    {
      "source": "endothelial function",
      "target": "24h of exposure",
      "label": "examined after"
    },
    {
      "source": "low-density lipoprotein",
      "target": "LVG",
      "label": "is part of"
    },
    {
      "source": "interaction of high fat and sugar diet",
      "target": "endothelial dysfunction",
      "label": "influenced"
    },
    {
      "source": "metabolic activities",
      "target": "cytochrome P450 (CYP) isozymes",
      "label": "are of"
    },
    {
      "source": "metabolic activities",
      "target": "rats",
      "label": "are in"
    },
    {
      "source": "metabolic activities",
      "target": "five-drug cocktail approach",
      "label": "evaluated by"
    },
    {
      "source": "influence of IR and IPC",
      "target": "activities of CYP1A2",
      "label": "affects"
    },
    {
      "source": "influence of IR and IPC",
      "target": "CYP2D6",
      "label": "affects activities of"
    },
    {
      "source": "influence of IR and IPC",
      "target": "CYP2C9",
      "label": "affects activities of"
    },
    {
      "source": "influence of IR and IPC",
      "target": "CYP2E1",
      "label": "affects activities of"
    },
    {
      "source": "influence of IR and IPC",
      "target": "CYP3A4",
      "label": "affects activities of"
    },
    {
      "source": "activities of CYP1A2",
      "target": "pharmacokinetic parameters",
      "label": "reflected by"
    },
    {
      "source": "K(10)",
      "target": "IPC group",
      "label": "lower in"
    },
    {
      "source": "K(10)",
      "target": "five probe drugs",
      "label": "are of"
    },
    {
      "source": "K(10)",
      "target": "IR group",
      "label": "lower in"
    },
    {
      "source": "pharmacokinetic parameters",
      "target": "five specific probe drugs",
      "label": "are of"
    },
    {
      "source": "pharmacokinetic parameters",
      "target": "software of DAS 2.0",
      "label": "calculated by"
    },
    {
      "source": "pharmacokinetic parameters",
      "target": "treatments",
      "label": "were compared between"
    },
    {
      "source": "pharmacokinetic parameters",
      "target": "CXM",
      "label": "are of"
    },
    {
      "source": "IPC",
      "target": "CYP isozymes",
      "label": "attenuates decrease of"
    },
    {
      "source": "IPC",
      "target": "metabolic activities",
      "label": "evaluates effects on"
    },
    {
      "source": "IPC",
      "target": "activities of cytochrome P450 isozymes",
      "label": "affects"
    },
    {
      "source": "five specific probe drugs",
      "target": "metoprolol",
      "label": "include"
    },
    {
      "source": "five specific probe drugs",
      "target": "tolbutamide",
      "label": "include"
    },
    {
      "source": "five specific probe drugs",
      "target": "chlorzoxazone",
      "label": "include"
    },
    {
      "source": "five specific probe drugs",
      "target": "caffeine",
      "label": "include"
    },
    {
      "source": "five specific probe drugs",
      "target": "midazolam",
      "label": "include"
    },
    {
      "source": "t(1/2\u03b2)",
      "target": "IPC group",
      "label": "increased in"
    },
    {
      "source": "t(1/2\u03b2)",
      "target": "five probe drugs",
      "label": "are of"
    },
    {
      "source": "t(1/2\u03b2)",
      "target": "IR group",
      "label": "increased in"
    },
    {
      "source": "CLs",
      "target": "IR group",
      "label": "decreased in"
    },
    {
      "source": "CLs",
      "target": "IPC group",
      "label": "lower in"
    },
    {
      "source": "CLs",
      "target": "five probe drugs",
      "label": "are of"
    },
    {
      "source": "activities of cytochrome P450 isozymes",
      "target": "five-drug cocktail approach",
      "label": "assessed by"
    },
    {
      "source": "activities of cytochrome P450 isozymes",
      "target": "rats",
      "label": "are in"
    },
    {
      "source": "tolbutamide",
      "target": "CYP2E1",
      "label": "is probe drug for"
    },
    {
      "source": "cocktail approach",
      "target": "influence of IR and IPC",
      "label": "used to evaluate"
    },
    {
      "source": "chlorzoxazone",
      "target": "CYP2C9",
      "label": "is probe drug for"
    },
    {
      "source": "concentrations of probe drugs",
      "target": "plasma",
      "label": "are in"
    },
    {
      "source": "concentrations of probe drugs",
      "target": "HPLC method",
      "label": "determined by"
    },
    {
      "source": "CYP2E1",
      "target": "pharmacokinetic parameters",
      "label": "activities reflected by"
    },
    {
      "source": "Blood samples",
      "target": "time-points",
      "label": "collected at"
    },
    {
      "source": "HPLC method",
      "target": "UV detection",
      "label": "uses"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "acylethanolamide derivatives",
      "label": "is_a"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "injections",
      "label": "administered_via"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "POMC",
      "label": "up_regulated"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "FAAH mRNA expression",
      "label": "down_regulated"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "1 mg/kg i.p.",
      "label": "has_dosage"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "CART",
      "label": "up_regulated"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "body weight",
      "label": "decreased"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "39 days",
      "label": "has_duration"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "antiobesity compounds",
      "label": "is_an"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "mice",
      "label": "investigated_in"
    },
    {
      "source": "oleoyl-D-valinolamide",
      "target": "CaMKK2",
      "label": "down_regulated"
    },
    {
      "source": "acylethanolamide derivatives",
      "target": "body weight",
      "label": "modulates"
    },
    {
      "source": "acylethanolamide derivatives",
      "target": "POMC",
      "label": "enhances"
    },
    {
      "source": "acylethanolamide derivatives",
      "target": "NPY",
      "label": "decreases"
    },
    {
      "source": "acylethanolamide derivatives",
      "target": "neuropeptide Y",
      "label": "decreases"
    },
    {
      "source": "acylethanolamide derivatives",
      "target": "hypothalamic pro-opiomelanocortin",
      "label": "enhances"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "1 mg/kg i.p.",
      "label": "has_dosage"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "mice",
      "label": "investigated_in"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "NPY",
      "label": "down_regulated"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "acylethanolamide derivatives",
      "label": "is_a"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "39 days",
      "label": "has_duration"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "antiobesity compounds",
      "label": "is_an"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "injections",
      "label": "administered_via"
    },
    {
      "source": "palmitoyl-L-valinolamide",
      "target": "body weight",
      "label": "decreased"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "POMC",
      "label": "up_regulated"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "injections",
      "label": "administered_via"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "1 mg/kg i.p.",
      "label": "has_dosage"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "FAAH mRNA expression",
      "label": "down_regulated"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "body weight",
      "label": "decreased"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "39 days",
      "label": "has_duration"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "NPY",
      "label": "down_regulated"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "antiobesity compounds",
      "label": "is_an"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "acylethanolamide derivatives",
      "label": "is_a"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "mice",
      "label": "investigated_in"
    },
    {
      "source": "stearoyl-L-valinolamide",
      "target": "CaMKK2",
      "label": "down_regulated"
    },
    {
      "source": "POMC",
      "target": "anorexigenic genes",
      "label": "is_a"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "locomotor activity",
      "label": "enhanced"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "orally",
      "label": "can_be_administered"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "1 mg/kg i.p.",
      "label": "has_dosage"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "CART",
      "label": "up_regulated"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "FAAH mRNA expression",
      "label": "down_regulated"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "body weight",
      "label": "decreased"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "glucose levels",
      "label": "decreased"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "NPY",
      "label": "down_regulated"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "39 days",
      "label": "has_duration"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "mice",
      "label": "investigated_in"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "acylethanolamide derivatives",
      "label": "is_a"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "antiobesity compounds",
      "label": "is_an"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "anorectic pathways",
      "label": "enhances"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "CaMKK2",
      "label": "down_regulated"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "cognition",
      "label": "improved"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "POMC",
      "label": "up_regulated"
    },
    {
      "source": "oleoyl-L-valinolamide",
      "target": "injections",
      "label": "administered_via"
    },
    {
      "source": "Receptor binding",
      "target": "TRPV1 receptors",
      "label": "indicated_no_activation_of"
    },
    {
      "source": "Receptor binding",
      "target": "CB2 receptors",
      "label": "indicated_no_activation_of"
    },
    {
      "source": "Receptor binding",
      "target": "PPAR\u03b1 receptors",
      "label": "indicated_no_activation_of"
    },
    {
      "source": "Receptor binding",
      "target": "CB1 receptors",
      "label": "indicated_no_activation_of"
    },
    {
      "source": "elaidoyl-L-valinolamide",
      "target": "mice",
      "label": "investigated_in"
    },
    {
      "source": "elaidoyl-L-valinolamide",
      "target": "antiobesity compounds",
      "label": "is_an"
    },
    {
      "source": "elaidoyl-L-valinolamide",
      "target": "acylethanolamide derivatives",
      "label": "is_a"
    },
    {
      "source": "elaidoyl-L-valinolamide",
      "target": "body weight",
      "label": "no_effect_on"
    },
    {
      "source": "CART",
      "target": "anorexigenic genes",
      "label": "is_a"
    },
    {
      "source": "elaidoyl-D-valinolamide",
      "target": "FAAH mRNA expression",
      "label": "down_regulated"
    },
    {
      "source": "elaidoyl-D-valinolamide",
      "target": "body weight",
      "label": "no_effect_on"
    },
    {
      "source": "elaidoyl-D-valinolamide",
      "target": "antiobesity compounds",
      "label": "is_an"
    },
    {
      "source": "elaidoyl-D-valinolamide",
      "target": "mice",
      "label": "investigated_in"
    },
    {
      "source": "elaidoyl-D-valinolamide",
      "target": "acylethanolamide derivatives",
      "label": "is_a"
    },
    {
      "source": "Hypothalamic RT-PCR",
      "target": "mRNA expression",
      "label": "showed_up_regulation_of"
    },
    {
      "source": "mRNA expression",
      "target": "p21(CIP1/WAF1)",
      "label": "is of"
    },
    {
      "source": "mRNA expression",
      "target": "OATP1B1",
      "label": "of"
    },
    {
      "source": "mRNA expression",
      "target": "selected genes",
      "label": "is of"
    },
    {
      "source": "CaMKK2",
      "target": "orexigenic genes",
      "label": "is_a"
    },
    {
      "source": "CYP3A4/5 substrate probe",
      "target": "alfentanil",
      "label": "is"
    },
    {
      "source": "CYP2B6 inhibition",
      "target": "methadone concentrations",
      "label": "alters"
    },
    {
      "source": "CYP2B6 inhibition",
      "target": "clearance",
      "label": "reduces"
    },
    {
      "source": "CYP2B6 inhibition",
      "target": "Methadone N-demethylation",
      "label": "reduces"
    },
    {
      "source": "dose-adjusted plasma area under the curve",
      "target": "R- and S-methadone",
      "label": "for"
    },
    {
      "source": "R- and S-methadone",
      "target": "oral dosing",
      "label": "administered via"
    },
    {
      "source": "R- and S-methadone",
      "target": "intravenous dosing",
      "label": "administered via"
    },
    {
      "source": "deuterium-labeled racemic methadone",
      "target": "oral dosing",
      "label": "administered via"
    },
    {
      "source": "deuterium-labeled racemic methadone",
      "target": "intravenous dosing",
      "label": "administered via"
    },
    {
      "source": "deuterium-labeled racemic methadone",
      "target": "deuterium",
      "label": "contains"
    },
    {
      "source": "deuterium-labeled racemic methadone",
      "target": "racemic methadone",
      "label": "is a type of"
    },
    {
      "source": "CYP2B6",
      "target": "Methadone N-demethylation",
      "label": "responsible for"
    },
    {
      "source": "CYP2B6",
      "target": "clinical disposition",
      "label": "has important role in"
    },
    {
      "source": "CYP2B6",
      "target": "CYP isoform",
      "label": "is a"
    },
    {
      "source": "CYP2B6",
      "target": "clearance",
      "label": "responsible for"
    },
    {
      "source": "clinical disposition",
      "target": "CYP3A4",
      "label": "attributed to"
    },
    {
      "source": "preliminary clinical investigation",
      "target": "CYP3A4/5 substrate probe",
      "label": "used"
    },
    {
      "source": "cytochrome P4502B6",
      "target": "methadone metabolism",
      "label": "involved in"
    },
    {
      "source": "cytochrome P4502B6",
      "target": "clearance",
      "label": "involved in"
    },
    {
      "source": "hepatic cytochrome P4502B6",
      "target": "Methadone N-demethylation",
      "label": "catalyzes"
    },
    {
      "source": "mechanism-based CYP2B6 inhibitor",
      "target": "CYP2B6",
      "label": "inhibits"
    },
    {
      "source": "Integrin-based adhesions",
      "target": "cell motility",
      "label": "promote"
    },
    {
      "source": "Integrin-based adhesions",
      "target": "cell survival",
      "label": "promote"
    },
    {
      "source": "Integrin-based adhesions",
      "target": "invasion",
      "label": "promote"
    },
    {
      "source": "isoforms 1 and 4",
      "target": "cell death",
      "label": "increases when knocked down"
    },
    {
      "source": "isoforms 1 and 4",
      "target": "p53",
      "label": "increases when knocked down"
    },
    {
      "source": "RNAi",
      "target": "isoforms 1 and 4",
      "label": "mediates knockdown of"
    },
    {
      "source": "RNAi",
      "target": "splice form of supervillin (isoform 4)",
      "label": "mediates knockdown of"
    },
    {
      "source": "p53 knockdown",
      "target": "cell metabolic activity",
      "label": "rescues"
    },
    {
      "source": "cell metabolic activity",
      "target": "cell proliferation",
      "label": "is a measure of"
    },
    {
      "source": "interaction partners",
      "target": "cell-substrate adhesion",
      "label": "are at sites of"
    },
    {
      "source": "HAUSP",
      "target": "p53 deubiquitinating enzyme",
      "label": "is a type of"
    },
    {
      "source": "etoposide",
      "target": "DNA damage",
      "label": "induces"
    },
    {
      "source": "supervillin overexpression",
      "target": "USP7-mediated p53 deubiquitination",
      "label": "attenuates"
    },
    {
      "source": "supervillin overexpression",
      "target": "p53",
      "label": "causes decrease in"
    },
    {
      "source": "supervillin overexpression",
      "target": "USP7 and p53 association",
      "label": "decreases"
    },
    {
      "source": "Supervillin",
      "target": "cell survival",
      "label": "increases"
    },
    {
      "source": "Supervillin",
      "target": "p53 protein",
      "label": "suppresses"
    },
    {
      "source": "Supervillin",
      "target": "downstream target genes",
      "label": "decreases levels of"
    },
    {
      "source": "Supervillin",
      "target": "p53",
      "label": "decreases levels of"
    },
    {
      "source": "Supervillin",
      "target": "adhesion regulatory protein",
      "label": "is a type of"
    },
    {
      "source": "Supervillin",
      "target": "locus",
      "label": "constitutes"
    },
    {
      "source": "Supervillin",
      "target": "interaction partners",
      "label": "has"
    },
    {
      "source": "USP7",
      "target": "supervillin phenotype",
      "label": "reverses when knocked down"
    },
    {
      "source": "USP7",
      "target": "p53",
      "label": "blocks increase in when knocked down"
    },
    {
      "source": "USP7",
      "target": "supervillin N terminus",
      "label": "binds to"
    },
    {
      "source": "USP7",
      "target": "Supervillin",
      "label": "deubiquitinates"
    },
    {
      "source": "USP7",
      "target": "p53 deubiquitinating enzyme",
      "label": "is a type of"
    },
    {
      "source": "locus",
      "target": "cross-talk",
      "label": "for"
    },
    {
      "source": "cross-talk",
      "target": "cell motility pathways",
      "label": "is between"
    },
    {
      "source": "cross-talk",
      "target": "survival signaling",
      "label": "is between"
    },
    {
      "source": "cross-talk",
      "target": "ErbB1",
      "label": "is between"
    },
    {
      "source": "cross-talk",
      "target": "ErbB3 signaling pathways",
      "label": "is between"
    },
    {
      "source": "splice form of supervillin (isoform 4)",
      "target": "cell death",
      "label": "increases when knocked down"
    },
    {
      "source": "splice form of supervillin (isoform 4)",
      "target": "p53",
      "label": "increases when knocked down"
    },
    {
      "source": "p53 inhibition",
      "target": "cell metabolic activity",
      "label": "rescues"
    },
    {
      "source": "SUMO1",
      "target": "ubiquitin-like protein",
      "label": "is a type of"
    },
    {
      "source": "SUMO1",
      "target": "Supervillin",
      "label": "stabilizes"
    },
    {
      "source": "supervillin knockdown cells",
      "target": "p53",
      "label": "causes increase in"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "fluorouracil",
      "label": "treated with"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "camptosar",
      "label": "treated with"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "5-FU",
      "label": "treated with"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "leucovorin",
      "label": "treated with"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "folic acid",
      "label": "treated with"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "irinotecan (camptosar)-based regimens",
      "label": "treated with"
    },
    {
      "source": "advanced colorectal cancer patients",
      "target": "irinotecan",
      "label": "treated with"
    },
    {
      "source": "novel genetic markers",
      "target": "250 Italian FOLFIRI-treated patients",
      "label": "investigated in"
    },
    {
      "source": "novel genetic markers",
      "target": "irinotecan toxicity",
      "label": "improve prediction of"
    },
    {
      "source": "novel genetic markers",
      "target": "response",
      "label": "improve prediction of"
    },
    {
      "source": "250 Italian FOLFIRI-treated patients",
      "target": "FOLFIRI",
      "label": "treated with"
    },
    {
      "source": "5-marker risk haplotype",
      "target": "P value",
      "label": "has"
    },
    {
      "source": "5-marker risk haplotype",
      "target": "odds ratio (OR)",
      "label": "has"
    },
    {
      "source": "5-marker risk haplotype",
      "target": "haplotype II (HII)",
      "label": "also known as"
    },
    {
      "source": "5-marker risk haplotype",
      "target": "severe neutropenia",
      "label": "associated with"
    },
    {
      "source": "5-marker risk haplotype",
      "target": "Italian cohort",
      "label": "reported in"
    },
    {
      "source": "5-marker risk haplotype",
      "target": "our cohort",
      "label": "found in"
    },
    {
      "source": "P value",
      "target": "significant differences",
      "label": "is related to"
    },
    {
      "source": "HIa",
      "target": "P value",
      "label": "has"
    },
    {
      "source": "HIa",
      "target": "absence of severe neutropenia",
      "label": "associated with"
    },
    {
      "source": "HIa",
      "target": "combined cohorts",
      "label": "found in"
    },
    {
      "source": "HIa",
      "target": "odds ratio (OR)",
      "label": "has"
    },
    {
      "source": "Haplotype analyses",
      "target": "markers",
      "label": "of"
    },
    {
      "source": "Haplotype analyses",
      "target": "3'UTR single-nucleotide polymorphism (SNP)",
      "label": "with"
    },
    {
      "source": "Haplotype analyses",
      "target": "protective HI",
      "label": "identified"
    },
    {
      "source": "Haplotype analyses",
      "target": "risk haplotypes",
      "label": "identified"
    },
    {
      "source": "5-FU",
      "target": "aggressive cancers",
      "label": "is used to treat"
    },
    {
      "source": "HIII",
      "target": "unfavorable alleles",
      "label": "characterized by"
    },
    {
      "source": "unfavorable alleles",
      "target": "dosage effect",
      "label": "reveals"
    },
    {
      "source": "3'UTR single-nucleotide polymorphism (SNP)",
      "target": "HI",
      "label": "permitted refinement of"
    },
    {
      "source": "functional UGT1A variants",
      "target": "UDP-glucuronosyltransferase (UGT) 1A1*28",
      "label": "includes"
    },
    {
      "source": "functional UGT1A variants",
      "target": "risk",
      "label": "influenced"
    },
    {
      "source": "UDP-glucuronosyltransferase (UGT) 1A1*28",
      "target": "irinotecan pharmacogenetics",
      "label": "important in"
    },
    {
      "source": "UDP-glucuronosyltransferase (UGT) 1A1*28",
      "target": "drug-induced severe toxicity",
      "label": "related to"
    },
    {
      "source": "3'untranscribed region (3'UTR)",
      "target": "UGT1A locus",
      "label": "part of"
    },
    {
      "source": "UGT1A variations",
      "target": "multivariate analyses",
      "label": "analyzed by"
    },
    {
      "source": "specific SNPs",
      "target": "UGT1A",
      "label": "located in"
    },
    {
      "source": "specific SNPs",
      "target": "pharmacogenetic testing",
      "label": "considered for"
    },
    {
      "source": "specific SNPs",
      "target": "irinotecan toxicity",
      "label": "influence"
    },
    {
      "source": "SNPs",
      "target": "neutropenia grade 3-4",
      "label": "linked to"
    },
    {
      "source": "SNPs",
      "target": "central region of UGT1A",
      "label": "located in"
    },
    {
      "source": "dosage effect",
      "target": "P value",
      "label": "has"
    },
    {
      "source": "dosage effect",
      "target": "odds ratio (OR)",
      "label": "has"
    },
    {
      "source": "irinotecan toxicity",
      "target": "advanced colorectal cancer patients",
      "label": "occurs in"
    },
    {
      "source": "risk haplotypes",
      "target": "haplotype II (HII)",
      "label": "includes"
    },
    {
      "source": "risk haplotypes",
      "target": "HIII",
      "label": "includes"
    },
    {
      "source": "haplotype II (HII)",
      "target": "UGTs 1A9/1A7/1A1",
      "label": "includes"
    },
    {
      "source": "haplotype II (HII)",
      "target": "unfavorable alleles",
      "label": "characterized by"
    },
    {
      "source": "UGT1A haplotype",
      "target": "irinotecan-induced hematological toxicity",
      "label": "associated with"
    },
    {
      "source": "irinotecan-induced hematological toxicity",
      "target": "metastatic colorectal cancer patients",
      "label": "occurs in"
    },
    {
      "source": "protective HI",
      "target": "P value",
      "label": "has"
    },
    {
      "source": "protective HI",
      "target": "odds ratio (OR)",
      "label": "has"
    },
    {
      "source": "HI",
      "target": "H",
      "label": "includes"
    },
    {
      "source": "HI",
      "target": "carbonyl iron",
      "label": "contains"
    },
    {
      "source": "UGT1A candidate markers",
      "target": "toxicity",
      "label": "relationship with"
    },
    {
      "source": "UGT1A candidate markers",
      "target": "167 patients",
      "label": "evaluated in"
    },
    {
      "source": "UGT1A candidate markers",
      "target": "gene",
      "label": "located across"
    },
    {
      "source": "FTIR experiments",
      "target": "DC gate",
      "label": "on"
    },
    {
      "source": "FTIR experiments",
      "target": "indirect model",
      "label": "described using"
    },
    {
      "source": "DC gate",
      "target": "channelrhodopsin-2",
      "label": "in"
    },
    {
      "source": "D115",
      "target": "dark-adapted state",
      "label": "in"
    },
    {
      "source": "D115",
      "target": "K states",
      "label": "in"
    },
    {
      "source": "dark-adapted state",
      "target": "bacteriorhodopsin",
      "label": "of"
    },
    {
      "source": "Vibrational spectroscopic experiments",
      "target": "structural changes",
      "label": "shed light on"
    },
    {
      "source": "structural changes",
      "target": "photocycle",
      "label": "occur during"
    },
    {
      "source": "structural changes",
      "target": "hydrogen-bonded network",
      "label": "occur in"
    },
    {
      "source": "interpretation",
      "target": "homology models",
      "label": "based on"
    },
    {
      "source": "approximate DFT method",
      "target": "DFTB",
      "label": "is"
    },
    {
      "source": "DFTB",
      "target": "full DFT results",
      "label": "agrees with"
    },
    {
      "source": "DFTB",
      "target": "recent reparametrization",
      "label": "combined with"
    },
    {
      "source": "DFTB",
      "target": "effects of hydrogen bonding",
      "label": "describes"
    },
    {
      "source": "DFTB",
      "target": "QM/MM framework",
      "label": "applied in"
    },
    {
      "source": "K states",
      "target": "bacteriorhodopsin",
      "label": "of"
    },
    {
      "source": "protonated D156",
      "target": "water molecule",
      "label": "bridged via"
    },
    {
      "source": "protonated D156",
      "target": "DC gate",
      "label": "is part of"
    },
    {
      "source": "channelrhodopsin-2",
      "target": "light-gated ion channel",
      "label": "is a"
    },
    {
      "source": "hydrogen-bonded network",
      "target": "protonated D156",
      "label": "surrounds"
    },
    {
      "source": "hydrogen-bonded network",
      "target": "C128",
      "label": "surrounds"
    },
    {
      "source": "C[double bond, length as m-dash]O stretch vibration",
      "target": "carboxylic acids",
      "label": "in"
    },
    {
      "source": "vibrational spectra",
      "target": "channelrhodopsin-2",
      "label": "of"
    },
    {
      "source": "vibrational spectra",
      "target": "bacteriorhodopsin",
      "label": "of"
    },
    {
      "source": "QM/MM framework",
      "target": "FTIR spectral difference",
      "label": "simulates"
    },
    {
      "source": "QM/MM framework",
      "target": "vibrational analysis",
      "label": "performs"
    },
    {
      "source": "FTIR spectral difference",
      "target": "D115",
      "label": "between"
    },
    {
      "source": "indirect model",
      "target": "C128",
      "label": "bridges"
    },
    {
      "source": "indirect model",
      "target": "protonated D156",
      "label": "bridges"
    },
    {
      "source": "C128",
      "target": "water molecule",
      "label": "bridged via"
    },
    {
      "source": "C128",
      "target": "DC gate",
      "label": "is part of"
    },
    {
      "source": "vibrational analysis",
      "target": "buried aspartic acids",
      "label": "of"
    },
    {
      "source": "effects of hydrogen bonding",
      "target": "C[double bond, length as m-dash]O stretch vibration",
      "label": "on"
    },
    {
      "source": "buried aspartic acids",
      "target": "channelrhodopsin-2",
      "label": "in"
    },
    {
      "source": "buried aspartic acids",
      "target": "bacteriorhodopsin",
      "label": "in"
    },
    {
      "source": "QM/MM simulations",
      "target": "vibrational spectra",
      "label": "simulate"
    },
    {
      "source": "activated mRNA expression",
      "target": "NR4A3",
      "label": "of"
    },
    {
      "source": "activated mRNA expression",
      "target": "NR4A2",
      "label": "of"
    },
    {
      "source": "activated mRNA expression",
      "target": "matrix metalloproteinases (MMPs) 1, 3 and 13",
      "label": "of"
    },
    {
      "source": "activated mRNA expression",
      "target": "NR4A1",
      "label": "of"
    },
    {
      "source": "activated mRNA expression",
      "target": "human cell lines",
      "label": "in"
    },
    {
      "source": "NR4A2",
      "target": "key regulator",
      "label": "is a"
    },
    {
      "source": "NR4A2",
      "target": "potential biomarker",
      "label": "is a"
    },
    {
      "source": "NR4A2",
      "target": "potentially valuable therapeutic target",
      "label": "represents a"
    },
    {
      "source": "hyaluronic acid (HA)",
      "target": "activated mRNA expression",
      "label": "attenuated"
    },
    {
      "source": "human cell lines",
      "target": "THP-1 monocytes",
      "label": "include"
    },
    {
      "source": "human cell lines",
      "target": "SW1353 chondrocytes",
      "label": "include"
    },
    {
      "source": "human cell lines",
      "target": "U937",
      "label": "include"
    },
    {
      "source": "nanocomplexes (NPs)",
      "target": "chitosan",
      "label": "using"
    },
    {
      "source": "intra-articular (I.A.) route",
      "target": "mouse knee",
      "label": "to"
    },
    {
      "source": "NR4A2 mRNA expression",
      "target": "in vitro",
      "label": "occurs"
    },
    {
      "source": "on-going inflammatory arthritis",
      "target": "K/BxN serum transfer model",
      "label": "of"
    },
    {
      "source": "key regulator",
      "target": "cell proliferation",
      "label": "of"
    },
    {
      "source": "salmon calcitonin (sCT)",
      "target": "cAMP production",
      "label": "stimulated"
    },
    {
      "source": "salmon calcitonin (sCT)",
      "target": "activated mRNA expression",
      "label": "attenuated"
    },
    {
      "source": "rationale",
      "target": "nanocomplexes (NPs)",
      "label": "for formulation in"
    },
    {
      "source": "intra-articular salmon calcitonin-based nanocomplex",
      "target": "experimental inflammatory arthritis",
      "label": "reduces"
    },
    {
      "source": "potential biomarker",
      "target": "inflammation",
      "label": "for"
    },
    {
      "source": "anti-arthritic effects",
      "target": "I.A. delivery",
      "label": "following"
    },
    {
      "source": "anti-arthritic effects",
      "target": "in vivo",
      "label": "occurs"
    },
    {
      "source": "Prolonged inappropriate inflammatory responses",
      "target": "pathogenesis",
      "label": "contribute to"
    },
    {
      "source": "human T47D breast cancer cells",
      "target": "sCT receptors",
      "label": "expressing"
    },
    {
      "source": "remarkable anti-inflammatory effects",
      "target": "NR4A2 mRNA expression",
      "label": "at the level of reducing"
    },
    {
      "source": "remarkable anti-inflammatory effects",
      "target": "hyaluronic acid (HA)",
      "label": "of"
    },
    {
      "source": "remarkable anti-inflammatory effects",
      "target": "salmon calcitonin (sCT)",
      "label": "of"
    },
    {
      "source": "expression of NR4A2",
      "target": "agent",
      "label": "compared to"
    },
    {
      "source": "Ad-mixtures of sCT and HA",
      "target": "expression of NR4A2",
      "label": "down-regulated"
    },
    {
      "source": "orphan nuclear receptor",
      "target": "NR4A2",
      "label": "is"
    },
    {
      "source": "effector",
      "target": "Cl(-) uptake",
      "label": "involved in"
    },
    {
      "source": "Cl(-) uptake",
      "target": "zebrafish",
      "label": "occurs in"
    },
    {
      "source": "PRL signaling",
      "target": "expression",
      "label": "regulates"
    },
    {
      "source": "PRL signaling",
      "target": "PRL receptors",
      "label": "through"
    },
    {
      "source": "ionocytes",
      "target": "gill",
      "label": "located in"
    },
    {
      "source": "ionocytes",
      "target": "mechanisms",
      "label": "regulate"
    },
    {
      "source": "ionocytes",
      "target": "systemic PRL",
      "label": "respond to"
    },
    {
      "source": "pituitary hormone",
      "target": "effector",
      "label": "linked with"
    },
    {
      "source": "oPRL",
      "target": "ncc transcripts",
      "label": "increased"
    },
    {
      "source": "oPRL",
      "target": "cultured gill filaments",
      "label": "added to"
    },
    {
      "source": "oPRL",
      "target": "nhe3b",
      "label": "did not affect"
    },
    {
      "source": "oPRL",
      "target": "ecac",
      "label": "did not affect"
    },
    {
      "source": "oPRL",
      "target": "ncc",
      "label": "stimulated"
    },
    {
      "source": "oPRL",
      "target": "prlra transcripts",
      "label": "increased"
    },
    {
      "source": "ovine PRL",
      "target": "oPRL",
      "label": "also known as"
    },
    {
      "source": "ovine PRL",
      "target": "ncc transcripts",
      "label": "increased"
    },
    {
      "source": "ovine PRL",
      "target": "nhe3b",
      "label": "did not affect"
    },
    {
      "source": "ovine PRL",
      "target": "ecac",
      "label": "did not affect"
    },
    {
      "source": "ovine PRL",
      "target": "prlra transcripts",
      "label": "increased"
    },
    {
      "source": "\u03941-9-G129R-hPRL",
      "target": "effect",
      "label": "blocked"
    },
    {
      "source": "Prolactin",
      "target": "ncc gene",
      "label": "regulates transcription of"
    },
    {
      "source": "Prolactin",
      "target": "zebrafish gill",
      "label": "acts in"
    },
    {
      "source": "Prolactin",
      "target": "regulator",
      "label": "is a"
    },
    {
      "source": "Prolactin",
      "target": "ion uptake Na+/Cl- cotransporter",
      "label": "regulates transcription of"
    },
    {
      "source": "Prolactin",
      "target": "PRL",
      "label": "also known as"
    },
    {
      "source": "Prolactin",
      "target": "transcription",
      "label": "regulates"
    },
    {
      "source": "pure human PRL receptor antagonist",
      "target": "effect",
      "label": "blocked"
    },
    {
      "source": "pure human PRL receptor antagonist",
      "target": "\u03941-9-G129R-hPRL",
      "label": "also known as"
    },
    {
      "source": "regulator",
      "target": "ion",
      "label": "regulates"
    },
    {
      "source": "regulator",
      "target": "water transport",
      "label": "regulates"
    },
    {
      "source": "ion",
      "target": "osmoregulatory tissues",
      "label": "transport within"
    },
    {
      "source": "PRL receptor",
      "target": "prlra",
      "label": "also known as"
    },
    {
      "source": "PRL receptors",
      "target": "gill",
      "label": "located in"
    },
    {
      "source": "epithelial Ca(2+) channel",
      "target": "ecac",
      "label": "also known as"
    },
    {
      "source": "epithelial Ca(2+) channel",
      "target": "Ca(2+)",
      "label": "transports"
    },
    {
      "source": "epithelial Ca(2+) channel",
      "target": "trpv6",
      "label": "also known as"
    },
    {
      "source": "ncc",
      "target": "concentration-dependent manner",
      "label": "stimulated in a"
    },
    {
      "source": "Na(+)/Cl(-) cotransporter",
      "target": "Cl(-)",
      "label": "transports"
    },
    {
      "source": "Na(+)/Cl(-) cotransporter",
      "target": "slc12a10.2",
      "label": "also known as"
    },
    {
      "source": "Na(+)/Cl(-) cotransporter",
      "target": "Na(+)",
      "label": "transports"
    },
    {
      "source": "Na(+)/Cl(-) cotransporter",
      "target": "ncc",
      "label": "also known as"
    },
    {
      "source": "Na(+)/H(+) exchanger",
      "target": "Na(+)",
      "label": "exchanges"
    },
    {
      "source": "Na(+)/H(+) exchanger",
      "target": "nhe3b",
      "label": "also known as"
    },
    {
      "source": "Na(+)/H(+) exchanger",
      "target": "slc9a3.2",
      "label": "also known as"
    },
    {
      "source": "Na(+)/H(+) exchanger",
      "target": "H(+)",
      "label": "exchanges"
    },
    {
      "source": "water transport",
      "target": "osmoregulatory tissues",
      "label": "within"
    },
    {
      "source": "ion uptake Na+/Cl- cotransporter",
      "target": "Na+",
      "label": "transports"
    },
    {
      "source": "ion uptake Na+/Cl- cotransporter",
      "target": "Cl-",
      "label": "transports"
    },
    {
      "source": "osmoregulatory tissues",
      "target": "vertebrate species",
      "label": "found across"
    },
    {
      "source": "Ion-poor conditions",
      "target": "expression",
      "label": "increased"
    },
    {
      "source": "PRL action",
      "target": "gill",
      "label": "occurs in"
    },
    {
      "source": "Parathyroid hormone (1-34)",
      "target": "osteoblast differentiation",
      "label": "stimulates"
    },
    {
      "source": "Parathyroid hormone (1-34)",
      "target": "interleukin-11",
      "label": "counteracts suppression of"
    },
    {
      "source": "Parathyroid hormone (1-34)",
      "target": "glucocorticoid",
      "label": "counteracts suppression by"
    },
    {
      "source": "Parathyroid hormone (1-34)",
      "target": "glucocorticoid excess",
      "label": "counteracts"
    },
    {
      "source": "IL-11 small interfering RNA",
      "target": "effect of dexamethasone on apoptosis of mPOBs",
      "label": "blunted"
    },
    {
      "source": "Glucocorticoid (GC) excess",
      "target": "bone",
      "label": "causes loss of"
    },
    {
      "source": "Glucocorticoid (GC) excess",
      "target": "bone formation",
      "label": "causes reduction in"
    },
    {
      "source": "Glucocorticoid (GC) excess",
      "target": "inhibition of bone formation",
      "label": "causes"
    },
    {
      "source": "PTH(1-34) and dexamethasone",
      "target": "osteoblast differentiation and apoptosis",
      "label": "regulate"
    },
    {
      "source": "PTH(1-34) and dexamethasone",
      "target": "IL-11 expression",
      "label": "regulate via effect on"
    },
    {
      "source": "PTH(1-34) and GCs",
      "target": "IL-11 expression",
      "label": "interact to regulate"
    },
    {
      "source": "PTH(1-34) and GCs",
      "target": "osteoblast differentiation and apoptosis",
      "label": "interact to regulate"
    },
    {
      "source": "PTH(1-34) treatment",
      "target": "IL-11 expression",
      "label": "enhanced"
    },
    {
      "source": "Dexamethasone",
      "target": "\u0394FosB expression",
      "label": "did not affect"
    },
    {
      "source": "Dexamethasone",
      "target": "Smad1 phosphorylation",
      "label": "did not affect"
    },
    {
      "source": "Dexamethasone",
      "target": "IL-11 gene transcription enhanced by PTH(1-34)",
      "label": "suppressed"
    },
    {
      "source": "Dexamethasone",
      "target": "Combination",
      "label": "is a component of"
    },
    {
      "source": "Dexamethasone",
      "target": "adipose triacylglycerol metabolism",
      "label": "mediates changes in"
    },
    {
      "source": "\u0394FosB expression",
      "target": "IL-11 gene transcription",
      "label": "stimulated"
    },
    {
      "source": "IL-11",
      "target": "bone formation",
      "label": "mediates"
    },
    {
      "source": "IL-11",
      "target": "expression of dickkopf-1 and -2",
      "label": "suppresses"
    },
    {
      "source": "IL-11",
      "target": "Wnt signaling",
      "label": "stimulates"
    },
    {
      "source": "IL-11",
      "target": "osteoblast differentiation",
      "label": "mediates"
    },
    {
      "source": "IL-11",
      "target": "effect of mechanical strain",
      "label": "mediates"
    },
    {
      "source": "JunD",
      "target": "heterodimers",
      "label": "forms"
    },
    {
      "source": "JunD",
      "target": "\u0394FosB",
      "label": "forms heterodimers with"
    },
    {
      "source": "Smad1 phosphorylation",
      "target": "IL-11 gene transcription",
      "label": "stimulated"
    },
    {
      "source": "dexamethasone-GC receptor complex",
      "target": "JunD",
      "label": "bound to"
    },
    {
      "source": "High doses of PTH(1-34)",
      "target": "effect of dexamethasone on apoptosis of mPOBs",
      "label": "counteracted"
    },
    {
      "source": "Intermittent PTH (1-34) administration",
      "target": "inhibition of bone formation",
      "label": "counteracts"
    },
    {
      "source": "Intermittent PTH (1-34) administration",
      "target": "bone formation",
      "label": "stimulates"
    },
    {
      "source": "mechanical strain",
      "target": "\u0394FosB expression",
      "label": "induces"
    },
    {
      "source": "mechanical strain",
      "target": "interleukin (IL)-11 gene transcription",
      "label": "enhances"
    },
    {
      "source": "mechanical strain",
      "target": "protein kinase C (PKC)-\u03b4-mediated phosphorylation",
      "label": "induces"
    },
    {
      "source": "PTH(1-34)",
      "target": "\u0394FosB expression",
      "label": "stimulated"
    },
    {
      "source": "PTH(1-34)",
      "target": "Smad1 phosphorylation",
      "label": "stimulated"
    },
    {
      "source": "PTH(1-34)-induced Smad1 phosphorylation",
      "target": "PKC\u03b4",
      "label": "mediated via"
    },
    {
      "source": "PTH(1-34)-induced Smad1 phosphorylation",
      "target": "mPOBs from PKC\u03b4 knockout mice",
      "label": "abrogated in"
    },
    {
      "source": "PKC\u03b4",
      "target": "Smad1 phosphorylation",
      "label": "mediates"
    },
    {
      "source": "neutralizing anti-IL-11 antibody",
      "target": "effect of dexamethasone on apoptosis of mPOBs",
      "label": "blunted"
    },
    {
      "source": "tumor specimens",
      "target": "MDA",
      "label": "exhibited increased levels of"
    },
    {
      "source": "tumor specimens",
      "target": "normal mucosa",
      "label": "compared with"
    },
    {
      "source": "tumor specimens",
      "target": "8-oxo-dG",
      "label": "exhibited increased levels of"
    },
    {
      "source": "tumor specimens",
      "target": "normal gastric tissue",
      "label": "compared with"
    },
    {
      "source": "DNA Damage",
      "target": "Human Gastric Carcinoma",
      "label": "is associated with"
    },
    {
      "source": "oxidative stress (OS) status",
      "target": "8-Oxo-7'8-dihydro-2'-deoxyguanosine",
      "label": "characterized by levels of"
    },
    {
      "source": "oxidative stress (OS) status",
      "target": "8-oxo-dG",
      "label": "characterized by levels of"
    },
    {
      "source": "oxidative stress (OS) status",
      "target": "malondialdehyde",
      "label": "characterized by levels of"
    },
    {
      "source": "oxidative stress (OS) status",
      "target": "MDA",
      "label": "characterized by levels of"
    },
    {
      "source": "oxidative stress (OS) status",
      "target": "reduced/oxidized glutathione",
      "label": "characterized by levels of"
    },
    {
      "source": "oxidative stress (OS) status",
      "target": "human gastric carcinoma (HGC) samples",
      "label": "measured in"
    },
    {
      "source": "8-Oxo-7'8-dihydro-2'-deoxyguanosine",
      "target": "8-oxo-dG",
      "label": "is also known as"
    },
    {
      "source": "8-Oxo-7'8-dihydro-2'-deoxyguanosine",
      "target": "Tumor Marker",
      "label": "is a possible"
    },
    {
      "source": "8-Oxo-7'8-dihydro-2'-deoxyguanosine",
      "target": "mutagenic base",
      "label": "is a type of"
    },
    {
      "source": "peripheral mononuclear cells (PMNC)",
      "target": "healthy control subjects",
      "label": "from"
    },
    {
      "source": "peripheral mononuclear cells (PMNC)",
      "target": "affected patients",
      "label": "from"
    },
    {
      "source": "8-oxo-dG",
      "target": "peripheral mononuclear cells (PMNC)",
      "label": "analyzed in"
    },
    {
      "source": "8-oxo-dG",
      "target": "PMNC",
      "label": "analyzed in"
    },
    {
      "source": "8-oxo-dG",
      "target": "urine",
      "label": "analyzed in"
    },
    {
      "source": "8-oxo-dG",
      "target": "Tumor Marker",
      "label": "is a possible"
    },
    {
      "source": "8-oxo-dG",
      "target": "DNA repair activity",
      "label": "related to"
    },
    {
      "source": "8-oxo-dG",
      "target": "mutagenic base",
      "label": "is a type of"
    },
    {
      "source": "DNA repair enzyme mRNA expression",
      "target": "hOGG1",
      "label": "includes"
    },
    {
      "source": "DNA repair enzyme mRNA expression",
      "target": "MTH1",
      "label": "includes"
    },
    {
      "source": "DNA repair enzyme mRNA expression",
      "target": "tumor tissues",
      "label": "induced in"
    },
    {
      "source": "DNA repair enzyme mRNA expression",
      "target": "tumor specimens",
      "label": "determined in"
    },
    {
      "source": "DNA repair enzyme mRNA expression",
      "target": "MUYTH",
      "label": "includes"
    },
    {
      "source": "DNA repair enzyme mRNA expression",
      "target": "RAD51",
      "label": "includes"
    },
    {
      "source": "PMNC",
      "target": "healthy control subjects",
      "label": "from"
    },
    {
      "source": "PMNC",
      "target": "affected patients",
      "label": "from"
    },
    {
      "source": "PMNC",
      "target": "gastric cancer patients",
      "label": "from"
    },
    {
      "source": "PMNC",
      "target": "healthy population",
      "label": "levels decreased to values of"
    },
    {
      "source": "tumor resection",
      "target": "8-oxo-dG",
      "label": "supports potential use of"
    },
    {
      "source": "damaged base",
      "target": "gastrectomy",
      "label": "decreased after"
    },
    {
      "source": "damaged base",
      "target": "PMNC",
      "label": "found in"
    },
    {
      "source": "damaged base",
      "target": "urine",
      "label": "found in"
    },
    {
      "source": "reduced/oxidized glutathione",
      "target": "GSSG",
      "label": "includes"
    },
    {
      "source": "reduced/oxidized glutathione",
      "target": "GSH",
      "label": "includes"
    },
    {
      "source": "affected patients",
      "target": "tumor resection",
      "label": "underwent"
    },
    {
      "source": "DNA repair activity",
      "target": "tumor tissues",
      "label": "occurs in"
    },
    {
      "source": "gastric cancer patients",
      "target": "healthy controls",
      "label": "compared with"
    },
    {
      "source": "human gastric carcinoma (HGC) samples",
      "target": "normal tissue",
      "label": "compared with"
    },
    {
      "source": "normal tissue",
      "target": "patients",
      "label": "from"
    },
    {
      "source": "Oxidative Stress",
      "target": "Human Gastric Carcinoma",
      "label": "is associated with"
    },
    {
      "source": "N-terminal PDZ domain",
      "target": "PDZ domain",
      "label": "is a"
    },
    {
      "source": "essential light chains",
      "target": "light chains",
      "label": "are"
    },
    {
      "source": "lever",
      "target": "long axis",
      "label": "is angled with respect to"
    },
    {
      "source": "long axis",
      "target": "motor domain",
      "label": "is of"
    },
    {
      "source": "Mus musculus myosin-18A gene",
      "target": "isoforms",
      "label": "expresses"
    },
    {
      "source": "\u03b2",
      "target": "receptors",
      "label": "functions as"
    },
    {
      "source": "\u03b2",
      "target": "cytoskeleton",
      "label": "has role in maintenance of"
    },
    {
      "source": "\u03b2",
      "target": "Golgi localization",
      "label": "has role in"
    },
    {
      "source": "GOLPH3",
      "target": "ATP hydrolysis",
      "label": "has no effect on"
    },
    {
      "source": "GOLPH3",
      "target": "myosin-18A binding partner",
      "label": "is a"
    },
    {
      "source": "Myosin-18A\u03b2-S1 molecules",
      "target": "actin",
      "label": "bind"
    },
    {
      "source": "Myosin-18A\u03b2-S1 molecules",
      "target": "Kd values",
      "label": "have"
    },
    {
      "source": "Myosin-18A\u03b2-S1 molecules",
      "target": "Myosin-18A\u03b2-S1",
      "label": "are"
    },
    {
      "source": "\u03b1",
      "target": "receptors",
      "label": "functions as"
    },
    {
      "source": "\u03b1",
      "target": "cytoskeleton",
      "label": "has role in maintenance of"
    },
    {
      "source": "\u03b1",
      "target": "Golgi localization",
      "label": "has role in"
    },
    {
      "source": "myosin-18A binding partner",
      "target": "myosin-18A",
      "label": "binds"
    },
    {
      "source": "myosin-18A",
      "target": "cells",
      "label": "does not operate in"
    },
    {
      "source": "myosin-18A",
      "target": "traditional molecular motor",
      "label": "does not operate as"
    },
    {
      "source": "constructs",
      "target": "regulatory light chains",
      "label": "bind"
    },
    {
      "source": "constructs",
      "target": "essential light chains",
      "label": "bind"
    },
    {
      "source": "constructs",
      "target": "Xenopus oocytes",
      "label": "expressed in"
    },
    {
      "source": "regulatory light chains",
      "target": "light chains",
      "label": "are"
    },
    {
      "source": "rate of ATP hydrolysis",
      "target": "ATP hydrolysis",
      "label": "is a type of"
    },
    {
      "source": "rate of ATP hydrolysis",
      "target": "actin",
      "label": "is not enhanced by"
    },
    {
      "source": "Mammalian myosin-18A",
      "target": "myosin",
      "label": "is a"
    },
    {
      "source": "subfragment-1 (S1)-like constructs",
      "target": "baculovirus/Sf9 cell expression system",
      "label": "purified from"
    },
    {
      "source": "subfragment-1 (S1)-like constructs",
      "target": "myosin-18\u03b2 species",
      "label": "are for"
    },
    {
      "source": "subfragment-1 (S1)-like constructs",
      "target": "myosin-18A\u03b1",
      "label": "are for"
    },
    {
      "source": "baculovirus/Sf9 cell expression system",
      "target": "baculovirus",
      "label": "comprises"
    },
    {
      "source": "baculovirus/Sf9 cell expression system",
      "target": "Sf9 cell expression system",
      "label": "comprises"
    },
    {
      "source": "Myosin-18A\u03b1-S1 molecules",
      "target": "Kd values",
      "label": "have"
    },
    {
      "source": "Myosin-18A\u03b1-S1 molecules",
      "target": "Myosin-18A\u03b1-S1",
      "label": "are"
    },
    {
      "source": "Myosin-18A\u03b1-S1 molecules",
      "target": "actin",
      "label": "bind"
    },
    {
      "source": "pre-power stroke conformation",
      "target": "ATP",
      "label": "is independent of"
    },
    {
      "source": "noncanonical light chain binding site",
      "target": "neck",
      "label": "is in"
    },
    {
      "source": "myosin-18A isoforms",
      "target": "coiled-coil",
      "label": "feature"
    },
    {
      "source": "myosin-18A isoforms",
      "target": "myosin motor domain",
      "label": "feature"
    },
    {
      "source": "myosin-18A isoforms",
      "target": "N-methylanthraniloyl-nucleotides",
      "label": "bind"
    },
    {
      "source": "myosin-18A isoforms",
      "target": "IQ motif",
      "label": "feature"
    },
    {
      "source": "coiled-coil",
      "target": "myosin-2",
      "label": "is reminiscent of"
    },
    {
      "source": "myosin-18A\u03b1 isoform",
      "target": "N-terminal PDZ domain",
      "label": "has"
    },
    {
      "source": "Sf9 cell expression system",
      "target": "Sf9 cell",
      "label": "comprises"
    },
    {
      "source": "equilibrium",
      "target": "myosin conformations",
      "label": "is between"
    },
    {
      "source": "equilibrium",
      "target": "functionally distinct assemblies",
      "label": "consists of"
    },
    {
      "source": "myosin conformations",
      "target": "incompetent form",
      "label": "include"
    },
    {
      "source": "myosin conformations",
      "target": "competent form",
      "label": "include"
    },
    {
      "source": "incompetent form",
      "target": "actin",
      "label": "binds"
    },
    {
      "source": "Phosphorylation",
      "target": "ATP hydrolysis",
      "label": "has no effect on"
    },
    {
      "source": "competent form",
      "target": "actin",
      "label": "binds"
    },
    {
      "source": "Electron microscopy",
      "target": "myosin-18A-S1",
      "label": "is of"
    },
    {
      "source": "myosin-18A-S1",
      "target": "lever",
      "label": "has a"
    },
    {
      "source": "myosin-18A-S1",
      "target": "pre-power stroke conformation",
      "label": "suggests"
    },
    {
      "source": "Recombinant heavy meromyosin-like constructs",
      "target": "myosin-18\u03b2 species",
      "label": "are for"
    },
    {
      "source": "Recombinant heavy meromyosin-like constructs",
      "target": "baculovirus/Sf9 cell expression system",
      "label": "purified from"
    },
    {
      "source": "Recombinant heavy meromyosin-like constructs",
      "target": "myosin-18A\u03b1",
      "label": "are for"
    },
    {
      "source": "Actin binding",
      "target": "nucleotide",
      "label": "is unaffected by"
    },
    {
      "source": "actin binding data",
      "target": "equilibrium",
      "label": "is modeled by"
    },
    {
      "source": "tropomyosin",
      "target": "ATP hydrolysis",
      "label": "has no effect on"
    },
    {
      "source": "AML",
      "target": "enhancement effect",
      "label": "possesses"
    },
    {
      "source": "AML",
      "target": "oral bioavailability",
      "label": "affects"
    },
    {
      "source": "AML",
      "target": "interaction",
      "label": "causes"
    },
    {
      "source": "crossover design",
      "target": "14-day washout",
      "label": "included"
    },
    {
      "source": "Twenty-four healthy men",
      "target": "CXM 500 mg alone",
      "label": "were administered"
    },
    {
      "source": "Twenty-four healthy men",
      "target": "treatments",
      "label": "randomized to"
    },
    {
      "source": "Twenty-four healthy men",
      "target": "CXM 500 mg 2 hours after oral administration of AML 5 mg",
      "label": "were administered"
    },
    {
      "source": "Twenty-four healthy men",
      "target": "overnight fast",
      "label": "underwent"
    },
    {
      "source": "Twenty-four healthy men",
      "target": "LEX 500 mg 2 hours after oral administration of AML 5 mg",
      "label": "were administered"
    },
    {
      "source": "Twenty-four healthy men",
      "target": "LEX 500 mg alone",
      "label": "were administered"
    },
    {
      "source": "participants",
      "target": "study",
      "label": "completed"
    },
    {
      "source": "significant differences",
      "target": "pharmacokinetic parameters",
      "label": "were not found in"
    },
    {
      "source": "significant differences",
      "target": "treatment groups",
      "label": "between"
    },
    {
      "source": "enhancement effect",
      "target": "\u03b2-lactam antibiotic bioavailability",
      "label": "is in"
    },
    {
      "source": "\u03b2-lactam antibiotic bioavailability",
      "target": "LEX",
      "label": "includes"
    },
    {
      "source": "geometric mean ratios",
      "target": "90% confidence interval",
      "label": "had"
    },
    {
      "source": "geometric mean ratios",
      "target": "area under the concentration-time curve",
      "label": "are for"
    },
    {
      "source": "geometric mean ratios",
      "target": "maximum concentration of drug in serum",
      "label": "are for"
    },
    {
      "source": "oral bioavailability",
      "target": "cephalexin",
      "label": "is of"
    },
    {
      "source": "oral bioavailability",
      "target": "LEX",
      "label": "is of"
    },
    {
      "source": "oral bioavailability",
      "target": "CXM",
      "label": "is of"
    },
    {
      "source": "oral bioavailability",
      "target": "cefuroxime axetil",
      "label": "is of"
    },
    {
      "source": "LEX 500 mg 2 hours after oral administration of AML 5 mg",
      "target": "geometric mean ratios",
      "label": "resulted in"
    },
    {
      "source": "Pharmacokinetic data",
      "target": "noncompartmental modeling",
      "label": "analyzed by"
    },
    {
      "source": "noncompartmental modeling",
      "target": "WinNonlin software",
      "label": "used"
    },
    {
      "source": "maximum concentration of drug in serum",
      "target": "LEX",
      "label": "is for"
    },
    {
      "source": "basis sets",
      "target": "insufficient basis set",
      "label": "are"
    },
    {
      "source": "MP2 data",
      "target": "insufficient basis set",
      "label": "with"
    },
    {
      "source": "High-level quantum chemical calculations",
      "target": "biologically-relevant conformers",
      "label": "carried out for"
    },
    {
      "source": "biologically-relevant conformers",
      "target": "tetrapeptides",
      "label": "of"
    },
    {
      "source": "Accurate quantum chemical energies",
      "target": "tetrapeptide conformations",
      "label": "for"
    },
    {
      "source": "MP2 approach",
      "target": "basis sets",
      "label": "used with"
    },
    {
      "source": "PI3K/AKT inhibition",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "PI3K/AKT inhibition",
      "target": "degeneration",
      "label": "implicated in"
    },
    {
      "source": "PI3K/AKT inhibition",
      "target": "neuronal apoptosis",
      "label": "induces"
    },
    {
      "source": "pro-survival signalling system",
      "target": "neurons",
      "label": "functions in"
    },
    {
      "source": "pharmacological inhibitors",
      "target": "primary cultures of rat CGCs",
      "label": "protected"
    },
    {
      "source": "neuronal apoptosis",
      "target": "process",
      "label": "is a"
    },
    {
      "source": "neuronal apoptosis",
      "target": "p38 MAPK/c-Jun/dp5",
      "label": "mediated by"
    },
    {
      "source": "pro-apoptotic gene dp5",
      "target": "c-Jun",
      "label": "is a target of"
    },
    {
      "source": "pro-apoptotic gene dp5",
      "target": "target of c-Jun",
      "label": "is a"
    },
    {
      "source": "participation",
      "target": "apoptosis",
      "label": "has role in"
    },
    {
      "source": "mitogen-activated protein kinase (MAPK) pathway",
      "target": "participation",
      "label": "has"
    },
    {
      "source": "glutathione S-transferase placental form",
      "target": "GST-P",
      "label": "is_abbreviation_for"
    },
    {
      "source": "heptachlor",
      "target": "promotion stage",
      "label": "affects"
    },
    {
      "source": "heptachlor",
      "target": "organochlorine pesticides",
      "label": "is_a"
    },
    {
      "source": "promotion stage",
      "target": "hepatocarcinogenesis",
      "label": "is_a_stage_of"
    },
    {
      "source": "HCB",
      "target": "cytochrome P450 (CYP) 3A1",
      "label": "induces"
    },
    {
      "source": "HCB",
      "target": "GST-P-positive foci",
      "label": "promotes_development_of"
    },
    {
      "source": "HCB",
      "target": "cytochrome P450 (CYP) 2B1",
      "label": "induces"
    },
    {
      "source": "HCB",
      "target": "cell proliferation induction",
      "label": "induces"
    },
    {
      "source": "HCB",
      "target": "hexachlorobenzene",
      "label": "is_abbreviation_for"
    },
    {
      "source": "HCB",
      "target": "preneoplastic foci",
      "label": "promotes_development_of"
    },
    {
      "source": "cytochrome P450 (CYP) 3A1",
      "target": "metabolic activation",
      "label": "leads_to"
    },
    {
      "source": "combination of residual organochlorine pesticides",
      "target": "foods",
      "label": "found_in"
    },
    {
      "source": "combination of residual organochlorine pesticides",
      "target": "risks",
      "label": "associated_with"
    },
    {
      "source": "mixtures",
      "target": "HCB",
      "label": "contain"
    },
    {
      "source": "mixtures",
      "target": "HEP",
      "label": "contain"
    },
    {
      "source": "medium-term rat liver bioassay",
      "target": "heptachlor",
      "label": "investigates"
    },
    {
      "source": "medium-term rat liver bioassay",
      "target": "rats",
      "label": "is_performed_on"
    },
    {
      "source": "medium-term rat liver bioassay",
      "target": "hexachlorobenzene",
      "label": "investigates"
    },
    {
      "source": "cytochrome P450 (CYP) 2B1",
      "target": "metabolic activation",
      "label": "leads_to"
    },
    {
      "source": "metabolic activation",
      "target": "HCB",
      "label": "is_of"
    },
    {
      "source": "metabolic activation",
      "target": "HEP",
      "label": "is_of"
    },
    {
      "source": "preneoplastic foci",
      "target": "GST-P",
      "label": "positive_for"
    },
    {
      "source": "preneoplastic foci",
      "target": "glutathione S-transferase placental form",
      "label": "positive_for"
    },
    {
      "source": "HEP",
      "target": "preneoplastic foci",
      "label": "promotes_development_of"
    },
    {
      "source": "HEP",
      "target": "heptachlor",
      "label": "is_abbreviation_for"
    },
    {
      "source": "HEP",
      "target": "GST-P-positive foci",
      "label": "promotes_development_of"
    },
    {
      "source": "HEP",
      "target": "cytochrome P450 (CYP) 3A1",
      "label": "induces"
    },
    {
      "source": "HEP",
      "target": "cytochrome P450 (CYP) 2B1",
      "label": "induces"
    },
    {
      "source": "HEP",
      "target": "cell proliferation induction",
      "label": "induces"
    },
    {
      "source": "hexachlorobenzene",
      "target": "promotion stage",
      "label": "affects"
    },
    {
      "source": "hexachlorobenzene",
      "target": "organochlorine pesticides",
      "label": "is_a"
    },
    {
      "source": "Male F344 rats",
      "target": "diethylnitrosamine",
      "label": "administered"
    },
    {
      "source": "Male F344 rats",
      "target": "rats",
      "label": "is_a"
    },
    {
      "source": "DEN",
      "target": "diethylnitrosamine",
      "label": "is_abbreviation_for"
    },
    {
      "source": "individual residual organochlorine pesticides",
      "target": "risks",
      "label": "associated_with"
    },
    {
      "source": "phytosteryl phenolates",
      "target": "lab",
      "label": "synthesized in"
    },
    {
      "source": "phytosteryl phenolates",
      "target": "LDL-C oxidation",
      "label": "inhibits"
    },
    {
      "source": "phytosteryl phenolates",
      "target": "\u03b2-carotene-linoleate assay",
      "label": "showed enhanced antioxidant activity in"
    },
    {
      "source": "phytosteryl phenolates",
      "target": "bulk oil system",
      "label": "showed antioxidant activity in"
    },
    {
      "source": "three different in vitro model systems",
      "target": "bulk oil model system",
      "label": "includes"
    },
    {
      "source": "three different in vitro model systems",
      "target": "\u03b2-carotene-linoleate model system",
      "label": "includes"
    },
    {
      "source": "three different in vitro model systems",
      "target": "low-density lipoprotein cholesterol (LDL-C) oxidation assay",
      "label": "includes"
    },
    {
      "source": "\u03b2-carotene-linoleate assay",
      "target": "emulsion model system",
      "label": "is a type of"
    },
    {
      "source": "phytosteryl ferulates",
      "target": "\u03b2-carotene-linoleate assay",
      "label": "did not show enhanced antioxidant activity in"
    },
    {
      "source": "multidimensional antioxidant activity determinations",
      "target": "reaction mechanisms",
      "label": "have"
    },
    {
      "source": "multidimensional antioxidant activity determinations",
      "target": "overall understanding",
      "label": "provides"
    },
    {
      "source": "overall understanding",
      "target": "mechanisms of antioxidant action",
      "label": "is of"
    },
    {
      "source": "mechanisms of antioxidant action",
      "target": "phytosteryl phenolates",
      "label": "is of"
    },
    {
      "source": "physiochemical and biological properties",
      "target": "phytosteryl phenolates",
      "label": "is property of"
    },
    {
      "source": "selective immobilization",
      "target": "proteins",
      "label": "of"
    },
    {
      "source": "selective immobilization",
      "target": "antibodies",
      "label": "of"
    },
    {
      "source": "selective immobilization",
      "target": "enzymes",
      "label": "of"
    },
    {
      "source": "SPBs",
      "target": "photoemulsion polymerization",
      "label": "synthesized by"
    },
    {
      "source": "SPBs",
      "target": "poly(2-aminoethylmethacrylate hydrochloride)",
      "label": "consists of"
    },
    {
      "source": "SPBs",
      "target": "polystyrene core",
      "label": "consists of"
    },
    {
      "source": "isothermal titration calorimetry",
      "target": "ITC",
      "label": "is also known as"
    },
    {
      "source": "isothermal titration calorimetry",
      "target": "GSNO binding",
      "label": "demonstrates"
    },
    {
      "source": "stoichiometry",
      "target": "SPBs",
      "label": "between"
    },
    {
      "source": "stoichiometry",
      "target": "protein",
      "label": "between"
    },
    {
      "source": "cationic spherical polyelectrolyte brushes",
      "target": "poly(2-aminoethylmethacrylate hydrochloride)",
      "label": "consists of"
    },
    {
      "source": "cationic spherical polyelectrolyte brushes",
      "target": "photoemulsion polymerization",
      "label": "synthesized by"
    },
    {
      "source": "cationic spherical polyelectrolyte brushes",
      "target": "polystyrene core",
      "label": "consists of"
    },
    {
      "source": "poly(2-aminoethylmethacrylate hydrochloride)",
      "target": "PAEMH shell",
      "label": "is a"
    },
    {
      "source": "Binding energetics",
      "target": "ITC",
      "label": "determined by"
    },
    {
      "source": "Binding energetics",
      "target": "proteins",
      "label": "of"
    },
    {
      "source": "Binding energetics",
      "target": "SPBs",
      "label": "onto"
    },
    {
      "source": "pH regions",
      "target": "binding",
      "label": "of"
    },
    {
      "source": "pH regions",
      "target": "ionic strength",
      "label": "tunable by"
    },
    {
      "source": "pH regions",
      "target": "stoichiometry",
      "label": "tunable by"
    },
    {
      "source": "aggregation",
      "target": "pH",
      "label": "tuned by"
    },
    {
      "source": "aggregation",
      "target": "proteins",
      "label": "of"
    },
    {
      "source": "aggregation",
      "target": "SPBs",
      "label": "by"
    },
    {
      "source": "polystyrene core",
      "target": "diameter",
      "label": "has"
    },
    {
      "source": "\u03b2-lactoglobulin",
      "target": "BLG",
      "label": "is also known as"
    },
    {
      "source": "amount",
      "target": "ITC",
      "label": "determined by"
    },
    {
      "source": "amount",
      "target": "proteins",
      "label": "of"
    },
    {
      "source": "amount",
      "target": "SPBs",
      "label": "onto"
    },
    {
      "source": "releasing",
      "target": "SPBs",
      "label": "by"
    },
    {
      "source": "releasing",
      "target": "pH",
      "label": "tuned by"
    },
    {
      "source": "releasing",
      "target": "proteins",
      "label": "of"
    },
    {
      "source": "PAEMH shell",
      "target": "core surface",
      "label": "grafted on"
    },
    {
      "source": "PAEMH shell",
      "target": "thickness",
      "label": "has"
    },
    {
      "source": "SPB applications",
      "target": "selective immobilization",
      "label": "include"
    },
    {
      "source": "SPB applications",
      "target": "protein purification",
      "label": "include"
    },
    {
      "source": "Jaffe, E.",
      "target": "Arch. Bioch. Biophys",
      "label": "authored"
    },
    {
      "source": "case study",
      "target": "disease mechanisms",
      "label": "illustrates lessons for"
    },
    {
      "source": "case study",
      "target": "porphobilinogen synthase",
      "label": "is of"
    },
    {
      "source": "case study",
      "target": "drug discovery",
      "label": "illustrates lessons for"
    },
    {
      "source": "case study",
      "target": "drug side effects",
      "label": "illustrates lessons for understanding"
    },
    {
      "source": "multimer",
      "target": "dynamic equilibrium",
      "label": "is in"
    },
    {
      "source": "dynamic equilibrium",
      "target": "ligands",
      "label": "is modulated by"
    },
    {
      "source": "quaternary structure dynamics",
      "target": "pyruvate kinase",
      "label": "is discussed for drug discovery of"
    },
    {
      "source": "quaternary structure dynamics",
      "target": "HIV integrase",
      "label": "is discussed for drug discovery of"
    },
    {
      "source": "quaternary structure dynamics",
      "target": "tumor necrosis factor \u03b1",
      "label": "is discussed for drug discovery of"
    },
    {
      "source": "quaternary structure dynamics",
      "target": "allosteric drug discovery",
      "label": "impacts"
    },
    {
      "source": "quaternary structure dynamics",
      "target": "phenylalanine hydroxylase",
      "label": "is discussed for drug discovery of"
    },
    {
      "source": "porphobilinogen synthase",
      "target": "PBGS",
      "label": "is also known as"
    },
    {
      "source": "morpheein model",
      "target": "allostery",
      "label": "is a model of"
    },
    {
      "source": "morpheein model",
      "target": "allosteric regulation",
      "label": "describes"
    },
    {
      "source": "morpheein model",
      "target": "disease-associated proteins",
      "label": "is applicable for"
    },
    {
      "source": "morpheein model",
      "target": "proteins",
      "label": "applies to"
    },
    {
      "source": "Selwood, T.",
      "target": "Arch. Bioch. Biophys",
      "label": "authored"
    },
    {
      "source": "successful drug discovery efforts",
      "target": "quaternary structure dynamics",
      "label": "control"
    },
    {
      "source": "subunit conformation",
      "target": "multimer",
      "label": "assembles into"
    },
    {
      "source": "quaternary structure equilibrium",
      "target": "transthyretin",
      "label": "is of"
    },
    {
      "source": "drug discovery efforts",
      "target": "quaternary structure dynamics",
      "label": "focus on"
    },
    {
      "source": "Four highly accepted assays",
      "target": "ORAC",
      "label": "include"
    },
    {
      "source": "Four highly accepted assays",
      "target": "\u03b2-CLAMS",
      "label": "include"
    },
    {
      "source": "Four highly accepted assays",
      "target": "FRAP",
      "label": "include"
    },
    {
      "source": "Four highly accepted assays",
      "target": "PCL",
      "label": "include"
    },
    {
      "source": "ORAC",
      "target": "values",
      "label": "has"
    },
    {
      "source": "\u03b2-CLAMS",
      "target": "values",
      "label": "has"
    },
    {
      "source": "Further studies",
      "target": "health beneficial effects",
      "label": "are on"
    },
    {
      "source": "Further studies",
      "target": "identification",
      "label": "are on"
    },
    {
      "source": "staghorn sumac fruit",
      "target": "antioxidant activities",
      "label": "is subject of"
    },
    {
      "source": "staghorn sumac fruit",
      "target": "Rhus hirta L.",
      "label": "is also known as"
    },
    {
      "source": "staghorn sumac fruit",
      "target": "chemical characterisation",
      "label": "is subject of"
    },
    {
      "source": "PCL",
      "target": "values",
      "label": "has"
    },
    {
      "source": "anthocyanidins",
      "target": "419 Da",
      "label": "have mass of"
    },
    {
      "source": "anthocyanidins",
      "target": "449 Da",
      "label": "have mass of"
    },
    {
      "source": "anthocyanidins",
      "target": "433 Da",
      "label": "have mass of"
    },
    {
      "source": "ethanolic extract",
      "target": "81.6 mg GAE/ g DW",
      "label": "has content of"
    },
    {
      "source": "total polyphenols content",
      "target": "ethanolic extract",
      "label": "was higher in"
    },
    {
      "source": "total polyphenols content",
      "target": "water extract",
      "label": "compared to"
    },
    {
      "source": "fruit",
      "target": "antioxidants",
      "label": "is a source of"
    },
    {
      "source": "fruit",
      "target": "phenolic acids",
      "label": "contained"
    },
    {
      "source": "fruit",
      "target": "anthocyanins",
      "label": "contained"
    },
    {
      "source": "fruit",
      "target": "aboriginal peoples",
      "label": "was used by"
    },
    {
      "source": "fruit",
      "target": "flavonoids",
      "label": "contained"
    },
    {
      "source": "fruit",
      "target": "novel group of unique anthocyanins",
      "label": "contained"
    },
    {
      "source": "aboriginal peoples",
      "target": "various illnesses",
      "label": "used to treat"
    },
    {
      "source": "water extract",
      "target": "46.3mg GAE/g DW",
      "label": "has content of"
    },
    {
      "source": "Staghorn sumac",
      "target": "native tree",
      "label": "is a type of"
    },
    {
      "source": "Staghorn sumac",
      "target": "Rhus hirta L.",
      "label": "is also known as"
    },
    {
      "source": "native tree",
      "target": "Eastern Canada",
      "label": "is located in"
    },
    {
      "source": "aglycones",
      "target": "anthocyanidins",
      "label": "are a type of"
    },
    {
      "source": "aglycones",
      "target": "cytotoxic activities",
      "label": "were evaluated for"
    },
    {
      "source": "phytochemical composition",
      "target": "Rhus hirta L.",
      "label": "is of"
    },
    {
      "source": "qualitative studies",
      "target": "HPLC-DAD-MS",
      "label": "used"
    },
    {
      "source": "novel group of unique anthocyanins",
      "target": "aglycones",
      "label": "have"
    },
    {
      "source": "polyphenols",
      "target": "antioxidant activities",
      "label": "play important role in"
    },
    {
      "source": "polyphenols",
      "target": "beneficial action",
      "label": "studied for"
    },
    {
      "source": "Quantitative data",
      "target": "UHPLC",
      "label": "is from"
    },
    {
      "source": "Paeoniflorin",
      "target": "radiation-induced oxidative injury",
      "label": "protected from"
    },
    {
      "source": "Paeoniflorin",
      "target": "mechanisms",
      "label": "elucidates"
    },
    {
      "source": "Paeoniflorin",
      "target": "HO-1 expression",
      "label": "induced"
    },
    {
      "source": "Paeoniflorin",
      "target": "cell viability",
      "label": "enhanced"
    },
    {
      "source": "Paeoniflorin",
      "target": "glutathione",
      "label": "enhanced production of"
    },
    {
      "source": "Paeoniflorin",
      "target": "heme oxygenase-1 pathway",
      "label": "activates"
    },
    {
      "source": "Paeoniflorin",
      "target": "NF-E2-related factor 2",
      "label": "activates"
    },
    {
      "source": "Paeoniflorin",
      "target": "EA.hy926 cells",
      "label": "protected"
    },
    {
      "source": "Paeoniflorin",
      "target": "human EA.hy926 endothelial cells",
      "label": "protects"
    },
    {
      "source": "Paeoniflorin",
      "target": "intracellular reactive oxygen species",
      "label": "reduced"
    },
    {
      "source": "Paeoniflorin",
      "target": "nuclear translocation",
      "label": "promoted"
    },
    {
      "source": "Paeoniflorin",
      "target": "apoptosis",
      "label": "inhibited"
    },
    {
      "source": "Paeoniflorin",
      "target": "radiation-induced injury",
      "label": "protected against"
    },
    {
      "source": "Paeoniflorin",
      "target": "GSH",
      "label": "enhanced production of"
    },
    {
      "source": "Paeoniflorin",
      "target": "ROS",
      "label": "reduced"
    },
    {
      "source": "Paeoniflorin",
      "target": "mitochondrial membrane potential",
      "label": "decreased"
    },
    {
      "source": "Paeoniflorin",
      "target": "oxidative injury",
      "label": "protects against"
    },
    {
      "source": "Paeoniflorin",
      "target": "protective effect",
      "label": "has"
    },
    {
      "source": "Paeoniflorin",
      "target": "LDH leakage",
      "label": "reduced"
    },
    {
      "source": "Paeoniflorin",
      "target": "Nrf2/HO-1 pathway",
      "label": "acts through"
    },
    {
      "source": "Paeoniflorin",
      "target": "nuclear factor erythroid 2 related factor-2",
      "label": "promoted nuclear translocation of"
    },
    {
      "source": "Paeoniflorin",
      "target": "malondialdehyde",
      "label": "reduced"
    },
    {
      "source": "Paeoniflorin",
      "target": "superoxide dismutase",
      "label": "enhanced production of"
    },
    {
      "source": "Paeoniflorin",
      "target": "SOD",
      "label": "enhanced production of"
    },
    {
      "source": "Paeoniflorin",
      "target": "MDA",
      "label": "reduced"
    },
    {
      "source": "Paeoniflorin",
      "target": "Nrf-2",
      "label": "promoted nuclear translocation of"
    },
    {
      "source": "ZNPP",
      "target": "protective effect",
      "label": "reversed"
    },
    {
      "source": "ZNPP",
      "target": "HO-1",
      "label": "inhibited"
    },
    {
      "source": "zinc protoporphyrin IX",
      "target": "protective effect",
      "label": "reversed"
    },
    {
      "source": "zinc protoporphyrin IX",
      "target": "HO-1",
      "label": "inhibited"
    },
    {
      "source": "NF-E2-related factor 2",
      "target": "GSH metabolism",
      "label": "plays critical role in"
    },
    {
      "source": "NF-E2-related factor 2",
      "target": "Transcription Factors",
      "label": "is a"
    },
    {
      "source": "Nrf2 siRNA",
      "target": "HO-1 expression",
      "label": "abrogated"
    },
    {
      "source": "Pulmonary endothelial cells",
      "target": "radiation-induced lung injury",
      "label": "has critical role in pathogenesis of"
    },
    {
      "source": "Vicia faba L.",
      "target": "subspecies minor",
      "label": "has subspecies"
    },
    {
      "source": "Vicia faba L.",
      "target": "subspecies major",
      "label": "has subspecies"
    },
    {
      "source": "whole seeds",
      "target": "aqueous (70%) acetone",
      "label": "extracted with"
    },
    {
      "source": "whole seeds",
      "target": "antioxidant activities",
      "label": "evaluated for"
    },
    {
      "source": "whole seeds",
      "target": "(80%) ethanol",
      "label": "extracted with"
    },
    {
      "source": "aqueous (70%) acetone",
      "target": "solvents",
      "label": "is a type of"
    },
    {
      "source": "faba bean",
      "target": "cotyledons",
      "label": "separated into"
    },
    {
      "source": "faba bean",
      "target": "Vicia faba L.",
      "label": "is also known as"
    },
    {
      "source": "faba bean",
      "target": "hulls",
      "label": "separated into"
    },
    {
      "source": "cotyledons",
      "target": "(80%) ethanol",
      "label": "extracted with"
    },
    {
      "source": "cotyledons",
      "target": "aqueous (70%) acetone",
      "label": "extracted with"
    },
    {
      "source": "cotyledons",
      "target": "antioxidant activities",
      "label": "evaluated for"
    },
    {
      "source": "hulls",
      "target": "aqueous (70%) acetone",
      "label": "extracted with"
    },
    {
      "source": "hulls",
      "target": "antioxidant activities",
      "label": "exhibited"
    },
    {
      "source": "hulls",
      "target": "(80%) ethanol",
      "label": "extracted with"
    },
    {
      "source": "(80%) ethanol",
      "target": "solvents",
      "label": "is a type of"
    },
    {
      "source": "antiradical activity (DPPH)",
      "target": "assays",
      "label": "is a type of"
    },
    {
      "source": "15-LOX",
      "target": "IC(50)",
      "label": "has"
    },
    {
      "source": "tannins",
      "target": "faba bean",
      "label": "from"
    },
    {
      "source": "Aqueous ethanol (80%) extract",
      "target": "COX-1",
      "label": "had inhibitory effects on"
    },
    {
      "source": "Aqueous ethanol (80%) extract",
      "target": "COX-2",
      "label": "had inhibitory effects on"
    },
    {
      "source": "Aqueous ethanol (80%) extract",
      "target": "anti-inflammatory activities",
      "label": "exhibited"
    },
    {
      "source": "Aqueous ethanol (80%) extract",
      "target": "15-LOX",
      "label": "inhibited"
    },
    {
      "source": "Aqueous ethanol (80%) extract",
      "target": "lentil hulls",
      "label": "is an extract of"
    },
    {
      "source": "Aqueous ethanol (80%) extract",
      "target": "antioxidant activities",
      "label": "exhibited"
    },
    {
      "source": "lentil seeds",
      "target": "hulls",
      "label": "separated into"
    },
    {
      "source": "lentil seeds",
      "target": "Algeria",
      "label": "grown in"
    },
    {
      "source": "lentil seeds",
      "target": "cotyledons",
      "label": "separated into"
    },
    {
      "source": "Acetone",
      "target": "tannins",
      "label": "extracted"
    },
    {
      "source": "reducing power (RP)",
      "target": "assays",
      "label": "is a type of"
    },
    {
      "source": "oxygen radical absorbance capacity (ORAC)",
      "target": "assays",
      "label": "is a type of"
    },
    {
      "source": "faba bean hull extracts",
      "target": "LOX inhibitory activity",
      "label": "exerted"
    },
    {
      "source": "Phenolics content",
      "target": "legume fractions",
      "label": "is a property of"
    },
    {
      "source": "deoxynivalenol",
      "target": "mitogen activated protein kinases",
      "label": "activates"
    },
    {
      "source": "deoxynivalenol",
      "target": "The food contaminant",
      "label": "is a type of"
    },
    {
      "source": "mitogen activated protein kinases",
      "target": "signaling pathways",
      "label": "play role in"
    },
    {
      "source": "mitogen activated protein kinases",
      "target": "intestine",
      "label": "located in"
    },
    {
      "source": "ex vivo models",
      "target": "in vivo experiments",
      "label": "are alternative to"
    },
    {
      "source": "in vivo experiments",
      "target": "models",
      "label": "is a type of"
    },
    {
      "source": "DON-contaminated diet",
      "target": "2.3 mg DON/kg feed",
      "label": "contains"
    },
    {
      "source": "Trichothecenes",
      "target": "cell junction proteins",
      "label": "decrease expression of"
    },
    {
      "source": "Trichothecenes",
      "target": "intestinal barrier function",
      "label": "induce changes in"
    },
    {
      "source": "Trichothecenes",
      "target": "apoptosis",
      "label": "induce"
    },
    {
      "source": "Twelve weaning piglets",
      "target": "DON-contaminated diet",
      "label": "received"
    },
    {
      "source": "Twelve weaning piglets",
      "target": "control diet",
      "label": "received"
    },
    {
      "source": "Explants",
      "target": "10 \u03bcM DON",
      "label": "exposed to"
    },
    {
      "source": "Explants",
      "target": "DON",
      "label": "exposed to"
    },
    {
      "source": "Explants",
      "target": "5 \u03bcM DON",
      "label": "exposed to"
    },
    {
      "source": "Explants",
      "target": "vehicle",
      "label": "exposed to"
    },
    {
      "source": "Explants",
      "target": "jejunal score",
      "label": "showed decrease in"
    },
    {
      "source": "in vivo exposure",
      "target": "intestinal tissue",
      "label": "of"
    },
    {
      "source": "in vivo exposure",
      "target": "activation",
      "label": "lead to"
    },
    {
      "source": "in vivo exposure",
      "target": "DON",
      "label": "to"
    },
    {
      "source": "in vivo exposure",
      "target": "intestinal lesions",
      "label": "lead to"
    },
    {
      "source": "intestinal lesions",
      "target": "similarity",
      "label": "exhibit"
    },
    {
      "source": "similarity",
      "target": "evidence",
      "label": "provides"
    },
    {
      "source": "similarity",
      "target": "in vivo results",
      "label": "is of"
    },
    {
      "source": "similarity",
      "target": "ex vivo results",
      "label": "is of"
    },
    {
      "source": "low doses of DON",
      "target": "MAPK",
      "label": "activate"
    },
    {
      "source": "low doses of DON",
      "target": "ERK 1/2",
      "label": "activate"
    },
    {
      "source": "low doses of DON",
      "target": "histological changes",
      "label": "induce"
    },
    {
      "source": "low doses of DON",
      "target": "JNK",
      "label": "activate"
    },
    {
      "source": "low doses of DON",
      "target": "p38",
      "label": "activate"
    },
    {
      "source": "homeostasis",
      "target": "intestinal tissue",
      "label": "of"
    },
    {
      "source": "homeostasis",
      "target": "barrier function",
      "label": "includes"
    },
    {
      "source": "homeostasis",
      "target": "immune protection",
      "label": "includes"
    },
    {
      "source": "in vivo results",
      "target": "results",
      "label": "is a type of"
    },
    {
      "source": "toxin",
      "target": "phosphorylation",
      "label": "enhanced"
    },
    {
      "source": "ex vivo results",
      "target": "results",
      "label": "is a type of"
    },
    {
      "source": "jejunal explants",
      "target": "models",
      "label": "is a type of"
    },
    {
      "source": "jejunal explants",
      "target": "ex vivo model",
      "label": "is a type of"
    },
    {
      "source": "Pigs",
      "target": "DON-diet",
      "label": "fed"
    },
    {
      "source": "Pigs",
      "target": "jejunal score",
      "label": "showed decrease in"
    },
    {
      "source": "jejunal explant model",
      "target": "toxicological studies",
      "label": "is alternative for"
    },
    {
      "source": "toxicological studies",
      "target": "intestinal tissue",
      "label": "in"
    },
    {
      "source": "Intestinal changes",
      "target": "histological score",
      "label": "graded using"
    },
    {
      "source": "Six weaning piglets",
      "target": "jejunal explants",
      "label": "used to prepare"
    },
    {
      "source": "normal 46,XY genital virilization",
      "target": "androgen receptor gene expression",
      "label": "depends on"
    },
    {
      "source": "normal 46,XY genital virilization",
      "target": "normal androgen receptor mRNA levels",
      "label": "requires"
    },
    {
      "source": "urethral mucosa",
      "target": "patients with middle idiopathic hypospadias",
      "label": "of"
    },
    {
      "source": "amount of androgen receptor mRNA",
      "target": "quantitative real time PCR",
      "label": "measured by"
    },
    {
      "source": "amount of androgen receptor mRNA",
      "target": "cells",
      "label": "is in"
    },
    {
      "source": "negative correlation",
      "target": "penile size",
      "label": "between"
    },
    {
      "source": "negative correlation",
      "target": "patients with hypospadias",
      "label": "detected in"
    },
    {
      "source": "negative correlation",
      "target": "CAG repeats",
      "label": "between"
    },
    {
      "source": "negative correlation",
      "target": "controls",
      "label": "not detected in"
    },
    {
      "source": "control phimosis subjects",
      "target": "eutopic urethral opening",
      "label": "have"
    },
    {
      "source": "Androgen Receptor mRNA",
      "target": "Quantitative Real Time PCR",
      "label": "measured by"
    },
    {
      "source": "Androgen Receptor mRNA",
      "target": "urethral mucosa of patients with hypospadias",
      "label": "is less in"
    },
    {
      "source": "Androgen Receptor mRNA",
      "target": "controls",
      "label": "is less than in"
    },
    {
      "source": "Androgen Receptor mRNA",
      "target": "Urethral Mucosa",
      "label": "is decreased in"
    },
    {
      "source": "Androgen Receptor mRNA",
      "target": "patients with middle idiopathic hypospadias",
      "label": "is decreased in"
    },
    {
      "source": "aim of this study",
      "target": "amount of androgen receptor mRNA",
      "label": "was to compare"
    },
    {
      "source": "aim of this study",
      "target": "androgen receptor mRNA levels",
      "label": "was to compare"
    },
    {
      "source": "Urethral Mucosa",
      "target": "patients with middle idiopathic hypospadias",
      "label": "of"
    },
    {
      "source": "Prepubertal individuals",
      "target": "hypospadias patients",
      "label": "included"
    },
    {
      "source": "Prepubertal individuals",
      "target": "controls",
      "label": "included"
    },
    {
      "source": "hypospadias patients",
      "target": "mean (SD) ages",
      "label": "had"
    },
    {
      "source": "correlation",
      "target": "penile size",
      "label": "between"
    },
    {
      "source": "correlation",
      "target": "hypospadias patients",
      "label": "observed in"
    },
    {
      "source": "correlation",
      "target": "level of androgen receptor mRNA expression",
      "label": "between"
    },
    {
      "source": "correlation",
      "target": "effects",
      "label": "with"
    },
    {
      "source": "reduced androgen sensitivity",
      "target": "genital tissues",
      "label": "is in"
    },
    {
      "source": "number of CAG repeats",
      "target": "exon 1",
      "label": "is in"
    },
    {
      "source": "number of CAG repeats",
      "target": "GeneScan analysis",
      "label": "established by"
    },
    {
      "source": "critical lower level of androgen receptor mRNA expression",
      "target": "determining factor",
      "label": "is a"
    },
    {
      "source": "determining factor",
      "target": "Middle Idiopathic Hypospadias",
      "label": "is in the development of"
    },
    {
      "source": "Hypospadias",
      "target": "reduced androgen sensitivity",
      "label": "is related to"
    },
    {
      "source": "Hypospadias",
      "target": "frequent male genital abnormality",
      "label": "is a"
    },
    {
      "source": "androgen receptor mRNA levels",
      "target": "control phimosis subjects",
      "label": "observed in"
    },
    {
      "source": "normal androgen receptor mRNA levels",
      "target": "androgen sensitive tissues",
      "label": "are in"
    },
    {
      "source": "Androgen action",
      "target": "androgen receptor",
      "label": "is exerted through"
    },
    {
      "source": "4-fluoroquinuclidine",
      "target": "pKa",
      "label": "lowered"
    },
    {
      "source": "4-fluoroquinuclidine",
      "target": "efflux",
      "label": "reduced"
    },
    {
      "source": "pKa",
      "target": "quinuclidine moiety",
      "label": "is a property of"
    },
    {
      "source": "HTS hit (1)",
      "target": "4-phenyl-1-(quinuclidin-3-ylmethyl)quinolin-2(1H)-one",
      "label": "was optimized to yield"
    },
    {
      "source": "quinolone",
      "target": "agonists",
      "label": "are"
    },
    {
      "source": "High throughput screening",
      "target": "quinolone",
      "label": "identified"
    },
    {
      "source": "brain penetrance",
      "target": "transporter-mediated efflux",
      "label": "attributed to"
    },
    {
      "source": "transporter-mediated efflux",
      "target": "pKa",
      "label": "due to"
    },
    {
      "source": "efflux",
      "target": "Caco-2 assay",
      "label": "measured by"
    },
    {
      "source": "efflux",
      "target": "3H-noradrenaline",
      "label": "of"
    },
    {
      "source": "histidine methyl ester",
      "target": "substrate analogue inhibitor",
      "label": "is a"
    },
    {
      "source": "rugosin A",
      "target": "main components",
      "label": "is a"
    },
    {
      "source": "rugosin A",
      "target": "K(i) values",
      "label": "has"
    },
    {
      "source": "rugosin A",
      "target": "non-competitive type of inhibition",
      "label": "exhibited"
    },
    {
      "source": "rugosin A",
      "target": "ellagitannins",
      "label": "is a type of"
    },
    {
      "source": "Agents",
      "target": "HDC activity",
      "label": "control"
    },
    {
      "source": "Agents",
      "target": "histamine-mediated symptoms",
      "label": "treat"
    },
    {
      "source": "Rugosin D",
      "target": "non-competitive type of inhibition",
      "label": "exhibited"
    },
    {
      "source": "Rugosin D",
      "target": "K(i) values",
      "label": "has"
    },
    {
      "source": "Rugosin D",
      "target": "ellagitannins",
      "label": "is a type of"
    },
    {
      "source": "Rugosin D",
      "target": "main components",
      "label": "is a"
    },
    {
      "source": "tellimagrandin II",
      "target": "main components",
      "label": "is a"
    },
    {
      "source": "tellimagrandin II",
      "target": "non-competitive type of inhibition",
      "label": "exhibited"
    },
    {
      "source": "tellimagrandin II",
      "target": "K(i) values",
      "label": "has"
    },
    {
      "source": "tellimagrandin II",
      "target": "ellagitannins",
      "label": "is a type of"
    },
    {
      "source": "rugosin A methyl ester",
      "target": "main components",
      "label": "is a"
    },
    {
      "source": "rugosin A methyl ester",
      "target": "K(i) values",
      "label": "has"
    },
    {
      "source": "rugosin A methyl ester",
      "target": "non-competitive type of inhibition",
      "label": "exhibited"
    },
    {
      "source": "rugosin A methyl ester",
      "target": "novel compound",
      "label": "is a"
    },
    {
      "source": "rugosin A methyl ester",
      "target": "ellagitannins",
      "label": "is a type of"
    },
    {
      "source": "HDC",
      "target": "histamine",
      "label": "catalyses formation of"
    },
    {
      "source": "histamine-mediated symptoms",
      "target": "stomach ulceration",
      "label": "include"
    },
    {
      "source": "histamine-mediated symptoms",
      "target": "allergies",
      "label": "include"
    },
    {
      "source": "stomach ulceration",
      "target": "ethanol",
      "label": "INDUCED_BY"
    },
    {
      "source": "stomach ulceration",
      "target": "ethanol ingestion",
      "label": "INDUCED_BY"
    },
    {
      "source": "active food constituents",
      "target": "clinically available HDC inhibitors",
      "label": "are useful for designing"
    },
    {
      "source": "Filipendula ulmaria",
      "target": "recombinant human histidine decarboxylase",
      "label": "has inhibitory activity on"
    },
    {
      "source": "Filipendula ulmaria",
      "target": "meadowsweet",
      "label": "is also called"
    },
    {
      "source": "Histidine decarboxylase",
      "target": "histamine",
      "label": "catalyses formation of"
    },
    {
      "source": "histamine",
      "target": "bioactive amine",
      "label": "is a"
    },
    {
      "source": "histamine",
      "target": "histamine induced vascular permeability changes",
      "label": "induces"
    },
    {
      "source": "food products",
      "target": "potent HDC inhibitors",
      "label": "contain"
    },
    {
      "source": "ethyl acetate extract",
      "target": "inhibitors",
      "label": "contains"
    },
    {
      "source": "ethyl acetate extract",
      "target": "petal",
      "label": "is extracted from"
    },
    {
      "source": "petal",
      "target": "Filipendula ulmaria",
      "label": "is part of"
    },
    {
      "source": "Chemotherapy cycles",
      "target": "CINV",
      "label": "influences"
    },
    {
      "source": "Management",
      "target": "Newer agents",
      "label": "focuses on"
    },
    {
      "source": "Management",
      "target": "Older agents",
      "label": "focuses on"
    },
    {
      "source": "Management",
      "target": "Chemotherapy-induced nausea and vomiting",
      "label": "is for"
    },
    {
      "source": "Rolapitant",
      "target": "NK1 receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "Rolapitant",
      "target": "Phase III clinical trials",
      "label": "is in"
    },
    {
      "source": "Rolapitant",
      "target": "NK1 receptor antagonist drug class",
      "label": "is a type of"
    },
    {
      "source": "Combination",
      "target": "Control",
      "label": "improves"
    },
    {
      "source": "Control",
      "target": "Emesis",
      "label": "is for"
    },
    {
      "source": "Control",
      "target": "CINV",
      "label": "is for"
    },
    {
      "source": "Control",
      "target": "Nausea",
      "label": "is for"
    },
    {
      "source": "Control",
      "target": "Delayed emesis",
      "label": "is for"
    },
    {
      "source": "Control",
      "target": "Acute emesis",
      "label": "is for"
    },
    {
      "source": "Control",
      "target": "Clinical settings",
      "label": "occurs in"
    },
    {
      "source": "Aprepitant",
      "target": "NK1 receptor antagonist drug class",
      "label": "is an agent in"
    },
    {
      "source": "Aprepitant",
      "target": "CINV",
      "label": "controls"
    },
    {
      "source": "Aprepitant",
      "target": "Dexamethasone",
      "label": "is an additive agent to"
    },
    {
      "source": "Aprepitant",
      "target": "First-generation 5-HT3 receptor antagonists",
      "label": "is an additive agent to"
    },
    {
      "source": "Aprepitant",
      "target": "NK1 receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "Ginger",
      "target": "Efficacy",
      "label": "has uncertain"
    },
    {
      "source": "Efficacy",
      "target": "Prevention",
      "label": "is for"
    },
    {
      "source": "Acute emesis",
      "target": "Single-day chemotherapy",
      "label": "occurs in"
    },
    {
      "source": "Emetogenicity",
      "target": "Chemotherapeutic agents",
      "label": "is a property of"
    },
    {
      "source": "Emetogenicity",
      "target": "CINV",
      "label": "influences"
    },
    {
      "source": "Delayed emesis",
      "target": "Single-day chemotherapy",
      "label": "occurs in"
    },
    {
      "source": "Netupitant",
      "target": "NK1 receptor antagonist drug class",
      "label": "is a type of"
    },
    {
      "source": "Netupitant",
      "target": "NK1 receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "Netupitant",
      "target": "Phase III clinical trials",
      "label": "is in"
    },
    {
      "source": "Gabapentin",
      "target": "Efficacy",
      "label": "has uncertain"
    },
    {
      "source": "Serotonin 5-HT3 receptor antagonist",
      "target": "5-HT3 receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "Serotonin 5-HT3 receptor antagonist",
      "target": "Combination",
      "label": "is a component of"
    },
    {
      "source": "Serotonin 5-HT3 receptor antagonist",
      "target": "Serotonin",
      "label": "is an antagonist of"
    },
    {
      "source": "Clinical settings",
      "target": "Bone marrow transplantation",
      "label": "include"
    },
    {
      "source": "Clinical settings",
      "target": "Multiple-day chemotherapy",
      "label": "include"
    },
    {
      "source": "Patient risk factors",
      "target": "CINV",
      "label": "influences"
    },
    {
      "source": "Prevention",
      "target": "CINV",
      "label": "is for"
    },
    {
      "source": "Cannabinoids",
      "target": "Efficacy",
      "label": "has uncertain"
    },
    {
      "source": "Neurokinin 1 (NK1) receptor antagonist",
      "target": "NK1 receptor",
      "label": "is an antagonist of"
    },
    {
      "source": "Neurokinin 1 (NK1) receptor antagonist",
      "target": "Combination",
      "label": "is a component of"
    },
    {
      "source": "dissolved oxygen",
      "target": "DO",
      "label": "is also known as"
    },
    {
      "source": "DO",
      "target": "Fe (II) ions",
      "label": "leads to release of"
    },
    {
      "source": "DO",
      "target": "hydrogen peroxide",
      "label": "leads to release of"
    },
    {
      "source": "DO",
      "target": "HPO",
      "label": "leads to release of"
    },
    {
      "source": "in vivo chicken embryo model",
      "target": "CEM",
      "label": "is also known as"
    },
    {
      "source": "in vivo chicken embryo model",
      "target": "gallic acid",
      "label": "revealed"
    },
    {
      "source": "CEM",
      "target": "gallic acid",
      "label": "demonstrated"
    },
    {
      "source": "in vitro polyphenolics erythrocyte model",
      "target": "gallic acid",
      "label": "revealed"
    },
    {
      "source": "prooxidant activity",
      "target": "hypoxia-related inflammation",
      "label": "elicits"
    },
    {
      "source": "prooxidant activity",
      "target": "hemolysis",
      "label": "elicits"
    },
    {
      "source": "hypoxia-related inflammation",
      "target": "chicken cervical muscles",
      "label": "occurs in"
    },
    {
      "source": "HPO",
      "target": "two-phase kinetic pattern",
      "label": "exhibits"
    },
    {
      "source": "GA",
      "target": "phase II HPO production",
      "label": "affects"
    },
    {
      "source": "GA",
      "target": "dissolved oxygen",
      "label": "could deplete"
    },
    {
      "source": "GA",
      "target": "prooxidant activity",
      "label": "has"
    },
    {
      "source": "GA",
      "target": "hypoxia-related inflammation",
      "label": "elicits"
    },
    {
      "source": "GA",
      "target": "DO",
      "label": "could deplete"
    },
    {
      "source": "GA",
      "target": "phase I HPO production",
      "label": "affects"
    },
    {
      "source": "GA",
      "target": "gallic acid",
      "label": "is also known as"
    },
    {
      "source": "GA",
      "target": "hemolysis",
      "label": "elicits"
    },
    {
      "source": "phase II HPO production",
      "target": "kinetic coefficients",
      "label": "has associated"
    },
    {
      "source": "liposis",
      "target": "cervical muscles",
      "label": "is a symptom of"
    },
    {
      "source": "Fe (II) ions",
      "target": "two-phase kinetic pattern",
      "label": "exhibits"
    },
    {
      "source": "semiquinone",
      "target": "ROS",
      "label": "favors"
    },
    {
      "source": "hydrogen peroxide",
      "target": "HPO",
      "label": "is also known as"
    },
    {
      "source": "kinetic coefficients",
      "target": "Fe (III) ion",
      "label": "are for"
    },
    {
      "source": "kinetic coefficients",
      "target": "Fe (II) ions",
      "label": "are for"
    },
    {
      "source": "Zenker's necrosis",
      "target": "cervical muscles",
      "label": "is a symptom of"
    },
    {
      "source": "PEM",
      "target": "DO",
      "label": "revealed"
    },
    {
      "source": "PEM",
      "target": "CEM",
      "label": "supports"
    },
    {
      "source": "gene hif-1\u03b1",
      "target": "cervical muscles",
      "label": "is located in"
    },
    {
      "source": "phase I HPO production",
      "target": "kinetic coefficients",
      "label": "has associated"
    },
    {
      "source": "hemolysis",
      "target": "cervical muscles",
      "label": "is a symptom of"
    },
    {
      "source": "hemolysis",
      "target": "atypical pathways",
      "label": "was stimulated by"
    },
    {
      "source": "hemolysis",
      "target": "TNF-\u03b1-canonical pathway",
      "label": "was stimulated by"
    },
    {
      "source": "hemolysis",
      "target": "chicken cervical muscles",
      "label": "occurs in"
    },
    {
      "source": "quinone",
      "target": "ROS",
      "label": "favors"
    },
    {
      "source": "cervical muscle inflammation",
      "target": "atypical pathways",
      "label": "was stimulated by"
    },
    {
      "source": "cervical muscle inflammation",
      "target": "TNF-\u03b1-canonical pathway",
      "label": "was stimulated by"
    },
    {
      "source": "in vitro polyphenolics-erythrocyte model",
      "target": "PEM",
      "label": "is also known as"
    },
    {
      "source": "Inflammatory edema",
      "target": "cervical muscles",
      "label": "is a symptom of"
    },
    {
      "source": "NF\u03baB",
      "target": "cervical muscles",
      "label": "is located in"
    },
    {
      "source": "SAR",
      "target": "Rock inhibitors",
      "label": "are for"
    },
    {
      "source": "SAR",
      "target": "HTS campaign",
      "label": "associated with"
    },
    {
      "source": "SAR",
      "target": "labile stereocenter",
      "label": "provided solution to"
    },
    {
      "source": "SAR",
      "target": "benzotriazepine scaffolds",
      "label": "transferred to"
    },
    {
      "source": "SAR",
      "target": "spirobenzodiazepine scaffolds",
      "label": "transferred to"
    },
    {
      "source": "Rock inhibitors",
      "target": "amino acid-derived quinazolines",
      "label": "are based on"
    },
    {
      "source": "Rock inhibitors",
      "target": "non-amino acid derived quinazolinones",
      "label": "are based on"
    },
    {
      "source": "amino acid derived quinazolinones",
      "target": "Rock",
      "label": "inhibit"
    },
    {
      "source": "amino acid derived quinazolinones",
      "target": "pan-Rock (I & II) inhibitors",
      "label": "are"
    },
    {
      "source": "Amino acid derived quinazolines",
      "target": "PKA",
      "label": "inhibit"
    },
    {
      "source": "Amino acid derived quinazolines",
      "target": "Rock",
      "label": "inhibit"
    },
    {
      "source": "Amino acid derived quinazolines",
      "target": "Rock inhibitors",
      "label": "are"
    },
    {
      "source": "sub-nanomolar inhibition",
      "target": "Rock",
      "label": "is of"
    },
    {
      "source": "non-amino acid derived quinazolinones",
      "target": "PKA",
      "label": "inhibit"
    },
    {
      "source": "nanomolar potency",
      "target": "ppMLC cell based assays",
      "label": "is in"
    },
    {
      "source": "lead optimization studies",
      "target": "Rock inhibitors",
      "label": "are for"
    },
    {
      "source": "ED50",
      "target": "potency",
      "label": "is a measure of"
    },
    {
      "source": "prodrugs",
      "target": "HSA",
      "label": "are based on"
    },
    {
      "source": "antibacterial activity",
      "target": "linezolid-resistant strains",
      "label": "against"
    },
    {
      "source": "antibacterial activity",
      "target": "Gram-positive pathogens",
      "label": "against"
    },
    {
      "source": "antibacterial activity",
      "target": "imidazolidinone ring",
      "label": "is superior to"
    },
    {
      "source": "Solubility",
      "target": "structural modification",
      "label": "drives"
    },
    {
      "source": "Solubility",
      "target": "polar groups",
      "label": "enhanced by"
    },
    {
      "source": "Solubility",
      "target": "(pyridin-3-yl) benzoxazinyl-oxazolidinones",
      "label": "drives optimization of"
    },
    {
      "source": "Solubility",
      "target": "antibacterial agent",
      "label": "leads to"
    },
    {
      "source": "Solubility",
      "target": "prodrugs",
      "label": "enhanced by"
    },
    {
      "source": "structural modification",
      "target": "new series of benzoxazinyl-oxazolidinone analogues",
      "label": "resulted in development of"
    },
    {
      "source": "structural modification",
      "target": "(pyridin-3-yl) benzoxazinyl-oxazolidinones",
      "label": "of"
    },
    {
      "source": "structural modification",
      "target": "drug",
      "label": "is on"
    },
    {
      "source": "compound 85",
      "target": "Solubility",
      "label": "exhibited excellent"
    },
    {
      "source": "compound 85",
      "target": "ED50",
      "label": "displayed"
    },
    {
      "source": "compound 85",
      "target": "MRSA systemic infection model",
      "label": "tested in"
    },
    {
      "source": "compound 85",
      "target": "pharmacokinetic profile",
      "label": "exhibited good"
    },
    {
      "source": "compound 85",
      "target": "prodrugs",
      "label": "is a type of"
    },
    {
      "source": "Oxazolidinone ring substitution",
      "target": "antibacterial activity",
      "label": "generated analogues with superior"
    },
    {
      "source": "Oxazolidinone ring substitution",
      "target": "pyridyl ring",
      "label": "on"
    },
    {
      "source": "various substituents",
      "target": "pyridyl ring",
      "label": "on"
    },
    {
      "source": "new series of benzoxazinyl-oxazolidinone analogues",
      "target": "hERG inhibition",
      "label": "has low"
    },
    {
      "source": "new series of benzoxazinyl-oxazolidinone analogues",
      "target": "antibacterial activity",
      "label": "has high"
    },
    {
      "source": "small and nonbasic substituents",
      "target": "sterically demanding or basic substituents",
      "label": "are preferable to"
    },
    {
      "source": "structure-activity relationship (SAR) trends",
      "target": "various substituents",
      "label": "among"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Genders",
      "label": "comparable in"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Male Fvb mice",
      "label": "lower in"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Females",
      "label": "observed in"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Strains",
      "label": "comparable in"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Fvb mice",
      "label": "lower in"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Swiss mice",
      "label": "higher in"
    },
    {
      "source": "Plasma NBUP concentrations",
      "target": "Female Fvb mice",
      "label": "higher in"
    },
    {
      "source": "NBUP",
      "target": "Expiratory time",
      "label": "increased"
    },
    {
      "source": "NBUP",
      "target": "BUP",
      "label": "is a metabolite of"
    },
    {
      "source": "NBUP",
      "target": "Metabolite",
      "label": "is a"
    },
    {
      "source": "NBUP",
      "target": "Toxic metabolite",
      "label": "is a"
    },
    {
      "source": "Asphyxia",
      "target": "BUP",
      "label": "related to"
    },
    {
      "source": "BUP",
      "target": "Inspiratory time",
      "label": "increased"
    },
    {
      "source": "BUP",
      "target": "Ceiling respiratory effects",
      "label": "causes"
    },
    {
      "source": "Deaths",
      "target": "Asphyxia",
      "label": "from"
    },
    {
      "source": "Deaths",
      "target": "Males",
      "label": "reported in"
    },
    {
      "source": "P-gp expression",
      "target": "Swiss mice",
      "label": "no differences between"
    },
    {
      "source": "P-gp expression",
      "target": "Female Fvb mice",
      "label": "no differences between"
    },
    {
      "source": "P-gp expression",
      "target": "Fvb mice",
      "label": "no differences between"
    },
    {
      "source": "P-gp expression",
      "target": "Western blot",
      "label": "studied using"
    },
    {
      "source": "P-gp expression",
      "target": "Male Fvb mice",
      "label": "no differences between"
    },
    {
      "source": "Female Fvb mice",
      "target": "NBUP",
      "label": "more susceptible to"
    },
    {
      "source": "Female Fvb mice",
      "target": "Males",
      "label": "more susceptible than"
    },
    {
      "source": "Female Fvb mice",
      "target": "BUP",
      "label": "more susceptible to"
    },
    {
      "source": "BUP-related respiratory toxicity",
      "target": "Mice",
      "label": "occurs in"
    },
    {
      "source": "Mice",
      "target": "Visceral Adiposity",
      "label": "have increased"
    },
    {
      "source": "Mice",
      "target": "visceral fat",
      "label": "have increased"
    },
    {
      "source": "Mice",
      "target": "Insulin Sensitivity",
      "label": "are more"
    },
    {
      "source": "Mice",
      "target": "T-bet",
      "label": "are deficient in"
    },
    {
      "source": "Mice",
      "target": "Immune Cell Transcription Factor",
      "label": "are deficient for"
    },
    {
      "source": "Mice",
      "target": "energy expenditure",
      "label": "have lower"
    },
    {
      "source": "NBUP transport",
      "target": "Swiss mice",
      "label": "no differences between"
    },
    {
      "source": "NBUP transport",
      "target": "Female Fvb mice",
      "label": "no differences between"
    },
    {
      "source": "NBUP transport",
      "target": "Fvb mice",
      "label": "no differences between"
    },
    {
      "source": "NBUP transport",
      "target": "BBB",
      "label": "across"
    },
    {
      "source": "NBUP transport",
      "target": "Male Fvb mice",
      "label": "no differences between"
    },
    {
      "source": "NBUP transport",
      "target": "Brain",
      "label": "into"
    },
    {
      "source": "Gender",
      "target": "Variability",
      "label": "contributes to"
    },
    {
      "source": "Gender",
      "target": "associations",
      "label": "moderated"
    },
    {
      "source": "Variability",
      "target": "BUP-related respiratory toxicity",
      "label": "of"
    },
    {
      "source": "NBUP-related reduction",
      "target": "Fvb mice",
      "label": "more marked in"
    },
    {
      "source": "NBUP-related reduction",
      "target": "Swiss mice",
      "label": "less marked in"
    },
    {
      "source": "NBUP-related reduction",
      "target": "Minute volume",
      "label": "affects"
    },
    {
      "source": "Blood-brain barrier",
      "target": "BBB",
      "label": "is also known as"
    },
    {
      "source": "P-gp-mediated transport",
      "target": "BBB",
      "label": "across"
    },
    {
      "source": "P-gp-mediated transport",
      "target": "Strain-related variability",
      "label": "does not play key-role in"
    },
    {
      "source": "Ventilation",
      "target": "Plethysmography",
      "label": "studied using"
    },
    {
      "source": "Transport",
      "target": "In situ cerebral perfusion",
      "label": "studied using"
    },
    {
      "source": "Transport",
      "target": "BBB",
      "label": "occurs at"
    },
    {
      "source": "Transport",
      "target": "cotransport",
      "label": "involves"
    },
    {
      "source": "Transport",
      "target": "NE+",
      "label": "of"
    },
    {
      "source": "Transport",
      "target": "antidepressant-sensitive transporters",
      "label": "mediated by"
    },
    {
      "source": "Transport",
      "target": "presynaptic terminals",
      "label": "occurs in"
    },
    {
      "source": "Plasma BUP concentrations",
      "target": "Fvb mice",
      "label": "higher in"
    },
    {
      "source": "Plasma BUP concentrations",
      "target": "Females",
      "label": "observed in"
    },
    {
      "source": "Plasma BUP concentrations",
      "target": "Swiss mice",
      "label": "lower in"
    },
    {
      "source": "Plasma BUP concentrations",
      "target": "Female Fvb mice",
      "label": "lower in"
    },
    {
      "source": "Plasma BUP concentrations",
      "target": "Male Fvb mice",
      "label": "higher in"
    },
    {
      "source": "Norbuprenorphine",
      "target": "Toxic metabolite",
      "label": "is a"
    },
    {
      "source": "Norbuprenorphine",
      "target": "BUP",
      "label": "is a metabolite of"
    },
    {
      "source": "Norbuprenorphine",
      "target": "Metabolite",
      "label": "is a"
    },
    {
      "source": "Ceiling respiratory effects",
      "target": "Male Fvb mice",
      "label": "observed in"
    },
    {
      "source": "Ceiling respiratory effects",
      "target": "Swiss mice",
      "label": "observed in"
    },
    {
      "source": "Respiratory effects",
      "target": "BUP",
      "label": "of"
    },
    {
      "source": "Respiratory effects",
      "target": "NBUP",
      "label": "not attributed to"
    },
    {
      "source": "NBUP administration",
      "target": "Plasma NBUP concentrations",
      "label": "leads to"
    },
    {
      "source": "Strain-related differences",
      "target": "Respiratory effects",
      "label": "in"
    },
    {
      "source": "BUP administration",
      "target": "Plasma BUP concentrations",
      "label": "leads to"
    },
    {
      "source": "Gender-related differences",
      "target": "Respiratory effects",
      "label": "in"
    },
    {
      "source": "Strain",
      "target": "Variability",
      "label": "contributes to"
    },
    {
      "source": "diflunisal",
      "target": "HSA",
      "label": "binds to"
    },
    {
      "source": "diflunisal",
      "target": "target enzyme",
      "label": "is unavailable for reaction with"
    },
    {
      "source": "diflunisal",
      "target": "Human serum albumin",
      "label": "binds to"
    },
    {
      "source": "diflunisal",
      "target": "circulation",
      "label": "is released into"
    },
    {
      "source": "diflunisal",
      "target": "acetylated albumin",
      "label": "is released from"
    },
    {
      "source": "diflunisal",
      "target": "clinic",
      "label": "is used in"
    },
    {
      "source": "diflunisal",
      "target": "cyclooxygenase-2",
      "label": "is an inhibitor of"
    },
    {
      "source": "diflunisal",
      "target": "dose",
      "label": "is part of"
    },
    {
      "source": "acetyldiflunisal",
      "target": "prodrug",
      "label": "is a"
    },
    {
      "source": "acetyldiflunisal",
      "target": "lysine 199",
      "label": "acetylates"
    },
    {
      "source": "acetyldiflunisal",
      "target": "IIA subdomain",
      "label": "binds to"
    },
    {
      "source": "acetyldiflunisal",
      "target": "Lys199",
      "label": "acetylates"
    },
    {
      "source": "Human serum albumin",
      "target": "prodrug",
      "label": "is a basis for design of"
    },
    {
      "source": "acetylated albumin",
      "target": "binding affinity",
      "label": "had"
    },
    {
      "source": "fluorescence quenching",
      "target": "binding affinity",
      "label": "demonstrated"
    },
    {
      "source": "Mass spectrometry",
      "target": "acetyldiflunisal",
      "label": "confirmed that"
    },
    {
      "source": "preliminary structure-activity relationship",
      "target": "SAR",
      "label": "is also known as"
    },
    {
      "source": "3-aryl acrylic amide derivatives",
      "target": "l-dopa",
      "label": "prepared from"
    },
    {
      "source": "3-aryl acrylic amide derivatives",
      "target": "simplified saframycin-ecteinascidin skeleton",
      "label": "are of"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "MCF-7",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "BGC-803",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "A2780",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "HCT-8",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "BEL-7402",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "MDA-MB-231",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "A549",
      "label": "include"
    },
    {
      "source": "eight human tumor cell lines",
      "target": "MX-1",
      "label": "include"
    },
    {
      "source": "MCF-7",
      "target": "breast derived cells",
      "label": "is a type of"
    },
    {
      "source": "Compound 28",
      "target": "3-thiophenyl acrylic amide side chain",
      "label": "has"
    },
    {
      "source": "Compound 28",
      "target": "selective cytotoxicity",
      "label": "exhibited"
    },
    {
      "source": "Twenty four compounds",
      "target": "3-aryl acrylic amide side chains",
      "label": "have"
    },
    {
      "source": "Twenty four compounds",
      "target": "14-step stereospecific route",
      "label": "synthesized via"
    },
    {
      "source": "3-aryl acrylic amide side chains",
      "target": "simplified saframycin-ecteinascidin pentacyclic skeleton",
      "label": "are of"
    },
    {
      "source": "selective cytotoxicity",
      "target": "MDA-MB-231",
      "label": "against"
    },
    {
      "source": "selective cytotoxicity",
      "target": "IC50 value",
      "label": "has"
    },
    {
      "source": "14-step stereospecific route",
      "target": "l-dopa",
      "label": "starting from"
    },
    {
      "source": "\u03b1-methyltyrosine",
      "target": "tyrosine hydroxylase inhibitor",
      "label": "is a"
    },
    {
      "source": "\u03b1-methyltyrosine",
      "target": "DA release",
      "label": "abolishes"
    },
    {
      "source": "DA release",
      "target": "cell death",
      "label": "associated with"
    },
    {
      "source": "DA release",
      "target": "undifferentiated pheochromocytoma (PC12) cells",
      "label": "occurs from"
    },
    {
      "source": "DA release",
      "target": "vesicular exocytosis",
      "label": "requires"
    },
    {
      "source": "de novo catecholamine synthesis",
      "target": "vesicular dopamine release",
      "label": "mediates"
    },
    {
      "source": "vesicular dopamine release",
      "target": "rat pheochromocytoma (PC12) cells",
      "label": "occurs from"
    },
    {
      "source": "MeHg",
      "target": "DA release",
      "label": "induces"
    },
    {
      "source": "MeHg",
      "target": "intracellular DA",
      "label": "increases"
    },
    {
      "source": "MeHg",
      "target": "vesicular exocytosis",
      "label": "augments"
    },
    {
      "source": "MeHg",
      "target": "tyrosine hydroxylase activity",
      "label": "increases"
    },
    {
      "source": "MeHg",
      "target": "DA synthesis",
      "label": "facilitates"
    },
    {
      "source": "MeHg",
      "target": "DA storage utilization",
      "label": "increases"
    },
    {
      "source": "MeHg",
      "target": "DA precursor accumulation",
      "label": "increases"
    },
    {
      "source": "methylmercury",
      "target": "DA release",
      "label": "induces"
    },
    {
      "source": "methylmercury",
      "target": "vesicular dopamine release",
      "label": "induces"
    },
    {
      "source": "DA synthesis",
      "target": "DA release",
      "label": "has role in"
    },
    {
      "source": "gonad phenotype",
      "target": "individuals",
      "label": "of"
    },
    {
      "source": "gonad phenotype",
      "target": "estradiol",
      "label": "affected by exposure to"
    },
    {
      "source": "gonad phenotype",
      "target": "japanese medaka",
      "label": "in"
    },
    {
      "source": "gonad phenotype",
      "target": "trenbolone",
      "label": "affected by exposure to"
    },
    {
      "source": "gonad phenotype",
      "target": "histological techniques",
      "label": "determined by"
    },
    {
      "source": "gonad phenotype",
      "target": "key endpoint",
      "label": "is a"
    },
    {
      "source": "EDCs",
      "target": "phenotypic status of the gonad",
      "label": "affect"
    },
    {
      "source": "Sox9b",
      "target": "gonad development",
      "label": "involved in"
    },
    {
      "source": "Sox9b",
      "target": "gonad maintenance",
      "label": "involved in"
    },
    {
      "source": "gonad development",
      "target": "japanese medaka",
      "label": "in"
    },
    {
      "source": "key endpoint",
      "target": "hazard assessment",
      "label": "inputted into"
    },
    {
      "source": "key endpoint",
      "target": "risk assessment",
      "label": "inputted into"
    },
    {
      "source": "aquatic bioassays",
      "target": "US Environmental Protection Agency",
      "label": "developed by"
    },
    {
      "source": "aquatic bioassays",
      "target": "fish species",
      "label": "use"
    },
    {
      "source": "aquatic bioassays",
      "target": "Office of Economic Cooperation and Development",
      "label": "developed by"
    },
    {
      "source": "aquatic bioassays",
      "target": "endocrine-disrupting chemicals",
      "label": "for testing"
    },
    {
      "source": "aquatic bioassays",
      "target": "gonad phenotype",
      "label": "involve assessment of"
    },
    {
      "source": "relative expression levels",
      "target": "17\u03b2-estradiol",
      "label": "after exposure to"
    },
    {
      "source": "relative expression levels",
      "target": "17\u03b2-trenbolone",
      "label": "after exposure to"
    },
    {
      "source": "relative expression levels",
      "target": "genes",
      "label": "of"
    },
    {
      "source": "Environ Toxicol Chem",
      "target": "SETAC",
      "label": "published by"
    },
    {
      "source": "Environ Toxicol Chem",
      "target": "32",
      "label": "has volume"
    },
    {
      "source": "Environ Toxicol Chem",
      "target": "2013",
      "label": "published in"
    },
    {
      "source": "Environ Toxicol Chem",
      "target": "1295-1303",
      "label": "has pages"
    },
    {
      "source": "permutational multivariate analysis of variance",
      "target": "significant differences",
      "label": "determines"
    },
    {
      "source": "protamine",
      "target": "gonad maintenance",
      "label": "involved in"
    },
    {
      "source": "protamine",
      "target": "gonad development",
      "label": "involved in"
    },
    {
      "source": "gonad maintenance",
      "target": "japanese medaka",
      "label": "in"
    },
    {
      "source": "sexual genotype",
      "target": "japanese medaka",
      "label": "determined in"
    },
    {
      "source": "reverse-transcription quantitative polymerase chain reaction",
      "target": "EDCs",
      "label": "determines effects of"
    },
    {
      "source": "reverse-transcription quantitative polymerase chain reaction",
      "target": "relative expression levels",
      "label": "determines"
    },
    {
      "source": "japanese medaka",
      "target": "Oryzias latipes",
      "label": "also known as"
    },
    {
      "source": "Fig1\u03b1",
      "target": "gonad development",
      "label": "involved in"
    },
    {
      "source": "Fig1\u03b1",
      "target": "gonad maintenance",
      "label": "involved in"
    },
    {
      "source": "ZPC1",
      "target": "gonad maintenance",
      "label": "involved in"
    },
    {
      "source": "ZPC1",
      "target": "gonad development",
      "label": "involved in"
    },
    {
      "source": "gene expression data",
      "target": "gonad phenotype",
      "label": "determine effects on"
    },
    {
      "source": "BPA",
      "target": "pancreatic insulin content",
      "label": "UpRegulator"
    },
    {
      "source": "BPA",
      "target": "(14)C-glucose oxidation",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "GLUT4 translocation",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "mice endocrine pancreas",
      "label": "Affects"
    },
    {
      "source": "BPA",
      "target": "serum insulin",
      "label": "UpRegulator"
    },
    {
      "source": "BPA",
      "target": "Akt protein levels",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "GLUT4 protein levels",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "phosphorylation of Akt",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "epoxy resins",
      "label": "UsedInProductionOf"
    },
    {
      "source": "BPA",
      "target": "serum testosterone levels",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "insulin resistance",
      "label": "Favors"
    },
    {
      "source": "BPA",
      "target": "200 mg/kg bw/day",
      "label": "AdministeredAtDose"
    },
    {
      "source": "BPA",
      "target": "plastic food and beverage containers",
      "label": "UsedInProductionOf"
    },
    {
      "source": "BPA",
      "target": "estrogenic monomer",
      "label": "IsA"
    },
    {
      "source": "BPA",
      "target": "insulin-signaling molecules",
      "label": "Affects"
    },
    {
      "source": "BPA",
      "target": "IR protein levels",
      "label": "DownRegulator"
    },
    {
      "source": "BPA",
      "target": "endocrine-disrupting chemical",
      "label": "IsA"
    },
    {
      "source": "BPA",
      "target": "fasting blood glucose level",
      "label": "Not"
    },
    {
      "source": "BPA",
      "target": "postprandial hyperinsulinemia",
      "label": "Favors"
    },
    {
      "source": "BPA",
      "target": "20 mg/kg bw/day",
      "label": "AdministeredAtDose"
    },
    {
      "source": "BPA",
      "target": "glucose oxidation",
      "label": "Affects"
    },
    {
      "source": "IR protein levels",
      "target": "gastrocnemius muscle",
      "label": "LocatedIn"
    },
    {
      "source": "IR protein levels",
      "target": "plasma membrane",
      "label": "LocatedIn"
    },
    {
      "source": "IR protein levels",
      "target": "cytosolic fraction",
      "label": "LocatedIn"
    },
    {
      "source": "GLUT4 protein levels",
      "target": "gastrocnemius muscle",
      "label": "LocatedIn"
    },
    {
      "source": "GLUT4 protein levels",
      "target": "plasma membrane",
      "label": "LocatedIn"
    },
    {
      "source": "GLUT4 protein levels",
      "target": "cytosolic fraction",
      "label": "LocatedIn"
    },
    {
      "source": "Adult male Wistar albino rats",
      "target": "three groups",
      "label": "DividedInto"
    },
    {
      "source": "cytosolic fraction",
      "target": "gastrocnemius muscle",
      "label": "PartOf"
    },
    {
      "source": "plastic food and beverage containers",
      "target": "human exposure",
      "label": "LeadsTo"
    },
    {
      "source": "Akt protein levels",
      "target": "gastrocnemius muscle",
      "label": "LocatedIn"
    },
    {
      "source": "Akt protein levels",
      "target": "plasma membrane",
      "label": "LocatedIn"
    },
    {
      "source": "Akt protein levels",
      "target": "cytosolic fraction",
      "label": "LocatedIn"
    },
    {
      "source": "epoxy resins",
      "target": "human exposure",
      "label": "LeadsTo"
    },
    {
      "source": "serum testosterone levels",
      "target": "180 days of age",
      "label": "were similar at"
    },
    {
      "source": "serum testosterone levels",
      "target": "genotypes",
      "label": "were similar for"
    },
    {
      "source": "serum testosterone levels",
      "target": "radioimmunoassay",
      "label": "measured by"
    },
    {
      "source": "bisphenol-A",
      "target": "estrogenic monomer",
      "label": "IsA"
    },
    {
      "source": "bisphenol-A",
      "target": "endocrine-disrupting chemical",
      "label": "IsA"
    },
    {
      "source": "bisphenol-A",
      "target": "insulin signal transduction",
      "label": "Affects"
    },
    {
      "source": "bisphenol-A",
      "target": "glucose oxidation",
      "label": "Affects"
    },
    {
      "source": "groups II and III",
      "target": "BPA",
      "label": "AdministeredWith"
    },
    {
      "source": "insulin signal transduction",
      "target": "skeletal muscle",
      "label": "LocatedIn"
    },
    {
      "source": "Group I",
      "target": "vehicle",
      "label": "TreatedWith"
    },
    {
      "source": "Group I",
      "target": "control",
      "label": "IsA"
    },
    {
      "source": "postprandial hyperinsulinemia",
      "target": "male mice",
      "label": "LocatedIn"
    },
    {
      "source": "insulin-signaling molecules",
      "target": "skeletal muscle",
      "label": "LocatedIn"
    },
    {
      "source": "glucose oxidation",
      "target": "skeletal muscle",
      "label": "LocatedIn"
    },
    {
      "source": "one-pot domino reactions",
      "target": "Tautomerization",
      "label": "involves step"
    },
    {
      "source": "one-pot domino reactions",
      "target": "Elimination sequence of reactions",
      "label": "involves step"
    },
    {
      "source": "one-pot domino reactions",
      "target": "intramolecular Thorpe-Ziegler cyclization",
      "label": "involves step"
    },
    {
      "source": "one-pot domino reactions",
      "target": "Michael addition",
      "label": "involves step"
    },
    {
      "source": "one-pot domino reactions",
      "target": "5-aryldihydro-3(2H)-thiophenones",
      "label": "involve reactant"
    },
    {
      "source": "one-pot domino reactions",
      "target": "malononitrile",
      "label": "involve reactant"
    },
    {
      "source": "one-pot domino reactions",
      "target": "aromatic aldehydes",
      "label": "involve reactant"
    },
    {
      "source": "one-pot domino reactions",
      "target": "Knoevenagel condensation",
      "label": "involves step"
    },
    {
      "source": "one-pot domino reactions",
      "target": "morpholine",
      "label": "occur in presence of"
    },
    {
      "source": "one-pot domino synthesis",
      "target": "highly functionalized dihydrobenzo[b]thiophenes",
      "label": "produces"
    },
    {
      "source": "highly functionalized dihydrobenzo[b]thiophenes",
      "target": "AChE inhibitors",
      "label": "are classified as"
    },
    {
      "source": "5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile",
      "target": "IC50",
      "label": "has"
    },
    {
      "source": "5-amino-2,7-bis(4-methoxyphenyl)-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitrile",
      "target": "AChE",
      "label": "is potent against"
    },
    {
      "source": "5-amino-2,7-diaryl-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitriles",
      "target": "one-pot domino reactions",
      "label": "synthesized through"
    },
    {
      "source": "5-amino-2,7-diaryl-2,3-dihydrobenzo[b]thiophene-4,6-dicarbonitriles",
      "target": "AChE inhibitory activity",
      "label": "evaluated for"
    },
    {
      "source": "AChE inhibitory activity",
      "target": "acetylcholinesterase",
      "label": "is activity against"
    },
    {
      "source": "AChE inhibitory activity",
      "target": "AChE",
      "label": "is activity against"
    },
    {
      "source": "Secondary point mutations",
      "target": "Fms-like tyrosine kinase 3",
      "label": "occur_in"
    },
    {
      "source": "Secondary point mutations",
      "target": "KD",
      "label": "occur_in"
    },
    {
      "source": "Secondary point mutations",
      "target": "FLT3",
      "label": "occur_in"
    },
    {
      "source": "Secondary point mutations",
      "target": "tyrosine kinase domain",
      "label": "occur_in"
    },
    {
      "source": "Secondary point mutations",
      "target": "acquired clinical resistance",
      "label": "are_causes_of"
    },
    {
      "source": "substitutions",
      "target": "high degree of resistance",
      "label": "conferred"
    },
    {
      "source": "substitutions",
      "target": "FLT3 activation loop",
      "label": "are_at"
    },
    {
      "source": "substitutions",
      "target": "residue D835",
      "label": "are_at"
    },
    {
      "source": "substitutions",
      "target": "AL",
      "label": "are_at"
    },
    {
      "source": "high degree of resistance",
      "target": "ponatinib",
      "label": "is_to"
    },
    {
      "source": "Saturation mutagenesis",
      "target": "FLT3 AL mutations",
      "label": "identified"
    },
    {
      "source": "FLT3 AL mutations",
      "target": "D835",
      "label": "are_at_position"
    },
    {
      "source": "FLT3 AL mutations",
      "target": "D839",
      "label": "are_at_position"
    },
    {
      "source": "FLT3 AL mutations",
      "target": "Y842",
      "label": "are_at_position"
    },
    {
      "source": "ponatinib",
      "target": "early clinical efficacy",
      "label": "demonstrated"
    },
    {
      "source": "ponatinib",
      "target": "in vitro activity",
      "label": "has"
    },
    {
      "source": "ponatinib",
      "target": "AP24534",
      "label": "is_also_known_as"
    },
    {
      "source": "ponatinib",
      "target": "kinase domain mutants",
      "label": "has_activity_against"
    },
    {
      "source": "ponatinib",
      "target": "clinical activity",
      "label": "has"
    },
    {
      "source": "ponatinib",
      "target": "multikinase inhibitor",
      "label": "is_a"
    },
    {
      "source": "early clinical efficacy",
      "target": "patients",
      "label": "is_in"
    },
    {
      "source": "ITD mutations",
      "target": "FLT3",
      "label": "are_in"
    },
    {
      "source": "Substitution",
      "target": "FLT3 \"gatekeeper\" phenylalanine",
      "label": "is_of"
    },
    {
      "source": "Substitution",
      "target": "leucine",
      "label": "is_with"
    },
    {
      "source": "in vitro activity",
      "target": "chronic myeloid leukemia",
      "label": "is_in"
    },
    {
      "source": "in vitro activity",
      "target": "FLT3 TKI-resistant F691 substitutions",
      "label": "is_against"
    },
    {
      "source": "in vitro activity",
      "target": "FLT3-ITD mutant isoforms",
      "label": "is_against"
    },
    {
      "source": "chronic myeloid leukemia",
      "target": "TKI",
      "label": "is_resistant_to"
    },
    {
      "source": "chronic myeloid leukemia",
      "target": "BCR-ABL KD mutation",
      "label": "is_irrespective_of"
    },
    {
      "source": "F691L",
      "target": "mild resistance",
      "label": "conferred"
    },
    {
      "source": "F691L",
      "target": "Substitution",
      "label": "is_a_type_of"
    },
    {
      "source": "mild resistance",
      "target": "ponatinib",
      "label": "is_to"
    },
    {
      "source": "quizartinib",
      "target": "FLT3 inhibitors",
      "label": "is_a_type_of"
    },
    {
      "source": "FLT3 inhibitors",
      "target": "sorafenib",
      "label": "include"
    },
    {
      "source": "FLT3 inhibitors",
      "target": "quizartinib",
      "label": "include"
    },
    {
      "source": "FLT3 inhibitors",
      "target": "AC220",
      "label": "include"
    },
    {
      "source": "Alternative strategies",
      "target": "patients",
      "label": "are_required_for"
    },
    {
      "source": "kinase domain mutants",
      "target": "FLT3-ITD",
      "label": "are_of"
    },
    {
      "source": "kinase domain mutants",
      "target": "AC220",
      "label": "are_resistant_to"
    },
    {
      "source": "resistance",
      "target": "sorafenib",
      "label": "is_to"
    },
    {
      "source": "resistance",
      "target": "AC220",
      "label": "is_to"
    },
    {
      "source": "resistance",
      "target": "decrease",
      "label": "conferred by"
    },
    {
      "source": "resistance",
      "target": "cadmium",
      "label": "to"
    },
    {
      "source": "resistance",
      "target": "manganese",
      "label": "to"
    },
    {
      "source": "sorafenib",
      "target": "FLT3 inhibitors",
      "label": "is_a_type_of"
    },
    {
      "source": "AC220",
      "target": "FLT3 inhibitors",
      "label": "is_a_type_of"
    },
    {
      "source": "FLT3-ITD mutant isoforms",
      "target": "resistance",
      "label": "confer"
    },
    {
      "source": "acquired clinical resistance",
      "target": "FLT3 inhibitors",
      "label": "is_to"
    },
    {
      "source": "DCC-2036",
      "target": "FLT3 AL mutations",
      "label": "was_inactive_against"
    },
    {
      "source": "DCC-2036",
      "target": "switch control inhibitor",
      "label": "is_a"
    },
    {
      "source": "central nervous system effects",
      "target": "\u03b3-aminobutyric acid inhibition",
      "label": "caused by"
    },
    {
      "source": "\u03b3-aminobutyric acid inhibition",
      "target": "RDX exposure",
      "label": "associated with"
    },
    {
      "source": "RDX",
      "target": "brain",
      "label": "quantified in"
    },
    {
      "source": "RDX",
      "target": "plasma",
      "label": "quantified in"
    },
    {
      "source": "RDX",
      "target": "liver",
      "label": "quantified in"
    },
    {
      "source": "RDX",
      "target": "stomach",
      "label": "quantified in"
    },
    {
      "source": "RDX",
      "target": "mechanism",
      "label": "transforms by"
    },
    {
      "source": "RDX",
      "target": "intestine",
      "label": "quantified in"
    },
    {
      "source": "RDX",
      "target": "N-nitroso metabolites",
      "label": "can transform into"
    },
    {
      "source": "toxicant action",
      "target": "animals",
      "label": "occurs in"
    },
    {
      "source": "Absorption",
      "target": "toxicant action",
      "label": "affects"
    },
    {
      "source": "Absorption",
      "target": "hexahydro-1,3,5-trinitro-1,3,5-triazine",
      "label": "is aspect of"
    },
    {
      "source": "490 ng/g",
      "target": "highest-exposure group",
      "label": "found in"
    },
    {
      "source": "DNX",
      "target": "stomach",
      "label": "present in"
    },
    {
      "source": "DNX",
      "target": "brain",
      "label": "present in"
    },
    {
      "source": "DNX",
      "target": "plasma",
      "label": "present in"
    },
    {
      "source": "DNX",
      "target": "higher exposures",
      "label": "present at"
    },
    {
      "source": "Average RDX concentrations",
      "target": "123 ng/g",
      "label": "ranged from"
    },
    {
      "source": "Average RDX concentrations",
      "target": "11.1 ng/mL",
      "label": "ranged from"
    },
    {
      "source": "Average RDX concentrations",
      "target": "233 ng/g",
      "label": "ranged to"
    },
    {
      "source": "Average RDX concentrations",
      "target": "3319 ng/g",
      "label": "ranged to"
    },
    {
      "source": "Average RDX concentrations",
      "target": "brain",
      "label": "found in"
    },
    {
      "source": "Average RDX concentrations",
      "target": "liver",
      "label": "found in"
    },
    {
      "source": "Average RDX concentrations",
      "target": "144 ng/g",
      "label": "ranged from"
    },
    {
      "source": "Average RDX concentrations",
      "target": "stomach",
      "label": "found in"
    },
    {
      "source": "Average RDX concentrations",
      "target": "intestine",
      "label": "found in"
    },
    {
      "source": "Average RDX concentrations",
      "target": "matrices",
      "label": "observed in"
    },
    {
      "source": "Average RDX concentrations",
      "target": "dose-dependent pattern",
      "label": "followed"
    },
    {
      "source": "Average RDX concentrations",
      "target": "25.6 ng/g",
      "label": "ranged from"
    },
    {
      "source": "Average RDX concentrations",
      "target": "2697 ng/g",
      "label": "ranged to"
    },
    {
      "source": "Average RDX concentrations",
      "target": "182 ng/mL",
      "label": "ranged to"
    },
    {
      "source": "Average RDX concentrations",
      "target": "tissues",
      "label": "found in"
    },
    {
      "source": "Average RDX concentrations",
      "target": "35900 ng/g",
      "label": "ranged to"
    },
    {
      "source": "Average RDX concentrations",
      "target": "51.1 ng/g",
      "label": "ranged from"
    },
    {
      "source": "Average RDX concentrations",
      "target": "plasma",
      "label": "found in"
    },
    {
      "source": "reductive transformation products",
      "target": "hexahydro-1,3,5-trinitroso-1,3,5-triazine",
      "label": "include"
    },
    {
      "source": "reductive transformation products",
      "target": "hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine",
      "label": "include"
    },
    {
      "source": "reductive transformation products",
      "target": "brain",
      "label": "quantified in"
    },
    {
      "source": "reductive transformation products",
      "target": "plasma",
      "label": "quantified in"
    },
    {
      "source": "reductive transformation products",
      "target": "liver",
      "label": "quantified in"
    },
    {
      "source": "reductive transformation products",
      "target": "hexahydro-1,3-dinitroso-5-nitro-1,3,5-triazine",
      "label": "include"
    },
    {
      "source": "reductive transformation products",
      "target": "stomach",
      "label": "quantified in"
    },
    {
      "source": "reductive transformation products",
      "target": "intestine",
      "label": "quantified in"
    },
    {
      "source": "hexahydro-1,3,5-trinitroso-1,3,5-triazine",
      "target": "TNX",
      "label": "is also known as"
    },
    {
      "source": "hexahydro-1,3,5-trinitro-1,3,5-triazine",
      "target": "B6C3F1 mice",
      "label": "studied in"
    },
    {
      "source": "hexahydro-1,3,5-trinitro-1,3,5-triazine",
      "target": "RDX",
      "label": "is also known as"
    },
    {
      "source": "B6C3F1 mice",
      "target": "Mus musculus",
      "label": "is species"
    },
    {
      "source": "B6C3F1 mice",
      "target": "28 d",
      "label": "exposed for"
    },
    {
      "source": "B6C3F1 mice",
      "target": "contaminated feed",
      "label": "exposed to"
    },
    {
      "source": "hexahydro-1-nitroso-3,5-dinitro-1,3,5-triazine",
      "target": "MNX",
      "label": "is also known as"
    },
    {
      "source": "TNX",
      "target": "higher exposures",
      "label": "present at"
    },
    {
      "source": "TNX",
      "target": "brain",
      "label": "present in"
    },
    {
      "source": "TNX",
      "target": "plasma",
      "label": "present in"
    },
    {
      "source": "TNX",
      "target": "stomach",
      "label": "present in"
    },
    {
      "source": "MNX",
      "target": "brain",
      "label": "accumulated in"
    },
    {
      "source": "MNX",
      "target": "maximum average concentration",
      "label": "accumulated at"
    },
    {
      "source": "MNX",
      "target": "RDX",
      "label": "formed from"
    },
    {
      "source": "amount of RDX",
      "target": "highest-exposure group",
      "label": "highest in"
    },
    {
      "source": "amount of RDX",
      "target": "brain",
      "label": "present in"
    },
    {
      "source": "2013",
      "target": "SETAC",
      "label": "copyright by"
    },
    {
      "source": "Average MNX concentrations",
      "target": "stomachs",
      "label": "found in"
    },
    {
      "source": "Average MNX concentrations",
      "target": "490 ng/g",
      "label": "ranged to"
    },
    {
      "source": "stomachs",
      "target": "mice",
      "label": "belong to"
    },
    {
      "source": "contaminated feed",
      "target": "hexahydro-1,3,5-trinitro-1,3,5-triazine",
      "label": "contained"
    },
    {
      "source": "contaminated feed",
      "target": "concentrations",
      "label": "contained"
    },
    {
      "source": "potential formation",
      "target": "brain",
      "label": "occurred in"
    },
    {
      "source": "maximum average concentration",
      "target": "165.1 ng/g",
      "label": "was"
    },
    {
      "source": "N-nitroso metabolites",
      "target": "dose-dependent pattern",
      "label": "followed"
    },
    {
      "source": "N-nitroso metabolites",
      "target": "RDX",
      "label": "are metabolites of"
    },
    {
      "source": "N-nitroso metabolites",
      "target": "tested tissues",
      "label": "present in"
    },
    {
      "source": "hexahydro-1,3-dinitroso-5-nitro-1,3,5-triazine",
      "target": "DNX",
      "label": "is also known as"
    },
    {
      "source": "RDX metabolites",
      "target": "tissues",
      "label": "present in"
    },
    {
      "source": "biotransformation",
      "target": "hexahydro-1,3,5-trinitro-1,3,5-triazine",
      "label": "is aspect of"
    },
    {
      "source": "biotransformation",
      "target": "toxicant action",
      "label": "affects"
    },
    {
      "source": "biotransformation",
      "target": "OP compounds",
      "label": "of"
    },
    {
      "source": "Pim-1",
      "target": "drug target",
      "label": "is a"
    },
    {
      "source": "Pim-1",
      "target": "chemotherapeutic resistance",
      "label": "associated with"
    },
    {
      "source": "Pim-1",
      "target": "target",
      "label": "is a"
    },
    {
      "source": "Pim-1",
      "target": "progression",
      "label": "involved in"
    },
    {
      "source": "Pim-1",
      "target": "serine/threonine kinase",
      "label": "is a"
    },
    {
      "source": "Pim-1",
      "target": "cancer",
      "label": "involved in"
    },
    {
      "source": "Pim-1",
      "target": "lymphomas",
      "label": "involved in"
    },
    {
      "source": "Pim-1",
      "target": "initiation",
      "label": "involved in"
    },
    {
      "source": "Pim-1",
      "target": "solid tumors",
      "label": "involved in"
    },
    {
      "source": "Pim-1",
      "target": "leukemia",
      "label": "involved in"
    },
    {
      "source": "2-aminothiazole derivatives",
      "target": "ATP",
      "label": "noncompetitive with respect to"
    },
    {
      "source": "2-aminothiazole derivatives",
      "target": "noncompetitive inhibitors",
      "label": "are"
    },
    {
      "source": "2-aminothiazole derivatives",
      "target": "peptide substrate",
      "label": "noncompetitive with respect to"
    },
    {
      "source": "potential",
      "target": "agents",
      "label": "of"
    },
    {
      "source": "potential",
      "target": "PTH-related protein",
      "label": "OF"
    },
    {
      "source": "potential",
      "target": "PTHrP",
      "label": "OF"
    },
    {
      "source": "synergistic inhibitory effect",
      "target": "enzymatic assays",
      "label": "observed in"
    },
    {
      "source": "adjuvant agents",
      "target": "treatment of cancer diseases",
      "label": "for"
    },
    {
      "source": "synergistic effect",
      "target": "prostate cancer cell lines",
      "label": "observed in"
    },
    {
      "source": "synergistic effect",
      "target": "inhibition of cell proliferation",
      "label": "observed in"
    },
    {
      "source": "prostate cancer cell lines",
      "target": "PC3",
      "label": "include"
    },
    {
      "source": "ATP-competitive indolyl-pyrrolone scaffold",
      "target": "structure-activity relationship data",
      "label": "derives"
    },
    {
      "source": "virtual screening campaign",
      "target": "ATP-competitive inhibitors",
      "label": "led to discovery of"
    },
    {
      "source": "virtual screening campaign",
      "target": "2-aminothiazole derivatives",
      "label": "led to discovery of"
    },
    {
      "source": "2-aminothiazoles",
      "target": "ATP-competitive inhibitors",
      "label": "showed synergism with"
    },
    {
      "source": "2-aminothiazoles",
      "target": "synergistic inhibitory effect",
      "label": "indicated"
    },
    {
      "source": "ATP-competitive compounds",
      "target": "synergistic effect",
      "label": "cause"
    },
    {
      "source": "Pim-1 inhibitors",
      "target": "paclitaxel",
      "label": "showed synergism with"
    },
    {
      "source": "ATP-noncompetitive compounds",
      "target": "synergistic effect",
      "label": "cause"
    },
    {
      "source": "combination strategy",
      "target": "Pim-1",
      "label": "inhibits"
    },
    {
      "source": "z-VAD-fmk",
      "target": "caspase",
      "label": "inhibits"
    },
    {
      "source": "z-VAD-fmk",
      "target": "cell death",
      "label": "does not prevent"
    },
    {
      "source": "z-VAD-fmk",
      "target": "pancaspase inhibitor",
      "label": "is a"
    },
    {
      "source": "BSC 3g",
      "target": "p53",
      "label": "causes no change in"
    },
    {
      "source": "BSC 3g",
      "target": "cyclin A an B1",
      "label": "causes no change in"
    },
    {
      "source": "BSC 3g",
      "target": "Chk2",
      "label": "reduces levels of"
    },
    {
      "source": "BSC 3g",
      "target": "caspase-2",
      "label": "activates"
    },
    {
      "source": "BSC 3g",
      "target": "CDK2",
      "label": "reduces expression of"
    },
    {
      "source": "BSC 3g",
      "target": "cell-cycle arrest",
      "label": "causes"
    },
    {
      "source": "BSC 3g",
      "target": "p21CIP1",
      "label": "reduces levels of"
    },
    {
      "source": "BSC 3g",
      "target": "CDK1",
      "label": "reduces expression of"
    },
    {
      "source": "G2/M Arrest",
      "target": "Human Breast Cancer MCF-7 Cells",
      "label": "occurs in"
    },
    {
      "source": "BSC treatment",
      "target": "cell death",
      "label": "results in"
    },
    {
      "source": "cytotoxic activity",
      "target": "tumour cells",
      "label": "acts against"
    },
    {
      "source": "BSC 3n",
      "target": "CDK1",
      "label": "reduces expression of"
    },
    {
      "source": "BSC 3n",
      "target": "p53",
      "label": "causes no change in"
    },
    {
      "source": "BSC 3n",
      "target": "Chk2",
      "label": "reduces levels of"
    },
    {
      "source": "BSC 3n",
      "target": "cyclin A an B1",
      "label": "causes no change in"
    },
    {
      "source": "BSC 3n",
      "target": "caspase-2",
      "label": "activates"
    },
    {
      "source": "BSC 3n",
      "target": "CDK2",
      "label": "reduces expression of"
    },
    {
      "source": "BSC 3n",
      "target": "p21CIP1",
      "label": "reduces levels of"
    },
    {
      "source": "BSC 3n",
      "target": "cell-cycle arrest",
      "label": "causes"
    },
    {
      "source": "Bisacylimidoselenocarbamate derivatives",
      "target": "cytotoxic activity",
      "label": "has"
    },
    {
      "source": "Bisacylimidoselenocarbamate derivatives",
      "target": "anticancer agents",
      "label": "are"
    },
    {
      "source": "cell-cycle arrest",
      "target": "late G2/M",
      "label": "is"
    },
    {
      "source": "cell-cycle arrest",
      "target": "MCF-7 Cells",
      "label": "occurs in"
    },
    {
      "source": "Bisacylimidoselenocarbamates",
      "target": "G2/M Arrest",
      "label": "causes"
    },
    {
      "source": "Bisacylimidoselenocarbamates",
      "target": "CDK1",
      "label": "modulates"
    },
    {
      "source": "Bisacylimidoselenocarbamates",
      "target": "Chk2",
      "label": "modulates"
    },
    {
      "source": "caspase-dependent pathway",
      "target": "cell death",
      "label": "is not involved in"
    },
    {
      "source": "BSC treated cells",
      "target": "lethal mitosis",
      "label": "die from"
    },
    {
      "source": "BSC",
      "target": "cell death",
      "label": "triggers"
    },
    {
      "source": "rapamycin",
      "target": "P-gp substrates",
      "label": "is a"
    },
    {
      "source": "rapamycin",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "DUN",
      "target": "apoptosis",
      "label": "induced"
    },
    {
      "source": "DUN",
      "target": "cytotoxic action",
      "label": "has"
    },
    {
      "source": "DUN",
      "target": "chemotherapeutic agent",
      "label": "is a type of"
    },
    {
      "source": "DUN",
      "target": "OPN",
      "label": "enhanced expression of"
    },
    {
      "source": "DUN",
      "target": "autofluorescence",
      "label": "has"
    },
    {
      "source": "DUN",
      "target": "cell death",
      "label": "induced"
    },
    {
      "source": "actinomycin-D",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "actinomycin-D",
      "target": "P-gp substrates",
      "label": "is a"
    },
    {
      "source": "OPN",
      "target": "extracellular matrix protein",
      "label": "is a type of"
    },
    {
      "source": "OPN",
      "target": "PC-3 prostate tumor cells",
      "label": "expressed in"
    },
    {
      "source": "OPN",
      "target": "p-glycoprotein",
      "label": "increased expression of"
    },
    {
      "source": "OPN",
      "target": "therapeutic target",
      "label": "is a"
    },
    {
      "source": "OPN",
      "target": "\u03b1v\u03b23",
      "label": "binds to"
    },
    {
      "source": "OPN",
      "target": "P-gp transporter",
      "label": "increases"
    },
    {
      "source": "OPN",
      "target": "protein",
      "label": "increased"
    },
    {
      "source": "OPN",
      "target": "cell death",
      "label": "inhibited"
    },
    {
      "source": "OPN",
      "target": "PC-3 cells",
      "label": "expressed in"
    },
    {
      "source": "OPN",
      "target": "pump activity",
      "label": "increased"
    },
    {
      "source": "OPN",
      "target": "drug resistance",
      "label": "reduces"
    },
    {
      "source": "OPN",
      "target": "drug pumping-out activity",
      "label": "increased"
    },
    {
      "source": "OPN",
      "target": "mRNA",
      "label": "increased"
    },
    {
      "source": "OPN",
      "target": "P-gp",
      "label": "increased expression of"
    },
    {
      "source": "OPN",
      "target": "arginine-glycine-aspartic acid (RGD) domain",
      "label": "has"
    },
    {
      "source": "OPN",
      "target": "\u03b1v\u03b23 integrin",
      "label": "binds to"
    },
    {
      "source": "drug resistance",
      "target": "sensitive tumors",
      "label": "occurs in"
    },
    {
      "source": "drug resistance",
      "target": "tumor microenvironment",
      "label": "induced in"
    },
    {
      "source": "osteopontin",
      "target": "prostate cancer cells",
      "label": "upregulates expression in"
    },
    {
      "source": "osteopontin",
      "target": "drug transporter",
      "label": "upregulates"
    },
    {
      "source": "osteopontin",
      "target": "prominent markers for differentiation of osteoblast",
      "label": "is a"
    },
    {
      "source": "Daunomycin",
      "target": "chemotherapeutic agent",
      "label": "is a type of"
    },
    {
      "source": "Daunomycin",
      "target": "autofluorescence",
      "label": "has"
    },
    {
      "source": "p-glycoprotein",
      "target": "ATP-binding cassette transporter",
      "label": "is a type of"
    },
    {
      "source": "hypoxic condition",
      "target": "OPN",
      "label": "upregulates"
    },
    {
      "source": "arginine-glycine-aspartic acid (RGD) domain",
      "target": "integrin",
      "label": "binds to"
    },
    {
      "source": "arginine-glycine-aspartic acid (RGD) domain",
      "target": "arginine",
      "label": "contains"
    },
    {
      "source": "arginine-glycine-aspartic acid (RGD) domain",
      "target": "aspartic acid",
      "label": "contains"
    },
    {
      "source": "arginine-glycine-aspartic acid (RGD) domain",
      "target": "glycine",
      "label": "contains"
    },
    {
      "source": "\u03b1v\u03b23 integrin",
      "target": "P-gp transporter",
      "label": "mediates increase of"
    },
    {
      "source": "\u03b1v\u03b23",
      "target": "P-gp transporter",
      "label": "mediates increase of"
    },
    {
      "source": "Multidrug resistance",
      "target": "chemotherapy",
      "label": "is a cause of"
    },
    {
      "source": "Osteopontin",
      "target": "arginine-glycine-aspartic acid (RGD) domain",
      "label": "has"
    },
    {
      "source": "Osteopontin",
      "target": "extracellular matrix protein",
      "label": "is a type of"
    },
    {
      "source": "OPN knockdown",
      "target": "apoptosis",
      "label": "potentiated"
    },
    {
      "source": "OPN knockdown",
      "target": "cytotoxic action",
      "label": "enhanced"
    },
    {
      "source": "OPN knockdown",
      "target": "cell death",
      "label": "enhanced"
    },
    {
      "source": "cell adhesion factors",
      "target": "soluble factors",
      "label": "is a type of"
    },
    {
      "source": "soluble factors",
      "target": "drug resistance",
      "label": "induces"
    },
    {
      "source": "RGD domain",
      "target": "integrin",
      "label": "binds to"
    },
    {
      "source": "\u03b1v\u03b23 monoclonal antibody",
      "target": "OPN",
      "label": "antagonized"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "cell cycle",
      "label": "affects"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "apoptosis",
      "label": "induces"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "A549 cell",
      "label": "increases"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "cell viability",
      "label": "increases"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "mRNA expression",
      "label": "induced"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "apoptosis regulating proteins",
      "label": "affects"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "release",
      "label": "affects"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "p27",
      "label": "induced"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "cell death",
      "label": "affects"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "apoptotic cells",
      "label": "reduced"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "JNK2 mRNA expression",
      "label": "enhanced"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "cyclin E mRNA expression",
      "label": "inhibited"
    },
    {
      "source": "diesel exhaust particles (DEP)",
      "target": "p53",
      "label": "induced"
    },
    {
      "source": "air pollutants",
      "target": "diesel exhaust particles (DEP)",
      "label": "include"
    },
    {
      "source": "chronic airway diseases",
      "target": "COPD",
      "label": "include"
    },
    {
      "source": "chronic airway diseases",
      "target": "asthma",
      "label": "include"
    },
    {
      "source": "airway epithelial cells",
      "target": "deleterious effects",
      "label": "are susceptible to"
    },
    {
      "source": "airway epithelial cells",
      "target": "in vitro",
      "label": "are studied"
    },
    {
      "source": "deleterious effects",
      "target": "diesel exhaust particles (DEP)",
      "label": "are of"
    },
    {
      "source": "foetal calf serum (FCS)",
      "target": "DEP-induced changes",
      "label": "affects"
    },
    {
      "source": "foetal calf serum (FCS)",
      "target": "diesel exhaust particles (DEP)",
      "label": "modulates effects of"
    },
    {
      "source": "foetal calf serum (FCS)",
      "target": "NF-\u03baB",
      "label": "activates"
    },
    {
      "source": "foetal calf serum (FCS)",
      "target": "oxidant stress pathways",
      "label": "activates"
    },
    {
      "source": "foetal calf serum (FCS)",
      "target": "c-jun N-terminal kinase (JNK)",
      "label": "activates"
    },
    {
      "source": "DEP-induced changes",
      "target": "inflammation",
      "label": "involve"
    },
    {
      "source": "DEP-induced changes",
      "target": "airway epithelial cell apoptosis",
      "label": "involve"
    },
    {
      "source": "3.3%FCS",
      "target": "apoptotic cells",
      "label": "abolished effect on"
    },
    {
      "source": "Extravasation",
      "target": "airway epithelial cells",
      "label": "renders susceptible"
    },
    {
      "source": "Extravasation",
      "target": "serum",
      "label": "is of"
    },
    {
      "source": "Extravasation",
      "target": "inflamed airways",
      "label": "occurs in"
    },
    {
      "source": "N-acetylcysteine (NAC)",
      "target": "cell viability",
      "label": "decreased"
    },
    {
      "source": "inflamed airways",
      "target": "Patients",
      "label": "are in"
    },
    {
      "source": "patent review",
      "target": "present",
      "label": "covers period"
    },
    {
      "source": "patent review",
      "target": "2009",
      "label": "covers period"
    },
    {
      "source": "patent review",
      "target": "patent applications",
      "label": "covers"
    },
    {
      "source": "patent review",
      "target": "earlier review",
      "label": "is a continuation of"
    },
    {
      "source": "patent applications",
      "target": "PAMs",
      "label": "concern"
    },
    {
      "source": "patent applications",
      "target": "December 2012",
      "label": "published between"
    },
    {
      "source": "patent applications",
      "target": "April 2009",
      "label": "published between"
    },
    {
      "source": "PAMs",
      "target": "alternative site",
      "label": "bind at"
    },
    {
      "source": "PAMs",
      "target": "mGlu2",
      "label": "are for"
    },
    {
      "source": "mGlu2 receptors",
      "target": "brain areas",
      "label": "located in"
    },
    {
      "source": "brain areas",
      "target": "amygdala",
      "label": "includes"
    },
    {
      "source": "brain areas",
      "target": "hippocampus",
      "label": "includes"
    },
    {
      "source": "brain areas",
      "target": "prefrontal cortex",
      "label": "includes"
    },
    {
      "source": "mGluR2 positive allosteric modulators",
      "target": "patent review",
      "label": "is a"
    },
    {
      "source": "mGlu2 receptor",
      "target": "brain",
      "label": "distributed in"
    },
    {
      "source": "mGlu2 receptor",
      "target": "group II subfamily of metabotropic glutamate receptors",
      "label": "belongs to"
    },
    {
      "source": "mGlu2 receptor",
      "target": "neuropharmacology",
      "label": "is important in"
    },
    {
      "source": "mGlu2 receptor",
      "target": "glutamate",
      "label": "modulates"
    },
    {
      "source": "mGlu2 receptor",
      "target": "presynaptic nerve terminals",
      "label": "expressed on"
    },
    {
      "source": "mGlu2 receptor",
      "target": "GABA release",
      "label": "modulates"
    },
    {
      "source": "positive allosteric modulators",
      "target": "PAMs",
      "label": "also known as"
    },
    {
      "source": "earlier review",
      "target": "journal",
      "label": "published in"
    },
    {
      "source": "group II subfamily of metabotropic glutamate receptors",
      "target": "mGlu3 receptor",
      "label": "includes"
    },
    {
      "source": "group II subfamily of metabotropic glutamate receptors",
      "target": "mGlu",
      "label": "includes"
    },
    {
      "source": "glutamate hyperfunction",
      "target": "diseases",
      "label": "implicated in"
    },
    {
      "source": "glutamate hyperfunction",
      "target": "disorders",
      "label": "implicated in"
    },
    {
      "source": "maximum drug dose",
      "target": "2 consecutive months",
      "label": "maintained for"
    },
    {
      "source": "maximum drug dose",
      "target": "two-thirds of patients",
      "label": "maintained in"
    },
    {
      "source": "recent years",
      "target": "2010",
      "label": "includes"
    },
    {
      "source": "recent years",
      "target": "2007",
      "label": "includes"
    },
    {
      "source": "prescription information",
      "target": "1.6 million people",
      "label": "is for"
    },
    {
      "source": "Cholinesterase inhibitors",
      "target": "pharmacological intervention",
      "label": "are"
    },
    {
      "source": "pharmacological intervention",
      "target": "cognitive symptoms",
      "label": "treats"
    },
    {
      "source": "donepezil",
      "target": "large-amplitude EPSCs",
      "label": "increased"
    },
    {
      "source": "donepezil",
      "target": "inter-event intervals",
      "label": "increased proportion of"
    },
    {
      "source": "donepezil",
      "target": "EPSCs",
      "label": "increased frequency of"
    },
    {
      "source": "donepezil",
      "target": "burst-like EPSCs",
      "label": "increased"
    },
    {
      "source": "donepezil",
      "target": "reversible AChE inhibitor",
      "label": "is a"
    },
    {
      "source": "drug type",
      "target": "hazards ratio (HR)",
      "label": "has"
    },
    {
      "source": "drug type",
      "target": "risk of non-persistence",
      "label": "increased"
    },
    {
      "source": "drug type",
      "target": "95 % confidence interval (CI)",
      "label": "has"
    },
    {
      "source": "drug type",
      "target": "donepezil",
      "label": "is"
    },
    {
      "source": "drug type",
      "target": "rivastigmine",
      "label": "is"
    },
    {
      "source": "cognitive symptoms",
      "target": "Alzheimer's disease (AD)",
      "label": "are a symptom of"
    },
    {
      "source": "Non-persistence",
      "target": "recent years",
      "label": "was lower in"
    },
    {
      "source": "Non-persistence",
      "target": "2007",
      "label": "was lower in"
    },
    {
      "source": "Non-persistence",
      "target": "multiple anti-dementia medications",
      "label": "was lower for"
    },
    {
      "source": "Non-persistence",
      "target": "AD medications",
      "label": "occurs in patients on"
    },
    {
      "source": "Non-persistence",
      "target": "6 months",
      "label": "rate at"
    },
    {
      "source": "Non-persistence",
      "target": "gap in prescribing",
      "label": "is defined by"
    },
    {
      "source": "Non-persistence",
      "target": "12 months",
      "label": "rate at"
    },
    {
      "source": "Non-persistence",
      "target": "2010",
      "label": "was lower in"
    },
    {
      "source": "AD drug",
      "target": "study period",
      "label": "commenced during"
    },
    {
      "source": "population-based study",
      "target": "dosing",
      "label": "concerns"
    },
    {
      "source": "population-based study",
      "target": "persistence",
      "label": "concerns"
    },
    {
      "source": "Older age",
      "target": "risk of non-persistence",
      "label": "increased"
    },
    {
      "source": "Older age",
      "target": "hazards ratio (HR)",
      "label": "has"
    },
    {
      "source": "Older age",
      "target": "95 % confidence interval (CI)",
      "label": "has"
    },
    {
      "source": "Older age",
      "target": "75+ years",
      "label": "is"
    },
    {
      "source": "Older age",
      "target": "<75 years",
      "label": "compared to"
    },
    {
      "source": "gap in prescribing",
      "target": "63 consecutive days",
      "label": "is longer than"
    },
    {
      "source": "failure to maintain dose-maximisation",
      "target": "AD medications",
      "label": "occurs in patients on"
    },
    {
      "source": "Health Service Executive-Primary Care Reimbursement Services prescription claims database",
      "target": "Republic of Ireland",
      "label": "is located in"
    },
    {
      "source": "Health Service Executive-Primary Care Reimbursement Services prescription claims database",
      "target": "prescription information",
      "label": "contains"
    },
    {
      "source": "prescriptions",
      "target": "donepezil",
      "label": "are for"
    },
    {
      "source": "prescriptions",
      "target": "rivastigmine",
      "label": "are for"
    },
    {
      "source": "prescriptions",
      "target": "memantine",
      "label": "are for"
    },
    {
      "source": "prescriptions",
      "target": "AD medications",
      "label": "are for"
    },
    {
      "source": "prescriptions",
      "target": "galantamine",
      "label": "are for"
    },
    {
      "source": "multiple anti-dementia medications",
      "target": "hazards ratio (HR)",
      "label": "has"
    },
    {
      "source": "multiple anti-dementia medications",
      "target": "95 % confidence interval (CI)",
      "label": "has"
    },
    {
      "source": "reasons",
      "target": "failure to maintain dose-maximisation",
      "label": "underlying"
    },
    {
      "source": "reasons",
      "target": "Non-persistence",
      "label": "underlying"
    },
    {
      "source": "dose-maximisation",
      "target": "dose titrations",
      "label": "rates recorded by examining"
    },
    {
      "source": "dose-maximisation",
      "target": "initiation dose",
      "label": "rates recorded by examining"
    },
    {
      "source": "rivastigmine",
      "target": "acetylcholinesterase inhibitors",
      "label": "is a type of"
    },
    {
      "source": "rivastigmine",
      "target": "pressor effect",
      "label": "induced"
    },
    {
      "source": "rivastigmine",
      "target": "intravenous (i.v.) route",
      "label": "administered by"
    },
    {
      "source": "persistence",
      "target": "anti-dementia medications",
      "label": "involves"
    },
    {
      "source": "persistence",
      "target": "AD medications",
      "label": "is of"
    },
    {
      "source": "persistence",
      "target": "memantine",
      "label": "was higher when"
    },
    {
      "source": "persistence",
      "target": "community",
      "label": "can be improved in"
    },
    {
      "source": "memantine",
      "target": "pharmacological intervention",
      "label": "is"
    },
    {
      "source": "memantine",
      "target": "donepezil",
      "label": "co-prescribed with"
    },
    {
      "source": "'real world'",
      "target": "clinical trial setting",
      "label": "is distinct from"
    },
    {
      "source": "initiation dose",
      "target": "AD drug",
      "label": "is of"
    },
    {
      "source": "20,729 patients",
      "target": "January 2006",
      "label": "received prescriptions during"
    },
    {
      "source": "20,729 patients",
      "target": "prescriptions",
      "label": "received"
    },
    {
      "source": "20,729 patients",
      "target": "December 2010",
      "label": "received prescriptions during"
    },
    {
      "source": "flexibility",
      "target": "S16 phosphorylation",
      "label": "affected by"
    },
    {
      "source": "flexibility",
      "target": "phospho-binding loop",
      "label": "of"
    },
    {
      "source": "S16 phosphorylation",
      "target": "decreased affinity",
      "label": "causes"
    },
    {
      "source": "(1)H,(15)N amide resonances",
      "target": "phosphorylation site",
      "label": "located near"
    },
    {
      "source": "(1)H,(15)N amide resonances",
      "target": "unphosphorylated state",
      "label": "broadened in"
    },
    {
      "source": "spectrum",
      "target": "folded protein",
      "label": "of"
    },
    {
      "source": "reduced conformational heterogeneity",
      "target": "S16 phosphorylation",
      "label": "caused by"
    },
    {
      "source": "NMR spectroscopy",
      "target": "level of phosphorylation",
      "label": "quantifies"
    },
    {
      "source": "NMR spectroscopy",
      "target": "phosphorylation",
      "label": "confirms"
    },
    {
      "source": "NMR spectroscopy",
      "target": "phosphorylation event",
      "label": "unravels"
    },
    {
      "source": "NMR spectroscopy",
      "target": "obstacles",
      "label": "overcomes"
    },
    {
      "source": "phosphate moiety",
      "target": "phospho-substrate",
      "label": "competes with"
    },
    {
      "source": "phosphate moiety",
      "target": "phospho-S16",
      "label": "is part of"
    },
    {
      "source": "Nuclear Magnetic Resonance (NMR) spectroscopy",
      "target": "PKA phosphorylation site",
      "label": "identifies"
    },
    {
      "source": "Nuclear Magnetic Resonance (NMR) spectroscopy",
      "target": "functional consequences",
      "label": "investigates"
    },
    {
      "source": "PKA phosphorylation site",
      "target": "Pin1 WW domain",
      "label": "located in"
    },
    {
      "source": "S16",
      "target": "WW domain",
      "label": "is part of"
    },
    {
      "source": "functional consequences",
      "target": "phosphorylation",
      "label": "of"
    },
    {
      "source": "functional consequences",
      "target": "three novel missense mutations",
      "label": "are of"
    },
    {
      "source": "WW phosphorylation",
      "target": "binding capacity",
      "label": "abolishes"
    },
    {
      "source": "WW phosphorylation",
      "target": "analytical characterization",
      "label": "based on"
    },
    {
      "source": "WW phosphorylation",
      "target": "S16",
      "label": "occurs on"
    },
    {
      "source": "functional regulation",
      "target": "hyperphosphorylated neuronal Tau protein",
      "label": "of"
    },
    {
      "source": "hyperphosphorylated neuronal Tau protein",
      "target": "Alzheimer's disease",
      "label": "associated with"
    },
    {
      "source": "resonances",
      "target": "spectrum",
      "label": "are part of"
    },
    {
      "source": "Pin1 protein",
      "target": "functional regulation",
      "label": "plays role in"
    },
    {
      "source": "Pin1 protein",
      "target": "phosphorylation",
      "label": "regulated by"
    },
    {
      "source": "decreased affinity",
      "target": "phosphorylated partner",
      "label": "for"
    },
    {
      "source": "Detection",
      "target": "phosphorylation",
      "label": "of"
    },
    {
      "source": "OATP1B1",
      "target": "lopinavir",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP1B1",
      "target": "xenobiotics",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP1B1",
      "target": "human hepatocytes",
      "label": "mediates uptake into"
    },
    {
      "source": "OATP1B1",
      "target": "rosuvastatin",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP1B1",
      "target": "hepatic uptake",
      "label": "contributes to"
    },
    {
      "source": "OATP1B1",
      "target": "valsartan",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP1B1",
      "target": "olmesartan",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP1B1",
      "target": "pitavastatin",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP1B1",
      "target": "estrone-3-sulfate",
      "label": "mediates uptake of"
    },
    {
      "source": "OATP isoforms",
      "target": "substrate specificity",
      "label": "have overlap in"
    },
    {
      "source": "OATP isoforms",
      "target": "hepatic uptake",
      "label": "are important for"
    },
    {
      "source": "substrate specificity",
      "target": "UGT2B10",
      "label": "of"
    },
    {
      "source": "siRNA technology",
      "target": "human hepatocytes",
      "label": "used in"
    },
    {
      "source": "siRNA technology",
      "target": "OATP1B1",
      "label": "decreases"
    },
    {
      "source": "hepatic uptake",
      "target": "new chemical entities",
      "label": "of"
    },
    {
      "source": "hepatic uptake",
      "target": "xenobiotics",
      "label": "of"
    },
    {
      "source": "Off-target effects",
      "target": "transporters",
      "label": "are minimal based on expression of"
    },
    {
      "source": "Off-target effects",
      "target": "drug metabolizing enzymes",
      "label": "are minimal based on expression of"
    },
    {
      "source": "Off-target effects",
      "target": "nuclear receptors",
      "label": "are minimal based on expression of"
    },
    {
      "source": "Off-target effects",
      "target": "co-regulators",
      "label": "are minimal based on expression of"
    },
    {
      "source": "Organic anion transporting polypeptide 1B1",
      "target": "disposition",
      "label": "plays role in"
    },
    {
      "source": "protein malnutrition",
      "target": "toxicity",
      "label": "affects"
    },
    {
      "source": "protein malnutrition",
      "target": "metabolism",
      "label": "affects"
    },
    {
      "source": "protein malnutrition",
      "target": "two-electron reduction",
      "label": "activates"
    },
    {
      "source": "protein malnutrition",
      "target": "gastrotoxicity",
      "label": "potentiates"
    },
    {
      "source": "protein malnutrition",
      "target": "CCBL pathway",
      "label": "enhances"
    },
    {
      "source": "protein malnutrition",
      "target": "5-fluorouracil (FU)",
      "label": "alters metabolism of"
    },
    {
      "source": "protein malnutrition",
      "target": "mitomycin C (MMC)",
      "label": "alters metabolism of"
    },
    {
      "source": "protein malnutrition",
      "target": "cisplatin (CP)",
      "label": "alters metabolism of"
    },
    {
      "source": "protein malnutrition",
      "target": "FU elimination",
      "label": "delays"
    },
    {
      "source": "gastrotoxicity",
      "target": "histopathological deterioration",
      "label": "manifested by"
    },
    {
      "source": "gastrotoxicity",
      "target": "mucus levels",
      "label": "manifested by lower"
    },
    {
      "source": "gastrotoxicity",
      "target": "rat stomach",
      "label": "occurs in"
    },
    {
      "source": "gastrotoxicity",
      "target": "permeability",
      "label": "manifested by higher"
    },
    {
      "source": "Weanling male Wistar rats",
      "target": "2.5% protein diet",
      "label": "received"
    },
    {
      "source": "Weanling male Wistar rats",
      "target": "normal (24%) protein diet",
      "label": "received"
    },
    {
      "source": "normally-fed control",
      "target": "Weanling male Wistar rats",
      "label": "is a group of"
    },
    {
      "source": "protein-malnourished drug-treated groups",
      "target": "Weanling male Wistar rats",
      "label": "is a group of"
    },
    {
      "source": "protein-malnourished drug-treated groups",
      "target": "gastrotoxicity",
      "label": "exhibited exacerbated"
    },
    {
      "source": "two-electron reduction",
      "target": "mitomycin C (MMC)",
      "label": "is of"
    },
    {
      "source": "PM-MMC rats",
      "target": "quinone reductase",
      "label": "showed higher"
    },
    {
      "source": "PM-MMC rats",
      "target": "xanthine oxidase",
      "label": "showed depleted"
    },
    {
      "source": "PM-MMC rats",
      "target": "prostaglandin E2 production",
      "label": "exhibited exaggerated"
    },
    {
      "source": "PM-CP rats",
      "target": "gamma-glutamyltransferase",
      "label": "exhibited lower"
    },
    {
      "source": "PM-CP rats",
      "target": "oxidative stress",
      "label": "exhibited increased"
    },
    {
      "source": "PM-CP rats",
      "target": "glutathione S-transferase",
      "label": "exhibited higher"
    },
    {
      "source": "PM-CP rats",
      "target": "cysteine S-conjugate beta-lyase (CCBL)",
      "label": "exhibited higher"
    },
    {
      "source": "PM-CP rats",
      "target": "aminopeptidase N",
      "label": "exhibited higher"
    },
    {
      "source": "normally-fed drug-treated groups",
      "target": "Weanling male Wistar rats",
      "label": "is a group of"
    },
    {
      "source": "CCBL pathway",
      "target": "CP activation",
      "label": "is for"
    },
    {
      "source": "PM-FU rats",
      "target": "cytochrome P450 1A1/2",
      "label": "exhibited decreased"
    },
    {
      "source": "PM-FU rats",
      "target": "dihydropyrimidine dehydrogenase",
      "label": "exhibited decreased"
    },
    {
      "source": "PM-FU",
      "target": "protein-malnourished drug-treated groups",
      "label": "is a type of"
    },
    {
      "source": "PM-CP",
      "target": "protein-malnourished drug-treated groups",
      "label": "is a type of"
    },
    {
      "source": "protein-malnourished control (PM)",
      "target": "Weanling male Wistar rats",
      "label": "is a group of"
    },
    {
      "source": "PM-MMC",
      "target": "protein-malnourished drug-treated groups",
      "label": "is a type of"
    },
    {
      "source": "magnesium oxide",
      "target": "free fatty acids",
      "label": "alters"
    },
    {
      "source": "magnesium oxide",
      "target": "FFAs",
      "label": "alters"
    },
    {
      "source": "spironolactone",
      "target": "free fatty acids",
      "label": "alters"
    },
    {
      "source": "spironolactone",
      "target": "insulin resistance",
      "label": "lowers"
    },
    {
      "source": "spironolactone",
      "target": "FFAs",
      "label": "alters"
    },
    {
      "source": "spironolactone",
      "target": "PCOS patients",
      "label": "lowers insulin resistance in"
    },
    {
      "source": "Serum free fatty acid",
      "target": "PCOS patients",
      "label": "levels in"
    },
    {
      "source": "PCOS patients",
      "target": "glucophage",
      "label": "treated with"
    },
    {
      "source": "PCOS patients",
      "target": "magnesium oxide",
      "label": "treated with"
    },
    {
      "source": "PCOS patients",
      "target": "spironolactone",
      "label": "treated with"
    },
    {
      "source": "FFA levels",
      "target": "magnesium oxide",
      "label": "unchanged by"
    },
    {
      "source": "FFA levels",
      "target": "glucophage",
      "label": "unchanged by"
    },
    {
      "source": "FFA levels",
      "target": "spironolactone-treated patients",
      "label": "measured for"
    },
    {
      "source": "FFA levels",
      "target": "spironolactone",
      "label": "decreased by"
    },
    {
      "source": "FFAs",
      "target": "repeated measure ANOVA",
      "label": "compared by"
    },
    {
      "source": "FFAs",
      "target": "area under the curve",
      "label": "represented as"
    },
    {
      "source": "FFAs",
      "target": "insulin resistance",
      "label": "involved in development of"
    },
    {
      "source": "PCOS women",
      "target": "Group 3",
      "label": "divided into"
    },
    {
      "source": "PCOS women",
      "target": "Group 1",
      "label": "divided into"
    },
    {
      "source": "PCOS women",
      "target": "Group 2",
      "label": "divided into"
    },
    {
      "source": "Group 3",
      "target": "spironolactone",
      "label": "treated with"
    },
    {
      "source": "glucophage",
      "target": "free fatty acids",
      "label": "alters"
    },
    {
      "source": "glucophage",
      "target": "FFAs",
      "label": "alters"
    },
    {
      "source": "glucose tolerance test",
      "target": "glucose load",
      "label": "performed with"
    },
    {
      "source": "glucose tolerance test",
      "target": "blood",
      "label": "involved collecting"
    },
    {
      "source": "ABT-288",
      "target": "rats",
      "label": "lacked locomotor-stimulant effects in"
    },
    {
      "source": "ABT-288",
      "target": "abuse liability",
      "label": "gives rise to"
    },
    {
      "source": "ABT-288",
      "target": "histamine H3 receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "ABT-288",
      "target": "mice",
      "label": "lacked locomotor-stimulant effects in"
    },
    {
      "source": "ABT-288",
      "target": "human population",
      "label": "is unlikely to possess potential for abuse in"
    },
    {
      "source": "ABT-288",
      "target": "stimulant-like properties",
      "label": "possesses"
    },
    {
      "source": "ABT-288",
      "target": "physical dependence",
      "label": "was studied for"
    },
    {
      "source": "ABT-288",
      "target": "stimulant effects",
      "label": "did not result in cross-sensitization to"
    },
    {
      "source": "ABT-288",
      "target": "reinforcing effects",
      "label": "was evaluated for"
    },
    {
      "source": "ABT-288",
      "target": "amphetamine-like discriminative stimulus effects",
      "label": "did not produce"
    },
    {
      "source": "ABT-288",
      "target": "locomotor-stimulant effects",
      "label": "lacked"
    },
    {
      "source": "ABT-288",
      "target": "Histamine H3 receptor antagonists",
      "label": "is a type of"
    },
    {
      "source": "ABT-288",
      "target": "motor activity",
      "label": "interacts for"
    },
    {
      "source": "ABT-288",
      "target": "cross-sensitization",
      "label": "did not result in"
    },
    {
      "source": "ABT-288",
      "target": "potential for abuse",
      "label": "is unlikely to possess"
    },
    {
      "source": "d-amphetamine",
      "target": "motor activity",
      "label": "interacts for"
    },
    {
      "source": "d-amphetamine",
      "target": "stimulant effects",
      "label": "has"
    },
    {
      "source": "H3 antagonists",
      "target": "potential for abuse",
      "label": "may have"
    },
    {
      "source": "H3 antagonists",
      "target": "psychomotor stimulant-like effects",
      "label": "possess"
    },
    {
      "source": "Histamine H3 receptor antagonists",
      "target": "wakefulness-promoting effects",
      "label": "possess"
    },
    {
      "source": "Histamine H3 receptor antagonists",
      "target": "cognitive-enhancing effects",
      "label": "possess"
    },
    {
      "source": "Drug discrimination",
      "target": "amphetamine-like stimulus properties",
      "label": "used to assess"
    },
    {
      "source": "preclinical data",
      "target": "H3 antagonists",
      "label": "applied to"
    },
    {
      "source": "drug self-administration",
      "target": "reinforcing effects",
      "label": "used to evaluate"
    },
    {
      "source": "binding model 12b",
      "target": "c-Met",
      "label": "with"
    },
    {
      "source": "binding model 12b",
      "target": "docking analysis",
      "label": "disclosed by"
    },
    {
      "source": "compound 12b",
      "target": "EBC-1 cell",
      "label": "exhibited inhibition of"
    },
    {
      "source": "compound 12b",
      "target": "selectivity",
      "label": "showed"
    },
    {
      "source": "compound 12b",
      "target": "c-Met IC50",
      "label": "has"
    },
    {
      "source": "EBC-1 cell",
      "target": "c-Met constitutive activation",
      "label": "associated with"
    },
    {
      "source": "5-(benzyloxy)pyridin-2(1H)-one derivatives",
      "target": "c-Met inhibitors",
      "label": "are"
    },
    {
      "source": "5-(benzyloxy)pyridin-2(1H)-ones",
      "target": "c-Met inhibition",
      "label": "evaluated for"
    },
    {
      "source": "amides",
      "target": "C-3 position",
      "label": "investigated at"
    },
    {
      "source": "c-Met IC50",
      "target": "12nM",
      "label": "is"
    },
    {
      "source": "benzoimidazoles",
      "target": "C-3 position",
      "label": "investigated at"
    },
    {
      "source": "Direct sequencing",
      "target": "T-to-C exchange",
      "label": "identified"
    },
    {
      "source": "T-to-C exchange",
      "target": "exon 1",
      "label": "located in"
    },
    {
      "source": "T-to-C exchange",
      "target": "SIRT1 gene",
      "label": "located in"
    },
    {
      "source": "T-to-C exchange",
      "target": "leucine-to-proline mutation at residue 107",
      "label": "corresponds to"
    },
    {
      "source": "SIRT1-L107P",
      "target": "chemokines",
      "label": "causes overproduction of"
    },
    {
      "source": "SIRT1-L107P",
      "target": "nitric oxide",
      "label": "causes overproduction of"
    },
    {
      "source": "SIRT1-L107P",
      "target": "cytokines",
      "label": "causes overproduction of"
    },
    {
      "source": "SIRT1-L107P",
      "target": "insulin-producing cells",
      "label": "expressed in"
    },
    {
      "source": "autoimmune-mediated \u03b2 cell destruction",
      "target": "insulin deficiency",
      "label": "leads to"
    },
    {
      "source": "SIRT1 mutation",
      "target": "leucine-to-proline mutation at residue 107",
      "label": "is"
    },
    {
      "source": "SIRT1 mutation",
      "target": "monogenic form of type 1 diabetes",
      "label": "unveils"
    },
    {
      "source": "SIRT1 mutation",
      "target": "family",
      "label": "identified in"
    },
    {
      "source": "leucine-to-proline mutation at residue 107",
      "target": "residue 107",
      "label": "at"
    },
    {
      "source": "leucine-to-proline mutation at residue 107",
      "target": "leucine",
      "label": "involves"
    },
    {
      "source": "leucine-to-proline mutation at residue 107",
      "target": "SIRT1-L107P",
      "label": "is"
    },
    {
      "source": "leucine-to-proline mutation at residue 107",
      "target": "proline",
      "label": "involves"
    },
    {
      "source": "type 1 diabetes",
      "target": "lean body mass",
      "label": "features"
    },
    {
      "source": "type 1 diabetes",
      "target": "autoimmune-mediated \u03b2 cell destruction",
      "label": "caused by"
    },
    {
      "source": "type 1 diabetes",
      "target": "insulin",
      "label": "causes dependence on"
    },
    {
      "source": "type 1 diabetes",
      "target": "T cell reactivity",
      "label": "features"
    },
    {
      "source": "type 1 diabetes",
      "target": "autoantibodies",
      "label": "features"
    },
    {
      "source": "exome sequencing",
      "target": "T-to-C exchange",
      "label": "identified"
    },
    {
      "source": "26-year-old man",
      "target": "type 1 diabetes",
      "label": "diagnosed with"
    },
    {
      "source": "affected members",
      "target": "autoimmune disorder",
      "label": "developed"
    },
    {
      "source": "affected members",
      "target": "type 1 diabetes",
      "label": "developed"
    },
    {
      "source": "affected members",
      "target": "ulcerative colitis",
      "label": "developed"
    },
    {
      "source": "T cell reactivity",
      "target": "\u03b2 cell antigens",
      "label": "targets"
    },
    {
      "source": "oxytocin receptor gene",
      "target": "polymorphism",
      "label": "has"
    },
    {
      "source": "oxytocin receptor gene",
      "target": "single nucleotide polymorphism",
      "label": "is a"
    },
    {
      "source": "Web-based assessments",
      "target": "quality of social environments",
      "label": "measured"
    },
    {
      "source": "Web-based assessments",
      "target": "PTS symptoms",
      "label": "measured"
    },
    {
      "source": "Web-based assessments",
      "target": "acute stress",
      "label": "measured"
    },
    {
      "source": "Web-based assessments",
      "target": "pre-9/11 mental health",
      "label": "measured"
    },
    {
      "source": "Web-based assessments",
      "target": "economic stress",
      "label": "measured"
    },
    {
      "source": "Web-based assessments",
      "target": "impaired functioning",
      "label": "measured"
    },
    {
      "source": "functioning of males",
      "target": "negative social environments",
      "label": "susceptibility depends on"
    },
    {
      "source": "functioning of males",
      "target": "genotype",
      "label": "susceptibility depends on"
    },
    {
      "source": "functioning of males",
      "target": "economic stress",
      "label": "susceptible to"
    },
    {
      "source": "functioning of males",
      "target": "OXTR",
      "label": "susceptibility depends on"
    },
    {
      "source": "negative social environments",
      "target": "constraint",
      "label": "include"
    },
    {
      "source": "negative social environments",
      "target": "interpersonal conflict",
      "label": "include"
    },
    {
      "source": "negative social environments",
      "target": "elevated PTS symptoms",
      "label": "predicted"
    },
    {
      "source": "negative social environments",
      "target": "PTS symptoms",
      "label": "increased"
    },
    {
      "source": "combined impact",
      "target": "Gender",
      "label": "involves"
    },
    {
      "source": "combined impact",
      "target": "impaired daily functioning",
      "label": "affects"
    },
    {
      "source": "combined impact",
      "target": "ongoing stress",
      "label": "involves"
    },
    {
      "source": "combined impact",
      "target": "post-traumatic stress symptoms",
      "label": "affects"
    },
    {
      "source": "combined impact",
      "target": "moderators",
      "label": "acts as"
    },
    {
      "source": "combined impact",
      "target": "negative social environments",
      "label": "involves"
    },
    {
      "source": "combined impact",
      "target": "economic stress",
      "label": "involves"
    },
    {
      "source": "ongoing stress",
      "target": "different domains",
      "label": "occurs in"
    },
    {
      "source": "functioning of females",
      "target": "genotype",
      "label": "unaffected by"
    },
    {
      "source": "functioning of females",
      "target": "negative social environments",
      "label": "affected by"
    },
    {
      "source": "functioning of females",
      "target": "economic stress",
      "label": "unaffected by"
    },
    {
      "source": "impaired daily functioning",
      "target": "collective stress",
      "label": "follows"
    },
    {
      "source": "associations",
      "target": "negative social environments",
      "label": "between"
    },
    {
      "source": "associations",
      "target": "economic stress",
      "label": "between"
    },
    {
      "source": "associations",
      "target": "impaired functioning",
      "label": "between"
    },
    {
      "source": "quality of social environments",
      "target": "9/11",
      "label": "occurred post"
    },
    {
      "source": "acute stress",
      "target": "9/11",
      "label": "occurred after"
    },
    {
      "source": "mental health",
      "target": "collective stress",
      "label": "following"
    },
    {
      "source": "collective stress",
      "target": "September 11th terrorist attacks",
      "label": "is exemplified by"
    },
    {
      "source": "PTS symptoms",
      "target": "level of economic stress",
      "label": "occurred without regard to"
    },
    {
      "source": "PTS symptoms",
      "target": "9/11",
      "label": "occurred post"
    },
    {
      "source": "economic stress",
      "target": "9/11",
      "label": "occurred post"
    },
    {
      "source": "post-traumatic stress symptoms",
      "target": "PTS symptoms",
      "label": "is also known as"
    },
    {
      "source": "OXTR",
      "target": "single nucleotide polymorphism",
      "label": "is a"
    },
    {
      "source": "OXTR",
      "target": "polymorphism",
      "label": "has"
    },
    {
      "source": "Saliva",
      "target": "mail",
      "label": "collected by"
    },
    {
      "source": "Saliva",
      "target": "704 respondents",
      "label": "used to genotype"
    },
    {
      "source": "impaired functioning",
      "target": "9/11",
      "label": "occurred post"
    },
    {
      "source": "genetic vulnerability",
      "target": "collective stress",
      "label": "follows"
    },
    {
      "source": "elevated PTS symptoms",
      "target": "high economic stress",
      "label": "associated with"
    },
    {
      "source": "rs53576 genotype",
      "target": "GG genotype",
      "label": "includes"
    },
    {
      "source": "rs53576 genotype",
      "target": "A allele",
      "label": "includes"
    },
    {
      "source": "rs53576 genotype",
      "target": "combined impact",
      "label": "buffers"
    },
    {
      "source": "704 respondents",
      "target": "GG genotype",
      "label": "have"
    },
    {
      "source": "moderators",
      "target": "genetic vulnerability",
      "label": "of"
    },
    {
      "source": "Environmental stress",
      "target": "collective stress",
      "label": "following"
    },
    {
      "source": "time-domains",
      "target": "delay",
      "label": "include"
    },
    {
      "source": "time-domains",
      "target": "minutes",
      "label": "include"
    },
    {
      "source": "delay",
      "target": "transcriptional regulation",
      "label": "involves"
    },
    {
      "source": "delay",
      "target": "h",
      "label": "measured in"
    },
    {
      "source": "CORT",
      "target": "s.c.",
      "label": "administered via"
    },
    {
      "source": "CORT",
      "target": "c-Fos expression",
      "label": "is associated with increased"
    },
    {
      "source": "CORT",
      "target": "30 min",
      "label": "administered at"
    },
    {
      "source": "CORT",
      "target": "180 min",
      "label": "administered at"
    },
    {
      "source": "CORT",
      "target": "1 mg/kg",
      "label": "has dosage"
    },
    {
      "source": "180 min",
      "target": "number of visits",
      "label": "did not affect"
    },
    {
      "source": "180 min",
      "target": "c-Fos labelling",
      "label": "did not affect"
    },
    {
      "source": "180 min",
      "target": "rapid and delayed time domain",
      "label": "is a time point for"
    },
    {
      "source": "180 min",
      "target": "behavioural testing",
      "label": "is prior to"
    },
    {
      "source": "number of visits",
      "target": "disadvantageous arm",
      "label": "to"
    },
    {
      "source": "number of visits",
      "target": "CORT",
      "label": "was attenuated by"
    },
    {
      "source": "number of visits",
      "target": "trial blocks",
      "label": "decreased over"
    },
    {
      "source": "reward-based decision-making",
      "target": "rat model",
      "label": "is studied in"
    },
    {
      "source": "reward-based decision-making",
      "target": "rapid versus delayed actions",
      "label": "is altered by"
    },
    {
      "source": "neuronal activity",
      "target": "time-domains",
      "label": "occurs in"
    },
    {
      "source": "rodent model",
      "target": "Iowa Gambling Task",
      "label": "is a model of"
    },
    {
      "source": "c-Fos expression",
      "target": "insular cortex",
      "label": "increased in"
    },
    {
      "source": "c-Fos expression",
      "target": "infralimbic cortex",
      "label": "increased in"
    },
    {
      "source": "c-Fos expression",
      "target": "lateral orbitofrontal cortex",
      "label": "increased in"
    },
    {
      "source": "Corticosteroid hormones",
      "target": "neuronal activity",
      "label": "change"
    },
    {
      "source": "Corticosteroid hormones",
      "target": "stress",
      "label": "released after"
    },
    {
      "source": "rapid and delayed time domain",
      "target": "corticosterone",
      "label": "targeted by injecting"
    },
    {
      "source": "saline treated rats",
      "target": "number of visits",
      "label": "showed decrease in"
    },
    {
      "source": "modes of corticosteroid action",
      "target": "cognitive tasks",
      "label": "affect"
    },
    {
      "source": "behavioural testing",
      "target": "behavioural paradigm",
      "label": "occurs during"
    },
    {
      "source": "rapid corticosteroid effect",
      "target": "180 min",
      "label": "contrasted with treatment at"
    },
    {
      "source": "rapid versus delayed actions",
      "target": "corticosterone",
      "label": "are actions of"
    },
    {
      "source": "minutes",
      "target": "non-genomic pathways",
      "label": "via"
    },
    {
      "source": "rapid corticosteroid actions",
      "target": "reward-based decision-making",
      "label": "impair"
    },
    {
      "source": "B16/F1 melanoma",
      "target": "Melanoma",
      "label": "is a type of"
    },
    {
      "source": "Melanoma",
      "target": "receptor",
      "label": "has"
    },
    {
      "source": "Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide",
      "target": "lactam bridge-cyclized alpha-MSH peptide",
      "label": "is a type of"
    },
    {
      "source": "Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide",
      "target": "Lu-177",
      "label": "is labeled with"
    },
    {
      "source": "Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide",
      "target": "Melanoma",
      "label": "targets"
    },
    {
      "source": "lactam bridge-cyclized alpha-MSH peptide",
      "target": "alpha-MSH peptide",
      "label": "is a type of"
    },
    {
      "source": "alpha-MSH peptide",
      "target": "peptide",
      "label": "is a type of"
    },
    {
      "source": "B16/F1 melanoma-bearing C57 mice",
      "target": "B16/F1 melanoma",
      "label": "bears"
    },
    {
      "source": "B16/F1 melanoma-bearing C57 mice",
      "target": "C57 mice",
      "label": "is a type of"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "urinary clearance",
      "label": "exhibited"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "Melanoma",
      "label": "targets"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "Lu-177-labeled lactam bridge-cyclized alpha-MSH peptide",
      "label": "is a specific form of"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "B16/F1 melanoma-bearing C57 mice",
      "label": "studied in"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "normal organ",
      "label": "has high tumor to organ uptake ratio for"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "kidneys",
      "label": "has lower tumor to organ uptake ratio for"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "imaging probe",
      "label": "is a type of"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "melanoma treatment",
      "label": "has potential for"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "tumor",
      "label": "has uptake in"
    },
    {
      "source": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "target": "receptor",
      "label": "binds to"
    },
    {
      "source": "SPECT/CT",
      "target": "(177)Lu-DOTA-GGNle-CycMSHhex",
      "label": "uses"
    },
    {
      "source": "tumor",
      "target": "Melanoma",
      "label": "is a manifestation of"
    },
    {
      "source": "melanoma lesions",
      "target": "SPECT/CT",
      "label": "visualized by"
    },
    {
      "source": "melanoma lesions",
      "target": "Melanoma",
      "label": "is a manifestation of"
    },
    {
      "source": "injected dose",
      "target": "urinary system",
      "label": "cleared via"
    },
    {
      "source": "injected dose",
      "target": "body",
      "label": "cleared out of"
    },
    {
      "source": "three novel missense mutations",
      "target": "p.Tyr1055Cys",
      "label": "include"
    },
    {
      "source": "three novel missense mutations",
      "target": "repression of E-cadherin",
      "label": "prevented"
    },
    {
      "source": "three novel missense mutations",
      "target": "partial loss of function of ZEB2",
      "label": "cause"
    },
    {
      "source": "three novel missense mutations",
      "target": "binding",
      "label": "prevented"
    },
    {
      "source": "three novel missense mutations",
      "target": "p.Ser1071Pro",
      "label": "include"
    },
    {
      "source": "three novel missense mutations",
      "target": "p.His1045Arg",
      "label": "include"
    },
    {
      "source": "p.Tyr1055Cys",
      "target": "highly conserved C-zinc-finger (C-ZF) domain",
      "label": "is identified in"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "patients",
      "label": "should be considered in"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "de novo heterozygous mutations",
      "label": "is caused by"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "Hirschsprung disease (HSCR)",
      "label": "associates"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "epilepsy",
      "label": "associates"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "multiple congenital anomaly syndrome",
      "label": "is a"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "distinctive facial gestalt",
      "label": "is a"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "severe intellectual disability (ID)",
      "label": "is a"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "corpus callosum agenesis",
      "label": "associates"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "microcephaly",
      "label": "associates"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "conotruncal heart defects",
      "label": "associates"
    },
    {
      "source": "Mowat-Wilson syndrome (MWS)",
      "target": "urogenital malformations",
      "label": "associates"
    },
    {
      "source": "de novo heterozygous mutations",
      "target": "ZEB2 gene",
      "label": "are in"
    },
    {
      "source": "zebrafish morphant technology",
      "target": "rescue experiments",
      "label": "was used for"
    },
    {
      "source": "rescue experiments",
      "target": "mutant human ZEB2 mRNAs",
      "label": "used"
    },
    {
      "source": "rescue experiments",
      "target": "wild-type (WT) human ZEB2 mRNAs",
      "label": "used"
    },
    {
      "source": "repression of E-cadherin",
      "target": "E-cadherin",
      "label": "involves"
    },
    {
      "source": "repression of E-cadherin",
      "target": "E-cadherin promoter",
      "label": "targets"
    },
    {
      "source": "E-cadherin promoter",
      "target": "ZEB2 target gene",
      "label": "is a"
    },
    {
      "source": "ZEB2 zinc-finger missense mutations",
      "target": "hypomorphic alleles",
      "label": "lead to"
    },
    {
      "source": "ZEB2 zinc-finger missense mutations",
      "target": "Mowat-Wilson syndrome (MWS)",
      "label": "lead to"
    },
    {
      "source": "p.Ser1071Pro",
      "target": "highly conserved C-zinc-finger (C-ZF) domain",
      "label": "is identified in"
    },
    {
      "source": "highly conserved C-zinc-finger (C-ZF) domain",
      "target": "ZEB2",
      "label": "is a domain of"
    },
    {
      "source": "Patients' phenotype",
      "target": "facial gestalt of MWS",
      "label": "included"
    },
    {
      "source": "Patients' phenotype",
      "target": "Hirschsprung disease (HSCR)",
      "label": "did not include"
    },
    {
      "source": "Patients' phenotype",
      "target": "heart defects",
      "label": "did not include"
    },
    {
      "source": "Patients' phenotype",
      "target": "moderate ID",
      "label": "included"
    },
    {
      "source": "Patients' phenotype",
      "target": "microcephaly",
      "label": "did not include"
    },
    {
      "source": "three missense mutations",
      "target": "known functional domain of ZEB2",
      "label": "do not reside in"
    },
    {
      "source": "ZEB2",
      "target": "repression of E-cadherin",
      "label": "has a role in"
    },
    {
      "source": "ZEB2",
      "target": "zinc-finger",
      "label": "has"
    },
    {
      "source": "ZEB2",
      "target": "highly conserved C-zinc-finger (C-ZF) domain",
      "label": "has"
    },
    {
      "source": "C-ZF",
      "target": "ZEB2",
      "label": "is a domain of"
    },
    {
      "source": "C-ZF",
      "target": "zinc-finger",
      "label": "is a"
    },
    {
      "source": "haplo-insufficiency",
      "target": "large gene deletions",
      "label": "is caused by"
    },
    {
      "source": "haplo-insufficiency",
      "target": "premature stop codons",
      "label": "is caused by"
    },
    {
      "source": "p.His1045Arg",
      "target": "highly conserved C-zinc-finger (C-ZF) domain",
      "label": "is identified in"
    },
    {
      "source": "Functional domains",
      "target": "C-ZF",
      "label": "are other than"
    },
    {
      "source": "Functional domains",
      "target": "early embryonic development",
      "label": "play a role in"
    },
    {
      "source": "embryo rescue",
      "target": "severity of patients' phenotype",
      "label": "correlated with"
    },
    {
      "source": "frequent-to-rare codon conversion",
      "target": "HtrA1's conformation",
      "label": "compromised"
    },
    {
      "source": "frequent-to-rare codon conversion",
      "target": "mRNA translation rate",
      "label": "reduced"
    },
    {
      "source": "frequent-to-rare codon conversion",
      "target": "HtrA1's function",
      "label": "compromised"
    },
    {
      "source": "synonymous SNPs",
      "target": "exon 1",
      "label": "located within"
    },
    {
      "source": "synonymous SNPs",
      "target": "less frequently used codons",
      "label": "convert to"
    },
    {
      "source": "synonymous SNPs",
      "target": "common codons",
      "label": "convert"
    },
    {
      "source": "common variants",
      "target": "high-temperature requirement A1 (HTRA1)",
      "label": "are variants of"
    },
    {
      "source": "common variants",
      "target": "inherited risk",
      "label": "increase"
    },
    {
      "source": "common variants",
      "target": "synonymous SNPs",
      "label": "harbor"
    },
    {
      "source": "Synonymous single nucleotide polymorphisms (SNPs)",
      "target": "protein product",
      "label": "produce no change in"
    },
    {
      "source": "Synonymous single nucleotide polymorphisms (SNPs)",
      "target": "protein function",
      "label": "assumed to have neutral effect on"
    },
    {
      "source": "Synonymous single nucleotide polymorphisms (SNPs)",
      "target": "transcript's coding region",
      "label": "located within"
    },
    {
      "source": "Synonymous single nucleotide polymorphisms (SNPs)",
      "target": "amino acid sequence",
      "label": "produce no change in"
    },
    {
      "source": "HtrA1's abilities",
      "target": "IGF-1",
      "label": "include associating with"
    },
    {
      "source": "HtrA1's abilities",
      "target": "cellular responses",
      "label": "include ameliorating"
    },
    {
      "source": "HtrA1's abilities",
      "target": "IGF-1-stimulated signaling events",
      "label": "include ameliorating"
    },
    {
      "source": "inherited risk",
      "target": "neovascular age-related macular degeneration (NvAMD)",
      "label": "of"
    },
    {
      "source": "common codons",
      "target": "Ala34",
      "label": "for"
    },
    {
      "source": "common codons",
      "target": "Gly36",
      "label": "for"
    },
    {
      "source": "homeostatic protein quality control mechanisms",
      "target": "NvAMD",
      "label": "may go awry in"
    },
    {
      "source": "synonymous codon usage",
      "target": "protein function",
      "label": "relevant to"
    },
    {
      "source": "NvAMD-associated synonymous polymorphisms",
      "target": "HtrA1's putative insulin-like growth factor 1 (IGF-1) binding domain",
      "label": "lie within"
    },
    {
      "source": "NvAMD-associated synonymous polymorphisms",
      "target": "HtrA1's abilities",
      "label": "reduced"
    },
    {
      "source": "Silent Polymorphisms",
      "target": "HtrA1's abilities",
      "label": "impair"
    },
    {
      "source": "Silent Polymorphisms",
      "target": "HtrA1",
      "label": "located in"
    },
    {
      "source": "Silent Polymorphisms",
      "target": "Age-Related Macular Degeneration",
      "label": "associated with"
    },
    {
      "source": "HtrA1",
      "target": "Insulin-Like Growth Factor 1",
      "label": "antagonizes"
    },
    {
      "source": "release of pro-inflammatory factors",
      "target": "monocyte chemotactic protein-1",
      "label": "like"
    },
    {
      "source": "anti-inflammatory effect",
      "target": "endothelial cells",
      "label": "on"
    },
    {
      "source": "anti-inflammatory effect",
      "target": "immune cells",
      "label": "on"
    },
    {
      "source": "potential beneficial action",
      "target": "anti-inflammatory effect",
      "label": "accompanied by"
    },
    {
      "source": "potential beneficial action",
      "target": "late stages of diabetes",
      "label": "in"
    },
    {
      "source": "potential beneficial action",
      "target": "membrane fluidity",
      "label": "exerted at"
    },
    {
      "source": "potential beneficial action",
      "target": "polyphenols",
      "label": "of"
    },
    {
      "source": "potential beneficial action",
      "target": "transmembrane potential",
      "label": "exerted at"
    },
    {
      "source": "membrane fluidity",
      "target": "human umbilical vein endothelial cells",
      "label": "of"
    },
    {
      "source": "membrane fluidity",
      "target": "Jurkat T lymphoblasts",
      "label": "of"
    },
    {
      "source": "Membranar effects",
      "target": "curcumin",
      "label": "exerted by"
    },
    {
      "source": "Membranar effects",
      "target": "Jurkat cells",
      "label": "on"
    },
    {
      "source": "Membranar effects",
      "target": "HUVEC",
      "label": "on"
    },
    {
      "source": "Membranar effects",
      "target": "epigallocatechin gallate",
      "label": "exerted by"
    },
    {
      "source": "Membranar effects",
      "target": "quercetin",
      "label": "exerted by"
    },
    {
      "source": "Membranar effects",
      "target": "polyphenols",
      "label": "exerted by"
    },
    {
      "source": "Membranar effects",
      "target": "diabetes mellitus",
      "label": "relevant for"
    },
    {
      "source": "experimental conditions",
      "target": "diabetes mellitus",
      "label": "mimicking"
    },
    {
      "source": "experimental conditions",
      "target": "increased concentration of advanced glycation end products",
      "label": "are"
    },
    {
      "source": "experimental conditions",
      "target": "high glucose conditions",
      "label": "are"
    },
    {
      "source": "transmembrane potential",
      "target": "human umbilical vein endothelial cells",
      "label": "of"
    },
    {
      "source": "transmembrane potential",
      "target": "Jurkat T lymphoblasts",
      "label": "of"
    },
    {
      "source": "beneficial action",
      "target": "various pathologies",
      "label": "in"
    },
    {
      "source": "advanced glycation end products",
      "target": "late stages of diabetes",
      "label": "specific for"
    },
    {
      "source": "investigated polyphenols",
      "target": "release of pro-inflammatory factors",
      "label": "limited"
    },
    {
      "source": "l-glutamine",
      "target": "stretpozotocin-nicotinamide induced diabetic rats",
      "label": "treats"
    },
    {
      "source": "l-glutamine",
      "target": "plasma active (GLP-1) (7-36) amide",
      "label": "increased"
    },
    {
      "source": "l-glutamine",
      "target": "blood sugar",
      "label": "decreased"
    },
    {
      "source": "l-glutamine",
      "target": "plasma insulin",
      "label": "increased"
    },
    {
      "source": "l-glutamine",
      "target": "oxidative stress",
      "label": "decreased"
    },
    {
      "source": "l-glutamine",
      "target": "pancreatic insulin",
      "label": "increased"
    },
    {
      "source": "l-glutamine",
      "target": "active GLP-1 (7-36) amide",
      "label": "increases"
    },
    {
      "source": "l-glutamine",
      "target": "glycemic control",
      "label": "improves"
    },
    {
      "source": "l-glutamine",
      "target": "Plasma glucose",
      "label": "decreased"
    },
    {
      "source": "l-glutamine",
      "target": "type 2 diabetic patients",
      "label": "treats"
    },
    {
      "source": "l-glutamine",
      "target": "non-essential amino acid",
      "label": "is a"
    },
    {
      "source": "l-glutamine",
      "target": "colonic active (GLP-1) (7-36) amide",
      "label": "increased"
    },
    {
      "source": "l-glutamine",
      "target": "insulin secretion",
      "label": "stimulated"
    },
    {
      "source": "l-glutamine",
      "target": "GLP-1 receptor",
      "label": "binds to"
    },
    {
      "source": "overnight fasted Sprague Dawley rats",
      "target": "Type 2 diabetes",
      "label": "have condition"
    },
    {
      "source": "nicotinamide",
      "target": "Type 2 diabetes",
      "label": "induced"
    },
    {
      "source": "Molecular docking study",
      "target": "molecular basis",
      "label": "elucidated"
    },
    {
      "source": "Pharmacological Characterization",
      "target": "present study",
      "label": "is part of"
    },
    {
      "source": "Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4)",
      "target": "Dmt(1)",
      "label": "contains"
    },
    {
      "source": "Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4)",
      "target": "analogue 12",
      "label": "is"
    },
    {
      "source": "Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4)",
      "target": "(R)-\u03b2Pro(2)",
      "label": "contains"
    },
    {
      "source": "Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4)",
      "target": "(2-furyl)Map(4)",
      "label": "contains"
    },
    {
      "source": "Dmt(1)-(R)-\u03b2Pro(2)-Trp(3)-(2-furyl)Map(4)",
      "target": "Trp(3)",
      "label": "contains"
    },
    {
      "source": "EM-1 analogues",
      "target": "(2-furyl)Map(4)",
      "label": "contain"
    },
    {
      "source": "EM-1 analogues",
      "target": "(R/S)-\u03b2Pro(2)",
      "label": "contain"
    },
    {
      "source": "EM-1 analogues",
      "target": "\u03b1-methylene-\u03b2-aminopropanoic acids",
      "label": "contain"
    },
    {
      "source": "EM-1 analogues",
      "target": "\u03bc-Opioid Agonists",
      "label": "are a type of"
    },
    {
      "source": "EM-1 analogues",
      "target": "Dmt(1)",
      "label": "contain"
    },
    {
      "source": "EM-1 analogues",
      "target": "(ph)Map(4)",
      "label": "contain"
    },
    {
      "source": "EM-1 analogues",
      "target": "Endomorphin-1",
      "label": "are derived from"
    },
    {
      "source": "Endomorphin-1",
      "target": "\u03bc-Opioid Agonists",
      "label": "is a type of"
    },
    {
      "source": "analogue 12",
      "target": "agonistic potency",
      "label": "displayed"
    },
    {
      "source": "analogue 12",
      "target": "affinity",
      "label": "displayed"
    },
    {
      "source": "analogue 12",
      "target": "tail-flick test",
      "label": "tested in"
    },
    {
      "source": "analogue 12",
      "target": "compounds",
      "label": "is a type of"
    },
    {
      "source": "analogue 12",
      "target": "morphine",
      "label": "compared to"
    },
    {
      "source": "analogue 12",
      "target": "blood-brain barrier",
      "label": "can cross"
    },
    {
      "source": "analogue 12",
      "target": "antinociceptive activity",
      "label": "displayed"
    },
    {
      "source": "agonistic potency",
      "target": "subpicomolar range",
      "label": "is in"
    },
    {
      "source": "cAMP accumulation assays",
      "target": "cAMP",
      "label": "measures"
    },
    {
      "source": "3.72 pM",
      "target": "Ki(\u03bc)",
      "label": "is value of"
    },
    {
      "source": "Ki(\u03bc)",
      "target": "3.72 pM",
      "label": "has value"
    },
    {
      "source": "99.5%",
      "target": "Emax",
      "label": "is value of"
    },
    {
      "source": "Emax",
      "target": "99.5%",
      "label": "has value"
    },
    {
      "source": "\u03b1-methylene-\u03b2-aminopropanoic acids",
      "target": "Map",
      "label": "is also known as"
    },
    {
      "source": "Design",
      "target": "present study",
      "label": "is part of"
    },
    {
      "source": "\u03bc-opioid receptor",
      "target": "MOR",
      "label": "is an abbreviation for"
    },
    {
      "source": "Forskolin-induced cAMP accumulation assays",
      "target": "cAMP accumulation assays",
      "label": "is a type of"
    },
    {
      "source": "EC50",
      "target": "0.0421 pM",
      "label": "has value"
    },
    {
      "source": "0.0421 pM",
      "target": "EC50",
      "label": "is value of"
    },
    {
      "source": "Forskolin",
      "target": "Forskolin-induced cAMP accumulation assays",
      "label": "induces"
    },
    {
      "source": "EM-1",
      "target": "Endomorphin-1",
      "label": "is an abbreviation for"
    },
    {
      "source": "structure-activity study",
      "target": "EM-1 analogues",
      "label": "investigated"
    },
    {
      "source": "Hinokitiol",
      "target": "platelet activation",
      "label": "inhibits"
    },
    {
      "source": "Hinokitiol",
      "target": "cosmetics",
      "label": "used in"
    },
    {
      "source": "Hinokitiol",
      "target": "binding",
      "label": "Not"
    },
    {
      "source": "Hinokitiol",
      "target": "thrombin",
      "label": "Not"
    },
    {
      "source": "Hinokitiol",
      "target": "activation of MAPKs",
      "label": "suppresses"
    },
    {
      "source": "Hinokitiol",
      "target": "tropolone-related bioactive compound",
      "label": "is a"
    },
    {
      "source": "Hinokitiol",
      "target": "Akt",
      "label": "suppresses"
    },
    {
      "source": "Hinokitiol",
      "target": "antimicrobial agent",
      "label": "used as"
    },
    {
      "source": "Hinokitiol",
      "target": "PKC activation",
      "label": "reduced"
    },
    {
      "source": "Hinokitiol",
      "target": "phosphorylation",
      "label": "inhibited"
    },
    {
      "source": "Hinokitiol",
      "target": "PLC\u03b32-PKC cascade",
      "label": "inhibits"
    },
    {
      "source": "Hinokitiol",
      "target": "thrombus formation",
      "label": "inhibits"
    },
    {
      "source": "Hinokitiol",
      "target": "collagen-induced aggregation",
      "label": "inhibited"
    },
    {
      "source": "Hinokitiol",
      "target": "anticancer activities",
      "label": "has"
    },
    {
      "source": "Hinokitiol",
      "target": "platelet aggregation",
      "label": "reduced"
    },
    {
      "source": "Hinokitiol",
      "target": "food",
      "label": "used in"
    },
    {
      "source": "Hinokitiol",
      "target": "intracellular calcium mobilization",
      "label": "reduced"
    },
    {
      "source": "Hinokitiol",
      "target": "\u03b1IIb\u03b23 integrin",
      "label": "Not"
    },
    {
      "source": "Hinokitiol",
      "target": "hair tonics",
      "label": "used in"
    },
    {
      "source": "Hinokitiol",
      "target": "therapeutic agent",
      "label": "is a potential"
    },
    {
      "source": "Hinokitiol",
      "target": "hydroxyl radical (OH) formation",
      "label": "inhibits"
    },
    {
      "source": "Hinokitiol",
      "target": "thrombogenesis",
      "label": "prolonged"
    },
    {
      "source": "Hinokitiol",
      "target": "arachidonic acid",
      "label": "Not"
    },
    {
      "source": "Hinokitiol",
      "target": "ADP",
      "label": "Not"
    },
    {
      "source": "platelet activation",
      "target": "atherothrombotic processes",
      "label": "plays a crucial role in"
    },
    {
      "source": "\u03b1IIb\u03b23 integrin",
      "target": "platelet membrane",
      "label": "on"
    },
    {
      "source": "blockade of CRFRs",
      "target": "DA",
      "label": "failed to alter effects of"
    },
    {
      "source": "blockade of CRFRs",
      "target": "ISO",
      "label": "failed to alter effects of"
    },
    {
      "source": "glutamatergic transmission",
      "target": "CeAL neurons",
      "label": "occurs onto"
    },
    {
      "source": "dopamine (DA)",
      "target": "presynaptic glutamate release",
      "label": "increase"
    },
    {
      "source": "dopamine (DA)",
      "target": "frequency",
      "label": "enhance"
    },
    {
      "source": "dopamine (DA)",
      "target": "sEPSC kinetics",
      "label": "does not alter"
    },
    {
      "source": "excitatory transmission",
      "target": "other subregions of the extended amygdala",
      "label": "occurs in"
    },
    {
      "source": "other subregions of the extended amygdala",
      "target": "extended amygdala",
      "label": "part of"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "behaviors",
      "label": "plays an important role in"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "lateral subdivision of the central amygdala",
      "label": "occurs in"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "CeA",
      "label": "occurs in"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "memory consolidation",
      "label": "plays an important role in"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "central nucleus of the amygdala (CeA)",
      "label": "occurs in"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "anxiety",
      "label": "plays an important role in"
    },
    {
      "source": "glutamatergic neurotransmission",
      "target": "cardiovascular responses",
      "label": "plays an important role in"
    },
    {
      "source": "behaviors",
      "target": "anxiety",
      "label": "includes"
    },
    {
      "source": "behaviors",
      "target": "cardiovascular responses",
      "label": "includes"
    },
    {
      "source": "behaviors",
      "target": "catecholamine signaling",
      "label": "modulated by"
    },
    {
      "source": "behaviors",
      "target": "CRF",
      "label": "modulated by"
    },
    {
      "source": "behaviors",
      "target": "memory consolidation",
      "label": "includes"
    },
    {
      "source": "CRFRs",
      "target": "excitatory transmission",
      "label": "mediate effect on"
    },
    {
      "source": "CRFRs",
      "target": "catecholamines",
      "label": "mediate effect of"
    },
    {
      "source": "catecholamine signaling",
      "target": "glutamatergic neurotransmission",
      "label": "modify"
    },
    {
      "source": "dissociable effects of CRF",
      "target": "different types of glutamatergic neurotransmission",
      "label": "on"
    },
    {
      "source": "spontaneous glutamate release",
      "target": "CeAL",
      "label": "occurs in"
    },
    {
      "source": "CRF",
      "target": "spontaneous glutamate release",
      "label": "increased"
    },
    {
      "source": "CRF",
      "target": "frequency",
      "label": "enhance"
    },
    {
      "source": "CRF",
      "target": "optogenetically evoked glutamate release",
      "label": "caused no significant changes to"
    },
    {
      "source": "CRF",
      "target": "sEPSC kinetics",
      "label": "does not alter"
    },
    {
      "source": "CRF",
      "target": "presynaptic glutamate release",
      "label": "increase"
    },
    {
      "source": "CRF",
      "target": "glutamatergic neurotransmission",
      "label": "modify"
    },
    {
      "source": "CRF",
      "target": "spontaneous excitatory transmission",
      "label": "regulate"
    },
    {
      "source": "frequency",
      "target": "calcium oscillations",
      "label": "is_of"
    },
    {
      "source": "optogenetically evoked glutamate release",
      "target": "region",
      "label": "occurs in"
    },
    {
      "source": "isoproterenol (ISO)",
      "target": "frequency",
      "label": "enhance"
    },
    {
      "source": "isoproterenol (ISO)",
      "target": "sEPSC kinetics",
      "label": "does not alter"
    },
    {
      "source": "isoproterenol (ISO)",
      "target": "presynaptic glutamate release",
      "label": "increase"
    },
    {
      "source": "CRF enhancement",
      "target": "distinct mechanisms",
      "label": "occurs via"
    },
    {
      "source": "CRF enhancement",
      "target": "glutamatergic transmission",
      "label": "of"
    },
    {
      "source": "effect of CRF",
      "target": "CRFR1",
      "label": "mediated by"
    },
    {
      "source": "effect of CRF",
      "target": "CRFR2 receptors",
      "label": "mediated by"
    },
    {
      "source": "Corticotropin releasing factor",
      "target": "glutamatergic neurotransmission",
      "label": "enhance"
    },
    {
      "source": "whole-cell patch-clamp electrophysiology recordings",
      "target": "neurons",
      "label": "from"
    },
    {
      "source": "BoNT/A",
      "target": "diseases",
      "label": "treats"
    },
    {
      "source": "BoNT/A",
      "target": "target",
      "label": "truncates"
    },
    {
      "source": "BoNT/A",
      "target": "Tetrodotoxin-sensitive spontaneous cholinergic neurotransmission",
      "label": "blocks"
    },
    {
      "source": "BoNT/A",
      "target": "neurotransmission",
      "label": "inhibits"
    },
    {
      "source": "BoNT/A",
      "target": "concentrations",
      "label": "blocks at low"
    },
    {
      "source": "SV2",
      "target": "neurons",
      "label": "co-localised in"
    },
    {
      "source": "SV2",
      "target": "non-neuronal cells",
      "label": "is absent from"
    },
    {
      "source": "therapeutic utility",
      "target": "clinic",
      "label": "is in"
    },
    {
      "source": "BoNT/E",
      "target": "SNAP-25",
      "label": "truncates"
    },
    {
      "source": "BoNT/E",
      "target": "concentrations",
      "label": "does not block at low"
    },
    {
      "source": "BoNT/E",
      "target": "neurotransmission",
      "label": "does not block"
    },
    {
      "source": "BoNT/E",
      "target": "intact cells",
      "label": "truncates SNAP-25 in"
    },
    {
      "source": "SNAP-25",
      "target": "non-neuronal cells",
      "label": "is absent from"
    },
    {
      "source": "SNAP-25",
      "target": "neurons",
      "label": "co-expressed in"
    },
    {
      "source": "SNAP-25",
      "target": "neurotransmission",
      "label": "is involved in"
    },
    {
      "source": "protease",
      "target": "BoNT/E",
      "label": "is from"
    },
    {
      "source": "protease",
      "target": "SNAP-25",
      "label": "cleaves"
    },
    {
      "source": "protease",
      "target": "N-terminus",
      "label": "fused to"
    },
    {
      "source": "Chimeras",
      "target": "BoNT/E",
      "label": "created by inserting into"
    },
    {
      "source": "Chimeras",
      "target": "acceptor-binding HC domain",
      "label": "created by inserting"
    },
    {
      "source": "Chimeras",
      "target": "SNAP-25",
      "label": "cleaves"
    },
    {
      "source": "non-cleavable SNAP-25",
      "target": "detergent-solubilised neurons",
      "label": "is absent in"
    },
    {
      "source": "acceptor-binding HC domain",
      "target": "BoNT/A",
      "label": "is of"
    },
    {
      "source": "BoNT/A protease",
      "target": "HC",
      "label": "has"
    },
    {
      "source": "BoNT/A protease",
      "target": "therapeutic utility",
      "label": "contributes to"
    },
    {
      "source": "BoNT/A protease",
      "target": "SNAP-25",
      "label": "inactivates"
    },
    {
      "source": "HC",
      "target": "counterparts",
      "label": "replaced with"
    },
    {
      "source": "botulinum neurotoxin type A",
      "target": "endoprotease",
      "label": "is a"
    },
    {
      "source": "endoprotease",
      "target": "SNAP-25",
      "label": "cleaves"
    },
    {
      "source": "botulinum neurotoxin A",
      "target": "SNAP-25",
      "label": "cleaves"
    },
    {
      "source": "botulinum neurotoxin A",
      "target": "autonomic transmission",
      "label": "blocks"
    },
    {
      "source": "toxin's acceptor",
      "target": "therapeutic utility",
      "label": "contributes to"
    },
    {
      "source": "toxin's acceptor",
      "target": "peri-somatic boutons",
      "label": "localised on"
    },
    {
      "source": "counterparts",
      "target": "BoNT/B",
      "label": "from"
    },
    {
      "source": "counterparts",
      "target": "BoNT/E",
      "label": "from"
    },
    {
      "source": "GR",
      "target": "effector mechanisms",
      "label": "has"
    },
    {
      "source": "effector mechanisms",
      "target": "dimerization-mediated transactivation",
      "label": "include"
    },
    {
      "source": "effector mechanisms",
      "target": "transcriptional repression",
      "label": "include"
    },
    {
      "source": "dimerization-mediated transactivation",
      "target": "DNA binding",
      "label": "occurs via"
    },
    {
      "source": "dimerization-mediated transactivation",
      "target": "target genes",
      "label": "affects"
    },
    {
      "source": "Chronic elevation of GCs",
      "target": "lethality",
      "label": "results in"
    },
    {
      "source": "Chronic elevation of GCs",
      "target": "severe runting",
      "label": "results in"
    },
    {
      "source": "Chronic elevation of GCs",
      "target": "GR(dim/dim) mice",
      "label": "occurs in"
    },
    {
      "source": "potent GC dexamethasone",
      "target": "GR(dim/dim) mice",
      "label": "administered to"
    },
    {
      "source": "potent GC dexamethasone",
      "target": "wild-type mice",
      "label": "administered to"
    },
    {
      "source": "GR(dim/dim) mice",
      "target": "exaggerated response",
      "label": "showed"
    },
    {
      "source": "GR(dim/dim) mice",
      "target": "muscle protein synthesis",
      "label": "equally sensitive to decreases in"
    },
    {
      "source": "GR(dim/dim) mice",
      "target": "insulin sensitivity",
      "label": "less sensitive to decreases in"
    },
    {
      "source": "Absolute triglyceride synthesis",
      "target": "epididymal fat depots",
      "label": "increased in"
    },
    {
      "source": "Absolute triglyceride synthesis",
      "target": "wild-type mice",
      "label": "increased in"
    },
    {
      "source": "Absolute triglyceride synthesis",
      "target": "inguinal fat depots",
      "label": "increased in"
    },
    {
      "source": "Absolute triglyceride synthesis",
      "target": "GR(dim/dim) mice",
      "label": "increased in"
    },
    {
      "source": "exaggerated response",
      "target": "DEX",
      "label": "to"
    },
    {
      "source": "transcriptional repression",
      "target": "protein-protein interactions",
      "label": "mediated by"
    },
    {
      "source": "adipose triacylglycerol metabolism",
      "target": "functional GR dimerization domain",
      "label": "is exaggerated in absence of"
    },
    {
      "source": "wild-type mice",
      "target": "muscle protein synthesis",
      "label": "equally sensitive to decreases in"
    },
    {
      "source": "wild-type mice",
      "target": "insulin sensitivity",
      "label": "more sensitive to decreases in"
    },
    {
      "source": "DEX",
      "target": "wild-type mice",
      "label": "administered to"
    },
    {
      "source": "DEX",
      "target": "insulin sensitivity",
      "label": "decreases"
    },
    {
      "source": "DEX",
      "target": "Absolute triglyceride synthesis",
      "label": "increased"
    },
    {
      "source": "DEX",
      "target": "inhibitory effect",
      "label": "has"
    },
    {
      "source": "DEX",
      "target": "muscle protein synthesis",
      "label": "decreases"
    },
    {
      "source": "DEX",
      "target": "De novo lipogenesis",
      "label": "increased"
    },
    {
      "source": "DEX",
      "target": "GR(dim/dim) mice",
      "label": "administered to"
    },
    {
      "source": "heavy water labeling",
      "target": "metabolic fluxes",
      "label": "used to measure"
    },
    {
      "source": "heavy water labeling",
      "target": "disease-relevant GC target pathways",
      "label": "used to measure"
    },
    {
      "source": "selective GR modulators",
      "target": "GR transactivation",
      "label": "based on dissociating"
    },
    {
      "source": "selective GR modulators",
      "target": "therapeutic anti-inflammatory effects",
      "label": "dissociate from"
    },
    {
      "source": "selective GR modulators",
      "target": "adverse effects",
      "label": "dissociate"
    },
    {
      "source": "selective GR modulators",
      "target": "repression",
      "label": "based on dissociating from"
    },
    {
      "source": "GR(dim/dim) mouse",
      "target": "mutation",
      "label": "has"
    },
    {
      "source": "GR(dim/dim) mouse",
      "target": "attenuated transactivation",
      "label": "has"
    },
    {
      "source": "GR(dim/dim) mouse",
      "target": "intact repression",
      "label": "has"
    },
    {
      "source": "De novo lipogenesis",
      "target": "GR(dim/dim) mice",
      "label": "increased in"
    },
    {
      "source": "De novo lipogenesis",
      "target": "wild-type mice",
      "label": "not increased in"
    },
    {
      "source": "glucocorticoid (GC) receptor",
      "target": "effector mechanisms",
      "label": "has"
    },
    {
      "source": "Goishi tea",
      "target": "obesity-related disorder",
      "label": "beneficial for prevention of"
    },
    {
      "source": "Goishi tea",
      "target": "normal group",
      "label": "has no influence on"
    },
    {
      "source": "Goishi tea",
      "target": "adiponectin levels",
      "label": "maintains"
    },
    {
      "source": "Goishi tea",
      "target": "induced obese mice",
      "label": "involved in"
    },
    {
      "source": "Goishi tea",
      "target": "adipose cell",
      "label": "decreased"
    },
    {
      "source": "Goishi tea",
      "target": "adipocytokines",
      "label": "decreased"
    },
    {
      "source": "Goishi tea",
      "target": "fat accumulation",
      "label": "inhibits"
    },
    {
      "source": "Goishi tea",
      "target": "visceral fat weight",
      "label": "influences"
    },
    {
      "source": "Goishi tea",
      "target": "obesity three sub-groups",
      "label": "administrated in"
    },
    {
      "source": "Goishi tea",
      "target": "fractions",
      "label": "includes"
    },
    {
      "source": "Goishi tea",
      "target": "tumor necrosis factor-alpha",
      "label": "does not increase"
    },
    {
      "source": "Goishi tea",
      "target": "cholesterol level",
      "label": "decreased"
    },
    {
      "source": "Goishi tea",
      "target": "metabolic syndrome",
      "label": "beneficial for prevention of"
    },
    {
      "source": "Goishi tea",
      "target": "normal sub-groups",
      "label": "administrated in"
    },
    {
      "source": "Goishi tea",
      "target": "interleukin-6",
      "label": "does not increase"
    },
    {
      "source": "fractions",
      "target": "water layer",
      "label": "include"
    },
    {
      "source": "fractions",
      "target": "ethyl-acetate layer",
      "label": "include"
    },
    {
      "source": "exogenous nonsteroidal agents",
      "target": "BK \u03b21 site",
      "label": "access"
    },
    {
      "source": "exogenous nonsteroidal agents",
      "target": "vasodilation",
      "label": "evoke"
    },
    {
      "source": "exogenous nonsteroidal agents",
      "target": "\u03b21-containing BK channels",
      "label": "activate"
    },
    {
      "source": "BK \u03b21 site",
      "target": "Thr169",
      "label": "includes"
    },
    {
      "source": "carotid artery-infusion",
      "target": "HENA",
      "label": "of"
    },
    {
      "source": "HENA",
      "target": "pressurized cerebral arteries",
      "label": "dilated"
    },
    {
      "source": "HENA",
      "target": "channels made of cbv1 + \u03b24",
      "label": "failed to activate"
    },
    {
      "source": "HENA",
      "target": "BK \u03b21 steroid-sensing site",
      "label": "targets via"
    },
    {
      "source": "HENA",
      "target": "channels made of \u03b21T169A",
      "label": "failed to activate"
    },
    {
      "source": "HENA",
      "target": "efficacy",
      "label": "has"
    },
    {
      "source": "HENA",
      "target": "potency",
      "label": "has"
    },
    {
      "source": "HENA",
      "target": "channels made of cbv1 + \u03b22",
      "label": "failed to activate"
    },
    {
      "source": "HENA",
      "target": "selective BK-channel targeting",
      "label": "dilated via"
    },
    {
      "source": "HENA",
      "target": "lithocholic acid (LCA)",
      "label": "has similar potency to"
    },
    {
      "source": "HENA",
      "target": "arteries",
      "label": "failed to dilate"
    },
    {
      "source": "HENA",
      "target": "BK (cbv1 + \u03b21) channels",
      "label": "activated"
    },
    {
      "source": "HENA",
      "target": "channels made of cbv1 + \u03b23",
      "label": "failed to activate"
    },
    {
      "source": "HENA",
      "target": "pial cerebral arterioles",
      "label": "dilated"
    },
    {
      "source": "HENA",
      "target": "\u03b21-containing BK channels",
      "label": "selectively targets"
    },
    {
      "source": "pressurized cerebral arteries",
      "target": "C57BL/6 mouse",
      "label": "from"
    },
    {
      "source": "pressurized cerebral arteries",
      "target": "rat",
      "label": "from"
    },
    {
      "source": "Novel Nonsteroidal Agent",
      "target": "steroid-sensing site",
      "label": "targets"
    },
    {
      "source": "Novel Nonsteroidal Agent",
      "target": "\u03b21-containing BK channels",
      "label": "selectively activates"
    },
    {
      "source": "Novel Nonsteroidal Agent",
      "target": "vasodilation",
      "label": "renders"
    },
    {
      "source": "Novel Nonsteroidal Agent",
      "target": "Cholane Steroid-Recognition Site",
      "label": "targets"
    },
    {
      "source": "Novel Nonsteroidal Agent",
      "target": "Cerebrovascular Dilation",
      "label": "causes"
    },
    {
      "source": "steroid-sensing site",
      "target": "BK \u03b21",
      "label": "located in"
    },
    {
      "source": "sodium 3-hydroxyolean-12-en-30-oate (HENA)",
      "target": "HENA",
      "label": "is also known as"
    },
    {
      "source": "Cholane Steroid-Recognition Site",
      "target": "BK Channel \u03b21-Subunit",
      "label": "located in"
    },
    {
      "source": "BK (cbv1 + \u03b21) channels",
      "target": "rat cerebral artery myocytes",
      "label": "cloned from"
    },
    {
      "source": "chemical structure database similarity search",
      "target": "lithocholic acid (LCA)",
      "label": "uses as template"
    },
    {
      "source": "lithocholic acid (LCA)",
      "target": "cerebral arteries",
      "label": "dilates"
    },
    {
      "source": "lithocholic acid (LCA)",
      "target": "BK channel activation",
      "label": "acts via"
    },
    {
      "source": "lithocholic acid (LCA)",
      "target": "template",
      "label": "is a"
    },
    {
      "source": "Cerebrovascular Dilation",
      "target": "Cholane Steroid-Recognition Site",
      "label": "via selective targeting of"
    },
    {
      "source": "two-step reaction",
      "target": "sodium 3-hydroxyolean-12-en-30-oate (HENA)",
      "label": "generates"
    },
    {
      "source": "BK channels",
      "target": "myogenic tone",
      "label": "reduces"
    },
    {
      "source": "BK channels",
      "target": "vasodilation",
      "label": "facilitates"
    },
    {
      "source": "endogenous steroid",
      "target": "lithocholic acid (LCA)",
      "label": "is"
    },
    {
      "source": "arteries",
      "target": "KCNMB1 knockout mouse",
      "label": "from"
    },
    {
      "source": "BK \u03b21",
      "target": "BK channels",
      "label": "allows"
    },
    {
      "source": "BK \u03b21",
      "target": "HENA action",
      "label": "has role in"
    },
    {
      "source": "BK \u03b21",
      "target": "phenotype",
      "label": "determines"
    },
    {
      "source": "native channels",
      "target": "rat cerebral artery myocytes",
      "label": "located in"
    },
    {
      "source": "Ca(2+)/voltage-gated K(+) large conductance (BK) channel \u03b21 subunit",
      "target": "vascular smooth muscle",
      "label": "abundant in"
    },
    {
      "source": "HENA action",
      "target": "native channels",
      "label": "replicated on"
    },
    {
      "source": "BK channel activation",
      "target": "BK \u03b21 site",
      "label": "requires recognition by"
    },
    {
      "source": "oral curcuminoids supplementation",
      "target": "study populations",
      "label": "needs validation in"
    },
    {
      "source": "oral curcuminoids supplementation",
      "target": "oxidative stress burden",
      "label": "is effective in reducing"
    },
    {
      "source": "carry-over effect",
      "target": "parameters",
      "label": "was not significant for"
    },
    {
      "source": "Curcuminoids",
      "target": "Obese Individuals",
      "label": "studied in"
    },
    {
      "source": "Curcuminoids",
      "target": "functional qualities",
      "label": "have"
    },
    {
      "source": "Curcuminoids",
      "target": "Pro-Oxidant-Antioxidant Balance",
      "label": "Modulate"
    },
    {
      "source": "Curcuminoids",
      "target": "Immune Response",
      "label": "do not modulate"
    },
    {
      "source": "Curcuminoids",
      "target": "period of 30 days",
      "label": "received for"
    },
    {
      "source": "serum concentrations",
      "target": "anti-Hsp27",
      "label": "of"
    },
    {
      "source": "serum concentrations",
      "target": "anti-oxLDL",
      "label": "of"
    },
    {
      "source": "anti-Hsp27",
      "target": "antibody titres",
      "label": "are a type of"
    },
    {
      "source": "Curcuminoid supplementation",
      "target": "decrease",
      "label": "associated with"
    },
    {
      "source": "serum pro-oxidant-antioxidant balance",
      "target": "PAB",
      "label": "is also known as"
    },
    {
      "source": "Immune Response",
      "target": "Oxidized LDL",
      "label": "is related to"
    },
    {
      "source": "Immune Response",
      "target": "Heat Shock Protein 27",
      "label": "is related to"
    },
    {
      "source": "antibody titres",
      "target": "oxLDL",
      "label": "to"
    },
    {
      "source": "antibody titres",
      "target": "Hsp27",
      "label": "to"
    },
    {
      "source": "obese individuals",
      "target": "Curcuminoids",
      "label": "received"
    },
    {
      "source": "obese individuals",
      "target": "placebo",
      "label": "received"
    },
    {
      "source": "randomized double-blind placebo-controlled cross-over trial",
      "target": "effects",
      "label": "investigated"
    },
    {
      "source": "functional qualities",
      "target": "anti-inflammatory properties",
      "label": "include"
    },
    {
      "source": "functional qualities",
      "target": "antioxidant properties",
      "label": "include"
    },
    {
      "source": "anti-oxLDL",
      "target": "antibody titres",
      "label": "are a type of"
    },
    {
      "source": "wash-out period",
      "target": "2 weeks",
      "label": "lasted"
    },
    {
      "source": "anti-Hsp27 titres",
      "target": "study period",
      "label": "was measured at"
    },
    {
      "source": "anti-oxLDL titres",
      "target": "study period",
      "label": "was measured at"
    },
    {
      "source": "Serum PAB",
      "target": "study period",
      "label": "was measured at"
    },
    {
      "source": "Steroidal glycosides",
      "target": "new compounds",
      "label": "include"
    },
    {
      "source": "Steroidal glycosides",
      "target": "cytotoxic activities",
      "label": "have"
    },
    {
      "source": "Steroidal glycosides",
      "target": "bulbs",
      "label": "were isolated from"
    },
    {
      "source": "Morphological observation",
      "target": "apoptotic cell death",
      "label": "showed induction of"
    },
    {
      "source": "(22R)-spirosolanol glycoside (11)",
      "target": "caspase-3 activity level",
      "label": "did not affect"
    },
    {
      "source": "(22R)-spirosolanol glycoside (11)",
      "target": "apoptosis",
      "label": "induced"
    },
    {
      "source": "cytotoxic activities",
      "target": "A549 human lung adenocarcinoma cells",
      "label": "were against"
    },
    {
      "source": "cytotoxic activities",
      "target": "HL-60 human promyelocytic leukemia cells",
      "label": "were against"
    },
    {
      "source": "cytotoxic activities",
      "target": "human cell lines",
      "label": "were studied in"
    },
    {
      "source": "cytotoxic activities",
      "target": "primary cells",
      "label": "were studied in"
    },
    {
      "source": "flow cytometry analysis",
      "target": "apoptotic cell death",
      "label": "showed induction of"
    },
    {
      "source": "Fritillaria meleagris",
      "target": "Liliaceae",
      "label": "belongs to"
    },
    {
      "source": "hydrolytic cleavage",
      "target": "spectroscopic analysis",
      "label": "was followed by"
    },
    {
      "source": "hydrolytic cleavage",
      "target": "chromatographic analysis",
      "label": "was followed by"
    },
    {
      "source": "5\u03b2-spirostanol glycoside (2)",
      "target": "apoptotic cell death",
      "label": "induced"
    },
    {
      "source": "bulbs",
      "target": "Fritillaria meleagris",
      "label": "are of"
    },
    {
      "source": "isolated compounds",
      "target": "cytotoxic activities",
      "label": "were evaluated for"
    },
    {
      "source": "cholestane derivative (17a)",
      "target": "apoptotic cell death",
      "label": "induced"
    },
    {
      "source": "IRE1",
      "target": "upstream activator",
      "label": "is an"
    },
    {
      "source": "X-box binding protein 1",
      "target": "transcription factor",
      "label": "is a"
    },
    {
      "source": "X-box binding protein 1",
      "target": "pancreatic alpha cell function",
      "label": "is essential for"
    },
    {
      "source": "X-box binding protein 1",
      "target": "unfolded protein response (UPR)",
      "label": "plays a role in"
    },
    {
      "source": "XBP1 deficiency",
      "target": "insulin secretion",
      "label": "impairs"
    },
    {
      "source": "XBP1 deficiency",
      "target": "glucose intolerance",
      "label": "leads to"
    },
    {
      "source": "XBP1 deficiency",
      "target": "dysfunctional glucagon secretion",
      "label": "induces"
    },
    {
      "source": "XBP1 deficiency",
      "target": "altered insulin signaling",
      "label": "induces"
    },
    {
      "source": "XBP1 deficiency",
      "target": "pancreatic \u03b1-cells",
      "label": "occurs in"
    },
    {
      "source": "XBP1",
      "target": "transcription factor",
      "label": "is a"
    },
    {
      "source": "XBP1",
      "target": "\u03b1-cells",
      "label": "has a role in"
    },
    {
      "source": "XBP1",
      "target": "unfolded protein response (UPR)",
      "label": "plays a role in"
    },
    {
      "source": "endoplasmic reticulum (ER) stress",
      "target": "\u03b1-cell biology",
      "label": "has a role in"
    },
    {
      "source": "endoplasmic reticulum (ER) stress",
      "target": "\u03b2-cell dysfunction",
      "label": "underlies"
    },
    {
      "source": "\u03b2-cell dysfunction",
      "target": "T2D",
      "label": "occurs in"
    },
    {
      "source": "stable XBP1 knock down \u03b1-cell line, \u03b1XBPKD",
      "target": "in vitro models",
      "label": "are"
    },
    {
      "source": "\u03b1XBPKO mice",
      "target": "blunted suppression",
      "label": "exhibited"
    },
    {
      "source": "\u03b1XBPKO mice",
      "target": "glucose intolerance",
      "label": "exhibited"
    },
    {
      "source": "\u03b1XBPKO mice",
      "target": "mild insulin resistance",
      "label": "exhibited"
    },
    {
      "source": "blunted suppression",
      "target": "insulin treatment",
      "label": "occurred following"
    },
    {
      "source": "blunted suppression",
      "target": "high glucose",
      "label": "occurred in presence of"
    },
    {
      "source": "blunted suppression",
      "target": "glucagon secretion",
      "label": "is of"
    },
    {
      "source": "upstream activator",
      "target": "XBP1",
      "label": "is of"
    },
    {
      "source": "tyrosine phosphorylation",
      "target": "IRS-1 (pY(896))",
      "label": "is of"
    },
    {
      "source": "tyrosine phosphorylation",
      "target": "insulin receptor substrate 1",
      "label": "is of"
    },
    {
      "source": "glucagon secretion",
      "target": "glucose stimulation",
      "label": "occurs following"
    },
    {
      "source": "\u03b1XBPKD cells",
      "target": "activation",
      "label": "exhibited"
    },
    {
      "source": "Type 2 diabetes mellitus (T2D) patients",
      "target": "hyperglycemia",
      "label": "exhibit"
    },
    {
      "source": "Type 2 diabetes mellitus (T2D) patients",
      "target": "hyperglucagonemia",
      "label": "exhibit"
    },
    {
      "source": "\u03b1-cell specific XBP1 knockout (\u03b1XBPKO) mice",
      "target": "in vivo models",
      "label": "are"
    },
    {
      "source": "hyperglucagonemia",
      "target": "\u03b1-cell function",
      "label": "suggests"
    },
    {
      "source": "serine phosphorylation (pS(307))",
      "target": "IRS-1",
      "label": "is of"
    },
    {
      "source": "GTLE",
      "target": "Neurotoxicity",
      "label": "reduces"
    },
    {
      "source": "GTLE",
      "target": "AChE",
      "label": "corrected activities of"
    },
    {
      "source": "GTLE",
      "target": "AlCl3",
      "label": "reversed damaging effects of"
    },
    {
      "source": "GTLE",
      "target": "total glutathione content",
      "label": "improved"
    },
    {
      "source": "GTLE",
      "target": "superoxide dismutase",
      "label": "reversed damaging effects on"
    },
    {
      "source": "GTLE",
      "target": "COX",
      "label": "corrected activities of"
    },
    {
      "source": "GTLE",
      "target": "AA",
      "label": "reversed damaging effects on"
    },
    {
      "source": "GTLE",
      "target": "Rats",
      "label": "evaluated effects in"
    },
    {
      "source": "GTLE",
      "target": "Green Tea Leaf Extract",
      "label": "is an abbreviation for"
    },
    {
      "source": "GTLE",
      "target": "Aluminium Chloride",
      "label": "evaluated effects on neurotoxicity of"
    },
    {
      "source": "Aluminium Chloride",
      "target": "Neurotoxicity",
      "label": "causes"
    },
    {
      "source": "BFb",
      "target": "basal forebrain",
      "label": "is an abbreviation for"
    },
    {
      "source": "AlCl3",
      "target": "Neurotoxicity",
      "label": "causes"
    },
    {
      "source": "AlCl3",
      "target": "AChE",
      "label": "reduced activities of"
    },
    {
      "source": "AlCl3",
      "target": "AA",
      "label": "reduced performance of"
    },
    {
      "source": "AlCl3",
      "target": "total glutathione content",
      "label": "decreased"
    },
    {
      "source": "AlCl3",
      "target": "superoxide dismutase",
      "label": "increased activity of"
    },
    {
      "source": "AlCl3",
      "target": "COX",
      "label": "reduced activities of"
    },
    {
      "source": "AlCl3",
      "target": "Aluminium Chloride",
      "label": "is an abbreviation for"
    },
    {
      "source": "AlCl3",
      "target": "acetylcholinesterase",
      "label": "reduced activities of"
    },
    {
      "source": "AlCl3",
      "target": "cytochrome c oxidase",
      "label": "reduced activities of"
    },
    {
      "source": "FbC",
      "target": "forebrain cortex",
      "label": "is an abbreviation for"
    },
    {
      "source": "green tea",
      "target": "central nervous system",
      "label": "has health-promoting effects in"
    },
    {
      "source": "green tea",
      "target": "Alzheimer's disease",
      "label": "is beneficial in"
    },
    {
      "source": "green tea",
      "target": "Camellia sinensis L.",
      "label": "is also known as"
    },
    {
      "source": "Green Tea Leaf Extract",
      "target": "Neurotoxicity",
      "label": "influences"
    },
    {
      "source": "Aluminium",
      "target": "Alzheimer's disease",
      "label": "has role in aetiology/pathogenesis/precipitation of"
    },
    {
      "source": "TGC",
      "target": "total glutathione content",
      "label": "is an abbreviation for"
    },
    {
      "source": "(-)-epigallocatechin gallate",
      "target": "GTLE",
      "label": "is found in"
    },
    {
      "source": "rutin",
      "target": "lipid peroxidation",
      "label": "protected against"
    },
    {
      "source": "rutin",
      "target": "steroidogenesis",
      "label": "protected against"
    },
    {
      "source": "rutin",
      "target": "antioxidant defence system",
      "label": "protected against"
    },
    {
      "source": "rutin",
      "target": "fruit",
      "label": "is found in"
    },
    {
      "source": "rutin",
      "target": "flavonoids",
      "label": "is a type of"
    },
    {
      "source": "rutin",
      "target": "osteoblast differentiation",
      "label": "Upregulator"
    },
    {
      "source": "rutin",
      "target": "vegetables",
      "label": "is found in"
    },
    {
      "source": "rutin",
      "target": "mineralization",
      "label": "demonstrated"
    },
    {
      "source": "rutin",
      "target": "osteoblast specific differentiation activities",
      "label": "has"
    },
    {
      "source": "rutin",
      "target": "osteodegenerative disorders",
      "label": "can be used for"
    },
    {
      "source": "rutin",
      "target": "bone development",
      "label": "affects"
    },
    {
      "source": "rutin",
      "target": "alkaline phosphatase activity",
      "label": "Upregulator"
    },
    {
      "source": "rutin",
      "target": "bark",
      "label": "is from"
    },
    {
      "source": "depletion",
      "target": "testicular Se levels",
      "label": "of"
    },
    {
      "source": "depletion",
      "target": "plasma Se levels",
      "label": "of"
    },
    {
      "source": "RUT",
      "target": "17\u03b2-HSD",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "abnormal sperm count",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "testicular steroidogenic enzymes",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "depletion",
      "label": "prevented"
    },
    {
      "source": "RUT",
      "target": "Cd-induced testes damage",
      "label": "prevented"
    },
    {
      "source": "RUT",
      "target": "synergistic role",
      "label": "not have"
    },
    {
      "source": "RUT",
      "target": "lactate dehydrogenase",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "HSD",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "acid phosphatase",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "3\u03b2-hydroxysteroid dehydrogenase",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "Cd-induced alterations",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "motility",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "lipid peroxidation",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "plasma testosterone",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "alkaline phosphatase",
      "label": "reversed"
    },
    {
      "source": "RUT",
      "target": "epididymal sperm counts",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "synergistic role",
      "label": "not have"
    },
    {
      "source": "Se",
      "target": "3\u03b2-hydroxysteroid dehydrogenase",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "motility",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "lactate dehydrogenase",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "HSD",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "acid phosphatase",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "lipid peroxidation",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "alkaline phosphatase",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "epididymal sperm counts",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "Cd-induced alterations",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "17\u03b2-HSD",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "abnormal sperm count",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "RUT",
      "label": "more potent than"
    },
    {
      "source": "Se",
      "target": "plasma testosterone",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "testicular steroidogenic enzymes",
      "label": "reversed"
    },
    {
      "source": "Se",
      "target": "Cd-induced testes damage",
      "label": "prevented"
    },
    {
      "source": "Se",
      "target": "recovery",
      "label": "potent in"
    },
    {
      "source": "Se",
      "target": "depletion",
      "label": "prevented"
    },
    {
      "source": "synergistic role",
      "target": "Cd-induced testicular injury",
      "label": "against"
    },
    {
      "source": "3\u03b2-hydroxysteroid dehydrogenase",
      "target": "Mitochondria",
      "label": "resides in"
    },
    {
      "source": "oxidative damage",
      "target": "liver tissue",
      "label": "is of"
    },
    {
      "source": "oxidative damage",
      "target": "chronic poisoning",
      "label": "occurs under"
    },
    {
      "source": "oxidative damage",
      "target": "lipid peroxidation",
      "label": "evaluated by"
    },
    {
      "source": "oxidative damage",
      "target": "antioxidant enzymes",
      "label": "evaluated by"
    },
    {
      "source": "oxidative damage",
      "target": "chronic arsenic poisoning",
      "label": "is of"
    },
    {
      "source": "oxidative damage",
      "target": "rat liver",
      "label": "occurs in"
    },
    {
      "source": "oxidative damage",
      "target": "cell function",
      "label": "causes loss of"
    },
    {
      "source": "oxidative damage",
      "target": "DNA",
      "label": "causes damage to"
    },
    {
      "source": "oxidative damage",
      "target": "proteins",
      "label": "causes damage to"
    },
    {
      "source": "selenium",
      "target": "lipid peroxidation",
      "label": "protected against"
    },
    {
      "source": "selenium",
      "target": "steroidogenesis",
      "label": "protected against"
    },
    {
      "source": "selenium",
      "target": "antioxidant defence system",
      "label": "protected against"
    },
    {
      "source": "selenium",
      "target": "oxidative damage",
      "label": "has protective effects on"
    },
    {
      "source": "selenium",
      "target": "gene expression",
      "label": "has protective effects on"
    },
    {
      "source": "cadmium",
      "target": "testicular pathophysiology",
      "label": "induced"
    },
    {
      "source": "Selenium",
      "target": "testicular pathophysiology",
      "label": "attenuated"
    },
    {
      "source": "normal neuronal functions",
      "target": "metabolites",
      "label": "are_of"
    },
    {
      "source": "normal neuronal functions",
      "target": "APP",
      "label": "are_of"
    },
    {
      "source": "neuronal calcium homeostasis",
      "target": "synaptic transmission",
      "label": "is_essential_for"
    },
    {
      "source": "amyloid precursor protein (APP)",
      "target": "amyloid \u03b2-peptide (A\u03b2)",
      "label": "forms"
    },
    {
      "source": "amyloid \u03b2-peptide (A\u03b2)",
      "target": "Alzheimer's disease (AD)",
      "label": "is_related_to"
    },
    {
      "source": "amyloid-degrading enzyme",
      "target": "neprilysin",
      "label": "is"
    },
    {
      "source": "physiological actions",
      "target": "APP",
      "label": "are_of"
    },
    {
      "source": "opportunities",
      "target": "therapeutic intervention",
      "label": "are_for"
    },
    {
      "source": "neurogeneration",
      "target": "learning and memory deficits",
      "label": "results_in"
    },
    {
      "source": "fuller understanding",
      "target": "physiological actions",
      "label": "is_of"
    },
    {
      "source": "fuller understanding",
      "target": "metabolic network",
      "label": "is_of"
    },
    {
      "source": "fuller understanding",
      "target": "opportunities",
      "label": "provides"
    },
    {
      "source": "fuller understanding",
      "target": "pathological actions",
      "label": "is_of"
    },
    {
      "source": "endogenous APP",
      "target": "primary cortical neurons",
      "label": "is_in"
    },
    {
      "source": "secretase-mediated processing",
      "target": "amyloid precursor protein (APP)",
      "label": "processes"
    },
    {
      "source": "amplitude",
      "target": "calcium oscillations",
      "label": "is_of"
    },
    {
      "source": "pathological actions",
      "target": "APP",
      "label": "are_of"
    },
    {
      "source": "diverse range of genes",
      "target": "APP itself",
      "label": "includes"
    },
    {
      "source": "diverse range of genes",
      "target": "amyloid-degrading enzyme",
      "label": "includes"
    },
    {
      "source": "diverse range of genes",
      "target": "aquaporin-1",
      "label": "includes"
    },
    {
      "source": "diverse range of genes",
      "target": "neprilysin",
      "label": "includes"
    },
    {
      "source": "intensive studies",
      "target": "secretase-mediated processing",
      "label": "focus_on"
    },
    {
      "source": "Synaptic spine loss",
      "target": "neurogeneration",
      "label": "is_feature_of"
    },
    {
      "source": "APP function",
      "target": "insights",
      "label": "provides"
    },
    {
      "source": "emerging evidence",
      "target": "role",
      "label": "indicates"
    },
    {
      "source": "metabolic network",
      "target": "APP",
      "label": "is_of"
    },
    {
      "source": "key epigenetic regulator",
      "target": "gene expression",
      "label": "regulates"
    },
    {
      "source": "emerging areas",
      "target": "APP function",
      "label": "are_of"
    },
    {
      "source": "intracellular domain of APP (AICD)",
      "target": "key epigenetic regulator",
      "label": "is"
    },
    {
      "source": "PTH therapy",
      "target": "osteoblastogenesis",
      "label": "INCREASES"
    },
    {
      "source": "PTH therapy",
      "target": "osteoblast survival",
      "label": "INCREASES"
    },
    {
      "source": "PTHrP",
      "target": "local factor",
      "label": "IS_A"
    },
    {
      "source": "PTHrP",
      "target": "bone regeneration",
      "label": "IMPROVES"
    },
    {
      "source": "PTHrP",
      "target": "bone anabolic therapies",
      "label": "IS_A"
    },
    {
      "source": "PTHrP",
      "target": "bone mass",
      "label": "INCREASES"
    },
    {
      "source": "PTHrP",
      "target": "PTH type 1 receptor",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "local factor",
      "target": "bone",
      "label": "LOCATED_IN"
    },
    {
      "source": "Osteoporosis",
      "target": "poor bone microarchitecture",
      "label": "CHARACTERIZED_BY"
    },
    {
      "source": "Osteoporosis",
      "target": "low bone mineral density",
      "label": "CHARACTERIZED_BY"
    },
    {
      "source": "poor bone microarchitecture",
      "target": "fractures",
      "label": "LEADS_TO"
    },
    {
      "source": "PTH-related protein",
      "target": "PTH type 1 receptor",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "PTH-related protein",
      "target": "bone mass",
      "label": "INCREASES"
    },
    {
      "source": "PTH-related protein",
      "target": "local factor",
      "label": "IS_A"
    },
    {
      "source": "PTH-related protein",
      "target": "bone regeneration",
      "label": "IMPROVES"
    },
    {
      "source": "PTH-related protein",
      "target": "bone anabolic therapies",
      "label": "IS_A"
    },
    {
      "source": "osteogenic actions",
      "target": "PTH-unrelated C-terminal region",
      "label": "ASCRIBED_TO"
    },
    {
      "source": "osteogenic actions",
      "target": "PTHrP",
      "label": "OF"
    },
    {
      "source": "osteogenic actions",
      "target": "N-terminal domain",
      "label": "ASCRIBED_TO"
    },
    {
      "source": "PTH type 1 receptor",
      "target": "affinities",
      "label": "HAS"
    },
    {
      "source": "N-terminal PTHrP peptides",
      "target": "bone anabolic therapies",
      "label": "IS_A"
    },
    {
      "source": "intermittent administration",
      "target": "parathyroid hormone",
      "label": "OF"
    },
    {
      "source": "intermittent administration",
      "target": "PTH",
      "label": "OF"
    },
    {
      "source": "parathyroid hormone",
      "target": "bone anabolic therapies",
      "label": "IS_A"
    },
    {
      "source": "low bone mineral density",
      "target": "fractures",
      "label": "LEADS_TO"
    },
    {
      "source": "Bone anabolism",
      "target": "PTH therapy",
      "label": "CAUSED_BY"
    },
    {
      "source": "PTH",
      "target": "bone anabolic therapies",
      "label": "IS_A"
    },
    {
      "source": "PTH",
      "target": "osteoblastogenesis",
      "label": "INCREASES"
    },
    {
      "source": "PTH",
      "target": "osteoblast survival",
      "label": "INCREASES"
    },
    {
      "source": "PTH",
      "target": "PTH type 1 receptor",
      "label": "INTERACTS_WITH"
    },
    {
      "source": "cellular and molecular mechanisms",
      "target": "anabolic actions",
      "label": "OF"
    },
    {
      "source": "anabolic actions",
      "target": "PTH",
      "label": "OF"
    },
    {
      "source": "skeletal alterations",
      "target": "Osteoporosis",
      "label": "OCCURS_IN"
    },
    {
      "source": "skeletal alterations",
      "target": "bone formation",
      "label": "CONSEQUENCE_OF"
    },
    {
      "source": "skeletal alterations",
      "target": "bone resorption",
      "label": "CONSEQUENCE_OF"
    },
    {
      "source": "N-terminal domain",
      "target": "Ca2+-sensitizing compounds",
      "label": "presents binding surface for"
    },
    {
      "source": "N-terminal domain",
      "target": "cardiac troponin C",
      "label": "is part of"
    },
    {
      "source": "N-terminal domain",
      "target": "cTnC",
      "label": "is part of"
    },
    {
      "source": "Osteoporosis therapies",
      "target": "antiresorptive drugs",
      "label": "RELIES_ON"
    },
    {
      "source": "extant literature",
      "target": "Pharmacotherapy",
      "label": "on"
    },
    {
      "source": "Pharmacotherapy",
      "target": "core symptoms",
      "label": "for"
    },
    {
      "source": "core symptoms",
      "target": "restricted and repetitive behaviors",
      "label": "include"
    },
    {
      "source": "core symptoms",
      "target": "impairments",
      "label": "include"
    },
    {
      "source": "core symptoms",
      "target": "autism",
      "label": "of"
    },
    {
      "source": "core symptoms",
      "target": "autistic disorder",
      "label": "in"
    },
    {
      "source": "impairments",
      "target": "communication",
      "label": "in"
    },
    {
      "source": "impairments",
      "target": "social interaction",
      "label": "in"
    },
    {
      "source": "impairments",
      "target": "cognitive function",
      "label": "affect"
    },
    {
      "source": "treatment of core symptoms",
      "target": "limitations",
      "label": "is plagued by"
    },
    {
      "source": "Newer lines of research",
      "target": "oxytocin",
      "label": "include"
    },
    {
      "source": "Newer lines of research",
      "target": "cholinergic and glutamatergic agents",
      "label": "include"
    },
    {
      "source": "issues",
      "target": "heterogeneity of the disorder",
      "label": "include"
    },
    {
      "source": "issues",
      "target": "study of treatments",
      "label": "inherent to"
    },
    {
      "source": "study of treatments",
      "target": "autism",
      "label": "for"
    },
    {
      "source": "efficacious treatments",
      "target": "core social symptoms",
      "label": "for"
    },
    {
      "source": "current review",
      "target": "extant literature",
      "label": "covers"
    },
    {
      "source": "mixed results",
      "target": "research",
      "label": "suggest"
    },
    {
      "source": "cytokine release",
      "target": "IL-10",
      "label": "includes"
    },
    {
      "source": "cytokine release",
      "target": "IL-6",
      "label": "includes"
    },
    {
      "source": "cytokine release",
      "target": "IL-12/23p40",
      "label": "includes"
    },
    {
      "source": "cytokine release",
      "target": "TNF\u03b1 levels",
      "label": "includes"
    },
    {
      "source": "damage",
      "target": "cell membranes",
      "label": "to"
    },
    {
      "source": "damage",
      "target": "concentrations",
      "label": "occurred at"
    },
    {
      "source": "JWH-073",
      "target": "DNA migration",
      "label": "induced"
    },
    {
      "source": "DNA migration",
      "target": "single cell gel electrophoresis assays",
      "label": "occurred in"
    },
    {
      "source": "DNA migration",
      "target": "buccal cells",
      "label": "occurred in"
    },
    {
      "source": "DNA migration",
      "target": "liver cells",
      "label": "occurred in"
    },
    {
      "source": "Toxicological profiles",
      "target": "synthetic cannabinoids",
      "label": "are of"
    },
    {
      "source": "synthetic cannabinoids",
      "target": "binding affinities",
      "label": "show"
    },
    {
      "source": "immunomodulatory activities",
      "target": "human cell lines",
      "label": "were studied in"
    },
    {
      "source": "immunomodulatory activities",
      "target": "primary cells",
      "label": "were studied in"
    },
    {
      "source": "cytotoxic responses",
      "target": "assays",
      "label": "not seen in"
    },
    {
      "source": "genotoxic effects",
      "target": "concentration range",
      "label": "are linear over"
    },
    {
      "source": "genotoxic activities",
      "target": "human cell lines",
      "label": "were studied in"
    },
    {
      "source": "genotoxic activities",
      "target": "primary cells",
      "label": "were studied in"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "immunomodulatory activities",
      "label": "have"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "cytotoxic activities",
      "label": "have"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "JWH-122",
      "label": "include"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "genotoxic activities",
      "label": "have"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "JWH-210",
      "label": "include"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "JWH-018",
      "label": "include"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "hormonal activities",
      "label": "have"
    },
    {
      "source": "naphthoylindole compounds",
      "target": "JWH-073",
      "label": "include"
    },
    {
      "source": "JWH-122",
      "target": "IL-12/23p40",
      "label": "decreased"
    },
    {
      "source": "JWH-122",
      "target": "TNF\u03b1 levels",
      "label": "decreased"
    },
    {
      "source": "JWH-122",
      "target": "DNA migration",
      "label": "induced"
    },
    {
      "source": "binding affinities",
      "target": "cannabinoid receptor subtype CB1",
      "label": "are to"
    },
    {
      "source": "benzoylindole",
      "target": "AM-694",
      "label": "includes"
    },
    {
      "source": "liver cells",
      "target": "[M5]",
      "label": "produced"
    },
    {
      "source": "liver cells",
      "target": "esterase-dependent metabolites",
      "label": "produced"
    },
    {
      "source": "liver cells",
      "target": "[M4]",
      "label": "produced"
    },
    {
      "source": "liver cells",
      "target": "[M6]",
      "label": "produced"
    },
    {
      "source": "estrogenic activities",
      "target": "bone marrow cells",
      "label": "not detected in"
    },
    {
      "source": "exposure levels",
      "target": "epithelial cells",
      "label": "may be higher in"
    },
    {
      "source": "exposure levels",
      "target": "serum",
      "label": "may be higher in"
    },
    {
      "source": "JWH-210",
      "target": "HepG2",
      "label": "was active in"
    },
    {
      "source": "JWH-210",
      "target": "IL-12/23p40",
      "label": "decreased"
    },
    {
      "source": "JWH-210",
      "target": "TNF\u03b1 levels",
      "label": "decreased"
    },
    {
      "source": "hormonal activities",
      "target": "human cell lines",
      "label": "were studied in"
    },
    {
      "source": "hormonal activities",
      "target": "primary cells",
      "label": "were studied in"
    },
    {
      "source": "body fluids",
      "target": "users",
      "label": "are of"
    },
    {
      "source": "experimental work",
      "target": "DNA damage",
      "label": "is required for"
    },
    {
      "source": "tetrahydrocannabinol",
      "target": "cannabinoid receptor ligand",
      "label": "is"
    },
    {
      "source": "U2-OS",
      "target": "bone marrow cells",
      "label": "is a type of"
    },
    {
      "source": "TR146",
      "target": "buccal cells",
      "label": "is a type of"
    },
    {
      "source": "colonic mRNA expression",
      "target": "IL-6",
      "label": "of"
    },
    {
      "source": "colonic mRNA expression",
      "target": "TNF-\u03b1",
      "label": "of"
    },
    {
      "source": "biorelevant media",
      "target": "colonic fluids",
      "label": "reflects"
    },
    {
      "source": "TNF-\u03b1 responses",
      "target": "PCR",
      "label": "measured by"
    },
    {
      "source": "TNF-\u03b1 responses",
      "target": "ELISA",
      "label": "measured by"
    },
    {
      "source": "CD.TNF-\u03b1 siRNA-treated mice",
      "target": "total colon weight",
      "label": "reduced"
    },
    {
      "source": "CD.TNF-\u03b1 siRNA-treated mice",
      "target": "DSS-control mice",
      "label": "compared to"
    },
    {
      "source": "CD.TNF-\u03b1 siRNA-treated mice",
      "target": "clinical signs of colitis",
      "label": "ameliorated"
    },
    {
      "source": "CD.TNF-\u03b1 siRNA-treated mice",
      "target": "colonic mRNA expression",
      "label": "reduced"
    },
    {
      "source": "RAW264.7 cells",
      "target": "lipopolysaccharide (LPS)",
      "label": "stimulated with"
    },
    {
      "source": "RAW264.7 cells",
      "target": "CD.siRNA TNF-\u03b1",
      "label": "transfected with"
    },
    {
      "source": "CD.siRNA TNF-\u03b1",
      "target": "gene levels",
      "label": "reduced"
    },
    {
      "source": "CD.siRNA TNF-\u03b1",
      "target": "protein levels",
      "label": "reduced"
    },
    {
      "source": "CD.siRNA",
      "target": "gel electrophoresis",
      "label": "stability examined by"
    },
    {
      "source": "CD.siRNA",
      "target": "biorelevant media",
      "label": "stability examined in"
    },
    {
      "source": "Gene silencing",
      "target": "murine model",
      "label": "performed in"
    },
    {
      "source": "Gene silencing",
      "target": "aberrantly expressed genes",
      "label": "targets"
    },
    {
      "source": "Gene silencing",
      "target": "modified cyclodextrin delivery system",
      "label": "uses"
    },
    {
      "source": "Gene silencing",
      "target": "TNF-alpha",
      "label": "targets"
    },
    {
      "source": "murine model",
      "target": "acute colitis",
      "label": "is a model of"
    },
    {
      "source": "TNF-alpha (TNF-\u03b1)",
      "target": "inflammatory response",
      "label": "mediates"
    },
    {
      "source": "TNF-alpha (TNF-\u03b1)",
      "target": "cytokine",
      "label": "is a type of"
    },
    {
      "source": "Inflammatory bowel disease (IBD)",
      "target": "chronic relapsing inflammation",
      "label": "is a type of"
    },
    {
      "source": "TNF-\u03b1 siRNA delivery",
      "target": "macrophage cells",
      "label": "targets"
    },
    {
      "source": "TNF-\u03b1 siRNA delivery",
      "target": "mice",
      "label": "targets"
    },
    {
      "source": "local CD-based TNF-\u03b1 siRNA delivery system",
      "target": "Inflammatory bowel disease (IBD)",
      "label": "is for treatment of"
    },
    {
      "source": "Female C57BL/6 mice",
      "target": "dextran sodium sulphate (DSS)",
      "label": "exposed to"
    },
    {
      "source": "Female C57BL/6 mice",
      "target": "intrarectal administration",
      "label": "treated by"
    },
    {
      "source": "Female C57BL/6 mice",
      "target": "control solution",
      "label": "treated with"
    },
    {
      "source": "Female C57BL/6 mice",
      "target": "CD.siRNA TNF-\u03b1",
      "label": "treated with"
    },
    {
      "source": "gene levels",
      "target": "TNF-\u03b1",
      "label": "of"
    },
    {
      "source": "gene levels",
      "target": "IL-6",
      "label": "of"
    },
    {
      "source": "aberrantly expressed genes",
      "target": "TNF-\u03b1",
      "label": "includes"
    },
    {
      "source": "RNA interference (RNAi)",
      "target": "Gene silencing",
      "label": "is a method for"
    },
    {
      "source": "amphiphilic cationic cyclodextrin (CD) vector",
      "target": "TNF-\u03b1 siRNA delivery",
      "label": "is used for"
    },
    {
      "source": "chronic relapsing inflammation",
      "target": "gastrointestinal tract",
      "label": "occurs in"
    },
    {
      "source": "putative microtubule-binding site",
      "target": "KIF4",
      "label": "of"
    },
    {
      "source": "KIF4",
      "target": "non-hydrolyzable ATP analog",
      "label": "complexed with"
    },
    {
      "source": "hydrolyzed phosphate",
      "target": "phosphate tube",
      "label": "released from"
    },
    {
      "source": "backdoor",
      "target": "phosphate tube",
      "label": "closure generates"
    },
    {
      "source": "backdoor",
      "target": "mobile regions",
      "label": "closure stabilizes"
    },
    {
      "source": "Kinesin",
      "target": "ATP-Induced Isomerization",
      "label": "undergoes"
    },
    {
      "source": "mobile regions",
      "target": "switch I",
      "label": "includes"
    },
    {
      "source": "mobile regions",
      "target": "switch II",
      "label": "includes"
    },
    {
      "source": "specific binding",
      "target": "KIF4",
      "label": "of"
    },
    {
      "source": "specific binding",
      "target": "5-carboxyamidotryptamine",
      "label": "not displaced by"
    },
    {
      "source": "specific binding",
      "target": "sumatriptan",
      "label": "displaced by"
    },
    {
      "source": "sole element",
      "target": "partner heads",
      "label": "connects"
    },
    {
      "source": "partner heads",
      "target": "dimeric KIFs",
      "label": "found in"
    },
    {
      "source": "tight structural coordination",
      "target": "catalytic center",
      "label": "involves"
    },
    {
      "source": "tight structural coordination",
      "target": "inter-domain communication",
      "label": "enables"
    },
    {
      "source": "tight structural coordination",
      "target": "neck linker",
      "label": "involves"
    },
    {
      "source": "inter-domain regulation",
      "target": "ATPase activity",
      "label": "regulates"
    },
    {
      "source": "inter-domain regulation",
      "target": "processive movement",
      "label": "guarantees"
    },
    {
      "source": "local conformational change",
      "target": "catalytic center",
      "label": "occurs at"
    },
    {
      "source": "local conformational change",
      "target": "neck-linker element",
      "label": "relayed to"
    },
    {
      "source": "processive movement",
      "target": "dimeric KIFs",
      "label": "occurs in"
    },
    {
      "source": "AMPPNP",
      "target": "adenylyl imidodiphosphate",
      "label": "is a type of"
    },
    {
      "source": "neck linker",
      "target": "sole element",
      "label": "is a"
    },
    {
      "source": "power stroke",
      "target": "motility",
      "label": "produces"
    },
    {
      "source": "ATP binding step",
      "target": "power stroke",
      "label": "is crucial for"
    },
    {
      "source": "ATP binding step",
      "target": "inter-domain regulation",
      "label": "is crucial for"
    },
    {
      "source": "molecular snapshots",
      "target": "ATP binding step",
      "label": "occur during"
    },
    {
      "source": "energy",
      "target": "hydrolysis",
      "label": "derived from"
    },
    {
      "source": "microtubule-based molecular motors",
      "target": "energy",
      "label": "driven by"
    },
    {
      "source": "nucleotide-binding pocket",
      "target": "ATP binding step",
      "label": "closes during"
    },
    {
      "source": "nucleotide-binding pocket",
      "target": "backdoor",
      "label": "closure achieved by"
    },
    {
      "source": "non-hydrolyzable ATP analog",
      "target": "AMPPNP",
      "label": "is a type of"
    },
    {
      "source": "KIF1A structures",
      "target": "ATP analogs",
      "label": "complexed with"
    },
    {
      "source": "stabilization",
      "target": "switch II",
      "label": "of"
    },
    {
      "source": "inter-domain communication",
      "target": "partner heads",
      "label": "between"
    },
    {
      "source": "Kinesin superfamily proteins",
      "target": "KIFs",
      "label": "is a type of"
    },
    {
      "source": "Kinesin superfamily proteins",
      "target": "microtubule-based molecular motors",
      "label": "is a type of"
    },
    {
      "source": "KIFs",
      "target": "microtubule-based molecular motors",
      "label": "is a type of"
    },
    {
      "source": "neck-linker element",
      "target": "power stroke",
      "label": "produces"
    },
    {
      "source": "neck-linker element",
      "target": "catalytic core",
      "label": "docks to"
    },
    {
      "source": "structural insights",
      "target": "specific binding",
      "label": "describe"
    },
    {
      "source": "artemisinin",
      "target": "Inducer Activity",
      "label": "contributes to"
    },
    {
      "source": "artemisinin",
      "target": "malaria",
      "label": "used for treatment of"
    },
    {
      "source": "Inducer Activity",
      "target": "extracts",
      "label": "found in"
    },
    {
      "source": "Inducer Activity",
      "target": "Artemisia monosperma",
      "label": "is of"
    },
    {
      "source": "Inducer Activity",
      "target": "Saudi Arabian Medicinal Plants",
      "label": "found in"
    },
    {
      "source": "active extracts",
      "target": "plants",
      "label": "from"
    },
    {
      "source": "NAD(P)H : quinone oxidoreductase",
      "target": "murine hepatoma cells",
      "label": "induced in"
    },
    {
      "source": "NAD(P)H : quinone oxidoreductase",
      "target": "multifunctional cytoprotective enzyme",
      "label": "is a type of"
    },
    {
      "source": "murine hepatoma cells",
      "target": "microtiter plate wells",
      "label": "grown in"
    },
    {
      "source": "endoperoxide moiety",
      "target": "artemisinin",
      "label": "is part of"
    },
    {
      "source": "endoperoxide moiety",
      "target": "Inducer Activity",
      "label": "is critical for"
    },
    {
      "source": "deoxyartemisinin",
      "target": "assay",
      "label": "is inactive in"
    },
    {
      "source": "NAD(P)H : quinone oxidoreductase inducer activity",
      "target": "extracts",
      "label": "of"
    },
    {
      "source": "Medicinal plants",
      "target": "traditional medicine",
      "label": "used in"
    },
    {
      "source": "Medicinal plants",
      "target": "biologically-active phytochemicals",
      "label": "are source of"
    },
    {
      "source": "NAD(P)H : Quinone Oxidoreductase 1",
      "target": "Inducer Activity",
      "label": "has"
    },
    {
      "source": "Brassicaceae",
      "target": "NAD(P)H : quinone oxidoreductase inducer activity",
      "label": "is a source of"
    },
    {
      "source": "27 Saudi Arabian medicinal plants",
      "target": "18 different plant families",
      "label": "belong to"
    },
    {
      "source": "viscus lumen",
      "target": "contrast agent",
      "label": "is filled with"
    },
    {
      "source": "DOTA linkage",
      "target": "pantoprazole molecule",
      "label": "was installed in"
    },
    {
      "source": "DOTA linkage",
      "target": "negative effect",
      "label": "was installed to minimize"
    },
    {
      "source": "DOTA linkage",
      "target": "mechanism-based strategic location",
      "label": "was installed at"
    },
    {
      "source": "proton pumps",
      "target": "stomach",
      "label": "are in"
    },
    {
      "source": "proton pumps",
      "target": "colon",
      "label": "are in"
    },
    {
      "source": "conjugate",
      "target": "pantoprazole",
      "label": "combines with"
    },
    {
      "source": "conjugate",
      "target": "limitation",
      "label": "was synthesized to overcome"
    },
    {
      "source": "conjugate",
      "target": "Gd-based MRI contrast agent",
      "label": "combines"
    },
    {
      "source": "pantoprazole",
      "target": "proton pump inhibitor",
      "label": "is a"
    },
    {
      "source": "Magnetic resonance imaging (MRI)",
      "target": "gastrointestinal (GI) structure",
      "label": "is used to evaluate"
    },
    {
      "source": "Magnetic resonance imaging (MRI)",
      "target": "humans",
      "label": "is used in"
    },
    {
      "source": "Magnetic resonance imaging (MRI)",
      "target": "functions",
      "label": "is used to evaluate"
    },
    {
      "source": "Magnetic resonance imaging (MRI)",
      "target": "GI tract",
      "label": "is of"
    },
    {
      "source": "proton pump inhibitor",
      "target": "proton pumps",
      "label": "binds to"
    },
    {
      "source": "DOTA (Gd(3+))-conjugate",
      "target": "conjugate",
      "label": "is a type of"
    },
    {
      "source": "DOTA (Gd(3+))-conjugate",
      "target": "imaging studies",
      "label": "is for"
    },
    {
      "source": "DOTA (Gd(3+))-conjugate",
      "target": "DOTA",
      "label": "contains"
    },
    {
      "source": "DOTA (Gd(3+))-conjugate",
      "target": "proton-pump inhibitor",
      "label": "is a conjugate of"
    },
    {
      "source": "DOTA (Gd(3+))-conjugate",
      "target": "Gd",
      "label": "contains"
    },
    {
      "source": "DOTA (Gd(3+))-conjugate",
      "target": "pantoprazole",
      "label": "is a conjugate of"
    },
    {
      "source": "Gd-based MRI contrast agent",
      "target": "Gd",
      "label": "contains"
    },
    {
      "source": "Gd-based MRI contrast agent",
      "target": "chelating agent",
      "label": "is encaged with"
    },
    {
      "source": "chelating agent",
      "target": "DOTA",
      "label": "is"
    },
    {
      "source": "wall",
      "target": "colon",
      "label": "is of"
    },
    {
      "source": "wall",
      "target": "stomach",
      "label": "is of"
    },
    {
      "source": "imaging studies",
      "target": "gastric wall",
      "label": "pertain to"
    },
    {
      "source": "viscus wall",
      "target": "limitation",
      "label": "has"
    },
    {
      "source": "histological assessment",
      "target": "HE staining",
      "label": "measured by"
    },
    {
      "source": "histological assessment",
      "target": "hematoxylin and eosin staining",
      "label": "measured by"
    },
    {
      "source": "OVA",
      "target": "eosinophil count",
      "label": "induced"
    },
    {
      "source": "OVA",
      "target": "eosinophilia",
      "label": "induced"
    },
    {
      "source": "OVA",
      "target": "allergic inflammation",
      "label": "induces"
    },
    {
      "source": "IL-17A level",
      "target": "bronchoalveolar lavage fluid",
      "label": "recovered in"
    },
    {
      "source": "eosinophilia",
      "target": "lung tissue",
      "label": "occurs in"
    },
    {
      "source": "Treg cells",
      "target": "flow cytometry",
      "label": "evaluated by"
    },
    {
      "source": "Treg cells",
      "target": "FCM",
      "label": "evaluated by"
    },
    {
      "source": "Treg cells",
      "target": "suppression function",
      "label": "have"
    },
    {
      "source": "Treg cells",
      "target": "suppressive function",
      "label": "possess"
    },
    {
      "source": "Treg cells",
      "target": "surface and intracellular markers",
      "label": "possess"
    },
    {
      "source": "Asthma mice model",
      "target": "ovalbumin",
      "label": "established by"
    },
    {
      "source": "ovalbumin",
      "target": "allergic inflammation",
      "label": "induces"
    },
    {
      "source": "ovalbumin",
      "target": "Th17 balance",
      "label": "broke"
    },
    {
      "source": "BALF levels",
      "target": "Treg/Th17 cytokines",
      "label": "are of"
    },
    {
      "source": "BALF levels",
      "target": "enzyme-linked immunosorbent assay",
      "label": "measured by"
    },
    {
      "source": "Curcumin",
      "target": "allergic airway inflammation",
      "label": "attenuates"
    },
    {
      "source": "Curcumin",
      "target": "CD4(+)CD25(+) regulatory T cells",
      "label": "regulates"
    },
    {
      "source": "Curcumin",
      "target": "ovalbumin-sensitized mice",
      "label": "acts in"
    },
    {
      "source": "Curcumin",
      "target": "Th17 balance",
      "label": "regulates"
    },
    {
      "source": "Curcumin",
      "target": "Tregs",
      "label": "regulates"
    },
    {
      "source": "differential cell count",
      "target": "Wright-Giemsa staining",
      "label": "measured by"
    },
    {
      "source": "differential cell count",
      "target": "BAL fluid",
      "label": "in"
    },
    {
      "source": "differential cell count",
      "target": "BALF",
      "label": "in"
    },
    {
      "source": "Flow cytometry (FCM) studies",
      "target": "curcumin",
      "label": "demonstrated"
    },
    {
      "source": "results in vivo",
      "target": "ovalbumin",
      "label": "show"
    },
    {
      "source": "therapeutic drug",
      "target": "patients",
      "label": "for"
    },
    {
      "source": "Th17 cells",
      "target": "flow cytometry",
      "label": "evaluated by"
    },
    {
      "source": "Th17 cells",
      "target": "FCM",
      "label": "evaluated by"
    },
    {
      "source": "allergic inflammation",
      "target": "mouse model",
      "label": "occurs in"
    },
    {
      "source": "FCM",
      "target": "curcumin",
      "label": "demonstrated"
    },
    {
      "source": "curcumin treatments",
      "target": "Th17 balance",
      "label": "regulated"
    },
    {
      "source": "curcumin treatments",
      "target": "inflammatory",
      "label": "attenuated"
    },
    {
      "source": "Airway resistance",
      "target": "forced oscillation technique",
      "label": "measured by"
    },
    {
      "source": "Histological studies",
      "target": "curcumin",
      "label": "demonstrated"
    },
    {
      "source": "IL-10 level",
      "target": "bronchoalveolar lavage fluid",
      "label": "in"
    },
    {
      "source": "Raw",
      "target": "forced oscillation technique",
      "label": "measured by"
    },
    {
      "source": "tetracyclic quino[3,2-b]benzo[1,4]thiazines",
      "target": "2,2'-dichloro-3,3'-diquinolinyl disulfide",
      "label": "obtained from"
    },
    {
      "source": "tetracyclic quino[3,2-b]benzo[1,4]thiazines",
      "target": "diquinodithiin",
      "label": "obtained from"
    },
    {
      "source": "tetracyclic quino[3,2-b]benzo[1,4]thiazines",
      "target": "azaphenothiazines",
      "label": "is a type of"
    },
    {
      "source": "tetracyclic quino[3,2-b]benzo[1,4]thiazines",
      "target": "substituents",
      "label": "possess"
    },
    {
      "source": "tetracyclic quino[3,2-b]benzo[1,4]thiazines",
      "target": "several-step syntheses",
      "label": "obtained via"
    },
    {
      "source": "tetracyclic quino[3,2-b]benzo[1,4]thiazines",
      "target": "aminoalkyl",
      "label": "possess"
    },
    {
      "source": "tumor necrosis factor alpha",
      "target": "TNF-\u03b1",
      "label": "abbreviated as"
    },
    {
      "source": "human peripheral blood mononuclear cells",
      "target": "PBMC",
      "label": "abbreviated as"
    },
    {
      "source": "structure-activity relationship",
      "target": "compounds",
      "label": "of"
    },
    {
      "source": "proliferative response",
      "target": "human peripheral blood mononuclear cells",
      "label": "of"
    },
    {
      "source": "proliferative response",
      "target": "phytohemagglutin A",
      "label": "induced by"
    },
    {
      "source": "phytohemagglutin A",
      "target": "PHA",
      "label": "abbreviated as"
    },
    {
      "source": "quino[3,2-b]benzo[1,4]thiazines",
      "target": "immunological properties",
      "label": "have"
    },
    {
      "source": "H",
      "target": "HIGH-FAT DIET",
      "label": "is"
    },
    {
      "source": "Cases",
      "target": "Pathogenetic Implications",
      "label": "have"
    },
    {
      "source": "Cases",
      "target": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "label": "are reported for"
    },
    {
      "source": "Cases",
      "target": "incidental cystic adrenal masses",
      "label": "presented as"
    },
    {
      "source": "Cases",
      "target": "adult females",
      "label": "occurred in"
    },
    {
      "source": "C cells",
      "target": "cromogranin",
      "label": "showed negativity for"
    },
    {
      "source": "C cells",
      "target": "synaptophysin",
      "label": "showed negativity for"
    },
    {
      "source": "C cells",
      "target": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "label": "are not present in"
    },
    {
      "source": "C cells",
      "target": "calcitonin",
      "label": "showed negativity for"
    },
    {
      "source": "thyroid transcription factor-1",
      "target": "TTF-1",
      "label": "is also known as"
    },
    {
      "source": "thyroid transcription factor-1",
      "target": "Titf-1",
      "label": "is also known as"
    },
    {
      "source": "thyroid transcription factor-1",
      "target": "Nkx2.1",
      "label": "is also known as"
    },
    {
      "source": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "target": "cystic adrenal mass",
      "label": "presents as"
    },
    {
      "source": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "target": "normal orthotopic thyroid tissue",
      "label": "is indistinguishable from"
    },
    {
      "source": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "target": "fifth decade",
      "label": "presents in"
    },
    {
      "source": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "target": "C cells",
      "label": "lacks"
    },
    {
      "source": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "target": "thyroid embryology",
      "label": "is not understood by"
    },
    {
      "source": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "target": "normal follicular cells",
      "label": "is composed of"
    },
    {
      "source": "cystic adrenal mass",
      "target": "abdominal ultrasonography",
      "label": "discovered on"
    },
    {
      "source": "cystic adrenal mass",
      "target": "computed tomography images",
      "label": "discovered on"
    },
    {
      "source": "Ectopic Thyroid Tissue",
      "target": "embryonic descent pathway",
      "label": "is found along"
    },
    {
      "source": "Ectopic Thyroid Tissue",
      "target": "Adrenal Gland",
      "label": "located in"
    },
    {
      "source": "embryonic descent pathway",
      "target": "tongue",
      "label": "extends from"
    },
    {
      "source": "embryonic descent pathway",
      "target": "medial thyroid anlage",
      "label": "is of"
    },
    {
      "source": "embryonic descent pathway",
      "target": "trachea",
      "label": "extends to"
    },
    {
      "source": "KRAS mutations",
      "target": "real-time polymerase chain reaction analysis",
      "label": "were not detected by"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "CK 7",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "human sodium iodide symporter",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "cytokeratin",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "thyroid transcription factor-1",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "pendrin",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "thyroperoxidase",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "FOXE1",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "thyroglobulin",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "CK AE1/AE3",
      "label": "is for"
    },
    {
      "source": "immunohistochemical positivity",
      "target": "paired box gene 8",
      "label": "is for"
    },
    {
      "source": "human sodium iodide symporter",
      "target": "hNIS",
      "label": "is also known as"
    },
    {
      "source": "congenital hernia of Morgagni",
      "target": "patient",
      "label": "coexists in"
    },
    {
      "source": "congenital hernia of Morgagni",
      "target": "over-descent",
      "label": "suggests"
    },
    {
      "source": "W\u00f6lfler area",
      "target": "embryonic descent pathway",
      "label": "is a region of"
    },
    {
      "source": "in situ hybridization analysis",
      "target": "messenger RNA",
      "label": "showed positivity for"
    },
    {
      "source": "FOXE1",
      "target": "TTF-2",
      "label": "is also known as"
    },
    {
      "source": "congenital defect of the anterior diaphragm",
      "target": "congenital hernia of Morgagni",
      "label": "is also known as"
    },
    {
      "source": "congenital defect of the anterior diaphragm",
      "target": "patients",
      "label": "coexists in"
    },
    {
      "source": "follicular nature",
      "target": "immunohistochemical positivity",
      "label": "confirmed by"
    },
    {
      "source": "follicular nature",
      "target": "in situ hybridization analysis",
      "label": "confirmed by"
    },
    {
      "source": "follicular nature",
      "target": "ectopic thyroid tissue in the adrenal gland (ETTAG)",
      "label": "is a characteristic of"
    },
    {
      "source": "over-descent",
      "target": "medial thyroid anlagen derived cells",
      "label": "is of"
    },
    {
      "source": "over-descent",
      "target": "medial thyroid anlage derived cells",
      "label": "is of"
    },
    {
      "source": "over-descent",
      "target": "heterotopia",
      "label": "is suggested as origin of"
    },
    {
      "source": "over-descent",
      "target": "ETTAG pathogenesis",
      "label": "is involved in"
    },
    {
      "source": "BRAF mutations",
      "target": "real-time polymerase chain reaction analysis",
      "label": "were not detected by"
    },
    {
      "source": "paired box gene 8",
      "target": "PAX8",
      "label": "is also known as"
    },
    {
      "source": "work-up",
      "target": "thyroid malignancy",
      "label": "did not show"
    },
    {
      "source": "nano- and microgram doses",
      "target": "midazolam pharmacokinetics",
      "label": "can predict"
    },
    {
      "source": "nano- and microgram doses",
      "target": "CYP3A",
      "label": "can be used to assess"
    },
    {
      "source": "nano- and microgram doses",
      "target": "Midazolam",
      "label": "are of"
    },
    {
      "source": "nano- and microgram doses",
      "target": "activity",
      "label": "can be used to assess"
    },
    {
      "source": "midazolam pharmacokinetics",
      "target": "therapeutic doses",
      "label": "in"
    },
    {
      "source": "midazolam pharmacokinetics",
      "target": "30,000-fold concentration range",
      "label": "is linear in"
    },
    {
      "source": "Area under the plasma concentration-time curve",
      "target": "AUC",
      "label": "is also known as"
    },
    {
      "source": "CYP3A",
      "target": "strong CYP3A inhibitors",
      "label": "activity can be assessed in presence of"
    },
    {
      "source": "in vivo method",
      "target": "activity",
      "label": "for assessing"
    },
    {
      "source": "in vivo method",
      "target": "cytochrome P450 3A",
      "label": "for assessing"
    },
    {
      "source": "in vivo method",
      "target": "CYP3A",
      "label": "for assessing"
    },
    {
      "source": "in vivo method",
      "target": "nanogram doses",
      "label": "uses"
    },
    {
      "source": "regular doses",
      "target": "Midazolam",
      "label": "are of"
    },
    {
      "source": "nanogram doses",
      "target": "Midazolam",
      "label": "are of"
    },
    {
      "source": "Midazolam",
      "target": "CYP3A Probe Substrate",
      "label": "is a"
    },
    {
      "source": "Midazolam",
      "target": "Drug Interactions",
      "label": "used to evaluate"
    },
    {
      "source": "ketoconazole",
      "target": "midazolam oral clearance",
      "label": "reduced"
    },
    {
      "source": "ketoconazole",
      "target": "400 mg q.d.",
      "label": "dose is"
    },
    {
      "source": "ketoconazole",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "ketoconazole",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "ketoconazole",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "ketoconazole",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "ketoconazole",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "midazolam oral clearance",
      "target": "92.8%",
      "label": "reduced by"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "2013",
      "label": "published in"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "advance online publication",
      "label": "has"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "doi:10.1038/clpt.2013.27",
      "label": "has DOI"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "doi:10.1038/clpt.2013.79",
      "label": "has DOI"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "accepted article preview",
      "label": "published"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "doi:10.1038/clpt.2013.69",
      "label": "has DOI"
    },
    {
      "source": "Clinical Pharmacology & Therapeutics",
      "target": "1 May 2013",
      "label": "published on"
    },
    {
      "source": "advance online publication",
      "target": "20 March 2013",
      "label": "date is"
    },
    {
      "source": "CYP3A inhibitor",
      "target": "ketoconazole",
      "label": "is"
    },
    {
      "source": "four escalating single doses",
      "target": "oral midazolam",
      "label": "are of"
    },
    {
      "source": "four escalating single doses",
      "target": "pharmacokinetics linearity",
      "label": "used to assess"
    },
    {
      "source": "four escalating single doses",
      "target": "healthy participants",
      "label": "administered to"
    },
    {
      "source": "oral midazolam",
      "target": "0.0001-3 mg",
      "label": "has dose range"
    },
    {
      "source": "healthy participants",
      "target": "CYP3A5 carrier status",
      "label": "stratified according to"
    },
    {
      "source": "CYP3A5 carrier status",
      "target": "midazolam oral clearance",
      "label": "had no influence on"
    },
    {
      "source": "CYP3A5 carrier status",
      "target": "inhibition",
      "label": "had no influence on"
    },
    {
      "source": "Cmax",
      "target": "entire range of doses",
      "label": "was linear over"
    },
    {
      "source": "Cmax",
      "target": "363%",
      "label": "increased by"
    },
    {
      "source": "epithelial phenotype",
      "target": "vimentin expression",
      "label": "has low"
    },
    {
      "source": "epithelial phenotype",
      "target": "E-cadherin",
      "label": "has high"
    },
    {
      "source": "elisidepsin",
      "target": "marine compound",
      "label": "is a"
    },
    {
      "source": "elisidepsin",
      "target": "potent and broad cytotoxic effects",
      "label": "showed"
    },
    {
      "source": "elisidepsin",
      "target": "rapid oncosis",
      "label": "induces"
    },
    {
      "source": "elisidepsin",
      "target": "phase II clinical development",
      "label": "is in"
    },
    {
      "source": "elisidepsin",
      "target": "kahalalide f",
      "label": "is derived from"
    },
    {
      "source": "elisidepsin",
      "target": "PM02734",
      "label": "is also known as"
    },
    {
      "source": "elisidepsin",
      "target": "Kahalalide F family",
      "label": "belongs to"
    },
    {
      "source": "elisidepsin",
      "target": "cells",
      "label": "is active in"
    },
    {
      "source": "elisidepsin",
      "target": "synthetic marine-derived cyclic peptide",
      "label": "is a type of"
    },
    {
      "source": "elisidepsin",
      "target": "Irvalec",
      "label": "is also known as"
    },
    {
      "source": "Predictive factors",
      "target": "sensitivity",
      "label": "are of"
    },
    {
      "source": "ErbB1",
      "target": "cross-talk",
      "label": "has"
    },
    {
      "source": "potent and broad cytotoxic effects",
      "target": "concentrations",
      "label": "active at"
    },
    {
      "source": "vimentin expression",
      "target": "vimentin",
      "label": "is of"
    },
    {
      "source": "23 cancer cell lines",
      "target": "origin",
      "label": "have"
    },
    {
      "source": "rapid oncosis",
      "target": "ErbB3-expressing cells",
      "label": "occurs in"
    },
    {
      "source": "DU-PM cells",
      "target": "acquired resistance",
      "label": "have"
    },
    {
      "source": "DU-PM cells",
      "target": "sensitivity",
      "label": "displayed"
    },
    {
      "source": "acquired resistance",
      "target": "elisidepsin",
      "label": "is to"
    },
    {
      "source": "Bcl2",
      "target": "DU-PM cells",
      "label": "was increased in"
    },
    {
      "source": "Combinations",
      "target": "elisidepsin",
      "label": "include"
    },
    {
      "source": "Combinations",
      "target": "synergistic effects",
      "label": "resulted in"
    },
    {
      "source": "Combinations",
      "target": "chemotherapies",
      "label": "include"
    },
    {
      "source": "Combinations",
      "target": "lapatinib",
      "label": "include"
    },
    {
      "source": "synergistic effects",
      "target": "clinical use",
      "label": "offer potential for"
    },
    {
      "source": "elisidepsin cytotoxicity",
      "target": "mRNA expression",
      "label": "correlated with"
    },
    {
      "source": "elisidepsin cytotoxicity",
      "target": "protein expression",
      "label": "correlated with"
    },
    {
      "source": "elisidepsin cytotoxicity",
      "target": "mutational state",
      "label": "correlated with"
    },
    {
      "source": "ErbB3 signaling pathways",
      "target": "cross-talk",
      "label": "has"
    },
    {
      "source": "ErbB3-expressing cells",
      "target": "ErbB3",
      "label": "express"
    },
    {
      "source": "KRAS activating mutations",
      "target": "resistance",
      "label": "associated with"
    },
    {
      "source": "KRAS activating mutations",
      "target": "KRAS",
      "label": "are of"
    },
    {
      "source": "chemotherapies",
      "target": "oxaliplatin",
      "label": "include"
    },
    {
      "source": "chemotherapies",
      "target": "5-FU",
      "label": "include"
    },
    {
      "source": "Muc1 expression",
      "target": "sensitivity",
      "label": "correlated with"
    },
    {
      "source": "catheterized rat model",
      "target": "intestinal components of oral bioavailability",
      "label": "used to define"
    },
    {
      "source": "catheterized rat model",
      "target": "hepatic components of oral bioavailability",
      "label": "used to define"
    },
    {
      "source": "catheterized rat model",
      "target": "estimates of hepatic and intestinal contribution to oral bioavailability",
      "label": "afforded"
    },
    {
      "source": "intestinal components of oral bioavailability",
      "target": "standard in vivo metabolism studies",
      "label": "integrated with"
    },
    {
      "source": "intestinal components of oral bioavailability",
      "target": "AMG 221",
      "label": "are for"
    },
    {
      "source": "in vivo metabolite characterization",
      "target": "administration of [(14)C] AMG 221",
      "label": "obtained after"
    },
    {
      "source": "administration of [(14)C] AMG 221",
      "target": "rat",
      "label": "administered to"
    },
    {
      "source": "hepatic bioavailability (FH)",
      "target": "animals",
      "label": "measured in"
    },
    {
      "source": "hepatic bioavailability (FH)",
      "target": "absorption phase",
      "label": "characterized by reduction during"
    },
    {
      "source": "hepatic bioavailability (FH)",
      "target": "time points",
      "label": "measured at"
    },
    {
      "source": "hepatic bioavailability (FH)",
      "target": "oral dose administration",
      "label": "measured after"
    },
    {
      "source": "hepatic bioavailability (FH)",
      "target": "elimination phase",
      "label": "characterized by increase during"
    },
    {
      "source": "hepatic first-pass extraction",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "hepatic first-pass extraction",
      "target": "AMG 221",
      "label": "of"
    },
    {
      "source": "AMG 221",
      "target": "gut lumen",
      "label": "absorbed from"
    },
    {
      "source": "AMG 221",
      "target": "oral dose",
      "label": "absorbed following"
    },
    {
      "source": "AMG 221",
      "target": "excretion",
      "label": "metabolized prior to"
    },
    {
      "source": "AMG 221",
      "target": "11\u03b2-HSD1 inhibitor",
      "label": "is an"
    },
    {
      "source": "AMG 221",
      "target": "urine",
      "label": "excreted in"
    },
    {
      "source": "hepatic components of oral bioavailability",
      "target": "standard in vivo metabolism studies",
      "label": "integrated with"
    },
    {
      "source": "hepatic components of oral bioavailability",
      "target": "AMG 221",
      "label": "are for"
    },
    {
      "source": "intestinal extraction",
      "target": "first-pass component of oral bioavailability",
      "label": "contributed to"
    },
    {
      "source": "hepatic distribution",
      "target": "AMG 221",
      "label": "of"
    },
    {
      "source": "standard in vivo metabolism studies",
      "target": "components contributing to the oral disposition",
      "label": "elucidate"
    },
    {
      "source": "components contributing to the oral disposition",
      "target": "novel drug candidate",
      "label": "are of"
    },
    {
      "source": "intestinal extraction ratios",
      "target": "catheterized rat model",
      "label": "obtained using"
    },
    {
      "source": "intestinal extraction ratios",
      "target": "AMG 221",
      "label": "of"
    },
    {
      "source": "estimates of hepatic and intestinal contribution to oral bioavailability",
      "target": "preclinical ADME characteristics",
      "label": "used to define"
    },
    {
      "source": "preclinical ADME characteristics",
      "target": "drug candidate",
      "label": "of"
    },
    {
      "source": "hepatic extraction ratios",
      "target": "catheterized rat model",
      "label": "obtained using"
    },
    {
      "source": "hepatic extraction ratios",
      "target": "AMG 221",
      "label": "of"
    },
    {
      "source": "intestinal first-pass extraction",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "intestinal first-pass extraction",
      "target": "AMG 221",
      "label": "of"
    },
    {
      "source": "gut extraction",
      "target": "systemically administered drug",
      "label": "not observed for"
    },
    {
      "source": "Mass balance data",
      "target": "administration of [(14)C] AMG 221",
      "label": "obtained after"
    },
    {
      "source": "hepatic extraction",
      "target": "first-pass component of oral bioavailability",
      "label": "contributed to"
    },
    {
      "source": "acetylcholinesterase (AChE) inhibitor",
      "target": "Acetylcholinesterase",
      "label": "inhibits"
    },
    {
      "source": "acetylcholinesterase (AChE) inhibitor",
      "target": "AChE",
      "label": "inhibits"
    },
    {
      "source": "Acetylcholinesterase",
      "target": "nicotinic modulation",
      "label": "inhibition reveals"
    },
    {
      "source": "EPSCs",
      "target": "rat hippocampal slices",
      "label": "recorded from"
    },
    {
      "source": "EPSCs",
      "target": "guinea pigs",
      "label": "recorded from"
    },
    {
      "source": "EPSCs",
      "target": "control animals",
      "label": "frequency compared to"
    },
    {
      "source": "EPSCs",
      "target": "control guinea pigs",
      "label": "recorded from"
    },
    {
      "source": "mecamylamine",
      "target": "donepezil",
      "label": "suppressed effects of"
    },
    {
      "source": "mecamylamine",
      "target": "biochemical parameters",
      "label": "affects"
    },
    {
      "source": "mecamylamine",
      "target": "memory extinction",
      "label": "affects"
    },
    {
      "source": "nAChR-dependent glutamate transmission",
      "target": "neurotoxicological effects",
      "label": "contributes to"
    },
    {
      "source": "nAChR-dependent glutamate transmission",
      "target": "hippocampus",
      "label": "occurs in"
    },
    {
      "source": "neurotoxicological effects",
      "target": "soman",
      "label": "are effects of"
    },
    {
      "source": "spontaneous glutamate excitatory postsynaptic currents",
      "target": "CA1 stratum radiatum interneurons",
      "label": "recorded from"
    },
    {
      "source": "CA1 stratum radiatum interneurons",
      "target": "hippocampal slices",
      "label": "in"
    },
    {
      "source": "nicotinic modulation",
      "target": "glutamate inputs",
      "label": "modulates"
    },
    {
      "source": "glutamate inputs",
      "target": "CA1 stratum radiatum interneurons",
      "label": "targets"
    },
    {
      "source": "irreversible AChE inhibitor",
      "target": "AChE",
      "label": "inhibits"
    },
    {
      "source": "whole-cell patch-clamp technique",
      "target": "spontaneous glutamate excitatory postsynaptic currents",
      "label": "used to record"
    },
    {
      "source": "brain nicotinic acetylcholine receptors",
      "target": "neurotoxicological effects",
      "label": "involved in"
    },
    {
      "source": "reversible AChE inhibitor",
      "target": "AChE",
      "label": "inhibits"
    },
    {
      "source": "infecting virus",
      "target": "mouse vagina",
      "label": "in"
    },
    {
      "source": "antiherpetic action",
      "target": "plaque reduction assay",
      "label": "measured by"
    },
    {
      "source": "CDM",
      "target": "TNF-\u03b1",
      "label": "synergized"
    },
    {
      "source": "CDM",
      "target": "microbicide",
      "label": "is a potential"
    },
    {
      "source": "CDM",
      "target": "IL-6",
      "label": "increased levels of"
    },
    {
      "source": "CDM",
      "target": "cytotoxic effect",
      "label": "has"
    },
    {
      "source": "CDM",
      "target": "clearance",
      "label": "leads to"
    },
    {
      "source": "CDM",
      "target": "HSV-2",
      "label": "used in combination with"
    },
    {
      "source": "CDM",
      "target": "Herpes Simplex Virus type 2",
      "label": "inhibited"
    },
    {
      "source": "CDM",
      "target": "1-cinnamoyl-3,11-dihydroxymeliacarpin",
      "label": "is an abbreviation for"
    },
    {
      "source": "CDM",
      "target": "IL-10",
      "label": "increased levels of"
    },
    {
      "source": "CDM",
      "target": "NO",
      "label": "increased levels of"
    },
    {
      "source": "CDM",
      "target": "immunomodulatory effect",
      "label": "has"
    },
    {
      "source": "CDM",
      "target": "antiherpetic action",
      "label": "has"
    },
    {
      "source": "CDM",
      "target": "IFN-\u03b3",
      "label": "increased levels of"
    },
    {
      "source": "CDM",
      "target": "replication",
      "label": "did not affect"
    },
    {
      "source": "CDM",
      "target": "cytokine production",
      "label": "increases"
    },
    {
      "source": "cytokine production",
      "target": "macrophages",
      "label": "in"
    },
    {
      "source": "cytokine production",
      "target": "bioassay",
      "label": "measured using"
    },
    {
      "source": "cytokine production",
      "target": "ELISA method",
      "label": "measured using"
    },
    {
      "source": "leaf extracts",
      "target": "Melia azedarach L",
      "label": "from"
    },
    {
      "source": "1-cinnamoyl-3,11-dihydroxymeliacarpin",
      "target": "antiherpetic effect",
      "label": "has"
    },
    {
      "source": "1-cinnamoyl-3,11-dihydroxymeliacarpin",
      "target": "leaf extracts",
      "label": "isolated from"
    },
    {
      "source": "1-cinnamoyl-3,11-dihydroxymeliacarpin",
      "target": "limonoid",
      "label": "is a"
    },
    {
      "source": "antiherpetic effect",
      "target": "epithelial cells",
      "label": "in"
    },
    {
      "source": "microbicide",
      "target": "herpetic infections",
      "label": "against"
    },
    {
      "source": "Murine Macrophages",
      "target": "HSV-2",
      "label": "stimulated with"
    },
    {
      "source": "HSV-2",
      "target": "epithelial cells",
      "label": "multiplication in"
    },
    {
      "source": "Meliacine",
      "target": "partially purified extract source",
      "label": "is a"
    },
    {
      "source": "Meliacine",
      "target": "therapeutic effect",
      "label": "has"
    },
    {
      "source": "partially purified extract source",
      "target": "CDM",
      "label": "of"
    },
    {
      "source": "acridine orange staining",
      "target": "living cells",
      "label": "used for"
    },
    {
      "source": "therapeutic effect",
      "target": "murine genital herpes",
      "label": "on"
    },
    {
      "source": "1-Cinnamoyl-3,11-Dihydroxymeliacarpin",
      "target": "Cytokine Production",
      "label": "has effect on"
    },
    {
      "source": "Cytokine Production",
      "target": "Murine Macrophages",
      "label": "by"
    },
    {
      "source": "Herpes Simplex Virus type 2",
      "target": "Vero cells",
      "label": "multiplication in"
    },
    {
      "source": "Copyright",
      "target": "John Wiley & Sons, Ltd.",
      "label": "held by"
    },
    {
      "source": "immunomodulatory effect",
      "target": "cytokine production",
      "label": "determined by measuring"
    },
    {
      "source": "lung cells",
      "target": "[M5]",
      "label": "produced"
    },
    {
      "source": "lung cells",
      "target": "esterase-dependent metabolites",
      "label": "produced"
    },
    {
      "source": "[M6]",
      "target": "action",
      "label": "formed by"
    },
    {
      "source": "cytochrome P450 3A enzyme-mediated metabolism",
      "target": "BDP",
      "label": "of"
    },
    {
      "source": "BDP",
      "target": "dehydrogenation",
      "label": "metabolized via"
    },
    {
      "source": "BDP",
      "target": "hydroxylation",
      "label": "metabolized via"
    },
    {
      "source": "BDP",
      "target": "Inhaled glucocorticoids",
      "label": "is a type of"
    },
    {
      "source": "BDP",
      "target": "inactive metabolites",
      "label": "metabolized to"
    },
    {
      "source": "contributions",
      "target": "esterases",
      "label": "of"
    },
    {
      "source": "contributions",
      "target": "CYP3A4",
      "label": "of"
    },
    {
      "source": "contributions",
      "target": "metabolism",
      "label": "in"
    },
    {
      "source": "contributions",
      "target": "CYP3A7",
      "label": "of"
    },
    {
      "source": "contributions",
      "target": "CYP3A5",
      "label": "of"
    },
    {
      "source": "changes",
      "target": "expression",
      "label": "in"
    },
    {
      "source": "changes",
      "target": "fertility capacity",
      "label": "related to"
    },
    {
      "source": "changes",
      "target": "impaired epididymal function",
      "label": "related to"
    },
    {
      "source": "changes",
      "target": "sperm quality",
      "label": "related to"
    },
    {
      "source": "individual differences",
      "target": "glucocorticoid receptor-mediated processes",
      "label": "involves"
    },
    {
      "source": "Inhaled glucocorticoids",
      "target": "treatment",
      "label": "are"
    },
    {
      "source": "BDP disposition",
      "target": "humans",
      "label": "in"
    },
    {
      "source": "Cytochrome P450 3A Enzymes",
      "target": "Beclomethasone Dipropionate",
      "label": "metabolizes"
    },
    {
      "source": "Beclomethasone Dipropionate",
      "target": "Inhaled glucocorticoids",
      "label": "is a type of"
    },
    {
      "source": "esterase-dependent metabolites",
      "target": "[M1-M3]",
      "label": "include"
    },
    {
      "source": "dehydrogenation",
      "target": "[M5]",
      "label": "produces"
    },
    {
      "source": "[M1]",
      "target": "CYP3A5 mRNA induction",
      "label": "correlated with"
    },
    {
      "source": "CYP3A5 mRNA induction",
      "target": "A549 lung cells",
      "label": "in"
    },
    {
      "source": "variations",
      "target": "glucocorticoid resistance",
      "label": "may contribute to"
    },
    {
      "source": "variations",
      "target": "insensitivity",
      "label": "may contribute to"
    },
    {
      "source": "variations",
      "target": "cytochrome P450 3A enzyme-mediated metabolism",
      "label": "in"
    },
    {
      "source": "glucocorticoid resistance",
      "target": "individual differences",
      "label": "attributable to"
    },
    {
      "source": "insensitivity",
      "target": "individual differences",
      "label": "attributable to"
    },
    {
      "source": "fumarate ion",
      "target": "small-amplitude motion",
      "label": "undergoes"
    },
    {
      "source": "fumarate ion",
      "target": "desolvate",
      "label": "is in"
    },
    {
      "source": "small-amplitude motion",
      "target": "activation parameter",
      "label": "has"
    },
    {
      "source": "small-amplitude motion",
      "target": "frequency scale",
      "label": "occurs on"
    },
    {
      "source": "small-amplitude motion",
      "target": "ambient temperature",
      "label": "occurs at"
    },
    {
      "source": "spin-lattice relaxation times",
      "target": "(2)H",
      "label": "are associated with"
    },
    {
      "source": "spin-lattice relaxation times",
      "target": "(13)C",
      "label": "are associated with"
    },
    {
      "source": "spin-lattice relaxation times",
      "target": "magic-angle spinning conditions",
      "label": "are measured under"
    },
    {
      "source": "relaxation times",
      "target": "MAS",
      "label": "are under"
    },
    {
      "source": "ethanol solvate",
      "target": "pharmaceutical material",
      "label": "is a solvate of"
    },
    {
      "source": "activation barriers",
      "target": "(13)C spin-lattice relaxation times",
      "label": "derived from"
    },
    {
      "source": "activation barriers",
      "target": "dynamic processes",
      "label": "are for"
    },
    {
      "source": "activation parameter",
      "target": "32 kJ mol(-1)",
      "label": "is"
    },
    {
      "source": "relaxation rate maxima",
      "target": "systems",
      "label": "are observed in"
    },
    {
      "source": "Jump rates",
      "target": "1D-EXSY",
      "label": "derived from"
    },
    {
      "source": "Jump rates",
      "target": "dynamic processes",
      "label": "are for"
    },
    {
      "source": "dynamics",
      "target": "desolvates",
      "label": "occurs in"
    },
    {
      "source": "dynamics",
      "target": "desolvate",
      "label": "occurs in"
    },
    {
      "source": "dynamics",
      "target": "solvates",
      "label": "occurs in"
    },
    {
      "source": "dynamics",
      "target": "ethanol solvate",
      "label": "occurs in"
    },
    {
      "source": "desolvates",
      "target": "formoterol fumarate",
      "label": "are of"
    },
    {
      "source": "Exact calculations",
      "target": "motional models",
      "label": "test"
    },
    {
      "source": "Exact calculations",
      "target": "relaxation times",
      "label": "are of"
    },
    {
      "source": "frequency scale",
      "target": "100s of MHz",
      "label": "is"
    },
    {
      "source": "dynamic processes",
      "target": "phenyl ring rotation",
      "label": "include"
    },
    {
      "source": "dynamic processes",
      "target": "methyl group rotational diffusion",
      "label": "include"
    },
    {
      "source": "Solid-state NMR",
      "target": "dynamics",
      "label": "characterises"
    },
    {
      "source": "solvates",
      "target": "formoterol fumarate",
      "label": "are of"
    },
    {
      "source": "formoterol fumarate",
      "target": "pharmaceutical material",
      "label": "is a"
    },
    {
      "source": "murine frontal cortex networks",
      "target": "neuroactive substances",
      "label": "detect"
    },
    {
      "source": "murine frontal cortex networks",
      "target": "toxin",
      "label": "are less sensitive to"
    },
    {
      "source": "\u03c9-agatoxin",
      "target": "toxin",
      "label": "is a type of"
    },
    {
      "source": "\u03c9-agatoxin",
      "target": "spontaneous action potential firing",
      "label": "affects"
    },
    {
      "source": "spontaneous action potential firing",
      "target": "murine frontal cortex networks",
      "label": "occurs within"
    },
    {
      "source": "spontaneous action potential firing",
      "target": "spinal cord networks",
      "label": "occurs within"
    },
    {
      "source": "spontaneous activity",
      "target": "neuronal networks",
      "label": "of"
    },
    {
      "source": "unit specific responses",
      "target": "effects",
      "label": "are a type of"
    },
    {
      "source": "unit specific responses",
      "target": "action potential firing rate",
      "label": "manifested as change in"
    },
    {
      "source": "spinal cord networks",
      "target": "toxin",
      "label": "are more sensitive to"
    },
    {
      "source": "spinal cord networks",
      "target": "neuroactive substances",
      "label": "detect"
    },
    {
      "source": "\u03c9-Agatoxin-IVA",
      "target": "P/Q-type Ca(2+) channel blocker",
      "label": "is a"
    },
    {
      "source": "\u03c9-Agatoxin-IVA",
      "target": "presynaptic Ca(2+) currents",
      "label": "affects"
    },
    {
      "source": "\u03c9-Agatoxin-IVA",
      "target": "postsynaptic potentials",
      "label": "affects"
    },
    {
      "source": "\u03c9-Agatoxin-IVA",
      "target": "neurotoxin",
      "label": "is a type of"
    },
    {
      "source": "two clusters",
      "target": "\u03c9-agatoxin exposure",
      "label": "are detected with"
    },
    {
      "source": "two clusters",
      "target": "differential responses",
      "label": "represent"
    },
    {
      "source": "P/Q-type voltage gated Ca(2+) channels",
      "target": "presynaptic neurotransmitter release",
      "label": "play a role in"
    },
    {
      "source": "P/Q-type voltage gated Ca(2+) channels",
      "target": "action potential generation",
      "label": "play a role in"
    },
    {
      "source": "differential responses",
      "target": "\u03c9-agatoxin IVA",
      "label": "are in response to"
    },
    {
      "source": "differential responses",
      "target": "murine frontal cortex",
      "label": "are in"
    },
    {
      "source": "differential responses",
      "target": "inhibitory neuronal populations",
      "label": "are from"
    },
    {
      "source": "differential responses",
      "target": "neuronal networks",
      "label": "are in"
    },
    {
      "source": "differential responses",
      "target": "spinal cord",
      "label": "are in"
    },
    {
      "source": "differential responses",
      "target": "excitatory neuronal populations",
      "label": "are from"
    },
    {
      "source": "bicuculline",
      "target": "single response",
      "label": "isolated"
    },
    {
      "source": "bicuculline",
      "target": "GABAA inhibitor",
      "label": "is a"
    },
    {
      "source": "single response",
      "target": "\u03c9-agatoxin",
      "label": "is to"
    },
    {
      "source": "single response",
      "target": "reduction",
      "label": "is characterized by"
    },
    {
      "source": "action potential firing rate",
      "target": "unique clusters",
      "label": "can be separated as"
    },
    {
      "source": "statistically significant effects",
      "target": "activity",
      "label": "are on"
    },
    {
      "source": "microelectrode arrays (MEAs)",
      "target": "neurotoxin",
      "label": "are a tool for examining"
    },
    {
      "source": "extracellular action potentials",
      "target": "synaptic function",
      "label": "are dependent on"
    },
    {
      "source": "LB-4b",
      "target": "anti-angiogenesis effects",
      "label": "evaluated for"
    },
    {
      "source": "LB-4b",
      "target": "IC50",
      "label": "has"
    },
    {
      "source": "LB-4b",
      "target": "block effects",
      "label": "has"
    },
    {
      "source": "LB-4b",
      "target": "bestatin",
      "label": "has more significant block effects than"
    },
    {
      "source": "LB-4b",
      "target": "synthetic APN inhibitor",
      "label": "is a"
    },
    {
      "source": "LB-4b",
      "target": "anti-invasion effects",
      "label": "evaluated for"
    },
    {
      "source": "LB-4b",
      "target": "potent synthetic APN inhibitor",
      "label": "is a"
    },
    {
      "source": "LB-4b",
      "target": "high total yield",
      "label": "is synthesized with"
    },
    {
      "source": "LB-4b",
      "target": "anticancer agent",
      "label": "is a potential"
    },
    {
      "source": "block effects",
      "target": "angiogenesis",
      "label": "on"
    },
    {
      "source": "block effects",
      "target": "cancer cell invasion",
      "label": "on"
    },
    {
      "source": "APN inhibitors",
      "target": "anticancer agent",
      "label": "are considered as potential"
    },
    {
      "source": "synthetic methods",
      "target": "bestatin",
      "label": "are for"
    },
    {
      "source": "modification of dopamine levels",
      "target": "striatum",
      "label": "in"
    },
    {
      "source": "Microglia",
      "target": "PQ-treated mice",
      "label": "were not activated in"
    },
    {
      "source": "Microglia",
      "target": "IBA-1 immunoreactivity",
      "label": "identified by"
    },
    {
      "source": "Microglia",
      "target": "hours",
      "label": "activated within"
    },
    {
      "source": "PQ-treated mice",
      "target": "hours",
      "label": "were assessed after"
    },
    {
      "source": "PQ-treated mice",
      "target": "doses of PQ",
      "label": "were assessed after"
    },
    {
      "source": "dopamine turnover",
      "target": "striatum",
      "label": "in"
    },
    {
      "source": "dopamine turnover",
      "target": "dosing",
      "label": "increased after"
    },
    {
      "source": "fluorescent-tagged antibodies",
      "target": "tyrosine hydroxylase",
      "label": "target"
    },
    {
      "source": "degenerating neuronal processes",
      "target": "substantia nigra pars compacta",
      "label": "increased in"
    },
    {
      "source": "degenerating neuronal processes",
      "target": "striatum",
      "label": "increased in"
    },
    {
      "source": "degenerating neuronal processes",
      "target": "reduced immunolabeling",
      "label": "indicated by absence of"
    },
    {
      "source": "degenerating neuronal processes",
      "target": "uptake of silver stain",
      "label": "indicated by absence of"
    },
    {
      "source": "HVA",
      "target": "striatium",
      "label": "measured in"
    },
    {
      "source": "HVA",
      "target": "deamination",
      "label": "derived from"
    },
    {
      "source": "HVA",
      "target": "plasma",
      "label": "measured in"
    },
    {
      "source": "HVA",
      "target": "treatment",
      "label": "after"
    },
    {
      "source": "paraquat dichloride",
      "target": "PQ",
      "label": "is also known as"
    },
    {
      "source": "neurotoxicity",
      "target": "administration",
      "label": "were assessed following"
    },
    {
      "source": "neurotoxicity",
      "target": "paraquat dichloride",
      "label": "of"
    },
    {
      "source": "DOPAC",
      "target": "striatium",
      "label": "measured in"
    },
    {
      "source": "DOPAC",
      "target": "plasma",
      "label": "measured in"
    },
    {
      "source": "DOPAC",
      "target": "cells",
      "label": "derived from"
    },
    {
      "source": "DOPAC concentrations",
      "target": "dosing",
      "label": "reduced after"
    },
    {
      "source": "chromogenic antibodies",
      "target": "tyrosine hydroxylase",
      "label": "target"
    },
    {
      "source": "neuronal degeneration",
      "target": "uptake of silver stain",
      "label": "indicated by absence of"
    },
    {
      "source": "neuronal degeneration",
      "target": "substantia nigra pars compacta",
      "label": "in"
    },
    {
      "source": "neuronal degeneration",
      "target": "reduced immunolabeling",
      "label": "indicated by absence of"
    },
    {
      "source": "astrocytic response",
      "target": "hours",
      "label": "continued through"
    },
    {
      "source": "astrocytic response",
      "target": "striatum",
      "label": "in"
    },
    {
      "source": "DA concentrations",
      "target": "dosing",
      "label": "reduced after"
    },
    {
      "source": "apparent phenotypic change",
      "target": "modification of dopamine levels",
      "label": "unaccompanied by"
    },
    {
      "source": "apparent phenotypic change",
      "target": "neuronal cell death",
      "label": "unaccompanied by"
    },
    {
      "source": "previous published stereological studies",
      "target": "loss of TH(+) neurons",
      "label": "report"
    },
    {
      "source": "inconsistent stereological evidence",
      "target": "loss of DA neurons",
      "label": "of"
    },
    {
      "source": "loss of DA neurons",
      "target": "chromogenic antibodies",
      "label": "identified by"
    },
    {
      "source": "loss of DA neurons",
      "target": "substantia nigra pars compacta",
      "label": "in"
    },
    {
      "source": "loss of DA neurons",
      "target": "fluorescent-tagged antibodies",
      "label": "identified by"
    },
    {
      "source": "number of TH(+) neurons",
      "target": "substantia nigra pars compacta",
      "label": "reduced in"
    },
    {
      "source": "reduced immunolabeling",
      "target": "tyrosine-hydroxylase-positive neurons",
      "label": "of"
    },
    {
      "source": "tyrosine-hydroxylase-positive neurons",
      "target": "TH(+) neurons",
      "label": "are also known as"
    },
    {
      "source": "microglial response",
      "target": "substantia nigra pars compacta",
      "label": "in"
    },
    {
      "source": "microglial response",
      "target": "hours",
      "label": "ended by"
    },
    {
      "source": "MPTP-mediated cell death",
      "target": "apoptosis",
      "label": "not attributed to"
    },
    {
      "source": "administered dose",
      "target": "half-life",
      "label": "has"
    },
    {
      "source": "administered dose",
      "target": "brain",
      "label": "taken up by"
    },
    {
      "source": "loss of TH(+) neurons",
      "target": "PQ-treated mice",
      "label": "in"
    },
    {
      "source": "loss of TH(+) neurons",
      "target": "substantia nigra pars compacta",
      "label": "in"
    },
    {
      "source": "degenerating neurons",
      "target": "striatum",
      "label": "increased in"
    },
    {
      "source": "degenerating neurons",
      "target": "substantia nigra pars compacta",
      "label": "increased in"
    },
    {
      "source": "stereological studies",
      "target": "potential effects",
      "label": "on"
    },
    {
      "source": "Pharmacokinetic studies",
      "target": "potential effects",
      "label": "on"
    },
    {
      "source": "reduction in TH(+) neurons",
      "target": "PQ-treated mice",
      "label": "occurs in"
    },
    {
      "source": "neurochemical studies",
      "target": "potential effects",
      "label": "on"
    },
    {
      "source": "neuropathological studies",
      "target": "potential effects",
      "label": "on"
    },
    {
      "source": "innovative in vitro HTS assay",
      "target": "640 FDA drugs",
      "label": "used for evaluation of"
    },
    {
      "source": "innovative in vitro HTS assay",
      "target": "CD4(+)Foxp3(+) regulatory T cells",
      "label": "used for evaluation of effect on"
    },
    {
      "source": "innovative in vitro HTS assay",
      "target": "CD4(+) T cells",
      "label": "uses"
    },
    {
      "source": "640 FDA drugs",
      "target": "CD4(+)Foxp3(+) regulatory T cells",
      "label": "evaluated for effect on"
    },
    {
      "source": "novel chemical entities",
      "target": "Treg-based immune therapies",
      "label": "for"
    },
    {
      "source": "regulatory T cells (Treg)",
      "target": "proliferation",
      "label": "suppress"
    },
    {
      "source": "regulatory T cells (Treg)",
      "target": "therapeutic potential",
      "label": "have"
    },
    {
      "source": "regulatory T cells (Treg)",
      "target": "immune homeostasis",
      "label": "maintain"
    },
    {
      "source": "75 drugs",
      "target": "Treg numbers",
      "label": "increased"
    },
    {
      "source": "75 drugs",
      "target": "TGF\u03b2",
      "label": "increased Treg numbers in absence of"
    },
    {
      "source": "GFP signal",
      "target": "Foxp3(+) Treg cells",
      "label": "in"
    },
    {
      "source": "Foxp3(+) Treg cells",
      "target": "FACS analysis",
      "label": "detectable by"
    },
    {
      "source": "32 drugs",
      "target": "TGF\u03b2",
      "label": "increased Treg numbers synergistically with"
    },
    {
      "source": "32 drugs",
      "target": "Treg numbers",
      "label": "increased"
    },
    {
      "source": "Treg-promoting drugs",
      "target": "drugs",
      "label": "include"
    },
    {
      "source": "Treg-promoting drugs",
      "target": "retinoic acid",
      "label": "include"
    },
    {
      "source": "Treg-promoting drugs",
      "target": "rapamycin",
      "label": "include"
    },
    {
      "source": "Treg-promoting drugs",
      "target": "glucocorticoids",
      "label": "include"
    },
    {
      "source": "Treg-promoting drugs",
      "target": "statins",
      "label": "include"
    },
    {
      "source": "70 drugs",
      "target": "TGF\u03b2",
      "label": "increased Treg cells in presence of"
    },
    {
      "source": "70 drugs",
      "target": "Treg cells",
      "label": "increased"
    },
    {
      "source": "high throughput screening (HTS) strategies",
      "target": "novel drug candidates",
      "label": "for identification of"
    },
    {
      "source": "high throughput screening (HTS) strategies",
      "target": "existing drugs",
      "label": "for evaluation of"
    },
    {
      "source": "surface and intracellular markers",
      "target": "natural Treg cells",
      "label": "characteristic of"
    },
    {
      "source": "CD4(+) T cells",
      "target": "Foxp3-GFP transgenic mice",
      "label": "from"
    },
    {
      "source": "Foxp3-GFP transgenic mice",
      "target": "GFP signal",
      "label": "express"
    },
    {
      "source": "clinical application",
      "target": "high throughput screening (HTS) strategies",
      "label": "hampered by lack of"
    },
    {
      "source": "Treg HTS assay",
      "target": "novel chemical entities",
      "label": "can be used to identify"
    },
    {
      "source": "Treg HTS assay",
      "target": "compound libraries",
      "label": "can be used to screen"
    },
    {
      "source": "novel series",
      "target": "ATP-competitive Janus kinase 3 (JAK3) inhibitors",
      "label": "of"
    },
    {
      "source": "novel series",
      "target": "5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers",
      "label": "of"
    },
    {
      "source": "ATP-competitive Janus kinase 3 (JAK3) inhibitors",
      "target": "Janus kinase 3",
      "label": "inhibit"
    },
    {
      "source": "ATP-competitive Janus kinase 3 (JAK3) inhibitors",
      "target": "5H-pyrrolo[2,3-b]pyrazine scaffold",
      "label": "based on"
    },
    {
      "source": "ATP-competitive Janus kinase 3 (JAK3) inhibitors",
      "target": "JAK3",
      "label": "inhibit"
    },
    {
      "source": "5H-pyrrolo[2,3-b]pyrazine-2-phenyl ethers",
      "target": "JAK3 kinase inhibitors",
      "label": "are"
    },
    {
      "source": "JAK3 kinase inhibitors",
      "target": "JAK3",
      "label": "inhibit"
    },
    {
      "source": "phenyl ether moiety",
      "target": "vector",
      "label": "possessed"
    },
    {
      "source": "vector",
      "target": "selectivity",
      "label": "to achieve"
    },
    {
      "source": "12b",
      "target": "potent JAK3 inhibitors",
      "label": "are"
    },
    {
      "source": "12b",
      "target": "kinase selectivity",
      "label": "demonstrated improved"
    },
    {
      "source": "12b",
      "target": "JAK family selectivity",
      "label": "demonstrated improved"
    },
    {
      "source": "potent JAK3 inhibitors",
      "target": "JAK3",
      "label": "inhibit"
    },
    {
      "source": "initial leads",
      "target": "compounds 1a",
      "label": "include"
    },
    {
      "source": "initial leads",
      "target": "compounds 1h",
      "label": "include"
    },
    {
      "source": "initial leads",
      "target": "series",
      "label": "in"
    },
    {
      "source": "compounds 1a",
      "target": "selectivity",
      "label": "lacked"
    },
    {
      "source": "compounds 1a",
      "target": "potencies",
      "label": "showed"
    },
    {
      "source": "compounds 1h",
      "target": "selectivity",
      "label": "lacked"
    },
    {
      "source": "compounds 1h",
      "target": "potencies",
      "label": "showed"
    },
    {
      "source": "12d",
      "target": "potent JAK3 inhibitors",
      "label": "are"
    },
    {
      "source": "12d",
      "target": "kinase selectivity",
      "label": "demonstrated improved"
    },
    {
      "source": "12d",
      "target": "JAK family selectivity",
      "label": "demonstrated improved"
    },
    {
      "source": "Computational and crystallographic analysis",
      "target": "phenyl ether moiety",
      "label": "suggested"
    },
    {
      "source": "Exploration",
      "target": "identification",
      "label": "resulted in"
    },
    {
      "source": "Exploration",
      "target": "vector",
      "label": "of"
    },
    {
      "source": "Discovery",
      "target": "novel series",
      "label": "of"
    },
    {
      "source": "interparticle spacing",
      "target": "Particle Size",
      "label": "is inversely dependent on"
    },
    {
      "source": "interparticle spacing",
      "target": "small-angle X-ray scattering measurements",
      "label": "studied with"
    },
    {
      "source": "interparticle spacing",
      "target": "equilibrium configuration",
      "label": "can reveal"
    },
    {
      "source": "interparticle spacing",
      "target": "assemblies",
      "label": "is of"
    },
    {
      "source": "equilibrium configuration",
      "target": "IgG",
      "label": "is of"
    },
    {
      "source": "peptide-capped particles",
      "target": "expanded hybrid material",
      "label": "form"
    },
    {
      "source": "peptide-capped particles",
      "target": "antibody",
      "label": "recognized by"
    },
    {
      "source": "peptide-capped particles",
      "target": "dimers",
      "label": "form"
    },
    {
      "source": "peptide-capped particles",
      "target": "sizes",
      "label": "have"
    },
    {
      "source": "expanded hybrid material",
      "target": "conditions",
      "label": "formed by controlling"
    },
    {
      "source": "Controlled Assembly",
      "target": "Antibody Recognition",
      "label": "achieved through"
    },
    {
      "source": "Controlled Assembly",
      "target": "Gold Nanoparticles",
      "label": "involves"
    },
    {
      "source": "Fab-Fab angle",
      "target": "IgG",
      "label": "is of"
    },
    {
      "source": "Fab-Fab angle",
      "target": "investigation",
      "label": "obtained based on"
    },
    {
      "source": "Fab arms",
      "target": "investigation",
      "label": "obtained based on"
    },
    {
      "source": "wnk8 mutant",
      "target": "severe salinity",
      "label": "more tolerant to"
    },
    {
      "source": "wnk8 mutant",
      "target": "Catalase activity",
      "label": "has higher"
    },
    {
      "source": "wnk8 mutant",
      "target": "Peroxidase activity",
      "label": "has higher"
    },
    {
      "source": "wnk8 mutant",
      "target": "Proline",
      "label": "accumulates"
    },
    {
      "source": "wnk8 mutant",
      "target": "Osmotic stresses",
      "label": "more tolerant to"
    },
    {
      "source": "WNKs",
      "target": "plant growth",
      "label": "plays role in"
    },
    {
      "source": "WNKs",
      "target": "development",
      "label": "plays role in"
    },
    {
      "source": "AtWNK8",
      "target": "hypocotyl",
      "label": "expressed in"
    },
    {
      "source": "AtWNK8",
      "target": "sorbitol treatment",
      "label": "induced by"
    },
    {
      "source": "AtWNK8",
      "target": "pistil",
      "label": "expressed in"
    },
    {
      "source": "AtWNK8",
      "target": "salt stress tolerance",
      "label": "enhances"
    },
    {
      "source": "AtWNK8",
      "target": "Catalase activity",
      "label": "modulates"
    },
    {
      "source": "AtWNK8",
      "target": "stamen",
      "label": "expressed in"
    },
    {
      "source": "AtWNK8",
      "target": "Proline content",
      "label": "modulates"
    },
    {
      "source": "AtWNK8",
      "target": "osmotic stress tolerance",
      "label": "enhances"
    },
    {
      "source": "AtWNK8",
      "target": "tolerance",
      "label": "enhances"
    },
    {
      "source": "AtWNK8",
      "target": "NaCl treatment",
      "label": "induced by"
    },
    {
      "source": "AtWNK8",
      "target": "Peroxidase activity",
      "label": "modulates"
    },
    {
      "source": "AtWNK8",
      "target": "primary root",
      "label": "expressed in"
    },
    {
      "source": "Catalase activity",
      "target": "salt stress tolerance",
      "label": "contributes to"
    },
    {
      "source": "Catalase activity",
      "target": "osmotic stress tolerance",
      "label": "contributes to"
    },
    {
      "source": "Peroxidase activity",
      "target": "osmotic stress tolerance",
      "label": "contributes to"
    },
    {
      "source": "Peroxidase activity",
      "target": "salt stress tolerance",
      "label": "contributes to"
    },
    {
      "source": "With no lysine kinases",
      "target": "development",
      "label": "plays role in"
    },
    {
      "source": "With no lysine kinases",
      "target": "plant growth",
      "label": "plays role in"
    },
    {
      "source": "Proline content",
      "target": "osmotic stress tolerance",
      "label": "contributes to"
    },
    {
      "source": "2'-aminoanilides",
      "target": "tert-butylcarbamate group",
      "label": "bear"
    },
    {
      "source": "2'-aminoanilides",
      "target": "histone deacetylase inhibitors",
      "label": "are"
    },
    {
      "source": "tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors",
      "target": "Apoptosis Induction",
      "label": "induces"
    },
    {
      "source": "tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors",
      "target": "Cytodifferentiation",
      "label": "induces"
    },
    {
      "source": "tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors",
      "target": "Antiproliferative Activities",
      "label": "exhibits"
    },
    {
      "source": "colony-forming potential",
      "target": "Cancer Cells",
      "label": "of"
    },
    {
      "source": "pyrrole-based hydroxamates",
      "target": "tert-butylcarbamate group",
      "label": "bear"
    },
    {
      "source": "pyrrole-based hydroxamates",
      "target": "histone deacetylase inhibitors",
      "label": "are"
    },
    {
      "source": "histone H3 acetylation",
      "target": "HT29 cancer cells",
      "label": "occurred in"
    },
    {
      "source": "Compound 10c",
      "target": "apoptosis",
      "label": "elicited"
    },
    {
      "source": "Compound 10c",
      "target": "HDAC6",
      "label": "inhibited"
    },
    {
      "source": "Compound 10c",
      "target": "histone H3 acetylation",
      "label": "increased"
    },
    {
      "source": "Compound 10c",
      "target": "colony-forming potential",
      "label": "decreased"
    },
    {
      "source": "Compound 10c",
      "target": "growth inhibition",
      "label": "exhibited"
    },
    {
      "source": "Compound 10c",
      "target": "antiproliferative effects",
      "label": "exhibited"
    },
    {
      "source": "Antiproliferative Activities",
      "target": "Cancer Cells",
      "label": "occurs in"
    },
    {
      "source": "benzene-based hydroxamates",
      "target": "tert-butylcarbamate group",
      "label": "bear"
    },
    {
      "source": "benzene-based hydroxamates",
      "target": "histone deacetylase inhibitors",
      "label": "are"
    },
    {
      "source": "acetyl-\u03b1-tubulin levels",
      "target": "human acute myeloid leukemia U937 cells",
      "label": "increased in"
    },
    {
      "source": "Compound 8b",
      "target": "apoptosis",
      "label": "elicited"
    },
    {
      "source": "Compound 8b",
      "target": "HDAC6",
      "label": "inhibited"
    },
    {
      "source": "hydroxamates",
      "target": "acetyl-\u03b1-tubulin levels",
      "label": "increased"
    },
    {
      "source": "hydroxamates",
      "target": "MMPIs",
      "label": "is a type of"
    },
    {
      "source": "SAHA",
      "target": "apoptosis",
      "label": "elicited"
    },
    {
      "source": "pyrrole anilide 9c",
      "target": "cytodifferentiating effect",
      "label": "displayed"
    },
    {
      "source": "Blood",
      "target": "12 weeks",
      "label": "removed after"
    },
    {
      "source": "Experiment 1",
      "target": "CE",
      "label": "includes"
    },
    {
      "source": "Experiment 1",
      "target": "C",
      "label": "includes"
    },
    {
      "source": "Experiment 1",
      "target": "H",
      "label": "includes"
    },
    {
      "source": "Experiment 1",
      "target": "HE",
      "label": "includes"
    },
    {
      "source": "Experiment 2",
      "target": "CIE",
      "label": "includes"
    },
    {
      "source": "Experiment 2",
      "target": "CI",
      "label": "includes"
    },
    {
      "source": "Experiment 2",
      "target": "HI",
      "label": "includes"
    },
    {
      "source": "Experiment 2",
      "target": "HIE",
      "label": "includes"
    },
    {
      "source": "CIE",
      "target": "CI",
      "label": "includes"
    },
    {
      "source": "CIE",
      "target": "ezetimibe",
      "label": "includes"
    },
    {
      "source": "HE",
      "target": "hepcidin",
      "label": "increases mRNA of"
    },
    {
      "source": "HE",
      "target": "ezetimibe",
      "label": "includes"
    },
    {
      "source": "HE",
      "target": "H",
      "label": "includes"
    },
    {
      "source": "HE",
      "target": "HEPATIC IRON LEVELS",
      "label": "increases"
    },
    {
      "source": "HE",
      "target": "ferritins",
      "label": "increases mRNA of"
    },
    {
      "source": "HE",
      "target": "transferrin receptor 1 and 2",
      "label": "increases mRNA of"
    },
    {
      "source": "carbonyl iron",
      "target": "22.4mg/day",
      "label": "has dosage"
    },
    {
      "source": "Phlebotomy",
      "target": "serum transaminase",
      "label": "reduces"
    },
    {
      "source": "EZETIMIBE",
      "target": "HEPATIC IRON LEVELS",
      "label": "increases"
    },
    {
      "source": "C",
      "target": "control diet",
      "label": "is"
    },
    {
      "source": "hepatic iron uptake transporter expression",
      "target": "hepatic iron concentrations",
      "label": "causes increased"
    },
    {
      "source": "HIE",
      "target": "hepatic iron concentrations",
      "label": "increases"
    },
    {
      "source": "HIE",
      "target": "ferritinL",
      "label": "increases mRNA of"
    },
    {
      "source": "HIE",
      "target": "hepcidin",
      "label": "increases mRNA of"
    },
    {
      "source": "HIE",
      "target": "ezetimibe",
      "label": "includes"
    },
    {
      "source": "HIE",
      "target": "HI",
      "label": "includes"
    },
    {
      "source": "dietary iron restriction",
      "target": "serum transaminase",
      "label": "reduces"
    },
    {
      "source": "MICE",
      "target": "HIGH-FAT DIET",
      "label": "fed"
    },
    {
      "source": "MICE",
      "target": "iron",
      "label": "fed"
    },
    {
      "source": "iron metabolism",
      "target": "lipid metabolism",
      "label": "interacts with"
    },
    {
      "source": "ATO",
      "target": "Notch signaling blockade",
      "label": "acted through"
    },
    {
      "source": "ATO",
      "target": "Notch pathway",
      "label": "downregulates"
    },
    {
      "source": "ATO",
      "target": "activation",
      "label": "inhibited"
    },
    {
      "source": "ATO",
      "target": "CSLCs",
      "label": "depleted"
    },
    {
      "source": "ATO",
      "target": "glioblastoma proliferation",
      "label": "decreases"
    },
    {
      "source": "ATO",
      "target": "neurosphere recovery",
      "label": "inhibited"
    },
    {
      "source": "ATO",
      "target": "secondary neurosphere formation",
      "label": "inhibited"
    },
    {
      "source": "ATO",
      "target": "phosphorylation",
      "label": "inhibited"
    },
    {
      "source": "ATO",
      "target": "recurrence",
      "label": "decreases"
    },
    {
      "source": "repopulation",
      "target": "neurosphere",
      "label": "of"
    },
    {
      "source": "repopulation",
      "target": "ATO treatment",
      "label": "occurs after"
    },
    {
      "source": "neurosphere",
      "target": "glioblastoma",
      "label": "derived from"
    },
    {
      "source": "downregulation",
      "target": "Notch pathway",
      "label": "of"
    },
    {
      "source": "downregulation",
      "target": "oocyte cell death",
      "label": "contributes to"
    },
    {
      "source": "downregulation",
      "target": "TAp63",
      "label": "of"
    },
    {
      "source": "CSLCs",
      "target": "glioblastoma cell lines",
      "label": "are found in"
    },
    {
      "source": "CSLCs",
      "target": "GBM",
      "label": "are found in"
    },
    {
      "source": "neurosphere recovery assay",
      "target": "neurosphere formation",
      "label": "measured"
    },
    {
      "source": "Arsenic trioxide",
      "target": "Notch pathway",
      "label": "downregulates"
    },
    {
      "source": "Arsenic trioxide",
      "target": "repopulation",
      "label": "inhibits"
    },
    {
      "source": "Arsenic trioxide",
      "target": "cancer stem-like cells",
      "label": "depletes"
    },
    {
      "source": "Notch signaling",
      "target": "cancer stem-like cells",
      "label": "has central role in"
    },
    {
      "source": "cancer stem-like cells",
      "target": "glioblastoma multiforme",
      "label": "are found in"
    },
    {
      "source": "STAT3",
      "target": "IL-6 signaling pathways",
      "label": "is phosphorylated by"
    },
    {
      "source": "STAT3",
      "target": "Th17 differentiation",
      "label": "is necessary for"
    },
    {
      "source": "rat bone marrow mesenchymal stem cells",
      "target": "rBMSCs",
      "label": "is"
    },
    {
      "source": "tPNS",
      "target": "expression",
      "label": "up-regulate"
    },
    {
      "source": "tPNS",
      "target": "angiogenesis",
      "label": "promote"
    },
    {
      "source": "tPNS",
      "target": "secretion",
      "label": "increase"
    },
    {
      "source": "tPNS",
      "target": "main constituents",
      "label": "are"
    },
    {
      "source": "tPNS",
      "target": "capillary network forming",
      "label": "increased"
    },
    {
      "source": "tPNS",
      "target": "protein expression",
      "label": "increase"
    },
    {
      "source": "tPNS",
      "target": "mRNA expression levels",
      "label": "enhanced"
    },
    {
      "source": "rBMSCs",
      "target": "endothelial-like cells",
      "label": "induced to differentiate into"
    },
    {
      "source": "rBMSCs",
      "target": "tPNS",
      "label": "stimulated by"
    },
    {
      "source": "implantation",
      "target": "rBMSCs",
      "label": "of"
    },
    {
      "source": "implantation",
      "target": "Matrigel model",
      "label": "with"
    },
    {
      "source": "Total saponins of Panax notoginseng",
      "target": "angiogenesis",
      "label": "promote"
    },
    {
      "source": "Total saponins of Panax notoginseng",
      "target": "relative receptors signals",
      "label": "enhance"
    },
    {
      "source": "Total saponins of Panax notoginseng",
      "target": "tPNS",
      "label": "is"
    },
    {
      "source": "Total saponins of Panax notoginseng",
      "target": "VEGF",
      "label": "enhance"
    },
    {
      "source": "angiogenesis ability",
      "target": "Matrigel model",
      "label": "assayed by"
    },
    {
      "source": "angiogenesis ability",
      "target": "rBMSCs",
      "label": "of"
    },
    {
      "source": "Matrigel model",
      "target": "vitro",
      "label": "used in"
    },
    {
      "source": "Matrigel model",
      "target": "vivo",
      "label": "used in"
    },
    {
      "source": "capillary network forming",
      "target": "rBMSCs",
      "label": "of"
    },
    {
      "source": "capillary network forming",
      "target": "vitro",
      "label": "in"
    },
    {
      "source": "main constituents",
      "target": "Panax Notoginseng",
      "label": "extracted from"
    },
    {
      "source": "Panax Notoginseng",
      "target": "traditional Chinese medicine",
      "label": "is a"
    },
    {
      "source": "AIMS OF THE STUDY",
      "target": "effects",
      "label": "concern"
    },
    {
      "source": "MAP3K5 expression",
      "target": "high fetal hemoglobin (HbF)",
      "label": "is studied in context of"
    },
    {
      "source": "MAP3K5 expression",
      "target": "HU treatment",
      "label": "is studied upon"
    },
    {
      "source": "MAP3K5 expression",
      "target": "erythroid progenitor cells",
      "label": "is studied in"
    },
    {
      "source": "disease severity",
      "target": "\u03b2-hemoglobinopathy patients",
      "label": "occurs in"
    },
    {
      "source": "PDE7B variant",
      "target": "severe disease phenotype",
      "label": "is associated with"
    },
    {
      "source": "PDE7B variant",
      "target": "low HbF levels",
      "label": "is associated with"
    },
    {
      "source": "genetic variations",
      "target": "\u03b2-thalassemia disease severity",
      "label": "is associated with"
    },
    {
      "source": "genetic variations",
      "target": "disease severity",
      "label": "are associated with"
    },
    {
      "source": "genetic variations",
      "target": "hydroxyurea treatment efficacy",
      "label": "is associated with"
    },
    {
      "source": "genetic variations",
      "target": "MAP3K5",
      "label": "are in"
    },
    {
      "source": "genetic variations",
      "target": "PDE7B genes",
      "label": "are in"
    },
    {
      "source": "genetic variations",
      "target": "MAP3K5 gene",
      "label": "are in"
    },
    {
      "source": "intronic MAP3K5 gene variants",
      "target": "low HbF levels",
      "label": "is associated with"
    },
    {
      "source": "intronic MAP3K5 gene variants",
      "target": "severe disease phenotype",
      "label": "is associated with"
    },
    {
      "source": "intronic MAP3K5 gene variants",
      "target": "MAP3K5 gene",
      "label": "are in"
    },
    {
      "source": "MAP3K5 mRNA expression levels",
      "target": "high fetal hemoglobin (HbF)",
      "label": "are altered by"
    },
    {
      "source": "MAP3K5 mRNA expression levels",
      "target": "HU",
      "label": "are affected by"
    },
    {
      "source": "compound heterozygous sickle cell disease/\u03b2-thalassemia patients",
      "target": "HU",
      "label": "receive"
    },
    {
      "source": "erythroid progenitor cells",
      "target": "KLF1 haploinsufficient individuals",
      "label": "are from"
    },
    {
      "source": "erythroid progenitor cells",
      "target": "healthy individuals",
      "label": "are from"
    },
    {
      "source": "MAP3K5",
      "target": "chromosome 6q23",
      "label": "resides on"
    },
    {
      "source": "short tandem repeat",
      "target": "low HbF levels",
      "label": "is associated with"
    },
    {
      "source": "short tandem repeat",
      "target": "MAP3K5 promoter",
      "label": "is in"
    },
    {
      "source": "short tandem repeat",
      "target": "severe disease phenotype",
      "label": "is associated with"
    },
    {
      "source": "PDE7B genes",
      "target": "chromosome 6q23",
      "label": "resides on"
    },
    {
      "source": "HTS campaign",
      "target": "M5 PAMs",
      "label": "identified"
    },
    {
      "source": "M5 PAMs",
      "target": "M5 EC50",
      "label": "have"
    },
    {
      "source": "M5 PAMs",
      "target": "isatin core",
      "label": "have"
    },
    {
      "source": "VU0467903",
      "target": "ML326",
      "label": "also known as"
    },
    {
      "source": "ML326",
      "target": "VU0467903",
      "label": "also known as"
    },
    {
      "source": "ML326",
      "target": "mAChR",
      "label": "is selective for"
    },
    {
      "source": "ML326",
      "target": "M1-M4 EC50s",
      "label": "has"
    },
    {
      "source": "ML326",
      "target": "human M5 EC50s",
      "label": "has"
    },
    {
      "source": "ML326",
      "target": "M5 PAM",
      "label": "is a"
    },
    {
      "source": "ML326",
      "target": "rat M5 EC50s",
      "label": "has"
    },
    {
      "source": "ML326",
      "target": "ACh CRC",
      "label": "affects"
    },
    {
      "source": "phenethyl ether linkage",
      "target": "ML129/ML172 cores",
      "label": "grafted onto"
    },
    {
      "source": "ML129",
      "target": "MLPCN probes",
      "label": "is a"
    },
    {
      "source": "MLPCN probes",
      "target": "M5 PAM",
      "label": "are a"
    },
    {
      "source": "isatin core",
      "target": "southern phenethyl ether linkage",
      "label": "has"
    },
    {
      "source": "ML172",
      "target": "MLPCN probes",
      "label": "is a"
    },
    {
      "source": "RXFP2 mRNA",
      "target": "TIC",
      "label": "levels are higher in"
    },
    {
      "source": "RXFP2 mRNA",
      "target": "granulosa cell",
      "label": "levels are lower in"
    },
    {
      "source": "RXFP2 mRNA",
      "target": "follicle maturation",
      "label": "increase during"
    },
    {
      "source": "INSL3 mRNA",
      "target": "TIC",
      "label": "levels are higher in"
    },
    {
      "source": "INSL3 mRNA",
      "target": "granulosa cell",
      "label": "levels are lower in"
    },
    {
      "source": "INSL3 mRNA",
      "target": "follicle maturation",
      "label": "increase during"
    },
    {
      "source": "luteinization",
      "target": "preovulatory LH surge",
      "label": "induced by"
    },
    {
      "source": "INSL3",
      "target": "LH surge",
      "label": "fell after"
    },
    {
      "source": "INSL3",
      "target": "developing bovine antral follicles",
      "label": "expression quantified in"
    },
    {
      "source": "INSL3",
      "target": "luteolysis",
      "label": "increased after"
    },
    {
      "source": "INSL3",
      "target": "testicular Leydig cells",
      "label": "is a product of"
    },
    {
      "source": "INSL3",
      "target": "steroidogenesis",
      "label": "is intrafollicular modulator of"
    },
    {
      "source": "INSL3",
      "target": "CL function",
      "label": "has potential contribution to"
    },
    {
      "source": "INSL3",
      "target": "CL",
      "label": "expression is lower in"
    },
    {
      "source": "INSL3",
      "target": "theca interna cell",
      "label": "expression quantified in"
    },
    {
      "source": "INSL3",
      "target": "TIC function",
      "label": "is intrafollicular modulator of"
    },
    {
      "source": "INSL3",
      "target": "granulosa cell",
      "label": "expression quantified in"
    },
    {
      "source": "INSL3",
      "target": "TIC",
      "label": "expression is higher in"
    },
    {
      "source": "INSL3",
      "target": "Corpora Lutea",
      "label": "expression quantified in"
    },
    {
      "source": "INSL3",
      "target": "large (11-18 mm) estrogen-active follicles",
      "label": "peaks in"
    },
    {
      "source": "In situ hybridization",
      "target": "INSL3 mRNA",
      "label": "confirmed expression of"
    },
    {
      "source": "In situ hybridization",
      "target": "expression",
      "label": "showed"
    },
    {
      "source": "theca-derived INSL3",
      "target": "dominant preovulatory follicle",
      "label": "is from"
    },
    {
      "source": "theca-derived INSL3",
      "target": "peripheral blood",
      "label": "is detectable in"
    },
    {
      "source": "theca-derived INSL3",
      "target": "luteinization",
      "label": "expression down-regulated during"
    },
    {
      "source": "theca-derived INSL3",
      "target": "cattle",
      "label": "is detectable in"
    },
    {
      "source": "RXFP2",
      "target": "developing bovine antral follicles",
      "label": "expression quantified in"
    },
    {
      "source": "RXFP2",
      "target": "9- to 10-mm follicles",
      "label": "peaks in"
    },
    {
      "source": "RXFP2",
      "target": "theca interna cell",
      "label": "expression quantified in"
    },
    {
      "source": "RXFP2",
      "target": "CL",
      "label": "expression is lower in"
    },
    {
      "source": "RXFP2",
      "target": "granulosa cell",
      "label": "expression quantified in"
    },
    {
      "source": "RXFP2",
      "target": "TIC",
      "label": "expression quantified in"
    },
    {
      "source": "RXFP2",
      "target": "Corpora Lutea",
      "label": "expression quantified in"
    },
    {
      "source": "Insulin-Like Peptide 3",
      "target": "testicular Leydig cells",
      "label": "is a product of"
    },
    {
      "source": "Circulating INSL3 Levels",
      "target": "Synchronized Estrous Cycles",
      "label": "measured during"
    },
    {
      "source": "INSL3 protein",
      "target": "TIC",
      "label": "expressed in"
    },
    {
      "source": "plasma INSL3",
      "target": "Synchronized Estrous Cycles",
      "label": "has cyclic variation during"
    },
    {
      "source": "Ovary",
      "target": "Insulin-Like Peptide 3",
      "label": "expresses"
    },
    {
      "source": "Ovary",
      "target": "RXFP2",
      "label": "expresses"
    },
    {
      "source": "Ovary",
      "target": "INSL3",
      "label": "expresses"
    },
    {
      "source": "estradiol-17\u03b2",
      "target": "luteolysis",
      "label": "increased after"
    },
    {
      "source": "estradiol-17\u03b2",
      "target": "LH surge",
      "label": "fell after"
    },
    {
      "source": "Corpora Lutea",
      "target": "Development",
      "label": "undergo"
    },
    {
      "source": "Bovine Antral Follicles",
      "target": "Development",
      "label": "undergo"
    },
    {
      "source": "follicular TIC",
      "target": "INSL3 action",
      "label": "is primary site of"
    },
    {
      "source": "follicular TIC",
      "target": "INSL3 production",
      "label": "is primary site of"
    },
    {
      "source": "INSL3 action",
      "target": "TIC",
      "label": "has autocrine/paracrine role"
    },
    {
      "source": "Z-stereoisomer 1",
      "target": "UV irradiation",
      "label": "prepared under"
    },
    {
      "source": "Z-stereoisomer 1",
      "target": "time-dependent photoisomerization",
      "label": "prepared by"
    },
    {
      "source": "2,3,5,7-tetramethoxyphenanthrene (5)",
      "target": "NMR spectroscopy",
      "label": "identified by"
    },
    {
      "source": "2,3,5,7-tetramethoxyphenanthrene (5)",
      "target": "UHPLC/APCI-MS",
      "label": "identified by"
    },
    {
      "source": "PMA-induced HL-60 cells",
      "target": "HL-60 cells",
      "label": "derived from"
    },
    {
      "source": "PMA-induced HL-60 cells",
      "target": "PMA",
      "label": "induced by"
    },
    {
      "source": "(Z)- and (E)-3,4,3',5'-Tetramethoxystilbene",
      "target": "Cancer-Related Signaling",
      "label": "modulates"
    },
    {
      "source": "(Z)- and (E)-3,4,3',5'-Tetramethoxystilbene",
      "target": "Modulation",
      "label": "causes"
    },
    {
      "source": "(Z)- and (E)-3,4,3',5'-Tetramethoxystilbene",
      "target": "Eugenia rigida",
      "label": "isolated from"
    },
    {
      "source": "(Z)- and (E)-3,4,3',5'-Tetramethoxystilbene",
      "target": "Cytotoxicity",
      "label": "causes"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "solid tumor cells",
      "label": "cytotoxic toward"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Wnt signaling",
      "label": "inhibits activation of"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "IC50 values",
      "label": "has"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "skin melanoma",
      "label": "cytotoxic toward"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Trolox",
      "label": "inactive compared to"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "myc",
      "label": "inhibits activation of"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Cytotoxicity",
      "label": "demonstrated"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "1D- and 2D-NMR spectroscopy",
      "label": "structure determined using"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Stat3",
      "label": "inhibits activation of"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "luciferase reporter gene assays",
      "label": "tested against"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Ets",
      "label": "inhibits activation of"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Notch",
      "label": "inhibits activation of"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "HRESIMS",
      "label": "structure determined using"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Smad3/4",
      "label": "inhibits activation of"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "human leukemia cells",
      "label": "cytotoxic toward"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "NF-\u03baB signaling",
      "label": "inhibits"
    },
    {
      "source": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "target": "Ap-1",
      "label": "inhibits"
    },
    {
      "source": "solid tumor cells",
      "target": "cervical carcinomas",
      "label": "include"
    },
    {
      "source": "solid tumor cells",
      "target": "breast carcinomas",
      "label": "include"
    },
    {
      "source": "solid tumor cells",
      "target": "epidermal carcinomas",
      "label": "include"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "NF-\u03baB signaling",
      "label": "inhibits"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "Ap-1",
      "label": "inhibits"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "ROS generation",
      "label": "inhibits"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "1D- and 2D-NMR spectroscopy",
      "label": "structure determined using"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "cervical carcinoma",
      "label": "weakly active against"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "luciferase reporter gene assays",
      "label": "tested against"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "skin melanoma cells",
      "label": "weakly active against"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "HRESIMS",
      "label": "structure determined using"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "antioxidant activity",
      "label": "showed"
    },
    {
      "source": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "target": "leukemia",
      "label": "weakly active against"
    },
    {
      "source": "time-dependent photoisomerization",
      "target": "E-isomer (2)",
      "label": "of"
    },
    {
      "source": "Bioassay-guided fractionation",
      "target": "stilbenes",
      "label": "yielded"
    },
    {
      "source": "Bioassay-guided fractionation",
      "target": "leaves of Eugenia rigida",
      "label": "performed on"
    },
    {
      "source": "stilbenes",
      "target": "(E)-3,5,4'-trimethoxystilbene (3)",
      "label": "include"
    },
    {
      "source": "stilbenes",
      "target": "(E)-3,4,3',5'-tetramethoxystilbene (2)",
      "label": "include"
    },
    {
      "source": "stilbenes",
      "target": "(Z)-3,4,3',5'-tetramethoxystilbene (1)",
      "label": "include"
    },
    {
      "source": "(E)-3,5,4'-trimethoxystilbene (3)",
      "target": "1D- and 2D-NMR spectroscopy",
      "label": "structure determined using"
    },
    {
      "source": "(E)-3,5,4'-trimethoxystilbene (3)",
      "target": "luciferase reporter gene assays",
      "label": "tested against"
    },
    {
      "source": "(E)-3,5,4'-trimethoxystilbene (3)",
      "target": "HRESIMS",
      "label": "structure determined using"
    },
    {
      "source": "luciferase reporter gene assays",
      "target": "Cancer-Related Signaling",
      "label": "assess activity of"
    },
    {
      "source": "reproductive competence",
      "target": "male rats",
      "label": "of"
    },
    {
      "source": "impairment",
      "target": "reproductive competence",
      "label": "on"
    },
    {
      "source": "impairment",
      "target": "precocious hormonal injury",
      "label": "occurs after"
    },
    {
      "source": "Androgen deprivation",
      "target": "pre-puberty",
      "label": "occurs from"
    },
    {
      "source": "Androgen deprivation",
      "target": "proteins expression",
      "label": "interferes in"
    },
    {
      "source": "Androgen deprivation",
      "target": "histological organization",
      "label": "did not alter"
    },
    {
      "source": "Androgen deprivation",
      "target": "peripuberty",
      "label": "occurs to"
    },
    {
      "source": "premature antiandrogen exposure",
      "target": "antiandrogen",
      "label": "involves"
    },
    {
      "source": "premature antiandrogen exposure",
      "target": "PND21",
      "label": "occurred from"
    },
    {
      "source": "premature antiandrogen exposure",
      "target": "PND44",
      "label": "occurred to"
    },
    {
      "source": "proteins expression",
      "target": "pubertal rat epididymis",
      "label": "occurs in"
    },
    {
      "source": "proteins expression",
      "target": "adult rat epididymis",
      "label": "occurs in"
    },
    {
      "source": "proteins expression",
      "target": "puberty",
      "label": "occurs at"
    },
    {
      "source": "proteins expression",
      "target": "organs",
      "label": "occurs in"
    },
    {
      "source": "proteins expression",
      "target": "adulthood",
      "label": "occurs at"
    },
    {
      "source": "proteins expression",
      "target": "epididymal tissue",
      "label": "occurs in"
    },
    {
      "source": "fertility capacity",
      "target": "previous study",
      "label": "observed in"
    },
    {
      "source": "histological organization",
      "target": "testes",
      "label": "of"
    },
    {
      "source": "histological organization",
      "target": "puberty",
      "label": "occurred at"
    },
    {
      "source": "histological organization",
      "target": "epididymis",
      "label": "of"
    },
    {
      "source": "histological organization",
      "target": "adulthood",
      "label": "occurred at"
    },
    {
      "source": "specific proteins",
      "target": "Rab11A",
      "label": "includes"
    },
    {
      "source": "specific proteins",
      "target": "calmodulin",
      "label": "includes"
    },
    {
      "source": "specific proteins",
      "target": "androgen receptor",
      "label": "includes"
    },
    {
      "source": "molecular mechanisms",
      "target": "impairment",
      "label": "involved in"
    },
    {
      "source": "molecular mechanisms",
      "target": "MR occupancy",
      "label": "link"
    },
    {
      "source": "molecular mechanisms",
      "target": "collagen deposition",
      "label": "link"
    },
    {
      "source": "experimental testosterone deprivation",
      "target": "immature animals",
      "label": "occurs in"
    },
    {
      "source": "experimental testosterone deprivation",
      "target": "testosterone",
      "label": "involves"
    },
    {
      "source": "impaired epididymal function",
      "target": "previous study",
      "label": "observed in"
    },
    {
      "source": "testosterone",
      "target": "seizure frequency",
      "label": "affects"
    },
    {
      "source": "testosterone",
      "target": "hypogonadism",
      "label": "treats"
    },
    {
      "source": "testosterone",
      "target": "epilepsy",
      "label": "treats"
    },
    {
      "source": "testosterone",
      "target": "sexual function",
      "label": "affects"
    },
    {
      "source": "testosterone",
      "target": "men",
      "label": "treats"
    },
    {
      "source": "testosterone",
      "target": "reproductive and sexual dysfunction",
      "label": "treats"
    },
    {
      "source": "hepatic mRNA expressions",
      "target": "SREBP1C",
      "label": "includes"
    },
    {
      "source": "hepatic mRNA expressions",
      "target": "SCD-1 genes",
      "label": "includes"
    },
    {
      "source": "hepatic mRNA expressions",
      "target": "PPAR\u03b3",
      "label": "includes"
    },
    {
      "source": "fisetin supplementation",
      "target": "hepatic lipogenesis",
      "label": "has effect on"
    },
    {
      "source": "fisetin supplementation",
      "target": "triglyceride (TG)",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "hepatic TG content",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "hepatic mRNA abundance",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "glucose concentrations",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "genes",
      "label": "modulates"
    },
    {
      "source": "fisetin supplementation",
      "target": "ATPCL",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "G6Pase",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "GLUT4",
      "label": "increased"
    },
    {
      "source": "fisetin supplementation",
      "target": "FAS",
      "label": "reduced"
    },
    {
      "source": "fisetin supplementation",
      "target": "glucose metabolism",
      "label": "has effect on"
    },
    {
      "source": "fisetin supplementation",
      "target": "epididymal mRNA abundance",
      "label": "increased"
    },
    {
      "source": "fisetin supplementation",
      "target": "hyperglycemia",
      "label": "modulates"
    },
    {
      "source": "triglyceride (TG)",
      "target": "high fat diet group",
      "label": "present in"
    },
    {
      "source": "hepatic TG content",
      "target": "high fat diet group",
      "label": "present in"
    },
    {
      "source": "high fat diet",
      "target": "hepatic mRNA expressions",
      "label": "increased"
    },
    {
      "source": "Fisetin supplementation",
      "target": "hepatic steatosis",
      "label": "ameliorates"
    },
    {
      "source": "Fisetin supplementation",
      "target": "circulating glucose concentrations",
      "label": "lowers"
    },
    {
      "source": "Fisetin supplementation",
      "target": "cardiovascular risks",
      "label": "decreases"
    },
    {
      "source": "epididymal mRNA abundance",
      "target": "GLUT4",
      "label": "of"
    },
    {
      "source": "hepatic mRNA abundance",
      "target": "ATPCL",
      "label": "of"
    },
    {
      "source": "hepatic mRNA abundance",
      "target": "G6Pase",
      "label": "of"
    },
    {
      "source": "hepatic mRNA abundance",
      "target": "FAS",
      "label": "of"
    },
    {
      "source": "glucose concentrations",
      "target": "high fat diet group",
      "label": "present in"
    },
    {
      "source": "fisetin",
      "target": "SREBP1C",
      "label": "reduced"
    },
    {
      "source": "fisetin",
      "target": "SCD-1 genes",
      "label": "reduced"
    },
    {
      "source": "fisetin",
      "target": "hepatic mRNA expressions",
      "label": "reduced"
    },
    {
      "source": "fisetin",
      "target": "GLUT4 expression",
      "label": "enhanced"
    },
    {
      "source": "fisetin",
      "target": "PPAR\u03b3",
      "label": "reduced"
    },
    {
      "source": "GLUT4 expression",
      "target": "differentiated 3T3-L1 adipocytes",
      "label": "confirmed in"
    },
    {
      "source": "loss of function approach",
      "target": "mechanisms",
      "label": "used to identify"
    },
    {
      "source": "IECs",
      "target": "injury",
      "label": "migrate in response to"
    },
    {
      "source": "IECs",
      "target": "wound closure",
      "label": "migrate to promote"
    },
    {
      "source": "Loss of AnxA2",
      "target": "IEC migration",
      "label": "inhibited"
    },
    {
      "source": "Loss of AnxA2",
      "target": "cell-matrix adhesion",
      "label": "promoted"
    },
    {
      "source": "dynamics of \u03b21 integrin",
      "target": "wound closure",
      "label": "is required for"
    },
    {
      "source": "dynamics of \u03b21 integrin",
      "target": "cell migration",
      "label": "is required for"
    },
    {
      "source": "dynamics of \u03b21 integrin",
      "target": "active turnover of cell-matrix associations",
      "label": "is required for"
    },
    {
      "source": "Annexin A2",
      "target": "membrane associated, Actin binding protein",
      "label": "is a type of"
    },
    {
      "source": "Annexin A2",
      "target": "\u03b21 integrin internalization",
      "label": "regulates"
    },
    {
      "source": "Annexin A2",
      "target": "intestinal epithelial cell migration",
      "label": "regulates"
    },
    {
      "source": "intestinal epithelial cells",
      "target": "injury",
      "label": "migrate in response to"
    },
    {
      "source": "intestinal epithelial cells",
      "target": "wound closure",
      "label": "migrate to promote"
    },
    {
      "source": "barrier",
      "target": "underlying tissue compartment",
      "label": "separates"
    },
    {
      "source": "barrier",
      "target": "luminal contents",
      "label": "separates"
    },
    {
      "source": "gastrointestinal epithelium",
      "target": "barrier",
      "label": "functions as"
    },
    {
      "source": "gastrointestinal epithelium",
      "target": "mucosal homeostasis",
      "label": "maintains"
    },
    {
      "source": "AnxA2",
      "target": "internalization of cell surface \u03b21 integrin",
      "label": "modulates"
    },
    {
      "source": "AnxA2",
      "target": "wound closure",
      "label": "promotes"
    },
    {
      "source": "AnxA2",
      "target": "migrating IECs",
      "label": "is up-regulated in"
    },
    {
      "source": "AnxA2",
      "target": "IEC movement",
      "label": "promotes"
    },
    {
      "source": "AnxA2",
      "target": "dynamics of \u03b21 integrin",
      "label": "controls"
    },
    {
      "source": "internalization of cell surface \u03b21 integrin",
      "target": "forward cell movement",
      "label": "is required for"
    },
    {
      "source": "cell migration",
      "target": "dynamic turnover of integrin based adhesions",
      "label": "requires"
    },
    {
      "source": "\u03b21 integrin protein",
      "target": "cell-matrix adhesive properties",
      "label": "mediates"
    },
    {
      "source": "cell surface \u03b21 integrin",
      "target": "degradation",
      "label": "accompanied by decreased"
    },
    {
      "source": "cell surface \u03b21 integrin",
      "target": "\u03b21 integrin internalization",
      "label": "accompanied by decreased"
    },
    {
      "source": "pulse-chase biotinylation experiments",
      "target": "cell surface \u03b21 integrin",
      "label": "demonstrated increase in"
    },
    {
      "source": "functional effects",
      "target": "\u03b21 integrin protein",
      "label": "associated with increased levels of"
    },
    {
      "source": "Mucosal wounds",
      "target": "epithelial barrier",
      "label": "compromise"
    },
    {
      "source": "AnxA2 specific shRNA",
      "target": "down-regulation of AnxA2",
      "label": "causes"
    },
    {
      "source": "Low-grade inflammation",
      "target": "insulin resistance",
      "label": "is associated with"
    },
    {
      "source": "Low-grade inflammation",
      "target": "fat",
      "label": "is in"
    },
    {
      "source": "metabolic phenotype",
      "target": "T-bet-deficient hosts",
      "label": "is observed in"
    },
    {
      "source": "metabolic phenotype",
      "target": "T-bet(-/-)xRag2(-/-) mice",
      "label": "was lost in"
    },
    {
      "source": "adoptive transfer",
      "target": "T-bet-deficient CD4(+) T cells",
      "label": "involves"
    },
    {
      "source": "adoptive transfer",
      "target": "wild-type CD4(+) T cells",
      "label": "did not involve"
    },
    {
      "source": "adoptive transfer",
      "target": "Rag2(-/-) mice",
      "label": "was performed to"
    },
    {
      "source": "adoptive transfer",
      "target": "Insulin Sensitivity",
      "label": "improved"
    },
    {
      "source": "T-bet",
      "target": "metabolic physiology",
      "label": "has a role in"
    },
    {
      "source": "T-bet",
      "target": "obesity-associated insulin resistance",
      "label": "has a role in"
    },
    {
      "source": "T-bet(-/-)xRag2(-/-) mice",
      "target": "adaptive immunity",
      "label": "lack"
    },
    {
      "source": "immune cell numbers",
      "target": "visceral adipose tissue",
      "label": "are in"
    },
    {
      "source": "Immune Cell Transcription Factor",
      "target": "T-bet",
      "label": "is"
    },
    {
      "source": "T-bet expression",
      "target": "adaptive immune system",
      "label": "is in"
    },
    {
      "source": "T-bet expression",
      "target": "host glucose homeostasis",
      "label": "impacts"
    },
    {
      "source": "cytokine secretion",
      "target": "visceral adipose tissue",
      "label": "is in"
    },
    {
      "source": "Chinese patients",
      "target": "non-small cell lung cancer",
      "label": "have"
    },
    {
      "source": "rs351855G/A",
      "target": "chemotherapy response",
      "label": "can predict"
    },
    {
      "source": "rs351855G/A",
      "target": "occurrence",
      "label": "can predict"
    },
    {
      "source": "rs351855G/A",
      "target": "FGFR4 gene",
      "label": "is a polymorphism of"
    },
    {
      "source": "rs351855G/A",
      "target": "prognosis",
      "label": "can predict"
    },
    {
      "source": "chemotherapy response",
      "target": "NSCLC",
      "label": "is of"
    },
    {
      "source": "chemotherapy response",
      "target": "Chinese patients",
      "label": "is of"
    },
    {
      "source": "AA genotype",
      "target": "21.1 months",
      "label": "has overall survival of"
    },
    {
      "source": "AA genotype",
      "target": "responders",
      "label": "occurred more frequently in"
    },
    {
      "source": "AA genotype",
      "target": "non-responders",
      "label": "compared to"
    },
    {
      "source": "AA genotype",
      "target": "NSCLC",
      "label": "lower in"
    },
    {
      "source": "AA genotype",
      "target": "rs351855G/A",
      "label": "is of"
    },
    {
      "source": "AA genotype",
      "target": "G genotype",
      "label": "compared to"
    },
    {
      "source": "AA genotype",
      "target": "healthy controls",
      "label": "compared to"
    },
    {
      "source": "AA genotype",
      "target": "prognosis",
      "label": "had better"
    },
    {
      "source": "AA genotype",
      "target": "GA genotype carriers",
      "label": "compared with"
    },
    {
      "source": "AA genotype",
      "target": "GG genotype carriers",
      "label": "compared with"
    },
    {
      "source": "chemotherapy effect",
      "target": "SPSS software",
      "label": "analyzed using"
    },
    {
      "source": "SPSS software",
      "target": "version 16.0",
      "label": "is"
    },
    {
      "source": "responders",
      "target": "chemotherapy",
      "label": "are to"
    },
    {
      "source": "Three polymorphisms",
      "target": "rs351855G/A",
      "label": "include"
    },
    {
      "source": "Three polymorphisms",
      "target": "rs145302848C/G",
      "label": "include"
    },
    {
      "source": "Three polymorphisms",
      "target": "FGFR4 gene",
      "label": "are in"
    },
    {
      "source": "Three polymorphisms",
      "target": "chemotherapy effect",
      "label": "associated with"
    },
    {
      "source": "Three polymorphisms",
      "target": "rs147603016G/A",
      "label": "include"
    },
    {
      "source": "non-responders",
      "target": "chemotherapy",
      "label": "are to"
    },
    {
      "source": "AA carrier",
      "target": "risk",
      "label": "had reduced"
    },
    {
      "source": "genotype frequencies",
      "target": "rs145302848C/G",
      "label": "of"
    },
    {
      "source": "genotype frequencies",
      "target": "responders",
      "label": "compared between"
    },
    {
      "source": "genotype frequencies",
      "target": "non-responders",
      "label": "compared between"
    },
    {
      "source": "genotype frequencies",
      "target": "NSCLC",
      "label": "compared between"
    },
    {
      "source": "genotype frequencies",
      "target": "rs147603016G/A",
      "label": "of"
    },
    {
      "source": "genotype frequencies",
      "target": "healthy controls",
      "label": "compared between"
    },
    {
      "source": "platinum-based chemotherapy",
      "target": "therapeutic effects",
      "label": "has"
    },
    {
      "source": "629 patients",
      "target": "Stage IV NSCLC",
      "label": "have"
    },
    {
      "source": "629 patients",
      "target": "Stage III (A+B) NSCLC",
      "label": "have"
    },
    {
      "source": "629 patients",
      "target": "729 age- and gender-matched healthy controls",
      "label": "recruited with"
    },
    {
      "source": "occurrence",
      "target": "NSCLC",
      "label": "is of"
    },
    {
      "source": "729 age- and gender-matched healthy controls",
      "target": "healthy controls",
      "label": "are a type of"
    },
    {
      "source": "FGFR4 genetic polymorphisms",
      "target": "response",
      "label": "have relationship with"
    },
    {
      "source": "FGFR4 genetic polymorphisms",
      "target": "chemotherapy response",
      "label": "determine"
    },
    {
      "source": "A-allele",
      "target": "NSCLC",
      "label": "lower in"
    },
    {
      "source": "A-allele",
      "target": "rs351855G/A",
      "label": "is of"
    },
    {
      "source": "A-allele",
      "target": "healthy controls",
      "label": "compared to"
    },
    {
      "source": "GG+GA genotype",
      "target": "16.5 months",
      "label": "has overall survival of"
    },
    {
      "source": "Con A-sandwiched microstructures",
      "target": "tag particles",
      "label": "formed between"
    },
    {
      "source": "Con A-sandwiched microstructures",
      "target": "functionalized magnetic particles",
      "label": "formed between"
    },
    {
      "source": "Tandem assays",
      "target": "Ag@SiO2 tag particles",
      "label": "uses"
    },
    {
      "source": "Tandem assays",
      "target": "SERS",
      "label": "enables"
    },
    {
      "source": "Tandem assays",
      "target": "Magnetic Separation",
      "label": "enables"
    },
    {
      "source": "Tandem assays",
      "target": "protein",
      "label": "assays of"
    },
    {
      "source": "Tandem assays",
      "target": "mannose-functionalized Fe3 O4 @SiO2",
      "label": "uses"
    },
    {
      "source": "Tandem assays",
      "target": "glucose",
      "label": "assays of"
    },
    {
      "source": "Ag@SiO2 tag particles",
      "target": "tag particles",
      "label": "is a type of"
    },
    {
      "source": "Ag@SiO2 tag particles",
      "target": "SiO2",
      "label": "contains"
    },
    {
      "source": "Ag@SiO2 tag particles",
      "target": "Ag",
      "label": "contains"
    },
    {
      "source": "Tandem Assays",
      "target": "Glucose",
      "label": "assays of"
    },
    {
      "source": "Tandem Assays",
      "target": "Functionalized Core/Shell Particles",
      "label": "uses"
    },
    {
      "source": "Tandem Assays",
      "target": "Protein",
      "label": "assays of"
    },
    {
      "source": "Tandem Assays",
      "target": "Surface-Enhanced Raman Scattering",
      "label": "based on"
    },
    {
      "source": "Tandem Assays",
      "target": "Magnetic Separation",
      "label": "based on"
    },
    {
      "source": "mannose-functionalized Fe3 O4 @SiO2",
      "target": "SiO2",
      "label": "contains"
    },
    {
      "source": "mannose-functionalized Fe3 O4 @SiO2",
      "target": "Fe3 O4",
      "label": "contains"
    },
    {
      "source": "tandem assay",
      "target": "SERS",
      "label": "developed using"
    },
    {
      "source": "tandem assay",
      "target": "Con A-sandwiched microstructures",
      "label": "based on"
    },
    {
      "source": "tandem assay",
      "target": "glucose",
      "label": "assays of"
    },
    {
      "source": "Sandcastle Worm",
      "target": "Multipart Copolyelectrolyte Adhesive",
      "label": "has"
    },
    {
      "source": "Sandcastle Worm",
      "target": "Phragmatopoma californica",
      "label": "is also known as"
    },
    {
      "source": "Sandcastle Worm",
      "target": "western coast of North America",
      "label": "lives along"
    },
    {
      "source": "Sandcastle Worm",
      "target": "Tube-building sabellariid polychaetes",
      "label": "is a type of"
    },
    {
      "source": "Multipart Copolyelectrolyte Adhesive",
      "target": "Sandcastle Worm",
      "label": "is adhesive of"
    },
    {
      "source": "Multipart Copolyelectrolyte Adhesive",
      "target": "Phragmatopoma californica",
      "label": "is adhesive of"
    },
    {
      "source": "Tube-building sabellariid polychaetes",
      "target": "geology",
      "label": "impact"
    },
    {
      "source": "Tube-building sabellariid polychaetes",
      "target": "ecology",
      "label": "impact"
    },
    {
      "source": "geology",
      "target": "shorelines",
      "label": "is of"
    },
    {
      "source": "Co-secretion",
      "target": "Catechol Oxidase",
      "label": "is of"
    },
    {
      "source": "Co-secretion",
      "target": "rapid and spatially homogeneous curing",
      "label": "guarantees"
    },
    {
      "source": "Catechol Oxidase",
      "target": "active cue",
      "label": "provides"
    },
    {
      "source": "Catechol Oxidase",
      "target": "fully cured glue",
      "label": "remains active after"
    },
    {
      "source": "Catechol Oxidase",
      "target": "oxidative cross-linking",
      "label": "catalyzes"
    },
    {
      "source": "ecology",
      "target": "shorelines",
      "label": "is of"
    },
    {
      "source": "active cue",
      "target": "conspecific larval settlement",
      "label": "is for"
    },
    {
      "source": "polyphosphoproteins",
      "target": "divalent cations",
      "label": "paired with"
    },
    {
      "source": "polyphosphoproteins",
      "target": "polycationic Pc1 proteins",
      "label": "paired with"
    },
    {
      "source": "Distinct sets",
      "target": "oppositely charged components",
      "label": "are of"
    },
    {
      "source": "oppositely charged components",
      "target": "concentrated granules",
      "label": "packaged in"
    },
    {
      "source": "polycationic Pc2 proteins",
      "target": "major components",
      "label": "become"
    },
    {
      "source": "major components",
      "target": "fully cured glue",
      "label": "are of"
    },
    {
      "source": "granules",
      "target": "Catechol Oxidase",
      "label": "contain"
    },
    {
      "source": "Phragmatopoma californica",
      "target": "Tube-building sabellariid polychaetes",
      "label": "is a type of"
    },
    {
      "source": "Phragmatopoma californica",
      "target": "Multipart Copolyelectrolyte Adhesive",
      "label": "has"
    },
    {
      "source": "Phragmatopoma californica",
      "target": "Fewkes",
      "label": "identified by"
    },
    {
      "source": "Phragmatopoma californica",
      "target": "western coast of North America",
      "label": "lives along"
    },
    {
      "source": "Pc3A/B",
      "target": "divalent cations",
      "label": "paired with"
    },
    {
      "source": "Pc3A/B",
      "target": "polycationic Pc1 proteins",
      "label": "paired with"
    },
    {
      "source": "oxidative cross-linking",
      "target": "L-DOPA",
      "label": "is of"
    },
    {
      "source": "sabellariid worms",
      "target": "multipart polyelectrolytic adhesive",
      "label": "use"
    },
    {
      "source": "sabellariid worms",
      "target": "tubular shells",
      "label": "build"
    },
    {
      "source": "sabellariid worms",
      "target": "Tube-building sabellariid polychaetes",
      "label": "is a type of"
    },
    {
      "source": "sabellariid worms",
      "target": "mineral particles",
      "label": "glue together"
    },
    {
      "source": "Curing",
      "target": "Peptidyl-DOPA",
      "label": "occurs through"
    },
    {
      "source": "Curing",
      "target": "Catechol Oxidase",
      "label": "catalyzed by"
    },
    {
      "source": "mineral particles",
      "target": "multipart polyelectrolytic adhesive",
      "label": "are glued with"
    },
    {
      "source": "counter-polyanion",
      "target": "polycationic Pc2 proteins",
      "label": "is counter to"
    },
    {
      "source": "Pc1",
      "target": "polycationic Pc1 proteins",
      "label": "is a type of"
    },
    {
      "source": "Heterogeneous granules",
      "target": "polyphosphoproteins",
      "label": "contain"
    },
    {
      "source": "Heterogeneous granules",
      "target": "Pc3A/B",
      "label": "contain"
    },
    {
      "source": "Pc2",
      "target": "polycationic Pc2 proteins",
      "label": "is a type of"
    },
    {
      "source": "concentrated granules",
      "target": "separate cell types",
      "label": "are in"
    },
    {
      "source": "Homogeneous granules",
      "target": "sulfated macromolecules",
      "label": "contain"
    },
    {
      "source": "sulfated macromolecules",
      "target": "counter-polyanion",
      "label": "act as"
    },
    {
      "source": "rapid and spatially homogeneous curing",
      "target": "preassembled adhesive packets",
      "label": "involves"
    },
    {
      "source": "DICO",
      "target": "growth",
      "label": "inhibited"
    },
    {
      "source": "DICO",
      "target": "human hepatoma cells",
      "label": "acts on"
    },
    {
      "source": "DICO",
      "target": "G2/M cell cycle arrest",
      "label": "induces"
    },
    {
      "source": "DICO",
      "target": "caspase-9",
      "label": "activated"
    },
    {
      "source": "DICO",
      "target": "Bcl-2",
      "label": "decreased"
    },
    {
      "source": "DICO",
      "target": "HepG2 cells",
      "label": "inhibited growth of"
    },
    {
      "source": "DICO",
      "target": "p-cdc25c",
      "label": "caused alteration of"
    },
    {
      "source": "DICO",
      "target": "antitumor activity",
      "label": "has"
    },
    {
      "source": "DICO",
      "target": "cyclin A",
      "label": "caused alteration of"
    },
    {
      "source": "DICO",
      "target": "caspase-3",
      "label": "activated"
    },
    {
      "source": "DICO",
      "target": "nonaromatic B-ring flavonoid",
      "label": "is a"
    },
    {
      "source": "DICO",
      "target": "apoptosis",
      "label": "displayed antitumor activity through"
    },
    {
      "source": "DICO",
      "target": "tumors",
      "label": "has therapeutic potential against"
    },
    {
      "source": "DICO",
      "target": "ROS-mediated mitochondrial pathway",
      "label": "acts through"
    },
    {
      "source": "DICO",
      "target": "p-CDK1",
      "label": "caused alteration of"
    },
    {
      "source": "DICO",
      "target": "cyclin B1",
      "label": "caused alteration of"
    },
    {
      "source": "DICO",
      "target": "Bax",
      "label": "induced"
    },
    {
      "source": "DICO",
      "target": "cytochrome c",
      "label": "caused release of"
    },
    {
      "source": "DICO",
      "target": "Macrothelypteris torresiana",
      "label": "obtained from"
    },
    {
      "source": "DICO",
      "target": "antineoplastic mechanism",
      "label": "has"
    },
    {
      "source": "Western blot assay",
      "target": "Bax",
      "label": "demonstrated induction of"
    },
    {
      "source": "Western blot assay",
      "target": "Bcl-2",
      "label": "demonstrated decrease of"
    },
    {
      "source": "Western blot assay",
      "target": "cytochrome c",
      "label": "demonstrated release of"
    },
    {
      "source": "RunX2",
      "target": "prominent markers for differentiation of osteoblast",
      "label": "is a"
    },
    {
      "source": "osteoprotegerin",
      "target": "prominent markers for differentiation of osteoblast",
      "label": "is a"
    },
    {
      "source": "mouse bone marrow mesenchymal stem cells (BMMSCs)",
      "target": "Quercetin",
      "label": "cultured with"
    },
    {
      "source": "mouse bone marrow mesenchymal stem cells (BMMSCs)",
      "target": "rutin",
      "label": "cultured with"
    },
    {
      "source": "mouse bone marrow mesenchymal stem cells (BMMSCs)",
      "target": "osteoblast differentiation",
      "label": "used for"
    },
    {
      "source": "osteocalcin",
      "target": "prominent markers for differentiation of osteoblast",
      "label": "is a"
    },
    {
      "source": "osterix",
      "target": "prominent markers for differentiation of osteoblast",
      "label": "is a"
    },
    {
      "source": "afferent arteriole (Ra)",
      "target": "age",
      "label": "adjusted for"
    },
    {
      "source": "afferent arteriole (Ra)",
      "target": "mean blood pressure",
      "label": "adjusted for"
    },
    {
      "source": "serum thyrotropin levels",
      "target": "intrarenal hemodynamic parameters",
      "label": "has relationship with"
    },
    {
      "source": "glomerular filtration rate (GFR)",
      "target": "creatinine metabolism",
      "label": "calculated on the basis of"
    },
    {
      "source": "glomerular filtration rate (GFR)",
      "target": "afferent arteriole (Ra)",
      "label": "caused by increase of"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "multiple regression analysis",
      "label": "association analyzed by"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "renal plasma flow (RPF)",
      "label": "negatively correlated with"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "afferent arteriole (Ra)",
      "label": "positively associated with"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "vascular resistance",
      "label": "positively correlated with"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "efferent arteriole (Re)",
      "label": "not correlated with"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "glomerular filtration rate (GFR)",
      "label": "negatively correlated with"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "normal range (0.69-4.30 \u03bcIU/ml)",
      "label": "is within"
    },
    {
      "source": "Serum thyroid stimulating hormone (TSH)",
      "target": "renal blood flow (RBF)",
      "label": "negatively correlated with"
    },
    {
      "source": "renal plasma flow (RPF)",
      "target": "afferent arteriole (Ra)",
      "label": "caused by increase of"
    },
    {
      "source": "Thyroid hormone",
      "target": "serum creatinine",
      "label": "directly affects"
    },
    {
      "source": "serum creatinine",
      "target": "muscle",
      "label": "is in"
    },
    {
      "source": "Renal hemodynamics",
      "target": "Gomez`s formulae",
      "label": "calculated using"
    },
    {
      "source": "Renal hemodynamics",
      "target": "plasma clearance",
      "label": "assessed by"
    },
    {
      "source": "Low thyroid function",
      "target": "glomerular filtration rate (GFR)",
      "label": "associated with"
    },
    {
      "source": "Low thyroid function",
      "target": "renal blood flow (RBF)",
      "label": "associated with reduced"
    },
    {
      "source": "Low thyroid function",
      "target": "renal plasma flow (RPF)",
      "label": "associated with reduced"
    },
    {
      "source": "Low thyroid function",
      "target": "kidney",
      "label": "exerts effect in"
    },
    {
      "source": "vascular resistance",
      "target": "afferent arteriole (Ra)",
      "label": "at"
    },
    {
      "source": "glomerular hemodynamics",
      "target": "Gomez`s formulae",
      "label": "calculated using"
    },
    {
      "source": "glomerular hemodynamics",
      "target": "plasma clearance",
      "label": "assessed by"
    },
    {
      "source": "plasma clearance",
      "target": "para-aminohippurate (CPAH)",
      "label": "of"
    },
    {
      "source": "plasma clearance",
      "target": "inulin (Cin)",
      "label": "of"
    },
    {
      "source": "renal blood flow (RBF)",
      "target": "afferent arteriole (Ra)",
      "label": "caused by increase of"
    },
    {
      "source": "Sardinian wine extracts",
      "target": "intestinal inflammation",
      "label": "act against"
    },
    {
      "source": "Sardinian wine extracts",
      "target": "phenolic content",
      "label": "effects due to"
    },
    {
      "source": "Cannonau red wine extract",
      "target": "phenolic fraction",
      "label": "contains"
    },
    {
      "source": "Cannonau red wine extract",
      "target": "Oxysterol-dependent NOX1 activation",
      "label": "prevents"
    },
    {
      "source": "Cannonau red wine extract",
      "target": "interleukin synthesis",
      "label": "prevents"
    },
    {
      "source": "phenolic fraction",
      "target": "phenolic acids",
      "label": "contains"
    },
    {
      "source": "phenolic fraction",
      "target": "flavonoids",
      "label": "contains"
    },
    {
      "source": "dietary oxysterols",
      "target": "interleukin synthesis",
      "label": "induces"
    },
    {
      "source": "dietary oxysterols",
      "target": "pro-inflammatory events",
      "label": "triggers"
    },
    {
      "source": "dietary oxysterols",
      "target": "pro-oxidant events",
      "label": "triggers"
    },
    {
      "source": "dietary oxysterols",
      "target": "intestinal inflammation",
      "label": "induces"
    },
    {
      "source": "phenolics",
      "target": "oxysterol-dependent ROS production",
      "label": "scavenge"
    },
    {
      "source": "Cholesterol auto-oxidation products",
      "target": "oxysterols",
      "label": "are"
    },
    {
      "source": "pro-inflammatory effect",
      "target": "red-ox equilibrium",
      "label": "dependent on"
    },
    {
      "source": "red-ox equilibrium",
      "target": "reactive oxygen species",
      "label": "imbalance leads to"
    },
    {
      "source": "typical grape varieties",
      "target": "Sardinia",
      "label": "grown in"
    },
    {
      "source": "Phenolic compounds",
      "target": "red wine",
      "label": "present in"
    },
    {
      "source": "Phenolic compounds",
      "target": "oxysterol-related NOX1 induction",
      "label": "block"
    },
    {
      "source": "Phenolic compounds",
      "target": "inflammatory cytokines",
      "label": "protect against"
    },
    {
      "source": "Phenolic compounds",
      "target": "pro-inflammatory events",
      "label": "prevent"
    },
    {
      "source": "Phenolic compounds",
      "target": "pro-oxidant events",
      "label": "prevent"
    },
    {
      "source": "Phenolic compounds",
      "target": "Sardinian wine extracts",
      "label": "present in"
    },
    {
      "source": "Vermentino white wine extract",
      "target": "interleukin synthesis",
      "label": "is ineffective in"
    },
    {
      "source": "Vermentino white wine extract",
      "target": "phenolic fraction",
      "label": "has"
    },
    {
      "source": "Vermentino white wine extract",
      "target": "NOX1 down-regulation",
      "label": "causes"
    },
    {
      "source": "mixture of oxysterols",
      "target": "high cholesterol diet",
      "label": "is representative of"
    },
    {
      "source": "mixture of oxysterols",
      "target": "inflammatory interleukins",
      "label": "causes up-regulation of"
    },
    {
      "source": "mixture of oxysterols",
      "target": "IL-8",
      "label": "causes up-regulation of"
    },
    {
      "source": "mixture of oxysterols",
      "target": "IL-6",
      "label": "causes up-regulation of"
    },
    {
      "source": "phenolic extracts",
      "target": "NOX1",
      "label": "inhibit"
    },
    {
      "source": "phenolic extracts",
      "target": "wines",
      "label": "obtained from"
    },
    {
      "source": "colonic NADPH-oxidase NOX1",
      "target": "reactive oxygen species",
      "label": "activation leads to production of"
    },
    {
      "source": "inflammatory interleukins",
      "target": "differentiated CaCo-2 colonic epithelial cells",
      "label": "up-regulated in"
    },
    {
      "source": "CaCo-2 cell pre-incubation",
      "target": "NOX1",
      "label": "inhibits"
    },
    {
      "source": "wines",
      "target": "typical grape varieties",
      "label": "from"
    },
    {
      "source": "IL-8",
      "target": "differentiated CaCo-2 colonic epithelial cells",
      "label": "up-regulated in"
    },
    {
      "source": "cytokine-modulating therapeutic proteins",
      "target": "inflammation",
      "label": "treats"
    },
    {
      "source": "cytokine-modulating therapeutic proteins",
      "target": "infection",
      "label": "treats"
    },
    {
      "source": "cytokine-modulating therapeutic proteins",
      "target": "Suppression",
      "label": "reverses"
    },
    {
      "source": "BMT patients",
      "target": "cyclosporine",
      "label": "treated with"
    },
    {
      "source": "500 pg/ml",
      "target": "IL-6",
      "label": "is concentration of"
    },
    {
      "source": "500 pg/ml",
      "target": "cyclosporine AUC",
      "label": "resulted in increase in"
    },
    {
      "source": "Physiologically-Based Pharmacokinetic Modelling Approach",
      "target": "Disease-Drug Interactions",
      "label": "predicts"
    },
    {
      "source": "100 pg/mL",
      "target": "IL-6",
      "label": "is concentration of"
    },
    {
      "source": "cyclosporine AUC",
      "target": "observed data",
      "label": "in good agreement with"
    },
    {
      "source": "physiologically-based pharmacokinetic model",
      "target": "IL-6",
      "label": "predicts impact of"
    },
    {
      "source": "accepted article preview",
      "target": "10 April 2013",
      "label": "published on"
    },
    {
      "source": "Suppression",
      "target": "TP-DDI",
      "label": "manifests as"
    },
    {
      "source": "Suppression",
      "target": "therapeutic protein-drug drug interactions",
      "label": "manifests as"
    },
    {
      "source": "TP-DDI",
      "target": "pathophysiological factors",
      "label": "highlights"
    },
    {
      "source": "simvastatin AUC",
      "target": "virtual rheumatoid arthritis patients",
      "label": "elevated in"
    },
    {
      "source": "simvastatin AUC",
      "target": "100 pg/mL",
      "label": "elevated following exposure to"
    },
    {
      "source": "simvastatin AUC",
      "target": "clinical data",
      "label": "comparable to"
    },
    {
      "source": "TP",
      "target": "Suppression",
      "label": "reverses"
    },
    {
      "source": "TP",
      "target": "Systemic lupus erythematosus",
      "label": "is used to treat"
    },
    {
      "source": "TP",
      "target": "14days",
      "label": "was administered for"
    },
    {
      "source": "TP",
      "target": "Leprosy",
      "label": "is used to treat"
    },
    {
      "source": "TP",
      "target": "TWHF",
      "label": "is a major component of"
    },
    {
      "source": "TP",
      "target": "Nephritis",
      "label": "is used to treat"
    },
    {
      "source": "TP",
      "target": "Rheumatoid arthritis",
      "label": "is used to treat"
    },
    {
      "source": "TP",
      "target": "1000\u03bcg/kg",
      "label": "was administered at a dose of"
    },
    {
      "source": "TP",
      "target": "300\u03bcg/kg",
      "label": "was administered at a dose of"
    },
    {
      "source": "TP",
      "target": "Wistar rats",
      "label": "was orally administered to"
    },
    {
      "source": "magnitude of interaction",
      "target": "~3-fold",
      "label": "was under predicted by"
    },
    {
      "source": "magnitude of interaction",
      "target": "IL-6",
      "label": "is with"
    },
    {
      "source": "cytokine levels",
      "target": "expression",
      "label": "down-regulate"
    },
    {
      "source": "cytokine levels",
      "target": "CYPs",
      "label": "down-regulate expression of"
    },
    {
      "source": "cytokine levels",
      "target": "cytochrome P450 enzymes",
      "label": "down-regulate expression of"
    },
    {
      "source": "cytokine levels",
      "target": "activity",
      "label": "suppress"
    },
    {
      "source": "triggered release",
      "target": "hydrophilic model compound",
      "label": "is of"
    },
    {
      "source": "triggered release",
      "target": "liposomes",
      "label": "is from"
    },
    {
      "source": "triggered release",
      "target": "lipophilic model compound",
      "label": "is of"
    },
    {
      "source": "stimuli-responsive nanoparticles",
      "target": "liposomes",
      "label": "include"
    },
    {
      "source": "PW-HIFU exposure",
      "target": "temperatures",
      "label": "did not result in"
    },
    {
      "source": "temperatures",
      "target": "Tm",
      "label": "were above"
    },
    {
      "source": "polydispersity index (PDI)",
      "target": "liposomes",
      "label": "is of"
    },
    {
      "source": "polydispersity index (PDI)",
      "target": "formulations",
      "label": "is for"
    },
    {
      "source": "polydispersity index (PDI)",
      "target": "PW-HIFU exposure",
      "label": "did not change after"
    },
    {
      "source": "polydispersity index (PDI)",
      "target": "CW-HIFU exposure",
      "label": "did not change after"
    },
    {
      "source": "liposomes",
      "target": "pulsed wave (PW)-HIFU",
      "label": "were subjected to"
    },
    {
      "source": "liposomes",
      "target": "continuous wave- (CW)-HIFU",
      "label": "were subjected to"
    },
    {
      "source": "liposomes",
      "target": "walls",
      "label": "collide at"
    },
    {
      "source": "shear forces",
      "target": "reversible liposome destabilization",
      "label": "result in"
    },
    {
      "source": "shear forces",
      "target": "release",
      "label": "result in"
    },
    {
      "source": "reversible liposome destabilization",
      "target": "release",
      "label": "results in"
    },
    {
      "source": "high-intensity focused ultrasound (HIFU)",
      "target": "release",
      "label": "triggers"
    },
    {
      "source": "inertial cavitation",
      "target": "release",
      "label": "is not essential for"
    },
    {
      "source": "new mechanism",
      "target": "HIFU-triggered release",
      "label": "is behind"
    },
    {
      "source": "new mechanism",
      "target": "release mechanism",
      "label": "is a"
    },
    {
      "source": "new mechanism",
      "target": "release",
      "label": "allows"
    },
    {
      "source": "HIFU-triggered release",
      "target": "liposomes",
      "label": "occurs from"
    },
    {
      "source": "HIFU-triggered release",
      "target": "approach",
      "label": "is a"
    },
    {
      "source": "fluorescein",
      "target": "thermosensitive liposomes (TSL)",
      "label": "was released from"
    },
    {
      "source": "fluorescein",
      "target": "non-thermosensitive liposomes (NTSL)",
      "label": "was loaded into"
    },
    {
      "source": "fluorescein",
      "target": "hydrophilic model compound",
      "label": "is a"
    },
    {
      "source": "phospholipid bilayer",
      "target": "thermosensitive liposomes (TSL)",
      "label": "is of"
    },
    {
      "source": "fluorescein release",
      "target": "temperatures",
      "label": "occurred at"
    },
    {
      "source": "fluorescein release",
      "target": "non-thermosensitive liposomes (NTSL)",
      "label": "was not observed from"
    },
    {
      "source": "Nile red",
      "target": "thermosensitive liposomes (TSL)",
      "label": "was loaded into"
    },
    {
      "source": "Nile red",
      "target": "lipophilic model compound",
      "label": "is a"
    },
    {
      "source": "Nile red",
      "target": "non-thermosensitive liposomes (NTSL)",
      "label": "was loaded into"
    },
    {
      "source": "release mechanism",
      "target": "HIFU-triggered release",
      "label": "is involved with"
    },
    {
      "source": "release mechanism",
      "target": "temperature",
      "label": "is beside"
    },
    {
      "source": "release mechanism",
      "target": "cavitation",
      "label": "is beside"
    },
    {
      "source": "radiation force-induced acoustic streaming",
      "target": "shear forces",
      "label": "leads to"
    },
    {
      "source": "radiation force-induced acoustic streaming",
      "target": "liposomes",
      "label": "causes"
    },
    {
      "source": "main mechanism",
      "target": "triggered release",
      "label": "is responsible for"
    },
    {
      "source": "mean liposome size",
      "target": "CW-HIFU exposure",
      "label": "did not change after"
    },
    {
      "source": "mean liposome size",
      "target": "liposomes",
      "label": "is of"
    },
    {
      "source": "mean liposome size",
      "target": "formulations",
      "label": "varied for"
    },
    {
      "source": "mean liposome size",
      "target": "PW-HIFU exposure",
      "label": "did not change after"
    },
    {
      "source": "CW-HIFU exposure",
      "target": "fluorescein release",
      "label": "resulted in"
    },
    {
      "source": "CW-HIFU exposure",
      "target": "NR release",
      "label": "resulted in"
    },
    {
      "source": "CW-HIFU exposure",
      "target": "thermosensitive liposomes (TSL)",
      "label": "was applied to"
    },
    {
      "source": "CW-HIFU exposure",
      "target": "temperature elevation",
      "label": "resulted in"
    },
    {
      "source": "temperature elevation",
      "target": "release",
      "label": "is not essential for"
    },
    {
      "source": "NR release",
      "target": "thermosensitive liposomes (TSL)",
      "label": "was not observed from"
    },
    {
      "source": "NR release",
      "target": "non-thermosensitive liposomes (NTSL)",
      "label": "was not observed from"
    },
    {
      "source": "NR release",
      "target": "loaded amount",
      "label": "was of"
    },
    {
      "source": "NR release",
      "target": "PW-HIFU exposure",
      "label": "occurred after"
    },
    {
      "source": "Tm",
      "target": "thermosensitive liposomes (TSL)",
      "label": "is of"
    },
    {
      "source": "Tm",
      "target": "phospholipid bilayer",
      "label": "is of"
    },
    {
      "source": "microbubbles",
      "target": "PW-HIFU exposure",
      "label": "were added prior to"
    },
    {
      "source": "microbubbles",
      "target": "liposomes",
      "label": "were added to"
    },
    {
      "source": "Dynamic light scattering analysis",
      "target": "mean liposome size",
      "label": "showed no change in"
    },
    {
      "source": "Dynamic light scattering analysis",
      "target": "polydispersity index (PDI)",
      "label": "showed no change in"
    },
    {
      "source": "walls",
      "target": "exposure chamber",
      "label": "are of"
    },
    {
      "source": "cavitation",
      "target": "main mechanism",
      "label": "is excluded as"
    },
    {
      "source": "Nrf2-Keap1 axis",
      "target": "Nrf2",
      "label": "deregulation leads to activation of"
    },
    {
      "source": "Nrf2",
      "target": "p62",
      "label": "activation by tert-butylhydroquinone does not depend on"
    },
    {
      "source": "Nrf2",
      "target": "Keap1-C151",
      "label": "activation by tert-butylhydroquinone depends on"
    },
    {
      "source": "Nrf2",
      "target": "cancer-promoting function",
      "label": "has"
    },
    {
      "source": "Nrf2",
      "target": "human cancers",
      "label": "constitutive activation found in"
    },
    {
      "source": "Nrf2",
      "target": "chemoprevention",
      "label": "activation is a strategy for"
    },
    {
      "source": "Nrf2",
      "target": "GSH levels",
      "label": "cooperates to increase"
    },
    {
      "source": "Nrf2",
      "target": "Transcription Factors",
      "label": "is a"
    },
    {
      "source": "Nrf2",
      "target": "GSH metabolism",
      "label": "plays critical role in"
    },
    {
      "source": "Nrf2",
      "target": "stress-sensing transcription factors",
      "label": "is a type of"
    },
    {
      "source": "Nrf2",
      "target": "antioxidant capacity",
      "label": "plays important role in"
    },
    {
      "source": "Arsenic",
      "target": "arsenic toxicity",
      "label": "underlies"
    },
    {
      "source": "Arsenic",
      "target": "Nrf2",
      "label": "activates"
    },
    {
      "source": "Arsenic",
      "target": "autophagic flux",
      "label": "inhibits"
    },
    {
      "source": "Arsenic",
      "target": "Nrf2-Keap1 pathway",
      "label": "activates"
    },
    {
      "source": "Arsenic",
      "target": "carcinogenicity",
      "label": "underlies"
    },
    {
      "source": "Arsenic",
      "target": "autophagic pathway",
      "label": "deregulates"
    },
    {
      "source": "Arsenic",
      "target": "autophagy dysfunction",
      "label": "activates Nrf2 via"
    },
    {
      "source": "Arsenic",
      "target": "angiotensin II Type I receptor",
      "label": "upregulates"
    },
    {
      "source": "Arsenic",
      "target": "AT1R expression",
      "label": "upregulates"
    },
    {
      "source": "tert-butylhydroquinone",
      "target": "Nrf2",
      "label": "activates"
    },
    {
      "source": "tert-butylhydroquinone",
      "target": "autophagy",
      "label": "has no effect on"
    },
    {
      "source": "tert-butylhydroquinone",
      "target": "autophagy dysfunction",
      "label": "alleviates"
    },
    {
      "source": "sulforaphane",
      "target": "autophagy dysfunction",
      "label": "alleviates"
    },
    {
      "source": "sulforaphane",
      "target": "Nrf2",
      "label": "activates"
    },
    {
      "source": "sulforaphane",
      "target": "autophagy",
      "label": "has no effect on"
    },
    {
      "source": "cancer-promoting function",
      "target": "tumors",
      "label": "observed in"
    },
    {
      "source": "Nrf2-Keap1 pathway",
      "target": "cell survival",
      "label": "promotes"
    },
    {
      "source": "C101",
      "target": "single step",
      "label": "is S-nitrosated in"
    },
    {
      "source": "C101",
      "target": "S-nitrosation",
      "label": "undergoes"
    },
    {
      "source": "C101",
      "target": "negative cooperativity",
      "label": "subject to"
    },
    {
      "source": "C101-NO",
      "target": "C47-NO",
      "label": "more resistant than"
    },
    {
      "source": "C101-NO",
      "target": "denitrosation",
      "label": "more resistant to"
    },
    {
      "source": "C101-NO",
      "target": "transfer",
      "label": "has role in"
    },
    {
      "source": "C101-NO",
      "target": "long term nitric oxide storage",
      "label": "has role in"
    },
    {
      "source": "post-translational control",
      "target": "GSTP1-1",
      "label": "of"
    },
    {
      "source": "human glutathione transferase (GST) P1-1",
      "target": "key regulator",
      "label": "is a"
    },
    {
      "source": "human glutathione transferase (GST) P1-1",
      "target": "detoxification enzyme",
      "label": "is a"
    },
    {
      "source": "steric hindrance",
      "target": "dimer interface",
      "label": "at"
    },
    {
      "source": "Kinetics experiments",
      "target": "C101-NO",
      "label": "shows"
    },
    {
      "source": "Kinetics experiments",
      "target": "cellular reductant",
      "label": "uses"
    },
    {
      "source": "long term nitric oxide storage",
      "target": "nitric oxide",
      "label": "of"
    },
    {
      "source": "S-nitrosation",
      "target": "cellular oxidative stress",
      "label": "occurs in response to"
    },
    {
      "source": "S-nitrosation",
      "target": "GSTP1-1",
      "label": "of"
    },
    {
      "source": "S-nitrosation",
      "target": "conformation",
      "label": "controlled by"
    },
    {
      "source": "S-nitrosation",
      "target": "physiologically important processes",
      "label": "linked to"
    },
    {
      "source": "S-nitrosation",
      "target": "glutathione transferase P1-1",
      "label": "occurs on"
    },
    {
      "source": "S-nitrosation",
      "target": "post-translational modification",
      "label": "is a"
    },
    {
      "source": "first report",
      "target": "spontaneous protein transnitrosation",
      "label": "of"
    },
    {
      "source": "nitrosation experiments",
      "target": "GSNO binding",
      "label": "demonstrates"
    },
    {
      "source": "nitrosation experiments",
      "target": "CysNO",
      "label": "uses"
    },
    {
      "source": "GSNO binding",
      "target": "S-nitrosation",
      "label": "does not precede"
    },
    {
      "source": "helix \u03b12",
      "target": "active site",
      "label": "at"
    },
    {
      "source": "chemical step",
      "target": "pre-equilibrium",
      "label": "limited by"
    },
    {
      "source": "pre-equilibrium",
      "target": "open and closed conformations",
      "label": "between"
    },
    {
      "source": "cellular reductant",
      "target": "GSH",
      "label": "is"
    },
    {
      "source": "minimal mechanism",
      "target": "spontaneous GSNO-mediated transnitrosation",
      "label": "for"
    },
    {
      "source": "spontaneous GSNO-mediated transnitrosation",
      "target": "human glutathione transferase (GST) P1-1",
      "label": "of"
    },
    {
      "source": "open and closed conformations",
      "target": "helix \u03b12",
      "label": "of"
    },
    {
      "source": "transfer",
      "target": "nitric oxide",
      "label": "of"
    },
    {
      "source": "negative cooperativity",
      "target": "steric hindrance",
      "label": "due to"
    },
    {
      "source": "transient kinetic methods",
      "target": "minimal mechanism",
      "label": "used to determine"
    },
    {
      "source": "C47",
      "target": "S-nitrosation",
      "label": "undergoes"
    },
    {
      "source": "C47",
      "target": "GSTP1-1",
      "label": "part of"
    },
    {
      "source": "GSNO binding site",
      "target": "active site",
      "label": "at"
    },
    {
      "source": "post-translational modification",
      "target": "protein cysteine residues",
      "label": "of"
    },
    {
      "source": "protein regulation",
      "target": "post-translational modification",
      "label": "by"
    },
    {
      "source": "systemic cilostazol treatment",
      "target": "retinal ischemia",
      "label": "relieves"
    },
    {
      "source": "systemic cilostazol treatment",
      "target": "protective effect",
      "label": "had"
    },
    {
      "source": "management",
      "target": "diabetic retinal vascular dysfunction",
      "label": "of"
    },
    {
      "source": "management",
      "target": "neuronal degeneration",
      "label": "of"
    },
    {
      "source": "RGCs",
      "target": "diabetic rats",
      "label": "are in"
    },
    {
      "source": "Retinal Ganglion Cell damage",
      "target": "Diabetic Rats",
      "label": "occurs in"
    },
    {
      "source": "Otsuka Long-Evans Tokushima Fatty (OLETF) rats",
      "target": "Cilostazol",
      "label": "treated with"
    },
    {
      "source": "Otsuka Long-Evans Tokushima Fatty (OLETF) rats",
      "target": "0.9 % saline solution",
      "label": "treated with"
    },
    {
      "source": "Otsuka Long-Evans Tokushima Fatty (OLETF) rats",
      "target": "30mg/kg",
      "label": "treated with"
    },
    {
      "source": "GFAP",
      "target": "retinas",
      "label": "expression in"
    },
    {
      "source": "GFAP",
      "target": "ramified pattern",
      "label": "shows"
    },
    {
      "source": "GFAP",
      "target": "immunofluorescence staining",
      "label": "detected by"
    },
    {
      "source": "GFAP",
      "target": "LETO rats",
      "label": "is upregulated compared to"
    },
    {
      "source": "GFAP",
      "target": "OLETF rats",
      "label": "is upregulated in"
    },
    {
      "source": "Terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNLEL) staining",
      "target": "RGC layer",
      "label": "revealed increase in"
    },
    {
      "source": "RGC layer",
      "target": "OLETF rats",
      "label": "increased in"
    },
    {
      "source": "RGC layer",
      "target": "LETO rats",
      "label": "increased compared to"
    },
    {
      "source": "immunofluorescence staining",
      "target": "vertical sections",
      "label": "performed on"
    },
    {
      "source": "immunofluorescence staining",
      "target": "cilostazol treatment",
      "label": "demonstrated effect of"
    },
    {
      "source": "retinal ganglion cell death",
      "target": "diabetic retina",
      "label": "occurs in"
    },
    {
      "source": "ramified pattern",
      "target": "whole-mount retinas",
      "label": "observed in"
    },
    {
      "source": "cilostazol treatment",
      "target": "TUNEL-positive cells",
      "label": "reduced"
    },
    {
      "source": "cilostazol treatment",
      "target": "GFAP",
      "label": "reduced"
    },
    {
      "source": "cilostazol treatment",
      "target": "VEGF",
      "label": "reduced"
    },
    {
      "source": "Neuroprotective Effects",
      "target": "Retinal Ganglion Cell damage",
      "label": "on"
    },
    {
      "source": "Neurodegeneration",
      "target": "diabetic retinopathy",
      "label": "is a component of"
    },
    {
      "source": "TUNEL-positive cells",
      "target": "OLETF rats",
      "label": "are in"
    },
    {
      "source": "Long-Evans Tokushima Otsuka (LETO) rats",
      "target": "30mg/kg",
      "label": "treated with"
    },
    {
      "source": "Long-Evans Tokushima Otsuka (LETO) rats",
      "target": "nondiabetic controls",
      "label": "are"
    },
    {
      "source": "Long-Evans Tokushima Otsuka (LETO) rats",
      "target": "Cilostazol",
      "label": "treated with"
    },
    {
      "source": "Long-Evans Tokushima Otsuka (LETO) rats",
      "target": "0.9 % saline solution",
      "label": "treated with"
    },
    {
      "source": "retinal ganglion cell (RGC) death",
      "target": "diabetes",
      "label": "occurs in"
    },
    {
      "source": "homozygous carriers of C29R",
      "target": "609\u2009\u00b1\u2009152 pmol 5-FU min(-1) mg(-1)",
      "label": "had DPD activity of"
    },
    {
      "source": "homozygous carriers of C29R",
      "target": "noncarriers",
      "label": "were compared with"
    },
    {
      "source": "homozygous carriers of C29R",
      "target": "DPD activity",
      "label": "showed higher"
    },
    {
      "source": "aggressive cancers",
      "target": "colon",
      "label": "include"
    },
    {
      "source": "aggressive cancers",
      "target": "breast",
      "label": "include"
    },
    {
      "source": "aggressive cancers",
      "target": "head and neck",
      "label": "include"
    },
    {
      "source": "noncarriers",
      "target": "480\u2009\u00b1\u2009152 pmol 5-FU min(-1) mg(-1)",
      "label": "had DPD activity of"
    },
    {
      "source": "noncarriers",
      "target": "514\u2009\u00b1\u2009168 pmol 5-FU min(-1) mg(-1)",
      "label": "had DPD activity of"
    },
    {
      "source": "activity levels",
      "target": "DPD",
      "label": "are levels of"
    },
    {
      "source": "activity levels",
      "target": "enzyme dihydropyrimidine dehydrogenase",
      "label": "are levels of"
    },
    {
      "source": "DPD",
      "target": "DPYD gene",
      "label": "is encoded by"
    },
    {
      "source": "genetic associations",
      "target": "European-American volunteers",
      "label": "were evaluated in"
    },
    {
      "source": "genetic associations",
      "target": "circulating mononuclear-cell DPD enzyme activity",
      "label": "are between"
    },
    {
      "source": "genetic associations",
      "target": "African-American volunteers",
      "label": "were evaluated in"
    },
    {
      "source": "genetic associations",
      "target": "DPYD variations",
      "label": "are between"
    },
    {
      "source": "DPYD-Y186C variant",
      "target": "Individuals of African Ancestry",
      "label": "is unique to"
    },
    {
      "source": "DPYD-Y186C variant",
      "target": "reduced DPD activity",
      "label": "is associated with"
    },
    {
      "source": "African Americans",
      "target": "Y186C",
      "label": "were carriers of"
    },
    {
      "source": "African Americans",
      "target": "reduced DPD activity",
      "label": "had"
    },
    {
      "source": "carriers",
      "target": "279\u2009\u00b1\u200935 pmol 5-FU min(-1) mg(-1)",
      "label": "had DPD activity of"
    },
    {
      "source": "responses to 5-FU",
      "target": "toxicity",
      "label": "include"
    },
    {
      "source": "responses to 5-FU",
      "target": "racial groups",
      "label": "vary among"
    },
    {
      "source": "responses to 5-FU",
      "target": "efficacy",
      "label": "include"
    },
    {
      "source": "enzyme dihydropyrimidine dehydrogenase",
      "target": "DPYD gene",
      "label": "is encoded by"
    },
    {
      "source": "African-American cohort",
      "target": "Y186C carriers",
      "label": "excluded"
    },
    {
      "source": "5-Fluorouracil",
      "target": "aggressive cancers",
      "label": "is used to treat"
    },
    {
      "source": "antinociceptive action",
      "target": "acute pain",
      "label": "effective in"
    },
    {
      "source": "antinociceptive action",
      "target": "rats",
      "label": "in"
    },
    {
      "source": "antinociceptive action",
      "target": "persistent pain",
      "label": "effective in"
    },
    {
      "source": "capsaicin-activated currents",
      "target": "patch-clamp recordings",
      "label": "in"
    },
    {
      "source": "patch-clamp recordings",
      "target": "HEK293 cells",
      "label": "of"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "capsaicin-induced Ca(2+) transients",
      "label": "inhibited"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "mechanical hypersensitivity",
      "label": "reduced"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "capsaicin-activated currents",
      "label": "did not inhibit"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "SB366791",
      "label": "acted similarly to"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "Ca(2+) transients",
      "label": "affects"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "nocifensive behavior",
      "label": "reduced"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "targets",
      "label": "acts through different"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "therapeutic strategy",
      "label": "effective as a"
    },
    {
      "source": "Ph\u03b11\u03b2",
      "target": "TRPV1 receptor",
      "label": "is not related to inhibition of"
    },
    {
      "source": "capsaicin-induced Ca(2+) transients",
      "target": "dorsal root ganglia (DRG) neurons",
      "label": "in"
    },
    {
      "source": "MVIIA",
      "target": "capsaicin-induced Ca(2+) transients",
      "label": "inhibited"
    },
    {
      "source": "SB366791",
      "target": "targets",
      "label": "acts through different"
    },
    {
      "source": "SB366791",
      "target": "capsaicin-induced Ca(2+) transients",
      "label": "inhibited"
    },
    {
      "source": "SB366791",
      "target": "TRPV1 antagonist",
      "label": "is a"
    },
    {
      "source": "rat model of spontaneous pain",
      "target": "capsaicin",
      "label": "induced by"
    },
    {
      "source": "Ca(2+) transients",
      "target": "dorsal root ganglia (DRG) neurons",
      "label": "in"
    },
    {
      "source": "Ca(2+) transients",
      "target": "HEK293 cells",
      "label": "in"
    },
    {
      "source": "venom",
      "target": "armed spider Phoneutria nigriventer",
      "label": "from"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "ziconotide",
      "label": "similar to"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "mechanical hypersensitivity",
      "label": "prevents"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "antinociceptive action",
      "label": "has"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "peptide",
      "label": "is a"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "nociceptive behavior",
      "label": "prevents"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "analgesic action",
      "label": "has"
    },
    {
      "source": "Ph\u03b11\u03b2 toxin",
      "target": "TRPV1 channels",
      "label": "does not act on"
    },
    {
      "source": "nocifensive behavior",
      "target": "capsaicin",
      "label": "induced by"
    },
    {
      "source": "\u03c9-conotoxin MVIIA",
      "target": "N-type Ca(2+) channel blocker",
      "label": "is a"
    },
    {
      "source": "analgesic action",
      "target": "high voltage activated calcium channels",
      "label": "related to inhibition of"
    },
    {
      "source": "high voltage activated calcium channels",
      "target": "N-type",
      "label": "has selectivity for"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "0.5MAhR group",
      "label": "detected_in"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "male rats",
      "label": "occurs_in"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "adulthood",
      "label": "occurs_in"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "MM groups",
      "label": "detected_in"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "metabolic impairments",
      "label": "associated_with"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "DNA methylation",
      "label": "mediated_by"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "CM group",
      "label": "detected_in"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "mental health impairments",
      "label": "associated_with"
    },
    {
      "source": "glucocorticoid stress-response (GSR)",
      "target": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "label": "detected_in"
    },
    {
      "source": "0.5MAhR group",
      "target": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "label": "is_combination_of"
    },
    {
      "source": "0.5MAhR group",
      "target": "0.5M group",
      "label": "is_combination_of"
    },
    {
      "source": "lactational exposure",
      "target": "DNA methylation",
      "label": "affects"
    },
    {
      "source": "lactational exposure",
      "target": "glucocorticoid stress-response (GSR)",
      "label": "affects"
    },
    {
      "source": "lactational exposure",
      "target": "mixtures of environmental contaminants",
      "label": "is_to"
    },
    {
      "source": "M group",
      "target": "1.0 mg/kg/day",
      "label": "received_dose"
    },
    {
      "source": "M group",
      "target": "liver",
      "label": "had_effect_in"
    },
    {
      "source": "M group",
      "target": "hippocampus",
      "label": "had_effect_in"
    },
    {
      "source": "1.0 mg/kg/day",
      "target": "chemical mixture (M)",
      "label": "is_dose_of"
    },
    {
      "source": "dams",
      "target": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "label": "received"
    },
    {
      "source": "dams",
      "target": "cookie",
      "label": "fed_with"
    },
    {
      "source": "dams",
      "target": "postnatal day (PND) 20",
      "label": "fed_until"
    },
    {
      "source": "dams",
      "target": "chemical mixture (M)",
      "label": "fed_with"
    },
    {
      "source": "dams",
      "target": "gestation day (GD) 0",
      "label": "fed_from"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "liver",
      "label": "had_effect_in"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "1.8 ng/kg/day",
      "label": "administered_at_dose"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "PC-dibenzodioxins",
      "label": "contains"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "PC-dibenzofurans",
      "label": "contains"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "non-ortho PCBs",
      "label": "contains"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "hippocampus",
      "label": "had_effect_in"
    },
    {
      "source": "mixture of aryl hydrocarbon receptor (AhR) agonists",
      "target": "M group",
      "label": "had_opposite_effects_to"
    },
    {
      "source": "Perinatal events",
      "target": "glucocorticoid stress-response (GSR)",
      "label": "leads_to"
    },
    {
      "source": "Perinatal events",
      "target": "hypothalamo-pituitary-adrenal axis",
      "label": "reprogram"
    },
    {
      "source": "0.5 mg/kg/day",
      "target": "chemical mixture (M)",
      "label": "is_dose_of"
    },
    {
      "source": "chemical mixture (M)",
      "target": "polychlorinated biphenyls (PCBs)",
      "label": "contains"
    },
    {
      "source": "chemical mixture (M)",
      "target": "methylmercury",
      "label": "contains"
    },
    {
      "source": "chemical mixture (M)",
      "target": "organochlorine pesticides",
      "label": "contains"
    },
    {
      "source": "experiment",
      "target": "treatment groups",
      "label": "includes"
    },
    {
      "source": "mixtures of environmental contaminants",
      "target": "glucocorticoid stress-response (GSR)",
      "label": "induces"
    },
    {
      "source": "cookie",
      "target": "corn oil",
      "label": "laced_with"
    },
    {
      "source": "C/C group",
      "target": "in utero/postnatal exposure",
      "label": "is_a"
    },
    {
      "source": "predisposition",
      "target": "stress-induced diseases",
      "label": "to"
    },
    {
      "source": "abundance of GR",
      "target": "treated groups",
      "label": "in"
    },
    {
      "source": "abundance of GR",
      "target": "control group",
      "label": "compared_to"
    },
    {
      "source": "abundance of GR",
      "target": "adult male offspring",
      "label": "measured_in"
    },
    {
      "source": "C/M group",
      "target": "in utero/postnatal exposure",
      "label": "is_a"
    },
    {
      "source": "in utero exposure",
      "target": "DNA methylation",
      "label": "affects"
    },
    {
      "source": "in utero exposure",
      "target": "glucocorticoid stress-response (GSR)",
      "label": "affects"
    },
    {
      "source": "in utero exposure",
      "target": "mixtures of environmental contaminants",
      "label": "is_to"
    },
    {
      "source": "in utero exposure",
      "target": "retinoic acid",
      "label": "is to"
    },
    {
      "source": "environmental contaminants",
      "target": "in utero exposure",
      "label": "involved_in"
    },
    {
      "source": "environmental contaminants",
      "target": "lactational exposure",
      "label": "involved_in"
    },
    {
      "source": "four groups",
      "target": "in utero/postnatal exposure",
      "label": "represent"
    },
    {
      "source": "M/C group",
      "target": "in utero/postnatal exposure",
      "label": "is_a"
    },
    {
      "source": "0.5M group",
      "target": "0.5 mg/kg/day",
      "label": "received_dose"
    },
    {
      "source": "developmental exposure",
      "target": "environmental contaminants",
      "label": "to"
    },
    {
      "source": "developmental exposure",
      "target": "predisposition",
      "label": "leads_to"
    },
    {
      "source": "control (C) litters",
      "target": "birth",
      "label": "cross_fostered_at"
    },
    {
      "source": "M/M group",
      "target": "in utero/postnatal exposure",
      "label": "is_a"
    },
    {
      "source": "M litters",
      "target": "birth",
      "label": "cross_fostered_at"
    },
    {
      "source": "phosphorylation of Extracellular-Signal-Regulated Kinase",
      "target": "biochemical parameters",
      "label": "is a"
    },
    {
      "source": "phosphorylation of Extracellular-Signal-Regulated Kinase",
      "target": "hippocampus",
      "label": "is a parameter of"
    },
    {
      "source": "cotinine",
      "target": "biochemical parameters",
      "label": "affects"
    },
    {
      "source": "cotinine",
      "target": "phosphorylation of Extracellular-Signal-Regulated Kinase",
      "label": "increased"
    },
    {
      "source": "cotinine",
      "target": "memory extinction",
      "label": "affects"
    },
    {
      "source": "cotinine",
      "target": "metabolite",
      "label": "is a"
    },
    {
      "source": "cotinine",
      "target": "oxidative stress",
      "label": "may increase"
    },
    {
      "source": "cotinine",
      "target": "nicotine",
      "label": "is a metabolite of"
    },
    {
      "source": "cotinine",
      "target": "neuroactive effects",
      "label": "has"
    },
    {
      "source": "cotinine",
      "target": "LPO",
      "label": "increased"
    },
    {
      "source": "cotinine",
      "target": "impairments",
      "label": "does not cause"
    },
    {
      "source": "LPO",
      "target": "lipid peroxidation",
      "label": "is an abbreviation for"
    },
    {
      "source": "LPO",
      "target": "stomach tissues",
      "label": "OBSERVED_IN"
    },
    {
      "source": "LPO",
      "target": "Enzyme activities",
      "label": "IS_A_TYPE_OF"
    },
    {
      "source": "LPO",
      "target": "colorimetric methods",
      "label": "DETERMINED_BY"
    },
    {
      "source": "LPO",
      "target": "liver samples",
      "label": "DETERMINED_IN"
    },
    {
      "source": "LPO",
      "target": "liver markers",
      "label": "IS_A"
    },
    {
      "source": "neuroactive effects",
      "target": "biochemical parameters",
      "label": "include"
    },
    {
      "source": "neuroactive effects",
      "target": "behavioral parameters",
      "label": "include"
    },
    {
      "source": "neuroactive effects",
      "target": "hippocampus",
      "label": "occur on"
    },
    {
      "source": "DH\u03b2E",
      "target": "dihydro-beta-eritroidine",
      "label": "is an abbreviation for"
    },
    {
      "source": "dihydro-beta-eritroidine",
      "target": "memory extinction",
      "label": "affects"
    },
    {
      "source": "dihydro-beta-eritroidine",
      "target": "biochemical parameters",
      "label": "affects"
    },
    {
      "source": "Extracellular-Signal-Regulated Kinase",
      "target": "ERK 1/2",
      "label": "is abbreviated as"
    },
    {
      "source": "COT",
      "target": "cotinine",
      "label": "is an abbreviation for"
    },
    {
      "source": "Young male rats",
      "target": "cannulae",
      "label": "were implanted with"
    },
    {
      "source": "Young male rats",
      "target": "memory extinction tests sessions",
      "label": "were submitted to"
    },
    {
      "source": "nicotine-attributed effects",
      "target": "alkaloid",
      "label": "are due to"
    },
    {
      "source": "nicotine-attributed effects",
      "target": "cotinine",
      "label": "could be due to"
    },
    {
      "source": "nicotine-attributed effects",
      "target": "cotinine-nicotine interactions",
      "label": "could be due to"
    },
    {
      "source": "cotinine-nicotine interactions",
      "target": "brain",
      "label": "occur within"
    },
    {
      "source": "MLA",
      "target": "methyllycaconitine",
      "label": "is an abbreviation for"
    },
    {
      "source": "NIC",
      "target": "nicotine",
      "label": "is an abbreviation for"
    },
    {
      "source": "sex steroid receptors",
      "target": "uteri",
      "label": "located in"
    },
    {
      "source": "sex steroid receptors",
      "target": "ovaries",
      "label": "located in"
    },
    {
      "source": "sex steroid receptors",
      "target": "oviducts",
      "label": "located in"
    },
    {
      "source": "uteri",
      "target": "adult rats",
      "label": "part of"
    },
    {
      "source": "uteri",
      "target": "ethanol-preferring rats",
      "label": "part of"
    },
    {
      "source": "ethanol intake",
      "target": "estradiol",
      "label": "has opposite effects on"
    },
    {
      "source": "ethanol intake",
      "target": "sex hormones",
      "label": "has effects on"
    },
    {
      "source": "ethanol intake",
      "target": "steroid receptors",
      "label": "has effects on"
    },
    {
      "source": "ethanol intake",
      "target": "progesterone",
      "label": "has opposite effects on"
    },
    {
      "source": "ethanol intake",
      "target": "sex steroid receptors",
      "label": "regulates"
    },
    {
      "source": "oviducts",
      "target": "adult rats",
      "label": "part of"
    },
    {
      "source": "oviducts",
      "target": "ethanol-preferring rats",
      "label": "part of"
    },
    {
      "source": "ovaries",
      "target": "adult rats",
      "label": "part of"
    },
    {
      "source": "ovaries",
      "target": "ethanol-preferring rats",
      "label": "part of"
    },
    {
      "source": "tissue samples",
      "target": "estrogen",
      "label": "evaluated for"
    },
    {
      "source": "tissue samples",
      "target": "animals",
      "label": "harvested from"
    },
    {
      "source": "tissue samples",
      "target": "progesterone",
      "label": "evaluated for"
    },
    {
      "source": "tissue samples",
      "target": "melatonin receptor subunits",
      "label": "evaluated for"
    },
    {
      "source": "tissue samples",
      "target": "androgen",
      "label": "evaluated for"
    },
    {
      "source": "E2",
      "target": "sexual dysfunction",
      "label": "elevation contributes to"
    },
    {
      "source": "sex hormones",
      "target": "oviducts",
      "label": "located in"
    },
    {
      "source": "sex hormones",
      "target": "ovaries",
      "label": "located in"
    },
    {
      "source": "sex hormones",
      "target": "uteri",
      "label": "located in"
    },
    {
      "source": "steroid receptors",
      "target": "oviducts",
      "label": "located in"
    },
    {
      "source": "steroid receptors",
      "target": "ovaries",
      "label": "located in"
    },
    {
      "source": "steroid receptors",
      "target": "uteri",
      "label": "located in"
    },
    {
      "source": "melatonin treatment",
      "target": "sex hormones",
      "label": "has effects on"
    },
    {
      "source": "melatonin treatment",
      "target": "doses",
      "label": "administered in"
    },
    {
      "source": "melatonin treatment",
      "target": "steroid receptors",
      "label": "has effects on"
    },
    {
      "source": "ER-\u03b1",
      "target": "estrogen",
      "label": "is a"
    },
    {
      "source": "PRB",
      "target": "progesterone",
      "label": "is a"
    },
    {
      "source": "Ovarian AR",
      "target": "treatment",
      "label": "Not"
    },
    {
      "source": "MT1R",
      "target": "melatonin receptor subunits",
      "label": "is a"
    },
    {
      "source": "ethanol-melatonin combination",
      "target": "E2",
      "label": "reduced"
    },
    {
      "source": "ethanol-melatonin combination",
      "target": "P4",
      "label": "reduced"
    },
    {
      "source": "Chronic ethanol intake",
      "target": "sex hormone disturbances",
      "label": "associated with"
    },
    {
      "source": "ER-\u03b2",
      "target": "estrogen",
      "label": "is a"
    },
    {
      "source": "SP6001325",
      "target": "AT1R expression",
      "label": "prevents"
    },
    {
      "source": "SP6001325",
      "target": "JNK",
      "label": "inhibits"
    },
    {
      "source": "JNK signaling pathway",
      "target": "AT1R upregulation",
      "label": "leads to"
    },
    {
      "source": "AT1R upregulation",
      "target": "ROS-mediated activation",
      "label": "is a result of"
    },
    {
      "source": "sodium arsenite",
      "target": "AT1AR",
      "label": "increases"
    },
    {
      "source": "sodium arsenite",
      "target": "AT1R",
      "label": "increases"
    },
    {
      "source": "sodium arsenite",
      "target": "AT1BR",
      "label": "increases"
    },
    {
      "source": "sodium arsenite",
      "target": "mRNA levels",
      "label": "increases"
    },
    {
      "source": "arsenic-induced aberrant AT1R signaling",
      "target": "pathogenesis of hypertension",
      "label": "has a role in"
    },
    {
      "source": "SA",
      "target": "phosphorylations",
      "label": "enhances"
    },
    {
      "source": "SA",
      "target": "JNK",
      "label": "enhances"
    },
    {
      "source": "SA",
      "target": "AP-1",
      "label": "enhances"
    },
    {
      "source": "SA",
      "target": "ROS",
      "label": "increases"
    },
    {
      "source": "SA",
      "target": "reactive oxygen species",
      "label": "increases"
    },
    {
      "source": "AP-1",
      "target": "CFVs",
      "label": "abolished"
    },
    {
      "source": "AP-1",
      "target": "monoclonal antibody",
      "label": "is a"
    },
    {
      "source": "AP-1",
      "target": "rabbit TF",
      "label": "targets"
    },
    {
      "source": "ROS-mediated activation",
      "target": "JNK signaling pathway",
      "label": "activates"
    },
    {
      "source": "chronic arsenic exposure",
      "target": "hypertension",
      "label": "correlates with"
    },
    {
      "source": "chronic arsenic exposure",
      "target": "cardiovascular disease",
      "label": "is a risk for"
    },
    {
      "source": "arsenic exposure-induced hypertension",
      "target": "molecular pathogenesis",
      "label": "involves"
    },
    {
      "source": "1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors",
      "target": "HIV capsid (CA) assembly",
      "label": "inhibit"
    },
    {
      "source": "favorable substitutions",
      "target": "SAR",
      "label": "resulted in"
    },
    {
      "source": "favorable substitutions",
      "target": "compound",
      "label": "enabled identification of"
    },
    {
      "source": "labile stereocenter",
      "target": "C3 position",
      "label": "located at"
    },
    {
      "source": "analog 27",
      "target": "compound",
      "label": "is a type of"
    },
    {
      "source": "analog 27",
      "target": "immature Gag assembly",
      "label": "may inhibit"
    },
    {
      "source": "analog 27",
      "target": "mature CA assembly",
      "label": "inhibits"
    },
    {
      "source": "immature Gag assembly",
      "target": "Gag",
      "label": "involves"
    },
    {
      "source": "C3-phenyl moiety",
      "target": "antiviral potency",
      "label": "enables optimization of"
    },
    {
      "source": "antiviral potency",
      "target": "1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione inhibitors",
      "label": "is a property of"
    },
    {
      "source": "1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series",
      "target": "HIV capsid assembly inhibitors",
      "label": "is a type of"
    },
    {
      "source": "Structure-activity relationships (SAR)",
      "target": "C3-phenyl moiety",
      "label": "concerns"
    },
    {
      "source": "Xanthium strumarium",
      "target": "galactitol",
      "label": "inhibits formation of"
    },
    {
      "source": "Xanthium strumarium",
      "target": "recombinant human AR",
      "label": "inhibits"
    },
    {
      "source": "Xanthium strumarium",
      "target": "rAR",
      "label": "inhibits"
    },
    {
      "source": "Xanthium strumarium",
      "target": "Aldose Reductase",
      "label": "inhibits"
    },
    {
      "source": "Xanthium strumarium",
      "target": "AR",
      "label": "inhibits"
    },
    {
      "source": "Xanthium strumarium",
      "target": "rat lens AR",
      "label": "inhibits"
    },
    {
      "source": "Xanthium strumarium",
      "target": "diabetic complications",
      "label": "provides agents for"
    },
    {
      "source": "Xanthium strumarium",
      "target": "aldose reductase",
      "label": "inhibits"
    },
    {
      "source": "Xanthium strumarium",
      "target": "rhAR",
      "label": "inhibits"
    },
    {
      "source": "galactitol",
      "target": "rat lens",
      "label": "forms in"
    },
    {
      "source": "galactitol",
      "target": "rat lenses",
      "label": "forms in"
    },
    {
      "source": "methyl-3,5-di-O-caffeoylquinate",
      "target": "rhAR",
      "label": "competitively inhibits"
    },
    {
      "source": "methyl-3,5-di-O-caffeoylquinate",
      "target": "galactitol",
      "label": "inhibits formation of"
    },
    {
      "source": "methyl-3,5-di-O-caffeoylquinate",
      "target": "rAR",
      "label": "inhibits"
    },
    {
      "source": "methyl-3,5-di-O-caffeoylquinate",
      "target": "diabetic complications",
      "label": "prevents"
    },
    {
      "source": "rat lens",
      "target": "glucose",
      "label": "incubated with"
    },
    {
      "source": "Lineweaver-Burk plots",
      "target": "rhAR",
      "label": "used to analyze inhibition of"
    },
    {
      "source": "phenolic",
      "target": "Xanthium strumarium",
      "label": "component of"
    },
    {
      "source": "erythrocytes",
      "target": "glucose",
      "label": "incubated with"
    },
    {
      "source": "rat lenses",
      "target": "glucose",
      "label": "contain"
    },
    {
      "source": "caffeoylquinic acids",
      "target": "Xanthium strumarium",
      "label": "component of"
    },
    {
      "source": "In Situ Conversion",
      "target": "Hydrothermally Etching",
      "label": "performed by"
    },
    {
      "source": "In Situ Conversion",
      "target": "Nanotube Arrays",
      "label": "produces"
    },
    {
      "source": "Growth Mechanism",
      "target": "TiO2 Nanorod Arrays",
      "label": "describes"
    },
    {
      "source": "Growth Mechanism",
      "target": "Nanotube Arrays",
      "label": "describes"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "FTO Substrate",
      "label": "hydrothermally grown on"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Hydrothermal Selective Etching",
      "label": "converted by"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Nanotube Arrays",
      "label": "converted to"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Quantum Dot-Sensitized Solar Cells",
      "label": "used for"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Electrode",
      "label": "is a type of"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Transparent Conductive Substrates",
      "label": "grown on"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "TiO2",
      "label": "contains"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Polycrystalline",
      "label": "demonstrated to be"
    },
    {
      "source": "TiO2 Nanorod Arrays",
      "target": "Single Crystalline",
      "label": "reported as"
    },
    {
      "source": "Quantum Dot-Sensitized Solar Cells",
      "target": "CdSe QDs",
      "label": "fabricated by coating"
    },
    {
      "source": "CdSe QDs",
      "target": "TiO2 arrays",
      "label": "coated on"
    },
    {
      "source": "CdSe QDs",
      "target": "CdSe",
      "label": "contains"
    },
    {
      "source": "Nanotube Arrays",
      "target": "TiO2",
      "label": "contains"
    },
    {
      "source": "Nanotube Arrays",
      "target": "Transparent Conductive Substrates",
      "label": "grown on"
    },
    {
      "source": "Nanotube Arrays",
      "target": "Quantum Dot-Sensitized Solar Cells",
      "label": "used for"
    },
    {
      "source": "Nanotube Arrays",
      "target": "Electrode",
      "label": "is a type of"
    },
    {
      "source": "TiO2 arrays",
      "target": "TiO2",
      "label": "contains"
    },
    {
      "source": "Hydrothermal Selective Etching",
      "target": "(001) core",
      "label": "targets"
    },
    {
      "source": "Hydrothermal Selective Etching",
      "target": "Inert Sidewall",
      "label": "preserves"
    },
    {
      "source": "Electrode",
      "target": "Solar Cells",
      "label": "used for"
    },
    {
      "source": "Hydrothermal Growth",
      "target": "TiO2 Nanorod Arrays",
      "label": "produces"
    },
    {
      "source": "Polycrystalline",
      "target": "Bundle of 2-5 nm single crystalline nanocolumns",
      "label": "contains"
    },
    {
      "source": "Bundle of 2-5 nm single crystalline nanocolumns",
      "target": "[001]",
      "label": "grows along"
    },
    {
      "source": "QDs",
      "target": "Nanotube Arrays",
      "label": "filled in"
    },
    {
      "source": "Inert Sidewall",
      "target": "(110) face",
      "label": "is a type of"
    },
    {
      "source": "Energy Conversion Efficiency",
      "target": "Quantum Dot-Sensitized Solar Cells",
      "label": "is property of"
    },
    {
      "source": "Mor32u",
      "target": "descriptors",
      "label": "is a type of"
    },
    {
      "source": "descriptors",
      "target": "cytotoxicities",
      "label": "accounted for"
    },
    {
      "source": "inactive p-methoxy analog (4d)",
      "target": "Gu value",
      "label": "had"
    },
    {
      "source": "cytotoxic compound (4k)",
      "target": "Gu value",
      "label": "had"
    },
    {
      "source": "tetrahydroisoquinolines 4k",
      "target": "lead pharmacophores",
      "label": "are"
    },
    {
      "source": "tetrahydroisoquinolines",
      "target": "cytotoxicity",
      "label": "displayed"
    },
    {
      "source": "tetrahydroisoquinolines",
      "target": "MOLT-3 cell lines",
      "label": "displayed cytotoxicity against"
    },
    {
      "source": "QSAR studies",
      "target": "Mor32u",
      "label": "identified as important"
    },
    {
      "source": "QSAR studies",
      "target": "total symmetry index (Gu)",
      "label": "identified as important"
    },
    {
      "source": "QSAR studies",
      "target": "3D Petitjean index (PJI3)",
      "label": "identified as important"
    },
    {
      "source": "QSAR studies",
      "target": "3D-MoRSE",
      "label": "identified as important"
    },
    {
      "source": "QSAR studies",
      "target": "Mor31v",
      "label": "identified as important"
    },
    {
      "source": "1-Substituted-N-tosyl-1,2,3,4-tetrahydroisoquinoline analogs",
      "target": "modified Pictet-Spengler reaction",
      "label": "synthesized using"
    },
    {
      "source": "1-Substituted-N-tosyl-1,2,3,4-tetrahydroisoquinoline analogs",
      "target": "cytotoxicity",
      "label": "evaluated for"
    },
    {
      "source": "N-tosyl-1,2,3,4-tetrahydroisoquinoline derivatives",
      "target": "QSAR study",
      "label": "is subject of"
    },
    {
      "source": "N-tosyl-1,2,3,4-tetrahydroisoquinoline derivatives",
      "target": "cytotoxicity",
      "label": "is subject of"
    },
    {
      "source": "molecular mass compound (4f)",
      "target": "HepG2",
      "label": "is most potent cytotoxic against"
    },
    {
      "source": "Trimethoxy analog 4f",
      "target": "HepG2",
      "label": "exerted activity against"
    },
    {
      "source": "Trimethoxy analog 4f",
      "target": "IC50 value",
      "label": "has"
    },
    {
      "source": "4a-4l",
      "target": "modified Pictet-Spengler reaction",
      "label": "synthesized using"
    },
    {
      "source": "4a-4l",
      "target": "cytotoxicity",
      "label": "evaluated for"
    },
    {
      "source": "QSAR models",
      "target": "physicochemical properties",
      "label": "provided insights into"
    },
    {
      "source": "o-hydroxy derivative 4k",
      "target": "MOLT-3 cell lines",
      "label": "is most potent cytotoxic against"
    },
    {
      "source": "o-hydroxy derivative 4k",
      "target": "A-549",
      "label": "is most potent cytotoxic against"
    },
    {
      "source": "o-hydroxy derivative 4k",
      "target": "HuCCA-1",
      "label": "is most potent cytotoxic against"
    },
    {
      "source": "3D Petitjean index (PJI3)",
      "target": "descriptors",
      "label": "is a type of"
    },
    {
      "source": "total symmetry index (Gu)",
      "target": "descriptors",
      "label": "is a type of"
    },
    {
      "source": "Mor31v",
      "target": "descriptors",
      "label": "is a type of"
    },
    {
      "source": "3D-MoRSE",
      "target": "descriptors",
      "label": "is a type of"
    },
    {
      "source": "p-methoxy analog 4d",
      "target": "cytotoxicity",
      "label": "did not display"
    },
    {
      "source": "tetrahydroisoquinolines 4f",
      "target": "lead pharmacophores",
      "label": "are"
    },
    {
      "source": "Cd-resistant cells",
      "target": "RBL-2H3 cells",
      "label": "developed from"
    },
    {
      "source": "Cd-resistant cells",
      "target": "continuous exposure",
      "label": "developed by"
    },
    {
      "source": "RBL-2H3 cells",
      "target": "high sensitivity",
      "label": "show"
    },
    {
      "source": "metal transporters",
      "target": "roles",
      "label": "have"
    },
    {
      "source": "roles",
      "target": "hyperaccumulation",
      "label": "in"
    },
    {
      "source": "ZIP8 expression",
      "target": "suppression",
      "label": "showed"
    },
    {
      "source": "ZIP8",
      "target": "Zrt-, Irt-related protein 8",
      "label": "is"
    },
    {
      "source": "ZIP8",
      "target": "Slc39a8",
      "label": "encoded by"
    },
    {
      "source": "ZIP8",
      "target": "pivotal role",
      "label": "plays a"
    },
    {
      "source": "hyperaccumulation",
      "target": "cadmium",
      "label": "of"
    },
    {
      "source": "hyperaccumulation",
      "target": "manganese",
      "label": "of"
    },
    {
      "source": "RBL-Mnr cells",
      "target": "cross-resistance",
      "label": "showed"
    },
    {
      "source": "RBL-Mnr cells",
      "target": "LC50 values",
      "label": "exhibited higher"
    },
    {
      "source": "high sensitivity",
      "target": "CdCl2",
      "label": "to"
    },
    {
      "source": "high sensitivity",
      "target": "MnCl2",
      "label": "to"
    },
    {
      "source": "high sensitivity",
      "target": "accumulation",
      "label": "due to"
    },
    {
      "source": "LC50 values",
      "target": "CdCl2",
      "label": "of"
    },
    {
      "source": "LC50 values",
      "target": "MnCl2",
      "label": "of"
    },
    {
      "source": "RBL-Cdr cells",
      "target": "cross-resistance",
      "label": "showed"
    },
    {
      "source": "RBL-Cdr cells",
      "target": "LC50 values",
      "label": "exhibited higher"
    },
    {
      "source": "Mn-resistant cells",
      "target": "RBL-2H3 cells",
      "label": "developed from"
    },
    {
      "source": "Mn-resistant cells",
      "target": "continuous exposure",
      "label": "developed by"
    },
    {
      "source": "pivotal role",
      "target": "toxicity",
      "label": "in"
    },
    {
      "source": "pivotal role",
      "target": "transport",
      "label": "in"
    },
    {
      "source": "continuous exposure",
      "target": "CdCl2",
      "label": "to"
    },
    {
      "source": "continuous exposure",
      "target": "MnCl2",
      "label": "to"
    },
    {
      "source": "Rat basophilic leukemia RBL-2H3 cells",
      "target": "high sensitivity",
      "label": "show"
    },
    {
      "source": "slow oxidative skeletal muscle myofiber gene program",
      "target": "PPAR\u03b3 coactivator 1\u03b1",
      "label": "includes"
    },
    {
      "source": "PPAR\u03b3 coactivator 1\u03b1",
      "target": "PGC-1\u03b1",
      "label": "is an alias for"
    },
    {
      "source": "MAPKAPK2/3",
      "target": "MAPK-activated protein kinases 2 and 3",
      "label": "is an alias for"
    },
    {
      "source": "MAPKAPK2/3",
      "target": "SERCA2a Expression",
      "label": "regulate"
    },
    {
      "source": "MAPKAPK2/3",
      "target": "Cardiomyocyte Function",
      "label": "modulate"
    },
    {
      "source": "MAPKAPK2/3",
      "target": "Skeletal Muscle",
      "label": "modulate"
    },
    {
      "source": "MAPKAPK2/3",
      "target": "Fiber Type Composition",
      "label": "regulate"
    },
    {
      "source": "MAPK-activated protein kinases 2 and 3",
      "target": "protein kinases",
      "label": "represent"
    },
    {
      "source": "MK2/3",
      "target": "cross-striated muscle",
      "label": "role analyzed in"
    },
    {
      "source": "MK2/3",
      "target": "calcium dynamics",
      "label": "is linked to regulation of"
    },
    {
      "source": "MK2/3",
      "target": "MAPK-activated protein kinases 2 and 3",
      "label": "is an alias for"
    },
    {
      "source": "cross-striated muscle",
      "target": "transcriptome analyses",
      "label": "analyzed by"
    },
    {
      "source": "cross-striated muscle",
      "target": "histology",
      "label": "analyzed by"
    },
    {
      "source": "cross-striated muscle",
      "target": "proteome analyses",
      "label": "analyzed by"
    },
    {
      "source": "SERCA2a gene expression",
      "target": "Sp1 ratio",
      "label": "caused by decreased"
    },
    {
      "source": "SERCA2a gene expression",
      "target": "contractility",
      "label": "associated with"
    },
    {
      "source": "SERCA2a gene expression",
      "target": "relaxation",
      "label": "associated with"
    },
    {
      "source": "enhanced force",
      "target": "MK2/3(-/-) mice",
      "label": "observed in"
    },
    {
      "source": "MK2/3(-/-) cardiomyocytes",
      "target": "force parameters",
      "label": "show improved"
    },
    {
      "source": "enzymatic activity of MK2/3",
      "target": "critical factor",
      "label": "identified as"
    },
    {
      "source": "critical factor",
      "target": "cross-striated muscle",
      "label": "modulates"
    },
    {
      "source": "critical factor",
      "target": "unique muscle phenotype",
      "label": "generates"
    },
    {
      "source": "unique muscle phenotype",
      "target": "reduced fatigability",
      "label": "exhibits"
    },
    {
      "source": "unique muscle phenotype",
      "target": "enhanced force",
      "label": "exhibits"
    },
    {
      "source": "reduced fatigability",
      "target": "MK2/3(-/-) mice",
      "label": "observed in"
    },
    {
      "source": "protein kinases",
      "target": "p38 mitogen-activated protein kinase",
      "label": "are downstream of"
    },
    {
      "source": "relaxation",
      "target": "MK2/3(-/-) cardiomyocytes",
      "label": "occurs in"
    },
    {
      "source": "promoters",
      "target": "slow fiber-specific sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) 2 gene",
      "label": "of"
    },
    {
      "source": "promoters",
      "target": "fast fiber-specific myosin heavy chain IId/x",
      "label": "of"
    },
    {
      "source": "slow fiber-specific sarco/endoplasmic reticulum Ca(2+)-ATPase (SERCA) 2 gene",
      "target": "SERCA2",
      "label": "is also known as"
    },
    {
      "source": "MK2/3 double knockout mice",
      "target": "MK2/3(-/-)",
      "label": "is an alias for"
    },
    {
      "source": "force parameters",
      "target": "MK2/3(-/-) soleus muscle",
      "label": "improved in"
    },
    {
      "source": "novel target",
      "target": "therapeutic strategies",
      "label": "for"
    },
    {
      "source": "therapeutic strategies",
      "target": "diseases",
      "label": "for"
    },
    {
      "source": "therapeutic strategies",
      "target": "CFTR function",
      "label": "increase"
    },
    {
      "source": "therapeutic strategies",
      "target": "CFTR expression",
      "label": "increase"
    },
    {
      "source": "MK2 catalytic activity",
      "target": "promoters",
      "label": "regulated"
    },
    {
      "source": "p38-MK2/3 axis",
      "target": "novel target",
      "label": "may represent"
    },
    {
      "source": "CAPE",
      "target": "phospho-Akt Thr 308",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "cell cycle inhibitor p27Kip",
      "label": "increased"
    },
    {
      "source": "CAPE",
      "target": "Akt1",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "G2/M phase cell population",
      "label": "increased"
    },
    {
      "source": "CAPE",
      "target": "phospho-FOXO1 Thr24",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "phospho-Akt Ser473",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "cyclin D1",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "Akt2",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "GSK3\u03b2",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "FOXO1",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "apoptosis",
      "label": "induced"
    },
    {
      "source": "CAPE",
      "target": "colony formation",
      "label": "suppressed"
    },
    {
      "source": "CAPE",
      "target": "growth inhibition",
      "label": "caused"
    },
    {
      "source": "CAPE",
      "target": "cell proliferation",
      "label": "suppressed"
    },
    {
      "source": "CAPE",
      "target": "Akt3",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "Skp2",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "Akt",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "phospho-NF-\u03baB Ser536",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "phospho-FoxO3a Thr32",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "Rb",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "G1 phase cell population",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "NF-\u03baB",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "phospho-Rb Ser807/811",
      "label": "decreased"
    },
    {
      "source": "CAPE",
      "target": "adjuvant therapy",
      "label": "is a potential"
    },
    {
      "source": "CAPE",
      "target": "FOXO3a",
      "label": "decreased"
    },
    {
      "source": "Akt2",
      "target": "growth inhibition",
      "label": "rescued"
    },
    {
      "source": "Caffeic acid phenethyl ester (CAPE)",
      "target": "honeybee hive propolis",
      "label": "is extracted from"
    },
    {
      "source": "Akt1",
      "target": "growth inhibition",
      "label": "rescued"
    },
    {
      "source": "Caffeic Acid Phenethyl Ester",
      "target": "cell proliferation",
      "label": "suppresses"
    },
    {
      "source": "Caffeic Acid Phenethyl Ester",
      "target": "Akt Signaling",
      "label": "inhibits"
    },
    {
      "source": "chemotherapeutic drug",
      "target": "oral cancers",
      "label": "used for"
    },
    {
      "source": "cell cycle-targeting activity",
      "target": "SB",
      "label": "is activity of"
    },
    {
      "source": "SB",
      "target": "IL-8 receptor B",
      "label": "is an antagonist of"
    },
    {
      "source": "SB",
      "target": "dual mechanisms",
      "label": "exerts activity through"
    },
    {
      "source": "SB",
      "target": "cell death",
      "label": "induced"
    },
    {
      "source": "SB",
      "target": "BubR1-dependent mitotic arrest",
      "label": "induced"
    },
    {
      "source": "SB",
      "target": "anti-nociceptive effects",
      "label": "possesses"
    },
    {
      "source": "SB",
      "target": "mitotic arrest",
      "label": "induced"
    },
    {
      "source": "SB",
      "target": "antitumor agent",
      "label": "is an"
    },
    {
      "source": "SB",
      "target": "antimitotic activity",
      "label": "has"
    },
    {
      "source": "SB",
      "target": "vinblastine-binding site",
      "label": "has affinity towards"
    },
    {
      "source": "SB",
      "target": "microtubule destabilizing activity",
      "label": "possesses"
    },
    {
      "source": "SB",
      "target": "IL-8RB",
      "label": "is an antagonist of"
    },
    {
      "source": "SB",
      "target": "p38 MAPK signaling",
      "label": "activated"
    },
    {
      "source": "SB",
      "target": "in vivo anti-inflammatory effects",
      "label": "possesses"
    },
    {
      "source": "SB",
      "target": "cancer cell invasion",
      "label": "inhibits"
    },
    {
      "source": "microtubules targeting",
      "target": "microtubules",
      "label": "targets"
    },
    {
      "source": "SB225002",
      "target": "SB",
      "label": "is also known as"
    },
    {
      "source": "SB225002",
      "target": "microtubule inhibitor",
      "label": "is a"
    },
    {
      "source": "dual mechanisms",
      "target": "IL-8-drivin cancer progression",
      "label": "involve interference with"
    },
    {
      "source": "dual mechanisms",
      "target": "microtubules targeting",
      "label": "involve"
    },
    {
      "source": "IL-8-drivin cancer progression",
      "target": "cancer progression",
      "label": "is a type of"
    },
    {
      "source": "IL-8-drivin cancer progression",
      "target": "IL-8",
      "label": "is driven by"
    },
    {
      "source": "Molecular Mechanisms",
      "target": "antitumor activity",
      "label": "are of"
    },
    {
      "source": "caspase-independent cell death",
      "target": "caspase",
      "label": "does not involve"
    },
    {
      "source": "colorectal adenocarcinoma cells SW480",
      "target": "SW480",
      "label": "is also known as"
    },
    {
      "source": "SB265610",
      "target": "SB225002",
      "label": "is a structural analogue of"
    },
    {
      "source": "SB265610",
      "target": "IL-8RB antagonistic activity",
      "label": "has"
    },
    {
      "source": "SB265610",
      "target": "antimitotic activity",
      "label": "did not exhibit"
    },
    {
      "source": "BAK-dependent mitochondrial apoptosis",
      "target": "BAK",
      "label": "is dependent on"
    },
    {
      "source": "BAK-dependent mitochondrial apoptosis",
      "target": "cell death",
      "label": "contributed to"
    },
    {
      "source": "BAK-dependent mitochondrial apoptosis",
      "target": "mitochondrial apoptosis",
      "label": "is a type of"
    },
    {
      "source": "vinblastine",
      "target": "vinblastine-binding site",
      "label": "binds to"
    },
    {
      "source": "vinblastine-binding site",
      "target": "\u03b2-tubulin subunit",
      "label": "is on"
    },
    {
      "source": "BubR1-dependent mitotic arrest",
      "target": "BubR1",
      "label": "is dependent on"
    },
    {
      "source": "microtubule destabilizing activity",
      "target": "prometaphase arrest",
      "label": "induces"
    },
    {
      "source": "microtubule destabilizing activity",
      "target": "microtubule polymerization",
      "label": "suppresses"
    },
    {
      "source": "microtubule destabilizing activity",
      "target": "hyperphosphorylation",
      "label": "is evidenced by"
    },
    {
      "source": "SB-induced caspase-independent cell death",
      "target": "caspase-independent cell death",
      "label": "is a type of"
    },
    {
      "source": "SB-induced caspase-independent cell death",
      "target": "SB",
      "label": "is induced by"
    },
    {
      "source": "hyperphosphorylation",
      "target": "Bcl2",
      "label": "is of"
    },
    {
      "source": "hyperphosphorylation",
      "target": "BclxL",
      "label": "is of"
    },
    {
      "source": "pharmacologic inhibition",
      "target": "p38 MAPK activity",
      "label": "is of"
    },
    {
      "source": "p38 MAPK activity",
      "target": "SB-induced caspase-independent cell death",
      "label": "mediates"
    },
    {
      "source": "invasive hepatocellular carcinoma HLE cells",
      "target": "HLE cells",
      "label": "is also known as"
    },
    {
      "source": "multivalent GAG",
      "target": "syndecan-1 proteoglycan",
      "label": "contains"
    },
    {
      "source": "multivalent GAG",
      "target": "elongation phenotype",
      "label": "recapitulates"
    },
    {
      "source": "syndecan-1 proteoglycan",
      "target": "elongation phenotype",
      "label": "recapitulates"
    },
    {
      "source": "library",
      "target": "bis- and tris-xylosides",
      "label": "contains"
    },
    {
      "source": "GAG valency",
      "target": "FGF/FGFR interactions",
      "label": "regulates"
    },
    {
      "source": "chain type",
      "target": "FGF/FGFR interactions",
      "label": "regulates"
    },
    {
      "source": "bis- and tris-xylosides",
      "target": "PGs",
      "label": "mimic"
    },
    {
      "source": "bis- and tris-xylosides",
      "target": "GAG chains",
      "label": "produce"
    },
    {
      "source": "bis- and tris-xylosides",
      "target": "elongation phenotype",
      "label": "caused"
    },
    {
      "source": "bis- and tris-xylosides",
      "target": "scaffold",
      "label": "produce on"
    },
    {
      "source": "PGs",
      "target": "development",
      "label": "modulate"
    },
    {
      "source": "PGs",
      "target": "GAG chains",
      "label": "possess"
    },
    {
      "source": "PGs",
      "target": "signaling pathways",
      "label": "modulate"
    },
    {
      "source": "elongated embryos",
      "target": "expression",
      "label": "have elevated"
    },
    {
      "source": "GAG multivalency",
      "target": "biological functions",
      "label": "is imperative for"
    },
    {
      "source": "sprouty4",
      "target": "FGFR",
      "label": "is an antagonist of"
    },
    {
      "source": "FGF Signaling",
      "target": "Zebrafish Development",
      "label": "is involved in"
    },
    {
      "source": "elongation",
      "target": "sprouty4",
      "label": "reversed by"
    },
    {
      "source": "elongation",
      "target": "FGF8",
      "label": "reversed by"
    },
    {
      "source": "elongation",
      "target": "SU5402",
      "label": "reversed by"
    },
    {
      "source": "elongation",
      "target": "FGF8 morpholino",
      "label": "reversed by"
    },
    {
      "source": "elongation",
      "target": "mRNA",
      "label": "reversed by"
    },
    {
      "source": "reporters",
      "target": "pathways",
      "label": "are for"
    },
    {
      "source": "SU5402",
      "target": "tyrosine kinase",
      "label": "is an inhibitor of"
    },
    {
      "source": "FGF/FGFR interactions",
      "target": "zebrafish",
      "label": "occur in"
    },
    {
      "source": "mono-xylosides",
      "target": "elongation phenotype",
      "label": "did not cause"
    },
    {
      "source": "elongation phenotype",
      "target": "bivalent xylosides",
      "label": "observed with"
    },
    {
      "source": "Endogenous GAGs",
      "target": "xyloside treatment",
      "label": "unaffected by"
    },
    {
      "source": "xyloside treatment",
      "target": "gain-of-function phenotype",
      "label": "results in"
    },
    {
      "source": "biological significance",
      "target": "GAG multivalency",
      "label": "is of"
    },
    {
      "source": "injection",
      "target": "embryos",
      "label": "into"
    },
    {
      "source": "embryos",
      "target": "in situ transcription/aRNA techniques",
      "label": "processed by"
    },
    {
      "source": "embryos",
      "target": "gene expression",
      "label": "analyzed for"
    },
    {
      "source": "monovalent GAG",
      "target": "elongation phenotype",
      "label": "does not recapitulate"
    },
    {
      "source": "dimerized GAG chains",
      "target": "FGF-mediated signal transduction pathways",
      "label": "activate"
    },
    {
      "source": "signaling molecules",
      "target": "fibroblast growth factors",
      "label": "include"
    },
    {
      "source": "signaling molecules",
      "target": "FGFs",
      "label": "include"
    },
    {
      "source": "Proteoglycans",
      "target": "development",
      "label": "modulate"
    },
    {
      "source": "Proteoglycans",
      "target": "signaling pathways",
      "label": "modulate"
    },
    {
      "source": "Proteoglycans",
      "target": "Versican",
      "label": "include"
    },
    {
      "source": "Proteoglycans",
      "target": "Serglycin",
      "label": "include"
    },
    {
      "source": "Dimerized Glycosaminoglycan Chains",
      "target": "FGF Signaling",
      "label": "increase"
    },
    {
      "source": "glycosaminoglycan (GAG) side chains",
      "target": "signaling molecules",
      "label": "bind to"
    },
    {
      "source": "FGF/FGFR signaling",
      "target": "FGF/FGFR signaling",
      "label": "was hyperactivated"
    },
    {
      "source": "in vivo findings",
      "target": "model",
      "label": "are basis for"
    },
    {
      "source": "Fisetin",
      "target": "GSH levels",
      "label": "increases"
    },
    {
      "source": "Fisetin",
      "target": "Nrf2",
      "label": "increases levels of"
    },
    {
      "source": "Fisetin",
      "target": "Nrf2-dependent gene transcription",
      "label": "increases"
    },
    {
      "source": "Fisetin",
      "target": "ATF4-dependent gene transcription",
      "label": "increases"
    },
    {
      "source": "Fisetin",
      "target": "ATF4",
      "label": "increases levels of"
    },
    {
      "source": "Fisetin",
      "target": "gene transcription",
      "label": "increases"
    },
    {
      "source": "Fisetin",
      "target": "stability",
      "label": "increases"
    },
    {
      "source": "GSH levels",
      "target": "diseases",
      "label": "is a treatment objective for"
    },
    {
      "source": "GSH-associated metabolism",
      "target": "cells",
      "label": "provides defense for"
    },
    {
      "source": "Glutathione",
      "target": "cells",
      "label": "provides defense for"
    },
    {
      "source": "Glutathione",
      "target": "GSH",
      "label": "IS_A"
    },
    {
      "source": "nuclear accumulation",
      "target": "upregulation",
      "label": "leads to"
    },
    {
      "source": "nuclear accumulation",
      "target": "downregulation",
      "label": "leads to"
    },
    {
      "source": "nuclear accumulation",
      "target": "c-Abl/TAp73",
      "label": "of"
    },
    {
      "source": "oocytes",
      "target": "primordial follicles",
      "label": "located within"
    },
    {
      "source": "oocytes",
      "target": "avascular regions",
      "label": "located within"
    },
    {
      "source": "oocytes",
      "target": "chemotherapy",
      "label": "are susceptible to"
    },
    {
      "source": "TAp73",
      "target": "expression",
      "label": "has"
    },
    {
      "source": "cisplatin-induced oocyte death",
      "target": "early follicles",
      "label": "occurs in"
    },
    {
      "source": "cisplatin-induced apoptosis",
      "target": "oocytes",
      "label": "affects"
    },
    {
      "source": "imatinib mesylate",
      "target": "fertoprotective drug",
      "label": "is a"
    },
    {
      "source": "imatinib mesylate",
      "target": "c-Abl kinase inhibitor",
      "label": "is a type of"
    },
    {
      "source": "fertoprotective drug",
      "target": "cisplatin",
      "label": "acts against"
    },
    {
      "source": "conditional deletion",
      "target": "apoptosis",
      "label": "inhibited"
    },
    {
      "source": "conditional deletion",
      "target": "accumulation",
      "label": "inhibited"
    },
    {
      "source": "master regulator",
      "target": "cisplatin-induced oocyte death",
      "label": "of"
    },
    {
      "source": "c-Abl kinase",
      "target": "TAp73-BAX-mediated apoptosis",
      "label": "activates"
    },
    {
      "source": "damage response",
      "target": "upregulation",
      "label": "includes"
    },
    {
      "source": "TAp63",
      "target": "master regulator",
      "label": "is the"
    },
    {
      "source": "Trp63",
      "target": "conditional deletion",
      "label": "undergoes"
    },
    {
      "source": "c-Abl",
      "target": "BAX",
      "label": "induces"
    },
    {
      "source": "c-Abl",
      "target": "expression",
      "label": "has"
    },
    {
      "source": "p53 family signaling network",
      "target": "programmed cell death",
      "label": "causes"
    },
    {
      "source": "avascular regions",
      "target": "ovary",
      "label": "are part of"
    },
    {
      "source": "endocrine function",
      "target": "chemotherapy",
      "label": "is conserved against"
    },
    {
      "source": "endocrine function",
      "target": "ovary",
      "label": "of"
    },
    {
      "source": "c-Abl kinase inhibitors",
      "target": "cisplatin-induced oocyte death",
      "label": "halt"
    },
    {
      "source": "c-Abl-induced BAX expression",
      "target": "TAp73",
      "label": "activates"
    },
    {
      "source": "MDRD and CKD-EPI equations",
      "target": "mClcr",
      "label": "significantly overestimated"
    },
    {
      "source": "MDRD and CKD-EPI equations",
      "target": "elderly individuals",
      "label": "overestimated in"
    },
    {
      "source": "MDRD and CKD-EPI equations",
      "target": "Cockcroft-Gault (CG)",
      "label": "were significantly positively biased compared with"
    },
    {
      "source": "MDRD and CKD-EPI equations",
      "target": "Creatinine Clearance",
      "label": "significantly overestimated"
    },
    {
      "source": "MDRD and CKD-EPI equations",
      "target": "median dose discordance rates",
      "label": "had"
    },
    {
      "source": "dose calculation errors",
      "target": "many drugs",
      "label": "for"
    },
    {
      "source": "dose calculation errors",
      "target": "individuals with severe renal impairment",
      "label": "occur in"
    },
    {
      "source": "low Scr values",
      "target": "arbitrary value of 1.0 mg/dl",
      "label": "rounded up to"
    },
    {
      "source": "performance",
      "target": "bias",
      "label": "assessed by measuring"
    },
    {
      "source": "performance",
      "target": "precision",
      "label": "assessed by measuring"
    },
    {
      "source": "bias",
      "target": "mClcr",
      "label": "relative to"
    },
    {
      "source": "Kidney function",
      "target": "Modification of Diet in Renal Disease (MDRD)",
      "label": "estimated by"
    },
    {
      "source": "Kidney function",
      "target": "Cockcroft-Gault (CG)",
      "label": "estimated by"
    },
    {
      "source": "Kidney function",
      "target": "Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)",
      "label": "estimated by"
    },
    {
      "source": "CG values",
      "target": "mClcr",
      "label": "were significantly lower than"
    },
    {
      "source": "CG values",
      "target": "Cockcroft-Gault (CG)",
      "label": "were significantly lower than"
    },
    {
      "source": "common practice of rounding or replacing low Scr values",
      "target": "arbitrary value of 1.0 mg/dl",
      "label": "involves"
    },
    {
      "source": "common practice of rounding or replacing low Scr values",
      "target": "low Scr values",
      "label": "involves"
    },
    {
      "source": "common practice of rounding or replacing low Scr values",
      "target": "CG equation",
      "label": "for use in"
    },
    {
      "source": "common practice of rounding or replacing low Scr values",
      "target": "CG values",
      "label": "resulted in"
    },
    {
      "source": "kidney function estimation equations",
      "target": "performance",
      "label": "performance of"
    },
    {
      "source": "Glomerular Filtration Rate Equations",
      "target": "Creatinine Clearance",
      "label": "overestimate"
    },
    {
      "source": "Glomerular Filtration Rate Equations",
      "target": "Older Individuals",
      "label": "overestimate in"
    },
    {
      "source": "Glomerular Filtration Rate Equations",
      "target": "Renal Drug Dosing",
      "label": "impact on"
    },
    {
      "source": "precision",
      "target": "mClcr",
      "label": "relative to"
    },
    {
      "source": "alternative eGFR equations",
      "target": "pharmacokinetic outcomes measures",
      "label": "incorporate"
    },
    {
      "source": "alternative eGFR equations",
      "target": "pharmacodynamic outcomes measures",
      "label": "incorporate"
    },
    {
      "source": "alternative eGFR equations",
      "target": "older populations",
      "label": "evaluate in"
    },
    {
      "source": "dosages",
      "target": "Food and Drug Administration",
      "label": "approved by"
    },
    {
      "source": "Older Individuals",
      "target": "Baltimore Longitudinal Study on Aging",
      "label": "enrolled in"
    },
    {
      "source": "community-dwelling volunteers",
      "target": "Baltimore Longitudinal Study of Aging",
      "label": "selected from"
    },
    {
      "source": "equations estimating glomerular filtration rate",
      "target": "older adults",
      "label": "should not be substituted in"
    },
    {
      "source": "equations estimating glomerular filtration rate",
      "target": "renal dosage adjustments",
      "label": "for the purpose of"
    },
    {
      "source": "equations estimating glomerular filtration rate",
      "target": "CG equation",
      "label": "should not be substituted in place of"
    },
    {
      "source": "CG equation",
      "target": "mClcr",
      "label": "was least biased estimate of"
    },
    {
      "source": "Dose calculation errors (discordance)",
      "target": "dosages",
      "label": "compared with"
    },
    {
      "source": "Dose calculation errors (discordance)",
      "target": "drugs",
      "label": "determined for"
    },
    {
      "source": "renal dosage adjustments",
      "target": "toxicity",
      "label": "avoid"
    },
    {
      "source": "drug dose discordance",
      "target": "older population",
      "label": "frequency in"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "rats",
      "label": "TESTED_IN"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "protective effect",
      "label": "EVALUATED_FOR"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "rat model",
      "label": "TESTED_IN"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "anti-ulcerogenic activities",
      "label": "HAS_HIGHER"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "Acacia ferruginea stem bark",
      "label": "IS_A_FRACTION_OF"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "AFE",
      "label": "IS_A"
    },
    {
      "source": "ethyl acetate fraction",
      "target": "antioxidant activities",
      "label": "HAS_HIGHER"
    },
    {
      "source": "stomach tissues",
      "target": "ethanol control group",
      "label": "COMPARED_WITH"
    },
    {
      "source": "AFE",
      "target": "antioxidant activities",
      "label": "HAS_HIGHER"
    },
    {
      "source": "AFE",
      "target": "crude acetone extract",
      "label": "COMPARED_TO"
    },
    {
      "source": "AFE",
      "target": "doses",
      "label": "ADMINISTERED_AT"
    },
    {
      "source": "AFE",
      "target": "stomach ulceration",
      "label": "PROTECTED_AGAINST"
    },
    {
      "source": "AFE",
      "target": "fractions",
      "label": "COMPARED_TO"
    },
    {
      "source": "AFE",
      "target": "quercetin",
      "label": "COMPARED_TO"
    },
    {
      "source": "AFE",
      "target": "Acacia ferruginea stem bark",
      "label": "IS_A_FRACTION_OF"
    },
    {
      "source": "AFE",
      "target": "free radical scavenging activities",
      "label": "HAS_HIGHER"
    },
    {
      "source": "AFE",
      "target": "IC50 values",
      "label": "HAS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "leucoderma",
      "label": "TREATS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "diseases of the blood",
      "label": "TREATS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "anti-ulcerogenic activities",
      "label": "HAS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "itching",
      "label": "TREATS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "anti-ulcer agent",
      "label": "IS_AN"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "stomatitis",
      "label": "TREATS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "antioxidant activities",
      "label": "HAS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "therapeutic approach",
      "label": "HAS_POTENTIAL_TO_PROVIDE"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "ulcers",
      "label": "TREATS"
    },
    {
      "source": "Acacia ferruginea stem bark",
      "target": "traditional systems of medicine",
      "label": "USED_IN"
    },
    {
      "source": "in vitro systems",
      "target": "ABTS(\u2022+) scavenging",
      "label": "INCLUDE"
    },
    {
      "source": "in vitro systems",
      "target": "DPPH(\u2022)",
      "label": "INCLUDE"
    },
    {
      "source": "in vitro systems",
      "target": "phosphomolybdenum reduction activities",
      "label": "INCLUDE"
    },
    {
      "source": "in vitro systems",
      "target": "FRAP",
      "label": "INCLUDE"
    },
    {
      "source": "Enzyme activities",
      "target": "lipid peroxidation",
      "label": "INCLUDE"
    },
    {
      "source": "Enzyme activities",
      "target": "superoxide dismutase",
      "label": "INCLUDE"
    },
    {
      "source": "Enzyme activities",
      "target": "catalase",
      "label": "INCLUDE"
    },
    {
      "source": "Enzyme activities",
      "target": "glutathione",
      "label": "INCLUDE"
    },
    {
      "source": "gastric ulcer",
      "target": "ethanol",
      "label": "INDUCED_BY"
    },
    {
      "source": "sub-fractions",
      "target": "antioxidant potential",
      "label": "HAS"
    },
    {
      "source": "antioxidant potential",
      "target": "in vitro systems",
      "label": "ASSESSED_USING"
    },
    {
      "source": "gastric damage",
      "target": "ethanol",
      "label": "INDUCED_BY"
    },
    {
      "source": "Acetone extract",
      "target": "antioxidant potential",
      "label": "HAS"
    },
    {
      "source": "RBV tripalmitate",
      "target": "enzymatic activity",
      "label": "releases RBV in presence of"
    },
    {
      "source": "RBV tripalmitate",
      "target": "nanostructures",
      "label": "is entrapped into"
    },
    {
      "source": "RBV tripalmitate",
      "target": "RBV",
      "label": "releases"
    },
    {
      "source": "RBV tripalmitate-loaded PHEA-EDA-PLA-GAL micelles",
      "target": "HepG2",
      "label": "showed specificity toward"
    },
    {
      "source": "RBV tripalmitate-loaded PHEA-EDA-PLA-GAL micelles",
      "target": "competitive inhibition assay",
      "label": "specificity demonstrated by"
    },
    {
      "source": "PHEA-EDA-PLA-GAL",
      "target": "PHEA-EDA-PLA-GAL copolymer",
      "label": "is also known as"
    },
    {
      "source": "PHEA-EDA-PLA-GAL copolymer",
      "target": "copolymer",
      "label": "is a"
    },
    {
      "source": "PHEA-EDA-PLA-GAL copolymer",
      "target": "PLA",
      "label": "obtained from"
    },
    {
      "source": "PHEA-EDA-PLA-GAL copolymer",
      "target": "PHEA-EDA",
      "label": "obtained from"
    },
    {
      "source": "PHEA-EDA-PLA-GAL copolymer",
      "target": "lactose",
      "label": "obtained from"
    },
    {
      "source": "ribavirin",
      "target": "prodrug",
      "label": "is a"
    },
    {
      "source": "ribavirin",
      "target": "RBV",
      "label": "is also known as"
    },
    {
      "source": "hepatitis C treatment",
      "target": "hepatitis C",
      "label": "is for"
    },
    {
      "source": "competitive inhibition assay",
      "target": "free GAL",
      "label": "used in presence of"
    },
    {
      "source": "free GAL",
      "target": "GAL",
      "label": "is also known as"
    },
    {
      "source": "Polymeric micelles",
      "target": "prodrug",
      "label": "carry"
    },
    {
      "source": "Polymeric micelles",
      "target": "HEPATOCYTES",
      "label": "carry to"
    },
    {
      "source": "Polymeric micelles",
      "target": "galactosylated polylactide-polyaminoacid conjugate",
      "label": "prepared from"
    },
    {
      "source": "Polymeric micelles",
      "target": "ribavirin",
      "label": "carry"
    },
    {
      "source": "alpha,beta-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-DL-aspartamide",
      "target": "PHEA-EDA",
      "label": "is also known as"
    },
    {
      "source": "Liver-targeted RBV tripalmitate-loaded micelles",
      "target": "aqueous media",
      "label": "obtained in"
    },
    {
      "source": "Liver-targeted RBV tripalmitate-loaded micelles",
      "target": "nanostructures",
      "label": "are a type of"
    },
    {
      "source": "Liver-targeted RBV tripalmitate-loaded micelles",
      "target": "PHEA-EDA-PLA-GAL copolymer",
      "label": "obtained using"
    },
    {
      "source": "Liver-targeted RBV tripalmitate-loaded micelles",
      "target": "RBV tripalmitate",
      "label": "are loaded with"
    },
    {
      "source": "Liver-targeted RBV tripalmitate-loaded micelles",
      "target": "micelles",
      "label": "are a type of"
    },
    {
      "source": "galactosylated polylactide-polyaminoacid conjugate",
      "target": "alpha,beta-poly(N-2-hydroxyethyl) (2-aminoethylcarbamate)-DL-aspartamide",
      "label": "obtained from"
    },
    {
      "source": "galactosylated polylactide-polyaminoacid conjugate",
      "target": "polylactic acid",
      "label": "obtained by reaction with"
    },
    {
      "source": "galactosylated polylactide-polyaminoacid conjugate",
      "target": "PLA",
      "label": "obtained by reaction with"
    },
    {
      "source": "galactosylated polylactide-polyaminoacid conjugate",
      "target": "lactose",
      "label": "obtained by reaction with"
    },
    {
      "source": "galactosylated polylactide-polyaminoacid conjugate",
      "target": "PHEA-EDA-PLA-GAL copolymer",
      "label": "is also known as"
    },
    {
      "source": "micelles-based liver-targeted drug delivery strategy",
      "target": "hepatitis C treatment",
      "label": "is for"
    },
    {
      "source": "micelles-based liver-targeted drug delivery strategy",
      "target": "drug delivery strategy",
      "label": "is a type of"
    },
    {
      "source": "polylactic acid",
      "target": "PLA",
      "label": "is also known as"
    },
    {
      "source": "in vitro experiments",
      "target": "HepG2",
      "label": "demonstrated specificity toward"
    },
    {
      "source": "in vitro experiments",
      "target": "RBV tripalmitate-loaded PHEA-EDA-PLA-GAL micelles",
      "label": "demonstrated specificity of"
    },
    {
      "source": "RIBAVIRIN PRODRUG",
      "target": "HEPATOCYTES",
      "label": "targets"
    },
    {
      "source": "hydrophobic RBV prodrug",
      "target": "RBV tripalmitate",
      "label": "is also known as"
    },
    {
      "source": "GALACTOSYLATED MICELLES",
      "target": "RIBAVIRIN PRODRUG",
      "label": "are for"
    },
    {
      "source": "Reconstitution",
      "target": "Complexes",
      "label": "of"
    },
    {
      "source": "Reconstitution",
      "target": "reduction sensitive heteromer",
      "label": "produces"
    },
    {
      "source": "Reconstitution",
      "target": "Versican",
      "label": "involves"
    },
    {
      "source": "Reconstitution",
      "target": "Serglycin",
      "label": "involves"
    },
    {
      "source": "Reconstitution",
      "target": "proMMP-9",
      "label": "involves"
    },
    {
      "source": "Reconstitution",
      "target": "CSPGs",
      "label": "involves"
    },
    {
      "source": "Reconstitution",
      "target": "SDS-stable heteromers",
      "label": "produces"
    },
    {
      "source": "Complexes",
      "target": "proMatrix Metalloproteinase-9",
      "label": "involve"
    },
    {
      "source": "Complexes",
      "target": "Proteoglycans",
      "label": "involve"
    },
    {
      "source": "macromolecules",
      "target": "reduction sensitive heteromer",
      "label": "are in"
    },
    {
      "source": "macromolecules",
      "target": "disulphide bonds",
      "label": "not linked by"
    },
    {
      "source": "macromolecules",
      "target": "SDS-stable heteromers",
      "label": "are in"
    },
    {
      "source": "reduction sensitive heteromer",
      "target": "Versican",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "reduction sensitive heteromer",
      "target": "Serglycin",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "reduction sensitive heteromer",
      "target": "proMMP-9",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "reduction sensitive heteromer",
      "target": "CSPGs",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "SDS-stable heteromers",
      "target": "CSPGs",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "SDS-stable heteromers",
      "target": "gelatin",
      "label": "binds weakly to"
    },
    {
      "source": "SDS-stable heteromers",
      "target": "Versican",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "SDS-stable heteromers",
      "target": "Serglycin",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "SDS-stable heteromers",
      "target": "proMMP-9",
      "label": "can be reconstituted by mixing with"
    },
    {
      "source": "CSPGs",
      "target": "monocytic cell lines",
      "label": "isolated from"
    },
    {
      "source": "gelatin",
      "target": "Reconstitution",
      "label": "inhibited"
    },
    {
      "source": "hemopexin-like (PEX) domain",
      "target": "heteromer formation",
      "label": "involved in"
    },
    {
      "source": "hemopexin-like (PEX) domain",
      "target": "enzyme",
      "label": "is part of"
    },
    {
      "source": "SDS-soluble proMMP-9\u00b7CSPG heteromer",
      "target": "proMMP-9",
      "label": "contains"
    },
    {
      "source": "SDS-soluble proMMP-9\u00b7CSPG heteromer",
      "target": "CSPG",
      "label": "contains"
    },
    {
      "source": "SDS-soluble proMMP-9\u00b7CSPG heteromer",
      "target": "proMMP-9\u00b7CSPG heteromer",
      "label": "is a type of"
    },
    {
      "source": "SDS-soluble proMMP-9\u00b7CSPG heteromer",
      "target": "gelatin",
      "label": "binds weakly to"
    },
    {
      "source": "fibronectin-like (FnII) module",
      "target": "heteromer formation",
      "label": "involved in"
    },
    {
      "source": "fibronectin-like (FnII) module",
      "target": "complex formation",
      "label": "involved in"
    },
    {
      "source": "fibronectin-like (FnII) module",
      "target": "enzyme",
      "label": "is part of"
    },
    {
      "source": "CSPG",
      "target": "core protein",
      "label": "is a"
    },
    {
      "source": "TIMP-1",
      "target": "proMMP-9\u00b7CSPG complexes",
      "label": "not detected in"
    },
    {
      "source": "TIMP-1",
      "target": "SDS-soluble proMMP-9\u00b7CSPG heteromer",
      "label": "inhibited formation of"
    },
    {
      "source": "chondroitin sulphate proteoglycan",
      "target": "CSPG",
      "label": "is also known as"
    },
    {
      "source": "proMMP-9 monomer",
      "target": "gelatin",
      "label": "binds strongly to"
    },
    {
      "source": "chronic exposure",
      "target": "drinking water",
      "label": "is through"
    },
    {
      "source": "chronic exposure",
      "target": "arsenic",
      "label": "is to"
    },
    {
      "source": "chronic exposure",
      "target": "public health",
      "label": "is a problem of"
    },
    {
      "source": "combined Na2SeO3+NaAsO2 treatment group",
      "target": "SOD1",
      "label": "increased mRNA levels of"
    },
    {
      "source": "combined Na2SeO3+NaAsO2 treatment group",
      "target": "CAT",
      "label": "increased mRNA levels of"
    },
    {
      "source": "combined Na2SeO3+NaAsO2 treatment group",
      "target": "Txnrd1",
      "label": "increased mRNA levels of"
    },
    {
      "source": "combined Na2SeO3+NaAsO2 treatment group",
      "target": "GPx",
      "label": "increased mRNA levels of"
    },
    {
      "source": "MDA content",
      "target": "Na2SeO3 intervention group",
      "label": "decreased in"
    },
    {
      "source": "MDA content",
      "target": "liver tissue",
      "label": "is in"
    },
    {
      "source": "MDA content",
      "target": "control groups",
      "label": "decreased compared to"
    },
    {
      "source": "MDA content",
      "target": "Na2SeO3 groups",
      "label": "decreased compared to"
    },
    {
      "source": "NaAsO2 group",
      "target": "HO-1",
      "label": "increased expressions of"
    },
    {
      "source": "NaAsO2 group",
      "target": "HSP70",
      "label": "increased expressions of"
    },
    {
      "source": "arsenic",
      "target": "metalloid",
      "label": "is a"
    },
    {
      "source": "Na2SeO3",
      "target": "antioxidant enzymes",
      "label": "improves activities of"
    },
    {
      "source": "Na2SeO3",
      "target": "liver cells",
      "label": "protects"
    },
    {
      "source": "Na2SeO3",
      "target": "Oxidative stress related genes",
      "label": "adjusts expression of"
    },
    {
      "source": "metalloid",
      "target": "environment",
      "label": "exists in"
    },
    {
      "source": "combined treatment group",
      "target": "HSP70",
      "label": "reduced expressions of"
    },
    {
      "source": "combined treatment group",
      "target": "HO-1",
      "label": "reduced expressions of"
    },
    {
      "source": "Oxidative stress related genes",
      "target": "liver stress state",
      "label": "reflect"
    },
    {
      "source": "chronic poisoning",
      "target": "arsenic",
      "label": "is of"
    },
    {
      "source": "As",
      "target": "metalloid",
      "label": "is a"
    },
    {
      "source": "NaAsO2",
      "target": "oxidative damage",
      "label": "causes"
    },
    {
      "source": "GPx",
      "target": "liver markers",
      "label": "IS_A"
    },
    {
      "source": "GPx",
      "target": "liver samples",
      "label": "DETERMINED_IN"
    },
    {
      "source": "GPx",
      "target": "colorimetric methods",
      "label": "DETERMINED_BY"
    },
    {
      "source": "chronic arsenic poisoning",
      "target": "rat liver",
      "label": "occurs in"
    },
    {
      "source": "AMPK\u03b11",
      "target": "SOCE",
      "label": "knockdown augments"
    },
    {
      "source": "AMPK\u03b11",
      "target": "p38\u03b2 phosphorylation",
      "label": "knockdown suppresses"
    },
    {
      "source": "AMPK\u03b11",
      "target": "p38\u03b2 MAPK",
      "label": "activates"
    },
    {
      "source": "SOCE",
      "target": "TRPC channels",
      "label": "occurs through"
    },
    {
      "source": "SOCE",
      "target": "isoform \u03b11",
      "label": "causes phosphorylation of"
    },
    {
      "source": "SOCE",
      "target": "Orai channels",
      "label": "occurs through"
    },
    {
      "source": "SOCE",
      "target": "AMP-activated Protein Kinase",
      "label": "activates"
    },
    {
      "source": "SOCE",
      "target": "CaMKK\u03b2",
      "label": "activates"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "AMP-activated Protein Kinase",
      "label": "occurs through"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "Endothelial Cells",
      "label": "occurs in"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "permeability responses",
      "label": "suppresses"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "endothelial SOCE",
      "label": "suppresses"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "SOCE",
      "label": "inhibits"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "p38beta Mitogen-activated Protein Kinase",
      "label": "occurs through"
    },
    {
      "source": "STIM1 Phosphorylation",
      "target": "serine residues",
      "label": "occurs on"
    },
    {
      "source": "p38\u03b2",
      "target": "SOCE",
      "label": "knockdown potentiates"
    },
    {
      "source": "p38\u03b2",
      "target": "STIM1 Phosphorylation",
      "label": "knockdown prevents"
    },
    {
      "source": "p38\u03b2",
      "target": "p38 MAPK isoforms",
      "label": "is an isoform of"
    },
    {
      "source": "PAR-1",
      "target": "p38\u03b2 phosphorylation",
      "label": "mediates"
    },
    {
      "source": "PAR-1",
      "target": "Ca2+ entry",
      "label": "induces"
    },
    {
      "source": "PAR-1",
      "target": "STIM1 Phosphorylation",
      "label": "mediates"
    },
    {
      "source": "p38\u03b2 phosphorylation",
      "target": "STIM1 Phosphorylation",
      "label": "leads to"
    },
    {
      "source": "CaMKK\u03b2",
      "target": "p38\u03b2 phosphorylation",
      "label": "inhibition suppresses"
    },
    {
      "source": "CaMKK\u03b2",
      "target": "SOCE",
      "label": "is a downstream target of"
    },
    {
      "source": "CaMKK\u03b2",
      "target": "AMPK\u03b11",
      "label": "activates"
    },
    {
      "source": "Protease-activated Receptor-1",
      "target": "Store-operated Ca2+ Entry",
      "label": "induces"
    },
    {
      "source": "Store-operated Ca2+ Entry",
      "target": "STIM1 Phosphorylation",
      "label": "mediates"
    },
    {
      "source": "isoform \u03b11",
      "target": "AMPK catalytic subunit",
      "label": "is part of"
    },
    {
      "source": "isoform \u03b12",
      "target": "AMPK catalytic subunit",
      "label": "is part of"
    },
    {
      "source": "p38\u03b2 MAPK",
      "target": "SOCE",
      "label": "inhibits"
    },
    {
      "source": "p38\u03b2 MAPK",
      "target": "STIM1",
      "label": "phosphorylates"
    },
    {
      "source": "AICAR pretreatment",
      "target": "PAR-1-induced increase in permeability",
      "label": "blocks"
    },
    {
      "source": "Ca2+ sensor STIM1",
      "target": "SOCE",
      "label": "activates"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "MMPs",
      "label": "can probe activity of"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "MMP-2",
      "label": "modulates activity of"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "kinetic and biological characteristics",
      "label": "has"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "intermediate- and deep-pocket MMPs",
      "label": "is selective to"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "MMPIs",
      "label": "is a type of"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "disease",
      "label": "can probe activity in"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "MMP-14",
      "label": "modulates activity of"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "shallow-pocketed MMPs",
      "label": "is not selective to"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "trans- form",
      "label": "has preference for"
    },
    {
      "source": "3-mercapto-4-arylsulfonamido pyrrolidine matrix metalloproteinase inhibitors",
      "target": "MMP-13",
      "label": "modulates activity of"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "kinetic and biological characteristics",
      "label": "has"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "MMPs",
      "label": "can probe activity of"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "intermediate- and deep-pocket MMPs",
      "label": "is selective to"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "MMP-2",
      "label": "modulates activity of"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "disease",
      "label": "can probe activity in"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "MMPIs",
      "label": "is a type of"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "shallow-pocketed MMPs",
      "label": "is not selective to"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "trans- form",
      "label": "has preference for"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "MMP-14",
      "label": "modulates activity of"
    },
    {
      "source": "pyrrolidine mercaptosulfide",
      "target": "MMP-13",
      "label": "modulates activity of"
    },
    {
      "source": "trans- form",
      "target": "biological compatibility",
      "label": "has increased"
    },
    {
      "source": "trans- form",
      "target": "oxidative stability",
      "label": "has increased"
    },
    {
      "source": "trans- form",
      "target": "mercaptosulfonamides",
      "label": "is a form of"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "disease",
      "label": "can probe activity in"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "MMPIs",
      "label": "is a type of"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "shallow-pocketed MMPs",
      "label": "is not selective to"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "trans- form",
      "label": "has preference for"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "MMP-14",
      "label": "modulates activity of"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "MMP-13",
      "label": "modulates activity of"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "intermediate- and deep-pocket MMPs",
      "label": "is selective to"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "MMPs",
      "label": "can probe activity of"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "kinetic and biological characteristics",
      "label": "has"
    },
    {
      "source": "2-mercaptocyclopentane arylsulfonamide",
      "target": "MMP-2",
      "label": "modulates activity of"
    },
    {
      "source": "cis-(3S,4R)- stereochemistry",
      "target": "MMPs",
      "label": "is optimal for"
    },
    {
      "source": "MMP-7",
      "target": "shallow-pocketed MMPs",
      "label": "is a type of"
    },
    {
      "source": "MMP-1",
      "target": "shallow-pocketed MMPs",
      "label": "is a type of"
    },
    {
      "source": "Matrix Metalloproteinase Inhibitors",
      "target": "3-Mercaptopyrrolidine Core",
      "label": "are based on"
    },
    {
      "source": "mercaptosulfide functionality",
      "target": "cyclopentane",
      "label": "is attached to"
    },
    {
      "source": "mercaptosulfide functionality",
      "target": "pyrrolidine frameworks",
      "label": "is attached to"
    },
    {
      "source": "PON1 gene polymorphism",
      "target": "AChE enzyme activities",
      "label": "affects"
    },
    {
      "source": "PON1 gene polymorphism",
      "target": "PON",
      "label": "affects"
    },
    {
      "source": "AChE enzyme activities",
      "target": "genotypes",
      "label": "increase according to"
    },
    {
      "source": "54 individuals",
      "target": "OPs",
      "label": "exposed to"
    },
    {
      "source": "OP compounds",
      "target": "acetylcholinesterase (AChE)",
      "label": "inhibits"
    },
    {
      "source": "OP compounds",
      "target": "toxic effects",
      "label": "shows"
    },
    {
      "source": "192 Q/R polymorphism",
      "target": "enzyme activities",
      "label": "has effect on"
    },
    {
      "source": "192 Q/R polymorphism",
      "target": "acetylcholinesterase",
      "label": "has effect on"
    },
    {
      "source": "192 Q/R polymorphism",
      "target": "paraoxonase",
      "label": "has effect on"
    },
    {
      "source": "192 Q/R polymorphism",
      "target": "standard polymerase chain reaction-restriction fragment length polymorphism technique",
      "label": "determined by"
    },
    {
      "source": "192 Q/R polymorphism",
      "target": "PON1 enzyme activities",
      "label": "compared with"
    },
    {
      "source": "Turkish population",
      "target": "organophosphate",
      "label": "exposed to"
    },
    {
      "source": "Organophosphate (OP) compounds",
      "target": "market",
      "label": "used in"
    },
    {
      "source": "Organophosphate (OP) compounds",
      "target": "local purposes",
      "label": "used for"
    },
    {
      "source": "Organophosphate (OP) compounds",
      "target": "pesticide groups",
      "label": "are"
    },
    {
      "source": "Organophosphate (OP) compounds",
      "target": "industrial purposes",
      "label": "used for"
    },
    {
      "source": "QQ genotype",
      "target": "192 R(-) genotype carriers",
      "label": "is"
    },
    {
      "source": "192 R(+)",
      "target": "192 R(-)",
      "label": "is greater than"
    },
    {
      "source": "mean AChE concentration",
      "target": "OP-exposed group",
      "label": "in"
    },
    {
      "source": "mean AChE concentration",
      "target": "haemoglobin (Hb)",
      "label": "measured in"
    },
    {
      "source": "mean AChE concentration",
      "target": "PON1 192 R(+) genotype carriers",
      "label": "determined for"
    },
    {
      "source": "probability of susceptibility",
      "target": "organophosphorus compounds",
      "label": "to"
    },
    {
      "source": "PON1 activities",
      "target": "genotypes",
      "label": "increase according to"
    },
    {
      "source": "QR + RR genotypes",
      "target": "PON1 192 R(+) genotype carriers",
      "label": "are"
    },
    {
      "source": "PON1 192 R(+) genotype carriers",
      "target": "192 R(-) genotype carriers",
      "label": "compared to"
    },
    {
      "source": "PON1 192 R(+) genotype carriers",
      "target": "PON1 activities",
      "label": "had higher"
    },
    {
      "source": "Paraoxonase 1 (PON1) enzyme",
      "target": "biotransformation",
      "label": "plays role in"
    },
    {
      "source": "pizotifen",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "pizotifen",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "pizotifen",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "pizotifen",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "pizotifen",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "pizotifen",
      "target": "mixed 5-HT1/5-HT2 receptor antagonists",
      "label": "is_a"
    },
    {
      "source": "pizotifen",
      "target": "lowest active doses",
      "label": "has"
    },
    {
      "source": "nortriptyline",
      "target": "secondary or primary amines",
      "label": "contains"
    },
    {
      "source": "UGT2B10",
      "target": "diphenhydramine",
      "label": "has higher affinity for"
    },
    {
      "source": "UGT2B10",
      "target": "carbamazepine",
      "label": "inactive in glucuronidation of"
    },
    {
      "source": "UGT2B10",
      "target": "trifluoperazine",
      "label": "did not conjugate"
    },
    {
      "source": "UGT2B10",
      "target": "amitriptyline",
      "label": "has higher affinity for"
    },
    {
      "source": "UGT2B10",
      "target": "desipramine",
      "label": "inactive in glucuronidation of"
    },
    {
      "source": "UGT2B10",
      "target": "N-glucuronidation",
      "label": "plays major role in"
    },
    {
      "source": "UGT2B10",
      "target": "UGT1A4",
      "label": "has higher clearance than"
    },
    {
      "source": "UGT2B10",
      "target": "tertiary cyclic amine",
      "label": "did not conjugate"
    },
    {
      "source": "UGT2B10",
      "target": "imipramine",
      "label": "has higher clearance for"
    },
    {
      "source": "UGT2B10",
      "target": "nortriptyline",
      "label": "inactive in glucuronidation of"
    },
    {
      "source": "UGT2B10",
      "target": "afloqualone",
      "label": "inactive in glucuronidation of"
    },
    {
      "source": "UGT2B10",
      "target": "drug clearance",
      "label": "has significance in"
    },
    {
      "source": "UGT2B10",
      "target": "UGT1A3",
      "label": "has higher clearance than"
    },
    {
      "source": "UGT2B10",
      "target": "tertiary amines",
      "label": "prefers to conjugate"
    },
    {
      "source": "diphenhydramine",
      "target": "imidazole group",
      "label": "contains"
    },
    {
      "source": "diphenhydramine",
      "target": "UGT1A4",
      "label": "is substrate for"
    },
    {
      "source": "diphenhydramine",
      "target": "tertiary aliphatic amines",
      "label": "contains"
    },
    {
      "source": "diphenhydramine",
      "target": "UGT1A3",
      "label": "is substrate for"
    },
    {
      "source": "diphenhydramine",
      "target": "cyclic amines",
      "label": "contains"
    },
    {
      "source": "UGT1A4",
      "target": "imipramine",
      "label": "has higher Vmax for"
    },
    {
      "source": "UGT1A4",
      "target": "diphenhydramine",
      "label": "has higher Vmax for"
    },
    {
      "source": "UGT1A4",
      "target": "amitriptyline",
      "label": "has higher Vmax for"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "ketotifen",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "ketoconazole",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "pizotifen",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "diphenhydramine",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "amitriptyline",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "midazolam",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "tamoxifen",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "imipramine",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "recombinant UGT2B10",
      "target": "olanzapine",
      "label": "catalyzes N-glucuronidation of"
    },
    {
      "source": "trifluoperazine",
      "target": "cardiac troponin C",
      "label": "binds to"
    },
    {
      "source": "trifluoperazine",
      "target": "cTnC",
      "label": "binds to"
    },
    {
      "source": "trifluoperazine",
      "target": "Ca2+",
      "label": "binding is dependent on"
    },
    {
      "source": "human UDP-glucuronosyltransferase (UGT) 2B10",
      "target": "N-glucuronidation",
      "label": "catalyzes"
    },
    {
      "source": "tertiary cyclic amine",
      "target": "trifluoperazine",
      "label": "is in"
    },
    {
      "source": "clinical significance",
      "target": "UGT2B10",
      "label": "of"
    },
    {
      "source": "Human UGT2B10",
      "target": "UGT1A3",
      "label": "compared with"
    },
    {
      "source": "Human UGT2B10",
      "target": "Drug N-glucuronidations",
      "label": "involved in"
    },
    {
      "source": "Human UGT2B10",
      "target": "UGT1A4",
      "label": "compared with"
    },
    {
      "source": "afloqualone",
      "target": "secondary or primary amines",
      "label": "contains"
    },
    {
      "source": "inhibition studies",
      "target": "hecogenin",
      "label": "conducted with"
    },
    {
      "source": "inhibition studies",
      "target": "nicotine",
      "label": "conducted with"
    },
    {
      "source": "Vmax values",
      "target": "UGT1A4",
      "label": "of"
    },
    {
      "source": "western blot analysis",
      "target": "C/EBP\u03b1",
      "label": "showed decrease in"
    },
    {
      "source": "western blot analysis",
      "target": "PPAR\u03b3",
      "label": "showed decrease in"
    },
    {
      "source": "western blot analysis",
      "target": "E2F1",
      "label": "showed decrease in"
    },
    {
      "source": "western blot analysis",
      "target": "leptin",
      "label": "showed decrease in"
    },
    {
      "source": "western blot analysis",
      "target": "LPL",
      "label": "showed decrease in"
    },
    {
      "source": "western blot analysis",
      "target": "adiponectin",
      "label": "showed increase in"
    },
    {
      "source": "western blot analysis",
      "target": "SIRT1",
      "label": "showed increase in"
    },
    {
      "source": "Tecomella undulata",
      "target": "bark",
      "label": "has part"
    },
    {
      "source": "bark",
      "target": "antiobesity activity",
      "label": "has"
    },
    {
      "source": "bark",
      "target": "anti obesity efficiency",
      "label": "has"
    },
    {
      "source": "bark",
      "target": "pharmacologic interventions",
      "label": "has beneficial effects in"
    },
    {
      "source": "bark",
      "target": "treatment",
      "label": "is traditionally claimed for"
    },
    {
      "source": "ethyl acetate extract of Tecomella undulata bark",
      "target": "anti obesity efficiency",
      "label": "has"
    },
    {
      "source": "active fractions",
      "target": "biomarkers",
      "label": "standardized using"
    },
    {
      "source": "In-vivo studies",
      "target": "F1",
      "label": "performed with"
    },
    {
      "source": "In-vivo studies",
      "target": "glucose levels",
      "label": "showed improvement in"
    },
    {
      "source": "In-vivo studies",
      "target": "obese mice",
      "label": "performed using"
    },
    {
      "source": "In-vivo studies",
      "target": "HFD induced obese mice",
      "label": "performed in"
    },
    {
      "source": "In-vivo studies",
      "target": "lipid profile",
      "label": "showed improvement in"
    },
    {
      "source": "F1",
      "target": "adipogenesis",
      "label": "decreased"
    },
    {
      "source": "F1",
      "target": "lipogenesis",
      "label": "decreased"
    },
    {
      "source": "F1",
      "target": "mRNA levels",
      "label": "affects"
    },
    {
      "source": "F1",
      "target": "ferulic acid",
      "label": "contains"
    },
    {
      "source": "F1",
      "target": "protein levels",
      "label": "affects"
    },
    {
      "source": "adipogenesis",
      "target": "adipocytes",
      "label": "occurs in"
    },
    {
      "source": "adipogenesis",
      "target": "preadipocytes",
      "label": "occurs in"
    },
    {
      "source": "sqRT-PCR",
      "target": "C/EBP\u03b1",
      "label": "showed decrease in"
    },
    {
      "source": "sqRT-PCR",
      "target": "PPAR\u03b3",
      "label": "showed decrease in"
    },
    {
      "source": "sqRT-PCR",
      "target": "E2F1",
      "label": "showed decrease in"
    },
    {
      "source": "sqRT-PCR",
      "target": "leptin",
      "label": "showed decrease in"
    },
    {
      "source": "sqRT-PCR",
      "target": "LPL",
      "label": "showed decrease in"
    },
    {
      "source": "sqRT-PCR",
      "target": "adiponectin",
      "label": "showed increase in"
    },
    {
      "source": "sqRT-PCR",
      "target": "SIRT1",
      "label": "showed increase in"
    },
    {
      "source": "disease ailments",
      "target": "cancer",
      "label": "includes"
    },
    {
      "source": "disease ailments",
      "target": "obesity",
      "label": "includes"
    },
    {
      "source": "modulation of SIRT1",
      "target": "mRNA levels",
      "label": "affects"
    },
    {
      "source": "modulation of SIRT1",
      "target": "protein levels",
      "label": "affects"
    },
    {
      "source": "adipogenesis mediators",
      "target": "adiponectin",
      "label": "includes"
    },
    {
      "source": "adipogenesis mediators",
      "target": "C/EBP\u03b1",
      "label": "includes"
    },
    {
      "source": "adipogenesis mediators",
      "target": "PPAR\u03b3",
      "label": "includes"
    },
    {
      "source": "adipogenesis mediators",
      "target": "E2F1",
      "label": "includes"
    },
    {
      "source": "adipogenesis mediators",
      "target": "leptin",
      "label": "includes"
    },
    {
      "source": "adipogenesis mediators",
      "target": "LPL",
      "label": "includes"
    },
    {
      "source": "semi quantitative RT-PCR",
      "target": "sqRT-PCR",
      "label": "is also known as"
    },
    {
      "source": "EATUB",
      "target": "active fractions",
      "label": "has part"
    },
    {
      "source": "EATUB",
      "target": "ethyl acetate extract of Tecomella undulata bark",
      "label": "is abbreviation for"
    },
    {
      "source": "EATUB fractions",
      "target": "3T3-L1 fibroblasts",
      "label": "activity investigated using"
    },
    {
      "source": "EATUB fractions",
      "target": "F1-F7",
      "label": "includes"
    },
    {
      "source": "scientific evidence",
      "target": "anti obesity efficiency",
      "label": "is for"
    },
    {
      "source": "pharmacologic interventions",
      "target": "obesity",
      "label": "related to"
    },
    {
      "source": "pharmacologic interventions",
      "target": "metabolic disorders",
      "label": "related to"
    },
    {
      "source": "antiobesity activity",
      "target": "traditional claim",
      "label": "is a"
    },
    {
      "source": "traditional claim",
      "target": "scientific evidence",
      "label": "has"
    },
    {
      "source": "High Fat Diet",
      "target": "HFD",
      "label": "is also known as"
    },
    {
      "source": "obese mice",
      "target": "High Fat Diet",
      "label": "induced by"
    },
    {
      "source": "bioactive fraction",
      "target": "F1",
      "label": "is also known as"
    },
    {
      "source": "overall conformational similarity",
      "target": "multiple closed structures",
      "label": "among"
    },
    {
      "source": "2B4-paroxetine structure",
      "target": "previously solved closed structure",
      "label": "is superimposable on"
    },
    {
      "source": "previously solved closed structure",
      "target": "ligand free state",
      "label": "is in"
    },
    {
      "source": "active site cavity volume",
      "target": "paroxetine complex",
      "label": "is of"
    },
    {
      "source": "paroxetine complex",
      "target": "active site cavity volume",
      "label": "has"
    },
    {
      "source": "complex with amlodipine",
      "target": "amlodipine",
      "label": "contains"
    },
    {
      "source": "new sub-chamber",
      "target": "active site side chains",
      "label": "resulted from rearrangements of"
    },
    {
      "source": "new sub-chamber",
      "target": "secondary structural elements",
      "label": "resulted from movement of"
    },
    {
      "source": "Cytochrome P450 2B4",
      "target": "drug paroxetine",
      "label": "in complex with"
    },
    {
      "source": "Cytochrome P450 2B4",
      "target": "Paroxetine",
      "label": "in complex with"
    },
    {
      "source": "cluster of protein conformations",
      "target": "various ligands",
      "label": "observed in presence of"
    },
    {
      "source": "new structure",
      "target": "active site size",
      "label": "revealed insights into"
    },
    {
      "source": "new structure",
      "target": "15 previously solved structures of P450 2B4",
      "label": "compared with"
    },
    {
      "source": "new structure",
      "target": "active site shape",
      "label": "revealed insights into"
    },
    {
      "source": "compact complex with 4-(4-chlorophenyl)imidazole",
      "target": "4-(4-chlorophenyl)imidazole",
      "label": "contains"
    },
    {
      "source": "X-ray crystal structure",
      "target": "compact complex with 4-(4-chlorophenyl)imidazole",
      "label": "revealed conformation intermediate to"
    },
    {
      "source": "X-ray crystal structure",
      "target": "F-G cassette",
      "label": "is intermediate in terms of placement of"
    },
    {
      "source": "X-ray crystal structure",
      "target": "complex with amlodipine",
      "label": "revealed conformation intermediate to"
    },
    {
      "source": "X-ray crystal structure",
      "target": "drug paroxetine",
      "label": "in complex with"
    },
    {
      "source": "X-ray crystal structure",
      "target": "Cytochrome P450 2B4",
      "label": "of"
    },
    {
      "source": "15 previously solved structures of P450 2B4",
      "target": "P450 2B4",
      "label": "are structures of"
    },
    {
      "source": "accessible space",
      "target": "heme",
      "label": "near"
    },
    {
      "source": "accessible space",
      "target": "new sub-chamber",
      "label": "reveals"
    },
    {
      "source": "binding pocket",
      "target": "heme",
      "label": "near"
    },
    {
      "source": "binding pocket",
      "target": "new sub-chamber",
      "label": "reveals"
    },
    {
      "source": "16 structures of P450 2B4",
      "target": "P450 2B4",
      "label": "are structures of"
    },
    {
      "source": "16 structures of P450 2B4",
      "target": "cluster of protein conformations",
      "label": "demonstrate"
    },
    {
      "source": "HP",
      "target": "NAC",
      "label": "INHIBITED_BY"
    },
    {
      "source": "HP",
      "target": "colorimetric methods",
      "label": "DETERMINED_BY"
    },
    {
      "source": "HP",
      "target": "toxicant groups",
      "label": "ENHANCED_IN"
    },
    {
      "source": "HP",
      "target": "liver samples",
      "label": "DETERMINED_IN"
    },
    {
      "source": "Alanine aminotransferase",
      "target": "ALT",
      "label": "IS_A"
    },
    {
      "source": "oxidative burden",
      "target": "chronic liver pathology",
      "label": "IN"
    },
    {
      "source": "co-treatment",
      "target": "changes",
      "label": "REVERSED"
    },
    {
      "source": "co-treatment",
      "target": "NAC",
      "label": "INCLUDES"
    },
    {
      "source": "Self reversal group",
      "target": "toxicant treatments",
      "label": "AFTER"
    },
    {
      "source": "Self reversal group",
      "target": "treatment",
      "label": "RECEIVED_NO"
    },
    {
      "source": "CCl4",
      "target": "ALT",
      "label": "Upregulator"
    },
    {
      "source": "CCl4",
      "target": "toxicants",
      "label": "IS_A"
    },
    {
      "source": "CCl4",
      "target": "hepatotoxic agents",
      "label": "IS_A"
    },
    {
      "source": "CCl4",
      "target": "toxicant groups",
      "label": "IS_IN"
    },
    {
      "source": "CCl4",
      "target": "Bilirubin",
      "label": "Upregulator"
    },
    {
      "source": "CCl4",
      "target": "ALP",
      "label": "Upregulator"
    },
    {
      "source": "CCl4",
      "target": "coconut oil",
      "label": "DILUTED_IN"
    },
    {
      "source": "CCl4",
      "target": "AST",
      "label": "Upregulator"
    },
    {
      "source": "N-acetyl cysteine",
      "target": "NAC",
      "label": "IS_A"
    },
    {
      "source": "Biochemical determinations",
      "target": "general findings",
      "label": "CORROBORATED_BY"
    },
    {
      "source": "Biochemical determinations",
      "target": "histological findings",
      "label": "CORROBORATED_BY"
    },
    {
      "source": "human etiology",
      "target": "micronodular cirrhosis",
      "label": "IS_A"
    },
    {
      "source": "experimental chronic hepatotoxicity models",
      "target": "TAA",
      "label": "INDUCED_BY"
    },
    {
      "source": "experimental chronic hepatotoxicity models",
      "target": "thioacetamide",
      "label": "INDUCED_BY"
    },
    {
      "source": "experimental chronic hepatotoxicity models",
      "target": "carbon tetrachloride",
      "label": "INDUCED_BY"
    },
    {
      "source": "experimental chronic hepatotoxicity models",
      "target": "CCl4",
      "label": "INDUCED_BY"
    },
    {
      "source": "administration of CCl4",
      "target": "GSH",
      "label": "Downregulator"
    },
    {
      "source": "administration of CCl4",
      "target": "GPx",
      "label": "Downregulator"
    },
    {
      "source": "administration of CCl4",
      "target": "CAT",
      "label": "Downregulator"
    },
    {
      "source": "administration of CCl4",
      "target": "LPO",
      "label": "Upregulator"
    },
    {
      "source": "protective activity",
      "target": "CCl4",
      "label": "AGAINST"
    },
    {
      "source": "protective activity",
      "target": "TAA",
      "label": "AGAINST"
    },
    {
      "source": "Bilirubin",
      "target": "serum",
      "label": "MEASURED_IN"
    },
    {
      "source": "Bilirubin",
      "target": "Serum markers of liver damage",
      "label": "IS_A"
    },
    {
      "source": "liver fibrosis",
      "target": "human etiology",
      "label": "HAS_PROXIMITY_TO"
    },
    {
      "source": "aniline",
      "target": "Cytochrome P450 2E1",
      "label": "Substrate"
    },
    {
      "source": "aniline",
      "target": "CYP 450 2E1",
      "label": "Substrate"
    },
    {
      "source": "Cytochrome P450 2E1",
      "target": "CYP 450 2E1",
      "label": "IS_A"
    },
    {
      "source": "hepatotoxic agents",
      "target": "liver fibrosis",
      "label": "PRODUCE"
    },
    {
      "source": "organosulfur compound",
      "target": "Allium plants",
      "label": "ORIGINATES_FROM"
    },
    {
      "source": "carbon tetrachloride",
      "target": "CCl4",
      "label": "IS_A"
    },
    {
      "source": "Aspartate aminotransferase",
      "target": "AST",
      "label": "IS_A"
    },
    {
      "source": "NAC treatment",
      "target": "toxicants",
      "label": "ADMINISTERED_WITH"
    },
    {
      "source": "CCl4 toxicity",
      "target": "CCl4",
      "label": "INDUCED_BY"
    },
    {
      "source": "Hydroxyproline",
      "target": "HP",
      "label": "IS_A"
    },
    {
      "source": "co-administration of NAC",
      "target": "liver markers",
      "label": "RESTORED"
    },
    {
      "source": "co-administration of NAC",
      "target": "normal levels",
      "label": "RESTORED_TO"
    },
    {
      "source": "hepatic prefibrogenic events",
      "target": "wistar rat",
      "label": "INDUCED_IN"
    },
    {
      "source": "Alkaline phosphatase",
      "target": "ALP",
      "label": "IS_A"
    },
    {
      "source": "TAA toxicity",
      "target": "TAA",
      "label": "INDUCED_BY"
    },
    {
      "source": "Mitochondria",
      "target": "P450scc",
      "label": "contain"
    },
    {
      "source": "Mitochondria",
      "target": "cholesterol side-chain cleavage enzyme",
      "label": "contain"
    },
    {
      "source": "Mitochondria",
      "target": "steroidogenic cells",
      "label": "located in"
    },
    {
      "source": "Mitochondria",
      "target": "electron-transfer partners",
      "label": "contain"
    },
    {
      "source": "Mitochondria",
      "target": "key enzymes",
      "label": "contain"
    },
    {
      "source": "Mitochondria",
      "target": "renal tubular cells",
      "label": "located in"
    },
    {
      "source": "Mitochondria",
      "target": "Steroid hormone biosynthesis",
      "label": "are essential sites for"
    },
    {
      "source": "Human deficiency diseases",
      "target": "mitochondrial steroidogenic enzymes",
      "label": "described for"
    },
    {
      "source": "Human deficiency diseases",
      "target": "StAR",
      "label": "described for"
    },
    {
      "source": "Human deficiency diseases",
      "target": "electron transfer proteins",
      "label": "not described for"
    },
    {
      "source": "Human deficiency diseases",
      "target": "cholesterol import machine",
      "label": "not described for"
    },
    {
      "source": "11\u03b2-hydroxylase",
      "target": "Mitochondria",
      "label": "resides in"
    },
    {
      "source": "StAR",
      "target": "acute regulator",
      "label": "serves as"
    },
    {
      "source": "acute regulator",
      "target": "steroidogenesis",
      "label": "regulates"
    },
    {
      "source": "Components",
      "target": "PKAR1A",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "TSPO",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "ACBD3",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "VDAC-1",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "18kDa translocator protein",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "TSPO-associated protein 7",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "protein kinase A regulatory subunit 1\u03b1",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "PAP7",
      "label": "include"
    },
    {
      "source": "Components",
      "target": "voltage-dependent anion chanel",
      "label": "include"
    },
    {
      "source": "TSPO-associated protein 7",
      "target": "PAP7",
      "label": "is also known as"
    },
    {
      "source": "TSPO-associated protein 7",
      "target": "ACBD3",
      "label": "is also known as"
    },
    {
      "source": "18kDa translocator protein",
      "target": "TSPO",
      "label": "is also known as"
    },
    {
      "source": "access of cholesterol",
      "target": "steroidogenic acute regulatory protein",
      "label": "regulated by"
    },
    {
      "source": "access of cholesterol",
      "target": "StAR",
      "label": "regulated by"
    },
    {
      "source": "steroidogenic acute regulatory protein",
      "target": "StAR",
      "label": "is also known as"
    },
    {
      "source": "electron-transfer partners",
      "target": "ferredoxin",
      "label": "include"
    },
    {
      "source": "electron-transfer partners",
      "target": "ferredoxin reductase",
      "label": "include"
    },
    {
      "source": "chronic regulator",
      "target": "steroidogenesis",
      "label": "regulates"
    },
    {
      "source": "protein kinase A regulatory subunit 1\u03b1",
      "target": "PKAR1A",
      "label": "is also known as"
    },
    {
      "source": "steroidogenic cells",
      "target": "placenta",
      "label": "include"
    },
    {
      "source": "steroidogenic cells",
      "target": "adrenal",
      "label": "include"
    },
    {
      "source": "steroidogenic cells",
      "target": "gonad",
      "label": "include"
    },
    {
      "source": "steroidogenic cells",
      "target": "brain",
      "label": "include"
    },
    {
      "source": "outer mitochondrial membrane",
      "target": "OMM",
      "label": "is also known as"
    },
    {
      "source": "voltage-dependent anion chanel",
      "target": "VDAC-1",
      "label": "is also known as"
    },
    {
      "source": "enzyme system",
      "target": "chronic regulator",
      "label": "serves as"
    },
    {
      "source": "enzyme system",
      "target": "cholesterol",
      "label": "converts"
    },
    {
      "source": "enzyme system",
      "target": "net steroidogenic capacity",
      "label": "determines"
    },
    {
      "source": "enzyme system",
      "target": "pregnenolone",
      "label": "produces"
    },
    {
      "source": "complex multi-component molecular machine",
      "target": "outer mitochondrial membrane",
      "label": "located on"
    },
    {
      "source": "Steroid hormone synthesis",
      "target": "Mitochondria",
      "label": "occurs in"
    },
    {
      "source": "StAR action",
      "target": "complex multi-component molecular machine",
      "label": "requires"
    },
    {
      "source": "bioactive RS -GRA",
      "target": "RS -GRA",
      "label": "is also known as"
    },
    {
      "source": "bioactive RS -GRA",
      "target": "pro-inflammatory cytokine production",
      "label": "Downregulator"
    },
    {
      "source": "bioactive RS -GRA",
      "target": "apoptosis",
      "label": "Downregulator"
    },
    {
      "source": "bioactive RS -GRA",
      "target": "NF-kB translocation",
      "label": "Downregulator"
    },
    {
      "source": "bioactive RS -GRA",
      "target": "(RS )-glucoraphanin",
      "label": "is a form of"
    },
    {
      "source": "bioactive RS -GRA",
      "target": "therapeutic perspective",
      "label": "offers"
    },
    {
      "source": "EAE",
      "target": "mice",
      "label": "induced in"
    },
    {
      "source": "EAE",
      "target": "model of multiple sclerosis",
      "label": "is a"
    },
    {
      "source": "EAE",
      "target": "immunization",
      "label": "induced by"
    },
    {
      "source": "interleukin-1\u03b2",
      "target": "IL-1\u03b2",
      "label": "is also known as"
    },
    {
      "source": "therapeutic perspective",
      "target": "disease",
      "label": "for the treatment of"
    },
    {
      "source": "caspase 3 expression",
      "target": "caspase 3",
      "label": "involves"
    },
    {
      "source": "immunization",
      "target": "myelin oligodendroglial glycoprotein peptide",
      "label": "performed with"
    },
    {
      "source": "Tuscan black kale",
      "target": "Brassica oleracea L. var. acephala sabellica",
      "label": "is a synonym for"
    },
    {
      "source": "Brassica vegetables",
      "target": "therapeutic effects",
      "label": "possess"
    },
    {
      "source": "Brassica vegetables",
      "target": "Cruciferae",
      "label": "is a type of"
    },
    {
      "source": "(RS )-glucoraphanin",
      "target": "Myrosinase",
      "label": "bioactivated with"
    },
    {
      "source": "(RS )-glucoraphanin",
      "target": "myrosinase",
      "label": "bioactivated with"
    },
    {
      "source": "(RS )-glucoraphanin",
      "target": "Tuscan black kale",
      "label": "is from"
    },
    {
      "source": "(RS )-glucoraphanin",
      "target": "Experimental Model of Multiple Sclerosis",
      "label": "has protective role in"
    },
    {
      "source": "myrosinase",
      "target": "hydrolysis",
      "label": "causes"
    },
    {
      "source": "glucosinolates",
      "target": "myrosinase",
      "label": "Substrate"
    },
    {
      "source": "glucosinolates",
      "target": "isothiocyanates",
      "label": "release"
    },
    {
      "source": "pro-inflammatory cytokine production",
      "target": "interleukin-1\u03b2",
      "label": "includes"
    },
    {
      "source": "myelin oligodendroglial glycoprotein peptide",
      "target": "MOG35-55",
      "label": "is also known as"
    },
    {
      "source": "Clinical score",
      "target": "standardized scoring system",
      "label": "evaluated using"
    },
    {
      "source": "Pathway analysis",
      "target": "Hepatotoxicity",
      "label": "of"
    },
    {
      "source": "Hepatotoxicity",
      "target": "Triptolide",
      "label": "induced by"
    },
    {
      "source": "Functions",
      "target": "Glucose metabolism",
      "label": "associated with"
    },
    {
      "source": "Functions",
      "target": "Cell cycle",
      "label": "associated with"
    },
    {
      "source": "Functions",
      "target": "Phosphoenolpyruvate carboxykinase activities",
      "label": "consistent with"
    },
    {
      "source": "Functions",
      "target": "Caspase-3 activity",
      "label": "consistent with"
    },
    {
      "source": "Functions",
      "target": "Oxidative stress",
      "label": "associated with"
    },
    {
      "source": "Functions",
      "target": "GSH/GSSG ratio",
      "label": "consistent with"
    },
    {
      "source": "Functions",
      "target": "Glucose-6-phosphatase activities",
      "label": "consistent with"
    },
    {
      "source": "Functions",
      "target": "Liver glycogen",
      "label": "consistent with"
    },
    {
      "source": "Functions",
      "target": "Apoptosis",
      "label": "associated with"
    },
    {
      "source": "Functions",
      "target": "Insulin signaling pathway",
      "label": "associated with"
    },
    {
      "source": "Functions",
      "target": "Serum glucose",
      "label": "consistent with"
    },
    {
      "source": "Differential expression of genes",
      "target": "Cell stress pathway",
      "label": "involved in"
    },
    {
      "source": "Differential expression of genes",
      "target": "Insulin signaling pathway",
      "label": "involved in"
    },
    {
      "source": "Differential expression of genes",
      "target": "Glucose metabolism pathway",
      "label": "involved in"
    },
    {
      "source": "Cell stress pathway",
      "target": "Overall TP-induced hepatotoxicity",
      "label": "might contribute to"
    },
    {
      "source": "Insulin signaling pathway",
      "target": "Overall TP-induced hepatotoxicity",
      "label": "might contribute to"
    },
    {
      "source": "3329 differentially expressed genes",
      "target": "Female rats",
      "label": "found in"
    },
    {
      "source": "3329 differentially expressed genes",
      "target": "Liver",
      "label": "found in"
    },
    {
      "source": "TP treatment",
      "target": "Differential expression of genes",
      "label": "consistent with"
    },
    {
      "source": "TP treatment",
      "target": "Serum glucose",
      "label": "could reduce"
    },
    {
      "source": "TP treatment",
      "target": "Hepatocyte apoptosis",
      "label": "could induce"
    },
    {
      "source": "TP treatment",
      "target": "Hepatic redox status",
      "label": "could alter"
    },
    {
      "source": "Glucose metabolism pathway",
      "target": "Overall TP-induced hepatotoxicity",
      "label": "might contribute to"
    },
    {
      "source": "IGF1",
      "target": "TP-induced hepatotoxicity",
      "label": "might be involved in"
    },
    {
      "source": "Hepatic gene expression profiles",
      "target": "Mechanism",
      "label": "were analyzed to elucidate"
    },
    {
      "source": "Triptolide",
      "target": "Systemic lupus erythematosus",
      "label": "is used to treat"
    },
    {
      "source": "Triptolide",
      "target": "Leprosy",
      "label": "is used to treat"
    },
    {
      "source": "Triptolide",
      "target": "TWHF",
      "label": "is a major component of"
    },
    {
      "source": "Triptolide",
      "target": "Nephritis",
      "label": "is used to treat"
    },
    {
      "source": "Triptolide",
      "target": "Rheumatoid arthritis",
      "label": "is used to treat"
    },
    {
      "source": "Genome-wide microarray analyses",
      "target": "3329 differentially expressed genes",
      "label": "identified"
    },
    {
      "source": "Current study",
      "target": "Female rats",
      "label": "indicated"
    },
    {
      "source": "Gene expression profiling",
      "target": "Hepatotoxicity",
      "label": "of"
    },
    {
      "source": "Clinical use",
      "target": "Hepatotoxicity",
      "label": "is limited by"
    },
    {
      "source": "esterase D",
      "target": "detoxication enzymes",
      "label": "is a type of"
    },
    {
      "source": "esterase D",
      "target": "radiosensitivity",
      "label": "does not increase"
    },
    {
      "source": "esterase D",
      "target": "S-formyl glutathione hydrolase",
      "label": "also called"
    },
    {
      "source": "gamma-ray radiation",
      "target": "S and G2 phases",
      "label": "applied during"
    },
    {
      "source": "Lymphocyte cultures",
      "target": "gamma-ray radiation",
      "label": "exposed to"
    },
    {
      "source": "Lymphocyte cultures",
      "target": "patients",
      "label": "are from"
    },
    {
      "source": "Chromatid and chromosome lesions",
      "target": "controls",
      "label": "compared to"
    },
    {
      "source": "Rates",
      "target": "FMO3 protein expression",
      "label": "correlated with"
    },
    {
      "source": "Rates",
      "target": "cynomolgus livers",
      "label": "varied among"
    },
    {
      "source": "Rates",
      "target": "benzydamine N-oxygenation",
      "label": "of"
    },
    {
      "source": "FMO2",
      "target": "benzydamine",
      "label": "metabolized"
    },
    {
      "source": "FMO2",
      "target": "kidney",
      "label": "expressed in"
    },
    {
      "source": "drug metabolism",
      "target": "human",
      "label": "similar to"
    },
    {
      "source": "drug metabolism",
      "target": "cynomolgus macaque",
      "label": "occurs in"
    },
    {
      "source": "FMO3 expression",
      "target": "inter-animal variations",
      "label": "accounts for"
    },
    {
      "source": "inter-animal variations",
      "target": "benzydamine N-oxygenation",
      "label": "in"
    },
    {
      "source": "cynomolgus FMO6",
      "target": "human FMO6P",
      "label": "is identical to"
    },
    {
      "source": "cynomolgus FMO6",
      "target": "benzydamine",
      "label": "metabolized"
    },
    {
      "source": "FMO5",
      "target": "benzydamine",
      "label": "metabolized"
    },
    {
      "source": "FMO5",
      "target": "liver",
      "label": "expressed in"
    },
    {
      "source": "Amino acid sequences",
      "target": "human FMO1-5",
      "label": "clustered with"
    },
    {
      "source": "Amino acid sequences",
      "target": "cynomolgus FMO1-5",
      "label": "of"
    },
    {
      "source": "Amino acid sequences",
      "target": "phylogenetic tree",
      "label": "clustered in"
    },
    {
      "source": "Amino acid sequences",
      "target": "sequence identities",
      "label": "shared"
    },
    {
      "source": "FMO3",
      "target": "benzydamine",
      "label": "metabolized"
    },
    {
      "source": "FMO3",
      "target": "trimethylamine",
      "label": "metabolized"
    },
    {
      "source": "FMO3",
      "target": "drug metabolism",
      "label": "important in"
    },
    {
      "source": "FMO3",
      "target": "benzydamine N-oxygenation",
      "label": "catalyzes"
    },
    {
      "source": "FMO3",
      "target": "methimazole",
      "label": "metabolized"
    },
    {
      "source": "FMO6",
      "target": "tissue types",
      "label": "has expression in"
    },
    {
      "source": "FMO6",
      "target": "drug metabolism",
      "label": "precludes importance in"
    },
    {
      "source": "FMO6",
      "target": "kidney",
      "label": "expressed in"
    },
    {
      "source": "FMOs",
      "target": "human",
      "label": "characterized in"
    },
    {
      "source": "FMOs",
      "target": "drug-metabolizing enzymes",
      "label": "is a type of"
    },
    {
      "source": "FMOs",
      "target": "cynomolgus macaque",
      "label": "remain to be investigated in"
    },
    {
      "source": "flavin-containing monooxygenases",
      "target": "human",
      "label": "characterized in"
    },
    {
      "source": "flavin-containing monooxygenases",
      "target": "cynomolgus macaque",
      "label": "remain to be investigated in"
    },
    {
      "source": "flavin-containing monooxygenases",
      "target": "drug-metabolizing enzymes",
      "label": "is a type of"
    },
    {
      "source": "cynomolgus FMO genes",
      "target": "FMO3",
      "label": "include"
    },
    {
      "source": "cynomolgus FMO genes",
      "target": "FMO1",
      "label": "include"
    },
    {
      "source": "FMO1",
      "target": "methimazole",
      "label": "metabolized"
    },
    {
      "source": "FMO4",
      "target": "kidney",
      "label": "expressed in"
    },
    {
      "source": "Cynomolgus FMO1",
      "target": "kidney",
      "label": "expressed in"
    },
    {
      "source": "Cynomolgus FMO1",
      "target": "benzydamine",
      "label": "metabolized"
    },
    {
      "source": "Cynomolgus FMO1",
      "target": "drug metabolism",
      "label": "important in"
    },
    {
      "source": "cynomolgus FMO3",
      "target": "liver",
      "label": "expressed in"
    },
    {
      "source": "monosaccharide",
      "target": "isomalyngamide A backbone",
      "label": "is appended to"
    },
    {
      "source": "monosaccharide",
      "target": "cell migration",
      "label": "influences"
    },
    {
      "source": "monosaccharide",
      "target": "invasive ability",
      "label": "influences"
    },
    {
      "source": "mechanism for inhibition of metastatic activities",
      "target": "integrin-mediated antimetastatic pathway",
      "label": "occurs through"
    },
    {
      "source": "mechanism for inhibition of metastatic activities",
      "target": "MDA-MB-231 cells",
      "label": "occurs in"
    },
    {
      "source": "mechanism for inhibition of metastatic activities",
      "target": "4",
      "label": "is by"
    },
    {
      "source": "mechanism for inhibition of metastatic activities",
      "target": "inactivation of the expression",
      "label": "involves"
    },
    {
      "source": "mechanism for inhibition of metastatic activities",
      "target": "5",
      "label": "is by"
    },
    {
      "source": "disaccharide appendages",
      "target": "isomalyngamide A backbone",
      "label": "is appended to"
    },
    {
      "source": "disaccharide appendages",
      "target": "invasive ability",
      "label": "influences"
    },
    {
      "source": "disaccharide appendages",
      "target": "cell migration",
      "label": "influences"
    },
    {
      "source": "two glycosylated derivatives 4 and 5",
      "target": "nontoxic concentration levels",
      "label": "suppress at"
    },
    {
      "source": "two glycosylated derivatives 4 and 5",
      "target": "metastatic events",
      "label": "suppress"
    },
    {
      "source": "two glycosylated derivatives 4 and 5",
      "target": "galactose appendages",
      "label": "contain"
    },
    {
      "source": "two glycosylated derivatives 4 and 5",
      "target": "mannose",
      "label": "contain"
    },
    {
      "source": "two glycosylated derivatives 4 and 5",
      "target": "human breast adenocarcinoma MDA-MB-231 cells",
      "label": "suppress in"
    },
    {
      "source": "metastatic events",
      "target": "migration",
      "label": "include"
    },
    {
      "source": "metastatic events",
      "target": "adhesion",
      "label": "include"
    },
    {
      "source": "metastatic events",
      "target": "invasion",
      "label": "include"
    },
    {
      "source": "Three, new, fully synthetic glycosylated isomalyngamide A analogs 4-6",
      "target": "anti-migratory activities",
      "label": "evaluated for"
    },
    {
      "source": "Three, new, fully synthetic glycosylated isomalyngamide A analogs 4-6",
      "target": "human breast cancer cells",
      "label": "evaluated in"
    },
    {
      "source": "anti-migratory activities",
      "target": "isomalyngamide A analogs",
      "label": "are of"
    },
    {
      "source": "Glycosylation",
      "target": "anti-migratory activities",
      "label": "enhances"
    },
    {
      "source": "inactivation of the expression",
      "target": "paxillin",
      "label": "targets"
    },
    {
      "source": "inactivation of the expression",
      "target": "p-FAK",
      "label": "targets"
    },
    {
      "source": "Evidence",
      "target": "mechanism for inhibition of metastatic activities",
      "label": "supports"
    },
    {
      "source": "derivative 6",
      "target": "potent activity",
      "label": "displays"
    },
    {
      "source": "derivative 6",
      "target": "lactose moiety",
      "label": "contains"
    },
    {
      "source": "ACTH increase",
      "target": "placebo administration",
      "label": "occurred after"
    },
    {
      "source": "early phase",
      "target": "response",
      "label": "is part of"
    },
    {
      "source": "CRH",
      "target": "ACTH increase",
      "label": "induced"
    },
    {
      "source": "ACTH curves",
      "target": "CRH",
      "label": "were after"
    },
    {
      "source": "pattern of ACTH response",
      "target": "CRH",
      "label": "is to"
    },
    {
      "source": "pattern of ACTH response",
      "target": "loperamide administration",
      "label": "was delayed after"
    },
    {
      "source": "Loperamide",
      "target": "plasma ACTH response",
      "label": "has effect on"
    },
    {
      "source": "Loperamide",
      "target": "peripheral opiate agonist",
      "label": "is a"
    },
    {
      "source": "Loperamide",
      "target": "ACTH response",
      "label": "does not block"
    },
    {
      "source": "plasma ACTH response",
      "target": "Corticotropin-releasing Hormone",
      "label": "is to"
    },
    {
      "source": "plasma ACTH response",
      "target": "patients",
      "label": "investigated in"
    },
    {
      "source": "inhibitory role",
      "target": "ACTH secretion",
      "label": "is on"
    },
    {
      "source": "inhibitory role",
      "target": "supra-pituitary level",
      "label": "is exerted at"
    },
    {
      "source": "inhibitory role",
      "target": "Loperamide",
      "label": "is of"
    },
    {
      "source": "Corticotropin-releasing Hormone",
      "target": "CRH",
      "label": "is also known as"
    },
    {
      "source": "corticotropin-releasing hormone",
      "target": "ACTH response",
      "label": "induced"
    },
    {
      "source": "ACTH response",
      "target": "patients",
      "label": "occurs in"
    },
    {
      "source": "lactate dehydrogenase-X activity",
      "target": "180 days of age",
      "label": "were similar at"
    },
    {
      "source": "lactate dehydrogenase-X activity",
      "target": "genotypes",
      "label": "were similar for"
    },
    {
      "source": "lactate dehydrogenase-X activity",
      "target": "jaundiced (jj) male Gunn rats",
      "label": "was significantly lower in"
    },
    {
      "source": "lactate dehydrogenase-X activity",
      "target": "young jaundiced male rats",
      "label": "occur in"
    },
    {
      "source": "lactate dehydrogenase-X activity",
      "target": "50 and 60 days of age",
      "label": "was significantly lower at"
    },
    {
      "source": "Testosterone level",
      "target": "jaundiced (jj) male Gunn rats",
      "label": "was significantly lower in"
    },
    {
      "source": "Testosterone level",
      "target": "50 days of age",
      "label": "was significantly lower at"
    },
    {
      "source": "testicular maturation",
      "target": "lactate dehydrogenase-X activity",
      "label": "indicated by"
    },
    {
      "source": "testicular maturation",
      "target": "serum testosterone levels",
      "label": "indicated by"
    },
    {
      "source": "testicular maturation",
      "target": "nonjaundiced (Jj) male Gunn rats",
      "label": "occurs in"
    },
    {
      "source": "testicular maturation",
      "target": "jaundiced (jj) male Gunn rats",
      "label": "occurs in"
    },
    {
      "source": "delay of testicular maturation",
      "target": "lactate dehydrogenase-X activity",
      "label": "due to lower"
    },
    {
      "source": "delay of testicular maturation",
      "target": "jaundiced males",
      "label": "occurs in"
    },
    {
      "source": "delay of testicular maturation",
      "target": "serum testosterone levels",
      "label": "due to lower"
    },
    {
      "source": "RIA",
      "target": "radioimmunoassay",
      "label": "is an abbreviation for"
    },
    {
      "source": "LDH-X",
      "target": "lactate dehydrogenase-X",
      "label": "is an abbreviation for"
    },
    {
      "source": "lactate dehydrogenase-X",
      "target": "testis and sperm-specific enzyme",
      "label": "is a type of"
    },
    {
      "source": "Testicular cytosolic LDH-X activity",
      "target": "nonjaundiced (Jj) male Gunn rats",
      "label": "increased in"
    },
    {
      "source": "Testicular cytosolic LDH-X activity",
      "target": "oxidation",
      "label": "determined by"
    },
    {
      "source": "Testicular cytosolic LDH-X activity",
      "target": "jaundiced (jj) male Gunn rats",
      "label": "increased in"
    },
    {
      "source": "Testicular cytosolic LDH-X activity",
      "target": "30 and 50 days of age",
      "label": "increased rapidly between"
    },
    {
      "source": "Developmental changes",
      "target": "lactate dehydrogenase-X activity",
      "label": "occur in"
    },
    {
      "source": "5L rat hepatoma cells",
      "target": "TCDD toxicity",
      "label": "is a model for"
    },
    {
      "source": "5L rat hepatoma cells",
      "target": "dioxin toxicity",
      "label": "used for studies on"
    },
    {
      "source": "5L rat hepatoma cells",
      "target": "chromosomal translocations",
      "label": "carry"
    },
    {
      "source": "eukaryotic translation initiation factor 4E-binding protein 1",
      "target": "mammalian target of rapamycin",
      "label": "is a substrate of"
    },
    {
      "source": "eukaryotic translation initiation factor 4E-binding protein 1",
      "target": "translation initiation",
      "label": "regulates"
    },
    {
      "source": "mammalian target of rapamycin",
      "target": "mTOR",
      "label": "is"
    },
    {
      "source": "insulin-like growth factor binding protein 4",
      "target": "IGFBP-4",
      "label": "is"
    },
    {
      "source": "insulin-like growth factor binding protein 4",
      "target": "5L rat hepatoma cells",
      "label": "is induced in"
    },
    {
      "source": "IGFBP-4",
      "target": "Fao",
      "label": "is not induced in"
    },
    {
      "source": "IGFBP-4",
      "target": "rat hepatoma cell lines",
      "label": "is not induced in"
    },
    {
      "source": "IGFBP-4",
      "target": "TCDD",
      "label": "is a transcriptional target of"
    },
    {
      "source": "TCDD-induced secreted factor",
      "target": "insulin-like growth factor binding protein 4",
      "label": "is"
    },
    {
      "source": "TCDD-induced secreted factor",
      "target": "AKT",
      "label": "mediated inhibition of"
    },
    {
      "source": "TCDD-induced secreted factor",
      "target": "ERK",
      "label": "mediated inhibition of"
    },
    {
      "source": "quantitative proteomic studies",
      "target": "TCDD",
      "label": "investigated actions of"
    },
    {
      "source": "quantitative proteomic studies",
      "target": "5L rat hepatoma cells",
      "label": "conducted in"
    },
    {
      "source": "Igfbp-4 gene",
      "target": "promoter",
      "label": "is under control of"
    },
    {
      "source": "promoter",
      "target": "dioxin responsive element(s)",
      "label": "contains"
    },
    {
      "source": "dioxin exposure",
      "target": "proteins",
      "label": "reduced abundance of"
    },
    {
      "source": "IGFBP-4 protein",
      "target": "aryl hydrocarbon receptor",
      "label": "induction dependent on"
    },
    {
      "source": "multicolour spectral karyotyping",
      "target": "SKY",
      "label": "is"
    },
    {
      "source": "fact",
      "target": "properties",
      "label": "suggests"
    },
    {
      "source": "ambenonium",
      "target": "muscarinic receptors",
      "label": "antagonizes"
    },
    {
      "source": "ambenonium",
      "target": "drug",
      "label": "is a"
    },
    {
      "source": "ambenonium",
      "target": "antagonist",
      "label": "is an"
    },
    {
      "source": "ambenonium",
      "target": "antimuscarinic effects",
      "label": "has"
    },
    {
      "source": "ambenonium",
      "target": "blockade",
      "label": "induced"
    },
    {
      "source": "ambenonium",
      "target": "dual effect",
      "label": "had a"
    },
    {
      "source": "ambenonium",
      "target": "responses",
      "label": "blocked"
    },
    {
      "source": "ambenonium",
      "target": "inhibitor",
      "label": "is an"
    },
    {
      "source": "property",
      "target": "Schild analyses",
      "label": "was confirmed by"
    },
    {
      "source": "Schild analyses",
      "target": "blockade",
      "label": "confirmed"
    },
    {
      "source": "pKB values",
      "target": "tissue",
      "label": "in"
    },
    {
      "source": "tissue responses",
      "target": "acetylcholine",
      "label": "to"
    },
    {
      "source": "Schild regressions",
      "target": "linear regression",
      "label": "are a type of"
    },
    {
      "source": "Schild regressions",
      "target": "criteria",
      "label": "satisfied"
    },
    {
      "source": "Schild regressions",
      "target": "ambenonium antagonism",
      "label": "obtained for"
    },
    {
      "source": "linear regression",
      "target": "slope",
      "label": "has"
    },
    {
      "source": "mean pKB",
      "target": "pKB values",
      "label": "is a type of"
    },
    {
      "source": "underestimation",
      "target": "treatment",
      "label": "was eliminated by"
    },
    {
      "source": "underestimation",
      "target": "pKB estimates",
      "label": "in"
    },
    {
      "source": "criteria",
      "target": "antagonism",
      "label": "for"
    },
    {
      "source": "antimuscarinic effects",
      "target": "organ selectivity",
      "label": "are a mode of"
    },
    {
      "source": "ambenonium antagonism",
      "target": "acetylcholine responses",
      "label": "of"
    },
    {
      "source": "dual effect",
      "target": "tissue responses",
      "label": "on"
    },
    {
      "source": "dual effect",
      "target": "potentiation",
      "label": "includes"
    },
    {
      "source": "dual effect",
      "target": "antagonism",
      "label": "includes"
    },
    {
      "source": "regressions",
      "target": "pKB values",
      "label": "yielded"
    },
    {
      "source": "slope",
      "target": "unity",
      "label": "equal to"
    },
    {
      "source": "Statistical analysis",
      "target": "ambenonium",
      "label": "showed"
    },
    {
      "source": "clorgyline",
      "target": "monoamine oxidase type A",
      "label": "inhibits"
    },
    {
      "source": "clorgyline",
      "target": "levels",
      "label": "decreased"
    },
    {
      "source": "clorgyline",
      "target": "MAO-A",
      "label": "inhibits"
    },
    {
      "source": "clorgyline",
      "target": "concentrations",
      "label": "decreased"
    },
    {
      "source": "clorgyline",
      "target": "inhibition",
      "label": "causes"
    },
    {
      "source": "monoamine oxidase type A",
      "target": "MAO-A",
      "label": "is a"
    },
    {
      "source": "debrisoquin",
      "target": "levels",
      "label": "decreased"
    },
    {
      "source": "debrisoquin",
      "target": "peripheral neuronal MAO",
      "label": "inhibits"
    },
    {
      "source": "debrisoquin",
      "target": "concentrations",
      "label": "decreased"
    },
    {
      "source": "debrisoquin",
      "target": "inhibition",
      "label": "causes"
    },
    {
      "source": "catechols",
      "target": "plasma",
      "label": "located in"
    },
    {
      "source": "catechols",
      "target": "striatum",
      "label": "located in"
    },
    {
      "source": "nialamide",
      "target": "MAO-A",
      "label": "inhibits"
    },
    {
      "source": "nialamide",
      "target": "levels",
      "label": "decreased"
    },
    {
      "source": "nialamide",
      "target": "concentrations",
      "label": "decreased"
    },
    {
      "source": "nialamide",
      "target": "MAO-B",
      "label": "inhibits"
    },
    {
      "source": "MAO-A",
      "target": "peripheral neurons",
      "label": "located in"
    },
    {
      "source": "deamination",
      "target": "MAO-A",
      "label": "performed by"
    },
    {
      "source": "deamination",
      "target": "DA",
      "label": "of"
    },
    {
      "source": "DHPG",
      "target": "striatium",
      "label": "measured in"
    },
    {
      "source": "DHPG",
      "target": "plasma",
      "label": "measured in"
    },
    {
      "source": "DHPG",
      "target": "metabolism",
      "label": "derived from"
    },
    {
      "source": "(-)deprenyl",
      "target": "inhibition",
      "label": "causes"
    },
    {
      "source": "(-)deprenyl",
      "target": "MAO-B",
      "label": "inhibits"
    },
    {
      "source": "(-)deprenyl",
      "target": "levels",
      "label": "did not affect"
    },
    {
      "source": "dihydroxyphenylglycol",
      "target": "DHPG",
      "label": "is a"
    },
    {
      "source": "monoamine oxidase inhibitors",
      "target": "levels",
      "label": "affects"
    },
    {
      "source": "MAO inhibitors",
      "target": "depression",
      "label": "produced"
    },
    {
      "source": "residual levels",
      "target": "HVA",
      "label": "of"
    },
    {
      "source": "residual levels",
      "target": "indication",
      "label": "provide"
    },
    {
      "source": "dihydroxyphenylacetic acid",
      "target": "DOPAC",
      "label": "is a"
    },
    {
      "source": "Indoxyl 3-sulfate",
      "target": "STAT3",
      "label": "enhances phosphorylation of"
    },
    {
      "source": "Indoxyl 3-sulfate",
      "target": "c-Src",
      "label": "enhances phosphorylation of"
    },
    {
      "source": "Indoxyl 3-sulfate",
      "target": "AhR activation",
      "label": "activates"
    },
    {
      "source": "Indoxyl 3-sulfate",
      "target": "Th17 differentiation",
      "label": "stimulates"
    },
    {
      "source": "Indoxyl 3-sulfate",
      "target": "uremic toxin",
      "label": "is a"
    },
    {
      "source": "Indoxyl 3-sulfate",
      "target": "experimental autoimmune encephalomyelitis (EAE)",
      "label": "worsens"
    },
    {
      "source": "AhR activation",
      "target": "CD4T cell differentiation",
      "label": "regulates"
    },
    {
      "source": "experimental autoimmune encephalomyelitis (EAE)",
      "target": "Th17 cells",
      "label": "is mediated by"
    },
    {
      "source": "I3S",
      "target": "Th17 differentiation",
      "label": "stimulates"
    },
    {
      "source": "I3S",
      "target": "uremic toxin",
      "label": "is a"
    },
    {
      "source": "I3S",
      "target": "STAT3 activation",
      "label": "stimulates"
    },
    {
      "source": "I3S",
      "target": "c-Src",
      "label": "increases phosphorylation of"
    },
    {
      "source": "I3S",
      "target": "IL-17-producing cells",
      "label": "enhances"
    },
    {
      "source": "I3S",
      "target": "AhR activation",
      "label": "activates"
    },
    {
      "source": "I3S",
      "target": "ROR\u03b3t",
      "label": "increases expression of"
    },
    {
      "source": "AhR ligands",
      "target": "c-Src",
      "label": "activate"
    },
    {
      "source": "ROR\u03b3t",
      "target": "Th17 differentiation",
      "label": "is a master transcription factor for"
    },
    {
      "source": "ROR\u03b3t",
      "target": "master transcription factor",
      "label": "is a"
    },
    {
      "source": "PP2",
      "target": "c-Src activity",
      "label": "inhibits"
    },
    {
      "source": "PP2",
      "target": "STAT3",
      "label": "inhibits phosphorylation of"
    },
    {
      "source": "PP2",
      "target": "c-Src",
      "label": "inhibits phosphorylation of"
    },
    {
      "source": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine",
      "target": "c-Src activity",
      "label": "inhibits"
    },
    {
      "source": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine",
      "target": "STAT3",
      "label": "inhibits phosphorylation of"
    },
    {
      "source": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine",
      "target": "c-Src",
      "label": "inhibits phosphorylation of"
    },
    {
      "source": "N-terminal portion",
      "target": "cartilage link protein family",
      "label": "shows sequence homology to"
    },
    {
      "source": "N-terminal portion",
      "target": "sequence homology",
      "label": "shows"
    },
    {
      "source": "cartilage link protein family",
      "target": "hyaluronan binding proteins",
      "label": "is a family of"
    },
    {
      "source": "synovial fluid",
      "target": "patients",
      "label": "is found in"
    },
    {
      "source": "TSG-6/I alpha I complex",
      "target": "chondroitin sulfate ABC lyase",
      "label": "was cleaved by"
    },
    {
      "source": "TSG-6/I alpha I complex",
      "target": "37 degrees C",
      "label": "is formed at"
    },
    {
      "source": "TSG-6/I alpha I complex",
      "target": "proteins",
      "label": "forms in absence of"
    },
    {
      "source": "TSG-6/I alpha I complex",
      "target": "4 degrees C",
      "label": "is not formed at"
    },
    {
      "source": "C-terminal half",
      "target": "CUB domain",
      "label": "contains"
    },
    {
      "source": "CUB domain",
      "target": "developmentally regulated proteins",
      "label": "is characteristic for"
    },
    {
      "source": "cross-linking",
      "target": "stability",
      "label": "is required for"
    },
    {
      "source": "cross-linking",
      "target": "chondroitin sulfate",
      "label": "is by"
    },
    {
      "source": "I alpha I",
      "target": "human serum",
      "label": "is purified from"
    },
    {
      "source": "I alpha I",
      "target": "N-terminal microsequencing",
      "label": "is identified by"
    },
    {
      "source": "TSG-6",
      "target": "complex",
      "label": "forms"
    },
    {
      "source": "TSG-6",
      "target": "35-kDa glycoprotein",
      "label": "is a"
    },
    {
      "source": "TSG-6",
      "target": "arthritis",
      "label": "is associated with"
    },
    {
      "source": "TSG-6",
      "target": "TNF",
      "label": "is inducible by"
    },
    {
      "source": "TSG-6",
      "target": "IL-1",
      "label": "is inducible by"
    },
    {
      "source": "TSG-6",
      "target": "serum protein inter-alpha-inhibitor",
      "label": "forms complex with"
    },
    {
      "source": "TSG-6",
      "target": "hyaluronan binding protein",
      "label": "is a type of"
    },
    {
      "source": "complex",
      "target": "reducing conditions",
      "label": "is stable under"
    },
    {
      "source": "complex",
      "target": "8 M urea",
      "label": "is stable in presence of"
    },
    {
      "source": "complex",
      "target": "protein",
      "label": "forms with"
    },
    {
      "source": "complex",
      "target": "SDS-PAGE",
      "label": "is stable during"
    },
    {
      "source": "complex",
      "target": "FX",
      "label": "activates"
    },
    {
      "source": "complex",
      "target": "FIX",
      "label": "activates"
    },
    {
      "source": "complex",
      "target": "thrombin formation",
      "label": "leads to"
    },
    {
      "source": "TSG-6 protein",
      "target": "synovial fluid",
      "label": "is found in"
    },
    {
      "source": "polypeptide chains",
      "target": "I alpha I",
      "label": "are part of"
    },
    {
      "source": "polypeptide chains",
      "target": "HC2",
      "label": "include"
    },
    {
      "source": "polypeptide chains",
      "target": "bikunin",
      "label": "include"
    },
    {
      "source": "recombinant TSG-6",
      "target": "TSG-6/I alpha I complex",
      "label": "forms"
    },
    {
      "source": "Microsequencing",
      "target": "TSG-6",
      "label": "revealed presence of"
    },
    {
      "source": "Microsequencing",
      "target": "polypeptide chains",
      "label": "revealed presence of"
    },
    {
      "source": "SDS-PAGE",
      "target": "125I-Factor XIIf -inhibitor complexes",
      "label": "analyzed"
    },
    {
      "source": "inter-alpha-inhibitor",
      "target": "N-terminal microsequencing",
      "label": "is identified by"
    },
    {
      "source": "calycopterin",
      "target": "H2O2-induced oxidative stress",
      "label": "has neuroprotective effect against"
    },
    {
      "source": "calycopterin",
      "target": "CREB",
      "label": "inhibited decrease in"
    },
    {
      "source": "calycopterin",
      "target": "Nrf2 pathway",
      "label": "modulates"
    },
    {
      "source": "calycopterin",
      "target": "MMP",
      "label": "prevented decrease in"
    },
    {
      "source": "calycopterin",
      "target": "DNA in tail",
      "label": "reduced"
    },
    {
      "source": "calycopterin",
      "target": "mitochondrial membrane potential",
      "label": "prevented decrease in"
    },
    {
      "source": "calycopterin",
      "target": "cytochrome C release",
      "label": "suppressed"
    },
    {
      "source": "calycopterin",
      "target": "SOD activity",
      "label": "inhibited decrease in"
    },
    {
      "source": "calycopterin",
      "target": "natural flavone",
      "label": "is a type of"
    },
    {
      "source": "calycopterin",
      "target": "CREB phosphorylation",
      "label": "modulates level of"
    },
    {
      "source": "calycopterin",
      "target": "natural neuroprotective flavonoid",
      "label": "is a type of"
    },
    {
      "source": "calycopterin",
      "target": "differentiated PC12 cells",
      "label": "has neuroprotective effect in"
    },
    {
      "source": "calycopterin",
      "target": "H2O2-induced disruption",
      "label": "affects"
    },
    {
      "source": "calycopterin",
      "target": "Nrf2",
      "label": "inhibited decrease in"
    },
    {
      "source": "calycopterin",
      "target": "GSH",
      "label": "inhibited decrease in level of"
    },
    {
      "source": "colorimetric assay",
      "target": "SOD activity",
      "label": "measured"
    },
    {
      "source": "SOD activity",
      "target": "Superoxide dismutase",
      "label": "is activity of"
    },
    {
      "source": "flavonoid calycopterin",
      "target": "Dracocephalum kotschyi",
      "label": "isolated from"
    },
    {
      "source": "flavonoid calycopterin",
      "target": "phase II detoxifying enzyme system",
      "label": "mediates neuroprotection involving"
    },
    {
      "source": "flavonoid calycopterin",
      "target": "p-CREB",
      "label": "mediates neuroprotection involving"
    },
    {
      "source": "PC12 cells",
      "target": "H2O2",
      "label": "treated with"
    },
    {
      "source": "PC12 cells",
      "target": "calycopterin",
      "label": "treated with"
    },
    {
      "source": "dithionitrobenzoic acid method",
      "target": "GSH",
      "label": "determined concentration of"
    },
    {
      "source": "dithionitrobenzoic acid method",
      "target": "glutathione",
      "label": "determined concentration of"
    },
    {
      "source": "whole cell lysate",
      "target": "GSH",
      "label": "contains"
    },
    {
      "source": "whole cell lysate",
      "target": "glutathione",
      "label": "contains"
    },
    {
      "source": "western blot method",
      "target": "\u03b3-GCS",
      "label": "measured level of"
    },
    {
      "source": "western blot method",
      "target": "nuclear factor erythroid 2-related factor 2",
      "label": "measured level of"
    },
    {
      "source": "western blot method",
      "target": "HO-1",
      "label": "measured level of"
    },
    {
      "source": "western blot method",
      "target": "phosphorylated CREB",
      "label": "measured level of"
    },
    {
      "source": "western blot method",
      "target": "glutamylcysteine synthetase",
      "label": "measured level of"
    },
    {
      "source": "western blot method",
      "target": "heme oxygenase 1",
      "label": "measured level of"
    },
    {
      "source": "western blot method",
      "target": "Nrf2",
      "label": "measured level of"
    },
    {
      "source": "comet assay",
      "target": "apoptosis",
      "label": "assessed"
    },
    {
      "source": "comet assay",
      "target": "DNA in tail",
      "label": "assessed"
    },
    {
      "source": "H2O2-induced disruption",
      "target": "cAMP response element binding protein",
      "label": "is of"
    },
    {
      "source": "H2O2-induced disruption",
      "target": "CREB phosphorylation",
      "label": "is of"
    },
    {
      "source": "H2O2-induced disruption",
      "target": "phase II detoxifying enzyme system",
      "label": "is of"
    },
    {
      "source": "cytochrome C release",
      "target": "mitochondrial homeostasis",
      "label": "is necessary for maintaining"
    },
    {
      "source": "cytochrome C release",
      "target": "cytosol",
      "label": "occurs to"
    },
    {
      "source": "mitochondrial homeostasis",
      "target": "survived cells",
      "label": "maintained in"
    },
    {
      "source": "calycopterin pretreated cells",
      "target": "\u03b3-GCS",
      "label": "showed increased levels of"
    },
    {
      "source": "calycopterin pretreated cells",
      "target": "HO-1",
      "label": "showed increased levels of"
    },
    {
      "source": "ophthalmic solutions",
      "target": "primary open-angle glaucoma (POAG)",
      "label": "are for treatment of"
    },
    {
      "source": "ophthalmic solutions",
      "target": "ocular hypertension (OHT)",
      "label": "are for treatment of"
    },
    {
      "source": "Double-blind comparative trials",
      "target": "betaxolol",
      "label": "suggest efficacy of"
    },
    {
      "source": "Double-blind comparative trials",
      "target": "levobunolol",
      "label": "suggest efficacy of"
    },
    {
      "source": "dosage and administration",
      "target": "betaxolol",
      "label": "is reviewed for"
    },
    {
      "source": "dosage and administration",
      "target": "levobunolol",
      "label": "is reviewed for"
    },
    {
      "source": "chemistry",
      "target": "levobunolol",
      "label": "is reviewed for"
    },
    {
      "source": "chemistry",
      "target": "betaxolol",
      "label": "is reviewed for"
    },
    {
      "source": "once-daily dosing",
      "target": "patients",
      "label": "controls"
    },
    {
      "source": "hereditary angioedema plasma",
      "target": "C-1-inhibitor",
      "label": "contained"
    },
    {
      "source": "hereditary angioedema plasma",
      "target": "125I-Factor XII",
      "label": "inactivated"
    },
    {
      "source": "C-1-inhibitor",
      "target": "Factor XIIf",
      "label": "has dominant role in inactivation of"
    },
    {
      "source": "C-1-inhibitor",
      "target": "factor XII active fragment",
      "label": "plays predominant role in inactivation of"
    },
    {
      "source": "Factor XIIf",
      "target": "alpha 2-macroglobulin",
      "label": "did not react with"
    },
    {
      "source": "Factor XIIf",
      "target": "alpha 2-antiplasmin",
      "label": "reacts with"
    },
    {
      "source": "Factor XIIf",
      "target": "C-1-inhibitor",
      "label": "reacts with"
    },
    {
      "source": "Factor XIIf",
      "target": "Factor XII",
      "label": "derived from"
    },
    {
      "source": "Factor XIIf",
      "target": "plasma",
      "label": "is inactivated in"
    },
    {
      "source": "Factor XIIf",
      "target": "alpha 1-antitrypsin",
      "label": "did not react with"
    },
    {
      "source": "Factor XIIf",
      "target": "antithrombin III",
      "label": "reacts with"
    },
    {
      "source": "normal plasma",
      "target": "factor XII active fragment",
      "label": "inactivates"
    },
    {
      "source": "active 125I-Factor XIIf",
      "target": "inhibitors",
      "label": "forms complexes with"
    },
    {
      "source": "active 125I-Factor XIIf",
      "target": "C-1-inhibitor",
      "label": "forms complex with"
    },
    {
      "source": "active 125I-Factor XIIf",
      "target": "normal plasma",
      "label": "was inactivated in"
    },
    {
      "source": "sodium dodecyl sulfate polyacrylamide gel electrophoresis",
      "target": "125I-Factor XIIf -inhibitor complexes",
      "label": "analyzed"
    },
    {
      "source": "prekallikrein-deficient plasma",
      "target": "Factor XIIf",
      "label": "inactivates"
    },
    {
      "source": "prekallikrein-deficient plasma",
      "target": "C-1-inhibitor",
      "label": "was immunodepleted of"
    },
    {
      "source": "Autoradiography",
      "target": "three protein bands",
      "label": "showed"
    },
    {
      "source": "Autoradiography",
      "target": "polyacrylamide gels",
      "label": "of"
    },
    {
      "source": "three protein bands",
      "target": "40 000 Da",
      "label": "have molecular mass"
    },
    {
      "source": "three protein bands",
      "target": "salmon calcitonin",
      "label": "bind"
    },
    {
      "source": "three protein bands",
      "target": "33 000 Da",
      "label": "have molecular mass"
    },
    {
      "source": "three protein bands",
      "target": "70 000 Da",
      "label": "have molecular mass"
    },
    {
      "source": "40 000-Da molecule",
      "target": "total binding species",
      "label": "is a part of"
    },
    {
      "source": "40 000-Da molecule",
      "target": "major band",
      "label": "represents"
    },
    {
      "source": "three proteins",
      "target": "principal components",
      "label": "are"
    },
    {
      "source": "principal components",
      "target": "calcitonin receptor",
      "label": "of"
    },
    {
      "source": "calcitonin receptors",
      "target": "rat kidney membranes",
      "label": "located in"
    },
    {
      "source": "calcitonin receptors",
      "target": "covalent cross-linking techniques",
      "label": "characterized by"
    },
    {
      "source": "molecular sieving",
      "target": "Sephacryl S-200",
      "label": "is"
    },
    {
      "source": "apparent molecular masses",
      "target": "100 000 Da",
      "label": "range to"
    },
    {
      "source": "apparent molecular masses",
      "target": "18 000 Da",
      "label": "range from"
    },
    {
      "source": "molecular masses",
      "target": "40 000 Da",
      "label": "include"
    },
    {
      "source": "molecular masses",
      "target": "33 000 Da",
      "label": "include"
    },
    {
      "source": "molecular masses",
      "target": "70 000 Da",
      "label": "include"
    },
    {
      "source": "protein bands",
      "target": "reducing agent",
      "label": "analyzed with"
    },
    {
      "source": "protein bands",
      "target": "apparent molecular masses",
      "label": "have"
    },
    {
      "source": "reducing agent",
      "target": "2-mercaptoethanol",
      "label": "is"
    },
    {
      "source": "Cross-linked receptor",
      "target": "volume",
      "label": "eluted in"
    },
    {
      "source": "Cross-linked receptor",
      "target": "solubilized membranes",
      "label": "eluted as"
    },
    {
      "source": "solubilization",
      "target": "binding parameters",
      "label": "effected"
    },
    {
      "source": "Synthetic salmon calcitonin",
      "target": "renal membranes",
      "label": "bound to"
    },
    {
      "source": "Synthetic salmon calcitonin",
      "target": "bifunctional reagent",
      "label": "bound using"
    },
    {
      "source": "Synthetic salmon calcitonin",
      "target": "photo-affinity cross-linking",
      "label": "bound using"
    },
    {
      "source": "solubilized membranes",
      "target": "salmon calcitonin",
      "label": "bind"
    },
    {
      "source": "Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis",
      "target": "purified fractions",
      "label": "of"
    },
    {
      "source": "Sodium dodecyl sulfate polyacrylamide gel electrophoresis analysis",
      "target": "protein bands",
      "label": "showed"
    },
    {
      "source": "bifunctional reagent",
      "target": "disuccinimidyl suberate",
      "label": "is"
    },
    {
      "source": "polyacrylamide gels",
      "target": "cross-linked calcitonin receptor",
      "label": "of"
    },
    {
      "source": "site II",
      "target": "number of binding sites",
      "label": "has"
    },
    {
      "source": "site II",
      "target": "Ka2",
      "label": "has"
    },
    {
      "source": "site I",
      "target": "number of binding sites",
      "label": "has"
    },
    {
      "source": "site I",
      "target": "Ka1",
      "label": "has"
    },
    {
      "source": "purification factor",
      "target": "molecular sieving",
      "label": "compared to"
    },
    {
      "source": "photo-affinity cross-linking",
      "target": "hydroxysuccinimidyl azidobenzonate reagent",
      "label": "uses"
    },
    {
      "source": "characterization",
      "target": "calcitonin receptors",
      "label": "of"
    },
    {
      "source": "renal receptors",
      "target": "binding parameters",
      "label": "characterized for"
    },
    {
      "source": "affinity chromatography",
      "target": "process",
      "label": "is a"
    },
    {
      "source": "S-S bonds",
      "target": "assembly",
      "label": "not involved in"
    },
    {
      "source": "high-affinity sites",
      "target": "affinity chromatography",
      "label": "preserved during"
    },
    {
      "source": "total loss",
      "target": "high-affinity site",
      "label": "of"
    },
    {
      "source": "Estramustine binding protein",
      "target": "metastases",
      "label": "found in"
    },
    {
      "source": "Estramustine binding protein",
      "target": "primary tumours",
      "label": "found in"
    },
    {
      "source": "Estramustine binding protein",
      "target": "EMBP",
      "label": "is also known as"
    },
    {
      "source": "EMBP",
      "target": "immunohistochemistry",
      "label": "demonstrated by"
    },
    {
      "source": "EMBP",
      "target": "estrogen receptor",
      "label": "is distinct from"
    },
    {
      "source": "EMBP",
      "target": "prognostic significance",
      "label": "has"
    },
    {
      "source": "EMBP",
      "target": "54 kD cytosolic glycoprotein",
      "label": "is a type of"
    },
    {
      "source": "EMBP",
      "target": "malignant melanoma",
      "label": "found in"
    },
    {
      "source": "EMBP",
      "target": "protein",
      "label": "measured in"
    },
    {
      "source": "percentage",
      "target": "positive melanoma cells",
      "label": "refers to"
    },
    {
      "source": "interval",
      "target": "diagnosis",
      "label": "between"
    },
    {
      "source": "interval",
      "target": "occurrence of metastases",
      "label": "between"
    },
    {
      "source": "pilot study",
      "target": "metastases",
      "label": "involved"
    },
    {
      "source": "pilot study",
      "target": "EMBP",
      "label": "investigated"
    },
    {
      "source": "pilot study",
      "target": "primary malignant melanomas",
      "label": "involved"
    },
    {
      "source": "pilot study",
      "target": "Estramustine binding protein",
      "label": "investigated"
    },
    {
      "source": "Radioimmunoassay",
      "target": "metastatic tissue",
      "label": "performed on"
    },
    {
      "source": "Radioimmunoassay",
      "target": "EMBP",
      "label": "revealed"
    },
    {
      "source": "primary tumours",
      "target": "malignant melanoma",
      "label": "associated with"
    },
    {
      "source": "positive stain",
      "target": "primary tumours",
      "label": "found in"
    },
    {
      "source": "positive stain",
      "target": "interval",
      "label": "correlated to"
    },
    {
      "source": "positive stain",
      "target": "EMBP",
      "label": "for"
    },
    {
      "source": "hormone-linked cytostatic drugs",
      "target": "treatment",
      "label": "have role in"
    },
    {
      "source": "craniofacial structures",
      "target": "first branchial arch",
      "label": "derived from"
    },
    {
      "source": "craniofacial structures",
      "target": "second branchial arch",
      "label": "derived from"
    },
    {
      "source": "first branchial arch",
      "target": "control embryos",
      "label": "removed from"
    },
    {
      "source": "first branchial arch",
      "target": "teratogen-treated embryos",
      "label": "removed from"
    },
    {
      "source": "teratogen",
      "target": "serious congenital malformations",
      "label": "associated with"
    },
    {
      "source": "serious congenital malformations",
      "target": "congenital malformations",
      "label": "is a type of"
    },
    {
      "source": "candidate genes",
      "target": "mammalian craniofacial development",
      "label": "important in"
    },
    {
      "source": "teratogen-treated embryos",
      "target": "embryos",
      "label": "is a type of"
    },
    {
      "source": "nicotinic acetylcholine receptor subunit alpha",
      "target": "NAChR",
      "label": "is also known as"
    },
    {
      "source": "isotretinoin",
      "target": "Accutane",
      "label": "is also known as"
    },
    {
      "source": "in situ transcription/aRNA techniques",
      "target": "aRNA techniques",
      "label": "includes"
    },
    {
      "source": "in situ transcription/aRNA techniques",
      "target": "in situ transcription",
      "label": "includes"
    },
    {
      "source": "Altered gene expression",
      "target": "retinoic acid receptor gamma",
      "label": "involves"
    },
    {
      "source": "Altered gene expression",
      "target": "type 1 cellular retinoid binding protein",
      "label": "involves"
    },
    {
      "source": "Altered gene expression",
      "target": "transforming growth factor beta 2",
      "label": "involves"
    },
    {
      "source": "Altered gene expression",
      "target": "RA",
      "label": "follows"
    },
    {
      "source": "Altered gene expression",
      "target": "RA-induced defects",
      "label": "contributes to"
    },
    {
      "source": "Altered gene expression",
      "target": "morphogenetic processes",
      "label": "prohibits"
    },
    {
      "source": "Altered gene expression",
      "target": "nicotinic acetylcholine receptor subunit alpha",
      "label": "involves"
    },
    {
      "source": "Altered gene expression",
      "target": "murine branchial arches",
      "label": "occurs in"
    },
    {
      "source": "Altered gene expression",
      "target": "cAMP response element binding protein",
      "label": "involves"
    },
    {
      "source": "Altered gene expression",
      "target": "in utero exposure",
      "label": "follows"
    },
    {
      "source": "Altered gene expression",
      "target": "malformations",
      "label": "leads to"
    },
    {
      "source": "retinoic acid receptor gamma",
      "target": "RAR gamma",
      "label": "is also known as"
    },
    {
      "source": "type 1 cellular retinoid binding protein",
      "target": "CRBP-1",
      "label": "is also known as"
    },
    {
      "source": "transforming growth factor beta 2",
      "target": "TGF beta 2",
      "label": "is also known as"
    },
    {
      "source": "control embryos",
      "target": "embryos",
      "label": "is a type of"
    },
    {
      "source": "panel of 40 candidate genes",
      "target": "candidate genes",
      "label": "is a type of"
    },
    {
      "source": "tretinoin",
      "target": "Retin-A",
      "label": "is also known as"
    },
    {
      "source": "morphogenetic processes",
      "target": "second branchial arch",
      "label": "occurs within"
    },
    {
      "source": "pregnant LM/Bc mice",
      "target": "LM/Bc mice",
      "label": "is a type of"
    },
    {
      "source": "pregnant LM/Bc mice",
      "target": "RA",
      "label": "administered"
    },
    {
      "source": "congenital malformations",
      "target": "craniofacial structures",
      "label": "involve"
    },
    {
      "source": "gestational day",
      "target": "GD",
      "label": "is also known as"
    },
    {
      "source": "second branchial arch",
      "target": "control embryos",
      "label": "removed from"
    },
    {
      "source": "second branchial arch",
      "target": "teratogen-treated embryos",
      "label": "removed from"
    },
    {
      "source": "male infant",
      "target": "lethargy",
      "label": "presented with"
    },
    {
      "source": "male infant",
      "target": "age 6 weeks",
      "label": "presented at"
    },
    {
      "source": "male infant",
      "target": "staring spells",
      "label": "presented with"
    },
    {
      "source": "male infant",
      "target": "vomiting",
      "label": "presented with"
    },
    {
      "source": "male infant",
      "target": "methyl-B12 deficiency",
      "label": "has"
    },
    {
      "source": "methyl-B12 deficiency",
      "target": "cblE",
      "label": "is"
    },
    {
      "source": "megaloblastic anemia",
      "target": "Vitamin B12",
      "label": "is responsive to"
    },
    {
      "source": "Methionine synthase activity",
      "target": "assay",
      "label": "was measured by"
    },
    {
      "source": "Methionine synthase activity",
      "target": "optimal reducing conditions",
      "label": "was decreased under"
    },
    {
      "source": "Methionine synthase activity",
      "target": "suboptimal reducing conditions",
      "label": "was decreased under"
    },
    {
      "source": "Methyl-B12 content",
      "target": "Fibroblasts",
      "label": "of"
    },
    {
      "source": "Fibroblasts",
      "target": "[14C]-methyl-tetrahydrofolate",
      "label": "incorporated abnormally small amounts of"
    },
    {
      "source": "Fibroblasts",
      "target": "patient",
      "label": "cultured from"
    },
    {
      "source": "Fibroblasts",
      "target": "[14C]-propionate",
      "label": "incorporated normal amounts of"
    },
    {
      "source": "Fibroblasts",
      "target": "medium",
      "label": "unable to grow in"
    },
    {
      "source": "homocystinuria",
      "target": "Vitamin B12",
      "label": "is responsive to"
    },
    {
      "source": "Psychometric testing",
      "target": "developmental age",
      "label": "showed"
    },
    {
      "source": "Psychometric testing",
      "target": "age 15 months",
      "label": "performed at"
    },
    {
      "source": "developmental age",
      "target": "9 months",
      "label": "was"
    },
    {
      "source": "adenosyl-B12 content",
      "target": "Fibroblasts",
      "label": "of"
    },
    {
      "source": "[14C]-propionate",
      "target": "protein",
      "label": "incorporated into"
    },
    {
      "source": "methylcobalamin deficiency",
      "target": "heterogeneity",
      "label": "has"
    },
    {
      "source": "Sodium-dependent norepinephrine-induced currents",
      "target": "antidepressants",
      "label": "blocked by"
    },
    {
      "source": "Sodium-dependent norepinephrine-induced currents",
      "target": "HEK-293 cells",
      "label": "are observed in"
    },
    {
      "source": "Sodium-dependent norepinephrine-induced currents",
      "target": "cocaine",
      "label": "blocked by"
    },
    {
      "source": "catecholamine transport",
      "target": "ion permeation",
      "label": "related to"
    },
    {
      "source": "ion permeation",
      "target": "NE transporter",
      "label": "occurs through"
    },
    {
      "source": "inhibitor sensitivities",
      "target": "native membranes",
      "label": "similar to"
    },
    {
      "source": "antidepressant-sensitive transporters",
      "target": "cocaine",
      "label": "are sensitive to"
    },
    {
      "source": "antidepressant-sensitive transporters",
      "target": "antidepressants",
      "label": "are sensitive to"
    },
    {
      "source": "cotransport",
      "target": "charge",
      "label": "results in"
    },
    {
      "source": "cotransport",
      "target": "Na+",
      "label": "of"
    },
    {
      "source": "cotransport",
      "target": "Cl-",
      "label": "of"
    },
    {
      "source": "transporter copies",
      "target": "radioligand binding",
      "label": "detected by"
    },
    {
      "source": "transporter copies",
      "target": "hNET-specific antibodies",
      "label": "detected by"
    },
    {
      "source": "Whole-cell voltage-clamp",
      "target": "hNET-293 cells",
      "label": "performed on"
    },
    {
      "source": "norepinephrine-transporter",
      "target": "HEK-293 cells",
      "label": "is transfected into"
    },
    {
      "source": "hNET cDNA",
      "target": "HEK-293 cells",
      "label": "transfected into"
    },
    {
      "source": "transfected cells",
      "target": "Na(+)-dependent transport of NE",
      "label": "exhibit"
    },
    {
      "source": "transfected cells",
      "target": "transporter copies",
      "label": "exhibit"
    },
    {
      "source": "transfected cells",
      "target": "inhibitor sensitivities",
      "label": "exhibit"
    },
    {
      "source": "Na(+)-dependent transport of NE",
      "target": "affinities",
      "label": "has"
    },
    {
      "source": "complete DNA sequence",
      "target": "dideoxy chain termination",
      "label": "established by"
    },
    {
      "source": "complete DNA sequence",
      "target": "5' flanking regions",
      "label": "is for"
    },
    {
      "source": "complete DNA sequence",
      "target": "3' flanking regions",
      "label": "is for"
    },
    {
      "source": "complete DNA sequence",
      "target": "38 kilobases",
      "label": "is approximately"
    },
    {
      "source": "complete DNA sequence",
      "target": "gene",
      "label": "is for"
    },
    {
      "source": "complete DNA sequence",
      "target": "chemical degradation methods",
      "label": "established by"
    },
    {
      "source": "Alu repetitive sequences",
      "target": "intron A",
      "label": "located in"
    },
    {
      "source": "Alu repetitive sequences",
      "target": "3' end of the gene",
      "label": "flanks"
    },
    {
      "source": "Alu repetitive sequences",
      "target": "intron F",
      "label": "located in"
    },
    {
      "source": "intron A",
      "target": "alternating purine-pyrimidine sequences",
      "label": "contained"
    },
    {
      "source": "gene for factor IX",
      "target": "gene for human prothrombin",
      "label": "has introns with identical positions to"
    },
    {
      "source": "gene for factor IX",
      "target": "gene for human protein C",
      "label": "has introns with similar positions to"
    },
    {
      "source": "human genomic DNA libraries",
      "target": "gene for blood coagulation factor IX",
      "label": "screened for"
    },
    {
      "source": "50 base pair insert",
      "target": "intron A",
      "label": "located in"
    },
    {
      "source": "50 base pair insert",
      "target": "clone",
      "label": "found in"
    },
    {
      "source": "50 base pair insert",
      "target": "clones",
      "label": "absent in"
    },
    {
      "source": "Z-DNA structures",
      "target": "gene",
      "label": "is for"
    },
    {
      "source": "mature protein",
      "target": "plasma",
      "label": "circulates in"
    },
    {
      "source": "KpnI repetitive sequences",
      "target": "region flanking the 5' end of the gene",
      "label": "identified in"
    },
    {
      "source": "KpnI repetitive sequences",
      "target": "intron D",
      "label": "identified in"
    },
    {
      "source": "eight exons",
      "target": "3' noncoding regions",
      "label": "located within"
    },
    {
      "source": "eight exons",
      "target": "415 amino acids",
      "label": "code for"
    },
    {
      "source": "eight exons",
      "target": "coding regions",
      "label": "located within"
    },
    {
      "source": "eight exons",
      "target": "prepro leader sequence",
      "label": "code for"
    },
    {
      "source": "3' noncoding regions",
      "target": "alternating purine-pyrimidine sequences",
      "label": "contained"
    },
    {
      "source": "cDNA",
      "target": "hybridization probe",
      "label": "used as"
    },
    {
      "source": "cDNA",
      "target": "human protein",
      "label": "is for"
    },
    {
      "source": "cDNA",
      "target": "patient's paternal allele",
      "label": "derived from"
    },
    {
      "source": "cDNA",
      "target": "119-bp insertion",
      "label": "had"
    },
    {
      "source": "cDNA",
      "target": "patient's maternal allele",
      "label": "derived from"
    },
    {
      "source": "Nucleotide sequence",
      "target": "gene",
      "label": "is sequence of"
    },
    {
      "source": "overlapping lambda phages",
      "target": "gene for factor IX",
      "label": "contained"
    },
    {
      "source": "intervening sequences",
      "target": "nucleotides",
      "label": "contain"
    },
    {
      "source": "intervening sequences",
      "target": "Alu repetitive sequences",
      "label": "contain"
    },
    {
      "source": "left-handed helical DNA",
      "target": "gene",
      "label": "is for"
    },
    {
      "source": "415 amino acids",
      "target": "mature protein",
      "label": "make up"
    },
    {
      "source": "alternating purine-pyrimidine sequences",
      "target": "left-handed helical DNA",
      "label": "provide"
    },
    {
      "source": "alternating purine-pyrimidine sequences",
      "target": "Z-DNA structures",
      "label": "provide"
    },
    {
      "source": "human factor IX",
      "target": "antihemophilic factor B",
      "label": "is also known as"
    },
    {
      "source": "clone",
      "target": "genomic libraries",
      "label": "from"
    },
    {
      "source": "5' flanking region",
      "target": "1.9-kb HindIII subfamily repeat",
      "label": "contained"
    },
    {
      "source": "33.5 kilobases",
      "target": "DNA",
      "label": "is type of"
    },
    {
      "source": "clones",
      "target": "library",
      "label": "from"
    },
    {
      "source": "seven introns",
      "target": "gene for factor IX",
      "label": "located in"
    },
    {
      "source": "Phenylpropanolamine",
      "target": "Anorexia",
      "label": "induces"
    },
    {
      "source": "Phenylpropanolamine",
      "target": "Reuptake",
      "label": "inhibits"
    },
    {
      "source": "Phenylpropanolamine",
      "target": "Dopamine",
      "label": "increases release of"
    },
    {
      "source": "Phenylpropanolamine",
      "target": "Noradrenaline",
      "label": "increases release of"
    },
    {
      "source": "Phenylpropanolamine",
      "target": "Food intake",
      "label": "has effect on"
    },
    {
      "source": "Phenylpropanolamine",
      "target": "Alpha 1-adrenoceptors",
      "label": "stimulates directly"
    },
    {
      "source": "Diethylpropion",
      "target": "Reuptake",
      "label": "inhibits"
    },
    {
      "source": "Diethylpropion",
      "target": "Dopamine",
      "label": "increases release of"
    },
    {
      "source": "Diethylpropion",
      "target": "Food intake",
      "label": "has effect on"
    },
    {
      "source": "Diethylpropion",
      "target": "Noradrenaline",
      "label": "increases release of"
    },
    {
      "source": "Diethylpropion",
      "target": "Anorexia",
      "label": "induces"
    },
    {
      "source": "Dopamine",
      "target": "Nerve terminals",
      "label": "is released from"
    },
    {
      "source": "Fluoxetine",
      "target": "Anorexia",
      "label": "causes"
    },
    {
      "source": "Fluoxetine",
      "target": "5-HT uptake inhibitors",
      "label": "is a type of"
    },
    {
      "source": "Phentermine",
      "target": "Anorexia",
      "label": "induces"
    },
    {
      "source": "Phentermine",
      "target": "Dopamine",
      "label": "increases release of"
    },
    {
      "source": "Phentermine",
      "target": "Reuptake",
      "label": "inhibits"
    },
    {
      "source": "Phentermine",
      "target": "Noradrenaline",
      "label": "increases release of"
    },
    {
      "source": "Phentermine",
      "target": "Food intake",
      "label": "has effect on"
    },
    {
      "source": "Beta- and alpha 1-adrenoceptors",
      "target": "Food intake",
      "label": "are involved in effect on"
    },
    {
      "source": "Noradrenaline",
      "target": "Nerve terminals",
      "label": "is released from"
    },
    {
      "source": "Anorectic action",
      "target": "Humans",
      "label": "occurs in"
    },
    {
      "source": "Satiating effect",
      "target": "Dexfenfluramine",
      "label": "is an effect of"
    },
    {
      "source": "Dexfenfluramine",
      "target": "5-hydroxytryptamine",
      "label": "releases"
    },
    {
      "source": "Dexfenfluramine",
      "target": "Anorectic agent",
      "label": "is an"
    },
    {
      "source": "Dexfenfluramine",
      "target": "Reuptake",
      "label": "inhibits"
    },
    {
      "source": "Dexfenfluramine",
      "target": "5-HT",
      "label": "releases"
    },
    {
      "source": "Sertraline",
      "target": "5-HT uptake inhibitors",
      "label": "is a type of"
    },
    {
      "source": "Sertraline",
      "target": "Anorexia",
      "label": "causes"
    },
    {
      "source": "5-HT uptake inhibitors",
      "target": "Anorexia",
      "label": "cause"
    },
    {
      "source": "Neurochemical mechanism",
      "target": "Anorectic drugs",
      "label": "is mechanism of action for"
    },
    {
      "source": "(+)-amphetamine",
      "target": "Anorexia",
      "label": "induces"
    },
    {
      "source": "(+)-amphetamine",
      "target": "Reuptake",
      "label": "inhibits"
    },
    {
      "source": "(+)-amphetamine",
      "target": "Dopamine",
      "label": "increases release of"
    },
    {
      "source": "(+)-amphetamine",
      "target": "Food intake",
      "label": "has effect on"
    },
    {
      "source": "(+)-amphetamine",
      "target": "Noradrenaline",
      "label": "increases release of"
    },
    {
      "source": "Subtypes",
      "target": "Neurotransmitters",
      "label": "are subtypes for"
    },
    {
      "source": "Receptor types",
      "target": "Neurotransmitters",
      "label": "are types for"
    },
    {
      "source": "Food craving",
      "target": "Eating disorders",
      "label": "is a type of"
    },
    {
      "source": "D1 dopamine receptors",
      "target": "Food intake",
      "label": "are involved in effect on"
    },
    {
      "source": "Binge-eating",
      "target": "Eating disorders",
      "label": "is a type of"
    },
    {
      "source": "emedastine",
      "target": "chlorpheniramine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "allergic conjunctivitis",
      "label": "has potential for treating"
    },
    {
      "source": "emedastine",
      "target": "clemastine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "antazoline",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "topical ocular administration",
      "label": "administered via"
    },
    {
      "source": "emedastine",
      "target": "vascular permeability changes",
      "label": "failed to attenuate"
    },
    {
      "source": "emedastine",
      "target": "pheniramine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "ketotifen",
      "label": "is equipotent to"
    },
    {
      "source": "emedastine",
      "target": "topical ocular anti-histaminic activity",
      "label": "evaluated for"
    },
    {
      "source": "emedastine",
      "target": "brompheniramine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "allergic response",
      "label": "inhibits"
    },
    {
      "source": "emedastine",
      "target": "anti-histamines",
      "label": "compared to"
    },
    {
      "source": "emedastine",
      "target": "histamine H1 antagonist",
      "label": "is a"
    },
    {
      "source": "emedastine",
      "target": "pyrilamine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "levocabastine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "diphenhydramine",
      "label": "is more potent than"
    },
    {
      "source": "emedastine",
      "target": "1-(2-ethoxyethyl)-2-(4-methyl-1-homopiperazinyl)- benzimidazole difumarate",
      "label": "is a"
    },
    {
      "source": "emedastine",
      "target": "histamine H1 receptor",
      "label": "has selectivity for"
    },
    {
      "source": "emedastine",
      "target": "topical ocular use",
      "label": "has"
    },
    {
      "source": "histamine induced vascular permeability changes",
      "target": "conjunctiva",
      "label": "occurs in"
    },
    {
      "source": "platelet-activating-factor",
      "target": "vascular permeability changes",
      "label": "induces"
    },
    {
      "source": "topical ocular anti-histaminic activity",
      "target": "conjunctivitis models",
      "label": "evaluated in"
    },
    {
      "source": "conjunctivitis models",
      "target": "antigen",
      "label": "stimulated by"
    },
    {
      "source": "conjunctivitis models",
      "target": "histamine",
      "label": "stimulated by"
    },
    {
      "source": "passive conjunctival anaphylaxis model",
      "target": "guinea pigs",
      "label": "involves"
    },
    {
      "source": "product",
      "target": "ultraviolet spectral studies",
      "label": "confirmed by"
    },
    {
      "source": "product",
      "target": "high-performance liquid chromatography (HPLC)",
      "label": "confirmed by"
    },
    {
      "source": "product",
      "target": "infrared spectral studies",
      "label": "confirmed by"
    },
    {
      "source": "potassium cyanide",
      "target": "reaction",
      "label": "inhibited"
    },
    {
      "source": "potassium cyanide",
      "target": "Phenol oxidase inhibitors",
      "label": "is a"
    },
    {
      "source": "potassium cyanide",
      "target": "Phenol oxidase",
      "label": "is an inhibitor of"
    },
    {
      "source": "4-Hydroxymandelic acid",
      "target": "reaction",
      "label": "did not inhibit"
    },
    {
      "source": "4-Hydroxymandelic acid",
      "target": "substrates",
      "label": "did not serve as"
    },
    {
      "source": "Mimosine",
      "target": "competitive inhibitor",
      "label": "is a"
    },
    {
      "source": "Mimosine",
      "target": "reaction",
      "label": "inhibited"
    },
    {
      "source": "Mimosine",
      "target": "Tyrosinase",
      "label": "is a competitive inhibitor of"
    },
    {
      "source": "3,4-dihydroxymandelic acid",
      "target": "mushroom tyrosinase",
      "label": "is a suitable substrate for"
    },
    {
      "source": "3,4-dihydroxymandelic acid",
      "target": "Tyrosinase",
      "label": "is a substrate for"
    },
    {
      "source": "mushroom tyrosinase",
      "target": "active site copper",
      "label": "uses"
    },
    {
      "source": "mushroom tyrosinase",
      "target": "quinone methide production",
      "label": "catalyzes"
    },
    {
      "source": "active site copper",
      "target": "enzyme",
      "label": "is part of"
    },
    {
      "source": "active site copper",
      "target": "catalysis",
      "label": "participates in"
    },
    {
      "source": "sodium azide",
      "target": "reaction",
      "label": "inhibited"
    },
    {
      "source": "sodium azide",
      "target": "Phenol oxidase inhibitors",
      "label": "is a"
    },
    {
      "source": "sodium azide",
      "target": "Phenol oxidase",
      "label": "is an inhibitor of"
    },
    {
      "source": "3-methoxy-4-hydroxymandelic acid",
      "target": "substrates",
      "label": "did not serve as"
    },
    {
      "source": "3-methoxy-4-hydroxymandelic acid",
      "target": "reaction",
      "label": "did not inhibit"
    },
    {
      "source": "monophenols",
      "target": "Tyrosinase",
      "label": "is a substrate for"
    },
    {
      "source": "Tyrosinase",
      "target": "oxidative decarboxylation",
      "label": "catalyzes"
    },
    {
      "source": "Tyrosinase",
      "target": "quinones",
      "label": "produces"
    },
    {
      "source": "Tyrosinase",
      "target": "oxidative decarboxylation reaction",
      "label": "catalyzed"
    },
    {
      "source": "Tyrosinase",
      "target": "diphenols",
      "label": "catalyzes oxidation of"
    },
    {
      "source": "Tyrosinase",
      "target": "o-diphenols",
      "label": "produces"
    },
    {
      "source": "Tyrosinase",
      "target": "monophenols",
      "label": "catalyzes conversion of"
    },
    {
      "source": "Sugumaran, M.",
      "target": "FEBS Lett.",
      "label": "reported in"
    },
    {
      "source": "3,4-dihydroxybenzyl alcohol",
      "target": "intermediates",
      "label": "is a putative"
    },
    {
      "source": "3,4-dihydroxybenzyl alcohol",
      "target": "reaction",
      "label": "did not accumulate during"
    },
    {
      "source": "galactose oxidase",
      "target": "reaction",
      "label": "did not catalyze"
    },
    {
      "source": "phenylthiourea",
      "target": "reaction",
      "label": "inhibited"
    },
    {
      "source": "phenylthiourea",
      "target": "Phenol oxidase inhibitors",
      "label": "is a"
    },
    {
      "source": "phenylthiourea",
      "target": "Phenol oxidase",
      "label": "is an inhibitor of"
    },
    {
      "source": "quinone methide derivative",
      "target": "oxidative decarboxylation reaction",
      "label": "accounts for"
    },
    {
      "source": "oxidative decarboxylation reaction",
      "target": "3,4-dihydroxybenzaldehyde",
      "label": "generates"
    },
    {
      "source": "(3,4-dihydroxybenzoyl)formic acid",
      "target": "reaction",
      "label": "did not accumulate during"
    },
    {
      "source": "(3,4-dihydroxybenzoyl)formic acid",
      "target": "intermediates",
      "label": "is a putative"
    },
    {
      "source": "diphenols",
      "target": "Tyrosinase",
      "label": "is a substrate for"
    },
    {
      "source": "ceruloplasmin",
      "target": "reaction",
      "label": "did not catalyze"
    },
    {
      "source": "o-diphenols",
      "target": "Tyrosinase",
      "label": "is a product of"
    },
    {
      "source": "3,4-dihydroxybenzaldehyde",
      "target": "product",
      "label": "is a"
    },
    {
      "source": "cuticular phenol oxidase",
      "target": "4-alkylcatechols",
      "label": "catalyzes conversion of"
    },
    {
      "source": "cuticular phenol oxidase",
      "target": "quinone methides",
      "label": "produces"
    },
    {
      "source": "3,4-dihydroxymandelate",
      "target": "Tyrosinase",
      "label": "is a substrate for"
    },
    {
      "source": "ascorbate oxidase",
      "target": "reaction",
      "label": "did not catalyze"
    },
    {
      "source": "peroxidase",
      "target": "reaction",
      "label": "did not catalyze"
    },
    {
      "source": "quinone methides",
      "target": "cuticular phenol oxidase",
      "label": "is a product of"
    },
    {
      "source": "Lipke, H.",
      "target": "FEBS Lett.",
      "label": "reported in"
    },
    {
      "source": "bradykinin",
      "target": "alpha-AR mRNA level",
      "label": "decreased"
    },
    {
      "source": "bradykinin",
      "target": "alpha-AR mRNA",
      "label": "caused down-regulation of"
    },
    {
      "source": "Actinomycin D",
      "target": "H-7",
      "label": "blocked effect of"
    },
    {
      "source": "Actinomycin D",
      "target": "alpha-AR mRNA level",
      "label": "caused decrease in"
    },
    {
      "source": "H-7",
      "target": "NE",
      "label": "abolished effect of"
    },
    {
      "source": "H-7",
      "target": "basal mRNA levels",
      "label": "decreased"
    },
    {
      "source": "H-7",
      "target": "Phorbol esters",
      "label": "abolished effect of"
    },
    {
      "source": "(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride",
      "target": "NE",
      "label": "abolished effect of"
    },
    {
      "source": "(+)-1-(5-isoquinolinesulfonyl)-2-methylpiperazine dihydrochloride",
      "target": "Phorbol esters",
      "label": "abolished effect of"
    },
    {
      "source": "ryanodine",
      "target": "down-regulation of alpha-AR mRNA",
      "label": "did not inhibit"
    },
    {
      "source": "Phorbol esters",
      "target": "rate of alpha-AR mRNA degradation",
      "label": "increased"
    },
    {
      "source": "Phorbol esters",
      "target": "alpha 1B-adrenergic receptor mRNA",
      "label": "destabilizes"
    },
    {
      "source": "Phorbol esters",
      "target": "alpha-AR mRNA",
      "label": "caused down-regulation of"
    },
    {
      "source": "Phorbol esters",
      "target": "alpha-AR mRNA level",
      "label": "decreased"
    },
    {
      "source": "protein kinase C inhibitor",
      "target": "NE",
      "label": "abolished effect of"
    },
    {
      "source": "protein kinase C inhibitor",
      "target": "Phorbol esters",
      "label": "abolished effect of"
    },
    {
      "source": "EGTA",
      "target": "down-regulation of alpha-AR mRNA",
      "label": "did not inhibit"
    },
    {
      "source": "sustained phosphorylation",
      "target": "protein kinase C substrate",
      "label": "occurs on"
    },
    {
      "source": "protein phosphatase inhibitor",
      "target": "NE",
      "label": "prolonged effect of"
    },
    {
      "source": "stability of the mRNA",
      "target": "sustained phosphorylation",
      "label": "requires"
    },
    {
      "source": "outer cell membrane",
      "target": "Gram-negative bacteria",
      "label": "is part of"
    },
    {
      "source": "Cefepime",
      "target": "PBPs 2 and 3",
      "label": "has affinity for"
    },
    {
      "source": "Cefepime",
      "target": "efficacy",
      "label": "shows"
    },
    {
      "source": "Cefepime",
      "target": "cefotaxime-resistant Enterobacteriaceae",
      "label": "is active against"
    },
    {
      "source": "Cefepime",
      "target": "chromosomally-mediated beta-lactamases",
      "label": "is resistant to degradation by"
    },
    {
      "source": "Cefepime",
      "target": "methoxyimino-aminothiazolyl cephalosporin",
      "label": "is a"
    },
    {
      "source": "Cefepime",
      "target": "Enterobacteriaceae",
      "label": "is active against"
    },
    {
      "source": "Cefepime",
      "target": "beta-lactamases",
      "label": "has no inducing capacity for"
    },
    {
      "source": "Cefepime",
      "target": "ceftazidime-resistant Enterobacteriaceae",
      "label": "is active against"
    },
    {
      "source": "Cefepime",
      "target": "ceftazidime",
      "label": "is more active than"
    },
    {
      "source": "Cefepime",
      "target": "plasmid",
      "label": "is resistant to degradation by"
    },
    {
      "source": "Cefepime",
      "target": "broad-spectrum of activity",
      "label": "has"
    },
    {
      "source": "Cefepime",
      "target": "outer cell membrane",
      "label": "penetrates"
    },
    {
      "source": "Cefepime",
      "target": "PBP 3",
      "label": "has affinity for"
    },
    {
      "source": "Cefepime",
      "target": "cefotaxime",
      "label": "is more active than"
    },
    {
      "source": "PBPs 2 and 3",
      "target": "Escherichia coli",
      "label": "are found in"
    },
    {
      "source": "N-methyl-pyrrolidine moiety",
      "target": "zwitterionic properties",
      "label": "confers"
    },
    {
      "source": "methicillin-susceptible Staphylococcus aureus",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "MIC90",
      "target": "latamoxef",
      "label": "is lower than"
    },
    {
      "source": "MIC90",
      "target": "cefpirome",
      "label": "is lower than"
    },
    {
      "source": "MIC90",
      "target": "Pseudomonas aeruginosa",
      "label": "is for"
    },
    {
      "source": "MIC90",
      "target": "cefoperazone",
      "label": "is lower than"
    },
    {
      "source": "MIC90",
      "target": "ceftazidime",
      "label": "is higher than"
    },
    {
      "source": "coagulase-negative staphylococci",
      "target": "beta-lactamase producers",
      "label": "are"
    },
    {
      "source": "coagulase-negative staphylococci",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "methoxyimino-aminothiazolyl cephalosporin",
      "target": "N-methyl-pyrrolidine moiety",
      "label": "has"
    },
    {
      "source": "broad-spectrum of activity",
      "target": "Gram-positive pathogens",
      "label": "includes"
    },
    {
      "source": "broad-spectrum of activity",
      "target": "Gram-negative pathogens",
      "label": "includes"
    },
    {
      "source": "Haemophilus influenzae",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "Gram-negative organisms",
      "target": "Cefepime",
      "label": "are susceptible to"
    },
    {
      "source": "meningitis",
      "target": "bacterial species",
      "label": "is induced by"
    },
    {
      "source": "meningitis",
      "target": "neonatal rats",
      "label": "occurs in"
    },
    {
      "source": "experimental infections",
      "target": "chronic staphylococcal osteomyelitis",
      "label": "include"
    },
    {
      "source": "experimental infections",
      "target": "meningitis",
      "label": "include"
    },
    {
      "source": "chronic staphylococcal osteomyelitis",
      "target": "rabbits",
      "label": "occurs in"
    },
    {
      "source": "Neiserria gonorrhoeae",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "strains of P. aeruginosa",
      "target": "Cefepime",
      "label": "are resistant to"
    },
    {
      "source": "strains of P. aeruginosa",
      "target": "ceftazidime",
      "label": "are resistant to"
    },
    {
      "source": "strains of P. aeruginosa",
      "target": "beta-lactamase",
      "label": "produce"
    },
    {
      "source": "PBP 3",
      "target": "Pseudomonas aeruginosa",
      "label": "is found in"
    },
    {
      "source": "Neiserria meningitidis",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "Streptococcus pyogenes",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "Streptococcus pneumoniae",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "Moraxella catarrhalis",
      "target": "Cefepime",
      "label": "is susceptible to"
    },
    {
      "source": "Degenerate oligonucleotides",
      "target": "conserved amino acids",
      "label": "correspond to"
    },
    {
      "source": "Degenerate oligonucleotides",
      "target": "primers",
      "label": "used as"
    },
    {
      "source": "conserved amino acids",
      "target": "transmembrane domains V",
      "label": "from"
    },
    {
      "source": "conserved amino acids",
      "target": "transmembrane domains VI",
      "label": "from"
    },
    {
      "source": "conserved amino acids",
      "target": "transmembrane domains III",
      "label": "from"
    },
    {
      "source": "unique sequence",
      "target": "rat hypothalamic cDNA",
      "label": "derived from"
    },
    {
      "source": "unique sequence",
      "target": "guanine nucleotide-binding protein (G-protein)-coupled receptor",
      "label": "represents"
    },
    {
      "source": "MR77",
      "target": "brain",
      "label": "expressed in"
    },
    {
      "source": "MR77",
      "target": "cortex",
      "label": "expressed in"
    },
    {
      "source": "MR77",
      "target": "5-HT receptor",
      "label": "represents"
    },
    {
      "source": "MR77",
      "target": "striatum",
      "label": "expressed in"
    },
    {
      "source": "MR77",
      "target": "intronless open reading frame",
      "label": "contains"
    },
    {
      "source": "MR77",
      "target": "hippocampus",
      "label": "expressed in"
    },
    {
      "source": "MR77",
      "target": "additional 5-HT1E-like receptor",
      "label": "represents"
    },
    {
      "source": "MR77",
      "target": "eukaryotic expression vector system",
      "label": "subcloned into"
    },
    {
      "source": "MR77",
      "target": "CosM6 cells",
      "label": "expressed in"
    },
    {
      "source": "full-length clone",
      "target": "MR77",
      "label": "is"
    },
    {
      "source": "transmembrane domains V",
      "target": "known receptors",
      "label": "part of"
    },
    {
      "source": "human homolog",
      "target": "encoded protein",
      "label": "has"
    },
    {
      "source": "encoded protein",
      "target": "amino acid identity",
      "label": "has"
    },
    {
      "source": "amino acid identity",
      "target": "rat 5-HT1B receptors",
      "label": "with"
    },
    {
      "source": "amino acid identity",
      "target": "rat 5-HT1A receptors",
      "label": "with"
    },
    {
      "source": "amino acid identity",
      "target": "human 5-HT1E receptors",
      "label": "with"
    },
    {
      "source": "amino acid identity",
      "target": "rat sequence",
      "label": "with"
    },
    {
      "source": "amino acid identity",
      "target": "rat 5-HT1D receptors",
      "label": "with"
    },
    {
      "source": "125I-labeled LSD binding",
      "target": "ergot alkaloids",
      "label": "antagonized by"
    },
    {
      "source": "ergot alkaloids",
      "target": "ergotamine",
      "label": "include"
    },
    {
      "source": "ergot alkaloids",
      "target": "methysergide",
      "label": "include"
    },
    {
      "source": "transmembrane domains III",
      "target": "known receptors",
      "label": "part of"
    },
    {
      "source": "known receptors",
      "target": "5-HT1C",
      "label": "include"
    },
    {
      "source": "known receptors",
      "target": "5-HT1A",
      "label": "include"
    },
    {
      "source": "known receptors",
      "target": "5-HT2",
      "label": "include"
    },
    {
      "source": "5-carboxyamidotryptamine",
      "target": "mixed 5-HT1A/1D agonist",
      "label": "is a"
    },
    {
      "source": "additional 5-HT1E-like receptor",
      "target": "pharmacological characterization",
      "label": "based on"
    },
    {
      "source": "expressed receptor",
      "target": "binding",
      "label": "exhibits"
    },
    {
      "source": "expressed receptor",
      "target": "125I-labeled d-lysergic acid diethylamide",
      "label": "exhibits"
    },
    {
      "source": "broken cell preparations",
      "target": "expressed receptor",
      "label": "used for studies on"
    },
    {
      "source": "sequences",
      "target": "amino acid identity",
      "label": "exhibit"
    },
    {
      "source": "sequences",
      "target": "conserved transmembrane domains",
      "label": "located within"
    },
    {
      "source": "rat genomic library",
      "target": "full-length clone",
      "label": "identified"
    },
    {
      "source": "methysergide",
      "target": "lowest active doses",
      "label": "has"
    },
    {
      "source": "methysergide",
      "target": "mixed 5-HT1/5-HT2 receptor antagonists",
      "label": "is_a"
    },
    {
      "source": "resulting product",
      "target": "rat genomic library",
      "label": "used to screen"
    },
    {
      "source": "Sequential polymerase chain reaction experiments",
      "target": "unique sequence",
      "label": "amplify"
    },
    {
      "source": "transmembrane domains VI",
      "target": "known receptors",
      "label": "part of"
    },
    {
      "source": "125I-labeled d-lysergic acid diethylamide",
      "target": "LSD",
      "label": "is also known as"
    },
    {
      "source": "intronless open reading frame",
      "target": "366-amino acid seven-transmembrane domain protein",
      "label": "encodes"
    },
    {
      "source": "fibrin(ogen)",
      "target": "( Glu1]Pg)",
      "label": "Upregulator"
    },
    {
      "source": "fibrin(ogen)",
      "target": "t-PA",
      "label": "Upregulator"
    },
    {
      "source": "fibrin(ogen)",
      "target": "human [Glu1]plasminogen",
      "label": "Upregulator"
    },
    {
      "source": "fibrin(ogen)",
      "target": "tissue plasminogen activator",
      "label": "Upregulator"
    },
    {
      "source": "Fibrinogen",
      "target": "two-chain rec-t-PA",
      "label": "Upregulator"
    },
    {
      "source": "Cl-(-)",
      "target": "[Glu1]Pg",
      "label": "Downregulator"
    },
    {
      "source": "Cl-(-)",
      "target": "two-chain rec-t-PA",
      "label": "Downregulator"
    },
    {
      "source": "Chloride",
      "target": "[Glu1]Pg",
      "label": "binds to"
    },
    {
      "source": "epsilon-aminocaproic acid",
      "target": "human [Glu1]plasminogen",
      "label": "Upregulator"
    },
    {
      "source": "epsilon-aminocaproic acid",
      "target": "tissue plasminogen activator",
      "label": "Upregulator"
    },
    {
      "source": "epsilon-aminocaproic acid",
      "target": "t-PA",
      "label": "Upregulator"
    },
    {
      "source": "epsilon-aminocaproic acid",
      "target": "( Glu1]Pg)",
      "label": "Upregulator"
    },
    {
      "source": "human tissue plasminogen activator",
      "target": "human [Glu1]plasminogen",
      "label": "Upregulator"
    },
    {
      "source": "amantadine induction of Fos",
      "target": "NMDA receptors",
      "label": "Regulator"
    },
    {
      "source": "amantadine induction of Fos",
      "target": "striatum",
      "label": "occurs_in"
    },
    {
      "source": "amantadine induction of Fos",
      "target": "rat striatum",
      "label": "occurs_in"
    },
    {
      "source": "amantadine induction of Fos",
      "target": "dopamine D1 receptors",
      "label": "Regulator"
    },
    {
      "source": "Amantadine",
      "target": "c-fos",
      "label": "Upregulator"
    },
    {
      "source": "Amantadine",
      "target": "Fos expression",
      "label": "Upregulator"
    },
    {
      "source": "Fos expression",
      "target": "ventral-medial part of the striatum",
      "label": "occurs_in"
    },
    {
      "source": "Fos expression",
      "target": "central part of the striatum",
      "label": "occurs_in"
    },
    {
      "source": "Fos expression",
      "target": "dorsal-medial part of the striatum",
      "label": "occurs_in"
    },
    {
      "source": "distribution pattern of Fos",
      "target": "dopaminomimetics",
      "label": "similar_to"
    },
    {
      "source": "distribution pattern of Fos",
      "target": "NMDA receptor antagonists",
      "label": "not_similar_to"
    },
    {
      "source": "distribution pattern of Fos",
      "target": "Amantadine",
      "label": "induced_by"
    },
    {
      "source": "distribution pattern of Fos",
      "target": "N-methyl-D-aspartate",
      "label": "not_similar_to"
    },
    {
      "source": "ventral-medial part of the striatum",
      "target": "striatum",
      "label": "part_of"
    },
    {
      "source": "1-aminoadamantane",
      "target": "Amantadine",
      "label": "is_a"
    },
    {
      "source": "1-aminoadamantane",
      "target": "Fos expression",
      "label": "Upregulator"
    },
    {
      "source": "dorsal-medial part of the striatum",
      "target": "striatum",
      "label": "part_of"
    },
    {
      "source": "central part of the striatum",
      "target": "striatum",
      "label": "part_of"
    },
    {
      "source": "ion channels",
      "target": "ions",
      "label": "carry"
    },
    {
      "source": "ion channels",
      "target": "channel open time",
      "label": "activity depends on"
    },
    {
      "source": "ions",
      "target": "fixed stoichiometry",
      "label": "cross with"
    },
    {
      "source": "ions",
      "target": "transmitter molecule",
      "label": "cotransport with"
    },
    {
      "source": "ions",
      "target": "membrane",
      "label": "cross"
    },
    {
      "source": "channel-like events",
      "target": "cocaine",
      "label": "blocked by"
    },
    {
      "source": "channel-like events",
      "target": "NE",
      "label": "stimulated by"
    },
    {
      "source": "channel-like events",
      "target": "antidepressant desipramine",
      "label": "blocked by"
    },
    {
      "source": "channel-like events",
      "target": "guanethidine",
      "label": "stimulated by"
    },
    {
      "source": "transmitter",
      "target": "net charge",
      "label": "sum to"
    },
    {
      "source": "fixed stoichiometry",
      "target": "norepinephrine",
      "label": "involves"
    },
    {
      "source": "fixed stoichiometry",
      "target": "Cl-",
      "label": "involves"
    },
    {
      "source": "fixed stoichiometry",
      "target": "NE",
      "label": "involves"
    },
    {
      "source": "fixed stoichiometry",
      "target": "Na+",
      "label": "involves"
    },
    {
      "source": "T-mode",
      "target": "substrates",
      "label": "gated by"
    },
    {
      "source": "T-mode",
      "target": "blockers",
      "label": "antagonized by"
    },
    {
      "source": "C-mode",
      "target": "substrates",
      "label": "gated by"
    },
    {
      "source": "C-mode",
      "target": "transmitter-induced current",
      "label": "carries"
    },
    {
      "source": "C-mode",
      "target": "low probability",
      "label": "occurs with"
    },
    {
      "source": "C-mode",
      "target": "blockers",
      "label": "antagonized by"
    },
    {
      "source": "Norepinephrine transporters",
      "target": "channel modes of conduction",
      "label": "have"
    },
    {
      "source": "channel modes of conduction",
      "target": "transporter regulation",
      "label": "has significance for"
    },
    {
      "source": "channel modes of conduction",
      "target": "fixed-stoichiometry transporter",
      "label": "exists in"
    },
    {
      "source": "channel modes of conduction",
      "target": "aqueous pore",
      "label": "suggests"
    },
    {
      "source": "guanethidine",
      "target": "hNET substrate",
      "label": "is a"
    },
    {
      "source": "reuptake",
      "target": "presynaptic terminals",
      "label": "occurs in"
    },
    {
      "source": "reuptake",
      "target": "transmitter",
      "label": "involves"
    },
    {
      "source": "coupled cotransport",
      "target": "fixed stoichiometry",
      "label": "characterized by"
    },
    {
      "source": "cotransported ions",
      "target": "net charge",
      "label": "sum to"
    },
    {
      "source": "aqueous pore",
      "target": "transporter protein",
      "label": "is through"
    },
    {
      "source": "aqueous pore",
      "target": "transport cycle",
      "label": "appears during"
    },
    {
      "source": "hNETs",
      "target": "T-mode",
      "label": "have"
    },
    {
      "source": "hNETs",
      "target": "C-mode",
      "label": "have"
    },
    {
      "source": "hNETs",
      "target": "functional modes of conduction",
      "label": "have"
    },
    {
      "source": "Neurotransmitter transporters",
      "target": "reuptake",
      "label": "achieve"
    },
    {
      "source": "Neurotransmitter transporters",
      "target": "ion gradients",
      "label": "couple to"
    },
    {
      "source": "C-mode opening",
      "target": "charges",
      "label": "transports"
    },
    {
      "source": "NE uptake data",
      "target": "functional modes of conduction",
      "label": "indicate"
    },
    {
      "source": "functional modes of conduction",
      "target": "classical transporter mode (T-mode)",
      "label": "includes"
    },
    {
      "source": "functional modes of conduction",
      "target": "novel channel mode (C-mode)",
      "label": "includes"
    },
    {
      "source": "Voltage-clamp data",
      "target": "functional modes of conduction",
      "label": "indicate"
    },
    {
      "source": "gamma-aminobutyric acid transporter gene family",
      "target": "fixed stoichiometry",
      "label": "function with"
    },
    {
      "source": "topoisomerase II inhibitor",
      "target": "topoisomerase II inhibitors",
      "label": "is a type of"
    },
    {
      "source": "topoisomerase II inhibitor",
      "target": "topoisomerase II",
      "label": "inhibits"
    },
    {
      "source": "secondary leukemia",
      "target": "myelodysplasia",
      "label": "is a type of"
    },
    {
      "source": "secondary leukemia",
      "target": "acute myeloid leukemia (AML)",
      "label": "is a type of"
    },
    {
      "source": "secondary leukemia",
      "target": "therapy",
      "label": "associated with"
    },
    {
      "source": "secondary leukemia",
      "target": "acute lymphoblastic leukemia (ALL)",
      "label": "is a type of"
    },
    {
      "source": "secondary leukemia",
      "target": "primary cancers",
      "label": "resulted from"
    },
    {
      "source": "secondary leukemia",
      "target": "mixed lineage",
      "label": "is a type of"
    },
    {
      "source": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements",
      "target": "ALL-1 gene",
      "label": "is a rearrangement of"
    },
    {
      "source": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements",
      "target": "sporadic cases",
      "label": "similar to"
    },
    {
      "source": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements",
      "target": "secondary leukemia",
      "label": "found in"
    },
    {
      "source": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements",
      "target": "leukemia",
      "label": "associated with"
    },
    {
      "source": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements",
      "target": "DNA topoisomerase II inhibitor",
      "label": "associated with"
    },
    {
      "source": "ALL-1 gene",
      "target": "chromosomal band 11q23",
      "label": "located at"
    },
    {
      "source": "Htrxl",
      "target": "ALL-1 gene",
      "label": "is part of"
    },
    {
      "source": "HRX",
      "target": "ALL-1 gene",
      "label": "is part of"
    },
    {
      "source": "morphologic features",
      "target": "secondary leukemia",
      "label": "are features of"
    },
    {
      "source": "primary cancers",
      "target": "leukemia",
      "label": "included"
    },
    {
      "source": "primary cancers",
      "target": "solid tumors",
      "label": "included"
    },
    {
      "source": "clinical features",
      "target": "secondary leukemia",
      "label": "are features of"
    },
    {
      "source": "breakpoint cluster region",
      "target": "ALL-1 gene",
      "label": "part of"
    },
    {
      "source": "breakpoint cluster region",
      "target": "t(8;21)",
      "label": "for"
    },
    {
      "source": "DNA topoisomerase II inhibitor",
      "target": "leukemia",
      "label": "causes"
    },
    {
      "source": "DNA topoisomerase II inhibitor",
      "target": "topoisomerase II inhibitors",
      "label": "is a type of"
    },
    {
      "source": "DNA topoisomerase II inhibitor",
      "target": "DNA topoisomerase II",
      "label": "inhibits"
    },
    {
      "source": "topoisomerase II inhibitor-associated leukemia",
      "target": "breakpoint cluster region",
      "label": "involves"
    },
    {
      "source": "topoisomerase II inhibitor-associated leukemia",
      "target": "topoisomerase II inhibitor",
      "label": "is associated with"
    },
    {
      "source": "MLL",
      "target": "ALL-1 gene",
      "label": "is part of"
    },
    {
      "source": "molecular rearrangement",
      "target": "11q23 involvement",
      "label": "is a type of"
    },
    {
      "source": "11q23 involvement",
      "target": "cytogenetic features",
      "label": "is a"
    },
    {
      "source": "Exposure histories",
      "target": "secondary 11q23 leukemia",
      "label": "vary in"
    },
    {
      "source": "Southern blot",
      "target": "ALL-1 (MLL, Htrxl, HRX) gene rearrangements",
      "label": "used for detecting"
    },
    {
      "source": "pediatric cases",
      "target": "topoisomerase II inhibitor-associated leukemia",
      "label": "are cases of"
    },
    {
      "source": "dactinomycin",
      "target": "topoisomerase II inhibitor",
      "label": "is a type of"
    },
    {
      "source": "cytogenetic features",
      "target": "secondary leukemia",
      "label": "are features of"
    },
    {
      "source": "collagen formation",
      "target": "cardiac fibroblasts",
      "label": "by"
    },
    {
      "source": "cardiac fibrosis",
      "target": "non-epithelial MR",
      "label": "is via"
    },
    {
      "source": "cardiac fibrosis",
      "target": "normotensive animals",
      "label": "found in"
    },
    {
      "source": "cardiac fibrosis",
      "target": "tissue renin-angiotensin systems",
      "label": "does not involve"
    },
    {
      "source": "cardiac fibrosis",
      "target": "left ventricles",
      "label": "observed in"
    },
    {
      "source": "cardiac fibrosis",
      "target": "mineralocorticoid-induced hypokalemia",
      "label": "not reversed by"
    },
    {
      "source": "cardiac fibrosis",
      "target": "cardiac hypertrophy",
      "label": "independent of"
    },
    {
      "source": "cardiac fibrosis",
      "target": "potassium canrenoate",
      "label": "blocked by"
    },
    {
      "source": "cardiac fibrosis",
      "target": "plasma renin-angiotensin systems",
      "label": "does not involve"
    },
    {
      "source": "cardiac fibrosis",
      "target": "cardiac effect",
      "label": "may be"
    },
    {
      "source": "cardiac fibrosis",
      "target": "elevated blood pressure",
      "label": "independent of"
    },
    {
      "source": "cardiac fibrosis",
      "target": "classical MR",
      "label": "is via"
    },
    {
      "source": "cardiac fibrosis",
      "target": "right ventricles",
      "label": "observed in"
    },
    {
      "source": "normotensive animals",
      "target": "aldosterone",
      "label": "infused with"
    },
    {
      "source": "normotensive animals",
      "target": "RU28318",
      "label": "infused with"
    },
    {
      "source": "salt",
      "target": "heart",
      "label": "affects"
    },
    {
      "source": "MR occupancy",
      "target": "aldosterone",
      "label": "by"
    },
    {
      "source": "MR occupancy",
      "target": "collagen deposition",
      "label": "links to"
    },
    {
      "source": "high salt intake",
      "target": "model of mineralocorticoid excess",
      "label": "contributes to"
    },
    {
      "source": "uninephrectomized rats",
      "target": "1% NaCl solution",
      "label": "on"
    },
    {
      "source": "perivascular cardiac fibrosis",
      "target": "animals",
      "label": "not observed in"
    },
    {
      "source": "interstitial cardiac fibrosis",
      "target": "animals",
      "label": "not observed in"
    },
    {
      "source": "Perindopril",
      "target": "cardiac fibrosis",
      "label": "does not affect"
    },
    {
      "source": "Mineralocorticoids",
      "target": "heart",
      "label": "affects"
    },
    {
      "source": "testolactone",
      "target": "aromatase inhibitor",
      "label": "is a type of"
    },
    {
      "source": "testolactone",
      "target": "seizure frequency",
      "label": "improves"
    },
    {
      "source": "testolactone",
      "target": "aromatase",
      "label": "inhibits"
    },
    {
      "source": "testolactone",
      "target": "reproductive and sexual dysfunction",
      "label": "treats"
    },
    {
      "source": "testolactone",
      "target": "hypogonadism",
      "label": "treats"
    },
    {
      "source": "testolactone",
      "target": "epilepsy",
      "label": "treats"
    },
    {
      "source": "testolactone",
      "target": "sexual function",
      "label": "improves"
    },
    {
      "source": "testolactone",
      "target": "men",
      "label": "treats"
    },
    {
      "source": "Antiepileptic drug",
      "target": "serum estradiol",
      "label": "causes elevation in"
    },
    {
      "source": "Antiepileptic drug",
      "target": "serum levels",
      "label": "causes reduction in"
    },
    {
      "source": "Antiepileptic drug",
      "target": "E2",
      "label": "causes elevation in"
    },
    {
      "source": "Antiepileptic drug",
      "target": "biologically active testosterone",
      "label": "causes reduction in"
    },
    {
      "source": "serum estradiol",
      "target": "sexual dysfunction",
      "label": "elevation contributes to"
    },
    {
      "source": "sexual dysfunction",
      "target": "epilepsy",
      "label": "associated with"
    },
    {
      "source": "sexual dysfunction",
      "target": "men",
      "label": "affects"
    },
    {
      "source": "biologically active testosterone",
      "target": "sexual dysfunction",
      "label": "reduction contributes to"
    },
    {
      "source": "thioridazine",
      "target": "calmodulin antagonists",
      "label": "is a type of"
    },
    {
      "source": "thioridazine",
      "target": "MCF-7 cells",
      "label": "blocked"
    },
    {
      "source": "thioridazine",
      "target": "neuroleptic agents",
      "label": "is a type of"
    },
    {
      "source": "thioridazine",
      "target": "ER-negative human breast tumors",
      "label": "controls growth of"
    },
    {
      "source": "thioridazine",
      "target": "polypeptide hormones",
      "label": "controls growth induced by"
    },
    {
      "source": "thioridazine",
      "target": "estradiol binding properties",
      "label": "has no effect on"
    },
    {
      "source": "thioridazine",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "thioridazine",
      "target": "MCF-7 ER",
      "label": "has no effect on"
    },
    {
      "source": "thioridazine",
      "target": "growth inhibition",
      "label": "causes"
    },
    {
      "source": "thioridazine",
      "target": "mechanisms of action",
      "label": "has"
    },
    {
      "source": "thioridazine",
      "target": "drugs",
      "label": "is a type of"
    },
    {
      "source": "thioridazine",
      "target": "estradiol",
      "label": "controls growth induced by"
    },
    {
      "source": "thioridazine",
      "target": "ER-positive human breast tumors",
      "label": "controls growth of"
    },
    {
      "source": "thioridazine",
      "target": "human breast cancer cell proliferation",
      "label": "inhibits"
    },
    {
      "source": "thioridazine",
      "target": "MCF-7 human breast cancer cell growth",
      "label": "inhibits"
    },
    {
      "source": "W-13",
      "target": "MCF-7 human breast cancer cell growth",
      "label": "inhibits"
    },
    {
      "source": "W-13",
      "target": "calmodulin antagonists",
      "label": "is a type of"
    },
    {
      "source": "W-13",
      "target": "MCF-7 cells",
      "label": "blocked"
    },
    {
      "source": "W-13",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "W-13",
      "target": "growth inhibition",
      "label": "causes"
    },
    {
      "source": "W-13",
      "target": "estradiol",
      "label": "blocked growth induced by"
    },
    {
      "source": "W-12",
      "target": "MCF-7 cells",
      "label": "blocked"
    },
    {
      "source": "W-12",
      "target": "MCF-7 human breast cancer cell growth",
      "label": "inhibits"
    },
    {
      "source": "W-12",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "W-12",
      "target": "calmodulin antagonists",
      "label": "is a type of"
    },
    {
      "source": "W-12",
      "target": "growth inhibition",
      "label": "causes"
    },
    {
      "source": "W-12",
      "target": "estradiol",
      "label": "blocked growth induced by"
    },
    {
      "source": "calmodulin antagonism",
      "target": "growth-inhibitory properties",
      "label": "contributes to"
    },
    {
      "source": "human breast cancer cell proliferation",
      "target": "tissue culture",
      "label": "occurs in"
    },
    {
      "source": "[3H]thymidine incorporation",
      "target": "serum-free medium",
      "label": "occurs in"
    },
    {
      "source": "[3H]thymidine incorporation",
      "target": "MCF-7 cells",
      "label": "occurs in"
    },
    {
      "source": "[3H]thymidine incorporation",
      "target": "proliferation assays",
      "label": "is a type of"
    },
    {
      "source": "Permanent cell culture lines",
      "target": "experimental models",
      "label": "are"
    },
    {
      "source": "Permanent cell culture lines",
      "target": "human breast cancer tissue",
      "label": "derived from"
    },
    {
      "source": "50% inhibition concentration values",
      "target": "[3H]thymidine incorporation",
      "label": "determined by"
    },
    {
      "source": "50% inhibition concentration values",
      "target": "cell number",
      "label": "determined by"
    },
    {
      "source": "administration of ketotifen",
      "target": "airway response",
      "label": "did not abolish"
    },
    {
      "source": "administration of HOE 140",
      "target": "airway response",
      "label": "did not abolish"
    },
    {
      "source": "gaseous formaldehyde",
      "target": "airway microvascular leakage",
      "label": "induces"
    },
    {
      "source": "gaseous formaldehyde",
      "target": "microvascular leakage",
      "label": "induces"
    },
    {
      "source": "airway microvascular leakage",
      "target": "rats",
      "label": "occurs in"
    },
    {
      "source": "Leakage of dye",
      "target": "trachea",
      "label": "occurs in"
    },
    {
      "source": "Leakage of dye",
      "target": "main bronchi",
      "label": "occurs in"
    },
    {
      "source": "Activation of bradykinin receptors",
      "target": "airway response",
      "label": "did not play role in"
    },
    {
      "source": "tachykinin and bradykinin receptors",
      "target": "airway microvascular leakage",
      "label": "has role in"
    },
    {
      "source": "Extravasation of Evans blue dye",
      "target": "airway microvascular leakage",
      "label": "is index of"
    },
    {
      "source": "Extravasation of Evans blue dye",
      "target": "airway tissues",
      "label": "occurs in"
    },
    {
      "source": "15 ppm formaldehyde",
      "target": "airway response",
      "label": "induces"
    },
    {
      "source": "mast cells",
      "target": "airway microvascular leakage",
      "label": "has role in"
    },
    {
      "source": "mast cells",
      "target": "airway response",
      "label": "did not play role in"
    },
    {
      "source": "administration of CP-99,994",
      "target": "airway response",
      "label": "abolished"
    },
    {
      "source": "(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)",
      "target": "mast cell-stabilizing properties",
      "label": "has"
    },
    {
      "source": "(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)",
      "target": "histamine H1 receptor",
      "label": "is antagonist of"
    },
    {
      "source": "increase in vascular permeability",
      "target": "rat airway",
      "label": "occurs in"
    },
    {
      "source": "CP-99,994",
      "target": "tachykinin NK1 receptor",
      "label": "is antagonist of"
    },
    {
      "source": "NK1 receptor stimulation",
      "target": "increase in vascular permeability",
      "label": "mediates"
    },
    {
      "source": "formaldehyde",
      "target": "Leakage of dye",
      "label": "causes"
    },
    {
      "source": "formaldehyde",
      "target": "increase in vascular permeability",
      "label": "induces"
    },
    {
      "source": "10 min inhalation",
      "target": "Leakage of dye",
      "label": "causes"
    },
    {
      "source": "HOE 140",
      "target": "bradykinin B2 receptor",
      "label": "is antagonist of"
    },
    {
      "source": "[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]",
      "target": "tachykinin NK1 receptor",
      "label": "is antagonist of"
    },
    {
      "source": "(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)",
      "target": "bradykinin B2 receptor",
      "label": "is antagonist of"
    },
    {
      "source": "dose-dependent reduction",
      "target": "urinary excretion",
      "label": "affects"
    },
    {
      "source": "dose-dependent reduction",
      "target": "serum TXB2 levels",
      "label": "affects"
    },
    {
      "source": "11-dehydro-thromboxane B2",
      "target": "TXB2",
      "label": "is also known as"
    },
    {
      "source": "11-dehydro-thromboxane B2",
      "target": "platelet",
      "label": "is a product of"
    },
    {
      "source": "11-dehydro-thromboxane B2",
      "target": "arachidonate metabolism",
      "label": "is a product of"
    },
    {
      "source": "cyclooxygenase activity",
      "target": "PGHS-1",
      "label": "is activity of"
    },
    {
      "source": "cyclooxygenase activity",
      "target": "platelet",
      "label": "is activity of"
    },
    {
      "source": "PGHS-1",
      "target": "NSAIDs",
      "label": "is_site_of_action_for"
    },
    {
      "source": "prostaglandin IF2 alpha",
      "target": "renal",
      "label": "is a product of"
    },
    {
      "source": "prostaglandin IF2 alpha",
      "target": "arachidonate metabolism",
      "label": "is a product of"
    },
    {
      "source": "prostaglandin IF2 alpha",
      "target": "PGF2 alpha",
      "label": "is also known as"
    },
    {
      "source": "inducible prostaglandin H synthase",
      "target": "PGHS",
      "label": "is also known as"
    },
    {
      "source": "eicosanoid biosynthesis",
      "target": "healthy subjects",
      "label": "occurs in"
    },
    {
      "source": "eicosanoid biosynthesis",
      "target": "oral dosing",
      "label": "occurs after"
    },
    {
      "source": "production of TXB2",
      "target": "whole blood clotting",
      "label": "occurs during"
    },
    {
      "source": "production of TXB2",
      "target": "ex vivo",
      "label": "assessed"
    },
    {
      "source": "production of TXB2",
      "target": "cyclooxygenase activity",
      "label": "is an index of"
    },
    {
      "source": "production of TXB2",
      "target": "PGHS-1",
      "label": "is an index of"
    },
    {
      "source": "timecourse",
      "target": "elimination half-life",
      "label": "is consistent with"
    },
    {
      "source": "timecourse",
      "target": "platelet turnover",
      "label": "is consistent with"
    },
    {
      "source": "prostanoid biosynthesis",
      "target": "humans",
      "label": "occurs in"
    },
    {
      "source": "discontinuation of nabumetone",
      "target": "predrug levels",
      "label": "causes return to"
    },
    {
      "source": "urinary 11-dehydro-TXB2 excretion",
      "target": "predrug levels",
      "label": "returns to"
    },
    {
      "source": "selective inhibitor",
      "target": "antiinflammatory agent",
      "label": "is_a"
    },
    {
      "source": "low-dose aspirin",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "low-dose aspirin",
      "target": "platelet",
      "label": "inhibits"
    },
    {
      "source": "low-dose aspirin",
      "target": "selective inhibitor",
      "label": "is a"
    },
    {
      "source": "low-dose aspirin",
      "target": "cumulative inhibition",
      "label": "causes"
    },
    {
      "source": "cumulative inhibition",
      "target": "whole blood TXB2 production",
      "label": "affects"
    },
    {
      "source": "cumulative inhibition",
      "target": "urinary 11-dehydro-TXB2 excretion",
      "label": "affects"
    },
    {
      "source": "whole blood TXB2 production",
      "target": "predrug levels",
      "label": "returns to"
    },
    {
      "source": "PGF2 alpha",
      "target": "renal",
      "label": "is a product of"
    },
    {
      "source": "PGF2 alpha",
      "target": "arachidonate metabolism",
      "label": "is a product of"
    },
    {
      "source": "daily administration",
      "target": "low-dose aspirin",
      "label": "involves"
    },
    {
      "source": "fluorescence in situ hybridization (FISH) analysis",
      "target": "bone marrow cells",
      "label": "of"
    },
    {
      "source": "fluorescence in situ hybridization (FISH) analysis",
      "target": "translocational splitting",
      "label": "revealed"
    },
    {
      "source": "fluorescence in situ hybridization (FISH) analysis",
      "target": "interphase",
      "label": "at"
    },
    {
      "source": "fluorescence in situ hybridization (FISH) analysis",
      "target": "metaphase",
      "label": "at"
    },
    {
      "source": "Southern blot analysis",
      "target": "rearrangement",
      "label": "did not detect"
    },
    {
      "source": "Southern blot analysis",
      "target": "bone marrow cells",
      "label": "of"
    },
    {
      "source": "rearrangement",
      "target": "AML1 gene",
      "label": "of"
    },
    {
      "source": "translocational splitting",
      "target": "chromosome 21",
      "label": "between"
    },
    {
      "source": "translocational splitting",
      "target": "chromosome 16",
      "label": "between"
    },
    {
      "source": "DNA-topoisomerase II inhibitors",
      "target": "etoposide",
      "label": "include"
    },
    {
      "source": "DNA-topoisomerase II inhibitors",
      "target": "mitoxantrone",
      "label": "include"
    },
    {
      "source": "1500 mg",
      "target": "intravenously",
      "label": "given"
    },
    {
      "source": "chromosome 21",
      "target": "AML1 gene",
      "label": "involving"
    },
    {
      "source": "breakpoint",
      "target": "breakpoint cluster region",
      "label": "is not located in"
    },
    {
      "source": "alkylating agent",
      "target": "cyclophosphamide",
      "label": "is"
    },
    {
      "source": "therapy-related acute myeloblastic leukemia",
      "target": "chemotherapy",
      "label": "developed after"
    },
    {
      "source": "therapy-related acute myeloblastic leukemia",
      "target": "t(16;21)(q24;q22)",
      "label": "has"
    },
    {
      "source": "therapy-related acute myeloblastic leukemia",
      "target": "t-AML",
      "label": "also known as"
    },
    {
      "source": "4000 mg",
      "target": "orally",
      "label": "given"
    },
    {
      "source": "Cytogenetic analysis",
      "target": "bone marrow cells",
      "label": "of"
    },
    {
      "source": "Cytogenetic analysis",
      "target": "deletion of 7q",
      "label": "revealed"
    },
    {
      "source": "Cytogenetic analysis",
      "target": "rare translocation",
      "label": "revealed"
    },
    {
      "source": "cumulative dose",
      "target": "etoposide administration",
      "label": "of"
    },
    {
      "source": "cumulative dose",
      "target": "5500 mg",
      "label": "was"
    },
    {
      "source": "59-year-old female",
      "target": "therapy-related acute myeloblastic leukemia",
      "label": "developed"
    },
    {
      "source": "59-year-old female",
      "target": "malignant lymphoma",
      "label": "suffered from"
    },
    {
      "source": "rare translocation",
      "target": "t(16;21)(q24;q22)",
      "label": "is"
    },
    {
      "source": "Cyclic flow variations",
      "target": "recurrent thrombus formation",
      "label": "caused by"
    },
    {
      "source": "Cyclic flow variations",
      "target": "external constrictor",
      "label": "initiated by"
    },
    {
      "source": "Infusion of FVIIa",
      "target": "CFVs",
      "label": "failed to restore"
    },
    {
      "source": "Infusion of FVIIa",
      "target": "AP-1 treated animals",
      "label": "restored CFVs in"
    },
    {
      "source": "Infusion of FVIIa",
      "target": "ridogrel e ATA treated rabbits",
      "label": "failed to restore CFVs in"
    },
    {
      "source": "Infusion of FVIIa",
      "target": "FVIIai treated animals",
      "label": "restored CFVs in"
    },
    {
      "source": "CFVs",
      "target": "external constrictor",
      "label": "initiated by"
    },
    {
      "source": "CFVs",
      "target": "New Zealand White rabbits",
      "label": "induced in"
    },
    {
      "source": "CFVs",
      "target": "recurrent thrombus formation",
      "label": "caused by"
    },
    {
      "source": "TF",
      "target": "factor VII",
      "label": "binds to"
    },
    {
      "source": "TF",
      "target": "FVIIa",
      "label": "binds to"
    },
    {
      "source": "TF",
      "target": "activated FVII",
      "label": "binds to"
    },
    {
      "source": "TF",
      "target": "FVII",
      "label": "binds to"
    },
    {
      "source": "TF",
      "target": "arterial damage",
      "label": "exposed due to"
    },
    {
      "source": "AP-1 and FVIIai bindings to TF",
      "target": "FVIIa",
      "label": "replaced by"
    },
    {
      "source": "FVIIa",
      "target": "dose",
      "label": "infused at"
    },
    {
      "source": "aurintrycarboxilic acid",
      "target": "von Willebrand factor",
      "label": "inhibits"
    },
    {
      "source": "aurintrycarboxilic acid",
      "target": "inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction",
      "label": "is an"
    },
    {
      "source": "aurintrycarboxilic acid",
      "target": "platelet glycoprotein Ib",
      "label": "inhibits"
    },
    {
      "source": "interaction between extrinsic coagulation pathway activation and platelet aggregation",
      "target": "intravascular thrombus formation",
      "label": "studied in"
    },
    {
      "source": "ATA",
      "target": "platelet glycoprotein Ib",
      "label": "inhibits"
    },
    {
      "source": "ATA",
      "target": "CFVs",
      "label": "abolished"
    },
    {
      "source": "ATA",
      "target": "von Willebrand factor",
      "label": "inhibits"
    },
    {
      "source": "ATA",
      "target": "inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction",
      "label": "is an"
    },
    {
      "source": "extrinsic coagulation pathway",
      "target": "tissue factor",
      "label": "activated by"
    },
    {
      "source": "extrinsic coagulation pathway",
      "target": "TF",
      "label": "activated by"
    },
    {
      "source": "tissue factor",
      "target": "arterial damage",
      "label": "exposed due to"
    },
    {
      "source": "activation of extrinsic coagulation by FVIIa",
      "target": "inhibition of platelet function",
      "label": "overcome by"
    },
    {
      "source": "ex vivo platelet aggregation",
      "target": "ADP",
      "label": "responds to"
    },
    {
      "source": "ex vivo platelet aggregation",
      "target": "FVIIai infusion",
      "label": "unaffected by"
    },
    {
      "source": "ex vivo platelet aggregation",
      "target": "thrombin",
      "label": "responds to"
    },
    {
      "source": "antithrombotic activity",
      "target": "experimental model",
      "label": "observed in"
    },
    {
      "source": "experimental model",
      "target": "recurrent arterial thrombosis",
      "label": "is of"
    },
    {
      "source": "external constrictor",
      "target": "endothelially-injured rabbit carotid arteries",
      "label": "placed around"
    },
    {
      "source": "endothelially-injured rabbit carotid arteries",
      "target": "Folt's model",
      "label": "part of"
    },
    {
      "source": "human recombinant FVIIa",
      "target": "dose",
      "label": "infused at"
    },
    {
      "source": "human recombinant FVIIa",
      "target": "FVIIai treated rabbits",
      "label": "infused in"
    },
    {
      "source": "Activated partial thromboplastin time",
      "target": "FVIIai infusion",
      "label": "unaffected by"
    },
    {
      "source": "dual thromboxane A2 synthetase inhibitor",
      "target": "thromboxane A2 synthetase",
      "label": "inhibits"
    },
    {
      "source": "inhibition of FVII binding to TF",
      "target": "antithrombotic effects",
      "label": "results in"
    },
    {
      "source": "activation of the extrinsic coagulation pathway",
      "target": "thrombus formation",
      "label": "failed to restore"
    },
    {
      "source": "ridogrel",
      "target": "dual thromboxane A2 synthetase inhibitor",
      "label": "is a"
    },
    {
      "source": "ridogrel",
      "target": "thromboxane A2 receptor antagonist",
      "label": "is a"
    },
    {
      "source": "ridogrel",
      "target": "CFVs",
      "label": "abolished"
    },
    {
      "source": "inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction",
      "target": "platelet glycoprotein Ib",
      "label": "inhibits"
    },
    {
      "source": "inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction",
      "target": "von Willebrand factor",
      "label": "inhibits"
    },
    {
      "source": "recombinant human FVIIa",
      "target": "antiplatelet-treated rabbits",
      "label": "administered in"
    },
    {
      "source": "intra-arterial infusion",
      "target": "human recombinant FVIIai",
      "label": "contains"
    },
    {
      "source": "thromboxane A2 receptor antagonist",
      "target": "thromboxane A2 receptor",
      "label": "antagonizes"
    },
    {
      "source": "Carotid blood flow",
      "target": "Doppler flow probe",
      "label": "measured by"
    },
    {
      "source": "Doppler flow probe",
      "target": "constrictor",
      "label": "placed proximally to"
    },
    {
      "source": "Inactivated factor VII",
      "target": "antithrombotic activity",
      "label": "exercises"
    },
    {
      "source": "FVIIai",
      "target": "CFVs",
      "label": "abolished"
    },
    {
      "source": "FVIIai",
      "target": "rabbit model of intravascular thrombus formation",
      "label": "used in"
    },
    {
      "source": "active site-blocked FVIIa",
      "target": "rabbit model of intravascular thrombus formation",
      "label": "used in"
    },
    {
      "source": "small catheter (26G)",
      "target": "stenosis",
      "label": "placed proximally to"
    },
    {
      "source": "Administration of FVIIai",
      "target": "antithrombotic effects",
      "label": "exerts"
    },
    {
      "source": "Administration of FVIIai",
      "target": "systemic coagulation",
      "label": "does not affect"
    },
    {
      "source": "FVII-VIIa",
      "target": "thrombus formation",
      "label": "initiates"
    },
    {
      "source": "chlorothiazide-inhibitable 22Na uptake",
      "target": "Peripheral blood mononuclear cells (PBMC)",
      "label": "measured in"
    },
    {
      "source": "chlorothiazide-inhibitable 22Na uptake",
      "target": "bumetanide",
      "label": "measured in presence of"
    },
    {
      "source": "chlorothiazide-inhibitable 22Na uptake",
      "target": "22Na",
      "label": "involves"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "chlorothiazide",
      "label": "failed to respond to"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "control subjects",
      "label": "from"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "patients",
      "label": "from"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "mutational analysis",
      "label": "can be used for"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "brothers",
      "label": "isolated from"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "healthy control subjects",
      "label": "isolated from"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "NCCT mRNA",
      "label": "express"
    },
    {
      "source": "Peripheral blood mononuclear cells (PBMC)",
      "target": "parents",
      "label": "isolated from"
    },
    {
      "source": "Gitelman's syndrome (GS)",
      "target": "thiazide-sensitive NaCl cotransport",
      "label": "is associated with abnormal"
    },
    {
      "source": "thiazide-sensitive NaCl cotransport",
      "target": "NaCl",
      "label": "transports"
    },
    {
      "source": "thiazide-sensitive NaCl cotransport",
      "target": "thiazide",
      "label": "is sensitive to"
    },
    {
      "source": "PBMC NaCl cotransport",
      "target": "Gitelman's syndrome (GS)",
      "label": "is defective in"
    },
    {
      "source": "underlying cause",
      "target": "defective NCCT NaCl cotransport",
      "label": "is"
    },
    {
      "source": "underlying cause",
      "target": "Gitelman's syndrome (GS)",
      "label": "of"
    },
    {
      "source": "defective NCCT NaCl cotransport",
      "target": "NaCl",
      "label": "transports"
    },
    {
      "source": "chlorothiazide",
      "target": "22Na uptake",
      "label": "inhibited"
    },
    {
      "source": "NCCT mRNA",
      "target": "Peripheral blood mononuclear cells (PBMC)",
      "label": "is expressed in"
    },
    {
      "source": "NCCT mRNA",
      "target": "Gitelman's syndrome (GS)",
      "label": "is found mutated in"
    },
    {
      "source": "GGT --> GTT",
      "target": "maternal allele",
      "label": "is on"
    },
    {
      "source": "patient's genomic DNA",
      "target": "3' splice site mutation",
      "label": "had"
    },
    {
      "source": "patient's genomic DNA",
      "target": "5' splice site mutation",
      "label": "had"
    },
    {
      "source": "3' splice site mutation",
      "target": "intron 3",
      "label": "is in"
    },
    {
      "source": "3' splice site mutation",
      "target": "CAG --> CAA",
      "label": "is"
    },
    {
      "source": "3' splice site mutation",
      "target": "cryptic splice site",
      "label": "resulted in activation of"
    },
    {
      "source": "22Na uptake",
      "target": "control PBMC",
      "label": "occurred in"
    },
    {
      "source": "22Na uptake",
      "target": "22Na",
      "label": "involves"
    },
    {
      "source": "patients' NCCT cDNA",
      "target": "compound heterozygote",
      "label": "is a"
    },
    {
      "source": "119-bp insertion",
      "target": "exons 3",
      "label": "is between"
    },
    {
      "source": "119-bp insertion",
      "target": "exons 4",
      "label": "is between"
    },
    {
      "source": "119-bp insertion",
      "target": "premature stop codon",
      "label": "generated"
    },
    {
      "source": "5' splice site mutation",
      "target": "intron 24",
      "label": "is in"
    },
    {
      "source": "5' splice site mutation",
      "target": "GGT --> GTT",
      "label": "is"
    },
    {
      "source": "full-length NCCT cDNA",
      "target": "normal PBMC",
      "label": "amplified from"
    },
    {
      "source": "functional significance",
      "target": "findings",
      "label": "of"
    },
    {
      "source": "Northern analysis",
      "target": "NCCT mRNA",
      "label": "revealed expression of"
    },
    {
      "source": "brothers",
      "target": "Gitelman's syndrome (GS)",
      "label": "have"
    },
    {
      "source": "human thiazide-sensitive sodium chloride cotransporter gene",
      "target": "Gitelman's syndrome (GS)",
      "label": "has linkage with"
    },
    {
      "source": "human thiazide-sensitive sodium chloride cotransporter gene",
      "target": "sodium chloride",
      "label": "transports"
    },
    {
      "source": "human thiazide-sensitive sodium chloride cotransporter gene",
      "target": "NCCT",
      "label": "is also known as"
    },
    {
      "source": "human thiazide-sensitive sodium chloride cotransporter gene",
      "target": "thiazide",
      "label": "is sensitive to"
    },
    {
      "source": "human thiazide-sensitive sodium chloride cotransporter gene",
      "target": "TSC",
      "label": "is also known as"
    },
    {
      "source": "premature stop codon",
      "target": "amino acid 187",
      "label": "is after"
    },
    {
      "source": "premature stop codon",
      "target": "amino acid 920",
      "label": "is after"
    },
    {
      "source": "amino acid 187",
      "target": "amino acid",
      "label": "is a type of"
    },
    {
      "source": "CAG --> CAA",
      "target": "paternal allele",
      "label": "is on"
    },
    {
      "source": "CAG --> CAA",
      "target": "normal chromosomes",
      "label": "not present in"
    },
    {
      "source": "NCCT",
      "target": "genomic NCCT mutations",
      "label": "has"
    },
    {
      "source": "amino acid 920",
      "target": "amino acid",
      "label": "is a type of"
    },
    {
      "source": "mutational analysis",
      "target": "patients",
      "label": "in"
    },
    {
      "source": "mutational analysis",
      "target": "NCCT mRNA",
      "label": "of"
    },
    {
      "source": "exon 24",
      "target": "cDNA",
      "label": "was deleted in"
    },
    {
      "source": "exon 24",
      "target": "premature stop codon",
      "label": "deletion resulted in"
    },
    {
      "source": "functional evidence",
      "target": "underlying cause",
      "label": "provided that"
    },
    {
      "source": "sequence",
      "target": "full-length NCCT cDNA",
      "label": "of"
    },
    {
      "source": "sequence",
      "target": "human renal NCCT cDNA",
      "label": "was identical to"
    },
    {
      "source": "Genetic analysis",
      "target": "human thiazide-sensitive sodium chloride cotransporter gene",
      "label": "demonstrated linkage between"
    },
    {
      "source": "cryptic splice site",
      "target": "intron 3",
      "label": "is in"
    },
    {
      "source": "nonreentrant catecholamine-mediated ventricular tachycardia",
      "target": "endogenous adenosine",
      "label": "responds to"
    },
    {
      "source": "nonreentrant catecholamine-mediated ventricular tachycardia",
      "target": "myocardial receptor-mediated effects",
      "label": "has evidence for"
    },
    {
      "source": "nonreentrant catecholamine-mediated ventricular tachycardia",
      "target": "acetylcholine",
      "label": "responds to"
    },
    {
      "source": "antiarrhythmic effects",
      "target": "noncardiac receptor-mediated effects",
      "label": "are due to"
    },
    {
      "source": "antiarrhythmic effects",
      "target": "receptor-mediated inhibition",
      "label": "are due to"
    },
    {
      "source": "muscarinic cholinergic receptor",
      "target": "inhibition",
      "label": "activation results in"
    },
    {
      "source": "Dipyridamole",
      "target": "sustained nonreentrant, nonautomatic, catecholamine-mediated VT",
      "label": "abolished"
    },
    {
      "source": "Dipyridamole",
      "target": "endogenous adenosine",
      "label": "potentiates effects of"
    },
    {
      "source": "Dipyridamole",
      "target": "nucleoside transport blocker",
      "label": "is a"
    },
    {
      "source": "tachycardia",
      "target": "catecholamine",
      "label": "is caused by"
    },
    {
      "source": "tachycardia",
      "target": "intracellular calcium",
      "label": "involves increase in"
    },
    {
      "source": "tachycardia",
      "target": "adenosine A1",
      "label": "is terminated by activation of"
    },
    {
      "source": "tachycardia",
      "target": "muscarinic cholinergic receptor",
      "label": "is terminated by activation of"
    },
    {
      "source": "tachycardia",
      "target": "cAMP",
      "label": "is mediated by"
    },
    {
      "source": "tachycardia",
      "target": "delayed afterdepolarizations",
      "label": "results in"
    },
    {
      "source": "tachycardia",
      "target": "triggered activity",
      "label": "results in"
    },
    {
      "source": "exogenous adenosine",
      "target": "autonomic tone",
      "label": "modulates through alterations in"
    },
    {
      "source": "exogenous adenosine",
      "target": "arterial chemoreceptors",
      "label": "modulates through activation of"
    },
    {
      "source": "exogenous adenosine",
      "target": "VT",
      "label": "may modulate"
    },
    {
      "source": "Valsalva",
      "target": "myocardial stretch",
      "label": "results in reduction in"
    },
    {
      "source": "Valsalva",
      "target": "cardiac dimensions",
      "label": "results in reduction in"
    },
    {
      "source": "Valsalva",
      "target": "venous return",
      "label": "decreases"
    },
    {
      "source": "dipyridamole",
      "target": "reentrant VT",
      "label": "had no effect on"
    },
    {
      "source": "dipyridamole",
      "target": "VT cycle length",
      "label": "had no effect on"
    },
    {
      "source": "dipyridamole",
      "target": "duration",
      "label": "had no effect on"
    },
    {
      "source": "Adenosine",
      "target": "catecholamine-mediated VT",
      "label": "had no effect on"
    },
    {
      "source": "catecholamine-mediated VT",
      "target": "automaticity",
      "label": "is caused by"
    },
    {
      "source": "Edrophonium",
      "target": "acetylcholine",
      "label": "potentiates effects of"
    },
    {
      "source": "Edrophonium",
      "target": "VT",
      "label": "terminated"
    },
    {
      "source": "Edrophonium",
      "target": "muscarinic cholinergic receptor",
      "label": "potentiates effects at"
    },
    {
      "source": "Edrophonium",
      "target": "cholinesterase inhibitor",
      "label": "is a"
    },
    {
      "source": "receptor-mediated effects",
      "target": "nonreentrant catecholamine-mediated VT",
      "label": "are specific for identifying"
    },
    {
      "source": "nonreentrant catecholamine-mediated VT",
      "target": "acetylcholine",
      "label": "has response to"
    },
    {
      "source": "nonreentrant catecholamine-mediated VT",
      "target": "endogenous adenosine",
      "label": "has response to"
    },
    {
      "source": "form of nonreentrant, catecholamine-mediated VT",
      "target": "rapid pacing",
      "label": "can be initiated with"
    },
    {
      "source": "form of nonreentrant, catecholamine-mediated VT",
      "target": "exogenous adenosine",
      "label": "is sensitive to"
    },
    {
      "source": "form of nonreentrant, catecholamine-mediated VT",
      "target": "cycle length dependence",
      "label": "demonstrates"
    },
    {
      "source": "form of nonreentrant, catecholamine-mediated VT",
      "target": "Valsalva maneuver",
      "label": "is sensitive to"
    },
    {
      "source": "adenosine A1",
      "target": "inhibition",
      "label": "activation results in"
    },
    {
      "source": "aminophylline",
      "target": "competitive adenosine A1-receptor antagonist",
      "label": "is a"
    },
    {
      "source": "aminophylline",
      "target": "VT",
      "label": "caused recurrence of"
    },
    {
      "source": "receptor-mediated inhibition",
      "target": "adenylate cyclase",
      "label": "is of"
    },
    {
      "source": "Reentrant ventricular tachycardia (VT)",
      "target": "nucleoside",
      "label": "is insensitive to"
    },
    {
      "source": "Reentrant ventricular tachycardia (VT)",
      "target": "adenosine",
      "label": "is insensitive to"
    },
    {
      "source": "vagal maneuvers",
      "target": "catecholamine-mediated VT",
      "label": "had no effect on"
    },
    {
      "source": "nonselective MAO inhibitors",
      "target": "adverse effect profiles",
      "label": "have"
    },
    {
      "source": "SSRIs",
      "target": "interactions",
      "label": "has fewer"
    },
    {
      "source": "SSRIs",
      "target": "fluoxetine",
      "label": "has fewer interactions than"
    },
    {
      "source": "meperidine",
      "target": "selegiline therapy",
      "label": "combined with"
    },
    {
      "source": "meperidine",
      "target": "adverse effects",
      "label": "causes"
    },
    {
      "source": "selegiline therapy",
      "target": "meperidine",
      "label": "concomitant use not recommended with"
    },
    {
      "source": "selegiline therapy",
      "target": "pethidine",
      "label": "concomitant use not recommended with"
    },
    {
      "source": "tyramine-induced hypertension",
      "target": "'cheese effect'",
      "label": "is also known as"
    },
    {
      "source": "low tyramine diet",
      "target": "nonselective MAO inhibitors",
      "label": "recommended with"
    },
    {
      "source": "low tyramine diet",
      "target": "moclobemide",
      "label": "recommended with"
    },
    {
      "source": "low tyramine diet",
      "target": "selegiline",
      "label": "recommended with"
    },
    {
      "source": "deprenyl",
      "target": "Parkinson's disease",
      "label": "used in treatment of"
    },
    {
      "source": "deprenyl",
      "target": "MAO-B",
      "label": "is an inhibitor of"
    },
    {
      "source": "deprenyl",
      "target": "MAO-B inhibitor",
      "label": "is a"
    },
    {
      "source": "deprenyl",
      "target": "monoamine oxidase type B",
      "label": "is an inhibitor of"
    },
    {
      "source": "MAO-B inhibitor",
      "target": "Parkinson's disease",
      "label": "approved for treatment of"
    },
    {
      "source": "pethidine",
      "target": "adverse effects",
      "label": "causes"
    },
    {
      "source": "pethidine",
      "target": "selegiline therapy",
      "label": "combined with"
    },
    {
      "source": "pethidine",
      "target": "meperidine",
      "label": "is also known as"
    },
    {
      "source": "moclobemide",
      "target": "selective, reversible MAO-A inhibitor",
      "label": "is a"
    },
    {
      "source": "murine PGHS-1",
      "target": "murine PGHS-2",
      "label": "is_pharmacologically_distinct_from"
    },
    {
      "source": "murine PGHS-1",
      "target": "cos-1 cells",
      "label": "expressed_in"
    },
    {
      "source": "murine PGHS-2",
      "target": "cos-1 cells",
      "label": "expressed_in"
    },
    {
      "source": "prostaglandin endoperoxide (PGH) synthase",
      "target": "PGH synthase-1 and -2",
      "label": "has_isozyme"
    },
    {
      "source": "prostaglandin endoperoxide (PGH) synthase",
      "target": "COX II",
      "label": "has_isozyme"
    },
    {
      "source": "prostaglandin endoperoxide (PGH) synthase",
      "target": "COX I",
      "label": "has_isozyme"
    },
    {
      "source": "tumor promoters",
      "target": "PGH synthase-2",
      "label": "induces"
    },
    {
      "source": "PGH synthase-2",
      "target": "PGG2",
      "label": "produces"
    },
    {
      "source": "PGH synthase-2",
      "target": "inflammation",
      "label": "is_associated_with"
    },
    {
      "source": "PGH synthase-2",
      "target": "COX II",
      "label": "is_also_called"
    },
    {
      "source": "PGH synthase-2",
      "target": "macrophages",
      "label": "is_induced_in"
    },
    {
      "source": "PGH synthase-2",
      "target": "ovarian follicles",
      "label": "is_induced_in"
    },
    {
      "source": "PGH synthase-2",
      "target": "fibroblasts",
      "label": "is_induced_in"
    },
    {
      "source": "PGH synthase-2",
      "target": "endothelial cells",
      "label": "is_induced_in"
    },
    {
      "source": "PGH synthase-2",
      "target": "NSAIDs",
      "label": "is_therapeutic_target_of"
    },
    {
      "source": "PGH synthase-2",
      "target": "cells",
      "label": "is_undetectable_in"
    },
    {
      "source": "PGH synthase-2",
      "target": "PGH2",
      "label": "produces"
    },
    {
      "source": "6-Methoxy-2-naphthylacetic acid",
      "target": "Relafen",
      "label": "is_active_metabolite_of"
    },
    {
      "source": "6-Methoxy-2-naphthylacetic acid",
      "target": "murine PGHS-2",
      "label": "inhibits"
    },
    {
      "source": "PGH synthase-1",
      "target": "tissues",
      "label": "is_expressed_in"
    },
    {
      "source": "PGH synthase-1",
      "target": "COX I",
      "label": "is_also_called"
    },
    {
      "source": "PGH synthase-1",
      "target": "PGH2",
      "label": "produces"
    },
    {
      "source": "PGH synthase-1",
      "target": "NSAIDs",
      "label": "is_site_of_action_for"
    },
    {
      "source": "PGH synthase-1",
      "target": "PGHS-1",
      "label": "is_also_called"
    },
    {
      "source": "PGH synthase-1",
      "target": "PGG2",
      "label": "produces"
    },
    {
      "source": "mitogens",
      "target": "PGH synthase-2",
      "label": "induces"
    },
    {
      "source": "sulindac sulfide",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "Indomethacin",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "IK",
      "label": "reduces"
    },
    {
      "source": "Ibuprofen",
      "target": "Cl- secretion",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "basolateral K+ currents",
      "label": "reduces"
    },
    {
      "source": "Ibuprofen",
      "target": "forskolin-induced Isc",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "CFTR Cl- channels",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "forskolin-dependent Isc",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "forskolin-stimulated Isc",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "cAMP-mediated Cl- secretion",
      "label": "inhibits"
    },
    {
      "source": "Ibuprofen",
      "target": "NSAIDs",
      "label": "is a type of"
    },
    {
      "source": "Ibuprofen",
      "target": "apical Cl- currents",
      "label": "reduces"
    },
    {
      "source": "Ibuprofen",
      "target": "ICl",
      "label": "reduces"
    },
    {
      "source": "Ibuprofen",
      "target": "CFTR Cl- current",
      "label": "reduces"
    },
    {
      "source": "Ibuprofen",
      "target": "basolateral membrane K+ channels",
      "label": "inhibits"
    },
    {
      "source": "meclofenamate",
      "target": "PGHS-1",
      "label": "inhibits"
    },
    {
      "source": "dofetilide",
      "target": "HERG/IKr channels",
      "label": "blocks"
    },
    {
      "source": "dofetilide",
      "target": "submicromolar concentrations",
      "label": "blocks at"
    },
    {
      "source": "HERG/IKr channels",
      "target": "pharmacological management",
      "label": "are target for"
    },
    {
      "source": "affinity of BEAG K+ channels",
      "target": "dofetilide",
      "label": "is for"
    },
    {
      "source": "loss of high-affinity drug binding",
      "target": "loss of C-type inactivation",
      "label": "correlated with"
    },
    {
      "source": "chimeric approach",
      "target": "domains",
      "label": "not able to identify"
    },
    {
      "source": "HERG S620T",
      "target": "high-affinity block",
      "label": "abolished"
    },
    {
      "source": "HERG S620T",
      "target": "point mutation",
      "label": "is a"
    },
    {
      "source": "HERG S620T",
      "target": "C-type inactivation",
      "label": "interfered with"
    },
    {
      "source": "high-affinity block",
      "target": "dofetilide",
      "label": "is by"
    },
    {
      "source": "BEAG T432S",
      "target": "affinity of BEAG K+ channels",
      "label": "increased"
    },
    {
      "source": "S5-S6 linker",
      "target": "HERG",
      "label": "transplanted into"
    },
    {
      "source": "S5-S6 linker",
      "target": "high-affinity block",
      "label": "removed"
    },
    {
      "source": "S5-S6 linker",
      "target": "BEAG",
      "label": "from"
    },
    {
      "source": "HERG",
      "target": "K+ channel",
      "label": "encodes"
    },
    {
      "source": "bovine ether-a-go-go channel",
      "target": "dofetilide",
      "label": "is less sensitive to"
    },
    {
      "source": "drug binding",
      "target": "direct interaction",
      "label": "is not due to"
    },
    {
      "source": "drug binding",
      "target": "indirect allosteric modifications",
      "label": "is due to"
    },
    {
      "source": "biophysical properties",
      "target": "IKr",
      "label": "are identical to"
    },
    {
      "source": "biophysical properties",
      "target": "rapid component of the cardiac delayed rectifier K+ current",
      "label": "are identical to"
    },
    {
      "source": "BEAG",
      "target": "dofetilide",
      "label": "is less sensitive to"
    },
    {
      "source": "single amino acid residues",
      "target": "dofetilide block",
      "label": "are responsible for"
    },
    {
      "source": "direct interaction",
      "target": "dofetilide",
      "label": "is of"
    },
    {
      "source": "direct interaction",
      "target": "respective mutated site chains",
      "label": "is with"
    },
    {
      "source": "serine",
      "target": "position HERG 620",
      "label": "is in"
    },
    {
      "source": "serine",
      "target": "dofetilide binding",
      "label": "participates in"
    },
    {
      "source": "Molecular determinants",
      "target": "dofetilide block",
      "label": "are of"
    },
    {
      "source": "dofetilide block",
      "target": "HERG K+ channels",
      "label": "affects"
    },
    {
      "source": "MK-499",
      "target": "HERG/IKr channels",
      "label": "blocks"
    },
    {
      "source": "MK-499",
      "target": "submicromolar concentrations",
      "label": "blocks at"
    },
    {
      "source": "E4031",
      "target": "HERG/IKr channels",
      "label": "blocks"
    },
    {
      "source": "E4031",
      "target": "submicromolar concentrations",
      "label": "blocks at"
    },
    {
      "source": "human ether-a-go-go-related gene",
      "target": "K+ channel",
      "label": "encodes"
    },
    {
      "source": "K+ channel",
      "target": "biophysical properties",
      "label": "has"
    },
    {
      "source": "dofetilide binding",
      "target": "pore region of HERG",
      "label": "determinants localized to"
    },
    {
      "source": "chimeras",
      "target": "molecular determinants for dofetilide block",
      "label": "identify"
    },
    {
      "source": "chimeras",
      "target": "HERG",
      "label": "are between"
    },
    {
      "source": "chimeras",
      "target": "BEAG",
      "label": "are between"
    },
    {
      "source": "class III antiarrhythmic methanesulfonanilide drugs",
      "target": "HERG/IKr channels",
      "label": "block"
    },
    {
      "source": "indirect allosteric modifications",
      "target": "structure of the channel protein",
      "label": "are in"
    },
    {
      "source": "pharmacological management",
      "target": "arrhythmias",
      "label": "is of"
    },
    {
      "source": "intact C-type inactivation process",
      "target": "high-affinity drug binding",
      "label": "is crucial for"
    },
    {
      "source": "i.v. injection",
      "target": "testing",
      "label": "precedes"
    },
    {
      "source": "ritanserin",
      "target": "lowest active doses",
      "label": "has"
    },
    {
      "source": "ritanserin",
      "target": "selective 5-HT2A/5-HT2C antagonist",
      "label": "is_a"
    },
    {
      "source": "lowest active doses",
      "target": "s.c. treatment",
      "label": "obtained_after"
    },
    {
      "source": "lowest active doses",
      "target": "i.v. treatment",
      "label": "obtained_after"
    },
    {
      "source": "lowest active doses",
      "target": "attentuation",
      "label": "for"
    },
    {
      "source": "neuroendocrine experiments",
      "target": "parallel group",
      "label": "conducted_in"
    },
    {
      "source": "neuroendocrine experiments",
      "target": "rats",
      "label": "conducted_in"
    },
    {
      "source": "mixed 5-HT and catecholamine antagonists",
      "target": "potent antagonists",
      "label": "are"
    },
    {
      "source": "mixed 5-HT and catecholamine antagonists",
      "target": "ritanserin",
      "label": "more_potent_than"
    },
    {
      "source": "mixed 5-HT and catecholamine antagonists",
      "target": "catecholamine",
      "label": "target"
    },
    {
      "source": "mixed 5-HT and catecholamine antagonists",
      "target": "5-HT",
      "label": "target"
    },
    {
      "source": "open field test",
      "target": "emergence procedure",
      "label": "evaluates"
    },
    {
      "source": "potent antagonists",
      "target": "rats",
      "label": "effective_in"
    },
    {
      "source": "potent antagonists",
      "target": "mCPP-induced behavioural inhibition",
      "label": "of"
    },
    {
      "source": "mirtazapine",
      "target": "mixed 5-HT and catecholamine antagonists",
      "label": "is_a"
    },
    {
      "source": "mirtazapine",
      "target": "lowest active doses",
      "label": "has"
    },
    {
      "source": "mixed 5-HT1/5-HT2 receptor antagonists",
      "target": "potent antagonists",
      "label": "are"
    },
    {
      "source": "mixed 5-HT1/5-HT2 receptor antagonists",
      "target": "5-HT1",
      "label": "target"
    },
    {
      "source": "mixed 5-HT1/5-HT2 receptor antagonists",
      "target": "ritanserin",
      "label": "more_potent_than"
    },
    {
      "source": "mixed 5-HT1/5-HT2 receptor antagonists",
      "target": "5-HT2",
      "label": "target"
    },
    {
      "source": "exploratory activity",
      "target": "dose-related manner",
      "label": "reduced_in"
    },
    {
      "source": "attentuation",
      "target": "mCPP-induced behavioural inhibition",
      "label": "of"
    },
    {
      "source": "attentuation",
      "target": "s.c. treatment",
      "label": "occurs_after"
    },
    {
      "source": "attentuation",
      "target": "oral administration",
      "label": "occurs_after"
    },
    {
      "source": "attentuation",
      "target": "i.v. treatment",
      "label": "occurs_after"
    },
    {
      "source": "meta-chlorophenylpiperazine",
      "target": "inhibition",
      "label": "induces"
    },
    {
      "source": "exploration",
      "target": "open field area",
      "label": "of"
    },
    {
      "source": "exploratory behaviour",
      "target": "open field test",
      "label": "studied_in"
    },
    {
      "source": "testing",
      "target": "open field test",
      "label": "occurs_in"
    },
    {
      "source": "emergence procedure",
      "target": "novel environment",
      "label": "involves"
    },
    {
      "source": "emergence procedure",
      "target": "rats",
      "label": "involves"
    },
    {
      "source": "mCPP-treated animals",
      "target": "general state of arousal",
      "label": "exhibit"
    },
    {
      "source": "mianserin",
      "target": "mixed 5-HT and catecholamine antagonists",
      "label": "is_a"
    },
    {
      "source": "mianserin",
      "target": "lowest active doses",
      "label": "has"
    },
    {
      "source": "selective 5-HT2A/5-HT2C antagonist",
      "target": "5-HT2A",
      "label": "targets"
    },
    {
      "source": "selective 5-HT2A/5-HT2C antagonist",
      "target": "5-HT2C",
      "label": "targets"
    },
    {
      "source": "behavioural inhibition",
      "target": "mCPP",
      "label": "induced_by"
    },
    {
      "source": "plasma prolactin",
      "target": "dose-related manner",
      "label": "increase_is"
    },
    {
      "source": "forskolin-stimulated Isc",
      "target": "primary cultures of mouse trachea epithelia",
      "label": "occurs in"
    },
    {
      "source": "forskolin-stimulated Isc",
      "target": "human bronchial epithelia",
      "label": "occurs in"
    },
    {
      "source": "CFTR Cl- channels",
      "target": "L-cells",
      "label": "found in"
    },
    {
      "source": "salicylic acid",
      "target": "NSAIDs",
      "label": "is a type of"
    },
    {
      "source": "salicylic acid",
      "target": "Isc",
      "label": "inhibits"
    },
    {
      "source": "salicylic acid",
      "target": "cAMP-mediated Cl- secretion",
      "label": "inhibits"
    },
    {
      "source": "salicylic acid",
      "target": "basolateral membrane K+ channels",
      "label": "inhibits"
    },
    {
      "source": "salicylic acid",
      "target": "single channel amplitude",
      "label": "causes reduction in"
    },
    {
      "source": "salicylic acid",
      "target": "CFTR Cl- current",
      "label": "reduces"
    },
    {
      "source": "salicylic acid",
      "target": "CFTR Cl- channels",
      "label": "inhibits"
    },
    {
      "source": "forskolin",
      "target": "forskolin-dependent Isc",
      "label": "induces"
    },
    {
      "source": "forskolin",
      "target": "basolateral K+ currents",
      "label": "stimulates"
    },
    {
      "source": "forskolin",
      "target": "Isc",
      "label": "induces"
    },
    {
      "source": "forskolin",
      "target": "apical Cl- currents",
      "label": "stimulates"
    },
    {
      "source": "forskolin-dependent Isc",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "forskolin-dependent Isc",
      "target": "T84 cells",
      "label": "occurs in"
    },
    {
      "source": "CFTR",
      "target": "ICl",
      "label": "regulates"
    },
    {
      "source": "CFTR",
      "target": "CFTR Cl- current",
      "label": "forms"
    },
    {
      "source": "CFTR",
      "target": "CFTR Cl- channels",
      "label": "forms"
    },
    {
      "source": "Isc",
      "target": "Ki",
      "label": "has"
    },
    {
      "source": "cAMP-mediated Cl- secretion",
      "target": "airway epithelia",
      "label": "occurs in"
    },
    {
      "source": "cAMP-mediated Cl- secretion",
      "target": "human colonic epithelia",
      "label": "occurs in"
    },
    {
      "source": "cAMP-mediated Cl- secretion",
      "target": "colonic epithelia",
      "label": "occurs in"
    },
    {
      "source": "cAMP-mediated Cl- secretion",
      "target": "Isc",
      "label": "is"
    },
    {
      "source": "basolateral K+ currents",
      "target": "IK",
      "label": "is"
    },
    {
      "source": "basolateral K+ currents",
      "target": "K+",
      "label": "involves"
    },
    {
      "source": "basolateral membrane K+ channels",
      "target": "K+",
      "label": "transports"
    },
    {
      "source": "CFTR function",
      "target": "secretory epithelia",
      "label": "occurs in"
    },
    {
      "source": "forskolin-induced Isc",
      "target": "MTEs",
      "label": "occurs in"
    },
    {
      "source": "forskolin-induced Isc",
      "target": "HBEs",
      "label": "occurs in"
    },
    {
      "source": "MTEs",
      "target": "primary cultures of mouse trachea epithelia",
      "label": "is"
    },
    {
      "source": "Cl- secretion",
      "target": "Cl-",
      "label": "involves"
    },
    {
      "source": "short-lived block",
      "target": "CFTR Cl- current",
      "label": "explains reduction of"
    },
    {
      "source": "short-lived block",
      "target": "single channel amplitude",
      "label": "causes reduction in"
    },
    {
      "source": "apical Cl- currents",
      "target": "ICl",
      "label": "is"
    },
    {
      "source": "apical Cl- currents",
      "target": "Cl-",
      "label": "involves"
    },
    {
      "source": "Nystatin",
      "target": "apical membrane",
      "label": "permeabilizes"
    },
    {
      "source": "Nystatin",
      "target": "basolateral membrane",
      "label": "permeabilizes"
    },
    {
      "source": "cystic fibrosis transmembrane conductance regulator",
      "target": "Cl- secretion",
      "label": "mediates"
    },
    {
      "source": "CFTR expression",
      "target": "secretory epithelia",
      "label": "occurs in"
    },
    {
      "source": "HBEs",
      "target": "human bronchial epithelia",
      "label": "is"
    },
    {
      "source": "Ca2+-sensitizing binding site",
      "target": "Met-80",
      "label": "includes"
    },
    {
      "source": "Ca2+-sensitizing binding site",
      "target": "Met-45",
      "label": "includes"
    },
    {
      "source": "Ca2+-sensitizing binding site",
      "target": "Met-60",
      "label": "includes"
    },
    {
      "source": "Met-80",
      "target": "helices C",
      "label": "is in"
    },
    {
      "source": "Met-80",
      "target": "helix B",
      "label": "is in"
    },
    {
      "source": "hydrophobic surfaces",
      "target": "N-terminal regulatory domain",
      "label": "are on"
    },
    {
      "source": "drug binding sites",
      "target": "N-terminal domain",
      "label": "are in"
    },
    {
      "source": "drug binding sites",
      "target": "cTnC",
      "label": "are on"
    },
    {
      "source": "drug binding sites",
      "target": "hydrophobic surfaces",
      "label": "are on"
    },
    {
      "source": "drug binding sites",
      "target": "shallow hydrophobic cup",
      "label": "are in"
    },
    {
      "source": "drug binding sites",
      "target": "bepridil",
      "label": "are for"
    },
    {
      "source": "drug binding sites",
      "target": "C-terminal domains",
      "label": "are in"
    },
    {
      "source": "drug binding sites",
      "target": "trifluoperazine",
      "label": "are for"
    },
    {
      "source": "Putkey, J. A.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "helices C",
      "target": "regulatory site II",
      "label": "is part of"
    },
    {
      "source": "NMR heteronuclear single-quantum coherence spectra",
      "target": "[methyl-13C]Met-labeled cTnC",
      "label": "are of"
    },
    {
      "source": "cTnC",
      "target": "cardiac troponin C",
      "label": "is an alias of"
    },
    {
      "source": "cTnC",
      "target": "Ca2+",
      "label": "is bound by"
    },
    {
      "source": "Ca2+-sensitizing compounds",
      "target": "cTnC",
      "label": "can be designed against"
    },
    {
      "source": "Liu, W.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "bepridil",
      "target": "Ca2+",
      "label": "binding is dependent on"
    },
    {
      "source": "bepridil",
      "target": "cardiac troponin C",
      "label": "binds to"
    },
    {
      "source": "bepridil",
      "target": "cTnC",
      "label": "binds to"
    },
    {
      "source": "Met-45",
      "target": "helix B",
      "label": "is in"
    },
    {
      "source": "Met-60",
      "target": "helices C",
      "label": "is in"
    },
    {
      "source": "Met-60",
      "target": "helix B",
      "label": "is in"
    },
    {
      "source": "cardiac troponin C",
      "target": "Ca2+",
      "label": "is bound by"
    },
    {
      "source": "cardiac troponin C",
      "target": "drug binding sites",
      "label": "has"
    },
    {
      "source": "shallow hydrophobic cup",
      "target": "C-terminal domains",
      "label": "is in"
    },
    {
      "source": "C-terminal domains",
      "target": "cTnC",
      "label": "is part of"
    },
    {
      "source": "isotope-filtered nuclear Overhauser effects",
      "target": "drug binding sites",
      "label": "used to identify"
    },
    {
      "source": "helix B",
      "target": "site I",
      "label": "is part of"
    },
    {
      "source": "helix B",
      "target": "regulatory site II",
      "label": "is part of"
    },
    {
      "source": "Spyracopoulos, L.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "spin-labeled phenothiazine",
      "target": "drug binding sites",
      "label": "used to identify"
    },
    {
      "source": "Sykes, B. D.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "Sia, S.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "Li, M. X.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "Met methyl groups",
      "target": "drug binding sites",
      "label": "used to identify"
    },
    {
      "source": "Gagne, S. M.",
      "target": "J. Biol. Chem.",
      "label": "authored"
    },
    {
      "source": "state-dependent cocaine block",
      "target": "steady-state inactivation",
      "label": "depends on"
    },
    {
      "source": "state-dependent cocaine block",
      "target": "sodium channel isoforms",
      "label": "is of"
    },
    {
      "source": "state-dependent cocaine block",
      "target": "chimeras",
      "label": "is of"
    },
    {
      "source": "state-dependent cocaine block",
      "target": "channel activation",
      "label": "depends on"
    },
    {
      "source": "state-dependent cocaine block",
      "target": "channels",
      "label": "is of"
    },
    {
      "source": "steady-state inactivation",
      "target": "hH1 channels",
      "label": "occurs at"
    },
    {
      "source": "steady-state inactivation",
      "target": "mu1 channels",
      "label": "occurs at"
    },
    {
      "source": "shifts",
      "target": "voltage dependence",
      "label": "are in"
    },
    {
      "source": "shifts",
      "target": "linear shifts",
      "label": "elicited"
    },
    {
      "source": "linear shifts",
      "target": "steady-state cocaine block",
      "label": "are in"
    },
    {
      "source": "Low affinity block",
      "target": "hH1 channels",
      "label": "is of"
    },
    {
      "source": "Low affinity block",
      "target": "resting mu1 channels",
      "label": "is of"
    },
    {
      "source": "Cocaine block",
      "target": "block",
      "label": "was greater than"
    },
    {
      "source": "Cocaine block",
      "target": "whole-cell voltage clamp",
      "label": "was examined under"
    },
    {
      "source": "Cocaine block",
      "target": "HEK293t cells",
      "label": "was examined in"
    },
    {
      "source": "Cocaine block",
      "target": "human cardiac (hH1) muscle sodium channels",
      "label": "is of"
    },
    {
      "source": "Cocaine block",
      "target": "rat skeletal (mu1) muscle sodium channels",
      "label": "is of"
    },
    {
      "source": "block",
      "target": "mu1 channels",
      "label": "is of"
    },
    {
      "source": "coexpression",
      "target": "mu1 channels",
      "label": "is with"
    },
    {
      "source": "coexpression",
      "target": "large positive shifts",
      "label": "produced"
    },
    {
      "source": "coexpression",
      "target": "hH1 channels",
      "label": "is with"
    },
    {
      "source": "coexpression",
      "target": "rat brain beta1 subunit",
      "label": "is with"
    },
    {
      "source": "coexpression",
      "target": "shifts",
      "label": "induces"
    },
    {
      "source": "large positive shifts",
      "target": "steady-state inactivation",
      "label": "are in"
    },
    {
      "source": "mu1/hH1 channel chimeras",
      "target": "shifts",
      "label": "induce"
    },
    {
      "source": "cocaine affinity",
      "target": "resting channels",
      "label": "is of"
    },
    {
      "source": "cocaine affinity",
      "target": "inactivated channels",
      "label": "is of"
    },
    {
      "source": "wild-type channels",
      "target": "rat brain beta1 subunit",
      "label": "are coexpressed with"
    },
    {
      "source": "high affinity block",
      "target": "inactivated channels",
      "label": "is of"
    },
    {
      "source": "manipulations",
      "target": "cocaine affinity",
      "label": "did not affect"
    },
    {
      "source": "central muscarinic M2 receptors",
      "target": "vasopressin release",
      "label": "increase"
    },
    {
      "source": "central muscarinic M2 receptors",
      "target": "sympathetic outflow",
      "label": "increase"
    },
    {
      "source": "Pressor and bradycardic effects",
      "target": "tacrine",
      "label": "are effects of"
    },
    {
      "source": "Pressor and bradycardic effects",
      "target": "rat",
      "label": "occur in"
    },
    {
      "source": "Pressor and bradycardic effects",
      "target": "acetylcholinesterase inhibitors",
      "label": "are effects of"
    },
    {
      "source": "cardiovascular effects",
      "target": "acetylcholinesterase inhibitors",
      "label": "are effects of"
    },
    {
      "source": "cardiovascular effects",
      "target": "i.v. cholinesterase inhibitors",
      "label": "are effects of"
    },
    {
      "source": "cardiovascular effects",
      "target": "Wistar rats",
      "label": "compared in"
    },
    {
      "source": "Atropine",
      "target": "tacrine-induced bradycardia",
      "label": "abolished"
    },
    {
      "source": "Atropine",
      "target": "tacrine pressor effects",
      "label": "abolished"
    },
    {
      "source": "non-selective muscarinic receptor antagonist atropine",
      "target": "tacrine pressor response",
      "label": "inhibited"
    },
    {
      "source": "non-selective muscarinic receptor antagonist atropine",
      "target": "i.c.v. administration",
      "label": "administered by"
    },
    {
      "source": "Central injection",
      "target": "muscarinic receptor antagonists",
      "label": "of"
    },
    {
      "source": "muscarinic receptor antagonists",
      "target": "tacrine-induced bradycardia",
      "label": "did not affect"
    },
    {
      "source": "methylatropine",
      "target": "tacrine-induced bradycardia",
      "label": "abolished"
    },
    {
      "source": "methylatropine",
      "target": "tacrine pressor effects",
      "label": "did not affect"
    },
    {
      "source": "[beta-mercapto-beta,beta-cyclopenta-methylenepropionyl1, O-Me-Tyr2, Arg8] vasopressin",
      "target": "vasopressin V1 receptor antagonist",
      "label": "is a type of"
    },
    {
      "source": "muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol",
      "target": "tacrine pressor response",
      "label": "inhibited"
    },
    {
      "source": "muscarinic M3 receptor antagonist para-fluoro-hexahydro-sila-difenidol",
      "target": "i.c.v. administration",
      "label": "administered by"
    },
    {
      "source": "muscarinic M1 receptor antagonist pirenzepine",
      "target": "tacrine pressor response",
      "label": "inhibited"
    },
    {
      "source": "muscarinic M1 receptor antagonist pirenzepine",
      "target": "i.c.v. administration",
      "label": "administered by"
    },
    {
      "source": "muscarinic M2 receptor antagonist methoctramine",
      "target": "tacrine pressor response",
      "label": "inhibited"
    },
    {
      "source": "muscarinic M2 receptor antagonist methoctramine",
      "target": "i.c.v. administration",
      "label": "administered by"
    },
    {
      "source": "acetylcholinesterase inhibitor-induced bradycardia",
      "target": "peripheral muscarinic mechanisms",
      "label": "mediated by"
    },
    {
      "source": "debrisoquine",
      "target": "fractional rate of loss",
      "label": "increased"
    },
    {
      "source": "debrisoquine",
      "target": "uptake1",
      "label": "is a substrate of"
    },
    {
      "source": "debrisoquine",
      "target": "pulmonary endothelial cells",
      "label": "is transported in"
    },
    {
      "source": "debrisoquine",
      "target": "noradrenaline deamination",
      "label": "inhibits"
    },
    {
      "source": "debrisoquine",
      "target": "rat lungs",
      "label": "is more potent in"
    },
    {
      "source": "debrisoquine",
      "target": "MAO inhibitor",
      "label": "is a"
    },
    {
      "source": "debrisoquine",
      "target": "monoamine oxidase (MAO)",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "Amezinium",
      "target": "pulmonary endothelial cells",
      "label": "is accumulated in"
    },
    {
      "source": "Amezinium",
      "target": "monoamine oxidase (MAO)",
      "label": "is a potent inhibitor of"
    },
    {
      "source": "Amezinium",
      "target": "MAO inhibitor",
      "label": "is less potent as a"
    },
    {
      "source": "Amezinium",
      "target": "cells",
      "label": "is less potent in"
    },
    {
      "source": "Amezinium",
      "target": "uptake1",
      "label": "is a substrate of"
    },
    {
      "source": "myocardial cells",
      "target": "cells",
      "label": "are a type of"
    },
    {
      "source": "myocardial cells",
      "target": "heart",
      "label": "are part of"
    },
    {
      "source": "myocardial cells",
      "target": "uptake2 transporter",
      "label": "have"
    },
    {
      "source": "amine",
      "target": "uptake2",
      "label": "is accumulated by"
    },
    {
      "source": "catecholamine transporter",
      "target": "non-neuronal uptake1",
      "label": "is"
    }
  ]
}